PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Lahdaoui, F; Delpu, Y; Vincent, A; Renaud, F; Messager, M; Duchene, B; Leteurtre, E; Mariette, C; Torrisani, J; Jonckheere, N; Van Seuningen, I				Lahdaoui, F.; Delpu, Y.; Vincent, A.; Renaud, F.; Messager, M.; Duchene, B.; Leteurtre, E.; Mariette, C.; Torrisani, J.; Jonckheere, N.; Van Seuningen, I.			miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer	ONCOGENE			English	Article							CELL-PROLIFERATION; GENE MUC4; ADENOCARCINOMA; TRANSCRIPTION; PROMOTER; GROWTH; IDENTIFICATION; MICRORNAS; MIRNA	Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers in the world with one of the worst outcome. The oncogenic mucin MUC4 has been identified as an actor of pancreatic carcinogenesis as it is involved in many processes regulating pancreatic cancer cell biology. MUC4 is not expressed in healthy pancreas whereas it is expressed very early in pancreatic carcinogenesis. Targeting MUC4 in these early steps may thus appear as a promising strategy to slow-down pancreatic tumorigenesis. miRNA negative regulation of MUC4 could be one mechanism to efficiently downregulate MUC4 gene expression in early pancreatic neoplastic lesions. Using in silico studies, we found two putative binding sites for miR-219-1-3p in the 3'-UTR of MUC4 and showed that miR-219-1-3p expression is downregulated both in PDAC-derived cell lines and human PDAC tissues compared with their normal counterparts. We then showed that miR-219-1-3p negatively regulates MUC4 mucin expression via its direct binding to MUC4 3'-UTR. MiR-219-1-3p overexpression (transient and stable) in pancreatic cancer cell lines induced a decrease of cell proliferation associated with a decrease of cyclin D1 and a decrease of Akt and Erk pathway activation. MiR-219-1-3p overexpression also decreased cell migration. Furthermore, miR-219-1-3p expression was found to be conversely correlated with Muc4 expression in early pancreatic intraepithelial neoplasia lesions of Pdx1-Cre;LSL-Kras(G12D) mice. Most interestingly, in vivo studies showed that miR-219-1-3p injection in xenografted pancreatic tumors in mice decreased both tumor growth and MUC4 mucin expression. Altogether, these results identify miR-219-1-3p as a new negative regulator of MUC4 oncomucin that possesses tumor-suppressor activity in PDAC.	[Lahdaoui, F.; Vincent, A.; Renaud, F.; Messager, M.; Duchene, B.; Leteurtre, E.; Mariette, C.; Jonckheere, N.; Van Seuningen, I.] INSERM, UMR837, JPARC, Team Mucins 5, F-59045 Lille, France; [Lahdaoui, F.; Vincent, A.; Renaud, F.; Messager, M.; Duchene, B.; Leteurtre, E.; Mariette, C.; Jonckheere, N.; Van Seuningen, I.] Univ Lille Nord France, Lille, France; [Lahdaoui, F.; Vincent, A.; Renaud, F.; Messager, M.; Duchene, B.; Leteurtre, E.; Mariette, C.; Jonckheere, N.; Van Seuningen, I.] CHRU Lille, F-59037 Lille, France; [Delpu, Y.; Torrisani, J.] INSERM, Canc Res Ctr Toulouse, UMR 1037, F-59045 Lille, France; [Delpu, Y.; Torrisani, J.] Univ Toulouse 3, F-31062 Toulouse, France	Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Van Seuningen, I (corresponding author), INSERM, JPARC UMR837, Rue Polonovski, F-59045 Lille, France.	isabelle.vanseuningen@inserm.fr	Renaud, Florence/V-5064-2019; Jonckheere, Nicolas/J-6028-2013; Vincent, Audrey/I-2934-2016; Torrisani, Jérôme/M-6203-2014; VAN SEUNINGEN, Isabelle/N-6176-2016	Jonckheere, Nicolas/0000-0002-0496-0661; Vincent, Audrey/0000-0003-0058-2058; Torrisani, Jérôme/0000-0001-6880-9357; Duchene, Belinda/0000-0002-4810-4680; RENAUD, Florence/0000-0003-3614-1713; VAN SEUNINGEN, Isabelle/0000-0002-3131-2694	PhD fellowship of la Ligue Nationale Contre le Cancer; la Ligue Nationale Contre le Cancer (Equipe Labellisee Ligue IVS); 'Contrat Hospitalier de Recherche Translationnelle' (AVIESAN/CHRT)	PhD fellowship of la Ligue Nationale Contre le Cancer; la Ligue Nationale Contre le Cancer (Equipe Labellisee Ligue IVS); 'Contrat Hospitalier de Recherche Translationnelle' (AVIESAN/CHRT)	We thank D Tuveson (Cambridge Research Institute, England, UK) for the kind gift of LStopL-Kras<SUP>G12D</SUP> mouse model, Dr MS Tsao (University Health Network, Toronto, Canada) for the kind gift of human pancreatic ductal cells, MH Gevaert and R Siminsky (Department of Histology, Faculty of Medicine, University of Lille 2) for their technical help, Dr C Cauffiez (EA4483, University of Lille 2) and Dr M Perrais (Inserm UMR837, team 5, Lille) for the in situ hybridization studies, the technical platforms IFR114/IMPRT for luciferase measurements (A.S Drucbert) and the animal facility (D. Taillieu). FL is a recipient of a PhD fellowship of la Ligue Nationale Contre le Cancer. This work is supported by a grant from la Ligue Nationale Contre le Cancer (Equipe Labellisee Ligue 2013, IVS). IVS is the recipient of a 'Contrat Hospitalier de Recherche Translationnelle' (AVIESAN/CHRT).	Andrianifahanana M, 2005, ONCOGENE, V24, P6143, DOI 10.1038/sj.onc.1208756; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bloomston M, 2007, JAMA-J AM MED ASSOC, V297, P1901, DOI 10.1001/jama.297.17.1901; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chaturvedi P, 2008, CANCER RES, V68, P2065, DOI 10.1158/0008-5472.CAN-07-6041; Chaturvedi P, 2007, MOL CANCER RES, V5, P309, DOI 10.1158/1541-7786.MCR-06-0353; Cheng HYM, 2007, NEURON, V54, P813, DOI 10.1016/j.neuron.2007.05.017; du Rieu MC, 2010, CLIN CHEM, V56, P603, DOI 10.1373/clinchem.2009.137364; Dugas JC, 2010, NEURON, V65, P597, DOI 10.1016/j.neuron.2010.01.027; Furukawa T, 1996, AM J PATHOL, V148, P1763; Hruban RH, 2008, INT J CLIN EXP PATHO, V1, P306; Humeau M, 2013, CLIN BIOCHEM, V46, P933, DOI 10.1016/j.clinbiochem.2013.03.019; Jonckheere N, 2004, ONCOGENE, V23, P5729, DOI 10.1038/sj.onc.1207769; Jonckheere N, 2007, J BIOL CHEM, V282, P22638, DOI 10.1074/jbc.M700905200; Jonckheere N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032232; Jonckheere Nicolas, 2010, Cancers (Basel), V2, P1794, DOI 10.3390/cancers2041794; Jonckheere N, 2010, BIOCHIMIE, V92, P1, DOI 10.1016/j.biochi.2009.09.018; Jonckheere Nicolas, 2008, Critical Reviews in Oncogenesis, V14, P177; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Lal A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002363; Lee EJ, 2007, INT J CANCER, V120, P1046, DOI 10.1002/ijc.22394; Lin MB, 2003, CHINESE MED J-PEKING, V116, P1156; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Mahlamaki EH, 2002, GENE CHROMOSOME CANC, V35, P353, DOI 10.1002/gcc.10122; Olive KP, 2006, CLIN CANCER RES, V12, P5277, DOI 10.1158/1078-0432.CCR-06-0436; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; Piessen G, 2007, BIOCHEM J, V402, P81, DOI 10.1042/BJ20061461; Rachagani S, 2012, CARCINOGENESIS, V33, P1953, DOI 10.1093/carcin/bgs225; Schultz NA, 2012, MODERN PATHOL, V25, P1609, DOI 10.1038/modpathol.2012.122; Singh AP, 2007, ONCOGENE, V26, P30, DOI 10.1038/sj.onc.1209764; Skrypek N, 2013, ONCOGENE, V32, P1714, DOI 10.1038/onc.2012.179; Srivastava SK, 2011, CARCINOGENESIS, V32, P1832, DOI 10.1093/carcin/bgr223; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Szafranska AE, 2007, ONCOGENE, V26, P4442, DOI 10.1038/sj.onc.1210228; Torrisani J, 2001, GASTROENTEROLOGY, V120, P200, DOI 10.1053/gast.2001.21192; Torrisani J, 2009, HUM GENE THER, V20, P831, DOI 10.1089/hum.2008.134; van der Sluis M, 2004, BIOCHEM BIOPH RES CO, V325, P952, DOI 10.1016/j.bbrc.2004.10.108; Van Seuningen I, 2000, BIOCHEM J, V348, P675; Vincent A, 2008, FASEB J, V22, P3035, DOI 10.1096/fj.07-103390; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Xu SB, 2007, J BIOL CHEM, V282, P25053, DOI 10.1074/jbc.M700501200; Yu J, 2012, CLIN CANCER RES, V18, P981, DOI 10.1158/1078-0432.CCR-11-2347; Zhang BZ, 2012, HUM GENE THER, V23, P1071, DOI 10.1089/hum.2012.070; Zhao XH, 2010, NEURON, V65, P612, DOI 10.1016/j.neuron.2010.02.018	45	52	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					780	788		10.1038/onc.2014.11	http://dx.doi.org/10.1038/onc.2014.11			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24608432	Green Published			2022-12-28	WOS:000348853800011
J	Ma, H; Zhou, H; Song, X; Shi, S; Zhang, J; Jia, L				Ma, H.; Zhou, H.; Song, X.; Shi, S.; Zhang, J.; Jia, L.			Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia	ONCOGENE			English	Article						sialylation; MDR; AML; PI3K/Akt signaling; P-gp; MRP1	BREAST-CANCER; SIALYLTRANSFERASE EXPRESSION; P-GLYCOPROTEIN; PATHWAY; CELLS; INHIBITION; ACTIVATION; PROLIFERATION; GLYCOSYLATION; GLYCANS	Aberrant cell surface sialylation patterns have been shown to correlate with tumor progression and metastasis. However, the role of sialylation regulation of cancer multidrug resistance (MDR) remains poorly understood. This study investigated sialylation in modification on MDR in acute myeloid leukemia (AML). Using mass spectrometry (MS) analysis, the composition profiling of sialylated N-glycans differed in three pairs of AML cell lines. Real-time PCR showed the differential expressional profiles of 20 sialyltransferase (ST) genes in the both AML cell lines and bone marrow mononuclear cells (BMMCs) of AML patients. The expression levels of ST3GAL5 and ST8SIA4 were detected, which were overexpressed in HL60 and HL60/adriamycin-resistant (ADR) cells. The altered levels of ST3GAL5 and ST8SIA4 were found in close association with the MDR phenotype changing of HL60 and HL60/ADR cells both in vitro and in vivo. Further data demonstrated that manipulation of these two genes' expression modulated the activity of phosphoinositide-3 kinase (PI3K)/Akt signaling pathway and its downstream target thus regulated the proportionally mutative expression of P-glycoprotein (P-gp) and MDR-related protein 1 (MRP1), both of which are known to be involved in MDR. Blocking the PI3K/Akt pathway by its specific inhibitor LY294002 or by Akt small interfering RNA resulted in the reduced chemosensitivity of HL60/ADR cells. Therefore, this study indicated that sialylation involved in the development of MDR of AML cells probably through ST3GAL5 or ST8SIA4 regulating the activity of PI3K/Akt signaling and the expression of P-gp and MRP1.	[Ma, H.; Shi, S.; Jia, L.] Dalian Med Univ, Coll Lab Med, Dept Med Basic Lab, Dalian 116044, Liaoning, Peoples R China; [Zhou, H.] Dalian Med Univ, Dept Microbiol, Dalian 116044, Liaoning, Peoples R China; [Song, X.] Univ Tromso, Fac Hlth Sci, Dept Med Biol, Tromso, Norway; [Zhang, J.] Dalian Med Univ, Inst Glycobiol, Dept Biochem, Dalian 116044, Liaoning, Peoples R China; [Zhang, J.] Dalian Univ Technol, Sch Life Sci & Med, Dept Biochem, Panjin, Peoples R China	Dalian Medical University; Dalian Medical University; UiT The Arctic University of Tromso; Dalian Medical University; Dalian University of Technology	Jia, L (corresponding author), Dalian Med Univ, Coll Lab Med, Dept Med Basic Lab, 9 Lvshunnan Rd Xiduan, Dalian 116044, Liaoning, Peoples R China.	jiali@dlmedu.edu.cn	li, jia/GVT-7587-2022; Jia, li/GPW-8015-2022		National Key Basic Research and Development Program (973 program) of China [2012CB822100]; National Natural Science Foundation of China [81271910]; Project for Liaoning BaiQianWan Talents Program [2012921014]	National Key Basic Research and Development Program (973 program) of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Project for Liaoning BaiQianWan Talents Program	This work was supported by grants from National Key Basic Research and Development Program (973 program) of China (no. 2012CB822100), from National Natural Science Foundation of China (81271910), and supported by Project for Liaoning BaiQianWan Talents Program (2012921014).	Abdul-Ghani R, 2006, ONCOGENE, V25, P1743, DOI 10.1038/sj.onc.1209201; Badura S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080070; Barancik M, 2006, EUR J PHARM SCI, V29, P426, DOI 10.1016/j.ejps.2006.08.006; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Billottet C, 2009, CANCER RES, V69, P1027, DOI 10.1158/0008-5472.CAN-08-2608; Deschler B, 2006, CANCER-AM CANCER SOC, V107, P2099, DOI 10.1002/cncr.22233; Dobbin ZC, 2013, INT J MOL SCI, V14, P8213, DOI 10.3390/ijms14048213; Domon B, 2006, SCIENCE, V312, P212, DOI 10.1126/science.1124619; Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b; Garcia MG, 2009, LEUKEMIA RES, V33, P288, DOI 10.1016/j.leukres.2008.06.010; Harvey DJ, 2005, EXPERT REV PROTEOMIC, V2, P87, DOI 10.1586/14789450.2.1.87; Hebbar M, 2003, INT J BIOL MARKER, V18, P116, DOI 10.1177/172460080301800204; Ishihara T, 2011, J PROTEOMICS, V74, P2159, DOI 10.1016/j.jprot.2011.06.010; Kim YJ, 1996, BIOCHEM BIOPH RES CO, V228, P324, DOI 10.1006/bbrc.1996.1660; Kourti M, 2007, INT J HEMATOL, V86, P166, DOI 10.1532/IJH97.E0624; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; Martersteck CM, 1996, GLYCOBIOLOGY, V6, P289, DOI 10.1093/glycob/6.3.289; Mirkin BL, 2002, CELL PROLIFERAT, V35, P105, DOI 10.1046/j.1365-2184.2002.00228.x; Miyagi T, 2003, GLYCOCONJUGATE J, V20, P189, DOI 10.1023/B:GLYC.0000024250.48506.bf; Mondal S, 2010, LEUKEMIA RES, V34, P463, DOI 10.1016/j.leukres.2009.07.042; Morishita N, 2012, PEDIATR BLOOD CANCER, V59, P83, DOI 10.1002/pbc.24034; Nakano M, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.009001; Nakayama J, 2006, METHOD ENZYMOL, V416, P120, DOI 10.1016/S0076-6879(06)16008-5; Neiiendam JL, 2004, J NEUROCHEM, V91, P920, DOI 10.1111/j.1471-4159.2004.02779.x; Parasrampuria Ridhi, 2011, Drug Metab Lett, V5, P64, DOI 10.2174/187231211794455244; Perez-Garay M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012524; Recchi MA, 1998, CANCER RES, V58, P4066; Russo RIC, 2008, INT J CANCER, V122, P1012, DOI 10.1002/ijc.23122; Schauer R, 2000, GLYCOCONJUGATE J, V17, P485, DOI 10.1023/A:1011062223612; Sewell R, 2006, J BIOL CHEM, V281, P3586, DOI 10.1074/jbc.M511826200; Su H., 2009, MOL CELL BIOCHEM, V331, P81, DOI DOI 10.1007/s11010-009-0147-9; Tang W, 2004, MOL BIOL CELL, V15, P4043, DOI 10.1091/mbc.E04-05-0402; Tazzari PL, 2007, LEUKEMIA, V21, P427, DOI 10.1038/sj.leu.2404523; Van Der Kolk DM, 2002, LEUKEMIA LYMPHOMA, V43, P685, DOI 10.1080/10428190290016773; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Varki NM, 2007, LAB INVEST, V87, P851, DOI 10.1038/labinvest.3700656; Wang XQ, 2003, J BIOL CHEM, V278, P48770, DOI 10.1074/jbc.M308818200; Yamada K, 2012, ANAL BIOCHEM, V421, P595, DOI 10.1016/j.ab.2011.12.017; Yu SC, 2011, MEDCHEMCOMM, V2, P524, DOI 10.1039/c1md00033k; Zhang ZH, 2012, INT J BIOCHEM CELL B, V44, P1244, DOI 10.1016/j.biocel.2012.04.026; Zhou H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.186; Zhu YT, 2001, BBA-MOL BASIS DIS, V1536, P148, DOI 10.1016/S0925-4439(01)00044-8	42	43	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					726	740		10.1038/onc.2014.7	http://dx.doi.org/10.1038/onc.2014.7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24531716	Green Submitted			2022-12-28	WOS:000348853800006
J	Yin, B; Ma, ZY; Zhou, ZW; Gao, WC; Du, ZG; Zhao, ZH; Li, QQ				Yin, B.; Ma, Z. Y.; Zhou, Z. W.; Gao, W. C.; Du, Z. G.; Zhao, Z. H.; Li, Q. Q.			The TrkB plus cancer stem cells contribute to post-chemotherapy recurrence of triple-negative breast cancers in an orthotopic mouse model	ONCOGENE			English	Article						cancer stem cells; brain-derived neurotrophic factor; TrkB; self-renewal; TNBC recurrence	EPITHELIAL-MESENCHYMAL TRANSITION; NEUROTROPHIC FACTOR; GENE-EXPRESSION; PROGRESSION; TARGETS; GROWTH	Cancer stem cells (CSCs) are believed to have a crucial role in triple-negative breast cancer (TNBC) recurrence. However, the exact mechanisms that are functionally critical in CSCs-mediated recurrence remain unclear. Here, we showed that CSCs derived from recurrent TNBCs are endowed with increased self-renewal capacity as compared with those from the matched primary lesions. Using patient-derived specimens, we demonstrated the existence of paracrine brain-derived neurotrophic factor (BDNF) signaling between differentiated recurrent TNBC cells and CSCs characterized by the expression of TrkB, the receptor of BDNF. We showed that paclitaxel induced BDNF expression and apoptosis simultaneously in a cell cycle-dependent manner. BDNF promotes the self-renewal potential of the TrkB + CSCs through induction of KLF4. The TrkB + CSCs represent a particular subset indispensable for TNBC relapse. In line with this, TrkB is proved to be a superior predictor for TNBC recurrence. Using a genetically engineered mouse model of TNBC, we observed that ablation of the TrkB + CSCs potentially prevents relapse of malignant tumors. Further preclinical investigation of this promising approach may lead to development of a novel therapeutic strategy to improve the devastating prognosis of TNBC patients.	[Yin, B.] Fudan Univ, HuaShan Hosp, Dept Radiol, Shanghai 200433, Peoples R China; [Ma, Z. Y.] Fudan Univ, HuaShan Hosp, Dept Gen Surg, Shanghai 200040, Peoples R China; [Zhou, Z. W.; Du, Z. G.] Fudan Univ, HuaShan Hosp, Dept Pathol, Shanghai 200040, Peoples R China; [Gao, W. C.] Second Mil Med Univ, ChangZheng Hosp, Dept Gen Surg, Shanghai, Peoples R China; [Zhao, Z. H.; Li, Q. Q.] Fudan Univ, Shanghai Med Coll, Dept Pathol, Shanghai 200040, Peoples R China	Fudan University; Fudan University; Fudan University; Naval Medical University; Fudan University	Li, QQ (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Pathol, Shanghai 200040, Peoples R China.	061101040@fudan.edu.cn			National Nature Science Foundation of China [81000957]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was generously supported by grants from the National Nature Science Foundation of China (81000957).	Aid T, 2007, J NEUROSCI RES, V85, P525, DOI 10.1002/jnr.21139; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alfonso J, 2006, BIOL PSYCHIAT, V59, P244, DOI 10.1016/j.biopsych.2005.06.036; Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Fernando RI, 2011, CANCER RES, V71, P5296, DOI 10.1158/0008-5472.CAN-11-0156; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Lorico A, 2011, J ONCOL, V2011, DOI 10.1155/2011/135039; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; McDermott SP, 2010, MOL ONCOL, V4, P404, DOI 10.1016/j.molonc.2010.06.005; Merchant AA, 2010, CLIN CANCER RES, V16, P3130, DOI 10.1158/1078-0432.CCR-09-2846; Millar HJ, 2008, CANCER EPIDEM BIOMAR, V17, P2180, DOI 10.1158/1055-9965.EPI-07-2915; Nair A, 2007, NEUROPSYCHOPHARMACOL, V32, P1504, DOI 10.1038/sj.npp.1301276; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Sneddon JB, 2007, CELL STEM CELL, V1, P607, DOI 10.1016/j.stem.2007.11.009; Tang DG, 2012, CELL RES, V22, P457, DOI 10.1038/cr.2012.13; Thijssen VL, 2010, CANCER RES, V70, P6216, DOI 10.1158/0008-5472.CAN-09-4150; Uemura Y, 2006, INT J MOL MED, V18, P365; Vanhecke E, 2011, CLIN CANCER RES, V17, P1741, DOI 10.1158/1078-0432.CCR-10-1890; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wang ZW, 2010, CURR PROTEIN PEPT SC, V11, P398, DOI 10.2174/138920310791824039; Yang XM, 2012, INT J ONCOL, V41, P1541, DOI 10.3892/ijo.2012.1581; Yang ZJ, 2007, CANCER CELL, V11, P3, DOI 10.1016/j.ccr.2006.12.007	32	36	35	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					761	770		10.1038/onc.2014.8	http://dx.doi.org/10.1038/onc.2014.8			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24531713				2022-12-28	WOS:000348853800009
J	Smith, JR; de Billy, E; Hobbs, S; Powers, M; Prodromou, C; Pearl, L; Clarke, PA; Worknnan, P				Smith, J. R.; de Billy, E.; Hobbs, S.; Powers, M.; Prodromou, C.; Pearl, L.; Clarke, P. A.; Worknnan, P.			Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins	ONCOGENE			English	Article						CDC37; HSP90; client; kinase; chaperone	MOLECULAR CHAPERONE; CO-CHAPERONE; CYCLIN D1; PHOSPHORYLATION; P50(CDC37); COMPLEX; DEGRADATION; INHIBITORS; STABILITY; ONCOGENE	The HSP90 molecular chaperone plays a key role in the maturation, stability and activation of its clients, including many oncogenic proteins. Kinases are a substantial and important subset of clients requiring the key cochaperone CDC37. We sought an improved understanding of protein kinase chaperoning by CDC37 in cancer cells. CDC37 overexpression in human colon cancer cells increased CDK4 protein levels, which was negated upon CDC37 knockdown. Overexpressing CDC37 increased CDK4 protein half-life and enhanced binding of HSP90 to CDK4, consistent with CDC37 promoting kinase loading onto chaperone complexes. Against expectation, expression of C-terminus-truncated CDC37 (Delta C-CDC37) that lacks HSP90 binding capacity did not affect kinase client expression or activity; moreover, as with wild-type CDC37 overexpression, it augmented CDK4-HSP90 complex formation. However, although truncation blocked binding to HSP90 in cells, Delta C-CDC37 also showed diminished client protein binding and was relatively unstable. CDC37 mutants with single and double point mutations at residues M164 and L205 showed greatly reduced binding to HSP90, but retained association with client kinases. Surprisingly, these mutants phenocopied wild-type CDC37 overexpression by increasing CDK4-HSP90 association and CDK4 protein levels in cells. Furthermore, expression of the mutants was sufficient to protect kinase clients CDK4, CDK6, CRAF and ERBB2 from depletion induced by silencing endogenous CDC37, indicating that CDC37's client stabilising function cannot be inactivated by substantially reducing its direct interaction with HSP90. However, CDC37 could not compensate for loss of HSP90 function, showing that CDC37 and HSP90 have their own distinct and non-redundant roles in maintaining kinase clients. Our data substantiate the important function of CDC37 in chaperoning protein kinases. Furthermore, we demonstrate that CDC37 can stabilise kinase clients by a mechanism that is not dependent on a substantial direct interaction between CDC37 and HSP90, but nevertheless requires HSP90 activity. These results have significant implications for therapeutic targeting of CDC37.	[Smith, J. R.; de Billy, E.; Hobbs, S.; Powers, M.; Clarke, P. A.; Worknnan, P.] Haddow Labs, Inst Canc Res, Div Canc Therapeut, Canc Res UK Canc Therapeut Unit, Surrey SM2 5NG, England; [Prodromou, C.; Pearl, L.] Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, London SW3 6JB, England	Cancer Research UK; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Clarke, PA (corresponding author), Haddow Labs, Canc Res UK Ctr Canc Therapeut, Inst Canc Res, Div Canc Therapeut, 15 Cotswold Rd, Surrey SM2 5NG, England.	paul.clarke@icr.ac.uk; paul.workman@icr.ac.uk	Prodromou, Chrisostomos/ABA-9133-2021; de billy, emmanuel/AAA-6095-2020	Prodromou, Chrisostomos/0000-0003-4320-1147; de Crespin de Billy, emmanuel/0000-0002-3610-7083; Clarke, Paul/0000-0001-9342-1290; Pearl, Laurence/0000-0002-6910-1809	Cancer Research UK Programme [C3091A8274, C309/A11566]; Cancer Research UK [11566] Funding Source: researchfish	Cancer Research UK Programme(Cancer Research UK); Cancer Research UK(Cancer Research UK)	We thank our colleagues in the Signal Transduction and Molecular Pharmacology Team and Chaperone Project Team for helpful discussions and Craig McAndrew for valuable assistance with gel filtration. The authors' work is supported by Cancer Research UK Programme grant number C3091A8274 and C309/A11566. PW is a Cancer Research UK Life Fellow.	Arlander SJH, 2006, J BIOL CHEM, V281, P2989, DOI 10.1074/jbc.M508687200; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Dias SD, 2005, CANCER RES, V65, P10686, DOI 10.1158/0008-5472.CAN-05-2632; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Farrell A, 2000, MOL CELL BIOL, V20, P749, DOI 10.1128/MCB.20.3.749-754.2000; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; Ghatak S, 2005, J BIOL CHEM, V280, P8875, DOI 10.1074/jbc.M410882200; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Gray J, 2007, DANCING TIMES, V97, P67; Gray PJ, 2008, NAT REV CANCER, V8, P491, DOI 10.1038/nrc2420; Grbovic OM, 2006, P NATL ACAD SCI USA, V103, P57, DOI 10.1073/pnas.0609973103; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; Jiang YQ, 2010, J BIOL CHEM, V285, P21023, DOI 10.1074/jbc.M110.103390; Karnitz LM, 2007, SCI STKE, V2007, pe22; Katayama Y, 2004, INT J ONCOL, V25, P579; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; Lavictoire SJ, 2003, J BIOL CHEM, V278, P5292, DOI 10.1074/jbc.M209494200; Lee P, 2002, J CELL BIOL, V159, P1051, DOI 10.1083/jcb.200210121; MacLean M, 2003, CELL STRESS CHAPERON, V8, P114, DOI 10.1379/1466-1268(2003)008<0114:CGBHAK>2.0.CO;2; Mandal AK, 2007, J CELL BIOL, V176, P319, DOI 10.1083/jcb.200604106; Marino-Enriiquez A, 2014, ONCOGENE, V33, P1872, DOI 10.1038/onc.2013.127; Miyata Y, 2004, ANN NY ACAD SCI, V1030, P150, DOI 10.1196/annals.1329.019; Pascale RM, 2005, HEPATOLOGY, V42, P1310, DOI 10.1002/hep.20962; Pearl LH, 2008, BIOCHEM J, V410, P439, DOI 10.1042/BJ20071640; Pearl LH, 2005, CURR OPIN GENET DEV, V15, P55, DOI 10.1016/j.gde.2004.12.011; Polier S, 2013, NAT CHEM BIOL, V9, P307, DOI [10.1038/NCHEMBIO.1212, 10.1038/nchembio.1212]; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Rao J, 2001, J BIOL CHEM, V276, P5814, DOI 10.1074/jbc.M007385200; Roe SM, 2004, CELL, V116, P87, DOI 10.1016/S0092-8674(03)01027-4; Salminen A, 2010, BIOCHEM BIOPH RES CO, V394, P439, DOI 10.1016/j.bbrc.2010.03.050; Scholz G, 2000, MOL CELL BIOL, V20, P6984, DOI 10.1128/MCB.20.18.6984-6995.2000; Schwarze SR, 2003, CANCER RES, V63, P4614; Shao JY, 2003, BIOCHEMISTRY-US, V42, P12577, DOI 10.1021/bi035138j; Shao JY, 2003, J BIOL CHEM, V278, P38117, DOI 10.1074/jbc.C300330200; Siligardi G, 2002, J BIOL CHEM, V277, P20151, DOI 10.1074/jbc.M201287200; Smith JR, 2009, ONCOGENE, V28, P157, DOI 10.1038/onc.2008.380; Smith JR, 2009, CELL CYCLE, V8, P362, DOI 10.4161/cc.8.3.7531; Sreeramulu S, 2009, J BIOL CHEM, V284, P3885, DOI 10.1074/jbc.M806715200; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Stepanova L, 2000, ONCOGENE, V19, P2186, DOI 10.1038/sj.onc.1203561; Stepanova L, 2000, MOL CELL BIOL, V20, P4462, DOI 10.1128/MCB.20.12.4462-4473.2000; Taipale M, 2012, CELL, V150, P987, DOI 10.1016/j.cell.2012.06.047; Taipale M, 2010, NAT REV MOL CELL BIO, V11, P515, DOI 10.1038/nrm2918; Terasawa K, 2005, FEBS J, V272, P4684, DOI 10.1111/j.1742-4658.2005.04884.x; Turnbull EL, 2005, FEBS J, V272, P4129, DOI 10.1111/j.1742-4658.2005.04825.x; Vaughan CK, 2008, MOL CELL, V31, P886, DOI 10.1016/j.molcel.2008.07.021; Vaughan CK, 2006, MOL CELL, V23, P697, DOI 10.1016/j.molcel.2006.07.016; Yu YK, 2010, BIOCHEM PHARMACOL, V79, P542, DOI 10.1016/j.bcp.2009.09.017; Zhang T, 2009, J BIOL CHEM, V284, P35381, DOI 10.1074/jbc.M109.051532; Zhang W, 2004, J MOL BIOL, V340, P891, DOI 10.1016/j.jmb.2004.05.007	50	32	32	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					15	26		10.1038/onc.2013.519	http://dx.doi.org/10.1038/onc.2013.519			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24292678	Green Accepted			2022-12-28	WOS:000349740100002
J	Newbold, A; Salmon, JM; Martin, BP; Stanley, K; Johnstone, RW				Newbold, A.; Salmon, J. M.; Martin, B. P.; Stanley, K.; Johnstone, R. W.			The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the E mu-myc model of B-cell lymphoma	ONCOGENE			English	Article						histone deacetylase inhibitors; CDKN1A; tumor-suppressor protein; cell cycle arrest	HISTONE-DEACETYLASE INHIBITORS; THERAPEUTIC ACTIVITIES; CANCER CELLS; APOPTOSIS; GROWTH; GENE; DIFFERENTIATION; P21(CIP1/WAF1); VORINOSTAT; BUTYRATE	Following the establishment of histone deacetylases (HDACs) as promising therapeutic targets for the reversal of aberrant epigenetic states associated with cancer, the development of HDAC inhibitors (HDACi) and their underlying mechanisms of action has been a significant area of scientific interest. HDACi induce diverse biological responses including the inhibition of cell proliferation by blocking progression through the G1 or G2/M phases of the cell cycle. As a putative tumor-suppressor protein, p21(waf1)/(cip1) influences cell proliferation by inhibiting the activity of cyclin-cyclin-dependent kinase (CDK) complexes at the G1/S and G2/M cell cycle checkpoints. HDACi transcriptionally activate CDKN1A, and it has been proposed that induction of p21waf1/cip1 can determine if a cell undergoes apoptosis or cell cycle arrest following HDACi treatment. In the E mu-myc transgenic mouse model of B-cell lymphoma, knockout of cdkn1a had no effect on disease latency, indicating that p21waf1/cip1 did not function as a tumor suppressor in this system. Although HDACi robustly induced expression of p21waf1/cip1 in wild-type Em-myc lymphomas, deletion of cdkn1a did not sensitize the lymphoma cells to HDACi-induced apoptosis and HDACi-induced cell cycle arrest still occurred. However, knockdown of cdkn1b in cdkn1a knockout lymphomas resulted in defective vorinostat-mediated arrest at G1/S indicating an essential role of p27(Kip1) in mediating this biological response to vorinostat. These data demonstrate that induction of cdkn1a does not regulate HDACi-mediated tumor cell apoptosis and refute the notion that p21(waf1)/(cip1) is an obligate mediator of HDACi-induced cell cycle arrest.	[Newbold, A.; Salmon, J. M.; Martin, B. P.; Stanley, K.; Johnstone, R. W.] Peter MacCallum Canc Ctr, Gene Regulat Lab, Canc Therapeut Program, East Melbourne, Vic 3002, Australia; [Johnstone, R. W.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3052, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne	Johnstone, RW (corresponding author), Peter MacCallum Canc Ctr, Gene Regulat Lab, Canc Therapeut Program, St Andrews Pl, East Melbourne, Vic 3002, Australia.	ricky.johnstone@petermac.org	Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237	NHMRC Program; Cancer Council Victoria; Leukemia Foundation of Australia; Victorian Cancer Agency; Victorian Breast Cancer Research Consortium	NHMRC Program(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Leukemia Foundation of Australia; Victorian Cancer Agency; Victorian Breast Cancer Research Consortium	RWJ is a Principal Research Fellow of the National Health and Medical Research Council of Australia (NHMRC) and supported by NHMRC Program and Project Grants, the Cancer Council Victoria, The Leukemia Foundation of Australia, the Victorian Cancer Agency and Victorian Breast Cancer Research Consortium.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Burgess AJ, 2001, MOL PHARMACOL, V60, P828; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Ellis L, 2009, BLOOD, V114, P380, DOI 10.1182/blood-2008-10-182758; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Hitomi T, 2003, FEBS LETT, V554, P347, DOI 10.1016/S0014-5793(03)01186-4; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kramer OH, 2008, ONCOGENE, V27, P732, DOI 10.1038/sj.onc.1210677; Lindemann RK, 2007, P NATL ACAD SCI USA, V104, P8071, DOI 10.1073/pnas.0702294104; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Newbold A, 2013, MOL CANC TH IN PRESS; Newbold A, 2008, MOL CANCER THER, V7, P1066, DOI 10.1158/1535-7163.MCT-07-2256; Ocker M, 2007, INT J BIOCHEM CELL B, V39, P1367, DOI 10.1016/j.biocel.2007.03.001; Peart MJ, 2003, CANCER RES, V63, P4460; Pitts TM, 2009, MOL CANCER THER, V8, P342, DOI 10.1158/1535-7163.MCT-08-0534; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Rosato RR, 2004, MOL PHARMACOL, V65, P571, DOI 10.1124/mol.65.3.571; Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598; Svechnikova I, 2007, BIOCHEM BIOPH RES CO, V354, P466, DOI 10.1016/j.bbrc.2006.12.222; Uehara N, 2012, ONCOL REP, V28, P105, DOI 10.3892/or.2012.1758	27	39	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2014	33	47					5415	5423		10.1038/onc.2013.482	http://dx.doi.org/10.1038/onc.2013.482			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MG	24292681				2022-12-28	WOS:000345120700003
J	Cioce, M; Ganci, F; Canu, V; Sacconi, A; Mori, F; Canino, C; Korita, E; Casini, B; Alessandrini, G; Cambria, A; Carosi, MA; Blandino, R; Panebianco, V; Facciolo, F; Visca, P; Volinia, S; Muti, P; Strano, S; Croce, CM; Pass, HI; Blandino, G				Cioce, M.; Ganci, F.; Canu, V.; Sacconi, A.; Mori, F.; Canino, C.; Korita, E.; Casini, B.; Alessandrini, G.; Cambria, A.; Carosi, M. A.; Blandino, R.; Panebianco, V.; Facciolo, F.; Visca, P.; Volinia, S.; Muti, P.; Strano, S.; Croce, C. M.; Pass, H. I.; Blandino, G.			Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma	ONCOGENE			English	Article						mesothelioma; OCT4; mir-145; mesothelial cysts; chemoresistance; senescence	EPITHELIAL-MESENCHYMAL TRANSITION; CANCER STEM-CELLS; HETEROCHROMATIN FORMATION; INHIBITS PROLIFERATION; ADENOCARCINOMA CELLS; PLURIPOTENCY FACTORS; LUNG ADENOCARCINOMA; CELLULAR SENESCENCE; GLIOMA-CELLS; OCT4	We identified a discrete number of microRNAs differentially expressed in benign or malignant mesothelial tissues. We focused on mir-145 whose levels were significantly downregulated in malignant mesothelial tissues and malignant pleural mesothelioma (MPM) cell lines as compared to benign tissues (pleura, peritoneum or cysts). We show that promoter hyper-methylation caused very low levels in MPM cell lines and specimens. Treatment of MPM cell lines with mir-145 agonists negatively modulated some protumorigenic properties of MPM cells, such as clonogenicity, cell migration and resistance to pemetrexed treatment. The main effector mechanism of the clonogenic death induced by mir-145 was that of accelerated senescence. We found that mir-145 targeted OCT4 via specific binding to its 30-UTR. Increased intracellular levels of mir-145 decreased the levels of OCT4 and its target gene ZEB1, thereby counteracting the increase of OCT4 induced by pemetrexed treatment which is known to favor the development of chemoresistant cells. In line with this, reintroduction of OCT4 into mimic-145 treated cells counteracted the effects on clonogenicity and replicative senescence. This further supports the relevance of the mir-145-OCT4 interaction for the survival of MPM cells. The potential use of mir-145 expression levels to classify benign vs malignant mesothelial tissues and the differences between pemetrexed-induced senescence and that induced by the re-expression of mir-145 are discussed.	[Cioce, M.; Canino, C.; Pass, H. I.] NYU, Dept Cardiothorac Surg, Langone Med Ctr, New York, NY USA; [Ganci, F.; Canu, V.; Sacconi, A.; Korita, E.; Blandino, G.] Italian Natl Canc Inst Regina Elena, Translat Oncogen Unit, Rome, Italy; [Mori, F.; Strano, S.] Italian Natl Canc Inst Regina Elena, Mol Chemoprevent Grp, Rome, Italy; [Casini, B.; Carosi, M. A.; Visca, P.] Italian Natl Canc Inst, Dept Pathol, Rome, Italy; [Alessandrini, G.; Facciolo, F.] Regina Elena Inst Canc Res, Unit Thorac Surg, Rome, Italy; [Cambria, A.; Blandino, R.; Panebianco, V.] San Vincenzo Hosp, Dept Surg Oncol, Taormina, Italy; [Volinia, S.; Croce, C. M.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Volinia, S.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Muti, P.] McMaster Univ, Dept Oncol, Hamilton, ON, Canada	New York University; NYU Langone Medical Center; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; McMaster University	Blandino, G (corresponding author), Regina Elena Inst Canc Res, Translat Oncogen Unit, Via Elio Chianesi 53, I-00144 Rome, Italy.	blandino@ifo.it	Volinia, Stefano/A-3029-2010; Strano, Sabrina/K-9654-2016; Cioce, Mario/R-9734-2017; Canu, Valeria/K-9333-2016; Volinia, Stefano/AAA-9264-2019; Young, Richard A/F-6495-2012; sacconi, andrea/J-3669-2018; Visca, Paolo/J-9547-2018; Ganci, Federica/K-9857-2016; Muti, Paola/AAD-9108-2020	Volinia, Stefano/0000-0003-0910-3893; Cioce, Mario/0000-0001-8129-6664; Canu, Valeria/0000-0001-9085-7320; Volinia, Stefano/0000-0003-0910-3893; Young, Richard A/0000-0001-8855-8647; sacconi, andrea/0000-0002-8276-0438; Visca, Paolo/0000-0001-8484-6991; Ganci, Federica/0000-0002-8010-2183; Alessandrini, Gabriele/0000-0002-4380-7627; Facciolo, Francesco/0000-0002-7137-8946; CASINI, BEATRICE/0000-0002-9038-0179; strano, sabrina/0000-0002-6341-4230; Pass, Harvey/0000-0003-3222-3471	INAIL (Italian Workers' Compensation Authority); NATIONAL CANCER INSTITUTE [U01CA152758, P30CA016087] Funding Source: NIH RePORTER	INAIL (Italian Workers' Compensation Authority); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge INAIL (Italian Workers' Compensation Authority) for grant support (to GB).	Adammek M, 2013, FERTIL STERIL, V99, P1346, DOI 10.1016/j.fertnstert.2012.11.055; Basu D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052188; Beltran AS, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3019; Bonifacio LN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012519; Cahu J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.183; Calin GA, 2006, LEUKEMIA RES, V30, P653, DOI 10.1016/j.leukres.2005.10.017; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Canino C, 2012, ONCOGENE, V31, P3148, DOI 10.1038/onc.2011.485; Carbone M, 2012, J CELL PHYSIOL, V227, P44, DOI 10.1002/jcp.22724; Casarsa C, 2011, CANCER LETT, V302, P136, DOI 10.1016/j.canlet.2011.01.009; Ceppi P, 2014, ONCOGENE, V33, P269, DOI 10.1038/onc.2013.55; Chen Z, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-151; Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638; Dai XZ, 2013, ONCOL REP, V29, P155, DOI 10.3892/or.2012.2086; Deng S, 2008, CELL CYCLE, V7, P2643, DOI 10.4161/cc.7.17.6597; Du ZH, 2009, GLIA, V57, P724, DOI 10.1002/glia.20800; Freund A, 2012, MOL BIOL CELL, V23, P2066, DOI 10.1091/mbc.E11-10-0884; Granville L, 2005, ARCH PATHOL LAB MED, V129, P1428; Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Hazarika M, 2005, CLIN CANCER RES, V11, P982; Jean D, 2012, ARCH PATHOL LAB MED, V136, P277, DOI 10.5858/arpa.2011-0215-RA; Ji XH, 2008, CURR TOP MICROBIOL, V320, P99; Kai K, 2010, LUNG CANCER, V70, P146, DOI 10.1016/j.lungcan.2010.04.020; Kashyap V, 2009, STEM CELLS DEV, V18, P1093, DOI 10.1089/scd.2009.0113; Kaufman AJ, 2008, EXPERT REV ANTICANC, V8, P293, DOI 10.1586/14737140.8.2.293; Klinge CM, 2011, MOL CANCER THER, V10, P2062, DOI 10.1158/1535-7163.MCT-11-0381; Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656; Kurashige J, 2012, ANN SURG ONCOL, V19, pS656, DOI 10.1245/s10434-012-2217-6; Lee HK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054652; Linn Douglas E, 2010, Genes Cancer, V1, P908, DOI 10.1177/1947601910388271; Lu Y, 2013, ONCOL REP, V29, P67, DOI 10.3892/or.2012.2084; Mujoomdar AA, 2010, J THORAC CARDIOV SUR, V140, P352, DOI 10.1016/j.jtcvs.2009.11.072; Nakanishi H, 2014, ONCOGENE, V33, P702, DOI 10.1038/onc.2013.13; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052; Pass HI, 2010, CANCER RES, V70, P1916, DOI 10.1158/0008-5472.CAN-09-3993; Peng S, 2010, ONCOGENE, V29, P2153, DOI 10.1038/onc.2009.500; Pignot G, 2013, INT J CANCER, V132, P2479, DOI 10.1002/ijc.27949; Rodier Francis, 2013, Methods Mol Biol, V965, P165, DOI 10.1007/978-1-62703-239-1_10; Romanov VS, 2012, BIOCHEMISTRY-MOSCOW+, V77, P575, DOI 10.1134/S000629791206003X; Rudd RM, 2010, BRIT MED BULL, V93, P105, DOI 10.1093/bmb/ldp047; Samardzija C, 2012, J OVARIAN RES, V5, DOI 10.1186/1757-2215-5-37; Schaefer A, 2010, INT J CANCER, V126, P1166, DOI 10.1002/ijc.24827; Schramm A, 2010, EUR J CARDIO-THORAC, V37, P566, DOI 10.1016/j.ejcts.2009.08.027; Speranza MC, 2012, ONCOTARGET, V3, P724; Tang GL, 2008, BBA-GENE REGUL MECH, V1779, P655, DOI 10.1016/j.bbagrm.2008.06.006; Tsai LL, 2011, J ORAL PATHOL MED, V40, P621, DOI 10.1111/j.1600-0714.2011.01015.x; Wajapeyee Narendra, 2013, Methods Mol Biol, V965, P373, DOI 10.1007/978-1-62703-239-1_25; Wang SH, 2009, INT J ONCOL, V34, P1461, DOI 10.3892/ijo_00000275; Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012; Weinberg WC, 2002, CRIT REV ORAL BIOL M, V13, P453, DOI 10.1177/154411130201300603; Wu YJ, 2011, CANCER-AM CANCER SOC, V117, P3989, DOI 10.1002/cncr.25944; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Zhang J, 2013, ONCOGENE, V32, P61, DOI 10.1038/onc.2012.28; Zhang JJ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-211	57	50	55	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2014	33	46					5319	5331		10.1038/onc.2013.476	http://dx.doi.org/10.1038/onc.2013.476			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MF	24240684	Green Accepted, Green Submitted			2022-12-28	WOS:000345120600002
J	El-Gazzar, A; Cai, X; Reeves, RS; Dai, Z; Caballero-Benitez, A; McDonald, DL; Vazquez, J; Gooley, TA; Sale, GE; Spies, T; Groh, V				El-Gazzar, A.; Cai, X.; Reeves, R. S.; Dai, Z.; Caballero-Benitez, A.; McDonald, D. L.; Vazquez, J.; Gooley, T. A.; Sale, G. E.; Spies, T.; Groh, V.			Effects on tumor development and metastatic dissemination by the NKG2D lymphocyte receptor expressed on cancer cells	ONCOGENE			English	Article						NKG2D receptor; breast cancer; xenotransplant; angiogenesis; metastasis	NK CELLS; T-CELLS; ACTIVATION; LIGANDS; INHIBITION; APOPTOSIS; GROWTH; MICA	The stimulatory NKG2D lymphocyte receptor together with its tumor-associated ligands enable the immune system to recognize and destroy cancer cells. However, with dynamic changes unfolding, cancers exploit NKG2D and its ligands for immune evasion and suppression. Recent findings have added yet another functional dimension, wherein cancer cells themselves co-opt NKG2D for their own benefit to complement the presence of its ligands for self-stimulation of parameters of tumorigenesis. Those findings are here extended to in vivo tumorigenicity testing by employing orthotopic xenotransplant breast cancer models in mice. Using human cancer lines with ectopic NKG2D expression and RNA interference (RNAi)-mediated protein depletion among other controls, we show that NKG2D self-stimulation has tumor-promoting capacity. NKG2D signals had no notable effects on cancer cell proliferation and survival but acted at the level of angiogenesis, thus promoting tumor growth, tumor cell intravasation and dissemination. NKG2D-mediated effects on tumor initiation may represent another factor in the observed overall enhancement of tumor development. Altogether, these results may have an impact on immunotherapy approaches, which currently do not account for such NKG2D effects in cancer patients and thus could be misdirected as underlying assumptions are incomplete.	[El-Gazzar, A.; Cai, X.; Reeves, R. S.; Dai, Z.; Caballero-Benitez, A.; McDonald, D. L.; Vazquez, J.; Gooley, T. A.; Sale, G. E.; Spies, T.; Groh, V.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98112 USA	Fred Hutchinson Cancer Center	Spies, T (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave North, Seattle, WA 98112 USA.	tspies@fhcrc.org		El-Gazzar, Ahmed/0000-0002-2859-7246	Erwin Schrodinger Fellowship from the Austrian Science Fund (FWF) [J3078]; NIH/NCI Pacific Ovarian Cancer Research Consortium (POCRC) SPORE [P50 CA083636]; NIH/NCI [R01 CA174470]; NATIONAL CANCER INSTITUTE [P50CA083636, R01CA174470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056465] Funding Source: NIH RePORTER	Erwin Schrodinger Fellowship from the Austrian Science Fund (FWF); NIH/NCI Pacific Ovarian Cancer Research Consortium (POCRC) SPORE; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Drs Steven Kelly and Sue Knoblaugh and all members of the Comparative Medicine Shared Resource laboratory for their expert veterinarian, pathology and histopathology support; Drs Julie Randolph-Habecker and Peggy Porter for their expert immunohistochemistry and histopathology advice, and all members of the Experimental Histopathology Shared Resource laboratory for their outstanding technical support. AE-G was supported by an Erwin Schrodinger Fellowship from the Austrian Science Fund (FWF; project number J3078). This study was supported by an NIH/NCI Pacific Ovarian Cancer Research Consortium (POCRC) SPORE (P50 CA083636) developmental research program grant (to VG) and NIH/NCI grant R01 CA174470 (to TS).	Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Ben-Batalla I, 2010, J CLIN INVEST, V120, P4289, DOI 10.1172/JCI42015; Benitez AC, 2011, P NATL ACAD SCI USA, V108, P4081, DOI 10.1073/pnas.1018603108; Cho HM, 2010, CANCER RES, V70, P10121, DOI 10.1158/0008-5472.CAN-10-1047; Eagle RA, 2007, NAT REV IMMUNOL, V7, P737, DOI 10.1038/nri2144; Gonzalez S, 2006, CURR TOP MICROBIOL, V298, P121; Groh V, 1999, P NATL ACAD SCI USA, V96, P6879, DOI 10.1073/pnas.96.12.6879; Jiang BH, 2009, ADV CANCER RES, V102, P19, DOI 10.1016/S0065-230X(09)02002-8; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kooijman R, 2006, CYTOKINE GROWTH F R, V17, P305, DOI 10.1016/j.cytogfr.2006.02.002; Lanier LL, 2008, NAT IMMUNOL, V9, P495, DOI 10.1038/ni1581; Lehner M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031210; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Nausch N, 2008, ONCOGENE, V27, P5944, DOI 10.1038/onc.2008.272; NOEL A, 1992, BIOCHEM PHARMACOL, V43, P1263, DOI 10.1016/0006-2952(92)90501-9; Raulet DH, 2013, ANNU REV IMMUNOL, V31, P413, DOI 10.1146/annurev-immunol-032712-095951; Song DG, 2013, HUM GENE THER, V24, P295, DOI 10.1089/hum.2012.143; Upshaw JL, 2006, SEMIN IMMUNOL, V18, P167, DOI 10.1016/j.smim.2006.03.001; von Strandmann EP, 2006, BLOOD, V107, P1955, DOI 10.1182/blood-2005-05-2177; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106; Zhang T, 2011, CANCER RES, V71, P2066, DOI 10.1158/0008-5472.CAN-10-3200	21	10	12	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2014	33	41					4932	4940		10.1038/onc.2013.435	http://dx.doi.org/10.1038/onc.2013.435			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OA	24141776	Green Accepted			2022-12-28	WOS:000343767900006
J	Wilson, CH; Gamper, I; Perfetto, A; Auw, J; Littlewood, TD; Evan, GI				Wilson, C. H.; Gamper, I.; Perfetto, A.; Auw, J.; Littlewood, T. D.; Evan, G. I.			The kinetics of ER fusion protein activation in vivo	ONCOGENE			English	Article							RECOMBINATION; TAMOXIFEN; MOUSE; TISSUES; VITRO; CELLS; MICE; CRE; MYC	Reversibly switchable proteins are powerful tools with which to explore protein function in vitro and in vivo. For example, the activity of many proteins fused to the hormone-binding domain of the modified oestrogen receptor (ERTAM) can be regulated by provision or removal of 4-hydroxytamoxifen (4-OHT). Despite the widespread use of ERTAM fusions in vivo, inadequate data are available as to the most efficacious routes for systemic tamoxifen delivery. In this study, we have used two well-characterized ERTAM fusion proteins, both reversibly activated by 4-OHT, to compare the effectiveness and kinetics of 4-OHT delivery in mice in vivo by either tamoxifen in food or by intraperitoneal injection. Our data indicate that dietary tamoxifen offers an effective, facile and ethically preferable means for long-term activation of ERTAM fusion proteins in vivo.	[Wilson, C. H.; Gamper, I.; Perfetto, A.; Auw, J.; Littlewood, T. D.; Evan, G. I.] Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	University of Cambridge	Evan, GI (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	gie20@cam.ac.uk		Wilson, Catherine/0000-0002-5333-0295	CRUK [A12077]; ERC [294851]; Cancer Research UK [12077, 13061] Funding Source: researchfish	CRUK(Cancer Research UK); ERC(European Research Council (ERC)European Commission); Cancer Research UK(Cancer Research UK)	We thank Debbie Burkhart for her advice with experimental procedures and the support staff within the biomedical facility of the Gurdon Institute. We thank Cyprotex Discovery Limited for LC/MS analysis. This work is supported by CRUK (Programme Grant A12077) and the ERC (Advanced Investigator Award 294851).	Christophorou MA, 2005, NAT GENET, V37, P718, DOI 10.1038/ng1572; Desta Z, 2004, J PHARMACOL EXP THER, V310, P1062, DOI 10.1124/jpet.104.065607; Ellisor D, 2010, MOL CELL NEUROSCI, V45, P132, DOI 10.1016/j.mcn.2010.06.004; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; Hameyer D, 2007, PHYSIOL GENOMICS, V31, P32, DOI 10.1152/physiolgenomics.00019.2007; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; ROBINSON SP, 1991, DRUG METAB DISPOS, V19, P36; Zhang Y, 1996, NUCLEIC ACIDS RES, V24, P543, DOI 10.1093/nar/24.4.543	11	21	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2014	33	40					4877	4880		10.1038/onc.2014.78	http://dx.doi.org/10.1038/onc.2014.78			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0EH	24662815	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000343240100009
J	Santini, R; Pietrobono, S; Pandolfi, S; Montagnani, V; D'Amico, M; Penachioni, JY; Vinci, MC; Borgognoni, L; Stecca, B				Santini, R.; Pietrobono, S.; Pandolfi, S.; Montagnani, V.; D'Amico, M.; Penachioni, J. Y.; Vinci, M. C.; Borgognoni, L.; Stecca, B.			SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells	ONCOGENE			English	Article							TRANSCRIPTION FACTOR SOX2; NEURAL STEM-CELL; SONIC HEDGEHOG; IN-VITRO; PROGENITOR; EXPRESSION; PROLIFERATION; SURVIVAL; LUNG; GLI1	Melanoma is one of the most aggressive types of human cancer, characterized by enhanced heterogeneity and resistance to conventional therapy at advanced stages. We and others have previously shown that HEDGEHOG-GLI (HH-GLI) signaling is required for melanoma growth and for survival and expansion of melanoma-initiating cells (MICs). Recent reports indicate that HH-GLI signaling regulates a set of genes typically expressed in embryonic stem cells, including SOX2 (sex-determining region Y (SRY)-Box2). Here we address the function of SOX2 in human melanomas and MICs and its interaction with HH-GLI signaling. We find that SOX2 is highly expressed in melanoma stem cells. Knockdown of SOX2 sharply decreases self-renewal in melanoma spheres and in putative melanoma stem cells with high aldehyde dehydrogenase activity (ALDH(high)). Conversely, ectopic expression of SOX2 in melanoma cells enhances their self-renewal in vitro. SOX2 silencing also inhibits cell growth and induces apoptosis in melanoma cells. In addition, depletion of SOX2 progressively abrogates tumor growth and leads to a significant decrease in tumor-initiating capability of ALDH(high) MICs upon xenotransplantation, suggesting that SOX2 is required for tumor initiation and for continuous tumor growth. We show that SOX2 is regulated by HH signaling and that the transcription factors GLI1 and GLI2, the downstream effectors of HH-GLI signaling, bind to the proximal promoter region of SOX2 in primary melanoma cells. In functional studies, we find that SOX2 function is required for HH-induced melanoma cell growth and MIC self-renewal in vitro. Thus SOX2 is a critical factor for self-renewal and tumorigenicity of MICs and an important mediator of HH-GLI signaling in melanoma. These findings could provide the basis for novel therapeutic strategies based on the inhibition of SOX2 for the treatment of a subset of human melanomas.	[Santini, R.; Pietrobono, S.; Pandolfi, S.; Montagnani, V.; Penachioni, J. Y.; Vinci, M. C.; Stecca, B.] Ist Toscano Tumori, Corp Res Lab, Tumor Cell Biol Lab, I-50139 Florence, Italy; [D'Amico, M.] Univ Florence, Dept Expt & Clin Med, Florence, Italy; [Borgognoni, L.] Ist Toscano Tumori, Reg Melanoma Referral Ctr, SM Annunziata Hosp, Plast Surg Unit, I-50139 Florence, Italy	ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; University of Florence; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica	Stecca, B (corresponding author), Ist Toscano Tumori, Corp Res Lab, Tumor Cell Biol Lab, Viale Pieraccini 6, I-50139 Florence, Italy.	barbara.stecca@ittumori.it	Pietrobono, Silvia S/K-3932-2016; Stecca, Barbara/J-7209-2016; Vinci, Maria Cristina/E-7401-2016; Borgognoni, Lorenzo/X-1981-2019	Pietrobono, Silvia S/0000-0002-5544-7286; Vinci, Maria Cristina/0000-0001-6323-147X; Borgognoni, Lorenzo/0000-0002-3571-0366; Stecca, Barbara/0000-0003-1197-1622	AIRC (Associazione Italiana per la Ricerca sul Cancro) [IG-9566]; Regional Health Research Program; Fondazione Cassa di Risparmio di Firenze (FiorGen Foundation) [2011.1072]; AIRC fellowship	AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); Regional Health Research Program; Fondazione Cassa di Risparmio di Firenze (FiorGen Foundation)(Fondazione Cassa Risparmio Firenze); AIRC fellowship(Fondazione AIRC per la ricerca sul cancro)	We thank Gianni Gerlini (S Maria Annunziata Hospital, Florence, Italy), Nicola Pimpinelli (Department of Dermatology, University of Florence, Florence, Italy) and Riccardo Gattai (Department of Medical-Surgical Critical Area, General and Oncological Surgery, University of Florence, Florence, Italy) for providing samples. We also thank Alessio Zippo (INGM, Milan, Italy) and Lucio Luzzatto (Istituto Toscano Tumori, Florence, Italy) for helpful comments on the paper and Elisabetta Rovida and Eugenio Torre (Department of Biomedical and Clinical Sciences, University of Florence, Italy) for assistance with confocal microscopy and histology. This work was supported by grants from AIRC (Associazione Italiana per la Ricerca sul Cancro, IG-9566), Regional Health Research Program 2009 and Fondazione Cassa di Risparmio di Firenze (2011.1072, FiorGen Foundation) to BS. SP was supported by an AIRC fellowship.	Adameyko I, 2012, DEVELOPMENT, V139, P397, DOI 10.1242/dev.065581; Ahlfeld J, 2013, CANCER RES, V73, P3796, DOI 10.1158/0008-5472.CAN-13-0238; Alexaki VI, 2010, JNCI-J NATL CANCER I, V102, P1148, DOI 10.1093/jnci/djq257; Arnold K, 2011, CELL STEM CELL, V9, P317, DOI 10.1016/j.stem.2011.09.001; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Baltus GA, 2009, STEM CELLS, V27, P2175, DOI 10.1002/stem.168; Bareiss PM, 2013, CANCER RES, V73, P5544, DOI 10.1158/0008-5472.CAN-12-4177; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Basu-Roy U, 2012, ONCOGENE, V31, P2270, DOI 10.1038/onc.2011.405; Basu-Roy U, 2010, CELL DEATH DIFFER, V17, P1345, DOI 10.1038/cdd.2010.57; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Boonyaratanakornkit JB, 2010, J INVEST DERMATOL, V130, P2799, DOI 10.1038/jid.2010.237; Brownell I, 2011, CELL STEM CELL, V8, P552, DOI 10.1016/j.stem.2011.02.021; Calloni GW, 2007, P NATL ACAD SCI USA, V104, P19879, DOI 10.1073/pnas.0708806104; Chartrain M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036762; Chen PL, 2013, MODERN PATHOL, V26, P44, DOI 10.1038/modpathol.2012.132; Chou YT, 2013, STEM CELLS, V31, P2607, DOI 10.1002/stem.1518; Civenni G, 2011, CANCER RES, V71, P3098, DOI 10.1158/0008-5472.CAN-10-3997; Eberl M, 2012, EMBO MOL MED, V4, P218, DOI 10.1002/emmm.201100201; Engelen E, 2011, NAT GENET, V43, P607, DOI 10.1038/ng.825; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Fang XF, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-11; Favaro R, 2009, NAT NEUROSCI, V12, P1248, DOI 10.1038/nn.2397; Frank NY, 2005, CANCER RES, V65, P4320, DOI 10.1158/0008-5472.CAN-04-3327; Freier K, 2010, GENE CHROMOSOME CANC, V49, P9, DOI 10.1002/gcc.20714; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Girouard SD, 2012, LAB INVEST, V92, P362, DOI 10.1038/labinvest.2011.188; Girouard SD, 2011, LAB INVEST, V91, P647, DOI 10.1038/labinvest.2011.50; Gopinath S, 2013, CARCINOGENESIS, V34, P550, DOI 10.1093/carcin/bgs375; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Herreros-Villanueva M, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.23; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Hu YP, 2012, AM J CANCER RES, V2, P340; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hutz K, 2014, CARCINOGENESIS, V35, P942, DOI 10.1093/carcin/bgt410; Hutchin ME, 2005, GENE DEV, V19, P214, DOI 10.1101/gad.1258705; Jalili A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069064; Jeong CH, 2010, STEM CELLS, V28, P2141, DOI 10.1002/stem.540; Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656; Laga AC, 2011, EXP DERMATOL, V20, P339, DOI 10.1111/j.1600-0625.2011.01247.x; Laga AC, 2010, AM J PATHOL, V176, P903, DOI 10.2353/ajpath.2010.090495; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Lee J, 1997, DEVELOPMENT, V124, P2537; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Luo YC, 2012, STEM CELLS, V30, P2100, DOI 10.1002/stem.1193; Machold R, 2003, NEURON, V39, P937, DOI 10.1016/S0896-6273(03)00561-0; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Miyagi S, 2006, J BIOL CHEM, V281, P13374, DOI 10.1074/jbc.M512669200; Monzani E, 2007, EUR J CANCER, V43, P935, DOI 10.1016/j.ejca.2007.01.017; Murphy GF, 2014, MOL ASPECTS MED, V39, P33, DOI 10.1016/j.mam.2013.10.003; Nakatsugawa M, 2011, LAB INVEST, V91, P1796, DOI 10.1038/labinvest.2011.140; Narasimhan K, 2011, ACS CHEM BIOL, V6, P573, DOI 10.1021/cb100432x; O'Reilly KE, 2013, PHARMACEUTICALS, V6, P1429, DOI 10.3390/ph6111429; Pandolfi S, 2013, ONCOGENE, V32, P4737, DOI 10.1038/onc.2012.502; Perego M, 2010, J INVEST DERMATOL, V130, P1877, DOI 10.1038/jid.2010.69; Pinc A, 2012, MOL THER, V20, P1056, DOI 10.1038/mt.2012.27; Piva M, 2014, EMBO MOL MED, V6, P66, DOI 10.1002/emmm.201303411; Po A, 2010, EMBO J, V29, P2646, DOI 10.1038/emboj.2010.131; Ramgolam K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018784; Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405; Rybak AP, 2013, CELL SIGNAL, V25, P2734, DOI 10.1016/j.cellsig.2013.08.041; Santini R, 2012, STEM CELLS, V30, P1808, DOI 10.1002/stem.1160; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Schlaak M, 2012, ONCOTARGET, V3, P22; Schmidt P, 2011, P NATL ACAD SCI USA, V108, P2474, DOI 10.1073/pnas.1009069108; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Stecca B, 2009, EMBO J, V28, P663, DOI 10.1038/emboj.2009.16; Stolzenburg S, 2012, NUCLEIC ACIDS RES, V40, P6725, DOI 10.1093/nar/gks360; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takanaga H, 2009, STEM CELLS, V27, P165, DOI 10.1634/stemcells.2008-0580; Utikal J, 2009, J CELL SCI, V122, P3502, DOI 10.1242/jcs.054783; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137	74	147	153	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2014	33	38					4697	4708		10.1038/onc.2014.71	http://dx.doi.org/10.1038/onc.2014.71			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3VX	24681955	Green Published, hybrid			2022-12-28	WOS:000342007200008
J	Havel, JJ; Li, Z; Cheng, D; Peng, J; Fu, H				Havel, J. J.; Li, Z.; Cheng, D.; Peng, J.; Fu, H.			Nuclear PRAS40 couples the Akt/mTORC1 signaling axis to the RPL11-HDM2-p53 nucleolar stress response pathway	ONCOGENE			English	Article							RICH AKT SUBSTRATE; RIBOSOMAL-PROTEIN L11; LUNG-CANCER CELLS; 40 KDA PRAS40; MAMMALIAN TARGET; CELLULAR SENESCENCE; RAPAMYCIN COMPLEX-1; TUMOR SUPPRESSION; GROWTH-FACTOR; MTOR	The ribosomal protein (RP)-HDM2-p53 pathway has been shown to have key roles in oncogene-induced apoptosis and senescence, but the mechanism regulating this pathway remains elusive. The proline-rich Akt substrate of 40 kDa (PRAS40) has recently been identified as a binding partner and inhibitor of the mechanistic (formerly referred to as mammalian) target of rapamycin complex 1 (mTORC1). Although other inhibitors of mTORC1 are known tumor suppressors, PRAS40 promotes cell survival and tumorigenesis. Here we demonstrate that Akt- and mTORC1-mediated phosphorylation of PRAS40 at T246 and S221, respectively, promotes nuclear-specific association of PRAS40 with ribosomal protein L11 (RPL11). Importantly, silencing of PRAS40 induces upregulation of p53 in a manner dependent on RPL11. This effect is rescued by wild-type PRAS40, but not by the RPL11-binding-null PRAS40T246A mutant. We found that PRAS40 negatively regulates the RPL11-HDM2-p53 nucleolar stress response pathway and suppresses induction of p53-mediated cellular senescence. This work identifies nuclear PRAS40 as a dual-input signaling checkpoint that links cell growth and proliferation to inhibition of cellular senescence. These findings may help to explain the protumorigenic effect of PRAS40 and identify the PRAS40-RPL11 complex as a promising target for p53-restorative anticancer drug discovery.	[Havel, J. J.; Li, Z.; Fu, H.] Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; [Havel, J. J.] Emory Univ, Grad Program Mol & Syst Pharmacol, Atlanta, GA 30322 USA; [Cheng, D.; Peng, J.] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Fu, H (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd NE,Room 5111, Atlanta, GA 30322 USA.	hfu@emory.edu	Peng, Junmin/N-2614-2018	Peng, Junmin/0000-0003-0472-7648; Havel, Jonathan/0000-0003-0951-510X	NIH predoctoral NRSA [F31NS067844, T32GM008602]; NIH [U01CA168449]; Georgia Cancer Coalition Award; Emory University Integrated Cellular Imaging Microscopy Core of the Emory Neuroscience NINDS Core Facilities Grant [P30NS055077]; NATIONAL CANCER INSTITUTE [U01CA168449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS067844, P30NS055077] Funding Source: NIH RePORTER	NIH predoctoral NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Georgia Cancer Coalition Award; Emory University Integrated Cellular Imaging Microscopy Core of the Emory Neuroscience NINDS Core Facilities Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This research was supported in part by NIH predoctoral NRSA F31NS067844 and training grant T32GM008602 (to JJH), NIH U01CA168449 and a Georgia Cancer Coalition Award (to HF) and the Emory University Integrated Cellular Imaging Microscopy Core of the Emory Neuroscience NINDS Core Facilities Grant P30NS055077. We thank Shannon Elf for assistance with plasmid generation, and Anita Corbett and Maureen Powers for helpful discussions.	Andersen J, 2010, DANCING TIMES, V100, P55; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Cassell A, 2012, NEOPLASIA, V14, P1005, DOI 10.1593/neo.121212; Chook YM, 2011, BBA-MOL CELL RES, V1813, P1593, DOI 10.1016/j.bbamcr.2010.10.014; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de Marval PLM, 2011, ONCOTARGET, V2, P234; Deisenroth C, 2010, ONCOGENE, V29, P4253, DOI 10.1038/onc.2010.189; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fonseca BD, 2007, J BIOL CHEM, V282, P24514, DOI 10.1074/jbc.M704406200; Fregoso OI, 2013, MOL CELL, V50, P56, DOI 10.1016/j.molcel.2013.02.001; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Harthill JE, 2002, BIOCHEM J, V368, P565, DOI 10.1042/BJ20020838; Havel LS, 2011, HUM MOL GENET, V20, P1424, DOI 10.1093/hmg/ddr023; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498; Huang L, 2012, CANCER RES, V72, P1260, DOI 10.1158/0008-5472.CAN-11-2254; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Kim W, 2013, PHARMACOL RES, V70, P90, DOI 10.1016/j.phrs.2013.01.005; Kim W, 2011, RADIAT RES, V176, P539, DOI 10.1667/RR2609.1; Kovacina KS, 2003, J BIOL CHEM, V278, P10189, DOI 10.1074/jbc.M210837200; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lange A, 2007, J BIOL CHEM, V282, P5101, DOI 10.1074/jbc.R600026200; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li H, 2006, NATURE, V442, P1058, DOI 10.1038/nature05020; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Madhunapantula SV, 2007, CANCER RES, V67, P3626, DOI 10.1158/0008-5472.CAN-06-4234; Makowski L, 2008, BRIT J CANCER, V99, P683, DOI 10.1038/sj.bjc.6604515; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285; Nascimento EBM, 2006, DIABETES, V55, P3221, DOI 10.2337/db05-1390; Nascimento Emmani B. M., 2009, Archives of Physiology and Biochemistry, V115, P163, DOI 10.1080/13813450902988580; Oshiro N, 2007, J BIOL CHEM, V282, P20329, DOI 10.1074/jbc.M702636200; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Rosner M, 2008, HUM MOL GENET, V17, P2934, DOI 10.1093/hmg/ddn192; Saito A, 2006, STROKE, V37, P513, DOI 10.1161/01.STR.0000198826.56611.a2; Saito A, 2004, J NEUROSCI, V24, P1584, DOI 10.1523/JNEUROSCI.5209-03.2004; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2005, J BIOL CHEM, V280, P39505, DOI 10.1074/jbc.M506096200; Sasaki M, 2011, NAT MED, V17, P944, DOI 10.1038/nm.2392; Sato T, 2010, ONCOGENE, V29, P2746, DOI 10.1038/onc.2010.28; Schmitt CA, 2007, BBA-REV CANCER, V1775, P5, DOI 10.1016/j.bbcan.2006.08.005; Scott MS, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-317; Scott MS, 2010, NUCLEIC ACIDS RES, V38, P7388, DOI 10.1093/nar/gkq653; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Thedieck K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001217; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Vredeveld LCW, 2012, GENE DEV, V26, P1055, DOI 10.1101/gad.187252.112; Wang L, 2008, J BIOL CHEM, V283, P15619, DOI 10.1074/jbc.M800723200; Wang LF, 2007, J BIOL CHEM, V282, P20036, DOI 10.1074/jbc.M702376200; Wei YH, 2009, EMBO J, V28, P2220, DOI 10.1038/emboj.2009.179; Wiza C, 2013, CELL SIGNAL, V25, P1762, DOI 10.1016/j.cellsig.2013.05.022; Wiza C, 2012, AM J PHYSIOL-ENDOC M, V302, pE1453, DOI 10.1152/ajpendo.00660.2011; Xu P, 2009, J PROTEOME RES, V8, P3944, DOI 10.1021/pr900251d; Yap TA, 2011, MOL CANCER THER, V10, P360, DOI 10.1158/1535-7163.MCT-10-0760; Yu FS, 2008, J CEREBR BLOOD F MET, V28, P44, DOI 10.1038/sj.jcbfm.9600501; Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484; Zhang XW, 2002, J BIOL CHEM, V277, P28127, DOI 10.1074/jbc.M202625200; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	68	29	32	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1487	1498		10.1038/onc.2014.91	http://dx.doi.org/10.1038/onc.2014.91			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24704832	Green Accepted			2022-12-28	WOS:000351416800002
J	Zhao, Z; Wang, L; Xu, W				Zhao, Z.; Wang, L.; Xu, W.			IL-13R alpha 2 mediates PNR-induced migration and metastasis in ER alpha-negative breast cancer	ONCOGENE			English	Article							NUCLEAR RECEPTOR NR2E3; S-CONE SYNDROME; IL-13 RECEPTOR; INTERLEUKIN-13 RECEPTOR; PHOTORECEPTOR DEVELOPMENT; ROD PHOTORECEPTORS; MOLECULAR-CLONING; EXPRESSION; IDENTIFICATION; CHAIN	Emerging evidence has linked photoreceptor cell-specific nuclear receptor (PNR/NR2E3), an orphan nuclear hormone receptor, to human breast cancer. PNR was shown to be a transcriptional activator of estrogen receptor-alpha (ER alpha) in ER alpha-positive breast cancer cell lines and high-level expression of PNR correlates with favorable response of ER alpha-positive breast cancer patients to tamoxifen. Interestingly, gene expression microarray study shows that PNR regulates distinct genes from those regulated by ER alpha, suggesting that PNR could have ER alpha-independent functions. Herein, we investigated the function of PNR in ER alpha-negative breast cancer cells. Our results showed that PNR-induced cell migration and metastasis of ER alpha-negative breast cancer cells both in vitro and in vivo, and the effect was attributed to the upregulation of interleukin (IL)-13R alpha 2, a high-affinity receptor for IL-13 that regulates tumor growth, invasion and metastasis of various human cancers. Mechanistically, PNR activated transcription of IL-13R alpha 2 through direct recruitment to IL-13R alpha 2 promoter. Upon stimulation with IL-13, IL-13R alpha 2 increased the extracellular signal-regulated kinases 1 and 2 phosphorylation, which led to breast cancer migration and metastasis. The IL-13 triggered signal cascade was specific to IL-13R alpha 2, as the closely related IL-13R alpha 1 was not regulated by PNR. IL-13R alpha 2 is a novel tumor antigen that is overexpressed in a variety of solid tumor types. This study presents the first evidence that PNR could promote ERa-negative breast cancer metastasis through activation of IL-13R alpha 2-mediated signaling pathway.	[Zhao, Z.; Wang, L.; Xu, W.] Univ Wisconsin, Dept Oncol, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Xu, W (corresponding author), Univ Wisconsin, Dept Oncol, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	wxu@oncology.wisc.edu			DOD ERA of HOPE Scholar Award [W81XWYH-11-1-0237]; NATIONAL CANCER INSTITUTE [P30CA014520] Funding Source: NIH RePORTER	DOD ERA of HOPE Scholar Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This project was supported by DOD ERA of HOPE Scholar Award (W81XWYH-11-1-0237) to WX.	Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Barderas R, 2012, CANCER RES, V72, P2780, DOI 10.1158/0008-5472.CAN-11-4090; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Cheng H, 2004, HUM MOL GENET, V13, P1563, DOI 10.1093/hmg/ddh173; Christofori G, 2007, NATURE, V446, P735, DOI 10.1038/446735a; Conzen SD, 2008, MOL ENDOCRINOL, V22, P2215, DOI 10.1210/me.2007-0421; Daines MO, 2006, J IMMUNOL, V176, P7495, DOI 10.4049/jimmunol.176.12.7495; David MD, 2003, ONCOGENE, V22, P3386, DOI 10.1038/sj.onc.1206352; De Monte L, 2011, J EXP MED, V208, P469, DOI 10.1084/jem.20101876; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; Fujisawa T, 2012, INT J CANCER, V131, P344, DOI 10.1002/ijc.26366; Fujisawa T, 2009, CANCER RES, V69, P8678, DOI 10.1158/0008-5472.CAN-09-2100; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Haider NB, 2000, NAT GENET, V24, P127, DOI 10.1038/72777; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; Husain SR, 2003, J NEURO-ONCOL, V65, P37, DOI 10.1023/A:1026242432647; Jezequel P, 2013, DATABASE-OXFORD, DOI 10.1093/database/bas060; Joshi BH, 2009, IMMUNOTHERAPY-UK, V1, P321, DOI 10.2217/IMT.09.8; Kapitskaya M, 2006, ASSAY DRUG DEV TECHN, V4, P253, DOI 10.1089/adt.2006.4.253; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kawakami K, 2001, J EXP MED, V194, P1743, DOI 10.1084/jem.194.12.1743; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4814, DOI 10.1073/pnas.96.9.4814; Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Mollema NJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017494; Murata T, 1997, BIOCHEM BIOPH RES CO, V238, P90, DOI 10.1006/bbrc.1997.7248; Muscat GEO, 2013, MOL ENDOCRINOL, V27, P350, DOI 10.1210/me.2012-1265; Noetzel E, 2012, ONCOGENE, V31, P2101, DOI 10.1038/onc.2011.403; O'Brien KMB, 2004, INVEST OPHTH VIS SCI, V45, P2807, DOI 10.1167/iovs.03-1317; Obiri NI, 1997, J IMMUNOL, V158, P756; Oh ECT, 2008, BRAIN RES, V1236, P16, DOI 10.1016/j.brainres.2008.01.028; Olkhanud PB, 2011, J IMMUNOL, V186, P5656, DOI 10.4049/jimmunol.1100463; PANKRATZ MJ, 1992, SCIENCE, V255, P986, DOI 10.1126/science.1546296; Park YY, 2012, EMBO MOL MED, V4, P52, DOI 10.1002/emmm.201100187; Pedroza-Gonzalez A, 2011, J EXP MED, V208, P479, DOI 10.1084/jem.20102131; Peng GH, 2005, HUM MOL GENET, V14, P747, DOI 10.1093/hmg/ddi070; Powell E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030993; Puri RK, 1996, BLOOD, V87, P4333, DOI 10.1182/blood.V87.10.4333.bloodjournal87104333; Qin Q, 2013, J OCUL PHARMACOL TH, V29, P298, DOI 10.1089/jop.2012.0135; Ring BZ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-12-241; Roduit R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007379; Sharon D, 2003, ARCH OPHTHALMOL-CHIC, V121, P1316, DOI 10.1001/archopht.121.9.1316; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; Takezawa S, 2007, EMBO J, V26, P764, DOI 10.1038/sj.emboj.7601548; Tan MHE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074359; Wang L, 2014, CANCER CELL, V25, P21, DOI 10.1016/j.ccr.2013.12.007; Wang L, 2013, NUCLEIC ACIDS RES, V41, P6870, DOI 10.1093/nar/gkt415; Wang L, 2009, MOL PHARMACOL, V76, P1238, DOI 10.1124/mol.109.059105; Webber AL, 2008, EXP EYE RES, V87, P35, DOI 10.1016/j.exer.2008.04.006; Wolkenberg SE, 2006, BIOORG MED CHEM LETT, V16, P5001, DOI 10.1016/j.bmcl.2006.07.056; Wu AH, 2003, NEURO-ONCOLOGY, V5, P179, DOI 10.1215/S1152851702000510; Yan CH, 2006, MOL CELL BIOL, V26, P6357, DOI 10.1128/MCB.00311-06; Zhao Z, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0052044, 10.1371/journal.pone.0061814, 10.1371/journal.pone.0080574]	60	26	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1596	1607		10.1038/onc.2014.53	http://dx.doi.org/10.1038/onc.2014.53			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24747967	Green Accepted			2022-12-28	WOS:000351416800012
J	Xue, G; Yan, HL; Zhang, Y; Hao, LQ; Zhu, XT; Mei, Q; Sun, SH				Xue, G.; Yan, H-L; Zhang, Y.; Hao, L-Q; Zhu, X-T; Mei, Q.; Sun, S-H			c-Myc-mediated repression of miR-15-16 in hypoxia is induced by increased HIF-2 alpha and promotes tumor angiogenesis and metastasis by upregulating FGF2	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; GENE-EXPRESSION; BREAST-CANCER; METABOLISM; CELLS; HIF-1; TUMORIGENESIS; BIOGENESIS; APOPTOSIS; PATHWAYS	Previous studies have established the link between aberrant microRNA (miRNA) expression and hypoxia in various neoplasms. However, how these hypoxia-related miRNAs modulate tumor progression is still unclear. Therefore, the patterns of miRNA in colorectal carcinoma cell lines in response to hypoxia or not were first screened and the hypoxia-induced repression of the miR-15-16 cluster was confirmed. Then, this repression was found to be associated with high tumor stage and poor prognosis in colorectal carcinoma and is shown to promote tumor angiogenesis and metastasis by the loss of restriction of its target gene, fibroblast growth factor-2 (FGF2). Moreover, the general and alterative promoters of the miR-15-16 host (deleted in lymphocytic leukemia 2, DLEU2) were mapped, and three c-Myc/Max binding sites in response to the hypoxia-induced repression of miR-15-16 were further identified. Finally, an enhanced stability of c-Myc/Max heterodimer promoted by increased hypoxia-inducible factor-2 alpha (HIF-2 alpha) was validated, and we also verified that the enhancement contributed to the hypoxia-induced repression of miR-15-16. In brief, the c-Myc-mediated transcriptional repression of miR-15-16 in hypoxia is induced by increased HIF-2 alpha and promoted tumor angiogenesis and hematogenous metastasis by the further loss of post-transcriptional inhibition of FGF2. Our study provides a better understanding of the coping mechanisms in response to tumor hypoxia and may be helpful in developing an effective prognostic marker or treatment target against solid tumors.	[Xue, G.; Yan, H-L; Zhang, Y.; Zhu, X-T; Mei, Q.; Sun, S-H] Second Mil Med Univ, Coll Basic Med Sci, Dept Med Genet, Shanghai 200433, Peoples R China; [Hao, L-Q] Second Mil Med Univ, Changhai Hosp, Dept Colorectal Surg, Shanghai 200433, Peoples R China	Naval Medical University; Naval Medical University	Sun, SH (corresponding author), Second Mil Med Univ, Coll Basic Med Sci, Dept Med Genet, Xiang Yin Rd 800, Shanghai 200433, Peoples R China.	shsun@vip.sina.com	May, Mere/HIK-1050-2022		National Natural Science Foundation of China [31100920, 30972877]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank the National Natural Science Foundation of China for the financial support (Nos. 31100920 and 30972877).	Aqeilan RI, 2010, CELL DEATH DIFFER, V17, P215, DOI 10.1038/cdd.2009.69; Banning A, 2008, CANCER RES, V68, P9746, DOI 10.1158/0008-5472.CAN-08-1321; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; Buendia MA, 2012, GASTROENTEROLOGY, V142, P214, DOI 10.1053/j.gastro.2011.12.023; Cao YH, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003149; Chan DA, 2007, CANCER METAST REV, V26, P333, DOI 10.1007/s10555-007-9063-1; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chaudary N, 2007, CLIN CANCER RES, V13, P1947, DOI 10.1158/1078-0432.CCR-06-2971; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274; Finger EC, 2010, CANCER METAST REV, V29, P285, DOI 10.1007/s10555-010-9224-5; Fong S, 2003, P NATL ACAD SCI USA, V100, P13543, DOI 10.1073/pnas.2230238100; FROMOWITZ FB, 1987, HUM PATHOL, V18, P1268, DOI 10.1016/S0046-8177(87)80412-4; Gordan JD, 2007, CANCER CELL, V12, P108, DOI 10.1016/j.ccr.2007.07.006; Gupta GP, 2007, P NATL ACAD SCI USA, V104, P19506, DOI 10.1073/pnas.0709185104; Hackl C, 2013, GUT, V62, P259, DOI 10.1136/gutjnl-2011-301585; Horan AD, 2001, RADIAT RES, V156, P388, DOI 10.1667/0033-7587(2001)156[0388:TKMFRO]2.0.CO;2; Huang X, 2009, MOL CELL, V35, P856, DOI 10.1016/j.molcel.2009.09.006; Ivan M, 2008, J CELL MOL MED, V12, P1426, DOI 10.1111/j.1582-4934.2008.00398.x; Kaluz S, 2009, BBA-REV CANCER, V1795, P162, DOI 10.1016/j.bbcan.2009.01.001; Katoh M, 2007, STEM CELL REV, V3, P30, DOI 10.1007/s12015-007-0006-6; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Khew-Goodall Y, 2010, NAT CELL BIOL, V12, P209, DOI 10.1038/ncb0310-209; Kulshreshtha R, 2008, CELL DEATH DIFFER, V15, P667, DOI 10.1038/sj.cdd.4402310; Le QT, 2004, CANCER METAST REV, V23, P293, DOI 10.1023/B:CANC.0000031768.89246.d7; Lerner M, 2009, EXP CELL RES, V315, P2941, DOI 10.1016/j.yexcr.2009.07.001; Marinescu VD, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-79; Ruan K, 2009, J CELL BIOCHEM, V107, P1053, DOI 10.1002/jcb.22214; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Shoushtari AN, 2011, NAT REV CLIN ONCOL, V8, P333, DOI 10.1038/nrclinonc.2011.65; Stockmann C, 2008, NATURE, V456, P814, DOI 10.1038/nature07445; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Voss MJ, 2010, CURR MOL MED, V10, P381, DOI 10.2174/156652410791317020; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107; Yan HL, 2009, EMBO J, V28, P2719, DOI 10.1038/emboj.2009.214; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001	40	58	61	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1393	1406		10.1038/onc.2014.82	http://dx.doi.org/10.1038/onc.2014.82			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24704828				2022-12-28	WOS:000350806500006
J	Wen, Z; Liu, H; Li, M; Li, B; Gao, W; Shao, Q; Fan, B; Zhao, F; Wang, Q; Xie, Q; Yang, Y; Yu, J; Qu, X				Wen, Z.; Liu, H.; Li, M.; Li, B.; Gao, W.; Shao, Q.; Fan, B.; Zhao, F.; Wang, Q.; Xie, Q.; Yang, Y.; Yu, J.; Qu, X.			Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltration	ONCOGENE			English	Article							NECROSIS-FACTOR-ALPHA; ISCHEMIC TISSUES; GENE-EXPRESSION; GROWTH-FACTOR; MOUSE MODEL; PROGRESSION; CARCINOMA; PATHWAYS; LIPOXYGENASE; MATRILYSIN	5-lipoxygenase (5-LOX), a member of the lipoxygenase gene family, is a key enzyme assisting in the conversion of arachidonic acid to 5-HETE and leukotrienes. Tumor-associated macrophages (TAMs) have a critical role in the progression and metastasis of many tumors, including ovarian tumors. Moreover, TAMs are often found in a high density in the hypoxic areas of tumors. However, the relevant mechanisms have not been studied explicitly until now. In this study, we found that the expression of 5-LOX strongly correlated with the density of TAMs in hypoxic areas of human ovarian tumor tissues. In cultured ovarian cancer cells, 5-LOX metabolites were increased under hypoxic conditons. Increased 5-LOX metabolites from hypoxic ovarian cancer cells promoted migration and invasion of macrophages, which was further demonstrated to be mediated by the upregulation of matrix metalloproteinase (MMP)-7 expression through the p38 pathway. Besides, we also showed that 5-LOX metabolites enhanced the release of tumor necrosis factor (TNF-alpha) and heparin-binding epidermal growth factor-like growth factor through upregulation of MMP-7. Furthermore, in animal models, Zileuton (a selective and specific 5-LOX inhibitor) reduced the MMP-7 expression and the number of macrophages infiltrating in the xenograft. Our findings suggest for the first time that increased metabolites of 5-LOX from hypoxic ovarian cancer cells promote TAM infiltration. These results of this study have immediate translational implications for the therapeutic exploitation of TAMs.	[Wen, Z.; Liu, H.; Gao, W.; Shao, Q.; Wang, Q.; Xie, Q.; Yang, Y.; Qu, X.] Shandong Univ, Qilu Hosp, Inst Basic Med Sci, Jinan 250100, Peoples R China; [Wen, Z.; Liu, H.; Gao, W.; Shao, Q.; Wang, Q.; Xie, Q.; Yang, Y.; Qu, X.] Shandong Univ, Qilu Hosp, Key Lab Cardiovasc Prote Shandong Prov, Jinan 250100, Peoples R China; [Li, M.; Li, B.; Fan, B.; Zhao, F.; Yu, J.] Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan 250117, Shandong, Peoples R China	Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences	Yu, J (corresponding author), Shandong Canc Hosp & Inst, Dept Radiat Oncol, 440 Jiyan Rd, Jinan 250117, Shandong, Peoples R China.	jinmingyusd@126.com; xunqusd@126.com		Qu, Xun/0000-0002-2521-3761	National Natural Science Foundation of China [31270971, 81072406]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Colin D Funk, Department of Physiology and Biochemistry, Queen's University for providing us with essential material and a technical guide. This study was supported by National Natural Science Foundation of China (Nos. 31270971, 81072406).	Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Ashwell JD, 2006, NAT REV IMMUNOL, V6, P532, DOI 10.1038/nri1865; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bingham BA, 2013, CLIN NUCL MED, V38, pE140, DOI 10.1097/RLU.0b013e318263869d; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; Brigatte P, 2011, AMINO ACIDS, V40, P101, DOI 10.1007/s00726-010-0512-8; Burke B, 2003, AM J PATHOL, V163, P1233, DOI 10.1016/S0002-9440(10)63483-9; Camp RL, 1999, CANCER, V86, P2259, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2; Chang MC, 2012, BIOCHEM J, V442, P293, DOI 10.1042/BJ20110282; Charles KA, 2009, J CLIN INVEST, V119, P3011, DOI 10.1172/JCI39065; Chu J, 2011, AM J PATHOL, V178, P1762, DOI 10.1016/j.ajpath.2010.12.032; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Dunsmore SE, 1998, J CLIN INVEST, V102, P1321, DOI 10.1172/JCI1516; Freedman RS, 2007, CLIN CANCER RES, V13, P5736, DOI 10.1158/1078-0432.CCR-07-0583; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Gonsalves CS, 2010, J IMMUNOL, V184, P3878, DOI 10.4049/jimmunol.0902594; Haeggstrom JZ, 2011, CHEM REV, V111, P5866, DOI 10.1021/cr200246d; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; Horiuchi A, 2012, INT J CANCER, V131, P1755, DOI 10.1002/ijc.27448; Imai T, 2003, AM J PATHOL, V163, P1437, DOI 10.1016/S0002-9440(10)63501-8; Johnson N, 2011, NAT MED, V17, P875, DOI 10.1038/nm.2377; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kioi M, 2003, ONCOGENE, V22, P8662, DOI 10.1038/sj.onc.1207181; Kummer NT, 2012, J CELL BIOCHEM, V113, P1998, DOI 10.1002/jcb.24069; Lee SK, 2012, INT J CANCER, V131, pE190, DOI 10.1002/ijc.27381; Lewis JS, 2000, J PATHOL, V192, P150, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH687>3.0.CO;2-G; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Maniecki MB, 2012, INT J CANCER, V131, P2320, DOI 10.1002/ijc.27506; Megias J, 2007, BRIT J PHARMACOL, V150, P977, DOI 10.1038/sj.bjp.0707184; Meng YR, 2010, CANCER RES, V70, P1534, DOI 10.1158/0008-5472.CAN-09-2995; Mitchem JB, 2013, CANCER RES, V73, P1128, DOI 10.1158/0008-5472.CAN-12-2731; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Murdoch C, 2005, INT J CANCER, V117, P701, DOI 10.1002/ijc.21422; Murdoch C, 2004, BLOOD, V104, P2224, DOI 10.1182/blood-2004-03-1109; Negus RPM, 1997, AM J PATHOL, V150, P1723; Negus RPM, 1998, J LEUKOCYTE BIOL, V63, P758, DOI 10.1002/jlb.63.6.758; Phuangsab A, 2001, CANCER LETT, V172, P27, DOI 10.1016/S0304-3835(01)00617-6; Pidgeon GP, 2007, CANCER METAST REV, V26, P503, DOI 10.1007/s10555-007-9098-3; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Reinartz S, 2014, INT J CANCER, V134, P32, DOI 10.1002/ijc.28335; Rocconi RP, 2008, REPROD SCI, V15, P321, DOI 10.1177/1933719108316390; Rolny C, 2011, CANCER CELL, V19, P31, DOI 10.1016/j.ccr.2010.11.009; Ruhrberg C, 2010, NAT MED, V16, P861, DOI 10.1038/nm0810-861; Schroder A, 2013, J UROLOGY, V189, P2377, DOI 10.1016/j.juro.2012.12.110; Sitia G, 2004, J CLIN INVEST, V113, P1158, DOI 10.1172/JCI200421087; Steidl C, 2010, NEW ENGL J MED, V362, P875, DOI 10.1056/NEJMoa0905680; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wen ZH, 2013, ONCOGENE, V32, P160, DOI 10.1038/onc.2012.47; Yamaguchi Tatsuyuki, 1995, Life Sciences, V56, P379; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702	54	61	63	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1241	1252		10.1038/onc.2014.85	http://dx.doi.org/10.1038/onc.2014.85			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24662827				2022-12-28	WOS:000350687100004
J	Hardy, S; Uetani, N; Wong, N; Kostantin, E; Labbe, DP; Begin, LR; Mes-Masson, A; Miranda-Saavedra, D; Tremblay, ML				Hardy, S.; Uetani, N.; Wong, N.; Kostantin, E.; Labbe, D. P.; Begin, L. R.; Mes-Masson, A.; Miranda-Saavedra, D.; Tremblay, M. L.			The protein tyrosine phosphatase PRL-2 interacts with the magnesium transporter CNNM3 to promote oncogenesis	ONCOGENE			English	Article							REGENERATING LIVER; CELL-MIGRATION; CANCER; MG2+; METASTASIS; IDENTIFICATION; PROLIFERATION; PURIFICATION; STIMULATION; MECHANISMS	The three PRL (phosphatases of regenerating liver) protein tyrosine phosphatases (PRL-1, -2 and -3) have been identified as key contributors to metastasis in several human cancers, yet the molecular basis of their pro-oncogenic property is unclear. Among the subfamily of PRL phosphatases, overexpression of PRL-2 in breast cancer cells has been shown to promote tumor growth by a mechanism that remains to be uncovered. Here we show that PRL-2 regulates intracellular magnesium levels by forming a functional heterodimer with the magnesium transporter CNNM3. We further reveal that CNNM3 is not a phosphorylated substrate of PRL-2, and that the interaction occurs through a loop unique to the CBS pair domains of CNNM3 that exists only in organisms having PRL orthologs. Supporting the role of PRL-2 in cellular magnesium transport is the observation that PRL-2 knockdown results in a substantial decrease of cellular magnesium influx. Furthermore, in PRL-2 knockout mice, serum magnesium levels were significantly elevated as compared with control animals, indicating a pivotal role for PRL-2 in regulating cellular magnesium homeostasis. Although the expression levels of CNNM3 remained unchanged after magnesium depletion of various cancer cell lines, the interaction between endogenous PRL-2 and CNNM3 was markedly increased. Importantly, xenograft tumor assays with CNNM3 and a mutant form that does not associate with PRL-2 confirm that CNNM3 is itself pro-oncogenic, and that the PRL-2/CNNM3 association is important for conferring transforming activities. This finding is further confirmed from data in human breast cancer tissues showing that CNNM3 levels correlate positively with both PRL-2 expression and the tumor proliferative index. In summary, we demonstrate that oncogenic PRL-2 controls tumor growth by modulating intracellular magnesium levels through binding with the CNNM3 magnesium transporter.	[Hardy, S.; Uetani, N.; Wong, N.; Kostantin, E.; Labbe, D. P.; Tremblay, M. L.] McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [Wong, N.; Kostantin, E.; Tremblay, M. L.] McGill Univ, Dept Biochem, Montreal, PQ H3A 1A3, Canada; [Labbe, D. P.; Tremblay, M. L.] McGill Univ, Dept Med, Div Expt Med, Montreal, PQ H3A 1A3, Canada; [Begin, L. R.] Hop Sacre Coeur, Serv Anatomopathol, Montreal, PQ H4J 1C5, Canada; [Mes-Masson, A.] Univ Montreal, CR CHUM, Inst Canc Montreal, Montreal, PQ, Canada; [Mes-Masson, A.] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; [Miranda-Saavedra, D.] Osaka Univ, World Premier Int Immunol Frontier Res Ctr, Osaka, Japan; [Miranda-Saavedra, D.] Newcastle Univ, Sch Med, Inst Cellular Med, Fibrosis Labs, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	McGill University; McGill University; McGill University; Universite de Montreal; Universite de Montreal; Universite de Montreal; Osaka University; Newcastle University - UK	Tremblay, ML (corresponding author), McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Canc Res Bldg,1160 Pine Ave West, Montreal, PQ H3A 1A3, Canada.	michel.tremblay@mcgill.ca	Labbé, David P./C-2702-2009	Labbé, David P./0000-0001-8864-8765; Mes-Masson, Anne-Marie/0000-0002-6498-266X	Canadian Institute of Health Research (CIHR); CIHR/Fonds de recherche du Quebec-Sante Training Grant in Cancer Research [FRN53888]; Quebec Breast Cancer Foundation; Canadian Breast Cancer Research Alliance	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR/Fonds de recherche du Quebec-Sante Training Grant in Cancer Research; Quebec Breast Cancer Foundation; Canadian Breast Cancer Research Alliance	We thank Dr Laurent Lessard (J. Wayne Cancer Institute) for his technical help. Dr Kalle Gehring, biochemistry department, McGill University for helpful discussion and colleagues at the Goodman Cancer Research Centre Drs Jose Teodoro and Jerry Pelletier for their constructive comments on the manuscript. MLT is a Jeanne and Jean-Louis Levesque chair in Cancer Research. DPL is a recipient of Canadian Institute of Health Research (CIHR) Frederick Banting and Charles Best Doctoral Research award and of CIHR/Fonds de recherche du Quebec-Sante Training Grant in Cancer Research FRN53888 the McGill Integrated Cancer Research Training Program. This research is supported by an operating grant from the Quebec Breast Cancer Foundation and the Canadian Breast Cancer Research Alliance to MLT.	Al-Aidaroos AQO, 2010, J CELL BIOCHEM, V111, P1087, DOI 10.1002/jcb.22913; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; Bennetts B, 2005, J BIOL CHEM, V280, P32452, DOI 10.1074/jbc.M502890200; Blanchetot C, 2005, METHODS, V35, P44, DOI 10.1016/j.ymeth.2004.07.007; Castiglioni S, 2011, MAGNESIUM RES, V24, pS92, DOI 10.1684/mrh.2011.0285; Chen GI, 2007, METHODS, V42, P298, DOI 10.1016/j.ymeth.2007.02.018; Chen SD, 2010, CHINESE MED J-PEKING, V123, P1447, DOI 10.3760/cma.j.issn.0366-6999.2010.11.018; DAI LJ, 1991, J CLIN INVEST, V88, P1255, DOI 10.1172/JCI115429; Dai LJ, 1997, AM J PHYSIOL-RENAL, V272, pF249, DOI 10.1152/ajprenal.1997.272.2.F249; de Baaij JHF, 2012, J BIOL CHEM, V287, P13644, DOI 10.1074/jbc.M112.342204; Dong YS, 2012, J BIOL CHEM, V287, P32172, DOI 10.1074/jbc.M112.393462; Dumaual CM, 2006, J HISTOCHEM CYTOCHEM, V54, P1401, DOI 10.1369/jhc.6A7019.2006; Feske S, 2012, NAT REV IMMUNOL, V12, P532, DOI 10.1038/nri3233; Fiordalisi JJ, 2006, CANCER RES, V66, P3153, DOI 10.1158/0008-5472.CAN-05-3116; Gomez-Garcia I, 2012, ACTA CRYSTALLOGR F, V68, P1198, DOI 10.1107/S1744309112035348; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hardy S, 2012, ANTI-CANCER AGENT ME, V12, P4, DOI 10.2174/187152012798764741; Hardy S, 2010, CANCER RES, V70, P8959, DOI 10.1158/0008-5472.CAN-10-2041; Hattori M, 2007, NATURE, V448, P1072, DOI 10.1038/nature06093; Ikari A, 2010, LIFE SCI, V86, P766, DOI 10.1016/j.lfs.2010.03.016; Julien SG, 2011, NAT REV CANCER, V11, P35, DOI 10.1038/nrc2980; Kolisek M, 2012, AM J PHYSIOL-CELL PH, V302, pC318, DOI 10.1152/ajpcell.00289.2011; Kozlov G, 2004, J BIOL CHEM, V279, P11882, DOI 10.1074/jbc.M312905200; Krndija D, 2012, J CELL SCI, V125, P3883, DOI 10.1242/jcs.104885; Li FY, 2011, NATURE, V475, P471, DOI 10.1038/nature10246; Meyer TE, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001045; Peng LR, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-110; Quamme GA, 2010, AM J PHYSIOL-CELL PH, V298, pC407, DOI 10.1152/ajpcell.00124.2009; Rios P, 2013, FEBS J, V280, P505, DOI 10.1111/j.1742-4658.2012.08565.x; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Skinner AL, 2009, BIOCHEMISTRY-US, V48, P4262, DOI 10.1021/bi900241k; Stephens B, 2008, MOL CANCER THER, V7, P202, DOI 10.1158/1535-7163.MCT-07-0542; Stuiver M, 2011, AM J HUM GENET, V88, P333, DOI 10.1016/j.ajhg.2011.02.005; Sun JP, 2005, BIOCHEMISTRY-US, V44, P12009, DOI 10.1021/bi0509191; Svotelis A, 2011, EMBO J, V30, P3947, DOI 10.1038/emboj.2011.284; Tonks NK, 2006, NAT REV MOL CELL BIO, V7, P833, DOI 10.1038/nrm2039; Touyz RM, 2008, AM J PHYSIOL-HEART C, V294, pH1103, DOI 10.1152/ajpheart.00903.2007; Wang CY, 2003, GENE, V306, P37, DOI 10.1016/S0378-1119(02)01210-6; Wang HH, 2007, CANCER RES, V67, P2922, DOI 10.1158/0008-5472.CAN-06-3598; Wang JY, 2011, J BIOL CHEM, V286, P10177, DOI 10.1074/jbc.M110.163295; Wang Y, 2012, ONCOGENE, V31, P818, DOI 10.1038/onc.2011.281; Wolf FI, 2012, CLIN SCI, V123, P417, DOI 10.1042/CS20120086; Wolf FI, 2004, FRONT BIOSCI-LANDMRK, V9, P2056, DOI 10.2741/1389; Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200; Zeng Q, 1998, BIOCHEM BIOPH RES CO, V244, P421, DOI 10.1006/bbrc.1998.8291	45	75	78	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					986	995		10.1038/onc.2014.33	http://dx.doi.org/10.1038/onc.2014.33			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632616				2022-12-28	WOS:000350121300005
J	Martin, Y; Cabrera, E; Amoedo, H; Hernandez-Perez, S; Dominguez-Kelly, R; Freire, R				Martin, Y.; Cabrera, E.; Amoedo, H.; Hernandez-Perez, S.; Dominguez-Kelly, R.; Freire, R.			USP29 controls the stability of checkpoint adaptor Claspin by deubiquitination	ONCOGENE			English	Article							DNA-DAMAGE-RESPONSE; REPEATED PHOSPHOPEPTIDE MOTIFS; CELL-CYCLE; REPLICATION; CHK1; PHOSPHORYLATION; DESTRUCTION; DEGRADATION; ACTIVATION; BINDING	The DNA damage checkpoint is essential for the maintenance of genome integrity after genotoxic stress, and also for cell survival in eukaryotes. Claspin has a key role in the ATR (ATM and Rad3-related)-Chk1 branch of the DNA damage checkpoint and is also required for correct DNA replication. To achieve properly these functions, Claspin is tightly regulated by ubiquitinin-dependent proteasomal degradation, which controls Claspin levels in a DNA-damage- and cell-cycle-dependent manner. Here, we identified a new regulator of Claspin, the ubiquitin-specific peptidase 29, USP29. Downregulation of USP29 destabilizes Claspin, whereas its overexpression promotes an increase in Claspin levels. USP29 interacts with Claspin and is able to deubiquitinate it both in vivo and in vitro. Most importantly, USP29 knockdown results in an impaired phosphorylation of Chk1 after DNA damage and USP29-depleted cells show a major defect in the S-phase progression. With these results, we identified USP29 as a new player in the ATR-Chk1 pathway and the control of DNA replication.	[Martin, Y.; Cabrera, E.; Amoedo, H.; Hernandez-Perez, S.; Dominguez-Kelly, R.; Freire, R.] Hosp Univ Canarias, Unidad Invest, Inst Tecnol Biomed, Tenerife 38320, Spain	Universidad de la Laguna	Freire, R (corresponding author), Hosp Univ Canarias, Unidad Invest, Ofra S-N, Tenerife 38320, Spain.	rfreire@ull.es	Freire, Raimundo/Q-7660-2019; Cabrera, Elisa/GPX-3455-2022	Freire, Raimundo/0000-0003-4473-8894; 	Spanish MINECO [SAF2010-22357, CONSOLIDER-Ingenio 2010 CDS2007-0015]	Spanish MINECO(Spanish Government)	We are grateful to V Smits for careful reading of the manuscript. We thank G Marfany, JW Harper and D Bohmann for helpful reagents. This work was supported by grants from the Spanish MINECO (SAF2010-22357, CONSOLIDER-Ingenio 2010 CDS2007-0015).	Bassermann F, 2008, CELL, V134, P256, DOI 10.1016/j.cell.2008.05.043; Chauhan D, 2012, CANCER CELL, V22, P345, DOI 10.1016/j.ccr.2012.08.007; Chini CCS, 2006, J BIOL CHEM, V281, P33276, DOI 10.1074/jbc.M604373200; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Clarke CAL, 2005, BIOCHEM J, V388, P705, DOI 10.1042/BJ20041966; Cummins JM, 2004, NATURE, V428, DOI 10.1038/nature02501; Dominguez-Kelly R, 2011, J CELL BIOL, V194, P567, DOI 10.1083/jcb.201101047; Faustrup H, 2009, J CELL BIOL, V184, P13, DOI 10.1083/jcb.200807137; Freire R, 2006, CELL CYCLE, V5, P2831, DOI 10.4161/cc.5.24.3559; Gao DM, 2009, MOL BIOL CELL, V20, P3305, DOI 10.1091/mbc.E09-01-0092; Jacq X, 2013, CELL BIOCHEM BIOPHYS, V67, P25, DOI 10.1007/s12013-013-9635-3; Perez-Castro AJ, 2012, J CELL SCI, V125, P1152, DOI 10.1242/jcs.091124; Kim JM, 2008, ONCOGENE, V27, P3475, DOI 10.1038/sj.onc.1210994; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Lee J, 2005, MOL BIOL CELL, V16, P5269, DOI 10.1091/mbc.E05-07-0671; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Liu JH, 2011, EMBO J, V30, P846, DOI 10.1038/emboj.2011.11; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2006, MOL CELL, V23, P307, DOI 10.1016/j.molcel.2006.06.016; Mamely I, 2006, CURR BIOL, V16, P1950, DOI 10.1016/j.cub.2006.08.026; Meng Z, 2011, MOL BIOL CELL, V22, P2834, DOI 10.1091/mbc.E11-01-0048; Mosbech A, 2013, J BIOL CHEM, V288, P16579, DOI 10.1074/jbc.M113.459917; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Petermann E, 2008, MOL BIOL CELL, V19, P2373, DOI 10.1091/mbc.E07-10-1035; Refolio E, 2011, J CELL SCI, V124, P2488, DOI 10.1242/jcs.081711; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Semple JI, 2007, CELL DEATH DIFFER, V14, P1433, DOI 10.1038/sj.cdd.4402134; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; Smits VAJ, 2010, FRONT BIOSCI-LANDMRK, V15, P840, DOI 10.2741/3649; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Uno S, 2011, GENES CELLS, V16, P842, DOI 10.1111/j.1365-2443.2011.01535.x; Verlinden L, 2007, CANCER RES, V67, P6574, DOI 10.1158/0008-5472.CAN-06-3545; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039	37	47	49	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					1058	1063		10.1038/onc.2014.38	http://dx.doi.org/10.1038/onc.2014.38			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632611				2022-12-28	WOS:000350121300012
J	Dudley, A; Sater, M; Le, PU; Trinh, G; Sadr, MS; Bergeron, J; Deleavey, GF; Bedell, B; Damha, MJ; Petrecca, K				Dudley, A.; Sater, M.; Le, P. U.; Trinh, G.; Sadr, M. S.; Bergeron, J.; Deleavey, G. F.; Bedell, B.; Damha, M. J.; Petrecca, K.			DRR regulates AKT activation to drive brain cancer invasion	ONCOGENE			English	Article						brain cancer; glioblastoma; invasion; AKT; DRR	TYROSINE KINASE INHIBITOR; FOCAL ADHESION KINASE; PHASE I/II TRIAL; GLIOBLASTOMA-MULTIFORME; GROWTH; PATHWAY; CELLS; THERAPY; AKT/PKB; SRC	Glioblastoma (GBM) is the most common and invasive adult brain cancer. The rapid invasion of cancer cells into the normal brain is a major cause of treatment failure, yet the mechanisms that regulate this process are poorly understood. We have identified a novel mechanism of brain cancer invasion. We show that downregulated in renal cell carcinoma (DRR), which is newly expressed in invasive gliomas, recruits AKT to focal adhesions. This DRR-induced pathological relocalization of AKT bypasses commonly altered upstream signaling events and leads to AKT activation and invasion. We also developed an oligonucleotide therapeutic that reduces DRR expression and prevents glioma invasion in an in vivo preclinical model of the disease. Our findings identify DRR as a novel GBM target and show that oligonucleotides targeting DRR is a novel therapeutic approach for the treatment of DRR-positive GBMs.	[Dudley, A.; Sater, M.; Le, P. U.; Trinh, G.; Sadr, M. S.; Bergeron, J.; Bedell, B.; Petrecca, K.] McGill Univ, Montreal Neurol Inst & Hosp, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; [Deleavey, G. F.; Damha, M. J.] McGill Univ, Dept Chem, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University	Petrecca, K (corresponding author), McGill Univ, Montreal Neurol Inst & Hosp, Dept Neurol & Neurosurg, 3801 Univ Ave,Suite 109c, Montreal, PQ H3A 2B4, Canada.	kevin.petrecca@mcgill.ca			Industry Canada, Centre of Excellence for Commercialization; Canadian Institutes for Health Research-Proof-of-Principle Grant; Canadian Institutes for Health Research-Operating Grant; McGill University Faculty of Medicine Scholarship; Vanier Canada Graduate Scholarship	Industry Canada, Centre of Excellence for Commercialization; Canadian Institutes for Health Research-Proof-of-Principle Grant; Canadian Institutes for Health Research-Operating Grant(Canadian Institutes of Health Research (CIHR)); McGill University Faculty of Medicine Scholarship; Vanier Canada Graduate Scholarship	This work was supported in part by grants from Industry Canada, Centre of Excellence for Commercialization (KP), Canadian Institutes for Health Research-Proof-of-Principle Grant (KP and MJD) and Canadian Institutes for Health Research-Operating Grant (MJD). AD was supported by a McGill University Faculty of Medicine Scholarship. GT was supported by a McGill University Faculty of Medicine Scholarship. GFD was supported by a Vanier Canada Graduate Scholarship.	AHMED NN, 1993, ONCOGENE, V8, P1957; Akhavan D, 2010, NEURO-ONCOLOGY, V12, P882, DOI 10.1093/neuonc/noq052; Anderson NG, 2001, INT J CANCER, V94, P774, DOI 10.1002/ijc.1557; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Asano Y, 2010, BIOCHEM BIOPH RES CO, V394, P829, DOI 10.1016/j.bbrc.2010.03.085; Barkovich KJ, 2012, CANCER DISCOV, V2, P450, DOI 10.1158/2159-8290.CD-11-0287; Bogdahn U, 2011, NEURO-ONCOLOGY, V13, P132, DOI 10.1093/neuonc/noq142; Brandes AA, 2008, CLIN CANCER RES, V14, P957, DOI 10.1158/1078-0432.CCR-07-1810; Brown PD, 2008, J CLIN ONCOL, V26, P5603, DOI 10.1200/JCO.2008.18.0612; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chin YR, 2009, CELL SIGNAL, V21, P470, DOI 10.1016/j.cellsig.2008.11.015; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Del Re DP, 2008, J BIOL CHEM, V283, P35622, DOI 10.1074/jbc.M804036200; Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202; Fan QW, 2011, CURR TOP MICROBIOL, V347, P279, DOI 10.1007/82_2010_67; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Franceschi E, 2012, NEURO-ONCOLOGY, V14, P1503, DOI 10.1093/neuonc/nos256; Gan HK, 2007, J BIOL CHEM, V282, P2840, DOI 10.1074/jbc.M605136200; Genot EM, 2000, MOL CELL BIOL, V20, P5469, DOI 10.1128/MCB.20.15.5469-5478.2000; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Kelly JJP, 2009, STEM CELLS, V27, P1722, DOI 10.1002/stem.98; Le PU, 2010, ONCOGENE, V29, P4636, DOI 10.1038/onc.2010.216; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Liu Q, 2009, ONCOL REP, V22, P1069, DOI 10.3892/or_00000538; Lu KV, 2009, CANCER RES, V69, P6889, DOI 10.1158/0008-5472.CAN-09-0347; Lu-Emerson C, 2011, J NEURO-ONCOL, V104, P287, DOI 10.1007/s11060-010-0489-x; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Maret D, 2010, NEOPLASIA, V12, P1066, DOI 10.1593/neo.10954; Martelli AM, 2006, CELL SIGNAL, V18, P1101, DOI 10.1016/j.cellsig.2006.01.011; Milano V, 2009, MOL CANCER THER, V8, P394, DOI 10.1158/1535-7163.MCT-08-0669; Molina JR, 2010, NEOPLASIA, V12, P453, DOI 10.1593/neo.10126; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Petrecca K, 2013, J NEURO-ONCOL, V111, P19, DOI 10.1007/s11060-012-0983-4; Rexer BN, 2009, CLIN CANCER RES, V15, P4518, DOI 10.1158/1078-0432.CCR-09-0872; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schmidt MV, 2011, P NATL ACAD SCI USA, V108, P17213, DOI 10.1073/pnas.1103318108; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2010, J CLIN ONCOL, V28, P2712, DOI 10.1200/JCO.2009.26.6650; van den Bent MJ, 2009, J CLIN ONCOL, V27, P5881, DOI 10.1200/JCO.2009.24.1034; Villavicencio AT, 2009, NEUROSURG REV, V32, P417, DOI 10.1007/s10143-009-0212-6; Vivanco I, 2012, CANCER DISCOV, V2, P458, DOI 10.1158/2159-8290.CD-11-0284; Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123; Wang L, 2000, GENE CHROMOSOME CANC, V27, P1, DOI 10.1002/(SICI)1098-2264(200001)27:1<1::AID-GCC1>3.0.CO;2-6; Wang SY, 2011, ANTI-CANCER AGENT ME, V11, P993, DOI 10.2174/187152011797927661; Wolfrum S, 2004, ARTERIOSCL THROM VAS, V24, P1842, DOI 10.1161/01.ATV.0000142813.33538.82	53	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2014	33	41					4952	4960		10.1038/onc.2013.436	http://dx.doi.org/10.1038/onc.2013.436			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OA	24141773				2022-12-28	WOS:000343767900008
J	Fujiya, M; Konishi, H; Kamel, MKM; Ueno, N; Inaba, Y; Moriichi, K; Tanabe, H; Ikuta, K; Ohtake, T; Kohgo, Y				Fujiya, M.; Konishi, H.; Kamel, M. K. Mohamed; Ueno, N.; Inaba, Y.; Moriichi, K.; Tanabe, H.; Ikuta, K.; Ohtake, T.; Kohgo, Y.			microRNA-18a induces apoptosis in colon cancer cells via the autophagolysosomal degradation of oncogenic heterogeneous nuclear ribonucleoprotein A1	ONCOGENE			English	Article						microRNAs; heterogeneous nuclear ribonucleoproteins; colon cancer; apoptosis; autophagy; ubiquitin	POSTTRANSCRIPTIONAL REGULATION; COLORECTAL-CANCER; NONCODING RNAS; C-ELEGANS; GENE; MUTATIONS; RAS; EXPRESSION; PROLIFERATION; TUMORIGENESIS	It is well known that microRNAs (miRs) are abnormally expressed in various cancers and target the messenger RNAs (mRNAs) of cancer-associated genes. While (miRs) are abnormally expressed in various cancers, whether miRs directly target oncogenic proteins is unknown. The present study investigated the inhibitory effects of miR-18a on colon cancer progression, which was considered to be mediated through its direct binding and degradation of heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1). An MTT assay and xenograft model demonstrated that the transfection of miR-18a induced apoptosis in SW620 cells. A binding assay revealed direct binding between miR-18a and hnRNP A1 in the cytoplasm of SW620 cells, which inhibited the oncogenic functions of hnRNP A1. A competitor RNA, which included the complementary sequence of the region of the miR-18a-hnRNP A1 binding site, repressed the effects of miR-18a on the induction of cancer cell apoptosis. In vitro single and in vivo double isotope assays demonstrated that miR-18a induced the degradation of hnRNP A1. An immunocytochemical study of hnRNP A1 and LC3-II and the inhibition of autophagy by 3-methyladenine and ATG7, p62 and BAG3 siRNA showed that miR-18a and hnRNP A1 formed a complex that was degraded through the autophagolysosomal pathway. This is the first report showing a novel function of a miR in the autophagolysosomal degradation of an oncogenic protein resulting from the creation of a complex consisting of the miR and a RNA-binding protein, which suppressed cancer progression.	[Fujiya, M.; Konishi, H.; Kamel, M. K. Mohamed; Ueno, N.; Inaba, Y.; Moriichi, K.; Tanabe, H.; Ikuta, K.; Ohtake, T.; Kohgo, Y.] Asahikawa Med Coll, Dept Med, Div Gastroenterol & Hematol Oncol, Asahikawa, Hokkaido 0788510, Japan	Asahikawa Medical College	Fujiya, M (corresponding author), Asahikawa Med Coll, Dept Med, Div Gastroenterol & Hematol Oncol, 2-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan.	fjym@asahikawa-med.ac.jp	Kohgo, Yutaka/AAN-4863-2020	Tanabe, Hiroki/0000-0001-9029-5081	Grants-in-Aid for Scientific Research [24790671] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; Eiring AM, 2010, CELL, V140, P652, DOI 10.1016/j.cell.2010.01.007; Eulalio A, 2008, CELL, V132, P9, DOI 10.1016/j.cell.2007.12.024; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; Guan RJ, 1999, GASTROENTEROLOGY, V116, P1063, DOI 10.1016/S0016-5085(99)70009-0; Guil S, 2007, NAT STRUCT MOL BIOL, V14, P591, DOI 10.1038/nsmb1250; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hope NR, 2011, HUM PATHOL, V42, P393, DOI 10.1016/j.humpath.2010.08.006; Jo OD, 2008, J BIOL CHEM, V283, P23274, DOI 10.1074/jbc.M801185200; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kettern N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016398; Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Liu WH, 2009, GASTROENTEROLOGY, V136, P683, DOI 10.1053/j.gastro.2008.10.029; Mattick JS, 2001, MOL BIOL EVOL, V18, P1611, DOI 10.1093/oxfordjournals.molbev.a003951; Michlewski G, 2008, MOL CELL, V32, P383, DOI 10.1016/j.molcel.2008.10.013; Motoyama K, 2009, INT J ONCOL, V34, P1069, DOI 10.3892/ijo_00000233; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Qased A, 2013, MOL MED REP, V7, P559, DOI 10.3892/mmr.2012.1214; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638; Tao J, 2012, MOL MED REP, V5, P167, DOI 10.3892/mmr.2011.591; Thiele BJ, 2004, CIRC RES, V95, P1058, DOI 10.1161/01.RES.0000149166.33833.08; Tsuchiya N, 2011, CANCER RES, V71, P4628, DOI 10.1158/0008-5472.CAN-10-2475; Ushigome M, 2005, INT J ONCOL, V26, P635; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Wu JM, 2012, CARCINOGENESIS, V33, P519, DOI 10.1093/carcin/bgr304; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107; Yu YJ, 2012, CARCINOGENESIS, V33, P68, DOI 10.1093/carcin/bgr246; Zhang Y, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-23; Zhao YC, 2011, BREAST CANCER RES TR, V127, P69, DOI 10.1007/s10549-010-0972-2	38	48	48	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2014	33	40					4847	4856		10.1038/onc.2013.429	http://dx.doi.org/10.1038/onc.2013.429			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0EH	24166503				2022-12-28	WOS:000343240100006
J	Chan, SH; Huang, WC; Chang, JW; Chang, KJ; Kuo, WH; Wang, MY; Lin, KY; Uen, YH; Hou, MF; Lin, CM; Jang, TH; Tu, CW; Lee, YR; Lee, YH; Tien, MT; Wang, LH				Chan, S-H; Huang, W-C; Chang, J-W; Chang, K-J; Kuo, W-H; Wang, M-Y; Lin, K-Y; Uen, Y-H; Hou, M-F; Lin, C-M; Jang, T-H; Tu, C-W; Lee, Y-R; Lee, Y-H; Tien, M-T; Wang, L-H			MicroRNA-149 targets GIT1 to suppress integrin signaling and breast cancer metastasis	ONCOGENE			English	Article							EXPRESSION PROFILES; FOCAL ADHESIONS; CELL-MIGRATION; TRAFFICKING; PROGRESSION; PROTEINS; DOMAIN	Metastasis is the predominant cause of death in breast cancer patients. Several lines of evidence have shown that microRNAs (miRs) can have an important role in cancer metastasis. Using isogenic pairs of low and high metastatic lines derived from a human breast cancer line, we have identified miR-149 to be a suppressor of breast cancer cell invasion and metastasis. We also identified GIT1 (G-protein-coupled receptor kinase-interacting protein 1) as a direct target of miR-149. Knockdown of GIT1 reduced migration/invasion and metastasis of highly invasive cells. Re-expression of GIT1 significantly rescued miR-149-mediated inhibition of cell migration/invasion and metastasis. Expression of miR-149 impaired fibronectin-induced focal adhesion formation and reduced phosphorylation of focal adhesion kinase and paxillin, which could be restored by re-expression of GIT1. Inhibition of GIT1 led to enhanced protein degradation of paxillin and alpha 5 beta 1 integrin via proteasome and lysosome pathways, respectively. Moreover, we found that GIT1 depletion in metastatic breast cancer cells greatly reduced alpha 5 beta 1-integrin-mediated cell adhesion to fibronectin and collagen. Low level of miR-149 and high level of GIT1 was significantly associated with advanced stages of breast cancer, as well as with lymph node metastasis. We conclude that miR-149 suppresses breast cancer cell migration/invasion and metastasis by targeting GIT1, suggesting potential applications of the miR-149-GIT1 pathway in clinical diagnosis and therapeutics.	[Chan, S-H; Huang, W-C; Chang, J-W; Lin, C-M; Jang, T-H; Wang, L-H] Natl Hlth Res Inst, Inst Mol & Genom Med, Miaoli, Taiwan; [Huang, W-C; Wang, L-H] Natl Cent Univ, Dept Life Sci, Taoyuan, Taiwan; [Chang, K-J; Kuo, W-H; Wang, M-Y] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; [Lin, K-Y; Uen, Y-H] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Hou, M-F] Kaohsiung Med Univ, Chung Ho Mem Hosp, Dept Surg, Kaohsiung, Taiwan; [Tu, C-W] Chiayi Christian Hosp, Dept Surg, Chiayi, Taiwan; [Lee, Y-R] Chiayi Christian Hosp, Dept Med Res, Chiayi, Taiwan; [Lee, Y-H] Natl Taiwan Univ Hosp, Hsin Chu Branch, Dept Pathol, Hsinchu, Taiwan; [Tien, M-T] Ind Technol Res Inst, Biomed Technol & Device Res Labs, Hsinchu, Taiwan; [Wang, L-H] Mt Sinai Sch Med, Dept Microbiol, New York, NY USA	National Health Research Institutes - Taiwan; National Central University; National Taiwan University; National Taiwan University Hospital; Chi Mei Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Chia-Yi Christian Hospital; Chia-Yi Christian Hospital; National Taiwan University; National Taiwan University Hospital; Industrial Technology Research Institute - Taiwan; Icahn School of Medicine at Mount Sinai	Wang, LH (corresponding author), Natl Hlth Res Inst, Inst Mol & Genom Med, 35 Keyan Rd, Zhunan Town 35053, Miaoli, Taiwan.	lu-hai.wang@nhri.org.tw	Chan, Shih-Hsuan/AAW-6857-2020; Chan, Shih-Hsuan/AAD-4317-2021; Wang, Lu-Hai/E-3986-2010	Hou, Ming-Feng/0000-0001-6030-9702; Chan, Shih-Hsuan/0000-0002-8703-5139; Chang, King jen/0000-0001-9811-3422; KUO, WEN-HUNG/0000-0002-9881-4605; Lee, Ying-Ray/0000-0002-0349-0960	National Science Council, Taiwan [01D2-MMNSC16]; Department of Health, Taiwan [DOH100-TD-111-004]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Department of Health, Taiwan	We thank the Pathology Core Laboratory and Microarray Core Laboratory of the National Health Research Institutes for H&E and immunohistochemical staining and miRNA array analysis, respectively. This work was supported by grants from National Science Council, Taiwan (01D2-MMNSC16) and the Department of Health, Taiwan (DOH100-TD-111-004).	Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; Li D, 2011, OMICS, V15, P673, DOI 10.1089/omi.2011.0064; Lin KT, 2012, CANCER RES, V72, P3000, DOI 10.1158/0008-5472.CAN-11-2502; Liu SC, 2000, J CELL SCI, V113, P3563; Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005; Luo ZH, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-3; Manabe R, 2002, J CELL SCI, V115, P1497; Narla RK, 2001, CLIN CANCER RES, V7, P2124; Negrini M, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1867; Packeisen J, 2002, J CLIN PATHOL, V55, P613, DOI 10.1136/jcp.55.8.613; Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957; Ramsay AG, 2007, CANCER METAST REV, V26, P567, DOI 10.1007/s10555-007-9078-7; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Schlenker O, 2009, J MOL BIOL, V386, P280, DOI 10.1016/j.jmb.2008.12.050; Schmalzigaug R, 2007, CELL SIGNAL, V19, P1733, DOI 10.1016/j.cellsig.2007.03.010; Silahtaroglu AN, 2007, NAT PROTOC, V2, P2520, DOI 10.1038/nprot.2007.313; Sreekumar Rahul, 2011, Frontiers in Genetics, V2, P58, DOI 10.3389/fgene.2011.00058; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Thievessen I, 2013, J CELL BIOL, V202, P163, DOI 10.1083/jcb.201303129; Wang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041693; White DE, 2007, J MAMMARY GLAND BIOL, V12, P135, DOI 10.1007/s10911-007-9045-5; Yin GY, 2005, J BIOL CHEM, V280, P27705, DOI 10.1074/jbc.M502271200	28	107	112	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2014	33	36					4496	4507		10.1038/onc.2014.10	http://dx.doi.org/10.1038/onc.2014.10			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MY	24608434	hybrid, Green Published			2022-12-28	WOS:000341158800005
J	Scortegagna, M; Ruller, C; Feng, Y; Lazova, R; Kluger, H; Li, JL; De, SK; Rickert, R; Pellecchia, M; Bosenberg, M; Ronai, ZA				Scortegagna, M.; Ruller, C.; Feng, Y.; Lazova, R.; Kluger, H.; Li, J-L; De, S. K.; Rickert, R.; Pellecchia, M.; Bosenberg, M.; Ronai, Z. A.			Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma	ONCOGENE			English	Article						PDK1; FOXO3a; melanoma; Braf; Pten; GSK2334470	AKT; DOWNSTREAM; MECHANISMS; RESISTANCE; MUTATIONS; SIZE; JNK	Phosphoinositide-dependent kinase-1 (PDK1) is a serine/threonine protein kinase that phosphorylates members of the conserved AGC kinase superfamily, including AKT and protein kinase C (PKC), and is implicated in important cellular processes including survival, metabolism and tumorigenesis. In large cohorts of nevi and melanoma samples, PDK1 expression was significantly higher in primary melanoma, compared with nevi, and was further increased in metastatic melanoma. PDK1 expression suffices for its activity, owing to auto-activation, or elevated phosphorylation by phosphoinositide 3'-OH-kinase (PI3K). Selective inactivation of Pdk1 in the melanocytes of Braf(V600E)::Pten(-/-) or Braf(V600E)::Cdkn2a(-/-)::Pten(-/-) mice delayed the development of pigmented lesions and melanoma induced by systemic or local administration of 4-hydroxytamoxifen. Melanoma invasion and metastasis were significantly reduced or completely prevented by Pdk1 deletion. Administration of the PDK1 inhibitor GSK2334470 (PDKi) effectively delayed melanomagenesis and metastasis in Braf(V600E)::Pten(-/-) mice. Pdk1(-/-) melanomas exhibit a marked decrease in the activity of AKT, P70S6K and PKC. Notably, PDKi was as effective in inhibiting AGC kinases and colony forming efficiency of melanoma with Pten wild-type (WT) genotypes. Gene expression analyses identified Pdk1-dependent changes in FOXO3a-regulated genes, and inhibition of FOXO3a restored proliferation and colony formation of Pdk1(-/-) melanoma cells. Our studies provide direct genetic evidence for the importance of PDK1, in part through FOXO3a-dependent pathway, in melanoma development and progression.	[Scortegagna, M.; Ruller, C.; Feng, Y.; Li, J-L; De, S. K.; Rickert, R.; Pellecchia, M.; Ronai, Z. A.] Sanford Burnham Med Res Inst, Ctr Canc, La Jolla, CA 92037 USA; [Lazova, R.; Kluger, H.; Bosenberg, M.] Yale Univ, Dept Dermatol Med & Pathol, New Haven, CT USA	Sanford Burnham Prebys Medical Discovery Institute; Yale University	Ronai, ZA (corresponding author), Sanford Burnham Med Res Inst, Ctr Canc, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ronai@sbmri.org	Li, Jian-Liang/AAE-9315-2019; Li, J L/E-6100-2018; Pellecchia, Maurizio/Y-7072-2018	Li, Jian-Liang/0000-0002-6487-081X; Li, J L/0000-0002-6487-081X; RONAI, ZEEV/0000-0002-3859-0400; De, SURYA/0000-0001-5014-0798	NIH [CA099961, CA128814]; Melanoma Research Alliance; NATIONAL CANCER INSTITUTE [R01CA099961, R01CA179170, P30CA030199, P01CA128814] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000142] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Melanoma Research Alliance; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This manuscript is dedicated in fond memory to Victor Fung, Ph.D., a former Program Officer at NCI and a former Scientific Review Officer of the Cancer Etiology study section of CSR, NIH, for his wisdom, compassion, integrity, his love of the sciences and the arts and his contributions to the career development of so many investigators during his own distinguished career. We thank Dario Alessi for providing the conditional Pdk1<SUP>-/-</SUP> mice, Vincent Hearing for the Tyrp1 antibody and Pedro Aza-Blanc for small interfering RNA library work. Support by NIH grants CA099961 (to ZR) and CA128814 (to ZR and MP) and a Melanoma Research Alliance grant (to ZR) is gratefully acknowledged.	Axten JM, 2011, CHEM COMPOUNDS; Aziz SA, 2009, CLIN CANCER RES, V15, P3029, DOI 10.1158/1078-0432.CCR-08-2768; Bagrodia S, 2012, PIGM CELL MELANOMA R, V25, P819, DOI 10.1111/pcmr.12007; Bayascas JR, 2005, CURR BIOL, V15, P1839, DOI 10.1016/j.cub.2005.08.066; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bosenberg M, 2006, GENESIS, V44, P262, DOI 10.1002/dvg.20205; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Choucair KA, 2012, TRANSL ONCOL, V5, P453, DOI 10.1593/tlo.12286; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Ellwood-Yen K, 2011, CANCER RES, V71, P3052, DOI 10.1158/0008-5472.CAN-10-2282; Eser S, 2013, CANCER CELL, V23, P406, DOI 10.1016/j.ccr.2013.01.023; Finlay DK, 2009, J EXP MED, V206, P2441, DOI 10.1084/jem.20090219; Gagliardi PA, 2012, NEOPLASIA, V14, P719, DOI 10.1593/neo.12856; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387; Lopez-Bergami P, 2005, MOL CELL, V19, P309, DOI 10.1016/j.molcel.2005.06.025; Lopez-Bergami P, 2007, CANCER CELL, V11, P447, DOI 10.1016/j.ccr.2007.03.009; Lopez-Bergami P, 2010, J BIOL CHEM, V285, P903, DOI 10.1074/jbc.M109.075630; Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820; Medina JR, 2011, J MED CHEM, V54, P1871, DOI 10.1021/jm101527u; Miao BC, 2010, P NATL ACAD SCI USA, V107, P20126, DOI 10.1073/pnas.1004522107; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Nagashima K, 2011, J BIOL CHEM, V286, P6433, DOI 10.1074/jbc.M110.156463; Najafov A, 2012, BIOCHEM J, V448, P285, DOI 10.1042/BJ20121287; Najafov A, 2011, BIOCHEM J, V433, P357, DOI 10.1042/BJ20101732; Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82_2010_43; Shen H, 2008, CANCER GENET CYTOGEN, V181, P100, DOI 10.1016/j.cancergencyto.2007.11.012; Shi W, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq871; Skurk C, 2005, J BIOL CHEM, V280, P20814, DOI 10.1074/jbc.M500528200; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Tsao H, 2012, GENE DEV, V26, P1131, DOI 10.1101/gad.191999.112; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Vultur A, 2009, PIGM CELL MELANOMA R, V22, P4, DOI 10.1111/j.1755-148X.2008.00527.x; You H, 2004, P NATL ACAD SCI USA, V101, P14057, DOI 10.1073/pnas.0406286101	35	34	34	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2014	33	34					4330	4339		10.1038/onc.2013.383	http://dx.doi.org/10.1038/onc.2013.383			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MK	24037523	Green Accepted			2022-12-28	WOS:000341156900006
J	Paz, H; Pathak, N; Yang, J				Paz, H.; Pathak, N.; Yang, J.			Invading one step at a time: the role of invadopodia in tumor metastasis	ONCOGENE			English	Review						invadopodia; tumor invasion; metastasis	FIBROBLAST ACTIVATION PROTEIN; TYPE-1 MATRIX-METALLOPROTEINASE; BREAST-CANCER CELLS; EPITHELIAL-MESENCHYMAL TRANSITIONS; DIPEPTIDYL-PEPTIDASE-IV; SRC FAMILY KINASES; PHASE-II TRIAL; PODOSOME FORMATION; MAMMARY-TUMORS; IN-VIVO	The ability to degrade extracellular matrix is critical for tumor cells to invade and metastasize. Recent studies show that tumor cells use specialized actin-based membrane protrusions termed invadopodia to perform matrix degradation. Invadopodia provide an elegant way for tumor cells to precisely couple focal matrix degradation with directional movement. Here we discuss several key components and regulators of invadopodia that have been uniquely implicated in tumor invasion and metastasis. Furthermore, we discuss existing and new therapeutic opportunities to target invadopodia for anti-metastasis treatment.	[Paz, H.; Pathak, N.; Yang, J.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Pathak, N.; Yang, J.] Univ Calif San Diego, Program Biomed Sci, La Jolla, CA 92093 USA; [Yang, J.] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Yang, J (corresponding author), Univ Calif San Diego, Dept Pharmacol, Program Biomed Sci, 9500 Gilman Dr,MC0636, La Jolla, CA 92093 USA.	jingyang@ucsd.edu			National Institutes of Health [1DP2OD002420]; National Cancer Institute [1RO1CA168689]; American Cancer Society [RSG-09-282-01-CSM]; Hartwell Foundation; DOD Breast Cancer Program [W81XWH-13-1-0132]; NIH IRACDA [5K12GM068524]; NIH [5T32GM007752]; NATIONAL CANCER INSTITUTE [R01CA168689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007752, K12GM068524] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD002420] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Hartwell Foundation; DOD Breast Cancer Program(United States Department of Defense); NIH IRACDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We apologize to the many researchers in this field whose work we were unable to cite due to space restrictions. Our research on tumor metastasis is supported by grants from National Institutes of Health 1DP2OD002420, National Cancer Institute 1RO1CA168689, American Cancer Society grant RSG-09-282-01-CSM, The Hartwell Foundation and DOD Breast Cancer Program W81XWH-13-1-0132 to JY, by the NIH IRACDA training grant 5K12GM068524 to HP, and by the NIH Pre-doctoral Training grant in Pharmaceutical Science 5T32GM007752 to NP.	Abram CL, 2003, J BIOL CHEM, V278, P16844, DOI 10.1074/jbc.M300267200; Albrechtsen R, 2011, EXP CELL RES, V317, P195, DOI 10.1016/j.yexcr.2010.10.003; Alexander NR, 2008, CURR BIOL, V18, P1295, DOI 10.1016/j.cub.2008.07.090; Allgayer H, 2002, CANCER, V94, P344, DOI 10.1002/cncr.10221; Anbalagan M, 2012, BREAST CANCER RES TR, V132, P391, DOI 10.1007/s10549-011-1513-3; [Anonymous], 2013, ANTICANCER RES, V33, P2345; Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Balzer EM, 2010, ONCOGENE, V29, P6402, DOI 10.1038/onc.2010.360; Basu B, 2012, INT J BIOCHEM CELL B, V44, P393, DOI 10.1016/j.biocel.2011.11.015; Beaty BT, 2013, MOL BIOL CELL, V24, P1661, DOI 10.1091/mbc.E12-12-0908; Blouw B, 2008, EUR J CELL BIOL, V87, P555, DOI 10.1016/j.ejcb.2008.02.008; Bowden ET, 2006, EXP CELL RES, V312, P1240, DOI 10.1016/j.yexcr.2005.12.012; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Branch KM, 2012, BIOL OPEN, V1, P711, DOI 10.1242/bio.20121867; Bravo-Cordero JJ, 2007, EMBO J, V26, P1499, DOI 10.1038/sj.emboj.7601606; Buschman MD, 2009, MOL BIOL CELL, V20, P1302, DOI 10.1091/mbc.E08-09-0949; Busek P, 2004, INT J BIOCHEM CELL B, V36, P408, DOI 10.1016/S1357-2725(03)00262-0; Chan PC, 2012, CANCER RES, V72, P2405, DOI 10.1158/0008-5472.CAN-11-3078; Chen DH, 2006, CANCER RES, V66, P9977, DOI 10.1158/0008-5472.CAN-06-1499; CHEN WT, 1985, NATURE, V316, P156, DOI 10.1038/316156a0; Christiansen VJ, 2007, ARCH BIOCHEM BIOPHYS, V457, P177, DOI 10.1016/j.abb.2006.11.006; Chuma M, 2004, J HEPATOL, V41, P629, DOI 10.1016/j.jhep.2004.06.018; Courtneidge SA, 2005, COLD SH Q B, V70, P167, DOI 10.1101/sqb.2005.70.014; Crimaldi L, 2009, EXP CELL RES, V315, P2581, DOI 10.1016/j.yexcr.2009.06.012; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Destaing O, 2010, MOL BIOL CELL, V21, P4108, DOI 10.1091/mbc.E10-07-0580; Devy L, 2011, BIOCHEM RES INT, V2011, DOI 10.1155/2011/191670; Devy L, 2009, CANCER RES, V69, P1517, DOI 10.1158/0008-5472.CAN-08-3255; Diaz B, 2013, J CELL BIOL, V201, P279, DOI 10.1083/jcb.201209151; Diaz B, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000368; Eager RM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-263; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Eisenach PA, 2012, J BIOL CHEM, V287, P11533, DOI 10.1074/jbc.M111.306340; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Fischer E, 2012, CLIN CANCER RES, V18, P6208, DOI 10.1158/1078-0432.CCR-12-0644; Fosang AJ, 1998, FEBS LETT, V430, P186, DOI 10.1016/S0014-5793(98)00667-X; Freije JMP, 2003, ADV EXP MED BIOL, V532, P91; Gertler F, 2011, TRENDS CELL BIOL, V21, P81, DOI 10.1016/j.tcb.2010.10.001; Ghersi G, 2006, CANCER RES, V66, P4652, DOI 10.1158/0008-5472.CAN-05-1245; Gialeli C, 2011, FEBS J, V278, P16, DOI 10.1111/j.1742-4658.2010.07919.x; Gil-Henn H, 2013, ONCOGENE, V32, P2622, DOI 10.1038/onc.2012.284; Gligorijevic B, 2012, J CELL SCI, V125, P724, DOI 10.1242/jcs.092726; Henry LR, 2007, CLIN CANCER RES, V13, P1736, DOI 10.1158/1078-0432.CCR-06-1746; Hofheinz RD, 2003, ONKOLOGIE, V26, P44, DOI 10.1159/000069863; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huck L, 2010, P NATL ACAD SCI USA, V107, P15559, DOI 10.1073/pnas.1003034107; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Ito S, 2001, INT J CANCER, V93, P212, DOI 10.1002/ijc.1318; Jallal H, 2007, CANCER RES, V67, P1580, DOI 10.1158/0008-5472.CAN-06-2027; Kelley LC, 2010, J CELL SCI, V123, P3923, DOI 10.1242/jcs.075200; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Kraman M, 2010, SCIENCE, V330, P827, DOI 10.1126/science.1195300; Kveiborg M, 2005, CANCER RES, V65, P4754, DOI 10.1158/0008-5472.CAN-05-0262; Kveiborg M, 2008, INT J BIOCHEM CELL B, V40, P1685, DOI 10.1016/j.biocel.2008.01.025; Lee J, 2005, CANCER RES, V65, P11156, DOI 10.1158/0008-5472.CAN-05-2805; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Li YS, 2001, CANCER RES, V61, P6906; Lin J, 2008, ONCOGENE, V27, P4385, DOI 10.1038/onc.2008.86; Linder S, 2007, TRENDS CELL BIOL, V17, P107, DOI 10.1016/j.tcb.2007.01.002; Loeffler M, 2006, J CLIN INVEST, V116, P1955, DOI 10.1172/JCI26532; Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432; Mayer EL, 2010, CLIN CANCER RES, V16, P3526, DOI 10.1158/1078-0432.CCR-09-1834; Meadows SA, 2007, BIOCHEMISTRY-US, V46, P4598, DOI 10.1021/bi062227y; Moss ML, 2002, ESSAYS BIOCHEM, V38, P141, DOI 10.1042/bse0380141; Mueller SC, 1999, J BIOL CHEM, V274, P24947, DOI 10.1074/jbc.274.35.24947; MUELLER SC, 1991, J CELL SCI, V99, P213; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Naing A, 2013, INVEST NEW DRUG, V31, P967, DOI 10.1007/s10637-013-9929-8; Nakahara H, 1996, J BIOL CHEM, V271, P27221, DOI 10.1074/jbc.271.44.27221; Narra K, 2007, CANCER BIOL THER, V6, P1691, DOI 10.4161/cbt.6.11.4874; Nyalendo C, 2008, CARCINOGENESIS, V29, P1655, DOI 10.1093/carcin/bgn159; Nyalendo C, 2007, J BIOL CHEM, V282, P15690, DOI 10.1074/jbc.M608045200; O'Brien P, 2008, BBA-PROTEINS PROTEOM, V1784, P1130, DOI 10.1016/j.bbapap.2008.01.006; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Oikawa T, 2008, J CELL BIOL, V182, P157, DOI 10.1083/jcb.200801042; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; Parekh A, 2011, BIOPHYS J, V100, P573, DOI 10.1016/j.bpj.2010.12.3733; Parekh A, 2009, CELL ADHES MIGR, V3, P288, DOI 10.4161/cam.3.3.8888; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Perentes JY, 2011, CANCER RES, V71, P4527, DOI 10.1158/0008-5472.CAN-10-4376; Philippar U, 2008, DEV CELL, V15, P813, DOI 10.1016/j.devcel.2008.09.003; Pignatelli J, 2012, J CELL BIOL, V197, P421, DOI 10.1083/jcb.201108143; Sanchez-Bailon MP, 2012, CELL SIGNAL, V24, P1276, DOI 10.1016/j.cellsig.2012.02.011; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Poincloux R, 2009, J CELL SCI, V122, P3015, DOI 10.1242/jcs.034561; Puls LN, 2011, ONCOLOGIST, V16, P566, DOI 10.1634/theoncologist.2010-0408; Pure E, 2009, EXPERT OPIN THER TAR, V13, P967, DOI 10.1517/14728220903103841; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Roussos ET, 2011, J CELL SCI, V124, P2120, DOI 10.1242/jcs.086231; Roussos ET, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2784; Roy R, 2004, J BIOL CHEM, V279, P51323, DOI 10.1074/jbc.M409565200; Roy R, 2011, J BIOL CHEM, V286, P20758, DOI 10.1074/jbc.M110.216036; Santos AM, 2009, J CLIN INVEST, V119, P3613, DOI 10.1172/JCI38988; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; Seals DF, 2005, CANCER CELL, V7, P155, DOI 10.1016/j.ccr.2005.01.006; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Smith-Pearson PS, 2010, J BIOL CHEM, V285, P40201, DOI 10.1074/jbc.M110.147330; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Steeg PS, 2012, NATURE, V485, pS58, DOI 10.1038/485S58a; Steffen A, 2008, CURR BIOL, V18, P926, DOI 10.1016/j.cub.2008.05.044; Stoletov K, 2010, J CELL SCI, V123, P2332, DOI 10.1242/jcs.069443; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Szabova L, 2008, ONCOGENE, V27, P3274, DOI 10.1038/sj.onc.1210982; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Toth M, 2003, BIOCHEM BIOPH RES CO, V308, P386, DOI 10.1016/S0006-291X(03)01405-0; Trevino JG, 2006, AM J PATHOL, V168, P962, DOI 10.2353/ajpath.2006.050570; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Wang S, 2009, P NATL ACAD SCI USA, V106, P151, DOI 10.1073/pnas.0808703105; Weaver AM, 2008, CANCER LETT, V265, P157, DOI 10.1016/j.canlet.2008.02.066; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Yamaguchi H, 2012, EUR J CELL BIOL, V91, P902, DOI 10.1016/j.ejcb.2012.04.005; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yu XZ, 2012, J CELL BIOL, V199, P527, DOI 10.1083/jcb.201203025; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017	126	134	139	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2014	33	33					4193	4202		10.1038/onc.2013.393	http://dx.doi.org/10.1038/onc.2013.393			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MB	24077283	Green Accepted			2022-12-28	WOS:000341155800001
J	Benson, EK; Mungamuri, SK; Attie, O; Kracikova, M; Sachidanandam, R; Manfredi, JJ; Aaronson, SA				Benson, E. K.; Mungamuri, S. K.; Attie, O.; Kracikova, M.; Sachidanandam, R.; Manfredi, J. J.; Aaronson, S. A.			p53-dependent gene repression through p21 is mediated by recruitment of E2F4 repression complexes	ONCOGENE			English	Article						p53; p21; E2F4; RB; p130; transcriptional repression	ARF TUMOR-SUPPRESSOR; WILD-TYPE P53; CELL-CYCLE; TRANSCRIPTIONAL REPRESSION; NEGATIVE REGULATION; DOWN-REGULATION; POCKET PROTEIN; DIRECT BINDING; SURVIVIN GENE; TARGET GENES	The p53 tumor suppressor protein is a major sensor of cellular stresses, and upon stabilization, activates or represses many genes that control cell fate decisions. While the mechanism of p53-mediated transactivation is well established, several mechanisms have been proposed for p53-mediated repression. Here, we demonstrate that the cyclin-dependent kinase inhibitor p21 is both necessary and sufficient for the downregulation of known p53-repression targets, including survivin, CDC25C, and CDC25B in response to p53 induction. These same targets are similarly repressed in response to p16 overexpression, implicating the involvement of the shared downstream retinoblastoma (RB)-E2F pathway. We further show that in response to either p53 or p21 induction, E2F4 complexes are specifically recruited onto the promoters of these p53-repression targets. Moreover, abrogation of E2F4 recruitment via the inactivation of RB pocket proteins, but not by RB loss of function alone, prevents the repression of these genes. Finally, our results indicate that E2F4 promoter occupancy is globally associated with p53-repression targets, but not with p53 activation targets, implicating E2F4 complexes as effectors of p21-dependent p53-mediated repression.	[Benson, E. K.; Mungamuri, S. K.; Kracikova, M.; Manfredi, J. J.; Aaronson, S. A.] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA; [Attie, O.; Sachidanandam, R.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Aaronson, SA (corresponding author), Mt Sinai Sch Med, Dept Oncol Sci, 1 Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.	stuart.aaronson@mssm.edu	sachidanandam, ravi/Q-6916-2019	sachidanandam, ravi/0000-0001-9844-4459; Mungamuri, Sathish Kumar/0000-0002-0012-5298	Breast Cancer Research Foundation; National Cancer Institute [P01CA080058]; NCI [T32CA078207]; NATIONAL CANCER INSTITUTE [T32CA078207, P01CA080058] Funding Source: NIH RePORTER	Breast Cancer Research Foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by grants from the Breast Cancer Research Foundation and by Award Number P01CA080058 from the National Cancer Institute. EB was supported by the NCI Training Program in Cancer Biology (T32CA078207). We thank S Lee, Cutaneous Biology Research, MGH Harvard Medical School for helpful discussions.	Akiri G, 2009, ONCOGENE, V28, P2163, DOI 10.1038/onc.2009.82; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Banerjee T, 2009, NUCLEIC ACIDS RES, V37, P2688, DOI 10.1093/nar/gkp110; Benson EK, 2010, J CELL SCI, V123, P2605, DOI 10.1242/jcs.067306; Bindra RS, 2006, CANCER BIOL THER, V5, P1400, DOI 10.4161/cbt.5.10.3454; Bohlig L, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/464916; Brooks CL, 2010, CELL RES, V20, P614, DOI 10.1038/cr.2010.53; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burger A, 2010, P NATL ACAD SCI USA, V107, P4016, DOI 10.1073/pnas.0915138107; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Crosby ME, 2004, CANCER BIOL THER, V3, P1208, DOI 10.4161/cbt.3.12.1494; Dalvai M, 2011, ONCOGENE, V30, P2282, DOI 10.1038/onc.2010.588; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Esteve PO, 2007, J BIOL CHEM, V282, P2615, DOI 10.1074/jbc.M606203200; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; Godefroy N, 2004, NUCLEIC ACIDS RES, V32, P4480, DOI 10.1093/nar/gkh773; Gottifredi V, 2001, MOL CELL BIOL, V21, P1066, DOI 10.1128/MCB.21.4.1066-1076.2001; Hammond EM, 2006, MOL CELL BIOL, V26, P3492, DOI 10.1128/MCB.26.9.3492-3504.2006; Helmbold H, 2009, ONCOGENE, V28, P3456, DOI 10.1038/onc.2009.222; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Innocente SA, 2005, FEBS LETT, V579, P1001, DOI 10.1016/j.febslet.2004.12.073; Jung YS, 2010, CELL SIGNAL, V22, P1003, DOI 10.1016/j.cellsig.2010.01.013; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Komori H, 2005, EMBO J, V24, P3724, DOI 10.1038/sj.emboj.7600836; Kracikova M, 2013, CELL DEATH DIFFER, V20, P576, DOI 10.1038/cdd.2012.155; Lammens T, 2009, TRENDS CELL BIOL, V19, P111, DOI 10.1016/j.tcb.2009.01.002; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Lee BK, 2011, NUCLEIC ACIDS RES, V39, P3558, DOI 10.1093/nar/gkq1313; Li BQ, 2001, J BIOL CHEM, V276, P29729, DOI 10.1074/jbc.M101167200; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Litovchick L, 2011, GENE DEV, V25, P801, DOI 10.1101/gad.2034211; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; Mandinova A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001366; Matsui T, 2004, J BIOL CHEM, V279, P25093, DOI 10.1074/jbc.M403232200; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; Mungamuri SK, 2012, NAT STRUCT MOL BIOL, V19, P478, DOI 10.1038/nsmb.2271; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Rashid NN, 2011, J GEN VIROL, V92, P2620, DOI 10.1099/vir.0.035352-0; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Rother K, 2007, CELL CYCLE, V6, P853, DOI 10.4161/cc.6.7.4017; Roy S, 2008, MOL CANCER THER, V7, P1931, DOI 10.1158/1535-7163.MCT-07-2353; Sengupta S, 2005, ONCOGENE, V24, P1738, DOI 10.1038/sj.onc.1208380; Shats I, 2004, J BIOL CHEM, V279, P50976, DOI 10.1074/jbc.M402502200; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Spurgers KB, 2006, J BIOL CHEM, V281, P25134, DOI 10.1074/jbc.M513901200; St Clair S, 2004, MOL CELL, V16, P725; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Takahashi Y, 2000, GENE DEV, V14, P804; Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; TSANG NM, 1994, RADIAT RES, V140, P172, DOI 10.2307/3578900; Ucar D, 2009, BIOINFORMATICS, V25, pI137, DOI 10.1093/bioinformatics/btp213; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang B, 2010, CELL CYCLE, V9, P870, DOI 10.4161/cc.9.5.10825; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Zeng YX, 2011, CANCER RES, V71, P2781, DOI 10.1158/0008-5472.CAN-10-3483; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	69	69	69	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3959	3969		10.1038/onc.2013.378	http://dx.doi.org/10.1038/onc.2013.378			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	24096481	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000339394700008
J	Liu, J; Visser-Grieve, S; Boudreau, J; Yeung, B; Lo, S; Chamberlain, G; Yu, F; Sun, T; Papanicolaou, T; Lam, A; Yang, X; Chin-Sang, I				Liu, J.; Visser-Grieve, S.; Boudreau, J.; Yeung, B.; Lo, S.; Chamberlain, G.; Yu, F.; Sun, T.; Papanicolaou, T.; Lam, A.; Yang, X.; Chin-Sang, I.			Insulin activates the insulin receptor to downregulate the PTEN tumour suppressor	ONCOGENE			English	Article						PTEN; C. elegans; tumour suppressor; cancer; insulin signaling; genetics	GROWTH-FACTOR RECEPTOR; CAENORHABDITIS-ELEGANS; C-ELEGANS; BREAST-CANCER; LIFE-SPAN; SIGNALING PATHWAY; DAUER FORMATION; CELL-MIGRATION; DAF-2; PHOSPHATASE	Insulin and insulin-like growth factor-1 signaling have fundamental roles in energy metabolism, growth and development. Recent research suggests hyperactive insulin receptor (IR) and hyperinsulinemia are cancer risk factors. However, the mechanisms that account for the link between the hyperactive insulin signaling and cancer risk are not well understood. Here we show that an insulin-like signaling inhibits the DAF-18/(phosphatase and tensin homolog) PTEN tumour suppressor in Caenorhabditis elegans and that this regulation is conserved in human breast cancer cells. We show that inhibiting the IR increases PTEN protein levels, while increasing insulin signaling decreases PTEN protein levels. Our results show that the kinase region of IR beta subunit physically binds to PTEN and phosphorylates on Y27 and Y174. Our genetic results also show that DAF-2/IR negatively regulates DAF-18/PTEN during C. elegans axon guidance. As PTEN is an important tumour suppressor, our results therefore suggest a possible mechanism for increased cancer risk observed in hyperinsulinemia and hyperactive IR individuals.	[Liu, J.; Boudreau, J.; Lo, S.; Chamberlain, G.; Yu, F.; Papanicolaou, T.; Lam, A.; Chin-Sang, I.] Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada; [Visser-Grieve, S.; Yeung, B.; Yang, X.] Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; [Sun, T.] Queens Univ, Dept Physiol, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada; Queens University - Canada	Chin-Sang, I (corresponding author), Queens Univ, Dept Biol, 116 Barrie St, Kingston, ON K7L 3N6, Canada.	chinsang@queensu.ca		Liu, Jun/0000-0001-6472-3871; Yu, Fabian/0000-0002-0358-2793; Chin-Sang, Ian/0000-0001-7480-9775; Grieve, Stacy/0000-0003-3090-5583	Natural Sciences and Engineering Research Council of Canada [NSERC 249779]; Canadian Cancer Society Research Institute [CCSRI 700219]; NIH Office of Research Infrastructure Programs [P40 OD010440]; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [P40OD010440] Funding Source: NIH RePORTER	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); NIH Office of Research Infrastructure Programs(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The work in the Chin-Sang lab is supported by grants from the Natural Sciences and Engineering Research Council of Canada (NSERC 249779) and the Canadian Cancer Society Research Institute (CCSRI 700219). We are grateful to Caenorhabditis Genomic Center for providing strains, which is funded by the NIH Office of Research Infrastructure Programs (P40 OD010440). The daf-18 (ok480) mutant was obtained from the C. elegans knockout consortium (Oklahoma Medical Research Foundation). We thank Drs Mei Zhen and Scott Clark for sharing strains. We thank all members of the Chin-Sang Lab, and Drs William Bendena and Hanzhi Wang for helpful discussion.	Adler CE, 2006, NAT NEUROSCI, V9, P511, DOI 10.1038/nn1666; Belfiore A, 2011, ENDOCR-RELAT CANCER, V18, pR125, DOI 10.1530/ERC-11-0074; Bowker SL, 2006, DIABETES CARE, V29, P254, DOI 10.2337/diacare.29.02.06.dc05-1558; BRENNER S, 1974, GENETICS, V77, P71; Brisbin S, 2009, DEV CELL, V17, P459, DOI 10.1016/j.devcel.2009.08.009; Chin-Sang ID, 1999, CELL, V99, P781, DOI 10.1016/S0092-8674(00)81675-X; Christensen R, 2011, DEVELOPMENT, V138, P5257, DOI 10.1242/dev.069062; Clark SG, 2003, DEVELOPMENT, V130, P3781, DOI 10.1242/dev.00571; Depowski PL, 2001, MODERN PATHOL, V14, P672, DOI 10.1038/modpathol.3880371; DORMAN JB, 1995, GENETICS, V141, P1399; Eckardt K, 2007, DIABETOLOGIA, V50, P2534, DOI 10.1007/s00125-007-0815-9; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Finch CE, 2001, ANNU REV GENOM HUM G, V2, P435, DOI 10.1146/annurev.genom.2.1.435; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Gallagher EJ, 2011, ENDOCRINOLOGY, V152, P2546, DOI 10.1210/en.2011-0231; Halaschek-Wiener J, 2005, GENOME RES, V15, P603, DOI 10.1101/gr.3274805; Kenyon C, 2010, ANN NY ACAD SCI, V1204, P156, DOI 10.1111/j.1749-6632.2010.05640.x; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Law JH, 2008, CANCER RES, V68, P10238, DOI 10.1158/0008-5472.CAN-08-2755; Li WQ, 2003, GENE DEV, V17, P844, DOI 10.1101/gad.1066503; Mahimainathan L, 2004, J BIOL CHEM, V279, P15258, DOI 10.1074/jbc.M314328200; Malone EA, 1996, GENETICS, V143, P1193; MILAZZO G, 1992, CANCER RES, V52, P3924; Mohamed AM, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002513; Mohamed AM, 2006, DEV BIOL, V290, P164, DOI 10.1016/j.ydbio.2005.11.019; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Naguib A, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-123; Nakdimon I, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002881; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Patel DS, 2008, GENETICS, V178, P931, DOI 10.1534/genetics.107.070813; Pocock R, 2008, NAT NEUROSCI, V11, P894, DOI 10.1038/nn.2152; Pollak M, 2012, CLIN CANCER RES, V18, P40, DOI 10.1158/1078-0432.CCR-11-0998; Porte D, 2005, DIABETES, V54, P1264, DOI 10.2337/diabetes.54.5.1264; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Sciacca L, 2002, ONCOGENE, V21, P8240, DOI 10.1038/sj.onc.1206058; Solari F, 2005, ONCOGENE, V24, P20, DOI 10.1038/sj.onc.1207978; Song JB, 2003, SCIENCE, V300, P502, DOI 10.1126/science.1081203; Song MS, 2011, CELL, V144, P187, DOI 10.1016/j.cell.2010.12.020; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tibarewal P, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002138; Tullet JMA, 2008, CELL, V132, P1025, DOI 10.1016/j.cell.2008.01.030; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Yang XL, 2011, CELL RES, V21, P715, DOI 10.1038/cr.2011.63; Yim EK, 2009, CANCER CELL, V15, P304, DOI 10.1016/j.ccr.2009.02.012; Yin Y, 2008, ONCOGENE, V27, P5443, DOI 10.1038/onc.2008.241; Zhang H, 2010, ONCOGENE, V29, P2517, DOI 10.1038/onc.2010.17	47	19	21	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3878	3885		10.1038/onc.2013.347	http://dx.doi.org/10.1038/onc.2013.347			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23995781				2022-12-28	WOS:000339394100014
J	Chen, CC; Liu, HP; Chao, M; Liang, Y; Tsang, NM; Huang, HY; Wu, CC; Chang, YS				Chen, C-C; Liu, H-P; Chao, M.; Liang, Y.; Tsang, N-M; Huang, H-Y; Wu, C-C; Chang, Y-S			NF-kappa B-mediated transcriptional upregulation of TNFAIP2 by the Epstein-Barr virus oncoprotein, LMP1, promotes cell motility in nasopharyngeal carcinoma	ONCOGENE			English	Article						TNFAIP2; LMP1; NPC; NF-kappa B; actin; migration	LYMPH-NODE METASTASIS; PRIMARY RESPONSE GENE; NECROSIS-FACTOR-ALPHA; MEMBRANE-PROTEIN 1; EBV LATENT-MEMBRANE-PROTEIN-1; LATENT MEMBRANE-PROTEIN-1; TUNNELING NANOTUBULES; ORGANELLE TRANSFER; EPITHELIAL-CELLS; FILOPODIA	Nasopharyngeal carcinoma (NPC), which is closely associated with Epstein-Barr virus (EBV), is a metastasis-prone epithelial cancer. We previously showed that tumor necrosis factor alpha-induced protein 2 (TNFAIP2) is highly expressed in NPC tumor tissues and is correlated with metastasis and poor survival in NPC patients. However, the underlying mechanism remains unclear. In this study, we demonstrate that the EBV oncoprotein, latent membrane protein 1 (LMP1), can transcriptionally induce TNFAIP2 expression via NF-kappa B. Quantitative RT-PCR and western blotting revealed that LMP1 induces TNFAIP2 expression through its C-terminal- activating region (CTAR2) domain, which is required for transduction of NF-kappa B (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling. Inhibition of NF-kappa B activation or depletion of p65 (a component of NF-kappa B) by RNA interference abolished the LMP1-induced expression of TNFAIP2, whereas ectopic expression of p65 was sufficient to induce TNFAIP2 expression. Luciferase reporter assays showed that LMP1 transcriptionally induces TNFAIP2 expression through a newly identified NF-kappa B-binding site within the TNFAIP2 promoter (- 3.869 to - 3.860 bp). Immunohistochemical analysis of NPC biopsy specimens further revealed a significant correlation between the protein levels of TNFAIP2 and activated p65 (R = 0.689, P < 0.001), indicating that our findings are clinically relevant. Immunofluorescence microscopy and co-immunoprecipitation assays showed that TNFAIP2 associates with actin and is involved in the formation of actin-based membrane protrusions. Furthermore, transwell migration assays demonstrated that TNFAIP2 contributes to LMP1-induced cell motility. Collectively, these findings provide novel insights into the regulation of TNFAIP2 and its role in promoting NPC tumor progression.	[Chen, C-C; Liu, H-P; Liang, Y.; Chang, Y-S] Chang Gung Univ, Grad Inst Biomed Sci, Chang Gung Mol Med Res Ctr, Taoyuan 333, Taiwan; [Chao, M.; Huang, H-Y] Chang Gung Univ, Grad Inst Biomed Sci, Taoyuan 333, Taiwan; [Tsang, N-M] Chang Gung Mem Hosp Lin Kou, Dept Radiat Oncol, Kwei Shan, Taiwan; [Wu, C-C] Chang Gung Univ, Dept Med Biotechnol & Lab Sci, Taoyuan 333, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University	Chang, YS (corresponding author), Chang Gung Univ, Grad Inst Biomed Sci, Chang Gung Mol Med Res Ctr, 259,Wen Hwa 1st Rd, Taoyuan 333, Taiwan.	ysc@mail.cgu.edu.tw	Liu, Hao-Ping/AAJ-3038-2020	Liu, Hao-Ping/0000-0001-5915-5128; Chao, Mei/0000-0002-2143-0531; Chang, Yu-Sun/0000-0002-6457-3890; Wu, Chih-Ching/0000-0002-7264-9672	Ministry of Education of Taiwan	Ministry of Education of Taiwan(Ministry of Education, Taiwan)	We are grateful to Ms Jennifer Cheng for her technical assistance in image acquisition and analysis using the IN Cell Analyzer 2000. This work was supported by the grant from the Ministry of Education of Taiwan (to Chang Gung University).	Abounit S, 2012, J CELL SCI, V125, P1089, DOI 10.1242/jcs.083279; Arjonen A, 2011, CELL ADHES MIGR, V5, P421, DOI 10.4161/cam.5.5.17723; Beckers J, 2005, INT J CANCER, V114, P590, DOI 10.1002/ijc.20798; Chen CC, 2010, CELL SIGNAL, V22, P1132, DOI 10.1016/j.cellsig.2010.03.008; Chen HL, 2010, EXP MOL PATHOL, V89, P367, DOI 10.1016/j.yexmp.2010.09.004; Chen LC, 2011, MODERN PATHOL, V24, P175, DOI 10.1038/modpathol.2010.193; Chen MC, 2008, ANN ONCOL, V19, P1180, DOI 10.1093/annonc/mdn003; Chen P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056929; Cheng YH, 2011, J MOL ENDOCRINOL, V46, P139, DOI 10.1530/JME-10-0064; Chevrier N, 2011, CELL, V147, P853, DOI 10.1016/j.cell.2011.10.022; Chinnery HR, 2008, J IMMUNOL, V180, P5779, DOI 10.4049/jimmunol.180.9.5779; Davis DM, 2008, NAT REV MOL CELL BIO, V9, P431, DOI 10.1038/nrm2399; Faix J, 2006, CURR OPIN CELL BIOL, V18, P18, DOI 10.1016/j.ceb.2005.11.002; Gourzones C, 2012, SEMIN CANCER BIOL, V22, P127, DOI 10.1016/j.semcancer.2012.01.002; Hase K, 2009, NAT CELL BIOL, V11, P1427, DOI 10.1038/ncb1990; Ho FCH, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-98; Hong EJ, 2011, MOL ENDOCRINOL, V25, P269, DOI 10.1210/me.2010-0483; Hui EP, 2002, CLIN CANCER RES, V8, P2595; Zheng H, 2007, CELL MOL IMMUNOL, V4, P185; Jia WH, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-178; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kimura S, 2012, EXP CELL RES, V318, P1699, DOI 10.1016/j.yexcr.2012.05.013; Kondratiev S, 2011, AM J SURG PATHOL, V35, P1531, DOI 10.1097/PAS.0b013e31822bd476; Larkin JD, 2012, MOL CELL BIOL, V32, P2738, DOI 10.1128/MCB.00179-12; LEE AWM, 1992, INT J RADIAT ONCOL, V23, P261, DOI 10.1016/0360-3016(92)90740-9; Li HP, 2003, J BIOMED SCI, V10, P490, DOI 10.1159/000072376; Lin SY, 2001, HEAD NECK-J SCI SPEC, V23, P194, DOI 10.1002/1097-0347(200103)23:3<194::AID-HED1018>3.0.CO;2-X; Liu HP, 2006, EMBO J, V25, P4120, DOI 10.1038/sj.emboj.7601282; Liu HP, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002690; Liu ZS, 2011, CARCINOGENESIS, V32, P1668, DOI 10.1093/carcin/bgr209; Lo AKF, 2006, NEOPLASIA, V8, P173, DOI 10.1593/neo.05625; Lui VWY, 2011, ONCOGENE, V30, P1518, DOI 10.1038/onc.2010.529; Ma Y, 2003, ONCOGENE, V22, P4924, DOI 10.1038/sj.onc.1206728; Marsman J, 2012, BBA-GENE REGUL MECH, V1819, P1217, DOI 10.1016/j.bbagrm.2012.10.008; Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406; Mookherjee N, 2006, J IMMUNOL, V176, P2455, DOI 10.4049/jimmunol.176.4.2455; Mothes W, 2010, J VIROL, V84, P8360, DOI 10.1128/JVI.00443-10; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Ranzinger J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029537; Rusiniak ME, 2000, CANCER RES, V60, P1824; SARMA V, 1992, J IMMUNOL, V148, P3302; Sherer NM, 2008, TRENDS CELL BIOL, V18, P414, DOI 10.1016/j.tcb.2008.07.003; Sherer NM, 2010, J VIROL, V84, P3248, DOI 10.1128/JVI.02155-09; Singh SK, 2010, FASEB J, V24, P3756, DOI 10.1096/fj.10-159046; Slaby O, 2013, NUTR CANCER, V65, P247, DOI 10.1080/01635581.2013.756530; Smith IF, 2011, BIOPHYS J, V100, pL37, DOI 10.1016/j.bpj.2011.03.007; Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682; Spano JP, 2003, EUR J CANCER, V39, P2121, DOI 10.1016/S0959-8049(03)00367-8; Tsai CL, 2006, CANCER RES, V66, P11668, DOI 10.1158/0008-5472.CAN-06-2194; Tsuji A, 2008, CLIN CANCER RES, V14, P5368, DOI 10.1158/1078-0432.CCR-08-0198; Van Prooyen N, 2010, P NATL ACAD SCI USA, V107, P20738, DOI 10.1073/pnas.1009635107; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Wang Y, 2011, CELL DEATH DIFFER, V18, P732, DOI 10.1038/cdd.2010.147; Watkins SC, 2005, IMMUNITY, V23, P309, DOI 10.1016/j.immuni.2005.08.009; WOLF FW, 1994, J BIOL CHEM, V269, P3633; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452	56	41	43	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3648	3659		10.1038/onc.2013.345	http://dx.doi.org/10.1038/onc.2013.345			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23975427				2022-12-28	WOS:000338942900004
J	de Giorgio, A; Castellano, L; Krell, J; Stebbing, J				de Giorgio, A.; Castellano, L.; Krell, J.; Stebbing, J.			Crosstalk-induced loss of miR-126 promotes angiogenesis	ONCOGENE			English	Editorial Material							ENDOTHELIAL GROWTH-FACTOR; EXPRESSION; MICRORNAS	A molecular environment that promotes vascularization around human carcinomas can materialise rapidly, and has been termed the angiogenic switch. Turning this switch toward a proangiogenic state involves an altered interplay between tumor cells and multiple components of the surrounding stroma. The regulatory landscape of these interactions in cervical cancer is now investigated by Huang et al. in this issue of Oncogene, who demonstrate that the microRNA miR-126 is downregulated during cancer progression, particularly in stromal cells. Such a reduction of miR-126 is shown to free at least one target, the proangiogenic adrenomedullin, from repression, enhancing vascular growth especially at the in situ to invasive carcinoma transition. The study implicates the temporal, spatial and progressive nature of tumor-stroma interactions during carcinogenesis, while in turn suggesting therapeutic strategies.	[de Giorgio, A.; Castellano, L.; Krell, J.; Stebbing, J.] Univ London Imperial Coll Sci Technol & Med, Div Oncol, Dept Surg & Canc, Imperial Ctr Translat & Expt Med, London W12 0NN, England	Imperial College London	Stebbing, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Oncol, Dept Surg & Canc, Imperial Ctr Translat & Expt Med, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	j.stebbing@imperial.ac.uk	Castellano, Leandro/AAE-1366-2021	Stebbing, Justin/0000-0002-1117-6947; Castellano, Leandro/0000-0002-3059-4829	National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish; Department of Health [NIHR-RP-011-053] Funding Source: Medline	National Institute for Health Research(National Institute for Health Research (NIHR)); Department of Health		Anand S, 2011, CURR OPIN HEMATOL, V18, P171, DOI 10.1097/MOH.0b013e328345a180; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008; GUIDI AJ, 1995, J NATL CANCER I, V87, P1237, DOI 10.1093/jnci/87.16.1237; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris TA, 2008, P NATL ACAD SCI USA, V105, P1516, DOI 10.1073/pnas.0707493105; Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3; Huang T- H, 2013, ONCOGENE UNPUB; Ribatti D, 2005, PEPTIDES, V26, P1670, DOI 10.1016/j.peptides.2005.02.017; Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156; Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002; Zhu N, 2011, MOL CELL BIOCHEM, V351, P157, DOI 10.1007/s11010-011-0723-7	13	11	11	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3634	3635		10.1038/onc.2013.317	http://dx.doi.org/10.1038/onc.2013.317			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	24013227				2022-12-28	WOS:000338942900002
J	Wu, YH; Chang, TH; Huang, YF; Huang, HD; Chou, CY				Wu, Y-H; Chang, T-H; Huang, Y-F; Huang, H-D; Chou, C-Y			COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer	ONCOGENE			English	Article						COL11A1; tumor progression; ovarian carcinoma	GENE-EXPRESSION PROFILES; ETS-1 TRANSCRIPTION FACTOR; SQUAMOUS-CELL CARCINOMA; MATRIX METALLOPROTEINASES; EXTRACELLULAR-MATRIX; CLEAR-CELL; TGF-BETA; IN-SITU; PROTOONCOGENE; METASTASIS	Biomarkers that predict disease progression might assist the development of better therapeutic strategies for aggressive cancers, such as ovarian cancer. Here, we investigated the role of collagen type XI alpha 1 (COL11A1) in cell invasiveness and tumor formation and the prognostic impact of COL11A1 expression in ovarian cancer. Microarray analysis suggested that COL11A1 is a disease progression-associated gene that is linked to ovarian cancer recurrence and poor survival. Small interference RNA-mediated specific reduction in COL11A1 protein levels suppressed the invasive ability and oncogenic potential of ovarian cancer cells and decreased tumor formation and lung colonization in mouse xenografts. A combination of experimental approaches, including real-time RT-PCR, casein zymography and chromatin immunoprecipitation (ChIP) assays, showed that COL11A1 knockdown attenuated MMP3 expression and suppressed binding of Ets-1 to its putative MMP3 promoter-binding site, suggesting that the Ets-1-MMP3 axis is upregulated by COL11A1. Transforming growth factor (TGF)-beta (TGF-beta 1) treatment triggers the activation of smad2 signaling cascades, leading to activation of COL11A1 and MMP3. Pharmacological inhibition of MMP3 abrogated the TGF-beta 1-triggered, COL11A1-dependent cell invasiveness. Furthermore, the NF-YA-binding site on the COL11A1 promoter was identified as the major determinant of TGF-beta 1-dependent COL11A1 activation. Analysis of 88 ovarian cancer patients indicated that high COL11A1 mRNA levels are associated with advanced disease stage. The 5-year recurrence-free and overall survival rates were significantly lower (P=0.006 and P=0.018, respectively) among patients with high expression levels of tissue COL11A1 mRNA compared with those with low expression. We conclude that COL11A1 may promote tumor aggressiveness via the TGF-beta 1-MMP3 axis and that COL11A1 expression can predict clinical outcome in ovarian cancer patients.	[Wu, Y-H] Natl Cheng Kung Univ Hosp, Canc Res Ctr, Tainan 70428, Taiwan; [Chang, T-H] Taipei Med Univ, Grad Inst Biomed Informat, Taipei, Taiwan; [Huang, Y-F; Chou, C-Y] Natl Cheng Kung Univ & Hosp, Dept Obstet & Gynecol, Coll Med, Tainan 70403, Taiwan; [Huang, H-D] Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu, Taiwan; [Huang, H-D] Natl Chiao Tung Univ, Inst Bioinformat & Syst Biol, Hsinchu, Taiwan	National Cheng Kung University; National Cheng Kung University Hospital; Taipei Medical University; National Cheng Kung University; National Cheng Kung University Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Chou, CY (corresponding author), Natl Cheng Kung Univ & Hosp, Dept Obstet & Gynecol, Coll Med, Tainan 70403, Taiwan.	bryan@mail.nctu.edu.tw; chougyn@mail.ncku.edu.tw	Huang, Hsien-Da/AAA-7376-2019		'To establish centers of excellence for cancer research in Taiwan', Department of Health, Executive Yuan, Taiwan [DOH101-TD-C-111-003]; Taipei Medical University [TMU101-AE1-B44];  [NSC 101-2911-I-009-101];  [NSC 101-2311-B-009-003-MY3];  [NSC 100-2627-B-009-002]	'To establish centers of excellence for cancer research in Taiwan', Department of Health, Executive Yuan, Taiwan; Taipei Medical University; ; ; 	This study was supported by 'To establish centers of excellence for cancer research in Taiwan' (DOH101-TD-C-111-003), Department of Health, Executive Yuan, Taiwan. This work was supported in part by National Science Council under Grant No.: NSC 101-2911-I-009-101, NSC 101-2311-B-009-003-MY3 and NSC 100-2627-B-009-002. The research was supported in part by Taipei Medical University under grant TMU101-AE1-B44.	Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Alabert C, 2006, ONCOGENE, V25, P3387, DOI 10.1038/sj.onc.1209385; Badea L, 2008, HEPATO-GASTROENTEROL, V55, P2016; Belotti D, 2003, CANCER RES, V63, P5224; Berchuck A, 2005, CLIN CANCER RES, V11, P3686, DOI 10.1158/1078-0432.CCR-04-2398; Bjorklund M, 2005, BBA-REV CANCER, V1755, P37, DOI 10.1016/j.bbcan.2005.03.001; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Bowen KB, 2008, J HISTOCHEM CYTOCHEM, V56, P275, DOI 10.1369/jhc.7A7310.2007; Choi JW, 2011, ONCOL LETT, V2, P1047, DOI 10.3892/ol.2011.391; Chong IW, 2006, ONCOL REP, V16, P981; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Fischer H, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-17; Fischer H, 2001, CARCINOGENESIS, V22, P875, DOI 10.1093/carcin/22.6.875; Gaspar NJ, 2007, MOL PHARMACOL, V72, P152, DOI 10.1124/mol.106.029025; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gentleman R, 2005, AFFYQCREPORT QC REPO; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hartmann LC, 2005, CLIN CANCER RES, V11, P2149, DOI 10.1158/1078-0432.CCR-04-1673; Hau P, 2007, OLIGONUCLEOTIDES, V17, P201, DOI 10.1089/oli.2006.0053; Horvath B, 2005, HEAD NECK-J SCI SPEC, V27, P585, DOI 10.1002/hed.20188; Ito T, 1998, MODERN PATHOL, V11, P209; Ito Y, 2000, AM J CLIN PATHOL, V114, P719, DOI 10.1309/RAVV-8NM1-CJB7-GJFR; Ito Y, 2000, ONCOLOGY-BASEL, V58, P248, DOI 10.1159/000012108; Jazaeri AA, 2005, CLIN CANCER RES, V11, P6300, DOI 10.1158/1078-0432.CCR-04-2682; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Kenny HA, 2008, J CLIN INVEST, V118, P1367, DOI 10.1172/JCI33775; Khatun S, 2003, CANCER SCI, V94, P769, DOI 10.1111/j.1349-7006.2003.tb01517.x; Kim HJ, 2010, J CERAM PROCESS RES, V11, P11; Kitange G, 1999, MODERN PATHOL, V12, P618; Knudsen ES, 2012, BREAST CANCER RES TR, V133, P1009, DOI 10.1007/s10549-011-1894-3; Konstantinopoulos PA, 2010, J CLIN ONCOL, V28, P3555, DOI 10.1200/JCO.2009.27.5719; Leroy-Dudal J, 2005, INT J CANCER, V114, P531, DOI 10.1002/ijc.20778; Matsuo N, 2003, J BIOL CHEM, V278, P32763, DOI 10.1074/jbc.M305599200; Nakayama T, 1999, MODERN PATHOL, V12, P61; Nakayama T, 1996, AM J PATHOL, V149, P1931; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Ozaki I, 2000, CANCER RES, V60, P6519; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Rae MT, 2009, FERTIL STERIL, V92, P703, DOI 10.1016/j.fertnstert.2008.06.040; Saeki H, 2000, CANCER, V89, P1670, DOI 10.1002/1097-0142(20001015)89:8<1670::AID-CNCR4>3.0.CO;2-J; Sato Y, 2000, ADV EXP MED BIOL, V476, P109; Schmalbach CE, 2004, ARCH OTOLARYNGOL, V130, P295, DOI 10.1001/archotol.130.3.295; Schuetz CS, 2006, CANCER RES, V66, P5278, DOI 10.1158/0008-5472.CAN-05-4610; Schwartz DR, 2002, CANCER RES, V62, P4722; Shridhar V, 2001, CANCER RES, V61, P5895; Spentzos D, 2004, J CLIN ONCOL, V22, P4700, DOI 10.1200/JCO.2004.04.070; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Stracke M L, 1994, In Vivo, V8, P49; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Turashvili G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-55; Vecchi M, 2007, ONCOGENE, V26, P4284, DOI 10.1038/sj.onc.1210208; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wu YH, 2010, CANCER RES, V70, P10422, DOI 10.1158/0008-5472.CAN-10-2615; Yamamura S, 2012, INT J CANCER, V130, P20, DOI 10.1002/ijc.25961; Zorn KK, 2005, CLIN CANCER RES, V11, P6422, DOI 10.1158/1078-0432.CCR-05-0508	58	136	138	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3432	3440		10.1038/onc.2013.307	http://dx.doi.org/10.1038/onc.2013.307			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23934190				2022-12-28	WOS:000338779300010
J	Cipriano, R; Bryson, BL; Miskimen, KLS; Bartel, CA; Hernandez-Sanchez, W; Bruntz, RC; Scott, SA; Lindsley, CW; Brown, HA; Jackson, MW				Cipriano, R.; Bryson, B. L.; Miskimen, K. L. S.; Bartel, C. A.; Hernandez-Sanchez, W.; Bruntz, R. C.; Scott, S. A.; Lindsley, C. W.; Brown, H. A.; Jackson, M. W.			Hyperactivation of EGFR and downstream effector phospholipase D1 by oncogenic FAM83B	ONCOGENE			English	Article						FAM83B; EGFR; PLD1; MAPK; mTOR; HMEC transformation	HUMAN BREAST-CANCER; PHOSPHATIDIC-ACID; CELLS; TRANSFORMATION; ACTIVATION; KINASE; SURVIVAL; RAS; RESISTANCE; NUTLIN-3	Despite the progress made in targeted anticancer therapies in recent years, challenges remain. The identification of new potential targets will ensure that the arsenal of cancer therapies continues to expand. FAM83B was recently discovered in a forward genetic screen for novel oncogenes that drive human mammary epithelial cell (HMEC) transformation. We report here that elevated FAM83B expression increases Phospholipase D (PLD) activity, and that suppression of PLD1 activity prevents FAM83B-mediated transformation. The increased PLD activity is engaged by hyperactivation of epidermal growth factor receptor (EGFR), which is regulated by an interaction involving FAM83B and EGFR. Preventing the FAM83B/EGFR interaction by site-directed mutation of lysine 230 of FAM83B suppressed PLD activity and MAPK signaling. Furthermore, ablation of FAM83B expression from breast cancer cells inhibited EGFR phosphorylation and suppressed cell proliferation. We propose that understanding the mechanism of FAM83B-mediated transformation will provide a foundation for future therapies aimed at targeting its function as an intermediary in EGFR, MAPK and mTOR activation.	[Cipriano, R.; Bryson, B. L.; Miskimen, K. L. S.; Bartel, C. A.; Hernandez-Sanchez, W.; Jackson, M. W.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; [Bruntz, R. C.; Scott, S. A.; Brown, H. A.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Vanderbilt Inst Chem Biol,Vanderbilt Ingram Canc, Nashville, TN 37232 USA; [Lindsley, C. W.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA; [Lindsley, C. W.] Vanderbilt Univ, Med Ctr, Dept Chem, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN USA; [Brown, H. A.] Vanderbilt Univ, Med Ctr, Vanderbilt Inst Chem Biol, Vanderbilt Ingram Canc Ctr,Dept Chem, Nashville, TN USA; [Brown, H. A.] Vanderbilt Univ, Med Ctr, Vanderbilt Inst Chem Biol, Vanderbilt Ingram Canc Ctr,Dept Biochem, Nashville, TN USA; [Jackson, M. W.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Case Western Reserve University	Jackson, MW (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pathol, Case Comprehens Canc Ctr, 2103 Cornell Rd,WRB 3-134, Cleveland, OH 44106 USA.	mark.w.jackson@case.edu	Bryson, Benjamin L/D-1070-2014	Bryson, Benjamin L/0000-0003-4131-0200; Hernandez-Sanchez, Wilnelly/0000-0003-0723-9738	US National Institutes of Health [R01CA138421, T32CA059366]; Department of Defense Breast Cancer Research Program [BC095847, BC074072]; American Cancer Society [RSG-10-072-01-TBG]; McDonnell Foundation; NIH MLPCN Vanderbilt Specialized Chemistry Center [U54 MH084659]; NATIONAL CANCER INSTITUTE [T32CA059366, P30CA043703, R01CA138421, T32CA009592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250, T32GM007628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [U54MH084659] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Breast Cancer Research Program(United States Department of Defense); American Cancer Society(American Cancer Society); McDonnell Foundation; NIH MLPCN Vanderbilt Specialized Chemistry Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We are grateful to Chase Foy for technical help and Damian Junk for helpful discussions. The core facilities provided by the Case Comprehensive Cancer Center (P30 CA43703; Athymic Animal and Xenograft Core Facility; Gene Expression and Genotyping Core Facility; Cytometry and Imaging Microscopy Core Facility; Radiation Resources Core Facility). This work was supported by the US National Institutes of Health (R01CA138421 to MWJ; T32CA059366 to RC and CB), the Department of Defense Breast Cancer Research Program (BC095847 and BC074072 to MWJ), the American Cancer Society (RSG-10-072-01-TBG to MWJ) and the McDonnell Foundation for brain cancer research (HAB) and the NIH MLPCN U54 MH084659 (CWL) Vanderbilt Specialized Chemistry Center for Accelerated Probe Development.	Brown HA, 2007, METHOD ENZYMOL, V434, P49, DOI 10.1016/S0076-6879(07)34004-4; Buchanan FG, 2005, P NATL ACAD SCI USA, V102, P1638, DOI 10.1073/pnas.0406698102; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Carraway H, 2004, BREAST CANCER RES, V6, P219, DOI 10.1186/bcr927; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034; Cipriano R, 2013, ONCOTARGET, V4, P729, DOI 10.18632/oncotarget.1027; Cipriano R, 2012, J CLIN INVEST, V122, P3197, DOI 10.1172/JCI60517; Cipriano R, 2010, CELL CYCLE, V9, P1373, DOI 10.4161/cc.9.7.11193; Foster D., 2006, CURRENT SIGNAL TRANS; Foster DA, 2003, MOL CANCER RES, V1, P789; Foster DA, 2007, CANCER RES, V67, P1, DOI 10.1158/0008-5472.CAN-06-3016; Foster DA, 2009, BBA-MOL CELL BIOL L, V1791, P949, DOI 10.1016/j.bbalip.2009.02.009; Ghosh S, 1997, BIOCHEM SOC T, V25, P561, DOI 10.1042/bst0250561; Grant S, 2008, J CLIN INVEST, V118, P3003, DOI 10.1172/JCI36898; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Jackson MW, 2004, ONCOGENE, V23, P4477, DOI 10.1038/sj.onc.1207575; Joseph T, 2001, BIOCHEM BIOPH RES CO, V289, P1019, DOI 10.1006/bbrc.2001.6118; Kan CE, 2007, CANCER RES, V67, P9862, DOI 10.1158/0008-5472.CAN-07-0259; Kassam F, 2009, CLIN BREAST CANCER, V9, P29, DOI 10.3816/CBC.2009.n.005; Kinkade CW, 2008, J CLIN INVEST, V118, P3051, DOI 10.1172/JCI34764; Kraft CA, 2008, J BIOL CHEM, V283, P36636, DOI 10.1074/jbc.M804633200; Ladeda V, 2001, BIOCHEM BIOPH RES CO, V283, P854, DOI 10.1006/bbrc.2001.4845; Lee SY, 2012, J CLIN INVEST, V122, P3211, DOI 10.1172/JCI60498; Noh DY, 2000, CANCER LETT, V161, P207, DOI 10.1016/S0304-3835(00)00612-1; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; REICH R, 1995, CLIN EXP METASTAS, V13, P134, DOI 10.1007/BF00133618; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Scott SA, 2009, NAT CHEM BIOL, V5, P108, DOI 10.1038/nchembio.140; Selvy PE, 2011, CHEM REV, V111, P6064, DOI 10.1021/cr200296t; Shi M, 2007, CANCER LETT, V258, P268, DOI 10.1016/j.canlet.2007.09.003; Toschi A, 2009, MOL CELL BIOL, V29, P1411, DOI 10.1128/MCB.00782-08; Uchida H, 1999, ANTICANCER RES, V19, P671; Uchida N, 1997, J CANCER RES CLIN, V123, P280, DOI 10.1007/s004320050060; Williger BT, 1999, J BIOL CHEM, V274, P735, DOI 10.1074/jbc.274.2.735; Xie Z, 1998, J BIOL CHEM, V273, P34679, DOI 10.1074/jbc.273.52.34679	39	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3298	3306		10.1038/onc.2013.293	http://dx.doi.org/10.1038/onc.2013.293			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23912460	Green Accepted			2022-12-28	WOS:000338443400009
J	Gilan, O; Diesch, J; Amalia, M; Jastrzebski, K; Chueh, AC; Verrills, NM; Pearson, RB; Mariadason, J; Tulchinsky, E; Hannan, RD; Dhillon, AS				Gilan, O.; Diesch, J.; Amalia, M.; Jastrzebski, K.; Chueh, A. C.; Verrills, N. M.; Pearson, R. B.; Mariadason, J. M.; Tulchinsky, E.; Hannan, R. D.; Dhillon, A. S.			PR55 alpha-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; FACTOR C-JUN; BETA-CATENIN; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; UP-REGULATION; DNA-BINDING; PP2A; FRA-1; PHOSPHORYLATION	The proto-oncogene c-Jun is a component of activator protein-1 (AP-1) transcription factor complexes that regulates processes essential for embryonic development, tissue homeostasis and malignant transformation. Induction of gene expression by c-Jun involves stimulation of its transactivation ability and upregulation of DNA binding capacity. While it is well established that the former requires JNK-mediated phosphorylation of S63/S73, the mechanism(s) through which binding of c-Jun to its endogenous target genes is regulated remains poorly characterized. Here we show that interaction of c-Jun with chromatin is positively regulated by protein phosphatase 2A (PP2A) complexes targeted to c-Jun by the PR55 alpha regulatory subunit. PR55 alpha-PP2A specifically dephosphorylates T239 of c-Jun, promoting its binding to genes regulating tumour cell migration and invasion. PR55 alpha-PP2A also enhanced transcription of these genes, without affecting phosphorylation of c-Jun on S63. These findings suggest a critical role for interplay between JNK and PP2A pathways determining the functional activity of c-Jun/AP-1 in tumour cells.	[Gilan, O.; Diesch, J.; Amalia, M.; Pearson, R. B.; Hannan, R. D.; Dhillon, A. S.] Peter MacCallum Canc Ctr, Div Res, East Melbourne, Vic, Australia; [Gilan, O.; Diesch, J.; Pearson, R. B.; Hannan, R. D.] Univ Melbourne, Inst Bio21, Biochem & Mol Biol, Parkville, Vic 3052, Australia; [Chueh, A. C.; Mariadason, J. M.] Ludwig Inst Canc Res, Heidelberg, Vic, Australia; [Verrills, N. M.] Univ Newcastle, Fac Hlth, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia; [Verrills, N. M.] Hunter Med Res Inst, New Lambton, NSW, Australia; [Pearson, R. B.; Hannan, R. D.; Dhillon, A. S.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, East Melbourne, Vic, Australia; [Pearson, R. B.; Hannan, R. D.] Monash Univ, Biochem & Mol Biol, Clayton, Vic, Australia; [Tulchinsky, E.] Univ Leicester, Canc Studies & Mol Med, Leicester, Leics, England; [Hannan, R. D.] Univ Queensland, SchBiomed Sci, St Lucia, Qld, Australia; [Dhillon, A. S.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia	Peter Maccallum Cancer Center; University of Melbourne; Ludwig Institute for Cancer Research; University of Newcastle; Hunter Medical Research Institute; University of Newcastle; Peter Maccallum Cancer Center; University of Melbourne; Monash University; University of Leicester; University of Queensland; University of Melbourne	Dhillon, AS (corresponding author), Peter MacCallum Canc Ctr, Div Res, St Andrews Pl, Melbourne, Vic 3002, Australia.	Amardeep.Dhillon@petermac.org	Chueh, Anderly C./D-8615-2015; Tulchinsky, Eugene/ABD-7070-2021; Chüeh, Anderly C/AFC-2076-2022; Diesch, Jeannine/J-8558-2017; Pearson, Richard Bruce/I-1451-2013; Chueh, Anderly/AAF-9375-2022	Chueh, Anderly C./0000-0003-1140-5516; Chüeh, Anderly C/0000-0003-1140-5516; Diesch, Jeannine/0000-0002-4667-3468; Pearson, Richard Bruce/0000-0001-5919-5090; Dhillon, Amardeep/0000-0002-6065-663X; Verrills, Nicole/0000-0002-7894-0137; Hannan, Ross/0000-0002-2166-4493; Jastrzesbki, Katarzyna/0000-0002-3062-9016; Mariadason, John/0000-0001-9123-7684	National Health and Medical Research Council of Australia; Cancer Institute NSW	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute NSW	We thank Drs David Gillespie, Eisuke Nishida, Chunming Liu, Kanaga Sabapathy and William Kaelin for providing reagents used in this study. This work was supported by project grants (to ASD and RDH) and Research Fellowships (to RDH, RBP and JMM) from the National Health and Medical Research Council of Australia and the Cancer Institute NSW (to NMV).	Adams DG, 2005, J BIOL CHEM, V280, P42644, DOI 10.1074/jbc.M502464200; Adiseshaiah P, 2007, CANCER RES, V67, P6204, DOI 10.1158/0008-5472.CAN-06-4687; Aguilera C, 2011, NATURE, V469, P231, DOI 10.1038/nature09607; Al-Murrani SWK, 1999, BIOCHEM J, V341, P293, DOI 10.1042/0264-6021:3410293; ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; Andreolas C, 2008, INT J CANCER, V122, P1745, DOI 10.1002/ijc.23309; Batut J, 2008, DEVELOPMENT, V135, P2927, DOI 10.1242/dev.020842; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Brabletz T, 2005, CELLS TISSUES ORGANS, V179, P56, DOI 10.1159/000084509; Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; Chen BK, 2007, MOL BIOL CELL, V18, P1118, DOI 10.1091/mbc.E06-09-0797; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2005, CANCER RES, V65, P8183, DOI 10.1158/0008-5472.CAN-05-1103; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; Desmet CJ, 2013, P NATL ACAD SCI USA, V110, P5139, DOI 10.1073/pnas.1222085110; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Francia G, 1999, INT J CANCER, V82, P709, DOI 10.1002/(SICI)1097-0215(19990827)82:5<709::AID-IJC14>3.3.CO;2-I; Fuchs SY, 1996, ONCOGENE, V13, P1531; Hartl M, 2003, CURR CANCER DRUG TAR, V3, P41, DOI 10.2174/1568009033333781; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Huang CC, 2008, ONCOGENE, V27, P2422, DOI 10.1038/sj.onc.1210888; Ito A, 2000, EMBO J, V19, P562, DOI 10.1093/emboj/19.4.562; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Morton S, 2003, EMBO J, V22, P3876, DOI 10.1093/emboj/cdg388; Mumby M, 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.034; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Raivich G, 2006, PROG NEUROBIOL, V78, P347, DOI 10.1016/j.pneurobio.2006.03.006; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Sayan AE, 2012, ONCOGENE, V31, P1493, DOI 10.1038/onc.2011.336; Schonthaler HB, 2011, ANN RHEUM DIS, V70, pI109, DOI 10.1136/ard.2010.140533; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Tan J, 2010, CANCER CELL, V18, P459, DOI 10.1016/j.ccr.2010.10.021; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Virshup DM, 2009, MOL CELL, V33, P537, DOI 10.1016/j.molcel.2009.02.015; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Young MR, 2006, GENE, V379, P1, DOI 10.1016/j.gene.2006.05.001; Zenz R, 2006, INT J BIOCHEM CELL B, V38, P1043, DOI 10.1016/j.biocel.2005.11.011; Zhang W, 2009, J BIOL CHEM, V284, P22649, DOI 10.1074/jbc.M109.013698	45	14	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1333	1339		10.1038/onc.2014.26	http://dx.doi.org/10.1038/onc.2014.26			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24632621				2022-12-28	WOS:000350687100013
J	Huang, Z; Choi, BK; Mujoo, K; Fan, X; Fa, M; Mukherjee, S; Owiti, N; Zhang, N; An, Z				Huang, Z.; Choi, B-K; Mujoo, K.; Fan, X.; Fa, M.; Mukherjee, S.; Owiti, N.; Zhang, N.; An, Z.			The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; BREAST-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE; DEPENDENT ACTIVATION; PROSTATE-CANCER; ERBB RECEPTORS; BINDING-SITE; HER3; DEGRADATION	HER3/ErbB3, a member of the epidermal growth factor receptor (EGFR) family, has a pivotal role in cancer and is emerging as a therapeutic antibody target. In this study, we identified NEDD4 (neural precursor cell expressed, developmentally downregulated 4) as a novel interaction partner and ubiquitin E3 ligase of human HER3. Using molecular and biochemical approaches, we demonstrated that the C-terminal tail of HER3 interacted with the WW domains of NEDD4 and the interaction was independent of neuregulin-1. Short hairpin RNA knockdown of NEDD4 elevated HER3 levels and resulted in increased HER3 signaling and cancer cell proliferation in vitro and in vivo. A similar inverse relationship between HER3 and NEDD4 levels was observed in prostate cancer tumor tissues. More importantly, the upregulated HER3 expression by NEDD4 knockdown sensitized cancer cells for growth inhibition by an anti-HER3 antibody. Taken together, our results suggest that low NEDD4 levels may predict activation of HER3 signaling and efficacies of anti-HER3 antibody therapies.	[Huang, Z.; Choi, B-K; Mujoo, K.; Fan, X.; Fa, M.; Mukherjee, S.; Owiti, N.; Zhang, N.; An, Z.] Univ Texas Houston, Texas Therapeut Inst, Brown Fdn Inst Mol Med, Hlth Sci Ctr, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Zhang, N (corresponding author), Univ Texas Houston, Texas Therapeut Inst, Brown Fdn Inst Mol Med, Hlth Sci Ctr, Houston, TX 77030 USA.	Ningyan.zhang@uth.tmc.edu; Zhiqiang.an@uth.tmc.edu	Mujoo, Kalpana/S-9933-2019	Mujoo, Kalpana/0000-0002-4275-1051; Owiti, Norah/0000-0002-5061-7434; Zhang, Ningyan/0000-0002-4348-2180; An, Zhiqiang/0000-0001-9309-2335	Texas Emerging Technology Fund; Johnson and Johnson; Welch Foundation [AU00024]	Texas Emerging Technology Fund; Johnson and Johnson(Johnson & JohnsonJohnson & Johnson USA); Welch Foundation(The Welch Foundation)	We thank Dr Hui Deng for help on cell cultures; Professor Renping Zhou and Dr Kendra Carmon for critical comments on the manuscript; Dr Stephen Hewitt of NIH/ NCI for providing the prostate cancer clinical samples; and Dr Rabih Said for interpretation of immunohistochemistry experiments. The work was partially funded by grants from the Texas Emerging Technology Fund, Johnson and Johnson, and the Welch Foundation grant no. AU00024 to ZA.	Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Baselga J, 2010, ANN ONCOL, V21, P36, DOI 10.1093/annonc/mdq421; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Bouyain S, 2007, PROTEIN SCI, V16, P654, DOI 10.1110/ps.062700307; Carraway KL, 2010, SEMIN CELL DEV BIOL, V21, P936, DOI 10.1016/j.semcdb.2010.09.006; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Chaib H, 2001, NEOPLASIA, V3, P43, DOI 10.1038/sj.neo.7900126; Choi BK, 2012, CANCER MED-US, V1, P28, DOI 10.1002/cam4.10; Choi BK, 2012, PROTEIN CELL, V3, P781, DOI 10.1007/s13238-012-2065-y; Diamonti AJ, 2002, P NATL ACAD SCI USA, V99, P2866, DOI 10.1073/pnas.052709799; Dornan D, 2004, CANCER RES, V64, P7226, DOI 10.1158/0008-5472.CAN-04-2601; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Feng SM, 2009, MOL CELL BIOL, V29, P892, DOI 10.1128/MCB.00595-08; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Hsieh AC, 2007, BRIT J CANCER, V97, P453, DOI 10.1038/sj.bjc.6603910; Huang QQ, 2010, J BIOL CHEM, V285, P42130, DOI 10.1074/jbc.M110.143412; Huang X, 2000, NATURE, P7634; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Jaiswal BS, 2013, CANCER CELL, V23, P603, DOI 10.1016/j.ccr.2013.04.012; Koumakpayi IH, 2006, CLIN CANCER RES, V12, P2730, DOI 10.1158/1078-0432.CCR-05-2242; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Li Z, 2006, CARCINOGENESIS, V27, P1054, DOI 10.1093/carcin/bgi324; Lipkowitz S, 2003, BREAST CANCER RES, V5, P8, DOI 10.1186/bcr541; Lyne JC, 1997, CANCER J SCI AM, V3, P21; Maspero E, 2011, EMBO REP, V12, P342, DOI 10.1038/embor.2011.21; Menendez JA, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1773; Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509; Omerovic J, 2007, FASEB J, V21, P2849, DOI 10.1096/fj.06-7925com; Persaud A, 2011, EMBO J, V30, P3259, DOI 10.1038/emboj.2011.234; Persaud A, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.85; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Qiu XB, 2002, P NATL ACAD SCI USA, V99, P14843, DOI 10.1073/pnas.232580999; Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690; Schaefer G, 2011, CANCER CELL, V20, P472, DOI 10.1016/j.ccr.2011.09.003; Schoeberl B, 2010, CANCER RES, V70, P2485, DOI 10.1158/0008-5472.CAN-09-3145; Schoeberl B, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000352; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107; Sithanandam G, 2008, CANCER GENE THER, V15, P413, DOI 10.1038/cgt.2008.15; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Sweeney C, 2004, BRIT J CANCER, V90, P289, DOI 10.1038/sj.bjc.6601500; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Tsang RY, 2012, BRIT J CANCER, V106, P6, DOI 10.1038/bjc.2011.516; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Vijapurkar U, 1998, J BIOL CHEM, V273, P20996, DOI 10.1074/jbc.273.33.20996; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Zeng FH, 2009, FASEB J, V23, P1935, DOI 10.1096/fj.08-121947	56	45	46	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1105	1115		10.1038/onc.2014.56	http://dx.doi.org/10.1038/onc.2014.56			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662824				2022-12-28	WOS:000350122100004
J	Walker, SR; Liu, S; Xiang, M; Nicolais, M; Hatzi, K; Giannopoulou, E; Elemento, O; Cerchietti, L; Melnick, A; Frank, DA				Walker, S. R.; Liu, S.; Xiang, M.; Nicolais, M.; Hatzi, K.; Giannopoulou, E.; Elemento, O.; Cerchietti, L.; Melnick, A.; Frank, D. A.			The transcriptional modulator BCL6 as a molecular target for breast cancer therapy	ONCOGENE			English	Article							B-CELL LYMPHOMAS; HUMAN TUMORS; BTB DOMAIN; CHIP-SEQ; IN-VITRO; EXPRESSION; STAT5; DIFFERENTIATION; IDENTIFICATION; COREPRESSOR	Inappropriate expression or activation of transcription factors can drive patterns of gene expression, leading to the malignant behavior of breast cancer cells. We have found that the transcriptional repressor BCL6 is highly expressed in breast cancer cell lines, and its locus is amplified in about half of primary breast cancers. To understand how BCL6 regulates gene expression in breast cancer cells, we used chromatin immunoprecipitation followed by deep sequencing to identify the BCL6 binding sites on a genomic scale. This revealed that BCL6 regulates a unique cohort of genes in breast cancer cell lines compared with B-cell lymphomas. Furthermore, BCL6 expression promotes the survival of breast cancer cells, and targeting BCL6 with a peptidomimetic inhibitor leads to apoptosis of these cells. Finally, combining a BCL6 inhibitor and a signal transducer and activator of transcription3 inhibitor provided enhanced cell killing in triple-negative breast cancer cell lines, suggesting that combination therapy may be particularly useful. Thus, targeting BCL6 alone or in conjunction with other signaling pathways may be a useful therapeutic strategy for treating breast cancer.	[Walker, S. R.; Liu, S.; Xiang, M.; Nicolais, M.; Frank, D. A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Walker, S. R.; Liu, S.; Frank, D. A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Walker, S. R.; Liu, S.; Frank, D. A.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Hatzi, K.; Cerchietti, L.; Melnick, A.] Weill Cornell Med Coll, Dept Med & Pharmacol, New York, NY USA; [Giannopoulou, E.; Elemento, O.] Weill Cornell Med Coll, HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsa, New York, NY USA; [Giannopoulou, E.; Elemento, O.] Weill Cornell Med Coll, Dept Physiol & Biophys, New York, NY USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Cornell University; Cornell University; Cornell University	Frank, DA (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,M522B, Boston, MA 02215 USA.	david_frank@dfci.harvard.edu	Melnick, Ari/AAA-5763-2020; Giannopoulou, Evgenia/K-9576-2019	Cerchietti, Leandro/0000-0003-0608-1350	BCRF-AACR grant for Translational Breast Cancer Research; National Cancer Institute [R01-CA160979]; Susan G Komen for the Cure; Brent Leahey Fund; Friends of the Dana-Farber Cancer Institute; NATIONAL CANCER INSTITUTE [R01CA104348, R01CA160979] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER	BCRF-AACR grant for Translational Breast Cancer Research; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); Brent Leahey Fund; Friends of the Dana-Farber Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by a BCRF-AACR grant for Translational Breast Cancer Research, and grants from the National Cancer Institute (R01-CA160979), Susan G Komen for the Cure, the Brent Leahey Fund and Friends of the Dana-Farber Cancer Institute.	Ahmad KF, 2003, MOL CELL, V12, P1551, DOI 10.1016/S1097-2765(03)00454-4; Alvarez JV, 2005, CANCER RES, V65, P5054, DOI 10.1158/0008-5472.CAN-04-4281; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Bos R, 2003, ONCOGENE, V22, P8948, DOI 10.1038/sj.onc.1206995; Cerchietti LC, 2010, CANCER CELL, V17, P400, DOI 10.1016/j.ccr.2009.12.050; Cerchietti LC, 2009, BLOOD, V113, P3397, DOI 10.1182/blood-2008-07-168773; Ci WM, 2009, BLOOD, V113, P5536, DOI 10.1182/blood-2008-12-193037; DiRenzo J, 2002, CANCER RES, V62, P89; Fujita N, 2004, CELL, V119, P75, DOI 10.1016/j.cell.2004.09.014; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Ghetu AF, 2008, MOL CELL, V29, P384, DOI 10.1016/j.molcel.2007.12.026; Giannopoulou EG, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-277; He HSHS, 2010, NAT GENET, V42, P343, DOI 10.1038/ng.545; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Kwon H, 2009, IMMUNITY, V31, P941, DOI 10.1016/j.immuni.2009.10.008; Lasho TL, 2008, LEUKEMIA, V22, P1790, DOI 10.1038/leu.2008.56; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Logarajah S, 2003, ONCOGENE, V22, P5572, DOI 10.1038/sj.onc.1206689; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Mendez LM, 2008, MOL CELL BIOL, V28, P2175, DOI 10.1128/MCB.01400-07; Nelson EA, 2004, J BIOL CHEM, V279, P54724, DOI 10.1074/jbc.M408464200; Nelson EA, 2008, BLOOD, V112, P5095, DOI 10.1182/blood-2007-12-129718; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Parekh S, 2007, BLOOD, V110, P2067, DOI 10.1182/blood-2007-01-069575; Polo JM, 2004, NAT MED, V10, P1329, DOI 10.1038/nm1134; Polo JM, 2008, BLOOD, V112, P644, DOI 10.1182/blood-2008-01-131813; Polo JM, 2007, P NATL ACAD SCI USA, V104, P3207, DOI 10.1073/pnas.0611399104; Shin HJ, 2009, BIOINFORMATICS, V25, P2605, DOI 10.1093/bioinformatics/btp479; Walker SR, 2007, ONCOGENE, V26, P224, DOI 10.1038/sj.onc.1209775; Walker SR, 2013, MOL CELL BIOL, V33, P2879, DOI 10.1128/MCB.01620-12; Walker SR, 2009, MOL CANCER RES, V7, P966, DOI 10.1158/1541-7786.MCR-08-0238; Wang X, 2002, P NATL ACAD SCI USA, V99, P15018, DOI 10.1073/pnas.232581199; Wang XZ, 2009, STUD FUZZ SOFT COMP, V245, P1; Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88; Werning G, 2008, CANCER CELL, V13, P311, DOI 10.1016/j.ccr.2008.02.009; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	38	46	48	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1073	1082		10.1038/onc.2014.61	http://dx.doi.org/10.1038/onc.2014.61			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662818	Green Accepted, Green Submitted			2022-12-28	WOS:000350122100001
J	Canesin, G; Cuevas, EP; Santos, V; Lopez-Menendez, C; Moreno-Bueno, G; Huang, Y; Csiszar, K; Portillo, F; Peinado, H; Lyden, D; Cano, A				Canesin, G.; Cuevas, E. P.; Santos, V.; Lopez-Menendez, C.; Moreno-Bueno, G.; Huang, Y.; Csiszar, K.; Portillo, F.; Peinado, H.; Lyden, D.; Cano, A.			Lysyl oxidase-like 2 (LOXL2) and E47 EMT factor: novel partners in E-cadherin repression and early metastasis colonization	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; SUPPRESSOR-CELLS; PROGENITOR CELLS; SNAIL; RECRUITMENT; REGULATOR; REQUIRES; POLARITY	Epithelial-mesenchymal transition (EMT) has been associated with increased aggressiveness and acquisition of migratory properties providing tumor cells with the ability to invade into adjacent tissues. Downregulation of E-cadherin, a hallmark of EMT, is mediated by several transcription factors (EMT-TFs) that act also as EMT inducers, among them, Snail1 and the bHLH transcription factor E47. We previously described lysyl oxidase-like 2 (LOXL2), a member of the lysyl oxidase family, as a Snail1 regulator and EMT inducer. Here we show that LOXL2 is also an E47-interacting partner and functionally collaborates in the repression of E-cadherin promoter. Loss and gain of function analyses combined with in vivo studies in syngeneic breast cancer models demonstrate the participation of LOXL2 and E47 in tumor growth and their requirement for lung metastasis. Furthermore, LOXL2 and E47 contribute to early steps of metastatic colonization by cell and noncell autonomous functions regulating the recruitment of bone marrow progenitor cells to the lungs and by direct transcriptional regulation of fibronectin and cytokines TNFa, ANG-1 and GM-CSF. Moreover, fibronectin and GM-CSF proved to be necessary for LOXL2/E47-mediated modulation of tumor growth and lung metastasis.	[Canesin, G.; Cuevas, E. P.; Santos, V.; Lopez-Menendez, C.; Moreno-Bueno, G.; Portillo, F.; Cano, A.] Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, IdiPAZ,Dept Bioquim, Madrid 28029, Spain; [Moreno-Bueno, G.] Fdn MD Anderson Int Madrid, Madrid, Spain; [Huang, Y.; Peinado, H.; Lyden, D.] Weill Cornell Med Coll, Dept Pediat Cell & Dev Biol, New York, NY USA; [Csiszar, K.] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Texas System; UTMD Anderson Cancer Center; Cornell University; University of Hawaii System	Cano, A (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Dept Bioquim, Arzobispo Morcillo 2, Madrid 28029, Spain.	acano@iib.uam.es	Menendez, Celia Lopez/ABG-7555-2020; Moreno-Bueno, Gema/K-9354-2016; Peinado, Hector/A-6417-2013; Cuevas, Eva P./P-4533-2019; Canesin, Giacomo/H-4541-2019	Menendez, Celia Lopez/0000-0002-5967-1955; Moreno-Bueno, Gema/0000-0002-5030-6687; Peinado, Hector/0000-0002-4256-3413; Cuevas, Eva P./0000-0001-6477-1283; Canesin, Giacomo/0000-0002-3318-4550; Portillo Perez, Francisco/0000-0003-4922-346X	Spanish Ministry of Science and Innovation [SAF2010-21143, Consolider 2007-CS00017]; AICR [12-1057]; ISCIII [RETIC-RD12/0036/0007]; Comunidad de Madrid [S2010/BMD-2302]; Worldwide Cancer Research [12-1057] Funding Source: researchfish	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); AICR; ISCIII(Instituto de Salud Carlos III); Comunidad de Madrid(Comunidad de Madrid); Worldwide Cancer Research	We thank members of A. Cano's group: Saleta Morales and Amalia Montes for technical support, Ana Villarejo and Fernando Salvador for help in flow cytometry and collagen crosslinking analyses, and Thomas Look, Manuel Fresno and Peter N. Cockerill for providing reagents, and Angela Nieto for reading the manuscript. The work was supported by the Spanish Ministry of Science and Innovation (SAF2010-21143; Consolider 2007-CS00017); AICR (12-1057) and ISCIII (RETIC-RD12/0036/0007) to AC, and Comunidad de Madrid (S2010/BMD-2302) to AC and GMB. EPC and VS are founded from the AICR grant.	Nieto MA, 2012, SEMIN CANCER BIOL, V22, P361, DOI 10.1016/j.semcancer.2012.05.003; Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Barker HE, 2012, NAT REV CANCER, V12, P540, DOI 10.1038/nrc3319; Barker HE, 2011, CANCER RES, V71, P1561, DOI 10.1158/0008-5472.CAN-10-2868; Barry-Hamilton V, 2010, NAT MED, V16, P1009, DOI 10.1038/nm.2208; Bosiljcic M, 2011, CANCER RES, V71, P5050, DOI 10.1158/0008-5472.CAN-10-3982; Cano A, 2012, FUTURE ONCOL, V8, P1095, DOI [10.2217/FON.12.105, 10.2217/fon.12.105]; Cox TR, 2013, CANCER RES, V73, P1721, DOI 10.1158/0008-5472.CAN-12-2233; Csiszar K, 2001, PROG NUCLEIC ACID RE, V70, P1, DOI 10.1016/S0079-6603(01)70012-8; Cubillo E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059948; Cuevas EP, 2014, BIOL OPEN, V3, P129, DOI 10.1242/bio.20146841; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Ewens A, 2005, ANTICANCER RES, V25, P3905; Fogelgren B, 2005, J BIOL CHEM, V280, P24690, DOI 10.1074/jbc.M412979200; Gao DC, 2012, CANCER RES, V72, P1384, DOI 10.1158/0008-5472.CAN-11-2905; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Liu XQ, 2004, NAT GENET, V36, P178, DOI 10.1038/ng1297; Maki JM, 2002, CIRCULATION, V106, P2503, DOI 10.1161/01.CIR.0000038109.84500.1E; Massari ME, 1996, MOL CELL BIOL, V16, P121; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Moreno-Bueno G, 2011, EMBO MOL MED, V3, P528, DOI 10.1002/emmm.201100156; Moreno-Bueno G, 2009, NAT PROTOC, V4, P1591, DOI 10.1038/nprot.2009.152; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Peinado H, 2004, J CELL SCI, V117, P2827, DOI 10.1242/jcs.01145; Peinado H, 2008, CANCER RES, V68, P4541, DOI 10.1158/0008-5472.CAN-07-6345; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Peinado H, 2011, SEMIN CANCER BIOL, V21, P139, DOI 10.1016/j.semcancer.2011.01.002; Peng L, 2009, CARCINOGENESIS, V30, P1660, DOI 10.1093/carcin/bgp178; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621; Sceneay J, 2012, CANCER RES, V72, P3906, DOI 10.1158/0008-5472.CAN-11-3873; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108; Ye XZ, 2010, J GENET GENOMICS, V37, P423, DOI 10.1016/S1673-8527(09)60061-8	43	66	71	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					951	964		10.1038/onc.2014.23	http://dx.doi.org/10.1038/onc.2014.23			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632622	Green Submitted			2022-12-28	WOS:000350121300002
J	Halaoui, R; McCaffrey, L				Halaoui, R.; McCaffrey, L.			Rewiring cell polarity signaling in cancer	ONCOGENE			English	Review							PROTEIN-KINASE-C; PEUTZ-JEGHERS-SYNDROME; LKB1 TUMOR-SUPPRESSOR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN-PAPILLOMAVIRUS E6; LYMPH-NODE METASTASIS; APICAL-BASAL POLARITY; BREAST-CANCER; SOMATIC MUTATIONS; DISCS LARGE	Disrupted cell polarity is a feature of epithelial cancers. The Crumbs, Par and Scribble polarity complexes function to specify and maintain apical and basolateral membrane domains, which are essential to organize intracellular signaling pathways that maintain epithelial homeostasis. Disruption of apical-basal polarity proteins facilitates rewiring of oncogene and tumor suppressor signaling pathways to deregulate proliferation, apoptosis, invasion and metastasis. Moreover, apical-basal polarity integrates intracellular signaling with the microenvironment by regulating metabolic signaling, extracellular matrix remodeling and tissue level organization. In this review, we discuss recent advances in our understanding of how polarity proteins regulate diverse signaling pathways throughout cancer progression from initiation to metastasis.	[Halaoui, R.; McCaffrey, L.] McGill Univ, Dept Oncol, Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ, Canada; [Halaoui, R.; McCaffrey, L.] McGill Univ, Div Expt Med, Montreal, PQ, Canada	McGill University; McGill University	McCaffrey, L (corresponding author), McGill Univ, Dept Oncol, Rosalind & Morris Goodman Canc Res Ctr, 1160 Pine Ave, Montreal, PQ, Canada.	luke.mccaffrey@mcgill.ca			Terry Fox Research Institute [1009]; Canadian Institutes of Health Research [MOP-119482]; McGill Integrated Cancer Research Training Program; Canderel Studentship award	Terry Fox Research Institute; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); McGill Integrated Cancer Research Training Program; Canderel Studentship award	Research by LM is supported by grants from the Terry Fox Research Institute (1009) and Canadian Institutes of Health Research (MOP-119482). LM is an FRQS Research Scholar. RH is supported by the McGill Integrated Cancer Research Training Program and a Canderel Studentship award.	Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Akhtar N, 2013, NAT CELL BIOL, V15, P17, DOI 10.1038/ncb2646; Al-Saad S, 2008, BRIT J CANCER, V99, P1476, DOI 10.1038/sj.bjc.6604713; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Anastas JN, 2012, ONCOGENE, V31, P3696, DOI 10.1038/onc.2011.528; Andrade-Vieira R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056567; Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Atwood SX, 2013, NATURE, V494, P484, DOI 10.1038/nature11889; Avizienyte E, 1998, CANCER RES, V58, P2087; Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Bambang IF, 2013, ONCOGENE, V32, P1240, DOI 10.1038/onc.2012.149; Bao YJ, 2011, J BIOCHEM, V149, P361, DOI 10.1093/jb/mvr021; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Beggs AD, 2010, GUT, V59, P975, DOI 10.1136/gut.2009.198499; Benton R, 2003, CELL, V115, P691, DOI 10.1016/S0092-8674(03)00938-3; Bergstralh DT, 2013, CURR BIOL, V23, P1707, DOI 10.1016/j.cub.2013.07.017; Bergstralh DT, 2012, ESSAYS BIOCHEM, V53, P129, DOI [10.1042/BSE0530129, 10.1042/bse0530129]; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x; Boggiano JC, 2012, DEV CELL, V22, P695, DOI 10.1016/j.devcel.2012.03.013; Bostwick DG, 2012, HISTOPATHOLOGY, V60, P4, DOI 10.1111/j.1365-2559.2011.04007.x; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598; Callahan CA, 2004, GENE DEV, V18, P2724, DOI 10.1101/gad.1221804; Carthew RW, 2005, CURR OPIN GENET DEV, V15, P358, DOI 10.1016/j.gde.2005.06.002; Cavatorta AL, 2004, INT J CANCER, V111, P373, DOI 10.1002/ijc.20275; Chatterjee S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034343; Cohen EEW, 2006, CANCER RES, V66, P6296, DOI 10.1158/0008-5472.CAN-05-3139; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Cunliffe HE, 2012, AM J CANCER RES, V2, P478; Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112; Dong SM, 1998, CANCER RES, V58, P3787; Dow LE, 2008, ONCOGENE, V27, P5988, DOI 10.1038/onc.2008.219; Du GS, 2009, ANN SURG ONCOL, V16, P1578, DOI 10.1245/s10434-009-0423-7; Du QS, 2004, CELL, V119, P503, DOI 10.1016/j.cell.2004.10.028; Du QS, 2001, NAT CELL BIOL, V3, P1069, DOI 10.1038/ncb1201-1069; Dugay F, 2013, INT J CANCER, V134, P251; Duivenvoorden WC, 2013, BRIT J CANCER, V108, P327, DOI 10.1038/bjc.2012.574; Durgan J, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.174235; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Ekizoglu S, 2013, TRANSL RES, V162, P122, DOI 10.1016/j.trsl.2013.06.001; Elsum I, 2012, ESSAYS BIOCHEM, V53, P141, DOI [10.1042/bse0530141, 10.1042/BSE0530141]; Elsum IA, 2013, J CELL SCI, V126, P3990, DOI 10.1242/jcs.129387; Elsum IA, 2013, CELLS TISSUES ORGANS, V198, P1, DOI 10.1159/000348423; Evans JD, 2003, AM J CLIN PATHOL, V119, P392, DOI 10.1309/BKPC9DX98R781B87; Ewald AJ, 2008, DEV CELL, V14, P570, DOI 10.1016/j.devcel.2008.03.003; Ewald AJ, 2012, J CELL SCI, V125, P2638, DOI 10.1242/jcs.096875; Fan Y, 2008, TRENDS CELL BIOL, V18, P467, DOI 10.1016/j.tcb.2008.08.001; Feng X, 2012, CANCER BIOMARK, V11, P99, DOI 10.3233/CBM-2012-0264; Forster LF, 2000, J CLIN PATHOL, V53, P791, DOI 10.1136/jcp.53.10.791; Frederick LA, 2008, ONCOGENE, V27, P4841, DOI 10.1038/onc.2008.119; Friedl P, 2010, J CELL BIOL, V188, P11, DOI 10.1083/jcb.200909003; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; Galvez AS, 2009, MOL CELL BIOL, V29, P104, DOI 10.1128/MCB.01294-08; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Geisbrecht ER, 2013, DEV DYNAM, V242, P414, DOI 10.1002/dvdy.23926; Goldstein B, 2007, DEV CELL, V13, P609, DOI 10.1016/j.devcel.2007.10.007; Gonzalez-Sanchez E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066933; Grifoni D, 2007, ONCOGENE, V26, P5960, DOI 10.1038/sj.onc.1210389; Grifoni D, 2004, ONCOGENE, V23, P8688, DOI 10.1038/sj.onc.1208023; Guldberg P, 1999, ONCOGENE, V18, P1777, DOI 10.1038/sj.onc.1202486; Gunaratne A, 2013, CELL ADHES MIGR, V7, P357, DOI 10.4161/cam.25651; Gustafson WC, 2004, J BIOL CHEM, V279, P9400, DOI 10.1074/jbc.M312840200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao Y, 2010, CURR BIOL, V20, P1809, DOI 10.1016/j.cub.2010.09.032; Hashizume A, 2006, BIOCHEM BIOPH RES CO, V339, P996, DOI 10.1016/j.bbrc.2005.11.106; Hayase J, 2013, J CELL BIOL, V200, P635, DOI 10.1083/jcb.201208150; Herrmann JL, 2011, CANCER LETT, V306, P1, DOI 10.1016/j.canlet.2011.01.014; Hidalgo-Carcedo C, 2011, NAT CELL BIOL, V13, P49, DOI 10.1038/ncb2133; Huang YH, 2013, ASIAN PAC J CANCER P, V14, P1985, DOI 10.7314/APJCP.2013.14.3.1985; Humbert PO, 2006, TRENDS CELL BIOL, V16, P622, DOI 10.1016/j.tcb.2006.10.005; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Hurov J, 2007, CELL CYCLE, V6, P1966, DOI 10.4161/cc.6.16.4576; Iden S, 2012, CANCER CELL, V22, P389, DOI 10.1016/j.ccr.2012.08.004; Jaffe AB, 2008, J CELL BIOL, V183, P625, DOI 10.1083/jcb.200807121; Jansen M, 2009, PHYSIOL REV, V89, P777, DOI 10.1152/physrev.00026.2008; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Justilien V, 2009, ONCOGENE, V28, P3597, DOI 10.1038/onc.2009.217; Justilien V, 2011, J BIOL CHEM, V286, P8149, DOI 10.1074/jbc.M110.196113; Karp CM, 2008, CANCER RES, V68, P4105, DOI 10.1158/0008-5472.CAN-07-6814; Kashyap A, 2013, ONCOGENE, V32, P1396, DOI 10.1038/onc.2012.162; Kato S, 2013, PANCREATOLOGY, V13, P360, DOI 10.1016/j.pan.2013.05.006; Kim JY, 2013, P NATL ACAD SCI USA, V110, P6418, DOI 10.1073/pnas.1221799110; Nguyen-Ngoc KV, 2012, P NATL ACAD SCI USA, V109, pE2595, DOI 10.1073/pnas.1212834109; Klezovitch O, 2004, GENE DEV, V18, P559, DOI 10.1101/gad.1178004; Knoblich JA, 2010, NAT REV MOL CELL BIO, V11, P849, DOI 10.1038/nrm3010; Kohjima M, 2002, BIOCHEM BIOPH RES CO, V299, P641, DOI 10.1016/S0006-291X(02)02698-0; Koivunen JP, 2008, BRIT J CANCER, V99, P245, DOI 10.1038/sj.bjc.6604469; Korsse SE, 2013, CARCINOGENESIS, V34, P1611, DOI 10.1093/carcin/bgt068; Korsse SE, 2013, J MED GENET, V50, P59, DOI 10.1136/jmedgenet-2012-101277; Kosinski C, 2010, GASTROENTEROLOGY, V139, P893, DOI 10.1053/j.gastro.2010.06.014; Krahn MP, 2010, CURR BIOL, V20, P636, DOI 10.1016/j.cub.2010.01.065; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Kuphal S, 2006, ONCOGENE, V25, P103, DOI 10.1038/sj.onc.1209008; Langzam L, 2001, AM J CLIN PATHOL, V116, P377, DOI 10.1309/1VKK-HWH7-YVJN-7UF7; Laprise P, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/868217; Laprise P, 2011, TRENDS CELL BIOL, V21, P401, DOI 10.1016/j.tcb.2011.03.005; Lazaro-Dieguez F, 2013, J CELL BIOL, V203, P251, DOI 10.1083/jcb.201303013; Lee JH, 2007, NATURE, V447, P1017, DOI 10.1038/nature05828; Levayer R, 2013, J CELL BIOL, V200, P689, DOI 10.1083/jcb.201301051; Lin HT, 2004, GYNECOL ONCOL, V93, P422, DOI 10.1016/j.ygyno.2004.01.025; Lin JI, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003813; Linch M, 2014, CARCINOGENESIS, V35, P396, DOI 10.1093/carcin/bgt313; Lisovsky M, 2010, VIRCHOWS ARCH, V457, P635, DOI 10.1007/s00428-010-0990-9; Lisovsky M, 2009, MODERN PATHOL, V22, P977, DOI 10.1038/modpathol.2009.68; Liu K, 2014, TUMOR BIOL, V35, P995, DOI 10.1007/s13277-013-1133-0; Liu Q, 1998, J IMMUNOL, V160, P1393; Lo B, 2012, J CELL BIOL, V199, P1117, DOI 10.1083/jcb.201208080; Lu XF, 2009, CLIN CANCER RES, V15, P3287, DOI 10.1158/1078-0432.CCR-08-2078; Ma L, 2013, CELL, V152, P599, DOI 10.1016/j.cell.2012.12.028; Mack HID, 2013, VIROLOGY, V446, P9, DOI 10.1016/j.virol.2013.07.009; Martin-Belmonte F, 2008, CURR OPIN CELL BIOL, V20, P227, DOI 10.1016/j.ceb.2008.01.001; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003; McCaffrey LM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a009654; McCaffrey LM, 2011, TRENDS CELL BIOL, V21, P727, DOI 10.1016/j.tcb.2011.06.005; McCaffrey LM, 2009, GENE DEV, V23, P1450, DOI 10.1101/gad.1795909; McCarthy A, 2009, J PATHOL, V219, P306, DOI 10.1002/path.2599; Moleirinho S, 2013, ONCOGENE, V32, P1821, DOI 10.1038/onc.2012.196; Morais-de-Sa E, 2010, CELL, V141, P509, DOI 10.1016/j.cell.2010.02.040; Murray NR, 2011, J CELL PHYSIOL, V226, P879, DOI 10.1002/jcp.22463; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; Nagaoka K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065127; Nagasaka K, 2010, ONCOGENE, V29, P5311, DOI 10.1038/onc.2010.265; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Nakajima Y, 2013, NATURE, V500, P359, DOI 10.1038/nature12335; Namdarian B, 2013, UROL ONCOL-SEMIN ORI, V31, P649, DOI 10.1016/j.urolonc.2011.03.012; Nance J, 2011, DEVELOPMENT, V138, P799, DOI 10.1242/dev.053538; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Nelson WJ, 2013, PROG MOL BIOL TRANSL, V116, P3, DOI 10.1016/B978-0-12-394311-8.00001-7; Nolan ME, 2008, CANCER RES, V68, P8201, DOI 10.1158/0008-5472.CAN-07-6567; O'Brien LE, 2001, NAT CELL BIOL, V3, P831, DOI 10.1038/ncb0901-831; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Park TJ, 2008, NAT GENET, V40, P871, DOI 10.1038/ng.104; Park WS, 1998, INT J ONCOL, V13, P601; Partanen JI, 2012, P NATL ACAD SCI USA, V109, pE388, DOI 10.1073/pnas.1120421109; Pearson HB, 2011, J CLIN INVEST, V121, P4257, DOI 10.1172/JCI58509; Petit MM, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-1; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Pocha SM, 2013, CURR BIOL, V23, pR289, DOI 10.1016/j.cub.2013.03.001; Powell CT, 1996, CANCER RES, V56, P4137; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Qin Y, 2010, J CELL BIOL, V189, P661, DOI 10.1083/jcb.201002097; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Richier L, 2010, J NEUROSCI, V30, P4796, DOI 10.1523/JNEUROSCI.3726-09.2010; Rothenberg SM, 2010, CANCER RES, V70, P2158, DOI 10.1158/0008-5472.CAN-09-3458; Rowan A, 1999, J INVEST DERMATOL, V112, P509, DOI 10.1046/j.1523-1747.1999.00551.x; Russ A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047734; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sato N, 2001, AM J PATHOL, V159, P2017, DOI 10.1016/S0002-9440(10)63053-2; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; Schlegelmilch K, 2011, CELL, V144, P782, DOI 10.1016/j.cell.2011.02.031; Schmoranzer J, 2009, CURR BIOL, V19, P1065, DOI 10.1016/j.cub.2009.05.065; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Siziopikou KP, 2013, ARCH PATHOL LAB MED, V137, P462, DOI 10.5858/arpa.2012-0078-RA; Smith CA, 2007, EMBO J, V26, P468, DOI 10.1038/sj.emboj.7601495; Sobottka SB, 2000, J NEURO-ONCOL, V49, P187, DOI 10.1023/A:1006442024874; Sohn J, 2013, ANN ONCOL, V24, P2522, DOI 10.1093/annonc/mdt248; Solinet S, 2011, HISTOCHEM CELL BIOL, V136, P245, DOI 10.1007/s00418-011-0840-0; Soltanian S, 2011, TUMOR BIOL, V32, P425, DOI 10.1007/s13277-011-0155-8; St Johnston D, 2010, CELL, V141, P757, DOI 10.1016/j.cell.2010.05.011; Stefanatos RKA, 2011, J GENET GENOMICS, V38, P431, DOI 10.1016/j.jgg.2011.09.004; Storrs CH, 2007, J VIROL, V81, P4080, DOI 10.1128/JVI.02545-06; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Suzuki A, 2004, CURR BIOL, V14, P1425, DOI 10.1016/j.cub.2004.08.021; Tamehiro N, 2009, J BIOL CHEM, V284, P24881, DOI 10.1074/jbc.M109.014365; Tanwar PS, 2014, CARCINOGENESIS, V35, P546, DOI 10.1093/carcin/bgt357; Tepass U, 2012, ANNU REV CELL DEV BI, V28, P655, DOI 10.1146/annurev-cellbio-092910-154033; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Tsai JH, 2000, CANCER LETT, V161, P171, DOI 10.1016/S0304-3835(00)00597-8; Tsuruga T, 2007, ONCOL RES, V16, P431, DOI 10.3727/000000007783980855; Varelas X, 2010, DEV CELL, V19, P831, DOI 10.1016/j.devcel.2010.11.012; Vidal M, 2006, CURR OPIN GENET DEV, V16, P10, DOI 10.1016/j.gde.2005.12.004; Viloria-Petit AM, 2010, CELL CYCLE, V9, P623, DOI 10.4161/cc.9.4.10779; Viloria-Petit AM, 2009, P NATL ACAD SCI USA, V106, P14028, DOI 10.1073/pnas.0906796106; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wang Y, 2013, MOL CANCER RES, V11, P1624, DOI 10.1158/1541-7786.MCR-13-0371-T; Wang ZJ, 1999, BRIT J CANCER, V80, P70, DOI 10.1038/sj.bjc.6690323; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; WEAVER VM, 1995, SEMIN CANCER BIOL, V6, P175, DOI 10.1006/scbi.1995.0021; Xiao L, 2011, J BIOL CHEM, V286, P7788, DOI 10.1074/jbc.M110.173468; Xue B, 2013, NAT CELL BIOL, V15, P189, DOI 10.1038/ncb2663; Yang YL, 2008, GENE CHROMOSOME CANC, V47, P127, DOI 10.1002/gcc.20514; Yang ZQ, 2012, MOL CELL, V47, P469, DOI 10.1016/j.molcel.2012.06.037; Yao S, 2012, BRIT J CANCER, V107, P388, DOI 10.1038/bjc.2012.162; Yao Sheng, 2010, Genes Cancer, V1, P444, DOI 10.1177/1947601910376079; Yin F, 2013, CELL, V154, P1342, DOI 10.1016/j.cell.2013.08.025; Yoshihama Y, 2011, CURR BIOL, V21, P705, DOI 10.1016/j.cub.2011.03.029; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Yu W, 2005, MOL BIOL CELL, V16, P433, DOI 10.1091/mbc.e04-05-0435; Zen K, 2009, ONCOGENE, V28, P2910, DOI 10.1038/onc.2009.148; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045; Zhang L, 2006, P NATL ACAD SCI USA, V103, P17272, DOI 10.1073/pnas.0608531103; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111; Zhuang ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067431; Zhuo OY, 2010, ONCOL RES, V18, P593, DOI 10.3727/096504010X12767359114045; Zubakov D, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-106	209	103	104	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					939	950		10.1038/onc.2014.59	http://dx.doi.org/10.1038/onc.2014.59			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632617				2022-12-28	WOS:000350121300001
J	Alves, IT; Hartjes, T; McClellan, E; Hiltemann, S; Bottcher, R; Dits, N; Temanni, MR; Janssen, B; van Workum, W; van der Spek, P; Stubbs, A; de Klein, A; Eussen, B; Trapman, J; Jenster, G				Alves, I. Teles; Hartjes, T.; McClellan, E.; Hiltemann, S.; Bottcher, R.; Dits, N.; Temanni, M. R.; Janssen, B.; van Workum, W.; van der Spek, P.; Stubbs, A.; de Klein, A.; Eussen, B.; Trapman, J.; Jenster, G.			Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer	ONCOGENE			English	Article						FAM71D; gene fusions; next-generation sequencing; prostate cancer; MPP5	ANDROGEN RECEPTOR; GENE FUSIONS; EXOME; GENOME; POLARITY; CELL; VARIANTS; RNAS	Gene fusions, mainly between TMPRSS2 and ERG, are frequent early genomic rearrangements in prostate cancer (PCa). In order to discover novel genomic fusion events, we applied whole-genome paired-end sequencing to identify structural alterations present in a primary PCa patient (G089) and in a PCa cell line (PC346C). Overall, we identified over 3800 genomic rearrangements in each of the two samples as compared with the reference genome. Correcting these structural variations for polymorphisms using whole-genome sequences of 46 normal samples, the numbers of cancer-related rearrangements were 674 and 387 for G089 and PC346C, respectively. From these, 192 in G089 and 106 in PC346C affected gene structures. Exclusion of small intronic deletions left 33 intergenic breaks in G089 and 14 in PC346C. Out of these, 12 and 9 reassembled genes with the same orientation, capable of generating a feasible fusion transcript. Using PCR we validated all the reliable predicted gene fusions. Two gene fusions were in-frame: MPP5-FAM71D in PC346C and ARHGEF3-C8ORF38 in G089. Downregulation of FAM71D and MPP5-FAM71D transcripts in PC346C cells decreased proliferation; however, no effect was observed in the RWPE-1-immortalized normal prostate epithelial cells. Together, our data showed that gene rearrangements frequently occur in PCa genomes but result in a limited number of fusion transcripts. Most of these fusion transcripts do not encode in-frame fusion proteins. The unique in-frame MPP5-FAM71D fusion product is important for proliferation of PC346C cells.	[Alves, I. Teles] Erasmus Univ, Med Ctr, Josephine Nefkens Inst, Dept Urol & Pathol, NL-3000 CA Rotterdam, Netherlands; [Hartjes, T.; Hiltemann, S.; Bottcher, R.; Dits, N.; Jenster, G.] Erasmus Univ, Med Ctr, Josephine Nefkens Inst, Dept Urol, NL-3000 CA Rotterdam, Netherlands; [McClellan, E.; van der Spek, P.; Stubbs, A.] Erasmus Univ, Med Ctr, Dept Bioinformat, NL-3000 CA Rotterdam, Netherlands; [McClellan, E.] Metropolitan State Univ Denver, Dept Math & Comp Sci, Denver, CO 80204 USA; [Temanni, M. R.] Univ Maryland, CMNS Inst Adv Comp Studies, College Pk, MD 20742 USA; [Janssen, B.; van Workum, W.] ServiceXS BV, Leiden, Netherlands; [de Klein, A.; Eussen, B.] Erasmus Univ, Med Ctr, Dept Clin Genet, NL-3000 CA Rotterdam, Netherlands; [Trapman, J.] Erasmus Univ, Med Ctr, Josephine Nefkens Inst, Dept Pathol, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Metropolitan State University of Denver; University System of Maryland; University of Maryland College Park; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Jenster, G (corresponding author), Erasmus Univ, Med Ctr, Josephine Nefkens Inst, Dept Urol, Be 362a,POB 2040, NL-3000 CA Rotterdam, Netherlands.	g.jenster@erasmusmc.nl	TEMANNI, Mohamed Ramzi/AAQ-6936-2020; Hiltemann, Saskia/AAY-9458-2020; Böttcher, René/A-5514-2015	TEMANNI, Mohamed Ramzi/0000-0001-9125-1136; Hiltemann, Saskia/0000-0003-3803-468X; Böttcher, René/0000-0001-8581-3876	CTMM; project PCMM [03O-203]; FP7 Marie Curie Initial Training Network PRO-NEST [238278]; Foundation for Scientific Urological Research (SUWO)	CTMM; project PCMM; FP7 Marie Curie Initial Training Network PRO-NEST; Foundation for Scientific Urological Research (SUWO)	We would like to thank Andre Uitterlinden from the Department of Internal Medicine, Erasmus MC for microarray assistance, Arno van Leenders from the Department of Pathology, Erasmus MC for patient sample selection, Wytske van Weerden from the Department of Urology, Erasmus MC for the expertise in PC346C cell line model systems, Complete Genomics Inc. for assistance with the NGS data and the patients whose material was used for this study. This research was made possible by financial contributions from CTMM, project PCMM (project number 03O-203), the FP7 Marie Curie Initial Training Network PRO-NEST (grant number 238278) and the Foundation for Scientific Urological Research (SUWO).	Asan, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046211; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Cheng I, 2012, GENE CHROMOSOME CANC, V51, P66, DOI 10.1002/gcc.20932; Cirulli ET, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-5-r57; Clegg NJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017449; Cuzick J, 2011, LANCET ONCOL, V12, P245, DOI 10.1016/S1470-2045(10)70295-3; Dong JT, 2001, CANCER METAST REV, V20, P173, DOI 10.1023/A:1015575125780; Drmanac R, 2010, SCIENCE, V327, P78, DOI 10.1126/science.1181498; Funke L, 2005, ANNU REV BIOCHEM, V74, P219, DOI 10.1146/annurev.biochem.74.082803.133339; Gosens I, 2007, EXP CELL RES, V313, P3959, DOI 10.1016/j.yexcr.2007.08.025; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Haimovich Adrian D., 2011, Yale Journal of Biology and Medicine, V84, P439; Hawkins RD, 2010, NAT REV GENET, V11, P476, DOI 10.1038/nrg2795; Hermans KG, 2009, CLIN CANCER RES, V15, P6398, DOI 10.1158/1078-0432.CCR-09-1176; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Jackson AP, 2012, P NATL ACAD SCI USA, V109, P3416, DOI 10.1073/pnas.1117313109; Jin GF, 2011, CARCINOGENESIS, V32, P1057, DOI 10.1093/carcin/bgr082; Kannan K, 2011, P NATL ACAD SCI USA, V108, P9172, DOI 10.1073/pnas.1100489108; Kim J, 2012, BBA-REV CANCER, V1825, P186, DOI 10.1016/j.bbcan.2011.12.003; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Kumar A, 2011, P NATL ACAD SCI USA, V108, P17087, DOI 10.1073/pnas.1108745108; Lapuk AV, 2012, J PATHOL, V227, P286, DOI 10.1002/path.4047; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Lindberg J, 2013, EUR UROL, V63, P347, DOI 10.1016/j.eururo.2012.03.050; Majewski J, 2011, J MED GENET, V48, P580, DOI 10.1136/jmedgenet-2011-100223; Marques RB, 2005, INT J CANCER, V117, P221, DOI 10.1002/ijc.21201; Meyerson M, 2010, NAT REV GENET, V11, P685, DOI 10.1038/nrg2841; Nacu S, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-11; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Pareek CS, 2011, J APPL GENET, V52, P413, DOI 10.1007/s13353-011-0057-x; Parkinson NJ, 2012, GENOME RES, V22, P125, DOI 10.1101/gr.124016.111; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Ren SC, 2012, CELL RES, V22, P806, DOI 10.1038/cr.2012.30; Rippe V, 2003, ONCOGENE, V22, P6111, DOI 10.1038/sj.onc.1206867; Sakharkar Meena Kishore, 2004, In Silico Biology, V4, P387; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Singleton AB, 2011, LANCET NEUROL, V10, P942, DOI 10.1016/S1474-4422(11)70196-X; Sneddon TP, 2012, METHODS MOL BIOL, V838, P273, DOI 10.1007/978-1-61779-507-7_13; Spans L, 2012, PROSTATE, V72, P1317, DOI 10.1002/pros.22480; Straight SW, 2004, MOL BIOL CELL, V15, P1981, DOI 10.1091/mbc.E03-08-0620; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Vainio P, 2012, PROSTATE, V72, P789, DOI 10.1002/pros.21487; Wang Q, 2007, MOL BIOL CELL, V18, P874, DOI 10.1091/mbc.E06-07-0651; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Wu CX, 2012, J PATHOL, V227, P53, DOI 10.1002/path.3987; Yao F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046152; Yeager M, 2008, HUM GENET, V124, P161, DOI 10.1007/s00439-008-0535-3; Yeager M, 2009, HUM GENET, V126, P743, DOI 10.1007/s00439-009-0723-9	52	12	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					568	577		10.1038/onc.2013.591	http://dx.doi.org/10.1038/onc.2013.591			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24488012				2022-12-28	WOS:000348853500004
J	Poortinga, G; Quinn, LM; Hannan, RD				Poortinga, G.; Quinn, L. M.; Hannan, R. D.			Targeting RNA polymerase I to treat MYC-driven cancer	ONCOGENE			English	Review							RIBOSOMAL-PROTEIN L11; C-MYC; DROSOPHILA-MYC; GENE-EXPRESSION; DNA-BINDING; ORNITHINE-DECARBOXYLASE; THERAPEUTIC STRATEGY; MYC/MAX DIMERIZATION; CELLULAR GROWTH; EMERGING TARGET	The MYC oncoprotein and transcription factor is dysregulated in a majority of human cancers and is considered a major driver of the malignant phenotype. As such, developing drugs for effective inhibition of MYC in a manner selective to malignancies is a 'holy grail' of transcription factor-based cancer therapy. Recent advances in elucidating MYC biology in both normal cells and pathological settings were anticipated to bring inhibition of tumorigenic MYC function closer to the clinic. However, while the extensive array of cellular pathways that MYC impacts present numerous fulcrum points on which to leverage MYC's therapeutic potential, identifying the critical target(s) for MYC-specific cancer therapy has been difficult to achieve. Somewhat unexpectedly, MYC's fundamental role in regulating the 'housekeeping' process of ribosome biogenesis, one of the most ubiquitously required and conserved cell functions, may provide the Achilles' heel for therapeutically targeting MYC-driven tumors.	[Poortinga, G.; Hannan, R. D.] Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic 8006, Australia; [Poortinga, G.; Hannan, R. D.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Poortinga, G.] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia; [Quinn, L. M.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3052, Australia; [Hannan, R. D.] Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic, Australia; [Hannan, R. D.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia; [Hannan, R. D.] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; St Vincent's Hospital Melbourne; University of Melbourne; University of Melbourne; University of Melbourne; Monash University; University of Queensland	Hannan, RD (corresponding author), Peter MacCallum Canc Ctr, Div Res, Locked Bag 1,ABeckett St, Melbourne, Vic 8006, Australia.	ross.hannan@petermac.org		Quinn, Leonie/0000-0002-3911-6508; Hannan, Ross/0000-0002-2166-4493				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Albihn A, 2010, ADV CANCER RES, V107, P163, DOI 10.1016/S0065-230X(10)07006-5; Amati B, 2007, NAT CELL BIOL, V9, P729, DOI 10.1038/ncb0707-729; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Benassayag C, 2005, MOL CELL BIOL, V25, P9897, DOI 10.1128/MCB.25.22.9897-9909.2005; Berg T, 2002, P NATL ACAD SCI USA, V99, P3830, DOI 10.1073/pnas.062036999; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boi M, 2012, ASH ANN M, V120, P4872; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Bonham AJ, 2013, NUCLEIC ACIDS RES, V41, P754, DOI 10.1093/nar/gks1085; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Boulon S, 2010, MOL CELL, V40, P216, DOI 10.1016/j.molcel.2010.09.024; Brooks Tracy A, 2010, Genes Cancer, V1, P641; Brown RV, 2011, J BIOL CHEM, V286, P41018, DOI 10.1074/jbc.M111.274720; Brown SJ, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-442; Bui Thi V, 2010, Genes Cancer, V1, P568; Burger K, 2010, J BIOL CHEM, V285, P12416, DOI 10.1074/jbc.M109.074211; Bywater MJ, 2013, NAT REV CANCER, V13, P299, DOI 10.1038/nrc3496; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Chakraborty A, 2011, WIRES RNA, V2, P507, DOI 10.1002/wrna.73; Chan JC, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001754; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen D, 2007, ONCOGENE, V26, P5029, DOI 10.1038/sj.onc.1210327; Clausen DM, 2010, J PHARMACOL EXP THER, V335, P715, DOI 10.1124/jpet.110.170555; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Cotterman R, 2008, CANCER RES, V68, P9654, DOI 10.1158/0008-5472.CAN-08-1961; Dai JX, 2011, J AM CHEM SOC, V133, P17673, DOI 10.1021/ja205646q; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2008, J CELL BIOCHEM, V105, P670, DOI 10.1002/jcb.21895; Daneshvar K, 2013, BIOL OPEN, V2, P1, DOI 10.1242/bio.20122725; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dang Chi V, 2010, Genes Cancer, V1, P526; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Dang CV, 1999, MOL CELL BIOL, V19, P1; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Deisenroth C, 2010, ONCOGENE, V29, P4253, DOI 10.1038/onc.2010.189; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Drygin D, 2013, DRUG DISCOV TODAY, pS1359; Drygin D, 2011, CANCER RES, V71, P1418, DOI 10.1158/0008-5472.CAN-10-1728; Drygin D, 2010, ANNU REV PHARMACOL, V50, P131, DOI 10.1146/annurev.pharmtox.010909.105844; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Eberhardy SR, 2002, J BIOL CHEM, V277, P40156, DOI 10.1074/jbc.M207441200; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Frenzel Anna, 2010, Genes Cancer, V1, P660, DOI 10.1177/1947601910377488; Fumagalli S, 2012, GENE DEV, V26, P1028, DOI 10.1101/gad.189951.112; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Gamble LD, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00162; Gomez-Curet I, 2006, J PEDIATR SURG, V41, P207, DOI 10.1016/j.jpedsurg.2005.10.025; Gomez-Roman N, 2006, BIOCHEM SOC SYMP, V73, P141, DOI 10.1042/bss0730141; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Guo JX, 2009, CANCER CHEMOTH PHARM, V63, P615, DOI 10.1007/s00280-008-0774-y; Gustafson WC, 2010, ONCOGENE, V29, P1249, DOI 10.1038/onc.2009.512; Hammoudeh DI, 2009, J AM CHEM SOC, V131, P7390, DOI 10.1021/ja900616b; Hamperl S, 2013, BBA-GENE REGUL MECH, V1829, P405, DOI 10.1016/j.bbagrm.2012.12.007; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hannan RD, 2013, EXPERT OPIN THER TAR, V17, P873, DOI 10.1517/14728222.2013.818658; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Hein N, 2013, TRENDS MOL MED, V19, P643, DOI 10.1016/j.molmed.2013.07.005; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Hogarty MD, 2008, CANCER RES, V68, P9735, DOI 10.1158/0008-5472.CAN-07-6866; Hornstein E, 2001, COLD SPRING HARB SYM, V66, P477, DOI 10.1101/sqb.2001.66.477; Huang MJ, 2006, EXP HEMATOL, V34, P1480, DOI 10.1016/j.exphem.2006.06.019; Hurley LH, 2006, SEMIN ONCOL, V33, P498, DOI 10.1053/j.seminoncol.2006.04.012; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Jamerson MH, 2004, J MAMMARY GLAND BIOL, V9, P27, DOI 10.1023/B:JOMG.0000023586.69263.0b; Ji HK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026057; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Kiessling A, 2006, CHEM BIOL, V13, P745, DOI 10.1016/j.chembiol.2006.05.011; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Koh JT, 2007, ACS CHEM BIOL, V2, P599, DOI 10.1021/cb700183s; Kong J, 2012, NAT REV GENET, V13, P383, DOI 10.1038/nrg3184; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Kumar N, 2008, BIOCHEMISTRY-US, V47, P13179, DOI 10.1021/bi801064j; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; Larsson LG, 2010, EXP CELL RES, V316, P1429, DOI 10.1016/j.yexcr.2010.03.025; Laurenti E, 2009, CURR OPIN CELL BIOL, V21, P844, DOI 10.1016/j.ceb.2009.09.006; Laurenti E, 2008, CELL STEM CELL, V3, P611, DOI 10.1016/j.stem.2008.09.005; Lawlor ER, 2006, CANCER RES, V66, P4591, DOI 10.1158/0008-5472.CAN-05-3826; Lee BK, 2012, GENOME RES, V22, P9, DOI 10.1101/gr.127597.111; Lee LA, 2006, CURR TOP MICROBIOL, V302, P145; Leung JY, 2012, ONCOGENE, V31, P2545, DOI 10.1038/onc.2011.433; Levens D, 2002, P NATL ACAD SCI USA, V99, P5757, DOI 10.1073/pnas.102173199; Levens David, 2010, Genes Cancer, V1, P547; Li MY, 2011, MOL CELL, V43, P1023, DOI 10.1016/j.molcel.2011.08.020; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Lin CP, 2007, ANTI-CANCER DRUG, V18, P161, DOI 10.1097/CAD.0b013e3280109424; Littlewood TD, 2012, CELL, V151, P11, DOI 10.1016/j.cell.2012.09.006; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Loven J, 2010, P NATL ACAD SCI USA, V107, P1553, DOI 10.1073/pnas.0913517107; Marine JCW, 2007, J CELL SCI, V120, P371, DOI 10.1242/jcs.03362; Marinkovic D, 2004, NUCLEIC ACIDS RES, V32, P5368, DOI 10.1093/nar/gkh877; Martinato F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003650; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Moberg KHK, 2004, CURR BIOL, V14, P10; Mustata G, 2009, J MED CHEM, V52, P1247, DOI 10.1021/jm801278g; Nemeth A, 2008, EMBO J, V27, P1255, DOI 10.1038/emboj.2008.57; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; O'Connell BC, 2003, J BIOL CHEM, V278, P12563, DOI 10.1074/jbc.M210462200; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ofir-Rosenfeld Y, 2008, MOL CELL, V32, P180, DOI 10.1016/j.molcel.2008.08.031; Orian A, 2005, COLD SH Q B, V70, P299, DOI 10.1101/sqb.2005.70.019; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Oskarsson T, 2005, NAT CELL BIOL, V7, P215, DOI 10.1038/ncb0305-215; Perna D, 2012, ONCOGENE, V31, P1695, DOI 10.1038/onc.2011.359; Pierce SB, 2004, DEVELOPMENT, V131, P2317, DOI 10.1242/dev.01108; Poortinga G, 2004, EMBO J, V23, P3325, DOI 10.1038/sj.emboj.7600335; Poortinga G, 2011, NUCLEIC ACIDS RES, V39, P3267, DOI 10.1093/nar/gkq1205; Pourdehnada M, 2013, P NATL ACAD SCI USA, V110, P11988, DOI 10.1073/pnas.1310230110; Prochownik Edward V, 2004, Expert Rev Anticancer Ther, V4, P289, DOI 10.1586/14737140.4.2.289; Prochownik Edward V, 2010, Genes Cancer, V1, P650; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030; Rounbehler RJ, 2009, CANCER RES, V69, P547, DOI 10.1158/0008-5472.CAN-08-2968; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Ruggero D, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003477; Russell J, 2006, BIOCHEM SOC SYMP, V73, P203; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sanij E, 2009, EPIGENETICS-US, V4, P274, DOI 10.4161/epi.4.6.9449; Sanij E, 2008, J CELL BIOL, V183, P1259, DOI 10.1083/jcb.200805146; Sasaki M, 2011, NAT MED, V17, P944, DOI 10.1038/nm.2392; Savino M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022284; Schlosser I, 2005, ONCOGENE, V24, P520, DOI 10.1038/sj.onc.1208198; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Schmidt EV, 2004, ONCOGENE, V23, P3217, DOI 10.1038/sj.onc.1207548; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schneider A, 1997, CURR TOP MICROBIOL, V224, P137; SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Sedoris KC, 2012, MOL CANCER THER, V11, P66, DOI 10.1158/1535-7163.MCT-11-0515; Seitz V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026837; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shaffer AL, 2006, IMMUNOL REV, V210, P67, DOI 10.1111/j.0105-2896.2006.00373.x; Shiue CN, 2009, ONCOGENE, V28, P1833, DOI 10.1038/onc.2009.21; Sodir NM, 2011, GENE DEV, V25, P907, DOI 10.1101/gad.2038411; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Sun D, 2009, J MED CHEM, V52, P2863, DOI 10.1021/jm900055s; Sundqvist A, 2009, EMBO REP, V10, P1132, DOI 10.1038/embor.2009.178; Suzuki A, 2012, CANCER SCI, V103, P632, DOI 10.1111/j.1349-7006.2012.02219.x; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Toyoshima M, 2012, P NATL ACAD SCI USA, V109, P9545, DOI 10.1073/pnas.1121119109; Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Varlakhanova NV, 2009, CANCER RES, V69, P7487, DOI 10.1158/0008-5472.CAN-08-4832; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; Wall M, 2013, CANCER DISCOV, V3, P82, DOI 10.1158/2159-8290.CD-12-0404; Wang HB, 2007, MOL CANCER THER, V6, P2399, DOI 10.1158/1535-7163.MCT-07-0005; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker MM, 2004, CURR BIOL, V14, P6; White RJ, 2005, NAT REV MOL CELL BIO, V6, P69, DOI 10.1038/nrm1551; Wierstra I, 2008, ADV CANCER RES, V99, P113, DOI 10.1016/S0065-230X(07)99004-1; Wu CH, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000090; Wu CH, 2007, P NATL ACAD SCI USA, V104, P13028, DOI 10.1073/pnas.0701953104; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yan CH, 2013, BBA-REV CANCER, V1835, P76, DOI 10.1016/j.bbcan.2012.11.002; Yang JP, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2469; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhao X, 2013, LEUKEMIA, V27, P2341, DOI 10.1038/leu.2013.94; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	182	61	61	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					403	412		10.1038/onc.2014.13	http://dx.doi.org/10.1038/onc.2014.13			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24608428				2022-12-28	WOS:000348451300001
J	Zhi, H; Zahoor, MA; Shudofsky, AMD; Giam, CZ				Zhi, H.; Zahoor, M. A.; Shudofsky, A. M. D.; Giam, C-Z			KSHV vCyclin counters the senescence/G1 arrest response triggered by NF-kappa B hyperactivation	ONCOGENE			English	Article						NF-kappa B hyperactivation; senescence; G1 cyclin-dependent kinase; CDK inhibitors; Kaposi's sarcoma herpesvirus; human T-lymphotropic virus type 1	SARCOMA-ASSOCIATED HERPESVIRUS; T-CELL LEUKEMIA; VIRUS TYPE-I; TAX TRANSFORMING PROTEIN; RIBOSOME ENTRY SITE; KAPOSIS-SARCOMA; IKK-GAMMA; CONSTITUTIVE ACTIVATION; INHIBITORY PROTEIN; MULTIPLE-MYELOMA	Many oncogenic viruses activate nuclear factor-kappa B (NF-kappa B) as a part of their replicative cycles. We have shown recently that persistent and potentially oncogenic activation of NF-kappa B by the human T-lymphotropic virus 1 (HTLV-1) oncoprotein Tax immediately triggers a host senescence response mediated by cyclin-dependent kinase inhibitors: p21(CIP1/WAF1) (p21) and p27(Kip1) (p27) Here we demonstrate that RelA/NF-kappa B activation by Kaposi sarcoma herpesvirus (KSHV) latency protein vFLIP also leads to p21/p27 upregulation and G1 cell cycle arrest. Remarkably, KSHV vCyclin, another latency protein coexpressed with vFLIP from a bicistronic latency-specific mRNA, was found to prevent the senescence and G1 arrest induced by HTLV-1 Tax and vFLIP, respectively. This is because of the known ability of vCyclin/cyclin-dependent kinase 6 complex to resist p21 and p27 inhibition and cause p27 degradation. In KSHV-transformed BCBL-1 cells, sustained vFLIP expression with small hairpin RNAs-mediated vCyclin depletion resulted in G1 arrest. The functional interdependence of vFLIP and vCyclin explains why they are cotranslated from the same viral mRNA. Importantly, deregulation of the G1 cyclin-dependent kinase can facilitate chronic I-kappa B kinases/NF-kappa B activation.	[Zhi, H.; Zahoor, M. A.; Shudofsky, A. M. D.; Giam, C-Z] Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Giam, CZ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	chou-zen.giam@usuhs.edu	Zahoor, Muhammad/ADH-5812-2022	Zahoor, Muhammad/0000-0003-2302-3689	National Institutes of Health [R01CA140963, RO1CA115884]; USU intramural research program [RO73NV]; NATIONAL CANCER INSTITUTE [R01CA115884, R01CA140963] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); USU intramural research program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Mary Collins, Johnan Kaleeba and Emmy Verschuren for the vFLIP antibody, vFLIP cDNA and vCyclin expression plasmid, respectively. This work was supported by grants from the National Institutes of Health (R01CA140963 and RO1CA115884) and the USU intramural research program (RO73NV).	Bagneris C, 2008, MOL CELL, V30, P620, DOI 10.1016/j.molcel.2008.04.029; Bieleski L, 2001, J VIROL, V75, P1864, DOI 10.1128/JVI.75.4.1864-1869.2001; Cereseto A, 1999, ONCOGENE, V18, P2441, DOI 10.1038/sj.onc.1202567; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Dittmer D, 1998, J VIROL, V72, P8309, DOI 10.1128/JVI.72.10.8309-8315.1998; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Fujimuro M, 2007, REV MED VIROL, V17, P405, DOI 10.1002/rmv.549; Ganem D, 2006, ANNU REV PATHOL-MECH, V1, P273, DOI 10.1146/annurev.pathol.1.110304.100133; Ganem D, 2010, J CLIN INVEST, V120, P939, DOI 10.1172/JCI40567; Godfrey A, 2005, BLOOD, V105, P2510, DOI 10.1182/blood-2004-08-3052; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Grossmann C, 2006, J VIROL, V80, P7179, DOI 10.1128/JVI.01603-05; Grundhoff A, 2001, J VIROL, V75, P1857, DOI 10.1128/JVI.75.4.1857-1863.2001; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Hasegawa H, 2006, NAT MED, V12, P466, DOI 10.1038/nm1389; Hatta Y, 2002, LEUKEMIA, V16, P1069, DOI 10.1038/sj.leu.2402458; Hayward S Diane, 2006, Sci STKE, V2006, pre4; Jarviluoma A, 2004, BLOOD, V104, P3349, DOI 10.1182/blood-2004-05-1798; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Koopal S, 2007, PLOS PATHOG, V3, P1348, DOI 10.1371/journal.ppat.0030140; Kuo YL, 2006, EMBO J, V25, P1741, DOI 10.1038/sj.emboj.7601054; Lee JS, 2009, NAT CELL BIOL, V11, P1355, DOI 10.1038/ncb1980; Leida AM, 2012, CELL HOST MICROBE, V11, P167, DOI 10.1016/j.chom.2012.01.005; Liu JY, 2007, J VIROL, V81, P10451, DOI 10.1128/JVI.00804-07; Liu MH, 2008, J VIROL, V82, P8442, DOI 10.1128/JVI.00091-08; Low W, 2001, J VIROL, V75, P2938, DOI 10.1128/JVI.75.6.2938-2945.2001; Mann DJ, 1999, EMBO J, V18, P654, DOI 10.1093/emboj/18.3.654; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; Ojala PM, 1999, CANCER RES, V59, P4984; Oshiro A, 2006, BLOOD, V107, P4500, DOI 10.1182/blood-2005-09-3801; Rivas C, 2001, J VIROL, V75, P429, DOI 10.1128/JVI.75.1.429-438.2001; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Shimizu A, 2011, J VIROL, V85, P7444, DOI 10.1128/JVI.02337-10; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; Verschuren EW, 2004, J GEN VIROL, V85, P1347, DOI 10.1099/vir.0.79812-0; Verschuren EW, 2002, CANCER CELL, V2, P229, DOI 10.1016/S1535-6108(02)00123-X; Xiao GT, 2000, ONCOGENE, V19, P5198, DOI 10.1038/sj.onc.1203894; Yamada Y, 1997, J CLIN ONCOL, V15, P1778, DOI 10.1200/JCO.1997.15.5.1778; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang LP, 2011, J VIROL, V85, P3001, DOI 10.1128/JVI.00086-10; Zhang L, 2006, J VIROL, V80, P7459, DOI 10.1128/JVI.00130-06; Zhi HJ, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002025	49	20	20	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					496	505		10.1038/onc.2013.567	http://dx.doi.org/10.1038/onc.2013.567			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24469036	Green Accepted			2022-12-28	WOS:000348451300010
J	Kang, Z; Yu, Y; Zhu, YJ; Davis, S; Walker, R; Meltzer, PS; Helman, LJ; Cao, L				Kang, Z.; Yu, Y.; Zhu, Y. J.; Davis, S.; Walker, R.; Meltzer, P. S.; Helman, L. J.; Cao, L.			Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma	ONCOGENE			English	Article						IGF1R; IGFBP2; rhabdomyosarcoma; antibody therapy; drug resistance; drug combination	GROWTH-FACTOR-I; FACTOR-BINDING PROTEIN-2; FACTOR RECEPTOR INHIBITORS; CHILDRENS ONCOLOGY GROUP; PHASE-II; CANDIDATE BIOMARKER; MONOCLONAL-ANTIBODY; PROSTATE-CANCER; INSULIN; TARGET	Agents targeting the insulin-like growth factor-1 receptor (IGF1R) are in clinical development, but, despite some initial success of single agents in sarcoma, response rates are low with brief durations. Thus, it is important to identify markers predictive of response, to understand mechanisms of resistance, and to explore combination therapies. In this study, we found that, although associated with PAX3-FKHR translocation, increased IGF1R level is an independent prognostic marker for worse overall survival, particularly in patients with PAX3-FKHR-positive rhabdomyosarcoma (RMS). IGF1R antibody-resistant RMS cells were generated using an in vivo model. Expression analysis indicated that IGFBP2 is both the most affected gene in the insulin-like growth factor (IGF) signaling pathway and the most significantly downregulated gene in the resistant lines, indicating that there is a strong selection to repress IGFBP2 expression in tumor cells resistant to IGF1R antibody. IGFBP2 is inhibitory to IGF1R phosphorylation and its signaling. Similar to antibodies to IGF1/2 or IGF2, the addition of exogenous IGFBP2 potentiates the activity of IGF1R antibody against the RMS cells, and it reverses the resistance to IGF1R antibody. In contrast to IGF1R, lower expression of IGFBP2 is associated with poorer overall survival, consistent with its inhibitory activity found in this study. Finally, blocking downstream Protein kinase B (AKT) activation with Phosphatidylinositide 3-kinases (PI3K)- or mammalian target of rapamycin (mTOR)-specific inhibitors significantly sensitized the resistant cells to the IGF1R antibody. These findings show that constitutive IGFBP2 downregulation may represent a novel mechanism for acquired resistance to IGF1R therapeutic antibody in vivo and suggest various drug combinations to enhance antibody activity and to overcome resistance.	[Kang, Z.; Yu, Y.; Zhu, Y. J.; Davis, S.; Walker, R.; Meltzer, P. S.; Cao, L.] NCI, Genet Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Kang, Z.] Leidos Biomed Res Inc, Canc Res Technol Program, Frederick, MD USA; [Helman, L. J.] NCI, Ctr Canc Res, Pediatr Oncol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cao, L (corresponding author), NCI, Genet Branch, 37 Convent Dr,MSC 4265, Bethesda, MD 20892 USA.	caoli@mail.nih.gov	Davis, Sean/AAD-1801-2021; Cao, Liang/K-7806-2017	Davis, Sean/0000-0002-8991-6458; Kang, zhigang/0000-0003-3444-4315; Walker, Robert/0000-0001-8235-4686; Cao, Liang/0000-0001-7293-8338	Intramural Research Program of the US National Cancer Institute (NCI); NCI; NIH [N01-CO-12400]; NATIONAL CANCER INSTITUTE [ZICBC011048] Funding Source: NIH RePORTER	Intramural Research Program of the US National Cancer Institute (NCI); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the Intramural Research Program of the US National Cancer Institute (NCI). This project was also funded in part with federal funds from the NCI, NIH, under contract N01-CO-12400.	Arai T, 1996, ENDOCRINOLOGY, V137, P4571, DOI 10.1210/en.137.11.4571; Baserga R, 2005, EXPERT OPIN THER TAR, V9, P753, DOI 10.1517/14728222.9.4.753; Bhat RV, 1997, J PHARMACOL EXP THER, V281, P522; Cao L, 2008, CANCER RES, V68, P8039, DOI 10.1158/0008-5472.CAN-08-1712; Cao LA, 2010, CANCER RES, V70, P6497, DOI 10.1158/0008-5472.CAN-10-0582; Clemmons DR, 2007, NAT REV DRUG DISCOV, V6, P821, DOI 10.1038/nrd2359; Crist WM, 2001, J CLIN ONCOL, V19, P3091, DOI 10.1200/JCO.2001.19.12.3091; Davicioni E, 2010, J CLIN ONCOL, V28, P1240, DOI 10.1200/JCO.2008.21.1268; Davicioni E, 2009, AM J PATHOL, V174, P550, DOI 10.2353/ajpath.2009.080631; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Garofalo C, 2011, ONCOGENE, V30, P2730, DOI 10.1038/onc.2010.640; Gualberto A, 2009, ONCOGENE, V28, P3009, DOI 10.1038/onc.2009.172; Hedbacker K, 2010, CELL METAB, V11, P11, DOI 10.1016/j.cmet.2009.11.007; Hendrickson AW, 2009, CURR OPIN INVEST DR, V10, P1032; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; Hoeflich A, 1999, ENDOCRINOLOGY, V140, P5488, DOI 10.1210/en.140.12.5488; Hoeflich A, 2001, CANCER RES, V61, P8601; Hoflich A, 1998, FEBS LETT, V434, P329, DOI 10.1016/S0014-5793(98)01011-4; Huang F, 2010, CANCER RES, V70, P7221, DOI 10.1158/0008-5472.CAN-10-0391; Kurmasheva RT, 2006, BBA-REV CANCER, V1766, P1, DOI 10.1016/j.bbcan.2006.05.003; Martin JL, 2007, ENDOCRINOLOGY, V148, P2532, DOI 10.1210/en.2006-1335; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; Mayeenuddin LH, 2010, ONCOGENE, V29, P6367, DOI 10.1038/onc.2010.364; Mehrian-Shai R, 2007, P NATL ACAD SCI USA, V104, P5563, DOI 10.1073/pnas.0609139104; Moore LM, 2009, P NATL ACAD SCI USA, V106, P16675, DOI 10.1073/pnas.0900807106; Olmos D, 2010, MOL CANCER THER, V9, P2447, DOI 10.1158/1535-7163.MCT-10-0719; Olmos D, 2010, LANCET ONCOL, V11, P129, DOI 10.1016/S1470-2045(09)70354-7; Pappo AS, 2011, J CLIN ONCOL, V29, P4541, DOI 10.1200/JCO.2010.34.0000; Petricoin EF, 2007, CANCER RES, V67, P3431, DOI 10.1158/0008-5472.CAN-06-1344; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; Potratz JC, 2010, CANCER RES, V70, P8770, DOI 10.1158/0008-5472.CAN-10-1093; Ramalingam SS, 2011, J CLIN ONCOL, V29, P4574, DOI 10.1200/JCO.2011.36.6799; Reidy DL, 2010, J CLIN ONCOL, V28, P4240, DOI 10.1200/JCO.2010.30.4154; Shariat SF, 2002, J CLIN ONCOL, V20, P833, DOI 10.1200/JCO.20.3.833; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Tolcher AW, 2009, J CLIN ONCOL, V27, P5800, DOI 10.1200/JCO.2009.23.6745; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Yee D, 2006, BRIT J CANCER, V94, P465, DOI 10.1038/sj.bjc.6602963; Yee D, 2012, JNCI-J NATL CANCER I, V104, P975, DOI 10.1093/jnci/djs258; Yuen JSP, 2008, EXPERT OPIN THER TAR, V12, P589, DOI 10.1517/14728222.12.5.589 ; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	43	18	20	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2014	33	50					5697	5705		10.1038/onc.2013.509	http://dx.doi.org/10.1038/onc.2013.509			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW2AB	24292683	Green Accepted			2022-12-28	WOS:000346089300005
J	Katara, GK; Jaiswal, MK; Kulshrestha, A; Kolli, B; Gilman-Sachs, A; Beaman, KD				Katara, G. K.; Jaiswal, M. K.; Kulshrestha, A.; Kolli, B.; Gilman-Sachs, A.; Beaman, K. D.			Tumor-associated vacuolar ATPase subunit promotes tumorigenic characteristics in macrophages	ONCOGENE			English	Article						a2V-ATPase; a2NTD; tumor-associated macrophages; M2 macrophages; invasion assay; angiogenesis	N-TERMINUS DOMAIN; H+-ATPASE; V-ATPASE; A2 ISOFORM; IN-VITRO; CANCER; POLARIZATION; ACTIVATION; CELLS; ATP6L	Macrophage polarization contributes to distinct human pathologies. In tumors, a polarized M2 phenotype called tumor-associated macrophages (TAMs) are associated with promotion of invasion and angiogenesis. In cancer cells, vacuolar ATPase (V-ATPase), a multi-subunit enzyme, is expressed on the plasma/vesicular membranes and critically influences the metastatic behavior. In addition, the soluble, cleaved N-terminal domain of a2 isoform of V-ATPase (a2NTD) is associated with in vitro induction of pro-tumorigenic properties in monocytes. This activity of a2 isoform of V-ATPase (a2V) caused us to investigate its role in cancer progression through the evaluation of the immunomodulatory properties of a2NTD. Here, we present direct evidence that surface expression of V-ATPase is associated with macrophage polarization in tumor tissue. Macrophages from BALB/c mice (peritoneal/bone marrow derived) were stimulated with recombinant a2NTD in both ex vivo and in vivo systems and evaluated for TAM characteristics. a2V was highly expressed in tumor tissues (breast and skin) as well as on the surface of tumor cell lines. The a2NTD-stimulated macrophages (a2M Phi) acquired TAM phenotype, which was characterized by elevated expression of mannose receptor-1, Arginase-1, interleukin-10 and transforming growth factor-beta. a2M Phi also exhibited increased production of other tumorigenic factors including matrix metalloproteinase-9 and vascular endothelial growth factor. Further, a2M Phi were cocultured with mouse B-16F0 melanoma cells for their functional characterization. The coculture of these a2M Phi subsequently increased the invasion and angiogenesis of less invasive B-16F0 cells. When cocultured with naive T cells, a2M Phi significantly inhibited T-cell activation. The present data establish the role of V-ATPase in modulating a macrophage phenotype towards TAMs through the action of a2NTD, suggesting it to be a potential therapeutic target in cancer.	[Katara, G. K.; Jaiswal, M. K.; Kulshrestha, A.; Kolli, B.; Gilman-Sachs, A.; Beaman, K. D.] Rosalind Franklin Univ Med & Sci, Dept Microbiol & Immunol, 3333 Green Bay Rd, N Chicago, IL 60064 USA	Rosalind Franklin University Medical & Science	Beaman, KD (corresponding author), Rosalind Franklin Univ Med & Sci, Dept Microbiol & Immunol, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	kenneth.beaman@rosalindfranklin.edu			Clinical Immunology Laboratory, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA	Clinical Immunology Laboratory, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA	We thank Robert Dickinson for technical assistance and the Rosalind Franklin University of Medicine and Science Flow Cytometry Core Facility. This work was supported by grants from the Clinical Immunology Laboratory, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA.	De Milito A, 2012, CURR PHARM DESIGN, V18, P1395, DOI 10.2174/138161212799504911; Derks R, 2004, HUM IMMUNOL, V65, P676, DOI 10.1016/j.humimm.2004.04.006; Farber MJ, 2011, MOL BIOL CELL, V22, P795, DOI 10.1091/mbc.E10-06-0505; Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Hao NB, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/948098; Hinton A, 2009, J BIOL CHEM, V284, P16400, DOI 10.1074/jbc.M901201200; Jaiswal MK, 2012, REPRODUCTION, V143, P713, DOI 10.1530/REP-12-0036; Kwong C, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22978; Kwong C, 2011, J IMMUNOL, V186, P1781, DOI 10.4049/jimmunol.1002998; Lu YD, 2005, CANCER RES, V65, P6843, DOI 10.1158/0008-5472.CAN-04-3822; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; Matlack R, 2006, IMMUNOLOGY, V117, P386, DOI 10.1111/j.1365-2567.2005.02312.x; Nishisho T, 2011, MOL CANCER RES, V9, P845, DOI 10.1158/1541-7786.MCR-10-0449; Ntrivalas E, 2007, HUM IMMUNOL, V68, P469, DOI 10.1016/j.humimm.2007.02.010; Ntrivalas E, 2007, AM J REPROD IMMUNOL, V57, P201, DOI 10.1111/j.1600-0897.2006.00463.x; Sennoune SR, 2004, AM J PHYSIOL-CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003; Sennoune SR, 2004, CELL BIOCHEM BIOPHYS, V40, P185, DOI 10.1385/CBB:40:2:185; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Torigoe T, 2002, J BIOL CHEM, V277, P36534, DOI 10.1074/jbc.M202605200; Watkins SK, 2007, J IMMUNOL, V178, P1357, DOI 10.4049/jimmunol.178.3.1357; You HY, 2009, CANCER LETT, V280, P110, DOI 10.1016/j.canlet.2009.02.023	25	33	35	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2014	33	49					5649	5654		10.1038/onc.2013.532	http://dx.doi.org/10.1038/onc.2013.532			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZW	24362525				2022-12-28	WOS:000346088700009
J	Oltean, S; Bates, DO				Oltean, S.; Bates, D. O.			Hallmarks of alternative splicing in cancer	ONCOGENE			English	Review						cancer; hallmarks; alternative splicing	ENDOTHELIAL GROWTH-FACTOR; TELOMERASE REVERSE-TRANSCRIPTASE; RB1 GENE-MUTATIONS; BCL-X; FACTOR RECEPTOR-2; SR PROTEINS; CASPASE 9; MESENCHYMAL TRANSITION; DOWN-REGULATION; FACTOR SF2/ASF	The immense majority of genes are alternatively spliced and there are many isoforms specifically associated with cancer progression and metastasis. The splicing pattern of specific isoforms of numerous genes is altered as cells move through the oncogenic process of gaining proliferative capacity, acquiring angiogenic, invasive, antiapoptotic and survival properties, becoming free from growth factor dependence and growth suppression, altering their metabolism to cope with hypoxia, enabling them to acquire mechanisms of immune escape, and as they move through the epithelial-mesenchymal and mesenchymal-epithelial transitions and metastasis. Each of the 'hallmarks of cancer' is associated with a switch in splicing, towards a more aggressive invasive cancer phenotype. The choice of isoforms is regulated by several factors (signaling molecules, kinases, splicing factors) currently being identified systematically by a number of high-throughput, independent and unbiased methodologies. Splicing factors are de-regulated in cancer, and in some cases are themselves oncogenes or pseudo-oncogenes and can contribute to positive feedback loops driving cancer progression. Tumour progression may therefore be associated with a coordinated splicing control, meaning that there is the potential for a relatively small number of splice factors or their regulators to drive multiple oncogenic processes. The understanding of how splicing contributes to the various phenotypic traits acquired by tumours as they progress and metastasise, and in particular how alternative splicing is coordinated, can and is leading to the development of a new class of anticancer therapeutics-the alternative-splicing inhibitors.	[Oltean, S.] Univ Bristol, Sch Physiol & Pharmacol, Bristol BS2 8EJ, Avon, England; [Bates, D. O.] Univ Nottingham, Queens Med Ctr, Sch Clin Sci, Div Preclin Oncol, Nottingham NG7 2RD, England	University of Bristol; University of Nottingham	Oltean, S (corresponding author), Univ Bristol, Sch Physiol & Pharmacol, Southwell St, Bristol BS2 8EJ, Avon, England.	sebastian.oltean@bristol.ac.uk; dave.bates@nottingham.ac.uk		Oltean, Sebastian/0000-0001-7890-8439; Bates, David/0000-0003-4850-2360	BBSRC [BB/J007293/1]; BHF [PG08/022/21636]; BBSRC [BB/J007293/2] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/J007293/2, BB/J007293/1] Funding Source: researchfish	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BHF(British Heart Foundation); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work has been supported by grants from BBSRC (BB/J007293/1) and the BHF (PG08/022/21636).	Abubaker J, 2009, J PATHOL, V219, P435, DOI 10.1002/path.2625; Albuquerque RJC, 2009, NAT MED, V15, P1023, DOI 10.1038/nm.2018; Amin EM, 2011, CANCER CELL, V20, P768, DOI 10.1016/j.ccr.2011.10.016; Amor S, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-571; Anczukow O, 2012, NAT STRUCT MOL BIOL, V19, P220, DOI 10.1038/nsmb.2207; Baraniak AP, 2006, MOL CELL BIOL, V26, P1209, DOI 10.1128/MCB.26.4.1209-1222.2006; Baraniak AP, 2003, MOL CELL BIOL, V23, P9327, DOI 10.1128/MCB.23.24.9327-9337.2003; Bates DO, 2002, CANCER RES, V62, P4123; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; Boeckel JN, 2011, P NATL ACAD SCI USA, V108, P3276, DOI 10.1073/pnas.1008098108; Bonnal S, 2008, MOL CELL, V32, P81, DOI 10.1016/j.molcel.2008.08.008; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; Cheng CH, 2006, GENE DEV, V20, P1715, DOI 10.1101/gad.1430906; Cloutier P, 2008, J BIOL CHEM, V283, P21315, DOI 10.1074/jbc.M800353200; Das S, 2012, CELL REP, V1, P110, DOI 10.1016/j.celrep.2011.12.001; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Diaz R, 2008, INT J CANCER, V123, P1060, DOI 10.1002/ijc.23619; Ergorul C, 2008, MOL VIS, V14, P1517; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Fregoso OI, 2013, MOL CELL, V50, P56, DOI 10.1016/j.molcel.2013.02.001; Fukuhara T, 2006, P NATL ACAD SCI USA, V103, P11329, DOI 10.1073/pnas.0604616103; Gammons MV, 2013, INVEST OPHTH VIS SCI, V54, P6052, DOI 10.1167/iovs.13-12422; Ghigna C, 2005, MOL CELL, V20, P881, DOI 10.1016/j.molcel.2005.10.026; Ghigna C, 2008, CURR GENOMICS, V9, P556, DOI 10.2174/138920208786847971; Goncalves V, 2009, HUM MOL GENET, V18, P3696, DOI 10.1093/hmg/ddp317; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Himeji D, 2002, BLOOD, V99, P4070, DOI 10.1182/blood.V99.11.4070; Horiguchi K, 2012, ONCOGENE, V31, P3190, DOI 10.1038/onc.2011.493; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Huang YQ, 2003, MOL CELL, V11, P837, DOI 10.1016/S1097-2765(03)00089-3; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Joukov V, 1996, EMBO J, V15, P290; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Keriel A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004533; Konrad L, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-318; Koslowski M, 2002, CANCER RES, V62, P6750; Krajewska M, 1996, CANCER RES, V56, P2422; Krajewska M, 1996, AM J PATHOL, V148, P1567; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Liu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038868; Lohmann DR, 1999, HUM MUTAT, V14, P283, DOI 10.1002/(SICI)1098-1004(199910)14:4<283::AID-HUMU2>3.0.CO;2-J; MAGLIONE D, 1993, ONCOGENE, V8, P925; Merdzhanova G, 2008, CELL DEATH DIFFER, V15, P1815, DOI 10.1038/cdd.2008.135; Merdzhanova G, 2010, ONCOGENE, V29, P5392, DOI 10.1038/onc.2010.281; Michlewski G, 2008, MOL CELL, V30, P179, DOI 10.1016/j.molcel.2008.03.013; Nowak DG, 2008, J CELL SCI, V121, P3487, DOI 10.1242/jcs.016410; Nowak DG, 2010, J BIOL CHEM, V285, P5532, DOI 10.1074/jbc.M109.074930; Okumura N, 2011, BIOCHEM BIOPH RES CO, V413, P395, DOI 10.1016/j.bbrc.2011.08.098; Olshavsky NA, 2010, CANCER RES, V70, P3975, DOI 10.1158/0008-5472.CAN-09-3468; Oltean S, 2008, CLIN EXP METASTAS, V25, P611, DOI 10.1007/s10585-008-9186-y; Oltean S, 2006, P NATL ACAD SCI USA, V103, P14116, DOI 10.1073/pnas.0603090103; Pan DM, 2011, ONCOL LETT, V2, P1309, DOI 10.3892/ol.2011.395; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Peiris-Pages M, 2010, J PATHOL, V222, P138, DOI 10.1002/path.2746; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Pritchard-Jones RO, 2007, BRIT J CANCER, V97, P223, DOI 10.1038/sj.bjc.6603839; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Reeve JG, 1996, BRIT J CANCER, V73, P1193, DOI 10.1038/bjc.1996.230; Reinke LM, 2012, J BIOL CHEM, V287, P36435, DOI 10.1074/jbc.M112.397125; Rennel ES, 2008, BRIT J CANCER, V98, P1250, DOI 10.1038/sj.bjc.6604309; Rha SY, 2009, ONCOL RES, V18, P213, DOI 10.3727/096504009X12596189659123; Rodriguez-Cruz TG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022939; Rouas-Freiss N, 2005, INT J CANCER, V117, P114, DOI 10.1002/ijc.21151; Sanford JR, 2004, GENE DEV, V18, P755, DOI 10.1101/gad.286404; Schumacher VA, 2007, J AM SOC NEPHROL, V18, P719, DOI 10.1681/ASN.2006020124; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Sharma S, 2011, MOL CANCER THER, V10, P1751, DOI 10.1158/1535-7163.MCT-11-0248; Shkreta L, 2008, MOL CANCER THER, V7, P1398, DOI 10.1158/1535-7163.MCT-08-0192; Shultz JC, 2012, MOL CANCER RES, V10, P660, DOI 10.1158/1541-7786.MCR-11-0363; Shultz JC, 2011, MOL CANCER RES, V9, P889, DOI 10.1158/1541-7786.MCR-11-0061; Shultz JC, 2010, CANCER RES, V70, P9185, DOI 10.1158/0008-5472.CAN-10-1545; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Thorsen K, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002998; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Varey AHR, 2008, BRIT J CANCER, V98, P1366, DOI 10.1038/sj.bjc.6604308; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Venables JP, 2013, MOL CELL BIOL, V33, P396, DOI 10.1128/MCB.01174-12; Venables JP, 2009, NAT STRUCT MOL BIOL, V16, P670, DOI 10.1038/nsmb.1608; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang H, 2011, NEOPLASIA, V13, P461, DOI 10.1593/neo.101744; WARBURG O, 1956, SCIENCE, V124, P269; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warzecha CC, 2012, SEMIN CANCER BIOL, V22, P417, DOI 10.1016/j.semcancer.2012.04.003; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Woolard J, 2004, CANCER RES, V64, P7822, DOI 10.1158/0008-5472.CAN-04-0934; Woolard J, 2011, CHEM SCI, V2, P273, DOI 10.1039/c0sc00297f; Xu JH, 2009, PATHOBIOLOGY, V76, P23, DOI 10.1159/000178152; Yea S, 2008, GASTROENTEROLOGY, V134, P1521, DOI 10.1053/j.gastro.2008.02.015; Zhang K, 2008, HUM MUTAT, V29, P475, DOI 10.1002/humu.20664; Zhang Z, 2004, MOL CELL, V16, P597, DOI 10.1016/j.molcel.2004.10.031; Zhou ZH, 2012, MOL CELL, V47, P422, DOI 10.1016/j.molcel.2012.05.014	96	411	423	0	87	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2014	33	46					5311	5318		10.1038/onc.2013.533	http://dx.doi.org/10.1038/onc.2013.533			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MF	24336324				2022-12-28	WOS:000345120600001
J	Berger, AH; Imielinski, M; Duke, F; Wala, J; Kaplan, N; Shi, GX; Andres, DA; Meyerson, M				Berger, A. H.; Imielinski, M.; Duke, F.; Wala, J.; Kaplan, N.; Shi, G-X; Andres, D. A.; Meyerson, M.			Oncogenic RIT1 mutations in lung adenocarcinoma	ONCOGENE			English	Article						lung adenocarcinoma; cancer genetics; RAS pathway; signal transduction; oncogene; GTPase	EML4-ALK FUSION GENE; NEURONAL DIFFERENTIATION; KINASE INHIBITOR; KRAS MUTATIONS; CANCER; GEFITINIB; PROTEIN; SENSITIVITY; ACTIVATION; GENOME	Lung adenocarcinoma is comprised of distinct mutational subtypes characterized by mutually exclusive oncogenic mutations in RTK/RAS pathway members KRAS, EGFR, BRAF and ERBB2, and translocations involving ALK, RET and ROS1. Identification of these oncogenic events has transformed the treatment of lung adenocarcinoma via application of therapies targeted toward specific genetic lesions in stratified patient populations. However, such mutations have been reported in only similar to 55% of lung adenocarcinoma cases in the United States, suggesting other mechanisms of malignancy are involved in the remaining cases. Here we report somatic mutations in the small GTPase gene RIT1 in similar to 2% of lung adenocarcinoma cases that cluster in a hotspot near the switch II domain of the protein. RIT1 switch II domain mutations are mutually exclusive with all other known lung adenocarcinoma driver mutations. Ectopic expression of mutated RIT1 induces cellular transformation in vitro and in vivo, which can be reversed by combined PI3K and MEK inhibition. These data identify RIT1 as a driver oncogene in a specific subset of lung adenocarcinomas and suggest PI3K and MEK inhibition as a potential therapeutic strategy in RIT1-mutated tumors.	[Berger, A. H.; Imielinski, M.; Duke, F.; Wala, J.; Meyerson, M.] Broad Inst Harvard & MIT, Canc Program, Cambridge, MA USA; [Berger, A. H.; Imielinski, M.; Wala, J.; Kaplan, N.; Meyerson, M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Imielinski, M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Imielinski, M.; Meyerson, M.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Wala, J.] MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Shi, G-X; Andres, D. A.] Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); University of Kentucky	Meyerson, M (corresponding author), Dana Farber Canc Inst, Ctr Canc Genome Discovery, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02115 USA.	matthew_meyerson@dfci.harvard.edu	Shi, Geng-Xian/AAK-6061-2021	Meyerson, Matthew/0000-0002-9133-8108	American Cancer Society; NCI Training Grant [T32CA9216]; NIH Training Grant [T32HG002295]; NIH [NS045103]; KSCHIRT [12-1A]; University of Kentucky Research Professorship; Department of Defense [W81XWH-12-1-0269]; National Cancer Institute [P01CA154303, R01CA109038]; Uniting Against Lung Cancer; Lung Cancer Research Foundation; American Lung Association; NATIONAL CANCER INSTITUTE [R01CA109038, U24CA143867, T32CA009216, P01CA154303] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG002295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045103, R56NS045103] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); NCI Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); KSCHIRT; University of Kentucky Research Professorship; Department of Defense(United States Department of Defense); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Uniting Against Lung Cancer; Lung Cancer Research Foundation; American Lung Association; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank A. Brooks, P. Choi, H. Gannon, H. Greulich, L. De Waal, B. Kaplan, R. Liao, T. Sharifnia, J. Boehm and A. Koehler for critical advice and discussion. AHB is supported by a postdoctoral fellowship from the American Cancer Society. MI is supported by NCI Training Grant T32CA9216. JW is supported by NIH Training Grant T32HG002295. DAA is supported by NIH NS045103, KSCHIRT 12-1A, and a University of Kentucky Research Professorship. This work was supported by grants from the Department of Defense (#W81XWH-12-1-0269) National Cancer Institute (P01CA154303 and R01CA109038), Uniting Against Lung Cancer, the Lung Cancer Research Foundation and the American Lung Association to MM.	Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Aoki Y, 2013, AM J HUM GENET, V93, P173, DOI 10.1016/j.ajhg.2013.05.021; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Cai WK, 2011, MOL BIOL CELL, V22, P3231, DOI 10.1091/mbc.E11-05-0400; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Forbes S, 2006, BRIT J CANCER, V94, P318, DOI 10.1038/sj.bjc.6602928; Gomez-Segui I, 2013, LEUKEMIA, V27, P1943, DOI 10.1038/leu.2013.179; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Janne PA, 2012, J CLIN ONCOL, V30, P878, DOI 10.1200/JCO.2011.39.4197; Ju YS, 2012, GENOME RES, V22, P436, DOI 10.1101/gr.133645.111; Kawazu M, 2013, P NATL ACAD SCI USA, V110, P3029, DOI 10.1073/pnas.1216141110; Koivunen JP, 2008, CLIN CANCER RES, V14, P4275, DOI 10.1158/1078-0432.CCR-08-0168; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lamprecht MR, 2007, BIOTECHNIQUES, V42, P71, DOI 10.2144/000112257; Lee CHJ, 1996, J NEUROSCI, V16, P6784; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; O'Brien C, 2010, CLIN CANCER RES, V16, P3670, DOI 10.1158/1078-0432.CCR-09-2828; Onozato R, 2009, J THORAC ONCOL, V4, P5, DOI 10.1097/JTO.0b013e3181913e0e; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pao W, 2012, NAT MED, V18, P349, DOI 10.1038/nm.2697; Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Riely Gregory J, 2009, Proc Am Thorac Soc, V6, P201, DOI 10.1513/pats.200809-107LC; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Rusyn EV, 2000, ONCOGENE, V19, P4685, DOI 10.1038/sj.onc.1203836; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Seo JS, 2012, GENOME RES, V22, P2109, DOI 10.1101/gr.145144.112; Shao HP, 1999, ARCH BIOCHEM BIOPHYS, V371, P207, DOI 10.1006/abbi.1999.1448; Shi GX, 2006, MOL CELL BIOL, V26, P9136, DOI 10.1128/MCB.00332-06; Shi GX, 2005, MOL CELL BIOL, V25, P830, DOI 10.1128/MCB.25.2.830-846.2005; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Sos ML, 2009, J CLIN INVEST, V119, P1727, DOI 10.1172/JCI37127; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Yang XP, 2011, NAT METHODS, V8, P659, DOI [10.1038/NMETH.1638, 10.1038/nmeth.1638]; Zenker M, 2007, J MED GENET, V44, P131, DOI 10.1136/jmg.2006.046300	43	57	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2014	33	35					4418	4423		10.1038/onc.2013.581	http://dx.doi.org/10.1038/onc.2013.581			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MR	24469055	hybrid, Green Published			2022-12-28	WOS:000341157800006
J	Cappellari, M; Bielli, P; Paronetto, MP; Ciccosanti, F; Fimia, GM; Saarikettu, J; Silvennoinen, O; Sette, C				Cappellari, M.; Bielli, P.; Paronetto, M. P.; Ciccosanti, F.; Fimia, G. M.; Saarikettu, J.; Silvennoinen, O.; Sette, C.			The transcriptional co-activator SND1 is a novel regulator of alternative splicing in prostate cancer cells	ONCOGENE			English	Article						alternative splicing; SND1; SAM68; CD44; prostate cancer	BINDING PROTEIN SAM68; RNA-POLYMERASE-II; MALE GERM-CELLS; ANDROGEN RECEPTOR; MESSENGER-RNAS; IN-VIVO; ELONGATION; CD44; P100; SPERMATOGENESIS	Splicing abnormalities have profound impact in human cancer. Several splicing factors, including SAM68, have pro-oncogenic functions, and their increased expression often correlates with human cancer development and progression. Herein, we have identified using mass spectrometry proteins that interact with endogenous SAM68 in prostate cancer (PCa) cells. Among other interesting proteins, we have characterized the interaction of SAM68 with SND1, a transcriptional co-activator that binds spliceosome components, thus coupling transcription and splicing. We found that both SAM68 and SND1 are upregulated in PCa cells with respect to benign prostate cells. Upregulation of SND1 exerts a synergic effect with SAM68 on exon v5 inclusion in the CD44 mRNA. The effect of SND1 on CD44 splicing required SAM68, as it was compromised after knockdown of this protein or mutation of the SAM68-binding sites in the CD44 pre-mRNA. More generally, we found that SND1 promotes the inclusion of CD44 variable exons by recruiting SAM68 and spliceosomal components on CD44 pre-mRNA. Inclusion of the variable exons in CD44 correlates with increased proliferation, motility and invasiveness of cancer cells. Strikingly, we found that knockdown of SND1, or SAM68, reduced proliferation and migration of PCa cells. Thus, our findings strongly suggest that SND1 is a novel regulator of alternative splicing that promotes PCa cell growth and survival.	[Cappellari, M.; Bielli, P.; Sette, C.] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy; [Cappellari, M.; Bielli, P.; Sette, C.] Fdn Santa Lucia, Lab Neuroembryol, Rome, Italy; [Paronetto, M. P.] Fdn Santa Lucia, Lab Cellular & Mol Neurobiol, Rome, Italy; [Paronetto, M. P.] Univ Rome Foro Italico, Dept Hlth Sci, Rome, Italy; [Ciccosanti, F.; Fimia, G. M.] Natl Inst Infect Dis Lazzaro Spallanzani, Dept Epidemiol & Preclin Res, Rome, Italy; [Saarikettu, J.; Silvennoinen, O.] Tampere Univ, Fac Med, Lab Mol Immunol, FIN-33101 Tampere, Finland; [Silvennoinen, O.] Tampere Univ, Inst Biomed Technol Biomeditech, Tampere, Finland; [Silvennoinen, O.] Tampere Univ Hosp, Dept Internal Med, Tampere, Finland	University of Rome Tor Vergata; IRCCS Santa Lucia; IRCCS Santa Lucia; Foro Italico University of Rome; IRCCS Lazzaro Spallanzani; Tampere University; Tampere University; Tampere University; Tampere University Hospital	Sette, C (corresponding author), Univ Roma Tor Vergata, Dept Biomed & Prevent, Via Montpellier 1, I-00133 Rome, Italy.	claudio.sette@uniroma2.it	Fimia, Gian Maria/K-3232-2016; Sette, Claudio/S-4307-2019; Ciccosanti, Fabiola/B-5284-2017; Paronetto, Maria Paola/A-9578-2012; Bielli, Pamela/K-1208-2018	Fimia, Gian Maria/0000-0003-4438-3325; Sette, Claudio/0000-0003-2864-8266; Ciccosanti, Fabiola/0000-0003-0481-6878; Paronetto, Maria Paola/0000-0001-5324-0903; Bielli, Pamela/0000-0003-3347-8345	Association for International Cancer Research (AICR) [12-0150]; Associazione Italiana Ricerca sul Cancro (AIRC) [10348]; Associazione Italiana Ricerca sul Cancro (MFAG) [11658]; Worldwide Cancer Research [12-0150] Funding Source: researchfish	Association for International Cancer Research (AICR); Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Associazione Italiana Ricerca sul Cancro (MFAG)(Fondazione AIRC per la ricerca sul cancro); Worldwide Cancer Research	We wish to thank Dr Roberta Busa for suggestions with chromatin immunoprecipitation experiments and Dr Maria Loiarro for assistance with luciferase reporter assays. This work was supported by the Association for International Cancer Research (AICR grant no. 12-0150 to CS) and the Associazione Italiana Ricerca sul Cancro (AIRC grant no. 10348 to CS and MFAG no. 11658 to MPP).	Babic I, 2006, ONCOGENE, V25, P4955, DOI 10.1038/sj.onc.1209504; Batsche E, 2006, NAT STRUCT MOL BIOL, V13, P22, DOI 10.1038/nsmb1030; Bielli P, 2011, ENDOCR-RELAT CANCER, V18, pR91, DOI 10.1530/ERC-11-0041; Blanco MA, 2011, J BIOL CHEM, V286, P19982, DOI 10.1074/jbc.M111.240077; Busa R, 2007, ONCOGENE, V26, P4372, DOI 10.1038/sj.onc.1210224; Busa R, 2010, NUCLEIC ACIDS RES, V38, P3005, DOI 10.1093/nar/gkq004; Caudy AA, 2003, NATURE, V425, P411, DOI 10.1038/nature01956; Chawla G, 2009, MOL CELL BIOL, V29, P201, DOI 10.1128/MCB.01349-08; Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777; Cheng CH, 2006, MOL CELL BIOL, V26, P362, DOI 10.1128/MCB.26.1.362-370.2006; Cheng CH, 2006, GENE DEV, V20, P1715, DOI 10.1101/gad.1430906; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; de la Mata M, 2003, MOL CELL, V12, P525, DOI 10.1016/j.molcel.2003.08.001; Dong XS, 2007, MOL CELL BIOL, V27, P4863, DOI 10.1128/MCB.02144-06; Elliott DJ, 2010, J PATHOL, V222, P223, DOI 10.1002/path.2753; Fong YW, 2001, NATURE, V414, P929, DOI 10.1038/414929a; Gao XJ, 2012, J BIOL CHEM, V287, P18130, DOI 10.1074/jbc.M111.311852; Germann S, 2012, J NUCLEIC ACIDS, V2012, DOI 10.1155/2012/269570; Grange J, 2009, J NEUROSCI RES, V87, P12, DOI 10.1002/jnr.21824; Grosso AR, 2008, EMBO REP, V9, P1087, DOI 10.1038/embor.2008.189; Ho J, 2009, J PROTEOME RES, V8, P583, DOI 10.1021/pr8007368; Hong W, 2002, MOL CANCER RES, V1, P48; Hsin JP, 2012, GENE DEV, V26, P2119, DOI 10.1101/gad.200303.112; Huot ME, 2009, J BIOL CHEM, V284, P31903, DOI 10.1074/jbc.M109.018465; Kalsotra A, 2011, NAT REV GENET, V12, P715, DOI 10.1038/nrg3052; Kornblihtt AR, 2013, NAT REV MOL CELL BIO, V14, P153, DOI 10.1038/nrm3525; Kuruma H, 2009, AM J PATHOL, V174, P2044, DOI 10.2353/ajpath.2009.080776; Lin SR, 2008, NAT STRUCT MOL BIOL, V15, P819, DOI 10.1038/nsmb.1461; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Messina V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039729; Niranjanakumari S, 2002, METHODS, V26, P182, DOI 10.1016/S1046-2023(02)00021-X; Oesterreich FC, 2011, TRENDS CELL BIOL, V21, P328, DOI 10.1016/j.tcb.2011.03.002; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Paronetto MP, 2007, J CELL BIOL, V176, P929, DOI 10.1083/jcb.200701005; Paronetto MP, 2011, NUCLEIC ACIDS RES, V39, P4961, DOI 10.1093/nar/gkr085; Paronetto MP, 2010, CANCER RES, V70, P229, DOI 10.1158/0008-5472.CAN-09-2788; Paronetto MP, 2009, J CELL BIOL, V185, P235, DOI 10.1083/jcb.200811138; Paronetto MP, 2006, MOL BIOL CELL, V17, P14, DOI 10.1091/mbc.e05-06-0548; Pedrotti S, 2010, EMBO J, V29, P1235, DOI 10.1038/emboj.2010.19; Rajan P, 2008, J PATHOL, V215, P67, DOI 10.1002/path.2324; Santhekadur PK, 2012, J BIOL CHEM, V287, P13952, DOI 10.1074/jbc.M111.321646; Sergeant KA, 2007, J CELL SCI, V120, P309, DOI 10.1242/jcs.03344; Sette C, 1998, J CELL BIOL, V142, P1063, DOI 10.1083/jcb.142.4.1063; Sette C, 2010, ADV EXP MED BIOL, V693, P54; Shukla S, 2012, BBA-GENE REGUL MECH, V1819, P673, DOI 10.1016/j.bbagrm.2012.01.014; Singh J, 2009, NAT STRUCT MOL BIOL, V16, P1128, DOI 10.1038/nsmb.1666; Song LB, 2010, J PATHOL, V222, P227, DOI 10.1002/path.2751; Taylor SJ, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-5; Tazi J, 2009, BBA-MOL BASIS DIS, V1792, P14, DOI 10.1016/j.bbadis.2008.09.017; Tisserant A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001418; Valineva T, 2005, J BIOL CHEM, V280, P14989, DOI 10.1074/jbc.M410465200; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Yang HP, 2002, ONCOGENE, V21, P7187, DOI 10.1038/sj.onc.1205759; Yang J, 2002, EMBO J, V21, P4950, DOI 10.1093/emboj/cdf463; Yang J, 2007, NUCLEIC ACIDS RES, V35, P4485, DOI 10.1093/nar/gkm470; Yoo BK, 2011, HEPATOLOGY, V53, P1538, DOI 10.1002/hep.24216; Zhou HL, 2011, P NATL ACAD SCI USA, V108, pE627, DOI 10.1073/pnas.1103344108; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	60	58	60	3	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3794	3802		10.1038/onc.2013.360	http://dx.doi.org/10.1038/onc.2013.360			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23995791				2022-12-28	WOS:000339394100005
J	Marxer, M; Ma, HT; Man, WY; Poon, RYC				Marxer, M.; Ma, H. T.; Man, W. Y.; Poon, R. Y. C.			p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases	ONCOGENE			English	Article						mitosis; mitotic catastrophe; mitotic slippage	P53-DEFICIENT CANCER-CELLS; SMALL-MOLECULE INHIBITOR; IN-VIVO; POSTMITOTIC CHECKPOINT; CYTOKINESIS FAILURE; MAMMALIAN-CELLS; APOPTOSIS; TETRAPLOIDY; MITOSIS; CYCLE	A number of small-molecule inhibitors of Aurora kinases have been developed and are undergoing clinical trials for anti-cancer therapies. Different Aurora kinases, however, behave as very different targets: while inhibition of Aurora A (AURKA) induces a delay in mitotic exit, inhibition of Aurora B (AURKB) triggers mitotic slippage. Furthermore, while it is evident that p53 is regulated by Aurora kinase-dependent phosphorylation, how p53 may in turn regulate Aurora kinases remains mysterious. To address these issues, isogenic p53-containing and -negative cells were exposed to classic inhibitors that target both AURKA and AURKB (Alisertib and ZM447439), as well as to new generation of inhibitors that target AURKA (MK-5108), AURKB (Barasertib) individually. The fate of individual cells was then tracked with time-lapse microscopy. Remarkably, loss of p53, either by gene disruption or small interfering RNA-mediated depletion, sensitized cells to inhibition of both AURKA and AURKB, promoting mitotic arrest and slippage respectively. As the p53-dependent post-mitotic checkpoint is also important for preventing genome reduplication after mitotic slippage, these studies indicate that the loss of p53 in cancer cells represents a major opportunity for anti-cancer drugs targeting the Aurora kinases.	[Poon, R. Y. C.] Hong Kong Univ Sci & Technol, Ctr Canc Res, Div Life Sci, Hong Kong, Hong Kong, Peoples R China; [Poon, R. Y. C.] Hong Kong Univ Sci & Technol, State Key Lab Mol Neurosci, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Poon, RYC (corresponding author), Hong Kong Univ Sci & Technol, Ctr Canc Res, Div Life Sci, Hong Kong, Hong Kong, Peoples R China.	rycpoon@ust.hk		Poon, Randy/0000-0001-5571-6231; MA, Hoi Tang/0000-0001-5876-0107	Research Grants Council [HKU7/CRG/09]	Research Grants Council(Hong Kong Research Grants Council)	Many thanks are due to Michelle Chen, Nelson Lee and Kenji Nishiura for technical assistance. This work was supported in part by the Research Grants Council grant HKU7/CRG/09 to RYCP.	Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Chan YW, 2008, J BIOL CHEM, V283, P15716, DOI 10.1074/jbc.M800629200; Chan YW, 2008, CELL CYCLE, V7, P1449, DOI 10.4161/cc.7.10.5880; Curry J, 2009, CELL CYCLE, V8, P1921, DOI 10.4161/cc.8.12.8741; Dar AA, 2008, CANCER RES, V68, P8998, DOI 10.1158/0008-5472.CAN-08-2658; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Gautschi O, 2008, CLIN CANCER RES, V14, P1639, DOI 10.1158/1078-0432.CCR-07-2179; Girdler F, 2006, J CELL SCI, V119, P3664, DOI 10.1242/jcs.03145; Gizatullin F, 2006, CANCER RES, V66, P7668, DOI 10.1158/0008-5472.CAN-05-3353; Green MR, 2011, EXPERT OPIN DRUG DIS, V6, P291, DOI 10.1517/17460441.2011.555395; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hegarat N, 2011, J CELL BIOL, V195, P1103, DOI 10.1083/jcb.201105058; Karthigeyan D, 2011, MED RES REV, V31, P757, DOI 10.1002/med.20203; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Kimura M, 1999, J BIOL CHEM, V274, P7334, DOI 10.1074/jbc.274.11.7334; Li QY, 2004, J BIOL CHEM, V279, P52175, DOI 10.1074/jbc.M406802200; Ma HT, 2011, METHODS MOL BIOL, V761, P151, DOI 10.1007/978-1-61779-182-6_10; Ma HT, 2011, BIOCHEM J, V435, P17, DOI 10.1042/BJ20100284; Manfredi MG, 2011, CLIN CANCER RES, V17, P7614, DOI 10.1158/1078-0432.CCR-11-1536; On KF, 2011, MOL CANCER THER, V10, P784, DOI 10.1158/1535-7163.MCT-10-0809; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Ruchaud S, 2007, NAT REV MOL CELL BIO, V8, P798, DOI 10.1038/nrm2257; Scutt PJ, 2009, J BIOL CHEM, V284, P15880, DOI 10.1074/jbc.M109.005694; Shao SJ, 2006, J BIOL CHEM, V281, P28943, DOI 10.1074/jbc.M600235200; Shimomura T, 2010, MOL CANCER THER, V9, P157, DOI 10.1158/1535-7163.MCT-09-0609; Siu WY, 2004, MOL CANCER THER, V3, P621; Siu WY, 1999, EXP CELL RES, V250, P131, DOI 10.1006/excr.1999.4551; Storchova Z, 2008, J CELL SCI, V121, P3859, DOI 10.1242/jcs.039537; Tao Y, 2008, ONCOGENE, V27, P3244, DOI 10.1038/sj.onc.1210990; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6; Yam CH, 2000, J BIOL CHEM, V275, P3158, DOI 10.1074/jbc.275.5.3158; Yang J, 2007, BLOOD, V110, P2034, DOI 10.1182/blood-2007-02-073700; Yasui Y, 2004, J BIOL CHEM, V279, P12997, DOI 10.1074/jbc.M311128200	36	46	46	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3550	3560		10.1038/onc.2013.325	http://dx.doi.org/10.1038/onc.2013.325			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23955083				2022-12-28	WOS:000338941100007
J	Raina, D; Uchida, Y; Kharbanda, A; Rajabi, H; Panchamoorthy, G; Jin, C; Kharbanda, S; Scaltriti, M; Baselga, J; Kufe, D				Raina, D.; Uchida, Y.; Kharbanda, A.; Rajabi, H.; Panchamoorthy, G.; Jin, C.; Kharbanda, S.; Scaltriti, M.; Baselga, J.; Kufe, D.			Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells	ONCOGENE			English	Article						MUC1; HER2; HER3; trastuzumab; resistance; breast cancer	GROWTH-FACTOR RECEPTOR; KINASE INHIBITOR P27(KIP1); FACTOR-I RECEPTOR; CYCLIN-E; PHOSPHORYLATION; CONTRIBUTES; LAPATINIB; ERBB3; CHEMOTHERAPY; MECHANISM	Patients with HER2-positive breast cancer often exhibit intrinsic or acquired resistance to trastuzumab treatment. The transmembrane mucin 1 (MUC1) oncoprotein is aberrantly overexpressed in breast cancer cells and associates with HER2. The present studies demonstrate that silencing MUC1 C-terminal subunit (MUC1-C) in HER2-overexpressing SKBR3 and BT474 breast cancer cells results in the downregulation of constitutive HER2 activation. Moreover, treatment with the MUC1-C inhibitor, GO-203, was associated with disruption of MUC1-C/HER2 complexes and decreases in tyrosine-phosphorylated HER2 (p-HER2) levels. In studies of trastuzumab-resistant SKBR3R and BT474R cells, we found that the association between MUC1-C and HER2 is markedly increased (B20-fold) as compared with that in sensitive cells. In addition, silencing MUC1-C in the trastuzumab-resistant cells or treatment with GO-203 decreased p-HER2 and AKT activation. Moreover, targeting MUC1-C was associated with the downregulation of phospho-p27 and cyclin E, which confer trastuzumab resistance. Consistent with these results, targeting MUC1-C inhibited the growth and clonogenic survival of both trastuzumab-resistant cells. Our results further demonstrate that silencing MUC1-C reverses resistance to trastuzumab and that the combination of GO-203 and trastuzumab is highly synergistic. These findings indicate that MUC1-C contributes to constitutive activation of the HER2 pathway and that targeting MUC1-C represents a potential approach to abrogate trastuzumab resistance.	[Raina, D.; Panchamoorthy, G.; Kharbanda, S.] Genus Oncol, Boston, MA USA; [Uchida, Y.; Kharbanda, A.; Rajabi, H.; Jin, C.; Kufe, D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA; [Scaltriti, M.; Baselga, J.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Memorial Sloan Kettering Cancer Center	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave,Dana 830, Boston, MA 02215 USA.	donald_kufe@dfci.harvard.edu			National Cancer Institute [CA97098, CA166480]; Susan G Komen for the Cure Grant [SAC110046]; NATIONAL CANCER INSTITUTE [R01CA097098, R01CA166480] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen for the Cure Grant(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Grants CA97098 and CA166480 awarded by the National Cancer Institute, and by the Susan G Komen for the Cure Grant SAC110046 (MS and JB).	Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Buck E, 2006, MOL CANCER THER, V5, P2676, DOI 10.1158/1535-7163.MCT-06-0166; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Duraisamy S, 2007, INT J ONCOL, V31, P671; Fessler SP, 2009, BREAST CANCER RES TR, V118, P113, DOI 10.1007/s10549-009-0412-3; Guertin AD, 2012, CANCER CELL INT, V12, DOI 10.1186/1475-2867-12-45; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Huang XP, 2010, CANCER RES, V70, P1204, DOI 10.1158/0008-5472.CAN-09-3321; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Klapper LN, 2000, CANCER RES, V60, P3384; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Lee-Hoeflich ST, 2011, CANCER DISCOV, V1, P326, DOI 10.1158/2159-8290.CD-11-0062; Leng YM, 2007, J BIOL CHEM, V282, P19321, DOI 10.1074/jbc.M703222200; Li PF, 2004, J BIOL CHEM, V279, P25260, DOI 10.1074/jbc.M311052200; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 2003, MOL CANCER RES, V1, P765; Mittendorf EA, 2010, ONCOGENE, V29, P3896, DOI 10.1038/onc.2010.151; Mittendorf EA, 2009, CLIN CANCER RES, V15, P7381, DOI 10.1158/1078-0432.CCR-09-1735; Motti ML, 2004, CELL CYCLE, V3, P1074; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2004, CANCER RES, V64, P3981, DOI 10.1158/0008-5472.CAN-03-3900; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Nahta R, 2007, MOL CANCER THER, V6, P667, DOI 10.1158/1535-7163.MCT-06-0423; Raina D, 2012, INT J ONCOL, V40, P1644, DOI 10.3892/ijo.2011.1308; Raina D, 2011, MOL CANCER THER, V10, P806, DOI 10.1158/1535-7163.MCT-10-1050; Raina D, 2009, CANCER RES, V69, P5133, DOI 10.1158/0008-5472.CAN-09-0854; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Scaltriti M, 2009, ONCOGENE, V28, P803, DOI 10.1038/onc.2008.432; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Scaltriti M, 2011, MOL CANCER THER, V10, P817, DOI 10.1158/1535-7163.MCT-10-0966; Scaltriti M, 2011, P NATL ACAD SCI USA, V108, P3761, DOI 10.1073/pnas.1014835108; Shattuck DL, 2008, CANCER RES, V68, P1471, DOI 10.1158/0008-5472.CAN-07-5962; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Spector NL, 2009, J CLIN ONCOL, V27, P5838, DOI 10.1200/JCO.2009.22.1507; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309	47	75	82	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3422	3431		10.1038/onc.2013.308	http://dx.doi.org/10.1038/onc.2013.308			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23912457	Green Submitted, Green Accepted			2022-12-28	WOS:000338779300009
J	Murakami, S; Chishima, S; Uemoto, H; Sakamoto, E; Sato, T; Kurabe, N; Kawasaki, Y; Shibata, T; Akiyama, H; Tashiro, F				Murakami, S.; Chishima, S.; Uemoto, H.; Sakamoto, E.; Sato, T.; Kurabe, N.; Kawasaki, Y.; Shibata, T.; Akiyama, H.; Tashiro, F.			The male-specific factor Sry harbors an oncogenic function	ONCOGENE			English	Article						SRY; SGF29; c-Myc; STAGA complex; hepatocarcinogenesis	HISTONE ACETYLTRANSFERASE COMPLEXES; C-MYC; HEPATOCELLULAR-CARCINOMA; ORNITHINE-DECARBOXYLASE; ESSENTIAL COFACTOR; SEX DETERMINATION; EXPRESSION; CELLS; GROWTH; TRRAP	Sgf29, a component of the SPT-ADA-GCN5 acetyltransferase (SAGA) complex, binds H3K4me2/3 marks and leads to histone H3 acetylation. Previously, we found that downregulation of Sgf29 suppresses c-Myc-mediated malignant transformation. Nonetheless, the upstream regulator of the Sgf29 gene is not yet known. Here, we report that Sry (sex-determining region Y), an HMG (high-mobility group) domain containing transcription factor, directly upregulates Sgf29 gene expression. Sry expression was deregulated in two out of the four tested male rodent hepatocellular carcinoma (rHCC) cell lines. Luciferase reporter and chromatin immunoprecipitation assays indicated that Sry could bind HMG-boxes in the proximal promoter region of the Sgf29 gene. Knockdown of Sry robustly lowered anchorage-independent growth, invasiveness and tumorigenicity of rHCC cells, whereas ectopic expression of Sry conferred more malignant properties. Thus, these data show that Sry is involved in male-specific malignant conversion of rHCCs via Sgf29 upregulation.	[Murakami, S.; Chishima, S.; Uemoto, H.; Sakamoto, E.; Sato, T.; Kurabe, N.; Kawasaki, Y.; Akiyama, H.; Tashiro, F.] Tokyo Univ Sci, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Tokyo 1258585, Japan; [Shibata, T.] Natl Canc Ctr, Res Inst, Div Canc Gen, Tokyo 104, Japan	Tokyo University of Science; National Cancer Center - Japan	Tashiro, F (corresponding author), Tokyo Univ Sci, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Katsushika Ku, Niijuku 6-3-1, Tokyo 1258585, Japan.	ftashir@rs.noda.tus.ac.jp	Shibata, Tatsuhiro/AAO-1278-2021; Shibata, Tatsuhiro/ABA-8234-2020		'Academic Frontier' project for Private University - MEXT (Ministry of Education, Culture, Sports, Science and Technology); Grants-in-Aid for Scientific Research [23501271] Funding Source: KAKEN	'Academic Frontier' project for Private University - MEXT (Ministry of Education, Culture, Sports, Science and Technology); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are grateful to K Katagiri for the technical assistance. This work was partly supported by the 'Academic Frontier' project for Private University: a matching fund subsidy from MEXT (Ministry of Education, Culture, Sports, Science and Technology), 2006-2010 (to FT) and 2010-2012 (to HA).	Albrecht KH, 2001, DEV BIOL, V240, P92, DOI 10.1006/dbio.2001.0438; Amati B, 2001, BBA-REV CANCER, V1471, pM135, DOI 10.1016/S0304-419X(01)00020-8; Bian CB, 2011, EMBO J, V30, P2829, DOI 10.1038/emboj.2011.193; Bradford ST, 2009, HUM MOL GENET, V18, P3429, DOI 10.1093/hmg/ddp283; Bullejos M, 2001, DEV DYNAM, V221, P201, DOI 10.1002/dvdy.1134; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Iyengar RV, 2001, CANCER RES, V61, P3045; Kaposi-Novak P, 2009, CANCER RES, V69, P2775, DOI 10.1158/0008-5472.CAN-08-3357; Katoh H, 2007, GASTROENTEROLOGY, V133, P1475, DOI 10.1053/j.gastro.2007.08.038; Kawasaki Y., 2007, Mycotoxins, V57, P87, DOI 10.2520/myco.57.87; Komiya Y, 2008, J BIOL CHEM, V283, P18753, DOI 10.1074/jbc.M802530200; Kurabe N, 2007, ONCOGENE, V26, P5626, DOI 10.1038/sj.onc.1210349; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Lefebvre V, 2007, INT J BIOCHEM CELL B, V39, P2195, DOI 10.1016/j.biocel.2007.05.019; Ling SZ, 2011, CANCER RES, V71, P3812, DOI 10.1158/0008-5472.CAN-10-3072; Liu LD, 2012, NATURE, V483, P608, DOI 10.1038/nature10927; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MURRAY JD, 1982, J VIROL, V44, P1072, DOI 10.1128/JVI.44.3.1072-1075.1982; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; Nishino K, 2004, J BIOL CHEM, V279, P22306, DOI 10.1074/jbc.M309513200; Palaskas N, 2011, CANCER RES, V71, P5164, DOI 10.1158/0008-5472.CAN-10-4633; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; Phillips NB, 2006, J MOL BIOL, V358, P172, DOI 10.1016/j.jmb.2006.01.060; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sekido R, 2008, NATURE, V453, P930, DOI 10.1038/nature06944; Sugiyama A, 2003, CARCINOGENESIS, V24, P1549, DOI 10.1093/carcin/bgg113; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thomsen MK, 2010, CANCER RES, V70, P979, DOI 10.1158/0008-5472.CAN-09-2370; Vermeulen M, 2010, CELL, V142, P967, DOI 10.1016/j.cell.2010.08.020; Zhang XY, 2005, P NATL ACAD SCI USA, V102, P13968, DOI 10.1073/pnas.0502330102; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137	36	19	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					2978	2986		10.1038/onc.2013.262	http://dx.doi.org/10.1038/onc.2013.262			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23893245				2022-12-28	WOS:000337232200004
J	Lo, D; Zhang, Y; Dai, MS; Sun, XX; Zeng, SX; Lu, H				Lo, D.; Zhang, Y.; Dai, M-S; Sun, X-X; Zeng, S. X.; Lu, H.			Nucleostemin stabilizes ARF by inhibiting the ubiquitin ligase ULF	ONCOGENE			English	Article							CELL-CYCLE ARREST; P53-DEPENDENT APOPTOSIS; RIBOSOME BIOGENESIS; TUMOR SUPPRESSION; ACTIVATES P53; P19(ARF); PROTEIN; MDM2; PROLIFERATION; DEGRADATION	Upregulated expression of nucleolar GTPase nucleostemin (NS) has been associated with increased cellular proliferation potential and tumor malignancy during cancer development. Recent reports attribute the growth regulatory effects of NS protein to its role in facilitating ribosome production. However, the oncogenic potential of NS remains unclear, as imbalanced levels of NS have been reported to exert growth inhibitory effect by modulating p53 tumor-suppressor activity. It also remains in questions if aberrant NS levels might have a p53-independent role in regulation of cell proliferation and growth. In this study, we performed affinity purification and mass spectrometry analysis to explore protein-protein interactions influencing NS growth regulatory properties independently of p53 tumor suppressor. We identified the alternative reading frame (ARF) protein as a key protein associating with NS and further verified the interaction through in vitro and in vivo assays. We demonstrated that NS is able to regulate cell cycle progression by regulating the stability of the ARF tumor suppressor. Furthermore, overexpression of NS suppressed ARF polyubiquitination by its E3 ligase Ubiquitin Ligase for ARF and elongated its half-life, whereas knockdown of NS led to the decrease of ARF levels. Also, we found that NS can enhance NPM stabilization of ARF. Thus, we propose that in the absence of p53, ARF can be stabilized by NS and nucleophosmin to serve as an alternative tumor-suppressor surveillance, preventing potential cellular transformation resulting from the growth-inducing effects of NS overexpression.	[Lo, D.; Zhang, Y.; Zeng, S. X.; Lu, H.] Tulane Univ, Tulane Canc Ctr, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; [Dai, M-S; Sun, X-X] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	Tulane University; Oregon Health & Science University	Lu, H (corresponding author), Tulane Univ, Tulane Canc Ctr, Sch Med, Dept Biochem & Mol Biol, 1430 Tulane Ave, New Orleans, LA 70112 USA.	hlu2@tulane.edu			NIH-NCI grant [CA095441, CA079721, CA129828, CA172468]; NATIONAL CANCER INSTITUTE [R01CA079721, R01CA160474, R01CA095441, R01CA129828, R01CA172468] Funding Source: NIH RePORTER	NIH-NCI grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank L David at Oregon Health and Science University for conducting the mass spectrometry analysis in the affinity purification, W Gu at Columbia University for supplying the ULF reagents, and Y Dong at Tulane University School of Medicine for offering the lentivirus vector. This work was supported in part by NIH-NCI grants CA095441, CA079721, CA129828 and CA172468 to HL.	Beekman C, 2006, MOL CELL BIOL, V26, P9291, DOI 10.1128/MCB.01183-06; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; Chen DL, 2010, NATURE, V464, P624, DOI 10.1038/nature08820; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2008, MOL CELL BIOL, V28, P4365, DOI 10.1128/MCB.01662-07; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang M, 2009, CANCER RES, V69, P3004, DOI 10.1158/0008-5472.CAN-08-3413; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Lessard F, 2010, MOL CELL, V38, P539, DOI 10.1016/j.molcel.2010.03.015; Lin T, 2010, CANCER RES, V70, P9444, DOI 10.1158/0008-5472.CAN-10-2159; Lindstrom MS, 2006, CELL BIOCHEM BIOPHYS, V46, P79, DOI 10.1385/CBB:46:1:79; Lo D, 2012, J BIOL CHEM, V287, P10013, DOI 10.1074/jbc.M111.335141; Lo D, 2010, CELL CYCLE, V9, P3227, DOI 10.4161/cc.9.16.12605; Ma HH, 2008, MOL BIOL CELL, V19, P2870, DOI 10.1091/mbc.E08-02-0128; Ma HH, 2007, MOL BIOL CELL, V18, P2630, DOI 10.1091/mbc.E07-03-0244; Maggi LB, 2008, MOL CELL BIOL, V28, P7050, DOI 10.1128/MCB.01548-07; Nakajima TE, 2012, CANCER SCI, V103, P233, DOI 10.1111/j.1349-7006.2011.02142.x; Narla A, 2010, BLOOD, V115, P3196, DOI 10.1182/blood-2009-10-178129; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Romanova L, 2009, J BIOL CHEM, V284, P26685, DOI 10.1074/jbc.M109.013342; Romanova L, 2009, J BIOL CHEM, V284, P4968, DOI 10.1074/jbc.M804594200; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sijin L, 2004, J EXP CLIN CANC RES, V23, P529; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Tamase A, 2009, P NATL ACAD SCI USA, V106, P17163, DOI 10.1073/pnas.0905016106; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Tsai RYL, 2005, J CELL BIOL, V168, P179, DOI 10.1083/jcb.200409053; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Ye F, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-108; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhou Xiang, 2012, Genes Cancer, V3, P298, DOI 10.1177/1947601912455200; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zwolinska AK, 2012, ONCOGENE, V31, P3311, DOI 10.1038/onc.2011.507	44	10	10	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1688	1697		10.1038/onc.2014.103	http://dx.doi.org/10.1038/onc.2014.103			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24769896	Green Accepted			2022-12-28	WOS:000351848400009
J	Ren, Z; Aerts, JL; Pen, JJ; Heirman, C; Breckpot, K; De Greve, J				Ren, Z.; Aerts, J. L.; Pen, J. J.; Heirman, C.; Breckpot, K.; De Greve, J.			Phosphorylated STAT3 physically interacts with NPM and transcriptionally enhances its expression in cancer	ONCOGENE			English	Article							NUCLEOLAR PROTEIN B23; NUCLEAR IMPORT; TYROSINE PHOSPHORYLATION; LOCALIZATION SIGNALS; CELL-DEATH; NUCLEOPHOSMIN; IDENTIFICATION; ACTIVATION; P53; INFLAMMATION	The signal transducer and activator of transcription 3 (STAT3) can be activated by the tyrosine kinase domain of the chimeric protein nucleophosmin/anaplastic lymphoma kinase (NPM/ALK), and has a pivotal role in mediating NPM/ALK-related malignant cell transformation. Although the role of STAT3 and wild-type NPM in oncogenesis has been extensively investigated, the relationship between both molecules in cancer remains poorly understood. In the present study, we first demonstrate that STAT3 phosphorylation at tyrosine 705 is accompanied by a concomitant increase in the expression level of NPM. Nuclear co-translocation of phosphorylated STAT3 with NPM can be triggered by interferon-alpha (IFN-alpha) stimulation of Jurkat cells and phosphorylated STAT3 co-localizes with NPM in cancer cells showing constitutive STAT3 activation. We further demonstrate that STAT3 phosphorylation can transcriptionally mediate NPM upregulation in IFN-alpha-stimulated Jurkat cells and is responsible for maintaining its expression in cancer cells showing constitutive STAT3 activation. Inhibition of STAT3 phosphorylation or knockdown of NPM expression abrogates their simultaneous transnuclear movements. Finally, we found evidence for a physical interaction between NPM and STAT3 in conditions of STAT3 activation. In conclusion, NPM is a downstream effector of the STAT3 signaling, and can facilitate the nuclear entry of phosphorylated STAT3. These observations might open novel opportunities for targeting the STAT3 pathway in cancer.	[Ren, Z.; De Greve, J.] Vrije Univ Brussel, UZ Brussel, Dept Med Oncol, LMMO, B-1090 Brussels, Belgium; [Ren, Z.] Shanghai Jiao Tong Univ, Peoples Hosp Shanghai 1, Dept Gen Surg, Shanghai 200030, Peoples R China; [Ren, Z.; Pen, J. J.; De Greve, J.] Vrije Univ Brussel, UZ Brussel, Ctr Oncol, Dept Med Oncol, B-1090 Brussels, Belgium; [Aerts, J. L.; Pen, J. J.; Heirman, C.; Breckpot, K.] Vrije Univ Brussel, Dept Immunol Physiol, B-1090 Brussels, Belgium	University Hospital Brussels; Vrije Universiteit Brussel; Shanghai Jiao Tong University; University Hospital Brussels; Vrije Universiteit Brussel; Vrije Universiteit Brussel	De Greve, J (corresponding author), Vrije Univ Brussel, UZ Brussel, Ctr Oncol, Dept Med Oncol, Laarbeeklaan 101, B-1090 Brussels, Belgium.	jacques.degreve@uzbrussel.be	De Greve, Jacques/J-4939-2012; Breckpot, Karine RP/A-4298-2008; Aerts, Joeri/J-6957-2014; Pen, Joeri/AAO-5644-2020	De Greve, Jacques/0000-0002-2389-0742; Breckpot, Karine RP/0000-0003-4331-3480; Aerts, Joeri/0000-0002-9902-3696; 	Stichting Tegen Kanker Belgium; FWO-Vlaanderen [FWOAL335, FWOAL455, FWOWO35]; VUB [OZR1144]; Chinese Scholarship Council (CSC)-VUB joint scholarship	Stichting Tegen Kanker Belgium; FWO-Vlaanderen(FWO); VUB; Chinese Scholarship Council (CSC)-VUB joint scholarship	We gratefully acknowledge technical and administrative assistance from Dr Erik Teugels, Dr Zhihai Peng, Eddy Himpe, Bill Roskams, Geert Stange, Petra Roman, Elsy Vaeremans, Cleo Goyvaerts. We sincerely thank Dr Jacqueline Bromberg, Dr Dorothee Herlyn, Dr Pravin Sehgal, Dr Qishen Pang for their provision of shSTAT3, shNPM, GFP-STAT3 Y705A, and NPM promoter vectors. We also express our gratitude to Dr Georges De Bruyne and Dr Peter de Witte for providing MDA-MB-231, MDA-MB-435 and MDA-MB-468 cell lines. This work was supported by the Stichting Tegen Kanker Belgium, FWO-Vlaanderen (FWOAL335, FWOAL455 and FWOWO35) and the VUB (OZR1144). ZR is a Ph. D student supported by Chinese Scholarship Council (CSC)-VUB joint scholarship. JLA and KB are postdoctoral fellows of the Foundation of Scientific Research Flanders (FWO-V).	Berishaj M, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1680; Bhat UG, 2011, J BIOL CHEM, V286, P41425, DOI 10.1074/jbc.M111.270843; Brady SN, 2009, ONCOGENE, V28, P3209, DOI 10.1038/onc.2009.178; Chan PK, 1997, NUCLEIC ACIDS RES, V25, P1225, DOI 10.1093/nar/25.6.1225; Cimica V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020188; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Falini B, 2009, LEUKEMIA, V23, P1731, DOI 10.1038/leu.2009.124; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Herrmann A, 2004, J CELL SCI, V117, P339, DOI 10.1242/jcs.00833; Kasprzycka M, 2006, P NATL ACAD SCI USA, V103, P9964, DOI 10.1073/pnas.0603507103; Kelley JB, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-63; Kujawski M, 2008, J CLIN INVEST, V118, P3367, DOI 10.1172/JCI35213; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lee H, 2010, NAT MED, V16, P1421, DOI 10.1038/nm.2250; Leslie K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2725; Li J, 2004, J BIOL CHEM, V279, P41275, DOI 10.1074/jbc.C400297200; Li YP, 1996, EUR J BIOCHEM, V237, P153, DOI 10.1111/j.1432-1033.1996.0153n.x; Liu L, 2005, P NATL ACAD SCI USA, V102, P8150, DOI 10.1073/pnas.0501643102; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marzec M, 2008, P NATL ACAD SCI USA, V105, P20852, DOI 10.1073/pnas.0810958105; MORRIS SW, 1995, SCIENCE, V267, P316, DOI 10.1126/science.267.5196.316-b; Pranada AL, 2004, J BIOL CHEM, V279, P15114, DOI 10.1074/jbc.M312530200; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Su L, 2000, J BIOL CHEM, V275, P12661, DOI 10.1074/jbc.275.17.12661; Swaminathan V, 2005, MOL CELL BIOL, V25, P7534, DOI 10.1128/MCB.25.17.7534-7545.2005; Swoboda RK, 2010, INT J CANCER, V127, P1124, DOI 10.1002/ijc.25133; Szebeni A, 1997, BIOCHEMISTRY-US, V36, P3941, DOI 10.1021/bi9627931; SZEBENI A, 1995, BIOCHEMISTRY-US, V34, P8037, DOI 10.1021/bi00025a009; Szebeni A, 1999, PROTEIN SCI, V8, P905; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; Vallania F, 2009, P NATL ACAD SCI USA, V106, P5117, DOI 10.1073/pnas.0900473106; Vassiliou GS, 2011, NAT GENET, V43, P470, DOI 10.1038/ng.796; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zheng P, 2012, J PROTEOMICS, V75, P1055, DOI 10.1016/j.jprot.2011.10.020; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	42	6	6	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1650	1657		10.1038/onc.2014.109	http://dx.doi.org/10.1038/onc.2014.109			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24793791				2022-12-28	WOS:000351848400005
J	Sato, T; Takahashi, H; Hatakeyama, S; Iguchi, A; Ariga, T				Sato, T.; Takahashi, H.; Hatakeyama, S.; Iguchi, A.; Ariga, T.			The TRIM-FLMN protein TRIM45 directly interacts with RACK1 and negatively regulates PKC-mediated signaling pathway	ONCOGENE			English	Article							KINASE-C; CANCER-CELLS; MAP KINASES; TRANSCRIPTION; ACTIVATION; RECEPTOR; SITE; MECHANISMS; STRESS; FAMILY	The receptor for activated C-kinase (RACK1), a scaffolding protein that participates in the protein kinase C (PKC) signaling pathway, has an important role in shuttling active PKCs to its substrate. Indeed, recent studies have revealed that RACK1 has an important role in tumorigenesis and that enhancement of the feed-forward mechanism of the c-Jun N-terminal kinase (JNK)-Jun pathway via RACK1 is associated with constitutive activation of MEK (MAPK-ERK kinase)-ERK (extracellular signal-regulated kinase) signaling in human melanoma cells. Taken together, RACK1 additionally has a very important role in the mitogen-activated protein kinase (MAPK) signaling pathway. Here, we show that one of the tripartite motif-containing (TRIM) family ubiquitin ligases, TRIM45, is a novel RACK1-interacting protein and downregulates MAPK signal transduction. Importantly, the expression of TRIM45 is induced when growth-promoting extracellular stimuli activate the MAPK signaling pathway, resulting in attenuation of activation of the MAPK pathway. These findings suggest that TRIM45 functions as a member of the negative feedback loop of the MAPK pathway.	[Sato, T.; Iguchi, A.; Ariga, T.] Hokkaido Univ, Grad Sch Med, Dept Pediat, Sapporo, Hokkaido 0608638, Japan; [Sato, T.; Takahashi, H.; Hatakeyama, S.] Hokkaido Univ, Grad Sch Med, Dept Biochem, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; Hokkaido University	Sato, T (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Pediat, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0608638, Japan.	tomsato@med.hokudai.ac.jp	Hatakeyama, Shigetsugu/C-8333-2012	Hatakeyama, Shigetsugu/0000-0002-2150-9979	Ministry of Education, Culture, Sports, Science and Technology in Japan; Japan Foundation for Applied Enzymology; Children's Cancer Association of Japan; Grants-in-Aid for Scientific Research [24112006, 24390065] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology in Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Foundation for Applied Enzymology; Children's Cancer Association of Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Toshio Kitamura (Tokyo University) for the plasmid and cell lines. This work was supported in part by a research grant from Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology in Japan, Japan Foundation for Applied Enzymology, and Children's Cancer Association of Japan.	Adams DR, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-22; Al-Reefy S, 2010, ONCOGENE, V29, P5651, DOI 10.1038/onc.2010.291; Arimoto K, 2008, NAT CELL BIOL, V10, P1324, DOI 10.1038/ncb1791; Avruch J, 2007, BBA-MOL CELL RES, V1773, P1150, DOI 10.1016/j.bbamcr.2006.11.006; Bauman AL, 2002, NAT CELL BIOL, V4, pE203, DOI 10.1038/ncb0802-e203; Bourd-Boittin K, 2008, J BIOL CHEM, V283, P26000, DOI 10.1074/jbc.M709829200; Calvo F, 2010, BIOESSAYS, V32, P412, DOI 10.1002/bies.200900155; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chou YC, 1999, BBA-GENE STRUCT EXPR, V1489, P315, DOI 10.1016/S0167-4781(99)00213-4; Dorn GW, 2002, ANNU REV PHYSIOL, V64, P407, DOI 10.1146/annurev.physiol.64.081501.155903; Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139; He DY, 2010, J BIOL CHEM, V285, P19043, DOI 10.1074/jbc.M110.100693; Imajo M, 2006, IUBMB LIFE, V58, P312, DOI 10.1080/15216540600746393; Kano S, 2008, CANCER RES, V68, P5572, DOI 10.1158/0008-5472.CAN-07-6231; Kondoh K, 2007, BBA-MOL CELL RES, V1773, P1227, DOI 10.1016/j.bbamcr.2006.12.002; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lopez-Bergami P, 2005, MOL CELL, V19, P309, DOI 10.1016/j.molcel.2005.06.025; Lopez-Bergami P, 2008, INT J BIOCHEM CELL B, V40, P1055, DOI 10.1016/j.biocel.2007.11.011; Lopez-Bergami P, 2007, CANCER CELL, V11, P447, DOI 10.1016/j.ccr.2007.03.009; Lopez-Bergami P, 2010, NAT REV CANCER, V10, P65, DOI 10.1038/nrc2681; Maurer G, 2011, ONCOGENE, V30, P3477, DOI 10.1038/onc.2011.160; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; Meroni G, 2005, BIOESSAYS, V27, P1147, DOI 10.1002/bies.20304; Miyajima N, 2008, CANCER RES, V68, P3486, DOI 10.1158/0008-5472.CAN-07-6059; Nisole S, 2005, NAT REV MICROBIOL, V3, P799, DOI 10.1038/nrmicro1248; Noguchi K, 2011, CARCINOGENESIS, V32, P995, DOI 10.1093/carcin/bgr068; Prusty BK, 2005, INT J CANCER, V113, P951, DOI 10.1002/ijc.20668; Quaderi NA, 1997, NAT GENET, V17, P285, DOI 10.1038/ng1197-285; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Rotenberg SA, 1998, J BIOL CHEM, V273, P2390, DOI 10.1074/jbc.273.4.2390; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Sato T, 2012, J CELL SCI, V125, P1544, DOI 10.1242/jcs.095273; Sato T, 2011, J CELL SCI, V124, P3492, DOI 10.1242/jcs.088799; Shi S, 2012, J BIOL CHEM, V287, P7845, DOI 10.1074/jbc.M111.315416; Shibata M, 2012, BIOCHEM BIOPH RES CO, V423, P104, DOI 10.1016/j.bbrc.2012.05.090; Soh JW, 2003, J BIOL CHEM, V278, P34709, DOI 10.1074/jbc.M302016200; Takahashi H, 2005, J BIOL CHEM, V280, P5611, DOI 10.1074/jbc.M408130200; Takahashi H, 2011, CELL, V146, P92, DOI 10.1016/j.cell.2011.06.005; Wang YQ, 2004, BIOCHEM BIOPH RES CO, V323, P9, DOI 10.1016/j.bbrc.2004.08.048; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Zhang WZ, 2008, J BIOL CHEM, V283, P16416, DOI 10.1074/jbc.M802360200	47	25	26	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1280	1291		10.1038/onc.2014.68	http://dx.doi.org/10.1038/onc.2014.68			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24681954				2022-12-28	WOS:000350687100008
J	Kim, B; Wang, S; Lee, JM; Jeong, Y; Ahn, T; Son, DS; Park, HW; Yoo, HS; Song, YJ; Lee, E; Oh, YM; Lee, SB; Choi, J; Murray, JC; Zhou, Y; Song, PH; Kim, KA; Weiner, LM				Kim, B.; Wang, S.; Lee, J. M.; Jeong, Y.; Ahn, T.; Son, D-S; Park, H. W.; Yoo, H-s; Song, Y-J; Lee, E.; Oh, Y. M.; Lee, S. B.; Choi, J.; Murray, J. C.; Zhou, Y.; Song, P. H.; Kim, K-A; Weiner, L. M.			Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; TYROSINE KINASE; HEPATOCYTE GROWTH; C-MET; GEFITINIB RESISTANCE; ACTIVATING MUTATIONS; MEDIATES RESISTANCE; SIGNALING PATHWAY; DRUG-RESISTANCE	Met is a receptor tyrosine kinase that promotes cancer progression. In addition, Met has been implicated in resistance of tumors to various targeted therapies such as epidermal growth factor receptor inhibitors in lung cancers, and has been prioritized as a key molecular target for cancer therapy. However, the underlying mechanism of resistance to Met-targeting drugs is poorly understood. Here, we describe screening of 1310 genes to search for key regulators related to drug resistance to an anti-Met therapeutic antibody (SAIT301) by using a small interfering RNA-based synthetic lethal screening method. We found that knockdown of 69 genes in Met-amplified MKN45 cells sensitized the antitumor activity of SAIT301. Pathway analysis of these 69 genes implicated fibroblast growth factor receptor (FGFR) as a key regulator for antiproliferative effects of Met-targeting drugs. Inhibition of FGFR3 increased target cell apoptosis through the suppression of Bcl-xL expression, followed by reduced cancer cell growth in the presence of Met-targeting drugs. Treatment of cells with the FGFR inhibitors substantially restored the efficacy of SAIT301 in SAIT301-resistant cells and enhanced the efficacy in SAIT301-sensitive cells. In addition to FGFR3, integrin beta 3 is another potential target for combination treatment with SAIT301. Suppression of integrin beta 3 decreased AKT phosphorylation in SAIT301-resistant cells and restored SAIT301 responsiveness in HCC1954 cells, which are resistant to SAIT301. Gene expression analysis using CCLE database shows that cancer cells with high levels of FGFR and integrin beta 3 are resistant to crizotinib treatment, suggesting that FGFR and integrin beta 3 could be used as predictive markers for Met-targeted therapy and provide a potential therapeutic option to overcome acquired and innate resistance for the Met-targeting drugs.	[Kim, B.; Lee, J. M.; Jeong, Y.; Ahn, T.; Son, D-S; Park, H. W.; Yoo, H-s; Song, Y-J; Lee, E.; Oh, Y. M.; Lee, S. B.; Choi, J.; Song, P. H.; Kim, K-A] SAIT, BioTherapeut Lab, Yongin 446712, Gyeonggi Do, South Korea; [Wang, S.; Murray, J. C.; Weiner, L. M.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20007 USA; [Zhou, Y.] Fox Chase Canc Ctr, Biostat & Bioinformat Fac, Philadelphia, PA 19111 USA	Samsung; Georgetown University; Fox Chase Cancer Center	Kim, KA (corresponding author), SAIT, BioTherapeut Lab, 95 Samsung2 Ro, Yongin 446712, Gyeonggi Do, South Korea.	ka10.kim@samsung.com	Murray, Joseph C/J-8916-2014; Lee, Ji Min/ABE-7494-2021; Jeong, Yunju/GRS-0008-2022	Murray, Joseph C/0000-0001-6159-7814; Lee, Ji Min/0000-0003-2978-2440; Wang, Shangzi/0000-0002-8936-6572	NCI [CA51008, CA50633]; Lombardi Comprehensive Cancer Center's Genomics and Epigenomics Shared Resource; NATIONAL CANCER INSTITUTE [P30CA051008, T32CA009686, R01CA050633] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Lombardi Comprehensive Cancer Center's Genomics and Epigenomics Shared Resource; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	LMW, SW and JCM are supported in part by NCI Grants CA51008 and CA50633. We thank Sandra A Jablonski, Wei Xu and Kyutaeg Lee for technical assistance. We are grateful for the support of the Lombardi Comprehensive Cancer Center's Genomics and Epigenomics Shared Resource.	Astsaturov I, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001083; Bachleitner-Hofmann T, 2008, MOL CANCER THER, V7, P3499, DOI 10.1158/1535-7163.MCT-08-0374; Basilico C, 2013, CLIN CANCER RES, V19, P2381, DOI 10.1158/1078-0432.CCR-12-3459; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Burke PA, 2002, CANCER RES, V62, P4263; Cecchi F, 2012, EXPERT OPIN THER TAR, V16, P553, DOI 10.1517/14728222.2012.680957; Cepero V, 2010, CANCER RES, V70, P7580, DOI 10.1158/0008-5472.CAN-10-0436; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; Corso S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-121; Dechantsreiter MA, 1999, J MED CHEM, V42, P3033, DOI 10.1021/jm970832g; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fong JT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078398; Garcia S, 2007, HUM PATHOL, V38, P830, DOI 10.1016/j.humpath.2006.11.015; Guagnano V, 2011, J MED CHEM, V54, P7066, DOI 10.1021/jm2006222; Harbinski F, 2012, CANCER DISCOV, V2, P948, DOI 10.1158/2159-8290.CD-12-0237; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Huang C, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2936; Iida Mari, 2013, Cancer Biol Ther, V14, P481, DOI 10.4161/cbt.24342; Janne PA, 2009, NAT REV DRUG DISCOV, V8, P709, DOI 10.1038/nrd2871; Ju LX, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-15; Kentsis A, 2012, NAT MED, V18, P1118, DOI 10.1038/nm.2819; Landi L, 2013, CURR OPIN ONCOL, V25, P130, DOI 10.1097/CCO.0b013e32835daf37; Langsenlehner U, 2006, BREAST CANCER RES TR, V97, P67, DOI 10.1007/s10549-005-9089-4; Lee HE, 2012, BRIT J CANCER, V107, P325, DOI 10.1038/bjc.2012.237; Lee JM, 2014, ONCOGENE, V33, P34, DOI 10.1038/onc.2012.551; Lee NV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039653; Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928; Lesniak D, 2009, CANCER RES, V69, P8620, DOI 10.1158/0008-5472.CAN-09-1591; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; Morse DL, 2010, BIOCHEM PHARMACOL, V80, P731, DOI 10.1016/j.bcp.2010.04.011; Nagilla M, 2012, ADV THER, V29, P925, DOI 10.1007/s12325-012-0060-6; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Ou SHI, 2011, J THORAC ONCOL, V6, P942, DOI 10.1097/JTO.0b013e31821528d3; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Scagliotti GV, 2013, CANCER TREAT REV, V39, P793, DOI 10.1016/j.ctrv.2013.02.001; Sequist LV, 2011, J CLIN ONCOL, V29, P3307, DOI 10.1200/JCO.2010.34.0570; Singleton KR, 2013, MOL PHARMACOL, V83, P882, DOI 10.1124/mol.112.084111; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Surati M, 2011, EXPERT OPIN BIOL TH, V11, P1655, DOI 10.1517/14712598.2011.626762; Tiedt R, 2011, CANCER RES, V71, P5255, DOI 10.1158/0008-5472.CAN-10-4433; Tuck AB, 2000, J CELL BIOCHEM, V78, P465, DOI 10.1002/1097-4644(20000901)78:3<465::AID-JCB11>3.0.CO;2-C; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Vogler M, 2010, CLIN CANCER RES, V16, P4217, DOI 10.1158/1078-0432.CCR-10-0777; Wickramasinghe D, 2005, CELL CYCLE, V4, P683, DOI 10.4161/cc.4.5.1688; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Yadav V, 2012, J BIOL CHEM, V287, P28087, DOI 10.1074/jbc.M112.377218; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643; Zhang Y, 2010, IDRUGS, V13, P112; Zhang YW, 2010, CANCER RES, V70, P6880, DOI 10.1158/0008-5472.CAN-10-0898; Zhu LJ, 2005, MOL CANCER THER, V4, P787, DOI 10.1158/1535-7163.MCT-04-0330	51	23	24	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1083	1093		10.1038/onc.2014.51	http://dx.doi.org/10.1038/onc.2014.51			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662823	Green Accepted			2022-12-28	WOS:000350122100002
J	Edmond, V; Dufour, F; Poiroux, G; Shoji, K; Malleter, M; Fouque, A; Tauzin, S; Rimokh, R; Sergent, O; Penna, A; Dupuy, A; Levade, T; Theret, N; Micheau, O; Segui, B; Legembre, P				Edmond, V.; Dufour, F.; Poiroux, G.; Shoji, K.; Malleter, M.; Fouque, A.; Tauzin, S.; Rimokh, R.; Sergent, O.; Penna, A.; Dupuy, A.; Levade, T.; Theret, N.; Micheau, O.; Segui, B.; Legembre, P.			Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility	ONCOGENE			English	Article							GENE-EXPRESSION PATTERNS; BREAST-CANCER; IN-VITRO; RECEPTOR; TRANSFORMATION; INVASION; RAFTS; SPHINGOLIPIDS; GANGLIOSIDE; PHENOTYPE	Epithelial-to-mesenchymal transition (EMT) promotes cell motility, which is important for the metastasis of malignant cells, and blocks CD95-mediated apoptotic signaling triggered by immune cells and chemotherapeutic regimens. CD95L, the cognate ligand of CD95, can be cleaved by metalloproteases and released as a soluble molecule (cl-CD95L). Unlike transmembrane CD95L, cl-CD95L does not induce apoptosis but triggers cell motility. Electron paramagnetic resonance was used to show that EMT and cl-CD95L treatment both led to augmentation of plasma membrane fluidity that was instrumental in inducing cell migration. Compaction of the plasma membrane is modulated, among other factors, by the ratio of certain lipids such as sphingolipids in the membrane. An integrative analysis of gene expression in NCI tumor cell lines revealed that expression of ceramide synthase-6 (CerS6) decreased during EMT. Furthermore, pharmacological and genetic approaches established that modulation of CerS6 expression/activity in cancer cells altered the level of C16-ceramide, which in turn influenced plasma membrane fluidity and cell motility. Therefore, this study identifies CerS6 as a novel EMT-regulated gene that has a pivotal role in the regulation of cell migration.	[Edmond, V.; Shoji, K.; Malleter, M.; Fouque, A.; Tauzin, S.; Sergent, O.; Penna, A.; Theret, N.; Legembre, P.] Univ Rennes 1, F-35043 Rennes, France; [Edmond, V.; Shoji, K.; Malleter, M.; Fouque, A.; Tauzin, S.; Sergent, O.; Penna, A.; Theret, N.; Legembre, P.] INSERM, UMR 1085, IRSET, Rennes, France; [Edmond, V.; Shoji, K.; Malleter, M.; Fouque, A.; Tauzin, S.; Penna, A.; Legembre, P.] Equipe Labellisee Ligue Contre Le Canc, Rennes, France; [Dufour, F.; Micheau, O.] INSERM, UMR 866, Dijon, France; [Poiroux, G.; Levade, T.; Segui, B.] INSERM, UMR 1037, Toulouse, France; [Poiroux, G.; Levade, T.; Segui, B.] Univ Toulouse 3, Toulouse, France; [Poiroux, G.; Levade, T.; Segui, B.] Equipe Labellisee Ligue Contre Le Canc, Toulouse, France; [Rimokh, R.] Univ Lyon, Ctr Rech Cancerol Lyon, CNRS UMR 5286, Ctr Leon Berard Lyon,Inserm U1052, Lyon, France; [Dupuy, A.] INSERM, U1048, Toulouse, France; [Legembre, P.] Ctr Eugene Marquis, Rennes, France	Universite de Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Eugene Marquis	Legembre, P (corresponding author), Univ Rennes 1, IRSET, U1085, INSERM, 2 Av Prof Leon Bernard, F-35043 Rennes, France.	patrick.legembre@inserm.fr	Theret, Nathalie/I-2871-2015; PENNA, aubin/E-2208-2018; Levade, Thierry/O-8948-2014; theret, nathalie/ABG-6780-2020; micheau, olivier/C-3574-2011; SERGENT, ODILE/K-1966-2015; Guillaume, Poiroux/M-2854-2015; Ségui, Bruno/O-8957-2014; legembre, patrick/L-3475-2016; penna, aubin/AAD-2550-2019; Legembre, Patrick/U-1882-2019; Rimokh, Ruth/G-7506-2014	Theret, Nathalie/0000-0002-5857-7828; PENNA, aubin/0000-0002-1070-5990; theret, nathalie/0000-0002-5857-7828; micheau, olivier/0000-0001-8499-7984; Guillaume, Poiroux/0000-0002-6769-3716; Ségui, Bruno/0000-0002-6119-1889; legembre, patrick/0000-0001-6649-8049; penna, aubin/0000-0002-1070-5990; Legembre, Patrick/0000-0001-6649-8049; Sergent, Odile/0000-0002-9488-2141	French National Research Agency (ANR) [ANR-11-LABX-0021-01-LipSTIC Labex]; Conseil General d'Ille-et-Vilaine, project Membratox [32508]; European union (FEDER)	French National Research Agency (ANR)(French National Research Agency (ANR)); Conseil General d'Ille-et-Vilaine, project Membratox; European union (FEDER)(European Commission)	We are grateful to the L3 and microscopy facilities of the SFR Biosit (Universite de Rennes-1, Rennes, France) for their technical assistance. We thank Nicole Therville and Julia Rochotte for their technical assistance. We also acknowledge the assistance of Dr Pauline Le Faouder and Dr Justine Bertrand-Michel from the lipidomic facilities (INSERM U1048, Toulouse, France). This work was supported by grants from the French Government managed by the French National Research Agency (ANR) and under the program 'Investissements d'Avenir' with reference ANR-11-LABX-0021-01-LipSTIC Labex, INCa, ARC, Canceropole Grand Ouest, Region Bretagne, Region Bourgogne, Rennes Metropole, Ligue Contre le Cancer (Comites d'Ille-et-Vilaine/du Morbihan/des Cotes d'Armor/du Maine et Loire et les comites du Doubs/de l'Yonne), Conseil General d'Ille-et-Vilaine, project Membratox (Grant number 32508) and the European union (FEDER).	Algeciras-Schimnich A, 2003, P NATL ACAD SCI USA, V100, P11445, DOI 10.1073/pnas.2034995100; ALONSO A, 1995, BBA-BIOMEMBRANES, V1237, P6, DOI 10.1016/0005-2736(95)00069-F; Asano S, 2012, MOL CELL BIOL, V32, P3242, DOI 10.1128/MCB.00121-12; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Goni FM, 2009, BBA-BIOMEMBRANES, V1788, P169, DOI 10.1016/j.bbamem.2008.09.002; Guan F, 2009, P NATL ACAD SCI USA, V106, P7461, DOI 10.1073/pnas.0902368106; Gulbins E, 2004, J MOL MED, V82, P357, DOI 10.1007/s00109-004-0539-y; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; HANAI N, 1988, J BIOL CHEM, V263, P6296; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Hesling C, 2011, EMBO REP, V12, P665, DOI 10.1038/embor.2011.78; Hoogwater FJH, 2010, GASTROENTEROLOGY, V138, P2357, DOI 10.1053/j.gastro.2010.02.046; Jezequel P, 2013, DATABASE-OXFORD, DOI 10.1093/database/bas060; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kleber S, 2008, CANCER CELL, V13, P235, DOI 10.1016/j.ccr.2008.02.003; Konishi H, 2007, CANCER RES, V67, P8460, DOI 10.1158/0008-5472.CAN-07-0108; LUCIANO L, 1989, CELL TISSUE RES, V258, P339; Malleter M, 2013, CANCER RES, V73, P6711, DOI 10.1158/0008-5472.CAN-13-1794; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Mullen TD, 2012, BIOCHEM J, V441, P789, DOI 10.1042/BJ20111626; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; NAKAZAWA I, 1989, TOHOKU J EXP MED, V157, P193, DOI 10.1620/tjem.157.193; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pewzner-Jung Y, 2010, J BIOL CHEM, V285, P10902, DOI 10.1074/jbc.M109.077594; Reilly LAO, 2009, NATURE, V461, P659, DOI 10.1038/nature08402; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Sergent O, 2005, BIOMETALS, V18, P567, DOI 10.1007/s10534-005-8488-7; Silva LC, 2007, BIOPHYS J, V92, P502, DOI 10.1529/biophysj.106.091876; Silva LC, 2012, J LIPID RES, V53, P430, DOI 10.1194/jlr.M022715; Sok M, 2002, ANN THORAC SURG, V73, P1567, DOI 10.1016/S0003-4975(02)03458-6; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Strasser A, 2009, IMMUNITY, V30, P180, DOI 10.1016/j.immuni.2009.01.001; TARABOLETTI G, 1989, INT J CANCER, V44, P707, DOI 10.1002/ijc.2910440426; Tauzin S, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001090; VLASIC N, 1993, LIFE SCI, V53, P1053, DOI 10.1016/0024-3205(93)90258-5; WANG E, 1991, J BIOL CHEM, V266, P14486; Weinmann A, 2005, INT J MOL MED, V16, P905; Xu LJ, 2006, J BIOL CHEM, V281, P35567, DOI 10.1074/jbc.M607702200; Zeisig R, 2007, ARCH BIOCHEM BIOPHYS, V459, P98, DOI 10.1016/j.abb.2006.09.030	40	52	55	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					996	1005		10.1038/onc.2014.55	http://dx.doi.org/10.1038/onc.2014.55			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632610	Green Submitted			2022-12-28	WOS:000350121300006
J	Rupp, C; Scherzer, M; Rudisch, A; Unger, C; Haslinger, C; Schweifer, N; Artaker, M; Nivarthi, H; Moriggl, R; Hengstschlager, M; Kerjaschki, D; Sommergruber, W; Dolznig, H; Garin-Chesa, P				Rupp, C.; Scherzer, M.; Rudisch, A.; Unger, C.; Haslinger, C.; Schweifer, N.; Artaker, M.; Nivarthi, H.; Moriggl, R.; Hengstschlaeger, M.; Kerjaschki, D.; Sommergruber, W.; Dolznig, H.; Garin-Chesa, P.			IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor-stroma interaction	ONCOGENE			English	Article							LASER CAPTURE MICRODISSECTION; GENE-EXPRESSION SIGNATURE; PROSTATE-CANCER; BREAST-CANCER; ADHESION FACTOR/MAC25; EPITHELIAL CANCERS; COLORECTAL-CANCER; POOR-PROGNOSIS; LUNG-CANCER; CELL-GROWTH	The activated tumor stroma participates in many processes that control tumorigenesis, including tumor cell growth, invasion and metastasis. Cancer-associated fibroblasts (CAFs) represent the major cellular component of the stroma and are the main source for connective tissue components of the extracellular matrix and various classes of proteolytic enzymes. The signaling pathways involved in the interactions between tumor and stromal cells and the molecular characteristics that distinguish normal 'resting' fibroblasts from cancer-associated or '-activated' fibroblasts remain poorly defined. Recent studies emphasized the prognostic and therapeutic significance of CAF-related molecular signatures and a number of those genes have been shown to serve as putative therapeutic targets. We have used immuno-laser capture microdissection and whole-genome Affymetrix GeneChip analysis to obtain transcriptional signatures from the activated tumor stroma of colon carcinomas that were compared with normal resting colonic fibroblasts. Several members of the Wnt-signaling pathway and gene sets related to hypoxia, epithelial-to-mesenchymal transition (EMT) and transforming growth factor-beta (TGF beta) pathway activation were induced in CAFs. The putative TGF beta-target IGFBP7 was identified as a tumor stroma marker of epithelial cancers and as a tumor antigen in mesenchyme-derived sarcomas. We show here that in contrast to its tumor-suppressor function in epithelial cells, IGFPB7 can promote anchorage-independent growth in malignant mesenchymal cells and in epithelial cells with an EMT phenotype when IGFBP7 is expressed by the tumor cells themselves and can induce colony formation in colon cancer cells co-cultured with IGFBP7-expressing CAFs by a paracrine tumor-stroma interaction.	[Rupp, C.; Kerjaschki, D.; Garin-Chesa, P.] Med Univ Vienna, Clin Inst Pathol, A-1090 Vienna, Austria; [Scherzer, M.; Unger, C.; Hengstschlaeger, M.; Dolznig, H.] Med Univ Vienna, Ctr Pathobiol & Genet, Inst Med Genet, A-1090 Vienna, Austria; [Rudisch, A.; Haslinger, C.; Schweifer, N.; Sommergruber, W.; Garin-Chesa, P.] Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; [Artaker, M.] Med Univ Vienna, Max F Perutz Labs, A-1090 Vienna, Austria; [Nivarthi, H.; Moriggl, R.] Ludwig Boltzmann Inst Canc Res, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Boehringer Ingelheim; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Ludwig Boltzmann Institute	Garin-Chesa, P (corresponding author), Med Univ Vienna, Inst Med Genet, Wahringer Str 10, A-1090 Vienna, Austria.	helmut.dolznig@meduniwien.ac.at; pilar.garin-chesa@boehringer-ingelheim.com	Moriggl, Richard/H-8118-2019; Dolznig, Helmut/L-7005-2015	Moriggl, Richard/0000-0003-0918-9463; Dolznig, Helmut/0000-0002-6063-3585	Boehringer Ingelheim Austria	Boehringer Ingelheim Austria(Boehringer Ingelheim)	This work was supported by Boehringer Ingelheim Austria. We are grateful to Christina Puri, Daniela Milovanovic, Oliver Bergner and Jakob Schnabl for help with immunohistochemistry, cell culture and in vitro assays.	Adachi Y, 2001, INT J CANCER, V95, P216, DOI 10.1002/1097-0215(20010720)95:4<216::AID-IJC1037>3.0.CO;2-O; Ahmed S, 2006, FEBS J, V273, P615, DOI 10.1111/j.1742-4658.2005.05094.x; Ahmed S, 2003, BIOCHEM BIOPH RES CO, V310, P612, DOI 10.1016/j.bbrc.2003.09.058; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bieche I, 2004, CLIN CANCER RES, V10, P6789, DOI 10.1158/1078-0432.CCR-04-0306; Breiteneder-Geleff S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6; Casey T, 2009, BREAST CANCER RES TR, V114, P47, DOI 10.1007/s10549-008-9982-8; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chen Y, 2011, LUNG CANCER, V73, P38, DOI 10.1016/j.lungcan.2010.10.015; Chi JT, 2006, PLOS MED, V3, P395, DOI 10.1371/journal.pmed.0030047; Christian S, 2001, J BIOL CHEM, V276, P48588, DOI 10.1074/jbc.M106152200; Degeorges A, 1999, CANCER RES, V59, P2787; Desmouliere A, 2004, INT J DEV BIOL, V48, P509, DOI 10.1387/ijdb.041802ad; Dolznig H, 2011, AM J PATHOL, V179, P487, DOI 10.1016/j.ajpath.2011.03.015; Evdokimova V, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003184; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Gallagher PG, 2005, CANCER RES, V65, P4134, DOI 10.1158/0008-5472.CAN-04-0415; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gregg JL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-165; Grum-Schwensen B, 2005, CANCER RES, V65, P3772, DOI 10.1158/0008-5472.CAN-04-4510; Herrera M, 2013, CANCER SCI, V104, P437, DOI 10.1111/cas.12096; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jiang W, 2008, NEOPLASIA, V10, P1335, DOI 10.1593/neo.08694; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kunz-Schughart LA, 2002, HISTOL HISTOPATHOL, V17, P599, DOI 10.14670/HH-17.599; Lin J, 2008, CANCER BIOL THER, V7, P1896, DOI 10.4161/cbt.7.12.6937; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massoner P, 2008, PROSTATE, V68, P1165, DOI 10.1002/pros.20785; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Navab R, 2011, P NATL ACAD SCI USA, V108, P7160, DOI 10.1073/pnas.1014506108; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Orimo A, 2007, CANCER BIOL THER, V6, P618, DOI 10.4161/cbt.6.4.4255; Ostermann E, 2008, CLIN CANCER RES, V14, P4584, DOI 10.1158/1078-0432.CCR-07-5211; Ostman A, 2007, ADV CANCER RES, V97, P247, DOI 10.1016/S0065-230X(06)97011-0; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; Pen A, 2008, ONCOGENE, V27, P6834, DOI 10.1038/onc.2008.287; Pilewski JM, 2005, AM J PATHOL, V166, P399, DOI 10.1016/S0002-9440(10)62263-8; Pure E, 2009, EXPERT OPIN THER TAR, V13, P967, DOI 10.1517/14728220903103841; Rasanen K, 2010, EXP CELL RES, V316, P2713, DOI 10.1016/j.yexcr.2010.04.032; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ruan WJ, 2007, CANCER BIOL THER, V6, P354, DOI 10.4161/cbt.6.3.3702; Rupp C, 2006, DIAGN MOL PATHOL, V15, P35, DOI 10.1097/00019606-200603000-00006; Santos AM, 2009, J CLIN INVEST, V119, P3613, DOI 10.1172/JCI38988; Sato N, 2004, CANCER RES, V64, P6950, DOI 10.1158/0008-5472.CAN-04-0677; Sato Y, 2007, CANCER SCI, V98, P1055, DOI 10.1111/j.1349-7006.2007.00502.x; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sullivan L, 2012, J UROLOGY, V188, P1354, DOI 10.1016/j.juro.2012.06.002; Tomimaru Y, 2012, INT J CANCER, V130, P319, DOI 10.1002/ijc.25994; van Beijnum JR, 2006, BLOOD, V108, P2339, DOI 10.1182/blood-2006-02-004291; Vizioli MG, 2010, ONCOGENE, V29, P3835, DOI 10.1038/onc.2010.136	57	74	78	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					815	825		10.1038/onc.2014.18	http://dx.doi.org/10.1038/onc.2014.18			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24632618				2022-12-28	WOS:000349472000002
J	Yin, M; Ren, X; Zhang, X; Luo, Y; Wang, G; Huang, K; Feng, S; Bao, X; Huang, K; He, X; Liang, P; Wang, Z; Tang, H; He, J; Zhang, B				Yin, M.; Ren, X.; Zhang, X.; Luo, Y.; Wang, G.; Huang, K.; Feng, S.; Bao, X.; Huang, K.; He, X.; Liang, P.; Wang, Z.; Tang, H.; He, J.; Zhang, B.			Selective killing of lung cancer cells by miRNA-506 molecule through inhibiting NF-kappa B p65 to evoke reactive oxygen species generation and p53 activation	ONCOGENE			English	Article						miR-506; NF-kappa B p65; ROS; p53; lung cancer; selective killing	OXIDATIVE STRESS; APOPTOSIS; INDUCTION; PATHWAY; MODULATION; CARCINOMA; MICRORNAS; MECHANISM; DAMAGE; REQUIREMENT	The tumor suppressor p53, nuclear factor-kappa B (NF-kappa B) and reactive oxygen species (ROS) have crucial roles in tumorigenesis, although the mechanisms of cross talk between these factors remain largely unknown. Here we report that miR-506 upregulation occurs in 83% of lung cancer patients (156 cases), and its expression highly correlates with ROS. Ectopic expression of miR-506 inhibits NF-kappa B p65 expression, induces ROS accumulation and then activates p53 to suppress lung cancer cell viability, but not in normal cells. Interestingly, p53 promotes miR-506 expression level, indicating that miR-506 mediates cross talk between p53, NF-kappa B p65 and ROS. Furthermore, we demonstrated that miR-506 mimics inhibited tumorigenesis in vivo, implicating that miR-506 might be a potential therapeutic molecule for selective killing of lung cancer cells.	[Yin, M.; Ren, X.; Wang, G.; Bao, X.; Wang, Z.; Zhang, B.] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, State Key Lab Resp Dis, Guangzhou 510530, Guangdong, Peoples R China; [Yin, M.; Ren, X.; He, X.; Zhang, B.] Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Peoples R China; [Zhang, X.; Tang, H.; He, J.] Guangzhou Med Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Guangzhou, Guangdong, Peoples R China; [Luo, Y.; Huang, K.; Feng, S.] Guangzhou RiboBio Co Ltd, Guangzhou, Guangdong, Peoples R China; [Huang, K.; Liang, P.] Univ Chinese Acad Sci, Beijing, Peoples R China	Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS; State Key Laboratory of Respiratory Disease; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Guangzhou Medical University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Zhang, B (corresponding author), Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, State Key Lab Resp Dis, 190 Kai Yuan Ave,Sci Pk, Guangzhou 510530, Guangdong, Peoples R China.	drjianxing.he@gmail.com; Zhang_biliang@gibh.org			Introduced Innovative R&D Team Program of Guangdong Province [201001Y0104789252]; 863 Program of China [2012AA022501]; Strategic Emerging Industry Key Technology Project of Guangdong Province [2012A080800006]; National Natural Science Foundation of China [30870535, 90913017]; "Hundred Talents Plan" of Guangzhou Municipality; Combination Project of Guangdong Province; "Hundred Talents Plan" of Guangzhou Municipality and Combination Project of Guangdong Province and the Ministry of Education [2011B090400478]	Introduced Innovative R&D Team Program of Guangdong Province; 863 Program of China(National High Technology Research and Development Program of China); Strategic Emerging Industry Key Technology Project of Guangdong Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); "Hundred Talents Plan" of Guangzhou Municipality; Combination Project of Guangdong Province; "Hundred Talents Plan" of Guangzhou Municipality and Combination Project of Guangdong Province and the Ministry of Education	We would like to thank Professor Craig Mello for valuable advice throughout this research, Professor Miguel Esteban for manuscripts revision and renal cell line RCC4, Professor Duanqing Pei for the lung cancer cell line 95D. This research was supported by Introduced Innovative R&D Team Program of Guangdong Province (no. 201001Y0104789252), 863 Program of China (no. 2012AA022501), Strategic Emerging Industry Key Technology Project of Guangdong Province (no. 2012A080800006), the National Natural Science Foundation of China (nos. 30870535 and 90913017), the "Hundred Talents Plan" of Guangzhou Municipality and Combination Project of Guangdong Province and the Ministry of Education (no. 2011B090400478).	Adhikary A, 2010, FEBS LETT, V584, P7, DOI 10.1016/j.febslet.2009.10.081; Amin ARMR, 2009, CANCER PREV RES, V2, P538, DOI 10.1158/1940-6207.CAPR-09-0063; Arora H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064273; Banales JM, 2012, J HEPATOL, V56, pS15, DOI 10.1016/S0168-8278(12)60048-8; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Basseres DS, 2010, CANCER RES, V70, P3537, DOI 10.1158/0008-5472.CAN-09-4290; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Braun CJ, 2008, CANCER RES, V68, P10094, DOI 10.1158/0008-5472.CAN-08-1569; Chaturvedi MM, 2011, ONCOGENE, V30, P1615, DOI 10.1038/onc.2010.566; Cheng YH, 2009, J MOL CELL CARDIOL, V47, P5, DOI 10.1016/j.yjmcc.2009.01.008; Dai Y, 2005, MOL CELL BIOL, V25, P5429, DOI 10.1128/MCB.25.13.5429-5444.2005; Dey A, 2008, BRIT J CANCER, V98, P4, DOI 10.1038/sj.bjc.6604098; Dey A, 2007, CELL CYCLE, V6, P2178, DOI 10.4161/cc.6.17.4643; Dijsselbloem N, 2007, J IMMUNOL, V178, P5048, DOI 10.4049/jimmunol.178.8.5048; Ebi H, 2009, ONCOGENE, V28, P3371, DOI 10.1038/onc.2009.201; Feng SP, 2011, NUCLEIC ACIDS RES, V39, P6669, DOI 10.1093/nar/gkr232; Gurova KV, 2005, P NATL ACAD SCI USA, V102, P17448, DOI 10.1073/pnas.0508888102; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hileman EO, 2004, CANCER CHEMOTH PHARM, V53, P209, DOI 10.1007/s00280-003-0726-5; Hsu YL, 2004, LIFE SCI, V75, P2303, DOI 10.1016/j.lfs.2004.04.027; Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868; JARUGA P, 1994, FEBS LETT, V341, P59, DOI 10.1016/0014-5793(94)80240-8; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Li F, 2010, BBA-REV CANCER, V1805, P167, DOI 10.1016/j.bbcan.2010.01.002; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Liu G, 2009, J IMMUNOL, V182, P5063, DOI 10.4049/jimmunol.0803526; Mateescu B, 2011, NAT MED, V17, P1627, DOI 10.1038/nm.2512; Mates JM, 2000, INT J BIOCHEM CELL B, V32, P157, DOI 10.1016/S1357-2725(99)00088-6; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Montero AJ, 2011, DRUGS, V71, P1385, DOI 10.2165/11592590-000000000-00000; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Raj L, 2011, NATURE, V475, P231, DOI 10.1038/nature10167; Ramalingam SS, 2011, CA-CANCER J CLIN, V61, P91, DOI 10.3322/caac.20102; Sethi G, 2008, EXP BIOL MED, V233, P21, DOI 10.3181/0707-MR-196; Streicher KL, 2012, ONCOGENE, V31, P1558, DOI 10.1038/onc.2011.345; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Tang XM, 2006, CANCER, V107, P2637, DOI 10.1002/cncr.22315; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Vazquez A, 2008, NAT REV DRUG DISCOV, V7, P979, DOI 10.1038/nrd2656; Vidya Priyadarsini R, 2010, Eur J Pharmacol, V649, P84, DOI 10.1016/j.ejphar.2010.09.020; Visconti R, 2009, IDRUGS, V12, P240; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107; Yang D, 2013, CANCER CELL, V23, P705, DOI 10.1016/j.ccr.2013.04.029; Zhang R, 2007, GENOME RES, V17, P612, DOI 10.1101/gr.6146507	58	73	79	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					691	703		10.1038/onc.2013.597	http://dx.doi.org/10.1038/onc.2013.597			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24469051				2022-12-28	WOS:000348853800003
J	Sahasrabuddhe, AA; Chen, X; Chung, F; Velusamy, T; Lim, MS; Elenitoba-Johnson, KSJ				Sahasrabuddhe, A. A.; Chen, X.; Chung, F.; Velusamy, T.; Lim, M. S.; Elenitoba-Johnson, K. S. J.			Oncogenic Y641 mutations in EZH2 prevent Jak2/beta-TrCP-mediated degradation	ONCOGENE			English	Article						EZH2; SCF beta-TrCP ubiquitin ligase; protein degradation; lymphoma	POLYCOMB GROUP PROTEINS; BETA-TRCP; UBIQUITIN LIGASES; MOUSE DEVELOPMENT; STEM-CELLS; CANCER; LYMPHOMA; COMPLEX; BINDING; METHYLATION	EZH2 (enhancer of zeste homolog 2) is a critical enzymatic subunit of the polycomb repressive complex 2 (PRC2), which trimethylates histone H3 (H3K27) to mediate gene repression. Somatic mutations, overexpression and hyperactivation of EZH2 have been implicated in the pathogenesis of several forms of cancer. In particular, recurrent gain-of-function mutations targeting EZH2 Y641 occur most frequently in follicular lymphoma and aggressive diffuse large B-cell lymphoma and are associated with H3K27me3 hyperactivation, which contributes to lymphoma pathogenesis. However, the post-translational mechanisms of EZH2 regulation are not completely understood. Here we show that EZH2 is a novel interactor and substrate of the SCF E3 ubiquitin ligase beta-TrCP (FBXW1). beta-TrCP ubiquitinates EZH2 and Jak2-mediated phosphorylation on Y641 directs beta-TrCP-mediated EZH2 degradation. RNA interference-mediated silencing of beta-TrCP or inhibition of Jak2 results in EZH2 stabilization with attendant increase in H3K27 trimethylation activity. Importantly, the EZH2(Y641) mutants recurrently implicated in lymphoma pathogenesis are unable to bind beta-TrCP. Further, endogenous EZH2(Y641) mutants in lymphoma cells exhibit increased EZH2 stability and H3K27me3 hyperactivity. Our studies demonstrate that beta-TrCP has an important role in controlling H3K27 trimethylation activity and lymphoma pathogenesis by targeting EZH2 for degradation.	[Sahasrabuddhe, A. A.; Chen, X.; Chung, F.; Velusamy, T.; Lim, M. S.; Elenitoba-Johnson, K. S. J.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Elenitoba-Johnson, KSJ (corresponding author), Univ Michigan, Dept Pathol, 2037 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	kojoelen@umich.edu		Elenitoba-Johnson, Kojo/0000-0002-1082-1545; Lim, Megan/0000-0002-0415-2867; Sahasrabuddhe, Anagh/0000-0002-3040-0019	NIH [R01 DE119249, R01 CA136905, R01 CA140806]; NATIONAL CANCER INSTITUTE [R01CA136905, R01CA140806] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by NIH Grants R01 DE119249, and R01 CA136905 to KSJ E-J, R01 CA140806 to MSL.	Argetsinger LS, 2004, MOL CELL BIOL, V24, P4955, DOI 10.1128/MCB.24.11.4955-4967.2004; Beguelin W, 2013, CANCER CELL, V23, P677, DOI 10.1016/j.ccr.2013.04.011; Bodor C, 2013, BLOOD, V122, P3165, DOI 10.1182/blood-2013-04-496893; Chen H, 2013, MOL CELL BIOL, V33, P1139, DOI 10.1128/MCB.01191-12; Ciferri C, 2012, ELIFE, V1, DOI 10.7554/eLife.00005; Dimri M, 2010, CARCINOGENESIS, V31, P489, DOI 10.1093/carcin/bgp305; Emanuele MJ, 2011, CELL, V147, P459, DOI 10.1016/j.cell.2011.09.019; Erhardt S, 2003, DEVELOPMENT, V130, P4235, DOI 10.1242/dev.00625; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Kaneko S, 2010, GENE DEV, V24, P2615, DOI 10.1101/gad.1983810; Knutson SK, 2013, P NATL ACAD SCI USA, V110, P7922, DOI 10.1073/pnas.1303800110; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407; Liu H, 2007, GENE DEV, V21, P2385, DOI 10.1101/gad.1574507; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Martin-Perez D, 2010, BLOOD, V116, P5465, DOI 10.1182/blood-2010-05-267096; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Mills AA, 2010, NAT REV CANCER, V10, P669, DOI 10.1038/nrc2931; Morey L, 2010, TRENDS BIOCHEM SCI, V35, P323, DOI 10.1016/j.tibs.2010.02.009; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Piunti A, 2011, FUTURE ONCOL, V7, P57, DOI 10.2217/FON.10.157; Popovic R, 2013, THER ADV HEMATOL, V4, P81, DOI 10.1177/2040620712466864; Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84; Sahasrabuddhe AA, 2011, CELL CYCLE, V10, P1322, DOI 10.4161/cc.10.8.15372; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Simon JA, 2013, MOL CELL, V49, P808, DOI 10.1016/j.molcel.2013.02.013; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Surface LE, 2010, CELL STEM CELL, V7, P288, DOI 10.1016/j.stem.2010.08.004; Tan MKM, 2011, MOL CELL BIOL, V31, P3687, DOI 10.1128/MCB.05746-11; Velichutina I, 2010, BLOOD, V116, P5247, DOI 10.1182/blood-2010-04-280149; Velusamy T, 2013, P NATL ACAD SCI USA, V110, P3035, DOI 10.1073/pnas.1214326110; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Yadav AK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-158; Yu YL, 2013, EMBO MOL MED, V5, P531, DOI 10.1002/emmm.201201783; Zoabi M, 2011, BIOCHEM BIOPH RES CO, V408, P393, DOI 10.1016/j.bbrc.2011.04.025	39	63	64	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					445	454		10.1038/onc.2013.571	http://dx.doi.org/10.1038/onc.2013.571			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24469040				2022-12-28	WOS:000348451300005
J	Kwon, SJ; Park, JH; Park, EJ; Lee, SA; Lee, HS; Kang, SW; Kwon, J				Kwon, S-J; Park, J-H; Park, E-J; Lee, S-A; Lee, H-S; Kang, S. W.; Kwon, J.			ATM-mediated phosphorylation of the chromatin remodeling enzyme BRG1 modulates DNA double-strand break repair	ONCOGENE			English	Article						BRG1 chromatin remodeling enzyme; DNA double-strand break repair; ATM phosphorylation; gamma-H2AX	DAMAGE RESPONSE; INO80 COMPLEX; SWI/SNF; REPLICATION; GAMMA-H2AX; RSC; CANCER; SITES; RECRUITMENT; TRANSCRIPTION	ATP-dependent chromatin remodeling complexes such as SWI/SNF (SWItch/Sucrose NonFermentable) have been implicated in DNA double-strand break (DSB) repair and damage responses. However, the regulatory mechanisms that control the function of chromatin remodelers in DNA damage response are largely unknown. Here, we show that ataxia telangiectasia mutated (ATM) mediates the phosphorylation of BRG1, the catalytic ATPase of the SWI/SNF complex that contributes to DSB repair by binding g-H2AX-containing nucleosomes via interaction with acetylated histone H3 and stimulating gamma-H2AX formation, at Ser-721 in response to DNA damage. ATM-mediated phosphorylation of BRG1 occurs rapidly and transiently after DNA damage. Phosphorylated BRG1 binds g-H2AX-containing nucleosomes to form the repair foci. The Ser-721 phosphorylation of BRG1 is critical for binding g-H2AX-containing nucleosomes and stimulating g-H2AX formation and DSB repair. BRG1 binds to acetylated H3 peptides much better after phosphorylation at Ser-721 by DNA damage. However, the phosphorylation of Ser-721 does not significantly affect the ATPase and transcriptional activities of BRG1. These results, establishing BRG1 as a novel and functional ATM substrate, suggest that the ATM-mediated phosphorylation of BRG1 facilitates DSB repair by stimulating the association of this remodeler with g-H2AX nucleosomes via enhancing the affinity to acetylated H3. Our work also suggests that the mechanism of BRG1 stimulation of DNA repair is independent of the remodeler's enzymatic or transcriptional activities.	[Kwon, S-J; Park, J-H; Park, E-J; Lee, S-A; Lee, H-S; Kang, S. W.; Kwon, J.] Ewha Womans Univ, Res Ctr Cellular Homeostasis, Coll Nat Sci, Dept Life Sci, Seoul 120750, South Korea	Ewha Womans University	Kwon, J (corresponding author), Ewha Womans Univ, Res Ctr Cellular Homeostasis, Coll Nat Sci, Dept Life Sci, Daehyun Dong 11-1,Sci Bld C 308, Seoul 120750, South Korea.	jongkwon@ewha.ac.kr			National Research Foundation (NRF) - Korea Ministry of Education and Science (MEST) [2012R1A2A2A01003744]; MEST [2012R1A5A1048236]; Ewha Global Top5 Grant; Ewha Womans University	National Research Foundation (NRF) - Korea Ministry of Education and Science (MEST)(National Research Foundation of Korea); MEST(Ministry of Education, Science & Technology (MEST), Republic of Korea); Ewha Global Top5 Grant; Ewha Womans University	We thank Rho H Seong (Seoul National University) for kindly providing the plasmids pREP4-p53RE-luc and flag-p53, and Seul-Ki Lee and Shin-Kyoung Hur for technical assistance. This work was supported by the National Research Foundation (NRF) grant funded by the Korea Ministry of Education and Science (MEST) (2012R1A2A2A01003744 to JK); the NRF grant funded by the MEST (2012R1A5A1048236); Ewha Global Top5 Grant 2013 and RP-Grant 2009 (to J-HP) funded by Ewha Womans University.	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bao YH, 2007, CURR OPIN GENET DEV, V17, P126, DOI 10.1016/j.gde.2007.02.010; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Bultman SJ, 2008, ONCOGENE, V27, P460, DOI 10.1038/sj.onc.1210664; Chai B, 2005, GENE DEV, V19, P1656, DOI 10.1101/gad.1273105; Chambers AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032016; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Cohen SM, 2010, NUCLEIC ACIDS RES, V38, P6906, DOI 10.1093/nar/gkq559; Conaway RC, 2009, TRENDS BIOCHEM SCI, V34, P71, DOI 10.1016/j.tibs.2008.10.010; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Downs JA, 2007, NATURE, V447, P951, DOI 10.1038/nature05980; Dykhuizen EC, 2013, NATURE, V497, P624, DOI 10.1038/nature12146; Falbo KB, 2009, NAT STRUCT MOL BIOL, V16, P1167, DOI 10.1038/nsmb.1686; Gong F, 2008, CELL CYCLE, V7, P1067, DOI 10.4161/cc.7.8.5647; Gospodinov A, 2011, MOL CELL BIOL, V31, P4735, DOI 10.1128/MCB.06182-11; Hendricks KB, 2004, MOL CELL BIOL, V24, P362, DOI 10.1128/MCB.24.1.362-376.2004; Hur SK, 2010, CELL MOL LIFE SCI, V67, P2283, DOI 10.1007/s00018-010-0337-3; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Kashiwaba S, 2010, BIOCHEM BIOPH RES CO, V402, P619, DOI 10.1016/j.bbrc.2010.10.066; Kato D, 2012, BIOCHEM BIOPH RES CO, V417, P433, DOI 10.1016/j.bbrc.2011.11.134; Kent NA, 2007, J BIOL CHEM, V282, P27693, DOI 10.1074/jbc.M704707200; Kinner A, 2008, NUCLEIC ACIDS RES, V36, P5678, DOI 10.1093/nar/gkn550; Lavin MF, 2008, NAT REV MOL CELL BIO, V9, P759, DOI 10.1038/nrm2514; Lee HS, 2010, EMBO J, V29, P1434, DOI 10.1038/emboj.2010.27; Liang B, 2007, CURR BIOL, V17, P1432, DOI 10.1016/j.cub.2007.07.035; Lukas J, 2011, NAT CELL BIOL, V13, P1161, DOI 10.1038/ncb2344; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Morrison AJ, 2004, CELL, V119, P767, DOI 10.1016/j.cell.2004.11.037; Morrison AJ, 2007, CELL, V130, P499, DOI 10.1016/j.cell.2007.06.010; Morrison AJ, 2009, NAT REV MOL CELL BIO, V10, P373, DOI 10.1038/nrm2693; Ogiwara H, 2011, ONCOGENE, V30, P2135, DOI [10.1038/onc.2010.592, 10.1038/onc.2010.592;]; Oh J, 2008, J BIOL CHEM, V283, P11924, DOI 10.1074/jbc.M705401200; Pandita TK, 2009, NUCLEIC ACIDS RES, V37, P1363, DOI 10.1093/nar/gkn1071; Papamichos-Chronakis M, 2008, NAT STRUCT MOL BIOL, V15, P338, DOI 10.1038/nsmb.1413; Papamichos-Chronakis M, 2006, GENE DEV, V20, P2437, DOI 10.1101/gad.1440206; Park EJ, 2010, BIOCHEM J, V431, P179, DOI 10.1042/BJ20100988; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Park JH, 2009, DNA REPAIR, V8, P29, DOI 10.1016/j.dnarep.2008.08.011; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Saha A, 2006, NAT REV MOL CELL BIO, V7, P437, DOI 10.1038/nrm1945; Shim EY, 2007, MOL CELL BIOL, V27, P1602, DOI 10.1128/MCB.01956-06; Shim EY, 2005, MOL CELL BIOL, V25, P3934, DOI 10.1128/MCB.25.10.3934-3944.2005; Shimada K, 2008, CURR BIOL, V18, P566, DOI 10.1016/j.cub.2008.03.049; Sinha M, 2009, CELL, V138, P1109, DOI 10.1016/j.cell.2009.07.013; Sulli G, 2012, NAT REV CANCER, V12, DOI 10.1038/nrc3344; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; van Attikum H, 2004, CELL, V119, P777, DOI 10.1016/j.cell.2004.11.033; van Attikum H, 2009, TRENDS CELL BIOL, V19, P207, DOI 10.1016/j.tcb.2009.03.001; Vincent JA, 2008, NAT STRUCT MOL BIOL, V15, P477, DOI 10.1038/nsmb.1419; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Wu S, 2007, NAT STRUCT MOL BIOL, V14, P1165, DOI 10.1038/nsmb1332; Zhang L, 2009, CELL CYCLE, V8, P3953, DOI 10.4161/cc.8.23.10115; Zhao Q, 2009, J BIOL CHEM, V284, P30424, DOI 10.1074/jbc.M109.044982	54	42	42	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					351	361		10.1038/onc.2013.556	http://dx.doi.org/10.1038/onc.2013.556			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24413084				2022-12-28	WOS:000348145500009
J	Li, L; Puliyappadam, V; Chakraborty, S; Rehman, A; Vemireddy, V; Saha, D; Souza, RF; Hatanpaa, KJ; Koduru, P; Burma, S; Boothman, DA; Habib, AA				Li, L.; Puliyappadam, V. T.; Chakraborty, S.; Rehman, A.; Vemireddy, V.; Saha, D.; Souza, R. F.; Hatanpaa, K. J.; Koduru, P.; Burma, S.; Boothman, D. A.; Habib, A. A.			EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma	ONCOGENE			English	Article						EGFRvIII; glioblastoma; EGFR wild type; Met; antagonistic interaction; temozolomide	GROWTH-FACTOR RECEPTOR; C-MET; SIGNALING NETWORKS; AUTOCRINE LOOP; BRAIN-TUMORS; CELLS; GLIOMA; EXPRESSION; CANCER; RADIORESISTANCE	Epidermal growth factor receptor (EGFR)vIII is the most common EGFR mutant found in glioblastoma (GBM). EGFRvIII does not bind ligand, is highly oncogenic and is usually coexpressed with EGFR wild type (EGFRwt). EGFRvIII activates Met, and Met contributes to EGFRvIII-mediated oncogenicity and resistance to treatment. Here, we report that addition of EGF results in a rapid loss of EGFRvIII-driven Met phosphorylation in glioma cells. Met is associated with EGFRvIII in a physical complex. Addition of EGF results in a dissociation of the EGFRvIII-Met complex with a concomitant loss of Met phosphorylation. Consistent with the abrogation of Met activation, addition of EGF results in the inhibition of EGFRvIII-mediated resistance to chemotherapy. Thus, our study suggests that ligand in the milieu of EGFRvIII-expressing GBM cells is likely to influence the EGFRvIII-Met interaction and resistance to treatment, and highlights a novel antagonistic interaction between EGFRwt and EGFRvIII in glioma cells.	[Li, L.; Puliyappadam, V. T.; Chakraborty, S.; Rehman, A.; Vemireddy, V.; Habib, A. A.] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75216 USA; [Saha, D.; Burma, S.; Boothman, D. A.] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75216 USA; [Souza, R. F.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75216 USA; [Souza, R. F.] Univ Texas SW Med Ctr Dallas, Esophagal Dis Ctr, Dallas, TX 75216 USA; [Hatanpaa, K. J.; Koduru, P.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75216 USA; [Boothman, D. A.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75216 USA; [Boothman, D. A.; Habib, A. A.] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75216 USA; [Habib, A. A.] VA North Texas Hlth Care Syst, Dallas, TX USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA North Texas Health Care System	Habib, AA (corresponding author), Univ Texas SW Med Ctr Dallas, North Texas VA Hlth care Syst, Dept Neurol, Mail Code 151,4500 South Lancaster Rd, Dallas, TX 75235 USA.	Amyn.Habib@UTSouthwestern.edu	Boothman, David/Q-7776-2019		NIH [RO1N5062080, RO1 CA139217]; National Institutes of Health [RO1 CA149461, R01-DK63621, R01-CA134571]; National Aeronautics and Space Administration [NNX13AI13G]; Cancer Prevention and Research Institute of Texas [RP100644]; Office of Medical Research, Departments of Veterans Affairs (RFS); NATIONAL CANCER INSTITUTE [R01CA139217, R01CA149461, R01CA134571, P30CA142543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS062080] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Aeronautics and Space Administration(National Aeronautics & Space Administration (NASA)); Cancer Prevention and Research Institute of Texas; Office of Medical Research, Departments of Veterans Affairs (RFS); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported in part by NIH grant RO1N5062080 to AAH and by RO1 CA139217 to DAB. SB is supported by grants from the National Institutes of Health (RO1 CA149461), National Aeronautics and Space Administration (NNX13AI13G) and the Cancer Prevention and Research Institute of Texas (RP100644). This work was also supported by the Office of Medical Research, Departments of Veterans Affairs (RFS) and the National Institutes of Health (R01-DK63621, R01-CA134571 to RFS).	Abounader R, 2001, FASEB J, V15, P108, DOI 10.1096/fj.01-0421fje; Biernat W, 2004, BRAIN PATHOL, V14, P131, DOI 10.1111/j.1750-3639.2004.tb00045.x; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chumbalkar V, 2011, J PROTEOME RES, V10, P1343, DOI 10.1021/pr101075e; Dulak AM, 2011, ONCOGENE, V30, P3625, DOI 10.1038/onc.2011.84; Eder JP, 2009, CLIN CANCER RES, V15, P2207, DOI 10.1158/1078-0432.CCR-08-1306; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Garnett J, 2013, NEOPLASIA, V15, P73, DOI 10.1593/neo.121536; Hatanpaa KJ, 2010, NEOPLASIA, V12, P675, DOI 10.1593/neo.10688; Heimberger AB, 2005, CLIN CANCER RES, V11, P1462, DOI 10.1158/1078-0432.CCR-04-1737; Huang PH, 2007, P NATL ACAD SCI USA, V104, P12867, DOI 10.1073/pnas.0705158104; Huang PH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.287re6; Hwang Y, 2011, MOL CANCER RES, V9, P1199, DOI 10.1158/1541-7786.MCR-11-0229; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Jiwani AJ, 2011, PROTEOME SCI, V9, DOI 10.1186/1477-5956-9-53; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Karpel-Massler G, 2009, MOL CANCER RES, V7, P1000, DOI 10.1158/1541-7786.MCR-08-0479; Li B, 2004, ONCOGENE, V23, P4594, DOI 10.1038/sj.onc.1207602; Li L, 2014, ONCOGENE, V33, P4253, DOI 10.1038/onc.2013.400; Lorimer IAJ, 2002, CURR CANCER DRUG TAR, V2, P91, DOI 10.2174/1568009023333926; Luwor RB, 2004, ONCOGENE, V23, P6095, DOI 10.1038/sj.onc.1207870; Mishima K, 1998, ACTA NEUROPATHOL, V96, P322, DOI 10.1007/s004010050901; Nishikawa Ryo, 2004, Brain Tumor Pathol, V21, P53, DOI 10.1007/BF02484510; Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162; Puliyappadamba VT, 2013, CELL REP, V4, P764, DOI 10.1016/j.celrep.2013.07.025; Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tang P, 1997, J NEURO-ONCOL, V35, P303, DOI 10.1023/A:1005824802617; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Xu L, 2010, ONCOGENE, V29, P2616, DOI 10.1038/onc.2010.16; Zhang Y, 2013, CLIN CANCER RES, V19, P1433, DOI 10.1158/1078-0432.CCR-12-2832; Zou HY, 2007, CANCER RES, V67, P4408, DOI 10.1158/0008-5472.CAN-06-4443	33	37	38	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					129	134		10.1038/onc.2013.534	http://dx.doi.org/10.1038/onc.2013.534			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24362532	Green Accepted			2022-12-28	WOS:000349740100012
J	Rahme, GJ; Israel, MA				Rahme, G. J.; Israel, M. A.			Id4 suppresses MMP2-mediated invasion of glioblastoma-derived cells by direct inactivation of Twist1 function	ONCOGENE			English	Article						Id4; glioma; invasion; MMP2; Twist1; helix-loop-helix	EPITHELIAL-MESENCHYMAL TRANSITION; MATRIX METALLOPROTEINASES; HEPATOCELLULAR-CARCINOMA; PROMOTER METHYLATION; GENE-EXPRESSION; DOWN-REGULATION; IN-VITRO; CANCER; GROWTH; DIFFERENTIATION	Tumor cell invasion is a major contributor to cancer morbidity, and is of particular importance in patients with glioblastoma multiforme (GBM), the highest grade and most aggressive primary brain tumor. Tumor cell invasion and the expression of matrix metalloproteinases (MMPs), which are required for GBM invasion, are enhanced by inhibitor of DNA binding (Id) gene family members, Id1, Id2 and Id3, which can be highly expressed in glioma. Id4 is expressed in GBM at more variable levels than these other family members and we sought to determine its role in invasion. We found, unexpectedly, that invasion was dramatically inhibited in cells expressing Id4 as a result of decreased MMP2, a secreted proteinase key for brain tumor invasion. We demonstrate that Id4 decreased MMP2 expression by a direct inhibitory interaction with Twist1, a basic helix-loop-helix transcription factor known to increase MMP2 expression. Importantly, using data from The Cancer Genome Atlas, we show that Id4 expression correlates with survival of glioblastoma patients and inversely correlates with MMP2 expression. These data suggest that the upregulation of MMP2 resulting from decreased Id4 expression in GBM may contribute to the morbidity and mortality of GBM patients.	[Rahme, G. J.; Israel, M. A.] Geisel Sch Med Dartmouth, Dept Genet, Hanover, NH USA; [Israel, M. A.] Geisel Sch Med Dartmouth, Dept Pediat, Hanover, NH USA; [Rahme, G. J.; Israel, M. A.] Norris Cotton Canc Ctr, Geisel Sch Med Dartmouth, Hanover, NH USA	Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Israel, MA (corresponding author), Norris Cotton Canc Ctr, Geisel Sch Med Dartmouth, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	Mark.A.Israel@dartmouth.edu		Rahme, Gilbert/0000-0001-6060-1279	Hitchcock Foundation; Jordan and Kyra Memorial Foundation; Theodora B. Betz Foundation; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER	Hitchcock Foundation; Jordan and Kyra Memorial Foundation; Theodora B. Betz Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Constance Brinckerhoff for assisting in the development of the project and for providing antibodies to MMP1, 3 and 13. We are grateful for all the Israel Laboratory members for stimulating discussion, especially Dr Zhonghua Zhang for his expert opinions. We thank Dr Constance Brinckerhoff, Dr Zhonghua Zhang, Pranam Chatterjee and Henna Jones for their help on preparing the manuscript. We would like to thank Kenneth A Orndorff from the shared fluorescence imaging core at the Norris Cotton Cancer Center for his expert advice on confocal images. We thank Dr Christopher Dant and Ms Tabatha Richardson at Dartmouth for their editorial advice. This work is supported by the Hitchcock Foundation (GJR), the Jordan and Kyra Memorial Foundation (MAI) and the Theodora B. Betz Foundation (MAI).	Andres-Barquin PJ, 2000, HISTOL HISTOPATHOL, V15, P603, DOI 10.14670/HH-15.603; Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Asirvatharn AJ, 2007, PROSTATE, V67, P1411, DOI 10.1002/pros.20633; Bhat KPL, 2011, GENE DEV, V25, P2594, DOI 10.1101/gad.176800.111; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Casas E, 2011, CANCER RES, V71, P245, DOI 10.1158/0008-5472.CAN-10-2330; Chan ASW, 2003, ONCOGENE, V22, P6946, DOI 10.1038/sj.onc.1206799; Chen BB, 1997, NUCLEIC ACIDS RES, V25, P423, DOI 10.1093/nar/25.2.423; Chen SS, 2011, BLOOD, V117, P862, DOI 10.1182/blood-2010-05-284638; Choe GY, 2002, CLIN CANCER RES, V8, P2894; Clark I. M., 2001, MATRIX METALLOPROTEI; COMA A, 2010, CIRC FARM, V68, P5; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elias MC, 2005, NEOPLASIA, V7, P824, DOI 10.1593/neo.04352; Fong S, 2003, P NATL ACAD SCI USA, V100, P13543, DOI 10.1073/pnas.2230238100; Forsyth PA, 1999, BRIT J CANCER, V79, P1828, DOI 10.1038/sj.bjc.6690291; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Garcia-Baquero R, 2013, J UROLOGY, V190, P723, DOI 10.1016/j.juro.2013.01.105; Itahana Y, 2003, CANCER RES, V63, P7098; Kappert K, 2009, INT J BIOCHEM CELL B, V41, P1511, DOI 10.1016/j.biocel.2009.01.004; Kargiotis O, 2008, ONCOGENE, V27, P4830, DOI 10.1038/onc.2008.122; Kophengnavong T, 2000, MOL CELL BIOL, V20, P261, DOI 10.1128/MCB.20.1.261-272.2000; Kuzontkoski PM, 2010, ONCOGENE, V29, P3793, DOI 10.1038/onc.2010.147; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Ling YX, 2011, EUR J CANCER PREV, V20, P9, DOI 10.1097/CEJ.0b013e32833ebaa0; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Meng YG, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-75; Mikheeva SA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-194; Murad JM, 2010, J BIOL CHEM, V285, P24164, DOI 10.1074/jbc.M110.128744; Nakamura H, 2000, J BIOL CHEM, V275, P38885, DOI 10.1074/jbc.M003875200; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; Niola F, 2013, J CLIN INVEST, V123, P405, DOI 10.1172/JCI63811; Noetzel E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-154; Paolella BR, 2011, STEM CELLS, V29, P1090, DOI 10.1002/stem.660; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Ruzinova MB, 2003, CANCER CELL, V4, P277, DOI 10.1016/S1535-6108(03)00240-X; Sakurai D, 2004, J IMMUNOL, V173, P5801, DOI 10.4049/jimmunol.173.9.5801; Sawaya RE, 1996, CLIN EXP METASTAS, V14, P35, DOI 10.1007/BF00157684; Sharma P, 2012, CANCER MED-US, V1, P176, DOI 10.1002/cam4.16; Shelton EL, 2008, DEV BIOL, V317, P282, DOI 10.1016/j.ydbio.2008.02.037; Smit MA, 2009, MOL CELL BIOL, V29, P3722, DOI 10.1128/MCB.01164-08; Soroceanu L, 2013, CANCER RES, V73, P1559, DOI 10.1158/0008-5472.CAN-12-1943; Sun T, 2010, HEPATOLOGY, V51, P545, DOI 10.1002/hep.23311; Tatenhorst L, 2005, BRAIN PATHOL, V15, P46; Tsunedomi R, 2008, CLIN CANCER RES, V14, P1025, DOI 10.1158/1078-0432.CCR-07-1116; Umetani N, 2004, CLIN CANCER RES, V10, P7475, DOI 10.1158/1078-0432.CCR-04-0689; Umetani N, 2005, ONCOGENE, V24, P4721, DOI 10.1038/sj.onc.1208538; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang Maode, 2003, Brain Tumor Pathol, V20, P65, DOI 10.1007/BF02483449; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521; Zeng WF, 2010, J CANCER, V1, P1; Zhang Y, 2007, J NEUROSCI, V27, P4499, DOI 10.1523/JNEUROSCI.0200-07.2007; Zhao XL, 2011, J CELL MOL MED, V15, P691, DOI 10.1111/j.1582-4934.2010.01052.x	58	46	50	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					53	62		10.1038/onc.2013.531	http://dx.doi.org/10.1038/onc.2013.531			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24413082				2022-12-28	WOS:000349740100005
J	Sato, T; Goyama, S; Kataoka, K; Nasu, R; Tsuruta-Kishino, T; Kagoya, Y; Nukina, A; Kumagai, K; Kubota, N; Nakagawa, M; Arai, S; Yoshimi, A; Honda, H; Kadowaki, T; Kurokawa, M				Sato, T.; Goyama, S.; Kataoka, K.; Nasu, R.; Tsuruta-Kishino, T.; Kagoya, Y.; Nukina, A.; Kumagai, K.; Kubota, N.; Nakagawa, M.; Arai, S.; Yoshimi, A.; Honda, H.; Kadowaki, T.; Kurokawa, M.			Evil defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; BLAST CRISIS CML; BCR-ABL; TUMOR-SUPPRESSOR; BONE-MARROW; EXPRESSION; GENE; BETA	Relapse of chronic myeloid leukemia (CML) is triggered by stem cells with a reconstituting capacity similar to that of hematopoietic stem cells (HSCs) and CML stem cells are a source of resistance in drug therapy with tyrosine kinase inhibitors (TKIs). Ecotropic viral integration site 1 (EVI1), a key transcription factor in HSC regulation, is known to predict poor outcomes in myeloid malignancies, however, incapability of prospective isolation of EVI1-high leukemic cells precludes the functional evaluation of intraindividual EVI1-high cells. Introduction of CML into Evi1-internal ribosomal entry site (IRES)-green fluorescent protein (GFP) knock-in mice, a versatile HSC-reporter strain, enables us to separate Evi1-high CML cells from the individual. Evi1-IRES-GFP allele models of CML in chronic phase (CML-CP), by retroviral overexpression of BCR-ABL and by crossing BCR-ABL transgenic mice, revealed that Evi1 is predominantly enriched in the stem cell fraction and associated with an enhanced proliferative as well as a leukemia-initiating capacity and that Evi1-high CML-CP cells exhibit resistance to TKIs. Overexpressing BCR-ABL and NUP98-HOXA9 in Evi1-IRES-GFP knock-in mice to model CML in blast crisis (CML-BC), in which Evi1-high cells turned to be a major population as opposed to a minor population in CML-CP models, showed that Evi1-high CML-BC cells have a greater potential to recapitulate the disease and appear resistant to TKIs. Furthermore, given that Evi1 heterozygosity ameliorates CML-CP and CML-BC development and that the combination of Evi1 and BCR-ABL causes acute myeloid leukemia resembling CML-BC, Evi1 could regulate CML development as a potent driver. In addition, in human CML-CP cases, we show that EVI1 is highly expressed in stem cell-enriched CD34+ CD38-CD90+ fraction at single-cell level. This is the first report to clarify directly that Evi1-high leukemic cells themselves possess the superior potential to Evi1-low cells in oncogenic self-renewal, which highlights the role of Evi1 as a valuable and a functional marker of CML stem cells.	[Sato, T.; Goyama, S.; Kataoka, K.; Nasu, R.; Tsuruta-Kishino, T.; Kagoya, Y.; Nukina, A.; Nakagawa, M.; Arai, S.; Yoshimi, A.; Kurokawa, M.] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, Japan; [Sato, T.] Tokyo Univ Hosp, Dept Transfus Med, Tokyo 113, Japan; [Kumagai, K.; Kubota, N.; Kadowaki, T.] Univ Tokyo, Grad Sch Med, Dept Metab & Diabet Dis, Tokyo 1138655, Japan; [Honda, H.] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Dis Model, Hiroshima, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Hiroshima University	Kurokawa, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kurokawa-tky@umin.ac.jp	Yoshimi, Akihide/I-3792-2019; Kagoya, Yuki/AAD-9870-2019; Kagoya, Yuki/GQH-4875-2022; Kataoka, Keisuke/AAS-2546-2020; Kubota, Naoto/N-7892-2015	Yoshimi, Akihide/0000-0002-0664-7281; Kataoka, Keisuke/0000-0002-8263-9902; Sato, Tomohiko/0000-0002-8244-075X; Nakagawa, Masahiro/0000-0002-6420-2555	Japan Society for the Promotion of Science and by Health; Grants-in-Aid for Scientific Research [26860474, 24790962] Funding Source: KAKEN	Japan Society for the Promotion of Science and by Health(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Takuro Nakamura for NUP98-HOXA9; Issay Kitabayashi for MOZ-TIF2; Michael Tomasson for TEL-PDGFR/IRES/AML1-ETO; Novartis for nilotinib. We appreciate expert technical supports by Yoshi Shimamura, Yuko Sawamoto and Rumi Takizawa-Toyama. We express our heartfelt sorrow over Yuko Sawamoto's sudden passing away. This work was carried out at the Joint Usage/Research Center (RIRBM), Hiroshima University, and supported in part by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science and by Health.	Arai S, 2011, BLOOD, V117, P6304, DOI 10.1182/blood-2009-07-234310; Balgobind BV, 2010, LEUKEMIA, V24, P942, DOI 10.1038/leu.2010.47; Buonamici S, 2004, J CLIN INVEST, V114, P713, DOI 10.1172/JCI200421716; Chen YY, 2009, NAT GENET, V41, P783, DOI 10.1038/ng.389; Chitteti BR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017498; Chomel JC, 2011, BLOOD, V118, P3657, DOI 10.1182/blood-2011-02-335497; Chu S, 2011, BLOOD, V118, P5565, DOI 10.1182/blood-2010-12-327437; Corbin AS, 2011, J CLIN INVEST, V121, P396, DOI 10.1172/JCI35721; Cuenco GM, 2004, ONCOGENE, V23, P569, DOI 10.1038/sj.onc.1207143; Daghistani M, 2010, BLOOD, V116, P6014, DOI 10.1182/blood-2010-01-264234; Dash AB, 2002, P NATL ACAD SCI USA, V99, P7622, DOI 10.1073/pnas.102583199; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Eguchi-Ishimae M, 2009, INT J HEMATOL, V89, P253, DOI 10.1007/s12185-009-0267-8; Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415; Forsberg EC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008785; Goyama S, 2004, BLOOD, V104, P3558, DOI 10.1182/blood-2004-04-1535; Goyama S, 2010, LEUKEMIA, V24, P81, DOI 10.1038/leu.2009.202; Goyama S, 2008, CELL STEM CELL, V3, P207, DOI 10.1016/j.stem.2008.06.002; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Groschel S, 2010, J CLIN ONCOL, V28, P2101, DOI 10.1200/JCO.2009.26.0646; Hamilton A, 2012, BLOOD, V119, P1501, DOI 10.1182/blood-2010-12-326843; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hermitte F, 2006, STEM CELLS, V24, P65, DOI 10.1634/stemcells.2004-0351; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; Hoyt PR, 1997, MECH DEVELOP, V65, P55, DOI 10.1016/S0925-4773(97)00057-9; Hu YG, 2006, P NATL ACAD SCI USA, V103, P16870, DOI 10.1073/pnas.0606509103; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Jiang X, 2007, LEUKEMIA, V21, P926, DOI 10.1038/sj.leu.2404609; Jones D, 2008, BLOOD, V112, P5190, DOI 10.1182/blood-2008-04-148791; Kataoka K, 2011, J EXP MED, V208, P2402, DOI 10.1084/jem.20110447; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 2000, EMBO J, V19, P2958, DOI 10.1093/emboj/19.12.2958; Lugthart S, 2008, BLOOD, V111, P4329, DOI 10.1182/blood-2007-10-119230; MaguerSatta V, 1996, BLOOD, V88, P1796; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Neviani P, 2005, CANCER CELL, V8, P355, DOI 10.1016/j.ccr.2005.10.015; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Ogawa S, 1996, LEUKEMIA, V10, P788; Paquette RL, 2011, CANCER GENET-NY, V204, P392, DOI 10.1016/j.cancergen.2011.06.002; Parmar K, 2007, P NATL ACAD SCI USA, V104, P5431, DOI 10.1073/pnas.0701152104; Radich JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI 10.1073/pnas.0510423103; Radich JP., 2007, HEMATOL AM SOC HEMAT, V2007, P384, DOI [10.1182/asheducation-2007.1.384, DOI 10.1182/ASHEDUCATION-2007.1.384]; Reynaud D, 2011, CANCER CELL, V20, P661, DOI 10.1016/j.ccr.2011.10.012; Roy S, 2012, BRIT J HAEMATOL, V157, P446, DOI 10.1111/j.1365-2141.2012.09078.x; RUSSELL M, 1993, LEUKEMIA, V7, P1654; Sato T, 2008, CANCER SCI, V99, P1407, DOI 10.1111/j.1349-7006.2008.00842.x; Schemionek M, 2010, BLOOD, V115, P3185, DOI 10.1182/blood-2009-04-215376; Shimabe M, 2009, ONCOGENE, V28, P4364, DOI 10.1038/onc.2009.288; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Watanabe-Okochi N, 2013, BLOOD, V121, P4142, DOI 10.1182/blood-2011-07-368654; Yoshimi A, 2011, BLOOD, V117, P3617, DOI 10.1182/blood-2009-12-261602; Yuasa H, 2005, EMBO J, V24, P1976, DOI 10.1038/sj.emboj.7600679; Zhang B, 2012, CANCER CELL, V21, P577, DOI 10.1016/j.ccr.2012.02.018; Zhang HJ, 2012, NAT GENET, V44, P861, DOI 10.1038/ng.2350; Zhao C, 2007, CANCER CELL, V12, P528, DOI 10.1016/j.ccr.2007.11.003; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737	60	35	35	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2014	33	42					5028	5038		10.1038/onc.2014.108	http://dx.doi.org/10.1038/onc.2014.108			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OB	24747972	hybrid, Green Published			2022-12-28	WOS:000343768000007
J	Wong, PP; Yeoh, CC; Ahmad, AS; Chelala, C; Gillett, C; Speirs, V; Jones, JL; Hurst, HC				Wong, P-P; Yeoh, C. C.; Ahmad, A. S.; Chelala, C.; Gillett, C.; Speirs, V.; Jones, J. L.; Hurst, H. C.			Identification of MAGEA antigens as causal players in the development of tamoxifen-resistant breast cancer	ONCOGENE			English	Article							P53-DEPENDENT APOPTOSIS; CANCER/TESTIS ANTIGENS; TUMOR-CELLS; MECHANISMS; PROTEIN; EXPRESSION; REPRESSION; COMPLEXES; DISCOVERY; ARREST	The antiestrogen tamoxifen is a well-tolerated, effective treatment for estrogen receptor-alpha-positive (ER+) breast cancer, but development of resistance eventually limits its use. Here we show that expression of MAGEA2, and related members of this cancertestis antigen family, is upregulated in tamoxifen-resistant tumor cells. Expression of MAGEA2 in tumor lines grown in vitro or as xenografts led to continued proliferation in the presence of tamoxifen. At the molecular level, we demonstrate that MAGEA2 protein localizes to the nucleus and forms complexes with p53 and ER alpha, resulting in repression of the p53 pathway but increased ER-dependent signaling. In a series of ER+, tamoxifen-treated breast cancer patients, we show a highly significant (P = 0.006) association between MAGEA (melanoma-associated antigen) expression and reduced overall survival, confirming the clinical significance of our observations.	[Wong, P-P; Yeoh, C. C.; Jones, J. L.; Hurst, H. C.] Queen Mary Univ London, Barts Canc Inst, Ctr Tumour Biol, London EC1M 6BQ, England; [Ahmad, A. S.] Queen Mary Univ London, Barts Canc Inst, Ctr Epidemiol Math & Stat, London EC1M 6BQ, England; [Chelala, C.] Queen Mary Univ London, Barts Canc Inst, Ctr Mol Oncol, London EC1M 6BQ, England; [Gillett, C.] Kings Coll London, Guys Hosp, Breast Pathol Res Grp, London, England; [Speirs, V.] Univ Leeds, Leeds Inst Mol Med, Leeds, W Yorkshire, England	University of London; Queen Mary University London; University of London; Queen Mary University London; University of London; Queen Mary University London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Leeds	Wong, PP (corresponding author), Queen Mary Univ London, John Vane Sci Ctr, Ctr Tumour Biol, Barts Canc Inst, Charterhouse Sq, London EC1M 6BQ, England.	p.p.wong@qmul.ac.uk; hchurst@btinternet.com	Speirs, Valerie/ABE-7377-2021	Speirs, Valerie/0000-0002-0602-4666; chelala, claude/0000-0002-2488-0669; Wong, Ping Pui/0000-0003-1592-4823; Jones, J Louise/0000-0003-3880-3274	Cancer Research UK; Barts and the London Charity; Cancer Research UK [12008] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Barts and the London Charity; Cancer Research UK(Cancer Research UK)	We are grateful to our colleagues Andrew Clear, Keyur Trivedi and Abeer Shaaban for technical assistance with the TMA for the BLT and Leeds cases, respectively, Dr Yaohe Wang for help with scoring the Immunohistochemistry study, Ian Hart and Steven Robinson for invaluable advice and help with the xenograft study and to Richard Grose for useful comments on the manuscript. We thank Tracey Chapman for expert handling of the Affymetrix arrays and Simak Ali, Dennis McCance and Hinrich Gronemeyer for the generous provision of reagents. This work was funded by Cancer Research UK and Barts and the London Charity.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Atanackovic D, 2008, P NATL ACAD SCI USA, V105, P1650, DOI 10.1073/pnas.0707140104; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Butt AJ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1779; Caballero OL, 2009, CANCER SCI, V100, P2014, DOI 10.1111/j.1349-7006.2009.01303.x; Chen YT, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0017876, 10.1371/journal.pone.0021428, 10.1371/journal.pone.0017844, 10.1371/journal.pone.0024144, 10.1371/journal.pone.0027163, 10.1371/journal.pone.0027333]; Clarke N, 2004, EMBO J, V23, P3051, DOI 10.1038/sj.emboj.7600302; DAUVOIS S, 1993, J CELL SCI, V106, P1377; Dowsett M, 2010, J CLIN ONCOL, V28, P509, DOI 10.1200/JCO.2009.23.1274; Doyle JM, 2010, MOL CELL, V39, P963, DOI 10.1016/j.molcel.2010.08.029; Fentiman IS, 2003, EUR J CANCER, V39, P309, DOI 10.1016/S0959-8049(02)00673-1; Fentiman IS, 2003, EUR J CANCER, V39, P300, DOI 10.1016/S0959-8049(02)00672-X; Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211; Grigoriadis A, 2009, P NATL ACAD SCI USA, V106, P13493, DOI 10.1073/pnas.0906840106; Hughes-Davies L, 2009, BRIT J CANCER, V101, P875, DOI 10.1038/sj.bjc.6605231; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620; Lain S, 2008, CANCER CELL, V13, P454, DOI 10.1016/j.ccr.2008.03.004; Laios I, 2003, J STEROID BIOCHEM, V87, P207, DOI 10.1016/j.jsbmb.2003.09.011; Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239; MAAS RA, 1995, CANCER LETT, V97, P107, DOI 10.1016/0304-3835(95)03959-Z; Maraqa L, 2008, CLIN CANCER RES, V14, P405, DOI 10.1158/1078-0432.CCR-07-1363; Marcar L, 2010, CANCER RES, V70, P10362, DOI 10.1158/0008-5472.CAN-10-1341; Markou A, 2011, CLIN CHEM, V57, P421, DOI 10.1373/clinchem.2010.154328; McDonnell DP, 2010, CURR OPIN PHARMACOL, V10, P620, DOI 10.1016/j.coph.2010.09.007; Monte M, 2006, P NATL ACAD SCI USA, V103, P11160, DOI 10.1073/pnas.0510834103; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nardiello T, 2011, CLIN CANCER RES, V17, P4309, DOI 10.1158/1078-0432.CCR-10-1820; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Toillon RA, 2002, BREAST CANCER RES TR, V71, P269, DOI 10.1023/A:1014422101452; VANDENEYNDE B, 1995, J EXP MED, V182, P689, DOI 10.1084/jem.182.3.689; Williams CMJ, 2009, EMBO J, V28, P3591, DOI 10.1038/emboj.2009.290; Yang B, 2007, CANCER RES, V67, P9954, DOI 10.1158/0008-5472.CAN-07-1478	35	28	28	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2014	33	37					4579	4588		10.1038/onc.2014.45	http://dx.doi.org/10.1038/onc.2014.45			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3UZ	24662835	Green Published, hybrid			2022-12-28	WOS:000342004800005
J	Dey, P; Strom, A; Gustafsson, JA				Dey, P.; Stroem, A.; Gustafsson, J-A			Estrogen receptor beta upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer	ONCOGENE			English	Article						ER beta; apoptosis; p53; FOXO3a; PUMA	FORKHEAD TRANSCRIPTION FACTOR; HUMAN BREAST-CANCER; ER-BETA; CELL-PROLIFERATION; OPPOSING ROLES; PATHWAY; 5-ALPHA-ANDROSTANE-3-BETA,17-BETA-DIOL; EXPRESSION; GROWTH; MICE	Estrogen receptor beta (ER beta) is emerging as a critical factor in understanding prostate cancer biology. Although reduced in prostate cancer above Gleason grade 3, ER beta is a potential drug target at the initial stage of the disease. In human prostate cancer cells, we found that ERb causes apoptosis by increasing the expression of pro-apoptotic factor p53-upregulated modulator of apoptosis (PUMA), independent of p53, but dependent on the forkhead transcription factor class-O family member, FOXO3a. FOXO3a has previously been shown to induce PUMA after growth factor withdrawal and inhibition of the Akt pathway. Surprisingly, the phosphorylation of FOXO3a remained unchanged, while the mRNA and total protein levels of FOXO3a were increased in response to ER beta expression or treatment of PC3, 22Rv1 and LNCaP cells with the ER beta-specific ligands 3 beta-Adiol (5 alpha-androstane-3 beta, 17 beta-diol), DPN (diarylpropionitrile) or 8 beta-VE2 (8-vinylestra-1,3,5 (10)-triene-3,17 beta-diol). Knockdown of FOXO3a or ER beta expression abolished the increase of PUMA in response to 3 beta-Adiol in LNCaP and PC3 cells, suggesting that FOXO3a mediates the apoptotic effect of 3 beta-Adiol-activated ER beta. Moreover, the ventral prostate of ER beta-/- mice had decreased expression of FOXO3a and PUMA compared with the ERb-/- mice, indicating a relationship between ER beta and FOXO3a expression. The regulation of FOXO3a by ER beta in normal basal epithelial cells indicates a function of ER beta in cell differentiation and maintenance of cells in a quiescent state. In addition, the expression of ER beta, FOXO3a and PUMA is comparable and higher in benign prostatic hyperplasia than in prostate cancer Gleason grade 4 or higher, where there is substantial loss of ER beta, FOXO3a and PUMA. We conclude that ER beta induces apoptosis of prostate cancer cells by increasing transcription of FOXO3a, leading to an increase of PUMA and subsequent triggering of apoptosis via the intrinsic pathway involving caspase-9. Furthermore, we conclude that ligands specifically activating ER beta could be useful pharmaceuticals in the treatment of prostate cancer.	[Dey, P.; Stroem, A.; Gustafsson, J-A] Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, Houston, TX 77204 USA; [Gustafsson, J-A] Karolinska Inst, Dept Biosci & Nutr, Huddinge, Sweden	University of Houston System; University of Houston; Karolinska Institutet	Strom, A (corresponding author), Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, 3605 Cullen Blvd,Sci & Engn Res Ctr Bldg 545, Houston, TX 77204 USA.	amstrom@uh.edu			Cancer Prevention and Research Institute of Texas (CPRIT) [HIRP100680, RP110444]; Texas Emerging Technology Fund [300-9-1958]; Robert A. Welch Foundation [E-0004]; Swedish Cancer Fund	Cancer Prevention and Research Institute of Texas (CPRIT); Texas Emerging Technology Fund; Robert A. Welch Foundation(The Welch Foundation); Swedish Cancer Fund	This work was supported by The Cancer Prevention and Research Institute of Texas (CPRIT) grants HIRP100680 and RP110444, the Texas Emerging Technology Fund under Agreement number 300-9-1958, the Robert A. Welch Foundation (E-0004) and the Swedish Cancer Fund. We are grateful to Linda Waage, Department of Urology at Danderyd Hospital, Stockholm, Sweden, for providing us the human prostate cancer samples, and Ulf Bergerheim for Gleason grading the tissue samples.	Bossard C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044787; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cornforth AN, 2008, ONCOGENE, V27, P4422, DOI 10.1038/onc.2008.80; Cvoro A, 2006, MOL CELL, V21, P555, DOI 10.1016/j.molcel.2006.01.014; Cvoro A, 2007, ENDOCRINOLOGY, V148, P538, DOI 10.1210/en.2006-0803; Dey P, 2012, MOL ENDOCRINOL, V26, P1991, DOI 10.1210/me.2012.1227; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dondi D, 2010, ENDOCR-RELAT CANCER, V17, P731, DOI 10.1677/ERC-10-0032; Ellem SJ, 2009, ANN NY ACAD SCI, V1155, P174, DOI 10.1111/j.1749-6632.2009.04360.x; Giroux V, 2008, INT J CANCER, V123, P303, DOI 10.1002/ijc.23532; Giroux V, 2011, MOL CARCINOGEN, V50, P359, DOI 10.1002/mc.20719; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hartman J, 2004, ONCOGENE, V23, P8826, DOI 10.1038/sj.onc.1208139; Hartman J, 2006, CANCER RES, V66, P11207, DOI 10.1158/0008-5472.CAN-06-0017; Hartman J, 2009, CANCER RES, V69, P6100, DOI 10.1158/0008-5472.CAN-09-0506; Helguero LA, 2006, ENDOCRINOLOGY, V147, P3249, DOI 10.1210/en.2005-1651; Hodges-Gallagher L, 2008, BREAST CANCER RES TR, V109, P241, DOI 10.1007/s10549-007-9640-6; Hussain S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040732; Ji Q, 2005, MOL CELL ENDOCRINOL, V229, P103, DOI 10.1016/j.mce.2004.08.012; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Leung YK, 2010, ENDOCR-RELAT CANCER, V17, P675, DOI 10.1677/ERC-09-0294; Maggiolini M, 2004, J MOL ENDOCRINOL, V32, P777, DOI 10.1677/jme.0.0320777; Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030; McPherson SJ, 2010, P NATL ACAD SCI USA, V107, P3123, DOI 10.1073/pnas.0905524107; Muthusamy S, 2011, P NATL ACAD SCI USA, V108, P20090, DOI 10.1073/pnas.1117772108; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nanni S, 2009, J CLIN INVEST, V119, P1093, DOI 10.1172/JCI35079; Oliveira AG, 2007, STEROIDS, V72, P914, DOI 10.1016/j.steroids.2007.08.001; Olsson M, 2007, PROSTATE, V67, P1439, DOI 10.1002/pros.20630; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Roberts CG, 2011, ONCOGENE, V30, P3186, DOI 10.1038/onc.2011.36; Saijo K, 2011, CELL, V145, P584, DOI 10.1016/j.cell.2011.03.050; Saleiro D, 2010, CANCER PREV RES, V3, P1198, DOI 10.1158/1940-6207.CAPR-10-0044; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Slusarz A, 2012, ENDOCRINOLOGY, V153, P4160, DOI 10.1210/en.2012-1030; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Weihua Z, 2002, P NATL ACAD SCI USA, V99, P13589, DOI 10.1073/pnas.162477299; Yamamoto M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016841; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zou YY, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1872	43	81	88	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2014	33	33					4213	4225		10.1038/onc.2013.384	http://dx.doi.org/10.1038/onc.2013.384			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MB	24077289				2022-12-28	WOS:000341155800003
J	Fernandez, S; Genis, L; Torres-Aleman, I				Fernandez, S.; Genis, L.; Torres-Aleman, I.			A phosphatase-independent gain-of-function mutation in PTEN triggers aberrant cell growth in astrocytes through an autocrine IGF-1 loop	ONCOGENE			English	Article						glioma; PTEN; IGF-1; gain-of-function; PKA	FACTOR-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; FACTOR-I RECEPTOR; SOMATIC MUTATIONS; RESPONSE ELEMENT; HUMAN GLIOMAS; PHOSPHORYLATION; CANCER; P53; EXPRESSION	Loss-of-function mutations in the phosphatase PTEN (phosphatase and tensin homolog deleted on chromosome10) contribute to aberrant cell growth in part through upregulation of the mitogenic IGF-1/PI3K/Akt pathway. In turn, this pathway exerts a homeostatic feedback over PTEN. Using mutagenesis analysis to explore a possible impact of this mutual control on astrocyte growth, we found that truncation of the C-terminal region of PTEN (Delta 51) associates with a marked increase in NF kappa B activity, a transcription factor overactivated in astrocyte tumors. Whereas mutations of PTEN are considered to lead to a loss-of-function, PTEN Delta 51, a truncation that comprises a region frequently mutated in human gliomas, displayed a neomorphic (gain-of-function) activity that was independent of its phosphatase activity. This gain-of-function of PTEN Delta 51 includes stimulation of IGF-1 synthesis through protein kinase A activation of the IGF-1 promoter. Increased IGF-1 originates an autocrine loop that activates Akt and NF kappa B. Constitutive activation of NF kappa B in PTEN Delta 51-expressing astrocytes leads to aberrant cell growth; astrocytes expressing this mutant PTEN generate colonies in vitro and tumors in vivo. Mutations converting a tumor suppressor such as PTEN into a tumor promoter through a gain-of-function involving IGF-1 production may further our understanding of the role played by this growth factor in glioma growth and help us define druggable targets for personalized therapy.	[Torres-Aleman, I.] Inst Cajal, CSIC, Dept Syst Neurosci, Madrid 28002, Spain; CIBERNED, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC); CIBERNED	Torres-Aleman, I (corresponding author), Inst Cajal, Neuroendocrinol Lab, Madrid 28002, Spain.	torres@cajal.csic.es	Fernandez, Silvia/Z-4848-2019; Torres-Aleman, Ignacio/A-1613-2008	Torres-Aleman, Ignacio/0000-0001-8107-7947	Spanish Ministry of Science [SAF2007-60051, SAF2010-17036]; CIBERNED	Spanish Ministry of Science(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); CIBERNED(Instituto de Salud Carlos III)	We are thankful to L. Guinea and M. Garcia for excellent technical support. This work was funded by Spanish Ministry of Science (SAF2007-60051 andSAF2010-17036) and by CIBERNED.	ANTONIADES HN, 1992, INT J CANCER, V50, P215, DOI 10.1002/ijc.2910500210; Bartkova J, 2010, ONCOGENE, V29, P5095, DOI 10.1038/onc.2010.249; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; BASERGA R, 1995, CANCER RES, V55, P249; Bredel M, 2011, NEW ENGL J MED, V364, P627, DOI 10.1056/NEJMoa1006312; Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Chen J, 2012, CELL, V149, P36, DOI 10.1016/j.cell.2012.03.009; Chen TC, 1998, LAB INVEST, V78, P165; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Feinman R, 1999, BLOOD, V93, P3044; Fernandez AM, 2007, J NEUROSCI, V27, P8745, DOI 10.1523/JNEUROSCI.1002-07.2007; Fernandez S, 2008, BBA-MOL CELL RES, V1783, P803, DOI 10.1016/j.bbamcr.2007.10.020; Forbes SA, 2008, CURR PROTOC HUM GENE, V39, pD945; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Franco C, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-51; Glick RP, 1997, J NEURO-ONCOL, V35, P315, DOI 10.1023/A:1005876819455; Green A, 2010, NEW ENGL J MED, V362, P369, DOI 10.1056/NEJMc0910063; Gustin JA, 2001, J BIOL CHEM, V276, P27740, DOI 10.1074/jbc.M102559200; Jacques TS, 2010, EMBO J, V29, P222, DOI 10.1038/emboj.2009.327; Jenkins LMM, 2012, CARCINOGENESIS, V33, P1441, DOI 10.1093/carcin/bgs145; Johnson RF, 2012, TRENDS BIOCHEM SCI, V37, P317, DOI 10.1016/j.tibs.2012.04.002; KACHRA Z, 1994, ENDOCRINOLOGY, V135, P1722, DOI 10.1210/en.135.5.1722; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Maier D, 1999, CANCER RES, V59, P5479; Maillet A, 2012, ANTIOXID REDOX SIGN, V16, P1285, DOI 10.1089/ars.2011.4434; MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901; Nowsheen S, 2009, MUTAT RES-GEN TOX EN, V674, P131, DOI 10.1016/j.mrgentox.2008.09.010; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Pons S, 2000, J BIOL CHEM, V275, P38620, DOI 10.1074/jbc.M004531200; Rahdar M, 2009, P NATL ACAD SCI USA, V106, P480, DOI 10.1073/pnas.0811212106; Rasheed BKA, 1997, CANCER RES, V57, P4187; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; SANDBERG AC, 1988, NEUROSCI LETT, V93, P114, DOI 10.1016/0304-3940(88)90022-5; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Shono T, 2001, CANCER RES, V61, P4375; TAKAHASHI K, 1993, INT J CANCER, V55, P453, DOI 10.1002/ijc.2910550322; Tang YF, 2006, CANCER RES, V66, P736, DOI 10.1158/0008-5472.CAN-05-1557; Taniguchi CM, 2006, P NATL ACAD SCI USA, V103, P12093, DOI 10.1073/pnas.0604628103; Thomas MJ, 1996, J BIOL CHEM, V271, P21835, DOI 10.1074/jbc.271.36.21835; Vasudevan KM, 2004, MOL CELL BIOL, V24, P1007, DOI 10.1128/MCB.24.3.1007-1021.2004; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wang Y, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-277; Werner Haim, 2009, Archives of Physiology and Biochemistry, V115, P58, DOI 10.1080/13813450902783106; Zumkeller W, 2001, J CLIN PATHOL-MOL PA, V54, P227, DOI 10.1136/mp.54.4.227	52	11	11	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2014	33	32					4114	4122		10.1038/onc.2013.376	http://dx.doi.org/10.1038/onc.2013.376			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YK	24056966				2022-12-28	WOS:000340595700002
J	Mishra, S; Deng, JJ; Gowda, PS; Rao, MK; Lin, CL; Chen, CL; Huang, T; Sun, LZ				Mishra, S.; Deng, J. J.; Gowda, P. S.; Rao, M. K.; Lin, C-L; Chen, C. L.; Huang, T.; Sun, L-Z			Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer	ONCOGENE			English	Article						microRNA; androgen receptor; tumor suppressor; prostate cancer	CROSS-TALK; MIR-21; PTEN; CELLS; METHYLATION; ACTIVATION; APOPTOSIS; PROTEIN	Prostate cancer cells escape growth inhibition from transforming growth factor beta (TGF beta) by downregulating TGF beta receptors. However, the mechanism by which cancer cells downregulate TGF beta receptors in prostate is not clear. Here, we showed that coordinated action of miR-21 and androgen receptor (AR) signaling had a critical role in inhibiting TGF beta receptor II (TGFBR2) expression in prostate cancer cells. Our results revealed that miR-21 suppresses TGFBR2 levels by binding to its 3'-UTR and AR signaling further potentiates this effect in both untransformed and transformed human prostate epithelial cells as well as in human prostate cancers. Analysis of primary prostate cancers showed that increased miR-21/AR expression parallel a significantly reduced expression of TGFBR2. Manipulation of androgen signaling or the expression levels of AR or miR-21 negatively altered TGFBR2 expression in untransformed and transformed human prostate epithelial cells, human prostate cancer xenografts and mouse prostate glands. Importantly, we demonstrated that miR-21 and AR regulated each other's expression resulting in a positive feedback loop. Our results indicated that miR-21/AR mediate its tumor-promoting function by attenuating TGF beta-mediated Smad2/3 activation, cell growth inhibition, cell migration and apoptosis. Together, these results suggest that the AR and miR-21 axis exerts its oncogenic effects in prostate tumors by downregulating TGFBR2, hence inhibiting the tumor-suppressive activity of TGF beta pathway. Targeting miR-21 alone or in combination with AR may restore the tumor inhibitory activity of TGF beta in prostate cancer.	[Mishra, S.; Deng, J. J.; Gowda, P. S.; Rao, M. K.; Sun, L-Z] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Lin, C-L; Chen, C. L.; Huang, T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA; [Huang, T.; Sun, L-Z] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio	Sun, LZ (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr,Mail Code 7762, San Antonio, TX 78229 USA.	SUNL@UTHSCSA.EDU	, LuZhe/AAW-4095-2021	Chen, Chun-Liang/0000-0002-6774-9003	NIH [R01CA75253, R01CA79683]; William and Ella Owens Foundation; Thrive Well foundation [U54 CA113001]; Cancer Therapy and Research Center at University of Texas Health Science Center at San Antonio through the NCI Cancer Center [2P30CA054174-17]; NATIONAL CANCER INSTITUTE [P30CA054174, R01CA075253, R01CA079683, U54CA113001] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); William and Ella Owens Foundation; Thrive Well foundation; Cancer Therapy and Research Center at University of Texas Health Science Center at San Antonio through the NCI Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by funding from NIH Grants R01CA75253 and R01CA79683 to LuZhe Sun, William and Ella Owens Foundation and Thrive Well foundation to Manjeet Rao, U54 CA113001 (Integrative Cancer Biology Program) to Tim Huang and the Cancer Therapy and Research Center at University of Texas Health Science Center at San Antonio through the NCI Cancer Center Support Grant 2P30CA054174-17 to the optical imaging core facility. We thank Dr Clifford G Tepper and Dr Paramita Ghosh at UC Davis Cancer Center for the CWR22 xenograft tissue and PSA-luciferase plasmid, respectively, and Dr Scott Lucia at University of Colorado Health Science Center for providing us with BPH-1 cells.	Agaoglu FY, 2011, TUMOR BIOL, V32, P583, DOI 10.1007/s13277-011-0154-9; Balk Steven P, 2008, Nucl Recept Signal, V6, pe001, DOI 10.1621/nrs.06001; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brattain Michael G., 1996, Current Opinion in Oncology, V8, P49, DOI 10.1097/00001622-199601000-00009; Brodin G, 1999, CANCER RES, V59, P2731; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; Chowdhury Sanjib, 2009, Mol Cell Pharmacol, V1, P57; Danielpour D, 2005, EUR J CANCER, V41, P846, DOI 10.1016/j.ejca.2004.12.027; Folini M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-12; Guo YP, 1997, INT J CANCER, V71, P573, DOI 10.1002/(SICI)1097-0215(19970516)71:4<573::AID-IJC11>3.3.CO;2-1; Hayes SA, 2001, CANCER RES, V61, P2112; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Huang WQ, 2005, J BIOL CHEM, V280, P10047, DOI 10.1074/jbc.M408680200; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Kim IY, 1996, MOL ENDOCRINOL, V10, P107, DOI 10.1210/me.10.1.107; Kim YJ, 2009, STEM CELLS, V27, P3093, DOI 10.1002/stem.235; Leite KR, 2011, UROL ONCOL, V31, P796; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li T, 2012, J UROLOGY, V187, P1466, DOI 10.1016/j.juro.2011.11.082; Lin HK, 2004, MOL ENDOCRINOL, V18, P2409, DOI 10.1210/me.2004-0117; Lou YH, 2010, INT J MOL MED, V26, P819, DOI 10.3892/ijmm_00000530; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lucia MS, 1998, J CELL PHYSIOL, V175, P184, DOI 10.1002/(SICI)1097-4652(199805)175:2<184::AID-JCP8>3.0.CO;2-K; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Mishra S, 2011, PROSTATE, V71, P1441, DOI 10.1002/pros.21361; Mulholland DJ, 2006, ONCOGENE, V25, P329, DOI 10.1038/sj.onc.1209020; Nagabhushan M, 1996, CANCER RES, V56, P3042; Osada H, 2001, CANCER RES, V61, P8331; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Ribas J, 2010, CELL CYCLE, V9, P923, DOI 10.4161/cc.9.5.10930; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Shen J, 2012, PROSTATE, V72, P1469, DOI 10.1002/pros.22499; Song K, 2008, CANCER RES, V68, P8173, DOI 10.1158/0008-5472.CAN-08-2290; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang T, 2012, INT J BIOCHEM CELL B, V44, P366, DOI 10.1016/j.biocel.2011.11.012; Williams RH, 1996, CLIN CANCER RES, V2, P635; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yamashita S, 2008, CANCER RES, V68, P2112, DOI 10.1158/0008-5472.CAN-07-5282; Zeng L, 2004, HUM PATHOL, V35, P290, DOI 10.1016/j.humpath.2003.11.001; Zhang HL, 2011, PROSTATE, V71, P326, DOI 10.1002/pros.21246; Zhang Q, 2005, MOL ENDOCRINOL, V19, P2390, DOI 10.1210/me.2005-0096; Zhu ML, 2008, PROSTATE, V68, P287, DOI 10.1002/pros.20698; Zhu ML, 2008, ENDOCR-RELAT CANCER, V15, P841, DOI 10.1677/ERC-08-0084	45	102	106	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2014	33	31					4097	4106		10.1038/onc.2013.374	http://dx.doi.org/10.1038/onc.2013.374			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YG	24037531	Green Accepted			2022-12-28	WOS:000340595300009
J	Pang, CL; Toh, SY; He, P; Teissier, S; Ben Khalifa, Y; Xue, Y; Thierry, F				Pang, C. L.; Toh, S. Y.; He, P.; Teissier, S.; Ben Khalifa, Y.; Xue, Y.; Thierry, F.			A functional interaction of E7 with B-Myb-MuvB complex promotes acute cooperative transcriptional activation of both S- and M-phase genes	ONCOGENE			English	Article						B-Myb-MuvB complex; HPV E7; B-Myb; FoxM1; mitosis; cervical carcinoma	HUMAN-PAPILLOMAVIRUS E7; CERVICAL-CANCER CELLS; DROSOPHILA-MYB; MITOTIC PATHWAY; CARCINOMA CELLS; E2 PROTEIN; EXPRESSION; FOXM1; PROGRESSION; SENESCENCE	High-risk human papillomaviruses are causative agents of cervical cancer. Viral protein E7 is required to establish and maintain the pro-oncogenic phenotype in infected cells, but the molecular mechanisms by which E7 promotes carcinogenesis are only partially understood. Our transcriptome analyses in primary human fibroblasts transduced with the viral protein revealed that E7 activates a group of mitotic genes via the activator B-Myb-MuvB complex. We show that E7 interacts with the B-Myb, FoxM1 and LIN9 components of this activator complex, leading to cooperative transcriptional activation of mitotic genes in primary cells and E7 recruitment to the corresponding promoters. E7 interaction with LIN9 and FoxM1 depended on the LXCXE motif, which is also required for pocket protein interaction and degradation. Using E7 mutants for the degradation of pocket proteins but intact for the LXCXE motif, we demonstrate that E7 functional interaction with the B-Myb-MuvB complex and pocket protein degradation are two discrete functions of the viral protein that cooperate to promote acute transcriptional activation of mitotic genes. Transcriptional level of E7 in patient's cervical lesions at different stages of progression was shown to correlate with those of B-Myb and FoxM1 as well as other mitotic gene transcripts, thereby linking E7 with cellular proliferation and progression in cervical cancer in vivo. E7 thus can directly activate the transcriptional levels of cell cycle genes independently of pocket protein stability.	[Pang, C. L.; Toh, S. Y.; He, P.; Teissier, S.; Xue, Y.; Thierry, F.] ASTAR, Inst Med Biol, Singapore 138648, Singapore; [Pang, C. L.] Natl Univ Singapore, Grad Sch Integrat Sci & Engn, Singapore 117548, Singapore; [Ben Khalifa, Y.] Inst Pasteur, Paris, France	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); National University of Singapore; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Thierry, F (corresponding author), ASTAR, Inst Med Biol, Immunos 06-05,8A Biomed Grove, Singapore 138648, Singapore.	francoise.thierry@imb.a-star.edu.sg		Toh, Shen Yon/0000-0002-6421-0862	Biomedical Sciences Institutes of A-star, Singapore	Biomedical Sciences Institutes of A-star, Singapore	We thank Dr DeCaprio for the generous gift of LIN9 and LIN54 antibodies and Birgit lane's lab for providing the primary human fibroblasts. We also thank Dr Perou for plasmid pBABE-B-Myb; Dr Teh for plasmid pSIN-CMV-FoxM1B; Dr Galloway for plasmids pLXSN-16E7, pLXSN-16E7D6 - 10 and pLXSN-16E7D21 - 24; Dr Manser for plasmid pXJ-Flag; Dr Colamonici for plasmid pEGFP-C3-LIN9; Dr Roman for plasmid pHA-p130; Dr Sage for shRNA vectors for pRB, p107 and p130. We would like to express our thanks to Dr Diana Lim from National University Hospital for providing us with the clinical specimens, Drs Zhi Liang and Jean-Pierre Abastado for help in the nanostring experiment design and analyses and John Connolly from SIgN Immunomonitoring Core. We would like to express our thanks to Dr Philipp Kaldis for valuable suggestions. We also greatly appreciate the careful reading of the manuscript by Dr Neil McCarthy of Insight Editing London. This work was supported by Biomedical Sciences Institutes of A-star, Singapore and Chai Ling Pang was a scholar of the National University of Singapore Graduate School for Integrative Science and Engineering.	Alvarez-Fernandez M, 2010, EMBO REP, V11, P452, DOI 10.1038/embor.2010.46; Balsitis SJ, 2003, MOL CELL BIOL, V23, P9094, DOI 10.1128/MCB.23.24.9094-9103.2003; Buitrago-Perez A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041743; Caldeira S, 2000, ONCOGENE, V19, P821, DOI 10.1038/sj.onc.1203375; Chan DW, 2008, J PATHOL, V215, P245, DOI 10.1002/path.2355; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; Down CF, 2012, BBA-GENE REGUL MECH, V1819, P855, DOI 10.1016/j.bbagrm.2012.03.008; Fung SM, 2002, DEVELOPMENT, V129, P347; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; Georlette D, 2007, GENE DEV, V21, P2880, DOI 10.1101/gad.1600107; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Huang C, 2012, CANCER RES, V72, P655, DOI 10.1158/0008-5472.CAN-11-3102; Johung K, 2007, J VIROL, V81, P2102, DOI 10.1128/JVI.02348-06; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Katzen AL, 1998, GENE DEV, V12, P831, DOI 10.1101/gad.12.6.831; Kim IM, 2006, CANCER RES, V66, P2153, DOI 10.1158/0008-5472.CAN-05-3003; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Li Q, 2009, CANCER RES, V69, P3501, DOI 10.1158/0008-5472.CAN-08-3045; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; Manak R, 2007, NAT CELL BIOL, V9, P581, DOI 10.1038/ncb1580; Martinez I, 2011, CANCER RES, V71, P5370, DOI 10.1158/0008-5472.CAN-11-1044; McLaughlin-Drubin ME, 2009, VIROLOGY, V384, P335, DOI 10.1016/j.virol.2008.10.006; Osterloh L, 2007, EMBO J, V26, P144, DOI 10.1038/sj.emboj.7601478; Peter M, 2010, J PATHOL, V221, P320, DOI 10.1002/path.2713; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; Pilkinton M, 2007, ONCOGENE, V26, P7535, DOI 10.1038/sj.onc.1210562; Pilkinton M, 2007, J BIOL CHEM, V282, P168, DOI 10.1074/jbc.M609924200; Psyrri A, 2004, CANCER RES, V64, P3079, DOI 10.1158/0008-5472.CAN-03-3739; Rashid NN, 2011, J GEN VIROL, V92, P2620, DOI 10.1099/vir.0.035352-0; Sadasivam S, 2012, GENE DEV, V26, P474, DOI 10.1101/gad.181933.111; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Schmit F, 2007, CELL CYCLE, V6, P1903, DOI 10.4161/cc.6.15.4512; Shepard JL, 2005, P NATL ACAD SCI USA, V102, P13194, DOI 10.1073/pnas.0506583102; Shin MK, 2012, CANCER RES, V72, P5418, DOI 10.1158/0008-5472.CAN-12-2083; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Teh MT, 2002, CANCER RES, V62, P4773; Teissier S, 2010, ONCOGENE, V29, P5061, DOI 10.1038/onc.2010.246; Teissier S, 2007, J VIROL, V81, P9368, DOI 10.1128/JVI.00427-07; Thierry F, 2004, CANCER RES, V64, P895, DOI 10.1158/0008-5472.CAN-03-2349; Ueno T, 2006, ONCOGENE, V25, P4155, DOI 10.1038/sj.onc.1209445; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wells SI, 2003, P NATL ACAD SCI USA, V100, P7093, DOI 10.1073/pnas.1232309100; Xue Yuezhen, 2012, Open Virol J, V6, P163, DOI 10.2174/1874357901206010163	46	28	30	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2014	33	31					4039	4049		10.1038/onc.2013.426	http://dx.doi.org/10.1038/onc.2013.426			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YG	24141769				2022-12-28	WOS:000340595300003
J	Michels, J; Vitale, I; Saparbaev, M; Castedo, M; Kroemer, G				Michels, J.; Vitale, I.; Saparbaev, M.; Castedo, M.; Kroemer, G.			Predictive biomarkers for cancer therapy with PARP inhibitors	ONCOGENE			English	Review						PAR; base excision repair; homologous recombination; BRCAness; synthetic lethality	POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; HOMOLOGOUS RECOMBINATION REPAIR; DOUBLE-STRAND BREAKS; POLYMERASE-1-DEPENDENT CELL-DEATH; PEGYLATED LIPOSOMAL DOXORUBICIN; NUCLEOTIDE EXCISION-REPAIR; APOPTOSIS-INDUCING FACTOR; DEPENDENT PROTEIN-KINASE; REFRACTORY SOLID TUMORS; ADP-RIBOSE POLYMERASE-1	Poly(ADP-ribose) polymerase (PARP) inhibitors have raised high expectations for the treatment of multiple malignancies. PARP inhibitors, which can be used as monotherapies or in combination with DNA-damaging agents, are particularly efficient against tumors with defects in DNA repair mechanisms, in particular the homologous recombination pathway, for instance due to BRCA mutations. Thus, deficient DNA repair provides a framework for the success of PARP inhibitors in medical oncology. Here, we review encouraging results obtained in recent clinical trials investigating the safety and efficacy of PARP inhibitors as anticancer agents. We discuss emerging mechanisms of regulation of homologous recombination and how inhibition of DNA repair might be used in cancer therapy. We surmise that the identification of patients that are likely to benefit from PARP inhibition will improve the clinical use of PARP inhibitors in a defined target population. Thus, we will place special emphasis on biomarker discovery.	[Michels, J.; Castedo, M.; Kroemer, G.] INSERM, U848, F-94805 Villejuif, France; [Michels, J.; Saparbaev, M.; Castedo, M.; Kroemer, G.] Inst Gustave Roussy, Villejuif, France; [Michels, J.; Saparbaev, M.; Castedo, M.; Kroemer, G.] Univ Paris Sud, Villejuif, France; [Vitale, I.] Regina Elena Inst Canc Res, Rome, Italy; [Vitale, I.] Natl Inst Hlth, Rome, Italy; [Saparbaev, M.] CNRS, UMR 8200, Villejuif, France; [Kroemer, G.] Inst Gustave Roussy, Metabol Platform, Villejuif, France; [Kroemer, G.] Ctr Rech Cordeliers, Paris, France; [Kroemer, G.] Hosp Europe Georges Pompidou, AP HP, Pole Biol, Paris, France; [Kroemer, G.] Univ Paris 05, Fac Med, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Istituto Superiore di Sanita (ISS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Castedo, M (corresponding author), Inst Gustave Roussy, INSERM U848, 114 Rue Edouard Vaillant, F-94805 Villejuif, France.	castedo@igr.fr	Saparbaev, Murat/AAC-5478-2020; Michels, Judith/Q-5693-2018; Vitale, Ilio/M-3960-2017; KROEMER, Guido/B-4263-2013; Saparbaev, Murat K/N-3225-2015; Kroemer, Guido/AAY-9859-2020	Saparbaev, Murat/0000-0002-4630-1074; Michels, Judith/0000-0002-9640-0222; Vitale, Ilio/0000-0002-5918-1841; KROEMER, Guido/0000-0002-9334-4405; Saparbaev, Murat K/0000-0002-4630-1074; 	Ligue contre le Cancer (equipe labellisee); Agence National de la Recherche; AXA Chair for Longevity Research; Association pour la Recherche sur le Cancer; Associazione Italiana per la Ricerca sul Cancro (AIRC); Canceropole Ile-de-France; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche Medicale; European Commission (ArtForce); European Research Council; LabEx Immuno-Oncology; Action Lions 'Vaincre le Cancer', Luxembourg; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (Socrate); Cancer Research and Personalized Medicine (Carpem); Paris Alliance of Cancer Research Institutes	Ligue contre le Cancer (equipe labellisee); Agence National de la Recherche(French National Research Agency (ANR)); AXA Chair for Longevity Research(AXA Research Fund); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Canceropole Ile-de-France(Region Ile-de-France); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Fondation Bettencourt-Schueller; Fondation de France(Fondation de France); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); European Commission (ArtForce)(European CommissionEuropean Commission Joint Research Centre); European Research Council(European Research Council (ERC)European Commission); LabEx Immuno-Oncology; Action Lions 'Vaincre le Cancer', Luxembourg; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (Socrate); Cancer Research and Personalized Medicine (Carpem); Paris Alliance of Cancer Research Institutes	The authors would like to thank Lorenzo Galluzzi (Universite Paris Descartes, Paris, France) for assistance with manuscript preparation. The authors are supported by the Ligue contre le Cancer (equipe labellisee), Agence National de la Recherche, AXA Chair for Longevity Research, Association pour la Recherche sur le Cancer, Associazione Italiana per la Ricerca sul Cancro (AIRC), Canceropole Ile-de-France, Institut National du Cancer (INCa), Fondation Bettencourt-Schueller, Fondation de France, Fondation pour la Recherche Medicale, the European Commission (ArtForce), the European Research Council, the LabEx Immuno-Oncology, Action Lions 'Vaincre le Cancer', Luxembourg, the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (Socrate) and Cancer Research and Personalized Medicine (Carpem) and the Paris Alliance of Cancer Research Institutes.	Abeti R, 2011, BRAIN, V134, P1658, DOI 10.1093/brain/awr104; Abkevich V, 2012, BRIT J CANCER, V107, P1776, DOI 10.1038/bjc.2012.451; Adams SF, 2011, GYNECOL ONCOL, V123, P486, DOI 10.1016/j.ygyno.2011.08.032; Andressoo JO, 2005, ADV EXP MED BIOL, V570, P45, DOI 10.1007/1-4020-3764-3_3; Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8; Aurelius J, 2012, BLOOD, V119, P5832, DOI 10.1182/blood-2011-11-391722; Ba XQ, 2011, AM J PATHOL, V178, P946, DOI 10.1016/j.ajpath.2010.12.004; Bai P, 2012, CELL METAB, V16, P290, DOI 10.1016/j.cmet.2012.06.016; Baker KM, 2003, J BIOL CHEM, V278, P17876, DOI 10.1074/jbc.M209480200; Bedikian AY, 2009, CANCER INVEST, V27, P756, DOI 10.1080/07357900802709159; Birkbak NJ, 2012, CANCER DISCOV, V2, P366, DOI 10.1158/2159-8290.CD-11-0206; Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; Brenner JC, 2009, BBA-REV CANCER, V1796, P201, DOI 10.1016/j.bbcan.2009.04.005; Bryant HE, 2006, NUCLEIC ACIDS RES, V34, P1685, DOI 10.1093/nar/gkl108; Bryant HE, 2009, EMBO J, V28, P2601, DOI 10.1038/emboj.2009.206; Bullrich F, 1999, CANCER RES, V59, P24; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Campalans A, 2013, NUCLEIC ACIDS RES, V41, P3115, DOI 10.1093/nar/gkt025; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Carbone M, 2008, ONCOGENE, V27, P6083, DOI 10.1038/onc.2008.221; Cavallo F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051563; Cazales M, 2005, CELL CYCLE, V4, P1233, DOI 10.4161/cc.4.9.1964; Cerbinskaite A, 2012, CANCER TREAT REV, V38, P89, DOI 10.1016/j.ctrv.2011.04.015; CHAMBON P, 1963, BIOCHEM BIOPH RES CO, V11, P39, DOI 10.1016/0006-291X(63)90024-X; Choudhury A, 2009, MOL CANCER THER, V8, P203, DOI 10.1158/1535-7163.MCT-08-0959; Cousineau I, 2011, MOL GENET GENOMICS, V285, P325, DOI 10.1007/s00438-011-0612-5; Couto CAM, 2011, J CELL BIOL, V194, P367, DOI 10.1083/jcb.201012132; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Daniel RA, 2009, CLIN CANCER RES, V15, P1241, DOI 10.1158/1078-0432.CCR-08-1095; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; De Vos M, 2012, BIOCHEM PHARMACOL, V84, P137, DOI 10.1016/j.bcp.2012.03.018; Dean E, 2012, BRIT J CANCER, V106, P468, DOI 10.1038/bjc.2011.555; Dedes KJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001538; Delaney CA, 2000, CLIN CANCER RES, V6, P2860; di Fagagna FD, 1999, NAT GENET, V23, P76; Drew Y, 2011, JNCI-J NATL CANCER I, V103, P334, DOI 10.1093/jnci/djq509; Dungey FA, 2008, INT J RADIAT ONCOL, V72, P1188, DOI 10.1016/j.ijrobp.2008.07.031; Dungey FA, 2009, MOL CANCER THER, V8, P2243, DOI 10.1158/1535-7163.MCT-09-0201; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548; Ethier C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047978; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fong PC, 2010, J CLIN ONCOL, V28, P2512, DOI 10.1200/JCO.2009.26.9589; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Fraser M, 2012, CLIN CANCER RES, V18, P1015, DOI 10.1158/1078-0432.CCR-11-2189; Fraser M, 2011, CELL CYCLE, V10, P2218, DOI 10.4161/cc.10.13.16305; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Gambi N, 2008, BIOCHEM PHARMACOL, V75, P2356, DOI 10.1016/j.bcp.2008.03.015; Gelmon KA, 2011, LANCET ONCOL, V12, P852, DOI 10.1016/S1470-2045(11)70214-5; Gonzalez-Angulo AM, 2011, CLIN CANCER RES, V17, P1082, DOI 10.1158/1078-0432.CCR-10-2560; Gordon AN, 2001, J CLIN ONCOL, V19, P3312, DOI 10.1200/JCO.2001.19.14.3312; Gottipati P, 2010, CANCER RES, V70, P5389, DOI 10.1158/0008-5472.CAN-09-4716; Graeser M, 2010, CLIN CANCER RES, V16, P6159, DOI 10.1158/1078-0432.CCR-10-1027; Gros L, 2003, MUTAT RES-FUND MOL M, V531, P219, DOI 10.1016/j.mrfmmm.2003.07.008; Gros L, 2002, ONCOGENE, V21, P8905, DOI 10.1038/sj.onc.1206005; Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Haince JF, 2008, J BIOL CHEM, V283, P1197, DOI 10.1074/jbc.M706734200; Hassa PO, 2006, MICROBIOL MOL BIOL R, V70, P789, DOI 10.1128/MMBR.00040-05; Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001; Herceg Z, 1999, MOL CELL BIOL, V19, P5124; Hochegger H, 2006, EMBO J, V25, P1305, DOI 10.1038/sj.emboj.7601015; Hong DS, 2013, CANCER TREAT REV, V39, P375, DOI 10.1016/j.ctrv.2012.10.001; Horton TM, 2009, MOL CANCER THER, V8, P2232, DOI 10.1158/1535-7163.MCT-09-0142; Hottiger MO, 2010, TRENDS BIOCHEM SCI, V35, P208, DOI 10.1016/j.tibs.2009.12.003; Huang Q, 2009, CELL DEATH DIFFER, V16, P264, DOI 10.1038/cdd.2008.151; Huang Q, 2009, AUTOPHAGY, V5, P273, DOI 10.4161/auto.5.2.7640; Huang SH, 2008, ONCOL REP, V20, P567, DOI 10.3892/or_00000043; Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9; Ibrahim YH, 2012, CANCER DISCOV, V2, P1036, DOI 10.1158/2159-8290.CD-11-0348; Jacinto FV, 2007, MUTAGENESIS, V22, P247, DOI 10.1093/mutage/gem009; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jankevicius G, 2013, NAT STRUCT MOL BIOL, V20, P508, DOI 10.1038/nsmb.2523; Johnson N, 2011, NAT MED, V17, P875, DOI 10.1038/nm.2377; Johnson N, 2009, MOL CELL, V35, P327, DOI 10.1016/j.molcel.2009.06.036; Jouan-Lanhouet S, 2012, CELL DEATH DIFFER, V19, P2003, DOI 10.1038/cdd.2012.90; Juvekar A, 2012, CANCER DISCOV, V2, P1048, DOI 10.1158/2159-8290.CD-11-0336; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kashima L, 2012, J BIOL CHEM, V287, P12975, DOI 10.1074/jbc.M111.321828; Kashiwaya K, 2009, CANCER SCI, V100, P457, DOI 10.1111/j.1349-7006.2008.01058.x; Kaye SB, 2012, J CLIN ONCOL, V30, P372, DOI 10.1200/JCO.2011.36.9215; Khan OA, 2011, BRIT J CANCER, V104, P750, DOI 10.1038/bjc.2011.8; King BS, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.393504; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Krishnakumar R, 2010, MOL CELL, V39, P8, DOI 10.1016/j.molcel.2010.06.017; Kumar A, 2010, P NATL ACAD SCI USA, V107, P7491, DOI 10.1073/pnas.0914242107; Kummar S, 2012, CLIN CANCER RES, V18, P1726, DOI 10.1158/1078-0432.CCR-11-2821; Kummar S, 2011, CANCER RES, V71, P5626, DOI 10.1158/0008-5472.CAN-11-1227; Langelier MF, 2012, SCIENCE, V336, P728, DOI 10.1126/science.1216338; Lavin MF, 2008, NAT REV MOL CELL BIO, V9, P759, DOI 10.1038/nrm2514; Ledermann J, 2012, NEW ENGL J MED, V366, P1382, DOI 10.1056/NEJMoa1105535; Li LP, 2008, CANCER RES, V68, P9141, DOI 10.1158/0008-5472.CAN-08-1127; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; Luo X, 2012, GENE DEV, V26, P417, DOI 10.1101/gad.183509.111; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maeta Y, 2005, TUMOR BIOL, V26, P300, DOI 10.1159/000089288; Magan N, 2012, ANTI-CANCER DRUG, V23, P627, DOI 10.1097/CAD.0b013e328350900f; Mansour WY, 2010, NUCLEIC ACIDS RES, V38, P6065, DOI 10.1093/nar/gkq387; Rodriguez-Vargas JM, 2012, CELL RES, V22, P1181, DOI 10.1038/cr.2012.70; Marsit CJ, 2004, ONCOGENE, V23, P1000, DOI 10.1038/sj.onc.1207256; McEllin B, 2010, CANCER RES, V70, P5457, DOI 10.1158/0008-5472.CAN-09-4295; Mendes-Pereira AM, 2009, EMBO MOL MED, V1, P315, DOI 10.1002/emmm.200900041; Menissier-de Murcia J, 2001, MOL CELL BIOL, V21, P1828; Merkhofer EC, 2010, ONCOGENE, V29, P1238, DOI 10.1038/onc.2009.410; Michels J, 2013, CANCER RES, V73, P2271, DOI 10.1158/0008-5472.CAN-12-3000; Michels J, 2013, CELL CYCLE, V12, P877, DOI 10.4161/cc.24034; Modi S, 2011, CLIN CANCER RES, V17, P5132, DOI 10.1158/1078-0432.CCR-11-0072; Montoni A, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00018; Moroni F, 2012, BRIT J PHARMACOL, V165, P1487, DOI 10.1111/j.1476-5381.2011.01666.x; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Moynahan ME, 2001, CANCER RES, V61, P4842; Mukhopadhyay A, 2010, CLIN CANCER RES, V16, P2344, DOI 10.1158/1078-0432.CCR-09-2758; Munoz-Gamez JA, 2011, CANCER LETT, V301, P47, DOI 10.1016/j.canlet.2010.10.026; Munoz-Gomez JA, 2009, AUTOPHAGY, V5, P61, DOI 10.4161/auto.5.1.7272; Narayan G, 2004, CANCER RES, V64, P2994, DOI 10.1158/0008-5472.CAN-04-0245; Noguchi M, 2006, BIOCHEM BIOPH RES CO, V351, P658, DOI 10.1016/j.bbrc.2006.10.094; Noren Hooten N, 2011, J BIOL CHEM, V286, P44679, DOI 10.1074/jbc.M111.255869; Nowsheen S, 2012, CANCER RES, V72, P4796, DOI 10.1158/0008-5472.CAN-12-1287; Nowsheen S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024148; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; O'Connor KW, 2013, CANCER RES, V73, P2529, DOI 10.1158/0008-5472.CAN-12-3313; Ocampo MTA, 2002, MOL CELL BIOL, V22, P6111, DOI 10.1128/MCB.22.17.6111-6121.2002; Pacher P, 2007, CARDIOVASC DRUG REV, V25, P235, DOI 10.1111/j.1527-3466.2007.00018.x; Palma JP, 2009, CLIN CANCER RES, V15, P7277, DOI 10.1158/1078-0432.CCR-09-1245; Pan Q, 2012, CELL BIOCHEM BIOPHYS, V62, P185, DOI 10.1007/s12013-011-9280-7; Park SY, 2005, CANCER RES, V65, P3894, DOI 10.1158/0008-5472.CAN-04-4014; Patel AG, 2012, CLIN CANCER RES, V18, P1655, DOI 10.1158/1078-0432.CCR-11-2890; Patel AG, 2011, P NATL ACAD SCI USA, V108, P3406, DOI 10.1073/pnas.1013715108; PEGG AE, 1990, CANCER RES, V50, P6119; Piao L, 2011, GENE CHROMOSOME CANC, V50, P13, DOI 10.1002/gcc.20828; Pines A, 2012, J CELL BIOL, V199, P235, DOI 10.1083/jcb.201112132; Plummer R, 2013, CANCER CHEMOTH PHARM, V71, P1191, DOI 10.1007/s00280-013-2113-1; Plummer R, 2008, CLIN CANCER RES, V14, P7917, DOI 10.1158/1078-0432.CCR-08-1223; Press JZ, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-17; Rajan A, 2012, CLIN CANCER RES, V18, P2344, DOI 10.1158/1078-0432.CCR-11-2425; Riffell JL, 2012, NAT REV DRUG DISCOV, V11, P923, DOI 10.1038/nrd3868; Robu M, 2013, P NATL ACAD SCI USA, V110, P1658, DOI 10.1073/pnas.1209507110; Rosado MM, 2013, IMMUNOLOGY, V139, P428, DOI 10.1111/imm.12099; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Rulten SL, 2011, MOL CELL, V41, P33, DOI 10.1016/j.molcel.2010.12.006; Russo AL, 2009, CLIN CANCER RES, V15, P607, DOI 10.1158/1078-0432.CCR-08-2079; Sahaboglu A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015495; Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633; Sakata KI, 2011, CANCER SCI, V102, P1712, DOI 10.1111/j.1349-7006.2011.02004.x; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Samol J, 2012, INVEST NEW DRUG, V30, P1493, DOI 10.1007/s10637-011-9682-9; Samper E, 2001, J CELL BIOL, V154, P49, DOI 10.1083/jcb.200103049; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; Schaffner C, 2000, P NATL ACAD SCI USA, V97, P2773, DOI 10.1073/pnas.050400997; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; Sedgwick B, 2004, NAT REV MOL CELL BIO, V5, P148, DOI 10.1038/nrm1312; Seki A, 2008, SCIENCE, V320, P1655, DOI 10.1126/science.1157425; Senra JM, 2011, MOL CANCER THER, V10, P1949, DOI 10.1158/1535-7163.MCT-11-0278; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sourisseau T, 2010, EMBO MOL MED, V2, P130, DOI 10.1002/emmm.201000068; Spagnolo L, 2012, NUCLEIC ACIDS RES, V40, P4168, DOI 10.1093/nar/gkr1231; Stefansson OA, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2334; Strom CE, 2011, NUCLEIC ACIDS RES, V39, P3166, DOI 10.1093/nar/gkq1241; Strosznajder JB, 2012, MOL NEUROBIOL, V46, P78, DOI 10.1007/s12035-012-8258-9; Strosznajder RP, 2010, MOL NEUROBIOL, V41, P187, DOI 10.1007/s12035-010-8124-6; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Sugimura K, 2008, J CELL BIOL, V183, P1203, DOI 10.1083/jcb.200806068; Sultana R, 2013, CANCER RES, V73, P1621, DOI 10.1158/0008-5472.CAN-12-2929; Szabo C, 2005, PHARMACOL RES, V52, P60, DOI 10.1016/j.phrs.2005.02.015; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852; Taverna P, 2000, CANCER CHEMOTH PHARM, V46, P507, DOI 10.1007/s002800000186; TAVERNA P, 1992, ANTI-CANCER DRUG, V3, P401, DOI 10.1097/00001813-199208000-00014; Tentori L, 2010, CURR CANCER DRUG TAR, V10, P368, DOI 10.2174/156800910791208571; Tentori L, 1999, LEUKEMIA, V13, P901, DOI 10.1038/sj.leu.2401423; Thomas HD, 2007, MOL CANCER THER, V6, P945, DOI 10.1158/1535-7163.MCT-06-0552; Tsutsumi M, 2001, CARCINOGENESIS, V22, P1, DOI 10.1093/carcin/22.1.1; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; Veuger SJ, 2009, ONCOGENE, V28, P832, DOI 10.1038/onc.2008.439; Veuger SJ, 2003, CANCER RES, V63, P6008; Veuger SJ, 2004, ONCOGENE, V23, P7322, DOI 10.1038/sj.onc.1207984; Virag L, MOL ASPECTS MED, VS0098-2997; Vodenicharov MD, 2005, J CELL SCI, V118, P589, DOI 10.1242/jcs.01636; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang ML, 2006, NUCLEIC ACIDS RES, V34, P6170, DOI 10.1093/nar/gkl840; Wang YF, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2000902; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Wesierska-Gadek J, 2012, BIOCHEM PHARMACOL, V84, P1318, DOI 10.1016/j.bcp.2012.07.024; Weston VJ, 2010, BLOOD, V116, P4578, DOI 10.1182/blood-2010-01-265769; Williamson CT, 2010, MOL CANCER THER, V9, P347, DOI 10.1158/1535-7163.MCT-09-0872; Wilson DM, 2001, MUTAT RES-DNA REPAIR, V485, P283, DOI 10.1016/S0921-8777(01)00063-5; Wooster R, 2003, NEW ENGL J MED, V348, P2339, DOI 10.1056/NEJMra012284; Yang G, 2010, CLIN CANCER RES, V16, P3171, DOI 10.1158/1078-0432.CCR-09-3171; Yang YG, 2004, ONCOGENE, V23, P3872, DOI 10.1038/sj.onc.1207491; Ying SM, 2012, CANCER RES, V72, P2814, DOI 10.1158/0008-5472.CAN-11-3417; Yoon JH, 2012, BIOCHEM PHARMACOL, V83, P747, DOI 10.1016/j.bcp.2011.12.029; Yu SW, 2006, P NATL ACAD SCI USA, V103, P18314, DOI 10.1073/pnas.0606528103; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799; Zaremba T, 2009, BRIT J CANCER, V101, P256, DOI 10.1038/sj.bjc.6605166; Zhang JX, 2012, HEPATOLOGY, V55, P1840, DOI 10.1002/hep.25566; Zhou J, 2013, FEBS LETT, V587, P170, DOI 10.1016/j.febslet.2012.11.018; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	207	83	83	1	41	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3894	3907		10.1038/onc.2013.352	http://dx.doi.org/10.1038/onc.2013.352			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	24037533				2022-12-28	WOS:000339394700002
J	Chen, Z; Chen, J; Gu, Y; Hu, C; Li, JL; Lin, S; Shen, H; Cao, C; Gao, R; Li, J; Ha, PK; Kaye, FJ; Griffin, JD; Wu, L				Chen, Z.; Chen, J.; Gu, Y.; Hu, C.; Li, J-L; Lin, S.; Shen, H.; Cao, C.; Gao, R.; Li, J.; Ha, P. K.; Kaye, F. J.; Griffin, J. D.; Wu, L.			Aberrantly activated AREG-EGFR signaling is required for the growth and survival of CRTC1-MAML2 fusion-positive mucoepidermoid carcinoma cells	ONCOGENE			English	Article						salivary gland tumors; mucoepidermoid carcinoma; CRTC1-MAML2; AREG; EGFR	TRANSCRIPTIONAL COACTIVATORS; T(11/19) TRANSLOCATION; NOTCH RECEPTORS; LUNG-CANCER; WILD-TYPE; TUMORS; ONCOGENE; MASTERMIND; CETUXIMAB; CREB	Salivary gland tumors (SGT) are a group of highly heterogeneous head and neck malignancies with widely varied clinical outcomes and no standard effective treatments. The CRTC1-MAML2 fusion oncogene, encoded by a recurring chromosomal translocation t(11; 19)(q14-21; p12-13), is a frequent genetic alteration found in > 50% of mucoepidermoid carcinomas (MEC), the most common malignant SGT. In this study, we aimed to define the role of the CRTC1-MAML2 oncogene in the maintenance of MEC tumor growth and to investigate critical downstream target genes and pathways for therapeutic targeting of MEC. By performing gene expression analyses and functional studies via RNA interference and pharmacological modulation, we determined the importance of the CRTC1-MAML2 fusion gene and its downstream AREG-EGFR signaling in human MEC cancer cell growth and survival in vitro and in vivo using human MEC xenograft models. We found that CRTC1-MAML2 fusion oncogene was required for the growth and survival of fusion-positive human MEC cancer cells in vitro and in vivo. The CRTC1-MAML2 oncoprotein induced the upregulation of the epidermal growth factor receptor (EGFR) ligand Amphiregulin (AREG) by co-activating the transcription factor CREB, and AREG subsequently activated EGFR signaling in an autocrine manner that promoted MEC cell growth and survival. Importantly, CRTC1-MAML2-positive MEC cells were highly sensitive to EGFR signaling inhibition. Therefore, our study revealed that aberrantly activated AREG-EGFR signaling is required for CRTC1-MAML2-positive MEC cell growth and survival, suggesting that EGFR-targeted therapies will benefit patients with advanced, unresectable CRTC1-MAML2-positive MEC.	[Chen, Z.; Gu, Y.; Hu, C.; Lin, S.; Wu, L.] Univ Florida, Shands Canc Ctr, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA; [Chen, J.; Griffin, J. D.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Li, J-L] Sanford Burnham Med Res Inst Lake Nona, Orlando, FL USA; [Shen, H.] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China; [Cao, C.; Gao, R.; Kaye, F. J.] Univ Florida, Shands Canc Ctr, Dept Med, Gainesville, FL USA; [Li, J.] Fujian Med Univ, Fujian Prov Tumor Hosp, Teaching Hosp, Fuzhou, Fujian, Peoples R China; [Ha, P. K.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA	State University System of Florida; University of Florida; Harvard University; Dana-Farber Cancer Institute; Sanford Burnham Prebys Medical Discovery Institute; Sun Yat Sen University; State University System of Florida; University of Florida; Fujian Medical University; Johns Hopkins University	Wu, L (corresponding author), Univ Florida, Shands Canc Ctr, Dept Mol Genet & Microbiol, 2033 Mowry Rd, Gainesville, FL 32610 USA.	lzwu@ufl.edu	Li, Jian-Liang/AAE-9315-2019; chen, zirong/S-4042-2016; Li, J L/E-6100-2018	Li, Jian-Liang/0000-0002-6487-081X; chen, zirong/0000-0002-0589-4619; Li, J L/0000-0002-6487-081X	University of Florida Shands Cancer Center Startup fund; Bankhead Coley Cancer Research Program; V foundation for Cancer Research	University of Florida Shands Cancer Center Startup fund; Bankhead Coley Cancer Research Program; V foundation for Cancer Research	We thank Marda Jorgensen for helping with immunohistochemical staining, Mei Zhang for helping with FACS analysis, and the Salivary Gland Tumor Biorepository (SGTB) for providing tumor specimens for this study. L Wu was supported by the University of Florida Shands Cancer Center Startup fund, Bankhead Coley Cancer Research Program, and the V foundation for Cancer Research.	Altarejos JY, 2011, NAT REV MOL CELL BIO, V12, P141, DOI 10.1038/nrm3072; Anzick SL, 2010, GENE CHROMOSOME CANC, V49, P59, DOI 10.1002/gcc.20719; Behboudi A, 2006, GENE CHROMOSOME CANC, V45, P470, DOI 10.1002/gcc.20306; Bell D, 2012, CURR ONCOL REP, V14, P166, DOI 10.1007/s11912-012-0220-5; Busser B, 2011, BBA-REV CANCER, V1816, P119, DOI 10.1016/j.bbcan.2011.05.003; Canettieri G, 2009, P NATL ACAD SCI USA, V106, P1445, DOI 10.1073/pnas.0808749106; Chiosea SI, 2012, LARYNGOSCOPE, V122, P1690, DOI 10.1002/lary.22419; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Coxon A, 2005, CANCER RES, V65, P7137, DOI 10.1158/0008-5472.CAN-05-1125; Enlund F, 2004, EXP CELL RES, V292, P21, DOI 10.1016/j.yexcr.2003.09.007; Eveson JW, 2011, PERIODONTOL 2000, V57, P150, DOI 10.1111/j.1600-0757.2011.00385.x; Fehr A, 2008, CANCER GENET CYTOGEN, V180, P135, DOI 10.1016/j.cancergencyto.2007.10.007; Grisanti Salvatore, 2008, J Med Case Rep, V2, P320, DOI 10.1186/1752-1947-2-320; Gu Y, 2012, ONCOGENE, V31, P469, DOI 10.1038/onc.2011.247; Han SW, 2008, LUNG CANCER, V61, P30, DOI 10.1016/j.lungcan.2007.11.014; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Komiya T, 2006, ONCOGENE, V25, P6128, DOI 10.1038/sj.onc.1209627; Komiya T, 2010, ONCOGENE, V29, P1672, DOI 10.1038/onc.2009.453; Kumar V, 2014, ROBBINS COTRAN PATHO; Lujan B, 2010, BRIT J CANCER, V103, P510, DOI 10.1038/sj.bjc.6605788; McElhinny AS, 2008, ONCOGENE, V27, P5138, DOI 10.1038/onc.2008.228; O'Neill ID, 2009, LUNG CANCER, V64, P129, DOI 10.1016/j.lungcan.2009.01.003; O'Neill ID, 2009, ORAL ONCOL, V45, P2, DOI 10.1016/j.oraloncology.2008.03.012; O'Neill ID, 2009, J ORAL PATHOL MED, V38, P145, DOI 10.1111/j.1600-0714.2008.00676.x; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Raben D, 2005, CLIN CANCER RES, V11, P795; Seethala RR, 2010, AM J SURG PATHOL, V34, P1106, DOI 10.1097/PAS.0b013e3181de3021; Steiner P, 2007, CLIN CANCER RES, V13, P1540, DOI 10.1158/1078-0432.CCR-06-1887; Stenman G, 2005, SEMIN CANCER BIOL, V15, P224, DOI 10.1016/j.semcancer.2005.01.002; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Wu LZ, 2005, EMBO J, V24, P2391, DOI 10.1038/sj.emboj.7600719; Yonesaka K, 2008, CLIN CANCER RES, V14, P6963, DOI 10.1158/1078-0432.CCR-08-0957	34	53	54	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3869	3877		10.1038/onc.2013.348	http://dx.doi.org/10.1038/onc.2013.348			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23975434				2022-12-28	WOS:000339394100013
J	Roy, SS; Gonugunta, VK; Bandyopadhyay, A; Rao, MK; Goodall, GJ; Sun, LZ; Tekmal, RR; Vadlamudi, RK				Roy, S. S.; Gonugunta, V. K.; Bandyopadhyay, A.; Rao, M. K.; Goodall, G. J.; Sun, L-Z; Tekmal, R. R.; Vadlamudi, R. K.			Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer	ONCOGENE			English	Article						ER coactivators; PELP1; breast cancer; metastasis; EMT; miR	EPITHELIAL-MESENCHYMAL TRANSITION; LEUCINE-RICH PROTEIN-1/MODULATOR; GLUTAMIC ACID-RICH; ESTROGEN-RECEPTOR; TUMOR-METASTASIS; MIR-200 FAMILY; PROLINE-RICH; PELP1; EXPRESSION; COREPRESSOR	Tumor metastasis is the leading cause of death among breast cancer patients. PELP1 (proline, glutamic acid and leucine rich protein 1) is a nuclear receptor coregulator that is upregulated during breast cancer progression to metastasis and is an independent prognostic predictor of shorter survival of breast cancer patients. Here, we show that PELP1 modulates expression of metastasis-influencing microRNAs (miRs) to promote cancer metastasis. Whole genome miR array analysis using PELP1-overexpressing and PELP1-underexpressing model cells revealed that miR-200 and miR-141 levels inversely correlated with PELP1 expression. Consistent with this, PELP1 knockdown resulted in lower expression of miR-200a target genes ZEB1 and ZEB2. PELP1 knockdown significantly reduced tumor growth and metastasis compared with parental cells in an orthotopic xenograft tumor model. Furthermore, re-introduction of miR-200a and miR-141 mimetics into PELP1-overexpressing cells reversed PELP1 target gene expression, decreased PELP1-driven migration/invasion in vitro and significantly reduced in vivo metastatic potential in a preclinical model of experimental metastasis. Our results demonstrated that PELP1 binds to miR-200a and miR-141 promoters and regulates their expression by recruiting chromatin modifier histone deacetylase 2 (HDAC2) as revealed by chromatin immunoprecipitation, small interfering RNA and HDAC inhibitor assays. Taken together, our results suggest that PELP1 regulates tumor metastasis by controlling the expression and functions of the tumor metastasis suppressors miR-200a and miR-141.	[Roy, S. S.; Gonugunta, V. K.; Tekmal, R. R.; Vadlamudi, R. K.] UT Hlth Sci Ctr, Dept Obstet & Gynecol, San Antonio, TX USA; [Bandyopadhyay, A.; Rao, M. K.; Sun, L-Z] UT Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX USA; [Rao, M. K.; Sun, L-Z; Tekmal, R. R.; Vadlamudi, R. K.] UT Hlth Sci Ctr, Canc Therapy & Res Ctr, San Antonio, TX USA; [Goodall, G. J.] Univ Adelaide, Dept Med, Ctr Canc Biol, SA Pathol,Sch Mol & Biomed Sci, Adelaide, SA 5001, Australia	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio; Centre for Cancer Biology; SA Pathology; University of Adelaide	Vadlamudi, RK (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, Div Reprod Res, San Antonio, TX 78229 USA.	vadlamudi@uthscsa.edu	, LuZhe/AAW-4095-2021	Goodall, Gregory/0000-0003-1294-0692	NIH/NCI [CA095681]; T32 training [CA148724]; William and Ella Owens foundation grant; Cancer Therapy and Research Center at the University of Texas Health Science Center at San Antonio through the NCI Cancer Center [P30CA054174-17]; NATIONAL CANCER INSTITUTE [T32CA148724, R01CA095681, P30CA054174] Funding Source: NIH RePORTER; National Breast Cancer Foundation [CG-10-04] Funding Source: researchfish	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); T32 training; William and Ella Owens foundation grant; Cancer Therapy and Research Center at the University of Texas Health Science Center at San Antonio through the NCI Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Breast Cancer Foundation	This study was supported by the NIH/NCI Grant CA095681 (R.K.V.) T32 training grant CA148724 (SSR), William and Ella Owens foundation grant (MKR) and the Cancer Therapy and Research Center at the University of Texas Health Science Center at San Antonio through the NCI Cancer Center Support Grant P30CA054174-17.	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Bandyopadhyay A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010365; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Chakravarty D, 2011, CLIN CANCER RES, V17, P2250, DOI 10.1158/1078-0432.CCR-10-2718; Chakravarty D, 2010, CANCER RES, V70, P4092, DOI 10.1158/0008-5472.CAN-09-3834; Chakravarty D, 2010, IUBMB LIFE, V62, P163, DOI 10.1002/iub.287; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Choi YB, 2004, J BIOL CHEM, V279, P50930, DOI 10.1074/jbc.M406831200; Cortez V, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3229; Eckhardt BL, 2012, NAT REV DRUG DISCOV, V11, P479, DOI 10.1038/nrd2372; Goldshaid L, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2579; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Habashy HO, 2010, BREAST CANCER RES TR, V120, P603, DOI 10.1007/s10549-009-0419-9; Hurst DR, 2009, CANCER RES, V69, P7495, DOI 10.1158/0008-5472.CAN-09-2111; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jenkins DE, 2005, BREAST CANCER RES, V7, pR444, DOI 10.1186/bcr1026; Khoshnaw SM, 2009, J CLIN PATHOL, V62, P422, DOI 10.1136/jcp.2008.060681; Mann M, 2012, Minerva Ginecol, V64, P75; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Nair BC, 2010, CANCER RES, V70, P7166, DOI 10.1158/0008-5472.CAN-10-0628; Nair SS, 2007, MOL ENDOCRINOL, V21, P613, DOI 10.1210/me.2006-0269; Nair SS, 2010, EMBO REP, V11, P438, DOI 10.1038/embor.2010.62; O'Malley BW, 2007, MOL ENDOCRINOL, V21, P1009, DOI 10.1210/me.2007-0012; O'Malley BW, 2006, SCIENCE, V313, P1749, DOI 10.1126/science.1132509; O'Malley BW, 2009, CANCER RES, V69, P8217, DOI 10.1158/0008-5472.CAN-09-2223; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Qin L, 2008, MOL CELL BIOL, V28, P5937, DOI 10.1128/MCB.00579-08; Qin L, 2009, CANCER RES, V69, P3819, DOI 10.1158/0008-5472.CAN-08-4389; Rajhans R, 2007, CANCER RES, V67, P5505, DOI 10.1158/0008-5472.CAN-06-3647; Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806; Roy S, 2012, MOL CANCER RES, V10, P25, DOI 10.1158/1541-7786.MCR-11-0456; Saha RS, 2012, INT J BREAST CANC, V2012; Schiff R, 2005, CANC CHEMOTHER PH S1, V56; Shi M, 2010, CANCER METAST REV, V29, P785, DOI 10.1007/s10555-010-9265-9; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; Vadlamudi Ratna K, 2007, Nucl Recept Signal, V5, pe004; Wang L, 2012, ONCOGENE, V31, P2499, DOI 10.1038/onc.2011.444; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Yang YN, 2011, J CLIN INVEST, V121, P1373, DOI 10.1172/JCI42579	42	75	79	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3707	3716		10.1038/onc.2013.332	http://dx.doi.org/10.1038/onc.2013.332			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23975430	Green Accepted			2022-12-28	WOS:000338942900010
J	Pradere, JP; Dapito, DH; Schwabe, RF				Pradere, J-P; Dapito, D. H.; Schwabe, R. F.			The Yin and Yang of Toll-like receptors in cancer	ONCOGENE			English	Review						MyD88; interleukin 6; tumor necrosis factor; NF-kappa B; Coley's toxin; imiquimod	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; DENDRITIC CELLS; CPG DNA; COMPENSATORY PROLIFERATION; PANCREATIC CARCINOGENESIS; HEPATOCELLULAR-CARCINOMA; LIVER-REGENERATION; GENE POLYMORPHISMS; TOPICAL IMIQUIMOD	Recognition of non-self molecular patterns by pattern recognition receptors is a cornerstone of innate immunity. Toll-like receptors (TLRs) exert a key role in recognizing pathogen-associated molecular patterns (PAMPs) but have also been implicated in the recognition of damage-associated molecular patterns (DAMPs). As such, TLRs regulate a wide range of biological responses including inflammatory and immune responses during carcinogenesis. The high expression of TLRs by antigen-presenting cells, including dendritic cells, and their ability to induce antitumor mediators such as type I interferon has led to efforts to utilize TLR agonists in tumor therapy in order to convert the often tolerant immune response toward antitumor responses. However, TLRs are also increasingly recognized as regulators of tumor-promoting inflammation and promoters of tumor survival signals. Here, we will review in detail the dichotomous role of TLRs in tumor biology, focusing on relevant TLR-dependent pro-and antitumor pathways, and discuss clinical applications of TLR-targeted therapies for tumor prevention and treatment.	[Pradere, J-P; Dapito, D. H.; Schwabe, R. F.] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; [Dapito, D. H.; Schwabe, R. F.] Columbia Univ, Inst Human Nutr, New York, NY 10032 USA	Columbia University; Columbia University	Schwabe, RF (corresponding author), Columbia Univ, Dept Med, Russ Berrie Pavil,1150 St Nicholas Ave,Room 415, New York, NY 10032 USA.	rfs2102@columbia.edu	Schwabe, Robert/AAY-6506-2021	Pradere, Jean-Philippe/0000-0003-1734-1429	NIH [U54CA163111, R01DK076920, R01AA020211, F31DK091980]; NATIONAL CANCER INSTITUTE [U54CA163111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076920, F31DK091980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA020211] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This work was supported by NIH grants U54CA163111, R01DK076920 and R01AA020211 (to RFS). Dianne H Dapito was supported by NIH grant F31DK091980.	Adams S, 2012, CLIN CANCER RES, V18, P6748, DOI 10.1158/1078-0432.CCR-12-1149; Ahmed A, 2013, ANN SURG ONCOL, V20, pS389, DOI 10.1245/s10434-012-2595-9; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Apte RN, 2008, IMMUNOL REV, V222, P222, DOI 10.1111/j.1600-065X.2008.00615.x; Arslan F, 2012, CIRC-CARDIOVASC INTE, V5, P279, DOI 10.1161/CIRCINTERVENTIONS.111.967596; Asano M, 1996, J EXP MED, V184, P387, DOI 10.1084/jem.184.2.387; Babjuk M, 2011, EUR UROL, V59, P997, DOI 10.1016/j.eururo.2011.03.017; Baines J, 2003, CLIN CANCER RES, V9, P2693; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Ballas ZK, 1996, J IMMUNOL, V157, P1840; Bass NM, 2010, NEW ENGL J MED, V362, P1071, DOI 10.1056/NEJMoa0907893; Bauer AK, 2005, J NATL CANCER I, V97, P1778, DOI 10.1093/jnci/dji403; BEKIERKUNST A, 1971, SCIENCE, V174, P1240, DOI 10.1126/science.174.4015.1240; Beutler B, 2006, ANNU REV IMMUNOL, V24, P353, DOI 10.1146/annurev.immunol.24.021605.090552; Bong AB, 2002, DERMATOLOGY, V205, P135, DOI 10.1159/000063904; Bourquin C, 2009, J IMMUNOL, V183, P6078, DOI 10.4049/jimmunol.0901594; Brignole C, 2010, CANCER RES, V70, P9816, DOI 10.1158/0008-5472.CAN-10-1251; BRUNS P, 1887, BEITR KLIN CHIR, V3, P443; Burdelya LG, 2008, SCIENCE, V320, P226, DOI 10.1126/science.1154986; Busch W., 1868, BERL KLIN WOCHENSCHR, V5, P137; Cai ZY, 2011, CANCER RES, V71, P2466, DOI 10.1158/0008-5472.CAN-10-1993; Campbell JS, 2006, J IMMUNOL, V176, P2522, DOI 10.4049/jimmunol.176.4.2522; Carpentier AF, 1999, CANCER RES, V59, P5429; Cataisson C, 2012, J EXP MED, V209, P1689, DOI 10.1084/jem.20101355; Cherfils-Vicini J, 2010, J CLIN INVEST, V120, P1285, DOI 10.1172/JCI36551; Chew V, 2012, JNCI-J NATL CANCER I, V104, P1796, DOI 10.1093/jnci/djs436; Chin AI, 2010, CANCER RES, V70, P2595, DOI 10.1158/0008-5472.CAN-09-1162; Coley W, 1894, T AM SURG ASS, V12, P183; CORNELL RP, 1990, HEPATOLOGY, V11, P916, DOI 10.1002/hep.1840110603; Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Couturier-Maillard A, 2013, J CLIN INVEST, V123, P700, DOI 10.1172/JCI62236; Csak T, 2011, AM J PHYSIOL-GASTR L, V300, pG433, DOI 10.1152/ajpgi.00163.2009; Cubillos-Ruiz JR, 2009, J CLIN INVEST, V119, P2231, DOI 10.1172/JCI37716; Damiano V, 2009, CLIN CANCER RES, V15, P6921, DOI 10.1158/1078-0432.CCR-09-1599; Dapito DH, 2012, CANCER CELL, V21, P504, DOI 10.1016/j.ccr.2012.02.007; de Oliveira JG, 2013, DIGEST DIS SCI, V58, P978, DOI 10.1007/s10620-012-2460-5; De Palma M, 2008, CANCER CELL, V14, P299, DOI 10.1016/j.ccr.2008.09.004; Diamond MS, 2011, J EXP MED, V208, P1989, DOI 10.1084/jem.20101158; DOLBERG DS, 1985, SCIENCE, V230, P676, DOI 10.1126/science.2996144; Drobits B, 2012, J CLIN INVEST, V122, P575, DOI 10.1172/JCI61034; Droemann D, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-1; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Ebihara T, 2010, J EXP MED, V207, P2675, DOI 10.1084/jem.20091573; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; Fort MM, 2005, J IMMUNOL, V174, P6416, DOI 10.4049/jimmunol.174.10.6416; Forte G, 2012, J IMMUNOL, V188, P5357, DOI 10.4049/jimmunol.1103811; Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159; Fukata M, 2007, GASTROENTEROLOGY, V133, P1869, DOI 10.1053/j.gastro.2007.09.008; Fukata M, 2006, GASTROENTEROLOGY, V131, P862, DOI 10.1053/j.gastro.2006.06.017; Fukata M, 2011, INFLAMM BOWEL DIS, V17, P1464, DOI 10.1002/ibd.21527; Fukata M, 2009, INFLAMM BOWEL DIS, V15, P997, DOI 10.1002/ibd.20880; Galluzzi L, 2012, ONCOIMMUNOLOGY, V1, P699, DOI 10.4161/onci.20696; Garaude J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002868; Geisse J, 2004, J AM ACAD DERMATOL, V50, P722, DOI 10.1016/j.jaad.2003.11.066; Gibson SJ, 2002, CELL IMMUNOL, V218, P74, DOI 10.1016/S0008-8749(02)00517-8; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Goldszmid RS, 2012, NAT IMMUNOL, V13, P932, DOI 10.1038/ni.2422; Goutagny N, 2012, TARGET ONCOL, V7, P29, DOI 10.1007/s11523-012-0213-1; Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; Grivennikov SI, 2011, ANN RHEUM DIS, V70, pI104, DOI 10.1136/ard.2010.140145; Guha M, 2012, NAT REV DRUG DISCOV, V11, P503, DOI 10.1038/nrd3775; Hall MC, 2007, J UROLOGY, V178, P2314, DOI 10.1016/j.juro.2007.09.003; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hasan UA, 2007, P NATL ACAD SCI USA, V104, P8047, DOI 10.1073/pnas.0700664104; Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47; Heckelsmiller K, 2002, J IMMUNOL, V169, P3892, DOI 10.4049/jimmunol.169.7.3892; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hennessy EJ, 2010, NAT REV DRUG DISCOV, V9, P293, DOI 10.1038/nrd3203; Huang B, 2005, CANCER RES, V65, P5009, DOI 10.1158/0008-5472.CAN-05-0784; Huebener P, 2013, BBA-MOL BASIS DIS, V1832, P1005, DOI 10.1016/j.bbadis.2012.11.017; Isayama F, 2006, AM J PHYSIOL-GASTR L, V290, pG1318, DOI 10.1152/ajpgi.00405.2005; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Kadowaki N, 2001, J IMMUNOL, V166, P2291, DOI 10.4049/jimmunol.166.4.2291; Karin M, 2006, MOL CARCINOGEN, V45, P355, DOI 10.1002/mc.20217; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Kirkwood JM, 2012, CA-CANCER J CLIN, V62, P309, DOI 10.3322/caac.20132; Kolida S, 2011, ANNU REV FOOD SCI T, V2, P373, DOI 10.1146/annurev-food-022510-133739; Kortylewski M, 2009, NAT BIOTECHNOL, V27, P925, DOI 10.1038/nbt.1564; Krieg AM, 2008, ONCOGENE, V27, P161, DOI 10.1038/sj.onc.1210911; Krieg AM, 2007, J CLIN INVEST, V117, P1184, DOI 10.1172/JCI31414; Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059; Kroemer G, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23687; Kuraishy A, 2011, IMMUNITY, V35, P467, DOI 10.1016/j.immuni.2011.09.006; Kurt-Jones EA, 2004, J ENDOTOXIN RES, V10, P419, DOI 10.1179/096805104225006516; Kutikhin AG, 2011, HUM IMMUNOL, V72, P193, DOI 10.1016/j.humimm.2010.11.003; Lan T, 2007, P NATL ACAD SCI USA, V104, P13750, DOI 10.1073/pnas.0706059104; Le Leu RK, 2010, CARCINOGENESIS, V31, P246, DOI 10.1093/carcin/bgp197; Lee J, 2012, CELL, V151, P547, DOI 10.1016/j.cell.2012.09.034; Li Y, 2014, ONCOGENE, V33, P369, DOI 10.1038/onc.2012.581; Li YH, 2012, CARCINOGENESIS, V33, P1231, DOI 10.1093/carcin/bgs137; Lin H, 2013, HEPATOLOGY, V57, P171, DOI 10.1002/hep.25991; Lofgren JL, 2011, GASTROENTEROLOGY, V140, P210, DOI 10.1053/j.gastro.2010.09.048; Lohr JG, 2012, P NATL ACAD SCI USA, V109, P3879, DOI 10.1073/pnas.1121343109; Lotze MT, 2007, IMMUNOL REV, V220, P60, DOI 10.1111/j.1600-065X.2007.00579.x; Love WE, 2009, ARCH DERMATOL, V145, P1431, DOI 10.1001/archdermatol.2009.291; Lowe EL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013027; Macedo L, 2007, AM J PATHOL, V171, P1774, DOI 10.2353/ajpath.2007.061048; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Mantovani A, 2008, LANCET, V371, P771, DOI 10.1016/S0140-6736(08)60241-X; Merrell MA, 2006, MOL CANCER RES, V4, P437, DOI 10.1158/1541-7786.MCR-06-0007; Minmin Shi, 2011, PLoS One, V6, pe19466, DOI 10.1371/journal.pone.0019466; Mittal D, 2010, EMBO J, V29, P2242, DOI 10.1038/emboj.2010.94; MORALES A, 1976, J UROLOGY, V116, P180, DOI 10.1016/S0022-5347(17)58737-6; Naik E, 2011, J EXP MED, V208, P417, DOI 10.1084/jem.20110367; Naseemuddin M, 2012, INT J CANCER, V130, P765, DOI 10.1002/ijc.26100; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Neufert C, 2013, J CLIN INVEST, V123, P1428, DOI 10.1172/JCI63748; Newton K., 2012, COLD SPRING HARB PER, V4; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Nierkens S, 2011, CANCER RES, V71, P6428, DOI 10.1158/0008-5472.CAN-11-2154; Ochi A, 2012, J CLIN INVEST, V122, P4118, DOI 10.1172/JCI63606; Ochi A, 2012, J EXP MED, V209, P1671, DOI 10.1084/jem.20111706; Otte JM, 2003, GASTROENTEROLOGY, V124, P1866, DOI 10.1016/S0016-5085(03)00403-7; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Paik YH, 2003, HEPATOLOGY, V37, P1043, DOI 10.1053/jhep.2003.50182; Paik YH, 2006, LAB INVEST, V86, P676, DOI 10.1038/labinvest.3700422; Palucka K, 2012, NAT REV CANCER, V12, P265, DOI 10.1038/nrc3258; Pandey S, 2009, GYNECOL ONCOL, V114, P501, DOI 10.1016/j.ygyno.2009.05.032; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Peng GY, 2005, SCIENCE, V309, P1380, DOI 10.1126/science.1113401; Pfeffer LM, 1997, SEMIN ONCOL, V24, P963; Pierer M, 2004, J IMMUNOL, V172, P1256, DOI 10.4049/jimmunol.172.2.1256; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Rajpar SF, 2006, BRIT J DERMATOL, V155, P653, DOI 10.1111/j.1365-2133.2006.07476.x; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; REDDY BS, 1974, CANCER RES, V34, P2368; REDDY BS, 1978, J NATL CANCER I, V61, P1269, DOI 10.1093/jnci/61.5.1269; Ren T, 2007, CANCER BIOL THER, V6, P1704, DOI 10.4161/cbt.6.11.4826; Ren T, 2009, PATHOL ONCOL RES, V15, P623, DOI 10.1007/s12253-009-9162-0; Rhee SH, 2008, GASTROENTEROLOGY, V135, P518, DOI 10.1053/j.gastro.2008.04.022; Rigoli L, 2010, ANTICANCER RES, V30, P513; Rossignol DP, 2002, J ENDOTOXIN RES, V8, P483, DOI 10.1179/096805102125001127; Rowland IR, 1998, CARCINOGENESIS, V19, P281, DOI 10.1093/carcin/19.2.281; Sakurai T, 2008, CANCER CELL, V14, P156, DOI 10.1016/j.ccr.2008.06.016; Salcedo R, 2010, J EXP MED, V207, P1625, DOI 10.1084/jem.20100199; Schon MP, 2008, ONCOGENE, V27, P190, DOI 10.1038/sj.onc.1210913; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Seki E, 2005, HEPATOLOGY, V41, P443, DOI 10.1002/hep.20603; Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663; Sfondrini L, 2006, J IMMUNOL, V176, P6624, DOI 10.4049/jimmunol.176.11.6624; Sha T, 2007, EUR J PHARMACOL, V571, P231, DOI 10.1016/j.ejphar.2007.06.027; Shime H, 2012, P NATL ACAD SCI USA, V109, P2066, DOI 10.1073/pnas.1113099109; SIDKY YA, 1987, CANCER RES, V47, P5155; SIDKY YA, 1992, CANCER RES, V52, P3528; SJOGREN HO, 1969, NATURE, V221, P863, DOI 10.1038/221863a0; Smits ELJM, 2008, ONCOLOGIST, V13, P859, DOI 10.1634/theoncologist.2008-0097; Smyth EC, 2011, J CLIN ONCOL, V29, pE809, DOI 10.1200/JCO.2011.36.8829; So EY, 2010, INT J BIOL SCI, V6, P675; Srivastava K, 2010, LIVER INT, V30, P1067, DOI 10.1111/j.1478-3231.2010.02268.x; STARNES CO, 1992, NATURE, V357, P11, DOI 10.1038/357011a0; Stary G, 2007, J EXP MED, V204, P1441, DOI 10.1084/jem.20070021; Swann JB, 2008, P NATL ACAD SCI USA, V105, P652, DOI 10.1073/pnas.0708594105; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Treon SP, 2012, NEW ENGL J MED, V367, P826, DOI 10.1056/NEJMoa1200710; TRINCHIERI G, 1978, J EXP MED, V147, P1314, DOI 10.1084/jem.147.5.1314; Trinchieri G, 2012, ANNU REV IMMUNOL, V30, P677, DOI 10.1146/annurev-immunol-020711-075008; Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011; Tye H, 2012, CANCER CELL, V22, P466, DOI 10.1016/j.ccr.2012.08.010; Vacchelli E, 2012, ONCOIMMUNOLOGY, V1, P894, DOI 10.4161/onci.20931; Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324; Wald D, 2003, NAT IMMUNOL, V4, P920, DOI 10.1038/ni968; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang ZY, 2013, HEPATOLOGY, V57, P1869, DOI 10.1002/hep.26234; Watanabe A, 2007, HEPATOLOGY, V46, P1509, DOI 10.1002/hep.21867; West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421; Wolf G, 2006, J AM SOC NEPHROL, V17, P1585, DOI 10.1681/ASN.2005070699; Wolf IH, 2003, ARCH DERMATOL, V139, P273, DOI 10.1001/archderm.139.3.273; Xiao H, 2007, IMMUNITY, V26, P461, DOI 10.1016/j.immuni.2007.02.012; Yu LX, 2010, HEPATOLOGY, V52, P1322, DOI 10.1002/hep.23845; Yu P, 2012, IMMUNITY, V37, P867, DOI 10.1016/j.immuni.2012.07.018; Yusuf N, 2008, CANCER RES, V68, P615, DOI 10.1158/0008-5472.CAN-07-5219; ZBAR B, 1970, SCIENCE, V170, P1217, DOI 10.1126/science.170.3963.1217; ZBAR B, 1971, SCIENCE, V172, P271, DOI 10.1126/science.172.3980.271; Zhang HL, 2012, J HEPATOL, V57, P803, DOI 10.1016/j.jhep.2012.06.011	187	210	217	0	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3485	3495		10.1038/onc.2013.302	http://dx.doi.org/10.1038/onc.2013.302			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23934186	Green Accepted			2022-12-28	WOS:000338941100001
J	Ha, GH; Kim, JL; Petersson, A; Oh, S; Denning, MF; Patel, T; Breuer, EK				Ha, G-H; Kim, J-L; Petersson, A.; Oh, S.; Denning, M. F.; Patel, T.; Breuer, E-K			TACC3 deregulates the DNA damage response and confers sensitivity to radiation and PARP inhibition	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; ACIDIC COILED-COIL; HOMOLOGOUS RECOMBINATION REPAIR; GENE-EXPRESSION PROFILES; HISTONE H2AX; S-PHASE; IONIZING-RADIATION; HUMAN-CELLS; CHROMOSOMAL-ABERRATIONS; GENOME INSTABILITY	Deregulation of the transforming acidic coiled-coil protein 3 (TACC3), an important factor in the centrosome-microtubule system, has been linked to a variety of human cancer types. We have recently reported on the oncogenic potential of TACC3; however, the molecular mechanisms by which TACC3 mediates oncogenic function remain to be elucidated. In this study, we show that high levels of TACC3 lead to the accumulation of DNA double-strand breaks (DSBs) and disrupt the normal cellular response to DNA damage, at least in part, by negatively regulating the expression of ataxia telangiectasia mutated (ATM) and the subsequent DNA damage response (DDR) signaling cascade. Cells expressing high levels of TACC3 display defective checkpoints and DSB-mediated homologous recombination (HR) and non-homologous end joining (NHEJ) repair systems, leading to genomic instability. Importantly, high levels of TACC3 confer cellular sensitization to radiation and poly(ADP-ribose) polymerase (PARP) inhibition. Overall, our findings provide critical information regarding the mechanisms by which TACC3 contributes to genomic instability, potentially leading to cancer development, and suggest a novel prognostic, diagnostic and therapeutic strategy for the treatment of cancer types expressing high levels of TACC3.	[Ha, G-H; Kim, J-L; Petersson, A.; Denning, M. F.; Breuer, E-K] Loyola Univ, Stritch Sch Med, Cardinal Bernardin Canc Ctr, Inst Oncol, Maywood, IL 60153 USA; [Ha, G-H; Kim, J-L; Petersson, A.; Oh, S.; Breuer, E-K] Loyola Univ, Stritch Sch Med, Dept Radiat Oncol, Maywood, IL 60153 USA; [Denning, M. F.] Loyola Univ, Stritch Sch Med, Dept Pathol, Maywood, IL 60153 USA; [Patel, T.] Loyola Univ, Stritch Sch Med, Dept Mol Pharmacol & Therapeut, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; Loyola University Chicago	Breuer, EK (corresponding author), Loyola Univ, Stritch Sch Med, Dept Radiat Oncol, 2160 South First Ave, Maywood, IL 60153 USA.	eubreuer@luc.edu		Denning, Mitchell/0000-0001-6165-6925; Ha, Geun-Hyoung/0000-0002-9125-1934	Program Development Startup from Loyola University Chicago	Program Development Startup from Loyola University Chicago	This study was supported by the Program Development Startup from Loyola University Chicago.	Aguilera A, 2008, NAT REV GENET, V9, P204, DOI 10.1038/nrg2268; Albee AJ, 2008, MOL BIOL CELL, V19, P3347, DOI 10.1091/mbc.E07-11-1204; Antoni L, 2007, NAT REV CANCER, V7, P925, DOI 10.1038/nrc2251; Asaithamby A, 2009, NUCLEIC ACIDS RES, V37, P3912, DOI 10.1093/nar/gkp237; Ashworth A, 2008, J CLIN ONCOL, V26, P3785, DOI 10.1200/JCO.2008.16.0812; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bargo S, 2010, BIOCHEM BIOPH RES CO, V400, P606, DOI 10.1016/j.bbrc.2010.08.111; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Beck H, 2010, J CELL BIOL, V188, P629, DOI 10.1083/jcb.200905059; Berkovich E, 2003, ONCOGENE, V22, P161, DOI 10.1038/sj.onc.1206144; Beucher A, 2009, EMBO J, V28, P3413, DOI 10.1038/emboj.2009.276; Bignold LP, 2006, EXP SUPPL, V96, P1; Bonome T, 2008, CANCER RES, V68, P5478, DOI 10.1158/0008-5472.CAN-07-6595; Bugler B, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-29; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chanoux RA, 2009, J BIOL CHEM, V284, P5994, DOI 10.1074/jbc.M806739200; Craig AL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-195; D'Errico M, 2009, EUR J CANCER, V45, P461, DOI 10.1016/j.ejca.2008.10.032; Deckbar D, 2007, J CELL BIOL, V176, P749, DOI 10.1083/jcb.200612047; Dell H, 1999, J BIOL CHEM, V274, P9013, DOI 10.1074/jbc.274.13.9013; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; di Fagagna FD, 2004, GENE DEV, V18, P1781, DOI 10.1101/gad.1214504; Dodson GE, 2004, J BIOL CHEM, V279, P34010, DOI 10.1074/jbc.C400242200; Downs JA, 2007, NATURE, V447, P951, DOI 10.1038/nature05980; FAIRBAIRN DW, 1995, MUTAT RES-REV GENET, V339, P37, DOI 10.1016/0165-1110(94)00013-3; Fernet M, 2010, DNA REPAIR, V9, P48, DOI 10.1016/j.dnarep.2009.10.006; FRANKENBERG D, 1981, RADIAT RES, V88, P524, DOI 10.2307/3575641; Gangisetty O, 2004, ONCOGENE, V23, P2559, DOI 10.1038/sj.onc.1207424; Garriga-Canut M, 2004, J BIOL CHEM, V279, P23597, DOI 10.1074/jbc.M313987200; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Goodarzi AA, 2008, MOL CELL, V31, P167, DOI 10.1016/j.molcel.2008.05.017; Grutzmann R, 2004, NEOPLASIA, V6, P611, DOI 10.1593/neo.04295; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Ha GH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070353; Ha GH, 2013, CANCER LETT, V336, P24, DOI 10.1016/j.canlet.2013.04.022; Ha GH, 2013, CANCER LETT, V332, P63, DOI 10.1016/j.canlet.2013.01.013; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Hong Y, 2010, CLIN EXP METASTAS, V27, P83, DOI 10.1007/s10585-010-9305-4; Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312; Hu N, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-576; Hurov KE, 2010, GENE DEV, V24, P1939, DOI 10.1101/gad.1934210; Ismail IH, 2010, J CELL BIOL, V191, P45, DOI 10.1083/jcb.201003034; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Jeggo P, 2007, ONCOGENE, V26, P7717, DOI 10.1038/sj.onc.1210868; Jung CK, 2006, PATHOL INT, V56, P503, DOI 10.1111/j.1440-1827.2006.01998.x; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kiemeney LA, 2010, NAT GENET, V42, P415, DOI 10.1038/ng.558; Kinoshita K, 2005, J CELL BIOL, V170, P1047, DOI 10.1083/jcb.200503023; Kobayashi J, 2009, BIOCHEM BIOPH RES CO, V380, P752, DOI 10.1016/j.bbrc.2009.01.109; Kocher S, 2012, NUCLEIC ACIDS RES, V40, P8336, DOI 10.1093/nar/gks604; Lauffart B, 2003, GENOMICS, V81, P192, DOI 10.1016/S0888-7543(02)00039-3; Lauffart B, 2002, BIOCHEM J, V363, P195, DOI 10.1042/0264-6021:3630195; Lauffart B., 2007, CANC THERAPY, V5, P409; Lauffart Brenda, 2005, BMC Womens Health, V5, P8, DOI 10.1186/1472-6874-5-8; Lauffart B, 2007, J CELL COMMUN SIGNAL, V1, P5, DOI 10.1007/s12079-007-0001-3; Li WR, 2011, CANCER RES, V71, P4130, DOI 10.1158/0008-5472.CAN-10-2540; Lin SY, 2005, P NATL ACAD SCI USA, V102, P15105, DOI 10.1073/pnas.0507722102; Lio YC, 2004, J BIOL CHEM, V279, P42313, DOI 10.1074/jbc.M405212200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lowndes NF, 2005, CURR BIOL, V15, pR99, DOI 10.1016/j.cub.2005.01.029; Ma WJ, 2012, P NATL ACAD SCI USA, V109, P6590, DOI 10.1073/pnas.1118078109; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; McKeveney PJ, 2001, BRIT J HAEMATOL, V112, P1016, DOI 10.1046/j.1365-2141.2001.02644.x; McKinnon PJ, 2004, EMBO REP, V5, P772, DOI 10.1038/sj.embor.7400210; Mistrik M, 2009, CELL CYCLE, V8, P2592, DOI 10.4161/cc.8.16.9331; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Mostoslavsky R, 2006, CELL, V124, P315, DOI 10.1016/J.CEL.2005.11.044; Nakada S, 2006, J CLIN INVEST, V116, P80, DOI 10.1172/JCI25716; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; OBE G, 1992, MUTAGENESIS, V7, P3, DOI 10.1093/mutage/7.1.3; Pan MR, 2011, J BIOL CHEM, V286, P28599, DOI 10.1074/jbc.M111.256297; Partch CL, 2011, P NATL ACAD SCI USA, V108, P7739, DOI 10.1073/pnas.1101357108; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Peng G, 2009, NAT CELL BIOL, V11, P865, DOI 10.1038/ncb1895; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Rai R, 2006, CANCER CELL, V10, P145, DOI 10.1016/j.ccr.2006.07.002; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sadek CM, 2000, MECH DEVELOP, V97, P13, DOI 10.1016/S0925-4773(00)00415-9; Sadek CM, 2003, GENE EXPR PATTERNS, V3, P203, DOI 10.1016/S1567-133X(02)00066-2; Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375; Schneider L, 2007, J BIOL CHEM, V282, P29273, DOI 10.1074/jbc.M704151200; Schuendeln MM, 2004, MOL CELL BIOL, V24, P6403, DOI 10.1128/MCB.24.14.6403-6409.2004; Shanware NP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012173; Shibata A, 2011, EMBO J, V30, P1079, DOI 10.1038/emboj.2011.27; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; Singh D, 2012, SCIENCE, V337, P1231, DOI 10.1126/science.1220834; Sourisseau T, 2010, EMBO MOL MED, V2, P130, DOI 10.1002/emmm.201000068; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stewart JP, 2004, BRIT J HAEMATOL, V126, P72, DOI 10.1111/j.1365-2141.2004.04996.x; Still IH, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-16; Stroup D, 2000, J LIPID RES, V41, P1; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Ulisse S, 2007, ENDOCR-RELAT CANCER, V14, P827, DOI 10.1677/ERC-07-0053; van den Bosch M, 2003, EMBO REP, V4, P844, DOI 10.1038/sj.embor.embor925; Vettaikkorumakankauv A., 2008, CANC THERAPY, V6, P805; Wang HY, 2005, J CELL PHYSIOL, V202, P492, DOI 10.1002/jcp.20141; Wang HY, 2004, CANCER RES, V64, P7139, DOI 10.1158/0008-5472.CAN-04-1289; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200; Wu J, 2012, MOL CELL, V46, P351, DOI 10.1016/j.molcel.2012.02.018; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yim EK, 2009, ONCOL REP, V21, P549, DOI 10.3892/or_00000256; Yochum GS, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-102; Zhai Y, 2007, CANCER RES, V67, P10163, DOI 10.1158/0008-5472.CAN-07-2056; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	114	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1667	1678		10.1038/onc.2014.105	http://dx.doi.org/10.1038/onc.2014.105			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24769898				2022-12-28	WOS:000351848400007
J	Liu, Z; Zhan, Y; Tu, Y; Chen, K; Liu, Z; Wu, C				Liu, Z.; Zhan, Y.; Tu, Y.; Chen, K.; Liu, Z.; Wu, C.			PDZ and LIM domain protein 1(PDLIM1)/CLP36 promotes breast cancer cell migration, invasion and metastasis through interaction with alpha-actinin	ONCOGENE			English	Article							RHO-GTPASES; GENE AMPLIFICATION; STRESS FIBERS; ADHESION; CLP36; ALPHA-ACTININ-1; MOTILITY; ACTIVATION; EXPRESSION; MIGFILIN	Increased CLP36 expression has been found to be closely associated with breast cancer progression. However, whether and how it contributes to malignant behavior of breast cancer cells were not known. We show here that CLP36 is critical for promoting breast cancer cell migration and invasion in vitro and metastasis in vivo, whereas it is dispensable for breast cell proliferation and anchorage-independent growth in vitro and tumor growth in vivo. CLP36 interacted with both alpha-actinin-1 and -4 in breast cancer cells. Depletion of either alpha-actinin-1 or -4 inhibited breast cancer cell migration. Furthermore, mutations inhibiting the a-actinin-binding activity abolished the ability of CLP36 to promote breast cancer cell migration. Finally, depletion of CLP36 or disruption of the CLP36-alpha-actinin complex in breast cancer cells substantially inhibited Cdc42 activation, cell polarization and migration. Our results identify CLP36 as an important regulator of breast cancer cell migration and metastasis, and shed light on how increased CLP36 expression contributes to the progression of breast cancer.	[Liu, Z.; Tu, Y.; Chen, K.; Wu, C.] Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA 15261 USA; [Zhan, Y.; Liu, Z.] Chinese Acad Med Sci, Peking Union Med Coll, Canc Inst & Hosp, State Key Lab Mol Oncol, Beijing 100730, Peoples R China; [Wu, C.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wu, C (corresponding author), Univ Pittsburgh, Dept Pathol, Sch Med, 3550 Terrace St,707B Scaife Hall, Pittsburgh, PA 15261 USA.	carywu@pitt.edu			NIH [GM65188]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065188] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH Grant GM65188 to CW.	Bauer K, 2000, BLOOD, V96, P4236; Bouzahzah B, 2001, MOL MED, V7, P816, DOI 10.1007/BF03401974; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Etienne-Manneville S, 2004, J CELL SCI, V117, P1291, DOI 10.1242/jcs.01115; Fritz G, 2002, BRIT J CANCER, V87, P635, DOI 10.1038/sj.bjc.6600510; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Honda K, 2005, GASTROENTEROLOGY, V128, P51, DOI 10.1053/j.gastro.2004.10.004; Johnson E, 2010, J BIOL CHEM, V285, P29491, DOI 10.1074/jbc.M110.136770; Kikuchi S, 2008, CLIN CANCER RES, V14, P5348, DOI 10.1158/1078-0432.CCR-08-0075; Klaavuniemi T, 2004, J BIOL CHEM, V279, P26402, DOI 10.1074/jbc.M401871200; Liu ZM, 2011, J BIOL CHEM, V286, P30795, DOI 10.1074/jbc.M111.255984; Miyazaki K, 2012, EXP CELL RES, V318, P1716, DOI 10.1016/j.yexcr.2012.05.006; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Pichot CS, 2010, CANCER RES, V70, P8347, DOI 10.1158/0008-5472.CAN-09-4149; Pitteri SJ, 2011, CANCER RES, V71, P5090, DOI 10.1158/0008-5472.CAN-11-0568; Quick Q, 2010, EXP CELL RES, V316, P1137, DOI 10.1016/j.yexcr.2010.02.011; Shao H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013921; Shi XH, 2008, MOL CANCER RES, V6, P715, DOI 10.1158/1541-7786.MCR-07-2026; Shi XH, 2007, J BIOL CHEM, V282, P20455, DOI 10.1074/jbc.M611680200; Tamura N, 2007, BIOCHEM BIOPH RES CO, V364, P589, DOI 10.1016/j.bbrc.2007.10.064; Tu YZ, 2003, CELL, V113, P37, DOI 10.1016/S0092-8674(03)00163-6; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Uehara N, 2008, MOL CANCER RES, V6, P186, DOI 10.1158/1541-7786.MCR-07-0254; Vallenius T, 2004, EXP CELL RES, V293, P117, DOI 10.1016/j.yexcr.2003.09.004; Vallenius T, 2000, J BIOL CHEM, V275, P11100, DOI 10.1074/jbc.275.15.11100; Velthuis AJWT, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000189; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yamamoto S, 2009, MODERN PATHOL, V22, P499, DOI 10.1038/modpathol.2008.234; Zhang YJ, 2006, J BIOL CHEM, V281, P12397, DOI 10.1074/jbc.M512107200	30	31	33	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1300	1311		10.1038/onc.2014.64	http://dx.doi.org/10.1038/onc.2014.64			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24662836	Green Accepted			2022-12-28	WOS:000350687100010
J	Miyagawa, S; Sato, M; Sudo, T; Yamada, G; Iguchi, T				Miyagawa, S.; Sato, M.; Sudo, T.; Yamada, G.; Iguchi, T.			Unique roles of estrogen-dependent Pten control in epithelial cell homeostasis of mouse vagina	ONCOGENE			English	Article							GROWTH-FACTOR-I; NF-KAPPA-B; RECEPTOR-ALPHA; ENDOMETRIAL CANCER; UTERINE EPITHELIUM; SIGNALING PATHWAYS; MTOR INHIBITION; PTEN(+/-) MICE; ACTIVATION; DIETHYLSTILBESTROL	Numerous studies support a role of phosphatase and tensin homolog deleted from chromosome 10 (Pten) as a tumor suppressor gene that controls epithelial cell homeostasis to prevent tumor formation. Mouse vaginal epithelium cyclically exhibits cell proliferation and differentiation in response to estrogen and provides a unique model for analyzing homeostasis of stratified squamous epithelia. We analyzed vaginal epithelium-specific Pten conditional knockout (CKO) mice to provide new insights into Pten/phosphoinositide-3-kinase (PI3K)/Akt function. The vaginal epithelium of ovariectomized (OVX) mice ( control) was composed of 1-2 layers of cuboidal cells, whereas OVX CKO mice exhibited epithelial hyperplasia in the suprabasal cells with increased cell mass and mucin production. This is possibly due to misactivation of mammalian target of rapamycin and mitogen-activated protein kinase. Intriguingly, estrogen administration to OVX Pten CKO mice induced stratification and keratinized differentiation in the vaginal epithelium, as in estrogen-treated controls. We found that Pten is exclusively expressed in the suprabasal cells in the absence of estrogens, whereas estrogen administration induced Pten expression in the basal cells. This suggests that Pten acts to prevent excessive cell proliferation as in the case of other squamous tissues. Thus, Pten exhibits a dual role on the control of vaginal homeostasis, depending on whether estrogens are present or absent. Our results provide new insights into how Pten functions in tissue homeostasis.	[Miyagawa, S.; Sato, M.; Iguchi, T.] Grad Univ Adv Studies, Okazaki Inst Integrat Biosci, Natl Inst Basic Biol, Natl Inst Nat Sci, Okazaki, Aichi 4448787, Japan; [Miyagawa, S.; Sato, M.; Iguchi, T.] Grad Univ Adv Studies, Dept Basic Biol, Okazaki, Aichi 4448787, Japan; [Sudo, T.] Hyogo Canc Ctr, Sect Translat Res, Akashi, Hyogo, Japan; [Sudo, T.] Hyogo Canc Ctr, Dept Gynecol Oncol, Akashi, Hyogo, Japan; [Yamada, G.] Wakayama Med Univ, Inst Adv Med, Dept Dev Genet, Wakayama, Wakayama, Japan; [Yamada, G.] Wakayama Med Univ, Inst Adv Med, Lab Anim Ctr, Wakayama, Wakayama, Japan	Graduate University for Advanced Studies - Japan; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Okazaki Institute for Integrative Bioscience (OIIB); Graduate University for Advanced Studies - Japan; Hyogo Cancer Center; Hyogo Cancer Center; Wakayama Medical University; Wakayama Medical University	Iguchi, T (corresponding author), Grad Univ Adv Studies, Okazaki Inst Integrat Biosci, Natl Inst Basic Biol, Natl Inst Nat Sci, Okazaki, Aichi 4448787, Japan.	taisen@nibb.ac.jp	Iguchi, Taisen/AAL-4225-2021		Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Health, Labour and Welfare, Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan)	We thank Dr J Takeda, Osaka University, Suita, Japan, for providing K5-Cre mice. We also thank Dr Y Mikami, Kyoto University, Kyoto, Japan, and Dr Bruce Blumberg, University of California, Irvine, CA, USA, for their support. This study was supported by Grant-in-Aid for Young Scientists B, Grant-in-Aid for Scientific Research B from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and Health Sciences Research Grant from the Ministry of Health, Labour and Welfare, Japan.	Blanco Veronica, 2006, Med Oral Patol Oral Cir Bucal, V11, pE12; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Brake T, 2005, P NATL ACAD SCI USA, V102, P2490, DOI 10.1073/pnas.0409883102; Buckanan DL, 1998, ENDOCRINOLOGY, V139, P4345, DOI 10.1210/en.139.10.4345; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Cooke PS, 1997, P NATL ACAD SCI USA, V94, P6535, DOI 10.1073/pnas.94.12.6535; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; Ebrahim S, 2001, GYNECOL ONCOL, V80, P89, DOI 10.1006/gyno.2000.5963; GHAHARY A, 1990, MOL ENDOCRINOL, V4, P191, DOI 10.1210/mend-4-2-191; GIMENEZCONTI IB, 1994, DIFFERENTIATION, V56, P143, DOI 10.1007/s002580050031; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; Joshi A, 2012, AM J PATHOL, V180, P2536, DOI 10.1016/j.ajpath.2012.03.006; Joshi A, 2011, EXP CELL RES, V317, P1580, DOI 10.1016/j.yexcr.2011.03.006; Kim TH, 2010, ONCOGENE, V29, P3770, DOI 10.1038/onc.2010.126; Klotz DM, 2002, J BIOL CHEM, V277, P8531, DOI 10.1074/jbc.M109592200; Kurita T, 2004, DEVELOPMENT, V131, P4955, DOI 10.1242/dev.01384; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Leao JC, 2005, ORAL SURG ORAL MED O, V99, P569, DOI 10.1016/j.tripleo.2004.08.032; Lee HW, 2002, J BIOL CHEM, V277, P32624, DOI 10.1074/jbc.M200353200; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; McCluggage WG, 2001, INT J GYNECOL PATHOL, V20, P399, DOI 10.1097/00004347-200110000-00015; Memarzadeh S, 2010, P NATL ACAD SCI USA, V107, P17298, DOI 10.1073/pnas.1012548107; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Miyagawa S, 2004, J MOL ENDOCRINOL, V32, P663, DOI 10.1677/jme.0.0320663; Miyagawa S, 2004, ONCOGENE, V23, P340, DOI 10.1038/sj.onc.1207207; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Mudhar HS, 2001, INT J GYNECOL PATHOL, V20, P204, DOI 10.1097/00004347-200104000-00016; NELSON KG, 1994, CELL GROWTH DIFFER, V5, P595; NELSON KG, 1991, P NATL ACAD SCI USA, V88, P21, DOI 10.1073/pnas.88.1.21; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; OZAWA S, 1991, CANCER LETT, V58, P167, DOI 10.1016/0304-3835(91)90096-Z; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; PLATZ CE, 1995, CANCER, V75, P270, DOI 10.1002/1097-0142(19950101)75:1+<270::AID-CNCR2820751312>3.0.CO;2-D; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Segrelles C, 2006, ONCOGENE, V25, P1174, DOI 10.1038/sj.onc.1209155; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Squarize CH, 2008, CANCER RES, V68, P7066, DOI 10.1158/0008-5472.CAN-08-0922; Suzuki A, 2003, CANCER RES, V63, P674; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Vilgelm A, 2006, CANCER RES, V66, P3375, DOI 10.1158/0008-5472.CAN-05-4019; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yoo LI, 2006, CANCER RES, V66, P1929, DOI 10.1158/0008-5472.CAN-05-1986	45	8	9	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					1035	1043		10.1038/onc.2014.62	http://dx.doi.org/10.1038/onc.2014.62			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632614				2022-12-28	WOS:000350121300009
J	Heim, D; Cornils, K; Schulze, K; Fehse, B; Lohse, AW; Brummendorf, TH; Wege, H				Heim, D.; Cornils, K.; Schulze, K.; Fehse, B.; Lohse, A. W.; Bruemmendorf, T. H.; Wege, H.			Retroviral insertional mutagenesis in telomerase-immortalized hepatocytes identifies RIPK4 as novel tumor suppressor in human hepatocarcinogenesis	ONCOGENE			English	Article						Hepatocarcinogenesis; hepatocellular carcinoma; retroviral insertional mutagenesis; telomerase	NF-KAPPA-B; HEMATOPOIETIC STEM-CELLS; PRECANCEROUS HEPATIC NODULES; HUMAN FETAL HEPATOCYTES; HEPATOCELLULAR-CARCINOMA; GENE-TRANSFER; INDUCED APOPTOSIS; LIVER-CANCER; PLAG1; PROTEIN	Carcinogenesis is a multistep process involving alterations in various cellular pathways. The critical genetic events driving the evolution of primary liver cancer, specifically hepatoblastoma and hepatocellular carcinoma (HCC), are still poorly understood. However, telomere stabilization is acknowledged as prerequisite for cancer progression in humans. In this project, human fetal hepatocytes were utilized as a cell culture model for untransformed, proliferating human liver cells, with telomerase activation as first oncogenic hit. To elucidate critical downstream genetic events driving further transformation of immortalized liver cells, we used retroviral insertional mutagenesis as an unbiased approach to induce genetic alterations. Following isolation of hyperproliferating, provirus-bearing cell clones, we monitored cancer-associated growth properties and characterized changes toward a malignant phenotype. Three transformed clones with the ability to form colonies in soft agar were expanded. As proof-ofprinciple for our experimental setup, we identified a transforming insertion on chromosome 8 within the pleiomorphic adenoma gene 1 (PLAG1), resulting in a 20-fold increase in PLAG1 expression. Upregulation of PLAG1 has already been described to promote human hepatoblastoma development. In a separate clone, a transforming insertion was detected in close proximity to the receptorinteracting serine-threonine kinase 4 (RIPK4) with an approximately eightfold suppression in RIPK4 expression. As validation for this currently unknown driver in hepatocarcinogenesis, we examined RIPK4 expression in human HCC samples and confirmed a significant suppression of RIPK4 in 80% of the samples. Furthermore, overexpression of RIPK4 in transformed human fetal hepatocytes resulted in an almost complete elimination of anchorage-independent growth. On the basis of these data, we propose RIPK4 as a novel putative tumor suppressor in human hepatocarcinogenesis.	[Heim, D.; Schulze, K.; Lohse, A. W.; Wege, H.] Univ Med Ctr Hamburg Eppendorf, Dept Gastroenterol & Hepatol, D-20246 Hamburg, Germany; [Cornils, K.; Fehse, B.] Univ Med Ctr Hamburg Eppendorf, Clin Stem Cell Transplantat, Res Dept Cell & Gene Therapy, D-20246 Hamburg, Germany; [Bruemmendorf, T. H.] Rhein Westfal TH Aachen, Univ Med Ctr, Dept Hematol & Oncol, D-52062 Aachen, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; RWTH Aachen University; RWTH Aachen University Hospital	Heim, D (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Gastroenterol & Hepatol, Martinistr 52, D-20246 Hamburg, Germany.	dheim@uke.de	Fehse, Boris/A-8721-2012; Fehse, Boris/HIR-6019-2022	Fehse, Boris/0000-0001-9780-7211; 	Deutsche Forschungsgemeinschaft [SFB 841, C5, C7]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We acknowledge the valuable technical assistance provided by N Knuth, J Polke, P Zemke-Trautmann and the FACS Core Unit of the UMC Hamburg-Eppendorf. We are grateful for the financial support by the Deutsche Forschungsgemeinschaft (SFB 841, projects C5 and C7).	Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Altekruse SF, 2009, J CLIN ONCOL, V27, P1485, DOI 10.1200/JCO.2008.20.7753; Astrom AK, 2000, INT J ONCOL, V16, P1107; Baum C, 2003, BLOOD, V101, P2099, DOI 10.1182/blood-2002-07-2314; BRECHOT C, 1980, NATURE, V286, P533, DOI 10.1038/286533a0; Declercq J, 2005, CANCER RES, V65, P4544, DOI 10.1158/0008-5472.CAN-04-4041; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Gabriel R, 2009, NAT MED, V15, P1431, DOI 10.1038/nm.2057; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Greider CW, 1991, CURR OPIN CELL BIOL, V3, P444, DOI 10.1016/0955-0674(91)90072-7; Haker B, 2007, CANCER LETT, V256, P120, DOI 10.1016/j.canlet.2007.06.007; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; Hibbard MK, 2000, CANCER RES, V60, P4869; Hoshida Yujin, 2009, Expert Rev Gastroenterol Hepatol, V3, P101, DOI 10.1586/egh.09.5; Hytiroglou P, 1998, CANCER, V82, P1831, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1831::AID-CNCR4>3.0.CO;2-Q; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; Keng VW, 2009, NAT BIOTECHNOL, V27, P264, DOI 10.1038/nbt.1526; KERMOUNI A, 1995, GENOMICS, V29, P371, DOI 10.1006/geno.1995.9992; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim SW, 2008, BLOOD, V111, P1644, DOI 10.1182/blood-2007-05-088591; KING W, 1985, SCIENCE, V228, P554, DOI 10.1126/science.3838595; Kojima H, 1997, GASTROENTEROLOGY, V112, P493, DOI 10.1053/gast.1997.v112.pm9024303; Komine F, 2000, J HEPATOL, V32, P235, DOI 10.1016/S0168-8278(00)80068-9; Kuhlcke K, 2002, MOL THER, V5, P473, DOI 10.1006/mthe.2002.0566; Kustikova O, 2005, SCIENCE, V308, P1171, DOI 10.1126/science.1105063; Kustikova Olga S., 2008, V430, P255, DOI 10.1007/978-1-59745-182-6_18; Kustikova OS, 2003, BLOOD, V102, P3934, DOI 10.1182/blood-2003-05-1424; Landrette SF, 2005, BLOOD, V105, P2900, DOI 10.1182/blood-2004-09-3630; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Li ZX, 2002, SCIENCE, V296, P497, DOI 10.1126/science.1068893; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Meylan E, 2002, EMBO REP, V3, P1201, DOI 10.1093/embo-reports/kvf236; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; Modlich U, 2005, BLOOD, V105, P4235, DOI 10.1182/blood-2004-11-4535; Oh BK, 2005, AM J PATHOL, V166, P73, DOI 10.1016/S0002-9440(10)62233-X; Oh BK, 2003, J HEPATOL, V39, P786, DOI 10.1016/S0168-8278(03)00395-7; Ranzani M, 2013, NAT METHODS, V10, P155, DOI [10.1038/NMETH.2331, 10.1038/nmeth.2331]; Sawey ET, 2011, CANCER CELL, V19, P347, DOI 10.1016/j.ccr.2011.01.040; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Takaishi H, 2000, CANCER, V88, P312, DOI 10.1002/(SICI)1097-0142(20000115)88:2<312::AID-CNCR10>3.3.CO;2-I; Thorgeirsson SS, 2006, HEPATOLOGY, V43, pS145, DOI 10.1002/hep.21063; Trevisani F, 2008, CARCINOGENESIS, V29, P1299, DOI 10.1093/carcin/bgn113; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wahlers A, 2001, GENE THER, V8, P477, DOI 10.1038/sj.gt.3301426; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Weber K, 2008, MOL THER, V16, P698, DOI 10.1038/mt.2008.6; Wege H, 2003, GASTROENTEROLOGY, V124, P432, DOI 10.1053/gast.2003.50064; Wege H, 2011, MOL CANCER RES, V9, P1222, DOI 10.1158/1541-7786.MCR-10-0474; Zatkova A, 2004, GENE CHROMOSOME CANC, V39, P126, DOI 10.1002/gcc.10307	52	22	25	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					385	393		10.1038/onc.2013.551	http://dx.doi.org/10.1038/onc.2013.551			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24413083				2022-12-28	WOS:000348145500012
J	Stampolidis, P; Ullrich, A; Lacobelli, S				Stampolidis, P.; Ullrich, A.; lacobelli, S.			LGALS3BP, lectin galactoside-binding soluble 3 binding protein, promotes oncogenic cellular events impeded by antibody intervention	ONCOGENE			English	Article						LGALS3BP; cancer biomarker; extracellular matrix; integrin signalling; therapeutic target	TUMOR-ASSOCIATED ANTIGEN; EXTRACELLULAR-MATRIX; MAC-2-BINDING PROTEIN; LUNG-CARCINOMA; CANCER; 90K; ACTIVATION; EXPRESSION; INTEGRINS; MARKER	The extracellular matrix protein lectin galactoside-binding soluble 3 binding protein (LGALS3BP) constitutes a negative prognostic marker of cancer onset and progression with increasing value in clinical application. Since its discovery, however, although the glycoprotein has been implicated in a growing number of disease-related processes, its actual role and mechanism of action have remained ambiguous, thus hindering opportunities for therapeutic development. In this study, we have determined that LGALS3BP constitutes a novel ligand for integrins alpha(5)beta(1), alpha(v)beta(1) and alpha(6)beta(1) and have identified that these newly established partnerships at the membrane level are responsible for exerting the molecule's involvement in cancer through manipulation of multiple canonical 'outside-in' integrin signalling events. We demonstrate that LGALS3BP-mediated integrin activation results into signal transmission via Akt, JNK and the Ras cascade via the Raf-ERK axis while p38 activity is kept at baseline levels. Transient cellular adherence to LGALS3BP favours survival and proliferation signalling while apoptosis is kept at bay. Sustained cellular exposure to LGALS3BP significantly supports viability, motility and migration. Importantly, an anti-LGALS3BP antibody, SP2 is capable of impeding these newly defined LGALS3BP-driven processes without, however, compromising cell viability. These novel findings reveal the mechanism of action of LGALS3BP during cellular adherence and warrant its further validation as a potential pharmacological target for anticancer therapies.	[Stampolidis, P.; Ullrich, A.] Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany; [lacobelli, S.] MediaPharma Srl, Chieti, Italy	Max Planck Society	Stampolidis, P (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, Am Klopferspitz 18, D-82152 Bavaria, Germany.	stampoli@biochem.mpg.de						Awasthi N, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-12; Barczyk M, 2010, CELL TISSUE RES, V339, P269, DOI 10.1007/s00441-009-0834-6; Block AS, 2011, PROSTATE, V71, P711, DOI 10.1002/pros.21287; Bode AM, 2007, MOL CARCINOGEN, V46, P591, DOI 10.1002/mc.20348; CARLIN CR, 1983, EXP CELL RES, V147, P359, DOI 10.1016/0014-4827(83)90218-5; Cesinaro AM, 2002, J INVEST DERMATOL, V119, P187, DOI 10.1046/j.1523-1747.2002.17642.x; Dreskin SC, 2001, J IMMUNOL, V166, P5646, DOI 10.4049/jimmunol.166.9.5646; Eisenach PA, 2010, J CELL SCI, V123, P4182, DOI 10.1242/jcs.062711; Faccio R, 2002, J CELL SCI, V115, P2919; Fomarini B, 2000, BLOOD, V96, P3282, DOI 10.1182/blood.V96.9.3282.h8003282_3282_3285; Martinez VG, 2011, PHARMACOL REV, V63, P967, DOI 10.1124/pr.111.004523; Geiger B, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005033; Goodman SL, 2012, TRENDS PHARMACOL SCI, V33, P405, DOI 10.1016/j.tips.2012.04.002; Grassadonia A, 2002, GLYCOCONJUGATE J, V19, P551, DOI 10.1023/B:GLYC.0000014085.00706.d4; Han SW, 2006, CANCER RES, V66, P315, DOI 10.1158/0008-5472.CAN-05-2367; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Huxley-Jones J, 2008, DRUG DISCOV TODAY, V13, P685, DOI 10.1016/j.drudis.2008.05.005; Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009; IACOBELLI S, 1994, BRIT J CANCER, V69, P172, DOI 10.1038/bjc.1994.29; Jarvelainen H, 2009, PHARMACOL REV, V61, P198, DOI 10.1124/pr.109.001289; Kashyap MK, 2010, CANCER BIOL THER, V10, P796, DOI 10.4161/cbt.10.8.12914; Koopmann J, 2004, CANCER-AM CANCER SOC, V101, P1609, DOI 10.1002/cncr.20469; Lacovazzi PA, 2001, CLIN CHEM LAB MED, V39, P961; Lee YJ, 2007, CLIN EXP RHEUMATOL, V25, pS41; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Lu XJ, 2008, PERSPECT MED CHEM, V2, P57; Marchetti A, 2002, CANCER RES, V62, P2535; Mbeunkui F, 2009, CANCER CHEMOTH PHARM, V63, P571, DOI 10.1007/s00280-008-0881-9; Mould A. P., 2011, CURRENT PROTOCOLS CE; Mould A. Paul, 2009, V522, P195, DOI 10.1007/978-1-59745-413-1_13; NATOLI C, 1993, J ACQ IMMUN DEF SYND, V6, P370; Niland S, 2012, J ONCOL, V2012, DOI 10.1155/2012/125278; Ohshima S, 2003, ARTHRITIS RHEUM-US, V48, P2788, DOI 10.1002/art.11287; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Ozaki Y, 2002, CANCER, V95, P1954, DOI 10.1002/cncr.10899; Park YP, 2007, INT J CANCER, V120, P813, DOI 10.1002/ijc.22369; Pelliccia P, 1999, J CLIN IMMUNOL, V19, P143, DOI 10.1023/A:1020562702083; Piccolo E, 2013, J MOL MED, V91, P83, DOI 10.1007/s00109-012-0936-6; Ruegg C, 2003, CELL MOL LIFE SCI, V60, P1135, DOI 10.1007/s00018-003-2297-3; Sardana G, 2007, CLIN CHEM, V53, P429, DOI 10.1373/clinchem.2006.077370; Sasaki T, 1998, EMBO J, V17, P1606, DOI 10.1093/emboj/17.6.1606; SCAMBIA G, 1988, ANTICANCER RES, V8, P761; Snider JL, 2008, J BIOL CHEM, V283, P13952, DOI 10.1074/jbc.M800289200; Srirajaskanthan R, 2010, MOL CELL PROTEOMICS, V9, P656, DOI 10.1074/mcp.M900401-MCP200; ULLRICH A, 1994, J BIOL CHEM, V269, P18401; Ulmer TA, 2006, J CELL BIOCHEM, V98, P1351, DOI 10.1002/jcb.20784; Van Slambrouck S, 2009, INT J ONCOL, V34, P1717, DOI 10.3892/ijo_00000302; Xue H, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-52; Zhang Dong-Sheng, 2003, Ai Zheng, V22, P870; Zhang H, 2004, CANCER SCI, V95, P878, DOI 10.1111/j.1349-7006.2004.tb02197.x	51	39	42	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					39	52		10.1038/onc.2013.548	http://dx.doi.org/10.1038/onc.2013.548			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24362527				2022-12-28	WOS:000349740100004
J	Nagel, D; Vincendeau, M; Eitelhuber, AC; Krappmann, D				Nagel, D.; Vincendeau, M.; Eitelhuber, A. C.; Krappmann, D.			Mechanisms and consequences of constitutive NF-kappa B activation in B-cell lymphoid malignancies	ONCOGENE			English	Review						NF-kappa B signaling; Hodgkin's lymphoma; MALT lymphoma; DLBCL; multiple myeloma	EPSTEIN-BARR-VIRUS; REED-STERNBERG CELLS; API2-MALT1 FUSION ONCOPROTEIN; CLASSICAL HODGKIN LYMPHOMA; ONCOGENIC CARD11 MUTATIONS; SMALL-MOLECULE INHIBITORS; TUMOR-SUPPRESSOR GENE; MEMBRANE-PROTEIN 1; MULTIPLE-MYELOMA; HELICOBACTER-PYLORI	The discovery of constitutive nuclear factor-kappa B (NF-kappa B) activation in Hodgkin's lymphoma tumor cells almost two decades ago was one of the first reports that directly connected deregulated NF-kappa B signaling to human cancer. Subsequent studies demonstrated that enhanced NF-kappa B signaling is a common hallmark of many lymphoid malignancies, including Hodgkin lymphoma, mucosa-associated lymphoid tissue lymphoma, diffuse large B-cell lymphoma and multiple myeloma. By inducing an anti-apoptotic and pro-proliferative gene program, NF-kappa B is involved in lymphoma survival and growth. Identification of somatic mutations that led to activation of oncogenes and inactivation of tumor suppressor genes in the pathway revealed that specific pathogenic mechanisms are responsible for constitutive NF-kappa B activation in different lymphoma entities. Thus, the identification of distinct oncogenic events is reflecting the diverse cellular origins of the different lymphomas. Further, elucidation of the mechanisms that drive NF-kappa B in lymphoma is of high clinical relevance as it will allow the design of target-directed precision therapy. Indeed, a number of drugs that impair constitutive NF-kappa B activation in lymphoid malignancies are currently in preclinical or clinical development.	[Nagel, D.; Vincendeau, M.; Eitelhuber, A. C.; Krappmann, D.] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Mol Toxicol & Pharmacol, Res Unit Cellular Signal Integrat, D-85764 Neuherberg, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Krappmann, D (corresponding author), German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Mol Toxicol & Pharmacol, Res Unit Cellular Signal Integrat, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.	daniel.krappmann@helmholtz-muenchen.de	Krappmann, Daniel/ABF-4038-2021; Vincendeau, Michelle/AAD-4320-2022; Krappmann, Daniel/AAT-4354-2021	Krappmann, Daniel/0000-0001-7640-3234; Krappmann, Daniel/0000-0001-7640-3234	Deutsche Krebshilfe; Wilhelm Sander Stiftung	Deutsche Krebshilfe(Deutsche Krebshilfe); Wilhelm Sander Stiftung	We apologize for incomplete citations due to space constraints. We acknowledge support from the Deutsche Krebshilfe and Wilhelm Sander Stiftung to DK.	Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Baens M, 2000, AM J PATHOL, V156, P1433, DOI 10.1016/S0002-9440(10)65012-2; Baens M, 2006, CANCER RES, V66, P5270, DOI 10.1158/0008-5472.CAN-05-4590; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Basak S, 2007, CELL, V128, P369, DOI 10.1016/j.cell.2006.12.033; Brauninger A, 2003, CANCER RES, V63, P1644; Calado DP, 2010, CANCER CELL, V18, P580, DOI 10.1016/j.ccr.2010.11.024; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Casola S, 2004, NAT IMMUNOL, V5, P317, DOI 10.1038/ni1036; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Conze DB, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000518; Coornaert B, 2008, NAT IMMUNOL, V9, P263, DOI 10.1038/ni1561; Copie-Bergman C, 2003, BLOOD, V101, P2756, DOI 10.1182/blood-2002-07-2215; Cormier F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059127; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Demchenko YN, 2010, BLOOD, V115, P3541, DOI 10.1182/blood-2009-09-243535; Du MQ, 2011, HISTOPATHOLOGY, V58, P26, DOI 10.1111/j.1365-2559.2010.03699.x; Eliopoulos AG, 2003, ONCOGENE, V22, P7557, DOI 10.1038/sj.onc.1207120; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Emmerich F, 2003, J PATHOL, V201, P413, DOI 10.1002/path.1454; Fabre C, 2012, CLIN CANCER RES, V18, P4669, DOI 10.1158/1078-0432.CCR-12-0779; Ferch U, 2009, J EXP MED, V206, P2313, DOI 10.1084/jem.20091167; Ferme C, 2007, NEW ENGL J MED, V357, P1916, DOI 10.1056/NEJMoa064601; Fontan L, 2012, CANCER CELL, V22, P812, DOI 10.1016/j.ccr.2012.11.003; Friedberg JW, 2010, BLOOD, V115, P2578, DOI 10.1182/blood-2009-08-236471; Fruehling S, 1997, VIROLOGY, V235, P241, DOI 10.1006/viro.1997.8690; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Garrison JB, 2009, ONCOGENE, V28, P1584, DOI 10.1038/onc.2009.17; Graham JP, 2010, IMMUNOL REV, V237, P226, DOI 10.1111/j.1600-065X.2010.00932.x; Hailfinger S, 2011, P NATL ACAD SCI USA, V108, P14596, DOI 10.1073/pnas.1105020108; Hailfinger S, 2009, P NATL ACAD SCI USA, V106, P19946, DOI 10.1073/pnas.0907511106; Harhaj EW, 2012, IMMUNOL REV, V246, P107, DOI 10.1111/j.1600-065X.2012.01100.x; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Hideshima T, 2006, CLIN CANCER RES, V12, P5887, DOI 10.1158/1078-0432.CCR-05-2501; Hinz M, 2002, J EXP MED, V196, P605, DOI 10.1084/jem.20020062; Ho L, 2005, BLOOD, V105, P2891, DOI 10.1182/blood-2004-06-2297; Hussell T, 1996, J PATHOL, V178, P122, DOI 10.1002/(SICI)1096-9896(199602)178:2<122::AID-PATH486>3.0.CO;2-D; Jeelall YS, 2012, J EXP MED, V209, P1907, DOI 10.1084/jem.20112744; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Jourdan M, 2007, BRIT J HAEMATOL, V138, P160, DOI 10.1111/j.1365-2141.2007.06629.x; Jungnickel B, 2000, J EXP MED, V191, P395, DOI 10.1084/jem.191.2.395; Kanarek N, 2012, IMMUNOL REV, V246, P77, DOI 10.1111/j.1600-065X.2012.01098.x; Kanzler H, 1996, J EXP MED, V184, P1495, DOI 10.1084/jem.184.4.1495; Kapatai G, 2007, J CLIN PATHOL, V60, P1342, DOI 10.1136/jcp.2007.050146; Kato M, 2009, NATURE, V459, P712, DOI 10.1038/nature07969; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; Kimm LR, 2007, GENE CHROMOSOME CANC, V46, P1090, DOI 10.1002/gcc.20495; Kingeter LM, 2010, CELL SIGNAL, V22, P9, DOI 10.1016/j.cellsig.2009.09.033; Kloo B, 2011, P NATL ACAD SCI USA, V108, P272, DOI 10.1073/pnas.1008969108; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; Kurosaki T, 2009, IMMUNOL REV, V228, P132, DOI 10.1111/j.1600-065X.2008.00748.x; Lake A, 2009, INT J CANCER, V125, P1334, DOI 10.1002/ijc.24502; Lam LT, 2008, BLOOD, V111, P3701, DOI 10.1182/blood-2007-09-111948; Lam LT, 2008, P NATL ACAD SCI USA, V105, P20798, DOI 10.1073/pnas.0806491106; Lam LT, 2005, CLIN CANCER RES, V11, P28; Lamason RL, 2010, BIOCHEMISTRY-US, V49, P8240, DOI 10.1021/bi101052d; Landgren O, 2009, BLOOD, V113, P5412, DOI 10.1182/blood-2008-12-194241; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Lenz G, 2008, P NATL ACAD SCI USA, V105, P13520, DOI 10.1073/pnas.0804295105; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; Li KX, 2013, BIOORG MED CHEM LETT, V23, P1238, DOI 10.1016/j.bmcl.2013.01.012; Li ZY, 2009, BLOOD, V114, P4158, DOI 10.1182/blood-2008-12-192583; Li ZW, 2008, CURR OPIN HEMATOL, V15, P391, DOI 10.1097/MOH.0b013e328302c7f4; Ling SCW, 2012, HAEMATOL-HEMATOL J, V97, P64, DOI 10.3324/haematol.2011.043331; Liu HX, 2002, GASTROENTEROLOGY, V122, P1286, DOI 10.1053/gast.2002.33047; Lohr JG, 2012, P NATL ACAD SCI USA, V109, P3879, DOI 10.1073/pnas.1121343109; Lucas PC, 2007, ONCOGENE, V26, P5643, DOI 10.1038/sj.onc.1210342; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Ma H, 2001, J IMMUNOL, V166, P1507, DOI 10.4049/jimmunol.166.3.1507; Mancao C, 2007, BLOOD, V110, P3715, DOI 10.1182/blood-2007-05-090142; Mandelbaum J, 2010, CANCER CELL, V18, P568, DOI 10.1016/j.ccr.2010.10.030; Mao Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060313; Marafioti T, 2000, BLOOD, V95, P1443, DOI 10.1182/blood.V95.4.1443.004k55_1443_1450; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Martin-Subero JI, 2006, BLOOD, V108, P401, DOI 10.1182/blood-2005-09-3843; Mathas S, 2005, BLOOD, V106, P4287, DOI 10.1182/blood-2004-09-3620; McAllister-Lucas LM, 2011, CLIN CANCER RES, V17, P6623, DOI 10.1158/1078-0432.CCR-11-0467; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; Moreau P, 2012, BLOOD, V120, P947, DOI 10.1182/blood-2012-04-403733; Moreaux J, 2005, BLOOD, V106, P1021, DOI 10.1182/blood-2004-11-4512; Mortier J, 2010, BIOORG MED CHEM LETT, V20, P4515, DOI 10.1016/j.bmcl.2010.06.027; Nagel D, 2012, CANCER CELL, V22, P825, DOI 10.1016/j.ccr.2012.11.002; Napetschnig J, 2013, ANNU REV BIOPHYS, V42, P443, DOI 10.1146/annurev-biophys-083012-130338; NAUMANN M, 1993, ONCOGENE, V8, P2275; Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394; Naylor TL, 2011, CANCER RES, V71, P2643, DOI 10.1158/0008-5472.CAN-10-2525; Ngo VN, 2006, NATURE, V441, P106, DOI 10.1038/nature04687; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Noels H, 2007, J BIOL CHEM, V282, P10180, DOI 10.1074/jbc.M611038200; Nogai H, 2013, BLOOD, V122, P2242, DOI 10.1182/blood-2013-06-508028; Nonaka M, 2005, ONCOGENE, V24, P3976, DOI 10.1038/sj.onc.1208564; O'Connor BP, 2004, J EXP MED, V199, P91, DOI 10.1084/jem.20031330; Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034; Ott G, 1997, CANCER RES, V57, P3944; Otto C, 2012, BRIT J HAEMATOL, V157, P702, DOI 10.1111/j.1365-2141.2012.09113.x; Pang MF, 2009, CELL MOL BIOL LETT, V14, P222, DOI 10.2478/s11658-008-0045-2; Pasqualucci L, 2011, NAT GENET, V43, P830, DOI 10.1038/ng.892; Pelzer C, 2013, NAT IMMUNOL, V14, P337, DOI 10.1038/ni.2540; Ramakrishnan P, 2004, IMMUNITY, V21, P477, DOI 10.1016/j.immuni.2004.08.009; Ranuncolo SM, 2012, BLOOD, V120, P3756, DOI 10.1182/blood-2012-01-405951; Rawlings DJ, 2006, NAT REV IMMUNOL, V6, P799, DOI 10.1038/nri1944; Re D, 2008, LEUKEMIA LYMPHOMA, V49, P362, DOI 10.1080/10428190701784722; Rebeaud F, 2008, NAT IMMUNOL, V9, P272, DOI 10.1038/ni1568; Rosebeck S, 2014, ONCOGENE, V33, P2520, DOI 10.1038/onc.2013.195; Rosebeck S, 2011, FUTURE ONCOL, V7, P613, DOI [10.2217/fon.11.35, 10.2217/FON.11.35]; Rosebeck S, 2011, SCIENCE, V331, P468, DOI 10.1126/science.1198946; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Rosenwald A, 2003, J EXP MED, V198, P851, DOI 10.1084/jem.20031074; Sanchez-Izquierdo D, 2003, BLOOD, V101, P4539, DOI 10.1182/blood-2002-10-3236; Savage KJ, 2003, BLOOD, V102, P3871, DOI 10.1182/blood-2003-06-1841; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; Schmidt A, 2010, GENE CHROMOSOME CANC, V49, P803, DOI 10.1002/gcc.20789; Schmitz R, 2009, ANNU REV PATHOL-MECH, V4, P151, DOI 10.1146/annurev.pathol.4.110807.092209; Schmitz R, 2009, J EXP MED, V206, P981, DOI 10.1084/jem.20090528; Schwering I, 2003, BLOOD, V101, P1505, DOI 10.1182/blood-2002-03-0839; Snow AL, 2012, J EXP MED, V209, P2247, DOI 10.1084/jem.20120831; Staal J, 2011, EMBO J, V30, P1742, DOI 10.1038/emboj.2011.85; Staudt LM, 2005, ADV IMMUNOL, V87, P163, DOI 10.1016/S0065-2776(05)87005-1; Streubel B, 2003, BLOOD, V101, P2335, DOI 10.1182/blood-2002-09-2963; Sun SC, 2011, CELL RES, V21, P71, DOI 10.1038/cr.2010.177; Thomas RK, 2004, BRIT J HAEMATOL, V126, P50, DOI 10.1111/j.1365-2141.2004.05000.x; Thome M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003004; Troen Gunhild, 2013, ISRN Oncol, V2013, P252318, DOI 10.1155/2013/252318; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; Uehata T, 2013, CELL, V153, P1036, DOI 10.1016/j.cell.2013.04.034; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Ushmorov A, 2006, BLOOD, V107, P2493, DOI 10.1182/blood-2005-09-3765; Vereecke L, 2009, TRENDS IMMUNOL, V30, P383, DOI 10.1016/j.it.2009.05.007; Vicente-Duenas C, 2012, P NATL ACAD SCI USA, V109, P10534, DOI 10.1073/pnas.1204127109; Weniger MA, 2007, GENE CHROMOSOME CANC, V46, P406, DOI 10.1002/gcc.20420; Wessendorf S, 2007, LEUKEMIA, V21, P2463, DOI 10.1038/sj.leu.2404919; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Wilson WH, 2012, 54 ASH ANN M EXP 8 1; Yang YB, 2012, CANCER CELL, V21, P723, DOI 10.1016/j.ccr.2012.05.024; Ye HT, 2003, BLOOD, V102, P1012, DOI 10.1182/blood-2002-11-3502; Ye HT, 2000, AM J PATHOL, V157, P1147, DOI 10.1016/S0002-9440(10)64630-5; Zhang J, 2013, P NATL ACAD SCI USA, V110, P1398, DOI 10.1073/pnas.1205299110	149	77	84	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2014	33	50					5655	5665		10.1038/onc.2013.565	http://dx.doi.org/10.1038/onc.2013.565			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW2AB	24469030				2022-12-28	WOS:000346089300001
J	Yoshida, H; Miyachi, M; Sakamoto, K; Ouchi, K; Yagyu, S; Kikuchi, K; Kuwahara, Y; Tsuchiya, K; Imamura, T; Iehara, T; Kakazu, N; Hojo, H; Hosoi, H				Yoshida, H.; Miyachi, M.; Sakamoto, K.; Ouchi, K.; Yagyu, S.; Kikuchi, K.; Kuwahara, Y.; Tsuchiya, K.; Imamura, T.; Iehara, T.; Kakazu, N.; Hojo, H.; Hosoi, H.			PAX3-NCOA2 fusion gene has a dual role in promoting the proliferation and inhibiting the myogenic differentiation of rhabdomyosarcoma cells	ONCOGENE			English	Article						rhabdomyosarcoma; PAX3-NCOA2; PAX3-FOXO1A; tumorigenesis; inhibiting differentiation	STEROID-RECEPTOR COACTIVATOR; NUCLEAR-RECEPTOR; ALVEOLAR RHABDOMYOSARCOMA; LXXLL MOTIF; EMBRYONAL RHABDOMYOSARCOMA; TRANSCRIPTIONAL ACTIVITY; PAX3-FKHR; BINDING; PAX; DOMAIN	We analyzed a complex chromosomal translocation in a case of embryonal rhabdomyosarcoma (RMS) and showed that it generates the fusion gene PAX3 (paired box 3)-NCOA2 (nuclear receptor coactivator 2). To understand the role of this translocation in RMS tumorigenesis, we established two types of stable mouse myoblast C2C12 cell lines expressing PAX3-NCOA2 and PAX3-FOXO1A (forkhead box O1A), respectively. Compared with control cells, PAX3-NCOA2 cells grew faster, were more motile, were less anchorage dependent, progressed more quickly through the G1/S phase of cell cycle and showed greater transcriptional activation of the PAX3 consensus-binding site. However, PAX3-NCOA2 cells proliferated more slowly and differentiated more weakly than did PAX3-FOXO1A cells. Both PAX3-NCOA2 cells and PAX3-FOXO1A cells formed tumors in nude mice, although the PAX3-NCOA2-induced tumors grew more slowly. Our results may explain why NCOA2 rearrangement is mainly found in embryonal rhabdomyosarcoma, which has a better prognosis than alveolar rhabdomyosarcoma, which expresses the PAX3-FOXO1A fusion gene. These results indicate that the PAX3-NCOA2 fusion gene has a dual role in the tumorigenesis of RMS: promotion of the proliferation and inhibition of the myogenic differentiation of RMS cells.	[Yoshida, H.; Miyachi, M.; Sakamoto, K.; Ouchi, K.; Yagyu, S.; Kikuchi, K.; Kuwahara, Y.; Tsuchiya, K.; Imamura, T.; Iehara, T.; Hosoi, H.] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pediat, Kyoto 6028566, Japan; [Kakazu, N.] Shimane Univ, Dept Environm & Prevent Med, Sch Med, Matsue, Shimane, Japan; [Hojo, H.] Fukushima Med Univ, Sch Med, Dept Pathol 1, Fukushima, Japan	Kyoto Prefectural University of Medicine; Shimane University; Fukushima Medical University	Hosoi, H (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pediat, Kamigyo Ku, Kajii Cho Hirokoji, Kyoto 6028566, Japan.	hhosoi@koto.kpu-m.ac.jp	Yagyu, Shigeki/H-9070-2019; Kikuchi, Ken/ABG-8290-2020	Yagyu, Shigeki/0000-0003-4256-9783; Kikuchi, Ken/0000-0003-3097-7480; Miyachi, Mitsuru/0000-0003-4522-2478	Ministry of Education, Culture, Sports, Science and Technology of Japan [21249085, 25253095, 22390239, 22591166, 24791078]; Grants-in-Aid for Scientific Research [24659500] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Grant-in-aid for Scientific Research (A) 21249085, (A) 25253095, (B) 22390239, (C) 22591166, Grant-in-aid for Young Scientists (B) 24791078 and Grant-in-aid for Project for Development of Innovative Research on Cancer Therapeutics from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Anderson J, 2001, AM J PATHOL, V159, P1089, DOI 10.1016/S0002-9440(10)61784-1; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Calhabeu F, 2013, ONCOGENE, V32, P651, DOI 10.1038/onc.2012.73; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen SL, 2000, GENE DEV, V14, P1209; Deguchi K, 2003, CANCER CELL, V3, P259, DOI 10.1016/S1535-6108(03)00051-5; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Finckenstein FG, 2008, ONCOGENE, V27, P2004, DOI 10.1038/sj.onc.1210835; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Hamburger AW, 1978, CANCER RES, V38, P4118; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4946; Hosoi H, 2009, CANCER GENET CYTOGEN, V189, P98, DOI 10.1016/j.cancergencyto.2008.10.016; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; Jothi M, 2012, CELL CYCLE, V11, P895, DOI 10.4161/cc.11.5.19346; Kikuchi K, 2008, BIOCHEM BIOPH RES CO, V365, P568, DOI 10.1016/j.bbrc.2007.11.017; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Lee YH, 2005, P NATL ACAD SCI USA, V102, P3611, DOI 10.1073/pnas.0407159102; Litterst CM, 2002, J BIOL CHEM, V277, P36052, DOI 10.1074/jbc.M203556200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma H, 1999, MOL CELL BIOL, V19, P6164; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Mosquera JM, 2013, GENE CHROMOSOME CANC, V52, P538, DOI 10.1002/gcc.22050; Naini S, 2008, CANCER RES, V68, P9583, DOI 10.1158/0008-5472.CAN-07-6178; Nakae J, 2006, J CLIN INVEST, V116, P2473, DOI 10.1172/JCI25518; Parker D, 1999, MOL CELL BIOL, V19, P5601; Robson EJD, 2006, NAT REV CANCER, V6, P52, DOI 10.1038/nrc1778; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Sumegi J, 2010, GENE CHROMOSOME CANC, V49, P224, DOI 10.1002/gcc.20731; Teyssier C, 2002, J BIOL CHEM, V277, P46066, DOI 10.1074/jbc.M207623200; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TREMBLAY P, 1994, PHARMACOL THERAPEUT, V61, P205, DOI 10.1016/0163-7258(94)90063-9; Tsuchiya K, 2007, INT J ONCOL, V31, P41; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang W, 1998, CANCER RES, V58, P4426; Zhang YB, 2009, INT J CLIN EXP PATHO, V2, P370	41	15	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2014	33	49					5601	5608		10.1038/onc.2013.491	http://dx.doi.org/10.1038/onc.2013.491			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZW	24213582				2022-12-28	WOS:000346088700004
J	Ye, H; Zhang, C; Wang, BJ; Tan, XH; Zhang, WP; Teng, Y; Yang, X				Ye, H.; Zhang, C.; Wang, B-J; Tan, X-H; Zhang, W-P; Teng, Y.; Yang, X.			Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice	ONCOGENE			English	Article						hepatocellular carcinoma; Kras(G12D); HBx; mouse model; Cre-LoxP; transgenic mice	HEPATITIS-B-VIRUS; X-PROTEIN; UP-REGULATION; SIGNALING PATHWAY; RAS ONCOGENES; BETA-CATENIN; GENE; EXPRESSION; LIVER; HEPATOCARCINOGENESIS	Although the activation of Ras pathway is frequently observed in human hepatocellular carcinoma (HCC), the in vivo role of Ras activation in HCC initiation and progression is underdetermined. To test the consequence of Kras activation in hepatocyte, we generated a hepatocyte-specific Kras(G12D) transgenic mouse strain and observed spontaneous development of HCC in these mice. Remarkably, HBV X protein (HBx) expression significantly promotes the formation and malignant progression of Kras(G12D)-driven HCC as shown with the accelerated tumor onset, the increased tumor burden and the more poorly differentiated lesions. At the cellular level, concomitant expression of Kras(G12D) and HBx results in a robust increase in hepatocellular proliferation. We reveal that the Akt, MAPK, p53 and TGF-beta pathways are deregulated in the Kras(G12D)-driven HCCs. Also, the dysregulation is more pronounced in the HCCs developed in Kras(G12D) and HBx double transgenic mice. In addition, the altered expressions of beta-catenin, CD44 and E-cadherin are only observed in the Kras(G12D) and HBx double transgenic mice. These results demonstrate a crucial role of Ras activation in hepatocellular carcinogenesis and the functional synergy between Kras(G12D) and HBx in HCC initiation and progression. The novel genetic mouse models that closely recapitulate the histopathologic progression and molecular alterations of human HCC may potentially facilitate the future therapeutic studies.	[Ye, H.; Zhang, C.; Yang, X.] Shanghai Jiao Tong Univ, Sch Med, E Inst Shanghai Univ, Model Organism Div, Shanghai, Peoples R China; [Ye, H.; Zhang, C.; Wang, B-J; Tan, X-H; Teng, Y.; Yang, X.] Inst Biotechnol, Genet Lab Dev & Dis, State Key Lab Prote, Beijing 100071, Peoples R China; [Zhang, W-P] Second Mil Med Univ, Dept Pathophysiol, Shanghai, Peoples R China	Shanghai Jiao Tong University; Naval Medical University	Teng, Y (corresponding author), Inst Biotechnol, Genet Lab Dev & Dis, State Key Lab Prote, 20 Dongdajie, Beijing 100071, Peoples R China.	tengyan0919@163.com; yangx@bmi.ac.cn	XIAO, YANG/GPW-5529-2022	Yang, Xiao/0000-0002-0298-9831	National Natural Science Foundation of China [81272702, 31171249, 31071295, 81123001]; Chinese National Key Program on Basic Research [2011CB504202, 2012CB945103, 2011CB910601]; National High Technology Research and Development program of China [2012AA022402]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese National Key Program on Basic Research; National High Technology Research and Development program of China(National High Technology Research and Development Program of China)	This work was supported by National Natural Science Foundation of China (81272702; 31171249; 31071295; 81123001), Chinese National Key Program on Basic Research (2011CB504202; 2012CB945103; 2011CB910601) and National High Technology Research and Development program of China (2012AA022402). We thank Xiao-Yan Chang for histopathologic analysis, You-Liang Wang, Xiu-Bin Li, Xiao-Jie Xu, Qi-Long Ye and Xin Chen for technical support.	Arzumanyan A, 2013, NAT REV CANCER, V13, P123, DOI 10.1038/nrc3449; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Bock CT, 2008, INTERVIROLOGY, V51, P432, DOI 10.1159/000209672; Calvisi DF, 2006, GASTROENTEROLOGY, V130, P1117, DOI 10.1053/j.gastro.2006.01.006; Cha MY, 2004, HEPATOLOGY, V39, P1683, DOI 10.1002/hep.20245; Chappell WH, 2011, ONCOTARGET, V2, P135, DOI 10.18632/oncotarget.240; Colnot S, 2004, P NATL ACAD SCI USA, V101, P17216, DOI 10.1073/pnas.0404761101; Cui F, 2006, PROTEOMICS, V6, P498, DOI 10.1002/pmic.200500218; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Fan RH, 2011, J MOL HISTOL, V42, P473, DOI 10.1007/s10735-011-9353-3; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Harada N, 2004, CANCER RES, V64, P48, DOI 10.1158/0008-5472.CAN-03-2123; Hsieh A, 2011, CANCER LETT, V300, P162, DOI 10.1016/j.canlet.2010.09.018; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Keng VW, 2011, HEPATOLOGY, V53, P781, DOI 10.1002/hep.24091; Kim HR, 2010, FEBS LETT, V584, P525, DOI 10.1016/j.febslet.2009.11.091; Kim YC, 2001, ONCOGENE, V20, P16, DOI 10.1038/sj.onc.1203840; Lara-Pezzi E, 2001, HEPATOLOGY, V33, P1270, DOI 10.1053/jhep.2001.1270; Lee SG, 2000, ONCOGENE, V19, P468, DOI 10.1038/sj.onc.1203312; Lee YI, 2001, J BIOL CHEM, V276, P16969, DOI 10.1074/jbc.M011263200; Li Y, 2012, NAT REV GASTRO HEPAT, V9, P32, DOI 10.1038/nrgastro.2011.196; Liu J, 2006, ONCOGENE, V25, P1008, DOI 10.1038/sj.onc.1209138; Longato L, 2009, HEPATOLOGY, V49, P1935, DOI 10.1002/hep.22856; MacNee W, 2013, THORAX, V68, P738, DOI 10.1136/thoraxjnl-2012-202744; Miyoshi K, 2011, J INVEST DERMATOL, V131, P108, DOI 10.1038/jid.2010.255; Morris SM, 2012, HEPATOLOGY, V55, P121, DOI 10.1002/hep.24653; NISHIDA N, 1994, INT J ONCOL, V4, P615; O'Dell MR, 2012, CANCER RES, V72, P1557, DOI 10.1158/0008-5472.CAN-11-3596; Oishi N, 2007, CANCER SCI, V98, P1540, DOI 10.1111/j.1349-7006.2007.00579.x; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Schmitz KJ, 2008, J HEPATOL, V48, P83, DOI 10.1016/j.jhep.2007.08.018; Sun Q, 2007, CANCER BIOL THER, V6, P668, DOI 10.4161/cbt.6.5.3955; Sun Q, 2007, CANCER BIOL THER, V6, P1532, DOI 10.4161/cbt.6.10.4683; Tang H, 2006, CANCER SCI, V97, P977, DOI 10.1111/j.1349-7006.2006.00299.x; Tarn C, 2002, J VIROL, V76, P9763, DOI 10.1128/JVI.76.19.9763-9772.2002; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Tuveson DA, 2006, CANCER RES, V66, P242, DOI 10.1158/0008-5472.CAN-05-2305; Wang SN, 2012, EUR J CLIN INVEST, V42, P1295, DOI 10.1111/eci.12003; Wang YL, 2004, HEPATOLOGY, V39, P318, DOI 10.1002/hep.20076; Xia LM, 2012, J IMMUNOL, V188, P753, DOI 10.4049/jimmunol.1101652; Yang SF, 2007, J CLIN PATHOL, V60, P642, DOI 10.1136/jcp.2006.036970; Zhang XD, 2006, J LAB CLIN MED, V147, P58, DOI 10.1016/j.lab.2005.10.003	45	38	40	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2014	33	43					5133	5138		10.1038/onc.2013.468	http://dx.doi.org/10.1038/onc.2013.468			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OF	24213574				2022-12-28	WOS:000343768400008
J	Cichon, MA; Szentpetery, Z; Caley, MP; Papadakis, ES; Mackenzie, IC; Brennan, CH; O'Toole, EA				Cichon, M. A.; Szentpetery, Z.; Caley, M. P.; Papadakis, E. S.; Mackenzie, I. C.; Brennan, C. H.; O'Toole, E. A.			The receptor tyrosine kinase Axl regulates cell-cell adhesion and stemness in cutaneous squamous cell carcinoma	ONCOGENE			English	Article						adhesion; Axl; cancer stem cell; chemotherapy resistance; epithelial-mesenchymal transition	EPITHELIAL-MESENCHYMAL TRANSITION; SIGNALING PATHWAY; GROWTH ARREST; UP-REGULATION; TUMOR-GROWTH; CANCER; CATENIN; RESISTANCE; IDENTIFICATION; INVOLVEMENT	Axl is a receptor tyrosine kinase (RTK) upregulated in various tumors including cutaneous squamous cell carcinoma (SCC). Axl expression correlates with poor prognosis and induction of epithelial-mesenchymal transition (EMT), hence we hypothesized that Axl is involved in the disruption of cell-cell adhesion to allow invasion and chemotherapy resistance of the cancer stem cell population. Cutaneous SCC cell lines with stable knockdown of Axl were generated using retroviral vectors. Axl depletion altered expression of intercellular junction molecules increasing cell-cell adhesion with downregulation of Wnt and TGF beta R signaling. Furthermore, Axl expression correlated with the expression of putative cancer stem cell markers, CD44 and ALDH1, increased resistance to chemotherapy drugs, enhanced sphere formation ability and expression of EMT features by cancer stem cells. Axl depletion resulted in loss of tumor formation in an in vivo zebrafish xenograft model. In conclusion, these data suggest that abrogation of Axl results in loss of cancer stem cell properties indicating a role for Axl as a therapeutic target in chemotherapy-resistant cancer.	[Cichon, M. A.; Szentpetery, Z.; Caley, M. P.; Mackenzie, I. C.; O'Toole, E. A.] Queen Mary Univ London, Barts & London SMD, Ctr Cutaneous Res, Blizard Inst, London E1 2AT, England; [Papadakis, E. S.] Univ Southampton, Canc Res UK Ctr, Canc Sci Div, Southampton, Hants, England; [Brennan, C. H.] Queen Mary Univ London, Sch Biol & Chem Sci, London, England	University of London; Queen Mary University London; Cancer Research UK; University of Southampton; University of London; Queen Mary University London	O'Toole, EA (corresponding author), Queen Mary Univ London, Barts & London SMD, Ctr Cutaneous Res, Blizard Inst, 4 Newark St, London E1 2AT, England.	e.a.otoole@qmul.ac.uk		O'Toole, Edel/0000-0002-4084-4836	DAT PhD studentship from the Medical Research Council; MRC Centenary award (MAC); DEBRA Ireland; British Skin Foundation; National Centre for the Replacement [G1000053/1, NC/L00061X/1] Funding Source: researchfish	DAT PhD studentship from the Medical Research Council; MRC Centenary award (MAC); DEBRA Ireland; British Skin Foundation; National Centre for the Replacement	We are grateful to Carolyn Byrne for the luciferase reporter plasmids, Irene Leigh and Charlotte Proby for the MET1 and SCC IC1 cell lines and Vera Martins-Cabecos for scientific advice. We would like to acknowledge Alan Storey who was integral to the initiation of this project. This work was supported by a DAT PhD studentship from the Medical Research Council, a MRC Centenary award (MAC) and project grants from DEBRA Ireland and the British Skin Foundation awarded to EAOT.	Asiedu MK, 2014, ONCOGENE, V33, P1316, DOI 10.1038/onc.2013.57; Bauer T, 2012, J EXP MED, V209, P2033, DOI 10.1084/jem.20120493; Biddle A, 2012, CANCER METAST REV, V31, P285, DOI 10.1007/s10555-012-9345-0; Biddle A, 2011, CANCER RES, V71, P5317, DOI 10.1158/0008-5472.CAN-11-1059; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Chen YC, 2009, BIOCHEM BIOPH RES CO, V385, P307, DOI 10.1016/j.bbrc.2009.05.048; Chidgey M, 2007, BRIT J CANCER, V96, P1783, DOI 10.1038/sj.bjc.6603808; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; de Oliveira SS, 2005, FEBS LETT, V579, P6179, DOI 10.1016/j.febslet.2005.09.091; del Valle-Perez B, 2011, J CELL SCI, V124, P2298, DOI 10.1242/jcs.082693; Dontu G, 2005, J MAMMARY GLAND BIOL, V10, P75, DOI 10.1007/s10911-005-2542-5; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Garcia-Gras E, 2006, J CLIN INVEST, V116, P2012, DOI 10.1172/JCI27751; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; Green J, 2006, BRIT J CANCER, V94, P1446, DOI 10.1038/sj.bjc.6603135; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Harper LJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-166; Harris TJ, 2012, NAT REV MOL CELL BIO, V11, P502; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; Honoki K, 2010, ONCOL REP, V24, P501, DOI 10.3892/or_00000885; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862; Jacob ANK, 1999, CANCER DETECT PREV, V23, P325; Kobielak A, 2004, NAT REV MOL CELL BIO, V5, P614, DOI 10.1038/nrm1433; Lee CH, 2012, ANN SURG ONCOL, V19, pS500, DOI 10.1245/s10434-011-1985-8; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Li Y, 2009, ONCOGENE, V28, P3442, DOI 10.1038/onc.2009.212; Linger RM, 2010, EXPERT OPIN THER TAR, V14, P1073, DOI 10.1517/14728222.2010.515980; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martins VL, 2009, J CELL SCI, V122, P1788, DOI 10.1242/jcs.042895; McManus EJ, 2005, EMBO J, V24, P1571, DOI 10.1038/sj.emboj.7600633; Miwa N, 2001, ONCOL RES, V12, P469, DOI 10.3727/096504001108747477; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Palka HL, 1997, J CELL SCI, V110, P2359; Papadakis ES, 2011, J INVEST DERMATOL, V131, P509, DOI 10.1038/jid.2010.326; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Polette M, 2005, CANCER RES, V65, P7691, DOI 10.1158/0008-5472.CAN-04-4230; Proby CM, 2000, EXP DERMATOL, V9, P104, DOI 10.1034/j.1600-0625.2000.009002104.x; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rochlitz C, 1999, LEUKEMIA, V13, P1352, DOI 10.1038/sj.leu.2401484; Song X, 2010, CANCER, V117, P734; Stemmler MP, 2008, MOL BIOSYST, V4, P835, DOI 10.1039/b719215k; Takahashi-Yanaga F, 2007, J PHARMACOL SCI, V104, P293, DOI 10.1254/jphs.CR0070024; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Wang JB, 2004, CURR OPIN GENET DEV, V14, P533, DOI 10.1016/j.gde.2004.07.013; Westerfield M, 2001, ZEBRAFISH BOOK GUIDE, P1; Ye X, 2010, ONCOGENE, V29, P5254, DOI 10.1038/onc.2010.268; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	53	46	47	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2014	33	32					4185	4192		10.1038/onc.2013.388	http://dx.doi.org/10.1038/onc.2013.388			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YK	24056961				2022-12-28	WOS:000340595700009
J	Ming, M; Soltani, K; Shea, CR; Li, X; He, YY				Ming, M.; Soltani, K.; Shea, C. R.; Li, X.; He, Y. Y.			Dual role of SIRT1 in UVB-induced skin tumorigenesis	ONCOGENE			English	Article						SIRT1; UVB; skin tumorigenesis; DNA repair; apoptosis	DNA-DAMAGE RESPONSE; CELL-SURVIVAL; CALORIE RESTRICTION; MAMMALIAN SIRTUINS; CANCER; MICE; P53; DEACETYLASE; PROTEIN; REPAIR	The protein deacetylase SIRT1 regulates various pathways in metabolism, aging and cancer. However, the role of SIRT1 in skin cancer remains unclear. Here, using mice with targeted deletions of SIRT1 in their epidermis in both resistant B6 and sensitive SKH1 hairless backgrounds, we show that the role of SIRT1 in skin cancer development induced by ultraviolet B (UVB) radiation is dependent on its gene dose. Keratinocyte-specific heterozygous deletion of SIRT1 promotes UVB-induced skin tumorigenesis, whereas homozygous deletion of SIRT1 suppresses skin tumor development but sensitizes the B6 mice to chronic solar injury. In mouse skin, SIRT1 is haploinsufficient for UVB-induced DNA damage repair and expression of xeroderma pigmentosum C (XPC), a protein critical for repairing UVB-induced DNA damage. As compared with normal human skin, downregulation of SIRT1 is in parallel with downregulation of XPC in human cutaneous squamous cell carcinoma at both the protein and mRNA levels. In contrast, homozygous SIRT1 deletion in mouse skin augments p53 acetylation and expression of its transcriptional target Noxa, and sensitizes the epidermis to UVB-induced apoptosis in vivo, while heterozygous SIRT1 deletion has no such effect. The gene dosage-dependent function of SIRT1 in DNA repair and cell survival is consistent with the dual roles of SIRT1 in UVB-induced skin tumorigenesis. Our results reveal the gene dosage-dependent in vivo functions of SIRT1 in skin tumorigenesis and may shed light on the role of SIRT1 in epithelial cancer induced by DNA damage.	[Ming, M.; Soltani, K.; Shea, C. R.; He, Y. Y.] Univ Chicago, Dermatol Sect, Dept Med, Chicago, IL 60637 USA; [Li, X.] NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC USA	University of Chicago; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	He, YY (corresponding author), Univ Chicago, Dermatol Sect, Dept Med, Chicago, IL 60637 USA.	yyhe@medicine.bsd.uchicago.edu	Shea, Christopher R./AAJ-7143-2021; Li, Xiaoling/A-2994-2015	Li, Xiaoling/0000-0001-5920-7784	NIH/NIEHS [ES016936]; American Cancer Society (ACS) [RSG-13-078-01]; University of Chicago Cancer Research Center [P30 CA014599]; CTSA [NIH UL1RR024999]; University of Chicago Friends of Dermatology Endowment Fund; NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016936] Funding Source: NIH RePORTER	NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); American Cancer Society (ACS)(American Cancer Society); University of Chicago Cancer Research Center; CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); University of Chicago Friends of Dermatology Endowment Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by the NIH/NIEHS Grant ES016936 (to YYH), the American Cancer Society (ACS) Grant RSG-13-078-01 (to YYH), the University of Chicago Cancer Research Center (P30 CA014599), the CTSA (NIH UL1RR024999) and the University of Chicago Friends of Dermatology Endowment Fund. We thank Terri Li for Ki67 and TUNEL and XPC immunohistochemical analysis, and Dr Xiaobing Shi for kindly providing the WT and K382R mutant p53 plasmids.	Berg RJW, 1998, J INVEST DERMATOL, V110, P405, DOI 10.1111/j.1523-1747.1998.00173.x; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Boily G, 2009, ONCOGENE, V28, P2882, DOI 10.1038/onc.2009.147; Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910; Brooks CL, 2009, NAT REV CANCER, V9, P123, DOI 10.1038/nrc2562; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Cheo DL, 2000, CANCER RES, V60, P1580; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147; Fan W, MOL CELL, V39, P247; Fan W, 2010, MOL CELL, V39, P247, DOI 10.1016/j.molcel.2010.07.006; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Herranz D, 2013, ONCOGENE, V32, P4052, DOI 10.1038/onc.2012.407; Herranz D, 2010, NAT REV CANCER, V10, P819, DOI 10.1038/nrc2962; Herranz D, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1001; Hida Y, 2007, ARCH DERMATOL RES, V299, P103, DOI 10.1007/s00403-006-0725-6; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Itoh T, 2004, P NATL ACAD SCI USA, V101, P2052, DOI 10.1073/pnas.0306551101; Jeong J, 2007, EXP MOL MED, V39, P8, DOI 10.1038/emm.2007.2; Kamel C, 2006, AGING CELL, V5, P81, DOI 10.1111/j.1474-9726.2006.00191.x; Li HZ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1632; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Ming M, P NATL ACAD SCI US, V107, P22623; Ming M, 2010, P NATL ACAD SCI USA, V107, P22623, DOI 10.1073/pnas.1010377108; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Oka M, 2010, CARCINOGENESIS, V31, P1897, DOI 10.1093/carcin/bgq164; Powell MJ, 2011, CANCER RES, V71, P964, DOI 10.1158/0008-5472.CAN-10-3172; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Smith JS, 2002, TRENDS CELL BIOL, V12, P404, DOI 10.1016/S0962-8924(02)02342-5; Solomon JM, 2006, MOL CELL BIOL, V26, P28, DOI 10.1128/MCB.26.1.28-38.2006; Stuenkel Walter, 2007, Biotechnology Journal, V2, P1360, DOI 10.1002/biot.200700087; Sugasawa K, 2008, CARCINOGENESIS, V29, P455, DOI 10.1093/carcin/bgm282; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Wu CL, 2013, ONCOGENE, V32, P2682, DOI 10.1038/onc.2012.279; Yuan Z, 2007, CELL CYCLE, V6, P2869, DOI 10.4161/cc.6.23.5026; Yuan Z, 2007, MOL CELL, V27, P149, DOI 10.1016/j.molcel.2007.05.029	45	37	37	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					281	287		10.1038/onc.2013.583	http://dx.doi.org/10.1038/onc.2013.583			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24441046	Green Accepted			2022-12-28	WOS:000348145500002
J	Parrish, JK; Sechler, M; Winn, RA; Jedlicka, P				Parrish, J. K.; Sechler, M.; Winn, R. A.; Jedlicka, P.			The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma	ONCOGENE			English	Article						Ewing sarcoma; microRNA; epigenetics; histone demethylase	ONCOGENIC TRANSCRIPTION; CELL-LINES; EXPRESSION; CHROMATIN; DIFFERENTIATION; SENSITIVITY; MICRORNAS; EPIGENOME; THERAPY; HYPOXIA	Ewing Sarcoma is a biologically aggressive bone and soft tissue malignancy affecting children and young adults. Ewing Sarcoma pathogenesis is driven by EWS/Ets fusion oncoproteins, of which EWS/Fli1 is the most common. We have previously shown that microRNAs (miRs) regulated by EWS/Fli1 contribute to the pro-oncogenic program in Ewing Sarcoma. Here we show that miR-22, an EWS/Fli1-repressed miR, is inhibitory to Ewing Sarcoma clonogenic and anchorage-independent cell growth, even at modest overexpression levels. Our studies further identify the H3K9me1/2 histone demethylase KDM3A (JMJD1A/JHDM2A) as a new miR-22-regulated gene. We show that KDM3A is overexpressed in Ewing Sarcoma, and that its depletion inhibits clonogenic and anchorage-independent growth in multiple patient-derived cell lines, and tumorigenesis in a xenograft model. KDM3A depletion further results in augmentation of the levels of the repressive H3K9me2 histone mark, and downregulation of pro-oncogenic factors in Ewing Sarcoma. Together, our studies identify the histone demethylase KDM3A as a new, miR-regulated, tumor promoter in Ewing Sarcoma.	[Parrish, J. K.; Jedlicka, P.] Univ Colorado Denver, Dept Pathol, Aurora, CO 80045 USA; [Sechler, M.; Jedlicka, P.] Univ Colorado Denver, Canc Biol Grad Program, Aurora, CO 80045 USA; [Winn, R. A.] Univ Illinois, Dept Med, Chicago, IL USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Jedlicka, P (corresponding author), Univ Colorado Denver, Dept Pathol, Anschutz Med Campus,12800 E 19th Ave,MS 8104, Aurora, CO 80045 USA.	paul.jedlicka@ucdenver.edu			Boettcher Foundation's Webb-Waring Biomedical Research Program, Department of Defense Discovery Award [W81XWH-12-1-0296]; Alex's Lemonade Stand Foundation for Childhood Cancer; University of Colorado School of Medicine and Cancer Center; US Department of Veterans' Affairs;  [R01CA138528-2522717]; NATIONAL CANCER INSTITUTE [R01CA138528, P30CA046934] Funding Source: NIH RePORTER	Boettcher Foundation's Webb-Waring Biomedical Research Program, Department of Defense Discovery Award; Alex's Lemonade Stand Foundation for Childhood Cancer; University of Colorado School of Medicine and Cancer Center; US Department of Veterans' Affairs(US Department of Veterans Affairs); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Kathrin Bernt and Tobias Neff for advice on histone mark analysis, Steve Lessnick for retroviral packaging constructs, Heide Ford for critical reading of the manuscript, and the University of Colorado Cancer Center DNA Sequencing, Flow Cytometry, and Functional Genomics core facilities. This work was supported by the Boettcher Foundation's Webb-Waring Biomedical Research Program, Department of Defense Discovery Award (W81XWH-12-1-0296), Alex's Lemonade Stand Foundation for Childhood Cancer, and funds from the University of Colorado School of Medicine and Cancer Center (to PJ); and Merit Award from the US Department of Veterans' Affairs and R01CA138528-2522717 (to RAW).	Ban J, 2011, ONCOGENE, V30, P2173, DOI 10.1038/onc.2010.581; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Chen HB, 2010, CARCINOGENESIS, V31, P2136, DOI 10.1093/carcin/bgq197; Cho HS, 2012, INT J CANCER, V131, pE179, DOI 10.1002/ijc.26501; Cittelly DM, 2012, MOL CANCER THER, V11, P2556, DOI 10.1158/1535-7163.MCT-12-0463; Cloos PAC, 2008, GENE DEV, V22, P1115, DOI 10.1101/gad.1652908; De Vito C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023592; Douglas D, 2008, CANCER RES, V68, P6507, DOI 10.1158/0008-5472.CAN-07-6152; Erkizan HV, 2009, NAT MED, V15, P750, DOI 10.1038/nm.1983; Franzetti GA, 2013, ONCOGENE, V32, P3915, DOI 10.1038/onc.2012.403; Fukuma M, 2003, ONCOGENE, V22, P1, DOI 10.1038/sj.onc.1206055; Geutjes EJ, 2012, ONCOGENE, V31, P3827, DOI 10.1038/onc.2011.552; Ghildiyal M, 2009, NAT REV GENET, V10, P94, DOI 10.1038/nrg2504; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Grohar PJ, 2011, JNCI-J NATL CANCER I, V103, P962, DOI 10.1093/jnci/djr156; Gurtan AM, 2013, J MOL BIOL, V425, P3582, DOI 10.1016/j.jmb.2013.03.007; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Lawlor ER, 2012, CLIN CANCER RES, V18, P2768, DOI 10.1158/1078-0432.CCR-11-1921; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Li J, 2011, MOL CELL BIOCHEM, V357, P31, DOI 10.1007/s11010-011-0872-8; Li J, 2010, GYNECOL ONCOL, V119, P543, DOI 10.1016/j.ygyno.2010.08.034; Ludwig JA, 2008, CURR OPIN ONCOL, V20, P412, DOI 10.1097/CCO.0b013e328303ba1d; McKinsey EL, 2011, ONCOGENE, V30, P4910, DOI 10.1038/onc.2011.197; Mimura I, 2012, MOL CELL BIOL, V32, P3018, DOI 10.1128/MCB.06643-11; Nagaraja AK, 2010, MOL ENDOCRINOL, V24, P447, DOI 10.1210/me.2009-0295; Nakatani F, 2012, J PATHOL, V226, P796, DOI 10.1002/path.3007; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Patel JB, 2011, ONCOGENE, V30, P1290, DOI 10.1038/onc.2010.510; Patel M, 2012, GENOME RES, V22, P259, DOI 10.1101/gr.125666.111; Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106; Riggi N, 2005, CANCER RES, V65, P11459, DOI 10.1158/0008-5472.CAN-05-1696; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Ryan RJH, 2012, SCIENCE, V336, P1513, DOI 10.1126/science.1223730; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shirato H, 2009, J BIOL CHEM, V284, P733, DOI 10.1074/jbc.M804994200; Sotiropoulou G, 2009, RNA, V15, P1443, DOI 10.1261/rna.1534709; Ting Y, 2010, BIOCHEM BIOPH RES CO, V394, P606, DOI 10.1016/j.bbrc.2010.03.030; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Toomey EC, 2010, ONCOGENE, V29, P4504, DOI 10.1038/onc.2010.205; Wai DH, 2002, INT J ONCOL, V20, P441; Xiong J, 2010, ONCOGENE, V29, P4980, DOI 10.1038/onc.2010.241; Xiong JH, 2010, FEBS J, V277, P1684, DOI 10.1111/j.1742-4658.2010.07594.x; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027; Zhang J, 2010, BRIT J CANCER, V103, P1215, DOI 10.1038/sj.bjc.6605895; Zhang JH, 2012, NATURE, V481, P329, DOI 10.1038/nature10733	45	62	64	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					257	262		10.1038/onc.2013.541	http://dx.doi.org/10.1038/onc.2013.541			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24362521	Green Accepted			2022-12-28	WOS:000347790500013
J	Wan, C; Hou, S; Ni, R; Lv, L; Ding, Z; Huang, X; Hang, Q; He, S; Wang, Y; Cheng, C; Gu, XX; Xu, G; Shen, A				Wan, C.; Hou, S.; Ni, R.; Lv, L.; Ding, Z.; Huang, X.; Hang, Q.; He, S.; Wang, Y.; Cheng, C.; Gu, X. X.; Xu, G.; Shen, A.			MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability	ONCOGENE			English	Article						p27; hepatocellular carcinoma; cell cycle regulation; MIF4GD	DEPENDENT KINASE INHIBITOR; HISTONE MESSENGER-RNA; HEPATOCELLULAR-CARCINOMA; EXPRESSION; P27(KIP1); BINDING; PHOSPHORYLATION; CANCER; PROLIFERATION; TRANSLATION	The CDK inhibitor p27(kip1) plays crucial roles in cell cycle regulation and cancer progression. Through yeast two-hybrid screening, we identified MIF4G domain containing protein (MIF4GD) as a novel binding partner for p27. The association of MIF4GD and p27 was verified using immunoprecipitation and glutathione S-transferase (GST) pull-down assays. Interaction with MIF4GD led to the stabilization of p27 both in the nucleus and in the cytoplasm in hepatocellular carcinoma (HCC) cells as a result of suppressed phosphorylation of p27 by CDK2 at threonine187. Serum stimulation decreased the levels of MIF4GD and p27 simultaneously. In addition, MIF4GD overexpression resulted in increased p27 levels and reduced cell proliferation, while knockdown of MIF4GD promoted cell cycle progression with decreased p27 levels in cells. Furthermore, overexpression of MIF4GD reduced colony formation and inhibited xenograft tumor growth in nude mice. Finally, we found that both MIF4GD and p27 were expressed at low levels in HCC tissues compared to non-cancerous tissues, and that low expression levels of MIF4GD and p27 were associated with significantly worse prognosis in HCC patients. Our results suggest that MIF4GD is a potential regulator of p27-dependent cell proliferation in HCC. These findings provide a rational framework for the development of potential HCC therapy by targeting the MIF4GD-p27 interaction.	[Wan, C.; Xu, G.] Nantong Univ, Sch Publ Hlth, Nantong 226001, Peoples R China; [Hou, S.; Ni, R.; Lv, L.; Huang, X.] Nantong Univ, Dept Gastroenterol, Nantong 226001, Peoples R China; [Ding, Z.; Hang, Q.; He, S.; Wang, Y.; Cheng, C.; Gu, X. X.; Shen, A.] Nantong Univ, Dept Immunol, Nantong 226001, Peoples R China	Nantong University; Nantong University; Nantong University	Shen, A (corresponding author), Nantong Univ, Dept Immun, 19 Qixiu Rd, Nantong 226001, Peoples R China.	Shen_aiguo@yahoo.com	Hang, Qinglei/GOP-0218-2022	Hang, Qinglei/0000-0003-0419-6621; ni, runzhou/0000-0001-8187-185X	National Basic Research Program of China (973 Program) [2012CB822104, 2011CB910604]; National Natural Science Foundation of China [31070723, 31270802, 81272708, 81300720]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	We thank Professor Joel Belasco of New York University School of Medicine for the generous gift of pCL-6E1 and pCL-6E1. HSL constructs. This work was supported by Grants from National Basic Research Program of China (973 Program, No. 2012CB822104, and No. 2011CB910604), the National Natural Science Foundation of China (No. 31070723, No. 31270802, No. 81272708 and No. 81300720), and a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Andrisani OM, 2011, SEMIN CANCER BIOL, V21, P4, DOI 10.1016/j.semcancer.2010.09.002; Bansal N, 2013, BIOCHEMISTRY-US, V52, P520, DOI 10.1021/bi301074r; Cakmakci NG, 2008, MOL CELL BIOL, V28, P1182, DOI 10.1128/MCB.01500-07; Chen L, 2010, J KOREAN MED SCI, V25, P1438, DOI 10.3346/jkms.2010.25.10.1438; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Coleman WB, 2003, CURR MOL MED, V3, P573, DOI 10.2174/1566524033479546; De Vita F, 2012, CELL CYCLE, V11, P1583, DOI 10.4161/cc.20003; Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj.onc.1205434; Finn RS, 2010, CLIN CANCER RES, V16, P390, DOI 10.1158/1078-0432.CCR-09-2084; Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178; Gorgoni B, 2005, RNA, V11, P1030, DOI 10.1261/rna.7281305; Greenbaum LE, 2004, CANCER BIOL THER, V3, P1200, DOI 10.4161/cbt.3.12.1392; He G, 2006, BRIT J CANCER, V95, P1514, DOI 10.1038/sj.bjc.6603448; Huang XD, 2011, HUM PATHOL, V42, P507, DOI 10.1016/j.humpath.2010.04.021; Ke Q, 2009, EXP MOL PATHOL, V87, P167, DOI 10.1016/j.yexmp.2009.07.011; Lee J, 2009, EXP MOL MED, V41, P765, DOI 10.3858/emm.2009.41.11.102; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Matsuda Y, 2008, WORLD J GASTROENTERO, V14, P1734, DOI 10.3748/wjg.14.1734; Motti ML, 2004, CELL CYCLE, V3, P1074; Naka T, 1998, ANTICANCER RES, V18, P555; Nakamura S, 2008, LEUKEMIA RES, V32, P1358, DOI 10.1016/j.leukres.2008.02.012; Nan KJ, 2004, WORLD J GASTROENTERO, V10, P1425; Narita T, 2007, MOL CELL, V26, P349, DOI 10.1016/j.molcel.2007.04.011; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Perez-Luna M, 2012, NUCLEIC ACIDS RES, V40, P6520, DOI 10.1093/nar/gks343; Pietras EM, 2011, J CELL BIOL, V195, P709, DOI 10.1083/jcb.201102131; Pippa R, 2012, ONCOGENE, V31, P4207, DOI 10.1038/onc.2011.582; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Qin J, 2010, HEPATO-GASTROENTEROL, V57, P547; Qin LF, 2001, CANCER LETT, V172, P7, DOI 10.1016/S0304-3835(01)00701-7; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sullivan E, 2001, GENE DEV, V15, P173, DOI 10.1101/gad.862801; Tannapfel A, 2000, INT J CANCER, V89, P350, DOI 10.1002/1097-0215(20000720)89:4<350::AID-IJC6>3.0.CO;2-3; Thun MJ, 2010, CARCINOGENESIS, V31, P100, DOI 10.1093/carcin/bgp263; Vervoorts J, 2008, CELL MOL LIFE SCI, V65, P3255, DOI 10.1007/s00018-008-8296-7; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; Zhao XJ, 2004, J CELL SCI, V117, P6043, DOI 10.1242/jcs.01523; Zhao YH, 2013, HUM PATHOL, V44, P365, DOI 10.1016/j.humpath.2012.03.030; Zhou Q, 2003, WORLD J GASTROENTERO, V9, P2450	40	54	54	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					237	245		10.1038/onc.2013.536	http://dx.doi.org/10.1038/onc.2013.536			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24336329				2022-12-28	WOS:000347790500011
J	Chen, J; Weiss, WA				Chen, J.; Weiss, W. A.			Alternative splicing in cancer: implications for biology and therapy	ONCOGENE			English	Review						alternative splicing; aberrant splicing; p53; BARD1; AR	HUMAN ANDROGEN RECEPTOR; WILD-TYPE P53; PRE-MESSENGER-RNA; DOMAIN BARD1 GENE; TUMOR-SUPPRESSOR; PYRUVATE-KINASE; SOLUBLE-FAS; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; CELL SENESCENCE	Alternative splicing has critical roles in normal development and can promote growth and survival in cancer. Aberrant splicing, the production of noncanonical and cancer-specific mRNA transcripts, can lead to loss-of-function in tumor suppressors or activation of oncogenes and cancer pathways. Emerging data suggest that aberrant splicing products and loss of canonically spliced variants correlate with stage and progression in malignancy. Here, we review the splicing landscape of TP53, BARD1 and AR to illuminate roles for alternative splicing in cancer. We also examine the intersection between alternative splicing pathways and novel therapeutic approaches.	[Chen, J.] Univ Calif San Francisco, Biomed Sci Grad Program, San Francisco, CA 94158 USA; [Chen, J.; Weiss, W. A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA; [Weiss, W. A.] Univ Calif San Francisco, Dept Neurol Surg & Pediat, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Chen, J (corresponding author), Univ Calif San Francisco, Dept Neurol, Box 0520,1450 3rd St HD-220, San Francisco, CA 94158 USA.	justin.chen@ucsf.edu		Chen, Justin/0000-0002-1661-4547; Weiss, William/0000-0003-2230-9132	NIH [CA176287, CA82104, CA133091, CA102321, CA148699, CA159859, CA163155, CA081403]; Cure Search Foundation; Katie Dougherty Foundation; Pediatric Brain Tumor Foundation; St Baldricks Foundation; Samuel G Waxman Foundation; NATIONAL CANCER INSTITUTE [R01CA102321, R01CA133091, U01CA176287, R01CA082104, R01CA148699, U54CA163155, R01CA159859, P01CA081403] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cure Search Foundation; Katie Dougherty Foundation; Pediatric Brain Tumor Foundation; St Baldricks Foundation; Samuel G Waxman Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Clay Gustafson, Miller Huang and Erin Simonds for reviewing the manuscript. The Weiss lab is supported by NIH grants CA176287, CA82104, CA133091, CA102321, CA148699, CA159859, CA163155 and CA081403; and the Cure Search, Katie Dougherty, Pediatric Brain Tumor, St Baldricks and Samuel G Waxman Foundations.	Ahrens-Fath I, 2005, FEBS J, V272, P74, DOI 10.1111/j.1432-1033.2004.04395.x; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; Attard G, 2009, CANCER RES, V69, P4937, DOI 10.1158/0008-5472.CAN-08-4531; Avery-Kiejda KA, 2008, CLIN CANCER RES, V14, P1659, DOI 10.1158/1078-0432.CCR-07-1422; Babic I, 2013, CELL METAB, V17, P1000, DOI 10.1016/j.cmet.2013.04.013; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bonnal S, 2012, NAT REV DRUG DISCOV, V11, P847, DOI 10.1038/nrd3823; Bosse KR, 2012, CANCER RES, V72, P2068, DOI 10.1158/0008-5472.CAN-11-3703; Bouillet P, 2009, NAT REV IMMUNOL, V9, P514, DOI 10.1038/nri2570; Boukakis G, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-434; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bourdon JC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2811; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Brinkmann AO, 2001, MOL CELL ENDOCRINOL, V179, P105, DOI 10.1016/S0303-7207(01)00466-X; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Bruggenwirth HT, 1997, AM J HUM GENET, V61, P1067, DOI 10.1086/301605; Burge CB, 1999, RNA WORLD, P525; Candeias MM, 2006, ONCOGENE, V25, P6936, DOI 10.1038/sj.onc.1209996; Capasso M, 2013, CARCINOGENESIS, V34, P605, DOI 10.1093/carcin/bgs380; Capasso M, 2009, NAT GENET, V41, P718, DOI 10.1038/ng.374; Cappellari M, 2013, ONCOGENE, P1; CASCINO I, 1995, J IMMUNOL, V154, P2706; Chan SC, 2012, J BIOL CHEM, V287, P19736, DOI 10.1074/jbc.M112.352930; Chen J, 2009, GENE DEV, V23, P278, DOI 10.1101/gad.1761609; Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777; Chen P, 2007, J FIRE SCI, V25, P5, DOI 10.1177/0734904107062356; Cheng CH, 2006, MOL CELL BIOL, V26, P362, DOI 10.1128/MCB.26.1.362-370.2006; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; COCQUERELLE C, 1992, EMBO J, V11, P1095, DOI 10.1002/j.1460-2075.1992.tb05148.x; Corrionero A, 2011, GENE DEV, V25, P445, DOI 10.1101/gad.2014311; Coulter LR, 1997, MOL CELL BIOL, V17, P2143, DOI 10.1128/MCB.17.4.2143; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Crawford JB, 2006, MOL CELL BIOL, V26, P8791, DOI 10.1128/MCB.01677-06; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Dizin E, 2010, INT J BIOCHEM CELL B, V42, P693, DOI 10.1016/j.biocel.2009.12.025; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Ellis JD, 2012, MOL CELL, V46, P884, DOI 10.1016/j.molcel.2012.05.037; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fairbrother WG, 2004, NUCLEIC ACIDS RES, V32, pW187, DOI 10.1093/nar/gkh393; Fairbrother WG, 2002, SCIENCE, V297, P1007, DOI 10.1126/science.1073774; Fan LY, 2011, ACS CHEM BIOL, V6, P582, DOI 10.1021/cb100356k; Feki A, 2005, ONCOGENE, V24, P3726, DOI 10.1038/sj.onc.1208491; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Flaman JM, 1996, ONCOGENE, V12, P813; Folco EG, 2011, GENE DEV, V25, P440, DOI 10.1101/gad.2009411; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Furumai R, 2010, CANCER SCI, V101, P2483, DOI 10.1111/j.1349-7006.2010.01686.x; Ghigna C, 1998, CANCER RES, V58, P5818; Ghimenti C, 2002, GENE CHROMOSOME CANC, V33, P235, DOI 10.1002/gcc.1223; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Graveley BR, 2001, RNA, V7, P806, DOI 10.1017/S1355838201010317; Guo X, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-35; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Hafsi H, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-134; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hellwinkel OJC, 1999, J STEROID BIOCHEM, V68, P1, DOI 10.1016/S0960-0760(98)00157-5; Hellwinkel OJC, 2001, J CLIN ENDOCR METAB, V86, P2569, DOI 10.1210/jc.86.6.2569; Heyd F, 2011, TRENDS BIOCHEM SCI, V36, P397, DOI 10.1016/j.tibs.2011.04.003; Hofstetter G, 2010, ONCOGENE, V29, P1997, DOI 10.1038/onc.2009.482; Holmila R, 2003, Hum Mutat, V21, P101, DOI 10.1002/humu.9104; Hong X, 2006, MOL BIOL EVOL, V23, P2392, DOI 10.1093/molbev/msl111; Hu R, 2011, PROSTATE, V71, P1656, DOI 10.1002/pros.21382; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Hua YM, 2011, NATURE, V478, P123, DOI 10.1038/nature10485; Huggins C, 1941, CANCER RES, V1, P293; Hui LJ, 2004, ONCOGENE, V23, P3013, DOI 10.1038/sj.onc.1207362; Ikonen T, 1998, FEBS LETT, V430, P393, DOI 10.1016/S0014-5793(98)00701-7; Irminger-Finger I, 2006, NAT REV CANCER, V6, P382, DOI 10.1038/nrc1878; Irminger-Finger I, 2001, MOL CELL, V8, P1255, DOI 10.1016/S1097-2765(01)00406-3; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Jagla M, 2007, ENDOCRINOLOGY, V148, P4334, DOI 10.1210/en.2007-0446; Jefford CE, 2004, ONCOGENE, V23, P3509, DOI 10.1038/sj.onc.1207427; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Kaida D, 2007, NAT CHEM BIOL, V3, P576, DOI 10.1038/nchembio.2007.18; Kalsotra A, 2011, NAT REV GENET, V12, P715, DOI 10.1038/nrg3052; Karni R, 2008, P NATL ACAD SCI USA, V105, P15323, DOI 10.1073/pnas.0801376105; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Karppinen SM, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.020669; Keren H, 2010, NAT REV GENET, V11, P345, DOI 10.1038/nrg2776; Knudsen KE, 2009, CLIN CANCER RES, V15, P4792, DOI 10.1158/1078-0432.CCR-08-2660; Kondera-Anasz Z, 2005, APOPTOSIS, V10, P1143, DOI 10.1007/s10495-005-1018-9; Kotake Y, 2007, NAT CHEM BIOL, V3, P570, DOI 10.1038/nchembio.2007.16; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LeFave CV, 2011, EMBO J, V30, P4084, DOI 10.1038/emboj.2011.259; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li L, 2007, CANCER RES, V67, P11876, DOI 10.1158/0008-5472.CAN-07-2370; Li XL, 2005, CELL, V122, P365, DOI 10.1016/j.cell.2005.06.008; Libertini SJ, 2007, CANCER RES, V67, P9001, DOI 10.1158/0008-5472.CAN-07-1072; Lim J, 1997, MOL CELL ENDOCRINOL, V131, P205, DOI 10.1016/S0303-7207(97)00109-3; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Liu HX, 2000, MOL CELL BIOL, V20, P1063, DOI 10.1128/MCB.20.3.1063-1071.2000; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Liu JH, 2002, BLOOD, V100, P1449, DOI 10.1182/blood.V100.4.1449.h81602001449_1449_1453; Lorson CL, 2010, HUM MOL GENET, V19, pR111, DOI 10.1093/hmg/ddq147; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Marabese M, 2008, EUR J CANCER, V44, P131, DOI 10.1016/j.ejca.2007.10.011; Marcel V, 2010, ONCOGENE, V29, P2691, DOI 10.1038/onc.2010.26; Marcel V, 2010, FEBS LETT, V584, P4463, DOI 10.1016/j.febslet.2010.10.005; Marcias G, 2010, HUM MUTAT, V31, P74, DOI 10.1002/humu.21138; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MATLASHEWSKI G, 1987, ONCOGENE RES, V1, P77; Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; Mazurek S, 2005, SEMIN CANCER BIOL, V15, P300, DOI 10.1016/j.semcancer.2005.04.009; McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILLERWIDEMAN M, 1992, J ANTIBIOT, V45, P914, DOI 10.7164/antibiotics.45.914; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Nakajima H, 1996, J ANTIBIOT, V49, P1204; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Piekielko-Witkowska A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013690; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RISSTALPERS C, 1994, AM J HUM GENET, V54, P609; Ryser S, 2009, CANCER RES, V69, P1125, DOI 10.1158/0008-5472.CAN-08-2134; Sakai T, 2004, J ANTIBIOT, V57, P173, DOI 10.7164/antibiotics.57.173; Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shaffer PL, 2004, P NATL ACAD SCI USA, V101, P4758, DOI 10.1073/pnas.0401123101; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Sheen-Chen SM, 2003, WORLD J SURG, V27, P10, DOI 10.1007/s00268-002-6378-5; Sporn JC, 2011, CLIN CANCER RES, V17, P5451, DOI 10.1158/1078-0432.CCR-11-0263; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Takehara T, 2001, HEPATOLOGY, V34, P55, DOI 10.1053/jhep.2001.25387; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tang Y, 2013, ONCOGENE, V32, P2792, DOI 10.1038/onc.2012.288; Taplin ME, 2007, NAT CLIN PRACT ONCOL, V4, P236, DOI 10.1038/ncponc0765; Tepper CG, 2002, CANCER RES, V62, P6606; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Thorsen K, 2008, MOL CELL PROTEOMICS, V7, P1214, DOI 10.1074/mcp.M700590-MCP200; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Tsuzuki M, 2006, CANCER LETT, V233, P108, DOI 10.1016/j.canlet.2005.03.012; Venables JP, 2009, NAT STRUCT MOL BIOL, V16, P670, DOI 10.1038/nsmb.1608; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Wang K, 2011, NATURE, V469, P216, DOI 10.1038/nature09609; Wang Y, 2012, NAT STRUCT MOL BIOL, V19, P1044, DOI 10.1038/nsmb.2377; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Webb TR, 2013, DRUG DISCOV TODAY, V18, P43, DOI 10.1016/j.drudis.2012.07.013; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Wu JQ, 2010, P NATL ACAD SCI USA, V107, P5254, DOI 10.1073/pnas.0914114107; Wu JY, 2006, INT J CANCER, V118, P1215, DOI 10.1002/ijc.21428; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xerri L, 1996, BRIT J HAEMATOL, V92, P900, DOI 10.1046/j.1365-2141.1996.423958.x; Xu Q, 2003, NUCLEIC ACIDS RES, V31, P5635, DOI 10.1093/nar/gkg786; Yeo G, 2004, P NATL ACAD SCI USA, V101, P15700, DOI 10.1073/pnas.0404901101; Yeo GW, 2007, PLOS GENET, V3, P814, DOI 10.1371/journal.pgen.0030085; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Yoshida K, 2011, NATURE, V478, P64, DOI 10.1038/nature10496; Zhang XT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027970; Zhang YQ, 2012, BRIT J CANCER, V107, P675, DOI 10.1038/bjc.2012.297; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	175	180	189	0	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					1	14		10.1038/onc.2013.570	http://dx.doi.org/10.1038/onc.2013.570			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24441040				2022-12-28	WOS:000349740100001
J	DeCaprio, JA				DeCaprio, J. A.			Human papillomavirus type 16 E7 perturbs DREAM to promote cellular proliferation and mitotic gene expression	ONCOGENE			English	Editorial Material							CERVICAL-CANCER; TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR; PROTEIN; COMPLEX; DEGRADATION; PROGRESSION; BINDS	The study of the small DNA tumor viruses continues to provide valuable new insights into oncogenesis and fundamental biological processes. Although much has already been revealed about how the human papillomaviruses (HPVs) can transform cells and contribute to cervical and oropharyngeal cancer, there clearly is much more to learn. In this issue of Oncogene, Pang et al., doi: 10.1038/onc.2013.426, demonstrate that the high-risk HPV16 E7 oncogene can promote cellular proliferation by interacting with the DREAM (DP, RB-like, E2F and MuvB) complex at two distinct phases of the cell cycle. Consistent with earlier work, HPV16 E7 can bind to the retinoblastoma tumor suppressor (RB) family member p130 (RBL2) protein and promote its proteasome-mediated destruction thereby disrupting the DREAM complex and can prevent exit from the cell cycle into quiescence. In addition, they demonstrate that HPV16 E7 can bind to MuvB core complex in association with BMYB and FOXM1 and activate gene expression during the G2 and M phase of the cell cycle. Thus, HPV16 E7 acts to prevent exit from the cell cycle entry and promotes mitotic proliferation and may account for the high levels of FOXM1 often observed in poor-risk cervical cancers.	[DeCaprio, J. A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [DeCaprio, J. A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [DeCaprio, J. A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	DeCaprio, JA (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Mayer 440, Boston, MA 02215 USA.	james_decaprio@dfci.harvard.edu			NCI NIH HHS [R01 CA063113, P01 CA050661, R01 CA173023] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063113, R01CA173023, P01CA050661] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chan DW, 2008, J PATHOL, V215, P245, DOI 10.1002/path.2355; Fu Z, 2008, NAT CELL BIOL, V10, P1076, DOI 10.1038/ncb1767; He SY, 2012, GYNECOL ONCOL, V127, P601, DOI 10.1016/j.ygyno.2012.08.036; Huh K, 2007, J VIROL, V81, P9737, DOI 10.1128/JVI.00881-07; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Litovchick L, 2011, GENE DEV, V25, P801, DOI 10.1101/gad.2034211; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; Muller GA, 2012, NUCLEIC ACIDS RES, V40, P1561, DOI 10.1093/nar/gkr793; Osterloh L, 2007, EMBO J, V26, P144, DOI 10.1038/sj.emboj.7601478; Pang CL, 2014, ONCOGENE, V33, P4039, DOI 10.1038/onc.2013.426; Roman A, 2013, VIROLOGY, V445, P138, DOI 10.1016/j.virol.2013.04.013; Sadasivam S, 2013, NAT REV CANCER, V13, P585, DOI 10.1038/nrc3556; Schmit F, 2009, FEBS J, V276, P5703, DOI 10.1111/j.1742-4658.2009.07261.x; Shin MK, 2012, CANCER RES, V72, P5418, DOI 10.1158/0008-5472.CAN-12-2083; Zhang BY, 2006, P NATL ACAD SCI USA, V103, P437, DOI 10.1073/pnas.0510012103	15	25	25	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2014	33	31					4036	4038		10.1038/onc.2013.449	http://dx.doi.org/10.1038/onc.2013.449			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YG	24166507	Green Accepted			2022-12-28	WOS:000340595300002
J	He, T; Haapa-Paananen, S; Kaminskyy, VO; Kohonen, P; Fey, V; Zhivotovsky, B; Kallioniemi, O; Perala, M				He, T.; Haapa-Paananen, S.; Kaminskyy, V. O.; Kohonen, P.; Fey, V.; Zhivotovsky, B.; Kallioniemi, O.; Perala, M.			Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis	ONCOGENE			English	Article						doxorubicin; pyrimidine pathway; mitochondria; brequinar; DHODH; TRAIL	DEATH RECEPTORS; CASPASE-8 EXPRESSION; UP-REGULATION; C-FLIP; LIGAND; IDENTIFICATION; MODULATORS; COMPLEX; TARGETS; SODIUM	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising agent in selectively killing tumor cells. However, TRAIL monotherapy has not been successful as many cancer cells are resistant to TRAIL. Chemotherapeutic agents, such as doxorubicin have been shown to act synergistically with TRAIL, but the exact mechanisms of actions are poorly understood. In this study, we performed high-throughput small interfering RNA screening and genome-wide gene expression profiling on doxorubicin-treated U1690 cells to explore novel mechanisms underlying doxorubicin-TRAIL synergy. The screening and expression profiling results were integrated and dihydroorotate dehydrogenase (DHODH) was identified as a potential candidate. DHODH is the rate-limiting enzyme in the pyrimidine synthesis pathway, and its expression was downregulated by doxorubicin. We demonstrated that silencing of DHODH or inhibition of DHODH activity by brequinar dramatically increased the sensitivity of U1690 cells to TRAIL-induced apoptosis both in 2D and 3D cultures, and was accompanied by downregulation of c-FLIPL as well as by mitochondrial depolarization. In addition, uridine, an end product of the pyrimidine synthesis pathway was able to rescue the sensitization effects initiated by both brequinar and doxorubicin. Furthermore, several other cancer cell lines, LNCaP, MCF-7 and HT-29 were also shown to be sensitized to TRAIL by brequinar. Taken together, our findings have identified a novel protein target and its inhibitor, brequinar, as a potential agent in TRAIL-based combinatorial cancer therapy and highlighted for the first time the importance of mitochondrial DHODH enzyme and pyrimidine pathway in mediating TRAIL sensitization in cancer cells.	[He, T.; Haapa-Paananen, S.; Kohonen, P.; Fey, V.; Kallioniemi, O.; Perala, M.] VTT Tech Res Ctr Finland, FI-20521 Turku, Finland; [Kaminskyy, V. O.; Zhivotovsky, B.] Karolinska Inst, Inst Environm Med, Div Toxicol, S-10401 Stockholm, Sweden; [Kohonen, P.] Karolinska Inst, Inst Environm Med, Div Mol Toxicol, S-10401 Stockholm, Sweden; [Kallioniemi, O.] Univ Helsinki, FIMM Inst Mol Med Finland, Helsinki, Finland	VTT Technical Research Center Finland; Karolinska Institutet; Karolinska Institutet; University of Helsinki	He, T (corresponding author), VTT Tech Res Ctr Finland, Itainen Pitkakatu 4C,POB 106, FI-20521 Turku, Finland.	tao.he@vtt.fi	Kohonen, Pekka/F-9596-2011; Zhivotovsky, Boris/A-4346-2014; Kallioniemi, Olli P/H-5111-2011	Kohonen, Pekka/0000-0002-7845-3611; Zhivotovsky, Boris/0000-0002-2238-3482; Kallioniemi, Olli P/0000-0002-3231-0332; Kaminskyy, Vitaliy/0000-0002-8151-5270	EU-APOSYS [HEALTH-F4-2007-200767]; EU (CHEMORES) project; Swedish Research Foundation; Swedish Cancer Foundation; Swedish Childhood Cancer Foundation; Stockholm Cancer Foundation	EU-APOSYS(European CommissionEuropean Commission Joint Research Centre); EU (CHEMORES) project; Swedish Research Foundation; Swedish Cancer Foundation; Swedish Childhood Cancer Foundation(European Commission); Stockholm Cancer Foundation	We acknowledge Jouni Latoniitty and Rami Makela for robotic technical assistance, Ville Harma and Johannes Virtanen for advices and help in 3D experiments, Pirjo Kapyla for excellent technical support and Drs I Lavrik and P Krammer for antibodies. Finnish DNA Microarray Centre is acknowledged for performing TaqMan qRT-PCR and Illumina gene expression analysis. This work was supported by EU-APOSYS project (contract HEALTH-F4-2007-200767), EU (CHEMORES) project, the Swedish Research Foundation, the Swedish and Stockholm Cancer Foundations, and the Swedish Childhood Cancer Foundation.	Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; Baumann P, 2009, MOL CANCER THER, V8, P366, DOI 10.1158/1535-7163.MCT-08-0664; Booth NL, 2009, CANCER IMMUNOL IMMUN, V58, P1229, DOI 10.1007/s00262-008-0637-8; Cleaveland ES, 1996, BIOCHEM BIOPH RES CO, V223, P654, DOI 10.1006/bbrc.1996.0950; Coussens MJ, 2011, JOVE-J VIS EXP, DOI 10.3791/3305; CRAMER DV, 1995, PEDIATR NEPHROL, V9, pS52, DOI 10.1007/BF00867685; Evans ME, 2005, AM J PHYSIOL-GASTR L, V289, pG388, DOI 10.1152/ajpgi.00072.2005; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Finlay D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013375; Harma V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010431; Hopkins-Donaldson S, 2003, CELL DEATH DIFFER, V10, P356, DOI 10.1038/sj.cdd.4401157; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; Kaminskyy VO, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.51; Kaminskyy VO, 2011, CARCINOGENESIS, V32, P1450, DOI 10.1093/carcin/bgr135; Kawasumi M, 2007, J INVEST DERMATOL, V127, P1577, DOI 10.1038/sj.jid.5700853; Kisim A, 2012, J CANCER RES CLIN, V138, P1155, DOI 10.1007/s00432-012-1187-1; Kojima Y, 2011, J BIOL CHEM, V286, P43383, DOI 10.1074/jbc.M111.309377; Koschny R, 2007, J MOL MED, V85, P923, DOI 10.1007/s00109-007-0194-1; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lee SC, 2011, ANTICANCER RES, V31, P3385; Lee YJ, 2011, MOL MED REP, V4, P1255, DOI 10.3892/mmr.2011.558; Liu SP, 2000, STRUCT FOLD DES, V8, P25, DOI 10.1016/S0969-2126(00)00077-0; Loffler M, 2005, TRENDS MOL MED, V11, P430, DOI 10.1016/j.molmed.2005.07.003; Mahmood Z, 2010, EXP CELL RES, V316, P887, DOI 10.1016/j.yexcr.2009.12.011; MAROUN J, 1993, CANCER CHEMOTH PHARM, V32, P64, DOI 10.1007/BF00685878; Mellier G, 2010, MOL ASPECTS MED, V31, P93, DOI 10.1016/j.mam.2009.12.002; Merrill JE, 2009, J NEUROL, V256, P89, DOI 10.1007/s00415-009-0075-3; O'Donnell EF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040926; Ovcharenko D, 2007, CANCER RES, V67, P10782, DOI 10.1158/0008-5472.CAN-07-1484; Papenfuss K, 2008, J CELL MOL MED, V12, P2566, DOI 10.1111/j.1582-4934.2008.00514.x; PETERS GJ, 1990, BIOCHEM PHARMACOL, V39, P135, DOI 10.1016/0006-2952(90)90657-7; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Safa A. R., 2012, Experimental Oncology, V34, P176; Shawver LK, 1997, CLIN CANCER RES, V3, P1167; Shivapurkar N, 2002, ONCOGENE, V21, P8510, DOI 10.1038/sj.onc.1205941; Szliszka E, 2012, INT J ONCOL, V41, P818, DOI 10.3892/ijo.2012.1527; Tang XM, 2009, BIOL PHARM BULL, V32, P963, DOI 10.1248/bpb.32.963; Taylor DJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-470; Vaculova A, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-87; Vyas VK, 2011, MINI-REV MED CHEM, V11, P1039; White RM, 2011, NATURE, V471, P518, DOI 10.1038/nature09882; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yan SC, 2012, J CANCER RES CLIN, V138, P1279, DOI 10.1007/s00432-012-1204-4; Zhu H, 2012, INT J MOL MED, V30, P1087, DOI 10.3892/ijmm.2012.1105	46	26	27	2	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3538	3549		10.1038/onc.2013.313	http://dx.doi.org/10.1038/onc.2013.313			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	24013224				2022-12-28	WOS:000338941100006
J	Guo, Q; Su, N; Zhang, J; Li, X; Miao, Z; Wang, G; Cheng, M; Xu, H; Cao, L; Li, F				Guo, Q.; Su, N.; Zhang, J.; Li, X.; Miao, Z.; Wang, G.; Cheng, M.; Xu, H.; Cao, L.; Li, F.			PAK4 kinase-mediated SCG10 phosphorylation involved in gastric cancer metastasis	ONCOGENE			English	Article						PAK4; SCG10; phosphorylation; gastric cancer; metastasis	ANCHORAGE-INDEPENDENT GROWTH; NEURONAL GROWTH; CELL-MIGRATION; POOR-PROGNOSIS; STATHMIN; EXPRESSION; PROLIFERATION; INVASION; OVEREXPRESSION; MICROTUBULES	Superior cervical ganglia 10 (SCG10), as a microtubule (MT) destabilizer, maintains MT homeostasis and has a critical role in neuronal development, but its function in tumorigenesis has not been characterized. In the present study, we demonstrated that p21-activated kinase 4 (PAK4)-mediated SCG10 phosphorylation regulates MT homeostasis in metastatic gastric cancer. Our results indicate that SCG10 is a physiological substrate of PAK4, which is phosphorylated on serine 50 (Ser50) in a PAK4-dependent manner. Phosphorylated SCG10 regulated MT dynamics to promote gastric cancer cell migration and invasion in vitro and metastasis in a xenograft mouse models. Inhibiting PAK4, either by LCH-7749944 or RNA interference, resulted in the inhibition of Ser50 phosphorylation and a blockade to cell invasion, suggesting that PAK4-SCG10 signaling occurs in gastric cancer cell invasion. Moreover, we demonstrated a strong positive correlation between PAK4 and phospho-Ser50 SCG10 expression in gastric cancer samples. We also showed that high expression of SCG10 phospho-Ser50 is highly correlated to an aggressive phenotype of clinical gastric cancer. These findings revealed a novel function of SCG10 in promoting invasive potential of gastric cancer cells, suggesting that blocking PAK4-mediated SCG10 phosphorylation might be a potential therapeutic strategy for metastasis of gastric cancer.	[Guo, Q.; Su, N.; Zhang, J.; Li, X.; Wang, G.; Cao, L.; Li, F.] China Med Univ, Minist Publ Hlth, Key Lab Cell Biol, Dept Cell Biol, Shenyang 110001, Peoples R China; [Guo, Q.; Su, N.; Zhang, J.; Li, X.; Wang, G.; Cao, L.; Li, F.] China Med Univ, Minist Educ, Key Lab Med Cell Biol, Shenyang 110001, Peoples R China; [Miao, Z.; Xu, H.] China Med Univ, Hosp 1, Dept Surg Oncol & Gen Surg, Shenyang 110001, Peoples R China; [Cheng, M.] Shenyang Pharmaceut Univ, Minist Educ, Key Lab Struct Based Drug Design & Discovery, Shenyang, Peoples R China	China Medical University; China Medical University; China Medical University; Shenyang Pharmaceutical University	Li, F (corresponding author), China Med Univ, Minist Publ Hlth, Key Lab Cell Biol, Dept Cell Biol, 92 Beier Rd, Shenyang 110001, Peoples R China.	fli@mail.cmu.edu.cn		Li, Feng/0000-0001-5868-7456; Wang, Guiling/0000-0001-7304-1610	National Natural Science Foundation of China [90813038, 31171360, 81230077, 81130042]; Doctoral fund of Ministry of Education of China [20102104110016]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Doctoral fund of Ministry of Education of China(Ministry of Education, China)	We thank Yongxi Song, Jianhua Wu and Feng Zhao for their technical assistance with the animal experiments. We are grateful to Gary M Bokoch, Audrey Minden and Bruce Mayer for providing essential expression vectors. This work was supported by grants from the National Natural Science Foundation of China (Nos 90813038, 31171360, 81230077 and 81130042) and Doctoral fund of Ministry of Education of China (No. 20102104110016).	Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Ahmed T, 2008, CELL SIGNAL, V20, P1320, DOI 10.1016/j.cellsig.2008.02.021; Ahn HK, 2011, TRANSL ONCOL, V4, P345, DOI 10.1593/tlo.11145; Begum A, 2009, CANCER SCI, V100, P1908, DOI 10.1111/j.1349-7006.2009.01252.x; Belletti B, 2008, MOL BIOL CELL, V19, P2003, DOI 10.1091/mbc.E07-09-0894; Bieche I, 2003, GENOMICS, V81, P400, DOI 10.1016/S0888-7543(03)00031-4; Callow MG, 2005, J CELL SCI, V118, P1861, DOI 10.1242/jcs.02313; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Charbaut E, 2001, J BIOL CHEM, V276, P16146, DOI 10.1074/jbc.M010637200; Chen G, 2003, MOL CELL PROTEOMICS, V2, P107, DOI 10.1074/mcp.M200055-MCP200; Ghosh R, 2007, PROSTATE, V67, P1038, DOI 10.1002/pros.20601; Grenningloh G, 2004, J NEUROBIOL, V58, P60, DOI 10.1002/neu.10279; Jeon TY, 2010, BRIT J CANCER, V102, P710, DOI 10.1038/sj.bjc.6605537; Kim JH, 2008, TUMOR BIOL, V29, P41, DOI 10.1159/000132570; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Li N, 2011, P NATL ACAD SCI USA, V108, P12851, DOI 10.1073/pnas.1017372108; Li XF, 2005, J BIOL CHEM, V280, P41192, DOI 10.1074/jbc.M506884200; Li XD, 2010, INT J BIOCHEM CELL B, V42, P70, DOI 10.1016/j.biocel.2009.09.008; Li Y, 2012, BBA-MOL CELL RES, V1823, P465, DOI 10.1016/j.bbamcr.2011.11.013; Liu Y, 2010, ONCOGENE, V29, P5883, DOI 10.1038/onc.2010.329; Liu YY, 2008, MOL CANCER RES, V6, P1215, DOI 10.1158/1541-7786.MCR-08-0087; Mak GWY, 2011, CANCER RES, V71, P2949, DOI 10.1158/0008-5472.CAN-10-4046; MCCARTY KS, 1986, CANCER RES, V46, P4244; Mori N, 2002, J NEUROSCI RES, V70, P264, DOI 10.1002/jnr.10353; Palazzo Alexander F, 2002, Sci STKE, V2002, ppe31, DOI 10.1126/stke.2002.139.pe31; Paliouras GN, 2009, MOL CELL BIOL, V29, P3018, DOI 10.1128/MCB.01286-08; Paradis V, 2010, AM J PATHOL, V177, P1791, DOI 10.2353/ajpath.2010.100166; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Schaefer AW, 2002, J CELL BIOL, V158, P139, DOI 10.1083/jcb.200203038; Siu MKY, 2010, P NATL ACAD SCI USA, V107, P18622, DOI 10.1073/pnas.0907481107; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; Takahashi M, 2002, CANCER RES, V62, P6598; Tararuk T, 2006, J CELL BIOL, V173, P265, DOI 10.1083/jcb.200511055; Togano T, 2005, J NEUROSCI RES, V80, P475, DOI 10.1002/jnr.20462; Wells CM, 2010, J CELL SCI, V123, P1663, DOI 10.1242/jcs.055707; Wells CM, 2002, J CELL SCI, V115, P3947, DOI 10.1242/jcs.00080; Westerlund N, 2011, NAT NEUROSCI, V14, P305, DOI 10.1038/nn.2755; Whale AD, 2013, ONCOGENE, V32, P2114, DOI 10.1038/onc.2012.233; Zhang HQ, 2002, J CELL BIOL, V158, P1287, DOI 10.1083/jcb.200207008; Zhang HJ, 2011, CARCINOGENESIS, V32, P765, DOI 10.1093/carcin/bgr033; Zhang J, 2012, CANCER LETT, V317, P24, DOI 10.1016/j.canlet.2011.11.007	42	51	57	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3277	3287		10.1038/onc.2013.296	http://dx.doi.org/10.1038/onc.2013.296			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23893240				2022-12-28	WOS:000338443400007
J	Xu, Y; Swartz, KL; Siu, KT; Bhattacharyya, M; Minella, AC				Xu, Y.; Swartz, K. L.; Siu, K. T.; Bhattacharyya, M.; Minella, A. C.			Fbw7-dependent cyclin E regulation ensures terminal maturation of bone marrow erythroid cells by restraining oxidative metabolism	ONCOGENE			English	Article						cyclin E; Fbw7; erythropoiesis; reactive oxygen species; p53	TUMOR-SUPPRESSOR; TRANSCRIPTION FACTOR; HEMATOPOIETIC STEM; UBIQUITIN LIGASE; S-PHASE; EXPRESSION; DIFFERENTIATION; P53; PROMOTES; DAMAGE	The mechanisms that coordinate the final mitotic divisions of terminally differentiated bone marrow (BM) erythroid cells with components of their structural and functional maturation program remain largely undefined. We previously identified phenotypes resembling those found in early-stage myelodysplastic syndromes (MDS), including ineffective erythropoiesis, morphologic dysplasia and BM hyper-cellularity, in a knock-in mouse model in which cyclin E mutations were introduced at its two Cdc4 phosphodegrons (CPDs) to ablate Fbw7-dependent ubiquitination and degradation. Here, we have examined the physiologic consequences of cyclin E dysregulation in BM erythroid cells during terminal maturation in vivo. We found that cyclin E protein levels in BM erythroid cells are dynamically regulated in a CPD-dependent manner and that disruption of Fbw7-dependent cyclin E regulation impairs terminal erythroid cell maturation at a discrete stage before enucleation. At this stage of erythroid cell maturation, CPD phosphorylation of cyclin E regulates both cell-cycle arrest and survival. We also found that normal regulation of cyclin E restrains mitochondrial reactive oxygen species (ROS) accumulation and expression of genes that promote mitochondrial biogenesis and oxidative metabolism during terminal erythroid maturation. In the setting of dysregulated cyclin E expression, p53 is activated in BM erythroid cells as part of a DNA damage response-type pathway, which mitigates ineffective erythropoiesis, in contrast to the role of p53 induction in other models of dyserythropoiesis. Finally, cyclin E dysregulation and ROS accumulation induce histone H3 lysine 9 hyper-methylation and disrupt components of the normal terminal erythroid maturation gene expression program. Thus, ubiquitin-proteasome pathway control of G1-to-S-phase progression is intrinsically linked to regulation of metabolism and gene expression in terminally differentiating BM erythroid cells.	[Xu, Y.; Swartz, K. L.; Siu, K. T.; Bhattacharyya, M.; Minella, A. C.] Northwestern Univ, Dept Med, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA; [Swartz, K. L.; Siu, K. T.] Northwestern Univ, Driskill Grad Program Life Sci, Feinberg Sch Med, Chicago, IL 60611 USA; [Minella, A. C.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Minella, AC (corresponding author), Northwestern Univ, Dept Med, Div Hematol Oncol, Feinberg Sch Med, 303 East Super St,Lurie 5-115, Chicago, IL 60611 USA.	a-minella@northwestern.edu		Minella, Alex/0000-0001-6693-3362	NIH [R01HL098608]; Leukemia Research Foundation; Sidney Kimmel Foundation for Cancer Research; American Cancer Society; American Society of Hematology; NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL098608] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia Research Foundation; Sidney Kimmel Foundation for Cancer Research; American Cancer Society(American Cancer Society); American Society of Hematology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Dr Navdeep Chandel and Laura Sena (Northwestern University) for providing reagents as well as invaluable advice. We also thank Dr Amit Verma (Albert Einstein College of Medicine) for helpful discussions. This work was supported by NIH grant R01HL098608 and funding from the Leukemia Research Foundation, the Sidney Kimmel Foundation for Cancer Research, the American Cancer Society and the American Society of Hematology.	Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Balamurugan K, 2010, EMBO J, V29, P4106, DOI 10.1038/emboj.2010.280; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Blanchet E, 2011, NAT CELL BIOL, V13, P1146, DOI 10.1038/ncb2309; Chen K, 2009, P NATL ACAD SCI USA, V106, P17413, DOI 10.1073/pnas.0909296106; Dirlam A, 2007, MOL CELL BIOL, V27, P8713, DOI 10.1128/MCB.01118-07; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; Dutt S, 2011, BLOOD, V117, P2567, DOI 10.1182/blood-2010-07-295238; Figueroa ME, 2009, BLOOD, V114, P3448, DOI 10.1182/blood-2009-01-200519; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Ishikawa-Sekigami T, 2006, BLOOD, V107, P341, DOI 10.1182/blood-2005-05-1896; Jaako P, 2011, BLOOD, V118, P6087, DOI 10.1182/blood-2011-08-371963; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kang YA, 2012, MOL CELL BIOL, V32, P226, DOI 10.1128/MCB.06166-11; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Kinross KM, 2006, BLOOD, V108, P886, DOI 10.1182/blood-2005-09-008656; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kossatz U, 2010, J CLIN INVEST, V120, P3820, DOI 10.1172/JCI41959; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Leung CG, 2007, J EXP MED, V204, P1603, DOI 10.1084/jem.20062395; Li FX, 2003, MOL CELL BIOL, V23, P3607, DOI 10.1128/MCB.23.10.3607-3622.2003; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Mavrakis KJ, 2011, NAT GENET, V43, P673, DOI 10.1038/ng.858; Minella AC, 2007, ONCOGENE, V26, P6948, DOI 10.1038/sj.onc.1210518; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Minella AC, 2008, GENE DEV, V22, P1677, DOI 10.1101/gad.1650208; Onoyama I, 2007, J EXP MED, V204, P2875, DOI 10.1084/jem.20062299; Pop R, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000484; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Sandoval H, 2008, NATURE, V454, P232, DOI 10.1038/nature07006; Sankaran VG, 2008, GENE DEV, V22, P463, DOI 10.1101/gad.1627208; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Santos Janine H, 2002, Methods Mol Biol, V197, P159, DOI 10.1385/1-59259-284-8:159; Schweers RL, 2007, P NATL ACAD SCI USA, V104, P19500, DOI 10.1073/pnas.0708818104; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048; Woo RA, 2004, GENE DEV, V18, P1317, DOI 10.1101/gad.1165204; Xu YF, 2010, J BIOL CHEM, V285, P34439, DOI 10.1074/jbc.M110.152306	44	26	26	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3161	3171		10.1038/onc.2013.289	http://dx.doi.org/10.1038/onc.2013.289			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23873023	Green Accepted			2022-12-28	WOS:000338410000009
J	Ivanova, IA; Vermeulen, JF; Ercan, C; Houthuijzen, JM; Saig, FA; Vlug, EJ; van der Wall, E; van Diest, PJ; Vooijs, M; Derksen, PWB				Ivanova, I. A.; Vermeulen, J. F.; Ercan, C.; Houthuijzen, J. M.; Saig, F. A.; Vlug, E. J.; van der Wall, E.; van Diest, P. J.; Vooijs, M.; Derksen, P. W. B.			FER kinase promotes breast cancer metastasis by regulating alpha(6)- and beta(1)-integrin-dependent cell adhesion and anoikis resistance	ONCOGENE			English	Article						breast cancer; cell adhesion; cell migration; FER kinase; metastasis	BONE-MARROW; N-CADHERIN; CORTACTIN; ACTIVATION; MIGRATION; LINES; GENE; PHOSPHORYLATION; CARCINOMA; INTEGRIN	Metastatic breast cancer cannot be treated successfully. Currently, the targeted therapies for metastatic disease are limited to human epidermal growth factor receptor 2 and hormone receptor antagonists. Understanding the mechanisms of breast cancer growth and metastasis is therefore crucial for the development of new intervention strategies. Here, we show that FER kinase (FER) controls migration and metastasis of invasive human breast cancer cell lines by regulating alpha(6)- and beta(1)-integrin-dependent adhesion. Conversely, the overexpression of FER in non-metastatic breast cancer cells induces pro-invasive features. FER drives anoikis resistance, regulates tumour growth and is necessary for metastasis in a mouse model of human breast cancer. In human invasive breast cancer, high FER expression is an independent prognostic factor that correlates with high-grade basal/triple-negative tumours and worse overall survival, especially in lymph node-negative patients. These findings establish FER as a promising target for the prevention and inhibition of metastatic breast cancer.	[Ivanova, I. A.; Vermeulen, J. F.; Ercan, C.; Houthuijzen, J. M.; Saig, F. A.; Vlug, E. J.; van der Wall, E.; van Diest, P. J.; Vooijs, M.; Derksen, P. W. B.] Univ Med Ctr Utrecht, Dept Pathol, NL-3584 CX Utrecht, Netherlands; [van der Wall, E.] Univ Med Ctr Utrecht, Div Internal Med & Dermatol, NL-3584 CX Utrecht, Netherlands; [Vooijs, M.] Maastricht Univ Med Ctr, Dept Radiat Oncol, Maastricht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Maastricht University; Maastricht University Medical Centre (MUMC)	Vooijs, M (corresponding author), Maastricht Univ Med Ctr 1, Dept Radiat Oncol, Postbox 616-23, NL-6200 Maastricht, Netherlands.	marc.vooijs@maastrichtuniversity.nl; pderksen@umcutrecht.nl	Derksen, Patrick/C-6643-2008; Vooijs, Marc/K-3522-2019	Derksen, Patrick/0000-0003-0732-7762; Houthuijzen, Julia/0000-0003-0404-1961	Aegon Inc.; The Netherlands Organization for Scientific Research Grant [NWO-VIDI 917.96.318]; Terry Fox Foundation [700041]	Aegon Inc.; The Netherlands Organization for Scientific Research Grant; Terry Fox Foundation	We thank N Heisterkamp for providing the pUHG10-3(FER) vector, E Danen and A Sonnenberg for anti-integrin antibodies and L Price for help with the Matrigel assays. Luciferase-expressing MDA-MB-231 cells were a kind gift from G van der Pluijm. We are grateful to C Pfauth, T Westphal and the Netherlands Cancer Institute for providing RAG2<SUP>-/-</SUP>;IL2R gamma c<SUP>-/-</SUP> recipient mice. M van Amersfoort and D van der Giezen are acknowledged for expert technical assistance with the mouse experiments and F Morsink for performing the vimentin IHC staining. We also thank S Huveneers for critically reviewing this manuscript. This research is supported by an unrestricted educational grant from Aegon Inc. and The Netherlands Organization for Scientific Research Grant (NWO-VIDI 917.96.318). IA Ivanova is a Research Fellow of the Terry Fox Foundation (Award #700041).	Allard P, 2000, MOL CELL ENDOCRINOL, V159, P63, DOI 10.1016/S0303-7207(99)00205-1; Arregui C, 2000, J CELL BIOL, V149, P1263, DOI 10.1083/jcb.149.6.1263; Bharadwaj S, 2005, ONCOGENE, V24, P8291, DOI 10.1038/sj.onc.1208993; Braun S, 2001, J CLIN ONCOL, V19, P1468, DOI 10.1200/JCO.2001.19.5.1468; Brew CT, 2009, INT J CANCER, V124, P2294, DOI 10.1002/ijc.24210; Caswell PT, 2008, J CELL BIOL, V183, P143, DOI 10.1083/jcb.200804140; Craig AWB, 2002, MOL CELL BIOL, V22, P6363, DOI 10.1128/MCB.22.18.6363-6374.2002; Craig AWB, 2001, MOL CELL BIOL, V21, P603, DOI 10.1128/MCB.21.2.603-613.2001; Danen EHJ, 2002, J CELL BIOL, V159, P1071, DOI 10.1083/jcb.200205014; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; El Sayegh TY, 2005, MOL BIOL CELL, V16, P5514, DOI 10.1091/mcbE05-05-0410; Fei F, 2010, BMC BIOCHEM, V11, DOI 10.1186/1471-2091-11-48; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Gimeno R, 2004, BLOOD, V104, P3886, DOI 10.1182/blood-2004-02-0656; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; Guo CH, 2011, P NATL ACAD SCI USA, V108, P7968, DOI 10.1073/pnas.1105369108; Heath RJW, 2008, J CELL SCI, V121, P1951, DOI 10.1242/jcs.023895; Hoefnagel LDC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2645; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Itoh T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000393; Ivanova IA, 2006, ONCOGENE, V25, P430, DOI 10.1038/sj.onc.1208999; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; KIM L, 1995, MOL CELL BIOL, V15, P4553; LEONE BA, 1988, AM J CLIN ONCOL-CANC, V11, P618, DOI 10.1097/00000421-198812000-00004; Li HY, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-366; MacGrath SM, 2012, J CELL SCI, V125, P1621, DOI 10.1242/jcs.093781; Mills GB, 2009, J CLIN INVEST, V119, P2123, DOI 10.1172/JCI40256; MIYATA Y, CANC SCI, V104, P681; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Pasder O, 2006, ONCOGENE, V25, P4194, DOI 10.1038/sj.onc.1209695; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; Rae JM, 2007, BREAST CANCER RES TR, V104, P13, DOI 10.1007/s10549-006-9392-8; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; ROSEN PP, 1989, J CLIN ONCOL, V7, P355, DOI 10.1200/JCO.1989.7.3.355; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sangrar W, 2007, MOL CELL BIOL, V27, P6140, DOI 10.1128/MCB.01744-06; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Schackmann RCJ, 2011, J CLIN INVEST, V121, P3176, DOI 10.1172/JCI41695; Sung BH, 2011, CURR BIOL, V21, P1460, DOI 10.1016/j.cub.2011.06.065; van Diest PJ, 2002, BMJ-BRIT MED J, V325, P648, DOI 10.1136/bmj.325.7365.648; Vermeulen JF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037864; Vespa A, 2005, MOL BIOL CELL, V16, P4084, DOI 10.1091/mbc.e05-02-0087; Voisset E, 2010, LEUKEMIA, V24, P721, DOI 10.1038/leu.2009.301; Wei C, 2013, ONCOL LETT, V5, P473, DOI 10.3892/ol.2012.1032; Wetterwald A, 2002, AM J PATHOL, V160, P1143, DOI 10.1016/S0002-9440(10)64934-6; Xu G, 2004, J CELL SCI, V117, P3207, DOI 10.1242/jcs.01174; Yoneyama T, 2012, MOL BIOL CELL, V23, P771, DOI 10.1091/mbc.E11-06-0517; Zirngibl R, 2001, EXP CELL RES, V266, P87, DOI 10.1006/excr.2001.5217; Zoubeidi A, 2009, MOL CANCER RES, V7, P142, DOI 10.1158/1541-7786.MCR-08-0117	54	47	51	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2013	32	50					5582	5592		10.1038/onc.2013.277	http://dx.doi.org/10.1038/onc.2013.277			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272LF	23873028	Green Published, hybrid			2022-12-28	WOS:000328461400003
J	Johansson, J; Berg, T; Kurzejamska, E; Pang, MF; Tabor, V; Jansson, M; Roswall, P; Pietras, K; Sund, M; Religa, P; Fuxe, J				Johansson, J.; Berg, T.; Kurzejamska, E.; Pang, M-F; Tabor, V.; Jansson, M.; Roswall, P.; Pietras, K.; Sund, M.; Religa, P.; Fuxe, J.			MiR-155-mediated loss of C/EBP beta shifts the TGF-beta response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer	ONCOGENE			English	Article						CCAAT-enhancer binding protein beta; epithelial-mesenchymal transition; transforming growth factor-beta; Breast cancer; metastasis	BINDING-PROTEIN-BETA; BONE MORPHOGENETIC PROTEIN-7; CELL-PROLIFERATION; TARGETING RHOA; MAMMARY-GLAND; C-MYC; TUMOR; SMAD; REPRESSION; PLASTICITY	During breast cancer progression, transforming growth factor-beta (TGF-beta) switches from acting as a growth inhibitor to become a major promoter of epithelial-mesenchymal transition (EMT), invasion and metastasis. However, the mechanisms involved in this switch are not clear. We found that loss of CCAAT-enhancer binding protein beta (C/EBP beta), a differentiation factor for the mammary epithelium, was associated with signs of EMT in triple-negative human breast cancer, and in invasive areas of mammary tumors in MMTV-PyMT mice. Using an established model of TGF-beta-induced EMT in mouse mammary gland epithelial cells, we discovered that C/EBP beta was repressed during EMT by miR-155, an oncomiR in breast cancer. Depletion of C/EBP beta potentiated the TGF-beta response towards EMT, and contributed to evasion of the growth inhibitory response to TGF-beta. Furthermore, loss of C/EBP beta enhanced invasion and metastatic dissemination of the mouse mammary tumor cells to the lungs after subcutaneous injection into mice. The mechanism by which loss of C/EBP beta promoted the TGF-beta response towards EMT, invasion and metastasis, was traced to a previously uncharacterized role of C/EBP beta as a transcriptional activator of genes encoding the epithelial junction proteins E-cadherin and coxsackie virus and adenovirus receptor. The results identify miR-155-mediated loss of C/EBP beta as a mechanism, which promotes breast cancer progression by shifting the TGF-beta response from growth inhibition to EMT, invasion and metastasis.	[Johansson, J.; Berg, T.; Pang, M-F; Tabor, V.; Roswall, P.; Pietras, K.; Fuxe, J.] Karolinska Inst, Dept Med Biochem & Biophys, Div Vasc Biol, S-17177 Stockholm, Sweden; [Kurzejamska, E.; Religa, P.] Karolinska Inst, Dept Med, Ctr Mol Med, S-17177 Stockholm, Sweden; [Kurzejamska, E.] Med Univ Warsaw, Dept Internal Med, Warsaw, Poland; [Jansson, M.; Sund, M.] Umea Univ, Dept Surg & Perioperat Sci, Umea, Sweden; [Pietras, K.] Lund Univ, Dept Lab Med Malmo, Ctr Canc, Malmo, Sweden	Karolinska Institutet; Karolinska Institutet; Medical University of Warsaw; Umea University; Lund University	Fuxe, J (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Vasc Biol, Scheeles V 2, S-17177 Stockholm, Sweden.	jonas.fuxe@ki.se	Pietras, Kristian/ABE-8727-2020; Fuxe, Jonas/T-4433-2017; Pietras, Kristian/ABG-2097-2021	Fuxe, Jonas/0000-0003-4576-9377; Pietras, Kristian/0000-0001-6738-4705; Kurzejamska, Ewa/0000-0002-8050-6516; Sund, Malin/0000-0002-7516-9543; Tabor, Vedrana/0000-0001-9224-208X; Religa, Piotr/0000-0002-3884-2954; Pang, Mei Fong/0000-0002-3030-1272	Swedish Research Council; Swedish Childhood Cancer Foundation; Swedish Cancer Society; Strategic Cancer Foundation (StratCan) at Karolinska Institute; Swedish Society of Medical Research; Vasterbotten County Council (VLL); Cancerforskningsfonden Norrland; Swedish Cancer Society an European Union RD Found; Foundation for Polish Science; Karolinska Institutet	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Childhood Cancer Foundation(European Commission); Swedish Cancer Society(Swedish Cancer Society); Strategic Cancer Foundation (StratCan) at Karolinska Institute; Swedish Society of Medical Research; Vasterbotten County Council (VLL); Cancerforskningsfonden Norrland; Swedish Cancer Society an European Union RD Found; Foundation for Polish Science(Foundation for Polish ScienceEuropean Commission); Karolinska Institutet(Karolinska Institutet)	We thank Mina Bissell (Berkeley University), Carl-Henrik Heldin (Uppsala University) and Marene Landstrom (Umea University) for valuable input on the manuscript. We also thank Mathilda Sjoberg (Karolinska Institutet) for assistance with lentivirus infections and Anette Berglund (Umea University) for handling of human tissue samples. This work was supported by research grants from the Swedish Research Council, the Swedish Childhood Cancer Foundation, the Swedish Cancer Society and the Strategic Cancer Foundation (StratCan) at Karolinska Institute to JF, by a fellowship from the Swedish Society of Medical Research to TB, as well as research grants from Vasterbotten County Council (VLL) and Cancerforskningsfonden Norrland to MS. VT was supported by a grant from the Swedish Cancer Society, PR was supported by the Swedish Cancer Society an European Union RD Found, Ewa Kurzejamska was supported by Foundation for Polish Science and the Karolinska Institutet.	Arnal-Estape A, 2010, CANCER RES, V70, P9927, DOI 10.1158/0008-5472.CAN-10-0869; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6; Brown KA, 2004, BREAST CANCER RES, V6, pR215, DOI 10.1186/bcr778; Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008-5472.CAN-06-2490; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Costinean S, 2009, BLOOD, V114, P1374, DOI 10.1182/blood-2009-05-220814; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Fuxe J, 2010, CELL CYCLE, V9, P2363, DOI 10.4161/cc.9.12.12050; Gal A, 2008, ONCOGENE, V27, P1218, DOI 10.1038/sj.onc.1210741; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; Gotoh T, 1997, J BIOL CHEM, V272, P3694, DOI 10.1074/jbc.272.6.3694; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He M, 2009, CELL MOL IMMUNOL, V6, P343, DOI 10.1038/cmi.2009.45; Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jeong H, 2012, HISTOPATHOLOGY, V60, pE87, DOI 10.1111/j.1365-2559.2012.04195.x; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mattiske S, 2012, CANCER EPIDEM BIOMAR, V21, P1236, DOI 10.1158/1055-9965.EPI-12-0173; McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sebastian T, 2005, EMBO J, V24, P3301, DOI 10.1038/sj.emboj.7600789; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Terry S, 2010, PHYSIOLOGY, V25, P16, DOI 10.1152/physiol.00034.2009; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tseng YH, 2008, NATURE, V454, P1000, DOI 10.1038/nature07221; Uhlen M, 2005, MOL CELL PROTEOMICS, V4, P1920, DOI 10.1074/mcp.M500279-MCP200; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Zahnow CA, 2001, CANCER RES, V61, P261; Zahnow CA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001033; Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888; Zhang LA, 2010, FEBS LETT, V584, P4646, DOI 10.1016/j.febslet.2010.10.038; Zuo L, 2012, BREAST CANCER RES, V12, pR34	46	124	129	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2013	32	50					5614	5624		10.1038/onc.2013.322	http://dx.doi.org/10.1038/onc.2013.322			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272LF	23955085	Green Published, hybrid			2022-12-28	WOS:000328461400006
J	Feuerborn, A; Mathow, D; Srivastava, PK; Gretz, N; Grone, HJ				Feuerborn, A.; Mathow, D.; Srivastava, P. K.; Gretz, N.; Groene, H-J			Basonuclin-1 modulates epithelial plasticity and TGF-beta 1-induced loss of epithelial cell integrity	ONCOGENE			English	Article							BREAST-CANCER CELLS; TGF-BETA; MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR; E-CADHERIN; GENE-EXPRESSION; GROWTH; METASTASIS; SUPPRESSOR; PROTEINS	Transforming growth factor-alpha 1 (TGF-beta 1) is a multifunctional cytokine and critically involved in the progression of a variety of cancers. TGF-beta 1 signaling can impair tumor development by its anti-proliferative and pro-apoptotic features. In contrast, it may actively promote tumor progression and cancer cell dissemination by inducing a gradual switch from epithelial towards mesenchymal-like cell features (EMT-like), including decreased intercellular adhesion. Here, we show that expression of the transcription factor Basonuclin-1 (Bnc1) modulates TGF-beta 1-induced epithelial dedifferentiation of mammary epithelial cells. RNAi-mediated repression of Bnc1 resulted in enhanced intercellular adhesion and strongly impaired TGF-beta 1-dependent sheet disintegration and cell scattering. In contrast, forced expression of Bnc1 modifies plasma membrane/cytoskeletal dynamics and seemingly interferes with the initiation of sustainable cell-cell contacts. Follow-up analyses revealed that Bnc1 affects the expression of numerous TGF-beta 1-responsive genes including distinct EMT-related transcription factors, some of which modulate the expression of Bnc1 themselves. These results suggest that Bnc1 is part of a transcription factor network related to epithelial plasticity with reciprocal feedback-loop connections on which Smad-factors integrate TGF-beta 1 signaling. Our study demonstrates that Bnc1 regulates epithelial plasticity of mammary epithelial cells and influences outcome of TGF-beta 1 signaling.	[Feuerborn, A.; Mathow, D.; Groene, H-J] German Canc Res Ctr, Dept Cellular & Mol Pathol, Heidelberg, Germany; [Srivastava, P. K.] Univ London Imperial Coll Sci Technol & Med, MRC Clin Sci, London, England; [Gretz, N.] Heidelberg Univ, Med Res Ctr ZMF, Fac Med, Dept Med Res, Mannheim, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Imperial College London; Ruprecht Karls University Heidelberg	Feuerborn, A (corresponding author), German Canc Res Ctr, Dept Cellular & Mol Pathol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	alexander.feuerborn@path.ox.ac.uk; h.-j.groene@dkfz.de			DFG [SFB-938]	DFG(German Research Foundation (DFG))	We kindly acknowledge Peter ten Dijke, David Danielpour, Sebastian Diecke and Roderick Beijersbergen for generously providing cells and plasmids. Support by the DKFZ Light Microscopy Facility is gratefully acknowledged. We thank Maria Muciek for excellent assistance with regard to microarray expression profiling and Ann Na Tan for excellent technical support. This study was supported by a grant of the DFG (SFB-938) to HJG.	Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Aigner K, 2007, FEBS LETT, V581, P1617, DOI 10.1016/j.febslet.2007.03.026; Boldrup L, 2012, EUR J CANCER, V48, P1401, DOI 10.1016/j.ejca.2011.06.032; Brena RM, 2006, PLOS MED, V3, P2184, DOI 10.1371/journal.pmed.0030479; Capaldo CT, 2007, MOL BIOL CELL, V18, P189, DOI 10.1091/mbc.E06-05-0471; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; Cui CH, 2004, CANCER RES, V64, P5651, DOI 10.1158/0008-5472.CAN-04-0801; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; de Rooij J, 2005, J CELL BIOL, V171, P153, DOI 10.1083/jcb.200506152; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Feuerborn A, 2011, J CELL PHYSIOL, V226, P710, DOI 10.1002/jcp.22385; Feuerborn A, 2011, CELL CYCLE, V10, P2454, DOI 10.4161/cc.10.15.16306; Garber M, 2012, MOL CELL, V47, P810, DOI 10.1016/j.molcel.2012.07.030; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gervasi M, 2012, J CELL BIOL, V196, P589, DOI 10.1083/jcb.201109045; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Guo LX, 2011, AM J PATHOL, V178, P2357, DOI 10.1016/j.ajpath.2011.01.047; Heldin CH, 2012, FEBS LETT, V586, P1959, DOI 10.1016/j.febslet.2012.02.037; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kenzelmann M, 2007, P NATL ACAD SCI USA, V104, P6164, DOI 10.1073/pnas.0610439104; Koinuma D, 2009, CANCER SCI, V100, P2133, DOI 10.1111/j.1349-7006.2009.01299.x; Koinuma D, 2009, MOL CELL BIOL, V29, P172, DOI 10.1128/MCB.01038-08; Kumper S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011801; Kwon AT, 2012, G3-GENES GENOM GENET, V2, P987, DOI 10.1534/g3.112.003202; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loerke D, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002677; Ma J, 2006, DEVELOPMENT, V133, P2053, DOI 10.1242/dev.02371; Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551; Mahoney MG, 1998, BIOL REPROD, V59, P388, DOI 10.1095/biolreprod59.2.388; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Morikawa M, 2013, ONCOGENE, V32, P1609, DOI 10.1038/onc.2012.191; Morris MR, 2010, ONCOGENE, V29, P2104, DOI 10.1038/onc.2009.493; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Mullen AC, 2011, CELL, V147, P565, DOI 10.1016/j.cell.2011.08.050; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Nakahata S, 2010, ONCOGENE, V29, P4157, DOI 10.1038/onc.2010.172; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Papantonis A, 2012, EMBO J, V31, P4404, DOI 10.1038/emboj.2012.288; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Qiao YY, 2011, CANCER RES, V71, P3076, DOI 10.1158/0008-5472.CAN-10-2787; Redmer T, 2011, EMBO REP, V12, P720, DOI 10.1038/embor.2011.88; Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shirakihara T, 2007, MOL BIOL CELL, V18, P3533, DOI 10.1091/mbc.E07-03-0249; Sundqvist A, 2013, ONCOGENE, V32, P3606, DOI 10.1038/onc.2012.370; Suzuki H, 2009, NAT GENET, V41, P553, DOI 10.1038/ng.375; Tang YN, 2011, CELL RES, V21, P316, DOI 10.1038/cr.2010.126; Tseng H, 1999, DIFFERENTIATION, V65, P221, DOI 10.1046/j.1432-0436.1999.6540221.x; Tseng H, 1998, FRONT BIOSCI, V3, pD985; Tsunoda T, 1999, BIOINFORMATICS, V15, P622, DOI 10.1093/bioinformatics/15.7.622; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vanhoutteghem A, 2011, BIOCHIMIE, V93, P127, DOI 10.1016/j.biochi.2010.09.010; Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0; Wang JW, 2006, BIOCHEM BIOPH RES CO, V348, P1261, DOI 10.1016/j.bbrc.2006.07.198; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; Zhang HJ, 2011, CANCER RES, V71, P1292, DOI 10.1158/0008-5472.CAN-10-2825; Zhang SL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000902; Zhang XH, 2012, GENESIS, V50, P517, DOI 10.1002/dvg.22014; Zhang XH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001087	62	6	6	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1185	1195		10.1038/onc.2014.54	http://dx.doi.org/10.1038/onc.2014.54			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662832				2022-12-28	WOS:000350122100011
J	Hosoda, F; Arai, Y; Okada, N; Shimizu, H; Miyamoto, M; Kitagawa, N; Katai, H; Taniguchi, H; Yanagihara, K; Imoto, I; Inazawa, J; Ohki, M; Shibata, T				Hosoda, F.; Arai, Y.; Okada, N.; Shimizu, H.; Miyamoto, M.; Kitagawa, N.; Katai, H.; Taniguchi, H.; Yanagihara, K.; Imoto, I.; Inazawa, J.; Ohki, M.; Shibata, T.			Integrated genomic and functional analyses reveal glyoxalase I as a novel metabolic oncogene in human gastric cancer	ONCOGENE			English	Article							DNA COPY NUMBER; TUMOR-SUPPRESSOR; GENE-EXPRESSION; POTENTIAL TARGET; UP-REGULATION; IDENTIFICATION; METHYLGLYOXAL; AMPLIFICATION; PROTEIN; OVEREXPRESSION	Chromosomal abnormalities are good guideposts when hunting for cancer-related genes. We analyzed copy number alterations of 163 primary gastric cancers using array-based comparative genomic hybridization and simultaneously performed a genome-wide integrated analysis of copy number and gene expression using microarray data for 58 tumors. We showed that chromosome 6p21 amplification frequently occurred secondary to ERBB2 amplification, was associated with poorer prognosis and caused overexpression of half of the genes mapped. A comprehensive small interfering RNA knockdown of 58 genes overexpressed in tumors identified 32 genes that reduced gastric cancer cell growth. Enforced expression of 16 of these genes promoted cell growth in vitro, and six genes showing more than two-fold activity conferred tumor-forming ability in vivo. Among these six candidates, GLO1, encoding a detoxifying enzyme glyoxalase I (GLO1), exhibited the strongest tumor-forming activity. Coexpression of other genes with GLO1 enhanced growth-stimulating activity. A GLO1 inhibitor, S-p-bromobenzyl glutathione cyclopentyl diester, inhibited the growth of two-thirds of 24 gastric cancer cell lines examined. The efficacy was found to be associated with the mRNA expression ratio of GLO1 to GLO2, encoding glyoxalase II (GLO2), another constituent of the glyoxalase system. GLO1 downregulation affected cell growth through inactivating central carbon metabolism and reduced the transcriptional activities of nuclear factor kappa B and activator protein-1. Our study demonstrates that GLO1 is a novel metabolic oncogene of the 6p21 amplicon, which promotes tumor growth and aberrant transcriptional signals via regulating cellular metabolic activities for energy production and could be a potential therapeutic target in gastric cancer.	[Hosoda, F.; Arai, Y.; Okada, N.; Shimizu, H.; Miyamoto, M.; Kitagawa, N.; Ohki, M.; Shibata, T.] Natl Canc Ctr, Div Canc Genom, Tokyo 1040045, Japan; [Katai, H.] Natl Canc Ctr, Div Gastr Surg, Tokyo, Japan; [Taniguchi, H.] Natl Canc Ctr, Div Clin Lab, Tokyo, Japan; [Yanagihara, K.] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Translat Res, Chiba, Japan; [Imoto, I.; Inazawa, J.] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Tokyo, Japan; [Imoto, I.] Univ Tokushima, Dept Human Genet & Publ Hlth, Inst Hlth Biosci, Grad Sch, Tokushima 770, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Tokyo Medical & Dental University (TMDU); Tokushima University	Shibata, T (corresponding author), Natl Canc Ctr, Div Canc Genom, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tashibat@ncc.go.jp	Shibata, Tatsuhiro/ABA-8234-2020; Imoto, Issei/AAD-5799-2020; Shibata, Tatsuhiro/AAO-1278-2021		Ministry of Health, Labor and Welfare, Japan; New Energy and Industrial Technology Development Organization (NEDO), Japan; National Institute of Biomedical Innovation (NiBio), Japan; Foundation for Promotion of Cancer Research in Japan; Grants-in-Aid for Scientific Research [22134002, 26293304] Funding Source: KAKEN	Ministry of Health, Labor and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); New Energy and Industrial Technology Development Organization (NEDO), Japan(New Energy and Industrial Technology Development Organization (NEDO)); National Institute of Biomedical Innovation (NiBio), Japan(National Institute of Biomedical Innovation); Foundation for Promotion of Cancer Research in Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Setsuo Hirohashi for generous support and encouragement; Yukihiro Nakanishi for advice on histological classification of gastric tumors; Tokuki Sakiyama and Go Maeno for helping with the analysis of the aCGH data; Jun Yasuda for advice on the RNA interference techniques; Yu Nakamura, Michiyo Fukushima, Satomi Uryu and Yasuko Kuwabara for providing considerable contributions to the sample preparation of BAC DNA and patients' DNA and array hybridization; and Sayaka Kadoguchi and Kenjiro Kami for advice on metabolome analysis. This research was supported in part by a Grant-in-Aid for the Comprehensive 10-Year-Strategy for Cancer Control and from the Ministry of Health, Labor and Welfare, Japan, a grant from the New Energy and Industrial Technology Development Organization (NEDO), Japan and a grant from the National Institute of Biomedical Innovation (NiBio), Japan. MM and NK were recipients of a Research Resident Fellowship from the Foundation for Promotion of Cancer Research in Japan.	Aggarwal BB, 2009, CURR OPIN PHARMACOL, V9, P351, DOI 10.1016/j.coph.2009.06.020; Antognelli C, 2013, INT J BIOCHEM CELL B, V45, P836, DOI 10.1016/j.biocel.2013.01.003; Antognelli C, 2013, PROSTATE, V73, P121, DOI 10.1002/pros.22547; Bair WB, 2010, MELANOMA RES, V20, P85, DOI 10.1097/CMR.0b013e3283364903; Chen J, 2009, AM J PATHOL, V175, P400, DOI 10.2353/ajpath.2009.080972; Chiang DY, 2008, CANCER RES, V68, P6779, DOI 10.1158/0008-5472.CAN-08-0742; de Hemptinne V, 2009, MOL CELL BIOCHEM, V325, P169, DOI 10.1007/s11010-009-0031-7; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Ghiorghi YK, 2007, J BIOL CHEM, V282, P8150, DOI 10.1074/jbc.M610648200; Gorringe KL, 2005, GENE CHROMOSOME CANC, V42, P247, DOI 10.1002/gcc.20136; Hansen F, 2012, METAB BRAIN DIS, V27, P531, DOI 10.1007/s11011-012-9329-3; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806; Kasugai Y, 2005, CLIN CANCER RES, V11, P8265, DOI 10.1158/1078-0432.CCR-05-1028; Kim DJ, 2010, P NATL ACAD SCI USA, V107, P21418, DOI 10.1073/pnas.1010153107; Kim SS, 2007, CANCER RES, V67, P9616, DOI 10.1158/0008-5472.CAN-07-0644; Kuiper RP, 2003, HUM MOL GENET, V12, P1661, DOI 10.1093/hmg/ddg178; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Lewis BC, 2000, CANCER RES, V60, P6178; Lochhead P, 2008, BRIT MED BULL, V85, P87, DOI 10.1093/bmb/ldn007; Lu XY, 2008, MOL CANCER RES, V6, P937, DOI 10.1158/1541-7786.MCR-07-2115; Maeda S, 2008, CANCER SCI, V99, P836, DOI 10.1111/j.1349-7006.2008.00763.x; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Myllykangas S, 2008, INT J CANCER, V123, P817, DOI 10.1002/ijc.23574; Nakamura Y, 2009, INT J CANCER, V125, P1859, DOI 10.1002/ijc.24538; Obama K, 2006, CLIN CANCER RES, V12, P70, DOI 10.1158/1078-0432.CCR-05-0588; ORAY B, 1982, METHOD ENZYMOL, V90, P542; RANGANATHAN S, 1995, BIOCHEM J, V309, P127, DOI 10.1042/bj3090127; Ranganathan S, 1999, GENE, V240, P149, DOI 10.1016/S0378-1119(99)00420-5; Sakamoto H, 2001, CLIN CANCER RES, V7, P2513; Santarius T, 2010, GENE CHROMOSOME CANC, V49, P711, DOI 10.1002/gcc.20784; Santos GC, 2007, J CLIN PATHOL, V60, P1, DOI 10.1136/jcp.2005.034389; Takada H, 2005, ONCOGENE, V24, P8051, DOI 10.1038/sj.onc.1208952; Tamura G, 2006, WORLD J GASTROENTERO, V12, P192, DOI 10.3748/wjg.v12.i2.192; Tanami H, 2005, LAB INVEST, V85, P1118, DOI 10.1038/labinvest.3700312; Thornalley Paul J., 2008, Drug Metabolism and Drug Interactions, V23, P125; THORNALLEY PJ, 1990, BIOCHEM J, V269, P1; Tsukamoto Y, 2008, J PATHOL, V216, P471, DOI 10.1002/path.2424; Varela-Rey M, 2009, HEPATOLOGY, V50, P443, DOI 10.1002/hep.23033; Vauhkonen H, 2006, CANCER GENET CYTOGEN, V167, P150, DOI 10.1016/j.cancergencyto.2005.11.014; Xue MZ, 2012, BIOCHEM J, V443, P213, DOI 10.1042/BJ20111648; Yagi T, 2003, BLOOD, V102, P1849, DOI 10.1182/blood-2003-02-0578; Yanagihara K, 2004, CANCER SCI, V95, P575, DOI 10.1111/j.1349-7006.2004.tb02489.x; Yang S, 2007, GENOMICS, V89, P451, DOI 10.1016/j.ygeno.2006.12.001	45	39	39	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1196	1206		10.1038/onc.2014.57	http://dx.doi.org/10.1038/onc.2014.57			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662817				2022-12-28	WOS:000350122100012
J	Chung, L; Onyango, D; Guo, Z; Jia, P; Dai, H; Liu, S; Zhou, M; Lin, W; Pang, I; Li, H; Yuan, YC; Huang, Q; Zheng, L; Lopes, J; Nicolas, A; Chai, W; Raz, D; Reckamp, KL; Shen, B				Chung, L.; Onyango, D.; Guo, Z.; Jia, P.; Dai, H.; Liu, S.; Zhou, M.; Lin, W.; Pang, I.; Li, H.; Yuan, Y-C; Huang, Q.; Zheng, L.; Lopes, J.; Nicolas, A.; Chai, W.; Raz, D.; Reckamp, K. L.; Shen, B.			The FEN1 E359K germline mutation disrupts the FEN1-WRN interaction and FEN1 GEN activity, causing aneuploidy-associated cancers	ONCOGENE			English	Article							OKAZAKI FRAGMENT MATURATION; DNA-DAMAGE RESPONSE; FLAP ENDONUCLEASE-1; REPLICATION FORK; CHROMOSOMAL INSTABILITY; SECONDARY STRUCTURES; TELOMERE STABILITY; TUMOR PROGRESSION; STRUCTURAL BASIS; MUTANT MICE	Polymorphisms and somatic mutations in Flap Endonuclease 1 (FEN1), an essential enzyme involved in DNA replication and repair, can lead to functional deficiencies of the FEN1 protein and a predisposition to cancer. We identified a FEN1 germline mutation that changed residue E359 to K in a patient whose family had a history of breast cancer. We determined that the E359K mutation, which is in the protein-protein domain of FEN1, abolished the interaction of FEN1 with Werner syndrome protein (WRN), an interaction that is critical for resolving stalled DNA replication forks. Furthermore, although the flap endonuclease activity of FEN1 E359K was unaffected, it failed to resolve bubble structures, which require the FEN1 gap-dependent endonuclease activity. To determine the etiological significance of E359K, we established a mouse model containing this mutation. E359K mouse embryonic fibroblasts (MEF) were more sensitive to DNA crosslinking agents that cause replication forks to stall. Cytological analysis suggested that the FEN1-WRN interaction was also required for telomere stability; mutant cell lines had fragile telomeres, increased numbers of spontaneous chromosomal anomalies and higher frequencies of transformation. Moreover, the incidence of cancer was significantly higher in mice homozygous for FEN1 E359K than in wild-type mice, suggesting that the FEN1 E359K mutation is oncogenic.	[Chung, L.; Onyango, D.; Guo, Z.; Dai, H.; Liu, S.; Zhou, M.; Lin, W.; Pang, I.; Zheng, L.; Shen, B.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Radiat Oncol, Duarte, CA 91010 USA; [Guo, Z.] Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing, Jiangsu, Peoples R China; [Jia, P.; Chai, W.] Washington State Univ, Sch Mol Biosci, WWAMI Med Educ Program, Spokane, WA USA; [Liu, S.] Zhejiang Univ, Coll Life Sci, Hangzhou 310058, Zhejiang, Peoples R China; [Li, H.; Yuan, Y-C] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Med, Duarte, CA 91010 USA; [Huang, Q.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Pathol, Duarte, CA 91010 USA; [Lopes, J.; Nicolas, A.] CNRS, Inst Curie, Sect Rech Inst, Paris, France; [Lopes, J.] Museum Natl Hist Nat, INSERM U565, USM 503, UMR7196, F-75231 Paris, France; [Raz, D.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Surg, Duarte, CA 91010 USA; [Reckamp, K. L.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; Nanjing Normal University; Washington State University; Zhejiang University; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN); City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Reckamp, KL (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Med Oncol & Therapeut Res, 107 East Duarte Rd, Duarte, CA 91010 USA.	kreckamp@coh.org; bshen@coh.org	Li, Hongzhi/E-8530-2012; Brodie, Matthew Andrew/HDN-0096-2022; LIU, SONGBAI/AFL-6448-2022; Chai, Weihang/AAG-5194-2021; Lopes, Judith/K-3788-2017; Brodie, Matthew A D/ABG-1640-2020	Brodie, Matthew Andrew/0000-0002-5711-3458; Lopes, Judith/0000-0003-4907-6797; Brodie, Matthew A D/0000-0002-5711-3458; Shen, Binghui/0000-0002-4408-407X; Reckamp, Karen/0000-0002-9213-0325; liu, songbai/0000-0002-3920-1032	NIH [R01 CA073764]; Ligue Nationale contre le Cancer [EL2007/LNCC, EL2010/LNCC]; NATIONAL CANCER INSTITUTE [R01CA073764, R29CA073764, P30CA033572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM112864] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the City of Hope Pathology Core Facility for technical assistance with characterization of mouse cancer specimens (P30CA033572). We thank M Lee and B Armstrong in the City of Hope Microscopy Core Facility for assistance with characterization of chromosomal aberrations and D Stoppa-Lyonnet (Institut Curie) to provide the breast cancer patient DNA. This work was supported by NIH grant R01 CA073764 and Ligue Nationale contre le Cancer (EL2007/LNCC and EL2010/LNCC).	Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; Ayyagari R, 2003, J BIOL CHEM, V278, P1618, DOI 10.1074/jbc.M209801200; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Blackburn EH, 2006, NAT MED, V12, P1133, DOI 10.1038/nm1006-1133; Bochman ML, 2012, NAT REV GENET, V13, P770, DOI 10.1038/nrg3296; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Branzei D, 2010, NAT REV MOL CELL BIO, V11, P208, DOI 10.1038/nrm2852; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; de Lange T, 2011, COLD SPRING HARB SYM, V75, P167; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Gilson E, 2007, NAT REV MOL CELL BIO, V8, P825, DOI 10.1038/nrm2259; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Guo ZG, 2008, J MOL BIOL, V377, P679, DOI 10.1016/j.jmb.2007.10.074; Kitano K, 2010, STRUCTURE, V18, P177, DOI 10.1016/j.str.2009.12.011; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; Larsen E, 2003, MOL CELL BIOL, V23, P5346, DOI 10.1128/MCB.23.15.5346-5353.2003; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Liu R, 2006, NUCLEIC ACIDS RES, V34, P1772, DOI 10.1093/nar/gkl106; Lo AWI, 2002, NEOPLASIA, V4, P531, DOI 10.1038/sj.neo.7900267; Lopes J, 2006, MOL CELL BIOL, V26, P6675, DOI 10.1128/MCB.00649-06; Michel B, 2004, P NATL ACAD SCI USA, V101, P12783, DOI 10.1073/pnas.0401586101; Murnane JP, 2010, CANCER RES, V70, P4255, DOI 10.1158/0008-5472.CAN-09-4357; Nussenzweig A, 2010, CELL, V141, P27, DOI 10.1016/j.cell.2010.03.016; O'Sullivan RJ, 2010, NAT REV MOL CELL BIO, V11, P171, DOI 10.1038/nrm2848; Pierce BG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024657; Saharia A, 2008, CURR BIOL, V18, P496, DOI 10.1016/j.cub.2008.02.071; Saharia A, 2010, J BIOL CHEM, V285, P27057, DOI 10.1074/jbc.M110.112276; Sakurai S, 2005, EMBO J, V24, P683, DOI 10.1038/sj.emboj.7600519; Sampathi S, 2009, J BIOL CHEM, V284, P3682, DOI 10.1074/jbc.M805362200; Schvartzman JM, 2010, NAT REV CANCER, V10, P102, DOI 10.1038/nrc2781; Singh P, 2007, J BIOL CHEM, V282, P3465, DOI 10.1074/jbc.M606582200; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; Sweasy JB, 2005, P NATL ACAD SCI USA, V102, P14350, DOI 10.1073/pnas.0505166102; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tsutakawa SE, 2011, CELL, V145, P198, DOI 10.1016/j.cell.2011.03.004; Wang YX, 2005, NAT GENET, V37, P750, DOI 10.1038/ng1587; Wu ZX, 2012, MUTAT RES-FUND MOL M, V731, P85, DOI 10.1016/j.mrfmmm.2011.11.009; Xu H, ONCOGENE, V30, P1072; Zheng L, 2005, EMBO REP, V6, P83, DOI 10.1038/sj.embor.7400313; Zheng L, 2007, NAT MED, V13, P812, DOI 10.1038/nm1599; Zheng L, 2007, MOL CELL BIOL, V27, P3176, DOI 10.1128/MCB.01652-06; Zheng L, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1825; Zheng L, 2011, CELL RES, V21, P1052, DOI 10.1038/cr.2011.35; Zheng L, 2011, NUCLEIC ACIDS RES, V39, P781, DOI 10.1093/nar/gkq884; Zheng L, 2011, J MOL CELL BIOL, V3, P23, DOI 10.1093/jmcb/mjq048	49	23	24	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					902	911		10.1038/onc.2014.19	http://dx.doi.org/10.1038/onc.2014.19			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24608430	Green Accepted			2022-12-28	WOS:000349472000010
J	Wang, G; Cao, X; Lai, S; Luo, X; Feng, Y; Wu, J; Ning, Q; Xia, X; Wang, J; Gong, J; Hu, J				Wang, G.; Cao, X.; Lai, S.; Luo, X.; Feng, Y.; Wu, J.; Ning, Q.; Xia, X.; Wang, J.; Gong, J.; Hu, J.			Altered p53 regulation of miR-148b and p55PIK contributes to tumor progression in colorectal cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; MICRORNA BIOGENESIS; THERAPEUTIC TARGET; GASTRIC-CANCER; CELL; EXPRESSION; SUBUNIT; SUPPRESSOR; CARCINOMA; PIK3R3	MicroRNAs are a class of small non-coding RNAs that regulate the expressions of many genes. Previously, we found that the expression of p55PIK, an isoform of phosphatidylinosotol 3-kinase that has important roles in the regulation of cell cycle, is increased significantly in several types of cancer and contributes to the tumor growth. However, the mechanism for this increased p55PIK expression is not well understood. In this study, we show that miR-148b binds specifically to the 3'-untranslated region of p55PIK and significantly suppresses p55PIK expression. MiR-148b overexpression abolished p55PIK stimulation of cell proliferation and cell cycle progression in colorectal cancer (CRC) cell lines and decreased tumor growth in vivo. Furthermore, we demonstrated that p53 directly activates the transcription of miR-148b by binding to its promoter. In CRC cell lines and tissues, p53 expression was associated with miR-148b expression, and both were negatively associated with p55PIK expression. Our study shows that the p53/miR-148b/p55PIK axis has an important role in cell proliferation and tumor growth, and may represent a novel therapeutic target for treating cancers containing p53 mutations or losses.	[Wang, G.; Cao, X.; Lai, S.; Luo, X.; Xia, X.; Hu, J.] Huazhong Univ Sci & Technol, Tongji Hosp, Canc Res Inst, Wuhan 430030, Peoples R China; [Feng, Y.; Wu, J.; Gong, J.] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Mol Med Ctr, Wuhan 430030, Peoples R China; [Ning, Q.] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Infect Dis, Wuhan 430030, Peoples R China; [Wang, J.] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Immunol, Wuhan 430030, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Gong, J (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Mol Med Ctr, Wuhan 430030, Peoples R China.	jpgong@tjh.tjmu.edu.cn; jbhu@tjh.tjmu.edu.cn	Wang, Guihua/AAX-3130-2021		National Natural Science Foundation [81300411, 81372662, 81072431, 81272278, 31000612]; '973' Program [2009CB521802]; Program for Changjiang Scholars and Innovative Research Team in University [PCSIRT1131]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); '973' Program(National Basic Research Program of China); Program for Changjiang Scholars and Innovative Research Team in University(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT))	This study was supported by National Natural Science Foundation (No. 81300411, No. 81372662, No. 81072431, No. 81272278, No. 31000612), '973' Program (No. 2009CB521802) and Program for Changjiang Scholars and Innovative Research Team in University (No. PCSIRT1131).	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Chang H, 2012, MOL MED REP, V5, P1277, DOI 10.3892/mmr.2012.794; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; De Santa F, 2013, CURR PHARM DESIGN, V19, P745, DOI 10.2174/138161213804581846; Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008-5472.CAN-05-0298; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hermeking H, 2012, NAT REV CANCER, V12, P613, DOI 10.1038/nrc3318; Hu JB, 2005, INT J ONCOL, V26, P1321; Hu JB, 2008, MOL CANCER THER, V7, P3719, DOI 10.1158/1535-7163.MCT-08-0499; Kim NH, 2011, J CELL BIOL, V195, P417, DOI 10.1083/jcb.201103097; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817; Nymark P, 2011, GENE CHROMOSOME CANC, V50, P585, DOI 10.1002/gcc.20880; PONS S, 1995, MOL CELL BIOL, V15, P4453; Russo A, 2005, J CLIN ONCOL, V23, P7518, DOI 10.1200/JCO.2005.00.471; Song YX, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-1; Song YX, 2012, INT J CANCER, V131, P1042, DOI 10.1002/ijc.26485; Szafranska AE, 2007, ONCOGENE, V26, P4442, DOI 10.1038/sj.onc.1210228; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang G, 2012, CELL DEATH DIFFER, V19, P1870, DOI 10.1038/cdd.2012.70; Wang GH, 2013, ANGIOGENESIS, V16, P561, DOI 10.1007/s10456-013-9336-y; Xia XM, 2003, MOL CELL BIOL, V23, P1717, DOI 10.1128/MCB.23.5.1717-1725.2003; Zhang L, 2007, CLIN CANCER RES, V13, P5314, DOI 10.1158/1078-0432.CCR-06-2660; Zhao G, 2013, MOL CANCER THER, V12, P83, DOI 10.1158/1535-7163.MCT-12-0534-T; Zhou J, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-34	29	30	31	4	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					912	921		10.1038/onc.2014.30	http://dx.doi.org/10.1038/onc.2014.30			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24632606				2022-12-28	WOS:000349472000011
J	Vassilopoulos, A; Chisholm, C; Lahusen, T; Zheng, H; Deng, CX				Vassilopoulos, A.; Chisholm, C.; Lahusen, T.; Zheng, H.; Deng, C-X			A critical role of CD29 and CD49f in mediating metastasis for cancer-initiating cells isolated from a Brca1-associated mouse model of breast cancer	ONCOGENE			English	Article						CD29; CD49f; CSCs; EMT; cancer metastasis	EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELLS; BRCA1; IDENTIFICATION; SUSCEPTIBILITY; EXPRESSION; MECHANISMS; SIGNATURE; MARKERS; TUMORS	Cancer metastasis is a lethal problem that claims the lives of over 90% of cancer patients. In this study, we have investigated metastatic potential of cancer stem cells (CSCs) isolated from mammary tumors of a Brca1-mutant mouse model. Our data indicated that CSCs, which are enriched in CD24(+)CD29(+)/CD49f(+) cell population, displayed much higher migration ability than CD24(-)CD29(-)/CD49f (-) cells in tissue culture and enhanced metastatic potential in allograft-nude mice. CD24(+)CD29(+) cells maintained the ability to differentiate and reconstitute heterogeneity in the metastatic tumors whereas CD24(-)CD29(-) cells could not. Corresponding to their enhanced metastatic ability, CD24(+)CD29(+) cells exhibited features of the epithelial to mesenchymal transition. Finally, using short hairpin RNA to knock down CD29 and/or CD49f in metastatic cancer cells, we demonstrated that while acute knockdown of CD29 or CD49f alone slightly decreased cell migration ability, knockdown of both genes generated a profound effect to block their migration, revealing an overlapping, yet critical function of both genes in the migration of CSCs. Our findings indicate that in addition to serving as markers of CSCs, CD29 and CD49f may also serve as potential therapeutic targets for cancer metastasis.	[Vassilopoulos, A.; Chisholm, C.; Lahusen, T.; Zheng, H.; Deng, C-X] NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Deng, CX (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA.	chuxiad@bdg10.niddk.nih.gov	deng, chuxia/N-6713-2016		Intramural Research Program of the National Institute of Diabetes, Digestive and Kidney Diseases; National Institutes of Health, USA	Intramural Research Program of the National Institute of Diabetes, Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank members of the Deng lab for critical reading of the manuscript. This work was supported by the Intramural Research Program of the National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; Ali HR, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3061; Baccelli I, 2012, J CELL BIOL, V198, P281, DOI 10.1083/jcb.201202014; Brody LC, 1998, MEDICINE, V77, P208, DOI 10.1097/00005792-199805000-00006; Dave B, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr2938; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Deng CX, 2003, HUM MOL GENET, V12, pR113, DOI 10.1093/hmg/ddg082; Deng CX, 2000, BIOESSAYS, V22, P728; Deng CX, 2002, ENVIRON MOL MUTAGEN, V39, P171, DOI 10.1002/em.10069; Diaz-Cruz Edgar S, 2010, Breast Dis, V32, P85, DOI 10.3233/BD-2010-0308; Dine J, 2013, CANCER METAST REV, V32, P25, DOI 10.1007/s10555-012-9403-7; Drost RM, 2009, BRIT J CANCER, V101, P1651, DOI 10.1038/sj.bjc.6605350; Eccles DM, 2005, LANCET ONCOL, V6, P705, DOI 10.1016/S1470-2045(05)70318-1; Foroni C, 2012, CANCER TREAT REV, V38, P689, DOI 10.1016/j.ctrv.2011.11.001; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gritsenko PG, 2012, J PATHOL, V226, P185, DOI 10.1002/path.3031; Hale JS, 2012, CELL ADHES MIGR, V6, P346, DOI 10.4161/cam.21294; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hu YF, 2009, INT J BIOL SCI, V5, P20; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Lahlou H, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2905; Lanza DG, 2012, TUMOR BIOL, V33, P1997, DOI 10.1007/s13277-012-0459-3; Lathia JD, 2011, CELL STEM CELL, V8, P482, DOI 10.1016/j.stem.2011.04.013; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Liu HP, 2010, P NATL ACAD SCI USA, V107, P18115, DOI 10.1073/pnas.1006732107; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NICOLSON GL, 1992, ONCOL RES, V4, P389; Nielsen PK, 2001, J BIOL CHEM, V276, P10906, DOI 10.1074/jbc.M008743200; NIESSEN CM, 1994, J CELL SCI, V107, P543; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Podsypanina K, 2008, SCIENCE, V321, P1841, DOI 10.1126/science.1161621; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Song LL, 2007, EXPERT OPIN BIOL TH, V7, P431, DOI 10.1517/14712598.7.4.431; SONNENBERG A, 1991, EXP CELL RES, V197, P234, DOI 10.1016/0014-4827(91)90428-W; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vassilopoulos A, 2008, INT J BIOL SCI, V4, P133, DOI 10.7150/ijbs.4.133; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Zhang JR, 2005, MOL CANCER RES, V3, P531, DOI 10.1158/1541-7786.MCR-05-0192; Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353	47	48	51	1	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2014	33	47					5477	5482		10.1038/onc.2013.516	http://dx.doi.org/10.1038/onc.2013.516			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MG	24317509				2022-12-28	WOS:000345120700010
J	Formosa, A; Markert, EK; Lena, AM; Italiano, D; Finazzi-Agro, E; Levine, AJ; Bernardini, S; Garabadgiu, AV; Melino, G; Candi, E				Formosa, A.; Markert, E. K.; Lena, A. M.; Italiano, D.; Finazzi-Agro, E.; Levine, A. J.; Bernardini, S.; Garabadgiu, A. V.; Melino, G.; Candi, E.			MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells	ONCOGENE			English	Article						microRNAs; prostate cancer; metastasis	MESENCHYMAL TRANSITION; EXPRESSION; CLUSTER; TUMOR; STEMNESS; TARGETS; MIRNAS; P53	miRNAs act as oncogenes or tumor suppressors in a wide variety of human cancers, including prostate cancer (PCa). We found a severe and consistent downregulation of miRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 region in metastatic cell lines as compared with normal prostatic epithelial cells (PrEC). In specimens of human prostate (28 normals, 99 primary tumors and 13 metastases), lower miRNA levels correlated significantly with a higher incidence of metastatic events and higher prostate specific antigen (PSA) levels, with similar trends observed for lymph node invasion and the Gleason score. We transiently transfected 10 members of the 14q32.31 cluster in normal prostatic epithelial cell lines and characterized their affect on malignant cell behaviors, including proliferation, apoptosis, migration and invasion. Finally, we identified FZD4, a gene important for epithelial-to-mesenchymal transition in (PCa), as a target of miR-377.	[Formosa, A.; Lena, A. M.; Italiano, D.; Finazzi-Agro, E.; Bernardini, S.; Melino, G.; Candi, E.] Univ Roma Tor Vergata, Dept Expt Med & Surg, I-00133 Rome, Italy; [Formosa, A.; Melino, G.] IDI IRCCS, Rome, Italy; [Markert, E. K.; Levine, A. J.] Simons Ctr Syst Biol, Inst Adv Study, Princeton, NJ USA; [Garabadgiu, A. V.] St Petersburg Technol Inst, Mol Pharmacol Lab, St Petersburg, Russia	University of Rome Tor Vergata; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Institute for Advanced Study - USA; Saint Petersburg State Institute of Technology	Candi, E (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy.	candi@uniroma2.it	Agrò, Enrico Finazzi/N-7969-2018; Lena, Anna Maria/AAI-5042-2020	Agrò, Enrico Finazzi/0000-0002-0308-8824; Garabadjiu, Alexander/0000-0001-9972-8517	AIRC grant [2013IG 13387]; AIRC [2011-IG11955]; Ministry of Education and Science of the Russian Federation [11.G34.31.0069]; Min. Salute [ric. Oncologica26/07]; IstitutoDermopatico-dell'Immacolata [RF06 c.73, RF07 c.57, RF08 c.15]; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	AIRC grant(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro); Ministry of Education and Science of the Russian Federation(Ministry of Education and Science, Russian Federation); Min. Salute(Ministry of Health, Italy); IstitutoDermopatico-dell'Immacolata; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work has been mainly supported by AIRC grant (2013IG 13387) to EC and partially supported by AIRC (2011-IG11955) and Ministry of Education and Science of the Russian Federation (11.G34.31.0069) to GM. Research described in this article was also supported in part by Min. Salute (ric. Oncologica26/07), 'IstitutoDermopatico-dell'Immacolata' (RF06 c.73, RF07 c.57, RF08 c.15, RF07 c.57) to GM.	Aberdam D, 2008, TRENDS BIOCHEM SCI, V33, P583, DOI 10.1016/j.tibs.2008.09.002; Afanasyeva EA, 2011, CELL DEATH DIFFER, V18, P974, DOI 10.1038/cdd.2010.164; Agueli C, 2010, AM J HEMATOL, V85, P575, DOI 10.1002/ajh.21758; Amelio I, 2012, J CELL BIOL, V199, P347, DOI 10.1083/jcb.201203134; Antonov AV, 2013, CELL DEATH DIFFER, V20, P367, DOI 10.1038/cdd.2012.137; Aqeilan RI, 2010, CELL DEATH DIFFER, V17, P215, DOI 10.1038/cdd.2009.69; Barlev NA, 2010, CELL DEATH DIFFER, V17, P373, DOI 10.1038/cdd.2009.73; Bartkowiak D, 1999, CYTOMETRY, V37, P191, DOI 10.1002/(SICI)1097-0320(19991101)37:3<191::AID-CYTO5>3.0.CO;2-U; Boll K, 2013, ONCOGENE, V32, P277, DOI 10.1038/onc.2012.55; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cervo PRD, 2012, P NATL ACAD SCI USA, V109, P1133, DOI 10.1073/pnas.1112257109; Costa FF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025114; Couts KL, 2013, ONCOGENE, V32, P1959, DOI 10.1038/onc.2012.209; Da Rocha ST, 2008, TRENDS GENET, V24, P306, DOI 10.1016/j.tig.2008.03.011; Devor EJ, 2012, EXP THER MED, V3, P677, DOI 10.3892/etm.2012.458; Ferlay J, 2010, IARC CANCERBASE; Formosa A, 2013, ONCOGENE, V32, P127, DOI 10.1038/onc.2012.14; Gandellini P, 2012, CELL DEATH DIFFER, V19, P1750, DOI 10.1038/cdd.2012.56; Gattolliat CH, 2011, BRIT J CANCER, V105, P1352, DOI 10.1038/bjc.2011.388; Gupta S, 2010, CANCER RES, V70, P6735, DOI 10.1158/0008-5472.CAN-10-0244; Haller F, 2010, J PATHOL, V220, P71, DOI 10.1002/path.2610; Hassan O, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-9; Hudson RS, 2013, ONCOGENE, V32, P4139, DOI 10.1038/onc.2012.424; Jurmeister S, 2012, MOL CELL BIOL, V32, P633, DOI 10.1128/MCB.06212-11; Kappelmann M, 2013, ONCOGENE, V32, P2984, DOI 10.1038/onc.2012.307; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kuriyama M, 1996, Int J Urol, V3, P462, DOI 10.1111/j.1442-2042.1996.tb00577.x; Lavon I, 2010, NEURO-ONCOLOGY, V12, P422, DOI 10.1093/neuonc/nop061; Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69; Lin J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.134; MacFarlane LA, 2010, CURR GENOMICS, V11, P537, DOI 10.2174/138920210793175895; Martens-Uzunova ES, 2012, ONCOGENE, V31, P978, DOI 10.1038/onc.2011.304; Musumeci M, 2011, ONCOGENE, V30, P4231, DOI 10.1038/onc.2011.140; Nair VS, 2012, JNCI-J NATL CANCER I, V104, P528, DOI 10.1093/jnci/djs027; Olive V, 2010, INT J BIOCHEM CELL B, V42, P1348, DOI 10.1016/j.biocel.2010.03.004; Peltier HJ, 2008, RNA, V14, P844, DOI 10.1261/rna.939908; Puissegur MP, 2011, CELL DEATH DIFFER, V18, P465, DOI 10.1038/cdd.2010.119; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Seitz H, 2004, GENOME RES, V14, P1741, DOI 10.1101/gr.2743304; Streicher KL, 2012, ONCOGENE, V31, P1558, DOI 10.1038/onc.2011.345; Takayama K, 2011, ONCOGENE, V30, P619, DOI 10.1038/onc.2010.436; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thayanithy V, 2012, BONE, V50, P171, DOI 10.1016/j.bone.2011.10.012; Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109; Ueno K, 2012, MOL CANCER THER, V11, P244, DOI 10.1158/1535-7163.MCT-11-0592; Viticchie G, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.174; Yu J, 2010, FASEB J, V24, P3950, DOI 10.1096/fj.10-157404; Zehavi L, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-44; Zhang H, 2011, CELL DEATH DIFFER, V18, P1702, DOI 10.1038/cdd.2011.28; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105	50	256	268	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2014	33	44					5173	5182		10.1038/onc.2013.451	http://dx.doi.org/10.1038/onc.2013.451			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR9RZ	24166498				2022-12-28	WOS:000343914900004
J	Liu, T; Wang, N; Cao, J; Sofiadis, A; Dinets, A; Zedenius, J; Larsson, C; Xu, D				Liu, T.; Wang, N.; Cao, J.; Sofiadis, A.; Dinets, A.; Zedenius, J.; Larsson, C.; Xu, D.			The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas	ONCOGENE			English	Article						TERT promoter mutation; telomere shortening; telomerase; thyroid cancer	REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; GENE-EXPRESSION; DIAGNOSIS; SURVIVAL; SAMPLES; LENGTH; TUMORS; PCR	Telomerase activation through induction of its catalytic component telomerase reverse transcriptase (TERT) expression is essential for malignant transformation. TERT promoter mutations namely C228T and C250T that stimulate TERT transcription and telomerase activation have recently been identified in many human malignancies. We thus determined these mutations and their biological and clinical implications in thyroid carcinomas in the present study. The TERT promoter was sequenced in 10 thyroid cancer cell lines and 144 tumors from 20 patients with anaplastic thyroid carcinoma (ATC), 51 with papillary thyroid carcinoma (PTC), 36 with follicular thyroid carcinoma (FTC), and 37 with medullary thyroid carcinoma (MTC). We identified C228T or C250T mutation in 6/8 of ATC cell lines, as well as in tumor tissue from 10/20, 13/51, 8/36 and 0/37 patients with ATC, PTC, FTC and MTC, respectively. In PTC patients, these mutations were exclusively present in the group with age 445 years (P<0.0001), and highly correlated shorter telomeres (P<0.0001) and distant metastasis (P = 0.028). The previous radioactivity exposure did not induce the mutation. The presence of C228T or C250T was an independent predictor associated with shorter disease-related survival (DRS) in the entire cohort (P<0.0001), as well as among patients 445 years (P = 0.021). ATC patients carrying the mutation survived shorter than those without mutations, although not statistically significant (P = 0.129). The TERT promoter mutation was associated with overall survival (P = 0.038) and DRS (P = 0.058) of FTC patients. Taken together, age-and shorter telomere-dependent TERT promoter mutations occur frequently in follicular cell-derived thyroid carcinoma (ATC, PTC and FTC) but not in parafollicular cell-originated MTC, and may serve as a marker for aggressive disease and poor outcome.	[Liu, T.; Xu, D.] Karolinska Inst, Dept Med, Div Hematol, S-17176 Stockholm, Sweden; [Liu, T.; Xu, D.] Karolinska Inst, Dept Med, Ctr Mol Med, S-17176 Stockholm, Sweden; [Liu, T.; Wang, N.; Cao, J.; Sofiadis, A.; Dinets, A.; Zedenius, J.; Larsson, C.; Xu, D.] Karolinska Univ Hosp Solna, Stockholm, Sweden; [Wang, N.; Sofiadis, A.; Larsson, C.] Karolinska Inst, Dept Oncol Pathol, S-17176 Stockholm, Sweden; [Wang, N.; Sofiadis, A.; Larsson, C.] Karolinska Inst, Canc Ctr Karolinska, S-17176 Stockholm, Sweden; [Cao, J.] Karolinska Inst, Dept Womens & Childrens Hlth, S-17176 Stockholm, Sweden; [Cao, J.] Karolinska Inst, Ctr Mol Med, S-17176 Stockholm, Sweden; [Dinets, A.; Zedenius, J.] Karolinska Inst, Dept Mol Med & Surg, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	Larsson, C (corresponding author), Karolinska Inst, Dept Oncol Pathol, S-17176 Stockholm, Sweden.	catharina.larsson@ki.se; Dawei.Xu@ki.se	Dinets, Andrii/AAA-3494-2019	Dinets, Andrii/0000-0001-9680-7519; Xu, Dawei/0000-0003-3141-4524; Sofiadis, Anastasios/0000-0003-4057-7739	Swedish Cancer Society, the Swedish Research Council; Cancer Society in Stockholm, the Stockholm County Council; Karolinska Institutet	Swedish Cancer Society, the Swedish Research Council(Swedish Research CouncilSwedish Cancer Society); Cancer Society in Stockholm, the Stockholm County Council; Karolinska Institutet(Karolinska Institutet)	We thank Drs N-E Heldin (Uppsala University, Sweden), and BG Robinson and Mr. E Wennerberg (University of Sydney, Australia) for cell lines. The study was funded by grants from the Swedish Cancer Society, the Swedish Research Council, Cancer Society in Stockholm, the Stockholm County Council and Karolinska Institutet. Dr M Hulchiy (Kyiv CIty Teaching Endocrinological Center, Ukraine) for help with retrieval of Ukraine PTC tissue samples.	Aogi K, 1998, CLIN CANCER RES, V4, P1965; Asaad Nancy Y, 2006, J Egypt Natl Canc Inst, V18, P8; Blackburn EH, 2006, NAT MED, V12, P1133, DOI 10.1038/nm1006-1133; Bornstein-Quevedo L, 2003, ENDOCR PATHOL, V14, P213, DOI 10.1007/s12022-003-0013-3; Brousset P, 1997, J CLIN ENDOCR METAB, V82, P4214, DOI 10.1210/jc.82.12.4214; Cao Y, 2002, ONCOGENE, V21, P3130, DOI 10.1038/sj.onc.1205419; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Cheng AJ, 1998, BRIT J CANCER, V77, P2177, DOI 10.1038/bjc.1998.363; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; Daniel M, 2012, GENE, V498, P135, DOI 10.1016/j.gene.2012.01.095; Dinets A, 2012, EUR J ENDOCRINOL, V166, P1049, DOI 10.1530/EJE-12-0144; Domomt J, 2005, J CLIN ONCOL, V23, P3086, DOI 10.1200/JCO.2005.06.944; Foukakis T, 2007, ENDOCR-RELAT CANCER, V14, P381, DOI 10.1677/ERC-06-0023; Gertler R, 2004, J CLIN ONCOL, V22, P1807, DOI 10.1200/JCO.2004.09.160; Guerra LN, 2006, CLIN CHIM ACTA, V370, P180, DOI 10.1016/j.cca.2006.02.009; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoang-Vu C, 2002, INT J ONCOL, V21, P265; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Kammori M, 2003, INT J ONCOL, V22, P985; Killela PJ, 2013, P NATL ACAD SCI USA, V110, P6021, DOI 10.1073/pnas.1303607110; Lerma E, 2005, CANCER CYTOPATHOL, V105, P492, DOI 10.1002/cncr.21380; Liu XL, 2013, ENDOCR-RELAT CANCER, V20, P603, DOI 10.1530/ERC-13-0210; Liu Z, 2013, ONCOGENE, V32, P4203, DOI 10.1038/onc.2012.441; Park JI, 2009, NATURE, V460, P66, DOI 10.1038/nature08137; Saji M, 1999, CLIN CANCER RES, V5, P1483; Sanders RP, 2004, J CLIN ONCOL, V22, P3790, DOI 10.1200/JCO.2004.03.043; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Sputova Klara, 2013, Genome Integr, V4, P4, DOI 10.1186/2041-9414-4-4; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Straight AM, 2002, J ENDOCRINOL INVEST, V25, P302, DOI 10.1007/BF03344009; Tallet A, 2014, ONCOGENE, V33, P3748, DOI 10.1038/onc.2013.351; Umbricht CB, 1997, CANCER RES, V57, P2144; Wang YC, 2008, THYROID, V18, P1055, DOI 10.1089/thy.2008.0101; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431	35	168	174	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2014	33	42					4978	4984		10.1038/onc.2013.446	http://dx.doi.org/10.1038/onc.2013.446			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OB	24141777				2022-12-28	WOS:000343768000002
J	Zhao, L; Ye, P; Gonda, TJ				Zhao, L.; Ye, P.; Gonda, T. J.			The MYB proto-oncogene suppresses monocytic differentiation of acute myeloid leukemia cells via transcriptional activation of its target gene GFI1	ONCOGENE			English	Article						U937; MYB; GFI1; monocytic differentiation; target gene	HUMAN HEMATOPOIETIC-CELLS; FINGER PROTEIN GFI-1; C-MYB; INSERTIONAL MUTAGENESIS; CONSTITUTIVE EXPRESSION; LYMPHOBLASTIC-LEUKEMIA; HUMAN NEUTROPENIA; REPRESSOR GFI-1; STEM-CELLS; T-ALL	The MYB gene is a master regulator of hematopoiesis and contributes to leukemogenesis in several species including humans. Although it is clear that MYB can promote proliferation, suppress apoptosis and block differentiation, the identities of the MYB target genes that mediate these effects have only been partially elucidated. Several studies, including our own, have collectively identified substantial numbers of MYB target genes, including candidates for each of these activities; however, functional validation, particularly in the case of differentiation suppression, has lagged well behind. Here we show that GFI1, which encodes an important regulator of hematopoietic stem cell (HSC) function and granulocytic differentiation, is a direct target of MYB in myeloid leukemia cells. Chromatin immunoprecipitation and reporter studies identified a functional MYB-binding site in the promoter region of GFI, whereas ectopic expression and small hairpin RNA-mediated knockdown of MYB resulted in concomitant increases and decreases, respectively, in GFI1 expression. We also demonstrate that GFI1, like MYB, can block the induced monocytic differentiation of a human acute myeloid leukemia cell line, and most importantly, that GFI1 is essential for MYB's ability to block monocytic differentiation. Thus, we have identified a target of MYB that is a likely mediator of its myeloid differentiation-blocking activity, and which may also be involved in MYB's activities in regulating normal HSC function and myeloid differentiation.	[Zhao, L.; Ye, P.; Gonda, T. J.] Univ Queensland, Diamantina Inst, Brisbane, Qld, Australia; [Ye, P.; Gonda, T. J.] Univ Queensland, Sch Pharm, Pharm Australia Ctr Excellence, Brisbane, Qld, Australia	University of Queensland; University of Queensland	Gonda, TJ (corresponding author), Univ Queensland, Pharm Australia Ctr Excellence, Sch Pharm, Level 4,20 Cornwall St, Woolloongabba, Qld 4102, Australia.	t.gonda@uq.edu.au	Zhao, Liang/K-1484-2014	Zhao, Liang/0000-0002-3489-7421; Gonda, Thomas/0000-0002-8792-3021	National Health and Medical Research Council of Australia; University of Queensland Postdoctoral Fellowship	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); University of Queensland Postdoctoral Fellowship(University of Queensland)	This work was supported in part by a grant from the National Health and Medical Research Council of Australia (to TJG) and a University of Queensland Postdoctoral Fellowship (to PY).	Adati Naoki, 2009, BMC Res Notes, V2, P153, DOI 10.1186/1756-0500-2-153; Barry SC, 2001, HUM GENE THER, V12, P1103, DOI 10.1089/104303401750214311; Belloni E, 2011, LEUKEMIA, V25, P733, DOI 10.1038/leu.2010.317; Bert AG, 2000, PLASMID, V44, P173, DOI 10.1006/plas.2000.1474; Bonadies N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016330; Brown CY, 2010, HUM GENE THER, V21, P1005, DOI 10.1089/hum.2009.107; CASTANEDA VL, 1991, LEUKEMIA, V5, P142; Clappier E, 2007, BLOOD, V110, P1251, DOI 10.1182/blood-2006-12-064683; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; Dahl R, 2007, J BIOL CHEM, V282, P6473, DOI 10.1074/jbc.M607613200; Drabsch Y, 2007, P NATL ACAD SCI USA; Dreyling MH, 1996, P NATL ACAD SCI USA, V93, P4804, DOI 10.1073/pnas.93.10.4804; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Fu SL, 1997, CELL GROWTH DIFFER, V8, P35; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; Horman SR, 2009, BLOOD, V113, P5466, DOI 10.1182/blood-2008-09-179747; Huang M, 2010, ACTA HAEMATOL-BASEL, V123, P1, DOI 10.1159/000253856; Karsunky H, 2002, NAT GENET, V30, P295, DOI 10.1038/ng831; Khandanpour C, 2013, CANCER CELL, V23, P200, DOI 10.1016/j.ccr.2013.01.011; Knopfova L, 2008, NEOPLASMA, V55, P286; Lahortiga I, 2007, NAT GENET, V39, P593, DOI 10.1038/ng2025; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Lidonnici MR, 2010, CANCER RES, V70, P7949, DOI 10.1158/0008-5472.CAN-10-1667; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; Murati A, 2009, LEUKEMIA, V23, P85, DOI 10.1038/leu.2008.257; Nakata Y, 2007, MOL CELL BIOL, V27, P2048, DOI 10.1128/MCB.01100-06; O'Neil J, 2007, J EXP MED, V204, P3059, DOI 10.1084/jem.20071637; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Pattabiraman DR, 2013, LEUKEMIA, V27, P269, DOI 10.1038/leu.2012.225; Person RE, 2003, NAT GENET, V34, P308, DOI 10.1038/ng1170; Phelan J, 2010, NARRATIVE, V18, P1; Quelen C, 2011, BLOOD, V117, P5719, DOI 10.1182/blood-2011-01-333013; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; Ramsay RG, 2005, INT J BIOCHEM CELL B, V37, P1254, DOI 10.1016/j.biocel.2004.12.011; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; Skalamera D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020057; Suzuki H, 2009, NAT GENET, V41, P553, DOI 10.1038/ng.375; van der Meer LT, 2010, LEUKEMIA, V24, P1834, DOI 10.1038/leu.2010.195; Vassen L, 2012, AM J BLOOD RES, V2, P228; Wang Tian-Tian, 2010, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V18, P834; Wei W, 2008, CELL RES, V18, P677, DOI 10.1038/cr.2008.60; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; Wolff L, 1996, CURR TOP MICROBIOL, V211, P191; Wolff L, 2001, BLOOD CELL MOL DIS, V27, P483, DOI 10.1006/bcmd.2001.0409; Ye P, 2013, LEUKEMIA RES, V37, P595, DOI 10.1016/j.leukres.2013.01.012; Zarebski A, 2008, IMMUNITY, V28, P370, DOI 10.1016/j.immuni.2007.12.020; Zeng H, 2004, EMBO J, V23, P4116, DOI 10.1038/sj.emboj.7600419; Zhan Rong, 2010, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V18, P849; Zhao L, 2011, NUCLEIC ACIDS RES, V39, P4664, DOI 10.1093/nar/gkr024; Zornig M, 1996, ONCOGENE, V12, P1789	57	21	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2014	33	35					4442	4449		10.1038/onc.2013.419	http://dx.doi.org/10.1038/onc.2013.419			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MR	24121275				2022-12-28	WOS:000341157800009
J	Yu, F; Gao, W; Yokochi, T; Suenaga, Y; Ando, K; Ohira, M; Nakamura, Y; Nakagawara, A				Yu, F.; Gao, W.; Yokochi, T.; Suenaga, Y.; Ando, K.; Ohira, M.; Nakamura, Y.; Nakagawara, A.			RUNX3 interacts with MYCN and facilitates protein degradation in neuroblastoma	ONCOGENE			English	Article						RUNX3; MYCN; neuroblastoma; tumor suppressor	N-MYC; TUMOR-SUPPRESSOR; EXPRESSION; CANCER; GROWTH; GENE; IDENTIFICATION; PROGRESSION; INHIBITION; PROGNOSIS	RUNX3, a runt-related transcription factor, has a crucial role in dorsal root ganglion neurogenesis. Recent studies have suggested that RUNX3 acts as a tumor suppressor in stomach, colon and breast cancer. However, the biological role of RUNX3 in neuroblastoma remains elusive. Here we report that high levels of RUNX3 expression contribute to the favorable outcome in patients with neuroblastoma, whereas low levels of RUNX3 expression result in poor outcome. Array-based analysis suggested that the allelic loss at chromosome 1p36 is one of the reasons why expression of RUNX3 is downregulated in advanced neuroblastomas. Interestingly, the several patients survived from neuroblastoma with both high mRNA expressions of MYCN and RUNX3, suggesting that RUNX3 high expression might overcome the aggressive behavior of MYCN. Exogenous expression of RUNX3 strongly inhibits cell proliferation and migration in neuroblastoma cell lines. Furthermore, RUNX3 reduces the stability of MYCN protein in MYCN-amplified neuroblastoma cell lines, and this RUNX3-mediated MYCN degradation may depend on the physical interaction between RUNX3 and MYCN. Thus, our findings provide a tumor-suppressing mechanism by which RUNX3 inhibits the MYCN activity in neuroblastoma.	[Yu, F.; Gao, W.; Yokochi, T.; Suenaga, Y.; Ando, K.; Nakamura, Y.; Nakagawara, A.] Chiba Canc Ctr, Res Inst, Div Biochem & Innovat Canc Therapeut, Chiba 2608717, Japan; [Yu, F.; Nakagawara, A.] Chiba Univ, Grad Sch Med, Dept Mol Biol & Oncol, Chiba, Japan; [Yu, F.] Hebei Med Univ, Forth Hosp, Dept Thorac Surg, Shijiazhuang, Hebei, Peoples R China; [Gao, W.] Hebei Med Univ, Forth Hosp, Dept Surg 1, Shijiazhuang, Hebei, Peoples R China; [Ohira, M.] Chiba Canc Ctr, Res Inst, Div Canc Genom, Chiba 2608717, Japan	Chiba Cancer Center; Chiba University; Hebei Medical University; Hebei Medical University; Chiba Cancer Center	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Chuo Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp		Suenaga, Yusuke/0000-0001-6902-5386	Ministry of Health, Labour and Welfare for Third Term Comprehensive Control Research for Cancer; JSPS [24249061]; Takeda Science Foundation	Ministry of Health, Labour and Welfare for Third Term Comprehensive Control Research for Cancer; JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Takeda Science Foundation(Takeda Science Foundation (TSF))	This work was supported in part by a Grant-in-Aid from the Ministry of Health, Labour and Welfare for Third Term Comprehensive Control Research for Cancer, JSPS KAKENHI (Grant number 24249061) and a Grant from Takeda Science Foundation.	Akter J, 2011, CLIN CANCER RES, V17, P6681, DOI 10.1158/1078-0432.CCR-11-0313; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Chen L, 2008, CANCER RES, V70, P1377; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Chuang LSH, 2010, ONCOGENE, V29, P2605, DOI 10.1038/onc.2010.88; Cotterill SJ, 2000, EUR J CANCER, V36, P901, DOI 10.1016/S0959-8049(00)00058-7; Fredlund E, 2008, P NATL ACAD SCI USA, V105, P14094, DOI 10.1073/pnas.0804455105; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Gustafson WC, 2010, ONCOGENE, V29, P1249, DOI 10.1038/onc.2009.512; Huang B, 2012, ONCOGENE, V31, P527, DOI 10.1038/onc.2011.252; Inoue KI, 2007, J BIOL CHEM, V282, P24175, DOI 10.1074/jbc.M703746200; Inoue K, 2011, GENE, V487, P151, DOI 10.1016/j.gene.2011.05.016; Inoue KI, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-20; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lee CWL, 2011, GYNECOL ONCOL, V122, P410, DOI 10.1016/j.ygyno.2011.04.044; Levanon D, 2004, ONCOGENE, V23, P4211, DOI 10.1038/sj.onc.1207670; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lin FC, 2012, ONCOGENE, V31, P4302, DOI 10.1038/onc.2011.596; Maris JM, 2000, J CLIN ONCOL, V18, P1888, DOI 10.1200/JCO.2000.18.9.1888; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Nakagawara A, 2004, PROG BRAIN RES, V146, P233, DOI 10.1016/S0079-6123(03)46015-9; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; Nakagawara A, 1998, Hum Cell, V11, P115; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Ohira M, 2003, ONCOGENE, V22, P5525, DOI 10.1038/sj.onc.1206853; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Park JR, 2010, HEMATOL ONCOL CLIN N, V24, P65, DOI 10.1016/j.hoc.2009.11.011; Riley RD, 2004, CLIN CANCER RES, V10, P4, DOI 10.1158/1078-0432.CCR-1051-2; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102; Suenaga Y, 2009, BIOCHEM BIOPH RES CO, V390, P21, DOI 10.1016/j.bbrc.2009.09.044; Takenobu H, 2011, ONCOGENE, V30, P97, DOI 10.1038/onc.2010.383; Tomioka N, 2008, ONCOGENE, V27, P441, DOI 10.1038/sj.onc.1210661; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; Yamada C, 2010, J BIOL CHEM, V285, P16693, DOI 10.1074/jbc.M109.055525; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05	42	9	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2601	2609		10.1038/onc.2013.221	http://dx.doi.org/10.1038/onc.2013.221			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23851507				2022-12-28	WOS:000336502700006
J	Postel-Vinay, S; Bajrami, I; Friboulet, L; Elliott, R; Fontebasso, Y; Dorvault, N; Olaussen, KA; Andre, F; Soria, JC; Lord, CJ; Ashworth, A				Postel-Vinay, S.; Bajrami, I.; Friboulet, L.; Elliott, R.; Fontebasso, Y.; Dorvault, N.; Olaussen, K. A.; Andre, F.; Soria, J-C; Lord, C. J.; Ashworth, A.			A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer	ONCOGENE			English	Article						non-small cell lung cancer; ERCC1; PARP1; synthetic lethality; DNA repair	NUCLEOTIDE EXCISION-REPAIR; DNA-REPAIR; OVARIAN-CANCER; ERCC1; EXPRESSION; RESISTANCE; CISPLATIN; ENDONUCLEASE; CHEMOTHERAPY; SENSITIVITY	Excision repair cross-complementation group 1 (ERCC1) is a DNA repair enzyme that is frequently defective in non-small cell lung cancer (NSCLC). Although low ERCC1 expression correlates with platinum sensitivity, the clinical effectiveness of platinum therapy is limited, highlighting the need for alternative treatment strategies. To discover new mechanism-based therapeutic strategies for ERCC1-defective tumours, we performed high-throughput drug screens in an isogenic NSCLC model of ERCC1 deficiency and dissected the mechanism underlying ERCC1-selective effects by studying molecular biomarkers of tumour cell response. The high-throughput screens identified multiple clinical poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitors, such as olaparib (AZD-2281), niraparib (MK-4827) and BMN 673, as being selective for ERCC1 deficiency. We observed that ERCC1-deficient cells displayed a significant delay in double-strand break repair associated with a profound and prolonged G2/M arrest following PARP1/2 inhibitor treatment. Importantly, we found that ERCC1 isoform 202, which has recently been shown to mediate platinum sensitivity, also modulated PARP1/2 sensitivity. A PARP1/2 inhibitor-synthetic lethal siRNA screen revealed that ERCC1 deficiency was epistatic with homologous recombination deficiency. However, ERCC1-deficient cells did not display a defect in RAD51 foci formation, suggesting that ERCC1 might be required to process PARP1/2 inhibitor-induced DNA lesions before DNA strand invasion. PARP1 silencing restored PARP1/2 inhibitor resistance in ERCC1-deficient cells but had no effect in ERCC1-proficient cells, supporting the hypothesis that PARP1 might be required for the ERCC1 selectivity of PARP1/2 inhibitors. This study suggests that PARP1/2 inhibitors as a monotherapy could represent a novel therapeutic strategy for NSCLC patients with ERCC1-deficient tumours.	[Postel-Vinay, S.; Bajrami, I.; Elliott, R.; Fontebasso, Y.; Lord, C. J.; Ashworth, A.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Postel-Vinay, S.; Bajrami, I.; Elliott, R.; Fontebasso, Y.; Lord, C. J.; Ashworth, A.] Inst Canc Res, CRUK Gene Funct Lab, London SW3 6JB, England; [Postel-Vinay, S.; Friboulet, L.; Dorvault, N.; Olaussen, K. A.; Andre, F.; Soria, J-C] Inst Gustave Roussy, Dept Med Unite INSERM 981, Villejuif, France; [Olaussen, K. A.; Andre, F.; Soria, J-C] Univ Paris 11, Paris, France	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Lord, CJ (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	chris.lord@icr.ac.uk; alan.ashworth@icr.ac.uk	Lord, Christopher J/B-3295-2012; Soria, Jean-Charles/F-3619-2014; friboulet, luc/N-7276-2015; Lord, Christopher/AAX-7130-2021; ANDRE, Fabrice/AAL-2683-2020	Lord, Christopher J/0000-0002-3226-0515; friboulet, luc/0000-0002-1129-4978; ANDRE, Fabrice/0000-0001-5795-8357; Olaussen, Ken/0000-0002-3115-8914	NHS; Cancer Research UK; European Union; European Society of Medical Oncology; Institut National du Cancer: Bourse pour la Formation a la Recherche Translationnelle; Cancer Research UK [14276] Funding Source: researchfish	NHS; Cancer Research UK(Cancer Research UK); European Union(European Commission); European Society of Medical Oncology; Institut National du Cancer: Bourse pour la Formation a la Recherche Translationnelle; Cancer Research UK(Cancer Research UK)	We thank David Roberston and Marieke Aarts for assistance with confocal microscopy and FACS analysis, and Jerry Shen and Len Post at Biomarin for the provision of BMN 673. We also acknowledge NHS funding to the NIHR Royal Marsden Hospital BRC. This work was supported by grants from Cancer Research UK and The European Union as part of the FP7 teams 'DDResponse' and 'Eurocan'. SPV is supported by a Translational Research Fellowship from the European Society of Medical Oncology (2011 and 2012) and by funding from the Institut National du Cancer: Bourse pour la Formation a la Recherche Translationnelle (2011)	Andre F, 2011, NAT REV CLIN ONCOL, V8, P171, DOI 10.1038/nrclinonc.2011.4; Bajrami I, 2012, EMBO MOL MED, V4, P1087, DOI 10.1002/emmm.201201250; Bergstralh DT, 2008, TRENDS GENET, V24, P70, DOI 10.1016/j.tig.2007.11.003; Camidge DR, 2012, LANCET ONCOL, V13, P1011, DOI 10.1016/S1470-2045(12)70344-3; Chen SF, 2010, LUNG CANCER, V70, P63, DOI 10.1016/j.lungcan.2010.05.010; Cheng HY, 2013, CARCINOGENESIS, V34, P739, DOI 10.1093/carcin/bgs393; Curtin NJ, 2012, NAT REV CANCER, V12, P801, DOI 10.1038/nrc3399; DABHOLKAR M, 1995, ONCOL REP, V2, P209; Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548; Fagbemi AF, 2011, DNA REPAIR, V10, P722, DOI 10.1016/j.dnarep.2011.04.022; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Friboulet L, 2013, NEW ENGL J MED, V368, P1101, DOI 10.1056/NEJMoa1214271; Graeser M, 2010, CLIN CANCER RES, V16, P6159, DOI 10.1158/1078-0432.CCR-10-1027; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Johnson N, 2011, NAT MED, V17, P875, DOI 10.1038/nm.2377; Kedar PS, 2012, MOL CANCER RES, V10, P360, DOI 10.1158/1541-7786.MCR-11-0477; Kirschner K, 2010, ANTICANCER RES, V30, P3223; Langelier MF, 2012, SCIENCE, V336, P728, DOI 10.1126/science.1216338; Langelier MF, 2011, J BIOL CHEM, V286, P10690, DOI 10.1074/jbc.M110.202507; Langer CJ, 2012, CANCER-AM CANCER SOC, V118, P3882, DOI 10.1002/cncr.26718; Lord CJ, 2009, J CLIN PATHOL, V62, P195, DOI 10.1136/jcp.2008.058735; Lord RVN, 2002, CLIN CANCER RES, V8, P2286; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Metzger R, 2010, FUTURE ONCOL, V6, P1735, DOI [10.2217/fon.10.140, 10.2217/FON.10.140]; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Niedernhofer LJ, 2001, EMBO J, V20, P6540, DOI 10.1093/emboj/20.22.6540; Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570; Patterson MJ, 2012, EUR J CANCER, V48, P106, DOI 10.1016/S0959-8049(12)72146-9; Postel-Vinay S, 2012, NAT REV CLIN ONCOL, V9, P144, DOI 10.1038/nrclinonc.2012.3; Rehman FL, 2010, NAT REV CLIN ONCOL, V7, P718, DOI 10.1038/nrclinonc.2010.172; Sijbers AM, 1996, NUCLEIC ACIDS RES, V24, P3370, DOI 10.1093/nar/24.17.3370; Simon GR, 2012, CANCER-AM CANCER SOC, V118, P2525, DOI 10.1002/cncr.26522; Steffensen KD, 2009, INT J GYNECOL CANCER, V19, P820, DOI 10.1111/IGC.0b013e3181a12e09; Sun YH, 2009, CANCER INVEST, V27, P891, DOI 10.3109/07357900902744536; Tripsianes K, 2005, STRUCTURE, V13, P1849, DOI 10.1016/j.str.2005.08.014; Turner NC, 2008, EMBO J, V27, P1368, DOI 10.1038/emboj.2008.61; Vilmar AC, 2011, EUR RESPIR REV, V20, P45, DOI 10.1183/09059180.00007310; Vilmar AC, 2010, ANN ONCOL, V21, P1817, DOI 10.1093/annonc/mdq053; Wang B, 2009, MOL CANCER THER, V8, DOI 10.1158/1535-7163.TARG-09-A121; Yin M, 2011, CLIN CANCER RES, V17, P1632, DOI 10.1158/1078-0432.CCR-10-2169; Zhang YW, 2011, NUCLEIC ACIDS RES, V39, P3607, DOI 10.1093/nar/gkq1304	41	65	67	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2013	32	47					5377	5387		10.1038/onc.2013.311	http://dx.doi.org/10.1038/onc.2013.311			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	254PM	23934192				2022-12-28	WOS:000327177600001
J	Tago, K; Funakoshi-Tago, M; Itoh, H; Furukawa, Y; Kikuchi, J; Kato, T; Suzuki, K; Yanagisawa, K				Tago, K.; Funakoshi-Tago, M.; Itoh, H.; Furukawa, Y.; Kikuchi, J.; Kato, T.; Suzuki, K.; Yanagisawa, K.			Arf tumor suppressor disrupts the oncogenic positive feedback loop including c-Myc and DDX5	ONCOGENE			English	Article						Arf; c-Myc; DDX5	RNA HELICASE P68; DEAD-BOX; RIBOSOME BIOGENESIS; TRANSCRIPTIONAL ACTIVITY; CELL-PROLIFERATION; PROTEIN; P53; P19(ARF); PATHWAYS; PROMOTES	Tumor suppressor protein p19(ARF) (Arf; p14(ARF) in humans) functions in both p53-dependent and -independent modes to counteract hyper-proliferative signals caused by proto-oncogene activation, but its p53-independent activities remain poorly understood. Using the tandem affinity purification-tag technique, we purified Arf-containing protein complexes and identified p68 DEAD-box protein (DDX5) as a novel interacting protein of Arf. In this study, we found that DDX5 interacts with c-Myc, and harbors essential roles for c-Myc-mediated transcription and its transforming activity. Furthermore, when c-Myc was forcibly expressed, the expression level of DDX5 protein was drastically increased through the acceleration of protein synthesis of DDX5, suggesting the presence of an oncogenic positive feedback loop including c-Myc and DDX5. Strikingly, Arf blocked the physical interaction between DDX5 and c-Myc, and drove away DDX5 from the promoter of c-Myc target genes. These observations most likely indicate the mechanism by which Arf causes p53-independent tumor-suppressive activity.	[Tago, K.; Yanagisawa, K.] Jichi Med Univ, Sch Med, Dept Biochem, Div Struct Biochem, Shimotsuke, Tochigi 3290498, Japan; [Funakoshi-Tago, M.] Keio Univ, Dept Biochem, Fac Pharm, Minato Ku, Tokyo 108, Japan; [Itoh, H.] Nara Inst Sci & Technol, Grad Sch Biol Sci, Dept Cell Biol, Lab Signal Transduct, Ikoma, Japan; [Furukawa, Y.; Kikuchi, J.] Jichi Med Univ, Ctr Mol Med, Div Stem Cell Regulat, Shimotsuke, Tochigi 3290498, Japan; [Kato, T.; Suzuki, K.] Jichi Med Univ, Saitama Med Ctr, Dept Surg, Omiya Ku, Shimotsuke, Tochigi 3290498, Japan	Jichi Medical University; Keio University; Nara Institute of Science & Technology; Jichi Medical University; Jichi Medical University	Tago, K (corresponding author), Jichi Med Univ, Sch Med, Dept Biochem, Div Struct Biochem, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	ktago@jichi.ac.jp	Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418	MEXT [20770103]; Takeda Science Foundation; Grants-in-Aid for Scientific Research [25118721] Funding Source: KAKEN	MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Charles Sherr and Martine Roussel for critical advice and reagents, and Michael Washburn of Stowers Institute for Medical Research Proteomics Center for performing MudPIT analysis. This work was supported by a grant-in-aid for scientific research from the MEXT (20770103), MEXT-supported program for the strategic research foundation at private universities (2013-2017) and the Takeda Science Foundation.	Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Chen LH, 2003, ONCOGENE, V22, P5348, DOI 10.1038/sj.onc.1206851; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Datta A, 2004, J BIOL CHEM, V279, P36698, DOI 10.1074/jbc.M312305200; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Dubey P, 1997, J EXP MED, V185, P695, DOI 10.1084/jem.185.4.695; Duran RV, 2012, MOL CELL, V47, P349, DOI 10.1016/j.molcel.2012.05.043; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Heinlein UAO, 1998, J PATHOL, V184, P345, DOI 10.1002/(SICI)1096-9896(199804)184:4<345::AID-PATH1243>3.0.CO;2-6; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jacobs AMF, 2007, ONCOGENE, V26, P5866, DOI 10.1038/sj.onc.1210387; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kelly-Spratt KS, 2004, PLOS BIOL, V2, P1138, DOI 10.1371/journal.pbio.0020242; Kuo ML, 2008, CELL CYCLE, V7, P3378, DOI 10.4161/cc.7.21.6930; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Martin DE, 2006, CELL METAB, V4, P259, DOI 10.1016/j.cmet.2006.09.002; Packham G, 1997, ONCOGENE, V15, P1219, DOI 10.1038/sj.onc.1201273; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; QUELLE DE, 1995, CELL, V83, P993; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Saporita AJ, 2011, CANCER RES, V71, P6708, DOI 10.1158/0008-5472.CAN-11-1472; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Tago K, 2005, P NATL ACAD SCI USA, V102, P7689, DOI 10.1073/pnas.0502978102; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Xirodimas DP, 2002, FEBS LETT, V528, P207, DOI 10.1016/S0014-5793(02)03310-0; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yang LQ, 2005, MOL CANCER RES, V3, P355, DOI 10.1158/1541-7786.MCR-05-0022; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	48	21	22	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					310	318		10.1038/onc.2013.561	http://dx.doi.org/10.1038/onc.2013.561			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24469041				2022-12-28	WOS:000348145500005
J	Montenegro, MF; Sanchez-del-Campo, L; Fernandez-Perez, MP; Saez-Ayala, M; Cabezas-Herrera, J; Rodriguez-Lopez, JN				Montenegro, M. F.; Sanchez-del-Campo, L.; Fernandez-Perez, M. P.; Saez-Ayala, M.; Cabezas-Herrera, J.; Rodriguez-Lopez, J. N.			Targeting the epigenetic machinery of cancer cells	ONCOGENE			English	Review						methionine; anti-folates; methylation; epigenetics; cancer therapy	SERUM FOLATE LEVELS; DNA METHYLATION; DIHYDROFOLATE-REDUCTASE; FOLIC-ACID; FUNCTIONAL-CHARACTERIZATION; CARBOXYL METHYLTRANSFERASE; MICROPHTHALMIA LOCUS; S-ADENOSYLMETHIONINE; ANTIFOLATE ACTIVITY; LYSINE METHYLATION	Cancer is characterized by uncontrolled cell growth and the acquisition of metastatic properties. In most cases, the activation of oncogenes and/or deactivation of tumour suppressor genes lead to uncontrolled cell cycle progression and inactivation of apoptotic mechanisms. Although the underlying mechanisms of carcinogenesis remain unknown, increasing evidence links aberrant regulation of methylation to tumourigenesis. In addition to the methylation of DNA and histones, methylation of nonhistone proteins, such as transcription factors, is also implicated in the biology and development of cancer. Because the metabolic cycling of methionine is a key pathway for many of these methylating reactions, strategies to target the epigenetic machinery of cancer cells could result in novel and efficient anticancer therapies. The application of these new epigenetic therapies could be of utility in the promotion of E2F1-dependent apoptosis in cancer cells, in avoiding metastatic pathways and/or in sensitizing tumour cells to radiotherapy.	[Montenegro, M. F.; Fernandez-Perez, M. P.; Saez-Ayala, M.; Rodriguez-Lopez, J. N.] Univ Murcia, Dept Biochem & Mol Biol A, E-30100 Murcia, Spain; [Sanchez-del-Campo, L.] Univ Oxford, Nuffield Dept Clin Med, Ludwig Inst Canc Res, Oxford, England; [Cabezas-Herrera, J.] Univ Hosp Virgen de la Arrixaca IMIB, Translat Canc Res Grp, Murcia, Spain	University of Murcia; Ludwig Institute for Cancer Research; University of Oxford	Rodriguez-Lopez, JN (corresponding author), Univ Murcia, Dept Biochem & Mol Biol A, Campus Espinardo, E-30100 Murcia, Spain.	neptuno@um.es	Montenegro, Maria Fernanda/AAF-2695-2021; Saez Ayala, Magali/T-9810-2017; Neptuno, Jose/F-5012-2016; del Campo, Luis Sanchez/R-1308-2018; CABEZAS-HERRERA, JUAN/J-9434-2015; Cabezas-Herrera, Juan/F-3850-2016	Saez Ayala, Magali/0000-0002-8726-0053; CABEZAS-HERRERA, JUAN/0000-0001-9053-5380; Montenegro, Maria Fernanda/0000-0002-0064-0484; Rodriguez-Lopez, Jose Neptuno/0000-0001-6863-1173; Cabezas-Herrera, Juan/0000-0002-6833-4977; FERNANDEZ PEREZ, MARIA PIEDAD/0000-0003-4916-1959; Sanchez del Campo, Luis/0000-0002-9537-7761	Ministerio de Ciencia e Innovacion (MICINN) [SAF2009-12043-C02-01]; Fundacion Seneca (FS) [15230/PI/10]; Fundacion de la Asociacion Espanola contra el Cancer (FAECC)	Ministerio de Ciencia e Innovacion (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Fundacion Seneca (FS)(Fundacion Seneca); Fundacion de la Asociacion Espanola contra el Cancer (FAECC)	This work was supported by grants from the Ministerio de Ciencia e Innovacion (MICINN) (SAF2009-12043-C02-01) and Fundacion Seneca (FS) (15230/PI/10). MFM is contracted by the Fundacion de la Asociacion Espanola contra el Cancer (FAECC).	Alemdaroglu NC, 2007, PLANTA MED, V73, P27, DOI 10.1055/s-2006-951745; Anderson ME, 1998, CHEM-BIOL INTERACT, V112, P1; Arnheiter H, 2010, PIGM CELL MELANOMA R, V23, P729, DOI 10.1111/j.1755-148X.2010.00759.x; Bell LA, 2004, CELL DEATH DIFFER, V11, P137, DOI 10.1038/sj.cdd.4401324; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Cellarier E, 2003, CANCER TREAT REV, V29, P489, DOI 10.1016/S0305-7372(03)00118-X; Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Chen KG, 2006, P NATL ACAD SCI USA, V103, P9903, DOI 10.1073/pnas.0600213103; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Copeland RA, 2009, NAT REV DRUG DISCOV, V8, P724, DOI 10.1038/nrd2974; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; Dong C, 2013, ONCOGENE, V32, P1351, DOI 10.1038/onc.2012.169; Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349; Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; FIDLER IJ, 1978, CANCER RES, V38, P2651; Goodall J, 2008, CANCER RES, V68, P7788, DOI 10.1158/0008-5472.CAN-08-1053; Guo C, 2011, J BIOL CHEM, V286, P6253, DOI 10.1074/jbc.M110.178210; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hannewald P, 2008, ANAL BIOANAL CHEM, V392, P1335, DOI 10.1007/s00216-008-2409-x; He YL, 2012, ACTA BIOCH BIOPH SIN, V44, P70, DOI 10.1093/abbs/gmr109; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; HOFFMAN DR, 1980, J BIOL CHEM, V255, P822; Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588; Huang ZM, 2012, P NATL ACAD SCI USA, V109, P553, DOI 10.1073/pnas.1118366109; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Ibanez C, 2012, ELECTROPHORESIS, V33, P2328, DOI 10.1002/elps.201200143; Issa JPJ, 2007, CLIN CANCER RES, V13, P1634, DOI 10.1158/1078-0432.CCR-06-2076; Jenal M, 2009, MOL CANCER RES, V7, P916, DOI 10.1158/1541-7786.MCR-08-0359; Jiang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036780; Jin Bilian, 2011, Genes Cancer, V2, P607, DOI 10.1177/1947601910393957; Johnson C, 2013, CANC LETT; Jorgensen S, 2007, J CELL BIOL, V179, P1337, DOI 10.1083/jcb.200706150; Kao TT, 2008, DRUG METAB DISPOS, V36, P508, DOI 10.1124/dmd.107.019299; Kawamoto K, 2007, CLIN CANCER RES, V13, P2541, DOI 10.1158/1078-0432.CCR-06-2225; Kishi T, 2000, CANCER-AM CANCER SOC, V89, P925, DOI 10.1002/1097-0142(20000815)89:4<925::AID-CNCR28>3.0.CO;2-W; Kobi D, 2010, PIGM CELL MELANOMA R, V23, P404, DOI 10.1111/j.1755-148X.2010.00697.x; Kontaki H, 2010, CELL CYCLE, V9, P3836, DOI 10.4161/cc.9.19.13384; Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; KUFE DW, 1980, J INVEST DERMATOL, V75, P357, DOI 10.1111/1523-1747.ep12531146; Kurash JK, 2008, MOL CELL, V29, P392, DOI 10.1016/j.molcel.2007.12.025; Lee J, 1996, P NATL ACAD SCI USA, V93, P6043, DOI 10.1073/pnas.93.12.6043; Lee JA, 2007, J BIOL CHEM, V282, P30974, DOI 10.1074/jbc.M704861200; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Limm K, 2013, EUR J CANCER, V49, P1305, DOI 10.1016/j.ejca.2012.11.026; Lin WC, 2001, GENE DEV, V15, P1833; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Loercher AE, 2005, J CELL BIOL, V168, P35, DOI 10.1083/jcb.200410115; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; Matsuzaki M, 2008, J OBSTET GYNAECOL RE, V34, P971, DOI 10.1111/j.1447-0756.2008.00821.x; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Montenegro MF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052231; Mund C, 2010, BIOESSAYS, V32, P949, DOI 10.1002/bies.201000061; Navarro-Martinez MD, 2006, J ANTIMICROB CHEMOTH, V57, P1083, DOI 10.1093/jac/dkl124; Navarro-Martinez MD, 2005, ANTIMICROB AGENTS CH, V49, P2914, DOI 10.1128/AAC.49.7.2914-2920.2005; Navarro-Peran E, 2005, BIOCHEMISTRY-US, V44, P7512, DOI 10.1021/bi050160t; Navarro-Peran E, 2005, CANCER RES, V65, P2059, DOI 10.1158/0008-5472.CAN-04-3469; Navarro-Peran E, 2007, INT J BIOCHEM CELL B, V39, P2215, DOI 10.1016/j.biocel.2007.06.005; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Pardee AB, 2004, CELL CYCLE, V3, P1091; Pei HD, 2011, NATURE, V470, P124, DOI 10.1038/nature09658; Philips Mark R, 2004, Sci STKE, V2004, ppe13, DOI 10.1126/stke.2252004pe13; Fernandez-Perez MP, 2013, NEOPLASIA, V15, P826, DOI 10.1593/neo.13320; Probst AV, 2009, NAT REV MOL CELL BIO, V10, P192, DOI 10.1038/nrm2640; Prokhortchouk E, 2002, ONCOGENE, V21, P5394, DOI 10.1038/sj.onc.1205631; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Saez-Ayala M, 2013, CANCER CELL, V24, P105, DOI 10.1016/j.ccr.2013.05.009; Saez-Ayala M, 2012, EXP CELL RES, V318, P1146, DOI 10.1016/j.yexcr.2012.03.022; Saez-Ayala M, 2011, CHEMMEDCHEM, V6, P440, DOI 10.1002/cmdc.201000482; Sanchez-del-Campo L, 2008, INT J CANCER, V123, P2446, DOI 10.1002/ijc.23813; Sanchez-Del-Campo L, 2008, J MED CHEM, V51, P2018, DOI 10.1021/jm701346h; Sanchez-del-Campo L, 2010, J CELL BIOCHEM, V110, P1399, DOI 10.1002/jcb.22656; Sanchez-del-Campo L, 2009, PIGM CELL MELANOMA R, V22, P588, DOI 10.1111/j.1755-148X.2009.00586.x; Sanchez-del-Campo L, 2009, MOL PHARMACEUT, V6, P883, DOI 10.1021/mp800259k; Schulze JM, 2009, MOL CELL, V35, P626, DOI 10.1016/j.molcel.2009.07.017; Shi XB, 2007, MOL CELL, V27, P636, DOI 10.1016/j.molcel.2007.07.012; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shiraishi M, 2010, BIOSCI TRENDS, V4, P225; Spano D, 2013, CLIN EXP METASTAS, V30, P47, DOI 10.1007/s10585-012-9506-0; Spina M, 2008, PROTEINS, V72, P240, DOI 10.1002/prot.21914; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Surova O, 2013, ONCOGENE, V32, P3789, DOI 10.1038/onc.2012.556; Szyf M, 2009, ANNU REV PHARMACOL, V49, P243, DOI 10.1146/annurev-pharmtox-061008-103102; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; Ulrey CL, 2005, HUM MOL GENET, V14, pR139, DOI 10.1093/hmg/ddi100; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; Ushijima T, 2005, CANCER SCI, V96, P206, DOI 10.1111/j.1349-7006.2005.00035.x; Versteeg R, 1997, AM J HUM GENET, V60, P751; VOLKER C, 1995, METHOD ENZYMOL, V255, P65; Wakeman TP, 2012, EMBO J, V31, P2169, DOI 10.1038/emboj.2012.50; Wang A, 2005, CANCER RES, V65, P7809, DOI 10.1158/0008-5472.CAN-05-0888; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606; Winter-Vann AM, 2003, P NATL ACAD SCI USA, V100, P6529, DOI 10.1073/pnas.1135239100; Xie Q, 2011, J RECEPT SIG TRANSD, V31, P139, DOI 10.3109/10799893.2011.552914; Xie T, 2009, CANCER RES, V69, P992, DOI 10.1158/0008-5472.CAN-08-0506; Yan PS, 2003, CANCER RES, V63, P6178; Yun J, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00163	116	40	41	2	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					135	143		10.1038/onc.2013.605	http://dx.doi.org/10.1038/onc.2013.605			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24469033				2022-12-28	WOS:000347790500001
J	Saxena, M; Dykes, SS; Malyarchuk, S; Wang, AE; Cardelli, JA; Pruitt, K				Saxena, M.; Dykes, S. S.; Malyarchuk, S.; Wang, A. E.; Cardelli, J. A.; Pruitt, K.			The sirtuins promote Dishevelled-1 scaffolding of TIAM1, Rac activation and cell migration	ONCOGENE			English	Article						SIRT1; SIRT2; TIAM1; Rac1-GTPase; Dishevelled; acetylation	NUCLEOTIDE EXCHANGE FACTOR; PREDICTS POOR-PROGNOSIS; HISTONE DEACETYLASE; BREAST-CANCER; HEPATOCELLULAR CARCINOMAS; COLORECTAL-CANCER; EPITHELIAL-CELLS; PROSTATE-CANCER; RHO GTPASES; SIRT1	Rac1-GTPases serve as intermediary cellular switches, which conduct transient and constitutive signals from upstream cues, including those from Ras oncoproteins. Although the sirtuin1 (SIRT1) deacetylase is overexpressed in several human cancers and has recently been linked to cancer cell motility as a context-dependent regulator of multiple pathways, its role in Rac1 activation has not been reported. Similarly, SIRT2 has been demonstrated to be upregulated in some cancers; however, studies have also reported its role in tumor suppression. Here, we demonstrate that SIRT1 and SIRT2 positively regulate the levels of Rac1-GTP and the activity of T-cell lymphoma invasion and metastasis 1 (TIAM1), a Rac guanine nucleotide exchange factor (GEF). Transient inhibition of SIRT1 and SIRT2 resulted in increased acetylation of TIAM1, whereas chronic SIRT2 knockdown resulted in enhanced acetylation of TIAM1. SIRT1 regulates Dishevelled (DVL) protein levels in cancer cells, and DVL along with TIAM1 are known to augment Rac activation; however, SIRT1 or 2 has not been previously linked with TIAM1. We found that diminished sirtuin activity led to the disruption of the DVL1-TIAM1 interaction. We hence propose a model for Rac activation where SIRT1/2 positively modulates the DVL/TIAM1/Rac axis and promotes sustained pathway activation.	[Saxena, M.; Malyarchuk, S.; Wang, A. E.; Pruitt, K.] LSU Hlth Shreveport, Dept Cellular & Mol Physiol, Shreveport, LA 71130 USA; [Dykes, S. S.; Cardelli, J. A.] LSU Hlth Shreveport, Dept Microbiol & Immunol, Shreveport, LA 71130 USA; [Cardelli, J. A.; Pruitt, K.] LSU Hlth Shreveport, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Pruitt, K (corresponding author), LSU Hlth Shreveport, Dept Cellular & Mol Physiol, BRI F4-26,1501 Kings Hwy, Shreveport, LA 71130 USA.	kpruit@lsuhsc.edu			Feist-Weiller Cancer Center Idea Award; Carroll-Feist Predoctoral Fellowship Award; NATIONAL CANCER INSTITUTE [R01CA155223] Funding Source: NIH RePORTER	Feist-Weiller Cancer Center Idea Award; Carroll-Feist Predoctoral Fellowship Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Channing Der at University of North Carolina and Dr Sharon Dent at University of Texas MD Anderson Cancer Center for providing the plasmids. The work described here is funded by a Feist-Weiller Cancer Center Idea Award to KP. MS is supported by the Carroll-Feist Predoctoral Fellowship Award.	Adam L, 2001, J BIOL CHEM, V276, P28443, DOI 10.1074/jbc.M009769200; Adams HC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2637; Allis CD, 2007, CELL, V131, P633, DOI 10.1016/j.cell.2007.10.039; Arthur WT, 2002, J BIOL CHEM, V277, P42964, DOI 10.1074/jbc.M207401200; Barrio-Real L, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003543; Bosco EE, 2009, CELL MOL LIFE SCI, V66, P370, DOI 10.1007/s00018-008-8552-x; Brooks CL, 2009, NAT REV CANCER, V9, P123, DOI 10.1038/nrc2562; Buongiorno P, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-73; Byles V, 2012, ONCOGENE, V31, P4619, DOI 10.1038/onc.2011.612; Byles V, 2010, INT J BIOL SCI, V6, P599; Cajanek L, 2013, MOL CELL BIOL, V33, P59, DOI 10.1128/MCB.00745-12; Chen J, 2013, HEPATOLOGY, V57, P2287, DOI 10.1002/hep.26278; Chen J, 2011, CANCER RES, V71, P4138, DOI 10.1158/0008-5472.CAN-10-4274; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; Cook DR, 2014, ONCOGENE, V33, P4021, DOI 10.1038/onc.2013.362; Ding Y, 2009, INT J CANCER, V124, P653, DOI 10.1002/ijc.23954; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Gysin Stephan, 2011, Genes Cancer, V2, P359, DOI 10.1177/1947601911412376; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Heltweg B, 2006, CANCER RES, V66, P4368, DOI 10.1158/0008-5472.CAN-05-3617; Holloway KR, 2013, MOL ENDOCRINOL, V27, P480, DOI 10.1210/me.2012-1347; Holloway KR, 2010, P NATL ACAD SCI USA, V107, P9216, DOI 10.1073/pnas.0911325107; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Hornbeck PV, 2012, NUCLEIC ACIDS RES, V40, pD261, DOI 10.1093/nar/gkr1122; Hou HL, 2012, J CLIN PATHOL, V65, P1088, DOI 10.1136/jclinpath-2012-200940; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lee H, 2011, HUM PATHOL, V42, P204, DOI 10.1016/j.humpath.2010.05.023; Li Y, 2008, CELL METAB, V8, P38, DOI 10.1016/j.cmet.2008.05.004; Liu HM, 2011, ONCOL REP, V25, P841, DOI 10.3892/or.2010.1122; Liu PY, 2013, CELL DEATH DIFFER, V20, P503, DOI 10.1038/cdd.2012.147; Liu T, 2009, CANCER RES, V69, P1702, DOI 10.1158/0008-5472.CAN-08-3365; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Minard ME, 2005, ONCOGENE, V24, P2568, DOI 10.1038/sj.onc.1208503; Napper AD, 2005, J MED CHEM, V48, P8045, DOI 10.1021/jm050522v; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; North BJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000784; Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049; Pegtel DM, 2007, CURR BIOL, V17, P1623, DOI 10.1016/j.cub.2007.08.035; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706; Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960; Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4; Wang SJ, 2012, J CELL BIOL, V199, P331, DOI 10.1083/jcb.201202041; Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990; Woodcock SA, 2009, MOL CELL, V33, P639, DOI 10.1016/j.molcel.2009.02.012; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Yang MH, 2013, MOL CANCER RES, V11, P1072, DOI 10.1158/1541-7786.MCR-13-0040-T; Zhang Y, 2009, ONCOGENE, V28, P445, DOI 10.1038/onc.2008.388; Zhao G, 2011, GENE THER, V18, P920, DOI 10.1038/gt.2011.81	60	34	35	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					188	198		10.1038/onc.2013.549	http://dx.doi.org/10.1038/onc.2013.549			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24362520	Green Accepted			2022-12-28	WOS:000347790500006
J	Robinson, JLL; Hickey, TE; Warren, AY; Vowler, SL; Carroll, T; Lamb, AD; Papoutsoglou, N; Neal, DE; Tilley, WD; Carroll, JS				Robinson, J. L. L.; Hickey, T. E.; Warren, A. Y.; Vowler, S. L.; Carroll, T.; Lamb, A. D.; Papoutsoglou, N.; Neal, D. E.; Tilley, W. D.; Carroll, J. S.			Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype	ONCOGENE			English	Article						androgen receptor; FOXA1; prostate cancer; CRPC; genomics	RESISTANT PROSTATE-CANCER; FORKHEAD-BOX A1; ESTROGEN-RECEPTOR; BREAST-CANCER; INCREASED SURVIVAL; TRANSCRIPTION; PROGRESSION; GENOME; COREGULATORS; EXPRESSION	Castration-resistant prostate cancer (CRPC) continues to pose a significant clinical challenge with new generation second-line hormonal therapies affording limited improvement in disease outcome. As the androgen receptor (AR) remains a critical driver in CRPC, understanding the determinants of its transcriptional activity is important for developing new AR-targeted therapies. FOXA1 is a key component of the AR transcriptional complex yet its role in prostate cancer progression and the relationship between AR and FOXA1 are not completely resolved. It is well established that FOXA1 levels are elevated in advanced prostate cancer and metastases. We mimicked these conditions by overexpressing FOXA1 in the androgen-responsive LNCaP prostate cancer cell line and observed a significant increase in AR genomic binding at novel regions that possess increased chromatin accessibility. High levels of FOXA1 resulted in increased proliferation at both sub-optimal and high 5 alpha-dihydrotestosterone (DHT) concentrations. Immunohistochemical staining for FOXA1 in a clinical prostate cancer cohort revealed that high FOXA1 expression is associated with shorter time to biochemical recurrence after radical prostatectomy (hazard ratio (HR) 5.0, 95% confidence interval (CI) 1.2-21.1, P = 0.028), positive surgical margins and higher stage disease at diagnosis. The gene expression program that results from FOXA1 overexpression is enriched for PTEN, Wnt and other pathways typically represented in CRPC gene signatures. Together, these results suggest that in an androgen-depleted state, elevated levels of FOXA1 enhance AR binding at genomic regions not normally occupied by AR, which in turn facilitates prostate cancer cell growth.	[Robinson, J. L. L.; Vowler, S. L.; Carroll, T.; Lamb, A. D.; Neal, D. E.; Carroll, J. S.] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge CB2 0RE, England; [Robinson, J. L. L.; Vowler, S. L.; Carroll, T.; Lamb, A. D.; Neal, D. E.; Carroll, J. S.] Univ Cambridge, Dept Oncol, Cambridge CB2 0RE, England; [Hickey, T. E.; Neal, D. E.; Tilley, W. D.] Univ Adelaide, Sch Med, Dame Roma Mitchell Canc Res Labs, Adelaide, SA, Australia; [Hickey, T. E.; Neal, D. E.; Tilley, W. D.] Univ Adelaide, Sch Med, Adelaide Prostate Canc Res Ctr, Adelaide, SA, Australia; [Warren, A. Y.] Cambridge Univ Hosp NHS Foundat Trust, Dept Histopathol, Cambridge, England; [Lamb, A. D.; Papoutsoglou, N.] Cambridge Univ Hosp NHS Foundat Trust, Dept Urol, Cambridge, England	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Cambridge; University of Adelaide; University of Adelaide	Carroll, JS (corresponding author), Univ Cambridge, Canc Res UK Cambridge Inst, Robinson Way, Cambridge CB2 0RE, England.	jason.carroll@cruk.cam.ac.uk	Lamb, Alastair/AAD-6375-2019	Neal, David/0000-0002-6033-5086; Tilley, Wayne/0000-0003-1893-2626; Hickey, Theresa/0000-0002-2752-730X; Carroll, Jason/0000-0003-3643-0080	University of Cambridge; Cancer Research UK; Hutchison Whampoa Limited; National Health and Medical Research Council of Australia [627185]; Cancer Australia [627229]; Prostate Cancer Foundation of Australia; US Department of Defense Breast Cancer Research Program (BCRP) [W81XWH-11-1-0592]; ERC starting grant; EMBO Young Investigator Award; Cancer Research UK [15602, 22310] Funding Source: researchfish; National Institute for Health Research [CL-2012-14-003] Funding Source: researchfish	University of Cambridge(University of Cambridge); Cancer Research UK(Cancer Research UK); Hutchison Whampoa Limited; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Australia; Prostate Cancer Foundation of Australia; US Department of Defense Breast Cancer Research Program (BCRP)(United States Department of Defense); ERC starting grant(European Research Council (ERC)); EMBO Young Investigator Award(European Molecular Biology Organization (EMBO)); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))	We would like to thank the members of the genomic, proteomic and histopathology core facilities at Cancer Research UK. We would like to acknowledge the support of The University of Cambridge, Cancer Research UK and Hutchison Whampoa Limited. We are grateful to study volunteers for their participation and staff at the Welcome Trust Clinical Research Facility, Addenbrooke's Clinical Research Centre, Cambridge. WDT is supported by grants from the National Health and Medical Research Council of Australia (ID 627185), Cancer Australia (ID 627229) and the Prostate Cancer Foundation of Australia. TEH holds a Postdoctoral Fellowship Award from the US Department of Defense Breast Cancer Research Program (BCRP; #W81XWH-11-1-0592). JSC is supported by an ERC starting grant and an EMBO Young Investigator Award.	Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Cairns JM, 2008, BIOINFORMATICS, V24, P2921, DOI 10.1093/bioinformatics/btn557; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chmelar R, 2007, INT J CANCER, V120, P719, DOI 10.1002/ijc.22365; Clarke CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035859; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Decker KF, 2012, NUCLEIC ACIDS RES, V40, P10765, DOI 10.1093/nar/gks888; Deutsch L, 2012, GENE CHROMOSOME CANC, V51, P618, DOI 10.1002/gcc.21950; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Dunning MJ, 2007, BIOINFORMATICS, V23, P2183, DOI 10.1093/bioinformatics/btm311; Gao N, 2005, DEVELOPMENT, V132, P3431, DOI 10.1242/dev.01917; Gao N, 2003, MOL ENDOCRINOL, V17, P1484, DOI 10.1210/me.2003-0020; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gerhardt J, 2012, AM J PATHOL, V180, P848, DOI 10.1016/j.ajpath.2011.10.021; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Hodgson MC, 2005, J BIOL CHEM, V280, P6511, DOI 10.1074/jbc.M408972200; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Imamura Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042456; Jain RK, 2011, HISTOPATHOLOGY, V58, P766, DOI 10.1111/j.1365-2559.2011.03796.x; Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760; Jia L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003645; Jin HJ, 2013, CANCER RES, V73, P3725, DOI 10.1158/0008-5472.CAN-12-3468; Jung C, 2004, CANCER RES, V64, P9185, DOI 10.1158/0008-5472.CAN-04-1330; Kikuchi M, 2009, BBA-MOL CELL RES, V1793, P1828, DOI 10.1016/j.bbamcr.2009.11.001; Li YM, 2011, CANCER RES, V71, P2108, DOI 10.1158/0008-5472.CAN-10-1998; Liao GQ, 2003, J BIOL CHEM, V278, P5052, DOI 10.1074/jbc.M206374200; Lin L, 2002, CANCER RES, V62, P5273; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Machanick P, 2011, BIOINFORMATICS, V27, P1696, DOI 10.1093/bioinformatics/btr189; Mahajan MC, 2005, P NATL ACAD SCI USA, V102, P15012, DOI 10.1073/pnas.0507596102; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; Nucera C, 2009, CLIN CANCER RES, V15, P3680, DOI 10.1158/1078-0432.CCR-08-3155; Robinson JLL, 2011, EMBO J, V30, P3019, DOI 10.1038/emboj.2011.216; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Ross-Innes CS, 2010, GENE DEV, V24, P171, DOI 10.1101/gad.552910; Sahu B, 2013, CANCER RES, V73, P1570, DOI 10.1158/0008-5472.CAN-12-2350; Sahu B, 2011, EMBO J, V30, P3962, DOI 10.1038/emboj.2011.328; Scher HI, 2004, ENDOCR-RELAT CANCER, V11, P459, DOI 10.1677/erc.1.00525; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001; Sharma NL, 2013, CANCER CELL, V23, P35, DOI 10.1016/j.ccr.2012.11.010; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Waltering KK, 2012, MOL CELL ENDOCRINOL, V360, P38, DOI 10.1016/j.mce.2011.12.019; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Wang L, 2013, J CLIN NEUROSCI, V20, P654, DOI 10.1016/j.jocn.2012.03.055; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Whitaker HC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013363; Zhang CP, 2011, CANCER RES, V71, P6738, DOI 10.1158/0008-5472.CAN-11-1882	54	57	58	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2014	33	50					5666	5674		10.1038/onc.2013.508	http://dx.doi.org/10.1038/onc.2013.508			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW2AB	24292680	Green Accepted, Green Submitted			2022-12-28	WOS:000346089300002
J	Chen, X; Makarewicz, JM; Knauf, JA; Johnson, LK; Fagin, JA				Chen, X.; Makarewicz, J. M.; Knauf, J. A.; Johnson, L. K.; Fagin, J. A.			Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition	ONCOGENE			English	Article						RAS; papilloma; farnesyl transferase inhibitor	WILD-TYPE RAS; H-RAS; PROTEIN TRANSFERASE; N-RAS; MOUSE SKIN; K-RAS; ACTIVATING MUTATIONS; GENE; CARCINOMAS; EXPRESSION	RAS-driven malignancies remain a major therapeutic challenge. The two-stage 7,12-dimethylbenz(a) anthracene (DMBA)/12-o-tetradecanoylphorbol-13-acetate (TPA) model of mouse skin carcinogenesis has been used to study mechanisms of epithelial tumor development by oncogenic Hras. We used mice with an Hras(G12V) knock-in allele to elucidate the early events after Hras activation, and to evaluate the therapeutic effectiveness of farnesyltransferase inhibition (FTI). Treatment of Caggs-Cre/FR-Hras(G12V) mice with TPA alone was sufficient to trigger papilloma development with a shorter latency and an similar to 10-fold greater tumor burden than DMBA/TPA-treated WT-controls. Hras(G12V) allele copy number was increased in all papillomas induced by TPA. DMBA/TPA treatment of Hras(G12V) knock-in mice induced an even greater incidence of papillomas, which either harbored Hras(G12V) amplification or developed an Hras(Q61L) mutation in the second allele. Laser-capture microdissection of normal skin, hyperplastic skin and papillomas showed that amplification occurred only at the papilloma stage. HRAS-mutant allelic imbalance was also observed in human cancer cell lines, consistent with a requirement for augmented oncogenic HRAS signaling for tumor development. The FTI SCH66336 blocks HRAS farnesylation and delocalizes it from the plasma membrane. NRAS and KRAS are not affected as they are alternatively prenylated. When tested in lines harboring HRAS, NRAS or KRAS mutations, SCH66336 delocalized, inhibited signaling and preferentially inhibited growth only of HRAS-mutant lines. Treatment with SCH66336 also induced near-complete regression of papillomas of TPA-treated Hras(G12V) knock-in mice. These data suggest that farnesyl transferase inhibitors should be reevaluated as targeted agents for human HRAS-driven cancers, such as those of bladder, thyroid and other epithelial lineages.	[Chen, X.; Makarewicz, J. M.; Knauf, J. A.; Fagin, J. A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY USA; [Knauf, J. A.; Fagin, J. A.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Johnson, L. K.] Sloan Kettering Inst, New York, NY USA; [Fagin, J. A.] Weill Cornell Med Coll, New York, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Fagin, JA (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave,Box 296,Zuckerman Bldg,ZRC 504, New York, NY 10065 USA.	Faginj@mskcc.org		Makarewicz, Jacek/0000-0003-2557-2817; Knauf, Jeffrey/0000-0003-4456-8792; chen, xu/0000-0003-2524-4979	NIH [RO1-CA72597, T32-DK07313]; Margot Rosenberg Pulitzer Foundation; Byrne Fund; Lefkofsky Family Foundation; NATIONAL CANCER INSTITUTE [P50CA172012, R01CA072597, R01CA050706, P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007313] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Margot Rosenberg Pulitzer Foundation; Byrne Fund; Lefkofsky Family Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH grants RO1-CA72597 and T32-DK07313, the Margot Rosenberg Pulitzer Foundation, the Byrne Fund and the Lefkofsky Family Foundation. We are indebted to the Molecular Cytology and Comparative Pathology Core facilities of Memorial Sloan Kettering Cancer Center. We are also grateful to Dr. Paul Kirschmeier and W Robert Bishop (formerly of Schering-Plough) for providing us with SCH 66336.	Ahearn IM, 2012, NAT REV MOL CELL BIO, V13, P39, DOI 10.1038/nrm3255; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Ashar HR, 2001, EXP CELL RES, V262, P17, DOI 10.1006/excr.2000.5076; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; Bastian BC, 2000, AM J PATHOL, V157, P967, DOI 10.1016/S0002-9440(10)64609-3; Bernhard EJ, 1998, CANCER RES, V58, P1754; Bishop WR, 1995, J BIOL CHEM, V270, P30611, DOI 10.1074/jbc.270.51.30611; Boichard A, 2012, J CLIN ENDOCR METAB, V97, pE2031, DOI 10.1210/jc.2012-2092; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BUCHMANN A, 1991, CANCER RES, V51, P4097; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Castellano Esther, 2011, Genes Cancer, V2, P216, DOI 10.1177/1947601911408081; Chen X, 2009, P NATL ACAD SCI USA, V106, P7979, DOI 10.1073/pnas.0900343106; Diaz R, 2005, INT J CANCER, V113, P241, DOI 10.1002/ijc.20563; Diaz R, 2002, CANCER RES, V62, P4514; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; Gordon LB, 2012, P NATL ACAD SCI USA, V109, P16666, DOI 10.1073/pnas.1202529109; Harousseau JL, 2009, BLOOD, V114, P1166, DOI 10.1182/blood-2009-01-198093; Hayes TK, 2013, CANCER DISCOV, V3, P24, DOI 10.1158/2159-8290.CD-12-0521; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Jeng HH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2173; Johnson BE, 2004, CLIN CANCER RES, V10, p4254S, DOI 10.1158/1078-0432.CCR-040016; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; Lim KH, 2008, NATURE, V452, P646, DOI 10.1038/nature06778; Modrek B, 2009, MOL CANCER RES, V7, P1244, DOI 10.1158/1541-7786.MCR-08-0532; Moura MM, 2011, J CLIN ENDOCR METAB, V96, pE863, DOI 10.1210/jc.2010-1921; NAMBA H, 1990, J CLIN ENDOCR METAB, V71, P223, DOI 10.1210/jcem-71-1-223; Plowman SJ, 2003, MOL CELL BIOL, V23, P9245, DOI 10.1128/MCB.23.24.9245-9250.2003; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Rao S, 2004, J CLIN ONCOL, V22, P3950, DOI 10.1200/JCO.2004.10.037; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Schuhmacher AJ, 2008, J CLIN INVEST, V118, P2169, DOI [10.1172/JCI3438S, 10.1172/JCI34385]; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Takano T, 2005, J CLIN ONCOL, V23, P6829, DOI 10.1200/JCO.2005.01.0793; To MD, 2013, ONCOGENE, V32, P4028, DOI 10.1038/onc.2012.404; Van Cutsem E, 2004, J CLIN ONCOL, V22, P1430, DOI 10.1200/JCO.2004.10.112; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Young A, 2013, CANCER DISCOV, V3, P112, DOI 10.1158/2159-8290.CD-12-0231; Zhang FL, 1997, J BIOL CHEM, V272, P10232; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721	46	32	37	3	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2014	33	47					5442	5449		10.1038/onc.2013.489	http://dx.doi.org/10.1038/onc.2013.489			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MG	24240680	Green Accepted			2022-12-28	WOS:000345120700006
J	Rajurkar, M; Huang, H; Cotton, JL; Brooks, JK; Sicklick, J; McMahon, AP; Mao, J				Rajurkar, M.; Huang, H.; Cotton, J. L.; Brooks, J. K.; Sicklick, J.; McMahon, A. P.; Mao, J.			Distinct cellular origin and genetic requirement of Hedgehog-Gli in postnatal rhabdomyosarcoma genesis	ONCOGENE			English	Article						Hedgehog; Gli; progenitor; rhbdomyosarcoma	FOLLICLE STEM-CELLS; SONIC HEDGEHOG; HUMAN HOMOLOG; MOUSE MODEL; EXPRESSION; AMPLIFICATION; PATHWAY; TARGET; CANCER; SOX4	Dysregulation of the Hedgehog (Hh)-Gli signaling pathway is implicated in a variety of human cancers, including basal cell carcinoma (BCC), medulloblastoma (MB) and embryonal rhabdhomyosarcoma (eRMS), three principle tumors associated with human Gorlin syndrome. However, the cells of origin of these tumors, including eRMS, remain poorly understood. In this study, we explore the cell populations that give rise to Hh-related tumors by specifically activating Smoothened (Smo) in both Hhproducing and -responsive cell lineages in postnatal mice. Interestingly, we find that unlike BCC and MB, eRMS originates from the stem/progenitor populations that do not normally receive active Hh signaling. Furthermore, we find that the myogenic lineage in postnatal mice is largely Hh quiescent and that Pax7-expressing muscle satellite cells are not able to give rise to eRMS upon Smo or Gli1/2 overactivation in vivo, suggesting that Hh-induced skeletal muscle eRMS arises from Hh/Gli quiescent non-myogenic cells. In addition, using the Gli1 null allele and a Gli3 repressor allele, we reveal a specific genetic requirement for Gli proteins in Hh-induced eRMS formation and provide molecular evidence for the involvement of Sox4/11 in eRMS cell survival and differentiation.	[Rajurkar, M.; Huang, H.; Cotton, J. L.; Brooks, J. K.; Mao, J.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; [Huang, H.] Cent S Univ, Xiangya Sch Med, Dept Histol & Embryol, Changsha, Hunan, Peoples R China; [Sicklick, J.] Univ Calif San Diego, Moores Canc Ctr, Div Surg Oncol, La Jolla, CA 92093 USA; [McMahon, A. P.] Univ So Calif, WM Keck Sch Med, Broad CIRM Ctr Regenerat Med & Stem Cell Res, Dept Stem Cell Biol & Regenerat Med, Los Angeles, CA USA	University of Massachusetts System; University of Massachusetts Worcester; Central South University; University of California System; University of California San Diego; University of Southern California	Mao, J (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, 364 Plantat St,LRB417, Worcester, MA 01605 USA.	junhao.mao@umassmed.edu	McMahon, Andrew P/ABE-7520-2020; Rajurkar, Mihir/I-6238-2019	Rajurkar, Mihir/0000-0002-0573-1705; Cotton, Jennifer/0000-0003-0106-1801	American Cancer Society [120376-RSG-11-04001-DDC]; Charles H Hood Foundation; Worcester Foundation for Biomedical Research; NIH [NS033642]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS033642, R01NS033642] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); Charles H Hood Foundation; Worcester Foundation for Biomedical Research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work is supported by grants from American Cancer Society (120376-RSG-11-040-01-DDC), Charles H Hood Foundation and Worcester Foundation for Biomedical Research to JM. APM is supported by a grant from NIH (NS033642). The authors thank Drs Michael Rudnicki (University of Ottawa) and Amy Wagers (Joslin Diabetes Center) for providing cell isolation protocols, Joe Vaughan and Zhiwei Pang for technical support, and members of the Mao lab for helpful discussion.	Ahn S, 2005, NATURE, V437, P894, DOI 10.1038/nature03994; Ahn S, 2004, CELL, V118, P505, DOI 10.1016/j.cell.2004.07.023; Asakura A, 2007, P NATL ACAD SCI USA, V104, P16552, DOI 10.1073/pnas.0708145104; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Bai CB, 2002, DEVELOPMENT, V129, P4753; Barakat MT, 2010, TRENDS MOL MED, V16, P337, DOI 10.1016/j.molmed.2010.05.003; Bhattaram P, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1008; Breneman JC, 2003, J CLIN ONCOL, V21, P78, DOI 10.1200/JCO.2003.06.129; Brennana DJ, 2009, EUR J CANCER, V45, P1510, DOI 10.1016/j.ejca.2009.01.028; Bridge JA, 2002, GENE CHROMOSOME CANC, V33, P310, DOI 10.1002/gcc.10026; Bridge JA, 2000, GENE CHROMOSOME CANC, V27, P337, DOI 10.1002/(SICI)1098-2264(200004)27:4<337::AID-GCC1>3.0.CO;2-1; Brownell I, 2011, CELL STEM CELL, V8, P552, DOI 10.1016/j.stem.2011.02.021; Gerber AN, 2007, ONCOGENE, V26, P1122, DOI 10.1038/sj.onc.1209891; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Grachtchouk M, 2011, J CLIN INVEST, V121, P1768, DOI 10.1172/JCI46307; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Harfe BD, 2004, CELL, V118, P517, DOI 10.1016/j.cell.2004.07.024; Hatley ME, 2012, CANCER CELL, V22, P536, DOI 10.1016/j.ccr.2012.09.004; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Hettmer S, 2011, P NATL ACAD SCI USA, V108, P20002, DOI 10.1073/pnas.1111733108; Hettmer S, 2010, NAT MED, V16, P171, DOI 10.1038/nm0210-171; Hirai H, 2010, J CELL BIOL, V191, P347, DOI 10.1083/jcb.201006025; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Hui CC, 2011, ANNU REV CELL DEV BI, V27, P513, DOI 10.1146/annurev-cellbio-092910-154048; Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kasper M, 2011, P NATL ACAD SCI USA, V108, P4099, DOI 10.1073/pnas.1014489108; Kimura H, 2005, ONCOGENE, V24, P4026, DOI 10.1038/sj.onc.1208567; Koleva M, 2005, CELL MOL LIFE SCI, V62, P1863, DOI 10.1007/s00018-005-5072-9; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Lee CJ, 2002, J NEURO-ONCOL, V57, P201, DOI 10.1023/A:1015773818302; Lee J, 1997, DEVELOPMENT, V124, P2537; Lepper C, 2009, NATURE, V460, P627, DOI 10.1038/nature08209; Liao YL, 2008, ONCOGENE, V27, P5578, DOI 10.1038/onc.2008.168; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; McMahon AP, 2003, CURR TOP DEV BIOL, V53, P1, DOI 10.1016/S0070-2153(03)53002-2; Medina PP, 2009, HUM MOL GENET, V18, P1343, DOI 10.1093/hmg/ddp034; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Pappo Alberto S., 1995, Current Opinion in Oncology, V7, P361, DOI 10.1097/00001622-199507000-00012; Ridky TW, 2010, CELL STEM CELL, V6, P292, DOI 10.1016/j.stem.2010.03.009; ROBERTS WM, 1989, CANCER RES, V49, P5407; Rowitch DH, 1999, J NEUROSCI, V19, P8954, DOI 10.1523/JNEUROSCI.19-20-08954.1999; Rubin BP, 2011, CANCER CELL, V19, P177, DOI 10.1016/j.ccr.2010.12.023; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Schuller U, 2008, CANCER CELL, P123; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stecca B, 2010, J MOL CELL BIOL, V2, P84, DOI 10.1093/jmcb/mjp052; Teglund S, 2010, BBA-REV CANCER, V1805, P181, DOI 10.1016/j.bbcan.2010.01.003; Tiffin N, 2003, BRIT J CANCER, V89, P327, DOI 10.1038/sj.bjc.6601040; Tostar U, 2006, J PATHOL, V208, P17, DOI 10.1002/path.1882; Tostar Ulrica, 2010, Genes Cancer, V1, P941, DOI 10.1177/1947601910385449; Vokes SA, 2008, GENE DEV, V22, P2651, DOI 10.1101/gad.1693008; Vokes SA, 2007, DEVELOPMENT, V134, P1977, DOI 10.1242/dev.001966; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Wang GY, 2011, CANCER CELL, V19, P114, DOI 10.1016/j.ccr.2010.11.007; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Youssef KK, 2010, NAT CELL BIOL, V12, P299, DOI 10.1038/ncb2031; Zibat A, 2010, ONCOGENE, V29, P6323, DOI 10.1038/onc.2010.368	65	15	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2014	33	46					5370	5378		10.1038/onc.2013.480	http://dx.doi.org/10.1038/onc.2013.480			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MF	24276242	Green Accepted			2022-12-28	WOS:000345120600007
J	Saiz-Ladera, C; Lara, MF; Garin, M; Ruiz, S; Santos, M; Lorz, C; Garcia-Escudero, R; Martinez-Fernandez, M; Bravo, A; Fernandez-Capetillo, O; Segrelles, C; Paramio, JM				Saiz-Ladera, C.; Lara, M. F.; Garin, M.; Ruiz, S.; Santos, M.; Lorz, C.; Garcia-Escudero, R.; Martinez-Fernandez, M.; Bravo, A.; Fernandez-Capetillo, O.; Segrelles, C.; Paramio, J. M.			p21 suppresses inflammation and tumorigenesis on pRB-deficient stratified epithelia	ONCOGENE			English	Article						pRb; p21; skin; differentiation; inflammation; tumorigenesis	SQUAMOUS-CELL CARCINOMA; MOUSE SKIN CARCINOGENESIS; EPIDERMAL KERATINOCYTE DIFFERENTIATION; GENE-EXPRESSION PROFILES; KINASE INHIBITOR P21; NF-KAPPA-B; NECK-CANCER; TUMOR-SUPPRESSOR; DNA-DAMAGE; RETINOBLASTOMA PROTEIN	The retinoblastoma gene product (pRb) controls proliferation and differentiation processes in stratified epithelia. Importantly, and in contrast to other tissues, Rb deficiency does not lead to spontaneous skin tumor formation. As the cyclin-dependent kinase inhibitor p21 regulates proliferation and differentiation in the absence of pRb, we analyzed the consequences of deleting p21 in pRb-ablated stratified epithelia (hereafter pRb(Delta Epi); p21 - / -). These mice display an enhancement of the phenotypic abnormalities observed in pRb(Delta Epi) animals, indicating that p21 partially compensates pRb absence. Remarkably, pRb(Delta Epi); p21 - / - mice show an acute skin inflammatory phenotype and develop spontaneous epithelial tumors, particularly affecting tongue and oral tissues. Biochemical analyses and transcriptome studies reveal changes affecting multiple pathways, including DNA damage and p53-dependent signaling responses. Comparative metagenomic analyses, together with the histopathological profiles, indicate that these mice constitute a faithful model for human head and neck squamous cell carcinomas. Collectively, our findings demonstrate that p21, in conjunction with pRb, has a central role in regulating multiple epithelial processes and orchestrating specific tumor suppressor functions.	[Saiz-Ladera, C.; Lara, M. F.; Santos, M.; Lorz, C.; Garcia-Escudero, R.; Martinez-Fernandez, M.; Segrelles, C.; Paramio, J. M.] CIEMAT, Ctr Invest Energet Medioambientales & Tecnol, Mol Oncol Unit ed70A, Div Biomed, E-28040 Madrid, Spain; [Garin, M.] CIEMAT, Ctr Invest Energet Medioambientales & Tecnol, Ctr Invest Biomed Red Enfermedades Raras, Div Hematopoiet Innovat Therapies HIT, E-28040 Madrid, Spain; [Ruiz, S.; Fernandez-Capetillo, O.] Spanish Natl Canc Res Ctr, Genom Instabil Grp, Madrid, Spain; [Bravo, A.] Univ Santiago de Compostela, Dept Vet Clin Sci, Lugo, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Centro Nacional de Investigaciones Oncologicas (CNIO); Universidade de Santiago de Compostela	Segrelles, C (corresponding author), CIEMAT, Ctr Invest Energet Medioambientales & Tecnol, Mol Oncol Unit ed70A, Ave Complutense 40, E-28040 Madrid, Spain.	carmen.segrelles@ciemat.es; jesusm.paramio@ciemat.es	Fernandez-Capetillo, Oscar/H-3508-2015; Garcia-Escudero, Ramon/A-2735-2012; Ruiz, Sergio/G-1561-2016; Paramio, Jesus M/M-8482-2014; Moral, Ana María Bravo/AAD-3339-2021; Santos, Mirentxu/AAA-1727-2020; Cabanás, María Lara/AAH-3621-2019; Garin, Marina I/C-5094-2014; Lorz, Corina/E-3651-2016; Segrelles, Carmen/E-3655-2016	Fernandez-Capetillo, Oscar/0000-0002-2690-6885; Garcia-Escudero, Ramon/0000-0001-5640-6542; Ruiz, Sergio/0000-0002-0177-6965; Paramio, Jesus M/0000-0001-7520-3177; Moral, Ana María Bravo/0000-0002-5282-8921; Garin, Marina I/0000-0001-7956-6792; Lorz, Corina/0000-0001-8214-9076; Segrelles, Carmen/0000-0001-9340-2102; Saiz Ladera, Cristina/0000-0001-8094-5992	MINECO [SAF2011-26122-C02-01, SAF2012-34378]; CAM Oncocycle Program [S2010/BMD-2470]; ISCIII-RETIC [RD06/0020/0029, RD12/0036/0009]; REGENER-AR; ISCIII [PI12/01959]; 'Juan de la Cierva' research fellowship from MICINN [JCI-2010-06167]; 'Ramon y Cajal' research fellowship from MICINN [11-866-25-04]; Spanish Ministry of Science [SAF2011-23753]; Association for International Cancer Research [12-0229]; Howard Hughes Medical Institute; European Research Council [ERC-210520]; EU [FP7-HEALTH-279174]; Worldwide Cancer Research [12-0229] Funding Source: researchfish	MINECO(Spanish Government); CAM Oncocycle Program; ISCIII-RETIC(Instituto de Salud Carlos III); REGENER-AR; ISCIII(Instituto de Salud Carlos III); 'Juan de la Cierva' research fellowship from MICINN; 'Ramon y Cajal' research fellowship from MICINN; Spanish Ministry of Science(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Association for International Cancer Research; Howard Hughes Medical Institute(Howard Hughes Medical Institute); European Research Council(European Research Council (ERC)European Commission); EU(European Commission); Worldwide Cancer Research	We thank Pilar Hernandez for her excellent technical support on histology preparations and sectioning. The technical support by the personnel of the CIEMAT Animal Facility is specially acknowledged. Grant support: MINECO grants SAF2011-26122-C02-01 and SAF2012-34378, CAM Oncocycle Program Grants S2010/BMD-2470, ISCIII-RETIC grants RD06/0020/0029 and RD12/0036/0009 to JMP. EU FP7-HEALTH-279174, REGENER-AR to MG. ISCIII grant PI12/01959 to MS. MMF is funded by a 'Juan de la Cierva' research fellowship (JCI-2010-06167) from MICINN. SR is funded by a 'Ramon y Cajal' research fellowship (11-866-25-04) from MICINN. Work in the laboratory of OF is supported by grants from the Spanish Ministry of Science (SAF2011-23753), the Association for International Cancer Research (12-0229), the Howard Hughes Medical Institute and the European Research Council (ERC-210520).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Afshari CA, 1996, CELL GROWTH DIFFER, V7, P979; Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Marques-Torrejon MA, 2013, CELL STEM CELL, V12, P88, DOI 10.1016/j.stem.2012.12.001; Arwert EN, 2012, NAT REV CANCER, V12, P170, DOI 10.1038/nrc3217; Balsitis SJ, 2003, MOL CELL BIOL, V23, P9094, DOI 10.1128/MCB.23.24.9094-9103.2003; Martinez-Cruz AB, 2010, METHODS MOL BIOL, V585, P361, DOI 10.1007/978-1-60761-380-0_25; Martinez-Cruz AB, 2009, ANTICANCER RES, V29, P3035; Bornachea O, 2012, SCI REP-UK, V2, DOI 10.1038/srep00434; Brocke-Heidrich K, 2004, BLOOD, V103, P242, DOI 10.1182/blood-2003-04-1048; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Buitrago-Perez A, 2009, CURR GENOMICS, V10, P26, DOI 10.2174/138920209787581235; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Chen Z, 1999, CLIN CANCER RES, V5, P1369; Chin D, 2006, EXPERT REV ANTICANC, V6, P1111, DOI 10.1586/14737140.6.7.1111; Chu C, 2011, MOL CELL, V44, P667, DOI 10.1016/j.molcel.2011.08.027; Chung CH, 2009, CLIN CANCER RES, V15, P6758, DOI 10.1158/1078-0432.CCR-09-0784; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Costa C, 2013, ONCOGENE, V32, P2937, DOI 10.1038/onc.2012.316; Costa C, 2012, SCI REP-UK, V2, DOI 10.1038/srep00828; D'Souza SJA, 2002, J BIOL CHEM, V277, P10626, DOI 10.1074/jbc.M111956200; D'Souza SJA, 2001, J BIOL CHEM, V276, P23531, DOI 10.1074/jbc.M100780200; Dannenberg JH, 2004, GENE DEV, V18, P2952, DOI 10.1101/gad.322004; De la Cueva E, 2006, ONCOGENE, V25, P4128, DOI 10.1038/sj.onc.1209432; de Marval PLM, 2004, ONCOGENE, V23, P1863, DOI 10.1038/sj.onc.1207309; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Devgan V, 2005, GENE DEV, V19, P1485, DOI 10.1101/gad.341405; Devgan V, 2006, J BIOL CHEM, V281, P30463, DOI 10.1074/jbc.M604684200; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; Duenas M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042494; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ford JW, 2009, CURR OPIN IMMUNOL, V21, P38, DOI 10.1016/j.coi.2009.01.009; Garcia-Escudero R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-193; Haile LA, 2012, IMMUNOL INVEST, V41, P581, DOI 10.3109/08820139.2012.680635; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; HARPER JW, 1993, CELL, V75, P805; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Kyng KJ, 2005, ONCOGENE, V24, P5026, DOI 10.1038/sj.onc.1208692; Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466; Lara MF, 2008, MOL CARCINOGEN, V47, P209, DOI 10.1002/mc.20376; Lara MF, 2008, MOL CARCINOGEN, V47, P105, DOI 10.1002/mc.20367; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Leeman RJ, 2006, EXPERT OPIN BIOL TH, V6, P231, DOI 10.1517/14712598.6.3.231; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Lopez-Contreras AJ, 2010, DNA REPAIR, V9, P1249, DOI 10.1016/j.dnarep.2010.09.012; Lui VWY, 2013, CANCER DISCOV, V3, P761, DOI 10.1158/2159-8290.CD-13-0103; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Martin-Caballero J, 2004, ONCOGENE, V23, P8231, DOI 10.1038/sj.onc.1207863; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Martinez LA, 1999, ONCOGENE, V18, P397, DOI 10.1038/sj.onc.1202300; Martinez-Cruz AB, 2008, CANCER RES, V68, P683, DOI 10.1158/0008-5472.CAN-07-3049; McMurray HR, 2008, NATURE, V453, P1112, DOI 10.1038/nature06973; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Moral M, 2008, HISTOL HISTOPATHOL, V23, P1269, DOI 10.14670/HH-23.1269; PAK AS, 1995, CLIN CANCER RES, V1, P95; Paramio JM, 2001, J BIOL CHEM, V276, P44203, DOI 10.1074/jbc.M105650200; Paramio JM, 2000, J BIOL CHEM, V275, P41219, DOI 10.1074/jbc.M004973200; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; Perez-Ordonez B, 2006, J CLIN PATHOL, V59, P445, DOI 10.1136/jcp.2003.007641; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Pickering CR, 2013, CANCER DISCOV, V3, P770, DOI 10.1158/2159-8290.CD-12-0537; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Poole AJ, 2004, ONCOGENE, V23, P8128, DOI 10.1038/sj.onc.1207994; Pyeon D, 2007, CANCER RES, V67, P4605, DOI 10.1158/0008-5472.CAN-06-3619; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rickman DS, 2008, ONCOGENE, V27, P6607, DOI 10.1038/onc.2008.251; Riley DJ, 1996, NAT MED, V2, P1316, DOI 10.1038/nm1296-1316; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Rodriguez-Puebla ML, 2002, AM J PATHOL, V161, P405, DOI 10.1016/S0002-9440(10)64196-X; Ruiz S, 2005, CANCER RES, V65, P9678, DOI 10.1158/0008-5472.CAN-05-1853; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Ruiz S, 2004, DEV DYNAM, V230, P410, DOI 10.1002/dvdy.20065; Ruiz S, 2003, DEVELOPMENT, V130, P2341, DOI 10.1242/dev.00453; Ruiz S, 2006, CELL CYCLE, V5, P625, DOI 10.4161/cc.5.6.2580; Santos M, 2003, J BIOL CHEM, V278, P13422, DOI 10.1074/jbc.M208170200; Santos M, 2008, MOL CARCINOGEN, V47, P815, DOI 10.1002/mc.20426; Serefoglou Z, 2008, ORAL ONCOL, V44, P1093, DOI 10.1016/j.oraloncology.2008.02.012; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shin MK, 2009, CANCER RES, V69, P5656, DOI 10.1158/0008-5472.CAN-08-3711; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Srivastava MK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040677; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Toledo LI, 2011, NAT STRUCT MOL BIOL, V18, P721, DOI 10.1038/nsmb.2076; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Wang DW, 2001, MOL CARCINOGEN, V31, P90, DOI 10.1002/mc.1044; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinberg WC, 2002, CRIT REV ORAL BIOL M, V13, P453, DOI 10.1177/154411130201300603; Weinberg WC, 1999, CANCER RES, V59, P2050; Woods KV, 1998, CANCER RES, V58, P3132; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	105	12	12	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2014	33	37					4599	4612		10.1038/onc.2013.417	http://dx.doi.org/10.1038/onc.2013.417			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3UZ	24121270	Green Accepted			2022-12-28	WOS:000342004800007
J	He, L; Guo, L; Vathipadiekal, V; Sergent, PA; Growdon, WB; Engler, DA; Rueda, BR; Birrer, MJ; Orsulic, S; Mohapatra, G				He, L.; Guo, L.; Vathipadiekal, V.; Sergent, P. A.; Growdon, W. B.; Engler, D. A.; Rueda, B. R.; Birrer, M. J.; Orsulic, S.; Mohapatra, G.			Identification of LMX1B as a novel oncogene in human ovarian cancer	ONCOGENE			English	Article						ovarian cancer; aCGH; LMX1B; tumor progression; transcription factor	NAIL-PATELLA-SYNDROME; COMPARATIVE GENOMIC HYBRIDIZATION; MOUSE MODEL; MOLECULAR CHARACTERIZATION; HOMEODOMAIN PROTEINS; TRANSCRIPTION FACTOR; GENETIC CHANGES; BREAST CANCERS; KAPPA-B; INFLAMMATION	Ovarian cancers are thought to result from the accumulation of multiple genetic aberrations that transform ovarian and/or fallopian tube surface epithelial cells, allowing for their abnormal growth, proliferation and metastasis. In the report presented here, we carried out genome-wide copy-number analysis using comparative genomic hybridization on a panel of mouse ovarian cancer (OVCA) cell lines previously established in our laboratory. We identified a recurrent focal amplification on mouse chromosomal region 2qB, which contains the LIM-homeodomain-containing transcription factor 1B (Lmx1b) gene. LMX1B is not expressed in normal human ovary, but is expressed in many human OVCA cell lines and primary tumors. High expression of LMX1B correlates with poor outcome. To clarify the role of LMX1B in ovarian carcinogenesis, we transduced LMX1B into a panel of mouse and human OVCA cell lines and demonstrated that LMX1B strongly promotes migration of cancer cells in culture and promotes xenograft growth in nude mice. Conversely, knockdown of LMX1B in a human cell line with endogenous high expression of LMX1B inhibits cell migration in vitro and tumor growth in vivo. Microarray analysis of cells overexpressing LMX1B identified the nuclear factor (NF)-kappa B pathway as a potential mediator of tumor progression and subsequent treatment of NF kappa B inhibitor decreased the migratory capacity of these cells. Thus, our data demonstrate that LMX1B is a novel oncogene in OVCA pathogenesis.	[He, L.; Mohapatra, G.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [He, L.; Vathipadiekal, V.; Growdon, W. B.; Rueda, B. R.; Birrer, M. J.; Mohapatra, G.] Harvard Univ, Sch Med, Boston, MA USA; [Guo, L.; Sergent, P. A.; Growdon, W. B.; Rueda, B. R.] Massachusetts Gen Hosp, Dept Vincent Obstet & Gynecol, Vincent Ctr Reprod Biol, Boston, MA 02114 USA; [Vathipadiekal, V.; Birrer, M. J.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA; [Vathipadiekal, V.; Birrer, M. J.] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA; [Engler, D. A.] Brigham Young Univ, Dept Stat, Provo, UT 84602 USA; [Orsulic, S.] Cedars Sinai Med Ctr, Womens Canc Res Inst, Los Angeles, CA 90048 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Brigham Young University; Cedars Sinai Medical Center	Mohapatra, G (corresponding author), Massachusetts Gen Hosp, Dept Pathol, 70 Blossom St, Boston, MA 02114 USA.	gmohapatra@partners.org		Sergent, Petra/0000-0002-8244-8209; /0000-0002-8181-6890	American Cancer Society [118900-RSG-10-252-01-TBG]; Advanced Medical Research Foundation; Vincent Memorial Research Funds; Michael Wall Gynecologic Oncology Research Fund	American Cancer Society(American Cancer Society); Advanced Medical Research Foundation; Vincent Memorial Research Funds; Michael Wall Gynecologic Oncology Research Fund	We thank Jinsong Liu (MD Anderson Cancer Center) for the T29-immortalized human ovarian surface epithelial cell line. This work was supported by the American Cancer Society Grant 118900-RSG-10-252-01-TBG (SO), Advanced Medical Research Foundation (BRR) and Vincent Memorial Research Funds (BRR) and the Michael Wall Gynecologic Oncology Research Fund (GM).	Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bongers EMHF, 2002, PEDIATR NEPHROL, V17, P703, DOI 10.1007/s00467-002-0911-5; Burbach JPH, 2003, ANN NY ACAD SCI, V991, P61; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; Chen H, 1998, NAT GENET, V19, P51, DOI 10.1038/ng0598-51; Cheng KW, 2004, NAT MED, V10, P1251, DOI 10.1038/nm1125; Dreyer SD, 1998, NAT GENET, V19, P47, DOI 10.1038/ng0598-47; Fishman A, 2005, INT J GYNECOL CANCER, V15, P261, DOI 10.1111/j.1525-1438.2005.15213.x; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gabeau-Lacet D, 2009, J NEUROPATH EXP NEUR, V68, P1155, DOI 10.1097/NEN.0b013e3181ba3952; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Guo C, 2007, DEVELOPMENT, V134, P317, DOI 10.1242/dev.02745; Hernandez L, 2010, CANCER RES, V70, P4005, DOI 10.1158/0008-5472.CAN-09-3912; Hunter C, 2005, MOL BIOL REP, V32, P67, DOI 10.1007/s11033-004-7657-z; Israeli O, 2004, CANCER GENET CYTOGEN, V154, P16, DOI 10.1016/j.cancergencyto.2004.02.006; Ivan C, 2013, GYNECOL ONCOL, V128, P506, DOI 10.1016/j.ygyno.2012.11.029; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johnson JD, 1997, MOL CELL BIOL, V17, P3488, DOI 10.1128/MCB.17.7.3488; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Lee TI, 2013, CELL, V152, P1237, DOI 10.1016/j.cell.2013.02.014; Liu GZ, 2010, JNCI-J NATL CANCER I, V102, P812, DOI 10.1093/jnci/djq127; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Mantovani A, 2010, ANN MED, V42, P161, DOI 10.3109/07853890903405753; Mayr D, 2006, AM J CLIN PATHOL, V126, P101, DOI 10.1309/N6X5MB24BP42KP20; McCann CK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028077; McIntosh I, 2005, ANN HUM GENET, V69, P349, DOI 10.1111/j.1529-8817.2005.00191.x; Miao J, 2007, P NATL ACAD SCI USA, V104, P17093, DOI 10.1073/pnas.0707938104; MOHAPATRA G, 1995, GENE CHROMOSOME CANC, V13, P86, DOI 10.1002/gcc.2870130203; Mok SC, 2009, CANCER CELL, V16, P521, DOI 10.1016/j.ccr.2009.10.018; Nanjundan M, 2007, CANCER RES, V67, P3074, DOI 10.1158/0008-5472.CAN-06-2366; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Ozols RF, 2004, CANCER CELL, V5, P19, DOI 10.1016/S1535-6108(04)00002-9; Pinkel D, 2005, NAT GENET, V37, pS11, DOI 10.1038/ng1569; Pressman CL, 2000, GENESIS, V26, P15, DOI 10.1002/(SICI)1526-968X(200001)26:1<15::AID-GENE5>3.0.CO;2-V; Rascle A, 2009, EXP CELL RES, V315, P76, DOI 10.1016/j.yexcr.2008.10.012; Sato U, 2005, PEDIATR RES, V57, P783, DOI 10.1203/01.PDR.0000157674.63621.2C; Stratton MR, 2011, SCIENCE, V331, P1553, DOI 10.1126/science.1204040; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; White KL, 2011, CANCER CAUSE CONTROL, V22, P785, DOI 10.1007/s10552-011-9745-4; Xing DY, 2006, CANCER RES, V66, P8949, DOI 10.1158/0008-5472.CAN-06-1495; Xing DY, 2005, P NATL ACAD SCI USA, V102, P6936, DOI 10.1073/pnas.0502256102; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030	49	16	16	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2014	33	33					4226	4235		10.1038/onc.2013.375	http://dx.doi.org/10.1038/onc.2013.375			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MB	24056967				2022-12-28	WOS:000341155800004
J	Garrido, G; Rabasa, A; Garrido, C; Lopez, A; Chao, L; Garcia-Lora, AM; Garrido, F; Fernandez, LE; Sanchez, B				Garrido, G.; Rabasa, A.; Garrido, C.; Lopez, A.; Chao, L.; Garcia-Lora, A. M.; Garrido, F.; Fernandez, L. E.; Sanchez, B.			Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms	ONCOGENE			English	Article						EGFR; monoclonal antibodies; resistance; MHC-I alterations	MHC CLASS-I; METASTATIC COLORECTAL-CANCER; COORDINATED DOWN-REGULATION; SQUAMOUS-CELL CARCINOMA; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; LUNG-CANCER; TUMOR-CELLS; PHASE-III; CETUXIMAB	To define the molecular basis of secondary resistance to epidermal growth factor receptor (EGFR)-specific antibodies is crucial to increase clinical benefit in patients. The limited access to posttreatment tumor samples constitutes the major barrier to conduct these studies, representing preclinical experimentation as a useful alternative. Anti-EGFR antibody-based therapy has been reported to mediate tumor regression by interrupting oncogenic signals and, more recently, by inducing antitumor immunological responses. However, resistance models have been focused only on tumor escape associated with EGFR blockade, whereas studies describing immune-associated escape mechanisms have not been reported thus far. To address this idea, we modeled resistance induction in D122 metastasis-bearing C57BL/6 mice treated with 7A7 (an anti-murine EGFR antibody). Similarly to patients receiving EGFR-specific antibodies, 7A7 resistance promotion represents an important drawback to successful therapy. Characterization of primary cultures derived from metastasis in 7A7-treated mice revealed a high frequency of tumor variants resistant to in vivo and in vitro antibody treatment. We showed, for the first time, the convergence of alterations in oncogenic and immunological pathways in 7A7-resistant variants. To identify key molecules behind resistance, seven 7A7-resistant variants were screened. HER3 overexpression and PTEN deficiency leading to hyperactivation of protumoral downstream signaling were found in these variants as a consequence of 7A7-mediated EGFR inhibition. Concomitantly, we found a high percentage of resistant variants carrying abnormalities in the constitutive and/or interferon gamma (IFN-gamma)-inducible major histocompatibility complex I (MHC-I) expression. A significant decrease in mRNA levels for MHC-I heavy chains, beta(2)-microglogulin and antigen processing machinery genes as well as transcriptional alterations in IFN-gamma pathway components were identified as the main mechanisms underlying MHC-I expression defects in 7A7-resistant variants. Notably, these defects have not been previously associated with EGFR-specific antibody resistance, providing novel immunological escape mechanisms. This study has strong implications for the development of new combination strategies to overcome anti-EGFR antibodies refractoriness.	[Garrido, G.; Rabasa, A.; Chao, L.; Sanchez, B.] Ctr Mol Immunol, Tumor Immunol Direct, Inst Mol Immunol, Havana 11600, Cuba; [Garrido, C.; Garcia-Lora, A. M.; Garrido, F.] Hosp Univ VirgenNieves, Dept Anal Clin & Inmunol, Granada, Spain; [Garrido, C.; Garrido, F.] Univ Granada, Fac Med, Dept Bioquim Biol Mol & Inmunol 3, Granada, Spain; [Lopez, A.] Ctr Mol Immunol, Syst Biol Direct, Inst Mol Immunol, Havana 11600, Cuba; [Fernandez, L. E.] Ctr Mol Immunol, Innovat Direct, Inst Mol Immunol, Havana 11600, Cuba	University of Granada	Sanchez, B (corresponding author), Ctr Mol Immunol, Tumor Immunol Direct, Inst Mol Immunol, 216 St & 15th Ave,POB 16040, Havana 11600, Cuba.	belinda@cim.sld.cu	Garrido, Cristina/H-5974-2015	Garrido, Cristina/0000-0002-6277-4920; Garcia Lora, Angel Miguel/0000-0002-8248-8235; Garrido Torres-Puchol, Federico/0000-0003-4770-9685; RABASA CAPOTE, AILEM/0000-0002-4250-2725	Cuban Government; Boehringer Ingelheim Fonds; Instituto de Salud Carlos III [CP03/0111, P112/02031, PI 08/1265, PI 11/01022, RETIC RD 06/020]; Junta de Andalucia, Spain [CTS-143, CTS-695, CTS-3952, CVI-4740]; MEC (FPU) [1631]; FPS [CP03/0111, I3]; ISCIII, Spain	Cuban Government; Boehringer Ingelheim Fonds(Boehringer Ingelheim); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Junta de Andalucia, Spain(Junta de AndaluciaEuropean Commission); MEC (FPU)(Spanish Government); FPS; ISCIII, Spain(Instituto de Salud Carlos III)	We thank Isabel Linares and Ignacio Algarra for technical assistance. This work was partially supported by Cuban Government, a grant from Boehringer Ingelheim Fonds and by grants from the Instituto de Salud Carlos III (CP03/0111, P112/02031, PI 08/1265, PI 11/01022, RETIC RD 06/020); Junta de Andalucia (Group CTS-143 and CTS-695, CTS-3952, CVI-4740 grants), Spain. CG was supported by the MEC (FPU, 1631). AMGL was supported by Miguel Servet Contract CP03/0111 and Contract I3 from FPS and ISCIII, Spain.	Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Aptsiauri N, 2007, INT REV CYTOL, V256, P139, DOI 10.1016/S0074-7696(07)56005-5; Bianchi F, 2006, P NATL ACAD SCI USA, V103, P18981, DOI 10.1073/pnas.0605821103; Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397; Brand TM, 2011, CANCER BIOL THER, V11, P777, DOI 10.4161/cbt.11.9.15050; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Correale P, 2012, INT J CANCER, V130, P1577, DOI 10.1002/ijc.26181; Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860; Duncan TJ, 2007, CLIN CANCER RES, V13, P4139, DOI 10.1158/1078-0432.CCR-06-2833; EISENBACH L, 1984, INT J CANCER, V34, P567, DOI 10.1002/ijc.2910340421; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Erjala K, 2006, CLIN CANCER RES, V12, P4103, DOI 10.1158/1078-0432.CCR-05-2404; Garcia-Lora A, 2003, INT J CANCER, V106, P521, DOI 10.1002/ijc.11241; Garrido C, 2012, CARCINOGENESIS, V33, P687, DOI 10.1093/carcin/bgr318; Garrido C, 2010, CANCER IMMUNOL IMMUN, V59, P13, DOI 10.1007/s00262-009-0716-5; Garrido F, 1997, IMMUNOL TODAY, V18, P89, DOI 10.1016/S0167-5699(96)10075-X; Garrido F, 2010, INT J CANCER, V127, P249, DOI 10.1002/ijc.25270; Garrido G, 2004, HYBRIDOMA HYBRIDOM, V23, P168, DOI 10.1089/1536859041224280; Garrido G, 2007, CANCER IMMUNOL IMMUN, V56, P1701, DOI 10.1007/s00262-007-0313-4; Garrido G, 2011, J IMMUNOL, V187, P4954, DOI 10.4049/jimmunol.1003477; Groettrup M, 1997, P NATL ACAD SCI USA, V94, P8970, DOI 10.1073/pnas.94.17.8970; Herrmann F, 2004, CANCER RES, V64, P215, DOI 10.1158/0008-5472.CAN-2522-2; Ishizawar RC, 2007, ONCOGENE, V26, P3503, DOI 10.1038/sj.onc.1210138; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kelly-Spratt KS, 2009, ONCOGENE, V28, P3652, DOI 10.1038/onc.2009.226; Kim SM, 2010, CANCER LETT, V296, P150, DOI 10.1016/j.canlet.2010.04.006; Meissner M, 2005, CLIN CANCER RES, V11, P2552, DOI 10.1158/1078-0432.CCR-04-2146; Peeters M, 2010, J CLIN ONCOL, V28, P4706, DOI 10.1200/JCO.2009.27.6055; Perez Rolando, 2011, Cancers (Basel), V3, P2014, DOI 10.3390/cancers3022014; Pollack BP, 2011, CLIN CANCER RES, V17, P4400, DOI 10.1158/1078-0432.CCR-10-3283; PORGADOR A, 1991, INT J CANCER, P54; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Reichert JM, 2012, DRUG DISCOV TODAY, V17, P954, DOI 10.1016/j.drudis.2012.04.006; Romero I, 2012, J PATHOL, V227, P367, DOI 10.1002/path.4029; Romero JM, 2005, INT J CANCER, V113, P605, DOI 10.1002/ijc.20499; Seliger B, 2008, ADV CANCER RES, V101, P249, DOI 10.1016/S0065-230X(08)00407-7; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Srivastava RM, 2013, CLIN CANCER RES, V19, P1858, DOI 10.1158/1078-0432.CCR-12-2426; Talavera A, 2011, MOL IMMUNOL, V48, P1578, DOI 10.1016/j.molimm.2011.03.016; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19; Wheeler DL, 2009, ONCOLOGIST, V14, P667, DOI 10.1634/theoncologist.2009-0009; Xi SC, 2006, JNCI-J NATL CANCER I, V98, P181, DOI 10.1093/jnci/djj020; Yang XM, 2013, MOL THER, V21, P91, DOI 10.1038/mt.2012.184; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309	48	22	22	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3129	3139		10.1038/onc.2013.288	http://dx.doi.org/10.1038/onc.2013.288			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23975426	Bronze			2022-12-28	WOS:000338410000006
J	Weis, B; Schmidt, J; Maamar, H; Raj, A; Lin, H; Toth, C; Riedmann, K; Raddatz, G; Seitz, HK; Ho, AD; Lyko, F; Linhart, HG				Weis, B.; Schmidt, J.; Maamar, H.; Raj, A.; Lin, H.; Toth, C.; Riedmann, K.; Raddatz, G.; Seitz, H-K; Ho, A. D.; Lyko, F.; Linhart, H. G.			Inhibition of intestinal tumor formation by deletion of the DNA methyltransferase 3a	ONCOGENE			English	Article							DE-NOVO METHYLATION; IN-VIVO; DNMT3A; CANCER; MOUSE; GENE; HYPOMETHYLATION; OVEREXPRESSION; EXPRESSION; 3B	Aberrant de novo methylation of DNA is considered an important mediator of tumorigenesis. To investigate the role of de novo DNA methyltransferase 3a (Dnmt3a) in intestinal tumor development, we analyzed the expression of Dnmt3a in murine colon crypts, murine colon adenomas and human colorectal cancer using RNA fluorescence in situ hybridization (FISH), quantitative PCR and immunostaining. Following conditional deletion of Dnmt3a in the colon of APC((Min/+)) mice, we analyzed tumor numbers, genotype of macroadenomas and laser dissected microadenomas, global and regional DNA methylation and gene expression. Our results showed increased Dnmt3a expression in colon adenomas of APC((Min/+)) mice and human colorectal cancer samples when compared with control tissue. Interestingly, in tumor tissue, RNA FISH analysis showed highest Dnmt3a expression in Lgr5-positive stem/progenitor cells. Deletion of Dnmt3a in APC((Min/+)) mice reduced colon tumor numbers by similar to 40%. Remaining adenomas and microadenomas almost exclusively contained the non-recombined Dnmt3a allele; no tumors composed of the inactivated Dnmt3a allele were detected. DNA methylation was reduced at the Oct4, Nanog, Tff2 and Cdkn1c promoters and expression of the tumor-suppressor genes Tff2 and Cdkn1c was increased. In conclusion, our results show that Dnmt3a is predominantly expressed in the stem/progenitor cell compartment of tumors and that deletion of Dnmt3a inhibits the earliest stages of intestinal tumor development.	[Weis, B.; Schmidt, J.; Riedmann, K.; Raddatz, G.; Lyko, F.; Linhart, H. G.] German Canc Res Ctr, Div Epigenet A130, D-69120 Heidelberg, Germany; [Maamar, H.; Raj, A.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Lin, H.] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA USA; [Toth, C.] Heidelberg Univ, Dept Pathol, Natl Ctr Tumor Dis NCT, Tissue Bank, Heidelberg, Germany; [Toth, C.] Univ Dusseldorf, Dept Pathol, Dusseldorf, Germany; [Seitz, H-K; Linhart, H. G.] Heidelberg Univ, Dept Med, Salem Med Ctr, Alcohol Res Ctr, Heidelberg, Germany; [Ho, A. D.; Linhart, H. G.] Heidelberg Univ, Dept Hematol Oncol, Med Ctr, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Pennsylvania; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Heinrich Heine University Dusseldorf; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Linhart, HG (corresponding author), German Canc Res Ctr, Div Epigenet A130, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	heinz.linhart@nct-heidelberg.de		Lin, Haijiang/0000-0003-2931-468X; Raj, Arjun/0000-0002-2915-6960	DKFZ Light Microscopy Facility; Helmholtz International Graduate School for Cancer Research; Burroughs-Wellcome Fund Career Award at the Scientific Interface; NIH [1DP2OD008514-01]; Lautenschlager foundation; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD008514] Funding Source: NIH RePORTER	DKFZ Light Microscopy Facility; Helmholtz International Graduate School for Cancer Research; Burroughs-Wellcome Fund Career Award at the Scientific Interface(Burroughs Wellcome Fund); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lautenschlager foundation; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Support by the DKFZ Light Microscopy Facility is gratefully acknowledged. We also thank E Herpel and the tissue bank of the NCT Heidelberg for providing human tissue samples and for technical support in histology and immunohistochemistry. We also thank J Gutekunst for bioinformatical support and R Jaenisch for critical discussions. This study was supported by a graduate scholarship from the Helmholtz International Graduate School for Cancer Research (B Weis), a Burroughs-Wellcome Fund Career Award at the Scientific Interface (A Raj, H Maamar), a NIH Director's New Innovator award (1DP2OD008514-01 to A Raj) and the Lautenschlager foundation (HK Seitz).	Bai XF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040024; Figliola R, 2008, J MOL BIOL, V380, P265, DOI 10.1016/j.jmb.2008.05.004; Fujimoto K, 2002, GASTROENTEROLOGY, V123, P1941, DOI 10.1053/gast.2002.37065; Gao Q, 2011, P NATL ACAD SCI USA, V108, P18061, DOI 10.1073/pnas.1114946108; He SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027684; Hlady RA, 2012, J CLIN INVEST, V122, P163, DOI 10.1172/JCI57292; Hon GC, 2013, NAT GENET, V45, P1198, DOI 10.1038/ng.2746; Hsieh CL, 1999, MOL CELL BIOL, V19, P8211; Jeong M, 2014, NAT GENET, V46, P17, DOI 10.1038/ng.2836; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kaneda M, 2004, NATURE, V429, P900, DOI 10.1038/nature02633; Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006; Katoh M, 2003, INT J MOL MED, V12, P3; Kavanagh E, 2011, BBA-REV CANCER, V1816, P50, DOI 10.1016/j.bbcan.2011.03.002; Kinney SM, 2011, J BIOL CHEM, V286, P24685, DOI 10.1074/jbc.M110.217083; Kinney SRM, 2008, MOL CANCER RES, V6, P1365, DOI 10.1158/1541-7786.MCR-08-0040; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Li JY, 2007, MOL CELL BIOL, V27, P8748, DOI 10.1128/MCB.01380-07; Lin HJ, 2006, MOL CELL BIOL, V26, P2976, DOI 10.1128/MCB.26.8.2976-2983.2006; Linhart HG, 2007, GENE DEV, V21, P3110, DOI 10.1101/gad.1594007; Luczak MW, 2012, INT J ONCOL, V40, P860, DOI 10.3892/ijo.2011.1183; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Nguyen' S, 2007, DEV DYNAM, V236, P1663, DOI 10.1002/dvdy.21176; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Peterson AJ, 2010, GASTROENTEROLOGY, V139, P2005, DOI 10.1053/j.gastro.2010.08.043; Qu Y, 2010, AM J CLIN PATHOL, V134, P826, DOI 10.1309/AJCPHGQ69FXDFWII; Raddatz G, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003146; Rahman MM, 2010, HUM PATHOL, V41, P1069, DOI 10.1016/j.humpath.2010.01.011; Raj A, 2008, NAT METHODS, V5, P877, DOI 10.1038/NMETH.1253; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; Samuel MS, 2009, GASTROENTEROLOGY, V137, P902, DOI 10.1053/j.gastro.2009.05.042; Steine EJ, 2011, J CLIN INVEST, V121, P1748, DOI 10.1172/JCI43169; Tang YA, 2012, CLIN CANCER RES, V18, P4325, DOI 10.1158/1078-0432.CCR-11-2617; Weis B, 2010, BMC BIOTECHNOL, V10, DOI 10.1186/1472-6750-10-75; Yamada Y, 2005, P NATL ACAD SCI USA, V102, P13580, DOI 10.1073/pnas.0506612102; Yamada Y, 2007, CANCER SCI, V98, P6, DOI 10.1111/j.1349-7006.2006.00348.x; Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032	38	18	18	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1822	1830		10.1038/onc.2014.114	http://dx.doi.org/10.1038/onc.2014.114			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24837369				2022-12-28	WOS:000352158000009
J	Gao, W; Gu, Y; Li, Z; Cai, H; Peng, Q; Tu, M; Kondo, Y; Shinjo, K; Zhu, Y; Zhang, J; Sekido, Y; Han, B; Qian, Z; Miao, Y				Gao, W.; Gu, Y.; Li, Z.; Cai, H.; Peng, Q.; Tu, M.; Kondo, Y.; Shinjo, K.; Zhu, Y.; Zhang, J.; Sekido, Y.; Han, B.; Qian, Z.; Miao, Y.			miR-615-5p is epigenetically inactivated and functions as a tumor suppressor in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							HUMAN CANCER-CELLS; DNA METHYLATION; MICRORNA EXPRESSION; MICROSATELLITE INSTABILITY; GENE POLYMORPHISMS; DISEASE; RISK; PROGNOSIS; IGF2	Pancreatic ductal adenocarcinoma (PDAC) is a highly invasive cancer with a poor prognosis. Although microRNA (miRNA) transcripts have a crucial role in carcinogenesis and development, little information is known regarding the aberrant DNA methylation of miRNAs in PDAC. Using methylated DNA immunoprecipitation-chip analysis, we found that miR-615-5p was hypermethylated in its putative promoter region, which silenced its expression in PDAC cell lines. In addition, the overexpression of miR-615-5p in pancreatic cancer cells suppressed cell proliferation, migration and invasion. Insulin-like growth factor 2 (IGF2) is an imprinted gene, and its abnormal expression contributes to tumor growth. Here, we identified IGF2 as a target of miR-615-5p using a luciferase reporter assay. IGF2 upregulation in PDAC tissues was not correlated with a loss of imprinting but was inversely correlated with miR-615-5p downregulation. In addition, miR-615-5p suppressed pancreatic cancer cell proliferation, migration and invasion by directly targeting IGF2, and this effect could be reversed by co-transfection with IGF2. Furthermore, the stable overexpression of miR-615-5p inhibited tumor growth in vivo and was correlated with IGF2 expression. Using RNA sequencing, we further identified miR-615-5p as potentially targeting other genes, such as the proto-oncogene JUNB, and interfering with the insulin signaling pathway. Taken together, our results demonstrate that miR-615-5p was abnormally downregulated in PDAC cells due to promoter hypermethylation, which limited its inhibition of IGF2 and other target genes, thereby contributing to tumor growth, invasion and migration. These data demonstrate a novel and important role of miR-615-5p as a tumor suppressor in PDAC.	[Gao, W.; Gu, Y.; Li, Z.; Tu, M.; Zhu, Y.; Zhang, J.; Qian, Z.; Miao, Y.] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing 210029, Jiangsu, Peoples R China; [Cai, H.] First Peoples Hosp Changzhou, Dept Hepatobiliary Surg, Changzhou, Peoples R China; [Peng, Q.] PLA 105 Hosp, Dept Gen Surg, Hefei, Peoples R China; [Kondo, Y.; Shinjo, K.] Aichi Canc Ctr, Res Inst, Div Epigenom, Nagoya, Aichi 464, Japan; [Sekido, Y.] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi 464, Japan; [Han, B.] Nanjing Med Univ, Nanjing Childrens Hosp, Dept Endocrinol, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Aichi Cancer Center; Aichi Cancer Center; Nanjing Medical University	Gao, W (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, 300 GuangZhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	gao11@hotmail.com; qianzhusilver@163.com; miaoyi@njmu.edu.cn	Sekido, Yoshitaka/P-9756-2015	Sekido, Yoshitaka/0000-0002-2428-3848	National Nature Science Foundation of China [81172267, 30901627]; National Project For Translational Research Of Early Diagnosis And Comprehensive Treatment In Pancreatic Cancer [201202007]; Priority Academic Program Development of Jiangsu Higher Education Institutions [JX10231801]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Project For Translational Research Of Early Diagnosis And Comprehensive Treatment In Pancreatic Cancer; Priority Academic Program Development of Jiangsu Higher Education Institutions	This work was supported by grants from the National Nature Science Foundation of China (Nos 81172267 and 30901627), the National Project For Translational Research Of Early Diagnosis And Comprehensive Treatment In Pancreatic Cancer (201202007) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (JX10231801).	Boeri M, 2011, P NATL ACAD SCI USA, V108, P3713, DOI 10.1073/pnas.1100048108; Chao W, 2008, CYTOKINE GROWTH F R, V19, P111, DOI 10.1016/j.cytogfr.2008.01.005; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045; Dong XQ, 2012, CANCER EPIDEMIOL, V36, P206, DOI 10.1016/j.canep.2011.05.013; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; El TH, 2012, FEBS LETT, V586, P3309; Fiorucci G, 2012, CURR MED CHEM, V19, P461, DOI 10.2174/092986712798918798; Gao W, 2008, CARCINOGENESIS, V29, P1901, DOI 10.1093/carcin/bgn170; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Han L, 2007, CANCER BIOL THER, V6, P1284; Ingram WJ, 2002, ONCOGENE, V21, P8196, DOI 10.1038/sj.onc.1205975; Jacinto FV, 2008, BIOTECHNIQUES, V44, P35, DOI 10.2144/000112708; Kim M, 2011, LANCET ONCOL, V12, P319, DOI 10.1016/S1470-2045(11)70067-5; Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797; Kunej T, 2011, MUTAT RES-FUND MOL M, V717, P77, DOI 10.1016/j.mrfmmm.2011.03.008; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Mardin W, 2009, ANN SURG ONCOL, V16, P3183, DOI 10.1245/s10434-009-0623-1; Mou HQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077217; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Rachagani S, 2010, CANCER LETT, V292, P8, DOI 10.1016/j.canlet.2009.11.010; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Sato F, 2011, FEBS J, V278, P1598, DOI 10.1111/j.1742-4658.2011.08089.x; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Soares MR, 2010, GROWTH HORM IGF RES, V20, P295, DOI 10.1016/j.ghir.2010.03.006; Suzuki H, 2008, CANCER EPIDEM BIOMAR, V17, P3467, DOI 10.1158/1055-9965.EPI-08-0514; Teschendorff AE, 2012, BIOINFORMATICS, V28, P1487, DOI 10.1093/bioinformatics/bts170; Tricoli James V, 2007, Cancer Res, V67, P4553, DOI 10.1158/0008-5472.CAN-07-0563; van Kouwenhove M, 2011, NAT REV CANCER, V11, P644, DOI 10.1038/nrc3107; Wang J, 2011, J BIOSCIENCES, V36, P481, DOI 10.1007/s12038-011-9083-4; Weber B, 2007, CELL CYCLE, V6, P1001, DOI 10.4161/cc.6.9.4209; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Yang Y, 2012, BIOCHEM GENET, V50, P122, DOI 10.1007/s10528-011-9478-9; Zhou X, 2007, PLOS COMPUT BIOL, V3	36	62	65	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1629	1640		10.1038/onc.2014.101	http://dx.doi.org/10.1038/onc.2014.101			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24769899				2022-12-28	WOS:000351848400003
J	de la Cruz-Herrera, CF; Campagna, M; Lang, V; Gonzalez-Santamaria, JD; Marcos-Villar, L; Rodriguez, MS; Vidal, A; Collado, M; Rivas, C				de la Cruz-Herrera, C. F.; Campagna, M.; Lang, V.; del Carmen Gonzalez-Santamaria, J.; Marcos-Villar, L.; Rodriguez, M. S.; Vidal, A.; Collado, M.; Rivas, C.			SUMOylation regulates AKT1 activity	ONCOGENE			English	Article							PROTEIN-KINASE B; HEAT-SHOCK; ONCOGENIC TRANSFORMATION; QUANTITATIVE PROTEOMICS; SUMO-1 MODIFICATION; NIH3T3 CELLS; ACTIVATION; PATHWAY; PHOSPHORYLATION; PML	Serine threonine kinase AKT has a central role in the cell, controlling survival, proliferation, metabolism and angiogenesis. Deregulation of its activity underlies a wide range of pathological situations, including cancer. Here we show that AKT is post-translationally modified by the small ubiquitin-like modifier (SUMO) protein. Interestingly, neither SUMO conjugation nor activation of SUMOylated AKT is regulated by the classical AKT targeting to the cell membrane or by the phosphoinositide 3-kinase pathway. We demonstrate that SUMO induces the activation of AKT, whereas, conversely, down-modulation of the SUMO machinery diminishes AKT activation and cell proliferation. Furthermore, an AKT SUMOylation mutant shows reduced activation, and decreased anti-apoptotic and pro-tumoral activities in comparison with the wild-type protein. These results identify SUMO as a novel key regulator of AKT phosphorylation and activity.	[de la Cruz-Herrera, C. F.; Campagna, M.; del Carmen Gonzalez-Santamaria, J.; Marcos-Villar, L.; Rivas, C.] CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Madrid 28049, Spain; [Lang, V.; Rodriguez, M. S.] Ubiquitylat & Canc Mol Biol Lab, Inbiomed, San Sebastian, Gipuzkoa, Spain; [Vidal, A.] Univ Santiago de Compostela, Inst Invest Sanitarias IDIS, Dept Fisiol, Santiago De Compostela, Spain; [Vidal, A.; Rivas, C.] Univ Santiago de Compostela, Inst Invest Sanitarias IDIS, Ctr Invest Med Mol CIMUS, Santiago De Compostela, Spain; [Collado, M.] Complexo Hosp Univ Santiago de Compostela CHUS, SERGAS, Inst Invest Sanit Santiago Compostela, Santiago De Compostela, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela	Rivas, C (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Darwin 3,Campus Univ Autonoma Madrid, Madrid 28049, Spain.	crivas@cnb.csic.es	Rivas, Carmen/L-3162-2017; Santamaria, Jose Gonzalez/AAN-1044-2020; Rivas, Carmen/AAB-6278-2019; RODRIGUEZ, Manuel S./D-5439-2018; Santamaría, José González/Q-2439-2015; Collado, Manuel/K-8140-2014; Vidal, Anxo/B-5010-2015	Rivas, Carmen/0000-0002-0518-7199; Rivas, Carmen/0000-0002-0518-7199; Santamaría, José González/0000-0003-1244-3477; Collado, Manuel/0000-0002-0330-0880; Vidal, Anxo/0000-0002-0866-4202; de la Cruz-Herrera, Carlos/0000-0002-7493-5154	Juan de la Cierva Programme; La Caixa fellowship;  [BFU-2011-27064]	Juan de la Cierva Programme; La Caixa fellowship(La Caixa Foundation); 	We thank Dr William R Sellers who deposited AKT plamids at Addgene. Funding at the laboratory of CR is provided by BFU-2011-27064. LM-V is supported by Juan de la Cierva Programme. CFC-H is supported by La Caixa fellowship. MC is an investigator of the Miguel Servet Program.	Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Bang OS, 2000, BIOCHEM BIOPH RES CO, V278, P306, DOI 10.1006/bbrc.2000.3805; Bawa-Khalfe Tasneem, 2010, Genes Cancer, V1, P748; Bossis G, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-13; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; Calleja Veronique, 2009, J Chem Biol, V2, P11, DOI 10.1007/s12154-009-0016-8; Campagna M, 2011, CELL DEATH DIFFER, V18, P72, DOI 10.1038/cdd.2010.77; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Flotho A, 2013, ANNU REV BIOCHEM, V82, P357, DOI 10.1146/annurev-biochem-061909-093311; Golebiowski F, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000282; Gonzalez-Santamaria J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.135; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Hsieh AC, 2004, NUCLEIC ACIDS RES, V32, P893, DOI 10.1093/nar/gkh238; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Liu XS, 2004, ANTICANCER RES, V24, P2697; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Marcos-Villar L, 2009, J VIROL, V83, P8849, DOI 10.1128/JVI.00339-09; Matic I, 2008, MOL CELL PROTEOMICS, V7, P132, DOI 10.1074/mcp.M700173-MCP200; Miller MJ, 2013, MOL CELL PROTEOMICS, V12, P449, DOI 10.1074/mcp.M112.025056; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Sakoda H, 2003, J BIOL CHEM, V278, P25802, DOI 10.1074/jbc.M301127200; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Steinacher R, 2005, CURR BIOL, V15, P616, DOI 10.1016/j.cub.2005.02.054; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Tatham MH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001484; Testa JR, 2005, ONCOGENE, V24, P7391, DOI 10.1038/sj.onc.1209100; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Vertegaal ACO, 2006, MOL CELL PROTEOMICS, V5, P2298, DOI 10.1074/mcp.M600212-MCP200; Warfel NA, 2011, J BIOL CHEM, V286, P39122, DOI 10.1074/jbc.M111.278747; Yoshihara T, 2013, ACTA PHYSIOL, V207, P416, DOI 10.1111/apha.12040	36	31	31	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1442	1450		10.1038/onc.2014.48	http://dx.doi.org/10.1038/onc.2014.48			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24704831	Green Published			2022-12-28	WOS:000350806500010
J	Wang, CY; Huang, EYH; Huang, SC; Chung, BC				Wang, C-Y; Huang, E. Y-H; Huang, S-c; Chung, B-c			DNA-PK/Chk2 induces centrosome amplification during prolonged replication stress	ONCOGENE			English	Article							DNA-DAMAGE; S-PHASE; CELLS; ATM; KINASE; PHOSPHORYLATION; ACTIVATION; RADIATION; PK; OVERDUPLICATION	The antineoplastic drug hydroxyurea (HU), when used at subtoxic doses, induces prolonged replication stress and centrosome amplification. This causes genomic instability and increases the malignancy of the recurring tumor. The mechanism of centrosome amplification induced by prolonged replication stress, however, is still unclear. Here, we examined the involvement of ataxia telangiectasia, mutated (ATM), ataxia telangiectasia, mutated and Rad3-related (ATR) and DNA-dependent protein kinase (DNA-PK) and found that HU-induced centrosome amplification was inhibited by the depletion of DNA-PKcs, but not ATM and ATR. Inactivation of ATM/ATR in U2OS cells instead caused aneuploidy and cell death. We found DNA-PKcs depletion also abrogated ATM phosphorylation, indicating that ATM activation during prolonged replication stress depends on DNA-PK. Depletion of DNA-PK abrogated checkpoint kinase (Chk) 2 activation and partially reduced Chk1 activation. Chk2 depletion blocked HU-induced centrosome amplification, indicating a function of Chk2 in centrosome amplification. We further found that Chk2 was phosphorylated at Thr68 on the mother centriole at late G2 and mitosis when unstressed and on all amplified centrioles induced by HU. In summary, we have elucidated that DNA-PK/Chk2 signaling induces centrosome amplification upon long-term HU treatment, therefore increasing our insight into tumor recurrence after initial chemotherapy.	[Wang, C-Y; Huang, E. Y-H; Huang, S-c; Chung, B-c] Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; [Wang, C-Y] Natl Cheng Kung Univ, Coll Med, Dept Cell Biol & Anat, Tainan 70101, Taiwan	Academia Sinica - Taiwan; National Cheng Kung University	Chung, BC (corresponding author), Acad Sinica, Inst Mol Biol, 128 Acad Rd Sect 2, Taipei 115, Taiwan.	mbchung@sinica.edu.tw		Chung, Bon-chu/0000-0002-8612-0219	Academia Sinica [NHRI-EX102-10210SI, NSC102-2923-B-001-003-MY3, NSC102-2320-B-006-051]	Academia Sinica(Academia Sinica - Taiwan)	We would like to thank Ya-Min Lin for technical assistance in FACS analysis. This study was supported by grants from Academia Sinica, NHRI-EX102-10210SI and NSC102-2923-B-001-003-MY3 to B-cC and NSC102-2320-B-006-051 to C-YW.	An J, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-32; Andreassen PR, 2004, GENE DEV, V18, P1958, DOI 10.1101/gad.1196104; Ayene IS, 2005, MOL CANCER THER, V4, P529, DOI 10.1158/1535-7163.MCT-04-0130; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bennett RA, 2004, ONCOGENE, V23, P6823, DOI 10.1038/sj.onc.1207561; Bourke E, 2010, ONCOGENE, V29, P616, DOI 10.1038/onc.2009.340; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Golan A, 2010, CELL CYCLE, V9, P2647, DOI 10.4161/cc.9.13.12121; Graser S, 2007, J CELL BIOL, V179, P321, DOI 10.1083/jcb.200707181; Joo K, 2013, P NATL ACAD SCI USA, V110, P5987, DOI 10.1073/pnas.1220927110; Khodjakov A, 2002, J CELL BIOL, V158, P1171, DOI 10.1083/jcb.200205102; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Lee KJ, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.212969; Liu QH, 2000, GENE DEV, V14, P1448; Nakagawa Y, 2001, MOL BIOL CELL, V12, P1687, DOI 10.1091/mbc.12.6.1687; Prosser SL, 2009, MOL CELL BIOL, V29, P1760, DOI 10.1128/MCB.01124-08; Rampakakis E, 2008, J CELL SCI, V121, P590, DOI 10.1242/jcs.021352; Robinson HMR, 2007, CELL CYCLE, V6, P982, DOI 10.4161/cc.6.8.4111; Sato N, 2000, ONCOGENE, V19, P5281, DOI 10.1038/sj.onc.1203902; Shang ZF, 2010, CANCER RES, V70, P3657, DOI 10.1158/0008-5472.CAN-09-3362; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Smith J, 2010, ADV CANCER RES, V108, P73, DOI [10.1016/B978-0-12-380888-2.00003-0, 10.1016/S0065.230X(10)08002.4]; Stehman FB, 1997, GYNECOL ONCOL, V66, P262, DOI 10.1006/gyno.1997.4761; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; Stolz A, 2010, NAT CELL BIOL, V12, P492, DOI 10.1038/ncb2051; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Wang CY, 2013, MOL CELL BIOL, V33, P476, DOI 10.1128/MCB.01064-12; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	31	27	28	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1263	1269		10.1038/onc.2014.74	http://dx.doi.org/10.1038/onc.2014.74			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24662822				2022-12-28	WOS:000350687100006
J	Lau, ST; Hansford, LM; Chan, WK; Chan, GCF; Wan, TSK; Wong, KKY; Kaplan, DR; Tam, PKH; Ngan, ESW				Lau, S-T; Hansford, L. M.; Chan, W-K; Chan, G. C-F; Wan, T. S-K; Wong, K. K-Y; Kaplan, D. R.; Tam, P. K-H; Ngan, E. S-W			Prokineticin signaling is required for the maintenance of a de novo population of c-KIT+ cells to sustain neuroblastoma progression	ONCOGENE			English	Article							GENE-EXPRESSION; STEM-CELLS; IN-VITRO; HIF-2-ALPHA; RECEPTOR; IDENTIFICATION; PROGNOSIS; IMMATURE; HYPOXIA; GROWTH	High cellular heterogeneity within neuroblastomas (NBs) may account for the non-uniform response to treatment. c-KIT+ cells are frequently detected in NB, but how they influence NB behavior still remains elusive. Here, we used NB tumor-initiating cells to reconstitute NB development and demonstrated that c-KIT+ cells are de novo generated and dynamically maintained within the tumors to sustain tumor progression. c-KIT+ NB cells express higher levels of neural crest and stem cell markers (SLUG, SOX2 and NANOG) and are endowed with high clonogenic capacity, differentiation plasticity and are refractory to drugs. With serial transplantation assays, we found that c-KIT expression is not required for tumor formation, but c-KIT+ cells are more aggressive and can induce tumors ninefold more efficiently than c-KIT-/low cells. Intriguingly, c-KIT+ cells exhibited a long-term in vivo self-renewal capacity to sustain the formation of secondary and tertiary tumors in mice. In addition, we showed that Prokineticin signaling and mitogen-activated protein kinase pathways are crucial for the maintenance of c-KIT+ cells in tumor to promote NB progression. Our results highlight the importance of this de novo population of NB cells in sustainable growth of NB and reveal specific signaling pathways that may provide targets leading to more effective NB therapies.	[Lau, S-T; Wong, K. K-Y; Tam, P. K-H; Ngan, E. S-W] Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; [Hansford, L. M.; Kaplan, D. R.] Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; [Chan, W-K; Chan, G. C-F] Univ Hong Kong, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China; [Wan, T. S-K] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Tam, P. K-H; Ngan, E. S-W] Univ Hong Kong, Ctr Reprod Dev & Growth, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Toronto; University of Hong Kong; University of Hong Kong; University of Hong Kong	Ngan, ESW (corresponding author), Univ Hong Kong, Fac Med Bldg, Dept Surg, L9-56,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	engan@hku.hk	Ngan, Elly/N-1543-2019; Wan, Thomas/AAY-7075-2020; Wong, Kenneth K. Y./B-9920-2008; Chan, Godfrey Chi Fung/C-4205-2009	Ngan, Elly/0000-0002-0022-7999; Chan, Godfrey Chi Fung/0000-0001-5032-8985	University of Hong Kong; Hong Kong Research Grants Council [HKU773909]; Hong Kong Children's Cancer Foundation; SK Yee Medical Research Fund	University of Hong Kong(University of Hong Kong); Hong Kong Research Grants Council(Hong Kong Research Grants Council); Hong Kong Children's Cancer Foundation; SK Yee Medical Research Fund	Seed funding grant for basic research from the University of Hong Kong, General Research Grant HKU773909 from the Hong Kong Research Grants Council, research grant from Hong Kong Children's Cancer Foundation and SK Yee Medical Research Fund to ES-WN. Small project grant from the University of Hong Kong to S-TL. We thank Robin Lovell-Badge (MRC National Institute for Medical Research, London, UK) and Chi-Chung Hui (University of Toronto, Canada) for critical reading of the manuscript.	Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330; Bellone G, 2006, INT J ONCOL, V29, P851; Biagiotti T, 2006, STEM CELLS, V24, P443, DOI 10.1634/stemcells.2004-0264; Chen QR, 2008, GENOMICS, V92, P195, DOI 10.1016/j.ygeno.2008.05.014; COHEN PS, 1994, BLOOD, V84, P3465; Coulon A, 2011, NEOPLASIA, V13, P991, DOI 10.1593/neo.11800; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Gomes AL, 2007, CELL ONCOL, V29, P399; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Hansford LM, 2007, CANCER RES, V67, P11234, DOI 10.1158/0008-5472.CAN-07-0718; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; Hutt KJ, 2006, MOL HUM REPROD, V12, P61, DOI 10.1093/molehr/gal010; Jogi A, 2002, P NATL ACAD SCI USA, V99, P7021, DOI 10.1073/pnas.102660199; Krams M, 2004, ONCOGENE, V23, P588, DOI 10.1038/sj.onc.1207145; Krystal GW, 1996, CANCER RES, V56, P370; Lacham-Kaplan O, 2004, REPRODUCTION, V128, P147, DOI 10.1530/rep.1.00220; LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000; Liegl-Atzwanger B, 2010, VIRCHOWS ARCH, V456, P111, DOI 10.1007/s00428-010-0891-y; Luo R, 2003, DEVELOPMENT, V130, P321, DOI 10.1242/dev.00213; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marzi F, 2007, CANCER RES, V67, P2402, DOI 10.1158/0008-5472.CAN-06-3208; Ngan ESW, 2007, CLIN CANCER RES, V13, P868, DOI 10.1158/1078-0432.CCR-06-2176; Nilsson MB, 2010, ONCOGENE, V29, P2938, DOI 10.1038/onc.2010.60; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Perez-Losada J, 2002, BLOOD, V100, P1274, DOI 10.1182/blood.V100.4.1274.h81602001274_1274_1286; Pietras A, 2008, J PATHOL, V214, P482, DOI 10.1002/path.2304; Pietras A, 2009, P NATL ACAD SCI USA, V106, P16805, DOI 10.1073/pnas.0904606106; Pittoni P, 2011, ONCOGENE, V30, P757, DOI 10.1038/onc.2010.494; Shimada A, 2008, PEDIATR BLOOD CANCER, V50, P213, DOI 10.1002/pbc.21288; Thiele CJ, 1999, HUMAN CELL CULTURE, V1, P21; Uccini S, 2005, CLIN CANCER RES, V11, P380; Vitali R, 2003, INT J CANCER, V106, P147, DOI 10.1002/ijc.11187; Walton JD, 2004, NEOPLASIA, V6, P838, DOI 10.1593/neo.04310	33	12	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					1019	1034		10.1038/onc.2014.24	http://dx.doi.org/10.1038/onc.2014.24			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632619				2022-12-28	WOS:000350121300008
J	Gillam, MP; Nimbalkar, D; Sun, L; Christov, K; Ray, D; Kaldis, P; Liu, X; Kiyokawa, H				Gillam, M. P.; Nimbalkar, D.; Sun, L.; Christov, K.; Ray, D.; Kaldis, P.; Liu, X.; Kiyokawa, H.			MEN1 tumorigenesis in the pituitary and pancreatic islet requires Cdk4 but not Cdk2	ONCOGENE			English	Article						cell cycle; menin; insulinoma; pituitary; knockout mice	MULTIPLE-ENDOCRINE-NEOPLASIA; DEPENDENT KINASE INHIBITORS; BETA-CELL PROLIFERATION; MAMMARY TUMORIGENESIS; GERMLINE MUTATIONS; KNOCKOUT MICE; MUTANT MICE; TUMORS; P27(KIP1); TYPE-1	Recent studies suggest that physiological and tumorigenic proliferation of mammalian cells is controlled by multiple cyclin-dependent kinases (CDKs) largely in tissue-specific manners. We and others previously demonstrated that adult mice deficient for the Cyclin D partner CDK4 (Cdk4(-/-) mice) exhibit hypoplasia in the pituitary and pancreatic islet due to primary postnatal defects in proliferation. Intriguingly, those neuroendocrine tissues affected in Cdk4(-/-) mice are the primary targets of tumorigenesis in the syndrome of multiple endocrine neoplasia type-1 (MEN1). Mice with heterozygous disruption of the tumor suppressor Men1 gene (Men1(+/-)) develop tumors in the pituitary, pancreatic islets and other neuroendocrine tissues, which is analogous to humans with MEN1 mutations. To explore the genetic interactions between loss of Men1 and activation of CDKs, we examined the impact of Cdk4 or Cdk2 disruption on tumorigenesis in Men1(+/-) mice. A majority of Men1(+/-) mice with wild-type CDKs developed pituitary and islet tumors by 15 months of age. Strikingly, Men1(+/-); Cdk4(-/-) mice did not develop any tumors, and their islets and pituitaries remained hypoplastic with decreased proliferation. In contrast, Men1(+/-); Cdk2(-/-) mice showed pituitary and islet tumorigenesis comparable to those in Men1(+/-) mice. Pituitaries of Men1(+/-); Cdk4(-/-) mice showed no signs of loss of heterozygosity (LOH) in the Men1 locus, whereas tumors in Men1(+/-) mice and Men1(+/-); Cdk2(-/-) mice exhibited LOH. Consistently, CDK4 knockdown in INS-1 insulinoma cells inhibited glucose-stimulated cell cycle progression with a significant decrease in phosphorylation of retinoblastoma protein (RB) at specific sites including Ser780. CDK2 knockdown had minimum effects on RB phosphorylation and cell cycle progression. These data suggest that CDK4 is a critical downstream target of MEN1-dependent tumor suppression and is required for tumorigenic proliferation in the pituitary and pancreatic islet, whereas CDK2 is dispensable for tumorigenesis in these neuroendocrine cell types.	[Gillam, M. P.; Nimbalkar, D.; Sun, L.; Liu, X.; Kiyokawa, H.] Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; [Christov, K.] Univ Illinois, Dept Surg Oncol, Chicago, IL USA; [Ray, D.] Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI USA; [Kaldis, P.] ASTAR, IMCB, Singapore, Singapore; [Kaldis, P.] Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore; [Kiyokawa, H.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Michigan System; University of Michigan; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Gillam, MP (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, 303 E Super St,Lurie 3-113, Chicago, IL 60611 USA.	Mary.p.gillam@gmail.com; kiyokawa@northwestern.edu	Kaldis, Philipp/G-2714-2010	Kaldis, Philipp/0000-0002-7247-7591; Kiyokawa, Hiroaki/0000-0002-7942-6455	National Institutes of Health [R01-HD38085, CA100204, CA112282, DK066044]; Lynn Sage Cancer Research Foundation; Phi Beta Psi Sorority; Searle Leadership Fund; Zell Fund; H. Foundation; Director Fund of Robert H. Lurie Comprehensive Cancer Center; Department of Molecular Pharmacology and Biological Chemistry; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038085] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA112282, R01CA100204] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK066044] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lynn Sage Cancer Research Foundation; Phi Beta Psi Sorority; Searle Leadership Fund; Zell Fund; H. Foundation; Director Fund of Robert H. Lurie Comprehensive Cancer Center; Department of Molecular Pharmacology and Biological Chemistry; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This paper is dedicated in fond memory to Patricia Lorenzo, a former member of the Molecular Oncogenesis NCI study section and the University of Hawaii Cancer Center, who brightened deliberations with her compassion, affability and dedication. Her remarkable courage in the face of terminal cancer has been inspirational. We thank William Lowe Jr, Alfred Rademaker, Evan Osmundson, Finola Moore and Yiran Zhou for their scientific advice, and Thomas O'Grady, Brian Zwecker, Alba Santana and Suchitra Prasad for their excellent technical assistance. This work was supported by funds from the National Institutes of Health (R01-HD38085, CA100204, and CA112282 to HK and DK066044 to MPG), Lynn Sage Cancer Research Foundation, Phi Beta Psi Sorority, Searle Leadership Fund, Zell Fund, H. Foundation, the Director Fund of Robert H. Lurie Comprehensive Cancer Center and the Department of Molecular Pharmacology and Biological Chemistry.	Agudo J, 2008, DIABETOLOGIA, V51, P1862, DOI 10.1007/s00125-008-1087-8; Akerblom B, 2007, MOL CELL ENDOCRINOL, V270, P73, DOI 10.1016/j.mce.2007.02.009; Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; Bazzi W, 2008, GASTROENTEROLOGY, V135, P1698, DOI 10.1053/j.gastro.2008.07.031; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Berthet C, 2006, DEV CELL, V10, P563, DOI 10.1016/j.devcel.2006.03.004; Bertolino P, 2003, MOL ENDOCRINOL, V17, P1880, DOI 10.1210/me.2003-0154; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Fatrai S, 2006, DIABETES, V55, P318, DOI 10.2337/diabetes.55.02.06.db05-0757; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fiaschi-Taesch N, 2009, DIABETES, V58, P882, DOI 10.2337/db08-0631; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harding B, 2009, ENDOCR-RELAT CANCER, V16, P1313, DOI 10.1677/ERC-09-0082; Jirawatnotai S, 2004, J BIOL CHEM, V279, P51100, DOI 10.1074/jbc.M409080200; Jirawatnotai S, 2003, J BIOL CHEM, V278, P17021, DOI 10.1074/jbc.M301206200; Karnik SK, 2007, SCIENCE, V318, P806, DOI 10.1126/science.1146812; Karnik SK, 2005, P NATL ACAD SCI USA, V102, P14659, DOI 10.1073/pnas.0503484102; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Malumbres M, 2007, CURR OPIN GENET DEV, V17, P60, DOI 10.1016/j.gde.2006.12.008; Martin J, 2003, ONCOGENE, V22, P5261, DOI 10.1038/sj.onc.1206506; Marx SJ, 2005, NAT REV CANCER, V5, P367, DOI 10.1038/nrc1610; Mettus RV, 2003, ONCOGENE, V22, P8413, DOI 10.1038/sj.onc.1206888; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Molven A, 2005, GENE CHROMOSOME CANC, V44, P10, DOI 10.1002/gcc.20202; Mould AW, 2007, INT J CANCER, V121, P776, DOI 10.1002/ijc.22734; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Pannett AAJ, 2001, J CLIN ENDOCR METAB, V86, P4371, DOI 10.1210/jc.86.9.4371; Pei XH, 2004, MOL CELL BIOL, V24, P6653, DOI 10.1128/mcb.24.15.6653-6664.2004; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Ray D, 2007, CANCER RES, V67, P984, DOI 10.1158/0008-5472.CAN-06-3927; Ray D, 2011, NEOPLASIA, V13, P439, DOI 10.1593/neo.101704; Sayo Y, 2002, ENDOCRINOLOGY, V143, P2437, DOI 10.1210/en.143.6.2437; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 2000, CANCER RES, V60, P3689; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; Tang LH, 2012, CLIN CANCER RES, V18, P4612, DOI 10.1158/1078-0432.CCR-11-3264; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Wu Xinjiang, 2008, Curr Mol Med, V8, P805, DOI 10.2174/156652408786733702; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	45	25	30	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					932	938		10.1038/onc.2014.3	http://dx.doi.org/10.1038/onc.2014.3			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24531709	Green Accepted			2022-12-28	WOS:000349472000013
J	Teneng, I; Tellez, CS; Picchi, MA; Klinge, DM; Yingling, CM; Snider, AM; Liu, Y; Belinsky, SA				Teneng, I.; Tellez, C. S.; Picchi, M. A.; Klinge, D. M.; Yingling, C. M.; Snider, A. M.; Liu, Y.; Belinsky, S. A.			Global identification of genes targeted by DNMT3b for epigenetic silencing in lung cancer	ONCOGENE			English	Article						DNMT3b; lung cancer; DNA methylation; MAL; OLIG2	DE-NOVO METHYLATION; NEURAL STEM-CELLS; DNA METHYLTRANSFERASES; PROMOTER HYPERMETHYLATION; TUMOR-SUPPRESSOR; MAL GENE; EXPRESSION; PROTEIN; EZH2; COMMON	The maintenance cytosine DNA methyltransferase DNMT1 and de novo methyltransferase DNMT3b cooperate to establish aberrant DNA methylation and chromatin complexes to repress gene transcription during cancer development. The expression of DNMT3b was constitutively increased 5-20-fold in hTERT/CDK4-immortalized human bronchial epithelial cells (HBECs) before treatment with low doses of tobacco carcinogens. Overexpression of DNMT3b increased and accelerated carcinogen-induced transformation. Genome-wide profiling of transformed HBECs identified 143 DNMT3b-target genes, many of which were transcriptionally regulated by the polycomb repressive complex 2 (PRC2) complex and silenced through aberrant methylation in non-small-cell lung cancer cell lines. Two genes studied in detail, MAL and OLIG2, were silenced during transformation, initially through enrichment for H3K27me3 and H3K9me2, commonly methylated in lung cancer, and exert tumor suppressor effects in vivo through modulating cancer-related pathways. Re-expression of MAL and OLIG2 to physiological levels dramatically reduced the growth of lung tumor xenografts. Our results identify a key role for DNMT3b in the earliest stages of initiation and provide a comprehensive catalog of genes targeted for silencing by this methyltransferase in non-small-cell lung cancer.	[Teneng, I.; Tellez, C. S.; Picchi, M. A.; Klinge, D. M.; Yingling, C. M.; Snider, A. M.; Liu, Y.; Belinsky, S. A.] Lovelace Resp Res Inst, Lung Canc Program, Albuquerque, NM 87108 USA	Lovelace Respiratory Research Institute	Belinsky, SA (corresponding author), Lovelace Resp Res Inst, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108 USA.	sbelinsk@LRRI.org	Liu, Yushi/A-1533-2014	Liu, Yushi/0000-0003-4185-4187	NIH [R01 ES015262, 1F32 CA157082]; NATIONAL CANCER INSTITUTE [F32CA157082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015262] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Data generated by The Cancer Genome Atlas (TCGA) project established by the NCI and NHGRI were used to validate part of our findings. The dbGaP accession number for TCGA data is phs000178.v8.p7. Information about TCGA and the investigators and institutions that constitute the TCGA research network can be found at http://cancergenome.nih.gov/. We acknowledge the following for technical support: Kieu Do, Randall Willink, Christopher Dagucon and Daniel E Juri. We also thank Dr Shuguang Leng for help with TCGA data acquisition, Dr Xiequn Zhang for help with bioinformatics analyses and Dr Julie Hutt for pathology review of xenografted tumors. This study was supported by NIH Grants R01 ES015262 to SAB and 1F32 CA157082 to IT.	ALONSO MA, 1987, P NATL ACAD SCI USA, V84, P1997, DOI 10.1073/pnas.84.7.1997; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200; Belinsky SA, 2002, CANCER RES, V62, P2370; Belinsky SA, 2003, CANCER RES, V63, P7089; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; Buffart TE, 2008, BRIT J CANCER, V99, P1802, DOI 10.1038/sj.bjc.6604777; Cao W, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-296; Copray S, 2006, STEM CELLS, V24, P1001, DOI 10.1634/stemcells.2005-0239; Damiani LA, 2008, CANCER RES, V68, P9005, DOI 10.1158/0008-5472.CAN-08-1276; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; Fan H, 2012, ONCOGENE, V31, P2298, DOI 10.1038/onc.2011.411; Fatemi M, 2002, EUR J BIOCHEM, V269, P4981, DOI 10.1046/j.1432-1033.2002.03198.x; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gao Q, 2011, P NATL ACAD SCI USA, V108, P18061, DOI 10.1073/pnas.1114946108; Ghoshal K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010338; Girault I, 2003, CLIN CANCER RES, V9, P4415; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; HIRANO T, 1994, AM J PATHOL, V144, P296; Horne HN, 2009, MOL CANCER RES, V7, P199, DOI 10.1158/1541-7786.MCR-08-0314; Janssen-Heijnen MLG, 2003, LUNG CANCER-J IASLC, V41, P245, DOI 10.1016/S0169-5002(03)00230-7; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kim GD, 2002, EMBO J, V21, P4183, DOI 10.1093/emboj/cdf401; KIM T, 1995, J NEUROSCI RES, V42, P413, DOI 10.1002/jnr.490420316; Ligon KL, 2007, NEURON, V53, P503, DOI 10.1016/j.neuron.2007.01.009; Linhart HG, 2007, GENE DEV, V21, P3110, DOI 10.1101/gad.1594007; Marsit CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012334; Mimori K, 2003, ONCOGENE, V22, P3463, DOI 10.1038/sj.onc.1206378; Mokhtari K, 2005, NEUROPATH APPL NEURO, V31, P62, DOI 10.1111/j.1365-2990.2004.00612.x; Niehrs C, 2012, EMBO J, V31, P2705, DOI 10.1038/emboj.2012.124; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pulling LC, 2003, CANCER RES, V63, P4842; Qi W, 2012, P NATL ACAD SCI USA, V109, P21360, DOI 10.1073/pnas.1210371110; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; Sato M, 2013, MOL CANCER RES, V11, P638, DOI 10.1158/1541-7786.MCR-12-0634-T; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Tabu K, 2006, J CELL SCI, V119, P1433, DOI 10.1242/jcs.02854; Tabu K, 2007, MOL CANCER RES, V5, P1099, DOI 10.1158/1541-7786.MCR-07-0096; Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035; Tessema M, 2010, ONCOGENE, V29, P5159, DOI 10.1038/onc.2010.255; Tessema M, 2013, J THR ONC IN PRESS; Tessema M, 2009, CARCINOGENESIS, V30, P1132, DOI 10.1093/carcin/bgp114; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Winklmeier A, 2009, CANCER SCI, V100, P261, DOI 10.1111/j.1349-7006.2008.01048.x; Yakushiji T, 2003, INT J ONCOL, V22, P1201; Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59; Zi XL, 2005, CANCER RES, V65, P9762, DOI 10.1158/0008-5472.CAN-05-0103	50	24	25	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					621	630		10.1038/onc.2013.580	http://dx.doi.org/10.1038/onc.2013.580			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24469050				2022-12-28	WOS:000348853500009
J	Hayashi, H; Arao, T; Togashi, Y; Kato, H; Fujita, Y; De Velasco, MA; Kimura, H; Matsumoto, K; Tanaka, K; Okamoto, I; Ito, A; Yamada, Y; Nakagawa, K; Nishio, K				Hayashi, H.; Arao, T.; Togashi, Y.; Kato, H.; Fujita, Y.; De Velasco, M. A.; Kimura, H.; Matsumoto, K.; Tanaka, K.; Okamoto, I.; Ito, A.; Yamada, Y.; Nakagawa, K.; Nishio, K.			The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer	ONCOGENE			English	Article						POU5F1B; OCT4; pseudogene; gastric cancer; gene amplification	GENOME-WIDE ASSOCIATION; COLORECTAL-CANCER; PROSTATE-CANCER; BREAST-CANCER; BLADDER-CANCER; CELLS; RISK; EXPRESSION; 8Q24; LOCUS	POU5F1B (POU domain class 5 transcription factor 1B), a processed pseudogene that is highly homologous to OCT4, was recently shown to be transcribed in cancer cells, but its clinical relevance and biological function have remained unclear. We now show that POU5F1B, which is located adjacent to MYC on human chromosome 8q24, is frequently amplified in gastric cancer (GC) cell lines. POU5F1B, but not OCT4, was also found to be expressed at a high level in GC cell lines and clinical specimens. In addition, the DNA copy number and mRNA abundance for POU5F1B showed a positive correlation in both cancer cell lines and GC specimens. Overexpression of POU5F1B in GC cells promoted colony formation in vitro as well as both tumorigenicity and tumor growth in vivo, and these effects were enhanced in the additional presence of MYC overexpression. Furthermore, knockdown of POU5F1B expression with a short hairpin RNA confirmed a role for the endogenous pseudogene in the promotion of cancer cell growth in vitro and tumor growth in vivo. POU5F1B overexpression induced upregulation of various growth factors in GC cells as well as exhibited mitogenic, angiogenic and antiapoptotic effects in GC xenografts. Finally, amplification of POU5F1B was detected in 17 (12%) of 145 cases of GC and was a significant predictor of poor prognosis in patients with stage IV disease. In conclusion, we found that the POU5F1B pseudogene is amplified and expressed at a high level in, as well as confers an aggressive phenotype on, GC, and that POU5F1B amplification is associated with a poor prognosis in GC patients.	[Hayashi, H.; Arao, T.; Togashi, Y.; Kato, H.; Fujita, Y.; De Velasco, M. A.; Kimura, H.; Matsumoto, K.; Nishio, K.] Kinki Univ, Fac Med, Dept Genome Biol, Sayama, Osaka 5898511, Japan; [Hayashi, H.; Tanaka, K.; Okamoto, I.; Nakagawa, K.] Kinki Univ, Fac Med, Dept Med Oncol, Sayama, Osaka 5898511, Japan; [Ito, A.] Kinki Univ, Fac Med, Dept Pathol, Sayama, Osaka 5898511, Japan; [Yamada, Y.] Natl Canc Ctr, Dept Gastrointestinal Oncol, Tokyo, Japan	Kindai University (Kinki University); Kindai University (Kinki University); Kindai University (Kinki University); National Cancer Center - Japan	Nishio, K (corresponding author), Kinki Univ, Fac Med, Dept Genome Biol, 377-2 Ohno Higashi, Sayama, Osaka 5898511, Japan.	knishio@med.kindai.ac.jp	De Velasco, Marco/R-1022-2019; Yamada, Yasuhide/AAH-9124-2020	De Velasco, Marco/0000-0002-4011-6572; 	Third-Term Comprehensive 10-Year Strategy for Cancer Control; Ministry of Health, Labor and Welfare of Japan	Third-Term Comprehensive 10-Year Strategy for Cancer Control(Ministry of Health, Labour and Welfare, Japan); Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan)	This study was supported by the Third-Term Comprehensive 10-Year Strategy for Cancer Control and a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare of Japan. We thank Shinji Kurashimo, Yoshihiro Mine, Ayaka Kurumatani and Tomoko Kitayama for technical assistance.	Amundadottir LT, 2006, NAT GENET, V38, P652, DOI 10.1038/ng1808; Atlasi Y, 2007, INT J CANCER, V120, P1598, DOI 10.1002/ijc.22508; Atlasi Y, 2008, STEM CELLS, V26, P3068, DOI 10.1634/stemcells.2008-0530; Bier A, 2009, MOL CANCER THER, V8, P786, DOI 10.1158/1535-7163.MCT-08-0930; Calcagno DQ, 2008, WORLD J GASTROENTERO, V14, P5962, DOI 10.3748/wjg.14.5962; Cantz T, 2008, STEM CELLS, V26, P692, DOI 10.1634/stemcells.2007-0657; Cauffman G, 2006, STEM CELLS, V24, P2685, DOI 10.1634/stemcells.2005-0611; Fletcher O, 2008, CANCER EPIDEM BIOMAR, V17, P702, DOI 10.1158/1055-9965.EPI-07-2564; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Furuta K, 2012, CANCER SCI, V103, P221, DOI 10.1111/j.1349-7006.2011.02132.x; Graziano F, 2011, J CLIN ONCOL, V29, P4789, DOI 10.1200/JCO.2011.36.7706; Gudmundsson J, 2007, NAT GENET, V39, P631, DOI 10.1038/ng1999; Haiman CA, 2007, NAT GENET, V39, P954, DOI 10.1038/ng2098; Kalyana-Sundaram S, 2012, CELL, V149, P1622, DOI 10.1016/j.cell.2012.04.041; Kaneda H, 2010, CANCER RES, V70, P2053, DOI 10.1158/0008-5472.CAN-09-2161; Kastler S, PROSTATE, V70, P666; Klapper W, 2008, LEUKEMIA, V22, P2226, DOI 10.1038/leu.2008.230; Liedtke S, 2007, CELL STEM CELL, V1, P364, DOI 10.1016/j.stem.2007.09.003; Matsumoto K, 2012, BRIT J CANCER, V106, P727, DOI 10.1038/bjc.2011.603; Monk M, 2001, ONCOGENE, V20, P8085, DOI 10.1038/sj.onc.1205088; Pain D, 2005, J BIOL CHEM, V280, P6265, DOI 10.1074/jbc.C400587200; Panagopoulos I, 2008, ONCOL REP, V20, P1029, DOI 10.3892/or_00000105; Pink RC, 2011, RNA, V17, P792, DOI 10.1261/rna.2658311; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Schoenhals M, 2009, BIOCHEM BIOPH RES CO, V383, P157, DOI 10.1016/j.bbrc.2009.02.156; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; Schumacher FR, 2007, CANCER RES, V67, P2951, DOI 10.1158/0008-5472.CAN-06-3591; Suo GL, 2005, BIOCHEM BIOPH RES CO, V337, P1047, DOI 10.1016/j.bbrc.2005.09.157; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takeda M, 2007, CLIN CANCER RES, V13, P3051, DOI 10.1158/1078-0432.CCR-06-2743; Tanaka K, 2009, INT J CANCER, V124, P1072, DOI 10.1002/ijc.24065; Wang X, 2010, STEM CELLS, V28, P885, DOI 10.1002/stem.419; Wu CL, 2008, CLIN CANCER RES, V14, P1228, DOI 10.1158/1078-0432.CCR-07-1047; Yamada Y, 2008, CANCER SCI, V99, P2193, DOI 10.1111/j.1349-7006.2008.00935.x; Yeager M, 2007, NAT GENET, V39, P645, DOI 10.1038/ng2022; Yu HJ, 2005, HUM MUTAT, V26, P487, DOI 10.1002/humu.20246; Zanke BW, 2007, NAT GENET, V39, P989, DOI 10.1038/ng2089; Zhang JY, 2006, FEBS J, V273, P1723, DOI 10.1111/j.1742-4658.2006.05186.x; Zhao SD, 2011, J PATHOL, V223, P672, DOI 10.1002/path.2827	39	93	98	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					199	208		10.1038/onc.2013.547	http://dx.doi.org/10.1038/onc.2013.547			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24362523				2022-12-28	WOS:000347790500007
J	Kershaw, RM; Siddiqui, YH; Roberts, D; Jayaraman, PS; Gaston, K				Kershaw, R. M.; Siddiqui, Y. H.; Roberts, D.; Jayaraman, P-S; Gaston, K.			PRH/HHex inhibits the migration of breast and prostate epithelial cells through direct transcriptional regulation of Endoglin	ONCOGENE			English	Article						HHex; PRH; cell migration; invasion; breast cancer; prostate cancer	MOUSE SKIN CARCINOGENESIS; RICH HOMEODOMAIN PROTEIN; MESSENGER-RNA TRANSPORT; VEGF-SIGNALING GENES; HEMATOPOIETIC-CELLS; ENDOTHELIAL-CELLS; EXPRESSION; HEX; CANCER; DIFFERENTIATION	PRH/HHex (proline-rich homeodomain protein) is a transcription factor that controls cell proliferation and cell differentiation in a variety of tissues. Aberrant subcellular localisation of PRH is associated with breast cancer and thyroid cancer. Further, in blast crisis chronic myeloid leukaemia, and a subset of acute myeloid leukaemias, PRH is aberrantly localised and its activity is downregulated. Here we show that PRH is involved in the regulation of cell migration and cancer cell invasion. We show for the first time that PRH is expressed in prostate cells and that a decrease in PRH protein levels increases the migration of normal prostate epithelial cells. We show that a decrease in PRH protein levels also increases the migration of normal breast epithelial cells. Conversely, PRH overexpression inhibits cell migration and cell invasion by PC3 and DU145 prostate cancer cells and MDA-MB-231 breast cancer cells. Previous work has shown that the transforming growth factor-b co-receptor Endoglin inhibits the migration of prostate and breast cancer cells. Here we show that PRH can bind to the Endoglin promoter in immortalised prostate and breast cells. PRH overexpression in these cells results in increased Endoglin protein expression, whereas PRH knockdown results in decreased Endoglin protein expression. Moreover, we demonstrate that Endoglin overexpression abrogates the increased migration shown by PRH knockdown cells. Our data suggest that PRH controls the migration of multiple epithelial cell lineages in part at least through the direct transcriptional regulation of Endoglin. We discuss these results in terms of the functions of PRH in normal cells and the mislocalisation of PRH seen in multiple cancer cell types.	[Kershaw, R. M.; Roberts, D.; Jayaraman, P-S] Univ Birmingham, Sch Med, Div Immun & Infect, Birmingham, W Midlands, England; [Siddiqui, Y. H.; Gaston, K.] Univ Bristol, Sch Biochem, Bristol B17 8QB, Avon, England	University of Birmingham; University of Bristol	Gaston, K (corresponding author), Univ Bristol, Sch Biochem, Univ Walk, Bristol B17 8QB, Avon, England.	kevin.gaston@bristol.ac.uk	Gaston, Kevin/K-9237-2019	Gaston, Kevin/0000-0002-7349-5513; SIDDIQUI, YUSRA/0000-0001-7231-4736; /0000-0002-6500-9095	Breast Cancer Campaign project grant; University of Bristol; Charles Wallace Pakistan Trust; MRC	Breast Cancer Campaign project grant; University of Bristol; Charles Wallace Pakistan Trust; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We are grateful to Professor Norman J Maitland (University of York) for PNT2-C2 cells and useful discussions, Professor Kate Nobes (University of Bristol) for access to live cell imaging, Professor Clare Isacke (Institute of Cancer Research) for the Endoglin expression vector, Professor Harry Mellor (University of Bristol) and Professor Roy Bicknell (University of Birmingham) for HUVECs and useful discussions, and Professor Carmelo Bernabeu (Centro de Investigaciones Biologicas, Madrid) for Endoglin-luciferase reporter constructs. We are grateful to Laura A V Rodriguez and Xin Yang for technical assistance. This work was funded by a Breast Cancer Campaign project grant to PSJ and KG. YHS is grateful to the University of Bristol for a PhD Scholarship and to the Charles Wallace Pakistan Trust for additional support. DR is grateful to the MRC for a PhD studentship.	Bernabeu C, 2007, J CELL BIOCHEM, V102, P1375, DOI 10.1002/jcb.21594; BERTHON P, 1995, INT J ONCOL, V6, P333; Botella LM, 2001, J BIOL CHEM, V276, P34486, DOI 10.1074/jbc.M011611200; Botella LM, 2002, BLOOD, V100, P4001, DOI 10.1182/blood.V100.12.4001; Craft CS, 2007, ONCOGENE, V26, P7240, DOI 10.1038/sj.onc.1210533; D'Elia AV, 2002, J CLIN ENDOCR METAB, V87, P1376, DOI 10.1210/jc.87.3.1376; Denson LA, 2000, AM J PHYSIOL-GASTR L, V279, pG347, DOI 10.1152/ajpgi.2000.279.2.G347; Desjobert C, 2009, BIOCHEM J, V417, P121, DOI 10.1042/BJ20080872; George A, 2003, ONCOGENE, V22, P6764, DOI 10.1038/sj.onc.1206822; Guerrero-Esteo M, 1999, EUR J CELL BIOL, V78, P614, DOI 10.1016/S0171-9335(99)80046-6; Guiral M, 2001, J BIOL CHEM, V276, P2961, DOI 10.1074/jbc.M004948200; Guo Y, 2003, BLOOD, V102, P2428, DOI 10.1182/blood-2003-02-0634; Henry LA, 2011, ONCOGENE, V30, P1046, DOI 10.1038/onc.2010.488; Jankovic D, 2008, BLOOD, V111, P5672, DOI 10.1182/blood-2007-09-108175; Kassouf W, 2004, PROSTATE CANCER P D, V7, P105, DOI 10.1038/sj.pcan.4500716; Lakshman M, 2011, CLIN EXP METASTAS, V28, P39, DOI 10.1007/s10585-010-9356-6; Lang SH, 2001, BRIT J CANCER, V85, P590, DOI 10.1054/bjoc.2001.1967; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; Ma C, 2008, CSH PROTOCOLS; McCormack MP, 2010, SCIENCE, V327, P879, DOI 10.1126/science.1182378; Nakagawa T, 2003, ARTERIOSCL THROM VAS, V23, P231, DOI 10.1161/01.ATV.0000052670.55321.87; Noy P, 2012, NUCLEIC ACIDS RES, V40, P9008, DOI 10.1093/nar/gks687; Noy P, 2012, LEUKEMIA RES, V36, P1434, DOI 10.1016/j.leukres.2012.07.013; Noy P, 2010, MOL CELL BIOL, V30, P2120, DOI 10.1128/MCB.01511-09; Oram SH, 2010, ONCOGENE, V29, P5796, DOI 10.1038/onc.2010.320; Oxmann D, 2008, ONCOGENE, V27, P3567, DOI 10.1038/sj.onc.1211025; Perez-Gomez E, 2007, CANCER RES, V67, P10268, DOI 10.1158/0008-5472.CAN-07-1348; Pimanda JE, 2006, BLOOD, V107, P4737, DOI 10.1182/blood-2005-12-4929; Pimanda JE, 2008, BLOOD, V112, P4512, DOI 10.1182/blood-2008-05-157560; Puppin C, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-192; Quintanilla M, 2003, ONCOGENE, V22, P5976, DOI 10.1038/sj.onc.1206841; Romero D, 2010, CARCINOGENESIS, V31, P359, DOI 10.1093/carcin/bgp217; Sanchez-Elsner T, 2002, J BIOL CHEM, V277, P43799, DOI 10.1074/jbc.M207160200; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Soufi A, 2008, BIOCHEM J, V412, P399, DOI 10.1042/BJ20080035; Soufi A, 2006, J MOL BIOL, V358, P943, DOI 10.1016/j.jmb.2006.02.020; Soufi A, 2009, NUCLEIC ACIDS RES, V37, P3288, DOI 10.1093/nar/gkp197; Swingler TE, 2004, J BIOL CHEM, V279, P34938, DOI 10.1074/jbc.M404488200; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Topisirovic I, 2003, EMBO J, V22, P689, DOI 10.1093/emboj/cdg069; Williams H, 2008, J MOL BIOL, V383, P10, DOI 10.1016/j.jmb.2008.08.004; Wong VCL, 2008, INT J CANCER, V123, P2816, DOI 10.1002/ijc.23882	42	17	17	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2014	33	49					5592	5600		10.1038/onc.2013.496	http://dx.doi.org/10.1038/onc.2013.496			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZW	24240683	Green Accepted			2022-12-28	WOS:000346088700003
J	Antonello, ZA; Nucera, C				Antonello, Z. A.; Nucera, C.			Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF	ONCOGENE			English	Review						metastatic human thyroid cancer; orthotopic; BRAF(V600E); preclinical and translational model; vemurafenib; tyrosine kinase inhibitors	RECEPTOR TYROSINE KINASES; ENDOTHELIAL GROWTH-FACTOR; TUMOR-CELL PROLIFERATION; IN-VIVO; THERAPEUTIC TARGET; PROGNOSTIC-FACTORS; CANCER CELLS; INCREASING INCIDENCE; TRANSCRIPTION FACTOR; GENETIC ALTERATIONS	Molecular signature of advanced and metastatic thyroid carcinoma involves deregulation of multiple fundamental pathways activated in the tumor microenvironment. They include BRAF(V600E) and AKT that affect tumor initiation, progression and metastasis. Human thyroid cancer orthotopic mouse models are based on human cell lines that generally harbor genetic alterations found in human thyroid cancers. They can reproduce in vivo and in situ (into the thyroid) many features of aggressive and refractory human advanced thyroid carcinomas, including local invasion and metastasis. Humanized orthotopic mouse models seem to be ideal and commonly used for preclinical and translational studies of compounds and therapies not only because they may mimic key aspects of human diseases (e. g. metastasis), but also for their reproducibility. In addition, they might provide the possibility to evaluate systemic effects of treatments. So far, human thyroid cancer in vivo models were mainly used to test single compounds, non selective and selective. Despite the greater antitumor activity and lower toxicity obtained with different selective drugs in respect to non-selective ones, most of them are only able to delay disease progression, which ultimately could restart with similar aggressive behavior. Aggressive thyroid tumors (for example, anaplastic or poorly differentiated thyroid carcinoma) carry several complex genetic alterations that are likely cooperating to promote disease progression and might confer resistance to single-compound approaches. Orthotopic models of human thyroid cancer also hold the potential to be good models for testing novel combinatorial therapies. In this article, we will summarize results on preclinical testing of selective and nonselective single compounds in orthotopic mouse models based on validated human thyroid cancer cell lines harboring the BRAF(V600E) mutation or with wild-type BRAF. Furthermore, we will discuss the potential use of this model also for combinatorial approaches, which are expected to take place in the upcoming human thyroid cancer basic and clinical research.	[Antonello, Z. A.; Nucera, C.] Harvard Univ, Expt Div Canc Biol & Angiogenesis, Beth Israel Deaconess Med Ctr,Lab Human Thyroid C, Dept Pathol,Simon C Fireman Res Ctr,Med Sch, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Nucera, C (corresponding author), Harvard Univ, Expt Div Canc Biol & Angiogenesis, Beth Israel Deaconess Med Ctr, Dept Pathol,Simon C Fireman Res Ctr,Med Sch, Boston, MA 02215 USA.	cnucera@bidmc.harvard.edu		Antonello, Zeus/0000-0002-5933-6794	National Institutes of Health Grants [NIHR21CA165039-01A1]; American Thyroid Association funds for Thyroid Cancer Research to Carmelo Nucera; Guido Berlucchi research award (Brescia, Italy); NATIONAL CANCER INSTITUTE [R21CA165039] Funding Source: NIH RePORTER	National Institutes of Health Grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Thyroid Association funds for Thyroid Cancer Research to Carmelo Nucera; Guido Berlucchi research award (Brescia, Italy); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health Grants NIHR21CA165039-01A1 and the American Thyroid Association funds for Thyroid Cancer Research to Carmelo Nucera (Principal Investigator: Human Thyroid Cancers Preclinical and Translational Research). Carmelo Nucera was also a recipient of the Guido Berlucchi research award (Brescia, Italy). Zeus A Antonello was a Masters Student at the BIDMC and is currently a PhD Student at the Instituto de Neurociencias (Alicante, Spain). We thank Mark Duquette and Neal Smith (BIDMC, Harvard Medical School) for critical reading of our manuscript. We thank those authors who we have neglected to cite owing to limitation on the number of references.	Abate-Shen Cory, 2013, Cold Spring Harb Protoc, V2013, DOI 10.1101/pdb.top078774; Araujo J, 2010, CANCER TREAT REV, V36, P492, DOI 10.1016/j.ctrv.2010.02.015; BANCROFT GJ, 1994, IMMUNOBIOLOGY, V191, P424, DOI 10.1016/S0171-2985(11)80448-1; Bellelli R, 2012, ENDOCR-RELAT CANCER, V19, P695, DOI 10.1530/ERC-12-0031; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Bos PD, 2010, CURR OPIN PHARMACOL, V10, P571, DOI 10.1016/j.coph.2010.06.003; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; Brassard M, 2011, J CLIN ENDOCR METAB, V96, P1352, DOI 10.1210/jc.2010-2708; Brown RL, 2011, J CANCER, V2, P193, DOI 10.7150/jca.2.193; Carlomagno F, 2006, JNCI-J NATL CANCER I, V98, P326, DOI 10.1093/jnci/djj069; Carlomagno F, 2011, NAT REV ENDOCRINOL, V7, P65, DOI 10.1038/nrendo.2010.232; Chakravarty D, 2011, J CLIN INVEST, V121, P4700, DOI 10.1172/JCI46382; Chan CM, 2012, CLIN CANCER RES, V18, P3580, DOI 10.1158/1078-0432.CCR-11-3359; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Charles RP, 2011, CANCER RES, V71, P3863, DOI 10.1158/0008-5472.CAN-10-4463; Ciampi R, 2007, ENDOCRINOLOGY, V148, P936, DOI 10.1210/en.2006-0921; Colston KW, 1997, BRIT J CANCER, V76, P1017, DOI 10.1038/bjc.1997.501; Cooper DS, 2009, THYROID, V19, P1167, DOI 10.1089/thy.2009.0110; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Dackiw APB, 2004, ENDOCRINOLOGY, V145, P5840, DOI 10.1210/en.2004-0785; Davies L, 2006, JAMA-J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164; Day E, 2008, EUR J PHARMACOL, V599, P44, DOI 10.1016/j.ejphar.2008.10.014; Deshpande HA, 2013, CURR OPIN ONCOL, V25, P44, DOI 10.1097/CCO.0b013e32835a448c; Dhar DK, 1998, AM J SURG, V176, P442, DOI 10.1016/S0002-9610(98)00238-4; Durante C, 2006, J CLIN ENDOCR METAB, V91, P2892, DOI 10.1210/jc.2005-2838; Ensinger C, 2004, ANN NY ACAD SCI, V1030, P69, DOI 10.1196/annals.1329.009; Fenton C, 2000, THYROID, V10, P349, DOI 10.1089/thy.2000.10.349; Fizazi K, 2007, ANN ONCOL, V18, P1765, DOI 10.1093/annonc/mdm086; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Franco AT, 2011, P NATL ACAD SCI USA, V108, P1615, DOI 10.1073/pnas.1015557108; Garcia-Rostan G, 2005, CANCER RES, V65, P10199, DOI 10.1158/0008-5472.CAN-04-4259; Girelli ME, 1998, THYROID, V8, P517, DOI 10.1089/thy.1998.8.517; Gule MK, 2011, CLIN CANCER RES, V17, P2281, DOI 10.1158/1078-0432.CCR-10-2762; Henderson YC, 2008, CLIN CANCER RES, V14, P4908, DOI 10.1158/1078-0432.CCR-07-1772; Henderson YC, 2014, HEAD NECK-J SCI SPEC, V36, P375, DOI 10.1002/hed.23316; Hershberger PA, 1999, CANCER RES, V59, P2644; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Ito Y, 2013, NAT REV ENDOCRINOL, V9, P178, DOI 10.1038/nrendo.2012.257; Johnson JI, 2001, BRIT J CANCER, V84, P1424, DOI 10.1054/bjoc.2001.1796; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Kandil E, 2013, J SURG RES, V184, P898, DOI 10.1016/j.jss.2013.03.052; Kerbel RS, 2003, CANCER BIOL THER, V2, pS134; Khanna C, 2005, CARCINOGENESIS, V26, P513, DOI 10.1093/carcin/bgh261; Killion JJ, 1998, CANCER METAST REV, V17, P279, DOI 10.1023/A:1006140513233; Kim KB, 2013, THYROID, V17, P17; Kim KB, 2013, THYROID, V23, P1277, DOI 10.1089/thy.2013.0057; Knauf JA, 2005, CANCER RES, V65, P4238, DOI 10.1158/0008-5472.CAN-05-0047; Knauf JA, 2009, CURR OPIN CELL BIOL, V21, P296, DOI 10.1016/j.ceb.2009.01.013; Kopetz S, 2007, CLIN CANCER RES, V13, P7232, DOI 10.1158/1078-0432.CCR-07-1902; Leboeuf R, 2008, J CLIN ENDOCR METAB, V93, P2194, DOI 10.1210/jc.2007-2825; Lee Jieun, 2013, Genomics & Informatics, V11, P68, DOI 10.5808/GI.2013.11.2.68; Liu DX, 2010, INT J CANCER, V127, P2965, DOI 10.1002/ijc.25304; Liu W, 2002, AM J PATHOL, V160, P511, DOI 10.1016/S0002-9440(10)64870-5; Liu W, 2008, CANCER RES, V68, P8104, DOI 10.1158/0008-5472.CAN-08-2132; Liu Z, 2008, J CLIN ENDOCR METAB, V93, P3106, DOI 10.1210/jc.2008-0273; Lu C, 2012, ONCOGENE, V31, P2007, DOI 10.1038/onc.2011.390; Lyons JF, 2001, ENDOCR-RELAT CANCER, V8, P219, DOI 10.1677/erc.0.0080219; Mathiasen IS, 2002, J BIOL CHEM, V277, P30738, DOI 10.1074/jbc.M201558200; Maxon HR, 1999, THYROID, V9, P443, DOI 10.1089/thy.1999.9.443; MAZZAFERRI EL, 1994, AM J MED, V97, P418, DOI 10.1016/0002-9343(94)90321-2; McClatchey AI, 1999, ONCOGENE, V18, P5334, DOI 10.1038/sj.onc.1203086; McDonald MP, 1996, SURGERY, V120, P1000, DOI 10.1016/S0039-6060(96)80046-8; Miller KA, 2009, CANCER RES, V69, P3689, DOI 10.1158/0008-5472.CAN-09-0024; Modigliani E, 1998, CLIN ENDOCRINOL, V48, P265, DOI 10.1046/j.1365-2265.1998.00392.x; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Montero-Conde C, 2013, CANCER DISCOV, V3, P520, DOI 10.1158/2159-8290.CD-12-0531; Nehs MA, 2012, ENDOCRINOLOGY, V153, P985, DOI 10.1210/en.2011-1519; Nehs MA, 2010, SURGERY, V148, P1154, DOI 10.1016/j.surg.2010.09.001; Nucera C, 2011, ONCOLOGIST, V16, P296, DOI 10.1634/theoncologist.2010-0317; Nucera C, 2010, P NATL ACAD SCI USA, V107, P10649, DOI 10.1073/pnas.1004934107; Nucera C, 2009, THYROID, V19, P1077, DOI 10.1089/thy.2009.0055; Nucera C, 2009, BBA-REV CANCER, V1795, P152, DOI 10.1016/j.bbcan.2009.01.003; Orim F, 2013, THYROID, V7, P7; Pal SK, 2010, EXPERT OPIN INV DRUG, V19, P1355, DOI 10.1517/13543784.2010.520701; Palmer HG, 2003, CANCER RES, V63, P7799; Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Priolo C, 2010, AM J PATHOL, V176, P1901, DOI 10.2353/ajpath.2010.090873; Radhakrishnan SK, 2006, CANCER RES, V66, P9731, DOI 10.1158/0008-5472.CAN-06-1576; Ricarte-Filho JC, 2009, CANCER RES, V69, P4885, DOI 10.1158/0008-5472.CAN-09-0727; Rosove MH, 2013, NEW ENGL J MED, V368, P684, DOI 10.1056/NEJMc1215697; Saji M, 2011, ONCOGENE, V30, P4307, DOI 10.1038/onc.2011.136; Saji M, 2010, MOL CELL ENDOCRINOL, V321, P20, DOI 10.1016/j.mce.2009.10.016; Salvatore G, 2006, CLIN CANCER RES, V12, P1623, DOI 10.1158/1078-0432.CCR-05-2378; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sanders LE, 1998, SURGERY, V124, P967, DOI 10.1067/msy.1998.92000; SCHOLZ CC, 1990, EUR J CANCER, V26, P901, DOI 10.1016/0277-5379(90)90196-Z; Schweppe RE, 2009, J CLIN ENDOCR METAB, V94, P2199, DOI 10.1210/jc.2008-2511; Schweppe RE, 2008, J CLIN ENDOCR METAB, V93, P4331, DOI 10.1210/jc.2008-1102; SHAHA AR, 1995, SURGERY, V118, P1131, DOI 10.1016/S0039-6060(05)80124-2; SHARKEY FE, 1979, INT J CANCER, V24, P733, DOI 10.1002/ijc.2910240605; Sharma V, 2010, THYROID, V20, P1103, DOI 10.1089/thy.2010.0096; Sherman SI, 2013, ORAL ONCOL, V49, P707, DOI 10.1016/j.oraloncology.2013.03.442; Shimamura M, 2013, ENDOCRINOLOGY, V154, P4423, DOI 10.1210/en.2013-1174; Smallridge RC, 2012, THYROID, V22, P1104, DOI 10.1089/thy.2012.0302; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Su F, 2012, CANCER RES, V72, P969, DOI 10.1158/0008-5472.CAN-11-1875; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Tisset H, 2013, J CLIN ENDOCR METAB, V98, P3981, DOI 10.1210/jc.2013-1357; Trunzer K, 2013, J CLIN ONCOL, V31, P1767, DOI 10.1200/JCO.2012.44.7888; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Tsimberidou AM, 2009, J CLIN ENDOCR METAB, V94, P4423, DOI 10.1210/jc.2009-0743; Van Dyke T, 2002, CELL, V108, P135, DOI 10.1016/S0092-8674(02)00621-9; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; Wierstra I, 2007, BIOL CHEM, V388, P1257, DOI 10.1515/BC.2007.159; Wilhelm S, 2002, CURR PHARM DESIGN, V8, P2255, DOI 10.2174/1381612023393026; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Xing JN, 2011, BIOCHEM BIOPH RES CO, V404, P958, DOI 10.1016/j.bbrc.2010.12.088; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Xing MZ, 2010, THYROID, V20, P697, DOI 10.1089/thy.2010.1646; Yang H, 2010, CANCER RES, V70, P5518, DOI 10.1158/0008-5472.CAN-10-0646; Yutan E, 2001, Curr Treat Options Oncol, V2, P331, DOI 10.1007/s11864-001-0026-4	113	22	22	3	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2014	33	47					5397	5404		10.1038/onc.2013.544	http://dx.doi.org/10.1038/onc.2013.544			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MG	24362526	Green Accepted			2022-12-28	WOS:000345120700001
J	Beltran, AS; Graves, LM; Blancafort, P				Beltran, A. S.; Graves, L. M.; Blancafort, P.			Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function	ONCOGENE			English	Article						Engrailed 1; inflammatory breast cancer; triple-negative breast cancer; dopaminergic neuron; reprogramming; interference peptides	TRANSFER-RNA SYNTHETASE; TUMOR-INITIATING CELLS; DOPAMINERGIC-NEURONS; MUTATIONAL PROCESSES; MOLECULAR PORTRAITS; GENE-EXPRESSION; OVARIAN-CANCER; TARGETING HOX; PBX; SUBTYPES	Basal-like breast tumors are aggressive cancers associated with high proliferation and metastasis. Chemotherapy is currently the only treatment option; however, resistance often occurs resulting in recurrence and patient death. Some extremely aggressive cancers are also associated with hypoxia, inflammation and high leukocyte infiltration. Herein, we discovered that the neural-specific transcription factor, Engrailed 1 (EN1), is exclusively overexpressed in these tumors. Short hairpin RNA (shRNA)-mediated knockdown of EN1 triggered potent and selective cell death. In contrast, ectopic overexpression of EN1 in normal cells activated survival pathways and conferred resistance to chemotherapeutic agents. Exogenous expression of EN1 cDNA reprogrammed the breast epithelial cells toward a long-lived, neural-like phenotype displaying dopaminergic markers. Gene expression microarrays demonstrated that the EN1 cDNA altered transcription of a high number of inflammatory molecules, notably chemokines and chemokine receptors, which could mediate prosurvival pathways. To block EN1 function, we engineered synthetic interference peptides (iPeps) comprising the EN1-specific sequences that mediate essential protein-protein interactions necessary for EN1 function and an N-terminal cell-penetrating peptide/nuclear localization sequence. These EN1-iPeps rapidly mediated a strong apoptotic response in tumor cells overexpressing EN1, with no toxicity to normal or non EN1-expressing cells. Delivery of EN1-iPeps into basal-like cancer cells significantly decreased the fifty percent inhibitory concentrations (IC50) of chemotherapeutic drugs routinely used to treat breast cancer. Lastly, matrix-assisted laser desorption/ionization-time of flight mass spectrometry and immunoprecipitation assays demonstrated that EN1-iPeps captured targets involved in transcriptional and post-transcriptional regulation. Importantly, the EN1-iPeps bound the glutamyl-prolyl tRNA synthetase (EPRS) target, which has been associated with the transcript-specific translational control of inflammatory proteins and activation of amino-acid stress pathways. This work unveils EN1 as an activator of intrinsic inflammatory pathways associated with prosurvival in basal-like breast cancer. We further build upon these results and describe the engineering of iPeps targeting EN1 (EN1-iPeps) as a novel and selective therapeutic strategy to combat these lethal forms of breast cancer.	[Beltran, A. S.; Graves, L. M.; Blancafort, P.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC USA; [Blancafort, P.] Univ Western Australia, Sch Anat Physiol & Human Biol, Canc Epigenet Grp, Crawley, WA 6009, Australia	University of North Carolina; University of North Carolina Chapel Hill; University of Western Australia	Blancafort, P (corresponding author), Univ Western Australia, Sch Anat Physiol & Human Biol, Canc Epigenet Grp, 35 Stirling Highway, Crawley, WA 6009, Australia.	pilar.blancafort@uwa.edu.au	Graves, Lee/AAG-5470-2021; , Proteomics Core UNC/AAH-3777-2022; , Proteomics Core UNC/AFQ-7201-2022; Peptide Synthesis and Array Facility, High-Throughput/AFI-7866-2022	Blancafort, Pilar/0000-0002-3881-7396	NIH-NCI [CA016086, 1R01CA125273, 3R01CA125273-03S1]; DOD [W81XWH-10-1-0265]; NATIONAL CANCER INSTITUTE [R01CA170370, P30CA016086, R01CA125273] Funding Source: NIH RePORTER	NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research is based in part upon work conducted using the UNC Michael Hooker Proteomics Center, which is supported in part by the NIH-NCI Grant No. CA016086 to the Lineberger Comprehensive Cancer Center and by NHI-NCI Grants 1R01CA125273, 3R01CA125273-03S1 and DOD W81XWH-10-1-0265 to PB. We thank Drs DC Connolly, L Vartikovski and JE Green for providing the murine cell lines from genetically engineered mouse models.	Alberi L, 2004, DEVELOPMENT, V131, P3229, DOI 10.1242/dev.01128; Alvarez-Fischer D, 2011, NAT NEUROSCI, V14, P1260, DOI 10.1038/nn.2916; Arif A, 2012, MOL CELL BIOL, V32, P5046, DOI 10.1128/MCB.01168-12; Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154; Bell D, 2012, CANCER-AM CANCER SOC, V118, P1288, DOI 10.1002/cncr.26412; Beltran AS, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3019; Beltran AS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024595; Ben-Baruch A, 2003, BREAST CANCER RES, V5, P31, DOI 10.1186/bcr554; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Craig DW, 2012, MOL CANCER THER, V2, P104; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; dos Santos MTMA, 2011, NEURAL DEV, V6, DOI 10.1186/1749-8104-6-23; Eiro N, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.24010; Fan C, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-3; Gray J, 2012, NATURE, V486, P328, DOI 10.1038/486328a; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Jiang X, 2013, MOL CELL ENDOCRINOL; Keller TL, 2012, NAT CHEM BIOL, V8, P311, DOI [10.1038/NCHEMBIO.790, 10.1038/nchembio.790]; Kim J., 2013, SCI WORLD J, V2013, P1, DOI DOI 10.5607/EN.2013.22.1.38; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kristensen VN, 2012, P NATL ACAD SCI USA, V109, P2802, DOI 10.1073/pnas.1108781108; LaRonde-LeBlanc NA, 2003, GENE DEV, V17, P2060, DOI 10.1101/gad.1103303; Morgan R, 2007, CANCER RES, V67, P5806, DOI 10.1158/0008-5472.CAN-06-4231; Morgan R, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-89; Morini M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-649; Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116; Morrison BE, 2012, J IMMUNOL, V189, P5498, DOI 10.4049/jimmunol.1102150; Mukhopadhyay R, 2009, TRENDS BIOCHEM SCI, V34, P324, DOI 10.1016/j.tibs.2009.03.004; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Ninkovic J, 2010, NEURON, V68, P682, DOI 10.1016/j.neuron.2010.09.030; Nokes BT, 2013, J CANCER, V4, P104, DOI 10.7150/jca.5002; Nolan YM, 2013, TRENDS MOL MED, V19, P187, DOI 10.1016/j.molmed.2012.12.003; Pandha H, 2012, BJU INT, V110, pE287, DOI 10.1111/j.1464-410X.2012.11208.x; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; Perou CM, 2010, ONCOLOGIST, V15, P39, DOI 10.1634/theoncologist.2010-S5-39; Perou CM, 2010, LANCET ONCOL, V11, P718, DOI 10.1016/S1470-2045(10)70176-5; Plowright L, 2009, BRIT J CANCER, V100, P470, DOI 10.1038/sj.bjc.6604857; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rachidi SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057911; Rody A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3035; Sasaki Y, 2009, BREAST CANCER-TOKYO, V16, P254, DOI 10.1007/s12282-009-0153-5; Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Shears L, 2008, J UROLOGY, V180, P2196, DOI 10.1016/j.juro.2008.07.018; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Varticovski L, 2007, CLIN CANCER RES, V13, P2168, DOI 10.1158/1078-0432.CCR-06-0918; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Wright MH, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-29; Yao P, 2012, CELL CYCLE, V11, P1868, DOI 10.4161/cc.20417; Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353	55	59	61	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2014	33	39					4767	4777		10.1038/onc.2013.422	http://dx.doi.org/10.1038/onc.2013.422			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0ED	24141779	Green Published, hybrid			2022-12-28	WOS:000343239500007
J	Dong, L; Jin, L; Tseng, HY; Wang, CY; Wilmott, JS; Yosufi, B; Yan, XG; Jiang, CC; Scolyer, RA; Zhang, XD; Guo, ST				Dong, L.; Jin, L.; Tseng, H-Y; Wang, C. Y.; Wilmott, J. S.; Yosufi, B.; Yan, X. G.; Jiang, C. C.; Scolyer, R. A.; Zhang, X. D.; Guo, S. T.			Oncogenic suppression of PHLPP1 in human melanoma	ONCOGENE			English	Article						PHLPP1; Akt; melanoma; DNA methylation	TUMOR-SUPPRESSOR; SIGNALING PATHWAYS; PHOSPHATASE PHLPP; CPG METHYLATION; PH DOMAIN; PROTEIN; AKT; PTEN; ACTIVATION; PI3K	Akt is constitutively activated in up to 70% of human melanomas and has an important role in the pathogenesis of the disease. However, little is known about protein phosphatases that dephosphorylate and thereby inactivate it in melanoma cells. Here we report that suppression of pleckstrin homology domain and leucine-rich repeat Ser/Thr protein phosphatase 1 (PHLPP1) by DNA methylation promotes Akt activation and has an oncogenic role in melanoma. While it is commonly downregulated, overexpression of PHLPP1 reduces Akt activation and inhibits melanoma cell proliferation in vitro, and retards melanoma growth in a xenograft model. In contrast, knockdown of PHLPP1 increases Akt activation, enhances melanoma cell and melanocyte proliferation, and results in anchorage-independent growth of melanocytes. Suppression of PHLPP1 involves blockade of binding of the transcription factor Sp1 to the PHLPP1 promoter. Collectively, these results suggest that suppression of PHLPP1 by DNA methylation contributes to melanoma development and progression.	[Dong, L.; Jin, L.; Tseng, H-Y; Yan, X. G.; Jiang, C. C.; Zhang, X. D.] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW 2308, Australia; [Wang, C. Y.; Guo, S. T.] Shanxi Med Univ, Shanxi Canc Hosp & Inst, Dept Mol Biol, Affiliated Hosp, Taiyuan, Peoples R China; [Wilmott, J. S.; Yosufi, B.; Scolyer, R. A.] Melanoma Inst Australia, Sydney, NSW, Australia; [Wilmott, J. S.; Scolyer, R. A.] Univ Sydney, Discipline Pathol, Sydney, NSW 2006, Australia; [Scolyer, R. A.] Royal Prince Alfred Hosp, Sydney, NSW, Australia	University of Newcastle; Shanxi Medical University; Melanoma Institute Australia; University of Sydney; University of Sydney	Zhang, XD (corresponding author), Univ Newcastle, Prior Res Ctr Canc Res, Sch Med & Publ Hlth, LS3-49,Life Sci Bldg, Newcastle, NSW 2308, Australia.	Xu.Zhang@newcastle.edu.au; gsutang@gmail.com	Wilmott, James/AGA-8227-2022; zhang, xu/GYE-3558-2022; Jin, Lei/K-2315-2019; zhang, xu/GRX-9733-2022; Scolyer, Richard/AAE-8511-2019; Tseng, Cindy Hsin-Yi/AAB-8958-2022; Zhang, xiaoyu/GXA-3206-2022; Jin, Lei/J-1896-2019; zhang, xian/GYA-0290-2022	Wilmott, James/0000-0002-6750-5244; Scolyer, Richard/0000-0002-8991-0013; Tseng, Cindy Hsin-Yi/0000-0002-7499-7515; Jin, Lei/0000-0001-7187-9671; Zhang, Xu Dong/0000-0001-9457-8003	National Health and Medical Research Council (NHMRC); Cancer Council NSW; Cancer Institute NSW; Hunter Medical Research Institute, Australia; National Natural Science Foundation of China; NHMRC; Cancer Institute NSW Fellowship Program	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council NSW(Cancer Council New South Wales); Cancer Institute NSW; Hunter Medical Research Institute, Australia; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute NSW Fellowship Program	This work was supported by the National Health and Medical Research Council (NHMRC), the Cancer Council NSW, Cancer Institute NSW and Hunter Medical Research Institute, Australia; and National Natural Science Foundation of China. XDZ is supported by senior research fellowships of NHMRC. RAS is supported by the Cancer Institute NSW Fellowship Program. We thank Dr Tianyan Gao (Markey Cancer Center, University of Kentucky) for the pcDNA3-PHLPP1-HA constructs.	Beezhold K, 2011, TOXICOL SCI, V123, P411, DOI 10.1093/toxsci/kfr188; Bozulic L, 2009, CURR OPIN CELL BIOL, V21, P256, DOI 10.1016/j.ceb.2009.02.002; Bradley EW, 2013, J BIOL CHEM, V288, P9572, DOI 10.1074/jbc.M112.423723; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chen MH, 2011, CANCER CELL, V20, P173, DOI 10.1016/j.ccr.2011.07.013; Cheung M, 2008, CANCER RES, V68, P3429, DOI 10.1158/0008-5472.CAN-07-5867; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Curtin JA, 2006, J INVEST DERMATOL, V126, P1660, DOI 10.1038/sj.jid.5700311; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Davies MA, 2009, CLIN CANCER RES, V15, P7538, DOI 10.1158/1078-0432.CCR-09-1985; Fayard E, 2005, J CELL SCI, V118, P5675, DOI 10.1242/jcs.02724; Fedele CG, 2010, P NATL ACAD SCI USA, V107, P22231, DOI 10.1073/pnas.1015245107; Ferte C, 2010, NAT REV CLIN ONCOL, V7, P367, DOI 10.1038/nrclinonc.2010.84; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gao T, 2008, J BIOL CHEM, V283, P6300, DOI 10.1074/jbc.M707319200; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Gewinner C, 2009, CANCER CELL, V16, P115, DOI 10.1016/j.ccr.2009.06.006; Gillespie S, 2005, MOL CANCER THER, V4, P668, DOI 10.1158/1535-7163.MCT-04-0332; Govindarajan B, 2007, J CLIN INVEST, V117, P719, DOI 10.1172/JCI30102; Guo ST, 2013, ONCOGENE, V32, P1910, DOI 10.1038/onc.2012.214; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Houslay MD, 2011, CANCER CELL, V19, P3, DOI 10.1016/j.ccr.2011.01.004; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Jiang CC, 2011, CLIN CANCER RES, V17, P721, DOI 10.1158/1078-0432.CCR-10-2225; Jin L, 2011, P NATL ACAD SCI USA, V108, P15840, DOI 10.1073/pnas.1019312108; Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032; Klug M, 2006, EPIGENETICS-US, V1, P127, DOI 10.4161/epi.1.3.3327; Li L, 2010, ANN ANAT, V192, P275, DOI 10.1016/j.aanat.2010.07.010; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Liu J, 2009, ONCOGENE, V28, P994, DOI 10.1038/onc.2008.450; Liu JY, 2011, MOL CELL BIOL, V31, P4917, DOI 10.1128/MCB.05799-11; Madhunapantula SV, 2009, PIGM CELL MELANOMA R, V22, P400, DOI 10.1111/j.1755-148X.2009.00585.x; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Mirmohammadsadegh A, 2006, CANCER RES, V66, P6546, DOI 10.1158/0008-5472.CAN-06-0384; Molina JR, 2012, ONCOGENE, V31, P1264, DOI 10.1038/onc.2011.324; Nitsche C, 2012, GASTROENTEROLOGY, V142, P377, DOI 10.1053/j.gastro.2011.10.026; O'Hayre M, 2012, LEUKEMIA, V26, P1689, DOI 10.1038/leu.2012.6; O'Neill AK, 2013, FEBS J, V280, P572, DOI 10.1111/j.1742-4658.2012.08537.x; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Park SJ, 2001, J BIOL CHEM, V276, P4781, DOI 10.1074/jbc.M010177200; Patterson SJ, 2011, J IMMUNOL, V186, P5533, DOI 10.4049/jimmunol.1002126; Poulikakos PI, 2011, CANCER CELL, V19, P11, DOI 10.1016/j.ccr.2011.01.008; Qiao M, 2010, MOL CELL, V38, P512, DOI 10.1016/j.molcel.2010.03.017; Ribas A, 2011, NAT REV CLIN ONCOL, V8, P426, DOI 10.1038/nrclinonc.2011.69; Rishi V, 2010, P NATL ACAD SCI USA, V107, P20311, DOI 10.1073/pnas.1008688107; Saavedra A, 2010, CELL DEATH DIFFER, V17, P324, DOI 10.1038/cdd.2009.127; Shimizu K, 2003, J BIOL CHEM, V278, P14920, DOI 10.1074/jbc.M213214200; Smalley KSM, 2010, J INVEST DERMATOL, V130, P28, DOI 10.1038/jid.2009.177; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Stark M, 2007, CANCER RES, V67, P2632, DOI 10.1158/0008-5472.CAN-06-4152; Tay KH, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.79; Warfel NA, 2012, J BIOL CHEM, V287, P3610, DOI 10.1074/jbc.R111.318675; Warfel NA, 2011, J BIOL CHEM, V286, P19777, DOI 10.1074/jbc.M111.237081; Ye Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2489; Zhuang LQ, 2009, HISTOPATHOLOGY, V54, P462, DOI 10.1111/j.1365-2559.2009.03242.x	60	21	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2014	33	39					4756	4766		10.1038/onc.2013.420	http://dx.doi.org/10.1038/onc.2013.420			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0ED	24121273	Green Submitted			2022-12-28	WOS:000343239500006
J	He, Y; Jiang, X; Chen, J				He, Y.; Jiang, X.; Chen, J.			The role of miR-150 in normal and malignant hematopoiesis	ONCOGENE			English	Review						miR-150; hematopoiesis; hematopoietic malignancies; expression profiles; gene regulation; target genes	B-CELL DEVELOPMENT; C-MYB; MICRORNA EXPRESSION; MEDIATED CONTROL; MLL; LEUKEMIA; IDENTIFICATION; LYMPHOMA; LINEAGE; DIFFERENTIATION	MicroRNAs are a class of small non-coding RNAs that have been implicated to mediate gene regulation in virtually all important biological processes. Recently there is accumulating evidence showing that miR-150 has essential regulatory roles in both normal and malignant hematopoiesis and holds great potential as a therapeutic target in treating various types of hematopoietic malignancies. The purpose of this review is to summarize our current knowledge about the expression patterns, biological functions and regulatory mechanisms of miR-150 in normal and malignant hematopoiesis, and to highlight the important questions to be answered in this burgeoning field.	[He, Y.; Jiang, X.; Chen, J.] Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA; [Jiang, X.; Chen, J.] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Chen, J (corresponding author), Univ Chicago, Dept Med, Hematol Oncol Sect, 900 E 57th St,Room 7134, Chicago, IL 60637 USA.	jchen@bsd.uchicago.edu			National Institutes of Health (NIH) [CA127277]; American Cancer Society (ACS); University of Chicago Committee on Cancer Biology (CCB); Gabrielle's Angel Foundation for Cancer Research; NATIONAL CANCER INSTITUTE [R01CA127277] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society (ACS)(American Cancer Society); University of Chicago Committee on Cancer Biology (CCB); Gabrielle's Angel Foundation for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the National Institutes of Health (NIH) R01 grant CA127277 (JC), American Cancer Society (ACS) Research Scholar grant (JC), The University of Chicago Committee on Cancer Biology (CCB) Fellowship Program (YH; XJ), and Gabrielle's Angel Foundation for Cancer Research (JC; XJ).	Adams BD, 2012, CELL REP, V2, P1048, DOI 10.1016/j.celrep.2012.09.014; Agirre X, 2008, MOL CANCER RES, V6, P1830, DOI 10.1158/1541-7786.MCR-08-0167; Barroga CF, 2008, EXP HEMATOL, V36, P1585, DOI 10.1016/j.exphem.2008.07.001; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Behm FG, 1996, BLOOD, V87, P2870, DOI 10.1182/blood.V87.7.2870.bloodjournal8772870; Bender TP, 2004, NAT IMMUNOL, V5, P721, DOI 10.1038/ni1085; Bezman NA, 2011, J EXP MED, V208, P2717, DOI 10.1084/jem.20111386; Bousquet M, 2013, MOL CANCER RES, V11, P912, DOI 10.1158/1541-7786.MCR-13-0002-T; Bruchova H, 2007, EXP HEMATOL, V35, P1657, DOI 10.1016/j.exphem.2007.08.021; Cai JP, 2012, GRAEF ARCH CLIN EXP, V250, P523, DOI 10.1007/s00417-011-1885-4; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chang TC, 2009, P NATL ACAD SCI USA, V106, P3384, DOI 10.1073/pnas.0808300106; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen JJ, 2010, NAT REV CANCER, V10, P23, DOI 10.1038/nrc2765; Chen SH, 2013, CANCER SCI, V104, P826, DOI 10.1111/cas.12156; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; Faber J, 2009, BLOOD, V113, P2375, DOI 10.1182/blood-2007-09-113597; Fang J, 2012, CURR PHARM DESIGN, V18, P3170, DOI 10.2174/1381612811209023170; Fayyad-Kazan H, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-31; Fulci V, 2007, BLOOD, V109, P4944, DOI 10.1182/blood-2006-12-062398; Garzon R, 2008, CURR OPIN HEMATOL, V15, P352, DOI 10.1097/MOH.0b013e328303e15d; Ghisi M, 2011, BLOOD, V117, P7053, DOI 10.1182/blood-2010-12-326629; Gibcus JH, 2009, NEOPLASIA, V11, P167, DOI 10.1593/neo.08980; Guo YS, 2009, BLOOD, V114, P2097, DOI 10.1182/blood-2009-01-197947; HE L, 2004, NAT REV GENET, V5, P522; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Hussein K, 2010, LEUKEMIA RES, V34, P328, DOI 10.1016/j.leukres.2009.06.014; Jiang X, 2012, ONCOTARGET, V3, P1268; Jiang X, 2012, CANCER CELL, V22, P524, DOI 10.1016/j.ccr.2012.08.028; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Lawrie CH, 2013, BRIT J HAEMATOL, V160, P571, DOI 10.1111/bjh.12157; Li ZJ, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1681; Lu J, 2008, DEV CELL, V14, P843, DOI 10.1016/j.devcel.2008.03.012; Machova Polakova K, 2011, MOL CANCER, V10, P41, DOI DOI 10.1186/1476-4598-10-41; Marcucci G, 2011, BLOOD, V117, P1121, DOI 10.1182/blood-2010-09-191312; Marcucci Guido, 2009, Curr Hematol Malig Rep, V4, P83, DOI 10.1007/s11899-009-0012-7; Mi SL, 2010, P NATL ACAD SCI USA, V107, P3710, DOI 10.1073/pnas.0914900107; Monticelli S, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-r71; Moussay E, 2011, P NATL ACAD SCI USA, V108, P6573, DOI 10.1073/pnas.1019557108; Mullighan CG, 2009, SEMIN HEMATOL, V46, P3, DOI 10.1053/j.seminhematol.2008.09.005; Muntean AG, 2012, ANNU REV PATHOL-MECH, V7, P283, DOI 10.1146/annurev-pathol-011811-132434; Newman MA, 2010, GENE DEV, V24, P1086, DOI 10.1101/gad.1919710; Ntziachristos P, 2013, ADV IMMUNOL, V117, P1, DOI 10.1016/B978-0-12-410524-9.00001-3; Orkin SH, 2008, CELL, V132, P631, DOI 10.1016/j.cell.2008.01.025; Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304; Popovic R, 2009, BLOOD, V113, P3314, DOI 10.1182/blood-2008-04-154310; Rowley JD, 2008, BLOOD, V112, P2183, DOI 10.1182/blood-2008-04-097931; Schotte D, 2009, LEUKEMIA, V23, P313, DOI 10.1038/leu.2008.286; Siomi H, 2010, MOL CELL, V38, P323, DOI 10.1016/j.molcel.2010.03.013; Thomas MD, 2005, IMMUNITY, V23, P275, DOI 10.1016/j.immuni.2005.08.005; Vegiopoulos A, 2006, BLOOD, V107, P4703, DOI 10.1182/blood-2005-07-2968; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang M, 2008, J PATHOL, V215, P13, DOI 10.1002/path.2333; Wang Y, 2006, CURR CANCER THER REV, V2, P271, DOI 10.2174/157339406777934717; Wang YG, 2010, BLOOD CELL MOL DIS, V44, P191, DOI 10.1016/j.bcmd.2009.12.010; Watanabe A, 2011, LEUKEMIA, V25, P1324, DOI 10.1038/leu.2011.81; Xiao CC, 2007, CELL, V131, P146, DOI 10.1016/j.cell.2007.07.021; Xiao CC, 2009, CELL, V136, P26, DOI 10.1016/j.cell.2008.12.027; Xu Ling, 2011, Zhonghua Xue Ye Xue Za Zhi, V32, P178; Zanette DL, 2007, BRAZ J MED BIOL RES, V40, P1435, DOI 10.1590/S0100-879X2007001100003; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004; Zhang H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007826; Zhao JJ, 2010, BLOOD, V115, P2630, DOI 10.1182/blood-2009-09-243147; Zheng QH, 2012, J IMMUNOL, V188, P2118, DOI 10.4049/jimmunol.1103342; Zhou BY, 2007, P NATL ACAD SCI USA, V104, P7080, DOI 10.1073/pnas.0702409104; Zuber J, 2011, GENE DEV, V25, P1628, DOI 10.1101/gad.17269211	67	85	93	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3887	3893		10.1038/onc.2013.346	http://dx.doi.org/10.1038/onc.2013.346			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	23955084				2022-12-28	WOS:000339394700001
J	Donley, C; McClelland, K; McKeen, HD; Nelson, L; Yakkundi, A; Jithesh, PV; Burrows, J; McClements, L; Valentine, A; Prise, KM; McCarthy, HO; Robson, T				Donley, C.; McClelland, K.; McKeen, H. D.; Nelson, L.; Yakkundi, A.; Jithesh, P. V.; Burrows, J.; McClements, L.; Valentine, A.; Prise, K. M.; McCarthy, H. O.; Robson, T.			Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen	ONCOGENE			English	Article						RBCK1; FKBPL; estrogen receptor; p21; tamoxifen	PROTEIN-KINASE-C; UBIQUITIN LIGASE COMPLEX; ESTROGEN-RECEPTOR-ALPHA; KAPPA-B ACTIVATION; BREAST-CANCER; CELL-PROLIFERATION; BINDING-PROTEIN; DEGRADATION; GENE; TRANSCRIPTION	FKBPL has been implicated in processes associated with cancer, including regulation of tumor growth and angiogenesis with high levels of FKBPL prognosticating for improved patient survival. Understanding how FKBPL levels are controlled within the cell is therefore critical. We have identified a novel role for RBCK1 as an FKBPL-interacting protein, which regulates FKBPL stability at the post-translational level via ubiquitination. Both RBCK1 and FKBPL are upregulated by 17-beta-estradiol and interact within heat shock protein 90 chaperone complexes, together with estrogen receptor-alpha (ER alpha). Furthermore, FKBPL and RBCK1 associate with ER alpha at the promoter of the estrogen responsive gene, pS2, and regulate pS2 levels. MCF-7 clones stably overexpressing RBCK1 were shown to have reduced proliferation and increased levels of FKBPL and p21. Furthermore, these clones were resistant to tamoxifen therapy, suggesting that RBCK1 could be a predictive marker of response to endocrine therapy. RBCK1 knockdown using targeted small interfering RNA resulted in increased proliferation and increased sensitivity to tamoxifen treatment. Moreover, in support of our in vitro data, analysis of mRNA microarray data sets demonstrated that high levels of FKBPL and RBCK1 correlated with increased patient survival, whereas high RBCK1 predicted for a poor response to tamoxifen. Our findings support a role for RBCK1 in the regulation of FKBPL with important implications for estrogen receptor signaling, cell proliferation and response to endocrine therapy.	[Donley, C.; McClelland, K.; McKeen, H. D.; Nelson, L.; Yakkundi, A.; Burrows, J.; McClements, L.; Valentine, A.; McCarthy, H. O.; Robson, T.] Queens Univ Belfast, Sch Pharm, McClay Res Ctr, Belfast BT9 7BL, Antrim, North Ireland; [Jithesh, P. V.] Univ Liverpool, Liverpool Canc Res UK Ctr, Liverpool L69 3BX, Merseyside, England; [Prise, K. M.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland	Queens University Belfast; University of Liverpool; Queens University Belfast	Robson, T (corresponding author), Queens Univ Belfast, Sch Pharm, McClay Res Ctr, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	t.robson@qub.ac.uk	Jithesh, Puthen Veettil/O-6262-2019; McClements, Lana/S-9458-2019; Prise, Kevin/N-7872-2015	Jithesh, Puthen Veettil/0000-0001-7747-0930; McClements, Lana/0000-0002-4911-1014; Prise, Kevin/0000-0001-6134-7946; Cochrane, Keeva/0000-0001-7961-0474; McCarthy, Helen/0000-0002-1254-3745; Robson, Tracy/0000-0003-4262-6872	Department of Employment and Learning, Northern Ireland; Action Cancer, Northern Ireland; Breast Cancer Campaign, United Kingdom; Medical Research Council, United Kingdom; Biotechnology and Biological Sciences Research Council, United Kingdom; Biotechnology and Biological Sciences Research Council [BB/I006958/1] Funding Source: researchfish; Medical Research Council [G1001473] Funding Source: researchfish; BBSRC [BB/I006958/1] Funding Source: UKRI; MRC [G1001473] Funding Source: UKRI	Department of Employment and Learning, Northern Ireland; Action Cancer, Northern Ireland; Breast Cancer Campaign, United Kingdom; Medical Research Council, United Kingdom(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council, United Kingdom(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The financial support for this work was provided by PhD studentships awarded to C Donley and K McClelland from Department of Employment and Learning, Northern Ireland and Action Cancer, Northern Ireland, respectively. HD McKeen was supported by grants from Breast Cancer Campaign, United Kingdom and then the Medical Research Council, United Kingdom and A Yakkundi was supported by a grant from the Biotechnology and Biological Sciences Research Council, United Kingdom. All grants were awarded to T Robson.	Bublik DR, 2010, J BIOL CHEM, V285, P5274, DOI 10.1074/jbc.M109.045948; Buffa FM, 2011, CANCER RES, V71, P5635, DOI 10.1158/0008-5472.CAN-11-0489; Burrows JF, 2009, J BIOL CHEM, V284, P9587, DOI 10.1074/jbc.M807216200; Cong YS, 1997, J BIOL CHEM, V272, P16482, DOI 10.1074/jbc.272.26.16482; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Galigniana MD, 2010, MOL CELL BIOL, V30, P1285, DOI 10.1128/MCB.01190-09; Gustafsson N, 2010, CANCER RES, V70, P1265, DOI 10.1158/0008-5472.CAN-09-2674; Gustafsson-Sheppard NN, 2012, J MOL ENDOCRINOL, V49, P277; Haas TL, 2009, MOL CELL, V36, P831, DOI 10.1016/j.molcel.2009.10.013; Hosey AM, 2007, J NATL CANCER I, V99, P1683, DOI 10.1093/jnci/djm207; Inn KS, 2011, MOL CELL, V41, P354, DOI 10.1016/j.molcel.2010.12.029; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; Kirisako T, 2006, EMBO J, V25, P4877, DOI 10.1038/sj.emboj.7601360; Landgraf K, 2010, MOL CELL BIOL, V30, P5764, DOI 10.1128/MCB.01645-09; Li Yue-Ying, 2007, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V15, P733; McKeen HD, 2008, ENDOCRINOLOGY, V149, P5724, DOI 10.1210/en.2008-0168; McKeen HD, 2011, BIOCHEM SOC T, V39, P663, DOI 10.1042/BST0390663; McKeen HD, 2010, CANCER RES, V70, P1090, DOI 10.1158/0008-5472.CAN-09-2515; Mullenders J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004798; Nakamura M, 2006, BIOCHEM BIOPH RES CO, V351, P340, DOI 10.1016/j.bbrc.2006.09.163; Ni L, 2010, MOL CELL BIOL, V30, P1243, DOI 10.1128/MCB.01891-08; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; Robson T, 1999, RADIAT RES, V152, P451, DOI 10.2307/3580140; Sinars CR, 2003, P NATL ACAD SCI USA, V100, P868, DOI 10.1073/pnas.0231020100; Sunnotel O, 2010, REPROD BIOL ENDOCRIN, V8, DOI 10.1186/1477-7827-8-22; Tian Y, 2007, J BIOL CHEM, V282, P16776, DOI 10.1074/jbc.M701913200; Tokunaga C, 1998, BIOCHEM BIOPH RES CO, V244, P353, DOI 10.1006/bbrc.1998.8270; Tokunaga F, 2009, NAT CELL BIOL, V11, P123, DOI 10.1038/ncb1821; Valentine A, 2011, CLIN CANCER RES, V17, P1044, DOI 10.1158/1078-0432.CCR-10-2241; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Yamanaka K, 2003, NAT CELL BIOL, V5, P336, DOI 10.1038/ncb952; Yao YL, 2011, CURR OPIN PHARMACOL, V11, P301, DOI 10.1016/j.coph.2011.03.005; Zenke-Kawasaki Y, 2007, MOL CELL BIOL, V27, P6962, DOI 10.1128/MCB.02415-06; Zhang M, 2008, CELL RES, V18, P1096, DOI 10.1038/cr.2008.277; Zhang Y, 2009, BREAST CANCER RES TR, V116, P303, DOI 10.1007/s10549-008-0183-2	36	19	21	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3441	3450		10.1038/onc.2013.306	http://dx.doi.org/10.1038/onc.2013.306			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23912458				2022-12-28	WOS:000338779300011
J	Im, YK; La Selva, R; Gandin, V; Ha, JR; Sabourin, V; Sonenberg, N; Pawson, T; Topisirovic, I; Ursini-Siegel, J				Im, Y. K.; La Selva, R.; Gandin, V.; Ha, J. R.; Sabourin, V.; Sonenberg, N.; Pawson, T.; Topisirovic, I.; Ursini-Siegel, J.			The ShcA adaptor activates AKT signaling to potentiate breast tumor angiogenesis by stimulating VEGF mRNA translation in a 4E-BP-dependent manner	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CANCER CELLS; PROTEIN-SYNTHESIS; MAMMALIAN TARGET; FACTOR EIF-4E; INITIATION; EXPRESSION; RECEPTOR; DISTINCT; MTOR	The ShcA adaptor protein is engaged by numerous receptor tyrosine kinases (RTKs) in breast cancer cells. Once activated, RTKs phosphorylate three key tyrosine phosphorylation sites (Y239, Y240 and Y317) within ShcA that creates a docking site for Grb2/SOS and Grb2/Gab-containing complexes to activate the MAPK and AKT signaling pathways, respectively. We previously demonstrated that a tyrosine to phenylalanine substitution of the ShcA tyrosine phosphorylation sites (Shc3F-Y239/240/313F) significantly impairs breast tumor growth and angiogenesis in transgenic mouse models, in part, through the regulation of vascular endothelial growth factor (VEGF) production. Despite this fact, the underlying molecular mechanisms by which ShcA transduces pro-tumorigenic signals in breast cancer cells remain poorly defined. In this study, we demonstrate that ShcA-dependent activation of AKT, but not the RAS/MAPK pathway, induces VEGF production by bolstering VEGF mRNA translation. Accordingly, ShcA drives breast tumor growth and angiogenesis in vivo in a 4E-BP-dependent manner. These findings establish ShcA as a biological bridge that links AKT activation downstream of RTKs to cap-dependent VEGF mRNA translation in order to promote mammary tumorigenesis.	[Im, Y. K.; La Selva, R.; Gandin, V.; Ha, J. R.; Sabourin, V.; Topisirovic, I.; Ursini-Siegel, J.] McGill Univ, Lady Davis Inst Med Res, Dept Oncol, Montreal, PQ H3T 1E2, Canada; [Sonenberg, N.] Goodman Canc Res Ctr, Montreal, PQ, Canada; [Pawson, T.] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Lady Davis Institute; McGill University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Ursini-Siegel, J (corresponding author), McGill Univ, Lady Davis Inst Med Res, Dept Oncol, 3999 Cote St Catherine Rd,Room F528-1, Montreal, PQ H3T 1E2, Canada.	giuseppina.ursini-siegel@mcgill.ca	Pawson, Tony J/E-4578-2013; Topisirovic, Ivan/A-9426-2008	Topisirovic, Ivan/0000-0002-5510-9762; Gandin, Valentina/0000-0003-2627-1303	Canadian Institutes of Health Research (CIHR) grant [MOP-111143]; TD/LDI; McGill Integrated Research Training Program; CIHR	Canadian Institutes of Health Research (CIHR) grant(Canadian Institutes of Health Research (CIHR)); TD/LDI; McGill Integrated Research Training Program; CIHR(Canadian Institutes of Health Research (CIHR))	We thank Dr Peter Siegel for critical reading of the manuscript and Dr Sonia del Rincon for the VEGF antibody. This work was supported by a Canadian Institutes of Health Research (CIHR) grant (MOP-111143) to JU-S. YKI is the recipient of a TD/LDI studentship. JRH is the recipient of a McGill Integrated Research Training Program studentship. JU-S and IT are recipients of a CIHR New Investigator Salary Support award.	Alain T, 2012, CANCER RES, V72, P6468, DOI 10.1158/0008-5472.CAN-12-2395; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Braunstein S, 2007, MOL CELL, V28, P501, DOI 10.1016/j.molcel.2007.10.019; Casanova ML, 2002, CANCER RES, V62, P3402; Christoffersson G, 2012, BLOOD, V120, P4653, DOI 10.1182/blood-2012-04-421040; Coleman LJ, 2009, BRIT J CANCER, V100, P1393, DOI 10.1038/sj.bjc.6605044; Dankort D, 2001, J BIOL CHEM, V276, P38921, DOI 10.1074/jbc.M106239200; Davol PA, 2003, CANCER RES, V63, P6772; Dowling RJO, 2010, BBA-PROTEINS PROTEOM, V1804, P433, DOI 10.1016/j.bbapap.2009.12.001; Flowers A, 2009, SURGERY, V146, P220, DOI 10.1016/j.surg.2009.05.010; Garcia-Garcia C, 2012, CLIN CANCER RES, V18, P2603, DOI 10.1158/1078-0432.CCR-11-2750; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hardy WR, 2007, SCIENCE, V317, P251, DOI 10.1126/science.1140114; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; Klos KS, 2006, CANCER RES, V66, P2028, DOI 10.1158/0008-5472.CAN-04-4559; Larsson O, 2012, P NATL ACAD SCI USA, V109, P8977, DOI 10.1073/pnas.1201689109; Li CH, 2011, CANCER BIOL THER, V12, P872, DOI 10.4161/cbt.12.10.17672; Liang YY, 2006, ENDOCR-RELAT CANCER, V13, P905, DOI 10.1677/erc.1.01221; Maity A, 2000, CANCER RES, V60, P5879; Miller TW, 2009, CLIN CANCER RES, V15, P7266, DOI 10.1158/1078-0432.CCR-09-1665; Nasr Z, 2013, ONCOGENE, V32, P861, DOI 10.1038/onc.2012.105; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Petroulakis E, 2009, CANCER CELL, V16, P439, DOI 10.1016/j.ccr.2009.09.025; Pettersson F, 2011, CLIN CANCER RES, V17, P2874, DOI 10.1158/1078-0432.CCR-10-2334; Rojo F, 2007, CLIN CANCER RES, V13, P81, DOI 10.1158/1078-0432.CCR-06-1560; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; SALCINI AE, 1994, ONCOGENE, V9, P2827; Salnikov AV, 2006, INT J CANCER, V119, P2795, DOI 10.1002/ijc.22217; Shama Silvian, 1995, Gene Expression, V4, P241; Tcherkezian JCM, 2014, GENES DEV, V28; Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; Ursini-Siegel J, 2007, MOL CELL BIOL, V27, P6361, DOI 10.1128/MCB.00686-07; Ursini-Siegel J, 2010, CANCER RES, V70, P7776, DOI 10.1158/0008-5472.CAN-10-2229; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; WARNER JR, 1963, P NATL ACAD SCI USA, V49, P122, DOI 10.1073/pnas.49.1.122; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Xiong SB, 2001, CANCER RES, V61, P1727; Yanagiya A, 2012, MOL CELL, V46, P847, DOI 10.1016/j.molcel.2012.04.004; Zindy P, 2011, CANCER RES, V71, P4068, DOI 10.1158/0008-5472.CAN-11-0420; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	48	17	18	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1729	1735		10.1038/onc.2014.110	http://dx.doi.org/10.1038/onc.2014.110			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24837366				2022-12-28	WOS:000351848400013
J	Tsai, LH; Wu, JY; Cheng, YW; Chen, CY; Sheu, GT; Wu, TC; Lee, H				Tsai, L-H; Wu, J-Y; Cheng, Y-W; Chen, C-Y; Sheu, G-T; Wu, T-C; Lee, H.			The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss	ONCOGENE			English	Article							BET BROMODOMAIN INHIBITION; ZINC-FINGER GENE; C-MYC; CANCER PROGRESSION; PREDICTS SURVIVAL; TUMOR-SUPPRESSOR; MUTATIONS; METASTASIS; EXPRESSION; TRANSCRIPTION	Liver kinase B1 (LKB1) loss in lung adenocarcinoma is commonly caused by genetic mutations, but these mutations rarely occur in Asian patients. We recently reported wild-type LKB1 loss via the alteration of NKX2-1/p53-axis-promoted tumor aggressiveness and predicted poor outcomes in cases of lung adenocarcinoma. The mechanistic action of wild-type LKB1 loss within tumor progression remains unknown. The suppression of MYC by LKB1 controls epithelial organization; therefore, we hypothesize that MYC expression can be increased via wild-type LKB1 loss and promotes tumor progression. Here, MYC transcription is upregulated by LKB1-loss-mediated MZF1 expression. The wild-type LKB1-loss-mediated MZF1/MYC axis is responsible for soft-agar growth, migration and invasion in lung adenocarcinoma cells. Moreover, wild-type LKB1 loss-induced cell invasiveness was markedly suppressed by MYC inhibitors (10058-F4 and JQ1). Patients with low-LKB1/high-MZF1 or low-LKB1/high-MYC tumors have shorter overall survival and relapse-free-survival periods than patients with high-LKB1/low-MZF1 or high-LKB1/low-MYC tumors. In summary, MZF1-mediated MYC expression may promote tumor progression, resulting in poor outcomes in cases of lung adenocarcinoma with low-wild-type-LKB1 tumors.	[Tsai, L-H; Sheu, G-T] Chung Shan Med Univ, Inst Med, Taichung 40201, Taiwan; [Wu, J-Y] Tzu Chi Univ, Buddhist Tzu Chi Gen Hosp, Dept Surg, Taichung Branch, Hualien, Taiwan; [Wu, J-Y] Tzu Chi Univ, Coll Med, Hualien, Taiwan; [Cheng, Y-W; Lee, H.] Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, Taipei 115, Taiwan; [Chen, C-Y] China Med Univ Hosp, Dept Surg, Taichung, Taiwan; [Wu, T-C] Chung Shan Med Univ Hosp, Dept Internal Med, Taichung 40201, Taiwan	Chung Shan Medical University; Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital; Tzu Chi University; Tzu Chi University; Taipei Medical University; China Medical University Taiwan; China Medical University Hospital - Taiwan; Chung Shan Medical University; Chung Shan Medical University Hospital	Lee, H (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, Inst Canc Biol & Drug Discovery, Room 5,12th Floor F Bldg,Pk St, Taipei 115, Taiwan.	hl@tmu.edu.tw	Sheu, Gwo-Tarng/H-8855-2019	Sheu, Gwo-Tarng/0000-0002-1299-3375	National Science Council of Taiwan, ROC [NSC1-100-2314-B-038-043-MY3]	National Science Council of Taiwan, ROC(Ministry of Science and Technology, Taiwan)	This work was jointly supported by grants from the National Science Council (NSC1-100-2314-B-038-043-MY3) of Taiwan, ROC.	Bin Cho K, 2010, CANCER LETT, V293, P230, DOI 10.1016/j.canlet.2010.01.013; Cheng YW, 2007, CANCER RES, V67, P10686, DOI 10.1158/0008-5472.CAN-07-1461; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Feng Y, 2012, CANCER RES, V72, P6502, DOI 10.1158/0008-5472.CAN-12-1909; Fernandez P, 2004, ONCOGENE, V23, P5084, DOI 10.1038/sj.onc.1207665; Gao YJ, 2010, P NATL ACAD SCI USA, V107, P18892, DOI 10.1073/pnas.1004952107; Gong FR, 2011, NUCLEIC ACIDS RES, V39, P4640, DOI 10.1093/nar/gkr023; Gu Y, 2012, ONCOGENE, V31, P469, DOI 10.1038/onc.2011.247; HROMAS R, 1991, J BIOL CHEM, V266, P14183; HROMAS R, 1995, CANCER RES, V55, P3610; Huang MJ, 2006, EXP HEMATOL, V34, P1480, DOI 10.1016/j.exphem.2006.06.019; Ischenko I, 2013, P NATL ACAD SCI USA, V110, P3937, DOI 10.1073/pnas.1219592110; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kim MJ, 2010, CANCER GENET CYTOGEN, V196, P204, DOI 10.1016/j.cancergencyto.2009.09.020; Koivunen JP, 2008, BRIT J CANCER, V99, P245, DOI 10.1038/sj.bjc.6604469; Liu H, 2012, NAT CELL BIOL, V14, P567, DOI 10.1038/ncb2491; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Makowski L, 2008, BRIT J CANCER, V99, P683, DOI 10.1038/sj.bjc.6604515; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Miyaki M, 2000, CANCER RES, V60, P6311; Mudduluru G, 2010, MOL CANCER RES, V8, P159, DOI 10.1158/1541-7786.MCR-09-0326; Onozato R, 2007, CANCER SCI, V98, P1747, DOI 10.1111/j.1349-7006.2007.00585.x; Ossipova O, 2003, NAT CELL BIOL, V5, P889, DOI 10.1038/ncb1048; Partanen JI, 2007, P NATL ACAD SCI USA, V104, P14694, DOI 10.1073/pnas.0704677104; Partanen JI, 2012, P NATL ACAD SCI USA, V109, pE388, DOI 10.1073/pnas.1120421109; Payne SL, 2007, J CELL BIOCHEM, V101, P1338, DOI 10.1002/jcb.21371; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Scott KD, 2007, CANCER RES, V67, P5622, DOI 10.1158/0008-5472.CAN-07-0762; Shimamura T, 2013, CLIN CANCER RES, V19, P6183, DOI 10.1158/1078-0432.CCR-12-3904; Steger DJ, 2008, MOL CELL BIOL, V28, P2825, DOI 10.1128/MCB.02076-07; Sun YH, 2010, J CLIN ONCOL, V28, P4616, DOI 10.1200/JCO.2010.29.6038; Sung WW, 2011, CLIN CANCER RES, V17, P5991, DOI 10.1158/1078-0432.CCR-11-0227; Tsai LH, 2014, ONCOGENE, V33, P3851, DOI 10.1038/onc.2013.353; Wang HB, 2007, MOL CANCER THER, V6, P2399, DOI 10.1158/1535-7163.MCT-07-0005; Wolfer A, 2010, P NATL ACAD SCI USA, V107, P3698, DOI 10.1073/pnas.0914203107; Wu DW, 2011, CLIN CANCER RES, V17, P1895, DOI 10.1158/1078-0432.CCR-10-2316; Wu DW, 2010, CANCER RES, V70, P10392, DOI 10.1158/0008-5472.CAN-10-2341; Wu HH, 2010, ONCOGENE, V29, P4330, DOI 10.1038/onc.2010.178	39	49	49	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1641	1649		10.1038/onc.2014.118	http://dx.doi.org/10.1038/onc.2014.118			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24793789				2022-12-28	WOS:000351848400004
J	Bolt, MJ; Stossi, F; Callison, AM; Mancini, MG; Dandekar, R; Mancini, MA				Bolt, M. J.; Stossi, F.; Callison, A. M.; Mancini, M. G.; Dandekar, R.; Mancini, M. A.			Systems level-based RNAi screening by high content analysis identifies UBR5 as a regulator of estrogen receptor-alpha protein levels and activity	ONCOGENE			English	Article						estrogen receptor; UBR5; high content screening; high throughput microscopy; ubiquitin ligase	BREAST-CANCER; ER-ALPHA; GENE-EXPRESSION; CHROMATIN DYNAMICS; POLYMERASE-II; CELLS; TRANSCRIPTION; ACTIVATION; PROMOTER; DEGRADATION	Estrogen receptor-alpha (ER alpha) is a central transcription factor that regulates mammary gland physiology and a key driver in breast cancer. In the present study, we aimed to identify novel modulators of ER alpha-mediated transcriptional regulation via a custom-built siRNA library screen. This screen was directed against a variety of coregulators, transcription modifiers, signaling molecules and DNA damage response proteins. By utilizing a microscopy-based, multi-end point, estrogen responsive biosensor cell line platform, the primary screen identified a wide range of factors that altered ER alpha protein levels, chromatin remodeling and mRNA output. We then focused on UBR5, a ubiquitin ligase and known oncogene that modulates ER alpha protein levels and transcriptional output. Finally, we demonstrated that UBR5 also affects endogenous ER alpha target genes and E2-mediated cell proliferation in breast cancer cells. In conclusion, our multi-end point RNAi screen identified novel modulators of ER alpha levels and activity, and provided a robust systems level view of factors involved in mechanisms of nuclear receptor action and pathophysiology. Utilizing a high throughput RNAi screening approach we identified UBR5, a protein commonly amplified in breast cancer, as a novel regulator of ER alpha protein levels and transcriptional activity.	[Bolt, M. J.; Stossi, F.; Callison, A. M.; Mancini, M. G.; Dandekar, R.; Mancini, M. A.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Mancini, MA (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza,DeBakey Bldg,Room 132C, Houston, TX 77030 USA.	mancini@bcm.edu			NIEHS [7RC2ES018789]; Keck Foundation; Keck Center NLM Training Program in Biomedical Informatics of the Gulf Coast Consortia National Library of Medicine [T15LM007093]; Integrated Microscopy Core at Baylor College of Medicine; NIH [HD007495, DK56338, CA125123]; Dan L Duncan Cancer Center; John S Dunn Gulf Coast Consortium for Chemical Genomics; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD007495] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA125123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [RC2ES018789] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007093] Funding Source: NIH RePORTER	NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Keck Foundation(W.M. Keck Foundation); Keck Center NLM Training Program in Biomedical Informatics of the Gulf Coast Consortia National Library of Medicine; Integrated Microscopy Core at Baylor College of Medicine; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dan L Duncan Cancer Center; John S Dunn Gulf Coast Consortium for Chemical Genomics; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We gratefully acknowledge ZD Sharp for aid in the development of the PRL-HeLA cell line, FJ Ashcroft for creation of the GFP-ERa:PRL-HeLa cells, and I Mikic, TJ Moran and JY Newberg for help in developing the automated high-content analysis tools used in this study. We also acknowledge R Lanz and C Stephan for curation, handling and upkeep of the RNAi library. We acknowledge NIEHS funding from 7RC2ES018789 (MAM), the Keck Foundation pre-doctoral fellowship and imaging/automation resource support from the John S Dunn Gulf Coast for Chemical Genomics (PJ Davies and MAM), Dan L Duncan Baylor Cancer Center (K Osborne), Center for Reproductive Biology (FJ Demayo), Keck Center NLM Training Program in Biomedical Informatics of the Gulf Coast Consortia National Library of Medicine (T15LM007093 to MB), and the Diana Helis Henry Medical Research Foundation (MAM) through its direct engagement in the continuous active conduct of medical research in conjunction with Baylor College of Medicine and the Cancer Program. This project was supported by the Integrated Microscopy Core at Baylor College of Medicine with funding from the NIH (HD007495, DK56338 and CA125123), the Dan L Duncan Cancer Center, and the John S Dunn Gulf Coast Consortium for Chemical Genomics.	Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Ansari SA, 2013, CELL MOL LIFE SCI, V70, P2743, DOI 10.1007/s00018-013-1265-9; Ashcroft FJ, 2011, GENE, V477, P42, DOI 10.1016/j.gene.2011.01.009; Bernardo GM, 2010, DEVELOPMENT, V137, P2045, DOI 10.1242/dev.043299; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Berno V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002286; Bhatt S, 2012, MOL CELL BIOL, V32, P1928, DOI 10.1128/MCB.06561-11; Bolt MJ, 2013, NUCLEIC ACIDS RES, V41, P4036, DOI 10.1093/nar/gkt100; Bourdoncle A, 2005, J MOL BIOL, V347, P921, DOI 10.1016/j.jmb.2005.01.048; Burandt E, 2013, BREAST CANCER RES TR, V137, P745, DOI 10.1007/s10549-013-2406-4; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen YJ, 2008, ENDOCRINOLOGY, V149, P4658, DOI 10.1210/en.2008-0063; Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215; Clancy JL, 2003, ONCOGENE, V22, P5070, DOI 10.1038/sj.onc.1206775; Cojocaru M, 2011, J BIOL CHEM, V286, P5012, DOI 10.1074/jbc.M110.176628; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Dickson R B, 1988, Cancer Treat Res, V40, P119; Dong J, 2006, J BIOL CHEM, V281, P18825, DOI 10.1074/jbc.M512826200; DUBIK D, 1992, ONCOGENE, V7, P1587; Ellison-Zelski SJ, 2009, MOL CELL BIOL, V29, P4949, DOI 10.1128/MCB.00383-09; Esslimani-Sahla M, 2004, CLIN CANCER RES, V10, P5769, DOI 10.1158/1078-0432.CCR-04-0389; Fan MY, 2005, MOL ENDOCRINOL, V19, P2901, DOI 10.1210/me.2005-0111; Fox EM, 2011, CANCER RES, V71, P6773, DOI 10.1158/0008-5472.CAN-11-1295; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Garcia-Becerra R, 2010, GENE, V458, P37, DOI 10.1016/j.gene.2010.03.007; Giamas G, 2011, NAT MED, V17, P715, DOI 10.1038/nm.2351; Gonzalez-Arenas A, 2012, BBA-MOL CELL RES, V1823, P379, DOI 10.1016/j.bbamcr.2011.11.004; Gudjonsson T, 2012, CELL, V150, P697, DOI 10.1016/j.cell.2012.06.039; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Gururaj AE, 2007, MOL ENDOCRINOL, V21, P1847, DOI 10.1210/me.2006-0514; Henderson MJ, 2002, J BIOL CHEM, V277, P26468, DOI 10.1074/jbc.M203527200; Hirose Y, 2007, J BIOCHEM, V141, P601, DOI 10.1093/jb/mvm090; Horner-Glister E, 2005, J MOL ENDOCRINOL, V35, P421, DOI 10.1677/jme.1.01784; JACQUEMIER JD, 1990, BREAST CANCER RES TR, V15, P109, DOI 10.1007/BF01810783; Jiang WQ, 2011, MOL CELL, V43, P33, DOI 10.1016/j.molcel.2011.04.028; Karmakar S, 2009, ENDOCRINOLOGY, V150, P1588, DOI 10.1210/en.2008-1001; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; La Rosa P, 2011, CELL SIGNAL, V23, P1128, DOI 10.1016/j.cellsig.2011.02.006; Lai F, 2013, NATURE, V494, P497, DOI 10.1038/nature11884; Li XF, 2013, CYTOKINE, V61, P876, DOI 10.1016/j.cyto.2012.12.017; Long XH, 2006, J BIOL CHEM, V281, P9607, DOI 10.1074/jbc.M510809200; Mendes-Pereira AM, 2012, P NATL ACAD SCI USA, V109, P2730, DOI 10.1073/pnas.1018872108; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Mook ORF, 2009, CANCER GENE THER, V16, P532, DOI 10.1038/cgt.2008.104; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Rudnik V, 2008, J CELL BIOCHEM, V103, P896, DOI 10.1002/jcb.21459; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Schaufele F, 1999, MOL ENDOCRINOL, V13, P935, DOI 10.1210/me.13.6.935; Sharp ZD, 2006, J CELL SCI, V119, P4101, DOI 10.1242/jcs.03161; Smits VAJ, 2012, CELL CYCLE, V11, P715, DOI 10.4161/cc.11.4.19154; Snow BE, 2003, CURR BIOL, V13, P698, DOI 10.1016/S0960-9822(03)00210-0; Stanlie A, 2012, PLOS GENET, V8; Stokes K, 2004, J MOL ENDOCRINOL, V33, P315, DOI 10.1677/jme.1.01456; Sun J, 2012, MOL ENDOCRINOL, V26, P1567, DOI 10.1210/me.2012-1140; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Toth-Petroczy A, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000243; Willis IM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000112; Wu Q, 2004, J BIOL CHEM, V279, P53602, DOI 10.1074/jbc.M409778200; Zhang XT, 2005, MOL CELL, V19, P89, DOI 10.1016/j.molcel.2005.05.015; Zwart W, 2010, J CELL SCI, V123, P1253, DOI 10.1242/jcs.061135	61	19	21	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					154	164		10.1038/onc.2013.550	http://dx.doi.org/10.1038/onc.2013.550			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24441042	Green Accepted			2022-12-28	WOS:000347790500003
J	Haricharan, S; Hein, SM; Dong, J; Toneff, MJ; Aina, OH; Rao, PH; Cardiff, RD; Li, Y				Haricharan, S.; Hein, S. M.; Dong, J.; Toneff, M. J.; Aina, O. H.; Rao, P. H.; Cardiff, R. D.; Li, Y.			Contribution of an alveolar cell of origin to the high-grade malignant phenotype of pregnancy-associated breast cancer	ONCOGENE			English	Article						pregnancy; breast cancer; alveolar cells; PABC	MAMMARY-GLAND DEVELOPMENT; CARCINOMA IN-SITU; PROGENITOR CELLS; STEM-CELLS; COLLAGEN; TARGETS; ADULT; WOMEN; ERBB2; YOUNG	Pregnancy-associated breast cancers (PABCs) are tumors diagnosed during pregnancy or up to 5 years following parturition, and are usually high-grade, connective tissue-rich, and estrogen receptor (ER)/progesterone receptor-negative. Little is known about the cellular origin of PABCs or the mechanisms by which PABCs are initiated. Using the RCAS retrovirus to deliver the ErbB2 oncogene into the mammary epithelium of our previously reported MMTV-tva transgenic mice, we detected high-grade, poorly differentiated, stroma-rich and ER-negative tumors during pregnancy and lactation. These high-grade and stroma-rich tumors were less frequent in involuted mice or in age-matched nulliparous mice. More importantly, by generating a WAP-tva transgenic line for expression of ErbB2 selectively in WAP(+) mammary alveolar cells, we found that tumors had similar morphological phenotypes (high grade, poorly differentiated, stroma-rich and ER-negative), irrespective of the time since pregnancy and even in the absence of pregnancy. These data suggest that PABCs arise preferentially from an alveolar cell population that expands during pregnancy and lactation. This somatic mouse model may also be useful for preclinical testing of new prophylactic and therapeutic strategies against PABC.	[Haricharan, S.; Hein, S. M.; Dong, J.; Toneff, M. J.; Li, Y.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Haricharan, S.; Hein, S. M.; Dong, J.; Toneff, M. J.; Li, Y.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Aina, O. H.; Cardiff, R. D.] Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; [Rao, P. H.] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; University of California System; University of California Davis; Baylor College of Medicine	Li, Y (corresponding author), Baylor Coll Med, Lester & Sue Smith Breast Ctr, One Baylor Plaza,N1220, Houston, TX 77030 USA.	liyi@bcm.edu	Li, Yi/A-7635-2009	Li, Yi/0000-0002-9976-518X	NIH [CA124820, U54CA149196]; CDMRP [BC085050, BC073703]; NCI [U01 CA141582]; Nancy Owens Memorial Foundation; Dan L. Duncan Cancer Center [P30CA125123]; Sue & Lester Breast Center [P50-CA058183]; NATIONAL CANCER INSTITUTE [P50CA058183, R01CA124820, U54CA149196, U01CA141582, P30CA125123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K12GM084897] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CDMRP(United States Department of Defense); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Nancy Owens Memorial Foundation; Dan L. Duncan Cancer Center; Sue & Lester Breast Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge the Varmus Laboratory for the resources in the generation and initial characterization of WAP-tva mice. This work was supported in part by funds from NIH CA124820 (to YL) and U54CA149196 (to YL; PI: Stephan Wong); from CDMRP BC085050 (to YL) and BC073703 (to YL); NCI U01 CA141582 (to RDC); and from the Nancy Owens Memorial Foundation (to YL); as well as by the resources from the Dan L. Duncan Cancer Center (P30CA125123) and the Sue & Lester Breast Center (P50-CA058183).	BARTOW SA, 1987, CANCER, V60, P2751, DOI 10.1002/1097-0142(19871201)60:11<2751::AID-CNCR2820601127>3.0.CO;2-M; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Brisken C, 2002, J MAMMARY GLAND BIOL, V7, P39, DOI 10.1023/A:1015718406329; Bu W, 2011, ONCOGENE, V30, P4399, DOI 10.1038/onc.2011.147; Bu W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078720; Bu W, 2009, J MAMMARY GLAND BIOL, V14, P401, DOI 10.1007/s10911-009-9154-4; CAMPBELL SM, 1984, NUCLEIC ACIDS RES, V12, P8685, DOI 10.1093/nar/12.22.8685; Cruz GI, 2013, BREAST CANCER RES TR, V137, P237, DOI 10.1007/s10549-012-2313-0; Du ZJ, 2006, P NATL ACAD SCI USA, V103, P17396, DOI 10.1073/pnas.0608607103; Fornetti J, 2012, CELL CYCLE, V11, P639, DOI 10.4161/cc.11.4.19358; Foulkes WD, 2004, CLIN CANCER RES, V10, P2029, DOI 10.1158/1078-0432.CCR-03-1061; Genin AS, 2012, BREAST, V21, P550, DOI 10.1016/j.breast.2012.05.002; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Keller PJ, 2012, P NATL ACAD SCI USA, V109, P2772, DOI 10.1073/pnas.1017626108; Khaled WT, 2007, DEVELOPMENT, V134, P2739, DOI 10.1242/dev.003194; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Lyons TR, 2011, NAT MED, V17, P1109, DOI 10.1038/nm.2416; Lyons TR, 2009, J MAMMARY GLAND BIOL, V14, P87, DOI 10.1007/s10911-009-9119-7; MACMAHON B, 1970, B WORLD HEALTH ORGAN, V43, P209; Mathelin C, 2008, ANTICANCER RES, V28, P2447; Medina D, 2004, CLIN CANCER RES, V10, p380S, DOI 10.1158/1078-0432.CCR-031211; Middleton LP, 2003, CANCER, V98, P1055, DOI 10.1002/cncr.11614; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Murphy CG, 2012, CANCER-AM CANCER SOC, V118, P3254, DOI 10.1002/cncr.26654; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; O'Brien J, 2011, INT J DEV BIOL, V55, P745, DOI 10.1387/ijdb.113379jo; O'Brien J, 2010, AM J PATHOL, V176, P1241, DOI 10.2353/ajpath.2010.090735; Pilewskie M, 2012, ANN SURG ONCOL, V19, P1167, DOI 10.1245/s10434-011-2104-6; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Reddy JP, 2009, J MAMMARY GLAND BIOL, V14, P405, DOI 10.1007/s10911-009-9157-1; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Schedin P, 2006, NAT REV CANCER, V6, P281, DOI 10.1038/nrc1839; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Smith GH, 2003, CELL PROLIFERAT, V36, P3, DOI 10.1046/j.1365-2184.36.s.1.2.x; Stensheim H, 2009, J CLIN ONCOL, V27, P45, DOI 10.1200/JCO.2008.17.4110; Toneff MJ, 2010, NEOPLASIA, V12, P718, DOI 10.1593/neo.10516; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Watson CJ, 2008, DEVELOPMENT, V135, P995, DOI 10.1242/dev.005439; Welch HG, 1997, ANN INTERN MED, V127, P1023, DOI 10.7326/0003-4819-127-11-199712010-00014; Yamaji D, 2009, GENE DEV, V23, P2382, DOI 10.1101/gad.1840109	42	10	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2014	33	50					5729	5739		10.1038/onc.2013.521	http://dx.doi.org/10.1038/onc.2013.521			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW2AB	24317513	Green Accepted, Green Submitted			2022-12-28	WOS:000346089300008
J	Leanza, L; Zoratti, M; Gulbins, E; Szabo, I				Leanza, L.; Zoratti, M.; Gulbins, E.; Szabo, I.			Mitochondrial ion channels as oncological targets	ONCOGENE			English	Review						mitochondria; ion channels; direct targeting; pharmacology	PERMEABILITY TRANSITION PORE; DEPENDENT ANION CHANNEL; POTASSIUM CHANNEL; CELL-DEATH; CANCER-CELLS; CALCIUM UNIPORTER; INDUCED APOPTOSIS; OXIDATIVE STRESS; INNER MEMBRANE; MUTATIONAL INACTIVATION	Mitochondria, the key bioenergetic intracellular organelles, harbor a number of proteins with proven or hypothetical ion channel functions. Growing evidence points to the important contribution of these channels to the regulation of mitochondrial function, such as ion homeostasis imbalances profoundly affecting energy transducing processes, reactive oxygen species production and mitochondrial integrity. Given the central role of mitochondria in apoptosis, their ion channels with the potential to compromise mitochondrial function have become promising targets for the treatment of malignancies. Importantly, in vivo evidence demonstrates the involvement of the proton-transporting uncoupling protein, a mitochondrial potassium channel, the outer membrane located porin and the permeability transition pore in tumor progression/control. In this review, we focus on mitochondrial channels that have been assigned a definite role in cell death regulation and possess clear oncological relevance. Overall, based on in vivo and in vitro genetic and pharmacological evidence, mitochondrial ion channels are emerging as promising targets for cancer treatment.	[Leanza, L.; Szabo, I.] Univ Padua, Dept Biol, I-35138 Padua, PD, Italy; [Zoratti, M.] Univ Padua, CNR, Inst Neurosci, I-35138 Padua, PD, Italy; [Zoratti, M.] Univ Padua, Dept Biomed Sci, I-35138 Padua, PD, Italy; [Gulbins, E.] Univ Duisburg Essen, Dept Mol Biol, Essen, Germany	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; University of Duisburg Essen	Szabo, I (corresponding author), Univ Padua, Dept Biol, Viale G Colombo 3, I-35138 Padua, PD, Italy.	ildi@civ.bio.unipd.it; ildiko.szabo@unipd.it	Szabo, Ildiko/AAW-5972-2021; Leanza, Luigi/K-3060-2016; Padova, Ildiko/K-5344-2016; Gulbins, Erich/L-6989-2014	Szabo, Ildiko/0000-0002-3637-3947; Leanza, Luigi/0000-0002-5919-7114; Gulbins, Erich/0000-0002-3117-1342	Italian Association for Cancer Research (AIRC) [11814]; EMBO Young Investigator Program grant; Progetti di Rilevante Interesse Nazionale (PRIN) program [2010CSJX4F, 20107Z8XBW_004]; Fondazione Cassa di Risparmio di Padova e Rovigo; CNR Project of Special Interest on Aging; DFG [Gu 335/13-3]; International Association for Cancer Research; Progetto Giovani Studiosi	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); EMBO Young Investigator Program grant; Progetti di Rilevante Interesse Nazionale (PRIN) program(Ministry of Education, Universities and Research (MIUR)); Fondazione Cassa di Risparmio di Padova e Rovigo(Fondazione Cariparo); CNR Project of Special Interest on Aging(Consiglio Nazionale delle Ricerche (CNR)); DFG(German Research Foundation (DFG)); International Association for Cancer Research; Progetto Giovani Studiosi	We are grateful to all co-authors for their important contributions to the work carried out in their laboratories and reported in this review. We apologize for not citing all publications that have been published on this topic. The work carried out in the authors' laboratories was supported in part by grants from the Italian Association for Cancer Research (AIRC; Grant 11814 to IS), the EMBO Young Investigator Program grant (to IS), the Progetti di Rilevante Interesse Nazionale (PRIN) program (2010CSJX4F to IS and 20107Z8XBW_004 to MZ), the Fondazione Cassa di Risparmio di Padova e Rovigo (to MZ), the CNR Project of Special Interest on Aging (to MZ), the DFG Grant Gu 335/13-3 (to EG), the International Association for Cancer Research (to EG) and the Progetto Giovani Studiosi 2012 (to LL).	Anastasiou D, 2011, SCIENCE, V334, P1278, DOI 10.1126/science.1211485; Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; Aon MA, 2010, BBA-BIOENERGETICS, V1797, P71, DOI 10.1016/j.bbabio.2009.08.002; Arbel N, 2012, J BIOL CHEM, V287, P23152, DOI 10.1074/jbc.M112.345918; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Arvizo RR, 2013, J BIOL CHEM, V288, P17610, DOI 10.1074/jbc.M112.435206; Ayyasamy V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024792; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; Baffy G, 2011, BRIT J CANCER, V105, P469, DOI 10.1038/bjc.2011.245; Baffy G, 2010, MITOCHONDRION, V10, P243, DOI 10.1016/j.mito.2009.12.143; Baines CP, 2007, NAT CELL BIOL, V9, P550, DOI 10.1038/ncb1575; Baughman JM, 2011, NATURE, V476, P341, DOI 10.1038/nature10234; Bednarczyk P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068125; Bender T, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011106; Bernardi P, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00095; Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615; Biasutto L, 2011, ANTIOXID REDOX SIGN, V15, P3039, DOI 10.1089/ars.2011.4021; Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Brenner C, 2012, CIRC RES, V111, P1237, DOI 10.1161/CIRCRESAHA.112.265942; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cannon B, 2006, BBA-BIOENERGETICS, V1757, P449, DOI 10.1016/j.bbabio.2006.05.016; Cardaci S, 2012, J BIOENERG BIOMEMBR, V44, P17, DOI 10.1007/s10863-012-9422-7; Cavalieri E, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-45; Cavalieri E, 2009, FEBS J, V276, P3990, DOI 10.1111/j.1742-4658.2009.07108.x; Chaudhuri D, 2013, ELIFE, V2, DOI 10.7554/eLife.00704; Chiara F, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.184; Chiara F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001852; Chiara F, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00016; Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022; Cogliati S, 2013, CELL, V155, P160, DOI 10.1016/j.cell.2013.08.032; CROMPTON M, 1988, BIOCHEM J, V255, P357; Curry MC, 2013, BIOCHEM BIOPH RES CO, V434, P695, DOI 10.1016/j.bbrc.2013.04.015; Davies NJ, 2009, CANCER RES, V69, P4769, DOI 10.1158/0008-5472.CAN-08-4533; Davis FM, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-76; De Marchi U, 2009, CELL CALCIUM, V45, P509, DOI 10.1016/j.ceca.2009.03.014; De Stefani D, 2011, NATURE, V476, P336, DOI 10.1038/nature10230; Debska-Vielhaber G, 2009, J PHYSIOL PHARMACOL, V60, P27; Dejean LM, 2010, BBA-BIOENERGETICS, V1797, P1231, DOI 10.1016/j.bbabio.2010.01.007; Demin OV, 1998, MOL CELL BIOCHEM, V184, P21, DOI 10.1023/A:1006849920918; Denton RM, 2009, BBA-BIOENERGETICS, V1787, P1309, DOI 10.1016/j.bbabio.2009.01.005; Derdak Z, 2008, CANCER RES, V68, P2813, DOI 10.1158/0008-5472.CAN-08-0053; Dolga AM, 2013, J BIOL CHEM, V288, P10792, DOI 10.1074/jbc.M113.453522; Dong JX, 2013, J MEMBRANE BIOL, V246, P375, DOI 10.1007/s00232-013-9543-x; Drago I, 2011, EMBO J, V30, P4119, DOI 10.1038/emboj.2011.337; el Dein OS, 2012, BIOCHEM PHARMACOL, V83, P1172, DOI 10.1016/j.bcp.2012.01.017; Elliott MA, 2012, INT J PHARMACEUT, V426, P67, DOI 10.1016/j.ijpharm.2012.01.024; Fedorenko A, 2012, CELL, V151, P400, DOI 10.1016/j.cell.2012.09.010; Felipe A, 2012, CURR MED CHEM, V19, P661, DOI 10.2174/092986712798992048; Fiaschi Tania, 2012, Int J Cell Biol, V2012, P762825, DOI 10.1155/2012/762825; Fingrut O, 2002, LEUKEMIA, V16, P608, DOI 10.1038/sj.leu.2402419; Flescher E, 2005, ANTI-CANCER DRUG, V16, P911, DOI 10.1097/01.cad.0000176501.63680.80; Flescher E, 2007, CANCER LETT, V245, P1, DOI 10.1016/j.canlet.2006.03.001; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; Friese MA, 2007, NAT MED, V13, P1483, DOI 10.1038/nm1668; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Gall JM, 2011, KIDNEY INT, V79, P1207, DOI 10.1038/ki.2010.532; Galluzzi L, 2008, CELL CYCLE, V7, P1949, DOI 10.4161/cc.7.13.6222; Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145; Galluzzi L, 2012, NAT REV MOL CELL BIO, V13, P780, DOI 10.1038/nrm3479; GELB BD, 1992, P NATL ACAD SCI USA, V89, P202, DOI 10.1073/pnas.89.1.202; Ghibelli L, 2010, MITOCHONDRION, V10, P604, DOI 10.1016/j.mito.2010.08.003; Giorgio V, 2013, P NATL ACAD SCI USA, V110, P5887, DOI 10.1073/pnas.1217823110; Grills C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014635; Gulbins E, 2010, BBA-BIOENERGETICS, V1797, P1251, DOI 10.1016/j.bbabio.2010.01.018; Gunter TE, 2000, CELL CALCIUM, V28, P285, DOI 10.1054/ceca.2000.0168; Guo X P, 1991, Zhong Xi Yi Jie He Za Zhi, V11, P598; HALESTRAP AP, 1987, BIOCHEM J, V244, P159, DOI 10.1042/bj2440159; Han WD, 2007, MOL CANCER THER, V6, P1641, DOI 10.1158/1535-7163.MCT-06-0511; Hoang T, 2012, BIOCHEMISTRY-US, V51, P4004, DOI 10.1021/bi3003378; Horton KL, 2012, CHEMBIOCHEM, V13, P476, DOI 10.1002/cbic.201100415; Innamaa A, 2013, ANTICANCER RES, V33, P1401; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Javadov S, 2011, CELL PHYSIOL BIOCHEM, V27, P179, DOI 10.1159/000327943; Ji Q, 2003, PROSTATE, V54, P275, DOI 10.1002/pros.10192; Jones S, 2008, BBA-MOL CELL RES, V1783, P849, DOI 10.1016/j.bbamcr.2008.01.009; Kadenbach B, 2003, BBA-BIOENERGETICS, V1604, P77, DOI 10.1016/S0005-2728(03)00027-6; Kim JH, 2004, ONCOL REP, V12, P1233; Kinnally KW, 2011, BBA-MOL CELL RES, V1813, P616, DOI 10.1016/j.bbamcr.2010.09.013; Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246; Klippel S, 2012, BRIT J HAEMATOL, V159, P340, DOI 10.1111/j.1365-2141.2012.09253.x; Ko JH, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-106; Ko YH, 2012, J BIOENERG BIOMEMBR, V44, P163, DOI 10.1007/s10863-012-9417-4; Ko YH, 2004, BIOCHEM BIOPH RES CO, V324, P269, DOI 10.1016/j.bbrc.2004.09.047; Koren I, 2010, CANCER BIOL THER, V9, P1046, DOI 10.4161/cbt.9.12.11879; Kosztka L, 2011, MELANOMA RES, V21, P308, DOI 10.1097/CMR.0b013e3283462713; Kovacs I, 2005, VIRCHOWS ARCH, V446, P402, DOI 10.1007/s00428-005-1205-7; Kowaltowski AJ, 2009, FREE RADICAL BIO MED, V47, P333, DOI 10.1016/j.freeradbiomed.2009.05.004; Landes T, 2011, BBA-MOL CELL RES, V1813, P540, DOI 10.1016/j.bbamcr.2011.01.021; Lau E, 2012, CELL, V148, P543, DOI 10.1016/j.cell.2012.01.016; Leanza L, 2013, LEUKEMIA, V27, P1782, DOI 10.1038/leu.2013.56; Leanza L, 2012, CURR MED CHEM, V19, P5394, DOI 10.2174/092986712803833281; Leanza L, 2013, CURR PHARM DES; Leanza L, 2012, EMBO MOL MED, V4, P577, DOI 10.1002/emmm.201200235; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Lee GW, 2012, ACTA PHYSIOL, V204, P513, DOI 10.1111/j.1748-1716.2011.02359.x; Lei XB, 2006, FASEB J, V20, P2147, DOI 10.1096/fj.05-5665fje; Lemasters JJ, 2006, BBA-MOL BASIS DIS, V1762, P181, DOI 10.1016/j.bbadis.2005.10.006; Lena A, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-13; Li L, 2007, CANCER RES, V67, P4894, DOI 10.1158/0008-5472.CAN-06-3818; Liu JH, 2013, FREE RADICAL BIO MED, V63, P485, DOI 10.1016/j.freeradbiomed.2013.05.038; Maack C, 2006, CIRC RES, V99, P172, DOI 10.1161/01.RES.0000232546.92777.05; Mader A, 2010, BIOCHEM J, V429, P147, DOI 10.1042/BJ20091338; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Malinska D, 2010, FEBS LETT, V584, P2043, DOI 10.1016/j.febslet.2010.01.013; Mallilankaraman K, 2012, CELL, V151, P630, DOI 10.1016/j.cell.2012.10.011; Marchi S, 2013, CURR BIOL, V23, P58, DOI 10.1016/j.cub.2012.11.026; Martinez-Caballero S, 2009, J BIOL CHEM, V284, P12235, DOI 10.1074/jbc.M806610200; Matassa DS, 2012, AM J CANCER RES, V2, P235; McCommis KS, 2012, BBA-BIOMEMBRANES, V1818, P1444, DOI 10.1016/j.bbamem.2011.10.025; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Ni BY, 2012, CLIN CANCER RES, V18, P140, DOI 10.1158/1078-0432.CCR-10-3450; NICHOLS BJ, 1995, MOL CELL BIOCHEM, V149, P203, DOI 10.1007/BF01076578; Norman KG, 2010, MITOCHONDRION, V10, P94, DOI 10.1016/j.mito.2009.10.001; O-Uchi J, 2013, ANTIOXID REDOX SIGNA; Orr AL, 2012, J BIOL CHEM, V287, P42921, DOI 10.1074/jbc.M112.397828; Palmieri B, 2011, EUR REV MED PHARMACO, V15, P333; Pan X, 2013, NAT CELL BIOL, V15, P1464, DOI 10.1038/ncb2868; Panieri E, 2013, FREE RADICAL BIO MED, V57, P176, DOI 10.1016/j.freeradbiomed.2012.12.024; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P1, DOI 10.1007/s10863-007-9070-5; Pedersen PL, 2012, J BIOENERG BIOMEMBR, V44, P1, DOI 10.1007/s10863-012-9425-4; Pelicano H, 2003, J BIOL CHEM, V278, P37832, DOI 10.1074/jbc.M301546200; Peng TI, 2010, ANN NY ACAD SCI, V1201, P183, DOI 10.1111/j.1749-6632.2010.05634.x; Pereira CV, 2008, TOXICOL SCI, V105, P408, DOI 10.1093/toxsci/kfn131; Pereira GC, 2007, J PHARMACOL EXP THER, V323, P636, DOI 10.1124/jpet.107.128017; Perevoshchikova IV, 2010, FEBS LETT, V584, P2397, DOI 10.1016/j.febslet.2010.04.033; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Plovanich M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055785; Prezma T, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.316; Quast SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039290; Quinlan CL, 2013, REDOX BIOL, V1, P304, DOI 10.1016/j.redox.2013.04.005; Raffaello A, 2013, EMBO J, V32, P2362, DOI 10.1038/emboj.2013.157; Ralph SJ, 2011, PHARM RES-DORDR, V28, P2695, DOI 10.1007/s11095-011-0566-7; Ralph SJ, 2010, MOL ASPECTS MED, V31, P145, DOI 10.1016/j.mam.2010.02.008; Rasola A, 2011, CELL CALCIUM, V50, P222, DOI 10.1016/j.ceca.2011.04.007; Rasola A, 2010, FEBS LETT, V584, P1989, DOI 10.1016/j.febslet.2010.02.022; Rasola A, 2010, P NATL ACAD SCI USA, V107, P726, DOI 10.1073/pnas.0912742107; Raviv Z, 2013, CANCER CHEMOTH PHARM, V71, P275, DOI 10.1007/s00280-012-2039-z; Ren YZR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004009; Risso A, 2002, MOL CELL BIOL, V22, P1926, DOI 10.1128/MCB.22.6.1926-1935.2002; Rizzuto R, 2012, NAT REV MOL CELL BIO, V13, P566, DOI 10.1038/nrm3412; Rodrigues-Ferreira C, 2012, J BIOENERG BIOMEMBR, V44, P39, DOI 10.1007/s10863-012-9413-8; Rusznak Z, 2008, VIRCHOWS ARCH, V452, P415, DOI 10.1007/s00428-007-0545-x; Samudio I, 2008, CANCER RES, V68, P5198, DOI 10.1158/0008-5472.CAN-08-0555; Sancak Y, 2013, SCIENCE, V342, P1379, DOI 10.1126/science.1242993; Sanchez-Alvarez R, 2013, CELL CYCLE, V12, P172, DOI 10.4161/cc.23058; Sassi N, 2010, BBA-BIOENERGETICS, V1797, P1260, DOI 10.1016/j.bbabio.2009.12.015; Schonherr R, 2005, J MEMBRANE BIOL, V205, P175, DOI 10.1007/s00232-005-0782-3; Scorrano L, 2009, INT J BIOCHEM CELL B, V41, P1875, DOI 10.1016/j.biocel.2009.04.016; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Shoshan MC, 2012, J BIOENERG BIOMEMBR, V44, P7, DOI 10.1007/s10863-012-9419-2; Shoshan-Barmatz V, 2012, CURR MED CHEM, V19, P714, DOI 10.2174/092986712798992110; Shoshan-Barmatz V, 2010, MOL ASPECTS MED, V31, P227, DOI 10.1016/j.mam.2010.03.002; Shoshan-Barmatzt V, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00164; Simamura E, 2008, J BIOENERG BIOMEMBR, V40, P213, DOI 10.1007/s10863-008-9158-6; Singh H, 2012, J PHYSIOL-LONDON, V590, P5937, DOI 10.1113/jphysiol.2011.215533; Smith RAJ, 2012, TRENDS PHARMACOL SCI, V33, P341, DOI 10.1016/j.tips.2012.03.010; Smith RAJ, 2011, ANTIOXID REDOX SIGN, V15, P3021, DOI 10.1089/ars.2011.3969; Starkov AA, 2008, ANN NY ACAD SCI, V1147, P37, DOI 10.1196/annals.1427.015; Stowe DF, 2013, BBA-BIOMEMBRANES, V1828, P427, DOI 10.1016/j.bbamem.2012.08.031; Szabo I, 2005, J BIOL CHEM, V280, P12790, DOI 10.1074/jbc.M413548200; Szabo I, 2011, CELL DEATH DIFFER, V18, P427, DOI 10.1038/cdd.2010.112; SZABO I, 1991, J BIOL CHEM, V266, P3376; Szabo I, 2012, PFLUG ARCH EUR J PHY, V463, P231, DOI 10.1007/s00424-011-1058-7; Szabo I, 2008, P NATL ACAD SCI USA, V105, P14861, DOI [10.1073/pnas.0804236105, 10.1073/pnas.0804236T05]; Tajeddine N, 2008, ONCOGENE, V27, P4221, DOI 10.1038/onc.2008.63; Takeda K, 2008, ANNU REV PHARMACOL, V48, P199, DOI 10.1146/annurev.pharmtox.48.113006.094606; Tan WZ, 2012, BBA-BIOMEMBRANES, V1818, P1555, DOI 10.1016/j.bbamem.2011.12.032; Tang ZJ, 2012, J BIOENERG BIOMEMBR, V44, P117, DOI 10.1007/s10863-012-9420-9; Tikunov A, 2010, ARCH BIOCHEM BIOPHYS, V495, P174, DOI 10.1016/j.abb.2010.01.008; Toczylowska-Maminska R, 2014, J INVEST DERMATOL, V134, P764, DOI 10.1038/jid.2013.422; Tomasello F, 2009, CELL RES, V19, P1363, DOI 10.1038/cr.2009.98; Tong OS, 2008, ANTI-CANCER DRUG, V19, P573, DOI 10.1097/CAD.0b013e3282fc46b0; Traba J, 2012, CELL DEATH DIFFER, V19, P650, DOI 10.1038/cdd.2011.139; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; Venediktova N, 2013, MOL CELL BIOCHEM, V383, P261, DOI 10.1007/s11010-013-1774-8; Vihko P, 2005, J STEROID BIOCHEM, V93, P277, DOI 10.1016/j.jsbmb.2005.01.002; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Wang J, 2008, CANCER BIOL THER, V7, P1875, DOI 10.4161/cbt.7.12.7067; Wang YZ, 2013, CELL DEATH DIFFER, V20, P1359, DOI 10.1038/cdd.2013.90; Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470; Wrzosek A, 2012, EUR J PHARMACOL, V690, P60, DOI 10.1016/j.ejphar.2012.06.029; Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151; Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859; Zaid H, 2005, CELL DEATH DIFFER, V12, P751, DOI 10.1038/sj.cdd.4401599; Zoratti M, 2009, BBA-BIOENERGETICS, V1787, P351, DOI 10.1016/j.bbabio.2008.11.015	193	69	71	1	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2014	33	49					5569	5581		10.1038/onc.2013.578	http://dx.doi.org/10.1038/onc.2013.578			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZW	24469031				2022-12-28	WOS:000346088700001
J	Zhang, L; Xu, Z; Xu, X; Zhang, B; Wu, H; Wang, M; Zhang, X; Yang, T; Cai, J; Yan, Y; Mao, F; Zhu, W; Shao, Q; Qian, H; Xu, W				Zhang, L.; Xu, Z.; Xu, X.; Zhang, B.; Wu, H.; Wang, M.; Zhang, X.; Yang, T.; Cai, J.; Yan, Y.; Mao, F.; Zhu, W.; Shao, Q.; Qian, H.; Xu, W.			SALL4, a novel marker for human gastric carcinogenesis and metastasis	ONCOGENE			English	Article						SALL4; gastric cancer; metastasis; EMT; stemness	EPITHELIAL-MESENCHYMAL TRANSITION; CANCER STEM-CELLS; EARLY EMBRYONIC-DEVELOPMENT; ACUTE MYELOID-LEUKEMIA; PROSPECTIVE IDENTIFICATION; BREAST-CANCER; GENE; PLURIPOTENCY; EPIDEMIOLOGY; EXPRESSION	SALL4, a zinc-finger transcriptional factor for embryonic stem cell self-renewal and pluripotency, has been suggested to be involved in tumorigenesis. The role of SALL4 in human gastric cancer, however, remains largely unknown. In this study, we demonstrated that SALL4 was aberrantly expressed at both mRNA and protein levels in human gastric cancer tissues, and SALL4 level was highly correlated with lymph node metastasis. Enforced expression of SALL4 enhanced the proliferation and migration of human gastric cancer cells, whereas knockdown of SALL4 by siRNA led to the opposite effects. In addition, SALL4 overexpression promoted the growth and metastasis of gastric xenograft tumor in vivo. SALL4 overexpression induced epithelial-mesenchymal transition (EMT) in gastric cancer cells, with increased expression of Twist1, N-cadherin and decreased expression of E-cadherin. Moreover, SALL4 promoted the acquirement of stemness in gastric cancer cells through the induction of Bmi-1 and Lin28B. Taken together, our findings indicate that SALL4 has oncogenic roles in gastric cancer through the modulation of EMT and cell stemness, suggesting SALL4 as a novel target for human gastric cancer diagnosis and therapy.	[Zhang, L.; Xu, Z.; Xu, X.; Zhang, B.; Wang, M.; Zhang, X.; Yang, T.; Cai, J.; Yan, Y.; Mao, F.; Zhu, W.; Shao, Q.; Qian, H.; Xu, W.] Jiangsu Univ, Sch Med Sci & Lab Med, Zhenjiang 212013, Jiangsu, Peoples R China; [Wu, H.] First Peoples Hosp Lianyungang, Dept Cent Lab, Lianyungang, Peoples R China; [Xu, W.] Jiangsu Univ, Affiliated Hosp, Zhenjiang 212013, Jiangsu, Peoples R China	Jiangsu University; Jiangsu University	Xu, W (corresponding author), Jiangsu Univ, Sch Med Sci & Lab Med, 301 Xuefu Rd, Zhenjiang 212013, Jiangsu, Peoples R China.	lstmmmlst@163.com; icls@ujs.edu.cn	B, Zhang/R-4316-2019; Zhang, Bin/HCP-1386-2022	B, Zhang/0000-0002-2879-379X; Qian, Hui/0000-0002-0098-3196	Major Research Plan of the National Natural Science Foundation of China [91129718]; National Natural Science Foundation of China [81071421]; Natural Science Foundation of the Jiangsu Province [BK2012709]; Jiangsu Province's Project of Scientific and Technological Innovation and Achievements Transformation [BL2012055]; Jiangsu Province's Outstanding Medical Academic Leader and Sci-tech Innovation Team Program [LJ201117]; Jiangsu Province Doctoral Innovation Fund [CXLX12_0678]; Doctoral Program Foundation of State Education Ministry [20113227110011]	Major Research Plan of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of the Jiangsu Province(Natural Science Foundation of Jiangsu Province); Jiangsu Province's Project of Scientific and Technological Innovation and Achievements Transformation; Jiangsu Province's Outstanding Medical Academic Leader and Sci-tech Innovation Team Program; Jiangsu Province Doctoral Innovation Fund; Doctoral Program Foundation of State Education Ministry	This work was supported by the Major Research Plan of the National Natural Science Foundation of China (Grant no. 91129718), the National Natural Science Foundation of China (Grant no. 81071421), the Natural Science Foundation of the Jiangsu Province (Grant no. BK2012709), Jiangsu Province's Project of Scientific and Technological Innovation and Achievements Transformation (Grant no. BL2012055), Jiangsu Province's Outstanding Medical Academic Leader and Sci-tech Innovation Team Program (Grant no. LJ201117), Jiangsu Province Doctoral Innovation Fund (Grant no. CXLX12_0678) and Doctoral Program Foundation of State Education Ministry (Grant no. 20113227110011).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bard JD, 2009, FASEB J, V23, P1405, DOI 10.1096/fj.08-117721; Bjerkvig R, 2005, NAT REV CANCER, V5, P899, DOI 10.1038/nrc1740; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Brenner Hermann, 2009, V472, P467, DOI 10.1007/978-1-60327-492-0_23; Cao DF, 2009, CANCER-AM CANCER SOC, V115, P2640, DOI 10.1002/cncr.24308; Chen Z, 2009, J SURG ONCOL, V99, P414, DOI 10.1002/jso.21270; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Crew KD, 2006, WORLD J GASTROENTERO, V12, P354, DOI 10.3748/wjg.v12.i3.354; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Desai Anant M, 2004, Gastric Cancer, V7, P196, DOI 10.1007/s10120-004-0289-0; Elling U, 2006, P NATL ACAD SCI USA, V103, P16319, DOI 10.1073/pnas.0607884103; Giraud AS, 2012, EXPERT OPIN THER TAR, V16, P889, DOI 10.1517/14728222.2012.709238; Kanda N, 2004, ONCOGENE, V23, P4921, DOI 10.1038/sj.onc.1207606; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kobayashi D, 2011, INT J ONCOL, V38, P933, DOI 10.3892/ijo.2011.929; Kopper L, 2004, PATHOL ONCOL RES, V10, P69, DOI 10.1007/BF02893458; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lim CY, 2008, CELL STEM CELL, V3, P543, DOI 10.1016/j.stem.2008.08.004; Lin T, 2012, MED ONCOL, V29, P878, DOI 10.1007/s12032-011-9860-9; Lu JY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005577; Ma YP, 2006, BLOOD, V108, P2726, DOI 10.1182/blood-2006-02-001594; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Matsuoka J, 2012, J SURG RES, V174, P130, DOI 10.1016/j.jss.2010.11.903; Oikawa T, 2013, HEPATOLOGY, V57, P1469, DOI 10.1002/hep.26159; Palafox M, 2012, CANCER RES, V72, P2879, DOI 10.1158/0008-5472.CAN-12-0044; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Takaishi S, 2008, J CLIN ONCOL, V26, P2876, DOI 10.1200/JCO.2007.15.2603; Ushiku T, 2010, AM J SURG PATHOL, V34, P533, DOI 10.1097/PAS.0b013e3181d1dcdd; Voon DCC, 2012, STEM CELLS, V30, P2088, DOI 10.1002/stem.1183; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Warren M, 2007, GENESIS, V45, P51, DOI 10.1002/dvg.20264; Wu Q, 2006, J BIOL CHEM, V281, P24090, DOI 10.1074/jbc.C600122200; Yang JC, 2008, BLOOD, V112, P805, DOI 10.1182/blood-2007-11-126326; Yang JC, 2007, P NATL ACAD SCI USA, V104, P10494, DOI 10.1073/pnas.0704001104; Yang JC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010766; Yang ZF, 2008, HEPATOLOGY, V47, P919, DOI 10.1002/hep.22082; Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481; Zhang XW, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-40; Zhou Q, 2007, P NATL ACAD SCI USA, V104, P16438, DOI 10.1073/pnas.0701014104	40	81	92	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2014	33	48					5491	5500		10.1038/onc.2013.495	http://dx.doi.org/10.1038/onc.2013.495			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZO	24276240				2022-12-28	WOS:000346087900002
J	Elias, HK; Schinke, C; Bhattacharyya, S; Will, B; Verma, A; Steidl, U				Elias, H. K.; Schinke, C.; Bhattacharyya, S.; Will, B.; Verma, A.; Steidl, U.			Stem cell origin of myelodysplastic syndromes	ONCOGENE			English	Review						MDS; myelodysplastic syndrome; stem cell; HSC; progenitor cell; cell-of-origin	ACUTE MYELOID-LEUKEMIA; GENE-EXPRESSION PROFILES; IN-SITU HYBRIDIZATION; BONE-MARROW-CELLS; HEMATOPOIETIC STEM; CD34(+) CELLS; SELF-RENEWAL; LINEAGE INVOLVEMENT; INITIATING CELLS; PROGENITOR CELLS	Myelodysplastic syndromes (MDS) are common hematologic disorders that are characterized by decreased blood counts due to ineffective hematopoiesis. MDS is considered a 'preleukemic' disorder linked to a significantly elevated risk of developing an overt acute leukemia. Cytopenias can be observed in all three myeloid lineages suggesting the involvement of multipotent, immature hematopoietic cells in the pathophysiology of this disease. Recent studies using murine models of MDS as well as primary patient-derived bone marrow samples have provided direct evidence that the most immature, self-renewing hematopoietic stem cells (HSC), as well as lineage-committed progenitor cells, are critically altered in patients with MDS. Besides significant changes in the number and distribution of stem as well as immature progenitor cells, genetic and epigenetic aberrations have been identified, which confer functional changes to these aberrant stem cells, impairing their ability to proliferate and differentiate. Most importantly, aberrant stem cells can persist and further expand after treatment, even upon transient achievement of clinical complete remission, pointing to a critical role of these cells in disease relapse. Ongoing preclinical and clinical studies are particularly focusing on the precise molecular and functional characterization of aberrant MDS stem cells in response to therapy, with the goal to develop stem cell-targeted strategies for therapy and disease monitoring that will allow for achievement of longer-lasting remissions in MDS.	[Elias, H. K.; Schinke, C.; Bhattacharyya, S.; Will, B.; Verma, A.; Steidl, U.] Albert Einstein Coll Med, Albert Einstein Canc Ctr, New York, NY 10461 USA; [Elias, H. K.; Schinke, C.; Bhattacharyya, S.; Will, B.; Verma, A.; Steidl, U.] NYU, Dept Cell Biol, New York, NY 10016 USA; [Elias, H. K.; Schinke, C.; Bhattacharyya, S.; Will, B.; Verma, A.; Steidl, U.] Dept Dev & Mol Biol, New York, NY USA; [Elias, H. K.; Schinke, C.; Bhattacharyya, S.; Will, B.; Verma, A.; Steidl, U.] Dept Med Oncol, Div Hematol Malignancies, New York, NY USA; [Elias, H. K.; Schinke, C.; Bhattacharyya, S.; Will, B.; Verma, A.; Steidl, U.] Chanin Inst Canc Res, Ruth L & David S Gottesman Inst Stem Cell & Regen, New York, NY USA	Yeshiva University; New York University	Will, B (corresponding author), Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, New York, NY 10461 USA.	britta.will@einstein.yu.edu; amit.verma@einstein.yu.edu; ulrich.steidl@einstein.yu.edu	Elias, Harold/F-6457-2015	Elias, Harold/0000-0002-6189-4752; Will, Britta/0000-0002-9534-6690				Abdel-Wahab O, 2013, J EXP MED, V210, P2641, DOI 10.1084/jem.20131141; Abdel-Wahab O, 2012, CANCER CELL, V22, P180, DOI 10.1016/j.ccr.2012.06.032; ABRAHAMSON G, 1991, BRIT J HAEMATOL, V79, P550, DOI 10.1111/j.1365-2141.1991.tb08080.x; Abramovich C, 2005, ANN NY ACAD SCI, V1044, P109, DOI 10.1196/annals.1349.014; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Bacher U, 2007, HAEMATOLOGICA, V92, P744, DOI 10.3324/haematol.10869; Bains A, 2011, AM J CLIN PATHOL, V135, P62, DOI 10.1309/AJCPEI9XU8PYBCIO; Barlow JL, 2010, NAT MED, V16, P59, DOI 10.1038/nm.2063; Barreyro L, 2012, BLOOD, V120, P1290, DOI 10.1182/blood-2012-01-404699; Bayliss R, 2002, J BIOL CHEM, V277, P50597, DOI 10.1074/jbc.M209037200; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; Benito AI, 2003, LEUKEMIA RES, V27, P425, DOI 10.1016/S0145-2126(02)00221-7; Bereshchenko O, 2009, CANCER CELL, V16, P390, DOI 10.1016/j.ccr.2009.09.036; Bernell P, 1996, LEUKEMIA, V10, P662; Boultwood J, 2010, LEUKEMIA, V24, P1062, DOI 10.1038/leu.2010.20; Boultwood J, 2001, INT J HEMATOL, V73, P411, DOI 10.1007/BF02994002; Broske AM, 2009, NAT GENET, V41, P1207, DOI 10.1038/ng.463; Buonamici S, 2004, J CLIN INVEST, V114, P713, DOI 10.1172/JCI200421716; Challen GA, 2012, NAT GENET, V44, P23, DOI 10.1038/ng.1009; Chaturvedi A, 2013, BLOOD, V122, P2877, DOI 10.1182/blood-2013-03-491571; Chen GB, 2004, BLOOD, V104, P4210, DOI 10.1182/blood-2004-01-0103; Chen W, 2008, CANCER CELL, V13, P432, DOI 10.1016/j.ccr.2008.03.005; Choi CW, 2008, HAEMATOL-HEMATOL J, V93, P1394, DOI 10.3324/haematol.13042; Chung SS, 2012, BLOOD, V120, P210; Craddock C, 2013, LEUKEMIA, V27, P1028, DOI 10.1038/leu.2012.312; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Figueroa ME, 2010, CANCER CELL, V17, P13, DOI 10.1016/j.ccr.2009.11.020; Figueroa ME, 2009, BLOOD, V114, P3448, DOI 10.1182/blood-2009-01-200519; Gan BY, 2010, NATURE, V468, P701, DOI 10.1038/nature09595; Giassi LJ, 2008, EXP BIOL MED, V233, P997, DOI 10.3181/0802-RM-70; Goardon N, 2011, CANCER CELL, V19, P138, DOI 10.1016/j.ccr.2010.12.012; Graf L, 2002, BLOOD, V100, P1509, DOI 10.1182/blood-2002-03-0844; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Gurumurthy S, 2010, NATURE, V468, P659, DOI 10.1038/nature09572; Haase D, 1997, LEUKEMIA, V11, P674, DOI 10.1038/sj.leu.2400638; Hiramatsu H, 2003, BLOOD, V102, P873, DOI 10.1182/blood-2002-09-2755; Hofmann WK, 2002, BLOOD, V100, P3553, DOI 10.1182/blood.V100.10.3553; Iriuchishima H, 2011, BLOOD, V117, P2373, DOI 10.1182/blood-2010-07-294801; Ishikawa F, 2008, CURR TOP MICROBIOL, V324, P87; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Jaju RJ, 2000, GENE CHROMOSOME CANC, V29, P276, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1035>3.0.CO;2-L; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jan M, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004315; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Kawahara M, 2012, CANCER CELL, V22, P194, DOI 10.1016/j.ccr.2012.06.027; Kerbauy DMB, 2004, BLOOD, V104, P2202, DOI 10.1182/blood-2004-04-1518; Khandanpour C, 2011, STEM CELLS, V29, P376, DOI 10.1002/stem.575; Kirstetter P, 2008, CANCER CELL, V13, P299, DOI 10.1016/j.ccr.2008.02.008; Kitagawa M, 1997, LEUKEMIA, V11, P2049, DOI 10.1038/sj.leu.2400844; Ko M, 2010, NATURE, V468, P839, DOI 10.1038/nature09586; Kosmider O, 2010, LEUKEMIA, V24, P1094, DOI 10.1038/leu.2010.52; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; Kroef MJPL, 1997, LEUKEMIA, V11, P519, DOI 10.1038/sj.leu.2400597; KROEF MJPL, 1993, BLOOD, V81, P1849; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Kuo YH, 2006, CANCER CELL, V9, P57, DOI 10.1016/j.ccr.2005.12.014; Lam DH, 2001, LEUKEMIA, V15, P1689, DOI 10.1038/sj.leu.2402269; Laricchia-Robbio L, 2006, MOL CELL BIOL, V26, P7658, DOI 10.1128/MCB.00363-06; Laurenti E, 2008, CELL STEM CELL, V3, P611, DOI 10.1016/j.stem.2008.09.005; Li X, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.11; Lin YW, 2005, BLOOD, V106, P287, DOI 10.1182/blood-2004-12-4794; Losman JA, 2013, SCIENCE, V339, P1621, DOI 10.1126/science.1231677; Louz D, 2000, LEUKEMIA, V14, P1876, DOI 10.1038/sj.leu.2401887; Ma YP, 2006, BLOOD, V108, P2726, DOI 10.1182/blood-2006-02-001594; Misaghian N, 2009, LEUKEMIA, V23, P25, DOI 10.1038/leu.2008.246; Miura I, 2000, INT J HEMATOL, V72, P310; Moran-Crusio K, 2011, CANCER CELL, V20, P11, DOI 10.1016/j.ccr.2011.06.001; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Muguruma Y, 2011, HAEMATOL-HEMATOL J, V96, P543, DOI 10.3324/haematol.2010.027557; Muto T, 2013, J EXP MED, V210, P2627, DOI 10.1084/jem.20131144; Nilsson L, 2000, BLOOD, V96, P2012, DOI 10.1182/blood.V96.6.2012.h8002012a_2012_2021; Nilsson L, 2002, BLOOD, V100, P259, DOI 10.1182/blood-2001-12-0188; Nilsson L, 2007, BLOOD, V110, P3005, DOI 10.1182/blood-2007-03-079368; Oda M, 2009, NUCLEIC ACIDS RES, V37, P3829, DOI 10.1093/nar/gkp260; Pang WW, 2013, P NATL ACAD SCI USA, V110, P3011, DOI 10.1073/pnas.1222861110; Papaemmanuil E, 2011, NEW ENGL J MED, V365, P1384, DOI 10.1056/NEJMoa1103283; Pardanani A, 2010, LEUKEMIA, V24, P1370, DOI 10.1038/leu.2010.98; Parkin B, 2013, BLOOD, V121, P369, DOI 10.1182/blood-2012-04-427039; Passegue E, 2004, CELL, V119, P431, DOI 10.1016/j.cell.2004.10.010; Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304; Patnaik MM, 2012, LEUKEMIA, V26, P101, DOI 10.1038/leu.2011.298; Pellagatti A, 2010, LEUKEMIA, V24, P756, DOI 10.1038/leu.2010.31; Pellagatti A, 2006, BLOOD, V108, P337, DOI 10.1182/blood-2005-12-4769; Petzer AL, 1996, P NATL ACAD SCI USA, V93, P1470, DOI 10.1073/pnas.93.4.1470; Prall WC, 2009, INT J HEMATOL, V89, P173, DOI 10.1007/s12185-008-0242-9; Quivoron C, 2011, CANCER CELL, V20, P25, DOI 10.1016/j.ccr.2011.06.003; Raaijmakers MHGP, 2010, NATURE, V464, P852, DOI 10.1038/nature08851; Raza-Egilmez SZ, 1998, CANCER RES, V58, P4269; Rhyasen GW, 2013, CANCER CELL, V24, P90, DOI 10.1016/j.ccr.2013.05.006; Rodrigues NP, 2012, INT J BIOCHEM CELL B, V44, P457, DOI 10.1016/j.biocel.2011.12.004; ROECKLEIN BA, 1995, BLOOD, V85, P997, DOI 10.1182/blood.V85.4.997.bloodjournal854997; Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Ruiz-Herguido C, 2012, J EXP MED, V209, P1457, DOI 10.1084/jem.20120225; Santaguida M, 2009, CANCER CELL, V15, P341, DOI 10.1016/j.ccr.2009.02.016; Sasaki M, 2012, NATURE, V488, P656, DOI 10.1038/nature11323; Shimizu R, 2004, MOL CELL BIOL, V24, P10814, DOI 10.1128/MCB.24.24.10814-10825.2004; Smith LL, 2011, CELL STEM CELL, V8, P649, DOI 10.1016/j.stem.2011.05.004; SOENEN V, 1995, BRIT J HAEMATOL, V90, P701, DOI 10.1111/j.1365-2141.1995.tb05604.x; Sportoletti P, 2008, BLOOD, V111, P3859, DOI 10.1182/blood-2007-06-098251; Starczynowski DT, 2010, NAT MED, V16, P49, DOI 10.1038/nm.2054; Steidl U, 2006, NAT GENET, V38, P1269, DOI 10.1038/ng1898; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Taketani T, 2002, CANCER RES, V62, P33; Takubo K, 2010, CELL STEM CELL, V7, P391, DOI 10.1016/j.stem.2010.06.020; Tanaka S, 2012, BLOOD, V120, P1107, DOI 10.1182/blood-2011-11-394932; Tehranchi R, 2010, NEW ENGL J MED, V363, P1025, DOI 10.1056/NEJMoa0912228; Thanopoulou E, 2004, BLOOD, V103, P4285, DOI 10.1182/blood-2003-09-3192; Thol F, 2012, BLOOD, V119, P3578, DOI 10.1182/blood-2011-12-399337; Thol F, 2010, HAEMATOL-HEMATOL J, V95, P1668, DOI 10.3324/haematol.2010.025494; Trowbridge JJ, 2009, CELL STEM CELL, V5, P442, DOI 10.1016/j.stem.2009.08.016; vanLom K, 1996, BRIT J HAEMATOL, V93, P594, DOI 10.1046/j.1365-2141.1996.d01-1692.x; Venner CP, 2013, HAEMATOLOGICA, V98, P409, DOI 10.3324/haematol.2012.066068; Verhaak RGW, 2005, BLOOD, V106, P3747, DOI 10.1182/blood-2005-05-2168; Verma Amit, 2005, Curr Hematol Rep, V4, P429; Walter MJ, 2011, LEUKEMIA, V25, P1153, DOI 10.1038/leu.2011.44; Wang F, 2013, SCIENCE, V340, P622, DOI 10.1126/science.1234769; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Welch JS, 2012, CELL, V150, P264, DOI 10.1016/j.cell.2012.06.023; Will B, 2012, BLOOD, V120, P2076, DOI 10.1182/blood-2011-12-399683; Will B, 2009, BLOOD, V114, P3899, DOI 10.1182/blood-2009-04-219493; Yang LP, 2005, J IMMUNOL, V174, P752, DOI 10.4049/jimmunol.174.2.752; Zeng WH, 2004, BLOOD, V103, P325, DOI 10.1182/blood-2003-02-0490; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747	129	30	32	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2014	33	44					5139	5150		10.1038/onc.2013.520	http://dx.doi.org/10.1038/onc.2013.520			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR9RZ	24336326				2022-12-28	WOS:000343914900001
J	Qi, Q; Liu, X; Brat, DJ; Ye, K				Qi, Q.; Liu, X.; Brat, D. J.; Ye, K.			Merlin sumoylation is required for its tumor suppressor activity	ONCOGENE			English	Article						Akt; merlin; NF2; sumoylation; tumor suppressor	PLASMA-MEMBRANE; FERM DOMAIN; RECEPTOR ENDOCYTOSIS; P21-ACTIVATED KINASE; AKT PHOSPHORYLATION; SUMO-1 MODIFICATION; GROWTH SUPPRESSION; CELL MOTILITY; GENE-PRODUCT; NF2	Merlin, encoded by the Neurofibromatosis 2 (NF2) gene, is a multifunctional tumor suppressor that integrates and regulates extracellular cues and intracellular signaling pathways, both at the plasma membrane and in the nucleus, to control cell proliferation, migration and invasion. Molecular mechanisms regulating merlin's tumor-suppressive activity have not been clearly defined. Here we report that merlin can be sumoylated on Lysine residue (K76) in vitro and in vivo. Sumoylation mediates merlin's intramolecular and intermolecular binding activities and regulates its cytoplasm/nucleus trafficking. Interestingly, sumoylation of merlin is regulated by its phosphorylation via Akt and PAK2 kinases. Mutation of K76 into arginine (R) abolishes its sumoylation, disrupts merlin cortical cytoskeleton residency and attenuates its stability. Using a K76R mutant merlin in a subcutaneous U87MG xenograft model, we demonstrate that merlin sumoylation is required for tumor-suppressive activity. Taken together, our findings indicate that merlin is sumoylated and that this post-translational modification is essential for tumor suppression.	[Qi, Q.; Liu, X.; Brat, D. J.; Ye, K.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Emory University	Ye, K (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Room 141,Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA.	kye@emory.edu			National Cancer Institute, National Institutes of Health R01 [CA127119]; NATIONAL CANCER INSTITUTE [R01CA127119] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health R01; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This project has been funded in whole or in part with Federal Funds from the National Cancer Institute, National Institutes of Health R01 (CA127119 to K Ye). We thank Dr Jolinda Traugh for providing various PAK2 plasmids.	Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Ammoun S, 2008, CANCER RES, V68, P5236, DOI 10.1158/0008-5472.CAN-07-5849; Bae SH, 2004, BIOCHEM BIOPH RES CO, V324, P394, DOI 10.1016/j.bbrc.2004.09.068; Bettermann K, 2012, CANCER LETT, V316, P113, DOI 10.1016/j.canlet.2011.10.036; Brault E, 2001, J CELL SCI, V114, P1901; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Cole BK, 2008, MOL CELL BIOL, V28, P1274, DOI 10.1128/MCB.01139-07; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; de Cristofaro T, 2009, J MOL ENDOCRINOL, V42, P35, DOI 10.1677/JME-08-0100; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Evans DGR, 2011, ADV OTO-RHINO-LARYNG, V70, P91, DOI 10.1159/000322482; Gascard P, 1999, MOL BIOL CELL, V10, P1783, DOI 10.1091/mbc.10.6.1783; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Gutmann DH, 1998, HUM MOL GENET, V7, P335, DOI 10.1093/hmg/7.3.335; Gutmann DH, 1999, J NEUROSCI RES, V58, P706, DOI 10.1002/(SICI)1097-4547(19991201)58:5<706::AID-JNR12>3.3.CO;2-Q; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Hilgarth RS, 2004, J BIOL CHEM, V279, P53899, DOI 10.1074/jbc.R400021200; James MF, 2009, MOL CELL BIOL, V29, P4250, DOI 10.1128/MCB.01581-08; Jukam D, 2011, DEV CELL, V21, P874, DOI 10.1016/j.devcel.2011.10.004; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Konopacki FA, 2011, P NATL ACAD SCI USA, V108, P19772, DOI 10.1073/pnas.1111575108; Kressel M, 2002, HUM MOL GENET, V11, P2269, DOI 10.1093/hmg/11.19.2269; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Lallemand D, 2009, ONCOGENE, V28, P854, DOI 10.1038/onc.2008.427; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Lau YKI, 2008, CANCER RES, V68, P5733, DOI 10.1158/0008-5472.CAN-08-0190; Li W, 2012, EMBO REP, V13, P204, DOI 10.1038/embor.2012.11; Li W, 2010, CELL, V140, P477, DOI 10.1016/j.cell.2010.01.029; Lopez-Lago MA, 2009, MOL CELL BIOL, V29, P4235, DOI 10.1128/MCB.01578-08; Lu JR, 2008, LARYNGOSCOPE, V118, P169, DOI 10.1097/MLG.0b013e3181566594; Maitra S, 2006, CURR BIOL, V16, P702, DOI 10.1016/j.cub.2006.02.063; Mani T, 2011, MOL CELL BIOL, V31, P1983, DOI 10.1128/MCB.00609-10; Martin S, 2007, NATURE, V447, P321, DOI 10.1038/nature05736; Meng JJ, 2000, J NEUROSCI RES, V62, P491, DOI 10.1002/1097-4547(20001115)62:4<491::AID-JNR3>3.0.CO;2-D; Merrill JC, 2010, J MOL BIOL, V398, P657, DOI 10.1016/j.jmb.2010.03.048; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Muranen T, 2005, ONCOGENE, V24, P1150, DOI 10.1038/sj.onc.1208283; Murray LB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043295; Okada M, 2009, CANCER RES, V69, P4043, DOI 10.1158/0008-5472.CAN-08-3931; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; Poulikakos PI, 2006, ONCOGENE, V25, P5960, DOI 10.1038/sj.onc.1209587; Rajan S, 2005, CELL, V121, P37, DOI 10.1016/j.cell.2005.01.019; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rong R, 2004, P NATL ACAD SCI USA, V101, P18200, DOI 10.1073/pnas.0405971102; Rong R, 2004, ONCOGENE, V23, P8447, DOI 10.1038/sj.onc.1207794; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sher I, 2012, DEV CELL, V22, P703, DOI 10.1016/j.devcel.2012.03.008; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Stamenkovic I, 2010, CURR PROTEIN PEPT SC, V11, P471, DOI 10.2174/138920310791824011; Tang XL, 2007, NAT CELL BIOL, V9, P1199, DOI 10.1038/ncb1641; Trofatter J A, 1993, Cell, V75, P826; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Vanhatupa S, 2008, BIOCHEM J, V409, P179, DOI 10.1042/BJ20070620; Wang YG, 2009, J CELL SCI, V122, P4249, DOI 10.1242/jcs.050542; Wei BL, 2005, J VIROL, V79, P14976, DOI 10.1128/JVI.79.23.14976-14980.2005; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Yi CL, 2011, CANCER CELL, V19, P527, DOI 10.1016/j.ccr.2011.02.017; Yu JX, 2009, EMBO J, V28, P21, DOI 10.1038/emboj.2008.238	63	12	13	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2014	33	41					4893	4903		10.1038/onc.2013.438	http://dx.doi.org/10.1038/onc.2013.438			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OA	24166499				2022-12-28	WOS:000343767900002
J	Erkan, EP; Strobel, T; Lewandrowski, G; Tannous, B; Madlener, S; Czech, T; Saydam, N; Saydam, O				Erkan, E. P.; Stroebel, T.; Lewandrowski, G.; Tannous, B.; Madlener, S.; Czech, T.; Saydam, N.; Saydam, O.			Depletion of minichromosome maintenance protein 7 inhibits glioblastoma multiforme tumor growth in vivo	ONCOGENE			English	Article						glioblastoma multiforme; minichromosome maintenance; MCM7; the cancer genome atlas; prognostic marker	CELL LUNG-CANCER; MCM PROTEINS; DNA-REPLICATION; PROGNOSTIC-SIGNIFICANCE; PHOSPHORYLATION; IDENTIFICATION; MARKER; FAMILY; PROLIFERATION; INITIATION	Minichromosome maintenance (MCM) proteins are key elements that function as a part of the pre-replication complex to initiate DNA replication in eukaryotes. Consistent with their roles in initiating DNA replication, overexpression of MCM family members has been observed in several malignancies. Through bioinformatic analysis of The Cancer Genome Atlas's data on glioblastoma multiforme (GBM), we found that the genomic region containing MCM7 gene was amplified in more than 80% of the present cases. To validate this finding and to identify the possible contribution of the remaining members of the MCM family to GBM progression, we used quantitative real-time PCR to analyze the gene expression profiles of all MCM family members in Grade IV (GBM) tissue samples and observed a significant upregulation in GBM samples compared with normal white matter tissues. In addition, we compared the observed gene expression profiles with those of Grade II and Grade III astrocytoma samples and determined that the observed upregulation was restricted and specific to Grade IV. MCM7 was the most upregulated gene in the gene set we analyzed, and therefore we wanted to identify the role of MCM7 in GBM progression. We determined that siRNA-mediated knockdown of MCM7 expression reduced GBM cell proliferation and also inhibited tumor growth in both xenograft and orthotopic mouse models of GBM. Taken together, our data suggest that MCM7 can be a potential prognostic marker and a novel therapeutic target in GBM therapy.	[Erkan, E. P.; Madlener, S.; Saydam, N.; Saydam, O.] Med Univ Vienna, Dept Pediat, Mol Neurooncol Res Unit, A-1090 Vienna, Austria; [Stroebel, T.] Med Univ Vienna, Inst Neurol, A-1090 Vienna, Austria; [Lewandrowski, G.; Tannous, B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Expt Therapeut & Mol Imaging Lab, Boston, MA USA; [Czech, T.] Med Univ Vienna, Dept Neurosurg, A-1090 Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Harvard University; Harvard Medical School; Massachusetts General Hospital; Medical University of Vienna	Saydam, O (corresponding author), Med Univ Vienna, Dept Pediat, Mol Neurooncol Res Unit, A-1090 Vienna, Austria.	okay.saydam@meduniwien.ac.at	Saydam, Okay/HDM-4999-2022; Madlener, Sibylle/AAP-2541-2020; Erkan, Erdogan Pekcan/GQR-2513-2022; Erkan, Erdogan Pekcan/ABI-6822-2020	Erkan, Erdogan Pekcan/0000-0001-9287-4773; Madlener, Sibylle/0000-0001-7099-9997	Forschungsgesellschaft for Brain Tumors; EU-FP7-PEOPLE-CIG; Association for Conduct of Scientific Research in the Field of Neonatology and Pediatric Intensive Care: 'Unser Kind'	Forschungsgesellschaft for Brain Tumors; EU-FP7-PEOPLE-CIG; Association for Conduct of Scientific Research in the Field of Neonatology and Pediatric Intensive Care: 'Unser Kind'	This work was supported, in part, by Forschungsgesellschaft for Brain Tumors (OS, NS), EU-FP7-PEOPLE-2011-CIG (OS) and Association for Conduct of Scientific Research in the Field of Neonatology and Pediatric Intensive Care: 'Unser Kind' (OS and NS).	BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Bruck I, 2009, J BIOL CHEM, V284, P28823, DOI 10.1074/jbc.M109.039123; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cho WH, 2006, P NATL ACAD SCI USA, V103, P11521, DOI 10.1073/pnas.0604990103; Chuang LC, 2009, MOL CELL, V35, P206, DOI 10.1016/j.molcel.2009.06.014; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Facoetti A, 2006, ANTICANCER RES, V26, P3513; Facoetti A, 2006, ANTICANCER RES, V26, P1071; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Gambus A, 2006, NAT CELL BIOL, V8, P358, DOI 10.1038/ncb1382; Giaginis C, 2011, DIGEST DIS SCI, V56, P777, DOI 10.1007/s10620-010-1348-5; Giaginis C, 2010, HISTOL HISTOPATHOL, V25, P351, DOI 10.14670/HH-25.351; Gozuacik D, 2003, NUCLEIC ACIDS RES, V31, P570, DOI 10.1093/nar/gkg136; Gruber-Olipitz M, 2006, CANCER LETT, V238, P76, DOI 10.1016/j.canlet.2005.06.024; Guida T, 2005, J CLIN ENDOCR METAB, V90, P4703, DOI 10.1210/jc.2004-2459; Ibarra A, 2008, P NATL ACAD SCI USA, V105, P8956, DOI 10.1073/pnas.0803978105; Kikuchi J, 2011, LUNG CANCER, V72, P229, DOI 10.1016/j.lungcan.2010.08.020; Lau KM, 2010, ONCOGENE, V29, P5475, DOI 10.1038/onc.2010.287; Lutzmann M, 2005, GENE, V362, P51, DOI 10.1016/j.gene.2005.07.031; MAINE GT, 1984, GENETICS, V106, P365; Maiorano D, 2006, CURR OPIN CELL BIOL, V18, P130, DOI 10.1016/j.ceb.2006.02.006; Maiorano D, 2005, CELL, V120, P315, DOI 10.1016/j.cell.2004.12.010; Montagnoli A, 2006, J BIOL CHEM, V281, P10281, DOI 10.1074/jbc.M512921200; Montagnoli A, 2010, CLIN CANCER RES, V16, P4503, DOI 10.1158/1078-0432.CCR-10-0185; Nishihara K, 2008, INT J ONCOL, V33, P245, DOI 10.3892/ijo_00000003; Ramnath N, 2001, J CLIN ONCOL, V19, P4259, DOI 10.1200/JCO.2001.19.22.4259; Randell JCW, 2006, MOL CELL, V21, P29, DOI 10.1016/j.molcel.2005.11.023; Saydam O, 2005, MOL THER, V12, P803, DOI 10.1016/j.ymthe.2005.07.534; Saydam O, 2011, CANCER RES, V71, P852, DOI 10.1158/0008-5472.CAN-10-1219; Saydam O, 2010, J PROTEOME RES, V9, P485, DOI 10.1021/pr900834h; Saydam O, 2009, MOL CELL BIOL, V29, P5923, DOI 10.1128/MCB.00332-09; Tamura T, 2010, J ORAL PATHOL MED, V39, P328, DOI 10.1111/j.1600-0714.2009.00861.x; The WHO, 2020, CLASSIFICATION TUMOU; Toyokawa G, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-65; Tsuji T, 2006, MOL BIOL CELL, V17, P4459, DOI 10.1091/mbc.E06-03-0241; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wurdinger T, 2008, NAT METHODS, V5, P171, DOI 10.1038/NMETH.1177; Yang J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-203; Yoshida K, 2005, BIOCHEM BIOPH RES CO, V331, P669, DOI 10.1016/j.bbrc.2005.03.222	39	30	32	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2014	33	39					4778	4785		10.1038/onc.2013.423	http://dx.doi.org/10.1038/onc.2013.423			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0ED	24166506				2022-12-28	WOS:000343239500008
J	Zhou, ZN; Sharma, VP; Beaty, BT; Roh-Johnson, M; Peterson, EA; Van Rooijen, N; Kenny, PA; Wiley, HS; Condeelis, JS; Segall, JE				Zhou, Z. N.; Sharma, V. P.; Beaty, B. T.; Roh-Johnson, M.; Peterson, E. A.; Van Rooijen, N.; Kenny, P. A.; Wiley, H. S.; Condeelis, J. S.; Segall, J. E.			Autocrine HBEGF expression promotes breast cancer intravasation, metastasis and macrophage-independent invasion in vivo	ONCOGENE			English	Article						HBEGF; breast cancer invasion; EGFR; metastasis	LIPOSOME-MEDIATED DEPLETION; SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR; HB-EGF; RECEPTOR; PARACRINE; CORTACTIN; INVADOPODIA; MIGRATION; MOTILITY	Increased expression of HBEGF in estrogen receptor-negative breast tumors is correlated with enhanced metastasis to distant organ sites and more rapid disease recurrence upon removal of the primary tumor. Our previous work has demonstrated a paracrine loop between breast cancer cells and macrophages in which the tumor cells are capable of stimulating macrophages through the secretion of colony-stimulating factor-1 while the tumor-associated macrophages (TAMs), in turn, aid in tumor cell invasion by secreting epidermal growth factor. To determine how the autocrine expression of epidermal growth factor receptor (EGFR) ligands by carcinoma cells would affect this paracrine loop mechanism, and in particular whether tumor cell invasion depends on spatial ligand gradients generated by TAMs, we generated cell lines with increased HBEGF expression. We found that autocrine HBEGF expression enhanced in vivo intravasation and metastasis and resulted in a novel phenomenon in which macrophages were no longer required for in vivo invasion of breast cancer cells. In vitro studies revealed that expression of HBEGF enhanced invadopodium formation, thus providing a mechanism for cell autonomous invasion. The increased invadopodium formation was directly dependent on EGFR signaling, as demonstrated by a rapid decrease in invadopodia upon inhibition of autocrine HBEGF/EGFR signaling as well as inhibition of signaling downstream of EGFR activation. HBEGF expression also resulted in enhanced invadopodium function via upregulation of matrix metalloprotease 2 (MMP2) and MMP9 expression levels. We conclude that high levels of HBEGF expression can short-circuit the tumor cell/macrophage paracrine invasion loop, resulting in enhanced tumor invasion that is independent of macrophage signaling.	[Zhou, Z. N.; Sharma, V. P.; Beaty, B. T.; Roh-Johnson, M.; Condeelis, J. S.; Segall, J. E.] Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; [Peterson, E. A.; Kenny, P. A.] Albert Einstein Coll Med, Dev & Mol Biol, Bronx, NY 10461 USA; [Van Rooijen, N.] Free Univ Amsterdam, Med Ctr, Dept Mol Cell Biol, Amsterdam, Netherlands; [Wiley, H. S.] Pacific NW Natl Lab, Syst Biol Program, Richland, WA 99352 USA; [Wiley, H. S.] Pacific NW Natl Lab, Environ Mol Sci Lab, Richland, WA 99352 USA; [Condeelis, J. S.; Segall, J. E.] Albert Einstein Coll Med, Gruss Lipper Ctr Biophoton, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Vrije Universiteit Amsterdam; United States Department of Energy (DOE); Pacific Northwest National Laboratory; United States Department of Energy (DOE); Pacific Northwest National Laboratory; Yeshiva University; Albert Einstein College of Medicine	Segall, JE (corresponding author), Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA.	jeffrey.segall@einstein.yu.edu	Van Rooijen, Nico/Z-1578-2019	Sharma, Ved P/0000-0001-9998-5070; Wiley, Steven/0000-0003-0232-6867	Susan G. Komen for the Cure [KG111405]; NIH F32 postdoctoral fellowship [F32-CA159663-01]; NIH [1K12GM102779-01];  [CA100324];  [CA77522];  [T32-GM007288]; NATIONAL CANCER INSTITUTE [R01CA077522, P30CA013330, F32CA159663, P01CA100324] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288, K12GM102779] Funding Source: NIH RePORTER	Susan G. Komen for the Cure(Susan G. Komen Breast Cancer Foundation); NIH F32 postdoctoral fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the Condeelis, Cox, Hodgson and Segall labs for their comments and suggestions. We thank Carl Manthey and Johnson and Johnson for providing the JnJ compound. JES is the Betty and Sheldon Feinberg Senior Faculty Scholar in Cancer Research. Funding was provided by CA100324 (ERS, ARB, DC, JWP, JC and JES), CA77522 (JES), T32-GM007288 (ZNZ), a postdoctoral fellowship from the Susan G. Komen for the Cure, KG111405 (VPS), an NIH F32 postdoctoral fellowship F32-CA159663-01 (MRJ) and an NIH 1K12GM102779-01 (EAP).	Ammer AG, 2008, CELL MOTIL CYTOSKEL, V65, P687, DOI 10.1002/cm.20296; Artacho-Cordon A, 2012, CANCER BIOL THER, V13, P14, DOI 10.4161/cbt.13.1.18869; Artym VV, 2011, EUR J CELL BIOL, V90, P172, DOI 10.1016/j.ejcb.2010.06.006; Artym Vira V., 2009, V522, P211, DOI 10.1007/978-1-59745-413-1_15; Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Bonde AK, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-35; Coniglio SJ, 2012, MOL MED, V18, P519, DOI 10.2119/molmed.2011.00217; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Garton KJ, 2002, BIOTECHNIQUES, V32, P830, DOI 10.2144/02324rr01; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Hayes KE, 2013, ONCOGENE, V32, P4766, DOI 10.1038/onc.2012.513; Hernandez L, 2009, METHODS MOL BIOL, V571, P227, DOI 10.1007/978-1-60761-198-1_15; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Joslin EJ, 2007, J CELL SCI, V120, P3688, DOI 10.1242/jcs.010488; Joslin EJ, 2010, MOL BIOSYST, V6, P1293, DOI 10.1039/c003921g; Kedrin D, 2007, CURR PROTOC CELL BIO, P1; Kedrin D, 2009, CLIN CANCER RES, V15, P3733, DOI 10.1158/1078-0432.CCR-08-2163; Lue HW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027720; Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Nishi E, 2004, GROWTH FACTORS, V22, P253, DOI 10.1080/08977190400008448; Ongusaha PP, 2004, CANCER RES, V64, P5283, DOI 10.1158/0008-5472.CAN-04-0925; Oser M, 2010, J CELL SCI, V123, P3662, DOI 10.1242/jcs.068163; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Patsialou A, 2009, CANCER RES, V69, P9498, DOI 10.1158/0008-5472.CAN-09-1868; Place AE, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2912; Qian BZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006562; Revillion F, 2008, ANN ONCOL, V19, P73, DOI 10.1093/annonc/mdm431; Roepstorff K, 2009, TRAFFIC, V10, P1115, DOI 10.1111/j.1600-0854.2009.00943.x; Roussos ET, 2011, CLIN EXP METASTAS, V28, P515, DOI 10.1007/s10585-011-9388-6; Roussos ET, 2011, J CELL SCI, V124, P2120, DOI 10.1242/jcs.086231; SCOTT J, 1985, J CELL SCI, P19; Sharma VP, 2013, METHODS MOL BIOL, V1046, P343, DOI 10.1007/978-1-62703-538-5_21; Shimura T, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-205; Singh AB, 2005, CELL SIGNAL, V17, P1183, DOI 10.1016/j.cellsig.2005.03.026; Smirnova T, 2012, ONCOGENE, V31, P706, DOI 10.1038/onc.2011.275; Smirnova T, 2011, AM J PATHOL, V178, P2857, DOI 10.1016/j.ajpath.2011.02.030; Tolino MA, 2011, BBA-GEN SUBJECTS, V1810, P875, DOI 10.1016/j.bbagen.2011.05.011; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; Wilson KJ, 2012, GROWTH FACTORS, V30, P107, DOI 10.3109/08977194.2011.649918; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823; Xue CS, 2006, CANCER RES, V66, P192, DOI 10.1158/0008-5472.CAN-05-1242; Yagi H, 2008, MOL CANCER THER, V7, P3441, DOI 10.1158/1535-7163.MCT-08-0417; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yotsumoto F, 2010, INT J CANCER, V127, P2707, DOI 10.1002/ijc.25472; Zaynagetdinov R, 2011, J IMMUNOL, V187, P5703, DOI 10.4049/jimmunol.1100558; Zeisberger SM, 2006, BRIT J CANCER, V95, P272, DOI 10.1038/sj.bjc.6603240	52	72	72	0	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3784	3793		10.1038/onc.2013.363	http://dx.doi.org/10.1038/onc.2013.363			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	24013225	Green Accepted			2022-12-28	WOS:000339394100004
J	Takwi, AA; Wang, YM; Wu, J; Michaelis, M; Cinatl, J; Chen, T				Takwi, A. A.; Wang, Y-M; Wu, J.; Michaelis, M.; Cinatl, J.; Chen, T.			miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells	ONCOGENE			English	Article						microRNA; constitutive androstane receptor; miR-137; MDR1; doxorubicin	MULTIDRUG-RESISTANCE; GENE-EXPRESSION; MICRORNA EXPRESSION; DRUG-RESISTANCE; PROMOTER METHYLATION; NUCLEAR RECEPTORS; LIVER-INJURY; IN-VIVO; AMPLIFICATION; INDUCTION	Chemotherapy is the most common treatment for cancer. However, multidrug resistance (MDR) remains a major obstacle to effective chemotherapy, limiting the efficacy of both conventional chemotherapeutic and novel biologic agents. The constitutive androstane receptor (CAR), a xenosensor, is a key regulator of MDR. It functions in xenobiotic detoxification by regulating the expression of phase I drug-metabolizing enzymes and ATP-binding cassette (ABC) transporters, whose overexpression in cancers and whose role in drug resistance make them potential therapeutic targets for reducing MDR. MicroRNAs (miRNAs) are endogenous negative regulators of gene expression and have been implicated in most cellular processes, including drug resistance. Here, we report the inversely related expression of miR-137 and CAR in parental and doxorubicin-resistant neuroblastoma cells, wherein miR-137 is downregulated in resistant cells. miR-137 overexpression resulted in downregulation of CAR protein and mRNA (via mRNA degradation); it sensitized doxorubicin-resistant cells to doxorubicin (as shown by reduced proliferation, increased apoptosis and increased G2-phase cell cycle arrest) and reduced the in vivo growth rate of neuroblastoma xenografts. We observed similar results in cellular models of hepatocellular and colon cancers, indicating that the doxorubicin-sensitizing effect of miR-137 is not tumor type-specific. Finally, we show for the first time a negative feedback loop whereby miR-137 downregulates CAR expression and CAR downregulates miR-137 expression. Hypermethylation of the miR-137 promoter and negative regulation of miR-137 by CAR contribute in part to reduced miR-137 expression and increased CAR and MDR1 expression in doxorubicin-resistant neuroblastoma cells. These findings demonstrate that miR-137 is a crucial regulator of cancer response to doxorubicin treatment, and they identify miR-137 as a highly promising target to reduce CAR-driven doxorubicin resistance.	[Takwi, A. A.; Wang, Y-M; Wu, J.; Chen, T.] St Jude Childrens Res Hosp, Dept Chem Biol & Therapeut, Memphis, TN 38105 USA; [Michaelis, M.] Univ Kent, Sch Biosci, Canterbury, Kent, England; [Cinatl, J.] Clin Goethe Univ, Inst Med Virol, Frankfurt, Germany	St Jude Children's Research Hospital; University of Kent; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Chen, T (corresponding author), St Jude Childrens Res Hosp, Dept Chem Biol & Therapeut, 262 Danny Thomas Pl, Memphis, TN 38105 USA.	taosheng.chen@stjude.org	Chen, Taosheng/I-6351-2013; Wang, Yueming/B-4658-2015	Chen, Taosheng/0000-0001-6420-3809; Michaelis, Martin/0000-0002-5710-5888	American Lebanese Syrian Associated Charities (ALSAC); St Jude Children's Research Hospital (SJCRH); National Cancer Institute [P30CA027165]; National Institute of General Medical Sciences [GM086415]; Hilfe fur krebskranke Kinder Frankfurt eV; Frankfurter Stiftung fur krebskranke Kinder; Kent Cancer Trust; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM086415] Funding Source: NIH RePORTER	American Lebanese Syrian Associated Charities (ALSAC)(American Lebanese Syrian Associated Charities (ALSAC)); St Jude Children's Research Hospital (SJCRH); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Hilfe fur krebskranke Kinder Frankfurt eV; Frankfurter Stiftung fur krebskranke Kinder; Kent Cancer Trust; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs David Moore and Hongbing Wang for plasmids; the Flow Cytometry and Cell Sorting Shared Resource, the St Jude Animal Resources Center and Veterinary Pathology Core for technical assistance; other members of the Chen group and Drs Yong Li, John Schuetz, and Kip Guy for valuable discussions; and Sharon Naron for editing the manuscript. This work was supported by the American Lebanese Syrian Associated Charities (ALSAC), St Jude Children's Research Hospital (SJCRH), National Cancer Institute grant P30CA027165, National Institute of General Medical Sciences Grant GM086415, the Hilfe fur krebskranke Kinder Frankfurt eV, the Frankfurter Stiftung fur krebskranke Kinder, and the Kent Cancer Trust.	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Balaguer F, 2010, CANCER RES, V70, P6609, DOI 10.1158/0008-5472.CAN-10-0622; Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Baskin-Bey ES, 2006, HEPATOLOGY, V44, P252, DOI 10.1002/hep.21236; Beilke LD, 2009, TOXICOL LETT, V188, P38, DOI 10.1016/j.toxlet.2009.03.005; Bemis LT, 2008, CANCER RES, V68, P1362, DOI 10.1158/0008-5472.CAN-07-2912; Benbow U, 1999, CLIN CANCER RES, V5, P203; Blower PE, 2008, MOL CANCER THER, V7, P1, DOI 10.1158/1535-7163.MCT-07-0573; Boyer DS, 2002, AM J OPHTHALMOL, V133, P484; Bray I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007850; Brennecke J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-228; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Buckley PG, 2010, CLIN CANCER RES, V16, P2971, DOI 10.1158/1078-0432.CCR-09-3215; Charlet J, 2012, BIOCHEM PHARMACOL, V83, P858, DOI 10.1016/j.bcp.2012.01.009; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chen QJ, 2011, DIGEST DIS SCI, V56, P2009, DOI 10.1007/s10620-010-1536-3; Chen T, 2010, J PHARMACOL EXP THER, V332, P106, DOI 10.1124/jpet.109.159210; Chen YK, 2012, BIOCHEM PHARMACOL, V83, P1112, DOI 10.1016/j.bcp.2012.01.030; Chen YX, 2007, CANCER RES, V67, P976, DOI 10.1158/0008-5472.CAN-06-3667; Cherian MT, 2012, J BIOL CHEM, V287, P23368, DOI 10.1074/jbc.M112.344671; Cinatl J, 1996, INT J CANCER, V65, P90, DOI 10.1002/(SICI)1097-0215(19960103)65:1<90::AID-IJC16>3.0.CO;2-M; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Esteve PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102; Fabbri M, 2011, CURR OPIN HEMATOL, V18, P266, DOI 10.1097/MOH.0b013e3283476012; Faucette SR, 2006, J PHARMACOL EXP THER, V317, P1200, DOI 10.1124/jpet.105.098160; Fiebig AA, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-213; Fojo T, 2007, DRUG RESIST UPDATE, V10, P59, DOI 10.1016/j.drup.2007.02.002; Haenisch S, 2012, EPIGENOMICS-UK, V4, P369, DOI [10.2217/EPI.12.39, 10.2217/epi.12.39]; Haldar Subrata, 2011, Mol Cell Pharmacol, V3, P135; HE L, 2004, NAT REV GENET, V5, P522; Hodzic J, 2011, NUCLEOS NUCLEOT NUCL, V30, P1214, DOI 10.1080/15257770.2011.629271; Ji M, 2009, BRIT J HAEMATOL, V145, P648, DOI 10.1111/j.1365-2141.2009.07678.x; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kotchetkov R, 2005, INT J ONCOL, V27, P1029; Kotchetkov R, 2003, INT J CANCER, V104, P36, DOI 10.1002/ijc.10917; Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194; KRISHAN A, 1980, CANCER RES, V40, P3895; KRISHAN A, 1985, CANCER RES, V45, P1046; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lahoti TS, 2012, CURR NEUROVASC RES, V9, P282; Langevin SM, 2011, CANCER-AM CANCER SOC, V117, P1454, DOI 10.1002/cncr.25689; Langevin SM, 2010, CARCINOGENESIS, V31, P864, DOI 10.1093/carcin/bgq051; Li Y, 2010, EUR J PHARMACOL, V640, P46, DOI 10.1016/j.ejphar.2010.05.017; Lin WW, 2008, J BIOL CHEM, V283, P30650, DOI 10.1074/jbc.M806132200; Liu JH, 2008, AM J PHYSIOL-HEART C, V295, pH1956, DOI 10.1152/ajpheart.00407.2008; Liu M, 2011, INT J CANCER, V128, P1269, DOI 10.1002/ijc.25452; Lu ZX, 2011, EMBO J, V30, P57, DOI 10.1038/emboj.2010.296; Lujambio A, 2007, CELL CYCLE, V6, P1455; Manohar CF, 2004, ONCOGENE, V23, P753, DOI 10.1038/sj.onc.1207151; Michaelis M, 2007, CANCER LETT, V250, P107, DOI 10.1016/j.canlet.2006.09.018; Michaelis M, 2009, CANCER RES, V69, P416, DOI 10.1158/0008-5472.CAN-08-1856; Moitra K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045268; Passetti F, 2009, PHARMACOGENOMICS J, V9, P1, DOI 10.1038/tpj.2008.14; Porro A, 2010, J BIOL CHEM, V285, P19532, DOI 10.1074/jbc.M109.078584; Porro A, 2010, CURR PHARM DESIGN, V16, P431, DOI 10.2174/138161210790232112; Schulte JH, 2010, INT J CANCER, V127, P2374, DOI 10.1002/ijc.25436; Shen F, 2008, J PHARMACOL EXP THER, V324, P95, DOI 10.1124/jpet.107.127704; St Clair S, 2004, MOL CELL, V16, P725; Tabe Y, 2006, BLOOD, V107, P1546, DOI 10.1182/blood-2004-10-4126; Takwi AAL, 2012, EMBO MOL MED, V4, P896, DOI 10.1002/emmm.201101045; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tojima H, 2012, TOXICOL LETT, V212, P288, DOI 10.1016/j.toxlet.2012.06.001; van Jaarsveld MTM, 2013, ONCOGENE, V32, P4284, DOI 10.1038/onc.2012.433; Venne A, 1996, CANCER RES, V56, P3626; Wang HB, 2003, J BIOL CHEM, V278, P14146, DOI 10.1074/jbc.M212482200; Wertz IE, 2011, NATURE, V471, P110, DOI 10.1038/nature09779; Zhang J, 2002, SCIENCE, V298, P422, DOI 10.1126/science.1073502; Zhao YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039102	71	54	59	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3717	3729		10.1038/onc.2013.330	http://dx.doi.org/10.1038/onc.2013.330			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23934188	Green Accepted			2022-12-28	WOS:000338942900011
J	Munro, S; Oppermann, U; La Thangue, NB				Munro, S.; Oppermann, U.; La Thangue, N. B.			Pleiotropic effect of somatic mutations in the E2F subunit DP-1 gene in human cancer	ONCOGENE			English	Article						DP-1; E2F; somatic mutation; cancer	TRANSCRIPTION FACTOR DRTF1/E2F; CELL-CYCLE CONTROL; DNA-DAMAGE; RETINOBLASTOMA PROTEIN; NUCLEAR-LOCALIZATION; FAMILY-MEMBERS; RB/E2F PATHWAY; PRB; APOPTOSIS; DISTINCT	Transcription factor E2F-1 and its interaction with pRb provide a key point of control in cell proliferation. E2F-1 participates in both cell cycle progression and apoptosis, and in cells exists with a DP dimerization partner protein, the most prominent being DP-1. By mining the tumor tissue and cancer cell line encyclopedia genomic databases, we identified the first somatic mutations in the DP-1 gene and describe 53 distinct mutation events here. The mutations are mostly missense mutations, but also include nonsense and frame-shift mutations that result in truncated DP-1 derivatives. Mutation occurs throughout the DP-1 gene but generally leaves protein dimerization activity intact. This allows the mutant derivatives to affect the properties of the E2F-1/DP-1 heterodimer through a transdominant mechanism, which changes the DNA binding, transcriptional activation and pRb-binding properties of the heterodimer. In particular, many DP-1 mutants were found to impair E2F-1-dependent apoptosis. Our results establish that somatic mutations in DP-1 uncouple normal control of the E2F pathway, and thus define a new mechanism that could contribute to aberrant proliferation in tumor cells.	[Munro, S.; La Thangue, N. B.] Univ Oxford, Div Med Sci, Dept Oncol, Canc Biol Lab, Oxford OX3 7DQ, England; [Oppermann, U.] Univ Oxford, Nuffield Orthopaed Ctr, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford OX3 7DQ, England	University of Oxford; Nuffield Orthopaedic Centre; University of Oxford	La Thangue, NB (corresponding author), Univ Oxford, Div Med Sci, Dept Oncol, Canc Biol Lab, Old Rd Campus Res Bldg,Old Rd Campus,Roosevelt Dr, Oxford OX3 7DQ, England.	nick.lathangue@oncology.ox.ac.uk			CRUK [C300/A13058]; MRC; LLR; EU; Oxford NIHR BRU; Bayer Healthcare; MRC [G1000807, G0500905] Funding Source: UKRI; Cancer Research UK [13058] Funding Source: researchfish; Medical Research Council [G0500905, G1000807] Funding Source: researchfish	CRUK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); LLR; EU(European Commission); Oxford NIHR BRU; Bayer Healthcare(Bayer AGBayer Healthcare Pharmaceuticals); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by grants from CRUK (programme award C300/A13058), MRC, LLR, EU, Oxford NIHR BRU and Bayer Healthcare. We thank Sarah Atkinson for her help with preparing the manuscript.	Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Biswas AK, 2012, CANCER RES, V72, P13, DOI 10.1158/0008-5472.CAN-11-2196; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Botz J, 1996, MOL CELL BIOL, V16, P3401; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DeGregori J, 2006, CURR MOL MED, V6, P739; delaLuna S, 1996, J CELL SCI, V109, P2443; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Kohn MJ, 2004, MOL CELL BIOL, V24, P7197, DOI 10.1128/MCB.24.16.7197-7205.2004; Kohn MJ, 2003, DEVELOPMENT, V130, P1295, DOI 10.1242/dev.00355; Lee TA, 2000, ONCOGENE, V19, P2257, DOI 10.1038/sj.onc.1203556; Lin WC, 2001, GENE DEV, V15, P1833; Magae J, 1996, J CELL SCI, V109, P1717; Markham D, 2006, EMBO REP, V7, P192, DOI 10.1038/sj.embor.7400591; Milton A, 2006, ONCOGENE, V25, P3212, DOI 10.1038/sj.onc.1209343; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Munro S, 2010, ONCOGENE, V29, P2357, DOI 10.1038/onc.2009.511; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Polager S, 2008, TRENDS CELL BIOL, V18, P528, DOI 10.1016/j.tcb.2008.08.003; Polager S, 2009, NAT REV CANCER, V9, P738, DOI 10.1038/nrc2718; Rubin SM, 2005, CELL, V123, P1093, DOI 10.1016/j.cell.2005.09.044; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; Sherr C J, 2000, Harvey Lect, V96, P73; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yamasaki Lili, 2003, Cancer Treat Res, V115, P209; Yu W, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-r96; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666	42	7	7	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3594	3603		10.1038/onc.2013.316	http://dx.doi.org/10.1038/onc.2013.316			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23934193				2022-12-28	WOS:000338941100011
J	Lin, YH; Liao, CJ; Huang, YH; Wu, MH; Chi, HC; Wu, SM; Chen, CY; Tseng, YH; Tsai, CY; Chung, IH; Wu, TI; Tsai, MM; Lin, CD; Lin, KH				Lin, Y-H; Liao, C-J; Huang, Y-H; Wu, M-H; Chi, H-C; Wu, S-M; Chen, C-Y; Tseng, Y-H; Tsai, C-Y; Chung, I-H; Wu, T-I; Tsai, M-M; Lin, C. D.; Lin, K-H			Thyroid hormone receptor represses miR-17 expression to enhance tumor metastasis in human hepatoma cells	ONCOGENE			English	Article						thyroid hormone; microRNA; p-AKT; matrix metalloproteinases-3; hepatocellular carcinoma	BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; NEGATIVE REGULATION; DOWN-REGULATION; CHROMOSOME 13Q; PROLIFERATION; INVASION; GENES; METALLOPROTEINASES; ACTIVATION	MicroRNAs (miRNAs) are thought to control tumor metastasis through direct interactions with target genes. Thyroid hormone (T-3) and its receptor (TR) are involved in cell growth and cancer progression. However, the issue of whether miRNAs participate in T-3/TR-mediated tumor migration is yet to be established. In the current study, we demonstrated that T-3/TR negatively regulates mature miR-17 transcript expression, both in vitro and in vivo. Luciferase reporter and chromatin immunoprecipitation (ChIP) assays localized the regions responding to TR-mediated repression to positions -2234/-2000 of the miR-17 promoter sequence. Overexpression of miR-17 markedly inhibited cell migration and invasion in vitro and in vivo, mediated via suppression of matrix metalloproteinases (MMP)-3. Moreover, p-AKT expression was increased in miR-17-knockdown cells that led to enhanced cell invasion, which was blocked by LY294002. Notably, low miR-17 expression was evident in highly metastatic cells. The cell migration ability was increased by T3, but partially reduced upon miR-17 overexpression. Notably, TR alpha 1 was frequently upregulated in hepatocellular carcinoma (HCC) samples and associated with low overall survival (P = 0.023). miR-17 expression was significantly negatively associated with TRa1 (P = 0.033) and MMP3 (P = 0.043) in HCC specimens. Data from our study suggest that T-3/TR, miR-17, p-AKT and MMP3 activities are interlinked in the regulation of cancer cell metastasis.	[Lin, Y-H; Liao, C-J; Wu, M-H; Chi, H-C; Wu, S-M; Chen, C-Y; Tseng, Y-H; Tsai, C-Y; Chung, I-H; Wu, T-I; Lin, K-H] Chang Gung Univ, Coll Med, Dept Biochem, Tao Yuan 333, Taiwan; [Huang, Y-H] Chang Gung Mem Hosp, Dept Hepatogastroenterol, Liver Res Ctr, Linkou, Taiwan; [Tsai, M-M] Chang Gung Univ Sci & Technol, Dept Nursing, Tao Yuan, Taiwan; [Lin, C. D.] Pacific Union Coll, Premed Program, Angwin, CA USA	Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University of Science & Technology	Lin, KH (corresponding author), Chang Gung Univ, Coll Med, Dept Biochem, 259 Wen Hwa 1 Rd, Tao Yuan 333, Taiwan.	khlin@mail.cgu.edu.tw			Chang-Gung University, Taoyuan, Taiwan [CMRPD 34013, NMRP 140511]; National Science Council of the Republic of China [NSC 94-2320-B-182-052, NSC 98-2312-B-182A-001-MY3]	Chang-Gung University, Taoyuan, Taiwan; National Science Council of the Republic of China(Ministry of Science and Technology, Taiwan)	This work was supported by grants from Chang-Gung University, Taoyuan, Taiwan (CMRPD 34013, NMRP 140511) and from the National Science Council of the Republic of China (NSC 94-2320-B-182-052, NSC 98-2312-B-182A-001-MY3).	Barrera-Hernandez G, 1999, ENDOCRINOLOGY, V140, P5267, DOI 10.1210/en.140.11.5267; Bramhall SR, 1996, BRIT J CANCER, V73, P972, DOI 10.1038/bjc.1996.190; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chang CC, 2013, ORAL ONCOL S, VS1040-8428, P00070; Chen CY, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.011270; Chen RN, 2008, ENDOCRINOLOGY, V149, P3817, DOI 10.1210/en.2007-0989; Cheng S Y, 2000, Rev Endocr Metab Disord, V1, P9, DOI 10.1023/A:1010052101214; Chi HC, 2012, CELL DEATH DIFFER, V19, P1802, DOI 10.1038/cdd.2012.58; Davis FB, 2006, CANCER RES, V66, P7270, DOI 10.1158/0008-5472.CAN-05-4365; Hall LC, 2008, J STEROID BIOCHEM, V109, P57, DOI 10.1016/j.jsbmb.2007.12.008; Huang YH, 2010, J CELL PHYSIOL, V222, P347, DOI 10.1002/jcp.21959; Huang Ya-Hui, 2008, Chang Gung Med J, V31, P325; Kress E, 2010, GASTROENTEROLOGY, V138, P1863, DOI 10.1053/j.gastro.2010.01.041; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Li HL, 2011, BREAST CANCER RES TR, V126, P565, DOI 10.1007/s10549-010-0954-4; Liao CH, 2010, ENDOCR-RELAT CANCER, V17, P99, DOI 10.1677/ERC-09-0050; Liao CJ, 2011, CANCER SCI, V102, P2255, DOI 10.1111/j.1349-7006.2011.02102.x; Lin KH, 2000, ENDOCRINOLOGY, V141, P2540, DOI 10.1210/en.141.7.2540; Lin YH, 2013, ONCOGENE, V32, P3904, DOI 10.1038/onc.2013.5; Lin YW, 1999, EUR J CANCER, V35, P1730, DOI 10.1016/S0959-8049(99)00205-1; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; Nakano K, 2004, BIOCHEM J, V378, P549, DOI 10.1042/BJ20031592; Nomura H, 1996, INT J CANCER, V69, P9, DOI 10.1002/(SICI)1097-0215(19960220)69:1<9::AID-IJC3>3.0.CO;2-8; Okamoto K, 2010, INTERNAL MED, V49, P887, DOI 10.2169/internalmedicine.49.3268; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; Shan SW, 2009, NAT CELL BIOL, V11, P1031, DOI 10.1038/ncb1917; Sze KMF, 2011, HEPATOLOGY, V53, P1558, DOI 10.1002/hep.24232; Thormeyer D, 1999, INT J MOL MED, V4, P351; Tsang YS, 1999, INT J CANCER, V83, P305, DOI 10.1002/(SICI)1097-0215(19991029)83:3<305::AID-IJC3>3.0.CO;2-D; Tsui KH, 2008, PROSTATE, V68, P610, DOI 10.1002/pros.20725; Wu SM, 2011, ONCOGENE, V30, P2057, DOI 10.1038/onc.2010.585; Xu CW, 2010, EUR J CANCER, V46, P2828, DOI 10.1016/j.ejca.2010.06.127; Yang F, 2010, HEPATOLOGY, V51, P1614, DOI 10.1002/hep.23566; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Yu ZR, 2008, J CELL BIOL, V182, P509, DOI 10.1083/jcb.200801079; Yu ZR, 2010, P NATL ACAD SCI USA, V107, P8231, DOI 10.1073/pnas.1002080107; Zhang MJ, 2011, MOL CELL BIOCHEM, V357, P387, DOI 10.1007/s11010-011-0909-z	38	39	40	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4509	4518		10.1038/onc.2013.309	http://dx.doi.org/10.1038/onc.2013.309			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23912452				2022-12-28	WOS:000324831300006
J	Macha, MA; Rachagani, S; Pai, P; Gupta, S; Lydiatt, WM; Smith, RB; Johansson, SL; Lele, SM; Kakar, SS; Lee, JH; Meza, J; Ganti, AK; Jain, M; Batra, SK				Macha, M. A.; Rachagani, S.; Pai, P.; Gupta, S.; Lydiatt, W. M.; Smith, R. B.; Johansson, S. L.; Lele, S. M.; Kakar, S. S.; Lee, J. H.; Meza, J.; Ganti, A. K.; Jain, M.; Batra, S. K.			MUC4 regulates cellular senescence in head and neck squamous cell carcinoma through p16/Rb pathway	ONCOGENE			English	Article							PANCREATIC-CANCER; HUMAN-PAPILLOMAVIRUS; MUCINS MUC1; EXPRESSION; GROWTH; PROLIFERATION; METASTASIS; OVEREXPRESSION; SURVIVAL; BIOLOGY	The limited effectiveness of therapy for patients with advanced stage head and neck squamous cell carcinoma (HNSCC) or recurrent disease is a reflection of an incomplete understanding of the molecular basis of HNSCC pathogenesis. MUC4, a high molecular weight glycoprotein, is differentially overexpressed in many human cancers and implicated in cancer progression and resistance to several chemotherapies. However, its clinical relevance and the molecular mechanisms through which it mediates HNSCC progression are not well understood. This study revealed a significant upregulation of MUC4 in 78% (68/87) of HNSCC tissues compared with 10% positivity (1/10) in benign samples (P = 0.006, odds ratio (95% confidence interval) = 10.74 (2.0-57.56). MUC4 knockdown (KD) in SCC1 and SCC10B HNSCC cell lines resulted in significant inhibition of growth in vitro and in vivo, increased senescence as indicated by an increase in the number of flat, enlarged and senescence-associated beta-galactosidase (SA-beta-Gal)positive cells. Decreased cellular proliferation was associated with G(0)/G(1) cell cycle arrest and decrease expression of cell cycle regulatory proteins like cyclin E, cyclin D1 and decrease in BrdU incorporation. Mechanistic studies revealed upregulation of p16, pRb dephosphorylation and its interaction with histone deacetylase 1/2. This resulted in decreased histone acetylation (H3K9) at cyclin E promoter leading to its downregulation. Orthotopic implantation of MUC4 KD SCC1 cells into the floor of the mouth in nude mice resulted in the formation of significantly smaller tumors (170 +/- 18.30 mg) compared to those (375 +/- 17.29 mg) formed by control cells (P = 0.00007). In conclusion, our findings showed that MUC4 overexpression has a critical role by regulating proliferation and cellular senescence of HNSCC cells. Downregulation of MUC4 may be a promising therapeutic approach for treating HNSCC patients.	[Macha, M. A.; Rachagani, S.; Pai, P.; Gupta, S.; Jain, M.; Batra, S. K.] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Lydiatt, W. M.; Smith, R. B.] Univ Nebraska, Med Ctr, Dept Otolaryngol, Omaha, NE 68198 USA; [Johansson, S. L.; Lele, S. M.] Univ Nebraska, Med Ctr, Dept Pathol, Omaha, NE 68198 USA; [Kakar, S. S.] Univ Louisville, Dept Physiol & Biophys, Louisville, KY 40292 USA; [Lee, J. H.] Sanford Canc Res Ctr, Sanford ENT Head & Neck Surg, Sioux Falls, SD USA; [Meza, J.] Univ Nebraska, Med Ctr, Coll Publ Hlth, Dept Biostat, Omaha, NE 68198 USA; [Ganti, A. K.] VA Nebraska Western Iowa Hlth Care Syst, Dept Internal Med, Omaha, NE USA; [Ganti, A. K.] Univ Nebraska, Med Ctr, Omaha, NE 68198 USA; [Jain, M.; Batra, S. K.] Buffett Canc Ctr, Omaha, NE USA; [Batra, S. K.] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Louisville; Sanford Health; University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Jain, M (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	mjain@unmc.edu; sbatra@unmc.edu	Ganti, Apar Kishor/D-5498-2015; MACHA, MUZAFAR AHMAD/AAN-5735-2020	Ganti, Apar Kishor/0000-0003-3724-2671; MACHA, MUZAFAR AHMAD/0000-0003-4468-4435	National Institutes of Health [RO1 CA133774, U54 CA163120, UO1 CA111294, P50 CA 127297, R21 CA156037, P20 RR021937]; NATIONAL CANCER INSTITUTE [R21CA156037, R01CA133774, P50CA127297, U54CA163120, U01CA111294] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR021937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103480] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge the invaluable technical support from Ms Kavita Mallya and Hanan I Farghaly. We also thank Janice A Taylor and James R Talaska of the confocal laser scanning microscope core facility at UNMC for their support. This work was supported, in part, by the grants from National Institutes of Health (RO1 CA133774, U54 CA163120, UO1 CA111294, P50 CA 127297, R21 CA156037 and P20 RR021937).	Alos L, 2005, AM J SURG PATHOL, V29, P806, DOI 10.1097/01.pas.0000155856.84553.c9; Argiris A, 2008, LANCET, V371, P1695, DOI 10.1016/S0140-6736(08)60728-X; Bafna S, 2008, CANCER RES, V68, P9231, DOI 10.1158/0008-5472.CAN-08-3135; Bandyopadhyay D, 2002, CANCER RES, V62, P6231; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cai Yang, 2007, Chinese Journal of Pathology, V36, P375; Califano J, 1996, CANCER RES, V56, P2488; Cammarano MS, 2005, MOL CELL BIOL, V25, P9532, DOI 10.1128/MCB.25.21.9532-9542.2005; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chakraborty Subhankar, 2008, Expert Opin Med Diagn, V2, P891, DOI 10.1517/17530059.2.8.891; Chaturvedi P, 2008, FASEB J, V22, P966, DOI 10.1096/fj.07-9673rev; Chaturvedi P, 2007, MOL CANCER RES, V5, P309, DOI 10.1158/1541-7786.MCR-06-0353; Chung IS, 2008, ORAL ONCOL, V44, P1118, DOI 10.1016/j.oraloncology.2008.01.017; Dey P, 2012, CLIN CANCER RES, V18, P6188, DOI 10.1158/1078-0432.CCR-12-1789; DIMRI GP, 1994, COLD SPRING HARB SYM, V59, P67, DOI 10.1101/SQB.1994.059.01.010; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fakhry C, 2008, JNCI-J NATL CANCER I, V100, P261, DOI 10.1093/jnci/djn011; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Gil Z, 2009, ISR MED ASSOC J, V11, P296; Hamada T, 2012, INT J CANCER, V130, P1768, DOI 10.1002/ijc.26187; Hammarstedt L, 2006, INT J CANCER, V119, P2620, DOI 10.1002/ijc.22177; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Kaur S, 2013, NAT REV GASTRO HEPAT, V10, P607, DOI 10.1038/nrgastro.2013.120; Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687; Kitazono I, 2013, PANCREAS, V42, P1120, DOI 10.1097/MPA.0b013e3182965915; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Liggett WH, 1996, CANCER RES, V56, P4119; LLeonart ME, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-3; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Macha MA, CANC LETT, V341, P166; Majhi PD, 2013, J THORAC ONCOL, V8, P398, DOI 10.1097/JTO.0b013e3182829e06; Moniaux N, 2004, J HISTOCHEM CYTOCHEM, V52, P253, DOI 10.1177/002215540405200213; Mukhopadhyay P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054455; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nichols Anthony C, 2012, ISRN Oncol, V2012, P809370, DOI 10.5402/2012/809370; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Peeper DS, 2002, NAT CELL BIOL, V4, P148, DOI 10.1038/ncb742; Ponnusamy MP, 2008, BRIT J CANCER, V99, P520, DOI 10.1038/sj.bjc.6604517; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Ponnusamy MP, 2008, J OVARIAN RES, V1, DOI 10.1186/1757-2215-1-4; Rabassa ME, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-253; Rachagani S, 2012, CARCINOGENESIS, V33, P1953, DOI 10.1093/carcin/bgs225; Rakha EA, 2005, MODERN PATHOL, V18, P1295, DOI 10.1038/modpathol.3800445; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Sano D, 2011, CLIN CANCER RES, V17, P6658, DOI 10.1158/1078-0432.CCR-11-0046; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Tanaka K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0027922; Tang AL, 2012, HEAD NECK-J SCI SPEC, V34, P1480, DOI 10.1002/hed.21962; Urnov FD, 2001, ONCOGENE, V20, P2991, DOI 10.1038/sj.onc.1204323; Weed DT, 2001, OTOLARYNG HEAD NECK, V124, P127, DOI 10.1067/mhn.2001.112575; Zhang XW, 2006, MOL CELL BIOL, V26, P8252, DOI 10.1128/MCB.00604-06	56	23	24	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1698	1708		10.1038/onc.2014.102	http://dx.doi.org/10.1038/onc.2014.102			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24747969	Green Accepted			2022-12-28	WOS:000351848400010
J	Ding, LW; Sun, QY; Lin, DC; Chien, W; Hattori, N; Dong, XM; Gery, S; Garg, M; Doan, NB; Said, JW; Xiao, JF; Yang, H; Liu, LZ; Meng, X; Huang, RYJ; Tang, K; Koeffler, H				Ding, L-W; Sun, Q-Y; Lin, D-C; Chien, W.; Hattori, N.; Dong, X-M; Gery, S.; Garg, M.; Doan, N. B.; Said, J. W.; Xiao, J-F; Yang, H.; Liu, L-Z; Meng, X.; Huang, R. Y-J; Tang, K.; Koeffler, H. P.			LNK (SH2B3): paradoxical effects in ovarian cancer	ONCOGENE			English	Article							ADAPTER PROTEIN LNK; ACUTE LYMPHOBLASTIC-LEUKEMIA; MYELOPROLIFERATIVE NEOPLASMS; HEMATOPOIETIC STEM; PLECKSTRIN HOMOLOGY; ENDOTHELIAL-CELLS; PROGENITOR CELLS; ACTIVATION; EXPRESSION; MUTATIONS	LNK (SH2B3) is an adaptor protein studied extensively in normal and malignant hematopoietic cells. In these cells, it downregulates activated tyrosine kinases at the cell surface resulting in an antiproliferative effect. To date, no studies have examined activities of LNK in solid tumors. In this study, we found by in silico analysis and staining tissue arrays that the levels of LNK expression were elevated in high-grade ovarian cancer. To test the functional importance of this observation, LNK was either overexpressed or silenced in several ovarian cancer cell lines. Remarkably, overexpression of LNK rendered the cells resistant to death induced by either serum starvation or nutrient deprivation, and generated larger tumors using a murine xenograft model. In contrast, silencing of LNK decreased ovarian cancer cell growth in vitro and in vivo. Western blot studies indicated that overexpression of LNK upregulated and extended the transduction of the mitogenic signal, whereas silencing of LNK produced the opposite effects. Furthermore, forced expression of LNK reduced cell size, inhibited cell migration and markedly enhanced cell adhesion. Liquid chromatography-mass spectroscopy identified 14-3-3 as one of the LNK-binding partners. Our results suggest that in contrast to the findings in hematologic malignancies, the adaptor protein LNK acts as a positive signal transduction modulator in ovarian cancers.	[Ding, L-W; Sun, Q-Y; Lin, D-C; Chien, W.; Hattori, N.; Garg, M.; Xiao, J-F; Yang, H.; Liu, L-Z; Meng, X.; Huang, R. Y-J; Koeffler, H. P.] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117599, Singapore; [Lin, D-C; Gery, S.; Koeffler, H. P.] Univ Calif Los Angeles, Sch Med, Cedar Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA USA; [Dong, X-M; Tang, K.] Nanyang Technol Univ, Sch Biol Sci, Singapore 639798, Singapore; [Doan, N. B.; Said, J. W.] Santa Monica Univ Calif, Los Angeles Med Ctr, Los Angeles, CA USA; [Koeffler, H. P.] Natl Univ Singapore Hosp, Natl Univ Canc Inst, Singapore 117548, Singapore	National University of Singapore; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; National University of Singapore	Ding, LW (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, 13 North,MD6,14 Med Dr, Singapore 117599, Singapore.	csidlw@nus.edu.sg	Huang, Ruby Yun-Ju/AAE-8854-2019; Garg, Manoj/C-4076-2019; Ding, Ling-Wen/H-6916-2019; Tang, Kai/A-2194-2011; Sun, Qiao-Yang/ABA-6813-2020	Huang, Ruby Yun-Ju/0000-0001-6376-3185; Garg, Manoj/0000-0002-3492-2957; Ding, Ling-Wen/0000-0003-0022-1551; Sun, Qiao-Yang/0000-0002-9855-5586	National Research Foundation Singapore; Singapore Ministry of Education under the Research Centres of Excellence initiative; National Institutes of Health of the USA [R01CA026038-33]; Singapore Ministry of Health's National Medical Research Council under its Singapore Translational Research Investigator Award; NATIONAL CANCER INSTITUTE [R01CA026038] Funding Source: NIH RePORTER	National Research Foundation Singapore(National Research Foundation, Singapore); Singapore Ministry of Education under the Research Centres of Excellence initiative(Ministry of Education, Singapore); National Institutes of Health of the USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Singapore Ministry of Health's National Medical Research Council under its Singapore Translational Research Investigator Award(Ministry of Health-SingaporeNational Medical Research Council, Singapore); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research is supported by the National Research Foundation Singapore and the Singapore Ministry of Education under the Research Centres of Excellence initiative, and by the National Institutes of Health of the USA (R01CA026038-33) and the Singapore Ministry of Health's National Medical Research Council under its Singapore Translational Research Investigator Award to HPK.	Ahmed Z, 2003, BIOCHEM J, V371, P405, DOI 10.1042/BJ20021589; Almudi I, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-26; Baran-Marszak F, 2010, BLOOD, V116, P5961, DOI 10.1182/blood-2009-12-256768; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bersenev A, 2010, J CLIN INVEST, V120, P2058, DOI 10.1172/JCI42032; Buza-Vidas N, 2006, GENE DEV, V20, P2018, DOI 10.1101/gad.385606; Chatelais M, 2011, XENOTRANSPLANTATION, V18, P108, DOI 10.1111/j.1399-3089.2011.00629.x; Dawson MR, 2009, NATURE, V461, pE4, DOI 10.1038/nature08254; Devalliere J, 2012, FASEB J, V26, P2592, DOI 10.1096/fj.11-193383; Devalliere J, 2011, BIOCHEM PHARMACOL, V82, P1391, DOI 10.1016/j.bcp.2011.06.023; Fitau J, 2006, J BIOL CHEM, V281, P20148, DOI 10.1074/jbc.M510997200; Gery S, 2013, ONCOGENE, V32, P3111, DOI 10.1038/onc.2012.435; Gery S, 2007, BLOOD, V110, P3360, DOI 10.1182/blood-2007-05-089326; Gery S, 2009, J LEUKOCYTE BIOL, V85, P957, DOI 10.1189/jlb.0908575; Gery S, 2009, EXP HEMATOL, V37, P585, DOI 10.1016/j.exphem.2009.01.009; Gueller S, 2008, BIOCHEM J, V415, P241, DOI 10.1042/BJ20080102; Gueller S, 2011, EXP HEMATOL, V39, P591, DOI 10.1016/j.exphem.2011.02.001; Gueller S, 2010, J LEUKOCYTE BIOL, V88, P699, DOI 10.1189/jlb.0309185; Ha JS, 2011, AM J HEMATOL, V86, P866, DOI 10.1002/ajh.22107; Hurtado C, 2011, LEUKEMIA RES, V35, P1537, DOI 10.1016/j.leukres.2011.07.009; Jiang J, 2012, J CLIN INVEST, V122, P2079, DOI 10.1172/JCI59719; Lanning NJ, 2011, J CELL SCI, V124, P3095, DOI 10.1242/jcs.081547; Lasho TL, 2010, NEW ENGL J MED, V363, P1189, DOI 10.1056/NEJMc1006966; Lee JI, 2008, PHYSIOL GENOMICS, V33, P218, DOI 10.1152/physiolgenomics.00263.2007; Li YJ, 2000, J IMMUNOL, V164, P5199, DOI 10.4049/jimmunol.164.10.5199; Lin DC, 2012, BLOOD, V120, P3310, DOI 10.1182/blood-2011-10-388611; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Maures TJ, 2009, MOL ENDOCRINOL, V23, P1077, DOI 10.1210/me.2009-0011; Nishi M, 2005, MOL CELL BIOL, V25, P2607, DOI 10.1128/MCB.25.7.2607-2621.2005; Oh ST, 2011, THER ADV HEMATOL, V2, P11, DOI 10.1177/2040620710393391; Oh ST, 2010, BLOOD, V116, P988, DOI 10.1182/blood-2010-02-270108; Pellinen T, 2008, DEV CELL, V15, P371, DOI 10.1016/j.devcel.2008.08.001; Perez-Garcia A, 2013, BLOOD, V122, P2425, DOI 10.1182/blood-2013-05-500850; Qian XZ, 2001, MOL CELL BIOL, V21, P1613, DOI 10.1128/MCB.21.5.1613-1620.2001; Roberts KG, 2012, CANCER CELL, V22, P153, DOI 10.1016/j.ccr.2012.06.005; Rudd C E, 2001, Sci STKE, V2001, ppe1; Seita J, 2007, P NATL ACAD SCI USA, V104, P2349, DOI 10.1073/pnas.0606238104; Simon C, 2008, BLOOD, V112, P1039, DOI 10.1182/blood-2008-05-154849; Takaki S, 2002, J EXP MED, V195, P151, DOI 10.1084/jem.20011170; Tan TZ, 2013, EMBO MOL MED, V5, P1051, DOI 10.1002/emmm.201201823; Tong W, 2005, BLOOD, V105, P4604, DOI 10.1182/blood-2004-10-4093; Tong W, 2004, J EXP MED, V200, P569, DOI 10.1084/jem.20040762; Velazquez L, 2002, J EXP MED, V195, P1599, DOI 10.1084/jem.20011883; Werz C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000596; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yoshida K, 2013, NAT GENET, V45, P1293, DOI 10.1038/ng.2759; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725	47	16	18	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1463	1474		10.1038/onc.2014.34	http://dx.doi.org/10.1038/onc.2014.34			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24704825	Green Submitted, Green Accepted			2022-12-28	WOS:000350806500012
J	Miyake, M; Goodison, S; Lawton, A; Gomes-Giacoia, E; Rosser, CJ				Miyake, M.; Goodison, S.; Lawton, A.; Gomes-Giacoia, E.; Rosser, C. J.			Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1/2 pathway	ONCOGENE			English	Article							BLADDER-CANCER; PROSTATE-CANCER; ENDOTHELIAL-CELLS; RIBONUCLEOLYTIC ACTIVITY; NUCLEAR TRANSLOCATION; UROTHELIAL CARCINOMA; BINDING-PROTEIN; ATHYMIC MICE; TISSUE; THERAPY	Tumor angiogenesis is essential for tumor growth and metastasis and is dependent on key angiogenic factors. Angiogenin (ANG), a 14.2-kDa polypeptide member of the RNase A superfamily, is an angiogenic protein that has been reported to be upregulated and associated with poor prognosis in some human cancers. The mechanisms through which aberrant ANG levels promote specific steps in tumor progression are unknown. Here, we show that ANG expression in human tissues is strongly correlated with an invasive cancer phenotype. We also show that ANG induces cellular survival, proliferation, endothelial tube formation and xenograft angiogenesis and growth. Novel mechanistic investigations revealed that ANG expression stimulated matrix metallopeptidase-2 (MMP2) expression through the phosphorylation of ERK1/2. Targeting ANG in vivo with N65828, a small-molecule inhibitor of the ribonucleolytic activity of human ANG, resulted in the diminution of xenograft tumoral growth through the inhibition of angiogenesis. Our findings support an unrecognized interplay between ANG, ERK1/2 and MMP2 that can impact tumor growth and progression. The targeting of ANG and associated factors could provide a novel strategy to inhibit tumor establishment and growth.	[Miyake, M.; Goodison, S.; Gomes-Giacoia, E.; Rosser, C. J.] MD Anderson Canc Ctr, Canc Res Inst, Orlando, FL USA; [Goodison, S.; Rosser, C. J.] Nonagen Biosci Corp, Orlando, FL USA; [Lawton, A.] Orlando Hlth, Dept Pathol, Orlando, FL USA	University of Texas System; UTMD Anderson Cancer Center	Rosser, CJ (corresponding author), Univ Hawaii, Ctr Canc, Sch Med, Clin & Translat Program, 701 Ilalo St, Honolulu, HI 96813 USA.	crosser@cc.hawaii.edu			Florida Biomedical Program James and Esther King Team Science Project [1KT-01]; NATIONAL CANCER INSTITUTE [R01CA116161] Funding Source: NIH RePORTER	Florida Biomedical Program James and Esther King Team Science Project; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by Florida Biomedical Program James and Esther King Team Science Project 1KT-01 (CJR). Dr Kwai Wa Cheng for reading this manuscript and offering editorial suggestions.	Anai S, 2007, MOL CANCER THER, V6, P101, DOI 10.1158/1535-7163.MCT-06-0367; Anai S, 2011, UROL ONCOL-SEMIN ORI, V29, P421, DOI 10.1016/j.urolonc.2009.04.009; BOCHNER BH, 1995, J NATL CANCER I, V87, P1603, DOI 10.1093/jnci/87.21.1603; Cantwell-Dorris ER, 2011, MOL CANCER THER, V10, P385, DOI 10.1158/1535-7163.MCT-10-0799; Chuang CK, 2010, ONCOL LETT, V1, P691, DOI 10.3892/ol_00000121; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gontero P, 2004, EUR UROL, V46, P296, DOI 10.1016/j.eururo.2004.04.001; Goodison S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047469; Grossfeld GD, 1997, J NATL CANCER I, V89, P219, DOI 10.1093/jnci/89.3.219; Hartmann A, 1999, CANCER RES, V59, P1578; Hirukawa S, 2005, CLIN CANCER RES, V11, P8745, DOI 10.1158/1078-0432.CCR-05-1495; Hisai H, 2003, CLIN CANCER RES, V9, P4852; HU GF, 1994, P NATL ACAD SCI USA, V91, P12096, DOI 10.1073/pnas.91.25.12096; HU GF, 1993, P NATL ACAD SCI USA, V90, P1217, DOI 10.1073/pnas.90.4.1217; HU GF, 1991, P NATL ACAD SCI USA, V88, P2227, DOI 10.1073/pnas.88.6.2227; Inoue K, 2000, CLIN CANCER RES, V6, P2104; Kao RYT, 2002, P NATL ACAD SCI USA, V99, P10066, DOI 10.1073/pnas.152342999; Katona TM, 2005, CLIN CANCER RES, V11, P8358, DOI 10.1158/1078-0432.CCR-05-0962; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; Knowles MA, 2006, CARCINOGENESIS, V27, P361, DOI 10.1093/carcin/bgi310; Kollermann J, 2001, AM J CLIN PATHOL, V116, P115; Kumar B, 2010, CANCER RES, V70, P832, DOI 10.1158/0008-5472.CAN-09-2918; LEE FS, 1989, BIOCHEM BIOPH RES CO, V161, P121, DOI 10.1016/0006-291X(89)91569-6; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1974, CANCER RES, V34, P997; Miyake H, 1999, CANCER, V86, P316, DOI 10.1002/(SICI)1097-0142(19990715)86:2<316::AID-CNCR16>3.0.CO;2-T; Miyake M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-322; Miyake M, 2012, BMC UROL, V12, DOI 10.1186/1471-2490-12-23; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; Nilsson UW, 2010, CLIN CANCER RES, V16, P3659, DOI 10.1158/1078-0432.CCR-10-0501; OBrien T, 1997, CANCER RES, V57, P136; OBrien TS, 1996, CANCER RES, V56, P4799; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Piccoli R, 1998, P NATL ACAD SCI USA, V95, P4579, DOI 10.1073/pnas.95.8.4579; Sakai Y, 2009, WORLD J UROL, V27, P659, DOI 10.1007/s00345-009-0422-0; Shapiro R, 2000, J MOL BIOL, V302, P497, DOI 10.1006/jmbi.2000.4075; Tello-Montoliu A, 2006, J THROMB HAEMOST, V4, P1864, DOI 10.1111/j.1538-7836.2006.01995.x; Tsuji T, 2005, CANCER RES, V65, P1352, DOI 10.1158/0008-5472.CAN-04-2058; Uehara H, 2005, PROSTATE, V64, P40, DOI 10.1002/pros.20223; Urquidi V, 2012, CANCER EPIDEM BIOMAR, V21, P2149, DOI 10.1158/1055-9965.EPI-12-0428; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; Yoshioka N, 2006, P NATL ACAD SCI USA, V103, P14519, DOI 10.1073/pnas.0606708103; Zhao H, 2005, CANCER-AM CANCER SOC, V104, P30, DOI 10.1002/cncr.21136	46	63	67	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					890	901		10.1038/onc.2014.2	http://dx.doi.org/10.1038/onc.2014.2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24561529	Green Accepted			2022-12-28	WOS:000349472000009
J	Yang, J; Kalogerou, M; Samsel, PA; Zhang, Y; Griffiths, DFR; Gallacher, J; Sampson, JR; Shen, MH				Yang, J.; Kalogerou, M.; Samsel, P. A.; Zhang, Y.; Griffiths, D. F. R.; Gallacher, J.; Sampson, J. R.; Shen, M. H.			Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin	ONCOGENE			English	Article							TUBEROUS SCLEROSIS COMPLEX; INSULIN-RESISTANCE; MAMMALIAN TARGET; MTOR; ACTIVATION; REVEALS; KINASE; IDENTIFICATION; LETHALITY; SUBSTRATE	Tuberous sclerosis (TSC) is an inherited syndrome in which tumours in multiple organs are characterised by activation of mammalian target of rapamycin complex 1 (mTORC1). Previous work suggests that mTORC1 activation is associated with feedback inhibition of Akt, a substrate of mTORC2. This could limit TSC-associated tumour growth but lead to paradoxical promotion of tumour cell survival upon treatment with mTOR inhibitors. However, Akt/mTOR signalling has not been fully investigated in TSC-associated tumours and it has been uncertain whether mTOR inhibition can prevent TSC-associated renal tumourigenesis. In this study, we investigated Akt/mTOR signalling in renal tumours using a Tsc2(+/-) mouse model and tested whether mTOR inhibition could prevent renal tumourigenesis. We found that all renal lesions including cysts, adenomas and carcinomas exhibited activation of both Akt and mTORC1 as evidenced by increased protein expression and phosphorylation of Akt and mTOR and their downstream targets. Protein kinase Ca was also highly expressed and phosphorylated in these lesions, consistent with activation of mTORC2. Surprisingly, IRS proteins were highly expressed, in contrast to a striking decrease seen in cultured Tsc2(-/-) mouse embryonic fibroblasts, suggesting one mechanism through which loss of feedback inhibition of Akt may occur in mTORC1 hyperactivated Tsc-associated tumours. Long-term treatment with rapamycin reduced both Akt and mTORC1 activity in normal kidney tissues and blocked the development of all types of renal lesions. In conclusion, in contrast to previous studies, we found that Akt signalling is not inhibited in Tsc-associated renal lesions and that by partially inhibiting the Akt/mTOR pathway, rapamycin is highly effective in preventing Tsc-associated tumours.	[Yang, J.; Kalogerou, M.; Samsel, P. A.; Zhang, Y.; Sampson, J. R.; Shen, M. H.] Cardiff Univ, Sch Med, Inst Canc & Genet, Inst Med Genet, Cardiff CF14 4XN, S Glam, Wales; [Griffiths, D. F. R.] Cardiff Univ, Sch Med, Inst Canc & Genet, Sect Pathol, Cardiff CF14 4XN, S Glam, Wales; [Gallacher, J.] Cardiff Univ, Sch Med, Dept Primary Care & Publ Hlth, Cardiff CF14 4XN, S Glam, Wales	Cardiff University; Cardiff University; Cardiff University	Shen, MH (corresponding author), Cardiff Univ, Sch Med, Inst Canc & Genet, Inst Med Genet, Cardiff CF14 4XN, S Glam, Wales.	Sampson@cf.ac.uk; shenmh@cf.ac.uk			Wales Gene Park, UK; Tuberous Sclerosis Association, UK	Wales Gene Park, UK; Tuberous Sclerosis Association, UK	We thank Dr David Kwiatkowski for providing the Tsc2<SUP>+/-</SUP> mouse model. This project was supported by the Wales Gene Park, UK and the Tuberous Sclerosis Association, UK.	Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Castedo M, 2002, CELL DEATH DIFFER, V9, P99, DOI 10.1038/sj/cdd/4400978; Dazert E, 2011, CURR OPIN CELL BIOL, V23, P744, DOI 10.1016/j.ceb.2011.09.003; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hasumi Y, 2009, P NATL ACAD SCI USA, V106, P18722, DOI 10.1073/pnas.0908853106; Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498; Huang JX, 2009, CANCER RES, V69, P6107, DOI 10.1158/0008-5472.CAN-09-0975; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Johannessen CM, 2008, CURR BIOL, V18, P56, DOI 10.1016/j.cub.2007.11.066; Kalogerou M, 2012, EUR J RADIOL, V81, P2069, DOI 10.1016/j.ejrad.2011.06.054; Krueger DA, 2010, NEW ENGL J MED, V363, P1801, DOI 10.1056/NEJMoa1001671; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lamming DW, 2012, SCIENCE, V335, P1638, DOI 10.1126/science.1215135; Lee L, 2005, GENE CHROMOSOME CANC, V42, P213, DOI 10.1002/gcc.20118; Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605; NELLIST M, 1993, CELL, V75, P1305; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Pollizzi K, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-38; Proud CG, 2011, BIOCHEM SOC T, V39, P431, DOI 10.1042/BST0390431; Russell RC, 2011, DEVELOPMENT, V138, P3343, DOI 10.1242/dev.058230; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Wilson C, 2005, HUM MOL GENET, V14, P1839, DOI 10.1093/hmg/ddi190; Xu NH, 2012, J ONCOL, V2012, DOI 10.1155/2012/951724; Xu XS, 2012, J BIOL CHEM, V287, P40758, DOI 10.1074/jbc.M112.405209; Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang HB, 2007, J CLIN INVEST, V117, P730, DOI 10.1172/JCI28984	38	13	13	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					922	931		10.1038/onc.2014.17	http://dx.doi.org/10.1038/onc.2014.17			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24632604	Green Accepted			2022-12-28	WOS:000349472000012
J	Pasmant, E; Gilbert-Dussardier, B; Petit, A; de Laval, B; Luscan, A; Gruber, A; Lapillonne, H; Deswarte, C; Goussard, P; Laurendeau, I; Uzan, B; Pflumio, F; Brizard, F; Vabres, P; Naguibneva, I; Fasola, S; Millot, F; Porteu, F; Vidaud, D; Landman-Parker, J; Ballerini, P				Pasmant, E.; Gilbert-Dussardier, B.; Petit, A.; de Laval, B.; Luscan, A.; Gruber, A.; Lapillonne, H.; Deswarte, C.; Goussard, P.; Laurendeau, I.; Uzan, B.; Pflumio, F.; Brizard, F.; Vabres, P.; Naguibneva, I.; Fasola, S.; Millot, F.; Porteu, F.; Vidaud, D.; Landman-Parker, J.; Ballerini, P.			SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia	ONCOGENE			English	Article						SPRED1; tumour suppressor gene; childhood leukaemia; Legius syndrome; cafe-au-lait spots; neurofibromatosis type 1	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; SIGNAL-TRANSDUCTION; MUTATIONS; CANCER; PHENOTYPE; GENES; SPECTRUM; DISEASE; PROTEIN	Constitutional dominant loss-of-function mutations in the SPRED1 gene cause a rare phenotype referred as neurofibromatosis type 1 (NF1)-like syndrome or Legius syndrome, consisted of multiple cafe-au-lait macules, axillary freckling, learning disabilities and macrocephaly. SPRED1 is a negative regulator of the RAS MAPK pathway and can interact with neurofibromin, the NF1 gene product. Individuals with NF1 have a higher risk of haematological malignancies. SPRED1 is highly expressed in haematopoietic cells and negatively regulates haematopoiesis. SPRED1 seemed to be a good candidate for leukaemia predisposition or transformation. We performed SPRED1 mutation screening and expression status in 230 paediatric lymphoblastic and acute myeloblastic leukaemias (AMLs). We found a loss-of-function frameshift SPRED1 mutation in a patient with Legius syndrome. In this patient, the leukaemia blasts karyotype showed a SPRED1 loss of heterozygosity, confirming SPRED1 as a tumour suppressor. Our observation confirmed that acute leukaemias are rare complications of the Legius syndrome. Moreover, SPRED1 was significantly decreased at RNA and protein levels in the majority of AMLs at diagnosis compared with normal or paired complete remission bone marrows. SPRED1 decreased expression correlated with genetic features of AML. Our study reveals a new mechanism which contributes to deregulate RAS MAPK pathway in the vast majority of paediatric AMLs.	[Pasmant, E.; Luscan, A.; Gruber, A.; Laurendeau, I.; Vidaud, D.] Univ Paris 05, Sorbonne Paris Cite, Fac Sci Pharmaceut & Biol, UMR INSERM S745, F-75006 Paris, France; [Pasmant, E.; Luscan, A.; Goussard, P.; Vidaud, D.] Hop Cochin, AP HP, Serv Biochim & Genet Mol, F-75674 Paris, France; [Gilbert-Dussardier, B.] CHU Poitiers, Serv Genet, Poitiers, France; [Petit, A.; Deswarte, C.; Fasola, S.; Landman-Parker, J.] Hop A Trousseau, AP HP, Serv Hematol Oncol, Paris, France; [Petit, A.; Deswarte, C.; Fasola, S.; Landman-Parker, J.] Univ Paris 06, Paris, France; [Petit, A.; Lapillonne, H.; Deswarte, C.; Landman-Parker, J.] Univ Paris 06, UMR938, Paris, France; [de Laval, B.; Porteu, F.] Univ Paris 05, CNRS UMR8104, Inst Cochin, INSERM 1016, Paris, France; [Lapillonne, H.; Ballerini, P.] Hop Trousseau, AP HP, Serv Hematol Biol, F-75571 Paris, France; [Uzan, B.; Pflumio, F.; Naguibneva, I.] Univ Paris 07, CEA, UMR967, Fontenay Aux Roses, France; [Brizard, F.] CHU Poitiers, Lab Hematol Biol, Poitiers, France; [Vabres, P.] Univ Bourgogne, CHU Dijon, Serv Dermatol, Dijon, France; [Vabres, P.] Univ Bourgogne, EA 4271, Dijon, France; [Millot, F.] CHU Poitiers, Serv Pediat, Poitiers, France	UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Poitiers; Universite de Poitiers; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; CEA; UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; CHU Poitiers; Universite de Poitiers; CHU Dijon Bourgogne; Universite de Bourgogne; Institut Agro; AgroSup Dijon; Universite de Bourgogne; CHU Poitiers; Universite de Poitiers	Pasmant, E (corresponding author), Univ Paris 05, Sorbonne Paris Cite, Fac Sci Pharmaceut & Biol, UMR INSERM S745, F-75006 Paris, France.	eric.pasmant@gmail.com; paola.ballerini@trs.aphp.fr	Vabres, Pierre/V-3850-2019; Luscan, Armelle/O-8081-2017; Deswarte, Caroline/H-8018-2017; PORTEU, Françoise/I-8445-2016; Pasmant, Eric/O-7249-2017; Vabres, Pierre/D-3906-2011; A, Petit/H-1633-2011; Pflumio, Francoise/E-2074-2017; VIDAUD, Dominique/O-7357-2017	Vabres, Pierre/0000-0001-8693-3183; Deswarte, Caroline/0000-0002-8775-3368; PORTEU, Françoise/0000-0002-2403-4163; Pasmant, Eric/0000-0002-1881-8762; Vabres, Pierre/0000-0001-8693-3183; A, Petit/0000-0001-8363-1622; UZAN, Benjamin/0000-0001-6323-5737; Pflumio, Francoise/0000-0001-8995-596X; GILBERT-DUSSARDIER, Brigitte/0000-0001-7182-9914; de Laval, Berengere/0000-0002-5616-2338	l'Association pour la Recherche sur les Maladies Hematologiques de l'Enfant (A.R.M.H.E.)	l'Association pour la Recherche sur les Maladies Hematologiques de l'Enfant (A.R.M.H.E.)	This work was supported in part by grant from l'Association pour la Recherche sur les Maladies Hematologiques de l'Enfant (A.R.M.H.E.). We thank the patients and their parents for their participation. We are grateful to Pr. Akihiko Yoshimura for providing anti-Spred-1 antibody, Mrs. Frederique Siotto for expert technical assistance, and Dr. Audrey Sabbagh for her statistical expertise.	Bentires-Alj M, 2006, NAT MED, V12, P283, DOI 10.1038/nm0306-283; Braun BS, 2008, CLIN CANCER RES, V14, P2249, DOI 10.1158/1078-0432.CCR-07-1005; Brems H, 2007, NAT GENET, V39, P1120, DOI 10.1038/ng2113; Brems H, 2012, HUM MUTAT, V33, P1538, DOI 10.1002/humu.22152; Bundschu K, 2006, J BIOL CHEM, V281, P36477, DOI 10.1074/jbc.R600023200; Case M, 2008, CANCER RES, V68, P6803, DOI 10.1158/0008-5472.CAN-08-0101; Christiansen DH, 2005, LEUKEMIA, V19, P2232, DOI 10.1038/sj.leu.2404009; Cutts BA, 2009, BLOOD, V114, P3629, DOI 10.1182/blood-2009-02-205146; Gabert J, 2003, LEUKEMIA, V17, P2318, DOI 10.1038/sj.leu.2403135; Inoue H, 2005, J EXP MED, V201, P73, DOI 10.1084/jem.20040616; Ishizaki T, 2011, GENES CELLS, V16, P803, DOI 10.1111/j.1365-2443.2011.01529.x; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kindler T, 2010, BLOOD, V116, P5089, DOI 10.1182/blood-2010-04-261867; Lapillonne H, 2010, LEUKEMIA, V24, P205, DOI 10.1038/leu.2009.172; Lee W, 2010, NATURE, V465, P473, DOI 10.1038/nature09004; Letourneux C, 2006, EMBO J, V25, P727, DOI 10.1038/sj.emboj.7600980; Levine RL, 2009, NAT GENET, V41, P957, DOI 10.1038/ng0909-957; Messiaen L, 2009, JAMA-J AM MED ASSOC, V302, P2111, DOI 10.1001/jama.2009.1663; Miyoshi K, 2004, ONCOGENE, V23, P5567, DOI 10.1038/sj.onc.1207759; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Nonami A, 2004, J BIOL CHEM, V279, P52543, DOI 10.1074/jbc.M405189200; Papaemmanuil E, 2009, NAT GENET, V41, P1006, DOI 10.1038/ng.430; Pasmant E, 2009, J MED GENET, V46, P425, DOI 10.1136/jmg.2008.065243; Pasmant E, 2009, BLOOD, V114, P1131, DOI 10.1182/blood-2009-04-218503; Renneville A, 2008, LEUKEMIA, V22, P915, DOI 10.1038/leu.2008.19; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Stowe IB, 2012, GENE DEV, V26, P1421, DOI 10.1101/gad.190876.112; Tartaglia M, 2004, BLOOD, V104, P307, DOI 10.1182/blood-2003-11-3876; Trevino LR, 2009, NAT GENET, V41, P1001, DOI 10.1038/ng.432; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Walter RB, 2010, BLOOD, V116, P2420, DOI 10.1182/blood-2010-05-285387; Yoshida T, 2006, ONCOGENE, V25, P6056, DOI 10.1038/sj.onc.1209635	32	32	34	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					631	638		10.1038/onc.2013.587	http://dx.doi.org/10.1038/onc.2013.587			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24469042				2022-12-28	WOS:000348853500010
J	Andrechek, ER				Andrechek, E. R.			HER2/Neu tumorigenesis and metastasis is regulated by E2F activator transcription factors	ONCOGENE			English	Article						MMTV-Neu; metastasis; E2F transcription factors; gene expression; signatures	HUMAN-BREAST-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; BINDING-SITES; NEU ONCOGENE; CYCLIN D1; PROLIFERATION; EXPRESSION; MICE; CARCINOMAS	HER2/Neu is amplified and overexpressed in a large proportion of human breast cancers, but the signaling pathways that contribute to tumor development and metastatic progression are not completely understood. Using gene expression data and pathway signatures, we predicted a role for activator E2F transcription factors in Neu-induced tumors. This was genetically tested by interbreeding Neu transgenics with knockouts of the three activator E2Fs. Loss of any E2F delayed Neu-induced tumor onset. E2F1 loss accelerated tumor growth, while E2F2 and E2F3 loss did not. Strikingly, it was observed that loss of E2F1 or E2F2 significantly reduced the metastatic capacity of the tumor and this was associated with a reduction in circulating tumor cells in the E2F2 knockout. Gene expression analysis between the tumors in the various E2F-mutant backgrounds revealed that there was extensive compensation by other E2F family members in the individual knockouts, underscoring the importance of the E2Fs in HER2/Neu-induced tumors. Extension to HER2-positive (HER2+) human breast cancer revealed a number of HER2+ subtypes based on E2F activity with differences in relapse-free survival times. Taken together, these data demonstrate that the E2F transcription factors are integral to HER2+ tumor development and progression.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA	Michigan State University	Andrechek, ER (corresponding author), Michigan State Univ, Dept Physiol, 2194 Biomed Phys Sci Bldg,567 Wilson Rd, E Lansing, MI 48824 USA.	andrech1@msu.edu		Andrechek, Eran/0000-0002-8680-3423	NCI [1R01CA160514]; NATIONAL CANCER INSTITUTE [R01CA160514] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	I thank Inez Yuwanita for providing a merged human breast cancer gene expression data set and Daniel Hollern for his cell signaling predictions from his mouse breast cancer gene expression database. I thank the members of my laboratory for numerous discussions and critical reading of the manuscript and Jordan Honeysett for technical support. This work was supported by a grant from the NCI (1R01CA160514).	Andrechek ER, 2008, DEVELOPMENT, V135, P2403, DOI 10.1242/dev.019018; Andrechek ER, 2009, P NATL ACAD SCI USA, V106, P16387, DOI 10.1073/pnas.0901250106; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; DeGregori J, 2006, CURR MOL MED, V6, P739; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eceles SA, 2001, J MAMMARY GLAND BIOL, V6, P393, DOI 10.1023/A:1014730829872; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fujiwara K, 2011, CANCER RES, V71, P1924, DOI 10.1158/0008-5472.CAN-10-2386; Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Humbert PO, 2000, GENE DEV, V14, P690; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lin NU, 2007, CLIN CANCER RES, V13, P1648, DOI 10.1158/1078-0432.CCR-06-2478; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Murga M, 2001, IMMUNITY, V15, P959, DOI 10.1016/S1074-7613(01)00254-0; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Qin GJ, 2006, P NATL ACAD SCI USA, V103, P11015, DOI 10.1073/pnas.0509533103; Rabinovich A, 2008, GENOME RES, V18, P1763, DOI 10.1101/gr.080622.108; Ranger JJ, 2009, CANCER RES, V69, P6823, DOI 10.1158/0008-5472.CAN-09-1684; Ren ZY, 2002, J BIOL CHEM, V277, P38486, DOI 10.1074/jbc.M112438200; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tsai SY, 2008, NATURE, V454, P1137, DOI 10.1038/nature07066; Verlinden L, 2007, CANCER RES, V67, P6574, DOI 10.1158/0008-5472.CAN-06-3545; Wang XY, 2011, CANCER RES, V71, P925, DOI 10.1158/0008-5472.CAN-10-1032; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Ziebold U, 2003, MOL CELL BIOL, V23, P6542, DOI 10.1128/MCB.23.18.6542-6552.2003	36	36	38	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					217	225		10.1038/onc.2013.540	http://dx.doi.org/10.1038/onc.2013.540			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24362522	Green Accepted			2022-12-28	WOS:000347790500009
J	Batlle-Lopez, A; Cortiguera, MG; Rosa-Garrido, M; Blanco, R; del Cerro, E; Torrano, V; Wagner, SD; Delgado, MD				Batlle-Lopez, A.; Cortiguera, M. G.; Rosa-Garrido, M.; Blanco, R.; del Cerro, E.; Torrano, V.; Wagner, S. D.; Delgado, M. D.			Novel CTCF binding at a site in exon1A of BCL6 is associated with active histone marks and a transcriptionally active locus	ONCOGENE			English	Article						CTCF; BCL6; lymphoma; germinal centre; epigenetics	CENTER B-CELLS; CANCER-TESTIS GENE; DNA METHYLATION; HUMAN GENOME; NEGATIVE AUTOREGULATION; EPIGENETIC REGULATION; TUMOR-SUPPRESSOR; PROTEIN CTCF; EXPRESSION; PROMOTER	BCL6 is a zinc-finger transcriptional repressor, which is highly expressed in germinal centre B-cells and is essential for germinal centre formation and T-dependent antibody responses. Constitutive BCL6 expression is sufficient to produce lymphomas in mice. Deregulated expression of BCL6 due to chromosomal rearrangements, mutations of a negative autoregulatory site in the BCL6 promoter region and aberrant post-translational modifications have been detected in a number of human lymphomas. Tight lineage and temporal regulation of BCL6 is, therefore, required for normal immunity, and abnormal regulation occurs in lymphomas. CCCTC-binding factor (CTCF) is a multi-functional chromatin regulator, which has recently been shown to bind in a methylation-sensitive manner to sites within the BCL6 first intron. We demonstrate a novel CTCF-binding site in BCL6 exon1A within a potential CpG island, which is unmethylated both in cell lines and in primary lymphoma samples. CTCF binding, which was found in BCL6-expressing cell lines, correlated with the presence of histone variant H2A. Z and active histone marks, suggesting that CTCF induces chromatin modification at a transcriptionally active BCL6 locus. CTCF binding to exon1A was required to maintain BCL6 expression in germinal centre cells by avoiding BCL6-negative autoregulation. Silencing of CTCF in BCL6-expressing cells reduced BCL6 mRNA and protein expression, which is sufficient to induce B-cell terminal differentiation toward plasma cells. Moreover, lack of CTCF binding to exon1A shifts the BCL6 local chromatin from an active to a repressive state. This work demonstrates that, in contexts in which BCL6 is expressed, CTCF binding to BCL6 exon1A associates with epigenetic modifications indicative of transcriptionally open chromatin.	[Batlle-Lopez, A.; Cortiguera, M. G.; Rosa-Garrido, M.; Blanco, R.; Torrano, V.; Delgado, M. D.] Univ Cantabria, CSIC, SODERCAN, Inst Biomed & Biotecnol Cantabria IBBTEC, E-39005 Santander, Spain; [Batlle-Lopez, A.; Cortiguera, M. G.; Rosa-Garrido, M.; Blanco, R.; Torrano, V.; Delgado, M. D.] Univ Cantabria, CSIC, SODERCAN, Dept Biol Mol, E-39005 Santander, Spain; [Batlle-Lopez, A.; Cortiguera, M. G.; del Cerro, E.] Hosp U Marques Valdecilla, Serv Hematol, Santander, Spain; [Batlle-Lopez, A.; Cortiguera, M. G.; del Cerro, E.] IFIMAV FMV, Santander, Spain; [Wagner, S. D.] Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE1 9HN, Leics, England; [Wagner, S. D.] Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC); Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; Hospital Universitario Marques de Valdecilla (HUMV); University of Leicester; University of Leicester	Wagner, SD (corresponding author), Univ Leicester, Dept Canc Studies & Mol Med, Lancaster Rd, Leicester LE1 9HN, Leics, England.	sw227@leicester.ac.uk; delgadmd@unican.es	Torrano Moya, Veronica/D-3285-2014; Rosa-Garrido, Manuel/AAE-4188-2019; Delgado, M. Dolores/K-9056-2014	Rosa-Garrido, Manuel/0000-0002-2169-3972; Delgado, M. Dolores/0000-0003-4682-4040; Wagner, Simon/0000-0002-8914-0370; Torrano, Veronica/0000-0002-4252-1977	Instituto de Salud Carlos III grants [PI11/00397]; RETIC (Red Tematica de Investigacion Cooperativa en Cancer) [RD06/0020/0017, RD12/0036/0033]; Lopez Albo fellowship (IFIMAV, Spain); University of Cantabria; Lady Tata Memorial Trust	Instituto de Salud Carlos III grants(Instituto de Salud Carlos III); RETIC (Red Tematica de Investigacion Cooperativa en Cancer); Lopez Albo fellowship (IFIMAV, Spain); University of Cantabria; Lady Tata Memorial Trust	We thank Elena Klenova and Rainer Renkawitz for CTCF expression vectors, Miguel Angel Piris and Noemi Nagy for cell lines and Javier Leon for useful comments on the manuscript. We are grateful to the Department of Hematology of Hospital U. Marques de Valdecilla (Santander) for help with patient recruitment. Funding for this work was provided by Instituto de Salud Carlos III grants PI11/00397 (Fondo Investigaciones Sanitarias) and RETIC (Red Tematica de Investigacion Cooperativa en Cancer) RD06/0020/0017 and RD12/0036/0033. AB was supported by a Lopez Albo fellowship (IFIMAV, Spain), MRG by a PhD fellowship from the University of Cantabria and VT by the Lady Tata Memorial Trust. Part of this work is in AB's PhD dissertation (split PhD Programme between Imperial College London and the University of Cantabria).	Bao L, 2008, NUCLEIC ACIDS RES, V36, pD83, DOI 10.1093/nar/gkm875; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Basso K, 2012, IMMUNOL REV, V247, P172, DOI 10.1111/j.1600-065X.2012.01112.x; Basso K, 2010, ADV IMMUNOL, V105, P193, DOI 10.1016/S0065-2776(10)05007-8; Batlle A, 2009, MOL IMMUNOL, V46, P1727, DOI 10.1016/j.molimm.2009.02.003; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; Bottardi S, 2003, BLOOD, V102, P3989, DOI 10.1182/blood-2003-05-1540; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Cattoretti G, 2005, CANCER CELL, V7, P445, DOI 10.1016/j.ccr.2005.03.037; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Cuddapah S, 2009, GENOME RES, V19, P24, DOI 10.1101/gr.082800.108; De la Rosa-Velazquez IA, 2007, CANCER RES, V67, P2577, DOI 10.1158/0008-5472.CAN-06-2024; Duan S, 2012, NATURE, V481, P90, DOI 10.1038/nature10688; Fearon DT, 2002, ADV EXP MED BIOL, V512, P21; Filippova GN, 2008, CURR TOP DEV BIOL, V80, P337, DOI 10.1016/S0070-2153(07)80009-3; Fitzpatrick GV, 2007, MOL CELL BIOL, V27, P2636, DOI 10.1128/MCB.02036-06; Herold M, 2012, DEVELOPMENT, V139, P1045, DOI 10.1242/dev.065268; Hong JA, 2005, CANCER RES, V65, P7763, DOI 10.1158/0008-5472.CAN-05-0823; Ishihara K, 2006, MOL CELL, V23, P733, DOI 10.1016/j.molcel.2006.08.008; Kikuchi M, 2000, ONCOGENE, V19, P4941, DOI 10.1038/sj.onc.1203864; Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kwon MJ, 2010, CARCINOGENESIS, V31, P974, DOI 10.1093/carcin/bgp336; Lai AY, 2010, J EXP MED, V207, P1939, DOI 10.1084/jem.20100204; Lee BK, 2012, GENOME RES, V22, P9, DOI 10.1101/gr.127597.111; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Ohlsson R, 2010, BIOESSAYS, V32, P37, DOI 10.1002/bies.200900118; Papadopoulou V, 2010, BIOCHEM J, V427, P541, DOI 10.1042/BJ20091578; Parelho V, 2008, CELL, V132, P422, DOI 10.1016/j.cell.2008.01.011; Pasqualucci L, 2003, BLOOD, V101, P2914, DOI 10.1182/blood-2002-11-3387; Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001; Pugacheva EM, 2005, HUM MOL GENET, V14, P953, DOI 10.1093/hmg/ddi089; Ramachandrareddy H, 2010, P NATL ACAD SCI USA, V107, P11930, DOI 10.1073/pnas.1004962107; Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841; Renaud S, 2005, NUCLEIC ACIDS RES, V33, P6850, DOI 10.1093/nar/gki989; Renaud S, 2007, NUCLEIC ACIDS RES, V35, P7372, DOI 10.1093/nar/gkm896; Rosa-Garrido M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039371; Saito M, 2007, CANCER CELL, V12, P280, DOI 10.1016/j.ccr.2007.08.011; Scheeren FA, 2005, NAT IMMUNOL, V6, P303, DOI 10.1038/ni1172; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Soto-Reyes E, 2010, ONCOGENE, V29, P2217, DOI 10.1038/onc.2009.509; Szutorisz H, 2005, MOL CELL BIOL, V25, P1804, DOI 10.1128/MCB.25.5.1804-1820.2005; Torrano V, 2005, J BIOL CHEM, V280, P28152, DOI 10.1074/jbc.M501481200; Torrano V, 2006, J CELL SCI, V119, P1746, DOI 10.1242/jcs.02890; van de Nobelen S, 2010, EPIGENET CHROMATIN, V3, DOI 10.1186/1756-8935-3-19; Vatolin S, 2005, CANCER RES, V65, P7751, DOI 10.1158/0008-5472.CAN-05-0858; Wagner SD, 2011, BRIT J HAEMATOL, V152, P3, DOI 10.1111/j.1365-2141.2010.08420.x; Wang H, 2012, GENOME RES, V22, P1680, DOI 10.1101/gr.136101.111; Wang X, 2002, P NATL ACAD SCI USA, V99, P15018, DOI 10.1073/pnas.232581199; Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990; Wendt KS, 2008, NATURE, V451, P796, DOI 10.1038/nature06634; Witcher M, 2009, MOL CELL, V34, P271, DOI 10.1016/j.molcel.2009.04.001; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Yoon B, 2005, MOL CELL BIOL, V25, P11184, DOI 10.1128/MCB.25.24.11184-11190.2005; Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2; Ziebarth JD, 2013, NUCLEIC ACIDS RES, V41, pD188, DOI 10.1093/nar/gks1165	59	12	13	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					246	256		10.1038/onc.2013.535	http://dx.doi.org/10.1038/onc.2013.535			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24362533	Green Accepted, Green Submitted			2022-12-28	WOS:000347790500012
J	Tanaka, I; Osada, H; Fujii, M; Fukatsu, A; Hida, T; Horio, Y; Kondo, Y; Sato, A; Hasegawa, Y; Tsujimura, T; Sekido, Y				Tanaka, I.; Osada, H.; Fujii, M.; Fukatsu, A.; Hida, T.; Horio, Y.; Kondo, Y.; Sato, A.; Hasegawa, Y.; Tsujimura, T.; Sekido, Y.			LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade	ONCOGENE			English	Article						malignant nnesothelioma; Hippo pathway; YAP; AJUBA; LATS2	SCAFFOLD PROTEINS; GROWTH-CONTROL; MITOTIC PROGRESSION; YAP PATHWAY; CANCER; DROSOPHILA; FOXM1; TRANSCRIPTION; ORGANIZATION; APOPTOSIS	Malignant mesothelioma (MM) is one of the most aggressive neoplasms usually associated with asbestos exposure and is highly refractory to current therapeutic modalities. MMs show frequent activation of a transcriptional coactivator Yes-associated protein (YAP), which is attributed to the neurofibromatosis type 2 (NF2)-Hippo pathway dysfunction, leading to deregulated cell proliferation and acquisition of a malignant phenotype. However, the whole mechanism of disordered YAP activation in MMs has not yet been well clarified. In the present study, we investigated various components of the NF2-Hippo pathway, and eventually found that MM cells frequently showed downregulation of LIM-domain protein AJUBA, a binding partner of large tumor suppressor type 2 (LATS2), which is one of the last-step kinases of the NF2-Hippo pathway. Although loss of AJUBA expression was independent of the alteration status of other Hippo pathway components, MM cell lines with AJUBA inactivation showed a more dephosphorylated (activated) level of YAP. Immunohistochemical analysis showed frequent downregulation of AJUBA in primary MMs, which was associated with YAP constitutive activation. We found that AJUBA transduction into MM cells significantly suppressed promoter activities of YAP-target genes, and the suppression of YAP activity by AJUBA was remarkably canceled by knockdown of LATS2. In connection with these results, transduction of AJUBA-expressing lentivirus significantly inhibited the proliferation and anchorage-independent growth of the MM cells that harbored ordinary LATS family expression. Taken together, our findings indicate that AJUBA negatively regulates YAP activity through the LATS family, and inactivation of AJUBA is a novel key mechanism in MM cell proliferation.	[Tanaka, I.; Osada, H.; Fujii, M.; Fukatsu, A.; Kondo, Y.; Sekido, Y.] Aichi Canc Ctr, Res Inst, Dept Thorac Oncol Oncol, Nagoya, Aichi 4648681, Japan; [Tanaka, I.; Hasegawa, Y.] Nagoya Univ, Grad Sch Med, Dept Resp Med, Nagoya, Aichi 4648601, Japan; [Osada, H.; Fukatsu, A.; Sekido, Y.] Nagoya Univ, Grad Sch Med, Dept Canc Genet, Program Funct Construct Med, Nagoya, Aichi 4648601, Japan; [Hida, T.; Horio, Y.] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi 464, Japan; [Sato, A.; Tsujimura, T.] Hyogo Coll Med, Dept Pathol, Nishinomiya, Hyogo 6638501, Japan	Aichi Cancer Center; Nagoya University; Nagoya University; Aichi Cancer Center; Hyogo College of Medicine	Sekido, Y (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Kanokoden 1-1, Nagoya, Aichi 4648681, Japan.	ysekido@aichi-cc.jp	Hasegawa, Yoshinori/I-1277-2012; Sekido, Yoshitaka/P-9756-2015	Sekido, Yoshitaka/0000-0002-2428-3848; Horio, Yoshitsugu/0000-0003-4661-6399	KAKENHI [24650650, 25290053]; Ministry of Health, Labor and Welfare of Japan; P-DIRECT; Takeda Science Foundation; Foundation for Promotion of Cancer Research	KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); P-DIRECT; Takeda Science Foundation(Takeda Science Foundation (TSF)); Foundation for Promotion of Cancer Research	This work was supported in part by KAKENHI (24650650,25290053), Grants-in-Aid for Third-Term Comprehensive Control Research for Cancer from the Ministry of Health, Labor and Welfare of Japan, P-DIRECT and the Takeda Science Foundation (YS). We thank Dr Adi F Gazdar for the cell lines and Mari Kizuki and Miwako Nishizawa for their excellent technical assistance. IT was supported by the Foundation for Promotion of Cancer Research.	Abe Y, 2006, FEBS LETT, V580, P782, DOI 10.1016/j.febslet.2005.12.096; Alvarez-Fernandez M, 2010, EMBO REP, V11, P452, DOI 10.1038/embor.2010.46; Badouel C, 2009, CURR OPIN CELL BIOL, V21, P837, DOI 10.1016/j.ceb.2009.09.010; Benzinger A, 2005, MOL CELL PROTEOMICS, V4, P785, DOI 10.1074/mcp.M500021-MCP200; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Boggiano JC, 2012, DEV CELL, V22, P695, DOI 10.1016/j.devcel.2012.03.013; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Carbone M, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30227; Carbone M, 2012, J CELL PHYSIOL, V227, P44, DOI 10.1002/jcp.22724; Das Thakur M, 2010, CURR BIOL, V20, P657, DOI 10.1016/j.cub.2010.02.035; Delgermaa V, 2011, B WORLD HEALTH ORGAN, V89, P716, DOI 10.2471/BLT.11.086678; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Feng YF, 2005, MOL CELL BIOL, V25, P4010, DOI 10.1128/MCB.25.10.4010-4022.2005; Ferrand A, 2009, BIOL CELL, V101, P221, DOI 10.1042/BC20080060; Fu Z, 2008, NAT CELL BIOL, V10, P1076, DOI 10.1038/ncb1767; Fujii M, 2012, J EXP MED, V209, P479, DOI 10.1084/jem.20111653; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; Locasale JW, 2007, P NATL ACAD SCI USA, V104, P13307, DOI 10.1073/pnas.0706311104; Marie H, 2003, J BIOL CHEM, V278, P1220, DOI 10.1074/jbc.M205391200; Mizuno T, 2012, ONCOGENE, V31, P5117, DOI 10.1038/onc.2012.5; Mo JS, 2012, GENE DEV, V26, P2138, DOI 10.1101/gad.197582.112; Murakami H, 2011, CANCER RES, V71, P873, DOI 10.1158/0008-5472.CAN-10-2164; Oh HJ, 2006, CANCER RES, V66, P2562, DOI 10.1158/0008-5472.CAN-05-2951; Pass HI, 2004, CURR PROB CANCER, V28, P85; Polesello C, 2006, CURR BIOL, V16, P2459, DOI 10.1016/j.cub.2006.10.060; Robinson BWS, 2005, LANCET, V366, P397, DOI 10.1016/S0140-6736(05)67025-0; Robinson BWS, 2005, NEW ENGL J MED, V353, P1591, DOI 10.1056/NEJMra050152; Sansores-Garcia L, 2011, EMBO J, V30, P2325, DOI 10.1038/emboj.2011.157; Sasaki H, 2010, DEV GROWTH DIFFER, V52, P263, DOI 10.1111/j.1440-169X.2009.01158.x; Saucedo LJ, 2007, NAT REV MOL CELL BIO, V8, P613, DOI 10.1038/nrm2221; SEKIDO Y, 1995, CANCER RES, V55, P1227; Sekido Y, 2010, CANCER SCI, V101, P1, DOI 10.1111/j.1349-7006.2009.01336.x; Shaw AS, 2009, NAT REV IMMUNOL, V9, P47, DOI 10.1038/nri2473; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Wada KI, 2011, DEVELOPMENT, V138, P3907, DOI 10.1242/dev.070987; Wang IC, 2008, J BIOL CHEM, V283, P20770, DOI 10.1074/jbc.M709892200; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wang ZW, 2007, CANCER RES, V67, P8293, DOI 10.1158/0008-5472.CAN-07-1265; Yang HN, 2008, CURR TREAT OPTION ON, V9, P147, DOI 10.1007/s11864-008-0067-z; Yokoyama T, 2008, CARCINOGENESIS, V29, P2139, DOI 10.1093/carcin/bgn200; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111	48	50	53	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					73	83		10.1038/onc.2013.528	http://dx.doi.org/10.1038/onc.2013.528			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24336325				2022-12-28	WOS:000349740100007
J	Avivar-Valderas, A; Wen, HC; Aguirre-Ghiso, JA				Avivar-Valderas, A.; Wen, H. C.; Aguirre-Ghiso, J. A.			Stress signaling and the shaping of the mammary tissue in development and cancer	ONCOGENE			English	Review						stress; anoikis; mammary gland; ECM; breast cancer; autophagy	UNFOLDED PROTEIN RESPONSE; EXTRACELLULAR-MATRIX DETACHMENT; ANCHORAGE-DEPENDENT FIBROBLASTS; HEAT-SHOCK PROTEINS; P38 MAP KINASE; EPITHELIAL-CELLS; BREAST-CANCER; ER STRESS; LUMEN FORMATION; TUMOR-GROWTH	The postnatal mammary gland develops extensively through cycles of proliferation, branching, involution and remodeling. We review recent advances made in the field of stress signaling pathways and its roles in mammary gland organogenesis, how they contribute to normal organ specification and homeostasis and how its subversion by oncogenes leads to cancer. We analyze stress signaling in mammary gland biology taking into account the interrelationship with the extracellular matrix and adhesion signaling during morphogenesis. By integrating the information gathered from in vivo and three dimensional in vitro organogenesis studies, we review the novel contribution of p38(SAPK), c-Jun NH2-terminal kinase and PKR-like endoplasmic reticulum kinase ( PERK) signaling pathways to the timely activation of cell death, correct establishment of polarity and growth arrest and autophagy, respectively. We also review the evidence supporting that the activation of the aforementioned stress kinases maintain breast acinar structures as part of a tumor suppressive program and that its deregulation is commonplace during breast cancer initiation.	[Avivar-Valderas, A.; Aguirre-Ghiso, J. A.] Mt Sinai Sch Med, Dept Med, Div Hematol & Oncol, New York, NY 10029 USA; [Avivar-Valderas, A.; Aguirre-Ghiso, J. A.] Mt Sinai Sch Med, Dept Otolaryngol, New York, NY 10029 USA; [Avivar-Valderas, A.; Wen, H. C.; Aguirre-Ghiso, J. A.] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY 10029 USA; [Wen, H. C.] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA; [Aguirre-Ghiso, J. A.] Mt Sinai Sch Med, Black Family Stem Cell Inst, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Avivar-Valderas, A (corresponding author), Mt Sinai Sch Med, Dept Med, One Gustave L Levy Pl, New York, NY 10029 USA.	alvaro.avivar-valderas@mssm.edu; huei-chi.wen@mssm.edu; julio.aguirre-ghiso@mssm.edu	Wen, Huei-Chi/ABD-7417-2021	Aguirre-Ghiso, Julio/0000-0002-6694-6507	Samuel Waxman Cancer Research Foundation Tumor Dormancy Program; NIH/National Cancer Institute [CA109182, CA163131]; NIEHS [ES017146]; NYSTEM; NATIONAL CANCER INSTITUTE [U54CA163131, R01CA109182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES017146] Funding Source: NIH RePORTER	Samuel Waxman Cancer Research Foundation Tumor Dormancy Program; NIH/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NYSTEM; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This study was supported by the grant from Samuel Waxman Cancer Research Foundation Tumor Dormancy Program, NIH/National Cancer Institute (CA109182, CA163131), NIEHS (ES017146) and NYSTEM to JAA-G.	Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Akaogi K, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-65; Almholt K, 2007, J MAMMARY GLAND BIOL, V12, P83, DOI 10.1007/s10911-007-9040-x; Avivar-Valderas A, 2013, ONCOGENE, V32, P4932, DOI 10.1038/onc.2012.512; Avivar-Valderas A, 2011, MOL CELL BIOL, V31, P3616, DOI 10.1128/MCB.05164-11; Barrantes ID, 2012, BIOCHEM SOC T, V40, P79, DOI 10.1042/BST20110676; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bateman JF, 2009, NAT REV GENET, V10, P173, DOI 10.1038/nrg2520; BENECKE BJ, 1978, CELL, V14, P931, DOI 10.1016/0092-8674(78)90347-1; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Blais JD, 2006, MOL CELL BIOL, V26, P9517, DOI 10.1128/MCB.01145-06; Bobrovnikova-Marjon E, 2010, ONCOGENE, V29, P3881, DOI 10.1038/onc.2010.153; Bobrovnikova-Marjon E, 2008, P NATL ACAD SCI USA, V105, P16314, DOI 10.1073/pnas.0808517105; Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Bruno RD, 2012, SEMIN CELL DEV BIOL, V23, P591, DOI 10.1016/j.semcdb.2012.03.007; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Cao JX, 2009, EMBO J, V28, P1505, DOI 10.1038/emboj.2009.101; Cellurale C, 2012, CANCER RES, V72, P472, DOI 10.1158/0008-5472.CAN-11-1628; Cellurale C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012469; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Danes CG, 2008, CANCER RES, V68, P1760, DOI 10.1158/0008-5472.CAN-07-3177; Das M, 2011, GENE DEV, V25, P634, DOI 10.1101/gad.1989311; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Debnath J, 2008, AUTOPHAGY, V4, P351, DOI 10.4161/auto.5523; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Dong J, 2011, DEVELOPMENT, V138, P5247, DOI 10.1242/dev.069203; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; Espina V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010240; FARMER SR, 1978, CELL, V15, P627, DOI 10.1016/0092-8674(78)90031-4; Feder ME, 1999, ANNU REV PHYSIOL, V61, P243, DOI 10.1146/annurev.physiol.61.1.243; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; Gorrini C, 2005, P NATL ACAD SCI USA, V102, P9200, DOI 10.1073/pnas.0409513102; Gupta S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.74; HALL HG, 1982, P NATL ACAD SCI-BIOL, V79, P4672, DOI 10.1073/pnas.79.15.4672; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Hart LS, 2012, J CLIN INVEST, V122, P4621, DOI 10.1172/JCI62973; Horak P, 2010, P NATL ACAD SCI USA, V107, P4675, DOI 10.1073/pnas.0907705107; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; Jechlinger M, 2009, GENE DEV, V23, P1677, DOI 10.1101/gad.1801809; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kim MS, 2003, CANCER RES, V63, P5454; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kultz D, 2003, J EXP BIOL, V206, P3119, DOI 10.1242/jeb.00549; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Lambros MB, 2010, MODERN PATHOL, V23, P1334, DOI 10.1038/modpathol.2010.121; LI S, 1994, MOL ENDOCRINOL, V8, P1328, DOI 10.1210/me.8.10.1328; Li XY, 2001, FEBS LETT, V492, P210, DOI 10.1016/S0014-5793(01)02254-2; Liang GQ, 2008, HUM MOL GENET, V17, P3254, DOI 10.1093/hmg/ddn221; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liu CL, 2012, J GERIATR CARDIOL, V9, P258, DOI 10.3724/SP.J.1263.2012.02292; Lockshin RA, 2007, J CELL MOL MED, V11, P1214, DOI 10.1111/j.1582-4934.2007.00150.x; Lyons TR, 2011, NAT MED, V17, P1109, DOI 10.1038/nm.2416; Maekawa T, 2007, MOL CELL BIOL, V27, P1730, DOI 10.1128/MCB.01579-06; Mailleux AA, 2007, DEV CELL, V12, P221, DOI 10.1016/j.devcel.2006.12.003; Mandriota SJ, 2010, J BIOL CHEM, V285, P13092, DOI 10.1074/jbc.M109.078360; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Mao LL, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2794; Martin-Belmonte F, 2008, CURR BIOL, V18, P507, DOI 10.1016/j.cub.2008.02.076; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Merksamer PI, 2010, J CELL SCI, V123, P1003, DOI 10.1242/jcs.035832; Mikhailov A, 2007, CURR BIOL, V17, P2162, DOI 10.1016/j.cub.2007.11.028; Milani M, 2009, CANCER RES, V69, P4415, DOI 10.1158/0008-5472.CAN-08-2839; Miller AL, 2007, CANCER CELL INT, V7, DOI 10.1186/1475-2867-7-3; Miller AL, 2005, MOL ENDOCRINOL, V19, P1569, DOI 10.1210/me.2004-0528; Murtagh J, 2004, J CELL BIOL, V166, P133, DOI 10.1083/jcb.200403020; O'Sullivan AW, 2009, WORLD J SURG ONCOL, V7, DOI 10.1186/1477-7819-7-89; OSSOWSKI L, 1979, CELL, V16, P929, DOI 10.1016/0092-8674(79)90108-9; Park MA, 2008, CANCER BIOL THER, V7, P1648, DOI 10.4161/cbt.7.10.6623; Park MA, 2008, AUTOPHAGY, V4, P513, DOI 10.4161/auto.5725; Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11; Puri PL, 2000, GENE DEV, V14, P574; Qi AQ, 2005, J NEUROSCI RES, V80, P510, DOI 10.1002/jnr.20491; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ravid D, 2005, ONCOGENE, V24, P1338, DOI 10.1038/sj.onc.1208337; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rodier F, 2007, NUCLEIC ACIDS RES, V35, P7475, DOI 10.1093/nar/gkm744; Rosen JM, 1998, BIOCHEM SOC SYMP, P101; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Ruark E, 2013, NATURE, V493, P406, DOI 10.1038/nature11725; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Schedin P., 2010, COLD SPRING HARB PER, V3; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Sequeira SJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000615; Sequeira SJ, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-64; Sivaraman L, 2001, P NATL ACAD SCI USA, V98, P12379, DOI 10.1073/pnas.221459098; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Talukder AH, 2002, ONCOGENE, V21, P4289, DOI 10.1038/sj.onc.1205529; Timofeev O, 2005, CELL CYCLE, V4, P118, DOI 10.4161/cc.4.1.1342; Verfaillie T, 2012, CELL DEATH DIFFER, V19, P1880, DOI 10.1038/cdd.2012.74; Waetzig V, 2003, J BIOL CHEM, V278, P567, DOI 10.1074/jbc.M207391200; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wei JW, 2008, J CELL PHYSIOL, V217, P693, DOI 10.1002/jcp.21543; Wen HC, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001684; Yazinski SA, 2009, P NATL ACAD SCI USA, V106, P21282, DOI 10.1073/pnas.0904965106; ZETTL KS, 1992, P NATL ACAD SCI USA, V89, P9069, DOI 10.1073/pnas.89.19.9069	112	21	22	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2014	33	48					5483	5490		10.1038/onc.2013.554	http://dx.doi.org/10.1038/onc.2013.554			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZO	24413078	Green Accepted			2022-12-28	WOS:000346087900001
J	Demajo, S; Uribesalgo, I; Gutierrez, A; Ballare, C; Capdevila, S; Roth, M; Zuber, J; Martin-Caballero, J; Di Croce, L				Demajo, S.; Uribesalgo, I.; Gutierrez, A.; Ballare, C.; Capdevila, S.; Roth, M.; Zuber, J.; Martin-Caballero, J.; Di Croce, L.			ZRF1 controls the retinoic acid pathway and regulates leukemogenic potential in acute myeloid leukemia	ONCOGENE			English	Article						acute myeloid leukemia; ZRF1; retinoic acid; transcription; differentiation	ACUTE PROMYELOCYTIC LEUKEMIA; TUMOR-ASSOCIATED ANTIGENS; RAR-ALPHA; DIFFERENTIATION; CANCER; CELLS; TRANSCRIPTION; EXPRESSION; RESPONSES; CHROMATIN	Acute myeloid leukemia (AML) is frequently linked to epigenetic abnormalities and deregulation of gene transcription, which lead to aberrant cell proliferation and accumulation of undifferentiated precursors. ZRF1, a recently characterized epigenetic factor involved in transcriptional regulation, is highly overexpressed in human AML, but it is not known whether it plays a role in leukemia progression. Here, we demonstrate that ZRF1 depletion decreases cell proliferation, induces apoptosis and enhances cell differentiation in human AML cells. Treatment with retinoic acid (RA), a differentiating agent currently used to treat certain AMLs, leads to a functional switch of ZRF1 from a negative regulator to an activator of differentiation. At the molecular level, ZRF1 controls the RA-regulated gene network through its interaction with the RA receptor alpha (RAR alpha) and its binding to RA target genes. Our genome-wide expression study reveals that ZRF1 regulates the transcription of nearly half of RA target genes. Consistent with our in vitro observations that ZRF1 regulates proliferation, apoptosis, and differentiation, ZRF1 depletion strongly inhibits leukemia progression in a xenograft mouse model. Finally, ZRF1 knockdown cooperates with RA treatment in leukemia suppression in vivo. Taken together, our data reveal that ZRF1 is a key transcriptional regulator in leukemia progression and suggest that ZRF1 inhibition could be a novel strategy to be explored for AML treatment.	[Demajo, S.; Uribesalgo, I.; Gutierrez, A.; Ballare, C.; Di Croce, L.] CRG, Barcelona, Spain; [Demajo, S.; Uribesalgo, I.; Gutierrez, A.; Ballare, C.; Di Croce, L.] UPF, Barcelona, Spain; [Capdevila, S.; Martin-Caballero, J.] PRBB, Unidad Anim Lab, Barcelona, Spain; [Roth, M.; Zuber, J.] Inst Mol Pathol, A-1030 Vienna, Austria; [Di Croce, L.] ICREA, Barcelona 08003, Spain	Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; Pompeu Fabra University; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); ICREA	Di Croce, L (corresponding author), ICREA, C Dr Aiguader 88, Barcelona 08003, Spain.	luciano.dicroce@crg.eu	Zuber, Johannes/E-7517-2011; Di Croce, Luciano/E-7759-2015; Gutierrez, Arantxa/K-8213-2015; Demajo, Santiago/AAB-1999-2021; Ballare, Cecilia/F-2593-2016	Zuber, Johannes/0000-0001-8810-6835; Di Croce, Luciano/0000-0003-3488-6228; Gutierrez, Arantxa/0000-0001-9033-3834; Ballare, Cecilia/0000-0002-9442-807X; Demajo Meseguer, Santiago/0000-0003-3998-8784; Uribesalgo, Iris/0000-0001-9492-1000	Spanish 'Ministerio de Educacion y Ciencia' [BFU2010-18692]; AGAUR; 'Fundacio La Marato and from by European Commission's 7th Framework Program 4DCellFate [277899]; PFIS fellowship of the 'Instituto de Salud Carlos III'; Worldwide Cancer Research [10-0177] Funding Source: researchfish; ICREA Funding Source: Custom	Spanish 'Ministerio de Educacion y Ciencia'(Spanish Government); AGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); 'Fundacio La Marato and from by European Commission's 7th Framework Program 4DCellFate; PFIS fellowship of the 'Instituto de Salud Carlos III'; Worldwide Cancer Research; ICREA(ICREA)	We thank the members of the LDC laboratory for discussions, the CRG Genomic Unit, and VA Raker for help in preparing the manuscript. This work was supported by grants from the Spanish 'Ministerio de Educacion y Ciencia' (BFU2010-18692), from AGAUR, from 'Fundacio La Marato and from by European Commission's 7th Framework Program 4DCellFate grant number 277899 to LDC; SD was supported by a PFIS fellowship of the 'Instituto de Salud Carlos III'.	Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Anguille S, 2012, LEUKEMIA, V26, P2186, DOI 10.1038/leu.2012.145; Berge T, 2007, BLOOD CELL MOL DIS, V39, P278, DOI 10.1016/j.bcmd.2007.05.007; Campos EI, 2009, ANNU REV GENET, V43, P559, DOI 10.1146/annurev.genet.032608.103928; Chanda B, 2013, CELL, V155, P215, DOI 10.1016/j.cell.2013.08.055; DERMIME S, 1995, LEUKEMIA LYMPHOMA, V16, P289, DOI 10.3109/10428199509049768; Deschler B, 2006, CANCER-AM CANCER SOC, V107, P2099, DOI 10.1002/cncr.22233; Duester G, 2008, CELL, V134, P921, DOI 10.1016/j.cell.2008.09.002; Friedman AD, 2007, ONCOGENE, V26, P6816, DOI 10.1038/sj.onc.1210764; Frith MC, 2004, NUCLEIC ACIDS RES, V32, P1372, DOI 10.1093/nar/gkh299; Giannopoulos K, 2006, INT J ONCOL, V29, P95; Greiner J, 2003, INT J CANCER, V106, P224, DOI 10.1002/ijc.11200; Greiner J, 2004, INT J CANCER, V108, P704, DOI 10.1002/ijc.11623; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Jaiswal H, 2011, MOL CELL BIOL, V31, P1160, DOI 10.1128/MCB.00986-10; Jolma A, 2013, CELL, V152, P327, DOI 10.1016/j.cell.2012.12.009; Kastner P, 2001, ONCOGENE, V20, P7178, DOI 10.1038/sj.onc.1204757; Lehmann S, 2001, CLIN CANCER RES, V7, P367; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; Nowak D, 2009, BLOOD, V113, P3655, DOI 10.1182/blood-2009-01-198911; Oren T, 2003, LEUKEMIA LYMPHOMA, V44, P1881, DOI 10.1080/1042819031000116661; Resto VA, 2000, CANCER RES, V60, P5529; Ribeiro JD, 2013, ONCOGENE, V32, P2161, DOI 10.1038/onc.2012.241; Richly H, 2010, NATURE, V468, P1124, DOI 10.1038/nature09574; Schmitt M, 2006, EXP HEMATOL, V34, P1709, DOI 10.1016/j.exphem.2006.07.009; SHOJI W, 1995, J BIOL CHEM, V270, P24818, DOI 10.1074/jbc.270.42.24818; Siegel S, 2012, ACTA HAEMATOL-BASEL, V127, P193, DOI 10.1159/000335133; Smith JC, 2007, J PROTEOME RES, V6, P3174, DOI 10.1021/pr070122r; Tang XH, 2011, ANNU REV PATHOL-MECH, V6, P345, DOI 10.1146/annurev-pathol-011110-130303; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Uckun FM, 1996, BLOOD, V88, P1135, DOI 10.1182/blood.V88.4.1135.bloodjournal8841135; Uribesalgo I, 2011, NAT CELL BIOL, V13, P1443, DOI 10.1038/ncb2355; Uribesalgo I, 2011, BRIEF FUNCT GENOMICS, V10, P18, DOI 10.1093/bfgp/elr002; Villa R, 2007, CANCER CELL, V11, P513, DOI 10.1016/j.ccr.2007.04.009; Wang ZY, 2008, BLOOD, V111, P2505, DOI 10.1182/blood-2007-07-102798; Zuber J, 2011, GENE DEV, V25, P1628, DOI 10.1101/gad.17269211	36	17	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2014	33	48					5501	5510		10.1038/onc.2013.501	http://dx.doi.org/10.1038/onc.2013.501			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZO	24292673				2022-12-28	WOS:000346087900003
J	Luis-Ravelo, D; Anton, I; Zandueta, C; Valencia, K; Ormazabal, C; Martinez-Canarias, S; Guruceaga, E; Perurena, N; Vicent, S; De Las Rivas, J; Lecanda, F				Luis-Ravelo, D.; Anton, I.; Zandueta, C.; Valencia, K.; Ormazabal, C.; Martinez-Canarias, S.; Guruceaga, E.; Perurena, N.; Vicent, S.; De Las Rivas, J.; Lecanda, F.			A gene signature of bone metastatic colonization sensitizes for tumor-induced osteolysis and predicts survival in lung cancer	ONCOGENE			English	Article						HDAC4; PITX1; ROBO1; microenvironment; osteoclastogenesis; MMP; outcome	HORMONE-RELATED PROTEIN; GROWTH-FACTOR-BETA; HISTONE DEACETYLASE-4; EXPRESSION; PITX1; RECEPTOR; ADENOCARCINOMA; ACTIVATION; KINASE; CELLS	Bone metastasis of lung adenocarcinoma (AC) is a frequent complication of advanced disease. The purpose of this study was to identify key mediators conferring robust prometastatic activity with clinical significance. We isolated highly metastatic subpopulations (HMS) using a previously described in vivo model of lung AC bone metastasis. We performed transcriptomic profiling of HMS and stringent bioinformatics filtering. Functional validation was assessed by overexpression and lentiviral silencing of single, double and triple combination in vivo and in vitro. We identified HDAC4, PITX1 and ROBO1 that decreased bone metastatic ability after their simultaneous abrogation. These effects were solely linked to defects in osseous colonization. The molecular mechanisms related to bone colonization were mediated by non-cell autonomous effects that include the following: (1) a marked decrease in osteoclastogenic activity in vitro and in vivo, an effect associated with reduced pro-osteoclastogenic cytokines IL-11 and PTHrP expression levels, as well as decreased in vitro expression of stromal rankl in conditions mimicking tumor-stromal interactions; (2) an abrogated response to TGF-beta signaling by decreased phosphorylation and levels of Smad2/3 in tumor cells and (3) an impaired metalloproteolytic activity in vitro. Interestingly, coexpression of HDAC4 and PITX1 conferred high prometastatic activity in vivo. Further, levels of both genes correlated with patients at higher risk of metastasis in a clinical lung AC data set and with a poorer clinical outcome. These findings provide functional and clinical evidence that this metastatic subset is an important determinant of osseous colonization. These data suggest novel therapeutic targets to effectively block lung AC bone metastasis.	[Luis-Ravelo, D.; Anton, I.; Zandueta, C.; Valencia, K.; Ormazabal, C.; Martinez-Canarias, S.; Perurena, N.; Vicent, S.; Lecanda, F.] Univ Navarra, Div Oncol, Adhes & Metastasis Lab, E-31080 Pamplona, Spain; [Guruceaga, E.] Univ Navarra, Ctr Appl Med Res CIMA, Bioinformat & Prote Unit, E-31080 Pamplona, Spain; [Vicent, S.] Univ Navarra, Sch Med, Dept Histol & Pathol, E-31080 Pamplona, Spain; [De Las Rivas, J.] Univ Salamanca CSIC USAL, Canc Res Ctr, Bioinformat & Funct Genom Res Grp, Salamanca, Spain	University of Navarra; University of Navarra; University of Navarra; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC)	Lecanda, F (corresponding author), Univ Navarra, Ctr Appl Med Res CIMA, E-31080 Pamplona, Spain.	flecanda@unav.es	Valencia, Karmele/I-8729-2017; De Las Rivas, Javier/G-5936-2014; Vicent, Silvestre/K-4261-2017; Guruceaga, Elizabeth/B-1796-2008	Valencia, Karmele/0000-0002-2882-7427; De Las Rivas, Javier/0000-0002-0984-9946; Vicent, Silvestre/0000-0002-9457-6881; Perurena, Naiara/0000-0003-0874-3389; Zandueta Pascual, Carolina/0000-0002-7931-8649; Luis-Ravelo, Diego/0000-0003-2876-9762; Guruceaga, Elizabeth/0000-0003-0547-681X	'UTE project FIMA' agreement, The Cancer Research Thematic Network of the Health Institute Carlos III [RTICC RD06/0020/0066, PI042282, SAF-2009-11280, SAF2012-40056]; Government of Navarra [67/2005, 09/2009]; La Caixa Foundation; FIMA; FPU; Basque Government; FIS-ISCIII grant [PI12/00624]; Ramon y Cajal Program (MICINN) [RYC-2011-09042]	'UTE project FIMA' agreement, The Cancer Research Thematic Network of the Health Institute Carlos III; Government of Navarra; La Caixa Foundation(La Caixa Foundation); FIMA; FPU(Spanish Government); Basque Government(Basque Government); FIS-ISCIII grant; Ramon y Cajal Program (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	We are grateful to the Core Histology Unit and Imaging Group facilities for their outstanding technical assistance. We also thank the Proteomics, Genomics and Bioinformatics Unit at the CIMA. This work was supported by 'UTE project FIMA' agreement, The Cancer Research Thematic Network of the Health Institute Carlos III (RTICC RD06/0020/0066), PI042282, SAF-2009-11280, SAF2012-40056, grants 67/2005 and 09/2009 from the Government of Navarra, and 'La Caixa Foundation' to FL. DL-R was supported by the FIMA and FPU. IA was funded by the Basque Government. JDLR was supported by FIS-ISCIII grant PI12/00624. SV is an investigator of the Ramon y Cajal Program (MICINN, RYC-2011-09042).	Anton I, 2012, AM J RESP CRIT CARE, V186, P96, DOI 10.1164/rccm.201110-1826OC; Backs J, 2006, J CLIN INVEST, V116, P1853, DOI 10.1172/JCI27438; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Catena R, 2011, CANCER RES, V71, P164, DOI 10.1158/0008-5472.CAN-10-1708; Chen Y, 2007, LUNG CANCER, V55, P287, DOI 10.1016/j.lungcan.2006.11.001; Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G; FELD R, 1984, J CLIN ONCOL, V2, P1352, DOI 10.1200/JCO.1984.2.12.1352; Fry WA, 1996, CANCER, V77, P1947, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1947::AID-CNCR27>3.0.CO;2-Z; Goldstraw P, 2011, LANCET, V378, P1727, DOI 10.1016/S0140-6736(10)62101-0; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; Hernandez I, 2010, ONCOGENE, V29, P3758, DOI 10.1038/onc.2010.130; Iguchi H, 2001, INT J CANCER, V94, P24, DOI 10.1002/ijc.1425; Justilien V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035040; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kolfschoten IGM, 2005, CELL, V121, P849, DOI 10.1016/j.cell.2005.04.017; Labbe E, 2007, CANCER RES, V67, P75, DOI 10.1158/0008-5472.CAN-06-2559; LECANDA F, 2011, DRUG DISCOV TODAY DI, V8, P87; Lord RVN, 2005, SURGERY, V138, P924, DOI 10.1016/j.surg.2005.05.007; Lu X, 2009, GENE DEV, V23, P1882, DOI 10.1101/gad.1824809; Luis-Ravelo D, 2011, CLIN EXP METASTAS, V28, P779, DOI 10.1007/s10585-011-9409-5; Marcil A, 2003, DEVELOPMENT, V130, P45, DOI 10.1242/dev.00192; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030; Reddy SDN, 2012, J BIOL CHEM, V287, P27843, DOI 10.1074/jbc.M112.348474; Rhee J, 2002, NAT CELL BIOL, V4, P798, DOI 10.1038/ncb858; Rhee J, 2007, NAT CELL BIOL, V9, P883, DOI 10.1038/ncb1614; Sapkota G, 2006, J BIOL CHEM, V281, P40412, DOI 10.1074/jbc.M610172200; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Stronach EA, 2011, CANCER RES, V71, P4412, DOI 10.1158/0008-5472.CAN-10-4111; Valencia K, 2012, CLIN CANCER RES, V18, P969, DOI 10.1158/1078-0432.CCR-11-1686; Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024; Vicent S, 2008, CANCER RES, V68, P2275, DOI 10.1158/0008-5472.CAN-07-6493; Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055; Wilson AJ, 2008, MOL BIOL CELL, V19, P4062, DOI 10.1091/mbc.E08-02-0139; Yang XM, 2010, BIOCHEM BIOPH RES CO, V396, P571, DOI 10.1016/j.bbrc.2010.04.152; Yasui T, 2011, J BONE MINER RES, V26, P1447, DOI 10.1002/jbmr.357; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523	38	32	32	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2014	33	43					5090	5099		10.1038/onc.2013.440	http://dx.doi.org/10.1038/onc.2013.440			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OF	24166494				2022-12-28	WOS:000343768400004
J	Zheng, XQ; Guo, JP; Yang, H; Kanai, M; He, LL; Li, YY; Koomen, JM; Minton, S; Gao, M; Ren, XB; Coppola, D; Cheng, JQ				Zheng, X. Q.; Guo, J. P.; Yang, H.; Kanai, M.; He, L. L.; Li, Y. Y.; Koomen, J. M.; Minton, S.; Gao, M.; Ren, X. B.; Coppola, D.; Cheng, J. Q.			Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ER alpha in breast cancer	ONCOGENE			English	Article						Aurora-A; tamoxifen resistance; ER alpha; phosphorylation; transcriptional activation	ESTROGEN-RECEPTOR-ALPHA; ANTIESTROGEN RESISTANCE; ENDOCRINE RESISTANCE; MAMMARY EPITHELIUM; SERINE 305; KINASE; AMPLIFICATION; EXPRESSION; CELLS; OVEREXPRESSION	Despite the clinical success of tamoxifen, its resistance remains a major challenge in breast cancer. Here we show that Aurora-A determines tamoxifen sensitivity by regulation of oestrogen receptor (ER)alpha. Ectopic expression of Aurora-A decreases and depletion of Aurora-A enhances tamoxifen sensitivity in ER alpha-positive breast cancer. Elevated Aurora-A was significantly associated with the recurrence of ER alpha-positive tumours. Notably, Aurora-A inhibitor MLN8237, which is currently in clinical trial, synergizes with tamoxifen and overcomes tamoxifen resistance. Furthermore, Aurora-A interacts with and phosphorylates ER alpha on serine-167 and -305, leading to increase in ER alpha DNA-binding and transcriptional activity. Elevated levels of Aurora-A are significantly associated with disease-free survival in ER alpha-positive but not ER alpha-negative breast cancers. These data suggest that Aurora-A has a pivotal role in tamoxifen resistance and ER alpha is a bona fide substrate of Aurora-A. Thus, Aurora-A represents a prognostic marker in ER alpha-positive tumour and a critical therapeutic target in tamoxifen-resistant breast cancer, and Aurora-A inhibitor could be used as either an independent or concurrent agent in tamoxifen-resistant tumour.	[Zheng, X. Q.; Guo, J. P.; Yang, H.; Kanai, M.; He, L. L.; Li, Y. Y.; Koomen, J. M.; Cheng, J. Q.] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA; [Zheng, X. Q.; Gao, M.] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Thyroid,Oncol Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China; [Zheng, X. Q.; Gao, M.] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Neck Tumour,Oncol Key Lab Canc Prevent & The, Tianjin, Peoples R China; [Zheng, X. Q.; Ren, X. B.] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Immunol,Oncol Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China; [Minton, S.] H Lee Moffitt Canc Ctr & Res Inst, Dept Womens Oncol, Tampa, FL 33612 USA; [Minton, S.; Coppola, D.] Res Inst, Tampa, FL USA; [Coppola, D.] H Lee Moffitt Canc Ctr & Res Inst, Dept Womens Pathol, Tampa, FL USA	H Lee Moffitt Cancer Center & Research Institute; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Zheng, XQ (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr,SRB3, Tampa, FL 33612 USA.	jin.cheng@moffitt.org	Kanai, Motomu/J-6807-2016	Kanai, Motomu/0000-0003-1977-7648	NIH [CA160455]; Florida James and Esther King Biomedical Research Program [1KG02]; NATIONAL CANCER INSTITUTE [R01CA137041, R01CA160455, P30CA076292] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Florida James and Esther King Biomedical Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciate Dr Kenji Fukasawa for his scientific input. We are grateful for Tissue Procurement, DNA Sequence, Proteomics and Image Core Facilities at H. Lee Moffitt Cancer Center for providing cancer specimens, sequencing and cell apoptosis analysis. This work was partially supported by grants from NIH grant CA160455 (JQC) and Florida James and Esther King Biomedical Research Program 1KG02 (JQC).	Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Barkhem Tomas, 2004, Am J Pharmacogenomics, V4, P19, DOI 10.2165/00129785-200404010-00003; Bodvarsdottir SK, 2007, CANCER LETT, V248, P96, DOI 10.1016/j.canlet.2006.06.003; Bostner J, 2007, ONCOGENE, V26, P6997, DOI 10.1038/sj.onc.1210506; Bostner J, 2010, CLIN CANCER RES, V16, P1624, DOI 10.1158/1078-0432.CCR-09-1733; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; Cutrupi S, 2012, ONCOGENE, V31, P4353, DOI 10.1038/onc.2011.627; D'Assoro AB, 2014, ONCOGENE, V33, P599, DOI 10.1038/onc.2012.628; Ferrari S, 2005, BIOCHEM J, V390, P293, DOI 10.1042/BJ20050343; Guo JP, 2010, J BIOL CHEM, V285, P3676, DOI 10.1074/jbc.M109.078212; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Holm C, 2009, J PATHOL, V217, P372, DOI 10.1002/path.2455; Holz MK, 2012, CELL CYCLE, V11, P3159, DOI 10.4161/cc.21194; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; JOHNSTON SRD, 1995, CANCER RES, V55, P3331; Jordan VC, 2007, J CLIN ONCOL, V25, P5815, DOI 10.1200/JCO.2007.11.3886; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Kok M, 2011, BREAST CANCER RES TR, V125, P1, DOI 10.1007/s10549-010-0798-y; Le Romancer M, 2011, ENDOCR REV, V32, P597, DOI 10.1210/er.2010-0016; Li JJ, 2004, P NATL ACAD SCI USA, V101, P18123, DOI 10.1073/pnas.0408273101; Li QY, 2004, J BIOL CHEM, V279, P52175, DOI 10.1074/jbc.M406802200; Lim KH, 2010, MOL CELL BIOL, V30, P508, DOI 10.1128/MCB.00916-08; Lundgren K, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3161; Lupien M, 2010, GENE DEV, V24, P2219, DOI 10.1101/gad.1944810; LYKKESFELDT AE, 1994, CANCER RES, V54, P1587; Manfredi MG, 2011, CLIN CANCER RES, V17, P7614, DOI 10.1158/1078-0432.CCR-11-1536; Michalides R, 2004, CANCER CELL, V5, P597, DOI 10.1016/j.ccr.2004.05.016; Murphy LC, 2011, ENDOCR-RELAT CANCER, V18, pR1, DOI 10.1677/ERC-10-0070; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nagashima T, 2007, J BIOL CHEM, V282, P4045, DOI 10.1074/jbc.M608653200; Ohishi T, 2010, CANCER RES, V70, P2041, DOI 10.1158/0008-5472.CAN-09-2008; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Qi WQ, 2011, BIOCHEM PHARMACOL, V81, P881, DOI 10.1016/j.bcp.2011.01.017; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; Sehdev V, 2012, MOL CANCER THER, V11, P763, DOI 10.1158/1535-7163.MCT-11-0623; TONETTI DA, 1995, ANTI-CANCER DRUG, V6, P498, DOI 10.1097/00001813-199508000-00002; Wang LH, 2010, CANCER RES, V70, P9118, DOI 10.1158/0008-5472.CAN-10-1246; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Wang X, 2006, ONCOGENE, V25, P7148, DOI 10.1038/sj.onc.1209707; Warner SL, 2003, MOL CANCER THER, V2, P589; Yang H, 2004, CANCER RES, V64, P463, DOI 10.1158/0008-5472.CAN-03-2907	44	25	27	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2014	33	42					4985	4996		10.1038/onc.2013.444	http://dx.doi.org/10.1038/onc.2013.444			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OB	24166501	Green Accepted			2022-12-28	WOS:000343768000003
J	Xiao, L; Hu, ZY; Dong, X; Tan, Z; Li, W; Tang, M; Chen, L; Yang, L; Tao, Y; Jiang, Y; Li, J; Yi, B; Li, B; Fan, S; You, S; Deng, X; Hu, F; Feng, L; Bode, AM; Dong, Z; Sun, LQ; Cao, Y				Xiao, L.; Hu, Z-Y; Dong, X.; Tan, Z.; Li, W.; Tang, M.; Chen, L.; Yang, L.; Tao, Y.; Jiang, Y.; Li, J.; Yi, B.; Li, B.; Fan, S.; You, S.; Deng, X.; Hu, F.; Feng, L.; Bode, A. M.; Dong, Z.; Sun, L-Q; Cao, Y.			Targeting Epstein-Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy	ONCOGENE			English	Article							LATENT MEMBRANE-PROTEIN-1; TUMOR-SUPPRESSOR; CANCER; GROWTH; DYSREGULATION; TRANSCRIPTION; MITOCHONDRIA; MAINTENANCE; TRAFFICKING; METABOLISM	Our goal in this work was to illustrate the Epstein-Barr virus (EBV)-modulated global biochemical profile and provide a novel metabolism-related target to improve the therapeutic regimen of nasopharyngeal carcinoma (NPC). We used a metabolomics approach to investigate EBV-modulated metabolic changes, and found that the exogenous overexpression of the EBV-encoded latent membrane protein 1 (LMP1) significantly increased glycolysis. The deregulation of several glycolytic genes, including hexokinase 2 (HK2), was determined to be responsible for the reprogramming of LMP1-mediated glucose metabolism in NPC cells. The upregulation of HK2 elevated aerobic glycolysis and facilitated proliferation by blocking apoptosis. More importantly, HK2 was positively correlated with LMP1 in NPC biopsies, and high HK2 levels were significantly associated with poor overall survival of NPC patients following radiation therapy. Knockdown of HK2 effectively enhanced the sensitivity of LMP1-overexpressing NPC cells to irradiation. Finally, c-Myc was demonstrated to be required for LMP1-induced upregulation of HK2. The LMP1-mediated attenuation of the PI3-K/Akt-GSK3beta-FBW7 signaling axis resulted in the stabilization of c-Myc. These findings indicate a close relationship between EBV and glycolysis in NPC. Notably, LMP1 is the key regulator of the reprogramming of EBV-mediated glycolysis in NPC cells. Given the importance of EBV-mediated deregulation of glycolysis, anti-glycolytic therapy might represent a worthwhile avenue of exploration in the treatment of EBV-related cancers.	[Xiao, L.; Hu, Z-Y; Dong, X.; Tan, Z.; Li, W.; Tang, M.; Chen, L.; Yang, L.; Tao, Y.; Jiang, Y.; Li, J.; Cao, Y.] Cent S Univ, Xiangya Sch Med, Canc Res Inst, Changsha 410078, Hunan, Peoples R China; [Xiao, L.; Hu, Z-Y; Dong, X.; Tan, Z.; Li, W.; Tang, M.; Chen, L.; Yang, L.; Tao, Y.; Jiang, Y.; Li, J.; Cao, Y.] Minist Educ, Key Lab Carcinogenesis & Canc Invas, Changsha, Hunan, Peoples R China; [Xiao, L.; Hu, Z-Y; Dong, X.; Tan, Z.; Li, W.; Tang, M.; Chen, L.; Yang, L.; Tao, Y.; Jiang, Y.; Li, J.; Cao, Y.] Minist Hlth, Key Lab Carcinogenesis, Changsha, Hunan, Peoples R China; [Hu, Z-Y] First Hosp Changsha City, Changsha, Hunan, Peoples R China; [Tang, M.; Hu, F.; Feng, L.] Cent S Univ, Xiangya Hosp 2, Metab Syndrome Res Ctr, Changsha 410078, Hunan, Peoples R China; [Sun, L-Q] Cent S Univ, Xiangya Hosp, Ctr Mol Med, Changsha 410078, Hunan, Peoples R China; [Yi, B.] Cent S Univ, Xiangya Hosp, Clin Biochem Lab, Changsha 410078, Hunan, Peoples R China; [Li, B.] Cent S Univ, Xiangya Hosp, Dept Pathol, Changsha 410078, Hunan, Peoples R China; [Fan, S.] Cent S Univ, Xiangya Hosp 2, Dept Pathol, Changsha 410078, Hunan, Peoples R China; [You, S.; Deng, X.] Emory Univ, Sch Med, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA USA; [You, S.] Cent S Univ, Xiangya Hosp 2, Dept Endocrinol, Changsha 410078, Hunan, Peoples R China; [Bode, A. M.; Dong, Z.] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	Central South University; Central South University; Central South University; Central South University; Central South University; Central South University; Emory University; Central South University; University of Minnesota System	Sun, LQ (corresponding author), Cent S Univ, Xiangya Hosp, Ctr Mol Med, Xiangya Rd 110, Changsha 410078, Hunan, Peoples R China.	lunquansun@csu.edu.cn; ycao98@vip.sina.com		Jiang, Yiqun/0000-0003-3262-9498	National Basic Research Program of China [2011CB504305]; National High Technology Research and Development Program of China [2012AA02A501]; National Natural Science Foundation of China (NSFC) [30930101, 81161120410]; China Postdoctoral Science Foundation funded project [2011M501300]	National Basic Research Program of China(National Basic Research Program of China); National High Technology Research and Development Program of China(National High Technology Research and Development Program of China); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation funded project(China Postdoctoral Science Foundation)	We thank Dr Ryan Michalek, Dr Sheng Quan and Dr Lining Guo at Metabolon for metabolomics analysis. We also thank Dr Giovanni Melillo from Bristol-Myers Squibb for their critical comments and suggestions. This study was supported by National Basic Research Program of China, No. 2011CB504305; The National High Technology Research and Development Program of China, No. 2012AA02A501; National Natural Science Foundation of China (NSFC), No. 30930101 and 81161120410; and China Postdoctoral Science Foundation funded project, No. 2011M501300.	Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Ascherio A, 2010, J NEUROIMMUNE PHARM, V5, P271, DOI 10.1007/s11481-010-9201-3; Bhatt AP, 2012, P NATL ACAD SCI USA, V109, P11818, DOI 10.1073/pnas.1205995109; Chen JQ, 2012, BBA-REV CANCER, V1826, P370, DOI 10.1016/j.bbcan.2012.06.004; Darekar S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042072; Dawson CW, 2012, SEMIN CANCER BIOL, V22, P144, DOI 10.1016/j.semcancer.2012.01.004; Delgado T, 2010, P NATL ACAD SCI USA, V107, P10696, DOI 10.1073/pnas.1004882107; Diamond DL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000719; Garcia-Cao I, 2012, CELL, V149, P49, DOI 10.1016/j.cell.2012.02.030; Gimenez-Cassina A, 2009, J BIOL CHEM, V284, P3001, DOI 10.1074/jbc.M808698200; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hu JY, 2005, CLIN CANCER RES, V11, P4658, DOI 10.1158/1078-0432.CCR-04-1798; Zheng H, 2007, CELL MOL IMMUNOL, V4, P185; Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07; Kohio HP, 2013, VIROLOGY, V444, P301, DOI 10.1016/j.virol.2013.06.026; Kondo S, 2006, CANCER RES, V66, P9870, DOI 10.1158/0008-5472.CAN-06-1679; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Liu WS, 2012, INT J RADIAT ONCOL, V82, P561, DOI 10.1016/j.ijrobp.2010.11.055; Lu ZX, 2008, CANCER LETT, V265, P226, DOI 10.1016/j.canlet.2008.02.019; Ma XQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024647; Mainou BA, 2005, ONCOGENE, V24, P6917, DOI 10.1038/sj.onc.1208846; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Marquitz AR, 2012, P NATL ACAD SCI USA, V109, P9593, DOI 10.1073/pnas.1202910109; Meckes DG, 2013, J VIROL, V87, P1301, DOI 10.1128/JVI.02519-12; Noch E, 2012, MOL CANCER THER, V11, P14, DOI 10.1158/1535-7163.MCT-11-0517; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014; Reitman ZJ, 2011, P NATL ACAD SCI USA, V108, P3270, DOI 10.1073/pnas.1019393108; Shair KHY, 2007, PLOS PATHOG, V3, P1669, DOI 10.1371/journal.ppat.0030166; Shin HJ, 2011, J BIOL CHEM, V286, P29872, DOI 10.1074/jbc.M111.259978; Sommermann TG, 2011, CANCER RES, V71, P7291, DOI 10.1158/0008-5472.CAN-11-1715; Soni V, 2007, ADV EXP MED BIOL, V597, P173; Tang LQ, 2013, J CLIN ONCOL, V31, P2861, DOI 10.1200/JCO.2012.46.0816; Terrin L, 2008, J VIROL, V82, P10175, DOI 10.1128/JVI.00321-08; Vastag L, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002124; Wakisaka N, 2004, MOL CELL BIOL, V24, P5223, DOI 10.1128/MCB.24.12.5223-5234.2004; Wallace DC, 2005, COLD SH Q B, V70, P363, DOI 10.1101/sqb.2005.70.035; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yang HN, 2006, P NATL ACAD SCI USA, V103, P10397, DOI 10.1073/pnas.0604008103; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yecies JL, 2011, CANCER RES, V71, P2815, DOI 10.1158/0008-5472.CAN-10-4158; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Yuan SP, 2008, FASEB J, V22, P2809, DOI 10.1096/fj.08-107417	45	130	135	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2014	33	37					4568	4578		10.1038/onc.2014.32	http://dx.doi.org/10.1038/onc.2014.32			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3UZ	24662831	Green Published, hybrid			2022-12-28	WOS:000342004800004
J	Huang, TH; Chu, TY				Huang, T-H; Chu, T-Y			Repression of miR-126 and upregulation of adrenomedullin in the stromal endothelium by cancer-stromal cross talks confers angiogenesis of cervical cancer	ONCOGENE			English	Article							GROWTH-FACTOR EXPRESSION; VASCULAR INTEGRITY; CARCINOMA CELLS; TUMOR; MICRORNA-126; NEOPLASIA; LYMPHANGIOGENESIS; ACTIVATION; ISCHEMIA	miR-126 is an endothelial-specific microRNA essential for maintaining vessel integrity during development. Its role of tumor angiogenesis in cancer stroma is unclear. This study investigated the temporal and spatial expression and the role of miR-126 in the course of cervical carcinogenesis. miR-126 was found to be mainly expressed in the stromal endothelium of the uterine cervix. This downregulation was recapitulated in a cell coculture model, wherein cross talk of cervical cancer cells and fibroblasts induced a downregulation of miR-126 in human umbilical vein endothelial cells, with consequent increase of tube formation. Coinjection of cancer-associated fibroblasts of human cervix enhanced tumorigenesis of cervical cancer cells, with an increase of microvessel density and dye retention in the tumor vasculature. In association with angiogenesis, host-originated miR-126 in these xenograft tumors was progressively downregulated, whereas supplement of the miR-126 precursor in the coinjection suppressed angiogenesis and tumor growth. A proangiogenic gene adrenomedullin (ADM), which was found to be upregulated in the stroma of cervical cancer and which localized mainly in the blood and lymphatic vessels, was identified as a target of inhibition by miR-126 at the carcinoma in situ-to-invasion stage. The study suggests a cancer stroma cross talk induced repression of miR-126 and upregulation of ADM, and probably other proangiogenic factors, to facilitate angiogenesis and invasion growth of cervical cancer.	[Huang, T-H; Chu, T-Y] Tzu Chi Gen Hosp, Dept Res, Ctr Cerv Canc Prevent, Hualien 970, Taiwan; [Huang, T-H; Chu, T-Y] Tzu Chi Univ, Inst Med Sci, Hualien, Taiwan; [Chu, T-Y] Tzu Chi Univ, Tzu Chi Gen Hosp, Dept Obstet & Gynecol, Hualien, Taiwan	Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital; Tzu Chi University; Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital; Tzu Chi University	Chu, TY (corresponding author), Tzu Chi Gen Hosp, Dept Obstet & Gynecol, 707,Sect 3,Chung Yang Rd, Hualien 970, Taiwan.	hidrchu@gmail.com		Chu, Tang-Yuan/0000-0003-2717-2681	National Science Council of the Republic of China, Taiwan [NSC 97-2314-B-303-008-MY3]; Buddhist Tzu Chi General Hospital, Hualien, Taiwan [TCRD100-54-01]	National Science Council of the Republic of China, Taiwan(Ministry of Science and Technology, Taiwan); Buddhist Tzu Chi General Hospital, Hualien, Taiwan	We thank Ms Yen-Jen Shih for the technical assistance. We also thank Dr Lu-Hai Wang for his comments during the preparation of this manuscript. Ted Knoy is appreciated for his editorial assistance. This study was supported by the National Science Council of the Republic of China, Taiwan (contract number NSC 97-2314-B-303-008-MY3) and by the Buddhist Tzu Chi General Hospital, Hualien, Taiwan (contract number TCRD100-54-01).	Bai YY, 2011, EXP MOL PATHOL, V91, P471, DOI 10.1016/j.yexmp.2011.04.016; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Botting SK, 2010, TRANSL ONCOL, V3, P170, DOI 10.1593/tlo.09292; CINTORINO M, 1991, INT J CANCER, V47, P843, DOI 10.1002/ijc.2910470609; Cooley LS, 2010, J CELL SCI, V123, P3808, DOI 10.1242/jcs.064279; Dellas A, 1997, GYNECOL ONCOL, V67, P27, DOI 10.1006/gyno.1997.4835; Dobbs SP, 1997, BRIT J CANCER, V76, P1410, DOI 10.1038/bjc.1997.571; Feng RH, 2010, CANCER LETT, V298, P50, DOI 10.1016/j.canlet.2010.06.004; Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008; Frede S, 2005, CANCER RES, V65, P4690, DOI 10.1158/0008-5472.CAN-04-3877; GUIDI AJ, 1995, J NATL CANCER I, V87, P1237, DOI 10.1093/jnci/87.16.1237; Guo CG, 2008, GENE CHROMOSOME CANC, V47, P939, DOI 10.1002/gcc.20596; Hamada S, 2012, MOL CANCER RES, V10, P3, DOI 10.1158/1541-7786.MCR-11-0272; Harris TA, 2008, P NATL ACAD SCI USA, V105, P1516, DOI 10.1073/pnas.0707493105; Iwase T, 2005, CIRCULATION, V111, P356, DOI 10.1161/01.CIR.0000153352.29335.B9; Karpinich NO, 2011, CURR HYPERTENS REV, V7, P228, DOI 10.2174/157340211799304761; Karpinich NO, 2013, FASEB J, V27, P590, DOI 10.1096/fj.12-214080; Kato H, 1997, ENDOCRINOLOGY, V138, P2615, DOI 10.1210/en.138.6.2615; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Lee JW, 2008, CLIN CANCER RES, V14, P2535, DOI 10.1158/1078-0432.CCR-07-1231; Liu B, 2009, LUNG CANCER, V66, P169, DOI 10.1016/j.lungcan.2009.01.010; Martinez I, 2008, ONCOGENE, V27, P2575, DOI 10.1038/sj.onc.1210919; McCall MN, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-78; Nikitenko LL, 2006, BRIT J CANCER, V94, P1, DOI 10.1038/sj.bjc.6602832; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Ribatti D, 2005, PEPTIDES, V26, P1670, DOI 10.1016/j.peptides.2005.02.017; Sasahira T, 2012, BRIT J CANCER, V107, P700, DOI 10.1038/bjc.2012.330; Sun YQ, 2010, BIOCHEM BIOPH RES CO, V391, P1483, DOI 10.1016/j.bbrc.2009.12.098; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156; Wang KH, 2009, CANCER SCI, V100, P2175, DOI 10.1111/j.1349-7006.2009.01285.x; Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002; Zernecke A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000610; Zhang L, 2003, CANCER RES, V63, P3403; Zhu N, 2011, MOL CELL BIOCHEM, V351, P157, DOI 10.1007/s11010-011-0723-7	36	55	58	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3636	3647		10.1038/onc.2013.335	http://dx.doi.org/10.1038/onc.2013.335			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	24037526				2022-12-28	WOS:000338942900003
J	Burkitt, MD; Williams, JM; Duckworth, CA; O'Hara, A; Hanedi, A; Varro, A; Caamano, JH; Pritchard, DM				Burkitt, M. D.; Williams, J. M.; Duckworth, C. A.; O'Hara, A.; Hanedi, A.; Varro, A.; Caamano, J. H.; Pritchard, D. M.			Signaling mediated by the NF-kappa B sub-units NF-kappa B1, NF-kappa B2 and c-Rel differentially regulate Helicobacter felis-induced gastric carcinogenesis in C57BL/6 mice	ONCOGENE			English	Article						Helicobacter felis infection; NF-kappa B; MALT lymphoma; gastric cancer	MOUSE MODEL; CELL PROLIFERATION; INFECTION; PYLORI; INFLAMMATION; LACKING; CANCER; APOPTOSIS; DEFECTS; FAMILY	The classical nuclear factor-kappaB (NF-kappa B) signaling pathway has been shown to be important in a number of models of inflammation-associated cancer. In a mouse model of Helicobacter-induced gastric cancer, impairment of classical NF-kappa B signaling in the gastric epithelium led to the development of increased preneoplastic pathology, however the role of specific NF-kappa B proteins in Helicobacter-associated gastric cancer development remains poorly understood. To investigate this C57BL/6, Nfkb1(-/-), Nfkb2(-/-) and c-Rel(-/-) mice were infected with Helicobacter felis for 6 weeks or 12 months. Bacterial colonization, gastric atrophy and preneoplastic changes were assessed histologically and cytokine expression was assessed by qPCR. Nfkb1(-/-) mice developed spontaneous gastric atrophy when maintained for 12 months in conventional animal house conditions. They also developed more pronounced gastric atrophy after short-term H. felis colonization with a similar extent of preneoplasia to wild-type (WT) mice after 12 months. c-Rel(-/-) mice developed a similar degree of gastric atrophy to WT mice; 3 of 6 of these animals also developed lymphoproliferative lesions after 12 months of infection. Nfkb2(-/-) mice developed minimal gastric epithelial pathology even 12 months after H. felis infection. These findings demonstrate that NF-kappa B1- and NF-kappa B2-mediated signaling pathways differentially regulate the epithelial consequences of H. felis infection in the stomach, while c-Rel-mediated signaling also appears to modulate the risk of lymphomagenesis in gastric mucosa-associated lymphoid tissue.	[Burkitt, M. D.; Williams, J. M.; Duckworth, C. A.; O'Hara, A.; Hanedi, A.; Pritchard, D. M.] Univ Liverpool, Dept Gastroenterol, Henry Wellcome Labs, Inst Translat Med, Liverpool L69 3GE, Merseyside, England; [Varro, A.] Univ Liverpool, Inst Translat Med, Dept Cellular & Mol Physiol, Liverpool L69 3GE, Merseyside, England; [Caamano, J. H.] Univ Birmingham, Coll Med & Dent Sci, IBR Sch Immun & Infect, Birmingham, W Midlands, England	University of Liverpool; University of Liverpool; University of Birmingham	Pritchard, DM (corresponding author), Univ Liverpool, Dept Gastroenterol, Henry Wellcome Labs, Inst Translat Med, 1st Floor,Nuffield Bldg,Ashton St, Liverpool L69 3GE, Merseyside, England.	mark.pritchard@liverpool.ac.uk	Duckworth, Carrie/AAC-8361-2020; Duckworth, Carrie A/K-7302-2014; O'Hara, Adrian/ABE-7987-2020; Varro, Andras/M-2647-2016; Burkitt, Michael/AAU-9506-2021; Caamano, Jorge/I-6778-2012; Caamano, Jorge/O-7530-2019	Duckworth, Carrie/0000-0001-9992-7540; Duckworth, Carrie A/0000-0001-9992-7540; O'Hara, Adrian/0000-0003-1837-680X; Burkitt, Michael/0000-0002-5055-6408; Caamano, Jorge/0000-0003-3530-7056; Caamano, Jorge/0000-0003-3530-7056; Pritchard, David Mark/0000-0001-7971-3561; Williams, Jonathan/0000-0002-6617-0323	Wellcome Trust Research Training Fellowship; North West Cancer Research project grant; EU FP7 integrated project INFLACARE; College of Medical and Dental Sciences-University of Birmingham; BBSRC [BB/K009400/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/K009400/1] Funding Source: researchfish; National Institute for Health Research [CL-2011-07-501] Funding Source: researchfish; North West Cancer Research [CR930] Funding Source: researchfish	Wellcome Trust Research Training Fellowship(Wellcome Trust); North West Cancer Research project grant; EU FP7 integrated project INFLACARE; College of Medical and Dental Sciences-University of Birmingham; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); National Institute for Health Research(National Institute for Health Research (NIHR)); North West Cancer Research	This work was supported by a Wellcome Trust Research Training Fellowship awarded to MDB, and a North West Cancer Research project grant. JC was supported by the EU FP7 integrated project INFLACARE and the College of Medical and Dental Sciences-University of Birmingham.	Artis D, 2002, J IMMUNOL, V169, P4481, DOI 10.4049/jimmunol.169.8.4481; Burkitt MD, 2009, WORLD J GASTROENTERO, V15, P1, DOI 10.3748/wjg.15.1; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Court M, 2003, J PATHOL, V201, P303, DOI 10.1002/path.1422; Curry Choladda V, 2009, J Hematop, V2, P20, DOI 10.1007/s12308-009-0021-4; Duckworth CA, 2012, AM J PHYSIOL-GASTR L, V303, pG915, DOI 10.1152/ajpgi.00068.2012; ENNO A, 1995, AM J PATHOL, V147, P217; Erdman SE, 2001, J IMMUNOL, V166, P1443, DOI 10.4049/jimmunol.166.3.1443; Ferreira BI, 2008, HAEMATOLOGICA, V93, P670, DOI 10.3324/haematol.12221; Ferrero RL, 2000, J PATHOL, V191, P333; Fox JG, CANC RES, V62, P696; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Mantovani A, 2009, NATURE, V457, P36, DOI 10.1038/457036b; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Ohmae T, 2005, J IMMUNOL, V175, P7162, DOI 10.4049/jimmunol.175.11.7162; Persson C, 2011, AM J EPIDEMIOL, V173, P259, DOI 10.1093/aje/kwq370; Pritchard DM, 2004, ALIMENT PHARM THER, V19, P841, DOI 10.1111/j.1365-2036.2004.01911.x; Rogers AB, 2005, CANCER RES, V65, P10709, DOI 10.1158/0008-5472.CAN-05-1846; Rogers Arlin B, 2012, Methods Mol Biol, V921, P189; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Shibata W, 2010, GASTROENTEROLOGY, V138, P1022, DOI 10.1053/j.gastro.2009.11.054; Smale ST, 2012, IMMUNOL REV, V246, P193, DOI 10.1111/j.1600-065X.2011.01091.x; Starczynowski DT, 2007, ONCOGENE, V26, P2685, DOI 10.1038/sj.onc.1210089; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Tu SP, 2011, CANCER RES, V71, P4247, DOI 10.1158/0008-5472.CAN-10-4009; Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011; Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739	34	29	30	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2013	32	50					5563	5573		10.1038/onc.2013.334	http://dx.doi.org/10.1038/onc.2013.334			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272LF	23975431	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000328461400001
J	Eden, CJ; Ju, B; Murugesan, M; Phoenix, TN; Nimmervoll, B; Tong, Y; Ellison, DW; Finkelstein, D; Wright, K; Boulos, N; Dapper, J; Thiruvenkatam, R; Lessman, CA; Taylor, MR; Gilbertson, RJ				Eden, C. J.; Ju, B.; Murugesan, M.; Phoenix, T. N.; Nimmervoll, B.; Tong, Y.; Ellison, D. W.; Finkelstein, D.; Wright, K.; Boulos, N.; Dapper, J.; Thiruvenkatam, R.; Lessman, C. A.; Taylor, M. R.; Gilbertson, R. J.			Orthotopic models of pediatric brain tumors in zebrafish	ONCOGENE			English	Article							NEURAL CREST; CANCER; MEDULLOBLASTOMA	High-throughput screens (HTS) of compound toxicity against cancer cells can identify thousands of potential new drug-leads. But only limited numbers of these compounds can progress to expensive and labor-intensive efficacy studies in mice, creating a 'bottle neck' in the drug development pipeline. Approaches that triage drug-leads for further study are greatly needed. Here we provide an intermediary platform between HTS and mice by adapting mouse models of pediatric brain tumors to grow as orthotopic xenografts in the brains of zebrafish. Freshly isolated mouse ependymoma, glioma and choroid plexus carcinoma cells expressing red fluorescence protein were conditioned to grow at 34 degrees C. Conditioned tumor cells were then transplanted orthotopically into the brains of zebrafish acclimatized to ambient temperatures of 34 degrees C. Live in vivo fluorescence imaging identified robust, quantifiable and reproducible brain tumor growth as well as spinal metastasis in zebrafish. All tumor xenografts in zebrafish retained the histological characteristics of the corresponding parent mouse tumor and efficiently recruited fish endothelial cells to form a tumor vasculature. Finally, by treating zebrafish harboring ERBB2-driven gliomas with an appropriate cytotoxic chemotherapy (5-fluorouracil) or tyrosine kinase inhibitor (erlotinib), we show that these models can effectively assess drug efficacy. Our data demonstrate, for the first time, that mouse brain tumors can grow orthotopically in fish and serve as a platform to study drug efficacy. As large cohorts of brain tumor-bearing zebrafish can be generated rapidly and inexpensively, these models may serve as a powerful tool to triage drug-leads from HTS for formal efficacy testing in mice.	[Eden, C. J.; Murugesan, M.; Phoenix, T. N.; Nimmervoll, B.; Tong, Y.; Boulos, N.; Dapper, J.; Thiruvenkatam, R.; Gilbertson, R. J.] St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; [Ju, B.; Taylor, M. R.] St Jude Childrens Res Hosp, Dept Chem Biol & Therapeut, Memphis, TN 38105 USA; [Ellison, D. W.] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; [Finkelstein, D.] St Jude Childrens Res Hosp, Dept Computat Biol & Bioinformat, Memphis, TN 38105 USA; [Wright, K.] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA; [Lessman, C. A.] St Jude Childrens Res Hosp, Dept Biol Sci, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Taylor, MR (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA.	Michael.Taylor@stjude.org; Richard.Gilbertson@stjude.org	Gilbertson, Richard James/ABE-1346-2021	Gilbertson, Richard James/0000-0001-7539-9472; Nimmervoll, Birgit/0000-0002-3324-092X; KM, Mohankumar/0000-0001-9407-1800	National Institutes of Health [R01CA129541, P01CA96832, P30CA021765]; Collaborative Ependymoma Research Network (CERN); ALSAC; NATIONAL CANCER INSTITUTE [P01CA096832, R01CA129541, P30CA021765] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Collaborative Ependymoma Research Network (CERN); ALSAC(American Lebanese Syrian Associated Charities (ALSAC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Institutes of Health (R01CA129541, P01CA96832 and P30CA021765, RJG), the Collaborative Ependymoma Research Network (CERN) and by ALSAC. We are grateful to the staff of the Hartwell Center for Bioinformatics and Biotechnology, and Flow Cytometry & Cell Sorting Shared Resource at St Jude Children's Research Hospital for technical assistance.	Atkinson JM, 2011, CANCER CELL, V20, P384, DOI 10.1016/j.ccr.2011.08.013; Caponigro G, 2011, NAT REV DRUG DISCOV, V10, P179, DOI 10.1038/nrd3385; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chow LML, 2011, CANCER CELL, V19, P305, DOI 10.1016/j.ccr.2011.01.039; Collymore C, 2013, JOVE-J VIS EXP, DOI 10.3791/50691; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HERBERT J, 1990, AM J PATHOL, V136, P1317; Hernan R, 2003, CANCER RES, V63, P140; Hong SK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002029; Johnson RA, 2010, NATURE, V466, P632, DOI 10.1038/nature09173; Kawauchi D, 2012, CANCER CELL, V21, P168, DOI 10.1016/j.ccr.2011.12.023; Lacy J, 2012, HEMATOL ONCOL CLIN N, V26, P779, DOI 10.1016/j.hoc.2012.04.007; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Lin NU, 2013, LANCET ONCOL, V14, pE407, DOI 10.1016/S1470-2045(13)70308-5; Macarron R, 2011, NAT REV DRUG DISCOV, V10, P188, DOI 10.1038/nrd3368; Pei YX, 2012, CANCER CELL, V21, P155, DOI 10.1016/j.ccr.2011.12.021; Pounds S, 2011, BIOINFORMATICS, V27, P2098, DOI 10.1093/bioinformatics/btr362; Prados MD, 2006, NEURO-ONCOLOGY, V8, P67, DOI 10.1215/S1522851705000451; Ridges S, 2012, BLOOD, V119, P5621, DOI 10.1182/blood-2011-12-398818; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Smith MA, 2010, J CLIN ONCOL, V28, P2625, DOI 10.1200/JCO.2009.27.0421; Stoletov K, 2008, ONCOGENE, V27, P4509, DOI 10.1038/onc.2008.95; Stoletov K, 2007, P NATL ACAD SCI USA, V104, P17406, DOI 10.1073/pnas.0703446104; Swartling FJ, 2010, GENE DEV, V24, P1059, DOI 10.1101/gad.1907510; Walbert T, 2011, J NEURO-ONCOL, V102, P273, DOI 10.1007/s11060-010-0313-7; White R, 2013, NAT REV CANCER, V13, P624, DOI 10.1038/nrc3589; White RM, 2008, CELL STEM CELL, V2, P183, DOI 10.1016/j.stem.2007.11.002; White RM, 2011, NATURE, V471, P518, DOI 10.1038/nature09882; Wienholds E, 2002, SCIENCE, V297, P99, DOI 10.1126/science.1071762	30	38	38	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1736	1742		10.1038/onc.2014.107	http://dx.doi.org/10.1038/onc.2014.107			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24747973	Green Accepted			2022-12-28	WOS:000351848400014
J	Wang, WL; Huang, HC; Kao, SH; Hsu, YC; Wang, YT; Li, KC; Chen, YJ; Yu, SL; Wang, SP; Hsiao, TH; Yang, PC; Hong, TM				Wang, W-L; Huang, H-C; Kao, S-H; Hsu, Y-C; Wang, Y-T; Li, K-C; Chen, Y-J; Yu, S-L; Wang, S-P; Hsiao, T-H; Yang, P-C; Hong, T-M			Slug is temporally regulated by cyclin E in cell cycle and controls genome stability	ONCOGENE			English	Article							REPRESSES E-CADHERIN; DEPENDENT KINASES; NEURAL CREST; EXPRESSION; CANCER; PROLIFERATION; DEGRADATION; INSTABILITY; TRANSCRIPTION; P27(KIP1)	The transcriptional repressor Slug is best known to control epithelial-mesenchymal transition (EMT) and promote cancer invasion/metastasis. In this study, we demonstrate that Slug is temporally regulated during cell cycle progression. At G1/S transition, cyclin E-cyclin-dependent kinase 2 mediates the phosphorylation of Slug at Ser-54 and Ser-104, resulting in its ubiquitylation and degradation. Non-phosphorylatable Slug is markedly stabilized at G1/S transition compared with wild-type Slug and greatly leads to downregulation of DNA synthesis and checkpoint-related proteins, including TOP1, DNA Ligase IV and Rad17, reduces cell proliferation, delays S-phase progression and contributes to genome instability. Our results indicate that Slug has multifaceted roles in cancer progression by controlling both EMT and genome stability.	[Wang, W-L; Kao, S-H; Wang, S-P; Yang, P-C] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; [Wang, W-L; Hong, T-M] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan 704, Taiwan; [Huang, H-C] Natl Taiwan Univ, Inst Mol & Cellular Biol, Taipei 10764, Taiwan; [Kao, S-H; Hsiao, T-H; Yang, P-C] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Hsu, Y-C; Li, K-C] Acad Sinica, Inst Stat Sci, Taipei 115, Taiwan; [Wang, Y-T; Chen, Y-J] Acad Sinica, Taiwan Int Grad Program, Chem Biol & Mol Biophys Program, Taipei 115, Taiwan; [Wang, Y-T; Chen, Y-J] Acad Sinica, Inst Chem, Taipei 115, Taiwan; [Yu, S-L] Natl Taiwan Univ, Coll Med, Dept Clin, Lab Sci & Med Biotechnol, Taipei 10764, Taiwan; [Yang, P-C] Natl Taiwan Univ, Coll Med, NTU Ctr Genom Med, Taipei 10764, Taiwan	Academia Sinica - Taiwan; National Cheng Kung University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; Academia Sinica - Taiwan; Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University	Hong, TM (corresponding author), Natl Cheng Kung Univ, Inst Clin Med, Coll Med, 138 Sheng Li Rd, Tainan 704, Taiwan.	tmhong@mail.ncku.edu.tw	Chen, Yu-Ju/E-9481-2015; Li, Ker-Chau/AAQ-4886-2021; Wang, Shu-Ping/S-4379-2018	Chen, Yu-Ju/0000-0002-3178-6697; Wang, Shu-Ping/0000-0002-5895-1269; YU, SUNG-LIANG/0000-0003-4535-9036; YANG, PAN-CHYR/0000-0001-6330-6048	Human Frontier Science Program long-term fellowship; National Science Council [NSC99-2628-B-006-031-MY3, NSC101-2325-B-006-018, NSC100-2321-B-002-071, NSC101-2321-B-002-068, NSC102-2811-B-002-069]; National Taiwan University [101R7601-2]	Human Frontier Science Program long-term fellowship(Human Frontier Science Program); National Science Council(Ministry of Science and Technology, Taiwan); National Taiwan University(National Taiwan University)	The proteomics data analysis by LTQ-Orbitrap XL hybrid mass spectrometer was performed by the Academia Sinica Common Mass Spectrometry Facilities located at the Institute of Biological Chemistry, Taipei, Taiwan. shRNA constructs were obtained from the National RNAi Core Facility at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica, Taipei, Taiwan. We thank Szu-Hua Pan, Pei-Fang Hung and Shu-Wei Lin for technical assistance. S-PW is supported by a Human Frontier Science Program long-term fellowship. This work was supported by grants from the National Science Council (NSC99-2628-B-006-031-MY3, NSC101-2325-B-006-018, NSC100-2321-B-002-071, NSC101-2321-B-002-068 and NSC102-2811-B-002-069) and National Taiwan University (101R7601-2).	Aguilera A, 2008, NAT REV GENET, V9, P204, DOI 10.1038/nrg2268; Baygi ME, 2010, TUMOR BIOL, V31, P297, DOI 10.1007/s13277-010-0037-5; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Dhar SK, 2001, J BIOL CHEM, V276, P29067, DOI 10.1074/jbc.M103078200; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Hajra KM, 2002, CANCER RES, V62, P1613; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; Liu J, 2010, PROSTATE, V70, P1768, DOI 10.1002/pros.21213; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; MAYOR R, 1995, DEVELOPMENT, V121, P767; Mills KD, 2004, GENE DEV, V18, P1283, DOI 10.1101/gad.1204304; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Sakaue-Sawano A, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-2; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Shih JY, 2011, CARCINOGENESIS, V32, P1299, DOI 10.1093/carcin/bgr110; Siu KT, 2012, CELL CYCLE, V11, P57, DOI 10.4161/cc.11.1.18775; Tuduri S, 2009, NAT CELL BIOL, V11, P1315, DOI 10.1038/ncb1984; Turner FE, 2006, J BIOL CHEM, V281, P21321, DOI 10.1074/jbc.M509731200; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Vernon AE, 2006, DEVELOPMENT, V133, P3359, DOI 10.1242/dev.02504; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Wang X, 2003, GENE DEV, V17, P965, DOI 10.1101/gad.1065103; Yuan A, 2002, J CLIN ONCOL, V20, P900, DOI 10.1200/JCO.20.4.900; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456	32	28	28	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1116	1125		10.1038/onc.2014.58	http://dx.doi.org/10.1038/onc.2014.58			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662826				2022-12-28	WOS:000350122100005
J	Dekanty, A; Barrio, L; Milan, M				Dekanty, A.; Barrio, L.; Milan, M.			Contributions of DNA repair, cell cycle checkpoints and cell death to suppressing the DNA damage-induced tumorigenic behavior of Drosophila epithelial cells	ONCOGENE			English	Article							DEPENDENT KINASE INHIBITOR; APOPTOSIS; PROLIFERATION; MORPHOGENESIS; ANEUPLOIDY; ABSENCE; MELANOGASTER; EXPRESSION; RADIATION; TRIBBLES	When exposed to DNA-damaging agents, components of the DNA damage response (DDR) pathway trigger apoptosis, cell cycle arrest and DNA repair. Although failures in this pathway are associated with cancer development, the tumor suppressor roles of cell cycle arrest and apoptosis have recently been questioned in mouse models. Using Drosophila epithelial cells that are unable to activate the apoptotic program, we provide evidence that ionizing radiation (IR)-induced DNA damage elicits a tumorigenic behavior in terms of E-cadherin delocalization, cell delamination, basement membrane degradation and neoplasic overgrowth. The tumorigenic response of the tissue to IR is enhanced by depletion of Okra/DmRAD54 or spnA/DmRAD51-genes required for homologous recombination (HR) repair of DNA double-strand breaks in G2-and it is independent of the activity of Lig4, a ligase required for nonhomologous end-joining repair in G1. Remarkably, depletion of Grapes/DmChk1 or Mei-41/dATR-genes affecting DNA damage-induced cell cycle arrest in G2-compromised DNA repair and enhanced the tumorigenic response of the tissue to IR. On the contrary, DDR-independent lengthening of G2 had a positive impact on the dynamics of DNA repair and suppressed the tumorigenic response of the tissue to IR. Our results support a tumor suppressor role of apoptosis, DNA repair by HR and cell cycle arrest in G2 in simple epithelia subject to IR-induced DNA damage.	[Dekanty, A.; Barrio, L.; Milan, M.] IRB Barcelona, Barcelona 08028, Spain; [Milan, M.] ICREA, Barcelona, Spain	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; ICREA	Milan, M (corresponding author), IRB Barcelona, Dept Cell & Dev Biol, Baldiri Reixac 10-12, Barcelona 08028, Spain.	marco.milan@irbbarcelona.org	Dekanty, Andres/C-3925-2018; Milan, Marco/H-1450-2015; Barrio Guerrero, Lara/F-4155-2016	Dekanty, Andres/0000-0002-0587-0449; Milan, Marco/0000-0002-7111-6444; Barrio Guerrero, Lara/0000-0001-7347-3114	Juan de la Cierva post-doctoral contract; Ministerio de Economia y Competitividad [BFU2010-21123, CSD2007-00008]; Generalitat de Catalunya [2005 SGR 00118]; EMBO Young Investigator Programme; ICREA Funding Source: Custom	Juan de la Cierva post-doctoral contract; Ministerio de Economia y Competitividad(Spanish Government); Generalitat de Catalunya(Generalitat de Catalunya); EMBO Young Investigator Programme(European Molecular Biology Organization (EMBO)); ICREA(ICREA)	We thank B Edgar and I Hariharan for flies and reagents, T Yates for help in editing the manuscript, and M Clemente-Ruiz for comments on the manuscript. AD is funded by a Juan de la Cierva post-doctoral contract and LB by a pre-doctoral fellowship (Ministerio de Economia y Competitividad), MM is an ICREA Research Professor and MM's laboratory was funded by Grants from the Ministerio de Economia y Competitividad (BFU2010-21123 and CSD2007-00008), the Generalitat de Catalunya (2005 SGR 00118), intramural funds and the EMBO Young Investigator Programme.	Beaucher M, 2007, DEV BIOL, V303, P625, DOI 10.1016/j.ydbio.2006.12.001; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Dar AC, 2012, NATURE, V486, P80, DOI 10.1038/nature11127; Dekanty A, 2012, P NATL ACAD SCI USA, V109, P20549, DOI 10.1073/pnas.1206675109; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; Foster SS, 2012, P NATL ACAD SCI USA, V109, P9953, DOI 10.1073/pnas.1120476109; Garcia AM, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-12-r121; Garcia AM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000950; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HAY BA, 1994, DEVELOPMENT, V120, P2121; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jaklevic BR, 2004, CURR BIOL, V14, P23, DOI 10.1016/j.cub.2003.12.032; Joyce EF, 2011, J CELL BIOL, V195, P359, DOI 10.1083/jcb.201104121; Kooistra R, 1997, MOL CELL BIOL, V17, P6097, DOI 10.1128/MCB.17.10.6097; Kusano K, 2001, SCIENCE, V291, P2600, DOI 10.1126/science.291.5513.2600; Lane D, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000893; Lane ME, 1996, CELL, V87, P1225, DOI 10.1016/S0092-8674(00)81818-8; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; McVey M, 2004, P NATL ACAD SCI USA, V101, P15694, DOI 10.1073/pnas.0406157101; McVey M, 2004, GENETICS, V167, P699, DOI 10.1534/genetics.103.025411; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Ohsawa S, 2012, NATURE, V490, P547, DOI 10.1038/nature11452; Oromendia AB, 2012, GENE DEV, V26, P2696, DOI 10.1101/gad.207407.112; Pacquelet A, 2005, J CELL BIOL, V170, P803, DOI 10.1083/jcb.200506131; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Perez-Garijo A, 2004, DEVELOPMENT, V131, P5591, DOI 10.1242/dev.01432; Peters M, 2002, P NATL ACAD SCI USA, V99, P11305, DOI 10.1073/pnas.172382899; Reis T, 2004, CELL, V117, P253, DOI 10.1016/S0092-8674(04)00247-8; Romeijn RJ, 2005, GENETICS, V169, P795, DOI 10.1534/genetics.104.033464; Salomon RN, 2008, FLY, V2, P265, DOI 10.4161/fly.7396; Seher TC, 2000, CURR BIOL, V10, P623, DOI 10.1016/S0960-9822(00)00502-9; Song YH, 2005, MOL CELLS, V19, P167; Song YH, 2004, CURR BIOL, V14, P1354, DOI 10.1016/j.cub.2004.06.064; Srivastava A, 2007, P NATL ACAD SCI USA, V104, P2721, DOI 10.1073/pnas.0611666104; Srivastava N, 2009, MUTAT RES-REV MUTAT, V681, P180, DOI 10.1016/j.mrrev.2008.08.003; Staeva-Vieira E, 2003, EMBO J, V22, P5863, DOI 10.1093/emboj/cdg564; Stingele S, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.40; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Warner SJ, 2010, CURR BIOL, V20, P677, DOI 10.1016/j.cub.2010.03.025	50	23	24	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					978	985		10.1038/onc.2014.42	http://dx.doi.org/10.1038/onc.2014.42			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632609				2022-12-28	WOS:000350121300004
J	Lung, HL; Man, OY; Yeung, MC; Ko, JMY; Cheung, AKL; Law, EWL; Yu, Z; Shuen, WH; Tung, E; Chan, SHK; Bangarusamy, DK; Cheng, Y; Yang, X; Kan, R; Phoon, Y; Chan, KC; Chua, D; Kwong, DL; Lee, AWM; Ji, MF; Lung, ML				Lung, H. L.; Man, O. Y.; Yeung, M. C.; Ko, J. M. Y.; Cheung, A. K. L.; Law, E. W. L.; Yu, Z.; Shuen, W. H.; Tung, E.; Chan, S. H. K.; Bangarusamy, D. K.; Cheng, Y.; Yang, X.; Kan, R.; Phoon, Y.; Chan, K. C.; Chua, D.; Kwong, D. L.; Lee, A. W. M.; Ji, M. F.; Lung, M. L.			SAA1 polymorphisms are associated with variation in antiangiogenic and tumor-suppressive activities in nasopharyngeal carcinoma	ONCOGENE			English	Article							SERUM AMYLOID-A; AORTIC SMOOTH-MUSCLE; EPSTEIN-BARR-VIRUS; ARG-GLY-ASP; ACUTE-PHASE; MONOCHROMOSOME TRANSFER; EXTRACELLULAR-MATRIX; EPITHELIAL-CELLS; EXPRESSION; PROTEIN	Nasopharyngeal carcinoma (NPC) is a cancer that occurs in high frequency in Southern China. A previous functional complementation approach and the subsequent cDNA microarray analysis have identified that serum amyloid A1 (SAA1) is an NPC candidate tumor suppressor gene. SAA1 belongs to a family of acute-phase proteins that are encoded by five polymorphic coding alleles. The SAA1 genotyping results showed that only three SAA1 isoforms (SAA1.1, 1.3 and 1.5) were observed in both Hong Kong NPC patients and healthy individuals. This study aims to determine the functional role of SAA1 polymorphisms in tumor progression and to investigate the relationship between SAA1 polymorphisms and NPC risk. Indeed, we have shown that restoration of SAA1.1 and 1.3 in the SAA1-deficient NPC cell lines could suppress tumor formation and angiogenesis in vitro and in vivo. The secreted SAA1.1 and SAA1.3 proteins can block cell adhesion and induce apoptosis in the vascular endothelial cells. In contrast, the SAA1.5 cannot induce apoptosis or inhibit angiogenesis because of its weaker binding affinity to alpha V beta 3 integrin. This can explain why SAA1.5 has no tumor-suppressive effects. Furthermore, the NPC tumors with this particular SAA1.5/1.5 genotype showed higher levels of SAA1 gene expression, and SAA1.1 and 1.3 alleles were preferentially inactivated in tumor tissues that were examined. These findings further strengthen the conclusion for the defective function of SAA1.5 in suppression of tumor formation and angiogenesis. Interestingly, the frequency of the SAA1.5/1.5 genotype in NPC patients was similar to 2-fold higher than in the healthy individuals (P = 0.00128, odds ratio = 2.28), which indicates that this SAA1 genotype is significantly associated with a higher NPC risk. Collectively, this homozygous SAA1.5/1.5 genotype appears to be a recessive susceptibility gene, which has lost the antiangiogenic function, whereas SAA1.1 and SAA1.3 are the dominant alleles of the tumor suppressor phenotype.	[Lung, H. L.; Man, O. Y.; Yeung, M. C.; Ko, J. M. Y.; Cheung, A. K. L.; Law, E. W. L.; Yu, Z.; Shuen, W. H.; Tung, E.; Chan, S. H. K.; Cheng, Y.; Yang, X.; Kan, R.; Phoon, Y.; Chan, K. C.; Chua, D.; Kwong, D. L.; Lung, M. L.] Univ Hong Kong, Dept Clin Oncol, Pokfulam, Hong Kong, Peoples R China; [Lung, H. L.; Man, O. Y.; Yeung, M. C.; Ko, J. M. Y.; Cheung, A. K. L.; Law, E. W. L.; Yu, Z.; Shuen, W. H.; Tung, E.; Chan, S. H. K.; Cheng, Y.; Yang, X.; Kan, R.; Phoon, Y.; Chan, K. C.; Chua, D.; Kwong, D. L.; Lung, M. L.] Univ Hong Kong, Ctr Canc Res, Pokfulam, Hong Kong, Peoples R China; [Tung, E.; Chua, D.; Kwong, D. L.; Lee, A. W. M.; Lung, M. L.] Univ Hong Kong, Ctr Nasopharyngeal Carcinoma Res, Hong Kong, Hong Kong, Peoples R China; [Bangarusamy, D. K.] Inst Biomed Sci, Genome Inst Singapore, Singapore, Singapore; [Chua, D.] Hong Kong Sanat & Hosp, Comprehens Oncol Ctr, Hong Kong, Hong Kong, Peoples R China; [Lee, A. W. M.] Pamela Youde Nethersole Eastern Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; [Lee, A. W. M.] Univ Hong Kong, Shenzhen Hosp, Dept Clin Oncol, Shenzhen, Peoples R China; [Ji, M. F.] Zhongshan City Hosp, Ctr Canc, Zhongshan, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Pamela Youde Nethersole Eastern Hospital; University of Hong Kong	Lung, HL (corresponding author), Univ Hong Kong, Dept Clin Oncol, L6-02,Fac Med Bldg,21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	hllung2@hku.hk; mlilung@hku.hk	Ko, Josephine/U-2972-2019; Cheng, Yue/Z-4456-2019; Chan, Ka Chung/HHR-8759-2022; Lung, Maria Li/C-4495-2009	Ko, Josephine/0000-0002-7997-331X; Ji, Mingfang/0000-0003-4727-2858; Lung, Maria Li/0000-0003-2559-3626	Research Grants Council of the Hong Kong Special Administrative Region [HKU772309]	Research Grants Council of the Hong Kong Special Administrative Region(Hong Kong Research Grants Council)	We acknowledge the AoE NPC Tissue Bank for providing the NPC specimens and the NPC TMA. We thank the Hong Kong Red Cross for providing us the blood from healthy individuals. We also thank Dr Edison Tak-Bun Liu for their microarray support in the Genome Institute of Singapore (GIS); Dr Sai Wah Tsao for providing us the immortalized cell lines; Dr John M Nicholls for the TMA analysis and Dr Pui Man Chiu for her help in constructing the NPC TMA and SAA immunohistochemistry staining; Dr Didier Trono for the supply of the lentiviral vectors, pWPI, pMD2. G and psPAX2. We thank Dr David Root for the supply of the lentihair pLKO. 1-TRC cloning vector and Dr David Sabatini for the pLKO. 1-scramble shRNA construct. This work was supported by the General Research Fund (HKU772309 to HLL) of the Research Grants Council of the Hong Kong Special Administrative Region.	Adham M, 2012, CHIN J CANCER, V31, P185, DOI 10.5732/cjc.011.10328; Amal Chandra Kataki, 2011, Chinese Journal of Cancer, V30, P106; Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353; BADOLATO R, 1994, J EXP MED, V180, P203, DOI 10.1084/jem.180.1.203; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CABANA VG, 1989, J LIPID RES, V30, P39; Chan KC, 2011, INT J CANCER, V129, P1826, DOI 10.1002/ijc.25855; Cheng Y, 2000, GENE CHROMOSOME CANC, V28, P82, DOI 10.1002/(SICI)1098-2264(200005)28:1<82::AID-GCC10>3.0.CO;2-8; Cheung ST, 1999, INT J CANCER, V83, P121, DOI 10.1002/(SICI)1097-0215(19990924)83:1<121::AID-IJC21>3.0.CO;2-F; CHIANG HS, 1995, BRIT J CANCER, V71, P265, DOI 10.1038/bjc.1995.54; Cho WCS, 2004, CLIN CANCER RES, V10, P43, DOI 10.1158/1078-0432.CCR-0413-3; Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; HOFFMAN JS, 1982, J BIOL CHEM, V257, P518; HUANG DP, 1980, INT J CANCER, V26, P127, DOI 10.1002/ijc.2910260202; Huang Z, 2012, ONCOGENE, V31, P3709, DOI 10.1038/onc.2011.529; Iwamoto Y, 1996, BRIT J CANCER, V73, P589, DOI 10.1038/bjc.1996.102; Ko JMY, 2008, MOL CANCER RES, V6, P592, DOI 10.1158/1541-7786.MCR-07-0154; Kumon Y, 2002, SCAND J IMMUNOL, V56, P504, DOI 10.1046/j.1365-3083.2002.01169.x; Li HM, 2006, INT J CANCER, V119, P1567, DOI 10.1002/ijc.22032; LIANG JS, 1995, J LIPID RES, V36, P37; Liang JS, 1996, J LIPID RES, V37, P2109; Liao QL, 2008, CLIN EXP METASTAS, V25, P465, DOI 10.1007/s10585-008-9152-8; Lindhorst E, 1997, BBA-PROTEIN STRUCT M, V1339, P143, DOI 10.1016/S0167-4838(96)00227-0; Liu CB, 2012, PATHOL ONCOL RES, V18, P117, DOI 10.1007/s12253-011-9459-7; Liu Q, 2013, CHIN J CANCER, V32, P325, DOI 10.5732/cjc.012.10189; Lo PHY, 2010, CANCER RES, V70, P5567, DOI 10.1158/0008-5472.CAN-09-4510; Lung HL, 2005, ONCOGENE, V24, P6525, DOI 10.1038/sj.onc.1208812; Lung HL, 2008, INT J CANCER, V123, P401, DOI 10.1002/ijc.23528; Lung HL, 2006, CANCER RES, V66, P9385, DOI 10.1158/0008-5472.CAN-06-0590; Malle E, 2009, CELL MOL LIFE SCI, V66, P9, DOI 10.1007/s00018-008-8321-x; MITCHELL TI, 1991, J CLIN INVEST, V87, P1177, DOI 10.1172/JCI115116; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Mould AP, 2011, CURR PROTOC CELL BIO; NICOSIA RF, 1991, AM J PATHOL, V138, P829; Perron-Sierra F, 2002, BIOORG MED CHEM LETT, V12, P3291, DOI 10.1016/S0960-894X(02)00696-0; PRECIADOPATT L, 1994, EUR J BIOCHEM, V223, P35, DOI 10.1111/j.1432-1033.1994.tb18963.x; PreciadoPatt L, 1996, J IMMUNOL, V156, P1189; Protopopov AI, 2002, J GENE MED, V4, P397, DOI 10.1002/jgm.283; Robertson G P, 1999, Mol Cell Biol Res Commun, V2, P1, DOI 10.1006/mcbr.1999.0141; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Strissel KJ, 1997, EXP CELL RES, V237, P275, DOI 10.1006/excr.1997.3783; Sung HJ, 2011, J PROTEOME RES, V10, P1383, DOI 10.1021/pr101154j; Thorn CF, 2002, J IMMUNOL, V169, P399, DOI 10.4049/jimmunol.169.1.399; Treuting P.M., 2012, COMP ANATOMY HISTOLO; Tsang CM, 2010, INT J CANCER, V127, P1570, DOI 10.1002/ijc.25173; Uhlar CM, 1999, EUR J BIOCHEM, V265, P501, DOI 10.1046/j.1432-1327.1999.00657.x; Urieli-Shoval S, 1998, J HISTOCHEM CYTOCHEM, V46, P1377, DOI 10.1177/002215549804601206; Venetsanakos E, 2002, EXP CELL RES, V273, P21, DOI 10.1006/excr.2001.5424; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; Wong VCL, 2012, INT J CANCER, V130, P83, DOI 10.1002/ijc.25970; XU LL, 1995, J IMMUNOL, V155, P1184; YAMADA T, 1994, BBA-MOL BASIS DIS, V1226, P323, DOI 10.1016/0925-4439(94)90044-2; Yamada T, 1999, CLIN CHEM LAB MED, V37, P381, DOI 10.1515/CCLM.1999.063; Zhang H, 2006, CANCER GENET CYTOGEN, V165, P25, DOI 10.1016/j.cancergencyto.2005.07.016	56	21	21	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					878	889		10.1038/onc.2014.12	http://dx.doi.org/10.1038/onc.2014.12			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24608426				2022-12-28	WOS:000349472000008
J	Carpenter, RL; Paw, I; Dewhirst, MW; Lo, HW				Carpenter, R. L.; Paw, I.; Dewhirst, M. W.; Lo, H-W			Akt phosphorylates and activates HSF-1 independent of heat shock, leading to Slug overexpression and epithelial-mesenchymal transition (EMT) of HER2-overexpressing breast cancer cells	ONCOGENE			English	Article						Slug; EMT; Akt; HSF-1; HER2; phosphorylation	TRANSCRIPTION FACTOR SNAIL; GROWTH-FACTOR RECEPTOR; E-CADHERIN; UP-REGULATION; PROTEIN; GENE; FACTOR-1; BINDING; TARGET; INHIBITOR	Epithelial-mesenchymal transition (EMT) is an essential step for tumor progression, although the mechanisms driving EMT are still not fully understood. In an effort to investigate these mechanisms, we observed that heregulin (HRG)-mediated activation of HER2, or HER2 overexpression, resulted in EMT, which is accompanied with increased expression of a known EMT regulator Slug, but not TWIST or Snail. We then investigated how HER2 induced Slug expression and found, for the first time, that there are four consensus HSF sequence-binding elements (HSEs), the binding sites for heat shock factor-1 (HSF-1), located in the Slug promoter. HSF-1 bound to and transactivated the Slug promoter independent of heat shock, leading to Slug expression in breast cancer cells. Mutation of the putative HSEs ablated Slug transcriptional activation induced by HRG or HSF-1 overexpression. Knockdown of HSF-1 expression by siRNA reduced Slug expression and HRG-induced EMT. The positive association between HSF-1 and Slug was confirmed by immunohistochemical staining of a cohort of 100 invasive breast carcinoma specimens. While investigating how HER2 activated HSF-1 independent of heat shock, we observed that HER2 activation resulted in concurrent phosphorylation of Akt and HSF-1. We then observed, also for the first time, that Akt directly interacted with HSF-1 and phosphorylated HSF-1 at S326. Inhibition of Akt using siRNA, dominant-negative Akt mutant, or small molecule inhibitors prevented HRG-induced HSF-1 activation and Slug expression. Conversely, constitutively active Akt induced HSF-1 phosphorylation and Slug expression. HSF-1 knockdown reduced the ability of Akt to induce Slug expression, indicating an essential role that HSF-1 plays in Akt-induced Slug upregulation. Altogether, our study uncovered the existence of a novel Akt-HSF-1 signaling axis that leads to Slug upregulation and EMT, and potentially contributes to progression of HER2-positive breast cancer.	[Carpenter, R. L.; Paw, I.; Lo, H-W] Duke Univ, Sch Med, Dept Surg, Div Surg Sci, Durham, NC 27710 USA; [Dewhirst, M. W.] Duke Univ, Sch Med, Dept Radiat Oncol, Durham, NC 27710 USA; [Dewhirst, M. W.; Lo, H-W] Duke Univ, Sch Med, Duke Canc Inst, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Lo, HW (corresponding author), Duke Univ, Sch Med, Duke Canc Inst, Div Surg Sci,Dept Surg, Box 3156,423 MSRB 1,103 Res Dr, Durham, NC 27710 USA.	huiwen.lo@duke.edu	Dewhirst, Mark/Q-1302-2019	Dewhirst, Mark/0000-0003-3459-6546; Carpenter, Richard/0000-0001-9986-6493	NIH [K01-CA118423]; US Department of Defense [W81XWH-11-1-0600]; Beez Foundation; Intramural Division of Surgical Sciences; Dani P. Bolognesi PhD Award; Clarence Gardner PhD Award; NATIONAL CANCER INSTITUTE [K01CA118423, P30CA014236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS087169] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Defense(United States Department of Defense); Beez Foundation; Intramural Division of Surgical Sciences; Dani P. Bolognesi PhD Award; Clarence Gardner PhD Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We are thankful to Dr Mong-Hong Lee at MD Anderson Cancer Center who provided CA-Akt and DN-Akt constructs. This study was supported by the NIH grant K01-CA118423, and W81XWH-11-1-0600 from the US Department of Defense, the Beez Foundation and the Intramural Division of Surgical Sciences grants, Dani P. Bolognesi PhD Award and Clarence Gardner PhD Award.	Anckar J, 2011, ANNU REV BIOCHEM, V80, P1089, DOI 10.1146/annurev-biochem-060809-095203; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cheng JC, 2013, BIOCHEM BIOPH RES CO, V434, P81, DOI 10.1016/j.bbrc.2013.03.062; Chou SD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039679; Ciocca DR, 2013, ARCH TOXICOL, V87, P19, DOI 10.1007/s00204-012-0918-z; Cobaleda C, 2007, ANNU REV GENET, V41, P41, DOI 10.1146/annurev.genet.41.110306.130146; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Gabai VL, 2012, MOL CELL BIOL, V32, P929, DOI 10.1128/MCB.05921-11; Giordano A, 2012, MOL CANCER THER, V11, P2526, DOI 10.1158/1535-7163.MCT-12-0460; Guettouche Toumy, 2005, BMC Biochemistry, V6, DOI 10.1186/1471-2091-6-4; Hajra KM, 2002, CANCER RES, V62, P1613; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Khaleque MA, 2005, ONCOGENE, V24, P6564, DOI 10.1038/sj.onc.1208798; KROEGER PE, 1994, MOL CELL BIOL, V14, P7592, DOI 10.1128/MCB.14.11.7592; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Lo HW, 2008, CLIN CANCER RES, V14, P6042, DOI 10.1158/1078-0432.CCR-07-4923; Lo HW, 2008, MOL CANCER RES, V6, P843, DOI 10.1158/1541-7786.MCR-07-2105; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Lo HW, 2009, CANCER RES, V69, P6790, DOI 10.1158/0008-5472.CAN-09-0886; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Mendillo ML, 2012, CELL, V150, P549, DOI 10.1016/j.cell.2012.06.031; Meng L, 2010, ONCOGENE, V29, P5204, DOI 10.1038/onc.2010.277; Ohnishi K, 2004, INT J RADIAT BIOL, V80, P607, DOI 10.1080/09553000412331283470; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Santagata S, 2011, P NATL ACAD SCI USA, V108, P18378, DOI 10.1073/pnas.1115031108; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Sekulic A, 2000, CANCER RES, V60, P3504; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Ursini-Siegel J, 2007, NAT REV CANCER, V7, P389, DOI 10.1038/nrc2127; Wang XZ, 2003, MOL CELL BIOL, V23, P6013, DOI 10.1128/MCB.23.17.6013-6026.2003; Westerheide SD, 2006, J BIOL CHEM, V281, P9616, DOI 10.1074/jbc.M512044200; Xi CX, 2012, J BIOL CHEM, V287, P35646, DOI 10.1074/jbc.M112.377481; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yoon YJ, 2011, J BIOL CHEM, V286, P1737, DOI 10.1074/jbc.M110.179440; Zhao RY, 2013, CELL CYCLE, V12, P935, DOI 10.4161/cc.23883; Zhu H, 2010, CANCER LETT, V294, P101, DOI 10.1016/j.canlet.2010.01.028	44	68	72	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					546	557		10.1038/onc.2013.582	http://dx.doi.org/10.1038/onc.2013.582			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24469056	Green Accepted			2022-12-28	WOS:000348853500002
J	Bedi, U; Scheel, AH; Hennion, M; Begus-Nahrmann, Y; Ruschoff, J; Johnsen, SA				Bedi, U.; Scheel, A. H.; Hennion, M.; Begus-Nahrmann, Y.; Rueschoff, J.; Johnsen, S. A.			SUPT6H controls estrogen receptor activity and cellular differentiation by multiple epigenomic mechanisms	ONCOGENE			English	Article						estrogen receptor; breast cancer; differentiation; chromatin	HUMAN BREAST-CANCER; GENE-EXPRESSION; HISTONE H2B; TRANSCRIPTIONAL ELONGATION; CHROMATIN MODIFICATIONS; HUMAN-CELLS; P-TEFB; MONOUBIQUITINATION; SPT6; ALPHA	The estrogen receptor alpha (ER alpha) is the central transcriptional regulator of ductal mammary epithelial lineage specification and is an important prognostic marker in human breast cancer. Although antiestrogen therapies are initially highly effective at treating ER alpha-positive tumors, a large number of tumors progress to a refractory, more poorly differentiated phenotype accompanied by reduced survival. A better understanding of the molecular mechanisms involved in the progression from estrogen-dependent to hormone-resistant breast cancer may uncover new targets for treatment and the discovery of new predictive markers. Recent studies have uncovered an important role for transcriptional elongation and chromatin modifications in controlling ER alpha activity and estrogen responsiveness. The human Suppressor of Ty Homologue-6 (SUPT6H) is a histone chaperone that links transcriptional elongation to changes in chromatin structure. We show that SUPT6H is required for estrogen-regulated transcription and the maintenance of chromatin structure in breast cancer cells, possibly in part through interaction with RNF40 and regulation of histone H2B monoubiquitination (H2Bub1). Moreover, we demonstrate that SUPT6H protein levels decrease with malignancy in breast cancer. Consistently, SUPT6H, similar to H2Bub1, is required for cellular differentiation and suppression of the repressive histone mark H3K27me3 on lineage-specific genes. Together, these data identify SUPT6H as a new epigenetic regulator of ER alpha activity and cellular differentiation.	[Bedi, U.; Johnsen, S. A.] Univ Med Ctr Hamburg Eppendorf UKE, Dept Tumor Biol, Ctr Med Expt, D-20251 Hamburg, Germany; [Bedi, U.; Hennion, M.; Begus-Nahrmann, Y.; Johnsen, S. A.] Univ Med Ctr Gottingen, Inst Mol Oncol, Gottingen, Germany; [Scheel, A. H.; Rueschoff, J.] Inst Pathol Nordhessen, Kassel, Germany; [Scheel, A. H.] Univ Med Ctr Gottinngen, Dept Pathol, Ctr Pathol & Forens Med, Gottingen, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Gottingen	Johnsen, SA (corresponding author), Univ Med Ctr Hamburg Eppendorf UKE, Dept Tumor Biol, Ctr Med Expt, D-20251 Hamburg, Germany.	sjohnsen@alumni.mayo.edu	Johnsen, Steven/AAX-2322-2020	Johnsen, Steven/0000-0003-1198-5805; Hennion, Magali/0000-0002-0352-2790	Erasmus Mundus External Cooperation Window EURINDIA; Gottingen Graduate School for Neurosciences, Biophysics and Molecular Biosciences; Deutsche Krebshilfe [109088]; Deutsche Forschungsgemeinschaft [JO 815/3]	Erasmus Mundus External Cooperation Window EURINDIA; Gottingen Graduate School for Neurosciences, Biophysics and Molecular Biosciences; Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank L Schreiber, J Schiller and CR Schlegel for initial efforts in establishing SUPT6H knockdown. UB was supported by doctoral fellowships from the Erasmus Mundus External Cooperation Window EURINDIA and the Gottingen Graduate School for Neurosciences, Biophysics and Molecular Biosciences. This work was supported by grants from the Deutsche Krebshilfe (109088) and the Deutsche Forschungsgemeinschaft (JO 815/3) to SAJ.	Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chen SZ, 2012, GENE DEV, V26, P1364, DOI 10.1101/gad.186056.111; Chen S, 2012, CELL RES, V22, P1402, DOI 10.1038/cr.2012.114; Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Diebold ML, 2010, J BIOL CHEM, V285, P38389, DOI 10.1074/jbc.M110.146696; Egloff S, 2008, TRENDS GENET, V24, P280, DOI 10.1016/j.tig.2008.03.008; El-Rehim DMA, 2004, J PATHOL, V203, P661, DOI 10.1002/path.1559; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Fuchs G, 2012, MOL CELL, V46, P662, DOI 10.1016/j.molcel.2012.05.023; Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497; Johnsen S A, 2006, Ernst Schering Found Symp Proc, P1; Johnsen SA, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002860; Johnsen SA, 2012, FEBS LETT, V586, P1592, DOI 10.1016/j.febslet.2012.04.002; Kari V, 2011, CELL CYCLE, V10, P3495, DOI 10.4161/cc.10.20.17769; Karpiuk O, 2012, MOL CELL, V46, P705, DOI 10.1016/j.molcel.2012.05.022; Ketchart W, 2011, ONCOGENE, V30, P3563, DOI 10.1038/onc.2011.76; Khan SA, 1998, J NATL CANCER I, V90, P37, DOI 10.1093/jnci/90.1.37; Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139; Kim J, 2009, CELL, V137, P459, DOI 10.1016/j.cell.2009.02.027; Kininis M, 2009, MOL CELL BIOL, V29, P1123, DOI 10.1128/MCB.00841-08; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Metivier R, 2006, EMBO REP, V7, P161, DOI 10.1038/sj.embor.7400626; Minsky N, 2008, NAT CELL BIOL, V10, P483, DOI 10.1038/ncb1712; Ogba N, 2008, CANCER RES, V68, P7015, DOI 10.1158/0008-5472.CAN-08-0814; Pirngruber J, 2010, ONCOGENE, V29, P2853, DOI 10.1038/onc.2010.42; Pirngruber J, 2009, CELL CYCLE, V8, P3636, DOI 10.4161/cc.8.22.9890; Pirngruber J, 2009, EMBO REP, V10, P894, DOI 10.1038/embor.2009.108; Prenzel T, 2011, CANCER RES, V71, P5739, DOI 10.1158/0008-5472.CAN-11-1896; Raaphorst FM, 2003, NEOPLASIA, V5, P481, DOI 10.1016/S1476-5586(03)80032-5; Reijm EA, 2011, BREAST CANCER RES TR, V125, P387, DOI 10.1007/s10549-010-0836-9; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shema E, 2008, GENE DEV, V22, P2664, DOI 10.1101/gad.1703008; Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602-592; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112; Wang AHJ, 2013, EMBO J, V32, P1075, DOI 10.1038/emboj.2013.54; Wittmann BM, 2005, ONCOGENE, V24, P5576, DOI 10.1038/sj.onc.1208728; Yoh SM, 2007, GENE DEV, V21, P160, DOI 10.1101/gad.1503107; Zhang F, 2011, MOL CELL, V41, P384, DOI 10.1016/j.molcel.2011.01.024	46	29	29	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					465	473		10.1038/onc.2013.558	http://dx.doi.org/10.1038/onc.2013.558			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24441044				2022-12-28	WOS:000348451300007
J	Yu, T; Li, J; Yan, M; Liu, L; Lin, H; Zhao, F; Sun, L; Zhang, Y; Cui, Y; Zhang, F; Li, J; He, X; Yao, M				Yu, T.; Li, J.; Yan, M.; Liu, L.; Lin, H.; Zhao, F.; Sun, L.; Zhang, Y.; Cui, Y.; Zhang, F.; Li, J.; He, X.; Yao, M.			MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway	ONCOGENE			English	Article						NSCLC; miR-193a-3p; miR-193a-5p; target genes; metastasis	COLORECTAL-CANCER; EXPRESSION; GENE; INVASION; GROWTH; PROLIFERATION; INHIBITION; MICRORNAS; MIGRATION; MIR-193A	The metastatic cascade is a complex and multistep process with many potential barriers. Recent evidence has shown that microRNAs (miRNAs) are involved in carcinogenesis and tumor progression in non-small-cell lung cancer (NSCLC). In this study, by comparing the miRNA expression profiles of SPC-A-1sci (high metastatic) and SPC-A-1 (weakly metastatic) cells, we demonstrated that the downregulation and function of miR-193a-3p and miR-193a-5p in NSCLC metastasis and the expression of these miRNAs was suppressed in NSCLC compared with corresponding non-tumorous tissues. Decreased miR-193a-3p/5p expression was significantly associated with tumor node metastasis (TNM) and lymph node metastasis. Furthermore, functional assays showed that the overexpression of miR-193a-3p/5p inhibited NSCLC cell migration, invasion and epithelial-mesenchymal transition (EMT) in vitro and lung metastasis formation in vivo. In addition, we discovered that ERBB4 and S6K2 were the direct targets of miR-193a-3p and that PIK3R3 and mTOR were the direct targets of miR-193a-5p in NSCLC. We also observed that miR-193a-3p/5p could inactivate the AKT/mTOR signaling pathway. Thus, miR-193a-3p/5p functions as a tumor suppressor and has an important role in NSCLC metastasis through ERBB signaling pathway.	[Yu, T.; Li, J.; Yan, M.; Liu, L.; Lin, H.; Zhao, F.; Sun, L.; Zhang, Y.; Cui, Y.; Zhang, F.; Li, J.; He, X.; Yao, M.] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Canc Inst,State Key Lab Oncogenes & Rela, Shanghai 200032, Peoples R China	Shanghai Jiao Tong University	Yao, M (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Canc Inst,State Key Lab Oncogenes & Rela, 25-2200 Xietu Rd, Shanghai 200032, Peoples R China.	myao@shsci.org	He, Xianghuo/I-1497-2014; Yu, Tao/GLN-8283-2022; Zhang, Fang/HHN-2153-2022	He, Xianghuo/0000-0001-8872-668X; Yu, Tao/0000-0001-5330-2086; 	Shanghai Science and Technology Developing Program [12140901500, 13140900502]	Shanghai Science and Technology Developing Program	This work was supported by Shanghai Science and Technology Developing Program (12140901500, 13140900502). We thank Deshui Jia and QiangTan for the kind suggestions and technical assistance.	Almeida MI, 2012, GASTROENTEROLOGY, V142, P886, DOI 10.1053/j.gastro.2011.12.047; Almeida MI, 2011, MUTAT RES-FUND MOL M, V717, P1, DOI 10.1016/j.mrfmmm.2011.03.009; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Farazi TA, 2011, J PATHOL, V223, P102, DOI 10.1002/path.2806; Feng B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043452; Goldberger N, 2013, CANCER RES, V73, P2671, DOI 10.1158/0008-5472.CAN-12-3513; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; Hegde GV, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004438; Heist Rebecca S, 2012, Cancer Cell, V21, DOI 10.1016/j.ccr.2012.03.007; Heller G, 2012, CLIN CANCER RES, V18, P1619, DOI 10.1158/1078-0432.CCR-11-2450; Hu HJ, 2012, ACTA BIOCH BIOPH SIN, V44, P424, DOI [10.1093/abbs/gms018, 10.1093/abbs/gms018.]; Iliopoulos D, 2011, CANCER RES, V71, P5144, DOI 10.1158/0008-5472.CAN-11-0425; Imbert AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043752; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jia DS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-364; Lai WW, 2001, ANN THORAC SURG, V72, P1868, DOI 10.1016/S0003-4975(01)03207-6; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li YH, 2013, BLOOD, V121, P499, DOI 10.1182/blood-2012-07-444729; Lin CW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2876; Lin HC, 2013, J PROTEOME RES, V12, P3423, DOI 10.1021/pr400273z; Mendoza-Naranjo A, 2013, EMBO MOL MED, V5, P1087, DOI 10.1002/emmm.201202343; Meng W, 2013, CLIN CANCER RES, V19, P5423, DOI 10.1158/1078-0432.CCR-13-0320; Minami A, 2013, J BIOL CHEM, V288, P11845, DOI 10.1074/jbc.M112.405993; Muraoka-Cook RS, 2008, MOL ENDOCRINOL, V22, P2307, DOI 10.1210/me.2008-0055; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Sasaki H, 2007, CLIN LUNG CANCER, V8, P429, DOI 10.3816/CLC.2007.n.027; Sharieff W, 2013, CLIN ONCOL-UK, V25, P697, DOI 10.1016/j.clon.2013.07.011; Sridharan S, 2011, CANCER RES, V71, P2590, DOI 10.1158/0008-5472.CAN-10-3253; Starr A, 2006, INT J CANCER, V119, P269, DOI 10.1002/ijc.21818; Tao ZH, 2013, J EXP MED, V210, P789, DOI 10.1084/jem.20120153; Tomizawa Kenji, 2010, J Thorac Oncol, V5, P1859, DOI 10.1097/JTO.0b013e3181f1c433; Trask MC, 2012, DEV BIOL, V368, P273, DOI 10.1016/j.ydbio.2012.05.031; Uhlmann S, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2011.100; Wander SA, 2013, BREAST CANCER RES TR, V138, P369, DOI 10.1007/s10549-012-2389-6; Wu X, 2014, ONCOGENE, V33, P1506, DOI 10.1038/onc.2013.108; Xu L, 2013, MOL BIOL CELL, V24, P42, DOI 10.1091/mbc.E12-07-0519; Yang H, 2013, HEPATOLOGY, V58, P205, DOI 10.1002/hep.26315; Yang X, 2013, CANCER LETT, V341, P265, DOI 10.1016/j.canlet.2013.08.020; Yang Y, 2013, ONCOGENE, V32, P3432, DOI 10.1038/onc.2012.360; Zheng BQ, 2011, CLIN CANCER RES, V17, P7574, DOI 10.1158/1078-0432.CCR-11-1714	44	214	222	3	59	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					413	423		10.1038/onc.2013.574	http://dx.doi.org/10.1038/onc.2013.574			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24469061				2022-12-28	WOS:000348451300002
J	Busch, S; Acar, A; Magnusson, Y; Gregersson, P; Ryden, L; Landberg, G				Busch, S.; Acar, A.; Magnusson, Y.; Gregersson, P.; Ryden, L.; Landberg, G.			TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer	ONCOGENE			English	Article						TGF-beta; tumour stroma; cancer-associated fibroblast; breast cancer; clonogenic survival	STROMAL FIBROBLASTS; CARCINOMA; MYOFIBROBLASTS; HETEROGENEITY; TAMOXIFEN	Transforming growth factor-beta (TGF-beta) is a pleiotropic cytokine with the capability to act as tumour suppressor or tumour promoter depending on the cellular context. TGF-beta receptor type-2 (TGFBR2) is the ligand-binding receptor for all members of the TGF-beta family. Data from mouse model experiments demonstrated that loss of Tgfbr2 expression in mammary fibroblasts was linked to tumour initiation and metastasis. Using a randomised tamoxifen trial cohort including in total 564 invasive breast carcinomas, we examined TGFBR2 expression (n = 252) and phosphorylation level of downstream target SMAD2 (pSMAD2) (n = 319) in cancer-associated fibroblasts (CAFs) and assessed links to clinicopathological markers, prognostic and treatment-predictive values. The study revealed that CAF-specific TGFBR2 expression correlated with improved recurrence-free survival. Multivariate analysis confirmed CAF-TGFBR2 to be an independent prognostic marker (multivariate Cox regression, hazard ratio: 0.534, 95% (Cl): 0.360-0.793, P = 0.002). CAF-specific pSMAD2 levels, however, did not associate with survival outcome. Experimentally, TGF-beta signalling in fibroblasts was modulated using a TGF-beta ligand and inhibitor or through lentiviral short hairpin RNA-mediated TGFBR2-specific knockdown. To determine the role of fibroblastic TGF-beta pathway on breast cancer cells, we used cell contact-dependent cell growth and clonogenicity assays, which showed that knockdown of TGFBR2 in CAFs resulted in increased cell growth, proliferation and clonogenic survival. Further, in a mouse model transfected CAFs were co-injected with MCF7 and tumour weight and proportion was monitored. We found that mouse xenograft tumours comprising TGFBR2 knockdown fibroblasts were slightly bigger and displayed increased tumour cell capacity. Overall, our data demonstrate that fibroblast-related biomarkers possess clinically relevant information and that fibroblasts confer effects on breast cancer cell growth and survival. Regulation of tumour-stromal cross-talk through fibroblastic TGF-beta pathway may depend on fibroblast phenotype, emphasising the importance to characterise tumour microenvironment subtypes.	[Busch, S.; Magnusson, Y.; Gregersson, P.; Landberg, G.] Gothenburg Univ, Sahlgrenska Canc Ctr, Dept Pathol, S-40530 Gothenburg, Sweden; [Acar, A.] Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester, Lancs, England; [Ryden, L.] Univ Lund Hosp, Inst Clin Sci, Dept Surg, S-22185 Lund, Sweden; [Landberg, G.] Univ Manchester, Paterson Inst Canc Res, Inst Canc Sci, Breakthrough Breast Canc Res Unit,Mol Pathol Grp, Manchester, Lancs, England	University of Gothenburg; University of Manchester; Lund University; Skane University Hospital; Paterson Institute for Cancer Research; University of Manchester	Landberg, G (corresponding author), Gothenburg Univ, Sahlgrenska Canc Ctr, Dept Pathol, Medicinaregatan 1F, S-40530 Gothenburg, Sweden.	Goran.landberg@gu.se	Acar, Ahmet/ABI-3298-2020	Acar, Ahmet/0000-0002-2478-8029	Swedish Cancer Society; Breakthrough Breast Cancer UK; BioCARE-a National Strategic Research Program at University of Gothenburg; Breast Cancer Now [MAN-Q1] Funding Source: researchfish	Swedish Cancer Society(Swedish Cancer Society); Breakthrough Breast Cancer UK; BioCARE-a National Strategic Research Program at University of Gothenburg; Breast Cancer Now	We thank Elise Nilsson for excellent technical assistance, the MCRC Biobank for providing us with patient material and Dr Akira Orimo for the kind gift of fibroblast model cell lines and lentiviral plasmids. We would further thank Eamon Hughes for his assistance with the animal work. This study was supported by the Swedish Cancer Society and Breakthrough Breast Cancer UK. The project was further supported by BioCARE-a National Strategic Research Program at University of Gothenburg.	Bacman D, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-156; Bauer M, 2010, ONCOGENE, V29, P1732, DOI 10.1038/onc.2009.463; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Busch S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045669; Casbas-Hernandez P, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/520987; Cheng N, 2005, ONCOGENE, V24, P5053, DOI 10.1038/sj.onc.1208685; Cheng N, 2008, MOL CANCER RES, V6, P1521, DOI 10.1158/1541-7786.MCR-07-2203; Cheng N, 2007, CANCER RES, V67, P4869, DOI 10.1158/0008-5472.CAN-06-3381; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; De Wever O, 2008, INT J CANCER, V123, P2229, DOI 10.1002/ijc.23925; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Polanska UM, 2011, JOVE-J VIS EXP, DOI 10.3791/3201; Ryden L, 2005, EUR J CANCER, V41, P256, DOI 10.1016/j.ejca.2004.06.030; Samoszuk M, 2005, BREAST CANCER RES, V7, pR274, DOI 10.1186/bcr995; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Stuelten CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009832; Sugimoto H, 2006, CANCER BIOL THER, V5, P1640, DOI 10.4161/cbt.5.12.3354; Yamashita S, 2008, CANCER RES, V68, P2112, DOI 10.1158/0008-5472.CAN-07-5282	29	75	78	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					27	38		10.1038/onc.2013.527	http://dx.doi.org/10.1038/onc.2013.527			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24336330				2022-12-28	WOS:000349740100003
J	Sun, J; Mohlin, S; Lundby, A; Kazi, JU; Hellman, U; Pahlman, S; Olsen, JV; Ronnstrand, L				Sun, J.; Mohlin, S.; Lundby, A.; Kazi, J. U.; Hellman, U.; Pahlman, S.; Olsen, J. V.; Ronnstrand, L.			The PI3-kinase isoform p110 delta is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner	ONCOGENE			English	Article						c-Kit; c-Kit/D816V; PI3-kinase; p110 delta; phosphorylation; cell transformation	ACUTE MYELOID-LEUKEMIA; PHOSPHOINOSITIDE 3-KINASE; GENE-MUTATIONS; AGGRESSIVE MASTOCYTOSIS; SYSTEMIC MASTOCYTOSIS; TYROSINE KINASE; BREAST-CANCER; ACTIVATION; DASATINIB; GROWTH	PI3-kinase has a crucial role in transformation mediated by the oncogenic c-Kit mutant D816V. In this study, we demonstrate that the c-Kit/D816V-mediated cell survival is dependent on an intact direct binding of PI3-kinase to c-Kit. However, mutation of this binding site had little effect on the PI3-kinase activity in the cells, suggesting that c-Kit/D816V-mediated cell survival is dependent on PI3-kinase but not its kinase activity. Furthermore, inhibition of the lipid kinase activity of PI3-kinase led only to a slight inhibition of cell survival. Knockdown of the predominant PI3-kinase isoform p110 delta in c-Kit/D816V-expressing Ba/F3 cells led to reduced cell transformation both in vitro and in vivo without affecting the overall PI3-kinase activity. This suggests that p110 delta has a lipid-kinaseindependent role in c-Kit/D816V-mediated cell transformation. We furthermore demonstrate that p110 delta is phosphorylated at residues Y524 and S1039 and that phosphorylation requires an intact binding site for PI3-kinase in c-Kit/D816V. Overexpression of p110 delta carrying the Y523F and S1038A mutations significantly reduced c-Kit/D816V-mediated cell survival and proliferation. Taken together, our results demonstrate an important lipid-kinase-independent role of p110 delta in c-Kit/D816V-mediated cell transformation. This furthermore suggests that p110 delta could be a potential diagnostic factor and selective therapeutic target for c-Kit/D816V-expressing malignancies.	[Sun, J.; Kazi, J. U.; Ronnstrand, L.] Lund Univ, Skane Univ Hosp, Dept Lab Med, Expt Clin Chem, Malmo, Sweden; [Mohlin, S.; Pahlman, S.] Lund Univ, Skane Univ Hosp, CREATE Hlth, Dept Lab Med,Ctr Mol Pathol, Malmo, Sweden; [Lundby, A.; Olsen, J. V.] Univ Copenhagen, Fac Hlth Sci, Dept Prote, Novo Nordisk Fdn Ctr Prot Res, Copenhagen, Denmark; [Hellman, U.] Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital; University of Copenhagen; Ludwig Institute for Cancer Research	Ronnstrand, L (corresponding author), Lund Univ, Dept Lab Med, Expt Clin Chem, Bldg 404 C3, SE-22381 Lund, Sweden.	Lars.Ronnstrand@med.lu.se	Lundby, Alicia/H-3322-2013; Olsen, Jesper/ABH-4638-2020; Kazi, Julhash U./D-9190-2011	Olsen, Jesper/0000-0002-4747-4938; Kazi, Julhash U./0000-0002-0719-5336; Ronnstrand, Lars/0000-0003-1275-5809; Lundby, Alicia/0000-0002-1612-6041; Mohlin, Sofie/0000-0002-2458-3963	Swedish Cancer Society; Swedish Research Council; Strategic Cancer Research Program at Lund University; BioCARE; ALF governmental clinical grant; Stiftelsen Olle Engkvist Byggmastare; Alfred Osterlund Foundation; Gunnar Nilsson Cancer Society; MAS Cancer Foundation	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Strategic Cancer Research Program at Lund University; BioCARE; ALF governmental clinical grant; Stiftelsen Olle Engkvist Byggmastare(Swedish Research Council); Alfred Osterlund Foundation; Gunnar Nilsson Cancer Society; MAS Cancer Foundation	This research was supported by grants from the Swedish Cancer Society, the Swedish Research Council, the Strategic Cancer Research Program at Lund University, BioCARE, ALF governmental clinical grant, Stiftelsen Olle Engkvist Byggmastare, Alfred Osterlund Foundation, Gunnar Nilsson Cancer Society and MAS Cancer Foundation.	Aichberger KJ, 2008, EUR J CLIN INVEST, V38, P869, DOI 10.1111/j.1365-2362.2008.02036.x; Arcaro A, 2002, EMBO J, V21, P5097, DOI 10.1093/emboj/cdf512; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; Boissel N, 2006, LEUKEMIA, V20, P965, DOI 10.1038/sj.leu.2404188; Boller D, 2008, CLIN CANCER RES, V14, P1172, DOI 10.1158/1078-0432.CCR-07-0737; Chian RJ, 2001, BLOOD, V98, P1365, DOI 10.1182/blood.V98.5.1365; Cohen SM, 2012, AM J SURG, V204, P895, DOI 10.1016/j.amjsurg.2012.07.027; Corless CL, 2011, NAT REV CANCER, V11, P865, DOI 10.1038/nrc3143; Cornillet-Lefebvre P, 2006, LEUKEMIA, V20, P374, DOI 10.1038/sj.leu.2404054; Cox J, 2009, NAT PROTOC, V4, P698, DOI 10.1038/nprot.2009.36; Czupalla C, 2003, J BIOL CHEM, V278, P11536, DOI 10.1074/jbc.M210351200; Eickholt BJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000869; Hantschel O, 2008, LEUKEMIA LYMPHOMA, V49, P615, DOI 10.1080/10428190801896103; Harir N, 2008, BLOOD, V112, P2463, DOI 10.1182/blood-2007-09-115477; Hashimoto K, 2003, BLOOD, V101, P1094, DOI 10.1182/blood-2002-01-0177; Hongyo T, 2000, CANCER RES, V60, P2345; Jia SD, 2009, CURR OPIN CELL BIOL, V21, P199, DOI 10.1016/j.ceb.2008.12.007; Lennartsson J, 2012, PHYSIOL REV, V92, P1619, DOI 10.1152/physrev.00046.2011; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Lundby A, 2011, METHODS MOL BIOL, V753, P143, DOI 10.1007/978-1-61779-148-2_10; Miller TW, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3039; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; Nijenhuis CM, 2013, CANCER TREAT REV, V39, P305, DOI 10.1016/j.ctrv.2012.10.006; Ning ZQ, 2001, LEUKEMIA LYMPHOMA, V41, P513, DOI 10.3109/10428190109060342; Ogita S, 2011, TARGET ONCOL, V6, P103, DOI 10.1007/s11523-011-0176-7; Olsen JV, 2009, MOL CELL PROTEOMICS, V8, P2759, DOI 10.1074/mcp.M900375-MCP200; Orfao A, 2007, BRIT J HAEMATOL, V138, P12, DOI 10.1111/j.1365-2141.2007.06619.x; Pardanani A, 2012, AM J HEMATOL, V87, P402, DOI 10.1002/ajh.23134; Sadrzadeh H, 2011, DISCOV MED, V12, P481; Sakuma Y, 2004, CANCER SCI, V95, P716, DOI 10.1111/j.1349-7006.2004.tb03251.x; Sawyer C, 2003, CANCER RES, V63, P1667; Schittenhelm MM, 2006, CANCER RES, V66, P473, DOI 10.1158/0008-5472.CAN-05-2050; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Sun JM, 2008, J BIOL CHEM, V283, P27444, DOI 10.1074/jbc.M709703200; Sun JM, 2009, J BIOL CHEM, V284, P11039, DOI 10.1074/jbc.M808058200; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292; Verstovsek S, 2008, CLIN CANCER RES, V14, P3906, DOI 10.1158/1078-0432.CCR-08-0366	43	13	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2014	33	46					5360	5369		10.1038/onc.2013.479	http://dx.doi.org/10.1038/onc.2013.479			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MF	24213578	Green Submitted			2022-12-28	WOS:000345120600006
J	Wang, IC; Ustiyan, V; Zhang, Y; Cai, Y; Kalin, TV; Kalinichenko, VV				Wang, I-C; Ustiyan, V.; Zhang, Y.; Cai, Y.; Kalin, T. V.; Kalinichenko, V. V.			Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D)	ONCOGENE			English	Article						FOXM1; K-Ras; non-small-cell lung cancer; transgenic mice	K-RAS; RESPIRATORY EPITHELIUM; TUMOR-SUPPRESSOR; EXPRESSION; FORKHEAD; CANCER; GENE; ADENOCARCINOMAS; ACTIVATION; SIGNATURE	Lung cancer is the leading cause of deaths in cancer patients in the United States. Identification of new molecular targets is clearly needed to improve therapeutic outcomes of this devastating human disease. Activating mutations in K-Ras oncogene and increased expression of FOXM1 protein are associated with poor prognosis in patients with non-small-cell lung cancer. Transgenic expression of activated Kras(G12D) in mouse respiratory epithelium is sufficient to induce lung adenocarcinomas; however, transcriptional mechanisms regulated by K-Ras during the initiation of lung cancer remain poorly understood. Foxm1 transcription factor, a downstream target of K-Ras, stimulates cellular proliferation during embryogenesis, organ repair and tumor growth, but its role in tumor initiation is unknown. In the present study, we used transgenic mice expressing KrasG12D under control of Sftpc promoter to demonstrate that Foxm1 was induced in type II epithelial cells before the formation of lung tumors. Conditional deletion of Foxm1 from Kras(G12D)-expressing respiratory epithelium prevented the initiation of lung tumors in vivo. The loss of Foxm1 inhibited expression of K-Ras target genes critical for the nuclear factor-kappa B (NF-kappa B) and c-Jun N-terminal kinase (JNK) pathways, including Ikbkb, Nfkb1, Nfkb2, Rela, Jnk1, N-Myc, Pttg1 and Cdkn2a. Transgenic overexpression of activated FOXM1 mutant was sufficient to induce expression of these genes in alveolar type II cells. FOXM1 directly bound to promoter regions of Ikbkb, Nfkb2, N-Myc, Pttg1 and Cdkn2a, indicating that these genes are direct FOXM1 targets. FOXM1 is required for K-Ras-mediated lung tumorigenesis by activating genes critical for the NF-kB and JNK pathways.	[Wang, I-C; Ustiyan, V.; Zhang, Y.; Cai, Y.; Kalin, T. V.; Kalinichenko, V. V.] Cincinnati Childrens Hosp Res Fdn, Perinatal Inst, Div Pulm Biol, Cincinnati, OH 45229 USA; [Wang, I-C] Natl Tsing Hua Univ, Dept Life Sci, Hsinchu, Taiwan; [Wang, I-C] Natl Tsing Hua Univ, Inst Biotechnol, Hsinchu, Taiwan	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; National Tsing Hua University; National Tsing Hua University	Kalinichenko, VV (corresponding author), Cincinnati Childrens Hosp Res Fdn, Perinatal Inst, Div Pulm Biol, 3333 Burnet Ave,MLC 7009, Cincinnati, OH 45229 USA.	Vladimir.Kalinichenko@cchmc.org		Wang, I-Ching/0000-0003-4398-2975	NIH [HL84151, CA142724]; Career Development Award from National Lung Cancer Partnership; National Science Council of Taiwan [102B0023V8]; Toward World-Class University Project of National Tsing Hua University [102N2052E1]; NATIONAL CANCER INSTITUTE [R01CA142724] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084151] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Career Development Award from National Lung Cancer Partnership; National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Toward World-Class University Project of National Tsing Hua University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Ron Pratt for technical support with microCT imaging and Craig Bolte for helpful comments. This work was supported by NIH grants HL84151 (VVK) and CA142724 (TVK), the Career Development Award from National Lung Cancer Partnership (I-CW), research grants from National Science Council of Taiwan 102B0023V8 (I-CW) and Toward World-Class University Project of National Tsing Hua University 102N2052E1 (I-CW).	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Ahn YH, 2011, MOL CELL BIOL, V31, P4270, DOI 10.1128/MCB.05562-11; Alberg AJ, 2003, CHEST, V123, p21S, DOI 10.1378/chest.123.1_suppl.21S; Behren A, 2010, ONCOGENE, V29, P1519, DOI 10.1038/onc.2009.436; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Cellurale C, 2011, MOL CELL BIOL, V31, P1565, DOI 10.1128/MCB.01122-10; Costa RH, 2005, CURR OPIN GENET DEV, V15, P42, DOI 10.1016/j.gde.2004.12.007; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; Ihara Y, 2010, P NATL ACAD SCI USA, V107, P17309, DOI 10.1073/pnas.1001165107; Iwao K, 2001, INT J CANCER, V91, P433, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1059>3.0.CO;2-B; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kalin TV, 2011, CELL CYCLE, V10, P396, DOI 10.4161/cc.10.3.14709; Kalin TV, 2008, P NATL ACAD SCI USA, V105, P19330, DOI 10.1073/pnas.0806748105; Kim IM, 2006, CANCER RES, V66, P2153, DOI 10.1158/0008-5472.CAN-05-3003; Koishi R, 2002, NAT GENET, V30, P151, DOI 10.1038/ng814; Kwei KA, 2008, ONCOGENE, V27, P3635, DOI 10.1038/sj.onc.1211012; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Magudia K, 2012, J CELL BIOL, V198, P185, DOI 10.1083/jcb.201202108; Major ML, 2004, MOL CELL BIOL, V24, P2649, DOI 10.1128/MCB.24.7.2649-2661.2004; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Wang IC, 2008, ONCOGENE, V27, P4137, DOI 10.1038/onc.2008.60; Wang IC, 2008, J BIOL CHEM, V283, P20770, DOI 10.1074/jbc.M709892200; Wang IC, 2012, MOL CELL BIOL, V32, P3838, DOI 10.1128/MCB.00355-12; Wang IC, 2010, DEV BIOL, V347, P301, DOI 10.1016/j.ydbio.2010.08.027; Wang IC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006609; Watters JW, 2006, MOL CANCER THER, V5, P2444, DOI 10.1158/1535-7163.MCT-06-0340; Whitsett JA, 1998, BIOCHIM BIOPHYS ACTA, V19, P2; Whitsett JA, 2010, ANNU REV MED, V61, P105, DOI 10.1146/annurev.med.60.041807.123500; Zhou YH, 2010, NAT BIOTECHNOL, V28, P71, DOI 10.1038/nbt.1595	33	54	54	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2014	33	46					5391	5396		10.1038/onc.2013.475	http://dx.doi.org/10.1038/onc.2013.475			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MF	24213573				2022-12-28	WOS:000345120600009
J	Yun, HM; Park, MH; Kim, DH; Ahn, YJ; Park, KR; Kim, TM; Yun, NY; Jung, YS; Hwang, DY; Yoon, DY; Han, SB; Hong, JT				Yun, H-M; Park, M. H.; Kim, D. H.; Ahn, Y. J.; Park, K-R; Kim, T. M.; Yun, N. Y.; Jung, Y. S.; Hwang, D. Y.; Yoon, D. Y.; Han, S. B.; Hong, J. T.			Loss of presenilin 2 is associated with increased iPLA2 activity and lung tumor development	ONCOGENE			English	Article							AMYLOID PRECURSOR PROTEIN; E-CADHERIN CLEAVAGE; GAMMA-SECRETASE; ALZHEIMERS-DISEASE; PEROXIREDOXIN 6; CANCER-CELLS; INDUCED APOPTOSIS; BRAIN; IDENTIFICATION; TUMORIGENESIS	Presenilins are the enzymatic components of gamma-secretase complex that cleaves amyloid precursor protein, Notch and beta-catenin, which has critical roles in the development of Alzheimer's disease and cancer cell growth. Therefore, in the present study, we studied the effects and mechanisms of PS2 knockout on lung cancer development and possible mechanisms as a key regulator of lung tumor development. We compared carcinogen-induced tumor growth between PS2 knockout mice and wild-type mice. PS2 knockout mice showed increased urethane (1 mg/g)-induced lung tumor incidence when compared with that of wild-type mice with decreased activity of gamma-secretase in the lung tumor tissues. Consequently, iPLA2 activities in lung tumor tissues of PS2 knockout mice were much higher than in tumor tissues of wild-type mice. Furthermore, knockdown of PS2 using PS2 siRNA decreased gamma-secretase activity with increased iPLA2 activity in the lung cancer cells (A549 and NCI-H460), leading to increased lung cancer cell growth. PS2 knockout mice and PS2 knockdown lung cancer cells showed increased DNA-binding activities of nuclear factor kappa-beta, signal transducer and activator of transcription 3 (STAT3) and AP-1 which are critical transcriptional factors of iPLA2 than those of PS2 wild-type mice and control lung cancer cells. Taken together, these results suggest that the loss of PS2 could have a critical role in lung tumor development through the upregulation of iPLA2 activity by reducing gamma-secretase.	[Yun, H-M; Park, M. H.; Kim, D. H.; Ahn, Y. J.; Park, K-R; Yun, N. Y.; Han, S. B.; Hong, J. T.] Chungbuk Natl Univ, Coll Pharm, Cheongju 361763, Chungbuk, South Korea; [Yun, H-M; Park, M. H.; Kim, D. H.; Ahn, Y. J.; Park, K-R; Yun, N. Y.; Han, S. B.; Hong, J. T.] Chungbuk Natl Univ, Med Res Ctr, Cheongju 361763, Chungbuk, South Korea; [Kim, T. M.] Chungbuk Natl Univ, Coll Vet Med, Cheongju 361763, Chungbuk, South Korea; [Jung, Y. S.] Pusan Natl Univ, Coll Pharm, Pusan, South Korea; [Hwang, D. Y.] Pusan Natl Univ, Dept Biomat Sci, Miryang, Kyungnam, South Korea; [Yoon, D. Y.] Konkuk Univ, Bio Mol Informat Ctr, Dept Biosci & Biotechnol, Seoul, South Korea	Chungbuk National University; Chungbuk National University; Chungbuk National University; Pusan National University; Pusan National University; Konkuk University	Hong, JT (corresponding author), Chungbuk Natl Univ, Coll Pharm, 48 Gaeshin Dong, Cheongju 361763, Chungbuk, South Korea.	jinthong@chungbuk.ac.kr			National Research Foundation of Korea (NRF) - Korea Government (MSIP) [MRC, 2008-0062275]	National Research Foundation of Korea (NRF) - Korea Government (MSIP)	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MSIP) (No; MRC, 2008-0062275).	Beel AJ, 2008, CELL MOL LIFE SCI, V65, P1311, DOI 10.1007/s00018-008-7462-2; Bertram L, 2010, NEURON, V68, P270, DOI 10.1016/j.neuron.2010.10.013; Borgegard T, 2012, J BIOL CHEM, V287, P11810, DOI 10.1074/jbc.M111.305227; Boulton ME, 2008, J CELL MOL MED, V12, P781, DOI 10.1111/j.1582-4934.2008.00274.x; Chatterjee S, 2011, J BIOL CHEM, V286, P11696, DOI 10.1074/jbc.M110.206623; Chen FS, 2006, NATURE, V440, P1208, DOI 10.1038/nature04667; Chhunchha B, 2013, AM J PHYSIOL-CELL PH, V304, pC636, DOI 10.1152/ajpcell.00345.2012; Conti A, 2011, AM J PATHOL, V178, P88, DOI 10.1016/j.ajpath.2010.11.035; Das I, 2004, J BIOL CHEM, V279, P30771, DOI 10.1074/jbc.M309252200; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 2010, ANNU REV CELL DEV BI, V26, P235, DOI 10.1146/annurev-cellbio-100109-104117; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Granville CA, 2005, AM J RESP CELL MOL, V32, P169, DOI 10.1165/rcmb.F290; Jo M, 2013, FREE RADICAL BIO MED, V61, P453, DOI 10.1016/j.freeradbiomed.2013.04.032; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Kim SY, 2011, CELL DEATH DIFFER, V18, P1573, DOI 10.1038/cdd.2011.21; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Kovacs DM, 1999, J NEUROCHEM, V73, P2278, DOI 10.1046/j.1471-4159.1999.0732278.x; Lehtonen ST, 2004, INT J CANCER, V111, P514, DOI 10.1002/ijc.20294; Liu B, 2012, NEURO-ONCOLOGY, V14, P994, DOI 10.1093/neuonc/nos138; Liu Hai-yan, 2013, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V35, P19, DOI 10.3881/j.issn.1000-503X.2013.01.004; Liu Y, 2004, J PROTEOME RES, V3, P728, DOI 10.1021/pr034127+; McHowat J, 2011, AM J PHYSIOL-CELL PH, V300, pC825, DOI 10.1152/ajpcell.00502.2010; Munter LM, 2007, EMBO J, V26, P1702, DOI 10.1038/sj.emboj.7601616; Murakami D, 2003, ONCOGENE, V22, P1511, DOI 10.1038/sj.onc.1206298; Oh S, 2010, BIOCHEM BIOPH RES CO, V399, P91, DOI 10.1016/j.bbrc.2010.07.047; Olahova M, 2008, P NATL ACAD SCI USA, V105, P19839, DOI 10.1073/pnas.0805507105; Park CS, 2008, TOXICOL SCI, V106, P413, DOI 10.1093/toxsci/kfn197; Rahimi N, 2009, CANCER RES, V69, P2607, DOI 10.1158/0008-5472.CAN-08-2905; Rocher-Ros V, 2010, ONCOGENE, V29, P2950, DOI 10.1038/onc.2010.57; Roe CM, 2005, NEUROLOGY, V64, P895, DOI 10.1212/01.WNL.0000152889.94785.51; Sagi SA, 2011, J BIOL CHEM, V286, P39794, DOI 10.1074/jbc.M111.277228; Schremmer Bruno, 2007, V44, P317; Serrano J, 2010, ONCOGENE, V29, P2165, DOI 10.1038/onc.2009.503; Song X, 2012, HEAD NECK ONCOL, V4, P47; Takahashi T, 2002, ONCOGENE, V21, P6868, DOI 10.1038/sj.onc.1205830; Tanii H, 2000, NEUROSCIENCE, V95, P593; Tarassishin L, 2004, P NATL ACAD SCI USA, V101, P17050, DOI 10.1073/pnas.0408007101; Thun MJ, 2008, PLOS MED, V5, P1357, DOI 10.1371/journal.pmed.0050185; To MD, 2006, ONCOGENE, V25, P3557, DOI 10.1038/sj.onc.1209397; Cespedes MV, 2010, AM J PATHOL, V177, P2067, DOI 10.2353/ajpath.2010.100079; Wakabayashi T, 2008, PHYSIOLOGY, V23, P194, DOI 10.1152/physiol.00009.2008; Wang L, 2008, MOL PHARMACOL, V73, P119, DOI 10.1124/mol.107.040873; Wood WJL, 2003, J COMB CHEM, V5, P869, DOI 10.1021/cc034008r; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Yan Ke-xia, 2004, Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, V22, P331; Yun HM, 2014, FREE RADICAL BIO MED, V69, P367, DOI 10.1016/j.freeradbiomed.2014.02.001; Zhang WP, 2007, MOL CARCINOGEN, V46, P372, DOI 10.1002/mc.20285; Zhang XZ, 2009, CANCER SCI, V100, P2396, DOI 10.1111/j.1349-7006.2009.01314.x	49	24	26	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2014	33	44					5193	5200		10.1038/onc.2014.128	http://dx.doi.org/10.1038/onc.2014.128			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR9RZ	24858037	hybrid, Green Published			2022-12-28	WOS:000343914900006
J	Yu, T; Liu, K; Wu, Y; Fan, J; Chen, J; Li, C; Yang, Q; Wang, Z				Yu, T.; Liu, K.; Wu, Y.; Fan, J.; Chen, J.; Li, C.; Yang, Q.; Wang, Z.			MicroRNA-9 inhibits the proliferation of oral squamous cell carcinoma cells by suppressing expression of CXCR4 via the Wnt/beta-catenin signaling pathway	ONCOGENE			English	Article						microRNA-9; CXC chemokine receptor 4; lentivirus; cell proliferation; oral squamous cell carcinoma; wnt/beta-catenin pathway	DOWN-REGULATION; CANCER; MIR-9; MIGRATION; TONGUE; IDENTIFICATION; INVASION; CADHERIN	Aberrant expression of microRNAs (miRNAs) has been involved in the development and progression of malignancy. MicroRNA-9 (miR-9) has been confirmed to be underexpressed in many types of cancers. However, the relationship between miR-9 and the Wnt/beta-catenin signaling pathway in oral squamous cell carcinoma (OSCC) remains largely unknown. Here we showed that the miR-9 was underexpressed in patients with OSCC and several OSCC cell lines. Lentivirus-mediated miR-9 overexpression in highly aggressive (Tca8113 and SCC-9) tumor cells significantly inhibited proliferation of the two cell lines in vitro and in vivo. Furthermore, we found that the CXC chemokine receptor 4 (CXCR4) gene was a direct target of miR-9. RNA interference silencing of CXCR4 proved that miR-9 underexpression led to constitutive activation of beta-catenin through activation of CXCR4 expression in OSCC cells. Finally, we also analyzed the possible relationship between miR-9 and the genes downstream of the Wnt/beta-catenin pathway in OSCC development and progression. These results provide new evidence of miR-9 as a promising tumor gene therapeutic target for OSCC patients.	[Yu, T.; Liu, K.; Fan, J.; Chen, J.; Li, C.; Yang, Q.; Wang, Z.] Sichuan Canc Hosp, Dept Head & Neck Oncol Surg, Chengdu 610041, Sichuan, Peoples R China; [Wu, Y.] Sichuan Univ, West China Coll Stomatol, State Key Lab Oral Dis, Chengdu 610064, Peoples R China	Sichuan University	Yu, T (corresponding author), Sichuan Canc Hosp, Dept Head & Neck Oncol Surg, 55 Sec 4,Renminnan Rd, Chengdu 610041, Sichuan, Peoples R China.	vince8181@163.com; zhaohuiwang512@163.com	YU, TAO/AAA-3089-2022					Al-Aynati MM, 2004, CLIN CANCER RES, V10, P1235, DOI 10.1158/1078-0432.CCR-03-0087; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Avissar M, 2009, CARCINOGENESIS, V30, P2059, DOI 10.1093/carcin/bgp277; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638; Bandyopadhyay Sanghamitra, 2010, Silence, V1, P6, DOI 10.1186/1758-907X-1-6; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Caruz A, 1998, FEBS LETT, V426, P271, DOI 10.1016/S0014-5793(98)00359-7; Chiyomaru T, 2010, BRIT J CANCER, V102, P883, DOI 10.1038/sj.bjc.6605570; Choe Y, 2012, DEV NEUROSCI-BASEL, V34, P502, DOI 10.1159/000345353; Fracalossi ACC, 2010, EXP MOL PATHOL, V88, P176, DOI 10.1016/j.yexmp.2009.11.004; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; Gao F, 2013, BIOCHEM BIOPH RES CO, V431, P610, DOI 10.1016/j.bbrc.2012.12.097; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Hu JZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058273; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Janda CY, 2012, SCIENCE, V337, P59, DOI 10.1126/science.1222879; Jiang L, 2010, INT J CANCER, V127, P505, DOI 10.1002/ijc.25320; Jin Z, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-480; Jing LJ, 2011, NEUROREPORT, V22, P206, DOI 10.1097/WNR.0b013e328344a666; Kademani D, 2007, MAYO CLIN PROC, V82, P878, DOI 10.4065/82.7.878; Kessler P, 2008, BRIT J ORAL MAX SURG, V46, P1, DOI 10.1016/j.bjoms.2007.08.006; Laios A, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-35; Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251; Leucci E, 2012, ONCOGENE, V31, P5081, DOI 10.1038/onc.2012.15; Li JS, 2009, CLIN CANCER RES, V15, P3998, DOI 10.1158/1078-0432.CCR-08-3053; Liu NN, 2012, ONCOL REP, V28, P961, DOI 10.3892/or.2012.1905; Liu SJ, 2012, J PATHOL, V226, P61, DOI 10.1002/path.2964; Lowy AM, 2003, ANN SURG ONCOL, V10, P284, DOI 10.1245/ASO.2003.05.003; Luo HC, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-82; Nass D, 2009, BRAIN PATHOL, V19, P375, DOI 10.1111/j.1750-3639.2008.00184.x; Nie K, 2008, AM J PATHOL, V173, P242, DOI 10.2353/ajpath.2008.080009; Omura N, 2008, CANCER BIOL THER, V7, P1146, DOI 10.4161/cbt.7.7.6208; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Petersen PE, 2003, COMMUNITY DENT ORAL, V31, P3, DOI 10.1046/j..2003.com122.x; Rotkrua P, 2011, INT J CANCER, V129, P2611, DOI 10.1002/ijc.25923; Selcuklu SD, 2012, J BIOL CHEM, V287, P29516, DOI 10.1074/jbc.M111.335943; Selcuklu SD, 2009, BIOCHEM SOC T, V37, P918, DOI 10.1042/BST0370918; Sun Z, 2013, MOL ONCOL; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Uchida F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056381; Wong TS, 2008, INT J CANCER, V123, P251, DOI 10.1002/ijc.23583; Yu T, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-64	47	100	104	2	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2014	33	42					5017	5027		10.1038/onc.2013.448	http://dx.doi.org/10.1038/onc.2013.448			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OB	24141785				2022-12-28	WOS:000343768000006
J	Banerjee, J; Mishra, R; Li, X; Jackson, RS; Sharma, A; Bhowmick, NA				Banerjee, J.; Mishra, R.; Li, X.; Jackson, R. S., II; Sharma, A.; Bhowmick, N. A.			A reciprocal role of prostate cancer on stromal DNA damage	ONCOGENE			English	Article						stromal coevolution; prostate cancer; TGF-beta; IL-6; DNA methylation	REACTIVE STROMA; TUMOR PROGRESSION; FIBROBLASTS; METHYLATION; GROWTH; TUMORIGENESIS; MECHANISMS; INDUCTION; PROMOTER; THERAPY	DNA damage found in prostate cancer-associated fibroblasts (CAF) promotes tumor progression. In the absence of somatic mutations in CAF, epigenetic changes dictate how stromal coevolution is mediated in tumors. Seventy percent of prostate cancer patients lose expression of transforming growth factor-beta type II receptor (TGFBR2) in the stromal compartment (n = 77, P-value = 0.0001), similar to the rate of glutathione S-transferase P1 (GSTP1) silencing. Xenografting of human prostate cancer epithelia, LNCaP, resulted in the epigenetic Tgfbr2 silencing of host mouse prostatic fibroblasts. Stromal Tgfbr2 promoter hypermethylation, initiated by LNCaP cells, was found to be dependent on interleukin 6 expression, based on neutralizing antibody studies. We further found that pharmacologic and transgenic knockout of TGF-beta responsiveness in prostatic fibroblasts induced Gstp1 promoter methylation. It is known that TGF-beta promotes DNA stability, however, the mechanism is not well understood. Both prostatic human CAF and mouse transgenic knockout of Tgbr2 had elevated DNA methyltransferase I (DNMT1) activity and histone H3 lysine 9 trimethylation (H3K9me3) to suggest greater promoter methylation. Interestingly, the conditional knockout of Tgfbr2 in mouse prostatic fibroblasts, in modeling epigenetic silencing of Tgfbr2, had greater epigenetic gene silencing of multiple DNA damage repair and oxidative stress response genes, based on promoter methylation array analysis. Homologous gene silencing was validated by reverse transcriptase (RT)-PCR in mouse and human prostatic CAF. Not surprisingly, DNA damage repair gene silencing in the prostatic stromal cells corresponded with the presence of DNA damage. Restoring the expression of the epigenetically silenced genes in wild-type fibroblasts with radiation-induced DNA damage reduced tumor progression. Tumor progression was inhibited even when epigenetic silencing was reversed in the Tgfbr2-knockout prostatic fibroblasts. Taken together, fibroblastic epigenetic changes causative of DNA damage, initiated by association with cancer epithelia, is a dominant mediator of tumor progression over TGF-beta responsiveness.	[Banerjee, J.; Li, X.; Jackson, R. S., II] Vanderbilt Univ, Dept Urol, Nashville, TN USA; [Mishra, R.; Bhowmick, N. A.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, Los Angeles, CA 90048 USA; [Jackson, R. S., II; Bhowmick, N. A.] Greater Los Angeles Vet Adm, Los Angeles, CA USA; [Sharma, A.] Univ Tennessee, Dept Mech Aerosp & Biomed Engn, Knoxville, TN USA	Vanderbilt University; Cedars Sinai Medical Center; University of Tennessee System; University of Tennessee Knoxville	Bhowmick, NA (corresponding author), Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, 8750 Beverly Blvd,Atrium 103, Los Angeles, CA 90048 USA.	bhowmickn@cshs.org	Mishra, Rajeev/AEX-2208-2022; Bhowmick, Neil/AAA-7302-2019; Mishra, Rajeev/T-4216-2017	Mishra, Rajeev/0000-0002-7411-4022; Bhowmick, Neil/0000-0001-8747-5989; , Xiaohong/0000-0001-5074-193X	National Cancer Institute [R01CA108646]; NATIONAL CANCER INSTITUTE [R01CA108646] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The work was supported by R01CA108646 (to NAB) from the National Cancer Institute.	Ahles TA, 2007, NAT REV CANCER, V7, P192, DOI 10.1038/nrc2073; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Cahill DP, 1999, TRENDS BIOCHEM SCI, V24, pM57, DOI 10.1016/S0968-0004(99)01466-8; Campbell I, 2009, CANCER RES, V69, P6765, DOI 10.1158/0008-5472.CAN-08-4253; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Cunha G R, 1984, Prog Clin Biol Res, V145, P81; Dakhova O, 2009, CLIN CANCER RES, V15, P3979, DOI 10.1158/1078-0432.CCR-08-1899; Du ZW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001462; Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; Hodge David R., 2007, Cancer Genomics & Proteomics, V4, P387; Jackson RS, 2012, NEOPLASIA, V14, P656, DOI 10.1593/neo.12640; Jeronimo C, 2001, J NATL CANCER I, V93, P1747, DOI 10.1093/jnci/93.22.1747; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792; Kantarjian H, 2007, CANCER-AM CANCER SOC, V109, P1705, DOI 10.1002/cncr.22602; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Kiskowski MA, 2011, CANCER RES, V71, P3459, DOI 10.1158/0008-5472.CAN-10-2999; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Lee SO, 2003, CLIN CANCER RES, V9, P370; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li X, 2011, ONCOGENE, V30, P167, DOI 10.1038/onc.2010.400; Li X, 2008, ONCOGENE, V27, P7118, DOI 10.1038/onc.2008.293; Martinez-Ferrer M, 2010, AM J PATHOL, V176, P98, DOI 10.2353/ajpath.2010.090283; Maruyama R, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001369; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Ohuchida K, 2004, CANCER RES, V64, P3215, DOI 10.1158/0008-5472.CAN-03-2464; Olumi AF, 1999, CANCER RES, V59, P5002; Placencio VR, 2008, CANCER RES, V68, P4709, DOI 10.1158/0008-5472.CAN-07-6289; Placencio VR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012920; Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117; Shen H, 2012, CELL STEM CELL, V10, P353, DOI 10.1016/j.stem.2012.03.012; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Trobridge P, 2009, GASTROENTEROLOGY, V136, P1680, DOI 10.1053/j.gastro.2009.01.066; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; Tuxhorn JA, 2001, J UROLOGY, V166, P2472, DOI 10.1016/S0022-5347(05)65620-0; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598	39	34	34	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2014	33	41					4924	4931		10.1038/onc.2013.431	http://dx.doi.org/10.1038/onc.2013.431			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OA	24141771	Green Accepted			2022-12-28	WOS:000343767900005
J	Tsai, CH; Teng, CH; Tu, YT; Cheng, TS; Wu, SR; Ko, CJ; Shyu, HY; Lan, SW; Huang, HP; Tzeng, SF; Johnson, MD; Lin, CY; Hsiao, PW; Lee, MS				Tsai, C-H; Teng, C-H; Tu, Y-T; Cheng, T-S; Wu, S-R; Ko, C-J; Shyu, H-Y; Lan, S-W; Huang, H-P; Tzeng, S-F; Johnson, M. D.; Lin, C-Y; Hsiao, P-W; Lee, M-S			HAI-2 suppresses the invasive growth and metastasis of prostate cancer through regulation of matriptase	ONCOGENE			English	Article						prostate cancer; hepatocyte growth factor activator inhibitor-2; cancer cell invasion; tumorigenicity; metastasis	SERINE-PROTEASE INHIBITOR; FACTOR ACTIVATOR INHIBITOR-1; HUMAN BREAST-CANCER; CELL-SURFACE; PLACENTAL DEVELOPMENT; ZYMOGEN ACTIVATION; EPITHELIAL-CELLS; TUMOR-GROWTH; IN-VITRO; HEPATOCYTE	Dysregulation of cell surface proteolysis has been strongly implicated in tumorigenicity and metastasis. In this study, we delineated the role of hepatocyte growth factor activator inhibitor-2 (HAI-2) in prostate cancer (PCa) cell migration, invasion, tumorigenicity and metastasis using a human PCa progression model (103E, N1, and N2 cells) and xenograft models. N1 and N2 cells were established through serial intraprostatic propagation of 103E human PCa cells and isolation of the metastatic cells from nearby lymph nodes. The invasion capability of these cells was revealed to gradually increase throughout the serial isolations (103E < N1 < N2). In this series of cells, the expression of HAI-2 but not HAI-1 was significantly decreased throughout the progression and occurred in parallel with increased activation of matriptase. The expression level and activity of matriptase increased whereas the HAI-2 protein level decreased over the course of orthotopic tumor growth in mice, which was consistent with the immunohistochemical profiles of matriptase and HAI-2 in archival PCa specimens. Knockdown of matriptase reduced the PCa cell invasion induced by HAI-2 knockdown. HAI-2 overexpression or matriptase silencing in N2 cells downregulated matriptase activity and significantly decreased tumorigenicity and metastatic capability in orthotopically xenografted mice. These results suggest that during the progression of human PCa, matriptase activity is primarily controlled by HAI-2 expression. The imbalance between HAI-2 and matriptase expression led to matriptase activation, thereby increasing cell migration, invasion, tumorigenicity and metastasis.	[Tsai, C-H; Tzeng, S-F; Hsiao, P-W] Acad Sinica, Agr Biotechnol Res Ctr, Taipei 115, Taiwan; [Teng, C-H; Tu, Y-T; Cheng, T-S; Wu, S-R; Ko, C-J; Shyu, H-Y; Lan, S-W; Lee, M-S] Natl Taiwan Univ, Coll Med, Dept Biochem & Mol Biol, Taipei 10764, Taiwan; [Shyu, H-Y] Minist Justice, Invest Bur, Taipei, Taiwan; [Huang, H-P] Natl Taiwan Univ, Coll Med, Grad Inst Med Genom & Prote, Taipei 10764, Taiwan; [Johnson, M. D.; Lin, C-Y] Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA	Academia Sinica - Taiwan; National Taiwan University; National Taiwan University; Georgetown University	Hsiao, PW (corresponding author), Acad Sinica, Agr Biotechnol Res Ctr, 128 Acad Rd,Sect 2, Taipei 115, Taiwan.	pwhsiao@gate.sinica.edu.tw; mslee2006@ntu.edu.tw	Ko, Chun-Jung/AAA-6187-2022; Hsiao, Pei-Wen/V-5653-2018	johnson, Michael/0000-0001-6260-7586; LEE, MING-SHYUE/0000-0002-8673-5088; LEE, MING-SHYUE/0000-0002-5884-4535; HUANG, HSIANG-PO/0000-0002-3382-305X; Hsiao, Pei-Wen/0000-0002-3589-6754; Ko, Chun-Jung/0000-0001-6565-7060	Taiwan National Health Research Institutes [NHRI-EX101-9909BC, NHRI-EX102-9909BC]; Taiwan National Science Council [NSC 97-2320-B-002-052-MY3, NSC 100-2628-B-002-004-MY4, NSC 101-2324-B-002-015, NSC 98-2320-B-001-018-MY3]; National Taiwan University [98R0305]; National Taiwan University Cutting-Edge Steering Research Project [10R71602C4]; Postdoctoral Fellowship from the Aim for Top University Program, National Taiwan University; Agricultural Biotechnology Research Center and Academia Sinica; NATIONAL CANCER INSTITUTE [R01CA123223, P30CA051008] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000101] Funding Source: NIH RePORTER	Taiwan National Health Research Institutes; Taiwan National Science Council(Ministry of Science and Technology, Taiwan); National Taiwan University(National Taiwan University); National Taiwan University Cutting-Edge Steering Research Project; Postdoctoral Fellowship from the Aim for Top University Program, National Taiwan University; Agricultural Biotechnology Research Center and Academia Sinica; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This study was supported by Taiwan National Health Research Institutes Grants NHRI-EX101-9909BC and NHRI-EX102-9909BC, Taiwan National Science Council Grants NSC 97-2320-B-002-052-MY3, NSC 100-2628-B-002-004-MY4 and NSC 101-2324-B-002-015, the Frontier and Innovative Research Grant of National Taiwan University 98R0305 and National Taiwan University Cutting-Edge Steering Research Project 10R71602C4 to M-S Lee; Postdoctoral Fellowship from the Aim for Top University Program, National Taiwan University, to T-S Cheng; and grants from the National Science Council, Taiwan (NSC 98-2320-B-001-018-MY3), financial and instrumental support from the Agricultural Biotechnology Research Center and Academia Sinica awarded to P-W Hsiao. We are also grateful to Miranda Loney (Editor, ABRC) for critical suggestions editing this article.	Antalis TM, 2010, BIOCHEM J, V428, P325, DOI 10.1042/BJ20100046; Bergum C, 2010, PROSTATE, V70, P1422, DOI 10.1002/pros.21177; Chen CJ, 2011, AM J PHYSIOL-CELL PH, V300, pC406, DOI 10.1152/ajpcell.00403.2010; Cheng TS, 2013, CANCER PREV RES, V6, P495, DOI 10.1158/1940-6207.CAPR-12-0293-T; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Fukai K, 2003, CANCER RES, V63, P8674; Heinz-Erian P, 2009, AM J HUM GENET, V84, P188, DOI 10.1016/j.ajhg.2009.01.004; Huang HP, 2012, HEPATOLOGY, V55, P161, DOI 10.1002/hep.24657; Jin XL, 2006, CANCER SCI, V97, P1327, DOI 10.1111/j.1349-7006.2006.00328.x; Kang JY, 2003, CANCER RES, V63, P1101; Kawaguchi T, 1997, J BIOL CHEM, V272, P27558, DOI 10.1074/jbc.272.44.27558; Kirchhofer D, 2005, FEBS LETT, V579, P1945, DOI 10.1016/j.febslet.2005.01.085; Kongkham PN, 2008, CANCER RES, V68, P9945, DOI 10.1158/0008-5472.CAN-08-2169; Lee MS, 2007, AM J PHYSIOL-CELL PH, V293, pC95, DOI 10.1152/ajpcell.00611.2006; Lee MS, 2005, AM J PHYSIOL-CELL PH, V288, pC932, DOI 10.1152/ajpcell.00497.2004; Lee MS, 2006, J CANC MOL, V2, P183; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lin CY, 2008, FRONT BIOSCI-LANDMRK, V13, P621, DOI 10.2741/2707; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; List K, 2006, MOL MED, V12, P1, DOI 10.2119/2006-00022.List; Marlor CW, 1997, J BIOL CHEM, V272, P12202, DOI 10.1074/jbc.272.18.12202; Morris MR, 2005, CANCER RES, V65, P4598, DOI 10.1158/0008-5472.CAN-04-3371; Muller-Pillasch F, 1998, BBA-GENE STRUCT EXPR, V1395, P88, DOI 10.1016/S0167-4781(97)00129-2; Nagakawa O, 2005, EUR UROL, V48, P686, DOI 10.1016/j.eururo.2005.05.020; Netzel-Arnett S, 2003, CANCER METAST REV, V22, P237, DOI 10.1023/A:1023003616848; Oberst M, 2001, AM J PATHOL, V158, P1301, DOI 10.1016/S0002-9440(10)64081-3; Oberst MD, 2003, J BIOL CHEM, V278, P26773, DOI 10.1074/jbc.M304282200; Oberst MD, 2003, J HISTOCHEM CYTOCHEM, V51, P1017, DOI 10.1177/002215540305100805; Parr C, 2004, CLIN CANCER RES, V10, P202, DOI 10.1158/1078-0432.CCR-0553-3; Parr C, 2006, INT J CANCER, V119, P1176, DOI 10.1002/ijc.21881; Saleem M, 2006, CANCER EPIDEM BIOMAR, V15, P217, DOI 10.1158/1055-9965.EPI-05-0737; Satomi S, 2001, BIOCHEM BIOPH RES CO, V287, P995, DOI 10.1006/bbrc.2001.5686; SHI YE, 1993, CANCER RES, V53, P1409; Szabo R, 2007, ONCOGENE, V26, P1546, DOI 10.1038/sj.onc.1209966; Szabo R, 2011, ONCOGENE, V30, P2003, DOI 10.1038/onc.2010.586; Szabo R, 2008, J BIOL CHEM, V283, P29495, DOI 10.1074/jbc.M801970200; Szabo R, 2009, DEVELOPMENT, V136, P2653, DOI 10.1242/dev.038430; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tsai CH, 2009, CLIN CANCER RES, V15, P5435, DOI 10.1158/1078-0432.CCR-09-0298; Uhland K, 2006, CELL MOL LIFE SCI, V63, P2968, DOI 10.1007/s00018-006-6298-x; Weiss L, 2000, Cancer Metastasis Rev, V19, pI; Wu SR, 2010, AM J PATHOL, V177, P3145, DOI 10.2353/ajpath.2010.100228	46	38	39	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2014	33	38					4643	4652		10.1038/onc.2013.412	http://dx.doi.org/10.1038/onc.2013.412			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3VX	24121274	Green Accepted			2022-12-28	WOS:000342007200003
J	Kumar, S; Pan, CC; Bloodworth, JC; Nixon, AB; Theuer, C; Hoyt, DG; Lee, NY				Kumar, S.; Pan, C. C.; Bloodworth, J. C.; Nixon, A. B.; Theuer, C.; Hoyt, D. G.; Lee, N. Y.			Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-beta signaling	ONCOGENE			English	Article						endoglin; soluble endoglin; TRC105; angiogenesis; TGF-beta	ENDOTHELIAL-CELL PROLIFERATION; TUMOR VASCULATURE; SOLUBLE ENDOGLIN; CORECEPTOR ENDOGLIN; RECEPTOR COMPLEXES; GROWTH; ANGIOGENESIS; CANCER; MICE; EXPRESSION	Endoglin is a transforming growth factor beta (TGF-beta) coreceptor that serves as a prognostic, diagnostic and therapeutic vascular target in human cancer. A number of endoglin ectodomain-targeting antibodies (Abs) can effectively suppress both normal and tumor-associated angiogenesis, but their molecular actions remain poorly characterized. Here we define a key mechanism for TRACON105 (TRC105), a humanized monoclonal Ab in clinical trials for treatment of advanced or metastatic tumors. TRC105, along with several other endoglin Abs tested, enhance endoglin shedding through direct coupling of endoglin and the membrane-type 1 matrix metalloproteinase (MMP)-14 at the cell surface to release the antiangiogenic factor, soluble endoglin (sEng). In addition to this coupling process, endoglin shedding is further amplified by increased MMP-14 expression that requires TRC105 concentration-dependent c-Jun N-terminal kinase (JNK) activation. There were also notable counterbalancing effects on canonical Smad signaling in which TRC105 abrogated both the steady-state and TGF-beta-induced Smad1/5/8 activation while augmenting Smad2/3 activation. Interestingly, TRC105-induced sEng and aberrant Smad signaling resulted in an excessive migratory response through enhanced stress fiber formation and disruption of endothelial cell-cell junctions. Collectively, our study defines endoglin shedding and deregulated TGF-beta signaling during migration as major mechanisms by which TRC105 inhibits angiogenesis.	[Kumar, S.; Pan, C. C.; Bloodworth, J. C.; Hoyt, D. G.; Lee, N. Y.] Ohio State Univ, Coll Pharm, Div Pharmacol, Columbus, OH 43210 USA; [Nixon, A. B.] Duke Canc Inst, Durham, NC USA; [Theuer, C.] TRACON Pharmaceut, San Diego, CA USA; [Lee, N. Y.] Davis Heart & Lung Res Inst, Columbus, OH USA	University System of Ohio; Ohio State University; Duke University; University System of Ohio; Ohio State University	Lee, NY (corresponding author), Ohio State Univ, Coll Pharm, Div Pharmacol, 500 West 12th Ave, Columbus, OH 43210 USA.	lee.5064@osu.edu	Lee, Nam/H-3073-2016; Nixon, Andrew/AAJ-4712-2020	Nixon, Andrew/0000-0003-3971-2964	National Institute of Health [R00 HL103791]; College of Pharmacy, Division of Pharmacology; Davis Heart and Lung Research Institute, at The Ohio State University; NATIONAL CANCER INSTITUTE [P30CA014236, R01CA178443] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R00HL103791] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); College of Pharmacy, Division of Pharmacology; Davis Heart and Lung Research Institute, at The Ohio State University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the National Institute of Health (R00 HL103791 to NYL) and internal funds from the College of Pharmacy, Division of Pharmacology, and Davis Heart and Lung Research Institute, at The Ohio State University. We thank Dr Jian Cao for the MMP-14 construct (Stony Brook University) and Dr Charles Theuer for the TRC105 antibody (TRACON Pharmaceuticals).	Anderberg C, 2013, J EXP MED, V210, P563, DOI 10.1084/jem.20120662; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Blazquez-Medela AM, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-86; Castonguay R, 2011, J BIOL CHEM, V286, P30034, DOI 10.1074/jbc.M111.260133; Cherney RJ, 2006, BIOORG MED CHEM LETT, V16, P1028, DOI 10.1016/j.bmcl.2005.10.078; Conley BA, 2004, J BIOL CHEM, V279, P27440, DOI 10.1074/jbc.M312561200; Covington MD, 2006, AM J PHYSIOL-RENAL, V290, pF43, DOI 10.1152/ajprenal.00179.2005; Dallas NA, 2008, CLIN CANCER RES, V14, P1931, DOI 10.1158/1078-0432.CCR-07-4478; Daly AC, 2008, MOL CELL BIOL, V28, P6889, DOI 10.1128/MCB.01192-08; David L, 2007, BLOOD, V109, P1953, DOI 10.1182/blood-2006-07-034124; Duwel A, 2007, TUMOR BIOL, V28, P1, DOI 10.1159/000097040; Ehrlich M, 2011, CELL SIGNAL, V23, P1424, DOI 10.1016/j.cellsig.2011.04.004; Fonsatti E, 2010, CARDIOVASC RES, V86, P12, DOI 10.1093/cvr/cvp332; Hawinkels LJAC, 2010, CANCER RES, V70, P4141, DOI 10.1158/0008-5472.CAN-09-4466; Landt S, 2011, ANTICANCER RES, V31, P2651; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Lee BH, 2007, J BIOL CHEM, V282, P17985, DOI 10.1074/jbc.M702664200; Lee NY, 2008, J BIOL CHEM, V283, P32527, DOI 10.1074/jbc.M803059200; Lee NY, 2007, J BIOL CHEM, V282, P21507, DOI 10.1074/jbc.M700176200; Lee NY, 2012, MOL BIOL CELL, V23, P2412, DOI 10.1091/mbc.E11-12-0993; Lee NY, 2009, FASEB J, V23, P3712, DOI 10.1096/fj.09-131607; Levine RJ, 2006, NEW ENGL J MED, V355, P992, DOI 10.1056/NEJMoa055352; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Liu XD, 2000, ONCOGENE, V19, P5926, DOI 10.1038/sj.onc.1203991; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lopez-Novoa JM, 2010, AM J PHYSIOL-HEART C, V299, pH959, DOI 10.1152/ajpheart.01251.2009; Lowrey GE, 2008, RESP MED, V102, P845, DOI 10.1016/j.rmed.2008.01.006; Marom B, 2011, J BIOL CHEM, V286, P19287, DOI 10.1074/jbc.M110.210377; Meng QJ, 2006, J BIOL CHEM, V281, P37069, DOI 10.1074/jbc.M608614200; Nasser MW, 2012, CANCER RES, V72, P604, DOI 10.1158/0008-5472.CAN-11-0669; Nolan-Stevaux O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050920; Pan CC, 2012, BIOCHEM BIOPH RES CO, V424, P620, DOI 10.1016/j.bbrc.2012.06.163; Park S, 2013, J CELL SCI, V126, P1392, DOI 10.1242/jcs.117275; Pece-Barbara N, 2005, J BIOL CHEM, V280, P27800, DOI 10.1074/jbc.M503471200; Perez-Gomez E, 2010, THESCIENTIFICWORLDJO, V10, P2367, DOI 10.1100/tsw.2010.230; Rosen LS, 2012, CLIN CANCER RES, V18, P4820, DOI 10.1158/1078-0432.CCR-12-0098; Santibanez JF, 2010, CARCINOGENESIS, V31, P2145, DOI 10.1093/carcin/bgq199; Sanz-Rodriguez F, 2004, J BIOL CHEM, V279, P32858, DOI 10.1074/jbc.M400843200; Shields MA, 2011, J BIOL CHEM, V286, P10495, DOI 10.1074/jbc.M110.195628; Tsirakis G, 2012, EUR J INTERN MED, V23, P368, DOI 10.1016/j.ejim.2012.01.012; Tsujie M, 2008, INT J CANCER, V122, P2266, DOI 10.1002/ijc.23314; Tsujie M, 2006, INT J ONCOL, V29, P1087; Uneda S, 2009, INT J CANCER, V125, P1446, DOI 10.1002/ijc.24482; Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537; Willis BC, 2007, AM J PHYSIOL-LUNG C, V293, pL525, DOI 10.1152/ajplung.00163.2007	45	29	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3970	3979		10.1038/onc.2013.386	http://dx.doi.org/10.1038/onc.2013.386			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	24077288	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000339394700009
J	van Oers, JMM; Edwards, Y; Chahwan, R; Zhang, W; Smith, C; Pechuan, X; Schaetzlein, S; Jin, B; Wang, Y; Bergman, A; Scharff, MD; Edelmann, W				van Oers, J. M. M.; Edwards, Y.; Chahwan, R.; Zhang, W.; Smith, C.; Pechuan, X.; Schaetzlein, S.; Jin, B.; Wang, Y.; Bergman, A.; Scharff, M. D.; Edelmann, W.			The MutS beta complex is a modulator of p53-driven tumorigenesis through its functions in both DNA double-strand break repair and mismatch repair	ONCOGENE			English	Article						DNA mismatch repair; MSH2-MSH3; DNA double-strand break repair; chromosomal instability; p53; sarcomagenesis	SACCHAROMYCES-CEREVISIAE MSH2; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; SOMATIC HYPERMUTATION; PROTEIN EXPRESSION; HOMOLOGOUS RECOMBINATION; TUMOR SUPPRESSION; DEFICIENT MICE; APC MUTATIONS; COLON-CANCER	Loss of the DNA mismatch repair (MMR) protein MSH3 leads to the development of a variety of tumors in mice without significantly affecting survival rates, suggesting a modulating role for the MutS beta (MSH2-MSH3) complex in late-onset tumorigenesis. To better study the role of MSH3 in tumor progression, we crossed Msh3(-/-) mice onto a tumor predisposing p53-deficient background. Survival of Msh3/p53 mice was not reduced compared with p53 single mutant mice; however, the tumor spectrum changed significantly from lymphoma to sarcoma, indicating MSH3 as a potent modulator of p53-driven tumorigenesis. Interestingly, Msh3(-/-) mouse embryonic fibroblasts displayed increased chromatid breaks and persistence of gamma H2AX foci following ionizing radiation, indicating a defect in DNA double-strand break repair (DSBR). Msh3/p53 tumors showed increased loss of heterozygosity, elevated genome-wide copy-number variation and a moderate microsatellite instability phenotype compared with Msh2/p53 tumors, revealing that MSH2-MSH3 suppresses tumorigenesis by maintaining chromosomal stability. Our results show that the MSH2-MSH3 complex is important for the suppression of late-onset tumors due to its roles in DNA DSBR as well as in DNA MMR. Further, they demonstrate that MSH2-MSH3 suppresses chromosomal instability and modulates the tumor spectrum in p53-deficient tumorigenesis and possibly has a role in other chromosomally unstable tumors as well.	[van Oers, J. M. M.; Edwards, Y.; Chahwan, R.; Schaetzlein, S.; Jin, B.; Wang, Y.; Scharff, M. D.; Edelmann, W.] Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; [Zhang, W.] Mt Sinai Sch Med, Dept Med, New York, NY USA; [Smith, C.; Pechuan, X.; Bergman, A.] Albert Einstein Coll Med, Dept Syst & Computat Biol, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine; Icahn School of Medicine at Mount Sinai; Yeshiva University; Albert Einstein College of Medicine	Edelmann, W (corresponding author), Albert Einstein Coll Med, Dept Cell Biol, 1301 Morris Pk Ave, Bronx, NY 10461 USA.	winfried.edelmann@einstein.yu.edu	Pechuan, Ximo/AAD-7775-2019; Pechuan, Joaquin/H-7327-2015; Chahwan, Richard/AAQ-9381-2021; Smith, Cameron/B-7683-2011	Pechuan, Ximo/0000-0001-8938-7931; Pechuan, Joaquin/0000-0001-8938-7931; Chahwan, Richard/0000-0002-8672-7790; Smith, Cameron/0000-0002-6347-7506; Wang, Yuxun/0000-0002-4252-6102	National Institutes of Health [CA76329, CA93484, CA72649, CA102705]; National Women's Division of the Albert Einstein College of Medicine; NATIONAL CANCER INSTITUTE [R01CA072649, P30CA013330, R01CA093484, R01CA102705, R01CA076329, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI112335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Women's Division of the Albert Einstein College of Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Rani Sellers from the Einstein Histotechnology and Comparative Pathology facility for mouse pathology and for reviewing the manuscript. This study was supported by National Institutes of Health grants CA76329 and CA93484 (WE), and CA72649 and CA102705 (MDS). MDS is supported by the Harry Eagle Chair provided by the National Women's Division of the Albert Einstein College of Medicine.	Bardwell PD, 2004, NAT IMMUNOL, V5, P224, DOI 10.1038/ni1031; Benachenhou N, 1998, INT J CANCER, V77, P173, DOI 10.1002/(SICI)1097-0215(19980717)77:2<173::AID-IJC1>3.0.CO;2-N; Benachenhou N, 1999, BRIT J CANCER, V79, P1012, DOI 10.1038/sj.bjc.6690162; Berndt SI, 2007, INT J CANCER, V120, P1548, DOI 10.1002/ijc.22510; Chen PC, 2005, CANCER RES, V65, P8662, DOI 10.1158/0008-5472.CAN-05-0742; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Edelmann W, 2000, CANCER RES, V60, P803; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Evans E, 2000, MOL CELL, V5, P789, DOI 10.1016/S1097-2765(00)80319-6; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Harrington JA, 2007, MOL CELL BIOL, V27, P6546, DOI 10.1128/MCB.00855-07; Haugen AC, 2008, CANCER RES, V68, P8465, DOI 10.1158/0008-5472.CAN-08-0002; Hirata H, 2008, J UROLOGY, V179, P2020, DOI 10.1016/j.juro.2008.01.009; Hong Z, 2008, J CELL SCI, V121, P3146, DOI 10.1242/jcs.026393; Iyer RR, 2006, CHEM REV, V106, P302, DOI 10.1021/cr0404794; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jacks T, 1996, J CANCER RES CLIN, V122, P319, DOI 10.1007/BF01220798; Kawakami T, 2004, BIOCHEM BIOPH RES CO, V325, P934, DOI 10.1016/j.bbrc.2004.10.114; Kumar C, 2013, J MOL BIOL, V425, P1881, DOI 10.1016/j.jmb.2013.02.024; Kuraguchi M, 2001, CANCER RES, V61, P7934; Lee SY, 2010, GASTROENTEROLOGY, V139, P1519, DOI 10.1053/j.gastro.2010.08.001; Li ZQ, 2006, DNA REPAIR, V5, P675, DOI 10.1016/j.dnarep.2006.02.003; Li ZQ, 2004, J EXP MED, V200, P47, DOI 10.1084/jem.20040355; Lyndaker AM, 2009, BIOESSAYS, V31, P315, DOI 10.1002/bies.200800195; Manley K, 1999, NAT GENET, V23, P471, DOI 10.1038/70598; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; Michiels S, 2007, CARCINOGENESIS, V28, P1731, DOI 10.1093/carcin/bgm111; Miura T, 2012, GENETICS, V191, P65, DOI 10.1534/genetics.112.139105; Orimo H, 2000, J HUM GENET, V45, P228, DOI 10.1007/s100380070031; Owen BAL, 2005, NAT STRUCT MOL BIOL, V12, P663, DOI 10.1038/nsmb965; Peled JU, 2010, AM J PATHOL, V177, P2597, DOI 10.2353/ajpath.2010.100234; Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065; Plaschke J, 2004, CANCER RES, V64, P864, DOI 10.1158/0008-5472.CAN-03-2807; Plaschke J, 2012, INT J COLORECTAL DIS, V27, P911, DOI 10.1007/s00384-011-1408-0; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Reynolds MF, 2009, CANCER RES, V69, P1071, DOI 10.1158/0008-5472.CAN-08-2306; ROUSSEEUW PJ, 1987, J COMPUT APPL MATH, V20, P53, DOI 10.1016/0377-0427(87)90125-7; Savouret C, 2003, EMBO J, V22, P2264, DOI 10.1093/emboj/cdg202; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Smits R, 2000, GENE CHROMOSOME CANC, V29, P229, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1033>3.0.CO;2-R; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; Svetlanov A, 2008, GENETICS, V178, P1937, DOI 10.1534/genetics.107.084798; Toft NJ, 2002, ONCOGENE, V21, P6299, DOI 10.1038/sj.onc.1205727; Tomasini R, 2008, TRENDS CELL BIOL, V18, P244, DOI 10.1016/j.tcb.2008.03.003; Tome S, 2013, DNA REPAIR, V12, P46, DOI 10.1016/j.dnarep.2012.10.006; Tome S, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000482; Tomimatsu N, 2012, DNA REPAIR, V11, P441, DOI 10.1016/j.dnarep.2012.01.006; van den Broek WJAA, 2002, HUM MOL GENET, V11, P191, DOI 10.1093/hmg/11.2.191; Varela I, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r100; Wang YX, 2010, P NATL ACAD SCI USA, V107, P5511, DOI 10.1073/pnas.1001223107; Wu XP, 2006, J IMMUNOL, V176, P5426, DOI 10.4049/jimmunol.176.9.5426	52	27	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3939	3946		10.1038/onc.2013.365	http://dx.doi.org/10.1038/onc.2013.365			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	24013230	Green Accepted, Green Submitted			2022-12-28	WOS:000339394700006
J	Bickeboller, M; Tagscherer, KE; Kloor, M; Jansen, L; Chang-Claude, J; Brenner, H; Hoffmeister, M; Toth, C; Schirmacher, P; Roth, W; Blaker, H				Bickeboeller, M.; Tagscherer, K. E.; Kloor, M.; Jansen, L.; Chang-Claude, J.; Brenner, H.; Hoffmeister, M.; Toth, C.; Schirmacher, P.; Roth, W.; Blaeker, H.			Functional characterization of the tumor-suppressor MARCKS in colorectal cancer and its association with survival	ONCOGENE			English	Article							PROTEIN-KINASE-C; APOPTOSIS-INDUCING LIGAND; PROMINENT CELLULAR SUBSTRATE; MICROSATELLITE INSTABILITY; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PLASMA-MEMBRANE; MELANOMA-CELLS; DIFFERENTIAL EXPRESSION; CALMODULIN-BINDING; EFFECTOR DOMAIN	The myristoylated alanine-rich C-kinase substrate (MARCKS) acts as a tumor suppressor in a variety of human neoplasms. In colorectal cancers (CRCs), MARCKS has been shown to be a preferential target of mutational inactivation in tumors following the microsatellite instability (MSI-H) pathway but little is known about its impact on intestinal carcinogenesis. To investigate the relevance of MARCKS inactivation in more detail, we analyzed 926 MSI-typed CRCs for MARCKS expression by immunohistochemistry and studied the functional consequences of MARCKS depletion in colorectal cancer cell lines. We found that loss of MARCKS expression was not restricted to MSI-H cancers but also occurred in microsatellite stable (MSS) tumors, where it was associated with an adverse outcome regarding overall survival, cancer-specific and disease-free survival (P = 0.002, P = 0.0018, P = 0.0001, respectively; univariate analysis). In MARCKS-positive MSS colon cancer cell lines (SW480 and SW707) small interfering RNA (siRNA)-mediated knockdown of MARCKS conferred resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. This was accompanied by the downregulation of the TRAIL receptors DR4 and DR5 at the cell surface and activation of AKT signaling. Inhibition of AKT signaling and transient overexpression of wild-type MARCKS, but not of MARCKS lacking the effector domain (ED), abolished the anti-apoptotic effect. In conclusion, our data show that inactivation of MARCKS is common in CRCs and is associated with adverse outcome in MSS cancers. The finding that MARCKS acts as a mediator of apoptosis in MSS CRC cells adds a novel tumor-suppressing function to the so far established roles of MARCKS in cell motility and proliferation and can explain the prognostic effect of MARCKS depletion in MSS CRC.	[Bickeboeller, M.; Tagscherer, K. E.; Roth, W.] German Canc Res Ctr, Div Mol Tumor Pathol, Heidelberg, Germany; [Bickeboeller, M.; Tagscherer, K. E.; Toth, C.; Schirmacher, P.; Roth, W.] Heidelberg Univ, Inst Pathol, Dept Gen Pathol, Heidelberg, Germany; [Kloor, M.] Heidelberg Univ, Inst Pathol, Dept Appl Tumor Biol, Heidelberg, Germany; [Jansen, L.; Brenner, H.; Hoffmeister, M.] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany; [Chang-Claude, J.] German Canc Res Ctr, Unit Genet Epidemiol, Div Canc Epidemiol, Heidelberg, Germany; [Blaeker, H.] Univ Hosp Charite, Inst Pathol, Dept Gen Pathol, D-10117 Berlin, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Blaker, H (corresponding author), Univ Hosp Charite, Inst Pathol, Dept Gen Pathol, Campus Mitte,Charitepl 1, D-10117 Berlin, Germany.	hendrik.blaeker@charite.de	Brenner, Hermann/B-4627-2017; Hoffmeister, Michael/T-7187-2019; Hoffmeister, Michael/B-5745-2012; Brenner, Hermann/ABE-6383-2020; Hoffmeister, Michael/AAB-2321-2022; Tagscherer, Katrin/AAS-3809-2021; Jansen, Lina/D-7255-2016	Brenner, Hermann/0000-0002-6129-1572; Hoffmeister, Michael/0000-0002-8307-3197; Hoffmeister, Michael/0000-0002-8307-3197; Brenner, Hermann/0000-0002-6129-1572; Hoffmeister, Michael/0000-0002-8307-3197; Tagscherer, Katrin/0000-0002-0657-6399; Jansen, Lina/0000-0001-8004-4940	German Research Council (Deutsche Forschungsgemeinschaft) [BL554/3-2, BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, CH 390 117/1-1]; German Federal Ministry of Education and Research [01KH0404, 01ER0814]; Interdisciplinary Research Program of the National Center for Tumor Diseases (NCT), Heidelberg, Germany	German Research Council (Deutsche Forschungsgemeinschaft)(German Research Foundation (DFG)); German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Interdisciplinary Research Program of the National Center for Tumor Diseases (NCT), Heidelberg, Germany	We thank the study participants and the interviewers who collected the data. We also greatly appreciate the help of the hospitals, pathology departments and cooperating institutions in recruiting patients for this study and providing tumor samples. We thank Jutta Richter, Ute Handte-Daub, Bettina Walter, Barbara Schreiber and Marina Gernold for their excellent technical assistance. H Blaker has been supported by a grant from the German Research Council (Deutsche Forschungsgemeinschaft; grant number: BL554/3-2). The DACHS study was supported by grants from the German Research Council (Deutsche Forschungsgemeinschaft, grant numbers BR 1704/6-1, BR 1704/6-3, BR 1704/6-4 and CH 390 117/1-1), the German Federal Ministry of Education and Research (grant numbers 01KH0404 and 01ER0814), and the Interdisciplinary Research Program of the National Center for Tumor Diseases (NCT), Heidelberg, Germany.	ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; Arbuzova A, 2002, BIOCHEM J, V362, P1, DOI 10.1042/0264-6021:3620001; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Brenner H, 2011, ANN INTERN MED, V154, P22, DOI 10.7326/0003-4819-154-1-201101040-00004; Brooks G, 1996, CARCINOGENESIS, V17, P683, DOI 10.1093/carcin/17.4.683; Castro F, 2013, INT J CANCER, V132, P308, DOI 10.1002/ijc.27675; Chen XY, 2010, CELL SIGNAL, V22, P1097, DOI 10.1016/j.cellsig.2010.03.003; Cho SJ, 2001, BIOCHEM BIOPH RES CO, V283, P273, DOI 10.1006/bbrc.2001.4773; Estrada-Bernal A, 2009, J CELL SCI, V122, P2300, DOI 10.1242/jcs.047860; Fassl A, 2012, ONCOGENE, V31, P4698, DOI 10.1038/onc.2011.615; Findeisen P, 2005, CANCER RES, V65, P8072, DOI 10.1158/0008-5472.CAN-04-4146; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; Hoffmeister M, 2013, CANCER EPIDEM BIOMAR, V22, P2303, DOI 10.1158/1055-9965.EPI-13-0239; Holz RW, 2000, J BIOL CHEM, V275, P17878, DOI 10.1074/jbc.M000925200; Honing S, 2005, MOL CELL, V18, P519, DOI 10.1016/j.molcel.2005.04.019; Jarboe JS, 2012, CLIN CANCER RES, V18, P3030, DOI 10.1158/1078-0432.CCR-11-3091; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; Jones SJ, 1999, J IMMUNOL, V162, P1042; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; Kim NG, 2002, ONCOGENE, V21, P5081, DOI 10.1038/sj.onc.1205703; Koh KH, 2005, LAB INVEST, V85, P1130, DOI 10.1038/labinvest.3700315; Kriegl L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051654; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Li YH, 2001, J BIOL CHEM, V276, P40982, DOI 10.1074/jbc.M105614200; Lilla C, 2006, CANCER EPIDEM BIOMAR, V15, P99, DOI 10.1158/1055-9965.EPI-05-0618; Michel S, 2010, MOL CARCINOGEN, V49, P175, DOI 10.1002/mc.20587; Miura K, 2002, MOL CELL, V9, P109, DOI 10.1016/S1097-2765(02)00428-8; Morash SC, 2005, NEUROCHEM RES, V30, P1353, DOI 10.1007/s11064-005-8220-6; Morton LA, 2013, ACS CHEM BIOL, V8, P218, DOI 10.1021/cb300429e; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; Nie ZZ, 2006, CURR BIOL, V16, P130, DOI 10.1016/j.cub.2005.11.069; Peuhu E, 2010, ONCOGENE, V29, P898, DOI 10.1038/onc.2009.386; Rombouts K, 2013, CANCER LETT, V333, P244, DOI 10.1016/j.canlet.2013.01.040; ROSE SD, 1994, J NEUROCHEM, V63, P2314; Rudolph A, 2012, BRIT J CANCER, V107, P831, DOI 10.1038/bjc.2012.323; Schmitt M, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp581; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; Shin N, 2011, INT J CANCER, V128, P2872, DOI 10.1002/ijc.25641; SIMEK SL, 1989, P NATL ACAD SCI USA, V86, P7410, DOI 10.1073/pnas.86.19.7410; Simova S, 2008, APOPTOSIS, V13, P423, DOI 10.1007/s10495-007-0171-8; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; Su R, 2010, NEUROSCI BULL, V26, P338, DOI 10.1007/s12264-010-0131-0; Sundaram M, 2004, BIOCHEM CELL BIOL, V82, P191, DOI 10.1139/o03-087; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Techasen A, 2010, CANCER SCI, V101, P658, DOI 10.1111/j.1349-7006.2009.01427.x; Wang JY, 2002, J BIOL CHEM, V277, P34401, DOI 10.1074/jbc.M203954200; Woerner SM, 2005, ONCOGENE, V24, P2525, DOI 10.1038/sj.onc.1208456; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; Yamaguchi T, 2006, DIS COLON RECTUM, V49, P399, DOI 10.1007/s10350-005-0293-4; Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961; Zhu YM, 2005, CANCER RES, V65, P4520, DOI 10.1158/0008-5472.CAN-04-4506	56	31	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1150	1159		10.1038/onc.2014.40	http://dx.doi.org/10.1038/onc.2014.40			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662837				2022-12-28	WOS:000350122100008
J	Bartucci, M; Dattilo, R; Moriconi, C; Pagliuca, A; Mottolese, M; Federici, G; Di Benedetto, A; Todaro, M; Stassi, G; Sperati, F; Amabile, MI; Pilozzi, E; Patrizii, M; Biffoni, M; Maugeri-Sacca, M; Piccolo, S; De Maria, R				Bartucci, M.; Dattilo, R.; Moriconi, C.; Pagliuca, A.; Mottolese, M.; Federici, G.; Di Benedetto, A.; Todaro, M.; Stassi, G.; Sperati, F.; Amabile, M. I.; Pilozzi, E.; Patrizii, M.; Biffoni, M.; Maugeri-Sacca, M.; Piccolo, S.; De Maria, R.			TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells	ONCOGENE			English	Article						breast cancer; cancer stem cells; chemotherapy; TAZ; metastasis	EPITHELIAL-MESENCHYMAL TRANSITION; CIRCULATING TUMOR-CELLS; IN-VITRO PROPAGATION; IDENTIFICATION; RESISTANCE; PHENOTYPE; PATHWAY; BLOOD; BONE	Metastatic growth in breast cancer (BC) has been proposed as an exclusive property of cancer stem cells (CSCs). However, formal proof of their identity as cells of origin of recurrences at distant sites and the molecular events that may contribute to tumor cell dissemination and metastasis development are yet to be elucidated. In this study, we analyzed a set of patient-derived breast cancer stem cell (BCSC) lines. We found that in vitro BCSCs exhibit a higher chemoresistance and migratory potential when compared with differentiated, nontumorigenic, breast cancer cells (dBCCs). By developing an in vivo metastatic model simulating the disease of patients with early BC, we observed that BCSCs is the only cell population endowed with metastatic potential. Gene-expression profile studies comparing metastagenic and non-metastagenic cells identified TAZ, a transducer of the Hippo pathway and biomechanical cues, as a central mediator of BCSCs metastatic ability involved in their chemoresistance and tumorigenic potential. Overexpression of TAZ in low-expressing dBCCs induced cell transformation and conferred tumorigenicity and migratory activity. Conversely, loss of TAZ in BCSCs severely impaired metastatic colonization and chemoresistance. In clinical data from 99 BC patients, high expression levels of TAZ were associated with shorter disease-free survival in multivariate analysis, thus indicating that TAZ may represent a novel independent negative prognostic factor. Overall, this study designates TAZ as a novel biomarker and a possible therapeutic target for BC.	[Bartucci, M.; Dattilo, R.; Moriconi, C.; Pagliuca, A.; Patrizii, M.; Biffoni, M.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; [Mottolese, M.; Federici, G.; Di Benedetto, A.; Sperati, F.; Maugeri-Sacca, M.; De Maria, R.] Regina Elena Inst Canc Res, Rome, Italy; [Todaro, M.; Stassi, G.] Univ Palermo, Dept Surg & Oncol Sci, Palermo, Italy; [Amabile, M. I.] Univ Roma La Sapienza, Dept Surg Sci, Rome, Italy; [Pilozzi, E.] Univ Roma La Sapienza, St Andrea Hosp, Dept Clin & Mol Med, Rome, Italy; [Piccolo, S.] Univ Padua, Sch Med, Dept Histol Microbiol & Med Biotechnol, Padua, Italy	Istituto Superiore di Sanita (ISS); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Palermo; Sapienza University Rome; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; University of Padua	Bartucci, M (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy.	monicabartucci@yahoo.com	Biffoni, Mauro/J-8318-2016; Dattilo, Rosanna/B-3014-2018; Stassi, Giorgio/AAC-1175-2022; Pagliuca, Alfredo/AAI-3689-2020; todaro, matilde/AAC-1003-2022; Dattilo, Rosanna/AAD-1910-2021; Sperati, Francesca/K-5843-2016; Federici, Giulia/K-7587-2016; De Maria, Ruggero/S-6385-2019; Maugeri-Saccà, Marcello/K-2350-2014; Federici, Giulia/AAC-8820-2019; PILOZZI, Emanuela/AAC-1854-2022; Moriconi, Chiara/B-7638-2015	Biffoni, Mauro/0000-0002-1304-9060; Dattilo, Rosanna/0000-0002-1462-5891; todaro, matilde/0000-0001-8686-8043; Sperati, Francesca/0000-0002-6038-2798; Federici, Giulia/0000-0002-4684-0270; De Maria, Ruggero/0000-0003-2255-0583; Maugeri-Saccà, Marcello/0000-0003-2287-9581; Federici, Giulia/0000-0002-4684-0270; PILOZZI, Emanuela/0000-0002-7110-9172; Di Benedetto, Anna/0000-0002-9853-8671; PICCOLO, STEFANO/0000-0002-2037-0004; Moriconi, Chiara/0000-0001-7942-2166; pagliuca, alfredo/0000-0002-8703-2077	Associazione Italiana Ricerca sul Cancro (AIRC) [IG-10254, IG 13431]	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro)	We thank Associazione Italiana Ricerca sul Cancro (AIRC) grants IG-10254 (MT) and IG 13431 (RDM) for financial support. We are grateful to Giuseppe Loreto for figure editing, Michele Signore and Mario Falchi for confocal acquisitions.	Abraham BK, 2005, CLIN CANCER RES, V11, P1154; Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333; Baccelli I, 2013, NAT BIOTECHNOL, V31, P539, DOI 10.1038/nbt.2576; Balic M, 2006, CLIN CANCER RES, V12, P5615, DOI 10.1158/1078-0432.CCR-06-0169; Bartucci M, 2012, CELL DEATH DIFFER, V19, P768, DOI 10.1038/cdd.2011.170; Bonci D, 2003, GENE THER, V10, P630, DOI 10.1038/sj.gt.3301936; Cardoso F, 2008, J CLIN ONCOL, V26, P729, DOI 10.1200/JCO.2007.14.3222; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; D'Amico L, 2013, BRIT J CANCER, V108, P2525, DOI 10.1038/bjc.2013.271; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1; Grefte S, 2012, BIOMED MATER, V7, DOI 10.1088/1748-6041/7/5/055004; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Kakarala M, 2008, J CLIN ONCOL, V26, P2813, DOI 10.1200/JCO.2008.16.3931; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; Lladser A, 2011, ADV CANCER RES, V111, P1, DOI 10.1016/B978-0-12-385524-4.00001-5; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Maugeri-Sacca M, 2011, CLIN CANCER RES, V17, P4942, DOI 10.1158/1078-0432.CCR-10-2538; Morris PG, 2009, EXPERT OPIN PHARMACO, V10, P967, DOI [10.1517/14656560902834961 , 10.1517/14656560902834961]; Pagliuca A, 2013, ONCOGENE, V32, P4806, DOI 10.1038/onc.2012.495; Perrone G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043110; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Saini V, 2010, CANCER SCI, V101, P16, DOI 10.1111/j.1349-7006.2009.01371.x; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Theodoropoulos PA, 2010, CANCER LETT, V288, P99, DOI 10.1016/j.canlet.2009.06.027; Yin D, 2010, INT J CANCER, V127, P2257, DOI 10.1002/ijc.25257; Zhao B, 2008, CURR OPIN CELL BIOL, V20, P638, DOI 10.1016/j.ceb.2008.10.001; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137	36	230	233	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					681	690		10.1038/onc.2014.5	http://dx.doi.org/10.1038/onc.2014.5			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24531710				2022-12-28	WOS:000348853800002
J	Satoyoshi, R; Kuriyama, S; Aiba, N; Yashiro, M; Tanaka, M				Satoyoshi, R.; Kuriyama, S.; Aiba, N.; Yashiro, M.; Tanaka, M.			Asporin activates coordinated invasion of scirrhous gastric cancer and cancer-associated fibroblasts	ONCOGENE			English	Article						aspirin; CAF; rac1; scirrhous gastric cancer; SLRP	GROWTH-FACTOR RECEPTOR; DOWN-REGULATION; DECORIN; PROTEOGLYCANS; EXPRESSION; PROTEIN; MYOFIBROBLASTS; METASTASIS; ROLES; CELLS	Scirrhous gastric cancer, which has the worst prognosis among the various types of gastric cancer, is highly invasive and associated with abundant stromal fibroblasts. Although cancer-associated fibroblasts (CAFs) have been proposed to generate a tumor-supportive extracellular matrix that promotes the expansion of this type of cancer, the molecular mechanisms by which CAFs assist cancer cells are not yet fully understood. Here, we show for the first time that Asporin, a small leucine-rich proteoglycan (SLRP), is predominantly expressed in CAFs, and has essential roles in promoting co-invasion of CAFs and cancer cells. CAFs of scirrhous gastric cancer possess high potential for invasion, and invasion by CAFs frequently proceeded invasion by cancer cells, both in vitro and in vivo. Expression of Asporin was induced in fibroblasts by exposure to gastric cancer cells. Asporin secreted from CAFs activates Rac1 via an interaction with CD44 and promotes invasion by CAFs themselves. Moreover, Asporin promoted invasion by neighboring cancer cells, via paracrine effects mediated by activation of the CD44-Rac1 pathway. These results suggest that Asporin is a unique SLRP that promotes progression of scirrhous gastric cancer and is required for coordinated invasion by CAFs and cancer cells. Therefore, Asporin may represent a new therapeutic target molecule for the development of drugs aimed at manipulating the cancer microenvironment.	[Satoyoshi, R.; Kuriyama, S.; Aiba, N.; Tanaka, M.] Akita Univ, Grad Sch Med, Dept Mol Med & Biochem, Akita 0108543, Japan; [Yashiro, M.] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Abeno Ku, Osaka 558, Japan	Akita University; Osaka Metropolitan University	Tanaka, M (corresponding author), Akita Univ, 1-1-1 Hondo, Akita 0108543, Japan.	mastanak@med.akita-u.ac.jp	Kuriyama, Sei/AAV-2368-2020	Kuriyama, Sei/0000-0002-5502-7177	JSPS KAKENHI [22300324, 25290042, 24700962]; MEXT KAKENHI [25111702]; National Cancer Center Research and Development Fund [23-A-9]; Grants-in-Aid for Scientific Research [24700962] Funding Source: KAKEN	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); MEXT KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); National Cancer Center Research and Development Fund(National Cancer Center - Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by JSPS KAKENHI (Grant Nos. 22300324 and 25290042; to MT, 24700962 to SK), MEXT KAKENHI 25111702 to SK and the National Cancer Center Research and Development Fund (Grant No. 23-A-9; to MT).	Chen SJ, 2013, FEBS J, V280, P2120, DOI 10.1111/febs.12136; Chong HC, 2012, J ONCOL, V2012, DOI 10.1155/2012/351089; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Duval E, 2011, MOL MED, V17, P816, DOI 10.2119/molmed.2011.00052; Edwards IJ, 2012, NAT REV UROL, V9, P196, DOI 10.1038/nrurol.2012.19; Franco OE, 2010, SEMIN CELL DEV BIOL, V21, P33, DOI 10.1016/j.semcdb.2009.10.010; Fuyuhiro Y, 2011, BRIT J CANCER, V105, P996, DOI 10.1038/bjc.2011.330; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Gruber HE, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2660; Hagiyama M, 2009, AM J PATHOL, V174, P2278, DOI 10.2353/ajpath.2009.080743; Horie M, 2012, BIOCHEM BIOPH RES CO, V423, P158, DOI 10.1016/j.bbrc.2012.05.104; Iozzo RV, 2011, J CELL MOL MED, V15, P1013, DOI 10.1111/j.1582-4934.2010.01236.x; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Karagiannis GS, 2012, MOL CANCER RES, V10, P1403, DOI 10.1158/1541-7786.MCR-12-0307; Klee EW, 2012, CLIN CHEM, V58, P599, DOI 10.1373/clinchem.2011.171637; Merline R, 2009, J CELL COMMUN SIGNAL, V3, P323, DOI 10.1007/s12079-009-0066-2; Nakajima M, 2007, J BIOL CHEM, V282, P32185, DOI 10.1074/jbc.M700522200; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; Pena C, 2013, CANCER RES, V73, P1287, DOI 10.1158/0008-5472.CAN-12-1875; Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Seidler DG, 2006, J BIOL CHEM, V281, P26408, DOI 10.1074/jbc.M602853200; Shimamura S, 2013, J BIOL CHEM, V288, P1171, DOI 10.1074/jbc.M112.386722; Sugimoto H, 2006, CANCER BIOL THER, V5, P1640, DOI 10.4161/cbt.5.12.3354; Terawaki S, 2010, EMBO J, V29, P236, DOI 10.1038/emboj.2009.323; Turashvili G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-55; Ungefroren H, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-18; Yashiro M, 2010, CANCER MICROENVIRON, V3, P127, DOI 10.1007/s12307-010-0036-5; Zhu JX, 2005, J BIOL CHEM, V280, P32468, DOI 10.1074/jbc.M503833200; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	31	70	71	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					650	660		10.1038/onc.2013.584	http://dx.doi.org/10.1038/onc.2013.584			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24441039				2022-12-28	WOS:000348853500012
J	Collins, DC; Cocchiglia, S; Tibbitts, P; Solon, G; Bane, FT; McBryan, J; Treumann, A; Eustace, A; Hennessy, B; Hill, AD; Young, LS				Collins, D. C.; Cocchiglia, S.; Tibbitts, P.; Solon, G.; Bane, F. T.; McBryan, J.; Treumann, A.; Eustace, A.; Hennessy, B.; Hill, A. D.; Young, L. S.			Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer	ONCOGENE			English	Article						human epidermal growth factor receptor; estrogen receptor; Myc; SMRT; trastuzumab; cross talk	ACQUIRED-RESISTANCE; OPEN-LABEL; REPRESSION; LAPATINIB; HER2; SENSITIVITY; MECHANISMS; INHIBITOR; COMPLEX; DRIVEN	Treatment with tyrosine kinase inhibitors (TKIs) including trastuzumab has revolutionized the management of HER2-positive breast cancer. Recent evaluation of clinical trial data suggests that a subset of HER2/ER double-positive cancers may not receive significant benefit from the TKI therapy. Here we investigate the cross talk between HER2 and ER in breast cancer and monitor the effect of trastuzumab on the tyrosine kinase effector transcription factor Myc. In HER2-positive breast cancer patients treated with neoadjuvant trastuzumab, steroid receptor-negative status (ER and PR negative) of pre-treatment biopsies predicted pathological complete response (pCR) (n = 31 patients, P = 0.0486), whereas elevated Myc protein inversely associated with pCR (P = 0.0446). Liquid chromatography mass spectrometry identified the corepressor SMRT as a novel Myc-interacting protein. Trastuzumab treatment enhanced Myc-SMRT interactions in HER2-overexpressing breast cancer cells (LCC1) and inhibited expression of the Myc target gene survivin. In HER2-low, ER-positive steroid-dominant cells (MCF7), trastuzumab therapy repressed Myc-SMRT interactions and upregulated survivin expression. Trastuzumab treatment induced ER-CBP interactions, enhanced ER transcriptional activity and upregulated expression of the ER target gene pS2. The absence of pS2 expression in pre-treatment biopsies predicted pCR to neoadjuvant trastuzumab in breast cancer patients (n = 25, P = 0.0089) and pS2 expression associated with residual cancer burden (P = 0.0196). Furthermore, metastatic tissues from patients who had failed trastuzumab therapy were pS2 positive. In HER2-overexpressing cells, trastuzumab treatment can repress Myc transcriptional activity and clinical response is favorable. However, with co-expression of the steroid pathway, this inhibition is lost and response to treatment is often poor.	[Collins, D. C.; Cocchiglia, S.; Tibbitts, P.; Solon, G.; Bane, F. T.; McBryan, J.; Hill, A. D.; Young, L. S.] Royal Coll Surgeons Ireland, Dept Surg, Dublin 2, Ireland; [Treumann, A.] Royal Coll Surgeons Ireland, Dept Mass Spectrometry Unit, Dublin 2, Ireland; [Eustace, A.; Hennessy, B.] Royal Coll Surgeons Ireland, Dept Med, Dublin 2, Ireland	Royal College of Surgeons - Ireland; Royal College of Surgeons - Ireland; Royal College of Surgeons - Ireland	Young, LS (corresponding author), Royal Coll Surgeons Ireland, Dept Surg, York House,York St, Dublin 2, Ireland.	lyoung@rcsi.ie		Hennessy, Bryan/0000-0002-7871-6477; McBryan, Jean/0000-0002-7568-2208; Eustace, Alex/0000-0002-4092-1360; Treumann, Achim/0000-0002-9417-3505	Science Foundation Ireland [08-IN1-B1853]; Health Research Board of Ireland [HRB/POR/2012/101]; Irish Cancer Society Collaborative Cancer Research Centre grant [CCRC13GAL]	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Health Research Board of Ireland; Irish Cancer Society Collaborative Cancer Research Centre grant	We thank Lance Hudson for his technical expertise and thank Dr Robert Clarke, Georgetown, Washington, for his kind gift of the LCC1 cells. We kindly acknowledge the funding support from Science Foundation Ireland (08-IN1-B1853) and the Health Research Board of Ireland (HRB/POR/2012/101). This material is also based on works supported by the Irish Cancer Society Collaborative Cancer Research Centre grant, CCRC13GAL.	Adams BD, 2009, MOL ENDOCRINOL, V23, P1215, DOI 10.1210/me.2009-0062; Baselga J, 2012, LANCET, V379, P633, DOI 10.1016/S0140-6736(11)61847-3; Brennan K, 2013, ONCOGENE, V32, P2799, DOI 10.1038/onc.2012.276; Chakrabarty A, 2013, CANCER RES, V73, P1190, DOI 10.1158/0008-5472.CAN-12-2440; Chen FL, 2008, CLIN CANCER RES, V14, P6730, DOI 10.1158/1078-0432.CCR-08-0581; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; Coombes RC, 2013, ANN ONCOL, V24, P924, DOI 10.1093/annonc/mds594; Cosgrave N, 2006, J MOL ENDOCRINOL, V37, P377, DOI 10.1677/jme.1.02118; Guarneri V, 2012, J CLIN ONCOL, V30, P1989, DOI 10.1200/JCO.2011.39.0823; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Kim C, 2005, BREAST CANCER RES TR, V94, pS6; Leary AF, 2010, CLIN CANCER RES, V16, P1486, DOI 10.1158/1078-0432.CCR-09-1764; Lobo VJSA, 2013, ONCOGENE, V32, P5261, DOI 10.1038/onc.2012.621; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; McBryan J, 2012, CANCER RES, V72, P548, DOI 10.1158/0008-5472.CAN-11-2073; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nahta R, 2012, BREAST CANCER RES TR, V135, P39, DOI 10.1007/s10549-012-2067-8; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Peck B, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00096; Perez EA, 2011, J CLIN ONCOL, V29, P651, DOI 10.1200/JCO.2010.30.2125; Pinzone JJ, 2004, MOL CELL BIOL, V24, P4605, DOI 10.1128/MCB.24.11.4605-4612.2004; Rexer Brent N., 2012, Critical Reviews in Oncogenesis, V17, P1; Sabnis G, 2009, CANCER RES, V69, P1416, DOI 10.1158/0008-5472.CAN-08-0857; Sankar N, 2008, ONCOGENE, V27, P5717, DOI 10.1038/onc.2008.181; Stoica A, 2000, J ENDOCRINOL, V165, P371, DOI 10.1677/joe.0.1650371; Xia W, 2006, P NATL ACAD SCI USA, V103, P7795, DOI 10.1073/pnas.0602468103	26	18	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					525	530		10.1038/onc.2013.586	http://dx.doi.org/10.1038/onc.2013.586			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24469058				2022-12-28	WOS:000348451300013
J	Bhattacharyya, S; Feferman, L; Tobacman, JK				Bhattacharyya, S.; Feferman, L.; Tobacman, J. K.			Arylsulfatase B regulates versican expression by galectin-3 and AP-1 mediated transcriptional effects	ONCOGENE			English	Article						chondroitin sulfate; arylsulfatase B; galectin-3; versican; glycosaminoglycan	FORMYLGLYCINE-GENERATING ENZYME; GROWTH-FACTOR RECEPTOR; STAGE PROSTATE-CANCER; EPITHELIAL-CELLS; BINDING SITE; IN-VITRO; ACTIVATION; N-ACETYLGALACTOSAMINE-4-SULFATASE; OVEREXPRESSION; PROGRESSION	Arylsulfatase B (N-acetylgalactosamine-4-sulfatase; ARSB) removes 4-sulfate groups from chondroitin-4-sulfate (C4S) and dermatan sulfate and is required for their degradation. In human prostate stromal and epithelial cells, when ARSB was silenced, C4S, versican and versican promoter activity increased, and the galectin-3 that co-immunoprecipitated with C4S declined. Galectin-3 silencing inhibited the ARSB-silencing-induced increases in versican and versican promoter due to effects on the AP-1-binding site in the versican promoter. These findings demonstrate for the first time the transcriptional mechanism whereby ARSB can regulate expression of an extracellular matrix proteoglycan with C4S attachments. In addition, following ARSB silencing, C4S that co-immunoprecipitated with versican increased, whereas co-immunoprecipitated EGFR declined, total EGFR increased and exogenous EGF-induced cell proliferation increased, suggesting profound effects of ARSB on vital cell processes.	[Bhattacharyya, S.; Feferman, L.; Tobacman, J. K.] Univ Illinois, Dept Med, Chicago, IL 60612 USA; [Bhattacharyya, S.; Feferman, L.; Tobacman, J. K.] Jesse Brown VA Med Ctr, Chicago, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Tobacman, JK (corresponding author), Univ Illinois, Dept Med, 840 South Wood St,CSN 440 M-C 718, Chicago, IL 60612 USA.	jkt@uic.edu			NCRR NIH HHS [UL1 RR029879] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR029879] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bhattacharyya S, 2008, J BIOL CHEM, V283, P9523, DOI 10.1074/jbc.M707967200; Bhattacharyya S, 2008, J NUTR, V138, P469, DOI 10.1093/jn/138.3.469; Bhattacharyya S, 2007, CLIN CHIM ACTA, V380, P122, DOI 10.1016/j.cca.2007.01.021; Bhattacharyya S, 2007, J STEROID BIOCHEM, V103, P20, DOI 10.1016/j.jsbmb.2006.08.002; Bhattacharyya S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033250; Bhattacharyya S, 2010, BBA-MOL BASIS DIS, V1802, P472, DOI 10.1016/j.bbadis.2010.01.014; Bhattacharyya S, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-303; Bhattacharyya S, 2010, AM J RESP CELL MOL, V42, P51, DOI 10.1165/rcmb.2008-0482OC; Bhattacharyya S, 2009, CLIN EXP METASTAS, V26, P535, DOI 10.1007/s10585-009-9253-z; Christianson TM, 2004, BIOCHEM J, V382, P581, DOI 10.1042/BJ20040447; Domenzain-Reyna C, 2009, J BIOL CHEM, V284, P12306, DOI 10.1074/jbc.M807108200; Du WW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013828; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; Feferman L, 2013, PROSTATE CANCER P D, V16, P277, DOI 10.1038/pcan.2013.18; Ferrero GB, 2008, MOL GENET METAB, V94, P139, DOI 10.1016/j.ymgme.2007.10.010; Hann A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020859; Harmatz P, 2004, J PEDIATR-US, V144, P574, DOI 10.1016/j.jpeds.2004.03.018; Holzberg D, 2003, J BIOL CHEM, V278, P40213, DOI 10.1074/jbc.M304058200; Iwaki J, 2008, BIOCHEM BIOPH RES CO, V373, P206, DOI 10.1016/j.bbrc.2008.05.190; Kischel P, 2010, INT J CANCER, V126, P640, DOI 10.1002/ijc.24812; Kotlo K, 2013, GLYCOCONJUGATE J, V30, P667, DOI 10.1007/s10719-013-9468-8; Mitsunaga-Nakatsubo K, 2009, MED MOL MORPHOL, V42, P63, DOI 10.1007/s00795-009-0447-x; Prabhu SV, 2011, J HISTOCHEM CYTOCHEM, V59, P328, DOI 10.1369/0022155410395511; Rao GJ, 1994, BIOCHIM BIOPHYS ACTA, V788, P58; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; Ricciardelli C, 1997, CLIN CANCER RES, V3, P983; Ricciardelli C, 1998, CLIN CANCER RES, V4, P963; Ricciardelli C, 2009, CANCER METAST REV, V28, P233, DOI 10.1007/s10555-009-9182-y; Roeser D, 2006, P NATL ACAD SCI USA, V103, P81, DOI 10.1073/pnas.0507592102; Roeser D, 2007, ACTA CRYSTALLOGR D, V63, P621, DOI 10.1107/S0907444907009961; Sakko AJ, 2003, CANCER RES, V63, P4786; Sharma G, 2013, PEDIATR PULM, V48, P236, DOI 10.1002/ppul.22567; Song SM, 2005, GASTROENTEROLOGY, V129, P1581, DOI 10.1053/j.gastro.2005.09.002; Wang H, 2008, J CELL SCI, V121, P3083, DOI 10.1242/jcs.032649; WANG L, 1995, BIOCHEM BIOPH RES CO, V217, P292, DOI 10.1006/bbrc.1995.2777; Wang Y, 2009, AM J PATHOL, V174, P1515, DOI 10.2353/ajpath.2009.080816; WOJCZYK B, 1986, BIOL CELL, V57, P147, DOI 10.1111/j.1768-322X.1986.tb00471.x; Wu YJ, 2004, J CELL SCI, V117, P2227, DOI 10.1242/jcs.01057; Xiang YY, 2006, J BIOL CHEM, V281, P19358, DOI 10.1074/jbc.M512980200; Yoo BC, 2009, CELL MOL LIFE SCI, V66, P350, DOI 10.1007/s00018-009-8562-3; Yoo M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057415	41	23	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2014	33	47					5467	5476		10.1038/onc.2013.483	http://dx.doi.org/10.1038/onc.2013.483			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MG	24240681	Green Accepted			2022-12-28	WOS:000345120700009
J	Lai, WL; Hung, WY; Ching, YP				Lai, W. L.; Hung, W. Y.; Ching, Y. P.			The tumor suppressor, TAX1BP2, is a novel substrate of ATM kinase	ONCOGENE			English	Article						ATM; TAX1BP2; HCC and phosphorylation	DNA-DAMAGE; HEPATOCELLULAR-CARCINOMA; PROTEIN; P53; PHOSPHORYLATION; ACTIVATION; CANCER; IDENTIFICATION	DNA damage repair response is a crucial process for cancer prevention. One of the key regulators of this process is ataxia telangiectasia mutated (ATM) kinase, which modulates the p53 level by direct and indirect phosphorylation. Recent data showed that ATM also localizes at the centrosome, but the function remains elusive. TAX1BP2 was initially identified as a novel centrosomal protein that interacts directly with the human T-cell leukemia virus type 1 (HTLV-1)-encoded oncoprotein, Tax, and inhibits centrosome overduplication. Subsequently, TAX1BP2 was found to be a tumor suppressor in hepatocellular carcinoma, and accumulation of TAX1BP2 was observed upon chemotherapeutic drug treatment. Here, we provide evidence that TAX1BP2 is a direct phosphorylation substrate of ATM. The protein level of TAX1BP2 is significantly upregulated in response to DNA damaging agents. Serine-922 of TAX1BP2 is the phosphorylation site of ATM, and such phosphorylation modulates the protein stability, ubiquitination and tumor suppressor activity of TAX1BP2. Taken together, we demonstrate for the first time that TAX1BP2 is a novel effector of ATM in DNA damage response and delineated a new mechanism by which ATM stabilizes the tumor suppressor TAX1BP2.	[Lai, W. L.; Hung, W. Y.; Ching, Y. P.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Pokfulam, Hong Kong, Peoples R China; [Ching, Y. P.] Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Hong Kong, Peoples R China; [Ching, Y. P.] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Ching, YP (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Room L1-43,Fac Med Bldg, Pokfulam, Hong Kong, Peoples R China.	ypching@hku.hk		CHING, Yick Pang/0000-0002-6461-8358	Hong Kong Health and Medical Research Fund [12110872]; Hong Kong Research Grant Council (HKU) [763509, 7/CRF/09]; SK Yee Medical Research Fund; University of Hong Kong [201209176008]	Hong Kong Health and Medical Research Fund; Hong Kong Research Grant Council (HKU)(University of Hong KongHong Kong Research Grants Council); SK Yee Medical Research Fund; University of Hong Kong(University of Hong Kong)	We are very grateful to Prof Jin DY for providing the HA-p38-expressing plasmid, Prof SW Tsao for providing the anti-Chk1 and anti-Chk2 antibodies and Dr MS Huen for providing the FLAG-ubiquitin-expressing plasmid. Financial support was received from the Hong Kong Health and Medical Research Fund (No. 12110872), the Hong Kong Research Grant Council (HKU 763509 and 7/CRF/09), the SK Yee Medical Research Fund 2011 (to YPC) and The University of Hong Kong (Small Project Funding 201209176008 to WLL).	Asghar U, 2012, J HEPATOL, V56, P686, DOI 10.1016/j.jhep.2011.07.031; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Ching YP, 2007, CANCER RES, V67, P3601, DOI 10.1158/0008-5472.CAN-06-3994; Ching YP, 2006, NAT CELL BIOL, V8, P717, DOI 10.1038/ncb1432; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Ikeda F, 2010, CELL, V143, P677, DOI 10.1016/j.cell.2010.10.026; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lai WL, 2012, HEPATOLOGY, V56, P1770, DOI 10.1002/hep.25851; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; Nigg EA, 2011, NAT CELL BIOL, V13, P1154, DOI 10.1038/ncb2345; Teoh N, 2010, GASTROENTEROLOGY, V138, P1155, DOI 10.1053/j.gastro.2009.11.008; Wysocki PJ, 2010, EXPERT OPIN INV DRUG, V19, P265, DOI 10.1517/13543780903514110; Zhang SS, 2007, J CELL BIOCHEM, V101, P451, DOI 10.1002/jcb.21195	16	2	2	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2014	33	45					5303	5309		10.1038/onc.2013.481	http://dx.doi.org/10.1038/onc.2013.481			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MD	24240686				2022-12-28	WOS:000345120400008
J	Sagoo, MS; Harbour, JW; Stebbing, J; Bowcock, AM				Sagoo, M. S.; Harbour, J. W.; Stebbing, J.; Bowcock, A. M.			Combined PKC and MEK inhibition for treating metastatic uveal melanoma	ONCOGENE			English	Editorial Material							SOMATIC MUTATIONS; GNAQ; SF3B1	Uveal melanoma (UM) is the most common primary intraocular malignancy and the second most common form of melanoma. UM has a strong tendency for metastatic disease, and no effective treatments have yet been identified. Activating oncogenic mutations are commonly found in GNAQ and GNA11 in UM, and inhibiting key downstream effectors of the GNAQ/11 signaling pathway represents a rational therapeutic approach for treating metastatic UM. Chen et al., doi:10.1038/onc.2013.418, now confirm activation of the MAPK and PKC pathways as a result of GNAQ and GNA11 activating mutations in melanocytes, and they demonstrate that MAPK activation occurs downstream of PKC activation. PKC inhibitors disrupt MAPK signaling and block proliferation of GNAQ/11 mutant UM cell lines and slow the in vivo growth of xenografted UM tumors without inducing their shrinkage. However, a combination of PKC and MEK inhibition led to sustained MAPK pathway inhibition and tumor regression in vivo. Hence, the authors concluded that MEK and PKC inhibition is synergistic, with superior efficacy to treatment of GNAQ/GNA11 mutant UMs with either drug alone.	[Sagoo, M. S.] Moorfields Eye Hosp, Ocular Oncol Serv, London, England; [Sagoo, M. S.] St Bartholomews Hosp, London, England; [Sagoo, M. S.] UCL Inst Ophthalmol, London, England; [Harbour, J. W.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst & Sylvester Comprehens Can, Ocular Oncol Serv, Miami, FL 33136 USA; [Stebbing, J.] Univ London Imperial Coll Sci Technol & Med, Dept Oncol, London SW3 6LY, England; [Bowcock, A. M.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England	University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; University of London; Queen Mary University London; University of London; University College London; Bascom Palmer Eye Institute; University of Miami; Imperial College London; Imperial College London	Bowcock, AM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Guy Scadding Bldg,Royal Brompton Campus, London SW3 6LY, England.	a.bowcock@imperial.ac.uk	Harbour, J. William/B-1448-2015	Harbour, J. William/0000-0002-1104-9809; Stebbing, Justin/0000-0002-1117-6947; Sagoo, Mandeep/0000-0003-1530-3824; Bowcock, Anne/0000-0001-8691-9090	NATIONAL CANCER INSTITUTE [R01CA125970] Funding Source: NIH RePORTER; Cancer Research UK [14549] Funding Source: researchfish; National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish; NCI NIH HHS [R01 CA125970, 1R01 CA16187001, 5R01 CA12597007] Funding Source: Medline; Department of Health [NIHR-RP-011-053] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Health		Chen X, 2014, ONCOGENE, V33, P4724, DOI 10.1038/onc.2013.418; Harbour J William, 2013, Am Soc Clin Oncol Educ Book, P388, DOI 10.1200/EdBook_AM.2013.33.388; Harbour JW, 2013, NAT GENET, V45, P133, DOI 10.1038/ng.2523; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Ho AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040439; Khalili JS, 2012, CLIN CANCER RES, V18, P4345, DOI 10.1158/1078-0432.CCR-11-3227; Landreville S, 2012, CLIN CANCER RES, V18, P408, DOI 10.1158/1078-0432.CCR-11-0946; Martin M, 2013, NAT GENET, V45, P933, DOI 10.1038/ng.2674; Onken MD, 2008, INVEST OPHTH VIS SCI, V49, P5230, DOI 10.1167/iovs.08-2145; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Wu XQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029622; Zuidervaart W, 2005, BRIT J CANCER, V92, P2032, DOI 10.1038/sj.bjc.6602598	13	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2014	33	39					4722	4723		10.1038/onc.2013.555	http://dx.doi.org/10.1038/onc.2013.555			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0ED	24413085	Green Accepted			2022-12-28	WOS:000343239500002
J	Lee, IH; Sohn, M; Lim, HJ; Yoon, S; Oh, H; Shin, S; Shin, JH; Oh, SH; Kim, J; Lee, DK; Noh, DY; Bae, DS; Seong, JK; Bae, YS				Lee, I. H.; Sohn, M.; Lim, H. J.; Yoon, S.; Oh, H.; Shin, S.; Shin, J. H.; Oh, S-H; Kim, J.; Lee, D. K.; Noh, D. Y.; Bae, D. S.; Seong, J. K.; Bae, Y. S.			Ahnak functions as a tumor suppressor via modulation of TGF beta/Smad signaling pathway	ONCOGENE			English	Article							MAMMARY-GLAND DEVELOPMENT; C-MYC; BETA; PROTEIN; IDENTIFICATION; TARGET; GENE; PHOSPHATASE; COMPLEX	We provide detailed mechanisms of Ahnak-mediated potentiation of transforming growth factor beta (TGF beta) signaling, which leads to a negative regulation of cell growth. We show that Smad3 interacts with Ahnak through MH2 domain and that Ahnak stimulates Smad3 localization into nucleus leading to potentiating TGF beta-induced transcriptional activity of R-Smad. Moreover, overexpression of Ahnak resulted in growth retardation and cell cycle arrest through downregulation of c-Myc and cyclin D1/D2. We describe results from analyses of Ahnak(-/-) mouse model expressing middle T antigen in a mammary gland-specific manner (MMTVTg/+ Ahnak(-/-)), which showed significantly progressed hyperplasia of mammary glands compared with MMTVTg/+ Ahnak(+/+). Finally, we screened multiple human breast cancer tissues and showed that the expression of Ahnak in cancer tissues is lower than that in control tissues by 50%. Taken together, these data indicate that Ahnak mediates a negative regulation of cell growth and acts as novel tumor suppressor through potentiation of TGF beta signaling.	[Lee, I. H.; Sohn, M.; Lim, H. J.; Yoon, S.; Oh, H.; Shin, S.; Kim, J.; Lee, D. K.; Bae, Y. S.] Ewha Womans Univ, Dept Life Sci, Seoul, South Korea; [Lee, I. H.; Sohn, M.; Lim, H. J.; Yoon, S.; Oh, H.; Shin, S.; Kim, J.; Lee, D. K.; Bae, Y. S.] Ewha Womans Univ, GT5 program, Seoul, South Korea; [Shin, J. H.; Seong, J. K.] Seoul Natl Univ, Coll Vet Med, Lab Dev Biol & Genom, Seoul 151742, South Korea; [Oh, S-H] Gachon Univ, Coll Pharm, Inchon, South Korea; [Noh, D. Y.] Seoul Natl Univ, Sch Med, Dept Surg, Seoul 151742, South Korea; [Bae, D. S.] Sungkyunkwan Univ, Samsung Hosp, Dept Obstet & Gynecol, Seoul, South Korea	Ewha Womans University; Ewha Womans University; Seoul National University (SNU); Gachon University; Seoul National University (SNU); Sungkyunkwan University (SKKU); Samsung Medical Center	Seong, JK (corresponding author), Seoul Natl Univ, Coll Vet Med, Lab Dev Biol & Genom, Seoul 151742, South Korea.	snumouse@snu.ac.kr; baeys@ewha.ac.kr	LEE, IN HYE/T-2714-2019	LEE, IN HYE/0000-0003-2334-3594; Seong, Je Kyung/0000-0003-1177-6958; Lee, Daekee/0000-0001-8130-2059	National Research Foundation of Korea (NRF) grant [2012R1A5A1048236]; Drug Target Validation program [20090093987]; Bio & Medical Technology Development Program [2012M3A9B4028785]; Redoxomics grant - Ministry of Science, ICT & Future Planning [2012M3A9C5048708]; Ewha Womans University Research Grant	National Research Foundation of Korea (NRF) grant; Drug Target Validation program; Bio & Medical Technology Development Program; Redoxomics grant - Ministry of Science, ICT & Future Planning; Ewha Womans University Research Grant	This work was supported by the National Research Foundation of Korea (NRF) grant (No. 2012R1A5A1048236), by the Drug Target Validation program (No. 20090093987), by the Bio & Medical Technology Development Program (No. 2012M3A9B4028785) and by Redoxomics grant (No. 2012M3A9C5048708) funded by Ministry of Science, ICT & Future Planning, and the Ewha Womans University Research Grant of 2013 (to I.H.L.).	Briones-Orta Marco A, 2011, Curr Mol Pharmacol, V4, P141; Conidi A, 2011, CYTOKINE GROWTH F R, V22, P287, DOI 10.1016/j.cytogfr.2011.11.006; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Florenes VA, 1996, ONCOGENE, V13, P2447; Forrester E, 2005, CANCER RES, V65, P2296, DOI 10.1158/0008-5472.CAN-04-3272; Gentil BJ, 2001, J BIOL CHEM, V276, P23253, DOI 10.1074/jbc.M010655200; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Haase H, 1999, FASEB J, V13, P2161, DOI 10.1096/fasebj.13.15.2161; HASHIMOTO T, 1995, EXP CELL RES, V217, P258, DOI 10.1006/excr.1995.1085; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heldin CH, 2012, CELL TISSUE RES, V347, P21, DOI 10.1007/s00441-011-1190-x; Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021; Hohaus A, 2002, FASEB J, V16, DOI 10.1096/fj.01-0855com; Jackson R, 2013, VIROLOGY, V435, P425, DOI 10.1016/j.virol.2012.09.032; Kang JS, 2009, TRENDS CELL BIOL, V19, P385, DOI 10.1016/j.tcb.2009.05.008; Lee IH, 2004, J BIOL CHEM, V279, P26645, DOI 10.1074/jbc.M311525200; Lee IH, 2008, J BIOL CHEM, V283, P6312, DOI 10.1074/jbc.M706878200; Lim HJ, 2013, CARDIOVASC RES, V97, P302, DOI 10.1093/cvr/cvs311; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Morikawa M, 2013, ONCOGENE, V32, P1609, DOI 10.1038/onc.2012.191; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Scollen S, 2011, CANCER EPIDEM BIOMAR, V20, P1112, DOI 10.1158/1055-9965.EPI-11-0062; SEEDORF K, 1987, EMBO J, V6, P139, DOI 10.1002/j.1460-2075.1987.tb04731.x; Sekiya F, 1999, J BIOL CHEM, V274, P13900, DOI 10.1074/jbc.274.20.13900; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; SHTIVELMAN E, 1993, J CELL BIOL, V120, P625, DOI 10.1083/jcb.120.3.625; SHTIVELMAN E, 1992, P NATL ACAD SCI USA, V89, P5472, DOI 10.1073/pnas.89.12.5472; Sundqvist A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3066; Tarasewicz E, 2012, CELL CYCLE, V11, P2443, DOI 10.4161/cc.20546; Wang CG, 2011, CELL CYCLE, V10, P57, DOI 10.4161/cc.10.1.14449; Zhang SP, 2007, MOL CELL BIOL, V27, P4488, DOI 10.1128/MCB.01636-06; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	35	83	84	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2014	33	38					4675	4684		10.1038/onc.2014.69	http://dx.doi.org/10.1038/onc.2014.69			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3VX	24662814	Green Published, hybrid			2022-12-28	WOS:000342007200006
J	Sacco, JJ; Yau, TY; Darling, S; Patel, V; Liu, H; Urbe, S; Clague, MJ; Coulson, JM				Sacco, J. J.; Yau, T. Y.; Darling, S.; Patel, V.; Liu, H.; Urbe, S.; Clague, M. J.; Coulson, J. M.			The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells	ONCOGENE			English	Article						deubiquitinase; ATXN3; phosphatase and tensin homolog; PTENP1; ceRNA; MJD	DEUBIQUITINATING ENZYME ATAXIN-3; TUMOR-SUPPRESSOR PTEN; PROTEIN STABILITY; PROSTATE-CANCER; DISEASE PROTEIN; MESSENGER-RNAS; IN-VIVO; UBIQUITINATION; EXPRESSION; MICE	The phosphatidylinositol-3-kinase (PI3K) pathway is commonly hyperactivated in cancer. One mechanism by which this occurs is by silencing of the phosphatase and tensin homolog (PTEN), a tumor suppressor and major antagonist of the pathway, through genetic, epigenetic or posttranscriptional mechanisms. Here, we used an unbiased siRNA screen in non-small-cell lung cancer cells to identify deubiquitylases (DUBs) that have an impact on PI3K signaling by regulating the abundance of PTEN. We found that PTEN expression was induced by depleting any of three members of the Josephin family DUBs: ataxin 3 (ATXN3), ataxin 3-like (ATXN3L) and Josephin domain containing 1 (JOSD1). However, this effect is not mediated through altered PTEN protein stability. Instead, depletion of each DUB increases expression of both the PTEN transcript and its competing endogenous RNA, PTENP1. In ATXN3-depleted cells, under conditions of transcriptional inhibition, PTEN and PTENP1 mRNAs rapidly decay, suggesting that ATXN3 acts primarily by repressing their transcription. Importantly, the PTEN induction observed in response to ATXN3 siRNA is sufficient to downregulate Akt phosphorylation and hence PI3K signaling. Histone deacetylase inhibitors (HDACi) have been suggested as potential mediators of PTEN transcriptional reactivation in non-small-cell lung cancer. Although PTEN exhibits a very limited response to the broad-spectrum HDACi Vorinostat (SAHA) in A549 cells, we find that combination with ATXN3 depletion enhances PTEN induction in an additive manner. Similarly, these interventions additively decrease cell viability. Thus, ATXN3 provides an autonomous, complementary therapeutic target in cancers with epigenetic downregulation of PTEN.	[Sacco, J. J.; Yau, T. Y.; Darling, S.; Patel, V.; Liu, H.; Urbe, S.; Clague, M. J.; Coulson, J. M.] Univ Liverpool, Inst Translat Med, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Coulson, JM (corresponding author), Univ Liverpool, Inst Translat Med, Crown St, Liverpool L69 3BX, Merseyside, England.	j.m.coulson@liv.ac.uk	Urbe, Sylvie/S-1433-2018; Clague, Michael J/A-7199-2008	Urbe, Sylvie/0000-0003-4735-9814; Clague, Michael J/0000-0003-3355-9479; Liu, Han/0000-0002-0014-4675; Coulson, Judy/0000-0003-2191-2001	North-West Cancer Research; Clatterbridge Cancer Charity; Wellcome Trust	North-West Cancer Research; Clatterbridge Cancer Charity; Wellcome Trust(Wellcome TrustEuropean Commission)	This work was funded by a project grant from Clatterbridge Cancer Research (now incorporated into North-West Cancer Research) and Clatterbridge Cancer Charity. Sarah Darling is supported by a Wellcome Trust Prize studentship. We thank Paul Todd for his input into initial phospho-Akt experiments.	Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; Amodio N, 2010, AM J PATHOL, V177, P2622, DOI 10.2353/ajpath.2010.091075; Andersen CL, 2013, LEUKEMIA RES REPORTS, V2, P1; Buus R, 2009, CURR BIOL, V19, P1463, DOI 10.1016/j.cub.2009.07.040; Cai JC, 2013, CANCER RES, V73, P5402, DOI 10.1158/0008-5472.CAN-13-0297; Clague MJ, 2013, PHYSIOL REV, V93, P1289, DOI 10.1152/physrev.00002.2013; Clague MJ, 2012, J CELL SCI, V125, P277, DOI 10.1242/jcs.090985; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Evert BO, 2006, J NEUROSCI, V26, P11474, DOI 10.1523/JNEUROSCI.2053-06.2006; Gan YH, 2009, ORAL ONCOL, V45, pE150, DOI 10.1016/j.oraloncology.2009.05.563; Gorski JJ, 2007, EMBO J, V26, P1560, DOI 10.1038/sj.emboj.7601601; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Jin G, 2010, LUNG CANCER, V69, P279, DOI 10.1016/j.lungcan.2009.11.012; Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032; Leslie NR, 2011, TRENDS PHARMACOL SCI, V32, P131, DOI 10.1016/j.tips.2010.12.005; Li FS, 2002, J BIOL CHEM, V277, P45004, DOI 10.1074/jbc.M205259200; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Maddika S, 2011, NAT CELL BIOL, V13, P728, DOI 10.1038/ncb2240; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mao JH, 2008, SCIENCE, V321, P1499, DOI 10.1126/science.1162981; Marks PA, 2007, ONCOGENE, V26, P1351, DOI 10.1038/sj.onc.1210204; Moss AC, 2009, CLIN CANCER RES, V15, P274, DOI 10.1158/1078-0432.CCR-08-1163; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Omerovic J, 2010, BIOCHEM J, V426, P65, DOI 10.1042/BJ20091413; Pan LN, 2007, CANCER, V109, P1676, DOI 10.1002/cncr.22585; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526; Rodriguez-Lebron E, 2013, MOL THER, V21, P1909, DOI 10.1038/mt.2013.152; Sacco JJ, 2010, IUBMB LIFE, V62, P140, DOI 10.1002/iub.300; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Seki T, 2013, J BIOL CHEM, V288, P17145, DOI 10.1074/jbc.M113.463406; Song EJ, 2010, GENE DEV, V24, P1434, DOI 10.1101/gad.1925010; Song MS, 2008, NATURE, V455, P813, DOI 10.1038/nature07290; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Soria JC, 2002, CLIN CANCER RES, V8, P1178; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tay Y, 2011, CELL, V147, P344, DOI 10.1016/j.cell.2011.09.029; Todi SV, 2009, EMBO J, V28, P372, DOI 10.1038/emboj.2008.289; Van Themsche C, 2009, J BIOL CHEM, V284, P20462, DOI 10.1074/jbc.C109.009522; Vasudevan KM, 2004, MOL CELL BIOL, V24, P1007, DOI 10.1128/MCB.24.3.1007-1021.2004; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Wang HL, 2013, NEUROPHARMACOLOGY, V70, P1, DOI 10.1016/j.neuropharm.2013.01.006; Weeks SD, 2011, J BIOL CHEM, V286, P4555, DOI 10.1074/jbc.M110.177360; Winborn BJ, 2008, J BIOL CHEM, V283, P26436, DOI 10.1074/jbc.M803692200; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Yang Y, 2009, J CELL BIOCHEM, V106, P1102, DOI 10.1002/jcb.22100; Yim EK, 2009, CANCER CELL, V15, P304, DOI 10.1016/j.ccr.2009.02.012	55	44	48	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2014	33	33					4265	4272		10.1038/onc.2013.512	http://dx.doi.org/10.1038/onc.2013.512			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MB	24292675	hybrid, Green Published			2022-12-28	WOS:000341155800008
J	Tan, J; Buache, E; Alpy, F; Daguenet, E; Tomasetto, CL; Ren, GS; Rio, MC				Tan, J.; Buache, E.; Alpy, F.; Daguenet, E.; Tomasetto, C-L; Ren, G-S; Rio, M-C			Stromal matrix metalloproteinase-11 is involved in the mammary gland postnatal development	ONCOGENE			English	Article						mammary gland postnatal development; breast cancer; epithelial-stromal cell crosstalk/interaction; MMP-11; collagen; paracrine function	BRANCHING MORPHOGENESIS; EXTRACELLULAR-MATRIX; DUCTAL MORPHOGENESIS; SIGNALING PATHWAYS; CANCER-CELLS; COLLAGEN-VI; C5 DOMAIN; IN-VIVO; END BUD; STROMELYSIN-3	MMP-11 is a bad prognosis paracrine factor in invasive breast cancers. However, its mammary physiological function remains largely unknown. In the present study we have investigated MMP-11 function during postnatal mammary gland development and function using MMP-11-deficient (MMP-11-/-) mice. Histological and immunohistochemical analyses as well as whole-mount mammary gland staining show alteration of the mammary gland in the absence of MMP-11, where ductal tree, alveolar structures and milk production are reduced. Moreover, a series of transplantation experiments allowed us to demonstrate that MMP-11 exerts an essential local paracrine function that favors mammary gland branching and epithelial cell outgrowth and invasion through adjacent connective tissues. Indeed, MMP-11-/- cleared fat pads are not permissive for wild-type epithelium development, whereasMMP-11-/- epithelium transplants grow normally when implanted in wild-type cleared fat pads. In addition, using primary mammary epithelial organoids, we show in vitro that this MMP-11 pro-branching effect is not direct, suggesting that MMP11 acts via production/release of stroma-associated soluble factor(s). Finally, the lack of MMP-11 leads to decreased periductal collagen content, suggesting that MMP-11 has a role in collagen homeostasis. Thus, local stromal MMP-11 might also regulate mammary epithelial cell behavior mechanically by promoting extracellular matrix stiffness. Collectively, the present data indicate that MMP-11 is a paracrine factor involved during postnatal mammary gland morphogenesis, and support the concept that the stroma strongly impact epithelial cell behavior. Interestingly, stromal MMP-11 has previously been reported to favor malignant epithelial cell survival and promote cancer aggressiveness. Thus, MMP-11 has a paracrine function during mammary gland development that might be harnessed to promote tumor progression, exposing a new link between development and malignancy.	[Tan, J.; Buache, E.; Alpy, F.; Daguenet, E.; Tomasetto, C-L; Rio, M-C] Univ Strasbourg, Inst Natl Sante & Rech Med U964, Ctr Natl Rech Sci UMR 7104, Inst Genet & Biol Mol & Cellulaire,Dept Funct Gen, Strasbourg, France; [Tan, J.; Ren, G-S] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, Chongqing, Peoples R China; [Rio, M-C] Equipe Labellise Ligue Natl Canc, Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Chongqing Medical University	Rio, MC (corresponding author), IGBMC, INSERM U964, CNRS UMR 7104, Inst Genet & Biol Mol & Cellulaire, 1 Rue L Fries,BP 10142, F-67404 Illkirch Graffenstaden, France.	rio@igbmc.fr	Daguenet, Elisabeth/N-4122-2019; Tomasetto, Catherine Laure/J-2783-2014; Alpy, Fabien/ABD-5893-2020; Daguenet, Elisabeth/K-5507-2015; Alpy, Fabien/H-8941-2016	Daguenet, Elisabeth/0000-0002-6101-1016; Tomasetto, Catherine Laure/0000-0002-1811-5848; Alpy, Fabien/0000-0002-0526-0720; Daguenet, Elisabeth/0000-0002-6101-1016; Alpy, Fabien/0000-0002-0526-0720	Institut National de la Sante et de la Recherche Medicale; Centre National de la Recherche Scientifique; Hopital Universitaire de Strasbourg; Association pour la Recherche sur le Cancer; Ligue Nationale Francaise Contre le Cancer (LNCC; Comites du Haut-Rhin, Bas-Rhin et de la Haute-Savoie); Institut National du Cancer (INCA PL-BIO ADIPOK); Chinese fellowship of National Natural Science Foundation of China [81102008]; LNCC; INCA fellowships	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Hopital Universitaire de Strasbourg; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nationale Francaise Contre le Cancer (LNCC; Comites du Haut-Rhin, Bas-Rhin et de la Haute-Savoie); Institut National du Cancer (INCA PL-BIO ADIPOK)(Institut National du Cancer (INCA) France); Chinese fellowship of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); LNCC; INCA fellowships	We thank Susan Chan and Gerard Gradwohl for helpful discussion, and Corinne Wendling, Laure Nivlet and Olivia Wendling for technical assistance. This work was supported by funds from the Institut National de la Sante et de la Recherche Medicale, the Centre National de la Recherche Scientifique, the Hopital Universitaire de Strasbourg, the Association pour la Recherche sur le Cancer, the Ligue Nationale Francaise Contre le Cancer (LNCC; Comites du Haut-Rhin, Bas-Rhin et de la Haute-Savoie) and the Institut National du Cancer (INCA PL-BIO ADIPOK 2011-2013). JT was a recipient of a Chinese fellowship of National Natural Science Foundation of China (number: 81102008); EB was a recipient of LNCC and INCA fellowships.	Aigner T, 2002, BIOCHEM BIOPH RES CO, V290, P743, DOI 10.1006/bbrc.2001.6227; Andarawewa KL, 2005, CANCER RES, V65, P10862, DOI 10.1158/0008-5472.CAN-05-1231; Basset P, 1997, CRIT REV ONCOL HEMAT, V26, P43, DOI 10.1016/S1040-8428(97)00010-3; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Cannata D, 2010, ENDOCRINOLOGY, V151, P5751, DOI 10.1210/en.2010-0792; Ching S, 2011, J CELL BIOCHEM, V112, P3393, DOI 10.1002/jcb.23273; Couldrey C, 2002, DEV DYNAM, V223, P459, DOI 10.1002/dvdy.10065; DEOME KB, 1959, CANCER RES, V19, P515; Dhimolea E, 2010, BIOMATERIALS, V31, P3622, DOI 10.1016/j.biomaterials.2010.01.077; Edwards PAW, 2000, ADV EXP MED BIOL, V480, P163; Ewald AJ, 2008, DEV CELL, V14, P570, DOI 10.1016/j.devcel.2008.03.003; Fata JE, 2007, DEV BIOL, V306, P193, DOI 10.1016/j.ydbio.2007.03.013; Green KA, 2005, BIOESSAYS, V27, P894, DOI 10.1002/bies.20281; Ha HY, 2001, CANCER RES, V61, P984; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; Hinck L, 2005, BREAST CANCER RES, V7, P245, DOI 10.1186/bcr1331; Holtz B, 1999, BIOCHEMISTRY-US, V38, P12174, DOI 10.1021/bi990876m; Hovey RC, 2010, J MAMMARY GLAND BIOL, V15, P279, DOI 10.1007/s10911-010-9187-8; Kannan R, 1999, PROTEIN EXPRES PURIF, V16, P76, DOI 10.1006/prep.1999.1068; KEELY PJ, 1995, DIFFERENTIATION, V59, P1, DOI 10.1046/j.1432-0436.1995.5910001.x; Khialeeva E, 2011, DEVELOPMENT, V138, P767, DOI 10.1242/dev.057588; Khokha R, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004333; Kren L, 2006, Cesk Patol, V42, P16; Kurley SJ, 2012, DEVELOPMENT, V139, P1754, DOI 10.1242/dev.072769; Kwon YJ, 2011, CLIN EXP METASTAS, V28, P437, DOI 10.1007/s10585-011-9382-z; Lamande SR, 2006, J BIOL CHEM, V281, P16607, DOI 10.1074/jbc.M510192200; Landskroner-Eiger S, 2010, DEV BIOL, V344, P968, DOI 10.1016/j.ydbio.2010.06.019; Lanigan F, 2007, CELL MOL LIFE SCI, V64, P3161, DOI 10.1007/s00018-007-7386-2; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; Lijnen HR, 2002, THROMB HAEMOSTASIS, V87, P530; Lo AT, 2012, J MAMMARY GLAND BIOL, V17, P103, DOI 10.1007/s10911-012-9251-7; Mailleux AA, 2007, DEV CELL, V12, P221, DOI 10.1016/j.devcel.2006.12.003; Maskos K, 2003, MOL BIOTECHNOL, V25, P241, DOI 10.1385/MB:25:3:241; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; McCave EJ, 2010, J MAMMARY GLAND BIOL, V15, P291, DOI 10.1007/s10911-010-9190-0; Mori H, 2013, DEVELOPMENT, V140, P343, DOI 10.1242/dev.084236; Motrescu ER, 2008, ONCOGENE, V27, P6347, DOI 10.1038/onc.2008.218; Motrescu ER, 2008, BIOL CHEM, V389, P1037, DOI 10.1515/BC.2008.110; Naylor MJ, 2002, DEV DYNAM, V225, P100, DOI 10.1002/dvdy.10133; Nelson CM, 2006, SCIENCE, V314, P298, DOI 10.1126/science.1131000; Noel A, 2000, ONCOGENE, V19, P1605, DOI 10.1038/sj.onc.1203465; Noel AC, 1996, J CLIN INVEST, V97, P1924, DOI 10.1172/JCI118624; Pavlovich AL, 2010, TISSUE ENG PT A, V16, P3719, DOI [10.1089/ten.tea.2009.0836, 10.1089/ten.TEA.2009.0836]; Pedersen G, 2009, CLIN EXP IMMUNOL, V155, P257, DOI 10.1111/j.1365-2249.2008.03836.x; Simian M, 2001, DEVELOPMENT, V128, P3117; Sternlicht MD, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1368; Sternlicht MD, 2005, DEVELOPMENT, V132, P3923, DOI 10.1242/dev.01966; Tan JX, 2011, INT J DEV BIOL, V55, P851, DOI 10.1387/ijdb.113365jt; Ucar A, 2010, NAT GENET, V42, P1101, DOI 10.1038/ng.709; Wasenius VM, 2003, CLIN CANCER RES, V9, P68; Wiseman BS, 2003, J CELL BIOL, V162, P1123, DOI 10.1083/jcb.200302090; WITTY EP, 1995, MOL BIOL CELL, V6, P1287, DOI 10.1091/mbc.6.10.1287; Wolf K, 2011, TRENDS CELL BIOL, V21, P736, DOI 10.1016/j.tcb.2011.09.006; Wu EX, 2001, J CELL BIOCHEM, V82, P549, DOI 10.1002/jcb.1181; Zhao ZS, 2010, HUM PATHOL, V41, P686, DOI 10.1016/j.humpath.2009.10.010	56	27	30	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2014	33	31					4050	4059		10.1038/onc.2013.434	http://dx.doi.org/10.1038/onc.2013.434			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YG	24141782	hybrid			2022-12-28	WOS:000340595300004
J	Huang, Y; Yu, P; Li, W; Ren, G; Roberts, AI; Cao, W; Zhang, X; Su, J; Chen, X; Chen, Q; Shou, P; Xu, C; Du, L; Lin, L; Xie, N; Zhang, L; Wang, Y; Shi, Y				Huang, Y.; Yu, P.; Li, W.; Ren, G.; Roberts, A. I.; Cao, W.; Zhang, X.; Su, J.; Chen, X.; Chen, Q.; Shou, P.; Xu, C.; Du, L.; Lin, L.; Xie, N.; Zhang, L.; Wang, Y.; Shi, Y.			p53 regulates mesenchymal stem cell-mediated tumor suppression in a tumor microenvironment through immune modulation	ONCOGENE			English	Article						mesenchymal stem cells; p53; immunomodulation; iNOS	NITRIC-OXIDE; INFILTRATING LYMPHOCYTES; GENETIC ALTERATIONS; STROMAL CELLS; MUTANT P53; T-CELLS; CANCER; MUTATIONS; CARCINOMA; EXPRESSION	p53 is one of the most studied genes in cancer biology, and mutations in this gene may be predictive for the development of many types of cancer in humans and in animals. However, whether p53 mutations in non-tumor stromal cells can affect tumor development has received very little attention. In this study, we show that B16F0 melanoma cells form much larger tumors in p53-deficient mice than in wild-type mice, indicating a potential role of p53 deficiency in non-tumor cells of the microenvironment. As mesenchymal stem cells (MSCs) are attracted to tumors and form a major component of the tumor microenvironment, we examined the potential role of p53 status in MSCs in tumor development. We found that larger tumors resulted when B16F0 melanoma cells were co-injected with bone marrow MSCs derived from p53-deficient mice rather than MSCs from wild-type mice. Interestingly, this tumor-promoting effect by p53-deficient MSCs was not observed in non-obese diabetic/severe combined immunodeficiency mice, indicating the immune response has a critical role. Indeed, in the presence of inflammatory cytokines, p53-deficient MSCs expressed more inducible nitric oxide synthase (iNOS) and exhibited greater immunosuppressive capacity. Importantly, tumor promotion by p53-deficient MSCs was abolished by administration of S-methylisothiourea, an iNOS inhibitor. Therefore, our data demonstrate that p53 status in tumor stromal cells has a key role in tumor development by modulating immune responses.	[Huang, Y.; Yu, P.; Li, W.; Cao, W.; Zhang, X.; Su, J.; Chen, X.; Chen, Q.; Shou, P.; Xu, C.; Du, L.; Lin, L.; Xie, N.; Wang, Y.; Shi, Y.] Shanghai Jiao Tong Univ, Chinese Acad Sci, Sch Med,Shanghai Inst Biol Sci, Inst Hlth Sci,Key Lab Stem Cell Biol, Shanghai 200025, Peoples R China; [Ren, G.; Roberts, A. I.; Zhang, L.; Shi, Y.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, New Brunswick, NJ USA; [Ren, G.; Roberts, A. I.; Zhang, L.; Shi, Y.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, New Brunswick, NJ USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Wang, Y (corresponding author), Shanghai Jiao Tong Univ, Chinese Acad Sci, Sch Med,Shanghai Inst Biol Sci, Inst Hlth Sci,Key Lab Stem Cell Biol, 225 S Chongqing Rd,1 Bldg, Shanghai 200025, Peoples R China.	yingwang@sibs.ac.cn; yufangshi@sibs.ac.cn	Yu, Pengfei/AHC-3497-2022; Li, Wenzhao/H-4235-2016; Xu, Chunliang/R-7065-2018; Shi, Yufang/AAE-4431-2020; Su, Juanjuan/C-4040-2018; Shou, Peishun/J-7985-2014; HUANG, YIN/AAH-6871-2020; Du, Liming/M-8227-2019	Yu, Pengfei/0000-0002-3894-5697; Li, Wenzhao/0000-0002-3878-3333; Shi, Yufang/0000-0001-8964-319X; Su, Juanjuan/0000-0002-6159-1954; Shou, Peishun/0000-0001-7685-7471; HUANG, YIN/0000-0001-5602-9871; Chen, Qing/0000-0002-2088-0370; wang, ying/0000-0002-2571-9367; Du, Liming/0000-0002-0527-3556	Ministry of Science and Technology of China [2010CB945600, 2011DFA30630]; Chinese Academy of Sciences [XDA01040107, KSCX1-YW-22-04]; NSFC [31010103908]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); Chinese Academy of Sciences(Chinese Academy of Sciences); NSFC(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the Ministry of Science and Technology of China (2010CB945600 and 2011DFA30630), Scientific Innovation Project of the Chinese Academy of Sciences (XDA01040107 and KSCX1-YW-22-04) and International Cooperation and Exchanges NSFC (31010103908). We are also grateful to Yikun Yao (IHS, CAS) for his assistance and suggestions.	Addadi Y, 2010, CANCER RES, V70, P9650, DOI 10.1158/0008-5472.CAN-10-1146; Andersen MH, 2009, J CLIN INVEST, V119, P2245, DOI 10.1172/JCI38739; Armesilla-Diaz A, 2009, EXP CELL RES, V315, P3598, DOI 10.1016/j.yexcr.2009.08.004; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bergfeld SA, 2010, CANCER METAST REV, V29, P249, DOI 10.1007/s10555-010-9222-7; Bingisser RM, 1998, J IMMUNOL, V160, P5729; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Brito C, 1999, J IMMUNOL, V162, P3356; Brown GC, 1997, BIOCHEM SOC T, V25, P901, DOI 10.1042/bst0250901; Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donia M, 2012, ONCOIMMUNOLOGY, V1, P1476, DOI 10.4161/onci.21940; Donia M, 2012, ONCOIMMUNOLOGY, V1, P1297, DOI 10.4161/onci.21659; Dougan M, 2009, ANNU REV IMMUNOL, V27, P83, DOI 10.1146/annurev.immunol.021908.132544; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Giono LE, 2006, J CELL PHYSIOL, V209, P13, DOI 10.1002/jcp.20689; Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; Hill R, 2005, CELL, V123, P1001, DOI 10.1016/j.cell.2005.09.030; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hussain SP, 2008, CANCER RES, V68, P7130, DOI 10.1158/0008-5472.CAN-08-0410; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kidd S, 2009, STEM CELLS, V27, P2614, DOI 10.1002/stem.187; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; Levine AJ, 2011, NAT REV MOL CELL BIO, V12, P259, DOI 10.1038/nrm3086; Li W, 2012, CELL DEATH DIFFER, V19, P1505, DOI 10.1038/cdd.2012.26; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Maffini MV, 2004, J CELL SCI, V117, P1495, DOI 10.1242/jcs.01000; Matsumoto N, 2003, BRIT J CANCER, V89, P707, DOI 10.1038/sj.bjc.6601141; Miranda KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319; Moinfar F, 2000, CANCER RES, V60, P2562; Moskovits N, 2006, CANCER RES, V66, P10671, DOI 10.1158/0008-5472.CAN-06-2323; Murray-Zmijewski F, 2008, NAT REV MOL CELL BIO, V9, P702, DOI 10.1038/nrm2451; Nakano O, 2001, CANCER RES, V61, P5132; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; Nishida N, 2012, CLIN CANCER RES, V18, P3054, DOI 10.1158/1078-0432.CCR-11-1078; Paterson RF, 2003, CANCER, V98, P1830, DOI 10.1002/cncr.11747; Patocs A, 2007, NEW ENGL J MED, V357, P2543, DOI 10.1056/NEJMoa071825; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Ren GW, 2012, CELL STEM CELL, V11, P812, DOI 10.1016/j.stem.2012.08.013; Rodriguez R, 2009, NEOPLASIA, V11, P397, DOI 10.1593/neo.81620; Roninson IB, 2003, CANCER RES, V63, P2705; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Sharma MD, 2009, BLOOD, V113, P6102, DOI 10.1182/blood-2008-12-195354; Sharma P, 2007, P NATL ACAD SCI USA, V104, P3967, DOI 10.1073/pnas.0611618104; Simelyte E, 2005, ARTHRITIS RHEUM-US, V52, P1876, DOI 10.1002/ART.21099; Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221; STRETCH JR, 1991, CANCER RES, V51, P5976; Studeny M, 2002, CANCER RES, V62, P3603; Suzuki YJ, 2010, ANTIOXID REDOX SIGN, V12, P323, DOI 10.1089/ars.2009.2887; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Tuhkanen H, 2004, INT J CANCER, V109, P247, DOI 10.1002/ijc.11733; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; Xu WM, 2002, CELL RES, V12, P311, DOI 10.1038/sj.cr.7290133; Yamanishi Y, 2002, P NATL ACAD SCI USA, V99, P10025, DOI 10.1073/pnas.152333199; Zhu H, 2010, NAT PROTOC, V5, P550, DOI 10.1038/nprot.2009.238; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883; Zou WB, 2012, CANCER RES, V72, P2980, DOI 10.1158/0008-5472.CAN-11-4216	77	50	54	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3830	3838		10.1038/onc.2013.355	http://dx.doi.org/10.1038/onc.2013.355			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23975435				2022-12-28	WOS:000339394100009
J	Shah, PP; Lockwood, WW; Saurabh, K; Kurlawala, Z; Shannon, SP; Waigel, S; Zacharias, W; Beverly, LJ				Shah, P. P.; Lockwood, W. W.; Saurabh, K.; Kurlawala, Z.; Shannon, S. P.; Waigel, S.; Zacharias, W.; Beverly, L. J.			Ubiquilin1 represses migration and epithelial-to-mesenchymal transition of human non-small cell lung cancer cells	ONCOGENE			English	Article							PROTEIN; METASTASIS; EXPRESSION; REVEALS; STRESS; ZEB1; GENE	Ubiquilin1 (UBQLN1) is a ubiquitin-like domain and a ubiquitin-associated domain containing protein that has been reported to be involved in shuttling proteins to the proteasome, especially during endoplasmic reticulum-associated protein degradation. Thus, UBQLN1 function has been shown to be critical for combating a number of neurological disorders caused by protein aggregation, such as amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's disease. A role for UBQLN1 in regulating processes involved in tumorigenesis has not been demonstrated. Herein, we show that loss of UBQLN1 causes increased cell migration and invasion, actin cytoskeleton reorganization and induction of epithelial-to-mesenchymal transition (EMT). Loss of UBQLN1 results in a significant decrease in the expression of epithelial markers including E-cadherin and claudin1, whereas expression of mesenchymal markers including Vimentin, Snail and ZEB1 are significantly elevated. Interestingly, we found that ZEB1 is required for induction of mesenchymal-like properties following loss of UBQLN1 and ZEB1 is capable of repressing expression of UBQLN1, suggesting a physiological, reciprocal regulation of EMT by UBQLN1 and ZEB1. Further, we find evidence for a role for UBQLN2 in also regulating EMT and cell migration. These observations have potential clinical relevance because the UBQLN1 gene is lost and underexpressed in a large percentage of human cancer cell lines, and primary human lung cancer samples and recurrent mutations in all five UBQLN family members have been identified in human lung cancers. Taken together, our results suggest for the first time a role for UBQLN family members in cancer biology.	[Shah, P. P.; Saurabh, K.; Kurlawala, Z.; Shannon, S. P.; Waigel, S.; Zacharias, W.; Beverly, L. J.] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40202 USA; [Lockwood, W. W.] NHGRI, Canc Biol & Genet Sect, Canc Genet Branch, NIH, Bethesda, MD USA; [Saurabh, K.; Zacharias, W.; Beverly, L. J.] Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA; [Zacharias, W.; Beverly, L. J.] Univ Louisville, Dept Med, Div Hematol & Oncol, Louisville, KY 40202 USA	University of Louisville; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Louisville; University of Louisville	Beverly, LJ (corresponding author), Univ Louisville, James Graham Brown Canc Ctr, Sch Med, Dept Med,Div Hematol & Oncol, 505 South Hancock St,CTRB Room 204, Louisville, KY 40202 USA.	Levi.Beverly@Louisville.edu	Kurlawala, Zimple/AAK-8303-2020	Kurlawala, Zimple/0000-0003-3925-9290	James Graham Brown Cancer Center, University of Louisville; Molecular Targets COBRE from NIH [8P20GM103482-10]; Lung Cancer Research Foundation; Rounsavall Foundation; Wendy Will Case Cancer Fund; National Cancer Institute [R25-CA-134283]; NIH/NIGMS Phase III COBRE [1P30 GM106396-01]; James Graham Brown Foundation; Kosair Pediatric Cancer Program; NIH/NIGMS KY-INBRE [P20GM103436]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007505] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R25CA134283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM106396, P20GM103482, P20GM103436] Funding Source: NIH RePORTER	James Graham Brown Cancer Center, University of Louisville; Molecular Targets COBRE from NIH; Lung Cancer Research Foundation; Rounsavall Foundation; Wendy Will Case Cancer Fund; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIGMS Phase III COBRE; James Graham Brown Foundation; Kosair Pediatric Cancer Program; NIH/NIGMS KY-INBRE; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Lavona Casson and current members of the Beverly lab for technical assistance and Dr Mohammad T Malik for valuable comments, discussion and technical advice. We would like to thank Douglas Darling for the gift of the ZEB1 antibody. The work was supported by the start-up funds from James Graham Brown Cancer Center, University of Louisville and Kosair Pediatric Cancer Program and Molecular Targets COBRE 8P20GM103482-10 from NIH, an award from the Lung Cancer Research Foundation to LJB, an award from the Rounsavall Foundation to LJB, an award from the Wendy Will Case Cancer Fund to LJB, R25-CA-134283 from the National Cancer Institute to SPS. Part of this work was performed with assistance of the UofL Genomics Facility, which is supported by NIH/NIGMS Phase III COBRE 1P30 GM106396-01, NIH/NIGMS KY-INBRE P20GM103436, the James Graham Brown Foundation, and user fees.	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Arias-Vasquez A, 2007, NEUROSCI LETT, V424, P1, DOI 10.1016/j.neulet.2007.07.015; Beverly LJ, 2012, P NATL ACAD SCI USA, V109, P119, DOI 10.1073/pnas.1119167109; Bevilacqua E, 2010, J BIOL CHEM, V285, P17098, DOI 10.1074/jbc.M110.109439; Chen GA, 2007, CANCER RES, V67, P3461, DOI 10.1158/0008-5472.CAN-06-4475; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Dohadwala M, 2006, CANCER RES, V66, P5338, DOI 10.1158/0008-5472.CAN-05-3635; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kamiya T, 2011, FREE RADICAL RES, V45, P692, DOI 10.3109/10715762.2011.567985; Keshamouni VG, 2006, J PROTEOME RES, V5, P1143, DOI 10.1021/pr050455t; Kim SH, 2009, J BIOL CHEM, V284, P8083, DOI 10.1074/jbc.M808064200; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; Lim PJ, 2009, J CELL BIOL, V187, P201, DOI 10.1083/jcb.200903024; Liu YH, 2010, J AM SOC NEPHROL, V21, P212, DOI 10.1681/ASN.2008121226; Lu A, 2009, J MOL NEUROSCI, V38, P19, DOI 10.1007/s12031-008-9155-6; Nurwidya F, 2012, CANCER RES TREAT, V44, P151, DOI 10.4143/crt.2012.44.3.151; Olzmann JA, 2008, CURR MED CHEM, V15, P47; Oyanagi J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053209; Rutherford NJ, 2013, BRAIN RES, V1524, P62, DOI 10.1016/j.brainres.2013.06.006; Shah PP, 2012, ONCOGENE, V31, P3124, DOI 10.1038/onc.2011.488; Soetandyo N, 2010, J CELL SCI, V123, P1031, DOI 10.1242/jcs.059758; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Vandewalle C, 2009, CELL MOL LIFE SCI, V66, P773, DOI 10.1007/s00018-008-8465-8; Wang QY, 2006, J CELL BIOL, V174, P963, DOI 10.1083/jcb.200605100; Wojcik C, 2006, MOL BIOL CELL, V17, P4606, DOI 10.1091/mbc.E06-05-0432; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang GJ, 2013, ONCOL LETT, V5, P564, DOI 10.3892/ol.2012.1026	31	38	41	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1709	1717		10.1038/onc.2014.97	http://dx.doi.org/10.1038/onc.2014.97			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24747970	Green Accepted			2022-12-28	WOS:000351848400011
J	Faye, MD; Beug, ST; Graber, TE; Earl, N; Xiang, X; Wild, B; Langlois, S; Michaud, J; Cowan, KN; Korneluk, RG; Holcik, M				Faye, M. D.; Beug, S. T.; Graber, T. E.; Earl, N.; Xiang, X.; Wild, B.; Langlois, S.; Michaud, J.; Cowan, K. N.; Korneluk, R. G.; Holcik, M.			IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1	ONCOGENE			English	Article							RNA-BINDING PROTEINS; ENDOPLASMIC-RETICULUM STRESS; ALPHA-DEPENDENT APOPTOSIS; LIGAND-INDUCED APOPTOSIS; RIBOSOME ENTRY SITES; NF-KAPPA-B; MESSENGER-RNA; SMAC MIMETICS; TNF; CANCER	Rhabdomyosarcoma (RMS), a neoplasm characterised by undifferentiated myoblasts, is the most common soft tissue tumour of childhood. Although aggressive treatment of RMS could provide long-term benefit, resistance to current therapies is an ongoing problem. We report here that insulin-like growth factor 2-binding protein 1 (IGF2BP1), an oncofetal protein, is expressed in RMS patient-derived cell lines and in primary tumours where it drives translation of the cellular inhibitor of apoptosis 1 (cIAP1), a key regulator of the nuclear factor-kappa B signalling pathway and of caspase-8-mediated cell death. We demonstrate that reducing the levels of cIAP1 in RMS, either by IGF2BP1 knockdown or by IAP antagonists, sensitises these cells to tumour necrosis factor-alpha-mediated cell death. Finally, we show that targeting cIAP1 by IAP antagonists delays RMS tumour growth and improve survival in mice. Our results identify IGF2BP1 as a critical translational regulator of cIAP1-mediated apoptotic resistance in RMS and advocate for the combined use of IAP antagonists and tumour necrosis factor-a as a therapeutic approach for this type of cancer.	[Faye, M. D.; Beug, S. T.; Graber, T. E.; Earl, N.; Xiang, X.; Wild, B.; Langlois, S.; Cowan, K. N.; Korneluk, R. G.; Holcik, M.] Childrens Hosp Eastern Ontario, Apoptosis Res Ctr, Res Inst, Ottawa, ON K1H 8L1, Canada; [Faye, M. D.; Korneluk, R. G.; Holcik, M.] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; [Xiang, X.; Wild, B.; Cowan, K. N.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Langlois, S.; Cowan, K. N.] Univ Ottawa, Dept Surg, Ottawa, ON, Canada; [Michaud, J.] Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON, Canada; [Korneluk, R. G.; Holcik, M.] Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa	Holcik, M (corresponding author), Childrens Hosp Eastern Ontario, Apoptosis Res Ctr, Res Inst, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	martin@arc.cheo.ca	Graber, Tyson/K-9385-2019; Holcik, Martin/AAC-6660-2019	Graber, Tyson/0000-0002-5337-3404; Holcik, Martin/0000-0002-1922-5299; Xiang, Xiao/0000-0002-3969-1668; Cowan, Kyle/0000-0003-0109-7716	Canadian Institutes of Health Research [FRN 74740]; Cancer Research Society (CRS); Vanier Canada Graduate Scholarship; Frederick Banting Graduate Scholarship Doctoral Award; Charles Best Canada Graduate Scholarship Doctoral Award	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Cancer Research Society (CRS); Vanier Canada Graduate Scholarship; Frederick Banting Graduate Scholarship Doctoral Award; Charles Best Canada Graduate Scholarship Doctoral Award	We thank the members of the Apoptosis Research Centre and Dr Eric LaCasse in particular for critical discussions. We are grateful to Novartis Pharmaceuticals for providing LCL161 compound and Dr P Houghton (Department of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN, USA) for the gift of RMS cell lines. This work forms part of the PhD dissertation of MDF and was supported by an operating grant from the Canadian Institutes of Health Research (FRN 74740) and Cancer Research Society (CRS) to MH. MDF was supported by the Vanier Canada Graduate Scholarship. TEG was supported by the Frederick Banting and Charles Best Canada Graduate Scholarships Doctoral Award.	Baird SD, 2007, NUCLEIC ACIDS RES, V35, P4664, DOI 10.1093/nar/gkm483; Basit F, 2012, J BIOL CHEM, V287, P38767, DOI 10.1074/jbc.M112.398966; Bell JL, 2013, CELL MOL LIFE SCI, V70, P2657, DOI 10.1007/s00018-012-1186-z; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Beug ST, 2014, NAT BIOTECHNOL, V32, P182, DOI 10.1038/nbt.2806; Dai N, 2013, GENE DEV, V27, P301, DOI 10.1101/gad.209130.112; Dai N, 2011, GENE DEV, V25, P1159, DOI 10.1101/gad.2042311; Farina KL, 2003, J CELL BIOL, V160, P77, DOI 10.1083/jcb.200206003; Faye MD, 2013, MOL CELL BIOL, V33, P307, DOI 10.1128/MCB.00546-12; Finlay D, 2013, MOL CANC THERAP; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; Fulda S, 2012, SARCOMA, V2012; Graber TE, 2010, CELL DEATH DIFFER, V17, P719, DOI 10.1038/cdd.2009.164; Gyrd-Hansen M, 2010, NAT REV CANCER, V10, P561, DOI 10.1038/nrc2889; Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009; Hansen TVO, 2004, MOL CELL BIOL, V24, P4448, DOI 10.1128/MCB.24.10.4448-4464.2004; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Holcik M, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-5; Houghton PJ, 2012, PEDIATR BLOOD CANCER, V58, P636, DOI 10.1002/pbc.23167; Huh WW, 2010, CURR ONCOL REP, V12, P402, DOI 10.1007/s11912-010-0130-3; Huttelmaier S, 2005, NATURE, V438, P512, DOI 10.1038/nature04115; Izeradjene K, 2004, CANCER RES, V64, P8036, DOI 10.1158/0008-5472.CAN-04-0762; Izeradjene K, 2004, CLIN CANCER RES, V10, P6650, DOI 10.1158/1078-0432.CCR-04-0576; Jonson L, 2007, MOL CELL PROTEOMICS, V6, P798, DOI 10.1074/mcp.M600346-MCP200; King HA, 2010, BIOCHEM SOC T, V38, P1581, DOI 10.1042/BST0381581; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lewis SM, 2008, NUCLEIC ACIDS RES, V36, P168, DOI 10.1093/nar/gkm1007; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Mongroo PS, 2011, CANCER RES, V71, P2172, DOI 10.1158/0008-5472.CAN-10-3295; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Petak I, 2000, CLIN CANCER RES, V6, P4119; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; Saab R, 2011, CURR TOP DEV BIOL, V94, P197, DOI 10.1016/B978-0-12-380916-2.00007-3; Stohr N, 2006, J CELL BIOL, V175, P527, DOI 10.1083/jcb.200608071; Stohr N, 2012, GENE DEV, V26, P176, DOI 10.1101/gad.177642.111; Tessier CR, 2004, CANCER RES, V64, P209, DOI 10.1158/0008-5472.CAN-03-2927; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; Van Eden ME, 2004, RNA, V10, P469, DOI 10.1261/rna.5156804; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Warnakulasuriyarachchi D, 2004, J BIOL CHEM, V279, P17148, DOI 10.1074/jbc.M308737200; Weidensdorfer D, 2009, RNA, V15, P104, DOI 10.1261/rna.1175909; Weingartner M, 2002, J BIOL CHEM, V277, P34853, DOI 10.1074/jbc.M205149200; Weinlich S, 2009, RNA, V15, P1528, DOI 10.1261/rna.1578409; Weisberg E, 2010, LEUKEMIA, V24, P2100, DOI 10.1038/leu.2010.212; Yaniv K, 2002, GENE, V287, P49, DOI 10.1016/S0378-1119(01)00866-6; Yisraeli JK, 2005, BIOL CELL, V97, P87	50	31	32	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1532	1541		10.1038/onc.2014.90	http://dx.doi.org/10.1038/onc.2014.90			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24704827				2022-12-28	WOS:000351416800006
J	Xu, S; Wen, Z; Jiang, Q; Zhu, L; Feng, S; Zhao, Y; Wu, J; Dong, Q; Mao, J; Zhu, Y				Xu, S.; Wen, Z.; Jiang, Q.; Zhu, L.; Feng, S.; Zhao, Y.; Wu, J.; Dong, Q.; Mao, J.; Zhu, Y.			CD58, a novel surface marker, promotes self-renewal of tumor-initiating cells in colorectal cancer	ONCOGENE			English	Article							STEM-CELLS; PROSPECTIVE IDENTIFICATION; METASTATIC CAPACITY; ADHESION MOLECULES; DRUG-RESISTANCE; COLON; EXPRESSION; DIFFERENTIATION; SUBPOPULATION; CONTRIBUTE	Colorectal tumor-initiating cells (CT-ICs) have self-renewal capabilities and have an important role in tumorigenesis, metastasis, recurrence and treatment resistance in colorectal cancer. Multiple cell-surface molecules targeting CT-ICs, possibly representing different CT-IC subpopulations, have been reported. However, whether new surface markers exist, as well as the mechanisms by which the markers regulate self-renewal, remain unclear. In this study, we enriched a CT-IC population through a serum-free low-adhesion system in vitro. Within this population, we found that CD58 and CD44 were upregulated using a cDNA GeneChip, and CD44(high)CD58(high) cancer cells, the common existence of which was demonstrated by flow cytometry in multiple colon cancer cell lines and primary specimens, exhibited enhanced self-renewal ability, epithelial-mesenchymal transition ability and tumorigenicity, both in vitro and in vivo. Furthermore, activated CD58 upregulated the Wnt/beta-catenin pathway and thus promoted self-renewal of CT-ICs; conversely, knockdown of CD58 significantly impaired sphere formation and tumor growth. With immunoprecipitation and western blotting approaches, CD58 was found to upregulate the Wnt pathway by degradation of Dickkopf 3. These results indicate that CD58 is a novel cell-surface marker that functionally regulates self-renewal of CT-ICs, which may provide an intriguing therapeutic target for the efficient killing and elimination of CT-ICs.	[Xu, S.; Wen, Z.; Zhu, L.; Feng, S.; Zhao, Y.; Wu, J.; Mao, J.; Zhu, Y.] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Lab Gastroenterol, Hangzhou 310009, Zhejiang, Peoples R China; [Jiang, Q.] Tongde Hosp Zhejiang Prov, Dept Gastroenterol, Hangzhou 310012, Zhejiang, Peoples R China; [Dong, Q.; Zhu, Y.] Zhejiang Univ, Sch Med, Inst Canc, Hangzhou 310009, Zhejiang, Peoples R China; [Dong, Q.; Zhu, Y.] Zhejiang Univ, Sch Med, Key Lab Canc Prevent & Intervent, Educ Minist, Hangzhou 310009, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University	Zhu, Y (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Lab Gastroenterol, Hangzhou 310009, Zhejiang, Peoples R China.	zhuyongliangch@gmail.com			National Science of Foundation Committee of China [81071768, 81071619, 31090361, 81372348]; Natural Science of Foundation of Zhejiang Province [R2090074, Y2110246]; Foundation of Scientific Technology Bureau of Zhejiang Province [2010C33118, 2011C23091, 2013C33129]	National Science of Foundation Committee of China; Natural Science of Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province); Foundation of Scientific Technology Bureau of Zhejiang Province	We thank Mr Qinghua Lu (Cancer Institute and Education Ministry Key Laboratory of Cancer Prevention and Intervention, Zhejiang University School of Medicine) for FCM analysis. This work was supported by grants from the National Science of Foundation Committee of China (81071768, 81071619, 31090361, 81372348), the Natural Science of Foundation of Zhejiang Province (R2090074, Y2110246) and the Foundation of Scientific Technology Bureau of Zhejiang Province (2010C33118, 2011C23091, 2013C33129).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ariel O, 2009, CELL SIGNAL, V21, P1100, DOI 10.1016/j.cellsig.2009.02.022; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bruno S, 2006, AM J PATHOL, V169, P2223, DOI 10.2353/ajpath.2006.060498; Challa-Malladi M, 2011, CANCER CELL, V20, P728, DOI 10.1016/j.ccr.2011.11.006; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Douard R, 2006, SURGERY, V139, P665, DOI 10.1016/j.surg.2005.10.012; Dreesen O, 2007, STEM CELL REV, V3, P7, DOI 10.1007/s12015-007-0004-8; Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034; Du L, 2013, CANCER RES, V73, P2682, DOI 10.1158/0008-5472.CAN-12-3759; DUSTIN ML, 1987, NATURE, V329, P846, DOI 10.1038/329846a0; Ebert EC, 2009, AM J PHYSIOL-GASTR L, V296, pG671, DOI 10.1152/ajpgi.90497.2008; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Gerger A, 2011, CLIN CANCER RES, V17, P6934, DOI 10.1158/1078-0432.CCR-11-1180; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; Kolligs FT, 2002, DIGESTION, V66, P131, DOI 10.1159/000066755; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; KVALE D, 1992, SCAND J IMMUNOL, V35, P669, DOI 10.1111/j.1365-3083.1992.tb02973.x; LaBarge MA, 2008, J CLIN INVEST, V118, P2021, DOI 10.1172/JCI36046; Lee JL, 2009, J CELL BIOL, V185, P949, DOI 10.1083/jcb.200812060; Lee RV, 2005, AM J CLIN PATHOL, V123, P119, DOI 10.1309/X5VV-6FKJ-Q6MU-BLPX; Li DW, 2011, ANN SURG ONCOL, V18, P2074, DOI 10.1245/s10434-011-1567-9; Lombardo Y, 2011, GASTROENTEROLOGY, V140, P297, DOI 10.1053/j.gastro.2010.10.005; Mayer B, 1995, INT J CANCER, V64, P415, DOI 10.1002/ijc.2910640611; Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956; Munz M, 2009, CANCER RES, V69, P5627, DOI 10.1158/0008-5472.CAN-09-0654; Najdi Rani, 2011, J Carcinog, V10, P5, DOI 10.4103/1477-3163.78111; Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Sagiv E, 2006, GASTROENTEROLOGY, V131, P630, DOI 10.1053/j.gastro.2006.04.028; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Shenoy AK, 2012, CANCER RES, V72, P5091, DOI 10.1158/0008-5472.CAN-12-1806; Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401; Sikandar SS, 2010, CANCER RES, V70, P1469, DOI 10.1158/0008-5472.CAN-09-2557; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Singh SK, 2003, CANCER RES, V63, P5821; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; Su YJ, 2011, EMBO J, V30, P3186, DOI 10.1038/emboj.2011.211; Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196; Tamada M, 2012, CANCER RES, V72, P1438, DOI 10.1158/0008-5472.CAN-11-3024; Todaro M, 2010, GASTROENTEROLOGY, V138, P2151, DOI 10.1053/j.gastro.2009.12.063; Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Yue W, 2008, CARCINOGENESIS, V29, P84, DOI 10.1093/carcin/bgm267; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589	55	23	24	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1520	1531		10.1038/onc.2014.95	http://dx.doi.org/10.1038/onc.2014.95			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24727892				2022-12-28	WOS:000351416800005
J	Adams, MN; Harrington, BS; He, Y; Davies, CM; Wallace, SJ; Chetty, NP; Crandon, AJ; Oliveira, NB; Shannon, CM; Coward, JI; Lumley, J; Perrin, LC; Armes, JE; Hooper, JD				Adams, M. N.; Harrington, B. S.; He, Y.; Davies, C. M.; Wallace, S. J.; Chetty, N. P.; Crandon, A. J.; Oliveira, N. B.; Shannon, C. M.; Coward, J. I.; Lumley, J. W.; Perrin, L. C.; Armes, J. E.; Hooper, J. D.			EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface	ONCOGENE			English	Article							DOMAIN-CONTAINING PROTEIN-1; CUB-DOMAIN; PKC-DELTA; SRC; RESISTANCE; SURVIVAL; IDENTIFICATION; METASTASIS; INVASION	Many cancers are dependent on inappropriate activation of epidermal growth factor receptor (EGFR), and drugs targeting this receptor can improve patient survival, although benefits are generally short-lived. We reveal a novel mechanism linking EGFR and the membrane-spanning, cancer-promoting protein CDCP1 (CUB domain-containing protein 1). Under basal conditions, cell surface CDCP1 constitutively internalizes and undergoes palmitoylation-dependent degradation by a mechanism in which it is palmitoylated in at least one of its four cytoplasmic cysteines. This mechanism is functional in vivo as CDCP1 is elevated and palmitoylated in high-grade serous ovarian tumors. Interestingly, activation of the EGFR system with EGF inhibits proteasome-mediated, palmitoylation-dependent degradation of CDCP1, promoting recycling of CDCP1 to the cell surface where it is available to mediate its procancer effects. We also show that mechanisms inducing relocalization of CDCP1 to the cell surface, including disruption of its palmitoylation and EGF treatment, promote cell migration. Our data provide the first evidence that the EGFR system can function to increase the lifespan of a protein and also promote its recycling to the cell surface. This information may be useful for understanding mechanisms of resistance to EGFR therapies and assist in the design of treatments for EGFR-dependent cancers.	[Adams, M. N.; Harrington, B. S.; He, Y.; Davies, C. M.; Coward, J. I.; Armes, J. E.; Hooper, J. D.] Univ Queensland, Translat Res Inst, Mater Res Inst, Brisbane, Qld 4102, Australia; [Davies, C. M.; Wallace, S. J.; Chetty, N. P.; Crandon, A. J.; Oliveira, N. B.; Shannon, C. M.; Coward, J. I.; Perrin, L. C.; Armes, J. E.] Mater Hlth Serv, South Brisbane, Qld, Australia; [Lumley, J. W.] Wesley Hosp, Auchenflower, Qld, Australia	Mater Research; University of Queensland; Mater Health Services; Wesley Hospital	Hooper, JD (corresponding author), Univ Queensland, Translat Res Inst, Mater Res Inst, Canc Biol & Management, 37 Kent St, Brisbane, Qld 4102, Australia.	john.hooper@mater.uq.edu.au	Adams, Mark/AAE-1209-2021; Harrington, Brittney/Z-5941-2019; Armes, Jane/D-6396-2012; Harrington, Brittney/P-1687-2016; Coward, Jermaine/C-1779-2012; Hooper, John/C-1481-2016; Coward, Jermaine/F-2903-2016	Adams, Mark/0000-0003-1906-5018; Harrington, Brittney/0000-0001-7083-069X; Armes, Jane/0000-0002-2215-0347; Harrington, Brittney/0000-0001-7083-069X; Hooper, John/0000-0003-1054-8486; Coward, Jermaine/0000-0002-2309-9379; Davies, Claire/0000-0001-8651-0914; Chetty, Naven/0000-0002-7158-7123; HE, Yaowu/0000-0002-7828-263X; Perrin, Lewis/0000-0002-6119-8458	Cancer Council Queensland [614205, 1021827]; Wesley Research Institute [2008/06]; Australian Research Council Future Fellowship [FT120100917]	Cancer Council Queensland(Cancer Council Queensland); Wesley Research Institute; Australian Research Council Future Fellowship(Australian Research Council)	We thank Dr Jon Whitehead for helpful discussions. This work was supported by Cancer Council Queensland Grants 614205 and 1021827 and Wesley Research Institute Grant 2008/06 to JDH. MNA and BSH received Australian Post-Graduate Awards. JDH holds Australian Research Council Future Fellowship FT120100917.	Adams MN, 2012, N-S ARCH PHARMACOL, V385, P861, DOI 10.1007/s00210-012-0783-6; Adams MN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028018; Awakura Y, 2008, J CANCER RES CLIN, V134, P1363, DOI 10.1007/s00432-008-0412-4; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Blaskovic S, 2013, FEBS J, V280, P2766, DOI 10.1111/febs.12263; Casar B, 2014, ONCOGENE, V33, P255, DOI 10.1038/onc.2012.547; Casar B, 2012, ONCOGENE, V31, P3924, DOI 10.1038/onc.2011.555; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Deryugina EI, 2009, MOL CANCER RES, V7, P1197, DOI 10.1158/1541-7786.MCR-09-0100; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Dong Y, 2012, J BIOL CHEM, V287, P9792, DOI 10.1074/jbc.M111.335448; Emerling BM, 2013, P NATL ACAD SCI USA, V110, P3483, DOI 10.1073/pnas.1222435110; Fukuchi K, 2010, MOL PHARMACEUT, V7, P245, DOI 10.1021/mp900236t; Gao WC, 2013, GASTROENTEROLOGY, V145, P636, DOI 10.1053/j.gastro.2013.05.049; He Y, 2010, J BIOL CHEM, V285, P26162, DOI 10.1074/jbc.M109.096453; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220; Ikeda JI, 2009, CANCER SCI, V100, P429, DOI 10.1111/j.1349-7006.2008.01066.x; Joffre C, 2011, NAT CELL BIOL, V13, P827, DOI 10.1038/ncb2257; Kollmorgen G, 2013, MOL ONCOL, V7, P1142, DOI 10.1016/j.molonc.2013.08.009; Kulbe H, 2012, CANCER RES, V72, P66, DOI 10.1158/0008-5472.CAN-11-2178; Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108; Macdonald JL, 2005, J LIPID RES, V46, P1061, DOI 10.1194/jlr.D400041-JLR200; Miyazawa Y, 2013, MOL CANCER RES, V11, P628, DOI 10.1158/1541-7786.MCR-12-0544; Miyazawa Y, 2010, CANCER RES, V70, P5136, DOI 10.1158/0008-5472.CAN-10-0220; Morris DP, 2008, J BIOL CHEM, V283, P2973, DOI 10.1074/jbc.M705795200; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Sandilands E, 2008, TRENDS CELL BIOL, V18, P322, DOI 10.1016/j.tcb.2008.05.004; Siva AC, 2008, CANCER RES, V68, P3759, DOI 10.1158/0008-5472.CAN-07-1657; Uekita T, 2008, AM J PATHOL, V172, P1729, DOI 10.2353/ajpath.2008.070981; Uekita T, 2007, MOL CELL BIOL, V27, P7649, DOI 10.1128/MCB.01246-07; Uekita T, 2011, CANCER SCI, V102, P1943, DOI 10.1111/j.1349-7006.2011.02052.x; Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97; Wortmann A, 2011, J BIOL CHEM, V286, P42303, DOI 10.1074/jbc.M111.227462; Wortmann A, 2009, IUBMB LIFE, V61, P723, DOI 10.1002/iub.198; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	37	26	26	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1375	1383		10.1038/onc.2014.88	http://dx.doi.org/10.1038/onc.2014.88			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24681947				2022-12-28	WOS:000350806500004
J	Seo, KS; Park, JH; Heo, JY; Jing, K; Han, J; Min, KN; Kim, C; Koh, G; Lim, K; Kang, GY; Lee, JU; Yim, YH; Shong, M; Kwak, TH; Kweon, G				Seo, K-S; Park, J-H; Heo, J-Y; Jing, K.; Han, J.; Min, K-N; Kim, C.; Koh, G. Y.; Lim, K.; Kang, G-Y; Lee, J. Uee; Yim, Y-H; Shong, M.; Kwak, T-H; Kweon, G. R.			SIRT2 regulates tumour hypoxia response by promoting HIF-1 alpha hydroxylation	ONCOGENE			English	Article							INDUCIBLE FACTOR-1-ALPHA; OXIDOREDUCTASE 1; METABOLISM; HIF1-ALPHA; DEGRADATION; ACTIVATION; PROTEIN; ACETYLATION; SUPPRESSION; OXIDATION	Hypoxia-inducible factor-1 alpha (HIF-1 alpha) is a transcription factor that has a central role in the regulation of tumour metabolism under hypoxic conditions. HIF-1 alpha stimulates glycolytic energy production and promotes tumour growth. Sirtuins are NAD(+)-dependent protein deacetylases that regulate cellular metabolism in response to stress; however, their involvement in the hypoxic response remains unclear. In this study, it is shown that SIRT2-mediated deacetylation of HIF-1 alpha regulates its stability in tumour cells. SIRT2 overexpression destabilized HIF-1 alpha under hypoxic conditions, whereas HIF-1 alpha protein levels were high in SIRT2-deficient cells. SIRT2 directly interacted with HIF-1 alpha and deacetylated Lys709 of HIF-1 alpha. Deacetylation of HIF-1 alpha by SIRT2 resulted in increased binding affinity for prolyl hydroxylase 2, a key regulator of HIF-1a stability, and increased HIF-1 alpha hydroxylation and ubiquitination. Moreover, a pharmacological agent that increased the intracellular NAD(+)/NADH ratio led to the degradation of HIF-1 alpha by increasing SIRT2-mediated deacetylation and subsequent hydroxylation. These findings suggest that SIRT2-mediated HIF-1 alpha deacetylation is critical for the destablization of HIF-1 alpha and the hypoxic response of tumour cells.	[Seo, K-S; Park, J-H; Heo, J-Y; Jing, K.; Han, J.; Lim, K.; Kweon, G. R.] Chungnam Natl Univ, Sch Med, Dept Biochem, Taejon 301747, South Korea; [Heo, J-Y; Jing, K.; Han, J.; Lim, K.] Chungnam Natl Univ, Sch Med, Infect Signaling Network Res Ctr, Taejon 301747, South Korea; [Min, K-N; Kwak, T-H] KT&G Life Sci Corp R&D Ctr, Suwon, South Korea; [Kim, C.; Koh, G. Y.] Korea Adv Inst Sci & Technol, Natl Res Lab Vasc Biol, Taejon 305701, South Korea; [Kim, C.; Koh, G. Y.] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Taejon 305701, South Korea; [Lim, K.] Chungnam Natl Univ, Sch Med, Canc Res Inst, Taejon 301747, South Korea; [Kang, G-Y] Diatech Korea Co Ltd, Seoul, South Korea; [Lee, J. Uee] Catholic Univ, St Marys Hosp, Dept Pathol, Taejon, South Korea; [Yim, Y-H] Korea Res Inst Standard & Sci, Taejon, South Korea; [Shong, M.] Chungnam Natl Univ, Sch Med, Dept Internal Med, Taejon 301747, South Korea	Chungnam National University; Chungnam National University; Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST); Chungnam National University; Catholic University of Korea; Catholic University Korea Hospital; Korea Research Institute of Standards & Science (KRISS); Chungnam National University	Kweon, G (corresponding author), Chungnam Natl Univ, Sch Med, Dept Biochem, Taejon 301747, South Korea.	bioalpha@ktngls.com; mitochondria@cnu.ac.kror	/H-7803-2012; Koh, Gou Young/C-1615-2011	Heo, Jun Young/0000-0002-0859-0063; Han, Jeongsu/0000-0001-6524-9841; Kim, Chan/0000-0001-9780-6155; shong, minho/0000-0002-0247-7115	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [2009-1176023, 2011-0011365]; NRF - Ministry of Science, ICT & Future Planning [2007-0054932]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education; NRF - Ministry of Science, ICT & Future Planning	We thank Dr HS Kim, Dr JH Lim and Dr JW Park for their skillful methodological assistance, Dr JJ Lee for the HRE luciferase plasmid and Dr KY Lee for the SIRT2 expression plasmids. This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2009-1176023, 2011-0011365) (GRK) and the NRF funded by the Ministry of Science, ICT & Future Planning (2007-0054932).	Berra E, 2006, EMBO REP, V7, P41, DOI 10.1038/sj.embor.7400598; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Chen R, 2011, J BIOL CHEM, V286, P13869, DOI 10.1074/jbc.M110.175414; Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045; Choi HJ, 2008, BRIT J PHARMACOL, V154, P114, DOI 10.1038/bjp.2008.70; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Dioum EM, 2009, SCIENCE, V324, P1289, DOI 10.1126/science.1169956; Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014; Geng H, 2012, J BIOL CHEM, V287, P35496, DOI 10.1074/jbc.M112.400697; Hiratsuka M, 2003, BIOCHEM BIOPH RES CO, V309, P558, DOI 10.1016/j.bbrc.2003.08.029; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Hwang JH, 2009, DIABETES, V58, P965, DOI 10.2337/db08-1183; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Jiang WQ, 2011, MOL CELL, V43, P33, DOI 10.1016/j.molcel.2011.04.028; Jin Y, 2011, J BIOL CHEM, V286, P22699, DOI 10.1074/jbc.M111.237024; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; Kim SY, 2009, CIRC RES, V104, P842, DOI 10.1161/CIRCRESAHA.108.189837; Kim YH, 2012, FREE RADICAL BIO MED, V52, P880, DOI 10.1016/j.freeradbiomed.2011.12.007; Krishnan J, 2012, GENE DEV, V26, P259, DOI 10.1101/gad.180406.111; Kwon SJ, 2005, CLIN CANCER RES, V11, P7607, DOI 10.1158/1078-0432.CCR-05-0981; Laemmle A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033433; Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023; Luthi-Carter R, 2010, P NATL ACAD SCI USA, V107, P7927, DOI 10.1073/pnas.1002924107; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Massudi H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042357; Melillo G, 2006, MOL CANCER RES, V4, P601, DOI 10.1158/1541-7786.MCR-06-0235; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; MIETTINEN M, 1994, MODERN PATHOL, V7, P82; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; North BJ, 2007, J BIOL CHEM, V282, P19546, DOI 10.1074/jbc.M702990200; Outeiro TF, 2007, SCIENCE, V317, P516, DOI 10.1126/science.1143780; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Papadakis AI, 2010, CANCER RES, V70, P7820, DOI 10.1158/0008-5472.CAN-10-0215; Schwer B, 2010, P NATL ACAD SCI USA, V107, P21790, DOI 10.1073/pnas.1016306107; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Tanaka H, 2012, CANCER SCI, V103, P767, DOI 10.1111/j.1349-7006.2011.02192.x; Terzuoli E, 2010, CANCER RES, V70, P6837, DOI 10.1158/0008-5472.CAN-10-1075; van Uden P, 2008, BIOCHEM J, V412, P477, DOI 10.1042/BJ20080476; Wang F, 2012, ONCOGENE, V31, P1546, DOI 10.1038/onc.2011.347; Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12; Zhang DY, 2010, CANCER RES, V70, P813, DOI 10.1158/0008-5472.CAN-09-0448; Zhang QH, 2006, P NATL ACAD SCI USA, V103, P9029, DOI 10.1073/pnas.0603269103	45	81	85	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1354	1362		10.1038/onc.2014.76	http://dx.doi.org/10.1038/onc.2014.76			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24681946				2022-12-28	WOS:000350806500002
J	Girardot, M; Pecquet, C; Chachoua, I; Van Hees, J; Guibert, S; Ferrant, A; Knoops, L; Baxter, EJ; Beer, PA; Giraudier, S; Moriggl, R; Vainchenker, W; Green, AR; Constantinescu, SN				Girardot, M.; Pecquet, C.; Chachoua, I.; Van Hees, J.; Guibert, S.; Ferrant, A.; Knoops, L.; Baxter, E. J.; Beer, P. A.; Giraudier, S.; Moriggl, R.; Vainchenker, W.; Green, A. R.; Constantinescu, S. N.			Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation	ONCOGENE			English	Article							TYROSINE KINASE JAK2; MYELOPROLIFERATIVE NEOPLASMS; FUNCTION-MUTATION; TRANSCRIPTION; REQUIREMENT; TARGETS; CDNA	STAT (Signal Transducer and Activator of Transcription) transcription factors are constitutively activated in most hematopoietic cancers. We previously identified a target gene, LPP/miR-28 (LIM domain containing preferred translocation partner in lipoma), induced by constitutive activation of STAT5, but not by transient cytokine-activated STAT5. miR-28 exerts negative effects on thrombopoietin receptor signaling and platelet formation. Here, we demonstrate that, in transformed hematopoietic cells, STAT5 and p53 must be synergistically bound to chromatin for induction of LPP/miR-28 transcription. Genome-wide association studies show that both STAT5 and p53 are co-localized on the chromatin at 463 genomic positions in proximal promoters. Chromatin binding of p53 is dependent on persistent STAT5 activation at these proximal promoters. The transcriptional activity of selected promoters bound by STAT5 and p53 was significantly changed upon STAT5 or p53 inhibition. Abnormal expression of several STAT5-p53 target genes (LEP, ATP5J, GTF2A2, VEGFC, NPY1R and NPY5R) is frequently detected in platelets of myeloproliferative neoplasm (MPN) patients, but not in platelets from healthy controls. In conclusion, persistently active STAT5 can recruit normal p53, like in the case of MPN cells, but also p53 mutants, such as p53 M133K in human erythroleukemia cells, leading to pathologic gene expression that differs from canonical STAT5 or p53 transcriptional programs.	[Girardot, M.; Pecquet, C.; Chachoua, I.; Van Hees, J.; Knoops, L.; Constantinescu, S. N.] Ludwig Inst Canc Res, Brussels, Belgium; [Girardot, M.; Pecquet, C.; Chachoua, I.; Van Hees, J.; Knoops, L.; Constantinescu, S. N.] Catholic Univ Louvain, Duve Inst, Brussels, Belgium; [Girardot, M.] Univ Montpellier, CNRS, Inst Mol Genet, UMR5535, F-34059 Montpellier, France; [Guibert, S.] Univ Strasbourg, CNRS, Biotechnol & Cell Signalling, ESBS,UMR 7242, Illkirch Graffenstaden, France; [Ferrant, A.; Knoops, L.] Clin Univ St Luc, Dept Hematol, B-1200 Brussels, Belgium; [Baxter, E. J.; Beer, P. A.; Green, A. R.] Univ Cambridge, Cambridge Inst Med Res, Cambridge, England; [Giraudier, S.; Vainchenker, W.] Inst Gustave Roussy, INSERM, U1009, F-94805 Villejuif, France; [Giraudier, S.] Univ Paris 12, Hop Henri Mondor, AP HP, PRB Cellulotheque Hematol,Lab Hematol, F-94010 Creteil, France; [Moriggl, R.] Ludwig Boltzmann Inst Canc Res, Vienna, Austria	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; University of Cambridge; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Ludwig Boltzmann Institute	Constantinescu, SN (corresponding author), Univ Louvain Brussels, Signal Transduct Unit, Ludwig Inst Canc Res, B-1200 Brussels, Belgium.	michael.girardot@igmm.cnrs.fr; stefan.constantinescu@bru.licr.org	Moriggl, Richard/H-8118-2019; Chachoua, Ilyas/AAB-3326-2019	Moriggl, Richard/0000-0003-0918-9463; Chachoua, Ilyas/0000-0002-5112-5394; Green, Anthony/0000-0002-9795-0218; Vainchenker, William/0000-0003-4705-202X; Christian, Pecquet/0000-0002-8623-3483; Baxter, Elizabeth Joanna/0000-0002-5946-5238; Constantinescu, Stefan N./0000-0002-8599-2699	FRS-FNRS, Belgium (Mandat d'Impulsion); FRS-FNRS, Belgium (FRSM); Salus Sanguinis Foundation; Action de Recherche Concertee projects of the University catholique de Louvain, Brussels [MEXP31C1, ARC10/15-027]; Fondation contre le Cancer, Brussels; PAI Programs [BCHM61B5]; Belgian Medical Genetics Initiative (BeMG), Belgium; Atlantic Philanthropies, New York; Austrian Science Fund (FWF) [SFB-F2807/SFB-F4707]; Austrian Science Fund (FWF) [F 2807] Funding Source: researchfish; Cancer Research UK [12765] Funding Source: researchfish	FRS-FNRS, Belgium (Mandat d'Impulsion); FRS-FNRS, Belgium (FRSM)(Fonds de la Recherche Scientifique - FNRS); Salus Sanguinis Foundation; Action de Recherche Concertee projects of the University catholique de Louvain, Brussels; Fondation contre le Cancer, Brussels; PAI Programs; Belgian Medical Genetics Initiative (BeMG), Belgium; Atlantic Philanthropies, New York; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Cancer Research UK(Cancer Research UK)	We thank Guido Bommer for invaluable p53 reagents and extremely useful criticisms and suggestions. We are grateful for generous support to SNC from the FRS-FNRS, Belgium (Mandat d'Impulsion and FRSM), the Salus Sanguinis Foundation, the Action de Recherche Concertee projects MEXP31C1 and ARC10/15-027 of the University catholique de Louvain, Brussels, the Fondation contre le Cancer, Brussels, the PAI Programs BCHM61B5 and Belgian Medical Genetics Initiative (BeMG), Belgium and the Atlantic Philanthropies, New York (for SNC). RM was supported by SFB-F2807/SFB-F4707 from the Austrian Science Fund (FWF).	BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Borgel J, 2010, NAT GENET, V42, P1093, DOI 10.1038/ng.708; Casetti L, 2013, CANCER RES, V73, P2052, DOI 10.1158/0008-5472.CAN-12-3955; Chipoy C, 2007, ONCOGENE, V26, P6653, DOI 10.1038/sj.onc.1210492; Constantinescu SN, 2008, TRENDS BIOCHEM SCI, V33, P122, DOI 10.1016/j.tibs.2007.12.002; Dawson MR, 2009, NATURE, V461, pE4, DOI 10.1038/nature08254; DEJONG J, 1995, P NATL ACAD SCI USA, V92, P3313, DOI 10.1073/pnas.92.8.3313; Fritsche M, 1998, MOL CELL ENDOCRINOL, V143, P143, DOI 10.1016/S0303-7207(98)00140-3; Girardot M, 2010, BLOOD, V116, P437, DOI 10.1182/blood-2008-06-165985; HIGUTI T, 1991, BIOCHEM BIOPH RES CO, V178, P793, DOI 10.1016/0006-291X(91)90178-A; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Klampfl T, 2013, NEW ENGL J MED, V369, P2379, DOI 10.1056/NEJMoa1311347; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kramer Oliver H, 2012, JAKSTAT, V1, P203, DOI 10.4161/jkst.21232; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Lin YP, 2002, BLOOD, V100, P3990, DOI 10.1182/blood-2002-02-0504; Liu F, 2011, CANCER CELL, V19, P283, DOI 10.1016/j.ccr.2010.12.020; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Moucadel V, 2005, J BIOL CHEM, V280, P13364, DOI 10.1074/jbc.M407326200; Mouzaki A, 2009, CYTOKINE, V48, P203, DOI 10.1016/j.cyto.2009.07.006; Nakatake M, 2012, ONCOGENE, V31, P1323, DOI 10.1038/onc.2011.313; Nangalia J, 2013, NEW ENGL J MED, V369, P2391, DOI 10.1056/NEJMoa1312542; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pecquet C, 2012, BLOOD, V119, P4625, DOI 10.1182/blood-2011-08-372524; Rajala HLM, 2013, BLOOD, V121, P4541, DOI 10.1182/blood-2012-12-474577; Shi S, 2006, NAT GENET, V38, P1071, DOI 10.1038/ng1860; Stark GR, 2012, IMMUNITY, V36, P503, DOI 10.1016/j.immuni.2012.03.013; Townsend PA, 2004, J BIOL CHEM, V279, P5811, DOI 10.1074/jbc.M302637200; Walz C, 2012, BLOOD, V119, P3550, DOI 10.1182/blood-2011-12-397554; Wood TJJ, 1997, MOL CELL ENDOCRINOL, V130, P69, DOI 10.1016/S0303-7207(97)00075-0; Yan DQ, 2012, BLOOD, V119, P3539, DOI 10.1182/blood-2011-03-345215; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	36	21	21	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1323	1332		10.1038/onc.2014.60	http://dx.doi.org/10.1038/onc.2014.60			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24681953	Green Accepted			2022-12-28	WOS:000350687100012
J	Kumagai, Y; Naoki, H; Nakasyo, E; Kamioka, Y; Kiyokawa, E; Matsuda, M				Kumagai, Y.; Naoki, H.; Nakasyo, E.; Kamioka, Y.; Kiyokawa, E.; Matsuda, M.			Heterogeneity in ERK activity as visualized by in vivo FRET imaging of mammary tumor cells developed in MMTV-Neu mice	ONCOGENE			English	Article							CANCER STEM-CELLS; BREAST-CANCER; INITIATING CELLS; SELF-RENEWAL; KINASE-ACTIVITY; MOUSE MODELS; MORPHOGENESIS; TUMORIGENESIS; EXPRESSION; TAMOXIFEN	Human epidermal growth factor receptor2/Neu, which is overexpressed in about 30% of human breast cancers, transduces growth signals in large part via the Ras-Raf-MEK-ERK pathway. Nevertheless, it is a matter of controversy whether high ERK activity in breast cancer tissues correlates with better or worse prognosis, leaving the role of ERK activity in the progression of breast cancers unresolved. To address this issue, we live-imaged ERK activity in mammary tumors developed in mouse mammary tumor virus-Neu transgenic mice, which had been crossed with transgenic mice expressing a Forster resonance energy transfer biosensor for ERK. Observation of the tumor by two-photon microscopy revealed significant heterogeneity in ERK activity among the mammary tumor cells. The level of ERK activity in each cell was stable up to several hours, implying a robust mechanism that maintained the ERK activity within a limited range. By sorting the mammary tumor cells on the basis of their ERK activity, we found that ERKhigh cells less efficiently generated tumorspheres in vitro and tumors in vivo than did ERKlow cells. In agreement with this finding, the expressions of the cancer stem cell markers CD49f, CD24 and CD61 were decreased in ERKhigh cells. These observations suggest that high ERK activity may suppress the self-renewal of mammary cancer stem cells.	[Kumagai, Y.; Matsuda, M.] Kyoto Univ, Grad Sch Biostudies, Dept Bioimaging & Cell Signaling, Kyoto 6068501, Japan; [Naoki, H.] Kyoto Univ, Kyoto 6068501, Japan; [Nakasyo, E.] Olympus Corp, R&D Div, Life & Ind Prod Dev Dept 1, Hachioji, Tokyo, Japan; [Kamioka, Y.; Matsuda, M.] Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Kyoto 6068501, Japan; [Kamioka, Y.] Kyoto Univ, Grad Sch Med, Kyoto 6068501, Japan; [Kiyokawa, E.] Kanazawa Med Univ, Dept Oncol Pathol, Uchinada, Ishikawa 92002, Japan	Kyoto University; Kyoto University; Olympus Corporation; Kyoto University; Kyoto University; Kanazawa Medical University	Matsuda, M (corresponding author), Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	matsuda.michiyuki.2c@kyoto-u.ac.jp	Naoki, Honda/AAW-6284-2020; Naoki, Honda/N-5674-2017	Naoki, Honda/0000-0001-6816-9126; Naoki, Honda/0000-0001-6816-9126; Matsuda, Michiyuki/0000-0002-5876-9969	Ministry of Education, Culture, Sports, Science and Technology (MEXT) [22113002]; Innovative Techno-Hub for the Integrated Medical Bio-imaging Project of the Special Coordination Funds for Promoting Science and Technology by MEXT, Japan; MEXT, Japan; Animal Care and Use Committee of Kyoto University Graduate School of Medicine [10584]; Grants-in-Aid for Scientific Research [15H05949, 22113001] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Innovative Techno-Hub for the Integrated Medical Bio-imaging Project of the Special Coordination Funds for Promoting Science and Technology by MEXT, Japan; MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Animal Care and Use Committee of Kyoto University Graduate School of Medicine; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	J3B1 cells were kindly provided by Roberto Montesano. We thank Y Inaoka, K Hirano, K Takakura, R Tabata, Y Kitagawa and A Kawagishi for their technical assistance. We are grateful to the members of the Matsuda Laboratory for their helpful discussions. MM was supported by a Grant-in-Aid for Scientific Research on the Innovative Area of 'Fluorescence Live imaging' (No. 22113002) of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), and by an Innovative Techno-Hub for the Integrated Medical Bio-imaging Project of the Special Coordination Funds for Promoting Science and Technology by MEXT, Japan. YK was supported by a Grant-in-Aid for JSPS Fellows from MEXT, Japan. The animal protocols were reviewed and approved by the Animal Care and Use Committee of Kyoto University Graduate School of Medicine (No. 10584).	Aoki K, 2009, NAT PROTOC, V4, P1623, DOI 10.1038/nprot.2009.175; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Bergqvist J, 2006, EUR J CANCER, V42, P1104, DOI 10.1016/j.ejca.2006.01.028; Brown AP, 2007, CANCER CHEMOTH PHARM, V59, P671, DOI 10.1007/s00280-006-0323-5; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Chappell J, 2013, GENE DEV, V27, P725, DOI 10.1101/gad.211300.112; Ewald AJ, 2008, DEV CELL, V14, P570, DOI 10.1016/j.devcel.2008.03.003; Goto A, 2013, J NEUROSCI, V33, P4901, DOI 10.1523/JNEUROSCI.4828-12.2013; Greber B, 2010, CELL STEM CELL, V6, P215, DOI 10.1016/j.stem.2010.01.003; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Izrailit J, 2013, P NATL ACAD SCI USA, V110, P1714, DOI 10.1073/pnas.1214014110; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; Kamioka Y, 2012, CELL STRUCT FUNCT, V37, P65, DOI 10.1247/csf.11045; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Kunath T, 2007, DEVELOPMENT, V134, P2895, DOI 10.1242/dev.02880; Liu JC, 2012, P NATL ACAD SCI USA, V109, P5832, DOI 10.1073/pnas.1201105109; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Lo PK, 2012, ONCOGENE, V31, P2614, DOI [10.1038/onc.2011.439, 10.1038/onc.2012.147]; Magnifico A, 2009, CLIN CANCER RES, V15, P2010, DOI 10.1158/1078-0432.CCR-08-1327; McGlynn LM, 2009, CLIN CANCER RES, V15, P1487, DOI 10.1158/1078-0432.CCR-07-4967; Milde-Langosch K, 2005, BRIT J CANCER, V92, P2206, DOI 10.1038/sj.bjc.6602655; Montesano R, 2002, J CELL SCI, V115, P4419, DOI 10.1242/jcs.00164; Mueller H, 2000, INT J CANCER, V89, P384, DOI 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R; Nobis M, 2013, CANCER RES, V73, P4674, DOI 10.1158/0008-5472.CAN-12-4545; Parashurama N, 2012, STEM CELLS, V30, P2114, DOI 10.1002/stem.1205; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Svensson S, 2005, ONCOGENE, V24, P4370, DOI 10.1038/sj.onc.1208626; Ursini-Siegel J, 2007, NAT REV CANCER, V7, P389, DOI 10.1038/nrc2127; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Whyte J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2361; Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137	36	17	17	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					1051	1057		10.1038/onc.2014.28	http://dx.doi.org/10.1038/onc.2014.28			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632612	Green Published			2022-12-28	WOS:000350121300011
J	Serasinghe, MN; Missert, DJ; Asciolla, JJ; Podgrabinska, S; Wieder, SY; Izadmehr, S; Belbin, G; Skobe, M; Chipuk, JE				Serasinghe, M. N.; Missert, D. J.; Asciolla, J. J.; Podgrabinska, S.; Wieder, S. Y.; Izadmehr, S.; Belbin, G.; Skobe, M.; Chipuk, J. E.			Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAF(V600E) inhibition and can be targeted to reduce resistance	ONCOGENE			English	Article							BH3 DOMAINS; BRAF; FAMILY; BAX; DIMERIZATION; RESPONSES; SURVIVAL; PATHWAY; POTENT	In theory, pharmacological inhibition of oncogenic signaling is an effective strategy to halt cellular proliferation, induce apoptosis and eliminate cancer cells. In practice, drugs (for example, PLX-4032) that inhibit oncogenes like B-RAFV600E provide relatively short-term success in patients, owing to a combination of incomplete cellular responses and the development of resistance. To define the relationship between PLX-4032-induced responses and resistance, we interrogated the contributions of anti-apoptotic BCL-2 proteins in determining the fate of B-RAFV600E-inhibited melanoma cells. Although PLX-4032 eliminated B-RAFV600E signaling leading to marked cell cycle arrest, only a fraction of cells eventually underwent apoptosis. These data proposed two hypotheses regarding B-RAFV600E inhibition: (1) only a few cells generate a pro-apoptotic signal, or (2) all the cells generate a pro-apoptotic signal but the majority silences this pathway to ensure survival. Indeed, the latter hypothesis is supported by our observations as the addition of ABT-737, an inhibitor to anti-apoptotic BCL-2 proteins, revealed massive apoptosis following PLX-4032 exposure. B-RAFV600E inhibition alone sensitized cells to the mitochondrial pathway of apoptosis characterized by the rapid accumulation of BIM on the outer mitochondrial membrane, which could be functionally revealed by ABT-737 to promote apoptosis and loss of clonogenic survival. Furthermore, PLX-4032-resistant cells demonstrated collateral resistance to conventional chemotherapy, yet could be re-sensitized to PLX-4032 by BCL-2 family inhibition in vivo and conventional chemotherapies in vitro. Our data suggest that inhibiting anti-apoptotic BCL-2 proteins will enhance primary responses to PLX-4032, along with reducing the development of resistance to both targeted and conventional therapies.	[Serasinghe, M. N.; Missert, D. J.; Asciolla, J. J.; Podgrabinska, S.; Wieder, S. Y.; Belbin, G.; Skobe, M.; Chipuk, J. E.] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA; [Serasinghe, M. N.; Missert, D. J.; Asciolla, J. J.; Wieder, S. Y.; Chipuk, J. E.] Dept Dermatol, New York, NY USA; [Serasinghe, M. N.; Missert, D. J.; Asciolla, J. J.; Podgrabinska, S.; Wieder, S. Y.; Skobe, M.; Chipuk, J. E.] Tisch Canc Inst, New York, NY USA; [Missert, D. J.; Izadmehr, S.; Belbin, G.; Skobe, M.; Chipuk, J. E.] Grad Sch Biomed Sci, New York, NY USA; [Izadmehr, S.] Dept Genet & Genom Sci, New York, NY USA; [Chipuk, J. E.] Diabet Obes & Metab Inst, New York, NY USA	Icahn School of Medicine at Mount Sinai	Chipuk, JE (corresponding author), Icahn Sch Med Mt Sinai, Dept Oncol Sci, One Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.	jerry.chipuk@mssm.edu		Wieder, Shira/0000-0002-3151-3947; Chipuk, Jerry Edward/0000-0002-1337-842X	NIH [CA157740, KL2TR000069]; JJR Foundation; Breast Cancer Alliance; Fridolin Charitable Trust; March of Dimes Foundation [FY13-238]; Department of Oncological Sciences at Mount Sinai [PO1]; Albert Einstein College of Medicine; American Skin Association Medical Students Grant; William A. Spivak Fund; Chipuk Laboratory; NATIONAL CANCER INSTITUTE [R01CA157740] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000069] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); JJR Foundation; Breast Cancer Alliance; Fridolin Charitable Trust; March of Dimes Foundation(March of Dimes); Department of Oncological Sciences at Mount Sinai; Albert Einstein College of Medicine; American Skin Association Medical Students Grant; William A. Spivak Fund; Chipuk Laboratory; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank everyone in the Chipuk Laboratory for their assistance and support; Dr Stuart Aaronson, Dr Mark Lebwohl, Dr Emily Bernstein, Dr E Premkumar Reddy and Dr Poulikos Poulikakos for mentorship, guidance and/or discussion about the melanoma field; and Dr Suvendu Das, Eliana Sarrou, Rana Elkholi and Andrew Cruz for technical assistance. This work was supported by: NIH CA157740 (to JEC), NIH KL2TR000069 (to SI), the JJR Foundation (to JEC), the Breast Cancer Alliance (MS), the William A. Spivak Fund (to JEC), and the Fridolin Charitable Trust (to JEC). This work was also supported in part by a Research Grant FY13-238 from the March of Dimes Foundation (to JEC), a developmental PO1 grant from the Department of Oncological Sciences at Mount Sinai (to JEC), an Albert Einstein College of Medicine Research Fellowship (to SYW) and an American Skin Association Medical Students Grant (to SYW).	Anvekar RA, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.161; Anvekar RA, 2011, FRONT ONCOL, V1, DOI 10.3389/fonc.2011.00034; Asciolla JJ, 2012, JOVE-J VIS EXP, DOI 10.3791/4291; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Chipuk JE, 2008, P NATL ACAD SCI USA, V105, P20327, DOI 10.1073/pnas.0808036105; Cragg MS, 2008, J CLIN INVEST, V118, P3651, DOI 10.1172/JCI35437; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Letai AG, 2008, NAT REV CANCER, V8, P121, DOI 10.1038/nrc2297; Logue SE, 2009, NAT PROTOC, V4, P1383, DOI 10.1038/nprot.2009.143; Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037; McArthur GA, 2012, J CLIN ONCOL, V30, P1628, DOI 10.1200/JCO.2011.39.1938; Montagut C, 2009, CANCER LETT, V283, P125, DOI 10.1016/j.canlet.2009.01.022; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2011, CANCER CELL, V19, P11, DOI 10.1016/j.ccr.2011.01.008; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; Whittaker S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000758; Young A, 2009, ADV CANCER RES, V102, P1, DOI 10.1016/S0065-230X(09)02001-6	30	39	39	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					857	867		10.1038/onc.2014.21	http://dx.doi.org/10.1038/onc.2014.21			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24608435	Green Accepted			2022-12-28	WOS:000349472000006
J	Wen, SY; Lin, Y; Yu, YQ; Cao, SJ; Zhang, R; Yang, XM; Li, J; Zhang, YL; Wang, YH; Ma, MZ; Sun, WW; Lou, XL; Wang, JH; Teng, YC; Zhang, ZG				Wen, S-Y; Lin, Y.; Yu, Y-Q; Cao, S-J; Zhang, R.; Yang, X-M; Li, J.; Zhang, Y-L; Wang, Y-H; Ma, M-Z; Sun, W-W; Lou, X-L; Wang, J-H; Teng, Y-C; Zhang, Z-G			miR-506 acts as a tumor suppressor by directly targeting the hedgehog pathway transcription factor Gli3 in human cervical cancer	ONCOGENE			English	Article							REGULATORY NETWORK; SONIC HEDGEHOG; UP-REGULATION; EXPRESSION; CELLS; DIFFERENTIATION; MICRORNAS	Although significant advances have recently been made in the diagnosis and treatment of cervical carcinoma, the long-term survival rate for advanced cervical cancer remains low. Therefore, an urgent need exists to both uncover the molecular mechanisms and identify potential therapeutic targets for the treatment of cervical cancer. MicroRNAs (miRNAs) have important roles in cancer progression and could be used as either potential therapeutic agents or targets. miR-506 is a component of an X chromosome-linked miRNA cluster. The biological functions of miR-506 have not been well established. In this study, we found that miR-506 expression was downregulated in approximately 80% of the cervical cancer samples examined and inversely correlated with the expression of Ki-67, a marker of cell proliferation. Gain-of-function and loss-of-function studies in human cervical cancer, Caski and SiHa cells, demonstrated that miR-506 acts as a tumor suppressor by inhibiting cervical cancer growth in vitro and in vivo. Further studies showed that miR-506 induced cell cycle arrest at the G1/S transition, and enhanced apoptosis and chemosensitivity of cervical cancer cell. We subsequently identified Gli3, a hedgehog pathway transcription factor, as a direct target of miR-506 in cervical cancer. Furthermore, Gli3 silencing recapitulated the effects of miR-506, and reintroduction of Gli3 abrogated miR-506-induced cell growth arrest and apoptosis. Taken together, we conclude that miR-506 exerts its anti-proliferative function by directly targeting Gli3. This newly identified miR-506/Gli3 axis provides further insight into the pathogenesis of cervical cancer and indicates a potential novel therapeutic agent for the treatment of cervical cancer.	[Wen, S-Y; Teng, Y-C] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Obstet & Gynecol, Shanghai 200233, Peoples R China; [Wen, S-Y; Lin, Y.] Shanghai Jiao Tong Univ, Sch Med, China Welf Inst, Dept Obstet & Gynecol,Int Peace Matern & Child Hl, Shanghai 200233, Peoples R China; [Wen, S-Y; Yang, X-M; Li, J.; Zhang, Y-L; Wang, Y-H; Ma, M-Z; Zhang, Z-G] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, State Key Lab Oncogenes & Related Genes,Shanghai, Shanghai 200233, Peoples R China; [Yu, Y-Q] China Med Univ, Coll Basic Med Sci, Dept Pathophysiol, Shenyang 110001, Peoples R China; [Cao, S-J; Sun, W-W] Shanghai Songjiang Dist Cent Hosp, Dept Obstet & Gynecol, Shanghai, Peoples R China; [Zhang, R.] Shanghai Fengxian Dist Cent Hosp, Dept Obstet & Gynecol, Shanghai, Peoples R China; [Wang, J-H] Southern Med Univ, Dept Obstet & Gynecol, Guangzhou, Guangdong, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; China Medical University; Southern Medical University - China	Teng, YC (corresponding author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Obstet & Gynecol, 600 Yisan Rd, Shanghai 200233, Peoples R China.	teng_yc@126.com; zzhang@shsci.org	Ma, Ming-Ze/ABC-4612-2021	Zhang, Yan-Li/0000-0002-8942-5325; Zhang, Zhi-gang/0000-0001-8965-223X	National Science Foundation of China [81071738, 81101600, 81201624]; Songjiang district of Science and Technology Commission of Shanghai Municipality [10SJGG26]; Shanghai Songjiang District Central Hospital [BY10A07]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Songjiang district of Science and Technology Commission of Shanghai Municipality; Shanghai Songjiang District Central Hospital	We are most grateful for Dr Lei-Zhu, Bo-Shi Wang, Ming-Xuan Feng and Doctor XingLin Yang of Medical and Biological Engineering Technology Co. Ltd of Heyuan of Shanghai. This work was supported by the National Science Foundation of China (no. 81071738; no. 81101600; no. 81201624), Songjiang district of Science and Technology Commission of Shanghai Municipality (no. 10SJGG26), and Shanghai Songjiang District Central Hospital (no. BY10A07).	Ambros Victor, 2004, Methods Mol Biol, V265, P131; Banales JM, 2012, HEPATOLOGY, V56, P687, DOI 10.1002/hep.25691; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Castro RE, 2012, CLIN RES HEPATOL GAS, V36, P402, DOI 10.1016/j.clinre.2012.05.019; Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Iwasaki H, 2013, CANCER SCI, V104, P328, DOI 10.1111/cas.12073; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kang HN, 2012, EXP CELL RES, V318, P539, DOI 10.1016/j.yexcr.2011.12.010; Kim KH, 2009, PATHOL INT, V59, P279, DOI 10.1111/j.1440-1827.2009.02366.x; Kutner RH, 2009, NAT PROTOC, V4, P495, DOI 10.1038/nprot.2009.22; Li KKW, 2009, HUM PATHOL, V40, P1234, DOI 10.1016/j.humpath.2009.02.003; Lim YY, 2013, J CELL SCI, V126, P2256, DOI 10.1242/jcs.122275; Liu KJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/867537; McManus MT, 2003, SEMIN CANCER BIOL, V13, P253, DOI 10.1016/S1044-579X(03)00038-5; Mitra AK, 2012, CANCER DISCOV, V2, P1100, DOI 10.1158/2159-8290.CD-12-0206; Pierson J, 2008, J NEURO-ONCOL, V90, P1, DOI 10.1007/s11060-008-9624-3; Renault MA, 2009, CIRC RES, V105, P818, DOI 10.1161/CIRCRESAHA.109.206706; Roy SS, 2014, ONCOGENE, V33, P3707, DOI 10.1038/onc.2013.332; Scherr M, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm971; Sengupta A, 2007, LEUKEMIA, V21, P949, DOI 10.1038/sj.leu.2404657; Shi XB, 2013, ONCOGENE, V32, P4130, DOI 10.1038/onc.2012.425; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; Steg A, 2010, CANCER BIOL THER, V10, P897, DOI 10.4161/cbt.10.9.13252; Streicher KL, 2012, ONCOGENE, V31, P1558, DOI 10.1038/onc.2011.345; Sun MM, 2014, ONCOGENE, V33, P2075, DOI 10.1038/onc.2013.165; Tong JL, 2011, FEBS LETT, V585, P3560, DOI 10.1016/j.febslet.2011.10.021; Vale C, 2008, J CLIN ONCOL, V26, P5802, DOI 10.1200/JCO.2008.16.4368; Wang P, 2014, ONCOGENE, V33, P514, DOI 10.1038/onc.2012.598; Wilting SM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-167; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Zhao Y, 2011, TOXICOL LETT, V205, P320, DOI 10.1016/j.toxlet.2011.06.022	32	113	117	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					717	725		10.1038/onc.2014.9	http://dx.doi.org/10.1038/onc.2014.9			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24608427				2022-12-28	WOS:000348853800005
J	Yim, DGR; Ghosh, S; Guy, GR; Virshup, DM				Yim, D. G. R.; Ghosh, S.; Guy, G. R.; Virshup, D. M.			Casein kinase 1 regulates Sprouty2 in FGF-ERK signaling	ONCOGENE			English	Article						growth factor signaling; SPRY; casein kinase 1; neurite outgrowth; gastric cancer	FACTOR RECEPTOR STIMULATION; KERATINOCYTE GROWTH-FACTOR; TRANSLOCATION DOMAIN; GASTRIC-CARCINOMA; TYROSINE KINASES; CANCER-CELLS; PHOSPHORYLATION; PATHWAY; PROTEIN; INHIBITION	Sprouty2 (SPRY2) is a potent negative regulator of receptor tyrosine kinase signaling, and is implicated as a tumor suppressor. SPRY2 inhibits FGF-RAS-ERK signaling by binding to growth factor receptor bound protein 2 (GRB2) during fibroblast growth factor receptor (FGFR) activation, disrupting the GRB2-SOS (son of sevenless) complex that transduces signals from FGFR to RAS. SPRY2 binding to GRB2 is modulated by phosphorylation but the key regulatory kinase(s) are not known. Prior studies identified the frequent presence of CK1 phosphorylation motifs on SPRY2. We therefore tested if CK1 has a role in SPRY2 phosphorylation and function. Loss of CK1 binding and inhibition of CK1 activity by two structurally distinct small molecules abrogated SPRY2 inhibition of FGF-ERK signaling, leading to decreased SPRY2 interaction with GRB2. Moreover, CK1 activity and binding are necessary for SPRY2 inhibition of FGF-stimulated neurite outgrowth in PC12 cells. Consistent with its proposed role as an inhibitor of FGF signaling, we find that CSNK1E transcript abundance negatively correlates with FGF1/FGF7 message in human gastric cancer samples. Modulation of CK1 activity may be therapeutically useful in the treatment of FGF/SPRY2-related diseases.	[Yim, D. G. R.; Virshup, D. M.] Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, Singapore 169857, Singapore; [Yim, D. G. R.; Guy, G. R.] Biopolis, Inst Mol & Cellular Biol, Signal Transduct Lab, Singapore, Singapore; [Ghosh, S.] Duke NUS Grad Med Sch, Ctr Computat Biol, Singapore 169857, Singapore; [Virshup, D. M.] Natl Univ Singapore, YYL Sch Med, Dept Biochem, Singapore 117548, Singapore; [Yim, D. G. R.] Biopolis, Genome Inst Singapore, Singapore, Singapore	National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Virshup, DM (corresponding author), Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, 8 Coll Rd, Singapore 169857, Singapore.	david.virshup@duke-nus.edu.sg	Virshup, David M/C-1449-2009; Ghosh, Sujoy/I-3729-2017; Yim, Daniel/J-8834-2013	Virshup, David M/0000-0001-6976-850X; Ghosh, Sujoy/0000-0002-7601-165X; Yim, Daniel/0000-0001-6153-4725	National Medical Research Council of Singapore; A*STAR Graduate Scholarship; Agency for Science, Technology and Research, Singapore	National Medical Research Council of Singapore(National Medical Research Council, Singapore); A*STAR Graduate Scholarship(Agency for Science Technology & Research (A*STAR)); Agency for Science, Technology and Research, Singapore(Agency for Science Technology & Research (A*STAR))	We thank Dr Permeen Yusoff and Dr Jit Kong Cheong for advice. This research was supported by the National Medical Research Council of Singapore under its STaR Award program to DMV, the A*STAR Graduate Scholarship (to DGRY) and by the Agency for Science, Technology and Research, Singapore.	Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Aranda S, 2008, MOL CELL BIOL, V28, P5899, DOI 10.1128/MCB.00394-08; Badura L, 2007, J PHARMACOL EXP THER, V322, P730, DOI 10.1124/jpet.107.122846; Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792; Belch J, 2011, LANCET, V377, P1929, DOI 10.1016/S0140-6736(11)60394-2; Birrer MJ, 2007, J CLIN ONCOL, V25, P2281, DOI 10.1200/JCO.2006.09.0795; Casaletto JB, 2012, NAT REV CANCER, V12, P386, DOI 10.1038/nrc3277; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; Chandramouli S, 2008, J BIOL CHEM, V283, P1679, DOI 10.1074/jbc.M705457200; Cheong JK, 2011, ONCOGENE, V30, P2558, DOI 10.1038/onc.2010.627; Cheong JK, 2011, INT J BIOCHEM CELL B, V43, P465, DOI 10.1016/j.biocel.2010.12.004; Chow SY, 2009, J BIOL CHEM, V284, P19623, DOI 10.1074/jbc.M109.021600; DaSilva J, 2006, MOL CELL BIOL, V26, P1898, DOI 10.1128/MCB.26.5.1898-1907.2006; Edwin F, 2009, MOL PHARMACOL, V76, P679, DOI 10.1124/mol.109.055848; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Fong CW, 2006, CANCER RES, V66, P2048, DOI 10.1158/0008-5472.CAN-05-1072; Greer YE, 2011, J CELL BIOL, V192, P993, DOI 10.1083/jcb.201011111; Gross I, 2007, CELL DEATH DIFFER, V14, P1802, DOI 10.1038/sj.cdd.4402188; Guy GR, 2009, J ENDOCRINOL, V203, P191, DOI 10.1677/JOE-09-0110; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Hausott B, 2009, MOL CELL NEUROSCI, V42, P328, DOI 10.1016/j.mcn.2009.08.005; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Lao DH, 2007, J BIOL CHEM, V282, P9117, DOI 10.1074/jbc.M607563200; Lao DH, 2006, J BIOL CHEM, V281, P29993, DOI 10.1074/jbc.M604044200; Lei ZD, 2013, GASTROENTEROLOGY, V145, P554, DOI 10.1053/j.gastro.2013.05.010; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Lim J, 2002, MOL CELL BIOL, V22, P7953, DOI 10.1128/MCB.22.22.7953-7966.2002; Liu F, 2002, J BIOL CHEM, V277, P45393, DOI 10.1074/jbc.M204499200; Lo TL, 2004, CANCER RES, V64, P6127, DOI 10.1158/0008-5472.CAN-04-1207; Lord C, 2011, NATURE, V473, P181, DOI 10.1038/nature09969; Meng QJ, 2008, NEURON, V58, P78, DOI 10.1016/j.neuron.2008.01.019; Metzger RJ, 2008, NATURE, V453, P745, DOI 10.1038/nature07005; Nakazawa K, 2003, CANCER RES, V63, P8848; Okamura H, 2004, MOL CELL BIOL, V24, P4184, DOI 10.1128/MCB.24.10.4184-4195.2004; Ooi CH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000676; Patel R, 2013, J CLIN INVEST, V123, P1157, DOI 10.1172/JCI63672; Pullar CE, 2003, J BIOL CHEM, V278, P22555, DOI 10.1074/jbc.M300205200; Rena G, 2004, EMBO REP, V5, P60, DOI 10.1038/sj.embor.7400048; Rubinfeld B, 2001, J BIOL CHEM, V276, P39037, DOI 10.1074/jbc.M105148200; Smith G, 2012, BRIT J CANCER, V107, P1327, DOI 10.1038/bjc.2012.410; Swiatek W, 2004, J BIOL CHEM, V279, P13011, DOI 10.1074/jbc.M304682200; Tang N, 2011, SCIENCE, V333, P342, DOI 10.1126/science.1204831; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Toyokawa T, 2009, ONCOL REP, V21, P875, DOI 10.3892/or_00000297; Tsai IC, 2007, DEV CELL, V12, P335, DOI 10.1016/j.devcel.2007.02.009; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Wong ESM, 2001, J BIOL CHEM, V276, P5866, DOI 10.1074/jbc.M006945200; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200	52	20	20	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					474	484		10.1038/onc.2013.564	http://dx.doi.org/10.1038/onc.2013.564			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24469046				2022-12-28	WOS:000348451300008
J	Petrova, E; Matevossian, A; Resh, MD				Petrova, E.; Matevossian, A.; Resh, M. D.			Hedgehog acyltransferase as a target in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article						hedgehog; palmitoylation; pancreatic cancer	SONIC-HEDGEHOG; SIGNALING PATHWAY; CANCER; PALMITOYLATION; PROTEIN; CELLS; IDENTIFICATION; TUMORIGENESIS; REQUIREMENT; MECHANISMS	Sonic Hedgehog (Shh) is abnormally expressed in pancreatic cancer and is associated with disease onset and progression. Inhibition of Shh signaling is thus an attractive clinical target for therapeutic intervention. Most efforts to block Shh signaling have focused on inhibitors of Smoothened, which target the canonical Shh signaling pathway. These approaches have met with limited success, in part due to development of resistance-conferring mutations and contributions from non-canonical signaling pathways. Here, we show that Hedgehog acyltransferase (Hhat), the enzyme responsible for the attachment of palmitate onto Shh, is a novel target for inhibition of Shh signaling in pancreatic cancer cells. Depletion of Hhat with lentivirally delivered small hairpin RNA decreased both anchorage-dependent and independent proliferation of human pancreatic cancer cells. In vivo, Hhat knockdown led to reduction of tumor growth in a mouse xenograft model of pancreatic cancer. RU-SKI 43, a small molecule inhibitor of Hhat recently developed by our group, reduced pancreatic cancer cell proliferation and Gli-1 activation through Smoothened-independent non-canonical signaling. In addition, RU-SKI 43 treatment inhibited two key proliferative pathways regulated by Akt and mTOR. This work demonstrates that Hhat has a critical role in pancreatic cancer and that a small molecule inhibitor of Hhat can successfully block pancreatic cancer cell proliferation. It also highlights the importance of developing optimized Hhat inhibitors to be used as therapeutics in pancreatic cancer, as well as in other malignancies characterized by Shh overexpression.	[Petrova, E.; Matevossian, A.; Resh, M. D.] Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; [Petrova, E.] Cornell Univ, Weill Grad Sch Med Sci, Grad Program Pharmacol, New York, NY 10021 USA; [Matevossian, A.; Resh, M. D.] Gerstner Sloan Kettering Grad Sch Biomed Sci, New York, NY USA; [Resh, M. D.] Cornell Univ, Weill Grad Sch Med Sci, Grad Program Cell Biol, New York, NY 10021 USA; [Resh, M. D.] Cornell Univ, Weill Grad Sch Med Sci, Grad Program Biochem, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University	Resh, MD (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave,Box 143, New York, NY 10021 USA.	reshm@mskcc.org		Resh, Marilyn/0000-0001-6118-9466	NIH [GM57966, CA158474]; MSKCC Cycle for Survival; Geoffrey Beene Cancer Research Foundation; Commonwealth Foundation for Cancer Research; Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center; NATIONAL CANCER INSTITUTE [R21CA186957, P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057966] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MSKCC Cycle for Survival; Geoffrey Beene Cancer Research Foundation; Commonwealth Foundation for Cancer Research; Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Raisa Louft-Nisenbaum for technical assistance, Dr Elisa de Stanchina for performing tumor xenograft studies, Dr Nian Wu for pharmacokinetic analyses, the MSKCC Genomics and Molecular Cytology Cores, and Jessica Rios-Esteves and Rayshonda Hardy for reading the manuscript. This work was supported by NIH grants GM57966 and CA158474, by MSKCC Cycle for Survival, by the Geoffrey Beene Cancer Research Foundation, by Mr William H Goodwin and Mrs Alice Goodwin and by the Commonwealth Foundation for Cancer Research and the Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center.	Barakat MT, 2010, TRENDS MOL MED, V16, P337, DOI 10.1016/j.molmed.2010.05.003; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Buglino JA, 2008, J BIOL CHEM, V283, P22076, DOI 10.1074/jbc.M803901200; Buglino JA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011195; Chen MH, 2004, GENE DEV, V18, P641, DOI 10.1101/gad.1185804; Chinchilla P, 2010, CELL CYCLE, V9, P570, DOI 10.4161/cc.9.3.10591; Dawber RJ, 2005, BMC DEV BIOL, V5, DOI 10.1186/1471-213X-5-21; Hardy RY, 2012, J BIOL CHEM, V287, P42881, DOI 10.1074/jbc.M112.426833; Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Mann RK, 2004, ANNU REV BIOCHEM, V73, P891, DOI 10.1146/annurev.biochem.73.011303.073933; Metcalfe C, 2011, CANCER RES, V71, P5057, DOI 10.1158/0008-5472.CAN-11-0923; Miura GI, 2006, DEV CELL, V10, P167, DOI 10.1016/j.devcel.2005.11.017; Morton JP, 2007, P NATL ACAD SCI USA, V104, P5103, DOI 10.1073/pnas.0701158104; Nolan-Stevaux O, 2009, GENE DEV, V23, P24, DOI 10.1101/gad.1753809; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Pan SF, 2010, ACS MED CHEM LETT, V1, P130, DOI 10.1021/ml1000307; Petrova E, 2013, NAT CHEM BIOL, V9, P247, DOI [10.1038/NCHEMBIO.1184, 10.1038/nchembio.1184]; Peukert S, 2010, CHEMMEDCHEM, V5, P500, DOI 10.1002/cmdc.201000011; Rodriguez-Blanco J, 2013, ONCOGENE, V32, P2335, DOI 10.1038/onc.2012.243; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Skvara H, 2011, J INVEST DERMATOL, V131, P1735, DOI 10.1038/jid.2011.48; Testaz S, 2001, P NATL ACAD SCI USA, V98, P12521, DOI 10.1073/pnas.221108698; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tian H, 2009, P NATL ACAD SCI USA, V106, P4254, DOI 10.1073/pnas.0813203106; Wu X, 2004, CHEM BIOL, V11, P1229, DOI 10.1016/j.chembiol.2004.06.010; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275	29	43	47	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					263	268		10.1038/onc.2013.575	http://dx.doi.org/10.1038/onc.2013.575			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24469057	Green Accepted			2022-12-28	WOS:000347790500014
J	Brundage, ME; Tandon, P; Eaves, DW; Williams, JP; Miller, SJ; Hennigan, RH; Jegga, A; Cripe, TP; Ratner, N				Brundage, M. E.; Tandon, P.; Eaves, D. W.; Williams, J. P.; Miller, S. J.; Hennigan, R. H.; Jegga, A.; Cripe, T. P.; Ratner, N.			MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1	ONCOGENE			English	Article						Neurofibromatosis; MPNST; Schwann; resistance; DEPTOR; differentiation	TUMOR-SUPPRESSOR; C-MAF; MAMMALIAN TARGET; EXPRESSION; CELLS; ACTIVATION; INHIBITION; PATHWAYS; SURVIVAL; GENE	Mutations in the neurofibromatosis type 1 (NF1) tumor suppressor gene are common in cancer and can cause resistance to therapy. Using transcriptome analysis we identified MAF as an NF1-regulated transcription factor and verified MAF regulation through RAS/MAPK/AP-1 signaling in malignant peripheral nerve sheath tumor (MPNST) cell lines. MAF was also downregulated in human MPNST. Acute re-expression of MAF promoted expression of glial differentiation markers in MPNST cells in vitro, decreased self-renewal of embryonic precursors and transiently affected tumor cell phenotypes in vitro by increasing MPNST cell death and reducing metabolic activity and anchorage-independent growth. Paradoxically, chronic MAF overexpression enhanced MPNST cell tumor growth in vivo, correlating with elevated pS6 in vitro and in vivo. RAD001 blocked MAF-mediated tumor growth, and MAF regulated the mTOR pathway through DEPTOR. MAPK inhibition with NF1 loss of function is predicted to show limited efficacy due to reactivation of mTOR signaling via MAF.	[Brundage, M. E.; Tandon, P.; Eaves, D. W.; Williams, J. P.; Miller, S. J.; Hennigan, R. H.; Ratner, N.] Univ Cincinnati, Div Expt Hematol & Canc Biol, Dept Pediat, Coll Med, Cincinnati, OH 45267 USA; [Jegga, A.] Univ Cincinnati, Div Expt Hematol & Canc Biol, Cincinnati Childrens Hosp Med Ctr, Div Biomed Informat,Dept Pediat, Cincinnati, OH 45267 USA; [Cripe, T. P.] Univ Cincinnati, Div Expt Hematol & Canc Biol, Dept Pediat, Div Oncol, Cincinnati, OH 45267 USA; [Cripe, T. P.] Ohio State Univ, Nationwide Childrens Hosp, Div Hematol Oncol BMT, Columbus, OH 43210 USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; Ohio State University; Nationwide Childrens Hospital	Ratner, N (corresponding author), Univ Cincinnati, Div Expt Hematol & Canc Biol, Cincinnati Childrens Hosp, Dept Pediat,Coll Med, 3333 Burnet Ave, Cincinnati, OH 45267 USA.	nancy.ratner@cchmc.org	Jegga, Anil/H-6140-2011; Williams, Jon/AAP-2761-2020	Jegga, Anil/0000-0002-4881-7752; RATNER, NANCY/0000-0001-5030-9354	NIH [AR-47363, DK78392, DK90971];  [R01 NS28840];  [T32HD07463];  [NIH-P50-NS057531]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007463] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA117846] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR047363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK090971, P30DK078392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028840, F32NS083249, P50NS057531] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Frank McCormick (UCSF) for providing NF1 constructs and Kohsuke Kataoka for providing the MAF reporter. We thank the Viral Vector Core in the Translational Core Laboratories at Cincinnati Children's Hospital Medical Center for viral vector production. We thank Monica DeLay for assistance with flow cytometry from the Research Flow Cytometry Core in the Division of Rheumatology at Cincinnati Children's Hospital Medical Center, supported in part by NIH AR-47363, NIH DK78392 and NIH DK90971. This work was supported by R01 NS28840 (to NR) and NIH-P50-NS057531 (to NR and TPC). MB was partially supported by a training grant, T32HD07463.	Annunziata CM, 2011, BLOOD, V117, P2396, DOI 10.1182/blood-2010-04-278788; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Brems H, 2009, LANCET ONCOL, V10, P508, DOI 10.1016/S1470-2045(09)70033-6; Buchstaller J, 2012, CANCER CELL, V21, P240, DOI 10.1016/j.ccr.2011.12.027; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Cheung M, 2003, DEVELOPMENT, V130, P5681, DOI 10.1242/dev.00808; De Raedt T, 2011, CANCER CELL, V20, P400, DOI 10.1016/j.ccr.2011.08.014; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Donovan S, 2002, CANCER CELL, V2, P507, DOI 10.1016/S1535-6108(02)00214-3; Endo M, 2013, CLIN CANCER RES, V19, P450, DOI 10.1158/1078-0432.CCR-12-1067; Eychene A, 2008, NAT REV CANCER, V8, P683, DOI 10.1038/nrc2460; Frank NY, 2010, J CLIN INVEST, V120, P41, DOI 10.1172/JCI41004; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Holzel M, 2010, CELL, V142, P218, DOI 10.1016/j.cell.2010.06.004; Huang WD, 2002, J BIOL CHEM, V277, P50668, DOI 10.1074/jbc.M206544200; Jessen WJ, 2013, J CLIN INVEST, V123, P340, DOI 10.1172/JCI60578; Johannessen CM, 2008, CURR BIOL, V18, P56, DOI 10.1016/j.cub.2007.11.066; Johansson G, 2008, MOL CANCER THER, V7, P1237, DOI 10.1158/1535-7163.MCT-07-2335; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kataoka K, 2001, J BIOL CHEM, V276, P34074, DOI 10.1074/jbc.M105383200; Keng VW, 2012, CANCER RES, V72, P3405, DOI 10.1158/0008-5472.CAN-11-4092; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kraniak JM, 2010, MOL CELL BIOCHEM, V344, P267, DOI 10.1007/s11010-010-0551-1; Lau N, 2000, J NEUROPATH EXP NEUR, V59, P759, DOI 10.1093/jnen/59.9.759; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; Maertens O, 2013, CANCER DISCOV, V3, P338, DOI 10.1158/2159-8290.CD-12-0313; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Miller SJ, 2010, ONCOGENE, V29, P368, DOI 10.1038/onc.2009.360; Miller SJ, 2009, EMBO MOL MED, V1, P236, DOI 10.1002/emmm.200900027; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Pouponnot C, 2006, ONCOGENE, V25, P1299, DOI 10.1038/sj.onc.1209171; Pytel P, 2010, INT J SURG PATHOL, V18, P449, DOI 10.1177/1066896909351698; Stowe IB, 2012, GENE DEV, V26, P1421, DOI 10.1101/gad.190876.112; Sun DC, 2013, MOL CANCER RES, V11, P616, DOI 10.1158/1541-7786.MCR-12-0593; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Wang ZW, 2012, NEOPLASIA, V14, P368, DOI 10.1593/neo.12542; Watson JEV, 2004, ONCOGENE, V23, P3487, DOI 10.1038/sj.onc.1207474; Wende H, 2012, SCIENCE, V335, P1373, DOI 10.1126/science.1214314; Whittaker SR, 2013, CANCER DISCOV, V3, P350, DOI 10.1158/2159-8290.CD-12-0470; Williams JP, 2008, CELL STEM CELL, V3, P658, DOI 10.1016/j.stem.2008.10.003; Wu J, 2014, ONCOGENE, V33, P173, DOI 10.1038/onc.2012.579; Yin B, 2006, LEUKEMIA, V20, P151, DOI 10.1038/sj.leu.2404033; Zhao YC, 2011, MOL CELL, V44, P304, DOI 10.1016/j.molcel.2011.08.029; Zou CYY, 2009, MOL CANCER THER, V8, P1157, DOI 10.1158/1535-7163.MCT-08-1008	49	22	22	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2014	33	49					5626	5636		10.1038/onc.2013.506	http://dx.doi.org/10.1038/onc.2013.506			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZW	24509877	Green Accepted, Green Submitted			2022-12-28	WOS:000346088700007
J	Barras, D; Lorusso, G; Ruegg, C; Widmann, C				Barras, D.; Lorusso, G.; Rueegg, C.; Widmann, C.			Inhibition of cell migration and invasion mediated by the TAT-RasGAP(317-326) peptide requires the DLC1 tumor suppressor	ONCOGENE			English	Article						RasGAP; DLC1; adhesion; migration; invasion; peptide	FOCAL ADHESION KINASE; RAS-GAP; CANCER; RHO; BINDING; PROTEIN; APOPTOSIS; CYTOSKELETON; INTEGRINS; GTPASE	TAT-RasGAP(317-326), a peptide corresponding to the 317-326 sequence of p120 RasGAP coupled with a cell-permeable TAT-derived peptide, sensitizes the death response of various tumor cells to several anticancer treatments. We now report that this peptide is also able to increase cell adherence, prevent cell migration and inhibit matrix invasion. This is accompanied by a marked modification of the actin cytoskeleton and focal adhesion redistribution. Interestingly, integrins and the small Rho GTP-binding protein, which are well-characterized proteins modulating actin fibers, adhesion and migration, do not appear to be required for the pro-adhesive properties of TAT-RasGAP(317-326). In contrast, deleted in liver cancer-1, a tumor suppressor protein, the expression of which is often deregulated in cancer cells, was found to be required for TAT-RasGAP(317-326) to promote cell adherence and inhibit migration. These results show that TAT-RasGAP(317-326), besides its ability to favor tumor cell death, hampers cell migration and invasion.	[Barras, D.; Widmann, C.] Univ Lausanne, Dept Physiol, CH-1005 Lausanne, Vaud, Switzerland; [Lorusso, G.; Rueegg, C.] Univ Fribourg, Dept Med, CH-1700 Fribourg, Switzerland	University of Lausanne; University of Fribourg	Widmann, C (corresponding author), Univ Lausanne, Dept Physiol, Bugnon 7, CH-1005 Lausanne, Vaud, Switzerland.	Christian.Widmann@unil.ch	Widmann, Christian/N-9851-2013	Widmann, Christian/0000-0002-6881-0363; Lorusso, Girieca/0000-0002-2807-3207	Oncosuisse [KFS-02543-02-2010]	Oncosuisse	This work was supported by a grant from Oncosuisse (KFS-02543-02-2010). We thank Professor Nicholas C. Popescu (National Cancer Institute, Bethesda) for the DLC1-null MEFs and Professor David Schlaepfer (Moores UCSD Cancer Center, La Jolla) for the FAK-null MEFs.	Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485; Barras D, 2011, CURR PHARM BIOTECHNO, V12, P1153, DOI 10.2174/138920111796117337; Beck M, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.82; Bravo-Cordero JJ, 2012, CURR OPIN CELL BIOL, V24, P277, DOI 10.1016/j.ceb.2011.12.004; Bulat N, 2009, J LIPID RES, V50, P81, DOI 10.1194/jlr.M800119-JLR200; Byron A, 2010, CURR BIOL, V20, pR1063, DOI 10.1016/j.cub.2010.10.059; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Hamadi A, 2005, J CELL SCI, V118, P4415, DOI 10.1242/jcs.02565; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358; Kawai K, 2004, BIOCHEM SOC T, V32, P1107, DOI 10.1042/BST0321107; Kulkarni SV, 2000, J CELL BIOL, V149, P457, DOI 10.1083/jcb.149.2.457; Lahoz A, 2008, GENE DEV, V22, P1724, DOI 10.1101/gad.1691408; Leblanc V, 1998, MOL CELL BIOL, V18, P5567, DOI 10.1128/MCB.18.9.5567; Li GR, 2011, P NATL ACAD SCI USA, V108, P17129, DOI 10.1073/pnas.1112122108; Mai A, 2011, J CELL BIOL, V194, P291, DOI 10.1083/jcb.201012126; McClatchey AI, 2005, GENE DEV, V19, P2265, DOI 10.1101/gad.1335605; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; Michod D, 2004, ONCOGENE, V23, P8971, DOI 10.1038/sj.onc.1207999; Michod D, 2009, JNCI-J NATL CANCER I, V101, P828, DOI 10.1093/jnci/djp100; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Pamonsinlapatham P, 2009, BIOCHIMIE, V91, P320, DOI 10.1016/j.biochi.2008.10.010; Pittet O, 2007, J PHOTOCH PHOTOBIO B, V88, P29, DOI 10.1016/j.jphotobiol.2007.04.009; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ross B, 2007, BIOCHEM BIOPH RES CO, V353, P463, DOI 10.1016/j.bbrc.2006.12.044; Sethi N, 2011, NAT REV CANCER, V11, P735, DOI 10.1038/nrc3125; Sheppard D, 2000, MATRIX BIOL, V19, P203, DOI 10.1016/S0945-053X(00)00065-2; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Yang JY, 2005, MOL BIOL CELL, V16, P3511, DOI 10.1091/mbc.E05-01-0080; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001; Yang XY, 2009, ONCOGENE, V28, P1401, DOI 10.1038/onc.2008.498; Yang XY, 2011, CANCER RES, V71, P2916, DOI 10.1158/0008-5472.CAN-10-2158; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517	45	17	18	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2014	33	44					5163	5172		10.1038/onc.2013.465	http://dx.doi.org/10.1038/onc.2013.465			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR9RZ	24213569	Green Accepted			2022-12-28	WOS:000343914900003
J	Nadratowska-Wesolowska, B; Haugsten, EM; Zakrzewska, M; Jakimowicz, P; Zhen, Y; Pajdzik, D; Wesche, J; Wiedlocha, A				Nadratowska-Wesolowska, B.; Haugsten, E. M.; Zakrzewska, M.; Jakimowicz, P.; Zhen, Y.; Pajdzik, D.; Wesche, J.; Wiedlocha, A.			RSK2 regulates endocytosis of FGF receptor 1 by phosphorylation on serine 789	ONCOGENE			English	Article						FGF1; FGFR1; signaling; ERK1/2; RSK2; serine phosphorylation; endocytosis	GROWTH-FACTOR RECEPTOR; RIBOSOMAL S6 KINASE; EPITHELIAL-CELLS; CANCER; PROTEIN; SITE; UBIQUITINATION; ACTIVATION; INHIBITOR; MUTATIONS	FGFR1 (fibroblast growth factor receptor 1) regulates many key cellular responses including proliferation, migration and differentiation through activation of signaling pathways. Irregularities in FGFR1 signaling have been implicated in several pathological conditions, including human cancer. In order to discover novel regulators of FGFR1 signaling, we performed yeast two-hybrid screens and identified RSK2 (p90 ribosomal S6 kinase 2) as a potential FGFR1 interaction partner. RSK2 belongs to the family of serine/threonine kinases that are activated through the Ras-MAPK signal transduction pathway. Both in vitro and in vivo experiments confirmed the interaction and we show that phosphorylated RSK2 binds to and phosphorylates serine 789 in the C-terminal tail of FGFR1. Inhibition of RSK2 activity led to prolonged tyrosine transphosphorylation of FGFR1. Furthermore, prevention of FGFR1 phosphorylation by inhibition of RSK2 activity or mutation of serine 789 to alanine reduced FGFR1 endocytosis and ubiquitination explaining mechanistically the prolonged signaling activity. We propose a novel regulatory mechanism whereby activated RSK2 directly interacts with and phosphorylates FGFR1, thereby modulating receptor signaling through regulation of endocytosis.	[Nadratowska-Wesolowska, B.; Haugsten, E. M.; Zhen, Y.; Wesche, J.; Wiedlocha, A.] Univ Oslo, Fac Med, Ctr Canc Biomed, Oslo, Norway; [Nadratowska-Wesolowska, B.; Haugsten, E. M.; Zhen, Y.; Wesche, J.; Wiedlocha, A.] Oslo Univ Hosp, Inst Canc Res, Dept Biochem, N-0379 Oslo, Norway; [Zakrzewska, M.] Univ Wroclaw, Fac Biotechnol, Dept Prot Engn, PL-50138 Wroclaw, Poland; [Jakimowicz, P.; Pajdzik, D.] Univ Wroclaw, Fac Biotechnol, Dept Prot Biotechnol, PL-50138 Wroclaw, Poland	University of Oslo; University of Oslo; University of Wroclaw; University of Wroclaw	Wiedlocha, A (corresponding author), Oslo Univ Hosp, Inst Canc Res, Dept Biochem, N-0379 Oslo, Norway.	Antoni.Wiedlocha@rr-research.no	Wesche, Jorgen/ABH-7524-2020; Nadratowska-Wesolowska, Beata/B-7613-2015	Wesche, Jorgen/0000-0002-9200-9162; Zakrzewska, Malgorzata/0000-0001-8214-1533; Haugsten, Ellen Margrethe/0000-0002-3111-5092	Norway through the Norwegian Financial Mechanism within the Polish-Norwegian Research Fund [PNRF-87-AI-1/07]; Polish Ministry of Science and Higher Education [0627/IP1/2011/71]; South-Eastern Norway Regional Health Authority	Norway through the Norwegian Financial Mechanism within the Polish-Norwegian Research Fund; Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland); South-Eastern Norway Regional Health Authority	This work was supported by grant PNRF-87-AI-1/07 from Norway through the Norwegian Financial Mechanism within the Polish-Norwegian Research Fund and by the Polish Ministry of Science and Higher Education (grant 0627/IP1/2011/71). The skilful technical assistance of Anne Gro Bergersen and Anne-Mari G. Pedersen is gratefully acknowledged. JW holds a senior scientist grant from South-Eastern Norway Regional Health Authority.	Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Casaletto JB, 2012, NAT REV CANCER, V12, P386, DOI 10.1038/nrc3277; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; GANDINO L, 1994, J BIOL CHEM, V269, P1815; Goh LK, 2010, J CELL BIOL, V189, P871, DOI 10.1083/jcb.201001008; Haglund K, 2012, J CELL SCI, V125, P265, DOI 10.1242/jcs.091280; Haugsten EM, 2008, MOL BIOL CELL, V19, P3390, DOI 10.1091/mbc.E07-12-1219; Haugsten EM, 2010, MOL CANCER RES, V8, P1439, DOI 10.1158/1541-7786.MCR-10-0168; Haugsten EM, 2005, J CELL SCI, V118, P3869, DOI 10.1242/jcs.02509; Jang MH, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3239; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kang SM, 2007, CANCER CELL, V12, P201, DOI 10.1016/j.ccr.2007.08.003; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Oksvold MP, 2003, ONCOGENE, V22, P8509, DOI 10.1038/sj.onc.1207117; Pan ZZ, 2004, MOL BIOL CELL, V15, P3106, DOI 10.1091/mbc.E04-01-0043; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Persaud A, 2011, EMBO J, V30, P3259, DOI 10.1038/emboj.2011.234; Romeo Y, 2012, BIOCHEM J, V441, P553, DOI 10.1042/BJ20110289; Sapkota GP, 2007, BIOCHEM J, V401, P29, DOI 10.1042/BJ20061088; Smith JA, 2005, CANCER RES, V65, P1027; Sorensen V, 2008, MOL CELL BIOL, V28, P4129, DOI 10.1128/MCB.02117-07; Sun QX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012819; THEROUX SJ, 1992, MOL ENDOCRINOL, V6, P1849, DOI 10.1210/me.6.11.1849; Tsang M., 2004, SCI STKE, V2004, pE17; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Wesche J, 2011, BIOCHEM J, V437, P199, DOI 10.1042/BJ20101603; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899; Xian W, 2009, CANCER RES, V69, P2244, DOI 10.1158/0008-5472.CAN-08-3398; Zakrzewska M, 2004, PROTEIN ENG DES SEL, V17, P603, DOI 10.1093/protein/gzh076; Zakrzewska M, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003087	36	18	18	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2014	33	40					4823	4836		10.1038/onc.2013.425	http://dx.doi.org/10.1038/onc.2013.425			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0EH	24141780				2022-12-28	WOS:000343240100004
J	Chen, X; Wu, Q; Tan, L; Porter, D; Jager, MJ; Emery, C; Bastian, BC				Chen, X.; Wu, Q.; Tan, L.; Porter, D.; Jager, M. J.; Emery, C.; Bastian, B. C.			Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations	ONCOGENE			English	Article						GNAQ/GNA11; MAPK signaling; protein kinase C; combined PKC and MEK inhibition; melanoma; PKC inhibitor	PROTEIN-KINASE-C; PROMOTING PHORBOL ESTERS; SIGNAL-REGULATED KINASE; PHASE-II; BRAF INHIBITION; ALPHA-SUBUNIT; LUNG-CANCER; PATHWAY; RESISTANCE; RAF	Uveal melanoma (UM) is a genetically and biologically distinct type of melanoma, and once metastatic there is no effective treatment currently available. Eighty percent of UMs harbor mutations in the G alpha(q) family members GNAQ and GNA11. Understanding the effector pathways downstream of these oncoproteins is important to identify opportunities for targeted therapy. We report consistent activation of the protein kinase C (PKC) and MAPK pathways as a consequence of GNAQ or GNA11 mutation. PKC inhibition with AEB071 or AHT956 suppressed PKC and MAPK signalling and induced G1 arrest selectively in melanoma cell lines carrying GNAQ or GNA11 mutations. In contrast, treatment with two different MEK inhibitors, PD0325901 and MEK162, inhibited the proliferation of melanoma cell lines irrespective of their mutation status, indicating that in the context of GNAQ or GNA11 mutation MAPK activation can be attributed to activated PKC. AEB071 significantly slowed the growth of tumors in an allograft model of GNAQ(Q209L)-transduced melanocytes, but did not induce tumor shrinkage. In vivo and in vitro studies showed that PKC inhibitors alone were unable to induce sustained suppression of MAP-kinase signaling. However, combinations of PKC and MEK inhibition, using either PD0325901or MEK162, led to sustained MAP-kinase pathway inhibition and showed a strong synergistic effect in halting proliferation and in inducing apoptosis in vitro. Furthermore, combining PKC and MEK inhibition was efficacious in vivo, causing marked tumor regression in a UM xenograft model. Our data identify PKC as a rational therapeutic target for melanoma patients with GNAQ or GNA11 mutations and demonstrate that combined MEK and PKC inhibition is synergistic, with superior efficacy compared to treatment with either approach alone.	[Chen, X.; Bastian, B. C.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA; [Chen, X.; Wu, Q.; Bastian, B. C.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Chen, X.; Wu, Q.; Bastian, B. C.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Chen, X.; Wu, Q.; Bastian, B. C.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA; [Tan, L.; Porter, D.; Emery, C.] Novartis, Novartis Inst BioMed Res, Cambridge, MA USA; [Jager, M. J.] Leiden Univ, Med Ctr, Dept Ophthalmol, Leiden, Netherlands	Memorial Sloan Kettering Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Novartis; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Emery, C (corresponding author), Novartis Inst BioMed Res, Cambridge, MA 02139 USA.	caroline.emery@novartis.com; Boris.Bastian@ucsf.edu	Jager, Martine/AAR-3525-2020	Jager, Martine/0000-0003-2261-3820; Bastian, Boris/0000-0003-1836-6062; chen, xu/0000-0003-2524-4979	National Cancer Institute [CA142873]; Melanoma Research Alliance Team Science Award; NATIONAL CANCER INSTITUTE [R01CA142873] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Melanoma Research Alliance Team Science Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grant CA142873 from the National Cancer Institute and a Melanoma Research Alliance Team Science Award.	ARITA Y, 1992, CANCER RES, V52, P4514; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Bosco R, 2011, MINI-REV MED CHEM, V11, P185, DOI 10.2174/138955711795049899; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Clement-Duchene C, 2012, LUNG CANCER, V78, P57, DOI 10.1016/j.lungcan.2012.06.003; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; EGAN KM, 1988, SURV OPHTHALMOL, V32, P239, DOI 10.1016/0039-6257(88)90173-7; Flaherty KT, 2012, NEW ENGL J MED, V367, P1694, DOI 10.1056/NEJMoa1210093; Friday BB, 2008, CANCER RES, V68, P6145, DOI 10.1158/0008-5472.CAN-08-1430; Goldsmith ZG, 2007, ONCOGENE, V26, P3122, DOI 10.1038/sj.onc.1210407; GRAGOUDAS ES, 1991, OPHTHALMOLOGY, V98, P383; Griewank KG, 2012, PIGM CELL MELANOMA R, V25, DOI 10.1111/j.1755-148X.2012.00971.x; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Gronberg BH, 2012, LUNG CANCER, V78, P63, DOI 10.1016/j.lungcan.2012.07.007; HEEMSKERK FMJ, 1993, BIOCHEM BIOPH RES CO, V190, P236, DOI 10.1006/bbrc.1993.1036; HERGET T, 1995, EUR J BIOCHEM, V233, P448, DOI 10.1111/j.1432-1033.1995.448_2.x; Hubbard KB, 2006, CELL SIGNAL, V18, P135, DOI 10.1016/j.cellsig.2005.08.004; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; Kirkwood JM, 2012, CLIN CANCER RES, V18, P555, DOI 10.1158/1078-0432.CCR-11-1491; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Lamba S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006833; Lehar J, 2009, NAT BIOTECHNOL, V27, P659, DOI 10.1038/nbt.1549; Mackay HJ, 2007, NAT REV CANCER, V7, P554, DOI 10.1038/nrc2168; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; McLean IW, 2004, CAN J OPHTHALMOL, V39, P343, DOI 10.1016/S0008-4182(04)80004-8; Millward MJ, 2006, BRIT J CANCER, V95, P829, DOI 10.1038/sj.bjc.6603331; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Naylor TL, 2011, CANCER RES, V71, P2643, DOI 10.1158/0008-5472.CAN-10-2525; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Paraiso KHT, 2010, BRIT J CANCER, V102, P1724, DOI 10.1038/sj.bjc.6605714; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Singh Arun D, 2005, Ophthalmol Clin North Am, V18, P75, DOI 10.1016/j.ohc.2004.07.002; Solit DB, 2011, NEW ENGL J MED, V364, P772, DOI 10.1056/NEJMcibr1013704; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sturm OE, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001212; Teicher BA, 2006, CLIN CANCER RES, V12, P5336, DOI 10.1158/1078-0432.CCR-06-0945; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Urtreger AJ, 2012, IUBMB LIFE, V64, P18, DOI 10.1002/iub.574; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Wagner J, 2009, J MED CHEM, V52, P6193, DOI 10.1021/jm901108b; Wu XQ, 2012, MOL CANCER THER, V11, P1905, DOI 10.1158/1535-7163.MCT-12-0121; Wu XQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029622	49	124	128	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2014	33	39					4724	4734		10.1038/onc.2013.418	http://dx.doi.org/10.1038/onc.2013.418			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0ED	24141786	Green Accepted			2022-12-28	WOS:000343239500003
J	Fahraeus, R; Olivares-Illana, V				Fahraeus, R.; Olivares-Illana, V.			MDM2's social network	ONCOGENE			English	Review						MDM2; interactome; interactions; p53	MESSENGER-RNA STABILIZATION; DNA-DAMAGE; E3 LIGASE; UBIQUITIN LIGASE; REGULATES P53; TRANSCRIPTIONAL ACTIVITY; PROTEASOMAL DEGRADATION; ANDROGEN RECEPTOR; INDUCED APOPTOSIS; INHIBITING MDM2	MDM2 is considered a hub protein due to its capacity to interact with a large number of different partners of which p53 is most well described. MDM2 is an E3 ubiquitin ligase, and many, but not all, of its interactions relate directly to this activity, such as substrates, adaptors or bridges, promoters, inhibitors or complementary factors. Some interactions serve regulatory functions that in response to cellular stresses control the localisation and functions of MDM2 including protein kinases, ribosomal proteins and proteases. Moreover, interactions with nucleotides serve other functions such as mRNA to regulate protein synthesis and DNA to control transcription. To perform such a pleiotropic panorama of different functions, MDM2 is subjected to a multitude of post-translational modifications and is expressed in different isoforms. The large and diverse interactome is made possible due to the plasticity of MDM2 and in this review we have listed the MDM2 interactions until now and we will discuss how this multifaceted protein can interact with such a variety of substrates to provide a key intermediary role in different signalling pathways.	[Fahraeus, R.] Univ Paris 07, Hop St Louis, INSERM Unite 940, Equipe Labellisee Ligue Canc,Inst Genet Mol, Paris, France; [Olivares-Illana, V.] Univ Autonoma San Luis Potosi, Inst Fis, San Luis Potosi 78290, Mexico	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universidad Autonoma de San Luis Potosi	Olivares-Illana, V (corresponding author), Univ Autonoma San Luis Potosi, Inst Fis, Av Manuel Nava 6 Zona Univ, San Luis Potosi 78290, Mexico.	vanesa@ifisica.uaslp.mx	Olivares-Illana, Vanesa/AAF-9710-2021; fahraeus, robin/K-8726-2014	Olivares-Illana, Vanesa/0000-0001-6949-5986	CONACyT [CB-166233]; Fondo de Apoyo a la Investigacion [C13-FAI-03-57.57]; La Ligue Contre le Cancer, Inserm; European Regional Development Fund; State Budget of the Czech Republic (RECAMO) [CZ.1.05/2.1.00/03.0101];  [PROMEP/103.5/12/3953]	CONACyT(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Fondo de Apoyo a la Investigacion; La Ligue Contre le Cancer, Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)); European Regional Development Fund(European Commission); State Budget of the Czech Republic (RECAMO); 	We apologise to those whose works have not been cited in this article owing to lack of space. This article is supported by CONACyT CB-166233; PROMEP/103.5/12/3953 and Fondo de Apoyo a la Investigacion (C13-FAI-03-57.57). RF is funded by La Ligue Contre le Cancer, Inserm and the European Regional Development Fund and the State Budget of the Czech Republic (RECAMO, CZ.1.05/2.1.00/03.0101). The authors thank Dr Gomez-Puyou for revision of the manuscript.	Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; Asahara H, 2003, NUCLEIC ACIDS RES, V31, P2451, DOI 10.1093/nar/gkg342; Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; Bae S, 2012, ONCOL REP, V28, P1924, DOI 10.3892/or.2012.2005; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Banks D, 2006, CELL CYCLE, V5, P1719, DOI 10.4161/cc.5.15.3150; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Biderman Lynn, 2012, Genes Cancer, V3, P264, DOI 10.1177/1947601912455331; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Boyd MT, 2000, J BIOL CHEM, V275, P31883, DOI 10.1074/jbc.M004252200; Brenkman AB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002819; Busso CS, 2009, ONCOGENE, V28, P1616, DOI 10.1038/onc.2009.5; Calabro V, 2002, J BIOL CHEM, V277, P2674, DOI 10.1074/jbc.M107173200; Candeias MM, 2008, NAT CELL BIOL, V10, P1098, DOI 10.1038/ncb1770; Challen C, 2012, INT J ONCOL, V40, P851, DOI 10.3892/ijo.2011.1267; Chen D, 2007, ONCOGENE, V26, P5029, DOI 10.1038/sj.onc.1210327; Chen D, 2009, EMBO REP, V10, P166, DOI 10.1038/embor.2008.231; Chen LH, 2010, EMBO J, V29, P2538, DOI 10.1038/emboj.2010.140; Chen S, 2004, NATURE, V432, P640; Cheng TH, 2007, MOL CELL BIOL, V27, P111, DOI 10.1128/MCB.00235-06; Chi XZ, 2009, CANCER RES, V69, P8111, DOI 10.1158/0008-5472.CAN-09-1057; Daftuar L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068667; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Dohmesen C, 2008, CELL CYCLE, V7, P222, DOI 10.4161/cc.7.2.5185; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; Embade N, 2012, HEPATOLOGY, V55, P1237, DOI 10.1002/hep.24795; Fu XY, 2010, P NATL ACAD SCI USA, V107, P4579, DOI 10.1073/pnas.0912094107; Gajjar M, 2012, CANCER CELL, V21, P25, DOI 10.1016/j.ccr.2011.11.016; Gama V, 2009, CELL DEATH DIFFER, V16, P758, DOI 10.1038/cdd.2009.6; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu L, 2012, ONCOGENE, V31, P1342, DOI 10.1038/onc.2011.343; Gu LB, 2002, BLOOD, V99, P3367, DOI 10.1182/blood.V99.9.3367; Gu LB, 2009, CANCER CELL, V15, P363, DOI 10.1016/j.ccr.2009.03.002; Hara MR, 2011, NATURE, V477, P349, DOI 10.1038/nature10368; Hew HC, 2011, MOL CARCINOGEN, V50, P719, DOI 10.1002/mc.20748; Higashitsuji H, 2005, CANCER CELL, V8, P75, DOI 10.1016/j.ccr.2005.06.006; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Huart AS, 2009, J BIOL CHEM, V284, P32384, DOI 10.1074/jbc.M109.052647; Inuzuka H, 2010, CANCER CELL, V18, P147, DOI 10.1016/j.ccr.2010.06.015; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Jeong MH, 2006, J BIOL CHEM, V281, P8707, DOI 10.1074/jbc.M513853200; Jin YT, 2002, J BIOL CHEM, V277, P30838, DOI 10.1074/jbc.M204078200; Jung CH, 2013, CANCER LETT, V335, P270, DOI 10.1016/j.canlet.2013.02.035; Jung CR, 2010, J CLIN INVEST, V120, P4493, DOI 10.1172/JCI42674; Jung YS, 2012, DNA REPAIR, V11, P177, DOI 10.1016/j.dnarep.2011.10.017; Kadakia M, 2001, DNA CELL BIOL, V20, P321, DOI 10.1089/10445490152122433; Kass EM, 2009, CELL CYCLE, V8, P430, DOI 10.4161/cc.8.3.7624; Kawai H, 2007, CANCER RES, V67, P6026, DOI 10.1158/0008-5472.CAN-07-1313; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kim MM, 2007, ONCOGENE, V26, P4209, DOI 10.1038/sj.onc.1210212; Knappskog S, 2011, TRANSCR-AUSTIN, V2, P207, DOI 10.4161/trns.2.5.16813; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Kostic M, 2006, J MOL BIOL, V363, P433, DOI 10.1016/j.jmb.2006.08.027; Kurki S, 2003, J CELL SCI, V116, P3917, DOI 10.1242/jcs.00714; Lai KP, 2010, EMBO J, V29, P2994, DOI 10.1038/emboj.2010.166; Lane David P, 2012, Genes Cancer, V3, P320, DOI 10.1177/1947601912458285; Lau R, 2012, CELL CYCLE, V11, P4009, DOI 10.4161/cc.22223; Lee D, 2012, EMBO REP, V13, P163, DOI 10.1038/embor.2011.235; Lee M. H., 2011, CELL CYCLE, V10, P3057, DOI [DOI 10.4161/CC.10.18, 10.4161/cc.10.18.17320, DOI 10.4161/CC.10.18.17320]; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; Lehman JA, 2012, INT J MOL SCI, V13, P16373, DOI 10.3390/ijms131216373; Lessard F, 2012, NUCLEIC ACIDS RES, V40, P5357, DOI 10.1093/nar/gks198; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; Liu T, 2013, J BIOL CHEM, V288, P3359, DOI 10.1074/jbc.M112.384289; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; Maguire M, 2008, CANCER RES, V68, P3232, DOI 10.1158/0008-5472.CAN-07-5271; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Mayo LD, 1997, CANCER RES, V57, P5013; Meek DW, 2010, SEMIN CANCER BIOL, V20, P19, DOI 10.1016/j.semcancer.2009.10.005; Minsky N, 2004, MOL CELL, V16, P631, DOI 10.1016/j.molcel.2004.10.016; Miyauchi Y, 2002, J BIOL CHEM, V277, P50131, DOI 10.1074/jbc.M208319200; Mo PL, 2010, J BIOL CHEM, V285, P26908, DOI 10.1074/jbc.M110.132597; Moumen A, 2005, CELL, V123, P1065, DOI 10.1016/j.cell.2005.09.032; Nicholson J, 2012, J PROTEOME RES, V11, P5464, DOI 10.1021/pr300698d; Nicholson J, 2010, CELL CYCLE, V9, P1878, DOI 10.4161/cc.9.10.11597; Ochocka AM, 2002, EMBO J, V7, P1704; Ofir-Rosenfeld Y, 2008, MOL CELL, V32, P180, DOI 10.1016/j.molcel.2008.08.031; Oh W, 2010, ONCOGENE, V29, P4101, DOI 10.1038/onc.2010.160; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Okoro Danielle R, 2012, Genes Cancer, V3, P311, DOI 10.1177/1947601912455323; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Oliver TG, 2011, MOL CELL, V43, P57, DOI 10.1016/j.molcel.2011.06.012; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Perry ME, 2004, MOL CANCER RES, V2, P9; Pettersson S, 2013, BIOCHEM J, V450, P523, DOI 10.1042/BJ20121249; Pettersson S, 2009, BIOCHEM J, V418, P575, DOI 10.1042/BJ20082087; Polanski R, 2011, CARCINOGENESIS, V32, P1133, DOI 10.1093/carcin/bgr070; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Riemenschneider MJ, 1999, CANCER RES, V59, P6091; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sczaniecka M, 2012, J BIOL CHEM, V287, P14052, DOI 10.1074/jbc.M111.303875; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Sheng Y, 2006, NAT STRUCT MOL BIOL, V13, P285, DOI 10.1038/nsmb1067; Shouse GP, 2011, ONCOGENE, V30, P3755, DOI 10.1038/onc.2011.95; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Singh S, 2013, CELL DEATH DIFFER, V20, P558, DOI 10.1038/cdd.2012.153; Song MS, 2008, EMBO J, V27, P1863, DOI 10.1038/emboj.2008.115; Sood R, 2013, BEHAV BRAIN RES, V240, P26, DOI 10.1016/j.bbr.2012.11.009; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Sun NK, 2012, BIOCHEM J, V444, P303, DOI 10.1042/BJ20112223; Sun XX, 2011, J BIOL CHEM, V286, P22730, DOI 10.1074/jbc.M111.223651; Sun Y, 2011, J CELL SCI, V124, P1067, DOI 10.1242/jcs.068965; Taira N, 2010, J BIOL CHEM, V285, P4909, DOI 10.1074/jbc.M109.042341; Tang J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Thotala DK, 2012, CELL DEATH DIFFER, V19, P387, DOI 10.1038/cdd.2011.94; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Uldrijan S, 2007, EMBO J, V26, P102, DOI 10.1038/sj.emboj.7601469; Vlatkovic N, 2000, NUCLEIC ACIDS RES, V28, P3581, DOI 10.1093/nar/28.18.3581; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wallace M, 2006, AM BOOK REV, V27, P3, DOI 10.1353/abr.2006.0081; Wang KS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023571; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Wang XJ, 2004, FEBS LETT, V561, P195, DOI 10.1016/S0014-5793(04)00168-1; Wang YV, 2007, P NATL ACAD SCI USA, V104, P12365, DOI 10.1073/pnas.0701497104; Wang YYV, 2009, CELL CYCLE, V8, P3443, DOI 10.4161/cc.8.21.9744; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wei XL, 2003, J BIOL CHEM, V278, P29288, DOI 10.1074/jbc.M212215200; Wen W, 2014, ONCOGENE, V33, P421, DOI 10.1038/onc.2012.605; Winter M, 2004, BIOCHEMISTRY-US, V43, P16356, DOI 10.1021/bi0489255; Wu CW, 2004, NATURE, V432, P640, DOI 10.1038/nature03173; Wu H, 2011, NAT MED, V17, P347, DOI 10.1038/nm.2283; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Xiong X, 2011, ONCOGENE, V30, P1798, DOI 10.1038/onc.2010.569; Xirodimas DP, 2002, FEBS LETT, V528, P207, DOI 10.1016/S0014-5793(02)03310-0; Xu HX, 2010, J BIOL CHEM, V285, P18407, DOI 10.1074/jbc.M109.059568; Xue Y, PAIL PREDICTION ACET; Yang HY, 2007, ONCOGENE, V26, P7355, DOI 10.1038/sj.onc.1210540; Yap DBS, 1999, ONCOGENE, V18, P7681, DOI 10.1038/sj.onc.1202954; Yogosawa S, 2003, BIOCHEM BIOPH RES CO, V302, P869, DOI 10.1016/S0006-291X(03)00282-1; Zdzalik M, 2010, CELL CYCLE, V9, P4584, DOI 10.4161/cc.9.22.13871; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhang Q, 2011, J BIOL CHEM, V286, P38264, DOI 10.1074/jbc.M111.277012; Zhang X, 2013, ONCOGENE, V32, P2782, DOI 10.1038/onc.2012.289; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhao RY, 2011, J CLIN INVEST, V121, P851, DOI 10.1172/JCI44111; Zheng M, 2010, J MOL CELL BIOL, V2, P96, DOI 10.1093/jmcb/mjp038; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou S, 2011, MOL CELL BIOL, V31, P4928, DOI 10.1128/MCB.06085-11; Zhou X, 2013, ONCOGENE, V32, P388, DOI 10.1038/onc.2012.63; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014	156	65	68	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2014	33	35					4365	4376		10.1038/onc.2013.410	http://dx.doi.org/10.1038/onc.2013.410			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MR	24096477				2022-12-28	WOS:000341157800001
J	Du, L; Zhao, Z; Ma, X; Hsiao, TH; Chen, Y; Young, E; Suraokar, M; Wistuba, I; Minna, JD; Pertsemlidis, A				Du, L.; Zhao, Z.; Ma, X.; Hsiao, T-H; Chen, Y.; Young, E.; Suraokar, M.; Wistuba, I.; Minna, J. D.; Pertsemlidis, A.			miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer	ONCOGENE			English	Article						DAB2; miRNA; miR-93; lung cancer	TUMOR-SUPPRESSOR GENE; OVARIAN-CANCER; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; DISABLED-2 EXPRESSION; GASTRIC-CANCER; CELL-GROWTH; MICRORNAS; MIR-93; PROTEIN	The disabled homolog 2 (DAB2) gene was recently identified as a tumor suppressor gene with its expression downregulated in multiple cancer types. The role of DAB2 in lung tumorigenesis, however, is not fully characterized, and the mechanisms of DAB2 dysregulation in lung cancer are not defined. Here we show that low DAB2 levels in lung tumor specimens are significantly correlated with poor patient survival, and that DAB2 overexpression significantly inhibits cell growth in cultured lung cancer cells, indicating its potent tumor suppressor function. We next identify that microRNA miR-93 functions as a potent repressor of DAB2 expression by directly targeting the 3'UTR of the DAB2 mRNA. Using in vitro and in vivo approaches, we demonstrate that miR-93 overexpression has an important role in promoting lung cancer cell growth, and that its oncogenic function is primarily mediated by downregulating DAB2 expression. Our clinical investigations further indicate that high tumor levels of miR-93 are correlated with poor survival of lung cancer patients. The correlations of both low DAB2 and high miR-93 expression levels with poor patient survival strongly support the critical role of the miR-93/DAB2 pathway in determining lung cancer progression.	[Du, L.; Zhao, Z.; Ma, X.; Hsiao, T-H; Chen, Y.; Young, E.; Pertsemlidis, A.] UT Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA; [Du, L.; Pertsemlidis, A.] UT Hlth Sci Ctr San Antonio, Dept Cell & Struct Biol, San Antonio, TX 78229 USA; [Chen, Y.] UT Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Suraokar, M.; Wistuba, I.] UT MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA; [Wistuba, I.] UT MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX USA; [Minna, J. D.] UT Southwestern Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA; [Minna, J. D.] UT Southwestern Med Ctr Dallas, Dept Pharmacol, Dallas, TX USA; [Minna, J. D.] UT Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX USA; [Pertsemlidis, A.] UT Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health San Antonio	Du, L (corresponding author), UT Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, 8403 Floyd Curl Dr,MC 7784, San Antonio, TX 78229 USA.	dul2@uthscsa.edu; pertsemlidis@uthscsa.edu	Pertsemlidis, Alexander/Q-7899-2017	Pertsemlidis, Alexander/0000-0003-1624-9372	Lung Cancer SPORE from NCI [P50 CA70907]; Department of Defense [W81XWH-07-1-0306]; Sun Microsystems [EDUD-7824-021007-US]; Cancer Center [P30 CA054174, P30 CA142543, P30 CA016672];  [R01 CA129632]; NATIONAL CANCER INSTITUTE [P30CA016672, P30CA054174, R01CA129632, P30CA142543, P50CA070907] Funding Source: NIH RePORTER	Lung Cancer SPORE from NCI; Department of Defense(United States Department of Defense); Sun Microsystems; Cancer Center; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Vivienne Rebel and Nicholas Dybdal-Hargreaves for critical reading of the manuscript. This work was supported in part by R01 CA129632 (A Pertsemlidis) and Lung Cancer SPORE P50 CA70907 (JD Minna and II Wistuba) from the NCI, W81XWH-07-1-0306 from the Department of Defense (II Wistuba), Academic Excellence grant EDUD-7824-021007-US (A Pertsemlidis) from Sun Microsystems and Cancer Center Support grants P30 CA054174, P30 CA142543 and P30 CA016672.	Anupam K, 2006, WORLD J GASTROENTERO, V12, P6041, DOI 10.3748/wjg.v12.i37.6041; Bagadi SAR, 2007, BREAST CANCER RES TR, V104, P277, DOI 10.1007/s10549-006-9422-6; Borchert GM, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-347; Calvisi DF, 2007, J CLIN INVEST, V117, P2713, DOI 10.1172/JCI31457; CARNEY DN, 1985, SEMIN ONCOL, V12, P289; CARNEY DN, 1982, CLIN CHEST MED, V3, P389; Chao A, 2012, ONCOGENE, V31, P764, DOI 10.1038/onc.2011.269; Chuang TD, 2012, MOL ENDOCRINOL, V26, P1028, DOI 10.1210/me.2012-1075; Du LQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039167; Du LQ, 2009, MOL CANCER RES, V7, P1234, DOI 10.1158/1541-7786.MCR-08-0507; Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465; Fang L, 2012, CELL CYCLE, V11, P4352, DOI 10.4161/cc.22670; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Fu X, 2012, FEBS LETT, V586, P1279, DOI 10.1016/j.febslet.2012.03.006; Garcia DM, 2011, NAT STRUCT MOL BIOL, V18, P1139, DOI 10.1038/nsmb.2115; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Hannigan A, 2010, J CLIN INVEST, V120, P2842, DOI 10.1172/JCI36125; He JQ, 2001, J BIOL CHEM, V276, P26814, DOI 10.1074/jbc.M101820200; Karam JA, 2007, CLIN CANCER RES, V13, P4400, DOI 10.1158/1078-0432.CCR-07-0287; Kim K, 2012, ONCOGENE, V31, P1034, DOI 10.1038/onc.2011.296; Kim YK, 2009, NUCLEIC ACIDS RES, V37, P1672, DOI 10.1093/nar/gkp002; Kluiver J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029275; Li Y, 2009, CANCER SCI, V100, P1234, DOI 10.1111/j.1349-7006.2009.01164.x; Long JY, 2010, J BIOL CHEM, V285, P23455, DOI 10.1074/jbc.M110.136168; Mayorga ME, 2012, J CELL MOL MED, V16, P1106, DOI 10.1111/j.1582-4934.2011.01385.x; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Pineau P, 2010, P NATL ACAD SCI USA, V107, P264, DOI 10.1073/pnas.0907904107; Prudkin L, 2008, CLIN CANCER RES, V14, P41, DOI 10.1158/1078-0432.CCR-07-1252; Smith AL, 2012, ONCOGENE, V31, P5162, DOI 10.1038/onc.2012.11; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; Wang TT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043268; Wang ZZ, 2010, INT J ONCOL, V37, P1315, DOI 10.3892/ijo_00000783; Wikman H, 2002, ONCOGENE, V21, P5804, DOI 10.1038/sj.onc.1205726; Xu HT, 2013, APMIS, V121, P111, DOI 10.1111/j.1600-0463.2012.02946.x; Xu HT, 2011, HUM PATHOL, V42, P1491, DOI 10.1016/j.humpath.2011.01.004; Yang DH, 2006, AM J PATHOL, V169, P258, DOI 10.2353/ajpath.2006.060036; Yang L, 2012, J BONE MINER RES, V27, P1598, DOI 10.1002/jbmr.1621; Yeung ML, 2008, CANCER RES, V68, P8976, DOI 10.1158/0008-5472.CAN-08-0769; Zhou J, 2005, CANCER RES, V65, P9906, DOI 10.1158/0008-5472.CAN-05-1481	42	60	65	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2014	33	34					4307	4315		10.1038/onc.2013.381	http://dx.doi.org/10.1038/onc.2013.381			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MK	24037530	Green Accepted, Bronze			2022-12-28	WOS:000341156900004
J	Greenow, KR; Clarke, AR; Williams, GT; Jones, R				Greenow, K. R.; Clarke, A. R.; Williams, G. T.; Jones, R.			Wnt-driven intestinal tumourigenesis is suppressed by Chk1 deficiency but enhanced by conditional haploinsufficiency	ONCOGENE			English	Article						Chk1; Apc; genomic instability; small intestine; apoptosis	DNA-DAMAGE RESPONSE; ANTICANCER BARRIER; COLORECTAL-CANCER; INSTABILITY; GENE; INHIBITION; CHECKPOINT; EXPRESSION; APOPTOSIS; STRESS	Chk1 is essential in maintaining genomic stability due to its role in cell cycle regulation. Several recent studies have indicated that the abrogation of checkpoints in tumourigenesis through the inhibition of Chk1 may be of therapeutic value. To further investigate the role of Chk1 in the mouse small intestine and its potential role as a therapy for colorectal cancer, we simultaneously deleted Chk1 and Apc in the mouse small intestine. We found that homozygous loss of Chk1 is not compatible with Wnt-driven proliferation and resulted in the suppression of Wnt-driven tumourigenesis in the mouse small intestine. In contrast, heterozygous loss of Chk1 in a Wnt-driven background resulted in an increase in DNA damage and apoptosis and accelerated both tumour development and progression.	[Greenow, K. R.; Clarke, A. R.; Jones, R.] Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3AX, S Glam, Wales; [Williams, G. T.] Cardiff Univ, Sch Med, Cardiff CF10 3AX, S Glam, Wales	Cardiff University; Cardiff University	Clarke, AR (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Museum Ave,POB 911, Cardiff CF10 3AX, S Glam, Wales.	clarkeAR@cardiff.ac.uk	clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X	Cancer Research UK; Cancer Research UK [15937] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	This work was supported by Cancer Research UK. Particular thanks go to Mark Bishop, Lucie Pietzka and Derek Scarborough for technical assistance. The authors declare no conflicts of interest.	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartek J, 2007, CELL CYCLE, V6, P2344, DOI 10.4161/cc.6.19.4754; Bartek J, 2012, NAT STRUCT MOL BIOL, V19, P5, DOI 10.1038/nsmb.2220; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; BJERKNES M, 1981, ANAT REC, V199, P565, DOI 10.1002/ar.1091990412; Bolderson E, 2009, CLIN CANCER RES, V15, P6314, DOI 10.1158/1078-0432.CCR-09-0096; Fishler T, 2010, ONCOGENE, V29, P4007, DOI 10.1038/onc.2010.163; Grady WM, 2004, CANCER METAST REV, V23, P11, DOI 10.1023/A:1025861527711; Greenow KR, 2009, ONCOGENE, V28, P1443, DOI 10.1038/onc.2008.482; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Liu QH, 2000, GENE DEV, V14, P1448; Ma CX, 2011, TRENDS MOL MED, V17, P88, DOI 10.1016/j.molmed.2010.10.009; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Montano R, 2012, MOL CANCER THER, V11, P427, DOI 10.1158/1535-7163.MCT-11-0406; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Plummer R, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2877; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; SALHAB N, 1989, DIS COLON RECTUM, V32, P659, DOI 10.1007/BF02555769; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Soreide K, 2006, BRIT J SURG, V93, P395, DOI 10.1002/bjs.5328; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tho LM, 2012, ONCOGENE, V31, P1366, DOI 10.1038/onc.2011.326; Venkatesha VA, 2012, NEOPLASIA, V14, P519, DOI 10.1593/neo.12538; Zaugg K, 2007, P NATL ACAD SCI USA, V104, P3805, DOI 10.1073/pnas.0611584104	27	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2014	33	31					4089	4096		10.1038/onc.2013.371	http://dx.doi.org/10.1038/onc.2013.371			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YG	24037525				2022-12-28	WOS:000340595300008
J	Oue, N; Naito, Y; Hayashi, T; Takigahira, M; Kawano-Nagatsuma, A; Sentani, K; Sakamoto, N; Oo, HZ; Uraoka, N; Yanagihara, K; Ochiai, A; Sasaki, H; Yasui, W				Oue, N.; Naito, Y.; Hayashi, T.; Takigahira, M.; Kawano-Nagatsuma, A.; Sentani, K.; Sakamoto, N.; Oo, H. Zarni; Uraoka, N.; Yanagihara, K.; Ochiai, A.; Sasaki, H.; Yasui, W.			Signal peptidase complex 18, encoded by SEC11A, contributes to progression via TGF-alpha secretion in gastric cancer	ONCOGENE			English	Article						SPC18; SEC11A; signal peptidase complex; prognosis; gastric cancer	GROWTH-FACTOR-ALPHA; GENE-EXPRESSION PROFILES; CDNA MICROARRAY; REG-IV; PROTEIN; CARCINOGENESIS; TUMORIGENESIS; CARCINOMA; BIOMARKER; INVASION	We built an in-house oligonucleotide array on which 394 genes were selected based on our Serial Analysis of Gene Expression (SAGE) data and previously reported array data and listed several genes related to cancer progression. Among these, we focused on SEC11A, which encodes the SPC18 protein. SEC11A mRNA expression was measured by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) in gastric cancer (GC) tissue samples. Expression and distribution of SPC18 protein were investigated by immunohistochemical analysis in two independent GC cohorts (Hiroshima cohort, n = 99 and Chiba cohort, n 989). To determine the effect of SPC18 on cell viability and invasiveness in vitro, MTT and Boyden chamber invasion assays were performed. To evaluate the influence of SPC18 on cell growth in vivo, GC cells were injected into severe combined immunodeficiency mice. Levels of TGF-alpha and EGF in media from the GC cells were measured by enzyme-linked immunosorbent assay (ELISA). Studies in human tissue revealed overexpression of SEC11A mRNA in 40% of 42 GC samples by qRT-PCR. Immunohistochemical analysis of SPC18 revealed that 26 and 20% of GC cases were SPC18-positive in the Hiroshima and Chiba cohorts, respectively. In both cohorts, the Kaplan-Meier analysis showed poorer survival in SPC18-positive GC cases than in SPC18-negative GC cases. Forced expression of SPC18 activates GC cell growth in vitro and in vivo. The levels of TGF-alpha in culture media from GC cells were reduced by knockdown of SPC18. These results indicate that SPC18 contributes to malignant progression through promotion of TGF-alpha secretion in GC.	[Oue, N.; Naito, Y.; Hayashi, T.; Sentani, K.; Sakamoto, N.; Oo, H. Zarni; Uraoka, N.; Yasui, W.] Hiroshima Univ Inst Biomed & Hlth Sci, Dept Mol Pathol, Minami Ku, Hiroshima 7348551, Japan; [Takigahira, M.] Natl Canc Ctr Hosp East, Res Ctr Innovat Oncol, Investigat Treatment Div, Kashiwa, Chiba, Japan; [Kawano-Nagatsuma, A.; Ochiai, A.] Natl Canc Ctr Hosp East, Res Ctr Innovat Oncol, Div Pathol, Kashiwa, Chiba, Japan; [Yanagihara, K.] Natl Canc Ctr Hosp East, Res Ctr Innovat Oncol, Div Translat Res, Kashiwa, Chiba, Japan; [Sasaki, H.] Natl Canc Ctr, Div Genet, Tokyo, Japan	Hiroshima University; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan	Yasui, W (corresponding author), Hiroshima Univ Inst Biomed & Hlth Sci, Dept Mol Pathol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	wyasui@hiroshima-u.ac.jp			Grants-in-Aid for Scientific Research [13J01171] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Aung PP, 2006, ONCOGENE, V25, P2546, DOI 10.1038/sj.onc.1209279; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; de Castro NP, 2010, FUTURE ONCOL, V6, P1127, DOI [10.2217/fon.10.68, 10.2217/FON.10.68]; Dedes KJ, 2011, NAT REV CLIN ONCOL, V8, P261, DOI 10.1038/nrclinonc.2010.216; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; Hasegawa S, 2002, CANCER RES, V62, P7012; Hippo Y, 2001, CANCER RES, V61, P889; Hippo Y, 2002, CANCER RES, V62, P233; Ii M, 2006, EXP BIOL MED, V231, P20; Inoue H, 2002, CLIN CANCER RES, V8, P3475; Kang MJ, 2008, GASTROENTEROLOGY, V135, P2030, DOI 10.1053/j.gastro.2008.08.009; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; Mitani Y, 2007, ONCOGENE, V26, P4383, DOI 10.1038/sj.onc.1210215; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; Nickel W, 2009, NAT REV MOL CELL BIO, V10, P148, DOI 10.1038/nrm2617; Nitadori JI, 2006, AM J CLIN PATHOL, V125, P682, DOI 10.1309/DT6BJ698LDX2NGGX; Oue N, 2004, CANCER RES, V64, P2397, DOI 10.1158/0008-5472.CAN-03-3514; Oue N, 2009, INT J CANCER, V125, P2383, DOI 10.1002/ijc.24624; Regalo G, 2010, LAB INVEST, V90, P1132, DOI 10.1038/labinvest.2010.79; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; TEIXIDO J, 1987, NATURE, V326, P883, DOI 10.1038/326883a0; Ueda Masatsugu, 1998, Invasion and Metastasis, V18, P176, DOI 10.1159/000024510; Yasui W, 1999, JPN J CANCER RES, V90, P589, DOI 10.1111/j.1349-7006.1999.tb00787.x; Yasui W, 2011, PATHOL RES PRACT, V207, P608, DOI 10.1016/j.prp.2011.09.006; Zembutsu H, 2002, CANCER RES, V62, P518	25	30	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3918	3926		10.1038/onc.2013.364	http://dx.doi.org/10.1038/onc.2013.364			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	23995782				2022-12-28	WOS:000339394700004
J	Ren, G; Liu, Y; Zhao, X; Zhang, J; Zheng, B; Yuan, ZR; Zhang, L; Qu, X; Tischfield, JA; Shao, C; Shi, Y				Ren, G.; Liu, Y.; Zhao, X.; Zhang, J.; Zheng, B.; Yuan, Z-R; Zhang, L.; Qu, X.; Tischfield, J. A.; Shao, C.; Shi, Y.			Tumor resident mesenchymal stromal cells endow naive stromal cells with tumor-promoting properties	ONCOGENE			English	Article						mesenchymal stem/stromal cells; lymphoma; tumor promotion; tumor microenvironment; chemokines; macrophages	STEM-CELLS; RECRUITMENT; FIBROBLASTS; TRANSITION; NICHE	Bone marrow mesenchymal stem/stromal cells (BM-MSCs) can infiltrate into tumors and subsequently evolve into tumor resident MSCs in tumor microenvironment. In this study, using a mouse lymphoma model, we showed that the lymphoma resident MSCs (L-MSCs) are able to confer tumor-promoting property to the naive cocultured BM-MSCs. Examination of cytokines and chemokines showed that post exposure to L-MSCs, BM-MSCs acquired an expression profile that is similar to that in L-MSCs. In vivo, BM-MSCs educated by L-MSCs (BM-L-MSCs) possess a greatly enhanced ability in promoting lymphoma growth. Consistent with an elevated CCL-2 expression in BM-L-MSCs, the tumor-promoting effect of BM-L-MSCs largely depends on CCR2-mediated macrophage recruitment to tumor sites. We further showed that the transmission of tumor-promoting effect is partially mediated by soluble factors. Our findings thus revealed a novel reinforcing mechanism in the maintenance of tumor microenvironment.	[Ren, G.; Zhang, J.; Yuan, Z-R; Zhang, L.; Shi, Y.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Rutgers Biomed & Hlth Sci, Child Hlth Inst New Jersey, New Brunswick, NJ 08901 USA; [Ren, G.; Shi, Y.] Chinese Acad Sci, Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Biol Sci,Inst Hlth Sci, Shanghai, Peoples R China; [Liu, Y.; Qu, X.] Shandong Univ, Qilu Hosp, Inst Basic Med Sci, Dept Med Oncol, Jinan 250100, Shandong, Peoples R China; [Liu, Y.; Zhao, X.; Zheng, B.; Tischfield, J. A.; Shao, C.] Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA; [Liu, Y.; Zhao, X.; Zheng, B.; Tischfield, J. A.; Shao, C.] Rutgers State Univ, Human Genet Inst New Jersey, Piscataway, NJ 08854 USA; [Shao, C.] Shandong Univ, Sch Med, Inst Mol Med & Genet, Minist Educ Key Lab Expt Teratol, Jinan 250100, Shandong, Peoples R China	Rutgers State University New Brunswick; Rutgers State University Medical Center; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Shandong University; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Shandong University	Shao, C (corresponding author), Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA.	shao@biology.rutgers.edu; shiyu@rwjms.rutgers.edu	Shao, Changshun/AAD-8977-2022; Shi, Yufang/AAE-4431-2020	Shao, Changshun/0000-0003-2618-9342; Shi, Yufang/0000-0001-8964-319X; Ren, Guangwen/0000-0003-2436-9593; Qu, Xun/0000-0002-2521-3761; Tischfield, Jay/0000-0003-3217-8287	National Institutes of Health of the United States of America [GM866889, DE014913, DE019932, ES005022]; Ministry of Science and Technology of China [2010CB945600, 2011DFA30630]; Human Genetics Institute of New Jersey; Robert Wood Johnson Foundation of the Child Health Institute of New Jersey [67038]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE019932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM866889] Funding Source: NIH RePORTER	National Institutes of Health of the United States of America(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Human Genetics Institute of New Jersey; Robert Wood Johnson Foundation of the Child Health Institute of New Jersey; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from National Institutes of Health of the United States of America (GM866889, DE014913, DE019932 and ES005022), Ministry of Science and Technology of China (2010CB945600 and 2011DFA30630) and a grant from the Human Genetics Institute of New Jersey. We would also like to thank the Robert Wood Johnson Foundation (Grant 67038) for their support of the Child Health Institute of New Jersey.	Djouad F, 2003, BLOOD, V102, P3837, DOI 10.1182/blood-2003-04-1193; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Goldstein RH, 2010, CANCER RES, V70, P10044, DOI 10.1158/0008-5472.CAN-10-1254; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Guilloton F, 2012, BLOOD, V119, P2556, DOI 10.1182/blood-2011-08-370908; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Kabashima-Niibe A, 2013, CANCER SCI, V104, P157, DOI 10.1111/cas.12059; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Li HJ, 2012, CANCER DISCOV, V2, P840, DOI 10.1158/2159-8290.CD-12-0101; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; McLean K, 2011, J CLIN INVEST, V121, P3206, DOI 10.1172/JCI45273; Mitra AK, 2012, CANCER DISCOV, V2, P1100, DOI 10.1158/2159-8290.CD-12-0206; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Ren GW, 2012, CELL STEM CELL, V11, P812, DOI 10.1016/j.stem.2012.08.013; Spaeth EL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004992; Studeny M, 2004, JNCI-J NATL CANCER I, V96, P1593, DOI 10.1093/jnci/djh299; Swartz MA, 2012, CANCER RES, V72, P2473, DOI 10.1158/0008-5472.CAN-12-0122	18	29	30	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					4016	4020		10.1038/onc.2013.387	http://dx.doi.org/10.1038/onc.2013.387			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	24077286				2022-12-28	WOS:000339394700013
J	Cowling, VH; Turner, SA; Cole, MD				Cowling, V. H.; Turner, S. A.; Cole, M. D.			Burkitt's lymphoma-associated c-Myc mutations converge on a dramatically altered target gene response and implicate Nol5a/Nop56 in oncogenesis	ONCOGENE			English	Article						Myc; lymphoma; mutations; Burkitt's; transcription	N-TERMINAL DOMAIN; RNA-POLYMERASE-I; TRANSACTIVATION DOMAIN; RIBOSOME BIOGENESIS; PROTEIN-SYNTHESIS; CODING REGION; DNA-BINDING; PHOSPHORYLATION; TRANSCRIPTION; EXPRESSION	Burkitt's lymphomas (BLs) acquire consistent point mutations in a conserved domain of Myc, Myc Box I. We report that the enhanced transforming activity of BL-associated Myc mutants can be uncoupled from loss of phosphorylation and increased protein stability. Furthermore, two different BL-associated Myc mutations induced similar gene expression profiles independently of T58 phosphorylation, and these profiles are dramatically different from MycWT. Nol5a/Nop56, which is required for ribosomal RNA methylation, was identified as a gene hyperactivated by the BL-associated Myc mutants. We show that Nol5a is necessary for Myc-induced cell transformation, enhances MycWT-induced cell transformation and increases the size of MycWT-induced tumors. Thus, Nol5a expands the link between Myc-induced regulation of nucleolar target genes, which are rate limiting for cell transformation and tumor growth.	[Cowling, V. H.; Cole, M. D.] Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Dept Pharmacol, Lebanon, NH 03756 USA; [Turner, S. A.; Cole, M. D.] Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Dept Genet, Lebanon, NH 03756 USA	Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center	Cole, MD (corresponding author), Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Dept Pharmacol, One Med Ctr Dr,Rubin 633, Lebanon, NH 03756 USA.	Michael.D.Cole@dartmouth.edu		Cowling, Victoria/0000-0001-7638-4870	National Cancer Institute [CA055248]; National Institute of General Medical Sciences [T32GM008704]; NATIONAL CANCER INSTITUTE [R01CA080320, R01CA055248, P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008704] Funding Source: NIH RePORTER; MRC [MR/K024213/1, G0700240] Funding Source: UKRI; Medical Research Council [MR/K024213/1, G0700240] Funding Source: researchfish	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Steve Hann and Chi Dang for providing cell lines. This project was supported by a grant from the National Cancer Institute (CA055248; MDC) and by Award Number T32GM008704 from the National Institute of General Medical Sciences (SAT). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health.	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Alawi F, 2007, BIOCHEM BIOPH RES CO, V362, P893, DOI 10.1016/j.bbrc.2007.08.071; ALBERT T, 1994, ONCOGENE, V9, P759; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Benassi B, 2006, MOL CELL, V21, P509, DOI 10.1016/j.molcel.2006.01.009; BHATIA K, 1994, BLOOD, V84, P883; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Bogomolnaya LM, 2004, CURR GENET, V45, P350, DOI 10.1007/s00294-004-0497-5; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; BRENNSCHEIDT U, 1994, LEUKEMIA, V8, P897; Brown SJ, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-442; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; CLARK HM, 1994, CANCER RES, V54, P3383; Cowling VH, 2007, MOL CELL BIOL, V27, P2059, DOI 10.1128/MCB.01828-06; Cowling VH, 2006, MOL CELL BIOL, V26, P4226, DOI 10.1128/MCB.01959-05; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dave SS, 2006, NEW ENGL J MED, V354, P2431, DOI 10.1056/NEJMoa055759; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Goy A, 2006, CANCER CYTOPATHOL, V108, P10, DOI 10.1002/cncr.21500; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Hann SR, 2006, SEMIN CANCER BIOL, V16, P288, DOI 10.1016/j.semcancer.2006.08.004; Hayano T, 2003, J BIOL CHEM, V278, P34309, DOI 10.1074/jbc.M304304200; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; JOHNSTON JM, 1991, BLOOD, V78, P2419; Kim S, 2000, P NATL ACAD SCI USA, V97, P11198, DOI 10.1073/pnas.200372597; Li Z, 2013, ONCOGENE, V32, P1988, DOI 10.1038/onc.2012.227; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Machida YJ, 2006, MOL BIOL CELL, V17, P4837, DOI 10.1091/mbc.E06-04-0340; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Newman DR, 2000, RNA, V6, P861, DOI 10.1017/S1355838200992446; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Pandolfi PP, 2004, ONCOGENE, V23, P3134, DOI 10.1038/sj.onc.1207618; Perna D, 2012, ONCOGENE, V31, P1695, DOI 10.1038/onc.2011.359; PULVERER BJ, 1994, ONCOGENE, V9, P59; Ruggero D, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003477; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Shaffer AL, 2006, IMMUNOL REV, V210, P67, DOI 10.1111/j.0105-2896.2006.00373.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vallat LD, 2007, BLOOD, V109, P3989, DOI 10.1182/blood-2006-09-045377; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Wang XY, 2011, CANCER RES, V71, P925, DOI 10.1158/0008-5472.CAN-10-1032; Warner JR, 2009, MOL CELL, V34, P3, DOI 10.1016/j.molcel.2009.03.006; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200; YANO T, 1993, ONCOGENE, V8, P2741; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yustein JT, 2007, CURR OPIN HEMATOL, V14, P375, DOI 10.1097/MOH.0b013e3281bccdee	60	32	34	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3519	3527		10.1038/onc.2013.338	http://dx.doi.org/10.1038/onc.2013.338			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	24013231	Green Accepted			2022-12-28	WOS:000338941100004
J	Dutruel, C; Bergmann, F; Rooman, I; Zucknick, M; Weichenhan, D; Geiselhart, L; Kaffenberger, T; Rachakonda, PS; Bauer, A; Giese, N; Hong, C; Xie, H; Costello, JF; Hoheisel, J; Kumar, R; Rehli, M; Schirmacher, P; Werner, J; Plass, C; Popanda, O; Schmezer, P				Dutruel, C.; Bergmann, F.; Rooman, I.; Zucknick, M.; Weichenhan, D.; Geiselhart, L.; Kaffenberger, T.; Rachakonda, P. S.; Bauer, A.; Giese, N.; Hong, C.; Xie, H.; Costello, J. F.; Hoheisel, J.; Kumar, R.; Rehli, M.; Schirmacher, P.; Werner, J.; Plass, C.; Popanda, O.; Schmezer, P.			Early epigenetic downregulation of WNK2 kinase during pancreatic ductal adenocarcinoma development	ONCOGENE			English	Article						genome-wide screen; CpG island methylation; chronic pancreatitis; pancreatic intraepithelial neoplasia; pancreatic cancer	DNA METHYLATION; CELL TRANSDIFFERENTIATION; INTRAEPITHELIAL NEOPLASIA; ABERRANT METHYLATION; PROTEIN-KINASE; CANCER; BIOLOGY; PROLIFERATION; PROFILE; GENES	Pancreatic ductal adenocarcinoma (PDAC) is usually incurable. Contrary to genetic mechanisms involved in PDAC pathogenesis, epigenetic alterations are ill defined. Here, we determine the contribution of epigenetically silenced genes to the development of PDAC. We analyzed enriched, highly methylated DNAs from PDACs, chronic pancreatitis (CP) and normal tissues using CpG island microarrays and identified WNK2 as a prominent candidate tumor suppressor gene being downregulated early in PDAC development. WNK2 was further investigated in tissue microarrays, methylation analysis of early pancreatic intraepithelial neoplasia (PanIN), mouse models for PDAC and pancreatitis, re-expression studies after demethylation, and cell growth assays using WNK2 overexpression. Demethylation assays confirmed the link between methylation and expression. WNK2 hypermethylation was higher in tumor than in surrounding inflamed tissues and was observed in PanIN lesions as well as in a PDAC mouse model. WNK2 mRNA and protein expressions were lower in PDAC and CP compared with normal tissues both in patients and mouse models. Overexpression of WNK2 led to reduced cell growth, and WNK2 expression in tissues correlated negatively with pERK1/2 expression, a downstream target of WNK2 responsible for cell proliferation. Downregulation of WNK2 by promoter hypermethylation occurs early in PDAC pathogenesis and may support tumor cell growth via the ERK-MAPK pathway.	[Dutruel, C.; Weichenhan, D.; Geiselhart, L.; Kaffenberger, T.; Plass, C.; Popanda, O.; Schmezer, P.] German Canc Res Ctr, Div Epigen & Canc Risk Factors, D-69120 Heidelberg, Germany; [Bergmann, F.; Schirmacher, P.] Univ Heidelberg Hosp, Inst Pathol, Heidelberg, Germany; [Rooman, I.] St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; [Zucknick, M.] German Canc Res Ctr, Div Biostat, D-69120 Heidelberg, Germany; [Rachakonda, P. S.; Xie, H.; Kumar, R.] German Canc Res Ctr, Div Mol Genet Epidemiol, D-69120 Heidelberg, Germany; [Bauer, A.; Hoheisel, J.] German Canc Res Ctr, D-69120 Heidelberg, Germany; [Giese, N.; Werner, J.] Heidelberg Univ, Dept Gen Visceral & Transplantat Surg, Heidelberg, Germany; [Hong, C.; Costello, J. F.] Univ Calif San Francisco, Dept Neurosurg, Helen Diller Family Comprehens Canc Ctr, Brain Tumor Res Ctr, San Francisco, CA USA; [Rehli, M.] Univ Hosp Regensburg, Dept Hematol & Oncol, Regensburg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Garvan Institute of Medical Research; St Vincents Hospital Sydney; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of Regensburg	Schmezer, P (corresponding author), German Canc Res Ctr, Div Epigen & Canc Risk Factors, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	p.schmezer@dkfz.de	Kumar, Rajiv/H-6431-2019; Rehli, Michael/E-9093-2011; Popanda, Odilia/P-6917-2019	Kumar, Rajiv/0000-0002-6093-0395; Rehli, Michael/0000-0003-3992-932X; Xie, Huaping/0000-0003-1474-2470; Rooman, Ilse/0000-0001-7264-2246; Bauer, Andrea/0000-0002-7919-0497	Cancer Institute New South Wales, Australia [10FRL203]; German Federal Ministry of Education and Research [PKB-01GS08114]; German Federal Ministry of Education and Research as part of the PaCaNct consortium within the NGFN program; Fulbright commission in Germany; US State Department	Cancer Institute New South Wales, Australia; German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); German Federal Ministry of Education and Research as part of the PaCaNct consortium within the NGFN program; Fulbright commission in Germany; US State Department	We would like to thank Reinhard Gliniorz, Oliver Mucke, Jana Petersen; Peter Waas and Otto Zelezny for their technical support, Dr Marta Faryna and Dr Carolin Konermann for discussions regarding the MCIp/microarray assays, Anna Poetsch and Christopher Schmidt for experimental advices; Dr Rainer Claus and Dr Christopher Oakes for stimulating discussions and Dr Ming-Sound Tsao (Ontario Cancer Institute, Toronto, Canada) for providing us the HPDE6-E6E7 cell line. This work is supported by grants from the Cancer Institute New South Wales, Australia (10FRL203 fellowship), from the German Federal Ministry of Education and Research (PKB-01GS08114) and from the German Federal Ministry of Education and Research as part of the PaCaNct consortium within the NGFN program. We thank the Fulbright commission in Germany and the US State Department for providing external funding (TK).	Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Buchholz M, 2005, ONCOGENE, V24, P6626, DOI 10.1038/sj.onc.1208804; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Fukushima N, 2002, AM J PATHOL, V160, P1573, DOI 10.1016/S0002-9440(10)61104-2; Ghaneh P, 2008, POSTGRAD MED J, V84, P478, DOI 10.1136/gut.2006.103333; Goggins M, 2005, J CLIN ONCOL, V23, P4524, DOI 10.1200/JCO.2005.19.711; Gold DV, 2010, CANCER EPIDEM BIOMAR, V19, P2786, DOI 10.1158/1055-9965.EPI-10-0667; Grapin-Botton A, 2005, INT J BIOCHEM CELL B, V37, P504, DOI 10.1016/j.biocel.2004.07.010; Haas BR, 2011, AM J PHYSIOL-CELL PH, V301, pC1150, DOI 10.1152/ajpcell.00203.2011; Hartwig W, 2011, ANN SURG, V254, P311, DOI 10.1097/SLA.0b013e31821fd334; Heller A, 2010, CANCER IMMUNOL IMMUN, V59, P1389, DOI 10.1007/s00262-010-0870-9; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hong CB, 2007, P NATL ACAD SCI USA, V104, P10974, DOI 10.1073/pnas.0700683104; Jansen M, 2002, CANCER BIOL THER, V1, P293, DOI 10.4161/cbt.84; Jensen JN, 2005, GASTROENTEROLOGY, V128, P728, DOI 10.1053/j.gastro.2004.12.008; Jun P, 2009, NEURO-ONCOLOGY, V11, P414, DOI 10.1215/15228517-2008-096; Kong B, 2011, NAT REV GASTRO HEPAT, V8, P467, DOI 10.1038/nrgastro.2011.114; Kuhmann C, 2011, RADIOTHER ONCOL, V101, P116, DOI 10.1016/j.radonc.2011.05.048; Lenertz LY, 2005, J BIOL CHEM, V280, P26653, DOI 10.1074/jbc.M502598200; Liggett T, 2010, CANCER-AM CANCER SOC, V116, P1674, DOI 10.1002/cncr.24893; LOWENFELS AB, 1993, NEW ENGL J MED, V328, P1433, DOI 10.1056/NEJM199305203282001; Matsubayashi H, 2006, CANCER RES, V66, P1208, DOI 10.1158/0008-5472.CAN-05-2664; Means AL, 2005, DEVELOPMENT, V132, P3767, DOI 10.1242/dev.01925; Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414; Moniz S, 2007, ONCOGENE, V26, P6071, DOI 10.1038/sj.onc.1210706; Moniz S, 2008, CELL SIGNAL, V20, P1762, DOI 10.1016/j.cellsig.2008.06.002; NIEDERAU C, 1985, GASTROENTEROLOGY, V88, P1192, DOI 10.1016/S0016-5085(85)80079-2; Omura Noriyuki, 2008, Proceedings of the American Association for Cancer Research Annual Meeting, V49, P7; Peng DF, 2006, CARCINOGENESIS, V27, P1160, DOI 10.1093/carcin/bgi361; Pinho AV, 2011, GUT, V60, P958, DOI 10.1136/gut.2010.225920; Sato N, 2003, CANCER RES, V63, P3735; Sato N, 2008, MODERN PATHOL, V21, P238, DOI 10.1038/modpathol.3800991; Schilling E, 2007, GENOMICS, V90, P314, DOI 10.1016/j.ygeno.2007.04.011; Sipos B, 2009, PANCREATOLOGY, V9, P45, DOI 10.1159/000178874; Strobel O, 2007, P NATL ACAD SCI USA, V104, P4419, DOI 10.1073/pnas.0605248104; Sun XT, 2006, J NEUROCHEM, V99, P1114, DOI 10.1111/j.1471-4159.2006.04159.x; Vincent A, 2011, CLIN CANCER RES, V17, P4341, DOI 10.1158/1078-0432.CCR-10-3431; Xu BE, 2004, J BIOL CHEM, V279, P7826, DOI 10.1074/jbc.M313465200	39	24	27	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3401	3410		10.1038/onc.2013.312	http://dx.doi.org/10.1038/onc.2013.312			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23912455				2022-12-28	WOS:000338779300007
J	Kasar, S; Underbayev, C; Yuan, Y; Hanlon, M; Aly, S; Khan, H; Chang, V; Batish, M; Gavrilova, T; Badiane, F; Degheidy, H; Marti, G; Raveche, E				Kasar, S.; Underbayev, C.; Yuan, Y.; Hanlon, M.; Aly, S.; Khan, H.; Chang, V.; Batish, M.; Gavrilova, T.; Badiane, F.; Degheidy, H.; Marti, G.; Raveche, E.			Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia	ONCOGENE			English	Article						miR-15a/16-1; BSAP; HDAC inhibitor; CLL; NZB	HISTONE DEACETYLASE INHIBITOR; ZEALAND BLACK MOUSE; MALIGNANT B-1 CELLS; TRANSCRIPTION FACTOR; MULTIPLE-MYELOMA; MANTLE CELL; B-CELLS; PAX5; 13Q14; EXPRESSION	Genetic lesions and other regulatory events lead to silencing of the 13q14 locus in a majority of chronic lymphocytic leukemia (CLL) patients. This locus encodes a pair of critical proapoptotic microRNAs, miR-15a/16-1. Decreased levels of miR-15a/16-1 are critical for the increased survival exhibited by CLL cells. Similarly, in a de novo murine model of CLL, the NZB strain, germline-encoded regulation of the syntenic region resulted in decreased miR-15a/16-1. In this paper, we have identified additional molecular mechanisms regulating miR-15a/16-1 levels and have shown that the transcription factor BSAP (B-cell-specific activator protein) directly interacts with Dleu2, the host gene containing the miR-15a/16-1 loci, and by negative regulation of the Dleu2 promoter, results in repression of miR-15a/16-1 expression. CLL patient B-cell expression levels of BSAP were increased compared with control sources of B cells. With the use of small interfering RNA-mediated repression, the levels of BSAP were decreased in vitro in the NZB-derived malignant B-1 cell line, LNC, and in ex vivo CLL patient peripheral blood mononuclear cells (PBMCs). BSAP knockdown led to an increase in the expression of miR-15a/16-1 and an increase in apoptosis, and a cell cycle arrest in both the cell line and patient PBMCs. Moreover, using Dleu2 promoter analysis by chromatin immunoprecipitation assay, we have shown that BSAP directly interacts with the Dleu2 promoter. Derepression of the Dleu2 promoter via inhibition of histone deacetylation combined with BSAP knockdown increased miR-15a/16-1 expression, and also increased malignant B-cell death. In summary, therapy targeting enhanced host gene Dleu2 transcription may augment CLL therapy.	[Kasar, S.; Underbayev, C.; Hanlon, M.; Aly, S.; Khan, H.; Chang, V.; Batish, M.; Gavrilova, T.; Badiane, F.; Raveche, E.] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; [Yuan, Y.] NIH, Bethesda, MD 20892 USA; [Chang, V.] Vet Affairs New Jersey Hlth Care Syst, E Orange, NJ USA; [Degheidy, H.; Marti, G.] OSEL CDRH FDA, White Oak, MD USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; US Food & Drug Administration (FDA)	Raveche, E (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol, 185S Orange Ave,MSB C-512, Newark, NJ 07103 USA.	batishmo@njms.rutgers.edu; raveches@njms.rutgers.edu	Underbayev, Chingiz/J-2970-2019; Batish, Mona/AAG-8296-2019	Batish, Mona/0000-0001-9039-6149; Chang, Victor/0000-0003-3640-7235	NSF/FDA/SIR [1238375]; NIH [R01CA12926]; Early Independence Award [1DP5OD012160-01]; UMDNJ-NJMS Flow Cytometry Core; NATIONAL CANCER INSTITUTE [R01CA129826] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP5OD012160] Funding Source: NIH RePORTER	NSF/FDA/SIR; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Early Independence Award; UMDNJ-NJMS Flow Cytometry Core; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by NSF/FDA/SIR No. 1238375 and NIH R01CA12926 (ESR). Early Independence Award # 1DP5OD012160-01 (MB). We thank the UMDNJ-NJMS Flow Cytometry Core for their support.	Barneda-Zahonero B, 2012, MOL ONCOL, V6, P579, DOI 10.1016/j.molonc.2012.07.003; Batish M, 2012, P NATL ACAD SCI USA, V109, P4645, DOI 10.1073/pnas.1111226109; Batish M, 2011, METHODS MOL BIOL, V714, P3, DOI 10.1007/978-1-61779-005-8_1; Bottcher S, 2012, J CLIN ONCOL, V30, P980, DOI 10.1200/JCO.2011.36.9348; Bougel S, 2010, J PATHOL, V220, P87, DOI 10.1002/path.2620; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Calin GA, 2008, P NATL ACAD SCI USA, V105, P5166, DOI 10.1073/pnas.0800121105; Campo E, 2011, BLOOD, V117, P5019, DOI 10.1182/blood-2011-01-293050; Chang H, 2004, LEUKEMIA LYMPHOMA, V45, P965, DOI 10.1080/10428190310001638832; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen L.-J., 2007, Experimental Oncology, V29, P116; Chong SY, 2001, CANCER IMMUNOL IMMUN, V50, P41, DOI 10.1007/s002620000165; Chung EY, 2012, J CLIN INVEST, V122, P2257, DOI 10.1172/JCI45851; Chung EY, 2008, CANCER BIOL THER, V7, P1758, DOI 10.4161/cbt.7.11.6722; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Cobaleda C, 2007, NAT IMMUNOL, V8, P463, DOI 10.1038/ni1454; Corcoran MM, 1998, BLOOD, V91, P1382, DOI 10.1182/blood.V91.4.1382; Crapoulet N, 2011, ANTI-CANCER AGENT ME, V11, P643, DOI 10.2174/187152011796817637; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Dubovsky JA, 2011, LEUKEMIA RES, V35, P394, DOI 10.1016/j.leukres.2010.08.001; El-Khoury V, 2010, MOL CANCER THER, V9, P1349, DOI 10.1158/1535-7163.MCT-09-1000; Firtina S, 2012, LEUKEMIA RES, V36, P87, DOI 10.1016/j.leukres.2011.07.017; Hamada T, 1998, BRIT J HAEMATOL, V102, P691; Hanlon K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007169; Humphrey RW, 2011, JNCI-J NATL CANCER I, V103, P1222, DOI 10.1093/jnci/djr246; Kanteti R, 2009, LAB INVEST, V89, P301, DOI 10.1038/labinvest.2008.168; Kasar S, 2012, GENES IMMUN, V13, P109, DOI 10.1038/gene.2011.58; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100; Klein U, 2010, CANCER CELL, V17, P28, DOI 10.1016/j.ccr.2009.11.019; Krenacs L, 1998, BLOOD, V92, P1308, DOI 10.1182/blood.V92.4.1308.416k32_1308_1316; Kubetzko FBB, 2004, CARCINOGENESIS, V25, P1839, DOI 10.1093/carcin/bgh190; Lanasa MC, 2011, LEUKEMIA, V25, P1459, DOI 10.1038/leu.2011.117; Laurie CC, 2012, NAT GENET, V44, P642, DOI 10.1038/ng.2271; Lucas DM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010941; Medvedovic J, 2011, ADV IMMUNOL, V111, P179, DOI 10.1016/B978-0-12-385991-4.00005-2; Mertens D, 2009, LEUKEMIA LYMPHOMA, V50, P502, DOI 10.1080/10428190902763509; Migliazza A, 2001, BLOOD, V97, P2098, DOI 10.1182/blood.V97.7.2098; Montserrat E, 2008, BLOOD, V112, P924, DOI 10.1182/blood-2008-05-155721; O'Brien P, 2011, CANCER RES, V71, P7345, DOI 10.1158/0008-5472.CAN-11-1874; Palamarchuk A, 2010, BLOOD, V115, P3916, DOI 10.1182/blood-2009-10-249367; PENG BH, 1994, J IMMUNOL, V153, P1869; Perez-Perarnau A, 2011, EPIGENETICS-US, V6, P1228, DOI 10.4161/epi.6.10.17200; Piller GJ, 2001, BRIT J HAEMATOL, V112, P282, DOI 10.1046/j.1365-2141.2001.02411.x; Poppe B, 2005, GENE CHROMOSOME CANC, V44, P218, DOI 10.1002/gcc.20214; Proulx M, 2010, INT J HEMATOL, V92, P451, DOI 10.1007/s12185-010-0691-9; Ramalingam SS, 2009, J THORAC ONCOL, V4, P97, DOI 10.1097/JTO.0b013e318191520c; Raveche ES, 2007, BLOOD, V109, P5079, DOI 10.1182/blood-2007-02-071225; ROBERTSON LE, 1992, BLOOD, V80, P29; Robichaud GA, 2008, NUCLEIC ACIDS RES, V36, P4609, DOI 10.1093/nar/gkn432; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Salerno E, 2010, CYTOM PART B-CLIN CY, V78B, pS98, DOI 10.1002/cyto.b.20544; Salerno E, 2009, MOL CANCER THER, V8, P2684, DOI 10.1158/1535-7163.MCT-09-0127; Sampath D, 2012, BLOOD, V119, P1162, DOI 10.1182/blood-2011-05-351510; Scaglione BJ, 2007, BRIT J HAEMATOL, V139, P645, DOI 10.1111/j.1365-2141.2007.06851.x; Siegel D, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-31; Stathis A, 2011, CLIN CANCER RES, V17, P1582, DOI 10.1158/1078-0432.CCR-10-1893; Thelander EF, 2007, LEUKEMIA RES, V31, P1219, DOI 10.1016/j.leukres.2006.10.022; Van Damme M, 2012, EPIGENETICS-US, V7, P1403, DOI 10.4161/epi.22674; Wang JC, 2011, ONCOLOGY-BASEL, V81, P325, DOI 10.1159/000334577; Yu D, 2003, BLOOD, V101, P1950, DOI 10.1182/blood-2002-06-1797; Zhang M, 1998, ONCOL REP, V5, P23; Zhang M, 2001, EXP CELL RES, V264, P233, DOI 10.1006/excr.2000.5122; Zhang X, 2012, ONCOGENE, V31, P3002, DOI 10.1038/onc.2011.470; Zhao HW, 2009, BLOOD, V113, P505, DOI 10.1182/blood-2008-01-136218	66	31	32	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3307	3315		10.1038/onc.2013.291	http://dx.doi.org/10.1038/onc.2013.291			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23995789	Green Accepted			2022-12-28	WOS:000338443400010
J	Ferraldeschi, R; Welti, J; Luo, J; Attard, G; de Bono, JS				Ferraldeschi, R.; Welti, J.; Luo, J.; Attard, G.; de Bono, J. S.			Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects	ONCOGENE			English	Review							IN-SITU HYBRIDIZATION; NH2-TERMINAL TRANSACTIVATION DOMAIN; MEDIATE ENZALUTAMIDE RESISTANCE; HUMAN CYTOCHROME P450(17-ALPHA); POLYMERASE PARP INHIBITORS; CIRCULATING TUMOR-CELLS; LIGAND-BINDING DOMAIN; ABIRATERONE ACETATE; ANTITUMOR-ACTIVITY; SPLICE VARIANTS	Androgen receptor (AR) signaling is a critical pathway for prostate cancer cells, and androgen-deprivation therapy (ADT) remains the principal treatment for patients with locally advanced and metastatic disease. However, over time, most tumors become resistant to ADT. The view of castration-resistant prostate cancer (CRPC) has changed dramatically in the last several years. Progress in understanding the disease biology and mechanisms of castration resistance led to significant advancements and to paradigm shift in the treatment. Accumulating evidence showed that prostate cancers develop adaptive mechanisms for maintaining AR signaling to allow for survival and further evolution. The aim of this review is to summarize molecular mechanisms of castration resistance and provide an update in the development of novel agents and strategies to more effectively target the AR signaling pathway.	[Ferraldeschi, R.; Welti, J.; Attard, G.; de Bono, J. S.] Inst Canc Res, Prostate Canc Targeted Therapy Grp, Sutton SM2 5PT, Surrey, England; [Ferraldeschi, R.; Welti, J.; Attard, G.; de Bono, J. S.] Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England; [Luo, J.] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21205 USA	University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Johns Hopkins University	de Bono, JS (corresponding author), Inst Canc Res, Prostate Canc Targeted Therapy Grp, Sutton SM2 5PT, Surrey, England.	Johann.De-Bono@icr.ac.uk		Welti, Jonathan/0000-0002-9433-8138; de Bono, Johann S/0000-0002-2034-595X; Attard, Gerhardt/0000-0002-4811-7983	Ortho Biotech Oncology Research and Development (a unit of Cougar Biotechnology); Amgen; Astellas; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Dendreon; Enzon; Exelixis; Genentech; GlaxoSmithKline; Medivation; Merck; Novartis; Pfizer; Roche; Sanofi-Aventis; Supergen; Takeda; Janssen-Cilag; Veridex; Roche/Ventana; Millennium Pharmaceuticals; Ipsen; Cancer Research UK [13239] Funding Source: researchfish; National Institute for Health Research [CL-2008-22-001] Funding Source: researchfish; Prostate Cancer UK [PG12-49] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER	Ortho Biotech Oncology Research and Development (a unit of Cougar Biotechnology); Amgen(Amgen); Astellas(Astellas Pharmaceuticals); AstraZeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); Bristol-Myers Squibb(Bristol-Myers Squibb); Dendreon; Enzon; Exelixis; Genentech(Roche HoldingGenentech); GlaxoSmithKline(GlaxoSmithKline); Medivation; Merck(Merck & Company); Novartis(Novartis); Pfizer(Pfizer); Roche(Roche Holding); Sanofi-Aventis(Sanofi-Aventis); Supergen; Takeda(Takeda Pharmaceutical Company Ltd); Janssen-Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Veridex; Roche/Ventana; Millennium Pharmaceuticals(Takeda Pharmaceutical Company Ltd); Ipsen(Ipsen); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR)); Prostate Cancer UK; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Abiraterone acetate was developed at The Institute of Cancer Research (ICR), which therefore has a commercial interest in the development of this agent. JSdB received consulting fees from Ortho Biotech Oncology Research and Development (a unit of Cougar Biotechnology), consulting fees and travel support from Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Dendreon, Enzon, Exelixis, Genentech, GlaxoSmithKline, Medivation, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Supergen and Takeda, and grant support from AstraZeneca and Genentech. GA received consulting fees and travel support from Janssen-Cilag, Veridex, Roche/Ventana and Millennium Pharmaceuticals, lecture fees from Janssen-Cilag, Ipsen, Takeda and Sanofi-Aventis and grant support from AstraZeneca and Genentech. GA is on the ICR rewards to inventors list of abiraterone acetate.	Andersen RJ, 2010, CANCER CELL, V17, P535, DOI 10.1016/j.ccr.2010.04.027; Araujo JC, 2013, LANCET ONCOL, V14, P1307, DOI 10.1016/S1470-2045(13)70479-0; Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Askew EB, 2012, MOL CELL ENDOCRINOL, V348, P403, DOI 10.1016/j.mce.2011.03.026; Attard G, 2008, J CLIN ONCOL, V26, P4563, DOI 10.1200/JCO.2007.15.9749; Attard G, 2010, CLIN CANCER RES, V16, P1340, DOI 10.1158/1078-0432.CCR-09-2253; Attard G, 2009, CANCER RES, V69, P2912, DOI 10.1158/0008-5472.CAN-08-3667; Balbas MD, 2013, ELIFE, V2, DOI 10.7554/eLife.00499; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Barrie SE, 1997, J STEROID BIOCHEM, V60, P347, DOI 10.1016/S0960-0760(96)00225-7; BARRIE SE, 1994, J STEROID BIOCHEM, V50, P267, DOI 10.1016/0960-0760(94)90131-7; Beer TM, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.4_suppl.lba1; Beltran H, 2013, J CLIN ONCOL, V31, P1782, DOI 10.1200/JCO.2012.48.4667; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Bergerat JP, 2009, HUM MUTAT, V30, P145, DOI 10.1002/humu.20848; Bianchini D, 2014, EUR J CANCER, V50, P78, DOI 10.1016/j.ejca.2013.08.020; Bianchini D, 2013, BRIT J CANCER, V109, P2579, DOI 10.1038/bjc.2013.619; Bohl CE, 2005, P NATL ACAD SCI USA, V102, P6201, DOI 10.1073/pnas.0500381102; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; Brooke GN, 2009, CURR GENOMICS, V10, P18, DOI 10.2174/138920209787581307; Bubendorf L, 1999, CANCER RES, V59, P803; Cai CM, 2011, CANCER RES, V71, P6503, DOI 10.1158/0008-5472.CAN-11-0532; Cariaga-Martinez AE, 2013, CELL SIGNAL, V25, P1586, DOI 10.1016/j.cellsig.2013.03.019; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Castoria G, 2004, STEROIDS, V69, P517, DOI 10.1016/j.steroids.2004.05.001; Chang KH, 2013, CELL, V154, P1074, DOI 10.1016/j.cell.2013.07.029; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen SY, 2006, P NATL ACAD SCI USA, V103, P15969, DOI 10.1073/pnas.0604193103; Chmelar R, 2007, INT J CANCER, V120, P719, DOI 10.1002/ijc.22365; Choi JI, 2011, KOREAN J UROL, V52, P461, DOI 10.4111/kju.2011.52.7.461; Cinar B, 2007, J BIOL CHEM, V282, P29584, DOI 10.1074/jbc.M703310200; Clegg NJ, 2012, CANCER RES, V72, P1494, DOI 10.1158/0008-5472.CAN-11-3948; Coffey K, 2012, J ENDOCRINOL, V215, P221, DOI 10.1530/JOE-12-0238; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; Cutress ML, 2008, J CELL SCI, V121, P957, DOI 10.1242/jcs.022103; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Di Lorenzo G, 2002, CLIN CANCER RES, V8, P3438; Eisner JR, 2012, J CLIN ONCOL, V30; Ferraldeschi R, 2013, CANCER J, V19, P34, DOI 10.1097/PPO.0b013e31827e0b6f; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; GELLER J, 1978, J CLIN ENDOCR METAB, V46, P440; Geng C, 2013, P NATL ACAD SCI USA, V110, P6997, DOI 10.1073/pnas.1304502110; Georget V, 2002, BIOCHEMISTRY-US, V41, P11824, DOI 10.1021/bi0259150; Gibbs A, 2009, P NATL ACAD SCI USA, V106, P16663, DOI 10.1073/pnas.0908908106; Godoy A, 2011, PROSTATE, V71, P1033, DOI 10.1002/pros.21318; Grad JM, 2001, ENDOCRINOLOGY, V142, P1107, DOI 10.1210/en.142.3.1107; Grad JM, 1999, MOL ENDOCRINOL, V13, P1896, DOI 10.1210/me.13.11.1896; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Ha S, 2013, ONCOGENE, V32, P3992, DOI 10.1038/onc.2012.412; Haapala K, 2007, HUM PATHOL, V38, P474, DOI 10.1016/j.humpath.2006.09.008; Handratta VD, 2005, J MED CHEM, V48, P2972, DOI 10.1021/jm040202w; Hara T, 2003, CANCER RES, V63, P149; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; Heath EI, 2013, J CLIN ONCOL S, V31; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Huggins C, 1941, CANCER RES, V1, P293; Jarman M, 1998, J MED CHEM, V41, P5375, DOI 10.1021/jm981017j; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Jiang XN, 2010, J BIOL CHEM, V285, P14980, DOI 10.1074/jbc.M109.085696; Joseph JD, 2013, CANCER DISCOV, V3, DOI 10.1158/2159-8290.CD-13-0226; Jozwik KM, 2012, NAT REV CANCER, V12, P381, DOI 10.1038/nrc3263; Jung ME, 2010, J MED CHEM, V53, P2779, DOI 10.1021/jm901488g; Kaku T, 2011, BIOORGAN MED CHEM, V19, P6383, DOI 10.1016/j.bmc.2011.08.066; Kikuchi A., 2013, J CLIN ONCOL, V31, pa5046; Koivisto P, 1997, CANCER RES, V57, P314; Kolvenbag GJCM, 1998, PROSTATE CANCER P D, V1, P307, DOI 10.1038/sj.pcan.4500262; Korpal M, 2013, CANCER DISCOV, V3, P1030, DOI 10.1158/2159-8290.CD-13-0142; Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006; Lamont KR, 2011, MOL ENDOCRINOL, V25, P897, DOI 10.1210/me.2010-0469; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; Lavery DN, 2008, BIOCHEMISTRY-US, V47, P3360, DOI 10.1021/bi702221e; Lavery DN, 2008, BIOCHEMISTRY-US, V47, P3352, DOI 10.1021/bi702220p; Leversha MA, 2009, CLIN CANCER RES, V15, P2091, DOI 10.1158/1078-0432.CCR-08-2036; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Li YM, 2011, CANCER RES, V71, P2108, DOI 10.1158/0008-5472.CAN-10-1998; Lin PC, 2013, CANCER RES, V73, P1232, DOI 10.1158/0008-5472.CAN-12-2968; Linja MJ, 2001, CANCER RES, V61, P3550; Liu LL, 2014, ONCOGENE, V33, P3140, DOI 10.1038/onc.2013.284; Liu Y, 2010, ONCOGENE, V29, P3208, DOI 10.1038/onc.2010.103; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; Logothetis CJ, 2012, LANCET ONCOL, V13, P1210, DOI 10.1016/S1470-2045(12)70473-4; Loriot Y, 2013, ANN ONCOL, V24, P1807, DOI 10.1093/annonc/mdt136; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Luo J, 2013, EUR UROL, V64, P339, DOI 10.1016/j.eururo.2013.05.012; Mahajan NP, 2007, P NATL ACAD SCI USA, V104, P8438, DOI 10.1073/pnas.0700420104; Massard C, 2012, 2012 ESMO C VIENN AU; Michaelson MD, 2014, J CLIN ONCOL, V32, P76, DOI 10.1200/JCO.2012.48.5268; Mitsiades N, 2012, CANCER RES, V72, P6142, DOI 10.1158/0008-5472.CAN-12-1335; Miyoshi Y, 2000, PROSTATE, V43, P225, DOI 10.1002/(SICI)1097-0045(20000515)43:3<225::AID-PROS9>3.0.CO;2-7; Montgomery B, 2014, ASIAN J ANDROL, V16, P354, DOI 10.4103/1008-682X.125392; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Mosquera JM, 2013, NEOPLASIA, V15, P1, DOI 10.1593/neo.121550; Mostaghel EA, 2007, CANCER RES, V67, P5033, DOI 10.1158/0008-5472.CAN-06-3332; Mostaghel EA, 2011, CLIN CANCER RES, V17, P5913, DOI 10.1158/1078-0432.CCR-11-0728; Ni J, 2012, CANCER DISCOV, V2, P425, DOI 10.1158/2159-8290.CD-12-0003; Noonan KL, 2013, ANN ONCOL, V24, P1802, DOI 10.1093/annonc/mdt138; O'Donnell A, 2004, BRIT J CANCER, V90, P2317, DOI 10.1038/sj.bjc.6601879; Okegawa T, 2010, INT J UROL, V17, P950, DOI 10.1111/j.1442-2042.2010.02620.x; Oksala R., 2013, ASCO M, V31, P65; Osguthorpe DJ, 2011, BIOCHEMISTRY-US, V50, P4105, DOI 10.1021/bi102059z; Pacey S, 2011, CLIN CANCER RES, V17, P1561, DOI 10.1158/1078-0432.CCR-10-1927; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Plymate SR, 2013, ANDROGEN RESPONSIVE; POTTER GA, 1995, J MED CHEM, V38, P2463, DOI 10.1021/jm00013a022; Prescott J, 2006, CANCER LETT, V231, P12, DOI 10.1016/j.canlet.2004.12.037; Rathkopf DE, 2013, J CLIN ONCOL, V31, P3525, DOI 10.1200/JCO.2013.50.1684; Ravindranathan P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2912; Reid AHM, 2010, BRIT J CANCER, V102, P678, DOI 10.1038/sj.bjc.6605554; Rhodes N, 2008, CANCER RES, V68, P2366, DOI 10.1158/0008-5472.CAN-07-5783; Richards J, 2012, CANCER RES, V72, P2176, DOI 10.1158/0008-5472.CAN-11-3980; Robbins CM, 2011, GENOME RES, V21, P47, DOI 10.1101/gr.107961.110; RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.bi.63.070194.000325; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Sahu B, 2013, CANCER RES, V73, P1570, DOI 10.1158/0008-5472.CAN-12-2350; Sandhu SK, 2013, ANN ONCOL, V24, P1416, DOI 10.1093/annonc/mdt074; Sandhu SK, 2013, LANCET ONCOL, V14, P882, DOI 10.1016/S1470-2045(13)70240-7; Schaufele F, 2005, P NATL ACAD SCI USA, V102, P9802, DOI 10.1073/pnas.0408819102; SCHER HI, 1993, J CLIN ONCOL, V11, P1566, DOI 10.1200/JCO.1993.11.8.1566; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Scher HI, 2010, LANCET, V375, P1437, DOI 10.1016/S0140-6736(10)60172-9; Schiewer MJ, 2012, CANCER DISCOV, V2, P1134, DOI 10.1158/2159-8290.CD-12-0120; Schrader AJ, 2014, EUR UROL, V65, P30, DOI 10.1016/j.eururo.2013.06.042; Sharma A, 2010, J CLIN INVEST, V120, P4478, DOI 10.1172/JCI44239; Shu SK, 2010, J BIOL CHEM, V285, P33045, DOI 10.1074/jbc.M110.121129; Signoretti S, 2000, JNCI-J NATL CANCER I, V92, P1918, DOI 10.1093/jnci/92.23.1918; Simard J, 1997, UROLOGY, V49, P580, DOI 10.1016/S0090-4295(97)00029-0; Smith DC, 2013, J CLIN ONCOL, V31, P412, DOI 10.1200/JCO.2012.45.0494; Smith MR, 2012, ANN ONCOL, V23, P303; Sonpavde G, 2010, ANN ONCOL, V21, P319, DOI 10.1093/annonc/mdp323; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Steinkamp MP, 2009, CANCER RES, V69, P4434, DOI 10.1158/0008-5472.CAN-08-3605; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Szmulewitz RZ, 2012, PROSTATE, V72, P157, DOI 10.1002/pros.21416; Taplin ME, 2012, J CLIN ONCOL, V30; Taplin ME, 1999, CANCER RES, V59, P2511; Taplin ME, 2003, J CLIN ONCOL, V21, P2673, DOI 10.1200/JCO.2003.11.102; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thomas C, 2013, MOL CANCER THER, V12, P2342, DOI 10.1158/1535-7163.MCT-13-0032; Titus MA, 2005, CLIN CANCER RES, V11, P4653, DOI 10.1158/1078-0432.CCR-05-0525; Tombal B, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.4_suppl.62; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Uemura M, 2008, CANCER SCI, V99, P81, DOI 10.1111/j.1349-7006.2007.00656.x; Unni E, 2004, CANCER RES, V64, P7156, DOI 10.1158/0008-5472.CAN-04-1121; van de Wijngaart DJ, 2012, MOL CELL ENDOCRINOL, V352, P57, DOI 10.1016/j.mce.2011.08.007; van Royen ME, 2007, J CELL BIOL, V177, P63, DOI 10.1083/jcb.200609178; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Verras M, 2007, CANCER RES, V67, P967, DOI 10.1158/0008-5472.CAN-06-3552; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wallen MJ, 1999, J PATHOL, V189, P559; Waltering KK, 2009, CANCER RES, V69, P8141, DOI 10.1158/0008-5472.CAN-09-0919; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Willder JM, 2013, BRIT J CANCER, V108, P139, DOI 10.1038/bjc.2012.480; Wiren KM, 1997, ENDOCRINOLOGY, V138, P2291, DOI 10.1210/en.138.6.2291; WOLF DA, 1993, MOL ENDOCRINOL, V7, P924, DOI 10.1210/me.7.7.924; Wu JD, 2006, J CELL BIOCHEM, V99, P392, DOI 10.1002/jcb.20929; Yap TA, 2011, CA-CANCER J CLIN, V61, P31, DOI 10.3322/caac.20095; Yu EY, 2009, CLIN CANCER RES, V15, P7421, DOI 10.1158/1078-0432.CCR-09-1691; Yu ZY, 2014, CLIN CANCER RES, V20, P1590, DOI 10.1158/1078-0432.CCR-13-1863; Zhang LY, 2009, AM J PATHOL, V175, P489, DOI 10.2353/ajpath.2009.080727; Zhang YX, 2011, MOL CANCER THER, V10, P2309, DOI 10.1158/1535-7163.MCT-11-0329; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287; Zhu Q, 2008, ONCOGENE, V27, P4569, DOI 10.1038/onc.2008.91; Zoubeidi A, 2007, CANCER RES, V67, P10455, DOI 10.1158/0008-5472.CAN-07-2057	172	122	128	3	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1745	1757		10.1038/onc.2014.115	http://dx.doi.org/10.1038/onc.2014.115			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24837363	Green Accepted			2022-12-28	WOS:000352158000002
J	Greenall, SA; Donoghue, JF; Gottardo, NG; Johns, TG; Adams, TE				Greenall, S. A.; Donoghue, J. F.; Gottardo, N. G.; Johns, T. G.; Adams, T. E.			Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo	ONCOGENE			English	Article							GROWTH-FACTOR-RECEPTOR; EXTRACELLULAR DOMAIN; TARGETED THERAPIES; TYROSINE KINASES; ERYTHROPOIETIN RECEPTOR; DISULFIDE BOND; ACTIVATION; GLIOBLASTOMA; CELLS; CANCER	A feature of many gliomas is the amplification of the epidermal growth factor receptor (EGFR), resulting in its overexpression. Missense mutations or deletions within the extracellular domain are associated with this amplification and can lead to constitutive activation of the receptor, with the Domain I/II deletion, EGFRvIII, being the most common. These changes have also been associated with increased sensitivity to EGFR inhibition using small molecule inhibitors. We have expressed, in human glioma cells, EGFR containing four glioma-specific EGFR missense mutations within Domain IV (C620Y, C624F, C628Y and C636Y) to analyze their biological properties and sensitivity to EGFR inhibition. One of these mutants, C620Y, exhibited an enhanced basal phosphorylation, which was partially dependent on an EGFR-ligand autocrine loop. All Domain IV mutants responded equally as well as wildtype EGFR (wtEGFR) to ligand stimulation. Biochemical analysis revealed that a pre-formed, disulfide-bonded dimer associated with these mutations was underglycosylated, inactive and cytoplasmically retained. Ligand stimulation resulted in the formation of a tyrosine-phosphorylated, disulfide-bonded dimer for all Domain IV mutants but not for wtEGFR. Following treatment with the next-generation, irreversible pan-ErbB inhibitor dacomitinib, the C620Y, C624F and EGFRvIII mutants were inactivated, covalently dimerized and were retained in the cytoplasm, resulting in cell-surface receptor loss and, for C620Y and C624F, decreased binding of EGF. Dacomitinib treatment significantly reduced the in vivo growth of human glioma xenografts bearing C620Y, but not wtEGFR. Collectively, these data indicate that the unique biochemical traits of Domain IV EGFR cysteine mutants can be exploited for enhanced sensitivity to EGFR small molecule inhibitors, with potential clinical applications.	[Greenall, S. A.; Adams, T. E.] CSIRO, Div Mat Sci & Engn, Parkville, Vic 3052, Australia; [Donoghue, J. F.; Johns, T. G.] Monash Inst Med Res, Oncogen Signaling Lab & Brain Canc Discovery Coll, Clayton, Vic, Australia; [Gottardo, N. G.] Telethon Inst Child Hlth Res & Brain Canc Discove, Ctr Child Hlth Res, Subiaco, WA, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); Monash University; University of Western Australia	Greenall, SA (corresponding author), CSIRO, Div Mat Sci & Engn, 343 Royal Parade, Parkville, Vic 3052, Australia.	sameer.greenall@csiro.au	Adams, Timothy E/I-6231-2012; Johns, Terrance/C-2441-2008	Adams, Timothy E/0000-0003-3436-0066; Johns, Terrance/0000-0002-8874-4543; Donoghue, Jacqueline/0000-0003-1370-2469; Gottardo, Nicholas/0000-0002-1082-6776; Greenall, Sameer/0000-0002-1461-7111	CSIRO OCE Postdoctoral Fellowship; Cure Cancer Australia Foundation Postdoctoral Fellowship; NHMRC project [1028552, 1012020]; Victorian Government's Operational Infrastructure Support Program; Cure for Life Foundation	CSIRO OCE Postdoctoral Fellowship; Cure Cancer Australia Foundation Postdoctoral Fellowship; NHMRC project(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government's Operational Infrastructure Support Program; Cure for Life Foundation	We would like to thank Professor Antony Burgess from the Walter and Eliza Hall Institute, Melbourne, Victoria for his critical review of the manuscript. SAG is supported by a CSIRO OCE Postdoctoral Fellowship. JFD is funded by a Cure Cancer Australia Foundation Postdoctoral Fellowship. TGJ was supported by NH&MRC project grants (1028552 and 1012020), the Victorian Government's Operational Infrastructure Support Program and Cure for Life Foundation.	Abe Y, 1998, J BIOL CHEM, V273, P11150, DOI 10.1074/jbc.273.18.11150; Adams TE, 2009, GROWTH FACTORS, V27, P141, DOI 10.1080/08977190902843565; Arkhipov A, 2013, CELL, V152, P557, DOI 10.1016/j.cell.2012.12.030; Arteaga CL, 1997, J BIOL CHEM, V272, P23247, DOI 10.1074/jbc.272.37.23247; Bae JH, 2010, MOL CELLS, V29, P443, DOI 10.1007/s10059-010-0080-5; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Bublil EM, 2010, FASEB J, V24, P4744, DOI 10.1096/fj.10-166199; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Cvrljevic AN, 2011, J CELL SCI, V124, P2938, DOI 10.1242/jcs.083295; Dawson JP, 2005, MOL CELL BIOL, V25, P7734, DOI 10.1128/MCB.25.17.7734-7742.2005; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Frederick L, 2000, CANCER RES, V60, P1383; Gan HK, 2007, J BIOL CHEM, V282, P2840, DOI 10.1074/jbc.M605136200; Greenall SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034658; He LJ, 2012, SCI REP-UK, V2, DOI 10.1038/srep00854; Idbaih A, 2009, NEUROPATH APPL NEURO, V35, P208, DOI 10.1111/j.1365-2990.2008.00977.x; Johns TG, 2005, FASEB J, V19, P780, DOI 10.1096/fj.04-1766fje; Johns TG, 2002, INT J CANCER, V98, P398, DOI 10.1002/ijc.10189; Laisney JAGC, 2013, ONCOGENE, V32, P2403, DOI 10.1038/onc.2012.267; Lee JC, 2006, PLOS MED, V3, P2264, DOI 10.1371/journal.pmed.0030485; Li L, 2014, ONCOGENE, V33, P4253, DOI 10.1038/onc.2013.400; Lichtner RB, 2001, CANCER RES, V61, P5790; Macdonald J, 2006, BBA-MOL CELL RES, V1763, P870, DOI 10.1016/j.bbamcr.2006.05.002; Mangasarian K, 1997, J CELL PHYSIOL, V172, P117, DOI 10.1002/(SICI)1097-4652(199707)172:1<117::AID-JCP13>3.3.CO;2-S; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pillay V, 2009, NEOPLASIA, V11, P448, DOI 10.1593/neo.09230; Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753; Robertson SC, 1998, P NATL ACAD SCI USA, V95, P4567, DOI 10.1073/pnas.95.8.4567; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Tebbutt N, 2013, NAT REV CANCER, V13, P663, DOI 10.1038/nrc3559; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Ymer Susie I, 2011, Cancers (Basel), V3, P2032, DOI 10.3390/cancers3022032; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411	39	17	18	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1658	1666		10.1038/onc.2014.106	http://dx.doi.org/10.1038/onc.2014.106			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24747966				2022-12-28	WOS:000351848400006
J	O'Flanagan, CH; Morais, VA; Wurst, W; De Strooper, B; O'Neill, C				O'Flanagan, C. H.; Morais, V. A.; Wurst, W.; De Strooper, B.; O'Neill, C.			The Parkinson's gene PINK1 regulates cell cycle progression and promotes cancer-associated phenotypes	ONCOGENE			English	Article							MITOCHONDRIAL FISSION; OXIDATIVE STRESS; DISEASE; APOPTOSIS; MUTATIONS; PROTECTS; DYSFUNCTION; GROWTH; DRP1; PHOSPHORYLATION	PINK1 (phosphatase and tensin homolog deleted on chromosome 10 (PTEN)-induced kinase 1), a Parkinson's disease-associated gene, was identified originally because of its induction by the tumor-suppressor PTEN. PINK1 promotes cell survival and potentially metastatic functions and protects against cell stressors including chemotherapeutic agents. However, the mechanisms underlying PINK1 function in cancer cell biology are unclear. Here, using several model systems, we show that PINK1 deletion significantly reduced cancer-associated phenotypes including cell proliferation, colony formation and invasiveness, which were restored by human PINK1 overexpression. Results show that PINK1 deletion causes major defects in cell cycle progression in immortalized mouse embryonic fibroblasts (MEFs) from PINK1(-/-) mice, and in BE(2)-M17 cells stably transduced with short hairpin RNA against PINK1. Detailed cell cycle analyses of MEF cell lines from several PINK1(-/-) mice demonstrate an increased proportion of cells in G2/M and decreased number of cells in G1 following release from nocodazole block. This was concomitant with increased double and multi-nucleated cells, a reduced ability to undergo cytokinesis and to re-enter G1, and significant alterations in cell cycle markers, including failure to increase cyclin D1, all indicative of mitotic arrest. PINK1(-/-) cells also demonstrated ineffective cell cycle exit following serum deprivation. Cell cycle defects associated with PINK1 deficiency occur at points critical for cell division, growth and stress resistance in cancer cells were rescued by ectopic expression of human PINK1 and demonstrated PINK1 kinase dependence. The importance of PINK1 for cell cycle control is further supported by results showing that cell cycle deficits induced by PINK1 deletion were linked mechanistically to aberrant mitochondrial fission and its regulation by dynamin-related protein-1 (Drp1), known to be critical for progression of mitosis. Our data indicate that PINK1 has tumor-promoting properties and demonstrates a new function for PINK1 as a regulator of the cell cycle.	[O'Flanagan, C. H.; O'Neill, C.] Natl Univ Ireland Univ Coll Cork, Sch Biochem & Cell Biol, BioSci Inst, Cork, Ireland; [Morais, V. A.; De Strooper, B.] VIB, Ctr Biol Dis, Leuven, Belgium; [Morais, V. A.; De Strooper, B.] Katholieke Univ Leuven, Ctr Human Genet, Leuven, Belgium; [Morais, V. A.; De Strooper, B.] Katholieke Univ Leuven, LIND, Leuven, Belgium; [Wurst, W.] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Dev Genet, Munich, Germany; [Wurst, W.] Tech Univ Munich, Helmholtz Zentrum Munchen, Lehrstuhl Entwicklungsgenet, Munich, Germany; [Wurst, W.] German Ctr Neurodegenerat Dis DZNE, Munich, Germany; [De Strooper, B.] UCL, Inst Neurol, London, England	University College Cork; Flanders Institute for Biotechnology (VIB); KU Leuven; KU Leuven; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of London; University College London	O'Neill, C (corresponding author), Natl Univ Ireland Univ Coll Cork, Sch Biochem & Cell Biol, BioSci Inst, Cork, Ireland.	c.oneill@ucc.ie	de+Strooper, Bart/Z-1638-2019	O'Neill, Cora/0000-0001-5386-7415; Wurst, Wolfgang/0000-0003-4422-7410	Health Research Board of Ireland; PhD Scholars' Programme in Cancer Biology; Science Foundation Ireland (SFI); FWO Foundation for Scientific Research Belgium, a Methusalem grant of the Flemish Government; KU Leuven; Helmholtz Alliance for Mental Health in an Ageing Society; SFI Programme Grant	Health Research Board of Ireland; PhD Scholars' Programme in Cancer Biology; Science Foundation Ireland (SFI)(Science Foundation Ireland); FWO Foundation for Scientific Research Belgium, a Methusalem grant of the Flemish Government; KU Leuven(KU Leuven); Helmholtz Alliance for Mental Health in an Ageing Society; SFI Programme Grant(Science Foundation Ireland)	We are grateful to Mark Cookson and Alexandra Beilina, National Institute on Aging, Bethesda, MD, USA for providing us with BE(2)-M17 cells transduced with control and PINK1 shRNA. We thank Rosemary O'Connor, School of Biochemistry and Cell Biology, University College Cork (UCC) for many helpful discussions, Sandra Yeomans UCC for technical assistance and Daniela Vogt-Weisenhorn, Helmholtz Centrum Munchen, for helpful input. This work was funded by the Health Research Board of Ireland, PhD Scholars' Programme in Cancer Biology. Support from Science Foundation Ireland (SFI) (RFP), the FWO Foundation for Scientific Research Belgium, a Methusalem grant of the Flemish Government and the KU Leuven, and the Helmholtz Alliance for Mental Health in an Ageing Society is also gratefully acknowledged. BDS is the Arthur Bax and Anna Vanluffelen Chair for Alzheimer's disease. The Molecular Cell Biology group, UCC, provided access to a Zeiss 510 Confocal microscope, funded by an SFI Programme Grant to Mary W McCaffrey.	Akundi RS, 2012, NEUROBIOL DIS, V45, P469, DOI 10.1016/j.nbd.2011.08.034; Akundi RS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016038; Arena G, 2013, CELL DEATH DIFFER, V20, P920, DOI 10.1038/cdd.2013.19; Ayllon V, 2007, ONCOGENE, V26, P3451, DOI 10.1038/sj.onc.1210142; Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095; Barbosa IA, 2012, BBA-REV CANCER, V1826, P238, DOI 10.1016/j.bbcan.2012.04.005; Beilina A, 2005, P NATL ACAD SCI USA, V102, P5703, DOI 10.1073/pnas.0500617102; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; Berthier A, 2011, HUM PATHOL, V42, P75, DOI 10.1016/j.humpath.2010.05.016; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Bonda DJ, 2010, NEUROPATH APPL NEURO, V36, P157, DOI 10.1111/j.1365-2990.2010.01064.x; Burgess DJ, 2011, NAT REV CANCER, V11, P692, DOI 10.1038/nrc3142; Cardona F, 2011, HUM MUTAT, V32, P369, DOI 10.1002/humu.21444; Chaiwatanasirikul KA, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.99; Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604; Cho KA, 2004, J BIOL CHEM, V279, P42270, DOI 10.1074/jbc.M402352200; Dagda RK, 2009, J BIOL CHEM, V284, P13843, DOI 10.1074/jbc.M808515200; Deng HS, 2008, P NATL ACAD SCI USA, V105, P14503, DOI 10.1073/pnas.0803998105; Dodson MW, 2007, CURR OPIN NEUROBIOL, V17, P331, DOI 10.1016/j.conb.2007.04.010; Favre C, 2010, ONCOGENE, V29, P3964, DOI 10.1038/onc.2010.146; Fujiwara M, 2008, ONCOGENE, V27, P6002, DOI 10.1038/onc.2008.199; Gandhi S, 2006, BRAIN, V129, P1720, DOI 10.1093/brain/awl114; Gispert S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005777; Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220; Grandemange S, 2009, SEMIN CANCER BIOL, V19, P50, DOI 10.1016/j.semcancer.2008.12.001; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haque ME, 2008, P NATL ACAD SCI USA, V105, P1716, DOI 10.1073/pnas.0705363105; Heeman B, 2011, J CELL SCI, V124, P1115, DOI 10.1242/jcs.078303; Herrup K, 2007, NAT REV NEUROSCI, V8, P368, DOI 10.1038/nrn2124; Herrup K, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt37; Horn SR, 2011, MOL BIOL CELL, V22, P1207, DOI 10.1091/mbc.E10-07-0567; Jin SM, 2012, J CELL SCI, V125, P795, DOI 10.1242/jcs.093849; Kashatus DF, 2011, NAT CELL BIOL, V13, P1108, DOI 10.1038/ncb2310; Kawajiri S, 2010, FEBS LETT, V584, P1073, DOI 10.1016/j.febslet.2010.02.016; Kitada T, 2007, P NATL ACAD SCI USA, V104, P11441, DOI 10.1073/pnas.0702717104; Klinkenberg M, 2010, NEUROSCIENCE, V166, P422, DOI 10.1016/j.neuroscience.2009.12.068; Knudsen KE, 2006, ONCOGENE, V25, P1620, DOI 10.1038/sj.onc.1209371; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Liu WC, 2011, P NATL ACAD SCI USA, V108, P12920, DOI 10.1073/pnas.1107332108; Lutz AK, 2009, J BIOL CHEM, V284, P22938, DOI 10.1074/jbc.M109.035774; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; Marongiu R, 2009, J NEUROCHEM, V108, P1561, DOI 10.1111/j.1471-4159.2009.05932.x; Martin SA, 2011, CANCER RES, V71, P1836, DOI 10.1158/0008-5472.CAN-10-2836; Mei Y, 2009, P NATL ACAD SCI USA, V106, P5153, DOI 10.1073/pnas.0901104106; Michiorri S, 2010, CELL DEATH DIFFER, V17, P962, DOI 10.1038/cdd.2009.200; Mitra K, 2009, P NATL ACAD SCI USA, V106, P11960, DOI 10.1073/pnas.0904875106; Morais VA, 2009, EMBO MOL MED, V1, P99, DOI 10.1002/emmm.200900006; Muqit MMK, 2006, J NEUROCHEM, V98, P156, DOI 10.1111/j.1471-4159.2006.03845.x; Murata H, 2011, J BIOL CHEM, V286, P7182, DOI 10.1074/jbc.M110.179390; Park J, 2009, BIOCHEM BIOPH RES CO, V378, P518, DOI 10.1016/j.bbrc.2008.11.086; Petit A, 2005, J BIOL CHEM, V280, P34025, DOI 10.1074/jbc.M505143200; Poole AC, 2008, P NATL ACAD SCI USA, V105, P1638, DOI 10.1073/pnas.0709336105; Poole AC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010054; Pridgeon JW, 2007, PLOS BIOL, V5, P1494, DOI 10.1371/journal.pbio.0050172; Rakovic A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016746; Rambold AS, 2011, P NATL ACAD SCI USA, V108, P10190, DOI 10.1073/pnas.1107402108; Sandebring A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005701; Silvestri L, 2005, HUM MOL GENET, V14, P3477, DOI 10.1093/hmg/ddi377; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Staropoli JF, 2008, BIOESSAYS, V30, P719, DOI 10.1002/bies.20784; Sun XD, 2013, CELL CYCLE, V12, P1133, DOI 10.4161/cc.24215; Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200; Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Veeriah S, 2010, NAT GENET, V42, P77, DOI 10.1038/ng.491; Wang HL, 2007, NEUROBIOL DIS, V28, P216, DOI 10.1016/j.nbd.2007.07.010; Wilhelmus MMM, 2012, FREE RADICAL BIO MED, V53, P983, DOI 10.1016/j.freeradbiomed.2012.05.040; Yamano K, 2011, NAT CELL BIOL, V13, P1026, DOI 10.1038/ncb2334; Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697	70	49	53	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1363	1374		10.1038/onc.2014.81	http://dx.doi.org/10.1038/onc.2014.81			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24681957	Green Published			2022-12-28	WOS:000350806500003
J	Hu, CM; Zhu, J; Guo, XE; Chen, W; Qiu, XL; Ngo, B; Chien, R; Wang, YV; Tsai, CY; Wu, G; Kim, Y; Lopez, R; Chamberlin, AR; Lee, EH; Lee, WH				Hu, C-M; Zhu, J.; Guo, X. E.; Chen, W.; Qiu, X-L; Ngo, B.; Chien, R.; Wang, Y. V.; Tsai, C. Y.; Wu, G.; Kim, Y.; Lopez, R.; Chamberlin, A. R.; Lee, Ey-Hp; Lee, W-H			Novel small molecules disrupting Hec1/Nek2 interaction ablate tumor progression by triggering Nek2 degradation through a death-trap mechanism	ONCOGENE			English	Article							FAITHFUL CHROMOSOME SEGREGATION; CENTROSOMAL KINASE NEK2; HUMAN BREAST-CANCER; IN-VIVO; MICROTUBULE DYNAMICS; TUMORIGENIC GROWTH; PROTEIN-KINASE; P53 FUNCTION; HEC1; CHECKPOINT	Hec1 (highly expressed in cancer 1) or Nek2 (NIMA-related kinase 2) is often overexpressed in cancers with poor prognosis. Both are critical mitotic regulators, and phosphorylation of Hec1 S165 by Nek2 is required for proper chromosome segregation. Therefore, inactivation of Hec1 and Nek2 by targeting their interaction with small molecules represents an ideal strategy for tackling these types of cancers. Here we showed that new derivatives of INH (inhibitor for Nek2 and Hec1 binding) bind to Hec1 at amino acids 394-408 on W395, L399 and K400 residues, effectively blocking Hec1 phosphorylation on S165 by Nek2, and killing cancer cells at the nanomolar range. Mechanistically, the D-box (destruction-box) region of Nek2 specifically binds to Hec1 at amino acids 408-422, immediately adjacent to the INH binding motif. Subsequent binding of Nek2 to INH-bound Hec1 triggered proteasome-mediated Nek2 degradation, whereas the Hec1 binding defective Nek2 mutant, Nek2 R361L, resisted INH-induced Nek2 degradation. This finding unveils a novel drug-action mechanism where the binding of INHs to Hec1 forms a virtual death-trap to trigger Nek2 degradation and eventually cell death. Furthermore, analysis of the gene expression profiles of breast cancer patient samples revealed that co-elevated expressions of Hec1 and Nek2 correlated with the shortest survival. Treatment of mice with this kind of tumor with INHs significantly suppressed tumor growth without obvious toxicity. Taken together, the new INH derivatives are suitable for translation into clinical application.	[Hu, C-M; Zhu, J.; Guo, X. E.; Chen, W.; Qiu, X-L; Ngo, B.; Chien, R.; Wang, Y. V.; Tsai, C. Y.; Wu, G.; Kim, Y.; Lee, Ey-Hp; Lee, W-H] Univ Calif Irvine, Sch Med, Dept Biol Chem, Irvine, CA 92697 USA; [Hu, C-M; Lee, W-H] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Lopez, R.; Chamberlin, A. R.] Univ Calif Irvine, Dept Chem, Irvine, CA 92717 USA; [Lee, W-H] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan	University of California System; University of California Irvine; Academia Sinica - Taiwan; University of California System; University of California Irvine; China Medical University Taiwan	Lee, WH (corresponding author), Univ Calif Irvine, Sch Med, Dept Biol Chem, 240 Med Sci D, Irvine, CA 92697 USA.	whlee@uci.edu	Zhu, Jiewen/P-8220-2018	Zhu, Jiewen/0000-0002-6742-8138; Ngo, Bryan/0000-0002-7733-2658	NIH [CA107568]; NATIONAL CANCER INSTITUTE [R01CA107568] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the initial efforts by Guideng Li, Randy Wei and Yumay Chen on this project. This work was supported by an NIH grant (CA107568) to WHL.	Andreasson U, 2009, AM J HEMATOL, V84, P803, DOI 10.1002/ajh.21549; Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343; Barbagallo F, 2009, J PATHOL, V217, P431, DOI 10.1002/path.2471; Bieche I, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-23; Cavasotto CN, 2003, PROTEINS, V51, P423, DOI 10.1002/prot.10362; Chan KS, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.148; Chen YM, 1997, MOL CELL BIOL, V17, P6049, DOI 10.1128/MCB.17.10.6049; Chen YM, 2002, J BIOL CHEM, V277, P49408, DOI 10.1074/jbc.M207069200; DeLuca JG, 2006, CELL, V127, P969, DOI 10.1016/j.cell.2006.09.047; Diaz-Rodriguez E, 2008, P NATL ACAD SCI USA, V105, P16719, DOI 10.1073/pnas.0803504105; Foley EA, 2013, NAT REV MOL CELL BIO, V14, P25, DOI 10.1038/nrm3494; Fry AM, 2002, ONCOGENE, V21, P6184, DOI 10.1038/sj.onc.1205711; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Gurzov EN, 2006, GENE THER, V13, P1, DOI 10.1038/sj.gt.3302595; Hames RS, 2001, EMBO J, V20, P7117, DOI 10.1093/emboj/20.24.7117; Hayward DG, 2006, CANCER LETT, V237, P155, DOI 10.1016/j.canlet.2005.06.017; Hayward DG, 2004, CANCER RES, V64, P7370, DOI 10.1158/0008-5472.CAN-04-0960; Hu J, 2012, J AM CHEM SOC, V124, P10940; Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146; Jackson JR, 2007, NAT REV CANCER, V7, P107, DOI 10.1038/nrc2049; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kokuryo T, 2007, CANCER RES, V67, P9637, DOI 10.1158/0008-5472.CAN-07-1489; Li L, 2007, GENE THER, V14, P814, DOI 10.1038/sj.gt.3302933; Lin YT, 2006, ONCOGENE, V25, P6901, DOI 10.1038/sj.onc.1209687; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; Ngo B, 2013, J BIOL CHEM, V288, P34403, DOI 10.1074/jbc.M113.490524; Perez EA, 2009, MOL CANCER THER, V8, P2086, DOI 10.1158/1535-7163.MCT-09-0366; Qiu XL, 2009, J MED CHEM, V52, P1757, DOI 10.1021/jm8015969; Rath O, 2012, NAT REV CANCER, V12, P527, DOI 10.1038/nrc3310; Rowinsky EK, 1997, ANNU REV MED, V48, P353; Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008-5472.CAN-03-3839; SCHMID I, 1994, CYTOMETRY, V15, P12, DOI 10.1002/cyto.990150104; Schmit TL, 2007, MOL CANCER THER, V6, P1920, DOI 10.1158/1535-7163.MCT-06-0781; Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723; Sundin LJR, 2011, MOL BIOL CELL, V22, P759, DOI 10.1091/mbc.E10-08-0671; Umbreit NT, 2012, P NATL ACAD SCI USA, V109, P16113, DOI 10.1073/pnas.1209615109; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Walczak CE, 2010, NAT REV MOL CELL BIO, V11, P91, DOI 10.1038/nrm2832; Wang SL, 2012, J CELL BIOCHEM, V113, P1904, DOI 10.1002/jcb.24059; Wei R, 2011, MOL BIOL CELL, V22, P3584, DOI 10.1091/mbc.E11-01-0012; Wu GK, 2008, CANCER RES, V68, P8393, DOI 10.1158/0008-5472.CAN-08-1915; Zhou W, 2013, CANCER CELL, V23, P48, DOI 10.1016/j.ccr.2012.12.001; Zhu JW, 2013, EMBO MOL MED, V5, P353, DOI 10.1002/emmm.201201760	48	36	41	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1220	1230		10.1038/onc.2014.67	http://dx.doi.org/10.1038/onc.2014.67			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24662830	Green Submitted, Green Accepted			2022-12-28	WOS:000350687100002
J	Tada, Y; Yamaguchi, Y; Kinjo, T; Song, X; Akagi, T; Takamura, H; Ohta, T; Yokota, T; Koide, H				Tada, Y.; Yamaguchi, Y.; Kinjo, T.; Song, X.; Akagi, T.; Takamura, H.; Ohta, T.; Yokota, T.; Koide, H.			The stem cell transcription factor ZFP57 induces IGF2 expression to promote anchorage-independent growth in cancer cells	ONCOGENE			English	Article						ZFP57; IGF2; anchorage-independent growth; HT1080; transformation	SELF-RENEWAL; DNA METHYLATION; PLURIPOTENCY; NANOG; GENE; ACTIVATION; OCT-3/4; DIFFERENTIATION; IDENTIFICATION; MAINTENANCE	Several common biological properties between cancer cells and embryonic stem (ES) cells suggest the possibility that some genes expressed in ES cells might have important roles in cancer cell growth. The transcription factor ZFP57 is expressed in self-renewing ES cells and its expression level decreases during ES cell differentiation. This study showed that ZFP57 is involved in the anchorage-independent growth of human fibrosarcoma HT1080 cells in soft agar. ZFP57 overexpression enhanced, whereas knockdown suppressed, HT1080 tumor formation in nude mice. Furthermore, ZFP57 regulates the expression of insulin-like growth factor 2 (IGF2), which has a critical role in ZFP57-induced anchorage-independent growth. ZFP57 also promotes anchorage-independent growth in ES cells and immortal fibroblasts. Finally, immunohistochemical analysis revealed that ZFP57 is overexpressed in human cancer clinical specimens. Taken together, these results suggest that the ES-specific transcription factor ZFP57 is a novel oncogene.	[Tada, Y.; Kinjo, T.; Song, X.; Akagi, T.; Yokota, T.; Koide, H.] Kanazawa Univ, Grad Sch Med Sci, Dept Stem Cell Biol, Kanazawa, Ishikawa 9208640, Japan; [Yamaguchi, Y.; Takamura, H.; Ohta, T.] Kanazawa Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, Kanazawa, Ishikawa 9208640, Japan	Kanazawa University; Kanazawa University	Koide, H (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Dept Stem Cell Biol, 13-1 Takara Machi, Kanazawa, Ishikawa 9208640, Japan.	hkoide@med.kanazawa-u.ac.jp	Yokota, Takashi/J-8483-2015; Akagi, Tadayuki/E-1078-2011	Akagi, Tadayuki/0000-0002-1733-9452; Koide, Hiroshi/0000-0001-5916-3179; Kinjo, Tomoaki/0000-0003-0939-7756	Ministry of Education, Culture, Sports, Science and Technology of Japan; Hokkoku Foundation for Cancer Research; Cancer Research Institute, Kanazawa University	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Hokkoku Foundation for Cancer Research; Cancer Research Institute, Kanazawa University	We are grateful to Drs Chuanhai Sun and Hitoshi Niwa for providing pCAGPMN(PvuII-MfeI)- CreER and pBRPyCAG-fKlf4-DsRed-IP, respectively. We also thank the Center for Biomedical Research and Education at Kanazawa University for the use of their DNA sequencer. This work was partly supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, a grant from the Hokkoku Foundation for Cancer Research and an Extramural Collaborative Research Grant from the Cancer Research Institute, Kanazawa University.	Akagi T, 2005, BIOCHEM BIOPH RES CO, V331, P23, DOI 10.1016/j.bbrc.2005.03.118; Alonso MBD, 2004, J BIOL CHEM, V279, P25653, DOI 10.1074/jbc.M400415200; Baglivo I, 2013, FEBS LETT, V587, P1474, DOI 10.1016/j.febslet.2013.02.045; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chambers I, 2007, NATURE, V450, P1230, DOI 10.1038/nature06403; Chao W, 2008, CYTOKINE GROWTH F R, V19, P111, DOI 10.1016/j.cytogfr.2008.01.005; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Evangelista M, 2006, CLIN CANCER RES, V12, P5924, DOI 10.1158/1078-0432.CCR-06-1736; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Falix FA, 2012, BBA-MOL BASIS DIS, V1822, P988, DOI 10.1016/j.bbadis.2012.02.003; Farazi TA, 2011, J PATHOL, V223, P102, DOI 10.1002/path.2806; Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723; Holm TM, 2005, CANCER CELL, V8, P275, DOI 10.1016/j.ccr.2005.09.007; Huarte M, 2010, HUM MOL GENET, V19, pR152, DOI 10.1093/hmg/ddq353; Jelinic P, 2007, J PATHOL, V211, P261, DOI 10.1002/path.2116; Jeter CR, 2009, STEM CELLS, V27, P993, DOI 10.1002/stem.29; Li XJ, 2008, DEV CELL, V15, P547, DOI 10.1016/j.devcel.2008.08.014; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Lui JC, 2013, P NATL ACAD SCI USA, V110, P6181, DOI 10.1073/pnas.1219079110; Mackay DJG, 2008, NAT GENET, V40, P949, DOI 10.1038/ng.187; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Mori S, 2009, ONCOGENE, V28, P2796, DOI 10.1038/onc.2009.139; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Niwa H, 2007, DEVELOPMENT, V134, P635, DOI 10.1242/dev.02787; Ogawa K, 2006, BIOCHEM BIOPH RES CO, V343, P159, DOI 10.1016/j.bbrc.2006.02.127; OKAZAKI S, 1994, J BIOL CHEM, V269, P6900; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Quenneville S, 2011, MOL CELL, V44, P361, DOI 10.1016/j.molcel.2011.08.032; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Royo H, 2008, BIOL CELL, V100, P149, DOI 10.1042/BC20070126; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Schoonjans K, 2005, P NATL ACAD SCI USA, V102, P2058, DOI 10.1073/pnas.0409756102; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; Taddei ML, 2012, J PATHOL, V226, P380, DOI 10.1002/path.3000; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takao Y, 2007, BIOCHEM BIOPH RES CO, V353, P699, DOI 10.1016/j.bbrc.2006.12.072; Ueda A., 2012, J JUZEN MED SOC, V121, P38; Yoshida-Koide U, 2004, BIOCHEM BIOPH RES CO, V313, P475, DOI 10.1016/j.bbrc.2003.11.138; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zuo XP, 2012, J BIOL CHEM, V287, P2107, DOI 10.1074/jbc.M111.322644	49	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					752	760		10.1038/onc.2013.599	http://dx.doi.org/10.1038/onc.2013.599			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24469060	Green Submitted			2022-12-28	WOS:000348853800008
J	Lei, Y; Henderson, BR; Emmanuel, C; Harnett, PR; Defazio, A				Lei, Y.; Henderson, B. R.; Emmanuel, C.; Harnett, P. R.; deFazio, A.			Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosis	ONCOGENE			English	Article						ANKRD1; apoptosis; ER stress and ER stress-induced apoptosis; ovarian cancer; platinum-based therapy	ANKYRIN REPEAT PROTEIN; X-LINKED INHIBITOR; CISPLATIN-INDUCED APOPTOSIS; CARCINOMA-CELLS; MELANOMA-CELLS; AKT PHOSPHORYLATION; SKELETAL-MUSCLE; CHOP GADD153; IN-VITRO; DEATH	High expression of Ankyrin Repeat Domain 1 (ANKRD1) in ovarian carcinoma is associated with poor survival, and in ovarian cancer cell lines is associated with platinum resistance. Importantly, decreasing ANKRD1 expression using siRNA increases cisplatin sensitivity. In this study, we investigated possible mechanisms underlying the association of ANKRD1 with cisplatin response. We first demonstrated that cisplatin-induced apoptosis in ovarian cancer cell lines was associated with endoplasmic reticulum (ER) stress, evidenced by induction of Glucose-Regulated Protein 78 (GRP78), growth arrest-and DNA damage-inducible gene 153 (GADD153) and increased intracellular Ca2+ release. The level of sensitivity to cisplatin-induced apoptosis was associated with ANKRD1 protein levels and poly (ADP-ribose) polymerase (PARP) cleavage. COLO 316 ovarian cancer cells, which express high ANKRD1 levels, were relatively resistant to cisplatin, and ER stress-induced apoptosis, whereas OAW42 and PEO14 cells, which express lower ANKRD1 levels, are more sensitive to ER stress-induced apoptosis. Furthermore, we show that overexpression of ANKRD1 attenuated cisplatin-induced cytotoxicity, and conversely siRNA knockdown of ANKRD1 sensitized ovarian cancer cells to cisplatin and ER stress-induced apoptosis associated with induction of GADD153, and downregulation of BCL2 and BCL-X-L. Taken together, these results suggest that ANKRD1 has a significant role in the regulation of apoptosis in human ovarian cancer cells, and is a potential molecular target to enhance sensitivity of ovarian cancer to chemotherapy.	[Lei, Y.; Emmanuel, C.; deFazio, A.] Westmead Hosp, Dept Gynaecol Oncol, Westmead, NSW 2145, Australia; [Lei, Y.; Henderson, B. R.; Emmanuel, C.; Harnett, P. R.; deFazio, A.] Univ Sydney, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead, NSW 2154, Australia; [Harnett, P. R.; deFazio, A.] Westmead Hosp, Crown Princess Mary Canc Ctr, Westmead, NSW 2145, Australia	University of Sydney; University of Sydney; Westmead Institute for Medical Research; University of Sydney	Defazio, A (corresponding author), Univ Sydney, Westmead Hosp, Dept Gynaecol Oncol, Westmead Millennium Inst, Westmead, NSW 2154, Australia.	anna.defazio@sydney.edu.au	DeFazio, Anna/O-2385-2019; Harnett, Paul R/D-4090-2014	DeFazio, Anna/0000-0003-0057-4744; Harnett, Paul R/0000-0001-7021-0642	Cancer Council New South Wales, Australia; Cancer Australia [632595]	Cancer Council New South Wales, Australia(Cancer Council New South Wales); Cancer Australia	This work was supported by grants from Cancer Council New South Wales, Australia and Cancer Australia (Project 632595). Special thanks to Dr Maggie Wang, Westmead Millennium Institute Flow Cytometry Facility, for her help with analysis.	Abedini MR, 2010, ONCOGENE, V29, P11, DOI 10.1038/onc.2009.300; Abedini MR, 2004, ONCOGENE, V23, P6997, DOI 10.1038/sj.onc.1207925; Adachi T, 2008, BIOCHEM BIOPH RES CO, V367, P377, DOI 10.1016/j.bbrc.2007.12.142; Ahmed AA, 2010, J PATHOL, V221, P49, DOI 10.1002/path.2696; Bakhshi J, 2008, APOPTOSIS, V13, P904, DOI 10.1007/s10495-008-0221-x; Boyce M, 2006, CELL DEATH DIFFER, V13, P363, DOI 10.1038/sj.cdd.4401817; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Bromati CR, 2011, AM J PHYSIOL-REG I, V300, pR92, DOI 10.1152/ajpregu.00169.2010; Chen R, 2011, FOLIA BIOL-PRAGUE, V57, P87; CHU W, 1995, J BIOL CHEM, V270, P10236, DOI 10.1074/jbc.270.17.10236; Corazzari M, 2007, BRIT J CANCER, V96, P1062, DOI 10.1038/sj.bjc.6603672; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Del Bello B, 2007, ONCOGENE, V26, P2717, DOI 10.1038/sj.onc.1210079; ENDRESEN PC, 1995, CYTOMETRY, V20, P162, DOI 10.1002/cyto.990200209; Ermak G, 2002, MOL IMMUNOL, V38, P713, DOI 10.1016/S0161-5890(01)00108-0; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fraser M, 2003, CANCER RES, V63, P7081; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Gorlach A, 2006, ANTIOXID REDOX SIGN, V8, P1391, DOI 10.1089/ars.2006.8.1391; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Guminski AD, 2002, LANCET ONCOL, V3, P312, DOI 10.1016/S1470-2045(02)00733-7; Han XJ, 2005, J BIOL CHEM, V280, P23122, DOI 10.1074/jbc.M501095200; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Hu LM, 2002, CANCER RES, V62, P1087; Ishiguro N, 2002, AM J PATHOL, V160, P1767, DOI 10.1016/S0002-9440(10)61123-6; Ishiguro N, 2008, HUM PATHOL, V39, P1673, DOI 10.1016/j.humpath.2008.04.009; Jeyaseelan R, 1997, J BIOL CHEM, V272, P22800, DOI 10.1074/jbc.272.36.22800; Jiang CC, 2009, CARCINOGENESIS, V30, P197, DOI 10.1093/carcin/bgn220; Kidd VJ, 2000, SEMIN CELL DEV BIOL, V11, P191, DOI 10.1006/scdb.2000.0165; Kojic S, 2010, ARCH BIOCHEM BIOPHYS, V502, P60, DOI 10.1016/j.abb.2010.06.029; Labbe E, 2007, CANCER RES, V67, P75, DOI 10.1158/0008-5472.CAN-06-2559; Laure L, 2009, FEBS J, V276, P669, DOI 10.1111/j.1742-4658.2008.06814.x; Lee AH, 2003, P NATL ACAD SCI USA, V100, P9946, DOI 10.1073/pnas.1334037100; Lee MJ, 2009, EXP MOL MED, V41, P243, DOI 10.3858/emm.2009.41.4.027; Lei Y, 2005, PARASITOLOGY, V131, P467, DOI 10.1017/S003118200500805X; Li G, 2009, J CELL BIOL, V186, P783, DOI 10.1083/jcb.200904060; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Masuda Y, 2007, BIOL PHARM BULL, V30, P880, DOI 10.1248/bpb.30.880; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Miller MK, 2003, J MOL BIOL, V333, P951, DOI 10.1016/j.jmb.2003.09.012; Nawrocki ST, 2005, CANCER RES, V65, P11658, DOI 10.1158/0008-5472.CAN-05-2370; PEREZSALA D, 1995, J CELL PHYSIOL, V163, P523, DOI 10.1002/jcp.1041630312; Peyrou M, 2007, TOXICOL SCI, V99, P346, DOI 10.1093/toxsci/kfm152; Pizzo P, 2007, TRENDS CELL BIOL, V17, P511, DOI 10.1016/j.tcb.2007.07.011; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Rabik CA, 2008, J PHARMACOL EXP THER, V327, P442, DOI 10.1124/jpet.108.141291; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Sasaki H, 2000, CANCER RES, V60, P5659; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Scurr LL, 2008, CLIN CANCER RES, V14, P6924, DOI 10.1158/1078-0432.CCR-07-5189; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Tombal B, 1999, CELL CALCIUM, V25, P19, DOI 10.1054/ceca.1998.0005; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yacoub A, 2010, MOL PHARMACOL, V77, P298, DOI 10.1124/mol.109.061820; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Yu H, 2011, EUR J CANCER, V47, P1585, DOI 10.1016/j.ejca.2011.01.019; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zou YM, 1997, DEVELOPMENT, V124, P793	67	25	26	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					485	495		10.1038/onc.2013.566	http://dx.doi.org/10.1038/onc.2013.566			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24531715				2022-12-28	WOS:000348451300009
J	Labidi-Galy, SI; Clauss, A; Ng, V; Duraisamy, S; Elias, KM; Piao, HY; Bilal, E; Davidowitz, RA; Lu, Y; Badalian-Very, G; Gyorffy, B; Kang, UB; Ficarro, S; Ganesan, S; Mills, GB; Marto, JA; Drapkin, R				Labidi-Galy, S. I.; Clauss, A.; Ng, V.; Duraisamy, S.; Elias, K. M.; Piao, H-Y; Bilal, E.; Davidowitz, R. A.; Lu, Y.; Badalian-Very, G.; Gyoerffy, B.; Kang, U-B; Ficarro, S.; Ganesan, S.; Mills, G. B.; Marto, J. A.; Drapkin, R.			Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors	ONCOGENE			English	Article						elafin; ovarian cancer; basal-like breast cancer; mitogen; MAP kinase	MAMMARY EPITHELIAL-CELLS; VERSUS-HOST-DISEASE; GENOMIC INSTABILITY; MICROARRAY DATA; EXPRESSION; PROTEIN; VALIDATION; SURVIVAL; GENES; HE-4	High-grade serous ovarian carcinoma (HGSOC) and basal-like breast cancer (BLBC) share many features including TP53 mutations, genomic instability and poor prognosis. We recently reported that Elafin is overexpressed by HGSOC and is associated with poor overall survival. Here, we confirm that Elafin overexpression is associated with shorter survival in 1000 HGSOC patients. Elafin confers a proliferative advantage to tumor cells through the activation of the MAP kinase pathway. This mitogenic effect can be neutralized by RNA interference, specific antibodies and a MEK inhibitor. Elafin expression in patient-derived samples was also associated with chemoresistance and strongly correlates with bcl-xL expression. We extended these findings into the examination of 1100 primary breast tumors and six breast cancer cell lines. We observed that Elafin is overexpressed and secreted specifically by BLBC tumors and cell lines, leading to a similar mitogenic effect through activation of the MAP kinase pathway. Here too, Elafin overexpression is associated with poor overall survival, suggesting that it may serve as a biomarker and therapeutic target in this setting.	[Labidi-Galy, S. I.; Clauss, A.; Ng, V.; Duraisamy, S.; Elias, K. M.; Piao, H-Y; Badalian-Very, G.; Drapkin, R.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Labidi-Galy, S. I.; Clauss, A.; Duraisamy, S.; Elias, K. M.; Badalian-Very, G.; Kang, U-B; Ficarro, S.; Marto, J. A.; Drapkin, R.] Harvard Univ, Sch Med, Boston, MA USA; [Elias, K. M.] Brigham & Womens Hosp, Div Gynecol Oncol, Boston, MA 02115 USA; [Bilal, E.; Ganesan, S.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ USA; [Davidowitz, R. A.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA; [Lu, Y.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Gyoerffy, B.] Hungarian Acad Sci, Res Lab Pediat & Nephrol, Budapest, Hungary; [Kang, U-B; Ficarro, S.; Marto, J. A.] Dana Farber Canc Inst, Blais Prote Ctr, Boston, MA 02215 USA; [Drapkin, R.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Harvard University; Harvard Medical School; University of Texas System; UTMD Anderson Cancer Center; Hungarian Academy of Sciences; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital	Drapkin, R (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, JF215D,450 Brookline Ave, Boston, MA 02215 USA.	ronny_drapkin@dfci.harvard.edu	Drapkin, Ronny/E-9944-2016; Badalian-Very, Gayane/GLN-6049-2022; Gyorffy, Balazs/AAA-9135-2021; Labidi-Galy, Intidhar/AAG-3915-2021; labidi-galy, sana intidhar/A-4163-2017	Drapkin, Ronny/0000-0002-6912-6977; Gyorffy, Balazs/0000-0002-5772-3766; Elias, Kevin/0000-0003-1502-5553; Clauss, Adam/0000-0002-6381-324X; labidi-galy, sana intidhar/0000-0002-0824-3475	NIH/NCI SPORE in OC [OC P50-CA105009, U01 CA-152990, R21 CA-156021]; NIH/NINDS [P01 NS047572]; Honorable Tina Brozman 'Tina's Wish' Foundation; Dr Miriam and Sheldon G. Adelson Medical Research Foundation; Robert and Debra First Fund; Gamel Family Fund; Ovarian Cancer Research Fund; Madeline Franchi Ovations for the Cure Fund; Mary Kay Foundation; Sandy Rollman Ovarian Cancer Foundation; Dana-Farber Cancer Institute (DFCI) Strategic Initiative; Executive Council of the Cancer Foundation; New Jersey Commission on Cancer Research; Arthur Sachs/Fulbright/Harvard; La Fondation Philippe; La Fondation de France-Recherche clinique en cancerologie-Aide a la mobilite des chercheurs; NATIONAL CANCER INSTITUTE [R21CA156021, P30CA016672, U01CA152990, P50CA105009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS047572] Funding Source: NIH RePORTER	NIH/NCI SPORE in OC; NIH/NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Honorable Tina Brozman 'Tina's Wish' Foundation; Dr Miriam and Sheldon G. Adelson Medical Research Foundation; Robert and Debra First Fund; Gamel Family Fund; Ovarian Cancer Research Fund; Madeline Franchi Ovations for the Cure Fund; Mary Kay Foundation; Sandy Rollman Ovarian Cancer Foundation; Dana-Farber Cancer Institute (DFCI) Strategic Initiative; Executive Council of the Cancer Foundation; New Jersey Commission on Cancer Research; Arthur Sachs/Fulbright/Harvard; La Fondation Philippe; La Fondation de France-Recherche clinique en cancerologie-Aide a la mobilite des chercheurs; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank Dr Michelle Hirsch for critical review of the manuscript, Laura Selfors of biocomputing analyzes of the RPPA data, and members of the Drapkin laboratory for fruitful discussions. This work was supported by the NIH/NCI SPORE in OC P50-CA105009 (RD), U01 CA-152990 (RD), R21 CA-156021 (RD); NIH/NINDS P01 NS047572 (JM), the Honorable Tina Brozman 'Tina's Wish' Foundation (JM, RD), the Dr Miriam and Sheldon G. Adelson Medical Research Foundation (GBM and RD), The Robert and Debra First Fund (RD), The Gamel Family Fund (RD), the Ovarian Cancer Research Fund (RD), The Madeline Franchi Ovations for the Cure Fund (AC), the Mary Kay Foundation (RD), the Sandy Rollman Ovarian Cancer Foundation (RD), the Dana-Farber Cancer Institute (DFCI) Strategic Initiative (JM), the Executive Council of the Cancer Foundation (SG), and the New Jersey Commission on Cancer Research (SG). SILG is a recipient of grants from Arthur Sachs/Fulbright/Harvard, La Fondation Philippe and La Fondation de France-'Recherche clinique en cancerologie-Aide a la mobilite des chercheurs'.	Askenazi M, 2010, PROTEOMICS, V10, P1880, DOI 10.1002/pmic.200900723; Aung G, 2011, J DERMATOL SCI, V63, P128, DOI 10.1016/j.jdermsci.2011.04.014; Bittner M., EXPRESSION PROJECT O; Bouchard D, 2006, LANCET ONCOL, V7, P167, DOI 10.1016/S1470-2045(06)70579-4; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Caruso JA, 2010, CANCER RES, V70, P7125, DOI 10.1158/0008-5472.CAN-10-1547; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Clauss A, 2002, BIOCHEM J, V368, P233, DOI 10.1042/BJ20020869; Clauss A, 2010, NEOPLASIA, V12, P161, DOI 10.1593/neo.91542; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Doucet A, 2007, BIOCHEM J, V405, P455, DOI 10.1042/BJ20070020; Drapkin R, 2005, CANCER RES, V65, P2162, DOI 10.1158/0008-5472.CAN-04-3924; Etemadmoghadam D, 2009, CLIN CANCER RES, V15, P1417, DOI 10.1158/1078-0432.CCR-08-1564; Ficarro SB, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.O111.011064; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Ghosh M, 2010, IMMUNOLOGY, V129, P207, DOI 10.1111/j.1365-2567.2009.03165.x; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Haibe-Kains B, 2012, JNCI-J NATL CANCER I, V104, P311, DOI 10.1093/jnci/djr545; Hellstrom I, 2003, CANCER RES, V63, P3695; Hennessy Bryan T, 2010, Clin Proteomics, V6, P129, DOI 10.1007/s12014-010-9055-y; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Huper G, 2007, CANCER RES, V67, P2990, DOI 10.1158/0008-5472.CAN-06-4065; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jinawath N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011198; Karst AM, 2011, P NATL ACAD SCI USA, V108, P7547, DOI 10.1073/pnas.1017300108; Karst AM, 2010, J ONCOL, V2010, DOI 10.1155/2010/932371; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kulasingam V, 2007, MOL CELL PROTEOMICS, V6, P1997, DOI 10.1074/mcp.M600465-MCP200; Kwei KA, 2010, MOL ONCOL, V4, P255, DOI 10.1016/j.molonc.2010.04.001; Levanon K, 2010, ONCOGENE, V29, P1103, DOI 10.1038/onc.2009.402; Levanon K, 2008, J CLIN ONCOL, V26, P5284, DOI 10.1200/JCO.2008.18.1107; Levine JE, 2012, BLOOD, V119, P3854, DOI 10.1182/blood-2012-01-403063; Li QY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015031; Lundwall A, 2002, BIOCHEM BIOPH RES CO, V290, P452, DOI 10.1006/bbrc.2001.6224; Manie E, 2009, CANCER RES, V69, P663, DOI 10.1158/0008-5472.CAN-08-1560; Mavaddat N, 2012, CANCER EPIDEM BIOMAR, V21, P134, DOI 10.1158/1055-9965.EPI-11-0775; Moore RG, 2009, GYNECOL ONCOL, V112, P40, DOI 10.1016/j.ygyno.2008.08.031; Morton S, 2004, FEBS LETT, V572, P177, DOI 10.1016/j.febslet.2004.07.031; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Paczesny S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000406; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Pazaiti A, 2011, WOMENS HEALTH, V7, P181, DOI [10.2217/whe.11.5, 10.2217/WHE.11.5]; Pfundt R, 1996, J CLIN INVEST, V98, P1389, DOI 10.1172/JCI118926; Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Saidi A, 2008, INT J CANCER, V122, P2187, DOI 10.1002/ijc.23313; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; Shaw L, 2011, BIOCHEM SOC T, V39, P1450, DOI 10.1042/BST0391450; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Vermeer PD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030447; Verrier T, 2012, INT J BIOCHEM CELL B, V44, P1377, DOI 10.1016/j.biocel.2012.05.007; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wang ZGC, 2012, CLIN CANCER RES, V18, P5806, DOI 10.1158/1078-0432.CCR-12-0857; Wei HF, 2012, GYNECOL ONCOL, V125, P727, DOI 10.1016/j.ygyno.2012.03.018; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Williams J, 2005, GYNECOL ONCOL, V96, P287, DOI 10.1016/j.ygyno.2004.10.026; Williams SE, 2006, CLIN SCI, V110, P21, DOI 10.1042/CS20050115; Yokota T, 2007, CANCER RES, V67, P11272, DOI 10.1158/0008-5472.CAN-07-2322; ZHANG M, 1995, CANCER RES, V55, P2537	63	31	31	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					299	309		10.1038/onc.2013.562	http://dx.doi.org/10.1038/onc.2013.562			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24469047	Green Accepted, Green Submitted			2022-12-28	WOS:000348145500004
J	Wu, L; de Bruin, A; Wang, H; Simmons, T; Cleghorn, W; Goldenberg, LE; Sites, E; Sandy, A; Trimboli, A; Fernandez, SA; Eng, C; Shapiro, C; Leone, G				Wu, L.; de Bruin, A.; Wang, H.; Simmons, T.; Cleghorn, W.; Goldenberg, L. E.; Sites, E.; Sandy, A.; Trimboli, A.; Fernandez, S. A.; Eng, C.; Shapiro, C.; Leone, G.			Selective roles of E2Fs for ErbB2-and Myc-mediated mammary tumorigenesis	ONCOGENE			English	Article						Myc; ErbB2; E2F; mammary tumorigenesis; oncogene	TRANSCRIPTION FACTOR; RB DEFICIENCY; MOUSE MODEL; OVEREXPRESSION; PROLIFERATION; EXPRESSION; CANCER; INACTIVATION; FAMILY; TARGET	Previous studies have demonstrated that cyclin D1, an upstream regulator of the Rb/E2F pathway, is an essential component of the ErbB2/Ras (but not the Wnt/Myc) oncogenic pathway in the mammary epithelium. However, the role of specific E2fs for ErbB2/Ras-mediated mammary tunnorigenesis remains unknown. Here, we show that in the majority of mouse and human primary mammary carcinomas with ErbB2/HER2 overexpression, E2f3a is up-regulated, raising the possibility that E2F3a is a critical effector of the ErbB2 oncogenic signaling pathway in the mammary gland. We examined the consequence of ablating individual E2fs in mice on ErbB2-triggered mammary tumorigenesis in comparison to a comparable Myc-driven mammary tumor model. We found that loss of E2f1 or E2f3 led to a significant delay in tumor onset in both oncogenic models, whereas loss of E2f2 accelerated mammary tumorigenesis driven by Myc-overexpression. Furthermore, southern blot analysis of final tumors derived from conditionally deleted E2f3(-/loxP) mammary glands revealed that there is a selection against E2f3(-/-) cells from developing mammary carcinomas, and that such selection pressure is higher in the presence of ErbB2 activation than in the presence of Myc activation. Taken together, our data suggest oncogenic activities of E2F1 and E2F3 in ErbB2- or Myc-triggered mammary tumorigenesis, and a tumor suppressor role of E2F2 in Myc-mediated mammary tumorigenesis.	[Wu, L.; de Bruin, A.; Wang, H.; Simmons, T.; Cleghorn, W.; Goldenberg, L. E.; Sites, E.; Sandy, A.; Trimboli, A.; Leone, G.] Ohio State Univ, Dept Mol Genet, Coll Biol Sci, Columbus, OH 43210 USA; [Wu, L.; de Bruin, A.; Wang, H.; Simmons, T.; Cleghorn, W.; Goldenberg, L. E.; Sites, E.; Sandy, A.; Trimboli, A.; Leone, G.] Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA; [Wu, L.; de Bruin, A.; Wang, H.; Simmons, T.; Cleghorn, W.; Goldenberg, L. E.; Sites, E.; Sandy, A.; Trimboli, A.; Leone, G.] Ohio State Univ, Coll Med, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Fernandez, S. A.] Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA; [Eng, C.] Cleveland Clin, Genom Med Inst, Cleveland, OH 44106 USA; [Shapiro, C.] Ohio State Univ, Coll Med, Div Hematol & Oncol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Cleveland Clinic Foundation; University System of Ohio; Ohio State University	Wu, L (corresponding author), Rutgers New Jersey Med Sch, Ctr Canc, 205 South Orange Ave, Newark, NJ 07103 USA.	wuli@njms.rutgers.edu	de Bruin, Alain/AAL-9195-2020	de Bruin, Alain/0000-0001-8579-2649	NIH [R01CA85619, R01CA82259, R01HD047470, R01 CA121275, P01CA097189]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD047470] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016058, R01CA082259, R01CA121275, R01CA085619, P01CA097189] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank L Rawahneh, J Moffitt and N Lovett for technical assistance with histology. We also thank OSUCCC Shared Resources for microarray and nucleic acid. This work was funded by NIH grants to GL (R01CA85619, R01CA82259, R01HD047470, R01 CA121275; P01CA097189). GL is a Pew Charitable Trust Scholar and a Leukemia and Lymphoma Society Scholar.	Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Agger K, 2005, ONCOGENE, V24, P780, DOI 10.1038/sj.onc.1208248; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Conner EA, 2000, ONCOGENE, V19, P5054, DOI 10.1038/sj.onc.1203885; Cooper CS, 2006, LUNG CANCER, V54, P155, DOI 10.1016/j.lungcan.2006.07.005; DeGregori J, 2004, J CELL SCI, V117, P3411, DOI 10.1242/jcs.01189; DeGregori J, 2006, CURR MOL MED, V6, P739; Denchi EL, 2005, MOL CELL BIOL, V25, P2660, DOI 10.1128/MCB.25.7.2660-2672.2005; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800; Fujiwara K, 2011, CANCER RES, V71, P1924, DOI 10.1158/0008-5472.CAN-10-2386; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Grasemann C, 2005, ONCOGENE, V24, P6441, DOI 10.1038/sj.onc.1208792; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He YW, 2002, J BIOL CHEM, V277, P23493, DOI 10.1074/jbc.M202629200; Humbert PO, 2000, GENE DEV, V14, P690; Hurst CD, 2008, ONCOGENE, V27, P2716, DOI 10.1038/sj.onc.1210934; Iwamoto M, 2004, CANCER BIOL THER, V3, P395, DOI 10.4161/cbt.3.4.733; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Maddison LA, 2004, CANCER RES, V64, P6018, DOI 10.1158/0008-5472.CAN-03-2509; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Opavsky R, 2007, P NATL ACAD SCI USA, V104, P15400, DOI 10.1073/pnas.0706307104; Orlic M, 2006, GENE CHROMOSOME CANC, V45, P72, DOI 10.1002/gcc.20263; Paulson QX, 2006, CELL CYCLE, V5, P184, DOI 10.4161/cc.5.2.2307; Pusapati RV, 2010, MOL CARCINOGEN, V49, P152, DOI 10.1002/mc.20584; Rempel RE, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000640; Rounbehler RJ, 2002, CANCER RES, V62, P3276; SANDGREN EP, 1995, CANCER RES, V55, P3915; Scheijen B, 2004, J BIOL CHEM, V279, P10476, DOI 10.1074/jbc.M313682200; Sharma N, 2006, J BIOL CHEM, V281, P36124, DOI 10.1074/jbc.M604152200; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Simin K, 2004, PLOS BIOL, V2, P194, DOI 10.1371/journal.pbio.0020022; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Suzuki T, 1999, INT J CANCER, V81, P535, DOI 10.1002/(SICI)1097-0215(19990517)81:4<535::AID-IJC5>3.0.CO;2-4; Timmers C, 2007, MOL CELL BIOL, V27, P65, DOI 10.1128/MCB.02147-06; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhou ZX, 2007, CANCER RES, V67, P5683, DOI 10.1158/0008-5472.CAN-07-0768; Zhou ZX, 2006, CANCER RES, V66, P7889, DOI 10.1158/0008-5472.CAN-06-0486; Ziebold U, 2003, MOL CELL BIOL, V23, P6542, DOI 10.1128/MCB.23.18.6542-6552.2003	50	25	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					119	128		10.1038/onc.2013.511	http://dx.doi.org/10.1038/onc.2013.511			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24276244	Green Accepted			2022-12-28	WOS:000349740100011
J	Delehouze, C; Godl, K; Loaec, N; Bruyere, C; Desban, N; Oumata, N; Galons, H; Roumeliotis, TI; Giannopoulou, EG; Grenet, J; Twitchell, D; Lahti, J; Mouchet, N; Galibert, MD; Garbis, SD; Meijer, L				Delehouze, C.; Godl, K.; Loaec, N.; Bruyere, C.; Desban, N.; Oumata, N.; Galons, H.; Roumeliotis, T. I.; Giannopoulou, E. G.; Grenet, J.; Twitchell, D.; Lahti, J.; Mouchet, N.; Galibert, M-D; Garbis, S. D.; Meijer, L.			CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells	ONCOGENE			English	Article						cyclin-dependent kinase; casein kinase 1; roscovitine; CR8; MYCN; neuroblastoma	CYCLIN-DEPENDENT KINASE; RNA-POLYMERASE-II; DRUG DISCOVERY; CDK INHIBITORS; BREAST-CANCER; INTRACELLULAR TARGETS; THERAPEUTIC TARGETS; PYRIDOXAL KINASE; DUAL-SPECIFICITY; K/CDK12 COMPLEX	To understand the mechanisms of action of (R)-roscovitine and (S)-CR8, two related pharmacological inhibitors of cyclin-dependent kinases (CDKs), we applied a variety of '-omics' techniques to the human neuroblastoma SH-SY5Y and IMR32 cell lines: (1) kinase interaction assays, (2) affinity competition on immobilized broad-spectrum kinase inhibitors, (3) affinity chromatography on immobilized (R)-roscovitine and (S)-CR8, (4) whole genome transcriptomics analysis and specific quantitative PCR studies, (5) global quantitative proteomics approach and western blot analysis of selected proteins. Altogether, the results show that the major direct targets of these two molecules belong to the CDKs (1,2,5,7,9,12), DYRKs, CLKs and CK1s families. By inhibiting CDK7, CDK9 and CDK12, these inhibitors transiently reduce RNA polymerase 2 activity, which results in downregulation of a large set of genes. Global transcriptomics and proteomics analysis converge to a central role of MYC transcription factors downregulation. Indeed, CDK inhibitors trigger rapid and massive downregulation of MYCN expression in MYCN-amplified neuroblastoma cells as well as in nude mice xenografted IMR32 cells. Inhibition of casein kinase 1 may also contribute to the antitumoral activity of (R)-roscovitine and (S)-CR8. This dual mechanism of action may be crucial in the use of these kinase inhibitors for the treatment of MYC-dependent cancers, in particular neuroblastoma where MYCN amplification is a strong predictor factor for high-risk disease.	[Delehouze, C.; Loaec, N.; Bruyere, C.; Oumata, N.; Meijer, L.] Ctr Perharidy, Hotel Rech, ManRos Therapeut, F-29680 Roscoff, France; [Godl, K.] Evotec Munchen GmbH, Martinsried, Germany; [Loaec, N.; Desban, N.; Meijer, L.] CNRS, Prot Phosphorylat & Human Dis Grp, Roscoff, Bretagne, France; [Galons, H.] Univ Paris 05, INSERM U648, Lab Chim Organ 2, Paris, France; [Roumeliotis, T. I.; Garbis, S. D.] Univ Southampton, Inst Life Sci, Ctr Prote & Metabol Res, Southampton, Hants, England; [Giannopoulou, E. G.] Weill Cornell Med Coll, Inst Computat Biomed, New York, NY USA; [Grenet, J.; Twitchell, D.; Lahti, J.] St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; [Mouchet, N.; Galibert, M-D] Univ Rennes 1, CNRS, UMR 6290, Inst Genet & Dev Rennes Equipe Express Gen & Onco, Rennes, France	Evotec; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Southampton; Cornell University; St Jude Children's Research Hospital; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Rennes	Meijer, L (corresponding author), Ctr Perharidy, Hotel Rech, ManRos Therapeut, F-29680 Roscoff, France.	herve.galons@univ-paris5.fr; S.D.Garbis@soton.ac.uk; meijer@manros-therapeutics.com	Giannopoulou, Evgenia/K-9576-2019; Garbis, Spiros D/L-3099-2013; MEIJER, Laurent/ABE-7465-2021; Mouchet, Nicolas/AAP-6126-2020	Garbis, Spiros D/0000-0002-1050-0805; Mouchet, Nicolas/0000-0002-2849-9953; , laurent/0000-0003-3511-4916	EEC (FP6 Life Sciences & Health PRO-KINASE Project); Canceropole Grand-Ouest; Association France-Alzheimer Finistere; Association pour la Recherche sur le Cancer [ARC-1092]; Ligue Nationale contre le Cancer (Comite Grand-Ouest); Polycystic Kidney Disease Foundation; Fondation Jerome Lejeune; Conseil Regional de Bretagne ('Fonds de Maturation'); Institut National contre le Cancer (INCa) GLIOMER program; CCCDK8 program; EEC (TEMPO Research Project); NATIONAL CANCER INSTITUTE [R01CA067938, P30CA021765] Funding Source: NIH RePORTER	EEC (FP6 Life Sciences & Health PRO-KINASE Project); Canceropole Grand-Ouest; Association France-Alzheimer Finistere; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nationale contre le Cancer (Comite Grand-Ouest); Polycystic Kidney Disease Foundation; Fondation Jerome Lejeune; Conseil Regional de Bretagne ('Fonds de Maturation')(Region Bretagne); Institut National contre le Cancer (INCa) GLIOMER program; CCCDK8 program; EEC (TEMPO Research Project); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This article is dedicated to the memory of Jill Lahti and Vincent Kidd. We are grateful to Jacint Boix and Jean Benard, for the neuroblastoma cell lines. This research was supported by grants from the EEC (FP6 Life Sciences & Health PRO-KINASE and TEMPO Research Projects), the 'Canceropole Grand-Ouest', the 'Association France-Alzheimer Finistere', the 'Association pour la Recherche sur le Cancer' (ARC-1092), the 'Ligue Nationale contre le Cancer (Comite Grand-Ouest)', the Polycystic Kidney Disease Foundation, the Fondation Jerome Lejeune, the 'Conseil Regional de Bretagne' ('Fonds de Maturation' 2009) and the 'Institut National contre le Cancer' (INCa) GLIOMER and CCCDK8 programs.	Albihn A, 2010, ADV CANCER RES, V107, P163, DOI 10.1016/S0065-230X(10)07006-5; Aldoss IT, 2009, EXPERT OPIN INV DRUG, V18, P1957, DOI 10.1517/13543780903418445; Azevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI DOI 10.1111/J.1432-1033.1997.0518A.X; Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Baumli S, 2012, STRUCTURE, V20, P1788, DOI 10.1016/j.str.2012.08.011; Becker F, 2004, CHEM BIOL, V11, P211, DOI 10.1016/j.chembiol.2004.02.001; Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Benson C, 2007, BRIT J CANCER, V96, P29, DOI 10.1038/sj.bjc.6603509; Bettayeb K, 2008, ONCOGENE, V27, P5797, DOI 10.1038/onc.2008.191; Bettayeb K, 2008, MOL CANCER THER, V7, P2713, DOI 10.1158/1535-7163.MCT-08-0080; Bettayeb Karima, 2010, Genes Cancer, V1, P369, DOI 10.1177/1947601910369817; Blazek D, 2012, CELL CYCLE, V11, P1049, DOI 10.4161/cc.11.6.19678; Blazek D, 2011, GENE DEV, V25, P2158, DOI 10.1101/gad.16962311; Breuer D, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-94; Campaner S, 2010, NAT CELL BIOL, V12, P54, DOI 10.1038/ncb2004; Cepeda D, 2013, EMBO MOL MED, V5, P1067, DOI 10.1002/emmm.201202341; Chen Y, 2013, SURGERY, V153, P4, DOI 10.1016/j.surg.2012.03.030; Cheng SWG, 2012, MOL CELL BIOL, V32, P4691, DOI 10.1128/MCB.06267-11; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cicenas J, 2011, J CANCER RES CLIN, V137, P1409, DOI 10.1007/s00432-011-1039-4; Cirillo D, 2011, CURR MED CHEM, V18, P2854, DOI 10.2174/092986711796150496; Conradt L, 2011, NEOPLASIA, V13, P1026, DOI 10.1593/neo.111016; Dai Q, 2012, J BIOL CHEM, V287, P25344, DOI 10.1074/jbc.M111.321760; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Debdab M, 2011, J MED CHEM, V54, P4172, DOI 10.1021/jm200274d; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Eglen R, 2011, PHARMACOL THERAPEUT, V130, P144, DOI 10.1016/j.pharmthera.2011.01.007; Eglen RM, 2009, ASSAY DRUG DEV TECHN, V7, P22, DOI 10.1089/adt.2008.164; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Faisal A, 2011, MOL CANCER THER, V10, P2115, DOI 10.1158/1535-7163.MCT-11-0333; Galons H, 2013, EXPERT OPIN THER PAT, V23, P945, DOI 10.1517/13543776.2013.789861; Garrofe-Ochoa X, 2011, APOPTOSIS, V16, P660, DOI 10.1007/s10495-011-0603-3; Goga A, 2007, NAT MED, V13, P820, DOI 10.1038/nm1606; Goldstein DM, 2008, NAT REV DRUG DISCOV, V7, P391, DOI 10.1038/nrd2541; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Grotzer MA, 2009, CURR CANCER DRUG TAR, V9, P176, DOI 10.2174/156800909787580962; Grunwald V, 2002, CANCER RES, V62, P6141; Gustafson WC, 2010, ONCOGENE, V29, P1249, DOI 10.1038/onc.2009.512; Horiuchi D, 2012, J EXP MED, V209, P679, DOI 10.1084/jem.20111512; Hsieh WS, 2009, CLIN CANCER RES, V15, P1435, DOI 10.1158/1078-0432.CCR-08-1748; Hui ABY, 2009, CLIN CANCER RES, V15, P3716, DOI 10.1158/1078-0432.CCR-08-2790; Hydbring P, 2010, P NATL ACAD SCI USA, V107, P58, DOI 10.1073/pnas.0900121106; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Jorda R, 2012, CURR PHARM DESIGN, V18, P2974, DOI 10.2174/138161212800672804; Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358; Knockaert M, 2000, CHEM BIOL, V7, P411, DOI 10.1016/S1074-5521(00)00124-1; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Knockaert M, 2002, J BIOL CHEM, V277, P25493, DOI 10.1074/jbc.M202651200; Kohoutek J, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-12; Krystof V, 2012, CURR PHARM DESIGN, V18, P2883, DOI 10.2174/138161212800672750; Larochelle S, 2012, NAT STRUCT MOL BIOL, V19, P1108, DOI 10.1038/nsmb.2399; Lee JH, 2012, BIOCHIP J, V6, P362, DOI 10.1007/s13206-012-6408-9; Loven J, 2012, CELL, V151, P476, DOI 10.1016/j.cell.2012.10.012; Malumbres M, 2008, TRENDS PHARMACOL SCI, V29, P16, DOI 10.1016/j.tips.2007.10.012; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; Meijer L, 2006, MONOGRAPHS ENZYME IN, V2, P187; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Misra RN, 2004, J MED CHEM, V47, P1719, DOI 10.1021/jm0305568; Molenaar JJ, 2009, P NATL ACAD SCI USA, V106, P12968, DOI 10.1073/pnas.0901418106; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Muraki M, 2004, J BIOL CHEM, V279, P24246, DOI 10.1074/jbc.M314298200; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Oumata N, 2008, J MED CHEM, V51, P5229, DOI 10.1021/jm800109e; Oumata N, 2009, ORG PROCESS RES DEV, V13, P641, DOI 10.1021/op800284k; Parry D, 2010, MOL CANCER THER, V9, P2344, DOI 10.1158/1535-7163.MCT-10-0324; Petrelli A, 2008, CURR MED CHEM, V15, P422; Popowycz F, 2009, J MED CHEM, V52, P655, DOI 10.1021/jm801340z; Rena G, 2004, EMBO REP, V5, P60, DOI 10.1038/sj.embor.7400048; Schonerr C, 2012, ONCOGENE, V31, P5193, DOI 10.1038/onc.2012.12; Schulte JH, 2013, ONCOGENE, V32, P1059, DOI 10.1038/onc.2012.106; Sharma K, 2009, NAT METHODS, V6, P741, DOI [10.1038/NMETH.1373, 10.1038/nmeth.1373]; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Squires MS, 2010, MOL CANCER THER, V9, P920, DOI 10.1158/1535-7163.MCT-09-1071; Tahtouh T, 2012, J MED CHEM, V55, P9312, DOI 10.1021/jm301034u; Tang L, 2005, J BIOL CHEM, V280, P31220, DOI 10.1074/jbc.M500805200; Tanramluk D, 2009, CHEM BIOL DRUG DES, V74, P16, DOI 10.1111/j.1747-0285.2009.00832.x; Toyoshima M, 2012, P NATL ACAD SCI USA, V109, P9545, DOI 10.1073/pnas.1121119109; Trova MP, 2009, BIOORG MED CHEM LETT, V19, P6613, DOI 10.1016/j.bmcl.2009.10.011; Trova MP, 2009, BIOORG MED CHEM LETT, V19, P6608, DOI 10.1016/j.bmcl.2009.10.025; Via MC, 2011, KINASE TARGETED THER, P124; Wang LM, 2010, MINI-REV MED CHEM, V10, P1058, DOI 10.2174/1389557511009011058; Wang XY, 2011, CANCER RES, V71, P925, DOI 10.1158/0008-5472.CAN-10-1032; Weinmann H, 2005, CHEMBIOCHEM, V6, P455, DOI 10.1002/cbic.200500034; Wesierska-Gadek J, 2011, EXPERT OPIN INV DRUG, V20, P1611, DOI 10.1517/13543784.2011.628985; Whittaker SR, 2007, CELL CYCLE, V6, P3114, DOI 10.4161/cc.6.24.5142; Zhu SZ, 2012, CANCER CELL, V21, P362, DOI 10.1016/j.ccr.2012.02.010	92	50	52	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2014	33	50					5675	5687		10.1038/onc.2013.513	http://dx.doi.org/10.1038/onc.2013.513			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW2AB	24317512	Green Accepted			2022-12-28	WOS:000346089300003
J	Di Giandomenico, S; Frapolli, R; Bello, E; Uboldi, S; Licandro, SA; Marchini, S; Beltrame, L; Brich, S; Mauro, V; Tamborini, E; Pilotti, S; Casali, PG; Grosso, F; Sanfilippo, R; Gronchi, A; Mantovani, R; Gatta, R; Galmarini, CM; Sousa-Faro, JMF; D'Incalci, M				Di Giandomenico, S.; Frapolli, R.; Bello, E.; Uboldi, S.; Licandro, S. A.; Marchini, S.; Beltrame, L.; Brich, S.; Mauro, V.; Tamborini, E.; Pilotti, S.; Casali, P. G.; Grosso, F.; Sanfilippo, R.; Gronchi, A.; Mantovani, R.; Gatta, R.; Galmarini, C. M.; Sousa-Faro, J. M. F.; D'Incalci, M.			Mode of action of trabectedin in myxoid liposarcomas	ONCOGENE			English	Article						trabectedin; myxoid liposarcoma; xenografts; differentiation; transcription regulation	NUCLEOTIDE-EXCISION-REPAIR; ROUND-CELL LIPOSARCOMA; CHOP FUSION PROTEIN; ANTITUMOR-ACTIVITY; SOFT-TISSUE; TRANSCRIPTIONAL ACTIVATION; ADIPOCYTE DIFFERENTIATION; ECTEINASCIDIN 743; BINDING PROTEIN; MINOR-GROOVE	To elucidate the mechanisms behind the high sensitivity of myxoid/round cell liposarcoma (MRCL) to trabectedin and the suggested selectivity for specific subtypes, we have developed and characterized three MRCL xenografts, namely ML017, ML015 and ML004 differing for the break point of the fusion gene FUS-CHOP, respectively of type I, II and III. FUS-CHOP binding to the promoters of some target genes such as Pentraxin 3 or Fibronectin 1, assessed by chromatin immunoprecipitation, was strongly reduced in the tumor 24 h after the first or the third weekly dose of trabectedin, indicating that the drug at therapeutic doses causes a detachment of the FUS-CHOP chimera from its target promoters as previously shown in vitro. Moreover, the higher sensitivity of MRCL types I and II appears to be related to a more prolonged block of the transactivating activity of the fusion protein. Doxorubicin did not affect the binding of FUS-CHOP to target promoters. Histologically, the response to trabectedin in ML017 and ML015 was associated with a marked depletion of non-lipogenic tumoral cells and vascular component, as well as lipidic maturation as confirmed by PPAR gamma 2 expression in western Blot. By contrast, in ML004 no major changes either in the cellularity or in the amount of mature were found, and consistently PPAR gamma 2 was null. In conclusion, the data support the view that the selective mechanism of action of trabectedin in MRCL is specific and related to its ability to cause a functional inactivation of the oncogenic chimera with consequent derepression of the adypocytic differentiation.	[Di Giandomenico, S.; Frapolli, R.; Bello, E.; Uboldi, S.; Licandro, S. A.; Marchini, S.; Beltrame, L.; D'Incalci, M.] Ist Ric Farmacol Mario Negri, IRCCS, Dept Oncol, I-20156 Milan, Italy; [Brich, S.; Mauro, V.; Tamborini, E.; Pilotti, S.] Fdn IRCCS Ist Nazl Tumori, Dept Pathol, Milan, Italy; [Casali, P. G.; Sanfilippo, R.] Fdn IRCCS Ist Nazl Tumori, Dept Canc Med, Adult Sarcoma Med Treatment Unit, Milan, Italy; [Grosso, F.] SS Antonio & Biagio Gen Hosp, Dept Oncol, Alessandria, Italy; [Gronchi, A.] Fdn IRCCS Ist Nazl Tumori, Dept Surg, Milan, Italy; [Mantovani, R.; Gatta, R.] Univ Milan, Dipartimento Biosci, Milan, Italy; [Galmarini, C. M.; Sousa-Faro, J. M. F.] PharmaMar SA, Madrid, Spain	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Azienda Ospedaliera SS Antonio Biagio Cesare Arrigo; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan; PharmaMar	D'Incalci, M (corresponding author), Ist Ric Farmacol Mario Negri, IRCCS, Dept Oncol, Via La Masa 19, I-20156 Milan, Italy.	maurizio.dincalci@marionegri.it	Tamborini, Elena/C-3307-2017; brich, silvia/K-4049-2016; D'Incalci, Maurizio/AAA-9021-2020; Marchini, sergio/J-3968-2018; Gronchi, Alessandro/O-6589-2016; casali, Paolo Giovanni/D-1524-2017; Bello, Ezia/AAB-2210-2020; Frapolli, Roberta/AAA-6729-2020; Brich, Silvia/AAC-1283-2019; Sanfilippo, Roberta/E-2123-2017; Beltrame, Luca/AAB-1998-2020	Tamborini, Elena/0000-0002-3819-8687; brich, silvia/0000-0002-6359-1712; D'Incalci, Maurizio/0000-0001-8784-1360; Marchini, sergio/0000-0003-1783-7651; Gronchi, Alessandro/0000-0002-4703-3534; casali, Paolo Giovanni/0000-0003-4056-8023; Bello, Ezia/0000-0001-5116-0758; Frapolli, Roberta/0000-0003-2907-273X; Brich, Silvia/0000-0002-6359-1712; Sanfilippo, Roberta/0000-0002-9704-0521; Beltrame, Luca/0000-0003-3631-6544; Licandro, Simonetta Andrea/0000-0001-7597-7084; Uboldi, Sarah/0000-0002-6430-0323; Galmarini, Carlos Maria/0000-0001-5494-6617	AIRC grants	AIRC grants(Fondazione AIRC per la ricerca sul cancro)	The study was supported by two AIRC grants to MD and SP.	Adelmant G, 1998, J BIOL CHEM, V273, P15574, DOI 10.1074/jbc.273.25.15574; [Anonymous], 2002, PATHOLOGY GENETICS T; Antonescu CR, 2001, CLIN CANCER RES, V7, P3977; Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; Bode-Lesniewska B, 2007, GENE CHROMOSOME CANC, V46, P961, DOI 10.1002/gcc.20478; Bonfanti M, 1999, ANTI-CANCER DRUG DES, V14, P179; BROGGINI M, 1994, ANTI-CANCER DRUG DES, V9, P373; BROGGINI M, 1995, NUCLEIC ACIDS RES, V23, P81, DOI 10.1093/nar/23.1.81; Charytonowicz E, 2012, J CLIN INVEST, V122, P886, DOI 10.1172/JCI60015; CHIANG SY, 1994, BIOCHEMISTRY-US, V33, P7033, DOI 10.1021/bi00189a003; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; D'Incalci A, 2003, EXPERT OPIN INV DRUG, V12, P1843; D'Incalci M, 2010, MOL CANCER THER, V9, P2157, DOI 10.1158/1535-7163.MCT-10-0263; Damia G, 1996, INT J CANCER, V66, P779, DOI 10.1002/(SICI)1097-0215(19960611)66:6<779::AID-IJC12>3.0.CO;2-Z; Demicco EG, 2012, MODERN PATHOL, V25, P212, DOI 10.1038/modpathol.2011.148; Dervan PB, 1999, CURR OPIN CHEM BIOL, V3, P688, DOI 10.1016/S1367-5931(99)00027-7; Erba E, 2001, EUR J CANCER, V37, P97, DOI 10.1016/S0959-8049(00)00357-9; Forni C, 2009, MOL CANCER THER, V8, P449, DOI 10.1158/1535-7163.MCT-08-0848; Frapolli R, 2010, CLIN CANCER RES, V16, P4958, DOI 10.1158/1078-0432.CCR-10-0317; Friedman D, 2002, CANCER RES, V62, P3377; Gajate C, 2002, J BIOL CHEM, V277, P41580, DOI 10.1074/jbc.M204644200; Germano G, 2013, CANCER CELL, V23, P249, DOI 10.1016/j.ccr.2013.01.008; Germano G, 2010, CANCER RES, V70, P2235, DOI 10.1158/0008-5472.CAN-09-2335; Goransson M, 2002, EXP CELL RES, V278, P125, DOI 10.1006/excr.2002.5566; Gronchi A, 2012, ANN ONCOL, V23, P771, DOI 10.1093/annonc/mdr265; Grosso F, 2009, ANN ONCOL, V20, P1439, DOI 10.1093/annonc/mdp004; Grosso F, 2007, LANCET ONCOL, V8, P595, DOI 10.1016/S1470-2045(07)70175-4; Hendriks HR, 1999, ANN ONCOL, V10, P1233, DOI 10.1023/A:1008364727071; Hurley LH, 2002, NAT REV CANCER, V2, P188, DOI 10.1038/nrc749; Izbicka E, 1998, ANN ONCOL, V9, P981, DOI 10.1023/A:1008224322396; Jin S, 2000, P NATL ACAD SCI USA, V97, P6775, DOI 10.1073/pnas.97.12.6775; KNIGHT JC, 1995, CANCER RES, V55, P24; Kuroda M, 1997, AM J PATHOL, V151, P735; Li WW, 2001, CLIN CANCER RES, V7, P2908; Licitra L, 2006, J CLIN ONCOL, V24, P5630, DOI 10.1200/JCO.2005.04.6136; Minuzzo M, 2005, MOL PHARMACOL, V68, P1496, DOI 10.1124/mol.105.013615; Minuzzo M, 2000, P NATL ACAD SCI USA, V97, P6780, DOI 10.1073/pnas.97.12.6780; Negri T, 2010, CLIN CANCER RES, V16, P3581, DOI 10.1158/1078-0432.CCR-09-2912; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; Perez-Losada J, 2000, ONCOGENE, V19, P2413, DOI 10.1038/sj.onc.1203572; Perez-Mancera PA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002569; Pommier Y, 1996, BIOCHEMISTRY-US, V35, P13303, DOI 10.1021/bi960306b; Powers MP, 2010, MODERN PATHOL, V23, P1307, DOI 10.1038/modpathol.2010.118; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Riggi N, 2006, CANCER RES, V66, P7016, DOI 10.1158/0008-5472.CAN-05-3979; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; Sandberg AA, 2004, CANCER GENET CYTOGEN, V155, P1, DOI 10.1016/j.cancergencyto.2004.08.005; Takebayashi Y, 2001, NAT MED, V7, P961, DOI 10.1038/91008; Tavecchio M, 2008, EUR J CANCER, V44, P609, DOI 10.1016/j.ejca.2008.01.003; Valoti G, 1998, CLIN CANCER RES, V4, P1977; van Roggen JFG, 1999, HISTOPATHOLOGY, V35, P291; Wang WL, 2012, CLIN SARCOMA RES, V2, DOI 10.1186/2045-3329-2-25; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zewail-Foote M, 1999, J MED CHEM, V42, P2493, DOI 10.1021/jm990241l	60	84	85	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2014	33	44					5201	5210		10.1038/onc.2013.462	http://dx.doi.org/10.1038/onc.2013.462			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR9RZ	24213580				2022-12-28	WOS:000343914900007
J	Hrdinka, M; Horejsi, V				Hrdinka, M.; Horejsi, V.			PAG - a multipurpose transmembrane adaptor protein	ONCOGENE			English	Review						PAG1; Cbp; Csk; Src family kinases; receptor signaling; membrane microdomains	CSK-BINDING PROTEIN; TERMINAL SRC KINASE; T-CELL-ACTIVATION; GLYCOSPHINGOLIPID-ENRICHED MICRODOMAINS; FAMILY TYROSINE KINASES; LIPID RAFT; NEGATIVE REGULATION; SIGNAL-TRANSDUCTION; DOWN-REGULATION; C-SRC	Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), also known as Csk-binding protein (Cbp), is a ubiquitously expressed transmembrane adaptor protein present in lipid rafts and involved in a number of signaling pathways. It helps recruit cytoplasmic C-terminal Src kinase (Csk) to lipid raft-associated Src kinases, mediates a link to actin cytoskeleton and interacts with several other important cytoplasmic and plasma membrane-associated proteins. In recent years, PAG has been implicated in various aspects of cancer cell biology. Our review covers all so far published data on this interesting protein.	[Hrdinka, M.; Horejsi, V.] Acad Sci Czech Republ, Inst Mol Genet, Prague, Czech Republic	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Horejsi, V (corresponding author), IMG AS CR, Dept Mol Immunol, Videnska 1083, CZ-14220 Prague, Czech Republic.	vaclav.horejsi@img.cas.cz	Hrdinka, Matous/B-9187-2011	Hrdinka, Matous/0000-0002-2981-2825	Czech Science Foundation [P302-12-G101]; Institute of Molecular Genetics ASCR [RVO 68378050]	Czech Science Foundation(Grant Agency of the Czech Republic); Institute of Molecular Genetics ASCR	This work was supported by Grant No. P302-12-G101 from the Czech Science Foundation and by the Institute of Molecular Genetics ASCR (RVO 68378050).	Abram Clare L, 2007, Sci STKE, V2007, pre2, DOI 10.1126/stke.3772007re2; Awasthi-Kalia M, 2001, BIOCHEM BIOPH RES CO, V287, P77, DOI 10.1006/bbrc.2001.5536; Bamberger M, 2011, J BIOL CHEM, V286, P30324, DOI 10.1074/jbc.M111.230102; Baniyash M, 2004, NAT REV IMMUNOL, V4, P675, DOI 10.1038/nri1434; Baumeister U, 2005, EMBO J, V24, P1686, DOI 10.1038/sj.emboj.7600647; Baumgartner M, 2003, BLOOD, V101, P1874, DOI 10.1182/blood-2002-02-0456; Boyd RS, 2009, MOL CELL PROTEOMICS, V8, P1501, DOI 10.1074/mcp.M800515-MCP200; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Brdickova N, 2003, J EXP MED, V198, P1453, DOI 10.1084/jem.20031484; Brdickova N, 2001, FEBS LETT, V507, P133, DOI 10.1016/S0014-5793(01)02955-6; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; Cao LL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046725; Capitani N, 2010, FEBS LETT, V584, P4915, DOI 10.1016/j.febslet.2010.08.046; Chen Y, 2009, J CELL SCI, V122, P3966, DOI 10.1242/jcs.049346; CINEK T, 1992, J IMMUNOL, V149, P2262; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Cohen S, 1999, BLOOD, V93, P2013, DOI 10.1182/blood.V93.6.2013.406k25_2013_2024; Cornez I, 2010, FEBS LETT, V584, P2681, DOI 10.1016/j.febslet.2010.04.056; Davidson D, 2003, MOL CELL BIOL, V23, P2017, DOI 10.1128/MCB.23.6.2017-2028.2003; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; Davidson D, 2007, MOL CELL BIOL, V27, P1960, DOI 10.1128/MCB.01983-06; Dobenecker MW, 2005, MOL CELL BIOL, V25, P10533, DOI 10.1128/MCB.25.23.10533-10542.2005; Draber P, 2011, MOL CELL BIOL, V31, P4550, DOI 10.1128/MCB.05817-11; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; Durrheim GA, 2001, CELL BIOL INT, V25, P33, DOI 10.1006/cbir.2000.0675; Feng X, 2009, ONCOGENE, V28, P3320, DOI 10.1038/onc.2009.185; Fuller DM, 2011, IMMUNOL RES, V49, P97, DOI 10.1007/s12026-010-8197-3; Fuller DM, 2009, IMMUNOL REV, V232, P72, DOI 10.1111/j.1600-065X.2009.00828.x; GARNETT D, 1993, EUR J IMMUNOL, V23, P2540, DOI 10.1002/eji.1830231024; Georgakopoulos A, 2011, FASEB J, V25, P3594, DOI 10.1096/fj.11-187856; Gupta N, 2006, NAT IMMUNOL, V7, P625, DOI 10.1038/ni1337; Hamerman JA, 2009, IMMUNOL REV, V232, P42, DOI 10.1111/j.1600-065X.2009.00841.x; Hermiston ML, 2009, IMMUNOL REV, V228, P288, DOI 10.1111/j.1600-065X.2008.00752.x; Hermiston ML, 2002, J CLIN INVEST, V109, P9; Hong H, 2007, BLOOD, V110, P2511, DOI 10.1182/blood-2007-01-066092; Horejsi V, 2004, NAT REV IMMUNOL, V4, P603, DOI 10.1038/nri1414; Horejsi V, 1998, IMMUNOL LETT, V63, P63, DOI 10.1016/S0165-2478(98)00054-6; Humphrey MB, 2005, IMMUNOL REV, V208, P50, DOI 10.1111/j.0105-2896.2005.00325.x; Hur EM, 2003, J EXP MED, V198, P1463, DOI 10.1084/jem.20030232; Ilangumaran S, 1999, MOL BIOL CELL, V10, P891, DOI 10.1091/mbc.10.4.891; Ingley E, 2006, J BIOL CHEM, V281, P31920, DOI 10.1074/jbc.M602637200; Inomata M, 2007, FEBS LETT, V581, P3039, DOI 10.1016/j.febslet.2007.05.063; Itoh K, 2002, J IMMUNOL, V168, P541, DOI 10.4049/jimmunol.168.2.541; Iwaki S, 2007, INT J BIOCHEM CELL B, V39, P868, DOI 10.1016/j.biocel.2006.10.018; Jiang LQ, 2006, ONCOGENE, V25, P5495, DOI 10.1038/sj.onc.1209554; Kalland ME, 2012, EXP CELL RES, V318, P1611, DOI 10.1016/j.yexcr.2012.05.014; Kanou T, 2011, MOL CANCER RES, V9, P103, DOI 10.1158/1541-7786.MCR-10-0340; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Ke Q, 2012, CANCER BIOTHER RADIO, V27, P678, DOI 10.1089/cbr.2012.1191; Kitaura J, 2007, J IMMUNOL, V178, P455, DOI 10.4049/jimmunol.178.1.455; Kusumi A, 2012, ANNU REV CELL DEV BI, V28, P215, DOI 10.1146/annurev-cellbio-100809-151736; Lanier LL, 2009, IMMUNOL REV, V227, P150, DOI 10.1111/j.1600-065X.2008.00720.x; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Lindquist S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023978; Lingwood D, 2010, SCIENCE, V327, P46, DOI 10.1126/science.1174621; Maksumova L, 2005, J IMMUNOL, V175, P7947, DOI 10.4049/jimmunol.175.12.7947; Marie-Cardine A, 1999, EUR J IMMUNOL, V29, P1175, DOI 10.1002/(SICI)1521-4141(199904)29:04<1175::AID-IMMU1175>3.0.CO;2-Z; Marie-Cardine A, 1999, J EXP MED, V189, P1181, DOI 10.1084/jem.189.8.1181; MarieCardine A, 1997, J BIOL CHEM, V272, P16077, DOI 10.1074/jbc.272.26.16077; Marinari B, 2003, EUR J IMMUNOL, V33, P2609, DOI 10.1002/eji.200324064; Matsubara T, 2010, J BONE MINER RES, V25, P1068, DOI 10.1359/jbmr.091039; Matsuoka H, 2004, J BIOL CHEM, V279, P5975, DOI 10.1074/jbc.M311278200; Mosenden R, 2011, CELL SIGNAL, V23, P1009, DOI 10.1016/j.cellsig.2010.11.018; Mutch CM, 2007, INT IMMUNOL, V19, P19, DOI 10.1093/intimm/dxl118; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NEET K, 1995, MOL CELL BIOL, V15, P4908; Odom S, 2004, J EXP MED, V199, P1491, DOI 10.1084/jem.20040382; Ohtake H, 2002, J IMMUNOL, V168, P2087, DOI 10.4049/jimmunol.168.5.2087; Okada M, 2012, INT J BIOL SCI, V8, P1385, DOI 10.7150/ijbs.5141; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; Oneyama C, 2009, MOL CELL BIOL, V29, P6462, DOI 10.1128/MCB.00941-09; Owen DM, 2012, BIOESSAYS, V34, P739, DOI 10.1002/bies.201200044; Palacios EH, 2004, ONCOGENE, V23, P7990, DOI 10.1038/sj.onc.1208074; Park Inyoung, 2009, Immune Netw, V9, P53, DOI 10.4110/in.2009.9.2.53; Place AT, 2011, MOL PHARMACOL, V80, P665, DOI 10.1124/mol.111.073957; Posevitz-Fejfar A, 2008, EUR J IMMUNOL, V38, P250, DOI 10.1002/eji.200636664; Rahmouni S, 2005, MOL CELL BIOL, V25, P2227, DOI 10.1128/MCB.25.6.2227-2241.2005; Relucio J, 2009, J NEUROSCI, V29, P11794, DOI 10.1523/JNEUROSCI.0888-09.2009; Resh MD, 2008, CANCER CELL, V13, P469, DOI 10.1016/j.ccr.2008.05.011; Rey-Barroso J, 2013, CELL SIGNAL, V25, P848, DOI 10.1016/j.cellsig.2013.01.010; Rivera J, 2005, TRENDS IMMUNOL, V26, P119, DOI 10.1016/j.it.2005.01.001; Ruppelt A, 2007, J IMMUNOL, V179, P5159, DOI 10.4049/jimmunol.179.8.5159; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Saito K, 2008, BIOCHEM BIOPH RES CO, V366, P969, DOI 10.1016/j.bbrc.2007.12.055; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schmedt C, 1998, NATURE, V394, P901, DOI 10.1038/29802; Sekino-Suzuki N, 2013, J NEUROCHEM, V124, P514, DOI 10.1111/jnc.12040; Semac I, 2003, CANCER RES, V63, P534; Shima T, 2003, P NATL ACAD SCI USA, V100, P14897, DOI 10.1073/pnas.2432139100; Shimada Y, 2005, FEBS J, V272, P5454, DOI 10.1111/j.1742-4658.2005.04938.x; Simeoni L, 2005, SEMIN IMMUNOL, V17, P35, DOI 10.1016/j.smim.2004.09.002; Sirvent A, 2010, ONCOGENE, V29, P1303, DOI 10.1038/onc.2009.450; Smida M, 2007, BLOOD, V110, P596, DOI 10.1182/blood-2006-07-038752; Solheim SA, 2008, FEBS J, V275, P4863, DOI 10.1111/j.1742-4658.2008.06626.x; Solheim SA, 2008, J BIOL CHEM, V283, P2773, DOI 10.1074/jbc.M705215200; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; Stepanek O, 2013, J IMMUNOL, V190, P1807, DOI 10.4049/jimmunol.1202401; Stokka AJ, 2010, BIOCHEM J, V425, P381, DOI 10.1042/BJ20091136; Suzuki K, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.195362; Svec A, 2005, IMMUNOL LETT, V100, P94, DOI 10.1016/j.imlet.2005.05.002; Svec A, 2008, PATHOL RES PRACT, V204, P785, DOI 10.1016/j.prp.2008.06.006; Svojgr K, 2009, IMMUNOL LETT, V122, P185, DOI 10.1016/j.imlet.2008.12.008; Takeuchi S, 2000, J BIOL CHEM, V275, P29183, DOI 10.1074/jbc.C000326200; Takeuchi S, 2006, PROTEIN J, V25, P295, DOI 10.1007/s10930-006-9015-6; Tanaka H, 2013, J BIOL CHEM, V288, P15240, DOI 10.1074/jbc.M112.439075; Tauzin S, 2008, BLOOD, V111, P2310, DOI 10.1182/blood-2007-05-090985; Tauzin S, 2011, EXP CELL RES, V317, P151, DOI 10.1016/j.yexcr.2010.09.011; Tedoldi S, 2006, BLOOD, V107, P213, DOI 10.1182/blood-2005-06-2273; Torgersen KM, 2001, J BIOL CHEM, V276, P29313, DOI 10.1074/jbc.C100014200; Turnbull IR, 2007, NAT REV IMMUNOL, V7, P155, DOI 10.1038/nri2014; Vacaresse N, 2008, J BIOL CHEM, V283, P35815, DOI 10.1074/jbc.M807964200; Vang T, 2003, J BIOL CHEM, V278, P17597, DOI 10.1074/jbc.C300077200; Vang T, 2012, NAT CHEM BIOL, V8, P437, DOI [10.1038/NCHEMBIO.916, 10.1038/nchembio.916]; Veracini L, 2008, J CELL BIOL, V182, P603, DOI 10.1083/jcb.200705102; Whiting RJ, 2012, BIOCHEM J, V442, P611, DOI 10.1042/BJ20111485; Wong L, 2005, J MOL BIOL, V351, P131, DOI 10.1016/j.jmb.2005.05.042; Xu SL, 2005, MOL CELL BIOL, V25, P8486, DOI 10.1128/MCB.25.19.8486-8495.2005; Xu YK, 2012, IMMUNOL CELL BIOL, V90, P903, DOI 10.1038/icb.2012.31; Yasuda K, 2002, J IMMUNOL, V169, P2813, DOI 10.4049/jimmunol.169.6.2813; Yerly S, 2010, EUR J HAEMATOL, V85, P93, DOI 10.1111/j.1600-0609.2010.01492.x; Yu LX, 2013, CELL SIGNAL, V25, P581, DOI 10.1016/j.cellsig.2012.11.017; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zhao MM, 2006, MOL CELL BIOL, V26, P2479, DOI 10.1128/MCB.26.7.2479-2489.2006; Zheng Y, 2008, EMBO REP, V9, P50, DOI 10.1038/sj.embor.7401138; Zhou Dong, 2011, Nan Fang Yi Ke Da Xue Xue Bao, V31, P1781	126	29	33	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2014	33	41					4881	4892		10.1038/onc.2013.485	http://dx.doi.org/10.1038/onc.2013.485			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OA	24213579				2022-12-28	WOS:000343767900001
J	Cagnoni, G; Tamagnone, L				Cagnoni, G.; Tamagnone, L.			Semaphorin receptors meet receptor tyrosine kinases on the way of tumor progression	ONCOGENE			English	Review						plexin; neuropilin; met; ErbB2; EGFR; VEGF	ENDOTHELIAL-GROWTH-FACTOR; CONTROLS INVASIVE GROWTH; SUPPRESSES C-MET; PLEXIN B1; HUMAN-BREAST; INDUCED ANGIOGENESIS; ACTIVATING PROTEIN; DOSE-ESCALATION; CARCINOMA-CELLS; CANCER-CELLS	Semaphorins are extracellular signals known to guide migrating cells during developmental morphogenesis and in adult tissues. Semaphorin receptors, that is plexins and neuropilins, have been found in association with diverse receptor tyrosine kinases (RTKs), such as Met, ErbB2 and VEGFR2. These receptor complexes are formed in a cell-specific manner and can mediate distinctive signalling cascades, sometimes leading to divergent functional outcomes. This is particularly intriguing in cancer, since the same semaphorin has been found to mediate either tumor-promoting or tumor-suppressing functions, depending on the cancer type and cellular context. We will therefore review the current understanding about the role of RTKs in neuropilin and plexin signalling, putatively accounting for the multifaceted role of semaphorins in cancer.	[Cagnoni, G.; Tamagnone, L.] IRCC Inst Canc Res Candiolo, Candiolo, Italy; [Cagnoni, G.; Tamagnone, L.] Univ Turin, Sch Med, Candiolo, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Tamagnone, L (corresponding author), Univ Turin, IRCC, Str Prov 142,Km 3-95, I-10060 Turin, Italy.	luca.tamagnone@ircc.it	Tamagnone, Luca/J-8948-2018	Tamagnone, Luca/0000-0002-2884-7946; Cagnoni, Gabriella/0000-0002-9718-0321	Italian Association for Cancer Research (AIRC) [IG-11598]; Italian Ministry for Research; University of Torino-Compagnia di San Paolo [ORTO11RKTW]	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry for Research(Ministry of Education, Universities and Research (MIUR)); University of Torino-Compagnia di San Paolo(Compagnia di San Paolo)	The authors wish to thank all Tamagnone lab members, in particular Sabrina Rizzolio for advice and suggestions. Thanks to Francesca Natale for revising the English. Research activity in the author's lab is supported by the Italian Association for Cancer Research (AIRC, IG-11598), the Italian Ministry for Research (PRIN Grant) and the University of Torino-Compagnia di San Paolo (Grant ORTO11RKTW).	Akagi M, 2003, BRIT J CANCER, V88, P796, DOI 10.1038/sj.bjc.6600811; Argast GM, 2009, ONCOGENE, V28, P2697, DOI 10.1038/onc.2009.133; Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Bachelder RE, 2001, CANCER RES, V61, P5736; Bachelder RE, 2003, CANCER RES, V63, P5230; Bais C, 2010, CELL, V141, P166, DOI 10.1016/j.cell.2010.01.033; Barberis D, 2005, J CELL SCI, V118, P4689, DOI 10.1242/jcs.02590; Barberis D, 2004, FASEB J, V18, P592, DOI 10.1096/fj.03-0957fje; Basile JR, 2006, P NATL ACAD SCI USA, V103, P9017, DOI 10.1073/pnas.0508825103; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Bellon A, 2010, NEURON, V66, P205, DOI 10.1016/j.neuron.2010.04.006; Bielenberg DR, 2006, EXP CELL RES, V312, P584, DOI 10.1016/j.yexcr.2005.11.024; Cai HB, 1999, J NEUROSCI, V19, P6519; Capparuccia L, 2009, J CELL SCI, V122, P1723, DOI 10.1242/jcs.030197; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Casazza A, 2012, EMBO MOL MED, V4, P234, DOI 10.1002/emmm.201100205; Casazza A, 2010, J CLIN INVEST, V120, P2684, DOI 10.1172/JCI42118; Catalano A, 2009, CANCER RES, V69, P1485, DOI 10.1158/0008-5472.CAN-08-3659; Christensen C, 2005, CANCER RES, V65, P6167, DOI 10.1158/0008-5472.CAN-04-4309; Conrotto P, 2005, BLOOD, V105, P4321, DOI 10.1182/blood-2004-07-2885; Conrotto P, 2004, ONCOGENE, V23, P5131, DOI 10.1038/sj.onc.1207650; Dhanabal M, 2005, CANCER BIOL THER, V4, P659, DOI 10.4161/cbt.4.6.1733; Ellis LM, 2006, MOL CANCER THER, V5, P1099, DOI 10.1158/1535-7163.MCT-05-0538; Franco M, 2008, EMBO REP, V9, P865, DOI 10.1038/embor.2008.139; Fuh G, 2000, J BIOL CHEM, V275, P26690; Fukushima Y, 2011, J CLIN INVEST, V121, P1974, DOI 10.1172/JCI44900; Gherardi E, 2004, CURR OPIN STRUC BIOL, V14, P669, DOI 10.1016/j.sbi.2004.10.010; Giacobini P, 2008, J CELL BIOL, V183, P555, DOI 10.1083/jcb.200806160; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; Gu CH, 2005, SCIENCE, V307, P265, DOI 10.1126/science.1105416; Gu CH, 2013, EXP CELL RES, V319, P1306, DOI 10.1016/j.yexcr.2013.02.003; Guttmann-Raviv N, 2006, CANCER LETT, V231, P1, DOI 10.1016/j.canlet.2004.12.047; Guttmann-Raviv N, 2007, J BIOL CHEM, V282, P26294, DOI 10.1074/jbc.M609711200; Hofman EG, 2010, J BIOL CHEM, V285, P39481, DOI 10.1074/jbc.M110.164731; Horowitz A, 2012, CELL SIGNAL, V24, P1810, DOI 10.1016/j.cellsig.2012.05.007; Hota PK, 2012, CELL MOL LIFE SCI, V69, P3765, DOI 10.1007/s00018-012-1019-0; Karpanen T, 2006, FASEB J, V20, P1462, DOI 10.1096/fj.05-5646com; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Kigel B, 2011, BLOOD, V118, P4285, DOI 10.1182/blood-2011-03-341388; Kluger HM, 2004, MELANOMA RES, V14, P207, DOI 10.1097/01.cmr.0000130874.33504.2f; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kruger RR, 2005, NAT REV MOL CELL BIO, V6, P789, DOI 10.1038/nrm1740; Lassen U, 2012, BRIT J CANCER, V106, P678, DOI 10.1038/bjc.2011.609; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; Lichtenberger BM, 2010, CELL, V140, P268, DOI 10.1016/j.cell.2009.12.046; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Martinsson-Niskanen T, 2011, CLIN THER, V33, P1142, DOI 10.1016/j.clinthera.2011.08.007; McClelland L, 2011, PIGM CELL MELANOMA R, V24, P165, DOI 10.1111/j.1755-148X.2010.00797.x; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; Muratori C, 2012, ADV CANCER RES, V114, P59, DOI 10.1016/B978-0-12-386503-8.00003-X; Narumiya S, 2009, CANCER METAST REV, V28, P65, DOI 10.1007/s10555-008-9170-7; Oinuma I, 2004, SCIENCE, V305, P862, DOI 10.1126/science.1097545; Otsuka T, 1998, CANCER RES, V58, P5157; Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018; Parikh AA, 2003, CANCER, V98, P720, DOI 10.1002/cncr.11560; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Pellet-Many C, 2008, BIOCHEM J, V411, P211, DOI 10.1042/BJ20071639; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; Prahst C, 2008, J BIOL CHEM, V283, P25110, DOI 10.1074/jbc.C800137200; Rehman M, 2013, SEMIN CELL DEV BIOL, V24, P179, DOI 10.1016/j.semcdb.2012.10.005; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Rizzolio S, 2011, CURR MED CHEM, V18, P3563, DOI 10.2174/092986711796642544; Rizzolio S, 2012, CANCER RES, V72, P5801, DOI 10.1158/0008-5472.CAN-12-0995; Rody A, 2007, CLIN CANCER RES, V13, P1115, DOI 10.1158/1078-0432.CCR-06-2433; Rody A, 2009, EUR J CANCER, V45, P405, DOI 10.1016/j.ejca.2008.10.016; Rohm B, 2000, FEBS LETT, V486, P68, DOI 10.1016/S0014-5793(00)02240-7; Roodink I, 2005, CANCER RES, V65, P8317, DOI 10.1158/0008-5472.CAN-04-4366; Rossiter H, 2004, CANCER RES, V64, P3508, DOI 10.1158/0008-5472.CAN-03-2581; Routhier A, 2010, ONCOL REP, V23, P861, DOI 10.3892/or_00000708; Sakurai A, 2011, J BIOL CHEM, V286, P34335, DOI 10.1074/jbc.M111.259499; Sakurai A, 2010, MOL CELL BIOL, V30, P3086, DOI 10.1128/MCB.01652-09; Salikhova A, 2008, CIRC RES, V103, pE71, DOI 10.1161/CIRCRESAHA.108.183327; Segarra M, 2012, BLOOD, V120, P4104, DOI 10.1182/blood-2012-02-410076; Serini G, 2003, NATURE, V424, P391, DOI 10.1038/nature01784; Sierra JR, 2008, J EXP MED, V205, P1673, DOI 10.1084/jem.20072602; Sigismund S, 2008, DEV CELL, V15, P209, DOI 10.1016/j.devcel.2008.06.012; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Slongo ML, 2007, NEURO-ONCOLOGY, V9, P384, DOI 10.1215/15228517-2007-032; Snuderl M, 2013, CELL, V152, P1065, DOI 10.1016/j.cell.2013.01.036; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Soone J, 2012, J INVEST DERMATOL, V132, P1230, DOI 10.1038/jid.2011.414; Soong J, 2013, J CELL SCI, V126, P688, DOI 10.1242/jcs.119487; Sorkin A, 2001, BIOCHEM SOC T, V29, P480, DOI 10.1042/BST0290480; Stevens L, 2010, J INVEST DERMATOL, V130, P1636, DOI 10.1038/jid.2010.13; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; Sun TL, 2012, J CELL SCI, V125, P3557, DOI 10.1242/jcs.101063; Suto F, 2005, J NEUROSCI, V25, P3628, DOI 10.1523/JNEUROSCI.4480-04.2005; Swiercz JM, 2008, J BIOL CHEM, V283, P1893, DOI 10.1074/jbc.M706822200; Swiercz JM, 2004, J CELL BIOL, V165, P869, DOI 10.1083/jcb.200312094; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962-8924(00)01816-X; Tamagnone L, 2012, CANCER CELL, V22, P145, DOI 10.1016/j.ccr.2012.06.031; Toyofuku T, 2004, GENE DEV, V18, P435, DOI 10.1101/gad.1167304; Uesugi K, 2009, J BIOL CHEM, V284, P6743, DOI 10.1074/jbc.M805213200; Valente G, 2009, CELL ONCOL, V31, P423, DOI 10.3233/CLO-2009-0504; van der ZB, 2002, DEV DYNAM, V225, P336; Wang H, 2011, J BIOL CHEM, V286, P26093, DOI 10.1074/jbc.M110.197053; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Wong OGW, 2007, P NATL ACAD SCI USA, V104, P19040, DOI 10.1073/pnas.0702544104; Worzfeld T, 2012, J CLIN INVEST, V122, P1296, DOI 10.1172/JCI60568; Yang TH, 2012, NEURON, V74, P108, DOI 10.1016/j.neuron.2011.12.034; Yao J, 2011, P NATL ACAD SCI USA, V108, P11590, DOI 10.1073/pnas.1109029108; Zhou C, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-11; Zhou YP, 2008, TRENDS BIOCHEM SCI, V33, P161, DOI 10.1016/j.tibs.2008.01.006	108	33	33	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2014	33	40					4795	4802		10.1038/onc.2013.474	http://dx.doi.org/10.1038/onc.2013.474			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0EH	24213581	Green Submitted			2022-12-28	WOS:000343240100001
J	Li, T; Lu, H; Shen, C; Lahiri, SK; Wason, MS; Mukherjee, D; Yu, L; Zhao, J				Li, T.; Lu, H.; Shen, C.; Lahiri, S. K.; Wason, M. S.; Mukherjee, D.; Yu, L.; Zhao, J.			Identification of epithelial stromal interaction 1 as a novel effector downstream of Kruppel-like factor 8 in breast cancer invasion and metastasis	ONCOGENE			English	Article						KLF8; EPSTI1; VCP; NF-kappa B; invasion and metastasis; breast cancer	FOCAL ADHESION KINASE; HUMAN SOMATIC-CELLS; MESENCHYMAL TRANSITION; KLF8 TRANSCRIPTION; CYCLIN D1; ACTIVATION; VCP/P97; TARGET; EPSTI1; GENE	Kruppel-like factor 8 (KLF8) is a transcriptional factor critical for metastatic progression of breast cancer. Epithelial stromal interaction 1 (EPSTI1), a recently identified stromal fibroblast-induced gene in non-invasive breast cancer cells is highly overexpressed in invasive breast carcinomas. The function and regulation of EPSTI1, however, remain largely unknown. In this paper, we report a novel KLF8 to EPSTI1 signaling pathway in breast cancer. Using various expression analyses, we revealed a high co-overexpression of KLF8 and EPSTI1 in invasive human breast cancer cells and patient tumors. Ectopic overexpression of KLF8 in the non-invasive MCF-10A cells induced the EPSTI1 expression, whereas KLF8 knockdown from the invasive, MDA-MB-231 cells decreased the EPSTI1 expression. Promoter activation and binding analyses indicated that KLF8 promoted the EPSTI1 expression by directly acting on the EPSTI1 gene promoter. EPSTI1 knockdown dramatically reduced the KLF8-promoted MCF-10A cell invasion, and ectopic expression of EPSTI1 in the non-invasive MCF-7 cells is sufficient to induce the cell invasion. Experiments using nude mice demonstrated that the ectopic EPSTI1 granted the MCF-7 cells capability of both invasive growth in the breasts and metastasis to the lungs. Using co-immunoprecipitation coupled with mass spectrometry, we discovered that EPSTI1 interacts with the valosin-containing protein (VCP), resulting in the degradation of I kappa B alpha and subsequent activation of NF-kappa B in the nucleus. These findings suggest a novel KLF8 to EPSTI1 to VCP to NF-kappa B signaling mechanism potentially critical for breast cancer invasion and metastasis.	[Li, T.; Lu, H.; Shen, C.; Lahiri, S. K.; Wason, M. S.; Mukherjee, D.; Yu, L.; Zhao, J.] Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32827 USA	State University System of Florida; University of Central Florida	Zhao, J (corresponding author), Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, 6900 Lake Nona Blvd, Orlando, FL 32827 USA.	Jihe.Zhao@ucf.edu	Li, Tianshu/L-6426-2014; Lahiri, Satadru/J-3483-2019	Li, Tianshu/0000-0002-9972-4644; 	NCI [CA132977]; Susan G. Komen for the Cure breast cancer foundation [KG090444, KG080616]; NATIONAL CANCER INSTITUTE [R01CA132977] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G. Komen for the Cure breast cancer foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciate Dr Vladimir Ponomarev of Memorial Sloan-Kettering Cancer Center for kindly providing the trimodal imaging reporter vector SFG-nTGL and Dr Qishan Lin of UAlbany for helping with the mass spectrometry. This work was supported by grants from NCI (CA132977) and Susan G. Komen for the Cure breast cancer foundation (KG090444 and KG080616) to JZ.	Asai T, 2002, JPN J CANCER RES, V93, P296, DOI 10.1111/j.1349-7006.2002.tb02172.x; Buess M, 2009, NEOPLASIA, V11, P987, DOI 10.1593/neo.09670; Carey BW, 2009, P NATL ACAD SCI USA, V106, P157, DOI 10.1073/pnas.0811426106; de Neergaard M, 2010, AM J PATHOL, V176, P1229, DOI 10.2353/ajpath.2010.090648; Ding SZ, 2013, TOXICOL APPL PHARM, V269, P61, DOI 10.1016/j.taap.2013.03.006; Gudjonsson T, 2003, METHODS, V30, P247, DOI 10.1016/S1046-2023(03)00031-8; Hockemeyer D, 2008, CELL STEM CELL, V3, P346, DOI 10.1016/j.stem.2008.08.014; Lahiri SK, 2012, AM J TRANSL RES, V4, P357; Lu H, 2014, ONCOGENE, V33, P10, DOI 10.1038/onc.2012.545; Lu H, 2012, J BIOL CHEM, V287, P43720, DOI 10.1074/jbc.M112.418053; Lu H, 2011, J BIOL CHEM, V286, P20335, DOI 10.1074/jbc.M110.215632; Mehta TS, 2009, CELL RES, V19, P1098, DOI 10.1038/cr.2009.64; Meyer H, 2012, NAT CELL BIOL, V14, P117, DOI 10.1038/ncb2407; Moserle L, 2008, CANCER RES, V68, P5658, DOI 10.1158/0008-5472.CAN-07-6341; Nielsen HL, 2002, GENOMICS, V79, P703, DOI 10.1006/geno.2002.6755; Ponomarev V, 2004, EUR J NUCL MED MOL I, V31, P740, DOI 10.1007/s00259-003-1441-5; Schnell O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030429; Tresse E, 2010, AUTOPHAGY, V6, P217, DOI 10.4161/auto.6.2.11014; Urvalek AM, 2011, AM J TRANSL RES, V3, P121; Urvalek AM, 2010, CELL CYCLE, V9, P601, DOI 10.4161/cc.9.3.10606; van Vliet J, 2000, NUCLEIC ACIDS RES, V28, P1955; Wang X, 2007, ONCOGENE, V26, P456, DOI 10.1038/sj.onc.1209796; Wang X, 2011, ONCOGENE, V30, P1901, DOI 10.1038/onc.2010.563; Wang XH, 2008, J BIOL CHEM, V283, P13934, DOI 10.1074/jbc.M709300200; Wang XH, 2007, CANCER RES, V67, P7184, DOI 10.1158/0008-5472.CAN-06-4729; Wei HJ, 2006, J BIOL CHEM, V281, P16664, DOI 10.1074/jbc.M513135200; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yang T, 2012, PLOS ONE, V7, P6; Zhang H, 2013, J CANCER RES CLIN, V139, P1033, DOI 10.1007/s00432-012-1363-3; Zhang XL, 2012, P NATL ACAD SCI USA, V109, P9623, DOI 10.1073/pnas.1121606109; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066; Zhao JH, 2000, J CELL SCI, V113, P3063; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zhao JH, 2003, MOL CELL, V11, P1503, DOI 10.1016/S1097-2765(03)00179-5; Zubair A, 2013, CURR ALLERGY ASTHM R, V13, P44, DOI 10.1007/s11882-012-0300-5	35	30	31	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2014	33	39					4746	4755		10.1038/onc.2013.415	http://dx.doi.org/10.1038/onc.2013.415			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0ED	24096480	Green Accepted			2022-12-28	WOS:000343239500005
J	Li, X; Roslan, S; Johnstone, CN; Wright, JA; Bracken, CP; Anderson, M; Bert, AG; Selth, LA; Anderson, RL; Goodall, GJ; Gregory, PA; Khew-Goodall, Y				Li, X.; Roslan, S.; Johnstone, C. N.; Wright, J. A.; Bracken, C. P.; Anderson, M.; Bert, A. G.; Selth, L. A.; Anderson, R. L.; Goodall, G. J.; Gregory, P. A.; Khew-Goodall, Y.			MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways	ONCOGENE			English	Article						miR-200; epithelial-mesenchymal transition; breast cancer; metastasis; actin cytoskeleton	EPITHELIAL-MESENCHYMAL TRANSITION; DIFFERENTIAL EXPRESSION; MIRNA-200 FAMILY; DOWN-REGULATION; CELL-MIGRATION; ZEB1; EMT; PROTEINS; INVASION; TARGETS	The microRNA-200 (miR-200) family has a critical role in regulating epithelial-mesenchymal transition and cancer cell invasion through inhibition of the E-cadherin transcriptional repressors ZEB1 and ZEB2. Recent studies have indicated that the miR-200 family may exert their effects at distinct stages in the metastatic process, with an overall effect of enhancing metastasis in a syngeneic mouse breast cancer model. We find in a xenograft orthotopic model of breast cancer metastasis that ectopic expression of members of the miR-200b/200c/429, but not the miR-141/200a, functional groups limits tumour cell invasion and metastasis. Despite modulation of the ZEB1-E-cadherin axis, restoration of ZEB1 in miR-200b-expressing cells was not able to alter metastatic potential suggesting that other targets contribute to this process. Instead, we found that miR-200b repressed several actin-associated genes, with the knockdown of the ezrin-radixin-moesin family member moesin alone phenocopying the repression of cell invasion by miR-200b. Moesin was verified to be directly targeted by miR-200b, and restoration of moesin in miR-200b-expressing cells was sufficient to alleviate metastatic repression. In breast cancer cell lines and patient samples, the expression of moesin significantly inversely correlated with miR-200 expression, and high levels of moesin were associated with poor relapse-free survival. These findings highlight the context-dependent effects of miR-200 in breast cancer metastasis and demonstrate the existence of a moesin-dependent pathway, distinct from the ZEB1-E-cadherin axis, through which miR-200 can regulate tumour cell plasticity and metastasis.	[Li, X.; Roslan, S.; Wright, J. A.; Bracken, C. P.; Anderson, M.; Bert, A. G.; Goodall, G. J.; Gregory, P. A.; Khew-Goodall, Y.] SA Pathol, Ctr Canc Biol, Div Human Immunol, Adelaide, SA 5000, Australia; [Johnstone, C. N.; Anderson, R. L.] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia; [Johnstone, C. N.; Anderson, R. L.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3052, Australia; [Johnstone, C. N.; Anderson, R. L.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; [Johnstone, C. N.] Univ Melbourne, Dept Pharmacol, Parkville, Vic 3052, Australia; [Wright, J. A.; Bracken, C. P.; Goodall, G. J.; Gregory, P. A.] Univ Adelaide, Discipline Med, Adelaide, SA, Australia; [Selth, L. A.] Univ Adelaide, Hanson Inst, Discipline Med, Dame Roma Mitchell Canc Res Labs, Adelaide, SA, Australia; [Goodall, G. J.; Khew-Goodall, Y.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA, Australia	Centre for Cancer Biology; SA Pathology; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne; University of Melbourne; University of Adelaide; Hanson Institute; University of Adelaide; University of Adelaide	Gregory, PA (corresponding author), SA Pathol, Ctr Canc Biol, Div Human Immunol, Frome Rd, Adelaide, SA 5000, Australia.	philip.gregory@health.sa.gov.au; yeesim.khew-goodall@health.sa.gov.au	Selth, Luke/AAH-4823-2021; Anderson, Robin/I-2306-2013; Anderson, Robin/K-6966-2019; Gregory, Philip/F-4089-2013; Anderson, Robin/S-1005-2017	Selth, Luke/0000-0002-4686-1418; Gregory, Philip/0000-0002-0999-0632; Anderson, Robin/0000-0002-6841-7422; Goodall, Gregory/0000-0003-1294-0692; Wright, Josephine/0000-0003-4588-8827; Bracken, Cameron/0000-0001-7722-625X; Bert, Andrew/0000-0003-3876-1537	National Breast Cancer Foundation of Australia [ECF-09-08, PF-09-03]; National Health and Medical Research Council of Australia [566871, APP1020280]; Cancer Council South Australia; Prostate Cancer Foundation of Australia [YI 0810]; National Breast Cancer Foundation [CG-10-04] Funding Source: researchfish	National Breast Cancer Foundation of Australia; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council South Australia(Cancer Council South Australia); Prostate Cancer Foundation of Australia; National Breast Cancer Foundation	We thank Professor Joan Massague for providing the MDA-MB-231 LM2 cell line and Dr Ross Dickins for providing the pLMP-puro-GFP construct. We thank Dr Agatha Labrinidis and Ms Yuka Harata-Lee for assistance with bioluminescence imaging and inoculation of tumour cells, respectively, Dr Peter Diamond for help with bone histological analysis and Professors Andreas Evdokiou and Shaun McColl for insightful discussions. This work was supported by fellowships from the National Breast Cancer Foundation of Australia (PAG, CPB and RLA, nos ECF-09-08 and PF-09-03) and grants from the National Health and Medical Research Council of Australia (PAG, YK-G, GJG, RLA and CNJ, nos 566871 and APP1020280), Cancer Council South Australia (GJG, PAG and YK-G) and Prostate Cancer Foundation of Australia (LAS, no. YI 0810).	Arpin M, 2011, CELL ADHES MIGR, V5, P199, DOI 10.4161/cam.5.2.15081; Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Bracken CP, 2009, CELL MOL LIFE SCI, V66, P1682, DOI 10.1007/s00018-009-8750-1; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Charafe-Jauffret E, 2007, INT J CANCER, V121, P1779, DOI 10.1002/ijc.22923; Cochrane DR, 2009, MOL CANCER THER, V8, P1055, DOI 10.1158/1535-7163.MCT-08-1046; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Elson-Schwab I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013176; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; Estecha A, 2009, J CELL SCI, V122, P3492, DOI 10.1242/jcs.053157; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Giusiano S, 2010, INT J ONCOL, V36, P889, DOI 10.3892/ijo_00000567; Gravgaard KH, 2012, BREAST CANCER RES TR, V134, P207, DOI 10.1007/s10549-012-1969-9; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Gunasinghe NPAD, 2012, CANCER METAST REV, V31, P469, DOI 10.1007/s10555-012-9377-5; Harrell JC, 2012, BREAST CANCER RES TR, V132, P523, DOI 10.1007/s10549-011-1619-7; Haynes J, 2011, MOL BIOL CELL, V22, P4750, DOI 10.1091/mbc.E11-02-0119; Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867; Hur K, 2013, GUT, V62, P1315, DOI 10.1136/gutjnl-2011-301846; Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Jurmeister S, 2012, MOL CELL BIOL, V32, P633, DOI 10.1128/MCB.06212-11; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651; Lo WL, 2011, J PATHOL, V223, P482, DOI 10.1002/path.2826; Lussier YA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028650; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Morel AP, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002723; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Paterson EL, 2013, NEOPLASIA, V15, P180, DOI 10.1593/neo.121828; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Renthal NE, 2010, P NATL ACAD SCI USA, V107, P20828, DOI 10.1073/pnas.1008301107; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Schickel R, 2010, MOL CELL, V38, P908, DOI 10.1016/j.molcel.2010.05.018; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Shin JO, 2012, HISTOCHEM CELL BIOL, V137, P459, DOI 10.1007/s00418-012-0915-6; Sossey-Alaoui K, 2009, J BIOL CHEM, V284, P33019, DOI 10.1074/jbc.M109.034553; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Sun BC, 2008, CLIN CANCER RES, V14, P7050, DOI 10.1158/1078-0432.CCR-08-0520; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Uhlmann S, 2010, ONCOGENE, V29, P4297, DOI 10.1038/onc.2010.201; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wang CC, 2012, HISTOPATHOLOGY, V61, P78, DOI 10.1111/j.1365-2559.2012.04204.x; Weigelt B, 2003, P NATL ACAD SCI USA, V100, P15901, DOI 10.1073/pnas.2634067100; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Xue CS, 2003, CANCER RES, V63, P3386	54	89	93	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2014	33	31					4077	4088		10.1038/onc.2013.370	http://dx.doi.org/10.1038/onc.2013.370			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YG	24037528				2022-12-28	WOS:000340595300007
J	Oshima, H; Ishikawa, T; Yoshida, GJ; Naoi, K; Maeda, Y; Naka, K; Ju, X; Yamada, Y; Minamoto, T; Mukaida, N; Saya, H; Oshima, M				Oshima, H.; Ishikawa, T.; Yoshida, G. J.; Naoi, K.; Maeda, Y.; Naka, K.; Ju, X.; Yamada, Y.; Minamoto, T.; Mukaida, N.; Saya, H.; Oshima, M.			TNF-alpha/TNFR1 signaling promotes gastric tumorigenesis through induction of Noxo1 and Gna14 in tumor cells	ONCOGENE			English	Article						gastric cancer; inflammation; TNF-alpha; mouse model	NECROSIS-FACTOR-ALPHA; PROSTAGLANDIN E-2; TNF-ALPHA; PATHWAY ACTIVATION; GENE-EXPRESSION; INCREASED RISK; CANCER; WNT; INFLAMMATION; RECEPTOR	Helicobacter pylori infection induces chronic inflammation that contributes to gastric tumorigenesis. Tumor necrosis factor (TNF-alpha) is a proinflammatory cytokine, and polymorphism in the TNF-alpha gene increases the risk of gastric cancer. We herein investigated the role of TNF-alpha in gastric tumorigenesis using Gan mouse model, which recapitulates human gastric cancer development. We crossed Gan mice with TNF-alpha (Tnf) or TNF-alpha receptor TNFR1 (Tnfrsf1a) knockout mice to generate Tnf -/- Gan and Tnfrsf1a -/- Gan mice, respectively, and examined their tumor phenotypes. Notably, both Tnf -/- Gan mice and Tnfrsf1a -/- Gan mice showed similar, significant suppression of gastric tumor growth compared with control Tnf +/+ or Tnfrsf1a +/+ Gan mice. These results indicate that TNF-alpha signaling through TNFR1 is important for gastric tumor development. Bone marrow (BM) transplantation experiments showed that TNF-alpha expressed by BM-derived cells (BMDCs) stimulates the TNFR1 on BMDCs by an autocrine or paracrine manner, which is important for gastric tumor promotion. Moreover, the microarray analysis and colony formation assay indicated that NADPH oxidase organizer 1 (Noxo1) and Gna14 are induced in tumor epithelial cells in a TNF-alpha-dependent manner, and have an important role in tumorigenicity and tumor-initiating cell property of gastric cancer cells. Accordingly, it is possible that the activation of TNF-alpha/TNFR1 signaling in the tumor microenvironment promotes gastric tumor development through induction of Noxo1 and Gna14, which contribute to maintaining the tumor cells in an undifferentiated state. The present results indicate that targeting the TNF-alpha/TNFR1 pathway may be an effective preventive or therapeutic strategy for gastric cancer.	[Oshima, H.; Ishikawa, T.; Naoi, K.; Maeda, Y.; Ju, X.; Oshima, M.] Kanazawa Univ, Canc Res Inst, Div Genet, Kanazawa, Ishikawa 9201192, Japan; [Yoshida, G. J.; Maeda, Y.; Saya, H.] Keio Univ, Inst Adv Med Res, Div Gene Regulat, Tokyo, Japan; [Naka, K.] Kanazawa Univ, Canc Res Inst, Canc & Stem Cell Res Program, Kanazawa, Ishikawa 9201192, Japan; [Yamada, Y.] Kanazawa Univ, Inst Sci & Engn, Fac Elect & Comp Engn, Kanazawa, Ishikawa 9201192, Japan; [Minamoto, T.] Kanazawa Univ, Canc Res Inst, Div Translat & Clin Oncol, Kanazawa, Ishikawa 9201192, Japan; [Mukaida, N.] Kanazawa Univ, Canc Res Inst, Div Mol Bioregulat, Kanazawa, Ishikawa 9201192, Japan	Kanazawa University; Keio University; Kanazawa University; Kanazawa University; Kanazawa University; Kanazawa University	Oshima, M (corresponding author), Kanazawa Univ, Canc Res Inst, Div Genet, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan.	oshimam@staff.kanazawa-u.ac.jp	Oshima, Masanobu/F-9958-2014; Mukaida, Naofumi/D-7623-2011; Naka, Kazuhito/X-3756-2019; Saya, Hideyuki/J-4325-2013	Oshima, Masanobu/0000-0002-3304-0004; Mukaida, Naofumi/0000-0002-4193-1851; Naka, Kazuhito/0000-0001-6646-6004; Oshima, Hiroko/0000-0001-6855-4008; Yoshida, Go/0000-0002-1472-892X; Saya, Hideyuki/0000-0001-6610-1902	Ministry of Education, Culture, Sports, Science and Technology of Japan [22114005]; CREST; Japan Science and Technology Agency, Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); CREST(Core Research for Evolutional Science and Technology (CREST)); Japan Science and Technology Agency, Japan(Japan Science & Technology Agency (JST))	We thank Manami Watanabe and Ayako Tsuda for their excellent technical assistance. This work was supported by Grants-in-Aid for Scientific Research on Innovative Areas (no. 22114005) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; and CREST, the Japan Science and Technology Agency, Japan.	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Adachi Y, 2008, ONCOGENE, V27, P4921, DOI 10.1038/onc.2008.133; Arnott CH, 2004, ONCOGENE, V23, P1902, DOI 10.1038/sj.onc.1207317; Balkwill F, 2006, CANCER METAST REV, V25, P409, DOI 10.1007/s10555-006-9005-3; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Block K, 2012, NAT REV CANCER, V12, P627, DOI 10.1038/nrc3339; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Clements WM, 2002, CANCER RES, V62, P3503; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; El-Omar EM, 2003, GASTROENTEROLOGY, V124, P1193, DOI 10.1016/S0016-5085(03)00157-4; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; El-Omar EM, 2006, BEST PRACT RES CL GA, V20, P675, DOI 10.1016/j.bpg.2006.04.006; Fox JG, 2007, J CLIN INVEST, V117, P60, DOI 10.1172/JCI30111; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Huch M, 2013, NATURE, V494, P247, DOI 10.1038/nature11826; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Ishimoto T, 2010, CANCER SCI, V101, P673, DOI 10.1111/j.1349-7006.2009.01430.x; Itadani H, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-615; Itzkovitz S, 2012, NAT CELL BIOL, V14, P106, DOI 10.1038/ncb2384; Juhasz A, 2009, FREE RADICAL RES, V43, P523, DOI 10.1080/10715760902918683; Kong D, 2012, ONCOGENE, V31, P3949, DOI 10.1038/onc.2011.558; Kostenis E, 2005, TRENDS PHARMACOL SCI, V26, P595, DOI 10.1016/j.tips.2005.09.007; Kulbe H, 2012, CANCER RES, V72, P66, DOI 10.1158/0008-5472.CAN-11-2178; Lee MMK, 2009, J LEUKOCYTE BIOL, V86, P1319, DOI 10.1189/jlb.0209052; Liu AMF, 2005, J BIOL CHEM, V280, P34617, DOI 10.1074/jbc.M504264200; Machado JC, 2003, GASTROENTEROLOGY, V125, P364, DOI 10.1016/S0016-5085(03)00899-0; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Oguma K, 2008, EMBO J, V27, P1671, DOI 10.1038/emboj.2008.105; Oshima H, 2006, GASTROENTEROLOGY, V131, P1086, DOI 10.1053/j.gastro.2006.07.014; Oshima H, 2011, GASTROENTEROLOGY, V140, P596, DOI 10.1053/j.gastro.2010.11.007; Oshima H, 2009, CANCER SCI, V100, P1779, DOI 10.1111/j.1349-7006.2009.01258.x; Parkin DM, 2005, CA CANC J CLIN, V55, P74; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Seno H, 2002, CANCER RES, V62, P506; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011; Tye H, 2012, CANCER CELL, V22, P466, DOI 10.1016/j.ccr.2012.08.010; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	44	87	93	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3820	3829		10.1038/onc.2013.356	http://dx.doi.org/10.1038/onc.2013.356			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23975421	hybrid			2022-12-28	WOS:000339394100008
J	Nie, J; Liu, L; Xing, G; Zhang, M; Wei, R; Guo, M; Li, X; Xie, P; Li, L; He, F; Han, W; Zhang, L				Nie, J.; Liu, L.; Xing, G.; Zhang, M.; Wei, R.; Guo, M.; Li, X.; Xie, P.; Li, L.; He, F.; Han, W.; Zhang, L.			CKIP-1 acts as a colonic tumor suppressor by repressing oncogenic Smurf1 synthesis and promoting Smurf1 autodegradation	ONCOGENE			English	Article						colon cancer; CKIP-1; Smurf1; PI3K/Akt/mTOR signaling; tumor suppression	DOMAIN-CONTAINING PROTEIN; UBIQUITIN LIGASE SMURF1; BETA-CATENIN; CANCER; IDENTIFICATION; DEGRADATION; ACTIVATION; MUTATIONS; POLARITY	Dysregulation of cellular signaling pathways can lead to colon cancer. However, research on the key signaling effectors or regulators in colon carcinogenesis is limited. Casein kinase-2 interacting protein-1 (CKIP-1; also known as PLEKHO1) is crucial during adult bone formation and is a promising drug target for osteoporosis therapy. In this study, we observed that CKIP-1 was downregulated in human colon cancer tissues and colon cancer cell lines, and this result was correlated with colon cancer progression. CKIP-1 silencing in colon cancers involved promoter methylation. In colon cancer HCT116 and SW480 cells, CKIP-1 overexpression inhibited cell growth and migration. CKIP-1 also suppressed in-vivo tumor formation. Notably, the growth-suppressive role of CKIP-1 was dependent on the downregulation of the cell cycle-regulated oncogene Smad ubiquitylation regulatory factor-1 (Smurf1). During cell cycle progression, phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling increased Smurf1 production by an mTOR-dependent translational control mechanism. Rapamycin, the mTOR inhibitor, significantly reduced Smurf1 protein levels, and Smurf1 was degraded in mitosis. In colon cancer, CKIP-1 controlled Smurf1 expression by suppressing PI3K/Akt/mTOR signaling and enhancing Smurf1 autodegradation, and CKIP-1 downregulation was correlated with Smurf1 upregulation in colon carcinogenesis. These findings provide novel insight into the mechanisms of the candidate tumor suppressor CKIP-1.	[Nie, J.; Li, X.; Han, W.] Peoples Liberat Army Gen Hosp, Inst Basic Med, Dept Mol Biol, Beijing, Peoples R China; [Nie, J.; Xing, G.; Zhang, M.; Wei, R.; Xie, P.; Li, L.; He, F.; Zhang, L.] Beijing Inst Radiat Med, Beijing Proteome Res Ctr, State Key Lab Prote, Beijing, Peoples R China; [Liu, L.] Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing, Peoples R China; [Wei, R.; He, F.] Tsinghua Univ, Sch Life Sci, Beijing 100084, Peoples R China; [Guo, M.] Peoples Liberat Army Gen Hosp, Dept Gastroenterol & Hepatol, Beijing, Peoples R China; [Zhang, L.] Dalian Med Univ, Inst Canc Stem Cell, Dalian, Peoples R China	Chinese People's Liberation Army General Hospital; Academy of Military Medical Sciences - China; Chinese People's Liberation Army General Hospital; Tsinghua University; Chinese People's Liberation Army General Hospital; Dalian Medical University	Han, W (corresponding author), Gen Hosp PLA, Dept Mol Biol, Beijing 100853, Peoples R China.	hanwdrsw69@yahoo.com; zhanglq@nic.bmi.ac.cn	Zhang, Minghua/AAC-4782-2020	Li, Li/0000-0003-2342-3658; Zhang, Lingqiang/0000-0002-9795-2141	National Basic Research Programs [2012CB910702, 2011CB910602, 2012CB518103]; National Natural Science Foundation Projects [31125010, 31100554, 31270820, 31230061, 81221004]; Beijing Nova Program [Z121107002512121]	National Basic Research Programs(National Basic Research Program of China); National Natural Science Foundation Projects(National Natural Science Foundation of China (NSFC)); Beijing Nova Program(Beijing Municipal Science & Technology Commission)	The excellent technical assistance of Qian Mei and Zhiqiang Wu is gratefully acknowledged. The study was supported by the National Basic Research Programs (2012CB910702, 2011CB910602 and 2012CB518103) and National Natural Science Foundation Projects (31125010, 31100554, 31270820, 31230061 and 81221004) and Beijing Nova Program (Z121107002512121).	Bosc DG, 2000, J BIOL CHEM, V275, P14295, DOI 10.1074/jbc.275.19.14295; Canton DA, 2006, J BIOL CHEM, V281, P36347, DOI 10.1074/jbc.M607595200; Chen XF, 2012, MOL BIOL REP, V39, P3549, DOI 10.1007/s11033-011-1128-0; Cui Y, 2011, EMBO J, V30, P2675, DOI 10.1038/emboj.2011.155; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Kannan M, 2012, DEVELOPMENT, V139, P3600, DOI 10.1242/dev.081786; Lammi L, 2004, AM J HUM GENET, V74, P1043, DOI 10.1086/386293; Li H, 2002, CANCER BIOL THER, V1, P621, DOI 10.4161/cbt.309; Lu KF, 2008, NAT CELL BIOL, V10, P994, DOI 10.1038/ncb1760; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Narimatsu M, 2009, CELL, V137, P295, DOI 10.1016/j.cell.2009.02.025; Nie J, 2011, CHINESE SCI BULL, V56, P3155, DOI 10.1007/s11434-011-4703-9; Nie J, 2010, J BIOL CHEM, V285, P22816, DOI 10.1074/jbc.M110.126920; Nie J, 2010, FEBS LETT, V584, P3005, DOI 10.1016/j.febslet.2010.05.033; Osmundson EC, 2008, J CELL BIOL, V183, P267, DOI 10.1083/jcb.200801049; Osmundson EC, 2009, CELL DIV, V4, DOI 10.1186/1747-1028-4-14; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Safi A, 2004, MOL CELL BIOL, V24, P1245, DOI 10.1128/MCB.24.3.1245-1255.2004; Suzuki A, 2008, CANCER SCI, V99, P986, DOI 10.1111/j.1349-7006.2008.00779.x; Tokuda E, 2007, CANCER RES, V67, P9666, DOI 10.1158/0008-5472.CAN-07-1050; Wang YF, 2012, EMBO REP, V13, P1004, DOI 10.1038/embor.2012.144; Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035; Zhang BX, 2010, GASTROENTEROLOGY, V138, P969, DOI 10.1053/j.gastro.2009.11.004; Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617; Zhang LQ, 2007, CELL SIGNAL, V19, P932, DOI 10.1016/j.cellsig.2006.11.002; Zhang LQ, 2005, EMBO J, V24, P766, DOI 10.1038/sj.emboj.7600532	27	33	36	3	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3677	3687		10.1038/onc.2013.340	http://dx.doi.org/10.1038/onc.2013.340			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23995790				2022-12-28	WOS:000338942900007
J	Wang, C; Li, Y; Zhang, H; Liu, F; Cheng, Z; Wang, D; Wang, G; Xu, H; Zhao, Y; Cao, L; Li, F				Wang, C.; Li, Y.; Zhang, H.; Liu, F.; Cheng, Z.; Wang, D.; Wang, G.; Xu, H.; Zhao, Y.; Cao, L.; Li, F.			Oncogenic PAK4 regulates Smad2/3 axis involving gastric tumorigenesis	ONCOGENE			English	Article						PAK4; TGF-beta; Smad2; Smad3; gastric cancer	GROWTH-FACTOR-BETA; TGF-BETA; TRANSCRIPTIONAL REPRESSION; SIGNALING PATHWAY; DOWN-REGULATION; C-MYC; CANCER; CELLS; PHOSPHORYLATION; PROLIFERATION	The alteration of p21-activated kinase 4 (PAK4) and transforming growth factor-beta (TGF-beta) signaling effector Smad2/3 was detected in several types of tumors, which acts as oncogenic factor and tumor suppressor, but the relationship between these events has not been explored. Here, we demonstrate that PAK4 interacts with and modulates phosphorylation of Smad2/3 via both kinase-dependent and kinase-independent mechanisms, which attenuate Smad2/3 axis transactivation and TGF-beta-mediated growth inhibition in gastric cancer cells. First, PAK4 interaction with Smad2/3, which is independent of PAK4 kinase activity, blocks TGF-beta-induced phosphorylation of Smad2 Ser465/467 or Smad3 Ser4231425 and the consequent activation. In addition, PAK4 phosphorylates Smad2 on Ser465, leading to the degradation of Smad2 through ubiquitin-proteasome-dependent pathway under hepatocyte growth factor (HGF) stimulation. Interestingly, PAK4 expression correlates negatively with phospho-Ser465/467 Smad2 but positively with phospho-Ser465 Smad2 in gastric cancer tissues. Furthermore, the expressions of HGF, phospho-Ser474 PAK4 and phospho-Ser465 Smad2 are markedly increased in gastric cancer tissues, and the expression of Smad2 is decreased in gastric cancer tissues. Our results document an oncogenic role of PAK4 in repression of Smad2/3 transactivation that involved in tumorigenesis, and suggest PAK4 as a potential therapeutic target for gastric cancer.	[Wang, C.; Li, Y.; Zhang, H.; Cheng, Z.; Wang, D.; Wang, G.; Zhao, Y.; Cao, L.; Li, F.] China Med Univ, Minist Publ Hlth, Key Lab Cell Biol, Dept Cell Biol, Shenyang 110001, Peoples R China; [Wang, C.; Li, Y.; Zhang, H.; Cheng, Z.; Wang, D.; Wang, G.; Zhao, Y.; Cao, L.; Li, F.] China Med Univ, Minist Educ, Key Lab Med Cell Biol, Shenyang 110001, Peoples R China; [Liu, F.; Xu, H.] China Med Univ, Hosp 1, Dept Surg Oncol, Shenyang 110001, Peoples R China	China Medical University; China Medical University; China Medical University	Li, F (corresponding author), China Med Univ, Minist Publ Hlth, Key Lab Cell Biol, Dept Cell Biol, 92 Beier Rd, Shenyang 110001, Peoples R China.	fli@mail.cmu.edu.cn		Li, Feng/0000-0001-5868-7456; Wang, Guiling/0000-0001-7304-1610	National Natural Science Foundation of China [90813038, 31171360, 81001092, 31171259, 30900752]; Ministry of Education of China [20102104110016]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of China(Ministry of Education, China)	We thank Azeddine Atfi, Isabelle VAN SEUNINGEN, Koichi Shimada, Susumu Itoh, Bert Vogelstein and Carl-Henrik Heldin, Masa-Aki Ikeda and Cobb MH for providing the plasmids. This work was supported by grants from the National Natural Science Foundation of China (90813038, 31171360, 81001092, 31171259 and 30900752) and Doctoral fund of Ministry of Education of China (No. 20102104110016).	Achyut BR, 2011, GASTROENTEROLOGY, V141, P1167, DOI 10.1053/j.gastro.2011.07.048; Ahn HK, 2011, TRANSL ONCOL, V4, P345, DOI 10.1593/tlo.11145; Bauer J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039381; Baughn LB, 2009, J IMMUNOL, V182, P1810, DOI 10.4049/jimmunol.0713726; BERCHUCK A, 1989, CANCER RES, V49, P2091; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Dai CS, 2004, J AM SOC NEPHROL, V15, P1402, DOI 10.1097/01.ASN.0000130568.53923.FD; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Eswaran J, 2009, CANCER METAST REV, V28, P209, DOI 10.1007/s10555-008-9181-4; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Gnesutta N, 2003, MOL CELL BIOL, V23, P7838, DOI 10.1128/MCB.23.21.7838-7848.2003; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; Guo W, 2012, MOL BIOL REP, V39, P9453, DOI 10.1007/s11033-012-1810-x; Han SU, 2004, ONCOGENE, V23, P1333, DOI 10.1038/sj.onc.1207259; Herszenyi L, 2010, EUR REV MED PHARMACO, V14, P249; Ijichi H, 2001, BIOCHEM BIOPH RES CO, V289, P350, DOI 10.1006/bbrc.2001.5988; Itoh S, 2011, GROWTH FACTORS, V29, P163, DOI 10.3109/08977194.2011.614236; Jonckheere N, 2004, ONCOGENE, V23, P5729, DOI 10.1038/sj.onc.1207769; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Lee BH, 2007, J BIOL CHEM, V282, P17985, DOI 10.1074/jbc.M702664200; Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200; Li XD, 2010, EXPERT OPIN THER TAR, V14, P419, DOI 10.1517/14728221003642019; Li XD, 2010, INT J BIOCHEM CELL B, V42, P70, DOI 10.1016/j.biocel.2009.09.008; Li Y, 2012, BBA-MOL CELL RES, V1823, P465, DOI 10.1016/j.bbamcr.2011.11.013; Li Ze, 2008, Zhonghua Zhongliu Zazhi, V30, P30; Liu FN, 2009, INT J CANCER, V125, P2511, DOI 10.1002/ijc.24588; Liu T, 2010, BIOCHEM J, V430, P191, DOI 10.1042/BJ20100427; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Minden Audrey, 2012, Cell Logist, V2, P95; Mori S, 2004, ONCOGENE, V23, P7416, DOI 10.1038/sj.onc.1207981; Noda D, 2006, ONCOGENE, V25, P5591, DOI 10.1038/sj.onc.1209571; Orian A, 2001, Sci STKE, V2001, ppe1; Shimada K, 2008, BONE, V42, P886, DOI 10.1016/j.bone.2008.01.009; Shitara Y, 1999, JPN J CLIN ONCOL, V29, P3, DOI 10.1093/jjco/29.1.3; Shukla MN, 2009, AM J RESP CELL MOL, V40, P643, DOI 10.1165/rcmb.2008-0217OC; Siu MKY, 2010, P NATL ACAD SCI USA, V107, P18622, DOI 10.1073/pnas.0907481107; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Suganuma T, 2002, P NATL ACAD SCI USA, V99, P13073, DOI 10.1073/pnas.192586699; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Wells CM, 2010, J CELL SCI, V123, P1663, DOI 10.1242/jcs.055707; Wells CM, 2002, J CELL SCI, V115, P3947, DOI 10.1242/jcs.00080; Wrighton KH, 2009, CELL RES, V19, P8, DOI 10.1038/cr.2008.327; Wu WKK, 2010, CANCER LETT, V295, P144, DOI 10.1016/j.canlet.2010.04.025; Wu YJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035684; Yan XH, 2012, J BIOL CHEM, V287, P13705, DOI 10.1074/jbc.M112.346221; Yang L, 2008, CANCER RES, V68, P9107, DOI 10.1158/0008-5472.CAN-08-2556; Zhang HJ, 2011, CARCINOGENESIS, V32, P765, DOI 10.1093/carcin/bgr033; Zhang J, 2012, CANCER LETT, V317, P24, DOI 10.1016/j.canlet.2011.11.007	56	43	44	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3473	3484		10.1038/onc.2013.300	http://dx.doi.org/10.1038/onc.2013.300			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23934187				2022-12-28	WOS:000338779300014
J	Soria-Valles, C; Gutierrez-Fernandez, A; Guiu, M; Mari, B; Fueyo, A; Gomis, RR; Lopez-Otin, C				Soria-Valles, C.; Gutierrez-Fernandez, A.; Guiu, M.; Mari, B.; Fueyo, A.; Gomis, R. R.; Lopez-Otin, C.			The anti-metastatic activity of collagenase-2 in breast cancer cells is mediated by a signaling pathway involving decorin and miR-21	ONCOGENE			English	Article						extracellular matrix; metalloprotease; metastasis; miRNA; TGF-beta	TUMOR-SUPPRESSOR GENE; MATRIX METALLOPROTEINASE-8; MICRORNA-21 TARGETS; LUNG-CANCER; METASTASIS; EXPRESSION; MODULATION; PROTEASES; CLEAVAGE; ROLES	Matrix metalloproteinases (MMPs) have been traditionally implicated in cancer progression because of their ability to degrade the extracellular matrix. However, some members of the MMP family have recently been identified as proteases with antitumor properties. Thus, it has been described that collagenase-2 (MMP-8) has a protective role in tumor and metastasis progression, but the molecular mechanisms underlying these effects are unknown. We show herein that Mmp8 expression causes a decrease in miR-21 levels that in turn leads to a reduction in tumor growth and lung metastasis formation by MDA-MB-231 (4175) breast cancer cells. By using both in vitro and in vivo models, we demonstrate that the mechanism responsible for these MMP-8 beneficial effects involves cleavage of decorin by MMP-8 and a subsequent reduction of transforming growth factor beta (TGF-beta) signaling that controls miR-21 levels. In addition, miR-21 downregulation induced by MMP-8 increases the levels of tumor suppressors such as programmed cell death 4, which may also contribute to the decrease in tumor formation and metastasis of breast cancer cells overexpressing this metalloproteinase. These findings reveal a new signaling pathway for cancer regulation controlled by MMP-8, and contribute to clarify the molecular mechanisms by which tumor-defying proteases may exert their protective function in cancer and metastasis.	[Soria-Valles, C.; Gutierrez-Fernandez, A.; Lopez-Otin, C.] Univ Oviedo, IUOPA, Fac Med, Dept Bioquim & Biol Mol, Oviedo 33006, Spain; [Guiu, M.; Gomis, R. R.] Inst Res Biomed IRB Barcelona, Barcelona, Spain; [Mari, B.] CNRS, Valbonne, France; [Mari, B.] Univ Nice, Inst Pharmacol Mol & Cellulaire, Valbonne, France; [Fueyo, A.] Univ Oviedo, IUOPA, Fac Med, Dept Biol,Area Fisiol, Oviedo, Spain	University of Oviedo; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Oviedo	Lopez-Otin, C (corresponding author), Univ Oviedo, IUOPA, Fac Med, Dept Bioquim & Biol Mol, C Fernando Bongera S-N, Oviedo 33006, Spain.	clo@uniovi.es	Fueyo, Antonio/ABH-3243-2020; Mari, Bernard P/GVS-3100-2022; López-Otín, Carlos/AAB-2106-2020; Gomis, Roger R/E-9788-2016; Mari, Bernard P/F-8960-2013; Gutierrez-Fernandez, Ana/ABG-6678-2020; Gutierrez-Fernandez, Ana/AAS-9954-2021; Mari, Bernard P/D-7445-2015; Mari, Bernard/Q-5832-2019	Fueyo, Antonio/0000-0002-7121-9398; Mari, Bernard P/0000-0002-0422-9182; López-Otín, Carlos/0000-0001-6964-1904; Gomis, Roger R/0000-0001-6473-2858; Mari, Bernard P/0000-0002-0422-9182; Gutierrez-Fernandez, Ana/0000-0002-9287-8843; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard/0000-0002-0422-9182	Ministerio de Economia y Competitividad-Spain; RTICC-Instituto de Salud Carlos III-Spain; European Union; BBVA foundation [2009 SGR1429, SAF2010-21171]; Obra Social Cajastur-Asturias	Ministerio de Economia y Competitividad-Spain; RTICC-Instituto de Salud Carlos III-Spain; European Union(European Commission); BBVA foundation(BBVA Foundation); Obra Social Cajastur-Asturias	We are very grateful to Dr JMP Freije and FG Osorio for helpful comments and to C Garabaya, MF Suarez y S Alvarez for their excellent technical assistance. We also thank the excellent support of the Nice-Sophia Antipolis Functional Genomics Platform. This work was supported by grants from Ministerio de Economia y Competitividad-Spain, RTICC-Instituto de Salud Carlos III-Spain, and European Union (FP7-Microenvimet). BBVA foundation, 2009 SGR1429 and SAF2010-21171 support to RRG was provided. The Instituto Universitario de Oncologia is supported by Obra Social Cajastur-Asturias. CL-O is an Investigator of the Botin Foundation.	Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Fanjul-Fernandez M, 2013, J BIOL CHEM, V288, P14647, DOI 10.1074/jbc.M112.439893; Farazi TA, 2011, CANCER RES, V71, P4443, DOI 10.1158/0008-5472.CAN-11-0608; Gutierrez-Fernandez A, 2008, CANCER RES, V68, P2755, DOI 10.1158/0008-5472.CAN-07-5154; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Knauper V, 1997, FEBS LETT, V405, P60, DOI 10.1016/S0014-5793(97)00158-0; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Kong YW, 2012, LANCET ONCOL, V13, pE249, DOI 10.1016/S1470-2045(12)70073-6; Korpi JT, 2008, BRIT J CANCER, V98, P766, DOI 10.1038/sj.bjc.6604239; Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x; Lopez-Otin C, 2008, J BIOL CHEM, V283, P30433, DOI 10.1074/jbc.R800035200; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Lopez-Otin C, 2010, NAT REV CANCER, V10, P278, DOI 10.1038/nrc2823; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Merline R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001868; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Montel V, 2004, CANCER RES, V64, P1687, DOI 10.1158/0008-5472.CAN-03-2047; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Noel A, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00140; Pan XA, 2010, CANCER BIOL THER, V10, P1224, DOI 10.4161/cbt.10.12.14252; Puissegur MP, 2011, CELL DEATH DIFFER, V18, P465, DOI 10.1038/cdd.2010.119; Qian BY, 2009, BREAST CANCER RES TR, V117, P131, DOI 10.1007/s10549-008-0219-7; Tester AM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000312; Turk B, 2012, EMBO J, V31, P1630, DOI 10.1038/emboj.2012.42; Van Lint P, 2006, CYTOKINE GROWTH F R, V17, P217, DOI 10.1016/j.cytogfr.2006.04.001; Yan LX, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2803; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhen EY, 2008, ARTHRITIS RHEUM-US, V58, P2420, DOI 10.1002/art.23654; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	35	53	56	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					3054	3063		10.1038/onc.2013.267	http://dx.doi.org/10.1038/onc.2013.267			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23851508				2022-12-28	WOS:000337232200012
J	Chen, WT; Zhu, GY; Pfaffenbach, K; Kanel, G; Stiles, B; Lee, AS				Chen, Wan-Ting; Zhu, Genyuan; Pfaffenbach, Kyle; Kanel, Gary; Stiles, Bangyan; Lee, Amy S.			GRP78 as a regulator of liver steatosis and cancer progression mediated by loss of the tumor suppressor PTEN	CANCER RESEARCH			English	Meeting Abstract									[Chen, Wan-Ting; Zhu, Genyuan; Kanel, Gary; Lee, Amy S.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA; [Pfaffenbach, Kyle] Eastern Oregon Univ, La Grande, OR USA; [Stiles, Bangyan] Univ So Calif, Sch Pharm, Los Angeles, CA USA	University of Southern California; Eastern Oregon University; University of Southern California			chen, want/GRX-0662-2022		NCI NIH HHS [R01 CA154986, R01 CA027607, P30 CA014089] Funding Source: Medline; NIA NIH HHS [P01 AG034906] Funding Source: Medline; NIDDK NIH HHS [R21 DK075928, P30 DK048522, R01 DK084241, P30DK048522] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))			0	8	8	0	0	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	0008-5472	1538-7445		CANCER RES	Cancer Res.	OCT 1	2013	73			19		C61				10.1158/1538-7445.FBCR13-C61	http://dx.doi.org/10.1158/1538-7445.FBCR13-C61			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	V40RV	24141775				2022-12-28	WOS:000209496600151
J	Garg, R; Benedetti, LG; Abera, MB; Wang, H; Abba, M; Kazanietz, MG				Garg, R.; Benedetti, L. G.; Abera, M. B.; Wang, H.; Abba, M.; Kazanietz, M. G.			Protein kinase C and cancer: what we know and what we do not	ONCOGENE			English	Review						protein kinase C (PKC); apoptosis; survival; tumorigenesis; metastasis; animal models	ESTER-INDUCED APOPTOSIS; DELTA PKC-DELTA; NF-KAPPA-B; DOMAIN-CONTAINING PROTEIN-1; BETA INHIBITOR ENZASTAURIN; AGGRESSIVE BREAST-CANCER; PHASE-II TRIAL; PROSTATE-CANCER; CELL-PROLIFERATION; GENE-EXPRESSION	Since their discovery in the late 1970s, protein kinase C (PKC) isozymes represent one of the most extensively studied signaling kinases. PKCs signal through multiple pathways and control the expression of genes relevant for cell cycle progression, tumorigenesis and metastatic dissemination. Despite the vast amount of information concerning the mechanisms that control PKC activation and function in cellular models, the relevance of individual PKC isozymes in the progression of human cancer is still a matter of controversy. Although the expression of PKC isozymes is altered in multiple cancer types, the causal relationship between such changes and the initiation and progression of the disease remains poorly defined. Animal models developed in the last years helped to better understand the involvement of individual PKCs in various cancer types and in the context of specific oncogenic alterations. Unraveling the enormous complexity in the mechanisms by which PKC isozymes have an impact on tumorigenesis and metastasis is key for reassessing their potential as pharmacological targets for cancer treatment.	[Garg, R.; Benedetti, L. G.; Abera, M. B.; Wang, H.; Kazanietz, M. G.] Univ Penn, Perelman Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; [Abba, M.] Univ Nacl La Plata, Fac Ciencias Med, Ctr Invest Inmunol Basicas & Aplicadas, La Plata, Buenos Aires, Argentina	University of Pennsylvania; Pennsylvania Medicine; National University of La Plata	Kazanietz, MG (corresponding author), Univ Penn, Perelman Sch Med, Dept Pharmacol, 1256 Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	marcelog@upenn.edu	Garg, Rachana/AAQ-9518-2020	Abba, Martin/0000-0002-9206-2369; Garg, Rachana/0000-0002-7808-1053	NIH [R01-CA89202, R01-CA139120]; Department of Defense [W81XWH-12-1-0009]; NATIONAL CANCER INSTITUTE [R01CA139120, R01CA089202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES013508] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Work in the laboratory of MGK is supported by grants R01-CA89202 and R01-CA139120 from NIH. RG is supported by a post-doctoral grant from the Department of Defense W81XWH-12-1-0009.	Advani R, 2004, CANCER-AM CANCER SOC, V100, P321, DOI 10.1002/cncr.11909; Akakura S, 2010, CELL CYCLE, V9, P4656, DOI 10.4161/cc.9.23.13974; Akita Y, 2002, J BIOCHEM, V132, P847, DOI 10.1093/oxfordjournals.jbchem.a003296; Akita Y, 2008, FEBS J, V275, P3995, DOI 10.1111/j.1742-4658.2008.06557.x; Allen-Petersen BL, 2014, ONCOGENE, V33, P1306, DOI 10.1038/onc.2013.59; Assender JW, 2007, J CLIN PATHOL, V60, P1216, DOI 10.1136/jcp.2006.041616; Atwood SX, 2013, NATURE, V494, P484, DOI 10.1038/nature11889; Aziz MH, 2007, CANCER RES, V67, P8828, DOI 10.1158/0008-5472.CAN-07-1604; Bae KM, 2007, CANCER RES, V67, P6053, DOI 10.1158/0008-5472.CAN-06-4037; Baldwin RM, 2008, ONCOGENE, V27, P3587, DOI 10.1038/sj.onc.1211027; BALTUCH GH, 1995, J NEURO-ONCOL, V24, P241, DOI 10.1007/BF01052840; Bao LW, 2009, CANCER RES, V69, P5829, DOI 10.1158/0008-5472.CAN-08-3465; Barry OP, 2001, CURR PHARM DESIGN, V7, P1725, DOI 10.2174/1381612013397041; Basso K, 2005, NAT GENET, V37, P382, DOI 10.1038/ng1532; Basu A, 2007, CELL SIGNAL, V19, P1633, DOI 10.1016/j.cellsig.2007.04.008; Basu A, 2010, THESCIENTIFICWORLDJO, V10, P2272, DOI 10.1100/tsw.2010.214; Benavides F, 2011, CELL CYCLE, V10, P268, DOI 10.4161/cc.10.2.14469; Besson A, 2001, ONCOGENE, V20, P7398, DOI 10.1038/sj.onc.1204899; Bezombes C, 2002, MOL PHARMACOL, V62, P1446, DOI 10.1124/mol.62.6.1446; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; Blackburn RV, 1998, CANCER, V82, P1137, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1137::AID-CNCR19>3.0.CO;2-7; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; Bredel M, 2005, CANCER RES, V65, P8679, DOI 10.1158/0008-5472.CAN-05-1204; Brenner W, 2003, ANTICANCER RES, V23, P4001; Buchholz M, 2005, ONCOGENE, V24, P6626, DOI 10.1038/sj.onc.1208804; Byers HR, 2010, MELANOMA RES, V20, P171, DOI 10.1097/CMR.0b013e32832f1581; CACACE AM, 1993, ONCOGENE, V8, P2095; Cacace AM, 1996, ONCOGENE, V13, P2517; Cacace AM, 1998, J CELL PHYSIOL, V175, P314, DOI 10.1002/(SICI)1097-4652(199806)175:3<314::AID-JCP9>3.0.CO;2-R; Cadoret A, 1998, ONCOGENE, V17, P877, DOI 10.1038/sj.onc.1202013; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Caino MC, 2012, ONCOGENE, V31, P2593, DOI 10.1038/onc.2011.428; Caino MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031714; Calcagno SR, 2008, INT J CANCER, V122, P2462, DOI 10.1002/ijc.23383; Cameron AJ, 2008, INT J CANCER, V123, P769, DOI 10.1002/ijc.23560; Cataldi A, 2003, J CELL BIOCHEM, V88, P144, DOI 10.1002/jcb.10305; Cesaro P, 2001, INT J CANCER, V93, P179, DOI 10.1002/ijc.1314; Chen CA, 2004, BBA-PROTEINS PROTEOM, V1697, P39, DOI 10.1016/j.bbapap.2003.11.012; Chisamore MJ, 2001, CLIN CANCER RES, V7, P3156; Civallero M, 2011, HEMATOL ONCOL, V29, P154, DOI 10.1002/hon.974; Civallero M, 2010, LEUKEMIA LYMPHOMA, V51, P671, DOI 10.3109/10428191003637290; Cornford P, 1999, AM J PATHOL, V154, P137, DOI 10.1016/S0002-9440(10)65260-1; CRAVEN PA, 1992, CANCER RES, V52, P2216; Dai CM, 2011, J HAZARD MATER, V198, P175, DOI 10.1016/j.jhazmat.2011.10.027; Dann SG, 2014, ONCOGENE, V33, P1385, DOI 10.1038/onc.2013.91; Dave SS, 2006, NEW ENGL J MED, V354, P2431, DOI 10.1056/NEJMoa055759; DAVIDSON D, 1994, MOL CELL BIOL, V14, P4554, DOI 10.1128/MCB.14.7.4554; Davidson LA, 1998, CARCINOGENESIS, V19, P253, DOI 10.1093/carcin/19.2.253; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Dhanasekaran SM, 2004, FASEB J, V18, P243, DOI 10.1096/fj.04-2415fje; Dupasquier S, 2009, J CELL SCI, V122, P2191, DOI 10.1242/jcs.036483; Dyrskjot L, 2004, CANCER RES, V64, P4040, DOI 10.1158/0008-5472.CAN-03-3620; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Espinosa I, 2006, ANN HEMATOL, V85, P597, DOI 10.1007/s00277-006-0144-y; Facchinetti MM, 2004, CANCER RES, V64, P3629, DOI 10.1158/0008-5472.CAN-03-3741; Felber M, 2007, PATHOL ONCOL RES, V13, P295, DOI 10.1007/BF02940308; Fikaris AJ, 2005, J BIOL CHEM, V280, P32107, DOI 10.1074/jbc.M504432200; Filomenko R, 2002, CANCER RES, V62, P1815; Fishman DD, 1998, INT J ONCOL, V12, P181; Frederick LA, 2008, ONCOGENE, V27, P4841, DOI 10.1038/onc.2008.119; French PJ, 2005, CANCER RES, V65, P11335, DOI 10.1158/0008-5472.CAN-05-1886; Frey MR, 2000, J CELL BIOL, V151, P763, DOI 10.1083/jcb.151.4.763; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Fukase N, 2011, ONCOL REP, V26, P1221, DOI 10.3892/or.2011.1415; Gallegos LL, 2006, J BIOL CHEM, V281, P30947, DOI 10.1074/jbc.M603741200; Gallegos LL, 2011, METHODS MOL BIOL, V756, P295, DOI 10.1007/978-1-61779-160-4_17; Galvez AS, 2009, MOL CELL BIOL, V29, P104, DOI 10.1128/MCB.01294-08; Garcia-Bermejo ML, 2002, J BIOL CHEM, V277, P645, DOI 10.1074/jbc.M107639200; Garg R, 2012, J BIOL CHEM, V287, P37570, DOI 10.1074/jbc.M112.398925; Gavrielides MV, 2004, CURR DRUG TARGETS, V5, P431, DOI 10.2174/1389450043345380; Gelardi T, 2008, BRIT J CANCER, V99, P473, DOI 10.1038/sj.bjc.6604493; Ghosh PM, 2002, CANCER RES, V62, P2630; Gokmen-Polar Y, 2010, BREAST CANCER RES TR, V124, P327, DOI 10.1007/s10549-010-0733-2; Gokmen-Polar Y, 1998, J BIOL CHEM, V273, P20261, DOI 10.1074/jbc.273.32.20261; GOLDSTEIN DR, 1995, CARCINOGENESIS, V16, P1121, DOI 10.1093/carcin/16.5.1121; Gonelli A, 2009, MINI-REV MED CHEM, V9, P498, DOI 10.2174/138955709787847967; Gonzalez-Guerrico AM, 2005, J BIOCHEM MOL BIOL, V38, P639; Gonzalez-Guerrico AM, 2005, J BIOL CHEM, V280, P38982, DOI 10.1074/jbc.M506767200; Gorin MA, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-9; Graff JR, 2005, CANCER RES, V65, P7462, DOI 10.1158/0008-5472.CAN-05-0071; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Grossman SA, 2005, NEURO-ONCOLOGY, V7, P32, DOI 10.1215/S1152851703000353; Grossoni VC, 2007, MOL CARCINOGEN, V46, P381, DOI 10.1002/mc.20287; Grossoni VC, 2009, BREAST CANCER RES TR, V118, P469, DOI 10.1007/s10549-008-0299-4; Guan LJ, 2007, J BIOL CHEM, V282, P14213, DOI 10.1074/jbc.M610513200; Gustafson WC, 2004, J BIOL CHEM, V279, P9400, DOI 10.1074/jbc.M312840200; Gwak J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046697; Gwak J, 2009, J CELL MOL MED, V13, P2171, DOI 10.1111/j.1582-4934.2009.00683.x; Hamilton M, 2001, J BIOL CHEM, V276, P29079, DOI 10.1074/jbc.M102001200; Hanauske AR, 2007, INVEST NEW DRUG, V25, P205, DOI 10.1007/s10637-007-9038-7; Hans CP, 2005, MODERN PATHOL, V18, P1377, DOI 10.1038/modpathol.3800434; Hao F, 2011, J BIOL CHEM, V286, P18104, DOI 10.1074/jbc.M110.208488; Hara T, 2012, ANTICANCER RES, V32, P3097; Haughian JM, 2009, INT J CANCER, V125, P2556, DOI 10.1002/ijc.24633; Hernandez RM, 2001, J CELL BIOCHEM, V83, P532, DOI 10.1002/jcb.1246; Hill KS, 2014, ONCOGENE, V33, P2134, DOI 10.1038/onc.2013.147; Hizli AA, 2006, J BIOL CHEM, V281, P14596, DOI 10.1074/jbc.M601959200; Huang B, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-88; Irie K, 2012, MED RES REV, V32, P518, DOI 10.1002/med.20220; Ishiguro H, 2009, P NATL ACAD SCI USA, V106, P16369, DOI 10.1073/pnas.0907044106; Jackson D, 2005, ONCOGENE, V24, P3067, DOI 10.1038/sj.onc.1208465; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Jamal MS, 2011, CANCER RES, V71, DOI 10.1158/1538-7445.AM2011-4204; Jansen AP, 2001, CANCER RES, V61, P808; Jasinski P, 2008, EUR J CANCER, V44, P1315, DOI 10.1016/j.ejca.2008.03.024; Justilien V, 2011, J BIOL CHEM, V286, P8149, DOI 10.1074/jbc.M110.196113; Kahana S, 2011, CELL SIGNAL, V23, P1348, DOI 10.1016/j.cellsig.2011.03.017; Kang GH, 2011, MODERN PATHOL, V24, P866, DOI 10.1038/modpathol.2011.11; KAZANIETZ MG, 1994, MOL PHARMACOL, V46, P374; Kharait S, 2006, BIOCHEM BIOPH RES CO, V343, P848, DOI 10.1016/j.bbrc.2006.03.044; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; Kiley SC, 1999, CANCER RES, V59, P3230; Kim J, 2011, ONCOGENE, V30, P323, DOI 10.1038/onc.2010.415; Kim JW, 2008, CANCER RES, V68, P6831, DOI 10.1158/0008-5472.CAN-07-6195; Kim J, 2011, PROSTATE, V71, P946, DOI 10.1002/pros.21310; Kim JY, 2013, P NATL ACAD SCI USA, V110, P6418, DOI 10.1073/pnas.1221799110; Kim KH, 2012, ANTICANCER RES, V32, P923; Kim S, 2012, J SURG RES, V176, pE21, DOI 10.1016/j.jss.2011.11.1041; Kong CZ, 2005, UROLOGY, V65, P1228, DOI 10.1016/j.urology.2005.01.007; Krasnitsky E, 2012, ANTICANCER RES, V32, P1507; Kreisl TN, 2010, NEURO-ONCOLOGY, V12, P181, DOI 10.1093/neuonc/nop042; Kruger JS, 2003, MOL CANCER RES, V1, P801; La Porta CAM, 2000, MELANOMA RES, V10, P527; La Porta CAM, 2000, MELANOMA RES, V10, P93, DOI 10.1097/00008390-200010020-00001; Lahn M, 2004, ONCOLOGY-BASEL, V67, P1, DOI 10.1159/000080279; LEACH KL, 1983, P NATL ACAD SCI-BIOL, V80, P4208, DOI 10.1073/pnas.80.14.4208; LEE HS, 1993, J BIOL CHEM, V268, P5255; Lee JM, 2010, MOL CELL, V37, P183, DOI 10.1016/j.molcel.2009.12.022; Lenburg ME, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-31; Li HY, 2006, CANCER RES, V66, P11399, DOI 10.1158/0008-5472.CAN-06-2386; Li N, 2013, ONCOGENE, V32, P4539, DOI 10.1038/onc.2012.466; Li SY, 2007, BIOL DIRECT, V2, DOI 10.1186/1745-6150-2-8; Lin CW, 2010, J CELL PHYSIOL, V225, P472, DOI 10.1002/jcp.22226; LIU B, 1994, J NATL CANCER I, V86, P1145, DOI 10.1093/jnci/86.15.1145; Liu SG, 2011, MOL CANCER RES, V9, P390, DOI 10.1158/1541-7786.MCR-10-0359; Lonne GK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-76; Lu DM, 2007, APOPTOSIS, V12, P1893, DOI 10.1007/s10495-007-0111-7; Lu DM, 2006, J BIOL CHEM, V281, P22799, DOI 10.1074/jbc.M603390200; Lu HC, 2010, PATHOL ONCOL RES, V16, P385, DOI 10.1007/s12253-009-9228-z; Lutzny G, 2013, CANCER CELL, V23, P77, DOI 10.1016/j.ccr.2012.12.003; Ma L, 2013, CELL, V152, P599, DOI 10.1016/j.cell.2012.12.028; Mahanivong C, 2008, ONCOGENE, V27, P1273, DOI 10.1038/sj.onc.1210746; Mandil R, 2001, CANCER RES, V61, P4612; Manni A, 1996, CELL GROWTH DIFFER, V7, P1187; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mauro LV, 2010, PANCREAS, V39, pE31, DOI 10.1097/MPA.0b013e3181bce796; McJilton MA, 2003, ONCOGENE, V22, P7958, DOI 10.1038/sj.onc.1206795; McKiernan E, 2008, BRIT J CANCER, V99, P1644, DOI 10.1038/sj.bjc.6604728; Meshki J, 2010, J BIOL CHEM, V285, P26033, DOI 10.1074/jbc.M110.128371; Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Miyazawa Y, 2010, CANCER RES, V70, P5136, DOI 10.1158/0008-5472.CAN-10-0220; Mochly-Rosen D, 2012, NAT REV DRUG DISCOV, V11, P937, DOI 10.1038/nrd3871; Motegi A, 2005, PATHOL INT, V55, P106, DOI 10.1111/j.1440-1827.2005.01806.x; Murray NR, 2011, J CELL PHYSIOL, V226, P879, DOI 10.1002/jcp.22463; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; Murray NR, 1999, J CELL BIOL, V145, P699, DOI 10.1083/jcb.145.4.699; Mustafi R, 2006, MOL CANCER RES, V4, P683, DOI 10.1158/1541-7786.MCR-06-0057; Mut M, 2010, TURK NEUROSURG, V20, P277, DOI 10.5137/1019-5149.JTN.3008-10.1; Nakagawa M, 2005, J BIOL CHEM, V280, P33926, DOI 10.1074/jbc.M505748200; Nakagawa S, 2003, MOL CARCINOGEN, V38, P106, DOI 10.1002/mc.10150; Nanjundan M, 2007, CANCER RES, V67, P3074, DOI 10.1158/0008-5472.CAN-06-2366; Nazarenko I, 2010, MOL CANCER RES, V8, P919, DOI 10.1158/1541-7786.MCR-09-0358; Okhrimenko H, 2005, CANCER RES, V65, P7301, DOI 10.1158/0008-5472.CAN-05-1064; Oliva JL, 2008, J BIOL CHEM, V283, P5466, DOI 10.1074/jbc.M707576200; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; Oster H, 2006, CANCER RES, V66, P6955, DOI 10.1158/0008-5472.CAN-06-0268; Pan Q, 2005, CANCER RES, V65, P8366, DOI 10.1158/0008-5472.CAN-05-0553; Pan Q, 2006, CANCER RES, V66, P9379, DOI 10.1158/0008-5472.CAN-06-2646; Paz-Ares L, 2006, J CLIN ONCOL, V24, P1428, DOI 10.1200/JCO.2005.04.3299; Perletti GP, 1998, ONCOGENE, V16, P3345, DOI 10.1038/sj.onc.1201871; Perletti GP, 1996, ONCOGENE, V12, P847; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Pysz MA, 2009, EXP CELL RES, V315, P1415, DOI 10.1016/j.yexcr.2009.02.002; Querfeld C, 2006, J INVEST DERMATOL, V126, P1641, DOI 10.1038/sj.jid.5700322; Querfeld C, 2011, LEUKEMIA LYMPHOMA, V52, P1474, DOI 10.3109/10428194.2011.572265; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Reddig PJ, 1999, CANCER RES, V59, P5710; Regala RP, 2008, CANCER RES, V68, P5888, DOI 10.1158/0008-5472.CAN-08-0438; Regala RP, 2009, CANCER RES, V69, P7603, DOI 10.1158/0008-5472.CAN-09-2066; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Reno EM, 2008, HUM PATHOL, V39, P21, DOI 10.1016/j.humpath.2007.05.023; Rhodes DR, 2007, NEOPLASIA, V9, P443, DOI 10.1593/neo.07292; Rickman DS, 2001, CANCER RES, V61, P6885; Rimessi A, 2012, CELL CYCLE, V11, P1040, DOI 10.4161/cc.11.5.19520; Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375; Sand JM, 2010, J INVEST DERMATOL, V130, P270, DOI 10.1038/jid.2009.212; Sarkar S, 2010, CARCINOGENESIS, V31, P311, DOI 10.1093/carcin/bgp297; Sauma S, 1996, CELL GROWTH DIFFER, V7, P587; Schleifenbaum A, 2004, J AM CHEM SOC, V126, P11786, DOI 10.1021/ja0460155; Scotti ML, 2010, CANCER RES, V70, P2064, DOI 10.1158/0008-5472.CAN-09-2684; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Sengupta A, 2011, P NATL ACAD SCI USA, V108, P9957, DOI 10.1073/pnas.1103132108; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; Shi MD, 2013, CELL BIOCHEM BIOPHYS, V66, P161, DOI 10.1007/s12013-012-9465-8; Spindler KLG, 2009, INT J COLORECTAL DIS, V24, P641, DOI 10.1007/s00384-009-0680-8; Stearman RS, 2005, AM J PATHOL, V167, P1763, DOI 10.1016/S0002-9440(10)61257-6; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Stewart JR, 2004, INVEST NEW DRUG, V22, P107, DOI 10.1023/B:DRUG.0000011787.75522.ec; Suga K, 1998, BIOCHEM MOL BIOL INT, V44, P523; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Symonds JM, 2011, CANCER RES, V71, P2087, DOI 10.1158/0008-5472.CAN-10-1511; Tachado SD, 2002, J CELL BIOCHEM, V85, P785, DOI 10.1002/jcb.10164; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005; Tan M, 2006, ONCOGENE, V25, P3286, DOI 10.1038/sj.onc.1209361; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; Teicher BA, 2001, CANCER CHEMOTH PHARM, V48, P473, DOI 10.1007/s002800100372; Teicher BA, 2002, INVEST NEW DRUG, V20, P241, DOI 10.1023/A:1016297611825; Teicher BA, 2001, CLIN CANCER RES, V7, P634; Tekle C, 2008, BRIT J CANCER, V99, P750, DOI 10.1038/sj.bjc.6604566; Tonetti DA, 2003, BRIT J CANCER, V88, P1400, DOI 10.1038/sj.bjc.6600923; Tonetti DA, 2000, BRIT J CANCER, V83, P782, DOI 10.1054/bjoc.2000.1326; Tonetti DA, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/740353; Truman JP, 2009, CANCER BIOL THER, V8, P54, DOI 10.4161/cbt.8.1.7119; Tsai JH, 2000, CANCER LETT, V161, P171, DOI 10.1016/S0304-3835(00)00597-8; Villar J, 2007, CANCER RES, V67, P10859, DOI 10.1158/0008-5472.CAN-07-2041; von Brandenstein M, 2012, AM J PATHOL, V180, P1787, DOI 10.1016/j.ajpath.2012.01.014; Wang HB, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M111.227991; Wang HB, 2010, MOL BIOL CELL, V21, P1398, DOI 10.1091/mbc.E09-08-0735; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Wheeler DL, 2005, AM J PATHOL, V166, P117, DOI 10.1016/S0002-9440(10)62237-7; Wheeler DL, 2004, CANCER RES, V64, P7756, DOI 10.1158/0008-5472.CAN-04-1881; Willey CD, 2010, INT J RADIAT ONCOL, V77, P1518, DOI 10.1016/j.ijrobp.2009.06.044; Win HY, 2008, CANCER LETT, V270, P302, DOI 10.1016/j.canlet.2008.05.023; Wu DQ, 2004, ONCOGENE, V23, P8659, DOI 10.1038/sj.onc.1207900; Wu DQ, 2002, CANCER RES, V62, P2423; Wu TT, 2008, J CELL BIOCHEM, V103, P9, DOI 10.1002/jcb.21378; Wu-Zhang AX, 2013, BIOCHEM J, V452, P195, DOI 10.1042/BJ20130220; Xiao LQ, 2008, METHOD ENZYMOL, V446, P123, DOI 10.1016/S0076-6879(08)01607-8; Xiao LQ, 2009, J BIOL CHEM, V284, P29365, DOI 10.1074/jbc.M109.007971; Xiao LQ, 2009, MOL CARCINOGEN, V48, P187, DOI 10.1002/mc.20476; Xin MG, 2007, J BIOL CHEM, V282, P21268, DOI 10.1074/jbc.M701613200; Yadav V, 2010, AM J PATHOL, V176, P1091, DOI 10.2353/ajpath.2010.090816; Yang MY, 2010, J AGR FOOD CHEM, V58, P5806, DOI 10.1021/jf100718b; Yonezawa Tomo, 2009, Recent Pat DNA Gene Seq, V3, P96; Yu LR, 2011, NEOPLASMA, V58, P491, DOI 10.4149/neo_2011_06_491; Yu WS, 2003, J BIOL CHEM, V278, P11167, DOI 10.1074/jbc.M211424200; Yun J, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.26; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527; Zhao M, 2012, ARCH IMMUNOL THER EX, V60, P361, DOI 10.1007/s00005-012-0188-8	244	172	180	1	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2014	33	45					5225	5237		10.1038/onc.2013.524	http://dx.doi.org/10.1038/onc.2013.524			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MD	24336328	Green Accepted, Green Published			2022-12-28	WOS:000345120400001
J	Guha, M; Srinivasan, S; Ruthel, G; KKashina, A; Carstens, RP; Mendoza, A; Khanna, C; Van Winkle, T; Avadhani, NG				Guha, M.; Srinivasan, S.; Ruthel, G.; Kashina, A. K.; Carstens, R. P.; Mendoza, A.; Khanna, C.; Van Winkle, T.; Avadhani, N. G.			Mitochondrial retrograde signaling induces epithelial-mesenchymal transition and generates breast cancer stem cells	ONCOGENE			English	Article						mitochondrial DNA; mitochondrial retrograde signaling; epithelial-mesenchymal transition; breast cancer; ESRP1; cancer stem cells	DNA DEPLETION; RESPIRATORY STRESS; GENOME INSTABILITY; MTDNA DEPLETION; COPY NUMBER; IN-VIVO; MUTATIONS; ACTIVATION; RESISTANCE; APOPTOSIS	Metastatic breast tumors undergo epithelial-to-mesenchymal transition (EMT), which renders them resistant to therapies targeted to the primary cancers. The mechanistic link between mtDNA (mitochondrial DNA) reduction, often seen in breast cancer patients, and EMT is unknown. We demonstrate that reducing mtDNA content in human mammary epithelial cells (hMECs) activates Calcineurin (Cn)-dependent mitochondrial retrograde signaling pathway, which induces EMT-like reprogramming to fibroblastic morphology, loss of cell polarity, contact inhibition and acquired migratory and invasive phenotype. Notably, mtDNA reduction generates breast cancer stem cells. In addition to retrograde signaling markers, there is an induction of mesenchymal genes but loss of epithelial markers in these cells. The changes are reversed by either restoring the mtDNA content or knockdown of CnA alpha mRNA, indicating the causal role of retrograde signaling in EMT. Our results point to a new therapeutic strategy for metastatic breast cancers targeted to the mitochondrial retrograde signaling pathway for abrogating EMT and attenuating cancer stem cells, which evade conventional therapies. We report a novel regulatory mechanism by which low mtDNA content generates EMT and cancer stem cells in hMECs.	[Guha, M.; Srinivasan, S.; Kashina, A. K.; Avadhani, N. G.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; [Guha, M.; Srinivasan, S.; Kashina, A. K.; Avadhani, N. G.] Univ Penn, Sch Vet Med, Marie Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA; [Ruthel, G.] Univ Penn, Sch Vet Med, Penn Vet Imaging Core, Philadelphia, PA 19104 USA; [Carstens, R. P.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA; [Mendoza, A.; Khanna, C.] NCI, Tumor & Metastasis Biol Sect, Ctr Canc Res, Bethesda, MD 20892 USA; [Van Winkle, T.] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Pennsylvania	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu	Ruthel, Gordon/GYU-9133-2022	Ruthel, Gordon/0000-0001-9193-5589	NIH grant [CA-22762]; Harriet Ellison Woodward Trust; NATIONAL CANCER INSTITUTE [R37CA022762, R01CA022762] Funding Source: NIH RePORTER	NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harriet Ellison Woodward Trust; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by NIH grant CA-22762 and an Endowment from the Harriet Ellison Woodward Trust to NGA. We thank Benjamin Cieply (Carstens laboratory) for providing reagents for the ESRP1 experiments; Drs Brett Kaufman and Jill Kolesar (Kaufman lab) for providing TFAM shRNA constructs; Dr Joseph Baur for the GFP shRNA plasmid; Dr Mauricio Reginato and members of his laboratory for sharing protocols and reagents for immunostaining of the MCF10A 3D spheres; and Drs Christopher Lengner and Qihong Huang for valuable comments on the manuscript. We thank Dr Leslie King for critical comments and editorial help.	Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BAE SN, 1993, BREAST CANCER RES TR, V24, P241, DOI 10.1007/BF01833264; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Biswas G, 2005, CELL DEATH DIFFER, V12, P266, DOI 10.1038/sj.cdd.4401553; Blaustein M, 2005, NAT STRUCT MOL BIOL, V12, P1037, DOI 10.1038/nsmb1020; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Campbell CT, 2012, BBA-GENE REGUL MECH, V1819, P921, DOI 10.1016/j.bbagrm.2012.03.002; Coller HA, 2001, NAT GENET, V28, P147, DOI 10.1038/88859; Correia RL, 2011, MITOCHONDRION, V11, P48, DOI 10.1016/j.mito.2010.07.001; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Fan WW, 2012, GENE DEV, V26, P384, DOI 10.1101/gad.175802.111; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Greaves LC, 2012, J PATHOL, V226, P274, DOI 10.1002/path.3028; Guha M, 2007, J BIOL CHEM, V282, P14536, DOI 10.1074/jbc.M611693200; Guha M, 2010, MOL BIOL CELL, V21, P3578, DOI 10.1091/mbc.E10-03-0192; Guha M, 2010, BBA-BIOENERGETICS, V1797, P1055, DOI 10.1016/j.bbabio.2010.02.008; Guha M, 2009, MOL BIOL CELL, V20, P4107, DOI 10.1091/mbc.E09-04-0296; Gumireddy K, 2007, P NATL ACAD SCI USA, V104, P6696, DOI 10.1073/pnas.0701145104; Guo JH, 2011, CANCER RES, V71, P2978, DOI 10.1158/0008-5472.CAN-10-3482; Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z; HORWITZ HB, 1971, J CELL BIOL, V49, P546, DOI 10.1083/jcb.49.2.546; Imanishi H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023401; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kulawiec M, 2008, CANCER BIOL THER, V7, P1732, DOI 10.4161/cbt.7.11.6729; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lee HC, 2005, ANN NY ACAD SCI, V1042, P109, DOI 10.1196/annals.1338.011; Magda D, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-521; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mendoza A, 2010, J CLIN INVEST, V120, P2979, DOI 10.1172/JCI40252; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Moro L, 2009, CELL DEATH DIFFER, V16, P571, DOI 10.1038/cdd.2008.178; Naito A, 2008, CANCER SCI, V99, P1584, DOI 10.1111/j.1349-7006.2008.00879.x; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Ryan MT, 2007, ANNU REV BIOCHEM, V76, P701, DOI 10.1146/annurev.biochem.76.052305.091720; Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207; Schonberg MA, 2010, J CLIN ONCOL, V28, P2038, DOI 10.1200/JCO.2009.25.9796; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012; Tang WG, 2012, CARCINOGENESIS, V33, P1762, DOI 10.1093/carcin/bgs190; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tseng LM, 2006, GENE CHROMOSOME CANC, V45, P629, DOI 10.1002/gcc.20326; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Warzecha CC, 2009, RNA BIOL, V6, P546, DOI 10.4161/rna.6.5.9606; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Woo DK, 2012, AM J PATHOL, V180, P24, DOI 10.1016/j.ajpath.2011.10.003; Xia P, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-454; Yu M, 2007, IUBMB LIFE, V59, P450, DOI 10.1080/15216540701509955; Yu M, 2009, EUR J CANCER PREV, V18, P445, DOI 10.1097/CEJ.0b013e32832f9bd6	54	88	90	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2014	33	45					5238	5250		10.1038/onc.2013.467	http://dx.doi.org/10.1038/onc.2013.467			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MD	24186204	Green Accepted			2022-12-28	WOS:000345120400002
J	Driemel, C; Kremling, H; Schumacher, S; Will, D; Wolters, J; Lindenlauf, N; Mack, B; Baldus, SA; Hoya, V; Pietsch, JM; Panagiotidou, P; Raba, K; Vay, C; Vallbohmer, D; Harreus, U; Knoefel, WT; Stoecklein, NH; Gires, O				Driemel, C.; Kremling, H.; Schumacher, S.; Will, D.; Wolters, J.; Lindenlauf, N.; Mack, B.; Baldus, S. A.; Hoya, V.; Pietsch, J. M.; Panagiotidou, P.; Raba, K.; Vay, C.; Vallboehmer, D.; Harreus, U.; Knoefel, W. T.; Stoecklein, N. H.; Gires, O.			Context-dependent adaption of EpCAM expression in early systemic esophageal cancer	ONCOGENE			English	Article						EpCAM; esophageal cancers; disseminated tumor cells	CELL ADHESION MOLECULE; DISSEMINATED TUMOR-CELLS; EP-CAM; CARCINOMA; MAINTENANCE; PHENOTYPE; HALLMARKS; TARGET; CD326	The role of the epithelial cell adhesion molecule EpCAM in cancer progression remains largely unclear. High expression of EpCAM in primary tumors is often associated with more aggressive phenotypes and EpCAM is the prime epithelial antigen in use to isolate circulating tumor cells (CTCs) and characterize disseminated tumor cells (DTCs). However, reduced expression of EpCAM was associated with epithelial-to-mesenchymal transition (EMT) and reports on a lack of EpCAM on CTCs emerged. These contradictory observations might reflect a context-dependent adaption of EpCAM expression during metastatic progression. To test this, EpCAM expression was monitored in esophageal cancer at different sites of early systemic disease. Although most of the primary esophageal tumors expressed high levels of EpCAM, the majority of DTCs in bone marrow lacked EpCAM. In vitro, downregulation of EpCAM expression at the plasma membrane was observed in migrating and invading cells, and was associated with a partial loss of the epithelial phenotype and with significantly decreased proliferation. Accordingly, induction of EMT through the action of TGF beta resulted in substantial loss of EpCAM cell surface expression on esophageal cancer cells. Knock-down or natural loss of EpCAM recapitulated these effects as it reduced proliferation while enhancing migration and invasion of cancer cells. Importantly, expression of EpCAM on DTCs was significantly associated with the occurrence of lymph node metastases and with significantly decreased overall survival of esophageal cancer patients. We validated this observation by showing that high expression of EpCAM promoted tumor outgrowth after xenotransplantation of esophageal carcinoma cells. The present data disclose a dynamic expression of EpCAM throughout tumor progression, where EpCAM(high) phenotypes correlate with proliferative stages, whereas EpCAM(low/negative) phenotypes associated with migration, invasion and dissemination. Thus, differing expression levels of EpCAM must be taken into consideration for therapeutic approaches and during clinical retrieval of disseminated tumor cells.	[Driemel, C.; Schumacher, S.; Wolters, J.; Lindenlauf, N.; Hoya, V.; Pietsch, J. M.; Panagiotidou, P.; Vay, C.; Vallboehmer, D.; Knoefel, W. T.; Stoecklein, N. H.] Univ Hosp, Dept Gen Visceral & Pediat Surg, Dusseldorf, Germany; [Driemel, C.; Schumacher, S.; Wolters, J.; Lindenlauf, N.; Baldus, S. A.; Hoya, V.; Pietsch, J. M.; Panagiotidou, P.; Raba, K.; Vay, C.; Vallboehmer, D.; Knoefel, W. T.; Stoecklein, N. H.] Univ Dusseldorf, Fac Med, Dusseldorf, Germany; [Kremling, H.; Will, D.; Mack, B.; Harreus, U.; Gires, O.] Univ Munich, Grosshadern Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, D-81377 Munich, Bavaria, Germany; [Baldus, S. A.] Univ Hosp, Inst Pathol, Dusseldorf, Germany; [Raba, K.] Univ Hosp, Inst Transplantat Diagnost & Cellular Therapy, Dusseldorf, Germany	Heinrich Heine University Dusseldorf; University of Munich	Gires, O (corresponding author), Univ Munich, Grosshadern Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Marchioninistr 15, D-81377 Munich, Bavaria, Germany.	Olivier.gires@med.uni-muenchen.de	Gires, Olivier/V-2689-2017; Raba, Katharina/B-8697-2017	Gires, Olivier/0000-0002-2292-7064; Raba, Katharina/0000-0001-8818-4219; Driemel, Christiane/0000-0001-9595-3768	Wilhelm-Sander-Stiftung [2009.083.1]; Deutsche Forschungsgemeinschaft (DFG) [STO464/2-2]; Rudolf-Bartling Stiftung [II/89]	Wilhelm-Sander-Stiftung; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Rudolf-Bartling Stiftung	This project was funded by The Wilhelm-Sander-Stiftung (2009.083.1), in part by the Deutsche Forschungsgemeinschaft (DFG STO464/2-2), the Rudolf-Bartling Stiftung (II/89). We thank Christof Seifarth for excellent technical support.	Alix-Panabieres C, 2008, CLIN CANCER RES, V14, P5013, DOI 10.1158/1078-0432.CCR-07-5125; Baeuerle PA, 2007, BRIT J CANCER, V96, P417, DOI 10.1038/sj.bjc.6603494; Bao B, 2011, J CELL BIOCHEM, V112, P2296, DOI 10.1002/jcb.23150; Biddle A, 2011, CANCER RES, V71, P5317, DOI 10.1158/0008-5472.CAN-11-1059; Chaves-Perez A, 2013, ONCOGENE, V32, P641, DOI 10.1038/onc.2012.75; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Floor SL, 2012, TRENDS MOL MED, V18, P509, DOI 10.1016/j.molmed.2012.06.005; Gonzalez B, 2009, STEM CELLS, V27, P1782, DOI 10.1002/stem.97; Gorges TM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-178; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Imrich S, 2012, CELL ADHES MIGR, V6, P30, DOI 10.4161/cam.18953; Kasai H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-56; Kimura H, 2007, INT J ONCOL, V30, P171; Klein CA, 2002, LANCET, V360, P683, DOI 10.1016/S0140-6736(02)09838-0; Klein CA, 2009, CANCER RES, V69, P5285, DOI 10.1158/0008-5472.CAN-08-4586; Litvinov SV, 1997, J CELL BIOL, V139, P1337, DOI 10.1083/jcb.139.5.1337; Lu TY, 2010, J BIOL CHEM, V285, P8719, DOI 10.1074/jbc.M109.077081; Maetzel D, 2009, NAT CELL BIOL, V11, P162, DOI 10.1038/ncb1824; Munz M, 2004, ONCOGENE, V23, P5748, DOI 10.1038/sj.onc.1207610; Munz M, 2009, CANCER RES, V69, P5627, DOI 10.1158/0008-5472.CAN-09-0654; Ng VY, 2010, STEM CELLS, V28, P29, DOI 10.1002/stem.221; Pantel K, 2008, NAT REV CANCER, V8, P329, DOI 10.1038/nrc2375; Patriarca C, 2012, CANCER TREAT REV, V38, P68, DOI 10.1016/j.ctrv.2011.04.002; Raffel A, 2010, EUR J ENDOCRINOL, V162, P391, DOI 10.1530/EJE-08-0916; Rao CG, 2005, INT J ONCOL, V27, P49; Sato M, 2006, CANCER RES, V66, P2116, DOI 10.1158/0008-5472.CAN-05-2521; Sleeman J, 2010, EUR J CANCER, V46, P1177, DOI 10.1016/j.ejca.2010.02.039; Songun I, 2005, BRIT J CANCER, V92, P1767, DOI 10.1038/sj.bjc.6602519; Stoecklein NH, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-165; Stoecklein NH, 2010, INT J CANCER, V126, P589, DOI 10.1002/ijc.24916; van der Gun BTF, 2010, CARCINOGENESIS, V31, P1913, DOI 10.1093/carcin/bgq187; Vannier C, 2013, J BIOL CHEM, V288, P18643, DOI 10.1074/jbc.M113.467787; Went P, 2006, BRIT J CANCER, V94, P128, DOI 10.1038/sj.bjc.6602924; Went PT, 2004, HUM PATHOL, V35, P122, DOI 10.1016/j.humpath.2003.08.026; Winter MJ, 2007, MOL CELL BIOCHEM, V302, P19, DOI 10.1007/s11010-007-9420-y	36	61	65	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2014	33	41					4904	4915		10.1038/onc.2013.441	http://dx.doi.org/10.1038/onc.2013.441			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OA	24141784				2022-12-28	WOS:000343767900003
J	Park, JY; Singh, TR; Nassar, N; Zhang, F; Freund, M; Hanenberg, H; Meetei, AR; Andreassen, PR				Park, J-Y; Singh, T. R.; Nassar, N.; Zhang, F.; Freund, M.; Hanenberg, H.; Meetei, A. R.; Andreassen, P. R.			Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair	ONCOGENE			English	Article						PALB2; RAD51C; BRCA2; homologous recombination; BRCA genes; DNA repair	HOMOLOGOUS RECOMBINATION REPAIR; CAUSE FANCONI-ANEMIA; SUSCEPTIBILITY GENE; GERMLINE MUTATIONS; CHROMOSOMAL BREAKS; PROTEIN COMPLEX; PATHWAY; XRCC3; IDENTIFICATION; DEFICIENCY	Heterozygous carriers of germ-line mutations in the BRCA2/FANCD1, PALB2/FANCN and RAD51C/FANCO DNA repair genes have an increased lifetime risk of developing breast, ovarian and other cancers; bi-allelic mutations in these genes clinically manifest as Fanconi anemia (FA). Here, we demonstrate that RAD51C is part of a novel protein complex that contains PALB2 and BRCA2. Further, the PALB2 WD40 domain can directly and independently bind RAD51C and BRCA2. To understand the role of these homologous recombination (HR) proteins in DNA repair, we functionally characterize effects of missense mutants of the PALB2 WD40 domain that have been reported in breast cancer patients. In contrast to large truncations of PALB2, which display a complete loss of interaction, the L939W, T1030I and L1143P missense mutants/variants of the PALB2 WD40 domain are associated with altered patterns of direct binding to the RAD51C, RAD51 and BRCA2 HR proteins in biochemical assays. Further, the T1030I missense mutant is unstable, whereas the L939W and L1143P proteins are stable but partially disrupt the PALB2-RAD51C-BRCA2 complex in cells. Functionally, the L939W and L1143P mutants display a decreased capacity for DNA double-strand break-induced HR and an increased cellular sensitivity to ionizing radiation. As further evidence for the functional importance of the HR complex, RAD51C mutants that are associated with cancer susceptibility and FA also display decreased complex formation with PALB2. Together, our results suggest that three different cancer susceptibility and FA proteins function in a DNA repair pathway based upon the PALB2 WD40 domain binding to RAD51C and BRCA2.	[Park, J-Y; Singh, T. R.; Nassar, N.; Zhang, F.; Meetei, A. R.; Andreassen, P. R.] Cincinnati Childrens Res Fdn, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA; [Nassar, N.; Meetei, A. R.; Andreassen, P. R.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Freund, M.; Hanenberg, H.] Univ Dusseldorf, Dept Otorhinolaryngol & Head Neck Surg, Sch Med, Dusseldorf, Germany; [Hanenberg, H.] Indiana Univ Sch Med, Riley Hosp, Dept Pediat, Unit Pediat Hematol Oncol,Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; [Hanenberg, H.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Heinrich Heine University Dusseldorf; Indiana University System; Indiana University Bloomington; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University Bloomington	Meetei, AR (corresponding author), Cincinnati Childrens Res Fdn, 3333 Burnet Ave ML S7-203, Cincinnati, OH 45229 USA.	Ruhikanta.Meetei@cchmc.org; Paul.Andreassen@cchmc.org	Nassar, Natasha/K-3918-2019	singh, thiyam/0000-0002-0441-6818	BMBF; NIH [R01 CA138237, CA155294, R01 HL084082, R01 HL085587]; NATIONAL CANCER INSTITUTE [R01CA138237, R01CA155294] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084082, R01HL085587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK090971] Funding Source: NIH RePORTER	BMBF(Federal Ministry of Education & Research (BMBF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are grateful to Dr Hans Joenje (Vrije Universiteit Medical Center), Dr Youngho Kim (Wonkwang University), Dr James Lessard (Cincinnati Children's Research Foundation), Dr Yoshihiro Nakatani (Dana-Farber Cancer Institute) and Drs Maria Jasin and Koji Nakanishi (Memorial Sloan-Kettering Cancer Center) for EUFA1341 fibroblasts, the human RAD51 cDNA, anti-actin antibodies, pOZ vectors, and U2OS-DR cells and pCBASce, respectively. This work was supported by the BMBF networks of 'Inherited bone marrow failure syndromes' and 'Foamyvirus-mediated genetic therapy for FNACA (FoneFA) and NIH R01 CA138237 and CA155294 (HH), NIH R01 HL084082 (ARM) and NIH R01 HL085587 (PRA).	Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; Adank MA, 2011, BREAST CANCER RES TR, V127, P357, DOI 10.1007/s10549-010-1001-1; Ali AM, 2012, BLOOD, V119, P3285, DOI 10.1182/blood-2011-10-385963; Andreassen PR, 2009, CURR CANCER DRUG TAR, V9, P101, DOI 10.2174/156800909787314011; Balia C, 2010, FAM CANCER, V9, P531, DOI 10.1007/s10689-010-9382-1; Bogdanova N, 2011, BREAST CANCER RES TR, V126, P545, DOI 10.1007/s10549-010-1290-4; Bogliolo M, 2013, AM J HUM GENET, V92, P800, DOI 10.1016/j.ajhg.2013.04.002; Buisson R, 2010, NAT STRUCT MOL BIOL, V17, P1247, DOI 10.1038/nsmb.1915; Carreira A, 2009, CELL, V136, P1032, DOI 10.1016/j.cell.2009.02.019; Casadei S, 2011, CANCER RES, V71, P2222, DOI 10.1158/0008-5472.CAN-10-3958; Catucci I, 2012, FAM CANCER, V11, P483, DOI 10.1007/s10689-012-9540-8; Chun J, 2013, MOL CELL BIOL, V33, P387, DOI 10.1128/MCB.00465-12; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Ding YC, 2011, BREAST CANCER RES TR, V126, P227, DOI 10.1007/s10549-010-1271-7; Dray E, 2010, NAT STRUCT MOL BIOL, V17, P1255, DOI 10.1038/nsmb.1916; Erkko H, 2007, NATURE, V446, P316, DOI 10.1038/nature05609; Hayakawa T, 2010, J CELL SCI, V123, P1124, DOI 10.1242/jcs.060178; Hellebrand H, 2011, HUM MUTAT, V32, pE2176, DOI 10.1002/humu.21478; Hofstatter EW, 2011, FAM CANCER, V10, P225, DOI 10.1007/s10689-011-9426-1; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Huang J, 2009, NAT CELL BIOL, V11, P592, DOI 10.1038/ncb1865; Kee Y, 2012, J CLIN INVEST, V122, P3799, DOI 10.1172/JCI58321; Lio YC, 2003, J BIOL CHEM, V278, P2469, DOI 10.1074/jbc.M211038200; Liu YL, 2007, J BIOL CHEM, V282, P1973, DOI 10.1074/jbc.M609066200; Makde RD, 2010, NATURE, V467, P562, DOI 10.1038/nature09321; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Meindl A, 2010, NAT GENET, V42, P410, DOI 10.1038/ng.569; Miller KA, 2004, NUCLEIC ACIDS RES, V32, P169, DOI 10.1093/nar/gkg925; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Oliver AW, 2009, EMBO REP, V10, P990, DOI 10.1038/embor.2009.126; Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959; Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Singh TR, 2010, MOL CELL, V37, P879, DOI 10.1016/j.molcel.2010.01.036; Somyajit K, 2012, J BIOL CHEM, V287, P3366, DOI 10.1074/jbc.M111.311241; Stark JM, 2002, J BIOL CHEM, V277, P20185, DOI 10.1074/jbc.M112132200; Stirnimann CU, 2010, TRENDS BIOCHEM SCI, V35, P565, DOI 10.1016/j.tibs.2010.04.003; Sy SMH, 2009, P NATL ACAD SCI USA, V106, P7155, DOI 10.1073/pnas.0811159106; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Tischkowitz M, 2007, P NATL ACAD SCI USA, V104, P6788, DOI 10.1073/pnas.0701724104; Tischkowitz M, 2012, HUM MUTAT, V33, P674, DOI 10.1002/humu.22022; Turnbull C, 2008, ANNU REV GENOM HUM G, V9, P321, DOI 10.1146/annurev.genom.9.081307.164339; Vaz F, 2010, NAT GENET, V42, P406, DOI 10.1038/ng.570; Vuorela M, 2011, BREAST CANCER RES TR, V130, P1003, DOI 10.1007/s10549-011-1677-x; Walsh T, 2007, CANCER CELL, V11, P103, DOI 10.1016/j.ccr.2007.01.010; Wilson JB, 2008, ONCOGENE, V27, P3641, DOI 10.1038/sj.onc.1211034; Wong MW, 2011, BREAST CANCER RES TR, V127, P853, DOI 10.1007/s10549-011-1443-0; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xia B, 2007, NAT GENET, V39, P159, DOI 10.1038/ng1942; Xia B, 2006, MOL CELL, V22, P719, DOI 10.1016/j.molcel.2006.05.022; Yoshihara T, 2004, EMBO J, V23, P670, DOI 10.1038/sj.emboj.7600087; Zhang F, 2009, MOL CANCER RES, V7, P1110, DOI 10.1158/1541-7786.MCR-09-0123; Zhang F, 2009, CURR BIOL, V19, P524, DOI 10.1016/j.cub.2009.02.018; Zheng YL, 2012, CANCER-AM CANCER SOC, V118, P1362, DOI 10.1002/cncr.26388	56	84	91	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2014	33	40					4803	4812		10.1038/onc.2013.421	http://dx.doi.org/10.1038/onc.2013.421			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0EH	24141787	Green Accepted, Green Submitted			2022-12-28	WOS:000343240100002
J	Wilson, IM; Vucic, EA; Enfield, KSS; Thu, KL; Zhang, YA; Chari, R; Lockwood, WW; Radulovich, N; Starczynowski, DT; Banath, JP; Zhang, M; Pusic, A; Fuller, M; Lonergan, KM; Rowbotham, D; Yee, J; English, JC; Buys, TPH; Selamat, SA; Laird-Offringa, IA; Liu, P; Anderson, M; You, M; Tsao, MS; Brown, CJ; Bennewith, KL; MacAulay, CE; Karsan, A; Gazdar, AF; Lam, S; Lam, WL				Wilson, I. M.; Vucic, E. A.; Enfield, K. S. S.; Thu, K. L.; Zhang, Y. A.; Chari, R.; Lockwood, W. W.; Radulovich, N.; Starczynowski, D. T.; Banath, J. P.; Zhang, M.; Pusic, A.; Fuller, M.; Lonergan, K. M.; Rowbotham, D.; Yee, J.; English, J. C.; Buys, T. P. H.; Selamat, S. A.; Laird-Offringa, I. A.; Liu, P.; Anderson, M.; You, M.; Tsao, M. S.; Brown, C. J.; Bennewith, K. L.; MacAulay, C. E.; Karsan, A.; Gazdar, A. F.; Lam, S.; Lam, W. L.			EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk	ONCOGENE			English	Article						EYA4; two hit; hypermethylation; tumor suppressor; TSG; non-small-cell lung cancer	GENE-EXPRESSION SIGNATURE; SUSCEPTIBILITY LOCUS; DNA METHYLATION; HISTONE H2AX; GENOME; SMOKING; ADENOCARCINOMA; DELETION; BRCA1	In an effort to identify novel biallelically inactivated tumor suppressor genes (TSGs) in sporadic invasive and preinvasive non-small-cell lung cancer (NSCLC) genomes, we applied a comprehensive integrated multiple 'omics' approach to investigate patient-matched, paired NSCLC tumor and non-malignant parenchymal tissues. By surveying lung tumor genomes for genes concomitantly inactivated within individual tumors by multiple mechanisms, and by the frequency of disruption in tumors across multiple cohorts, we have identified a putative lung cancer TSG, Eyes Absent 4 (EYA4). EYA4 is frequently and concomitantly deleted, hypermethylated and underexpressed in multiple independent lung tumor data sets, in both major NSCLC subtypes and in the earliest stages of lung cancer. We found that decreased EYA4 expression is not only associated with poor survival in sporadic lung cancers but also that EYA4 single-nucleotide polymorphisms are associated with increased familial cancer risk, consistent with EYA4s proximity to the previously reported lung cancer susceptibility locus on 6q. Functionally, we found that EYA4 displays TSG-like properties with a role in modulating apoptosis and DNA repair. Cross-examination of EYA4 expression across multiple tumor types suggests a cell-type-specific tumorigenic role for EYA4, consistent with a tumor suppressor function in cancers of epithelial origin. This work shows a clear role for EYA4 as a putative TSG in NSCLC.	[Wilson, I. M.; Vucic, E. A.; Enfield, K. S. S.; Thu, K. L.; Chari, R.; Lockwood, W. W.; Banath, J. P.; Zhang, M.; Pusic, A.; Fuller, M.; Lonergan, K. M.; Rowbotham, D.; Buys, T. P. H.; Bennewith, K. L.; MacAulay, C. E.; Karsan, A.; Lam, S.; Lam, W. L.] British Columbia Canc Res Ctr, Integrat Oncol Genet Unit, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada; [Zhang, Y. A.; Gazdar, A. F.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; [Chari, R.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA; [Lockwood, W. W.] NHGRI, Canc Genet Branch, Bethesda, MD 20892 USA; [Radulovich, N.; Tsao, M. S.] Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M4X 1K9, Canada; [Starczynowski, D. T.] Cincinnati Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol, Cincinnati, OH USA; [Yee, J.] Vancouver Gen Hosp, Dept Surg, Vancouver, BC, Canada; [English, J. C.] Vancouver Gen Hosp, Dept Pathol, Vancouver, BC V5Z 1M9, Canada; [Selamat, S. A.; Laird-Offringa, I. A.] Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA USA; [Liu, P.; Anderson, M.; You, M.] Med Coll Wisconsin, Ctr Canc, Milwaukee, WI 53226 USA; [Brown, C. J.] Univ British Columbia, Life Sci Ctr, Dept Med Genet, Vancouver, BC, Canada	British Columbia Cancer Agency; University of Texas System; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University of British Columbia; University of British Columbia; University of Southern California; Medical College of Wisconsin; University of British Columbia	Wilson, IM (corresponding author), British Columbia Canc Res Ctr, Integrat Oncol Genet Unit, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada.	iwilson@bccrc.ca	Brown, Carolyn J/A-5159-2014; Chari, Raj/G-3285-2019; Offringa, Ite/R-4101-2019; Karsan, Aly/K-2067-2015; Tsao, Ming Sound/AFQ-7332-2022; Tsao, Ming-Sound/M-3503-2017; MacAulay, Calum/K-1795-2016	Brown, Carolyn J/0000-0002-8959-0101; Tsao, Ming Sound/0000-0002-9160-5405; Selamat, Suhaida/0000-0002-7185-6995; Thu, Kelsie/0000-0001-9262-7238; Vucic, Emily/0000-0002-2728-8708; Fuller, Megan/0000-0002-8752-8312; MacAulay, Calum/0000-0003-4440-2792	Canadian Institutes of Health Research (CIHR) [MOP86731, MOP77903, MOP94867]; Canadian Cancer Society [CCS017076, CCS20485]; Terry Fox Foundation [20395]; NCI Early Detection Research Network [5U01 CA84971-10]; Canary Foundation; NIH Genetic Epidemiology of Lung Cancer Consortium [U01CA76293]; CIHR, Canada; Vanier Canada; NATIONAL CANCER INSTITUTE [U01CA084971, P50CA070907, U01CA076293] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000077] Funding Source: NIH RePORTER	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society(Canadian Cancer Society (CCS)); Terry Fox Foundation; NCI Early Detection Research Network(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Canary Foundation; NIH Genetic Epidemiology of Lung Cancer Consortium; CIHR, Canada(Canadian Institutes of Health Research (CIHR)); Vanier Canada; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank Miwa Suzuki, Denise McDougal, Chad Malloff and Bradley Coe for assistance. Grant supports were from Canadian Institutes of Health Research (CIHR MOP86731, MOP77903, MOP94867), Canadian Cancer Society (CCS017076, CCS20485); Terry Fox Foundation (20395); NCI Early Detection Research Network (5U01 CA84971-10), Canary Foundation, NIH Genetic Epidemiology of Lung Cancer Consortium (U01CA76293); and scholarships from CIHR (IMW, EAV, KSSE and WWL) and Vanier Canada (RC, KLT and NR).	Amos CI, 2010, CANCER RES, V70, P2359, DOI 10.1158/0008-5472.CAN-09-3096; Bailey-Wilson JE, 2004, AM J HUM GENET, V75, P460, DOI 10.1086/423857; Barrett T, 2009, NUCLEIC ACIDS RES, V37, pD885, DOI 10.1093/nar/gkn764; Bell DW, 2002, CANCER RES, V62, P2741; Bibikova M, 2009, EPIGENOMICS-UK, V1, P177, DOI [10.2217/epi.09.14, 10.2217/EPI.09.14]; Bijron JG, 2012, ENDOCR-RELAT CANCER, V19, P69, DOI 10.1530/ERC-11-0338; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522; Boelens MC, 2009, J PATHOL, V218, P182, DOI 10.1002/path.2520; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chitale D, 2009, ONCOGENE, V28, P2773, DOI 10.1038/onc.2009.135; Clark SW, 2002, J BIOL CHEM, V277, P3560, DOI 10.1074/jbc.M108410200; Coe BP, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq548; De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kim YH, 2011, ANN SURG ONCOL, V18, P2338, DOI 10.1245/s10434-011-1573-y; Kisiel JB, 2013, ALIMENT PHARM THER, V37, P546, DOI 10.1111/apt.12218; Kisiel JB, 2012, CANCER-AM CANCER SOC, V118, P2623, DOI 10.1002/cncr.26558; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Landi MT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001651; Liu PY, 2008, JNCI-J NATL CANCER I, V100, P1326, DOI 10.1093/jnci/djn268; Liu X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042725; Lockwood WW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037775; Lonergan KM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009162; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; MacPhail SH, 2003, INT J RADIAT BIOL, V79, P351, DOI 10.1080/0955300032000093128; Miller SJ, 2010, ONCOGENE, V29, P368, DOI 10.1038/onc.2009.360; Nagayama K, 2007, GENE CHROMOSOME CANC, V46, P1000, DOI 10.1002/gcc.20485; Okabe Y, 2009, NATURE, V460, P520, DOI 10.1038/nature08138; Olive PL, 2004, INT J RADIAT ONCOL, V58, P331, DOI 10.1016/j.ijrobp.2003.09.028; Osborn NK, 2006, CLIN GASTROENTEROL H, V4, P212, DOI 10.1016/j.cgh.2005.11.009; Oster B, 2011, INT J CANCER, V129, P2855, DOI 10.1002/ijc.25951; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; Sadatomi D, 2013, INT J MOL SCI, V14, P4596, DOI 10.3390/ijms14034596; Selamat SA, 2012, GENOME RES, V22, P1197, DOI 10.1101/gr.132662.111; Selamat SA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021443; SELLERS TA, 1990, J NATL CANCER I, V82, P1272, DOI 10.1093/jnci/82.15.1272; SELLERS TA, 1992, CANCER RES, V52, pS2694; Tessema M, 2008, CANCER RES, V68, P1707, DOI 10.1158/0008-5472.CAN-07-6325; Thu KL, 2014, ONCOGENE, V33, P279, DOI 10.1038/onc.2012.595; Thu KL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033003; Thu KL, 2011, J THORAC ONCOL, V6, P1521, DOI 10.1097/JTO.0b013e3182289479; Thusberg J, 2011, HUM MUTAT, V32, P358, DOI 10.1002/humu.21445; TOKUHATA GEORGE K., 1963, JOUR NATL CANCER INST, V30, P289; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; You M, 2009, CLIN CANCER RES, V15, P2666, DOI 10.1158/1078-0432.CCR-08-2335; Zhang X, 2002, J CLIN ENDOCR METAB, V87, P1262, DOI 10.1210/jc.87.3.1262; Zou HZ, 2005, CANCER EPIDEM BIOMAR, V14, P830, DOI 10.1158/1055-9965.EPI-04-0506	53	29	30	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2014	33	36					4464	4473		10.1038/onc.2013.396	http://dx.doi.org/10.1038/onc.2013.396			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MY	24096489	Green Accepted, Green Submitted			2022-12-28	WOS:000341158800002
J	Brighenti, E; Calabrese, C; Liguori, G; Giannone, FA; Trere, D; Montanaro, L; Derenzini, M				Brighenti, E.; Calabrese, C.; Liguori, G.; Giannone, F. A.; Trere, D.; Montanaro, L.; Derenzini, M.			Interleukin 6 downregulates p53 expression and activity by stimulating ribosome biogenesis: a new pathway connecting inflammation to cancer	ONCOGENE			English	Article						IL-6; ribosome biogenesis; p53; chronic inflammation; EMT; cancer	MULTIPLE-MYELOMA CELLS; C-MYC TRANSLATION; E-CADHERIN; HEPATOCELLULAR-CARCINOMA; LIVER INFLAMMATION; STAT3; ACTIVATION; IMMUNITY; IL-6; RNA	Chronic inflammation is an established risk factor for the onset of cancer, and the inflammatory cytokine IL-6 has a role in tumorigenesis by enhancing proliferation and hindering apoptosis. As factors stimulating proliferation also downregulate p53 expression by enhancing ribosome biogenesis, we hypothesized that IL-6 may cause similar changes in inflamed tissues, thus activating a mechanism that favors neoplastic transformation. Here, we showed that IL-6 downregulated the expression and activity of p53 in transformed and untransformed human cell lines. This was the consequence of IL-6-dependent stimulation of c-MYC mRNA translation, which was responsible for the upregulation of rRNA transcription. The enhanced rRNA transcription stimulated the MDM2-mediated proteasomal degradation of p53, by reducing the availability of ribosome proteins for MDM2 binding. The p53 downregulation induced the acquisition of cellular phenotypic changes characteristic of epithelial-mesenchymal transition, such as a reduced level of E-cadherin expression, increased cell invasiveness and a decreased response to cytotoxic stresses. We found that these changes also occurred in colon epithelial cells of patients with ulcerative colitis, a very representative example of chronic inflammation at high risk for tumor development. Histochemical and immunohistochemical analysis of colon biopsy samples showed an upregulation of ribosome biogenesis, a reduced expression of p53, together with a focal reduction or absence of E-cadherin expression in chronic colitis in comparison with normal mucosa samples. These changes disappeared after treatment with anti-inflammatory drugs. Taken together, the present results highlight a new mechanism that may link chronic inflammation to cancer, based on p53 downregulation, which is activated by the enhancement of rRNA transcription upon IL-6 exposure.	[Brighenti, E.; Trere, D.; Montanaro, L.; Derenzini, M.] Univ Bologna, Dept Expt Diagnost & Specialty Med, I-40138 Bologna, Italy; [Calabrese, C.; Liguori, G.; Giannone, F. A.] Univ Bologna, Dept Med & Surg Sci, I-40138 Bologna, Italy; [Giannone, F. A.] Azienda Osped Univ Bologna, Policlin S Orsola Malpighi, Biomed & Appl Res Ctr, Bologna, Italy	University of Bologna; University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna	Derenzini, M (corresponding author), Univ Bologna, Dept Expt Diagnost & Specialty Med, Via Massarenti 9, I-40138 Bologna, Italy.	massimo.derenzini@unibo.it	Trere', Davide/AAC-4725-2021; Montanaro, Lorenzo/I-4236-2019	Trere', Davide/0000-0003-1127-1052; Montanaro, Lorenzo/0000-0001-9776-9518; Calabrese, Carlo/0000-0003-3657-4463	Roberto and Cornelia Pallotti's Legacy; Vanini-Cavagnino Grant (Centro Interdipartimentale per le Ricerche sul Cancro, Bologna, Italy); Italian Ministry of Education, University and Research (MIUR); Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG13480]	Roberto and Cornelia Pallotti's Legacy; Vanini-Cavagnino Grant (Centro Interdipartimentale per le Ricerche sul Cancro, Bologna, Italy); Italian Ministry of Education, University and Research (MIUR); Associazione Italiana per la Ricerca sul Cancro (AIRC)	This work was supported by the Roberto and Cornelia Pallotti's Legacy for Cancer Research, the Vanini-Cavagnino Grant (Centro Interdipartimentale per le Ricerche sul Cancro, Bologna, Italy), the Italian Ministry of Education, University and Research (MIUR: grants for orientated fundamental research) and Associazione Italiana per la Ricerca sul Cancro (AIRC, grant no IG13480).	Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Deisenroth C, 2010, ONCOGENE, V29, P4253, DOI 10.1038/onc.2010.189; Derenzini M, 1998, AM J PATHOL, V152, P1291; Donati G, 2011, ONCOGENE, V30, P3274, DOI 10.1038/onc.2011.48; Faccioli S, 1996, MODERN PATHOL, V9, P120; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Kim S, 2008, CANCER RES, V68, P323, DOI 10.1158/0008-5472.CAN-07-2924; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; LENNARDJONES JE, 1989, SCAND J GASTROENTERO, V24, P2, DOI 10.3109/00365528909091339; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Moran DM, 2008, J SURG RES, V147, P23, DOI 10.1016/j.jss.2007.04.022; Nakagawa H, 2009, INT J CANCER, V125, P2264, DOI 10.1002/ijc.24720; Niu GL, 2005, MOL CELL BIOL, V25, P7432, DOI 10.1128/MCB.25.17.7432-7440.2005; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Risques RA, 2011, CANCER RES, V71, P1669, DOI 10.1158/0008-5472.CAN-10-1966; Rocchi L, 2013, NUCLEIC ACIDS RES, V41, P8308, DOI 10.1093/nar/gkt587; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Shi YJ, 2011, J BIOL CHEM, V286, P67, DOI 10.1074/jbc.M110.153221; Shi YJ, 2008, CANCER RES, V68, P10215, DOI 10.1158/0008-5472.CAN-08-1066; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Trere D, 2003, HEPATOLOGY, V37, P72, DOI 10.1053/jhep.2003.50039; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	35	71	74	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2014	33	35					4396	4406		10.1038/onc.2014.1	http://dx.doi.org/10.1038/onc.2014.1			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MR	24531714	Green Published, hybrid			2022-12-28	WOS:000341157800004
J	Lim, KS; Lim, KJ; Price, AC; Orr, BA; Eberhart, CG; Bar, EE				Lim, K. S.; Lim, K. J.; Price, A. C.; Orr, B. A.; Eberhart, C. G.; Bar, E. E.			Inhibition of monocarboxylate transporter-4 depletes stem-like glioblastoma cells and inhibits HIF transcriptional response in a lactate-independent manner	ONCOGENE			English	Article						hypoxia; monocarboxylate transporter-4; stem cells; glioma	HYPOXIA-INDUCIBLE FACTORS; MALIGNANT GLIOMA; LACTIC-ACID; OXYGEN; GROWTH; EXPRESSION; MCT4; ACTIVATION; EXPANSION; PATHWAY	Hypoxic regions are frequent in glioblastoma (GBM), the most common type of malignant adult brain tumor, and increased levels of tumor hypoxia have been associated with worse clinical outcomes. To unmask genes important in hypoxia, we treated GBM neurospheres in hypoxia and identified monocarboxylate transporter-4 (MCT4) as one of the most upregulated genes. To investigate the clinical importance of MCT4 in GBM, we examined clinical outcomes and found that MCT4 overexpression is associated with shorter patient survival. Consistent with this, MCT4 upregulation correlated with the aggressive mesenchymal subset of GBM, and MCT4 downregulation correlated with the less aggressive G-CIMP (Glioma CpG Methylator Phenotype) subset of GBM. Immunohistochemical analysis of tissue microarrays confirmed that MCT4 protein levels were increased in high-grade as compared with lower-grade astrocytomas, further suggesting that MCT4 is a clinically relevant target. To test the requirement for MCT4 in vitro, we transduced neurospheres with lentiviruses encoding short-hairpin RNAs (shRNAs) against MCT4, resulting in growth inhibition of 50-80% under hypoxia in two lines. MCT4 knockdown was associated with a decreased percentage of cells expressing the stem-cell marker CD133 and increased apoptotic fraction. We also found that flow-sorted CD133-positive cells had almost sixfold higher MCT4 levels than CD133-negative cells, suggesting that the stem-like population might have a greater requirement for MCT4. Most importantly, MCT4 silencing also slowed GBM intracranial xenograft growth in vivo. Interestingly, whereas MCT4 is a well-characterized lactate exporter, we found that both intracellular and extracellular lactate levels did not change following MCT4 silencing, suggesting a novel lactate export-independent mechanism for growth inhibition in GBMs. To identify this potential mechanism, we performed microarray analysis on control and shMCT4-expressing neurospheres and found a dramatic reduction in the expression of multiple Hypoxia-Inducible Factor (HIF)-regulated genes following MCT4 knockdown. The overall reduction in HIF transcriptional response was further validated using a hypoxia response element (HRE)dependent green-fluorescent protein (GFP) reporter line.	[Lim, K. S.; Lim, K. J.; Price, A. C.; Eberhart, C. G.; Bar, E. E.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Orr, B. A.] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; [Eberhart, C. G.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; [Eberhart, C. G.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Bar, E. E.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH 44106 USA	Johns Hopkins University; St Jude Children's Research Hospital; Johns Hopkins University; Johns Hopkins University; Case Western Reserve University	Bar, EE (corresponding author), Case Western Reserve Univ, Sch Med, Dept Neurol Surg, Robbins Bldg,Room E750A,10900 Euclid Ave, Cleveland, OH 44106 USA.	eli.bar@case.edu	Orr, Brent/N-8068-2018		Brain Tumor Funders Collaborative;  [R01 NS55089]; NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS055089] Funding Source: NIH RePORTER	Brain Tumor Funders Collaborative; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the Brain Tumor Funders Collaborative and R01 NS55089.	Bar EE, 2007, STEM CELLS, V25, P2524, DOI 10.1634/stemcells.2007-0166; Bar EE, 2011, BRAIN PATHOL, V21, P119, DOI 10.1111/j.1750-3639.2010.00460.x; Bar EE, 2010, AM J PATHOL, V177, P1491, DOI 10.2353/ajpath.2010.091021; Cheng C, 2012, CELL ONCOL, V35, P217, DOI 10.1007/s13402-012-0081-9; Chiche J, 2012, INT J CANCER, V130, P1511, DOI 10.1002/ijc.26125; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Colen CB, 2011, NEOPLASIA, V13, P620, DOI 10.1593/neo.11134; Collins PC, 1998, BIOTECHNOL PROGR, V14, P466, DOI 10.1021/bp980032e; Dimmer KS, 2000, BIOCHEM J, V350, P219, DOI 10.1042/0264-6021:3500219; Ehtesham M, 2007, ONCOGENE, V26, P5752, DOI 10.1038/sj.onc.1210359; Estrada JC, 2012, CELL DEATH DIFFER, V19, P743, DOI 10.1038/cdd.2011.172; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Fan X, 2010, STEM CELLS, V28, P5, DOI 10.1002/stem.254; Fang J, 2006, MOL PHARMACOL, V70, P2108, DOI 10.1124/mol.106.026245; Fox JEM, 2000, J PHYSIOL-LONDON, V529, P285, DOI 10.1111/j.1469-7793.2000.00285.x; Froberg MK, 2001, NEUROREPORT, V12, P761, DOI 10.1097/00001756-200103260-00030; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gong AH, 2012, CANCER RES, V72, P5658, DOI 10.1158/0008-5472.CAN-12-0953; Grabmaier K, 2004, ONCOGENE, V23, P5624, DOI 10.1038/sj.onc.1207764; Heddleston JM, 2010, BRIT J CANCER, V102, P789, DOI 10.1038/sj.bjc.6605551; Heddleston JM, 2009, CELL CYCLE, V8, P3274, DOI 10.4161/cc.8.20.9701; Hu YY, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-82; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; Kita Y, 2011, ANN SURG ONCOL, V18, P261, DOI 10.1245/s10434-010-1271-1; Kobayashi M, 2005, BIOL PHARM BULL, V28, P1197, DOI 10.1248/bpb.28.1197; Le Floch R, 2011, P NATL ACAD SCI USA, V108, P16663, DOI 10.1073/pnas.1106123108; Li KKW, 2009, HUM PATHOL, V40, P1234, DOI 10.1016/j.humpath.2009.02.003; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Lin Q, 2008, GENE REGUL SYST BIO, V2, P43; Mathupala SP, 2004, NEUROSURGERY, V55, P1410, DOI 10.1227/01.NEU.0000143034.62913.59; Miranda-Goncalves V, 2013, NEURO-ONCOLOGY, V15, P172, DOI 10.1093/neuonc/nos298; Pistollato F, 2007, MOL CELL NEUROSCI, V35, P424, DOI 10.1016/j.mcn.2007.04.003; Pistollato F, 2009, STEM CELLS, V27, P7, DOI 10.1634/stemcells.2008-0402; Purow BW, 2005, CANCER RES, V65, P2353, DOI 10.1158/0008-5472.CAN-04-1890; Schietke R, 2010, J BIOL CHEM, V285, P6658, DOI 10.1074/jbc.M109.042424; Seidel S, 2010, BRAIN, V133, P983, DOI 10.1093/brain/awq042; Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252; Stiehl DP, 2012, ONCOGENE, V31, P2283, DOI 10.1038/onc.2011.417; Szeto MD, 2009, CANCER RES, V69, P4502, DOI 10.1158/0008-5472.CAN-08-3884; Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vordermark D, 2001, NEOPLASIA, V3, P527, DOI 10.1038/sj.neo.7900192; Wang Q, 2013, MOL BIOL REP, V40, P3723, DOI 10.1007/s11033-012-2448-4; Westerman KA, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-96; Westfall SD, 2008, STEM CELLS DEV, V17, P869, DOI 10.1089/scd.2007.0240; Zhang KL, 2012, J NEUROIMMUNE PHARM, V7, P740, DOI 10.1007/s11481-012-9359-y; Zhang XP, 2008, MOL CELL BIOCHEM, V307, P101, DOI 10.1007/s11010-007-9589-0; Zhou YF, 2011, J BIOL CHEM, V286, P32843, DOI 10.1074/jbc.M111.260935; Zhu LL, 2011, CELL REPROGRAM, V13, P113, DOI 10.1089/cell.2010.0043	49	48	48	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2014	33	35					4433	4441		10.1038/onc.2013.390	http://dx.doi.org/10.1038/onc.2013.390			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MR	24077291	Green Accepted			2022-12-28	WOS:000341157800008
J	Macdonald, FH; Yao, D; Quinn, JA; Greenhalgh, DA				Macdonald, F. H.; Yao, D.; Quinn, J. A.; Greenhalgh, D. A.			PTEN ablation in Ras(Ha)/Fos skin carcinogenesis invokes p53-dependent p21 to delay conversion while p53-independent p21 limits progression via cyclin D1/E2 inhibition	ONCOGENE			English	Article						epidermis; transgenic; carcinogenesis; ras(Ha); fos; PTEN	UP-REGULATION; DNA-DAMAGE; TUMOR SUPPRESSION; CELL-CYCLE; MALIGNANT CONVERSION; GENE-EXPRESSION; FOS; P53; DIFFERENTIATION; P21(WAF1/CIP1)	To investigate tumour progression mechanism in transgenic mouse skin carcinogenesis, inducible PTEN ablation (Delta 5PTEN(flx)) was targeted to the epidermis of mice expressing activated ras(Ha)/fos oncogenes (HK1.ras and HK1.fos). RU486-treated HK1.ras/fos-Delta 5PTEN(flx) epidermis exhibited significant keratinocyte proliferation resulting in hyperplasia and proliferating cysts. While HK1.ras/fos-Delta 5PTEN(flx) papillomatogenesis was accelerated, malignant conversion was delayed and tumours exhibited well-differentiated squamous cell carcinoma (wdSCC) histotypes, suggesting inhibition of early-stage malignant progression. Immediate elevated p53/p21 expression was observed in HK1.ras/fos-Delta 5PTEN(flx) hyperplasia, cysts and papillomas, and while malignant conversion required p53 loss, elevated p21 expression persisted in most wdSCCs to limit further progression, unless p21 was also lost and wdSCC progressed to more aggressive carcinomas. In contrast, TPA-promoted (that is, c-fos-activated) bi-genic HK1.ras-Delta 5PTEN(flx) cohorts lost p53/p21 expression during early papillomatogenesis and rapidly produced poorly differentiated carcinomas (pdSCCs) with high BrdU-labelling and elevated cyclin D1/E2 expression levels, indicative of a progression mechanism driven by failures in cell-cycle control. Intriguingly, HK1.ras/fos-Delta 5PTEN(flx) wdSCCs did not exhibit similar failures, as western and immunofluorescence analysis found downregulated cyclin E2 whenever p21 persisted; further, while westerns detected elevated cyclin D1, immunofluorescence identified reduced expression in proliferative basal layer nuclei and a redistributed expression profile throughout p21-positive wdSCC keratinocytes. These data demonstrate that rapid early epidermal responses to ras(Ha)/fos/Delta PTEN co-operation involve induction of p53/p21 to alter differentiation and divert excessive proliferation into cyst formation. Further, despite three potent oncogenic insults p53 loss was required for malignant conversion, and following p53 loss persistent, p53-independent p21 expression possessed the potency to limit early-stage malignant progression via cyclin D1/E2 inhibition.	[Macdonald, F. H.; Yao, D.; Quinn, J. A.; Greenhalgh, D. A.] Univ Glasgow, Coll Med Vet & Life Sci, Sch Med Dent & Nursing, Dermatol Sect, Glasgow G11 6NU, Lanark, Scotland	University of Glasgow	Greenhalgh, DA (corresponding author), Univ Glasgow, Coll Med Vet & Life Sci, Sch Med Dent & Nursing, Dermatol Sect, Robertson Bldg Level 6,56 Dumbarton Rd, Glasgow G11 6NU, Lanark, Scotland.	david.greenhalgh@glasgow.ac.uk	Quinn, Jean/J-6440-2015	Quinn, Jean/0000-0002-8267-0993; Yao, Denggao/0000-0002-3031-126X	British Skin Foundation from Cancer Research UK [610, 3013, C1361/A2395]; Scott Endowment	British Skin Foundation from Cancer Research UK; Scott Endowment	We would like to thank Professor Hong Wu, Department of Molecular and Medical Pharmacology, UCLA, for the original gift of PTEN mice. Professor Dennis Roop, Center for Regenerative Medicine and Stem Cell Biology, Uiversity of Colorado, for the gift of K14.creP mice. Graham Chadwick for assistance with figure preparation; Dennis Duggan for assistance with animal husbandry and Ms Claire Gilbert for assistance with cyclin immunefluorescence analysis. This work was supported by: British Skin Foundation (Grants 610 & 3013), based on initial funding from Cancer Research UK (grant C1361/A2395) and the Scott Endowment to GU Dermatology.	Akli S, 2004, CANCER RES, V64, P3198, DOI 10.1158/0008-5472.CAN-03-3672; Barboza JA, 2006, P NATL ACAD SCI USA, V103, P19842, DOI 10.1073/pnas.0606343104; Berton TR, 2000, GENESIS, V26, P160, DOI 10.1002/(SICI)1526-968X(200002)26:2<160::AID-GENE20>3.0.CO;2-#; Birkbak NJ, 2011, CANCER RES, V71, P3447, DOI 10.1158/0008-5472.CAN-10-3667; Brown K, 1998, CURR BIOL, V8, P516, DOI 10.1016/S0960-9822(98)70203-9; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Devgan V, 2006, J BIOL CHEM, V281, P30463, DOI 10.1074/jbc.M604684200; Driessens G, 2012, NATURE, V488, P527, DOI 10.1038/nature11344; Fistarol SK, 2002, EUR J DERMATOL, V12, P411; Floor SL, 2012, TRENDS MOL MED, V18, P509, DOI 10.1016/j.molmed.2012.06.005; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Ghaffar SA, 2007, CLIN EXP DERMATOL, V32, P223, DOI 10.1111/j.1365-2230.2006.02303.x; Ghosh JC, 2005, CLIN CANCER RES, V11, P4580, DOI 10.1158/1078-0432.CCR-04-2624; GREENHALGH DA, 1993, CANCER RES, V53, P5071; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He G, 2006, BRIT J CANCER, V95, P1514, DOI 10.1038/sj.bjc.6603448; Hinds PW, 2006, MOL CELL, V22, P432, DOI 10.1016/j.molcel.2006.05.006; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Jirawatnotai S, 2012, CANCER RES, V72, P4289, DOI 10.1158/0008-5472.CAN-11-3549; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Koul D, 2007, MOL CELL BIOCHEM, V300, P77, DOI 10.1007/s11010-006-9371-8; Leong WF, 2009, MOL CANCER RES, V7, P354, DOI 10.1158/1541-7786.MCR-08-0373; Macias E, 2008, AM J PATHOL, V173, P526, DOI 10.2353/ajpath.2008.071124; Mao JH, 2004, GENE DEV, V18, P1800, DOI 10.1101/gad.1213804; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Mehic D, 2005, J INVEST DERMATOL, V124, P212, DOI 10.1111/j.0022-202X.2004.23558.x; Milde-Langosch K, 2000, INT J CANCER, V87, P468, DOI 10.1002/1097-0215(20000815)87:4<468::AID-IJC2>3.0.CO;2-R; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Ming M, 2011, CANCER RES, V71, P5287, DOI 10.1158/0008-5472.CAN-10-4614; Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008-5472.CAN-11-3132; Mulholland DJ, 2006, ONCOGENE, V25, P329, DOI 10.1038/sj.onc.1209020; Niemann C, 2002, DEVELOPMENT, V129, P95; Ohtani N, 2007, P NATL ACAD SCI USA, V104, P15034, DOI 10.1073/pnas.0706949104; Schlingemann J, 2003, INT J CANCER, V104, P699, DOI 10.1002/ijc.11008; Sprouffske K, 2011, CANCER PREV RES, V4, P1135, DOI 10.1158/1940-6207.CAPR-10-0374; Subauste MC, 2005, J BIOL CHEM, V280, P5676, DOI 10.1074/jbc.M405561200; Suzuki A, 2003, CANCER RES, V63, P674; Swanton C, 2012, CANCER RES, V72, P4875, DOI 10.1158/0008-5472.CAN-12-2217; Takeuchi S, 2010, CANCER RES, V70, P9381, DOI 10.1158/0008-5472.CAN-10-0801; Tibarewal P, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002138; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Torchia EC, 2012, ONCOGENE, V31, P2680, DOI 10.1038/onc.2011.441; Vasudevan KM, 2007, CANCER RES, V67, P10343, DOI 10.1158/0008-5472.CAN-07-1827; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; Warfel NA, 2013, CURR OPIN ONCOL, V25, P52, DOI 10.1097/CCO.0b013e32835b639e; Weinberg WC, 1999, CANCER RES, V59, P2050; Yao DG, 2008, J CELL SCI, V121, P1758, DOI 10.1242/jcs.021147; Yao DG, 2006, CANCER RES, V66, P1302, DOI 10.1158/0008-5472.CAN-05-2341; Yoo LI, 2006, CANCER RES, V66, P1929, DOI 10.1158/0008-5472.CAN-05-1986	52	10	10	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2014	33	32					4132	4143		10.1038/onc.2013.372	http://dx.doi.org/10.1038/onc.2013.372			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YK	24037529				2022-12-28	WOS:000340595700004
J	De Saedeleer, CJ; Porporato, PE; Copetti, T; Perez-Escuredo, J; Payen, VL; Brisson, L; Feron, O; Sonveaux, P				De Saedeleer, C. J.; Porporato, P. E.; Copetti, T.; Perez-Escuredo, J.; Payen, V. L.; Brisson, L.; Feron, O.; Sonveaux, P.			Glucose deprivation increases monocarboxylate transporter 1 (MCT1) expression and MCT1-dependent tumor cell migration	ONCOGENE			English	Article						monocarboxylate transporter 1 (MCT1); basigin; glucose metabolism; mitochondrial dysfunction; reactive oxygen species (ROS); tumor cell migration	MITOCHONDRIAL SUPEROXIDE; GLYCOLYTIC TUMORS; LACTIC-ACID; HYPOXIA; LACTATE; CD147; CANCER; METASTASIS; METABOLISM; PROGRESSION	The glycolytic end-product lactate is a pleiotropic tumor growth-promoting factor. Its activities primarily depend on its uptake, a process facilitated by the lactate-proton symporter monocarboxylate transporter 1 (MCT1). Therefore, targeting the transporter or its chaperon protein CD147/basigin, itself involved in the aggressive malignant phenotype, is an attractive therapeutic option for cancer, but basic information is still lacking regarding the regulation of the expression, interaction and activities of both proteins. In this study, we found that glucose deprivation dose-dependently upregulates MCT1 and CD147 protein expression and their interaction in oxidative tumor cells. While this posttranslational induction could be recapitulated using glycolysis inhibition, hypoxia, oxidative phosphorylation (OXPHOS) inhibitor rotenone or hydrogen peroxide, it was blocked with alternative oxidative substrates and specific antioxidants, pointing out at a mitochondrial control. Indeed, we found that the stabilization of MCT1 and CD147 proteins upon glucose removal depends on mitochondrial impairment and the associated generation of reactive oxygen species. When glucose was a limited resource (a situation occurring naturally or during the treatment of many tumors), MCT1-CD147 heterocomplexes accumulated, including in cell protrusions of the plasma membrane. It endowed oxidative tumor cells with increased migratory capacities towards glucose. Migration increased in cells overexpressing MCT1 and CD147, but it was inhibited in glucose-starved cells provided with an alternative oxidative fuel, treated with an antioxidant, lacking MCT1 expression, or submitted to pharmacological MCT1 inhibition. While our study identifies the mitochondrion as a glucose sensor promoting tumor cell migration, MCT1 is also revealed as a transducer of this response, providing a new rationale for the use of MCT1 inhibitors in cancer.	[De Saedeleer, C. J.; Porporato, P. E.; Copetti, T.; Perez-Escuredo, J.; Payen, V. L.; Brisson, L.; Feron, O.; Sonveaux, P.] Catholic Univ Louvain, Inst Rech Expt & Clin, Pole Pharmacol, B-1200 Brussels, Belgium	Universite Catholique Louvain	Sonveaux, P (corresponding author), Catholic Univ Louvain, Inst Rech Expt & Clin, Pole Pharmacol, Ave Emmanuel Mounier 53 Box B1-53-09, B-1200 Brussels, Belgium.	pierre.sonveaux@uclouvain.be	Brisson, Lucie/R-1179-2016; FERON, Olivier/AAM-6395-2020; Porporato, Paolo E./A-9932-2018	Brisson, Lucie/0000-0001-7811-1382; FERON, Olivier/0000-0001-5360-0286; Porporato, Paolo E./0000-0001-8519-1552; Sonveaux, Pierre/0000-0001-6484-8834	European Research Council (FP7); European Research Council Independent Researcher Starting Grant [243188]; Belgian Science Policy Office (Belspo) [UP7-03]; Communaute Francaise de Belgique [ARC 09/14-020]; Fondation Belge contre le Cancer; Fonds National de la Recherche Scientifique (FRS-FNRS); Fonds National de la Recherche Scientifique Medicale; Televie	European Research Council (FP7); European Research Council Independent Researcher Starting Grant; Belgian Science Policy Office (Belspo)(Belgian Federal Science Policy Office); Communaute Francaise de Belgique(Australian Research Council); Fondation Belge contre le Cancer; Fonds National de la Recherche Scientifique (FRS-FNRS)(Fonds de la Recherche Scientifique - FNRS); Fonds National de la Recherche Scientifique Medicale(Fonds de la Recherche Scientifique - FNRS); Televie	This work was supported by the European Research Council (FP7/2007-2013 European Research Council Independent Researcher Starting Grant No. 243188 TUMETABO to PS), Interuniversity Attraction Pole grant #UP7-03 from the Belgian Science Policy Office (Belspo), an Action de Recherche Concertee from the Communaute Francaise de Belgique (ARC 09/14-020 to PS and OF), the Fondation Belge contre le Cancer, the Fonds National de la Recherche Scientifique (FRS-FNRS), the Fonds National de la Recherche Scientifique Medicale, and the Televie. OF is a Honorary Research Director and PS is a Research Associate of the FRS-FNRS. CJD is a Televie Research Fellow. Funding bodies had no role in the design of the study, collection and analysis of data and decision to publish. The authors thank Prof Jacques Pouyssegur (University of Nice Sophia Antipolis, France) for the kind gift of the CD147 vector, and Elise Beneteau, Morgane Tardy, Fabien Rodriguez, Thibaut Vazeille and Floriane Ribeiro for excellent technical assistance. This paper is dedicated to the loving memory of Mrs Anne-Sophie Brouckaert, PharmD.	Asada K, 2003, ONCOLOGY-BASEL, V64, P380, DOI 10.1159/000070297; Birsoy K, 2013, NAT GENET, V45, P104, DOI 10.1038/ng.2471; Boidot R, 2012, CANCER RES, V72, P939, DOI 10.1158/0008-5472.CAN-11-2474; Cardaci S, 2012, CANCER RES, V72, P4526, DOI 10.1158/0008-5472.CAN-12-1741; Cheng C, 2012, CELL ONCOL, V35, P217, DOI 10.1007/s13402-012-0081-9; Dang CV, 2011, J MOL MED, V89, P205, DOI 10.1007/s00109-011-0730-x; De Bock K, 2011, NAT REV CLIN ONCOL, V8, P393, DOI 10.1038/nrclinonc.2011.83; De Saedeleer CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046571; Dhup S, 2012, CURR PHARM DESIGN, V18, P1319, DOI 10.2174/138161212799504902; Dikalova AE, 2010, CIRC RES, V107, P106, DOI 10.1161/CIRCRESAHA.109.214601; Dimmer KS, 2000, BIOCHEM J, V350, P219, DOI 10.1042/0264-6021:3500219; Eyster CA, 2009, TRAFFIC, V10, P590, DOI 10.1111/j.1600-0854.2009.00894.x; Ferretti AC, 2012, MOL GENET METAB, V105, P186, DOI 10.1016/j.ymgme.2011.11.007; Fox JEM, 2000, J PHYSIOL-LONDON, V529, P285, DOI 10.1111/j.1469-7793.2000.00285.x; Gallagher SM, 2009, AM J PHYSIOL-CELL PH, V296, pC414, DOI 10.1152/ajpcell.00430.2008; Halestrap AP, 2012, IUBMB LIFE, V64, P109, DOI 10.1002/iub.572; Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806; Iacono KT, 2007, EXP MOL PATHOL, V83, P283, DOI 10.1016/j.yexmp.2007.08.014; Izumi H, 2011, CANCER SCI, V102, P1007, DOI 10.1111/j.1349-7006.2011.01908.x; Jia L, 2008, CANCER INVEST, V26, P977, DOI 10.1080/07357900802072723; Ke X, 2012, CARCINOGENESIS, V33, P1598, DOI 10.1093/carcin/bgs196; Kennedy KM, 2010, FUTURE ONCOL, V6, P127, DOI [10.2217/fon.09.145, 10.2217/FON.09.145]; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; Le Floch R, 2011, P NATL ACAD SCI USA, V108, P16663, DOI 10.1073/pnas.1106123108; Lee GH, 2011, ONCOL LETT, V2, P831, DOI 10.3892/ol.2011.353; Li J, 2010, J DERMATOL SCI, V58, P204, DOI 10.1016/j.jdermsci.2010.03.022; Lu HS, 2002, J BIOL CHEM, V277, P23111, DOI 10.1074/jbc.M202487200; Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406; Merezhinskaya N, 2009, HISTOL HISTOPATHOL, V24, P243, DOI 10.14670/HH-24.243; Moon EJ, 2010, P NATL ACAD SCI USA, V107, P20477, DOI 10.1073/pnas.1006646107; Mukhopadhyay P, 2007, NAT PROTOC, V2, P2295, DOI 10.1038/nprot.2007.327; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Porporato PE, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00049; Rademakers SE, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-167; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; SCHEWE T, 1995, GEN PHARMACOL-VASC S, V26, P1153, DOI 10.1016/0306-3623(95)00003-J; Smith JK, 2012, PSYCHOL AESTHET CREA, V6, P1, DOI 10.1037/a0027241; Sonveaux P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033418; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Stock C, 2009, PFLUG ARCH EUR J PHY, V458, P981, DOI 10.1007/s00424-009-0677-8; Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200; Vegran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008-5472.CAN-10-2828; Walenta S, 2004, SEMIN RADIAT ONCOL, V14, P267, DOI 10.1016/j.semradonc.2004.04.004; Walenta S, 2001, INT J RADIAT ONCOL, V51, P840, DOI 10.1016/S0360-3016(01)01700-X; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Webb BA, 2011, NAT REV CANCER, V11, P671, DOI 10.1038/nrc3110; WU R, 1959, J BIOL CHEM, V234, P1036; Xu DS, 2005, MOL CELL PROTEOMICS, V4, P1061, DOI 10.1074/mcp.M400207-MCP200; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229	49	65	66	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2014	33	31					4060	4068		10.1038/onc.2013.454	http://dx.doi.org/10.1038/onc.2013.454			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YG	24166504	hybrid			2022-12-28	WOS:000340595300005
J	Than, BLN; Goos, JACM; Sarver, AL; O'Sullivan, MG; Rod, A; Starr, TK; Fijneman, RJA; Meijer, GA; Zhao, L; Zhang, Y; Largaespada, DA; Scott, PM; Cormier, RT				Than, B. L. N.; Goos, J. A. C. M.; Sarver, A. L.; O'Sullivan, M. G.; Rod, A.; Starr, T. K.; Fijneman, R. J. A.; Meijer, G. A.; Zhao, L.; Zhang, Y.; Largaespada, D. A.; Scott, P. M.; Cormier, R. T.			The role of KCNQ1 in mouse and human gastrointestinal cancers	ONCOGENE			English	Article						colorectal cancer; KCNQ1; tumor suppressor	GATED POTASSIUM CHANNELS; CYSTIC-FIBROSIS MOUSE; INTESTINAL TUMORIGENESIS; COLORECTAL-CANCER; TARGETED DISRUPTION; PHENOTYPIC ANALYSIS; MICE; SUSCEPTIBILITY; EXPRESSION; GENES	Kcnq1, which encodes for the pore-forming alpha-subunit of a voltage-gated potassium channel, was identified as a gastrointestinal (GI) tract cancer susceptibility gene in multiple Sleeping Beauty DNA transposon-based forward genetic screens in mice. To confirm that Kcnq1 has a functional role in GI tract cancer, we created Apc(Min) mice that carried a targeted deletion mutation in Kcnq1. Results demonstrated that Kcnq1 is a tumor suppressor gene as Kcnq1 mutant mice developed significantly more intestinal tumors, especially in the proximal small intestine and colon, and some of these tumors progressed to become aggressive adenocarcinomas. Gross tissue abnormalities were also observed in the rectum, pancreas and stomach. Colon organoid formation was significantly increased in organoids created from Kcnq1 mutant mice compared with wild-type littermate controls, suggesting a role for Kcnq1 in the regulation of the intestinal crypt stem cell compartment. To identify gene expression changes due to loss of Kcnq1, we carried out microarray studies in the colon and proximal small intestine. We identified altered genes involved in innate immune responses, goblet and Paneth cell function, ion channels, intestinal stem cells, epidermal growth factor receptor and other growth regulatory signaling pathways. We also found genes implicated in inflammation and in cellular detoxification. Pathway analysis using Ingenuity Pathway Analysis and Gene Set Enrichment Analysis confirmed the importance of these gene clusters and further identified significant overlap with genes regulated by MUC2 and CFTR, two important regulators of intestinal homeostasis. To investigate the role of KCNQ1 in human colorectal cancer (CRC), we measured protein levels of KCNQ1 by immunohistochemistry in tissue microarrays containing samples from CRC patients with liver metastases who had undergone hepatic resection. Results showed that low expression of KCNQ1 expression was significantly associated with poor overall survival.	[Than, B. L. N.; Rod, A.; Zhao, L.; Scott, P. M.; Cormier, R. T.] Univ Minnesota, Sch Med, Dept Biomed Sci, Duluth, MN 55812 USA; [Than, B. L. N.] Univ Minnesota, Toxicol Grad Program, Duluth, MN 55812 USA; [Goos, J. A. C. M.; Fijneman, R. J. A.; Meijer, G. A.] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands; [Sarver, A. L.] Univ Minnesota, Mason Canc Ctr, Dept Biostat & Informat, Minneapolis, MN USA; [O'Sullivan, M. G.] Univ Minnesota, Coll Vet Med, St Paul, MN 55108 USA; [Starr, T. K.] Univ Minnesota, Mason Canc Ctr, Ctr Genome Engn, Dept Genet Cell Biol & Dev, Minneapolis, MN USA; [Starr, T. K.; Largaespada, D. A.] Univ Minnesota, Mason Canc Ctr, Dept Obstet Gynecol & Womens Hlth, Duluth, MN 55812 USA; [Zhang, Y.] Univ Minnesota, Supercomp Inst, Minneapolis, MN USA	University of Minnesota System; University of Minnesota Duluth; University of Minnesota System; University of Minnesota Duluth; Vrije Universiteit Amsterdam; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Duluth; University of Minnesota System; University of Minnesota Twin Cities	Cormier, RT (corresponding author), Univ Minnesota, Sch Med, Dept Biomed Sci, 1035 Univ Dr,247 Med, Duluth, MN 55812 USA.	rcormier@d.umn.edu	Starr, Tim/AAX-9342-2021; Fijneman, Remond/X-4199-2019; goos, jeroen/AAL-8405-2020	Fijneman, Remond/0000-0003-2076-5521; Starr, Timothy/0000-0002-6308-3451; Meijer, Gerrit/0000-0003-0330-3130; Goos, Jeroen/0000-0003-2010-7377	Center for Translational Molecular Medicine, DeCoDe project grant [03O-101];  [NCI R01 CA134759-01A1];  [NCI R00 4R00CA151672-02]; NATIONAL CANCER INSTITUTE [P30CA077598, R01CA134759, R00CA151672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651] Funding Source: NIH RePORTER	Center for Translational Molecular Medicine, DeCoDe project grant; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Karl Pfeifer at the NIH for generously providing Kcnq1 mutant mice and reviewing the manuscript. Research was supported by a grant to RC and DL (NCI R01 CA134759-01A1) and to JG and RF (Center for Translational Molecular Medicine, DeCoDe project grant 03O-101) and to TKS (NCI R00 4R00CA151672-02).	Belt EJT, 2011, EUR J CANCER, V47, P1837, DOI 10.1016/j.ejca.2011.04.025; Burger-van Paassen N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038798; Casimiro MC, 2004, GENOMICS, V84, P555, DOI 10.1016/j.ygeno.2004.06.007; Casimiro MC, 2001, P NATL ACAD SCI USA, V98, P2526, DOI 10.1073/pnas.041398998; De Lisle RC, 2011, J PEDIATR GASTR NUTR, V53, P371, DOI 10.1097/MPG.0b013e318219c397; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Dedek K, 2001, PFLUG ARCH EUR J PHY, V442, P896, DOI 10.1007/s004240100609; Demolombe S, 2001, AM J PHYSIOL-CELL PH, V280, pC359, DOI 10.1152/ajpcell.2001.280.2.C359; Duerkop BA, 2009, IMMUNITY, V31, P368, DOI 10.1016/j.immuni.2009.08.009; Dziarski R, 2010, INNATE IMMUN-LONDON, V16, P168, DOI 10.1177/1753425910366059; Elso CM, 2004, HUM MOL GENET, V13, P2813, DOI 10.1093/hmg/ddh307; Fijneman RJA, 2012, CANCER SCI, V103, P593, DOI 10.1111/j.1349-7006.2011.02189.x; Fong Y, 1999, ANN SURG, V230, P309, DOI 10.1097/00000658-199909000-00004; Grahammer F, 2001, GASTROENTEROLOGY, V120, P1363, DOI 10.1053/gast.2001.24053; Hashimoto T, 2012, NATURE, V487, P477, DOI 10.1038/nature11228; Kang SJ, 2012, J IMMUNOL, V188, P1108, DOI 10.4049/jimmunol.1102084; Knobloch M, 2013, NATURE, V493, P226, DOI 10.1038/nature11689; Lang F, 2013, FASEB J, V27, P3, DOI 10.1096/fj.12-218230; Lee MP, 2000, J CLIN INVEST, V106, P1447, DOI 10.1172/JCI10897; Maisonneuve P, 2003, JNCI-J NATL CANCER I, V95, P381, DOI 10.1093/jnci/95.5.381; Mann KM, 2012, P NATL ACAD SCI USA, V109, P5934, DOI 10.1073/pnas.1202490109; March HN, 2011, NAT GENET, V43, P1202, DOI 10.1038/ng.990; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Nikou GC, 2011, INT J SURG, V9, P248, DOI 10.1016/j.ijsu.2010.12.003; Norkina O, 2004, AM J PHYSIOL-GASTR L, V286, pG1032, DOI 10.1152/ajpgi.00473.2003; Perez-Mancera PA, 2012, NATURE, V486, P266, DOI 10.1038/nature11114; Peroz D, 2008, J PHYSIOL-LONDON, V586, P1785, DOI 10.1113/jphysiol.2007.148254; Preston P, 2010, J BIOL CHEM, V285, P7165, DOI 10.1074/jbc.M109.047829; Rice KS, 2011, HEART RHYTHM, V8, P551, DOI 10.1016/j.hrthm.2010.11.039; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Shalapour S, 2010, EUR J IMMUNOL, V40, P2391, DOI 10.1002/eji.201040441; Simon R, 2004, BIOTECHNIQUES, V36, P98, DOI 10.2144/04361RV01; Starr TK, 2011, P NATL ACAD SCI USA, V108, P5765, DOI 10.1073/pnas.1018012108; Starr TK, 2009, SCIENCE, V323, P1747, DOI 10.1126/science.1163040; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takagi T, 2007, EXP ANIM TOKYO, V56, P295, DOI 10.1538/expanim.56.295; Unoki H, 2008, NAT GENET, V40, P1098, DOI 10.1038/ng.208; Vaishnava S, 2011, SCIENCE, V334, P255, DOI 10.1126/science.1209791; Vallon V, 2005, P NATL ACAD SCI USA, V102, P17864, DOI 10.1073/pnas.0505860102; Warth R, 2002, PFLUG ARCH EUR J PHY, V443, P822, DOI 10.1007/s00424-001-0751-3; Winbo A, 2012, CARDIOL YOUNG, V18, P1; Wulff H, 2009, NAT REV DRUG DISCOV, V8, P982, DOI 10.1038/nrd2983; Xiong QJ, 2008, TRENDS PHARMACOL SCI, V29, P99, DOI 10.1016/j.tips.2007.11.010; Yang K, 2008, CANCER RES, V68, P7313, DOI 10.1158/0008-5472.CAN-08-0598; Yasuda K, 2008, NAT GENET, V40, P1092, DOI 10.1038/ng.207; Zlobec I, 2007, J CLIN PATHOL, V60, P1112, DOI 10.1136/jcp.2006.044537	47	67	69	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3861	3868		10.1038/onc.2013.350	http://dx.doi.org/10.1038/onc.2013.350			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23975432	Green Accepted			2022-12-28	WOS:000339394100012
J	Lengyel, E; Burdette, JE; Kenny, HA; Matei, D; Pilrose, J; Haluska, P; Nephew, KP; Hales, DB; Stack, MS				Lengyel, E.; Burdette, J. E.; Kenny, H. A.; Matei, D.; Pilrose, J.; Haluska, P.; Nephew, K. P.; Hales, D. B.; Stack, M. S.			Epithelial ovarian cancer experimental models	ONCOGENE			English	Review						ovarian cancer; mouse model; cell lines; hen; organotypic models; metastasis	TYPE-1 MATRIX-METALLOPROTEINASE; GENE-EXPRESSION PATTERNS; IN-VITRO MODEL; MOUSE-MODEL; FALLOPIAN-TUBE; CELL-LINES; CARCINOMA CELLS; MESOTHELIAL CELLS; EXTRACELLULAR-MATRIX; MICROENVIRONMENTAL REGULATION	Epithelial ovarian cancer (OvCa) is associated with high mortality and, as the majority (> 75%) of women with OvCa have metastatic disease at the time of diagnosis, rates of survival have not changed appreciably over 30 years. A mechanistic understanding of OvCa initiation and progression is hindered by the complexity of genetic and/or environmental initiating events and lack of clarity regarding the cell(s) or tissue(s) of origin. Metastasis of OvCa involves direct extension or exfoliation of cells and cellular aggregates into the peritoneal cavity, survival of matrix-detached cells in a complex ascites fluid phase and subsequent adhesion to the mesothelium lining covering abdominal organs to establish secondary lesions containing host stromal and inflammatory components. Development of experimental models to recapitulate this unique mechanism of metastasis presents a remarkable scientific challenge, and many approaches used to study other solid tumors (for example, lung, colon and breast) are not transferable to OvCa research given the distinct metastasis pattern and unique tumor microenvironment (TME). This review will discuss recent progress in the development and refinement of experimental models to study OvCa. Novel cellular, three-dimensional organotypic, and ex vivo models are considered and the current in vivo models summarized. The review critically evaluates currently available genetic mouse models of OvCa, the emergence of xenopatients and the utility of the hen model to study OvCa prevention, tumorigenesis, metastasis and chemoresistance. As these new approaches more accurately recapitulate the complex TME, it is predicted that new opportunities for enhanced understanding of disease progression, metastasis and therapeutic response will emerge.	[Lengyel, E.; Kenny, H. A.] Univ Chicago, Dept Obstet & Gynecol, Gynecol Oncol Sect, Chicago, IL 60637 USA; [Burdette, J. E.] Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL USA; [Matei, D.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA; [Pilrose, J.; Nephew, K. P.] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Bloomington, IN USA; [Haluska, P.] Mayo Clin, Div Med Oncol, Rochester, MN USA; [Hales, D. B.] So Illinois Univ, Dept Physiol, Carbondale, IL 62901 USA; [Stack, M. S.] Univ Notre Dame, Dept Chem & Biochem, Harper Canc Res Inst, South Bend, IN USA	University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Mayo Clinic; Southern Illinois University System; Southern Illinois University; University of Notre Dame	Lengyel, E (corresponding author), Univ Chicago, Dept Obstet & Gynecol, 5841 South Maryland Ave,MC 2050, Chicago, IL 60637 USA.	elengyel@uchicago.edu; sstack@nd.edu	Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507; Matei, Daniela/0000-0003-2169-5035; Haluska, Paul/0000-0003-3283-4512	National Institutes of Health/National Cancer Institute Research [CA086984, CA109545, CA085289]; Integrative Cancer Biology Program [CA1113001]; Ovarian Cancer Research Fund (PPD/IU); NIH/National Center for Complementary and Alternative Medicine [AT00408, AT005295]; National Cancer Institute Award [CA133915]; American Institute for Cancer Research [06-A043]; Ovarian Cancer Research Fund (PPD/UofC) [NIH/NCI CA111882]; Ovarian Cancer Research Fund Liz Tilberis Ovarian Cancer Scholar Award (L/T UIC); American Cancer Society Illinois Division Research [RSG-12-230-01-TBG]; Department of Defense [OC110133]; Mayo Clinic SPORE in Ovarian Cancer [CA136393]; NATIONAL CANCER INSTITUTE [R01CA111882, R01CA109545, R01CA086984, R01CA085289, P50CA136393, R03CA133915, R01CA169604] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT005295] Funding Source: NIH RePORTER	National Institutes of Health/National Cancer Institute Research; Integrative Cancer Biology Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ovarian Cancer Research Fund (PPD/IU); NIH/National Center for Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Cancer Institute Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Institute for Cancer Research; Ovarian Cancer Research Fund (PPD/UofC); Ovarian Cancer Research Fund Liz Tilberis Ovarian Cancer Scholar Award (L/T UIC); American Cancer Society Illinois Division Research; Department of Defense(United States Department of Defense); Mayo Clinic SPORE in Ovarian Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The impetus for this collaborative compendium arose from the inaugural workshop of the Indiana-Illinois End Epithelial Ovarian Cancer Coalition (IIEEOC) held at the University of Notre Dame in 2012. The IIEEOCC Workshop was supported by the Harper Cancer Research Institute, the University of Notre Dame, the Indiana University Simon Cancer Center and the Indiana Clinical and Translational Sciences Institute. We gratefully acknowledge the lively and informative discussion contributed by all workshop participants. Funding for our work was provided by National Institutes of Health/National Cancer Institute Research Grants, CA086984 (MSS), CA109545 (MSS); CA085289 (KN), CA085289 (KN), the Integrative Cancer Biology Program CA1113001 (KN) and an Ovarian Cancer Research Fund (PPD/IU) to KN and DM; NIH/National Center for Complementary and Alternative Medicine grants AT00408 and AT005295 (BH); National Cancer Institute Award CA133915 (BH); American Institute for Cancer Research 06-A043 (BH); NIH/NCI CA111882 (EL) and an Ovarian Cancer Research Fund (PPD/UofC) to EL. JB was supported by the Ovarian Cancer Research Fund Liz Tilberis Ovarian Cancer Scholar Award (L/T UIC), the American Cancer Society Illinois Division Research Grant RSG-12-230-01-TBG and the Department of Defense OC110133. PH was supported by the Mayo Clinic SPORE in Ovarian Cancer-CA136393.	ADAMS AT, 1985, EXP CELL BIOL, V53, P181; Alfonso M, 2005, AVIAN DIS, V49, P430, DOI 10.1637/0005-2086(2005)49[430:MAITLO]2.0.CO;2; ALLEN HJ, 1987, EXP CELL BIOL, V55, P194; Ando H, 2000, HUM REPROD, V15, P1597, DOI 10.1093/humrep/15.7.1597; ANDREWS PA, 1985, CANCER RES, V45, P6250; Ansenberger K, 2010, GYNECOL ONCOL, V117, P341, DOI 10.1016/j.ygyno.2010.01.021; Ansenberger K, 2009, GYNECOL ONCOL, V113, P362, DOI 10.1016/j.ygyno.2009.02.011; Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Awadhiya R P, 1967, Indian Vet J, V44, P917; Bai F, 2006, INT J GYNECOL CANCER, V16, P202, DOI 10.1111/j.1525-1438.2006.00296.x; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Barbolina MV, 2007, J BIOL CHEM, V282, P4924, DOI 10.1074/jbc.M608428200; Barbolina MV, 2009, CANCER TREAT RES, V149, P319, DOI 10.1007/978-0-387-98094-2_15; Barker SD, 2001, GYNECOL ONCOL, V82, P57, DOI 10.1006/gyno.2001.6226; Barnes MN, 2002, GYNECOL ONCOL, V87, P57, DOI 10.1006/gyno.2002.6806; Barry CP, 2013, CANC PREV RES, V2, P114; Barua A, 2006, AACR INT C 2006; Barua A, 2010, J ULTRAS MED, V29, P173, DOI 10.7863/jum.2010.29.2.173; Barua A, 2009, INT J GYNECOL CANCER, V19, P500, DOI 10.1111/IGC.0b013e3181a39db1; Barua A, 2009, INT J GYNECOL CANCER, V19, P531, DOI 10.1111/IGC.0b013e3181a41613; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bijron JG, 2012, AACR ANN M; Bosquet JG, 2011, GYNECOL ONCOL, V120, P256, DOI 10.1016/j.ygyno.2010.10.030; BUICK RN, 1985, CANCER RES, V45, P3668; Burleson KM, 2004, CLIN EXP METASTAS, V21, P685, DOI 10.1007/s10585-004-5768-5; Burleson KM, 2004, GYNECOL ONCOL, V93, P170, DOI 10.1016/j.ygyno.2003.12.034; Burnside J, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-13; CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75; Carver DK, 2011, CANCER PREV RES, V4, P562, DOI 10.1158/1940-6207.CAPR-10-0294; CASAGRANDE JT, 1979, LANCET, V2, P170; Casey RC, 2003, CLIN EXP METASTAS, V20, P343, DOI 10.1023/A:1024009131191; Cheng LH, 2010, GYNECOL ONCOL, V117, P159, DOI 10.1016/j.ygyno.2010.01.041; Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108; Chodankar R, 2005, CURR BIOL, V15, P561, DOI 10.1016/j.cub.2005.01.052; Clark-Knowles KV, 2007, EXP CELL RES, V313, P133, DOI 10.1016/j.yexcr.2006.09.026; Clauss A, 2010, NEOPLASIA, V12, P161, DOI 10.1593/neo.91542; Connolly DC, 2003, CANCER RES, V63, P1389; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Drew AF, 2004, GYNECOL ONCOL, V95, P437, DOI 10.1016/j.ygyno.2004.08.032; Duan ZF, 1999, GENE, V229, P75, DOI 10.1016/S0378-1119(99)00042-6; Dunfield Lesley D., 2002, Biol Proced Online, V4, P55; Eilati E, 2012, PROSTAG LEUKOTR ESS, V87, P177, DOI 10.1016/j.plefa.2012.09.003; Elkas JC, 2002, GYNECOL ONCOL, V87, P200, DOI 10.1006/gyno.2002.6819; Evans CL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023434; Flesken-Nikitin A, 2003, CANCER RES, V63, P3459; FREDRICKSON TN, 1987, ENVIRON HEALTH PERSP, V73, P35, DOI 10.2307/3430596; FREEDMAN RS, 1978, CANCER, V42, P2352, DOI 10.1002/1097-0142(197811)42:5<2352::AID-CNCR2820420536>3.0.CO;2-#; FU XY, 1993, ANTICANCER RES, V13, P283; Garson K, 2012, J OVARIAN RES, V5, DOI 10.1186/1757-2215-5-39; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Gilead Assaf, 1999, Neoplasia (New York), V1, P226, DOI 10.1038/sj.neo.7900032; Giles JR, 2006, EXP BIOL MED, V231, P1718, DOI 10.1177/153537020623101108; Giles JR, 2010, INT J GYNECOL CANCER, V20, P738, DOI 10.1111/IGC.0b013e3181da2c49; Giles JR, 2004, GYNECOL ONCOL, V95, P530, DOI 10.1016/j.ygyno.2004.07.061; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GORAI I, 1995, GYNECOL ONCOL, V57, P33, DOI 10.1006/gyno.1995.1097; GREEN JA, 1984, CANCER RES, V44, P5427; Greenaway J, 2008, GYNECOL ONCOL, V108, P385, DOI 10.1016/j.ygyno.2007.10.035; Hales DB, 2008, ENDOCRINE, V33, P235, DOI 10.1007/s12020-008-9080-z; Hoekstra A, 2009, CANCER TREAT RES, V149, P3, DOI 10.1007/978-0-387-98094-2_1; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Hu L, 2010, BRIT J CANCER, V102, P1276, DOI 10.1038/sj.bjc.6605626; Hu LM, 2005, CLIN CANCER RES, V11, P6966, DOI 10.1158/1078-0432.CCR-05-0910; Hu LM, 2002, CANCER RES, V62, P1087; Hua WH, 1995, J STEROID BIOCHEM, V55, P279, DOI 10.1016/0960-0760(95)00187-5; Hudson LG, 2008, CLIN EXP METASTAS, V25, P643, DOI 10.1007/s10585-008-9171-5; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Iwanicki M, 2011, CANCER DISCOV, V2, pOF1, DOI Cancer Discov; Jackson E, 2007, GYNECOL ONCOL, V104, P192, DOI 10.1016/j.ygyno.2006.07.024; Jackson KS, 2009, ENDOCRINOLOGY, V150, P3921, DOI 10.1210/en.2008-1674; Johnson PA, 2013, NAT REV CANCER, V13, P432, DOI 10.1038/nrc3535; JOHNSON SW, 1994, CANCER RES, V54, P5911; JONES LMH, 1995, CLIN EXP METASTAS, V13, P373; KARLAN BY, 1994, GYNECOL ONCOL, V53, P70; Karst AM, 2012, NAT PROTOC, V7, P1755, DOI 10.1038/nprot.2012.097; Karst AM, 2011, P NATL ACAD SCI USA, V108, P7547, DOI 10.1073/pnas.1017300108; Kaur S, 2009, AM J PATHOL, V175, P2184, DOI 10.2353/ajpath.2009.090028; Kenny HA, 2008, J CLIN INVEST, V118, P1367, DOI 10.1172/JCI33775; Kenny HA, 2007, INT J CANCER, V121, P1463, DOI 10.1002/ijc.22874; Kenny HA, 2011, CANCER DISCOV, V1, P100, DOI 10.1158/2159-8290.CD-11-0117; Khabele D, 2012, INT J CLIN EXP PATHO, V5, P37; Khan SM, 2012, CLIN EXP METASTAS, V27, P185; Kim J, 2013, AACR ANN M 2013; Kim J, 2012, P NATL ACAD SCI USA, V109, P3921, DOI 10.1073/pnas.1117135109; King SM, 2011, JOVE-J VIS EXP, DOI 10.3791/2804; King SM, 2011, ENDOCR-RELAT CANCER, V18, P627, DOI 10.1530/ERC-11-0107; Kinross KM, 2012, J CLIN INVEST, V122, P553, DOI 10.1172/JCI59309; KISHIKAWA T, 1995, INVAS METAST, V15, P11; Klein OJ, 2012, MOL PHARMACEUT, V9, P3171, DOI 10.1021/mp300262x; Ko SY, 2012, J CLIN INVEST, V122, P3603, DOI 10.1172/JCI62229; Kong BW, 2008, ANIM GENET, V39, P180, DOI 10.1111/j.1365-2052.2008.01702.x; Korch C, 2012, GYNECOL ONCOL, V127, P241, DOI 10.1016/j.ygyno.2012.06.017; KRUK PA, 1990, LAB INVEST, V63, P132; Kuo KT, 2009, AM J PATHOL, V174, P1597, DOI 10.2353/ajpath.2009.081000; Landen CN, 2008, J CLIN ONCOL, V26, P995, DOI 10.1200/JCO.2006.07.9970; Landen CN, 2010, MOL CANCER THER, V9, P3186, DOI 10.1158/1535-7163.MCT-10-0563; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; LAU DHM, 1991, CANCER RES, V51, P5181; Laviolette LA, 2010, ENDOCRINOLOGY, V151, P929, DOI 10.1210/en.2009-0602; Lee CH, 2005, GYNECOL ONCOL, V96, P48, DOI 10.1016/j.ygyno.2004.09.025; Lessan K, 1999, AM J PATHOL, V154, P1525, DOI 10.1016/S0002-9440(10)65406-5; Levanon K, 2010, ONCOGENE, V29, P1103, DOI 10.1038/onc.2009.402; Li QH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019428; Li XY, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-60; Lin Ruei-Zhen, 2008, Biotechnology Journal, V3, P1172, DOI 10.1002/biot.200700228; Lorenzi PL, 2009, MOL CANCER THER, V8, P713, DOI 10.1158/1535-7163.MCT-08-0921; MAINESBANDIERA SL, 1992, AM J OBSTET GYNECOL, V167, P729, DOI 10.1016/S0002-9378(11)91579-8; McLean K, 2011, J CLIN INVEST, V121, P3206, DOI 10.1172/JCI45273; MIYAJIMA Y, 1995, ANN OTO RHINOL LARYN, V104, P678, DOI 10.1177/000348949510400902; Miyoshi I, 2002, MOL REPROD DEV, V63, P168, DOI 10.1002/mrd.10175; Moss NM, 2009, CANCER RES, V69, P7121, DOI 10.1158/0008-5472.CAN-08-4151; Mullany LK, 2011, ONCOGENE, V30, P3522, DOI 10.1038/onc.2011.70; Mullen P, 1996, INT J CANCER, V67, P816, DOI 10.1002/(SICI)1097-0215(19960917)67:6<816::AID-IJC10>3.0.CO;2-#; Nature, 2004, FOC CHICK GEN 2004; NCBI, 2013, GALL GALL CHICK GEN; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; NIEDBALA MJ, 1985, EXP CELL RES, V160, P499, DOI 10.1016/0014-4827(85)90197-1; NIEDBALA MJ, 1987, CLIN EXP METASTAS, V5, P181, DOI 10.1007/BF00058063; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; PAPASOLOMONTOS PA, 1969, VET REC, V85, P459, DOI 10.1136/vr.84.17.459; Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000; Pommier Y, 2013, CELLMINER 2013; Provencher DM, 2000, IN VITRO CELL DEV-AN, V36, P357; Quinn BA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008404; Rieppi M, 1999, INT J CANCER, V80, P303, DOI 10.1002/(SICI)1097-0215(19990118)80:2<303::AID-IJC21>3.3.CO;2-N; Roberts PC, 2005, NEOPLASIA, V7, P944, DOI 10.1593/neo.05358; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Rodriguez-Burford C, 2001, GYNECOL ONCOL, V81, P373, DOI 10.1006/gyno.2001.6191; Romero IL, 2009, CANCER PREV RES, V2, P792, DOI 10.1158/1940-6207.CAPR-08-0236; RUNNEBAUM IB, 1994, FEBS LETT, V353, P29, DOI 10.1016/0014-5793(94)00953-8; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; Sawada K, 2007, CANCER RES, V67, P1670, DOI 10.1158/0008-5472.CAN-06-1147; SAWADA M, 1994, LAB INVEST, V70, P333; SELBY PJ, 1980, BRIT J CANCER, V41, P52, DOI 10.1038/bjc.1980.7; Shao MH, 2009, CANCER RES, V69, P9192, DOI 10.1158/0008-5472.CAN-09-1257; Shepherd TG, 2006, NAT PROTOC, V1, P2643, DOI 10.1038/nprot.2006.328; SIMON WE, 1983, J NATL CANCER I, V70, P839; Stakleff KDS, 2005, INT J GYNECOL CANCER, V15, P246; Stewart C Allison, 2012, Results Probl Cell Differ, V55, P247, DOI 10.1007/978-3-642-30406-4_14; Suzuki N, 2004, GYNECOL ONCOL, V95, P290, DOI 10.1016/j.ygyno.2004.06.024; Symowicz J, 2007, CANCER RES, V67, P2030, DOI 10.1158/0008-5472.CAN-06-2808; Szabova L, 2012, CANCER RES, V72, P4141, DOI 10.1158/0008-5472.CAN-11-3834; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Trevino LS, 2012, CANCER PREV RES, V5, P343, DOI 10.1158/1940-6207.CAPR-11-0344; Trevino Lindsey S., 2010, Hormones & Cancer, V1, P177, DOI 10.1007/s12672-010-0024-8; Tseng CL, 2013, J BIOMATER APPL, V27, P1055, DOI 10.1177/0885328211434089; Urick ME, 2009, GYNECOL ONCOL, V112, P166, DOI 10.1016/j.ygyno.2008.09.032; VANDENBERGBAKKER CAM, 1993, INT J CANCER, V53, P613, DOI 10.1002/ijc.2910530415; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Weroha SJ, 2013, ANN ONCOL, V24, P16; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wilson AP, 1996, BRIT J CANCER, V74, P722, DOI 10.1038/bjc.1996.428; Wu R, 2007, CANCER CELL, V11, P321, DOI 10.1016/j.ccr.2007.02.016; Wu R, 2013, AM J PATHOL, V182, P1391, DOI 10.1016/j.ajpath.2012.12.031; Xing DY, 2006, CANCER RES, V66, P8949, DOI 10.1158/0008-5472.CAN-06-1495; Xing DY, 2005, P NATL ACAD SCI USA, V102, P6936, DOI 10.1073/pnas.0502256102; Xu Y, 1999, GYNECOL ONCOL, V72, P161, DOI 10.1006/gyno.1998.5238; Yip KW, 2006, MOL CANCER THER, V5, P2234, DOI 10.1158/1535-7163.MCT-06-0134; Yu D, 1992, CANCER RES, V53, P891; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364; Zietarska M, 2007, MOL CARCINOGEN, V46, P872, DOI 10.1002/mc.20315	163	138	142	1	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3619	3633		10.1038/onc.2013.321	http://dx.doi.org/10.1038/onc.2013.321			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23934194	Green Submitted, Green Accepted			2022-12-28	WOS:000338942900001
J	Bi, X; Feng, D; Korczeniewska, J; Alper, N; Hu, G; Barnes, BJ				Bi, X.; Feng, D.; Korczeniewska, J.; Alper, N.; Hu, G.; Barnes, B. J.			Deletion of Irf5 protects hematopoietic stem cells from DNA damage-induced apoptosis and suppresses gamma-irradiation-induced thymic lymphomagenesis	ONCOGENE			English	Article						IRF5; thymic lymphoma; gamma-irradiation; apoptosis; stem cells	INTERFERON REGULATORY FACTOR; PRISTANE-INDUCED LUPUS; TUMOR-SUPPRESSOR; GENE-EXPRESSION; IRF5(-/-) MICE; PUMA; P53; DEATH; INDUCTION; TUMORIGENESIS	Repeated low-dose gamma-irradiation (IR) induces thymic lymphoma in mice because of oncogenic mutations propagating from a primitive hematopoietic stem/progenitor cell (HSC) in the bone marrow. It is well known that IR-induced thymic lymphomagenesis is markedly enhanced by p53 deficiency, yet data also indicate that p53-dependent apoptosis can actively drive tumor formation in this model. The latter was recently expounded on by findings from Puma-deficient mice, indicating that loss of this proapoptotic p53 target gene results in protection from IR-induced lymphomagenesis rather than enhanced susceptibility to. Similar to Puma, the transcription factor interferon regulatory factor 5 (Irf5) has been reported as a p53 target gene and is required for DNA damage-induced apoptosis. To date, no studies have been performed to elucidate the in vivo role of IRF5 in tumorigenesis. Given its essential role in DNA damage-induced apoptosis, we explored the tumor suppressor function of IRF5 in IR-induced thymic lymphomagenesis. Somewhat surprisingly, we found that thymic lymphoma development was significantly suppressed in Irf5(-/-) mice as compared with wild-type littermates. Suppression was due, in part, to reduced thymocyte and HSC apoptosis, resulting in reduced compensatory proliferation, and reduced replication stress-associated DNA damage. The observed effects were independent of p53 or Puma as these proteins were upregulated in Irf5(-/-) mice in response to IR. This study demonstrates an important new role for IRF5 in maintaining HSC homeostasis after IR and supports the non-redundant functions of IRF5, p53 and PUMA in DNA damage-induced lymphomagenesis. We propose that IRF5 may be an attractive target for developing therapeutic agents to ameliorate radiation-induced bone marrow injury.	[Bi, X.; Feng, D.; Korczeniewska, J.; Barnes, B. J.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; [Bi, X.; Feng, D.; Korczeniewska, J.; Alper, N.; Hu, G.; Barnes, B. J.] Univ Med & Dent New Jersey, New Jersey Med Sch, Univ Hosp, Ctr Canc, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Barnes, BJ (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Univ Hosp,Canc Ctr, G1224,205 South Orange Ave, Newark, NJ 07103 USA.	barnesbe@umdnj.edu			New Jersey Medical School-University Hospital Cancer Center; UMDNJ Foundation; New Jersey Commission on Cancer Research (NJCCR)	New Jersey Medical School-University Hospital Cancer Center; UMDNJ Foundation; New Jersey Commission on Cancer Research (NJCCR)	We gratefully acknowledge Dr David Lagunoff for pathology assistance and Dr Lisong Yang for technical assistance. This work was supported in part by funds from the New Jersey Medical School-University Hospital Cancer Center, the UMDNJ Foundation and the New Jersey Commission on Cancer Research (NJCCR).	Barnes BJ, 2003, CANCER RES, V63, P6424; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Bi XH, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3053; Botcheva K, 2011, CELL CYCLE, V10, P4237, DOI 10.4161/cc.10.24.18383; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Erlacher M, 2006, J EXP MED, V203, P2939, DOI 10.1084/jem.20061552; Feng D, 2012, EUR J IMMUNOL, V42, P1477, DOI 10.1002/eji.201141642; Feng D, 2010, J IMMUNOL, V185, P6003, DOI 10.4049/jimmunol.1000482; Fresquet V, 2012, BRIT J HAEMATOL, V158, P712, DOI 10.1111/j.1365-2141.2012.09226.x; Garrison SP, 2008, MOL CELL BIOL, V28, P5391, DOI 10.1128/MCB.00907-07; Hu GD, 2005, CANCER RES, V65, P7403, DOI 10.1158/0008-5472.CAN-05-0583; Hu GD, 2009, J BIOL CHEM, V284, P2767, DOI 10.1074/jbc.M804744200; KAPLAN HENRY S., 1964, NAT CANCER INST MONOGR, V14, P207; KAPLAN HS, 1952, J NATL CANCER I, V13, P185; Kelly PN, 2010, CELL DEATH DIFFER, V17, P1655, DOI 10.1038/cdd.2010.43; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Kim HJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011439; Kominami R, 2006, CANCER SCI, V97, P575, DOI 10.1111/j.1349-7006.2006.00218.x; Labi V, 2010, GENE DEV, V24, P1602, DOI 10.1101/gad.1940210; Liu C, 2011, LEUKEMIA, V25, P1516, DOI 10.1038/leu.2011.113; MAUCH P, 1995, INT J RADIAT ONCOL, V31, P1319, DOI 10.1016/0360-3016(94)00430-S; Michalak EM, 2008, CELL DEATH DIFFER, V15, P1019, DOI 10.1038/cdd.2008.16; Michalak EM, 2009, CELL DEATH DIFFER, V16, P684, DOI 10.1038/cdd.2008.195; Michalak EM, 2010, GENE DEV, V24, P1608, DOI 10.1101/gad.1940110; Mori T, 2002, ONCOGENE, V21, P2914, DOI 10.1038/sj.onc.1205459; Nikulenkov F, 2012, CELL DEATH DIFFER, V19, P1992, DOI 10.1038/cdd.2012.89; Purtha WE, 2012, P NATL ACAD SCI USA, V109, pE898, DOI 10.1073/pnas.1118155109; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Schoenemeyer A, 2005, J BIOL CHEM, V280, P17005, DOI 10.1074/jbc.M412584200; Stankovic T, 2004, BLOOD, V103, P291, DOI 10.1182/blood-2003-04-1161; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wang Y, 2006, BLOOD, V107, P358, DOI 10.1182/blood-2005-04-1418; Watkins AJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044997; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029; Xu DS, 2011, J BIOL CHEM, V286, P18261, DOI 10.1074/jbc.M110.210542; Yanai H, 2007, P NATL ACAD SCI USA, V104, P3402, DOI 10.1073/pnas.0611559104; Yang LS, 2012, J IMMUNOL, V189, P3741, DOI 10.4049/jimmunol.1201162; Yang L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005500; Yu H, 2010, BLOOD, V115, P3472, DOI 10.1182/blood-2009-10-248278	40	11	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3288	3297		10.1038/onc.2013.295	http://dx.doi.org/10.1038/onc.2013.295			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23912454				2022-12-28	WOS:000338443400008
J	Nopparat, J; Zhang, J; Lu, JP; Chen, YH; Zheng, D; Neufer, PD; Fan, JM; Hong, H; Boykin, C; Lu, Q				Nopparat, J.; Zhang, J.; Lu, J-P; Chen, Y-H; Zheng, D.; Neufer, P. D.; Fan, J. M.; Hong, H.; Boykin, C.; Lu, Q.			delta-Catenin, a Wnt/beta-catenin modulator, reveals inducible mutagenesis promoting cancer cell survival adaptation and metabolic reprogramming	ONCOGENE			English	Article							E-CADHERIN; ARMADILLO PROTEIN; PROSTATE; MEMBER; KAISO; GENE; MORPHOGENESIS; P190RHOGEF; EXPRESSION; MUTATIONS	Mutations of Wnt/beta-catenin signaling pathway has essential roles in development and cancer. Although beta-catenin and adenomatous polyposis coli (APC) gene mutations are well established and are known to drive tumorigenesis, discoveries of mutations in other components of the pathway lagged, which hinders the understanding of cancer mechanisms. Here we report that delta-catenin (gene designation: CTNND2), a primarily neural member of the beta-catenin superfamily that promotes canonical Wnt/beta-catenin/LEF-1-mediated transcription, displays exonic mutations in human prostate cancer and promotes cancer cell survival adaptation and metabolic reprogramming. When overexpressed in cells derived from prostate tumor xenografts, delta-catenin gene invariably gives rise to mutations, leading to sequence disruptions predicting functional alterations. Ectopic delta-catenin gene integrating into host chromosomes is locus nonselective. delta-Catenin mutations promote tumor development in mouse prostate with probasin promoter (ARR(2)PB)-driven, prostate-specific expression of Myc oncogene, whereas mutant cells empower survival advantage upon overgrowth and glucose deprivation. Reprogramming energy utilization accompanies the downregulation of glucose transporter-1 and poly (ADP-ribose) polymerase cleavage while preserving tumor type 2 pyruvate kinase expression. delta-Catenin mutations increase beta-catenin translocation to the nucleus and hypoxia-inducible factor 1 alpha (HIF-1 alpha) expression. Therefore, introducing delta-catenin mutations is an important milestone in prostate cancer metabolic adaptation by modulating beta-catenin and HIF-1 alpha signaling under glucose shortage to amplify its tumor-promoting potential.	[Nopparat, J.; Zhang, J.; Lu, J-P; Fan, J. M.; Boykin, C.; Lu, Q.] E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27834 USA; [Lu, J-P] Zhejiang Univ, Coll Life Sci, Hangzhou 310003, Zhejiang, Peoples R China; [Chen, Y-H; Lu, Q.] E Carolina Univ, Brody Sch Med, Leo Jenkins Canc Ctr, Greenville, NC 27834 USA; [Chen, Y-H; Lu, Q.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Zheng, D.; Neufer, P. D.] E Carolina Univ, Dept Kinesiol, Greenville, NC 27834 USA; [Zheng, D.; Neufer, P. D.] E Carolina Univ, East Carolina Diabet & Obes Inst, Greenville, NC 27834 USA; [Neufer, P. D.] E Carolina Univ, Brody Sch Med, Dept Physiol, Greenville, NC 27834 USA; [Hong, H.] E Carolina Univ, Brody Sch Med, Dept Pathol & Lab Med, Greenville, NC 27834 USA	University of North Carolina; East Carolina University; Zhejiang University; University of North Carolina; East Carolina University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University	Lu, Q (corresponding author), E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, 7N72A Brody Sci Bldg,600 Moye Blvd, Greenville, NC 27834 USA.	luq@ecu.edu	Nopparat, Jongdee/AAX-1690-2020; Lu, Jianping/AFL-6811-2022	Nopparat, Jongdee/0000-0003-3532-1405; Lu, Jianping/0000-0001-9601-0040	DOD [PC040569]; NIH [CA111891, CA165202, ES016888, DK073488, DK074825]; NATIONAL CANCER INSTITUTE [R01CA111891, R15CA165202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK096907, R01DK073488, R01DK074825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R03ES016888] Funding Source: NIH RePORTER	DOD(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Joani Zary Oswald for technical assistance. This work was supported, in part, by DOD Grant PC040569 (to QL), NIH Grants CA111891 and CA165202 (to QL), ES016888 (to Y-HC) and DK073488 and DK074825 (to PDN).	Bareiss S, 2010, J NEUROSCI RES, V88, P2350, DOI 10.1002/jnr.22414; Baum C, 2004, MOL THER, V9, P5, DOI 10.1016/j.ymthe.2003.10.013; Burger MJ, 2002, INT J CANCER, V100, P228, DOI 10.1002/ijc.10468; Dai SD, 2011, CANCER SCI, V102, P95, DOI 10.1111/j.1349-7006.2010.01766.x; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Deng W, 2003, CYTOM PART A, V51A, P46, DOI 10.1002/cyto.a.10004; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Fang Y, 2004, J CANCER RES CLIN, V138, P1769; Gu DM, 2009, J CELL SCI, V122, P4049, DOI 10.1242/jcs.031948; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hirsch D, 2013, CANCER RES, V73, P1454, DOI 10.1158/0008-5472.CAN-12-0928; Huang XT, 2007, GENES GENET SYST, V82, P257, DOI 10.1266/ggs.82.257; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Israely I, 2004, CURR BIOL, V14, P1657, DOI 10.1016/j.cub.2004.08.065; Jun G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043728; Kim H, 2008, J BIOL CHEM, V283, P977, DOI 10.1074/jbc.M707158200; Kim H, 2012, BBA-MOL BASIS DIS, V1822, P509, DOI 10.1016/j.bbadis.2011.12.015; Kim H, 2008, BIOCHEM BIOPH RES CO, V377, P636, DOI 10.1016/j.bbrc.2008.10.030; Kim JS, 2006, BIOCHEM BIOPH RES CO, V351, P903, DOI 10.1016/j.bbrc.2006.10.135; Kim K, 2002, EXP CELL RES, V275, P171, DOI 10.1006/excr.2002.5503; Kim SW, 2004, NAT CELL BIOL, V6, P1212, DOI 10.1038/ncb1191; Kouchi Z, 2009, J BIOL CHEM, V284, P1954, DOI 10.1074/jbc.M806250200; Lu BY, 2011, INVEST OPHTH VIS SCI, V52, P8258, DOI 10.1167/iovs.11-7914; Lu Q, 2005, HUM PATHOL, V36, P1037, DOI 10.1016/j.humpath.2005.07.012; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; Lu Q, 2010, J PATHOL, V222, P119, DOI 10.1002/path.2755; Martinez MC, 2003, J CELL BIOL, V162, P99, DOI 10.1083/jcb.200211025; Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603; Oh M, 2009, J BIOL CHEM, V284, P28579, DOI 10.1074/jbc.M109.002659; Paffenholz R, 1997, DIFFERENTIATION, V61, P293, DOI 10.1046/j.1432-0436.1997.6150293.x; Papadopoulos N, 2006, NAT BIOTECHNOL, V24, P985, DOI 10.1038/nbt1234; Rios-Doria J, 2003, J BIOL CHEM, V278, P1372, DOI 10.1074/jbc.M208772200; Rodova M, 2004, MOL CELL BIOL, V24, P7188, DOI 10.1128/MCB.24.16.7188-7196.2004; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang T, 2009, ONCOGENE, V28, P555, DOI 10.1038/onc.2008.399; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Wilson KF, 2013, TRENDS MOL MED, V19, P74, DOI 10.1016/j.molmed.2012.10.011; Wolf A, 2006, NAT CELL BIOL, V8, P1432, DOI 10.1038/ncb1504; Wu M, 2007, AM J PHYSIOL-CELL PH, V292, pC125, DOI 10.1152/ajpcell.00247.2006; Yuan H, 2009, AM J PHYSIOL-HEART C, V296, pH470, DOI 10.1152/ajpheart.01051.2008; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Zeng Y, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-19; Zhang H, 2013, TARGET ONCOL, DOI [10.1007/s11523-013-0269-6, DOI 10.1007/S11523-013-0269-6)]; Zhang JY, 2010, J PATHOL, V222, P76, DOI 10.1002/path.2742; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	48	23	24	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1542	1552		10.1038/onc.2014.89	http://dx.doi.org/10.1038/onc.2014.89			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24727894	Green Accepted, Green Submitted			2022-12-28	WOS:000351416800007
J	Bharadwaj, U; Eckols, TK; Kolosov, M; Kasembeli, MM; Adam, A; Torres, D; Zhang, X; Dobrolecki, LE; Wei, W; Lewis, MT; Dave, B; Chang, JC; Landis, MD; Creighton, CJ; Mancini, MA; Tweardy, DJ				Bharadwaj, U.; Eckols, T. K.; Kolosov, M.; Kasembeli, M. M.; Adam, A.; Torres, D.; Zhang, X.; Dobrolecki, L. E.; Wei, W.; Lewis, M. T.; Dave, B.; Chang, J. C.; Landis, M. D.; Creighton, C. J.; Mancini, M. A.; Tweardy, D. J.			Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; UNPHOSPHORYLATED STAT3; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCER; GENE-EXPRESSION; DOWN-REGULATION; STEM-CELL; TRANSCRIPTION; BINDING; ACTIVATION	Signal transducer and activator of transcription (STAT) 3 regulates many cardinal features of cancer including cancer cell growth, apoptosis resistance, DNA damage response, metastasis, immune escape, tumor angiogenesis, the Warburg effect and oncogene addiction and has been validated as a drug target for cancer therapy. Several strategies have been used to identify agents that target Stat3 in breast cancer but none has yet entered into clinical use. We used a high-throughput fluorescence microscopy search strategy to identify compounds in a drug-repositioning library (Prestwick library) that block ligand-induced nuclear translocation of Stat3 and identified piperlongumine (PL), a natural product isolated from the fruit of the pepper Piper longum. PL inhibited Stat3 nuclear translocation, inhibited ligand-induced and constitutive Stat3 phosphorylation, and modulated expression of multiple Stat3-regulated genes. Surface plasmon resonance assay revealed that PL directly inhibited binding of Stat3 to its phosphotyrosyl peptide ligand. Phosphoprotein antibody array analysis revealed that PL does not modulate kinases known to activate Stat3 such as Janus kinases, Src kinase family members or receptor tyrosine kinases. PL inhibited anchorage-independent and anchorage-dependent growth of multiple breast cancer cell lines having increased pStat3 or total Stat3, and induced apoptosis. PL also inhibited mammosphere formation by tumor cells from patient-derived xenografts. PL's antitumorigenic function was causally linked to its Stat3-inhibitory effect. PL was non-toxic in mice up to a dose of 30 mg/kg/day for 14 days and caused regression of breast cancer cell line xenografts in nude mice. Thus, PL represents a promising new agent for rapid entry into the clinic for use in treating breast cancer, as well as other cancers in which Stat3 has a role.	[Bharadwaj, U.; Eckols, T. K.; Kolosov, M.; Kasembeli, M. M.; Adam, A.; Torres, D.; Tweardy, D. J.] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA; [Zhang, X.; Dobrolecki, L. E.; Wei, W.; Lewis, M. T.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Wei, W.; Lewis, M. T.; Mancini, M. A.; Tweardy, D. J.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Lewis, M. T.] Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; [Lewis, M. T.; Tweardy, D. J.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Dave, B.; Chang, J. C.; Landis, M. D.] Methodist Hosp, Res Inst, Methodist Canc Ctr, Houston, TX 77030 USA; [Creighton, C. J.] Baylor Coll Med, Dept Med, Hematol Oncol Sect, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine	Tweardy, DJ (corresponding author), Baylor Coll Med, Dept Med, Infect Dis Sect, BCM 286,Room N-1319,1 Baylor Plaza, Houston, TX 77030 USA.	dtweardy@bcm.edu	Tweardy, David/L-3929-2019; Lewis, Michael T/A-9572-2009; Dave, Bhuvanesh/ABF-8334-2020	Dave, Bhuvanesh/0000-0001-6741-1363	National Institutes of Health [CA149783, P50-CA058183, U54-CA149196]; BCM Cancer Center [P30 CA125123]; John S Dunn Gulf Coast Consortium for Chemical Genomics Screening Grant Program; NCRR [S10RR024574]; NIAID [AI036211]; NCI [P30 CA125123]; NATIONAL CANCER INSTITUTE [R41CA153658, P30CA125123, R21CA149783, U54CA149196, P50CA058183] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR024574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); BCM Cancer Center; John S Dunn Gulf Coast Consortium for Chemical Genomics Screening Grant Program; NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank various BCM core facilities for providing the infrastructure, instrumentation and expertise for performing many of our experiments; the Integrated Microscopy core (Director: Michael Mancini, PhD) for assistance with the HTFM screening assay; the Cytometry and Cell Sorting Core (Director: Joel M Sederstrom, MBS/Christine Beeton, PhD) for the Phosphoflow experiments; the Protein and Antibody Array Proteomics Core (Director: Shixia Huang, PhD) for the phosphoproteomic analysis. This project was supported, in part, by the following grants: National Institutes of Health grant CA149783 (DJT), P50-CA058183 (MTL), U54-CA149196 (MTL), the BCM Cancer Center Support Grant P30 CA125123, research grants from the John S Dunn Gulf Coast Consortium for Chemical Genomics Screening Grant Program (DJT), NCRR grant S10RR024574, NIAID AI036211 and NCI P30 CA125123 (BCM Cytometry and Cell Sorting Core funding).	Adams DJ, 2012, P NATL ACAD SCI USA, V109, P15115, DOI 10.1073/pnas.1212802109; Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333; Barry SP, 2010, INT J EXP PATHOL, V91, P506, DOI 10.1111/j.1365-2613.2010.00734.x; Barry SP, 2009, BIOCHEM BIOPH RES CO, V385, P324, DOI 10.1016/j.bbrc.2009.05.051; Bezerra DP, 2007, TOXICOL IN VITRO, V21, P1, DOI 10.1016/j.tiv.2006.07.007; Bolli R, 2011, J MOL CELL CARDIOL, V50, P589, DOI 10.1016/j.yjmcc.2011.01.002; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dave B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030207; Demaria M, 2010, AGING-US, V2, P823, DOI 10.18632/aging.100232; Doucette TA, 2012, NEURO-ONCOLOGY, V14, P1136, DOI 10.1093/neuonc/nos139; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106; Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haviland R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024923; Hedvat M, 2009, CANCER CELL, V16, P487, DOI 10.1016/j.ccr.2009.10.015; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hochgrafe F, 2010, CANCER RES, V70, P9391, DOI 10.1158/0008-5472.CAN-10-0911; Huang Y, 2007, J BIOL CHEM, V282, P34958, DOI 10.1074/jbc.M704548200; Jang JH, 2012, ANTIOXID REDOX SIGN, V16, P383, DOI 10.1089/ars.2011.4134; Jarnicki A, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-14; Jing N, 2005, ANTI-CANCER DRUG, V16, P601, DOI 10.1097/00001813-200507000-00002; Johnston PA, 2011, MOL INTERV, V11, P18, DOI 10.1124/mi.11.1.4; Jung JE, 2009, J NEUROSCI, V29, P7003, DOI 10.1523/JNEUROSCI.1110-09.2009; Kim BK, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2247; Kim JK, 2005, J BIOL CHEM, V280, P32512, DOI 10.1074/jbc.M502431200; Kim SW, 2007, J NEUROSCI RES, V85, P1252, DOI 10.1002/jnr.21236; Koskela HLM, 2012, NEW ENGL J MED, V366, P1905, DOI 10.1056/NEJMoa1114885; Kotecha Nikesh, 2010, Curr Protoc Cytom, VChapter 10, DOI 10.1002/0471142956.cy1017s53; Lee SM, 2001, BIOCHIMIE, V83, P1057, DOI 10.1016/S0300-9084(01)01351-7; Litzenburger BC, 2011, CLIN CANCER RES, V17, P2314, DOI 10.1158/1078-0432.CCR-10-1903; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Nikulenkov F, 2012, CELL DEATH DIFFER, V19, P1992, DOI 10.1038/cdd.2012.89; Oshima Y, 2005, CARDIOVASC RES, V65, P428, DOI 10.1016/j.cardiores.2004.10.021; Pilati C, 2011, J EXP MED, V208, P1359, DOI 10.1084/jem.20110283; Quesnelle KM, 2007, J CELL BIOCHEM, V102, P311, DOI 10.1002/jcb.21475; Raj L, 2011, NATURE, V475, P231, DOI 10.1038/nature10167; Ram PT, 2001, ONCOGENE, V20, P1601, DOI 10.1038/sj.onc.1204186; Redell MS, 2005, CURR PHARM DESIGN, V11, P2873, DOI 10.2174/1381612054546699; Sarafian TA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009532; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Shao H, 2004, J BIOL CHEM, V279, P18967, DOI 10.1074/jbc.M314037200; Shao H, 2001, BLOOD, V98, P3853, DOI 10.1182/blood.V98.13.3853; Sharma SV, 2006, CANCER CELL, V10, P425, DOI 10.1016/j.ccr.2006.09.014; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159; Song LX, 2011, MOL CANCER THER, V10, P481, DOI 10.1158/1535-7163.MCT-10-0502; Timofeeva OA, 2012, J BIOL CHEM, V287, P14192, DOI 10.1074/jbc.M111.323899; Welte T, 2003, P NATL ACAD SCI USA, V100, P1879, DOI 10.1073/PNAS.0237137100; Xiong H, 2012, J BIOL CHEM, V287, P5819, DOI 10.1074/jbc.M111.295964; Xu XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004783; Yang J, 2005, CANCER RES, V65, P939; Yang JB, 2008, CELL RES, V18, P443, DOI 10.1038/cr.2008.41; Yang JB, 2007, GENE DEV, V21, P1396, DOI 10.1101/gad.1553707; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Zhang XM, 2013, CANCER RES, V73, P4885, DOI 10.1158/0008-5472.CAN-12-4081; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhou HK, 2011, BONE, V49, P404, DOI 10.1016/j.bone.2011.04.020	60	108	111	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1341	1353		10.1038/onc.2014.72	http://dx.doi.org/10.1038/onc.2014.72			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24681959	Green Accepted			2022-12-28	WOS:000350806500001
J	Hansen, MT; Forst, B; Cremers, N; Quagliata, L; Ambartsumian, N; Grum-Schwensen, B; Klingelhofer, J; Abdul-Al, A; Herrmann, P; Osterland, M; Stein, U; Nielsen, GH; Scherer, PE; Lukanidin, E; Sleeman, JP; Grigorian, M				Hansen, M. T.; Forst, B.; Cremers, N.; Quagliata, L.; Ambartsumian, N.; Grum-Schwensen, B.; Klingelhoefer, J.; Abdul-Al, A.; Herrmann, P.; Osterland, M.; Stein, U.; Nielsen, G. H.; Scherer, P. E.; Lukanidin, E.; Sleeman, J. P.; Grigorian, M.			A link between inflammation and metastasis: serum amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4	ONCOGENE			English	Article						inflammation; metastasis; S100A4; serum amyloid A	PROTEIN S100A4; RHEUMATOID-ARTHRITIS; UP-REGULATION; KAPPA-B; EXPRESSION; RECEPTOR; CELLS; PROGRESSION; BINDING; GROWTH	S100A4 is implicated in metastasis and chronic inflammation, but its function remains uncertain. Here we establish an S100A4-dependent link between inflammation and metastatic tumor progression. We found that the acute-phase response proteins serum amyloid A (SAA) 1 and SAA3 are transcriptional targets of S100A4 via Toll-like receptor 4 (TLR4)/nuclear factor-kappa B signaling. SAA proteins stimulated the transcription of RANTES (regulated upon activation normal T-cell expressed and presumably secreted), G-CSF (granulocyte-colony-stimulating factor) and MMP2 (matrix metalloproteinase 2), MMP3, MMP9 and MMP13. We have also shown for the first time that SAA stimulate their own transcription as well as that of proinflammatory S100A8 and S100A9 proteins. Moreover, they strongly enhanced tumor cell adhesion to fibronectin, and stimulated migration and invasion of human and mouse tumor cells. Intravenously injected S100A4 protein induced expression of SAA proteins and cytokines in an organ-specific manner. In a breast cancer animal model, ectopic expression of SAA1 or SAA3 in tumor cells potently promoted widespread metastasis formation accompanied by a massive infiltration of immune cells. Furthermore, coordinate expression of S100A4 and SAA in tumor samples from colorectal carcinoma patients significantly correlated with reduced overall survival. These data show that SAA proteins are effectors for the metastasis-promoting functions of S100A4, and serve as a link between inflammation and tumor progression.	[Hansen, M. T.; Forst, B.; Ambartsumian, N.; Grum-Schwensen, B.; Klingelhoefer, J.; Abdul-Al, A.; Lukanidin, E.; Grigorian, M.] Danish Canc Soc Res Ctr, Copenhagen, Denmark; [Cremers, N.; Quagliata, L.; Sleeman, J. P.] Heidelberg Univ, Univ Med Mannheim, Mannheim, Germany; [Cremers, N.; Sleeman, J. P.] KIT Karlsruhe, Eggenstein Leopoldshafen, Germany; [Ambartsumian, N.; Klingelhoefer, J.; Grigorian, M.] Univ Copenhagen, Inst Neurosci & Pharmacol, Neurooncol Grp, Lab Neural Plast, DK-2200 Copenhagen, Denmark; [Osterland, M.; Stein, U.; Nielsen, G. H.] Charite, Max Delbruck Ctr Mol Med, Expt & Clin Res Ctr, D-13353 Berlin, Germany; [Nielsen, G. H.] Air Liquide Danmark AS, Horsens, Denmark; [Scherer, P. E.] Univ Texas SW Med Ctr Dallas, Touchstone Diabet Ctr, Dallas, TX 75390 USA	Danish Cancer Society; Ruprecht Karls University Heidelberg; University of Copenhagen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Air Liquide; University of Texas System; University of Texas Southwestern Medical Center Dallas	Grigorian, M (corresponding author), Univ Copenhagen, Inst Neurosci & Pharmacol, Neurooncol Grp, Lab Neural Plast, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark.	grigorian@sund.ku.dk	Sleeman, Jonathan P/H-2515-2013; Scherer, Philipp E/K-7819-2012; Quagliata, Luca/B-8321-2015	Sleeman, Jonathan P/0000-0003-1718-7687; Scherer, Philipp E/0000-0003-0680-3392; Quagliata, Luca/0000-0001-8249-9914; Stein, Ulrike/0000-0001-7006-282X; Grum-Schwensen, Birgitte/0000-0001-6677-1869	European Union (TuMIC) [Health-F2-2008-201662]; INARMERA [FP7-INCO-2010-6]; Danish Cancer Society; Dansk Kraeftforsknings Fond	European Union (TuMIC); INARMERA; Danish Cancer Society(Danish Cancer Society); Dansk Kraeftforsknings Fond	We thank Ekaterina Dulina, Inge Skibshoj and Lene Bregnholt Larsen for careful technical assistance. We gratefully acknowledge funding by the European Union (TuMIC, Health-F2-2008-201662) and INARMERA (FP7-INCO-2010-6), the Danish Cancer Society and the Dansk Kraeftforsknings Fond.	Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Ambartsumian N, 2005, CELL BIOL, V1, P363; Ambartsumian NS, 1996, ONCOGENE, V13, P1621; Bang CA, 2007, AM J PHYSIOL-RENAL, V293, pF1325, DOI 10.1152/ajprenal.00039.2007; Baumann P, 2005, CANCER RES, V65, P10783, DOI 10.1158/0008-5472.CAN-05-0619; Cabezon T, 2007, INT J CANCER, V121, P1433, DOI 10.1002/ijc.22850; Cerezo LA, 2011, RHEUMATOLOGY, V50, P1766, DOI 10.1093/rheumatology/ker218; Cunnane G, 2001, CURR OPIN RHEUMATOL, V13, P67, DOI 10.1097/00002281-200101000-00011; Davies MPA, 1996, ONCOGENE, V13, P1631; DeNardo DG, 2008, CANCER METAST REV, V27, P11, DOI 10.1007/s10555-007-9100-0; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; Ehrchen JM, 2009, J LEUKOCYTE BIOL, V86, P557, DOI 10.1189/jlb.1008647; Forst B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010374; Fridman WH, 2011, CANCER RES, V71, P5601, DOI 10.1158/0008-5472.CAN-11-1316; Fritz G, 2010, FEBS J, V277, P4578, DOI 10.1111/j.1742-4658.2010.07887.x; Furlaneto CJ, 2000, BIOCHEM BIOPH RES CO, V268, P405, DOI 10.1006/bbrc.2000.2143; Gregory AD, 2011, CANCER RES, V71, P2411, DOI 10.1158/0008-5472.CAN-10-2583; GRIGORIAN M, 1994, ELECTROPHORESIS, V15, P463, DOI 10.1002/elps.1150150163; Grigorian M, 1996, INT J CANCER, V67, P831, DOI 10.1002/(SICI)1097-0215(19960917)67:6<831::AID-IJC13>3.0.CO;2-4; Grigorian M, 2008, CURR MOL MED, V8, P492, DOI 10.2174/156652408785747942; Grum-Schwensen B, 2010, CANCER RES, V70, P936, DOI 10.1158/0008-5472.CAN-09-3220; He R, 2006, J IMMUNOL, V177, P4072, DOI 10.4049/jimmunol.177.6.4072; He RL, 2009, BLOOD, V113, P429, DOI 10.1182/blood-2008-03-139923; Helfman DM, 2005, BRIT J CANCER, V92, P1955, DOI 10.1038/sj.bjc.6602613; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Klingelhofer J, 2007, ARTHRITIS RHEUM-US, V56, P779, DOI 10.1002/art.22398; Klingelhofer J, 2012, NEOPLASIA, V14, P1260, DOI 10.1593/neo.121554; Klingelhofer J, 2009, FEBS J, V276, P5936, DOI 10.1111/j.1742-4658.2009.07274.x; Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031; Larson MA, 2003, BIOCHEM BIOPH RES CO, V301, P1030, DOI 10.1016/S0006-291X(03)00045-7; Lee HY, 2005, BIOCHEM BIOPH RES CO, V330, P989, DOI 10.1016/j.bbrc.2005.03.069; Lin Y, 2001, J BIOL CHEM, V276, P42077, DOI 10.1074/jbc.M107101200; Lukanidin E, 2012, SEMIN CANCER BIOL, V22, P216, DOI 10.1016/j.semcancer.2012.02.006; Maelandsmo GM, 1996, CANCER RES, V56, P5490; Malle E, 2009, CELL MOL LIFE SCI, V66, P9, DOI 10.1007/s00018-008-8321-x; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; Moller HD, 2011, MOL CANCER RES, V9, P553, DOI 10.1158/1541-7786.MCR-11-0093; Mullan RH, 2006, ARTHRITIS RHEUM-US, V54, P105, DOI 10.1002/art.21518; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Okamoto H, 2008, J RHEUMATOL, V35, P752; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Schmid MC, 2010, J ONCOL, V2010, DOI 10.1155/2010/201026; Schmidt-Hansen B, 2004, J BIOL CHEM, V279, P24498, DOI 10.1074/jbc.M400441200; Song CJ, 2009, ATHEROSCLEROSIS, V207, P374, DOI 10.1016/j.atherosclerosis.2009.05.007; Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889; Sung HJ, 2011, J PROTEOME RES, V10, P1383, DOI 10.1021/pr101154j; Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707; Yamada T, 1999, CLIN CHEM LAB MED, V37, P381, DOI 10.1515/CCLM.1999.063; Zhao YL, 2009, J VASC RES, V46, P64, DOI 10.1159/000139134; Zibert JR, 2010, J INVEST DERMATOL, V130, P150, DOI 10.1038/jid.2009.206	52	102	107	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					424	435		10.1038/onc.2013.568	http://dx.doi.org/10.1038/onc.2013.568			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24469032				2022-12-28	WOS:000348451300003
J	Rojas-Rivera, D; Hetz, C				Rojas-Rivera, D.; Hetz, C.			TMBIM protein family: ancestral regulators of cell death	ONCOGENE			English	Review						TMBIM; BI-1; BCL-2; apoptosis; ER-stress; calcium	ENDOPLASMIC-RETICULUM STRESS; BREAST-CANCER CELLS; OUTER MITOCHONDRIAL-MEMBRANE; GLUTAMATE-BINDING SUBUNIT; BAX INHIBITOR MOTIF; CYTOCHROME-C; ER STRESS; TRANSMEMBRANE PROTEIN; SENSOR IRE1-ALPHA; DOWN-REGULATION	The control of apoptosis in mammals has been historically associated with the activity of the BCL-2 family of proteins at the mitochondria. In the past years, a novel group of cell death regulators have emerged, known as the Transmembrane BAX Inhibitor-1 Motif-containing (TMBIM) protein family. This group of proteins is composed of at least six highly conserved members expressed in mammals, with homologs in insects, fish, plants, viruses and yeast. Different studies indicate that all TMBIM family members have inhibitory activities in different setting of apoptosis. Here, we overview and integrate possible mechanisms underlying the impact of the TMBIM protein family in the regulation of cell death, which include activities at diverse subcellular compartments, including death receptor regulation, modulation of endoplasmic reticulum (ER) calcium homeostasis, ER stress signaling, autophagy, reactive oxygen species production, among other effects. The possible intersection between the BCL-2 and TMBIM family in the control of cell death is also discussed, in addition to their implication in the progression of cancer.	[Rojas-Rivera, D.; Hetz, C.] Univ Chile, Fac Med, Biomed Neurosci Inst, Santiago 70086, Chile; [Rojas-Rivera, D.; Hetz, C.] Univ Chile, Fac Med, Inst Biomed Sci, Ctr Mol Studies Cell, Santiago 70086, Chile; [Hetz, C.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Hetz, C.] Neurounion Biomed Fdn, Santiago, Chile	Universidad de Chile; Universidad de Chile; Harvard University; Harvard T.H. Chan School of Public Health	Hetz, C (corresponding author), Univ Chile, Fac Med, Inst Biomed Sci, Program Cellular & Mol Biol, 1027 Independencia Ave, Santiago 70086, Chile.	chetz@med.uchile.cl	Rojas-Riviera, Diego/AAN-5222-2020; Rivera, Diego Rojas/ABF-5865-2020; Rojas Rivera, Diego/N-1870-2016; Hetz, Claudio/ABD-7514-2021	Rivera, Diego Rojas/0000-0002-8773-9830; Rojas Rivera, Diego/0000-0002-8773-9830; 	FONDEF [D11l1007, 3130365]; Ring Initiative [ACT1109]; Millennium Institute [P09-015-F]; Alzheimers Association, FONDECYT [1100176]; Muscular Dystrophy Association, ALS Therapy Alliance; FONDECYT [3130365, 1140549]; ECOS CONICYT C13S02 CONICYT Grant [USA2013-0003]	FONDEF; Ring Initiative; Millennium Institute(Takeda Pharmaceutical Company Ltd); Alzheimers Association, FONDECYT(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); Muscular Dystrophy Association, ALS Therapy Alliance(Muscular Dystrophy Association); FONDECYT(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); ECOS CONICYT C13S02 CONICYT Grant	This work was funded by FONDEF D11l1007, Ring Initiative ACT1109, Millennium Institute No. P09-015-F, the Alzheimers Association, FONDECYT No. 1100176, FONDECYT No. 1140549, ECOS CONICYT C13S02 CONICYT Grant USA2013-0003, the Muscular Dystrophy Association, ALS Therapy Alliance (CH) and FONDECYT No. 3130365 Post-doctoral grant (DRR).	Ahn T, 2010, CELL CALCIUM, V47, P387, DOI 10.1016/j.ceca.2010.02.003; ALCAMI A, 1995, J VIROL, V69, P4633; Ameisen JC, 1996, SCIENCE, V272, P1278, DOI 10.1126/science.272.5266.1278; Antignani A, 2006, CURR OPIN CELL BIOL, V18, P685, DOI 10.1016/j.ceb.2006.10.004; Aouacheria A, 2013, TRENDS CELL BIOL, V23, P103, DOI 10.1016/j.tcb.2012.10.010; Bailly-Maitre B, 2006, P NATL ACAD SCI USA, V103, P2809, DOI 10.1073/pnas.0506854103; Bailly-Maitre B, 2007, CANCER RES, V67, P1442, DOI 10.1158/0008-5472.CAN-06-0850; Bailly-Maitre B, 2010, J BIOL CHEM, V285, P6198, DOI 10.1074/jbc.M109.056648; Bucan V, 2011, ONCOL LETT, V2, P419, DOI 10.3892/ol.2011.285; Bucan V, 2010, APOPTOSIS, V15, P814, DOI 10.1007/s10495-010-0493-9; Bucan V, 2010, CELL MOL BIOL LETT, V15, P296, DOI 10.2478/s11658-010-0009-1; Buttner S, 2007, MOL CELL, V25, P233, DOI 10.1016/j.molcel.2006.12.021; Buttner S, 2011, EMBO J, V30, P2779, DOI 10.1038/emboj.2011.197; Bultynck G, 2012, J BIOL CHEM, V287, P2544, DOI 10.1074/jbc.M111.275354; Cakir B, 2012, YEAST, V29, P395, DOI 10.1002/yea.2918; Carmona-Gutierrez D, 2010, CELL DEATH DIFFER, V17, P763, DOI 10.1038/cdd.2009.219; Carrara G, 2012, J BIOL CHEM, V287, P15896, DOI 10.1074/jbc.M111.336149; Castillo K, 2011, EMBO J, V30, P4465, DOI 10.1038/emboj.2011.318; Cebulski J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020882; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; Chae HJ, 2003, GENE, V323, P101, DOI 10.1016/j.gene.2003.09.011; Chen YB, 2011, J CELL BIOL, V195, P263, DOI 10.1083/jcb.201108059; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; de Mattia F, 2009, MOL BIOL CELL, V20, P3638, DOI 10.1091/mbc.E09-05-0385; de Mendoza TH, 2011, P NATL ACAD SCI USA, V108, P17189, DOI 10.1073/pnas.1114226108; Dejeans N, 2014, TRENDS MOL MED; Dussmann H, 2003, J CELL SCI, V116, P525, DOI 10.1242/jcs.00236; Eisenberg T, 2007, APOPTOSIS, V12, P1011, DOI 10.1007/s10495-007-0758-0; Fernandez M, 2007, J NEUROCHEM, V103, P190, DOI 10.1111/j.1471-4159.2007.04767.x; Galindo KA, 2009, DEVELOPMENT, V136, P275, DOI 10.1242/dev.019042; Goswami DB, 2013, PROG NEURO-PSYCHOPH, V43, P126, DOI 10.1016/j.pnpbp.2012.12.010; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Grzmil M, 2006, J PATHOL, V208, P340, DOI 10.1002/path.1902; Grzmil M, 2003, AM J PATHOL, V163, P543, DOI 10.1016/S0002-9440(10)63682-6; Gubser C, 2007, PLOS PATHOG, V3, P246, DOI 10.1371/journal.ppat.0030017; Happo L, 2012, J CELL SCI, V125, P1081, DOI 10.1242/jcs.090514; Hemrajani C, 2010, P NATL ACAD SCI USA, V107, P3129, DOI 10.1073/pnas.0911609106; Henke N, 2011, CELL CALCIUM, V50, P251, DOI 10.1016/j.ceca.2011.05.005; Hetz C, 2006, SCIENCE, V312, P572, DOI 10.1126/science.1123480; Hetz C, 2013, NAT REV DRUG DISCOV, V12, P703, DOI 10.1038/nrd3976; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Hetz C, 2011, PHYSIOL REV, V91, P1219, DOI 10.1152/physrev.00001.2011; Hetz C, 2009, MOL CELL, V35, P551, DOI 10.1016/j.molcel.2009.08.021; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Hsu CF, 2011, INT J BIOCHEM CELL B, V43, P666, DOI 10.1016/j.biocel.2011.01.010; Hu L, 2009, APOPTOSIS, V14, P1255, DOI 10.1007/s10495-009-0402-2; Huckelhoven R, 2004, APOPTOSIS, V9, P299, DOI 10.1023/B:APPT.0000025806.71000.1c; Hunsberger JG, 2011, BRAIN RES, V1403, P19, DOI 10.1016/j.brainres.2011.05.067; Ishikawa T, 2011, CELL DEATH DIFFER, V18, P1271, DOI 10.1038/cdd.2011.59; Jette CA, 2008, CELL DEATH DIFFER, V15, P1063, DOI 10.1038/cdd.2008.42; Kawai M, 1999, FEBS LETT, V464, P143, DOI 10.1016/S0014-5793(99)01695-6; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kim HR, 2008, J BIOL CHEM, V283, P15946, DOI 10.1074/jbc.M800075200; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kim JH, 2012, BBA-MOL CELL RES, V1823, P876, DOI 10.1016/j.bbamcr.2012.01.016; Kiviluoto S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.103; Kiviluoto S, 2013, CELL CALCIUM, V54, P186, DOI 10.1016/j.ceca.2013.06.002; Kiviluoto S, 2013, BBA-MOL CELL RES, V1833, P1612, DOI 10.1016/j.bbamcr.2013.01.026; Kotsafti A, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-35; Krajewska M, 2011, BRAIN RES, V1370, P227, DOI 10.1016/j.brainres.2010.11.015; Kroemer G, 1997, CELL DEATH DIFFER, V4, P443, DOI 10.1038/sj.cdd.4400266; KUMAR KN, 1991, NATURE, V354, P70, DOI 10.1038/354070a0; Lee GH, 2010, ONCOGENE, V29, P2130, DOI 10.1038/onc.2009.491; Lee GH, 2012, INT J BIOCHEM CELL B, V44, P600, DOI 10.1016/j.biocel.2011.12.017; Lee GH, 2011, INT J BIOCHEM CELL B, V43, P1305, DOI 10.1016/j.biocel.2011.05.004; Lee GH, 2011, J BIOL CHEM, V286, P24743, DOI 10.1074/jbc.M110.167734; Lee GH, 2011, INT J ONCOL, V39, P209, DOI 10.3892/ijo.2011.1024; Lee GH, 2010, MOL CELL BIOL, V30, P1800, DOI 10.1128/MCB.01357-09; Lee Geung-Joo, 2007, V2, P1; Lewis TB, 1996, GENOMICS, V32, P131, DOI 10.1006/geno.1996.0088; Li XY, 2011, HUM GENE THER, V22, P1201, DOI 10.1089/hum.2010.178; Li XY, 2010, CELL BIOL INT, V34, P1099, DOI 10.1042/CBI20090400; Li YS, 2001, ENDOCRINOLOGY, V142, P2937, DOI 10.1210/en.142.7.2937; Ligr M, 1998, FEBS LETT, V438, P61, DOI 10.1016/S0014-5793(98)01227-7; Lima RT, 2004, CANCER GENE THER, V11, P309, DOI 10.1038/sj.cgt.7700706; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lisbona F, 2009, MOL CELL, V33, P679, DOI 10.1016/j.molcel.2009.02.017; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Ludovico P, 2002, MOL BIOL CELL, V13, P2598, DOI 10.1091/mbc.E01-12-0161; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Markkula E, 2013, MICROB PATHOGENESIS, V54, P46, DOI 10.1016/j.micpath.2012.09.004; Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017; MOORE JB, 1992, EMBO J, V11, P1973, DOI 10.1002/j.1460-2075.1992.tb05251.x; Nielsen JA, 2011, MOL CELL BIOCHEM, V357, P73, DOI 10.1007/s11010-011-0877-3; Oka T, 2008, MOL BIOL CELL, V19, P2597, DOI 10.1091/mbc.E07-12-1205; Ow YLP, 2008, NAT REV MOL CELL BIO, V9, P532, DOI 10.1038/nrm2434; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Priault M, 1999, FEBS LETT, V456, P232, DOI 10.1016/S0014-5793(99)00957-6; Reich A, 2011, J NEUROSCI, V31, P225, DOI 10.1523/JNEUROSCI.2188-10.2011; Reimers K, 2008, CURR MOL MED, V8, P148, DOI 10.2174/156652408783769562; Reimers K, 2007, INT J BIOL SCI, V3, P471; Ren DC, 2010, SCIENCE, V330, P1390, DOI 10.1126/science.1190217; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Robinson KS, 2011, ONCOGENE, V30, P2391, DOI 10.1038/onc.2010.636; Robinson KS, 2010, MICROBIOL-SGM, V156, P1815, DOI 10.1099/mic.0.037259-0; Rodriguez DA, 2012, EMBO J, V31, P2322, DOI 10.1038/emboj.2012.84; Rojas-Rivera D, 2012, CELL DEATH DIFFER, V19, P1013, DOI 10.1038/cdd.2011.189; Rong JA, 2011, J BIOL CHEM, V286, P1453, DOI 10.1074/jbc.M110.175232; Sano R, 2012, GENE DEV, V26, P1041, DOI 10.1101/gad.184325.111; Saraiva N, 2013, J CELL BIOL, V202, P699, DOI 10.1083/jcb.201301016; Saraiva N, 2013, J BIOL CHEM, V288, P13057, DOI 10.1074/jbc.M112.414367; Schmidt SM, 2009, LEUKEMIA, V23, P1818, DOI 10.1038/leu.2009.138; Schmits R, 2002, INT J CANCER, V98, P73, DOI 10.1002/ijc.10170; Schweitzer B, 2002, MOL BRAIN RES, V107, P47, DOI 10.1016/S0169-328X(02)00445-X; Sevrioukov EA, 2007, GENESIS, V45, P184, DOI 10.1002/dvg.20279; Shukla S, 2011, APOPTOSIS, V16, P162, DOI 10.1007/s10495-010-0556-y; Somia NV, 1999, P NATL ACAD SCI USA, V96, P12667, DOI 10.1073/pnas.96.22.12667; Szuchet S, 2001, BIOCHEM BIOPH RES CO, V283, P900, DOI 10.1006/bbrc.2001.4859; Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Tanaka R, 2006, CANCER-AM CANCER SOC, V106, P648, DOI 10.1002/cncr.21639; Tsujimoto Y, 2007, APOPTOSIS, V12, P835, DOI 10.1007/s10495-006-0525-7; Urra H, 2013, BBA-MOL CELL RES, V1833, P3507, DOI 10.1016/j.bbamcr.2013.07.024; Villalva C, 2002, BRIT J HAEMATOL, V118, P791, DOI 10.1046/j.1365-2141.2002.03671.x; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Westphalen BC, 2005, CELL DEATH DIFFER, V12, P304, DOI 10.1038/sj.cdd.4401547; Wissing S, 2004, J CELL BIOL, V166, P969, DOI 10.1083/jcb.200404138; Wu XF, 2013, CANCER RES, V73, P4028, DOI 10.1158/0008-5472.CAN-12-4033; Xu CY, 2008, J BIOL CHEM, V283, P11477, DOI 10.1074/jbc.M708385200; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yamaji T, 2010, J BIOL CHEM, V285, P35505, DOI 10.1074/jbc.M110.154229; Yoshida T, 2006, BIOCHEM BIOPH RES CO, V341, P13, DOI 10.1016/j.bbrc.2005.12.141; Yoshisue H, 2002, ATHEROSCLEROSIS, V162, P323, DOI 10.1016/S0021-9150(01)00735-3; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yun CH, 2012, J PHARM SCI-US, V101, P1314, DOI 10.1002/jps.23007; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zhang MH, 2010, MOL CELL BIOCHEM, V333, P1, DOI 10.1007/s11010-009-0198-y; Zhao H, 2006, GENES GENET SYST, V81, P41, DOI 10.1266/ggs.81.41; Zhivotovsky B, 2009, CELL DEATH DIFFER, V16, P1419, DOI 10.1038/cdd.2009.118; Zhou JH, 2008, COMPUT BIOL CHEM, V32, P159, DOI 10.1016/j.compbiolchem.2008.01.002	131	70	73	3	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					269	280		10.1038/onc.2014.6	http://dx.doi.org/10.1038/onc.2014.6			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24561528	Bronze			2022-12-28	WOS:000348145500001
J	Pham, DH; Powell, JA; Gliddon, BL; Moretti, PAB; Tsykin, A; Van der Hoek, M; Kenyon, R; Goodall, GJ; Pitson, SM				Pham, D. H.; Powell, J. A.; Gliddon, B. L.; Moretti, P. A. B.; Tsykin, A.; Van der Hoek, M.; Kenyon, R.; Goodall, G. J.; Pitson, S. M.			Enhanced expression of transferrin receptor 1 contributes to oncogenic signalling by sphingosine kinase 1	ONCOGENE			English	Article						expression profiling; DNA microarray; neoplastic transformation; sphingosine kinase; transferrin receptor	CANCER-CELLS; IN-VITRO; C-MYC; 1-PHOSPHATE; GROWTH; SPHINGOSINE-1-PHOSPHATE; ACTIVATION; CARCINOMA; APOPTOSIS; HEAT-SHOCK-PROTEIN-105	Sphingosine kinase 1 (SK1) is a lipid kinase that catalyses the formation of sphingosine-1-phosphate (S1P). Considerable evidence has implicated elevated cellular SK1 in tumour development, progression and disease severity. In particular, SK1 has been shown to enhance cell survival and proliferation and induce neoplastic transformation. Although S1P has been found to have both cellsurface G-protein-coupled receptors and intracellular targets, the specific downstream pathways mediating oncogenic signalling by SK1 remain poorly defined. Here, using a gene expression array approach, we have demonstrated a novel mechanism whereby SK1 regulates cell survival, proliferation and neoplastic transformation through enhancing expression of transferrin receptor 1 (TFR1). We showed that elevated levels of SK1 enhanced total as well as cell-surface TFR1 expression, resulting in increased transferrin uptake into cells. Notably, we also found that SK1 activation and localization to the plasma membrane, which are critical for its oncogenic effects, are necessary for regulation of TFR1 expression specifically through engagement of the S1P G-protein coupled receptor, S1P(2). Furthermore, we showed that blocking TFR1 function with a neutralizing antibody inhibits SK1-induced cell proliferation, survival and neoplastic transformation of NIH3T3 fibroblasts. Similar effects were observed following antagonism of S1P2. Together these findings suggest that TFR1 has an important role in SK1-mediated oncogenesis.	[Pham, D. H.; Powell, J. A.; Gliddon, B. L.; Moretti, P. A. B.; Tsykin, A.; Goodall, G. J.; Pitson, S. M.] SA Pathol, Ctr Canc Biol, Frome Rd, Adelaide, SA 5000, Australia; [Pham, D. H.; Tsykin, A.; Goodall, G. J.; Pitson, S. M.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA, Australia; [Van der Hoek, M.; Kenyon, R.] SA Pathol, Adelaide Microarray Facil, Adelaide, SA, Australia; [Goodall, G. J.; Pitson, S. M.] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia	Centre for Cancer Biology; SA Pathology; University of Adelaide; SA Pathology; University of South Australia	Pitson, SM (corresponding author), SA Pathol, Ctr Canc Biol, Frome Rd, Adelaide, SA 5000, Australia.	stuart.pitson@health.sa.gov.au	Pitson, Stuart/B-9342-2009; Pham, Duyen/V-6101-2019	Pitson, Stuart/0000-0002-9527-2740; Pham, Duyen/0000-0003-0664-4133; Tsykin, Anna/0000-0001-5965-6803; Goodall, Gregory/0000-0003-1294-0692; Powell, jason/0000-0001-8493-9178; Moretti, Paul/0000-0002-3523-1496; Gliddon, Briony/0000-0003-3928-7478	Fay Fuller Foundation; University of Adelaide Postgraduate Scholarship; National Health and Medical Research Council of Australia [626936];  [508098];  [1042589]	Fay Fuller Foundation; University of Adelaide Postgraduate Scholarship; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); ; 	This work was supported by the Fay Fuller Foundation, a University of Adelaide Postgraduate Scholarship (to DHP), Senior Research Fellowships (508098 and 1042589) and Project Grant (626936) from the National Health and Medical Research Council of Australia (to SMP). We thank Julia Zebol for technical assistance and Andrew Bert for assistance with Figure preparation.	Ader I, 2008, CANCER RES, V68, P8635, DOI 10.1158/0008-5472.CAN-08-0917; Ader I, 2009, CANCER RES, V69, P3723, DOI 10.1158/0008-5472.CAN-09-0389; Baran Y, 2007, J BIOL CHEM, V282, P10922, DOI 10.1074/jbc.M610157200; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bianchi L, 1999, NUCLEIC ACIDS RES, V27, P4223, DOI 10.1093/nar/27.21.4223; Callens C, 2008, LEUKEMIA, V22, P42, DOI 10.1038/sj.leu.2404958; Cattoretti G, 2009, CANCER RES, V69, P8686, DOI 10.1158/0008-5472.CAN-09-1110; Chan HS, 2013, BBA-MOL CELL BIOL L, V1831, P147, DOI 10.1016/j.bbalip.2012.07.005; Daniels TR, 2006, CLIN IMMUNOL, V121, P144, DOI 10.1016/j.clim.2006.06.010; Das Gupta A, 1990, Hematol Pathol, V4, P37; El-Shewy HM, 2006, J BIOL CHEM, V281, P31399, DOI 10.1074/jbc.M605339200; French KJ, 2003, CANCER RES, V63, P5962; Habashy HO, 2010, BREAST CANCER RES TR, V119, P283, DOI 10.1007/s10549-009-0345-x; HABESHAW JA, 1983, LANCET, V1, P498; Helpman L, 2009, AM J OBSTET GYNECOL, V201, DOI 10.1016/j.ajog.2009.05.013; Heringdorf DMZ, 2001, EUR J PHARMACOL, V414, P145, DOI 10.1016/S0014-2999(01)00789-0; Hosaka S, 2006, CANCER SCI, V97, P623, DOI 10.1111/j.1349-7006.2006.00217.x; Huang WJ, 2009, INT J CANCER, V124, P298, DOI 10.1002/ijc.23906; Jarman KE, 2010, J BIOL CHEM, V285, P483, DOI 10.1074/jbc.M109.068395; Jiang XP, 2010, ANTICANCER RES, V30, P759; Jose-Eneriz ES, 2008, BRIT J HAEMATOL, V142, P571, DOI 10.1111/j.1365-2141.2008.07221.x; Kawamori T, 2006, FASEB J, V20, P386, DOI 10.1096/fj.05-4331fje; Kawamori T, 2009, FASEB J, V23, P405, DOI 10.1096/fj.08-117572; Kohno M, 2006, MOL CELL BIOL, V26, P7211, DOI 10.1128/MCB.02341-05; Le Scolan E, 2005, BLOOD, V106, P1808, DOI 10.1182/blood-2004-12-4832; Li MH, 2009, J UROLOGY, V181, P1347, DOI 10.1016/j.juro.2008.10.140; Long JS, 2010, J BIOL CHEM, V285, P35957, DOI 10.1074/jbc.M110.117945; Loveridge C, 2010, J BIOL CHEM, V285, P38841, DOI 10.1074/jbc.M110.127993; Michaud MD, 2009, ARTERIOSCL THROM VAS, V29, P902, DOI 10.1161/ATVBAHA.109.185280; Muchemwa FC, 2006, BRIT J DERMATOL, V155, P582, DOI 10.1111/j.1365-2133.2006.07362.x; Muchemwa FC, 2008, MELANOMA RES, V18, P166, DOI 10.1097/CMR.0b013e3282fe9a16; O'Donnell KA, 2006, MOL CELL BIOL, V26, P2373, DOI 10.1128/MCB.26.6.2373-2386.2006; Okazaki F, 2010, CANCER RES, V70, P6238, DOI 10.1158/0008-5472.CAN-10-0184; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Pantopoulos K, 2004, ANN NY ACAD SCI, V1012, P1, DOI 10.1196/annals.1306.001; Park HS, 2009, J CUTAN PATHOL, V36, P511, DOI 10.1111/j.1600-0560.2008.01085.x; Pchejetski D, 2005, CANCER RES, V65, P11667, DOI 10.1158/0008-5472.CAN-05-2702; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Pham DH, 2008, BIOTECHNIQUES, V45, P155, DOI 10.2144/000112896; Pitman MR, 2010, CURR CANCER DRUG TAR, V10, P354, DOI 10.2174/156800910791208599; Pitman Melissa R, 2012, Methods Mol Biol, V874, P21, DOI 10.1007/978-1-61779-800-9_2; Pitman MR, 2011, INT J BIOCHEM CELL B, V43, P342, DOI 10.1016/j.biocel.2010.11.001; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Pitson SM, 2000, BIOCHEM J, V350, P429, DOI 10.1042/0264-6021:3500429; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Pitson SM, 2011, ANTI-CANCER AGENT ME, V11, P799; Pitson SM, 2011, TRENDS BIOCHEM SCI, V36, P97, DOI 10.1016/j.tibs.2010.08.001; Ponnusamy S, 2012, EMBO MOL MED, V4, P761, DOI 10.1002/emmm.201200244; PRIOR R, 1990, VIRCHOWS ARCH A, V416, P491, DOI 10.1007/BF01600299; Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875; Ryschich E, 2004, EUR J CANCER, V40, P1418, DOI 10.1016/j.ejca.2004.01.036; Salas A, 2011, BLOOD, V117, P5941, DOI 10.1182/blood-2010-08-300772; Salomone S, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00009; Schwock J, 2008, CANCER CHEMOTH PHARM, V61, P669, DOI 10.1007/s00280-007-0522-8; Shen X, 2008, INT IMMUNOPHARMACOL, V8, P1813, DOI 10.1016/j.intimp.2008.08.022; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Strub GM, 2010, ADV EXP MED BIOL, V688, P141; Sun J, 2010, CANCER BIOTHER RADIO, V25, P155, DOI 10.1089/cbr.2009.0664; Takeshita A, 2000, J BIOL CHEM, V275, P32220, DOI 10.1074/jbc.M002569200; Takuwa N, 2011, AM J CANCER RES, V1, P460; Tran PLCHB, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-276; TROWBRIDGE IS, 1982, P NATL ACAD SCI-BIOL, V79, P1175, DOI 10.1073/pnas.79.4.1175; TROWBRIDGE IS, 1986, BIOCHEM SOC SYMP, P117; van Dam EM, 2002, J BIOL CHEM, V277, P48876, DOI 10.1074/jbc.M206271200; Wirth GJ, 2006, ONCOLOGY-BASEL, V71, P86, DOI 10.1159/000100476; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Yang Y H, 2001, Brief Bioinform, V2, P341, DOI 10.1093/bib/2.4.341; Young JC, 2003, TRENDS BIOCHEM SCI, V28, P541, DOI 10.1016/j.tibs.2003.08.009; Zhou HJ, 2008, ANTI-CANCER DRUG, V19, P247, DOI 10.1097/CAD.0b013e3282f3f152	72	23	23	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2014	33	48					5559	5568		10.1038/onc.2013.502	http://dx.doi.org/10.1038/onc.2013.502			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZO	24276247				2022-12-28	WOS:000346087900008
J	Leconet, W; Larbouret, C; Chardes, T; Thomas, G; Neiveyans, M; Busson, M; Jarlier, M; Radosevic-Robin, N; Pugniere, M; Bernex, F; Penault-Llorca, F; Pasquet, JM; Pelegrin, A; Robert, B				Leconet, W.; Larbouret, C.; Chardes, T.; Thomas, G.; Neiveyans, M.; Busson, M.; Jarlier, M.; Radosevic-Robin, N.; Pugniere, M.; Bernex, F.; Penault-Llorca, F.; Pasquet, J-M; Pelegrin, A.; Robert, B.			Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy	ONCOGENE			English	Article						RTK; monoclonal antibodies; pancreatic cancer; targeted therapy	TO-MESENCHYMAL TRANSITION; TYROSINE KINASE AXL; THERAPEUTIC TARGET; DRUG-RESISTANCE; MONOCLONAL-ANTIBODY; CELL INVASION; TUMOR-GROWTH; ACTIVATION; EGFR; OVEREXPRESSION	AXL receptor tyrosine kinase (RTK) is implicated in proliferation and invasion of many cancers, particularly in pancreatic ductal adenocarcinoma (PDAC), for which new therapeutic options are urgently required. We investigated whether inhibition of AXL activity by specific monoclonal antibodies (mAbs) is efficient in limiting proliferation and migration of pancreatic cancer cells. Expression of AXL was evaluated by immunohistochemistry in 42 PDAC. The AXL role in oncogenesis was studied using the short hairpin RNA approach in a pancreatic carcinoma cell line. We further generated antihuman AXL mAbs and evaluated their inhibitory effects and the AXL downstream signaling pathways first in vitro, in a panel of pancreatic cancer cell lines and then in vivo, using subcutaneous or orthotopic pancreatic tumor xenografts. AXL receptor was found expressed in 76% (32/ 42) of PDAC and was predominantly present in invasive cells. The AXL-knockdown Panc-1 cells decreased in vitro cell migration, survival and proliferation, and reduced in vivo tumor growth. Two selected anti-AXL mAbs (D9 and E8), which inhibited phosphorylation of AXL and of its downstream target AKT without affecting growth arrest-specific factor 6 (GAS6) binding, induced downexpression of AXL by internalization, leading to an inhibition of proliferation and migration in the four pancreatic cancer cell lines studied. In vivo, treatment by anti-AXL mAbs significantly reduced growth of both subcutaneous and orthotopic pancreatic tumor xenografts independently of their KRAS mutation status. Our in vitro and preclinical in vivo data demonstrate that anti-human AXL mAbs could represent a new approach to the pancreatic cancer immunotherapy.	[Leconet, W.; Larbouret, C.; Chardes, T.; Thomas, G.; Neiveyans, M.; Busson, M.; Pugniere, M.; Bernex, F.; Pelegrin, A.; Robert, B.] Univ Montpellier I, INSERM U896, IRCM, CRLC Val dAurelle Paul Lamarque, Montpellier 5, France; [Jarlier, M.] CRLC Val dAurelle Paul Lamarque, Unite Biostat, F-34298 Montpellier 5, Languedoc Rouss, France; [Radosevic-Robin, N.; Penault-Llorca, F.] Ctr Jean Perrin, Dept Biopathol, F-63011 Clermont Ferrand 1, France; [Radosevic-Robin, N.; Penault-Llorca, F.] Univ Auvergne, ERTICa EA4677, Clermont Ferrand, France; [Pasquet, J-M] Univ Victor Segalen, Hematol Lab, CHU Bordeaux, INSERM U876, Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Centre Jean Perrin; Universite Clermont Auvergne (UCA); CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Robert, B (corresponding author), CRLC Val dAurelle Paul Lamarque, IRCM INSERM U896, 208 Rue Apothicaires, F-34298 Montpellier 5, Languedoc Rouss, France.	bruno.robert@inserm.fr	PASQUET, JEAN-MAX/T-4906-2019; Pèlegrin, André/J-3167-2016; ROBERT, Bruno/AAB-7581-2020; PASQUET, JEAN-MAX/I-9702-2014; Chardès, Thierry/B-5420-2019; PUGNIERE, Martine/AAD-4315-2020; Pugniere, Martine/T-1355-2017; Leconet, Wilhem/AAH-5681-2020	PASQUET, JEAN-MAX/0000-0002-1345-3776; ROBERT, Bruno/0000-0001-5573-6945; Chardès, Thierry/0000-0002-1836-7439; PUGNIERE, Martine/0000-0002-2049-2909; Pugniere, Martine/0000-0002-2049-2909; Pelegrin, Andre/0000-0001-9254-2648	INSERM; Oribase Pharma	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Oribase Pharma	We thank Florence Frayssinoux, Sabine Bousquie and Genevieve Heintz for their technical help. We also thank the ICRM animal facility staff and the 'Reseau d'Histologie Experimentale de Montpellier' histology facility for processing our animal tissues and RIO Imaging facilities. This work was supported by INSERM and Oribase Pharma.	Beck A, 2010, NAT REV IMMUNOL, V10, P345, DOI 10.1038/nri2747; Bibeau F, 2009, J CLIN ONCOL, V27, P1122, DOI 10.1200/JCO.2008.18.0463; Bossard C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044787; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Gaborit N, 2011, J BIOL CHEM, V286, P11337, DOI 10.1074/jbc.M111.223503; Gioia R, 2011, BLOOD, V118, P2211, DOI 10.1182/blood-2010-10-313692; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Hong CC, 2008, CANCER LETT, V268, P314, DOI 10.1016/j.canlet.2008.04.017; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kim EJ, 2011, CURR OPIN GASTROEN, V27, P460, DOI 10.1097/MOG.0b013e328349e31f; Koorstra JBM, 2009, CANCER BIOL THER, V8, P618, DOI 10.4161/cbt.8.7.7923; Krantz SB, 2012, J SURG RES, V173, P105, DOI 10.1016/j.jss.2011.09.020; Larbouret C, 2007, CLIN CANCER RES, V13, P3356, DOI 10.1158/1078-0432.CCR-06-2302; Lay JD, 2007, CANCER RES, V67, P3878, DOI 10.1158/0008-5472.CAN-06-3191; Li Y, 2009, ONCOGENE, V28, P3442, DOI 10.1038/onc.2009.212; Linger RMA, 2013, ONCOGENE, V32, P3420, DOI 10.1038/onc.2012.355; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Linger RM, 2010, EXPERT OPIN THER TAR, V14, P1073, DOI 10.1517/14728222.2010.515980; LIU E, 1988, P NATL ACAD SCI USA, V85, P1952, DOI 10.1073/pnas.85.6.1952; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Macleod K, 2005, CANCER RES, V65, P6789, DOI 10.1158/0008-5472.CAN-04-2684; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Mishra A, 2012, MOL CANCER RES, V10, P703, DOI 10.1158/1541-7786.MCR-11-0569; Musolino A, 2008, J CLIN ONCOL, V26, P1789, DOI 10.1200/JCO.2007.14.8957; Nelson NJ, 2007, J NATL CANCER I, V99, P1432, DOI 10.1093/jnci/djm180; Rankin EB, 2010, CANCER RES, V70, P7570, DOI 10.1158/0008-5472.CAN-10-1267; Robert B, 1996, CANCER RES, V56, P4758; Song XZ, 2011, CANCER-AM CANCER SOC, V117, P734, DOI 10.1002/cncr.25483; Tai KY, 2008, ONCOGENE, V27, P4044, DOI 10.1038/onc.2008.57; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135; Troiani T, 2012, CURR DRUG TARGETS, V13, P802, DOI 10.2174/138945012800564158; Vanneman M, 2012, NAT REV CANCER, V12, P237, DOI 10.1038/nrc3237; Verma A, 2011, MOL CANCER THER, V10, P1763, DOI 10.1158/1535-7163.MCT-11-0116; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Wong HH, 2009, NAT REV GASTRO HEPAT, V6, P412, DOI 10.1038/nrgastro.2009.89; Ye X, 2010, ONCOGENE, V29, P5254, DOI 10.1038/onc.2010.268; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	40	69	78	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2014	33	47					5405	5414		10.1038/onc.2013.487	http://dx.doi.org/10.1038/onc.2013.487			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MG	24240689	Green Accepted, Green Published, Green Submitted			2022-12-28	WOS:000345120700002
J	Kim, J; Wu, L; Zhao, JC; Jin, HJ; Yu, J				Kim, J.; Wu, L.; Zhao, J. C.; Jin, H-J; Yu, J.			TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c	ONCOGENE			English	Article						TMPRSS2-ERG; miR-200c; EMT; prostate cancer	TO-MESENCHYMAL TRANSITION; CANCER-CELLS; ANDROGEN RECEPTOR; DNA METHYLATION; EXPRESSION; POLYCOMB; ERG; FAMILY; TRANSFORMATION; SIGNATURE	Chromosomal translocations that juxtapose the androgen-sensitive transmembrane protease, serine 2 (TMPRSS2) gene promoter to the oncogenic ETS-family transcription factor ERG result in excessive ERG overexpression in approximately 50% of prostate cancer (PCa) patients. Although numerous studies have investigated ERG-downstream genes, such studies have not attempted to examine miRNAs, which however are emerging to be important regulators of cancer. Through bioinformatics analysis of ChIP-Seq ERG data and miRNA expression profiling data we nominated miR-200c as a direct target of ERG. Experimentation of PCa cells with ERG overexpression or knockdown demonstrated that ERG directly repressed miR-200c expression by physically binding to the erythroblast transformation-specific (ETS) motif within its promoter. Consequently, miR-200c was downregulated in ERG-positive PCa, and miR-200c target gene expression was restored. In addition, the expression pattern of miR-200c target genes predicted ERG status in clinical PCa specimens. Furthermore, miR-200c was found to be important in modulating ZEB1 upregulation by ERG. Most importantly, miR-200c reconstitution fully reversed ERG-induced epithelial-to-mesenchymal transition (EMT), cell migration and invasion. Therefore, our study report miR-200c as the first miRNA target of ERG and a critical inhibitor of PCa cell motility. Therapeutic delivery of miR-200c may provide personalized treatment for patients with the molecular subtype of PCa that harbors TMPRSS2-ERG gene fusions.	[Kim, J.; Wu, L.; Zhao, J. C.; Jin, H-J; Yu, J.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Dept Med, Chicago, IL 60611 USA; [Yu, J.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Yu, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Med, Lurie 5-117,303 E Super St, Chicago, IL 60611 USA.	jindan-yu@northwestern.edu	Kim, Jung/Q-7801-2016	Kim, Jung/0000-0001-6274-2841; Jin, Hongjian/0000-0003-3833-7170	NIH [R01CA172384, R00CA129565]; Research Scholar Award [RSG-12-085-01]; American Cancer Society; NRSA pre-doctoral fellowship [T32 CA080621]; NATIONAL CANCER INSTITUTE [R00CA129565, T32CA080621, R01CA172384] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research Scholar Award; American Cancer Society(American Cancer Society); NRSA pre-doctoral fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Jianjun Yu for helpful discussions. This work was supported by funding from the NIH R01CA172384 (to JY), NIH R00CA129565 (to JY) the Research Scholar Award RSG-12-085-01 (to JY) from the American Cancer Society and the NRSA pre-doctoral fellowship T32 CA080621 (to JK).	Adam L, 2009, CLIN CANCER RES, V15, P5060, DOI 10.1158/1078-0432.CCR-08-2245; Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X; Baffa R, 2009, J PATHOL, V219, P214, DOI 10.1002/path.2586; Becker-Santos DD, 2012, CARCINOGENESIS, V33, P2558, DOI 10.1093/carcin/bgs285; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cai CM, 2013, J CLIN INVEST, V123, P1109, DOI 10.1172/JCI66666; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Cao Q, 2011, CANCER CELL, V20, P187, DOI 10.1016/j.ccr.2011.06.016; Carver BS, 2009, NATURE, V457, pE1, DOI 10.1038/nature07738; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Cittelly DM, 2012, MOL CANCER THER, V11, P2556, DOI 10.1158/1535-7163.MCT-12-0463; Clark J, 2007, ONCOGENE, V26, P2667, DOI 10.1038/sj.onc.1210070; Fang YX, 2014, ONCOGENE, V33, P135, DOI 10.1038/onc.2013.54; Gordanpour A, 2011, ANTICANCER RES, V31, P403; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gupta S, 2010, CANCER RES, V70, P6735, DOI 10.1158/0008-5472.CAN-10-0244; Hart M, 2013, FEBS J, V280, P2105, DOI 10.1111/febs.12236; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Hu M, 2010, NUCLEIC ACIDS RES, V38, P2154, DOI 10.1093/nar/gkp1180; Huang S, 2012, ONCOL REP, V28, P1831, DOI 10.3892/or.2012.2015; Iljin K, 2006, CANCER RES, V66, P10242, DOI 10.1158/0008-5472.CAN-06-1986; Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105; Kopp F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050469; Kumar-Sinha C, 2008, NAT REV CANCER, V8, P497, DOI 10.1038/nrc2402; Kunderfranco P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010547; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Leshem O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021650; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Peltier HJ, 2008, RNA, V14, P844, DOI 10.1261/rna.939908; Perner S, 2007, AM J SURG PATHOL, V31, P882, DOI 10.1097/01.pas.0000213424.38503.aa; Puhr M, 2012, AM J PATHOL, V181, P2188, DOI 10.1016/j.ajpath.2012.08.011; Rokavec M, 2012, MOL CELL, V45, P777, DOI 10.1016/j.molcel.2012.01.015; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Shi XB, 2008, J CELL MOL MED, V12, P1456, DOI 10.1111/j.1582-4934.2008.00420.x; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Sun C, 2008, ONCOGENE, V27, P5348, DOI 10.1038/onc.2008.183; Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Vallejo DM, 2011, EMBO J, V30, P756, DOI 10.1038/emboj.2010.358; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697; Wang JH, 2008, CANCER RES, V68, P8516, DOI 10.1158/0008-5472.CAN-08-1147; Wang JH, 2011, CANCER RES, V71, P1325, DOI 10.1158/0008-5472.CAN-10-2210; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Yamamura S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029722; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhao JC, 2012, GENOME RES, V22, P322, DOI 10.1101/gr.131508.111	55	30	30	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2014	33	44					5183	5192		10.1038/onc.2013.461	http://dx.doi.org/10.1038/onc.2013.461			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR9RZ	24186205	Green Accepted			2022-12-28	WOS:000343914900005
J	Lane, A; Segura-Cabrera, A; Komurov, K				Lane, A.; Segura-Cabrera, A.; Komurov, K.			A comparative survey of functional footprints of EGFR pathway mutations in human cancers	ONCOGENE			English	Article						oncogenic networks; functional footprints; EGFR oncogenes	AKT PHOSPHORYLATION; TARGETING EGFR; GENE; KNOWLEDGEBASE; DATABASE; ENCYCLOPEDIA; INHIBITORS; GEFITINIB; NETWORKS; SURVIVAL	Genes functioning in epidermal growth factor receptor (EGFR) signaling pathways are among the most frequently activated oncogenes in human cancers. We have conducted a comparative analysis of functional footprints (that is, effect on signaling and transcriptional landscapes in cells) associated with oncogenic and tumor suppressor mutations in EGFR pathway genes in human cancers. We have found that mutations in the EGFR pathway differentially have an impact on signaling and metabolic pathways in cancer cells in a mutation- and tissue-selective manner. For example, although signaling and metabolic profiles of breast tumors with PIK3CA or AKT1 mutations are, as expected, highly similar, they display markedly different, sometimes even opposite, profiles to those with ERBB2 or EGFR amplifications. On the other hand, although low-grade gliomas and glioblastomas, both brain cancers, driven by EGFR amplifications are highly functionally similar, their functional footprints are significantly different from lung and breast tumors driven by EGFR or ERBB2. Overall, these observations argue that, contrary to expectations, the mechanisms of tumorigenicity associated with mutations in different genes along the same pathway, or in the same gene across different tissues, may be highly different. We present evidence that oncogenic functional footprints in cancer cell lines have significantly diverged from those in tumor tissues, which potentially explains the discrepancy of our findings with the current knowledge. Nevertheless, our analyses reveal a common inflammatory response signature in EGFR-driven human cancers of different tissue origins. Our results may have implications in the design of therapeutic strategies in cancers driven by these oncogenes.	[Lane, A.; Segura-Cabrera, A.; Komurov, K.] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA; [Komurov, K.] Cincinnati Childrens Hosp Med Ctr, Div Biomed Informat, Cincinnati, OH 45229 USA; [Komurov, K.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Komurov, K (corresponding author), Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Div Expt Hematol & Canc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Kakajan.Komurov@cchmc.org		Segura-Cabrera, Aldo/0000-0003-3044-8028	Marlene-Ride Cincinnati Breast Cancer Foundation; Cincinnati Children's; CONACYT-Mexico from Estancias Posdoctorales al Extranjero [203863]	Marlene-Ride Cincinnati Breast Cancer Foundation; Cincinnati Children's; CONACYT-Mexico from Estancias Posdoctorales al Extranjero	This work was supported in part by Marlene-Ride Cincinnati Breast Cancer Foundation Award and Cincinnati Children's Trustee Award to KK. We thank Biplab DasGupta for helpful discussions of the results. ASG acknowledges CONACYT-Mexico for support from Estancias Posdoctorales al Extranjero (grant number 203863).	Akavia UD, 2010, CELL, V143, P1005, DOI 10.1016/j.cell.2010.11.013; Bader GD, 2001, NUCLEIC ACIDS RES, V29, P242, DOI 10.1093/nar/29.1.242; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Breitkreutz BJ, 2008, NUCLEIC ACIDS RES, V36, pD637, DOI 10.1093/nar/gkm1001; Cerami EG, 2011, NUCLEIC ACIDS RES, V39, pD685, DOI 10.1093/nar/gkq1039; Chen YQ, 2008, NATURE, V452, P429, DOI 10.1038/nature06757; Ciardiello F, 2004, CURR OPIN ONCOL, V16, P130, DOI 10.1097/00001622-200403000-00008; Cresswell P, 2005, IMMUNOL REV, V207, P145, DOI 10.1111/j.0105-2896.2005.00316.x; Dahabreh IJ, 2010, CLIN CANCER RES, V16, P291, DOI 10.1158/1078-0432.CCR-09-1660; De Luca A, 2012, EXPERT OPIN THER TAR, V16, pS17, DOI 10.1517/14728222.2011.639361; Fukuoka M, 2011, J CLIN ONCOL, V29, P2866, DOI 10.1200/JCO.2010.33.4235; Gallay N, 2009, LEUKEMIA, V23, P1029, DOI 10.1038/leu.2008.395; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Gerstein MB, 2012, NATURE, V489, P91, DOI 10.1038/nature11245; Griffith OL, 2008, NUCLEIC ACIDS RES, V36, pD107, DOI 10.1093/nar/gkm967; Hegi ME, 2011, MOL CANCER THER, V10, P1102, DOI 10.1158/1535-7163.MCT-11-0048; Joshi-Tope G, 2005, NUCLEIC ACIDS RES, V33, pD428, DOI 10.1093/nar/gki072; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Komurov K, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-282; Komurov K, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000889; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Maglott D, 2007, NUCLEIC ACIDS RES, V35, pD26, DOI 10.1093/nar/gkl993; Mishra GR, 2006, NUCLEIC ACIDS RES, V34, pD411, DOI 10.1093/nar/gkj141; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Oda K, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100014; Parekh DB, 2000, BIOCHEM J, V352, P425, DOI 10.1042/0264-6021:3520425; Pearson G, 2000, J BIOL CHEM, V275, P37303, DOI 10.1074/jbc.C000570200; Salama AKS, 2013, CLIN CANCER RES, V19, P4326, DOI 10.1158/1078-0432.CCR-13-0779; Saxena R, 2012, MED RES REV, V32, P166, DOI 10.1002/med.20209; Schellenberger J, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-213; Segal E, 2003, NAT GENET, V34, P166, DOI 10.1038/ng1165; Taylor TE, 2012, CURR CANCER DRUG TAR, V12, P197; Troiani T, 2012, CURR DRUG TARGETS, V13, P802, DOI 10.2174/138945012800564158; Uribe P, 2006, J INVEST DERMATOL, V126, P161, DOI 10.1038/sj.jid.5700011; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vincent EE, 2011, BRIT J CANCER, V104, P1755, DOI 10.1038/bjc.2011.132; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Vyas JM, 2008, NAT REV IMMUNOL, V8, P607, DOI 10.1038/nri2368; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Wishart DS, 2009, NUCLEIC ACIDS RES, V37, pD603, DOI 10.1093/nar/gkn810; Wolpert F, 2012, J NEUROIMMUNOL, V250, P27, DOI 10.1016/j.jneuroim.2012.05.010; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	45	10	10	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2014	33	43					5078	5089		10.1038/onc.2013.452	http://dx.doi.org/10.1038/onc.2013.452			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OF	24166508				2022-12-28	WOS:000343768400003
J	Nguyen, HG; Yang, JC; Kung, HJ; Shi, XB; Tilki, D; Lara, PN; White, RWD; Gao, AC; Evans, CP				Nguyen, H. G.; Yang, J. C.; Kung, H-J; Shi, X-B; Tilki, D.; Lara, P. N., Jr.; White, R. W. DeVere; Gao, A. C.; Evans, C. P.			Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model	ONCOGENE			English	Article							ANDROGEN RECEPTOR; APOPTOSIS; DEPRIVATION; METFORMIN; SURVIVAL; RAPTOR; PHOSPHORYLATION; COMBINATION; INHIBITION; INDUCTION	Macro-autophagy is associated with drug resistance in various cancers and can function as an adaptive response to maintain cell survival under metabolic stresses, including androgen deprivation. Androgen deprivation or treatment with androgen receptor (AR) signaling inhibitor (ARSI), Enzalutamide (MDV-3100, ENZA) or bicalutamide induced autophagy in androgen-dependent and in castration-resistant CaP (castration-resistant prostate cancer (CRPC)) cell lines. The autophagic cascade triggered by AR blockage, correlated with the increased light chain 3-II/I ratio and ATG-5 expression. Autophagy was observed in a subpopulation of C4-2B cells that developed insensitivity to ENZA after sustained exposure in culture. Using flow cytometry and clonogenic assays, we showed that inhibiting autophagy with clomipramine (CMI), chloroquine or metformin increased apoptosis and significantly impaired cell viability. This autophagic process was mediated by AMP-dependent protein kinase (AMPK) activation and the suppression of mammalian target of rapamycin (mTOR) through Raptor phosphorylation (Serine 792). Furthermore, small interfering RNA targeting AMPK significantly inhibited autophagy and promoted cell death in CaP cells acutely or chronically exposed to ENZA or androgen deprivation, suggesting that autophagy is an important survival mechanism in CRPC. Lastly, in vivo studies with mice orthotopically implanted with ENZA-resistant cells demonstrated that the combination of ENZA and autophagy modulators, CMI or metformin significantly reduced tumor growth when compared with control groups (P < 0.005). In conclusion, autophagy is as an important mechanism of resistance to ARSI in CRPC. Antiandrogen-induced autophagy is mediated through the activation of AMPK pathway and the suppression of mTOR pathway. Blocking autophagy pharmacologically or genetically significantly impairs prostate cancer cell survival in vitro and in vivo, implying the therapeutics potential of autophagy inhibitors in the antiandrogen-resistance setting.	[Nguyen, H. G.; Yang, J. C.; Shi, X-B; Tilki, D.; White, R. W. DeVere; Gao, A. C.; Evans, C. P.] Univ Calif Davis, Sch Med, Dept Urol, Sacramento, CA 95817 USA; [Kung, H-J] Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Sacramento, CA 95817 USA; [Kung, H-J; Lara, P. N., Jr.; White, R. W. DeVere; Gao, A. C.; Evans, C. P.] Univ Calif Davis, Sch Med, UC Davis Comprehens Canc Ctr, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Evans, CP (corresponding author), Univ Calif Davis, Sch Med, Dept Urol, 4860 Y St,Suite 3500, Sacramento, CA 95817 USA.	christopher.evans@ucdmc.ucdavis.edu		Nguyen, Hao/0000-0001-8275-5375	DOD [PC111467]; Medivation/Astellas; NIH [RO1 CA 165263 - 13]; Stand Up To Cancer-Prostate Cancer Foundation-Prostate Dream Team Translational Cancer Research Grant [SU2C-AACR-PCF DT0812]; Movember Foundation; NATIONAL CANCER INSTITUTE [R01CA165263, P30CA093373] Funding Source: NIH RePORTER	DOD(United States Department of Defense); Medivation/Astellas; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Stand Up To Cancer-Prostate Cancer Foundation-Prostate Dream Team Translational Cancer Research Grant; Movember Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported in part by Grants DOD PC111467 and Medivation/Astellas to CPE, NIH RO1 CA 165263 - 13 to H-JK and by a Stand Up To Cancer-Prostate Cancer Foundation-Prostate Dream Team Translational Cancer Research Grant SU2C-AACR-PCF DT0812 to Eric Small, Owen Witte and CPE. This research grant is made possible by the generous support of the Movember Foundation. Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research: The costs of publication of this article were defrayed. Mention of trade name, proprietary product or specific equipment does not constitute a guaranty of warranty by the Department of Defense, nor does it imply approval to the exclusion of other products. The views expressed herein represent those of the authors and do not necessarily represent the position of the Department of Defense.	Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562; Ben Sahra I, 2010, AUTOPHAGY, V6, P670, DOI 10.4161/auto.6.5.12434; Ben Sahra I, 2010, CANCER RES, V70, P2465, DOI 10.1158/0008-5472.CAN-09-2782; Bennett HL, 2013, BJU INT, V111, P672, DOI 10.1111/j.1464-410X.2012.11409.x; Boutin B, 2013, PROSTATE, V73, P1090, DOI 10.1002/pros.22658; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chhipa RR, 2011, CELL SIGNAL, V23, P1466, DOI 10.1016/j.cellsig.2011.04.008; Gillman PK, 2007, BRIT J PHARMACOL, V151, P737, DOI 10.1038/sj.bjp.0707253; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jiang Q, 2012, J UROLOGY, V188, P1361, DOI 10.1016/j.juro.2012.06.004; Kim RH, 2009, AUTOPHAGY, V5, P567, DOI 10.4161/auto.5.4.8252; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Korpal M, 2013, CANCER DISCOV, V3, P1030, DOI 10.1158/2159-8290.CD-13-0142; Kung H- J, 2013, PROSTATE CANC, V16, P497; Kung Hsing-Jien, 2011, Hormones & Cancer, V2, P38, DOI 10.1007/s12672-010-0053-3; Lee JHW, 2009, J HYDRO-ENVIRON RES, V3, P1, DOI 10.1016/j.jher.2009.05.002; Leprivier G, 2013, CELL, V153, P1064, DOI 10.1016/j.cell.2013.04.055; Li MQ, 2008, AUTOPHAGY, V4, P54, DOI 10.4161/auto.5209; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Liu DL, 2011, MED ONCOL, V28, P105, DOI 10.1007/s12032-009-9397-3; Liu HY, 2012, ANTICANCER RES, V32, P1627; Luo J, 2013, EUR UROL, V64, P339, DOI 10.1016/j.eururo.2013.05.012; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Nadiminty N, 2013, MOL CANCER THER, V12, P1629, DOI 10.1158/1535-7163.MCT-13-0027; Nguyen HG, 2009, FASEB J, V23, P2741, DOI 10.1096/fj.09-130963; Nguyen HG, 2005, MOL CELL BIOL, V25, P4977, DOI 10.1128/MCB.25.12.4977-4992.2005; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Rossi M, 2009, J CELL SCI, V122, P3330, DOI 10.1242/jcs.048181; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Shi WY, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.13; Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008; Tomic T, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.86; Wu Zhaoju, 2010, Genes Cancer, V1, P40, DOI 10.1177/1947601909358324	37	128	134	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2014	33	36					4521	4530		10.1038/onc.2014.25	http://dx.doi.org/10.1038/onc.2014.25			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MY	24662833	Green Published, hybrid			2022-12-28	WOS:000341158800007
J	Ueda, J; Matsuda, Y; Yamahatsu, K; Uchida, E; Naito, Z; Korc, M; Ishiwata, T				Ueda, J.; Matsuda, Y.; Yamahatsu, K.; Uchida, E.; Naito, Z.; Korc, M.; Ishiwata, T.			Epithelial splicing regulatory protein 1 is a favorable prognostic factor in pancreatic cancer that attenuates pancreatic metastases	ONCOGENE			English	Article						ESRP1; pancreatic cancer; FGFR-2 IIIb; FGFR-2 IIIc; EMT	KERATINOCYTE GROWTH-FACTOR; IMMOBILIZED PH GRADIENTS; MESENCHYMAL TRANSITION; INTRAEPITHELIAL NEOPLASIA; DUCTAL ADENOCARCINOMA; ENHANCED EXPRESSION; COLORECTAL-CANCER; RECEPTOR; CELLS; CARCINOMA	Epithelial splicing regulatory protein 1 (ESRP1) binds the FGFR-2 auxiliary cis-element ISE/ISS-3, located in the intron between exon IIIb and IIIc, and primarily promotes FGFR-2 IIIb expression. Here we assessed the role of ESRP1 in pancreatic ductal adenocarcinoma (PDAC). Immunohistochemical analysis was performed using anti-ESRP1, FGFR-2 IIIb and FGFR-2 IIIc antibodies in 123 PDAC cases. ESRP1 expression vector and small interference RNA (siRNA) targeting ESRP1 were transfected into human PDAC cells, and cell growth, migration and invasion were analyzed. In vivo heterotopic and orthotopic implantations using ESRP1 overexpression clones were performed and effects on pancreatic tumor volumes and hepatic and pulmonary metastases determined. ESRP1 immunoreactivity was strong in the nuclei of cancer cells in well-to-moderately differentiated PDACs but weak in poorly differentiated cancers. Well-to-moderately differentiated cancers also exhibited high FGFR-2 IIIb and low FGFR-2 IIIc expression, whereas this ratio was reversed in the poorly differentiated cancers. Increased ESRP1 expression was associated with longer survival in comparison with low ESRP1 expression, and PANC-1 cells engineered to express ESRP1 exhibited increased FGFR-2 IIIb expression and decreased migration and invasion in vitro, whereas ESRP1 siRNA-transfected KLM-1 cells exhibited increased FGFR-2 IIIc expression and increased cell growth, migration and invasion. In vivo, ESRP1-overexpressing clones formed significantly fewer liver metastases as compared with control clones. ESRP1 regulates the expression pattern of FGFR-2 isoforms, attenuates cell growth, migration, invasion and metastasis, and is a favorable prognostic factor in PDAC. Therefore, devising mechanisms to upregulate ESRP1 may exert a beneficial therapeutic effect in PDAC.	[Ueda, J.; Matsuda, Y.; Yamahatsu, K.; Naito, Z.; Ishiwata, T.] Nippon Med Sch, Dept Pathol, Tokyo 1138602, Japan; [Ueda, J.; Matsuda, Y.; Yamahatsu, K.; Naito, Z.; Ishiwata, T.] Nippon Med Sch, Dept Integrat Oncol Pathol, Tokyo 1138602, Japan; [Ueda, J.; Yamahatsu, K.; Uchida, E.] Nippon Med Sch, Grad Sch Med, Dept Surg Organ & Biol Regulat, Tokyo 1138602, Japan; [Korc, M.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA; [Korc, M.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Korc, M.] Melvin & Bren Simon Canc Ctr, Indianapolis, IN USA	Nippon Medical School; Nippon Medical School; Nippon Medical School; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Ishiwata, T (corresponding author), Nippon Med Sch, Dept Pathol, 1-1-5 Sendagi, Tokyo 1138602, Japan.	ishiwata@nms.ac.jp	Ishiwata, Toshiyuki/H-1151-2014	Ishiwata, Toshiyuki/0000-0002-4180-0069	Japan Society for the Promotion of Science [22591531, 22689038, 23650604]; NIH [R37-CA-075059]; NATIONAL CANCER INSTITUTE [R01CA075059, R37CA075059] Funding Source: NIH RePORTER	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We express our appreciation to Dr Masahito Hagio for helpful discussion and Dr Tetsushi Yamamoto, Mr Yuji Yanagisawa, Ms Taeko Suzuki, Ms Yoko Kawamoto and Ms Kiyoko Kawahara (Department of Pathology, Nippon Medical School) for their excellent technical assistance. We also thank Dr Shin-ichi Tsuchiya (Division of Surgical Pathology, Nippon Medical School Hospital) for preparing tissue blocks. This work was supported by Grants-in-Aid for Scientific Research (C, No.22591531 for TI), a Grant-in-Aid for Young Scientists (A, No. 22689038 for YM) a Grant-in-Aid for Challenging Exploratory Research (No. 23650604 for YM) from the Japan Society for the Promotion of Science, and in part by NIH grant R37-CA-075059 to MK.	Bailey KM, 2008, J BIOL CHEM, V283, P13714, DOI 10.1074/jbc.M709329200; Baum B, 2008, SEMIN CELL DEV BIOL, V19, P294, DOI 10.1016/j.semcdb.2008.02.001; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Cho K, 2007, AM J PATHOL, V170, P1964, DOI 10.2353/ajpath.2007.060935; Di Modugno F, 2012, P NATL ACAD SCI USA, V109, P19280, DOI 10.1073/pnas.1214394109; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; Esposito I, 2004, J CLIN PATHOL, V57, P630, DOI 10.1136/jcp.2003.014498; Feig C, 2012, CLIN CANCER RES, V18, P4266, DOI 10.1158/1078-0432.CCR-11-3114; Gemmill RM, 2011, CANCER LETT, V300, P66, DOI 10.1016/j.canlet.2010.09.007; Gorg A, 1997, ELECTROPHORESIS, V18, P328, DOI 10.1002/elps.1150180306; Gorg A, 1999, ELECTROPHORESIS, V20, P712; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hovhannisyan RH, 2007, J BIOL CHEM, V282, P36265, DOI 10.1074/jbc.M704188200; Hruban RH, 2008, INT J CLIN EXP PATHO, V1, P306; Ishiwata T, 1998, AM J PATHOL, V153, P213, DOI 10.1016/S0002-9440(10)65562-9; Ishiwata T, 2012, AM J PATHOL, V180, P1928, DOI 10.1016/j.ajpath.2012.01.020; Johnson M, 2009, CELL SIGNAL, V21, P1471, DOI 10.1016/j.cellsig.2009.02.023; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Katoh M, 2009, J INVEST DERMATOL, V129, P1861, DOI 10.1038/jid.2009.97; Kawase R, 2010, INT J ONCOL, V36, P331, DOI 10.3892/ijo_00000504; Korc M, 1998, Surg Oncol Clin N Am, V7, P25; Korc M, 2009, CURR CANCER DRUG TAR, V9, P639, DOI 10.2174/156800909789057006; Leontieva OV, 2009, CELL CYCLE, V8, P490, DOI 10.4161/cc.8.3.7679; Matsuda Y, 2011, CANCER BIOL THER, V11, P512, DOI 10.4161/cbt.11.5.14673; Matsuda Y, 2008, INT J ONCOL, V33, P1177, DOI 10.3892/ijo_00000107; Mauger DM, 2008, MOL CELL BIOL, V28, P5403, DOI 10.1128/MCB.00739-08; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; Seiden-Long I, 2008, CARCINOGENESIS, V29, P647, DOI 10.1093/carcin/bgn009; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Suemizu H, 2007, INT J ONCOL, V31, P741; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tuveson DA, 2012, CELL, V148, P21, DOI 10.1016/j.cell.2011.12.021; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Warzecha CC, 2009, RNA BIOL, V6, P546, DOI 10.4161/rna.6.5.9606; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Wickstrom SA, 2010, DEV CELL, V19, P574, DOI 10.1016/j.devcel.2010.09.007; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yan L, 2013, DIGEST DIS SCI, V58, P389, DOI 10.1007/s10620-012-2341-y	48	61	63	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2014	33	36					4485	4495		10.1038/onc.2013.392	http://dx.doi.org/10.1038/onc.2013.392			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MY	24077287	Green Submitted, Green Accepted			2022-12-28	WOS:000341158800004
J	Barbetti, V; Morandi, A; Tusa, I; Digiacomo, G; Riverso, M; Marzi, I; Cipolleschi, MG; Bessi, S; Giannini, A; Di Leo, A; Dello Sbarba, P; Rovida, E				Barbetti, V.; Morandi, A.; Tusa, I.; Digiacomo, G.; Riverso, M.; Marzi, I.; Cipolleschi, M. G.; Bessi, S.; Giannini, A.; Di Leo, A.; Dello Sbarba, P.; Rovida, E.			Chromatin-associated CSF-1R binds to the promoter of proliferation-related genes in breast cancer cells	ONCOGENE			English	Article						CSF-1; nuclear proteins; breast cancer; Fms; nuclear receptor tyrosine kinase	COLONY-STIMULATING FACTOR; FIBROBLAST-GROWTH-FACTOR; FACTOR-I; NUCLEAR TRANSLOCATION; FACTOR-RECEPTOR; C-FMS; MACROPHAGE PRODUCTION; SIGNAL-TRANSDUCTION; TYROSINE KINASE; CERVICAL-CANCER	The colony-stimulating factor-1 (CSF-1) and its receptor CSF-1R physiologically regulate the monocyte/macrophage system, trophoblast implantation and breast development. An abnormal CSF-1R expression has been documented in several human epithelial tumors, including breast carcinomas. We recently demonstrated that CSF-1/CSF-1R signaling drives proliferation of breast cancer cells via 'classical' receptor tyrosine kinase signaling, including activation of the extracellular signal-regulated kinase 1/2. In this paper, we show that CSF-1R can also localize within the nucleus of breast cancer cells, either cell lines or tissue specimens, irrespectively of their intrinsic molecular subtype. We found that the majority of nuclear CSF-1R is located in the chromatin-bound subcellular compartment. Chromatin immunoprecipitation revealed that CSF-1R, once in the nucleus, binds to the promoters of the proliferation-related genes CCND1, c-JUN and c-MYC. CSF-1R also binds the promoter of its ligand CSF-1 and positively regulates CSF-1 expression. The existence of such a receptor/ligand regulatory loop is a novel aspect of CSF-1R signaling. Moreover, our results provided the first evidence of a novel localization site of CSF-1R in breast cancer cells, suggesting that CSF-1R could act as a transcriptional regulator on proliferation-related genes.	[Barbetti, V.; Morandi, A.; Tusa, I.; Digiacomo, G.; Riverso, M.; Marzi, I.; Cipolleschi, M. G.; Dello Sbarba, P.; Rovida, E.] Univ Florence, Sez Patol, Dipartimento Sci Biomed Sperimentali & Clin, Ist Toscano Tumori, I-50134 Florence, Italy; [Bessi, S.; Giannini, A.] Osped Prato, Prato, Italy; [Di Leo, A.] Hosp Prato, Ist Toscano Tumori, Dept Oncol, Sandro Pitigliani Med Oncol Unit, Prato, Italy	ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; University of Florence; Prato Hospital; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; Prato Hospital	Rovida, E (corresponding author), Univ Florence, Sez Patol, Dipartimento Sci Biomed Sperimentali & Clin, Viale GB Morgagni 50, I-50134 Florence, Italy.	erovida@unifi.it	Dello Sbarba, Persio/AAX-9887-2020; Rovida, Elisabetta/F-3565-2015; Morandi, Andrea/AAC-1901-2022	Rovida, Elisabetta/0000-0002-5949-3239; Morandi, Andrea/0000-0002-9222-5332; Tusa, Ignazia/0000-0002-9198-2630	Istituto Toscano Tumori, Associazione Italiana per la Ricerca sul Cancro, Ministero della Salute (Ricerca Finalizzata) [RF-TOS-2008-1163728]; Regione Toscana (Programma per la Ricerca in Materia di Salute); Associazione Italiana per la Lotta contro le Leucemie e i Linfomi (sezione di Prato); Fondazione Cassa di Risparmio di Volterra; Fondazione Oretta Bartolomei-Corsi	Istituto Toscano Tumori, Associazione Italiana per la Ricerca sul Cancro, Ministero della Salute (Ricerca Finalizzata)(Fondazione AIRC per la ricerca sul cancro); Regione Toscana (Programma per la Ricerca in Materia di Salute)(Regione Toscana); Associazione Italiana per la Lotta contro le Leucemie e i Linfomi (sezione di Prato)(Fondazione AIRC per la ricerca sul cancro); Fondazione Cassa di Risparmio di Volterra; Fondazione Oretta Bartolomei-Corsi(Fondazione CarifeFondazione Caritro)	This work was supported by Istituto Toscano Tumori, Associazione Italiana per la Ricerca sul Cancro, Ministero della Salute (Ricerca Finalizzata, Grant number RF-TOS-2008-1163728), Regione Toscana (Programma per la Ricerca in Materia di Salute), Associazione Italiana per la Lotta contro le Leucemie e i Linfomi (sezione di Prato), Fondazione Cassa di Risparmio di Volterra, Fondazione Oretta Bartolomei-Corsi. We thank Professor Clare M Isacke (Breakthrough Breast Cancer Research Centre, London, UK) for revising the manuscript.	Barbetti V, 2008, ONCOGENE, V27, P1767, DOI 10.1038/sj.onc.1210820; Barbetti V, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.49; Barbetti V, 2013, EPIGENETICS-US, V8, P210, DOI 10.4161/epi.23538; Brameier M, 2007, BIOINFORMATICS, V23, P1159, DOI 10.1093/bioinformatics/btm066; Bryant DM, 2005, TRAFFIC, V6, P947, DOI 10.1111/j.1600-0854.2005.00332.x; Chioni AM, 2012, J CELL BIOL, V197, P801, DOI 10.1083/jcb.201108077; D'Angelo MA, 2008, TRENDS CELL BIOL, V18, P456, DOI 10.1016/j.tcb.2008.07.009; Dittmann K, 2010, STRAHLENTHER ONKOL, V186, P1, DOI 10.1007/s00066-009-2026-4; Feng YY, 1999, BIOCHEM BIOPH RES CO, V256, P192, DOI 10.1006/bbrc.1998.9790; GUILBERT LJ, 1986, J BIOL CHEM, V261, P4024; Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145; Hammes LS, 2008, GYNECOL ONCOL, V110, P445, DOI 10.1016/j.ygyno.2008.04.038; Ide H, 2002, P NATL ACAD SCI USA, V99, P14404, DOI 10.1073/pnas.222537099; Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643; KACINSKI BM, 1991, ONCOGENE, V6, P941; Kacinski BM, 1997, MOL REPROD DEV, V46, P71, DOI 10.1002/(SICI)1098-2795(199701)46:1<71::AID-MRD11>3.0.CO;2-6; Kirma N, 2007, CANCER RES, V67, P1918, DOI 10.1158/0008-5472.CAN-06-1991; Kluger HM, 2004, CLIN CANCER RES, V10, P173, DOI 10.1158/1078-0432.CCR-0699-3; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Lin HS, 2008, SCIENCE, V320, P807, DOI 10.1126/science.1154370; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Maher MG, 1998, CLIN CANCER RES, V4, P1851; Mancini A, 2004, ONCOGENE, V23, P6581, DOI 10.1038/sj.onc.1207841; Mayo LD, 2001, J BIOL CHEM, V276, P25184, DOI 10.1074/jbc.M102932200; Morandi A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027450; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Offterdinger M, 2004, J BIOL CHEM, V279, P36972, DOI 10.1074/jbc.M405830200; Offterdinger M, 2002, J CELL BIOL, V157, P929, DOI 10.1083/jcb.200109033; Peng H, 2001, MOL BIOL CELL, V12, P449, DOI 10.1091/mbc.12.2.449; Pixley FJ, 2004, TRENDS CELL BIOL, V14, P628, DOI 10.1016/j.tcb.2004.09.016; Reilly JF, 2001, J CELL BIOL, V152, P1307, DOI 10.1083/jcb.152.6.1307; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1994, J CELL SCI, P105; Rovida E, 2005, BIOL CHEM, V386, P919, DOI 10.1515/BC.2005.107; Rovida E, 2002, ONCOGENE, V21, P3670, DOI 10.1038/sj.onc.1205409; Rovida E, 2008, J IMMUNOL, V180, P4166, DOI 10.4049/jimmunol.180.6.4166; SCHOLL SM, 1994, JNCI-J NATL CANCER I, V86, P120, DOI 10.1093/jnci/86.2.120; Sehat B, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000628; Seol KC, 2003, BIOCHEM BIOPH RES CO, V306, P898, DOI 10.1016/S0006-291X(03)01046-5; SHADLE PJ, 1989, J CELL BIOCHEM, V40, P91, DOI 10.1002/jcb.240400110; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; STANLEY ER, 1978, NATURE, V274, P168, DOI 10.1038/274168a0; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; Toy EP, 2009, NEOPLASIA, V11, P136, DOI 10.1593/neo.81150; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Wang YN, 2010, ONCOGENE, V29, P3997, DOI 10.1038/onc.2010.157; Yee LD, 2000, ANTICANCER RES, V20, P4379; Yeung YG, 1998, J BIOL CHEM, V273, P17128, DOI 10.1074/jbc.273.27.17128; Zwaenepoel O, 2012, FASEB J, V26, P691, DOI 10.1096/fj.11-189753	51	21	24	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2014	33	34					4359	4364		10.1038/onc.2013.542	http://dx.doi.org/10.1038/onc.2013.542			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MK	24362524	Green Published, hybrid			2022-12-28	WOS:000341156900009
J	Park, JW; Shin, MK; Lambert, PF				Park, J. W.; Shin, M-K; Lambert, P. F.			High incidence of female reproductive tract cancers in FA-deficient HPV16-transgenic mice correlates with E7's induction of DNA damage response, an activity mediated by E7's inactivation of pocket proteins	ONCOGENE			English	Article						HPV16 E7; HPV-positive cancer; Fanconi anemia	HUMAN-PAPILLOMAVIRUS TYPE-16; FANCONI-ANEMIA PATHWAY; FANCD2 KNOCKOUT MICE; CERVICAL-CANCER; MOUSE MODEL; NECK-CANCER; CELL-CYCLE; S-PHASE; GENOMIC INSTABILITY; LIFE-CYCLE	Fanconi anemia (FA) is a rare genetic disorder caused by defects in a DNA damage repair system, the FA pathway. FA patients frequently develop squamous cell carcinoma (SCC) at sites that are associated with human papillomavirus (HPV)-driven cancer including the female reproductive tract. To assess experimentally whether FA deficiency increases susceptibility to HPV-associated cervical/vaginal cancer, we monitored cancer incidence in the female lower reproductive tract of FA-deficient mice expressing HPV16 oncogenes, E6 and/or E7. FA deficiency specifically increased the incidence of cancers in mice expressing E7; but this effect was not observed in mice just expressing E6. We also observed that E7, but not E6, induced DNA damage as scored by induction of g-H2AX and 53BP1 (p53 binding protein 1) nuclear foci, and this induction was heightened in FA-deficient tissue. Finally, we discovered that this induction of DNA damage responses was recapitulated in mice deficient in expression of `pocket' proteins, pRb, p107 and p130, which are established targets of E7. Our findings support the hypothesis that E7 induces cancer by causing DNA damage at least in part through the inactivation of pocket proteins. This hypothesis explains why a deficiency in DNA damage repair would increase susceptibility to E7-driven cancer.	[Park, J. W.; Shin, M-K; Lambert, P. F.] Univ Wisconsin, McArdle Lab Canc Res, Sch Med & Publ Hlth, Dept Oncol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Lambert, PF (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	lambert@oncology.wisc.edu		Park, Jung Wook/0000-0003-4798-9621	NIH [CA098428, CA022443]; NATIONAL CANCER INSTITUTE [R01CA098428, P01CA022443] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Norman Drinkwater for advice on statistical analysis of the data reported in this study and Markus Grompe for the fancD2-null mouse strain. This study was supported by grants from the NIH (CA098428 and CA022443).	Alter BP, 2003, BLOOD, V101, P2072, DOI 10.1182/blood-2002-11-3597; Balsitis SJ, 2003, MOL CELL BIOL, V23, P9094, DOI 10.1128/MCB.23.24.9094-9103.2003; Begum S, 2005, CLIN CANCER RES, V11, P5694, DOI 10.1158/1078-0432.CCR-05-0587; Brake T, 2003, CANCER RES, V63, P8173; Chung SH, 2008, CANCER RES, V68, P9928, DOI 10.1158/0008-5472.CAN-08-2051; Collins AS, 2005, J VIROL, V79, P14769, DOI 10.1128/JVI.79.23.14769-14780.2005; Crossan GP, 2012, J PATHOL, V226, P326, DOI 10.1002/path.3002; de Araujo MR, 2011, ORAL DIS, V17, P572, DOI 10.1111/j.1601-0825.2011.01803.x; Duensing S, 2002, CANCER RES, V62, P7075; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Duensing S, 2001, J VIROL, V75, P7712, DOI 10.1128/JVI.75.16.7712-7716.2001; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; Garner E, 2011, FEBS LETT, V585, P2853, DOI 10.1016/j.febslet.2011.04.078; Genther SM, 2003, J VIROL, V77, P2832, DOI 10.1128/JVI.77.5.2832-2842.2003; Gillison ML, 2004, LANCET, V363, P1488, DOI 10.1016/S0140-6736(04)16194-1; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Ho VM, 2009, ONCOGENE, V28, P1393, DOI 10.1038/onc.2008.491; Hoskins EE, 2009, ONCOGENE, V28, P674, DOI 10.1038/onc.2008.416; Hoskins EE, 2012, J VIROL, V86, P8131, DOI 10.1128/JVI.00408-12; Houghtaling S, 2005, CANCER RES, V65, P85; Houghtaling S, 2003, GENE DEV, V17, P2021, DOI 10.1101/gad.1103403; Huh KW, 2005, P NATL ACAD SCI USA, V102, P11492, DOI 10.1073/pnas.0505337102; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Juko-Pecirep I, 2011, GYNECOL ONCOL, V122, P377, DOI 10.1016/j.ygyno.2011.04.014; Kennedy RD, 2005, GENE DEV, V19, P2925, DOI 10.1101/gad.1370505; Knipscheer P, 2009, SCIENCE, V326, P1698, DOI 10.1126/science.1182372; Kutler DI, 2003, BLOOD, V101, P1249, DOI 10.1182/blood-2002-07-2170; Liu TX, 2003, DEV CELL, V5, P903, DOI 10.1016/S1534-5807(03)00339-3; Longworth MS, 2004, MICROBIOL MOL BIOL R, V68, P362, DOI 10.1128/MMBR.68.2.362-372.2004; MAYOL X, 1993, ONCOGENE, V8, P2561; McLaughlin-Drubin ME, 2009, VIROLOGY, V384, P335, DOI 10.1016/j.virol.2008.10.006; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Park JW, 2010, CANCER RES, V70, P9959, DOI 10.1158/0008-5472.CAN-10-1291; Pichierri P, 2004, EMBO J, V23, P1178, DOI 10.1038/sj.emboj.7600113; Pyeon D, 2007, CANCER RES, V67, P4605, DOI 10.1158/0008-5472.CAN-06-3619; Pyeon D, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000318; Riley RR, 2003, CANCER RES, V63, P4862; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Schaffer BE, 2010, CANCER RES, V70, P3877, DOI 10.1158/0008-5472.CAN-09-4228; Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(13)60022-7; Shai A, 2008, CANCER RES, V68, P2622, DOI 10.1158/0008-5472.CAN-07-5266; Shai A, 2007, CANCER RES, V67, P1626, DOI 10.1158/0008-5472.CAN-06-3344; Shin MK, 2012, CANCER RES, V72, P5418, DOI 10.1158/0008-5472.CAN-12-2083; Shin MK, 2012, CANCER RES, V72, P1280, DOI 10.1158/0008-5472.CAN-11-2833; Shin MK, 2009, CANCER RES, V69, P5656, DOI 10.1158/0008-5472.CAN-08-3711; Simpson DS, 2009, CANCER RES, V69, P8733, DOI 10.1158/0008-5472.CAN-09-1359; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Spardy N, 2007, J VIROL, V81, P13265, DOI 10.1128/JVI.01121-07; Strati K, 2006, P NATL ACAD SCI USA, V103, P14152, DOI 10.1073/pnas.0606698103; Sun A, 2007, J CELL BIOCHEM, V102, P1400, DOI 10.1002/jcb.21609; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Wang SS, 2009, J INFECT DIS, V199, P20, DOI 10.1086/595563; Watson M, 2008, CANCER-AM CANCER SOC, V113, P2841, DOI 10.1002/cncr.23758; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; Zhang QS, 2010, BLOOD, V116, P5140, DOI 10.1182/blood-2010-04-278226	59	22	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3383	3391		10.1038/onc.2013.327	http://dx.doi.org/10.1038/onc.2013.327			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	24013229	Green Accepted			2022-12-28	WOS:000338779300005
J	Shang, Y; Zhang, Z; Liu, Z; Feng, B; Ren, G; Li, K; Zhou, L; Sun, Y; Li, M; Zhou, J; An, Y; Wu, K; Nie, Y; Fan, D				Shang, Y.; Zhang, Z.; Liu, Z.; Feng, B.; Ren, G.; Li, K.; Zhou, L.; Sun, Y.; Li, M.; Zhou, J.; An, Y.; Wu, K.; Nie, Y.; Fan, D.			miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1	ONCOGENE			English	Article						miR-508-5p; gastric cancer; drug resistance; ABCB1; ZNRD1	P-GLYCOPROTEIN; HEPATOCELLULAR-CARCINOMA; DOWN-REGULATION; CELLS; EXPRESSION; MICRORNAS; CISPLATIN; GLYCOSYLATION; MECHANISM; CHEMORESISTANCE	Multidrug resistance (MDR) is usually correlated with the poor prognosis of gastric cancer. In this study, we revealed a total of 11 microRNAs (miRNA) that regulated MDR of gastric cancer via high-throughput functional screening, and miR-508-5p reversed MDR most efficiently among these candidate miRNAs. The overexpression of miR-508-5p was sufficient to reverse cancer cell resistance to multiple chemotherapeutics in vitro and sensitize tumours to chemotherapy in vivo. Further studies showed that miR-508-5p could directly target the 3'-untranslated regions of ABCB1 and Zinc ribbon domain-containing 1 (ZNRD1), and suppress their expression at the mRNA and protein levels. Meanwhile, the suppression of ZNRD1 led to a decrease in ABCB1. These findings suggest that a miR-508-5p/ZNRD1/ABCB1 regulatory loop has a critical role in MDR in gastric cancer. In addition, miR-508-5p could be used as a prognostic factor for overall survival in gastric cancer. These data reveal an important role for miR-508-5p in the regulation of MDR in gastric cancer, and suggest the potential application of miR-508-5p in drug resistance prediction and treatment.	[Shang, Y.; Zhang, Z.; Liu, Z.; Feng, B.; Ren, G.; Li, K.; Zhou, L.; Sun, Y.; Li, M.; Zhou, J.; Wu, K.; Nie, Y.; Fan, D.] Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Xian 710032, Peoples R China; [Shang, Y.; Zhang, Z.; Liu, Z.; Feng, B.; Ren, G.; Li, K.; Zhou, L.; Sun, Y.; Li, M.; Zhou, J.; Wu, K.; Nie, Y.; Fan, D.] Fourth Mil Med Univ, Xijing Hosp, Xijing Hosp Digest Dis, Xian 710032, Peoples R China; [An, Y.] Jinan Mil Command, Gen Hosp, Dept Gen Surg, Jinan, Peoples R China	Air Force Military Medical University; Air Force Military Medical University	Nie, Y (corresponding author), Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, West Changle Rd, Xian 710032, Peoples R China.	yongznie@fmmu.edu.cn; daimingfan@fmmu.edu.cn	meng, li/GVT-2063-2022		 [81030044];  [2010CB529300];  [2010CB529305];  [2010CB529306];  [2010CB529302];  [NSFC-81120108005];  [81172096];  [863-2012AA02A203];  [8632012AA02A504]	; ; ; ; ; ; ; ; 	This work was supported by grants 81030044, 2010CB529300, 2010CB529305, 06, 02, NSFC-81120108005, 81172096, 863-2012AA02A203 and 8632012AA02A504. We would like to thank Zheng Chen and Jianhua Dou from the Fourth Military Medical University for providing excellent technical assistance.	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Catuogno S, 2012, ONCOGENE, V27, P1; Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190; Eitan R, 2009, GYNECOL ONCOL, V114, P253, DOI 10.1016/j.ygyno.2009.04.024; Feng DD, 2011, J CELL MOL MED, V15, P2164, DOI 10.1111/j.1582-4934.2010.01213.x; Fodale V, 2011, CANCER J, V17, P89, DOI 10.1097/PPO.0b013e318212dd3d; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Gribar JJ, 2000, J MEMBRANE BIOL, V173, P203, DOI 10.1007/s002320001020; Guo W, 2008, TUMOR BIOL, V29, P188, DOI 10.1159/000146864; Han JY, 2003, MED ONCOL, V20, P355, DOI 10.1385/MO:20:4:355; Hendrikx JJMA, 2013, INT J CANCER, V132, P2439, DOI 10.1002/ijc.27912; Hermeking H, 2012, NAT REV CANCER, V12, P613, DOI 10.1038/nrc3318; Hong L, 2004, BRIT J BIOMED SCI, V61, P206, DOI 10.1080/09674845.2004.11732673; Hong L, 2006, BIOCHEM CELL BIOL, V84, P199, DOI 10.1139/O05-173; Hou J, 2011, CANCER CELL, V19, P232, DOI 10.1016/j.ccr.2011.01.001; Huang DY, 2009, ENVIRON SCI TECHNOL, V43, P7803, DOI 10.1021/es901189c; Hwang JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010630; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Kim CH, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-79; Kovalchuk O, 2008, MOL CANCER THER, V7, P2152, DOI 10.1158/1535-7163.MCT-08-0021; KRAMER R, 1995, BRIT J CANCER, V71, P670, DOI 10.1038/bjc.1995.133; Ma KL, 2012, J BIOL CHEM, V287, P5639, DOI 10.1074/jbc.M111.291229; Michaud WA, 2009, CLIN CANCER RES, V15, P1645, DOI 10.1158/1078-0432.CCR-08-2581; Nishida N, 2012, ANN SURG ONCOL, V19, P3065, DOI 10.1245/s10434-012-2246-1; Plenchette S, 2007, CURR OPIN INVEST DR, V8, P469; Rao X, 2011, ONCOGENE, V30, P1082, DOI 10.1038/onc.2010.487; Seres M, 2011, INT J MOL SCI, V12, P7772, DOI 10.3390/ijms12117772; Shi YQ, 2004, CANCER BIOL THER, V3, P377, DOI 10.4161/cbt.3.4.724; Shi YQ, 2004, EXP CELL RES, V296, P337, DOI 10.1016/j.yexcr.2004.02.009; Song B, 2009, ONCOGENE, V28, P4065, DOI 10.1038/onc.2009.274; Sun L, 2012, ONCOGENE, V31, P432, DOI 10.1038/onc.2011.263; Tsuji K, 2012, HEMATOL REP, V4, P56, DOI 10.4081/hr.2012.e18; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wang Y, 2008, NAT GENET, V40, P1478, DOI 10.1038/ng.250; Williams J, 2005, GYNECOL ONCOL, V96, P287, DOI 10.1016/j.ygyno.2004.10.026; Xia L, 2008, INT J CANCER, V123, P372, DOI 10.1002/ijc.23501; Zhang HW, 2010, DIGEST DIS SCI, V55, P2545, DOI 10.1007/s10620-009-1051-6; Zhao L, 2009, J BIOL CHEM, V284, P26273, DOI 10.1074/jbc.M109.028068; Zhao XH, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-55; Zhu HR, 2012, EUR J PHARMACOL, V696, P43, DOI 10.1016/j.ejphar.2012.09.046; Zhu H, 2008, BIOCHEM PHARMACOL, V76, P582, DOI 10.1016/j.bcp.2008.06.007; Zhu W, 2012, CANCER CHEMOTH PHARM, V69, P723, DOI 10.1007/s00280-011-1752-3; Zhu W, 2012, MED ONCOL, V29, P384, DOI 10.1007/s12032-010-9797-4; Zhu W, 2010, INT J CANCER, V127, P2520, DOI 10.1002/ijc.25260; Zhu YH, 2011, CLIN CANCER RES, V17, P7105, DOI 10.1158/1078-0432.CCR-11-0071	45	148	152	0	27	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3267	3276		10.1038/onc.2013.297	http://dx.doi.org/10.1038/onc.2013.297			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23893241				2022-12-28	WOS:000338443400006
J	Timme, S; Ihde, S; Fichter, CD; Waehle, V; Bogatyreva, L; Atanasov, K; Kohler, I; Schopflin, A; Geddert, H; Faller, G; Klimstra, D; Tang, L; Reinheckel, T; Hauschke, D; Busch, H; Boerries, M; Werner, M; Lassmann, S				Timme, S.; Ihde, S.; Fichter, C. D.; Waehle, V.; Bogatyreva, L.; Atanasov, K.; Kohler, I.; Schoepflin, A.; Geddert, H.; Faller, G.; Klimstra, D.; Tang, L.; Reinheckel, T.; Hauschke, D.; Busch, H.; Boerries, M.; Werner, M.; Lassmann, S.			STAT3 expression, activity and functional consequences of STAT3 inhibition in esophageal squamous cell carcinomas and Barrett's adenocarcinomas	ONCOGENE			English	Article						STAT3; esophageal cancer; inhibition; cell proliferation; cell migration	GROWTH-FACTOR RECEPTOR; TYROSINE-PHOSPHORYLATED STAT3; ACTIVATED SIGNAL TRANSDUCER; MULTIPOLAR MITOSES; GENE AMPLIFICATION; COLORECTAL-CANCER; TRANSCRIPTION 3; IN-VIVO; PROTEIN; PATHWAY	Signal transducer and activator of transcription 3 (STAT3) is altered in several epithelial cancers and represents a potential therapeutic target. Here, STAT3 expression, activity and cellular functions were examined in two main histotypes of esophageal carcinomas. In situ, immunohistochemistry for STAT3 and STAT3-Tyr705 phosphorylation (P-STAT3) in esophageal squamous cell carcinomas (ESCC, n = 49) and Barrett's adenocarcinomas (BAC, n = 61) revealed similar STAT3 expression in ESCCs and BACs (P = 0.109), but preferentially activated P-STAT3 in ESCCs (P = 0.013). In vitro, strong STAT3 activation was seen by epidermal growth factor (EGF) stimulation in OE21 (ESCC) cells, whereas OE33 (BAC) cells showed constitutive weak STAT3 activation. STAT3 knockdown significantly reduced cell proliferation of OE21 (P = 0.0148) and OE33 (P = 0.0243) cells. Importantly, STAT3 knockdown reduced cell migration of OE33 cells by 2.5-fold in two types of migration assays (P = 0.073, P = 0.015), but not in OE21 cells (P = 0.1079, P = 0.386). Investigation of transcriptome analysis of STAT3 knockdown revealed a reduced STAT3 level associated with significant downregulation of cell cycle genes in both OE21 (P<0.0001) and OE33 (P = 0.01) cells. In contrast, genes promoting cell migration (CTHRC1) were markedly upregulated in OE21 cells, whereas a gene linked to tight-junction stabilization and restricted cell motility (SHROOM2) was downregulated in OE21 but upregulated in OE33 cells. This study shows frequent, but distinct, patterns of STAT3 expression and activation in ESCCs and BACs. STAT3 knockdown reduces cell proliferation in ESCC and BAC cells, inhibits migration of BAC cells and may support cell migration of ESCC cells. Thereby, novel STAT3-regulated genes involved in ESCC and BAC cell proliferation and cell migration were identified. Thus, STAT3 may be further exploited as a potential novel therapeutic target, however, by careful distinction between the two histotypes of esophageal cancers.	[Timme, S.; Ihde, S.; Fichter, C. D.; Waehle, V.; Atanasov, K.; Kohler, I.; Schoepflin, A.; Werner, M.; Lassmann, S.] Univ Freiburg, Univ Med Ctr, Inst Clin Pathol, D-79106 Freiburg, Germany; [Fichter, C. D.] Univ Freiburg, Fac Biol, D-79106 Freiburg, Germany; [Bogatyreva, L.; Hauschke, D.] Univ Freiburg, Univ Med Ctr, Inst Med Biometry & Med Informat, D-79106 Freiburg, Germany; [Geddert, H.; Faller, G.] St Vincentius Kliniken, Dept Pathol, Karlsruhe, Germany; [Klimstra, D.; Tang, L.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Reinheckel, T.; Busch, H.; Boerries, M.] Univ Freiburg, Univ Med Ctr, Inst Mol Med & Cell Res, D-79106 Freiburg, Germany; [Reinheckel, T.; Lassmann, S.] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, D-79106 Freiburg, Germany; [Reinheckel, T.; Werner, M.; Lassmann, S.] Univ Freiburg, Univ Med Ctr, Comprehens Canc Ctr Freiburg, D-79106 Freiburg, Germany; [Busch, H.; Boerries, M.; Werner, M.; Lassmann, S.] German Canc Consortium DKTK, Heidelberg, Germany; [Busch, H.; Boerries, M.; Werner, M.; Lassmann, S.] German Canc Res Ctr, Heidelberg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; Memorial Sloan Kettering Cancer Center; University of Freiburg; University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Lassmann, S (corresponding author), Univ Med Ctr, Inst Clin Pathol, Breisacherstr 115A, D-79106 Freiburg, Germany.	silke.lassmann@uniklinik-freiburg.de	Boerries, Melanie/AAM-2602-2021; Busch, Hauke/R-6452-2016; Reinheckel, Thomas/AAL-9761-2021	Busch, Hauke/0000-0003-4763-4521; Reinheckel, Thomas/0000-0001-9866-9105; Waehle, Verena/0000-0003-0189-8812	Deutsche Forschungsgemeinschaft [SFB850]; Mushett Family Foundation, Chester, NJ, USA; DFG [SFB850]; Mushett Family Foundation, Chester, NJ	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Mushett Family Foundation, Chester, NJ, USA; DFG(German Research Foundation (DFG)); Mushett Family Foundation, Chester, NJ	We thank Martina Gansz for assistance with Cathepsin analyses. We acknowledge the support of the study by the Deutsche Forschungsgemeinschaft (SFB850 project C5 to SL, MW; SFB850 project B7 to TR; Gerok stipend of SFB850 project Z1 to ST). Preliminary work for this study has been supported by the Mushett Family Foundation, Chester, NJ, USA (grant to SL, MW, LT, DK). TR and SL are member and associate members of BIOSS Centre for Biological Signalling Studies, Albert-Ludwigs-University, Freiburg, Germany. This study was supported by DFG SFB850 C5 (MW, SL); DFG SFB850 B7 (TR); DFG SFB850 Z1 (Gerok position to ST); and Mushett Family Foundation, Chester, NJ (DK, LT, MW, SL).	Aggarwal BB, 2009, ANN NY ACAD SCI, V1171, P59, DOI 10.1111/j.1749-6632.2009.04911.x; Andl CD, 2004, AM J PHYSIOL-GASTR L, V287, pG1227, DOI 10.1152/ajpgi.00253.2004; Boehm AL, 2008, MOL PHARMACOL, V73, P1632, DOI 10.1124/mol.107.044636; Boerries M, 2013, KIDNEY INT, V83, P1052, DOI 10.1038/ki.2012.487; Bonner JA, 2011, RADIOTHER ONCOL, V99, P339, DOI 10.1016/j.radonc.2011.05.070; Boonstra JJ, 2010, JNCI-J NATL CANCER I, V102, P271, DOI 10.1093/jnci/djp499; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Dvorak K, 2007, CLIN CANCER RES, V13, P5305, DOI 10.1158/1078-0432.CCR-07-0483; Etournay R, 2007, J CELL SCI, V120, P2838, DOI 10.1242/jcs.002568; Farber MJ, 2011, MOL BIOL CELL, V22, P795, DOI 10.1091/mbc.E10-06-0505; Fichter CD, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-13; Gabbert HE, WHO CLASSIFICATION T, V3; Gerlach U, 2006, J PATHOL, V208, P462, DOI 10.1002/path.1914; Gong WD, 2005, CLIN CANCER RES, V11, P1386, DOI 10.1158/1078-0432.CCR-04-0487; Hanawa M, 2006, INT J CANCER, V118, P1173, DOI 10.1002/ijc.21454; Haura EB, 2005, CLIN CANCER RES, V11, P8288, DOI 10.1158/1078-0432.CCR-05-0827; Herz C, 2012, MOL CARCINOGEN, V51, P696, DOI 10.1002/mc.20823; Jaganathan S, 2010, J PHARMACOL EXP THER, V333, P373, DOI 10.1124/jpet.109.162669; Jiang RC, 2011, MOL DIAGN THER, V15, P347, DOI 10.2165/11599190-000000000-00000; Jove R, 2000, ONCOGENE, V19, P2466, DOI 10.1038/sj.onc.1203549; Kamburov A, 2013, NUCLEIC ACIDS RES, V41, pD793, DOI 10.1093/nar/gks1055; Khoury JD, 2003, CLIN CANCER RES, V9, P3692; Kreuzaler PA, 2011, NAT CELL BIOL, V13, P303, DOI 10.1038/ncb2171; Lassmann S, 2007, J CLIN PATHOL, V60, P173, DOI 10.1136/jcp.2005.035113; Lassmann S, 2009, MODERN PATHOL, V22, P1385, DOI 10.1038/modpathol.2009.111; Lassmann S, 2009, J MOL MED, V87, P211, DOI 10.1007/s00109-008-0419-y; Lee J, 2009, APMIS, V117, P598, DOI 10.1111/j.1600-0463.2009.02512.x; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo WJ, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-161; Morikawa T, 2011, CLIN CANCER RES, V17, P1452, DOI 10.1158/1078-0432.CCR-10-2694; Nagaraj NS, 2011, CLIN CANCER RES, V17, P483, DOI 10.1158/1078-0432.CCR-10-1670; Nasr MR, 2007, AM J CLIN PATHOL, V127, P770, DOI 10.1309/FNY8Y4H6PK1V2MGE; Park EH, 2013, CARCINOGENESIS, V34, P694, DOI 10.1093/carcin/bgs378; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Rauser S, 2007, CLIN CANCER RES, V13, P5115, DOI 10.1158/1078-0432.CCR-07-0465; Reipschlager S, 2012, J BIOL CHEM, V287, P11183, DOI 10.1074/jbc.M111.313395; Reiser J, 2010, J CLIN INVEST, V120, P3421, DOI 10.1172/JCI42918; Sansone P, 2012, J CLIN ONCOL, V30, P1005, DOI 10.1200/JCO.2010.31.8907; Seethala RR, 2008, CLIN CANCER RES, V14, P1303, DOI 10.1158/1078-0432.CCR-07-1543; Sobin L, 2009, TNM CLASSIFICATION M; Souissi I, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-14; Tischoff I, 2007, GUT, V56, P1047, DOI 10.1136/gut.2006.111633; Vinkemeier U, 2004, J CELL BIOL, V167, P197, DOI 10.1083/jcb.200407163; Werner M, WHO CLASSIFICATION T, V3; Yan S, 2008, CANCER LETT, V271, P85, DOI 10.1016/j.canlet.2008.05.035; Yoon HH, 2012, CLIN CANCER RES, V18, P546, DOI 10.1158/1078-0432.CCR-11-2272; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Yu WW, 2011, HEPATO-GASTROENTEROL, V58, P426; Zhang HY, 2011, AM J PHYSIOL-GASTR L, V300, pG454, DOI 10.1152/ajpgi.00458.2010; Zhang Y, 2012, GASTROENTEROLOGY, V142, P521, DOI 10.1053/j.gastro.2011.11.023; Zhao W, 2010, J BIOL CHEM, V285, P35855, DOI 10.1074/jbc.M110.154088	52	38	45	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3256	3266		10.1038/onc.2013.298	http://dx.doi.org/10.1038/onc.2013.298			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23912451				2022-12-28	WOS:000338443400005
J	Moti, N; Malcolm, T; Hamoudi, R; Mian, S; Garland, G; Hook, CE; Burke, GAA; Wasik, MA; Merkel, O; Kenner, L; Laurenti, E; Dick, JE; Turner, SD				Moti, N.; Malcolm, T.; Hamoudi, R.; Mian, S.; Garland, G.; Hook, C. E.; Burke, G. A. A.; Wasik, M. A.; Merkel, O.; Kenner, L.; Laurenti, E.; Dick, J. E.; Turner, S. D.			Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin	ONCOGENE			English	Article							HEMATOPOIETIC STEM-CELLS; NPM-ALK; T-CELLS; KINASE; DISEASE; FUSION; IDENTIFICATION; TRANSFORMATION; MODELS; GENE	Cancer stem cells or tumour-propagating cells (TPCs) have been identified for a number of cancers, but data pertaining to their existence in lymphoma so far remain elusive. We show for the first time that a small subset of cells purified from human anaplastic lymphoma kinase (ALK)-positive and -negative, anaplastic large cell lymphoma cell lines and primary patient tumours using the side population (SP) technique have serial tumour-propagating capacity both in vitro and in vivo; they give rise to both themselves and the bulk tumour population as well as supporting growth of the latter through the production of soluble factors. In vivo serial dilution assays utilising a variety of model systems inclusive of human cell lines, primary human tumours and nucleophosmin (NPM)-ALK-induced murine tumours demonstrate the TPC frequency to vary from as many as 1/54 to 1/1336 tumour cells. In addition, the SP cells express higher levels of pluripotency-associated transcription factors and are enriched for a gene expression profile consistent with early thymic progenitors. Finally, our data show that the SP cells express higher levels of the NPM-ALK oncogene and are sensitive to an ALK inhibitor.	[Moti, N.; Malcolm, T.; Hamoudi, R.; Garland, G.; Turner, S. D.] Univ Cambridge, Div Mol Histopathol, Dept Pathol, Cambridge CB2 0QQ, England; [Mian, S.] Univ Hail, Coll Appl Med Sci, Mol Diagnost & Personalised Therapeut Unit, Hail, Saudi Arabia; [Hook, C. E.] Addenbrookes Hosp, Dept Histopathol & Cytol, Cambridge, England; [Burke, G. A. A.] Addenbrookes Hosp, Dept Paediat Oncol, Cambridge, England; [Wasik, M. A.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA; [Merkel, O.] German Canc Res Ctr, Dept Translat Oncol, Natl Ctr Tumor Dis NCT, Heidelberg, Germany; [Merkel, O.; Kenner, L.; Turner, S. D.] Med Univ Vienna, European Res Initiat ALK Related Malignancies ERI, Vienna, Austria; [Kenner, L.] Med Univ Vienna, Clin Inst Pathol, Vienna, Austria; [Kenner, L.] Ludwig Boltzmann Inst Canc Res, Vienna, Austria; [Laurenti, E.; Dick, J. E.] Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Campbell Family Inst, Toronto, ON, Canada; [Laurenti, E.; Dick, J. E.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada	University of Cambridge; University Ha'il; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Pennsylvania; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Medical University of Vienna; Medical University of Vienna; Ludwig Boltzmann Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Turner, SD (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Div Mol Histopathol, Lab Block Level 3,Box 231, Cambridge CB2 0QQ, England.	sdt36@cam.ac.uk	Turner, Suzanne Dawn/K-4405-2013; Burke, Amos/AAT-1358-2021	Turner, Suzanne Dawn/0000-0002-8439-4507; Burke, Amos/0000-0003-2671-9972; Merkel, Olaf/0000-0001-5089-344X; Laurenti, Elisa/0000-0002-9917-9092; Moti, Naushad/0000-0002-8649-9919; MIAN, SYED SHARIQ/0000-0001-7563-5121; Dick, John/0000-0002-9527-8317; Kenner, Lukas/0000-0003-2184-1338; Hamoudi, Rifat/0000-0002-1402-0868	Sam Foye Fund; Leukaemia and Lymphoma Research Bennett [07006, 11051, 12065]; Cambridge Commonwealth Trust; University of Karachi, Pakistan; Elimination of Leukaemia Fund; Leukaemia and Lymphoma Research Gordon Piller Studentship [08064]	Sam Foye Fund; Leukaemia and Lymphoma Research Bennett; Cambridge Commonwealth Trust; University of Karachi, Pakistan; Elimination of Leukaemia Fund; Leukaemia and Lymphoma Research Gordon Piller Studentship	We thank past and present members of the 'Turner lab' for their helpful discussions and critical appraisal of the manuscript. We are grateful to N Miller of the Department of Pathology, University of Cambridge, FACS facility for his assistance with SP analysis and to S Johnson of the Biological Services Unit. We are also indebted to R Jarrett, L Shield and S Crae at the Leukaemia and Lymphoma Research Virus Centre, University of Glasgow, UK, for the provision of primary disaggregated, viable patient material. We also acknowledge the support of the Sam Foye Fund and dedicate this research to the memory of Sam. SDT is a Leukaemia and Lymphoma Research Bennett Fellow (grant numbers 07006, 11051, 12065). NM receives support from the Cambridge Commonwealth Trust, University of Karachi, Pakistan, and the Elimination of Leukaemia Fund. TM is supported by a Leukaemia and Lymphoma Research Gordon Piller Studentship (Grant Number 08064).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Benharroch D, 1998, BLOOD, V91, P2076, DOI 10.1182/blood.V91.6.2076; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Christensen JG, 2007, MOL CANCER THER, V6, P3314, DOI 10.1158/1535-7163.MCT-07-0365; Cobaleda C, 2007, NATURE, V449, P473, DOI 10.1038/nature06159; Cui YX, 2009, BLOOD, V113, P5217, DOI 10.1182/blood-2008-06-160168; DELMISTRO A, 1994, LEUKEMIA, V8, P1214; Dick JE, 2008, BLOOD, V112, P4793, DOI 10.1182/blood-2008-08-077941; Doulatov S, 2010, NAT IMMUNOL, V11, P585, DOI 10.1038/ni.1889; Gelebart P, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.27; Georgantas RW, 2004, CANCER RES, V64, P4434, DOI 10.1158/0008-5472.CAN-03-3247; Gibbs KD, 2012, CELL STEM CELL, V10, P210, DOI 10.1016/j.stem.2012.01.004; Golebiewska A, 2011, CELL STEM CELL, V8, P136, DOI 10.1016/j.stem.2011.01.007; Goodell MA, 2002, CYTOTHERAPY, V4, P507, DOI 10.1080/146532402761624638; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Goodell Margaret A, 2005, Methods Mol Biol, V290, P343; Goodell Margaret A, 2005, Curr Protoc Cytom, VChapter 9, DOI 10.1002/0471142956.cy0918s34; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Jager R, 2005, ANTICANCER RES, V25, P3191; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Laurent C, 2012, LEUKEMIA, V26, P188, DOI 10.1038/leu.2011.209; Le Deley MC, 2010, J CLIN ONCOL, V28, P3987, DOI 10.1200/JCO.2010.28.5999; Lutz C, 2013, LEUKEMIA, V27, P1204, DOI 10.1038/leu.2012.306; Marko NF, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-27; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mussolin L, 2005, LEUKEMIA, V19, P1643, DOI 10.1038/sj.leu.2403888; Mussolin L, 2013, LEUKEMIA, V27, P416, DOI 10.1038/leu.2012.205; Notta F, 2011, SCIENCE, V333, P218, DOI 10.1126/science.1201219; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Pearson JD, 2011, INT J CLIN EXP PATHO, V4, P124; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Singh SK, 2003, CANCER RES, V63, P5821; Swerdlow SH, 2008, WHO CLASSIFICATION T; Turner SD, 2006, LEUKEMIA, V20, P572, DOI 10.1038/sj.leu.2404125; Turner SD, 2005, LEUKEMIA, V19, P1128, DOI 10.1038/sj.leu.2403797; Turner SD, 2003, ONCOGENE, V22, P7750, DOI 10.1038/sj.onc.1207048; Turner SD, 2006, ANTICANCER RES, V26, P3275; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Wang X, 2011, J CLIN INVEST, V121, P3834, DOI 10.1172/JCI37210	41	29	29	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1843	1852		10.1038/onc.2014.112	http://dx.doi.org/10.1038/onc.2014.112			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24814516				2022-12-28	WOS:000352158000011
J	Costa, ET; Barnabee, GF; Li, M; Dias, AAM; Machado, TR; Asprino, PF; Cavalher, FP; Ferreira, EN; Inda, MD; Nagai, MH; Malnic, B; Duarte, ML; Leite, KRM; de Barros, ACSD; Carraro, DM; Chammas, R; Armelin, HA; Cavenee, W; Furnari, F; Camargo, A				Costa, E. T.; Barnabe, G. F.; Li, M.; Dias, A. A. M.; Machado, T. R.; Asprino, P. F.; Cavalher, F. P.; Ferreira, E. N.; Inda, M. del Mar; Nagai, M. H.; Malnic, B.; Duarte, M. L.; Leite, K. R. M.; de Barros, A. C. S. D.; Carraro, D. M.; Chammas, R.; Armelin, H. A.; Cavenee, W.; Furnari, F.; Camargo, A. A.			Intratumoral heterogeneity of ADAM23 promotes tumor growth and metastasis through LGI4 and nitric oxide signals	ONCOGENE			English	Article							CELL-LINES; EVOLUTION; CANCER; METHYLATION; CARCINOMA; GENE; PROGRESSION; EXPRESSION; INTEGRIN; ADHESION	Intratumoral heterogeneity (ITH) represents an obstacle for cancer diagnosis and treatment, but little is known about its functional role in cancer progression. The A Desintegrin And Metalloproteinase 23 (ADAM23) gene is epigenetically silenced in different types of tumors, and silencing is often associated with advanced disease and metastasis. Here, we show that invasive breast tumors exhibit significant ADAM23-ITH and that this heterogeneity is critical for tumor growth and metastasis. We demonstrate that while loss of ADAM23 expression enhances invasion, it causes a severe proliferative deficiency and is not itself sufficient to trigger metastasis. Rather, we observed that, in ADAM23-heterotypic environments, ADAM23-negative cells promote tumor growth and metastasis by enhancing the proliferation and invasion of adjacent A23-positive cells through the production of LGI4 (Leucine-rich Glioma Inactivated 4) and nitric oxide (NO). Ablation of LGI4 and NO in A23-negative cells significantly attenuates A23-positive cell proliferation and invasion. Our work denotes a driving role of ADAM23-ITH during disease progression, shifting the malignant phenotype from the cellular to the tissue level. Our findings also provide insights for therapeutic intervention, enforcing the need to ascertain ITH to improve cancer diagnosis and therapy.	[Costa, E. T.; Barnabe, G. F.; Asprino, P. F.; Duarte, M. L.; Camargo, A. A.] Hosp Sirio Libanes, Ctr Mol Oncol, BR-01308060 Sao Paulo, Brazil; [Costa, E. T.; Barnabe, G. F.; Machado, T. R.; Asprino, P. F.; Cavalher, F. P.; Duarte, M. L.; Camargo, A. A.] LICR, Sao Paulo, Brazil; [Li, M.; Inda, M. del Mar; Cavenee, W.; Furnari, F.] Univ Calif San Diego, LICR, San Diego, CA 92103 USA; [Dias, A. A. M.] Univ Fed Minas Gerais, Dept Biol Geral ICB, Belo Horizonte, MG, Brazil; [Ferreira, E. N.; Carraro, D. M.] Hosp AC Camargo Fund Antonio Prudente, Ctr Internacl Pesquisa, Sao Paulo, Brazil; [Nagai, M. H.; Malnic, B.; Armelin, H. A.] Univ Sao Paulo, Dept Bioquim IQ, Sao Paulo, Brazil; [Leite, K. R. M.; Chammas, R.] Univ Sao Paulo, Fac Med, Dept Urol, Sao Paulo, Brazil; [de Barros, A. C. S. D.] Hosp Sirio Libanes, Dept Mastol, BR-01308060 Sao Paulo, Brazil; [Armelin, H. A.] Inst Butantan, Sao Paulo, Brazil	University of California System; University of California San Diego; Universidade Federal de Minas Gerais; A.C.Camargo Cancer Center; Universidade de Sao Paulo; Universidade de Sao Paulo; Instituto Butantan	Camargo, A (corresponding author), Hosp Sirio Libanes, Ctr Mol Oncol, LICR, Rua Cel Nicolau Dos Santos 69, BR-01308060 Sao Paulo, Brazil.	aacamargo@mochsl.org.br	Armelin, Hugo/P-4390-2015; LEITE, KATIA RM/C-2055-2008; Chammas, Roger/A-8004-2011; Barros, Alfredo/M-2525-2017; Malnic, Bettina/A-4905-2008; Ferreira, Elisa N/A-6485-2011; Asprino, Paula/AAB-5600-2021; Instituto Butantan, Center of Toxins Immune Response and Cell Signaling CeTICS/J-5731-2015; Lemos Duarte, Mariana/K-6233-2012; carraro, dirce/C-9179-2009; Dias, Adriana Abalen Martins/B-4974-2014; Camargo, Anamaria A/E-9388-2012	Armelin, Hugo/0000-0001-9557-0804; LEITE, KATIA RM/0000-0002-2615-7730; Chammas, Roger/0000-0003-0342-8726; Barros, Alfredo/0000-0003-2535-3040; Malnic, Bettina/0000-0002-5877-4784; Ferreira, Elisa N/0000-0001-7809-7349; Lemos Duarte, Mariana/0000-0002-1611-7102; carraro, dirce/0000-0001-5667-1418; Camargo, Anamaria A/0000-0002-6076-9597; Abalen Martins Dias, Adriana/0000-0001-9415-3240; Furnari, Frank/0000-0003-1909-4361; Li, Ming/0000-0002-2540-1738	FAPESP [06/60219-2, 07/51194-9, 07/52920-5, 11/50541-2]; LICR; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS080939] Funding Source: NIH RePORTER	FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); LICR; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We are grateful to Dr Andrew Simpson and Dr Raphael Parmigiani for critical reading of this manuscript and to Dr Rodrigo Perez, Dr Alicia Kowaltowski, Dr Beatriz Geronymo, Dr Camila Machado, Dr Vilma Martins, Dr Tiago dos Santos and Dr Anibal Vercesi for scientific discussions and technical assistance. This work was supported by grants from FAPESP (06/60219-2, 07/51194-9, 07/52920-5, 11/50541-2) and LICR.	Almendro V, 2013, ANNU REV PATHOL-MECH, V8, P277, DOI 10.1146/annurev-pathol-020712-163923; Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Axelrod R, 2006, P NATL ACAD SCI USA, V103, P13474, DOI 10.1073/pnas.0606053103; Bermingham JR, 2006, NAT NEUROSCI, V9, P76, DOI 10.1038/nn1598; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457; Calmon MF, 2007, CANCER GENET CYTOGEN, V173, P31, DOI 10.1016/j.cancergencyto.2006.09.008; Choi JS, 2009, INT J CANCER, V124, P1258, DOI 10.1002/ijc.24023; Clark J, 2008, ONCOGENE, V27, P1993, DOI 10.1038/sj.onc.1210843; Costa FF, 2005, NEUROSCI LETT, V380, P260, DOI 10.1016/j.neulet.2005.01.050; Costa FF, 2004, ONCOGENE, V23, P1481, DOI 10.1038/sj.onc.1207263; Cottu PH, 2008, ANN ONCOL, V19, P596, DOI 10.1093/annonc/mdn021; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Gauthier N, 2004, CARCINOGENESIS, V25, P1559, DOI 10.1093/carcin/bgh158; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Hagihara A, 2004, ONCOGENE, V23, P8705, DOI 10.1038/sj.onc.1207783; Hu CY, 2011, INT J EXP PATHOL, V92, P333, DOI 10.1111/j.1365-2613.2011.00766.x; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Jadeski LC, 2000, INT J CANCER, V86, P30, DOI 10.1002/(SICI)1097-0215(20000401)86:1<30::AID-IJC5>3.0.CO;2-I; Kim HA, 2012, BBA-MOL CELL BIOL L, V1821, P914, DOI 10.1016/j.bbalip.2012.02.010; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Lampson BL, 2012, CANCER RES, V72, P4472, DOI 10.1158/0008-5472.CAN-12-0057; Maley CC, 2006, NAT GENET, V38, P468, DOI 10.1038/ng1768; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Michor F, 2010, CANCER PREV RES, V3, P1361, DOI 10.1158/1940-6207.CAPR-10-0234; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Nishino J, 2010, J NEUROSCI, V30, P15228, DOI 10.1523/JNEUROSCI.2286-10.2010; Notta F, 2011, NATURE, V469, P362, DOI 10.1038/nature09733; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Orucevic A, 1999, INT J CANCER, V81, P889, DOI 10.1002/(SICI)1097-0215(19990611)81:6<889::AID-IJC9>3.0.CO;2-2; Ozkaynak E, 2010, J NEUROSCI, V30, P3857, DOI 10.1523/JNEUROSCI.6287-09.2010; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PRICE JE, 1990, CANCER RES, V50, P717; Sagane K, 2008, INT J BIOL SCI, V4, P387; Senechal KR, 2005, HUM MOL GENET, V14, P1613, DOI 10.1093/hmg/ddi169; Sens-Abuazar C, 2012, TRANSL ONCOL, V5, P113, DOI 10.1593/tlo.11280; SUZUKI N, 1978, CANCER RES, V38, P3349; Swanton C, 2012, CANCER RES, V72, P4875, DOI 10.1158/0008-5472.CAN-12-2217; Takada H, 2005, ONCOGENE, V24, P8051, DOI 10.1038/sj.onc.1208952; Takahashi T, 1998, CANCER RES, V58, P5835; Teixeira MR, 1996, CANCER RES, V56, P855; Verbisck NV, 2009, CANCER RES, V69, P5546, DOI 10.1158/0008-5472.CAN-08-2976; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006; Yancovitz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029336; Yap TA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003854	49	12	12	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1270	1279		10.1038/onc.2014.70	http://dx.doi.org/10.1038/onc.2014.70			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24662834				2022-12-28	WOS:000350687100007
J	Eberlein, C; Rooney, C; Ross, SJ; Farren, M; Weir, HM; Barry, ST				Eberlein, C.; Rooney, C.; Ross, S. J.; Farren, M.; Weir, H. M.; Barry, S. T.			E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin alpha v beta 6 and maintained through TGF beta signalling	ONCOGENE			English	Article						NSCLC; stroma; CAF; integrin; alpha v beta 6; TGF beta	CARCINOMA-ASSOCIATED-FIBROBLASTS; GROWTH-FACTOR-BETA; STROMAL MYOFIBROBLASTS; CANCER; INHIBITION; INVASION; KINASE; INTEGRIN-ALPHA-V-BETA-6; SIGNATURE; RECEPTOR	Fibroblasts in the tumour stroma (cancer-associated fibroblasts) influence tumour progression and response to therapeutics; little is known about the mechanisms through which the tumour cell co-opts a normal fibroblast. To study the activation of fibroblasts by tumour cells, a panel of non-small cell lung cancer (NSCLC) cell lines and normal human dermal fibroblasts were co-cultured. A subset of the NSCLC cells induced an activated cancer-associated fibroblast-like fibroblast phenotype defined by induction of fibroblast alpha-smooth muscle actin expression. Tumour cells that activated fibroblasts were associated with E-Cadherin and EpCAM expression and expression of integrin alpha v beta 6. Co-culture of activating tumour cells with fibroblasts resulted in induction of transcripts associated with tumour cell invasion and growth, TGF beta 1 and TGFBR1, SERPINE-1, BMP6, SPHK1 and MMP9. Fibroblast activation was inhibited by an alpha v beta 6/8 integrin blocking antibody (264RAD) and a small molecule inhibitor of the TGF-beta type I receptor activin-like kinase (ALK5) (SB431542), demonstrating that transactivation of the TGF beta pathway initiates fibroblast activation. Both integrin and ALK5 antagonists inhibited initiation. Only ALK5 was effective when added after 3 days of co-culture. This suggests that although activation is alpha v beta 6-dependent, once fibroblasts are activated alternative TGF beta pathway regulators maintain an activation loop. In co-culture activating cells had reduced sensitivity to selumetinib, AZD8931 and afatinib compared with mono-culture. In contrast, non-activating cells were insensitive to selumetinib and AZD8931 in both mono-culture and co-culture. In conclusion NSCLC cell lines, positive for E-Cadherin, EpCAM and alpha v beta 6 expression, activate normal fibroblasts through alpha v beta 6/TGF beta signalling in vitro, and influence both gene expression and response to therapeutic agents.	[Eberlein, C.; Rooney, C.; Ross, S. J.; Farren, M.; Weir, H. M.; Barry, S. T.] AstraZeneca, Oncol iMED, Macclesfield SK10 4TG, Cheshire, England	AstraZeneca	Barry, ST (corresponding author), AstraZeneca, Oncol iMED, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.	Simon.T.Barry@astrazeneca.com						Aluwihare P, 2009, J CELL SCI, V122, P227, DOI 10.1242/jcs.035246; Bremnes RM, 2011, J THORAC ONCOL, V6, P209, DOI 10.1097/JTO.0b013e3181f8a1bd; Brentnall TA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030219; Cardone A, 1997, PANMINERVA MED, V39, P174; Cascone T, 2011, J CLIN INVEST, V121, P1313, DOI 10.1172/JCI42405; Eberlein C, 2013, ONCOGENE, V32, P4406, DOI 10.1038/onc.2012.460; Egeblad M, 2010, DEV CELL, V18, P884, DOI 10.1016/j.devcel.2010.05.012; Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hickinson DM, 2010, CLIN CANCER RES, V16, P1159, DOI 10.1158/1078-0432.CCR-09-2353; Horan GS, 2008, AM J RESP CRIT CARE, V177, P56, DOI 10.1164/rccm.200706-805OC; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kano MR, 2007, P NATL ACAD SCI USA, V104, P3460, DOI 10.1073/pnas.0611660104; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Lebret SC, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1656; Lewis MP, 2004, BRIT J CANCER, V90, P822, DOI 10.1038/sj.bjc.6601611; Maeshima AM, 2002, CANCER, V95, P2546, DOI 10.1002/cncr.11006; Marsh D, 2008, CANCER RES, V68, P3295, DOI 10.1158/0008-5472.CAN-08-0174; Marsh D, 2011, J PATHOL, V223, P470, DOI 10.1002/path.2830; McMillin DW, 2010, NAT MED, V16, P483, DOI 10.1038/nm.2112; Mink SR, 2010, MOL CANCER RES, V8, P809, DOI 10.1158/1541-7786.MCR-09-0460; Minkovsky N, 2008, CURR OPIN INVEST DR, V9, P1336; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Navab R, 2011, P NATL ACAD SCI USA, V108, P7160, DOI 10.1073/pnas.1014506108; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Popov Y, 2008, J HEPATOL, V48, P453, DOI 10.1016/j.jhep.2007.11.021; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Puthawala K, 2008, AM J RESP CRIT CARE, V177, P82, DOI 10.1164/rccm.200706-806OC; Rasanen K, 2010, EXP CELL RES, V316, P2713, DOI 10.1016/j.yexcr.2010.04.032; RONNOVJESSEN L, 1993, LAB INVEST, V68, P696; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; Ross S, 2008, INT J BIOCHEM CELL B, V40, P383, DOI 10.1016/j.biocel.2007.09.006; Schiller M, 2004, J DERMATOL SCI, V35, P83, DOI 10.1016/j.jdermsci.2003.12.006; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Surowiak P, 2006, FOLIA HISTOCHEM CYTO, V44, P111; Thomas GJ, 2001, J INVEST DERMATOL, V117, P67, DOI 10.1046/j.0022-202x.2001.01379.x; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Varga J, 2002, ARTHRITIS RHEUM-US, V46, P1703, DOI 10.1002/art.10413; Yazhou C, 2004, TUMOR BIOL, V25, P290, DOI 10.1159/000081394; Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150; Zieba A, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.013482	47	31	33	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					704	716		10.1038/onc.2013.600	http://dx.doi.org/10.1038/onc.2013.600			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24488011				2022-12-28	WOS:000348853800004
J	Kreis, NN; Sanhaji, M; Rieger, MA; Louwen, F; Yuan, J				Kreis, N-N; Sanhaji, M.; Rieger, M. A.; Louwen, F.; Yuan, J.			p21Waf1/Cip1 deficiency causes multiple mitotic defects in tumor cells	ONCOGENE			English	Article						p21; Cdk1; Aurora B; chromosome segregation; cytokinesis	SMALL-MOLECULE INHIBITOR; DNA-REPLICATION; CYCLIN B1; P21; PHOSPHORYLATION; CANCER; P21(WAF1/CIP1); MITOSIS; ARREST; PRC1	As a multifaceted molecule, p21 plays multiple critical roles in cell cycle regulation, differentiation, apoptosis, DNA repair, senescence, aging and stem cell reprogramming. The important roles of p21 in the interphase of the cell cycle have been intensively investigated. The function of p21 in mitosis has been proposed but not systematically studied. We show here that p21 is abundant in mitosis and binds to and inhibits the activity of Cdk1/cyclin B1. Deficiency of p21 prolongs the duration of mitosis by extending metaphase, anaphase and cytokinesis. The activity of Aurora B is reduced and the localization of Aurora B on the central spindle is disturbed in anaphase cells without p21. Moreover, HCT116 p21(-/-), HeLa and Saos-2 cells depleted of p21 encounter problems in chromosome segregation and cytokinesis. Gently inhibiting the mitotic Cdk1 or add-back of p21 rescues segregation defect in HCT116 p21(-/-) cells. Our data demonstrate that p21 is important for a fine-tuned control of the Cdk1 activity in mitosis, and its proper function facilitates a smooth mitotic progression. Given that p21 is downregulated in the majority of tumors, either by the loss of tumor suppressors like p53 or by hyperactive oncogenes such as c-myc, this finding also sheds new light on the molecular mechanisms by which p21 functions as a tumor suppressor.	[Kreis, N-N; Sanhaji, M.; Louwen, F.; Yuan, J.] Dept Gynecol & Obstet, Frankfurt, Germany; [Rieger, M. A.] Goethe Univ Frankfurt, Dept Hematol Oncol, D-60590 Frankfurt, Germany; [Rieger, M. A.] Georg Speyer Haus, Frankfurt, Germany; [Rieger, M. A.] German Canc Consortium DKTK, Heidelberg, Germany; [Rieger, M. A.] German Canc Res Ctr, Heidelberg, Germany	Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Yuan, J (corresponding author), Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	yuan@em.uni-frankfurt.de	Strebhardt, Klaus/E-8765-2011; Rieger, Michael A/L-8324-2017; Kreis, Nina-Naomi/AAF-5407-2019	Rieger, Michael A/0000-0002-4158-5872; Kreis, Nina-Naomi/0000-0003-4304-0160; Yuan, Juping/0000-0003-0694-0565	Deutsche Krebshilfe [108553, 109672]; Deutsche Forschungsgemeinschaft [Yu 156/2-1]; LOEWE Center for Cell and Gene Therapy Frankfurt [III L 4-518/17.004 (2010)]	Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); LOEWE Center for Cell and Gene Therapy Frankfurt	The work was supported by Deutsche Krebshilfe (#108553 and #109672 to JY), Deutsche Forschungsgemeinschaft (#Yu 156/2-1 to JY) and by the LOEWE Center for Cell and Gene Therapy Frankfurt (III L 4-518/17.004 (2010) to MAR). We thank Dr TU Mayer, University of Konstanz, for kindly providing the MKLP2 antibody. We are grateful to Drs KW Kinzler and B Vogelstein, Ludwig Center at Johns Hopkins, Howard Hughes Medical Institute, Baltimore, for the cell lines HCT116 p21 +/+ and HCT116 p21 -/-.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Amador V, 2007, MOL CELL, V27, P462, DOI 10.1016/j.molcel.2007.06.013; Barrett RMA, 2009, CELL CYCLE, V8, P278, DOI 10.4161/cc.8.2.7587; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Baus F, 2003, EMBO J, V22, P3992, DOI 10.1093/emboj/cdg387; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Bloom J, 2004, CELL CYCLE, V3, P138; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cazzalini O, 2010, MUTAT RES-REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009; Charrier-Savournin FB, 2004, MOL BIOL CELL, V15, P3965, DOI 10.1091/mbc.E03-12-0871; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Dash BC, 2005, MOL CELL BIOL, V25, P3364, DOI 10.1128/MCB.25.8.3364-3387.2005; Date D, 2012, J BIOCHEM, V151, P361, DOI 10.1093/jb/mvs015; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 2009, BIOFACTORS, V35, P161, DOI 10.1002/biof.26; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; Hall CC, 1995, BIOCHEM BIOPH RES CO, V217, P728, DOI 10.1006/bbrc.1995.2833; HARPER JW, 1993, CELL, V75, P805; Hu CK, 2012, MOL BIOL CELL, V23, P2702, DOI 10.1091/mbc.E12-01-0058; Hummer S, 2009, CURR BIOL, V19, P607, DOI 10.1016/j.cub.2009.02.046; Jiang W, 1998, MOL CELL, V2, P877, DOI 10.1016/S1097-2765(00)80302-0; Kreis NN, 2010, ONCOGENE, V29, P5591, DOI 10.1038/onc.2010.290; Kreis NN, 2009, CELL CYCLE, V8, P460, DOI 10.4161/cc.8.3.7651; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lindqvist A, 2007, PLOS BIOL, V5, P1127, DOI 10.1371/journal.pbio.0050123; Lindqvist A, 2009, J CELL BIOL, V185, P193, DOI 10.1083/jcb.200812045; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Mishima M, 2004, NATURE, V430, P908, DOI 10.1038/nature02767; Mollinari C, 2002, J CELL BIOL, V157, P1175, DOI 10.1083/jcb.200111052; Nakajima Y, 2011, J CELL BIOL, V194, P137, DOI 10.1083/jcb.201009137; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Pomerening JR, 2008, MOL BIOL CELL, V19, P3426, DOI 10.1091/mbc.E08-02-0172; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Sanhaji M, 2013, CELL CYCLE, V12, P1340, DOI 10.4161/cc.24573; Sanhaji M, 2010, MOL CELL BIOL, V30, P2594, DOI 10.1128/MCB.00098-10; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Trakala M, 2013, CELL CYCLE, V12, P1030, DOI 10.4161/cc.24004; Tsukahara T, 2010, NATURE, V467, P719, DOI 10.1038/nature09390; van der Waal MS, 2012, EXP CELL RES, V318, P1407, DOI 10.1016/j.yexcr.2012.03.015; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; WALDMAN T, 1995, CANCER RES, V55, P5187; Wolf F, 2007, CELL CYCLE, V6, P1408; Wolf F, 2006, EMBO J, V25, P2802, DOI 10.1038/sj.emboj.7601163; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu ZJ, 2009, J CELL BIOL, V187, P637, DOI 10.1083/jcb.200906053; Yang WC, 2001, CANCER RES, V61, P6297; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Yuan JP, 2011, AM J PATHOL, V179, P2091, DOI 10.1016/j.ajpath.2011.06.031; Zimniak T, 2012, CURR BIOL, V22, P787, DOI 10.1016/j.cub.2012.03.007	60	34	37	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2014	33	50					5716	5728		10.1038/onc.2013.518	http://dx.doi.org/10.1038/onc.2013.518			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW2AB	24317508				2022-12-28	WOS:000346089300007
J	Buck, MJ; Raaijmakers, LM; Ramakrishnan, S; Wang, D; Valiyaparambil, S; Liu, S; Nowak, NJ; Pili, R				Buck, M. J.; Raaijmakers, L. M.; Ramakrishnan, S.; Wang, D.; Valiyaparambil, S.; Liu, S.; Nowak, N. J.; Pili, R.			Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma	ONCOGENE			English	Article						Epigenetics; epigenome; FAIRE; FAIRE-seq; renal cell carcinoma	REGULATORY ELEMENTS; FAIRE	Recent studies have demonstrated that in clear cell renal cell carcinoma (ccRCC) several chromatin remodeling enzymes are genetically inactivated. Although, growing evidence in cancer models has demonstrated the importance of epigenetic changes, currently only changes in DNA methylation can be accurately determined from clinical samples. To address this limitation, we have applied formaldehyde-assisted isolation of regulatory elements (FAIREs) combined with next-generation sequencing (FAIRE-seq) to identify specific changes in chromatin accessibility in clinical samples of ccRCC. We modified the FAIRE procedure to allow us to examine chromatin accessibility for small samples of solid tumors. Our FAIRE results were compared with DNA-methylation analysis and show how chromatin accessibility decreases at many sites where DNA-methylation remains unchanged. In addition, our FAIRE-seq analysis allowed us to identify regulatory elements associated with both normal and tumor tissue. We have identified decreases in chromatin accessibility at key ccRCC-linked genes, including PBRM1, SETD2 and MLL2. Overall, our results demonstrate the power of examining multiple aspects of the epigenome.	[Buck, M. J.; Valiyaparambil, S.; Nowak, N. J.] SUNY Buffalo, State Ctr Excellence Bioinformat & Life Sci, Dept Biochem, Buffalo, NY 14214 USA; [Buck, M. J.; Wang, D.; Liu, S.; Nowak, N. J.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA; [Raaijmakers, L. M.] Roswell Pk Canc Inst, CanSys Program, Buffalo, NY 14263 USA; [Ramakrishnan, S.; Pili, R.] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute	Buck, MJ (corresponding author), SUNY Buffalo, State Ctr Excellence Bioinformat & Life Sci, Dept Biochem, Buffalo, NY 14214 USA.	mjbuck@buffalo.edu; njnowak@buffalo.edu; Roberto.Pili@RoswellPark.org			National Cancer Institute at the National Institutes of Health [P30CA016056]; RPCI -Alliance Foundation; Bruce Cuvelier Family Trust; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER	National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); RPCI -Alliance Foundation; Bruce Cuvelier Family Trust; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported in part by the National Cancer Institute at the National Institutes of Health (P30CA016056; to RP), a grant from the RPCI -Alliance Foundation (to RP) and a donation from the, The Bruce Cuvelier Family Trust (to RP).	[Anonymous], 2013, NATURE, V499, P43, DOI [10.1038/nature12222, DOI 10.1038/NATURE12222, DOI 10.1038/nature12222]; Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007; Cairns P, 2011, CANCER BIOMARK, V9, P461, DOI 10.3233/CBM-2011-0176; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906; Gaulton KJ, 2010, NAT GENET, V42, P255, DOI 10.1038/ng.530; Giresi PG, 2007, GENOME RES, V17, P877, DOI 10.1101/gr.5533506; Henrique Rui, 2012, Frontiers in Genetics, V3, P94, DOI 10.3389/fgene.2012.00094; Lai WKM, 2012, BIOINFORMATICS, V28, P1021, DOI 10.1093/bioinformatics/bts063; O'Rourke CJ, 2013, PHARMACOL THERAPEUT, V138, P185, DOI 10.1016/j.pharmthera.2013.01.007; Pena-LlopiS S, 2012, NAT GENET, V44, P751, DOI 10.1038/ng.2323; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Rizzo JM, 2012, CANCER PREV RES, V5, P887, DOI 10.1158/1940-6207.CAPR-11-0432; Simon JM, 2012, NAT PROTOC, V7, P256, DOI 10.1038/nprot.2011.444; Sonpavde G, 2012, CURR ONCOL REP, V14, P295, DOI 10.1007/s11912-012-0237-9; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Ververis K, 2013, BIOL-TARGETS THER, V7, P47, DOI 10.2147/BTT.S29965; Wang H, 2012, GENOME RES, V22, P1680, DOI 10.1101/gr.136101.111; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	21	16	16	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2014	33	41					4961	4965		10.1038/onc.2013.455	http://dx.doi.org/10.1038/onc.2013.455			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OA	24186201				2022-12-28	WOS:000343767900009
J	Fogarty, FM; O'Keeffe, J; Zhadanov, A; Papkovsky, D; Ayllon, V; O'Connor, R				Fogarty, F. M.; O'Keeffe, J.; Zhadanov, A.; Papkovsky, D.; Ayllon, V.; O'Connor, R.			HRG-1 enhances cancer cell invasive potential and couples glucose metabolism to cytosolic/extracellular pH gradient regulation by the vacuolar-H+ ATPase	ONCOGENE			English	Article						V-ATPase; HRG-1; glucose metabolism; pH; IGF-1	PROTON PUMPS; PHOSPHATIDYLINOSITOL 3-KINASE; PLASMA-MEMBRANE; CYTOSOLIC PH; A3 ISOFORM; V-ATPASES; SUBUNIT; TRANSLOCATION; EXPRESSION; TRANSPORTERS	Haeme-responsive gene (HRG)-1 encodes a 16-kDa transmembrane protein that is induced by insulin-like growth factor-1 (IGF-1) and associates with the vacuolar-(H+) ATPase (V-ATPase). We previously reported that HRG-1 is essential for V-ATPase activity in endosomal acidification and receptor trafficking. Here, we show that in highly invasive and migratory cancer cell lines, HRG-1 and the V-ATPase are co-expressed at the plasma membrane, whereas in less invasive cell lines and non-transformed cells HRG-1 overexpression remains confined to intracellular compartments. Stable suppression of HRG-1 in invasive breast cancer MDA-MB-231 cells decreases extracellular pH, cell growth, migration and invasion. Ectopic expression of HRG-1 in non-invasive MCF-7 cells enhances V-ATPase activity, lowers the extracellular pH and increases the pH-dependent activity of MMP2 and MMP9 matrix metalloproteinases. HRG-1 enhances trafficking of the glucose transporter-1 (GLUT-1) with a concomitant increase in glucose uptake and lactate production. HRG-1 also promotes trafficking of the insulin-like growth factor I receptor (IGF-1R), beta 1-integrin and IGF-1 signalling. Taken together, our findings indicate that HRG-1 expression at the plasma membrane enhances V-ATPase activity, drives glycolytic flux and facilitates cancer cell growth, migration and invasion. Thus, HRG-1 may represent a novel target for selectively disrupting V-ATPase activity and the metastatic potential of cancer cells.	[Fogarty, F. M.; O'Keeffe, J.; Ayllon, V.; O'Connor, R.] Natl Univ Ireland Univ Coll Cork, BioSci Inst, Cell Biol Lab, Cork, Ireland; [Zhadanov, A.; Papkovsky, D.] Natl Univ Ireland Univ Coll Cork, BioSci Inst, Dept Biochem, Lab Biophys & Bioanal, Cork, Ireland	University College Cork; University College Cork	O'Connor, R (corresponding author), Natl Univ Ireland Univ Coll Cork, BioSci Inst, Dept Biochem, Lab Biophys & Bioanal, Coll Rd, Cork, Ireland.	r.oconnor@ucc.ie	O'Connor, Rosemary/B-7902-2014; Ayllon, Veronica/L-7069-2014	O'Connor, Rosemary/0000-0002-0687-3422; Ayllon, Veronica/0000-0002-7322-9282; Papkovsky, Dmitri/0000-0003-1556-1145	Health Research Board (PhD Scholars Programme in Cancer Biology(FF)); Science Foundation Ireland (PI) [06/INI/B107]	Health Research Board (PhD Scholars Programme in Cancer Biology(FF)); Science Foundation Ireland (PI)(Science Foundation Ireland)	We are grateful to our colleagues in the Cell Biology Laboratory and Dr Kellie Dean for helpful discussions, and to Kurt Tidmore for preparing illustrations. This work was supported by the Health Research Board (PhD Scholars Programme in Cancer Biology (FF)) and Science Foundation Ireland (PI Award: 06/INI/B107).	Balgi AD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021549; Beyenbach KW, 2006, J EXP BIOL, V209, P577, DOI 10.1242/jeb.02014; Cardone RA, 2005, NAT REV CANCER, V5, P786, DOI 10.1038/nrc1713; Chiche J, 2012, INT J CANCER, V130, P1511, DOI 10.1002/ijc.26125; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Dechant R, 2010, EMBO J, V29, P2515, DOI 10.1038/emboj.2010.138; Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hernandez A, 2012, CURR PHARM DESIGN, V18, P1383, DOI 10.2174/138161212799504821; Hinton A, 2009, J BIOL CHEM, V284, P16400, DOI 10.1074/jbc.M901201200; Kubota S, 2000, BIOCHEM BIOPH RES CO, V278, P390, DOI 10.1006/bbrc.2000.3802; Lu M, 2004, J BIOL CHEM, V279, P8732, DOI 10.1074/jbc.M303871200; Lu X, 2005, CANCER RES, V65, P6843; Martinez-Munoz GA, 2008, J BIOL CHEM, V283, P20309, DOI 10.1074/jbc.M710470200; Martinez-Zaguilan R, 1999, BIOCHEM PHARMACOL, V57, P1037, DOI 10.1016/S0006-2952(99)00022-2; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; Murakami T, 2001, INT J CANCER, V93, P869, DOI 10.1002/ijc.1418; Nilsson Cathrine, 2003, Methods Cell Sci, V25, P185; Nishisho T, 2011, MOL CANCER RES, V9, P845, DOI 10.1158/1541-7786.MCR-10-0449; O'Callaghan KM, 2010, J BIOL CHEM, V285, P381, DOI 10.1074/jbc.M109.063248; Ohta T, 1998, J PATHOL, V185, P324, DOI 10.1002/(SICI)1096-9896(199807)185:3<324::AID-PATH72>3.0.CO;2-9; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; Pastor-Soler N, 2005, PHYSIOLOGY, V20, P417, DOI 10.1152/physiol.00036.2005; Perez-Sayans M, 2012, BRAZ J BIOL, V72, P189, DOI 10.1590/S1519-69842012000100023; Perez-Sayans M, 2009, CANCER TREAT REV, V35, P707, DOI 10.1016/j.ctrv.2009.08.003; Samih N, 2000, ENDOCRINOLOGY, V141, P4146, DOI 10.1210/en.141.11.4146; Sautin YY, 2005, MOL CELL BIOL, V25, P575, DOI 10.1128/MCB.25.2.575-589.2005; Sennoune SR, 2012, CURR PROTEIN PEPT SC, V13, P152; Sennoune SR, 2004, AM J PHYSIOL-CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003; Spugnini EP, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-44; Su Y, 2003, J BIOL CHEM, V278, P20013, DOI 10.1074/jbc.M210077200; Swietach P, 2010, ONCOGENE, V29, P6509, DOI 10.1038/onc.2010.455; Thomsen P, 1999, BBA-MOL CELL RES, V1452, P285, DOI 10.1016/S0167-4889(99)00132-9; Toei M, 2010, BIOCHEMISTRY-US, V49, P4715, DOI 10.1021/bi100397s; Toyomura T, 2003, J BIOL CHEM, V278, P22023, DOI 10.1074/jbc.M302436200; Wagner CA, 2004, PHYSIOL REV, V84, P1263, DOI 10.1152/physrev.00045.2003; Webb BA, 2011, NAT REV CANCER, V11, P671, DOI 10.1038/nrc3110; Yanatori I, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-39; Zhdanov AV, 2013, BBA-GEN SUBJECTS, V1830, P3553, DOI 10.1016/j.bbagen.2013.02.016	39	23	25	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2014	33	38					4653	4663		10.1038/onc.2013.403	http://dx.doi.org/10.1038/onc.2013.403			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3VX	24141772				2022-12-28	WOS:000342007200004
J	Bengsch, F; Buck, A; Gunther, SC; Seiz, JR; Tacke, M; Pfeifer, D; von Elverfeldt, D; Sevenich, L; Hillebrand, LE; Kern, U; Sameni, M; Peters, C; Sloane, BF; Reinheckel, T				Bengsch, F.; Buck, A.; Guenther, S. C.; Seiz, J. R.; Tacke, M.; Pfeifer, D.; von Elverfeldt, D.; Sevenich, L.; Hillebrand, L. E.; Kern, U.; Sameni, M.; Peters, C.; Sloane, B. F.; Reinheckel, T.			Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression	ONCOGENE			English	Article						CTSB; breast cancer; macrophages; invasion	CYSTEINE CATHEPSINS; TUMOR-GROWTH; PLASMINOGEN-ACTIVATOR; PROMOTES PROGRESSION; PROTEASE ACTIVITY; MOUSE MODEL; EXPRESSION; METASTASIS; INVASION; MACROPHAGES	The cysteine protease cathepsin B (CTSB) is frequently overexpressed in human breast cancer and correlated with a poor prognosis. Genetic deficiency or pharmacological inhibition of CTSB attenuates tumor growth, invasion and metastasis in mouse models of human cancers. CTSB is expressed in both cancer cells and cells of the tumor stroma, in particular in tumor-associated macrophages (TAM). In order to evaluate the impact of tumor- or stromal cell-derived CTSB on Polyoma Middle T (PyMT)-induced breast cancer progression, we used in vivo and in vitro approaches to induce human CTSB overexpression in PyMT cancer cells or stromal cells alone or in combination. Orthotopic transplantation experiments revealed that CTSB overexpression in cancer cells rather than in the stroma affects PyMT tumor progression. In 3D cultures, primary PyMT tumor cells showed higher extracellular matrix proteolysis and enhanced collective cell invasion when CTSB was overexpressed and proteolytically active. Coculture of PyMT cells with bone marrow-derived macrophages induced a TAM-like macrophage phenotype in vitro, and the presence of such M2-polarized macrophages in 3D cultures enhanced sprouting of tumor spheroids. We employed a doxycycline (DOX)-inducible CTSB expression system to selectively overexpress human CTSB either in cancer cells or in macrophages in 3D cocultures. Tumor spheroid invasiveness was only enhanced when CTSB was overexpressed in cancer cells, whereas CTSB expression in macrophages alone did not further promote invasiveness of tumor spheroids. We conclude that CTSB overexpression in the PyMT mouse model promotes tumor progression not by a stromal effect, but by a direct, cancer cell-inherent mode of action: CTSB overexpression renders the PyMT cancers more invasive by increasing proteolytic extracellular matrix protein degradation fostering collective cell invasion into adjacent tissue.	[Bengsch, F.; Buck, A.; Guenther, S. C.; Seiz, J. R.; Tacke, M.; Sevenich, L.; Hillebrand, L. E.; Kern, U.; Peters, C.; Reinheckel, T.] Univ Freiburg, Inst Mol Med & Cell Res, D-79104 Freiburg, Germany; [Bengsch, F.; Kern, U.] Univ Freiburg, Spemann Grad Sch Biol & Med, D-79104 Freiburg, Germany; [Bengsch, F.; Hillebrand, L. E.; Kern, U.] Univ Freiburg, Fac Biol, D-79104 Freiburg, Germany; [Pfeifer, D.] Univ Med Ctr, Genom Core Lab, Dept Hematol Oncol, Freiburg, Germany; [von Elverfeldt, D.] Univ Med Ctr, Dept Radiol, Freiburg, Germany; [Hillebrand, L. E.; Peters, C.; Reinheckel, T.] BIOSS Ctr Biol Signalling Studies, Freiburg, Germany; [Sameni, M.; Sloane, B. F.] Wayne State Univ, Dept Pharmacol, Detroit, MI 48201 USA; [Sloane, B. F.] Wayne State Univ, Barbara Ann Carmanos Canc Inst, Detroit, MI USA	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; Wayne State University; Wayne State University	Reinheckel, T (corresponding author), Univ Freiburg, Inst Mol Med & Cell Res, Stefan Meier Str 17, D-79104 Freiburg, Germany.	thomas.reinheckel@uniklinik-freiburg.de	Reinheckel, Thomas/AAL-9761-2021; Buck, Achim/S-4843-2016; Buck, Achim/A-5092-2017; Sloane, Bonnie F/A-1050-2009	Reinheckel, Thomas/0000-0001-9866-9105; von Elverfeldt, Dominik/0000-0002-6219-3528; Buck, Achim/0000-0001-9135-9032	NIH [P30CA22453]; Excellence Initiative of the German Federal and State Governments [EXC 294, GSC-4]; Deutsche Forschungsgemeinschaft [SFB 850, B7]; NATIONAL CANCER INSTITUTE [R01CA140314, P30CA022453] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Excellence Initiative of the German Federal and State Governments; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The CTSB<SUP>+/0</SUP> mice were kindly provided by Dr L. Pennacchio, Genomics Division, Lawrence Berkeley Laboratory, Berkeley, USA. The immortalized macrophage cell line from FVB/n mice was kindly provided by Eike Latz, currently University of Bonn, Germany. We thank Nicole Klemm, Anja Faulhaber and Julia Wolanski for excellent technical assistance. Proteolysis imaging was mainly performed with kind help of the Microscopy, Imaging & Cytometry Resources Core at Wayne State University, Detroit, MI, USA, directed by Dr Kamiar Moin and supported in part by NIH Center grant P30CA22453 to the Karmanos Cancer Institute, Wayne State University. This work was supported by the Excellence Initiative of the German Federal and State Governments (EXC 294 and GSC-4, Spemann Graduate School), and the Deutsche Forschungsgemeinschaft SFB 850 project B7.	Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bell-McGuinn KM, 2007, CANCER RES, V67, P7378, DOI 10.1158/0008-5472.CAN-07-0602; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Brisson L, 2012, EUR J CELL BIOL, V91, P847, DOI 10.1016/j.ejcb.2012.04.004; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; Cavallo-Medved D, 2005, J CELL SCI, V118, P1493, DOI 10.1242/jcs.02278; Cesen MH, 2012, EXP CELL RES, V318, P1245, DOI 10.1016/j.yexcr.2012.03.005; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018; Fehrenbacher N, 2005, CANCER RES, V65, P2993, DOI 10.1158/0008-5472.CAN-05-0476; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; GABRIJELCIC D, 1992, EUR J CLIN CHEM CLIN, V30, P69; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; Gondi CS, 2004, ONCOGENE, V23, P8486, DOI 10.1038/sj.onc.1207879; Gopinathan A, 2012, GUT, V61, P877, DOI 10.1136/gutjnl-2011-300850; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harbeck N, 2001, CLIN CANCER RES, V7, P2757; Herroon MK, 2013, ONCOGENE, V32, P1580, DOI 10.1038/onc.2012.166; Hirschhaeuser F, 2010, J BIOTECHNOL, V148, P3, DOI 10.1016/j.jbiotec.2010.01.012; Houseweart MK, 2003, J NEUROBIOL, V56, P315, DOI 10.1002/neu.10253; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jane DT, 2006, BIOL CHEM, V387, P223, DOI 10.1515/BC.2006.030; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Kallunki T, 2013, ONCOGENE, V32, P1995, DOI 10.1038/onc.2012.292; Keppler D, 1996, ENZYME PROTEIN, V49, P94, DOI 10.1159/000468619; Lakka SS, 2004, ONCOGENE, V23, P4681, DOI 10.1038/sj.onc.1207616; MACIEWICZ RA, 1988, BIOCHEM J, V256, P433, DOI 10.1042/bj2560433; Malla RR, 2011, CANCER GENE THER, V18, P419, DOI 10.1038/cgt.2011.9; Mao Y, 2013, CANCER METAST REV, V32, P303, DOI 10.1007/s10555-012-9415-3; Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002; Mikhaylov G, 2011, NAT NANOTECHNOL, V6, P594, DOI [10.1038/nnano.2011.112, 10.1038/NNANO.2011.112]; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Nouh MA, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-1; Payne SL, 2005, CANCER RES, V65, P11429, DOI 10.1158/0008-5472.CAN-05-1274; Pollard JW, 2008, J LEUKOCYTE BIOL, V84, P623, DOI 10.1189/jlb.1107762; Rafn B, 2012, MOL CELL, V45, P764, DOI 10.1016/j.molcel.2012.01.029; Rawlings ND, 2008, NUCLEIC ACIDS RES, V36, pD320, DOI 10.1093/nar/gkm954; Ruffell B, 2012, TRENDS IMMUNOL, V33, P119, DOI 10.1016/j.it.2011.12.001; Sameni M, 2009, CLIN EXP METASTAS, V26, P299, DOI 10.1007/s10585-008-9218-7; Schurigt U, 2008, BIOL CHEM, V389, P1067, DOI 10.1515/BC.2008.115; Sevenich L, 2011, ONCOGENE, V30, P54, DOI 10.1038/onc.2010.387; Sevenich L, 2010, P NATL ACAD SCI USA, V107, P2497, DOI 10.1073/pnas.0907240107; Shree T, 2011, GENE DEV, V25, P2465, DOI 10.1101/gad.180331.111; SINHA AA, 1993, ANAT REC, V235, P233, DOI 10.1002/ar.1092350207; Tu C, 2008, CANCER RES, V68, P9147, DOI 10.1158/0008-5472.CAN-07-5127; Vasiljeva O, 2008, BIOCHIMIE, V90, P380, DOI 10.1016/j.biochi.2007.10.004; Vasiljeva O, 2006, CANCER RES, V66, P5242, DOI 10.1158/0008-5472.CAN-05-4463; Victor BC, 2007, BIOL CHEM, V388, P1131, DOI 10.1515/BC.2007.150; Withana NP, 2012, CANCER RES, V72, P1199, DOI 10.1158/0008-5472.CAN-11-2759; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823	55	70	71	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2014	33	36					4474	4484		10.1038/onc.2013.395	http://dx.doi.org/10.1038/onc.2013.395			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MY	24077280	Green Accepted			2022-12-28	WOS:000341158800003
J	Fiore, LS; Ganguly, SS; Sledziona, J; Cibull, ML; Wang, C; Richards, DL; Neltner, JM; Beach, C; McCorkle, JR; Kaetzel, DM; Plattner, R				Fiore, L. S.; Ganguly, S. S.; Sledziona, J.; Cibull, M. L.; Wang, C.; Richards, D. L.; Neltner, J. M.; Beach, C.; McCorkle, J. R.; Kaetzel, D. M.; Plattner, R.			c-Abl and Arg induce cathepsin-mediated lysosomal degradation of the NM23-H1 metastasis suppressor in invasive cancer	ONCOGENE			English	Article						metastasis suppressor; c-Abl; Arg; NM23-H1; cathepsin	MESSENGER-RNA EXPRESSION; TUMOR-CELL MOTILITY; BREAST-CANCER; CYSTEINE CATHEPSINS; ADHERENS JUNCTIONS; TYROSINE KINASES; GENE-EXPRESSION; MELANOMA-CELLS; GROWTH; ENDOCYTOSIS	Metastasis suppressors comprise a growing class of genes whose downregulation triggers metastatic progression. In contrast to tumor suppressors, metastasis suppressors are rarely mutated or deleted, and little is known regarding the mechanisms by which their expression is downregulated. Here, we demonstrate that the metastasis suppressor, NM23-H1, is degraded by lysosomal cysteine cathepsins (L,B), which directly cleave NM23-H1. In addition, activation of c-Abl and Arg oncoproteins induces NM23-H1 degradation in invasive cancer cells by increasing cysteine cathepsin transcription and activation. Moreover, c-Abl activates cathepsins by promoting endosome maturation, which facilitates trafficking of NM23-H1 to the lysosome where it is degraded. Importantly, the invasion- and metastasis-promoting activity of c-Abl/Arg is dependent on their ability to induce NM23-H1 degradation, and the pathway is clinically relevant as c-Abl/Arg activity and NM23-H1 expression are inversely correlated in primary breast cancers and melanomas. Thus, we demonstrate a novel mechanism by which cathepsin expression is upregulated in cancer cells (via Abl kinases). We also identify a novel role for intracellular cathepsins in invasion and metastasis (degradation of a metastasis suppressor). Finally, we identify novel crosstalk between oncogenic and metastasis suppressor pathways, thereby providing mechanistic insight into the process of NM23-H1 loss, which may pave the way for new strategies to restore NM23-H1 expression and block metastatic progression.	[Fiore, L. S.; Ganguly, S. S.; Sledziona, J.; McCorkle, J. R.; Plattner, R.] Univ Kentucky, Sch Med, Dept Mol & Biomed Pharmacol, Lexington, KY 40536 USA; [Cibull, M. L.; Richards, D. L.; Neltner, J. M.] Univ Kentucky, Sch Med, Dept Pathol, Lexington, KY 40536 USA; [Wang, C.] Univ Kentucky, Sch Med, Dept Biostat, Lexington, KY 40536 USA; [Wang, C.] Univ Kentucky, Sch Med, Markey Canc Ctr, Lexington, KY 40536 USA; [Beach, C.] Univ Kentucky, Sch Med, Dept Biochem, Lexington, KY 40536 USA; [Kaetzel, D. M.] Univ Maryland, Sch Med, Dept Mol & Cellular Biol, Baltimore, MD 21201 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University System of Maryland; University of Maryland Baltimore	Plattner, R (corresponding author), Univ Kentucky, Sch Med, Dept Mol & Biomed Pharmacol, Combs Res Bldg,Room 209,800 Rose St, Lexington, KY 40536 USA.	rplat2@uky.edu	McCorkle, Rob/AAH-3759-2019	McCorkle, Rob/0000-0002-5028-8853	NIH/NCI/R01 [CA116784, CA166499]; NIH/NCI; Office of the Vice President for Research; NATIONAL CANCER INSTITUTE [R01CA116784, R01CA159871, R01CA166499, P30CA177558] Funding Source: NIH RePORTER	NIH/NCI/R01(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Office of the Vice President for Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the following individuals for their assistance. Garretson Epperly and James Begley (confocal), Spear/Peterson Labs (qPCR), Jonathan Sims and Divya Srinivasan (cell lysates), Vivek Rangnekar, Suzanne Ridges, Aditi Jain (manuscript review) and Woodrow Friend (Figures 1a and 6d). Mass spectrometry was performed at the University of Kentucky Proteomics Core Facility, which is supported in part by the Office of the Vice President for Research. Edman Degradation was performed at the University of Nebraska Protein Structure Core Facility. This work was supported by NIH/NCI/R01 grants to RP (CA116784, CA166499). Dr Plattner is funded by NIH/NCI. DMK also is funded by NIH/NCI, but this work was not supported by his grants.	Allington TM, 2011, CELLS TISSUES ORGANS, V193, P98, DOI 10.1159/000320163; Allington TM, 2009, FASEB J, V23, P4231, DOI 10.1096/fj.09-138412; Annesley SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026024; Authier F, 1999, J BIOL CHEM, V274, P33723, DOI 10.1074/jbc.274.47.33723; Balaji K, 2012, J CELL SCI, V125, P5887, DOI 10.1242/jcs.113688; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Bauer B, 2009, CELL MICROBIOL, V11, P156, DOI 10.1111/j.1462-5822.2008.01246.x; Boissan M, 2010, CANCER RES, V70, P7710, DOI 10.1158/0008-5472.CAN-10-1887; Chambers AF, 2009, CANCER RES, V69, P5292, DOI 10.1158/0008-5472.CAN-09-1528; Curtis CD, 2007, CANCER RES, V67, P10600, DOI 10.1158/0008-5472.CAN-07-0055; De Braekeleer E, 2011, EUR J HAEMATOL, V86, P361, DOI 10.1111/j.1600-0609.2011.01586.x; De Wever O, 2010, INT J DEV BIOL, V54, P887, DOI 10.1387/ijdb.092948ow; Easty DJ, 1996, BRIT J CANCER, V74, P109, DOI 10.1038/bjc.1996.323; ENGEL M, 1993, INT J CANCER, V55, P375, DOI 10.1002/ijc.2910550306; Fenyo David, 2007, J Vis Exp, P192, DOI 10.3791/192; Ganguly SS, 2012, ONCOGENE, V31, P1804, DOI 10.1038/onc.2011.361; Ganguly Sourik S, 2012, Genes Cancer, V3, P414, DOI 10.1177/1947601912458586; GOODALL RJ, 1994, PATHOLOGY, V26, P423, DOI 10.1080/00313029400169122; Horak CE, 2008, APMIS, V116, P586, DOI 10.1111/j.1600-0463.2008.01213.x; Horak CE, 2007, CANCER RES, V67, P7238, DOI 10.1158/0008-5472.CAN-07-0962; Hsu T, 2006, J BIOL CHEM, V281, P12069, DOI 10.1074/jbc.M511621200; Huang SY, 2000, CYTOKINES CELL MOL T, V6, P9, DOI 10.1080/13684730050515868; Huotari J, 2011, EMBO J, V30, P3481, DOI 10.1038/emboj.2011.286; Hwang Byung-Gap, 1997, Journal of Korean Medical Science, V12, P514; IIZUKA N, 1995, CANCER RES, V55, P652; Jacob F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059180; Jacob M, 2009, CELL SIGNAL, V21, P1308, DOI 10.1016/j.cellsig.2009.03.016; Krishnan KS, 2001, NEURON, V30, P197, DOI 10.1016/S0896-6273(01)00273-2; Lin LI, 1998, ANTICANCER RES, V18, P541; Lorenzi PL, 2009, MOL CANCER THER, V8, P713, DOI 10.1158/1535-7163.MCT-08-0921; Ma D, 1996, INVEST OPHTH VIS SCI, V37, P2293; Ma DQ, 2004, J BIOL CHEM, V279, P18073, DOI 10.1074/jbc.M400185200; Marshall JC, 2010, EUR J CANCER, V46, P1278, DOI 10.1016/j.ejca.2010.02.042; McDermott WG, 2008, CLIN EXP METASTAS, V25, P131, DOI 10.1007/s10585-007-9128-0; Mesaki K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019764; MYEROFF LL, 1993, J NATL CANCER I, V85, P147, DOI 10.1093/jnci/85.2.147; Novak M, 2011, N-S ARCH PHARMACOL, V384, P433, DOI 10.1007/s00210-011-0621-2; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Platta HW, 2011, CURR OPIN CELL BIOL, V23, P393, DOI 10.1016/j.ceb.2011.03.008; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Press B, 1998, J CELL BIOL, V140, P1075, DOI 10.1083/jcb.140.5.1075; Radonic A, 2004, BIOCHEM BIOPH RES CO, V313, P856, DOI 10.1016/j.bbrc.2003.11.177; Rae JM, 2007, BREAST CANCER RES TR, V104, P13, DOI 10.1007/s10549-006-9392-8; Reiser J, 2010, J CLIN INVEST, V120, P3421, DOI 10.1172/JCI42918; Rosenfeld JL, 2001, J CELL SCI, V114, P4499; Rotty JD, 2013, NAT REV MOL CELL BIO, V14, P7, DOI 10.1038/nrm3492; Saha A, 2011, FEBS LETT, V585, P3174, DOI 10.1016/j.febslet.2011.08.007; Sgouros J, 2007, IN VIVO, V21, P519; Sims JT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055509; Smith SC, 2009, NAT REV CANCER, V9, P253, DOI 10.1038/nrc2594; Sossey-Alaoui K, 2007, J BIOL CHEM, V282, P26257, DOI 10.1074/jbc.M701484200; Srinivasan D, 2008, ONCOGENE, V27, P1095, DOI 10.1038/sj.onc.1210714; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Srinivasan D, 2009, CELL SIGNAL, V21, P1143, DOI 10.1016/j.cellsig.2009.03.003; Steeg PS, 2008, CLIN CANCER RES, V14, P5006, DOI 10.1158/1078-0432.CCR-08-0238; Taha TA, 2006, FEBS LETT, V580, P6047, DOI 10.1016/j.febslet.2006.09.070; Tanos B, 2006, J BIOL CHEM, V281, P32714, DOI 10.1074/jbc.M603126200; Turk V, 2012, BBA-PROTEINS PROTEOM, V1824, P68, DOI 10.1016/j.bbapap.2011.10.002; Wetzel DM, 2012, MOL CELL BIOL, V32, P3176, DOI 10.1128/MCB.00086-12; Woolworth JA, 2009, MOL CELL BIOL, V29, P4679, DOI 10.1128/MCB.00297-09; Wright PK, 2008, RECENT PAT ANTI-CANC, V3, P137, DOI 10.2174/157489208784638730; Xiong WJ, 2013, DEVELOPMENT, V140, P176, DOI 10.1242/dev.088799; Yogalingam G, 2008, J BIOL CHEM, V283, P35941, DOI 10.1074/jbc.M804543200	65	32	34	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2014	33	36					4508	4520		10.1038/onc.2013.399	http://dx.doi.org/10.1038/onc.2013.399			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MY	24096484	Green Accepted			2022-12-28	WOS:000341158800006
J	Kamekura, R; Kolegraff, KN; Nava, P; Hilgarth, RS; Feng, M; Parkos, CA; Nusrat, A				Kamekura, R.; Kolegraff, K. N.; Nava, P.; Hilgarth, R. S.; Feng, M.; Parkos, C. A.; Nusrat, A.			Loss of the desmosomal cadherin desmoglein-2 suppresses colon cancer cell proliferation through EGFR signaling	ONCOGENE			English	Article						Desmosome; intestinal epithelium; EGFR; desmoglein; desmocollin; cancer	ADHESION; EXPRESSION; INHIBITION; CARCINOMAS; APOPTOSIS; RECEPTOR; DSG2	Desmosomal cadherins mediate cell-cell adhesion in epithelial tissues and have been known to be altered in cancer. We have previously shown that one of the two intestinal epithelial desmosomal cadherins, desmocollin-2 (Dsc2) loss promotes colonic epithelial carcinoma cell proliferation and tumor formation. In this study we show that loss of the other intestinal desmosomal cadherin, desmoglein-2 (Dsg2) that pairs with Dsc2, results in decreased epithelial cell proliferation and suppressed xenograft tumor growth in mice. Dsg2-deficient cells demonstrated a compensatory increase in Dsc2 expression, and small interfering RNA-mediated loss of Dsc2 restored proliferation in Dsg2-deficient cells. Dsg2 downregulation inhibited epidermal growth factor receptor (EGFR) signaling and cell proliferation through altered phosphorylation of EGFR and downstream extracellular signal-regulated kinase activation in parallel with inhibited EGFR receptor internalization. Additionally, we demonstrated a central role of Dsc2 in controlling EGFR signaling and cell proliferation in intestinal epithelial cells. Consistent with these findings, analyses of human colon cancers demonstrated increased Dsg2 protein expression. Taken together, these data demonstrate that partner desmosomal cadherins Dsg2 and Dsc2 play opposing roles in controlling colonic carcinoma cell proliferation through differential effects on EGFR signaling.	[Kamekura, R.; Kolegraff, K. N.; Hilgarth, R. S.; Feng, M.; Parkos, C. A.; Nusrat, A.] Emory Univ, Dept Pathol & Lab Med, Epithelial Pathobiol & Mucosal Inflammat Res Unit, Atlanta, GA 30322 USA; [Nava, P.] Ctr Res & Adv Studies CINVESTAV, Dept Physiol Biophys & Neurosci, Mexico City, DF, Mexico	Emory University; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional	Nusrat, A (corresponding author), Emory Univ, Dept Pathol & Lab Med, Epithelial Pathobiol & Mucosal Inflammat Res Unit, Whitehead Biomed Res Bldg,Room 105M, Atlanta, GA 30322 USA.	anusrat@emory.edu	Nava, Porfirio/D-8306-2012	Nava, Porfirio/0000-0002-0506-1510	Japan Society of Immunology and Allergology in Otolaryngology; American Gastroenterological Association Research Scholar Award; Crohn's and Colitis Foundation of America Career Development Award; CONACyT [175854]; National Institutes of Health [DK061379, DK072564, DK055679, DK059888]; DDRDC [DK064399]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007771, R01DK055679, R01DK072564, R24DK064399, R01DK061379, R01DK079392, R01DK059888, R29DK055679] Funding Source: NIH RePORTER	Japan Society of Immunology and Allergology in Otolaryngology; American Gastroenterological Association Research Scholar Award; Crohn's and Colitis Foundation of America Career Development Award; CONACyT(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DDRDC; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the 12th Glaxo-SmithKline International Award from Japan Society of Immunology and Allergology in Otolaryngology (RK), an American Gastroenterological Association Research Scholar Award (PN), a Crohn's and Colitis Foundation of America Career Development Award (PN), a CONACyT grant 175854 (PN) and National Institutes of Health grants DK061379, DK072564 (CAP), DK055679, DK059888 (AN) and DDRDC DK064399.	Baron S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050024; Biedermann K, 2005, J PATHOL, V207, P199, DOI 10.1002/path.1821; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Brennan D, 2007, J CELL SCI, V120, P758, DOI 10.1242/jcs.03392; Brennan D, 2009, CELL ADHES MIGR, V3, P148, DOI 10.4161/cam.3.2.7539; Chen YJ, 2007, ONCOGENE, V26, P467, DOI 10.1038/sj.onc.1209802; Getsios S, 2004, DIFFERENTIATION, V72, P419, DOI 10.1111/j.1432-0436.2004.07208008.x; Getsios S, 2009, J CELL BIOL, V185, P1243, DOI 10.1083/jcb.200809044; Holthofer B, 2007, INT REV CYTOL, V264, P65, DOI 10.1016/S0074-7696(07)64003-0; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Ishii K, 2001, J INVEST DERMATOL, V117, P26, DOI 10.1046/j.0022-202x.2001.01400.x; Kolegraff K, 2011, CELL ADHES MIGR, V5, P306, DOI 10.4161/cam.5.4.16911; Kolegraff K, 2011, MOL BIOL CELL, V22, P1121, DOI 10.1091/mbc.E10-10-0845; Lock JG, 2005, MOL BIOL CELL, V16, P1744, DOI 10.1091/mbc.E04-10-0867; Mannan T, 2011, CELL PROLIFERAT, V44, P301, DOI 10.1111/j.1365-2184.2011.00765.x; Nava P, 2007, MOL BIOL CELL, V18, P4565, DOI 10.1091/mbc.E07-05-0426; Oksvold MP, 2003, ONCOGENE, V22, P8509, DOI 10.1038/sj.onc.1207117; Resnik N, 2011, J BIOL CHEM, V286, P1499, DOI 10.1074/jbc.M110.189464; Schlegel N, 2010, AM J PHYSIOL-GASTR L, V298, pG774, DOI 10.1152/ajpgi.00239.2009; SHIMOYAMA Y, 1989, CANCER RES, V49, P2128; Tselepis C, 1998, P NATL ACAD SCI USA, V95, P8064, DOI 10.1073/pnas.95.14.8064; Wex T, 2012, HUM PATHOL, V43, P1745, DOI 10.1016/j.humpath.2011.12.024	22	73	75	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2014	33	36					4531	4536		10.1038/onc.2013.442	http://dx.doi.org/10.1038/onc.2013.442			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MY	24166502	Green Accepted			2022-12-28	WOS:000341158800008
J	Hitosugi, T; Chen, J				Hitosugi, T.; Chen, J.			Post-translational modifications and the Warburg effect	ONCOGENE			English	Review						the Warburg effect; post-translational modifications; cancer metabolism	PYRUVATE-KINASE M2; PHOSPHOGLYCERATE MUTASE; TYROSINE PHOSPHORYLATION; NUCLEAR TRANSLOCATION; LACTATE-DEHYDROGENASE; GLYCOLYTIC-ENZYMES; METABOLIC TRANSFORMATION; GENE-TRANSCRIPTION; 3T3-L1 ADIPOCYTES; CELL METABOLISM	Post-translational modification (PTM) is an important step of signal transduction that transfers chemical groups such as phosphate, acetyl and glycosyl groups from one protein to another protein. As most of the PTMs are reversible, normal cells use PTMs as a 'switch' to determine the resting and proliferating state of cells that enables rapid and tight regulation of cell proliferation. In cancer cells, activation of oncogenes and/or inactivation of tumor suppressor genes provide continuous proliferative signals in part by adjusting the state of diverse PTMs of effector proteins that are involved in regulation of cell survival, cell cycle and proliferation, leading to abnormally fast proliferation of cancer cells. In addition to dysregulated proliferation, 'altered tumor metabolism' has recently been recognized as an emerging cancer hallmark. The most common metabolic phenotype of cancer is known as the Warburg effect or aerobic glycolysis that consists of increased glycolysis and enhanced lactate production even in the presence of oxygen. Although Otto Warburg observed aerobic glycolysis nearly 90 years ago, the detailed molecular mechanisms how increased glycolysis is regulated by oncogenic and/or tumor suppressive signaling pathways remain unclear. In this review, we summarize recent advances revealing how these signaling pathways reprogram metabolism through diverse PTMs to provide a metabolic advantage to cancer cells, thereby promoting tumor cell proliferation, tumorigenesis and tumor growth.	[Hitosugi, T.] Mayo Clin, Dept Oncol, Div Oncol Res, Rochester, MN USA; [Chen, J.] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst Emory, Atlanta, GA 30322 USA	Mayo Clinic; Emory University	Hitosugi, T (corresponding author), Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst Emory, 1365-C Clifton Rd NE,Room C-3002, Atlanta, GA 30322 USA.	Hitosugi.Taro@mayo.edu; jchen@emory.edu			NIH [CA140515]; DoD [W81XWH-12-1-0217]; NATIONAL CANCER INSTITUTE [R01CA140515] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We apologize to authors whose contributions were not directly cited owing to space limitations. This study is supported in part by NIH grants CA140515 (JC) and DoD grant W81XWH-12-1-0217 (JC). JC is a Georgia Cancer Coalition Distinguished Cancer Scholar and a Scholar of the Leukemia and Lymphoma Society.	Anastasiou D, 2012, NAT CHEM BIOL, V8, P839, DOI 10.1038/NCHEMBIO.1060; Anastasiou D, 2011, SCIENCE, V334, P1278, DOI 10.1126/science.1211485; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Brahimi-Horn MC, 2007, CURR OPIN CELL BIOL, V19, P223, DOI 10.1016/j.ceb.2007.02.003; BRITTON HG, 1972, BIOCHEM J, V130, P397, DOI 10.1042/bj1300397; Cheung EC, 2010, CURR OPIN CELL BIOL, V22, P186, DOI 10.1016/j.ceb.2009.12.006; Chouchani ET, 2011, CURR OPIN CHEM BIOL, V15, P120, DOI 10.1016/j.cbpa.2010.11.003; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; COOPER JA, 1983, NATURE, V302, P218, DOI 10.1038/302218a0; COOPER JA, 1981, MOL CELL BIOL, V1, P394, DOI 10.1128/MCB.1.5.394; COOPER JA, 1984, J BIOL CHEM, V259, P7835; Corcoran CA, 2006, CANCER BIOL THER, V5, P1610, DOI 10.4161/cbt.5.12.3617; Dang CV, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.297pe75; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Doskeland AP, 1996, BIOCHEM J, V319, P941, DOI 10.1042/bj3190941; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Evans MJ, 2007, MOL BIOSYST, V3, P495, DOI 10.1039/b705113a; Evans MJ, 2005, NAT BIOTECHNOL, V23, P1303, DOI 10.1038/nbt1149; Fan J, 2011, MOL CELL BIOL, V31, P4938, DOI 10.1128/MCB.06120-11; Foran PGP, 1999, J BIOL CHEM, V274, P28087, DOI 10.1074/jbc.274.40.28087; Fothergill-Gilmore L. A., 1989, ADV ENZYMOLOGY RELAT, V62, P227; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Gordan JD, 2007, CANCER CELL, V12, P108, DOI 10.1016/j.ccr.2007.07.006; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; GRISOLIA S, 1968, BIOCHEMISTRY-US, V7, P1115, DOI 10.1021/bi00843a032; Hallows WC, 2012, J BIOL CHEM, V287, P3850, DOI 10.1074/jbc.M111.317404; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Heiden MGV, 2010, SCIENCE, V329, P1492, DOI 10.1126/science.1188015; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Hitosugi T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2759; Hitosugi T, 2012, CANCER CELL, V22, P585, DOI 10.1016/j.ccr.2012.09.020; Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Hoshino A, 2007, J BIOL CHEM, V282, P17706, DOI 10.1074/jbc.M700094200; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kondoh H, 2005, CANCER RES, V65, P177; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kupriyanova TA, 1999, J BIOL CHEM, V274, P1458, DOI 10.1074/jbc.274.3.1458; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Medina RA, 2002, BIOL RES, V35, P9, DOI 10.4067/S0716-97602002000100004; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Miyamoto S, 2008, CELL DEATH DIFFER, V15, P521, DOI 10.1038/sj.cdd.4402285; Morelle W, 2006, PROTEOMICS, V6, P3993, DOI 10.1002/pmic.200600129; Parnell KM, 2013, MOL CANCER THER, V12, P1453, DOI 10.1158/1535-7163.MCT-13-0026; Patel MS, 2001, EXP MOL MED, V33, P191, DOI 10.1038/emm.2001.32; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Robey RB, 2009, SEMIN CANCER BIOL, V19, P25, DOI 10.1016/j.semcancer.2008.11.010; Roche TE, 2007, CELL MOL LIFE SCI, V64, P830, DOI 10.1007/s00018-007-6380-z; ROSE ZB, 1976, J BIOL CHEM, V251, P4817; ROSE ZB, 1975, J BIOL CHEM, V250, P7939; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Stetak A, 2007, CANCER RES, V67, P1602, DOI 10.1158/0008-5472.CAN-06-2870; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Tennant DA, 2009, CARCINOGENESIS, V30, P1269, DOI 10.1093/carcin/bgp070; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yi W, 2012, SCIENCE, V337, P975, DOI 10.1126/science.1222278; Zhao D, 2013, CANCER CELL, V23, P464, DOI 10.1016/j.ccr.2013.02.005	71	80	80	3	52	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2014	33	34					4279	4285		10.1038/onc.2013.406	http://dx.doi.org/10.1038/onc.2013.406			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MK	24096483				2022-12-28	WOS:000341156900001
J	Zhang, JP; Zeng, C; Xu, L; Gong, J; Fang, JH; Zhuang, SM				Zhang, J-P; Zeng, C.; Xu, L.; Gong, J.; Fang, J-H; Zhuang, S-M			MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling	ONCOGENE			English	Article						miR-148a; epithelial-mesenchymal transition; metastasis; met; hepatocellular carcinoma	HEPATOCELLULAR-CARCINOMA; E-CADHERIN; PROMOTES APOPTOSIS; GASTRIC-CANCER; EXPRESSION; SNAIL; CONTRIBUTES; INVASION; BETA; MET	Metastasis is responsible for the rapid recurrence and poor survival of malignancies. Epithelial-mesenchymal transition (EMT) has a critical role in metastasis. Increasing evidence indicates that EMT can be regulated by microRNAs (miRNAs). miR-148a is a liver-abundant miRNA. However, the role of miR-148a in the development of liver cancer remains largely unknown. In this study, we found that, compared with normal livers, miR-148a was significantly decreased in hepatocellular carcinoma (HCC) tissues, especially in those with the portal vein tumor thrombus. An in vitro transwell assay and an in vivo orthotopic liver xenograft model showed that the restoration of miR-148a expression significantly repressed the migration and pulmonary metastasis of hepatoma cells. Linear regression analysis revealed a positive correlation between the expression of miR-148a and the mRNA level of E-cadherin gene in human HCC tissues. Both gain-and loss-of-function studies disclosed that miR-148a promoted the expression of epithelial marker (E-cadherin) and reduced the levels of mesenchymal markers (N-cadherin, fibronectin or vimentin) in hepatoma cells. These data suggest that miR-148a may suppress EMT and cancer metastasis. Further mechanistic investigations showed that miR-148a directly inhibited Met expression by binding to its 3'-UTR. Moreover, the reintroduction of miR-148a attenuated the downstream signaling of Met, like activated phosphorylation of AKT-Ser473 and inhibitory phosphorylation of GSK-3b-Ser9, and consequently reduced the nuclear accumulation of Snail, a transcription factor that promotes EMT. Taken together, miR-148a may negatively regulate Met/Snail signaling and therefore inhibit the EMT and metastasis of hepatoma cells. These findings highlight the significance of miR-148a downregulation in tumor progression and implicate miR-148a as an attractive candidate for cancer therapy.	[Zhang, J-P; Zeng, C.; Gong, J.; Fang, J-H; Zhuang, S-M] Sun Yat Sen Univ, Sch Life Sci, State Key Lab Biocontrol, Key Lab Gene Engn,Minist Educ, Guangzhou 510275, Guangdong, Peoples R China; [Zhang, J-P; Xu, L.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University	Zhuang, SM (corresponding author), Sun Yat Sen Univ, Sch Life Sci, Xin Gang Xi Rd 135, Guangzhou 510275, Guangdong, Peoples R China.	zhuangshimei@163.com	Fang, Jian-hong/HCH-6747-2022; ZHANG, JINGPING/AAT-8229-2021; zhang, jingping/AAM-2751-2021	zhang, jingping/0000-0003-0090-6710; Fang, Jian-hong/0000-0002-7723-5348; Zhuang, Shi-Mei/0000-0002-2512-3942	Ministry of Science and Technology of China [2010CB912803, 2011CB811305]; Ministry of Health of China [2012ZX10002011]; National Natural Science Foundation of China [81101593, 30925036]; Ministry of Education of China [20110171120043]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); Ministry of Health of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of China(Ministry of Education, China)	This study was supported by grants from Ministry of Science and Technology of China (2010CB912803, 2011CB811305), Ministry of Health of China (2012ZX10002011), National Natural Science Foundation of China (81101593, 30925036), Ministry of Education of China (20110171120043).	Barad O, 2004, GENOME RES, V14, P2486, DOI 10.1101/gr.2845604; Braconi C, 2010, HEPATOLOGY, V51, P881, DOI 10.1002/hep.23381; Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008; Fujita Y, 2010, J BIOL CHEM, V285, P19076, DOI 10.1074/jbc.M109.079525; Gailhouste L, 2013, HEPATOLOGY, V58, P1153, DOI 10.1002/hep.26422; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Khew-Goodall Y, 2010, NAT CELL BIOL, V12, P209, DOI 10.1038/ncb0310-209; Kim NH, 2011, J CELL BIOL, V195, P417, DOI 10.1083/jcb.201103097; Kumarswamy R, 2012, INT J CANCER, V130, P2044, DOI 10.1002/ijc.26218; Liffers ST, 2011, LAB INVEST, V91, P1472, DOI 10.1038/labinvest.2011.99; Lim SO, 2008, GASTROENTEROLOGY, V135, P2128, DOI 10.1053/j.gastro.2008.07.027; Liu XQ, 2011, BIOCHEM J, V440, P23, DOI 10.1042/BJ20111006; Meng ZP, 2010, HEPATOLOGY, V52, P2148, DOI 10.1002/hep.23915; Oishi N, 2012, HEPATOLOGY, V56, P1792, DOI 10.1002/hep.25890; Papadimitriou E, 2012, ONCOGENE, V31, P2862, DOI 10.1038/onc.2011.457; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886; Vetter G, 2010, ONCOGENE, V29, P4436, DOI 10.1038/onc.2010.181; Wei Y, 2002, HEPATOLOGY, V36, P692, DOI 10.1053/jhep.2002.35342; Xu Q, 2013, CARCINOGENESIS, V34, P539, DOI 10.1093/carcin/bgs374; Xu Q, 2013, J MOL CELL BIOL, V5, P3, DOI 10.1093/jmcb/mjs049; Yang MH, 2009, HEPATOLOGY, V50, P1464, DOI 10.1002/hep.23221; You HN, 2011, HEPATOLOGY, V54, P879, DOI 10.1002/hep.24450; Yu J, 2011, J BIOMED RES, V25, P170, DOI 10.1016/S1674-8301(11)60022-5; Zhang H, 2011, CELL DEATH DIFFER, V18, P1702, DOI 10.1038/cdd.2011.28; Zhao X, 2013, ONCOGENE, V32, P1363, DOI 10.1038/onc.2012.156; Zheng BQ, 2011, CLIN CANCER RES, V17, P7574, DOI 10.1158/1078-0432.CCR-11-1714; Zheng F, 2012, GUT, V61, P278, DOI 10.1136/gut.2011.239145; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	34	112	119	1	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2014	33	31					4069	4076		10.1038/onc.2013.369	http://dx.doi.org/10.1038/onc.2013.369			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YG	24013226				2022-12-28	WOS:000340595300006
J	Albinet, V; Bats, ML; Huwiler, A; Rochaix, P; Chevreau, C; Segui, B; Levade, T; Andrieu-Abadie, N				Albinet, V.; Bats, M-L; Huwiler, A.; Rochaix, P.; Chevreau, C.; Segui, B.; Levade, T.; Andrieu-Abadie, N.			Dual role of sphingosine kinase-1 in promoting the differentiation of dermal fibroblasts and the dissemination of melanoma cells	ONCOGENE			English	Article						dermal fibroblasts; melanoma; migration; sphingosine-1-phosphate; Sphk1(-/-) mice	STROMAL FIBROBLASTS; TUMOR-DEVELOPMENT; SPHINGOSINE-1-PHOSPHATE; INVASION; RECEPTOR; GROWTH; ANGIOGENESIS; SPHINGOLIPIDS; 1-PHOSPHATE; EXPRESSION	Despite progress in the understanding of the biology and genetics of melanoma, no effective treatment against this cancer is available. The adjacent microenvironment has an important role in melanoma progression. Defining the molecular signals that control the bidirectional dialog between malignant cells and the surrounding stroma is crucial for efficient targeted therapy. Our study aimed at defining the role of sphingosine-1-phosphate (S1P) in melanoma-stroma interactions. Transcriptomic analysis of human melanoma cell lines showed increased expression of sphingosine kinase-1 (SPHK1), the enzyme that produces S1P, as compared with normal melanocytes. Such an increase was also observed by immunohistochemistry in melanoma specimens as compared with nevi, and occurred downstream of ERK activation because of BRAF or NRAS mutations. Importantly, migration of melanoma cells was not affected by changes in SPHK1 activity in tumor cells, but was stimulated by comparable modifications of S1P-metabolizing enzymes in cocultured dermal fibroblasts. Reciprocally, incubation of fibroblasts with the conditioned medium from SPHK1-expressing melanoma cells resulted in their differentiation to myofibroblasts, increased production of matrix metalloproteinases and enhanced SPHK1 expression and activity. In vivo tumorigenesis experiments showed that the lack of S1P in the microenvironment prevented the development of orthotopically injected melanoma cells. Finally, local tumor growth and dissemination were enhanced more efficiently by coinjection of wild-type skin fibroblasts than by fibroblasts from Sphk1(-/-) mice. This report is the first to document that SPHK1/S1P modulates the communication between melanoma cells and dermal fibroblasts. Altogether, our findings highlight SPHK1 as a potential therapeutic target in melanoma progression.	[Albinet, V.; Bats, M-L; Segui, B.; Levade, T.; Andrieu-Abadie, N.] Ctr Rech Cancerol Toulouse, Equipe Labellisee Ligue Canc 2013, INSERM, UMR1037, Toulouse, France; [Albinet, V.; Bats, M-L; Segui, B.; Levade, T.; Andrieu-Abadie, N.] Univ Toulouse 3, F-31062 Toulouse, France; [Huwiler, A.] Univ Bern, Inst Pharmacol, Bern, Switzerland; [Rochaix, P.] Serv Anat & Cytol Pathol, Toulouse, France; [Chevreau, C.] Inst Claudius Regaud, Dept Med Oncol, Toulouse, France; [Levade, T.] CHU, Lab Biochim Metab, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Bern; UNICANCER; Institut Claudius Regaud; CHU de Toulouse	Andrieu-Abadie, N (corresponding author), CHU Rangueil, Ctr Rech Cancerol Toulouse, Equipe Labellisee Ligue Canc 2013, Inserm,UMR1037, BP84225, F-31432 Toulouse, France.	nathalie.andrieu@inserm.fr	Levade, Thierry/O-8948-2014; Rochaix, Philippe/O-4710-2014; Ségui, Bruno/O-8957-2014; Chevreau, Christine/A-5565-2015; Andrieu-Abadie, Nathalie/N-6793-2013	Rochaix, Philippe/0000-0001-6238-1599; Ségui, Bruno/0000-0002-6119-1889; Andrieu-Abadie, Nathalie/0000-0003-2698-1970; Bats, Marie-Lise/0000-0002-8359-4662	INSERM; Paul Sabatier University; Ligue Nationale Contre le Cancer; Association pour la Recherche sur le Cancer	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Paul Sabatier University; Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council)	We thank Drs D Bennett (London, UK), R Marais (London, UK), SM Pitson (Adelaide, SA, Australia) and H Tsao (Boston, MA, USA) for providing cells and vectors, Drs G Fabrias and J Casas for mass spectrometry analysis, and C David, C Fourreau and C Nevoit for technical support. The financial support by INSERM, Paul Sabatier University and Ligue Nationale Contre le Cancer is gratefully acknowledged. VA is a recipient of a fellowship from Association pour la Recherche sur le Cancer.	Arikawa K, 2003, J BIOL CHEM, V278, P32841, DOI 10.1074/jbc.M305024200; Asnacios A, 2008, J CLIN ONCOL, V26, P963, DOI 10.1200/JCO.2007.12.7431; Beacham DA, 2005, SEMIN CANCER BIOL, V15, P329, DOI 10.1016/j.semcancer.2005.05.003; Bektas M, 2005, ONCOGENE, V24, P178, DOI 10.1038/sj.onc.1208019; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; Caballero S, 2009, EXP EYE RES, V88, P367, DOI 10.1016/j.exer.2008.07.012; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; Colie S, 2009, CANCER RES, V69, P9346, DOI 10.1158/0008-5472.CAN-09-2198; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Deng JH, 2012, CANCER CELL, V21, P642, DOI 10.1016/j.ccr.2012.03.039; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Flach EH, 2011, MOL PHARMACEUT, V8, P2039, DOI 10.1021/mp200421k; French KJ, 2003, CANCER RES, V63, P5962; Gault CR, 2012, J BIOL CHEM, V287, P31794, DOI 10.1074/jbc.M112.385765; Geller AC, 2007, J AM ACAD DERMATOL, V57, P555, DOI 10.1016/j.jaad.2007.06.032; Gellings Lowe N, 2009, CARDIOVASC RES, V82, P303, DOI 10.1093/cvr/cvp056; Hofmann UB, 2005, BIOCHIMIE, V87, P307, DOI 10.1016/j.biochi.2005.01.013; Huwiler A, 2008, BIOCHEM PHARMACOL, V75, P1893, DOI 10.1016/j.bcp.2007.12.018; Jolly PS, 2005, BLOOD, V105, P4736, DOI 10.1182/blood-2004-12-4686; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Keller CD, 2007, AM J PATHOL, V170, P281, DOI 10.2353/ajpath.2007.060485; Kono Y, 2007, AM J RESP CELL MOL, V37, P395, DOI 10.1165/rcmb.2007-0065OC; Kunz-Schughart LA, 2002, HISTOL HISTOPATHOL, V17, P599, DOI 10.14670/HH-17.599; LaMontagne K, 2006, CANCER RES, V66, P221, DOI 10.1158/0008-5472.CAN-05-2001; Lavieu Gregory, 2008, V445, P159, DOI 10.1007/978-1-59745-157-4_11; Li CY, 2011, J HEPATOL, V54, P1205, DOI 10.1016/j.jhep.2010.08.028; Li G, 2003, ONCOGENE, V22, P3162, DOI 10.1038/sj.onc.1206455; Liu SQ, 2012, INT J COLORECTAL DIS, V27, P1569, DOI 10.1007/s00384-012-1510-y; Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003; Madhunapantula SV, 2012, PIGM CELL MELANOMA R, V25, DOI 10.1111/j.1755-148X.2012.00970.x; Mitra P, 2007, METHOD ENZYMOL, V434, P257, DOI 10.1016/S0076-6879(07)34014-7; Platz A, 2008, MOL ONCOL, V1, P395, DOI 10.1016/j.molonc.2007.12.003; Ponnusamy S, 2012, EMBO MOL MED, V4, P761, DOI 10.1002/emmm.201200244; Pushparaj PN, 2009, J IMMUNOL, V183, P221, DOI 10.4049/jimmunol.0803430; Pyne NJ, 2012, BIOCHIM BIOPHYS ACTA, V1831, P228; Rebecca VW, 2012, MELANOMA RES, V22, P114, DOI 10.1097/CMR.0b013e328351fa4d; Rolin J, 2011, CANCER MICROENVIRON, V4, P393, DOI 10.1007/s12307-011-0088-1; Ruiter D, 2002, LANCET ONCOL, V3, P35, DOI 10.1016/S1470-2045(01)00620-9; Schwalm S, 2013, BBA-MOL CELL BIOL L, V1831, P239, DOI 10.1016/j.bbalip.2012.07.022; Shimoda M, 2010, SEMIN CELL DEV BIOL, V21, P19, DOI 10.1016/j.semcdb.2009.10.002; Sly W S, 1979, Methods Enzymol, V58, P444; Smalley KSM, 2005, EXPERT REV ANTICANC, V5, P1069, DOI 10.1586/14737140.5.6.1069; Takuwa Y, 2012, BIOCHIM BIOPHYS ACTA, V1831, P185; Urata Yoshiko, 2005, Kobe Journal of Medical Sciences, V51, P17; Vasseur S, 2002, EMBO REP, V3, P165, DOI 10.1093/embo-reports/kvf023; Visentin B, 2006, CANCER CELL, V9, P225, DOI 10.1016/j.ccr.2006.02.023; Watterson KR, 2007, WOUND REPAIR REGEN, V15, P607, DOI 10.1111/j.1524-475X.2007.00292.x; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Yamaguchi H, 2003, BIOCHEM J, V374, P715, DOI 10.1042/BJ20030381; Yamanaka M, 2004, J BIOL CHEM, V279, P53994, DOI 10.1074/jbc.M410144200; Yin M, 2012, AM J PATHOL, V181, P2202, DOI 10.1016/j.ajpath.2012.08.027; Youm JK, 2008, J DERMATOL SCI, V51, P89, DOI 10.1016/j.jdermsci.2008.03.002	53	37	45	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3364	3373		10.1038/onc.2013.303	http://dx.doi.org/10.1038/onc.2013.303			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23893239				2022-12-28	WOS:000338779300003
J	Ryan, AE; Colleran, A; O'Gorman, A; O'Flynn, L; Pindjacova, J; Lohan, P; O'Malley, G; Nosov, M; Mureau, C; Egan, LJ				Ryan, A. E.; Colleran, A.; O'Gorman, A.; O'Flynn, L.; Pindjacova, J.; Lohan, P.; O'Malley, G.; Nosov, M.; Mureau, C.; Egan, L. J.			Targeting colon cancer cell NF-kappa B promotes an anti-tumour M1-like macrophage phenotype and inhibits peritoneal metastasis	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; COLORECTAL-CANCER; CYTOREDUCTIVE SURGERY; MOUSE MODEL; T-CELLS; INFLAMMATION; ALPHA; CARCINOMATOSIS; MONOCYTES; GROWTH	In a model of peritoneal metastasis in immune-competent mice, we show that nuclear factor (NF)-kappa B inhibition in CT26 colon cancer cells prevents metastasis. NF-kappa B inhibition, by stable overexpression of I kappa B-a super-repressor, induced differential polarization of co-cultured macrophages to an M1-like anti-tumour phenotype in vitro. NF-kappa B-deficient cancer cell-conditioned media (CT26/I kappa B-alpha SR) induced interleukin (IL)-12 and nitric oxide (NO) synthase (inducible NO synthase (iNOS)) expression in macrophages. Control cell (CT26/EV) conditioned media induced high levels of IL-10 and arginase in macrophages. In vivo, this effect translated to reduction in metastasis in mice injected with CT26/I kappa B-alpha SR cells and was positively associated with increased CD8(+)CD44(+)CD62L- and CD4(+)CD44(+)CD62L-effector T cells. Furthermore, inhibition of NF-kappa B activity induced high levels of NO in infiltrating immune cells and decreases in matrix metalloproteinase-9 expression, simultaneous with increases in tissue inhibitor of metalloproteinases 1 and 2 within tumours. CT26/I kappa B-alpha SR tumours displayed increased pro-inflammatory gene expression, low levels of angiogenesis and extensive intratumoral apoptosis, consistent with the presence of an anti-tumour macrophage phenotype. Macrophage depletion reduced tumour size in CT26/EV-injected animals and increased tumour size in CT26/I kappa B-alpha SR cells compared with untreated tumours. Our data demonstrate, for the first time, that an important implication of targeting tumour cell NF-kappa B is skewing of macrophage polarization to an anti-tumour phenotype. This knowledge offers novel therapeutic opportunities for anticancer treatment.	[Ryan, A. E.; Colleran, A.; O'Gorman, A.; O'Malley, G.; Mureau, C.; Egan, L. J.] Natl Univ Ireland, Sch Med, Discipline Pharmacol & Therapeut, Galway, Ireland; [Ryan, A. E.; O'Flynn, L.; Pindjacova, J.; Lohan, P.; O'Malley, G.; Nosov, M.] Natl Univ Ireland, Sch Med, NCBES, Regenerat Med Inst REMEDI, Galway, Ireland	Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway	Egan, LJ (corresponding author), Univ Hosp Galway, Inst Clin Sci, Newcastle Rd, Galway, Ireland.	laurence.egan@nuigalway.ie	Ryan, Aideen/H-3909-2019	Ryan, Aideen/0000-0002-5831-6783	Irish Cancer Society [CRF12RYA]; Science Foundation Ireland [04/IN3/B748]; Irish Cancer Society	Irish Cancer Society; Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Irish Cancer Society	This work was supported by funding from the Irish Cancer Society to AER (CRF12RYA) and from the Science Foundation Ireland (04/IN3/B748) and the Irish Cancer Society to LJE.	Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Camus M, 2009, CANCER RES, V69, P2685, DOI 10.1158/0008-5472.CAN-08-2654; Cintron JR, 1996, SEMIN SURG ONCOL, V12, P267, DOI 10.1002/(SICI)1098-2388(199607/08)12:4<267::AID-SSU6>3.0.CO;2-3; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cook NR, 2005, JAMA-J AM MED ASSOC, V294, P47, DOI 10.1001/jama.294.1.47; De Palma M, 2008, CANCER CELL, V14, P299, DOI 10.1016/j.ccr.2008.09.004; DeNardo DG, CANC METASTASIS REV, V29, P309; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Eaden J, 2003, ALIMENT PHARM THER, V18, P15, DOI 10.1046/j.1365-2036.18.s2.3.x; Egan LJ, 1999, J BIOL CHEM, V274, P26448, DOI 10.1074/jbc.274.37.26448; Flemming A, 2011, NAT REV DRUG DISCOV, V10, DOI 10.1038/nrd3399; Foran E, MOL CANC RES, V8, P471; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hagemann T, 2008, J EXP MED, V205, P1261, DOI 10.1084/jem.20080108; Hallam S, 2009, J PATHOL, V219, P143, DOI 10.1002/path.2602; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kianmanesh R, 2007, ANN SURG, V245, P597, DOI 10.1097/01.sla.0000255561.87771.11; Klug F, 2013, CANCER CELL, V24, P589, DOI 10.1016/j.ccr.2013.09.014; Kojima M, 2004, ANTICANCER RES, V24, P675; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Koppe MJ, 2006, ANN SURG, V243, P212, DOI 10.1097/01.sla.0000197702.46394.16; Koppelman B, 1997, IMMUNITY, V7, P861, DOI 10.1016/S1074-7613(00)80404-5; Kubota Y, 2009, J EXP MED, V206, P1089, DOI 10.1084/jem.20081605; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278; Lin Y, 2010, EXPERT OPIN THER TAR, V14, P45, DOI 10.1517/14728220903431069; Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012; MANCINO A, CLIN CANC RES, V16, P784; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Matsuzaki S, 2005, ALLERGY, V60, P780, DOI 10.1111/j.1398-9995.2005.00793.x; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; O'Gorman A, 2010, AM J PHYSIOL-GASTR L, V299, pG96, DOI 10.1152/ajpgi.00460.2009; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Ridnour LA, 2007, P NATL ACAD SCI USA, V104, P16898, DOI 10.1073/pnas.0702761104; Rolny C, 2011, CANCER CELL, V19, P31, DOI 10.1016/j.ccr.2010.11.009; Ryan AE, 2014, MOL THER, V22, P655, DOI 10.1038/mt.2013.261; Shen P, 2004, ANN SURG ONCOL, V11, P178, DOI 10.1245/ASO.2004.05.009; Soudja SM, 2012, IMMUNITY, V37, P549, DOI 10.1016/j.immuni.2012.05.029; Toruner M, 2006, J BIOL CHEM, V281, P8686, DOI 10.1074/jbc.M512178200; Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907; Wang YC, 2010, CANCER RES, V70, P4840, DOI 10.1158/0008-5472.CAN-10-0269; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Zins K, 2007, CANCER RES, V67, P1038, DOI 10.1158/0008-5472.CAN-06-2295	49	35	39	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1563	1574		10.1038/onc.2014.86	http://dx.doi.org/10.1038/onc.2014.86			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24704833				2022-12-28	WOS:000351416800009
J	Zhang, J; Pan, YF; Ding, ZW; Yang, GZ; Tan, YX; Yang, C; Jiang, TY; Liu, LJ; Zhang, B; Han, T; Cao, D; Yang, T; Yang, N; Wu, MC; Dong, LW; Wang, HY				Zhang, J.; Pan, Y-F; Ding, Z-W; Yang, G-Z; Tan, Y-X; Yang, C.; Jiang, T-Y; Liu, L-J; Zhang, B.; Han, T.; Cao, D.; Yang, T.; Yang, N.; Wu, M-C; Dong, L-W; Wang, H-Y			RMP promotes venous metastases of hepatocellular carcinoma through promoting IL-6 transcription	ONCOGENE			English	Article							RNA-POLYMERASE-II; VIRUS X PROTEIN; NF-KAPPA-B; CANCER-CELLS; LIVER-CANCER; HEPATITIS-B; SERUM INTERLEUKIN-6; STEM-CELLS; EXPRESSION; PROLIFERATION	Hepatocellular carcinoma (HCC) is believed to arise from tumor-initiating cells (T-ICs), which are responsible for tumor relapse and metastases. Portal vein tumor thrombus (PVTT) is raised from HCC and strongly correlated to a poor prognosis. However, the mechanism underling the formation of PVTT is largely unknown. Herein, we provide evidence that RNA polymerase II subunit 5 (RPB5)-mediating protein (RMP) was progressively upregulated in PVTT and overexpressed RMP appeared to increase T-ICs self-renewal. Moreover, RMP promoted metastases of PVTT cells and HCC cells in vitro and in vivo. Knockdown of RMP attenuated T-ICs self-renewal and reversed epithelial-mesenchymal transition (EMT) in HCC and PVTT cells. The neutralizing assays suggested that interleukin-6 (IL-6) had an indispensable role in RMP regulating metastases and self-renewal of HCC cells. Furthermore, the transcription of IL-6 was verified to be modulated by RMP via interaction with p65 and RPB5, through which expanding the T-IC/cancer stem cell populations, as well as inducing EMT was promoted. These results suggested that RMP may promote PVTT formation by promoting IL-6 transcription. Thus, RMP serves as a potent factor contributed to develop PVTT and a promising therapeutic target for HCC patients.	[Zhang, J.; Pan, Y-F; Ding, Z-W; Yang, G-Z; Tan, Y-X; Yang, C.; Jiang, T-Y; Liu, L-J; Zhang, B.; Han, T.; Cao, D.; Dong, L-W; Wang, H-Y] Natl Ctr Liver Canc, Shanghai, Peoples R China; [Zhang, J.; Pan, Y-F; Ding, Z-W; Yang, G-Z; Tan, Y-X; Yang, C.; Jiang, T-Y; Liu, L-J; Zhang, B.; Han, T.; Cao, D.; Dong, L-W; Wang, H-Y] Second Mil Med Univ, Eastern Hepatobiliary Surg Inst, Int Cooperat Lab Signal Transduct, Shanghai 200438, Peoples R China; [Yang, T.; Yang, N.; Wu, M-C] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Surg, Shanghai 200438, Peoples R China; [Wang, H-Y] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Canc Inst,State Key Lab Oncogenes & Rela, Shanghai 200030, Peoples R China	Naval Medical University; Naval Medical University; Shanghai Jiao Tong University	Wang, HY (corresponding author), Second Mil Med Univ, Eastern Hepatobiliary Surg Inst, Int Cooperat Lab Signal Transduct, 225 Changhai Rd, Shanghai 200438, Peoples R China.	donliwei@126.com; hywangk@vip.sina.com	Yang, Tian/W-6668-2019; Yang, Tian/M-5484-2018	Yang, Tian/0000-0003-1544-0976; Dong, Li-Wei/0000-0003-2116-1674	National Natural Science Foundation of China [81370066, 81372355, 81001075, 91229205, BWS11J036]; Funds for Creative Research Groups of China [81221061]; State Key Project for Liver Cancer [2012ZX10002-009, 2013ZX10002-010]; Stem Cell and Medicine Research Center's Innovation Research Program of the Second Military Medical University [SCMRC1306]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Funds for Creative Research Groups of China(Science Fund for Creative Research Groups); State Key Project for Liver Cancer; Stem Cell and Medicine Research Center's Innovation Research Program of the Second Military Medical University	We thank Liang Tang, Dong-Ping Hu, Shan-Na Huang, Dan-Dan Huang, Shan-Hua Tang, Lin-Na Guo and Huan-Lin Sun for technical assistance. We thank Dr Xiao-Ni Kong for providing luciferase reporter constructs and Ad-caSTAT3 virus. This work was supported by grants from National Natural Science Foundation of China (81370066, 81372355, 81001075, 91229205, BWS11J036), the Funds for Creative Research Groups of China (81221061) and the State Key Project for Liver Cancer (2012ZX10002-009, 2013ZX10002-010), Stem Cell and Medicine Research Center's Innovation Research Program of the Second Military Medical University (SCMRC1306).	Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; dGM Acker J, 1997, J BIOL CHEM, V272, P16815; Dong LW, 2011, AUTOPHAGY, V7, P1222, DOI 10.4161/auto.7.10.16610; Dorjsuren D, 1998, MOL CELL BIOL, V18, P7546, DOI 10.1128/MCB.18.12.7546; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; He GB, 2013, CELL, V155, P384, DOI 10.1016/j.cell.2013.09.031; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Jang JW, 2012, CYTOKINE, V60, P686, DOI 10.1016/j.cyto.2012.07.017; Ji JF, 2012, SEMIN ONCOL, V39, P461, DOI 10.1053/j.seminoncol.2012.05.011; JOHNSON C, 2012, NATL GEOGR, V222, P6; Lee TKW, 2011, CELL STEM CELL, V9, P50, DOI 10.1016/j.stem.2011.06.005; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Nakagawa H, 2009, INT J CANCER, V125, P2264, DOI 10.1002/ijc.24720; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Parusel CT, 2006, DEVELOPMENT, V133, P621, DOI 10.1242/dev.02235; Portolani N, 2006, ANN SURG, V243, P229, DOI 10.1097/01.sla.0000197706.21803.a1; Spooren A, 2010, CELL SIGNAL, V22, P871, DOI 10.1016/j.cellsig.2010.01.018; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Theurillat JP, 2011, CANCER CELL, V19, P317, DOI 10.1016/j.ccr.2011.01.019; Wang Q, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-271; Wang T, 2010, BRIT J CANCER, V102, P1618, DOI 10.1038/sj.bjc.6605689; Wei WX, 2001, J BIOL CHEM, V276, P12266, DOI 10.1074/jbc.M009634200; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wong CM, 2005, CANCER RES, V65, P8861, DOI 10.1158/0008-5472.CAN-05-1318; Wong VWS, 2009, INT J CANCER, V124, P2766, DOI 10.1002/ijc.24281; Xiang WQ, 2011, J HEPATOL, V54, P26, DOI 10.1016/j.jhep.2010.08.006; Yamashita T, 2010, CANCER RES, V70, P4687, DOI 10.1158/0008-5472.CAN-09-4210; Yang SJ, 2013, INT J BIOL SCI, V9, P637, DOI 10.7150/ijbs.6439; Yoon S, 2010, AUTOPHAGY, V6, P1125, DOI 10.4161/auto.6.8.13547; Zhang YQ, 2010, CLIN CANCER RES, V16, P1423, DOI 10.1158/1078-0432.CCR-09-2405	31	28	32	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1575	1583		10.1038/onc.2014.84	http://dx.doi.org/10.1038/onc.2014.84			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24704835				2022-12-28	WOS:000351416800010
J	Kuo, PY; Leshchenko, VV; Fazzari, MJ; Perumal, D; Gellen, T; He, T; Iqbal, J; Baumgartner-Wennerholm, S; Nygren, L; Zhang, F; Zhang, W; Suh, KS; Goy, A; Yang, DT; Chan, WC; Kahl, BS; Verma, AK; Gascoyne, RD; Kimby, E; Sander, B; Ye, BH; Melnick, AM; Parekh, S				Kuo, P-Y; Leshchenko, V. V.; Fazzari, M. J.; Perumal, D.; Gellen, T.; He, T.; Iqbal, J.; Baumgartner-Wennerholm, S.; Nygren, L.; Zhang, F.; Zhang, W.; Suh, K. S.; Goy, A.; Yang, D. T.; Chan, W-C; Kahl, B. S.; Verma, A. K.; Gascoyne, R. D.; Kimby, E.; Sander, B.; Ye, B. H.; Melnick, A. M.; Parekh, S.			High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma	ONCOGENE			English	Article							TRANSCRIPTION FACTOR SOX11; BETA-CATENIN DEGRADATION; DEPENDENT PHOSPHORYLATION; PROTEIN-KINASE; FOLLOW-UP; EXPRESSION; PROLIFERATION; ACTIVATION; PATHWAY; GENE	Sex determining region Y-box 11 (SOX11) expression is specific for mantle cell lymphoma ( MCL) as compared with other non-Hodgkin's lymphomas. However, the function and direct-binding targets of SOX11 in MCL are largely unknown. We used high-resolution chromatin immunoprecipitation sequencing to identify the direct target genes of SOX11 in a genome-wide, unbiased manner and elucidate its functional significance. Pathway analysis identified WNT, PKA and TGF-beta signaling pathways as significantly enriched by SOX11-target genes. Quantitative chromatin immunoprecipitation sequencing and promoter reporter assays confirmed that SOX11 directly binds to individual genes and modulates their transcription activities in these pathways in MCL. Functional studies using RNA interference demonstrate that SOX11 directly regulates WNT in MCL. We analyzed SOX11 expression in three independent well-annotated tissue microarrays from the University of Wisconsin (UW), Karolinska Institute and British Columbia Cancer Agency. Our findings suggest that high SOX11 expression is associated with improved survival in a subset of MCL patients, particularly those treated with intensive chemotherapy. Transcriptional regulation of WNT and other biological pathways affected by SOX11-target genes may help explain the impact of SOX11 expression on patient outcomes.	[Kuo, P-Y; Leshchenko, V. V.; Perumal, D.; He, T.; Parekh, S.] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, New York, NY 10029 USA; [Fazzari, M. J.] Yeshiva Univ, Albert Einstein Coll Med, Dept Populat Hlth, Bronx, NY USA; [Fazzari, M. J.] Yeshiva Univ, Albert Einstein Coll Med, Dept Genet, Bronx, NY USA; [Gellen, T.; Verma, A. K.] Yeshiva Univ, Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY USA; [Iqbal, J.; Chan, W-C] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Baumgartner-Wennerholm, S.; Kimby, E.] Karolinska Inst, Ctr Haematol, Dept Med, Stockholm, Sweden; [Baumgartner-Wennerholm, S.; Nygren, L.; Kimby, E.; Sander, B.] Karolinska Univ Hosp, Stockholm, Sweden; [Nygren, L.; Sander, B.] Karolinska Inst, Dept Lab Med, Div Pathol, Stockholm, Sweden; [Zhang, F.; Zhang, W.] Icahn Sch Med Mt Sinai, Dept Med, Bioinformat Lab, New York, NY 10029 USA; [Suh, K. S.; Goy, A.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Genom & Biomarkers Program, Hackensack, NJ USA; [Yang, D. T.; Kahl, B. S.] Univ Wisconsin, Dept Pathol, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Kahl, B. S.] Univ Wisconsin, UW Carbone Canc Ctr, Madison, WI USA; [Gascoyne, R. D.] British Columbia Canc Agcy, Dept Pathol & Expt Therapeut, Vancouver, BC V5Z 4E6, Canada; [Ye, B. H.] Yeshiva Univ, Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY USA; [Melnick, A. M.] Weill Cornell Med Coll, Div Hematol & Oncol, New York, NY USA; [Melnick, A. M.] Weill Cornell Med Coll, Dept Pharmacol, New York, NY USA	Icahn School of Medicine at Mount Sinai; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Nebraska System; University of Nebraska Medical Center; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Icahn School of Medicine at Mount Sinai; Hackensack University Medical Center; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; British Columbia Cancer Agency; Yeshiva University; Albert Einstein College of Medicine; Cornell University; Cornell University	Parekh, S (corresponding author), Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, 1470 Madison Ave 5-114,Box 1079, New York, NY 10029 USA.	samir.parekh@mssm.edu	Goy, Andre/AHC-0473-2022; Melnick, Ari/AAA-5763-2020; Goy, Andre/AAS-4464-2020; Gascoyne, Randy D/A-6009-2013	Goy, Andre/0000-0001-5125-6522; Goy, Andre/0000-0001-5125-6522; Gascoyne, Randy D/0000-0002-2610-5690; Fazzari, Melissa/0000-0002-5674-3589; Iqbal, Javeed/0000-0003-3668-0629; He, Tianfang/0000-0003-3307-3110; Kimby, Eva/0000-0003-3078-6131	Chemotherapy Foundation; NATIONAL CANCER INSTITUTE [P30CA013330, P30CA014520, K12CA132783] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011] Funding Source: NIH RePORTER	Chemotherapy Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank the Epigenomics cores at Weil Cornell Medical College and Albert Einstein College of Medicine for the service support in next generation sequencing. We would also like to thank Eugenia (Jenny) Giannopoulou, PhD, and Olivier Elemento, PhD, for the assistance in ChIP-seq analysis and Chris Benner, PhD, for the support in motif analysis. We are grateful for Stuart A Aaronson, MD, for the expert consultation on WNT signaling pathway and the DN-TCF4 construct and Thomas J Kelly, MD, PhD for the SMAD3 reporter construct. This project was funded in part by the Chemotherapy Foundation (SP), Gabrielle's Angel Foundation (SP), Leukemia and Lymphoma Society Translational Research Project Grant (SP), Paul Calabresi Career Development Award K12-CA132783-01 (SP), the Swedish Cancer Society (BS), the Swedish Research Council (BS), the Cancer Society in Stockholm (BS), the Karolinska Institutet Funds (BS) and the Stockholm County Council (BS). DTY is supported by the Clinical and Translational Science Award (CTSA) program, previously through the National Center for Research Resources grant 1UL1RR025011, and now by the National Center for Advancing Translational Sciences (NCATS), grant 9U54TR000021 (DTY), grant P30 CA014520 from the National Cancer Institute and Forward Lymphoma (DTY).	Asciutti S, 2011, ONCOGENE, V30, P956, DOI 10.1038/onc.2010.475; Badis G, 2009, SCIENCE, V324, P1720, DOI 10.1126/science.1162327; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Brennana DJ, 2009, EUR J CANCER, V45, P1510, DOI 10.1016/j.ejca.2009.01.028; Vegliante MC, 2013, BLOOD, V121, P2175, DOI 10.1182/blood-2012-06-438937; Vegliante MC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021382; Carvajal-Cuenca A, 2012, HAEMATOL-HEMATOL J, V97, P270, DOI 10.3324/haematol.2011.052621; Chen YH, MOD PATHOL, V23, P105; Chung EJ, 2002, BLOOD, V100, P982, DOI 10.1182/blood.V100.3.982; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; de Bont JM, 2008, NEURO-ONCOLOGY, V10, P648, DOI 10.1215/15228517-2008-032; Dictor M, 2009, HAEMATOL-HEMATOL J, V94, P1563, DOI 10.3324/haematol.2009.008474; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; Dy P, 2008, NUCLEIC ACIDS RES, V36, P3101, DOI 10.1093/nar/gkn162; Fernandez V, 2010, CANCER RES, V70, P1408, DOI 10.1158/0008-5472.CAN-09-3419; Geisler CH, 2012, BRIT J HAEMATOL, V158, P355, DOI 10.1111/j.1365-2141.2012.09174.x; Gelebart P, 2008, BLOOD, V112, P5171, DOI 10.1182/blood-2008-02-139212; Giannopoulou EG, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-277; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Greiner TC, 1996, BLOOD, V87, P4302, DOI 10.1182/blood.V87.10.4302.bloodjournal87104302; Grumolato L, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003603; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Kimura Y, 2013, INT J ONCOL, V43, P457, DOI 10.3892/ijo.2013.1982; Kormish JD, 2010, DEV DYNAM, V239, P56, DOI 10.1002/dvdy.22046; Kridel R, 2012, BLOOD, V119, P1963, DOI 10.1182/blood-2011-11-391474; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lee JY, 2004, AM J RESP CELL MOL, V31, P234, DOI 10.1165/rcmb.2003-0447OC; Leshchenko VV, 2010, BLOOD, V116, P1025, DOI 10.1182/blood-2009-12-257485; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Murugan S, 2012, EXP CELL RES, V318, P1134, DOI 10.1016/j.yexcr.2012.03.008; Nygren L, 2012, BLOOD, V119, P4215, DOI 10.1182/blood-2011-12-400580; Oberley MJ, 2013, HISTOPATHOLOGY, V63, P499, DOI 10.1111/his.12207; Pan X, 2009, P NATL ACAD SCI USA, V106, P3788, DOI 10.1073/pnas.0810147106; Rhind N, 2012, COLD SPRING HARB PER, V4, P1; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; Romaguera JE, 2010, BRIT J HAEMATOL, V150, P200, DOI 10.1111/j.1365-2141.2010.08228.x; Sakamoto I, 2000, J BIOL CHEM, V275, P32871, DOI 10.1074/jbc.M004089200; Sernbo S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-405; Sinner D, 2007, MOL CELL BIOL, V27, P7802, DOI 10.1128/MCB.02179-06; Sock E, 2004, MOL CELL BIOL, V24, P6635, DOI 10.1128/mcb.24.15.6635-6644.2004; Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wang X, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014085; Weigle B, 2005, ONCOL REP, V13, P139; Wiestner A, 2007, BLOOD, V109, P4599, DOI 10.1182/blood-2006-08-039859; Witzig TE, 2005, J CLIN ONCOL, V23, P6409, DOI 10.1200/JCO.2005.55.017; Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057; Zhang M, 2010, J BIOL CHEM, V285, P8703, DOI 10.1074/jbc.M109.093526; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	55	47	48	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1231	1240		10.1038/onc.2014.44	http://dx.doi.org/10.1038/onc.2014.44			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24681958	Green Accepted			2022-12-28	WOS:000350687100003
J	Carrillo, AM; Bouska, A; Arrate, MP; Eischen, CM				Carrillo, A. M.; Bouska, A.; Arrate, M. P.; Eischen, C. M.			Mdmx promotes genomic instability independent of p53 and Mdm2	ONCOGENE			English	Article							STRAND BREAK REPAIR; DNA-DAMAGE; TUMOR-FORMATION; ATM ACTIVATION; HISTONE H2AX; S-PHASE; EXPRESSION; COMPLEX; DEGRADATION; PROTEIN	The oncogene Mdmx is overexpressed in many man malignancies, and together with Mdm2, negatively regulates the p53 tumor suppressor. However, a p53-independent function of Mdmx that impacts genome stability has been described, but this function is not well understood. In the present study, we determined that of the 13 different cancer types evaluated, 6-90% of those that had elevated levels of Mdmx had concurrent inactivation (mutated or deleted) of p53. We show elevated levels of Mdmx-inhibited double-strand DNA break repair and induced chromosome and chromatid breaks independent of p53, leading to genome instability. Mdmx impaired early DNA damage-response signaling, such as phosphorylation of the serine/threonine-glutamine motif, mediated by the ATM kinase. Moreover, we identified Mdmx associated with Nbs1 of the Mre11-Rad50-Nbs1 (MRN) DNA repair complex, and this association increased upon DNA damage and was detected at chromatin. Elevated Mdmx levels also increased cellular transformation in a p53-independent manner. Unexpectedly, all Mdmx-mediated phenotypes also occurred in cells lacking Mdm2 and were independent of the Mdm2-binding domain (RING) of Mdmx. Therefore, Mdmx-mediated inhibition of the DNA damage response resulted in delayed DNA repair and increased genome instability and transformation independent of p53 and Mdm2. Our results reveal a novel p53- and Mdm2-independent oncogenic function of Mdmx that provides new insight into the many cancers that overexpress Mdmx.	[Carrillo, A. M.; Arrate, M. P.; Eischen, C. M.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Bouska, A.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA	Vanderbilt University; University of Nebraska System; University of Nebraska Medical Center	Eischen, CM (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, MCN C3321 1161 21st Ave South, Nashville, TN 37232 USA.	christine.eischen@vanderbilt.edu		Bouska, Alyssa/0000-0003-1324-6678; Carrillo, Alexia/0000-0002-2827-6952	NCI [F31CA150546, T32CA009582, R01CA117935, R01CA160432]; NCI Cancer Center [P30CA068485]; NATIONAL CANCER INSTITUTE [R01CA160432, F31CA150546, R01CA117935, P30CA068485, T32CA009582] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Brandon Metge for technical expertise; Dr Jean-Christophe Marine for providing the Mdmx vector; Dr Stephen Jones for providing the Mdmx<SUP>-/-</SUP>p53<SUP>-/-</SUP>MEFs; members of the Eischen lab for thoughtful discussions and critical review of this manuscript. This work was supported by NCI grants F31CA150546 (AMC), T32CA009582 (AMC), R01CA117935 (CME) and R01CA160432 (CME), and NCI Cancer Center Support Grant P30CA068485 utilizing the Flow Cytometry Shared Resource.	Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; Bekker-Jensen S, 2010, DNA REPAIR, V9, P1219, DOI 10.1016/j.dnarep.2010.09.010; Bouska A, 2008, MOL CELL BIOL, V28, P4862, DOI 10.1128/MCB.01584-07; Braden WA, 2006, MOL CELL BIOL, V26, P7667, DOI 10.1128/MCB.00045-06; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; De Clercq S, 2010, MOL CELL BIOL, V30, P5394, DOI 10.1128/MCB.00330-10; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gembarska A, 2012, NAT MED, V18, P1239, DOI 10.1038/nm.2863; Giglio S, 2005, CANCER RES, V65, P9687, DOI 10.1158/0008-5472.CAN-05-0450; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang L, 2011, P NATL ACAD SCI USA, V108, P12001, DOI 10.1073/pnas.1102309108; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Kamijo T, 1999, CANCER RES, V59, P2464; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lam S, 2010, ONCOGENE, V29, P2415, DOI 10.1038/onc.2009.522; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Leventaki V, 2012, BRIT J HAEMATOL, V158, P763, DOI 10.1111/j.1365-2141.2012.09243.x; Li X, 2012, ONCOGENE, V31, P3721, DOI 10.1038/onc.2011.534; Lukas C, 2004, EMBO J, V23, P2674, DOI 10.1038/sj.emboj.7600269; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Marine JCW, 2007, J CELL SCI, V120, P371, DOI 10.1242/jcs.03362; Matijasevic Z, 2008, CELL CYCLE, V7, P2967, DOI 10.4161/cc.7.19.6797; Matijasevic Z, 2008, MOL CELL BIOL, V28, P1265, DOI 10.1128/MCB.01108-07; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Melo Alexia N, 2012, Genes Cancer, V3, P283, DOI 10.1177/1947601912454139; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Pant V, 2011, P NATL ACAD SCI USA, V108, P11995, DOI 10.1073/pnas.1102241108; Pei DS, 2012, ONCOTARGET, V3, P228; Pereg Y, 2005, P NATL ACAD SCI USA, V102, P5056, DOI 10.1073/pnas.0408595102; Ramos YFM, 2001, CANCER RES, V61, P1839; Rayburn E, 2005, CURR CANCER DRUG TAR, V5, P27, DOI 10.2174/1568009053332636; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Stracker TH, 2011, NAT REV MOL CELL BIO, V12, P90, DOI 10.1038/nrm3047; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wang P, 2008, ONCOGENE, V27, P1590, DOI 10.1038/sj.onc.1210788; White JS, 2008, CELL CYCLE, V7, P1277, DOI 10.4161/cc.7.9.5961; White JS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000758; Xiong SB, 2010, CANCER RES, V70, P7148, DOI 10.1158/0008-5472.CAN-10-1457; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	55	40	40	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					846	856		10.1038/onc.2014.27	http://dx.doi.org/10.1038/onc.2014.27			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24608433	Green Accepted			2022-12-28	WOS:000349472000005
J	Chudasama, P; Konrad, A; Jochmann, R; Lausen, B; Holz, P; Naschberger, E; Neipel, F; Britzen-Laurent, N; Sturzl, M				Chudasama, P.; Konrad, A.; Jochmann, R.; Lausen, B.; Holz, P.; Naschberger, E.; Neipel, F.; Britzen-Laurent, N.; Stuerzl, M.			Structural proteins of Kaposi's sarcoma-associated herpesvirus antagonize p53-mediated apoptosis	ONCOGENE			English	Article						KSHV; p53; apoptosis; reversely transfected cell microarray; early infection; lytic replication	P53 TUMOR-SUPPRESSOR; SMALL-MOLECULE ANTAGONISTS; LYTIC REPLICATION; DNA-SEQUENCES; CELL-LINE; BOVINE HERPESVIRUS-1; ENDOTHELIAL ORIGIN; SYSTEMS BIOLOGY; EXPRESSION; KSHV	The tumor suppressor p53 is a central regulatory molecule of apoptosis and is commonly mutated in tumors. Kaposi's sarcoma-associated herpesvirus (KSHV)-related malignancies express wild-type p53. Accordingly, KSHV encodes proteins that counteract the cell death-inducing effects of p53. Here, the effects of all KSHV genes on the p53 signaling pathway were systematically analyzed using the reversely transfected cell microarray technology. With this approach we detected eight KSHV-encoded genes with potent p53 inhibiting activity in addition to the previously described inhibitory effects of KSHV genes ORF50, K10 and K10.5. Interestingly, the three most potent newly identified inhibitors were KSHV structural proteins, namely ORF22 (glycoprotein H), ORF25 (major capsid protein) and ORF64 (tegument protein). Validation of these results with a classical transfection approach showed that these proteins inhibited p53 signaling in a dose-dependent manner and that this effect could be reversed by small interfering RNA-mediated knockdown of the respective viral gene. All three genes inhibited p53-mediated apoptosis in response to Nutlin-3 treatment in non-infected and KSHV-infected cells. Addressing putative mechanisms, we could show that these proteins could also inhibit the transactivation of the promoters of apoptotic mediators of p53 such as BAX and PIG3. Altogether, we demonstrate for the first time that structural proteins of KSHV can counteract p53-induced apoptosis. These proteins are expressed in the late lytic phase of the viral life cycle and are incorporated into the KSHV virion. Accordingly, these genes may inhibit cell death in the productive and in the early entrance phase of KSHV infection.	[Chudasama, P.; Konrad, A.; Jochmann, R.; Holz, P.; Naschberger, E.; Britzen-Laurent, N.; Stuerzl, M.] Univ Erlangen Nurnberg, Univ Med Ctr Erlangen, Dept Surg, Div Mol & Expt Surg, D-91054 Erlangen, Germany; [Lausen, B.] Univ Essex, Dept Math Sci, Colchester CO4 3SQ, Essex, England; [Neipel, F.] Univ Erlangen Nurnberg, Univ Med Ctr Erlangen, Inst Clin & Mol Virol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg; University of Essex; University of Erlangen Nuremberg	Sturzl, M (corresponding author), Univ Erlangen Nurnberg, Univ Med Ctr Erlangen, Dept Surg, Div Mol & Expt Surg, Schwabachanlage 10, D-91054 Erlangen, Germany.	michael.stuerzl@uk-erlangen.de	Naschberger, Elisabeth/AAV-5289-2021; Britzen-Laurent, Nathalie/HDM-6965-2022; Stürzl, Michael/B-3019-2015; Lausen, Berthold/D-4063-2012	Naschberger, Elisabeth/0000-0003-1291-622X; Britzen-Laurent, Nathalie/0000-0002-0494-7117; Stürzl, Michael/0000-0002-9276-2824; Lausen, Berthold/0000-0002-0594-7258	German Federal Ministry of Education and Research (BMBF); Deutsche Forschungsgemeinschaft [DFG-GRK1071, STU238/6-1, SFB796]; German Cancer Aid [109510]; Interdisciplinary Center for Clinical Research (IZKF); Emerging Fields Initiative of the Friedrich-Alexander University of Erlangen; Programm zur Forderung der Chancengleichheit fur Frauen in Forschung und Lehre (FFL); University Medical Center Erlangen	German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); German Cancer Aid(Deutsche Krebshilfe); Interdisciplinary Center for Clinical Research (IZKF); Emerging Fields Initiative of the Friedrich-Alexander University of Erlangen; Programm zur Forderung der Chancengleichheit fur Frauen in Forschung und Lehre (FFL); University Medical Center Erlangen	We thank Professor Moshe Oren, Professor Wafik S El-Deiry and Professor Bert Vogelstein for sharing plasmids. In addition, we thank PD Dr Reiner Strick and PD Dr Pamela Strissel (University Medical Center Erlangen, Department of Obstetrics and Gynecology) for providing the MCF7 cells. This work was supported by grants of the German Federal Ministry of Education and Research (BMBF, Polyprobe-Study), the Deutsche Forschungsgemeinschaft (DFG-GRK1071, STU238/6-1, SFB796 (sub-project B9)) and the German Cancer Aid (109510). Additional support was obtained from the Interdisciplinary Center for Clinical Research (IZKF) and the Emerging Fields Initiative of the Friedrich-Alexander University of Erlangen to MS, by a grant for the promotion of young researchers (ELAN) of the University Medical Center Erlangen to AK and a grant of the 'Programm zur Forderung der Chancengleichheit fur Frauen in Forschung und Lehre (FFL)' to PC.	Austgen K, 2012, J VIROL, V86, P1877, DOI 10.1128/JVI.06600-11; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Blasig C, 1997, J VIROL, V71, P7963, DOI 10.1128/JVI.71.10.7963-7968.1997; Britzen-Laurent N, 2013, CARCINOGENESIS, V34, P153, DOI 10.1093/carcin/bgs310; Burbelo PD, 2010, J INFECT DIS, V201, P1919, DOI 10.1086/652869; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chandran B, 2010, J VIROL, V84, P2188, DOI 10.1128/JVI.01334-09; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen WG, 2010, J VIROL, V84, P3898, DOI 10.1128/JVI.01321-09; de Oliveira DE, 2010, TRENDS MICROBIOL, V18, P248, DOI 10.1016/j.tim.2010.04.001; Dittmer DP, 2011, MBIO, V2, DOI 10.1128/mBio.00138-11; Dittmer DP, 2003, CANCER RES, V63, P2010; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Grundhoff A, 2004, J CLIN INVEST, V113, P124, DOI 10.1172/JCI200417803; Gwack Y, 2001, J VIROL, V75, P6245, DOI 10.1128/JVI.75.13.6245-6248.2001; Hahn A, 2009, J VIROL, V83, P396, DOI 10.1128/JVI.01170-08; Hahn AS, 2012, NAT MED, V18, P961, DOI 10.1038/nm.2805; Hanon E, 1998, J VIROL, V72, P7638, DOI 10.1128/JVI.72.9.7638-7641.1998; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUTCHINSON L, 1992, J VIROL, V66, P2240, DOI 10.1128/JVI.66.4.2240-2250.1992; Ilkow CS, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001291; Inn KS, 2011, J VIROL, V85, P10899, DOI 10.1128/JVI.00690-11; Jerome KR, 2001, J IMMUNOL, V167, P3928, DOI 10.4049/jimmunol.167.7.3928; Jochmann R, 2013, GLYCOBIOLOGY, V23, P1114, DOI 10.1093/glycob/cwt028; Katano H, 2000, VIROLOGY, V269, P335, DOI 10.1006/viro.2000.0196; Konrad A, 2011, METHODS MOL BIOL, V706, P107, DOI 10.1007/978-1-61737-970-3_9; Konrad A, 2009, J VIROL, V83, P2563, DOI 10.1128/JVI.01512-08; Kuhn E, 2012, LAB CHIP, V12, P1363, DOI 10.1039/c2lc20724a; Kurosu T, 2010, APOPTOSIS, V15, P608, DOI 10.1007/s10495-010-0457-0; Kwon JA, 2003, BIOL CHEM, V384, P203, DOI 10.1515/BC.2003.022; Lagunoff M, 2003, INT REV IMMUNOL, V22, P373, DOI 10.1080/08830180305218; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lee HR, 2009, J VIROL, V83, P6739, DOI 10.1128/JVI.02353-08; Leida AM, 2012, CELL HOST MICROBE, V11, P167, DOI 10.1016/j.chom.2012.01.005; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Marcelin AG, 2007, J INFECT DIS, V196, P1163, DOI 10.1086/521625; MIYASHITA T, 1995, CELL, V80, P293; Moore PS, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P540; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Morris SJ, 1999, J GEN VIROL, V80, P137, DOI 10.1099/0022-1317-80-1-137; Myoung J, 2011, J VIROL METHODS, V174, P12, DOI 10.1016/j.jviromet.2011.03.012; Nakamichi K, 2001, VIROLOGY, V279, P488, DOI 10.1006/viro.2000.0740; Nakamura H, 2001, J VIROL, V75, P7572, DOI 10.1128/JVI.75.16.7572-7582.2001; Naranatt PP, 2002, ARCH VIROL, V147, P1349, DOI 10.1007/s00705-002-0813-7; Naschberger E, 2004, BIOCHEM J, V379, P409, DOI 10.1042/BJ20031873; Nealon K, 2001, J VIROL, V75, P2866, DOI 10.1128/JVI.75.6.2866-2878.2001; Pertel PE, 2002, J VIROL, V76, P4390, DOI 10.1128/JVI.76.9.4390-4400.2002; Petre CE, 2007, J VIROL, V81, P1912, DOI 10.1128/JVI.01757-06; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Raftery MJ, 1999, J EXP MED, V190, P1103, DOI 10.1084/jem.190.8.1103; Rivas C, 2001, J VIROL, V75, P429, DOI 10.1128/JVI.75.1.429-438.2001; Rozen R, 2008, J VIROL, V82, P4742, DOI 10.1128/JVI.02745-07; Sander G, 2008, J VIROL, V82, P1908, DOI 10.1128/JVI.01716-07; Sarek G, 2013, ONCOGENE, V32, P1091, DOI 10.1038/onc.2012.118; Sarek G, 2007, J CLIN INVEST, V117, P1019, DOI 10.1172/JCI30945; Sathish N, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00098; Schulz TF, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P490; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; SPAETE RR, 1993, VIROLOGY, V193, P853, DOI 10.1006/viro.1993.1194; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Sturzl M, 2008, COMB CHEM HIGH T SCR, V11, P159, DOI 10.2174/138620708783744499; Sturzl M, 2013, INT J CANCER, V132, P1954, DOI 10.1002/ijc.27849; Sturzl M, 2009, THROMB HAEMOSTASIS, V102, P1117, DOI 10.1160/TH09-07-0472; Sturzl M, 1997, INT J CANCER, V72, P68, DOI 10.1002/(SICI)1097-0215(19970703)72:1&lt;68::AID-IJC10&gt;3.0.CO;2-6; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Tornesello ML, 2009, ONCOLOGY-BASEL, V77, P328, DOI 10.1159/000260905; Urbanowski MD, 2013, J VIROL, V87, P872, DOI 10.1128/JVI.02030-12; Vassilev LT, 2004, CELL CYCLE, V3, P419; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Voltan R, 2014, MOL CARCINOGEN, V53, P498, DOI 10.1002/mc.21985; Ye FC, 2012, CELL CYCLE, V11, P1393, DOI 10.4161/cc.19756; Ziauddin J, 2001, NATURE, V411, P107, DOI 10.1038/35075114	76	15	15	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					639	649		10.1038/onc.2013.595	http://dx.doi.org/10.1038/onc.2013.595			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24469037				2022-12-28	WOS:000348853500011
J	Zhang, LH; Yin, AA; Cheng, JX; Huang, HY; Li, XM; Zhang, YQ; Han, N; Zhang, X				Zhang, L-H; Yin, A-A; Cheng, J-X; Huang, H-Y; Li, X-M; Zhang, Y-Q; Han, N.; Zhang, X.			TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway	ONCOGENE			English	Article						glioblastoma; TRIM24; TIF1 alpha; PI3K; Akt; MGMT	GENE-EXPRESSION; MYELOID-LEUKEMIA; P53; TUMORS; VIRUS; CELLS; CHEMOTHERAPY; TEMOZOLOMIDE; INDUCTION; TARGETS	The tripartite motif protein TRIM24 (tripartite motif-containing 24) has been found to play distinct roles in tumor development and progression, according to different tumor contexts. However, it remains elusive whether TRIM24 plays a role in malignant gliomas that are the most common and deadly primary brain tumors in adults. We report here that TRIM24 expression is positively correlated with glioma malignancy and is negatively associated with prognosis of patients with newly diagnosed glioblastoma, which is the most malignant form of gliomas but displays highly heterogeneous clinical outcome. The multivariate Cox regression analysis demonstrates the independent predictive value of TRIM24 expression level for overall and progression-free survival. Knockdown of TRIM24 suppresses cell proliferation, cell cycle progression, clone formation and in vivo tumor development, whereas overexpression of TRIM24 promotes cell growth. Chromatin immunoprecipitation, real-time reverse transcription-PCR and mutation analyses demonstrate that TRIM24 binds to the PIK3CA promoter via its PHD-Bromo domain to activate the transcription of PIK3CA gene, thus enhancing phosphatidylinositide 3-kinase (PI3K)/Akt signaling. The pan-PI3K inhibitor LY294002 and small interfering RNA targeting PIK3CA both abrogate the growth-promoting effect of TRIM24. Moreover, TRIM24 regulates the expression of DNA repair enzyme O-6-methylguanine-DNA methyltransferase (MGMT) through PI3K/Akt/nuclear factor-kappa B signaling transduction and enhances resistance to temozolomide, the standard chemotherapeutic agent for glioblastoma. Finally, glioblastoma patients with low TRIM24 expression benefit from chemotherapy, whereas those with high TRIM24 expression do not have such benefit. Our results suggest that TRIM24 might serve as a potential prognostic marker and therapeutic target for the management of malignant gliomas.	[Zhang, L-H; Yin, A-A; Cheng, J-X; Huang, H-Y; Li, X-M; Zhang, Y-Q; Han, N.; Zhang, X.] Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian 710032, Shaanxi Provinc, Peoples R China	Air Force Military Medical University	Zhang, X (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Changle West Rd 127, Xian 710032, Shaanxi Provinc, Peoples R China.	zhangluhua211@163.com		Yin, An-An/0000-0002-1888-5551	National Natural Science Foundation of China [30870843, 81171087]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Xiao-Liang Yang, Xi-Qiang Cai and Juan Li for helpful assistance. This work was supported by the National Natural Science Foundation of China (no. 30870843 and no. 81171087) to X Zhang. The funding body does not play any role in the design of the study, collection and analysis of data and decision to publish.	Aghi M, 2008, ONCOGENE, V27, P4249, DOI 10.1038/onc.2008.53; Aghi M, 2006, JNCI-J NATL CANCER I, V98, P38, DOI 10.1093/jnci/djj003; Allton K, 2009, P NATL ACAD SCI USA, V106, P11612, DOI 10.1073/pnas.0813177106; Barbus S, 2011, JNCI-J NATL CANCER I, V103, P598, DOI 10.1093/jnci/djr036; Chambon M, 2011, AM J PATHOL, V178, P1461, DOI 10.1016/j.ajpath.2010.12.026; Chen J, 2012, CELL, V149, P36, DOI 10.1016/j.cell.2012.03.009; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chowdhry S, 2013, ONCOGENE, V32, P3765, DOI 10.1038/onc.2012.388; Danam RP, 2005, MOL CANCER THER, V4, P61; Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218; Fritsch R, 2013, CELL, V153, P1050, DOI 10.1016/j.cell.2013.04.031; Gandini D, 2002, LEUKEMIA, V16, P886, DOI 10.1038/sj.leu.2402452; Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Herquel B, 2013, NAT STRUCT MOL BIOL, V20, P339, DOI 10.1038/nsmb.2496; Herquel B, 2011, TRANSCR-AUSTIN, V2, P231, DOI 10.4161/trns.2.5.17725; Herquel B, 2011, P NATL ACAD SCI USA, V108, P8212, DOI 10.1073/pnas.1101544108; Hui RCY, 2008, MOL CELL BIOL, V28, P5886, DOI 10.1128/MCB.01265-07; Ignat M, 2008, P NATL ACAD SCI USA, V105, P2598, DOI 10.1073/pnas.0712030105; Ikegami D, 2011, DEVELOPMENT, V138, P1507, DOI 10.1242/dev.057802; Jain AK, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001268; Jain AK, 2009, CELL CYCLE, V8, P3668, DOI 10.4161/cc.8.22.9979; Josset L, 2012, J VIROL, V86, P7192, DOI 10.1128/JVI.00563-12; Kaina B, 2007, DNA REPAIR, V6, P1079, DOI 10.1016/j.dnarep.2007.03.008; Kanai R, 2012, JNCI-J NATL CANCER I, V104, P42, DOI 10.1093/jnci/djr509; Khetchoumian K, 2007, NAT GENET, V39, P1500, DOI 10.1038/ng.2007.15; Kikuchi M, 2009, BBA-MOL CELL RES, V1793, P1828, DOI 10.1016/j.bbamcr.2009.11.001; Ledda-Columbano GM, 2004, CARCINOGENESIS, V25, P2061, DOI 10.1093/carcin/bgh221; Li HY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037657; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Ou HD, 2012, CELL, V151, P304, DOI 10.1016/j.cell.2012.08.035; Quintas-Cardama A, 2012, CANCER-AM CANCER SOC, V118, P5283, DOI 10.1002/cncr.27568; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Tisserand J, 2011, J BIOL CHEM, V286, P33369, DOI 10.1074/jbc.M111.225680; Tolcher AW, 2003, BRIT J CANCER, V88, P1004, DOI 10.1038/sj.bjc.6600827; Tsai WW, 2010, NATURE, V468, P927, DOI 10.1038/nature09542; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Worster DT, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2001986	41	85	89	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					600	610		10.1038/onc.2013.593	http://dx.doi.org/10.1038/onc.2013.593			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24469053				2022-12-28	WOS:000348853500007
J	Lin, C; Song, L; Liu, A; Gong, H; Lin, X; Wu, J; Li, M; Li, J				Lin, C.; Song, L.; Liu, A.; Gong, H.; Lin, X.; Wu, J.; Li, M.; Li, J.			Overexpression of AKIP1 promotes angiogenesis and lymphangiogenesis in human esophageal squamous cell carcinoma	ONCOGENE			English	Article						AKIP1; angiogenesis; lymphangiogenesis; VEGF-C	ENDOTHELIAL GROWTH-FACTOR; LYMPH-NODE METASTASIS; NF-KAPPA-B; VEGF-C; TUMOR LYMPHANGIOGENESIS; CANCER-CELLS; GENE-EXPRESSION; UP-REGULATION; IN-VIVO; SURVIVAL	A-kinase-interacting protein 1 (AKIP1) is found to be overexpressed in breast and prostate cancers, suggesting that AKIP1 might act as a potent oncogenic protein. However, the clinical significance and biological role of AKIP1 in cancer progression remain largely unknown. Herein, we report that AKIP1 is markedly overexpressed in esophageal squamous cell carcinoma (ESCC) cell lines and clinical ESCC samples. AKIP1 expression significantly correlates with ESCC progression and patients' shorter survival time. Furthermore, we find that overexpressing AKIP1 induces, whereas silencing AKIP1 reduces, ESCC angiogenesis and lymphangiogenesis both in vitro and in vivo. Moreover, we demonstrate that AKIP1 transcriptionally upregulates vascular endothelial growth factor-C (VEGF-C) via interaction with its promoter through cooperation with multiple transcriptional factors, including SP1, AP2 and nuclear factor-kappa B (NF-kappa B). Importantly, significant correlation between levels of AKIP1 and VEGF-C is observed in a cohort of human ESCC, as well as in non-small cell lung cancer, hepatocellular carcinoma and ovarian cancer. Hence, these findings indicate an important role for AKIP1 in ESCC angiogenesis and lymphangiogenesis, and uncover a novel mechanism for the upregulation of VEGF-C in cancers.	[Lin, C.; Song, L.; Lin, X.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol Southern China, Dept Expt Res, Guangzhou 510080, Guangdong, Peoples R China; [Lin, C.; Liu, A.; Gong, H.; Li, J.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou 510080, Guangdong, Peoples R China; [Wu, J.; Li, M.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Guangzhou 510080, Guangdong, Peoples R China; [Wu, J.; Li, M.; Li, J.] Sun Yat Sen Univ, Minist Educ, Key Lab Trop Dis Control, Guangzhou 510080, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Li, J (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, 74 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.	lijun37@mail.sysu.edu.cn	Lin, Chuyong/AAA-9931-2020; Song, LB/AAL-1968-2020; Liu, Aibin/S-7252-2019	Lin, Chuyong/0000-0003-4887-5386; Liu, Aibin/0000-0003-1600-8288	Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS); Natural Science Foundation of China [81325013, 81071780, 81030048, 91229101, U1201121, 81272196, 81272198]; Science and Technology Department of Guangdong Province [S2011020002757, S2012020010946]; Ministry of Education of China [20130171110085, 20120171110055]	Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Department of Guangdong Province; Ministry of Education of China(Ministry of Education, China)	This work was supported by the Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS, 2012), Natural Science Foundation of China (81325013, 81071780, 81030048, 91229101, U1201121, 81272196 and 81272198), the Science and Technology Department of Guangdong Province (S2011020002757 and S2012020010946) and Ministry of Education of China (20130171110085, 20120171110055).	Achen MG, 2008, ANN NY ACAD SCI, V1131, P225, DOI 10.1196/annals.1413.020; Albini A, 2012, NAT REV CLIN ONCOL, V9, P498, DOI 10.1038/nrclinonc.2012.120; Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480; Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; BLOT WJ, 2006, CANC EPIDEMIOLOGY PR, P697, DOI DOI 10.1093/ACPROF:OSO/9780195149616.003.0036; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Cao YH, 2005, NAT REV CANCER, V5, P735, DOI 10.1038/nrc1693; Chen XT, 2013, J CLIN INVEST, V123, P2576, DOI 10.1172/JCI68143; Chien MH, 2009, CARCINOGENESIS, V30, P2005, DOI 10.1093/carcin/bgp244; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Feng YK, 2011, EUR J CANCER, V47, P2353, DOI 10.1016/j.ejca.2011.05.006; Gao N, 2008, J BIOL CHEM, V283, P7834, DOI 10.1074/jbc.M710285200; Gao N, 2010, J BIOL CHEM, V285, P28097, DOI 10.1074/jbc.M110.116566; Gomes FG, 2013, LIFE SCI, V92, P101, DOI 10.1016/j.lfs.2012.10.008; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Hirakawa S, 2007, BLOOD, V109, P1010, DOI 10.1182/blood-2006-05-021758; Hosch SB, 2001, J CLIN ONCOL, V19, P1970, DOI 10.1200/JCO.2001.19.7.1970; Joukov V, 1996, EMBO J, V15, P290; Karpanen T, 2001, CANCER RES, V61, P1786; Kimura H, 1999, DIS ESOPHAGUS, V12, P205; Kitadai Y, 2004, ONCOL REP, V11, P315; Kitching R, 2003, BBA-GENE STRUCT EXPR, V1625, P116, DOI 10.1016/S0167-4781(02)00562-6; Krzystek-Korpacka M, 2007, CANCER LETT, V249, P171, DOI 10.1016/j.canlet.2006.08.011; Kubota Y, 2009, FRONT BIOSCI-LANDMRK, V14, P3872, DOI [10.2735/3495, 10.2741/3495]; Kumar B, 2011, ANGIOGENESIS, V14, P371, DOI 10.1007/s10456-011-9221-5; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054; Li K, 2002, INT J CANCER, V102, P271, DOI [10.1002/ijc.10706, 10.1002/jhc.10706]; Lin CY, 2013, CANCER RES, V73, P3638, DOI 10.1158/0008-5472.CAN-12-4028; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Mariette C, 2003, CANCER-AM CANCER SOC, V97, P1616, DOI 10.1002/cncr.11228; Miebach S, 2006, J NEURO-ONCOL, V76, P39, DOI 10.1007/s11060-005-3674-6; Ooki A, 2007, WORLD J SURG, V31, P2184, DOI 10.1007/s00268-007-9198-9; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Saaristo A, 2002, FASEB J, V16, P1041, DOI 10.1096/fj.01-1042com; Sastri M, 2005, P NATL ACAD SCI USA, V102, P349, DOI 10.1073/pnas.0408608102; Sato T, 2006, INT J ONCOL, V28, P1043; Scavelli C, 2004, LEUKEMIA, V18, P1054, DOI 10.1038/sj.leu.2403355; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Sobin LH, 1997, TNM CLASSIFICATION M, P54; Su JL, 2006, CANCER CELL, V9, P209, DOI 10.1016/j.ccr.2006.02.018; Tanigawa N, 1997, CANCER, V79, P220; Tsai PW, 2003, J BIOL CHEM, V278, P5750, DOI 10.1074/jbc.M204863200; Zhang HL, 2010, DIS ESOPHAGUS, V23, P53, DOI 10.1111/j.1442-2050.2009.00971.x; Zhang Y, 2012, GASTROENTEROLOGY, V142, P521, DOI 10.1053/j.gastro.2011.11.023	46	50	53	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					332	341		10.1038/onc.2013.559	http://dx.doi.org/10.1038/onc.2013.559			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24413079				2022-12-28	WOS:000348145500007
J	Xiang, T; Long, H; He, L; Han, X; Lin, K; Liang, Z; Zhuo, W; Xie, R; Zhu, B				Xiang, T.; Long, H.; He, L.; Han, X.; Lin, K.; Liang, Z.; Zhuo, W.; Xie, R.; Zhu, B.			Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133(+) cancer stem-like cells in ovarian cancer	ONCOGENE			English	Article						cancer stem cells; IL-17; self-renewal; ovarian cancer	BREAST-CANCER; INITIATING CELLS; IL-17 PROMOTES; MESSENGER-RNA; LUNG-CANCER; EXPRESSION; GROWTH; POPULATION; BETA; DIFFERENTIATION	Inflammatory cytokines, components of cancer stem cells (CSCs) niche, could affect the characteristics of CSCs such as self-renewal and metastasis. Interleukin-17 (IL-17) is a new pro-inflammatory cytokine mainly produced by T-helper (Th17) cells and macrophages. The effects of IL-17 on the characteristics of CSCs remain to be explored. Here we first demonstrated a role of IL-17 in promoting the self-renewal of ovarian CD133(+) cancer stem-like cells (CSLCs). We detected IL-17-producing cells (CD4(+) cells and CD68(+) macrophages) in the niche of CD133(+) CSLCs. Meanwhile, there was IL-17 receptor expression on CD133(+)CSLCs derived from A2780 cell line and primary ovarian cancer tissues. By recombinant human IL-17 stimulation and IL-17 transfection, the growth and sphere formation capacities of ovarian CD133(+)CSLCs were significantly enhanced in a dose-dependent manner. Moreover, ovarian CD133(+)CSLCs transfected with IL-17 showed greater tumorigenesis capacity in nude mice. These data suggest that IL-17 promoted the self-renewal of ovarian CD133(+)CSLCs. Further investigation through gene profiling revealed that the stimulation function of IL-17 on self-renewal of ovarian CD133(+)CSLCs might be mediated by the nuclear factor (NF)-kappa B and p38 mitogen-activated protein kinases (MAPK) signaling pathway. NF-kappa B and p38 MAPK were activated by IL-17. More importantly, IL-17 promoted self-renewal was inhibited by specific inhibitors of NF-kappa B and p38 MAPK. Taken together, our data indicate that IL-17 contributed to ovarian cancer malignancy through promoting the self-renewal of CD133(+)CSLCs and that IL-17 and its signaling pathway might serve as therapeutic targets for the treatment of ovarian cancer.	[Xiang, T.; Long, H.; He, L.; Han, X.; Lin, K.; Zhuo, W.; Xie, R.; Zhu, B.] Third Mil Med Univ, Xinqiao Hosp, Inst Canc, Chongqing 400037, Peoples R China; [Liang, Z.] Third Mil Med Univ, Southwest Hosp, Dept Obstet & Gynecol, Chongqing 400037, Peoples R China; [Xie, R.] Third Mil Med Univ, Xinqiao Hosp, Dept Obstet & Gynecol, Chongqing 400037, Peoples R China; [Zhu, B.] Third Mil Med Univ, Biomed Anal Ctr, Chongqing 400037, Peoples R China	Army Medical University; Army Medical University; Army Medical University; Army Medical University	Xie, R (corresponding author), Third Mil Med Univ, Xinqiao Hosp, Dept Obstet & Gynecol, Chongqing 400037, Peoples R China.	xrkai@163.com; b.davis.zhu@gmail.com			National Nature Science Foundation of China [81070018, 81071772, 81222031]; outstanding Youth Scientist Foundation of Chongqing [CSTC 2008BA5035]; National Key Basic Research Program of China (973 program) [2010CB529404, 2012CB526603]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); outstanding Youth Scientist Foundation of Chongqing; National Key Basic Research Program of China (973 program)(National Basic Research Program of China)	This work was supported by National Nature Science Foundation of China (grant nos. 81070018, 81071772 and 81222031), by the outstanding Youth Scientist Foundation of Chongqing (no. CSTC, 2008BA5035) and by National Key Basic Research Program of China (973 program, grant nos. 2010CB529404 and 2012CB526603).	Antonysamy MA, 1999, J IMMUNOL, V162, P577; Armstrong L, 2006, HUM MOL GENET, V15, P1894, DOI 10.1093/hmg/ddl112; Azzi S, 2011, J NATL CANCER I, V103, P1884, DOI 10.1093/jnci/djr451; Baba T, 2009, ONCOGENE, V28, P209, DOI 10.1038/onc.2008.374; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Chang SH, 2006, J BIOL CHEM, V281, P35603, DOI 10.1074/jbc.C600256200; Chen X, 2010, CANCER SCI, V101, P2384, DOI 10.1111/j.1349-7006.2010.01684.x; Ciucci A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060145; Curley MD, 2009, STEM CELLS, V27, P2875, DOI 10.1002/stem.236; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Du JW, 2012, MOL MED REP, V6, P1099, DOI 10.3892/mmr.2012.1036; Filatova A, 2013, BBA-GEN SUBJECTS, V1830, P2496, DOI 10.1016/j.bbagen.2012.10.008; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; HAMILTON TC, 1983, P AM ASSOC CANC RES, V24, P313; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hu L, 2010, BRIT J CANCER, V102, P1276, DOI 10.1038/sj.bjc.6605626; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; Kang ZH, 2013, NAT NEUROSCI, V16, P1401, DOI 10.1038/nn.3505; Kato T, 2001, BIOCHEM BIOPH RES CO, V282, P735, DOI 10.1006/bbrc.2001.4618; Kusumbe AP, 2009, STEM CELLS, V27, P498, DOI 10.1634/stemcells.2008-0868; Lai DM, 2012, CANCER IMMUNOL IMMUN, V61, P979, DOI 10.1007/s00262-011-1166-4; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Lan CY, 2013, CELL TISSUE RES, V352, P351, DOI 10.1007/s00441-013-1567-0; Le Gouvello S, 2008, GUT, V57, P772, DOI 10.1136/gut.2007.123794; Long HX, 2012, STEM CELLS, V30, P2309, DOI 10.1002/stem.1194; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Miyahara Y, 2008, P NATL ACAD SCI USA, V105, P15505, DOI 10.1073/pnas.0710686105; Murugaiyan G, 2009, J IMMUNOL, V183, P4169, DOI 10.4049/jimmunol.0901017; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Numasaki M, 2004, IMMUNOL LETT, V93, P39, DOI 10.1016/j.imlet.2004.01.014; Numasaki M, 2005, J IMMUNOL, V175, P6177, DOI 10.4049/jimmunol.175.9.6177; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Pasquier J, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/630782; ROUVIER E, 1993, J IMMUNOL, V150, P5445; Sfanos KS, 2008, CLIN CANCER RES, V14, P3254, DOI 10.1158/1078-0432.CCR-07-5164; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Shostak K, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2886; Silva IA, 2011, CANCER RES, V71, P3991, DOI 10.1158/0008-5472.CAN-10-3175; Steiner GE, 2003, PROSTATE, V56, P171, DOI 10.1002/pros.10238; Subramaniam SV, 1999, BIOCHEM BIOPH RES CO, V259, P172, DOI 10.1006/bbrc.1999.0746; Subramaniam SV, 1999, BIOCHEM BIOPH RES CO, V262, P14, DOI 10.1006/bbrc.1999.1156; Takahashi H, 2005, IMMUNOL LETT, V98, P189, DOI 10.1016/j.imlet.2004.11.012; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Villalva C, 2011, INT J CANCER, V128, P826, DOI 10.1002/ijc.25416; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Yi LA, 2011, J NEUROIMMUNOL, V232, P75, DOI 10.1016/j.jneuroim.2010.10.011; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364; Zhu XW, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2195	50	99	104	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					165	176		10.1038/onc.2013.537	http://dx.doi.org/10.1038/onc.2013.537			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24362529				2022-12-28	WOS:000347790500004
J	Valdmanis, PN; Roy-Chaudhuri, B; Kim, HK; Sayles, LC; Zheng, Y; Chuang, CH; Caswell, DR; Chu, K; Zhang, Y; Winslow, MM; Sweet-Cordero, EA; Kay, MA				Valdmanis, P. N.; Roy-Chaudhuri, B.; Kim, H. K.; Sayles, L. C.; Zheng, Y.; Chuang, C-H; Caswell, D. R.; Chu, K.; Zhang, Y.; Winslow, M. M.; Sweet-Cordero, E. A.; Kay, M. A.			Upregulation of the microRNA cluster at the Dlkl-Dio3 locus in lung adenocarcinoma	ONCOGENE			English	Article						lung adenocarcinorna; NSCLC; RNAseq; nnicroRNAs	K-RAS ONCOGENE; PROMOTER HYPERMETHYLATION; HEPATOCELLULAR-CARCINOMA; SOMATIC MUTATIONS; IMPRINTED GENES; NEVER SMOKERS; CANCER; RNA; EXPRESSION; ACTIVATION	Mice in which lung epithelial cells can be induced to express an oncogenic Kras(G12D) develop lung adenocarcinomas in a manner analogous to humans. A myriad of genetic changes accompany lung adenocarcinomas, many of which are poorly understood. To get a comprehensive understanding of both the transcriptional and post-transcriptional changes that accompany lung adenocarcinomas, we took an omics approach in profiling both the coding genes and the non-coding small RNAs in an induced mouse model of lung adenocarcinoma. RNAseq transcriptome analysis of Kras(G12D) tumors from F1 hybrid mice revealed features specific to tumor samples. This includes the repression of a network of GTPase-related genes (Prkg1, Gnao1 and Rgs9) in tumor samples and an enrichment of Apobec1-mediated cytosine to uridine RNA editing. Furthermore, analysis of known single-nucleotide polymorphisms revealed not only a change in expression of Cd22 but also that its expression became allele specific in tumors. The most salient finding, however, came from small RNA sequencing of the tumor samples, which revealed that a cluster of 53 microRNAs and mRNAs at the Dlk1-Dio3 locus on mouse chromosome 12qF1 was markedly and consistently increased in tumors. Activation of this locus occurred specifically in sorted tumor-originating cancer cells. Interestingly, the 12qF1 RNAs were repressed in cultured Kras(G12D) tumor cells but reactivated when transplanted in vivo. These microRNAs have been implicated in stem cell pleuripotency and proteins targeted by these microRNAs are involved in key pathways in cancer as well as embryogenesis. Taken together, our results strongly imply that these microRNAs represent key targets in unraveling the mechanism of lung oncogenesis.	[Valdmanis, P. N.; Roy-Chaudhuri, B.; Kim, H. K.; Chu, K.; Zhang, Y.; Sweet-Cordero, E. A.; Kay, M. A.] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA; [Valdmanis, P. N.; Roy-Chaudhuri, B.; Kim, H. K.; Chuang, C-H; Caswell, D. R.; Chu, K.; Zhang, Y.; Winslow, M. M.; Kay, M. A.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Sayles, L. C.; Zheng, Y.; Sweet-Cordero, E. A.] Stanford Univ, Dept Pediat, Div Hematol Oncol, Stanford, CA 94305 USA; [Chuang, C-H; Caswell, D. R.; Winslow, M. M.] Stanford Univ, Canc Biol Program, Stanford, CA 94305 USA; [Chuang, C-H; Caswell, D. R.; Winslow, M. M.; Sweet-Cordero, E. A.] Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Stanford Cancer Institute; Stanford University	Kay, MA (corresponding author), Stanford Univ, Dept Pediat & Genet, 269 Campus Dr,CCSR 2105, Stanford, CA 94305 USA.	markay@stanford.edu		Valdmanis, Paul/0000-0001-8840-6969; Kay, Mark/0000-0002-2799-2615	Baxter Foundation Scholar Award; Stanford Dean's Fellowship; Canadian Institutes of Health Research;  [R01 DK078424]; NATIONAL CANCER INSTITUTE [T32CA009302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI071068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK078424] Funding Source: NIH RePORTER	Baxter Foundation Scholar Award; Stanford Dean's Fellowship; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	PNV is a Banting Postdoctoral Fellow supported by the Canadian Institutes of Health Research. MMW is funded by a Baxter Foundation Scholar Award and C-HC is supported by a Stanford Dean's Fellowship. We thank Julien Sage for SCLC samples. This work was supported by grant R01 DK078424 (MAK).	Al-Mulla F, 1999, J PATHOL, V187, P433, DOI 10.1002/(SICI)1096-9896(199903)187:4<433::AID-PATH273>3.0.CO;2-E; Castilla MA, 2011, J PATHOL, V223, P72, DOI 10.1002/path.2802; Benetatos L, 2012, CRIT REV EUKAR GENE, V22, P1; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Bhaskaran M, 2009, PHYSIOL GENOMICS, V37, P268, DOI 10.1152/physiolgenomics.90268.2008; Burns MB, 2013, NAT GENET, V45, P977, DOI 10.1038/ng.2701; Chess A, 2012, NAT REV GENET, V13, P421, DOI 10.1038/nrg3239; Danecek P, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-4-r26; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Dixon-McIver A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002141; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Edwards CA, 2007, CURR OPIN CELL BIOL, V19, P281, DOI 10.1016/j.ceb.2007.04.013; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Garcia-Marcos M, 2011, ONCOGENE, V30, P2691, DOI 10.1038/onc.2010.645; Govindan R, 2012, CELL, V150, P1121, DOI 10.1016/j.cell.2012.08.024; Hagan JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004352; Haller F, 2010, J PATHOL, V220, P71, DOI 10.1002/path.2610; Harris KS, 2006, P NATL ACAD SCI USA, V103, P2208, DOI 10.1073/pnas.0510839103; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Ju YS, 2012, GENOME RES, V22, P436, DOI 10.1101/gr.133645.111; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Kaneda A, 2004, CANCER LETT, V212, P203, DOI 10.1016/j.canlet.2004.03.020; Kim JH, 2011, BMB REP, V44, P523, DOI 10.5483/BMBRep.2011.44.8.523; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lee Jennifer, 2010, Genes Cancer, V1, P690, DOI 10.1177/1947601910382899; Lee S, 2009, INT J ONCOL, V34, P161, DOI 10.3892/ijo_00000138; Leung SO, 1995, MOL IMMUNOL, V32, P1413, DOI 10.1016/0161-5890(95)00080-1; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liu X, 2010, J CLIN INVEST, V120, P1298, DOI 10.1172/JCI39566; Luk JM, 2011, J BIOL CHEM, V286, P30706, DOI 10.1074/jbc.M111.229831; Ma Y, 2007, P NATL ACAD SCI USA, V104, P4089, DOI 10.1073/pnas.0606537104; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mita H, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-198; Mosakhani N, 2012, GENE CHROMOSOME CANC, V51, P1, DOI 10.1002/gcc.20925; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Proudfoot NJ, 2011, GENE DEV, V25, P1770, DOI 10.1101/gad.17268411; Ricketts SL, 2003, MOL CARCINOGEN, V36, P90, DOI 10.1002/mc.10101; Riely GJ, 2008, CLIN CANCER RES, V14, P5731, DOI 10.1158/1078-0432.CCR-08-0646; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Roberts SA, 2013, NAT GENET, V45, P970, DOI 10.1038/ng.2702; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; Rosenberg BR, 2011, NAT STRUCT MOL BIOL, V18, P230, DOI 10.1038/nsmb.1975; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; Sekita Y, 2006, CYTOGENET GENOME RES, V113, P223, DOI 10.1159/000090836; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; Son JW, 2011, RESPIROLOGY, V16, P1203, DOI 10.1111/j.1440-1843.2011.01994.x; Stadtfeld M, 2010, NATURE, V465, P175, DOI 10.1038/nature09017; Sun S, 2007, NAT REV CANCER, V7, P778, DOI 10.1038/nrc2190; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Takahashi N, 2009, HUM MOL GENET, V18, P1879, DOI 10.1093/hmg/ddp108; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Tuscano JM, 2012, CANCER RES, V72, P5556, DOI 10.1158/0008-5472.CAN-12-0173; Uckun FM, 2010, P NATL ACAD SCI USA, V107, P16852, DOI 10.1073/pnas.1007896107; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483	65	35	37	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					94	103		10.1038/onc.2013.523	http://dx.doi.org/10.1038/onc.2013.523			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24317514	Green Accepted, Green Submitted			2022-12-28	WOS:000349740100009
J	Hou, Y; Gao, J; Xu, H; Xu, Y; Zhang, Z; Xu, Q; Zhang, C				Hou, Y.; Gao, J.; Xu, H.; Xu, Y.; Zhang, Z.; Xu, Q.; Zhang, C.			PPAR gamma E3 ubiquitin ligase regulates MUC1-C oncoprotein stability	ONCOGENE			English	Article						PPAR gamma; MUC1-C; ubiquitin; degradation; ubiquitination; cancer	NF-KAPPA-B; RECEPTOR-GAMMA; COLON-CANCER; CELLS; TRANSCRIPTION; EXPRESSION; DEGRADATION; ACTIVATION; LIGANDS; DOMAIN	MUC1-C oncoprotein is associated with colon, breast, ovarian, lung and pancreatic cancers. MUC1-C interacts with intracellular proteins to elicit signaling cascades that induce cell proliferation and tumor growth. Here we report that peroxisome proliferator-activated receptor gamma (PPAR gamma), an E3 ubiquitin ligase, is an inhibitor of MUC1-C-mediated cell proliferation. PPAR gamma does so by binding to and inducing MUC1-C proteasome-dependent degradation that was independent of PPAR gamma transcriptional activity. Lys134 residue was found to be critically important for PPAR gamma-mediated MUC1-C degradation, as it terminated MUC1-C-mediated cell proliferation. These findings demonstrate PPAR gamma induces MUC1-C ubiquitination and degradation that is critical to terminate MUC1-C signaling pathway-elicited cancer.	[Hou, Y.; Gao, J.; Xu, H.; Xu, Y.; Zhang, Z.; Xu, Q.; Zhang, C.] Jiangsu Univ, Inst Life Sci, Zhenjiang 212013, Jiangsu, Peoples R China	Jiangsu University	Hou, Y (corresponding author), Jiangsu Univ, Inst Life Sci, Zhenjiang 212013, Jiangsu, Peoples R China.	houyz@mail.ujs.edu.cn	hou, YONGZHONG/K-7771-2013	xu, qinggang/0000-0002-8659-7041; Hou, Yongzhong/0000-0003-2019-8686	Jiangsu Province Natural Science Foundation [SBK201320232]; Start Fund of University of JiangSu [12JDG071]	Jiangsu Province Natural Science Foundation(Natural Science Foundation of Jiangsu Province); Start Fund of University of JiangSu	This work was supported by Jiangsu Province Natural Science Foundation (SBK201320232) and Start Fund of University of JiangSu (12JDG071).	Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2012, J BIOL CHEM, V287, P20866, DOI 10.1074/jbc.M112.357293; Ahmad R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001426; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Berger Joel, 2002, Diabetes Technol Ther, V4, P163, DOI 10.1089/15209150260007381; Carson DD, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.127pe35; Cascio S, 2011, J BIOL CHEM, V286, P42248, DOI 10.1074/jbc.M111.297630; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811; Girnun GD, 2007, CANCER CELL, V11, P395, DOI 10.1016/j.ccr.2007.02.025; Heaney AP, 2003, J CLIN INVEST, V111, P1381, DOI 10.1172/JCI200316575; Hou Y, 2014, ONCOGENE, V33, P1997, DOI 10.1038/onc.2013.135; Hou YZ, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2270; Hou YZ, 2010, J BIOL CHEM, V285, P35497, DOI 10.1074/jbc.M109.066035; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kufe DW, 2008, CANCER BIOL THER, V7, P81, DOI 10.4161/cbt.7.1.5631; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; Ogino S, 2009, GASTROENTEROLOGY, V136, P1242, DOI 10.1053/j.gastro.2008.12.048; Park YS, 2012, AM J PHYSIOL-GASTR L, V303, pG765, DOI 10.1152/ajpgi.00023.2012; Park YS, 2012, AM J PHYSIOL-LUNG C, V302, P1679, DOI 10.1152/ajplung.00360.2011; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; Raina D, 2006, EMBO J, V25, P3774, DOI 10.1038/sj.emboj.7601263; Ruan H, 2003, J BIOL CHEM, V278, P28181, DOI 10.1074/jbc.M303141200; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Shalom-Barak T, 2004, MOL CELL BIOL, V24, P10661, DOI 10.1128/MCB.24.24.10661-10669.2004; Shimada T, 2002, GUT, V50, P658, DOI 10.1136/gut.50.5.658; Straus DS, 2007, TRENDS IMMUNOL, V28, P551, DOI 10.1016/j.it.2007.09.003; Uchida Y, 2013, CANCER BIOL THER, V14, P127, DOI 10.4161/cbt.22634; Wang P, 2010, MOL ENDOCRINOL, V24, P1368, DOI 10.1210/me.2009-0221; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008	33	31	32	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2014	33	49					5619	5625		10.1038/onc.2013.504	http://dx.doi.org/10.1038/onc.2013.504			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZW	24292674				2022-12-28	WOS:000346088700006
J	Zhong, J; Cao, RX; Liu, JH; Liu, YB; Wang, J; Liu, LP; Chen, YJ; Yang, J; Zhang, QH; Wu, Y; Ding, WJ; Hong, T; Xiao, XH; Zu, XY; Wen, GB				Zhong, J.; Cao, R-X; Liu, J-H; Liu, Y-B; Wang, J.; Liu, L-P; Chen, Y-J; Yang, J.; Zhang, Q-H; Wu, Y.; Ding, W-J; Hong, T.; Xiao, X-H; Zu, X-Y; Wen, G-B			Nuclear loss of protein arginine N-methyltransferase 2 in breast carcinoma is associated with tumor grade and overexpression of cyclin D1 protein	ONCOGENE			English	Article						nuclear loss; PRMT2; cyclin D1; breast cancer	ESTROGEN-RECEPTOR-ALPHA; GENE-EXPRESSION; KAPPA-B; IN-VIVO; CANCER; IDENTIFICATION; METHYLATION; PROMOTER; PRMT2; CELL	Human protein arginine N-methyltransferase 2 (PRMT2, HRMT1L1) is a protein that belongs to the arginine methyltransferase family, and it has diverse roles in transcriptional regulation through different mechanisms depending on its binding partners. In this study, we provide evidences for the negative effect of PRMT2 on breast cancer cell proliferation in vitro and in vivo. Morever, cyclin D1, one of the key modulators of cell cycle, was found to be downregulated by PRMT2, and PRMT2 was further shown to suppress the estrogen receptor alpha-binding affinity to the activator protein-1 (AP-1) site in cyclin D1 promoter through indirect binding with AP-1 site, resulting in the inhibition of cyclin D1 promoter activity in MCF-7 cells. Furthermore, a positive correlation between the expression of PRMT2 and cyclin D1 was confirmed in the breast cancer tissues by using tissue microarray assay. In addition, PRMT2 was found to show a high absent percentage in breast caner cell nuclei and the nuclear loss ratio of PRMT2 was demonstrated to positively correlate with cyclin D1 expression and the increasing tumor grade of invasive ductal carcinoma. Those results offer an essential insight into the effect of PRMT2 on breast carcinogenesis, and PRMT2 nuclear loss might be an important biological marker for the diagnosis of breast cancer.	[Zhong, J.; Cao, R-X; Liu, J-H; Liu, Y-B; Wang, J.; Liu, L-P; Chen, Y-J; Yang, J.; Zhang, Q-H; Wu, Y.; Ding, W-J; Hong, T.; Xiao, X-H; Zu, X-Y; Wen, G-B] Univ South China, Affiliated Hosp 1, Inst Clin Med, 69 Chuanshan Rd, Hengyang 421001, Peoples R China; [Cao, R-X; Liu, J-H; Yang, J.; Hong, T.; Xiao, X-H] Univ South China, Affiliated Hosp 1, Dept Metab & Endocrinol, Hengyang 421001, Peoples R China	University of South China; University of South China	Zu, XY (corresponding author), Univ South China, Affiliated Hosp 1, Inst Clin Med, 69 Chuanshan Rd, Hengyang 421001, Peoples R China.	zuxuyu0108@hotmail.com; wen_gb@hotmail.com	Zhong, Jing/M-1057-2018	Zhong, Jing/0000-0003-4593-4897	National Natural Science Foundation of P.R.China [31200573, 81272906, 81272355, 81172542]; Hunan Provincial Natural Science Foundation of China [12JJ3116]; Education Department of Hunan Province Youth Fund [12B108]	National Natural Science Foundation of P.R.China(National Natural Science Foundation of China (NSFC)); Hunan Provincial Natural Science Foundation of China(Natural Science Foundation of Hunan Province); Education Department of Hunan Province Youth Fund	This work is supported by projects from the National Natural Science Foundation of P.R.China (Grant No. 31200573, 81272906, 81272355 and 81172542), Hunan Provincial Natural Science Foundation of China (12JJ3116) and The Education Department of Hunan Province Youth Fund (12B108).	ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Arnold A, 2005, J CLIN ONCOL, V23, P4215, DOI 10.1200/JCO.2005.05.064; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartusel T, 2005, GENE, V351, P171, DOI 10.1016/j.gene.2005.03.035; Besson V, 2007, HUM MOL GENET, V16, P2040, DOI 10.1093/hmg/ddm152; Blythe SA, 2010, DEV CELL, V19, P220, DOI 10.1016/j.devcel.2010.07.007; Bocchinfuso WP, 1997, J MAMMARY GLAND BIOL, V2, P323, DOI 10.1023/A:1026339111278; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Chen SL, 2002, J BIOL CHEM, V277, P4324, DOI 10.1074/jbc.M109835200; Cheng ASL, 2006, MOL CELL, V21, P393, DOI 10.1016/j.molcel.2005.12.016; Chung KH, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl143; DeNardo DG, 2005, MOL ENDOCRINOL, V19, P362, DOI 10.1210/me.2004-0267; Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006; El Messaoudi S, 2006, P NATL ACAD SCI USA, V103, P13351, DOI 10.1073/pnas.0605692103; Feng Y, 2007, P NATL ACAD SCI USA, V104, P14718, DOI 10.1073/pnas.0706933104; Ferguson AT, 1997, CRIT REV ONCOGENESIS, V8, P29, DOI 10.1615/CritRevOncog.v8.i1.20; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Ganesh L, 2006, MOL CELL BIOL, V26, P3864, DOI 10.1128/MCB.26.10.3864-3874.2006; Goulet I, 2007, J BIOL CHEM, V282, P33009, DOI 10.1074/jbc.M704349200; Herrmann F, 2009, J CELL SCI, V122, P667, DOI 10.1242/jcs.039933; Iwasaki H, 2010, CIRC RES, V107, P992, DOI 10.1161/CIRCRESAHA.110.225326; Katsanis N, 1997, MAMM GENOME, V8, P526, DOI 10.1007/s003359900491; Katzenellenbogen BS, 2000, RECENT PROG HORM RES, V55, P163; Katzenellenbogen BS, 2000, RECENT PROG HORM RES, V55, P194; Kawakubo H, 2006, CANCER RES, V66, P7075, DOI 10.1158/0008-5472.CAN-06-0379; Kim JK, 2009, J CELL PHYSIOL, V220, P292, DOI 10.1002/jcp.21791; Klein EA, 2008, J CELL SCI, V121, P3853, DOI 10.1242/jcs.039131; Lakowski TM, 2009, BIOCHEM J, V421, P253, DOI 10.1042/BJ20090268; Le Romancer M, 2011, ENDOCR REV, V32, P597, DOI 10.1210/er.2010-0016; Li HW, 2002, J BIOL CHEM, V277, P44623, DOI 10.1074/jbc.M206187200; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Lukong KE, 2004, NAT STRUCT MOL BIOL, V11, P914, DOI 10.1038/nsmb1004-914; Marampon F, 2008, MOL BIOL CELL, V19, P2566, DOI 10.1091/mbc.E06-12-1110; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Meister G, 2002, EMBO J, V21, P5853, DOI 10.1093/emboj/cdf585; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Meyer R, 2007, J STEROID BIOCHEM, V107, P1, DOI 10.1016/j.jsbmb.2007.05.006; Ong CS, 2010, CANCER LETT, V298, P167, DOI 10.1016/j.canlet.2010.07.001; Qi C, 2002, J BIOL CHEM, V277, P28624, DOI 10.1074/jbc.M201053200; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Sayeed A, 2007, CANCER RES, V67, P7746, DOI 10.1158/0008-5472.CAN-06-3724; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Shen Q, 2008, ONCOGENE, V27, P366, DOI 10.1038/sj.onc.1210643; Steeg PS, 1998, BREAST CANCER RES TR, V52, P17, DOI 10.1023/A:1006102916060; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Takahashi-Yanaga F, 2008, CELL SIGNAL, V20, P581, DOI 10.1016/j.cellsig.2007.10.018; Tashiro E, 2007, CANCER SCI, V98, P629, DOI 10.1111/j.1349-7006.2007.00449.x; Thomassen M, 2009, BREAST CANCER RES TR, V113, P239, DOI 10.1007/s10549-008-9927-2; Torres-Padilla ME, 2007, NATURE, V445, P214, DOI 10.1038/nature05458; Ye XM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055615; Ye Y, 2010, ONCOGENE, V29, P1451, DOI 10.1038/onc.2009.433; Yildirim AO, 2006, AM J RESP CELL MOL, V35, P436, DOI 10.1165/rcmb.2006-0097OC; Yoshimoto T, 2006, EXP CELL RES, V312, P2040, DOI 10.1016/j.yexcr.2006.03.001; Zhong J, 2012, FEBS J, V279, P316, DOI 10.1111/j.1742-4658.2011.08426.x; Zhong J, 2011, GENE, V487, P1, DOI 10.1016/j.gene.2011.06.022; Zu XY, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2843	57	25	28	3	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2014	33	48					5546	5558		10.1038/onc.2013.500	http://dx.doi.org/10.1038/onc.2013.500			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZO	24292672				2022-12-28	WOS:000346087900007
J	Philips, ST; Hildenbrand, ZL; Oravecz-Wilson, KI; Foley, SB; Mgbemena, VE; Ross, TS				Philips, S. T.; Hildenbrand, Z. L.; Oravecz-Wilson, K. I.; Foley, S. B.; Mgbemena, V. E.; Ross, T. S.			Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells	ONCOGENE			English	Article						myeloproliferation; Imatinib; arsenic	HEMATOPOIETIC STEM-CELLS; CHRONIC MYELOID-LEUKEMIA; HUNTINGTIN-INTERACTING PROTEIN-1; CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; HISTONE DEACETYLASE INHIBITORS; RECEPTOR-BETA; CML PATIENTS; QUIESCENT; GENE	Myeloproliferative neoplasms (MPNs) such as chronic myelogenous (CML) and chronic myelomonocytic leukemias (CMML) are frequently induced by tyrosine kinase oncogenes. Although these MPNs are sensitive to tyrosine kinase inhibitors such as imatinib, patients often relapse upon withdrawal of therapy. We used a model of MPN, which is induced by co-expression of the oncoproteins HIP1/PDGFbR (H/P) and AML1/ETO from their endogenous loci, to examine the mechanisms of disease development and recurrence following imatinib withdrawal. Although the MPN displayed a full hematologic response to imatinib, 100% of the diseased mice relapsed upon drug withdrawal. MPN persistence was not due to imatinib resistance mutations in the H/P oncogene or massive gene expression changes. Within 1 week of imatinib treatment, more than 98% of gene expression changes induced by the oncogenes in isolated hematopoietic stem and progenitor cells (lineage(-)Sca-1(+)c-Kit(+) immunophenotype) normalized. Supplementation of imatinib with granulocyte colony-stimulating factor or arsenic trioxide reduced MPN-initiating cell frequencies and the combination of imatinib with arsenic trioxide cured a large fraction of mice with MPNs. In contrast, no mice in the imatinibtreated control cohorts were cured. These data suggest that treatment with a combination of arsenic trioxide and imatinib can eliminate refractory MPN-initiating cells and reduce disease relapse.	[Philips, S. T.; Hildenbrand, Z. L.; Foley, S. B.; Mgbemena, V. E.; Ross, T. S.] Univ Texas Dallas, SW Med Ctr, Dept Internal Med, Div Hematol Oncol, Dallas, TX 75390 USA; [Oravecz-Wilson, K. I.] Univ Michigan, Ann Arbor, MI 48109 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Michigan System; University of Michigan	Ross, TS (corresponding author), Univ Texas Dallas, SW Med Ctr, Dept Internal Med, Div Hematol Oncol, 5323 Harry Hines Blvd,ND3-214, Dallas, TX 75390 USA.	Theo.Ross@utsouthwestern.edu		Ross, Theodora/0000-0002-9166-1802	Burroughs Wellcome Fund Clinical Scientist Award in Translational Research; TSR holds the Jeanne Ann Plitt Professorship in Breast Cancer Research; H Ben and Isabelle T Decherd Chair in Internal Medicine at UT Southwestern Medical Center; Leukemia and Lymphoma Society Scholar;  [CBTG CA009676];  [R01 CA82363-03];  [R01 CA098730-01]; NATIONAL CANCER INSTITUTE [T32CA124334, R01CA098730, R01CA082363, T32CA009676] Funding Source: NIH RePORTER	Burroughs Wellcome Fund Clinical Scientist Award in Translational Research(Burroughs Wellcome Fund); TSR holds the Jeanne Ann Plitt Professorship in Breast Cancer Research; H Ben and Isabelle T Decherd Chair in Internal Medicine at UT Southwestern Medical Center; Leukemia and Lymphoma Society Scholar(Leukemia and Lymphoma Society); ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Bob Rooney, Luke Peterson, Phil (Zhe) Guan, Ivan Maillard, Yipin Wu and Alice Gauvin for their intellectual input and technical assistance. This work was supported by the following grants: CBTG CA009676 (STP), R01 CA82363-03 (TSR) and R01 CA098730-01 (TSR), and a Burroughs Wellcome Fund Clinical Scientist Award in Translational Research (TSR). TSR holds the Jeanne Ann Plitt Professorship in Breast Cancer Research and the H Ben and Isabelle T Decherd Chair in Internal Medicine at UT Southwestern Medical Center. TSR was supported as a Leukemia and Lymphoma Society Scholar during the time this work was completed.	Agarwal A, 2012, BLOOD, V120, P2658, DOI 10.1182/blood-2011-05-355396; Ames HM, 2013, MOL CELL BIOL, V33, P3580, DOI 10.1128/MCB.00473-13; Antman KH, 2001, ONCOLOGIST, V6, P1, DOI 10.1634/theoncologist.6-suppl_2-1; Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; Boissel N, 2006, LEUKEMIA, V20, P965, DOI 10.1038/sj.leu.2404188; Connor RF, 2006, LEUKEMIA RES, V30, P1249, DOI 10.1016/j.leukres.2006.02.020; Corbin AS, 2011, J CLIN INVEST, V121, P396, DOI 10.1172/JCI35721; Cortes J, 2004, BLOOD, V104, P2204, DOI 10.1182/blood-2004-04-1335; David M, 2007, BLOOD, V109, P61, DOI 10.1182/blood-2006-05-024828; DiPersio JF, 2009, BLOOD, V113, P5720, DOI 10.1182/blood-2008-08-174946; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Drummond MW, 2009, LEUKEMIA, V23, P1199, DOI 10.1038/leu.2009.43; Essers MAG, 2009, NATURE, V458, P904, DOI 10.1038/nature07815; Forsberg EC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008785; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Grand FH, 2004, CANCER RES, V64, P7216, DOI 10.1158/0008-5472.CAN-04-2005; Graves CW, 2008, CANCER RES, V68, P1064, DOI 10.1158/0008-5472.CAN-07-5892; Grossmann V, 2011, LEUKEMIA, V25, P557, DOI 10.1038/leu.2010.298; Higashi T, 2004, AM J HEMATOL, V76, P275, DOI 10.1002/ajh.20096; Holtz M, 2007, CANCER RES, V67, P1113, DOI 10.1158/0008-5472.CAN-06-2014; Huang HJ, 1999, CANCER RES, V59, P2981; Irizarry RA, 2006, BIOINFORMATICS, V22, P789, DOI 10.1093/bioinformatics/btk046; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Jaiswal S, 2003, P NATL ACAD SCI USA, V100, P10002, DOI 10.1073/pnas.1633833100; Jaiswal S, 2009, CELL, V138, P271, DOI 10.1016/j.cell.2009.05.046; Jones AV, 2004, CELL MOL LIFE SCI, V61, P2912, DOI 10.1007/s00018-004-4272-z; Jorgensen HG, 2006, CLIN CANCER RES, V12, P626, DOI 10.1158/1078-0432.CCR-05-0429; Kavalerchik E, 2008, J CLIN ONCOL, V26, P2911, DOI 10.1200/JCO.2008.17.5745; Kiel MJ, 2007, NATURE, V449, P238, DOI 10.1038/nature06115; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; Lee KH, 2000, J IMMUNOL, V165, P4970, DOI 10.4049/jimmunol.165.9.4970; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Mauro MJ, 2004, LEUKEMIA RES, V28, pS71, DOI 10.1016/j.leukres.2003.10.017; Morrison SJ, 1997, P NATL ACAD SCI USA, V94, P1908, DOI 10.1073/pnas.94.5.1908; Oravecz-Wilson KI, 2009, CANCER CELL, V16, P137, DOI 10.1016/j.ccr.2009.06.007; Preudhomme C, 2010, NEW ENGL J MED, V363, P2511, DOI 10.1056/NEJMoa1004095; Provenzano JD, 2013, CASE REP HEMATOL, V2013, DOI 10.1155/2013/709164; Roberts KG, 2012, CANCER CELL, V22, P153, DOI 10.1016/j.ccr.2012.06.005; Ross TS, 1998, BLOOD, V91, P4419, DOI 10.1182/blood.V91.12.4419.412k43_4419_4426; Savona M, 2008, NAT REV CANCER, V8, P341, DOI 10.1038/nrc2368; Strout MP, 1999, ANN HEMATOL, V78, P251, DOI 10.1007/s002770050511; Tefferi A, 2008, LEUKEMIA, V22, P14, DOI 10.1038/sj.leu.2404955; Torres J, 2003, J BIOL CHEM, V278, P30652, DOI 10.1074/jbc.M212610200; Vainio P, 2011, ONCOTARGET, V2, P1176; Wang JCY, 2005, TRENDS CELL BIOL, V15, P494, DOI 10.1016/j.tcb.2005.07.004; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Zhang B, 2010, CANCER CELL, V17, P427, DOI 10.1016/j.ccr.2010.03.011; Zuccolo J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009369	49	1	1	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2014	33	46					5379	5390		10.1038/onc.2013.484	http://dx.doi.org/10.1038/onc.2013.484			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MF	24240679	Green Accepted			2022-12-28	WOS:000345120600008
J	Fu, X; Meng, Z; Liang, W; Tian, Y; Wang, X; Han, W; Lou, G; Wang, X; Lou, F; Yen, Y; Yu, H; Jove, R; Huang, W				Fu, X.; Meng, Z.; Liang, W.; Tian, Y.; Wang, X.; Han, W.; Lou, G.; Wang, X.; Lou, F.; Yen, Y.; Yu, H.; Jove, R.; Huang, W.			miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis	ONCOGENE			English	Article						miR-26a; Zcchc11; let-7; miRNA biogenesis; tumorigenesis; metastasis	MICRORNA EXPRESSION; LET-7; TRANSFORMATION; PROLIFERATION; TUMORIGENESIS; MATURATION; REGULATOR; BLOCKADE; ABSENCE; HMGA2	Human cancers often exhibit attenuated microRNA (miRNA) biogenesis and global underexpression of miRNAs; thus, targeting the miRNA biogenesis pathway represents a novel strategy for cancer therapy. Here, we report that miR-26a enhances miRNA biogenesis, which acts as a common mechanism partially accounting for miR-26a function in diverse cancers including melanoma, prostate and liver cancer. miR-26a was broadly reduced in multiple cancers, and overexpression of miR-26a significantly suppressed tumor growth and metastasis both in vitro and in vivo, including melanoma, prostate and liver cancers. Notably, miR-26a overexpression was accompanied by global upregulation of miRNAs, especially let-7, and let-7 expression was concordant with miR-26a expression in cancer cell lines, xenograft tumors and normal human tissues, underscoring their biological relevance. We showed that miR-26a directly targeted Lin28B and Zcchc11-two critical repressors of let-7 maturation. Furthermore, we have demonstrated that Zcchc11 promoted tumor growth and metastasis, and it was prominently overexpressed in human cancers. Our findings thus provide a novel mechanism by which a miRNA acts as a modulator of miRNA biogenesis. These results also define a role of the miR-26a and Zcchc11 in tumorigenesis and metastasis and have implications to develop new strategies for cancer therapy.	[Fu, X.; Meng, Z.; Wang, X.; Han, W.; Lou, G.; Wang, X.; Lou, F.; Huang, W.] City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Diabet Res, Dept Diabet & Metab Dis Res, Duarte, CA 91010 USA; [Meng, Z.; Yen, Y.; Yu, H.; Jove, R.; Huang, W.] City Hope Natl Med Ctr, Beckman Res Inst, Irell & Manella Grad Sch Biol Sci, Duarte, CA 91010 USA; [Liang, W.; Tian, Y.; Jove, R.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Med, Duarte, CA 91010 USA; [Yen, Y.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Pharmacol, Duarte, CA 91010 USA; [Yu, H.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Immunotherapy & Tumor Immunol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Huang, W (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Diabet Res, Dept Diabet & Metab Dis Res, 1500 E Duarte Rd, Duarte, CA 91010 USA.	whuang@coh.org	Yen, Yun/H-9591-2016	Fu, Xianghui/0000-0001-9808-3892; YU, Hua/0000-0003-0931-1000	National Cancer Institute [P30 CA033572]; American Cancer Society [RSG-11-132-01-CCE]; NATIONAL CANCER INSTITUTE [R01CA139158, P30CA033572] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Arthur Riggs and Rama Natarajan for reviewing the manuscript, Dr Kyle Sousa and other members of the Huang laboratory for their helpful discussions and Dr Keely Walker for editing the manuscript. This work was supported by the National Cancer Institute (P30 CA033572) and the American Cancer Society (RSG-11-132-01-CCE).	Blahna MT, 2011, J BIOL CHEM, V286, P42381, DOI 10.1074/jbc.M111.259689; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; Farazi TA, 2011, J PATHOL, V223, P102, DOI 10.1002/path.2806; Guo L, 2013, ONCOGENE, V32, P5272, DOI 10.1038/onc.2012.573; Hagan JP, 2009, NAT STRUCT MOL BIOL, V16, P1021, DOI 10.1038/nsmb.1676; Hammond SM, 2008, CELL, V135, P1013, DOI 10.1016/j.cell.2008.11.026; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heo I, 2008, MOL CELL, V32, P276, DOI 10.1016/j.molcel.2008.09.014; Heo I, 2009, CELL, V138, P696, DOI 10.1016/j.cell.2009.08.002; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Ji JF, 2009, NEW ENGL J MED, V361, P1437, DOI 10.1056/NEJMoa0901282; Jiang X, 2012, CANCER CELL, V22, P524, DOI 10.1016/j.ccr.2012.08.028; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; King CE, 2011, ONCOGENE, V30, P4185, DOI 10.1038/onc.2011.131; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Mavrakis KJ, 2011, NAT GENET, V43, P673, DOI 10.1038/ng.858; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Melo SA, 2010, CANCER CELL, V18, P303, DOI 10.1016/j.ccr.2010.09.007; Melo SA, 2009, NAT GENET, V41, P365, DOI 10.1038/ng.317; Meng ZP, 2010, HEPATOLOGY, V52, P2148, DOI 10.1002/hep.23915; Newman MA, 2010, INT J BIOCHEM CELL B, V42, P1330, DOI 10.1016/j.biocel.2009.02.023; Newman MA, 2010, GENE DEV, V24, P1086, DOI 10.1101/gad.1919710; Piskounova E, 2011, CELL, V147, P1066, DOI 10.1016/j.cell.2011.10.039; Ravi A, 2012, CANCER CELL, V21, P848, DOI 10.1016/j.ccr.2012.04.037; Raymond CK, 2005, RNA, V11, P1737, DOI 10.1261/rna.2148705; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645; Talmadge JE, 2010, METHODS MOL BIOL, V602, P215, DOI 10.1007/978-1-60761-058-8_13; Thornton JE, 2012, TRENDS CELL BIOL, V22, P474, DOI 10.1016/j.tcb.2012.06.001; van Kouwenhove M, 2011, NAT REV CANCER, V11, P644, DOI 10.1038/nrc3107; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Viswanathan SR, 2010, CELL, V140, P445, DOI 10.1016/j.cell.2010.02.007; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Yang F, 2007, CANCER RES, V67, P863, DOI 10.1158/0008-5472.CAN-06-1078; Yuan J, 2012, SCIENCE, V335, P1195, DOI 10.1126/science.1216557; Yun JU, 2011, EMBO J, V30, P4500, DOI 10.1038/emboj.2011.312; Zhu H, 2011, CELL, V147, P81, DOI 10.1016/j.cell.2011.08.033	46	93	97	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2014	33	34					4296	4306		10.1038/onc.2013.385	http://dx.doi.org/10.1038/onc.2013.385			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MK	24056962	Green Accepted			2022-12-28	WOS:000341156900003
J	Wolf, J; Muller-Decker, K; Flechtenmacher, C; Zhang, F; Shahmoradgoli, M; Mills, GB; Hoheisel, JD; Boettcher, M				Wolf, J.; Mueller-Decker, K.; Flechtenmacher, C.; Zhang, F.; Shahmoradgoli, M.; Mills, G. B.; Hoheisel, J. D.; Boettcher, M.			An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation	ONCOGENE			English	Article						In vivo RNAi screening; shRNA screen; tumor suppressor; SALL1; CDH1; EMT	EPITHELIAL-MESENCHYMAL TRANSITION; TOWNES-BROCKS-SYNDROME; EXPRESSION; CELLS; CARCINOMAS; MUTATIONS; MOESIN; GENES	The gold standard for determining the tumorigenic potential of human cancer cells is a xenotransplantation into immunodeficient mice. Higher tumorigenicity of cells is associated with earlier tumor onset. Here, we used xenotransplantation to assess the tumorigenic potential of human breast cancer cells following RNA interference-mediated inhibition of over 5000 genes. We identify 16 candidate tumor suppressors, one of which is the zinc-finger transcription factor SALL1. Analyzing this particular molecule in more detail, we show that inhibition of SALL1 correlates with reduced levels of CDH1, an important contributor to epithelial-to-mesenchymal transition. Furthermore, SALL1 expression led to an increased migration and more than twice as many cells expressing a cancer stem cell signature. Also, SALL1 expression correlates with the survival of breast cancer patients. These findings cast new light on a gene that has previously been described to be relevant during embryogenesis, but not carcinogenesis.	[Wolf, J.; Hoheisel, J. D.; Boettcher, M.] Deutsch Krebsforschungszentrum, Div Funct Genome Anal, D-69120 Heidelberg, Germany; [Mueller-Decker, K.] Deutsch Krebsforschungszentrum, Core Facil Tumor Models, D-69120 Heidelberg, Germany; [Flechtenmacher, C.] Univ Heidelberg Hosp, Inst Pathol, Heidelberg, Germany; [Zhang, F.; Shahmoradgoli, M.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Texas System; UTMD Anderson Cancer Center	Hoheisel, JD (corresponding author), Deutsch Krebsforschungszentrum, Div Funct Genome Anal, Neuenheimer Feld 580, D-69120 Heidelberg, Germany.	j.hoheisel@dkfz.de		Boettcher, Michael/0000-0003-0986-4465	DKFZ; DKFZ PhD scholarship; NIH [44RR024095, 44HG003355]	DKFZ(Helmholtz Association); DKFZ PhD scholarship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by a grant from the DKFZ intramural funding program awarded to MB, and a DKFZ PhD scholarship awarded to JW. Lentiviral shRNA libraries were kindly provided and developed by Cellecta based on NIH-funded research grant support 44RR024095, 44HG003355.	Argos M, 2008, CANCER GENET CYTOGEN, V182, P69, DOI 10.1016/j.cancergencyto.2008.01.001; Bric A, 2009, CANCER CELL, V16, P324, DOI 10.1016/j.ccr.2009.08.015; Chien WW, 2011, INT J ONCOL, V38, P1741, DOI 10.3892/ijo.2011.985; Chin SF, 2007, ONCOGENE, V26, P1959, DOI 10.1038/sj.onc.1209985; de Celis JF, 2009, INT J DEV BIOL, V53, P1385, DOI 10.1387/ijdb.072408jd; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Fredebohm J, 2013, J CELL SCI, V126, P3380, DOI 10.1242/jcs.124768; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Haynes J, 2011, MOL BIOL CELL, V22, P4750, DOI 10.1091/mbc.E11-02-0119; Hill VK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-51; Hsu TH, 2012, FEBS LETT, V586, P1287, DOI 10.1016/j.febslet.2012.03.020; Jing C, 2002, JNCI-J NATL CANCER I, V94, P482; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Karantzali E, 2011, J BIOL CHEM, V286, P1037, DOI 10.1074/jbc.M110.170050; Kiefer SM, 2010, DEVELOPMENT, V137, P3099, DOI 10.1242/dev.037812; Kohlhase J, 2000, HUM MUTAT, V16, P460, DOI 10.1002/1098-1004(200012)16:6<460::AID-HUMU2>3.0.CO;2-4; Krelin Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062124; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Loi S, 2010, P NATL ACAD SCI USA, V107, P10208, DOI 10.1073/pnas.0907011107; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; May CD, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2789; Netzer C, 2001, HUM MOL GENET, V10, P3017, DOI 10.1093/hmg/10.26.3017; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Ricardo S, 2011, J CLIN PATHOL, V64, P937, DOI 10.1136/jcp.2011.090456; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Wang CC, 2012, HISTOPATHOLOGY, V61, P78, DOI 10.1111/j.1365-2559.2012.04204.x; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Zender L, 2008, CELL, V135, P852, DOI 10.1016/j.cell.2008.09.061	34	28	29	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2014	33	33					4273	4278		10.1038/onc.2013.515	http://dx.doi.org/10.1038/onc.2013.515			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MB	24292671	Green Accepted, hybrid			2022-12-28	WOS:000341155800009
J	Yao, R; Kondoh, Y; Natsume, Y; Yamanaka, H; Inoue, M; Toki, H; Takagi, R; Shimizu, T; Yamori, T; Osada, H; Noda, T				Yao, R.; Kondoh, Y.; Natsume, Y.; Yamanaka, H.; Inoue, M.; Toki, H.; Takagi, R.; Shimizu, T.; Yamori, T.; Osada, H.; Noda, T.			A small compound targeting TACC3 revealed its different spatiotemporal contributions for spindle assembly in cancer cells	ONCOGENE			English	Article						TACC3; TOGp; spindle assembly	KINETOCHORE FIBERS CONTRIBUTES; POLE ORGANIZATION; GENE-EXPRESSION; PROTEIN; MICROTUBULES; CH-TOG/XMAP215; CAPTURE; MITOSIS; MCAK	The mitotic spindle is assembled by the coordinated action of centrosomes and kinetochore microtubules. An evolutionally conserved protein family, transforming acidic coiled-coil (TACC), has been shown to be involved in this process. In humans, TACC3 is aberrantly expressed in a variety of human cancers, but its biological significance remains to be elucidated. Here, using a novel compound targeting TACC3, spindlactone (SPL), we show that the perturbation of TACC3 selectively inhibited the nucleation of centrosome microtubules in ovarian cancer cells. In contrast to centrosome microtubules, the kinetochore microtubules were robustly assembled, forming ectopic spindle poles that resulted in multipolar spindles. Interestingly, the extensive inhibition of TACC3 partially suppressed the nucleation of kinetochore microtubules. These dose-dependent effects of SPL were consistent with the results observed by the depletion of TACC3 and its binding partner, colonic and hepatic tumor overexpressed gene protein (TOGp). Although these proteins both have roles in the assembly of centrosome and kinetochore microtubules, their contributions were spatiotemporally different. Notably, SPL did not affect spindle assembly in normal cells. Furthermore, the oral administration of SPL significantly suppressed tumor growth in vivo. The unique mechanism of action of SPL not only enables it to be used as a tool to dissect the molecular basis of spindle assembly but also to provide a rationale for the use of TACC3 as a molecular target for cancer treatment. This rationale offers an opportunity to develop new strategies for cancer chemotherapy that overcome the limitations of microtubule toxins and expand their scope and clinical efficacy.	[Yao, R.; Natsume, Y.; Yamanaka, H.; Inoue, M.; Noda, T.] Japanese Fdn Canc Res, Dept Cell Biol, Inst Canc, Tokyo 1358550, Japan; [Kondoh, Y.; Takagi, R.; Shimizu, T.; Osada, H.] RIKEN, Chem Biol Core Facil, Adv Sci Inst, Saitama, Japan; [Inoue, M.; Toki, H.; Noda, T.] RIKEN, Bioresource Ctr, Team Adv Dev & Evaluat Human Dis Models, Tsukuba, Ibaraki, Japan; [Yamori, T.] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Div Mol Pharmacol, Tokyo 1358550, Japan	Japanese Foundation for Cancer Research; RIKEN; RIKEN; Japanese Foundation for Cancer Research	Yao, R (corresponding author), Japanese Fdn Canc Res, Dept Cell Biol, Inst Canc, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.	ryao@jfcr.or.jp	Osada, Hiroyuki/N-4305-2014; KONDOH, Yasumitsu/C-7461-2017; Osada, Hiroyuki/AAY-6254-2020; Noda, Tetsuo/B-1667-2016	KONDOH, Yasumitsu/0000-0002-3481-5481; 	Ministry of Education, Culture, Sports, Science and Technology of Japan; Grants-in-Aid for Scientific Research [221S0001, 26350976] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank T Hirota for providing the mCherry-CENP-A construct, K Yamazaki for preparing the cells for the JFCR cancer panels, K Honda for excellent technical support with the chemical screening and T Saito for supplying compounds from NPDepo. This study was performed as a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of Education, Culture, Sports, Science and Technology of Japan, and was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Barr AR, 2008, MOL CELL BIOL, V28, P7199, DOI 10.1128/MCB.01040-08; Brouhard GJ, 2008, CELL, V132, P79, DOI 10.1016/j.cell.2007.11.043; Bruning-Richardson A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038945; Cappell KM, 2012, MOL CELL BIOL, V32, P4131, DOI 10.1128/MCB.00686-12; Cassimeris L, 2004, MOL BIOL CELL, V15, P1580, DOI 10.1091/mbc.E03-07-0544; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; Cullen CF, 2001, NAT CELL BIOL, V3, P637, DOI 10.1038/35083025; DEBRABANDER M, 1981, CELL MOTIL CYTOSKEL, V1, P469, DOI 10.1002/cm.970010407; Fielding AB, 2011, ONCOGENE, V30, P521, DOI 10.1038/onc.2010.431; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Harrison Michael R, 2009, Clin Adv Hematol Oncol, V7, P54; Hayama S, 2006, CANCER RES, V66, P10339, DOI 10.1158/0008-5472.CAN-06-2137; Hayashi K, 1999, J CELL SCI, V112, P1149; Holmfeldt P, 2004, EMBO J, V23, P627, DOI 10.1038/sj.emboj.7600076; Jackson JR, 2007, NAT REV CANCER, V7, P107, DOI 10.1038/nrc2049; Kavallaris M, 2010, NAT REV CANCER, V10, P194, DOI 10.1038/nrc2803; Kawatani M, 2008, P NATL ACAD SCI USA, V105, P11691, DOI 10.1073/pnas.0712239105; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Khodjakov A, 2003, J CELL BIOL, V160, P671, DOI 10.1083/jcb.200208143; Kiemeney LA, 2010, NAT GENET, V42, P415, DOI 10.1038/ng.558; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Lauffart Brenda, 2005, BMC Womens Health, V5, P8, DOI 10.1186/1472-6874-5-8; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Maiato H, 2004, J CELL BIOL, V167, P831, DOI 10.1083/jcb.200407090; Mashima T, 2005, JNCI-J NATL CANCER I, V97, P765, DOI 10.1093/jnci/dji133; Miyazaki I, 2010, METHODS MOL BIOL, V669, P95, DOI 10.1007/978-1-60761-845-4_8; Peset I, 2008, TRENDS CELL BIOL, V18, P379, DOI 10.1016/j.tcb.2008.06.005; Peters DG, 2005, CANCER EPIDEM BIOMAR, V14, P1717, DOI 10.1158/1055-9965.EPI-04-0704; Radulescu AE, 2010, TRENDS CELL BIOL, V20, P214, DOI 10.1016/j.tcb.2010.01.003; Schneider L, 2007, J BIOL CHEM, V282, P29273, DOI 10.1074/jbc.M704151200; Shamma A, 2009, CANCER CELL, V15, P255, DOI 10.1016/j.ccr.2009.03.001; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Sudakin V, 2007, BIODRUGS, V21, P225, DOI 10.2165/00063030-200721040-00003; Tulu US, 2006, CURR BIOL, V16, P536, DOI 10.1016/j.cub.2006.01.060; Ulisse S, 2007, ENDOCR-RELAT CANCER, V14, P827, DOI 10.1677/ERC-07-0053; Urbanucci A, 2012, ONCOGENE, V31, P2153, DOI 10.1038/onc.2011.401; Wacker SA, 2012, NAT CHEM BIOL, V8, P235, DOI [10.1038/NCHEMBIO.779, 10.1038/nchembio.779]; Wollman R, 2005, CURR BIOL, V15, P828, DOI 10.1016/j.cub.2005.03.019; Yao R, 2012, ONCOGENE, V31, P135, DOI 10.1038/onc.2011.235; Yao R, 2007, CANCER SCI, V98, P555, DOI 10.1111/j.1349-7006.2007.00433.x	44	25	25	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2014	33	33					4242	4252		10.1038/onc.2013.382	http://dx.doi.org/10.1038/onc.2013.382			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MB	24077290				2022-12-28	WOS:000341155800006
J	Khongkow, P; Karunarathna, U; Khongkow, M; Gong, C; Gomes, AR; Yague, E; Monteiro, LJ; Kongsema, M; Zona, S; Man, EPS; Tsang, JWH; Coombes, RC; Wu, KJ; Khoo, US; Medema, RH; Freire, R; Lam, EWF				Khongkow, P.; Karunarathna, U.; Khongkow, M.; Gong, C.; Gomes, A. R.; Yague, E.; Monteiro, L. J.; Kongsema, M.; Zona, S.; Man, E. P. S.; Tsang, J. W-H; Coombes, R. C.; Wu, K-J; Khoo, U-S; Medema, R. H.; Freire, R.; Lam, E. W-F			FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance	ONCOGENE			English	Article						FOXM1; senescence; DNA damage; NBS1; epirubicin; resistance; breast cancer	STRAND BREAK REPAIR; ATR-DEPENDENT PHOSPHORYLATION; CANCER; ACTIVATION; EXPRESSION; LINKAGE; CELLS; P53	FOXM1 is implicated in genotoxic drug resistance but its mechanism of action remains elusive. We show here that FOXM1-depletion can sensitize breast cancer cells and mouse embryonic fibroblasts (MEFs) into entering epirubicin-induced senescence, with the loss of long-term cell proliferation ability, the accumulation of gamma H2AX foci, and the induction of senescence-associated beta-galactosidase activity and cell morphology. Conversely, reconstitution of FOXM1 in FOXM1-deficient MEFs alleviates the accumulation of senescence-associated gamma H2AX foci. We also demonstrate that FOXM1 regulates NBS1 at the transcriptional level through an forkhead response element on its promoter. Like FOXM1, NBS1 is overexpressed in the epirubicin-resistant MCF-7Epi(R) cells and its expression level is low but inducible by epirubicin in MCF-7 cells. Consistently, overexpression of FOXM1 augmented and FOXM1 depletion reduced NBS1 expression and epirubicin-induced ataxia-telangiectasia mutated (ATM)phosphorylation in breast cancer cells. Together these findings suggest that FOXM1 increases NBS1 expression and ATM phosphorylation, possibly through increasing the levels of the MRN(MRE11/RAD50/NBS1) complex. Consistent with this idea, the loss of P-ATM induction by epirubicin in the NBS1-deficient NBS1-LBI fibroblasts can be rescued by NBS1 reconstitution. Resembling FOXM1, NBS1 depletion also rendered MCF-7 and MCF-7Epi(R) cells more sensitive to epirubicin-induced cellular senescence. In agreement, the DNA repair-defective and senescence phenotypes in FOXM1-deficent cells can be effectively rescued by overexpression of NBS1. Moreover, overexpression of NBS1 and FOXM1 similarly enhanced and their depletion downregulated homologous recombination (HR) DNA repair activity. Crucially, overexpression of FOXM1 failed to augment HR activity in the background of NBS1 depletion, demonstrating that NBS1 is indispensable for the HR function of FOXM1. The physiological relevance of the regulation of NBS1 expression by FOXM1 is further underscored by the strong and significant correlation between nuclear FOXM1 and total NBS1 expression in breast cancer patient samples, further suggesting that NBS1 as a key FOXM1 target gene involved in DNA damage response, genotoxic drug resistance and DNA damage-induced senescence.	[Khongkow, P.; Karunarathna, U.; Khongkow, M.; Gong, C.; Gomes, A. R.; Yague, E.; Monteiro, L. J.; Kongsema, M.; Zona, S.; Coombes, R. C.; Lam, E. W-F] Imperial Coll London, Dept Surg & Canc, London W12 0NN, England; [Gong, C.; Man, E. P. S.; Khoo, U-S] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Tsang, J. W-H] Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; [Wu, K-J] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan; [Medema, R. H.] Netherlands Canc Inst, Div Cell Biol, Amsterdam, Netherlands; [Freire, R.] Hosp Univ Canarias, Inst Tecnol Biomed, Unidad Invest, San Cristobal la Laguna, Spain	Imperial College London; University of Hong Kong; University of Hong Kong; National Yang Ming Chiao Tung University; Netherlands Cancer Institute; Universidad de la Laguna	Lam, EWF (corresponding author), Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus,Cane Rd, London W12 0NN, England.	eric.lam@imperial.ac.uk	Khoo, Ui Soon/K-2041-2019; Wu, Kou-Juey/P-4654-2015; Kongsema, Mesayamas/H-3063-2017; Khoo, Ui Soon/C-1345-2014; Khoo, Ui Soon/C-4293-2009; Lam, Eric W-F/AAW-8566-2020; Freire, Raimundo/Q-7660-2019; Monteiro, Lara J/AAU-8518-2020	Khoo, Ui Soon/0000-0003-2200-7505; Khoo, Ui Soon/0000-0003-2200-7505; Lam, Eric W-F/0000-0003-1274-3576; Freire, Raimundo/0000-0003-4473-8894; Khongkow, Mattaka/0000-0002-4424-8898; Kongsema, Mesayamas/0000-0001-7146-9349; Khongkow, Pasarat/0000-0003-3068-2412; Medema, Rene/0000-0002-6754-0381; Coombes, Raoul Charles/0000-0002-4811-1100	Cancer Research UK; Breast Cancer Campaign; Fundacao para a Ciencia e a Tecnologia; Royal Thai Government Scholarships; Biotechnology and Biological Sciences Research Council [1243234] Funding Source: researchfish; Cancer Research UK [12011] Funding Source: researchfish; Breast Cancer Campaign [2012MayPR070, 2012NovPhD016] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Breast Cancer Campaign; Fundacao para a Ciencia e a Tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission); Royal Thai Government Scholarships; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Breast Cancer Campaign	EW-F Lam, AR Gomes, RC Coombes were supported by grants from Cancer Research UK, EW-F Lam and S Zona by grants from Breast Cancer Campaign, LJ Monteiro grants from Fundacao para a Ciencia e a Tecnologia, and P Khongkow, M Khongkow and M Kongsema from the Royal Thai Government Scholarships. We also thank Julie Millour for initiating the study and help with this work.	Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012293; Chiang YC, 2003, J BIOL CHEM, V278, P19286, DOI 10.1074/jbc.M212043200; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; de Olano N, 2012, MOL CANCER RES, V10, P1189, DOI 10.1158/1541-7786.MCR-11-0559; Delacote F, 2002, NUCLEIC ACIDS RES, V30, P3454, DOI 10.1093/nar/gkf452; Dupre A, 2006, NAT STRUCT MOL BIOL, V13, P451, DOI 10.1038/nsmb1090; Gorospe M, 2008, TRENDS CELL BIOL, V18, P77, DOI 10.1016/j.tcb.2007.11.007; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Helleday T, 2007, DNA REPAIR, V6, P923, DOI 10.1016/j.dnarep.2007.02.006; Kang J, 2005, MOL CELL BIOL, V25, P661, DOI 10.1128/MCB.25.2.661-670.2005; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Kobayashi J, 2004, DNA REPAIR, V3, P855, DOI 10.1016/j.dnarep.2004.03.023; Kuo LJ, 2008, IN VIVO, V22, P305; Kwok JMM, 2010, MOL CANCER RES, V8, P24, DOI 10.1158/1541-7786.MCR-09-0432; Kwok JMM, 2008, MOL CANCER THER, V7, P2022, DOI 10.1158/1535-7163.MCT-08-0188; Lam EWF, 2013, NAT REV CANCER, V13, P482, DOI 10.1038/nrc3539; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Millour J, 2010, ONCOGENE, V29, P2983, DOI 10.1038/onc.2010.47; Millour J, 2011, MOL CANCER THER, V10, P1046, DOI 10.1158/1535-7163.MCT-11-0024; Monteiro LJ, 2013, ONCOGENE, V32, P4634, DOI 10.1038/onc.2012.491; NERI B, 1989, INT J CLIN PHARM TH, V27, P388; Nowak DE, 2005, BIOTECHNIQUES, V39, P715, DOI 10.2144/000112014; Riches LC, 2008, MUTAGENESIS, V23, P331, DOI 10.1093/mutage/gen039; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Seviour EG, 2010, AGING-US, V2, P900, DOI 10.18632/aging.100248; So SR, 2009, J CELL BIOL, V187, P977, DOI 10.1083/jcb.200906064; Stearns V, 2004, PHARMACOGENOMICS J, V4, P143, DOI 10.1038/sj.tpj.6500242; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; Weinstock David M, 2007, Nat Cell Biol, V9, P978; Weinstock DM, 2006, METHOD ENZYMOL, V409, P524, DOI 10.1016/S0076-6879(05)09031-2	36	86	86	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2014	33	32					4144	4155		10.1038/onc.2013.457	http://dx.doi.org/10.1038/onc.2013.457			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YK	24141789	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000340595700005
J	Qi, J; Dong, Z; Liu, J; Zhang, JT				Qi, J.; Dong, Z.; Liu, J.; Zhang, J-T			EIF3i promotes colon oncogenesis by regulating COX-2 protein synthesis and beta-catenin activation	ONCOGENE			English	Article						eIF3i; COX-2; beta-catenin; translational control; colon cancer; RNA-binding	INTESTINAL-CELL DIFFERENTIATION; INITIATION-FACTOR EIF3; TRANSLATIONAL CONTROL; MESSENGER-RNA; CANCER; EXPRESSION; SUBUNITS; CYCLOOXYGENASE-2; REVEALS; GROWTH	Translational control of gene expression has recently been recognized as an important mechanism controlling cell proliferation and oncogenesis, and it mainly occurs in the initiation step of protein synthesis that involves multiple eukaryotic initiation factors (eIFs). Many eIFs have been found to have aberrant expression in human tumors and the aberrant expression may contribute to oncogenesis. However, how these previously considered house-keeping proteins are potentially oncogenic remains elusive. In this study, we investigated the expression of eIF3i in human colon cancers, tested its contribution to colon oncogenesis and determined the mechanism of eIF3i action in colon oncogenesis. We found that eIF3i expression was upregulated in both human colon adenocarcinoma and adenoma polyps as well as in model inducible colon tumorigenic cell lines. Overexpression of ectopic eIF3i in intestinal epithelial cells causes oncogenesis by directly upregulating the synthesis of cyclooxygenase-2 (COX-2) protein and activates the beta-catenin/T-cell factor 4 signaling pathway that mediates the oncogenic function of eIF3i. Together, we conclude that eIF3i is a proto-oncogene that drives colon oncogenesis by translationally upregulating COX-2 and activating the beta-catenin signaling pathway. These findings imply that proto-oncogenic eIFs likely exert their tumorigenic function by regulating/altering the synthesis level of downstream tumor suppressor or oncogenes.	Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; Indiana Univ Sch Med, IU Simon Canc Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Zhang, JT (corresponding author), Indiana Univ Sch Med, IU Simon Canc Ctr, Dept Pharmacol & Toxicol, 980 W Walnut St,R3-C510, Indianapolis, IN 46202 USA.	jianzhan@iupui.edu	Zhang, Jian-Ting/L-8334-2015	Zhang, Jian-Ting/0000-0002-2803-9914	NIH grant [R01 CA94961]; NATIONAL CANCER INSTITUTE [R01CA094961] Funding Source: NIH RePORTER	NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Hongmiao Sheng for the generous gift of the rat intestinal epithelial cell lines. This work was supported in part by a NIH grant R01 CA94961 (JTZ).	Ahlemann M, 2006, MOL CARCINOGEN, V45, P957, DOI 10.1002/mc.20269; Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Bernardini S, 1997, BIOCHEM BIOPH RES CO, V234, P278, DOI 10.1006/bbrc.1997.6626; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Ding QM, 1998, AM J PHYSIOL-CELL PH, V275, pC1193, DOI 10.1152/ajpcell.1998.275.5.C1193; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dong ZZ, 2006, CRIT REV ONCOL HEMAT, V59, P169, DOI 10.1016/j.critrevonc.2006.03.005; Dong ZZ, 2009, EXP CELL RES, V315, P1889, DOI 10.1016/j.yexcr.2009.03.009; Dong ZZ, 2004, ONCOGENE, V23, P3790, DOI 10.1038/sj.onc.1207465; Dong ZZ, 2003, MOL BIOL CELL, V14, P3942, DOI 10.1091/mbc.E02-12-0784; Gray SG, 2000, INT J MOL MED, V5, P33; Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Herrmannova A, 2012, NUCLEIC ACIDS RES, V40, P2294, DOI 10.1093/nar/gkr765; Kikuchi A, 2003, CANCER SCI, V94, P225, DOI 10.1111/j.1349-7006.2003.tb01424.x; Kuroda T, 2006, CANCER RES, V66, P10127, DOI 10.1158/0008-5472.CAN-06-2744; Liu RY, 2011, ONCOGENE, V30, P4814, DOI 10.1038/onc.2011.189; Liu Y, 2006, CANCER RES, V66, P3248, DOI 10.1158/0008-5472.CAN-05-3801; Liu ZQ, 2007, DIFFERENTIATION, V75, P652, DOI 10.1111/j.1432-0436.2007.00165.x; Markowitz AJ, 1995, AM J PHYSIOL-GASTR L, V269, pG925, DOI 10.1152/ajpgi.1995.269.6.G925; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Masutani M, 2007, EMBO J, V26, P3373, DOI 10.1038/sj.emboj.7601765; MATHEWS MB, 2007, TRANSLATIONAL CONTRO; Matsuda S, 2000, CANCER RES, V60, P13; Phan L, 2001, EMBO J, V20, P2954, DOI 10.1093/emboj/20.11.2954; PINTO M, 1983, BIOL CELL, V47, P323; Rauch J, 2004, BIOCHEM BIOPH RES CO, V323, P156, DOI 10.1016/j.bbrc.2004.08.071; SCHNEIDER RJ, 2007, TRANSLATIONAL CONTRO, P401; Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Sheng HM, 2001, CANCER RES, V61, P2670; Wang Y, 2013, ADV CIV ENG, V2013, DOI 10.1155/2013/189105; Yin JY, 2013, CARCINOGENESIS, V34, P1224, DOI 10.1093/carcin/bgt052; Yin JY, 2011, CLIN CANCER RES, V17, P4600, DOI 10.1158/1078-0432.CCR-10-2591; Yin JY, 2011, BIOSCIENCE REP, V31, P1, DOI 10.1042/BSR20100077; Zhang LL, 2007, J BIOL CHEM, V282, P5790, DOI 10.1074/jbc.M606284200; Zhou M, 2008, P NATL ACAD SCI USA, V105, P18139, DOI 10.1073/pnas.0801313105; Zweibaum A, 1989, ADAPTATION DEV GASTR, P103	39	32	32	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2014	33	32					4156	4163		10.1038/onc.2013.397	http://dx.doi.org/10.1038/onc.2013.397			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YK	24056964	Green Accepted, Green Submitted			2022-12-28	WOS:000340595700006
J	Bosch-Presegue, L; Vaquero, A				Bosch-Presegue, L.; Vaquero, A.			Sirtuins in stress response: guardians of the genome	ONCOGENE			English	Review						Sirtuins; genome stability; stress response; SIRT1-7; epigenetics	METHYL-TRANSFERASE SUV39H1; FOXO TRANSCRIPTION FACTORS; HISTONE DEACETYLASE SIRT6; FATTY-ACID OXIDATION; DNA-DAMAGE RESPONSE; TUMOR-SUPPRESSOR; GENE-EXPRESSION; CALORIE RESTRICTION; TELOMERE LENGTH; HOMOLOGOUS RECOMBINATION	Sirtuins, a family of NAD(+)-dependent deacetylases, help organisms to respond to metabolic and genotoxic stress through diverse pathways, including metabolic homeostasis, cell survival pathways and cell-cycle control. Evidence accumulated over the past decade, including recent descriptions of mouse knockout models for each of the seven mammalian Sirtuins, suggests that protection of genome stability is among the most important roles of Sirtuins during stress response. Our current knowledge suggests that Sirtuins promote genome integrity through a variety of mechanisms, the majority of which involve a direct role in chromatin-related functions. Here, we review these mechanisms and discuss their implications for cell physiology and tumorigenesis.	[Bosch-Presegue, L.; Vaquero, A.] Inst Invest Biomed Bellvitge IDIBEL, Canc Epigenet & Biol Program PEBC, Chromatin Biol Lab, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)	Vaquero, A (corresponding author), Hosp Llobregat, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Av Gran Via Hosp 199-203, Barcelona 08908, Spain.	avaquero@idibell.cat	Vaquero, Alejandro/I-9845-2014; Vaquero, Alejandro/ABG-8634-2020	Vaquero, Alejandro/0000-0002-8735-4156; Bosch-Presegue, Laia/0000-0001-8025-2416	Spanish Ministry of Science and Innovation (MICINN) [SAF2011-25860]; Catalonian Government Agency AGAUR [2009SGR914]; Association Francaise Ataxie de Friedreich (AFAF)	Spanish Ministry of Science and Innovation (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Catalonian Government Agency AGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); Association Francaise Ataxie de Friedreich (AFAF)	We wish to apologize to many colleagues whose work could not be cited in this review due to space limitations. We thank members of the Vaquero group for fruitful discussions. The Chromatin Biology group is supported by the Spanish Ministry of Science and Innovation (MICINN) grant SAF2011-25860, the Catalonian Government Agency AGAUR grant 2009SGR914 and a grant from the Association Francaise Ataxie de Friedreich (AFAF).	Ahn BH, 2008, P NATL ACAD SCI USA, V105, P14447, DOI 10.1073/pnas.0803790105; Allison SJ, 2007, CELL CYCLE, V6, P2669, DOI 10.4161/cc.6.21.4866; Aster JC, 2008, ANNU REV PATHOL-MECH, V3, P587, DOI 10.1146/annurev.pathmechdis.3.121806.154300; Aykin-Burns N, 2009, BIOCHEM J, V418, P29, DOI 10.1042/BJ20081258; Bae NS, 2004, J BIOCHEM, V135, P695, DOI 10.1093/jb/mvh084; Barber MF, 2012, NATURE, V487, P114, DOI 10.1038/nature11043; Binda O, 2008, ONCOGENE, V27, P3384, DOI 10.1038/sj.onc.1211014; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Boily G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001759; Bordone L, 2006, PLOS BIOL, V4, P210, DOI 10.1371/journal.pbio.0040031; Borra MT, 2002, J BIOL CHEM, V277, P12632, DOI 10.1074/jbc.M111830200; Bosch-Presegue Laia, 2011, Genes Cancer, V2, P648, DOI 10.1177/1947601911417862; Bosch-Presegue L, 2011, MOL CELL, V42, P210, DOI 10.1016/j.molcel.2011.02.034; Burkle A, 2000, BIOGERONTOLOGY, V1, P41, DOI 10.1023/A:1010089924898; Celic I, 2006, CURR BIOL, V16, P1280, DOI 10.1016/j.cub.2006.06.023; Chang CJ, 2012, BRIT J CANCER, V106, P243, DOI 10.1038/bjc.2011.551; Chen J, 2012, CANCER RES, V71, P4138; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Chua KF, 2005, CELL METAB, V2, P67, DOI 10.1016/j.cmet.2005.06.007; Cimini D, 2003, MOL BIOL CELL, V14, P3821, DOI 10.1091/mbc.E03-01-0860; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Craig JM, 2005, BIOESSAYS, V27, P17, DOI 10.1002/bies.20145; Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861; di Fagagna FD, 1999, NAT GENET, V23, P76; Dotto GP, 2008, ONCOGENE, V27, P5115, DOI 10.1038/onc.2008.225; Dryden SC, 2003, MOL CELL BIOL, V23, P3173, DOI 10.1128/MCB.23.9.3173-3185.2003; Du JT, 2011, SCIENCE, V334, P806, DOI 10.1126/science.1207861; El Ramy R, 2009, CELL MOL LIFE SCI, V66, P3219, DOI 10.1007/s00018-009-0105-4; Fan W, 2010, MOL CELL, V39, P247, DOI 10.1016/j.molcel.2010.07.006; Fatoba ST, 2011, CELL CYCLE, V10, P2317, DOI 10.4161/cc.10.14.15913; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Ford E, 2006, GENE DEV, V20, P1075, DOI 10.1101/gad.1399706; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Furukawa-Hibi Y, 2005, ANTIOXID REDOX SIGN, V7, P752, DOI 10.1089/ars.2005.7.752; Garcia-Cao M, 2004, NAT GENET, V36, P94, DOI 10.1038/ng1278; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Grob A, 2009, J CELL SCI, V122, P489, DOI 10.1242/jcs.042382; Grummt I, 2003, NAT REV MOL CELL BIO, V4, P641, DOI 10.1038/nrm1171; Gupta A, 2008, MOL CELL BIOL, V28, P397, DOI 10.1128/MCB.01045-07; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Hallows WC, 2011, MOL CELL, V41, P139, DOI 10.1016/j.molcel.2011.01.002; Han MK, 2008, CELL STEM CELL, V2, P241, DOI 10.1016/j.stem.2008.01.002; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Hassa PO, 2006, MICROBIOL MOL BIOL R, V70, P789, DOI 10.1128/MMBR.00040-05; Herranz D, 2011, CELL CYCLE, V10, P2215, DOI 10.4161/cc.10.13.16185; Hirschey MD, 2011, MOL CELL, V44, P177, DOI 10.1016/j.molcel.2011.07.019; Hirschey MD, 2010, NATURE, V464, P121, DOI 10.1038/nature08778; Hochegger H, 2006, EMBO J, V25, P1305, DOI 10.1038/sj.emboj.7601015; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Inoue T, 2007, ONCOGENE, V26, P945, DOI 10.1038/sj.onc.1209857; Inoue T, 2007, CELL CYCLE, V6, P1011, DOI 10.4161/cc.6.9.4219; Iwahara T, 2012, MOL CELL BIOL, V32, P5022, DOI 10.1128/MCB.00822-12; Jeggo PA, 1998, CURR BIOL, V8, pR49, DOI 10.1016/S0960-9822(98)70032-6; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jeong J, 2007, EXP MOL MED, V39, P8, DOI 10.1038/emm.2007.2; Jeong SM, 2013, CANCER CELL, V23, P450, DOI 10.1016/j.ccr.2013.02.024; Jia GX, 2012, MOL CELL BIOCHEM, V364, P345, DOI 10.1007/s11010-012-1236-8; Jiang H, 2013, NATURE, V496, P110, DOI 10.1038/nature12038; Jing EX, 2011, P NATL ACAD SCI USA, V108, P14608, DOI 10.1073/pnas.1111308108; Kahyo T, 2008, FEBS LETT, V582, P2479, DOI 10.1016/j.febslet.2008.06.031; Kaidi A, 2010, SCIENCE, V329, P1348, DOI 10.1126/science.1192049; Karachentsev D, 2005, GENE DEV, V19, P431, DOI 10.1101/gad.1263005; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kawahara TLA, 2009, CELL, V136, P62, DOI 10.1016/j.cell.2008.10.052; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Law IKM, 2009, PROTEOMICS, V9, P2444, DOI 10.1002/pmic.200800738; Lee CW, 2012, CANCER RES, V72, P4394, DOI 10.1158/0008-5472.CAN-12-0429; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Li K, 2008, J BIOL CHEM, V283, P7590, DOI 10.1074/jbc.M709707200; Li YZ, 2011, GENES CELLS, V16, P34, DOI 10.1111/j.1365-2443.2010.01460.x; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lombard DB, 2008, J INTERN MED, V263, P128, DOI 10.1111/j.1365-2796.2007.01902.x; Lombard DB, 2007, MOL CELL BIOL, V27, P8807, DOI 10.1128/MCB.01636-07; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Magnaghi-Jaulin L, 2006, CHROMOSOME RES, V14, P319, DOI 10.1007/s10577-006-1049-2; Mao ZY, 2012, P NATL ACAD SCI USA, V109, P11800, DOI 10.1073/pnas.1200583109; Mao ZY, 2011, SCIENCE, V332, P1443, DOI 10.1126/science.1202723; Martinez-Redondo P, 2013, GENES CANC, DOI 10.11771947601913483767; Matsushita N, 2005, GENES CELLS, V10, P321, DOI 10.1111/j.1365-2443.2005.00836.x; McAinsh AD, 1999, CURR BIOL, V9, P963, DOI 10.1016/S0960-9822(99)80424-2; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; McCord RA, 2009, AGING-US, V1, P109, DOI 10.18632/aging.100011; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Michishita E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736; Michishita E, 2009, CELL CYCLE, V8, P2664, DOI 10.4161/cc.8.16.9367; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; Min LH, 2012, NAT CELL BIOL, V14, P1203, DOI 10.1038/ncb2590; Ming M, 2010, P NATL ACAD SCI USA, V107, P22623, DOI 10.1073/pnas.1010377108; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Moss T, 2007, CELL MOL LIFE SCI, V64, P29, DOI 10.1007/s00018-006-6278-1; Mostoslavsky R, 2006, CELL, V124, P315, DOI 10.1016/J.CEL.2005.11.044; Mulligan P, 2011, MOL CELL, V42, P689, DOI 10.1016/j.molcel.2011.04.020; Murayama A, 2008, CELL, V133, P627, DOI 10.1016/j.cell.2008.03.030; Muth V, 2001, EMBO J, V20, P1353, DOI 10.1093/emboj/20.6.1353; Nakagawa T, 2009, CELL, V137, P560, DOI 10.1016/j.cell.2009.02.026; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Narala SR, 2008, MOL BIOL CELL, V19, P1210, DOI 10.1091/mbc.E07-09-0965; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; North BJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000784; North BJ, 2007, J BIOL CHEM, V282, P19546, DOI 10.1074/jbc.M702990200; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Oda H, 2009, MOL CELL BIOL, V29, P2278, DOI 10.1128/MCB.01768-08; Onyango P, 2002, P NATL ACAD SCI USA, V99, P13653, DOI 10.1073/pnas.222538099; Ou XA, 2011, BLOOD, V117, P440, DOI 10.1182/blood-2010-03-273011; Paddock MN, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000428; Palacios JA, 2010, J CELL BIOL, V191, P1299, DOI 10.1083/jcb.201005160; Palacios OM, 2009, AGING-US, V1, P771, DOI 10.18632/aging.100075; Peng C, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.012658; Peng LR, 2012, MOL CELL BIOL, V32, P2823, DOI 10.1128/MCB.00496-12; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Planavila A, 2012, J MOL CELL CARDIOL, V53, P521, DOI 10.1016/j.yjmcc.2012.07.019; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Qiu XL, 2010, CELL METAB, V12, P662, DOI 10.1016/j.cmet.2010.11.015; Raptis S, 2006, EXP SUPPL, V96, P303; Rea S, 2007, ONCOGENE, V26, P5385, DOI 10.1038/sj.onc.1210607; RINE J, 1979, GENETICS, V93, P877; Rusin M, 2009, MECH AGEING DEV, V130, P528, DOI 10.1016/j.mad.2009.06.005; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Sasaki T, 2006, AGING CELL, V5, P413, DOI 10.1111/j.1474-9726.2006.00235.x; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Scher MB, 2007, GENE DEV, V21, P920, DOI 10.1101/gad.1527307; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Schotta G, 2008, GENE DEV, V22, P2048, DOI 10.1101/gad.476008; Schwer B, 2002, J CELL BIOL, V158, P647, DOI 10.1083/jcb.200205057; Sebastian C, 2012, J BIOL CHEM, V287, P42444, DOI 10.1074/jbc.R112.402768; Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; Serrano L, 2013, GENE DEV, V27, P639, DOI 10.1101/gad.211342.112; Shen ZY, 2011, J MOL CELL BIOL, V3, P1, DOI 10.1093/jmcb/mjq057; Shimazu T, 2010, CELL METAB, V12, P654, DOI 10.1016/j.cmet.2010.11.003; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Singh KK, 2006, ANN NY ACAD SCI, V1067, P182, DOI 10.1196/annals.1354.022; Someya S, 2010, CELL, V143, P802, DOI 10.1016/j.cell.2010.10.002; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Sun YL, 2009, NAT CELL BIOL, V11, P1376, DOI 10.1038/ncb1982; Sundaresan NR, 2008, MOL CELL BIOL, V28, P6384, DOI 10.1128/MCB.00426-08; Sundaresan NR, 2009, J CLIN INVEST, V119, P2758, DOI 10.1172/JCI39162; Takata T, 2003, BIOCHEM BIOPH RES CO, V301, P250, DOI 10.1016/S0006-291X(02)03020-6; Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013; Tennen RI, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1443; Uhl M, 2010, DNA REPAIR, V9, P383, DOI 10.1016/j.dnarep.2009.12.020; Vaitiekunaite R, 2007, MECH AGEING DEV, V128, P650, DOI 10.1016/j.mad.2007.09.004; Vakhrusheva O, 2008, CIRC RES, V102, P703, DOI 10.1161/CIRCRESAHA.107.164558; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vaquero A, 2007, ONCOGENE, V26, P5505, DOI 10.1038/sj.onc.1210617; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaquero A, 2007, NATURE, V450, P440, DOI 10.1038/nature06268; Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706; Vaquero A, 2009, INT J DEV BIOL, V53, P303, DOI 10.1387/ijdb.082675av; Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Wilson JM, 2006, EMBO REP, V7, P1247, DOI 10.1038/sj.embor.7400829; Wong S, 2007, BIOCHEM J, V407, P451, DOI 10.1042/BJ20070151; Wu SM, 2010, GENE DEV, V24, P2531, DOI 10.1101/gad.1984210; Yang B, 2009, CELL CYCLE, V8, P2662, DOI 10.4161/cc.8.16.9329; Yang XJ, 2008, MOL CELL, V31, P449, DOI 10.1016/j.molcel.2008.07.002; Yang YJ, 2010, J BIOL CHEM, V285, P7417, DOI 10.1074/jbc.M109.053421; Yuan J, 2009, CELL CYCLE, V8, P1747, DOI 10.4161/cc.8.11.8620; Yuan Z, 2007, CELL CYCLE, V6, P2869, DOI 10.4161/cc.6.23.5026; Yuan Z, 2007, MOL CELL, V27, P149, DOI 10.1016/j.molcel.2007.05.029; Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041	179	62	65	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3764	3775		10.1038/onc.2013.344	http://dx.doi.org/10.1038/onc.2013.344			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23995787				2022-12-28	WOS:000339394100002
J	Drost, R; Jonkers, J				Drost, R.; Jonkers, J.			Opportunities and hurdles in the treatment of BRCA1-related breast cancer	ONCOGENE			English	Review						BRCA1; breast cancer; treatment	DNA-DAMAGE RESPONSE; INHIBITS HOMOLOGOUS RECOMBINATION; ANTICANCER DRUG CISPLATIN; CELL-CYCLE CHECKPOINT; BRCA1 MESSENGER-RNA; INTERACT IN-VIVO; POLY(ADP-RIBOSE) POLYMERASE; SPORADIC BREAST; PARP INHIBITOR; MAMMARY-TUMORS	BRCA1 functions as a classical tumor suppressor in breast and ovarian cancer. While the role of BRCA1 in homology-directed repair of DNA double-strand breaks contributes to its tumor suppressive activity, it also renders BRCA1-deficient cells highly sensitive to DNA-damaging agents. Although BRCA1 deficiency is therefore considered to be an attractive therapeutic target, re-activation of BRCA1 by secondary mutations has been shown to cause therapy resistance. In this review, we will assess the role of BRCA1 in both hereditary and sporadic breast cancer and discuss how different functionalities of the BRCA1 protein can contribute to its tumor suppressor function. In addition, we will discuss how this knowledge on BRCA1 function can help to overcome the hurdles encountered in the clinic and improve current treatment strategies for patients with BRCA1-related breast cancer.	[Jonkers, J.] Netherlands Canc Inst, Div Mol Pathol, NL-1066 CX Amsterdam, Noord Holland, Netherlands; Netherlands Canc Inst, Canc Genom Ctr Netherlands, NL-1066 CX Amsterdam, Noord Holland, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Jonkers, J (corresponding author), Netherlands Canc Inst, Div Mol Pathol, Plesmanlaan 121, NL-1066 CX Amsterdam, Noord Holland, Netherlands.	j.jonkers@nki.nl	Jonkers, Jos/AAG-3246-2019	Jonkers, Jos/0000-0002-9264-9792	European Union; TI Center for Translational Molecular Medicine (CTMM); Netherlands Organization for Scientific Research (NWO); Cancer Systems Biology Center; Cancer Genomics Centre Netherlands; Dutch Cancer Society (KWF)	European Union(European Commission); TI Center for Translational Molecular Medicine (CTMM); Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Cancer Systems Biology Center; Cancer Genomics Centre Netherlands; Dutch Cancer Society (KWF)(KWF Kankerbestrijding)	We thank Peter Bouwman and Sven Rottenberg for helpful discussions and comments on the manuscript. This work was supported by grants from the European Union, the TI Center for Translational Molecular Medicine (CTMM), the Netherlands Organization for Scientific Research (NWO), the Cancer Systems Biology Center, the Cancer Genomics Centre Netherlands and the Dutch Cancer Society (KWF).	Althuis MD, 2005, INT J EPIDEMIOL, V34, P405, DOI 10.1093/ije/dyh414; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8; Baldassarre G, 2003, MOL CELL BIOL, V23, P2225, DOI 10.1128/MCB.23.7.2225-2238.2003; Baldwin RL, 2000, CANCER RES, V60, P5329; Ben David Y, 2002, J CLIN ONCOL, V20, P463, DOI 10.1200/JCO.20.2.463; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Birkbak NJ, 2012, CANCER DISCOV, V2, P366, DOI 10.1158/2159-8290.CD-11-0206; Bordeleau L, 2010, BREAST CANCER RES TR, V119, P13, DOI 10.1007/s10549-009-0566-z; Bouwman P, 2012, NAT REV CANCER, V12, P587, DOI 10.1038/nrc3342; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Boyd J, 2000, JAMA-J AM MED ASSOC, V283, P2260, DOI 10.1001/jama.283.17.2260; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Brzovic PS, 2006, MOL CELL, V21, P873, DOI 10.1016/j.molcel.2006.02.008; Bunting SF, 2012, MOL CELL, V46, P125, DOI 10.1016/j.molcel.2012.02.015; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Byrski T, 2008, BREAST CANCER RES TR, V108, P289, DOI 10.1007/s10549-007-9600-1; Byrski T, 2009, BREAST CANCER RES TR, V115, P359, DOI 10.1007/s10549-008-0128-9; Byrski T, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3231; Byrski T, 2010, J CLIN ONCOL, V28, P375, DOI 10.1200/JCO.2008.20.7019; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Cass I, 2003, CANCER, V97, P2187, DOI 10.1002/cncr.11310; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1; Chabalier C, 2006, CELL CYCLE, V5, P1001, DOI 10.4161/cc.5.9.2726; Chalmers AJ, 2009, BRIT MED BULL, V89, P23, DOI 10.1093/bmb/ldp005; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen LC, 2008, J BIOL CHEM, V283, P7713, DOI 10.1074/jbc.M710245200; Chetrit A, 2008, J CLIN ONCOL, V26, P20, DOI 10.1200/JCO.2007.11.6905; Christensen DE, 2007, NAT STRUCT MOL BIOL, V14, P941, DOI 10.1038/nsmb1295; Clark AS, 2011, J MAMMARY GLAND BIOL, V16, P17, DOI 10.1007/s10911-011-9200-x; Clark CC, 2012, MOL CANCER THER, V11, P1948, DOI 10.1158/1535-7163.MCT-11-0597; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; Deans AJ, 2006, CANCER RES, V66, P8219, DOI 10.1158/0008-5472.CAN-05-3945; Deans AJ, 2011, NAT REV CANCER, V11, P467, DOI 10.1038/nrc3088; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Dobrovic A, 1997, CANCER RES, V57, P3347; Donawho CK, 2007, CLIN CANCER RES, V13, P2728, DOI 10.1158/1078-0432.CCR-06-3039; Drost R, 2011, CANCER CELL, V20, P797, DOI 10.1016/j.ccr.2011.11.014; Dungey FA, 2009, MOL CANCER THER, V8, P2243, DOI 10.1158/1535-7163.MCT-09-0201; Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Evers B, 2008, CLIN CANCER RES, V14, P3916, DOI 10.1158/1078-0432.CCR-07-4953; Evers B, 2010, CLIN CANCER RES, V16, P99, DOI 10.1158/1078-0432.CCR-09-2434; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fong PC, 2010, J CLIN ONCOL, V28, P2512, DOI 10.1200/JCO.2009.26.9589; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Galizia E, 2010, ANAL QUANT CYTOL, V32, P24; Gelmon KA, 2011, LANCET ONCOL, V12, P852, DOI 10.1016/S1470-2045(11)70214-5; Glover JNM, 2006, FAM CANCER, V5, P89, DOI 10.1007/s10689-005-2579-z; Guha M, 2011, NAT BIOTECHNOL, V29, P373, DOI 10.1038/nbt0511-373; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Holloman WK, 2011, NAT STRUCT MOL BIOL, V18, P748, DOI 10.1038/nsmb.2096; Holstege H, 2009, CANCER RES, V69, P3625, DOI 10.1158/0008-5472.CAN-08-3426; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; Huen MSY, 2010, NAT REV MOL CELL BIO, V11, P138, DOI 10.1038/nrm2831; Ibrahim YH, 2012, CANCER DISCOV, V2, P1036, DOI 10.1158/2159-8290.CD-11-0348; Ishida S, 2010, CANCER CELL, V17, P574, DOI 10.1016/j.ccr.2010.04.011; Jacquemont C, 2007, CANCER RES, V67, P7395, DOI 10.1158/0008-5472.CAN-07-1015; Jaspers JE, 2013, CANCER DISCOV, V3, P68, DOI 10.1158/2159-8290.CD-12-0049; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jensen RB, 2010, NATURE, V467, P678, DOI 10.1038/nature09399; Jones P, 2009, J MED CHEM, V52, P7170, DOI 10.1021/jm901188v; Joukov V, 2006, CELL, V127, P539, DOI 10.1016/j.cell.2006.08.053; Juvekar A, 2012, CANCER DISCOV, V2, P1048, DOI 10.1158/2159-8290.CD-11-0336; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kass EM, 2013, P NATL ACAD SCI USA, V110, P5564, DOI 10.1073/pnas.1216824110; Kennedy RD, 2004, JNCI-J NATL CANCER I, V96, P1659, DOI 10.1093/jnci/djh312; Kimbung S, 2012, CANCER LETT, V319, P232, DOI 10.1016/j.canlet.2012.01.015; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Krawczyk PM, 2011, P NATL ACAD SCI USA, V108, P9851, DOI 10.1073/pnas.1101053108; Kriege M, 2012, CANCER-AM CANCER SOC, V118, P899, DOI 10.1002/cncr.26351; Kummar S, 2012, CLIN CANCER RES, V18, P1726, DOI 10.1158/1078-0432.CCR-11-2821; Lafarge S, 2001, ONCOGENE, V20, P6597, DOI 10.1038/sj.onc.1204812; Li LP, 2008, CANCER RES, V68, P9141, DOI 10.1158/0008-5472.CAN-08-1127; Li ML, 2012, TRENDS BIOCHEM SCI, V37, P418, DOI 10.1016/j.tibs.2012.06.007; Liu J, 2010, NAT STRUCT MOL BIOL, V17, P1260, DOI 10.1038/nsmb.1904; Liu XS, 2012, CLIN CANCER RES, V18, P510, DOI 10.1158/1078-0432.CCR-11-1973; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; Metcalfe KA, 2010, J CLIN ONCOL, V28, P387, DOI 10.1200/JCO.2009.25.0712; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Norquist B, 2011, J CLIN ONCOL, V29, P3008, DOI 10.1200/JCO.2010.34.2980; O'Shaughnessy J, 2011, NEW ENGL J MED, V364, P205, DOI 10.1056/NEJMoa1011418; Ohta T, 2011, FEBS LETT, V585, P2836, DOI 10.1016/j.febslet.2011.05.005; Osher DJ, 2011, J CLIN PATHOL, V64, P924, DOI 10.1136/jcp.2010.086405; Ouchi T, 2006, CANCER BIOL THER, V5, P470, DOI 10.4161/cbt.5.5.2845; Pajic M, 2010, CELL CYCLE, V9, P3780, DOI 10.4161/cc.9.18.13002; Patel AG, 2012, CLIN CANCER RES, V18, P1655, DOI 10.1158/1078-0432.CCR-11-2890; Pathania S, 2011, MOL CELL, V44, P235, DOI 10.1016/j.molcel.2011.09.002; Penning TD, 2009, J MED CHEM, V52, P514, DOI 10.1021/jm801171j; Piccart MJ, 2001, ANN ONCOL, V12, P1195, DOI 10.1023/A:1012259625746; Plummer R, 2008, CLIN CANCER RES, V14, P7917, DOI 10.1158/1078-0432.CCR-08-1223; Quinn JE, 2003, CANCER RES, V63, P6221; Rabik CA, 2007, CANCER TREAT REV, V33, P9, DOI 10.1016/j.ctrv.2006.09.006; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748; Reis-Filho JS, 2008, HISTOPATHOLOGY, V52, P108, DOI 10.1111/j.1365-2559.2007.02889.x; Reis JS, 2011, LANCET, V378, P1812, DOI 10.1016/S0140-6736(11)61539-0; Rennert G, 2007, NEW ENGL J MED, V357, P115, DOI 10.1056/NEJMoa070608; Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761; Risch HA, 2006, JNCI-J NATL CANCER I, V98, P1694, DOI 10.1093/jnci/djj465; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; Rodriguez JA, 2004, EXP CELL RES, V293, P14, DOI 10.1016/j.yexcr.2003.09.027; Rottenberg S, 2008, P NATL ACAD SCI USA, V105, P17079, DOI 10.1073/pnas.0806092105; Rottenberg S, 2007, P NATL ACAD SCI USA, V104, P12117, DOI 10.1073/pnas.0702955104; Rottenberg S, 2012, CANCER RES, V72, P2350, DOI 10.1158/0008-5472.CAN-11-4201; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Russell PA, 2000, INT J CANCER, V87, P317, DOI 10.1002/1097-0215(20000801)87:3<317::AID-IJC2>3.0.CO;2-B; Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39; Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633; Sakai W, 2009, CANCER RES, V69, P6381, DOI 10.1158/0008-5472.CAN-09-1178; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shabbeer S, 2013, ONCOGENE, V32, P5005, DOI 10.1038/onc.2012.522; Shafee N, 2008, CANCER RES, V68, P3243, DOI 10.1158/0008-5472.CAN-07-5480; Shakya R, 2008, P NATL ACAD SCI US; Shakya R, 2011, SCIENCE, V334, P525, DOI 10.1126/science.1209909; Shuen AY, 2011, J MAMMARY GLAND BIOL, V16, P3, DOI 10.1007/s10911-011-9213-5; Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Swisher EM, 2008, CANCER RES, V68, P2581, DOI 10.1158/0008-5472.CAN-08-0088; Sy SMH, 2009, P NATL ACAD SCI USA, V106, P7155, DOI 10.1073/pnas.0811159106; Tassone P, 2003, BRIT J CANCER, V88, P1285, DOI 10.1038/sj.bjc.6600859; Tassone P, 2009, CANCER BIOL THER, V8, P648, DOI 10.4161/cbt.8.7.7968; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Thompson ME, 2005, J BIOL CHEM, V280, P21854, DOI 10.1074/jbc.M502676200; Thorslund T, 2010, NAT STRUCT MOL BIOL, V17, P1263, DOI 10.1038/nsmb.1905; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vollebergh MA, 2011, ANN ONCOL, V22, P1561, DOI 10.1093/annonc/mdq624; Wang B, 2007, SCIENCE, V316, P1194, DOI 10.1126/science.1139476; Wang B, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-6; Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636; Whittemore AS, 1997, AM J HUM GENET, V60, P496; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Wysocki PJ, 2008, MED SCI MONITOR, V14, pSC7; Xia B, 2006, MOL CELL, V22, P719, DOI 10.1016/j.molcel.2006.05.022; Xiang T, 2011, ONCOGENE, V30, P2443, DOI 10.1038/onc.2010.603; Xiang T, 2008, CANCER RES, V68, P10040, DOI 10.1158/0008-5472.CAN-08-3009; Xu B, 2002, CANCER RES, V62, P4588; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yang ES, 2012, CANCER RES, V72, P5547, DOI 10.1158/0008-5472.CAN-12-0934; Yang ES, 2010, FEBS J, V277, P3079, DOI 10.1111/j.1742-4658.2010.07734.x; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zamble DB, 1996, BIOCHEMISTRY-US, V35, P10004, DOI 10.1021/bi960453+; Zander SAL, 2010, CANCER RES, V70, P1700, DOI 10.1158/0008-5472.CAN-09-3367; Zhang F, 2009, MOL CANCER RES, V7, P1110, DOI 10.1158/1541-7786.MCR-09-0123; Zhang F, 2009, CURR BIOL, V19, P524, DOI 10.1016/j.cub.2009.02.018; Zhu Q, 2011, NATURE, V477, P179, DOI 10.1038/nature10371	172	20	22	0	38	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3753	3763		10.1038/onc.2013.329	http://dx.doi.org/10.1038/onc.2013.329			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23955079				2022-12-28	WOS:000339394100001
J	Tsai, LH; Chen, PM; Cheng, YW; Chen, CY; Sheu, GT; Wu, TC; Lee, H				Tsai, L-H; Chen, P-M; Cheng, Y-W; Chen, C-Y; Sheu, G-T; Wu, T-C; Lee, H.			LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas	ONCOGENE			English	Article						LKB1; NKX2-1; p53; lung adenocarcinoma	GENE-EXPRESSION; CANCER; MUTATIONS; P53; TRANSCRIPTION; SUPPRESSOR; LKB1/STK11; GENOME	LKB1 loss is a frequent homozygous deletion and/or gene mutation found in lung adenocarcinomas. However, few cases of LKB1 loss by either deletion or mutation are seen in Asian patients. Our preliminary data showed that LKB1 loss was associated with p53 mutation in lung tumors from Taiwanese adenocarcinoma patients and p53 transcription is directly regulated by NKX2-1. Therefore, we hypothesized that LKB1 loss could occur due to aberration of p53 regulation mediated by NKX2-1. In the present study, 16 lung adenocarcinoma cell lines were investigated to determine if LKB1 transcription could be deregulated by NKX2-1-mediated p53 aberration. Mechanistic studies indicated that LKB1 was directly upregulated by p53 and that NKX2-1-mediated p53 expression may positively regulate LKB1 expression in p53 wild-type cells. However, in p53-mutated cells, LKB1 transcription was deregulated by NKX2-1 via suppression of SP1 binding onto the LKB1 promoter. Therefore, the action of the NKX2-1/p53 pathway on LKB1 loss differed in p53 wild-type versus p53-mutated cells. As expected, soft-agar growth and invasion capability was significantly reduced by ectopic expression of NKX2-1 in p53 wild-type cells, but it was markedly elevated by silencing NKX2-1 in p53-mutated cells. Similar reciprocal observations were also seen in lung tumors from lung adenocarcinoma patients with either wild-type or mutated p53 tumors. Cox regression analysis showed that patients with low-LKB1 tumors had poorer overall survival (OS) and relapse-free survival (RFS) when compared with patients with high-LKB1 tumors. In p53 wild-type patients, shorter OS and RFS periods were predicted for low-NKX2-1/low-LKB1 tumors than for high-NKX2-1/high-LKB1 tumors. In patients with p53-mutated tumors, poorer OS and RFS were predicted for high-NKX2-1/low-LKB1 tumors than for low-NKX2-1/high-LKB1 tumors. In summary, losses of LKB1 at the transcriptional level by altered activity of the NKX2-1/p53 pathway may promote tumor malignancy and poor patient outcome.	[Tsai, L-H; Chen, P-M; Lee, H.] Inst Med & Mol Toxicol, Taichung, Taiwan; [Tsai, L-H; Chen, P-M; Sheu, G-T; Lee, H.] Chung Shan Med Univ, Inst Med, Taichung, Taiwan; [Cheng, Y-W; Lee, H.] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Taipei, Taiwan; [Chen, C-Y] China Med Univ Hosp, Dept Surg, Taichung, Taiwan; [Wu, T-C] Chung Shan Med Univ Hosp, Dept Internal Med, Taichung, Taiwan	Chung Shan Medical University; Taipei Medical University; China Medical University Taiwan; China Medical University Hospital - Taiwan; Chung Shan Medical University; Chung Shan Medical University Hospital	Lee, H (corresponding author), Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, 250 Wu Hsing St, Taipei 110, Taiwan.	hl@tmu.edu.tw	Sheu, Gwo-Tarng/H-8855-2019	Sheu, Gwo-Tarng/0000-0002-1299-3375	National Science Council of Taiwan, ROC [NSC99-2628-B-038-016-MY3, NSC1-100-2314-B-038-043-MY3]	National Science Council of Taiwan, ROC(Ministry of Science and Technology, Taiwan)	This work was jointly supported by Grants from the National Science Council (NSC99-2628-B-038-016-MY3 and NSC1-100-2314-B-038-043-MY3) of Taiwan, ROC.	Au NHC, 2004, J PATHOL, V204, P101, DOI 10.1002/path.1612; Carretero J, 2010, CANCER CELL, V17, P547, DOI 10.1016/j.ccr.2010.04.026; Charloux A, 1997, INT J EPIDEMIOL, V26, P14, DOI 10.1093/ije/26.1.14; Chen F, 2007, CANCER EPIDEM BIOMAR, V16, P2724, DOI 10.1158/1055-9965.EPI-07-0455; Chen JJW, 2001, CANCER RES, V61, P5223; Cheng YW, 2007, CANCER RES, V67, P10686, DOI 10.1158/0008-5472.CAN-07-1461; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Fernandez P, 2004, ONCOGENE, V23, P5084, DOI 10.1038/sj.onc.1207665; Gill RK, 2011, ONCOGENE, V30, P3784, DOI 10.1038/onc.2011.98; Gong FR, 2011, NUCLEIC ACIDS RES, V39, P4640, DOI 10.1093/nar/gkr023; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kim MJ, 2010, CANCER GENET CYTOGEN, V196, P204, DOI 10.1016/j.cancergencyto.2009.09.020; Koivunen JP, 2008, BRIT J CANCER, V99, P245, DOI 10.1038/sj.bjc.6604469; Makowski L, 2008, BRIT J CANCER, V99, P683, DOI 10.1038/sj.bjc.6604515; Matsumoto S, 2007, ONCOGENE, V26, P5911, DOI 10.1038/sj.onc.1210418; Morton JP, 2010, GASTROENTEROLOGY, V139, P586, DOI 10.1053/j.gastro.2010.04.055; Onozato R, 2007, CANCER SCI, V98, P1747, DOI 10.1111/j.1349-7006.2007.00585.x; Saad RS, 2004, HUM PATHOL, V35, P3, DOI 10.1016/j.humpath.2003.08.011; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Scott KD, 2007, CANCER RES, V67, P5622, DOI 10.1158/0008-5472.CAN-07-0762; Shiraishi K, 2012, NAT GENET, V44, P900, DOI 10.1038/ng.2353; Steger DJ, 2008, MOL CELL BIOL, V28, P2825, DOI 10.1128/MCB.02076-07; Sun YH, 2010, J CLIN ONCOL, V28, P4616, DOI 10.1200/JCO.2010.29.6038; Sung WW, 2011, CLIN CANCER RES, V17, P5991, DOI 10.1158/1078-0432.CCR-11-0227; Takeda H, 2006, ONCOGENE, V25, P1816, DOI 10.1038/sj.onc.1209207; Tang XM, 2011, CLIN CANCER RES, V17, P2434, DOI 10.1158/1078-0432.CCR-10-1412; Thun MJ, 1997, JNCI-J NATL CANCER I, V89, P1580, DOI 10.1093/jnci/89.21.1580; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; Wei CJ, 2005, CANCER RES, V65, P11297, DOI 10.1158/0008-5472.CAN-05-0716; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Wu DW, 2011, CLIN CANCER RES, V17, P1895, DOI 10.1158/1078-0432.CCR-10-2316; Wu DW, 2010, CANCER RES, V70, P10392, DOI 10.1158/0008-5472.CAN-10-2341; Wu HH, 2010, ONCOGENE, V29, P4330, DOI 10.1038/onc.2010.178; Wu YH, 2010, CANCER RES, V70, P10422, DOI 10.1158/0008-5472.CAN-10-2615; Zeng PY, 2006, CANCER RES, V66, P10701, DOI 10.1158/0008-5472.CAN-06-0999	38	29	30	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3851	3860		10.1038/onc.2013.353	http://dx.doi.org/10.1038/onc.2013.353			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23995788				2022-12-28	WOS:000339394100011
J	Petrilli, A; Copik, A; Posadas, M; Chang, LS; Welling, DB; Giovannini, M; Fernandez-Valle, C				Petrilli, A.; Copik, A.; Posadas, M.; Chang, L-S; Welling, D. B.; Giovannini, M.; Fernandez-Valle, C.			LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2	ONCOGENE			English	Article						LIMK; cell proliferation; Neurofibromatosis; schwannomas; cytoskeleton dynamics; cell cycle	NF2 TUMOR-SUPPRESSOR; COFILIN PHOSPHORYLATION; ACTIN DYNAMICS; PROTEIN-KINASE; SCHWANN-CELLS; AURORA-A; MERLIN; GENE; RAC; PROLIFERATION	Neurofibromatosis type 2 (NF2) is caused by mutations in the NF2 gene that encodes a tumor-suppressor protein called merlin. NF2 is characterized by formation of multiple schwannomas, meningiomas and ependymomas. Merlin loss-of-function is associated with increased activity of Rac and p21-activated kinases (PAKs) and deregulation of cytoskeletal organization. LIM domain kinases (LIMK1 and 2) are substrate for Cdc42/Rac-PAK and modulate actin dynamics by phosphorylating cofilin at serine-3. This modification inactivates the actin severing and depolymerizing activity of cofilin. LIMKs also translocate into the nucleus and regulate cell cycle progression. Significantly, LIMKs are overexpressed in several tumor types, including skin, breast, lung, liver and prostate. Here we report that mouse Schwann cells (MSCs) in which merlin function is lost as a result of Nf2 exon2 deletion (Nf2(Delta Ex2)) exhibited increased levels of LIMK1, LIMK2 and active phospho-Thr508/505-LIMK1/2, as well as phospho-Ser3-cofilin, compared with wild-type normal MSCs. Similarly, levels of LIMK1 and 2 total protein and active phosphorylated forms were elevated in human vestibular schwannomas compared with normal human Schwann cells (SCs). Reintroduction of wild-type NF2 into Nf2(Delta Ex2) MSC reduced LIMK1 and LIMK2 levels. We show that pharmacological inhibition of LIMK with BMS-5 decreased the viability of Nf2(Delta Ex2) MSCs in a dose-dependent manner, but did not affect viability of control MSCs. Similarly, LIMK knockdown decreased viability of Nf2(Delta Ex2) MSCs. The decreased viability of Nf2(Delta Ex2) MSCs was not due to caspase-dependent or -independent apoptosis, but rather due to inhibition of cell cycle progression as evidenced by accumulation of cells in G(2)/M phase. Inhibition of LIMKs arrests cells in early mitosis by decreasing aurora A activation. Our results suggest that LIMKs are potential drug targets for NF2 and tumors associated with merlin deficiency.	[Petrilli, A.; Copik, A.; Posadas, M.; Fernandez-Valle, C.] Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32827 USA; [Chang, L-S] Nationwide Childrens Hosp, Res Inst, Ctr Childhood Canc, Columbus, OH USA; [Chang, L-S] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Welling, D. B.] Ohio State Univ, Coll Med, Dept Otolaryngol, Columbus, OH 43210 USA; [Giovannini, M.] House Res Inst, Div Clin & Translat Res, Los Angeles, CA USA	State University System of Florida; University of Central Florida; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Fernandez-Valle, C (corresponding author), Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, 6900 Lake Nona Blvd, Orlando, FL 32827 USA.	cfv@ucf.edu	Welling, D Bradley/H-1503-2014	Welling, D. Bradley/0000-0002-9963-469X; Chang, Long-Sheng/0000-0002-5178-2992	DHHS/NIH [5R01DC10189]; Children's Tumor Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS062825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC010189] Funding Source: NIH RePORTER	DHHS/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Tumor Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We thank Dr Patrick Wood, The Miami Project to Cure Paralysis, Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, USA, for vials of cultured human Schwann cells, Dr Maria Elisa Manetti for the Halo-tag NF2 plasmid, Nicklaus Sparrow and Marga Bott for their creation of the Nf2<SUP>Delta Ex2</SUP> MSCs and Rashell Hallford for animal husbandry. This work was supported in part by a DHHS/NIH award to CF-V (5R01DC10189), and AP is the recipient of a Young Investigator Award from the Children's Tumor Foundation.	Amano T, 2002, J BIOL CHEM, V277, P22093, DOI 10.1074/jbc.M201444200; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Asthagiri AR, 2009, LANCET, V373, P1974, DOI 10.1016/S0140-6736(09)60259-2; Bagheri-Yarmand R, 2006, INT J CANCER, V118, P2703, DOI 10.1002/ijc.21650; Barr AR, 2007, J CELL SCI, V120, P2987, DOI 10.1242/jcs.013136; Baser ME, 2002, NEUROLOGY, V59, P290, DOI 10.1212/WNL.59.2.290; Bashour AM, 2002, MOL CELL BIOL, V22, P1150, DOI 10.1128/MCB.22.4.1150-1157.2002; Cote MC, 2010, J BIOL CHEM, V285, P8013, DOI 10.1074/jbc.M109.098665; Giovannini M, 2000, GENE DEV, V14, P1617; Goyal P, 2005, J BIOL CHEM, V280, P27569, DOI 10.1074/jbc.M504448200; Horita Y, 2008, J BIOL CHEM, V283, P6013, DOI 10.1074/jbc.M706538200; Hung G, 2002, INT J ONCOL, V20, P475; Iacovelli J, 2007, GLIA, V55, P1638, DOI 10.1002/glia.20578; Johnson EO, 2012, J CELL SCI, V125, P1204, DOI 10.1242/jcs.092304; Kaji N, 2008, J BIOL CHEM, V283, P4983, DOI 10.1074/jbc.M708644200; Kalamarides Michel, 2012, Acta Neuropathol, V123, P369, DOI 10.1007/s00401-011-0905-0; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Li W, 2012, EMBO REP, V13, P204, DOI 10.1038/embor.2012.11; Manetti F, 2012, CURR CANCER DRUG TAR, V12, P543, DOI 10.2174/156800912800673266; Manetti F, 2012, MED RES REV, V32, P968, DOI 10.1002/med.20230; McConnell BV, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-75; Nakai Y, 2006, J NEUROSCI, V26, P3390, DOI 10.1523/JNEUROSCI.4865-05.2006; Nikonova AS, 2013, CELL MOL LIFE SCI, V70, P661, DOI 10.1007/s00018-012-1073-7; Okamoto I, 2005, NEOPLASIA, V7, P303, DOI 10.1593/neo.04514; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; Plotkin SR, 2009, NEW ENGL J MED, V361, P358, DOI 10.1056/NEJMoa0902579; Po'uha ST, 2010, ONCOGENE, V29, P597, DOI 10.1038/onc.2009.367; Ritchey L, 2012, CELL CYCLE, V11, P296, DOI 10.4161/cc.11.2.18734; Ross-Macdonald P, 2008, MOL CANCER THER, V7, P3490, DOI 10.1158/1535-7163.MCT-08-0826; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Scott RW, 2007, J MOL MED, V85, P555, DOI 10.1007/s00109-007-0165-6; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sparrow N, 2012, J NEUROSCI, V32, P5284, DOI 10.1523/JNEUROSCI.6207-11.2012; Stamenkovic I, 2010, CURR PROTEIN PEPT SC, V11, P471, DOI 10.2174/138920310791824011; Sumi T, 2006, EXP CELL RES, V312, P1021, DOI 10.1016/j.yexcr.2005.12.030; Thaxton C, 2008, ONCOGENE, V27, P2705, DOI 10.1038/sj.onc.1210923; Thaxton C, 2011, MOL CELL NEUROSCI, V47, P1, DOI 10.1016/j.mcn.2010.12.006; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yi CL, 2008, CANCER RES, V68, P7932, DOI 10.1158/0008-5472.CAN-08-0866; Yokoo T, 2003, J BIOL CHEM, V278, P52919, DOI 10.1074/jbc.M309334200	42	33	34	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3571	3582		10.1038/onc.2013.320	http://dx.doi.org/10.1038/onc.2013.320			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23934191	Green Accepted			2022-12-28	WOS:000338941100009
J	Serres, E; Debarbieux, F; Stanchi, F; Maggiorella, L; Grall, D; Turchi, L; Burel-Vandenbos, F; Figarella-Branger, D; Virolle, T; Rougon, G; Van Obberghen-Schilling, E				Serres, E.; Debarbieux, F.; Stanchi, F.; Maggiorella, L.; Grall, D.; Turchi, L.; Burel-Vandenbos, F.; Figarella-Branger, D.; Virolle, T.; Rougon, G.; Van Obberghen-Schilling, E.			Fibronectin expression in glioblastomas promotes cell cohesion, collective invasion of basement membrane in vitro and orthotopic tumor growth in mice	ONCOGENE			English	Article						extracellular matrix; adhesion; glioma; migration; angiogenesis	EXTRACELLULAR-MATRIX COMPONENTS; STEM-LIKE CELLS; VASCULOGENIC MIMICRY; ENDOTHELIAL-CELLS; GENE-EXPRESSION; MALIGNANT GLIOMAS; ASTROCYTOMA; VIVO; ALPHA-5-BETA-1; SPHEROIDS	Glioblastoma multiforme (GBM) are highly invasive and angiogenic malignancies with a median survival time from diagnosis of <15 months. Previous work has revealed robust overexpression of fibronectin (FN) mRNA in GBM, although immunohistochemical staining of FN in these tumors is typically associated with the angiogenic vasculature. Here we sought to examine the expression of tumor cell FN and address its possible involvement in the invasive phenotype of GBM. We found that FN was expressed and assembled into fibrillar arrays in human tumors and in established GBM lines. Cultured cells spontaneously formed dense cellular networks and spheroid-like domes. Depletion of FN by targeted-short hairpin RNA expression disrupted matrix assembly and multicellular network organization by exerting profound effects on cell adhesion and motility. Although FN depletion enhanced persistent directional migration of single cells, it compromised collective invasion of spheroids through a laminin-rich matrix and sensitized cells to ionizing radiation. In orthotopic grafts, FN depletion significantly reduced tumor growth and angiogenesis. Together our results show that FN produced by the tumor cells has a role in GBM pathophysiology and they provide insights into the implications that targeting FN interactions may have for combating this dreaded disease.	[Serres, E.; Maggiorella, L.; Grall, D.; Turchi, L.; Burel-Vandenbos, F.; Virolle, T.; Van Obberghen-Schilling, E.] Univ Nice Sophia Antipolis, F-06108 Nice 2, France; [Serres, E.; Grall, D.; Turchi, L.; Burel-Vandenbos, F.; Virolle, T.; Van Obberghen-Schilling, E.] Fac Med Nice, INSERM, Inst Biol Valrose, CNRS,UMR7277,U1091, F-06034 Nice, France; [Debarbieux, F.; Stanchi, F.; Rougon, G.] Aix Marseille Univ, IBDML, CNRS, UMR7288, Marseille, France; [Burel-Vandenbos, F.] CHU Nice, Hop Pasteur, Serv Anatomopathol, F-06202 Nice, France; [Figarella-Branger, D.] Aix Marseille Univ, INSERM, UMR911, Marseille, France	UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Aix-Marseille Universite; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Van Obberghen-Schilling, E (corresponding author), Univ Nice Sophia Antipolis, CNRS, IBV, UMR7277,INSERM,U1091,UNS, Parc Valrose, F-06108 Nice 2, France.	vanobber@unice.fr	Van Obberghen-Schilling, Ellen/Q-4372-2019; Virolle, Thierry/E-5838-2016; Van Obberghen-Schilling, Ellen/O-1581-2016	Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Stanchi, Fabio/0000-0003-3393-2472; Turchi, Laurent/0000-0003-2020-5831; ROUGON, Genevieve/0000-0003-1316-8200	French National Institute of Cancer (INCa) [RS018]; French Association of Cancer Research (ARC) [4965, 5095]; National Agency for Research (JCC PathoVisu3dyn); Fondation de Recherche sur le Cerveau; Canceropole PACA; l'Agence Nationale pour la Recherche (ANR, Jeunes Chercheurs, 'GLIOMIRSTEM')	French National Institute of Cancer (INCa)(Institut National du Cancer (INCA) France); French Association of Cancer Research (ARC); National Agency for Research (JCC PathoVisu3dyn)(French National Research Agency (ANR)); Fondation de Recherche sur le Cerveau; Canceropole PACA(Region Grand-Est); l'Agence Nationale pour la Recherche (ANR, Jeunes Chercheurs, 'GLIOMIRSTEM')(French National Research Agency (ANR))	We thank Jean-Francois Michiels and Philippe Paquis (Pathology and Neurosurgery Departments of the Nice CHU) for their collaboration. We also thank Botond Cseh, Nathalie Baeza-Kallee, Clement Ricard, Sandeep Gopal and Juliette Thariat for valuable discussions, cell lines, help with intracranial xenograft experiments and statistical analyses. Patrick Stern and Richard Hynes are kindly acknowledged for providing the lentiviral vector, Aurelie Rossin for assistance with cytometry, Sebastien Schaub (PRISM Platform, CNRS-UMR6543) and the PICSIL Platform (CNRS-6216) for expert help with image analyses. Serge Marcie and Jean-Louis Fischel (Centre A. Lacassagnc) are gratefully acknowledged for helping with irradiation experiments, and Arnaud Borderie, Sandrine Destree, Coralie Hagnere et Berengere Szczepaniak for immunohistochemistry. Financial support for this work was provided by the French National Institute of Cancer (INCa, RS018), the French Association of Cancer Research (ARC 4965 to EVO-S and 5095 to GB), the National Agency for Research (JCC PathoVisu3dyn to FD), la Fondation de Recherche sur le Cerveau to FD, Canceropole PACA and l'Agence Nationale pour la Recherche (ANR Jeunes Chercheurs, 'GLIOMIRSTEM' to TV).	Argyriou AA, 2009, CRIT REV ONCOL HEMAT, V69, P199, DOI 10.1016/j.critrevonc.2008.05.005; Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; BERNSTEIN JJ, 1995, NEUROSURGERY, V36, P124, DOI 10.1227/00006123-199501000-00016; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; Burden-Gulley SM, CANC RES, V71, P5932; Casey RC, 2001, AM J PATHOL, V159, P2071, DOI 10.1016/S0002-9440(10)63058-1; Castellani P, 2002, AM J PATHOL, V161, P1695, DOI 10.1016/S0002-9440(10)64446-X; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Claes A, 2007, ACTA NEUROPATHOL, V114, P443, DOI 10.1007/s00401-007-0293-7; Colin C, 2006, ONCOGENE, V25, P2818, DOI 10.1038/sj.onc.1209305; Cseh B, 2010, J CELL SCI, V123, P3989, DOI 10.1242/jcs.073346; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Farber K, 2008, MOL CELL NEUROSCI, V39, P579, DOI 10.1016/j.mcn.2008.08.005; Friedlander DR, 1996, CANCER RES, V56, P1939; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009; Kelm JM, 2003, BIOTECHNOL BIOENG, V83, P173, DOI 10.1002/bit.10655; Lal A, 1999, CANCER RES, V59, P5403; Maglott A, 2006, CANCER RES, V66, P6002, DOI 10.1158/0008-5472.CAN-05-4105; Mahesparan R, 2003, ACTA NEUROPATHOL, V105, P49, DOI 10.1007/s00401-002-0610-0; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Martinkova E, 2010, INT J CANCER, V127, P1240, DOI 10.1002/ijc.25187; Maubant S, 2006, BLOOD, V108, P3035, DOI 10.1182/blood-2006-05-023580; Nam JM, 2010, CANCER RES, V70, P5238, DOI 10.1158/0008-5472.CAN-09-2319; Ohnishi T, 1997, CLIN EXP METASTAS, V15, P538, DOI 10.1023/A:1018422926361; Ohnishi T, 1998, CLIN EXP METASTAS, V16, P729, DOI 10.1023/A:1006532812408; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Rauch U, 2004, CELL MOL LIFE SCI, V61, P2031, DOI 10.1007/s00018-004-4043-x; Ricard C, 2013, PLOS ONE IN PRESS; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Salmenpera P, 2008, EXP CELL RES, V314, P3444, DOI 10.1016/j.yexcr.2008.09.004; Singh P, 2010, ANNU REV CELL DEV BI, V26, P397, DOI 10.1146/annurev-cellbio-100109-104020; Spencer VA, 2010, J MAMMARY GLAND BIOL, V15, P65, DOI 10.1007/s10911-010-9163-3; Stern P, 2008, P NATL ACAD SCI USA, V105, P13895, DOI 10.1073/pnas.0806907105; Tabatabai G, 2010, TARGET ONCOL, V5, P175, DOI 10.1007/s11523-010-0156-3; Ulrich TA, 2009, CANCER RES, V69, P4167, DOI 10.1158/0008-5472.CAN-08-4859; VENSTROM KA, 1993, FASEB J, V7, P996, DOI 10.1096/fasebj.7.11.8370483; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vouret-Craviari V, 2004, J CELL SCI, V117, P4559, DOI 10.1242/jcs.01331; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Yuan L, 2007, ONCOGENE, V26, P2563, DOI 10.1038/sj.onc.1210048; Yue WY, 2005, J HISTOCHEM CYTOCHEM, V53, P997, DOI 10.1369/jhc.4A6521.2005; Zamecnik J, 2005, ACTA NEUROPATHOL, V110, P435, DOI 10.1007/s00401-005-1078-5	44	93	93	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3451	3462		10.1038/onc.2013.305	http://dx.doi.org/10.1038/onc.2013.305			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23912459				2022-12-28	WOS:000338779300012
J	O'Leary, KA; Rugowski, DE; Sullivan, R; Schuler, LA				O'Leary, K. A.; Rugowski, D. E.; Sullivan, R.; Schuler, L. A.			Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas	ONCOGENE			English	Article						p53; breast cancer; prolactin; AP-1	BREAST-CANCER CELLS; TO-MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR GENE; TRANSCRIPTION FACTOR; GLAND DEVELOPMENT; MATRIX METALLOPROTEINASES; GROWTH-FACTOR; EXPRESSION; TUMORIGENESIS; AP-1	TP53 is one of the most commonly mutated genes in cancer. In breast cancer, it is mutated in about 40% of primary clinical tumors and is associated with poor survival. The mammotrophic hormone, prolactin (PRL), and/or its receptor are also expressed in many breast cancers, and accumulating epidemiologic data link PRL to breast cancer development and progression. Like TP53 mutations, evidence for PRL activity is evident across several molecular cancer subtypes, and elevated PRL expression and loss of p53 have been observed in some of the same clinical tumors. In order to examine the interaction of these factors, we used genetically modified mouse models of mammary-specific p53 loss and local overexpression of PRL. We demonstrated that mammary PRL decreased the latency of tumors in the absence of p53, and increased the proportion of triple-negative claudin-low carcinomas, which display similarities to human clinical metaplastic carcinomas. Moreover, PRL/p53(-/-) carcinomas displayed higher rates of proliferation and more aggressive behavior. Transcripts associated with cell cycle progression, invasion and stromal reactivity were differentially expressed in carcinomas that developed in the presence of elevated PRL. PRL/p53(-/-) carcinomas also exhibited selectively altered expression of activating protein-1 components, including higher levels of c-Jun and FosL1, which can drive transcription of many of these genes and the epithelial-mesenchymal transition. The ability of PRL to promote claudin-low carcinomas demonstrates that PRL can influence this subset of triple-negative breast cancers, which may have been obscured by the relative infrequency of this cancer subtype. Our findings suggest novel therapeutic approaches, and provide a preclinical model to develop possible agents.	[O'Leary, K. A.; Rugowski, D. E.; Schuler, L. A.] Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA; [Sullivan, R.; Schuler, L. A.] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Schuler, LA (corresponding author), Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, 2015 Linden Dr, Madison, WI 53706 USA.	schulerl@svm.vetmed.wisc.edu			CDMRP [W81XWH-06-1-0647]; NIH [R01CA157675]; Department of Comparative Biosciences (LAS); UWCCC Core Grant [P30 CA014520]; NATIONAL CANCER INSTITUTE [R01CA157675, P30CA014520] Funding Source: NIH RePORTER	CDMRP(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Comparative Biosciences (LAS); UWCCC Core Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciate the assistance of William Mulligan and Craig Barcus with the collagen imaging. This work was supported in part by CDMRP W81XWH-06-1-0647 (KAO), NIH R01CA157675 and funds from the Department of Comparative Biosciences (LAS) and UWCCC Core Grant P30 CA014520 (RS).	Ameyar-Zazoua M, 2005, ONCOGENE, V24, P2298, DOI 10.1038/sj.onc.1208424; Arendt LM, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2819; Arendt LM, 2009, J ENDOCRINOL, V203, P99, DOI 10.1677/JOE-09-0221; Arendt LM, 2009, AM J PATHOL, V174, P1065, DOI 10.2353/ajpath.2009.080719; Asher JM, 2012, AM J PATHOL, V181, P294, DOI 10.1016/j.ajpath.2012.03.041; Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Barcus CE, 2013, J BIOL CHEM, V288, P12722, DOI 10.1074/jbc.M112.447631; Ben-Jonathan N, 2002, TRENDS ENDOCRIN MET, V13, P245, DOI 10.1016/S1043-2760(02)00603-3; Bhatavdekar JM, 2000, EUR J SURG ONCOL, V26, P540, DOI 10.1053/ejso.2000.0943; Bhatavdekar JM, 2000, ANN SURG ONCOL, V7, P305, DOI 10.1007/s10434-000-0305-5; BHATAVDEKAR JM, 1990, CANCER, V65, P2028, DOI 10.1002/1097-0142(19900501)65:9&lt;2028::AID-CNCR2820650924&gt;3.0.CO;2-9; Camarillo IG, 2001, J ENDOCRINOL, V171, P85, DOI 10.1677/joe.0.1710085; Cardiff RD, 2010, J MAMMARY GLAND BIOL, V15, P225, DOI 10.1007/s10911-010-9184-y; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chakrabarti R, 2012, NAT CELL BIOL, V14, P1212, DOI 10.1038/ncb2607; Clevenger CV, 1997, J MAMMARY GLAND BIOL, V2, P59, DOI 10.1023/A:1026325630359; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Conklin MW, 2011, AM J PATHOL, V178, P1221, DOI 10.1016/j.ajpath.2010.11.076; Cotarla I, 2004, INT J CANCER, V108, P665, DOI 10.1002/ijc.11619; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Donehower LA, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001081; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Gass S, 2003, J MAMMARY GLAND BIOL, V8, P269, DOI 10.1023/B:JOMG.0000010029.85796.63; Ghosh AK, 2002, EXP BIOL MED, V227, P301, DOI 10.1177/153537020222700502; GINSBURG E, 1995, CANCER RES, V55, P2591; Gutzman JH, 2007, ONCOGENE, V26, P6341, DOI 10.1038/sj.onc.1210454; Gutzman JH, 2004, MOL ENDOCRINOL, V18, P3064, DOI 10.1210/me.2004-0187; Hasen NS, 2010, CANCER PREV RES, V3, P620, DOI 10.1158/1940-6207.CAPR-09-0225; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; HOLTKAMP W, 1984, INT J CANCER, V34, P323, DOI 10.1002/ijc.2910340307; Hovey RC, 2001, DEV DYNAM, V222, P192, DOI 10.1002/dvdy.1179; Howell SJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2129; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson JG, 2013, ONCOGENE, V32, P4325, DOI 10.1038/onc.2012.610; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kohrmann A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-188; Lopez-Bergami P, 2010, NAT REV CANCER, V10, P65, DOI 10.1038/nrc2681; Matthews CP, 2007, CURR CANCER DRUG TAR, V7, P317, DOI 10.2174/156800907780809723; McHale K, 2008, MODERN PATHOL, V21, P565, DOI 10.1038/modpathol.2008.7; Medina D, 2005, CANCER RES, V65, P3493, DOI 10.1158/0008.5472.CAN-04-3869; Medina D, 2003, CANCER RES, V63, P1067; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299; Meng JP, 2004, CANCER RES, V64, P5677, DOI 10.1158/0008-5472.CAN-04-1019; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; MONTES GS, 1991, MEM I OSWALDO CRUZ, V86, P1; Mujagic Z, 2004, CROAT MED J, V45, P176; Nomura T, 2005, J MED INVESTIG, V52, P1, DOI 10.2152/jmi.52.1; Oakes SR, 2007, ONCOGENE, V26, P543, DOI 10.1038/sj.onc.1209838; Oakes SR, 2008, J MAMMARY GLAND BIOL, V13, P13, DOI 10.1007/s10911-008-9069-5; Oakes SR, 2008, GENE DEV, V22, P581, DOI 10.1101/gad.1614608; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Peck AR, 2011, J CLIN ONCOL, V29, P2448, DOI 10.1200/JCO.2010.30.3552; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Ridgeway AG, 2006, ONCOGENE, V25, P3518, DOI 10.1038/sj.onc.1209391; Rose-Hellekant TA, 2003, ONCOGENE, V22, P4664, DOI 10.1038/sj.onc.1206619; Sakamoto K, 2010, ONCOGENE, V29, P5359, DOI 10.1038/onc.2010.274; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; Sharpless NE, 2002, CANCER RES, V62, P2761; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shen Q, 2008, ONCOGENE, V27, P366, DOI 10.1038/sj.onc.1210643; Shen Q, 2006, DEV BIOL, V295, P589, DOI 10.1016/j.ydbio.2006.03.042; Shen Q, 2008, CANCER PREV RES, V1, P45, DOI 10.1158/1940-6207.CAPR-08-0034; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Swaminathan G, 2008, J MAMMARY GLAND BIOL, V13, P81, DOI 10.1007/s10911-008-9068-6; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; Tworoger SS, 2008, J MAMMARY GLAND BIOL, V13, P41, DOI 10.1007/s10911-008-9063-y; Vleugel MM, 2006, HUM PATHOL, V37, P668, DOI 10.1016/j.humpath.2006.01.022; Young MR, 2006, GENE, V379, P1, DOI 10.1016/j.gene.2006.05.001; Zhang SL, 2003, ONCOGENE, V22, P2285, DOI 10.1038/sj.onc.1206257; Zhou YM, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-59	78	13	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					3075	3082		10.1038/onc.2013.278	http://dx.doi.org/10.1038/onc.2013.278			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23873024	Green Accepted			2022-12-28	WOS:000337232200014
J	Khanna, P; Chung, CY; Neves, RI; Robertson, GP; Dong, C				Khanna, P.; Chung, C-Y; Neves, R. I.; Robertson, G. P.; Dong, C.			CD82/KAI expression prevents IL-8-mediated endothelial gap formation in late-stage melanomas	ONCOGENE			English	Article						melanoma metastasis; CD82; IL-8; adhesion	DUFFY ANTIGEN RECEPTOR; CANCER-RELATED INFLAMMATION; TUMOR-SUPPRESSOR MECHANISM; METASTASIS SUPPRESSION; CELLULAR SENESCENCE; BARRIER FUNCTION; LUNG METASTASIS; CELLS; INTERLEUKIN-8; DARC	Melanoma cells facilitate endothelial gap formation, the first step during tumor transendothelial migration, which is mediated by both adhesion and endogenously produced chemokines (in particular, interleukin-8 ( IL- 8)). Tetraspanins are localized to the cell surface in cancer and participate in various functions including invasion of tissues mediated by secretion of cytokines and matrix metalloproteinases. However, little is known about the role of CD82 tetraspanins in malignant melanomas during cancer cell invasion. In this study, we investigated the functional importance of CD82 expression in melanoma-mediated gap formation by using cDNAs to induce CD82 expression in highly invasive melanoma cell lines. Results showed that CD82 expression inhibited melanoma cell-induced gap formation, melanoma cell extravasation in vitro and subsequent lung metastasis development in vivo. Mechanistic studies showed that inducible expression of CD82 in highly metastatic melanoma cells significantly increased p21 expression upon binding of Duffy antigen receptor group (DARC), inducing tumor cell senescence and interrupting IL-8-mediated vascular endothelial (VE)-cadherin disassembly. Taken together, these studies provide a rationale for using drug therapies that restore CD82 expression and inhibit IL-8 production to inhibit late-stage melanoma cell extravasation and subsequent metastasis development.	[Khanna, P.; Dong, C.] Penn State Univ, Dept Bioengn, University Pk, PA 16802 USA; [Chung, C-Y; Neves, R. I.; Robertson, G. P.] Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA; [Neves, R. I.; Robertson, G. P.] Penn State Univ, Coll Med, Dept Dermatol, Hershey, PA 17033 USA; [Neves, R. I.; Robertson, G. P.] Penn State Univ, Coll Med, Penn State Melanoma Therapeut Program, Hershey, PA 17033 USA; [Neves, R. I.] Penn State Univ, Coll Med, Cutaneous Oncol Program, Hershey, PA 17033 USA; [Neves, R. I.] Penn State Univ, Coll Med, Div Plast Surg, Dept Surg, Hershey, PA 17033 USA; [Robertson, G. P.] Penn State Univ, Coll Med, Dept Pathol, Hershey, PA 17033 USA; [Robertson, G. P.; Dong, C.] Penn State Univ, Coll Med, Penn State Melanoma Ctr, Hershey, PA 17033 USA; [Robertson, G. P.] Penn State Univ, Coll Med, Foreman Fdn Melanoma Res, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Dong, C (corresponding author), Penn State Univ, Dept Bioengn, 205 Hallowell Bldg, University Pk, PA 16802 USA.	gprobertson@psu.edu; cxd23@psu.edu	Neves, Rogerio Izar/AAV-5842-2020; Robertson, Gavin P./A-6106-2017	Neves, Rogerio Izar/0000-0003-4866-5215; Robertson, Gavin P./0000-0003-0152-2997	NIH [CA-127892-01A1, CA-125707]; American Cancer Society [RSG-04-053-01-GMC]; Foreman Foundation for Melanoma Research; Johnson & Johnson Innovative Technology Research Seed Grant Program; NATIONAL CANCER INSTITUTE [R01CA127892, R01CA125707] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Foreman Foundation for Melanoma Research; Johnson & Johnson Innovative Technology Research Seed Grant Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Chris Goodrich who kindly provided technical support. We also acknowledge Dr Meenhard Herlyn for kindly providing WM35 and WM793 cells. We thank Dr Justin Brown for letting us use his Odyssey system to develop the western blots. This work was supported by NIH Grant CA-127892-01A1, American Cancer Society Grant RSG-04-053-01-GMC and The Foreman Foundation for Melanoma Research (GPR); NIH Grants CA-125707 (CD); and Johnson & Johnson Innovative Technology Research Seed Grant Program (CD and GPR).	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Acosta JC, 2009, CANCER RES, V69, P2167, DOI 10.1158/0008-5472.CAN-08-3772; Bandyopadhyay S, 2006, NAT MED, V12, P933, DOI 10.1038/nm1444; BRODLAND DG, 1992, J AM ACAD DERMATOL, V27, P1, DOI 10.1016/0190-9622(92)70146-7; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Criscuoli ML, 2005, BLOOD, V105, P1508, DOI 10.1182/blood-2004-06-2246; Dejana E, 1999, EXP CELL RES, V252, P13, DOI 10.1006/excr.1999.4601; Dong Cheng, 2005, Molecular & Cellular Biomechanics, V2, P145; Fan T, 2011, MOL CANCER RES, V9, P418, DOI 10.1158/1541-7786.MCR-10-0511; Gabellini C, 2009, EUR J CANCER, V45, P2618, DOI 10.1016/j.ejca.2009.07.007; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gavard J, 2009, FEBS LETT, V583, P1, DOI 10.1016/j.febslet.2008.11.032; Germano G, 2008, CYTOKINE, V43, P374, DOI 10.1016/j.cyto.2008.07.014; Giuliano S, 2011, PIGM CELL MELANOMA R, V24, P295, DOI 10.1111/j.1755-148X.2010.00820.x; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Houben R, 2009, J INVEST DERMATOL, V129, P406, DOI 10.1038/jid.2008.214; Huh SJ, 2010, CANCER RES, V70, P6071, DOI 10.1158/0008-5472.CAN-09-4442; Iiizumi M, 2007, CANCER RES, V67, P1411, DOI 10.1158/0008-5472.CAN-06-3801; Ishikawa F, 2003, CANCER SCI, V94, P944, DOI 10.1111/j.1349-7006.2003.tb01382.x; Khanna P, 2010, AM J PHYSIOL-CELL PH, V298, pC1140, DOI 10.1152/ajpcell.00242.2009; Leong SR, 1997, PROTEIN SCI, V6, P609; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Liang S, 2008, CELL MOL BIOENG, V1, P189, DOI 10.1007/s12195-008-0016-8; Liu SC, 2009, CANCER LETT, V286, P240, DOI 10.1016/j.canlet.2009.05.038; Liu WM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051797; LLeonart ME, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-3; Lombardi DP, 1999, CANCER RES, V59, P5724; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Murdoch C, 1999, CYTOKINE, V11, P704, DOI 10.1006/cyto.1998.0465; Nagasawa K, 2006, J CELL PHYSIOL, V208, P123, DOI 10.1002/jcp.20647; NICOLSON GL, 1982, J HISTOCHEM CYTOCHEM, V30, P214, DOI 10.1177/30.3.7061823; PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311; Peng HH, 2005, FRONT BIOSCI-LANDMRK, V10, P1597, DOI 10.2741/1643; Peng HH, 2007, EXP CELL RES, V313, P551, DOI 10.1016/j.yexcr.2006.10.030; Romanska HM, 2011, J PATHOL, V223, P4, DOI 10.1002/path.2779; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Sharma A, 2006, CANCER RES, V66, P8200, DOI 10.1158/0008-5472.CAN-06-0809; Shevde LA, 2003, CANCER LETT, V198, P1, DOI 10.1016/S0304-3835(03)00304-5; Singethan Katrin, 2008, Commun Integr Biol, V1, P11; Singh RK, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-57; Singh RK, 2000, HISTOL HISTOPATHOL, V15, P843, DOI 10.14670/HH-15.843; SINGH RK, 1994, CANCER RES, V54, P3242; Singh S, 2009, CANCER RES, V69, P411, DOI 10.1158/0008-5472.CAN-08-3378; Takaoka A, 1998, JPN J CANCER RES, V89, P397, DOI 10.1111/j.1349-7006.1998.tb00577.x; Tran MA, 2008, CANCER RES, V68, P7638, DOI 10.1158/0008-5472.CAN-07-6614; Tsai YC, 2011, FEBS LETT, V585, P3166, DOI 10.1016/j.febslet.2011.08.031; VERIN AD, 1995, AM J PHYSIOL-LUNG C, V269, pL99, DOI 10.1152/ajplung.1995.269.1.L99; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130; Wu SW, 2012, ARCH IRAN MED, V15, P707, DOI 0121511/AIM.0012; Xu CF, 2009, FASEB J, V23, P3273, DOI 10.1096/fj.08-123414; Zarbock A, 2010, AM J PHYSIOL-LUNG C, V298, pL462, DOI 10.1152/ajplung.00224.2009; Zijlstra A, 2006, CANCER CELL, V10, P177, DOI 10.1016/j.ccr.2006.08.012; Zoller M, 2009, NAT REV CANCER, V9, P40, DOI 10.1038/nrc2543	55	22	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2898	2908		10.1038/onc.2013.249	http://dx.doi.org/10.1038/onc.2013.249			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23873025				2022-12-28	WOS:000337231800009
J	Li, X; Liu, Y; Granberg, KJ; Wang, Q; Moore, LM; Ji, P; Gumin, J; Sulman, EP; Calin, GA; Haapasalo, H; Nykter, M; Shmulevich, I; Fuller, GN; Lang, FF; Zhang, W				Li, X.; Liu, Y.; Granberg, K. J.; Wang, Q.; Moore, L. M.; Ji, P.; Gumin, J.; Sulman, E. P.; Calin, G. A.; Haapasalo, H.; Nykter, M.; Shmulevich, I.; Fuller, G. N.; Lang, F. F.; Zhang, W.			Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma	ONCOGENE			English	Article							CHROMOSOME 9P21 DELETIONS; TUMOR STEM-CELLS; MOLECULAR PROCESSES; GROWTH; IDENTIFICATION; EXPRESSION; MICRORNA; IGFBP2; GENE; PATHWAY	MIR-491 is commonly co-deleted with its adjacent CDKN2A on chromosome 9p21.3 in glioblastoma multiforme (GBM). However, it is not known whether deletion of MIR-491 is only a passenger event or has an important role. Small-RNA sequencing of samples from GBM patients demonstrated that both mature products of MIR-491 (miR-491-5p and -3p) are downregulated in tumors compared with the normal brain. The integration of GBM data from The Cancer Genome Atlas (TCGA), miRNA target prediction and reporter assays showed that miR-491-5p directly targets EGFR, CDK6 and Bcl-xL, whereas miR-491-3p targets IGFBP2 and CDK6. Functionally, miR-491-3p inhibited glioma cell invasion; overexpression of both miR-491-5p and -3p inhibited proliferation of glioma cell lines and impaired the propagation of glioma stem cells (GSCs), thereby prolonging survival of xenograft mice. Moreover, knockdown of miR-491-5p in primary Ink4a-Arf-null mouse glial progenitor cells exacerbated cell proliferation and invasion. Therefore, MIR-491 is a tumor suppressor gene that, by utilizing both mature forms, coordinately controls the key cancer hallmarks: proliferation, invasion and stem cell propagation.	[Li, X.; Liu, Y.; Granberg, K. J.; Moore, L. M.; Ji, P.; Fuller, G. N.; Zhang, W.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Li, X.; Wang, Q.] Fourth Mil Med Univ, Dept Biochem & Mol Biol, State Key Lab Canc Biol, Xian 710032, Peoples R China; [Granberg, K. J.; Nykter, M.] Tampere Univ Technol, Dept Signal Proc, FIN-33101 Tampere, Finland; [Granberg, K. J.; Haapasalo, H.] Fimlab Labs, Dept Pathol, Tampere, Finland; [Granberg, K. J.; Haapasalo, H.] Univ Tampere, FIN-33101 Tampere, Finland; [Gumin, J.; Lang, F. F.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; [Sulman, E. P.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA; [Calin, G. A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Calin, G. A.; Zhang, W.] Univ Texas MD Anderson Canc Ctr, Noncoding RNA Ctr, Houston, TX 77030 USA; [Nykter, M.] Univ Tampere, Inst Biomed Technol, FIN-33101 Tampere, Finland; [Shmulevich, I.] Inst Syst Biol, Seattle, WA USA	University of Texas System; UTMD Anderson Cancer Center; Air Force Military Medical University; Tampere University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Tampere University; Institute for Systems Biology (ISB)	Zhang, W (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd Unit 85, Houston, TX 77030 USA.	wzhang@mdanderson.org	Calin, George/E-9390-2011	Sulman, Erik/0000-0003-4933-9120; Rautajoki, Kirsi Johanna/0000-0001-6549-7810; Calin, George/0000-0002-7427-0578; Calin, George/0000-0001-6704-5615; Fuller, Gregory/0000-0001-9447-2647; Nykter, Matti/0000-0001-6956-2843	National Institutes of Health [CA098503, CA141432, CA143835, CA115729, CA127001]; Broach Foundation; Gene Pennebaker Brain Cancer Fund; Academy of Finland [259038]; Fourth Military Medical University [4138C4IA1Z]; American Cancer Society; IVY Foundation; Elias Foundation; NATIONAL CANCER INSTITUTE [R56CA098503, R01CA141432, R01CA098503, U24CA143835, P30CA016672, R01CA115729, P50CA127001] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Broach Foundation; Gene Pennebaker Brain Cancer Fund; Academy of Finland(Academy of Finland); Fourth Military Medical University; American Cancer Society(American Cancer Society); IVY Foundation; Elias Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciate Xinna Zhang at the MicroRNA Core Facility for help with miRNA hybridization experiments, Zhimin Lu at the Department of Neuro-Oncology-Research for helpful comments, and Kathryn L Hale at the Department of Scientific Publications at MD Anderson Cancer Center for manuscript editing. This work was supported by grants from the National Institutes of Health (CA098503 to WZ and IS, CA141432 and CA143835 to WZ and CA115729 and CA127001 to FFL), IVY, Elias and Broach Foundations, the Gene Pennebaker Brain Cancer Fund, and the Academy of Finland (grant 259038 to KG); Xia Li was supported by a fellowship from The Fourth Military Medical University (4138C4IA1Z). Lynette Moore was supported by a fellowship from the American Cancer Society.	Ayuso-Sacido A, 2010, J NEURO-ONCOL, V97, P323, DOI 10.1007/s11060-009-0035-x; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Beukelaers P, 2011, STEM CELLS, V29, P713, DOI 10.1002/stem.616; Bexell D, 2013, CANCER TREAT REV, V39, P358, DOI 10.1016/j.ctrv.2012.06.006; Brockschmidt A, 2012, BRAIN, V135, P1027, DOI 10.1093/brain/aws045; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Das S, 2008, NAT CLIN PRACT NEURO, V4, P427, DOI 10.1038/ncpneuro0862; Dong JT, 2001, CANCER METAST REV, V20, P173, DOI 10.1023/A:1015575125780; Dunlap SM, 2007, P NATL ACAD SCI USA, V104, P11736, DOI 10.1073/pnas.0703145104; Feng JJ, 2012, CANCER-AM CANCER SOC, V118, P232, DOI 10.1002/cncr.26250; Fukushima T, 2007, J BIOL CHEM, V282, P18634, DOI 10.1074/jbc.M609567200; Fuxe J, 2000, CELL GROWTH DIFFER, V11, P373; Griffero F, 2009, J BIOL CHEM, V284, P7138, DOI 10.1074/jbc.M807111200; Guessous F, 2010, CELL CYCLE, V9, P1031, DOI 10.4161/cc.9.6.10987; Gursky S, 2001, CANCER GENET CYTOGEN, V129, P93, DOI 10.1016/S0165-4608(01)00444-7; Hai C, 2012, CHIN J CANCER, V31, P233, DOI 10.5732/cjc.011.10367; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He H, 2010, J PROTEOME RES, V9, P2098, DOI 10.1021/pr900793a; Hegi ME, 2011, MOL CANCER THER, V10, P1102, DOI 10.1158/1535-7163.MCT-11-0048; Holmes KM, 2012, P NATL ACAD SCI USA, V109, P3475, DOI 10.1073/pnas.1120375109; Hsieh D, 2010, BIOCHEM BIOPH RES CO, V397, P367, DOI 10.1016/j.bbrc.2010.05.145; Hwang DW, 2011, BIOMATERIALS, V32, P4968, DOI 10.1016/j.biomaterials.2011.03.047; Jiang H, 2007, J NATL CANCER I, V99, P1410, DOI 10.1093/jnci/djm102; Jin X, 2011, CANCER RES, V71, P7125, DOI 10.1158/0008-5472.CAN-11-1330; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Kim BN, 2005, INT J ONCOL, V26, P1217; Kohno T, 2006, DNA REPAIR, V5, P1273, DOI 10.1016/j.dnarep.2006.05.021; Lee EJ, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-7; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Mirimanoff RO, 2014, CHIN J CANCER, V33, P1, DOI 10.5732/cjc.013.10215; Moore LM, 2013, J PATHOL, V229, P449, DOI 10.1002/path.4109; Moore LM, 2009, P NATL ACAD SCI USA, V106, P16675, DOI 10.1073/pnas.0900807106; Nakano H, 2010, INT J CANCER, V127, P1072, DOI 10.1002/ijc.25143; Papagiannakopoulos T, 2012, ONCOGENE, V31, P1884, DOI 10.1038/onc.2011.380; Parker BC, 2013, J CLIN INVEST, V123, P855, DOI 10.1172/JCI67144; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110; Sasaki S, 2003, ONCOGENE, V22, P3792, DOI 10.1038/sj.onc.1206589; Sato M, 2005, GENE CHROMOSOME CANC, V44, P405, DOI 10.1002/gcc.20253; Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Soeda A, 2008, J BIOL CHEM, V283, P10958, DOI 10.1074/jbc.M704205200; Testa JR, 1997, CANCER GENET CYTOGEN, V95, P20, DOI 10.1016/S0165-4608(96)00337-8; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang GK, 2006, J BIOL CHEM, V281, P14085, DOI 10.1074/jbc.M513686200; Wang H, 2003, CANCER RES, V63, P4315; Yan W, 2011, BRAIN RES, V1411, P108, DOI 10.1016/j.brainres.2011.07.002; Yin J, 2011, MOL THER, V19, P1161, DOI 10.1038/mt.2011.28; Zhang W, 2007, CANCER BIOL THER, V6, P995; Zhou ZM, 2011, CANCER BIOTHER RADIO, V26, P77, DOI 10.1089/cbr.2010.0857	55	69	72	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1619	1628		10.1038/onc.2014.98	http://dx.doi.org/10.1038/onc.2014.98			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24747968	Green Accepted			2022-12-28	WOS:000351848400002
J	Mishra, R; Thorat, D; Soundararajan, G; Pradhan, SJ; Chakraborty, G; Lohite, K; Karnik, S; Kundu, GC				Mishra, R.; Thorat, D.; Soundararajan, G.; Pradhan, S. J.; Chakraborty, G.; Lohite, K.; Karnik, S.; Kundu, G. C.			Semaphorin 3A upregulates FOXO 3a-dependent MelCAM expression leading to attenuation of breast tumor growth and angiogenesis	ONCOGENE			English	Article							PROSTATE-CANCER CELLS; TRANSCRIPTION FACTORS; ANDROGEN RECEPTOR; HUMAN-MELANOMA; PTEN; AKT; APOPTOSIS; NEUROPILIN-1; KINASE; PHOSPHORYLATION	Semaphorin 3A (Sema 3A), a member of semaphorin family, serves as a guidance clue during embryonic development and is known as a candidate tumor suppressor that attenuates breast tumor progression by binding with its co-receptor, neuropilin-1 (NRP-1). However, the underlying mechanism by which Sema 3A suppresses breast tumor growth is still unexplored. In this study, we report that Sema 3A regulates phosphorylation and nuclear translocation of phosphatase and tensin homolog (PTEN) and FOXO 3a. Moreover, Sema 3A controls NRP-1-mediated PTEN-dependent FOXO 3a activation. Overexpression of PTEN and FOXO 3a enhances Sema 3A-induced attenuation of breast cancer cell migration. Chromatin immunoprecipitation and electrophoretic mobility shift assay data revealed that FOXO 3a regulates MelCAM at the transcriptional level. Furthermore, Sema 3A induces NRP-1-mediated MelCAM expression through PTEN and FOXO 3a. The data also showed that vascular endothelial growth factor-induced angiogenesis is inhibited by Sema 3A. Loss of or gain in function study revealed that Sema 3A modulates phosphorylation of PTEN and FOXO 3a and expression of MelCAM, leading to suppression of tumor growth and angiogenesis using in vivo mice model. Clinical specimen analysis revealed that reduced expression of Sema 3A and p-PTEN are correlated with enhanced breast cancer progression, further strengthening our in vitro and in vivo findings. Correlation of relapse-free survival of breast cancer patients (n = 2878) with expression levels of Sema 3A, NRP-1, FOXO 3a and MelCAM were studied by Kaplan-Meier analysis. Statistical analysis revealed a close association between reduced expression of Sema 3A and MelCAM with that of poor patient's survival. Our study demonstrated a novel mechanism of regulation of tumor suppression by Sema 3A in coordination with a chain of tumor-suppressor genes, which in turn inhibits breast cancer cell migration, tumor growth and angiogenesis.	[Mishra, R.; Thorat, D.; Soundararajan, G.; Pradhan, S. J.; Kundu, G. C.] Natl Ctr Cell Sci, Lab Tumor Biol Angiogenesis & Nanomed Res, Pune 411007, Maharashtra, India; [Chakraborty, G.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Lohite, K.; Karnik, S.] Ruby Hall Clin, Grant Med Fdn, Pune, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS); Memorial Sloan Kettering Cancer Center	Kundu, GC (corresponding author), Natl Ctr Cell Sci, Lab Tumor Biol Angiogenesis & Nanomed Res, NCCS Complex, Pune 411007, Maharashtra, India.	kundu@nccs.res.in	Kundu, Gopal C./ABA-9897-2020; Chakraborty, Goutam/U-5559-2019; MISHRA, ROSALIN/L-4319-2017	MISHRA, ROSALIN/0000-0002-9808-8797; Pradhan, Saurabh Jagdish/0000-0002-5306-9138	Council of Scientific and Industrial Research (CSIR); Department of Science and Technology (DST), Government of India; CSIR; DST, Government of India	Council of Scientific and Industrial Research (CSIR)(Council of Scientific & Industrial Research (CSIR) - India); Department of Science and Technology (DST), Government of India(Department of Science & Technology (India)); CSIR(Council of Scientific & Industrial Research (CSIR) - India); DST, Government of India(Department of Science & Technology (India))	We thank Dr B Ramanamurthy, In-charge, Experimental Animal Facility, NCCS for breeding and maintaining NOD-SCID mice. This work was supported by a grant from the Council of Scientific and Industrial Research (CSIR) (to RM and GS) and the Department of Science and Technology (DST) (to DT), Government of India. Financial support: This project was funded by the CSIR and DST, Government of India.	Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Acevedo LM, 2008, BLOOD, V111, P2674, DOI 10.1182/blood-2007-08-110205; American Cancer Society, 2013, CANC FACTS FIG 2013; Arden KC, 2007, CELL, V128, P235, DOI 10.1016/j.cell.2007.01.009; Bachelder RE, 2003, CANCER RES, V63, P5230; Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Bouchard C, 2004, EMBO J, V23, P2830, DOI 10.1038/sj.emboj.7600279; Castro-Rivera E, 2008, CANCER RES, V68, P8295, DOI 10.1158/0008-5472.CAN-07-6601; Chadborn NH, 2006, J CELL SCI, V119, P951, DOI 10.1242/jcs.02801; Chakraborty G, 2006, J BIOL CHEM, V281, P11322, DOI 10.1074/jbc.M512546200; Chakraborty G, 2008, CANCER RES, V68, P152, DOI 10.1158/0008-5472.CAN-07-2126; Chakraborty G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033633; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Emerling BM, 2008, P NATL ACAD SCI USA, V105, P2622, DOI 10.1073/pnas.0706790105; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Gabrovska PN, 2011, GENE, V489, P63, DOI 10.1016/j.gene.2011.08.024; Gil A, 2006, MOL BIOL CELL, V17, P4002, DOI 10.1091/mbc.E06-05-0380; Glauser DA, 2007, J ENDOCRINOL, V193, P195, DOI 10.1677/JOE-06-0191; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Jain S, 2008, CANCER RES, V68, P7750, DOI 10.1158/0008-5472.CAN-07-6689; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kumar V, 2010, CANCER RES, V70, P10381, DOI 10.1158/0008-5472.CAN-10-1470; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; Li G, 2003, ONCOGENE, V22, P6891, DOI 10.1038/sj.onc.1206819; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Liu JL, 2005, MOL CELL BIOL, V25, P6211, DOI 10.1128/MCB.25.14.6211-6224.2005; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nasarre C, 2010, ONCOGENE, V29, P2381, DOI 10.1038/onc.2010.9; Nho RS, 2010, J BIOL CHEM, V285, P14195, DOI 10.1074/jbc.M109.052845; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Potente M, 2005, J CLIN INVEST, V115, P2382, DOI 10.1172/JCI23126; Raja R, 2014, ONCOGENE, V33, P2053, DOI 10.1038/onc.2013.171; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rampalli S, 2005, MOL CELL BIOL, V25, P8415, DOI 10.1128/MCB.25.19.8415-8429.2005; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Satyamoorthy K, 2001, ONCOGENE, V20, P4676, DOI 10.1038/sj.onc.1204616; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Sharma P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-178; Shi IM, 1999, J PATHOL, V189, P4, DOI 10.1002/(SICI)1096-9896(199909)189:1<4::AID-PATH332>3.0.CO;2-P; Shih IM, 1997, AM J PATHOL, V151, P745; Sinha S, 2010, EMBO J, V29, P830, DOI 10.1038/emboj.2009.395; Staton CA, 2011, HISTOPATHOLOGY, V59, P274, DOI 10.1111/j.1365-2559.2011.03922.x; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Vacca A, 2006, BLOOD, V108, P1661, DOI 10.1182/blood-2006-04-014563; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Wang L, 2007, 2007 IEEE SYMPOSIUM ON COMPUTATIONAL INTELLIGENCE IN SECURITY AND DEFENSE APPLICATIONS, P1; Xie SH, 1997, CANCER RES, V57, P2295; Yacoub M, 2009, HISTOPATHOLOGY, V55, P392, DOI 10.1111/j.1365-2559.2009.03406.x; Yang L, 2005, J BIOL CHEM, V280, P33558, DOI 10.1074/jbc.M504461200; Yazdani U, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-3-211	59	41	44	0	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1584	1595		10.1038/onc.2014.79	http://dx.doi.org/10.1038/onc.2014.79			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24727891				2022-12-28	WOS:000351416800011
J	Li, H; Jiang, X; Yu, Y; Huang, W; Xing, H; Agar, NY; Yang, HW; Yang, B; Carroll, RS; Johnson, MD				Li, H.; Jiang, X.; Yu, Y.; Huang, W.; Xing, H.; Agar, N. Y.; Yang, H. W.; Yang, B.; Carroll, R. S.; Johnson, M. D.			KAP regulates ROCK2 and Cdk2 in an RNA-activated glioblastoma invasion pathway	ONCOGENE			English	Article							CYCLIN-DEPENDENT KINASES; RHO-KINASE; HEPATOCELLULAR-CARCINOMA; PROTEIN PHOSPHATASE; CENTROSOME DUPLICATION; CELL INVASION; TUMOR-GROWTH; LIGHT-CHAIN; IN-VIVO; METASTASIS	Aberrant splicing of the cyclin-dependent kinase-associated phosphatase, KAP, promotes glioblastoma invasion in a Cdc2-dependent manner. However, the mechanism by which this occurs is unknown. Here we show that miR-26a, which is often amplified in glioblastoma, promotes invasion in phosphatase and tensin homolog (PTEN)-competent and PTEN-deficient glioblastoma cells by directly downregulating KAP expression. Mechanistically, we find that KAP binds and activates ROCK2. Thus, RNA-mediated downregulation of KAP leads to decreased ROCK2 activity and this, in turn, increases Rac1-mediated invasion. In addition, the decrease in KAP expression activates the cyclin-dependent kinase, Cdk2, and this directly promotes invasion by increasing retinoblastoma phosphorylation, E2F-dependent Cdc2 expression and Cdc2-mediated inactivation of the actomyosin inhibitor, caldesmon. Importantly, glioblastoma cell invasion mediated by this pathway can be antagonized by Cdk2/Cdc2 inhibitors in vitro and in vivo. Thus, two distinct RNA-based mechanisms activate this novel KAP/ROCK2/Cdk2-dependent invasion pathway in glioblastoma.	[Li, H.; Jiang, X.; Yu, Y.; Huang, W.; Xing, H.; Agar, N. Y.; Yang, H. W.; Yang, B.; Carroll, R. S.; Johnson, M. D.] Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02446 USA; [Li, H.; Jiang, X.; Yu, Y.; Huang, W.; Xing, H.; Agar, N. Y.; Yang, H. W.; Yang, B.; Carroll, R. S.; Johnson, M. D.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Li, H.; Yang, B.] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou 450052, Peoples R China; [Johnson, M. D.] Program Neuro Oncol, Dana Farber Brigham, Boston, MA USA; [Johnson, M. D.] Womens Canc Ctr, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Zhengzhou University	Johnson, MD (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02138 USA.	mjohnson27@partners.org			National Institute of Neurological Disorders and Stroke [R01 NS062219]; National Institutes of Health Director's New Innovator Award [DP2OD002319]; Brain Science Foundation Research Award; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS062219] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD002319] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institutes of Health Director's New Innovator Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Brain Science Foundation Research Award; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by R01 NS062219 from the National Institute of Neurological Disorders and Stroke, a National Institutes of Health Director's New Innovator Award (DP2OD002319) and a Brain Science Foundation Research Award to MDJ.	Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; Bales E, 2005, CANCER RES, V65, P692; Berthet C, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-10; Corsino PE, 2008, NEOPLASIA, V10, P1240, DOI 10.1593/neo.08710; Ferretti R, 2010, DEV CELL, V18, P486, DOI 10.1016/j.devcel.2009.12.020; Han IS, 2007, J CELL SCI, V120, P246, DOI 10.1242/jcs.03322; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409; Jacobs M, 2006, J BIOL CHEM, V281, P260, DOI 10.1074/jbc.M508847200; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kim H, 2010, P NATL ACAD SCI USA, V107, P2183, DOI 10.1073/pnas.0909896107; Kim TM, 2011, CANCER RES, V71, P3387, DOI 10.1158/0008-5472.CAN-10-4117; Knights MJ, 2012, BRAIN PATHOL, V22, P592, DOI 10.1111/j.1750-3639.2012.00573.x; Kwiatkowska A, 2013, ADV EXP MED BIOL, V986, P121, DOI 10.1007/978-94-007-4719-7_7; Lee SW, 2000, MOL CELL BIOL, V20, P1723, DOI 10.1128/MCB.20.5.1723-1732.2000; Li JQ, 2002, HUM PATHOL, V33, P1006, DOI 10.1053/hupa.2002.125774; Li JQ, 2001, HUM PATHOL, V32, P945, DOI 10.1053/hupa.2001.27116; Lin WR, 2013, ONCOL REP, V29, P903, DOI 10.3892/or.2012.2208; Liu BN, 2012, BBA-MOL BASIS DIS, V1822, P1692, DOI 10.1016/j.bbadis.2012.07.019; Lowery DM, 2007, EMBO J, V26, P2262, DOI 10.1038/sj.emboj.7601683; Ma Z, 2006, MOL CELL BIOL, V26, P9016, DOI 10.1128/MCB.01383-06; Morrison DL, 1996, BIOCHEM CELL BIOL, V74, P549, DOI 10.1139/o96-459; Mrugala MM, 2013, DISCOV MED, V15, P221; Nalepa G, 2013, J CELL BIOL, V201, P997, DOI 10.1083/jcb.201205125; Pandithage R, 2008, J CELL BIOL, V180, P915, DOI 10.1083/jcb.200707126; Salhia B, 2005, CANCER RES, V65, P8792, DOI 10.1158/0008-5472.CAN-05-0160; SATTERWHITE LL, 1992, J CELL BIOL, V118, P595, DOI 10.1083/jcb.118.3.595; Tawara S, 2007, J CARDIOVASC PHARM, V50, P195, DOI 10.1097/FJC.0b013e31806befe6; Wang HF, 2011, CANCER RES, V71, P68, DOI 10.1158/0008-5472.CAN-10-0030; Wilkinson S, 2005, NAT CELL BIOL, V7, P255, DOI 10.1038/ncb1230; Yamaguchi H, 2006, STRUCTURE, V14, P589, DOI 10.1016/j.str.2005.11.024; Yang HW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-301; Yang X, 2013, HEPATOLOGY, V58, P158, DOI 10.1002/hep.26305; Yeh CT, 2000, CANCER RES, V60, P4697; Yoneda A, 2005, J CELL BIOL, V170, P443, DOI 10.1083/jcb.200412043; Yu L, 2013, ONCOL LETT, V5, P1223, DOI 10.3892/ol.2013.1173; Yu Y, 2007, CANCER RES, V67, P130, DOI 10.1158/0008-5472.CAN-06-2478	37	17	18	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1432	1441		10.1038/onc.2014.49	http://dx.doi.org/10.1038/onc.2014.49			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24704824				2022-12-28	WOS:000350806500009
J	Wu, TS; Tan, CT; Chang, CC; Lin, BR; Lai, WT; Chen, ST; Kuo, MYP; Rau, CL; Jaw, FS; Chang, HH				Wu, T-S; Tan, C-T; Chang, C-C; Lin, B-R; Lai, W-T; Chen, S-T; Kuo, M. Yen-Ping; Rau, C-L; Jaw, F-S; Chang, H-H			B-cell lymphoma/leukemia 10 promotes oral cancer progression through STAT1/ATF4/S100P signaling pathway	ONCOGENE			English	Article							NF-KAPPA-B; S100 PROTEINS; PANCREATIC-CANCER; EPITHELIAL-CELLS; GENE-EXPRESSION; NECK-CANCER; ACTIVATION; BCL10; BINDING; METASTASIS	B-cell lymphoma/leukemia 10 (BCL10) is an apoptotic regulatory protein related to advanced TNM stage and disease recurrence in oral squamous cell carcinoma (OSCC). However, the regulatory mechanism of BCL10 in OSCC progression is still unknown. Here, we showed that knockdown of endogenous BCL10 could significantly reduce cell migration and invasion abilities, retard cell proliferation by G(0)/G(1) phase accumulation and inhibit tumorigenicity in vivo. In molecular level, we identified S100P as a crucial downstream effector of BCL10-inhibited OSCC progression by high-throughput microarray analysis. S100P messenger RNA and protein expression levels were significantly diminished in silenced-BCL10 clones, and transfected S100P expression plasmids restored migration, invasion, proliferation abilities and tumorigenicity in shBCL10 transfectants. Furthermore, we provided evidence that BCL10 regulated S100P expression through signal transducers and activators of transcription 1 (STAT1) and activating transcription factor 4 (ATF4). Knockdown of BCL10 decreased S100P promoter activity, but showed no effect in truncated STAT1/ATF4 S100P promoter. In addition, we also found that the P50/P65 signaling pathway was involved in BCL10-enhanced OSCC progression. Restored S100P in silenced-BCL10 clones could markedly reverse P65 activation via outside-in signaling. Taken together, we discovered a novel axis of BCL10-regulated OSCC progression via STAT1/ATF4/S100P/P65 signaling, which could predict the prognosis of OSCC and will be beneficial for developing therapeutic strategy against advanced OSCC.	[Wu, T-S; Chang, C-C; Lai, W-T] Natl Taiwan Univ, Sch Dent, Grad Inst Oral Biol, Taipei 100, Taiwan; [Tan, C-T] Natl Taiwan Univ Hosp, Dept Otolaryngol, Taipei, Taiwan; [Lin, B-R] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; [Chen, S-T] Natl Taiwan Univ Hosp, Dept Pediat, Taipei 10016, Taiwan; [Chen, S-T] Natl Taiwan Univ Hosp, Dept Pediat, YunLin Branch, Taipei 10016, Taiwan; [Kuo, M. Yen-Ping; Chang, H-H] Natl Taiwan Univ, Sch Dent, Dept Dent, Taipei 100, Taiwan; [Kuo, M. Yen-Ping; Chang, H-H] Natl Taiwan Univ, Sch Dent, Grad Inst Clin Dent, Taipei 100, Taiwan; [Rau, C-L; Jaw, F-S] Natl Taiwan Univ, Inst Biomed Engn, Taipei 100, Taiwan; [Rau, C-L] Taipei Med Univ, Shuang Ho Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University; Taipei Medical University; Shuang Ho Hospital	Chang, HH (corresponding author), Natl Taiwan Univ, Sch Dent, Dept Dent, 1 Chang Te St, Taipei 100, Taiwan.	changhh@ntu.edu.tw		LIN, BEEN-REN/0000-0001-8354-1758; Chen, Szu-Ta/0000-0002-9715-1221; Tan, Ching-Ting/0000-0001-8317-2235	National Science Council, Taiwan [NSC-100-2314-B-002-097, NSC-101-2314-B-002-102]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by grants from National Science Council, Taiwan NSC-100-2314-B-002-097 (to C-CC), NSC-101-2314-B-002-102 (to H-HC).	Arumugam T, 2004, J BIOL CHEM, V279, P5059, DOI 10.1074/jbc.M310124200; Austermann J, 2008, J BIOL CHEM, V283, P29331, DOI 10.1074/jbc.M806145200; Averboukh L, 1996, PROSTATE, V29, P350; Bertram J, 1998, ANTI-CANCER DRUG, V9, P311, DOI 10.1097/00001813-199804000-00004; Bhattacharyya S, 2008, J BIOL CHEM, V283, P10550, DOI 10.1074/jbc.M708833200; BOYLE P, 1995, EUR J CANCER, V31A, P1395, DOI 10.1016/0959-8049(95)00334-F; Cancemi P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-476; Chang HH, 2009, ORAL ONCOL, V45, P589, DOI 10.1016/j.oraloncology.2008.08.003; Da Silva IDCG, 2000, INT J ONCOL, V16, P231; Diederichs S, 2004, CANCER RES, V64, P5564, DOI 10.1158/0008-5472.CAN-04-2004; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hacker Hans, 2006, Sci STKE, V2006, pre13, DOI 10.1126/stke.3572006re13; Haddad RI, 2008, NEW ENGL J MED, V359, P1143, DOI 10.1056/NEJMra0707975; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Holzmann K, 2004, CANCER RES, V64, P4428, DOI 10.1158/0008-5472.CAN-04-0431; Huttunen HJ, 2002, CANCER RES, V62, P4805; Jiang T, 2011, CANCER RES, V71, P2183, DOI 10.1158/0008-5472.CAN-10-3626; Klemm S, 2007, P NATL ACAD SCI USA, V104, P134, DOI 10.1073/pnas.0608388103; Koltzscher M, 2003, MOL BIOL CELL, V14, P2372, DOI 10.1091/mbc.E02-09-0553; Lee SH, 1999, CANCER RES, V59, P5674; Logsdon CD, 2003, CANCER RES, V63, P2649; Martin D, 2009, J BIOL CHEM, V284, P6038, DOI 10.1074/jbc.C800207200; McAllister-Lucas LM, 2007, P NATL ACAD SCI USA, V104, P139, DOI 10.1073/pnas.0601947103; NEGRI E, 1993, CANCER EPIDEM BIOMAR, V2, P189; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Parkkila S, 2008, BMC CLIN PATHOL, V8, DOI 10.1186/1472-6890-8-2; Salama I, 2008, EJSO-EUR J SURG ONC, V34, P357, DOI 10.1016/j.ejso.2007.04.009; Sato N, 2002, ANAT REC, V267, P60, DOI 10.1002/ar.10085; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Shyu RY, 2003, J BIOMED SCI, V10, P313, DOI 10.1159/000070096; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Wang DH, 2007, P NATL ACAD SCI USA, V104, P145, DOI 10.1073/pnas.0601894104; Whiteman HJ, 2007, CANCER RES, V67, P8633, DOI 10.1158/0008-5472.CAN-07-0545; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Wutzl A, 2007, J ORAL MAXIL SURG, V65, P255, DOI 10.1016/j.joms.2006.09.007; Yao R, 2007, HISTOL HISTOPATHOL, V22, P1025, DOI 10.14670/HH-22.1025; Yeh PY, 2006, J BIOL CHEM, V281, P167, DOI 10.1074/jbc.M511014200	39	10	11	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1207	1219		10.1038/onc.2014.43	http://dx.doi.org/10.1038/onc.2014.43			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24681956				2022-12-28	WOS:000350687100001
J	Subramanian, M; Francis, P; Bilke, S; Li, XL; Hara, T; Lu, X; Jones, MF; Walker, RL; Zhu, Y; Pineda, M; Lee, C; Varanasi, L; Yang, Y; Martinez, LA; Luo, J; Ambs, S; Sharma, S; Wakefield, LM; Meltzer, PS; Lal, A				Subramanian, M.; Francis, P.; Bilke, S.; Li, X. L.; Hara, T.; Lu, X.; Jones, M. F.; Walker, R. L.; Zhu, Y.; Pineda, M.; Lee, C.; Varanasi, L.; Yang, Y.; Martinez, L. A.; Luo, J.; Ambs, S.; Sharma, S.; Wakefield, L. M.; Meltzer, P. S.; Lal, A.			A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis	ONCOGENE			English	Article							P53 MUTANTS; ACTIVATION; P63; P73; MYC; EXPRESSION; REPRESSION; MICRORNAS; GAIN; TRANSACTIVATION	Most p53 mutations in human cancers are missense mutations resulting in a full-length mutant p53 protein. Besides losing tumor suppressor activity, some hotspot p53 mutants gain oncogenic functions. This effect is mediated in part, through gene expression changes due to inhibition of p63 and p73 by mutant p53 at their target gene promoters. Here, we report that the tumor suppressor microRNA let-7i is downregulated by mutant p53 in multiple cell lines expressing endogenous mutant p53. In breast cancer patients, significantly decreased let-7i levels were associated with missense mutations in p53. Chromatin immunoprecipitation and promoter luciferase assays established let-7i as a transcriptional target of mutant p53 through p63. Introduction of let-7i to mutant p53 cells significantly inhibited migration, invasion and metastasis by repressing a network of oncogenes including E2F5, LIN28B, MYC and NRAS. Our findings demonstrate that repression of let-7i expression by mutant p53 has a key role in enhancing migration, invasion and metastasis.	[Subramanian, M.; Francis, P.; Bilke, S.; Li, X. L.; Hara, T.; Jones, M. F.; Walker, R. L.; Zhu, Y.; Pineda, M.; Meltzer, P. S.; Lal, A.] NCI, Genet Branch, NIH, Bethesda, MD 20892 USA; [Lu, X.; Sharma, S.] Howard Univ, Dept Biochem & Mol Biol, Coll Med, Washington, DC 20059 USA; [Lee, C.; Luo, J.] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA; [Varanasi, L.; Martinez, L. A.] Univ Mississippi, Med Ctr, Inst Canc, Dept Biochem, Jackson, MS 39216 USA; [Yang, Y.; Wakefield, L. M.] NCI, Lab Canc Biol & Genet, NIH, Bethesda, MD 20892 USA; [Ambs, S.] NCI, Lab Human Carcinogenesis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Mississippi; University of Mississippi Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lal, A (corresponding author), NCI, Regulatory RNAs & Canc Sect, Genet Branch, NIH, Bldg 37,Room 6134,37 Convent Dr, Bethesda, MD 20892 USA.	ashish.lal@nih.gov	Sharma, Sudha/AAV-6152-2021; Wakefield, Lalage M/M-1963-2017	Sharma, Sudha/0000-0003-2765-2482; Wakefield, Lalage M/0000-0003-4124-5250; Ambs, Stefan/0000-0001-7651-9309; Walker, Robert/0000-0001-8235-4686	Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research; National Institute of General Medical Sciences of the National Institutes of Health [SC1GM093999]; NATIONAL CANCER INSTITUTE [ZIABC011091, ZIABC011399, ZIABC011400] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [SC1GM093999] Funding Source: NIH RePORTER	Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of General Medical Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research. Sudha Sharma was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number SC1GM093999. We thank K Prasanth, W Bodmer, B Hassel, M Thomas, J Lieberman and M Gorospe for their comments on this manuscript. We thank B Vogelstein for the DLD1 isogenic cell lines, K Vousden for the H1299-EV and H1299-p53R273H cells, S O'Hara for the pGL4-let-7i and Z Mourelators for the Ago2 (2A8) antibody.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chang TC, 2009, P NATL ACAD SCI USA, V106, P3384, DOI 10.1073/pnas.0808300106; Chi SW, 2012, NAT STRUCT MOL BIOL, V19, P321, DOI 10.1038/nsmb.2230; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Djuranovic S, 2012, SCIENCE, V336, P237, DOI 10.1126/science.1215691; Do PM, 2012, GENE DEV, V26, P830, DOI 10.1101/gad.181685.111; Dong P, 2013, ONCOGENE, V32, P3286, DOI 10.1038/onc.2012.334; Esquela-Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834; Forman JJ, 2008, P NATL ACAD SCI USA, V105, P14879, DOI 10.1073/pnas.0803230105; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Girardini JE, 2011, CANCER CELL, V20, P79, DOI 10.1016/j.ccr.2011.06.004; Guo YQ, 2006, GENE, V384, P51, DOI 10.1016/j.gene.2006.07.011; Hamano R, 2012, BRIT J CANCER, V106, P1415, DOI 10.1038/bjc.2012.90; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hermeking H, 2012, NAT REV CANCER, V12, P613, DOI 10.1038/nrc3318; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; King CE, 2011, ONCOGENE, V30, P4185, DOI 10.1038/onc.2011.131; Lal A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002363; Lal A, 2009, MOL CELL, V35, P610, DOI 10.1016/j.molcel.2009.08.020; Li Y, 2007, ONCOGENE, V26, P2220, DOI 10.1038/sj.onc.1210311; Liu K, 2011, MOL CELL BIOL, V31, P4464, DOI 10.1128/MCB.05574-11; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Muller PAJ, 2013, ONCOGENE, V32, P1252, DOI 10.1038/onc.2012.148; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Neilsen PM, 2013, ONCOGENE, V32, P2992, DOI 10.1038/onc.2012.305; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; O'Hara SP, 2010, J BIOL CHEM, V285, P216, DOI 10.1074/jbc.M109.041640; Prueitt RL, 2007, INT J CANCER, V120, P796, DOI 10.1002/ijc.22336; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Scian MJ, 2005, MOL CELL BIOL, V25, P10097, DOI 10.1128/MCB.25.22.10097-10110.2005; Stambolsky P, 2010, CANCER CELL, V17, P273, DOI 10.1016/j.ccr.2009.11.025; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Thomas M, 2010, NAT STRUCT MOL BIOL, V17, P1169, DOI 10.1038/nsmb.1921; Thomson DW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055214; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.97; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Yang WH, 2012, NAT CELL BIOL, V14, P366, DOI 10.1038/ncb2455; Zhu H, 2011, CELL, V147, P81, DOI 10.1016/j.cell.2011.08.033	53	55	55	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1094	1104		10.1038/onc.2014.46	http://dx.doi.org/10.1038/onc.2014.46			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662829	Green Accepted			2022-12-28	WOS:000350122100003
J	Tomiyama, L; Sezaki, T; Matsuo, M; Ueda, K; Kioka, N				Tomiyama, L.; Sezaki, T.; Matsuo, M.; Ueda, K.; Kioka, N.			Loss of Dlg5 expression promotes the migration and invasion of prostate cancer cells via Girdin phosphorylation	ONCOGENE			English	Article							BINDING PROTEIN GIRDIN; G-ALPHA-I; DOWN-REGULATION; KINASE; METASTASIS; MOTILITY; RECEPTOR; GROWTH; GIV; DIFFERENTIATION	Dlg5 has been reported to participate in cancer progression; however, its role in prostate cancer still remains poorly understood. In this study, we demonstrate that Dlg5 is frequently downregulated in prostate cancer. We show here that Dlg5 is involved in the regulation of cell migration and cancer cell invasion. Knockdown of endogenous Dlg5 markedly increased prostate cancer cell migration and invasion. Our studies, for the first time, demonstrate the interaction between Dlg5 and Girdin, an actin-binding Akt substrate. Importantly, we found that levels of Akt-mediated Girdin phosphorylation (p-Girdin-Ser1416) are increased in Dlg5-depleted cells. Small interfering RNA directed against Girdin and wortmannin treatment, which was found to reduce Girdin phosphorylation, impaired the effect of Dlg5 depletion on cell migration. Taken together, our findings demonstrate that Dlg5 interacts with and inhibits the activity of Girdin, thereby suppressing the migration of prostate cancer cells.	[Tomiyama, L.; Sezaki, T.; Matsuo, M.; Ueda, K.; Kioka, N.] Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Kyoto 6068502, Japan; [Ueda, K.] Kyoto Univ, Inst Integrated Cell Mat Sci iCeMS, Kyoto 6068502, Japan	Kyoto University; Kyoto University	Kioka, N (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan.	nkioka@kais.kyoto-u.ac.jp		Ueda, Kazumitsu/0000-0003-2980-6078; Kioka, Noriyuki/0000-0002-2708-537X	Asahi Glass Foundation; Ministry of Education, Culture, Sports, Science and Technology of Japan; Bio-oriented Technology Research Advancement Institution; Grants-in-Aid for Scientific Research [26660291] Funding Source: KAKEN	Asahi Glass Foundation; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Bio-oriented Technology Research Advancement Institution; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported in part by the Asahi Glass Foundation, a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and a grant from the Bio-oriented Technology Research Advancement Institution.	Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Aranjuez G, 2012, G3-GENES GENOM GENET, V2, P1379, DOI 10.1534/g3.112.004093; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chang YJ, 2010, CELL CYCLE, V9, P1990, DOI 10.4161/cc.9.10.11730; Enomoto A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001; Enomoto A, 2009, NEURON, V63, P774, DOI 10.1016/j.neuron.2009.08.015; Gan Y, 2010, ONCOGENE, V29, P4947, DOI 10.1038/onc.2010.240; Garcia-Marcos M, 2011, MOL BIOL CELL, V22, P673, DOI 10.1091/mbc.E10-08-0738; Garcia-Marcos M, 2011, FASEB J, V25, P590, DOI 10.1096/fj.10-167304; Garcia-Marcos M, 2009, P NATL ACAD SCI USA, V106, P3178, DOI 10.1073/pnas.0900294106; Ghosh P, 2008, J CELL BIOL, V182, P381, DOI 10.1083/jcb.200712066; Ghosh P, 2010, MOL BIOL CELL, V21, P2338, DOI 10.1091/mbc.E10-01-0028; Goel HL, 2008, ENDOCR-RELAT CANCER, V15, P657, DOI 10.1677/ERC-08-0019; Hong SK, 2011, EXP CELL RES, V317, P2671, DOI 10.1016/j.yexcr.2011.08.008; Jiang P, 2008, CANCER RES, V68, P1310, DOI 10.1158/0008-5472.CAN-07-5111; Kitamura T, 2008, NAT CELL BIOL, V10, P329, DOI 10.1038/ncb1695; Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272; Lee YC, 2013, MOL CANCER RES, V11, P405, DOI 10.1158/1541-7786.MCR-12-0551; Lopez-Sanchez I, 2013, P NATL ACAD SCI USA, V110, P5510, DOI 10.1073/pnas.1303392110; Miyake H, 2011, CIRC RES, V108, P1170, DOI 10.1161/CIRCRESAHA.110.236174; Nakamura H, 1998, FEBS LETT, V433, P63, DOI 10.1016/S0014-5793(98)00882-5; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Natsume A, 2012, ONCOGENE, V31, P2715, DOI 10.1038/onc.2011.466; Nechiporuk T, 2007, DEV CELL, V13, P338, DOI 10.1016/j.devcel.2007.07.017; Nechiporuk T, 2013, DEV BIOL, V377, P375, DOI 10.1016/j.ydbio.2013.02.019; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Sezaki T, 2013, FEBS LETT, V587, P1624, DOI 10.1016/j.febslet.2013.04.015; Sezaki T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035519; Shah C, 2002, BMC GENOMICS, V3; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Smolen GA, 2010, GENE DEV, V24, P2654, DOI 10.1101/gad.1989110; Stoll M, 2004, NAT GENET, V36, P476, DOI 10.1038/ng1345; Taniuchi K, 2005, CANCER RES, V65, P105; Umemoto T, 2009, BIOCHEM BIOPH RES CO, V387, P191, DOI 10.1016/j.bbrc.2009.07.009; Wakabayashi M, 2003, J BIOL CHEM, V278, P21709, DOI 10.1074/jbc.M211004200; Woollard DJ, 2013, PROSTATE, V73, P563, DOI 10.1002/pros.22596; Yamashita H, 2011, J BIOL CHEM, V286, P3907, DOI 10.1074/jbc.M110.145409	37	22	24	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1141	1149		10.1038/onc.2014.31	http://dx.doi.org/10.1038/onc.2014.31			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662825				2022-12-28	WOS:000350122100007
J	Camacho, CV; Todorova, PK; Hardebeck, MC; Tomimatsu, N; del Alcazar, CRG; Ilcheva, M; Mukherjee, B; McEllin, B; Vemireddy, V; Hatanpaa, K; Story, MD; Habib, AA; Murty, VV; Bachoo, R; Burma, S				Camacho, C. V.; Todorova, P. K.; Hardebeck, M. C.; Tomimatsu, N.; del Alcazar, C. R. Gil; Ilcheva, M.; Mukherjee, B.; McEllin, B.; Vemireddy, V.; Hatanpaa, K.; Story, M. D.; Habib, A. A.; Murty, V. V.; Bachoo, R.; Burma, S.			DNA double-strand breaks cooperate with loss of Ink4 and Arf tumor suppressors to generate glioblastomas with frequent Met amplification	ONCOGENE			English	Article							CENTRAL-NERVOUS-SYSTEM; IONIZING-RADIATION; GROWTH-FACTOR; LET RADIATION; BRAIN-TUMORS; STEM-CELLS; CANCER; GLIOMAS; REPAIR; EXPRESSION	Glioblastomas (GBM) are highly radioresistant and lethal brain tumors. Ionizing radiation (IR)-induced DNA double-strand breaks (DSBs) are a risk factor for the development of GBM. In this study, we systematically examined the contribution of IR-induced DSBs to GBM development using transgenic mouse models harboring brain-targeted deletions of key tumor suppressors frequently lost in GBM, namely Ink4a, Ink4b, Arf and/or PTEN. Using low linear energy transfer (LET) X-rays to generate simple breaks or high LET HZE particles (Fe ions) to generate complex breaks, we found that DSBs induce high-grade gliomas in these mice which, otherwise, do not develop gliomas spontaneously. Loss of Ink4a and Arf was sufficient to trigger IR-induced glioma development but additional loss of Ink4b significantly increased tumor incidence. We analyzed IR-induced tumors for copy number alterations to identify oncogenic changes that were generated and selected for as a consequence of stochastic DSB events. We found Met amplification to be the most significant oncogenic event in these radiation-induced gliomas. Importantly, Met activation resulted in the expression of Sox2, a GBM cancer stem cell marker, and was obligatory for tumor formation. In sum, these results indicate that radiation-induced DSBs cooperate with loss of Ink4 and Arf tumor suppressors to generate high-grade gliomas that are commonly driven by Met amplification and activation.	[Camacho, C. V.; Todorova, P. K.; Hardebeck, M. C.; Tomimatsu, N.; del Alcazar, C. R. Gil; Ilcheva, M.; Mukherjee, B.; Story, M. D.; Burma, S.] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA; [McEllin, B.; Vemireddy, V.; Habib, A. A.; Bachoo, R.] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Hatanpaa, K.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Habib, A. A.] VA North Texas Hlth Care Syst, Dallas, TX USA; [Murty, V. V.] Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, New York, NY USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA North Texas Health Care System; Columbia University	Burma, S (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Div Mol Radiat Biol, 2201 Inwood Rd,NC7-214E, Dallas, TX 75390 USA.	sandeep.burma@utsouthwestern.edu	Story, Michael/AAX-2864-2021; Camacho, Cristel/Q-6197-2017	Story, Michael/0000-0001-6522-4169; Camacho, Cristel/0000-0003-1723-579X; vemireddy, vamsidhara/0000-0001-7068-6640	National Aeronautics and Space Administration [NNX13AI13G]; National Institutes of Health [RO1 CA149461, R01 NS062080]; Cancer Prevention and Research Institute of Texas [RP100644]; National Institute of General Medical Sciences [5T32GM008203]; NCI training [T32CA124334]; NATIONAL CANCER INSTITUTE [R01CA149461, T32CA124334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS062080] Funding Source: NIH RePORTER	National Aeronautics and Space Administration(National Aeronautics & Space Administration (NASA)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas; National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI training(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	SB is supported by grants from the National Aeronautics and Space Administration (NNX13AI13G), National Institutes of Health (RO1 CA149461) and the Cancer Prevention and Research Institute of Texas(RP100644). AAH is supported by a National Institutes of Health grant (R01 NS062080). MCH is supported by a National Institute of General Medical Sciences training grant 5T32GM008203 in cellular and molecular biology. CVC was supported by a NCI training grant (T32CA124334). CVC completed this work in partial fulfillment of the requirements for her PhD degree. We thank Dr Chaitanya Nirodi for valuable advice on cloning and lentivirus production strategies. We also thank the support staff at the NASA Space Radiation Research Laboratory, Brookhaven National Laboratory, Upton, NY, USA, for facilitating particle radiation experiments.	Attolini CSO, 2010, P NATL ACAD SCI USA, V107, P17604, DOI 10.1073/pnas.1009117107; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; BIGNER SH, 1990, CANCER RES, V50, P8017; Bondy ML, 2008, CANCER-AM CANCER SOC, V113, P1953, DOI 10.1002/cncr.23741; Camacho CV, 2010, CARCINOGENESIS, V31, P1889, DOI 10.1093/carcin/bgq153; Chef T, 2008, RADIAT RES, V170, P553, DOI 10.1667/RR1393.1; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Costes SV, 2006, RADIAT RES, V165, P505, DOI 10.1667/RR3538.1; De Bacco F, 2012, CANCER RES, V72, P4537, DOI 10.1158/0008-5472.CAN-11-3490; De Bacco F, 2011, J NATL CANCER I, V103, P645, DOI 10.1093/jnci/djr093; Durante M, 2008, NAT REV CANCER, V8, P465, DOI 10.1038/nrc2391; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; FISCHER U, 1995, GENE CHROMOSOME CANC, V12, P63, DOI 10.1002/gcc.2870120111; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Hambardzumyan D, 2011, GLIA, V59, P1155, DOI 10.1002/glia.21142; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Isaka F, 1999, EUR J NEUROSCI, V11, P2582, DOI 10.1046/j.1460-9568.1999.00699.x; Joo KM, 2012, CANCER RES, V72, P3828, DOI 10.1158/0008-5472.CAN-11-3760; Jun HJ, 2012, ONCOGENE, V31, P3039, DOI 10.1038/onc.2011.474; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; Laterra J, 1997, BIOCHEM BIOPH RES CO, V235, P743, DOI 10.1006/bbrc.1997.6853; Li YQ, 2005, CANCER RES, V65, P9355, DOI 10.1158/0008-5472.CAN-05-1946; Li YQ, 2011, P NATL ACAD SCI USA, V108, P9951, DOI 10.1073/pnas.1016912108; Liu W, 2011, J CLIN NEUROSCI, V18, P119, DOI 10.1016/j.jocn.2010.05.010; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Mukherjee B, 2008, DNA REPAIR, V7, P1717, DOI 10.1016/j.dnarep.2008.06.016; Mukherjee B, 2009, CANCER RES, V69, P4252, DOI 10.1158/0008-5472.CAN-08-4853; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1330, DOI 10.1056/NEJM199111073251902; Okayasu R, 2012, INT J CANCER, V130, P991, DOI 10.1002/ijc.26445; Paulino AC, 2008, INT J RADIAT ONCOL, V71, P1381, DOI 10.1016/j.ijrobp.2007.12.018; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Purow B, 2009, NAT REV NEUROL, V5, P419, DOI 10.1038/nrneurol.2009.96; Ron E, 2002, PEDIATR RADIOL, V32, P232, DOI 10.1007/s00247-002-0672-0; Sage E, 2011, MUTAT RES-FUND MOL M, V711, P123, DOI 10.1016/j.mrfmmm.2010.12.010; Saha J, 2013, DNA REPAIR, V12, P1143, DOI 10.1016/j.dnarep.2013.10.004; Salvati M, 2003, SURG NEUROL, V60, P60, DOI 10.1016/S0090-3019(03)00137-X; Scotto L, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-58; Smolen GA, 2006, CANCER RES, V66, P3452, DOI 10.1158/0008-5472.CAN-05-4181; Sottoriva A, 2013, P NATL ACAD SCI USA, V110, P4009, DOI 10.1073/pnas.1219747110; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Sutter R, 2007, BBA-REV CANCER, V1776, P125, DOI 10.1016/j.bbcan.2007.07.006; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Wang HY, 2008, DNA REPAIR, V7, P725, DOI 10.1016/j.dnarep.2008.01.010; Westphal M, 2011, NAT REV NEUROSCI, V12, P495, DOI 10.1038/nrn3060; Yajima H, 2013, DNA REPAIR, V12, P936, DOI 10.1016/j.dnarep.2013.08.009	50	17	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					1064	1072		10.1038/onc.2014.29	http://dx.doi.org/10.1038/onc.2014.29			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632607	Green Accepted, Green Submitted			2022-12-28	WOS:000350121300013
J	Zhou, X; Zhang, CZ; Lu, SX; Chen, GG; Li, LZ; Liu, LL; Yi, C; Fu, J; Hu, W; Wen, JM; Yun, JP				Zhou, X.; Zhang, C. Z.; Lu, S-X; Chen, G. G.; Li, L-Z; Liu, L-L; Yi, C.; Fu, J.; Hu, W.; Wen, J-M; Yun, J-P			miR-625 suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma	ONCOGENE			English	Article							CELL-MIGRATION; VICKZ PROTEINS; C-MYC; EXPRESSION; MICRORNA; TRANSLATION; METASTASIS; FAMILY; INVOLVEMENT; ADHESION	Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies and the third leading cause of cancer-related deaths worldwide. Tumour metastasis is one of the major causes of high mortality. microRNAshave been implicated in HCC metastasis. In this study, we found that miR-625 was frequently downregulated in HCC samples. A decrease in miR-625 was significantly correlated with lymph node anddistance metastasis (P = 0.013), the presence of portal venous invasion (P = 0.036), tumor-nodemetastasis (TNM) stage (P = 0.027) and unfavourable overall survival (P = 0.003). Compared with primary tumours, miR-625 expression was markedly reduced in portal venous metastatic tumours. Re-expression of miR-625 in HCC cells was remarkably effective in suppressing cell migration andinvasiveness in vitro and in vivo. Mechanistically, miR-625 was confirmed to downregulate IGF2 mRNA-binding protein 1(IGF2BP1) directly, the expression of which was inversely correlated with the level of miR-625 in HCC cell lines and tissues. High expression of IGF2BP1 was frequently found in HCC samples, and associated with poor prognosis. Knockdown of endogenous IGF2BP1 by siRNA exhibited similar effects as the overexpression of miR-625, whereas overexpression of IGF2BP1 (without the 3'-UTR) abrogated miR-625-mediated metastasis inhibition. Interference of the PTEN/HSP27 pathway contributed to miR-625-mediated metastasis inhibition. Taken together, our data suggest that miR-625 might function as an antimetastatic miRNA to have an important role in HCC progression by modulating the IGF2BP1/PTEN pathway. The newly identified miR-625/IGF2BP1 axis represents a new potential therapeutic target for HCC treatment.	[Zhou, X.; Zhang, C. Z.; Lu, S-X; Li, L-Z; Liu, L-L; Yi, C.; Fu, J.; Hu, W.; Yun, J-P] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China; [Zhou, X.; Zhang, C. Z.; Lu, S-X; Li, L-Z; Liu, L-L; Yi, C.; Fu, J.; Hu, W.; Yun, J-P] Sun Yat Sen Univ, Ctr Canc, Dept Pathol, Guangzhou 510060, Guangdong, Peoples R China; [Zhou, X.; Wen, J-M] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou 510060, Guangdong, Peoples R China; [Chen, G. G.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Chinese University of Hong Kong; Prince of Wales Hospital	Yun, JP (corresponding author), Sun Yat Sen Univ, Ctr Canc, Dept Pathol, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China.	yunjp@sysucc.org.cn	Zhang, Chris Zhiyi/F-9862-2013; Chen, George Gong/I-2757-2016		National Natural Science Foundation of China [81372572, 81201717]; State Key Laboratory of Oncology in South China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Laboratory of Oncology in South China	This study was supported by grants from the National Natural Science Foundation of China (No. 81372572, 81201717), and the Project of State Key Laboratory of Oncology in South China.	Aravalli RN, 2008, HEPATOLOGY, V48, P2047, DOI 10.1002/hep.22580; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; During RL, 2007, EMBO J, V26, P2240, DOI 10.1038/sj.emboj.7601687; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Forner A, 2006, CRIT REV ONCOL HEMAT, V60, P89, DOI 10.1016/j.critrevonc.2006.06.001; Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huttelmaier S, 2005, NATURE, V438, P512, DOI 10.1038/nature04115; Ioannidis P, 2005, J BIOL CHEM, V280, P20086, DOI 10.1074/jbc.M410036200; Kobel M, 2007, ONCOGENE, V26, P7584, DOI 10.1038/sj.onc.1210563; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lapidus K, 2007, J CELL SCI, V120, P3173, DOI 10.1242/jcs.000638; Leung KM, 2006, NAT NEUROSCI, V9, P1247, DOI 10.1038/nn1775; Li LZ, 2014, CARCINOGENESIS, V35, P469, DOI 10.1093/carcin/bgt330; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Negrini M, 2009, CURR OPIN CELL BIOL, V21, P470, DOI 10.1016/j.ceb.2009.03.002; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Oberman F, 2007, RNA, V13, P1558, DOI 10.1261/rna.559507; Read DE, 2009, CELL MOL LIFE SCI, V66, P2975, DOI 10.1007/s00018-009-0057-8; Read DE, 2009, BIOCHEM BIOPH RES CO, V382, P6, DOI 10.1016/j.bbrc.2009.02.114; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; Shimizu S, 2010, J HEPATOL, V52, P698, DOI 10.1016/j.jhep.2009.12.024; Stohr N, 2012, GENE DEV, V26, P176, DOI 10.1101/gad.177642.111; Tan S, 2011, FEBS LETT, V585, P2229, DOI 10.1016/j.febslet.2011.05.042; Tang ZY, 2001, WORLD J GASTROENTERO, V7, P445; Tsai WC, 2009, HEPATOLOGY, V49, P1571, DOI 10.1002/hep.22806; Vainer G, 2008, J PATHOL, V215, P445, DOI 10.1002/path.2376; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Wong CCL, 2011, GASTROENTEROLOGY, V140, P322, DOI 10.1053/j.gastro.2010.10.006; Yan Y, 2013, HEPATOLOGY, V57, P667, DOI 10.1002/hep.26071; Yaniv K, 2002, GENE, V287, P49, DOI 10.1016/S0378-1119(01)00866-6; Yao J, 2010, HEPATOLOGY, V51, P846, DOI 10.1002/hep.23443; Yao JQ, 2006, NAT NEUROSCI, V9, P1265, DOI 10.1038/nn1773; Yisraeli JK, 2005, BIOL CELL, V97, P87; Zhang XY, 2009, HEPATOLOGY, V50, P490, DOI 10.1002/hep.23008	35	77	80	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					965	977		10.1038/onc.2014.35	http://dx.doi.org/10.1038/onc.2014.35			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632613				2022-12-28	WOS:000350121300003
J	Yeung, F; Ramsey, CS; Popko-Scibor, AE; Allison, DF; Gray, LG; Shin, M; Kumar, M; Li, D; McCubrey, JA; Mayo, MW				Yeung, F.; Ramsey, C. S.; Popko-Scibor, A. E.; Allison, D. F.; Gray, L. G.; Shin, M.; Kumar, M.; Li, D.; McCubrey, J. A.; Mayo, M. W.			Regulation of the mitogen-activated protein kinase kinase (MEK)-1 by NAD(+)-dependent deacetylases	ONCOGENE			English	Article							HIGH EXPRESSION; CANCER; SIRT1; TRANSCRIPTION; TUMORIGENESIS; METABOLISM; PROGNOSIS; SIRTUINS; SIGNAL; CELLS	Sirtuins are class III deacetylases that regulate many essential processes, including cellular stress, genome stability and metabolism. Although these NAD(+)-dependent deacetylases control adaptive cellular responses, identification of sirtuin-regulated signaling targets remain under-studied. Here, we demonstrate that acetylation of the mitogen-activated protein kinase kinase-1 (MEK1) stimulates its kinase activity, and that acetylated MEK1 is under the regulatory control of the sirtuin family members SIRT1 and SIRT2. Treatment of cells with sirtuin inhibitors, or siRNA knockdown of SIRT1 or SIRT2 proteins, increases MEK1 acetylation and subsequent phosphorylation of the extracellular signal-regulated kinase. Generation of an acetyl-specific MEK1 antibody demonstrates that endogenous acetylated MEK1 is extensively enriched in the nucleus following epidermal growth factor stimulation. An acetyl-mimic of MEK1 increases inappropriate growth properties, suggesting that acetylation of MEK1 has oncogenic potential.	[Yeung, F.; Ramsey, C. S.; Popko-Scibor, A. E.; Allison, D. F.; Gray, L. G.; Shin, M.; Kumar, M.; Li, D.; Mayo, M. W.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; [McCubrey, J. A.] E Carolina Univ, Dept Microbiol & Immunol, Greenville, NC USA	University of Virginia; University of North Carolina; East Carolina University	Mayo, MW (corresponding author), Univ Virginia, Dept Biochem & Mol Genet, Box 800733, Charlottesville, VA 22908 USA.	mwm3y@virginia.edu		McCubrey, James/0000-0001-6027-3156	National Cancer Institute [CA132580, CA104397];  [CA110552]; NATIONAL CANCER INSTITUTE [R01CA132580, R01CA104397, F32CA110552, T32CA009156] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs JS Smith, PT Stukenberg, JJ Wamsley and Ms A Sherman for scientific and editorial review. HA-MEK1, HA-MEK1(S218/222D) and Flag-ERK1 were gifts from Dr M Weber, University of Virginia. p300 was provided by Dr D Livingston, Dana-Farber Cancer Institute. Gal4-ELK1 was a gift from Dr C Der, University of North Carolina. V5-SIRT1 and Flag-SIRT2 were gifts from E Verdin, Gladstone Institute. The pBabe-puro vector was provided by Dr Robert Weinberg, Whitehead Institute, MIT. Work was supported by the National Cancer Institute (CA132580 and CA104397) to MWM, and CA110552 awarded to FY.	Allison DF, 2012, P NATL ACAD SCI USA, V109, P16888, DOI 10.1073/pnas.1208468109; Bajpe PK, 2015, ONCOGENE, V34, P531, DOI 10.1038/onc.2013.588; Blalock WL, 2000, ONCOGENE, V19, P526, DOI 10.1038/sj.onc.1203337; Brooks CL, 2009, NAT REV CANCER, V9, P123, DOI 10.1038/nrc2562; Catalanotti F, 2009, NAT STRUCT MOL BIOL, V16, P294, DOI 10.1038/nsmb.1564; Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147; Duffy A, 2009, TARGET ONCOL, V4, P267, DOI 10.1007/s11523-009-0125-x; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Huang PY, 2010, PROTEIN CELL, V1, P218, DOI 10.1007/s13238-010-0019-9; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lawrence MC, 2008, P NATL ACAD SCI USA, V105, P13315, DOI 10.1073/pnas.0806465105; Li M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-5; Park ER, 2007, CELL SIGNAL, V19, P1488, DOI 10.1016/j.cellsig.2007.01.018; RESING KA, 1995, BIOCHEMISTRY-US, V34, P2610, DOI 10.1021/bi00008a027; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Verdin E, 2010, TRENDS BIOCHEM SCI, V35, P669, DOI 10.1016/j.tibs.2010.07.003; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Xiao XS, 2011, CHINESE J CANCER RES, V23, P201, DOI 10.1007/s11670-011-0201-5; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244	26	10	10	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					798	804		10.1038/onc.2014.39	http://dx.doi.org/10.1038/onc.2014.39			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24681949	Green Accepted, Green Submitted			2022-12-28	WOS:000348853800013
J	Kim, Y; Kim, J; Jang, SW; Ko, J				Kim, Y.; Kim, J.; Jang, S-W; Ko, J.			The role of sLZIP in cyclin D3-mediated negative regulation of androgen receptor transactivation and its involvement in prostate cancer	ONCOGENE			English	Article						prostate cancer; androgen receptor; sLZIP; cyclin D3	CELLS; MECHANISMS; GROWTH; GENE; D3; PROGRESSION; EXPRESSION; RAPAMYCIN; INVASION; COMPLEX	Androgen and the androgen receptor (AR) have important roles in prostate cancer (PCa) development, and androgen ablation has been the main therapeutic option for the treatment of PCa. However, the transition mechanism from androgen-dependent to -independent PCa after androgen depletion remains unclear. We investigated the distinct roles of small leucine zipper protein (sLZIP) in proliferation of androgen-dependent and -independent PCa cells. Cyclin D3 is known to interact with AR and attenuates the ligand-dependent function of AR in PCa cells. sLZIP regulates the transcription of cyclin D3 by binding directly to the AP-1 region in the cyclin D3 promoter. sLZIP represses AR transcriptional activity by interaction with AR that is phosphorylated by cyclin D3/cyclin-dependent kinase11(p58), leading to the suppression of androgen-dependent proliferation of PCa cells. The expression level of sLZIP is elevated in androgen-independent PCa cells and advanced human prostate tumors. Knockdown of endogenous sLZIP suppresses proliferation of androgen-independent PCa cells. LNCaP cells transformed to androgen-independent PCa cells exhibit increased expressions of sLZIP and cyclin D3. Tumor formation is inhibited in nude mouse xenografts from two androgen-independent PCa cells that are stably transfected with sh-sLZIP. Our findings indicate that sLZIP negatively regulates AR transactivation in androgen-dependent PCa cells and functions as a positive regulator in tumor progression of androgen-independent PCa. sLZIP contributes to the malignant phenotype of PCa and constitutes a novel therapeutic target for human PCa.	[Kim, Y.; Kim, J.; Ko, J.] Korea Univ, Div Life Sci, Seoul 136701, South Korea; [Jang, S-W] Univ Ulsan, Grad Sch, Dept Med, Seoul, South Korea	Korea University; University of Ulsan	Ko, J (corresponding author), Korea Univ, Div Life Sci, 5-1 Anam Dong, Seoul 136701, South Korea.	jesangko@korea.ac.kr			Korea University; Basic Research Laboratory Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [2009-0087099]	Korea University; Basic Research Laboratory Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology	This work was supported by a Korea University Grant and the Basic Research Laboratory Program (2009-0087099) through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology.	Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Compagno D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001006; Cui JJ, 2011, CELL MOL LIFE SCI, V68, P1091, DOI 10.1007/s00018-010-0511-7; Galderisi U, 2003, ONCOGENE, V22, P5208, DOI 10.1038/sj.onc.1206558; Garcia-Morales P, 2006, MOL CANCER THER, V5, P2172, DOI 10.1158/1535-7163.MCT-05-0363; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Henzinger T, 1998, J BIOL CHEM, V273, P14958, DOI 10.1074/jbc.273.24.14958; Hleb M, 2004, J BIOL CHEM, V279, P31948, DOI 10.1074/jbc.M400638200; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Jang SY, 2012, CANCER LETT, V314, P185, DOI 10.1016/j.canlet.2011.09.028; Kang H, 2011, J BIOL CHEM, V286, P42072, DOI 10.1074/jbc.M111.272302; Kang H, 2009, MOL ENDOCRINOL, V23, P1746, DOI 10.1210/me.2009-0009; Li YR, 2009, CANCER RES, V69, P3332, DOI 10.1158/0008-5472.CAN-08-3380; Lin DY, 2004, MOL CELL BIOL, V24, P10529, DOI 10.1128/MCB.24.24.10529-10541.2004; Lu S, 1999, ENDOCRINOLOGY, V140, P5054, DOI 10.1210/en.140.11.5054; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Olshavsky NA, 2008, ONCOGENE, V27, P3111, DOI 10.1038/sj.onc.1210981; Pienta KJ, 2006, CLIN CANCER RES, V12, P1665, DOI 10.1158/1078-0432.CCR-06-0067; REISMAN D, 1995, MOL ENDOCRINOL, V9, P1500, DOI 10.1210/me.9.11.1500; Tilley WD, 1996, CLIN CANCER RES, V2, P277; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Zong HL, 2007, MOL CELL BIOL, V27, P7125, DOI 10.1128/MCB.01753-06	25	14	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					226	236		10.1038/onc.2013.538	http://dx.doi.org/10.1038/onc.2013.538			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24441043				2022-12-28	WOS:000347790500010
J	Glenn, ST; Jones, CA; Sexton, S; Levea, CM; Caraker, SM; Hajduczok, G; Gross, KW				Glenn, S. T.; Jones, C. A.; Sexton, S.; Levea, C. M.; Caraker, S. M.; Hajduczok, G.; Gross, K. W.			Conditional deletion of p53 and Rb in the renin-expressing compartment of the pancreas leads to a highly penetrant metastatic pancreatic neuroendocrine carcinoma	ONCOGENE			English	Article						glucagonoma; renin; pancreas; PanNET	MULTIPLE ENDOCRINE NEOPLASIA; ANGIOTENSIN SYSTEM; TRANSGENIC MICE; MOUSE MODEL; MUTANT MICE; ALPHA-CELLS; TUMORS; TYPE-1; INHIBITORS; MEN1	Efforts to model human pancreatic neuroendocrine tumors (PanNETs) in animals have been moderately successful, with minimal evidence for glucagonomas or metastatic spread. The renin gene, although classically associated with expression in the kidney, is also expressed in many other extrarenal tissues including the pancreas. To induce tumorigenesis within renin-specific tissues, floxed alleles of p53 and Rb were selectively abrogated using Cre-recombinase driven by the renin promoter. The primary neoplasm generated is a highly metastatic islet cell carcinoma of the pancreas. Lineage tracing identifies descendants of renin-expressing cells as pancreatic alpha cells despite a lack of active renin expression in the mature pancreas. Both primary and metastatic tumors express high levels of glucagon; furthermore, an increased level of glucagon is found in the serum, identifying the pancreatic cancer as a functional glucagonoma. This new model is highly penetrant and exhibits robust frequency of metastases to the lymph nodes and the liver, mimicking human disease, and provides a useful platform for better understanding pancreatic endocrine differentiation and development, as well as islet cell carcinogenesis. The use of fluorescent reporters for lineage tracing of the cells contributing to disease initiation and progression provides an unique opportunity to dissect the timeline of disease, examining mechanisms of the metastatic process, as well as recovering primary and metastatic cells for identifying cooperating mutations that are necessary for progression of disease.	[Glenn, S. T.; Jones, C. A.; Gross, K. W.] Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; [Sexton, S.] Roswell Pk Canc Inst, Dept Lab Anim Resources, Buffalo, NY 14263 USA; [Levea, C. M.] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA; [Caraker, S. M.] IDEXX RADIL, Columbia, MO USA; [Hajduczok, G.] SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14260 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Gross, KW (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Elm & Carlton Str, Buffalo, NY 14263 USA.	Kenneth.Gross@roswellpark.org			NIH [5R01HL048459, R21CA164795, R21CA169717]; CCSG [CA016056]; Genomics Shared Resource (GSR); National Science Foundation Major Research Instrumentation [DBI 0923133]; NATIONAL CANCER INSTITUTE [P30CA016056, R21CA164795, R21CA169717] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048459] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CCSG; Genomics Shared Resource (GSR); National Science Foundation Major Research Instrumentation(National Science Foundation (NSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was funded by the NIH grants 5R01HL048459, R21CA164795 and R21CA169717. We would like to thank the CCSG funded (CA016056) Roswell Park Gene Targeting and Transgenic Resource and the Genomics Shared Resource (GSR). Confocal Microscopy was performed at the University at Buffalo North Campus Imaging Facility using a Zeiss LSM 710 purchased through National Science Foundation Major Research Instrumentation grant DBI 0923133. We would also like to thank MK Ellsworth and Caretta Reese for maintenance of the mouse colonies, as well as Dominic Smiraglia and Elizabeth Repasky for critical reading and discussion of work. A special thank you to Dr George Deeb for his insightful observations on anatomy.	Benson C, 2005, BRIT J CANCER, V92, P7, DOI 10.1038/sj.bjc.6602229; Bertolino P, 2003, MOL ENDOCRINOL, V17, P1880, DOI 10.1210/me.2003-0154; Bertolino P, 2003, CANCER RES, V63, P4836; Carlsson P O, 2001, JOP, V2, P26; Crabtree JS, 2003, MOL CELL BIOL, V23, P6075, DOI 10.1128/MCB.23.17.6075-6085.2003; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; Desgraz R, 2009, DEVELOPMENT, V136, P3567, DOI 10.1242/dev.039214; Ehehalt F, 2009, ONCOLOGIST, V14, P456, DOI 10.1634/theoncologist.2008-0259; Flesken-Nikitin A, 2003, CANCER RES, V63, P3459; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Glenn ST, 2008, PHYSIOL GENOMICS, V35, P243, DOI 10.1152/physiolgenomics.00017.2008; Gomez RA, 1998, KIDNEY INT, V54, pS12, DOI 10.1046/j.1523-1755.1998.06703.x; Gromada J, 2007, ENDOCR REV, V28, P84, DOI 10.1210/er.2006-0007; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HARVEY M, 1995, CANCER RES, V55, P1146; Haumaitre C, 2008, MOL CELL BIOL, V28, P6373, DOI 10.1128/MCB.00413-08; Hu Wenwei, 2010, Genes Cancer, V1, P360; Johansson KA, 2007, DEV CELL, V12, P457, DOI 10.1016/j.devcel.2007.02.010; Jones CA, 2000, PHYSIOL GENOMICS, V4, P75, DOI 10.1152/physiolgenomics.2000.4.1.75; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Lam K Y, 2001, JOP, V2, P40; Lam KY, 2002, EUR J ENDOCRINOL, V146, P567, DOI 10.1530/eje.0.1460567; Lammert E, 2003, MECH DEVELOP, V120, P59, DOI 10.1016/S0925-4773(02)00332-5; Lau T, 2004, DIABETOLOGIA, V47, P240, DOI 10.1007/s00125-003-1295-1; Leung KK, 2012, STEM CELLS, V30, P525, DOI 10.1002/stem.1008; Leung PS, 2007, J PHYSIOL-LONDON, V580, P31, DOI 10.1113/jphysiol.2006.126193; Leung PS, 2005, PANCREAS, V30, P293, DOI 10.1097/01.mpa.0000158028.76666.76; Leung PS, 2003, INT J BIOCHEM CELL B, V35, P838, DOI 10.1016/S1357-2725(02)00179-6; Leung PS, 2001, J MOL ENDOCRINOL, V26, P155, DOI 10.1677/jme.0.0260155; Liu LX, 2005, MODERN PATHOL, V18, P1632, DOI 10.1038/modpathol.3800490; Loffler KA, 2007, INT J CANCER, V120, P259, DOI 10.1002/ijc.22288; Lopez MLSS, 2004, DEV CELL, V6, P719; Lu JL, 2010, GASTROENTEROLOGY, V138, P1954, DOI 10.1053/j.gastro.2010.01.046; Marino S, 2000, GENE DEV, V14, P994; Nishimura H, 1999, INTERNAL MED, V38, P315, DOI 10.2169/internalmedicine.38.315; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; RINDI G, 1991, VIRCHOWS ARCH A, V419, P115, DOI 10.1007/BF01600225; RUTTMAN E, 1980, VIRCHOWS ARCH A, V388, P51, DOI 10.1007/BF00430676; Schwitzgebel VM, 2000, DEVELOPMENT, V127, P3533; Shen HCJ, 2010, ENDOCRINOLOGY, V151, P4024, DOI 10.1210/en.2009-1251; Shen HCJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004897; Shen HCJ, 2009, CANCER RES, V69, P1858, DOI 10.1158/0008-5472.CAN-08-3662; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; Snippert HJ, 2010, CELL, V143, P134, DOI 10.1016/j.cell.2010.09.016; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Sparwasser T, 2004, GENESIS, V38, P39, DOI 10.1002/gene.10249; Tahmasebi M, 1999, J ENDOCRINOL, V161, P317, DOI 10.1677/joe.0.1610317; Tang LH, 2012, CLIN CANCER RES, V18, P4612, DOI 10.1158/1078-0432.CCR-11-3264; Tikellis C, 2006, INT J BIOCHEM CELL B, V38, P737, DOI 10.1016/j.biocel.2005.08.007; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480	51	21	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2014	33	50					5706	5715		10.1038/onc.2013.514	http://dx.doi.org/10.1038/onc.2013.514			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW2AB	24292676	Green Accepted			2022-12-28	WOS:000346089300006
J	Zaganjor, E; Osborne, JK; Weil, LM; Diaz-Martinez, LA; Gonzales, JX; Singel, SM; Larsen, JE; Girard, L; Minna, JD; Cobb, MH				Zaganjor, E.; Osborne, J. K.; Weil, L. M.; Diaz-Martinez, L. A.; Gonzales, J. X.; Singel, S. M.; Larsen, J. E.; Girard, L.; Minna, J. D.; Cobb, M. H.			Ras regulates kinesin 13 family members to control cell migration pathways in transformed human bronchial epithelial cells	ONCOGENE			English	Article						kinesin; K-Ras; MAPK; ERK; microtubules	ACTIVATED PROTEIN-KINASE; SUPERFAMILY PROTEIN; MEDIATED TRANSFORMATION; MORPHOLOGICAL-CHANGES; SIGNALING PATHWAYS; TUMOR-SUPPRESSOR; GENE-EXPRESSION; CANCER-CELLS; LUNG-CANCER; K-RAS	We show that expression of the microtubule depolymerizing kinesin KIF2C is induced by transformation of immortalized human bronchial epithelial cells (HBEC) by expression of K-Ras(G12V) and knockdown of p53. Further investigation demonstrates that this is due to the K-Ras/ERK1/2 MAPK pathway, as loss of p53 had little effect on KIF2C expression. In addition to KIF2C, we also found that the related kinesin KIF2A is modestly upregulated in this model system; both proteins are expressed more highly in many lung cancer cell lines compared to normal tissue. As a consequence of their depolymerizing activity, these kinesins increase dynamic instability of microtubules. Depletion of either of these kinesins impairs the ability of cells transformed with mutant K-Ras to migrate and invade matrigel. However, depletion of these kinesins does not reverse the epithelial to mesenchymal transition (EMT) caused by mutant K-Ras. Our studies indicate that increased expression of microtubule destabilizing factors can occur during oncogenesis to support enhanced migration and invasion of tumor cells.	[Zaganjor, E.; Osborne, J. K.; Weil, L. M.; Diaz-Martinez, L. A.; Gonzales, J. X.; Girard, L.; Minna, J. D.; Cobb, M. H.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA; [Singel, S. M.] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA; [Larsen, J. E.; Girard, L.; Minna, J. D.] Hamon Canc Ctr Therapeut Oncol Res, Dallas, TX USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Pharmacol, 6001 Forest Pk, Dallas, TX 75390 USA.	Melanie.Cobb@UTSouthwestern.edu	Larsen, Jill E/G-3787-2010	Larsen, Jill E/0000-0001-7806-3931; Cobb, Melanie/0000-0003-0833-5473; Diaz-Martinez, Laura/0000-0002-7226-7068	National Institutes of Health [R37 DK34128, P50CA70907]; Cancer Prevention and Research Institute of Texas (CPRIT); DOD PROSPECT; Longenbaugh Foundation; Robert A. Welch Foundation [I1243]; NIGMS Pharmacological Sciences Training Grant [5-T32 GM007062]; NHMRC Biomedical Fellowship [494511]; TSANZ/Allen & Hanburys Respiratory Research Fellowship; NATIONAL CANCER INSTITUTE [P30CA142543, P50CA070907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas (CPRIT); DOD PROSPECT; Longenbaugh Foundation; Robert A. Welch Foundation(The Welch Foundation); NIGMS Pharmacological Sciences Training Grant; NHMRC Biomedical Fellowship(National Health and Medical Research Council (NHMRC) of Australia); TSANZ/Allen & Hanburys Respiratory Research Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Andres Lorente-Rodriguez and Michael Kalwat in the Cobb lab for comments and suggestions and Dionne Ware for administrative assistance. This work was supported by grants from the National Institutes of Health (R37 DK34128 to MHC and P50CA70907 to JDM), grants from the Cancer Prevention and Research Institute of Texas (CPRIT) to JDM, DOD PROSPECT and Longenbaugh Foundation to JDM, and the Robert A. Welch Foundation I1243 to MHC. JKO was supported by NIGMS Pharmacological Sciences Training Grant 5-T32 GM007062. JEL was supported by NHMRC Biomedical Fellowship (494511)TSANZ/Allen & Hanburys Respiratory Research Fellowship.	Ahmed SM, 2012, J CELL BIOL, V199, P951, DOI 10.1083/jcb.201206051; Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Ding LH, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn234; Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Duesbery NS, 2001, P NATL ACAD SCI USA, V98, P4089, DOI 10.1073/pnas.061031898; Fotiadou PP, 2007, MOL CELL BIOL, V27, P6742, DOI 10.1128/MCB.00234-07; Fukazawa H, 2000, CANCER RES, V60, P2104; Ganem NJ, 2004, J CELL BIOL, V166, P473, DOI 10.1083/jcb.200404012; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; Groth-Pedersen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045381; Harrison RE, 2001, NEOPLASIA, V3, P385, DOI 10.1038/sj.neo.7900180; Helenius J, 2006, NATURE, V441, P115, DOI 10.1038/nature04736; Homma N, 2003, CELL, V114, P229, DOI 10.1016/S0092-8674(03)00522-1; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Jimenez C, 2000, J CELL BIOL, V151, P249, DOI 10.1083/jcb.151.2.249; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kolsch V, 2008, J CELL SCI, V121, P551, DOI 10.1242/jcs.023333; Korolchuk VI, 2011, NAT CELL BIOL, V13, P453, DOI 10.1038/ncb2204; Larsen JE, 2011, CLIN CHEST MED, V32, P703, DOI 10.1016/j.ccm.2011.08.003; Leinweber BD, 1999, BIOCHEM J, V344, P117, DOI 10.1042/0264-6021:3440117; LIAO GJ, 1995, J CELL SCI, V108, P3473; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634; Manning AL, 2007, MOL BIOL CELL, V18, P2970, DOI 10.1091/mbc.E07-02-0110; Maor-Nof M, 2013, CELL REP, V3, P971, DOI 10.1016/j.celrep.2013.03.005; Miki H, 2005, TRENDS CELL BIOL, V15, P467, DOI 10.1016/j.tcb.2005.07.006; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Moore AT, 2005, J CELL BIOL, V169, P391, DOI 10.1083/jcb.200411089; Olsen MK, 1998, J CELL PHYSIOL, V176, P525, DOI 10.1002/(SICI)1097-4652(199809)176:3<525::AID-JCP9>3.0.CO;2-Q; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; Pollock CB, 2005, CANCER RES, V65, P1244, DOI 10.1158/0008-5472.CAN-04-1911; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Rogers GC, 2004, NATURE, V427, P364, DOI 10.1038/nature02256; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sanhaji M, 2011, ONCOTARGET, V2, P935; Sato M, 2006, CANCER RES, V66, P2116, DOI 10.1158/0008-5472.CAN-05-2521; Sato M, 2013, MOL CANCER RES, V11, P638, DOI 10.1158/1541-7786.MCR-12-0634-T; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Sunaga N, 2011, MOL CANCER THER, V10, P336, DOI 10.1158/1535-7163.MCT-10-0750; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P10499, DOI 10.1073/pnas.95.18.10499; Tanuma N, 2009, ONCOGENE, V28, P752, DOI 10.1038/onc.2008.431; Tiwari N, 2012, SEMIN CANCER BIOL, V22, P194, DOI 10.1016/j.semcancer.2012.02.013; van Es JH, 2001, EXP CELL RES, V264, P126, DOI 10.1006/excr.2000.5142; VASILIEV JM, 1970, J EMBRYOL EXP MORPH, V24, P625; Wang CQ, 2010, ORAL ONCOL, V46, P65, DOI 10.1016/j.oraloncology.2009.11.003; Yamashita J, 2012, ACTA DERM-VENEREOL, V92, P593, DOI 10.2340/00015555-1416; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	57	20	20	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2014	33	47					5457	5466		10.1038/onc.2013.486	http://dx.doi.org/10.1038/onc.2013.486			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MG	24240690	Green Accepted			2022-12-28	WOS:000345120700008
J	Yun, SM; Yoon, K; Lee, S; Kim, E; Kong, SH; Choe, J; Kang, JM; Han, TS; Kim, P; Choi, Y; Jho, S; Yoo, H; Bhak, J; Yang, HK; Kim, SJ				Yun, S. M.; Yoon, K.; Lee, S.; Kim, E.; Kong, S-H; Choe, J.; Kang, J. M.; Han, T-S; Kim, P.; Choi, Y.; Jho, S.; Yoo, H.; Bhak, J.; Yang, H-K; Kim, S-J			PPP1R1B-STARD3 chimeric fusion transcript in human gastric cancer promotes tumorigenesis through activation of PI3K/AKT signaling	ONCOGENE			English	Article						fusion transcript; gastric cancer; transcriptome sequencing	GENE FUSIONS; PROSTATE-CANCER; DARPP-32; PATHWAY; RNAS; REARRANGEMENTS; EXPRESSION; MUTATIONS; DOPAMINE; RECEPTOR	Fusion genes act as potent oncogenes, resulting from chromosomal rearrangements or abnormal transcription in many human cancers. Although multiple gastric cancer genomes have been sequenced, the driving recurrent gene fusions have not been well characterized. Here, we used paired-end transcriptome sequencing to identify novel gene fusions in 18 human gastric cancer cell lines and 18 pairs of primary human gastric cancer tissues and their adjacent normal tissues. Multiple samples revealed expression of PPP1R1B-STARD3 fusion transcript. The presence of PPP1R1B-STARD3 correlated with elevated levels of PPP1R1B mRNA. PPP1R1B-STARD3 fusion transcript was detected in 21.3% of primary human gastric cancers but not in adjacent matched normal gastric tissues. Based on reverse transcription PCR analysis of DNA, unlike other fusions described in gastric cancer, the PPP1R1B-STARD3 appears to be generated by RNA processing without chromosomal rearrangement. Overexpression of PPP1R1B-STARD3 in MKN-28 significantly increased cell proliferation and colony formation. This increased proliferation was mediated by activation of phosphatidylinositol-3-kinase (PI3K)/AKT signaling. Furthermore, expression of PPP1R1B-STARD3 fusion transcript enhanced the tumor growth of MKN-28 cells in athymic nude mice. These findings show that PPP1R1B-STARD3 fusion transcript has a key role in subsets of gastric cancers through the activation of PI3K/AKT signaling.	[Yun, S. M.; Yoon, K.; Kim, E.; Choe, J.; Kang, J. M.; Kim, P.; Choi, Y.; Yoo, H.; Kim, S-J] CHA Univ, CHA Canc Inst, Seoul 135081, South Korea; [Yun, S. M.; Kim, S-J] CHA Univ, Dept Biomed Sci, Coll Life Sci, Seoul 135081, South Korea; [Lee, S.; Jho, S.; Bhak, J.] Genome Res Fdn, Personal Genom Inst, Suwon, South Korea; [Lee, S.; Bhak, J.] TheragenEtex Inc, TheragenEtex Bio Inst, Suwon, South Korea; [Kong, S-H; Han, T-S; Yang, H-K] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea; [Kong, S-H; Yang, H-K] Seoul Natl Univ, Coll Med, Dept Surg, Seoul, South Korea	Pochon Cha University; Pochon Cha University; Seoul National University (SNU); Seoul National University (SNU)	Kim, SJ (corresponding author), CHA Univ, CHA Canc Inst, 605 Yeoksam 1 Dong, Seoul 135081, South Korea.	kimsj@cha.ac.kr		Lee, Sunghoon/0000-0002-6682-119X; Lee, Sunghoon/0000-0002-8916-2035; Kang, Jin Muk/0000-0002-7949-9160	National Research Foundation of Korea (NRF) [2009-0081756, 2012M3A9C4048736]; TheragenEtex; Industrial Strategic Technology Development Program - Ministry of Knowledge Economy (MKE, Korea) [10040231]; Genome Research Foundation	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); TheragenEtex; Industrial Strategic Technology Development Program - Ministry of Knowledge Economy (MKE, Korea); Genome Research Foundation	This work was supported in part by the National Research Foundation of Korea (NRF) grants (2009-0081756 and 2012M3A9C4048736 to S-JK). JB and SL were supported by TheragenEtex and Genome Research Foundation internal funds. JB was supported by the Industrial Strategic Technology Development Program (10040231) funded by the Ministry of Knowledge Economy (MKE, Korea).	Akiva P, 2006, GENOME RES, V16, P30, DOI 10.1101/gr.4137606; Beckler A, 2003, CANCER, V98, P1547, DOI 10.1002/cncr.11654; Belkhiri A, 2005, CANCER RES, V65, P6583, DOI 10.1158/0008-5472.CAN-05-1433; BRENE S, 1994, J NEUROSCI, V14, P985, DOI 10.1523/JNEUROSCI.14-03-00985.1994; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Deng NT, 2012, GUT, V61, P673, DOI 10.1136/gutjnl-2011-301839; El-Rifai W, 2002, CANCER RES, V62, P4061; Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838; Greengard P, 1999, NEURON, V23, P435, DOI 10.1016/S0896-6273(00)80798-9; Guggenheim DE, 2013, J SURG ONCOL, V107, P230, DOI 10.1002/jso.23262; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hold GL, 2007, GASTROENTEROLOGY, V132, P905, DOI 10.1053/j.gastro.2006.12.026; Ito Kosei, 2012, Seikagaku, V84, P278; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kannan K, 2011, P NATL ACAD SCI USA, V108, P9172, DOI 10.1073/pnas.1100489108; Katoh M, 2004, INT J ONCOL, V24, P757; Li H, 2008, SCIENCE, V321, P1357, DOI 10.1126/science.1156725; McPherson A, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001138; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Mukherjee K, 2010, SURGERY, V148, P354, DOI 10.1016/j.surg.2010.05.011; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Poulin F, 2003, J BIOL CHEM, V278, P52290, DOI 10.1074/jbc.M310761200; Prensner JR, 2009, CURR OPIN GENET DEV, V19, P82, DOI 10.1016/j.gde.2008.11.008; Robinson DR, 2011, NAT MED, V17, P1646, DOI 10.1038/nm.2580; Tao J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001423; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Wang K, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-348; Wang XS, 2009, NAT BIOTECHNOL, V27, P1005, DOI 10.1038/nbt.1584; Wei JX, 2012, P NATL ACAD SCI USA, V109, pE2543, DOI 10.1073/pnas.1205664109; Yoon K, 2013, GENOME RES, V23, P1109, DOI 10.1101/gr.145706.112; Zayed A, 2007, LEUKEMIA LYMPHOMA, V48, P489, DOI 10.1080/10428190601136163; Zhu SM, 2011, GASTROENTEROLOGY, V141, P1738, DOI 10.1053/j.gastro.2011.06.070	35	26	26	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2014	33	46					5341	5347		10.1038/onc.2013.472	http://dx.doi.org/10.1038/onc.2013.472			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MF	24276243				2022-12-28	WOS:000345120600004
J	Sparks, A; Dayal, S; Das, J; Robertson, P; Menendez, S; Saville, MK				Sparks, A.; Dayal, S.; Das, J.; Robertson, P.; Menendez, S.; Saville, M. K.			The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a	ONCOGENE			English	Article						p53; Mdm2; S5a; Rpn10; proteasome; proteasomal recognition	CONJUGATING ENZYMES; PROTEIN-DEGRADATION; 26S PROTEASOME; TUMOR-CELLS; SUBUNIT; ACTIVATION; BINDING; ONCOPROTEIN; RECOGNITION; SUBSTRATE	p53 and its major E3 ligase Mdm2 are both ubiquitinated and targeted to the proteasome for degradation. Despite the importance of this in regulating the p53 pathway, little is known about the mechanisms of proteasomal recognition of ubiquitinated p53 and Mdm2. In this study, we show that knockdown of the proteasomal ubiquitin receptor S5a/PSMD4/Rpn10 inhibits p53 protein degradation and results in the accumulation of ubiquitinated p53. Overexpression of a dominant-negative deletion of S5a lacking its ubiquitin-interacting motifs (UIM)s, but which can be incorporated into the proteasome, also causes the stabilization of p53. Furthermore, small-interferring RNA (siRNA) rescue experiments confirm that the UIMs of S5a are required for the maintenance of low p53 levels. These observations indicate that S5a participates in the recognition of ubiquitinated p53 by the proteasome. In contrast, targeting S5a has no effect on the rate of degradation of Mdm2, indicating that proteasomal recognition of Mdm2 can be mediated by an S5a-independent pathway. S5a knockdown results in an increase in the transcriptional activity of p53. The selective stabilization of p53 and not Mdm2 provides a mechanism for p53 activation. Depletion of S5a causes a p53-dependent decrease in cell proliferation, demonstrating that p53 can have a dominant role in the response to targeting S5a. This study provides evidence for alternative pathways of proteasomal recognition of p53 and Mdm2. Differences in recognition by the proteasome could provide a means to modulate the relative stability of p53 and Mdm2 in response to cellular signals. In addition, they could be exploited for p53-activating therapies. This work shows that the degradation of proteins by the proteasome can be selectively dependent on S5a in human cells, and that this selectivity can extend to an E3 ubiquitin ligase and its substrate.	[Sparks, A.; Dayal, S.; Das, J.; Saville, M. K.] Univ Dundee, Ninewells Hosp & Med Sch, Jacqui Wood Canc Ctr, Div Canc Res,Med Res Inst, Dundee DD1 9SY, Scotland; [Robertson, P.] Univ Dundee, Coll Life Sci, Div Mol Med, Dundee DD1 9SY, Scotland; [Menendez, S.] Univ Edinburgh, MRC, Ctr Regenerat Med, Edinburgh, Midlothian, Scotland	University of Dundee; University of Dundee; University of Edinburgh	Saville, MK (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Jacqui Wood Canc Ctr, Div Canc Res,Med Res Inst, James Arrott Dr, Dundee DD1 9SY, Scotland.	m.k.saville@dundee.ac.uk		Menendez, Sergio/0000-0002-7929-8641; Das, Joyutpal/0000-0002-9166-4624	Wellcome Trust [094208/Z/10/Z]; European Research Council; Cancer Research UK	Wellcome Trust(Wellcome TrustEuropean Commission); European Research Council(European Research Council (ERC)European Commission); Cancer Research UK(Cancer Research UK)	This work was funded by the Wellcome Trust (grant no. 094208/Z/10/Z), the European Research Council and Cancer Research UK.	Allende-Vega N, 2013, ONCOGENE, V32, P1, DOI 10.1038/onc.2012.38; Allende-Vega N, 2010, ONCOGENE, V29, P432, DOI 10.1038/onc.2009.330; Allende-Vega N, 2010, SEMIN CANCER BIOL, V20, P29, DOI 10.1016/j.semcancer.2009.10.004; Arlt A, 2009, ONCOGENE, V28, P3983, DOI 10.1038/onc.2009.264; Bedford L, 2010, TRENDS CELL BIOL, V20, P391, DOI 10.1016/j.tcb.2010.03.007; Boehringer J, 2012, BIOCHEM J, V448, P55, DOI 10.1042/BJ20120542; Bond GL, 2007, ONCOGENE, V26, P1317, DOI 10.1038/sj.onc.1210199; Bousquet-Dubouch MP, 2011, EXPERT REV PROTEOMIC, V8, P459, DOI 10.1586/EPR.11.41; Brignone C, 2004, ONCOGENE, V23, P4121, DOI 10.1038/sj.onc.1207540; Carter S, 2007, NAT CELL BIOL, V9, P428, DOI 10.1038/ncb1562; Cheok CF, 2007, MOL CANCER RES, V5, P1133, DOI 10.1158/1541-7786.MCR-07-0161; Crawford LJ, 2011, J CELL COMMUN SIGNAL, V5, P101, DOI 10.1007/s12079-011-0121-7; Cross B, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M111.228981; Dantuma NP, 2009, DNA REPAIR, V8, P449, DOI 10.1016/j.dnarep.2009.01.005; Dantuma NP, 2006, J CELL BIOL, V173, P19, DOI 10.1083/jcb.200510071; Dayal S, 2009, J BIOL CHEM, V284, P5030, DOI 10.1074/jbc.M805871200; Dick LR, 2010, DRUG DISCOV TODAY, V15, P243, DOI 10.1016/j.drudis.2010.01.008; Dikic I, 2009, NAT REV MOL CELL BIO, V10, P659, DOI 10.1038/nrm2767; Elangovan M, 2010, BIOCHEM BIOPH RES CO, V396, P425, DOI 10.1016/j.bbrc.2010.04.108; Elangovan M, 2009, BIOCHEM BIOPH RES CO, V388, P723, DOI 10.1016/j.bbrc.2009.08.078; Elsasser S, 2005, NAT CELL BIOL, V7, P742, DOI 10.1038/ncb0805-742; Fatimababy AS, 2010, FEBS J, V277, P796, DOI 10.1111/j.1742-4658.2009.07531.x; Finley D, 2009, ANNU REV BIOCHEM, V78, P477, DOI 10.1146/annurev.biochem.78.081507.101607; Fu HY, 2010, TRENDS PLANT SCI, V15, P375, DOI 10.1016/j.tplants.2010.03.004; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; Gallastegui N, 2010, TRENDS BIOCHEM SCI, V35, P634, DOI 10.1016/j.tibs.2010.05.005; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Gomez TA, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-33; Hamazaki J, 2007, MOL CELL BIOL, V27, P6629, DOI 10.1128/MCB.00509-07; Haririnia A, 2008, J MOL BIOL, V375, P979, DOI 10.1016/j.jmb.2007.11.016; Higashitsuji H, 2005, CANCER CELL, V8, P75, DOI 10.1016/j.ccr.2005.06.006; Hishiya A, 2006, EMBO J, V25, P554, DOI 10.1038/sj.emboj.7600945; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hock AK, 2013, BIOCHIM BIOPHYS ACTA; Husnjak K, 2008, NATURE, V453, P481, DOI 10.1038/nature06926; Inuzuka H, 2010, ONCOTARGET, V1, P685; Inuzuka H, 2010, CANCER CELL, V18, P147, DOI 10.1016/j.ccr.2010.06.015; Isasa M, 2010, MOL CELL, V38, P733, DOI 10.1016/j.molcel.2010.05.001; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Jin Y, 2008, MOL CELL BIOL, V28, P1218, DOI 10.1128/MCB.01198-07; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; Kaneko T, 2009, CELL, V137, P914, DOI 10.1016/j.cell.2009.05.008; Kaur M, 2007, ONCOGENE, V26, P1231, DOI 10.1038/sj.onc.1209865; Kawahara H, 2000, EMBO J, V19, P4144, DOI 10.1093/emboj/19.15.4144; Kim HT, 2009, EMBO J, V28, P1867, DOI 10.1038/emboj.2009.115; Kleijnen MF, 2003, MOL BIOL CELL, V14, P3868, DOI 10.1091/mbc.E02-11-0766; Kravtsova-Ivantsiv Y, 2012, J CELL SCI, V125, P539, DOI 10.1242/jcs.093567; Kulikov R, 2010, P NATL ACAD SCI USA, V107, P10038, DOI 10.1073/pnas.0911716107; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lee MJ, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.R110.003871; Linares LK, 2007, NAT CELL BIOL, V9, P331, DOI 10.1038/ncb1545; Lipinszki Z, 2012, BIOCHEMISTRY-US, V51, P2461, DOI 10.1021/bi3001006; Lipinszki Z, 2009, J CELL SCI, V122, P3083, DOI 10.1242/jcs.049049; Lozano G, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001115; Mayor T, 2007, MOL CELL PROTEOMICS, V6, P1885, DOI 10.1074/mcp.M700264-MCP200; Midorikawa Y, 2002, JPN J CANCER RES, V93, P636, DOI 10.1111/j.1349-7006.2002.tb01301.x; Mimnaugh EG, 1997, BIOCHEMISTRY-US, V36, P14418, DOI 10.1021/bi970998j; Nair VD, 2006, J BIOL CHEM, V281, P39550, DOI 10.1074/jbc.M603950200; Nickell S, 2009, P NATL ACAD SCI USA, V106, P11943, DOI 10.1073/pnas.0905081106; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pei DS, 2012, ONCOTARGET, V3, P228; Peth A, 2010, MOL CELL, V40, P671, DOI 10.1016/j.molcel.2010.11.002; Raasi S, 2005, NAT STRUCT MOL BIOL, V12, P708, DOI 10.1038/nsmb962; Ruschak AM, 2011, J NATL CANCER I, V103, P1007, DOI 10.1093/jnci/djr160; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V293, P986, DOI 10.1016/S0006-291X(02)00340-6; Santamaria PG, 2003, J BIOL CHEM, V278, P6687, DOI 10.1074/jbc.M209420200; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Shaughnessy JD, 2011, BLOOD, V118, P3512, DOI 10.1182/blood-2010-12-328252; Shen YH, 2011, TOXICOL LETT, V205, P341, DOI 10.1016/j.toxlet.2011.06.028; Stevenson LF, 2007, EMBO J, V26, P976, DOI 10.1038/sj.emboj.7601567; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Su V, 2009, CELL MOL LIFE SCI, V66, P2819, DOI 10.1007/s00018-009-0048-9; Sun XM, 2004, MOL CELL, V14, P81, DOI 10.1016/S1097-2765(04)00156-X; Szlanka T, 2003, J CELL SCI, V116, P1023, DOI 10.1242/jcs.00332; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014; Wade M, 2006, J BIOL CHEM, V281, P33036, DOI 10.1074/jbc.M605405200; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wan Y, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-208; Wang YV, 2007, P NATL ACAD SCI USA, V104, P12365, DOI 10.1073/pnas.0701497104; Wei SJ, 2008, J MOL BIOL, V383, P693, DOI 10.1016/j.jmb.2008.08.044; Winget JM, 2010, MOL CELL, V38, P627, DOI 10.1016/j.molcel.2010.05.003; Wojcik C, 2002, J BIOL CHEM, V277, P6188, DOI 10.1074/jbc.M109996200; Xu Q, 2004, MOL CANCER THER, V3, P1263; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461; Zhu Q, 2007, ONCOGENE, V26, P4199, DOI 10.1038/sj.onc.1210191	88	25	25	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2014	33	38					4685	4696		10.1038/onc.2013.413	http://dx.doi.org/10.1038/onc.2013.413			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3VX	24121268	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000342007200007
J	Li, H; Huang, F; Fan, L; Jiang, Y; Wang, X; Li, J; Wang, Q; Pan, H; Sun, J; Cao, X; Wang, X				Li, H.; Huang, F.; Fan, L.; Jiang, Y.; Wang, X.; Li, J.; Wang, Q.; Pan, H.; Sun, J.; Cao, X.; Wang, X.			Phosphatidylethanolamine-binding protein 4 is associated with breast cancer metastasis through Src-mediated Akt tyrosine phosphorylation	ONCOGENE			English	Article						breast cancer metastasis; hPEBP4; Akt; Src	KINASE INHIBITOR PROTEIN; TRAIL-INDUCED APOPTOSIS; ALPHA-INDUCED APOPTOSIS; RAF KINASE; MESENCHYMAL TRANSITION; PATHWAY ACTIVATION; CELLS; EXPRESSION; PROSTATE; RESISTANCE	Metastasis is responsible for more than 90% of the mortality observed among patients with breast cancer. Human phosphatidylethanolamine-binding protein 4 (hPEBP4) is a novel member of the PEBP family and functions as an anti-apoptotic molecule. Here, we found that the metastatic MDA-MB-231 breast cancer cells expressed much higher levels of hPEBP4 than the nonmetastatic MCF-7 breast cancer cells and that the expression levels of hPEBP4 were positively correlated with the metastasis of clinical breast cancer. The hPEBP4 overexpression in the MDA-MB-231 cells significantly promoted cell invasion in vitro and increased the development of lymph node metastasis in vivo. Conversely, the silencing of hPEBP4 suppressed the cell-invasive ability both in vitro and in vivo. Further investigation showed that hPEBP4 promoted the expression or activity of the metastasis-related proteinases MMP (matrix metalloproteinase) 2, MMP9 and MMP13. This hPEBP4-potentiated cell invasion and MMP expression is due to an increase in Akt activation. Knockdown of Akt restored hPEBP4-induced breast tumor metastasis in the hPEBP4-MDA-MB-231 xenograft mouse model. Moreover, we found that hPEBP4 functioned as a scaffolding molecule and enhanced the association of Akt with Src to promote Akt tyrosine phosphorylation, a prerequisite for the full activation of Akt, in a phosphatidylethanolamine-binding domain-dependent manner. Given the present information about human breast cancer, these functional data from cell culture and animal studies suggest that, in human breast cancer hPEBP4 is a novel and clinically relevant metastasis accelerator gene and may be a new diagnostic marker and therapeutic target for breast cancer metastasis.	[Li, H.; Huang, F.; Fan, L.; Jiang, Y.; Wang, X.; Wang, Q.; Cao, X.; Wang, X.] Zhejiang Univ, Inst Immunol, Sch Med, Hangzhou 310058, Zhejiang, Peoples R China; [Li, J.; Pan, H.; Sun, J.] Zhejiang Univ, Sch Med, Hangzhou 310058, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University	Wang, X (corresponding author), Zhejiang Univ, Inst Immunol, 388 Yuhang Tang Rd,Med Res Bldg B819, Hangzhou 310058, Zhejiang, Peoples R China.	wangxiaojian@cad.zju.edu.cn			National Basic Research Program of China (973) [2014CB542101, 2013CB530502]; National Natural Science Foundation of China [81282353, 81072437, 81000302]; Doctoral Fund of Ministry of Education of China [20120101110022]; Zhejiang Major Science and Technology Special Project [2009C13018, 2009C14015]; Research Fund of Science Base [J1103603]; Qianjiang Talent Program of Zhejiang Province [2012R10027]; Scientific Research Foundation of the Health Bureau of Zhejiang Province [WKJ2012-2-030]	National Basic Research Program of China (973)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Doctoral Fund of Ministry of Education of China(Ministry of Education, China); Zhejiang Major Science and Technology Special Project; Research Fund of Science Base; Qianjiang Talent Program of Zhejiang Province; Scientific Research Foundation of the Health Bureau of Zhejiang Province	This work was supported by grants from the National Basic Research Program of China (973) (2014CB542101, 2013CB530502), the National Natural Science Foundation of China (81282353, 81072437, 81000302), the Doctoral Fund of Ministry of Education of China (20120101110022), Zhejiang Major Science and Technology Special Project (2009C13018, 2009C14015), the Research Fund of Science Base (J1103603), Qianjiang Talent Program of Zhejiang Province (2012R10027) and Scientific Research Foundation of the Health Bureau of Zhejiang Province (WKJ2012-2-030).	Al Saleh S, 2011, INT J ONCOL, V38, P1197, DOI 10.3892/ijo.2011.942; Baritaki S, 2007, J IMMUNOL, V179, P5441, DOI 10.4049/jimmunol.179.8.5441; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Castaneda CA, 2010, CANCER METAST REV, V29, P751, DOI 10.1007/s10555-010-9261-0; Chatterjee D, 2004, J BIOL CHEM, V279, P17515, DOI 10.1074/jbc.M313816200; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Cheung LWT, 2006, CANCER RES, V66, P10902, DOI 10.1158/0008-5472.CAN-06-2217; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; Fu Z, 2003, J NATL CANCER I, V95, P878, DOI 10.1093/jnci/95.12.878; Garcia R, 2009, EMBO REP, V10, P278, DOI 10.1038/embor.2009.4; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hagan S, 2005, CLIN CANCER RES, V11, P7392, DOI 10.1158/1078-0432.CCR-05-0283; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Li HZ, 2007, J BIOL CHEM, V282, P4943, DOI 10.1074/jbc.M609494200; Li P, 2006, INT J MOL MED, V18, P505; Liu HB, 2010, J BIOL CHEM, V285, P21934, DOI 10.1074/jbc.M110.109876; Liu HY, 2012, TUMOR BIOL, V33, P267, DOI 10.1007/s13277-011-0279-x; Lopez-Knowles E, 2010, INT J CANCER, V126, P1121, DOI 10.1002/ijc.24831; Luan B, 2009, NATURE, V457, P1146, DOI 10.1038/nature07617; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Min CY, 2008, J CELL BIOCHEM, V104, P733, DOI 10.1002/jcb.21695; Odabaei G, 2004, ADV CANCER RES, V91, P169, DOI 10.1016/S0065-230X(04)91005-6; Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2; Qiao M, 2008, CELL CYCLE, V7, P2991, DOI 10.4161/cc.7.19.6784; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Wang XJ, 2005, CLIN CANCER RES, V11, P7545, DOI 10.1158/1078-0432.CCR-05-0879; Wang XJ, 2004, J BIOL CHEM, V279, P45855, DOI 10.1074/jbc.M405147200; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Yang WL, 2010, CELL CYCLE, V9, P486, DOI 10.4161/cc.9.3.10508; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yu GP, 2012, TUMOR BIOL, V33, P223, DOI 10.1007/s13277-011-0265-3; Yu GP, 2011, TUMOR BIOL, V32, P1257, DOI 10.1007/s13277-011-0230-1; Yu GP, 2013, TUMOR BIOL, V34, P91, DOI 10.1007/s13277-012-0514-0; Zhang YY, 2007, INT J MOL MED, V19, P55; Zheng Y, 2010, MOL CELL BIOL, V30, P4280, DOI 10.1128/MCB.00024-10; Zhu QS, 2011, ONCOGENE, V30, P457, DOI 10.1038/onc.2010.421	39	26	30	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2014	33	37					4589	4598		10.1038/onc.2013.408	http://dx.doi.org/10.1038/onc.2013.408			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3UZ	24276246				2022-12-28	WOS:000342004800006
J	Cook, DR; Rossman, KL; Der, CJ				Cook, D. R.; Rossman, K. L.; Der, C. J.			Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease	ONCOGENE			English	Review						Rac1; RhoA; Cdc42; guanine nucleotide exchange factors; cancer; mouse models	EXPRESSION CDNA CLONING; LINKED MENTAL-RETARDATION; SIGNAL TRANSDUCER VAV1; CELL LYMPHOMA INVASION; RAC ACTIVATOR TIAM1; METASTASIS 2 TIAM2; PROTEIN-KINASE-C; B-CELL; PROSTATE-CANCER; T-CELL	The aberrant activity of Ras homologous (Rho) family small GTPases (20 human members) has been implicated in cancer and other human diseases. However, in contrast to the direct mutational activation of Ras found in cancer and developmental disorders, Rho GTPases are activated most commonly in disease by indirect mechanisms. One prevalent mechanism involves aberrant Rho activation via the deregulated expression and/or activity of Rho family guanine nucleotide exchange factors (RhoGEFs). RhoGEFs promote formation of the active GTP-bound state of Rho GTPases. The largest family of RhoGEFs is comprised of the Dbl family RhoGEFs with 70 human members. The multitude of RhoGEFs that activate a single Rho GTPase reflects the very specific role of each RhoGEF in controlling distinct signaling mechanisms involved in Rho activation. In this review, we summarize the role of Dbl RhoGEFs in development and disease, with a focus on Ect2 (epithelial cell transforming squence 2), Tiam1 (T-cell lymphoma invasion and metastasis 1), Vav and P-Rex1/2 (PtdIns(3,4,5) P3 (phosphatidylinositol (3,4,5)-triphosphate)-dependent Rac exchanger).	[Cook, D. R.] Univ N Carolina, Div Chem Biol & Med Chem, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Rossman, K. L.; Der, C. J.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; [Rossman, K. L.; Der, C. J.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Der, CJ (corresponding author), Univ N Carolina, Dept Pharmacol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	cjder@med.unc.edu		Der, Channing/0000-0002-7751-2747	NIH; AACR/Pancreatic Cancer Action Network; Lustgarten Pancreatic Cancer Foundation;  [CA71341];  [CA159821]; NATIONAL CANCER INSTITUTE [T32CA071341, R01CA042978, F31CA159821] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AACR/Pancreatic Cancer Action Network; Lustgarten Pancreatic Cancer Foundation; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Adrienne D Cox for careful and critical reading of our manuscript. We apologize to colleagues whose studies we did not cite due to space limitations. CJD is supported by grants from the NIH, AACR/Pancreatic Cancer Action Network and the Lustgarten Pancreatic Cancer Foundation. DRC was supported by a T32 training grant (CA71341) and an F31 predoctoral fellowship (CA159821).	Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Adam L, 2001, J BIOL CHEM, V276, P28443, DOI 10.1074/jbc.M009769200; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Alto NM, 2006, CELL, V124, P133, DOI 10.1016/j.cell.2005.10.031; Aoki Y, 2013, INT J HEMATOL, V97, P30, DOI 10.1007/s12185-012-1239-y; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Balakrishnan A, 2007, CANCER RES, V67, P3545, DOI 10.1158/0008-5472.CAN-07-0065; Barrio-Real L, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003543; Bartolome RA, 2006, CANCER RES, V66, P248, DOI 10.1158/0008-5472.CAN-05-2489; Berger MF, 2012, NATURE, V485, P502, DOI 10.1038/nature11071; Berken A, 2005, NATURE, V436, P1176, DOI 10.1038/nature03883; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Buchsbaum RJ, 2003, J BIOL CHEM, V278, P18833, DOI 10.1074/jbc.M207876200; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Buchwald G, 2002, EMBO J, V21, P3286, DOI 10.1093/emboj/cdf329; Bulgin R, 2010, INFECT IMMUN, V78, P1417, DOI 10.1128/IAI.01250-09; Burkard ME, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000111; Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; Bustelo XR, 2002, FRONT BIOSCI, V7, pD24, DOI 10.2741/bustelo; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; Cahill ME, 2009, P NATL ACAD SCI USA, V106, P13058, DOI 10.1073/pnas.0904636106; Cai HB, 2005, J NEUROSCI, V25, P7567, DOI 10.1523/JNEUROSCI.1645-05.2005; Chan AML, 1996, ONCOGENE, V12, P1259; CHAN AML, 1994, ONCOGENE, V9, P1057; Chen JS, 2012, INT J CANCER, V130, P1302, DOI 10.1002/ijc.26117; Chiu CY, 1999, GENOMICS, V61, P66, DOI 10.1006/geno.1999.5936; Citterio C, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002962; Clapcott SJ, 2003, MAMM GENOME, V14, P495, DOI 10.1007/s00335-002-2258-4; Coleman Natalia, 2012, Cell Logist, V2, P132; Cook Danielle R, 2011, Genes Cancer, V2, P932, DOI 10.1177/1947601912437035; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Cox Adrienne D, 2010, Small GTPases, V1, P2; Creedon Helen, 2012, Critical Reviews in Oncogenesis, V17, P145; de Mora JF, 2003, EMBO J, V22, P3039, DOI 10.1093/emboj/cdg280; Delague V, 2007, AM J HUM GENET, V81, P1, DOI 10.1086/518428; Deng HX, 2007, HUM MOL GENET, V16, P2911, DOI 10.1093/hmg/ddm251; Devon RS, 2006, P NATL ACAD SCI USA, V103, P9595, DOI 10.1073/pnas.0510197103; Devon RS, 2003, CLIN GENET, V64, P210, DOI 10.1034/j.1399-0004.2003.00138.x; Donald S, 2004, FEBS LETT, V572, P172, DOI 10.1016/j.febslet.2004.06.096; Donald S, 2008, P NATL ACAD SCI USA, V105, P4483, DOI 10.1073/pnas.0712324105; Dong N, 2010, EMBO J, V29, P1363, DOI 10.1038/emboj.2010.33; Dong ZY, 2006, MOL ENDOCRINOL, V20, P2315, DOI 10.1210/me.2006-0048; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; Engers R, 2006, BRIT J CANCER, V95, P1081, DOI 10.1038/sj.bjc.6603385; Engers R, 2001, J BIOL CHEM, V276, P41889, DOI 10.1074/jbc.M105049200; Esteban LM, 2000, MOL CELL BIOL, V20, P6410, DOI 10.1128/MCB.20.17.6410-6413.2000; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1987, ONCOGENE, V1, P355; Eymard-Pierre E, 2002, AM J HUM GENET, V71, P518, DOI 10.1086/342359; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; Fernandez-Medarde A, 2002, MOL CELL BIOL, V22, P2498, DOI 10.1128/MCB.22.8.2498-2504.2002; Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024; Fields AP, 2010, ADV ENZYME REGUL, V50, P190, DOI 10.1016/j.advenzreg.2009.10.010; Fine B, 2009, SCIENCE, V325, P1261, DOI 10.1126/science.1173569; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Francis SA, 2006, BLOOD, V107, P1627, DOI 10.1182/blood-2005-03-1164; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; Galan JE, 2009, CELL HOST MICROBE, V5, P571, DOI 10.1016/j.chom.2009.04.008; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Garcia-Mata R, 2011, NAT REV MOL CELL BIO, V12, P493, DOI 10.1038/nrm3153; Genot E, 2012, J CELL SCI, V125, P3265, DOI 10.1242/jcs.093419; Gerloff DL, 2012, FEBS LETT, V586, P2711, DOI 10.1016/j.febslet.2012.05.005; Giese KP, 2001, NEUROPHARMACOLOGY, V41, P791, DOI 10.1016/S0028-3908(01)00096-X; Girkontaite I, 2001, NAT IMMUNOL, V2, P855, DOI 10.1038/ni0901-855; GRAY BN, 1992, AUST NZ J SURG, V62, P105; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hadano S, 2006, HUM MOL GENET, V15, P233, DOI 10.1093/hmg/ddi440; Hadano S, 2001, NAT GENET, V29, P166, DOI 10.1038/ng1001-166; Hall A, 2012, BIOCHEM SOC T, V40, P1378, DOI 10.1042/BST20120103; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Harenberg A, 2005, EUR J IMMUNOL, V35, P1977, DOI 10.1002/eji.200425769; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Harvey K, 2004, J NEUROSCI, V24, P5816, DOI 10.1523/JNEUROSCI.1184-04.2004; Heid I, 2011, GASTROENTEROLOGY, V141, P719, DOI 10.1053/j.gastro.2011.04.043; HENSKE EP, 1995, ANN HUM GENET, V59, P25, DOI 10.1111/j.1469-1809.1995.tb01603.x; Himmel KL, 2002, J BIOL CHEM, V277, P13463, DOI 10.1074/jbc.M110981200; Hirata D, 2009, CLIN CANCER RES, V15, P256, DOI 10.1158/1078-0432.CCR-08-1672; Hirsch E, 2002, MOL CELL BIOL, V22, P3140, DOI 10.1128/MCB.22.9.3140-3148.2002; Hocker HJ, 2013, P NATL ACAD SCI USA, V110, P10201, DOI 10.1073/pnas.1300016110; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Hornstein I, 2003, J PATHOL, V199, P526, DOI 10.1002/path.1314; Hoshinoso M, 1999, J BIOL CHEM, V274, P17837, DOI 10.1074/jbc.274.25.17837; Itier JM, 1998, NATURE, V393, P125, DOI 10.1038/30120; Iyoda M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014082; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Jin H, 2011, HUM PATHOL, V42, P541, DOI 10.1016/j.humpath.2010.08.013; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Jung Y, 2011, CLIN CANCER RES, V17, P700, DOI 10.1158/1078-0432.CCR-10-1300; Justilien V, 2009, ONCOGENE, V28, P3597, DOI 10.1038/onc.2009.217; Kaartinen V, 2002, DEV DYNAM, V223, P517, DOI 10.1002/dvdy.10071; Kaartinen V, 2001, DEVELOPMENT, V128, P4217; Kalscheuer VM, 2009, HUM MUTAT, V30, P61, DOI 10.1002/humu.20814; Kanekura K, 2005, J BIOL CHEM, V280, P4532, DOI 10.1074/jbc.M410508200; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kawasaki Y, 2010, J BIOL CHEM, V285, P1199, DOI 10.1074/jbc.M109.040691; Kawasaki Y, 2009, EMBO REP, V10, P1355, DOI 10.1038/embor.2009.233; Kim JE, 2005, J BIOL CHEM, V280, P5733, DOI 10.1074/jbc.M409298200; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Kino T, 2006, J BIOL CHEM, V281, P9118, DOI 10.1074/jbc.M509339200; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lane Jane, 2008, Int Semin Surg Oncol, V5, P23, DOI 10.1186/1477-7800-5-23; Lange S, 2009, J CELL SCI, V122, P2640, DOI 10.1242/jcs.046193; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Lazer G, 2011, CELL SIGNAL, V23, P969, DOI 10.1016/j.cellsig.2010.10.022; Lazer G, 2009, J PATHOL, V219, P25, DOI 10.1002/path.2579; Lesca G, 2011, AM J MED GENET A, V155A, P1706, DOI 10.1002/ajmg.a.34004; Leung CCY, 2011, CELL CYCLE, V10, P2461, DOI 10.4161/cc.10.15.16312; Lin KY, 2012, MOL CANCER RES, V10, P750, DOI 10.1158/1541-7786.MCR-11-0598-T; Lindsay CR, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1560; Liot C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023676; Liu L, 2006, NEOPLASIA, V8, P917, DOI 10.1593/neo.06364; Liu Y, 2008, CANCER RES, V68, P6396, DOI 10.1158/0008-5472.CAN-08-0645; Lyons LS, 2008, MOL ENDOCRINOL, V22, P597, DOI 10.1210/me.2007-0158; Lyons LS, 2006, MOL ENDOCRINOL, V20, P1061, DOI 10.1210/me.2005-0346; Ma XM, 2008, J NEUROSCI, V28, P12368, DOI 10.1523/JNEUROSCI.4269-08.2008; Malliri A, 2006, J BIOL CHEM, V281, P543, DOI 10.1074/jbc.M507582200; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Mandela P, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/728161; Marco EJ, 2008, J MED GENET, V45, P100, DOI 10.1136/jmg.2007.052324; Maurer T, 2012, P NATL ACAD SCI USA, V109, P5299, DOI 10.1073/pnas.1116510109; Mayers CM, 2010, J BIOL CHEM, V285, P12344, DOI 10.1074/jbc.M110.106856; Meller N, 2005, J CELL SCI, V118, P4937, DOI 10.1242/jcs.02671; Mikelis CM, 2013, J BIOL CHEM, V288, P12232, DOI 10.1074/jbc.M112.428599; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Miller MB, 2013, NEUROSCIENTIST, V19, P255, DOI 10.1177/1073858413475486; Minard ME, 2006, CLIN EXP METASTAS, V23, P301, DOI 10.1007/s10585-006-9040-z; Missy K, 2008, MOL CELL BIOL, V28, P3776, DOI 10.1128/MCB.00507-07; Mochly-Rosen D, 2012, NAT REV DRUG DISCOV, V11, P937, DOI 10.1038/nrd3871; Montero JC, 2011, ONCOGENE, V30, P1059, DOI 10.1038/onc.2010.489; Mossessova E, 2003, MOL CELL, V12, P1403, DOI 10.1016/S1097-2765(03)00475-1; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Nagawa Shingo, 2010, Small GTPases, V1, P78, DOI 10.4161/sgtp.1.2.14544; NOGUCHI T, 1988, ONCOGENE, V3, P709; Nomura T, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-27; O'Brien SP, 2000, P NATL ACAD SCI USA, V97, P12074, DOI 10.1073/pnas.97.22.12074; Orchard RC, 2012, CELL MICROBIOL, V14, P10, DOI 10.1111/j.1462-5822.2011.01703.x; Otomo A, 2003, HUM MOL GENET, V12, P1671, DOI 10.1093/hmg/ddg184; Pakes Nicholl K, 2013, Small GTPases, V4, P22, DOI 10.4161/sgtp.22087; Papadopoulos T, 2007, EMBO J, V26, P3888, DOI 10.1038/sj.emboj.7601819; PASTERIS NG, 1994, CELL, V79, P669; Peng YJ, 2010, J BIOL CHEM, V285, P24834, DOI 10.1074/jbc.M109.096537; Perry NA, 2013, IUBMB LIFE, V65, P479, DOI 10.1002/iub.1157; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Prieto-Sanchez RM, 2006, BRIT J HAEMATOL, V133, P642, DOI 10.1111/j.1365-2141.2006.06094.x; Qian XL, 2000, EMBO J, V19, P642, DOI 10.1093/emboj/19.4.642; Qin J, 2009, ONCOGENE, V28, P1853, DOI 10.1038/onc.2009.30; Ramakers GJA, 2012, HUM MOL GENET, V21, P268, DOI 10.1093/hmg/ddr457; Rao S, 2012, ONCOGENE, V31, P716, DOI 10.1038/onc.2011.273; Rath N, 2012, EMBO REP, V13, P900, DOI 10.1038/embor.2012.127; Roberts AE, 2007, NAT GENET, V39, P70, DOI 10.1038/ng1926; Robineau S, 2000, P NATL ACAD SCI USA, V97, P9913, DOI 10.1073/pnas.170290597; Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10; Rosenfeldt H, 2004, FEBS LETT, V572, P167, DOI 10.1016/j.febslet.2004.06.097; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Roversi G, 2006, ONCOGENE, V25, P1571, DOI 10.1038/sj.onc.1209177; Rubtsov A, 2005, IMMUNITY, V23, P527, DOI 10.1016/j.immuni.2005.09.018; Ruiz S, 2007, MOL CELL BIOL, V27, P8127, DOI 10.1128/MCB.00912-07; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Saito S, 2004, J BIOL CHEM, V279, P7169, DOI 10.1074/jbc.M306725200; Saito S, 2003, J CELL BIOCHEM, V90, P819, DOI 10.1002/jcb.10688; Salhia B, 2008, AM J PATHOL, V173, P1828, DOI 10.2353/ajpath.2008.080043; Sano M, 2006, ONCOL REP, V16, P1093; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuebel KE, 1996, ONCOGENE, V13, P363; Shang X, 2013, P NATL ACAD SCI USA, V110, P3155, DOI 10.1073/pnas.1212324110; Shang X, 2012, CHEM BIOL, V19, P699, DOI 10.1016/j.chembiol.2012.05.009; Shimojima K, 2011, J HUM GENET, V56, P561, DOI 10.1038/jhg.2011.58; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Solski PA, 2004, J BIOL CHEM, V279, P25226, DOI 10.1074/jbc.M313792200; Sosa MS, 2010, MOL CELL, V40, P877, DOI 10.1016/j.molcel.2010.11.029; Spindler MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062705; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Stebel A, 2009, ONCOL REP, V21, P217, DOI 10.3892/or_00000211; Stendel C, 2007, AM J HUM GENET, V81, P158, DOI 10.1086/518770; Strumane K, 2009, J CANCER RES CLIN, V135, P69, DOI 10.1007/s00432-008-0437-8; Sugihara K, 1998, ONCOGENE, V17, P3427, DOI 10.1038/sj.onc.1202595; Sun Q, 2012, ANGEW CHEM INT EDIT, V51, P6140, DOI 10.1002/anie.201201358; Tanaka M, 2004, EMBO J, V23, P1075, DOI 10.1038/sj.emboj.7600128; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Tartaglia M, 2007, NAT GENET, V39, P75, DOI 10.1038/ng1939; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; Terawaki S, 2010, EMBO J, V29, P236, DOI 10.1038/emboj.2009.323; TOKSOZ D, 1994, ONCOGENE, V9, P621; Tolias KF, 2007, P NATL ACAD SCI USA, V104, P7265, DOI 10.1073/pnas.0702044104; Topp JD, 2004, J BIOL CHEM, V279, P24612, DOI 10.1074/jbc.M313504200; Trenkle T, 2000, GENE, V245, P139, DOI 10.1016/S0378-1119(00)00026-3; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Uhlenbrock K, 2004, J CELL SCI, V117, P4863, DOI 10.1242/jcs.01367; Van de Putte T, 2001, MECH DEVELOP, V102, P33, DOI 10.1016/S0925-4773(01)00279-9; Vega FM, 2007, CELL, V129, P1430, DOI 10.1016/j.cell.2007.06.021; Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; Wang DZM, 1997, GENE DEV, V11, P309, DOI 10.1101/gad.11.3.309; Wang ZL, 2009, J BIOL CHEM, V284, P28599, DOI 10.1074/jbc.M109.047282; Weeks A, 2012, AM J PATHOL, V181, P662, DOI 10.1016/j.ajpath.2012.04.011; Welch HCE, 2005, CURR BIOL, V15, P1867, DOI 10.1016/j.cub.2005.09.050; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Wirth A, 2008, NAT MED, V14, P64, DOI 10.1038/nm1666; Wolfe BA, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000110; Wu G, 2000, PLANT PHYSIOL, V124, P1625, DOI 10.1104/pp.124.4.1625; Yamanaka K, 2006, ANN NEUROL, V60, P95, DOI 10.1002/ana.20888; Yang J, 2009, SCIENCE, V325, P1398, DOI 10.1126/science.1174468; Yang Y, 2001, NAT GENET, V29, P160, DOI 10.1038/ng1001-160; YANG ZB, 1993, P NATL ACAD SCI USA, V90, P8732, DOI 10.1073/pnas.90.18.8732; Yoo S, 2012, MOL CELLS, V34, P103, DOI 10.1007/s10059-012-0119-x; Yoon B, 2005, MOL CELL BIOL, V25, P11184, DOI 10.1128/MCB.25.24.11184-11190.2005; Yu BK, 2010, CELL, V140, P246, DOI 10.1016/j.cell.2009.12.033; Zhang ML, 2008, HEPATOB PANCREAT DIS, V7, P533; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; Zizer E, 2010, GASTROENTEROLOGY, V139, P1344, DOI 10.1053/j.gastro.2010.06.041	225	239	245	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2014	33	31					4021	4035		10.1038/onc.2013.362	http://dx.doi.org/10.1038/onc.2013.362			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YG	24037532	Green Accepted, Green Submitted			2022-12-28	WOS:000340595300001
J	Chen, CH; Thai, P; Yoneda, K; Adler, KB; Yang, PC; Wu, R				Chen, C-H; Thai, P.; Yoneda, K.; Adler, K. B.; Yang, P-C; Wu, R.			A peptide that inhibits function of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis	ONCOGENE			English	Article						MARCKS; MANS peptide; migration; metastasis; lung cancer	PROTEIN-KINASE; IN-VITRO; THERAPEUTIC TARGET; TUMOR-METASTASIS; PLASMA-MEMBRANE; GENE-EXPRESSION; MOUSE MODEL; RHO-KINASE; PHOSPHORYLATION; CELLS	Myristoylated Alanine-Rich C Kinase Substrate (MARCKS), a substrate of protein kinase C, is a key regulatory molecule controlling mucus granule secretion by airway epithelial cells as well as directed migration of leukocytes, stem cells and fibroblasts. Phosphorylation of MARKCS may be involved in these responses. However, the functionality of MARCKS and its related phosphorylation in lung cancer malignancy have not been characterized. This study demonstrated elevated levels of MARCKS and phospho-MARCKS in highly invasive lung cancer cell lines and lung cancer specimens from non-small-cell lung cancer patients. siRNA knockdown of MARCKS expression in these highly invasive lung cancer cell lines reduced cell migration and suppressed PI3K (phosphatidylinositol 30-kinase)/Akt phosphorylation and Slug level. Interestingly, treatment with a peptide identical to the MARCKS N-terminus sequence (the MANS peptide) impaired cell migration in vitro and also the metastatic potential of invasive lung cancer cells in vivo. Mechanistically, MANS peptide treatment resulted in a coordination of increase of E-cadherin expression, suppression of MARCKS phosphorylation and AKT/Slug signalling pathway but not the expression of total MARCKS. These results indicate a crucial role for MARCKS, specifically its phosphorylated form, in potentiating lung cancer cell migration/metastasis and suggest a potential use of MARCKS-related peptides in the treatment of lung cancer metastasis.	[Chen, C-H; Thai, P.; Yoneda, K.; Wu, R.] Univ Calif Davis, Dept Internal Med, Div Pulm & Crit Care Med, Davis, CA 95616 USA; [Chen, C-H; Thai, P.; Yoneda, K.; Wu, R.] Univ Calif Davis, Ctr Comparat Resp Biol & Med, Davis, CA 95616 USA; [Adler, K. B.] N Carolina State Univ, Dept Mol Biomed Sci, Raleigh, NC 27695 USA; [Yang, P-C] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei, Taiwan	University of California System; University of California Davis; University of California System; University of California Davis; University of North Carolina; North Carolina State University; National Taiwan University	Wu, R (corresponding author), Univ Calif Davis, Dept Internal Med, Div Pulm & Crit Care Med, GBSF Room 6510-6523, Davis, CA 95616 USA.	rwu@ucdavis.edu	Tsou, YY/H-4160-2011	Tsou, YY/0000-0003-3345-4351; YANG, PAN-CHYR/0000-0001-6330-6048	NIH-NHLBI [HL077902, HL096373, HL36982]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036982, R01HL096373, R01HL036982, R01HL077902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009701] Funding Source: NIH RePORTER	NIH-NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This study was supported, in parts, by Grants from the NIH-NHLBI (HL077902, HL096373, and HL36982).	Botto L, 2004, FEBS LETT, V557, P143, DOI 10.1016/S0014-5793(03)01463-7; Brooks G, 1996, CARCINOGENESIS, V17, P683, DOI 10.1093/carcin/17.4.683; Chen JJW, 2001, CANCER RES, V61, P5223; Chen XY, 2010, CELL SIGNAL, V22, P1097, DOI 10.1016/j.cellsig.2010.03.003; Chen Y, 2011, CANCER RES, V71, P1721, DOI 10.1158/0008-5472.CAN-09-4683; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Eckert RE, 2010, AM J RESP CELL MOL, V42, P586, DOI 10.1165/rcmb.2008-0394OC; Fan T, 2007, CANCER RES, V67, P7901, DOI 10.1158/0008-5472.CAN-07-0090; Fenouille N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040378; Garcia J, 2012, EMBO REP, V13, P431, DOI 10.1038/embor.2012.29; Gonzalez-Guerrico AM, 2005, J BIOCHEM MOL BIOL, V38, P639; Hanigan Marie H, 2003, Cancer Ther, V1, P47; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Jarboe JS, 2012, CLIN CANCER RES, V18, P3030, DOI 10.1158/1078-0432.CCR-11-3091; Kalwa H, 2011, J BIOL CHEM, V286, P2320, DOI 10.1074/jbc.M110.196022; Kim J, 2011, ONCOGENE, V30, P323, DOI 10.1038/onc.2010.415; Li YH, 2001, J BIOL CHEM, V276, P40982, DOI 10.1074/jbc.M105614200; Liu SJ, 2009, CANCER RES, V69, P8742, DOI 10.1158/0008-5472.CAN-09-1541; Lukk M, 2010, NAT BIOTECHNOL, V28, P322, DOI 10.1038/nbt0410-322; McLaughlin S, 2005, NATURE, V438, P605, DOI 10.1038/nature04398; Micallef J, 2009, CANCER RES, V69, P7548, DOI 10.1158/0008-5472.CAN-08-4783; Michel S, 2010, MOL CARCINOGEN, V49, P175, DOI 10.1002/mc.20587; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; NAIRN AC, 1992, CIBA F SYMP, V164, P145; Naylor TL, 2011, CANCER RES, V71, P2643, DOI 10.1158/0008-5472.CAN-10-2525; Ohmitsu M, 1999, J BIOL CHEM, V274, P408, DOI 10.1074/jbc.274.1.408; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Rath N, 2012, EMBO REP, V13, P900, DOI 10.1038/embor.2012.127; Reddy MM, 2011, LEUKEMIA, V25, P281, DOI 10.1038/leu.2010.263; Roffey J, 2009, CURR OPIN CELL BIOL, V21, P268, DOI 10.1016/j.ceb.2009.01.019; Rombouts K, 2013, CANCER LETT, V333, P244, DOI 10.1016/j.canlet.2013.01.040; Shih JY, 2011, CARCINOGENESIS, V32, P1299, DOI 10.1093/carcin/bgr110; Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687; Singer M, 2004, NAT MED, V10, P193, DOI 10.1038/nm983; Takashi S, 2006, AM J RESP CELL MOL, V34, P647, DOI 10.1165/rcmb.2006-0030RC; Tanabe A, 2006, BIOCHEM BIOPH RES CO, V345, P156, DOI 10.1016/j.bbrc.2006.04.082; Tatsumi S, 2005, NEUROSCIENCE, V131, P491, DOI 10.1016/j.neuroscience.2004.10.022; Tauskela JS, 2009, NEUROSCI LETT, V466, P41, DOI 10.1016/j.neulet.2009.09.028; Techasen A, 2010, CANCER SCI, V101, P658, DOI 10.1111/j.1349-7006.2009.01427.x; Teicher BA, 2006, CLIN CANCER RES, V12, P5336, DOI 10.1158/1078-0432.CCR-06-0945; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Yamaguchi H, 2009, J CELL PHYSIOL, V220, P748, DOI 10.1002/jcp.21822; Yarmola EG, 2001, J BIOL CHEM, V276, P22351, DOI 10.1074/jbc.M101457200; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yokoyama Y, 1998, INT J CANCER, V75, P774, DOI 10.1002/(SICI)1097-0215(19980302)75:5<774::AID-IJC18>3.3.CO;2-P; Zhang K, 2012, DIS ESOPHAGUS, V25, P731, DOI 10.1111/j.1442-2050.2012.01323.x	49	52	57	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3696	3706		10.1038/onc.2013.336	http://dx.doi.org/10.1038/onc.2013.336			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23955080	Green Accepted			2022-12-28	WOS:000338942900009
J	Sun, M; Gomes, S; Chen, P; Frankenberger, CA; Sankarasharma, D; Chung, CH; Chada, KK; Rosner, MR				Sun, M.; Gomes, S.; Chen, P.; Frankenberger, C. A.; Sankarasharma, D.; Chung, C. H.; Chada, K. K.; Rosner, M. R.			RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2	ONCOGENE			English	Article						RKIP; HMGA2; LOX; SDC2; breast; metastasis	INHIBITOR PROTEIN EXPRESSION; CANCER METASTASIS; MESENCHYMAL TRANSITION; COLORECTAL-CANCER; SIGNALING PATHWAY; PROSTATE-CANCER; MIR-200 FAMILY; GENES; PROGRESSION; LET-7	Elucidating targets of physiological tumor metastasis suppressors can highlight key signaling pathways leading to invasion and metastasis. To identify downstream targets of the metastasis suppressor Raf-1 kinase inhibitory protein (RKIP/PEBP1), we utilized an integrated approach based upon statistical analysis of tumor gene expression data combined with experimental validation. Previous studies from our laboratory identified the architectural transcription factor and oncogene, high mobility group AT-hook 2 (HMGA2), as a target of inhibition by RKIP. Here we identify two signaling pathways that promote HMGA2-driven metastasis. Using both human breast tumor cells and an MMTV-Wnt mouse breast tumor model, we show that RKIP induces and HMGA2 inhibits expression of miR-200b; miR-200b directly inhibits expression of lysyl oxidase (LOX), leading to decreased invasion. RKIP also inhibits syndecan-2 (SDC2), which is aberrantly expressed in breast cancer, via downregulation of HMGA2; but this mechanism is independent of miR-200. Depletion of SDC2 induces apoptosis and suppresses breast tumor growth and metastasis in mouse xenografts. RKIP, LOX and SDC2 are coordinately regulated and collectively encompass a prognostic signature for metastasis-free survival in ER-negative breast cancer patients. Taken together, our findings reveal two novel signaling pathways targeted by the metastasis suppressor RKIP that regulate remodeling of the extracellular matrix and tumor survival.	[Sun, M.; Gomes, S.; Frankenberger, C. A.; Rosner, M. R.] Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA; [Sun, M.; Rosner, M. R.] Univ Chicago, Comm Genet Genom & Syst Biol, Chicago, IL 60637 USA; [Chen, P.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Sankarasharma, D.; Chada, K. K.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ USA; [Chung, C. H.] Vanderbilt Univ, Sch Med, Dept Med & Canc Biol, Div Hematol Oncol, Nashville, TN 37212 USA	University of Chicago; University of Chicago; University of Chicago; Rutgers State University New Brunswick; Rutgers State University Medical Center; Vanderbilt University	Rosner, MR (corresponding author), Univ Chicago, Ben May Dept Canc Res, GCIS W421C,929 E 57th St, Chicago, IL 60637 USA.	m-rosner@uchicago.edu			NIH [GM087630]; DOD Predoctoral Traineeship Award [W81XWH-10-1-0396]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM087630] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD Predoctoral Traineeship Award; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH grant GM087630 to MRR and DOD Predoctoral Traineeship Award W81XWH-10-1-0396 to MS. We also thank Eva Eves for technical support and helpful discussion.	Al-Mulla F, 2006, J CLIN ONCOL, V24, P5672, DOI 10.1200/JCO.2006.07.5499; Barbareschi M, 2003, CANCER-AM CANCER SOC, V98, P474, DOI 10.1002/cncr.11515; Berger JA, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-194; Corbit KC, 2003, J BIOL CHEM, V278, P13061, DOI 10.1074/jbc.M210015200; Csiszar K, 2001, PROG NUCLEIC ACID RE, V70, P1, DOI 10.1016/S0079-6603(01)70012-8; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; De Oliveira T, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-19; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Efron B, 2007, ANN APPL STAT, V1, P107, DOI 10.1214/07-AOAS101; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Fu Z, 2003, J NATL CANCER I, V95, P878, DOI 10.1093/jnci/95.12.878; Fu Z, 2006, PROSTATE, V66, P248, DOI 10.1002/pros.20319; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Hagan S, 2005, CLIN CANCER RES, V11, P7392, DOI 10.1158/1078-0432.CCR-05-0283; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jiang X, 2012, CANCER CELL, V22, P524, DOI 10.1016/j.ccr.2012.08.028; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lambaerts K, 2009, CURR OPIN CELL BIOL, V21, P662, DOI 10.1016/j.ceb.2009.05.002; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li YW, 2009, CANCER RES, V69, P6704, DOI 10.1158/0008-5472.CAN-09-1298; Li ZJ, 2008, P NATL ACAD SCI USA, V105, P15535, DOI 10.1073/pnas.0808266105; Loussouarn D, 2008, BRIT J CANCER, V98, P1993, DOI 10.1038/sj.bjc.6604400; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Marion A, 2012, INT J CANCER, V130, P2514, DOI 10.1002/ijc.26246; Massague J, 2007, NEW ENGL J MED, V356, P294, DOI 10.1056/NEJMe068292; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; Minn AJ, 2012, CELL CYCLE, V11, P2452, DOI 10.4161/cc.20624; Minoo P, 2007, AM J CLIN PATHOL, V127, P820, DOI 10.1309/5D7MM22DAVGDT1R8; Morishita A, 2013, CANCER RES, V73, P4289, DOI 10.1158/0008-5472.CAN-12-3848; Nikolova V, 2009, CARCINOGENESIS, V30, P397, DOI 10.1093/carcin/bgp001; Park H, 2002, J BIOL CHEM, V277, P29730, DOI 10.1074/jbc.M202435200; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Peter ME, 2009, CELL CYCLE, V8, P843, DOI 10.4161/cc.8.6.7907; Popovic A, 2010, PROSTATE CANCER P D, V13, P78, DOI 10.1038/pcan.2009.43; Ritchie ME, 2007, BIOINFORMATICS, V23, P2700, DOI 10.1093/bioinformatics/btm412; Schuetz CS, 2006, CANCER RES, V66, P5278, DOI 10.1158/0008-5472.CAN-05-4610; Smith SC, 2009, NAT REV CANCER, V9, P253, DOI 10.1038/nrc2594; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Sun M, 2013, P NATL ACAD SCI USA, V110, P9920, DOI 10.1073/pnas.1305172110; Team RDC, 2009, R LANG ENV STAT COMP; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Xu YF, 2010, J HEPATOL, V53, P872, DOI 10.1016/j.jhep.2010.05.019; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yun JU, 2011, EMBO J, V30, P4500, DOI 10.1038/emboj.2011.312	55	64	68	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3528	3537		10.1038/onc.2013.328	http://dx.doi.org/10.1038/onc.2013.328			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23975428	Green Accepted			2022-12-28	WOS:000338941100005
J	Qian, X; Anzovino, A; Kim, S; Suyama, K; Yao, J; Hulit, J; Agiostratidou, G; Chandiramani, N; McDaid, HM; Nagi, C; Cohen, HW; Phillips, GR; Norton, L; Hazan, RB				Qian, X.; Anzovino, A.; Kim, S.; Suyama, K.; Yao, J.; Hulit, J.; Agiostratidou, G.; Chandiramani, N.; McDaid, H. M.; Nagi, C.; Cohen, H. W.; Phillips, G. R.; Norton, L.; Hazan, R. B.			N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties	ONCOGENE			English	Article						ErbB2; N-cadherin; FGFR; mammospheres; metastasis	BREAST-CANCER; STEM-CELLS; GROWTH; MIGRATION; FGF; POPULATION; INVASION; SUBPOPULATIONS; PROLIFERATION; ESTABLISHMENT	N-cadherin and HER2/neu were found to be co-expressed in invasive breast carcinomas. To test the contribution of N-cadherin and HER2 in mammary tumor metastasis, we targeted N-cadherin expression in the mammary epithelium of the MMTV-Neu mouse. In the context of ErbB2/Neu, N-cadherin stimulated carcinoma cell invasion, proliferation and metastasis. N-cadherin caused fibroblast growth factor receptor (FGFR) upmodulation, resulting in epithelial-to-mesenchymal transition (EMT) and stem/progenitor like properties, involving Snail and Slug upregulation, mammosphere formation and aldehyde dehydrogenase activity. N-cadherin potentiation of the FGFR stimulated extracellular signal regulated kinase (ERK) and protein kinase B (AKT) phosphorylation resulting in differential effects on metastasis. Although ERK inhibition suppressed cyclin D1 expression, cell proliferation and stem/progenitor cell properties, it did not affect invasion or EMT. Conversely, AKT inhibition suppressed invasion through Akt 2 attenuation, and EMT through Snail inhibition, but had no effect on cyclin D1 expression, cell proliferation or mammosphere formation. These findings suggest N-cadherin/FGFR has a pivotal role in promoting metastasis through differential regulation of ERK and AKT, and underscore the potential for targeting the FGFR in advanced ErbB2-amplified breast tumors.	[Qian, X.; Anzovino, A.; Kim, S.; Suyama, K.; Yao, J.; Agiostratidou, G.; Chandiramani, N.; Hazan, R. B.] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; [Hulit, J.] Univ Manchester, Manchester Breast Ctr, Manchester, Lancs, England; [Hulit, J.] Univ Manchester, Paterson Inst Canc Res, Breakthrough Breast Canc Res Unit, Manchester, Lancs, England; [McDaid, H. M.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; [Nagi, C.] Mt Sinai Sch Med, Dept Pathol, New York, NY USA; [Cohen, H. W.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA; [Phillips, G. R.] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA; [Norton, L.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; University of Manchester; Paterson Institute for Cancer Research; University of Manchester; Yeshiva University; Albert Einstein College of Medicine; Icahn School of Medicine at Mount Sinai; Yeshiva University; Albert Einstein College of Medicine; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center	Hazan, RB (corresponding author), Albert Einstein Coll Med, Dept Pathol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	Rachel.hazan@einstein.yu.edu		Emmanuel, Natasha/0000-0003-0130-1094; Cohen, Hillel/0000-0002-4524-0898; Norton, Larry/0000-0003-3701-9250	Breast Cancer Research Foundation; National Cancer Institute [1R01 CA135061-01A1]; CTSA from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [UL1RR025750, KL2RR025749, TL1RR025748]; NIH roadmap for Medical Research; NATIONAL CANCER INSTITUTE [R01CA077263, P30CA013330, R01CA135061] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001073] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [TL1RR025748, KL2RR025749, UL1RR025750] Funding Source: NIH RePORTER	Breast Cancer Research Foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CTSA from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIH roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Dr Jeffrey Segall for providing the wild-type MMTV-ErbB2 mouse. We thank Dr Peng Guo for expert assistance in confocal imaging and the imaging facility at Albert Einstein College of Medicine. This work was supported by grants from the Breast Cancer Research Foundation (RB Hazan and Larry Norton) and the National Cancer Institute grant (1R01 CA135061-01A1; RB Hazan). This publication was also supported in part by the CTSA Grant UL1RR025750, KL2RR025749 and TL1RR025748 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and NIH roadmap for Medical Research.	BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Chin YR, 2009, CELL SIGNAL, V21, P470, DOI 10.1016/j.cellsig.2008.11.015; Chung S, 2013, ONCOGENE, V32, P422, DOI 10.1038/onc.2012.65; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x; Eceles SA, 2001, J MAMMARY GLAND BIOL, V6, P393, DOI 10.1023/A:1014730829872; Eirew P, 2012, STEM CELLS, V30, P344, DOI 10.1002/stem.1001; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Giordano A, 2012, MOL CANCER THER, V11, P2526, DOI 10.1158/1535-7163.MCT-12-0460; Gotoh N, 2009, CURR STEM CELL RES T, V4, P9, DOI 10.2174/157488809787169048; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hulit J, 2007, CANCER RES, V67, P3106, DOI 10.1158/0008-5472.CAN-06-3401; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Issa A, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3379; Knudsen KA, 2005, J CELL BIOCHEM, V95, P1093, DOI 10.1002/jcb.20469; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Koziczak M, 2004, J BIOL CHEM, V279, P50004, DOI 10.1074/jbc.M404252200; Koziczak M, 2004, ONCOGENE, V23, P3501, DOI 10.1038/sj.onc.1207331; Larocca D, 1998, HYBRIDOMA, V17, P21, DOI 10.1089/hyb.1998.17.21; Lelievre EC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033206; Liao MJ, 2007, CANCER RES, V67, P8131, DOI 10.1158/0008-5472.CAN-06-4493; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Nagi C, 2005, BREAST CANCER RES TR, V94, P225, DOI 10.1007/s10549-005-7727-5; Nahta R, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1612; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Qian BZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006562; Qian X, 2013, ONCOGENE, V32, P2292, DOI 10.1038/onc.2012.249; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Sharpe R, 2011, CLIN CANCER RES, V17, P5275, DOI 10.1158/1078-0432.CCR-10-2727; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smalley MJ, 2012, J MAMMARY GLAND BIOL, V17, P91, DOI 10.1007/s10911-012-9257-1; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Toker A, 2006, CANCER RES, V66, P3963, DOI 10.1158/0008-5472.CAN-06-0743; Tomaskovic-Crook E, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2416; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Walsh MM, 2001, HUM PATHOL, V32, P583, DOI 10.1053/hupa.2001.24988; Warzecha CC, 2009, RNA BIOL, V6, P546, DOI 10.4161/rna.6.5.9606; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Xue GD, 2013, JNCI-J NATL CANCER I, V105, P393, DOI 10.1093/jnci/djs648; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033	47	83	92	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3411	3421		10.1038/onc.2013.310	http://dx.doi.org/10.1038/onc.2013.310			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23975425	Green Accepted			2022-12-28	WOS:000338779300008
J	Mukhopadhyay, NK; Kim, J; You, S; Morello, M; Hager, MH; Huang, WC; Ramachandran, A; Yang, J; Cinar, B; Rubin, MA; Adam, RM; Oesterreich, S; Di Vizio, D; Freeman, MR				Mukhopadhyay, N. K.; Kim, J.; You, S.; Morello, M.; Hager, M. H.; Huang, W-C; Ramachandran, A.; Yang, J.; Cinar, B.; Rubin, M. A.; Adam, R. M.; Oesterreich, S.; Di Vizio, D.; Freeman, M. R.			Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2	ONCOGENE			English	Article						AR; MST1/STK4; Hippo-RASSF1-LATS; prostate cancer; castration resistance	BREAST-CANCER CELLS; PROSTATE-CANCER; CHROMATIN CONDENSATION; ACTIVATION; PROTEIN; GENE; PROGRESSION; EXPRESSION; PATHWAY; PHOSPHORYLATION	The androgen receptor (AR) is a transcription factor that employs many diverse interactions with coregulatory proteins in normal physiology and in prostate cancer (PCa). The AR mediates cellular responses in association with chromatin complexes and kinase cascades. Here we report that the nuclear matrix protein, scaffold attachment factor B1 (SAFB1), regulates AR activity and AR levels in a manner that suggests its involvement in PCa. SAFB1 mRNA expression was lower in PCa in comparison with normal prostate tissue in a majority of publicly available RNA expression data sets. SAFB1 protein levels were also reduced with disease progression in a cohort of human PCa that included metastatic tumors. SAFB1 bound to AR and was phosphorylated by the MST1 (Hippo homolog) serine-threonine kinase, previously shown to be an AR repressor, and MST1 localization to AR-dependent promoters was inhibited by SAFB1 depletion. Knockdown of SAFB1 in androgen-dependent LNCaP PCa cells increased AR and prostate-specific antigen (PSA) levels, stimulated growth of cultured cells and subcutaneous xenografts and promoted a more aggressive phenotype, consistent with a repressive AR regulatory function. SAFB1 formed a complex with the histone methyltransferase EZH2 at AR-interacting chromatin sites in association with other polycomb repressive complex 2 (PRC2) proteins. We conclude that SAFB1 acts as a novel AR co-regulator at gene loci where signals from the MST1/Hippo and EZH2 pathways converge.	[Mukhopadhyay, N. K.; Kim, J.; You, S.; Morello, M.; Huang, W-C; Yang, J.; Cinar, B.; Di Vizio, D.; Freeman, M. R.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Canc Biol Program, Dept Surg, Los Angeles, CA 90048 USA; [Mukhopadhyay, N. K.; Kim, J.; You, S.; Morello, M.; Huang, W-C; Yang, J.; Cinar, B.; Di Vizio, D.; Freeman, M. R.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Canc Biol Program, Dept Med, Los Angeles, CA 90048 USA; [Mukhopadhyay, N. K.; Kim, J.; You, S.; Morello, M.; Huang, W-C; Yang, J.; Cinar, B.; Di Vizio, D.; Freeman, M. R.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Canc Biol Program, Dept Biomed Sci, Los Angeles, CA 90048 USA; [Kim, J.; Hager, M. H.; Ramachandran, A.; Adam, R. M.; Di Vizio, D.; Freeman, M. R.] Harvard Univ, Sch Med, Dept Surg, Urol Dis Res Ctr,Boston Childrens Hosp, Boston, MA 02115 USA; [Rubin, M. A.] Weill Cornell Med Ctr, Dept Pathol & Lab Med, New York, NY USA; [Oesterreich, S.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Harvard University; Boston Children's Hospital; Harvard Medical School; Cornell University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Freeman, MR (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Canc Biol & Therapeut, Davis 5072, Los Angeles, CA 90048 USA.	Michael.freeman@cshs.org	CİNAR, BEKIR MURAT/AAL-4474-2021; You, Sungyong/AAJ-7372-2020; Huang, Wen-Chin/X-5879-2019	CİNAR, BEKIR MURAT/0000-0002-7906-5039; You, Sungyong/0000-0003-3513-1783; Rubin, Mark/0000-0002-8321-9950; Cinar, Bekir/0000-0003-4028-7600; Huang, Wen-Chin/0000-0003-2342-9099	NIH [1R01CA143777]; US Department of Defense [PC093459, NIH 5R00CA131472, NIH R01 CA097213];  [1R01CA112303]; NATIONAL CANCER INSTITUTE [R00CA131472, R01CA097213, R01CA112303, R01CA143777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK087806] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Defense(United States Department of Defense); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Thomas Roberts (Dana-Farber Cancer Institute) for critical comments and Delia Lopez, Kristine Pelton and Paul Guthrie for technical assistance. This study was supported by NIH 1R01CA143777, 1R01CA112303, and US Department of Defense PC093459 (to MRF), NIH 5R00CA131472 (to DDV) and NIH R01 CA097213 (to SO).	Aldiri I, 2009, DEV DYNAM, V238, P3185, DOI 10.1002/dvdy.22120; Baek SH, 2011, MOL CELL, V42, P274, DOI 10.1016/j.molcel.2011.03.022; Beisel C, 2011, NAT REV GENET, V12, P123, DOI 10.1038/nrg2932; Burd CJ, 2006, ENDOCR-RELAT CANCER, V13, P979, DOI 10.1677/erc.1.01115; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen Z, 2010, EPIGENOMICS-UK, V2, P551, DOI 10.2217/EPI.10.31; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; Chng KR, 2012, EMBO J, V31, P2810, DOI 10.1038/emboj.2012.112; Cinar B, 2007, EMBO J, V26, P4523, DOI 10.1038/sj.emboj.7601872; Cinar B, 2007, J BIOL CHEM, V282, P29584, DOI 10.1074/jbc.M703310200; Cinar B, 2011, CANCER RES, V71, P4303, DOI 10.1158/0008-5472.CAN-10-4532; Collak FK, 2012, J BIOL CHEM, V287, P23698, DOI 10.1074/jbc.M112.358713; Crea F, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-40; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; Debril MB, 2005, J MOL ENDOCRINOL, V35, P503, DOI 10.1677/jme.1.01856; Di Vizio D, 2009, CELL CYCLE, V8, P2420, DOI 10.4161/cc.8.15.9116; Gao AC, 1999, PROSTATE, V38, P46, DOI 10.1002/(SICI)1097-0045(19990101)38:1<46::AID-PROS6>3.0.CO;2-9; Garee JP, 2010, J CELL BIOCHEM, V109, P312, DOI 10.1002/jcb.22420; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Hammerich-Hille S, 2010, J BIOL CHEM, V285, P3608, DOI 10.1074/jbc.M109.066431; Hara T, 2003, CANCER RES, V63, P5622; Hara T, 2008, CANCER RES, V68, P1128, DOI 10.1158/0008-5472.CAN-07-1929; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Hu Y, 2007, CELL DEATH DIFFER, V14, P2035, DOI 10.1038/sj.cdd.4402214; Hu YX, 2005, EMBO J, V24, P3543, DOI 10.1038/sj.emboj.7600823; Kim J, 2011, IN VITRO CELL DEV-AN, V47, P2, DOI 10.1007/s11626-010-9350-y; Knudsen KE, 2010, TRENDS ENDOCRIN MET, V21, P315, DOI 10.1016/j.tem.2010.01.002; Lawrence MG, 2010, ENDOCR REV, V31, P407, DOI 10.1210/er.2009-0034; Li LC, 2005, JNCI-J NATL CANCER I, V97, P103, DOI 10.1093/jnci/dji010; LI SSL, 1993, GENOMICS, V17, P765, DOI 10.1006/geno.1993.1403; Magee JA, 2006, ENDOCRINOLOGY, V147, P590, DOI 10.1210/en.2005-1001; Mukhopadhyay NK, 2007, MOL ENDOCRINOL, V21, P2056, DOI 10.1210/me.2006-0503; Mukhopadhyay NK, 2006, EXP CELL RES, V312, P3782, DOI 10.1016/j.yexcr.2006.07.017; Mukhopadhyay NK, 2009, CANCER RES, V69, P2210, DOI 10.1158/0008-5472.CAN-08-2308; Oesterreich S, 2003, J CELL BIOCHEM, V90, P653, DOI 10.1002/jcb.10685; Oesterreich S, 1997, J CELL BIOCHEM, V67, P275, DOI 10.1002/(SICI)1097-4644(19971101)67:2<275::AID-JCB13>3.0.CO;2-E; Vicent GP, 2011, GENE DEV, V25, P845, DOI 10.1101/gad.621811; Pinskaya M, 2009, EPIGENETICS-US, V4, P302, DOI 10.4161/epi.4.5.9369; Renz A, 1996, NUCLEIC ACIDS RES, V24, P843, DOI 10.1093/nar/24.5.843; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Ross PJ, 2008, REPRODUCTION, V136, P777, DOI 10.1530/REP-08-0045; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Townson SM, 2004, J BIOL CHEM, V279, P26074, DOI 10.1074/jbc.M313726200; Townson SM, 2003, J BIOL CHEM, V278, P20059, DOI 10.1074/jbc.M212988200; Ura S, 2007, MOL CELL BIOL, V27, P5514, DOI 10.1128/MCB.00199-07; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Waltering KK, 2009, CANCER RES, V69, P8141, DOI 10.1158/0008-5472.CAN-09-0919; Wang X, 2001, J BIOL CHEM, V276, P40417, DOI 10.1074/jbc.M104765200; Wiklund F, 2003, PROSTATE, V57, P290, DOI 10.1002/pros.10303; Xu LL, 2000, GENOMICS, V66, P257, DOI 10.1006/geno.2000.6214; Yamamoto S, 2003, J CLIN INVEST, V111, P1463, DOI 10.1172/JCI200317459	53	19	20	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3235	3245		10.1038/onc.2013.294	http://dx.doi.org/10.1038/onc.2013.294			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23893242	Green Accepted			2022-12-28	WOS:000338443400003
J	Guo, G; Kang, Q; Zhu, X; Chen, Q; Wang, X; Chen, Y; Ouyang, J; Zhang, L; Tan, H; Chen, R; Huang, S; Chen, JL				Guo, G.; Kang, Q.; Zhu, X.; Chen, Q.; Wang, X.; Chen, Y.; Ouyang, J.; Zhang, L.; Tan, H.; Chen, R.; Huang, S.; Chen, J-L			A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA	ONCOGENE			English	Article							CHRONIC MYELOID-LEUKEMIA; STEM-CELLS; NORMAL HEMATOPOIESIS; MOLECULAR PATHWAYS; TUMOR-SUPPRESSOR; GENE-EXPRESSION; MESSENGER-RNAS; C-MYC; CANCER; PTEN	Aberrant expression of long noncoding RNAs (lncRNAs) is associated with various human cancers. However, the role of lncRNAs in Bcr-Abl-mediated chronic myeloid leukemia (CML) is unknown. In this study, we performed a comprehensive analysis of lncRNAs in human CML cells using an lncRNA cDNA microarray and identified an lncRNA termed lncRNA-BGL3 that acted as a key regulator of Bcr-Abl-mediated cellular transformation. Notably, we observed that lncRNA-BGL3 was highly induced in response to disruption of Bcr-Abl expression or by inhibiting Bcr-Abl kinase activity in K562 cells and leukemic cells derived from CML patients. Ectopic expression of lncRNA-BGL3 sensitized leukemic cells to undergo apoptosis and inhibited Bcr-Abl-induced tumorigenesis. Furthermore, transgenic (TG) mice expressing lncRNA-BGL3 were generated. We found that TG expression of lncRNA-BGL3 alone in mice was sufficient to impair primary bone marrow transformation by Bcr-Abl. Interestingly, we identified that lncRNA-BGL3 was a target of miR-17, miR-93, miR-20a, miR-20b, miR-106a and miR-106b, microRNAs that repress mRNA of phosphatase and tensin homolog (PTEN). Further experiments demonstrated that lncRNA-BGL3 functioned as a competitive endogenous RNA for binding these microRNAs to cross-regulate PTEN expression. Additionally, our experiments have begun to address the mechanism of how lncRNA-BGL3 is regulated in the leukemic cells and showed that Bcr-Abl repressed lncRNA-BGL3 expression through c-Myc-dependent DNA methylation. Taken together, these results reveal that Bcr-Abl-mediated cellular transformation critically requires silence of tumor-suppressor lncRNA-BGL3 and suggest a potential strategy for the treatment of Bcr-Abl-positive leukemia.	[Guo, G.; Kang, Q.; Zhu, X.; Wang, X.; Chen, Y.; Ouyang, J.; Chen, J-L] Chinese Acad Sci, Inst Microbiol, Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China; [Zhu, X.] Anhui Univ, Sch Life Sci, Hefei 230039, Peoples R China; [Chen, Q.] Fujian Agr & Forestry Univ, Coll Anim Sci, Fuzhou, Peoples R China; [Zhang, L.] Chinese Acad Med Sci, Inst Lab Anim Sci, Beijing 100730, Peoples R China; [Zhang, L.] Peking Union Med Coll, Comparat Med Ctr, Beijing 100021, Peoples R China; [Tan, H.] Guangzhou Med Univ, Affiliated Hosp 1, Ctr Oncol & Hematol, Guangzhou, Guangdong, Peoples R China; [Chen, R.] Chinese Acad Sci, Inst Biophys, Beijing 100080, Peoples R China; [Huang, S.] Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71105 USA	Chinese Academy of Sciences; Institute of Microbiology, CAS; Anhui University; Fujian Agriculture & Forestry University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Laboratory Animal Science - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Guangzhou Medical University; Chinese Academy of Sciences; Institute of Biophysics, CAS; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Chen, JL (corresponding author), Chinese Acad Sci, Inst Microbiol, Key Lab Pathogen Microbiol & Immunol, West Beichen Rd, Beijing 100101, Peoples R China.	chenjl@im.ac.cn	Huang, Shile/I-1632-2019; Chen, Runsheng/S-9834-2017; Chen, Ji-Long/AAJ-2134-2021	Huang, Shile/0000-0002-3239-1072; Chen, Runsheng/0000-0001-6049-8347; Chen, Ji-Long/0000-0002-4274-0563; Ouyang, Jing/0000-0002-4592-2688; Guo, Guijie/0000-0002-9031-1915	National Key Technologies Research and Development Program of China [2013ZX10004-611]; National Basic Research Program (973) of China [2014CB541804]; Intramural grant of the Chinese Academy of Sciences [KJZD-EW-L01-3]; Natural Science Foundation of China [81171943, U1305212]; Hundreds of Talents Program of Chinese Academy of Sciences	National Key Technologies Research and Development Program of China(National Key Technology R&D Program); National Basic Research Program (973) of China(National Basic Research Program of China); Intramural grant of the Chinese Academy of Sciences; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hundreds of Talents Program of Chinese Academy of Sciences(Chinese Academy of Sciences)	We thank Dr Paul B Rothman from the School of Medicine, The Johns Hopkins University for valuable discussions. This work was supported by the National Key Technologies Research and Development Program of China (2013ZX10004-611), National Basic Research Program (973) of China (2014CB541804), Intramural grant of the Chinese Academy of Sciences (KJZD-EW-L01-3), Natural Science Foundation of China (81171943, U1305212) and Hundreds of Talents Program of Chinese Academy of Sciences 2009-2014 to J-LC.	Barcelona SL, 2005, PEDIATR ANESTH, V15, P716, DOI 10.1111/j.1460-9592.2005.01548.x; Bu DC, 2012, NUCLEIC ACIDS RES, V40, pD210, DOI 10.1093/nar/gkr1175; Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028; Chan CM, 2013, NUCLEIC ACIDS RES, V41, P9663, DOI 10.1093/nar/gkt761; Chen CC, 2012, GENE DEV, V26, P2154, DOI 10.1101/gad.197343.112; Chen JL, 2008, BLOOD, V111, P1677, DOI 10.1182/blood-2007-04-083808; Chen Y, 2010, LEUKEMIA, V24, P1545, DOI 10.1038/leu.2010.143; Chen YY, 2013, BIOMARK RES, V1, DOI 10.1186/2050-7771-1-21; Cilloni D, 2012, CLIN CANCER RES, V18, P930, DOI 10.1158/1078-0432.CCR-10-1613; de Giorgio A, 2013, MOL CELL BIOL, V33, P3976, DOI 10.1128/MCB.00683-13; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; Guffanti A, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-163; Guo G, 2010, ONCOGENE, V29, P3845, DOI 10.1038/onc.2010.149; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Guttman M, 2010, NAT BIOTECHNOL, V28, P756, DOI 10.1038/nbt0710-756b; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; Heuston Elisabeth F., 2011, Frontiers in Genetics, V2, P94, DOI 10.3389/fgene.2011.00094; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Kapranov P, 2007, SCIENCE, V316, P1484, DOI 10.1126/science.1138341; Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032; Kiefer CM, 2011, BLOOD, V118, P6200, DOI 10.1182/blood-2011-06-363101; Klattenhoff CA, 2013, CELL, V152, P570, DOI 10.1016/j.cell.2013.01.003; Kong L, 2007, NUCLEIC ACIDS RES, V35, pW345, DOI 10.1093/nar/gkm391; Lin MF, 2011, BIOINFORMATICS, V27, pI275, DOI 10.1093/bioinformatics/btr209; Lu D, 2012, HYPERTENSION, V60, P81, DOI 10.1161/HYPERTENSIONAHA.112.191478; Luo JH, 2006, HEPATOLOGY, V44, P1012, DOI 10.1002/hep.21328; Ma F, 2011, NAT IMMUNOL, V12, P861, DOI 10.1038/ni.2073; Mishra A, 2012, CANCER CELL, V22, P645, DOI 10.1016/j.ccr.2012.09.009; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; Mott JL, 2010, J CELL BIOCHEM, V110, P1155, DOI 10.1002/jcb.22630; Nishikawa T, 2000, BIOINFORMATICS, V16, P960, DOI 10.1093/bioinformatics/16.11.960; O'Hare T, 2011, CLIN CANCER RES, V17, P212, DOI 10.1158/1078-0432.CCR-09-3314; Orom UA, 2010, CELL, V143, P46, DOI 10.1016/j.cell.2010.09.001; Peng C, 2010, BLOOD, V115, P626, DOI 10.1182/blood-2009-06-228130; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Prasanth KV, 2005, CELL, V123, P249, DOI 10.1016/j.cell.2005.08.033; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Qiu XX, 2012, NEOPLASIA, V14, P547, DOI 10.1596/neo.12230; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Sigova AA, 2013, P NATL ACAD SCI USA, V110, P2876, DOI 10.1073/pnas.1221904110; Tay Y, 2011, CELL, V147, P344, DOI 10.1016/j.cell.2011.09.029; Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011; Tsai MC, 2011, CANCER RES, V71, P3, DOI 10.1158/0008-5472.CAN-10-2483; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Venturini L, 2007, BLOOD, V109, P4399, DOI 10.1182/blood-2006-09-045104; Wang KC, 2011, J INVEST DERMATOL, V131, pS63; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang S, 2012, J BIOL CHEM, V287, P9804, DOI 10.1074/jbc.M111.312959; Xie SH, 2002, ONCOGENE, V21, P7137, DOI 10.1038/sj.onc.1205942; Yang F, 2013, MOL CELL, V49, P1083, DOI 10.1016/j.molcel.2013.01.010; Yang JL, 2013, CANCER RES, V73, P4898, DOI 10.1158/0008-5472.CAN-12-4277; Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027	55	121	142	0	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1768	1779		10.1038/onc.2014.131	http://dx.doi.org/10.1038/onc.2014.131			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24837367				2022-12-28	WOS:000352158000004
J	Jin, JK; Tien, PC; Cheng, CJ; Song, JH; Huang, C; Lin, SH; Gallick, GE				Jin, J-K; Tien, P-C; Cheng, C-J; Song, J. H.; Huang, C.; Lin, S-H; Gallick, G. E.			Talin1 phosphorylation activates beta 1 integrins: a novel mechanism to promote prostate cancer bone metastasis	ONCOGENE			English	Article							INTEGRIN EXPRESSION; BINDING; PROGRESSION; ADHESION; CARCINOMA; SUBUNIT; DOMAIN; TAILS; SITES; CELLS	Talins are adaptor proteins that regulate focal adhesion signaling by conjugating integrins to the cytoskeleton. Talins directly bind integrins and are essential for integrin activation. We previously showed that beta 1 integrins are activated in metastatic prostate cancer (PCa) cells, increasing PCa metastasis to lymph nodes and bone. However, how beta 1 integrins are activated in PCa cells is unknown. In this study, we identified a novel mechanism of beta 1 integrin activation. Using knockdown experiments, we first demonstrated that talin1, but not talin2, is important in beta 1 integrin activation. We next showed that talin1 S425 phosphorylation, but not total talin1 expression, correlates with metastatic potential of PCa cells. Expressing a non-phosphorylatable mutant, talin1(S425A), in talin1-silenced PC3-MM2 and C4-2B4 PCa cells, decreased activation of beta 1 integrins, integrin-mediated adhesion, motility and increased the sensitivity of the cells to anoikis. In contrast, reexpression of the phosphorylation-mimicking mutant talin1(S425D) led to increased beta 1 integrin activation and generated biologic effects opposite to talin1(S425A) expression. In the highly metastatic PC3-MM2 cells, expression of a non-phosphorylatable mutant, talin1(S425A), in talin1-silenced PC3-MM2 cells, abolished their ability to colonize in the bone following intracardiac injection, while reexpression of phosphorylation-mimicking mutant talin1(S425D) restored their ability to metastasize to bone. Immunohistochemical staining demonstrated that talin S425 phosphorylation is significantly increased in human bone metastases when compared with normal tissues, primary tumors or lymph node metastases. We further showed that p35 expression, an activator of Cdk5, and Cdk5 activity were increased in metastatic tumor cells, and that Cdk5 kinase activity is responsible for talin1 phosphorylation and subsequent beta 1 integrin activation. Together, our study reveals Cdk5-mediated phosphorylation of talin1 leading to beta 1 integrin activation is a novel mechanism that increases metastatic potential of PCa cells.	[Jin, J-K; Tien, P-C; Song, J. H.; Lin, S-H; Gallick, G. E.] Univ Texas MD Anderson Canc Ctr, David H Koch Ctr Appl Res Genitourinary Canc, Dept Genitourinary Med Oncol, Unit 18 4, Houston, TX 77030 USA; [Jin, J-K; Lin, S-H; Gallick, G. E.] Univ Texas Houston, Grad Sch Biomed Sci, Program Canc Metastasis, Houston, TX USA; [Cheng, C-J] Taipei Med Univ, Dept Pathol, Coll Med, Taipei, Taiwan; [Huang, C.] Univ Kentucky, Dept Mol & Biomed Pharmacol, Lexington, KY USA; [Lin, S-H] Univ Texas MD Anderson Canc Ctr, David H Koch Ctr Appl Res Genitourinary Canc, Dept Translat Mol Pathol, Unit 89, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Taipei Medical University; University of Kentucky; University of Texas System; UTMD Anderson Cancer Center	Lin, SH (corresponding author), Univ Texas MD Anderson Canc Ctr, David H Koch Ctr Appl Res Genitourinary Canc, Dept Translat Mol Pathol, Unit 89, 1515 Holcombe Blvd, Houston, TX 77030 USA.	slin@mdanderson.org; ggallick@mdanderson.org	Jin, Jungkang/H-6285-2011	Tien, Pei-Chieh/0000-0002-0012-0155	National Institutes of Health (NIH) [P50 CA140388, RO-1 CA174798, CA16672]; Prostate Cancer Foundation Challenge Award; DOD [PC093132]; Cancer Prevention and Research Institute of Texas [CPRIT RP110327]; NATIONAL CANCER INSTITUTE [R01CA174798, P30CA016672, P50CA140388] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Prostate Cancer Foundation Challenge Award; DOD(United States Department of Defense); Cancer Prevention and Research Institute of Texas; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Joseph H McCarty for critically reviewing the manuscript. This work was supported by the National Institutes of Health (NIH) P50 CA140388 (GEG, S-HL), a Prostate Cancer Foundation Challenge Award (GEG, S-HL), NIH RO-1 CA174798 (S-HL), DOD PC093132 (S-HL), a Cancer Prevention and Research Institute of Texas, CPRIT RP110327 (S-HL) and NIH CA16672 (CCSG, M. D. Anderson Cancer Center core grant).	American Cancer Society, 2013, CANC FACTS FIG; Barthel SR, 2013, CANCER RES, V73, P942, DOI 10.1158/0008-5472.CAN-12-3264; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2013, NAT REV MOL CELL BIO, V14, P503, DOI 10.1038/nrm3624; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Chang SK, 2011, P NATL ACAD SCI USA, V108, P8402, DOI 10.1073/pnas.1019437108; CRESS AE, 1995, CANCER METAST REV, V14, P219, DOI 10.1007/BF00690293; Critchley DR, 2008, J CELL SCI, V121, P1345, DOI 10.1242/jcs.018085; Das M, 2014, BBA-BIOMEMBRANES, V1838, P579, DOI 10.1016/j.bbamem.2013.07.017; Debrand E, 2009, FEBS J, V276, P1610, DOI 10.1111/j.1742-4658.2009.06893.x; Desiniotis A, 2011, INT REV CEL MOL BIO, V289, P117, DOI 10.1016/B978-0-12-386039-2.00004-3; Edlund M, 2001, CELL GROWTH DIFFER, V12, P99; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Goult BT, 2013, J STRUCT BIOL, V184, P21, DOI 10.1016/j.jsb.2013.05.014; Hall CL, 2006, CANCER RES, V66, P8648, DOI 10.1158/0008-5472.CAN-06-1544; Jin JK, 2011, INT J CANCER, V128, P2545, DOI 10.1002/ijc.26024; Lai MT, 2011, J PATHOL, V224, P367, DOI 10.1002/path.2867; Lang SH, 1997, CLIN EXP METASTAS, V15, P218, DOI 10.1023/A:1018465213641; Lee YC, 2013, MOL CANCER RES, V11, P405, DOI 10.1158/1541-7786.MCR-12-0551; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Lin TH, 2013, BBA-GEN SUBJECTS, V1830, P4917, DOI 10.1016/j.bbagen.2013.06.033; Manso AM, 2013, J BIOL CHEM, V288, P4252, DOI 10.1074/jbc.M112.427484; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; Monkley SJ, 2001, BIOCHEM BIOPH RES CO, V286, P880, DOI 10.1006/bbrc.2001.5497; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Ratnikov B, 2005, J CELL SCI, V118, P4921, DOI 10.1242/jcs.02682; Sakamoto S, 2010, CANCER RES, V70, P1885, DOI 10.1158/0008-5472.CAN-09-2833; Sayeed A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076513; Song XQ, 2012, CELL RES, V22, P1533, DOI 10.1038/cr.2012.97; Sottnik JL, 2013, CLIN EXP METASTAS, V30, P569, DOI 10.1007/s10585-012-9561-6; Stachurska A, 2012, CELL BIOL INT, V36, P883, DOI 10.1042/CBI20110522; Strock CJ, 2006, CANCER RES, V66, P7509, DOI 10.1158/0008-5472.CAN-05-3048; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Takeshita F, 2010, MOL THER, V18, P181, DOI 10.1038/mt.2009.207; Tang HS, 2013, INT J MOL MED, V32, P381, DOI 10.3892/ijmm.2013.1400; THALMANN GN, 1994, CANCER RES, V54, P2577; Trerotola M, 2013, CANCER RES, V73, P3155, DOI 10.1158/0008-5472.CAN-12-3266; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; VanderVeldeZimmermann D, 1997, EXP CELL RES, V230, P111, DOI 10.1006/excr.1996.3405; Varkaris A, 2013, INT J CANCER, V133, P1536, DOI 10.1002/ijc.28169; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200; Ye F, 2011, J THROMB HAEMOST, V9, P20, DOI 10.1111/j.1538-7836.2011.04355.x; Ye F, 2013, CURR BIOL, V23, P2288, DOI 10.1016/j.cub.2013.09.050; Zheng DQ, 1999, CANCER RES, V59, P1655	44	76	80	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1811	1821		10.1038/onc.2014.116	http://dx.doi.org/10.1038/onc.2014.116			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24793790	Green Accepted			2022-12-28	WOS:000352158000008
J	Castellone, MD; Laukkanen, MO; Teramoto, H; Bellelli, R; Ali, G; Fontanini, G; Santoro, M; Gutkind, JS				Castellone, M. D.; Laukkanen, M. O.; Teramoto, H.; Bellelli, R.; Ali, G.; Fontanini, G.; Santoro, M.; Gutkind, J. S.			Cross talk between the bombesin neuropeptide receptor and Sonic hedgehog pathways in small cell lung carcinoma	ONCOGENE			English	Article							GASTRIN-RELEASING-PEPTIDE; NF-KAPPA-B; AUTOCRINE GROWTH; CANCER; ACTIVATION; RHO; BINDING; REQUIREMENT; INHIBITION; GTPASES	Small cell lung carcinoma (SCLC) often features the upregulation of the Sonic hedgehog (Shh) pathway leading to activation of Gli transcription factors. SCLC cells secrete bombesin (BBS)-like neuropeptides that act as autocrine growth factors. Here, we show that SCLC tumor samples feature co-expression of Shh and BBS-cognate receptor (gastrin-releasing peptide receptor (GRPR)). We also demonstrate that BBS activates Gli in SCLC cells, which is crucial for BBS-mediated SCLC proliferation, because cyclopamine, an inhibitor of the Shh pathway, hampered the BBS-mediated effects. BBS binding to GRPR stimulated Gli through its downstream G alpha(q) and G alpha(12/13) GTPases, and consistently, other G alpha(q) and G alpha(13) coupled receptors (such as muscarinic receptor, m1, and thrombin receptor, PAR-1) and constitutively active G alpha(q)QL and G alpha(12/13)QL mutants stimulated Gli. By using cells null for G alpha(q) and G alpha(12/13), we demonstrate that these G proteins are strictly necessary for Gli activation by BBS. Moreover, by using constitutively active Rho small G-protein (Rho QL) as well as its inhibitor, C3 toxin, we show that Rho mediates G-protein-coupled receptor (GPCR)-, G alpha(q)- and G alpha(12/13)-dependent Gli stimulation. At the molecular level, BBS caused a significant increase in Shh gene transcription and protein secretion that was dependent on BBS-induced GPCR/G alpha(q)-(12/13)/Rho mediated activation of nuclear factor kappa B (NF kappa B), which can stimulate a NF-kappa B response element in the Shh gene promoter. Our data identify a novel molecular network acting in SCLC linking autocrine BBS and Shh circuitries and suggest Shh inhibitors as novel therapeutic strategies against this aggressive cancer type.	[Castellone, M. D.; Teramoto, H.; Gutkind, J. S.] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA; [Castellone, M. D.; Bellelli, R.; Santoro, M.] Univ Naples Federico II, Ist Endocrinol Oncol Sperimentale G Salvatore IEO, Dipartimento Med Mol & Biotecnol Med, I-80131 Naples, Italy; [Laukkanen, M. O.] SDN Fdn, Naples, Italy; [Teramoto, H.] Kojin Hosp, Dept Internal Med, Nagoya, Aichi, Japan; [Ali, G.; Fontanini, G.] Univ Pisa, Dept Surg, Div Anat Pathol, Pisa, Italy	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; IRCCS Istituto di Ricerca Diagnostica e Nucleare (SDN); University of Pisa	Castellone, MD (corresponding author), Univ Naples Federico II, Ist Endocrinol Oncol Sperimentale G Salvatore IEO, Dipartimento Med Mol & Biotecnol Med, Via S Pansini 5, I-80131 Naples, Italy.	mcastell@unina.it	Alì, Greta/J-9642-2016; Fontanini, Gabriella/O-7636-2015; Gutkind, J. Silvio/J-1201-2016; Laukkanen, Mikko/K-5868-2016	Alì, Greta/0000-0001-9258-3466; Fontanini, Gabriella/0000-0003-1957-2052; Gutkind, J. Silvio/0000-0002-5150-4482; Laukkanen, Mikko/0000-0002-1004-7131; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037	Associazione Italiana per la Ricerca sul Cancro (AIRC); Intramural Research Program of NIH, National Institute of Dental and Craniofacial Research [Z01DE00551]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Intramural Research Program of NIH, National Institute of Dental and Craniofacial Research; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This study was in part supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC) and by the Intramural Research Program of NIH, National Institute of Dental and Craniofacial Research, Z01DE00551.	ALEXANDER RW, 1988, CANCER RES, V48, P1439; BRENNAN J, 1991, CANCER RES, V51, P1708; Bruzzese F, 2009, MOL CANCER THER, V8, P3075, DOI 10.1158/1535-7163.MCT-09-0254; CARNEY DN, 1987, CANCER RES, V47, P821; CARNEY DN, 1985, CANCER RES, V45, P2913; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; Chinchilla P, 2010, CELL CYCLE, V9, P570, DOI 10.4161/cc.9.3.10591; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; Dierks C, 2007, NAT MED, V13, P944, DOI 10.1038/nm1614; Douglas AE, 2011, J BIOL CHEM, V286, P30714, DOI 10.1074/jbc.M111.219279; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Kasperczyk H, 2009, FASEB J, V23, P21, DOI 10.1096/fj.08-111096; Kiaris H, 1999, ONCOGENE, V18, P7168, DOI 10.1038/sj.onc.1203213; Kim HJ, 2006, CELL DEATH DIFFER, V13, P738, DOI 10.1038/sj.cdd.4401877; Kim S, 2002, ANN SURG, V235, P621, DOI 10.1097/00000658-200205000-00003; Lango MN, 2002, J NATL CANCER I, V94, P375; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Mulshine JL, 2005, NEW ENGL J MED, V352, P2714, DOI 10.1056/NEJMcp042630; Offermanns S, 1998, ONCOGENE, V17, P1375, DOI 10.1038/sj.onc.1202173; Pacifico F, 2004, J BIOL CHEM, V279, P54610, DOI 10.1074/jbc.M403492200; Park KS, 2011, NAT MED, V17, P1504, DOI 10.1038/nm.2473; Pepicelli CV, 1998, CURR BIOL, V8, P1083, DOI 10.1016/S0960-9822(98)70446-4; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Polizio AH, 2011, J BIOL CHEM, V286, P19589, DOI 10.1074/jbc.M110.197111; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; Ruiz I, 2002, NAT REV CANCER, V2, P361, DOI DOI 10.1038/NRC796; Saurin JC, 2002, CANCER RES, V62, P4829; Schally AV, 2004, CELL MOL LIFE SCI, V61, P1042, DOI 10.1007/s00018-004-3434-3; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; THOMAS F, 1992, CANCER RES, V52, P4872; ToiScott M, 1996, LUNG CANCER-J IASLC, V15, P341, DOI 10.1016/0169-5002(95)00597-8; Travis W, 2004, WHO CLASSIFICATION T; Watkins DN, 2003, CELL CYCLE, V2, P196, DOI 10.4161/cc.2.3.378; Weaver M, 2003, DEV BIOL, V258, P169, DOI 10.1016/S0012-1606(03)00117-9; Yang L, 2010, ONCOGENE, V29, P469, DOI 10.1038/onc.2009.392; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275; Ye RD, 2001, J LEUKOCYTE BIOL, V70, P839; Zakowski MF, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50015; Zhou JH, 2004, ANTI-CANCER DRUG, V15, P921, DOI 10.1097/00001813-200411000-00001	46	29	30	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1679	1687		10.1038/onc.2014.104	http://dx.doi.org/10.1038/onc.2014.104			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24747971	Green Accepted			2022-12-28	WOS:000351848400008
J	Feduska, JM; Aller, SG; Garcia, PL; Cramer, SL; Council, LN; van Waardenburg, RCAM; Yoon, KJ				Feduska, J. M.; Aller, S. G.; Garcia, P. L.; Cramer, S. L.; Council, L. N.; van Waardenburg, R. C. A. M.; Yoon, K. J.			ICAM-2 confers a non-metastatic phenotype in neuroblastoma cells by interaction with alpha-actinin	ONCOGENE			English	Article							INTERCELLULAR-ADHESION MOLECULE-2; CYTOPLASMIC DOMAIN; SUBCELLULAR-LOCALIZATION; LEUKOCYTE ADHESION; STRUCTURAL BASIS; BINDING; CANCER; LIGAND; EXPRESSION; ANCHORAGE	Progressive metastatic disease is a major cause of mortality for patients diagnosed with multiple types of solid tumors. One of the long-term goals of our laboratory is to identify molecular interactions that regulate metastasis, as a basis for developing agents that inhibit this process. Toward this goal, we recently demonstrated that intercellular adhesion molecule-2 (ICAM-2) converted neuroblastoma (NB) cells from a metastatic to a non-metastatic phenotype, a previously unknown function for ICAM-2. Interestingly, ICAM-2 suppressed metastatic but not tumorigenic potential in preclinical models, supporting a novel mechanism of regulating metastasis. We hypothesized that the effects of ICAM-2 on NB cell phenotype depend on the interaction of ICAM-2 with the cytoskeletal linker protein alpha-actinin. The goal of the study presented here was to evaluate the impact of alpha-actinin binding to ICAM-2 on the phenotype of NB tumor cells. We used in silico approaches to examine the likelihood that the cytoplasmic domain of ICAM-2 binds directly to alpha-actinin. We then expressed variants of ICAM-2 with mutated a-actinin-binding domains, and compared the impact of ICAM-2 and each variant on NB cell adhesion, migration, anchorage-independent growth, co-precipitation with alpha-actinin and production of localized and disseminated tumors in vivo. The in vitro and in vivo characteristics of cells expressing ICAM-2 variants with modified alpha-actinin-binding domains differed from cells expressing ICAM-2 wild type (WT) and also from cells that expressed no detectable ICAM-2. Like the WT protein, ICAM-2 variants inhibited cell adhesion, migration and colony growth in vitro. However, unlike the WT protein, ICAM-2 variants did not completely suppress development of disseminated NB tumors in vivo. The data suggest the presence of alpha-actinin-dependent and alpha-actinin-independent mechanisms, and indicate that the interaction of ICAM-2 with alpha-actinin is critical to conferring an ICAM-2-mediated non-metastatic phenotype in NB cells.	[Feduska, J. M.; Aller, S. G.; Garcia, P. L.; van Waardenburg, R. C. A. M.; Yoon, K. J.] Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; [Cramer, S. L.] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35294 USA; [Council, L. N.] Univ Alabama Birmingham, Dept Pathol, Div Anat Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Yoon, KJ (corresponding author), Univ Alabama Birmingham, Dept Pharmacol & Toxicol, 1670 Univ Blvd, Birmingham, AL 35294 USA.	kyoon@uab.edu		Aller, Stephen/0000-0003-0379-5534	University of Alabama at Birmingham-Comprehensive Cancer Center- YSB-New Faculty Development Award (YSB-NFDA) [P30 CA013148]; NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER	University of Alabama at Birmingham-Comprehensive Cancer Center- YSB-New Faculty Development Award (YSB-NFDA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are indebted to Dr Mary Danks for her support. We thank Dr Phil Potter for allowing us to use the mouse strain developed in his laboratory. We are also grateful to Joanna Remack and Rebecca Bush for outstanding technical assistance. This work was supported by the University of Alabama at Birmingham-Comprehensive Cancer Center- YSB-New Faculty Development Award (YSB-NFDA: P30 CA013148).	[Anonymous], 2010, PYMOL MOL GRAPHICS S; Atkinson RA, 2001, NAT STRUCT BIOL, V8, P853, DOI 10.1038/nsb1001-853; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; Casasnovas JM, 1997, NATURE, V387, P312, DOI 10.1038/387312a0; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DIACOVO TG, 1994, J CLIN INVEST, V94, P1243, DOI 10.1172/JCI117442; Eccles SA, 2005, BIOTECHNOL ANN REV, V11, P391, DOI 10.1016/S1387-2656(05)11013-8; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; Feduska JM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-261; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Garcia PL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078183; Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815; Hamada K, 2003, EMBO J, V22, P502, DOI 10.1093/emboj/cdg039; Hariharan R, 2008, PROTEINS, V71, P1853, DOI 10.1002/prot.21869; Heiska L, 1998, J BIOL CHEM, V273, P21893, DOI 10.1074/jbc.273.34.21893; Heiska L, 1996, J BIOL CHEM, V271, P26214, DOI 10.1074/jbc.271.42.26214; Hiraoka N, 2011, GASTROENTEROLOGY, V140, P310, DOI 10.1053/j.gastro.2010.10.009; Hogg N, 1999, J CLIN INVEST, V103, P97, DOI 10.1172/JCI3312; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Honda K, 2005, GASTROENTEROLOGY, V128, P51, DOI 10.1053/j.gastro.2004.10.004; Huang MT, 2005, BLOOD, V106, P1636, DOI 10.1182/blood-2004-12-4716; Humphries M. J., 2001, CURR PROTOC CELL BIO, V00, DOI DOI 10.1002/0471143030.CB0901500; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kotovuori A, 1999, J IMMUNOL, V162, P6613; Liu J, 2004, J MOL BIOL, V338, P115, DOI 10.1016/j.jmb.2004.02.034; Liu ZY, 2009, J GASTROEN HEPATOL, V24, P900, DOI 10.1111/j.1440-1746.2008.05668.x; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Melero I, 2002, CANCER RES, V62, P3167; Mohamet L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012921; Mori S, 2009, ONCOGENE, V28, P2796, DOI 10.1038/onc.2009.139; Morton CL, 2005, CANCER CHEMOTH PHARM, V56, P629, DOI 10.1007/s00280-005-1027-y; Nishiya T, 2004, J BIOL CHEM, V279, P19008, DOI 10.1074/jbc.M311618200; NORTAMO P, 1991, EUR J IMMUNOL, V21, P2629, DOI 10.1002/eji.1830211049; Nyman-Huttunen H, 2006, J CELL SCI, V119, P3057, DOI 10.1242/jcs.03045; OTEY CA, 1993, J BIOL CHEM, V268, P21193; Otey CA, 2004, CELL MOTIL CYTOSKEL, V58, P104, DOI 10.1002/cm.20007; PASQUALINI R, 1994, J CELL BIOL, V125, P447, DOI 10.1083/jcb.125.2.447; Perez OD, 2002, IMMUNITY, V16, P51, DOI 10.1016/S1074-7613(02)00266-2; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Tovchigrechko A, 2005, PROTEINS, V60, P296, DOI 10.1002/prot.20573; Yang YT, 2004, MOL CELL, V14, P269, DOI 10.1016/S1097-2765(04)00204-7; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yoon KJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003629	46	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1553	1562		10.1038/onc.2014.87	http://dx.doi.org/10.1038/onc.2014.87			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24704826	Green Accepted			2022-12-28	WOS:000351416800008
J	Knight, ERW; Patel, EY; Flowers, CA; Crowther, AJ; Ting, JP; Miller, CR; Gershon, TR; Deshmukh, M				Knight, E. R. W.; Patel, E. Y.; Flowers, C. A.; Crowther, A. J.; Ting, J. P.; Miller, C. R.; Gershon, T. R.; Deshmukh, M.			ASC deficiency suppresses proliferation and prevents medulloblastoma incidence	ONCOGENE			English	Article						medulloblastoma; ASC; TMS-1; proliferation; TGF-beta; tumor	SPECK-LIKE PROTEIN; ABERRANT METHYLATION; GENETIC PROFILES; DOWN-REGULATION; MOUSE MODEL; DUAL ROLE; CARD ASC; INFLAMMASOME; GROWTH; CELLS	Apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) is silenced by promoter methylation in many types of tumors, yet ASC's role in most cancers remains unknown. Here, we show that ASC is highly expressed in a model of medulloblastoma, the most common malignant pediatric brain cancer; ASC is also expressed in human medulloblastomas. Importantly, while ASC deficiency did not affect normal cerebellar development, ASC knockout mice on the Smoothened (ND2: SmoA1) transgenic model of medulloblastoma exhibited a profound reduction in medulloblastoma incidence and a delayed tumor onset. A similar decrease in tumorigenesis with ASC deficiency was also seen in the hGFAP-Cre: SmoM2 mouse model of medulloblastoma. Interestingly, hyperproliferation of the external granule layer (EGL) was comparable at P20 in both wild-type and ASC-deficient SmoA1 mice. However, while the apoptosis and differentiation markers remained unchanged at this age, proliferation makers were decreased, and the EGL was reduced in thickness and area by P60. This reduction in proliferation with ASC deficiency was also seen in isolated SmoA1 cerebellar granule precursor cells in vitro, indicating that the effect of ASC deletion on proliferation was cell autonomous. Interestingly, ASC-deficient SmoA1 cerebella exhibited disrupted expression of genes in the transforming growth factor-beta pathway and increased level of nuclear Smad3. Taken together, these results demonstrate an unexpected role for ASC in Sonic hedgehog-driven medulloblastoma tumorigenesis, thus identifying ASC as a promising novel target for antitumor therapy.	[Knight, E. R. W.; Ting, J. P.; Gershon, T. R.; Deshmukh, M.] Univ N Carolina, Neurobiol Curriculum, Chapel Hill, NC 27599 USA; [Knight, E. R. W.; Patel, E. Y.; Flowers, C. A.; Crowther, A. J.; Miller, C. R.; Gershon, T. R.; Deshmukh, M.] Univ N Carolina, Ctr Neurosci, Chapel Hill, NC 27599 USA; [Crowther, A. J.; Ting, J. P.; Miller, C. R.; Gershon, T. R.; Deshmukh, M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Ting, J. P.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; [Miller, C. R.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; [Miller, C. R.; Gershon, T. R.] Univ N Carolina, Dept Neurol, Chapel Hill, NC 27599 USA; [Deshmukh, M.] Univ N Carolina, Dept Cell Biol & Physiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Deshmukh, M (corresponding author), Univ N Carolina, Dept Cell Biol & Physiol, 7109E Neurosci Res Bldg,105 Mason Farm Rd, Chapel Hill, NC 27599 USA.	mohanish@med.unc.edu	Miller, Ryan/B-9365-2008; , Pathology Services Core/CEZ-2246-2022; Gershon, Timothy/H-5398-2019	Miller, Ryan/0000-0002-0096-8762; Gershon, Timothy/0000-0001-7034-6400	National Cancer Institute [3P30CA016086]; UNC University Cancer Research Fund; NIH [1K08NS077978]; St Baldrick's Foundation;  [NS042197];  [GM078366]; NATIONAL CANCER INSTITUTE [P30CA016086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS045892, R01NS042197, K08NS077978] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UNC University Cancer Research Fund; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); St Baldrick's Foundation; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Drs Vishva Dixit (Genentech), James Olson (Fred Hutchinson Cancer Research Center), Eva Anton (UNC) for generously sharing ASC<SUP>-/-</SUP>, ND2: SmoA1 and hGFAP-cre mice, respectively. We appreciate the technical assistance provided by Vivian Xu, Michael Conlin and Meera Patel in the Deshmukh Lab; Janice Weaver, Lily Wai and Yongjuan Xia in the UNC Histopathology Core; Terese Camp and Ling Li in the UNC Genomics Core; Mark Vincent Olorvida, Stephanie Cohen and Bentley Midkiff in the UNC Translational Pathology Laboratory (TPL); and Joel Parker, George Wu, Chandri Yandava and Chris Fan at UNC for bioinformatics and biostatistics guidance. The UNC TPL is supported in part by grants from the National Cancer Institute (3P30CA016086) and the UNC University Cancer Research Fund. We would like to thank members of the Deshmukh Laboratory for critical review of this manuscript. TRG is supported by NIH Grant 1K08NS077978 and St Baldrick's Foundation. This work was supported by Grants NS042197 and GM078366 to MD.	Alaminos M, 2004, JNCI-J NATL CANCER I, V96, P1208, DOI 10.1093/jnci/djh224; Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050; Apte RN, 2006, CANCER METAST REV, V25, P387, DOI 10.1007/s10555-006-9004-4; Aref D, 2013, BRAIN PATHOL, V23, P178, DOI 10.1111/j.1750-3639.2012.00631.x; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; Conway KE, 2000, CANCER RES, V60, P6236; Dabiri G, 2008, J INVEST DERMATOL, V128, P280, DOI 10.1038/sj.jid.5700975; Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405; Drexler SK, 2012, P NATL ACAD SCI USA, V109, P18384, DOI 10.1073/pnas.1209171109; Fattet S, 2009, J PATHOL, V218, P86, DOI 10.1002/path.2514; Feierabend D, 2013, J NEUROONCOL, DOI [10.1007/s11060-11013-11286-11060, DOI 10.1007/S11060-11013-11286-11060]; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Franchi L, 2009, NAT IMMUNOL, V10, P241, DOI 10.1038/ni.1703; Guan X, 2003, INT J CANCER, V107, P202, DOI 10.1002/ijc.11376; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Hatten ME, 2011, TRENDS NEUROSCI, V34, P134, DOI 10.1016/j.tins.2011.01.002; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; Hong S, 2013, CANCER LETT, V331, P183, DOI 10.1016/j.canlet.2012.12.020; Ippagunta SK, 2010, J BIOL CHEM, V285, P12454, DOI 10.1074/jbc.M109.093252; Jeong JH, 2004, GENE DEV, V18, P937, DOI 10.1101/gad.1190304; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kole AJ, 2011, GENE DEV, V25, P125, DOI 10.1101/gad.1975411; Kolly L, 2009, J IMMUNOL, V183, P4003, DOI 10.4049/jimmunol.0802173; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Liu WM, 2013, J INVEST DERMATOL, V133, P518, DOI 10.1038/jid.2012.317; Machida EO, 2006, CANCER RES, V66, P6210, DOI 10.1158/0008-5472.CAN-05-4447; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Narayan S, 2011, IMMUNOLOGY, V134, P33, DOI 10.1111/j.1365-2567.2011.03462.x; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Ohtsuka T, 2006, ONCOGENE, V25, P1807, DOI 10.1038/sj.onc.1209204; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; Parsons MJ, 2006, ONCOGENE, V25, P6948, DOI 10.1038/sj.onc.1209684; Parsons MJ, 2009, CANCER RES, V69, P1706, DOI 10.1158/0008-5472.CAN-08-2351; Polkinghorn WR, 2007, NAT CLIN PRACT ONCOL, V4, P295, DOI 10.1038/ncponc0794; Ramachandran K, 2010, ANTICANCER RES, V30, P3919; Rich JN, 2003, FRONT BIOSCI-LANDMRK, V8, pE245, DOI 10.2741/992; Rios I, 2004, DEVELOPMENT, V131, P3159, DOI 10.1242/dev.01188; Shaw PJ, 2010, J IMMUNOL, V184, P4610, DOI 10.4049/jimmunol.1000217; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; Shibanuma M, 1998, INT J BIOCHEM CELL B, V30, P39, DOI 10.1016/S1357-2725(97)00155-6; Stone AR, 2004, AM J PATHOL, V165, P1151, DOI 10.1016/S0002-9440(10)63376-7; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Zaki MH, 2010, J IMMUNOL, V185, P4912, DOI 10.4049/jimmunol.1002046; Zhao H, 2008, GENE DEV, V22, P722, DOI 10.1101/gad.1636408	46	7	7	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					394	402		10.1038/onc.2013.577	http://dx.doi.org/10.1038/onc.2013.577			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24469054	Green Accepted, Green Submitted			2022-12-28	WOS:000348145500013
J	Sulahian, R; Casey, F; Shen, J; Qian, ZR; Shin, H; Ogino, S; Weir, BA; Vazquez, F; Liu, XS; Hahn, WC; Bass, AJ; Chan, V; Shivdasani, RA				Sulahian, R.; Casey, F.; Shen, J.; Qian, Z. R.; Shin, H.; Ogino, S.; Weir, B. A.; Vazquez, F.; Liu, X. S.; Hahn, W. C.; Bass, A. J.; Chan, V.; Shivdasani, R. A.			An integrative analysis reveals functional targets of GATA6 transcriptional regulation in gastric cancer	ONCOGENE			English	Article						transcriptional control of cancer; synexpression groups; somatic copy number alterations; ChIP-seq; GATA transcription factors	LINEAGE-SURVIVAL ONCOGENE; GENE-EXPRESSION; STEM-CELLS; PATTERNS; STOMACH; GENOME; DIFFERENTIATION; AMPLIFICATION; INTESTINE; FAMILY	Lineage-restricted transcription factors (TFs) are frequently mutated or overexpressed in cancer and contribute toward malignant behaviors; however, the molecular bases of their oncogenic properties are largely unknown. As TF activities are difficult to inhibit directly with small molecules, the genes and pathways they regulate might represent more tractable targets for drug therapy. We studied GATA6, a TF gene that is frequently amplified or overexpressed in gastric, esophageal and pancreatic adenocarcinomas. GATA6-overexpressing gastric cancer cell lines cluster in gene expression space, separate from non-overexpressing lines. This expression clustering signifies a shared pathogenic group of genes that GATA6 may regulate through direct cis-element binding. We used chromatin immunoprecipitation and sequencing (ChIP-seq) to identify GATA6-bound genes and considered TF occupancy in relation to genes that respond to GATA6 depletion in cell lines and track with GATA6 mRNA (synexpression groups) in primary gastric cancers. Among other cellular functions, GATA6-occupied genes control apoptosis and govern the M-phase of the cell cycle. Depletion of GATA6 reduced the levels of the latter transcripts and arrested cells in G2 and M phases of the cell cycle. Synexpression in human tumor samples identified likely direct transcriptional targets substantially better than consideration only of transcripts that respond to GATA6 loss in cultured cells. Candidate target genes responded to the loss of GATA6 or its homolog GATA4 and even more to the depletion of both proteins. Many GATA6-dependent genes lacked nearby binding sites but several strongly dependent, synexpressed and GATA6-bound genes encode TFs such as MYC, HES1, RARB and CDX2. Thus, many downstream effects occur indirectly through other TFs and GATA6 activity in gastric cancer is partially redundant with GATA4. This integrative analysis of locus occupancy, gene dependency and synexpression provides a functional signature of GATA6-overexpressing gastric cancers, revealing both limits and new therapeutic directions for a challenging and frequently fatal disease.	[Sulahian, R.; Qian, Z. R.; Ogino, S.; Weir, B. A.; Vazquez, F.; Hahn, W. C.; Bass, A. J.; Shivdasani, R. A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Sulahian, R.; Hahn, W. C.; Bass, A. J.; Shivdasani, R. A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Casey, F.; Shen, J.; Chan, V.] Novartis Inst Biomed Res, Emeryville, CA USA; [Qian, Z. R.; Ogino, S.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA USA; [Qian, Z. R.; Ogino, S.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Shin, H.; Liu, X. S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA; [Hahn, W. C.; Bass, A. J.; Shivdasani, R. A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Novartis; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital	Shivdasani, RA (corresponding author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.	ramesh_shivdasani@dfci.harvard.edu			Dana-Farber Cancer Institute-Novartis Drug Discovery Program; National Institutes of Health [R01CA151993, R01HG4069, K08CA134931]; SPORE program in GI cancers [P50 CA127003]; NATIONAL CANCER INSTITUTE [R01CA151993, P50CA127003, U01CA176058, K08CA134931] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004069] Funding Source: NIH RePORTER	Dana-Farber Cancer Institute-Novartis Drug Discovery Program; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); SPORE program in GI cancers; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This study was supported by the Dana-Farber Cancer Institute-Novartis Drug Discovery Program and National Institutes of Health awards R01CA151993 (SO), R01HG4069 (XSL), K08CA134931 (AJB) and the SPORE program in GI cancers P50 CA127003. Data associated with this study are available in the GEO, GSE51936.	Abdi H, 2010, WIRES COMPUT STAT, V2, P433, DOI 10.1002/wics.101; Alvarez H, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001356; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Beuling E, 2011, GASTROENTEROLOGY, V140, P1219, DOI 10.1053/j.gastro.2011.01.033; Chen X, 2003, MOL BIOL CELL, V14, P3208, DOI 10.1091/mbc.E02-12-0833; Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Deng NT, 2012, GUT, V61, P673, DOI 10.1136/gutjnl-2011-301839; Dulak AM, 2012, CANCER RES, V72, P4383, DOI 10.1158/0008-5472.CAN-11-3893; Eeckhoute J, 2009, GENOME RES, V19, P372, DOI 10.1101/gr.084582.108; Fang RX, 2006, GENE EXPR PATTERNS, V6, P426, DOI 10.1016/j.modgep.2005.09.003; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fu BJ, 2008, CANCER BIOL THER, V7, P1593, DOI 10.4161/cbt.7.10.6565; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Guiu J, 2013, J EXP MED, V210, P71, DOI 10.1084/jem.20120993; Heng JCD, 2010, CELL STEM CELL, V6, P167, DOI 10.1016/j.stem.2009.12.009; Holtzinger A, 2005, DEVELOPMENT, V132, P4005, DOI 10.1242/dev.01978; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jang JH, 2001, CANCER RES, V61, P3541; Kageyama R, 2007, DEVELOPMENT, V134, P1243, DOI 10.1242/dev.000786; Kim TH, 2011, J EXP MED, V208, P677, DOI 10.1084/jem.20101737; Kunii K, 2008, CANCER RES, V68, P2340, DOI 10.1158/0008-5472.CAN-07-5229; Kwei KA, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000081; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928; Lin L, 2012, P NATL ACAD SCI USA, V109, P4251, DOI 10.1073/pnas.1011989109; Liu T, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r83; Matsuda A, 2012, JPN J CLIN ONCOL, V42, P154, DOI 10.1093/jjco/hys004; Nakajima M, 1999, CANCER, V85, P1894; Okines A, 2011, NAT REV CLIN ONCOL, V8, P492, DOI 10.1038/nrclinonc.2011.45; Redell MS, 2005, CURR PHARM DESIGN, V11, P2873, DOI 10.2174/1381612054546699; Robinson JT, 2012, GUT, V61, P673; Ross J, 2012, MOL CELL BIOL, V32, P3624, DOI 10.1128/MCB.00163-12; Schmidt PH, 1999, LAB INVEST, V79, P639; Shechter D, 2007, NAT PROTOC, V2, P1445, DOI 10.1038/nprot.2007.202; TAMURA S, 1994, P NATL ACAD SCI USA, V91, P4609, DOI 10.1073/pnas.91.10.4609; Verzi MP, 2011, MOL CELL BIOL, V31, P2026, DOI 10.1128/MCB.01250-10; Verzi MP, 2010, DEV CELL, V19, P713, DOI 10.1016/j.devcel.2010.10.006; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Welch JJ, 2004, BLOOD, V104, P3136, DOI 10.1182/blood-2004-04-1603; Yu M, 2009, MOL CELL, V36, P682, DOI 10.1016/j.molcel.2009.11.002; Zeitlinger J, 2007, GENE DEV, V21, P385, DOI 10.1101/gad.1509607; Zhao R, 2008, DEV BIOL, V317, P614, DOI 10.1016/j.ydbio.2008.03.013	49	44	46	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2014	33	49					5637	5648		10.1038/onc.2013.517	http://dx.doi.org/10.1038/onc.2013.517			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZW	24317510	Green Submitted, Green Accepted			2022-12-28	WOS:000346088700008
J	Zhu, B; Ferry, CH; Blazanin, N; Bility, MT; Khozoie, C; Kang, BH; Glick, AB; Gonzalez, FJ; Peters, JM				Zhu, B.; Ferry, C. H.; Blazanin, N.; Bility, M. T.; Khozoie, C.; Kang, B-H; Glick, A. B.; Gonzalez, F. J.; Peters, J. M.			PPAR beta/delta promotes HRAS-induced senescence and tumor suppression by potentiating p-ERK and repressing p-AKT signaling	ONCOGENE			English	Article						peroxisome proliferator-activated receptor-beta/delta; HRAS-induced senescence; mechanisms of senescence; inhibition of tumorigenesis	ACTIVATED RECEPTOR-BETA/DELTA; INTEGRIN-LINKED KINASE; INHIBITS CELL-PROLIFERATION; LIGAND ACTIVATION; TRANSCRIPTION FACTORS; PROTEIN-KINASE; RAS ONCOGENE; MOUSE SKIN; HA-RAS; EXPRESSION	Peroxisome proliferator-activated receptor-beta/delta (PPAR beta/delta) inhibits skin tumorigenesis through mechanisms that may be dependent on HRAS signaling. The present study examined the hypothesis that PPAR beta/delta promotes HRAS-induced senescence resulting in suppression of tumorigenesis. PPAR beta/delta expression increased p-ERK and decreased p-AKT activity. Increased p-ERK activity results from the dampened HRAS-induced negative feedback response mediated in part through transcriptional upregulation of RAS guanyl-releasing protein 1 (RASGRP1) by PPAR beta/delta. Decreased p-AKT activity results from repression of integrin-linked kinase (ILK) and phosphoinositide-dependent protein kinase-1 (PDPK1) expression. Decreased p-AKT activity in turn promotes cellular senescence through upregulation of p53 and p27 expression. Both over-expression of RASGRP1 and shRNA-mediated knockdown of ILK partially restore cellular senescence in Ppar beta/delta-null cells. Higher PPAR beta/delta expression is also correlated with increased senescence observed in human benign neurofibromas and colon adenoma lesions in vivo. These results demonstrate that PPAR beta/delta promotes senescence to inhibit tumorigenesis and provide new mechanistic insights into HRAS-induced cellular senescence.	[Zhu, B.; Ferry, C. H.; Blazanin, N.; Bility, M. T.; Khozoie, C.; Glick, A. B.; Peters, J. M.] Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, Dept Vet & Biomed Sci, University Pk, PA 16802 USA; [Kang, B-H] Preclin Res Ctr, Chemon, Yongin Si, South Korea; [Gonzalez, F. J.] NCI, Lab Metab, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Peters, JM (corresponding author), Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, Dept Vet & Biomed Sci, University Pk, PA 16802 USA.	jmp21@psu.edu	Zhu, Bokai/AAF-7502-2020	Zhu, Bokai/0000-0003-0827-5757; Peters, Jeffrey/0000-0003-2782-2998; Bility, Moses/0000-0001-5153-2718	National Institutes of Health [CA124533, CA141029, CA140369, AA018863, CA122109, CA117957]; National Cancer Institute Intramural Research Program [ZIABC005561, ZIABC005562, ZIABC005708]; NATIONAL CANCER INSTITUTE [R01CA126826, R01CA124533, R01CA117957, R01CA141029, R01CA140369, ZIABC005708, ZIABC005562, ZIABC005561, R01CA122109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA018863] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute Intramural Research Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	We gratefully acknowledge Drs Andrew Billin and Timothy Willson for providing the GW0742, the Center for Quantitative Cell Analysis and the Genomic Core Facility at the Huck Institutes of Life Sciences of The Pennsylvania State University for their technical support with flow cytometry and data analysis. This work was supported by the National Institutes of Health (CA124533, CA141029, CA140369 and AA018863 to JMP; CA122109 and CA117957 to ABG) and the National Cancer Institute Intramural Research Program (ZIABC005561, ZIABC005562 and ZIABC005708 to FJG).	Adhikary T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016344; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alexander K, 2001, MOL CELL BIOL, V21, P3616, DOI 10.1128/MCB.21.11.3616-3631.2001; Bility MT, 2010, TOXICOL SCI, V113, P27, DOI 10.1093/toxsci/kfp212; Bility MT, 2008, CARCINOGENESIS, V29, P2406, DOI 10.1093/carcin/bgn219; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Borland MG, 2008, MOL PHARMACOL, V74, P1429, DOI 10.1124/mol.108.050609; Borland MG, 2011, CELL SIGNAL, V23, P2039, DOI 10.1016/j.cellsig.2011.07.020; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; Burdick AD, 2006, CELL SIGNAL, V18, P9, DOI 10.1016/j.cellsig.2005.07.009; Burdick AD, 2007, CELL SIGNAL, V19, P1163, DOI 10.1016/j.cellsig.2006.12.007; Busuttil V, 2010, P NATL ACAD SCI USA, V107, P18061, DOI 10.1073/pnas.1006163107; Cao XX, 2011, J BIOL CHEM, V286, P33447, DOI 10.1074/jbc.M111.225565; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Dai CY, 2000, GASTROENTEROLOGY, V119, P929, DOI 10.1053/gast.2000.17952; Dai DL, 2003, CLIN CANCER RES, V9, P4409; de Keizer PLJ, 2010, CANCER RES, V70, P8526, DOI 10.1158/0008-5472.CAN-10-1563; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Foreman JE, 2011, MOL CARCINOGEN, V50, P884, DOI 10.1002/mc.20757; Girroir EE, 2008, BIOCHEM BIOPH RES CO, V371, P456, DOI 10.1016/j.bbrc.2008.04.086; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Grimaldi PA, 2010, CURR OPIN LIPIDOL, V21, P186, DOI 10.1097/MOL.0b013e32833884a4; He PF, 2008, TOXICOLOGY, V254, P112, DOI 10.1016/j.tox.2008.09.023; Hong Y, 2010, CLIN EXP METASTAS, V27, P83, DOI 10.1007/s10585-010-9305-4; Kaiser S, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r131; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kennedy AL, 2011, MOL CELL, V42, P36, DOI 10.1016/j.molcel.2011.02.020; Kilgore KS, 2008, CURR OPIN INVEST DR, V9, P463; Kim DJ, 2004, J BIOL CHEM, V279, P23719, DOI 10.1074/jbc.M312063200; KNUTSEN GL, 1986, ENVIRON HEALTH PERSP, V68, P91, DOI 10.2307/3430253; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002; Mandard S, 2004, J BIOL CHEM, V279, P34411, DOI 10.1074/jbc.M403058200; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Marin HE, 2006, CANCER RES, V66, P4394, DOI 10.1158/0008-5472.CAN-05-4277; Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820; Miller SJ, 2009, EMBO MOL MED, V1, P236, DOI 10.1002/emmm.200900027; Modica S, 2010, GASTROENTEROLOGY, V138, P636, DOI 10.1053/j.gastro.2009.09.060; MORGAN D, 1992, CANCER RES, V52, P3145; Nagashima T, 2010, MOL PHARMACOL, V78, P961, DOI 10.1124/mol.110.065714; Notterman DA, 2001, CANCER RES, V61, P3124; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Palkar PS, 2010, MOL PHARMACOL, V78, P419, DOI 10.1124/mol.110.065508; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Peters JM, 2008, CLIN SCI, V115, P107, DOI 10.1042/CS20080022; Peters Jeffrey M, 2011, Drug Discov Today Dis Mech, V8, pe85; Peters JM, 2012, NAT REV CANCER, V12, P181, DOI 10.1038/nrc3214; Peters JM, 2011, CANCER METAST REV, V30, P619, DOI 10.1007/s10555-011-9320-1; Peters JM, 2009, BBA-REV CANCER, V1796, P230, DOI 10.1016/j.bbcan.2009.06.002; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Sabates-Beliver J, 2007, MOL CANCER RES, V5, P1263, DOI 10.1158/1541-7786.MCR-07-0267; Satyanarayana A, 2004, MOL CELL BIOL, V24, P5459, DOI 10.1128/MCB.24.12.5459-5474.2004; Schramek H, 1997, J BIOL CHEM, V272, P11426; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharma A, 2010, J BIOL CHEM, V285, P15724, DOI 10.1074/jbc.M109.100016; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; Skrzypczak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013091; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248; Vijayachandra K, 2003, CANCER RES, V63, P3447; Yang L, 2010, ONCOGENE, V29, P516, DOI 10.1038/onc.2009.370; Yang L, 2011, CLIN CANCER RES, V17, P3760, DOI 10.1158/1078-0432.CCR-10-2779; Yu JH, 2011, VIRCHOWS ARCH, V458, P99, DOI 10.1007/s00428-010-1016-3; Zhu BK, 2012, MOL CELL BIOL, V32, P2065, DOI 10.1128/MCB.00092-12; Zhu BK, 2010, MOL CANCER THER, V9, P3267, DOI 10.1158/1535-7163.MCT-10-0820; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	72	38	38	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2014	33	46					5348	5359		10.1038/onc.2013.477	http://dx.doi.org/10.1038/onc.2013.477			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MF	24213576	Green Accepted			2022-12-28	WOS:000345120600005
J	Tamura, M; Sasaki, Y; Koyama, R; Takeda, K; Idogawa, M; Tokino, T				Tamura, M.; Sasaki, Y.; Koyama, R.; Takeda, K.; Idogawa, M.; Tokino, T.			Forkhead transcription factor FOXF1 is a novel target gene of the p53 family and regulates cancer cell migration and invasiveness	ONCOGENE			English	Article						FOXF1; p53 family; cell invasion; cell migration; E-cadherin	E-CADHERIN EXPRESSION; MESENCHYMAL TRANSITION; CARCINOMA-CELLS; P63; SUPPRESSOR; METASTASIS; ADHESION; PROTEIN; P73; IDENTIFICATION	p53 is an established tumor suppressor that can activate the transcription of multiple target genes. Recent evidence suggests that p53 may contribute to the regulation of cell invasion and migration. In this study, we show that the forkhead box transcription factor FOXF1 is a novel target of the p53 family because FOXF1 is upregulated by p53, TAp73 and TAp63. We show that FOXF1 is induced upon DNA damage in a p53-dependent manner. Furthermore, we identified a response element located within the FOXF1 gene that is responsive to wild-type p53, TAp73 beta and TAp63 gamma. The ectopic expression of FOXF1 inhibited cancer cell invasion and migration, whereas the inactivation of FOXF1 stimulated cell invasion and migration. We also show that FOXF1 regulates the transcriptional activity of E-cadherin (CDH1) by acting on its FOXF1 consensus binding site located upstream of the E-cadherin gene. Collectively, our results show that FOXF1 is a p53 family target gene, and our data suggest that FOXF1 and p53 form a portion of a regulatory transcriptional network that appears to have an important role in cancer cell invasion and migration.	[Tamura, M.; Sasaki, Y.; Koyama, R.; Takeda, K.; Idogawa, M.; Tokino, T.] Sapporo Med Univ, Res Inst Frontier Med, Dept Med Genome Sci, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University	Tokino, T (corresponding author), Sapporo Med Univ, Res Inst Frontier Med, Dept Med Genome Sci, Chuo Ku, S-1,W-17, Sapporo, Hokkaido 0608556, Japan.	yasushi@sapmed.ac.jp; tokino@sapmed.ac.jp	Tokino, Takashi/AAI-9887-2021; Sasaki, Yasushi/AAA-3079-2019; Idogawa, Masashi/B-5208-2008	Sasaki, Yasushi/0000-0002-3500-8059; Idogawa, Masashi/0000-0002-8507-1726	Ministry of Education, Culture, Sports, Science and Technology of Japan; Grants-in-Aid for Scientific Research [221S0001] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This research was supported in part by Grants-in-Aid for Cancer Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1291, DOI 10.1006/bbrc.1994.2322; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Chen F, 2010, BIOCHEM PHARMACOL, V80, P724, DOI 10.1016/j.bcp.2010.04.031; Cheng JC, 2011, ONCOGENE, V30, P3930, DOI 10.1038/onc.2011.117; Don ASA, 2006, EXP CELL RES, V312, P4181, DOI 10.0116/j.yexcr.2006.09.023; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fomenkov A, 2004, CELL CYCLE, V3, P1285, DOI 10.4161/cc.3.10.1155; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; Graziano V, 2011, BBA-REV CANCER, V1816, P57, DOI 10.1016/j.bbcan.2011.04.002; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Harms KL, 2006, CELL DEATH DIFFER, V13, P890, DOI 10.1038/sj.cdd.4401904; Hsiao BY, 2011, J MOL MED, V89, P481, DOI 10.1007/s00109-010-0717-z; Hwang CI, 2011, CELL CYCLE, V10, P3834, DOI 10.4161/cc.10.22.18294; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Liefer KM, 2000, CANCER RES, V60, P4016; Liu JJ, 2010, FEBS LETT, V584, P619, DOI 10.1016/j.febslet.2009.12.011; Lo PK, 2013, EXP MOL PATHOL, V94, P262, DOI 10.1016/j.yexmp.2012.10.014; Lo PK, 2012, CELL SIGNAL, V24, P316, DOI 10.1016/j.cellsig.2011.09.017; Lo PK, 2010, CANCER RES, V70, P6047, DOI 10.1158/0008-5472.CAN-10-1576; Lomenick JP, 2006, AM J PHYSIOL-ENDOC M, V291, pE947, DOI 10.1152/ajpendo.00128.2006; Lu C, 2008, CANCER BIOL THER, V7, P2039, DOI 10.4161/cbt.7.12.7461; Melino G, 2011, CELL DEATH DIFFER, V18, P1487, DOI 10.1038/cdd.2011.81; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mizuno H, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-18; Nilsson J, 2010, CANCER RES, V70, P2020, DOI 10.1158/0008-5472.CAN-09-1677; Pecina-Slaus N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-17; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Sasaki Y, 2005, ONCOGENE, V24, P5131, DOI 10.1038/sj.onc.1208695; Sasaki Y, 2003, CANCER RES, V63, P8145; Sasaki Y, 2008, MOL CANCER RES, V6, P395, DOI 10.1158/1541-7786.MCR-07-0108; Sasaki Y, 2011, CANCER RES, V71, P7038, DOI 10.1158/0008-5472.CAN-11-1053; Shaw-Smith C, 2010, EUR J MED GENET, V53, P6, DOI 10.1016/j.ejmg.2009.10.001; Shiota M, 2010, CLIN CANCER RES, V16, P5654, DOI 10.1158/1078-0432.CCR-10-0376; Stankiewicz P, 2009, AM J HUM GENET, V84, P780, DOI 10.1016/j.ajhg.2009.05.005; Stiewe T, 2007, NAT REV CANCER, V7, P165, DOI 10.1038/nrc2072; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Su XH, 2013, NAT REV CANCER, V13, P136, DOI 10.1038/nrc3446; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Teh MT, 2002, CANCER RES, V62, P4773; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Watson JEV, 2004, ONCOGENE, V23, P3487, DOI 10.1038/sj.onc.1207474; Wu N, 2012, J BIOL CHEM, V287, P5627, DOI 10.1074/jbc.M111.328120; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhang YH, 2012, J BIOL CHEM, V287, P17746, DOI 10.1074/jbc.M112.358143; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051	62	42	44	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2014	33	40					4837	4846		10.1038/onc.2013.427	http://dx.doi.org/10.1038/onc.2013.427			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0EH	24186199				2022-12-28	WOS:000343240100005
J	Butt, AQ; Mills, KHG				Butt, A. Q.; Mills, K. H. G.			Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines	ONCOGENE			English	Review						immunotherapy; vaccine; antitumor immunity; immune checkpoint; regulatory T cell; Toll-like receptor agonist	REGULATORY T-CELLS; TUMOR-ASSOCIATED MACROPHAGES; MYELOID SUPPRESSOR-CELLS; SURFACE SIGNALING MOLECULES; TYROSINE KINASE INHIBITOR; TOLL-LIKE; DENDRITIC CELLS; ALTERNATIVE ACTIVATION; MONOCLONAL-ANTIBODY; RECEPTOR AGONIST	Vaccines that promote protective adaptive immune responses have been successfully developed against a range of infectious diseases, and these are normally administered prior to exposure with the relevant virus or bacteria. Adaptive immunity also plays a critical role in the control of tumors. Immunotherapeutics and vaccines that promote effector T cell responses have the potential to eliminate tumors when used in a therapeutic setting. However, the induction of protective antitumor immunity is compromised by innate immunosuppressive mechanisms and regulatory cells that often dominate the tumor microenvironment. Recent studies have shown that blocking these suppressor cells and immune checkpoints to allow induction of antitumor immunity is a successful immunotherapeutic modality for the treatment of cancer. Furthermore, stimulation of innate and consequently adaptive immune responses with concomitant inhibition of immune suppression, especially that mediated by regulatory T (Treg) cells, is emerging as a promising approach to enhance the efficacy of therapeutic vaccines against cancer. This review describes the immunosuppressive mechanisms controlling antitumor immunity and the novel strategies being employed to design effective immunotherapeutics against tumors based on inhibition of suppressor cells or blockade of immune checkpoints to allow induction of more potent effector T cell responses. This review also discusses the potential of using a combination of adjuvants with inhibition of immune checkpoint or suppressor cells for therapeutic vaccines and the translation of pre-clinical studies to the next-generation vaccines against cancer in humans.	[Butt, A. Q.; Mills, K. H. G.] Univ Dublin Trinity Coll, Trinity Biomed Sci Inst, Sch Biochem & Immunol, Immune Regulat Res Grp, Dublin 2, Ireland	Trinity College Dublin	Mills, KHG (corresponding author), Univ Dublin Trinity Coll, Trinity Biomed Sci Inst, Sch Biochem & Immunol, Immune Regulat Res Grp, Dublin 2, Ireland.	kingston.mills@tcd.ie	Mills, Kingston H/F-5684-2013	Mills, Kingston H/0000-0003-3646-8222	Science Foundation Ireland	Science Foundation Ireland(Science Foundation IrelandEuropean Commission)	Kingston Mills's research group is supported by grants from Science Foundation Ireland.	Ahn GO, 2010, P NATL ACAD SCI USA, V107, P8363, DOI 10.1073/pnas.0911378107; Akdis CA, 2003, EUR J IMMUNOL, V33, P2717, DOI 10.1002/eji.200323329; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Amendola M, 2009, MOL THER, V17, P1039, DOI 10.1038/mt.2009.48; Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592; Baxevanis CN, 2009, CANCER IMMUNOL IMMUN, V58, P317, DOI 10.1007/s00262-008-0576-4; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Bronte V, 1998, J IMMUNOL, V161, P5313; Bunt SK, 2009, J LEUKOCYTE BIOL, V85, P996, DOI 10.1189/jlb.0708446; Byrne WL, 2011, CANCER RES, V71, P6915, DOI 10.1158/0008-5472.CAN-11-1156; Casares N, 2010, J IMMUNOL, V185, P5150, DOI 10.4049/jimmunol.1001114; Chen W, 2012, CANCER RES, V72, P1363, DOI 10.1158/0008-5472.CAN-11-2684; Chung KY, 2010, J CLIN ONCOL, V28, P3485, DOI 10.1200/JCO.2010.28.3994; Cluff CW, 2009, ADV EXP MED BIOL, V667, P111, DOI 10.1007/978-1-4419-1603-7_10; Coe D, 2010, CANCER IMMUNOL IMMUN, V59, P1367, DOI 10.1007/s00262-010-0866-5; Conroy H, 2008, ONCOGENE, V27, P168, DOI 10.1038/sj.onc.1210910; Conroy H, 2012, CANCER IMMUNOL IMMUN, V61, P425, DOI 10.1007/s00262-011-1188-y; Corsello SM, 2013, J CLIN ENDOCR METAB, V98, P1361, DOI 10.1210/jc.2012-4075; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Curiel TJ, 2003, NAT MED, V9, P562, DOI 10.1038/nm863; Dangaj D, 2013, CANCER RES, V73, P4820, DOI 10.1158/0008-5472.CAN-12-3457; De Santo C, 2005, P NATL ACAD SCI USA, V102, P4185, DOI 10.1073/pnas.0409783102; Delano MJ, 2007, J EXP MED, V204, P1463, DOI 10.1084/jem.20062602; Di Giacomo AM, 2010, SEMIN ONCOL, V37, P499, DOI 10.1053/j.seminoncol.2010.09.007; Doedens AL, 2010, CANCER RES, V70, P7465, DOI 10.1158/0008-5472.CAN-10-1439; Edwards JP, 2010, INT IMMUNOPHARMACOL, V10, P1220, DOI 10.1016/j.intimp.2010.07.002; Fischer C, 2007, CELL, V131, P463, DOI 10.1016/j.cell.2007.08.038; Fong L, 2008, J CLIN ONCOL, V26, P5275, DOI 10.1200/JCO.2008.17.8954; Fourcade J, 2010, J EXP MED, V207, P2175, DOI 10.1084/jem.20100637; Fujita M, 2011, CANCER RES, V71, P2664, DOI 10.1158/0008-5472.CAN-10-3055; Fujiwara Y, 2011, ONCOL REP, V26, P1533, DOI 10.3892/or.2011.1454; Fujiwara Y, 2011, CANCER SCI, V102, P206, DOI 10.1111/j.1349-7006.2010.01772.x; Gabrilovich DI, 2001, J IMMUNOL, V166, P5398, DOI 10.4049/jimmunol.166.9.5398; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Garbi N, 2004, J IMMUNOL, V172, P5861, DOI 10.4049/jimmunol.172.10.5861; Goding SR, 2013, J IMMUNOL, V190, P4899, DOI 10.4049/jimmunol.1300271; Goldberg MV, 2011, CURR TOP MICROBIOL, V344, P269, DOI 10.1007/82_2010_114; Golgher D, 2002, EUR J IMMUNOL, V32, P3267, DOI 10.1002/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO;2-1; Hiraoka K, 2008, CANCER SCI, V99, P1595, DOI 10.1111/j.1349-7006.2008.00880.x; Hoechst B, 2011, BLOOD, V117, P6532, DOI 10.1182/blood-2010-11-317321; HOON DSB, 1990, CANCER RES, V50, P5358; Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008-5472.CAN-05-1299; Hussain SF, 2007, CANCER RES, V67, P9630, DOI 10.1158/0008-5472.CAN-07-1243; Jarnicki AG, 2008, J IMMUNOL, V180, P3797, DOI 10.4049/jimmunol.180.6.3797; Jarnicki AG, 2006, J IMMUNOL, V177, P896, DOI 10.4049/jimmunol.177.2.896; Jiang JT, 2010, CANCER IMMUNOL IMMUN, V59, P1707, DOI 10.1007/s00262-010-0900-7; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kanzler H, 2007, NAT MED, V13, P552, DOI 10.1038/nm1589; Karanikas V, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-19; KIKKAWA F, 1993, EUR J CANCER, V29A, P1542, DOI 10.1016/0959-8049(93)90291-M; Ko HJ, 2007, CANCER RES, V67, P7477, DOI 10.1158/0008-5472.CAN-06-4639; Ko JS, 2010, CANCER RES, V70, P3526, DOI 10.1158/0008-5472.CAN-09-3278; Ko JS, 2009, CLIN CANCER RES, V15, P2148, DOI 10.1158/1078-0432.CCR-08-1332; Ko K, 2005, J EXP MED, V202, P885, DOI 10.1084/jem.20050940; Kodumudi KN, 2010, CLIN CANCER RES, V16, P4583, DOI 10.1158/1078-0432.CCR-10-0733; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059; Kryczek I, 2006, J EXP MED, V203, P871, DOI 10.1084/jem.20050930; Kubota Y, 2009, J EXP MED, V206, P1089, DOI 10.1084/jem.20081605; Kusmartsev S, 2003, CANCER RES, V63, P4441; Lanier LL, 2008, NAT IMMUNOL, V9, P495, DOI 10.1038/ni1581; Lathers DMR, 2004, CANCER IMMUNOL IMMUN, V53, P422, DOI 10.1007/s00262-003-0459-7; Liao XD, 2011, J CLIN INVEST, V121, P2736, DOI 10.1172/JCI45444; Love WE, 2009, ARCH DERMATOL, V145, P1431, DOI 10.1001/archdermatol.2009.291; Manthey CL, 2009, MOL CANCER THER, V8, P3151, DOI 10.1158/1535-7163.MCT-09-0255; Marshall NA, 2012, CANCER RES, V72, P581, DOI 10.1158/0008-5472.CAN-11-0307; Melief CJM, 2008, IMMUNITY, V29, P372, DOI 10.1016/j.immuni.2008.08.004; Mills KHG, 2004, NAT REV IMMUNOL, V4, P841, DOI 10.1038/nri1485; Mirza N, 2006, CANCER RES, V66, P9299, DOI 10.1158/0008-5472.CAN-06-1690; Miselis NR, 2008, MOL CANCER THER, V7, P788, DOI 10.1158/1535-7163.MCT-07-0579; Mizutani K, 2009, NEOPLASIA, V11, P1235, DOI 10.1593/neo.09988; Morita R, 2012, IMMUNOTHERAPY-UK, V4, P1103, DOI [10.2217/IMT.12.116, 10.2217/imt.12.116]; Mougiakakos D, 2010, ADV CANCER RES, V107, P57, DOI 10.1016/S0065-230X(10)07003-X; Mullard A, 2013, NAT REV DRUG DISCOV, V12, P489, DOI 10.1038/nrd4066; Nagai T, 2009, CANCER IMMUNOL IMMUN, V58, P1577, DOI 10.1007/s00262-009-0667-x; Nagaraj S, 2010, CLIN CANCER RES, V16, P1812, DOI 10.1158/1078-0432.CCR-09-3272; Nava-Parada P, 2007, CANCER RES, V67, P1326, DOI 10.1158/0008-5472.CAN-06-3290; Nefedova Y, 2007, CANCER RES, V67, P11021, DOI 10.1158/0008-5472.CAN-07-2593; Obermajer N, 2011, BLOOD, V118, P5498, DOI 10.1182/blood-2011-07-365825; Ostrand-Rosenberg S, 2010, CANCER IMMUNOL IMMUN, V59, P1593, DOI 10.1007/s00262-010-0855-8; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Ozao-Choy J, 2009, CANCER RES, V69, P2514, DOI 10.1158/0008-5472.CAN-08-4709; Palucka K, 2010, CURR OPIN IMMUNOL, V22, P258, DOI 10.1016/j.coi.2010.02.010; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Paulus P, 2006, CANCER RES, V66, P4349, DOI 10.1158/0008-5472.CAN-05-3523; Pello OM, 2012, BLOOD, V119, P411, DOI 10.1182/blood-2011-02-339911; Peng GY, 2005, SCIENCE, V309, P1380, DOI 10.1126/science.1113401; Peranzoni E, 2010, CURR OPIN IMMUNOL, V22, P238, DOI 10.1016/j.coi.2010.01.021; Puig-Kroger A, 2009, CANCER RES, V69, P9395, DOI 10.1158/0008-5472.CAN-09-2050; Pyonteck SM, 2012, ONCOGENE, V31, P1459, DOI 10.1038/onc.2011.337; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Ralph C, 2010, CLIN CANCER RES, V16, P1662, DOI 10.1158/1078-0432.CCR-09-2870; Rasku MA, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-12; Rech AJ, 2009, ANN NY ACAD SCI, V1174, P99, DOI 10.1111/j.1749-6632.2009.04939.x; Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643; Schmidt C, 2007, NAT BIOTECHNOL, V25, P825, DOI 10.1038/nbt0807-825; Serafini P, 2008, CANCER RES, V68, P5439, DOI 10.1158/0008-5472.CAN-07-6621; Seya T, 2012, ONCOIMMUNOLOGY, V1, P1000, DOI 10.4161/onci.19894; Sharma S, 2013, EXPERT OPIN THER TAR, V17, P481, DOI 10.1517/14728222.2013.781585; Shime H, 2012, P NATL ACAD SCI USA, V109, P2066, DOI 10.1073/pnas.1113099109; Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Sinha P, 2005, CANCER IMMUNOL IMMUN, V54, P1137, DOI 10.1007/s00262-005-0703-4; Sinha P, 2005, CANCER RES, V65, P11743, DOI 10.1158/0008-5472.CAN-05-0045; Sinha P, 2005, J IMMUNOL, V174, P636, DOI 10.4049/jimmunol.174.2.636; Sinha P, 2007, J IMMUNOL, V179, P977, DOI 10.4049/jimmunol.179.2.977; Sinha P, 2007, CANCER RES, V67, P4507, DOI 10.1158/0008-5472.CAN-06-4174; Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065-2776(06)90001-7; Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385; Speiser DE, 2005, J CLIN INVEST, V115, P739, DOI 10.1172/JCI200523373; Steitz J, 2001, CANCER RES, V61, P8643; Stewart TJ, 2011, CANCER METAST REV, V30, P125, DOI 10.1007/s10555-011-9280-5; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; Suzuki E, 2005, CLIN CANCER RES, V11, P6713, DOI 10.1158/1078-0432.CCR-05-0883; Suzuki T, 2007, PLOS PATHOG, V3, P1082, DOI 10.1371/journal.ppat.0030111; Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tormo D, 2006, CANCER RES, V66, P5427, DOI 10.1158/0008-5472.CAN-06-0399; Ugel S, 2009, CURR OPIN PHARMACOL, V9, P470, DOI 10.1016/j.coph.2009.06.014; Vincent J, 2010, CANCER RES, V70, P3052, DOI 10.1158/0008-5472.CAN-09-3690; Waickman AT, 2012, CANCER IMMUNOL IMMUN, V61, P917, DOI 10.1007/s00262-011-1155-7; Walter S, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22246; Wang RF, 2006, SEMIN IMMUNOL, V18, P136, DOI 10.1016/j.smim.2006.01.008; WATANABE Y, 1987, J BIOL RESP MODIF, V6, P169; Weisser SB, 2011, EUR J IMMUNOL, V41, P1742, DOI 10.1002/eji.201041105; Wilson HL, 2006, INT REV IMMUNOL, V25, P183, DOI 10.1080/08830180600785868; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Woo EY, 2001, CANCER RES, V61, P4766; Woo SR, 2012, CANCER RES, V72, P917, DOI 10.1158/0008-5472.CAN-11-1620; Xin H, 2009, CANCER RES, V69, P2506, DOI 10.1158/0008-5472.CAN-08-4323; Yang YP, 2004, NAT IMMUNOL, V5, P508, DOI 10.1038/ni1059; Yao S, 2013, NAT REV DRUG DISCOV, V12, P130, DOI 10.1038/nrd3877; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Zabuawala T, 2010, CANCER RES, V70, P1323, DOI 10.1158/0008-5472.CAN-09-1474; Zeisberger SM, 2006, BRIT J CANCER, V95, P272, DOI 10.1038/sj.bjc.6603240; Zhang W, 2010, CLIN CANCER RES, V16, P3420, DOI 10.1158/1078-0432.CCR-09-2904; Zhao ED, 2012, ONCOIMMUNOLOGY, V1, P152, DOI 10.4161/onci.1.2.18480; Zhu XM, 2011, J NEURO-ONCOL, V104, P83, DOI 10.1007/s11060-010-0473-5; Zhu YW, 2011, IMMUNITY, V34, P466, DOI 10.1016/j.immuni.2011.04.008; Zou LH, 2004, CANCER RES, V64, P8451, DOI 10.1158/0008-5472.CAN-04-1987	142	101	109	1	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2014	33	38					4623	4631		10.1038/onc.2013.432	http://dx.doi.org/10.1038/onc.2013.432			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3VX	24141774	Green Submitted			2022-12-28	WOS:000342007200001
J	Chen, Z; Zhang, Y; Jia, C; Wang, Y; Lai, P; Zhou, X; Wang, Y; Song, Q; Lin, J; Ren, Z; Gao, Q; Zhao, Z; Zheng, H; Wan, Z; Gao, T; Zhao, A; Dai, Y; Bai, X				Chen, Z.; Zhang, Y.; Jia, C.; Wang, Y.; Lai, P.; Zhou, X.; Wang, Y.; Song, Q.; Lin, Jun; Ren, Z.; Gao, Q.; Zhao, Z.; Zheng, H.; Wan, Z.; Gao, T.; Zhao, A.; Dai, Y.; Bai, X.			mTORC1/2 targeted by n-3 polyunsaturated fatty acids in the prevention of mammary tumorigenesis and tumor progression	ONCOGENE			English	Article						mTORC1; mTORC2; breast cancer; n-3 polyunsaturated fatty acids (n-3 PUFAs); fat-1	BREAST-CANCER; DOCOSAHEXAENOIC ACID; MAMMALIAN TARGET; DIETARY-FAT; GROWTH; OMEGA-3-FATTY-ACIDS; COMPLEX; LONG; OIL; METASTASIS	Although epidemiological and preclinical studies have shown the preventative effects of n-3 polyunsaturated fatty acids (PUFAs) on breast cancer, inconsistencies still remain in the data and the underlying mechanisms remain unclear. In this study, we identified mammalian target of rapamycin (mTOR) signaling, which plays an essential role in cell proliferation and breast tumorigenesis, as a target of n-3 PUFAs. In breast cancer cell lines, n-3 PUFAs rapidly and efficiently suppress both mTOR complex 1 (mTORC1) and mTORC2 and their downstream signaling, and subsequently inhibit cell proliferation and angiogenesis while promoting apoptosis. Further study indicates that stabilization of the mTOR-raptor complex by n-3 PUFAs may contribute to their inhibitory effect on mTORC1. Importantly, four complementary and well-controlled animal models were utilized to identify the role and molecular target of n-3 PUFAs in the prevention of breast carcinogenesis and progression, namely: (1) chemically induced mammary tumor rats with a high dietary intake of n-3 PUFAs; (2) nude mice implanted with mammary tumor cell lines stably expressing fat-1, a desaturase that catalyzes the conversion of n-6 to n-3 PUFAs and produces n-3 PUFAs endogenously; (3) fat-1 transgenic severe combined immune deficiency mice implanted with breast tumor cells; and (4) the fat-1 transgenic mouse mammary tumor virus-polyoma virus middle T oncogene double-hybrid mice, a model of aggressive breast cancer. In summary, dietary and endogenous n-3 PUFAs abrogate the activity of mTORC1/2 pathways in vitro and in vivo and prevent breast carcinogenesis, tumor growth and metastasis. Taken together, our findings convincingly clarify the causal relationship between n-3 PUFAs and breast cancer prevention and establish mTORC1/2 as a target of n-3 PUFAs.	[Chen, Z.; Zhang, Y.; Jia, C.; Lai, P.; Zhou, X.; Song, Q.; Lin, Jun; Bai, X.] Southern Med Univ, Sch Basic Med Sci, Dept Cell Biol, Guangzhou 510515, Guangdong, Peoples R China; [Wang, Y.; Wang, Y.; Ren, Z.; Gao, Q.; Wan, Z.; Zhao, A.; Dai, Y.] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China; [Wang, Y.; Wang, Y.; Ren, Z.; Gao, Q.; Wan, Z.; Zhao, A.; Dai, Y.] Nanjing Med Univ, Jiangsu Key Lab Xenotransplantat, Nanjing, Jiangsu, Peoples R China; [Zhao, Z.] Nankai Univ, Coll Life Sci, Tianjin 300071, Peoples R China; [Zheng, H.] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou, Guangdong, Peoples R China; [Gao, T.] Southern Med Univ, Dept Anat & Neurobiol, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China; Nanjing Medical University; Nanjing Medical University; Nankai University; Southern Medical University - China; Southern Medical University - China	Dai, Y (corresponding author), Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China.	yifandai08@gmail.com; baixc15@smu.edu.cn	qiancheng, song/C-4159-2014	zhang, yue/0000-0002-6612-8002; Chen, Zhenguo/0000-0003-3280-5201; Song, Qiancheng/0000-0002-9335-5147; Bai, Xiaochun/0000-0001-9631-4781	State Key Development Program for Basic Research of China [2009CB918904, 2013CB945203]; National Natural Sciences Foundation of China [91029727]; Guangdong Natural Science Foundation [s2012010008209]; Program for Changjiang Scholars and Innovative Research Team in University [IRT1142]	State Key Development Program for Basic Research of China(State Key Development Program for Basic Research of China); National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Program for Changjiang Scholars and Innovative Research Team in University(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT))	We greatly appreciate the gift of TSC2<SUP>+/+</SUP> and TSC2<SUP>-/-</SUP> MEFs from Dr David J Kwiatkowski (Brigham and Women's Hospital, Boston, MA, USA). This work was supported by the State Key Development Program for Basic Research of China (2009CB918904, 2013CB945203), National Natural Sciences Foundation of China (91029727), Guangdong Natural Science Foundation (s2012010008209) and Program for Changjiang Scholars and Innovative Research Team in University (IRT1142). TSC2<SUP>+/+</SUP>P53<SUP>-/-</SUP> and TSC2<SUP>-/-</SUP>P53<SUP>-/-</SUP> mouse embryonic fibroblasts (MEF) were provided by Dr David J Kwiatkowski (Brigham and Women's Hospital, Boston, MA, USA).	Bai XC, 2010, CELL MOL LIFE SCI, V67, P239, DOI 10.1007/s00018-009-0163-7; Berquin IM, 2008, CANCER LETT, V269, P363, DOI 10.1016/j.canlet.2008.03.044; BRADEN LM, 1986, LIPIDS, V21, P285, DOI 10.1007/BF02536414; COHEN LA, 1993, LIPIDS, V28, P449, DOI 10.1007/BF02535944; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; Engeset D, 2006, INT J CANCER, V119, P175, DOI 10.1002/ijc.21819; GABOR H, 1985, J NATL CANCER I, V74, P1299; Gerber M, 2012, BRIT J NUTR, V107, pS228, DOI 10.1017/S0007114512001614; Gingras AA, 2007, J PHYSIOL-LONDON, V579, P269, DOI 10.1113/jphysiol.2006.121079; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; Jiang WQ, 2012, CANCER RES, V72, P3795, DOI 10.1158/0008-5472.CAN-12-1047; Jing K, 2011, AUTOPHAGY, V7, P1348, DOI 10.4161/auto.7.11.16658; JURKOWSKI JJ, 1985, J NATL CANCER I, V74, P1145; Kang JX, 2008, J NUTRIGENET NUTRIGE, V1, P172, DOI 10.1159/000119714; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim EK, 2011, ONCOGENE, V30, P2954, DOI 10.1038/onc.2011.22; Kwiatkowski DJ, 2005, HUM MOL GENET, V14, pR251, DOI 10.1093/hmg/ddi260; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; Larsson SC, 2004, AM J CLIN NUTR, V79, P935; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; MacLean CH, 2006, JAMA-J AM MED ASSOC, V295, P403, DOI 10.1001/jama.295.4.403; MacLennan MB, 2013, J NUTR BIOCHEM, V24, P388, DOI 10.1016/j.jnutbio.2012.08.002; Manni A, 2010, CANCER PREV RES, V3, P322, DOI 10.1158/1940-6207.CAPR-09-0173; O'Regan R, 2011, EXPERT OPIN THER TAR, V15, P859, DOI 10.1517/14728222.2011.575362; Olivo SE, 2005, CARCINOGENESIS, V26, P1563, DOI 10.1093/carcin/bgi118; ROSE DP, 1995, JNCI-J NATL CANCER I, V87, P587, DOI 10.1093/jnci/87.8.587; ROSE DP, 1993, JNCI-J NATL CANCER I, V85, P1743, DOI 10.1093/jnci/85.21.1743; Sarbassov DD, 2005, J BIOL CHEM, V280, P39505, DOI 10.1074/jbc.M506096200; SCHATZKIN A, 1989, JAMA-J AM MED ASSOC, V261, P3284, DOI 10.1001/jama.261.22.3284; Signori C, 2011, CANCER RES, V71, P6091, DOI 10.1158/0008-5472.CAN-11-0977; van Veelen W, 2011, ONCOGENE, V30, P2289, DOI 10.1038/onc.2010.630; Warner E, 2011, NEW ENGL J MED, V365, P1025, DOI 10.1056/NEJMcp1101540; Wei D, 2010, DIABETES, V59, P471, DOI 10.2337/db09-0284; Wen ZH, 2013, ONCOGENE, V32, P160, DOI 10.1038/onc.2012.47; Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501; Xia SH, 2006, P NATL ACAD SCI USA, V103, P12499, DOI 10.1073/pnas.0605394103; Yoshida S, 2011, J BIOL CHEM, V286, P32651, DOI 10.1074/jbc.M111.238014; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	39	47	51	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2014	33	37					4548	4557		10.1038/onc.2013.402	http://dx.doi.org/10.1038/onc.2013.402			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3UZ	24096482				2022-12-28	WOS:000342004800002
J	Reynolds, AB; Kanner, SB; Bouton, AH; Schaller, MD; Weed, SA; Flynn, DC; Parsons, JT				Reynolds, A. B.; Kanner, S. B.; Bouton, A. H.; Schaller, M. D.; Weed, S. A.; Flynn, D. C.; Parsons, J. T.			SRChing for the substrates of Src	ONCOGENE			English	Review						Src; cortactin; p130Cas; FAK; p120-catenin; AFAP1	FOCAL ADHESION KINASE; EPIDERMAL-GROWTH-FACTOR; ACTIN-FILAMENT INTEGRITY; BREAST-CANCER CELLS; CHRONIC MYELOID-LEUKEMIA; RESEARCH-AND-DEVELOPMENT; E-CADHERIN COMPLEXES; ADAPTER PROTEIN CAS; TYROSINE PHOSPHORYLATION; C-SRC	By the mid 1980's, it was clear that the transforming activity of oncogenic Src was linked to the activity of its tyrosine kinase domain and attention turned to identifying substrates, the putative next level of control in the pathway to transformation. Among the first to recognize the potential of phosphotyrosine-specific antibodies, Parsons and colleagues launched a risky shotgun-based approach that led ultimately to the cDNA cloning and functional characterization of many of today's best-known Src substrates (for example, p85-Cortactin, p110-AFAP1, p130Cas, p125FAK and p120-catenin). Two decades and over 6000 citations later, the original goals of the project may be seen as secondary to the enormous impact of these protein substrates in many areas of biology. At the request of the editors, this review is not restricted to the current status of the substrates, but reflects also on the anatomy of the project itself and some of the challenges and decisions encountered along the way.	[Reynolds, A. B.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37235 USA; [Kanner, S. B.] Arrowhead Res Corp, Madison, WI USA; [Bouton, A. H.] Univ Virginia, Sch Med, Dept Microbiol, Charlottesville, VA 22908 USA; [Bouton, A. H.] Univ Virginia, Sch Med, Dept Immunol, Charlottesville, VA 22908 USA; [Bouton, A. H.] Univ Virginia, Sch Med, Dept Canc Biol, Charlottesville, VA 22908 USA; [Schaller, M. D.] W Virginia Univ, Sch Med, Dept Biochem, Robert C Byrd Hlth Sci Ctr,HSN 3124, Morgantown, WV USA; [Weed, S. A.] W Virginia Univ, Dept Neurobiol & Anat, Mary Babb Randolph Canc Ctr 1833, Robert C Byrd Hlth Sci Ctr,Sch Med, Morgantown, WV USA; [Flynn, D. C.] Univ Delaware, Coll Hlth Sci, Dept Med Lab Sci, Newark, DE 19716 USA; [Parsons, J. T.] Univ Virginia, Ctr Canc, Dept Microbiol, Charlottesville, VA 22908 USA; [Parsons, J. T.] Univ Virginia, Ctr Canc, Dept Immunol, Charlottesville, VA 22908 USA; [Parsons, J. T.] Univ Virginia, Ctr Canc, Dept Canc Biol, Charlottesville, VA 22908 USA	Vanderbilt University; University of Virginia; University of Virginia; University of Virginia; West Virginia University; West Virginia University; University of Delaware; University of Virginia; University of Virginia; University of Virginia	Flynn, DC (corresponding author), Univ Delaware, Coll Hlth Sci, Newark, DE 19716 USA.	dflynn@udel.edu		Weed, Scott/0000-0001-7033-9999	NIGMS NIH HHS [R01 GM102524] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM102524] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott BL, 2012, CLIN THER, V34, P272, DOI 10.1016/j.clinthera.2012.01.009; Ammer AG, 2008, CELL MOTIL CYTOSKEL, V65, P687, DOI 10.1002/cm.20296; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Avizienyte E, 2002, NAT CELL BIOL, V4, P632, DOI 10.1038/ncb829; Baisden JM, 2001, ONCOGENE, V20, P6435, DOI 10.1038/sj.onc.1204784; Beggs HE, 2003, NEURON, V40, P501, DOI 10.1016/S0896-6273(03)00666-4; Berggren R, 2012, NAT REV DRUG DISCOV, V11, P435, DOI 10.1038/nrd3744; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Birukova AA, 2011, EXP CELL RES, V317, P859, DOI 10.1016/j.yexcr.2010.11.011; Boguslavsky S, 2007, P NATL ACAD SCI USA, V104, P10882, DOI 10.1073/pnas.0702731104; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Brandt D, 2002, J BIOL CHEM, V277, P20903, DOI 10.1074/jbc.M200946200; Braren R, 2006, J CELL BIOL, V172, P151, DOI 10.1083/jcb.200506184; Brinkman A, 2000, JNCI-J NATL CANCER I, V92, P112, DOI 10.1093/jnci/92.2.112; Bruce-Staskal PJ, 2001, EXP CELL RES, V264, P296, DOI 10.1006/excr.2000.5137; Brunton VG, 2008, CURR OPIN PHARMACOL, V8, P427, DOI 10.1016/j.coph.2008.06.012; Bryce NS, 2005, CURR BIOL, V15, P1276, DOI 10.1016/j.cub.2005.06.043; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Cabodi S, 2006, CANCER RES, V66, P4672, DOI 10.1158/0008-5472.CAN-05-2909; Cabodi S, 2010, NAT REV CANCER, V10, P858, DOI 10.1038/nrc2967; Casamassima A, 1998, J BIOL CHEM, V273, P26149, DOI 10.1074/jbc.273.40.26149; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; Cho SY, 2002, J CELL BIOL, V156, P725, DOI 10.1083/jcb.200111032; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; Creedon Helen, 2012, Critical Reviews in Oncogenesis, V17, P145; David E, 2009, NAT REV DRUG DISCOV, V8, P609, DOI 10.1038/nrd2948; Davis MA, 2006, DEV CELL, V10, P21, DOI 10.1016/j.devcel.2005.12.004; Dillon DA, 1998, AM J PATHOL, V152, P75; Dorssers LCJ, 2004, CLIN CANCER RES, V10, P6194, DOI 10.1158/1078-0432.CCR-04-0444; DOWNING JR, 1991, ONCOGENE, V6, P607; Dunn KB, 2010, ANTI-CANCER AGENT ME, V10, P722; Eke I, 2012, J CLIN INVEST, V122, P1529, DOI 10.1172/JCI61350; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; FLYNN DC, 1995, J BIOL CHEM, V270, P3894, DOI 10.1074/jbc.270.8.3894; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; Forrest AD, 2009, J NEUROSCI RES, V87, P3456, DOI 10.1002/jnr.22022; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; Fromont G, 2007, PROSTATE, V67, P268, DOI 10.1002/pros.20516; FURUTA Y, 1995, ONCOGENE, V11, P1989; Gallick GE, 2012, FUTURE MED CHEM, V4, P107, DOI [10.4155/FMC.11.161, 10.4155/fmc.11.161]; Gatesman A, 2004, MOL CELL BIOL, V24, P7578, DOI 10.1128/MCB.24.17.7578-7597.2004; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Guappone AC, 1998, MOL CARCINOGEN, V22, P110, DOI 10.1002/(SICI)1098-2744(199806)22:2<110::AID-MC6>3.0.CO;2-Q; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; Guerrero Michael S, 2012, Genes Cancer, V3, P371, DOI 10.1177/1947601912458585; Hakim ZS, 2007, MOL CELL BIOL, V27, P5352, DOI 10.1128/MCB.00068-07; Han EKH, 2007, ANTI-CANCER AGENT ME, V7, P681, DOI 10.2174/187152007784111296; Hantschel O, 2012, CANCER RES, V72, P4890, DOI 10.1158/0008-5472.CAN-12-1276; Harte MT, 2000, BBA-MOL CELL RES, V1499, P34, DOI 10.1016/S0167-4889(00)00104-X; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hauck CR, 2001, CANCER RES, V61, P7079; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118; Huang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036124; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; ILLC D, 1995, NATURE, V377, P539; Iwanicki MP, 2008, J CELL SCI, V121, P895, DOI 10.1242/jcs.020941; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Khan SH, 2011, J BIOMOL STRUCT DYN, V28, P929, DOI 10.1080/07391102.2011.10508619; Kim W, 2004, J BIOL CHEM, V279, P8333, DOI 10.1074/jbc.M312026200; Kirkbride KC, 2011, CELL ADHES MIGR, V5, P187, DOI 10.4161/cam.5.2.14773; Klein EA, 2009, CURR BIOL, V19, P1511, DOI 10.1016/j.cub.2009.07.069; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kopetz S, 2007, CLIN CANCER RES, V13, P7232, DOI 10.1158/1078-0432.CCR-07-1902; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; Kowalski JR, 2005, J CELL SCI, V118, P79, DOI 10.1242/jcs.01586; Kurley SJ, 2012, DEVELOPMENT, V139, P1754, DOI 10.1242/dev.072769; Lawson C, 2012, J CELL BIOL, V196, P223, DOI 10.1083/jcb.201108078; Lim Y, 2008, J CELL BIOL, V180, P187, DOI 10.1083/jcb.200708194; Linder S, 2011, ANNU REV CELL DEV BI, V27, P185, DOI 10.1146/annurev-cellbio-092910-154216; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Ma WW, 2011, ANTI-CANCER AGENT ME, V11, P638; Magalhaes MAO, 2011, J CELL BIOL, V195, P903, DOI 10.1083/jcb.201103045; Manley PW, 2010, BBA-PROTEINS PROTEOM, V1804, P445, DOI 10.1016/j.bbapap.2009.11.008; Martinez-Quiles N, 2004, MOL CELL BIOL, V24, P5269, DOI 10.1128/MCB.24.12.5269-5280.2004; Meenderink LM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013412; Midwood KS, 2002, MOL BIOL CELL, V13, P3601, DOI 10.1091/mbc.E02-05-0292; Miyashita Y, 2007, J BIOL CHEM, V282, P11540, DOI 10.1074/jbc.M608351200; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Nagy T, 2007, J BIOL CHEM, V282, P31766, DOI 10.1074/jbc.M705403200; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nayal A, 2004, CURR OPIN CELL BIOL, V16, P94, DOI 10.1016/j.ceb.2003.11.007; Nick AM, 2011, JNCI-J NATL CANCER I, V103, P1596, DOI 10.1093/jnci/djr372; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Oser M, 2010, J CELL SCI, V123, P3662, DOI 10.1242/jcs.068163; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Owen KA, 2007, J CELL BIOL, V179, P1275, DOI 10.1083/jcb.200708093; Pan YR, 2011, J CELL BIOL, V195, P113, DOI 10.1083/jcb.201103016; Parekh A, 2009, CELL ADHES MIGR, V3, P288, DOI 10.4161/cam.3.3.8888; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Paul SM, 2010, NAT REV DRUG DISCOV, V9, P203, DOI 10.1038/nrd3078; PAWSON T, 1981, J VIROL, V40, P665, DOI 10.1128/JVI.40.3.665-672.1981; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; Perez-Moreno M, 2006, CELL, V124, P631, DOI 10.1016/j.cell.2005.11.043; Playford MP, 2008, EXP CELL RES, V314, P3187, DOI 10.1016/j.yexcr.2008.08.010; Ponik SM, 2013, MOL BIOL CELL, V24, P1688, DOI 10.1091/mbc.E12-05-0386; Provenzano PP, 2009, ONCOGENE, V28, P4326, DOI 10.1038/onc.2009.299; Qian Y, 2004, J CELL BIOCHEM, V91, P602, DOI 10.1002/jcb.10725; Qian Y, 2000, EXP CELL RES, V255, P102, DOI 10.1006/excr.1999.4795; Quintas-Cardama A, 2012, DRUG TODAY, V48, P177, DOI 10.1358/dot.2012.48.3.1750274; Radi M, 2013, CURR PHARM BIOTECHNO, V14, P477, DOI 10.2174/138920101405131111103750; Ren XD, 2000, J CELL SCI, V113, P3673; Ren XR, 2001, J CELL BIOL, V152, P971, DOI 10.1083/jcb.152.5.971; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; Reynolds AB, 2007, BBA-MOL CELL RES, V1773, P2, DOI 10.1016/j.bbamcr.2006.09.019; Rico B, 2004, NAT NEUROSCI, V7, P1059, DOI 10.1038/nn1317; Riggins RB, 2003, J BIOL CHEM, V278, P28264, DOI 10.1074/jbc.M303535200; Riggins RB, 2006, CANCER RES, V66, P7007, DOI 10.1158/0008-5472.CAN-05-3952; Rodrigo JP, 2009, J PATHOL, V217, P516, DOI 10.1002/path.2462; Rodrigo JP, 2000, CLIN CANCER RES, V6, P3177; Rodrigo JP, 2011, CANCER PREV RES, V4, P1333, DOI 10.1158/1940-6207.CAPR-10-0338; Rodriguez FJ, 2012, BBA-REV CANCER, V1826, P23, DOI 10.1016/j.bbcan.2012.03.002; Rothsschild BL, 2006, CANCER RES, V66, P8017, DOI 10.1158/0008-5472.CAN-05-4490; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sato K, 2011, MOL BIOL CELL, V22, P3103, DOI 10.1091/mbc.E11-03-0274; Sawada Y, 2006, CELL, V127, P1015, DOI 10.1016/j.cell.2006.09.044; SCHALLER MD, 1993, PROG NUCLEIC ACID RE, V44, P205, DOI 10.1016/S0079-6603(08)60221-4; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112; Schnoor M, 2011, J EXP MED, V208, P1721, DOI 10.1084/jem.20101920; Schuh NR, 2010, J BIOL CHEM, V285, P2309, DOI 10.1074/jbc.M109.046631; Schultze A, 2011, ANTI-CANCER AGENT ME, V11, P593, DOI 10.2174/187152011796817727; SCHUURING E, 1992, ONCOGENE, V7, P355; Schwock J, 2010, EXPERT OPIN THER TAR, V14, P77, DOI 10.1517/14728220903460340; Shen TL, 2005, J CELL BIOL, V169, P941, DOI 10.1083/jcb.200411155; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Smalley-Freed WG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019880; Smalley-Freed WG, 2010, J CLIN INVEST, V120, P1824, DOI 10.1172/JCI41414; Smith AL, 2012, MOL BIOL CELL, V23, P99, DOI 10.1091/mbc.E11-06-0497; Snyder BN, 2011, EUR J CELL BIOL, V90, P376, DOI 10.1016/j.ejcb.2010.11.016; Stairs DB, 2011, CANCER CELL, V19, P470, DOI 10.1016/j.ccr.2011.02.007; Summy JM, 2000, ONCOGENE, V19, P155, DOI 10.1038/sj.onc.1203265; Ta HQ, 2008, CANCER RES, V68, P8796, DOI 10.1158/0008-5472.CAN-08-2426; Tehrani S, 2007, P NATL ACAD SCI USA, V104, P11933, DOI 10.1073/pnas.0701077104; Thoreson MA, 2002, DIFFERENTIATION, V70, P583, DOI 10.1046/j.1432-0436.2002.700911.x; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Tikhmyanova N, 2010, CELL MOL LIFE SCI, V67, P1025, DOI 10.1007/s00018-009-0213-1; Tilghman RW, 2008, SEMIN CANCER BIOL, V18, P45, DOI 10.1016/j.semcancer.2007.08.002; Timpson P, 2007, CANCER RES, V67, P9304, DOI 10.1158/0008-5472.CAN-07-0798; Tomar A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044041; Tomar A, 2009, CURR OPIN CELL BIOL, V21, P676, DOI 10.1016/j.ceb.2009.05.006; Tomar A, 2009, J CELL SCI, V122, P1852, DOI 10.1242/jcs.046870; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Vallejo-Illarramendi A, 2009, J CLIN INVEST, V119, P2218, DOI 10.1172/JCI38194; van der Flier S, 2000, JNCI-J NATL CANCER I, V92, P120, DOI 10.1093/jnci/92.2.120; Vogt PK, 2012, NAT REV CANCER, V12, P639, DOI 10.1038/nrc3320; Walker VG, 2007, AM J PHYSIOL-CELL PH, V293, pC119, DOI 10.1152/ajpcell.00525.2006; Wang Y, 2012, J CELL BIOL, V196, P375, DOI 10.1083/jcb.201105153; Wang Y, 2011, MOL BIOL CELL, V22, P1529, DOI 10.1091/mbc.E10-09-0785; Weaver AM, 2002, CURR BIOL, V12, P1270, DOI 10.1016/S0960-9822(02)01035-7; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Wei L, 2004, J CELL BIOCHEM, V91, P325, DOI 10.1002/jcb.10760; Wells JA, 2007, NATURE, V450, P1001, DOI 10.1038/nature06526; Wildenberg GA, 2006, CELL, V127, P1027, DOI 10.1016/j.cell.2006.09.046; Wilkerson PM, 2013, GENE CHROMOSOME CANC, V52, P333, DOI 10.1002/gcc.22037; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Wu XY, 2005, DEV CELL, V9, P185, DOI 10.1016/j.devcel.2005.06.006; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamakita Y, 1999, J CELL BIOL, V144, P315, DOI 10.1083/jcb.144.2.315; Yano H, 2004, J CELL BIOL, V166, P283, DOI 10.1083/jcb.200312013; Yu D, 2010, EXP CELL RES, V316, P848, DOI 10.1016/j.yexcr.2009.11.018; ZHAN X, 1993, J BIOL CHEM, V268, P9611; Zhang J, 2007, J CLIN INVEST, V117, P2962, DOI 10.1172/JCI30710; Zhao X, 2011, ADV DRUG DELIVER REV, V63, P610, DOI 10.1016/j.addr.2010.11.001	191	32	33	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2014	33	37					4537	4547		10.1038/onc.2013.416	http://dx.doi.org/10.1038/onc.2013.416			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3UZ	24121272				2022-12-28	WOS:000342004800001
J	Zhu, J; Zhao, C; Kharman-Biz, A; Zhuang, T; Jonsson, P; Liang, N; Williams, C; Lin, CY; Qiao, Y; Zendehdel, K; Stromblad, S; Treuter, E; Dahlman-Wright, K				Zhu, J.; Zhao, C.; Kharman-Biz, A.; Zhuang, T.; Jonsson, P.; Liang, N.; Williams, C.; Lin, C-Y; Qiao, Y.; Zendehdel, K.; Stroemblad, S.; Treuter, E.; Dahlman-Wright, K.			The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor alpha and modulates estrogen-stimulated breast cancer cell proliferation	ONCOGENE			English	Article						RNF31; ubiquitin; ER alpha; estrogen signaling; breast cancer	TRANSCRIPTIONAL REPRESSION; TUMOR PROGRESSION; ER-ALPHA; P53; DEGRADATION; ACTIVATION; EXPRESSION; COMPLEX; PARKIN; TRANSACTIVATION	Estrogen receptor alpha (ER alpha) is initially expressed in the majority of breast cancers and promotes estrogen-dependent cancer progression by regulating the transcription of genes linked to cell proliferation. ER alpha status is of clinical importance, as ER alpha-positive breast cancers can be successfully treated by adjuvant therapy with antiestrogens or aromatase inhibitors. Complications arise from the frequent development of drug resistance that might be caused by multiple alterations, including components of ER alpha signaling, during tumor progression and metastasis. Therefore, insights into the molecular mechanisms that control ER alpha expression and stability are of utmost importance to improve breast cancer diagnostics and therapeutics. Here we report that the atypical E3 ubiquitin ligase RNF31 stabilizes ER alpha and facilitates ER alpha-stimulated proliferation in breast cancer cell lines. We show that depletion of RNF31 decreases the number of cells in the S phase and reduces the levels of ER alpha and its downstream target genes, including cyclin D1 and c-myc. Analysis of data from clinical samples confirms correlation between RNF31 expression and the expression of ER alpha target genes. Immunoprecipitation indicates that RNF31 associates with ER alpha and increases its stability and mono-ubiquitination, dependent on the ubiquitin ligase activity of RNF31. Our data suggest that association of RNF31 and ER alpha occurs mainly in the cytosol, consistent with the lack of RNF31 recruitment to ER alpha-occupied promoters. In conclusion, our study establishes a non-genomic mechanism by which RNF31 via stabilizing ER alpha levels controls the transcription of estrogen-dependent genes linked to breast cancer cell proliferation.	[Zhu, J.; Zhao, C.; Kharman-Biz, A.; Zhuang, T.; Liang, N.; Qiao, Y.; Stroemblad, S.; Treuter, E.; Dahlman-Wright, K.] Karolinska Inst, Dept Biosci & Nutr, S-14183 Huddinge, Sweden; [Kharman-Biz, A.; Zendehdel, K.] Univ Tehran Med Sci, Canc Inst Iran, Canc Res Ctr, Tehran, Iran; [Jonsson, P.; Williams, C.; Lin, C-Y] Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, Houston, TX USA	Karolinska Institutet; Tehran University of Medical Sciences; University of Houston System; University of Houston	Dahlman-Wright, K (corresponding author), Karolinska Inst, Dept Biosci & Nutr, S-14183 Huddinge, Sweden.	karin.dahlman-wright@ki.se	Williams, Cecilia/A-6677-2009; Qiao, yichun/Q-6498-2018; zhu, jian/D-7361-2017	Williams, Cecilia/0000-0002-0602-2062; Jonsson, Philip/0000-0002-1537-0624; Stromblad, Staffan/0000-0002-1236-6339; zhu, jian/0000-0003-0171-4251; zhu, jian/0000-0003-3596-4339; Zendehdel, Kazem/0000-0002-0269-4945; Liang, Ning/0000-0002-7848-2893; Treuter, Eckardt/0000-0002-4147-8989; Zhuang, Ting/0000-0002-6308-1253	China Scholarship Council; KID faculty grant from the Karolinska Institutet; Center for Biosciences; Swedish Cancer Society; Karolinska Institutet; Swedish Research Council; Cancer Institute of Tehran University; Knut & Alice Wallenberg foundation	China Scholarship Council(China Scholarship Council); KID faculty grant from the Karolinska Institutet; Center for Biosciences; Swedish Cancer Society(Swedish Cancer Society); Karolinska Institutet(Karolinska Institutet); Swedish Research Council(Swedish Research CouncilEuropean Commission); Cancer Institute of Tehran University; Knut & Alice Wallenberg foundation(Knut & Alice Wallenberg Foundation)	We are grateful to the BEA core facility for performing microarray analysis. We thank Indranil Sinha for uploading the microarray data. This work was supported by scholarship from the China Scholarship Council and by a KID faculty grant from the Karolinska Institutet (Jian Zhu), funding from the Center for Biosciences, the Swedish Cancer Society and the Karolinska Institutet (Karin Dahlman-Wright), and grants from the center for Biosciences, the Swedish Cancer Society and the Swedish Research Council (Eckardt Treuter). Human samples were provided by the Iran National Tumor Bank, which is funded by the Cancer Institute of Tehran University. Imaging, performed at the live cell imaging unit at the Department of Biosciences and Nutrition, was supported by the Knut & Alice Wallenberg foundation, the Swedish Research Council and the Center for Biosciences. This work was supported by scholarship from the China Scholarship Council and by a KID faculty grant from the Karolinska Institutet, funding from the Center for Biosciences, the Swedish Cancer Society, the Swedish Research Council and the Karolinska Institutet. Human samples were provided by the IRAN NATIONAL TUMOR BANK, which is funded by the Cancer Institute of Tehran University. Imaging was performed at the live cell imaging unit at the Department of Biosciences and Nutrition, supported by the Knut & Alice Wallenberg foundation, the Swedish Research Council and the Center for Biosciences.	Berry NB, 2008, MOL ENDOCRINOL, V22, P1535, DOI 10.1210/me.2007-0449; Brekman A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2804; Brown RJ, 2006, SEMIN ONCOL, V33, P657, DOI 10.1053/j.seminoncol.2006.08.014; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; da Costa CA, 2009, NAT CELL BIOL, V11, P1370, DOI 10.1038/ncb1981; Duong V, 2007, CANCER RES, V67, P5513, DOI 10.1158/0008-5472.CAN-07-0967; Ehrlund A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032080; Ehrlund A, 2009, MOL CELL BIOL, V29, P2230, DOI 10.1128/MCB.00743-08; Eisenhaber B, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-3-209; Fan MY, 2005, MOL ENDOCRINOL, V19, P2901, DOI 10.1210/me.2005-0111; Frasor J, 2009, CANCER RES, V69, P8918, DOI 10.1158/0008-5472.CAN-09-2608; Geschickter C F, 1934, Am J Cancer, V21, P828; Gustafsson N, 2010, CANCER RES, V70, P1265, DOI 10.1158/0008-5472.CAN-09-2674; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hicks C, 2012, BREAST CANCER-BASIC, V6, P47, DOI 10.4137/BCBCR.S8652; Ikeda F, 2011, NATURE, V471, P637, DOI 10.1038/nature09814; Kastan MB, 2003, CELL, V112, P1, DOI 10.1016/S0092-8674(02)01281-3; Kirisako T, 2006, EMBO J, V25, P4877, DOI 10.1038/sj.emboj.7601360; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; La Rosa P, 2011, CELL SIGNAL, V23, P1128, DOI 10.1016/j.cellsig.2011.02.006; Le Romancer M, 2011, ENDOCR REV, V32, P597, DOI 10.1210/er.2010-0016; LECLERCQ G, 1986, CANCER RES, V46, P4233; Lindstrom LS, 2012, J CLIN ONCOL, V30, P2601, DOI 10.1200/JCO.2011.37.2482; Lonard DM, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.113pe16; Ma YX, 2010, MOL ENDOCRINOL, V24, P76, DOI 10.1210/me.2009-0218; Mulhall JP, 2010, BJU INT, V106, P1706, DOI 10.1111/j.1464-410X.2010.09754.x; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nettles KW, 2008, NAT CHEM BIOL, V4, P241, DOI 10.1038/nchembio.76; Putnik M, 2012, BIOCHEM BIOPH RES CO, V426, P26, DOI 10.1016/j.bbrc.2012.08.007; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Shaaban AM, 2002, AM J PATHOL, V160, P597, DOI 10.1016/S0002-9440(10)64879-1; Smit JJ, 2012, EMBO J, V31, P3833, DOI 10.1038/emboj.2012.217; Stevens TA, 2006, ONCOGENE, V25, P5426, DOI 10.1038/sj.onc.1209529; Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093; Thompson HGR, 2004, EXP CELL RES, V295, P448, DOI 10.1016/j.yexcr.2004.01.019; Tokunaga F, 2011, NATURE, V471, P633, DOI 10.1038/nature09815; Tokunaga F, 2009, NAT CELL BIOL, V11, P123, DOI 10.1038/ncb1821; Wong SCC, 2001, J PATHOL, V194, P35, DOI 10.1002/path.838; Woo MG, 2012, J BIOL CHEM, V287, P3963, DOI 10.1074/jbc.M111.314765; Zhao CY, 2007, CANCER RES, V67, P3955, DOI 10.1158/0008-5472.CAN-06-3505; Zwart W, 2011, WIRES SYST BIOL MED, V3, P216, DOI 10.1002/wsbm.109	41	68	70	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2014	33	34					4340	4351		10.1038/onc.2013.573	http://dx.doi.org/10.1038/onc.2013.573			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MK	24441041	Green Published, hybrid			2022-12-28	WOS:000341156900007
J	Mori, T; Sato, Y; Miyamoto, K; Kobayashi, T; Shimizu, T; Kanagawa, H; Katsuyama, E; Fujie, A; Hao, W; Tando, T; Iwasaki, R; Kawana, H; Morioka, H; Matsumoto, M; Saya, H; Toyama, Y; Miyamoto, T				Mori, T.; Sato, Y.; Miyamoto, K.; Kobayashi, T.; Shimizu, T.; Kanagawa, H.; Katsuyama, E.; Fujie, A.; Hao, W.; Tando, T.; Iwasaki, R.; Kawana, H.; Morioka, H.; Matsumoto, M.; Saya, H.; Toyama, Y.; Miyamoto, T.			TNF alpha promotes osteosarcoma progression by maintaining tumor cells in an undifferentiated state	ONCOGENE			English	Article						osteosarcoma; tumorigenesis; osteoblast differentiation; gene-mutation; TNF alpha	INFLAMMATION; PATHWAY; CANCER; EPIDEMIOLOGY	Chronic inflammation is frequently associated with tumorigenesis in elderly people. By contrast, young people without chronic inflammation often develop tumors considered independent of chronic inflammation but driven instead by mutations. Thus, whether inflammation has a significant role in tumor progression in tumors driven by mutations remains largely unknown. Here we show that TNF alpha is required for the tumorigenesis of osteosarcoma, the most common tumor in children and adolescents. We show that transplantation of AX osteosarcoma cells, which harbor mutations driving c-Myc overexpression and Ink4a-deficiency, in wild-type mice promotes lethal tumorigenesis accompanied by ectopic bone formation and multiple metastases, phenotypes seen in osteosarcoma patients. Such tumorigenesis was completely abrogated in TNF alpha-deficient mice. AX cells have the capacity to undergo osteoblastic differentiation; however, that activity was significantly inhibited by TNF alpha treatment, suggesting that TNF alpha maintains AX cells in an undifferentiated state. TNF alpha inhibition of AX cell osteoblastic differentiation occurred through ERK activation, and a pharmacological TNF alpha inhibitor effectively inhibited both AX cell tumorigenesis and increased osteoblastic gene expression and increased survival of tumor-bearing mice. Lethal tumorigenesis of AX cells was also abrogated in IL-1 alpha/IL-1 beta doubly deficient mice. We found that both TNF alpha and IL-1 maintained AX cells in an undifferentiated state via ERK activation. Thus, inflammatory cytokines are required to promote tumorigenesis even in mutation-induced tumors, and TNF alpha/IL-1 and ERK may represent therapeutic targets for osteosarcoma.	[Mori, T.; Sato, Y.; Miyamoto, K.; Kobayashi, T.; Kanagawa, H.; Katsuyama, E.; Fujie, A.; Hao, W.; Tando, T.; Morioka, H.; Matsumoto, M.; Toyama, Y.; Miyamoto, T.] Keio Univ, Sch Med, Dept Orthoped Surg, Tokyo 1608582, Japan; [Sato, Y.] Keio Univ, Sch Med, Dept Musculoskeletal Reconstruct & Regenerat Surg, Tokyo 1608582, Japan; [Kobayashi, T.; Miyamoto, T.] Keio Univ, Sch Med, Dept Integrated Bone Metab & Immunol, Tokyo 1608582, Japan; [Shimizu, T.; Saya, H.] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat, Tokyo 1608582, Japan; [Shimizu, T.] Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Pathophysiol, Tokyo 142, Japan; [Iwasaki, R.; Kawana, H.] Keio Univ, Sch Med, Dept Dent & Oral Surg, Tokyo 1608582, Japan	Keio University; Keio University; Keio University; Keio University; Hoshi University; Keio University	Miyamoto, T (corresponding author), Keio Univ, Sch Med, Dept Orthoped Surg, 35 Shinano Machi, Tokyo 1608582, Japan.	miyamoto@z5.keio.jp	Saya, Hideyuki/J-4325-2013	Saya, Hideyuki/0000-0001-6610-1902	Takeda Science Foundation, Japan	Takeda Science Foundation, Japan(Takeda Science Foundation (TSF))	T Miyamoto was supported by a Grant-in-aid for Scientific Research, Takeda Science Foundation, Japan.	BENSTED JPM, 1961, BRIT J RADIOL, V34, P160, DOI 10.1259/0007-1285-34-399-160; DAHLIN DC, 1975, CLIN ORTHOP RELAT R, P23; Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hoejberg L, 2012, MELANOMA RES, V22, P327, DOI 10.1097/CMR.0b013e3283543d72; Ishikawa T, 2013, CANCER SCI, V104, P880, DOI 10.1111/cas.12163; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Kim SJ, 2004, CLIN IMAG, V28, P291, DOI 10.1016/S0899-7071(03)00206-7; Kubota Y, 2009, J EXP MED, V206, P1089, DOI 10.1084/jem.20081605; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mavaddat N, 2013, JNCI-J NATL CANCER I, V105, P812, DOI 10.1093/jnci/djt095; Mirabello L, 2009, CANCER-AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121; Morrison WB, 2012, J VET INTERN MED, V26, P18, DOI 10.1111/j.1939-1676.2011.00836.x; Nakamura T, 2011, ONCOL LETT, V2, P315, DOI 10.3892/ol.2011.238; Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978-1-4419-0284-9_1; Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Picci P, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-6; Rutkowski P, 2003, J SURG ONCOL, V84, P151, DOI 10.1002/jso.10305; Sansone P, 2012, J CLIN ONCOL, V30, P1005, DOI 10.1200/JCO.2010.31.8907; Sheppard DG, 2001, CLIN RADIOL, V56, P22, DOI 10.1053/crad.2000.0599; Shimizu T, 2010, ONCOGENE, V29, P5687, DOI 10.1038/onc.2010.312; Shimizu T, 2012, MOL CANCER RES, V10, P454, DOI 10.1158/1541-7786.MCR-11-0347; Ueki A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050621; Vasto S, 2009, MECH AGEING DEV, V130, P40, DOI 10.1016/j.mad.2008.06.003; Vendramini-Costa DB, 2012, CURR PHARM DESIGN, V18, P3831; Waldner MJ, 2012, INT J BIOL SCI, V8, P1248, DOI 10.7150/ijbs.4614; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; World Health Organization, 2007, 10 STAT HIGHL GLOB P; YOSHIKAWA H, 1985, CANCER, V56, P1682, DOI 10.1002/1097-0142(19851001)56:7<1682::AID-CNCR2820560735>3.0.CO;2-8	31	46	46	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2014	33	33					4236	4241		10.1038/onc.2013.545	http://dx.doi.org/10.1038/onc.2013.545			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MB	24336323	hybrid			2022-12-28	WOS:000341155800005
J	Niedan, S; Kauer, M; Aryee, DNT; Kofler, R; Schwentner, R; Meier, A; Potschger, U; Kontny, U; Kovar, H				Niedan, S.; Kauer, M.; Aryee, D. N. T.; Kofler, R.; Schwentner, R.; Meier, A.; Poetschger, U.; Kontny, U.; Kovar, H.			Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma	ONCOGENE			English	Article						CDK2; Ewing sarcoma; EWS-FLI1; FOXO1	CELL-CYCLE ARREST; METHYLSELENINIC ACID; GENE-EXPRESSION; TUMOR-CELLS; IN-VITRO; CANCER; EWS/FLI-1; TRANSFORMATION; INHIBITION; PATHWAYS	The Ewing sarcoma (ES) EWS-FLI1 chimeric oncoprotein is a prototypic aberrant ETS transcription factor with activating and repressive regulatory functions. We report that EWS-FLI1-repressed promoters are enriched in forkhead box ( FOX) recognition motifs, and identify FOXO1 as a EWS-FLI1-suppressed regulator orchestrating a major subset of EWS-FLI1-repressed genes. In addition to FOXO1 regulation by direct promoter binding of EWS-FLI1, its subcellular localization and activity is regulated by cyclin-dependent kinase 2- and AKT-mediated phosphorylation downstream of EWS-FLI1. Restoration of nuclear FOXO1 expression in ES cells impaired proliferation and significantly reduced clonogenicity. Gene-expression profiling revealed a significant overlap between EWS-FLI1-repressed and FOXO1-activated genes. As a proof of principle for a potential therapeutic application of our findings, the treatment of ES cell lines with methylseleninic acid (MSA) reactivated endogenous FOXO1 in the presence of EWS-FLI1 in a dose- and time-dependent manner and induced massive cell death dependent on FOXO1. In an orthotopic xenograft mouse model, MSA increased FOXO1 expression in the tumor paralleled by a significant decrease in ES tumor growth. FOXO1 reactivation by small molecules may therefore serve as a promising strategy for a future ES-specific therapy.	[Niedan, S.; Kauer, M.; Aryee, D. N. T.; Schwentner, R.; Poetschger, U.; Kovar, H.] St Anna Kinderkrebsforschung, Childrens Canc Res Inst, A-1090 Vienna, Austria; [Aryee, D. N. T.; Kovar, H.] Med Univ, Dept Pediat, Vienna, Austria; [Kofler, R.] Med Univ Innsbruck, Div Mol Pathophysiol Bioctr, Innsbruck, Austria; [Meier, A.; Kontny, U.] Univ Med Ctr, Dept Pediat & Adolescent Med, Div Pediat Hematol Oncol, Freiburg, Germany	Saint Anna Children's Hospital; Medical University of Innsbruck; University of Freiburg	Kovar, H (corresponding author), St Anna Kinderkrebsforschung, Childrens Canc Res Inst, Zimmermannplatz 10, A-1090 Vienna, Austria.	heinrich.kovar@ccri.at		Schwentner, Raphaela/0000-0001-6839-0322; Kovar, Heinrich/0000-0001-6873-9109; Potschger, Ulrike/0000-0001-7024-7082	Austrian Science Fund (FWF) [22328-B09]; 7th framework program of the European Commission [259348]; Austrian Academy of Sciences; Austrian Science Fund (FWF) [P 22328] Funding Source: researchfish	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); 7th framework program of the European Commission(European Commission); Austrian Academy of Sciences; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We thank Lukas Kenner for processing tumor sections and hematoxylin and eosin stainings. This study was supported in part by the Austrian Science Fund (FWF), grant 22328-B09, and by the 7th framework program of the European Commission, grant 259348 ('ASSET'). Raphaela Schwentner is a recipient of a DOC-fFORTE fellowship of the Austrian Academy of Sciences.	Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Aryee DNT, 2010, CANCER RES, V70, P4015, DOI 10.1158/0008-5472.CAN-09-4333; Bernstein M, 2006, ONCOLOGIST, V11, P503, DOI 10.1634/theoncologist.11-5-503; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Dong Y, 2003, CANCER RES, V63, P52; Duffield-Lillico AJ, 2003, JNCI-J NATL CANCER I, V95, P1477, DOI 10.1093/jnci/djg061; France KA, 2011, J BIOL CHEM, V286, P22750, DOI 10.1074/jbc.M111.225433; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gonzalez-Moreno O, 2007, INT J CANCER, V121, P1197, DOI 10.1002/ijc.22764; Hancock JD, 2008, CELL CYCLE, V7, P250, DOI 10.4161/cc.7.2.5229; Hotfilder M, 2005, BRIT J CANCER, V92, P705, DOI 10.1038/sj.bjc.6602384; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Huang HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512; Kauer M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005415; Kelland LR, 2004, EUR J CANCER, V40, P827, DOI 10.1016/j.ejca.2003.11.028; Kinsey M, 2009, CANCER RES, V69, P9047, DOI 10.1158/0008-5472.CAN-09-1540; Kovar H, 2005, SEMIN CANCER BIOL, V15, P189, DOI 10.1016/j.semcancer.2005.01.004; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; KOZIOL JA, 1981, BIOMETRICS, V37, P383, DOI 10.2307/2530427; Li QX, 2008, CELL DEATH DIFFER, V15, P1197, DOI 10.1038/cdd.2008.48; Maiese K, 2009, MED RES REV, V29, P395, DOI 10.1002/med.20139; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Owen LA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001965; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pW249, DOI 10.1093/nar/gkh372; Sankar S, 2013, ONCOGENE, V32, P5089, DOI 10.1038/onc.2012.525; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Siligan C, 2005, ONCOGENE, V24, P2512, DOI 10.1038/sj.onc.1208455; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Teixeira CC, 2010, J BIOL CHEM, V285, P31055, DOI 10.1074/jbc.M109.079962; Tirado OM, 2006, CANCER RES, V66, P9937, DOI 10.1158/0008-5472.CAN-06-0927; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Toretsky JA, 1999, CANCER RES, V59, P5745; Uren Aykut, 2005, Future Oncol, V1, P521, DOI 10.2217/14796694.1.4.521; Weidinger C, 2008, ENDOCR-RELAT CANCER, V15, P917, DOI 10.1677/ERC-08-0153; Wettenhall JM, 2004, BIOINFORMATICS, V20, P3705, DOI 10.1093/bioinformatics/bth449; Winter GE, 2011, MOL CANCER THER, V10, P1846, DOI 10.1158/1535-7163.MCT-11-0100; Wu Y, 2005, CANCER RES, V65, P9073, DOI 10.1158/0008-5472.CAN-05-2016; Yang L, 2010, BIOCHEM BIOPH RES CO, V402, P129, DOI 10.1016/j.bbrc.2010.09.129; Zhang Haitao, 2005, Cancer Genomics & Proteomics, V2, P97; Zhu ZJ, 2002, CANCER RES, V62, P156	50	24	27	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3927	3938		10.1038/onc.2013.361	http://dx.doi.org/10.1038/onc.2013.361			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	23995784	Green Published, hybrid			2022-12-28	WOS:000339394700005
J	Tsuchida, R; Osawa, T; Wang, F; Nishii, R; Das, B; Tsuchida, S; Muramatsu, M; Takahashi, T; Inoue, T; Wada, Y; Minami, T; Yuasa, Y; Shibuya, M				Tsuchida, R.; Osawa, T.; Wang, F.; Nishii, R.; Das, B.; Tsuchida, S.; Muramatsu, M.; Takahashi, T.; Inoue, T.; Wada, Y.; Minami, T.; Yuasa, Y.; Shibuya, M.			BMP4/Thrombospondin-1 loop paracrinically inhibits tumor angiogenesis and suppresses the growth of solid tumors	ONCOGENE			English	Article						Bone Morphogenetic Protein 4 (BMP4); Thrombospondin-1 (TSP1); angiogenesis; tumor microenvironment; tumor endothelial cells; vascular endothelial growth factor (VEGF)	BONE MORPHOGENETIC PROTEIN-4; SIDE-POPULATION FRACTION; EMBRYONIC STEM-CELLS; ENDOTHELIAL-CELLS; CANCER-CELLS; SIGNALING PATHWAY; DOWN-REGULATION; BMP4; APOPTOSIS; EXPRESSION	Bone morphogenetic protein 4 (BMP4) has potential as an anticancer agent. Recent studies have suggested that BMP4 inhibits the survival of cancer stem cells (CSCs) of neural and colon cancers. Here, we showed that BMP4 paracrinically inhibited tumor angiogenesis via the induction of Thrombospondin-1 (TSP1), and consequently suppressed tumor growth in vivo. Although HeLa (human cervical cancer), HCl-H460-LNM35 (highly metastatic human lung cancer) and B16 (murine melanoma) cells did not respond to the BMP4 treatment in vitro, the growth of xeno- and allografts of these cells was suppressed via reductions in tumor angiogenesis after intraperitoneal treatment with BMP4. When we assessed the mRNA expression of major angiogenesis-related factors in grafted tumors, we found that the expression of TSP1 was significantly upregulated by BMP4 administration. We then confirmed that BMP4 was less effective in suppressing the tumor growth of TSP1-knockdown cancer cells. Furthermore, we found that BMP4 reduced vascular endothelial growth factor (VEGF) expression in vivo in a TSP1-dependent manner, which indicates that BMP4 interfered with the stabilization of tumor angiogenesis. In conclusion, the BMP4/TSP1 loop paracrinically suppressed tumor angiogenesis in the tumor microenvironment, which subsequently reduced the growth of tumors. BMP4 may become an antitumor agent and open a new field of antiangiogenic therapy.	[Tsuchida, R.; Osawa, T.; Wang, F.; Nishii, R.; Tsuchida, S.; Muramatsu, M.; Yuasa, Y.; Shibuya, M.] Tokyo Med & Dent Univ, Dept Mol Oncol, Tokyo, Japan; [Tsuchida, R.; Nishii, R.] Tokyo Med & Dent Univ, Dept Pediat, Tokyo, Japan; [Osawa, T.; Inoue, T.; Wada, Y.; Minami, T.] Univ Tokyo, RCAST, Lab Syst Biol & Med, Tokyo, Japan; [Wang, F.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA; [Das, B.] Stanford Univ, Sch Med, Dept Pathol & Med, Div Oncol, Stanford, CA 94305 USA; [Tsuchida, S.] Tokyo Univ Hosp, Dept Pediat, Tokyo 113, Japan; [Muramatsu, M.] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; [Takahashi, T.] Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis, Nagoya, Aichi 4648601, Japan; [Shibuya, M.] Jobu Univ, Inst Physiol & Med, Takasaki, Gunma, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); University of Tokyo; Memorial Sloan Kettering Cancer Center; Stanford University; University of Tokyo; Roswell Park Cancer Institute; Nagoya University	Tsuchida, R (corresponding author), Tokyo Med & Dent Univ, Dept Pediat, Bunkyo Ku, 1-5-45 Yushima, Tokyo, Japan.	rtsuped@tmd.ac.jp; shibuya@ims.u-tokyo.ac.jp	Takahashi, Takashi/I-7262-2014; Das, Bikul/ABF-9292-2020; Wang, Feng/Q-7386-2017; Nishii, Rina/AAC-4177-2022	Takahashi, Takashi/0000-0003-0615-7001; 	Japan Society for the Promotion of Science [22-400024]; Takeda Science Foundation; Ministry of Education, Culture, Sports, Science, and Technology of Japan [17014020];  [23701047];  [24116509]; Grants-in-Aid for Scientific Research [23701047, 24116509] Funding Source: KAKEN	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Takeda Science Foundation(Takeda Science Foundation (TSF)); Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); ; ; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Takashi Koda and Ms Kiyomi Kaneki for assisting in analysis of microarray data, Mr Daichi Yamanaka for operating of FACS sorting and Ms Shigeko Shimizu for preparing of immunohistochemistry. RT is a Research Fellow of the Japan Society of the Promotion of Science. This work was supported by the Research Fellowships of the Japan Society for the Promotion of Science for Young Scientists (22-400024), Grant-in-Aid for Young Scientist (23701047), Grant-in-Aid for Scientific Research on Innovative Areas (24116509), the Takeda Science Foundation and a Grant-in-Aid Special Project Research on Cancer-Bioscience (17014020) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Bakrania P, 2008, AM J HUM GENET, V82, P304, DOI 10.1016/j.ajhg.2007.09.023; Buckley S, 2004, AM J PHYSIOL-LUNG C, V286, pL81, DOI 10.1152/ajplung.00160.2003; Chiu CY, 2012, MOL CANCER RES, V10, P415, DOI 10.1158/1541-7786.MCR-11-0293; Das B, 2008, STEM CELLS, V26, P1818, DOI 10.1634/stemcells.2007-0724; de Fraipont F, 2001, TRENDS MOL MED, V7, P401, DOI 10.1016/S1471-4914(01)02102-5; Farnsworth RH, 2011, CANCER RES, V71, P6547, DOI 10.1158/0008-5472.CAN-11-0200; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Gee MFW, 2005, ONCOGENE, V24, P8025, DOI 10.1038/sj.onc.1208939; Giuriato S, 2006, P NATL ACAD SCI USA, V103, P16266, DOI 10.1073/pnas.0608017103; Guo NH, 1997, CANCER RES, V57, P1735; Guo W, 1999, CLIN ORTHOP RELAT R, P175; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Haubold M, 2010, INT J BIOL SCI, V6, P700; Hayashi S, 2008, AM J MED GENET A, V146A, P2905, DOI 10.1002/ajmg.a.32519; Heinke J, 2007, CARDIOVASC RES, V76, P390, DOI 10.1016/j.cardiores.2007.08.003; Hida K, 2004, CANCER RES, V64, P8249, DOI 10.1158/0008-5472.CAN-04-1567; Iantosca MR, 1999, J NEUROSCI RES, V56, P248; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Kim IY, 2004, CANCER RES, V64, P7355, DOI 10.1158/0008-5472.CAN-04-0154; Kiyono M, 2006, ONCOGENE, V25, P7131, DOI 10.1038/sj.onc.1209700; Kiyono M, 2003, MOL CELL BIOL, V23, P4627, DOI 10.1128/MCB.23.13.4627-4636.2003; Komuro A, 2009, JNCI-J NATL CANCER I, V101, P592, DOI 10.1093/jnci/djp058; Kozaki K, 2000, CANCER RES, V60, P2535; Li ZW, 2012, CELL STEM CELL, V10, P171, DOI 10.1016/j.stem.2011.12.016; Lombardo Y, 2011, GASTROENTEROLOGY, V140, P297, DOI 10.1053/j.gastro.2010.10.005; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Moreno-Miralles I, 2011, ARTERIOSCL THROM VAS, V31, P2216, DOI 10.1161/ATVBAHA.111.230235; Muramatsu M, 2010, CANCER RES, V70, P8211, DOI 10.1158/0008-5472.CAN-10-0202; Nishanian TG, 2004, CANCER BIOL THER, V3, P667; Nor JE, 2000, J VASC RES, V37, P209, DOI 10.1159/000025733; Osawa T, 2011, P NATL ACAD SCI USA, V108, P20725, DOI 10.1073/pnas.1108462109; Osawa T, 2009, CANCER SCI, V100, P844, DOI 10.1111/j.1349-7006.2009.01105.x; Paez-Pereda M, 2003, P NATL ACAD SCI USA, V100, P1034, DOI 10.1073/pnas.0237312100; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Qi XX, 2004, P NATL ACAD SCI USA, V101, P6027, DOI 10.1073/pnas.0401367101; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Rothhammer T, 2008, EUR J CANCER, V44, P2526, DOI 10.1016/j.ejca.2008.07.029; Sarnat HB, 2005, J CHILD NEUROL, V20, P637, DOI 10.1177/08830738050200080101; Shepherd TG, 2008, GENE, V414, P95, DOI 10.1016/j.gene.2008.02.015; Shibuya M, 2008, BMB REP, V41, P278, DOI 10.5483/BMBRep.2008.41.4.278; Su DM, 2009, J BIOL CHEM, V284, P12153, DOI 10.1074/jbc.M807930200; Thawani JP, 2010, NEUROSURGERY, V66, P233, DOI 10.1227/01.NEU.0000363722.42097.C2; Tsuchida R, 2008, ONCOGENE, V27, P3923, DOI 10.1038/onc.2008.38; Wang F, 2011, CANCER SCI, V102, P2007, DOI 10.1111/j.1349-7006.2011.02065.x; Wang F, 2011, J BIOL CHEM, V286, P9097, DOI 10.1074/jbc.M110.165605; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Yamauchi M, 2007, CANCER SCI, V98, P1491, DOI 10.1111/j.1349-7006.2007.00534.x; Zaslavsky A, 2010, MOL CANCER RES, V8, P1198, DOI 10.1158/1541-7786.MCR-10-0047; Zhao H, 2008, GENE DEV, V22, P722, DOI 10.1101/gad.1636408; Zhou ZM, 2011, CANCER BIOTHER RADIO, V26, P77, DOI 10.1089/cbr.2010.0857	50	29	31	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3803	3811		10.1038/onc.2013.358	http://dx.doi.org/10.1038/onc.2013.358			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	24013228	Bronze			2022-12-28	WOS:000339394100006
J	Tallet, A; Nault, JC; Renier, A; Hysi, I; Galateau-Salle, F; Cazes, A; Copin, MC; Hofman, P; Andujar, P; Le Pimpec-Barthes, F; Zucman-Rossi, J; Jaurand, MC; Jean, D				Tallet, A.; Nault, J-C; Renier, A.; Hysi, I.; Galateau-Salle, F.; Cazes, A.; Copin, M-C; Hofman, P.; Andujar, P.; Le Pimpec-Barthes, F.; Zucman-Rossi, J.; Jaurand, M-C; Jean, D.			Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma	ONCOGENE			English	Article						thoracic neoplasm; mesothelioma; asbestos; telomere; telomerase reverse transcriptase; mutation	INDUCED MURINE; TELOMERASE; SUPPRESSION; MECHANISMS; EXPRESSION; PROFILES; SUBUNIT; CELLS; BAP1	Malignant pleural mesothelioma (MPM) is a very aggressive tumor with no known curative treatment. Better knowledge of the molecular mechanisms of mesothelial carcinogenesis is required to develop new therapeutic strategies. MPM, like all cancer cells, needs to maintain telomere length to prevent senescence. Previous studies suggested that the telomere lengthening mechanism in MPM is based mainly on telomerase activity. For this reason, we focused on the key catalytic enzyme, TERT (telomerase reverse transcriptase), by analyzing its gene expression in MPM and by studying the mechanism underlying its upregulation. We used our large collection of MPM composed of 61 MPM in culture and 71 frozen MPM tumor samples. Evaluation of TERT mRNA expression by quantitative RT-PCR showed overexpression in MPM in culture compared with normal mesothelial cells, and in MPM tumor samples compared with normal pleura. We identified a 'hot spot' of mutations in the TERT gene core promoter in both MPM in culture and in MPM tumor samples with an overall frequency of 15%. Furthermore, data clearly identified mutation in the TERT promoter as a mechanism of TERT mRNA upregulation in MPM. In contrast, gene copy number amplification was not associated with TERT overexpression. Then, we analyzed the clinicopathological, etiological and genetic characteristics of MPM with mutations in the TERT promoter. TERT promoter mutations were more frequent in MPM with sarcomatoid histologic subtype (P<0.01), and they were frequently associated with CDKN2A gene inactivation (P = 0.03). In conclusion, a subgroup of MPM presents TERT promoter mutations, which lead to TERT mRNA upregulation. This is the first recurrent gain-of-function oncogenic mutations identified in MPM.	[Tallet, A.; Nault, J-C; Renier, A.; Le Pimpec-Barthes, F.; Zucman-Rossi, J.; Jaurand, M-C; Jean, D.] INSERM, UMR 674, IUH, F-75010 Paris, France; [Tallet, A.; Nault, J-C; Renier, A.; Le Pimpec-Barthes, F.; Zucman-Rossi, J.; Jaurand, M-C; Jean, D.] Univ Paris 05, Labex Immunooncol, Sorbonne Paris Cite, Fac Med, Paris, France; [Hysi, I.] CHRU Lille, Serv Chirurg Card, F-59037 Lille, France; [Galateau-Salle, F.] CHU Caen, Serv Anatomopathol, F-14000 Caen, France; [Galateau-Salle, F.] INSERM, U1086, Caen, France; [Cazes, A.] Hop Europeen Georges Pompidou, AP HP, GHU Ouest, Anat Pathol Lab, Paris, France; [Copin, M-C] Univ Lille 2, CHRU Lille, Inst Pathol, Ctr Biol Pathol, Lille, France; [Hofman, P.] CHU Nice, Hop Louis Pasteur, Lab Pathol Clin & LPCE & Biobanque Humaine, F-06202 Nice, France; [Andujar, P.] Ctr Hosp Intercommunal Creteil, Serv Pneumol & Pathol Profess, Creteil, France; [Andujar, P.] Hop Henri Mondor, INSERM, U955, Equipe 4, F-94010 Creteil, France; [Le Pimpec-Barthes, F.] Hop Europe Georges Pompidou, AP HP, GHU Ouest, Serv Chirurg Thorac, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Universite de Lille - ISITE; CHU Lille; CHU de Caen NORMANDIE; Universite de Caen Normandie; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Lille - ISITE; CHU Lille; Universite de Lille; CHU Nice; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Jean, D (corresponding author), INSERM, UMR S 674, 27 Rue Juliette Dodu, F-75010 Paris, France.	didier.jean@inserm.fr	Hofman, Paul/P-7654-2018; Jean, Didier/A-1615-2009; j, zucman-rossi/AAV-3594-2021; Salle, Francoise BJ Galateau/J-1530-2015; JAURAND, MARIE-CLAUDE/S-3538-2017; Le+Pimpec-Barthes, Francoise/ABD-1300-2021; zucman-rossi, Jessica/B-5098-2009; Andujar, Pascal/A-2395-2013	Hofman, Paul/0000-0003-0431-9353; Jean, Didier/0000-0001-5823-7404; j, zucman-rossi/0000-0002-5687-0334; Salle, Francoise BJ Galateau/0000-0003-3642-0165; JAURAND, MARIE-CLAUDE/0000-0002-0915-6728; zucman-rossi, Jessica/0000-0002-5687-0334; Le Pimpec-Barthes, Francoise/0000-0001-6364-4813; nault, jean charles/0000-0002-4875-9353; Andujar, Pascal/0000-0002-9408-7033	INSERM; University of Paris-Descartes; French League against Cancer (Ligue Nationale Contre le Cancer); 'Carte d'Identite des Tumeurs' CIT1 program; 'Carte d'Identite des Tumeurs' CIT2 program; Chancellerie des Universite ' s de Paris (Legs POIX); Comite de l'Oise	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); University of Paris-Descartes; French League against Cancer (Ligue Nationale Contre le Cancer); 'Carte d'Identite des Tumeurs' CIT1 program; 'Carte d'Identite des Tumeurs' CIT2 program; Chancellerie des Universite ' s de Paris (Legs POIX); Comite de l'Oise	This work was supported by funds and grants from INSERM, the University of Paris-Descartes, the French League against Cancer (Ligue Nationale Contre le Cancer, 'Carte d'Identite des Tumeurs' CIT1 and CIT2 programs and the Comite ' de l'Oise) and the Chancellerie des Universite ' s de Paris (Legs POIX).	Andujar P, 2013, MUTAGENESIS, V28, P323, DOI 10.1093/mutage/get008; Andujar P, 2010, LUNG CANCER, V67, P23, DOI 10.1016/j.lungcan.2009.03.018; Au AYM, 2011, LUNG CANCER, V73, P283, DOI 10.1016/j.lungcan.2010.12.023; Bazarov AV, 2010, AGING CELL, V9, P736, DOI 10.1111/j.1474-9726.2010.00599.x; Bott M, 2011, NAT GENET, V43, P668, DOI 10.1038/ng.855; Cao Y, 2008, CANCER SCI, V99, P1092, DOI 10.1111/j.1349-7006.2008.00815.x; Cesare AJ, 2010, NAT REV GENET, V11, P319, DOI 10.1038/nrg2763; Chretien JB J, 1985, PLEURA HLTH DIS, P23; Daniel M, 2012, GENE, V498, P135, DOI 10.1016/j.gene.2012.01.095; Dhaene K, 1998, THORAX, V53, P915, DOI 10.1136/thx.53.11.915; Ganem NJ, 2012, J CELL BIOL, V199, P871, DOI 10.1083/jcb.201210040; Gladych M, 2011, BIOCHEM CELL BIOL, V89, P359, DOI 10.1139/O11-037; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Huang SXL, 2011, J TOXICOL ENV HEAL B, V14, P179, DOI 10.1080/10937404.2011.556051; Husain AN, 2009, ARCH PATHOL LAB MED, V133, P1317, DOI 10.1043/1543-2165-133.8.1317; Jasani B, 2012, ARCH PATHOL LAB MED, V136, P262, DOI 10.5858/arpa.2011-0039-RA; Jean D, 2012, ARCH PATHOL LAB MED, V136, P277, DOI 10.5858/arpa.2011-0215-RA; Jean D, 2011, AM J PATHOL, V178, P881, DOI 10.1016/j.ajpath.2010.10.039; Killela PJ, 2013, P NATL ACAD SCI USA, V110, P6021, DOI 10.1073/pnas.1303607110; Kumaki F, 2002, AM J SURG PATHOL, V26, P365, DOI 10.1097/00000478-200203000-00011; Larsson LG, 2011, SEMIN CANCER BIOL, V21, P367, DOI 10.1016/j.semcancer.2011.10.005; Lecomte C, 2005, CELL CYCLE, V4, P1862, DOI 10.4161/cc.4.12.2300; Mutsaers SE, 2002, RESPIROLOGY, V7, P171, DOI 10.1046/j.1440-1843.2002.00404.x; RAMAEL M, 1995, HISTOL HISTOPATHOL, V10, P639; Shen XH, 2013, INT IMMUNOPHARMACOL, V16, P261, DOI 10.1016/j.intimp.2013.04.003; Testa JR, 2011, NAT GENET, V43, P1022, DOI 10.1038/ng.912; Villa R, 2008, CLIN CANCER RES, V14, P4134, DOI 10.1158/1078-0432.CCR-08-0099; ZENG L, 1993, INT J CANCER, V55, P515, DOI 10.1002/ijc.2910550331	30	54	54	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3748	3752		10.1038/onc.2013.351	http://dx.doi.org/10.1038/onc.2013.351			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23975423	Green Submitted			2022-12-28	WOS:000338942900014
J	Zhu, Y; Yao, Z; Wu, Z; Mei, Y; Wu, M				Zhu, Y.; Yao, Z.; Wu, Z.; Mei, Y.; Wu, M.			Role of tumor necrosis factor alpha-induced protein 1 in paclitaxel resistance	ONCOGENE			English	Article						TNFAIP1; tubulin; paclitaxel resistance	HELA-CELLS; POLYMERIZED TUBULIN; NATURAL-PRODUCTS; MITOTIC ARREST; BETA-TUBULIN; TAXOL; CANCER; MICROTUBULES; EXPRESSION; DEATH	Paclitaxel has been extensively used as an antitumor drug to treat a broad range of epithelial cancers, including breast and cervical cancers. However, the efficacy of this drug is greatly limited by the development of acquired resistance. Identification of the underlying resistance mechanisms may inform the development of new therapies that elicit long-term response of tumors to paclitaxel treatment. Here we report that increased expression of TNFAIP1 (tumor necrosis factor alpha-induced protein 1) confers acquired resistance to paclitaxel. TNFAIP1 is shown to compete with paclitaxel for binding to beta-tubulin, thereby preventing paclitaxel-induced tubulin polymerization, cell cycle arrest and ultimate cell death. We also show that expression of TNFAIP1 is regulated by the transcriptional factor Sp1. In a xenograft mouse model, increased expression of TNFAIP1 decreases, whereas knockdown of TNFAIP1 increases tumor response to paclitaxel. Therefore, these results reveal tnfaip1 as a novel paclitaxel-resistance associated gene and suggest that TNFAIP1 may represent a valuable therapeutic target for the treatment of cancer.	[Zhu, Y.; Yao, Z.; Mei, Y.; Wu, M.] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; [Zhu, Y.; Yao, Z.; Mei, Y.; Wu, M.] Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China; [Wu, Z.] Anhui Med Univ, Dept Pathol, Hefei, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Anhui Medical University	Mei, Y (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, 96 Huangshan Rd, Hefei 230027, Anhui, Peoples R China.	meiyide@ustc.edu.cn; wumian@ustc.edu.cn	Mei, Yide/M-4468-2013; Wu, Mian/H-2494-2018; Yao, Zhan/AAK-6756-2020	Wu, Mian/0000-0002-2714-0500; YAO, ZHAN/0000-0001-5391-5691	National Natural Science Foundation of China [31030046, 31171316]; Ministry of Science and Technology of China [2010CB912804, 2011CB966302]; Chinese Academy of Sciences [XDA01020104]; Fundamental Research Funds for Central Universities [WK2060190018]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Chinese Academy of Sciences(Chinese Academy of Sciences); Fundamental Research Funds for Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by grants from National Natural Science Foundation of China 31030046 (to MW) and 31171316 (to YM); the Ministry of Science and Technology of China (2010CB912804 and 2011CB966302); Chinese Academy of Sciences (XDA01020104) and the Fundamental Research Funds for Central Universities (WK2060190018).	Bai ZG, 2010, MOL MED REP, V3, P1071, DOI 10.3892/mmr.2010.371; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; Burkhart C.A., 2001, BIOCHIM BIOPHYS ACTA, V1471, P1; CAMBRAYDEAKIN MA, 1987, J CELL BIOL, V104, P1569, DOI 10.1083/jcb.104.6.1569; CERNY T, 1994, BRIT J CANCER, V70, P384, DOI 10.1038/bjc.1994.311; Cheung CHA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012564; DEBRABANDER M, 1981, P NATL ACAD SCI-BIOL, V78, P5608; Dong Y, 2010, CANCER RES, V70, P2624, DOI 10.1158/0008-5472.CAN-09-3415; Duan ZF, 2006, CANCER CHEMOTH PHARM, V57, P25, DOI 10.1007/s00280-005-0026-3; Einzig A I, 1991, Cancer Treat Res, V58, P89; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; HENNEQUIN C, 1995, BRIT J CANCER, V71, P1194, DOI 10.1038/bjc.1995.232; Horwitz Susan Band, 1993, Journal of the National Cancer Institute Monographs, V0, P55; Ilson DH, 2007, ANN ONCOL, V18, P898, DOI 10.1093/annonc/mdm004; Jordan MA, 1996, CANCER RES, V56, P816; Kamath K, 2005, J BIOL CHEM, V280, P12902, DOI 10.1074/jbc.M414477200; Kim DM, 2009, INT J CANCER, V125, P2520, DOI 10.1002/ijc.24617; Lih CJ, 2006, GENE DEV, V20, P2082, DOI 10.1101/gad.1441306; Lin MC, 2005, WORLD J GASTROENTERO, V11, P7564, DOI 10.3748/wjg.v11.i48.7564; Link CD, 2003, NEUROBIOL AGING, V24, P397, DOI 10.1016/S0197-4580(02)00224-5; Liu MJ, 2010, MOL BIOL REP, V37, P1699, DOI 10.1007/s11033-009-9588-1; Milross CG, 1996, JNCI-J NATL CANCER I, V88, P1308, DOI 10.1093/jnci/88.18.1308; MINOTTI AM, 1991, J BIOL CHEM, V266, P3987; Ojima I, 1999, P NATL ACAD SCI USA, V96, P4256, DOI 10.1073/pnas.96.8.4256; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; Rowinsky EK, 1997, ANNU REV MED, V48, P353; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SEIDMAN AD, 1995, CLIN CANCER RES, V1, P247; Seve P, 2010, LUNG CANCER, V67, P136, DOI 10.1016/j.lungcan.2009.09.007; SLICHENMYER WJ, 1990, J CLIN PHARMACOL, V30, P770, DOI 10.1002/j.1552-4604.1990.tb01873.x; Stordal B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040717; Suzuki M, 2003, JPN J CLIN ONCOL, V33, P297, DOI 10.1093/jjco/hyg054; Torres K, 1998, CANCER RES, V58, P3620; Wang JX, 2012, STEM CELLS, V30, P1405, DOI 10.1002/stem.1121; Wang YQ, 2006, BIOCHEMISTRY-US, V45, P185, DOI 10.1021/bi051207d; Wang YQ, 2005, BBA-MOL CELL RES, V1744, P245, DOI 10.1016/j.bbamcr.2004.12.003; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; WOLF FW, 1992, J BIOL CHEM, V267, P1317; Yao Z, 2007, EMBO J, V26, P1068, DOI 10.1038/sj.emboj.7601571; Yin SH, 2010, MOL CANCER THER, V9, P327, DOI 10.1158/1535-7163.MCT-09-0674; Zhou JL, 2005, J EXP ZOOL PART A, V303A, P227, DOI 10.1002/jez.a.150	42	18	20	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3246	3255		10.1038/onc.2013.299	http://dx.doi.org/10.1038/onc.2013.299			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23912453				2022-12-28	WOS:000338443400004
J	Krakowiak, MS; Noto, JM; Piazuelo, MB; Hardbower, DM; Romero-Gallo, J; Delgado, A; Chaturvedi, R; Correa, P; Wilson, KT; Peek, RM				Krakowiak, M. S.; Noto, J. M.; Piazuelo, M. B.; Hardbower, D. M.; Romero-Gallo, J.; Delgado, A.; Chaturvedi, R.; Correa, P.; Wilson, K. T.; Peek, R. M., Jr.			Matrix metalloproteinase 7 restrains Helicobacter pylori-induced gastric inflammation and premalignant lesions in the stomach by altering macrophage polarization	ONCOGENE			English	Article							EXPRESSION; ACTIVATION; MATRILYSIN; RESPONSES; CANCER; MMP-7; HOST	Helicobacter pylori is the strongest risk factor for the development of gastric cancer. Although the specific mechanisms by which this pathogen induces carcinogenesis have not been fully elucidated, high-expression interleukin (IL)-1 beta alleles are associated with increased gastric cancer risk among H. pylori-infected persons. In addition, loss of matrix metalloproteinase 7 (MMP7) increases mucosal inflammation in mouse models of epithelial injury, and we have shown that gastric inflammation is increased in H. pylori-infected MMP7(-/-) C57BL/6 mice. In this report, we define mechanisms that underpin such responses and extend these results into a genetic model of MMP7 deficiency and gastric cancer. Wild-type (WT) or MMP7(-/-) C57BL/6 mice were challenged with broth alone as an uninfected control or the H. pylori strain PMSS1. All H. pylori-challenged mice were successfully colonized. As expected, H. pylori-infected MMP7(-/-) C57BL/6 mice exhibited a significant increase in gastric inflammation compared with uninfected or infected WT C57BL/6 animals. Loss of MMP7 resulted in M1 macrophage polarization within H. pylori-infected stomachs, as assessed by Luminex technology and immunohistochemistry, and macrophages isolated from infected MMP7-deficient mice expressed significantly higher levels of the M1 macrophage marker IL-1 beta compared with macrophages isolated from WT mice. To extend these findings into a model of gastric cancer, hypergastrinemic WT INS-GAS or MMP7(-/-) INS-GAS mice were challenged with H. pylori strain PMSS1. Consistent with findings in the C57BL/6 model, H. pylori-infected MMP7-deficient INS-GAS mice exhibited a significant increase in gastric inflammation compared with either uninfected or infected WT INS-GAS mice. In addition, the incidence of gastric hyperplasia and dysplasia was significantly increased in H. pylori-infected MMP7(-/-) INS-GAS mice compared with infected WT INS-GAS mice, and loss of MMP7 promoted M1 macrophage polarization. These results suggest that MMP7 exerts a restrictive role on H. pylori-induced gastric injury and the development of premalignant lesions by suppressing M1 macrophage polarization.	[Krakowiak, M. S.; Wilson, K. T.; Peek, R. M., Jr.] Vanderbilt Univ, Dept Canc Biol, Med Ctr, Nashville, TN 37232 USA; [Noto, J. M.; Piazuelo, M. B.; Hardbower, D. M.; Romero-Gallo, J.; Delgado, A.; Chaturvedi, R.; Correa, P.; Wilson, K. T.; Peek, R. M., Jr.] Vanderbilt Univ, Div Gastroenterol, Dept Med, Med Ctr, Nashville, TN 37232 USA; [Hardbower, D. M.; Wilson, K. T.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Wilson, K. T.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Peek, RM (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, 2215 Garland Ave,MRB 4 1030C, Nashville, TN 37232 USA.	richard.peek@vanderbilt.edu		Wilson, Keith/0000-0003-4421-1830	Department of Veterans Affairs [T32CA009592, F32CA153539, T32GM008554, K01AT007324, P01CA028842, R01DK053620, 1I01BX001453];  [R01DK058587];  [R01CA077955];  [P30DK058404];  [P01CA116087]; NATIONAL CANCER INSTITUTE [R01CA190612, R01CA077955, P01CA028842, F32CA153539, T32CA009592, P01CA116087] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [K01AT007324] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT004821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058587, P30DK058404, R01DK053620] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008554] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001453] Funding Source: NIH RePORTER	Department of Veterans Affairs(US Department of Veterans Affairs); ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	This study was supported by T32CA009592 (MSK), F32CA153539 (JMN), T32GM008554 (DMH), K01AT007324 (RC), P01CA028842 (KTW and PC), R01DK053620 and 1I01BX001453 from the Department of Veterans Affairs (KTW), R01DK058587, R01CA077955, P30DK058404 and P01CA116087 (RMP).	Barry DP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029046; Bray F, 2013, INT J CANCER, V132, P1133, DOI 10.1002/ijc.27711; Cassetta L, 2011, THESCIENTIFICWORLDJO, V11, P2391, DOI 10.1100/2011/213962; Chung WC, 2010, GASTRIC CANCER, V13, P162, DOI 10.1007/s10120-010-0552-5; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Fox JG, 2003, GASTROENTEROLOGY, V124, P1879, DOI 10.1016/S0016-5085(03)00406-2; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kassim SY, 2007, INFECT IMMUN, V75, P5640, DOI 10.1128/IAI.00799-07; Lifsted T, 1998, INT J CANCER, V77, P640, DOI 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; MCDONNELL S, 1991, MOL CARCINOGEN, V4, P527, DOI 10.1002/mc.2940040617; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Noto JM, 2013, J CLIN INVEST, V123, P479, DOI 10.1172/JCI64373; Ogden SR, 2010, CANCER RES, V70, P30, DOI 10.1158/0008-5472.CAN-09-2899; Polk DB, 2010, NAT REV CANCER, V10, P403, DOI 10.1038/nrc2857; Quante M, 2013, GASTROENTEROLOGY, V145, P63, DOI 10.1053/j.gastro.2013.03.052; Schumacher MA, 2012, GASTROENTEROLOGY, V142, P1150, DOI 10.1053/j.gastro.2012.01.029; Senota A, 1998, CLIN EXP METASTAS, V16, P313; Sierra JC, 2013, AM J PHYSIOL-GASTR L, V305, pG196, DOI 10.1152/ajpgi.00495.2012; Weischenfeldt Joachim, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot5080; Wilson CL, 1996, INT J BIOCHEM CELL B, V28, P123, DOI 10.1016/1357-2725(95)00121-2; Zhang Xia, 2008, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1401s83	23	27	27	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1865	1871		10.1038/onc.2014.135	http://dx.doi.org/10.1038/onc.2014.135			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24837365	Green Accepted			2022-12-28	WOS:000352158000013
J	Valdes-Mora, F; Clark, SJ				Valdes-Mora, F.; Clark, S. J.			Prostate cancer epigenetic biomarkers: next-generation technologies	ONCOGENE			English	Review							CPG ISLAND HYPERMETHYLATION; ANDROGEN RECEPTOR COACTIVATOR; POLYMERASE-CHAIN-REACTION; HISTONE VARIANT H2A.Z; DNA-BASED DETECTION; GENOMICS X PRIZE; HIGH-THROUGHPUT; METHYLATION ANALYSIS; MOLECULAR-DETECTION; PROGNOSTIC MARKERS	Cancer is caused by a combination of genetic alterations and gross changes to the epigenetic landscape that together result in aberrant cancer gene regulation. Therefore, we need to fully sequence both the cancer genome and the matching cancer epigenomes before we can fully integrate the suite of molecular mechanisms involved in initiation and progression of cancer. A further understanding of epigenetic aberrations has a great potential in the next era of molecular genomic pathology in cancer detection and treatment in all types of cancer, including prostate cancer. In this review, we discuss the most common epigenetic aberrations identified in prostate cancer with the biomarker potential. We also describe the innovative and current epigenomic technologies used for the identification of epigenetic-associated changes in prostate cancer and future translational applications in molecular pathology for cancer detection and prognosis.	[Valdes-Mora, F.; Clark, S. J.] Garvan Inst Med Res, Canc Res Div, Epigenet Lab, Canc Res Program, Sydney, NSW 2010, Australia; [Valdes-Mora, F.; Clark, S. J.] Garvan Inst Med Res, Kinghorn Canc Ctr, Sydney, NSW 2010, Australia; [Valdes-Mora, F.; Clark, S. J.] St Vincents Hosp, St Vincents Clin Sch, Darlinghurst, NSW 2010, Australia; [Valdes-Mora, F.; Clark, S. J.] Univ New S Wales, Darlinghurst, NSW, Australia	Garvan Institute of Medical Research; Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney	Clark, SJ (corresponding author), Garvan Inst Med Res, Canc Res Div, Epigenet Lab, Canc Res Program, 384 Victoria Rd, Sydney, NSW 2010, Australia.	s.clark@garvan.org.au	Mora, Fatima Valdes/AAB-9728-2021; Clark, Susan J/U-7365-2019; Clark, Susan J/B-2272-2008	Mora, Fatima Valdes/0000-0001-7490-0114; Clark, Susan J/0000-0001-5925-5030; Clark, Susan J/0000-0001-5925-5030	Prostate Cancer Foundation of Australia (PCFA) Project Grant [PG 4310]	Prostate Cancer Foundation of Australia (PCFA) Project Grant	F.V.M. is a National Breast Cancer Foundation/Cure Cancer Australia Foundation Postdoctoral Training Fellow. S.J.C. is a National Health and Medical Research Council (NH&MRC) Senior Principal Research Fellow. This work was further supported by Prostate Cancer Foundation of Australia (PCFA) Project Grant (PG 4310) (to F.V.M and S.J.C).	Arand J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002750; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Baden J, 2011, J UROLOGY, V186, P2101, DOI 10.1016/j.juro.2011.06.052; Bae Jae-Bum, 2013, Genomics & Informatics, V11, P7, DOI 10.5808/GI.2013.11.1.7; Banez LL, 2010, J UROLOGY, V184, P149, DOI 10.1016/j.juro.2010.03.012; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bastian PJ, 2005, CLIN CANCER RES, V11, P4097, DOI 10.1158/1078-0432.CCR-04-1832; Bastian PJ, 2005, CLIN CANCER RES, V11, P4037, DOI 10.1158/1078-0432.CCR-04-2446; Behbahani TE, 2012, BMC UROL, V12, DOI 10.1186/1471-2490-12-5; Beltran H, 2013, CLIN CANCER RES, V19, P517, DOI 10.1158/1078-0432.CCR-12-1452; Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969; Bert SA, 2013, CANCER CELL, V23, P9, DOI 10.1016/j.ccr.2012.11.006; Bhusari S, 2011, PROSTATE, V71, P1621, DOI 10.1002/pros.21379; Bianco-Miotto T, 2010, CANCER EPIDEM BIOMAR, V19, P2611, DOI 10.1158/1055-9965.EPI-10-0555; Bock C, 2010, NAT BIOTECHNOL, V28, P1106, DOI 10.1038/nbt.1681; Booth MJ, 2012, SCIENCE, V336, P934, DOI 10.1126/science.1220671; Brase JC, 2011, INT J CANCER, V128, P608, DOI 10.1002/ijc.25376; Brothman AR, 2005, CANCER GENET CYTOGEN, V156, P31, DOI 10.1016/j.cancergencyto.2004.04.004; Bryant RJ, 2012, BRIT J CANCER, V106, P768, DOI 10.1038/bjc.2011.595; Cairns P, 2001, CLIN CANCER RES, V7, P2727; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Cho NY, 2007, J PATHOL, V211, P269, DOI 10.1002/path.2106; Cho NY, 2009, VIRCHOWS ARCH, V454, P17, DOI 10.1007/s00428-008-0706-6; Chou R, 2011, ANN INTERN MED, V155, P762, DOI 10.7326/0003-4819-155-11-201112060-00375; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Clark SJ, 2006, NAT PROTOC, V1, P2353, DOI 10.1038/nprot.2006.324; Comuzzi B, 2004, J PATHOL, V204, P159, DOI 10.1002/path.1609; Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662; Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023; Cottrell S, 2007, J UROLOGY, V177, P1753, DOI 10.1016/j.juro.2007.01.010; de Matos LL, 2010, BIOMARK INSIGHTS, V5, P9; Dedeurwaerder S, 2011, EPIGENOMICS-UK, V3, P771, DOI [10.2217/EPI.11.105, 10.2217/epi.11.105]; Deligezer U, 2010, CLIN CHIM ACTA, V411, P1452, DOI 10.1016/j.cca.2010.05.040; Desai AN, 2012, CLIN GENET, V81, P503, DOI 10.1111/j.1399-0004.2012.01865.x; Devaney J, 2011, CANCER EPIDEM BIOMAR, V20, P148, DOI 10.1158/1055-9965.EPI-10-0719; Draisma G, 2009, JNCI-J NATL CANCER I, V101, P374, DOI 10.1093/jnci/djp001; Draker R, 2011, NUCLEIC ACIDS RES, V39, P3529, DOI 10.1093/nar/gkq1352; Dryhurst D, 2012, CANCER LETT, V315, P38, DOI 10.1016/j.canlet.2011.10.003; Ellinger J, 2008, UROLOGY, V71, P161, DOI 10.1016/j.urology.2007.09.056; Ellinger J, 2012, CANCER INVEST, V30, P92, DOI 10.3109/07357907.2011.636117; Ellinger J, 2010, PROSTATE, V70, P61, DOI 10.1002/pros.21038; Enokida H, 2005, CLIN CANCER RES, V11, P6582, DOI 10.1158/1078-0432.CCR-05-0658; Fraga ME, 2002, BIOTECHNIQUES, V33, P632, DOI 10.2144/02333rv01; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Globisch D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015367; Goessl C, 2000, CANCER RES, V60, P5941; Goessl C, 2001, UROLOGY, V58, P335, DOI 10.1016/S0090-4295(01)01268-7; Gonzalgo ML, 2003, CLIN CANCER RES, V9, P2673; Gregory CW, 2001, CANCER RES, V61, P4315; Gu H, 2010, NAT METHODS, V7, P133, DOI 10.1038/nmeth.1414; Guil S, 2009, INT J BIOCHEM CELL B, V41, P87, DOI 10.1016/j.biocel.2008.09.005; Haffner MC, 2011, ONCOTARGET, V2, P627; Hagman Z, 2010, INT J CANCER, V127, P2768, DOI 10.1002/ijc.25269; Halkidou K, 2003, ONCOGENE, V22, P2466, DOI 10.1038/sj.onc.1206342; Harris RA, 2010, NAT BIOTECHNOL, V28, P1097, DOI 10.1038/nbt.1682; Heemers HV, 2007, CANCER RES, V67, P3422, DOI 10.1158/0008-5472.CAN-06-2836; Henrique R, 2007, CLIN CANCER RES, V13, P6122, DOI 10.1158/1078-0432.CCR-07-1042; Holdenrieder S, 2008, ANN NY ACAD SCI, V1137, P180, DOI 10.1196/annals.1448.012; Hoque MO, 2005, J CLIN ONCOL, V23, P6569, DOI 10.1200/JCO.2005.07.009; Hsu CH, 2012, CELL REP, V2, P568, DOI 10.1016/j.celrep.2012.08.030; Hua S, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.25; Hulf T, 2013, ONCOGENE, V32, P2891, DOI 10.1038/onc.2012.300; Iqbal K, 2011, P NATL ACAD SCI USA, V108, P3642, DOI 10.1073/pnas.1014033108; Irizarry RA, 2008, GENOME RES, V18, P780, DOI 10.1101/gr.7301508; Jarrard DF, 1995, CLIN CANCER RES, V1, P1471; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jeronimo C, 2002, UROLOGY, V60, P1131; Jeronimo C, 2011, EUR UROL, V60, P753, DOI 10.1016/j.eururo.2011.06.035; Jin SG, 2011, CANCER RES, V71, P7360, DOI 10.1158/0008-5472.CAN-11-2023; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Kedes L, 2011, NAT GENET, V43, P1055, DOI 10.1038/ng.988; Kedes L, 2011, NAT GENET, V43, P175, DOI 10.1038/ng0311-175; Kim J, 2012, BBA-REV CANCER, V1825, P186, DOI 10.1016/j.bbcan.2011.12.003; Kim JH, 2011, GENOME RES, V21, P1028, DOI 10.1101/gr.119347.110; Ko M, 2010, NATURE, V468, P839, DOI 10.1038/nature09586; Kobayashi Y, 2011, GENOME RES, V21, P1017, DOI 10.1101/gr.119487.110; Kriaucionis S, 2009, SCIENCE, V324, P929, DOI 10.1126/science.1169786; Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732; Laitinen S, 2008, INT J CANCER, V122, P595, DOI 10.1002/ijc.23145; Leite KRM, 2011, UROL ONCOL-SEMIN ORI, V29, P533, DOI 10.1016/j.urolonc.2009.05.008; Li YW, 2012, EPIGENETICS-US, V7, P940, DOI 10.4161/epi.21236; Lin PC, 2013, NEOPLASIA, V15, P373, DOI 10.1593/neo.122146; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Lorincz Attila T, 2011, Expert Opin Med Diagn, V5, P375; Martens-Uzunova ES, 2012, ONCOGENE, V31, P978, DOI 10.1038/onc.2011.304; Masser DR, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-33; Masson S, 2012, BJU INT, V110, P1110, DOI 10.1111/j.1464-410X.2012.11076.x; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; Metzker Michael L, 2010, Nat Rev Genet, V11, P31, DOI 10.1038/nrg2626; Millar DS, 1999, ONCOGENE, V18, P1313, DOI 10.1038/sj.onc.1202415; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Nakayama M, 2004, J CELL BIOCHEM, V91, P540, DOI 10.1002/jcb.10740; Ngollo M, 2014, OMICS, V18, P207, DOI 10.1089/omi.2013.0117; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Ozsolak F, 2011, NAT REV GENET, V12, P87, DOI 10.1038/nrg2934; Pellakuru LG, 2012, AM J PATHOL, V181, P560, DOI 10.1016/j.ajpath.2012.04.021; Perez C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031605; Perkel J, 2013, BIOTECHNIQUES, V54, P71, DOI 10.2144/000113988; Prensner JR, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003180; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Robinson MD, 2010, GENOME RES, V20, P1719, DOI 10.1101/gr.110601.110; Roupret M, 2007, CLIN CANCER RES, V13, P1720, DOI 10.1158/1078-0432.CCR-06-2467; Ruijter ET, 1996, J PATHOL, V180, P295; Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196; Schaefer A, 2010, INT J CANCER, V126, P1166, DOI 10.1002/ijc.24827; Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Serre D, 2010, NUCLEIC ACIDS RES, V38, P391, DOI 10.1093/nar/gkp992; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Slupianek A, 2010, J CELL PHYSIOL, V224, P369, DOI 10.1002/jcp.22132; Song CX, 2011, NAT BIOTECHNOL, V29, P68, DOI 10.1038/nbt.1732; Sporn JC, 2009, ONCOGENE, V28, P3423, DOI 10.1038/onc.2009.26; Sporn JC, 2012, AM J PATHOL, V180, P2516, DOI 10.1016/j.ajpath.2012.02.027; Spruijt CG, 2013, CELL, V152, P1146, DOI 10.1016/j.cell.2013.02.004; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Talbert PB, 2010, NAT REV MOL CELL BIO, V11, P264, DOI 10.1038/nrm2861; Tomizawa S, 2011, DEVELOPMENT, V138, P811, DOI 10.1242/dev.061416; Tong AW, 2009, CANCER GENE THER, V16, P206, DOI 10.1038/cgt.2008.77; Tsai HC, 2011, CELL RES, V21, P502, DOI 10.1038/cr.2011.24; Valdes-Mora F, 2012, GENOME RES, V22, P307, DOI 10.1101/gr.118919.110; Van Neste L, 2012, PROSTATE, V72, P1248, DOI 10.1002/pros.22459; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vardabasso C, 2014, CELL MOL LIFE SCI, V71, P379, DOI 10.1007/s00018-013-1343-z; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Woodson K, 2006, EPIGENETICS-US, V1, P183, DOI 10.4161/epi.1.4.3530; Wossidlo M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1240; Wu H, 2011, GENE DEV, V25, P2436, DOI 10.1101/gad.179184.111; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yang B, 2013, UROL ONCOL-SEMIN ORI, V31, P628, DOI 10.1016/j.urolonc.2011.05.009; Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67; Yavartanoo Maryam, 2013, Genomics & Informatics, V11, P2, DOI 10.5808/GI.2013.11.1.2; Yegnasubramanian S, 2004, CANCER RES, V64, P1975, DOI 10.1158/0008-5472.CAN-03-3972; Yegnasubramanian S, 2008, CANCER RES, V68, P8954, DOI 10.1158/0008-5472.CAN-07-6088; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Yu M, 2012, CELL, V149, P1368, DOI 10.1016/j.cell.2012.04.027; Yu YP, 2005, CARCINOGENESIS, V26, P471, DOI 10.1093/carcin/bgh310; Ziller MJ, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002389	138	36	36	0	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1609	1618		10.1038/onc.2014.111	http://dx.doi.org/10.1038/onc.2014.111			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24837368				2022-12-28	WOS:000351848400001
J	Zhu, M; Yin, F; Fan, X; Jing, W; Chen, R; Liu, L; Zhang, L; Liu, Y; Liang, Y; Bu, F; Tong, X; Zheng, H; Zhao, J; Guo, Y				Zhu, M.; Yin, F.; Fan, X.; Jing, W.; Chen, R.; Liu, L.; Zhang, L.; Liu, Y.; Liang, Y.; Bu, F.; Tong, X.; Zheng, H.; Zhao, J.; Guo, Y.			Decreased TIP30 promotes Snail-mediated epithelial-mesenchymal transition and tumor-initiating properties in hepatocellular carcinoma	ONCOGENE			English	Article							DEPENDENT UP-REGULATION; E-CADHERIN EXPRESSION; NF-KAPPA-B; POOR-PROGNOSIS; NUCLEAR IMPORT; CANCER CELLS; STEM-CELLS; TGF-BETA; METASTASIS; TRANSCRIPTION	The poor prognosis of hepatocellular carcinoma (HCC) is mainly due to tumor recurrence and metastases. Recently, epithelial-mesenchymal transition (EMT) has been implicated in tumor invasion and metastasis. However, the underlying molecular mechanisms are yet to be elucidated. Here, we show that 30-kDa Tat-interacting protein (TIP30), also called CC3, is significantly downregulated during transforming growth factor-beta-induced EMT. In our in vitro and in vivo studies, we show that decreased TIP30 expression leads to EMT, as well as enhanced motility and invasion of HCC cells. Also, increased self-renewal ability and chemotherapeutic resistance are observed with TIP30 depletion. Moreover, Snail is one of the key transcription factors promoting EMT, and overexpression of TIP30 greatly decreased nucleic accumulation in Snail through the regulation of intracellular localization. Small interfering RNAs targeting Snail attenuated EMT and tumor-initiating properties induced by TIP30 deficiency. We further confirmed that TIP30 competitively interrupted the interaction of Snail with importin-beta 2 to block the nuclear import of Snail. Consistently, TIP30 expression significantly correlates with E-cadherin expression in HCC patients. TIP30 or combination of E-cadherin is a powerful marker in predicting the prognosis of HCC. Taken together, our results suggest a novel and critical role of TIP30 involved in HCC progression and aggressiveness.	[Zhu, M.; Yin, F.; Fan, X.; Chen, R.; Zhang, L.; Liu, Y.; Liang, Y.; Bu, F.; Tong, X.; Zhao, J.; Guo, Y.] Second Mil Med Univ, Int Joint Canc Res Inst, Shanghai 200433, Peoples R China; [Zhu, M.; Jing, W.; Liu, L.; Zheng, H.] Second Mil Med Univ, Changhai Hosp, Shanghai 200433, Peoples R China; [Yin, F.; Zhao, J.; Guo, Y.] Peoples Liberat Army Gen Hosp, Ctr Canc, PLA Postgrad Sch Med, Beijing, Peoples R China	Naval Medical University; Naval Medical University; Chinese People's Liberation Army General Hospital	Zheng, H (corresponding author), Second Mil Med Univ, Changhai Hosp, 800 Xiangyin Rd, Shanghai 200433, Peoples R China.	zheng_hl2004@163.com; zhaojian@smmu.edu.cn			Ministry of Science and Technology of China [2010CB945600, 2010CB833600, 2011CB966200]; National Nature Science Foundation of China; State Key Project for Infection Disease and New Drug Development and Programs of Shanghai Subject Chief Scientists; Municipal Commission of Education; Municipal Commission of Science and Technology	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Project for Infection Disease and New Drug Development and Programs of Shanghai Subject Chief Scientists; Municipal Commission of Education; Municipal Commission of Science and Technology	This work is supported in part by grants from Ministry of Science and Technology of China '973' and '863' programs (2010CB945600, 2010CB833600, 2011CB966200), National Nature Science Foundation of China, State Key Project for Infection Disease and New Drug Development and Programs of Shanghai Subject Chief Scientists, Municipal Commission of Education and Municipal Commission of Science and Technology.	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Banerjee SK, 2012, J CELL COMMUN SIGNAL, V6, P63, DOI 10.1007/s12079-012-0158-2; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chen XB, 2010, DIGEST DIS SCI, V55, P2219, DOI 10.1007/s10620-009-0992-0; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Coleman WB, 2003, CURR MOL MED, V3, P573, DOI 10.2174/1566524033479546; Dang HE, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-396; Fujiki K, 2013, ARCH TOXICOL, V87, P2119, DOI 10.1007/s00204-013-1077-6; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gao Q, 2007, J CLIN ONCOL, V25, P2586, DOI 10.1200/JCO.2006.09.4565; Graham TR, 2008, CANCER RES, V68, P2479, DOI 10.1158/0008-5472.CAN-07-2559; He J, 2005, NEW ENGL J MED, V353, P1124, DOI 10.1056/NEJMsa050467; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Hwang WL, 2011, GASTROENTEROLOGY, V141, P279, DOI 10.1053/j.gastro.2011.04.008; Ito M, 2003, CANCER RES, V63, P8763; Jiang C, 2007, CANCER RES, V67, P3574, DOI 10.1158/0008-5472.CAN-06-0831; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim MS, 2013, MOL CELLS, V36, P177, DOI 10.1007/s10059-013-0061-6; King FW, 2004, MOL CELL BIOL, V24, P7091, DOI 10.1128/MCB.24.16.7091-7101.2004; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Li A, 2013, ONCOGENE, V32, P2273, DOI 10.1038/onc.2012.253; Lu B, 2008, CLIN CANCER RES, V14, P7405, DOI 10.1158/1078-0432.CCR-08-0409; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Medici D, 2008, MOL BIOL CELL, V19, P4875, DOI 10.1091/mbc.E08-05-0506; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Nakahara J, 2009, J CLIN INVEST, V119, P169, DOI 10.1172/JCI35440; NicAmhlaoibh R, 2001, ONCOGENE, V20, P270, DOI 10.1038/sj.onc.1204075; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Pecha J, 2007, ONCOGENE, V26, P7423, DOI 10.1038/sj.onc.1210548; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Poon RTP, 2001, J CLIN ONCOL, V19, P3037, DOI 10.1200/JCO.2001.19.12.3037; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; Taura K, 2010, HEPATOLOGY, V51, P1027, DOI 10.1002/hep.23368; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tong X, 2009, AM J PATHOL, V174, P1931, DOI 10.2353/ajpath.2009.080846; Wang HT, 2013, PSYCHOPHARMACOLOGY, V228, P129, DOI 10.1007/s00213-013-3017-9; Wu KJ, 2012, CELL SIGNAL, V24, P2273, DOI 10.1016/j.cellsig.2012.08.004; Xue GD, 2012, CANCER DISCOV, V2, P248, DOI 10.1158/2159-8290.CD-11-0270; Yamasaki H, 2005, GENES CELLS, V10, P455, DOI 10.1111/j.1365-2443.2005.00850.x; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang XR, 2009, CLIN CANCER RES, V15, P5518, DOI 10.1158/1078-0432.CCR-09-0151; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843; Zhang CL, 2010, CANCER RES, V70, P10224, DOI 10.1158/0008-5472.CAN-10-3057; Zhang W, 2012, GASTROENTEROLOGY, V143, P1641, DOI 10.1053/j.gastro.2012.08.032; Zhao J, 2008, HEPATOLOGY, V48, P265, DOI 10.1002/hep.22280; Zhao J, 2008, CANCER RES, V68, P4133, DOI 10.1158/0008-5472.CAN-08-0432; Zhao J, 2007, HUM PATHOL, V38, P293, DOI 10.1016/j.humpath.2006.08.005	51	22	26	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1420	1431		10.1038/onc.2014.73	http://dx.doi.org/10.1038/onc.2014.73			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24681951				2022-12-28	WOS:000350806500008
J	Bojovic, B; Booth, RE; Jin, Y; Zhou, X; Crowe, DL				Bojovic, B.; Booth, R. E.; Jin, Y.; Zhou, X.; Crowe, D. L.			Alternative lengthening of telomeres in cancer stem cells in vivo	ONCOGENE			English	Article						DNA damage; metastasis; squamous cell carcinoma; basal cells; keratin 15	HUMAN ORAL KERATINOCYTES; CATALYTIC SUBUNIT; MAMMALIAN TELOMERES; MOUSE CELLS; MAINTENANCE; SKIN; GENE; IMMORTALIZATION; TRANSFORMATION; PROLIFERATION	Chromosome ends are protected by telomeres that prevent DNA damage response and degradation. Telomerase expression extends telomeres and inhibits DNA damage response. Telomeres are also maintained by the recombination-based alternative lengthening pathway. Telomerase is believed to be the sole mechanism for telomere maintenance in the epidermis. We show that basal cells in the epidermis maintain telomeres both by telomerase and alternative lengthening of telomere (ALT) mechanisms in vivo. ALT was detected in epidermal stem cells in Terc(-/-) mice, and normal human epidermal keratinocytes are also ALT-positive. The ALT pathway is suppressed in primary, but not metastatic, epidermal squamous cell carcinomas (SCC) in Terc(+/+) mice. The ALT pathway is expressed in stem cells and basal cells in epidermal SCC in Terc(-/-) mice, and in some telomerase-positive human SCC lines. Telomeres shorten markedly in stem cells and basal cells in epidermal SCC in vivo. Telomere shortening is associated with telomeric DNA damage response and apoptosis in stem cells and basal cells. Stem cells were transformed in both primary and metastatic epidermal SCC. Genetic ablation of this small cell population resulted in significant tumor regression in vivo. We concluded that alternative lengthening of telomeres is important in epidermal homeostasis and tumorigenesis in vivo.	[Bojovic, B.; Booth, R. E.; Jin, Y.; Zhou, X.; Crowe, D. L.] Univ Illinois, Ctr Canc, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Crowe, DL (corresponding author), Univ Illinois, Ctr Canc, 801 S Paulina St,Room 530C, Chicago, IL 60612 USA.	dlcrowe@uic.edu			National Institutes of Health [DE14283]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE014283] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr Chiayeng Wang (University of Illinois, Chicago, IL, USA) for U2OS cells. This research was supported by National Institutes of Health grant DE14283.	Belair CD, 1997, P NATL ACAD SCI USA, V94, P13677, DOI 10.1073/pnas.94.25.13677; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Callicott RJ, 2006, COMPARATIVE MED, V56, P17; Celli GB, 2006, NAT CELL BIOL, V8, P885, DOI 10.1038/ncb1444; Cotsarelis G, 2006, J INVEST DERMATOL, V126, P1459, DOI 10.1038/sj.jid.5700376; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Flores I, 2008, GENE DEV, V22, P654, DOI 10.1101/gad.451008; Ford LP, 2001, J BIOL CHEM, V276, P32198, DOI 10.1074/jbc.M104469200; Fuchs E, 2008, J CELL BIOL, V180, P273, DOI 10.1083/jcb.200708185; Fuchs E, 2007, NATURE, V445, P834, DOI 10.1038/nature05659; Fuchs E, 2009, CELL, V137, P811, DOI 10.1016/j.cell.2009.05.002; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Grobelny JV, 2001, HUM MOL GENET, V10, P1953, DOI 10.1093/hmg/10.18.1953; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Heaphy CM, 2011, AM J PATHOL, V179, P1608, DOI 10.1016/j.ajpath.2011.06.018; Hemann MT, 1999, NUCLEIC ACIDS RES, V27, P3964, DOI 10.1093/nar/27.20.3964; Henderson S, 1996, J CELL BIOL, V134, P1, DOI 10.1083/jcb.134.1.1; Henson JD, 2010, FEBS LETT, V584, P3800, DOI 10.1016/j.febslet.2010.06.009; Henson JD, 2009, NAT BIOTECHNOL, V27, P1181, DOI 10.1038/nbt.1587; Kang MK, 2004, J CELL PHYSIOL, V199, P364, DOI 10.1002/jcp.10410; Kang MK, 1998, CELL GROWTH DIFFER, V9, P85; Liu YP, 2003, J INVEST DERMATOL, V121, P963, DOI 10.1046/j.1523-1747.2003.12600.x; Malanchi I, 2008, NATURE, V452, P650, DOI 10.1038/nature06835; Martinez P, 2010, AGING CELL, V9, P653, DOI 10.1111/j.1474-9726.2010.00596.x; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; Nabetani A, 2009, MOL CELL BIOL, V29, P703, DOI 10.1128/MCB.00603-08; Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350; Rajaraman S, 2007, P NATL ACAD SCI USA, V104, P17747, DOI 10.1073/pnas.0706485104; Ramakrishnan S, 1998, CANCER RES, V58, P622; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Siegl-Cachedenier I, 2007, J CELL BIOL, V179, P277, DOI 10.1083/jcb.200704141; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wu GK, 2003, CANCER RES, V63, P2589; Wu YL, 2007, DNA REPAIR, V6, P157, DOI 10.1016/j.dnarep.2006.09.005	42	17	18	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					611	620		10.1038/onc.2013.603	http://dx.doi.org/10.1038/onc.2013.603			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24531712	Green Accepted			2022-12-28	WOS:000348853500008
J	Sanchez-Perez, T; Medema, RH; Lopez-Rivas, A				Sanchez-Perez, T.; Medema, R. H.; Lopez-Rivas, A.			Delaying mitotic exit downregulates FLIP expression and strongly sensitizes tumor cells to TRAIL	ONCOGENE			English	Article						mitotic exit; TRAIL; FLIP; apoptosis; tumor cells	SPINDLE CHECKPOINT; INDUCED APOPTOSIS; CANCER-CELLS; CYCLIN-B; ANAPHASE; RECEPTOR; PHOSPHORYLATION; DEGRADATION; MITOSIS; ARREST	Many of the current antitumor therapeutic strategies are based on the perturbation of the cell cycle, especially during mitosis. Antimitotic drugs trigger mitotic checkpoint activation, mitotic arrest and eventually cell death. However, mitotic slippage represents a major mechanism of resistance to these treatments. In an attempt to circumvent the process of slippage, targeting mitotic exit has been proposed as a better strategy to kill tumor cells. In this study, we show that treatments that induce mitotic checkpoint activation and mitotic arrest downregulate FLICE-like inhibitory protein (FLIP) levels and sensitize several tumor cell lines to TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis. Interestingly, we also demonstrate that in absence of mitotic checkpoint activation, mitotic arrest induced either by Cdc20 knockdown or overexpression of nondegradable cyclin B is sufficient to induce both FLIP downregulation and sensitivity to TRAIL. In summary, our data suggest that a combination of antimitotic drugs targeting cyclin B degradation and TRAIL might prevent mitotic slippage and allow tumor cells to reach the threshold for apoptosis induction, thereby facilitating tumor suppression.	[Sanchez-Perez, T.; Lopez-Rivas, A.] CSIC, Ctr Andaluz Biol Mol & Med Regenerat CABIMER, Seville 41092, Spain; [Sanchez-Perez, T.; Medema, R. H.] Netherlands Canc Inst, Div Cell Biol, Amsterdam, Netherlands	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; University of Sevilla; CSIC - Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Netherlands Cancer Institute	Lopez-Rivas, A (corresponding author), CSIC, Ctr Andaluz Biol Mol & Med Regenerat CABIMER, Aven Amer Vespucio S-N, Seville 41092, Spain.	abelardo.lopez@cabimer.es	Lopez-Rivas, Abelardo/E-5115-2015	Lopez-Rivas, Abelardo/0000-0002-9351-9690; Medema, Rene/0000-0002-6754-0381	Ministerio de Ciencia e Innovacion [SAF2009-07163, SAF2012-32824]; Red Tematica de Investigacion Cooperativa en Cancer (RTICC) [RD06/0020/0068, RD12/0036/0026]; European Community through the regional development funding program (FEDER); Junta de Andalucia [P09-CVI-4497]; Ministerio de Economia y Competitividad (MINECO)	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Red Tematica de Investigacion Cooperativa en Cancer (RTICC)(European Commission); European Community through the regional development funding program (FEDER); Junta de Andalucia(Junta de Andalucia); Ministerio de Economia y Competitividad (MINECO)(Spanish Government)	This work was supported by grants SAF2009-07163 and SAF2012-32824 from Ministerio de Ciencia e Innovacion, Red Tematica de Investigacion Cooperativa en Cancer (RTICC: RD06/0020/0068 and RD12/0036/0026), the European Community through the regional development funding program (FEDER) and Junta de Andalucia (P09-CVI-4497) to AL-R. TS-P was supported by contracts from Ministerio de Economia y Competitividad (MINECO). We are grateful to Aniek Janssen, Monica Alvarez and Martin Vromans for providing helpful advice and discussions. We also thank FJ Fernandez-Farran for excellent technical assistance.	Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Allan LA, 2007, MOL CELL, V26, P301, DOI 10.1016/j.molcel.2007.03.019; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 2008, NAT REV DRUG DISCOV, V7, P1001, DOI 10.1038/nrd2637; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Chang DC, 2003, J BIOL CHEM, V278, P37865, DOI 10.1074/jbc.M306376200; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; Griffith TS, 1998, J IMMUNOL, V161, P2833; Grosse-Wilde A, 2008, J CLIN INVEST, V118, P100, DOI 10.1172/JCI33061; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harley ME, 2010, EMBO J, V29, P2407, DOI 10.1038/emboj.2010.112; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; Huang HC, 2009, CANCER CELL, V16, P347, DOI 10.1016/j.ccr.2009.08.020; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Janssen A, 2011, ONCOGENE, V30, P2799, DOI 10.1038/onc.2011.30; Jordan MA, 1996, CANCER RES, V56, P816; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Manchado E, 2010, CANCER CELL, V18, P641, DOI 10.1016/j.ccr.2010.10.028; Matthess Y, 2010, MOL CELL BIOL, V30, P5726, DOI 10.1128/MCB.00731-10; Palacios C, 2006, CANCER RES, V66, P8858, DOI 10.1158/0008-5472.CAN-06-0808; Piao XH, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003558; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Rath O, 2012, NAT REV CANCER, V12, P527, DOI 10.1038/nrc3310; Ruiz-Ruiz C, 2002, BIOCHEM J, V365, P825, DOI 10.1042/BJ20020184; Sanchez-Perez T, 2010, CELL DEATH DIFFER, V17, P883, DOI 10.1038/cdd.2009.176; Santaguida S, 2010, J CELL BIOL, V190, P73, DOI 10.1083/jcb.201001036; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Terrano DT, 2010, MOL CELL BIOL, V30, P640, DOI 10.1128/MCB.00882-09; Tighe A, 2008, J CELL BIOL, V181, P893, DOI 10.1083/jcb.200712028; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; Wertz IE, 2011, NATURE, V471, P110, DOI 10.1038/nature09779; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zeng X, 2010, CANCER CELL, V18, P382, DOI 10.1016/j.ccr.2010.08.010; Zhang XD, 1999, CANCER RES, V59, P2747	40	5	5	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					661	669		10.1038/onc.2013.601	http://dx.doi.org/10.1038/onc.2013.601			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24488010				2022-12-28	WOS:000348853500013
J	Savar, A; Acin, S; Gonzalez, CL; El-Sawy, T; Mejia, O; Li, Z; Esmaeli, B; Lacy-Hulbert, A; El-Naggar, AK; McCarty, JH; Caulin, C				Savar, A.; Acin, S.; Gonzalez, C. L.; El-Sawy, T.; Mejia, O.; Li, Z.; Esmaeli, B.; Lacy-Hulbert, A.; El-Naggar, A. K.; McCarty, J. H.; Caulin, C.			Loss of epithelial p53 and alpha v integrin cooperate through Akt to induce squamous cell carcinoma yet prevent remodeling of the tumor microenvironment	ONCOGENE			English	Article						p53; squamous cell carcinoma; mouse model; integrins; tumor microenvironment	GAIN-OF-FUNCTION; SKIN-CANCER; MOUSE MODEL; EXPRESSION; MUTATIONS; KERATINOCYTES; INACTIVATION; NEOPLASIA; ABLATION; LEADS	Most of the squamous cell carcinomas (SCCs) of the skin and head and neck contain p53 mutations. The presence of p53 mutations in premalignant lesions suggests that they represent early events during tumor progression and additional alterations may be required for SCC development. Here we show that codeletion of the p53 and alpha v integrin genes in mouse stratified epithelia induced SCCs in 100% of the mice, more frequently and with much shorter latency than deletion of either gene alone. The SCCs that lacked p53 and alpha v in the epithelial tumor cells exhibited high Akt activity, lacked multiple types of infiltrating immune cells, contained a defective vasculature and grew slower than tumors that expressed p53 or alpha v. These results reveal that loss of alpha v in epithelial cells that lack p53 promotes SCC development, but also prevents remodeling of the tumor microenvironment and delays tumor growth. We observed that Akt inactivation in SCC cells that lack p53 and alpha v promoted anoikis. Thus, tumors may arise in these mice as a result of the increased cell survival induced by Akt activation triggered by loss of alpha v and p53, and by the defective recruitment of immune cells to these tumors, which may allow immune evasion. However, the defective vasculature and lack of a supportive stroma create a restrictive microenvironment in these SCCs that slows their growth. These mechanisms may underlie the rapid onset and slow growth of SCCs that lack p53 and alpha v.	[Savar, A.; Acin, S.; Gonzalez, C. L.; El-Sawy, T.; Mejia, O.; Li, Z.; Esmaeli, B.; Caulin, C.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; [Lacy-Hulbert, A.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; [El-Naggar, A. K.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [McCarty, J. H.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; [Caulin, C.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Harvard University; Massachusetts General Hospital; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Caulin, C (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Unit 123, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ccaulin@mdanderson.org	Acin, Sergio/S-5185-2017	Acin, Sergio/0000-0001-7335-2865	National Institutes of Health [DE015344]; Pilot Project grant from the American Cancer Society Institutional Research Grant Program; National Institutes of Health through Cancer Center Support Grant [CA16672]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS078402] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pilot Project grant from the American Cancer Society Institutional Research Grant Program; National Institutes of Health through Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dennis Roop for the K14.CrePR1 mice, Anton Berns for the floxed p53 mice and Sarah Bronson and Dawn Chalaire for editorial assistance. This study was supported by the National Institutes of Health through Grant DE015344 (C Caulin) and a Pilot Project grant from the American Cancer Society Institutional Research Grant Program (JH McCarty). Veterinary services and core facilities at The University of Texas MD Anderson Cancer Center were supported in part by the National Institutes of Health through Cancer Center Support Grant CA16672.	Acin S, 2011, J PATHOL, V225, P479, DOI 10.1002/path.2971; Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Bao WJ, 2004, J CELL BIOL, V167, P745, DOI 10.1083/jcb.200404018; Bolshakov S, 2003, CLIN CANCER RES, V9, P228; Brantsch KD, 2008, LANCET ONCOL, V9, P713, DOI 10.1016/S1470-2045(08)70178-5; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BREUSS JM, 1995, J CELL SCI, V108, P2241; CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717; Caulin C, 2004, CANCER RES, V64, P5054, DOI 10.1158/0008-5472.CAN-04-1488; Caulin C, 2007, J CLIN INVEST, V117, P1893, DOI 10.1172/JCI31721; DELUCA M, 1990, P NATL ACAD SCI USA, V87, P6888, DOI 10.1073/pnas.87.17.6888; Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137; Haapasalmi K, 1996, J INVEST DERMATOL, V106, P42, DOI 10.1111/1523-1747.ep12327199; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; HERTLE MD, 1992, J CLIN INVEST, V89, P1892, DOI 10.1172/JCI115794; Hsu A, 2011, J CUTAN PATHOL, V38, P570, DOI 10.1111/j.1600-0560.2011.01687.x; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Janes SM, 2004, J CELL BIOL, V166, P419, DOI 10.1083/jcb.200312074; Jin H, 2006, CANCER RES, V66, P2146, DOI 10.1158/0008-5472.CAN-05-2704; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Jones J, 1996, ONCOGENE, V12, P119; Jones J, 1997, J ORAL PATHOL MED, V26, P63, DOI 10.1111/j.1600-0714.1997.tb00023.x; Jones SM, 2006, NAT REV CANCER, V6, P175, DOI 10.1038/nrc1817; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Lacy-Hulbert A, 2007, P NATL ACAD SCI USA, V104, P15823, DOI 10.1073/pnas.0707421104; Lindelof B, 2000, BRIT J DERMATOL, V143, P513, DOI 10.1046/j.1365-2133.2000.03703.x; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Martinez-Cruz AB, 2008, CANCER RES, V68, P683, DOI 10.1158/0008-5472.CAN-07-3049; McCarty JH, 2005, DEVELOPMENT, V132, P165, DOI 10.1242/dev.01551; McCarty JH, 2008, AM J PATHOL, V172, P1740, DOI 10.2353/ajpath.2008.070700; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; NAPPI O, 1989, J CUTAN PATHOL, V16, P114, DOI 10.1111/j.1600-0560.1989.tb00024.x; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; Spike Benjamin T, 2011, Genes Cancer, V2, P404, DOI 10.1177/1947601911410224; Streuli CH, 2009, BIOCHEM J, V418, P491, DOI 10.1042/BJ20081948; Stromblad S, 2002, J BIOL CHEM, V277, P13371, DOI 10.1074/jbc.C200044200; Torchia EC, 2012, ONCOGENE, V31, P2680, DOI 10.1038/onc.2011.441; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	41	17	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					516	524		10.1038/onc.2013.585	http://dx.doi.org/10.1038/onc.2013.585			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24469034	Green Accepted			2022-12-28	WOS:000348451300012
J	Tennakoon, JB; Shi, Y; Han, JJ; Tsouko, E; White, MA; Burns, AR; Zhang, A; Xia, X; Ilkayeva, OR; Xin, L; Ittmann, MM; Rick, FG; Schally, AV; Frigo, DE				Tennakoon, J. B.; Shi, Y.; Han, J. J.; Tsouko, E.; White, M. A.; Burns, A. R.; Zhang, A.; Xia, X.; Ilkayeva, O. R.; Xin, L.; Ittmann, M. M.; Rick, F. G.; Schally, A. V.; Frigo, D. E.			Androgens regulate prostate cancer cell growth via an AMPK-PGC-1 alpha-mediated metabolic switch	ONCOGENE			English	Article						androgen receptor; prostate cancer; AMP-activated protein kinase; peroxisome proliferator-activated receptor gamma coactivator 1 alpha; metabolism	FATTY-ACID OXIDATION; PROTEIN-KINASE AMPK; SKELETAL-MUSCLE; MOLECULAR-FEATURES; EXPRESSION; GLUCOSE; PROMOTES; PATHWAY; PHOSPHORYLATION; C-11-ACETATE	Prostate cancer is the most commonly diagnosed malignancy among men in industrialized countries, accounting for the second leading cause of cancer-related deaths. Although we now know that the androgen receptor (AR) is important for progression to the deadly advanced stages of the disease, it is poorly understood what AR-regulated processes drive this pathology. Here we demonstrate that AR regulates prostate cancer cell growth via the metabolic sensor 5'-AMP-activated protein kinase (AMPK), a kinase that classically regulates cellular energy homeostasis. In patients, activation of AMPK correlated with prostate cancer progression. Using a combination of radiolabeled assays and emerging metabolomic approaches, we also show that prostate cancer cells respond to androgen treatment by increasing not only rates of glycolysis, as is commonly seen in many cancers, but also glucose and fatty acid oxidation. Importantly, this effect was dependent on androgen-mediated AMPK activity. Our results further indicate that the AMPK-mediated metabolic changes increased intracellular ATP levels and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 alpha)-mediated mitochondrial biogenesis, affording distinct growth advantages to the prostate cancer cells. Correspondingly, we used outlier analysis to determine that PGC-1 alpha is overexpressed in a subpopulation of clinical cancer samples. This was in contrast to what was observed in immortalized benign human prostate cells and a testosterone-induced rat model of benign prostatic hyperplasia. Taken together, our findings converge to demonstrate that androgens can co-opt the AMPK-PGC-1 alpha signaling cascade, a known homeostatic mechanism, to increase prostate cancer cell growth. The current study points to the potential utility of developing metabolic-targeted therapies directed toward the AMPK-PGC-1 alpha signaling axis for the treatment of prostate cancer.	[Tennakoon, J. B.; Shi, Y.; Han, J. J.; Tsouko, E.; White, M. A.; Frigo, D. E.] Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, Houston, TX 77204 USA; [Burns, A. R.] Univ Houston, Coll Optometry, Houston, TX 77204 USA; [Zhang, A.; Xia, X.; Frigo, D. E.] Houston Methodist Res Inst, Ctr Genom Med, Houston, TX USA; [Ilkayeva, O. R.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC USA; [Xin, L.] Baylor Coll Med, Dept Mol Biol, Houston, TX 77030 USA; [Xin, L.] Baylor Coll Med, Dept Cellular Biol, Houston, TX 77030 USA; [Xin, L.; Ittmann, M. M.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Xin, L.; Ittmann, M. M.] Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; [Xin, L.; Ittmann, M. M.] Dan L Duncan Canc Ctr, Houston, TX USA; [Ittmann, M. M.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Rick, F. G.; Schally, A. V.] Vet Affairs Med Ctr, Miami, FL 33125 USA; [Rick, F. G.; Schally, A. V.] South Florida VA Fdn Res & Educ, Miami, FL 33125 USA; [Rick, F. G.] Florida Int Univ, Herbert Wertheim Coll Med, Dept Urol, Miami, FL 33199 USA; [Schally, A. V.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA; [Schally, A. V.] Univ Miami, Miller Sch Med, Div Hematol Oncol, Miami, FL 33136 USA; [Schally, A. V.] Univ Miami, Miller Sch Med, Dept Med, Div Endocrinol, Miami, FL USA	University of Houston System; University of Houston; University of Houston System; University of Houston; The Methodist Hospital System; The Methodist Hospital - Houston; Duke University; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); State University System of Florida; Florida International University; University of Miami; University of Miami; University of Miami	Frigo, DE (corresponding author), Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, 3605 Cullen Blvd,Bldg 545, Houston, TX 77204 USA.	frigo@uh.edu		Rick, Ferenc/0000-0001-6549-7597; Schally, Andrew/0000-0003-1273-6747; Frigo, Daniel/0000-0002-0713-471X	NIH [K01DK084205, P30EY007551, R00CA125937, P30CA125123]; DoD/PCRP grant [W81XWH-12-1-0204]; CPRIT grant [RP110005]; Texas Emerging Technology Fund; Golfers Against Cancer; Urology Care Foundation Research Scholars Program; AUA Southeastern Section; NATIONAL CANCER INSTITUTE [P30CA125123, R00CA125937] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY007551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK084205] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD/PCRP grant; CPRIT grant; Texas Emerging Technology Fund; Golfers Against Cancer; Urology Care Foundation Research Scholars Program; AUA Southeastern Section; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank members of the Frigo Laboratory for technical advice, helpful suggestions and critical comments on this study and manuscript. We also thank Paul Landry for his assistance with Amira and mitochondrial volume measurements, the Duke University Department of Pathology's Electron Microscopy Core for help with transmission electron microscopy; Drs Dean Tang, Geoffrey Girnun and Thomas Westbrook for generously providing the LAPC9-derived tumors, shPGC-1 alpha constructs and pINDUCER22, respectively; Drs Timothy Koves and Pradip Saha for their advice on the CO<INF>2</INF> trap assays; Dr Christopher Newgard for help with the metabolomics; and Drs Sean McGuire and Kevin Phillips for critically reading this manuscript. This work was supported by NIH grants K01DK084205 (DEF), P30EY007551 (ARB), R00CA125937 (LX), P30CA125123 (Dan L Duncan Cancer Center Human Tissue Acquisition and Pathology Core), DoD/PCRP grant W81XWH-12-1-0204 (DEF), CPRIT grant RP110005 (LX) and grants from the Texas Emerging Technology Fund, the Golfers Against Cancer (DEF), the Urology Care Foundation Research Scholars Program and AUA Southeastern Section (FGR).	Agoulnik IU, 2005, CANCER RES, V65, P7959, DOI 10.1158/0008-5472.CAN-04-3541; Arredouani MS, 2009, CLIN CANCER RES, V15, P5794, DOI 10.1158/1078-0432.CCR-09-0911; Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; Bhalla K, 2011, CANCER RES, V71, P6888, DOI 10.1158/0008-5472.CAN-11-1011; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Chang CY, 2011, CANCER CELL, V20, P500, DOI 10.1016/j.ccr.2011.08.023; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Cormio A, 2009, BIOCHEM BIOPH RES CO, V390, P1182, DOI 10.1016/j.bbrc.2009.10.114; Costello LC, 2005, MITOCHONDRION, V5, P143, DOI 10.1016/j.mito.2005.02.001; Dakubo GD, 2006, J CLIN PATHOL, V59, P10, DOI 10.1136/jcp.2005.027664; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Ding ZH, 2012, CELL, V148, P896, DOI 10.1016/j.cell.2012.01.039; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Ertel A, 2012, CELL CYCLE, V11, P253, DOI 10.4161/cc.11.2.19006; Frigo DE, 2011, CANCER RES, V71, P528, DOI 10.1158/0008-5472.CAN-10-2581; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hodgson MC, 2011, CANCER RES, V71, P572, DOI 10.1158/0008-5472.CAN-10-2314; Hofer C, 1999, EUR UROL, V36, P31, DOI 10.1159/000019923; Hu J, 2012, CELL, V148, P651, DOI 10.1016/j.cell.2011.12.028; Irrcher I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003614; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Jin CL, 2003, PROSTATE, V57, P160, DOI 10.1002/pros.10283; Jung SN, 2009, EXP CELL RES, V315, P2433, DOI 10.1016/j.yexcr.2009.05.018; Karacosta LG, 2012, J BIOL CHEM, V287, P24832, DOI 10.1074/jbc.M112.370783; Klimcakova E, 2012, CANCER RES, V72, P1538, DOI 10.1158/0008-5472.CAN-11-2967; Knudsen KE, 2009, CLIN CANCER RES, V15, P4792, DOI 10.1158/1078-0432.CCR-08-2660; Koves TR, 2008, CELL METAB, V7, P45, DOI 10.1016/j.cmet.2007.10.013; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; Liu Y, 2006, PROSTATE CANCER P D, V9, P230, DOI 10.1038/sj.pcan.4500879; Liu YY, 2010, ANTICANCER RES, V30, P369; Marin-Valencia I, 2012, CELL METAB, V15, P827, DOI 10.1016/j.cmet.2012.05.001; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Moon JS, 2011, BIOCHEM J, V433, P225, DOI 10.1042/BJ20101104; O'Mahony F, 2012, MOL ENDOCRINOL, V26, P2058, DOI 10.1210/me.2012-1191; Oyama N, 2003, J NUCL MED, V44, P549; Park HU, 2009, MOL CANCER THER, V8, P733, DOI 10.1158/1535-7163.MCT-08-0631; Pillarsetty NV, 2009, J NUCL MED, V50, P1709, DOI 10.2967/jnumed.109.064212; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Rick FG, 2011, P NATL ACAD SCI USA, V108, P3755, DOI 10.1073/pnas.1018086108; Rick FG, 2011, PROSTATE, V71, P736, DOI 10.1002/pros.21289; Sahin E, 2011, NATURE, V470, P359, DOI 10.1038/nature09787; Shiota M, 2010, MOL ENDOCRINOL, V24, P114, DOI 10.1210/me.2009-0302; Skrtic M, 2011, CANCER CELL, V20, P674, DOI 10.1016/j.ccr.2011.10.015; Sreekumar A, 2009, NATURE, V457, P910, DOI 10.1038/nature07762; Stoss O, 2008, PROSTATE CANCER P D, V11, P166, DOI 10.1038/sj.pcan.4501001; Tamura K, 2007, CANCER RES, V67, P5117, DOI 10.1158/0008-5472.CAN-06-4040; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Wang JH, 2011, CANCER RES, V71, P1325, DOI 10.1158/0008-5472.CAN-10-2210; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Whitaker-Menezes D, 2011, CELL CYCLE, V10, P4047, DOI 10.4161/cc.10.23.18151; Xiang XQ, 2004, BIOCHEM BIOPH RES CO, V321, P161, DOI 10.1016/j.bbrc.2004.06.133; Xiao D, 2010, J BIOL CHEM, V285, P26558, DOI 10.1074/jbc.M109.063255; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yu EY, 2011, CLIN NUCL MED, V36, P192, DOI 10.1097/RLU.0b013e318208f140; Zha S, 2005, PROSTATE, V63, P316, DOI 10.1002/pros.20177; Zhang B, 2014, ONCOGENE, V33, P3099, DOI 10.1038/onc.2013.281	62	140	145	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2014	33	45					5251	5261		10.1038/onc.2013.463	http://dx.doi.org/10.1038/onc.2013.463			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MD	24186207	Green Accepted			2022-12-28	WOS:000345120400003
J	Lin, KT; Shann, YJ; Chau, GY; Hsu, CN; Huang, CYF				Lin, K-T; Shann, Y-J; Chau, G-Y; Hsu, C-N; Huang, C-Y F.			Identification of latent biomarkers in hepatocellular carcinoma by ultra-deep whole-transcriptome sequencing	ONCOGENE			English	Article						hepatocellular carcinoma; DUNQU1; FGFR2; alternative splicing; RNA-Seq	ALTERNATIVE EXON USE; ADAM15 GENE; EXPRESSION; CANCER; QUANTIFICATION; PATHWAYS	There is an urgent need to identify biomarkers for hepatocellular carcinoma due to limited treatment options and the poor prognosis of this common lethal disease. Whole-transcriptome shotgun sequencing (RNA-Seq) provides new possibilities for biomarker identification. We sequenced similar to 250 million pair-end reads from a pair of adjacent normal and tumor liver samples. With the aid of bioinformatics tools, we determined the transcriptome landscape and sought novel biomarkers by further empirical validations in 55 pairs of adjacent normal and tumor liver samples with various viral statuses such as HBV(+), HCV(+) and HBV(-) HCV(-). We identified a novel gene with coding regions, termed DUNQU1, which has a tissue-specific expression pattern in tumor liver samples of HCV(+) and HBV(-) HCV(-) hepatocellular carcinomas. Overexpression of DUNQU1 in Huh7 cell lines enhances the ability to form colonies in soft agar. Also, we identified three novel differentially-expressed protein-coding genes (ALG1L, SERPINA11 and TMEM82) that lack documented expression profiles in liver cancer and showed that the level of SREPINA11 is correlated with pathology stages. Moreover, we showed that the alternative splicing event of FGFR2 is associated with virus infection, tumor size, cirrhosis and tumor recurrence. The findings indicate that these new markers of hepatocellular carcinoma may be of value in improving prognosis and could have potential as new targets for developing new treatment options.	[Lin, K-T; Huang, C-Y F.] Natl Yang Ming Univ, Inst Biomed Informat, Taipei 112, Taiwan; [Shann, Y-J; Huang, C-Y F.] Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan; [Chau, G-Y] Taipei Vet Gen Hosp, Div Gen Surg, Dept Surg, Taipei, Taiwan; [Hsu, C-N] Acad Sinica, Inst Informat Sci, Taipei, Taiwan; [Hsu, C-N] USC Informat Sci Inst, Marina Del Rey, CA USA; [Hsu, C-N] Univ Calif San Diego, Dept Med, Div Biomed Informat, La Jolla, CA 92093 USA; [Huang, C-Y F.] Natl Yang Ming Univ, Canc Res Ctr, Taipei 112, Taiwan; [Huang, C-Y F.] Natl Yang Ming Univ, Genome Res Ctr, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; Academia Sinica - Taiwan; University of Southern California; University of California System; University of California San Diego; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Huang, CYF (corresponding author), Natl Yang Ming Univ, Inst Clin Med, 155,Li Non St,Sec 2, Taipei 112, Taiwan.	cyhuang5@ym.edu.tw	Huang, Chi-Ying/AFL-7729-2022; Huang, Chi-Ying/AAG-7672-2022	Huang, Chi-Ying/0000-0003-4898-4937; Huang, Chi-Ying/0000-0003-4898-4937	National Science Council [NSC94-3112-B-182-002, NSC97-3112-B-182-004, NSC101-2627-B-010-001-, NSC102-2627-B-010-001-, NSC 100-2917-I-010-001]; National Health Research Institutes, Taiwan; Taipei Veterans General Hospital [V102E2-006]; National Health Research Institutes [NHRI-EX102-10029BI]; Ministry of Economic Affairs [101-EC-17-A-17-S1-152]; Ministry of Education, Aim for the Top University Plan (National Yang-Ming University)	National Science Council(Ministry of Science and Technology, Taiwan); National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan); Taipei Veterans General Hospital(Taipei Veterans General Hospital); National Health Research Institutes(National Health Research Institutes, Japan); Ministry of Economic Affairs; Ministry of Education, Aim for the Top University Plan (National Yang-Ming University)	We thank the Taiwan Liver Cancer Network for providing the liver tumor tissue samples and related clinical data (all are anonymous) for this work. This network currently includes five major medical centers in Taiwan (National Taiwan University Hospital, Chang-Gung Memorial Hospital-Linko, Veteran General Hospital-Taichung, Chang-Gung Memorial Hospital-Kaohsiung and Veteran General Hospital-Kaohsiung). Taiwan Liver Cancer Network is supported by grants from the National Science Council (NSC94-3112-B-182-002, NSC97-3112-B-182-004) and National Health Research Institutes, Taiwan. We also want to thank National Core Facility Program for Biotechnology (Bioinformatics Consortium of Taiwan, NSC102-2319-B-010-002), National Research Program for Biopharmaceuticals (NRPB, NSC10102325-B-492-001) and National Center for High-performance Computing of National Applied Research Laboratories (NCHC, NARLabs) for providing computing and storage resources. Finally, we want to thank Professor Adrian R Krainer for his valuable comments on the manuscript and hosting at Cold Spring Harbor Laboratory.; This research was supported by grants from the National Science Council (NSC101-2627-B-010-001- and NSC102-2627-B-010-001-), Taipei Veterans General Hospital (V102E2-006), the National Health Research Institutes (NHRI-EX102-10029BI), Ministry of Economic Affairs (101-EC-17-A-17-S1-152) and the Ministry of Education, Aim for the Top University Plan (National Yang-Ming University) to C-YF. Huang. This research was also supported by the research aboard grant from the National Science Council (NSC 100-2917-I-010-001) to K-T. Lin.	Amann T, 2010, AM J PATHOL, V176, P1433, DOI 10.2353/ajpath.2010.090356; Barrett T, 2011, NUCLEIC ACIDS RES, V39, pD1005, DOI 10.1093/nar/gkq1184; Bochukova EG, 2010, NATURE, V463, P666, DOI 10.1038/nature08689; Cheng Y, 2007, BRIT J CANCER, V97, P1441, DOI 10.1038/sj.bjc.6604013; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; Ecker JR, 2012, NATURE, V489, P52, DOI 10.1038/489052a; Eichler EE, 2008, NEW ENGL J MED, V358, P737, DOI 10.1056/NEJMe0708756; Flicek P, 2011, NUCLEIC ACIDS RES, V39, pD800, DOI 10.1093/nar/gkq1064; Garber M, 2011, NAT METHODS, V8, P469, DOI [10.1038/nmeth.1613, 10.1038/NMETH.1613]; Grosso AR, 2008, EMBO REP, V9, P1087, DOI 10.1038/embor.2008.189; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Hertervig E, 1997, CANCER, V79, P448, DOI 10.1002/(SICI)1097-0142(19970201)79:3<448::AID-CNCR4>3.0.CO;2-E; Hua YM, 2011, NATURE, V478, P123, DOI 10.1038/nature10485; Huang QC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026168; Huijts PEA, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2917; Kamburov A, 2011, NUCLEIC ACIDS RES, V39, pD712, DOI 10.1093/nar/gkq1156; Kapushesky M, 2012, NUCLEIC ACIDS RES, V40, pD1077, DOI 10.1093/nar/gkr913; Kleino I, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-90; Lander ES, 2011, NATURE, V470, P187, DOI 10.1038/nature09792; Lin R, 2007, ONCOGENE, V26, P851, DOI 10.1038/sj.onc.1209846; Mochizuki S, 2007, CANCER SCI, V98, P621, DOI 10.1111/j.1349-7006.2007.00434.x; Morin RD, 2008, BIOTECHNIQUES, V45, P81, DOI 10.2144/000112900; Myers RM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001046; Ortiz RM, 2004, GENE CHROMOSOME CANC, V41, P366, DOI 10.1002/gcc.20102; Ozsolak F, 2011, NAT REV GENET, V12, P87, DOI 10.1038/nrg2934; Panzitt K, 2007, GASTROENTEROLOGY, V132, P330, DOI 10.1053/j.gastro.2006.08.026; Parkinson H, 2011, NUCLEIC ACIDS RES, V39, pD1002, DOI 10.1093/nar/gkq1040; Parris TZ, 2010, CLIN CANCER RES, V16, P3860, DOI 10.1158/1078-0432.CCR-10-0889; Petretti T, 2000, GUT, V46, P359, DOI 10.1136/gut.46.3.359; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Somarelli JA, 2013, RNA, V19, P116, DOI 10.1261/rna.035097.112; Sultan M, 2008, SCIENCE, V321, P956, DOI 10.1126/science.1160342; Takai H, 2007, CELL, V131, P1248, DOI 10.1016/j.cell.2007.10.052; Toung JM, 2011, GENOME RES, V21, P991, DOI 10.1101/gr.116335.110; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq622; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Wu J, 2011, BIOINFORMATICS, V27, P3010, DOI 10.1093/bioinformatics/btr508; Zdobnov EM, 2001, BIOINFORMATICS, V17, P847, DOI 10.1093/bioinformatics/17.9.847	42	33	37	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2014	33	39					4786	4794		10.1038/onc.2013.424	http://dx.doi.org/10.1038/onc.2013.424			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0ED	24141781				2022-12-28	WOS:000343239500009
J	Mei, Y; Zhang, P; Zuo, H; Clark, D; Xia, R; Li, J; Liu, Z; Mao, L				Mei, Y.; Zhang, P.; Zuo, H.; Clark, D.; Xia, R.; Li, J.; Liu, Z.; Mao, L.			Ebp1 activates podoplanin expression and contributes to oral tumorigenesis	ONCOGENE			English	Article						EBP1; podoplanin; oral; tumorigenesis	BINDING-PROTEIN EBP1; ECTOPIC EXPRESSION; CANCER; ERBB3; LYMPHANGIOGENESIS; PROGRESSION; METASTASIS; CARCINOMAS; INVASION; ANTIGEN	Podoplanin is highly expressed in human cancers. However, mechanisms regulating podoplanin expression remain elusive. Here we show that podoplanin promotes tumorigenesis of oral squamous cell carcinoma (OSCC) and precancerous cells both in vitro and in vivo, and the ErbB3-binding protein-1 (Ebp1) can be activated in oral tumorigenesis and can serve as a transcriptional activator to drive podoplanin expression in the malignant progression. Most of the OSCC cell lines have no detectable podoplanin protein in low-density cultures. However, the protein becomes detectable in high-density cultures and is required for in-vivo tumor formation of OSCC and oral premalignancies. In a high-density culture condition, podoplanin expression can be triggered at both mRNA and protein levels. In this condition, we showed that Ebp1 is upregulated, translocated from the cytoplasm to the nucleus and binds to the podoplanin promoter to result in a dramatic increase of podoplanin mRNA and protein. Ebp1 downregulation significantly reduced podoplanin expression levels in OSCC cells with a decreased anchorage-dependent growth, invasion and wound healing. Conversely, Ebp1 overexpression enhanced these malignant features through podoplanin upregulation both in vitro and in vivo. In 81 patients with oral premalignant lesions, we found that Ebp1 expression is strongly related to OSCC development. We conclude that Ebp1 has a key role in the upregulation of podoplanin and may contribute to oral tumorigenesis.	[Mei, Y.; Zuo, H.; Clark, D.; Mao, L.] Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, Baltimore, MD 21201 USA; [Zhang, P.; Xia, R.; Li, J.] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9,Sch Stomatoloty, Dept Oral & Maxillofacial Surg,Shanghai Key Lab S, Shanghai, Peoples R China; [Zhang, P.; Xia, R.; Li, J.] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9,Sch Stomatoloty, Dept Oral & Maxillofacial Surg,Shanghai Res Inst, Shanghai, Peoples R China; [Liu, Z.; Mao, L.] Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; Shanghai Jiao Tong University; Shanghai Jiao Tong University; University System of Maryland; University of Maryland Baltimore	Mao, L (corresponding author), Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, 650 W Baltimore St,Room 7259, Baltimore, MD 21201 USA.	lmao@umaryland.edu		Clark, David/0000-0003-0527-8469				Cortez MA, 2010, GENE CHROMOSOME CANC, V49, P981, DOI 10.1002/gcc.20808; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; de Sousa SF, 2012, APPL IMMUNOHISTO M M, V20, P588, DOI 10.1097/PAI.0b013e31824bb3ea; Funayama A, 2011, PATHOBIOLOGY, V78, P171, DOI 10.1159/000324926; Hamburger AW, 2008, J MAMMARY GLAND BIOL, V13, P225, DOI 10.1007/s10911-008-9077-5; Hantusch B, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-20; Honma M, 2012, J DERMATOL SCI, V65, P134, DOI 10.1016/j.jdermsci.2011.11.011; Huber GF, 2011, INT J CANCER, V129, P1404, DOI 10.1002/ijc.25795; Hwang YS, 2012, CARCINOGENESIS, V33, P2135, DOI 10.1093/carcin/bgs258; Inoue H, 2012, TUMOR BIOL, V33, P183, DOI 10.1007/s13277-011-0261-7; Kawaguchi H, 2008, J CLIN ONCOL, V26, P354, DOI 10.1200/JCO.2007.13.4072; Kim CK, 2010, CANCER RES, V70, P9730, DOI 10.1158/0008-5472.CAN-10-1882; Kreppel M, 2012, ORAL DIS, V18, P692, DOI 10.1111/j.1601-0825.2012.01927.x; Kunita A, 2011, AM J PATHOL, V179, P1041, DOI 10.1016/j.ajpath.2011.04.027; Lessor TJ, 2000, J CELL PHYSIOL, V183, P321, DOI 10.1002/(SICI)1097-4652(200006)183:3<321::AID-JCP4>3.0.CO;2-O; Martin-Villar E, 2009, INT J BIOCHEM CELL B, V41, P1421, DOI 10.1016/j.biocel.2008.12.010; Mashhadiabbas F, 2012, OR SURG OR MED OR PA, V114, P240, DOI 10.1016/j.oooo.2012.04.009; Mei Y, 2008, NEUROSCIENCE, V151, P771, DOI 10.1016/j.neuroscience.2007.10.057; Mei YP, 2012, ONCOGENE, V31, P2794, DOI 10.1038/onc.2011.449; Monie TP, 2007, EMBO J, V26, P3936, DOI 10.1038/sj.emboj.7601817; Neph S, 2012, CELL, V150, P1274, DOI 10.1016/j.cell.2012.04.040; Ohta M, 2013, ORAL ONCOL, V49, P20, DOI 10.1016/j.oraloncology.2012.06.017; Peterziel H, 2012, NEURO-ONCOLOGY, V14, P426, DOI 10.1093/neuonc/nos055; Raica M, 2008, ANTICANCER RES, V28, P2997; Scholl FG, 2000, LAB INVEST, V80, P1749, DOI 10.1038/labinvest.3780185; Shen YQ, 2010, J BIOL CHEM, V285, P9649, DOI 10.1074/jbc.M109.047696; Shimamura Y, 2011, ACTA HISTOCHEM CYTOC, V44, P239, DOI 10.1267/ahc.11032; Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045; Wicki A, 2006, CANCER CELL, V9, P261, DOI 10.1016/j.ccr.2006.03.010; Wicki A, 2007, BRIT J CANCER, V96, P1, DOI 10.1038/sj.bjc.6603518; Yuan P, 2006, CANCER, V107, P563, DOI 10.1002/cncr.22061; Zhang YX, 2010, CANCER RES, V70, P240, DOI 10.1158/0008-5472.CAN-09-2904; Zhang YX, 2005, NUCLEIC ACIDS RES, V33, P6024, DOI 10.1093/nar/gki903; Zhou X, 2010, J CANCER RES CLIN, V136, P891, DOI 10.1007/s00432-009-0730-1	34	31	33	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3839	3850		10.1038/onc.2013.354	http://dx.doi.org/10.1038/onc.2013.354			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23975429				2022-12-28	WOS:000339394100010
J	Zhang, Z; Yang, M; Chen, R; Su, W; Li, P; Chen, S; Chen, Z; Chen, A; Li, S; Hu, C				Zhang, Z.; Yang, M.; Chen, R.; Su, W.; Li, P.; Chen, S.; Chen, Z.; Chen, A.; Li, S.; Hu, C.			IBP regulates epithelial-to-mesenchymal transition and the motility of breast cancer cells via Rac1, RhoA and Cdc42 signaling pathways	ONCOGENE			English	Article						IBP; EMT; breast cancer; migration; invasion	PROTEIN; EMT; EXPRESSION; GTPASES; DEF6; PROLIFERATION; CYTOSKELETON; ACTIVATOR; SYSTEM; GENE	Epithelial-to-mesenchymal transition (EMT) is a crucial process for the invasion and metastasis of epithelial tumors. However, the molecular mechanisms underlying this transition are poorly understood. In this study, we demonstrate that interferon regulatory factor 4 binding protein (IBP) regulates EMT and the motility of breast cancer cells through Rac1, RhoA and Cdc42 signaling pathways. We found that increased expression of IBP was associated with the progression of breast cancer and that IBP protein levels were significantly elevated in matched distant metastases. High IBP levels also predict shorter overall survival of breast cancer patients. Furthermore, the forced expression of IBP decreased the expression of the epithelial marker E-cadherin but increased the mesenchymal markers in breast cancer cells. In contrast, silencing IBP in metastatic breast tumor cells promoted a shift toward an epithelial morphology concomitant with increased expression of E-cadherin and decreased expression of mesenchymal markers. IBP silencing also reduced the expression of EMT-inducing transcription factors (Snail, Slug, ZEB1 and ZEB2). Moreover, we identified a role for IBP in endogenous EMT induced by epidermal growth factor (EGF) and deletion of IBP attenuated EGF receptor (EGFR) signaling in breast cancer cells. Furthermore, IBP regulates the migration, invasion and matrix metalloprotease production in breast cancer cells as well as actin cytoskeleton rearrangement and the activation of GTP-Rac1, GTP-RhoA and GTP-Cdc42. Taken together, our findings demonstrate an oncogenic property for IBP in promoting the metastatic potential of breast cancer cells.	[Zhang, Z.; Yang, M.; Li, P.; Chen, S.; Chen, Z.; Chen, A.; Li, S.; Hu, C.] Third Mil Med Univ, Southwest Hosp, Fac Med Lab Sci, Dept Clin Biochem, Chongqing 400038, Peoples R China; [Chen, R.] Third Mil Med Univ, Xinqiao Hosp, Dept Pathol, Chongqing 400038, Peoples R China; [Su, W.] Beibei Maternal & Child Hlth Hosp, Dept Lab Med, Chongqing, Peoples R China	Army Medical University; Army Medical University	Hu, C (corresponding author), Third Mil Med Univ, Southwest Hosp, Fac Med Lab Sci, Dept Clin Biochem, 30 Gaotanyan Ctr St, Chongqing 400038, Peoples R China.	chuminhu@163.com			National Natural Science Foundation of China [81201952, 81172538, 81072154]; SRF for ROCS, SEM	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); SRF for ROCS, SEM(Scientific Research Foundation for the Returned Overseas Chinese Scholars)	We thank Wei Sun and Liting Wang (Central Laboratories, TMMU, China) for their help with laser scanning confocal microscopy work. This project was supported by the National Natural Science Foundation of China (no. 81201952, 81172538 and 81072154) and SRF for ROCS, SEM.	ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; Barr S, 2008, CLIN EXP METASTAS, V25, P685, DOI 10.1007/s10585-007-9121-7; Becart S, 2008, IMMUNITY, V29, P704, DOI 10.1016/j.immuni.2008.08.015; Becart S, 2007, J CLIN INVEST, V117, P2164, DOI 10.1172/JCI31640; Bendris Nawal, 2012, Small GTPases, V3, P225, DOI 10.4161/sgtp.20791; Byles V, 2012, ONCOGENE, V31, P4619, DOI 10.1038/onc.2011.612; Canonigo-Balancio AJ, 2009, J IMMUNOL, V183, P7259, DOI 10.4049/jimmunol.0902573; Fanzo JC, 2006, J CLIN INVEST, V116, P703, DOI 10.1172/JCI24096; Gupta S, 2003, HUM IMMUNOL, V64, P389, DOI 10.1016/S0198-8859(03)00024-7; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hardy KM, 2010, J MAMMARY GLAND BIOL, V15, P191, DOI 10.1007/s10911-010-9172-2; Hey F, 2012, J BIOL CHEM, V287, P31073, DOI 10.1074/jbc.M112.346767; Hotfilder M, 1999, BRIT J HAEMATOL, V106, P335, DOI 10.1046/j.1365-2141.1999.01551.x; Hugo HJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-235; Jian CX, 2012, CANCER INVEST, V30, P748, DOI 10.3109/07357907.2012.734355; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Li P, 2009, INT IMMUNOPHARMACOL, V9, P1002, DOI 10.1016/j.intimp.2009.04.008; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Mavrakis KJ, 2004, EXP CELL RES, V294, P335, DOI 10.1016/j.yexcr.2003.12.004; Mimeault M, 2007, ANN ONCOL, V18, P1605, DOI 10.1093/annonc/mdm070; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Oka T, 2007, J BIOL CHEM, V282, P2011, DOI 10.1074/jbc.M605153200; Samson T, 2007, J BIOL CHEM, V282, P15730, DOI 10.1074/jbc.M611197200; Tanaka Y, 2003, IMMUNITY, V18, P403, DOI 10.1016/S1074-7613(03)00054-2; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Yang MZ, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-54; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Zhang ZJ, 2009, CANCER EPIDEMIOL, V33, P130, DOI 10.1016/j.canep.2009.05.004	29	39	43	4	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3374	3382		10.1038/onc.2013.337	http://dx.doi.org/10.1038/onc.2013.337			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23975422	hybrid, Green Published			2022-12-28	WOS:000338779300004
J	Zhou, JZ; Riquelme, MA; Gao, X; Ellies, LG; Sun, LZ; Jiang, JX				Zhou, J. Z.; Riquelme, M. A.; Gao, X.; Ellies, L. G.; Sun, L. Z.; Jiang, J. X.			Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis	ONCOGENE			English	Article							HUMAN-TUMOR-CELLS; RECEPTORS; SURVIVAL; ATP; 5'-TRIPHOSPHATE; HEMICHANNELS; ACTIVATION; MECHANISMS; MIGRATION; MODELS	Extracellular ATP has been shown to either inhibit or promote cancer growth and migration; however, the mechanism underlying this discrepancy remained elusive. Here we demonstrate the divergent roles of ATP and adenosine released by bone osteocytes on breast cancers. We showed that conditioned media (CM) collected from osteocytes treated with alendronate (AD), a bisphosphonate drug, inhibited the migration of human breast cancer MDA-MB-231 cells. Removal of the extracellular ATP by apyrase in CM abolished this effect, suggesting the involvement of ATP. ATP exerted its inhibitory effect through the activation of purinergic P2X receptor signaling in breast cancer cells evidenced by the attenuation of the inhibition by an antagonist, oxidized ATP, as well as knocking down P2X7 with small interfering RNA (siRNA), and the inhibition of migration by an agonist, BzATP. Intriguingly, ATP had a biphasic effect on breast cancer cells-lower dosage inhibited but higher dosage promoted its migration. The stimulatory effect on migration was blocked by an adenosine receptor antagonist, MRS1754, ARL67156, an ecto-ATPase inhibitor, and A(2A) receptor siRNA, suggesting that in contrast to ATP, adenosine, a metabolic product of ATP, promoted migration of breast cancer cells. Consistently, non-hydrolyzable ATP, ATP gamma S, only inhibited but did not promote cancer cell migration. ATP also had a similar inhibitory effect on the Py8119 mouse mammary carcinoma cells; however, adenosine had no effect owing to the absence of the A(2A) receptor. Consistently, ATP.S inhibited, whereas adenosine promoted anchorage-independent growth of MDA-MB-231 cells. Our in vivo xenograft study showed a significant delay of tumor growth with the treatment of ATP gamma S. Moreover, the extent of bone metastasis in a mouse intratibial model was significantly reduced with the treatment of ATP gamma S. Together, our results suggest the distinct roles of ATP and adenosine released by osteocytes and the activation of corresponding receptors P2X7 and A(2A) signaling on breast cancer cell growth, migration and bone metastasis.	[Zhou, J. Z.; Riquelme, M. A.; Gao, X.; Jiang, J. X.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA; [Ellies, L. G.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Sun, L. Z.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Sun, L. Z.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of California System; University of California San Diego; University of Texas System; University of Texas Health San Antonio; Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio	Jiang, JX (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	jiangj@uthscsa.edu	Riquelme, Manuel/B-1082-2015; , LuZhe/AAW-4095-2021	Riquelme, Manuel/0000-0002-1915-0434; Jiang, Jean/0000-0002-2185-5716	Welch Foundation [AQ-1507]; National Institutes of Health [EY012085, ES022057, CA118182]; NCI Cancer Center Support grant [2 P30 CA054174-17]; NATIONAL CANCER INSTITUTE [P30CA054174, K22CA118182] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R29EY012085, R01EY012085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES022057] Funding Source: NIH RePORTER	Welch Foundation(The Welch Foundation); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI Cancer Center Support grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr Sumin Gu, Dr Sweta Mishra and Dr Tanuka Biswas for technical assistance. The work was supported by the Welch Foundation grant AQ-1507 and National Institutes of Health grant EY012085 to JXJ, ES022057 to L-ZS, CA118182 to LGE and the NCI Cancer Center Support grant 2 P30 CA054174-17 to Cancer Therapy and Research Center.	Abbracchio MP, 2006, PHARMACOL REV, V58, P281, DOI 10.1124/pr.58.3.3; Agteresch HJ, 2003, ANTI-CANCER DRUG, V14, P639, DOI 10.1097/00001813-200309000-00009; Agteresch HJ, 2000, EUR J CLIN PHARMACOL, V56, P49, DOI 10.1007/s002280050719; Batra N, 2012, BBA-BIOMEMBRANES, V1818, P1909, DOI 10.1016/j.bbamem.2011.09.018; Beijer S, 2009, ANTI-CANCER DRUG, V20, P625, DOI 10.1097/CAD.0b013e32832d4f22; Bonewald LF, 2007, ANN NY ACAD SCI, V1116, P281, DOI 10.1196/annals.1402.018; Brown Sue A, 2007, Curr Osteoporos Rep, V5, P120; Burnstock G, 2008, J PHYSIOL-LONDON, V586, P3307, DOI 10.1113/jphysiol.2008.155903; Campbell JP, 2012, JOVE-J VIS EXP, DOI 10.3791/4260; Deli T, 2008, PATHOL ONCOL RES, V14, P219, DOI 10.1007/s12253-008-9071-7; Falzoni S, 2013, INTERFACE FOCUS, V3, DOI 10.1098/rsfs.2012.0101; Genetos DC, 2007, J CELL PHYSIOL, V212, P207, DOI 10.1002/jcp.21021; Gessi S, 2011, BBA-BIOMEMBRANES, V1808, P1400, DOI 10.1016/j.bbamem.2010.09.020; Jelassi B, 2011, ONCOGENE, V30, P2108, DOI 10.1038/onc.2010.593; Jin JK, 2011, INT J CANCER, V128, P2545, DOI 10.1002/ijc.26024; Kohno N, 2008, INT J CLIN ONCOL, V13, P18, DOI 10.1007/s10147-007-0726-2; Kretschmann KL, 2012, CANCER METAST REV, V31, P579, DOI 10.1007/s10555-012-9378-4; Leth-Larsen R, 2009, MOL CELL PROTEOMICS, V8, P1436, DOI 10.1074/mcp.M800061-MCP200; Matsuo K, 2009, CURR OPIN NEPHROL HY, V18, P292, DOI 10.1097/MNH.0b013e32832b75f1; Mishra S, 2011, PROSTATE, V71, P1441, DOI 10.1002/pros.21361; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200; RAPAPORT E, 1983, CANCER RES, V43, P4402; RAPAPORT E, 1988, EUR J CANCER CLIN ON, V24, P1491, DOI 10.1016/0277-5379(88)90340-9; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Salvestrini V, 2012, BLOOD, V119, P217, DOI 10.1182/blood-2011-07-370775; Savariar EN, 2013, CANCER RES, V73, P855, DOI 10.1158/0008-5472.CAN-12-2969; Shabbir M, 2009, INT J UROL, V16, P143, DOI 10.1111/j.1442-2042.2008.02207.x; Van der Pluijm G, 2001, J BONE MINER RES, V16, P1077, DOI 10.1359/jbmr.2001.16.6.1077; Wang L, 2008, J CANCER RES CLIN, V134, P365, DOI 10.1007/s00432-007-0292-z; Welch D. R., 2003, Journal of Musculoskeletal & Neuronal Interactions, V3, P30; White N, 2006, TRENDS PHARMACOL SCI, V27, P211, DOI 10.1016/j.tips.2006.02.004; Woodhouse EC, 1998, BIOCHEM BIOPH RES CO, V246, P888, DOI 10.1006/bbrc.1998.8714; Zhang W, 2011, BIOCHEM PHARMACOL, V82, P411, DOI 10.1016/j.bcp.2011.05.009; Zhi XL, 2007, CLIN EXP METASTAS, V24, P439, DOI 10.1007/s10585-007-9081-y	35	69	73	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1831	1842		10.1038/onc.2014.113	http://dx.doi.org/10.1038/onc.2014.113			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24837364	Green Accepted			2022-12-28	WOS:000352158000010
J	Miller, A; Brooks, GD; McLeod, L; Ruwanpura, S; Jenkins, BJ				Miller, A.; Brooks, G. D.; McLeod, L.; Ruwanpura, S.; Jenkins, B. J.			Differential involvement of gp130 signalling pathways in modulating tobacco carcinogen-induced lung tumourigenesis	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; K-RAS; GASTRIC TUMORIGENESIS; STAT3 ACTIVATION; CIGARETTE-SMOKE; AKT ACTIVATION; CELL-SURVIVAL; MUTANT MICE; CANCER; TUMORS	Interleukin (IL)-6 family cytokines signal exclusively via the gp130 coreceptor, and are implicated in smoking-associated lung cancer, the most lethal cancer worldwide. However, the role of gp130 signalling pathways in transducing the carcinogenic effects of tobacco-related compounds is ill-defined. Here, we report that lung tumourigenesis induced by the potent tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (Nicotine-derived Nitrosamine Ketone; NNK) is suppressed in gp130(F/F) knock-in mice characterized by the contrasting gp130-dependant hypoactivation of extracellular signal-regulated kinase mitogen-activated protein kinase (ERK MAPK) and phosphatidylinositol 3-kinase/Akt, and hyperactivation of signal transducer and activator of transcription (STAT) 3 signalling cascades. Specifically, in response to NNK, the absolute number and size of lung lesions in gp130(F/F) mice were significantly reduced compared with gp130(+/+) littermate controls, and associated with lower cellular proliferation without any alteration to the level of apoptosis in gp130(F/F) lung tumours. At the molecular level, reduced activation of ERK MAPK, but not Akt, was observed in lung tumours of gp130(F/F) mice, and corresponded with impaired expression of several tumour suppressor genes (for example, Trp53, Tsc2). Notably, STAT3 was not activated in the lungs of gp130(+/+) mice by NNK, and genetic normalization of STAT3 activation in gp130(F/F): Stat3(-/+) mice had no effect on NNK-induced tumourigenesis. The expression of tumour suppressor genes was reduced in tumours from current versus never-smoking lung cancer patients, and in vitro pharmacological inhibition of ERK MAPK signalling in human lung cancer cells abrogated NNK-induced downmodulation of tumour suppressor gene expression. Among IL-6 cytokine family members, IL-6 gene expression was specifically upregulated by NNK in vitro and in vivo, and inversely correlated with tumour suppressor gene expression. Collectively, our data reveal that a key molecular mechanism by which NNK promotes tumour cell proliferation during tobacco carcinogen-induced lung carcinogenesis is via upregulation of IL-6 and the preferential usage of gp130-dependant ERK MAPK signalling to downmodulate tumour suppressor gene expression.	[Miller, A.; Brooks, G. D.; McLeod, L.; Ruwanpura, S.; Jenkins, B. J.] Monash Univ, Monash Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic 3168, Australia	Monash University	Jenkins, BJ (corresponding author), Monash Univ, Monash Inst Med Res, Ctr Innate Immun & Infect Dis, 27-31 Wright St, Clayton, Vic 3168, Australia.	Brendan.Jenkins@monash.edu	Miller, Alistair/AAE-8766-2022	Miller, Alistair/0000-0002-0439-9747; Ruwanpura, saleela/0000-0002-4074-2012; Jenkins, Brendan/0000-0002-7552-4656	National Health and Medical Research Council (NHMRC) of Australia; Operational Infrastructure Support Program by the Victorian Government of Australia; NHMRC Post-doctoral Training Fellowship; Sylvia and Charles Viertel Senior Medical Research Fellowship	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Operational Infrastructure Support Program by the Victorian Government of Australia; NHMRC Post-doctoral Training Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Sylvia and Charles Viertel Senior Medical Research Fellowship	This work was supported by the National Health and Medical Research Council (NHMRC) of Australia, as well as the Operational Infrastructure Support Program by the Victorian Government of Australia. SMR is supported by a NHMRC Post-doctoral Training Fellowship. BJJ is supported by a Sylvia and Charles Viertel Senior Medical Research Fellowship.	Ahn YH, 2011, MOL CELL BIOL, V31, P4270, DOI 10.1128/MCB.05562-11; Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H; Akopyan G, 2006, INT J ONCOL, V29, P745; Brognard J, 2001, CANCER RES, V61, P3986; Brugger W, 2012, LUNG CANCER, V77, P2, DOI 10.1016/j.lungcan.2011.12.014; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Greenberg AK, 2002, AM J RESP CELL MOL, V27, P320, DOI 10.1165/rcmb.4710; Guo J, 2013, ONCOGENE, V32, P151, DOI 10.1038/onc.2012.39; Halappanavar S, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-56; Haura EB, 2006, CLIN LUNG CANCER, V7, P273, DOI 10.3816/CLC.2006.n.006; Hayashi H, 2001, LUNG CANCER-J IASLC, V34, P59, DOI 10.1016/S0169-5002(01)00211-2; Hollander MC, 2011, ONCOGENE, V30, P1812, DOI 10.1038/onc.2010.556; Hollander MC, 2008, NEOPLASIA, V10, P866, DOI 10.1593/neo.08406; Hollander MC, 2011, CARCINOGENESIS, V32, P1279, DOI 10.1093/carcin/bgr097; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Huang RY, 2011, ONCOGENE, V30, P106, DOI 10.1038/onc.2010.390; Ihara S, 2012, CANCER RES, V72, P2990, DOI 10.1158/0008-5472.CAN-11-4062; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jenkins BJ, 2005, NAT MED, V11, P845, DOI 10.1038/nm1282; Ji HB, 2007, CANCER RES, V67, P4933, DOI 10.1158/0008-5472.CAN-06-4592; Jiang RC, 2011, MOL DIAGN THER, V15, P347, DOI 10.2165/11599190-000000000-00000; Jin ZH, 2004, J BIOL CHEM, V279, P40209, DOI 10.1074/jbc.M404056200; Kennedy CL, 2011, J PATHOL, V225, P255, DOI 10.1002/path.2933; Liu XD, 2007, BIOCHEM BIOPH RES CO, V353, P121, DOI 10.1016/j.bbrc.2006.11.147; Marson VJ, 2004, HISTOPATHOLOGY, V45, P125, DOI 10.1111/j.1365-2559.2004.01893.x; McClelland MR, 2007, AM J RESP CELL MOL, V36, P343, DOI 10.1165/rcmb.2006-0311OC; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Pine SR, 2011, JNCI-J NATL CANCER I, V103, P1112, DOI 10.1093/jnci/djr216; Qu P, 2009, LUNG CANCER, V63, P341, DOI 10.1016/j.lungcan.2008.05.025; Ramakrishna G, 2002, TOXICOL APPL PHARM, V179, P21, DOI 10.1006/taap.2001.9344; Razani-Boroujerdi S, 2007, AM J RESP CELL MOL, V36, P13, DOI 10.1165/rcmb.2005-0330OC; Ruwanpura SM, 2012, AM J PHYSIOL-LUNG C, V302, P1627, DOI 10.1152/ajplung.00285.2011; Ruwanpura SM, 2011, AM J RESP CELL MOL, V45, P720, DOI 10.1165/rcmb.2010-0462OC; Steels E, 2001, EUR RESPIR J, V18, P705, DOI 10.1183/09031936.01.00062201; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; Thiem S, 2013, J CLIN INVEST, V123, P767, DOI 10.1172/JCI65086; Tominaga M, 2003, LUNG CANCER-J IASLC, V40, P45, DOI 10.1016/S0169-5002(02)00529-9; Trejo CL, 2012, CANCER RES, V72, P3048, DOI 10.1158/0008-5472.CAN-11-3649; Tsao AS, 2003, CANCER EPIDEM BIOMAR, V12, P660; Tsurutani J, 2006, J CLIN ONCOL, V24, P306, DOI 10.1200/JCO.2005.02.4133; Tye H, 2012, CANCER CELL, V22, P466, DOI 10.1016/j.ccr.2012.08.010; Vicent S, 2004, BRIT J CANCER, V90, P1047, DOI 10.1038/sj.bjc.6601644; Walser Tonya, 2008, Proc Am Thorac Soc, V5, P811, DOI 10.1513/pats.200809-100TH; West KA, 2004, CANCER RES, V64, P446, DOI 10.1158/0008-5472.CAN-03-3241; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; YANAGAWA H, 1995, BRIT J CANCER, V71, P1095, DOI 10.1038/bjc.1995.212; Yang YP, 2004, J BIOL CHEM, V279, P29336, DOI 10.1074/jbc.C400162200	48	12	12	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1510	1519		10.1038/onc.2014.99	http://dx.doi.org/10.1038/onc.2014.99			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24727895				2022-12-28	WOS:000351416800004
J	Zhang, Y; Gong, Y; Hu, D; Zhu, P; Wang, N; Zhang, Q; Wang, M; Aldeewan, A; Xia, H; Qu, X; Ring, BZ; Minato, N; Su, L				Zhang, Y.; Gong, Y.; Hu, D.; Zhu, P.; Wang, N.; Zhang, Q.; Wang, M.; Aldeewan, A.; Xia, H.; Qu, X.; Ring, B. Z.; Minato, N.; Su, L.			Nuclear SIPA1 activates integrin beta 1 promoter and promotes invasion of breast cancer cells	ONCOGENE			English	Article							DOWN-REGULATION; FOCAL ADHESION; MATRIX-METALLOPROTEINASE-9 SECRETION; SUBCELLULAR-LOCALIZATION; TUMOR PROGRESSION; MELANOMA-CELLS; RAP1 GTPASE; EXPRESSION; METASTASIS; MIGRATION	SIPA1 (signal-induced proliferation-associated protein 1) is a GTPase activation protein that can catalyze the hydrolysis of Rap1 bound GTP to GDP. Recently attention has been paid to a potential role for SIPA1 in cancer metastasis; however, the underlying mechanism of how changes in SIPA1 levels may lead to increased metastasis remains poorly understood. In this study, we showed that SIPA1 was mainly localized to the nuclei in highly invasive breast cancer tumor tissue and MDA-MB-231 cells. Knockdown of SIPA1 in MDA-MB-231 altered cell morphology and cell proliferation ability. Furthermore, this study is the first to establish that nuclear SIPA1 can interact with the integrin beta 1 promoter and activate its transcription; this interaction appears to be important for SIPA1-dependent MDA-MB-231 cell adhesion and invasion. We also demonstrated that the phosphorylation of FAK, Akt and the expression of MMP9, downstream signaling molecules of integrin beta 1, were decreased upon SIPA1 knockdown, and MDA-MB-231 cell invasion was impaired. Taken together, these results suggest nuclear SIPA1 contributes to breast cancer cell invasion through the regulation of integrin beta 1 signaling.	[Zhang, Y.; Hu, D.; Zhu, P.; Wang, N.; Zhang, Q.; Aldeewan, A.; Su, L.] Huazhong Univ Sci & Technol, Sch Life Sci & Technol, Minist Educ, Key Lab Mol Biophys, Wuhan 430074, Peoples R China; [Gong, Y.] Hubei Canc Hosp, Dept Breast Surg, Wuhan, Peoples R China; [Wang, M.; Xia, H.] Hubei Canc Hosp, Dept Pathol, Wuhan, Peoples R China; [Qu, X.] Huazhong Univ Sci & Technol, Union Hosp Tongji Med Coll, Dept Thyroid & Breast Surg, Wuhan 430074, Peoples R China; [Ring, B. Z.] Huazhong Univ Sci & Technol, Sch Life Sci & Technol, Inst Genom & Personalized Med, Wuhan 430074, Peoples R China; [Minato, N.] Kyoto Univ, Grad Sch Med, Dept Immunol & Cell Biol, Kyoto, Japan	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Kyoto University	Su, L (corresponding author), Huazhong Univ Sci & Technol, Sch Life Sci & Technol, Minist Educ, Key Lab Mol Biophys, 1037 Luoyu Rd, Wuhan 430074, Peoples R China.	lisu@mail.hust.edu.cn	Zhang, Yilei/I-8997-2014	Zhang, Yilei/0000-0003-1407-0301	National Basic Research Program of China [2011CB910401]; NSFC [31271504]; Ministry of Science and Technology, China [2009DFA31940]	National Basic Research Program of China(National Basic Research Program of China); NSFC(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology, China(Ministry of Science and Technology, China)	This work was supported partly by grants of National Basic Research Program of China (2011CB910401), NSFC (31271504) and 2009DFA31940 from The Ministry of Science and Technology, China.	Alsarraj J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080746; Alsarraj J, 2011, CANCER RES, V71, P3121, DOI 10.1158/0008-5472.CAN-10-4417; Bailey CL, 2009, CANCER RES, V69, P4962, DOI 10.1158/0008-5472.CAN-08-4269; Bivona TG, 2004, J CELL BIOL, V164, P461, DOI 10.1083/jcb.200311093; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Camp RL, 1999, CANCER, V86, P2259, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2; Carmona G, 2009, BLOOD, V113, P488, DOI 10.1182/blood-2008-02-138438; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Cayrol C, 2006, ONCOGENE, V25, P4421, DOI 10.1038/sj.onc.1209484; Chen C, 2009, BIOMATERIALS, V30, P2912, DOI 10.1016/j.biomaterials.2009.02.010; Chou KC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009931; Colzani E, 2011, J CLIN ONCOL, V29, P4014, DOI 10.1200/JCO.2010.32.6462; Crawford NPS, 2008, P NATL ACAD SCI USA, V105, P6380, DOI 10.1073/pnas.0710331105; Crawford NPS, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1389; Drukker CA, 2013, INT J CANCER, V133, P929, DOI 10.1002/ijc.28082; Farina A, 2004, MOL CELL BIOL, V24, P9059, DOI 10.1128/MCB.24.20.9059-9069.2004; FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.1093/biomet/38.1-2.141; Gao L, 2006, CANCER RES, V66, P7880, DOI 10.1158/0008-5472.CAN-06-0254; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hernandez-Varas P, 2011, J BIOL CHEM, V286, P18492, DOI 10.1074/jbc.M110.189811; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Hsu TI, 2012, ONCOGENE, V31, P3973, DOI 10.1038/onc.2011.568; Hung MC, 2011, J CELL SCI, V124, P3381, DOI 10.1242/jcs.089110; Ji K, 2012, CANCER GENOM PROTEOM, V9, P321; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Keely S, 2009, FASEB J, V23, P1338, DOI 10.1096/fj.08-125344; Kunapuli P, 2003, ONCOGENE, V22, P3985, DOI 10.1038/sj.onc.1206584; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Lindberg K, 2010, J CELL PHYSIOL, V222, P156, DOI 10.1002/jcp.21932; Liu JF, 2002, BIOCHEM BIOPH RES CO, V293, P1174, DOI 10.1016/S0006-291X(02)00350-9; Lyle KS, 2008, CELL SIGNAL, V20, P1104, DOI 10.1016/j.cellsig.2008.01.018; Maity G, 2011, TUMOR BIOL, V32, P129, DOI 10.1007/s13277-010-0106-9; Maity G, 2010, MOL CELL BIOCHEM, V336, P65, DOI 10.1007/s11010-009-0256-5; Malchinkhuu E, 2009, MOL BIOL CELL, V20, P5156, DOI 10.1091/mbc.E09-08-0692; Marques IJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-128; Mathieu V, 2012, ONCOTARGET, V3, P399; McSherry EA, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2853; Mitra RS, 2008, CANCER RES, V68, P3959, DOI 10.1158/0008-5472.CAN-07-2755; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Mizugaki H, 2012, BRIT J CANCER, V106, P1953, DOI 10.1038/bjc.2012.178; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; Park YG, 2005, NAT GENET, V37, P1055, DOI 10.1038/ng1635; Redig AJ, 2013, J INTERN MED, V274, P113, DOI 10.1111/joim.12084; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; Scott MS, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-317; Sen T, 2010, BIOCHIMIE, V92, P1422, DOI 10.1016/j.biochi.2010.07.005; Shimizu Y, 2011, CANCER SCI, V102, P828, DOI 10.1111/j.1349-7006.2011.01876.x; Su L, 2003, J BIOL CHEM, V278, P15232, DOI 10.1074/jbc.M211888200; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Tsygankova OA, 2007, MOL CELL BIOL, V27, P6647, DOI 10.1128/MCB.00155-07; Tu HJ, 2010, J NEUROSCI, V30, P749, DOI 10.1523/JNEUROSCI.2343-09.2010; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Valles AM, 2004, J BIOL CHEM, V279, P44490, DOI 10.1074/jbc.M405144200; Zheng H, 2009, CANCER RES, V69, P449, DOI 10.1158/0008-5472.CAN-08-2399; Zuo H, 2010, CANCER RES, V70, P1389, DOI 10.1158/0008-5472.CAN-09-2812	59	33	33	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1451	1462		10.1038/onc.2014.36	http://dx.doi.org/10.1038/onc.2014.36			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24704834				2022-12-28	WOS:000350806500011
J	Dodd, K; Nance, S; Quezada, M; Janke, L; Morrison, JB; Williams, RT; Beere, HM				Dodd, K.; Nance, S.; Quezada, M.; Janke, L.; Morrison, J. B.; Williams, R. T.; Beere, H. M.			Tumor-derived inducible heat-shock protein 70 (HSP70) is an essential component of anti-tumor immunity	ONCOGENE			English	Article							HEAT-SHOCK PROTEINS; ANTIGEN; CELLS; PEPTIDES; TOLERANCE; FACTOR-1; INNATE; ROLES	The anti-apoptotic function and tumor-associated expression of heat-shock protein 70 (HSP70) is consistent with HSP70 functioning as a survival factor to promote tumorigenesis. However, its immunomodulatory activities to induce anti-tumor immunity predict the suppression of tumor growth. Using the Hsp70.1/3(-/-) (Hsp70(-/-)) mouse model, we observed that tumor-derived HSP70 was neither required for cellular transformation nor for in vivo tumor growth. Hsp70(-/-) murine embryonic fibroblasts (MEFs) were transformed by E1A/Ras and generated tumors in immunodeficient hosts as efficiently as wild-type (WT) transformants. Comparison of Bcr-Abl-mediated transformation of WT and Hsp70(-/-) bone marrow and progression of B-cell leukemogenesis in vivo revealed no differences in disease onset or survival rates, and E mu-Myc-driven lymphoma in Hsp70(-/-) mice was phenotypically indistinguishable from that in WT E mu-Myc mice. However, Hsp70(-/-)E1A/Ras MEFs generated significantly larger tumors than their WT counterparts in C57BL/6 J immune-competent hosts. Concurrent with this was a reduction in intra-tumoral infiltration of innate and adaptive immune cells, including macrophages and CD8(+) T cells. Evaluation of several potential mechanisms revealed an HSP70-chemokine-like activity to promote cellular migration. These observations support a role for tumor-derived HSP70 in facilitating anti-tumor immunity to limit tumor growth and highlight the potential consequences of anti-HSP70 therapy as an efficacious anti-cancer strategy.	[Dodd, K.; Nance, S.; Quezada, M.; Beere, H. M.] St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; [Janke, L.] St Jude Childrens Res Hosp, Vet Pathol Core, Memphis, TN 38105 USA; [Morrison, J. B.; Williams, R. T.] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA; [Williams, R. T.] PUMA Biotechnol, Los Angeles, CA USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Beere, HM (corresponding author), St Jude Childrens Res Hosp, Dept Immunol, 262 Danny Thomas Pl, Memphis, TN 38105 USA.	helen.beere@stjude.org	Janke, Laura/N-8121-2018	Janke, Laura/0000-0002-9871-6239	core funding; Cancer Center Supporting Grant (CCSG) developmental funds [5P30CA021765-29]; American Lebanese-Syrian Associated Charities of St Jude Children's Research Hospital; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	core funding; Cancer Center Supporting Grant (CCSG) developmental funds; American Lebanese-Syrian Associated Charities of St Jude Children's Research Hospital(American Lebanese Syrian Associated Charities (ALSAC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Douglas Green for discussion during the preparation of this manuscript and Eleanora Puetz and Alex Yu for genotyping. Special thanks to the husbandry staff of the Animal Resource Center and to the Animal Imaging Center, including Christopher Calabrese, Melissa Johnson and Monique Payton. We are grateful to the flow cytometry facility for their assistance in FACS and flow analysis. This work was funded in part by core funding and Cancer Center Supporting Grant (CCSG) developmental funds (5P30CA021765-29) (to HMB) and the American Lebanese-Syrian Associated Charities of St Jude Children's Research Hospital.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Binder RJ, 2005, NAT IMMUNOL, V6, P593, DOI 10.1038/ni1201; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Borges TJ, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00095; Chalmin F, 2010, J CLIN INVEST, V120, P457, DOI 10.1172/JCI40483; Chen TY, 2009, J IMMUNOL, V182, P1449, DOI 10.4049/jimmunol.182.3.1449; Ciocca DR, 2013, ARCH TOXICOL, V87, P19, DOI 10.1007/s00204-012-0918-z; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; DuPage M, 2012, NATURE, V482, P405, DOI 10.1038/nature10803; Effendi K, 2010, ONCOLOGY-BASEL, V78, P157, DOI 10.1159/000312658; Elsner L, 2007, J IMMUNOL, V179, P5523, DOI 10.4049/jimmunol.179.8.5523; Gross C, 2003, BIOL CHEM, V384, P267, DOI 10.1515/BC.2003.030; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; Kottke T, 2009, CANCER RES, V69, P7767, DOI 10.1158/0008-5472.CAN-09-1597; Leu JIJ, 2009, MOL CELL, V36, P15, DOI 10.1016/j.molcel.2009.09.023; Li ZH, 2002, CURR OPIN IMMUNOL, V14, P45, DOI 10.1016/S0952-7915(01)00297-7; Malusecka E, 2008, ANTICANCER RES, V28, P501; Mambula SS, 2006, J IMMUNOL, V177, P7849, DOI 10.4049/jimmunol.177.11.7849; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Mignot G, 2011, AM J PATHOL, V178, P1403, DOI 10.1016/j.ajpath.2010.11.078; Millar DG, 2003, NAT MED, V9, P1469, DOI 10.1038/nm962; Min JN, 2007, ONCOGENE, V26, P5086, DOI 10.1038/sj.onc.1210317; Multhoff G, INT J HYPERTHERMIA, V18, P576; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Rohde M, 2005, GENE DEV, V19, P570, DOI 10.1101/gad.305405; Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749; Srivastava P, 2002, ANNU REV IMMUNOL, V20, P395, DOI 10.1146/annurev.immunol.20.100301.064801; Stocki P, 2012, AUTOIMMUN DIS, V2012, DOI 10.1155/2012/617213; Stocki P, 2012, J BIOL CHEM, V287, P12387, DOI 10.1074/jbc.M111.307579; Torronteguy C, 2006, CELL STRESS CHAPERON, V11, P34, DOI 10.1379/CSC-159R.1; UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391; van Eden W, 2012, CELL STRESS CHAPERON, V17, P281, DOI 10.1007/s12192-011-0311-5; van Herwijnen MJC, 2012, P NATL ACAD SCI USA, V109, P14134, DOI 10.1073/pnas.1206803109; Vega VL, 2008, J IMMUNOL, V180, P4299, DOI 10.4049/jimmunol.180.6.4299; Wachstein J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051747; Williams RT, 2006, P NATL ACAD SCI USA, V103, P6688, DOI 10.1073/pnas.0602030103; Zietara N, 2009, J IMMUNOL, V183, P1099, DOI 10.4049/jimmunol.0803214	39	15	15	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1312	1322		10.1038/onc.2014.63	http://dx.doi.org/10.1038/onc.2014.63			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24662819	Green Accepted			2022-12-28	WOS:000350687100011
J	Pierobon, M; Wulfkuhle, J; Liotta, L; Petricoin, E				Pierobon, M.; Wulfkuhle, J.; Liotta, L.; Petricoin, E.			Application of molecular technologies for phosphoproteomic analysis of clinical samples	ONCOGENE			English	Review							PHASE PROTEIN MICROARRAYS; HUMAN BREAST-CANCER; LASER CAPTURE MICRODISSECTION; FLOW-CYTOMETRY; TISSUE; TRIAL; PHOSPHORYLATION; PROTEOMICS; INHIBITOR; PATHWAY	The integration of small kinase inhibitors and monoclonal antibodies into oncological practice has opened a new paradigm for treating cancer patients. As proteins are the direct targets of the new generations of targeted therapeutics, many of which are kinase/enzymatic inhibitors, there is an increasing interest in developing technologies capable of monitoring post-translational changes of the human proteome for the identification of new predictive, prognostic and therapeutic biomarkers. It is well known that the vast majority of the activation/deactivation of these drug targets is driven by phosphorylation. This review provides a description of the main proteomic platforms (planar and bead array, reverse phase protein microarray, phosphoflow, AQUA and mass spectrometry) that have successfully been used for measuring changes in phosphorylation level of drug targets and downstream substrates using clinical specimens. Major emphasis was given to the strengths and weaknesses of the different platforms and to the major barriers that are associated with the analysis of the phosphoproteome. Finally, a number of examples of application of the above-mentioned technologies in the clinical setting are reported.	[Pierobon, M.; Wulfkuhle, J.; Liotta, L.; Petricoin, E.] George Mason Univ, Ctr Appl Prote & Mol Med, Manassas, VA 20110 USA	George Mason University	Petricoin, E (corresponding author), George Mason Univ, Ctr Appl Prote & Mol Med, 10900 Univ Blvd,Bull Run Hall,Room 324, Manassas, VA 20110 USA.	epetrico@gmu.edu	Pierobon, Mariaelena/GXA-0544-2022					Angevin E, 2013, CLIN CANCER RES, V19, P1257, DOI 10.1158/1078-0432.CCR-12-2885; Arends JW, 2000, J PATHOL, V190, P412; Balboni I, 2006, ANNU REV IMMUNOL, V24, P391, DOI 10.1146/annurev.immunol.24.021605.090709; Bantscheff M, 2007, NAT BIOTECHNOL, V25, P1035, DOI 10.1038/nbt1328; Barker AD, 2009, CLIN PHARMACOL THER, V86, P97, DOI 10.1038/clpt.2009.68; Baselga J, 2010, CLIN CANCER RES, V16, P4876, DOI 10.1158/1078-0432.CCR-10-0748; Braeckmans K, 2002, NAT REV DRUG DISCOV, V1, P447, DOI 10.1038/nrd817; Breen EC, 2011, CLIN VACCINE IMMUNOL, V18, P1229, DOI 10.1128/CVI.05032-11; Brennan DJ, 2010, NAT REV CANCER, V10, P605, DOI 10.1038/nrc2902; Camp RL, 2002, NAT MED, V8, P1323, DOI 10.1038/nm791; Camp RL, 2008, J CLIN ONCOL, V26, P5630, DOI 10.1200/JCO.2008.17.3567; Carbone M, 2004, SEMIN CANCER BIOL, V14, P399, DOI 10.1016/j.semcancer.2004.06.002; Chen L, 2011, ELECTROPHORESIS, V32, P1984, DOI 10.1002/elps.201100101; Chowdhury F, 2009, J IMMUNOL METHODS, V340, P55, DOI 10.1016/j.jim.2008.10.002; Dabitao D, 2011, J IMMUNOL METHODS, V372, P71, DOI 10.1016/j.jim.2011.06.033; Dahut WL, 2008, CLIN CANCER RES, V14, P209, DOI 10.1158/1078-0432.CCR-07-1355; Daub H, 2008, MOL CELL, V31, P438, DOI 10.1016/j.molcel.2008.07.007; Drobin Kimi, 2013, Methods Mol Biol, V1023, P137, DOI 10.1007/978-1-4614-7209-4_8; Du JY, 2009, NAT BIOTECHNOL, V27, P77, DOI 10.1038/nbt.1513; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Espina V, 2008, MOL CELL PROTEOMICS, V7, P1998, DOI 10.1074/mcp.M700596-MCP200; Espina V, 2011, METHODS MOL BIOL, V785, P23, DOI 10.1007/978-1-61779-286-1_3; Espina V, 2009, CLIN LAB MED, V29, P1, DOI 10.1016/j.cll.2009.03.001; Esserman LJ, 2012, J CLIN ONCOL, V30, P3242, DOI 10.1200/JCO.2011.39.2779; Faratian D, 2011, EUR J CANCER, V47, P1420, DOI 10.1016/j.ejca.2011.01.014; Fu Q, 2010, CLIN CHEM, V56, P314, DOI 10.1373/clinchem.2009.135087; Gamez-Pozo A, 2011, MOL BIOSYST, V7, P2368, DOI 10.1039/c1mb05113j; Geiger T, 2010, NAT METHODS, V7, P383, DOI 10.1038/nmeth.1446; Haura EB, 2010, J CLIN ONCOL, V28, P1387, DOI 10.1200/JCO.2009.25.4029; Institute of Cancer Research (United Kingdom), 2000, AN PHARM CHANG AUY92; Irish JM, 2004, CELL, V118, P217, DOI 10.1016/j.cell.2004.06.028; Irwin ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070608; Jameson GS, 2012, J CLIN ONCOL, V30; Kornblau SM, 2010, CLIN CANCER RES, V16, P3721, DOI 10.1158/1078-0432.CCR-10-0093; Krutzik Peter O, 2011, Curr Protoc Cytom, VChapter 6, DOI 10.1002/0471142956.cy0631s55; Krutzik PO, 2011, METHODS MOL BIOL, V699, P179, DOI 10.1007/978-1-61737-950-5_9; Kummar S, 2011, EUR J CANCER, V47, P997, DOI 10.1016/j.ejca.2010.12.016; Leng SX, 2008, J GERONTOL A-BIOL, V63, P879, DOI 10.1093/gerona/63.8.879; Lineberger Comprehensive Cancer Center, 2000, DEF TRIPL NEG BREAST; Liu Angen, 2010, J Biomol Tech, V21, P120; Mascaux C, 2011, CLIN CANCER RES, V17, P7796, DOI 10.1158/1078-0432.CCR-11-0209; Mueller C, 2010, MOL ONCOL, V4, P461, DOI 10.1016/j.molonc.2010.09.003; Narumi R, 2012, J PROTEOME RES, V11, P5311, DOI 10.1021/pr3005474; Oberprieler NG, 2011, CELL SIGNAL, V23, P14, DOI 10.1016/j.cellsig.2010.07.009; Osborne CK, 2011, CLIN CANCER RES, V17, P1147, DOI 10.1158/1078-0432.CCR-10-1869; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; Peck AR, 2011, J CLIN ONCOL, V29, P2448, DOI 10.1200/JCO.2010.30.3552; Pectasides E, 2011, CLIN CANCER RES, V17, P2947, DOI 10.1158/1078-0432.CCR-10-2040; Perkins G, 2010, INT J CANCER, V127, P1321, DOI 10.1002/ijc.25152; Perl AE, 2012, CLIN CANCER RES, V18, P1716, DOI 10.1158/1078-0432.CCR-11-2346; Petricoin EF, 2007, CANCER RES, V67, P3431, DOI 10.1158/0008-5472.CAN-06-1344; Pierobon M, 2012, METHODS MOL BIOL, V823, P215, DOI 10.1007/978-1-60327-216-2_14; Pierobon M, 2011, METHODS MOL BIOL, V785, P3, DOI 10.1007/978-1-61779-286-1_1; Rimm D, 2012, CANCER RES, V72, DOI 10.1158/0008-5472.SABCS12-S5-4; Rimm DL, 2011, J CLIN ONCOL, V29, P2282, DOI 10.1200/JCO.2010.33.2023; Roth BJ, 2013, J CLIN ONCOL, V31, P131, DOI 10.1200/JCO.2012.47.1938; Sato T, 2011, AM J CANCER RES, V1, P347; Schwenk JM, 2011, METHODS MOL BIOL, V723, P29, DOI 10.1007/978-1-61779-043-0_3; Shah MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054014; Shi TJ, 2012, P NATL ACAD SCI USA, V109, P15395, DOI 10.1073/pnas.1204366109; Silvestri A, 2010, LAB INVEST, V90, P787, DOI 10.1038/labinvest.2010.47; Sourial S, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/187426; Speer R, 2006, P AM ASS CANC RES, V47; Sprung RW, 2012, J PROTEOME RES, V11, P3498, DOI 10.1021/pr300130t; Stasyk T, 2012, TRENDS MOL MED, V18, P43, DOI 10.1016/j.molmed.2011.11.001; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Tong FK, 2006, CYTOM PART B-CLIN CY, V70B, P107, DOI 10.1002/cyto.b.20092; University of Michigan University Hospital, 2000, CET BEV TREAT PAT RE; VanMeter A, 2007, EXPERT REV MOL DIAGN, V7, P625, DOI 10.1586/14737159.7.5.625; VanMeter AJ, 2008, MOL CELL PROTEOMICS, V7, P1902, DOI 10.1074/mcp.M800204-MCP200; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wulfkuhle JD, 2008, J PROTEOME RES, V7, P1508, DOI 10.1021/pr7008127; Wulfkuhle JD, 2012, CLIN CANCER RES, V18, P6426, DOI 10.1158/1078-0432.CCR-12-0452; Xu BJ, 2010, PROTEOM CLIN APPL, V4, P116, DOI 10.1002/prca.200900138; Yap TA, 2011, J CLIN ONCOL, V29, P4688, DOI 10.1200/JCO.2011.35.5263	75	58	58	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					805	814		10.1038/onc.2014.16	http://dx.doi.org/10.1038/onc.2014.16			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24608425				2022-12-28	WOS:000349472000001
J	Bunda, S; Qin, K; Kommaraju, K; Heir, P; Ohh, M				Bunda, S.; Qin, K.; Kommaraju, K.; Heir, P.; Ohh, M.			Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance to apoptosis via the Lyn-PI3K/AKT pathway	ONCOGENE			English	Article						apoptosis; Cbl; chemoresistance; juvenile myelomonocytic leukaemia; Lyn; PI3K	C-CBL; MYELODYSPLASTIC SYNDROME; IN-VIVO; SRC; ACTIVATION; HYPERSENSITIVITY; CELLS; RAS; UBIQUITINATION; CHEMOTHERAPY	Juvenile myelomonocytic leukaemia (JMML) is an aggressive myeloproliferative neoplasm in children characterized by granulocyte macrophage colony-stimulating factor (GM-CSF) hypersensitivity and resistance to chemotherapy. We recently identified c-Cbl (henceforth referred to as Cbl) as a GM-CSF receptor (GMR) responsive protein that targets Src for ubiquitin-mediated destruction upon GM-CSF stimulation and showed that a loss of negative regulation of Src is pivotal in the hyperactivation of GMR signalling in JMML cells. However, the mechanism regulating the chemoresistant nature of JMML has remained largely unknown. Here, we show that the JMML-associated Cbl mutant in complex with the Src family kinase Lyn promotes Cbl's adapter function, leading to increased association to PI3K regulatory subunit p85 and Lyn-dependent AKT pro-survival signalling. Notably, molecular or pharmacologic inhibition of the Lyn-PI3K/AKT pathway, but not the Ras/mitogen-activated protein kinase signalling axis, markedly increased the sensitivity of the otherwise chemoresistant Cbl mutant-JMML cells to chemotherapeutic agents currently used in the treatment of JMML patients. These results support the potential translational benefit of combining modalities that inhibit Lyn-PI3K/AKT signalling with traditional antileukaemia agents in the management of JMML.	[Bunda, S.; Qin, K.; Kommaraju, K.; Heir, P.; Ohh, M.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada	University of Toronto	Ohh, M (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	michael.ohh@utoronto.ca			Canadian Institutes of Health Research [MOP119356]; Cancer Research Society; CIHR; Kidney Cancer Foundation fellowship award	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Cancer Research Society; CIHR(Canadian Institutes of Health Research (CIHR)); Kidney Cancer Foundation fellowship award	We thank Dr Tim Hercus for helpful discussions and for providing GMR reagents. We thank Stephanie Sybingco for the generation of shCbl and shLyn stable cell lines. This work was supported by grants from the Canadian Institutes of Health Research (MOP119356) and the Cancer Research Society. SB is a recipient of the CIHR and Kidney Cancer Foundation fellowship award.	Aplenc R, 2011, J CLIN ONCOL, V29, P839, DOI 10.1200/JCO.2010.30.7231; Balasis ME, 2011, CLIN CANCER RES, V17, P2852, DOI 10.1158/1078-0432.CCR-10-2544; Beckwith M, 1996, BLOOD, V88, P3502, DOI 10.1182/blood.V88.9.3502.bloodjournal8893502; Bergstraesser E, 2007, PEDIATR BLOOD CANCER, V49, P629, DOI 10.1002/pbc.21038; Bunda S, 2013, CANCER RES, V73, P2540, DOI 10.1158/0008-5472.CAN-12-3425; CASTLEBERRY RP, 1994, NEW ENGL J MED, V331, P1680, DOI 10.1056/NEJM199412223312503; CHAN HSL, 1987, J CLIN ONCOL, V5, P1960, DOI 10.1200/JCO.1987.5.12.1960; Chan RJ, 2005, BLOOD, V105, P3737, DOI 10.1182/blood-2004-10-4002; de Vries ACH, 2010, HAEMATOL-HEMATOL J, V95, P179, DOI 10.3324/haematol.2009.016865; Demetri GD, 2009, CLIN CANCER RES, V15, P6232, DOI 10.1158/1078-0432.CCR-09-0224; DombroskyFerlan PM, 1997, ONCOGENE, V14, P2019, DOI 10.1038/sj.onc.1201031; Duan L, 2004, IMMUNITY, V21, P7, DOI 10.1016/j.immuni.2004.06.012; EMANUEL PD, 1991, BLOOD, V77, P925; Emanuel PD, 2008, ACTA HAEMATOL-BASEL, V119, P207, DOI 10.1159/000140632; Flotho C, 2007, CURR DRUG TARGETS, V8, P715, DOI 10.2174/138945007780830773; Guthridge MA, 2004, BLOOD, V103, P820, DOI 10.1182/blood-2003-06-1999; Hasle H, 1996, LEUKEMIA, V10, P1269; Hasle H, 2007, CURR OPIN PEDIATR, V19, P1, DOI 10.1097/MOP.0b013e3280128ce8; Kang HJ, 2004, LEUKEMIA RES, V28, P167, DOI 10.1016/S0145-2126(03)00217-0; Lancet JE, 2011, CLIN CANCER RES, V17, P1140, DOI 10.1158/1078-0432.CCR-10-1878; Le DT, 2004, BLOOD, V103, P4243, DOI 10.1182/blood-2003-08-2650; Lee JH, 2011, J IMMUNOL, V187, P1807, DOI 10.4049/jimmunol.1100296; Loh ML, 2010, HEMATOL-AM SOC HEMAT, P357, DOI 10.1182/asheducation-2010.1.357; Lyubynska N, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001069; Mak AB, 2012, METHODS, V57, P409, DOI 10.1016/j.ymeth.2012.06.005; Niemeyer CM, 2010, NAT GENET, V42, P794, DOI 10.1038/ng.641; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Perugini M, 2010, BLOOD, V115, P3346, DOI 10.1182/blood-2009-08-235846; Sanada M, 2009, NATURE, V460, P904, DOI 10.1038/nature08240; Song JJ, 2010, CELL SIGNAL, V22, P377, DOI 10.1016/j.cellsig.2009.10.007; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Woods WG, 2002, J CLIN ONCOL, V20, P434, DOI 10.1200/JCO.20.2.434; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Zhou ZR, 2008, PROTEIN SCI, V17, P1805, DOI 10.1110/ps.036384.108	35	10	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					789	797		10.1038/onc.2013.596	http://dx.doi.org/10.1038/onc.2013.596			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24469048	Bronze			2022-12-28	WOS:000348853800012
J	Xu, C; Fan, CD; Wang, X				Xu, C.; Fan, C. D.; Wang, X.			Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase	ONCOGENE			English	Article						Mdm2; p53; NEDD4-1; E3 ligases; degradation; ubiquitination	ACUTE LYMPHOBLASTIC-LEUKEMIA; UBIQUITIN LIGASE; NEGATIVE REGULATOR; PROMOTES; ACTIVATION; CANCER; INACTIVATION; DEGRADATION; ONCOPROTEIN; PATHWAY	Mdm2 is a critical negative regulator of the tumor suppressor protein p53. Mdm2 is an E3 ligase whose overexpression leads to functional inactivation of p53. Mdm2 protein stability is regulated by several mechanisms including RING (Really Interesting New Gene) domain-mediated autoubiquitination. Here we report biochemical identification of NEDD4-1 as an E3 ligase for Mdm2 that contributes to the regulation of Mdm2 protein stability in cells. NEDD4-1 was identified from Jurkat cytosolic fractions using an enzyme-dead Mdm2 mutant protein as a substrate for in vitro E3 ligase assays. We show that lysates from Nedd4-1 knockout (KO) mouse embryonic fibroblasts (MEFs) have significantly diminished E3 ligase activity toward Mdm2 compared with lysates from wildtype (WT) MEFs. Recombinant NEDD4-1 promotes Mdm2 ubiquitination in vitro in a concentration-and time-dependent manner. In cells, NEDD4-1 physically interacts with Mdm2 via the RING domain of Mdm2. Overexpression of NEDD4-1, but not an enzyme-dead NEDD4-1CS mutant, increases ubiquitination of Mdm2. NEDD4-1 catalyzes the formation of K63-type polyubiquitin chains on Mdm2 that are distinct from K48-type polyubiquitination chains mediated by the Mdm2/MdmX complex. Importantly, K63-type polyubiquitination by NEDD4-1 competes with K48-type polyubiquitination on Mdm2 in cells. As a result, NEDD4-1-mediated ubiquitination stabilizes Mdm2. NEDD4-1 knockdown reduces the t(1/2) (half-life) of endogenous Mdm2 from 20 to 12 min in U2OS cells. Nedd4-1 KO MEFs manifest increased p53 levels and activity, a more robust DNA damage response and increased G1 arrest compared with WT MEFs. Similarly, NEDD4-1 knockdown in WT-p53-bearing cells increases basal p53 levels and activity in an Mdm2-dependent manner, causes stronger p53 responses to DNA damage and results in p53-dependent growth inhibition compared with corresponding NEDD4-1-proficient control cells. This study identifies NEDD4-1 as a novel component of the p53/Mdm2 regulatory feedback loop that controls p53 activity during stress responses.	[Xu, C.; Fan, C. D.; Wang, X.] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Wang, X (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	xinjiang.wang@roswellpark.org			Roswell Park Cancer Institute; Roswell Park Core Grant [CA16056]; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER	Roswell Park Cancer Institute; Roswell Park Core Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by start-p funds from Roswell Park Cancer Institute (XW). The Roswell Park Core Grant CA16056 is also gratefully acknowledged. We sincerely thank Dr Baoli Yang for providing Nedd4-1 -/- and parental MEFs; Dr Yosef Shiloh and Dr Jiandong Chen and Dr Dirk P Bohmann for providing DNA constructs; Dr Moshe Oren for antibodies, Bert Vogelstein for providing HCT116-p53 -/- cells and Dr Gigi Lozano for p53/Mdm2 DKO MEFs, respectively. We also thank Dr David Goodrich and other faculty colleagues at the Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute for their critical reading of the manuscript.	Amodio N, 2010, AM J PATHOL, V177, P2622, DOI 10.2353/ajpath.2010.091075; Chen ZJJ, 2009, MOL CELL, V33, P275, DOI 10.1016/j.molcel.2009.01.014; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Dai BB, 2010, CANCER RES, V70, P2951, DOI 10.1158/0008-5472.CAN-09-3909; Eide PW, 2013, CELL SIGNAL, V25, P12, DOI 10.1016/j.cellsig.2012.08.012; Fan CD, 2013, J BIOL CHEM, V288, P1674, DOI 10.1074/jbc.M112.416339; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Inuzuka H, 2010, CANCER CELL, V18, P147, DOI 10.1016/j.ccr.2010.06.015; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Khor LY, 2009, J CLIN ONCOL, V27, P3177, DOI 10.1200/JCO.2008.19.8267; Lai ZH, 2001, J BIOL CHEM, V276, P31357, DOI 10.1074/jbc.M011517200; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li Q, 2013, CLIN CANCER RES, V19, P34, DOI 10.1158/1078-0432.CCR-12-0053; Linares LK, 2007, NAT CELL BIOL, V9, P331, DOI 10.1038/ncb1545; Linke K, 2008, CELL DEATH DIFFER, V15, P841, DOI 10.1038/sj.cdd.4402309; LUNA RMD, 1995, NATURE, V378, P203; Marks DI, 1996, BLOOD, V87, P1155, DOI 10.1182/blood.V87.3.1155.bloodjournal8731155; Mosesson Y, 2009, DEV CELL, V16, P687, DOI 10.1016/j.devcel.2009.03.015; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang X, J BIOL CHEM, V286, P23725; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Wang ZW, 2012, ONCOTARGET, V3, P1026; Yang JY, 2006, MOL CELL BIOL, V26, P7269, DOI 10.1128/MCB.00172-06; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608	30	47	48	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					342	350		10.1038/onc.2013.557	http://dx.doi.org/10.1038/onc.2013.557			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24413081				2022-12-28	WOS:000348145500008
J	Li, A; Jiao, Y; Yong, KJ; Wang, F; Gao, C; Yan, B; Srivastava, S; Lim, GSD; Tang, P; Yang, H; Tenen, DG; Chai, L				Li, A.; Jiao, Y.; Yong, K. J.; Wang, F.; Gao, C.; Yan, B.; Srivastava, S.; Lim, G. S. D.; Tang, P.; Yang, H.; Tenen, D. G.; Chai, L.			SALL4 is a new target in endometrial cancer	ONCOGENE			English	Article						endonnetrial cancer; SALL4; metastasis; chemoresistance	GENE-EXPRESSION SIGNATURE; EMBRYONIC STEM-CELLS; C-MYC ONCOGENE; LEUKEMIC-CELLS; BREAST-CANCER; LUNG-CANCER; CARCINOMA; PROLIFERATION; PLURIPOTENCY; METASTASIS	Aggressive cancers and embryonic stem (ES) cells share a common gene expression signature. Identifying the key factors/pathway(s) within this ES signature responsible for the aggressiveness of cancers can lead to a potential cure. In this study, we find that SALL4, a gene involved in the maintenance of ES cell self-renewal, is aberrantly expressed in 47.7% of primary human endometrial cancer samples. It is not expressed in normal or hyperplastic endometrial. More importantly, SALL4 expression is positively correlated with worse patient survival and aggressive features such as metastasis in endometrial carcinoma. Further functional studies have shown that loss of SALL4 inhibits endometrial cancer cell growth in vitro and tumorigenicity in vivo, as a result of inhibition of cell proliferation and increased apoptosis. In addition, downregulation of SALL4 significantly impedes the migration and invasion properties of endometrial cancer cells in vitro and their metastatic potential in vivo. Furthermore, manipulation of SALL4 expression can affect drug sensitivity of endometrial cancer cells to carboplatin. Moreover, we show that SALL4 specifically binds to the c-Myc promoter region in endometrial cancer cells. While downregulation of SALL4 leads to a decreased expression of c-Myc at both protein and nnRNA levels, ectopic SALL4 overexpression causes increased c-Myc protein and mRNA expression, indicating that c-Myc is one of the SALL4 downstream targets in endometrial tumorigenesis. In summary, we are the first to demonstrate that SALL4 has functional role(s) in metastasis and drug resistance in aggressive endometrial cancer. As a consequence of its functional roles in cancer cell and absence in normal tissue, SALL4 is a potential novel therapeutic target for the high-risk endometrial cancer patient population.	[Li, A.; Jiao, Y.; Wang, F.; Gao, C.; Tang, P.; Chai, L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Yong, K. J.; Srivastava, S.; Yang, H.; Tenen, D. G.] Natl Univ Singapore, Ctr Translat Med, Canc Sci Inst Singapore, Singapore 117548, Singapore; [Wang, F.] Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Clin Lab, Beijing 100021, Peoples R China; [Wang, F.] Chinese Acad Med Sci, Beijing 100730, Peoples R China; [Yan, B.; Lim, G. S. D.] Natl Univ Hlth Syst, Dept Pathol, Singapore, Singapore; [Yan, B.; Lim, G. S. D.] Natl Univ Singapore, Singapore 117548, Singapore; [Tenen, D. G.] Harvard Stem Cell Inst, Ctr Life Sci, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; National University of Singapore; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; National University of Singapore; National University of Singapore; Harvard University	Chai, L (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	lchai@partners.org	Srivastava, Supriya/HDJ-9671-2022	Tenen, Daniel/0000-0002-6423-3888; Srivastava, Supriya/0000-0002-6727-3076; Chai, Li/0000-0003-1937-4750	NIH [PO1DK080665, RO1HL092437, PO1HL095489]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092437, P01HL095489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK080665] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in part through NIH grants PO1DK080665, NIH RO1HL092437, and PO1HL095489 (to LC). We also thank Nicole Tenen and Joline Lim in assisting with the preparation of the manuscript and Xi Tian in helping with mouse work.	Amant F, 2005, LANCET, V366, P491, DOI 10.1016/S0140-6736(05)67063-8; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; BORST MP, 1990, GYNECOL ONCOL, V38, P364, DOI 10.1016/0090-8258(90)90074-U; Cao DF, 2009, CANCER-AM CANCER SOC, V115, P2640, DOI 10.1002/cncr.24308; Du YCN, 2011, P NATL ACAD SCI USA, V108, P16753, DOI 10.1073/pnas.1114022108; Elit L, 2002, CURR OPIN OBSTET GYN, V14, P67, DOI 10.1097/00001703-200202000-00011; Elling U, 2006, P NATL ACAD SCI USA, V103, P16319, DOI 10.1073/pnas.0607884103; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Hermeking H, 2003, CURR CANCER DRUG TAR, V3, P163, DOI 10.2174/1568009033481949; Jeong HW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018372; Knapp DC, 2003, ANTI-CANCER DRUG, V14, P39, DOI 10.1097/00001813-200301000-00006; Kobayashi D, 2011, ONCOL REP, V26, P965, DOI 10.3892/or.2011.1374; Kobayashi D, 2011, INT J ONCOL, V38, P933, DOI 10.3892/ijo.2011.929; Levan K, 2010, GENE EXPRESSION, V14, P361, DOI 10.3727/105221610X12735213181242; Liao DJ, 2000, ENDOCR-RELAT CANCER, V7, P143, DOI 10.1677/erc.0.0070143; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; Ma YP, 2006, BLOOD, V108, P2726, DOI 10.1182/blood-2006-02-001594; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Renaud EJ, 2005, P NATL ACAD SCI USA, V102, P111, DOI 10.1073/pnas.0407772101; Sakaki-Yumoto M, 2006, DEVELOPMENT, V133, P3005, DOI 10.1242/dev.02457; Saso S, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3954; vanWaardenburg RCAM, 1996, ANTICANCER RES, V16, P1963; Wolfer A, 1996, P NATL ACAD SCI USA, V107, P3698; Wong JYY, 2008, GYNECOL ONCOL, V109, P394, DOI 10.1016/j.ygyno.2008.01.038; Wu Q, 2006, J BIOL CHEM, V281, P24090, DOI 10.1074/jbc.C600122200; Yang JC, 2008, BLOOD, V112, P805, DOI 10.1182/blood-2007-11-126326; Yang JC, 2007, P NATL ACAD SCI USA, V104, P10494, DOI 10.1073/pnas.0704001104; Yang JC, 2008, P NATL ACAD SCI USA, V105, P19756, DOI 10.1073/pnas.0809321105; Yong KJ, 2013, NEW ENGL J MED, V368, P2266, DOI 10.1056/NEJMoa1300297; You JS, 2009, CANCER RES, V69, P5716, DOI 10.1158/0008-5472.CAN-08-4953; Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481	31	73	77	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					63	72		10.1038/onc.2013.529	http://dx.doi.org/10.1038/onc.2013.529			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24336327	Green Accepted, Green Submitted			2022-12-28	WOS:000349740100006
J	Azzi, S; Smith, SS; Dwyer, J; Leclair, HM; Alexia, C; Hebda, JK; Dupin, N; Bidere, N; Gavard, J				Azzi, S.; Smith, S. S.; Dwyer, J.; Leclair, H. M.; Alexia, C.; Hebda, J. K.; Dupin, N.; Bidere, N.; Gavard, J.			YGLF motif in the Kaposi sarcoma herpes virus G-protein-coupled receptor adjusts NF-kappa B activation and paracrine actions	ONCOGENE			English	Article						KSHV; vGPCR; NF-kappa B; trafficking; B-lymphocytes; HIV malignancies	PRIMARY EFFUSION LYMPHOMA; ENDOTHELIAL-CELLS; IN-VIVO; MULTIPLE PATHWAYS; KSHV VFLIP; VGPCR; CONTRIBUTES; PROGRESSION; EXPRESSION; NEOPLASIA	Kaposi sarcoma (KS) and primary effusion lymphoma (PEL) are two pathologies associated with KS herpes virus (KSHV/HHV-8) infection. KSHV genome contains several oncogenes, among which, the viral G-protein-coupled receptor (vGPCR open reading frame 74) has emerged as a major factor in KS pathogenicity. Indeed, vGPCR is a constitutively active receptor, whose expression is sufficient to drive cell transformation in vitro and tumour development in mice. However, neither the role of vGPCR in KSHV-infected B-lymphocytes nor the molecular basis for its constitutive activation is well understood. Here, we show that vGPCR expression contributes to nuclear factor-kappa B (NF-kappa B)-dependent cellular survival in both PEL cells and primary B cells from HIV-negative KS patients. We further identified within vGPCR an AP2 consensus binding motif, Y(326)GLF, that directs its localization between the plasma membrane and clathrin-coated vesicles. The introduction of a mutation in this site (Y(326)A) increased NF-kappa B activity and proinflammatory cytokines production. This correlated with exacerbated morphological rearrangement, migration and proliferation of non-infected monocytes. Collectively, our work raises the possibility that KSHV-infected B-lymphocytes use vGPCR to impact ultimately the immune response and communication within the tumour microenvironment in KSHV-associated pathologies.	[Azzi, S.; Smith, S. S.; Dwyer, J.; Leclair, H. M.; Hebda, J. K.; Gavard, J.] CNRS, UMR8104, Paris, France; [Azzi, S.; Smith, S. S.; Dwyer, J.; Leclair, H. M.; Hebda, J. K.; Gavard, J.] INSERM, U1016, Paris, France; [Azzi, S.; Smith, S. S.; Dwyer, J.; Leclair, H. M.; Hebda, J. K.; Dupin, N.; Gavard, J.] Univ Paris 05, Sorbonne Paris Cite, F-75014 Paris, France; [Alexia, C.; Bidere, N.] Hop Paul Brousse, INSERM, U1014, Villejuif, France; [Alexia, C.] Univ Paris 11, Orsay, France; [Alexia, C.] Equipe Labellisee Ligue Contre Canc, Villejuif, France; [Dupin, N.] Hop Cochin Tarnier, AP HP, Serv Dermatol, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Gavard, J (corresponding author), Univ Paris 05, Inst Cochin, CNRS, UMR8104,INSERM U1016, 22 Rue Mech,Room 306, F-75014 Paris, France.	julie.gavard@inserm.fr	Gavard, Julie/I-5487-2012; Bidère, Nicolas/K-8887-2015; Gavard, Julie/I-5487-2012	Gavard, Julie/0000-0002-7985-9007; Bidère, Nicolas/0000-0001-9177-0008; Leclair, Heloise/0000-0002-9517-9079; Dupin, Nicolas/0000-0002-6237-4951; Gavard, Julie/0000-0003-3107-2026	ANR JCJC; Fondation ARC; Fondation pour la Recherche Medicale; Ligue nationale contre le cancer comite de Paris; Marie Curie International Reintegration Grant within The Seventh Framework Program; Canceropole Ile-de-France; ANRS; Universite Paris Descartes;  [INCA_6508]	ANR JCJC(French National Research Agency (ANR)); Fondation ARC; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Ligue nationale contre le cancer comite de Paris; Marie Curie International Reintegration Grant within The Seventh Framework Program; Canceropole Ile-de-France(Region Ile-de-France); ANRS(ANRSFrench National Research Agency (ANR)); Universite Paris Descartes; 	We thank the members of JG laboratory for comments on the manuscript. We are grateful to Dr A Benmerah (Institut Necker, Paris, France) for the EPS15 constructs and helpful discussion and to C Catherinet (INSA, Rennes, France) for technical support. This research was funded by: ANR JCJC, Fondation ARC, Fondation pour la Recherche Medicale, INCA_6508, Ligue nationale contre le cancer comite de Paris and a Marie Curie International Reintegration Grant within The Seventh Framework Program. SA, SSS and JD are supported by postdoctoral fellowships from Fondation ARC, Canceropole Ile-de-France and ANRS, respectively. JKH is supported by a doctoral fellowship from Universite Paris Descartes.	An J, 2004, LEUKEMIA, V18, P1699, DOI 10.1038/sj.leu.2403460; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 2003, CANCER CELL, V3, P131, DOI 10.1016/S1535-6108(03)00024-2; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Ballon G, 2011, J CLIN INVEST, V121, P1141, DOI 10.1172/JCI44417; Benmerah A, 1999, J CELL SCI, V112, P1303; BOSHOFF C, 1995, LANCET, V345, P1043; Boshoff C, 2011, J CLIN INVEST, V121, P838, DOI 10.1172/JCI46499; Cannon M, 2003, J VIROL, V77, P57, DOI 10.1128/JVI.77.1.57-67.2003; Cannon ML, 2004, ONCOGENE, V23, P514, DOI 10.1038/sj.onc.1207021; Caselli E, 2007, BLOOD, V109, P2718, DOI 10.1182/blood-2006-03-012500; Cesarman E, 1996, AM J PATHOL, V149, P53; Chang HH, 2013, CELL HOST MICROBE, V13, P429, DOI 10.1016/j.chom.2013.03.009; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen YB, 2007, ONCOLOGIST, V12, P569, DOI 10.1634/theoncologist.12-5-569; Chugh P, 2005, P NATL ACAD SCI USA, V102, P12885, DOI 10.1073/pnas.0408577102; Couty JP, 2001, J BIOL CHEM, V276, P33805, DOI 10.1074/jbc.M104631200; de Oliveira DE, 2010, TRENDS MICROBIOL, V18, P248, DOI 10.1016/j.tim.2010.04.001; Dwyer J, 2011, ONCOGENE, V30, P190, DOI 10.1038/onc.2010.411; Dwyer J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045562; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Grossmann C, 2006, J VIROL, V80, P7179, DOI 10.1128/JVI.01603-05; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Hassman LM, 2011, J CLIN INVEST, V121, P752, DOI 10.1172/JCI44185; Keller SA, 2006, BLOOD, V107, P3295, DOI 10.1182/blood-2005-07-2730; Lagos D, 2008, CELL HOST MICROBE, V4, P470, DOI 10.1016/j.chom.2008.09.012; Lanternier F, 2008, AIDS, V22, P1163, DOI 10.1097/QAD.0b013e3283031a8a; Liu F, 2012, IMMUNOL REV, V246, P239, DOI 10.1111/j.1600-065X.2012.01107.x; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Lodi S, 2010, JNCI-J NATL CANCER I, V102, P784, DOI 10.1093/jnci/djq134; Martin D, 2008, ONCOGENE, V27, P1844, DOI [10.1038/sj.onc.1210817, 10.1038/onc.2009.351]; Martin D, 2011, CANCER CELL, V19, P805, DOI 10.1016/j.ccr.2011.05.005; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Mesri EA, 1996, J EXP MED, V183, P2385, DOI 10.1084/jem.183.5.2385; Mesri EA, 2010, NAT REV CANCER, V10, P707, DOI 10.1038/nrc2888; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Montaner S, 2004, BLOOD, V104, P2903, DOI 10.1182/blood-2003-12-4436; Montaner S, 2013, ANNU REV PHARMACOL, V53, P331, DOI 10.1146/annurev-pharmtox-010510-100608; Myoung J, 2011, J CLIN INVEST, V121, P1130, DOI 10.1172/JCI43755; Rosenkilde MM, 2000, J BIOL CHEM, V275, P26309, DOI 10.1074/jbc.M003800200; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; Sin SH, 2013, BLOOD, V121, P2952, DOI 10.1182/blood-2012-03-415620; Smit MJ, 2002, J VIROL, V76, P1744, DOI 10.1128/JVI.76.4.1744-1752.2002; Sodhi A, 2004, P NATL ACAD SCI USA, V101, P4821, DOI 10.1073/pnas.0400835101; Tan WF, 2006, J BIOL CHEM, V281, P39542, DOI 10.1074/jbc.M609062200; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445	48	11	11	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2014	33	49					5609	5618		10.1038/onc.2013.503	http://dx.doi.org/10.1038/onc.2013.503			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZW	24292677	Green Published			2022-12-28	WOS:000346088700005
J	Geng, L; Chaudhuri, A; Talmon, G; Wisecarver, JL; Are, C; Brattain, M; Wang, J				Geng, L.; Chaudhuri, A.; Talmon, G.; Wisecarver, J. L.; Are, C.; Brattain, M.; Wang, J.			MicroRNA-192 suppresses liver metastasis of colon cancer	ONCOGENE			English	Article						colon cancer; liver metastasis; miR-192; Bcl-2; Zeb2; VEGFA	GROWTH-FACTOR-BETA; EPITHELIAL-MESENCHYMAL TRANSITION; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; REPRESSORS ZEB1; EXPRESSION; RECEPTOR; CARCINOMA; CELLS; GENES	Metastasis causes most deaths from colon cancer yet mechanistic understanding and therapeutic options remain limited. Here we show that expression of microRNA (miR)-192 is inversely correlated with metastatic potential of colon cancer cells. Ectopic expression of miR-192 sensitizes colon cancer cells to growth factor deprivation stress-induced apoptosis, whereas inhibition of miR-192 confers resistance. Overexpression of miR-192 inhibits metastatic colonization to the liver in an orthotopic mouse model of colon cancer. Alterations associated with the metastatic phenotype in the primary tumors include increased apoptosis, decreased proliferation and angiogenesis. Further studies indicate that miR-192 downregulates expression of Bcl-2, Zeb2 and VEGFA in vitro and in vivo, which is responsible for enhanced apoptosis, increased expression of E-cadherin and decreased angiogenesis in vivo, respectively. Finally, studies performed on human colonic adenocarcinoma show that expression of miR-192 is significantly reduced in neoplastic cells as compared with normal colonic epithelium. Importantly, there is a significant decrease in miR-192 expression in stage IV tumors when compared with stage I or II lesions. These findings indicate that miR-192 has an important role in colon cancer development and progression. Our studies underscore the clinical relevance and prognostic significance of miR-192 expression in colon cancer. Therefore, a major implication of our studies is that restoration of miR-192 expression or antagonism of its target genes (Bcl-2, Zeb2 or VEGFA) may have considerable therapeutic potential for anti-metastatic therapy in patients with colon cancer.	[Geng, L.; Chaudhuri, A.; Brattain, M.; Wang, J.] Eppley Inst Res Canc & Allied Dis, Omaha, NE USA; [Talmon, G.; Wisecarver, J. L.] Dept Pathol & Microbiol, Omaha, NE USA; [Are, C.] Univ Nebraska Med Ctr, Dept Surg Oncol, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA; [Wang, J.] Dept Genet Cell Biol & Anat, Omaha, NE USA; [Wang, J.] Dept Biochem & Mol Biol, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center	Wang, J (corresponding author), Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Eppley Inst Res Canc & Allied Dis, 985950 Nebraska Med Ctr, Omaha, NE 68198 USA.	jjwang@unmc.edu	Chaudhuri, Anathbandhu/F-2501-2017	Chaudhuri, Anathbandhu/0000-0003-4833-3077	NIH/NCI [R01CA140988-01]; Nebraska Department of Health and Human Services [(LB506) 2013-40]; NATIONAL CANCER INSTITUTE [R01CA140988] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Nebraska Department of Health and Human Services; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH/NCI funding R01CA140988-01 and Nebraska Department of Health and Human Services (LB506) 2013-40 to JW.	Agui T, 2002, ANTICANCER RES, V22, P1769; Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bendardaf R, 2008, ANTICANCER RES, V28, P3865; Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90; BOYD DD, 1988, CANCER RES, V48, P2469; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chiang YP, 2012, EXP THER MED, V3, P560, DOI 10.3892/etm.2011.436; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Du TT, 2005, DEVELOPMENT, V132, P4645, DOI 10.1242/dev.02070; Fang L, 2012, CELL CYCLE, V11, P4352, DOI 10.4161/cc.22670; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Forrester E, 2005, CANCER RES, V65, P2296, DOI 10.1158/0008-5472.CAN-04-3272; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Grady WM, 1999, CANCER RES, V59, P320; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jiang YJ, 2011, CANCER RES, V71, P234, DOI 10.1158/0008-5472.CAN-10-1487; Jin Z, 2011, ONCOGENE, V30, P1577, DOI 10.1038/onc.2010.534; Kahlert C, 2011, CLIN CANCER RES, V17, P7654, DOI 10.1158/1078-0432.CCR-10-2816; Kang MH, 2009, CLIN CANCER RES, V15, P1126, DOI 10.1158/1078-0432.CCR-08-0144; Karakas T, 1998, ANN ONCOL, V9, P159, DOI 10.1023/A:1008255511404; Kato M, 2009, NAT CELL BIOL, V11, P881, DOI 10.1038/ncb1897; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Klinger M, 2010, ANN SURG ONCOL, V17, P2059, DOI 10.1245/s10434-010-0972-9; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kriegel AJ, 2010, NUCLEIC ACIDS RES, V38, P8338, DOI 10.1093/nar/gkq718; Krupa A, 2010, J AM SOC NEPHROL, V21, P438, DOI 10.1681/ASN.2009050530; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liu XQ, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M111.221697; Majid S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046743; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mehrotra S, 2010, CANCER CELL, V17, P53, DOI 10.1016/j.ccr.2009.11.021; Meng FY, 2012, CANCER METAST REV, V31, P455, DOI 10.1007/s10555-012-9379-3; Moreira JN, 2006, REV RECENT CLIN TRIA, V1, P217, DOI 10.2174/157488706778250050; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Salovaara R, 2002, GUT, V51, P56, DOI 10.1136/gut.51.1.56; Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425; Simms NAK, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-221; Stoeltzing O, 2003, ANN SURG ONCOL, V10, P722, DOI 10.1245/ASO.2003.07.019; Tejpar S, 2012, ONCOLOGIST, V17, P1039, DOI 10.1634/theoncologist.2012-0068; Tian Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048958; Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965; Wang B, 2010, DIABETES, V59, P1794, DOI 10.2337/db09-1736; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Ye SC, 1999, CANCER RES, V59, P4725; Yokoi K, 2005, CANCER RES, V65, P3716, DOI 10.1158/0008-5472.CAN-04-3700; Yokota J, 2000, CARCINOGENESIS, V21, P497, DOI 10.1093/carcin/21.3.497; Yue X, 2012, ONCOL REP, V27, P1200, DOI 10.3892/or.2011.1588; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhao SJ, 2008, CANCER RES, V68, P4221, DOI 10.1158/0008-5472.CAN-07-5123; Zubeldia IG, 2013, EXP CELL RES, V319, P12, DOI 10.1016/j.yexcr.2012.11.004	59	99	108	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2014	33	46					5332	5340		10.1038/onc.2013.478	http://dx.doi.org/10.1038/onc.2013.478			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MF	24213572	Green Accepted			2022-12-28	WOS:000345120600003
J	Yan, BX; Ma, JX; Zhang, J; Guo, Y; Riedel, H; Mueller, MD; Remick, SC; Yu, JJ				Yan, B-x; Ma, J-x; Zhang, J.; Guo, Y.; Riedel, H.; Mueller, M. D.; Remick, S. C.; Yu, J. J.			PSP94 contributes to chemoresistance and its peptide derivative PCK3145 represses tumor growth in ovarian cancer	ONCOGENE			English	Article						PSP94; chemoresistance; PCK3145; signaling pathway; ovarian cancer	PROSTATIC SECRETORY PROTEIN; MESSENGER-RNA LEVELS; STEM-CELLS; DRUG-RESISTANCE; MOLECULAR-MECHANISMS; BREAST-CANCER; LET-7; EXPRESSION; LIN28B; ERCC1	Tumor drug resistance remains a major challenge in the treatment of cancer. Here, we show that Prostatic secretory protein 94 (PSP94) levels are reduced in ovarian cancer patients with high levels of excision repair cross-complementing 1 (ERCC1), a marker for chemoresistance. We find that PSP94 is decreased in an ovarian cancer drug-resistant cell line, and plays an important role in the development of drug resistance in vitro. Our studies indicate that PSP94 can partially reverse drug resistance in mouse tumor models in vivo and that a PSP94 peptide derivative PCK3145 suppresses chemoresistant cancer cell and tumor growth in vitro and in vivo. Our investigation of the involved molecular mechanisms suggests that PSP94 may confer drug resistance by modulating the Lin28b/Let-7 signaling pathway. We introduce PSP94 and its peptide derivative PCK3145 as potential target to reverse chemoresistance in ovarian cancer and have begun to identify their relevant molecular targets in specific signaling pathways.	[Yan, B-x; Ma, J-x; Guo, Y.; Riedel, H.; Mueller, M. D.; Remick, S. C.; Yu, J. J.] W Virginia Univ, Sch Pharm, Dept Biochem, Sch Med,Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA; [Yan, B-x; Zhang, J.] W Virginia Univ, Mary Babb Randolph Canc Ctr, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA; [Ma, J-x] IcesnowYanyan Biosci Assoc, Beijing, Peoples R China; [Zhang, J.] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA; [Yan, B-x; Ma, J-x] Beijing Anim Sci Inst, Beijing, Peoples R China	West Virginia University; West Virginia University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Yan, BX (corresponding author), W Virginia Univ, Sch Pharm, Dept Biochem, Sch Med,Dept Basic Pharmaceut Sci, 1 Med Ctr Dr, Morgantown, WV 26506 USA.	bxueyan@hotmail.com			Molecular Medicine Core Facility, Mary Babb Randolph Cancer Center, West Virginia University; Icesnow Yanyan Bioscience Association, Beijing	Molecular Medicine Core Facility, Mary Babb Randolph Cancer Center, West Virginia University; Icesnow Yanyan Bioscience Association, Beijing	We acknowledge the Molecular Medicine Core Facility, Mary Babb Randolph Cancer Center, West Virginia University and Icesnow Yanyan Bioscience Association, Beijing for supporting this study.	ABRAHAMSSON PA, 1990, ANDROLOGIA, V22, P122; Baijal-Gupta M, 2000, J ENDOCRINOL, V165, P425, DOI 10.1677/joe.0.1650425; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bitarte N, 2011, STEM CELLS, V29, P1661, DOI 10.1002/stem.741; Boyerinas B, 2010, ENDOCR-RELAT CANCER, V17, pF19, DOI 10.1677/ERC-09-0184; Bussing I, 2008, TRENDS MOL MED, V14, P400, DOI 10.1016/j.molmed.2008.07.001; Chan PSF, 1999, PROSTATE, V41, P99; Chang TC, 2009, P NATL ACAD SCI USA, V106, P3384, DOI 10.1073/pnas.0808300106; Chen TS, 2010, ADV DRUG DELIVER REV, V62, P1257, DOI 10.1016/j.addr.2010.07.008; DABHOLKAR M, 1994, J CLIN INVEST, V94, P703, DOI 10.1172/JCI117388; FUCHTNER C, 1993, GYNECOL ONCOL, V48, P203, DOI 10.1006/gyno.1993.1034; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Guo YQ, 2006, GENE, V384, P51, DOI 10.1016/j.gene.2006.07.011; Hagan JP, 2009, NAT STRUCT MOL BIOL, V16, P1021, DOI 10.1038/nsmb.1676; Hawkins Robert E, 2005, Clin Prostate Cancer, V4, P91, DOI 10.3816/CGC.2005.n.016; Honma K, 2008, NAT MED, V14, P939, DOI 10.1038/nm.1858; Jeong SH, 2009, EXP MOL MED, V41, P912, DOI 10.3858/emm.2009.41.12.097; Ji JF, 2010, J HEPATOL, V53, P974, DOI 10.1016/j.jhep.2010.07.001; King CE, 2011, ONCOGENE, V30, P4185, DOI 10.1038/onc.2011.131; Lage H, 2008, CELL MOL LIFE SCI, V65, P3145, DOI 10.1007/s00018-008-8111-5; Li QD, 2000, ANTICANCER RES, V20, P645; LILJA H, 1988, PROSTATE, V12, P29, DOI 10.1002/pros.2990120105; Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706; Lv KZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040008; Olaussen KA, 2007, CURR OPIN PULM MED, V13, P284, DOI 10.1097/MCP.0b013e32816b5c63; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Piskounova E, 2011, CELL, V147, P1066, DOI 10.1016/j.cell.2011.10.039; Rabik CA, 2007, CANCER TREAT REV, V33, P9, DOI 10.1016/j.ctrv.2006.09.006; Redmond KM, 2008, FRONT BIOSCI-LANDMRK, V13, P5138, DOI 10.2741/3070; Reed E, 2003, CLIN CANCER RES, V9, P5299; Schickel R, 2008, ONCOGENE, V27, P5959, DOI 10.1038/onc.2008.274; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shukeir N, 2004, CANCER RES, V64, P5370, DOI 10.1158/0008-5472.CAN-04-0788; Shukeir N, 2003, CANCER RES, V63, P2072; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; WEIBER H, 1990, AM J PATHOL, V137, P593; Whitaker HC, 2010, PROSTATE, V70, P333, DOI 10.1002/pros.21059; XUAN JW, 1995, ONCOGENE, V11, P1041; Yeung J, 2010, CANCER CELL, V18, P606, DOI 10.1016/j.ccr.2010.10.032; Yi Guo B Y, 2012, AACR AM ASS CANC RES, V53; Yu JJ, 1996, INT J ONCOL, V8, P313	43	10	10	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2014	33	45					5288	5294		10.1038/onc.2013.466	http://dx.doi.org/10.1038/onc.2013.466			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MD	24186202				2022-12-28	WOS:000345120400006
J	Nehil, M; Paquette, J; Tokuyasu, T; McCormick, F				Nehil, M.; Paquette, J.; Tokuyasu, T.; McCormick, F.			High mobility group box 1 promotes tumor cell migration through epigenetic silencing of semaphorin 3A	ONCOGENE			English	Article						HMGB1; SEMA3A; migration; chromatin; metastasis	END-PRODUCTS RAGE; INCREASED EXPRESSION; MURINE COLITIS; HMGB1; CANCER; BINDING; PROTEIN; CARCINOMA; RECEPTOR; GROWTH	High mobility group box 1 (HMGB1) is a 25-kDa chromatin-associated protein that aids in transcription and DNA repair by directly binding to DNA and altering its conformation. Additionally, HMGB1 can act as an extracellular ligand. When released from dying or stressed cells, HMGB1 binds to the RAGE receptor and activates the p42/44 MAP kinase (MAPK) cascade. HMGB1 is overexpressed in many types of cancer and frequently associated with tumor stage and metastasis. This has predominantly been attributed to an autocrine function that drives MAPK pathway activity. However, by using tumor cells with activating MAPK pathway mutations, we have identified a role for HMGB1 in promoting metastasis and tumor growth that is independent of this pathway. In the absence of HMGB1, these tumor cells show defective in vitro migration as well as reduced metastasis and tumor growth in vivo despite high p42/44 phosphorylation. We found that semaphorin 3A (SEMA3A), previously shown to act as a suppressor of angiogenesis and migration, was highly increased during expression in the absence of HMGB1. SEMA3A/HMGB1 double knockdown rescued the migration defect in HMGB1 single knockdown cells. HMGB1 bound at the semaphorin 3A genomic locus, promoted hetrochromatin formation, and decreased occupancy of acetylated histones. Based on human tumor gene expression databases, HMGB1 was significantly inversely correlated with SEMA3A, suggesting that this mechanism may be more widely relevant in different cancer types.	[Nehil, M.] Harvard Univ, Med Scool, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Paquette, J.; Tokuyasu, T.; McCormick, F.] Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, Program Biomed Sci, San Francisco, CA 94158 USA; [Paquette, J.; Tokuyasu, T.; McCormick, F.] Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, Bioinformat Program, San Francisco, CA 94158 USA	Harvard University; Dana-Farber Cancer Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	McCormick, F (corresponding author), Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, 1450 3rd St,Rm HD-371 UCSF Box 0128, San Francisco, CA 94158 USA.	mccormick@cc.ucsf.edu		Tokuyasu, Taku/0000-0003-3401-3195	UCSF Tetrad program	UCSF Tetrad program	We thank the UCSF Tetrad program for providing funding. We thank Dr Lewis Lanier for all of his advice. We thank Dr Byron Hann, Dr Paul Phojanakong and the UCSF Clinical Therapeutics core for all of their help with mouse xenograft experiments and the UCSF Genome core for their help with gene expression studies.	Agresti A, 2003, BIOCHEM BIOPH RES CO, V302, P421, DOI 10.1016/S0006-291X(03)00184-0; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Brezniceanu ML, 2003, FASEB J, V17, P1295, DOI 10.1096/fj.02-0621fje; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; Casazza A, 2011, ARTERIOSCL THROM VAS, V31, P741, DOI 10.1161/ATVBAHA.110.211920; Cheng BQ, 2008, DIGEST LIVER DIS, V40, P446, DOI 10.1016/j.dld.2007.11.024; Dave SH, 2009, J LEUKOCYTE BIOL, V86, P633, DOI 10.1189/jlb.1008662; El Gazzar M, 2009, MOL CELL BIOL, V29, P1959, DOI 10.1128/MCB.01862-08; Ellerman JE, 2007, CLIN CANCER RES, V13, P2836, DOI 10.1158/1078-0432.CCR-06-1953; GE H, 1994, J BIOL CHEM, V269, P17136; Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Ishiguro H, 2005, PROSTATE, V64, P92, DOI 10.1002/pros.20219; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Joshi SR, 2012, NUCLEIC ACIDS RES, V40, P10161, DOI 10.1093/nar/gks815; Liang XY, 2009, J LEUKOCYTE BIOL, V86, P599, DOI 10.1189/jlb.0908578; Lin Q, 2011, ARTERIOSCL THROM VAS, V31, P1024, DOI 10.1161/ATVBAHA.111.224048; Maeda S, 2007, BIOCHEM BIOPH RES CO, V360, P394, DOI 10.1016/j.bbrc.2007.06.065; Malarkey CS, 2012, TRENDS BIOCHEM SCI, V37, P553, DOI 10.1016/j.tibs.2012.09.003; McCauley MJ, 2007, J MOL BIOL, V374, P993, DOI 10.1016/j.jmb.2007.09.073; Neufeld G, 2008, NAT REV CANCER, V8, P632, DOI 10.1038/nrc2404; Paquette J, 2010, BIOINFORMATICS, V26, P285, DOI 10.1093/bioinformatics/btp656; Poser I, 2003, MOL CELL BIOL, V23, P2991, DOI 10.1128/MCB.23.8.2991-2998.2003; Ranzato E, 2010, CELL BIOCHEM BIOPHYS, V57, P9, DOI 10.1007/s12013-010-9077-0; Sapojnikova N, 2005, BBA-GENE STRUCT EXPR, V1729, P57, DOI 10.1016/j.bbaexp.2005.03.002; Schmidt EF, 2008, J NEUROSCI, V28, P2287, DOI 10.1523/JNEUROSCI.5646-07.2008; Schmidt EF, 2007, ADV EXP MED BIOL, V600, P1; Staton CA, 2011, HISTOPATHOLOGY, V59, P274, DOI 10.1111/j.1365-2559.2011.03922.x; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; van Beijnum JR, 2008, ANGIOGENESIS, V11, P91, DOI 10.1007/s10456-008-9093-5; Volp K, 2006, GUT, V55, P234, DOI 10.1136/gut.2004.062729; Wu D, 2008, J PATHOL, V216, P167, DOI 10.1002/path.2391; Yao XJ, 2010, J CANCER RES CLIN, V136, P677, DOI 10.1007/s00432-009-0706-1	34	17	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2014	33	44					5151	5162		10.1038/onc.2013.459	http://dx.doi.org/10.1038/onc.2013.459			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR9RZ	24213571				2022-12-28	WOS:000343914900002
J	Park, TJ; Curran, T				Park, T-J; Curran, T.			Essential roles of Crk and CrkL in fibroblast structure and motility	ONCOGENE			English	Article						Crk; CrkL; focal adhesion; actin; cytoskeleton; motility	ADAPTER PROTEIN CRK; KEY SIGNALING INTEGRATORS; MICE LACKING; V-CRK; CANCER; ONCOGENE; PAXILLIN; PHOSPHORYLATION; TRANSFORMATION; P130(CAS)	Cytosolic proteins containing SH2 and SH3 domains, such as Crk and Crk-like (CrkL), are broadly expressed adapters that interact with a variety of proteins to fulfill key roles in signal transduction pathways triggered by activation of receptor and non-receptor tyrosine kinases. Crk and CrkL are similar to each other in structure and biochemical function, although they provide both distinct, as well as overlapping, biological roles during development. We developed a systematic approach to investigate Crk family functions at the cellular level by generating a conditional knock-out system for ablation of Crk and CrkL in cultured fibroblasts. The loss of both Crk and CrkL from fibroblasts resulted in reduced cell surface area and adoption of a rounded, refractile cellular phenotype. These morphological alterations were accompanied by a decrease in focal adhesion sites, reduced actin stress fibers and a collapse of microtubule structures. In addition, cells exhibited decreases in spontaneous motility and wound-healing behavior. Reduced p130Cas phosphorylation and actin levels closely followed the loss of Crk and CrkL, and stabilization of polymerized actin by jasplakinolide suppressed the morphological conversion. Ablation of Crk or CrkL alone conferred a much more modest phenotype suggesting that Crk and CrkL have overlapping functions that are critical for maintaining cell structure. The morphological alterations could be partially rescued by reintroduction of CrkII, and, to a lesser extent, CrkL. Taken together, our results suggest that Crk and CrkL have critical roles in cell structure and motility by maintaining cytoskeletal integrity.	[Park, T-J; Curran, T.] Childrens Hosp Philadelphia, Res Inst, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Curran, T (corresponding author), Childrens Hosp Philadelphia, Res Inst, Colket Translat Res Bldg,Room 4060, Philadelphia, PA 19104 USA.	currant@email.chop.edu	Curran, Tom/F-5234-2018; Curran, Tom/D-7515-2011; Curran, Thomas/AAE-7631-2019	Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Park, Taeju/0000-0003-3897-3994	Pennsylvania Department of Health Cure Formulary grant (SAP) [4100047628]	Pennsylvania Department of Health Cure Formulary grant (SAP)	We thank Hanna Li and Erin Finn for their technical assistance and Mateusz Koptyra for critical reading of the manuscript. This work was supported by a Pennsylvania Department of Health Cure Formulary grant (SAP#4100047628 to TC).	Antoku S, 2009, J CELL SCI, V122, P4228, DOI 10.1242/jcs.054627; Birge RB, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-13; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Du J, 2004, J CLIN INVEST, V113, P115, DOI 10.1172/JCI200418330; Fathers KE, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3183; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; George B, 2012, J CLIN INVEST, V122, P674, DOI 10.1172/JCI60070; Guris DL, 2001, NAT GENET, V27, P293, DOI 10.1038/85855; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Hallock PT, 2010, GENE DEV, V24, P2451, DOI 10.1101/gad.1977710; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Kim YH, 2010, ONCOGENE, V29, P1421, DOI 10.1038/onc.2009.437; Kobashigawa Y, 2007, NAT STRUCT MOL BIOL, V14, P503, DOI 10.1038/nsmb1241; Kong JY, 2004, CELL BIOL INT, V28, P781, DOI 10.1016/j.cellbi.2004.07.012; Linghu H, 2006, ONCOGENE, V25, P3547, DOI 10.1038/sj.onc.1209398; Mashima T, 1999, ONCOGENE, V18, P2423, DOI 10.1038/sj.onc.1202558; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Miller CT, 2003, ONCOGENE, V22, P7950, DOI 10.1038/sj.onc.1206529; Nishihara H, 2002, CANCER LETT, V180, P55, DOI 10.1016/S0304-3835(01)00763-7; Park TJ, 2006, MOL CELL BIOL, V26, P6272, DOI 10.1128/MCB.00472-06; Park TJ, 2008, J NEUROSCI, V28, P13551, DOI 10.1523/JNEUROSCI.4323-08.2008; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Rodrigues SP, 2005, MOL CANCER RES, V3, P183; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Sarkar P, 2007, MOL CELL, V25, P413, DOI 10.1016/j.molcel.2007.01.004; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Sriram Ganapathy, 2010, Genes Cancer, V1, P1132, DOI 10.1177/1947601910397188; Tikhmyanova N, 2010, CELL MOL LIFE SCI, V67, P1025, DOI 10.1007/s00018-009-0213-1; Watanabe T, 2006, MOL CANCER RES, V4, P499, DOI 10.1158/1541-7786.MCR-05-0141	35	22	22	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2014	33	43					5121	5132		10.1038/onc.2013.453	http://dx.doi.org/10.1038/onc.2013.453			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OF	24166500				2022-12-28	WOS:000343768400007
J	Chan, LH; Wang, W; Yeung, W; Deng, Y; Yuan, P; Mak, KK				Chan, L. H.; Wang, W.; Yeung, W.; Deng, Y.; Yuan, P.; Mak, K. K.			Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression	ONCOGENE			English	Article						osteosarcoma; yes-associated protein1; long non-coding RNA H19	YES-ASSOCIATED PROTEIN; TUMOR-SUPPRESSOR; NONCODING RNA; CANDIDATE ONCOGENE; CTCF-BINDING; CELL-CYCLE; EXPRESSION; BONE; CANCER; PATHWAY	Osteosarcoma is one of the most common bone tumors. However, the genetic basis for its pathogenesis remains elusive. Here, we investigated the roles of Hedgehog (Hh) signaling in osteosarcoma development. Genetically-engineered mice with ubiquitous upregulated Hh signaling specifically in mature osteoblasts develop focal bone overgrowth, which greatly resembles the early stage of osteosarcoma. However, these mice die within three months, which prohibits further analysis of tumor progression. We therefore generated a mouse model with partial upregulated Hh signaling in mature osteoblasts and crossed it into a p53 heterozygous background to potentiate tumor development. We found that these mutant mice developed malignant osteosarcoma with high penetrance. Isolated primary tumor cells were mainly osteoblastic and highly proliferative with many characteristics of human osteosarcomas. Allograft transplantation into immunocompromised mice displayed high tumorigenic potential. More importantly, both human and mouse tumor tissues express high level of yes-associated protein 1 (Yap1), a potent oncogene that is amplified in various cancers. We show that inhibition of Hh signaling reduces Yap1 expression and knockdown of Yap1 significantly inhibits tumor progression. Moreover, long non-coding RNA H19 is aberrantly expressed and induced by upregulated Hh signaling and Yap1 overexpression. Our results demonstrate that aberrant Hh signaling in mature osteoblasts is responsible for the pathogenesis of osteoblastic osteosarcoma through Yap1 and H19 overexpression.	[Chan, L. H.; Wang, W.; Yeung, W.; Deng, Y.; Mak, K. K.] Chinese Univ Hong Kong, Sch Biomed Sci, Fac Med, Key Labs Regenerat Med,Minist Educ, Shatin, Hong Kong, Peoples R China; [Yuan, P.] Chinese Univ Hong Kong, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China; [Mak, K. K.] Chinese Univ Hong Kong, Sch Biomed Sci, Stem Cell & Regenerat Themat Res Program, Shatin, Hong Kong, Peoples R China; [Mak, K. K.] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Shenzhen, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong, Shenzhen	Mak, KK (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Stem Cell & Regenerat Themat Res Program, Shatin, Hong Kong, Peoples R China.	kmak@cuhk.edu.hk		Yuan, Ping/0000-0001-7243-3487; Mak, Kingston King-Lun/0000-0002-4733-9146; Deng, Youping/0000-0002-5951-8213	School of Biomedical Sciences, The Chinese University of Hong Kong [4620504]; Research Grant Council of the Hong Kong Special Administrative Region [CUHK479012]; United College, The Chinese University of Hong Kong [CA11189];  [CUHK2041745]	School of Biomedical Sciences, The Chinese University of Hong Kong; Research Grant Council of the Hong Kong Special Administrative Region(Hong Kong Research Grants Council); United College, The Chinese University of Hong Kong(Chinese University of Hong Kong); 	We thank Drs. Tin-lap Lee and David John Wilmshurst for critical comments on the manuscript. This work is supported by the Seed Fund of the School of Biomedical Sciences, The Chinese University of Hong Kong (4620504), Early Career Scheme of the Research Grant Council of the Hong Kong Special Administrative Region (CUHK479012), Direct Grant for research (CUHK2041745) and the Endowment Fund Research Grant of the United College, The Chinese University of Hong Kong (CA11189).	Andela VB, 2005, J CLIN PATHOL, V58, P328, DOI 10.1136/jcp.2004.017640; Arima T, 1997, CANCER GENET CYTOGEN, V93, P39, DOI 10.1016/S0165-4608(96)00221-X; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Calo E, 2010, NATURE, V466, P1110, DOI 10.1038/nature09264; DORFMAN HD, 1995, CANCER, V75, P203, DOI 10.1002/1097-0142(19950101)75:1+<203::AID-CNCR2820751308>3.0.CO;2-V; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Fults Daniel W, 2005, Neurosurg Focus, V19, pE7, DOI 10.3171/foc.2005.19.5.8; Galindo M, 2005, J BIOL CHEM, V280, P20274, DOI 10.1074/jbc.M413665200; Hibi K, 1996, CANCER RES, V56, P480; Hirotsu M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-5; Jones KB, 2012, CANCER RES, V72, P1865, DOI 10.1158/0008-5472.CAN-11-2663; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; Mak KK, 2006, DEVELOPMENT, V133, P3695, DOI 10.1242/dev.02546; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Li N, 2009, CANCER-AM CANCER SOC, V115, P4795, DOI 10.1002/cncr.24519; Lu XY, 2008, MOL CANCER RES, V6, P937, DOI 10.1158/1541-7786.MCR-07-2115; Mak KK, 2008, DEV CELL, V14, P674, DOI 10.1016/j.devcel.2008.02.003; Matouk IJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000845; Matouk IJ, 2009, EUR J GASTROEN HEPAT, V21, P688, DOI 10.1097/MEG.0b013e328306a3a2; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Mohseny AB, 2009, J PATHOL, V219, P294, DOI 10.1002/path.2603; Molyneux SD, 2010, J CLIN INVEST, V120, P3310, DOI 10.1172/JCI42391; Muramatsu T, 2011, CARCINOGENESIS, V32, P389, DOI 10.1093/carcin/bgq254; Mutsaers AJ, 2013, BONE, V55, P166, DOI 10.1016/j.bone.2013.02.016; Nagao H, 2011, J PATHOL, V224, P169, DOI 10.1002/path.2880; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581-8591.2005; Raffel C, 1997, CANCER RES, V57, P842; Reifenberger J, 1998, CANCER RES, V58, P1798; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Sadikovic B, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-202; Schmidt LH, 2011, J THORAC ONCOL, V6, P1984, DOI 10.1097/JTO.0b013e3182307eac; SWEETNAM R, 1982, BRIT J HOSP MED, V28, P112; Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999-008-0335-z; Tanos V, 2004, INT J GYNECOL CANCER, V14, P521, DOI 10.1111/j.1048-891x.2004.014314.x; Teplyuk NM, 2008, J BIOL CHEM, V283, P27585, DOI 10.1074/jbc.M802453200; Ulaner GA, 2003, ENDOCRINOLOGY, V144, P4420, DOI 10.1210/en.2003-0681; Ulaner GA, 2003, HUM MOL GENET, V12, P535, DOI 10.1093/hmg/ddg034; Venkatachalam S, 2001, TOXICOL PATHOL, V29, P147, DOI 10.1080/019262301753178555; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Wang JY, 2010, NUCLEIC ACIDS RES, V38, P5366, DOI 10.1093/nar/gkq285; Warzecha J, 2007, J CHEMOTHERAPY, V19, P554, DOI 10.1179/joc.2007.19.5.554; Wetmore C, 2003, CURR OPIN GENET DEV, V13, P34, DOI 10.1016/S0959-437X(03)00002-9; Won KY, 2009, TUMORI J, V95, P311; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073; Zhang JM, 2009, NAT CELL BIOL, V11, P1444, DOI 10.1038/ncb1993; Zhang L, 2008, DEV CELL, V14, P377, DOI 10.1016/j.devcel.2008.01.006; Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8	54	117	121	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2014	33	40					4857	4866		10.1038/onc.2013.433	http://dx.doi.org/10.1038/onc.2013.433			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0EH	24141783				2022-12-28	WOS:000343240100007
J	Hede, SM; Savov, V; Weishaupt, H; Sangfelt, O; Swartling, FJ				Hede, S-M; Savov, V.; Weishaupt, H.; Sangfelt, O.; Swartling, F. J.			Oncoprotein stabilization in brain tumors	ONCOGENE			English	Review						glioma; medulloblastoma; ubiquitin-proteasome system; brain tumor development; E3 ligases	F-BOX PROTEIN; NF-KAPPA-B; ANAPHASE-PROMOTING COMPLEX; E3 UBIQUITIN LIGASES; SMALL-MOLECULE INHIBITORS; GROWTH-FACTOR-B; C-MYC; BETA-CATENIN; SONIC HEDGEHOG; SIGNALING PATHWAY	Proteins involved in promoting cell proliferation and viability need to be timely expressed and carefully controlled for the proper development of the brain but also efficiently degraded in order to prevent cells from becoming brain cancer cells. A major pathway for targeted protein degradation in cells is the ubiquitin-proteasome system (UPS). Oncoproteins that drive tumor development and tumor maintenance are often deregulated and stabilized in malignant cells. This can occur when oncoproteins escape degradation by the UPS because of mutations in either the oncoprotein itself or in the UPS components responsible for recognition and ubiquitylation of the oncoprotein. As the pathogenic accumulation of an oncoprotein can lead to effectively sustained cell growth, viability and tumor progression, it is an indisputable target for cancer treatment. The most common types of malignant brain tumors in children and adults are medulloblastoma and glioma, respectively. Here, we review different ways of how deregulated proteolysis of oncoproteins involved in major signaling cancer pathways contributes to medulloblastoma and glioma development. We also describe means of targeting relevant oncoproteins in brain tumors with treatments affecting their stability or therapeutic strategies directed against the UPS itself.	[Hede, S-M; Savov, V.; Weishaupt, H.; Swartling, F. J.] Uppsala Univ, Rudbeck Lab, Dept Immunol Genet & Pathol, SE-75185 Uppsala, Sweden; [Sangfelt, O.] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden	Uppsala University; Karolinska Institutet	Swartling, FJ (corresponding author), Uppsala Univ, Rudbeck Lab, Dept Immunol Genet & Pathol, SE-75185 Uppsala, Sweden.	fredrik.swartling@igp.uu.se	Swartling, Fredrik J/B-8170-2014	Swartling, Fredrik J/0000-0002-8460-4367	Swedish Childhood Cancer Foundation; Swedish Cancer Society; Swedish Research Council; Swedish Society of Medicine; Swedish Brain Foundation; Ake Widgers Stiftelse; Ake Olssons Stifelse; Lions Cancerforskningsfond; Stiftelsen Lars Hiertas Minne; Radiumhemmets Forskningsfonder; Karolinska Institute Foundations; Association for International Cancer Research; Worldwide Cancer Research [13-0175] Funding Source: researchfish	Swedish Childhood Cancer Foundation(European Commission); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Society of Medicine; Swedish Brain Foundation; Ake Widgers Stiftelse; Ake Olssons Stifelse; Lions Cancerforskningsfond; Stiftelsen Lars Hiertas Minne; Radiumhemmets Forskningsfonder; Karolinska Institute Foundations(Karolinska Institutet); Association for International Cancer Research; Worldwide Cancer Research	This work was supported by research from the Swedish Childhood Cancer Foundation (FJS, OS), the Swedish Cancer Society (FJS, OS), the Swedish Research Council (FJS, OS), the Swedish Society of Medicine (FJS), the Swedish Brain Foundation (FJS), Ake Widgers Stiftels (FJS), Ake Olssons Stiftelse (OS), Lions Cancerforskningsfond (FJS), Stiftelsen Lars Hiertas Minne (FJS), Radiumhemmets Forskningsfonder (OS), Karolinska Institute Foundations (OS) and the Association for International Cancer Research (FJS). We apologize to authors not cited due to space restrictions in this review.	Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Aldosari N, 2002, ARCH PATHOL LAB MED, V126, P540; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Arabi A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1975; Ayrault O, 2009, MOL CANCER RES, V7, P33, DOI 10.1158/1541-7786.MCR-08-0369; Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Bhatia N, 2006, J BIOL CHEM, V281, P19320, DOI 10.1074/jbc.M513203200; Bjerke L, 2013, CANCER DISCOV, V3, P512, DOI 10.1158/2159-8290.CD-12-0426; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Bredel M, 2005, CANCER RES, V65, P8679, DOI 10.1158/0008-5472.CAN-05-1204; Bredel M, 2011, NEW ENGL J MED, V364, P627, DOI 10.1056/NEJMoa1006312; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Brockmann M, 2013, CANCER CELL, V24, P75, DOI 10.1016/j.ccr.2013.05.005; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Buckley SM, 2012, CELL STEM CELL, V11, P783, DOI 10.1016/j.stem.2012.09.011; Buczkowicz P, 2011, J NEUROPATH EXP NEUR, V70, P430, DOI 10.1097/NEN.0b013e31821b94db; Busino L, 2012, NAT CELL BIOL, V14, P375, DOI 10.1038/ncb2463; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cepeda D, 2013, EMBO MOL MED, V5, P1067, DOI 10.1002/emmm.201202341; Chan CH, 2013, CELL, V154, P556, DOI 10.1016/j.cell.2013.06.048; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; Chen J, 2012, CELL, V149, P36, DOI 10.1016/j.cell.2012.03.009; Chen Q, 2008, BLOOD, V111, P4690, DOI 10.1182/blood-2007-09-112904; Chen ZJJ, 2009, MOL CELL, V33, P275, DOI 10.1016/j.molcel.2009.01.014; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; CHOI OR, 1986, MOL CELL BIOL, V6, P1751, DOI 10.1128/MCB.6.5.1751; Choi SH, 2010, GENE DEV, V24, P1236, DOI 10.1101/gad.1920310; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; Clague MJ, 2012, J CELL SCI, V125, P277, DOI 10.1242/jcs.090985; Cohen P, 2010, CELL, V143, P686, DOI 10.1016/j.cell.2010.11.016; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; De Boeck M, 2012, UPSALA J MED SCI, V117, P153, DOI 10.3109/03009734.2012.654858; Di K, 2013, ONCOGENE, V32, P5038, DOI 10.1038/onc.2012.531; Di Marcotullio L, 2006, NAT CELL BIOL, V8, P1415, DOI 10.1038/ncb1510; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; Eichhorn PJA, 2012, NAT MED, V18, P429, DOI 10.1038/nm.2619; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Fan QW, 2012, METHODS MOL BIOL, V821, P349, DOI 10.1007/978-1-61779-430-8_22; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Fang D, 2001, J BIOL CHEM, V276, P4872, DOI 10.1074/jbc.M008901200; Fang DY, 2001, NAT IMMUNOL, V2, P870, DOI 10.1038/ni0901-870; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fouladkou F, 2008, P NATL ACAD SCI USA, V105, P8585, DOI 10.1073/pnas.0803233105; Frange P, 2009, J NEURO-ONCOL, V95, P271, DOI 10.1007/s11060-009-9927-z; Frederick L, 2000, CANCER RES, V60, P1383; Friday BB, 2012, NEURO-ONCOLOGY, V14, P215, DOI 10.1093/neuonc/nor198; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Fukushima H, 2012, CELL REP, V1, P434, DOI 10.1016/j.celrep.2012.04.002; Garcia D, 2011, GENE DEV, V25, P1746, DOI 10.1101/gad.16722111; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Guardavaccaro D, 2004, ONCOGENE, V23, P2037, DOI 10.1038/sj.onc.1207413; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Guo H, 2012, CELL REPORTS, V1, P472, DOI 10.1016/j.celrep.2012.04.008; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Harhaj EW, 2011, CELL RES, V21, P22, DOI 10.1038/cr.2010.166; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hartman Z, 2013, ONCOGENE, V32, P4169, DOI 10.1038/onc.2012.418; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hede SM, 2009, GLIA, V57, P1143, DOI 10.1002/glia.20837; Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021; Hermanson M, 1996, CANCER RES, V56, P164; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoeck JD, 2010, NAT NEUROSCI, V13, P1365, DOI 10.1038/nn.2644; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Huang HT, 2000, AM J PATHOL, V156, P433, DOI 10.1016/S0002-9440(10)64747-5; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Hussain SF, 2006, NEURO-ONCOLOGY, V8, P261, DOI 10.1215/15228517-2006-008; Inuzuka H, 2011, NATURE, V471, P104, DOI 10.1038/nature09732; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146; Jackson EL, 2006, NEURON, V51, P187, DOI 10.1016/j.neuron.2006.06.012; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jandke A, 2011, DEV BIOL, V358, P201, DOI 10.1016/j.ydbio.2011.07.030; Johnsen JI, 2008, ONCOGENE, V27, P2910, DOI 10.1038/sj.onc.1210938; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Jung YS, 2012, FEBS LETT, V586, P1397, DOI 10.1016/j.febslet.2012.03.052; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Kawauchi D, 2012, CANCER CELL, V21, P168, DOI 10.1016/j.ccr.2011.12.023; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kim HS, 2012, CANCER RES, V72, P6065, DOI 10.1158/0008-5472.CAN-12-2594; Kim J, 2010, P NATL ACAD SCI USA, V107, P13432, DOI 10.1073/pnas.1006822107; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Koch U, 2013, DEVELOPMENT, V140, P689, DOI 10.1242/dev.080614; Koochekpour S, 1997, CANCER RES, V57, P5391; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Korshunov A, 2012, ACTA NEUROPATHOL, V123, P515, DOI 10.1007/s00401-011-0918-8; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Kuchay S, 2013, NAT CELL BIOL, V15, P472, DOI 10.1038/ncb2731; Kunkele A, 2012, NEURO-ONCOLOGY, V14, P859, DOI 10.1093/neuonc/nos115; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Lambert JMR, 2009, CANCER CELL, V15, P376, DOI 10.1016/j.ccr.2009.03.003; Larsson LG, 2010, EXP CELL RES, V316, P1429, DOI 10.1016/j.yexcr.2010.03.025; Lasorella A, 2006, NATURE, V442, P471, DOI 10.1038/nature04895; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Lee J, 1997, DEVELOPMENT, V124, P2537; Lee JH, 2010, NEUROBIOL DIS, V38, P167, DOI 10.1016/j.nbd.2009.12.022; Lehman NL, 2006, CELL CYCLE, V5, P1569, DOI 10.4161/cc.5.14.2925; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Li W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001487; Lokker NA, 2002, CANCER RES, V62, P3729; Louvi A, 2006, NAT REV NEUROSCI, V7, P93, DOI 10.1038/nrn1847; Love Ian M, 2012, Genes Cancer, V3, P249, DOI 10.1177/1947601912455198; Maddika S, 2011, NAT CELL BIOL, V13, P728, DOI 10.1038/ncb2240; Mao JH, 2008, SCIENCE, V321, P1499, DOI 10.1126/science.1162981; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Menn B, 2006, J NEUROSCI, V26, P7907, DOI 10.1523/JNEUROSCI.1299-06.2006; Metzger MB, 2012, J CELL SCI, V125, P531, DOI 10.1242/jcs.091777; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Nakajima H, 2008, BIOCHEM BIOPH RES CO, V368, P1007, DOI 10.1016/j.bbrc.2008.01.166; Natarajan S, 2013, CANCER RES, V73, P5381, DOI 10.1158/0008-5472.CAN-13-0033; Northcott PA, 2012, NAT REV CANCER, V12, P818, DOI 10.1038/nrc3410; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Northcott PA, 2011, ACTA NEUROPATHOL, V122, P231, DOI 10.1007/s00401-011-0846-7; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Ohshima-Hosoyama S, 2011, J NEURO-ONCOL, V105, P475, DOI 10.1007/s11060-011-0619-0; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; Peart MJ, 2010, CELL CYCLE, V9, P3956, DOI 10.4161/cc.9.19.13162; Pei YX, 2012, CANCER CELL, V21, P155, DOI 10.1016/j.ccr.2011.12.021; Penas C, 2012, FRONT ONCOL, V1, DOI 10.3389/fonc.2011.00060; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Popov N, 2010, NAT CELL BIOL, V12, P973, DOI 10.1038/ncb2104; Puram SV, 2011, SEMIN CELL DEV BIOL, V22, P586, DOI 10.1016/j.semcdb.2011.03.006; Reavie L, 2013, CANCER CELL, V23, P362, DOI 10.1016/j.ccr.2013.01.025; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Roth RB, 2006, NEUROGENETICS, V7, P67, DOI 10.1007/s10048-006-0032-6; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Ruschak AM, 2011, J NATL CANCER I, V103, P1007, DOI 10.1093/jnci/djr160; Saifo MS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-310; Sanchez I, 2001, NEURON, V29, P563, DOI 10.1016/S0896-6273(01)00232-X; Schiffer D, 2002, NEUROSCI LETT, V328, P125, DOI 10.1016/S0304-3940(02)00483-4; Schmidt MHH, 2003, P NATL ACAD SCI USA, V100, P6505, DOI 10.1073/pnas.1031790100; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shih AH, 2004, CANCER RES, V64, P4783, DOI 10.1158/0008-5472.CAN-03-3831; Skaar JR, 2009, CELL, V137, P1358, DOI 10.1016/j.cell.2009.05.040; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Swartling FJ, 2013, CANCER METAST REV, V32, P5, DOI 10.1007/s10555-012-9407-3; Swartling FJ, 2012, CANCER CELL, V21, P601, DOI 10.1016/j.ccr.2012.04.012; Swartling FJ, 2012, UPSALA J MED SCI, V117, P122, DOI 10.3109/03009734.2012.658975; Swartling FJ, 2010, GENE DEV, V24, P1059, DOI 10.1101/gad.1907510; Swords RT, 2010, BLOOD, V115, P3796, DOI 10.1182/blood-2009-11-254862; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tan YM, 2008, CANCER LETT, V271, P1, DOI 10.1016/j.canlet.2008.04.036; Teixeira LK, 2013, ANNU REV BIOCHEM, V82, P387, DOI 10.1146/annurev-biochem-060410-105307; Thomas LR, 2011, ADV CANCER RES, V110, P77, DOI 10.1016/B978-0-12-386469-7.00004-9; Thomas WD, 2009, ONCOGENE, V28, P1605, DOI 10.1038/onc.2009.3; Uhrbom L, 1998, CANCER RES, V58, P5275; Valentijn LJ, 2012, P NATL ACAD SCI USA, V109, P19190, DOI 10.1073/pnas.1208215109; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Veeriah S, 2010, NAT GENET, V42, P77, DOI 10.1038/ng.491; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Vlachostergios PJ, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-18; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang BW, 2006, P NATL ACAD SCI USA, V103, P33, DOI 10.1073/pnas.0509927103; Wang CB, 2010, DEVELOPMENT, V137, P2001, DOI 10.1242/dev.052126; Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123; Wang SI, 1997, CANCER RES, V57, P4183; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Wang XJ, 2012, FEBS LETT, V586, P1390, DOI 10.1016/j.febslet.2012.02.049; Wang ZW, 2011, BIOESSAYS, V33, P851, DOI 10.1002/bies.201100101; Weiss WA, 2003, CANCER RES, V63, P1589; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wolff JE, 2012, PEDIATR BLOOD CANCER, V59, P27, DOI 10.1002/pbc.23402; Wu H, 2011, NAT MED, V17, P347, DOI 10.1038/nm.2283; Wu L, 2012, CHEM BIOL, V19, P1515, DOI 10.1016/j.chembiol.2012.09.015; Xu P, 2009, CELL, V137, P133, DOI 10.1016/j.cell.2009.01.041; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhao XD, 2008, NAT CELL BIOL, V10, P643, DOI 10.1038/ncb1727; Zhao YC, 2012, NEOPLASIA, V14, P360, DOI 10.1593/neo.12532; Zhou L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023936; Zhukova N, 2013, J CLIN ONCOL, V31, P2927, DOI 10.1200/JCO.2012.48.5052; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025; Zurawel RH, 1998, CANCER RES, V58, P896	198	10	10	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2014	33	39					4709	4721		10.1038/onc.2013.445	http://dx.doi.org/10.1038/onc.2013.445			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0ED	24166497				2022-12-28	WOS:000343239500001
J	Li, L; Chakraborty, S; Yang, CR; Hatanpaa, KJ; Cipher, DJ; Puliyappadamba, VT; Rehman, A; Jiwani, AJ; Mickey, B; Madden, C; Raisanen, J; Burma, S; Saha, D; Wang, Z; Pingle, SC; Kesari, S; Boothman, DA; Habib, AA				Li, L.; Chakraborty, S.; Yang, C-R; Hatanpaa, K. J.; Cipher, D. J.; Puliyappadamba, V. T.; Rehman, A.; Jiwani, A. J.; Mickey, B.; Madden, C.; Raisanen, J.; Burma, S.; Saha, D.; Wang, Z.; Pingle, S. C.; Kesari, S.; Boothman, D. A.; Habib, A. A.			An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII	ONCOGENE			English	Article						EGFRvIII; glioblastoma; EGFR wild type; activation; dimerization; HB-EGF	GROWTH-FACTOR RECEPTOR; CONFERS ENHANCED TUMORIGENICITY; TYROSINE KINASES; SIGNAL-TRANSDUCTION; TARGETED THERAPIES; GLIOBLASTOMA CELLS; GLIOMA-CELLS; EXPRESSION; GENE; PATHWAYS	EGFRvIII is a key oncogene in glioblastoma (GBM). EGFRvIII results from an in-frame deletion in the extracellular domain of EGFR, does not bind ligand and is thought to be constitutively active. Although EGFRvIII dimerization is known to activate EGFRvIII, the factors that drive EGFRvIII dimerization and activation are not well understood. Here we present a new model of EGFRvIII activation and propose that oncogenic activation of EGFRvIII in glioma cells is driven by co-expressed activated EGFR wild type (EGFRwt). Increasing EGFRwt leads to a striking increase in EGFRvIII tyrosine phosphorylation and activation while silencing EGFRwt inhibits EGFRvIII activation. Both the dimerization arm and the kinase activity of EGFRwt are required for EGFRvIII activation. EGFRwt activates EGFRvIII by facilitating EGFRvIII dimerization. We have previously identified HB-EGF, a ligand for EGFRwt, as a gene induced specifically by EGFRvIII. In this study, we show that HB-EGF is induced by EGFRvIII only when EGFRwt is present. Remarkably, altering HB-EGF recapitulates the effect of EGFRwt on EGFRvIII activation. Thus, increasing HB-EGF leads to a striking increase in EGFRvIII tyrosine phosphorylation while silencing HB-EGF attenuates EGFRvIII phosphorylation, suggesting that an EGFRvIII-HB-EGF-EGFRwt feed-forward loop regulates EGFRvIII activation. Silencing EGFRwt or HB-EGF leads to a striking inhibition of EGFRvIII-induced tumorigenicity, while increasing EGFRwt or HB-EGF levels resulted in accelerated EGFRvIII-mediated oncogenicity in an orthotopic mouse model. Furthermore, we demonstrate the existence of this loop in human GBM. Thus, our data demonstrate that oncogenic activation of EGFRvIII in GBM is likely maintained by a continuous EGFRwt-EGFRvIII-HB-EGF loop, potentially an attractive target for therapeutic intervention.	[Li, L.; Chakraborty, S.; Puliyappadamba, V. T.; Rehman, A.; Jiwani, A. J.; Habib, A. A.] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75216 USA; [Yang, C-R; Boothman, D. A.; Habib, A. A.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Simmons Comprehens Canc Ctr, Dallas, TX 75216 USA; [Hatanpaa, K. J.; Raisanen, J.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75216 USA; [Cipher, D. J.] Univ Texas Arlington, Coll Nursing, Arlington, TX 76019 USA; [Mickey, B.; Madden, C.] Univ Texas SW Med Ctr Dallas, Dept Neurosurg, Dallas, TX 75216 USA; [Burma, S.; Saha, D.] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75216 USA; [Wang, Z.] Univ Alberta, Dept Cell Biol, Edmonton, AB, Canada; [Pingle, S. C.; Kesari, S.] Moores Canc Ctr, Translat Neurooncol Labs, Dept Neurosci, UC San Diego, CA USA; [Habib, A. A.] VA North Texas Hlth Care Syst, Dallas, TX USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Arlington; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Alberta; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA North Texas Health Care System	Habib, AA (corresponding author), Univ Texas SW Med Ctr Dallas, North Texas VA Healthcare Syst, Dept Neurol & Neurotherapeut, Mail Code 151,4500 S Lancaster Rd, Dallas, TX 75216 USA.	Amyn.Habib@UTSouthwestern.edu	Kesari, Santosh/E-8461-2013; Boothman, David/Q-7776-2019		NIH [RO1NS062080, RO1 CA139217]; National Institutes of Health [RO1 CA149461]; National Aeronautics and Space Administration [NNX13AI13G]; Cancer Prevention and Research Institute of Texas [RP100644]; NATIONAL CANCER INSTITUTE [R01CA149461, P30CA142543, R01CA139217] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS062080] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Aeronautics and Space Administration(National Aeronautics & Space Administration (NASA)); Cancer Prevention and Research Institute of Texas; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr Mien-Chie Hung (MD Anderson Cancer Center) for the EGFRwt-Myc plasmid and Dr James Van Brocklyn (Ohio State University) for GBM9 cells. This work was supported in part by NIH grant RO1NS062080 to AH and by RO1 CA139217 to DAB. SB is supported by grants from the National Institutes of Health (RO1 CA149461), National Aeronautics and Space Administration (NNX13AI13G) and the Cancer Prevention and Research Institute of Texas (RP100644).	Acquaviva J, 2011, CANCER RES, V71, P7198, DOI 10.1158/0008-5472.CAN-11-1514; Barkovich KJ, 2012, CANCER DISCOV, V2, P450, DOI 10.1158/2159-8290.CD-11-0287; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; Biernat W, 2004, BRAIN PATHOL, V14, P131, DOI 10.1111/j.1750-3639.2004.tb00045.x; Chung I, 2010, NATURE, V464, P783, DOI 10.1038/nature08827; Del Vecchio CA, 2013, ONCOGENE, V32, P2670, DOI 10.1038/onc.2012.280; Dowlati A, 2004, MOL CANCER THER, V3, P459; Estrada-Bernal A, 2011, J NEURO-ONCOL, V102, P353, DOI 10.1007/s11060-010-0345-z; Feng HZ, 2011, J CLIN INVEST, V121, P4670, DOI 10.1172/JCI58559; Ferguson KM, 2008, ANNU REV BIOPHYS, V37, P353, DOI 10.1146/annurev.biophys.37.032807.125829; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Hatanpaa KJ, 2010, NEOPLASIA, V12, P675, DOI 10.1593/neo.10688; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Huang PH, 2007, P NATL ACAD SCI USA, V104, P12867, DOI 10.1073/pnas.0705158104; Huang PH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.287re6; Hwang Y, 2011, MOL CANCER RES, V9, P1199, DOI 10.1158/1541-7786.MCR-11-0229; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Johns TG, 2007, CLIN CANCER RES, V13, P1911, DOI 10.1158/1078-0432.CCR-06-1453; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Luwor RB, 2004, ONCOGENE, V23, P6095, DOI 10.1038/sj.onc.1207870; Magnus N, 2010, BLOOD, V116, P815, DOI 10.1182/blood-2009-10-250639; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Mishima K, 1998, ACTA NEUROPATHOL, V96, P322, DOI 10.1007/s004010050901; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Nishikawa Ryo, 2004, Brain Tumor Pathol, V21, P53, DOI 10.1007/BF02484510; Pillay V, 2009, NEOPLASIA, V11, P448, DOI 10.1593/neo.09230; Puliyappadamba VT, 2013, CELL REP, V4, P764, DOI 10.1016/j.celrep.2013.07.025; Ramnarain DB, 2008, CELL DEATH DIFFER, V15, P344, DOI 10.1038/sj.cdd.4402268; Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753; Reardon DA, 2006, ONCOLOGIST, V11, P152, DOI 10.1634/theoncologist.11-2-152; SAMUELS V, 1989, AM J PATHOL, V134, P895; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Smith K, 2005, CANCER RES, V65, P5221, DOI 10.1158/0008-5472.CAN-05-0169; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Tang CK, 2000, CANCER RES, V60, P3081; Thomas CY, 2003, INT J CANCER, V104, P19, DOI 10.1002/ijc.10880; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vivanco I, 2012, CANCER DISCOV, V2, P458, DOI 10.1158/2159-8290.CD-11-0284; Wang Q, 2005, EMBO REP, V6, P942, DOI 10.1038/sj.embor.7400491; Zhu H, 2009, P NATL ACAD SCI USA, V106, P2712, DOI 10.1073/pnas.0813314106	43	33	36	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2014	33	33					4253	4264		10.1038/onc.2013.400	http://dx.doi.org/10.1038/onc.2013.400			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MB	24077285	Green Accepted			2022-12-28	WOS:000341155800007
J	Kim, IG; Kim, SY; Choi, SI; Lee, JH; Kim, KC; Cho, EW				Kim, I. G.; Kim, S. Y.; Choi, S. I.; Lee, J. H.; Kim, K. C.; Cho, E. W.			Fibulin-3-mediated inhibition of epithelial-to-mesenchymal transition and self-renewal of ALDH plus lung cancer stem cells through IGF1R signaling	ONCOGENE			English	Article						FBLN3; lung; EMT; cancer stem cells; IGF1R/PI3K/AKT/GSK3 beta pathway	GROWTH-FACTOR RECEPTOR; GLIOMA GROWTH; BETA-CATENIN; TGF-BETA; PATHWAY; RESISTANCE; INVASION; INSULIN; TARGET; PROGRESSION	Fibulins (FBLNs), a family of extracellular matrix proteins, have recently been shown to act as tumor suppressors or activators in different cancers, and the underlying molecular mechanisms of their action in cancer remain unclear. We have previously shown that the expression of FBLN3 is suppressed by promoter hypermethylation and is associated with invasiveness in aggressive non-small cell lung cancer. In this study, we evaluated the roles and signaling mechanism of FBLN3 in lung cancer stem cells (CSCs). Forced expression of FBLN3 suppressed invasion and migration of lung adenocarcinoma cells and decreased the expression of epithelial-to-mesenchymal transition (EMT) activators, including N-cadherin and Snail. Stemness activities of lung adenocarcinoma cells were also suppressed by FBLN3 as indicated by a decrease in spheroid formation and the levels of stemness markers such as Sox2 and beta-catenin. These effects of FBLN3 were mediated by the glycogen synthase kinase-3 beta, GSK3 beta/beta-catenin pathway, and the upstream regulators of GSK3 beta, including phosphoinositide 3-kinase (PI3K)/AKT and insulin-like growth factor-1 receptor (IGF1R), were inactivated by FBLN3. Moreover, IGF1R was shown to be a direct target of FBLN3, which competitively inhibited insulin-like growth factor (IGF) action. To confirm the effect of FBLN3 on lung CSCs, aldehyde dehydrogenase-positive (ALDH +) A549 lung CSCs were sorted and treated with recombinant FBLN3 protein. FBLN3 clearly suppressed EMT, stemness activity and the over-activated IGF1R/PI3K/AKT/GSK3 beta pathway of the ALDH + CSC subpopulation. In addition, injection of recombinant FBLN3 protein around subcutaneous xenografts established with ALDH + CSCs in athymic nude mice significantly suppressed tumor growth and progression. Overall, our results show that FBLN3 suppresses both EMT and self-renewal of the lung CSCs by modulating the IGF1R/PI3K/AKT/GSK3 beta pathway and that FBLN3 would be useful as an alternative CSC therapy.	[Kim, I. G.; Kim, S. Y.; Choi, S. I.; Lee, J. H.; Kim, K. C.] KAERI, Environm Radiat Res Grp, Dept Radiat Biol, Taejon 305353, South Korea; [Kim, I. G.; Choi, S. I.; Lee, J. H.] Univ Sci & Technol, Dept Radiat Biotechnol & Appl Radioisotope, Taejon, South Korea; [Cho, E. W.] Korea Res Inst Biosci & Biotechnol, Canc Biomarkers Dev Res Ctr, Taejon, South Korea	Korea Atomic Energy Research Institute (KAERI); Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Kim, IG (corresponding author), KAERI, Environm Radiat Res Grp, Dept Radiat Biol, 989-111 Daedeok daero, Taejon 305353, South Korea.	igkim@kaeri.re.kr			Ministry of Science, ICT & Future Planning (Nuclear Research and Development Program) of the Republic of Korea; Korea Atomic Energy Research Institute	Ministry of Science, ICT & Future Planning (Nuclear Research and Development Program) of the Republic of Korea; Korea Atomic Energy Research Institute	We acknowledge the financial supports from the Ministry of Science, ICT & Future Planning (Nuclear Research and Development Program) of the Republic of Korea and basic program of Korea Atomic Energy Research Institute.	Alison MR, 2012, CANCER TREAT REV, V38, P589, DOI 10.1016/j.ctrv.2012.03.003; Araki K, 2011, BRIT J CANCER, V105, P1885, DOI 10.1038/bjc.2011.452; Bendall SC, 2007, NATURE, V448, P1015, DOI 10.1038/nature06027; Biddle A, 2012, CANCER METAST REV, V31, P285, DOI 10.1007/s10555-012-9345-0; Bill A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041179; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Brognard J, 2001, CANCER RES, V61, P3986; Camaj P, 2009, BIOL CHEM, V390, P1293, DOI 10.1515/BC.2009.140; Cappuzzo F, 2010, ANN ONCOL, V21, P562, DOI 10.1093/annonc/mdp357; de Vega S, 2009, CELL MOL LIFE SCI, V66, P1890, DOI 10.1007/s00018-009-8632-6; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Desbois-Mouthon C, 2009, CLIN CANCER RES, V15, P5445, DOI 10.1158/1078-0432.CCR-08-2980; Doble BW, 2007, CELLS TISSUES ORGANS, V185, P73, DOI 10.1159/000101306; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Esposito L, 2010, CURR GENOMICS, V11, P513, DOI 10.2174/138920210793175903; Fuxe J, 2010, CELL CYCLE, V9, P2363, DOI 10.4161/cc.9.12.12050; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gorelik E, 2010, ANTI-CANCER AGENT ME, V10, P164, DOI 10.2174/187152010790909308; Heist RS, 2009, PHARMACOGENOMICS, V10, P59, DOI 10.2217/14622416.10.1.59; Hu B, 2012, CANCER RES, V72, P3873, DOI 10.1158/0008-5472.CAN-12-1060; Hu B, 2009, MOL CANCER RES, V7, P1756, DOI 10.1158/1541-7786.MCR-09-0207; Hu YJ, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-123; Hwang CF, 2010, J PATHOL, V222, P367, DOI 10.1002/path.2776; Ischenko I, 2008, CURR MED CHEM, V15, P3171, DOI 10.2174/092986708786848541; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jiang TY, 2009, CANCER RES, V69, P845, DOI 10.1158/0008-5472.CAN-08-2762; Jiang YG, 2007, INT J UROL, V14, P1034, DOI 10.1111/j.1442-2042.2007.01866.x; Jones RA, 2009, ONCOGENE, V28, P2152, DOI 10.1038/onc.2009.79; Kim EJ, 2012, INT J ONCOL, V40, P402, DOI 10.3892/ijo.2011.1191; Korkaya H, 2007, BIODRUGS, V21, P299, DOI 10.2165/00063030-200721050-00002; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Li JL, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-49; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; McCubrey JA, 2012, CURR PHARM DESIGN, V18, P1784; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Morrison R, 2011, J ONCOL, V2011, DOI 10.1155/2011/941876; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Perona R, 2011, CLIN TRANSL ONCOL, V13, P289, DOI 10.1007/s12094-011-0656-3; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Prud'homme GJ, 2012, CURR PHARM DESIGN, V18, P2838; Rivera C, 2011, J ONCOL, V2011, DOI 10.1155/2011/549181; Rui W, 2010, LUNG CANCER, V69, P239, DOI 10.1016/j.lungcan.2009.10.009; Schiemann WP, 2002, J BIOL CHEM, V277, P27367, DOI 10.1074/jbc.M200148200; Shan JJ, 2012, HEPATOLOGY, V56, P1004, DOI 10.1002/hep.25745; Sung JM, 2008, BIOCHEM BIOPH RES CO, V371, P163, DOI 10.1016/j.bbrc.2008.04.038; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Ucar D, 2009, CHEM-BIOL INTERACT, V178, P48, DOI 10.1016/j.cbi.2008.09.029; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Yang JL, 2011, CLIN CANCER RES, V17, P7563, DOI 10.1158/1078-0432.CCR-11-1707; Yue W, 2009, CANCER RES, V69, P6339, DOI 10.1158/0008-5472.CAN-09-0398	53	57	61	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3908	3917		10.1038/onc.2013.373	http://dx.doi.org/10.1038/onc.2013.373			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	24013232				2022-12-28	WOS:000339394700003
J	Yu, H; Liu, T; Zhao, Z; Chen, Y; Zeng, J; Liu, S; Zhu, F				Yu, H.; Liu, T.; Zhao, Z.; Chen, Y.; Zeng, J.; Liu, S.; Zhu, F.			Mutations in 3 '-long terminal repeat of HERV-W family in chromosome 7 upregulate syncytin-1 expression in urothelial cell carcinoma of the bladder through interacting with c-Myb	ONCOGENE			English	Article						urothelial cell carcinoma of the bladder; syncytin-1; human endogenous retrovirus; long terminal repeat; c-Myb	MARROW-DERIVED CELLS; HUMAN BREAST-CANCER; MOLECULAR-DYNAMICS; ENDOGENOUS RETROVIRUSES; HUMAN TISSUES; IN-VITRO; PROTEIN; FUSION; GENE; TRANSFORMATION	Human endogenous retrovirus (HERV) accounts for similar to 8% of the human genome. Recent studies have reported that multiple HERV genes and long terminal repeats (LTRs) are involved in human tumorigenesis. Here we demonstrated that HERV-W env (syncytin-1) was overexpressed in 75.6% (62/82) of urothelial cell carcinoma (UCC) tissues of the bladder compared with only 6.1% (5/82) of matched tumor-adjacent tissues (P<0.001). Syncytin-1 overexpression increased proliferation and viability of immortalized human uroepithelial cells. Colony-formation experiments and in-vivo tumor xenografts suggested that syncytin-1 overexpression had oncogenic potential. Syncytin-1 3'-LTR mutations (142T>C and 277A>G) were present in 87.8% (72/82) of UCC tissues. Normal 3'-LTR was found in 12.2% (10/82) of UCC tissues compared with 95.1% (78/82) of matched tumor-adjacent tissues (P<0.001). Interestingly, 3'-LTR mutations were significantly associated with syncytin-1 overexpression. Luciferase assay and expression analysis revealed that 3'-LTR mutations, especially the 142T>C mutation, enhanced the syncytin-1 promoter activity and expression. In-silico analysis, electrophoretic mobility shift assays and chromatin immunoprecipitation assays demonstrated the binding of c-Myb to 3'-LTRs when the mutations occurred. This alternative interaction was found to be dependent on 142T>C mutation. C-Myb activated syncytin-1 promoter activity and expression by binding to mutant 3'-LTRs. Taken together, these data indicate that syncytin-1 overexpression may be an indicator of UCC risk. The 3'-LTR mutations may upregulate syncytin-1 expression, enabling it to participate in UCC tumorigenesis and development by interacting with c-Myb.	[Yu, H.; Chen, Y.; Zeng, J.; Zhu, F.] Wuhan Univ, Sch Med, Dept Med Microbiol, Wuhan 430071, Peoples R China; [Liu, T.; Liu, S.] Beijing Inst Basic Med Sci, State Key Lab Prote, Dept Neurobiol, Beijing, Peoples R China; [Zhao, Z.] Wuhan Univ, Zhongnan Hosp, Dept Urol, Wuhan, Peoples R China	Wuhan University; Academy of Military Medical Sciences - China; Wuhan University	Zhu, F (corresponding author), Wuhan Univ, Sch Med, Dept Med Microbiol, 185 Donghu Rd, Wuhan 430071, Peoples R China.	zhufan@hotmail.com	; Liu, Tao/C-7796-2011	Yu, Honglian/0000-0003-3915-056X; Liu, Tao/0000-0003-1701-6618; zhu, fan/0000-0001-7031-2956	National Natural Sciences Foundation of China [81271820, 30870789, 30300117]; Stanley Foundation from the Stanley Medical Research Institute (SMRI), USA [06R-1366]; Hubei Provincial Natural Science Foundation for Innovative Research Team [2012FFA043]; Wuhan University [274041]	National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); Stanley Foundation from the Stanley Medical Research Institute (SMRI), USA; Hubei Provincial Natural Science Foundation for Innovative Research Team; Wuhan University	We thank Wei Jin (Fudan University, Shanghai, China) for providing the plasmid pCMV-c-Myb. We would like to thank Don Banting, Awadhesh Kumar Sah and Navin Shrestha for polishing our writing. This work was supported by grants from the National Natural Sciences Foundation of China (No. 81271820, No. 30870789 and No. 30300117), the Stanley Foundation from the Stanley Medical Research Institute (SMRI), USA (No. 06R-1366) for Dr F Zhu, Hubei Provincial Natural Science Foundation for Innovative Research Team (No. 2012FFA043) and the project of Innovative Research Team of Wuhan University (No. 274041).	Ahn K, 2009, MOL CELLS, V28, P99, DOI 10.1007/s10059-009-0107-y; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Bjerregaard B, 2006, CELL MOL LIFE SCI, V63, P1906, DOI 10.1007/s00018-006-6201-9; Boese A, 2000, ONCOGENE, V19, P4328, DOI 10.1038/sj.onc.1203794; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHRISTIAN BJ, 1987, CANCER RES, V47, P6066; Chung KY, 2005, J CLIN ONCOL, V23, P1803, DOI 10.1200/JCO.2005.08.037; Delidaki M, 2011, MOL CELL ENDOCRINOL, V332, P213, DOI 10.1016/j.mce.2010.10.013; Doern CD, 2008, MICROBIOL-SGM, V154, P1998, DOI 10.1099/mic.0.2007/013466-0; Eble JN, 2004, PATHOLOGY GENETICS T; Edge SB, 2010, AJCC CANC STAGING MA; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Feng WJN, 2007, INT J CANCER, V120, P81, DOI 10.1002/ijc.22256; Frendo JL, 2003, MOL CELL BIOL, V23, P3566, DOI 10.1128/MCB.23.10.3566-3574.2003; Gimenez J, 2010, NUCLEIC ACIDS RES, V38, P2229, DOI 10.1093/nar/gkp1214; Huang WJ, 2011, SCHIZOPHRENIA BULL, V37, P988, DOI 10.1093/schbul/sbp166; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Joshi R, 2007, CELL, V131, P530, DOI 10.1016/j.cell.2007.09.024; KERBEL RS, 1983, MOL CELL BIOL, V3, P523, DOI 10.1128/MCB.3.4.523; Knerr I, 2007, APOPTOSIS, V12, P37, DOI 10.1007/s10495-006-0329-9; Lamprecht B, 2010, NAT MED, V16, P571, DOI 10.1038/nm.2129; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Landry JR, 2002, GENOMICS, V80, P499, DOI 10.1006/geno.2002.6863; Liu F, 2006, ONCOGENE, V25, P795, DOI 10.1038/sj.onc.1209105; Lu X, 2011, ADV EXP MED BIOL, V714, P129, DOI 10.1007/978-94-007-0782-5_6; Lu X, 2009, CANCER RES, V69, P8536, DOI 10.1158/0008-5472.CAN-09-2159; LUTY BA, 1994, MOL SIMULAT, V14, P11, DOI 10.1080/08927029408022004; Mackerell AD, 2004, J COMPUT CHEM, V25, P1400, DOI 10.1002/jcc.20065; Mallet F, 2004, P NATL ACAD SCI USA, V101, P1731, DOI 10.1073/pnas.0305763101; Nellaker C, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-44; Okamoto M, 1996, CANCER RES, V56, P4649; Perron H, 2012, MULT SCLER J, V18, P1721, DOI 10.1177/1352458512441381; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Prudhomme S, 2004, J VIROL, V78, P12157, DOI 10.1128/JVI.78.22.12157-12168.2004; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Rizvi AZ, 2006, P NATL ACAD SCI USA, V103, P6321, DOI 10.1073/pnas.0508593103; Romanish MT, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030010; ROSZELL JA, 1977, CANCER RES, V37, P239; Ruprecht K, 2008, CELL MOL LIFE SCI, V65, P3366, DOI 10.1007/s00018-008-8496-1; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schubert SW, 2008, NUCLEIC ACIDS RES, V36, P3834, DOI 10.1093/nar/gkn306; Sin HS, 2006, ARCH VIROL, V151, P1985, DOI 10.1007/s00705-006-0764-5; Stauffer Yves, 2004, Cancer Immun, V4, P2; Strick R, 2007, J MOL MED, V85, P23, DOI 10.1007/s00109-006-0104-y; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5; Wang-Johanning F, 2003, ONCOGENE, V22, P1528, DOI 10.1038/sj.onc.1206241; Wang-Johanning F, 2001, CLIN CANCER RES, V7, P1553; Wei W, 2006, CANCER LETT, V244, P119, DOI 10.1016/j.canlet.2005.12.008; Xiao X, 2010, CURR CANCER DRUG TAR, V10, P384, DOI 10.2174/156800910791208535; Yu CC, 2002, J BIOL CHEM, V277, P50062, DOI 10.1074/jbc.M209316200; Zhao Jing, 2011, Genes Cancer, V2, P914, DOI 10.1177/1947601911431841; Zhu F, 2005, BIOCHEMISTRY-MOSCOW+, V70, P920, DOI 10.1007/s10541-005-0203-3	53	43	44	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3947	3958		10.1038/onc.2013.366	http://dx.doi.org/10.1038/onc.2013.366			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	24013223				2022-12-28	WOS:000339394700007
J	Maynard, MA; Ferretti, R; Hilgendorf, KI; Perret, C; Whyte, P; Lees, JA				Maynard, M. A.; Ferretti, R.; Hilgendorf, K. I.; Perret, C.; Whyte, P.; Lees, J. A.			Bmi1 is required for tumorigenesis in a mouse model of intestinal cancer	ONCOGENE			English	Article						Bmi1; Apc; colorectal cancer; intestine; apoptosis; Arf	STEM-CELLS; EXPRESSION; PROGRESSION; MICE	The epigenetic regulator BMI1 is upregulated progressively in a wide variety of human tumors including colorectal cancer. In this study, we assessed the requirement for Bmi1 in intestinal tumorigenesis using an autochthonous mouse model in which Apc was conditionally ablated in the intestinal epithelium. Germline mutation of Bmi1 significantly reduced both the number and size of small intestinal adenomas arising in this model, and it acted in a dose-dependent manner. Moreover, in contrast to wild-type controls, Bmi1(-/-) mice showed no increase in median tumor size, and a dramatic decrease in tumor number, between 3 and 4 months of age. Thus, Bmi1 is required for both progression and maintenance of small intestinal adenomas. Importantly, Bmi1 deficiency did not disrupt oncogenic events arising from Apc inactivation. Instead, the Arf tumor suppressor, a known target of Bmi1 epigenetic silencing, was upregulated in Bmi1 mutant tumors. This was accompanied by significant upregulation of p53, which was confirmed by sequencing to be wild-type, and also elevated apoptosis within the smallest Bmi1(-/-) adenomas. By crossing Arf into this cancer model, we showed that Arf is required for the induction of both p53 and apoptosis, and it is a key determinant of the ability of Bmi1 deficiency to suppress intestinal tumorigenesis. Finally, a conditional Bmi1 mutant strain was generated and used to determine the consequences of deleting Bmi1 specifically within the intestinal epithelium. Strikingly, intestinal-specific Bmi1 deletion suppressed small intestinal adenomas in a manner that was indistinguishable from germline Bmi1 deletion. Thus, we conclude that Bmi1 deficiency impairs the progression and maintenance of small intestinal tumors in a cell autonomous and highly Arf-dependent manner.	[Maynard, M. A.; Ferretti, R.; Hilgendorf, K. I.; Lees, J. A.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Hilgendorf, K. I.; Lees, J. A.] MIT, Dept Biol, Cambridge, MA 02139 USA; [Perret, C.] Univ Paris 05, INSERM, Inst Cochin, Paris, France; [Whyte, P.] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; McMaster University	Lees, JA (corresponding author), MIT, David H Koch Inst Integrat Canc Res, 77 Massachusetts ave, Cambridge, MA 02139 USA.	jalees@mit.edu	Perret-Mayeux, Christine/L-3297-2017	perret, christine/0000-0003-4710-7051	NCI/NIH grant; NATIONAL CANCER INSTITUTE [P01CA042063, P30CA014051] Funding Source: NIH RePORTER	NCI/NIH grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We dedicate this paper to the memory of Officer Sean Collier, for his caring service to the MIT community and for his sacrifice. This work was supported by an NCI/NIH grant to JAL who is a Ludwig Scholar at MIT, and fellowships to MAM (CIHR), RF (Ludwig) and KIH (NSF). We thank the Koch Institute Swanson Biotechnology Center for key technical support, particularly personnel in the ES Cell & Transgenic, Histology and Microscopy facilities. We also thank Sylvie Robine (Institut Curie) for the Vil-cre mouse and members of the Lees and Jacks labs for thoughtful comments.	Abdouh M, 2009, J NEUROSCI, V29, P8884, DOI 10.1523/JNEUROSCI.0968-09.2009; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Colnot S, 2004, LAB INVEST, V84, P1619, DOI 10.1038/labinvest.3700180; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Fasano CA, 2007, CELL STEM CELL, V1, P87, DOI 10.1016/j.stem.2007.04.001; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gibson SL, 2003, CANCER RES, V63, P742; Gieni RS, 2009, BIOCHEM CELL BIOL, V87, P711, DOI 10.1139/O09-057; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Grinstein E, 2007, CELL SIGNAL, V19, P2428, DOI 10.1016/j.cellsig.2007.06.021; Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Li DW, 2010, J CANCER RES CLIN, V136, P997, DOI 10.1007/s00432-009-0745-7; Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165; Sherr CJ, 2005, COLD SH Q B, V70, P129, DOI 10.1101/sqb.2005.70.004; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Subkhankulova T, 2010, MOL CELL NEUROSCI, V45, P151, DOI 10.1016/j.mcn.2010.06.006; Tallquist MD, 2000, GENESIS, V26, P113, DOI 10.1002/(SICI)1526-968X(200002)26:2<113::AID-GENE3>3.0.CO;2-2; Tateishi K, 2006, CLIN CANCER RES, V12, P6960, DOI 10.1158/1078-0432.CCR-06-0449; Tian H, 2011, NATURE, V478, P255, DOI 10.1038/nature10408; van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Yu TX, 2012, J BIOL CHEM, V287, P3760, DOI 10.1074/jbc.M111.316349	25	29	30	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3742	3747		10.1038/onc.2013.333	http://dx.doi.org/10.1038/onc.2013.333			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23955081	Green Submitted, Green Accepted, Bronze			2022-12-28	WOS:000338942900013
J	Huang, J; Stewart, A; Maity, B; Hagen, J; Fagan, RL; Yang, J; Quelle, DE; Brenner, C; Fisher, RA				Huang, J.; Stewart, A.; Maity, B.; Hagen, J.; Fagan, R. L.; Yang, J.; Quelle, D. E.; Brenner, C.; Fisher, R. A.			RGS6 suppresses Ras-induced cellular transformation by facilitating Tip60-mediated Dnmt1 degradation and promoting apoptosis	ONCOGENE			English	Article						RGS protein; Ras; cellular transformation; Dnmt1; Tip60; apoptosis	PROTEIN SIGNALING 6; HETEROTRIMERIC G-PROTEINS; DNA METHYLTRANSFERASE; PROSTATE-CANCER; P53 ACTIVATION; BREAST-CANCER; CPG ISLANDS; EXPRESSION; CELLS; METHYLATION	The RAS protooncogene has a central role in regulation of cell proliferation, and point mutations leading to oncogenic activation of Ras occur in a large number of human cancers. Silencing of tumor-suppressor genes by DNA methyltransferase 1 (Dnmt1) is essential for oncogenic cellular transformation by Ras, and Dnmt1 is overexpressed in numerous human cancers. Here we provide new evidence that the pleiotropic regulator of G protein signaling (RGS) family member RGS6 suppresses Ras-induced cellular transformation by facilitating Tip60-mediated degradation of Dmnt1 and promoting apoptosis. Employing mouse embryonic fibroblasts from wild-type and RGS6(-/-) mice, we found that oncogenic Ras induced upregulation of RGS6, which in turn blocked Ras-induced cellular transformation. RGS6 functions to suppress cellular transformation in response to oncogenic Ras by downregulating Dnmt1 protein expression leading to inhibition of Dnmt1-mediated anti-apoptotic activity. Further experiments showed that RGS6 functions as a scaffolding protein for both Dnmt1 and Tip60 and is required for Tip60-mediated acetylation of Dnmt1 and subsequent Dnmt1 ubiquitylation and degradation. The RGS domain of RGS6, known only for its GTPase-activating protein activity toward G alpha subunits, was sufficient to mediate Tip60 association with RGS6. This work demonstrates a novel signaling action for RGS6 in negative regulation of oncogene-induced transformation and provides new insights into our understanding of the mechanisms underlying Ras-induced oncogenic transformation and regulation of Dnmt1 expression. Importantly, these findings identify RGS6 as an essential cellular defender against oncogenic stress and a potential therapeutic target for developing new cancer treatments.	[Huang, J.; Stewart, A.; Maity, B.; Hagen, J.; Yang, J.; Quelle, D. E.; Fisher, R. A.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA; [Fagan, R. L.; Brenner, C.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Fisher, RA (corresponding author), Univ Iowa, Carver Coll Med, Dept Pharmacol, Roy J & Lucille A Carver Coll Med, 2-512 Bowen Sci Bldg, Iowa City, IA 52242 USA.	rory-fisher@uiowa.edu	Brenner, Charles/D-6339-2014	Brenner, Charles/0000-0002-4955-3226; Quelle, Dawn/0000-0001-8776-0122; Stewart, Adele/0000-0003-4968-2471; Fisher, Rory/0000-0003-3108-4836; Switzer, Rebecca/0000-0003-0591-2538	National Cancer Institute [CA161882, HHSN261200433000C, CA075954, CA090367]; American Cancer Society [PF-11-141-01]; NATIONAL CANCER INSTITUTE [R01CA161882, P30CA086862, R01CA090367, R01CA075954] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr John Koland for his careful reading of and useful suggestions for this manuscript, and Sara Reed for identifying effective Tip60 small hairpin RNAs for our assays. This project was supported by National Cancer Institute grants and contracts CA161882 (RAF), HHSN261200433000C (CB), CA075954 (CB), CA090367 (DEQ) and American Cancer Society (PF-11-141-01 (RLF)).	Berman DM, 2004, CANCER RES, V64, P6820, DOI 10.1158/0008-5472.CAN-04-1916; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Cheever ML, 2008, NAT STRUCT MOL BIOL, V15, P155, DOI 10.1038/nsmb.1377; Chen M, 2012, MOL CANCER THER, V11, P370, DOI 10.1158/1535-7163.MCT-11-0458; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Du ZW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001462; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2; Fagan RL, 2013, J BIOL CHEM, V288, P23858, DOI 10.1074/jbc.M113.480517; Geutjes EJ, 2012, ONCOGENE, V31, P3827, DOI 10.1038/onc.2011.552; He SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027684; Huang J, 2011, CANCER RES, V71, P6310, DOI 10.1158/0008-5472.CAN-10-3397; Leonhardt H, 2000, J CELL BIOCHEM, P78; Li LC, 2004, BBA-REV CANCER, V1704, P87, DOI 10.1016/j.bbcan.2004.06.001; Li QX, 2009, NAT CELL BIOL, V11, P1128, DOI 10.1038/ncb1927; Liu ZY, 2004, J BIOL CHEM, V279, P14120, DOI 10.1074/jbc.M309547200; Liu ZY, 2002, J BIOL CHEM, V277, P37832, DOI 10.1074/jbc.M205908200; Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932; Maity B, 2013, CARCINOGENESIS, V34, P1747, DOI 10.1093/carcin/bgt128; Maity B, 2012, J BIOL CHEM, V287, P4972, DOI 10.1074/jbc.M111.297218; Maity B, 2011, J BIOL CHEM, V286, P1409, DOI 10.1074/jbc.M110.186700; Martemyanov KA, 2005, J BIOL CHEM, V280, P5133, DOI 10.1074/jbc.C400596200; Maslov AY, 2012, ONCOGENE, V31, P5172, DOI 10.1038/onc.2012.9; Nakagawa T, 2003, J UROLOGY, V170, P2463, DOI 10.1097/01.ju.0000095919.50869.c9; Ordway JM, 2004, ONCOGENE, V23, P3737, DOI 10.1038/sj.onc.1207483; Pakneshan P, 2005, CARCINOGENESIS, V26, P557, DOI 10.1093/carcin/bgi009; Patra SK, 2008, FEBS J, V275, P5217, DOI 10.1111/j.1742-4658.2008.06658.x; Patra SK, 2008, EXP CELL RES, V314, P1193, DOI 10.1016/j.yexcr.2008.01.012; Patra SK, 2002, MOL CARCINOGEN, V33, P163, DOI 10.1002/mc.10033; Peng DF, 2005, CANCER SCI, V96, P403, DOI 10.1111/j.1349-7006.2005.00071.x; Pruitt K, 2005, J BIOL CHEM, V280, P23363, DOI 10.1074/jbc.M503083200; Reu FJ, 2006, J CLIN ONCOL, V24, P3771, DOI 10.1200/JCO.2005.03.4074; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Saito Y, 2003, INT J CANCER, V105, P527, DOI 10.1002/ijc.11127; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; Santourlidis S, 2001, MOL CARCINOGEN, V32, P36, DOI 10.1002/mc.1062; Seaberg RM, 2002, J NEUROSCI, V22, P1784, DOI 10.1523/JNEUROSCI.22-05-01784.2002; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Syeda F, 2011, J BIOL CHEM, V286, P15344, DOI 10.1074/jbc.M110.209882; Xu M, 2010, MOL MED REP, V3, P699, DOI 10.3892/mmr_00000320; Zhu YM, 2007, INT J COLORECTAL DIS, V22, P661, DOI 10.1007/s00384-006-0224-4	46	27	28	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3604	3611		10.1038/onc.2013.324	http://dx.doi.org/10.1038/onc.2013.324			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23995786	Green Accepted			2022-12-28	WOS:000338941100012
J	Wang, Z; Wang, B; Shi, Y; Xu, C; Xiao, HL; Ma, LN; Xu, SL; Yang, L; Wang, QL; Dang, WQ; Cui, W; Yu, SC; Ping, YF; Cui, YH; Kung, HF; Qian, C; Zhang, X; Bian, XW				Wang, Z.; Wang, B.; Shi, Y.; Xu, C.; Xiao, H. L.; Ma, L. N.; Xu, S. L.; Yang, L.; Wang, Q. L.; Dang, W. Q.; Cui, W.; Yu, S. C.; Ping, Y. F.; Cui, Y. H.; Kung, H. F.; Qian, C.; Zhang, X.; Bian, X. W.			Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2	ONCOGENE			English	Article							FORMYLPEPTIDE RECEPTOR; MICRORNA POLYCISTRON; MIR-17-92 CLUSTER; TUMOR PROGRESSION; CANCER; PROLIFERATION; EXPRESSION; INVASION; BRAIN; DIFFERENTIATION	Emerging evidence has shown that cancer stem cells (CSCs) are the cellular determinants to promote cancer invasion and metastasis. However, the mechanism underlying CSC invasion remains unknown. MicroRNAs are evolutionally conserved small noncoding RNAs that are critical for the regulation of gene expression, and their expressions are often dysregulated in cancers. In the present study, we demonstrated that two functionally related microRNAs, miR-20a and -106a (miR-20a/106a), were capable of enhancing the invasiveness of CD133(+) glioma stem cells (GSCs) isolated from both glioblastoma cell line U87 and primary human glioma specimens. We found that the level of miR-20a/106a in GSCs was significantly higher than that in the committed CD133(-) glioma cells, and correlated with the invasive capability of GSCs. By bioinformatic analysis, we identified tissue inhibitor of metalloproteinases-2 (TIMP-2) as one of the miR-20a/106a-targeted genes. TIMP-2 level correlated inversely with miR-20/106 expression. Directly targeting by miR-20a/106a on 3'-untranslation region (3'-UTR) of TIMP-2 mRNA was confirmed by 3'-UTR dual-luciferase reporter assay. Knockdown of miR-20a/106a in GSCs increased endogenous TIMP-2 protein abundance, thereby inhibiting GSC invasion. We also found that Nordy, a synthetic lipoxygenase inhibitor, inhibited GSC invasiveness by elevating the expression of TIMP-2 via downregulation of miR-20a/106a. Our results indicate that miR-20a/106a has a key role in GSC invasion and may serve as targets for treatment of glioblastoma.	[Zhang, X.] Third Mil Med Univ, Southwest Hosp, Inst Pathol, Key Lab Tumor Immunopathol,Minist Educ China, Chongqing 400038, Peoples R China; Third Mil Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing 400038, Peoples R China	Army Medical University; Ministry of Education, China; Army Medical University	Zhang, X (corresponding author), Third Mil Med Univ, Southwest Hosp, Inst Pathol, Key Lab Tumor Immunopathol,Minist Educ China, 30 Gaotanyan, Chongqing 400038, Peoples R China.	zhangxia45@gmail.com; zhangxia45@gmail.com; bianxiuwu@263.net	Zhang, Xia/B-8152-2008; Bian, Xiu-Wu/D-4736-2017	Zhang, Xia/0000-0002-9040-1486; Bian, Xiu-Wu/0000-0003-4383-0197; XU, CHUAN/0000-0002-5320-2277	National Natural Science Foundation of China (NSFC) [81101606, 81101631, 30725035, 30930103]; National Basic Research Program of China (973 Program) [2010CB529403]; Natural Science Foundation Project of CQ CSTC [CSTC2012JJA10124]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China (973 Program)(National Basic Research Program of China); Natural Science Foundation Project of CQ CSTC(Natural Science Foundation Project of CQ CSTC)	We are grateful to our colleagues for helpful comments. This work was supported by the grants from National Natural Science Foundation of China (NSFC, Nos. 81101606, 81101631, 30725035 and 30930103), National Basic Research Program of China (973 Program, No. 2010CB529403) and Natural Science Foundation Project of CQ CSTC (CSTC2012JJA10124).	ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; Ara T, 1998, J PEDIATR SURG, V33, P1272, DOI 10.1016/S0022-3468(98)90167-1; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bian XW, 2008, PROTEOMICS, V8, P484, DOI 10.1002/pmic.200700054; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Caraglia M, 2012, CURR CANCER DRUG TAR, V12, P185, DOI 10.2174/156800912799277458; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen JH, 2006, BIOCHEM BIOPH RES CO, V342, P1368, DOI 10.1016/j.bbrc.2006.02.113; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; Croce CM, 2011, NAT MED, V17, P935, DOI 10.1038/nm0811-935; Davis F G, 2001, Expert Rev Anticancer Ther, V1, P395, DOI 10.1586/14737140.1.3.395; DECLERCK YA, 1991, CANCER RES, V51, P2151; Drappatz J, 2009, EXPERT REV NEUROTHER, V9, P519, DOI [10.1586/ern.09.10, 10.1586/ERN.09.10]; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Foshay KM, 2009, DEV BIOL, V326, P431, DOI 10.1016/j.ydbio.2008.11.016; Furstenberger G, 2006, INT J CANCER, V119, P2247, DOI 10.1002/ijc.22153; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Gunther HS, 2008, ONCOGENE, V27, P2897, DOI 10.1038/sj.onc.1210949; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hossain A, 2006, MOL CELL BIOL, V26, P8191, DOI 10.1128/MCB.00242-06; Hyde CAC, 2009, INT IMMUNOPHARMACOL, V9, P701, DOI 10.1016/j.intimp.2009.02.003; Imren S, 1996, CANCER RES, V56, P2891; Le Mercier M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045475; Legler JM, 1999, JNCI-J NATL CANCER I, V91, P1382, DOI 10.1093/jnci/91.16.1382; Li F, 2007, CELL RES, V17, P3, DOI 10.1038/sj.cr.7310118; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu JQ, 2011, CLIN CANCER RES, V17, P3638, DOI 10.1158/1078-0432.CCR-10-2456; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu Y, 2007, DEV BIOL, V310, P442, DOI 10.1016/j.ydbio.2007.08.007; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Nakada M, 2007, CELL MOL LIFE SCI, V64, P458, DOI 10.1007/s00018-007-6342-5; Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371; Pidgeon GP, 2007, CANCER METAST REV, V26, P503, DOI 10.1007/s10555-007-9098-3; Ping YF, 2011, CURR MOL MED, V11, P69, DOI 10.2174/156652411794474383; Ping YF, 2011, J PATHOL, V224, P344, DOI 10.1002/path.2908; Ping YF, 2011, STEM CELLS, V29, P888, DOI 10.1002/stem.650; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sayed D, 2011, PHYSIOL REV, V91, P827, DOI 10.1152/physrev.00006.2010; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Slack FJ, 2008, NEW ENGL J MED, V359, P2720, DOI 10.1056/NEJMe0808667; Uziel T, 2009, P NATL ACAD SCI USA, V106, P2812, DOI 10.1073/pnas.0809579106; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang B, 2011, STEM CELL REV REP, V7, P458, DOI 10.1007/s12015-010-9175-9; Wienholds E, 2005, FEBS LETT, V579, P5911, DOI 10.1016/j.febslet.2005.07.070; Wong P, 2010, CANCER RES, V70, P3833, DOI 10.1158/0008-5472.CAN-09-3268; Xu C, 2013, CANCER RES, V73, P3181, DOI 10.1158/0008-5472.CAN-12-4403; Yang XJ, 2013, INT IMMUNOPHARMACOL, V15, P191, DOI 10.1016/j.intimp.2012.12.002; Yao XH, 2008, J PATHOL, V215, P369, DOI 10.1002/path.2356; Ye XZ, 2012, J IMMUNOL, V189, P444, DOI 10.4049/jimmunol.1103248; Yi L, 2007, MODERN PATHOL, V20, P1061, DOI 10.1038/modpathol.3800942; Yu SC, 2008, CANCER LETT, V265, P124, DOI 10.1016/j.canlet.2008.02.010; Yu SC, 2009, STEM CELL REV REP, V5, P66, DOI 10.1007/s12015-008-9047-8; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103; Zhao Y, 2012, BIOCHEM BIOPH RES CO, V418, P647, DOI 10.1016/j.bbrc.2012.01.068	58	99	106	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1407	1419		10.1038/onc.2014.75	http://dx.doi.org/10.1038/onc.2014.75			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24704830				2022-12-28	WOS:000350806500007
J	Baumgart, A; Mazur, PK; Anton, M; Rudelius, M; Schwamborn, K; Feuchtinger, A; Behnke, K; Walch, A; Braren, R; Peschel, C; Duyster, J; Siveke, JT; Dechow, T				Baumgart, A.; Mazur, P. K.; Anton, M.; Rudelius, M.; Schwamborn, K.; Feuchtinger, A.; Behnke, K.; Walch, A.; Braren, R.; Peschel, C.; Duyster, J.; Siveke, J. T.; Dechow, T.			Opposing role of Notch1 and Notch2 in a Kras(G12D)-driven murine non-small cell lung cancer model	ONCOGENE			English	Article						Notch; Ras; mouse model; beta-catenin; DUSP1	GROWTH-FACTOR RECEPTOR; E-CADHERIN; SECRETASE INHIBITION; IN-VITRO; ACTIVATION; EXPRESSION; PATHWAY; P53; TUMORIGENESIS; PHENOTYPE	Lung cancer is the leading cause of cancer-related deaths worldwide. Recently, we have shown that Notch1 inhibition resulted in substantial cell death of non-small cell lung cancer (NSCLC) cells in vitro. New compounds targeting Notch signal transduction have been developed and are now being tested in clinical trials. However, the tumorigenic role of individual Notch receptors in vivo remains largely unclear. Using a Kras(G12D)-driven endogenous NSCLC mouse model, we analyzed the effect of conditional Notch1 and Notch2 receptor deletion on NSCLC tumorigenesis. Notch1 deficiency led to a reduced early tumor formation and lower activity of MAPK compared with the controls. Unexpectedly, Notch2 deletion resulted in a dramatically increased carcinogenesis and increased MAPK activity. These mice died significantly earlier due to rapidly growing tumor burden. We found that Notch1 regulates Ras/MAPK pathway via HES1-induced repression of the DUSP1 promoter encoding a phosphatase specifically suppressing pERK1/2. Interestingly, Notch1 but not Notch2 ablation leads to decreased HES1 and DUSP1 expression. However, Notch2-depleted tumors showed an appreciable increase in beta-catenin expression, a known activator of HES1 and important lung cancer oncogene. Characteristically for beta-catenin upregulation, we found that the majority of Notch2-deficient tumors revealed an undifferentiated phenotype as determined by their morphology, E-Cadherin and TTF1 expression levels. In addition, these carcinomas showed aggressive growth patterns with bronchus invasion and obstruction. Together, we show that Notch2 mediates differentiation and has tumor suppressor functions during lung carcinogenesis, whereas Notch1 promotes tumor initiation and progression. These data are further supported by immunohistochemical analysis of human NSCLC samples showing loss or downregulation of Notch2 compared with normal lung tissue. In conclusion, this is the first study characterizing the in vivo functions of Notch1 and Notch2 in Kras(G12D)-driven NSCLC tumorigenesis. These data highlight the clinical importance of a thorough understanding of Notch signaling especially with regard to Notch-targeted therapies.	[Baumgart, A.; Behnke, K.; Peschel, C.; Dechow, T.] Tech Univ Munich, Dept Internal Med 3, D-81675 Munich, Germany; [Mazur, P. K.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Mazur, P. K.] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA; [Anton, M.] Tech Univ Munich, Dept Expt Oncol, D-81675 Munich, Germany; [Rudelius, M.; Schwamborn, K.] Tech Univ Munich, Dept Pathol, D-81675 Munich, Germany; [Feuchtinger, A.; Walch, A.] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Res Unit Analyt Pathol, Neuherberg, Germany; [Braren, R.] Tech Univ Munich, Inst Diagnost Imaging, D-81675 Munich, Germany; [Duyster, J.] Univ Klinikum Freiburg, Dept Internal Med 1, Freiburg, Germany; [Siveke, J. T.] Tech Univ Munich, Dept Internal Med 2, D-81675 Munich, Germany; [Dechow, T.] Onkol Ravensburg, Ravensburg, Germany	Technical University of Munich; University of Munich; Stanford University; Stanford University; Technical University of Munich; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Freiburg; Technical University of Munich	Siveke, JT (corresponding author), Tech Univ Munich, Dept Internal Med 2, Ismaninger Str 22, D-81675 Munich, Germany.	jens.siveke@lrz.tum.de	Feuchtinger, Annette/O-4569-2014; Siveke, Jens/AAQ-6170-2021; Braren, Rickmer/U-3254-2018; Mazur, Pawel K./AAU-6343-2021; Walch, Axel/B-4554-2012	Braren, Rickmer/0000-0001-6039-6957; Mazur, Pawel K./0000-0002-5820-8344; Walch, Axel/0000-0001-5578-4023	Wilhelm Sander-Stiftung [2005.158.1]; Deutsche Krebshilfe [109606]; Deutsche Forschungsgemeinschaft [SI 1549/1-1]; Tobacco-Related Disease Research Program; Dean's Fellowship from Stanford University; Child Health Research Institute; Lucile Packard Foundation for Children's Health at Stanford	Wilhelm Sander-Stiftung; Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Tobacco-Related Disease Research Program(University of California System); Dean's Fellowship from Stanford University; Child Health Research Institute; Lucile Packard Foundation for Children's Health at Stanford	We would like to thank Dr Tibor Schuster for the help with statistical calculations, Nadya Mitova and Birgit Geist for her excellent technical help with the experiments and Joachim Alfer for providing histological pictures. We also thank Freddy Radtke for the Notch1<SUP>lox/lox</SUP> mice, Ursula Zimber-Strobl for the Notch2<SUP>lox/lox</SUP> mice and David Tuveson and Tyler Jacks for the Kras<SUP>+/LSL-G12D</SUP> mice. TD received a grant from the Wilhelm Sander-Stiftung (#2005.158.1). TD and JTS have been supported by grants from the Deutsche Krebshilfe (#109606 to TD and JTS) and the Deutsche Forschungsgemeinschaft (SI 1549/1-1 to JTS). PKM was supported by the Tobacco-Related Disease Research Program, a Dean's Fellowship from Stanford University and the Child Health Research Institute and Lucile Packard Foundation for Children's Health at Stanford.	Allen TD, 2011, CANCER RES, V71, P6010, DOI 10.1158/0008-5472.CAN-11-0595; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Asnaghi L, 2010, ONCOGENE, V29, P2760, DOI 10.1038/onc.2010.39; Baumgart A, 2010, CANCER RES, V70, P5368, DOI 10.1158/0008-5472.CAN-09-3763; Besseyrias V, 2007, J EXP MED, V204, P331, DOI 10.1084/jem.20061442; Bettstetter M, 2013, HUM PATHOL, V44, P829, DOI 10.1016/j.humpath.2012.08.005; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Bremnes RM, 2002, LUNG CANCER, V36, P115, DOI 10.1016/S0169-5002(01)00471-8; Huynh C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025264; Cheng HT, 2007, DEVELOPMENT, V134, P801, DOI 10.1242/dev.02773; Chu D, 2009, ANN SURG ONCOL, V16, P3259, DOI 10.1245/s10434-009-0655-6; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Eliasz S, 2010, ONCOGENE, V29, P2488, DOI 10.1038/onc.2010.7; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Graziani I, 2008, CANCER RES, V68, P9678, DOI 10.1158/0008-5472.CAN-08-0969; Hanlon L, 2010, CANCER RES, V70, P4280, DOI 10.1158/0008-5472.CAN-09-4645; Haruki N, 2005, CANCER RES, V65, P3555, DOI 10.1158/0008-5472.CAN-04-3132; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Kim HA, 2012, J CLIN INVEST, V122, P3248, DOI 10.1172/JCI61216; Kim MY, 2005, BIOCHEM BIOPH RES CO, V332, P609, DOI 10.1016/j.bbrc.2005.05.001; Konishi J, 2007, CANCER RES, V67, P8051, DOI 10.1158/0008-5472.CAN-07-1022; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Maraver A, 2012, ONCOTARGET, V3, P917; Maraver A, 2012, CANCER CELL, V22, P222, DOI 10.1016/j.ccr.2012.06.014; Mazur PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013578; Mazur PK, 2010, P NATL ACAD SCI USA, V107, P13438, DOI 10.1073/pnas.1002423107; Michie AM, 2007, INT IMMUNOL, V19, P1421, DOI 10.1093/intimm/dxm113; Myong Na-Hye, 2004, Cancer Res Treat, V36, P56, DOI 10.4143/crt.2004.36.1.56; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Osanyingbemi-Obidi J, 2011, MOL CANCER RES, V9, P1746, DOI 10.1158/1541-7786.MCR-11-0286; Pacheco-Pinedo EC, 2011, J CLIN INVEST, V121, P1935, DOI 10.1172/JCI44871; Peignon G, 2011, GUT, V60, P166, DOI 10.1136/gut.2009.204719; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; RODENHUIS S, 1988, CANCER RES, V48, P5738; Saad AG, 2008, CANCER-AM CANCER SOC, V113, P2129, DOI 10.1002/cncr.23826; Sato M, 2006, CANCER RES, V66, P2116, DOI 10.1158/0008-5472.CAN-05-2521; Sjolund J, 2008, J CLIN INVEST, V118, P217, DOI 10.1172/JCI32086; Slotta-Huspenina J, 2012, HAEMATOL-HEMATOL J, V97, P1422, DOI 10.3324/haematol.2011.055715; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Sriuranpong V, 2001, CANCER RES, V61, P3200; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Wang XQ, 2009, MOL BIOL CELL, V20, P791, DOI 10.1091/mbc.E08-07-0732; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Westhoff B, 2009, P NATL ACAD SCI USA, V106, P22293, DOI 10.1073/pnas.0907781106; Wu Y, 2010, NATURE, V464, P1052, DOI 10.1038/nature08878; Zheng YY, 2013, CANCER CELL, V24, P59, DOI 10.1016/j.ccr.2013.05.021	55	53	54	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					578	588		10.1038/onc.2013.592	http://dx.doi.org/10.1038/onc.2013.592			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24509876				2022-12-28	WOS:000348853500005
J	Moy, I; Todorovic, V; Dubash, AD; Coon, JS; Parker, JB; Buranapramest, M; Huang, CC; Zhao, H; Green, KJ; Bulun, SE				Moy, I.; Todorovic, V.; Dubash, A. D.; Coon, J. S.; Parker, J. B.; Buranapramest, M.; Huang, C. C.; Zhao, H.; Green, K. J.; Bulun, S. E.			Estrogen-dependent sushi domain containing 3 regulates cytoskeleton organization and migration in breast cancer cells	ONCOGENE			English	Article						sushi domain containing 3; estrogen receptor; aromatase inhibitors; breast cancer; migration	FOCAL ADHESION KINASE; AROMATASE INHIBITORS; MESENCHYMAL TRANSITION; RHO-GTPASES; RECEPTOR; EXPRESSION; CADHERIN; THERAPY; PREDICTORS; DYNAMICS	Aromatase inhibitors (AIs) are the standard endocrine therapy for postmenopausal breast cancer; however, currently used biomarkers, such as, estrogen receptor-alpha/progesterone receptor (ER alpha/PR), predict only slightly more than half of the potential responders to AI treatment. To identify novel markers of AI responsiveness, a genome-wide microarray analysis was performed using primary breast tumor samples from 50 postmenopausal women who later developed metastatic breast cancer. Sushi domain containing 3 (SUSD3) is a significantly differentially expressed gene, with 3.38-fold higher mRNA levels in AI-responsive breast tumors vs non-responders (P<0.001). SUSD3 was highly expressed in ER alpha-positive breast tumors and treatment with estradiol increased SUSD3 expression in ERa-positive breast cancer cells. Treatment with an antiestrogen or ER alpha knockdown abolished basal and estradiol-dependent SUSD3 expression. Recruitment of ERa upstream of the transcription start site of SUSD3 was demonstrated by chromatin immunoprecipitation-PCR. Flow cytometric analysis of SUSD3-knockdown cells revealed blunted estradiol effects on progression into S and M phases. SUSD3 was localized to the plasma membrane of breast cancer cells. SUSD3 knockdown decreased the appearance of actin-rich protrusions, stress fibers and large basal focal adhesions, while increasing the presence of cortical actin concomitant with a decrease in Rho and focal adhesion kinase activity. SUSD3-deficient cells demonstrated diminished cell spreading, cell-cell adhesion and motility. In conclusion, SUSD3 is a novel promoter of estrogen-dependent cell proliferation and regulator of cell-cell and cell-substrate interactions and migration in breast cancer. It may serve as a novel predictor of response to endocrine therapy and potential therapeutic target.	[Moy, I.; Coon, J. S.; Parker, J. B.; Buranapramest, M.; Zhao, H.; Bulun, S. E.] Northwestern Univ, Dept Obstet & Gynecol, Div Reprod Biol, Feinberg Sch Med, Chicago, IL 60610 USA; [Todorovic, V.; Dubash, A. D.; Green, K. J.] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60610 USA; [Huang, C. C.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60610 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Bulun, SE (corresponding author), Northwestern Univ, Dept Obstet & Gynecol, Div Reprod Biol, 303 East Super,Suite 4-123, Chicago, IL 60610 USA.	s-bulun@northwestern.edu		Zhao, Hong/0000-0003-4616-3123	AVON Foundation; Northwestern Memorial Foundation Dixon Priority Initiative Grant; National Cancer Institute [CA122151]; NCI CCSG [P30 CA060553]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD038691] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA070085, P30CA060553, R01CA122151, R01CA067167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007169] Funding Source: NIH RePORTER	AVON Foundation; Northwestern Memorial Foundation Dixon Priority Initiative Grant; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI CCSG; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the AVON Foundation (to SEB), a Northwestern Memorial Foundation Dixon Priority Initiative Grant (SEB) and National Cancer Institute (CA122151, to KJG). The imaging work performed at Northwestern University Cell Imaging Facility was supported by NCI CCSG P30 CA060553 awarded to the Robert H Lurie Comprehensive Cancer Center. We thank Satya Khuon for her assistance in our confocal work. We thank Mitch Dowsett, Helen Cotterill, Roger A'Hern, Ben Haynes and Ian Smith from the Royal Marsden Hospital in London, England, for making the patient samples available.	Abba MC, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-37; Ahn RW, 2010, CLIN CANCER RES, V16, P3607, DOI 10.1158/1078-0432.CCR-10-0068; Anderson H, 2011, ANN ONCOL, V22, P1770, DOI 10.1093/annonc/mdq700; Anderson H, 2007, J STEROID BIOCHEM, V106, P49, DOI 10.1016/j.jsbmb.2007.05.024; Anderson WF, 2002, BREAST CANCER RES TR, V76, P27, DOI 10.1023/A:1020299707510; Apweiler R, 2011, NUCLEIC ACIDS RES, V39, pD214, DOI 10.1093/nar/gkq1020; Bernhard J, 1999, J CLIN ONCOL, V17, P1672, DOI 10.1200/JCO.1999.17.6.1672; Burbelo P, 2004, BREAST CANCER RES TR, V84, P43, DOI 10.1023/B:BREA.0000018422.02237.f9; Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI 10.1200/JOP.000082; Butt AJ, 2005, ENDOCR-RELAT CANCER, V12, pS47, DOI 10.1677/erc.1.00993; Chakravarty D, 2010, CANCER RES, V70, P4092, DOI 10.1158/0008-5472.CAN-09-3834; Chan KT, 2009, J CELL BIOL, V185, P357, DOI 10.1083/jcb.200809110; Cheng YH, 2011, J MOL ENDOCRINOL, V46, P139, DOI 10.1530/JME-10-0064; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Chumsri S, 2011, J STEROID BIOCHEM, V125, P13, DOI 10.1016/j.jsbmb.2011.02.001; Coombes RC, 2007, LANCET, V369, P559, DOI 10.1016/S0140-6736(07)60200-1; Deramaudt TB, 2011, MOL BIOL CELL, V22, P964, DOI 10.1091/mbc.E10-08-0725; Eiermann W, 2001, ANN ONCOL, V12, P1527, DOI 10.1023/A:1013128213451; Galanina N, 2011, CANCER J, V17, P96, DOI 10.1097/PPO.0b013e318212dee3; Goldhirsch A, 2009, ANN ONCOL, V20, P1319, DOI 10.1093/annonc/mdp322; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hudson TY, 2004, METHOD CELL BIOL, V78, P757; Jacobberger JW, 2000, IMMUNOPHENOTYPING, P361; Juan G, 2004, CURR PROTOC CYTOMETR; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; Kim JM, 2006, DNA RES, V13, P275, DOI 10.1093/dnares/dsl016; KNIGHT WA, 1980, CLIN ENDOCRINOL META, V9, P361, DOI 10.1016/S0300-595X(80)80038-7; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Li Y, 2010, ENDOCRINOLOGY, V151, P5146, DOI 10.1210/en.2009-1506; Lin Z, 2010, ONCOGENE, V29, P1114, DOI 10.1038/onc.2009.409; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Makrilia N, 2009, CANCER INVEST, V27, P1023, DOI 10.3109/07357900902769749; Miller WR, 2006, MATURITAS, V54, P335, DOI 10.1016/j.maturitas.2006.04.020; Miller WR, 2010, EXPERT OPIN PHARMACO, V11, P1873, DOI 10.1517/14656566.2010.487863; Moy I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077543; Parker JB, 2012, MOL CELL BIOL, V32, P1654, DOI 10.1128/MCB.06033-11; Parris TZ, 2010, CLIN CANCER RES, V16, P3860, DOI 10.1158/1078-0432.CCR-10-0889; Provenzano PP, 2009, CELL ADHES MIGR, V3, P347, DOI 10.4161/cam.3.4.9458; Sanchez AM, 2010, MOL ENDOCRINOL, V24, P2114, DOI 10.1210/me.2010-0252; Schug J, 2008, CURR PROTOC BIOINFOR; Sieg DJ, 1999, J CELL SCI, V112, P2677; Smith IE, 2006, J CLIN ONCOL, V24, P2444, DOI 10.1200/JCO.2005.05.3694; Smith IE, 2005, J CLIN ONCOL, V23, P5108, DOI 10.1200/JCO.2005.04.005; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Spiering D, 2011, CELL ADHES MIGR, V5, P170, DOI 10.4161/cam.5.2.14403; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Stuart-Harris R, 2009, BREAST, V18, P351, DOI 10.1016/j.breast.2009.09.002; Tang Y, 2008, FRONT BIOSCI-LANDMRK, V13, P759, DOI 10.2741/2718; Thurlimann B, 2005, NEW ENGL J MED, V353, P2747; Tilghman RW, 2005, J CELL SCI, V118, P2613, DOI 10.1242/jcs.02380; Tomar A, 2009, CURR OPIN CELL BIOL, V21, P676, DOI 10.1016/j.ceb.2009.05.006; Watson AP, 2013, MOL CANCER RES, V11, P74, DOI 10.1158/1541-7786.MCR-12-0501-T; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Weigel MT, 2010, ENDOCR-RELAT CANCER, V17, pR245, DOI 10.1677/ERC-10-0136; Williams N, 2008, LANCET ONCOL, V9, P45, DOI 10.1016/S1470-2045(07)70385-6	56	10	11	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					362	372		10.1038/onc.2013.553	http://dx.doi.org/10.1038/onc.2013.553			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24413080	Green Accepted			2022-12-28	WOS:000348145500010
J	Kwon, Y; Smith, BD; Zhou, Y; Kaufman, MD; Godwin, AK				Kwon, Y.; Smith, B. D.; Zhou, Y.; Kaufman, M. D.; Godwin, A. K.			Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment	ONCOGENE			English	Article						ovarian cancer; human ovarian fibroblast; c-MET; hepatocyte growth factor; DCC-2701	TUMOR-ASSOCIATED FIBROBLASTS; HEPARAN-SULFATE; KINASE; MATRIX; OLIGOSACCHARIDES; TRANSFORMATION; STROMAGENESIS; RESISTANCE	The signaling mediated by c-MET and its ligand, hepatocyte growth factor (HGF), has been implicated in malignant progression of cancer involving stimulation of proliferation, invasion and metastasis. We studied the c-MET/HGF axis as a mediator of tumor-stromal interaction in ovarian cancer and the value of targeting c-MET for the treatment of ovarian cancer. To assess c-MET signaling, we established in vitro models of the microenvironment using primary and immortalized human fibroblasts from normal ovary and tumor samples and epithelial ovarian cancer cell lines. We found that fibroblast from normal ovaries secreted high levels of HGF (1500-3800 pg/ml) as compared with tumor-derived fibroblasts (undetectable level) and could elicit cellular biological responses on c-MET-expressing ovarian cancer cells including increase of cell proliferation and migration (2- to 140-fold increase). HGF secreted by fibroblasts was also found sequestered within extracellular matrices (ECMs) and when degraded this ECM-derived HGF stimulated cancer cell migration (1.5- to 24-fold). In cells containing constitutive c-MET phosphorylation, recombinant HGF and fibroblast-derived HGF negligibly affect c-MET phosphorylation on Tyr(1234) and Tyr(1003). However, both sources of HGF increased the phosphorylation of c-MET on Tyr(1349), the multi-substrate docking site, by more than sixfold and led to activation of downstream signaling transducers. DCC-2701 (Deciphera Pharmaceuticals, LLC), a novel c-MET/TIE-2/VEGFR inhibitor was able to effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro. Importantly, DCC-2701's anti-proliferative activity was dependent on c-MET activation induced by stromal human fibroblasts and to a lesser extent exogenous HGF. Our data suggest for the first time that DCC-2701 may be superior to HGF antagonists that are in clinical trials and that pTyr(134)(levels might be a good indicator of c-MET activation and likely response to targeted therapy as a result of signals from the microenvironment.	[Kwon, Y.; Godwin, A. K.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA; [Kwon, Y.] Ewha Womans Univ, Dept Food Sci & Engn, Seoul, South Korea; [Smith, B. D.; Kaufman, M. D.] Deciphera Pharmaceut LLC, Lawrence, KS USA; [Zhou, Y.] Fox Chase Canc Ctr, Biostat & Bioinformat Facil, Philadelphia, PA 19111 USA; [Godwin, A. K.] Univ Kansas, Ctr Canc, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; Ewha Womans University; Fox Chase Cancer Center; University of Kansas	Godwin, AK (corresponding author), Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Mail Stop 3040,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	AGodwin@kumc.edu		Kwon, Youngjoo/0000-0003-3582-4192	Ovarian Cancer Research Fund; NCI [R01 CA140323]; University of Kansas Cancer Center's CCSG [P30 CA168524]; Kansas Bioscience Authority Eminent Scholar Program; NATIONAL CANCER INSTITUTE [R01CA140323, P30CA168524] Funding Source: NIH RePORTER	Ovarian Cancer Research Fund; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Kansas Cancer Center's CCSG; Kansas Bioscience Authority Eminent Scholar Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Ziyan Pessetto for her expertise in the cell viability assays and Dr Daniel Flynn for his helpful comments and guidance in regards the biology and activity of DCC-2701. The study was supported in part by a program project grant from Ovarian Cancer Research Fund (http://www.ocrf.org) and a grant from the NCI (R01 CA140323) to AKG. We would also like to acknowledge support from the University of Kansas Cancer Center's CCSG (P30 CA168524), the Kansas Bioscience Authority Eminent Scholar Program. AKG is the Chancellors Distinguished Chair in Biomedical Sciences endowed Professor.	Amatangelo MD, 2005, AM J PATHOL, V167, P475, DOI 10.1016/S0002-9440(10)62991-4; ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; Ayhan A, 2005, INT J GYNECOL CANCER, V15, P618, DOI 10.1111/j.1525-1438.2005.00117.x; Beacham DA, 2005, SEMIN CANCER BIOL, V15, P329, DOI 10.1016/j.semcancer.2005.05.003; Beacham Dorothy A, 2007, Curr Protoc Cell Biol, VChapter 10, DOI 10.1002/0471143030.cb1009s33; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Castello-Cros Remedios, 2009, V522, P275, DOI 10.1007/978-1-59745-413-1_19; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Corps AN, 1997, INT J CANCER, V73, P151, DOI 10.1002/(SICI)1097-0215(19970926)73:1<151::AID-IJC23>3.0.CO;2-I; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Flynn DL, 2013, ACS NAT M NEW ORL 8; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Gordon MS, 2010, CLIN CANCER RES, V16, P699, DOI 10.1158/1078-0432.CCR-09-1365; HAMILTON TC, 1983, CANCER RES, V43, P5379; Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009; Kwon Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018872; LANGDON SP, 1988, CANCER RES, V48, P6166; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Liu XD, 2010, TRENDS MOL MED, V16, P37, DOI 10.1016/j.molmed.2009.11.005; LYON M, 1994, J BIOL CHEM, V269, P11216; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Marchand-Adam S, 2003, AM J RESP CRIT CARE, V168, P1156, DOI 10.1164/rccm.200212-1514OC; Matsumoto K, 2006, INT J CANCER, V119, P477, DOI 10.1002/ijc.21808; Matsuoka H, 2006, AM J RESP CELL MOL, V35, P705, DOI 10.1165/rcmb.2006-0006OC; Michieli P, 1999, ONCOGENE, V18, P5221, DOI 10.1038/sj.onc.1202899; Miyata Y, 2006, CLIN CANCER RES, V12, P4876, DOI 10.1158/1078-0432.CCR-06-0362; Nayeri F, 2008, GROWTH FACTORS, V26, P163, DOI 10.1080/08977190802128083; Ozols RF, 2004, CANCER CELL, V5, P19, DOI 10.1016/S1535-6108(04)00002-9; Pan BS, 2010, CANCER RES, V70, P1524, DOI 10.1158/0008-5472.CAN-09-2541; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Quiros RM, 2008, GYNECOL ONCOL, V110, P99, DOI 10.1016/j.ygyno.2008.03.006; Sawada K, 2007, CANCER RES, V67, P1670, DOI 10.1158/0008-5472.CAN-06-1147; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sierra J Rafael, 2011, Ther Adv Med Oncol, V3, pS21, DOI 10.1177/1758834011422557; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Tatsumi R, 2004, MUSCLE NERVE, V30, P654, DOI 10.1002/mus.20114; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Zillhardt M, 2011, CLIN CANCER RES, V17, P4042, DOI 10.1158/1078-0432.CCR-10-3387; Zillhardt M, 2010, NEOPLASIA, V12, P1, DOI 10.1593/neo.09948; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871	41	45	46	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					144	153		10.1038/onc.2013.539	http://dx.doi.org/10.1038/onc.2013.539			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24362531	Green Accepted			2022-12-28	WOS:000347790500002
J	Shen, RR; Zhou, AY; Kim, E; O'Connell, JT; Hagerstrand, D; Beroukhim, R; Hahn, WC				Shen, R. R.; Zhou, A. Y.; Kim, E.; O'Connell, J. T.; Hagerstrand, D.; Beroukhim, R.; Hahn, W. C.			TRAF2 is an NF-kappa B-activating oncogene in epithelial cancers	ONCOGENE			English	Article						TRAF2; NF-kappa B; cancer; 9q34 amplification	TUMOR-SUPPRESSOR CYLD; K63-LINKED POLYUBIQUITINATION; MULTIPLE-MYELOMA; CELL LYMPHOMA; MOUSE MODEL; IKK; PHOSPHORYLATION; TUMORIGENESIS; MUTATIONS; PATHWAY	Aberrant nuclear factor (NF)-kappa B activation is frequently observed in human cancers. Genome characterization efforts have identified genetic alterations in multiple components of the NF-kappa B pathway, some of which have been shown to be essential for cancer initiation and tumor maintenance. Here, using patient tumors and cancer cell lines, we identify the NF-kappa B regulator, TRAF2 (tumor necrosis factor (TNF) receptor-associated factor 2), as an oncogene that is recurrently amplified and rearranged in 15% of human epithelial cancers. Suppression of TRAF2 in cancer cells harboring TRAF2 copy number gain inhibits proliferation, NF-kappa B activation, anchorage-independent growth and tumorigenesis. Cancer cells that are dependent on TRAF2 also require NF-kappa B for survival. The phosphorylation of TRAF2 at serine 11 is essential for the survival of cancer cells harboring TRAF2 amplification. Together, these observations identify TRAF2 as a frequently amplified oncogene.	[Shen, R. R.; Zhou, A. Y.; Kim, E.; O'Connell, J. T.; Hagerstrand, D.; Beroukhim, R.; Hahn, W. C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Shen, R. R.; Zhou, A. Y.; Kim, E.; O'Connell, J. T.; Hagerstrand, D.; Beroukhim, R.; Hahn, W. C.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; [Shen, R. R.; Zhou, A. Y.; Kim, E.; O'Connell, J. T.; Hagerstrand, D.; Beroukhim, R.; Hahn, W. C.] Broad Inst Harvard & MIT, Cambridge, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Hahn, WC (corresponding author), Dana Farber Canc Inst, 450 Brookline Ave,Dana 1538, Boston, MA 02215 USA.	William_Hahn@dfci.harvard.edu	Hägerstrand, Daniel/AAH-3009-2019; Hägerstrand, Daniel C/D-1584-2014	Hägerstrand, Daniel/0000-0001-7270-0776; Hägerstrand, Daniel C/0000-0001-7270-0776; Zhou, Alicia/0000-0003-0388-8909	Ruth L. Kirschstein National Research Service Award [F32 CA128265]; Aid for Cancer Research;  [R01 CA130988]; NATIONAL CANCER INSTITUTE [P30CA006516, F32CA128265, P01CA154303, R01CA130988] Funding Source: NIH RePORTER	Ruth L. Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Aid for Cancer Research; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Hahn lab and the Cichowski lab for thoughtful discussion, reagents and technical assistance. We also thank Hasem Habelhah for providing the pTRAF2 (Ser11) antibody. We further thank Shumei Wang, Anita Hawkins, Chengzeng Zhang and Cynthia Morton at the DFCI Cytogenetics Core for TRAF2 FISH analysis and discussion. This work was supported in part by R01 CA130988 (to WCH), a Ruth L. Kirschstein National Research Service Award F32 CA128265 (to RRS) and The Aid for Cancer Research (to RRS).	Aggarwal BB, 2011, CANCER DISCOV, V1, P469, DOI 10.1158/2159-8290.CD-11-0260; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Basseres DS, 2010, CANCER RES, V70, P3537, DOI 10.1158/0008-5472.CAN-09-4290; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Billie Au PY, 2007, ADV EXP MED BIOL, V597, P32; Bivona TG, 2011, NATURE, V471, P523, DOI 10.1038/nature09870; Blackwell K, 2009, MOL CELL BIOL, V29, P303, DOI 10.1128/MCB.00699-08; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Fuerer C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009370; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hutti JE, 2009, MOL CELL, V34, P461, DOI 10.1016/j.molcel.2009.04.031; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Karin M, 2009, IMMUNOL REV, V228, P225, DOI 10.1111/j.1600-065X.2008.00755.x; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; Li S, 2009, MOL CELL, V33, P30, DOI 10.1016/j.molcel.2008.11.023; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Novak U, 2009, BLOOD, V113, P4918, DOI 10.1182/blood-2008-08-174110; Pflueger D, 2011, GENOME RES, V21, P56, DOI 10.1101/gr.110684.110; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Starczynowski DT, 2011, J CLIN INVEST, V121, P4095, DOI 10.1172/JCI58818; Staudt LM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000109; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Thomas GS, 2009, CANCER RES, V69, P3665, DOI 10.1158/0008-5472.CAN-08-4867; Wood KC, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002612; Zhou AY, 2013, CELL REP, V3, P724, DOI 10.1016/j.celrep.2013.01.031	43	42	44	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					209	216		10.1038/onc.2013.543	http://dx.doi.org/10.1038/onc.2013.543			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24362534	Green Accepted, Green Submitted			2022-12-28	WOS:000347790500008
J	Lindner, SE; Wissler, M; Grunder, A; Aumann, K; Ottina, E; Peintner, L; Brauns-Schubert, P; Preiss, F; Herzog, S; Borner, C; Charvet, C; Villunger, A; Pahl, HL; Maurer, U				Lindner, S. E.; Wissler, M.; Gruender, A.; Aumann, K.; Ottina, E.; Peintner, L.; Brauns-Schubert, P.; Preiss, F.; Herzog, S.; Borner, C.; Charvet, C.; Villunger, A.; Pahl, H. L.; Maurer, U.			Increased leukocyte survival and accelerated onset of lymphoma in the absence of MCL-1 S159-phosphorylation	ONCOGENE			English	Article						GSK-3; MCL-1; E mu-Myc; lymphoma; apoptosis	GLYCOGEN-SYNTHASE KINASE-3; APOPTOSIS; MYC; MEDIATE; PI3K	The antiapoptotic BCL-2 protein MCL-1, which opposes mitochondrial outer membrane permeabilization, was shown to have a crucial role in the survival of hematopoietic cells. We have previously shown that, upon loss of phosphatidylinositol 3-kinase signaling, S159 of MCL-1 is phosphorylated by glycogen synthase kinase-3 (GSK-3), earmarking MCL-1 for enhanced ubiquitylation and degradation. In this study, we introduced MCL-1(wt) or the phosphorylation-deficient mutant MCL-1(S159A) in mouse BM cells, followed by adoptive transfer to recipient mice. Mice expressing MCL-1(S159A) exhibited significantly elevated white blood cell and lymphocyte counts, whereas no effect was observed on the distribution of T and B lymphocyte subsets or the numbers of monocytes, red blood cells or platelets. Expression of MCL-1(S159A) in E mu-Myc transgenic bone marrow significantly accelerated the onset of disease, and these mice displayed increased spleen weights compared with E mu-Myc/MCL-1(wt) mice. Our data demonstrate that the absence of MCL-1 S159 phosphorylation provides a survival advantage for hematopoietic cells in vivo and facilitates oncogenesis.	[Lindner, S. E.; Wissler, M.; Brauns-Schubert, P.; Preiss, F.; Borner, C.; Maurer, U.] Univ Freiburg, Inst Mol Med & Cell Res, D-79104 Freiburg, Germany; [Lindner, S. E.; Brauns-Schubert, P.; Preiss, F.] Univ Freiburg, Fac Biol, D-79104 Freiburg, Germany; [Gruender, A.; Pahl, H. L.] Univ Hosp, Clin Res Ctr, Dept Mol Hematol, Freiburg, Germany; [Aumann, K.] Univ Med Ctr Freiburg, Inst Pathol, Freiburg, Germany; [Ottina, E.; Peintner, L.; Herzog, S.; Villunger, A.] Med Univ Innsbruck, Bioctr, Div Dev Immunol, A-6020 Innsbruck, Austria; [Brauns-Schubert, P.; Preiss, F.; Borner, C.; Maurer, U.] Univ Freiburg, Spemann Grad Sch Biol & Med SGBM, D-79104 Freiburg, Germany; [Borner, C.; Maurer, U.] Ctr Biol Signaling Studies, BIOSS, Freiburg, Germany; [Charvet, C.] Univ Paris 05, CNRS UMR 8104, INSERM U1016, Inst Cochin, Paris, France	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; Medical University of Innsbruck; University of Freiburg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Maurer, U (corresponding author), Univ Freiburg, Inst Mol Med & Cell Res, Stefan Meier Str 17, D-79104 Freiburg, Germany.	ulrich.maurer@mol-med.uni-freiburg.de	Lindner, Silke/AAF-6063-2021; Pahl, Heike/AGM-5260-2022; Aumann, Konrad/GSN-1821-2022	Aumann, Konrad/0000-0001-8178-1571; Peintner, Lukas/0000-0002-0445-1445; Herzog, Sebastian/0000-0001-7167-3489; Ottina, Eleonora/0000-0002-9630-496X	Deutsche Forschungsgemeinschaft [Ma 1967/1, Ma 1967/2]; Deutsche Krebshilfe [109199, 107397]; Spemann Graduate School of Biology and Medicine (SGBM) - Excellence Initiative of the German Federal and State Governments, Germany [GSC-4]; Centre for Biological Signalling Studies (BIOSS) - Excellence Initiative, Germany [EXC-294]; Austrian Science Fund (FWF); Austrian Science Fund (FWF) [P 23510] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [P01CA108671] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); Spemann Graduate School of Biology and Medicine (SGBM) - Excellence Initiative of the German Federal and State Governments, Germany; Centre for Biological Signalling Studies (BIOSS) - Excellence Initiative, Germany; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Martin Brandenburg, Katharina Thumm, Heiko Bauer, Klaus Geiger, Jan Bodinek-Wersing and Karin Neubert. This study was supported by Grants Ma 1967/1 and Ma 1967/2 from the Deutsche Forschungsgemeinschaft to UM, Grants 109199 and 107397 from the Deutsche Krebshilfe to UM the Spemann Graduate School of Biology and Medicine (SGBM, GSC-4) funded by the Excellence Initiative of the German Federal and State Governments, Germany to PBS, FP and UM, by the Centre for Biological Signalling Studies (BIOSS, EXC-294) funded by the Excellence Initiative, Germany to UM and CB and a fellowship from the Dr Heinrich Kircher-Stiftung to SEL as well as the Austrian Science Fund (FWF) to AV.	Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Brunelle JK, 2009, J CELL BIOL, V187, P429, DOI 10.1083/jcb.200904049; Campbell KJ, 2010, BLOOD, V116, P3197, DOI 10.1182/blood-2010-04-281071; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Ding QQ, 2007, MOL CELL BIOL, V27, P4006, DOI 10.1128/MCB.00620-06; Dzhagalov I, 2007, BLOOD, V109, P1620, DOI 10.1182/blood-2006-03-013771; Gutierrez A, 2009, BLOOD, V114, P647, DOI 10.1182/blood-2009-02-206722; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Inuzuka H, 2011, NATURE, V471, P104, DOI 10.1038/nature09732; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Morel C, 2009, MOL CELL BIOL, V29, P3845, DOI 10.1128/MCB.00279-09; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Sander S, 2012, CANCER CELL, V22, P167, DOI 10.1016/j.ccr.2012.06.012; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Steimer DA, 2009, BLOOD, V113, P2805, DOI 10.1182/blood-2008-05-159145; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Xiang ZF, 2010, J CLIN INVEST, V120, P2109, DOI 10.1172/JCI39964; Zhao Y, 2007, MOL CELL BIOL, V27, P4328, DOI 10.1128/MCB.00153-07	20	4	4	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2014	33	44					5221	5224		10.1038/onc.2013.469	http://dx.doi.org/10.1038/onc.2013.469			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR9RZ	24213575	Green Accepted			2022-12-28	WOS:000343914900009
J	Liao, JM; Zhou, X; Gatignol, A; Lu, H				Liao, J-M; Zhou, X.; Gatignol, A.; Lu, H.			Ribosomal proteins L5 and L11 co-operatively inactivate c-Myc via RNA-induced silencing complex	ONCOGENE			English	Article						c-Myc; TRBP2; microRNA; RPL11; RPL5; ribosomal stress	EMBRYONIC STEM-CELLS; P53 ACTIVATION; NEOPLASTIC PHENOTYPE; COLORECTAL-CANCER; MDM2; INHIBITION; STRESS; BIOGENESIS; PROLIFERATION; DEGRADATION	Oncogene MYC is highly expressed in many human cancers and functions as a global regulator of ribosome biogenesis. Previously, we reported that ribosomal protein (RP) L11 binds to c-Myc and inhibits its transcriptional activity in response to ribosomal stress. Here, we show that RPL5, co-operatively with RPL11, guides the RNA-induced silencing complex (RISC) to c-Myc mRNA and mediates the degradation of the mRNA, consequently leading to inhibition of c-Myc activity. Knocking down of RPL5 induced c-Myc expression at both mRNA and protein levels, whereas overexpression of RPL5 suppressed c-Myc expression and activity. Immunoprecipitation revealed that RPL5 binds to 3'UTR of c-Myc mRNA and two subunits of RISC, TRBP (HIV-1 TAR RNA-binding protein) and Ago2, mediating the targeting of c-Myc mRNA by miRNAs. Interestingly, RPL5 and RPL11 co-resided on c-Myc mRNA and suppressed c-Myc expression co-operatively. These findings uncover a mechanism by which these two RPs can co-operatively suppress c-Myc expression, allowing a tightly controlled ribosome biogenesis in cells.	[Liao, J-M; Zhou, X.; Lu, H.] Tulane Univ, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; [Liao, J-M; Zhou, X.; Lu, H.] Tulane Univ, Sch Med, Tulane Canc Ctr, New Orleans, LA 70112 USA; [Gatignol, A.] McGill Univ, AIDS Ctr, Lady Davis Inst Med Res, Montreal, PQ, Canada	Tulane University; Tulane University; Lady Davis Institute; McGill University	Lu, H (corresponding author), Tulane Univ, Sch Med, Dept Biochem & Mol Biol, 1430 Tulane Ave, New Orleans, LA 70112 USA.	hlu2@tulane.edu	Gatignol, Anne/AAA-6501-2020; Zhou, Xiang/J-5046-2017	Gatignol, Anne/0000-0002-4553-0836; Zhou, Xiang/0000-0002-1172-7948	National Institutes of Health (NIH)-National Cancer Institute (NCI) [CA095441, CA079721, CA129828, CA172468]; NATIONAL CANCER INSTITUTE [R01CA172468, R01CA129828, R01CA095441, R01CA079721] Funding Source: NIH RePORTER	National Institutes of Health (NIH)-National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Karen Vousden for providing us with the RPL11 mutant plasmid, Mu-shui Dai for offering some reagents and Shelya X Zeng as well as other members of the Lu laboratory for advices and active discussion. This work was supported in part by National Institutes of Health (NIH)-National Cancer Institute (NCI) grants CA095441, CA079721, CA129828 and CA172468 to H. L.	Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Bursac S, 2012, P NATL ACAD SCI USA, V109, P20467, DOI 10.1073/pnas.1218535109; Challagundla KB, 2011, MOL CELL BIOL, V31, P4007, DOI 10.1128/MCB.05810-11; Chen D, 2007, ONCOGENE, V26, P5029, DOI 10.1038/sj.onc.1210327; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2007, EMBO J, V26, P3332, DOI 10.1038/sj.emboj.7601776; Dai MS, 2008, J CELL BIOCHEM, V105, P670, DOI 10.1002/jcb.21895; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Flores I, 2004, ONCOGENE, V23, P5923, DOI 10.1038/sj.onc.1207796; Gallant P, 2005, CANCER RES, V65, P6485, DOI 10.1158/0008-5472.CAN-05-1101; Golomb L, 2012, MOL CELL, V45, P222, DOI 10.1016/j.molcel.2011.11.022; GOURSE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2722, DOI 10.1073/pnas.78.5.2722; Haase AD, 2005, EMBO REP, V6, P961, DOI 10.1038/sj.embor.7400509; Horn HF, 2008, ONCOGENE, V27, P5774, DOI 10.1038/onc.2008.189; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Jin Y, 2008, MOL CELL BIOL, V28, P1218, DOI 10.1128/MCB.01198-07; Jin YT, 2006, EMBO J, V25, P1207, DOI 10.1038/sj.emboj.7601010; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Koscianska E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028548; Liao JM, 2011, J BIOL CHEM, V286, P33901, DOI 10.1074/jbc.M111.262030; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lu H, 2011, NAT MED, V17, P930, DOI 10.1038/nm.2434; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Ota H, 2013, CELL, V153, P575, DOI 10.1016/j.cell.2013.03.024; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PFEIFEROHLSSON S, 1984, CELL, V38, P585, DOI 10.1016/0092-8674(84)90513-0; Pomerantz MM, 2009, NAT GENET, V41, P882, DOI 10.1038/ng.403; Sasaki M, 2011, NAT MED, V17, P944, DOI 10.1038/nm.2392; Sodir NM, 2011, GENE DEV, V25, P907, DOI 10.1101/gad.2038411; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Sun XX, 2008, J BIOL CHEM, V283, P12387, DOI 10.1074/jbc.M801387200; Sun XX, 2011, J BIOL CHEM, V286, P22730, DOI 10.1074/jbc.M111.223651; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Wright JB, 2010, MOL CELL BIOL, V30, P1411, DOI 10.1128/MCB.01384-09; Xiong X, 2011, ONCOGENE, V30, P1798, DOI 10.1038/onc.2010.569; Yadavilli S, 2009, DNA REPAIR, V8, P1215, DOI 10.1016/j.dnarep.2009.07.003; Zarnack K, 2013, CELL, V152, P453, DOI 10.1016/j.cell.2012.12.023; Zeng SX, 2002, EMBO J, V21, P5487, DOI 10.1093/emboj/cdf540; Zhang Q, 2011, J BIOL CHEM, V286, P38264, DOI 10.1074/jbc.M111.277012; Zhang X, 2013, ONCOGENE, V32, P2782, DOI 10.1038/onc.2012.289; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang Y, 2010, NUCLEIC ACIDS RES, V38, P6544, DOI 10.1093/nar/gkq536; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhou X, 2013, ONCOGENE, V32, P388, DOI 10.1038/onc.2012.63; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014	57	55	55	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2014	33	41					4916	4923		10.1038/onc.2013.430	http://dx.doi.org/10.1038/onc.2013.430			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OA	24141778	Green Accepted			2022-12-28	WOS:000343767900004
J	Lai, CH; Park, KS; Lee, DH; Alberobello, AT; Raffeld, M; Pierobon, M; Pin, E; Petricoin, EF; Wang, Y; Giaccone, G				Lai, C-H; Park, K-S; Lee, D-H; Alberobello, A. T.; Raffeld, M.; Pierobon, M.; Pin, E.; Petricoin, E. F., III; Wang, Y.; Giaccone, G.			HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer	ONCOGENE			English	Article						doxorubicin; Ganetespib; hsp90 inhibitor; rip1; SCLC	KAPPA-B ACTIVATION; POTENT ANTITUMOR-ACTIVITY; HSP90 INHIBITOR; SIGNALING PATHWAYS; PROTEIN; APOPTOSIS; CYCLOPHOSPHAMIDE; VINCRISTINE; DEATH; CISPLATIN	Small cell lung cancer (SCLC) at advanced stage is considered an incurable disease. Despite good response to initial chemotherapy, the responses in SCLC patients with metastatic disease are of short duration and resistance inevitably occurs. Although several target-specific drugs have altered the paradigm of treatment for many other cancers, we have yet to witness a revolution of the same magnitude in SCLC treatment. Anthracyclines, such as doxorubicin, have definite activity in this disease, and ganetespib has shown promising activity in preclinical models but underwhelming activity as a single agent in SCLC patients. Using SCLC cell lines, we demonstrated that ganetespib (IC50: 31 nM) was much more potent than 17-allylamino-17-demethoxygeldanamycin (17-AAG), a geldanamycin derivative (IC50: 16 mu M). Ganetespib inhibited SCLC cell growth via induction of persistent G2/M arrest and Caspase 3-dependent cell death. MTS assay revealed that ganetespib synergized with both doxorubicin and etoposide, two topoisomerase II inhibitors commonly used in SCLC chemotherapy. Expression of receptor-interacting serine/threonine-protein kinase 1 (RIP1), a protein that may function as a pro-survival scaffold protein or a pro-death kinase in TNFR1-activated cells, was induced by doxorubicin and downregulated by ganetespib. Depletion of RIP1 by either RIP1 small interfering RNA (siRNA) or ganetespib sensitized doxorubicin-induced cell death, suggesting that RIP1 may promote survival in doxorubicin-treated cells and that ganetespib may synergize with doxorubicin in part through the downregulation of RIP1. In comparison to ganetespib or doxorubicin alone, the ganetespib + doxorubicin combination caused significantly more growth regression and death of human SCLC xenografts in immunocompromised mice. We conclude that ganetespib and doxorubicin combination exhibits significant synergy and is efficacious in inhibiting SCLC growth in vitro and in mouse xenograft models. Our preclinical study suggests that ganetespib and doxorubicin combination therapy may be an effective strategy for SCLC treatment, which warrants clinical testing.	[Lai, C-H; Park, K-S; Lee, D-H; Alberobello, A. T.; Wang, Y.; Giaccone, G.] NCI, Med Oncol Branch, NIH, Bethesda, MD USA; [Raffeld, M.] NCI, Pathol Lab, NIH, Bethesda, MD USA; [Pierobon, M.; Pin, E.; Petricoin, E. F., III] George Masson Univ, Ctr Appl Prote & Mol Med, Manassas, VI USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wang, Y (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, 3970 Reservoir Rd NW,W503 Res Bldg, Washington, DC 20007 USA.	yw350@georgetown.edu; gg496@georgetown.edu	Pierobon, Mariaelena/GXA-0544-2022; Giaccone, Giuseppe/E-8297-2017	Giaccone, Giuseppe/0000-0002-5023-7562; PIN, ELISA/0000-0002-2158-2674	National Cancer Institute; NATIONAL CANCER INSTITUTE [Z01BC010854, ZICBC011079, P30CA051008] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Leonard M Neckers for stimulating discussion during the course of the study and Dr Weiwen Ying (Synta Pharmaceuticals) for his valuable comments on the manuscript and for providing ganetespib for the study. This research was funded by the National Cancer Institute Intramural Program.	Banerji U, 2003, CURR CANCER DRUG TAR, V3, P385, DOI 10.2174/1568009033481813; Bansal H, 2010, BLOOD, V116, P4591, DOI 10.1182/blood-2009-10-247239; Bian X, 2001, J BIOL CHEM, V276, P48921, DOI 10.1074/jbc.M108674200; Blagosklonny MV, 2001, LEUKEMIA, V15, P1537, DOI 10.1038/sj.leu.2402257; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Califano R, 2012, DRUGS, V72, P471, DOI 10.2165/11597640-000000000-00000; Chaitanya GV, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-31; Chandele A, 2004, NEOPLASIA, V6, P29, DOI 10.1016/S1476-5586(04)80051-4; Choi HJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024312; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; COOK RM, 1993, CURR PROB CANCER, V17, P71; Davenport EL, 2007, BLOOD, V110, P2641, DOI 10.1182/blood-2006-11-053728; Declercq W, 2009, CELL, V138, P229, DOI 10.1016/j.cell.2009.07.006; Demidenko ZN, 2006, CELL DEATH DIFFER, V13, P1434, DOI 10.1038/sj.cdd.4401812; Ettinger DS, 2010, J CLIN ONCOL, V28, P2598, DOI 10.1200/JCO.2009.26.7682; FUKUOKA M, 1991, J NATL CANCER I, V83, P855, DOI 10.1093/jnci/83.12.855; Gangadharan C, 2009, J CELL BIOCHEM, V107, P203, DOI 10.1002/jcb.22115; Jackman DM, 2005, LANCET, V366, P1385, DOI 10.1016/S0140-6736(05)67569-1; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Kim YS, 2009, CURR TOP MED CHEM, V9, P1479, DOI 10.2174/156802609789895728; Kotani Y, 2012, J CLIN ONCOL M ABS S, V30, P7003; Lally BE, 2007, ONCOLOGIST, V12, P1096, DOI 10.1634/theoncologist.12-9-1096; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Mahoney DJ, 2008, P NATL ACAD SCI USA, V105, P11778, DOI 10.1073/pnas.0711122105; Nishizuka S, 2003, P NATL ACAD SCI USA, V100, P14229, DOI 10.1073/pnas.2331323100; Park Kang-Seo, 2011, Front Biosci (Elite Ed), V3, P341, DOI 10.2741/e249; Pelayo Alvarez M, 2009, COCHRANE DB SYST REV, V7, DOI DOI 10.1002/SYSTREV14651858.CD001990.PUB2; Pierobon M, 2012, METHODS MOL BIOL, V823, P215, DOI 10.1007/978-1-60327-216-2_14; Powers MV, 2006, ENDOCR-RELAT CANCER, V13, pS125, DOI 10.1677/erc.1.01324; Proia DA, 2012, INVEST NEW DRUG, V30, P2201, DOI 10.1007/s10637-011-9790-6; Proia DA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018552; Robles AI, 2006, CLIN CANCER RES, V12, P6547, DOI 10.1158/1078-0432.CCR-06-1178; Rodina A, 2007, NAT CHEM BIOL, V3, P498, DOI 10.1038/nchembio.2007.10; ROTH BJ, 1992, J CLIN ONCOL, V10, P282, DOI 10.1200/JCO.1992.10.2.282; Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Schmittel A, 2011, EXPERT REV ANTICANC, V11, P631, DOI [10.1586/ERA.11.7, 10.1586/era.11.7]; Sculier JP, 1990, LUNG CANCER, V6, P110; Sheehan KM, 2008, ONCOGENE, V27, P323, DOI 10.1038/sj.onc.1210647; SHEPHERD FA, 1987, CANCER TREAT REP, V71, P941; Shibakura M, 2003, INT J CANCER, V103, P380, DOI 10.1002/ijc.10842; Shimamura T, 2012, CLIN CANCER RES, V18, P4973, DOI 10.1158/1078-0432.CCR-11-2967; Singhal SS, 2006, FEBS LETT, V580, P2258, DOI 10.1016/j.febslet.2006.03.038; Sos ML, 2012, P NATL ACAD SCI USA, V109, P17034, DOI 10.1073/pnas.1207310109; Srethapakdi M, 2000, CANCER RES, V60, P3940; Sugimoto K, 2008, ONCOGENE, V27, P3091, DOI 10.1038/sj.onc.1210978; Varfolomeev E, 2008, J BIOL CHEM, V283, P24295, DOI 10.1074/jbc.C800128200; von Pawel J, 1999, J CLIN ONCOL, V17, P658, DOI 10.1200/JCO.1999.17.2.658; Wang YS, 2010, CURR OPIN INVEST DR, V11, P1466; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Xu WP, 2007, CLIN CANCER RES, V13, P1625, DOI 10.1158/1078-0432.CCR-06-2966; Ying WW, 2012, MOL CANCER THER, V11, P475, DOI 10.1158/1535-7163.MCT-11-0755; Zhang HB, 2011, NATURE, V471, P373, DOI 10.1038/nature09878	53	40	43	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2014	33	40					4867	4876		10.1038/onc.2013.439	http://dx.doi.org/10.1038/onc.2013.439			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0EH	24166505	Green Accepted			2022-12-28	WOS:000343240100008
J	Kim, YR; Kim, IJ; Kang, TW; Choi, C; Kim, KK; Kim, MS; Nam, KI; Jung, C				Kim, Y-R; Kim, I-J; Kang, T. W.; Choi, C.; Kim, K. K.; Kim, M. S.; Nam, K. I.; Jung, C.			HOXB13 downregulates intracellular zinc and increases NF-kappa B signaling to promote prostate cancer metastasis	ONCOGENE			English	Article						HOXB13; metastasis; prostate cancer; zinc; ZnT4	ANDROGEN RECEPTOR GENE; UPTAKE TRANSPORTER; IN-VITRO; EXPRESSION; CELLS; ACTIVATION; SUPPRESSION; ADENOCARCINOMA; PROGRESSION; GROWTH	Characteristically, prostate cancer (PCa) cells exhibit marked decrease in intracellular zinc; however, the mechanism responsible is not clearly understood. HOXB13 is involved in PCa progression and is overexpressed in castration-resistant PCa. DNA microarray analysis of LNCaP Pca cells showed that ZnT zinc output transporters were strikingly upregulated among androgen-independent HOXB13 target genes. Furthermore, exogenous HOXB13 caused intracellular zinc concentrations to fall in PCa cells, stimulated NF-kappa B-mediated signaling by reducing inhibitor of NF-kappa B alpha (I kappa B alpha) and enhanced the nuclear translocation of RelA/p65. Human prostate tumors also exhibited strong inverse correlation between the protein expressions of HOXB13 and I kappa B alpha. Consequently, HOXB13 stimulated PCa cell invasion, and this was inhibited by the suppression of ZnT4. In addition, studies in a PC3 orthotopic mouse model of PCa metastasis showed that HOXB13 is a strong metastatic stimulator. Taken together, these results show that HOXB13 promotes PCa invasion and metastasis by decreasing intracellular zinc levels, thus stimulating NF-kappa B signals, and suggest that HOXB13 acts as a modulator of intracellular zinc levels that promotes the malignant characteristics of PCa.	[Kim, Y-R; Kim, I-J; Nam, K. I.; Jung, C.] Chonnam Natl Univ, Sch Med, Dept Anat, Kwangju 501190, South Korea; [Kang, T. W.] Chonnam Natl Univ, Sch Med, Dept Urol, Kwangju 501190, South Korea; [Choi, C.] Chonnam Natl Univ, Sch Med, Dept Pathol, Kwangju 501190, South Korea; [Kim, K. K.] Chonnam Natl Univ, Sch Med, Dept Pharmacol, Kwangju 501190, South Korea; [Kim, M. S.] Chonnam Natl Univ, Coll Nat Sci, Dept Stat, Kwangju 501190, South Korea	Chonnam National University; Chonnam National University; Chonnam National University; Chonnam National University; Chonnam National University	Jung, C (corresponding author), Chonnam Natl Univ, Sch Med, Dept Anat, 5 Hak Dong, Kwangju 501190, South Korea.	chjung@chonnam.ac.kr	Jung, Chaeyong/AAD-8357-2021; Nam, Kwang Il/C-4580-2019	Jung, Chaeyong/0000-0002-5557-4576; Nam, Kwang Il/0000-0001-5380-6815	Korea Science and Engineering Foundation through the Medical Research Center for Gene Regulation [2012-0009445]; Basic Science Research Program of the National Research Foundation of Korea (NRF) grant - Korea Government [2010-0003838]; Chonnam National University Research Institute of Medical Sciences [2010-CURIMS-DR011]	Korea Science and Engineering Foundation through the Medical Research Center for Gene Regulation(Korea Science and Engineering Foundation); Basic Science Research Program of the National Research Foundation of Korea (NRF) grant - Korea Government; Chonnam National University Research Institute of Medical Sciences	This work was supported by the Korea Science and Engineering Foundation through the Medical Research Center for Gene Regulation (2012-0009445), by the Basic Science Research Program of the National Research Foundation of Korea (NRF) grant funded by the Korea Government (2010-0003838), and by a grant from the Chonnam National University Research Institute of Medical Sciences ((2010-CURIMS-DR011).	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Beck FWJ, 2004, PROSTATE, V58, P374, DOI 10.1002/pros.10344; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen CD, 2002, MOL CELL BIOL, V22, P2862, DOI 10.1128/MCB.22.8.2862-2870.2002; Costello LC, 1999, J BIOL CHEM, V274, P17499, DOI 10.1074/jbc.274.25.17499; Costello LC, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-17; Economides KD, 2003, DEVELOPMENT, V130, P2061, DOI 10.1242/dev.00432; Edwards J, 2003, BRIT J CANCER, V89, P552, DOI 10.1038/sj.bjc.6601127; Franklin RB, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-32; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Golovine K, 2008, CLIN CANCER RES, V14, P5376, DOI 10.1158/1078-0432.CCR-08-0455; Golovine K, 2008, PROSTATE, V68, P1443, DOI 10.1002/pros.20810; Henshall SM, 2003, ONCOGENE, V22, P6005, DOI 10.1038/sj.onc.1206797; Ho LH, 2004, J IMMUNOL, V172, P7750, DOI 10.4049/jimmunol.172.12.7750; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Jeon KI, 2000, J IMMUNOL, V164, P5981, DOI 10.4049/jimmunol.164.11.5981; Jung C, 2005, BRIT J CANCER, V92, P2233, DOI 10.1038/sj.bjc.6602631; Jung C, 2004, CANCER RES, V64, P9185, DOI 10.1158/0008-5472.CAN-04-1330; Jung CY, 2001, GENE, V271, P143, DOI 10.1016/S0378-1119(01)00513-3; Kim SD, 2010, ANAT CELL BIOL, V43, P284, DOI 10.5115/acb.2010.43.4.284; Kim YR, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-124; Linja MJ, 2001, CANCER RES, V61, P3550; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; McMahon RJ, 1998, J NUTR, V128, P667, DOI 10.1093/jn/128.4.667; Michalczyk AA, 2002, BIOCHEM J, V364, P105, DOI 10.1042/bj3640105; Muenchen HJ, 2000, CLIN CANCER RES, V6, P1969; Murgia C, 1999, AM J PHYSIOL-GASTR L, V277, pG1231, DOI 10.1152/ajpgi.1999.277.6.G1231; Palmiter RD, 2004, PFLUG ARCH EUR J PHY, V447, P744, DOI 10.1007/s00424-003-1070-7; Rosoff B, 1981, Prog Clin Biol Res, V75A, P447; Salsi V, 2006, J BIOL CHEM, V281, P1992, DOI 10.1074/jbc.M510900200; Shaut CA, 2007, DEV DYNAM, V236, P951, DOI 10.1002/dvdy.21077; Shukla S, 2004, NEOPLASIA, V6, P390, DOI 10.1593/neo.04112; Shukla S, 2004, CLIN CANCER RES, V10, P3169, DOI 10.1158/1078-0432.CCR-03-0586; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sreenath T, 1999, PROSTATE, V41, P203, DOI 10.1002/(SICI)1097-0045(19991101)41:3<203::AID-PROS8>3.0.CO;2-J; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Sweeney C, 2004, CLIN CANCER RES, V10, P5501, DOI 10.1158/1078-0432.CCR-0571-03; Tricoli JV, 1996, GENE CHROMOSOME CANC, V15, P108, DOI 10.1002/(SICI)1098-2264(199602)15:2<108::AID-GCC5>3.0.CO;2-7; Uzzo RG, 2002, CLIN CANCER RES, V8, P3579; Uzzo RG, 2006, CARCINOGENESIS, V27, P1980, DOI 10.1093/carcin/bgl034; Yamashita A, 1996, PROSTATE, V29, P1; Zaichick V. Ye., 1997, International Urology and Nephrology, V29, P565, DOI 10.1007/BF02552202; Zhang LY, 2009, AM J PATHOL, V175, P489, DOI 10.2353/ajpath.2009.080727; Zou J, 2011, PROSTATE, V71, P1518, DOI 10.1002/pros.21368	46	46	50	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2014	33	37					4558	4567		10.1038/onc.2013.404	http://dx.doi.org/10.1038/onc.2013.404			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3UZ	24096478				2022-12-28	WOS:000342004800003
J	Vidal, SJ; Rodriguez-Bravo, V; Galsky, M; Cordon-Cardo, C; Domingo-Domenech, J				Vidal, S. J.; Rodriguez-Bravo, V.; Galsky, M.; Cordon-Cardo, C.; Domingo-Domenech, J.			Targeting cancer stem cells to suppress acquired chemotherapy resistance	ONCOGENE			English	Review						chemotherapy; cancer stem cells; self-renewal; quiescence; differentiation; apoptosis and survival	COLONY-STIMULATING FACTOR; TUMOR-INITIATING CELLS; CHRONIC MYELOID-LEUKEMIA; METASTATIC BREAST-CANCER; MYELOGENOUS LEUKEMIA; PROSTATE-CANCER; SELF-RENEWAL; BETA-CATENIN; TGF-BETA; PROSPECTIVE IDENTIFICATION	Acquired resistance has curtailed cancer survival since the dawn of the chemotherapy age more than half a century ago. Although the application of stem cell (SC) concepts to cancer captured the imagination of scientists for many years, only the last decade has yielded substantial evidence that cancer SCs (CSCs) contribute to chemotherapy resistance. Recent studies suggest that the functional and molecular properties of CSCs constitute therapeutic opportunities to improve the efficacy of chemotherapy. Here we review how these properties have stimulated combination strategies that suppress acquired resistance across a spectrum of malignancies. The clinical implementation of these strategies promises to rejuvenate the effort against an enduring challenge.	[Vidal, S. J.; Cordon-Cardo, C.; Domingo-Domenech, J.] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA; [Vidal, S. J.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Rodriguez-Bravo, V.] Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; [Galsky, M.] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Oncol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Columbia University; Memorial Sloan Kettering Cancer Center; Icahn School of Medicine at Mount Sinai	Domingo-Domenech, J (corresponding author), Icahn Sch Med Mt Sinai, Dept Pathol, Annenberg Bldg,Room 24-16,1468 Madison Ave, New York, NY 10029 USA.	carlos.cordon-cardo@mssm.edu; josep.domingo-domenech@mssm.edu		Rodriguez-Bravo, Veronica/0000-0002-7363-3672	Hariri Family Foundation; TJ Martell Foundation	Hariri Family Foundation; TJ Martell Foundation	This work was supported by the Hariri Family Foundation and the TJ Martell Foundation.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Beier D, 2008, CANCER RES, V68, P5706, DOI 10.1158/0008-5472.CAN-07-6878; Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106; Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780; Bhola NE, 2013, J CLIN INVEST, V123, P1348, DOI 10.1172/JCI65416; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Borovski T, 2013, ONCOGENE, V32, P1539, DOI 10.1038/onc.2012.172; Borovski T, 2011, CANCER RES, V71, P634, DOI 10.1158/0008-5472.CAN-10-3220; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Carracedo A, 2013, NAT REV CANCER, V13, P227, DOI 10.1038/nrc3483; Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Chirasani SR, 2010, BRAIN, V133, P1961, DOI 10.1093/brain/awq128; Chu S, 2011, BLOOD, V118, P5565, DOI 10.1182/blood-2010-12-327437; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Copland M, 2006, BLOOD, V107, P4532, DOI 10.1182/blood-2005-07-2947; Cortes J, 2011, J CLIN ONCOL, V29, P524, DOI 10.1200/JCO.2010.31.3619; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Culig Z, 2011, BBA-MOL CELL RES, V1813, P308, DOI 10.1016/j.bbamcr.2010.12.010; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dalerba P, 2011, NAT BIOTECHNOL, V29, P1120, DOI 10.1038/nbt.2038; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Dick JE, 2008, BLOOD, V112, P4793, DOI 10.1182/blood-2008-08-077941; Dierks C, 2008, CANCER CELL, V14, P238, DOI 10.1016/j.ccr.2008.08.003; Domen J, 2000, J EXP MED, V191, P253, DOI 10.1084/jem.191.2.253; Domen J, 1998, BLOOD, V91, P2272, DOI 10.1182/blood.V91.7.2272.2272_2272_2282; Domingo-Domenech J, 2012, CANCER CELL, V22, P373, DOI 10.1016/j.ccr.2012.07.016; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415; Essers MAG, 2009, NATURE, V458, P904, DOI 10.1038/nature07815; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Evangelista M, 2006, CLIN CANCER RES, V12, P5924, DOI 10.1158/1078-0432.CCR-06-1736; Fuchs E, 2009, CELL, V137, P811, DOI 10.1016/j.cell.2009.05.002; Gerber JM, 2012, BLOOD, V119, P3571, DOI 10.1182/blood-2011-06-364182; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Ginestier C, 2012, STEM CELLS, V30, P1327, DOI 10.1002/stem.1122; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Goff DJ, 2013, CELL STEM CELL, V12, P316, DOI 10.1016/j.stem.2012.12.011; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Goss PE, 2010, NAT REV CANCER, V10, P871, DOI 10.1038/nrc2933; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris CA, 2011, ANN ONCOL, V22, P1308, DOI 10.1093/annonc/mdq593; Heidel FH, 2012, CELL STEM CELL, V10, P412, DOI 10.1016/j.stem.2012.02.017; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; Hirsch HA, 2013, P NATL ACAD SCI USA, V110, P972, DOI 10.1073/pnas.1221055110; Hirsch HA, 2010, CANCER CELL, V17, P348, DOI 10.1016/j.ccr.2010.01.022; Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994; Hoey T, 2009, CELL STEM CELL, V5, P168, DOI 10.1016/j.stem.2009.05.019; Hu Y, 2009, LEUKEMIA, V23, P109, DOI 10.1038/leu.2008.262; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Huntly BJP, 2005, NAT REV CANCER, V5, P311, DOI 10.1038/nrc1592; Iliopoulos D, 2011, CANCER RES, V71, P3196, DOI 10.1158/0008-5472.CAN-10-3471; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350; Ishizawa K, 2010, CELL STEM CELL, V7, P279, DOI 10.1016/j.stem.2010.08.009; Jin LH, 2008, MOL CANCER THER, V7, P48, DOI 10.1158/1535-7163.MCT-07-0042; Jorgensen HG, 2007, BLOOD, V109, P4016, DOI 10.1182/blood-2006-11-057521; Jorgensen HG, 2006, CLIN CANCER RES, V12, P626, DOI 10.1158/1078-0432.CCR-05-0429; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Korkaya H, 2013, CANCER RES, V73, P3489, DOI 10.1158/0008-5472.CAN-13-0260; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670; Lang JY, 2011, CANCER CELL, V20, P341, DOI 10.1016/j.ccr.2011.07.017; Lee TKW, 2011, CELL STEM CELL, V9, P50, DOI 10.1016/j.stem.2011.06.005; Li CW, 2011, GASTROENTEROLOGY, V141, P2218, DOI 10.1053/j.gastro.2011.08.009; Li L, 2012, CANCER CELL, V21, P266, DOI 10.1016/j.ccr.2011.12.020; Li L, 2011, CLIN CANCER RES, V17, P4936, DOI 10.1158/1078-0432.CCR-10-1499; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liu C, 2011, CANCER RES, V71, P5950, DOI 10.1158/0008-5472.CAN-11-1035; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; Liu SP, 2013, GASTROENTEROLOGY, V144, P1031, DOI 10.1053/j.gastro.2013.01.046; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Lombardo Y, 2011, GASTROENTEROLOGY, V140, P297, DOI 10.1053/j.gastro.2010.10.005; Lonardo E, 2012, CELL CYCLE, V11, P1282, DOI 10.4161/cc.19679; Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001; Lowenberg B, 1997, J CLIN ONCOL, V15, P3496; Lowenberg B, 2003, NEW ENGL J MED, V349, P743, DOI 10.1056/NEJMoa025406; Lu J, 2013, CANCER CELL, V23, P171, DOI 10.1016/j.ccr.2012.12.021; Luo YC, 2012, STEM CELLS, V30, P2100, DOI 10.1002/stem.1193; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Magnifico A, 2009, CLIN CANCER RES, V15, P2010, DOI 10.1158/1078-0432.CCR-08-1327; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Menendez JA, 2013, CELL CYCLE, V12, P1166, DOI 10.4161/cc.24479; Minami Y, 2012, LEUKEMIA, V26, P2142, DOI 10.1038/leu.2012.73; Nadal R, 2013, INT J CANCER, V133, P2398, DOI 10.1002/ijc.28263; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Oak PS, 2012, INT J CANCER, V131, P2808, DOI 10.1002/ijc.27595; Pabst T, 2012, BLOOD, V119, P5367, DOI 10.1182/blood-2011-11-389841; Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001; Patrawala L, 2007, CANCER RES, V67, P6796, DOI 10.1158/0008-5472.CAN-07-0490; Persano L, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.153; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Pistollato F, 2010, STEM CELLS, V28, P851, DOI 10.1002/stem.415; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Qin JC, 2012, CELL STEM CELL, V10, P556, DOI 10.1016/j.stem.2012.03.009; Qiu M, 2013, CANCER LETT, V328, P261, DOI 10.1016/j.canlet.2012.09.023; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Quintana E, 2010, CANCER CELL, V18, P510, DOI 10.1016/j.ccr.2010.10.012; Raimondi C, 2011, BREAST CANCER RES TR, V130, P449, DOI 10.1007/s10549-011-1373-x; Rajeshkumar NV, 2010, MOL CANCER THER, V9, P2582, DOI 10.1158/1535-7163.MCT-10-0370; Reedijk M, 2012, ADV EXP MED BIOL, V727, P241, DOI 10.1007/978-1-4614-0899-4_18; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Roesch A, 2013, CANCER CELL, V23, P811, DOI 10.1016/j.ccr.2013.05.003; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Rousseau B, 2010, CANCER J, V16, P202, DOI 10.1097/PPO.0b013e3181ddc5bf; Saito Y, 2010, NAT BIOTECHNOL, V28, P275, DOI 10.1038/nbt.1607; Sakakibara M, 2012, CANCER-AM CANCER SOC, V118, P3899, DOI 10.1002/cncr.26725; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Schott AF, 2013, CLIN CANCER RES, V19, P1512, DOI 10.1158/1078-0432.CCR-11-3326; Schurch C, 2013, J EXP MED, V210, P605, DOI 10.1084/jem.20121229; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016; Tajima H, 2012, ONCOL LETT, V3, P1186, DOI 10.3892/ol.2012.657; Takeishi S, 2013, CANCER CELL, V23, P347, DOI 10.1016/j.ccr.2013.01.026; Tamaki A, 2011, ESSAYS BIOCHEM, V50, P209, DOI [10.1042/BSE0500209, 10.1042/bse0500209]; Tate CM, 2012, CELL DEATH DIFFER, V19, P1644, DOI 10.1038/cdd.2012.44; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; van Rhenen A, 2005, CLIN CANCER RES, V11, P6520, DOI 10.1158/1078-0432.CCR-05-0468; van Vlerken LE, 2012, J MOL MED, V90, P791, DOI 10.1007/s00109-012-0917-9; Vazquez-Martin A, 2011, BREAST CANCER RES TR, V126, P355, DOI 10.1007/s10549-010-0924-x; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Voog J, 2010, CELL STEM CELL, V6, P103, DOI 10.1016/j.stem.2010.01.011; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Weisberg E, 2012, LEUKEMIA, V26, P985, DOI 10.1038/leu.2011.360; Wurth R, 2013, CELL CYCLE, V12, P145, DOI 10.4161/cc.23050; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zhang B, 2013, BLOOD, V121, P1824, DOI 10.1182/blood-2012-02-412890; Zhang B, 2010, CANCER CELL, V17, P427, DOI 10.1016/j.ccr.2010.03.011; Zhang GC, 2013, BBA-REV CANCER, V1836, P49, DOI 10.1016/j.bbcan.2013.03.001; Zhang WC, 2012, CELL, V148, P259, DOI 10.1016/j.cell.2011.11.050; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737; Zittoun R, 1996, J CLIN ONCOL, V14, P2150, DOI 10.1200/JCO.1996.14.7.2150; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	164	186	188	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2014	33	36					4451	4463		10.1038/onc.2013.411	http://dx.doi.org/10.1038/onc.2013.411			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MY	24096485				2022-12-28	WOS:000341158800001
J	Levanon, K; Sapoznik, S; Bahar-Shany, K; Brand, H; Shapira-Frommer, R; Korach, J; Hirsch, MS; Roh, MH; Miron, A; Liu, JF; Vena, N; Ligon, AH; Fotheringham, S; Bailey, D; Flavin, RJ; Birrer, MJ; Drapkin, RI				Levanon, K.; Sapoznik, S.; Bahar-Shany, K.; Brand, H.; Shapira-Frommer, R.; Korach, J.; Hirsch, M. S.; Roh, M. H.; Miron, A.; Liu, J. F.; Vena, N.; Ligon, A. H.; Fotheringham, S.; Bailey, D.; Flavin, R. J.; Birrer, M. J.; Drapkin, R. I.			FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis	ONCOGENE			English	Article						serous ovarian carcinoma; fallopian tube epithelium; FOXO3a; AKT; ERK; miRNA-182	LUNG-CANCER CELLS; TRANSCRIPTION FACTOR; OVARIAN-CANCER; FALLOPIAN-TUBE; PROMOTES TUMORIGENESIS; CANDIDATE PRECURSOR; EXPRESSION; INHIBITORS; CARCINOMA; CHEMOTHERAPY	Serous ovarian carcinoma is the most lethal gynecological malignancy in Western countries. The molecular events that underlie the development of the disease have been elusive for many years. The recent identification of the fallopian tube secretory epithelial cells (FTSECs) as the cell-of-origin for most cases of this disease has led to studies aimed at elucidating new candidate therapeutic pathways through profiling of normal FTSECs and serous carcinomas. Here we describe the results of transcriptional profiles that identify the loss of the tumor suppressive transcription factor FOXO3a in a vast majority of high-grade serous ovarian carcinomas. We show that FOXO3a loss is a hallmark of the earliest stages of serous carcinogenesis and occurs both at the DNA, RNA and protein levels. We describe several mechanisms responsible for FOXO3a inactivity, including chromosomal deletion (chromosome 6q21), upregulation of miRNA-182 and destabilization by activated PI3K and MEK. The identification of pathways involved in the pathogenesis of ovarian cancer can advance the management of this disease from being dependant on surgery and cytotoxic chemotherapy alone to the era of targeted therapy. Our data strongly suggest FOXO3a as a possible target for clinical intervention.	[Levanon, K.] Chaim Sheba Med Ctr, Sheba Canc Res Ctr, Dr Pinchas Borenstein Talpiot Med Leadership Prog, IL-52621 Ramat Gan, Israel; [Levanon, K.; Drapkin, R. I.] Dept Med Oncol, Boston, MA USA; [Levanon, K.; Drapkin, R. I.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Sapoznik, S.; Bahar-Shany, K.; Brand, H.] Sheba Canc Res Ctr, Ramat Gan, Israel; [Sapoznik, S.; Bahar-Shany, K.; Brand, H.] Chaim Sheba Med Ctr, IL-52621 Ramat Gan, Israel; [Brand, H.] Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel; [Shapira-Frommer, R.] Chaim Sheba Med Ctr, Inst Oncol, IL-52621 Ramat Gan, Israel; [Korach, J.; Ligon, A. H.] Chaim Sheba Med Ctr, Dept Gynecol Oncol, IL-52621 Ramat Gan, Israel; [Hirsch, M. S.; Roh, M. H.; Drapkin, R. I.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Miron, A.; Liu, J. F.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Liu, J. F.; Ligon, A. H.; Drapkin, R. I.] Harvard Univ, Sch Med, Boston, MA USA; [Vena, N.; Ligon, A. H.; Fotheringham, S.; Bailey, D.; Flavin, R. J.] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA; [Birrer, M. J.] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA	Chaim Sheba Medical Center; Harvard University; Dana-Farber Cancer Institute; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital	Levanon, K (corresponding author), Chaim Sheba Med Ctr, Sheba Canc Res Ctr, Dr Pinchas Borenstein Talpiot Med Leadership Prog, IL-52621 Ramat Gan, Israel.	Keren.Levanon@sheba.health.gov.il	Drapkin, Ronny/E-9944-2016	Drapkin, Ronny/0000-0002-6912-6977; Levanon, Keren/0000-0002-5122-064X; Fotheringham, Susan/0000-0001-5440-8747; Flavin, Richard/0000-0002-4993-4563	National Institutes of Health/National Cancer Institute [P50 CA105009, U01 CA152990, R21 CA156021]; Ovarian Cancer Research Fund; Mary Kay Foundation; Tina Brozman Foundation; Robert and Debra First Fund; Gamel Family Fund for Ovarian Cancer; Marsha Rivkin Foundation Scientific Scholar Award; AACR- George and Patricia Sehl Fellowship; American Physicians Fellowship for Medicine in Israel-Claire and Emmanuel G. Rosenblatt Foundation Grant; Israel Science Foundation Legacy Heritage Clinical Research Initiative; Israel Cancer Research Fund Clinical Research Career Development Award; Chaim Sheba Medical Center Dr Pinchas Bornstein Talpiot Medical Leadership Program; NATIONAL CANCER INSTITUTE [P50CA105009, U01CA152990, R21CA156021] Funding Source: NIH RePORTER	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ovarian Cancer Research Fund; Mary Kay Foundation; Tina Brozman Foundation; Robert and Debra First Fund; Gamel Family Fund for Ovarian Cancer; Marsha Rivkin Foundation Scientific Scholar Award; AACR- George and Patricia Sehl Fellowship; American Physicians Fellowship for Medicine in Israel-Claire and Emmanuel G. Rosenblatt Foundation Grant; Israel Science Foundation Legacy Heritage Clinical Research Initiative; Israel Cancer Research Fund Clinical Research Career Development Award; Chaim Sheba Medical Center Dr Pinchas Bornstein Talpiot Medical Leadership Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by research grants from the National Institutes of Health/National Cancer Institute (P50 CA105009, U01 CA152990, and R21 CA156021), the Ovarian Cancer Research Fund, The Mary Kay Foundation, The Tina Brozman Foundation, The Robert and Debra First Fund, the Gamel Family Fund for Ovarian Cancer, the Marsha Rivkin Foundation Scientific Scholar Award, the AACR- George and Patricia Sehl Fellowship for Cancer Genetics Research, the American Physicians Fellowship for Medicine in Israel-Claire and Emmanuel G. Rosenblatt Foundation Grant, The Israel Science Foundation Legacy Heritage Clinical Research Initiative, The Israel Cancer Research Fund Clinical Research Career Development Award and the Chaim Sheba Medical Center Dr Pinchas Bornstein Talpiot Medical Leadership Program. We thank Drs. John Quackenbush, Massimo Loda, Keith Ligon and Sekhar Duraisamy, Dana-Farber Cancer Institute, for their suggestions and generous assistance with reagents and bioinformatics; Dr Ravid Straussman, the Broad Institute, for his guidance with methylation detection; Dr Sol Efroni and Rotem Ben-Hamo, Bar Ilan University, Israel, for bioinformatic support; and The Chaim Sheba Tissue Bank.	Barreyro FJ, 2007, J BIOL CHEM, V282, P27141, DOI 10.1074/jbc.M704391200; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Carter ME, 2007, CURR BIOL, V17, pR113, DOI 10.1016/j.cub.2007.01.008; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Dejean AS, 2009, NAT IMMUNOL, V10, P504, DOI 10.1038/ni.1729; Fei M, 2009, CANCER INVEST, V27, P52, DOI 10.1080/07357900802146204; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Folkins AK, 2008, GYNECOL ONCOL, V109, P168, DOI 10.1016/j.ygyno.2008.01.012; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Gomes AR, 2008, CELL CYCLE, V7, P3133, DOI 10.4161/cc.7.20.6920; Greer EL, 2007, J BIOL CHEM, V282, P30107, DOI 10.1074/jbc.M705325200; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Jarboe EA, 2008, HISTOPATHOLOGY, V53, P127, DOI 10.1111/j.1365-2559.2007.02938.x; Karst AM, 2012, NAT PROTOC, V7, P1755, DOI 10.1038/nprot.2012.097; Karst AM, 2011, P NATL ACAD SCI USA, V108, P7547, DOI 10.1073/pnas.1017300108; Kim W, 2013, PHARMACOL RES, V70, P90, DOI 10.1016/j.phrs.2013.01.005; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; Kornblau SM, 2010, CLIN CANCER RES, V16, P1865, DOI 10.1158/1078-0432.CCR-09-2551; Kuhn RM, 2009, NUCLEIC ACIDS RES, V37, pD755, DOI 10.1093/nar/gkn875; Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091; Levanon K, 2008, J CLIN ONCOL, V26, P5284, DOI 10.1200/JCO.2008.18.1107; Lu MD, 2012, MED ONCOL, V29, P3409, DOI 10.1007/s12032-012-0275-z; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Medeiros F, 2006, AM J SURG PATHOL, V30, P230, DOI 10.1097/01.pas.0000180854.28831.77; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nakamura T, 2008, MOL CELL ENDOCRINOL, V281, P47, DOI 10.1016/j.mce.2007.10.007; Osuka S, 2013, STEM CELLS, V31, P627, DOI 10.1002/stem.1328; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Potente M, 2005, J CLIN INVEST, V115, P2382, DOI 10.1172/JCI23126; Rathbone CR, 2008, MUSCLE NERVE, V37, P84, DOI 10.1002/mus.20897; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Santo EE, 2007, CANCER RES, V73, P2189; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Su JL, 2011, CANCER RES, V71, P6878, DOI 10.1158/0008-5472.CAN-11-0295; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x; Wilicox BJ, 2008, P NATL ACAD SCI USA, V105, P13987, DOI 10.1073/pnas.0801030105; Yamaguchi H, 2013, CLIN CANCER RES, V19, P845, DOI 10.1158/1078-0432.CCR-12-2621; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yap TA, 2009, NAT REV CANCER, V9, P167, DOI 10.1038/nrc2583; Zhao Fung, 2012, Front Med, V6, P376, DOI 10.1007/s11684-012-0228-0	47	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2014	33	35					4424	4432		10.1038/onc.2013.394	http://dx.doi.org/10.1038/onc.2013.394			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MR	24077281	Green Accepted, Green Submitted			2022-12-28	WOS:000341157800007
J	Wu, DW; Wu, TC; Wu, JY; Cheng, YW; Chen, YC; Lee, MC; Chen, CY; Lee, H				Wu, D-W; Wu, T-C; Wu, J-Y; Cheng, Y-W; Chen, Y-C; Lee, M-C; Chen, C-Y; Lee, H.			Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression	ONCOGENE			English	Article						PXN; Bcl-2; cisplatin-based chemotherapy; NSCLC	OVARIAN-CANCER; REGULATES ADHESION; PREDICTS SURVIVAL; GROWTH; INVASION; PROLIFERATION; SENSITIVITY; CARCINOMA; APOPTOSIS; RELAPSE	Paxillin (PXN) is required for receptor tyrosine kinase-mediated ERK activation, and the activation of the Raf/MEK/ERK cascade has been linked with Bcl-2 expression. We hypothesized that phosphorylation of PXN by the EGFR/Src pathway might contribute to cisplatin resistance via increased Bcl-2 expression. We show that cisplatin resistance was dependent on PXN expression, as evidenced by PXN overexpression in TL-13 and TL-10 cells and PXN knockdown in H23 and CL1-5 cells. Specific inhibitors of signaling pathways indicated that the phosphorylation of PXN at Y118 and Y31 via the Src pathway was responsible for cisplatin resistance. We further demonstrated that ERK activation was also dependent on this PXN phosphorylation. Bcl-2 transcription was upregulated by phosphorylated PXN-mediated ERK activation via increased binding of phosphorylated CREB to the Bcl-2 promoter. A subsequent increase in Bcl-2 levels by a PXN/ERK axis was responsible for the resistance to cisplatin. Animal models further confirmed the findings of in vitro cells indicating that xenograft tumors induced by TL-13-overexpressing cells were successfully suppressed by cisplatin combined with Src or ERK inhibitor compared with treatment of cisplatin, Src inhibitor or ERK inhibitor alone. A positive correlation of phosphorylated PXN with phosphorylated ERK and Bcl-2 was observed in lung tumors from NSCLC patients. Patients with tumors positive for PXN, phosphorylated PXN, phosphorylated ERK and Bcl-2 more commonly showed a poorer response to cisplatin-based chemotherapy than did patients with negative tumors. Collectively, PXN phosphorylation might contribute to cisplatin resistance via activating ERK-mediated Bcl-2 transcription. Therefore, we suggest that Src or ERK inhibitor might be helpful to improve the sensitivity for cisplatin-based chemotherapy in NSCLC patients with PXN-positive tumors.	[Wu, D-W; Cheng, Y-W; Lee, H.] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Taipei, Taiwan; [Wu, T-C] Chung Shan Med Univ, Dept Internal Med, Taichung, Taiwan; [Wu, J-Y] Buddhist Tzu Chi Taichung Gen Hosp, Div Thorac Surg, Taichung, Taiwan; [Wu, J-Y] Tzu Chi Univ, Coll Med, Hualien, Taiwan; [Chen, Y-C] Taipei Med Univ, Grad Inst Med Sci, Coll Med, Taichung, Taiwan; [Lee, M-C] Taichung Vet Gen Hosp, Dept Thorac Surg, Taichung, Taiwan; [Chen, C-Y] China Med Univ Hosp, Dept Surg, Taichung, Taiwan	Taipei Medical University; Chung Shan Medical University; Buddhist Tzu Chi General Hospital; Tzu Chi University; Taipei Medical University; Taichung Veterans General Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan	Lee, H (corresponding author), Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Room 5,12F,3,Pk St, Taipei, Taiwan.	hl@tmu.edu.tw			National Health Research Institute [NHRI96-TD-G-111-006, NHRI97-TD-G-111-006]; National Science Council of Taiwan, ROC [NSC-100-2314-B-038-043-MY3]	National Health Research Institute(National Health Research Institutes - Taiwan); National Science Council of Taiwan, ROC(Ministry of Science and Technology, Taiwan)	This work was jointly supported by grants from the National Health Research Institute (NHRI96-TD-G-111-006; NHRI97-TD-G-111-006) and the National Science Council (NSC-100-2314-B-038-043-MY3) of Taiwan, ROC.	Aponte M, 2008, CANCER RES, V68, P5839, DOI 10.1158/0008-5472.CAN-07-5771; Arany I, 2005, KIDNEY INT, V68, P1573, DOI 10.1111/j.1523-1755.2005.00569.x; Bai LF, 2012, INT J CANCER, V130, P2693, DOI 10.1002/ijc.26303; Bendardaf R, 2008, ONCOL REP, V20, P999, DOI 10.3892/or_00000101; Bertotti A, 2010, CLIN CANCER RES, V16, P3933, DOI 10.1158/1078-0432.CCR-10-0106; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0; Bray K, 2009, MOL CANCER RES, V7, P1487, DOI 10.1158/1541-7786.MCR-09-0166; Creson TK, 2009, J MOL NEUROSCI, V37, P123, DOI 10.1007/s12031-008-9122-2; Deakin NO, 2008, J CELL SCI, V121, P2435, DOI 10.1242/jcs.018044; Haslehurst AM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-91; Hiscox S, 2006, BREAST CANCER RES TR, V97, P263, DOI 10.1007/s10549-005-9120-9; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4; Jagadeeswaran R, 2008, CANCER RES, V68, P132, DOI 10.1158/0008-5472.CAN-07-1998; Johnson FM, 2005, CLIN CANCER RES, V11, P6924, DOI 10.1158/1078-0432.CCR-05-0757; Lee JH, 2013, MOL CELL, V49, P668, DOI 10.1016/j.molcel.2012.12.004; Li J, 2008, CANCER CHEMOTH PHARM, V61, P525, DOI 10.1007/s00280-007-0499-3; Low SY, 2012, CANCER LETT, V314, P166, DOI 10.1016/j.canlet.2011.09.025; Mano Y, 1999, EUR J CANCER, V35, P1214, DOI 10.1016/S0959-8049(99)00124-0; Meller R, 2005, J CEREBR BLOOD F MET, V25, P234, DOI 10.1038/sj.jcbfm.9600024; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; Nayal A, 2006, J CELL BIOL, V173, P587, DOI 10.1083/jcb.200509075; Sachdev S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-12; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; Sen A, 2012, J CLIN INVEST, V122, P2469, DOI 10.1172/JCI62044; Sen A, 2010, J BIOL CHEM, V285, P28787, DOI 10.1074/jbc.M110.134064; Sheibani N, 2008, J CELL PHYSIOL, V214, P655, DOI 10.1002/jcp.21256; Shintani Y, 2011, ANN THORAC SURG, V92, P1794, DOI 10.1016/j.athoracsur.2011.07.032; Sorenson CM, 2004, J BIOL CHEM, V279, P11368, DOI 10.1074/jbc.M310079200; Subramanian M, 2007, J IMMUNOL, V179, P2330, DOI 10.4049/jimmunol.179.4.2330; Sung WW, 2011, CLIN CANCER RES, V17, P5991, DOI 10.1158/1078-0432.CCR-11-0227; Tabassam FH, 2011, AM J PHYSIOL-GASTR L, V301, pG601, DOI 10.1152/ajpgi.00375.2010; Turner CE, 2000, J CELL SCI, V113, P4139; Wang J, 2007, CANCER RES, V67, P11933, DOI 10.1158/0008-5472.CAN-07-5185; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wu DW, 2014, ONCOGENE, V33, P1515, DOI 10.1038/onc.2013.107; Wu DW, 2012, AM J PATHOL, V181, P1796, DOI 10.1016/j.ajpath.2012.07.032; Wu DW, 2011, CLIN CANCER RES, V17, P1895, DOI 10.1158/1078-0432.CCR-10-2316; Wu DW, 2010, CANCER RES, V70, P10392, DOI 10.1158/0008-5472.CAN-10-2341; Yang TM, 2009, AM J RESP CELL MOL, V41, P14, DOI 10.1165/rcmb.2008-0320OC; Yoon H, 2011, BIOCHEM BIOPH RES CO, V405, P333, DOI 10.1016/j.bbrc.2010.11.130; Zhuo WL, 2008, BIOCHEM BIOPH RES CO, V369, P1098, DOI 10.1016/j.bbrc.2008.02.143; Zou W, 2012, J BONE MINER RES, V27, P2490, DOI 10.1002/jbmr.1706	43	51	52	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2014	33	35					4385	4395		10.1038/onc.2013.389	http://dx.doi.org/10.1038/onc.2013.389			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MR	24096476	Bronze			2022-12-28	WOS:000341157800003
J	Hug, E; Hobeika, E; Reth, M; Jumaa, H				Hug, E.; Hobeika, E.; Reth, M.; Jumaa, H.			Inducible expression of hyperactive Syk in B cells activates Blimp-1-dependent terminal differentiation	ONCOGENE			English	Article						B-cell transformation; Bcl-2; Blimp-1; hyperactive Syk; terminal differentiation	LYMPHOCYTES DEPENDS; TYROSINE KINASES; BLIMP-1; GENE; BCL-2; SURVIVAL; APOPTOSIS; 3-KINASE; TARGETS; MCL-1	The non-receptor protein tyrosine kinase Syk (spleen tyrosine kinase) is an important mediator of signal transduction in B cells. By acting downstream of the B-cell antigen receptor, Syk promotes signaling pathways involved in proliferation, differentiation and survival of B cells. To study the oncogenic potential of Syk, we generated a mouse model for the inducible expression of the leukemia-derived TEL-Syk fusion protein exhibiting constitutive kinase activity. To achieve B-cell-specific expression of TEL-Syk in adult mice, we used a tamoxifen-inducible Cre mouse line. This study shows that inducible expression of TEL-Syk in B cells leads to transient proliferation and subsequent plasma cell differentiation. However, it does not lead to B-cell transformation. Instead, Syk activation induces the tumor suppressor B-lymphocyte-induced maturation protein-1 (Blimp-1), which interferes with the expression of the antiapoptotic protein Bcl-2. Combined induction of TEL-Syk with transgenic expression of Bcl-2 results in a severe phenotype and plasma cell expansion. Our results suggest that deregulated Syk activity by itself is not sufficient for the transformation of B cells, as downstream effectors, such as Blimp-1, limit the survival and expansion of the activated B cell.	[Hug, E.; Reth, M.; Jumaa, H.] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, D-79106 Freiburg, Germany; [Hug, E.; Hobeika, E.; Reth, M.; Jumaa, H.] Univ Freiburg, Fac Biol, Dept Mol Immunol, D-79106 Freiburg, Germany; [Hug, E.; Hobeika, E.; Reth, M.; Jumaa, H.] Max Planck Inst Immunbiol & Epigenet, D-79108 Freiburg, Germany	University of Freiburg; University of Freiburg; Max Planck Society	Jumaa, H (corresponding author), Max Planck Inst Immunbiol & Epigenet, Stuebeweg 51, D-79108 Freiburg, Germany.	jumaa@ie-freiburg.mpg.de	hobeika, elias/AAV-6663-2021		Deutsche Krebshilfe [108935]	Deutsche Krebshilfe(Deutsche Krebshilfe)	We thank A Nil for critical discussion and help with mouse analyses. We thank M Bach, C Eschbach, I Fiedler, C Sainz Rueda for technical assistance; U Zimber-Strobl for providing Rosa26-targeting construct; Benoit Kanzler and the transgenic mouse unit for ES cell injection; A Wuerch and S Hobitz for cell sorting; F Koehler and M Bach for proofreading the manuscript; S Srinivas for the Rosa26-YFP mice, A Strasser for the Bcl-2 tg mice, A Tarakhovsky for the Syk<SUP>fl</SUP>/<SUP>fl</SUP> mice and K Rajewsky for the CD21-Cre mice. This work was supported by the Deutsche Krebshilfe (project no. 108935), the Deutsche Forschungsgemeinschaft (SFB620) and the Excellence Initiative of the German Federal and State Governments (EXC294).	Adachi T, 1996, EMBO J, V15, P1534, DOI 10.1002/j.1460-2075.1996.tb00497.x; Beitz LO, 1999, J BIOL CHEM, V274, P32662, DOI 10.1074/jbc.274.46.32662; Calado DP, 2010, CANCER CELL, V18, P580, DOI 10.1016/j.ccr.2010.11.024; Carrington EM, 2010, P NATL ACAD SCI USA, V107, P10967, DOI 10.1073/pnas.1005256107; Chen LF, 2008, BLOOD, V111, P2230, DOI 10.1182/blood-2007-07-100115; Cretney E, 2011, NAT IMMUNOL, V12, P304, DOI 10.1038/ni.2006; De Vos J, 2006, IMMUNOL REV, V210, P86, DOI 10.1111/j.0105-2896.2006.00362.x; Feil R, 1997, BIOCHEM BIOPH RES CO, V237, P752, DOI 10.1006/bbrc.1997.7124; Gobessi S, 2009, LEUKEMIA, V23, P686, DOI 10.1038/leu.2008.346; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Herzog S, 2008, NAT IMMUNOL, V9, P623, DOI 10.1038/ni.1616; Homig-Holzel C, 2008, J EXP MED, V205, P1317, DOI 10.1084/jem.20080238; Holmes ML, 2008, IMMUNOL CELL BIOL, V86, P47, DOI 10.1038/sj.icb.7100134; Kallies A, 2006, NAT IMMUNOL, V7, P466, DOI 10.1038/ni1321; Kallies A, 2007, CURR OPIN IMMUNOL, V19, P156, DOI 10.1016/j.coi.2007.01.003; Kanie T, 2004, LEUKEMIA, V18, P548, DOI 10.1038/sj.leu.2403266; Knodel M, 1999, EUR J IMMUNOL, V29, P2988; Kraus M, 2004, CELL, V117, P787, DOI 10.1016/j.cell.2004.05.014; Kulathu Y, 2008, EMBO J, V27, P1333, DOI 10.1038/emboj.2008.62; Kuno Y, 2001, BLOOD, V97, P1050, DOI 10.1182/blood.V97.4.1050; Leseux L, 2006, BLOOD, V108, P4156, DOI 10.1182/blood-2006-05-026203; Mandelbaum J, 2010, CANCER CELL, V18, P568, DOI 10.1016/j.ccr.2010.10.030; Marshall AJ, 2000, IMMUNOL REV, V176, P30; Martins G, 2008, ANNU REV IMMUNOL, V26, P133, DOI 10.1146/annurev.immunol.26.021607.090241; Merino D, 2012, BLOOD, V119, P5807, DOI 10.1182/blood-2011-12-400929; Peperzak V, 2013, NAT IMMUNOL, V14, P290, DOI 10.1038/ni.2527; Riccaboni M, 2010, DRUG DISCOV TODAY, V15, P517, DOI 10.1016/j.drudis.2010.05.001; Rinaldi A, 2006, BRIT J HAEMATOL, V132, P303, DOI 10.1111/j.1365-2141.2005.05883.x; Saijo K, 2003, NAT IMMUNOL, V4, P274, DOI 10.1038/ni893; Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010; Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7; Shapiro-Shelef M, 2003, IMMUNITY, V19, P607, DOI 10.1016/S1074-7613(03)00267-X; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; Visan I, 2003, EUR J IMMUNOL, V33, P1163, DOI 10.1002/eji.200323747; Werner M, 2010, IMMUNOL REV, V237, P55, DOI 10.1111/j.1600-065X.2010.00934.x; Wossning T, 2006, J EXP MED, V203, P2829, DOI 10.1084/jem.20060967; Young RM, 2009, BLOOD, V113, P2508, DOI 10.1182/blood-2008-05-158618	39	14	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3730	3741		10.1038/onc.2013.326	http://dx.doi.org/10.1038/onc.2013.326			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23955076				2022-12-28	WOS:000338942900012
J	Farnsworth, RH; Lackmann, M; Achen, MG; Stacker, SA				Farnsworth, R. H.; Lackmann, M.; Achen, M. G.; Stacker, S. A.			Vascular remodeling in cancer	ONCOGENE			English	Review						angiogenesis; metastasis; endothelial cell; lymph node; tumor microenvironment; stroma	ENDOTHELIAL GROWTH-FACTOR; SENTINEL LYMPH-NODE; GLOMERULOID MICROVASCULAR PROLIFERATION; PROMOTES TUMOR-METASTASIS; SQUAMOUS-CELL CARCINOMA; VEGF-D PROMOTES; STEM-LIKE CELLS; BREAST-CANCER; PROGENITOR CELLS; BONE-MARROW	The growth and dissemination of tumors rely on an altered vascular network, which supports their survival and expansion and provides accessibility to the vasculature and a route of transport for metastasizing tumor cells. The remodeling of vascular structures through generation of new vessels (for example, via tumor angiogenesis) is a well studied, even if still quite poorly understood, process in human cancer. Antiangiogenic therapies have provided insight into the contribution of angiogenesis to the biology of human tumors, yet have also revealed the ease with which resistance to antiangiogenic drugs can develop, presumably involving alterations to vascular signaling mechanisms. Furthermore, cellular and/or molecular changes to pre-existing vessels could represent subtle pre-metastatic alterations to the vasculature, which are important for cancer progression. These changes, and associated molecular markers, may forecast the behavior of individual tumors and contribute to the early detection, diagnosis and prognosis of cancer. This review, which primarily focuses on the blood vasculature, explores current knowledge of how tumor vessels can be remodeled, and the cellular and molecular events responsible for this process.	[Farnsworth, R. H.; Lackmann, M.] Monash Univ, Dept Biochem & Mol Biol, Prot Interact & Canc Res Lab, Clayton, Vic, Australia; [Achen, M. G.; Stacker, S. A.] Peter MacCallum Canc Ctr, Tumour Angiogenesis Program, East Melbourne, Vic 8006, Australia; [Achen, M. G.; Stacker, S. A.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3052, Australia	Monash University; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne	Stacker, SA (corresponding author), Peter MacCallum Canc Ctr, Tumour Angiogenesis Program, Locked Bag 1,ABeckett St, East Melbourne, Vic 8006, Australia.	steven.stacker@petermac.org		Stacker, Steven/0000-0003-4096-9273; Farnsworth, Rae/0000-0002-7930-1206; Achen, Marc/0000-0002-3791-803X	Research Fellowships and a Program Grant from the National Health and Medical Research Council of Australia	Research Fellowships and a Program Grant from the National Health and Medical Research Council of Australia	MGA and SAS are supported by Research Fellowships and a Program Grant from the National Health and Medical Research Council of Australia. We apologize to authors whose work could not be quoted due to space limitations.	Achen MG, 2006, BRIT J CANCER, V94, P1355, DOI 10.1038/sj.bjc.6603120; Achen MG, 2008, ANN NY ACAD SCI, V1131, P225, DOI 10.1196/annals.1413.020; Achen MG, 2012, GROWTH FACTORS, V30, P283, DOI 10.3109/08977194.2012.704917; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Ahn GO, 2009, ANGIOGENESIS, V12, P159, DOI 10.1007/s10456-009-9135-7; Aird WC, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006429; ALGIRE GH, 1945, J NATL CANCER I, V6, P73, DOI 10.1093/jnci/6.1.73; Alitalo K, 2011, NAT MED, V17, P1371, DOI 10.1038/nm.2545; Alvero AB, 2009, STEM CELLS, V27, P2405, DOI 10.1002/stem.191; Aranguren XL, 2008, J CLIN INVEST, V118, P505, DOI [10.1172/JC131153, 10.1172/JCI31153]; Arapandoni-Dadioti P, 1999, CANCER LETT, V137, P145, DOI 10.1016/S0304-3835(98)00343-7; Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bertolini F, 2006, NAT REV CANCER, V6, P833, DOI 10.1039/nrc1971; Birner P, 2003, BRAIN PATHOL, V13, P133, DOI 10.1111/j.1750-3639.2003.tb00013.x; Bruno S, 2006, AM J PATHOL, V169, P2223, DOI 10.2353/ajpath.2006.060498; Bussolati B, 2008, FASEB J, V22, P3696, DOI 10.1096/fj.08-102590; Bussolati B, 2010, CURR VASC PHARMACOL, V8, P220, DOI 10.2174/157016110790887036; Bussolati B, 2009, J CELL MOL MED, V13, P309, DOI 10.1111/j.1582-4934.2008.00338.x; Cao RH, 2004, CIRC RES, V94, P664, DOI 10.1161/01.RES.0000118600.91698.BB; Cardone RA, 2005, NAT REV CANCER, V5, P786, DOI 10.1038/nrc1713; Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Carriere V, 2005, CANCER RES, V65, P11639, DOI 10.1158/0008-5472.CAN-05-1190; Cassoni P, 2008, J Cell Mol Med, V12, P564, DOI 10.1111/j.1582-4934.2007.00206.x; Chung MK, 2012, ANN SURG ONCOL, V19, P1595, DOI 10.1245/s10434-011-2154-9; Cipponi A, 2012, CANCER RES, V72, P3997, DOI 10.1158/0008-5472.CAN-12-1377; Clasper S, 2008, CANCER RES, V68, P7293, DOI 10.1158/0008-5472.CAN-07-6506; Cochran AJ, 2006, NAT REV IMMUNOL, V6, P659, DOI 10.1038/nri1919; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Cutsem E, 2005, SCIENCE, V307, P58; de Chaisemartin L, 2011, CANCER RES, V71, P6391, DOI 10.1158/0008-5472.CAN-11-0952; De Palma M, 2003, NAT MED, V9, P789, DOI 10.1038/nm871; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; De Palma M, 2007, TRENDS IMMUNOL, V28, P519, DOI 10.1016/j.it.2007.09.004; Dieu-Nosjean MC, 2008, J CLIN ONCOL, V26, P4410, DOI 10.1200/JCO.2007.15.0284; Dirkx AEM, 2006, FASEB J, V20, P621, DOI 10.1096/fj.05-4493com; Duda DG, 2007, NAT PROTOC, V2, P805, DOI 10.1038/nprot.2007.111; Dvorak AM, 1996, J LEUKOCYTE BIOL, V59, P100, DOI 10.1002/jlb.59.1.100; Farnsworth RH, 2011, CANCER RES, V71, P6547, DOI 10.1158/0008-5472.CAN-11-0200; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1966, ANN SURG, V164, P491, DOI 10.1097/00000658-196609000-00012; Fridman WH, 2011, CANCER RES, V71, P5601, DOI 10.1158/0008-5472.CAN-11-1316; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gao DC, 2008, SCIENCE, V319, P195, DOI 10.1126/science.1150224; Gerald D, 2013, CANCER RES, V73, P1649, DOI 10.1158/0008-5472.CAN-12-4697; Gerhardt H, 2008, J MOL MED, V86, P135, DOI 10.1007/s00109-007-0258-2; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; GIMBRONE MA, 1969, NATURE, V222, P33, DOI 10.1038/222033a0; Girard JP, 2012, NAT REV IMMUNOL, V12, P762, DOI 10.1038/nri3298; Goffin JR, 2003, BRIT J CANCER, V89, P1031, DOI 10.1038/sj.bjc.6601195; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241; Greene HSN, 1941, J EXP MED, V73, P461, DOI 10.1084/jem.73.4.461; Griffioen AW, 2008, CANCER IMMUNOL IMMUN, V57, P1553, DOI 10.1007/s00262-008-0524-3; Guidi AJ, 2000, J NATL CANCER I, V92, P486, DOI 10.1093/jnci/92.6.486; Halford MM, 2012, COLORECTAL CANCER, V1, P149, DOI 10.2217/CRC.12.9; Hamzah J, 2008, NATURE, V453, P410, DOI 10.1038/nature06868; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harrell MI, 2007, AM J PATHOL, V170, P774, DOI 10.2353/ajpath.2007.060761; Hayasaka H, 2010, CANCER SCI, V101, P2302, DOI 10.1111/j.1349-7006.2010.01687.x; Herve MA, 2008, AM J PATHOL, V172, P167, DOI 10.2353/ajpath.2008.070181; Hindley JP, 2012, CANCER RES, V72, P5473, DOI 10.1158/0008-5472.CAN-12-1912; Hirakawa S, 2005, J EXP MED, V201, P1089, DOI 10.1084/jem.20041896; Hirakawa S, 2007, BLOOD, V109, P1010, DOI 10.1182/blood-2006-05-021758; Hirakawa S, 2009, AM J PATHOL, V175, P2235, DOI 10.2353/ajpath.2009.090420; Hirakawa S, 2009, CANCER SCI, V100, P983, DOI 10.1111/j.1349-7006.2009.01142.x; Hockel M, 2001, SEMIN ONCOL, V28, P36, DOI 10.1016/S0093-7754(01)90211-8; Hoffman JA, 2003, CANCER CELL, V4, P383, DOI 10.1016/S1535-6108(03)00273-3; Hoshida T, 2006, CANCER RES, V66, P8065, DOI 10.1158/0008-5472.CAN-06-1392; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Hurwitz Herbert, 2004, Clin Colorectal Cancer, V4 Suppl 2, pS62, DOI 10.3816/CCC.2004.s.010; Ishii H, 2010, ORAL ONCOL, V46, P373, DOI 10.1016/j.oraloncology.2010.02.014; Jakob C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027402; Joukov V, 1996, EMBO J, V15, P290; Joyce JA, 2003, CANCER CELL, V4, P393, DOI 10.1016/S1535-6108(03)00271-X; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kaplan RN, 2006, CANCER RES, V66, P11089, DOI 10.1158/0008-5472.CAN-06-2407; Karnezis T, 2012, CANCER CELL, V21, P181, DOI 10.1016/j.ccr.2011.12.026; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kerjaschki D, 2011, J CLIN INVEST, V121, P2000, DOI 10.1172/JCI44751; Keskitalo S, 2007, CIRC RES, V100, P1460, DOI 10.1161/01.RES.0000269042.58594.f6; Konerding MA, 1998, AM J PATHOL, V152, P1607; Konerding MA, 1999, BRIT J CANCER, V80, P724, DOI 10.1038/sj.bjc.6690416; Kurahara H, 2010, J SURG ONCOL, V102, P809, DOI 10.1002/jso.21744; Kushner EJ, 2013, CURR OPIN HEMATOL, V20, P231, DOI 10.1097/MOH.0b013e328360614b; Laakkonen P, 2002, NAT MED, V8, P751, DOI 10.1038/nm720; Lee SY, 2012, ANN ACAD MED SINGAP, V41, P21; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Liao S, 2006, J IMMUNOL, V177, P3369, DOI 10.4049/jimmunol.177.5.3369; Liu PA, 2011, J IMMUNOTHER, V34, P320, DOI 10.1097/CJI.0b013e318213cd12; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Mancuso P, 2009, CLIN CANCER RES, V15, P267, DOI 10.1158/1078-0432.CCR-08-0432; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Martinet L, 2011, CANCER RES, V71, P5678, DOI 10.1158/0008-5472.CAN-11-0431; McAllister SS, 2010, J CLIN ONCOL, V28, P4022, DOI 10.1200/JCO.2010.28.4257; McColl BK, 2007, FASEB J, V21, P1088, DOI 10.1096/fj.06-7060com; Moeller BJ, 2007, CANCER METAST REV, V26, P241, DOI 10.1007/s10555-007-9056-0; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Nagy JA, 2006, LAB INVEST, V86, P767, DOI 10.1038/labinvest.3700436; Nagy JA, 2012, CLIN EXP METASTAS, V29, P657, DOI 10.1007/s10585-012-9500-6; Nagy JA, 2010, SEMIN THROMB HEMOST, V36, P321, DOI 10.1055/s-0030-1253454; Nolan DJ, 2007, GENE DEV, V21, P1546, DOI 10.1101/gad.436307; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; PAKU S, 1991, LAB INVEST, V65, P334; Patenaude A, 2010, MICROVASC RES, V79, P217, DOI 10.1016/j.mvr.2010.01.007; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Peinado H, 2011, SEMIN CANCER BIOL, V21, P139, DOI 10.1016/j.semcancer.2011.01.002; Peters BA, 2005, NAT MED, V11, P261, DOI 10.1038/nm1200; Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013; Pezzolo A, 2007, J CLIN ONCOL, V25, P376, DOI 10.1200/JCO.2006.09.0696; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Potenta S, 2008, BRIT J CANCER, V99, P1375, DOI 10.1038/sj.bjc.6604662; Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621; Purhonen S, 2008, P NATL ACAD SCI USA, V105, P6620, DOI 10.1073/pnas.0710516105; Qian CN, 2007, CELL CYCLE, V6, P514, DOI 10.4161/cc.6.5.3931; Qian CN, 2006, CANCER RES, V66, P10365, DOI 10.1158/0008-5472.CAN-06-2977; Qian CN, 2013, NAT REV UROL, V10, P300, DOI 10.1038/nrurol.2013.26; Qin L, 2012, ADV CANCER RES, V113, P191, DOI 10.1016/B978-0-12-394280-7.00006-3; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Raza A, 2010, AM J HEMATOL, V85, P593, DOI 10.1002/ajh.21745; Reyes M, 2002, J CLIN INVEST, V109, P337, DOI 10.1172/JCI200214327; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Ruddell A, 2008, ONCOGENE, V27, P3145, DOI 10.1038/sj.onc.1210973; Ruddell A, 2003, AM J PATHOL, V163, P2233, DOI 10.1016/S0002-9440(10)63581-X; Rybak SM, 2003, CANCER RES, V63, P2812; Schiffer D, 1999, J NEURO-ONCOL, V44, P99, DOI 10.1023/A:1006206920822; Schrama D, 2001, IMMUNITY, V14, P111, DOI 10.1016/S1074-7613(01)00094-2; Seaman S, 2007, CANCER CELL, V11, P539, DOI 10.1016/j.ccr.2007.04.017; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Shaked Y, 2005, CANCER CELL, V7, P101, DOI 10.1016/j.ccr.2004.11.023; Shaked Y, 2008, CANCER CELL, V14, P263, DOI 10.1016/j.ccr.2008.08.001; Shaked Y, 2006, SCIENCE, V313, P1785, DOI 10.1126/science.1127592; Shen RL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001652; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Sleeman JP, 2007, CLIN EXP METASTAS, V24, P707, DOI 10.1007/s10585-007-9122-6; Sleeman JP, 2011, INT J CANCER, V128, P2511, DOI 10.1002/ijc.26027; Soderberg KA, 2005, P NATL ACAD SCI USA, V102, P16315, DOI 10.1073/pnas.0506190102; Song S, 2005, NAT CELL BIOL, V7, P870, DOI 10.1038/ncb1288; SRIVASTAVA A, 1988, AM J PATHOL, V133, P419; Stacker SA, 1999, J BIOL CHEM, V274, P32127, DOI 10.1074/jbc.274.45.32127; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Straume O, 2002, CANCER RES, V62, P6808; Stubbs M, 2000, MOL MED TODAY, V6, P15, DOI 10.1016/S1357-4310(99)01615-9; Sullivan R, 2007, CANCER METAST REV, V26, P319, DOI 10.1007/s10555-007-9062-2; Sundberg C, 2001, AM J PATHOL, V158, P1145, DOI 10.1016/S0002-9440(10)64062-X; Tammela T, 2007, CIRC RES, V100, P1468, DOI 10.1161/01.RES.0000269043.51272.6d; Van den Eynden GG, 2006, BRIT J CANCER, V95, P1362, DOI 10.1038/sj.bjc.6603443; Van den Eynden GG, 2005, BRIT J CANCER, V93, P1128, DOI 10.1038/sj.bjc.6602828; Van der Auwera I, 2005, CLIN CANCER RES, V11, P7637, DOI 10.1158/1078-0432.CCR-05-1142; van der Schaft DWJ, 2007, CANCER LETT, V254, P128, DOI 10.1016/j.canlet.2007.03.001; von Baumgarten L, 2011, CLIN CANCER RES, V17, P6192, DOI 10.1158/1078-0432.CCR-10-1868; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537; Wels J, 2008, GENE DEV, V22, P559, DOI 10.1101/gad.1636908; Wirzenius M, 2007, J EXP MED, V204, P1431, DOI 10.1084/jem.20062642; Woolard J, 2009, MICROCIRCULATION, V16, P572, DOI 10.1080/10739680902997333; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Yoder MI, 2009, CURR OPIN HEMATOL, V16, P269, DOI 10.1097/MOH.0b013e32832bbcab; Yu JL, 2003, BREAST CANCER RES, V5, P83, DOI 10.1186/bcr573; Yu JL, 2002, CANCER RES, V62, P1838; Yu P, 2004, NAT IMMUNOL, V5, P141, DOI 10.1038/ni1029; Zhang LL, 2006, CANCER RES, V66, P5696, DOI 10.1158/0008-5472.CAN-05-3876; Zhao YC, 2012, MED ONCOL, V29, P2594, DOI 10.1007/s12032-012-0205-0	174	107	114	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3496	3505		10.1038/onc.2013.304	http://dx.doi.org/10.1038/onc.2013.304			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23912450				2022-12-28	WOS:000338941100002
J	Kim, ES; Cha, Y; Ham, M; Jung, J; Kim, SG; Hwang, S; Kleemann, R; Moon, A				Kim, E-S; Cha, Y.; Ham, M.; Jung, J.; Kim, S. G.; Hwang, S.; Kleemann, R.; Moon, A.			Inflammatory lipid sphingosine-1-phosphate upregulates C-reactive protein via C/EBP beta and potentiates breast cancer progression	ONCOGENE			English	Article						C-reactive protein; S1P; MMP-9; invasion; breast cell	PHOSPHOLIPASE C-CA2+ SYSTEM; GROWTH-FACTOR RECEPTOR; NADPH OXIDASE ACTIVITY; NF-KAPPA-B; SPHINGOSINE 1-PHOSPHATE; GENE-EXPRESSION; H-RAS; ENDOTHELIAL-CELLS; DNA-SEQUENCE; ACTIVATION	A crucial role of the inflammatory lipid sphingosine-1-phosphate (S1P) in breast cancer aggressiveness has been reported. Recent clinical studies have suggested that C-reactive protein (CRP) has a role in breast cancer development. However, limited information is available on the molecular basis for the expression of CRP and its functional significance in breast cell invasion. The present study aimed to elucidate the molecular link between S1P and CRP during the invasive process of breast epithelial cells. This is the first report showing that transcription of CRP was markedly activated by S1P in breast cells. Our data suggest that not only S1P treatment but also the endogenously produced S1P may upregulate CRP in breast carcinoma cells. Transcription factors CCAAT/enhancer-binding protein beta and c-fos were required for S1P-induced CRP expression. Coupling of S1P(3) to heterotrimeric G(alpha q) triggered the expression of CRP, utilizing signaling pathways involving reactive oxygen species (ROS), Ca2- and extracellular signal-related kinases (ERKs). S1P-induced CRP expression was crucial for the transcriptional activation of matrix metalloproteinase-9 through ERKs, ROS and c-fos, leading to breast cell invasion. Using a xenograft mice tumor model, we demonstrated that S1P induced CRP expression both in vitro and in vivo. Taken together, our findings have revealed a molecular basis for S1P-induced transcriptional activation of CRP and its functional significance in the acquisition of the invasive phenotype of human breast epithelial cells under inflammatory conditions. Our findings may provide useful information on the identification of useful therapeutic targets for inflammatory breast cancer.	[Kim, E-S; Cha, Y.; Ham, M.; Jung, J.; Moon, A.] Duksung Womens Univ, Coll Pharm, Seoul 132714, South Korea; [Kim, S. G.] Seoul Natl Univ, Coll Pharm, Seoul, South Korea; [Kim, S. G.] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul, South Korea; [Hwang, S.] Hanyang Univ, Coll Med, Seoul 133791, South Korea; [Kleemann, R.] TNO, Ck Leiden, Netherlands	Duksung Women's University; Seoul National University (SNU); Seoul National University (SNU); Hanyang University; Netherlands Organization Applied Science Research	Moon, A (corresponding author), Duksung Womens Univ, Coll Pharm, 419 Ssangmun Dong, Seoul 132714, South Korea.	armoon@duksung.ac.kr			National Research Foundation of Korea (NRF) [ROA-2012-0006262, R11-2007-0056817, 2013R1A2A2A04013379]; Korea Drug Development Fund [A100030101002011]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Korea Drug Development Fund(Korea Drug Development Fund (KDDF))	This work was supported by the National Research Foundation of Korea (NRF) grants (no. ROA-2012-0006262, no R11-2007-0056817, and no. 2013R1A2A2A04013379) and Korea Drug Development Fund (no. A100030101002011).	Allin KH, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2891; Ammit AJ, 2001, FASEB J, V15, P1212, DOI 10.1096/fj.00-0742fje; Azuma H, 2002, CANCER RES, V62, P1410; BODMER B, 1977, J IMMUNOL, V118, P1086; Bonnaud S, 2010, CANCER RES, V70, P9905, DOI 10.1158/0008-5472.CAN-10-2043; Catarzi S, 2007, BBA-GEN SUBJECTS, V1770, P872, DOI 10.1016/j.bbagen.2007.01.008; Cha Y, 2012, BMB REP, V45, P719, DOI 10.5483/BMBRep.2012.45.12.164; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chang JW, 2005, NEPHRON EXP NEPHROL, V101, pE165, DOI 10.1159/000087940; Cole SW, 2009, J CLIN ONCOL, V27, P3418, DOI 10.1200/JCO.2009.21.9782; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dai DF, 2011, J AM COLL CARDIOL, V58, P73, DOI 10.1016/j.jacc.2010.12.044; DEPRAETERE S, 1991, AGENTS ACTIONS, V34, P369, DOI 10.1007/BF01988730; Devaraj S, 2009, ATHEROSCLEROSIS, V203, P67, DOI 10.1016/j.atherosclerosis.2008.05.060; Doronzo G, 2005, J LAB CLIN MED, V146, P287, DOI 10.1016/j.lab.2005.07.010; Du Clos TW, 2000, ANN MED, V32, P274, DOI 10.3109/07853890009011772; Erlinger TP, 2004, JAMA-J AM MED ASSOC, V291, P585, DOI 10.1001/jama.291.5.585; French KJ, 2003, CANCER RES, V63, P5962; GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x; Goetzl EJ, 1999, CANCER RES, V59, P4732; Goldberg JE, 2010, CURR DRUG TARGETS, V11, P1133; Gong YQ, 2008, J CLIN INVEST, V118, P3012, DOI 10.1172/JCI32750; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Haider DG, 2006, CLIN EXP IMMUNOL, V146, P533, DOI 10.1111/j.1365-2249.2006.03224.x; Hammad SM, 2008, PROSTAG OTH LIPID M, V85, P107, DOI 10.1016/j.prostaglandins.2007.11.002; Han CJ, 2010, ATHEROSCLEROSIS, V212, P206, DOI 10.1016/j.atherosclerosis.2010.05.020; Hojilla CV, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1980; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; HURST HC, 1994, PROTEIN PROFILE, V1, P123; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jongsma M, 2009, BRIT J PHARMACOL, V156, P1305, DOI 10.1111/j.1476-5381.2009.00134.x; Kaur G, 2007, J THROMB HAEMOST, V5, P1309, DOI 10.1111/j.1538-7836.2007.02527.x; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kilareski EM, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-118; Kim ES, 2011, J CELL SCI, V124, P2220, DOI 10.1242/jcs.076794; Kim ES, 2010, BREAST CANCER RES TR, V124, P49, DOI 10.1007/s10549-009-0697-2; Kim MS, 2003, CANCER RES, V63, P5454; Kleemann R, 2003, BLOOD, V101, P545, DOI 10.1182/blood-2002-06-1762; Kleemann R, 2011, ATHEROSCLEROSIS, V218, P44, DOI 10.1016/j.atherosclerosis.2011.04.023; Koide Y, 2002, J MED CHEM, V45, P4629, DOI 10.1021/jm020080c; LEI KJ, 1985, J BIOL CHEM, V260, P3377; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lelongt B, 1997, J CELL BIOL, V136, P1363, DOI 10.1083/jcb.136.6.1363; Lewis CE, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1679; Li J, 2012, ARCH PHARM RES, V35, P1259, DOI 10.1007/s12272-012-0717-3; Long JS, 2010, J BIOL CHEM, V285, P35957, DOI 10.1074/jbc.M110.117945; Lu JH, 2011, P NATL ACAD SCI USA, V108, P4974, DOI 10.1073/pnas.1018369108; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; Masamune A, 2008, AM J PHYSIOL-GASTR L, V294, pG99, DOI 10.1152/ajpgi.00272.2007; Montero I, 2006, J AM COLL CARDIOL, V47, P1369, DOI 10.1016/j.jacc.2005.10.070; Moon A, 2000, INT J CANCER, V85, P176, DOI 10.1002/(SICI)1097-0215(20000115)85:2<176::AID-IJC5>3.0.CO;2-E; MOSHAGE HJ, 1988, BIOCHEM BIOPH RES CO, V155, P112, DOI 10.1016/S0006-291X(88)81056-8; Nabata A, 2008, ATHEROSCLEROSIS, V196, P129, DOI 10.1016/j.atherosclerosis.2007.03.003; Nagahashi M, 2012, CANCER RES, V72, P726, DOI 10.1158/0008-5472.CAN-11-2167; Nava VE, 2002, EXP CELL RES, V281, P115, DOI 10.1006/excr.2002.5658; Nishikawa T, 2008, J IMMUNOL, V180, P3492, DOI 10.4049/jimmunol.180.5.3492; Okajima F, 1997, ENDOCRINOLOGY, V138, P220, DOI 10.1210/en.138.1.220; Patel DN, 2007, J BIOL CHEM, V282, P27229, DOI 10.1074/jbc.M703250200; Paugh SW, 2003, FEBS LETT, V554, P189, DOI 10.1016/S0014-5793(03)01168-2; Pchejetski D, 2010, CANCER RES, V70, P8651, DOI 10.1158/0008-5472.CAN-10-1388; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; Pierce BL, 2009, J CLIN ONCOL, V27, P3437, DOI 10.1200/JCO.2008.18.9068; Price MO, 2002, J BIOL CHEM, V277, P19220, DOI 10.1074/jbc.M200061200; Przybylowska K, 2006, BREAST CANCER RES TR, V95, P65, DOI 10.1007/s10549-005-9042-6; Radeke HH, 2005, J IMMUNOL, V174, P2778, DOI 10.4049/jimmunol.174.5.2778; Ravishankaran P, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-18; Salmenpera P, 2003, AM J PHYSIOL-CELL PH, V284, pC1133, DOI 10.1152/ajpcell.00293.2002; Saren P, 1996, J IMMUNOL, V157, P4159; Sato K, 1999, FEBS LETT, V443, P25, DOI 10.1016/S0014-5793(98)01676-7; Schneider G, 2013, MOL CANCER RES, V11, P793, DOI 10.1158/1541-7786.MCR-12-0600; Shida D, 2008, CANCER RES, V68, P6569, DOI 10.1158/0008-5472.CAN-08-0411; Shin I, 2005, J BIOL CHEM, V280, P14675, DOI 10.1074/jbc.M411625200; Singh P, 2007, ARTERIOSCL THROM VAS, V27, pE302, DOI 10.1161/ATVBAHA.107.148353; Smicun Y, 2006, GYNECOL ONCOL, V103, P952, DOI 10.1016/j.ygyno.2006.06.036; Song H, 2006, CANCER RES, V66, P10487, DOI 10.1158/0008-5472.CAN-06-1461; Suresh MV, 2004, J BIOL CHEM, V279, P52552, DOI 10.1074/jbc.M409054200; SWANSON SJ, 1989, J CELL BIOCHEM, V40, P121, DOI 10.1002/jcb.240400112; Tanimoto T, 2004, CIRC RES, V94, P1050, DOI 10.1161/01.RES.0000126404.41421.BE; Teoh H, 2008, ATHEROSCLEROSIS, V201, P318, DOI 10.1016/j.atherosclerosis.2008.02.034; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Tobar N, 2010, BRIT J CANCER, V103, P1040, DOI 10.1038/sj.bjc.6605847; Tron K, 2008, EUR J IMMUNOL, V38, P1414, DOI 10.1002/eji.200738002; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Venugopal SK, 2005, AM J PATHOL, V166, P1265, DOI 10.1016/S0002-9440(10)62345-0; Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6; Wilsher N, 2007, DRUG METAB DISPOS, V35, P1017, DOI 10.1124/dmd.106.014498; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; WOO P, 1985, J BIOL CHEM, V260, P3384; Wu ZS, 2008, INT J CANCER, V122, P2050, DOI 10.1002/ijc.23337; Yong HY, 2011, NEOPLASIA, V13, P98, DOI 10.1593/neo.101088; Young DP, 2008, J IMMUNOL, V181, P2420, DOI 10.4049/jimmunol.181.4.2420	92	30	31	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3583	3593		10.1038/onc.2013.319	http://dx.doi.org/10.1038/onc.2013.319			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23955082				2022-12-28	WOS:000338941100010
J	Pyne, NJ; Pyne, S				Pyne, N. J.; Pyne, S.			Sphingosine kinase 1 enables communication between melanoma cells and fibroblasts that provides a new link to metastasis	ONCOGENE			English	Editorial Material							1-PHOSPHATE; DIFFERENTIATION; GROWTH	In this issue of Oncogene, Albinet et al. have demonstrated a critical role of melanoma sphingosine kinase 1, which catalyses formation of sphingosine 1-phosphate (S1P), in promoting the differentiation of fibroblasts into myofibroblasts. The myofibroblast sphingosine kinase 1 then promotes the S1P-dependent dissemination (metastasis) of melanoma cells via a S1P receptor 3-mediated mechanism. These findings are of major significance because they provide a novel mechanism of interaction between melanoma and the microenvironment niche in promoting metastasis. These studies therefore identify S1P derived from myofibroblasts and melanoma cells as a novel target for therapeutic intervention.	[Pyne, N. J.; Pyne, S.] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Cell Biol Grp, Glasgow G4 0RE, Lanark, Scotland	University of Strathclyde	Pyne, NJ (corresponding author), Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Cell Biol Grp, Glasgow G4 0RE, Lanark, Scotland.	n.j.pyne@strath.ac.uk		Pyne, Nigel/0000-0002-5657-4578; Pyne, Susan/0000-0002-6608-9584				Albinet V, 2014, ONCOGENE, V33, P3364, DOI 10.1038/onc.2013.303; Deng JH, 2012, CANCER CELL, V21, P642, DOI 10.1016/j.ccr.2012.03.039; Gellings Lowe N, 2009, CARDIOVASC RES, V82, P303, DOI 10.1093/cvr/cvp056; Kono Y, 2007, AM J RESP CELL MOL, V37, P395, DOI 10.1165/rcmb.2007-0065OC; Li CY, 2011, J HEPATOL, V54, P1205, DOI 10.1016/j.jhep.2010.08.028; Liang J, 2013, CANCER CELL, V23, P107, DOI 10.1016/j.ccr.2012.11.013; Long JS, 2010, MOL CELL BIOL, V30, P3827, DOI 10.1128/MCB.01133-09; Ponnusamy S, 2012, EMBO MOL MED, V4, P761, DOI 10.1002/emmm.201200244; Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875; Pyne S, 2011, CANCER RES, V71, P6576, DOI 10.1158/0008-5472.CAN-11-2364; Schnute ME, 2012, BIOCHEM J, V444, P79, DOI 10.1042/BJ20111929; Visentin B, 2006, CANCER CELL, V9, P225, DOI 10.1016/j.ccr.2006.02.023	12	9	10	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3361	3363		10.1038/onc.2013.292	http://dx.doi.org/10.1038/onc.2013.292			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23873031	Green Accepted			2022-12-28	WOS:000338779300002
J	Galli, GG; Multhaupt, HA; Carrara, M; de Lichtenberg, KH; Christensen, IBJ; Linnemann, D; Santoni-Rugiu, E; Calogero, RA; Lund, AH				Galli, G. G.; Multhaupt, H. A.; Carrara, M.; de Lichtenberg, K. H.; Christensen, I. B. J.; Linnemann, D.; Santoni-Rugiu, E.; Calogero, R. A.; Lund, A. H.			Prdm5 suppresses Apc(Min)-driven intestinal adenomas and regulates monoacylglycerol lipase expression	ONCOGENE			English	Article						PRDM5; APC; adenoma; intestinal cancer	ATP CITRATE LYASE; DNA METHYLATION; CELL-GROWTH; CANCER; DIFFERENTIATION; IDENTIFICATION; BIOCONDUCTOR; BIOLOGY; PROTEIN; TOPHAT	PRDM proteins are tissue-specific transcription factors often deregulated in diseases, particularly in cancer where different members have been found to act as oncogenes or tumor suppressors. PRDM5 is a poorly characterized member of the PRDM family for which several studies have reported a high frequency of promoter hypermethylation in cancer types of gastrointestinal origin. We report here the characterization of Prdm5 knockout mice in the context of intestinal carcinogenesis. We demonstrate that loss of Prdm5 increases the number of adenomas throughout the murine small intestine on an Apc(Min) background. By using the genome-wide ChIP-seq (chromatin immunoprecipitation (ChIP) followed by DNA sequencing) and transcriptome analyses we identify loci encoding proteins involved in metabolic processes as prominent PRDM5 targets and characterize monoacylglycerol lipase (Mgll) as a direct PRDM5 target in human colon cancer cells and in Prdm5 mutant mouse intestines. Moreover, we report the downregulation of PRDM5 protein expression in human colon neoplastic lesions. In summary, our data provide the first causal link between Prdm5 loss and intestinal carcinogenesis, and uncover an extensive and novel PRDM5 target repertoire likely facilitating the tumor-suppressive functions of PRDM5.	[Galli, G. G.; de Lichtenberg, K. H.; Lund, A. H.] Univ Copenhagen, Ctr Epigenet, BRIC, DK-2200 Copenhagen, Denmark; [Multhaupt, H. A.] Univ Copenhagen, Dept Biomed Sci, DK-2200 Copenhagen, Denmark; [Carrara, M.; Calogero, R. A.] Univ Turin, Ctr Mol Biotechnol, Dept Clin & Biol Sci, Turin, Italy; [Christensen, I. B. J.] Univ Copenhagen, Rigshosp, Fac Hlth Sci, Finsen Lab, DK-2200 Copenhagen, Denmark; [Linnemann, D.] Herlev Hosp, Dept Pathol, DK-2730 Herlev, Denmark; [Santoni-Rugiu, E.] Rigshosp, Ctr Diagnost, Dept Pathol, DK-2100 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; University of Turin; Rigshospitalet; University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital; Rigshospitalet; University of Copenhagen	Lund, AH (corresponding author), Univ Copenhagen, Ctr Epigenet, BRIC, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark.	anders.lund@bric.ku.dk	Calogero, Raffaele/K-9428-2019; Carrara, Matteo/J-8692-2016; Santoni-Rugiu, Eric/H-4913-2019; Lund, Anders H./F-4786-2014; Santoni-Rugiu, Eric/AAH-3368-2020	Calogero, Raffaele/0000-0002-2848-628X; Carrara, Matteo/0000-0002-8559-8296; Lund, Anders H./0000-0002-7407-3398; Santoni-Rugiu, Eric/0000-0002-2283-3535; Galli, Giorgio/0000-0002-9401-060X; Honnens de Lichtenberg, Kristian/0000-0002-3905-9574	Danish National Research Foundation; Danish National Advanced Technology Foundation; Novo Nordisk Foundation; EC FP7 programs (ONCOMIRS) [201102]; Lundbeck Foundation; Danish Cancer Society	Danish National Research Foundation(Danmarks Grundforskningsfond); Danish National Advanced Technology Foundation; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); EC FP7 programs (ONCOMIRS); Lundbeck Foundation(Lundbeckfonden); Danish Cancer Society(Danish Cancer Society)	We would like to acknowledge Julia Sidenius Johansen for her advice on TMA stainings, Bettina Mentz for excellent technical assistance and Fengqin Jia for mouse genotyping. This work was supported by the Danish National Research Foundation, the Danish National Advanced Technology Foundation, the Novo Nordisk Foundation, the EC FP7 programs (ONCOMIRS, grant agreement number 201102), the Lundbeck Foundation and the Danish Cancer Society.	Bauer DE, 2005, ONCOGENE, V24, P6314, DOI 10.1038/sj.onc.1208773; Cheng HY, 2010, J CANCER RES CLIN, V136, P1821, DOI 10.1007/s00432-010-0840-9; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Deng QD, 2004, ONCOGENE, V23, P4903, DOI 10.1038/sj.onc.1207615; Duan Z, 2007, MOL CELL BIOL, V27, P6889, DOI 10.1128/MCB.00762-07; Fog CK, 2012, BIOESSAYS, V34, P50, DOI 10.1002/bies.201100107; Galli GG, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002711; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kim D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r72; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Meani N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004273; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Nathke IS, 2004, ANNU REV CELL DEV BI, V20, P337, DOI 10.1146/annurev.cellbio.20.012103.094541; Nomura DK, 2011, CHEM BIOL, V18, P846, DOI 10.1016/j.chembiol.2011.05.009; Nomura DK, 2010, CELL, V140, P49, DOI 10.1016/j.cell.2009.11.027; PURDIE CA, 1994, ONCOGENE, V9, P603; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Roberts A, 2011, BIOINFORMATICS, V27, P2325, DOI 10.1093/bioinformatics/btr355; Sanges R, 2007, BIOINFORMATICS, V23, P3406, DOI 10.1093/bioinformatics/btm469; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Shu XS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027346; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Watanabe Y, 2007, CLIN CANCER RES, V13, P4786, DOI 10.1158/1078-0432.CCR-07-0305; Watanabe Y, 2009, GASTROENTEROLOGY, V136, P2149, DOI 10.1053/j.gastro.2009.02.085; Wright EMMB, 2011, AM J HUM GENET, V88, P767, DOI 10.1016/j.ajhg.2011.05.007; Ye L, 2011, CANCER LETT, V307, P6, DOI 10.1016/j.canlet.2011.03.007	36	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3342	3350		10.1038/onc.2013.283	http://dx.doi.org/10.1038/onc.2013.283			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23873026	Green Submitted			2022-12-28	WOS:000338443400014
J	Hirsch, E; Ciraolo, E; Franco, I; Ghigo, A; Martin, M				Hirsch, E.; Ciraolo, E.; Franco, I.; Ghigo, A.; Martin, M.			PI3K in cancer-stroma interactions: bad in seed and ugly in soil	ONCOGENE			English	Review						PI3K; tumorigenesis; microenvironment	EPITHELIAL-MESENCHYMAL TRANSITION; ENDOTHELIAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION PATHWAY; CELL-SURVIVAL; PHOSPHATIDYLINOSITOL 3'-KINASE; PROSTATE-CANCER; BREAST-CANCER; TRASTUZUMAB RESISTANCE; INHIBITOR NVP-BEZ235; ONCOGENIC MUTATIONS	Over the past decade the phosphoinositide-3 kinase (PI3K) signaling pathway emerged as an important player for tumor initiation and growth and, currently, PI3K inhibition constitutes a promising therapeutic approach for solid and hematological tumors. Beside its role in tumor cell evolution, PI3K signaling also provides integral functions for noncancerous cells that reside in healthy tissues surrounding the tumor, also referred as tumor microenvironment (TME). This review will address how PI3K signaling participates to the tumorigenic process and discuss the interaction between tumor cells and the surrounding TME, with particular focus on the role of PI3Ks in tumor-associated immune responses, tumor angiogenesis and metastasis formation.	[Hirsch, E.; Ciraolo, E.; Franco, I.; Ghigo, A.; Martin, M.] Univ Turin, Dept Mol Biotechnol & Hlth Sci, Ctr Mol Biotechnol, I-10126 Turin, Italy	University of Turin	Hirsch, E (corresponding author), Univ Turin, Dept Mol Biotechnol & Hlth Sci, Via Nizza 52, I-10126 Turin, Italy.	emilio.hirsch@unito.it	Franco, Irene/AAA-9170-2022; Ciraolo, Elisa/AAA-3430-2022; Martini, Miriam/K-3053-2016; Hirsch, Emilio/F-4848-2013	Franco, Irene/0000-0002-4272-239X; Martini, Miriam/0000-0002-4262-946X; Ghigo, Alessandra/0000-0002-1193-5296; Hirsch, Emilio/0000-0002-9073-6024; Ciraolo, Elisa/0000-0002-5601-1695	Fondazione Cariplo; Associazione Italiana Ricerca Cancro (AIRC); Italian Foundation for Cancer Research (FIRC)	Fondazione Cariplo(Fondazione Cariplo); Associazione Italiana Ricerca Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Foundation for Cancer Research (FIRC)(Fondazione AIRC per la ricerca sul cancro)	We thank MC Schmid for critical reading of the manuscript. This work was supported by a grant from Fondazione Cariplo and Associazione Italiana Ricerca Cancro (AIRC). AG is recipient of a fellowship from Italian Foundation for Cancer Research (FIRC).	Adamo B, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3071; Awad AE, 2010, AM J PHYSIOL-CELL PH, V298, pC679, DOI 10.1152/ajpcell.00351.2009; Barber DF, 2005, NAT MED, V11, P933, DOI 10.1038/nm1291; Bartholomeusz C, 2012, EXPERT OPIN THER TAR, V16, P121, DOI 10.1517/14728222.2011.644788; Beatty GL, 2011, SCIENCE, V331, P1612, DOI 10.1126/science.1198443; Beer-Hammer S, 2010, J LEUKOCYTE BIOL, V87, P1083, DOI 10.1189/jlb.0809585; Benistant C, 2000, ONCOGENE, V19, P5083, DOI 10.1038/sj.onc.1203871; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Blajecka K, 2011, CURR DRUG TARGETS, V12, P1056, DOI 10.2174/138945011795677773; Burke JE, 2012, P NATL ACAD SCI USA, V109, P15259, DOI 10.1073/pnas.1205508109; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carvalho S, 2010, VIRCHOWS ARCH, V456, P235, DOI 10.1007/s00428-010-0881-0; Castillo JJ, 2012, EXPERT OPIN INV DRUG, V21, P15, DOI 10.1517/13543784.2012.640318; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chavakis E, 2008, CIRC RES, V102, P942, DOI 10.1161/CIRCRESAHA.107.164376; Chen JS, 2009, HEPATOL RES, V39, P177, DOI 10.1111/j.1872-034X.2008.00449.x; Cheng GZ, 2008, CANCER RES, V68, P957, DOI 10.1158/0008-5472.CAN-07-5067; Ciraolo E, 2011, CURR MED CHEM, V18, P2674, DOI 10.2174/092986711796011193; Ciraolo E, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1161577; Clark AS, 2002, MOL CANCER THER, V1, P707; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Crawford Y, 2009, CANCER CELL, V15, P21, DOI 10.1016/j.ccr.2008.12.004; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Damilano F, 2011, CIRCULATION, V123, P391, DOI 10.1161/CIRCULATIONAHA.110.950543; Dbouk HA, 2010, P NATL ACAD SCI USA, V107, P19897, DOI 10.1073/pnas.1008739107; De Wever O, 2004, FASEB J, V18, P1016, DOI 10.1096/fj.03-1110fje; Edling CE, 2010, CLIN CANCER RES, V16, P4928, DOI 10.1158/1078-0432.CCR-10-1210; Falasca M, 2010, CURR PHARM DESIGN, V16, P1410, DOI 10.2174/138161210791033950; Fang J, 2007, CELL SIGNAL, V19, P2487, DOI 10.1016/j.cellsig.2007.07.025; Fougerat A, 2008, CIRCULATION, V117, P1310, DOI 10.1161/CIRCULATIONAHA.107.720466; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Garlich JR, 2008, CANCER RES, V68, P206, DOI 10.1158/0008-5472.CAN-07-0669; Geng L, 2004, CANCER RES, V64, P4893, DOI 10.1158/0008-5472.CAN-03-3955; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Ghigo A, 2010, BIOESSAYS, V32, P185, DOI 10.1002/bies.200900150; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Gonzalez-Garcia A, 2010, GASTROENTEROLOGY, V138, P1374, DOI 10.1053/j.gastro.2009.12.001; Grassian AR, 2011, COLD SH Q B, V76, P313, DOI 10.1101/sqb.2011.76.010967; Graupera M, 2008, NATURE, V453, P662, DOI 10.1038/nature06892; Grille SJ, 2003, CANCER RES, V63, P2172; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heller R, 2008, CARDIOVASC RES, V80, P96, DOI 10.1093/cvr/cvn159; Hill KM, 2010, PROSTATE, V70, P755, DOI 10.1002/pros.21108; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hoellenriegel J, 2011, BLOOD, V118, P3603, DOI 10.1182/blood-2011-05-352492; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Hu LM, 2005, CLIN CANCER RES, V11, P8208, DOI 10.1158/1078-0432.CCR-05-0206; Hutti JE, 2012, CANCER RES, V72, P3260, DOI 10.1158/0008-5472.CAN-11-4141; Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114; Jia SD, 2008, NATURE, V454, P776, DOI 10.1038/nature07091; Jones GE, 2003, EXP CELL RES, V290, P120, DOI 10.1016/S0014-4827(03)00318-5; Kim A, 2012, LEUKEMIA RES, V36, P912, DOI 10.1016/j.leukres.2012.02.010; Kim D, 2005, FRONT BIOSCI-LANDMRK, V10, P975, DOI 10.2741/1592; Kim S, 2010, BIOCHIM BIOPHYS ACTA, V1803, P1287; Knobbe CB, 2003, BRAIN PATHOL, V13, P507; Kong D, 2009, EUR J CANCER, V45, P857, DOI 10.1016/j.ejca.2008.12.007; Lau MT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059083; Lee H, 2013, CANCER LETT, V328, P152, DOI 10.1016/j.canlet.2012.08.020; Lee JH, 2013, CANCER LETT, V329, P99, DOI 10.1016/j.canlet.2012.10.028; Lelievre E, 2005, BLOOD, V105, P3935, DOI 10.1182/blood-2004-10-3955; Li H, 2011, ADV MED SCI-POLAND, V56, P275, DOI 10.2478/v10039-011-0043-x; Li SY, 2006, BREAST CANCER RES TR, V96, P91, DOI 10.1007/s10549-005-9048-0; Littlepage LE, 2005, CANCER CELL, V7, P499, DOI 10.1016/j.ccr.2005.05.019; Liu D, 2009, J IMMUNOL, V183, P1921, DOI 10.4049/jimmunol.0901099; Lorusso G, 2008, HISTOCHEM CELL BIOL, V130, P1091, DOI 10.1007/s00418-008-0530-8; Lu PF, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005058; Madeddu P, 2008, ARTERIOSCL THROM VAS, V28, P68, DOI 10.1161/ATVBAHA.107.145573; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marshall NA, 2012, CANCER RES, V72, P581, DOI 10.1158/0008-5472.CAN-11-0307; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Mizoguchi M, 2004, BRAIN PATHOL, V14, P372, DOI 10.1111/j.1750-3639.2004.tb00080.x; Morgan SC, 2011, NAT REV CLIN ONCOL, V8, P504, DOI 10.1038/nrclinonc.2011.88; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nombela-Arrieta C, 2004, IMMUNITY, V21, P429, DOI 10.1016/j.immuni.2004.07.012; PAGET S, 1989, CANCER METAST REV, V8, P98; Palucka K, 2012, NAT REV CANCER, V12, P265, DOI 10.1038/nrc3258; Patrucco E, 2004, CELL, V118, P375, DOI 10.1016/j.cell.2004.07.017; Philp AJ, 2001, CANCER RES, V61, P7426; Putz EM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040852; Qayum N, 2012, CLIN CANCER RES, V18, P161, DOI 10.1158/1078-0432.CCR-11-1413; Rommel C, 2007, NAT REV IMMUNOL, V7, P191, DOI 10.1038/nri2036; Salvesen HB, 2009, P NATL ACAD SCI USA, V106, P4834, DOI 10.1073/pnas.0806514106; Sampaio NG, 2011, J CELL SCI, V124, P2021, DOI 10.1242/jcs.075309; Samuels Y, 2004, CELL CYCLE, V3, P1221, DOI 10.4161/cc.3.10.1164; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Schmid MC, 2007, CANCER LETT, V250, P1, DOI 10.1016/j.canlet.2006.09.002; Schmid MC, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0060226, 10.1371/journal.pone.0061623]; Schmid MC, 2011, CANCER CELL, V19, P715, DOI 10.1016/j.ccr.2011.04.016; Schmid MC, 2010, J ONCOL, V2010, DOI 10.1155/2010/201026; Schnell CR, 2008, CANCER RES, V68, P6598, DOI 10.1158/0008-5472.CAN-08-1044; Shoman N, 2005, MODERN PATHOL, V18, P250, DOI 10.1038/modpathol.3800296; So L, 2012, BIOCHEM J, V442, P465, DOI 10.1042/BJ20112092; Soond DR, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00244; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224; Torsvik A, 2013, CANCER TREAT REV, V39, P180, DOI 10.1016/j.ctrv.2012.03.005; Tsutsui S, 2005, ONCOLOGY-BASEL, V68, P398, DOI 10.1159/000086981; Urick ME, 2011, CANCER RES, V71, P4061, DOI 10.1158/0008-5472.CAN-11-0549; Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882; Vogt PK, 2007, TRENDS BIOCHEM SCI, V32, P342, DOI 10.1016/j.tibs.2007.05.005; Wallin JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036402; Wang W, 2009, CLIN CANCER RES, V15, P6630, DOI 10.1158/1078-0432.CCR-09-1001; Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537; Wik E, 2013, CLIN CANCER RES, V19, P1094, DOI 10.1158/1078-0432.CCR-12-3039; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Xia C, 2006, J CELL PHYSIOL, V209, P56, DOI 10.1002/jcp.20707; Xing F, 2010, FRONT BIOSCI-LANDMRK, V15, P166, DOI 10.2741/3613; Xue GD, 2012, CANCER DISCOV, V2, P248, DOI 10.1158/2159-8290.CD-11-0270; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yoshimoto M, 2006, CANCER GENET CYTOGEN, V169, P128, DOI 10.1016/j.cancergencyto.2006.04.003; Yoshioka K, 2012, NAT MED, V18, P1560, DOI 10.1038/nm.2928; Yu Q, 2000, GENE DEV, V14, P163; Yuan TL, 2008, P NATL ACAD SCI USA, V105, P9739, DOI 10.1073/pnas.0804123105; Zarrabi K, 2011, J BIOL CHEM, V286, P33167, DOI 10.1074/jbc.M111.256644; Zebedin E, 2008, BLOOD, V112, P4655, DOI 10.1182/blood-2008-02-139105; Zhang L, 2012, BLOOD, V120, P3783, DOI 10.1182/blood-2012-04-424630; Zhang T, 2010, ONCOL REP, V24, P1683, DOI 10.3892/or_00001034; Zhao L, 2008, ONCOGENE, V27, P5486, DOI 10.1038/onc.2008.244; Zhong H, 2000, CANCER RES, V60, P1541	127	45	46	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3083	3090		10.1038/onc.2013.265	http://dx.doi.org/10.1038/onc.2013.265			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23893246				2022-12-28	WOS:000338410000001
J	Li, N; Lee, K; Xi, Y; Zhu, B; Gary, BD; Ramirez-Alcantara, V; Gurpinar, E; Canzoneri, JC; Fajardo, A; Sigler, S; Piazza, JT; Chen, X; Andrews, J; Thomas, M; Lu, W; Li, Y; Laan, DJ; Moyer, MP; Russo, S; Eberhardt, BT; Yet, L; Keeton, AB; Grizzle, WE; Piazza, GA				Li, N.; Lee, K.; Xi, Y.; Zhu, B.; Gary, B. D.; Ramirez-Alcantara, V.; Gurpinar, E.; Canzoneri, J. C.; Fajardo, A.; Sigler, S.; Piazza, J. T.; Chen, X.; Andrews, J.; Thomas, M.; Lu, W.; Li, Y.; Laan, D. J.; Moyer, M. P.; Russo, S.; Eberhardt, B. T.; Yet, L.; Keeton, A. B.; Grizzle, W. E.; Piazza, G. A.			Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and beta-catenin-dependent TCF transcriptional activity	ONCOGENE			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; PROTEIN-KINASE-G; SULINDAC SULFIDE; EXPRESSION; EXISULIND; APOPTOSIS; CANCER; ACTIVATION; PDE10A; LOCALIZATION	The cyclic nucleotide phosphodiesterase 10A (PDE10) has been mostly studied as a therapeutic target for certain psychiatric and neurological conditions, although a potential role in tumorigenesis has not been reported. Here we show that PDE10 is elevated in human colon tumor cell lines compared with normal colonocytes, as well as in colon tumors from human clinical specimens and intestinal tumors from Apc(Min/+) mice compared with normal intestinal mucosa, respectively. An isozyme and tumor-selective role of PDE10 were evident by the ability of small-molecule inhibitors and small interfering RNA knockdown to suppress colon tumor cell growth with reduced sensitivity of normal colonocytes. Stable knockdown of PDE10 by short hairpin RNA also inhibits colony formation and increases doubling time of colon tumor cells. PDE10 inhibition selectively activates cGMP/cGMP-dependent protein kinase signaling to suppress beta-catenin levels and T-cell factor (TCF) transcriptional activity in colon tumor cells. Conversely, ectopic expression of PDE10 in normal and precancerous colonocytes increases proliferation and activates TCF transcriptional activity. These observations suggest a novel role of PDE10 in colon tumorigenesis and that inhibitors may be useful for the treatment or prevention of colorectal cancer.	[Li, N.] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL USA; [Lee, K.; Xi, Y.; Zhu, B.; Gary, B. D.; Ramirez-Alcantara, V.; Canzoneri, J. C.; Fajardo, A.; Sigler, S.; Piazza, J. T.; Chen, X.; Andrews, J.; Thomas, M.; Russo, S.; Keeton, A. B.; Piazza, G. A.] Univ S Alabama, Drug Discovery Res Ctr, Mitchell Canc Inst, Dept Oncol Sci & Pharmacol, Mobile, AL 36004 USA; [Gurpinar, E.] Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL USA; [Lu, W.; Li, Y.] So Res Inst, Drug Discovery Div, Birmingham, AL 35255 USA; [Laan, D. J.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA; [Moyer, M. P.] INCELL Corp LLC, San Antonio, TX USA; [Eberhardt, B. T.; Yet, L.] Univ S Alabama, Dept Chem, Mobile, AL 36004 USA; [Grizzle, W. E.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of South Alabama; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of South Alabama; University of Alabama System; University of Alabama Birmingham	Piazza, GA (corresponding author), Univ S Alabama, Drug Discovery Res Ctr, Mitchell Canc Inst, Dept Oncol Sci & Pharmacol, 1660 Springhill Ave,Suite 3029, Mobile, AL 36004 USA.	gpiazza@health.southalabama.edu	Li, Nan/I-3589-2015; Ramirez-Alcantara, Verónica/AAM-5424-2020	Xi, Yaguang/0000-0003-3681-9352; Piazza, Gary/0000-0003-4418-887X	National Institutes of Health [1R01CA131378, 1R01CA148817, 1R01CA155638]; NATIONAL CANCER INSTITUTE [R01CA155638, R01CA131378, R01CA148817] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R24HL123767] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Dr Graeme Bolger for critical reading of the manuscript. We also thank Dr Marian from Medical University Vienna, Austria for the generous gift of LT97 adenoma cell line and Dr Dan Dixon from University of Kansas Cancer Center for providing specimens from the Apc<SUP>Min/+</SUP> mouse model. We are also grateful to Dr Darren Browning from Georgia Regents University Cancer Center for providing the CTNNB1 luciferase reporter construct. This work was supported by National Institutes of Health Grants, 1R01CA131378, 1R01CA148817 and 1R01CA155638 to GAP.	Anderson CB, 2002, P NATL ACAD SCI USA, V99, P8683, DOI 10.1073/pnas.122235399; Bender AT, 2006, PHARMACOL REV, V58, P488, DOI 10.1124/pr.58.3.5; Chappie TA, 2007, J MED CHEM, V50, P182, DOI 10.1021/jm060653b; Coskran TM, 2006, J HISTOCHEM CYTOCHEM, V54, P1205, DOI 10.1369/JHC.6A6930.2006; D'Andrea MR, 2005, J HISTOCHEM CYTOCHEM, V53, P895, DOI 10.1369/jhc.5A6625.2005; Deguchi A, 2004, CANCER RES, V64, P3966, DOI 10.1158/0008-5472.CAN-03-3740; Deguchi A, 2002, MOL CANCER THER, V1, P803; Francis SH, 2011, PHYSIOL REV, V91, P651, DOI 10.1152/physrev.00030.2010; Fujishige K, 1999, J BIOL CHEM, V274, P18438, DOI 10.1074/jbc.274.26.18438; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; Hou YL, 2006, CANCER LETT, V240, P60, DOI 10.1016/j.canlet.2005.08.035; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Kwon IK, 2010, ONCOGENE, V29, P3423, DOI 10.1038/onc.2010.91; Kwon IK, 2008, CANCER-AM CANCER SOC, V112, P1462, DOI 10.1002/cncr.23334; Li N, 2013, MOL CANCER THER, V12, P1848, DOI 10.1158/1535-7163.MCT-13-0048; Li QJ, 2004, GENOMICS, V83, P231, DOI 10.1016/j.ygeno.2003.08.004; Li X, 2012, ONCOGENE, V31, P4979, DOI 10.1038/onc.2011.655; Liu L, 2001, J PHARMACOL EXP THER, V299, P583; Loughney K, 1999, GENE, V234, P109, DOI 10.1016/S0378-1119(99)00171-7; Lucas KA, 2000, PHARMACOL REV, V52, P375; Marko D, 2000, CHEM RES TOXICOL, V13, P944, DOI 10.1021/tx000090l; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315; Piazza GA, 2001, CANCER RES, V61, P3961; Pitari GM, 2001, P NATL ACAD SCI USA, V98, P7846, DOI 10.1073/pnas.141124698; Pusztai L, 2003, J CLIN ONCOL, V21, P3454, DOI 10.1200/JCO.2003.02.114; Richter M, 2002, EUR J CANCER, V38, P1937, DOI 10.1016/S0959-8049(02)00158-2; Saravani R, 2012, CELL PROLIFERAT, V45, P199, DOI 10.1111/j.1365-2184.2012.00819.x; Savai R, 2010, EXPERT OPIN INV DRUG, V19, P117, DOI 10.1517/13543780903485642; Shailubhai K, 2000, CANCER RES, V60, P5151; Shimizu K, 2009, ANTICANCER RES, V29, P1119; Siuciak JA, 2006, NEUROPHARMACOLOGY, V51, P386, DOI 10.1016/j.neuropharm.2006.04.013; Siuciak JA, 2006, NEUROPHARMACOLOGY, V51, P374, DOI 10.1016/j.neuropharm.2006.01.012; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; Soderling SH, 1999, P NATL ACAD SCI USA, V96, P7071, DOI 10.1073/pnas.96.12.7071; Steinbrecher KA, 2000, BIOCHEM BIOPH RES CO, V273, P225, DOI 10.1006/bbrc.2000.2917; Thompson WJ, 2000, CANCER RES, V60, P3338; Tian X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018136; Tinsley HN, 2010, CANCER PREV RES, V3, P1303, DOI 10.1158/1940-6207.CAPR-10-0030; Tinsley HN, 2009, MOL CANCER THER, V8, P3331, DOI 10.1158/1535-7163.MCT-09-0758; Whitehead CM, 2003, MOL CANCER THER, V2, P479; Whitt JD, 2012, CANCER PREV RES, V5, P822, DOI 10.1158/1940-6207.CAPR-11-0559; Xie Z, 2006, NEUROSCIENCE, V139, P597, DOI 10.1016/j.neuroscience.2005.12.042; Zhang LZ, 2008, P NATL ACAD SCI USA, V105, P19532, DOI 10.1073/pnas.0806152105	44	47	49	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1499	1509		10.1038/onc.2014.94	http://dx.doi.org/10.1038/onc.2014.94			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24704829	Green Accepted			2022-12-28	WOS:000351416800003
J	Biyanee, A; Ohnheiser, J; Singh, P; Klempnauer, KH				Biyanee, A.; Ohnheiser, J.; Singh, P.; Klempnauer, K-H			A novel mechanism for the control of translation of specific mRNAs by tumor suppressor protein Pdcd4: inhibition of translation elongation	ONCOGENE			English	Article							A-MYB PROTEIN; C-MYB; CODING REGION; BINDING-PROTEIN; EUKARYOTIC TRANSLATION; STRUCTURAL BASIS; GENE-EXPRESSION; CANCER; TRANSFORMATION; TRANSCRIPTION	The tumor suppressor gene Pdcd4 (programmed cell death gene 4) has drawn considerable attention because its downregulation is involved in the development of several types of cancer. Because Pdcd4 interacts with the translation initiation factor eIF4A and inhibits its helicase activity, Pdcd4 has been implicated in the translational suppression of cellular mRNAs containing structured 5'-untranslated regions. However, Pdcd4's role in translation regulation is still poorly understood, because only very few physiological Pdcd4 target mRNAs are known. By using a Pdcd4-deficient clone of the chicken B-cell line DT40, we have discovered that the mRNA of the A-myb proto-oncogene is a novel Pdcd4 target RNA whose translation is suppressed by Pdcd4. Interestingly, the inhibitory effect of Pdcd4 is independent of the Pdcd4-eIF4A interaction, but is dependent on an RNA-binding domain at the N terminus of Pdcd4 and on sequences located within the coding region of A-myb mRNA, indicating that Pdcd4 suppresses A-myb translation by a novel mechanism. Our data show that the Pdcd4 RNA-binding domain preferentially recognizes an RNA secondary structure element formed by the part of the A-myb coding region that mediates Pdcd4-dependent suppression. Previously, we have shown that Pdcd4 also suppresses the translation of the c-myb mRNA by a similar mechanism involving binding of Pdcd4 to RNA secondary structure formed by the c-myb coding region. Surprisingly, our data show that Pdcd4 exerts its inhibitory activity only when the target region of Pdcd4 in A-myb and c-myb mRNA is itself translated, consistent with a mechanism in which Pdcd4 suppresses translation by interfering with translation elongation. Taken together, our work reveals a novel mechanism by which Pdcd4 affects the translational of cellular RNAs. Furthermore, as c-myb and A-myb are members of the Myb proto-oncogene family whose deregulation has been implicated in tumorigenesis, inhibiting their translation might contribute to the tumor-suppressive activity of Pdcd4.	[Biyanee, A.; Ohnheiser, J.; Singh, P.; Klempnauer, K-H] Univ Munster, Inst Biochem, D-48149 Munster, Germany; [Biyanee, A.] Univ Munster, GSC MS, D-48149 Munster, Germany	University of Munster; University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de	Singh, Priyanka/N-1372-2018; Singh, Priyanka/GRF-6098-2022	Singh, Priyanka/0000-0003-0841-1544; Singh, Priyanka/0000-0002-5928-6280	Deutsche Krebshilfe; Deutsche Forschungsgemeinschaft; Graduate School of Chemistry (GSC-MS) at the University of Munster	Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Graduate School of Chemistry (GSC-MS) at the University of Munster	We thank J Golay for the human A-Myb expression vector. This work was supported by a grant from the Deutsche Krebshilfe and the Deutsche Forschungsgemeinschaft. AB and PS were supported by fellowships from the Graduate School of Chemistry (GSC-MS) at the University of Munster.	Afonja O, 2004, ONCOGENE, V23, P8135, DOI 10.1038/sj.onc.1207983; Appl H, 2002, ONCOGENE, V21, P3076, DOI 10.1038/sj.onc.1205427; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Baltz AG, 2012, MOL CELL, V46, P674, DOI 10.1016/j.molcel.2012.05.021; Biroccio A, 2001, AM J PATHOL, V158, P1289, DOI 10.1016/S0002-9440(10)64080-1; Bitomsky N, 2008, ONCOGENE, V27, P4820, DOI 10.1038/onc.2008.115; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; Brummer A, 2013, RNA, V19, P1317, DOI 10.1261/rna.037531.112; Chang JH, 2009, P NATL ACAD SCI USA, V106, P3148, DOI 10.1073/pnas.0808275106; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Clappier E, 2007, BLOOD, V110, P1251, DOI 10.1182/blood-2006-12-064683; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Drabsch Y, 2007, P NATL ACAD SCI USA, V104, P13762, DOI 10.1073/pnas.0700104104; ErcikanAbali EA, 1997, BIOCHEMISTRY-US, V36, P12317, DOI 10.1021/bi971026e; FOOS G, 1994, ONCOGENE, V9, P2481; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; GOLAY J, 1994, ONCOGENE, V9, P2469; Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009; Hogan DJ, 2008, PLOS BIOL, V6, P2297, DOI 10.1371/journal.pbio.0060255; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; Kumar N, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2012.37; Kumarswamy R, 2011, RNA BIOL, V8, P706, DOI 10.4161/rna.8.5.16154; Lahortiga I, 2007, NAT GENET, V39, P593, DOI 10.1038/ng2025; LaRonde-LeBlanc N, 2007, MOL CELL BIOL, V27, P147, DOI 10.1128/MCB.00867-06; Leupold JH, 2007, ONCOGENE, V26, P4550, DOI 10.1038/sj.onc.1210234; Lin XK, 2000, NUCLEIC ACIDS RES, V28, P1381, DOI 10.1093/nar/28.6.1381; Loh PG, 2009, EMBO J, V28, P274, DOI 10.1038/emboj.2008.278; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Mudduluru G, 2007, CANCER-AM CANCER SOC, V110, P1697, DOI 10.1002/cncr.22983; Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469; Perez-Leal O, 2012, MOL CELL BIOL, V32, P1453, DOI 10.1128/MCB.06444-11; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Prechtel AT, 2006, J BIOL CHEM, V281, P10912, DOI 10.1074/jbc.M510306200; Ramkissoon LA, 2013, P NATL ACAD SCI USA, V110, P8188, DOI 10.1073/pnas.1300252110; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Schlichter U, 2001, BBA-GENE STRUCT EXPR, V1520, P99, DOI 10.1016/S0167-4781(01)00252-4; Schmid T, 2008, CANCER RES, V68, P1254, DOI 10.1158/0008-5472.CAN-07-1719; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Shiota M, 2009, CANCER RES, V69, P3148, DOI 10.1158/0008-5472.CAN-08-2334; Singh P, 2011, ONCOGENE, V30, P4864, DOI 10.1038/onc.2011.202; Singh P, 2009, ONCOGENE, V28, P3758, DOI 10.1038/onc.2009.239; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; Suzuki C, 2008, P NATL ACAD SCI USA, V105, P3274, DOI 10.1073/pnas.0712235105; Wang Q, 2008, ONCOGENE, V27, P1527, DOI 10.1038/sj.onc.1210793; Waters LC, 2007, ONCOGENE, V26, P4941, DOI 10.1038/sj.onc.1210305; Wedeken L, 2011, J BIOL CHEM, V286, P42855, DOI 10.1074/jbc.M111.269456; Wedeken Lena, 2010, Genes Cancer, V1, P293, DOI 10.1177/1947601910364227; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Zhang H, 2006, ONCOGENE, V25, P6101, DOI 10.1038/sj.onc.1209634; Zhang JH, 2013, NAT GENET, V45, P602, DOI 10.1038/ng.2611; Zhang YY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010618	57	27	27	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1384	1392		10.1038/onc.2014.83	http://dx.doi.org/10.1038/onc.2014.83			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24681950				2022-12-28	WOS:000350806500005
J	Beristain, AG; Molyneux, SD; Joshi, PA; Pomroy, NC; Di Grappa, MA; Chang, MC; Kirschner, LS; Prive, GG; Pujana, MA; Khokha, R				Beristain, A. G.; Molyneux, S. D.; Joshi, P. A.; Pomroy, N. C.; Di Grappa, M. A.; Chang, M. C.; Kirschner, L. S.; Prive, G. G.; Pujana, M. A.; Khokha, R.			PKA signaling drives mammary tumorigenesis through Src	ONCOGENE			English	Article							PROTEIN-KINASE-A; ELEVATED AROMATASE EXPRESSION; ESTROGEN-RECEPTOR-ALPHA; SUBUNIT TYPE 1A; BREAST-CANCER; CARNEY COMPLEX; REGULATORY SUBUNITS; CELL-CYCLE; C-SRC; PRKAR1A	Protein kinase A (PKA) hyperactivation causes hereditary endocrine neoplasias; however, its role in sporadic epithelial cancers is unknown. Here, we show that heightened PKA activity in the mammary epithelium generates tumors. Mammary-restricted biallelic ablation of Prkar1a, which encodes for the critical type-I PKA regulatory subunit, induced spontaneous breast tumors characterized by enhanced type-II PKA activity. Downstream of this, Src phosphorylation occurs at residues serine-17 and tyrosine-416 and mammary cell transformation is driven through a mechanism involving Src signaling. The phenotypic consequences of these alterations consisted of increased cell proliferation and, accordingly, expansion of both luminal and basal epithelial cell populations. In human breast cancer, low PRKAR1A/high SRC expression defines basal-like and HER2 breast tumors associated with poor clinical outcome. Together, the results of this study define a novel molecular mechanism altered in breast carcinogenesis and highlight the potential strategy of inhibiting SRC signaling in treating this cancer subtype in humans.	[Beristain, A. G.; Molyneux, S. D.; Joshi, P. A.; Pomroy, N. C.; Di Grappa, M. A.; Khokha, R.] Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M4X 1K9, Canada; [Molyneux, S. D.; Joshi, P. A.; Prive, G. G.; Khokha, R.] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; [Chang, M. C.; Khokha, R.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada; [Kirschner, L. S.] Ohio State Univ, Div Endocrinol Diabet & Metab, Columbus, OH 43210 USA; [Pujana, M. A.] Hosp Llobregat, IDIBELL, Catalan Inst Oncol, Breast Canc & Syst Biol Unit,Translat Res Lab, Barcelona, Spain	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University System of Ohio; Ohio State University; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona	Khokha, R (corresponding author), Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada.	rkhokha@uhnres.utoronto.ca	Chang, Martin/J-2329-2016; Pujana, Miquel Angel/N-3127-2014	Pujana, Miquel Angel/0000-0003-3222-4044; Khokha, Rama/0000-0002-6028-1524; Joshi, Purna/0000-0002-1628-9940; Beristain, Alexander/0000-0002-1117-6242; Prive, Gilbert/0000-0002-0712-4319	Canadian Breast Cancer Foundation (CBCF); Spanish Ministry of Health grant [FIS-PI12/01528, RD12/0036/0008]; CBCF fellowship; NATIONAL CANCER INSTITUTE [P01CA124570] Funding Source: NIH RePORTER	Canadian Breast Cancer Foundation (CBCF); Spanish Ministry of Health grant; CBCF fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Megan K Barker and Paul Waterhouse for critical reading of the manuscript. We would also like to acknowledge Shareen Ezzat for sharing the small molecule Dasatinib, Vuk Stambolic for offering insight into biochemistry experiments and the IDIBELL's Biostatistics Unit for help in analyzing breast cancer data sets. This work was supported by a Canadian Breast Cancer Foundation (CBCF) grant to RK and the Spanish Ministry of Health grant FIS-PI12/01528 and RD12/0036/0008 to MAP. AGB holds a CBCF fellowship.	Almeida MQ, 2011, MOL CELL ENDOCRINOL, V336, P162, DOI 10.1016/j.mce.2010.11.018; Almeida MQ, 2010, HUM MOL GENET, V19, P1387, DOI 10.1093/hmg/ddq014; Amieux PS, 2002, ANN NY ACAD SCI, V968, P75, DOI 10.1111/j.1749-6632.2002.tb04328.x; Baker MA, 2006, J CELL SCI, V119, P3182, DOI 10.1242/jcs.03055; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bossis I, 2004, ENDOCRINOLOGY, V145, P5452, DOI 10.1210/en.2004-0900; Burton KA, 1997, P NATL ACAD SCI USA, V94, P11067, DOI 10.1073/pnas.94.20.11067; CARNEY JA, 1991, AM J SURG PATHOL, V15, P722, DOI 10.1097/00000478-199108000-00002; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Elsberger B, 2009, AM J PATHOL, V175, P1389, DOI 10.2353/ajpath.2009.090273; Fink MA, 2001, CIRC RES, V88, P291, DOI 10.1161/01.RES.88.3.291; Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107; Gold MG, 2013, J BIOL CHEM, V288, P17111, DOI 10.1074/jbc.M112.447326; Griffin KJ, 2004, CANCER RES, V64, P8811, DOI 10.1158/0008-5472.CAN-04-3620; Griffin KJ, 2004, J MED GENET, V41, P923, DOI 10.1136/jmg.2004.028043; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kirschner LS, 2000, HUM MOL GENET, V9, P3037, DOI 10.1093/hmg/9.20.3037; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; Kirschner LS, 2005, CANCER RES, V65, P4506, DOI 10.1158/0008-5472.CAN-05-0580; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kok M, 2011, BREAST CANCER RES TR, V125, P1, DOI 10.1007/s10549-010-0798-y; Lim CJ, 2007, NAT CELL BIOL, V9, P415, DOI 10.1038/ncb1561; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Marcotte R, 2012, P NATL ACAD SCI USA, V109, P2808, DOI 10.1073/pnas.1018861108; Michalides R, 2004, CANCER CELL, V5, P597, DOI 10.1016/j.ccr.2004.05.016; Miller WR, 2002, ANN NY ACAD SCI, V968, P37, DOI 10.1111/j.1749-6632.2002.tb04325.x; Molyneux SD, 2010, J CLIN INVEST, V120, P3310, DOI 10.1172/JCI42391; Moujalled D, 2011, EMBO REP, V12, P77, DOI 10.1038/embor.2010.190; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nadella KS, 2008, CANCER RES, V68, P2671, DOI 10.1158/0008-5472.CAN-07-6002; Neary CL, 2004, ONCOGENE, V23, P8847, DOI 10.1038/sj.onc.1208165; Obara Y, 2004, J CELL SCI, V117, P6085, DOI 10.1242/jcs.01527; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Pavel E, 2008, MOL ENDOCRINOL, V22, P430, DOI 10.1210/me.2007-0369; Prat A, 2012, BREAST CANCER RES TR, V135, P301, DOI 10.1007/s10549-012-2143-0; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Smalley MJ, 2012, J MAMMARY GLAND BIOL, V17, P91, DOI 10.1007/s10911-012-9257-1; Soulard A, 2010, MOL BIOL CELL, V21, P3475, DOI 10.1091/mbc.E10-03-0182; Subbaramaiah K, 2008, J BIOL CHEM, V283, P3433, DOI 10.1074/jbc.M705409200; Subbaramaiah K, 2012, CANCER DISCOV, V2, P356, DOI 10.1158/2159-8290.CD-11-0241; Subbaramaiah K, 2011, CANCER PREV RES, V4, P329, DOI 10.1158/1940-6207.CAPR-10-0381; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tharakan R, 2008, MOL CELL ENDOCRINOL, V295, P70, DOI 10.1016/j.mce.2008.07.018; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Wilson GR, 2006, BRIT J CANCER, V95, P1410, DOI 10.1038/sj.bjc.6603444; Yin ZR, 2008, CIRCULATION, V117, P1414, DOI 10.1161/CIRCULATIONAHA.107.759233	48	61	61	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1160	1173		10.1038/onc.2014.41	http://dx.doi.org/10.1038/onc.2014.41			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662820				2022-12-28	WOS:000350122100009
J	Essers, PB; Klasson, TD; Pereboom, TC; Mans, DA; Nicastro, M; Boldt, K; Giles, RH; MacInnes, AW				Essers, P. B.; Klasson, T. D.; Pereboom, T. C.; Mans, D. A.; Nicastro, M.; Boldt, K.; Giles, R. H.; MacInnes, A. W.			The von Hippel-Lindau tumor suppressor regulates programmed cell death 5-mediated degradation of Mdm2	ONCOGENE			English	Article						renal cell carcinoma; von Hippel-Lindau tumor suppressor; programmed cell death 5	ZEBRAFISH MODEL; P53 PATHWAY; PROTEIN; GENE; VHL; APOPTOSIS; EXPRESSION; CHECKPOINT; INHIBITION; CARCINOMA	Functional loss of the von Hippel-Lindau (VHL) tumor suppressor protein (pVHL), which is part of an E3-ubiquitin ligase complex, initiates most inherited and sporadic clear-cell renal cell carcinomas (ccRCC). Genetic inactivation of the TP53 gene in ccRCC is rare, suggesting that an alternate mechanism alleviates the selective pressure for TP53 mutations in ccRCC. Here we use a zebrafish model to describe the functional consequences of pVHL loss on the p53/Mdm2 pathway. We show that p53 is stabilized in the absence of pVHL and becomes hyperstabilized upon DNA damage, which we propose is because of a novel in vivo interaction revealed between human pVHL and a negative regulator of Mdm2, the programmed cell death 5 (PDCD5) protein. PDCD5 is normally localized at the plasma membrane and in the cytoplasm. However, upon hypoxia or loss of pVHL, PDCD5 relocalizes to the nucleus, an event that is coupled to the degradation of Mdm2. Despite the subsequent hyperstabilization and normal transcriptional activity of p53, we find that zebrafish vhl(-/-) cells are still as highly resistant to DNA damage-induced cell cycle arrest and apoptosis as human ccRCC cells. We suggest this is because of a marked increase in expression of birc5a, the zebrafish homolog of Survivin. Accordingly, when we knock down Survivin in human ccRCC cells we are able to restore caspase activity in response to DNA damage. Taken together, our study describes a new mechanism for p53 stabilization through PDCD5 upon hypoxia or pVHL loss, and reveals new clinical potential for the treatment of pathobiological disorders linked to hypoxic stress.	[Essers, P. B.; Pereboom, T. C.; MacInnes, A. W.] KNAW, Hubrecht Inst Dev Biol & Stem Cell Res, NL-3584 CT Utrecht, Netherlands; [Essers, P. B.; Pereboom, T. C.; MacInnes, A. W.] Univ Med Ctr Utrecht, NL-3584 CT Utrecht, Netherlands; [Klasson, T. D.; Nicastro, M.; Giles, R. H.] Univ Med Ctr Utrecht, Dept Hypertens & Nephrol, Utrecht, Netherlands; [Mans, D. A.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands; [Mans, D. A.] Radboud Univ Nijmegen, Nijmegen Ctr Mol Life Sci, NL-6525 ED Nijmegen, Netherlands; [Boldt, K.] Univ Tubingen, Med Proteome Ctr, Ctr Ophthalm Res, Tubingen, Germany	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Radboud University Nijmegen; Radboud University Nijmegen; Eberhard Karls University of Tubingen	MacInnes, AW (corresponding author), KNAW, Hubrecht Inst Dev Biol & Stem Cell Res, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	a.macinnes@hubrecht.eu		Giles, Rachel/0000-0001-9133-2008	European Community [241955, 305608]	European Community(European Commission)	This research was supported by grants from the European Community's Seventh Framework Programme FP7/2009 under grant agreement 241955, SYSCILIA and 305608, EURenOmics (RHG). We would like to thank Susanne Lens for the kind gift of siRNA against Survivin, the animal caretakers of the Hubrecht Institute, and www. art-4-science.com for the creation of the graphic illustration.	Alarcon R, 1999, CANCER RES, V59, P6046; Albers J, 2013, EMBO MOL MED, V5, P949, DOI 10.1002/emmm.201202231; Boldt K, 2011, J CLIN INVEST, V121, P2169, DOI 10.1172/JCI45627; Chen LN, 2006, APOPTOSIS, V11, P101, DOI 10.1007/s10495-005-3134-y; Chen YY, 2001, FEBS LETT, V509, P191, DOI 10.1016/S0014-5793(01)03062-9; Coene KLM, 2011, HUM MOL GENET, V20, P3592, DOI 10.1093/hmg/ddr280; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Cui D, 2014, ONCOGENE, V33, P2225, DOI 10.1038/onc.2013.170; Dong Z, 2003, AM J PATHOL, V163, P663, DOI 10.1016/S0002-9440(10)63693-0; Dong Z, 2002, BIOCHEM J, V364, P413, DOI 10.1042/BJ20011431; Esteban MA, 2006, CANCER RES, V66, P3567, DOI 10.1158/0008-5472.CAN-05-2670; Frew IJ, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.124pe30; Fu LP, 2011, CANCER RES, V71, P6848, DOI 10.1158/0008-5472.CAN-11-1745; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Horn HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263; Hsu T, 2012, ONCOGENE, V31, P2247, DOI 10.1038/onc.2011.442; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kim EL, 2010, NEURO-ONCOLOGY, V12, P389, DOI 10.1093/neuonc/nop046; Kleymenova E, 2004, CARCINOGENESIS, V25, P309, DOI 10.1093/carcin/bgh017; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lai YL, 2011, J PROTEOME RES, V10, P5175, DOI 10.1021/pr200642c; Lane DP, 2005, COLD SH Q B, V70, P489, DOI 10.1101/sqb.2005.70.049; MacInnes AW, 2008, P NATL ACAD SCI USA, V105, P10408, DOI 10.1073/pnas.0805036105; Mack FA, 2003, CANCER CELL, V3, P75, DOI 10.1016/S1535-6108(02)00240-4; Mans DA, 2013, J PATHOL, V231, P117, DOI 10.1002/path.4219; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Pereboom TC, 2011, BLOOD, V118, P5458, DOI 10.1182/blood-2011-04-351460; Qi H, 2003, CANCER RES, V63, P7076; Rankin EB, 2006, CANCER RES, V66, P2576, DOI 10.1158/0008-5472.CAN-05-3241; Roe JS, 2006, MOL CELL, V22, P395, DOI 10.1016/j.molcel.2006.04.006; Roe JS, 2011, CELL CYCLE, V10, P3920, DOI 10.4161/cc.10.22.18096; Sansam CL, 2010, GENE DEV, V24, P183, DOI 10.1101/gad.1860310; Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sermeus A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.48; Shepard JL, 2004, METHOD CELL BIOL, V76, P109; Spinola M, 2006, J CLIN ONCOL, V24, P1672, DOI 10.1200/JCO.2005.04.4339; Szymanska K, 2010, CANCER LETT, V293, P92, DOI 10.1016/j.canlet.2009.11.024; Tan Wan-long, 2006, Nan Fang Yi Ke Da Xue Xue Bao, V26, P1316; Tsuchiya H, 1996, CANCER RES, V56, P2881; van Rooijen E, 2011, METHOD CELL BIOL, V105, P163, DOI 10.1016/B978-0-12-381320-6.00007-2; van Rooijen E, 2009, BLOOD, V113, P6449, DOI 10.1182/blood-2008-07-167890; Westerfield M., 1993, ZEBRAFISH BOOK GUIDE; Xiong Lin, 2006, Nan Fang Yi Ke Da Xue Xue Bao, V26, P805; Xu LJ, 2012, APOPTOSIS, V17, P1235, DOI 10.1007/s10495-012-0754-x; Xu LJ, 2009, NEOPLASIA, V11, P345, DOI 10.1593/neo.81524; Yang YH, 2006, APOPTOSIS, V11, P993, DOI 10.1007/s10495-006-6714-6; Yuen JSP, 2011, BRIT J CANCER, V104, P941, DOI 10.1038/bjc.2011.55; Zucchi I, 2004, P NATL ACAD SCI USA, V101, P18147, DOI 10.1073/pnas.0408260101	56	14	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					771	779		10.1038/onc.2013.598	http://dx.doi.org/10.1038/onc.2013.598			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24469044				2022-12-28	WOS:000348853800010
J	Vallot, C; Herault, A; Boyle, S; Bickmore, WA; Radvanyi, F				Vallot, C.; Herault, A.; Boyle, S.; Bickmore, W. A.; Radvanyi, F.			PRC2-independent chromatin compaction and transcriptional repression in cancer	ONCOGENE			English	Article						cancer; chromatin compaction; gene cluster; histone deacetylase inhibitors; polycomb	TRANSITIONAL-CELL-CARCINOMA; GENE-EXPRESSION; NUCLEAR REORGANIZATION; HISTONE DEACETYLASE; EZH2; PROSTATE; COMPLEX; GENOME; DECONDENSATION; MUTATIONS	The silencing of large chromosomal regions by epigenetic mechanisms has been reported to occur frequently in cancer. Epigenetic marks, such as histone methylation and acetylation, are altered at these loci. However, the mechanisms of formation of such aberrant gene clusters remain largely unknown. Here, we show that, in cancer cells, the epigenetic remodeling of chromatin into hypoacetylated domains covered with histone H3K27 trimethylation is paralleled by changes in higher-order chromatin structures. Using fluorescence in situ hybridization, we demonstrate that regional epigenetic silencing corresponds to the establishment of compact chromatin domains. We show that gene repression is tightly correlated to the state of chromatin compaction and not to the levels of H3K27me3-its removal through the knockdown of EZH2 does not induce significant gene expression nor chromatin decompaction. Moreover, transcription can occur with intact high-H3K27me3 levels; treatment with histone deacetylase inhibitors can relieve chromatin compaction and gene repression, without altering H3K27me3 levels. Our findings imply that compaction and subsequent repression of large chromatin domains are not direct consequences of PRC2 deregulation in cancer cells. By challenging the role of EZH2 in aberrant gene silencing in cancer, these findings have therapeutical implications, notably for the choice of epigenetic drugs for tumors with multiple regional epigenetic alterations.	[Vallot, C.; Herault, A.; Radvanyi, F.] Inst Curie, CNRS, UMR 144, Dept Cell Biol, F-75231 Paris, France; [Vallot, C.; Herault, A.; Radvanyi, F.] Inst Curie, Ctr Rech, Paris, France; [Boyle, S.; Bickmore, W. A.] Univ Edinburgh, Inst Genet & Mol Med, MRC, Chromosome & Gene Express Sect,Human Genet Unit, Edinburgh EH8 9YL, Midlothian, Scotland; [Bickmore, W. A.] Univ Edinburgh, Breakthrough Breast Canc Res Unit, Edinburgh EH8 9YL, Midlothian, Scotland	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Edinburgh; University of Edinburgh	Vallot, C (corresponding author), Univ Paris Diderot, UMR7216, 35 Rue Helene Brion, F-75205 Paris, France.	celine.vallot@univ-paris-diderot.fr; francois.radvanyi@curie.fr	; Bickmore, Wendy/C-7314-2013	Radvanyi, Francois/0000-0002-5696-6424; Bickmore, Wendy/0000-0001-6660-7735	Institut Curie; Centre National de la Recherche Scientifique; Institut National de la Sante et de la Recherche Medicale; Institut National Contre le Cancer; Ligue Nationale Contre le Cancer; national program Cartes d'Identite des Tumeurs (CIT) - Ligue Nationale Contre le Cancer; UK Medical Research Council; Breakthrough Breast Cancer; MRC [MC_PC_U127527202] Funding Source: UKRI; Medical Research Council [MC_PC_U127527202] Funding Source: researchfish	Institut Curie; Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Institut National Contre le Cancer; Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); national program Cartes d'Identite des Tumeurs (CIT) - Ligue Nationale Contre le Cancer; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Breakthrough Breast Cancer; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Institut Curie; the Centre National de la Recherche Scientifique; the Institut National de la Sante et de la Recherche Medicale; the Institut National Contre le Cancer (program GepiG, program Tumult); the Ligue Nationale Contre le Cancer (CV, AH and FR, Equipe labellisee) and the national program Cartes d'Identite des Tumeurs (CIT), funded and developed by the Ligue Nationale Contre le Cancer. WAB and SB are supported by a unit program from the UK Medical Research Council and WAB is also supported by Breakthrough Breast Cancer. We thank Jennifer Southgate for providing us normal human urothelial (NHU) cells and Claire Rougeulle for critical reading of the manuscript.	Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; Boumber Y, 2011, ONCOLOGY-NY, V25, P220; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Chambeyron S, 2005, DEVELOPMENT, V132, P2215, DOI 10.1242/dev.01813; Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104; Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200; Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023; Crawley JJ, 2002, GENOME BIOL, V3; DeBoer WI, 1997, INT J CANCER, V71, P284, DOI 10.1002/(SICI)1097-0215(19970410)71:2<284::AID-IJC25>3.0.CO;2-G; Eskeland R, 2011, COLD SPRING HARB SYM, V75, P71; Eskeland R, 2010, MOL CELL, V38, P452, DOI 10.1016/j.molcel.2010.02.032; Francis NJ, 2004, SCIENCE, V306, P1574, DOI 10.1126/science.1100576; Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781; Garrick D, 2008, BLOOD, V112, P3889, DOI 10.1182/blood-2008-06-161901; Gilbert N, 2004, CELL, V118, P555, DOI 10.1016/j.cell.2004.08.011; Illingworth RS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034848; Karantzali E, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-4-r65; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lleres D, 2009, J CELL BIOL, V187, P481, DOI 10.1083/jcb.200907029; Margueron R, 2010, NAT REV GENET, V11, P285, DOI 10.1038/nrg2752; Margueron R, 2008, MOL CELL, V32, P503, DOI 10.1016/j.molcel.2008.11.004; Morey C, 2007, DEVELOPMENT, V134, P909, DOI 10.1242/dev.02779; Morey L, 2013, CELL REP, V3, P60, DOI 10.1016/j.celrep.2012.11.026; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Nagano T, 2008, SCIENCE, V322, P1717, DOI 10.1126/science.1163802; Nguyen CT, 2002, CANCER RES, V62, P6456; Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761; Nozawa RS, 2013, NAT STRUCT MOL BIOL; Pandey RR, 2008, MOL CELL, V32, P232, DOI 10.1016/j.molcel.2008.08.022; Pauler FM, 2009, GENOME RES, V19, P221, DOI 10.1101/gr.080861.108; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047; Roh TY, 2005, GENE DEV, V19, P542, DOI 10.1101/gad.1272505; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Simon JA, 2013, MOL CELL, V49, P808, DOI 10.1016/j.molcel.2013.02.013; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Soshnikova N, 2009, SCIENCE, V324, P1320, DOI 10.1126/science.1171468; SOUTHGATE J, 1994, LAB INVEST, V71, P583; Sproul D, 2005, NAT REV GENET, V6, P775, DOI 10.1038/nrg1688; Sproul D, 2011, P NATL ACAD SCI USA, V108, P4364, DOI 10.1073/pnas.1013224108; Stransky N, 2006, NAT GENET, V38, P1386, DOI 10.1038/ng1923; Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531; Tavares L, 2012, CELL, V148, P664, DOI 10.1016/j.cell.2011.12.029; Toth KF, 2004, J CELL SCI, V117, P4277, DOI 10.1242/jcs.01293; Vallot C, 2011, JNCI-J NATL CANCER I, V103, P47, DOI 10.1093/jnci/djq470; van Oers JMM, 2005, CLIN CANCER RES, V11, P7743, DOI 10.1158/1078-0432.CCR-05-1045; VANDENENGH G, 1992, SCIENCE, V257, P1410, DOI 10.1126/science.1388286; Wen B, 2009, NAT GENET, V41, P246, DOI 10.1038/ng.297; Wu XD, 2013, MOL CELL, V49, P1134, DOI 10.1016/j.molcel.2013.01.016; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Zhao XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004	59	9	9	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					741	751		10.1038/onc.2013.604	http://dx.doi.org/10.1038/onc.2013.604			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24469045				2022-12-28	WOS:000348853800007
J	Akeno, N; Miller, AL; Ma, X; Wikenheiser-Brokamp, KA				Akeno, N.; Miller, A. L.; Ma, X.; Wikenheiser-Brokamp, K. A.			p53 suppresses carcinoma progression by inhibiting mTOR pathway activation	ONCOGENE			English	Article						p53; Rb; medullary thyroid cancer; mTOR	MEDULLARY-THYROID CARCINOMA; SOMATIC INACTIVATION; CELL LINEAGES; LUNG-CANCER; MUTANT MICE; MOUSE MODEL; RETINOBLASTOMA; RB; MUTATION; TUMORIGENESIS	Genetic alterations in human cancers and murine models indicate that retinoblastoma (Rb) and p53 have critical tumor suppressive functions in retinoblastoma, a tumor of neural origin, and neuroendocrine tumors including small cell lung cancer and medullary thyroid cancer (MTC). Rb inactivation is the initiating lesion in retinoblastoma and current models propose that induction of apoptosis is a key p53 tumor suppressive function. Genetic studies in mice, however, indicate that other undefined p53 tumor suppressive functions are operative in vivo. How p53 loss cooperates with Rb inactivation to promote carcinogenesis is also not fully understood. In the current study, genetically engineered mice were generated to determine the role of Rb and p53 in MTC pathogenesis and test the hypothesis that p53 suppresses carcinogenesis by inhibiting mammalian target of rapamycin (mTOR) signaling. Conditional Rb ablation resulted in thyroid tumors mimicking human MTC, and additional p53 loss led to rapid tumor progression. p53 suppressed tumorigenesis by inhibiting cell cycle progression, but did not induce apoptosis. On the contrary, p53 loss led to increased apoptosis that had to be overcome for tumor progression. The mTOR activity was markedly increased in p53-deficient tumors and rapamycin treatment suppressed tumor cell growth, identifying mTOR inhibition as a critical p53 tumor suppressive function. Rapamycin treatment did not result in AKT/mitogen-activated protein kinase activation, providing evidence that this feedback mechanism operative in other cancers is not a general response to mTORC1 inhibition. Together, these studies provide mechanistic links between genetic alterations and aberrant signaling pathways critical in carcinogenesis, and identify essential Rb and p53 tumor suppressive functions in vivo.	[Akeno, N.; Miller, A. L.; Ma, X.; Wikenheiser-Brokamp, K. A.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Wikenheiser-Brokamp, K. A.] Univ Cincinnati, Coll Med, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Wikenheiser-Brokamp, KA (corresponding author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Kathryn.Wikenheiser-Brokamp@cchmc.org			American Cancer Society [RSG-10-194-01-TBG]; NIH/NHLBI [RO1 HL079193]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079193] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Mingyan Yang and Susan E Wert for technical expertise, Veterinary Services for excellent animal care, and Susanne I Wells and Elizabeth E Hoskins for reagents and technical expertise. This work was supported by grants from the American Cancer Society RSG-10-194-01-TBG and NIH/NHLBI RO1 HL079193 (to KAW-B).	Almeida MQ, 2012, CURR OPIN ONCOL, V24, P229, DOI 10.1097/CCO.0b013e328351c71a; Anwar F, 2000, MODERN PATHOL, V13, P562, DOI 10.1038/modpathol.3880097; Basolo F, 2000, THYROID, V10, P741, DOI 10.1089/thy.2000.10.741; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Cerrato A, 2009, J MOL ENDOCRINOL, V43, P143, DOI 10.1677/JME-09-0024; Conkrite K, 2012, J CLIN INVEST, V122, P1726, DOI 10.1172/JCI61403; Dong M, 2012, CLIN CANCER RES, V18, P1830, DOI 10.1158/1078-0432.CCR-11-2105; Faggiano A, 2012, J CELL MOL MED, V16, P1563, DOI 10.1111/j.1582-4934.2011.01438.x; Feng ZH, 2010, TRENDS CELL BIOL, V20, P427, DOI 10.1016/j.tcb.2010.03.004; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Frisk T, 2001, INT J ONCOL, V18, P1219; Goutas N, 2008, ANTICANCER RES, V28, P305; Grozinsky-Glasberg S, 2010, MOL CELL ENDOCRINOL, V315, P87, DOI 10.1016/j.mce.2009.09.027; HARVEY M, 1995, CANCER RES, V55, P1146; Hasty P, 2013, CELL CYCLE, V12, P20, DOI 10.4161/cc.22912; Hemmer S, 1999, AM J PATHOL, V154, P1539, DOI 10.1016/S0002-9440(10)65407-7; Herfarth KKF, 1997, GENE CHROMOSOME CANC, V20, P24, DOI 10.1002/(SICI)1098-2264(199709)20:1<24::AID-GCC4>3.3.CO;2-V; Hinze R, 2000, VIRCHOWS ARCH, V437, P256, DOI 10.1007/s004280000233; HOLM R, 1994, J PATHOL, V172, P267, DOI 10.1002/path.1711720307; Kouvaraki MA, 2011, SURGERY, V150, P1258, DOI 10.1016/j.surg.2011.09.022; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Marino S, 2000, GENE DEV, V14, P994; Marsh DJ, 2003, J CLIN ENDOCR METAB, V88, P1866, DOI 10.1210/jc.2002-021155; Matthew EM, 2009, CELL CYCLE, V8, P4168, DOI 10.4161/cc.8.24.10800; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Moura MM, 2011, J CLIN ENDOCR METAB, V96, pE863, DOI 10.1210/jc.2010-1921; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; Pavelic K, 2006, MUTAT RES-FUND MOL M, V599, P45, DOI 10.1016/j.mrfmmm.2006.01.021; Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499; Pitt SC, 2010, SEMIN ONCOL, V37, P567, DOI 10.1053/j.seminoncol.2010.10.010; Rapa I, 2011, J CLIN ENDOCR METAB, V96, P2146, DOI 10.1210/jc.2010-2655; Sheikh HA, 2004, AM J SURG PATHOL, V28, P101, DOI 10.1097/00000478-200401000-00012; Simpson DS, 2009, CANCER RES, V69, P8733, DOI 10.1158/0008-5472.CAN-09-1359; Sippel RS, 2008, ONCOLOGIST, V13, P539, DOI 10.1634/theoncologist.2007-0239; Smith-Hicks CL, 2000, EMBO J, V19, P612, DOI 10.1093/emboj/19.4.612; Stiewe T, 2007, NAT REV CANCER, V7, P165, DOI 10.1038/nrc2072; Tamburrino A, 2012, CLIN CANCER RES, V18, P3532, DOI 10.1158/1078-0432.CCR-11-2700; Vilar E, 2011, MOL CANCER THER, V10, P395, DOI 10.1158/1535-7163.MCT-10-0905; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wander SA, 2011, J CLIN INVEST, V121, P1231, DOI 10.1172/JCI44145; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Wikenheiser-Brokamp KA, 2004, DEVELOPMENT, V131, P4299, DOI 10.1242/dev.01232; Wikenheiser-Brokamp KA, 2006, CURR MOL MED, V6, P783; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Wise-Draper TM, 2006, MOL CELL BIOL, V26, P7506, DOI 10.1128/MCB.00430-06; Wu LS, 2011, CURR OPIN ONCOL, V23, P22, DOI 10.1097/CCO.0b013e328340b527; YOSHIMOTO K, 1992, CANCER RES, V52, P5061	50	38	40	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					589	599		10.1038/onc.2013.589	http://dx.doi.org/10.1038/onc.2013.589			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24469052	Green Accepted			2022-12-28	WOS:000348853500006
J	Cyr, AR; Kulak, MV; Park, JM; Bogachek, MV; Spanheimer, PM; Woodfield, GW; White-Baer, LS; O'Malley, YQ; Sugg, SL; Olivier, AK; Zhang, W; Domann, FE; Weigel, RJ				Cyr, A. R.; Kulak, M. V.; Park, J. M.; Bogachek, M. V.; Spanheimer, P. M.; Woodfield, G. W.; White-Baer, L. S.; O'Malley, Y. Q.; Sugg, S. L.; Olivier, A. K.; Zhang, W.; Domann, F. E.; Weigel, R. J.			TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis	ONCOGENE			English	Article						TFAP2C; breast cancer; mammary development; luminal; gene expression; EMT	BREAST-CANCER CELLS; STEM-CELLS; MESENCHYMAL TRANSITION; EXPRESSION PATTERNS; ESTROGEN-RECEPTOR; TRANSCRIPTION; AP-2-GAMMA; IDENTIFICATION; MARKERS; DIFFERENTIATION	Molecular subtypes of breast cancer are characterized by distinct patterns of gene expression that are predictive of outcome and response to therapy. The luminal breast cancer subtypes are defined by the expression of estrogen receptor-alpha (ER alpha)-associated genes, many of which are directly responsive to the transcription factor activator protein 2C (TFAP2C). TFAP2C participates in a gene regulatory network controlling cell growth and differentiation during ectodermal development and regulating ESR1/ER alpha and other luminal cell-associated genes in breast cancer. TFAP2C has been established as a prognostic factor in human breast cancer, however, its role in the establishment and maintenance of the luminal cell phenotype during carcinogenesis and mammary gland development have remained elusive. Herein, we demonstrate a critical role for TFAP2C in maintaining the luminal phenotype in human breast cancer and in influencing the luminal cell phenotype during normal mammary development. Knockdown of TFAP2C in luminal breast carcinoma cells induced epithelial-mesenchymal transition with morphological and phenotypic changes characterized by a loss of luminal-associated gene expression and a concomitant gain of basal-associated gene expression. Conditional knockout of the mouse homolog of TFAP2C, Tcfap2c, in mouse mammary epithelium driven by MMTV-Cre promoted aberrant growth of the mammary tree leading to a reduction in the CD24(hi)/CD49f(mid) luminal cell population and concomitant gain of the CD24(mid)/CD49f(hi) basal cell population at maturity. Our results establish TFAP2C as a key transcriptional regulator for maintaining the luminal phenotype in human breast carcinoma. Furthermore, Tcfap2c influences development of the luminal cell type during mammary development. The data suggest that TFAP2C has an important role in regulated luminal-specific genes and may be a viable therapeutic target in breast cancer.	[Cyr, A. R.; Kulak, M. V.; Park, J. M.; Bogachek, M. V.; Spanheimer, P. M.; Woodfield, G. W.; White-Baer, L. S.; O'Malley, Y. Q.; Sugg, S. L.; Domann, F. E.; Weigel, R. J.] Univ Iowa, Dept Surg, Iowa City, IA 52242 USA; [Cyr, A. R.; Domann, F. E.] Univ Iowa, Dept Radiat Oncol, Iowa City, IA 52242 USA; [Olivier, A. K.; Zhang, W.; Domann, F. E.] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; [Weigel, R. J.] Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa	Weigel, RJ (corresponding author), Univ Iowa, Dept Surg, 200 Hawkins Dr, Iowa City, IA 52242 USA.	Ronald-Weigel@uiowa.edu		Weigel, Ronald/0000-0002-9249-0793; Kulak, Mikhail/0000-0002-4307-5868; Sugg, Sonia/0000-0001-7530-8526; Domann, Frederick/0000-0002-0489-2179	National Institutes of Health [R01CA109294, T32CA148062, K99/R00CA158055]; Department of Pathology; NIH [T32CA148062]; NATIONAL CANCER INSTITUTE [R00CA158055, R01CA109294, K99CA158055, T32CA148062, T32CA078586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Pathology; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the National Institutes of Health grants R01CA109294 (PI: RJW), T32CA148062 (PI: RJW), K99/R00CA158055 (PI: WZ), a Startup Fund from the Department of Pathology (PI: WZ) and by a generous gift from the Kristen Olewine Milke Breast Cancer Research Fund. PMS was supported by the NIH grant T32CA148062.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Auman HJ, 2002, DEVELOPMENT, V129, P2733; Bai F, 2013, ONCOGENE, V32, P2715, DOI 10.1038/onc.2012.293; Balko JM, 2012, P NATL ACAD SCI USA, V109, P221, DOI 10.1073/pnas.1115802109; Bernardo GM, 2013, ONCOGENE, V32, P554, DOI 10.1038/onc.2012.62; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Buchwalter G, 2013, CANCER CELL, V23, P753, DOI 10.1016/j.ccr.2013.04.026; Carr JR, 2012, CELL REP, V1, P715, DOI 10.1016/j.celrep.2012.05.005; DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191; Delacroix L, 2005, DNA CELL BIOL, V24, P582, DOI 10.1089/dna.2005.24.582; dos Santos CO, 2013, P NATL ACAD SCI USA, V110, P7123, DOI 10.1073/pnas.1303919110; Friedrichs N, 2007, HISTOPATHOLOGY, V51, P814, DOI 10.1111/j.1365-2559.2007.02887.x; Friedrichs N, 2005, MODERN PATHOL, V18, P431, DOI 10.1038/modpathol.3800292; Gee JMW, 2009, J PATHOL, V217, P32, DOI 10.1002/path.2430; Groger CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051136; Guttormsen J, 2008, DEV BIOL, V317, P187, DOI 10.1016/j.ydbio.2008.02.017; He AL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-279; Hoffman TL, 2007, J EXP ZOOL PART B, V308B, P679, DOI 10.1002/jez.b.21189; Jager R, 2010, DEV DYNAM, V239, P1027, DOI 10.1002/dvdy.22239; Jager R, 2005, BREAST CANCER RES TR, V90, P273, DOI 10.1007/s10549-004-4815-x; Kalyuga M, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001461; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Lee HE, 2011, BRIT J CANCER, V104, P1730, DOI 10.1038/bjc.2011.159; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; Park SY, 2010, CLIN CANCER RES, V16, P876, DOI 10.1158/1078-0432.CCR-09-1532; Plante I, 2011, JOVE-J VIS EXP, DOI 10.3791/2828; Qiao YB, 2012, CELL RES, V22, P1546, DOI 10.1038/cr.2012.122; Ricardo S, 2011, J CLIN PATHOL, V64, P937, DOI 10.1136/jcp.2011.090456; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Smalley MJ, 2010, METHODS MOL BIOL, V633, P139, DOI 10.1007/978-1-59745-019-5_11; Spanheimer PM, 2013, J SURG RES, V184, P519, DOI 10.1016/j.jss.2013.04.042; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Tan SK, 2011, EMBO J, V30, P2569, DOI 10.1038/emboj.2011.151; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Woodfield GW, 2007, CANCER RES, V67, P8439, DOI 10.1158/0008-5472.CAN-07-2293; Woodfield GW, 2010, GENE CHROMOSOME CANC, V49, P948, DOI 10.1002/gcc.20807	37	38	38	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					436	444		10.1038/onc.2013.569	http://dx.doi.org/10.1038/onc.2013.569			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24469049	Green Accepted			2022-12-28	WOS:000348451300004
J	Jagadeeshan, S; Krishnamoorthy, YR; Singhal, M; Subramanian, A; Mavuluri, J; Lakshmi, A; Roshini, A; Baskar, G; Ravi, M; Joseph, LD; Sadasivan, K; Krishnan, A; Nair, AS; Venkatraman, G; Rayala, SK				Jagadeeshan, S.; Krishnamoorthy, Y. R.; Singhal, M.; Subramanian, A.; Mavuluri, J.; Lakshmi, A.; Roshini, A.; Baskar, G.; Ravi, M.; Joseph, L. D.; Sadasivan, K.; Krishnan, A.; Nair, A. S.; Venkatraman, G.; Rayala, S. K.			Transcriptional regulation of fibronectin by p21-activated kinase-1 modulates pancreatic tumorigenesis	ONCOGENE			English	Article						Pak1; fibronectin; PDAC; NF-kappa B-p65; KRAS intact model	NF-KAPPA-B; DUCTAL ADENOCARCINOMA; CANCER; EXPRESSION; PAK1; PATHWAY; RAS; LOCALIZATION; TARGETS; BIOLOGY	Pancreatic ductal adenocarcinoma (PDAC) is the eighth largest cause of cancer-related mortality across the world, with a median 5-year survival rate of less than 3.5%. This is partly because the molecules and the molecular mechanisms that contribute to PDAC are not well understood. Our goal is to understand the role of p21-activated kinase 1 (Pak1) signaling axis in the progression of PDAC. Pak1, a serine/threonine kinase, is a well-known regulator of cytoskeletal remodeling, cell motility, cell proliferation and cell survival. Recent reports suggest that Pak1 by itself can have an oncogenic role in a wide variety of cancers. In this study, we analyzed the expression of Pak1 in human pancreatic cancer tissues and found that Pak1 levels are significantly upregulated in PDAC samples as compared with adjacent normals. Further, to study the functional role of Pak1 in pancreatic cancer model systems, we developed stable overexpression and lentiviral short hairpin RNA-mediated knockdown (KD) clones of Pak1 and studied the changes in transforming properties of the cells. We also observed that Pak1 KD clones failed to form tumors in nude mice. By adopting a quantitative PCR array-based approach, we identified fibronectin, a component of the extracellular matrix and a mesenchymal marker, as a transcriptional target of Pak1 signaling. The underlying molecular mechanism of Pak1-mediated transformation includes its nuclear import and recruitment to the fibronectin promoter via interaction with nuclear factor-kappa B (NF-kappa B)-p65 complex. To our knowledge, this is the first study illustrating Pak1-NF-kappa B-p65-mediated fibronectin regulation as a potent tumor-promoting mechanism in KRAS intact model.	[Jagadeeshan, S.; Krishnamoorthy, Y. R.; Singhal, M.; Subramanian, A.; Mavuluri, J.; Lakshmi, A.; Roshini, A.; Rayala, S. K.] IIT Madras, Dept Biotechnol, Chennai 600036, Tamil Nadu, India; [Baskar, G.; Ravi, M.] Sri Ramachandra Univ, Dept Human Genet, Chennai 600116, Tamil Nadu, India; [Joseph, L. D.] Sri Ramachandra Univ, Dept Pathol, Chennai 600116, Tamil Nadu, India; [Sadasivan, K.] Govt Med Coll, Dept Plast & Reconstruct Surg, Thiruvananthapuram, Kerala, India; [Nair, A. S.] RGCB, Thiruvananthapuram 695014, Kerala, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Madras; Sri Ramachandra Institute of Higher Education & Research; Sri Ramachandra Institute of Higher Education & Research; Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Rayala, SK (corresponding author), IIT Madras, Dept Biotechnol, Chennai 600036, Tamil Nadu, India.	sasha@rgcb.res.in; ganeshv@sriramachandra.edu.in; rayala@iitm.ac.in	JAGADEESHAN, SANKAR/S-8384-2019; Joseph, Leena Dennis/AAS-9420-2020; Mavuluri, Jayadev/AAW-6724-2021; Venkatraman, Ganesh/AAB-1467-2020; Arivazhagan, Lakshmi/AAD-8613-2020; Singhal, Mahak/V-4017-2019; Krishnan, Anand/H-1314-2016	JAGADEESHAN, SANKAR/0000-0002-3778-8757; Venkatraman, Ganesh/0000-0003-0179-9785; Arivazhagan, Lakshmi/0000-0002-3713-442X; Singhal, Mahak/0000-0002-7303-9585; Rayala, Suresh/0000-0003-4394-4450; Muralikrishnan, Anirudh Subramanian/0000-0001-7102-9968	Department of Biotechnology (DBT), Government of India [BT/PR13559/Med/30/283/2010]; Indian Institute of Technology Madras (IITM)	Department of Biotechnology (DBT), Government of India(Department of Biotechnology (DBT) India); Indian Institute of Technology Madras (IITM)	We thank Silpa for help in mutagenesis and cloning and Swarnalatha for help with Pak1 lentiviral clones. Thanks to Sekar Sathiya, Rohan Prasad, Hemadev and the entire team of the Centre for Toxicology and Developmental Research (CEFT), Sri Ramachandra University, Chennai, for help with animal experiments. We thank the Department of Biotechnology (DBT), Government of India for the financial support to SKR (grant no.: BT/PR13559/Med/30/283/2010) and Indian Institute of Technology Madras (IITM) for all other facilities.	ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Arias-Romero LE, 2008, BIOL CELL, V100, P97, DOI 10.1042/BC20070109; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Costello E, 2012, NAT REV GASTRO HEPAT, V9, P435, DOI 10.1038/nrgastro.2012.119; Crnogorac-Jurcevic T, 2001, ONCOGENE, V20, P7437, DOI 10.1038/sj.onc.1204935; Falasca M, 2011, ANTI-CANCER AGENT ME, V11, P455, DOI 10.2174/187152011795677382; Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; He H, 2008, BBA-MOL CELL RES, V1783, P1943, DOI 10.1016/j.bbamcr.2008.04.016; Hidalgo M, 2012, CLIN CANCER RES, V18, P4249, DOI 10.1158/1078-0432.CCR-12-1327; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Kichina JV, 2010, EXPERT OPIN THER TAR, V14, P703, DOI 10.1517/14728222.2010.492779; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; Krautz C, 2011, ANTI-CANCER AGENT ME, V11, P411, DOI 10.2174/187152011795677409; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Linder S, 2001, HEPATO-GASTROENTEROL, V48, P1321; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Mao Y, 2005, J CELL SCI, V118, P4427, DOI 10.1242/jcs.02566; Menard RE, 2003, CELL SIGNAL, V15, P1099, DOI 10.1016/S0898-6568(03)00087-1; Morris JP, 2010, NAT REV CANCER, V10, P683, DOI 10.1038/nrc2899; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Ong CC, 2011, ONCOTARGET, V2, P491; Ong CC, 2011, P NATL ACAD SCI USA, V108, P7177, DOI 10.1073/pnas.1103350108; Sanchez-Solana B, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.404061; Singh RR, 2005, J BIOL CHEM, V280, P18130, DOI 10.1074/jbc.M412607200; Stanisavljevic J, 2011, J CELL SCI, V124, P4159, DOI 10.1242/jcs.078824; Ungefroren H, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-67; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; World Cancer Research Fund/ American Institute for Cancer Research, 2012, CONT UPD PROJ SUMM F; Wu R, 2010, INT J CANCER, V127, P2230, DOI 10.1002/ijc.25226; Ye Diana Zi, 2012, Cell Logist, V2, P105; Yeh JJ, 2007, EXPERT OPIN THER TAR, V11, P673, DOI 10.1517/14728222.11.5.673	34	37	38	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					455	464		10.1038/onc.2013.576	http://dx.doi.org/10.1038/onc.2013.576			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24561527				2022-12-28	WOS:000348451300006
J	Yan, S; Qiu, L; Ma, K; Zhang, X; Zhao, Y; Zhang, J; Li, X; Hao, X; Li, Z				Yan, S.; Qiu, L.; Ma, K.; Zhang, X.; Zhao, Y.; Zhang, J.; Li, X.; Hao, X.; Li, Z.			FATS is an E2-independent ubiquitin ligase that stabilizes p53 and promotes its activation in response to DNA damage	ONCOGENE			English	Article						FATS; ubiquitin linkage; p53; DNA damage; Mdm2	TUMOR-SUPPRESSOR P53; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; FRAGILE SITES; DEGRADATION; EXPRESSION; CANCER; CHAINS; REVEALS; ENZYMES	Ubiquitin linkage is critical in directing the cellular fate of a ubiquitinated protein. Although K48-linked polyubiquitination of p53 leads to its degradation, whether K48-independent ubiquitin linkages are involved in p53 activation remains unknown. Here, we show that FATS acts as a p53 activator by inhibiting Mdm2 binding to p53 and stimulating non-proteolytic polyubiquitination of p53. Knockdown of FATS impairs p53 stabilization and activation in response to DNA damage. Furthermore, the NH2-terminal domain of FATS is sufficient to exhibit ubiquitin ligase (E3) activity and assemble ubiquitin polymers through K11-, K29-and K63-linkages, independently of the ubiquitin-conjugating enzyme (E2). FATS promotes p53-dependent transcription of p21, leading to robust checkpoint response. The E3 activity of FATS is required for promoting p53 stability and activation in response to DNA damage. Our findings reveal K48-linkage-independent non-linear polyubiquitination of p53 as a new barcode for p53 activation.	[Yan, S.; Qiu, L.; Ma, K.; Zhang, X.; Zhao, Y.; Zhang, J.; Li, X.; Li, Z.] Tianjin Med Univ, Canc Inst & Hosp, Dept Biochem & Mol Biol, Tianjin 300060, Peoples R China; [Yan, S.; Qiu, L.; Ma, K.; Zhang, X.; Zhao, Y.; Zhang, J.; Li, X.; Hao, X.; Li, Z.] Tianjin Med Univ, Canc Inst & Hosp, Minist Educ, Key Lab Breast Canc Prevent & Therapy, Tianjin 300060, Peoples R China	Tianjin Medical University; Tianjin Medical University	Li, Z (corresponding author), Tianjin Med Univ, Canc Inst & Hosp, Dept Biochem & Mol Biol, Huan Hu Xi Rd, Tianjin 300060, Peoples R China.	zhengli@tijmu.edu.cn			Ministry of Science and Technology of China 973-program concept award [2009CB526407]; National Natural Science Foundation of China [81272283]; Tianjin Municipal Science and Technology Foundation [10JCZDJC18600]	Ministry of Science and Technology of China 973-program concept award; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Municipal Science and Technology Foundation	We are grateful to Dr X Lu (The University of Texas MD Anderson Cancer Center, USA) for providing us with HA-Mdm2 plasmid. This work was supported by grants from Ministry of Science and Technology of China 973-program concept award (2009CB526407 to ZL), National Natural Science Foundation of China (81272283 to ZL), and Tianjin Municipal Science and Technology Foundation (10JCZDJC18600 to ZL).	Bellail AC, 2012, CANCER DISCOV, V2, P140, DOI 10.1158/2159-8290.CD-11-0172; Brzovic PS, 2006, MOL CELL, V21, P873, DOI 10.1016/j.molcel.2006.02.008; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Durkin SG, 2007, ANNU REV GENET, V41, P169, DOI 10.1146/annurev.genet.41.042007.165900; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hurley JH, 2006, BIOCHEM J, V399, P361, DOI 10.1042/BJ20061138; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Jain AK, 2010, CANCER BIOL THER, V10, P665, DOI 10.4161/cbt.10.7.13445; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jung YS, 2011, MOL CELL BIOL, V31, P3997, DOI 10.1128/MCB.05808-11; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Laine A, 2007, ONCOGENE, V26, P1477, DOI 10.1038/sj.onc.1209924; Laine A, 2006, MOL CELL BIOL, V26, P8901, DOI 10.1128/MCB.01156-06; Le Cam L, 2006, CELL, V127, P775, DOI 10.1016/j.cell.2006.09.031; Lee JT, 2010, CELL DEATH DIFFER, V17, P86, DOI 10.1038/cdd.2009.77; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li Z, 2004, CANCER RES, V64, P9080, DOI 10.1158/0008-5472.CAN-04-2419; Li Z, 2010, ONCOGENE, V29, P2659, DOI 10.1038/onc.2010.19; LUNA RMD, 1995, NATURE, V378, P203; Ma K, 2012, INT J MOL SCI, V13, P11974, DOI 10.3390/ijms130911974; Mahmoud S, 2003, BIOCHEM BIOPH RES CO, V305, P1099, DOI 10.1016/S0006-291X(03)00905-7; Mao JH, 2005, ONCOGENE, V24, P7924, DOI 10.1038/sj.onc.1208926; Migliorini D, 2011, J CLIN INVEST, V121, P1329, DOI 10.1172/JCI45784; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Tian Y, 2012, LUNG CANCER, V76, P416, DOI 10.1016/j.lungcan.2011.11.009; Ulrich HD, 2010, NAT REV MOL CELL BIO, V11, P479, DOI 10.1038/nrm2921; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wenzel DM, 2011, NATURE, V474, P105, DOI 10.1038/nature09966; Wu H, 2011, NAT MED, V17, P347, DOI 10.1038/nm.2283; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xu P, 2009, CELL, V137, P133, DOI 10.1016/j.cell.2009.01.041; Ye YH, 2009, NAT REV MOL CELL BIO, V10, P755, DOI 10.1038/nrm2780; Zhang J, 2011, CHINESE MED J-PEKING, V124, P2894, DOI 10.3760/cma.j.issn.0366-6999.2011.18.018; Zhang XF, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-244	39	12	13	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2014	33	47					5424	5433		10.1038/onc.2013.494	http://dx.doi.org/10.1038/onc.2013.494			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MG	24240685				2022-12-28	WOS:000345120700004
J	Whitaker, HC; Shiong, LL; Kay, JD; Gronberg, H; Warren, AY; Seipel, A; Wiklund, F; Thomas, B; Wiklund, P; Miller, JL; Menon, S; Ramos-Montoya, A; Vowler, SL; Massie, C; Egevad, L; Neal, DE				Whitaker, H. C.; Shiong, L. L.; Kay, J. D.; Groenberg, H.; Warren, A. Y.; Seipel, A.; Wiklund, F.; Thomas, B.; Wiklund, P.; Miller, J. L.; Menon, S.; Ramos-Montoya, A.; Vowler, S. L.; Massie, C.; Egevad, L.; Neal, D. E.			N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 is overexpressed in cancer and promotes a pro-migratory and pro-metastatic phenotype	ONCOGENE			English	Article						NAALase; prostate cancer; colon cancer; prognostic; biomarker	PROSTATE-SPECIFIC ANTIGEN; FOCAL ADHESION KINASE; CARBOXYPEPTIDASE-II; CELL-MIGRATION; RADICAL PROSTATECTOMY; RECEPTOR; AGR2; IDENTIFICATION; RECURRENCE; EXPRESSION	N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2) is a member of the glutamate carboxypeptidase II family, best characterized by prostate-specific membrane antigen (PSMA/NAALAD1). Using immunohistochemistry (IHC), we have shown overexpression of NAALADL2 in colon and prostate tumours when compared with benign tissue. In prostate cancer, NAALADL2 expression was associated with stage and Grade, as well as circulating mRNA levels of the NAALADL2 gene. Overexpression of NAALADL2 was shown to predict poor survival following radical prostatectomy. In contrast to PSMA/ NAALAD1, NAALADL2 was localized at the basal cell surface where it promotes adhesion to extracellular matrix proteins. Using stable knockdown and overexpression cell lines, we have demonstrated NAALADL2-dependent changes in cell migration, invasion and colony-forming potential. Expression arrays of the knockdown and overexpression cell lines have identified nine genes that co-expressed with NAALADL2, which included membrane proteins and genes known to be androgen regulated, including the prostate cancer biomarkers AGR2 and SPON2. Androgen regulation was confirmed in a number of these genes, although NAALADL2 itself was not found to be androgen regulated. NAALADL2 was also found to regulate levels of Ser133 phosphorylated C-AMP-binding protein (CREB), a master regulator of a number of cellular processes involved in cancer development and progression. In combination, these data suggest that changes in expression of NAALADL2 can impact upon a number of pro-oncogenic pathways and processes, making it a useful biomarker for both diagnosis and prognosis.	[Whitaker, H. C.; Shiong, L. L.; Kay, J. D.; Thomas, B.; Ramos-Montoya, A.; Massie, C.; Neal, D. E.] Univ Cambridge, Canc Res UK Cambridge Inst, Urooncol Res Grp, Cambridge CB2 0RE, England; [Whitaker, H. C.] Univ Cambridge, Canc Res UK Cambridge Inst, Canc Res UK Biomarker Initiat, Cambridge CB2 0RE, England; [Groenberg, H.; Wiklund, F.] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Warren, A. Y.; Miller, J. L.] Univ Cambridge, Canc Res UK Cambridge Inst, Dept Histopathol, Cambridge CB2 0RE, England; [Warren, A. Y.; Miller, J. L.] Univ Cambridge, Canc Res UK Cambridge Inst, ISH Core Facil, Cambridge CB2 0RE, England; [Warren, A. Y.; Miller, J. L.] Cambridge Univ Hosp NHS Fdn Trust, Dept Histopathol, Cambridge, England; [Seipel, A.; Wiklund, P.; Egevad, L.] Karolinska Inst, Dept Pathol, S-10401 Stockholm, Sweden; [Menon, S.; Vowler, S. L.] Univ Cambridge, Canc Res UK Cambridge Inst, Bioinformat Core Facil, Cambridge CB2 0RE, England	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Karolinska Institutet; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Cambridge; Karolinska Institutet; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Whitaker, HC (corresponding author), Univ Cambridge, Canc Res UK Cambridge Inst, Canc Res UK Biomarker Initiat, Robinson Way, Cambridge CB2 0RE, England.	Hayley.Whitaker@cruk.cam.ac.uk	Kay, Jonathan/HGE-1248-2022	Neal, David/0000-0002-6033-5086; Wiklund, Peter/0000-0001-6497-4697; Massie, Charlie/0000-0003-2314-4843	University of Cambridge, Cancer Research UK; Hutchison Whampoa Limited; National Institute of Health Research - Cambridge Biomedical Research Centre, Cambridge, UK; National Cancer Research Prostate Cancer: mechanisms of Progression and Treatment (PROMPT) collaborative [G0500966/75466]; Prostate Cancer UK; National Medical Research Council, Singapore; MRC [G0900871] Funding Source: UKRI; Cancer Research UK [22310] Funding Source: researchfish; Medical Research Council [G0900871] Funding Source: researchfish; Prostate Cancer UK [G2012/50] Funding Source: researchfish	University of Cambridge, Cancer Research UK(Cancer Research UKUniversity of Cambridge); Hutchison Whampoa Limited; National Institute of Health Research - Cambridge Biomedical Research Centre, Cambridge, UK; National Cancer Research Prostate Cancer: mechanisms of Progression and Treatment (PROMPT) collaborative; Prostate Cancer UK; National Medical Research Council, Singapore(National Medical Research Council, SingaporeUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Prostate Cancer UK	We would like to acknowledge the support of The University of Cambridge, Cancer Research UK, National Medical Research Council, Singapore and Hutchison Whampoa Limited; the National Institute of Health Research, which funds the Cambridge Biomedical Research Centre, Cambridge, UK; the National Cancer Research Prostate Cancer: mechanisms of Progression and Treatment (PROMPT) collaborative (grant code G0500966/75466), which has funded tissue collections in Cambridge. We would like to thank Prostate Cancer UK for funding a proportion of this work. We are very grateful to the Cancer Research UK Cambridge Institute Genomics Core Facility, Histopathology and ISH Facility, and Bioinformatics and Statistics Core Facility for their assistance with the work in this manuscript. We would also like to thank Erik Sahai (Cancer Research UK London Research Institute) and Ian Mills (Centre for Molecular Medicine Norway) for their helpful discussions in preparing this manuscript.	[Anonymous], 2010, CANC STAT REG; Augustin H, 2013, PROSTATE, V73, P203, DOI 10.1002/pros.22558; Barinka C, 2004, EUR J BIOCHEM, V271, P2782, DOI 10.1111/j.1432-1033.2004.04209.x; Barinka C, 2004, PROTEIN SCI, V13, P1627, DOI 10.1110/ps.04622104; Barrett JA, 2013, J NUCL MED, V54, P380, DOI 10.2967/jnumed.112.111203; Bennett HL, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.50; Botchorishvili G, 2009, CURR OPIN UROL, V19, P221, DOI 10.1097/MOU.0b013e32832a2d10; Brychtova V, 2011, CANCER LETT, V304, P1, DOI 10.1016/j.canlet.2010.12.023; Bu H, 2013, FEBS J, V280, P1249, DOI 10.1111/febs.12118; Burgner D, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000319; Cairns JM, 2008, BIOINFORMATICS, V24, P2921, DOI 10.1093/bioinformatics/btn557; Cao KY, 2007, PROSTATE, V67, P1791, DOI 10.1002/pros.20664; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Conkright MD, 2005, TRENDS CELL BIOL, V15, P457, DOI 10.1016/j.tcb.2005.07.007; D'Amico AV, 1999, J CLIN ONCOL, V17, P168, DOI 10.1200/JCO.1999.17.1.168; Daneshmand S, 2007, HUM PATHOL, V38, P1547, DOI 10.1016/j.humpath.2007.03.014; Dunning MJ, 2007, BIOINFORMATICS, V23, P2183, DOI 10.1093/bioinformatics/btm311; Frigerio B, 2013, EUR J CANCER; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hessels D, 2009, NAT REV UROL, V6, P255, DOI 10.1038/nrurol.2009.40; Ho ME, 2013, MODERN PATHOL, V26, P849, DOI 10.1038/modpathol.2012.238; Hrkach J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003651; Kani K, 2013, PROSTATE, V73, P306, DOI 10.1002/pros.22569; Kattan MW, 1998, JNCI-J NATL CANCER I, V90, P766, DOI 10.1093/jnci/90.10.766; Lee SF, 2011, J BIOL CHEM, V286, P27447, DOI 10.1074/jbc.M111.243154; Liao CH, 2010, ENDOCR-RELAT CANCER, V17, P99, DOI 10.1677/ERC-09-0050; Liu TC, 2012, BIOORG MED CHEM LETT, V22, P3931, DOI 10.1016/j.bmcl.2012.04.110; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Mesters JR, 2006, EMBO J, V25, P1375, DOI 10.1038/sj.emboj.7600969; Osborne JR, 2012, UROL ONCOL, V31, P144; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Partin AW, 1997, JAMA-J AM MED ASSOC, V277, P1445, DOI 10.1001/jama.277.18.1445; Powell SM, 2006, BIOCHEM SOC T, V34, P1124, DOI 10.1042/BST0341124; Qian XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037225; Rojas C, 2002, ANAL BIOCHEM, V310, P50, DOI 10.1016/S0003-2697(02)00286-5; Rosario DJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.d7894; Silver DA, 1997, CLIN CANCER RES, V3, P81; Smyth G, 2005, LIMMA LINEAR MODELS; Tan SS, 2011, J PATHOL, V223, P81, DOI 10.1002/path.2795; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thirkettle HJ, 2009, CLIN CANCER RES, V15, P3003, DOI 10.1158/1078-0432.CCR-08-2046; Tonkin ET, 2004, HUM GENET, V115, P139, DOI 10.1007/s00439-004-1134-6; Tradonsky A, 2012, AM J CLIN PATHOL, V137, P918, DOI 10.1309/AJCPF3QWIG8FWXIH; Trojan L, 2005, ANTICANCER RES, V25, P183; Tsuchiya N, 1998, J BIOCHEM-TOKYO, V123, P499; Varisli L, 2012, MOL CELL ENDOCRINOL, V350, P107, DOI 10.1016/j.mce.2011.11.027; Varisli L, 2011, DNA CELL BIOL, V30, P419, DOI 10.1089/dna.2010.1128; Ventura A, 2004, P NATL ACAD SCI USA, V101, P10380, DOI 10.1073/pnas.0403954101; Wang Z, 2008, CANCER RES, V68, P492, DOI 10.1158/0008-5472.CAN-07-2930; Wayner EA, 2012, PROSTATE, V72, P1023, DOI 10.1002/pros.21508; Whitaker HC, 2007, PROSTATE, V67, P943, DOI 10.1002/pros.20580; Whitaker HC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013363; Wu YY, 2008, CELL BIOCHEM FUNCT, V26, P467, DOI 10.1002/cbf.1468; Zheng DQ, 1999, CANCER RES, V59, P1655	54	27	32	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2014	33	45					5274	5287		10.1038/onc.2013.464	http://dx.doi.org/10.1038/onc.2013.464			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MD	24240687				2022-12-28	WOS:000345120400005
J	Xu, C; Lin, L; Cao, G; Chen, Q; Shou, P; Huang, Y; Han, Y; Wang, Y; Shi, Y				Xu, C.; Lin, L.; Cao, G.; Chen, Q.; Shou, P.; Huang, Y.; Han, Y.; Wang, Y.; Shi, Y.			Interferon-alpha-secreting mesenchymal stem cells exert potent antitumor effect in vivo	ONCOGENE			English	Article						mesenchymal stem cells; IFN alpha; NK cells; CD8(+) T cells; immune system; tumor	NATURAL-KILLER-CELLS; STROMAL CELLS; DELIVERY; TISSUE	Mesenchymal stem cells (MSCs) are a kind of adult stem cells that can be isolated easily from bone marrow, adipose tissue, umbilical cord and many other tissues. MSCs have been shown to specifically migrate to inflammatory sites, including tumors, and hold great promise as tumor-specific vectors to deliver antitumor agents. Interferon-alpha (IFN alpha) has been used in clinic to treat various types of tumors; however, because of its short half-life, significant therapeutic effects require high doses that often results in serious side effects. Here, we tested whether MSCs continuingly secreting IFN alpha can exert a persistent antitumor effect and eliminate the side effects associated with high clinical doses of recombinant IFN alpha. We found that even a small number of IFN alpha-secreting MSCs could potently halt B16 tumor growth in vivo. The antitumor activity of IFN alpha-secreting MSCs was largely abolished in immunodeficient mice, an effect largely attributed to natural killer cells and CD8(+) T cells. Therefore, IFNa-secreting MSCs provide an innovative strategy for tumor therapy.	[Xu, C.; Lin, L.; Cao, G.; Chen, Q.; Shou, P.; Huang, Y.; Han, Y.; Wang, Y.; Shi, Y.] Chinese Acad Sci, Shanghai Jiao Tong Univ, Shanghai Inst Biol Sci,Sch Med, Key Lab Stem Cell Biol,Inst Hlth Sci, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University	Shi, Y (corresponding author), Chinese Acad Sci, Shanghai Jiao Tong Univ, Shanghai Inst Biol Sci,Sch Med, Key Lab Stem Cell Biol,Inst Hlth Sci, 225 South Chongqing Rd,1 Bldg, Shanghai, Peoples R China.	yingwang@sibs.ac.cn; yufangshi@sibs.ac.cn	lin, liping/HGE-0871-2022; Xu, Chunliang/R-7065-2018; Shi, Yufang/AAE-4431-2020; Shou, Peishun/J-7985-2014; HUANG, YIN/AAH-6871-2020	Shi, Yufang/0000-0001-8964-319X; Shou, Peishun/0000-0001-7685-7471; HUANG, YIN/0000-0001-5602-9871; Chen, Qing/0000-0002-2088-0370; wang, ying/0000-0002-2571-9367	Scientific Innovation Project of the Chinese Academy of Science [XDA 01040107, XDA 01040110]; Ministry of Science and Technology of China [2010CB945600, 2011DFA30630]; National Science and Technology Project of China [31010103908, 81273316]; Shanghai Municipal Key Projects of Basic Research [12JC1409200]; Shanghai Municipal Natural Science Foundation [12ZR1452600]; Knowledge Innovation Program of Shanghai Institutes for Biological Sciences; Chinese Academy of Sciences [2012KIP202]	Scientific Innovation Project of the Chinese Academy of Science; Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Science and Technology Project of China; Shanghai Municipal Key Projects of Basic Research; Shanghai Municipal Natural Science Foundation; Knowledge Innovation Program of Shanghai Institutes for Biological Sciences(Knowledge Innovation Program of the Chinese Academy of Sciences); Chinese Academy of Sciences(Chinese Academy of Sciences)	This work was supported by grants from Scientific Innovation Project of the Chinese Academy of Science (XDA 01040107 and XDA 01040110), the Ministry of Science and Technology of China (2010CB945600 and 2011DFA30630), the National Science and Technology Project of China (31010103908 and 81273316), Shanghai Municipal Key Projects of Basic Research (12JC1409200), Shanghai Municipal Natural Science Foundation (12ZR1452600), the Knowledge Innovation Program of Shanghai Institutes for Biological Sciences and the Chinese Academy of Sciences (2012KIP202).	Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002; Bracarda S, 2010, EUR J CANCER, V46, P284, DOI 10.1016/j.ejca.2009.10.013; Cerwenka A, 2001, NAT REV IMMUNOL, V1, P41, DOI 10.1038/35095564; Elzaouk L, 2006, EXP DERMATOL, V15, P865, DOI 10.1111/j.1600-0625.2006.00479.x; Hainaut P, 2012, CURR OPIN ONCOL, V25, P50; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234; Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001; Keating A, 2012, CELL STEM CELL, V10, P709, DOI 10.1016/j.stem.2012.05.015; Kidd S, 2009, STEM CELLS, V27, P2614, DOI 10.1002/stem.187; Kim SM, 2008, CANCER RES, V68, P9614, DOI 10.1158/0008-5472.CAN-08-0451; Kolf CM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2116; Loebinger MR, 2009, CANCER RES, V69, P8862, DOI 10.1158/0008-5472.CAN-09-1912; Pestka S, 2003, CANCER CELL, V4, P85, DOI 10.1016/S1535-6108(03)00193-4; Pestka S, 2007, J BIOL CHEM, V282, P20047, DOI 10.1074/jbc.R700004200; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Ranganath SH, 2012, CELL STEM CELL, V10, P244, DOI 10.1016/j.stem.2012.02.005; Ren GW, 2012, CELL STEM CELL, V11, P812, DOI 10.1016/j.stem.2012.08.013; Ren GW, 2012, STEM CELL TRANSL MED, V1, P51, DOI 10.5966/sctm.2011-0019; Sensebe L, 2012, CELL STEM CELL, V10, P9, DOI 10.1016/j.stem.2011.12.005; Shi YF, 2010, CELL RES, V20, P510, DOI 10.1038/cr.2010.44; Studeny M, 2002, CANCER RES, V62, P3603; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; Vanneman M, 2012, NAT REV CANCER, V12, P237, DOI 10.1038/nrc3237; Vivier E, 2012, NAT REV IMMUNOL, V12, P239, DOI 10.1038/nri3174; Wang B, 2010, EXPERT OPIN DRUG DEL, V7, P1159, DOI 10.1517/17425247.2010.513968; Wang H, 2009, STEM CELLS, V27, P1548, DOI 10.1002/stem.81; Zou WB, 2012, CANCER RES, V72, P2980, DOI 10.1158/0008-5472.CAN-11-4216; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	29	34	36	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2014	33	42					5047	5052		10.1038/onc.2013.458	http://dx.doi.org/10.1038/onc.2013.458			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OB	24186200				2022-12-28	WOS:000343768000009
J	Basova, P; Pospisil, V; Savvulidi, F; Burda, P; Vargova, K; Stanek, L; Dluhosova, M; Kuzmova, E; Jonasova, A; Steidl, U; Laslo, P; Stopka, T				Basova, P.; Pospisil, V.; Savvulidi, F.; Burda, P.; Vargova, K.; Stanek, L.; Dluhosova, M.; Kuzmova, E.; Jonasova, A.; Steidl, U.; Laslo, P.; Stopka, T.			Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice	ONCOGENE			English	Article						PU.1; leukemia; differentiation; microRNA; p53; AML	HEMATOPOIETIC STEM-CELLS; TRANSCRIPTION FACTOR; MYELODYSPLASTIC SYNDROMES; MICRORNA EXPRESSION; P53 MUTATIONS; MYB; DIFFERENTIATION; GENE; TUMORS		[Basova, P.; Pospisil, V.; Savvulidi, F.; Burda, P.; Vargova, K.; Stanek, L.; Dluhosova, M.; Kuzmova, E.; Jonasova, A.; Stopka, T.] Charles Univ Prague, Dept Pathophysiol, Fac Med 1, Prague 12853 2, Czech Republic; [Basova, P.] Charles Univ Prague, Dept Expt Biomodels, Fac Med 1, Prague 12853 2, Czech Republic; [Stanek, L.] Charles Univ Prague, Dept Pathol, Fac Med 1, Prague 12853 2, Czech Republic; [Jonasova, A.; Stopka, T.] Charles Univ Prague, Dept Med Hematol, Fac Med 1, Prague 12853 2, Czech Republic; [Steidl, U.] Yeshiva Univ, Albert Einstein Coll Med, Bronx, NY USA; [Laslo, P.] Univ Leeds, St Jamess Univ Hosp, Leeds Inst Canc & Pathol, Sect Expt Haematol, Leeds, W Yorkshire, England	Charles University Prague; Charles University Prague; Charles University Prague; Charles University Prague; Yeshiva University; Albert Einstein College of Medicine; Saint James's University Hospital; University of Leeds	Stopka, T (corresponding author), Charles Univ Prague, Dept Pathophysiol, Fac Med 1, U Nemocnice 5, Prague 12853 2, Czech Republic.	tstopka@lf1.cuni.cz	Anna, Jonasona/U-6166-2017; Dluhošová, Martina/AAQ-7694-2021; Vargova, Karina/G-9642-2017; Burda, Pavel/K-8219-2017; Savvulidi Vargova, Karina/ABE-7513-2021; Pospisil, Vit/M-9429-2017; Basova, Petra/I-8930-2017; Kužmová, Erika/H-1520-2014	Anna, Jonasona/0000-0003-0246-1524; Vargova, Karina/0000-0002-4969-4133; Burda, Pavel/0000-0002-2841-792X; Savvulidi Vargova, Karina/0000-0002-4969-4133; Pospisil, Vit/0000-0003-2144-0438; Basova, Petra/0000-0003-0587-4471; Savvulidi, Filipp Georgijevic/0000-0002-4889-837X; Kuzmova, Erika/0000-0002-0728-9578	BIOCEV-Biotechnology and Biomedicine Centre of the Academy of Sciences [GACR P305/12/1033, UNCE 204021, PRVOUK-P24/LF1/3, SVV-2013-266509]; Charles University, from the European Regional Development Fund [CZ.1.05/1.1.00/02.0109]; Leukemia and Lymphoma Research grant;  [GAUK 251135 82210];  [GACR P301/12/P380];  [GAUK 251070 45410];  [GACR 305 13-12449P]	BIOCEV-Biotechnology and Biomedicine Centre of the Academy of Sciences; Charles University, from the European Regional Development Fund; Leukemia and Lymphoma Research grant; ; ; ; 	Primary support: GACR P305/12/1033 Institutional: UNCE 204021, PRVOUK-P24/LF1/3, SVV-2013-266509, BIOCEV-Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University (CZ.1.05/1.1.00/02.0109), from the European Regional Development Fund. Other: PB: GAUK 251135 82210, GACR P301/12/P380; MD: GAUK 251070 45410; VP: GACR 305 13-12449P; PL: Leukemia and Lymphoma Research grant.	Abbas HA, 2011, CELL CYCLE, V10, P3257, DOI 10.4161/cc.10.19.17721; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Burda P, 2009, MOL CANCER RES, V7, P1693, DOI 10.1158/1541-7786.MCR-09-0031; Curik N, 2012, LEUKEMIA, V26, P1804, DOI 10.1038/leu.2012.47; Dahl R, 2003, BLOOD CELL MOL DIS, V31, P229, DOI 10.1016/S1079-9796(03)00152-9; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Epstein CB, 1998, ONCOGENE, V16, P2115, DOI 10.1038/sj.onc.1201734; Ghani S, 2011, BLOOD, V118, P2275, DOI 10.1182/blood-2011-02-335141; Haferlach C, 2008, LEUKEMIA, V22, P1539, DOI 10.1038/leu.2008.143; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Leddin M, 2011, BLOOD, V117, P2827, DOI 10.1182/blood-2010-08-302976; Mannefeld M, 2009, CANCER RES, V69, P4073, DOI 10.1158/0008-5472.CAN-08-4156; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Nakano Y, 2000, EUR J HAEMATOL, V65, P23, DOI 10.1034/j.1600-0609.2000.90138.x; Neiman PE, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000132; Noel G, 2012, J IMMUNOL METHODS, V382, P81, DOI 10.1016/j.jim.2012.05.008; O'Connell RM, 2008, J EXP MED, V205, P585, DOI 10.1084/jem.20072108; O'Connell RM, 2011, BLOOD, V118, P2960, DOI 10.1182/blood-2011-03-291971; Pattabiraman DR, 2013, LEUKEMIA, V27, P269, DOI 10.1038/leu.2012.225; Pospisil V, 2011, EMBO J, V30, P4450, DOI 10.1038/emboj.2011.317; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Sokol L, 2011, BRIT J HAEMATOL, V153, P24, DOI 10.1111/j.1365-2141.2011.08581.x; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; Vargova K, 2011, BLOOD, V117, P3816, DOI 10.1182/blood-2010-05-285064; Vigorito E, 2007, IMMUNITY, V27, P847, DOI 10.1016/j.immuni.2007.10.009; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; Zhao Z, 2010, GENE DEV, V24, P1389, DOI 10.1101/gad.1940710	29	22	23	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2014	33	39					4735	4745		10.1038/onc.2013.414	http://dx.doi.org/10.1038/onc.2013.414			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0ED	24121269				2022-12-28	WOS:000343239500004
J	Dong, Y; Richards, JAE; Gupta, R; Aung, PP; Emley, A; Kluger, Y; Dogra, SK; Mahalingam, M; Wajapeyee, N				Dong, Y.; Richards, J-A E.; Gupta, R.; Aung, P. P.; Emley, A.; Kluger, Y.; Dogra, S. K.; Mahalingam, M.; Wajapeyee, N.			PTEN functions as a melanoma tumor suppressor by promoting host immune response	ONCOGENE			English	Article						tumor suppressor; melanoma; immune evasion	NF-KAPPA-B; BRAF MUTATIONS; EXPRESSION; CANCER; STAT3; CYTOKINES; PATHWAY; PHOSPHORYLATION; SENESCENCE; FAMILY	Cancer cells acquire several traits that allow for their survival and progression, including the ability to evade the host immune response. However, the mechanisms by which cancer cells evade host immune responses remain largely elusive. Here we study the phenomena of immune evasion in malignant melanoma cells. We find that the tumor suppressor phosphatase and tensin homolog (PTEN) is an important regulator of the host immune response against melanoma cells. Mechanistically, PTEN represses the expression of immunosuppressive cytokines by blocking the phosphatidylinositide 3-kinase (PI3K) pathway. In melanoma cells lacking PTEN, signal transducer and activator of transcription 3 activates the transcription of immunosuppressive cytokines in a PI3K-dependent manner. Furthermore, conditioned media from PTEN-deficient, patient-derived short-term melanoma cultures and established melanoma cell lines blocked the production of the interleukin-12 (IL-12) in human monocyte-derived dendritic cells. Inhibition of IL-12 production was rescued by restoring PTEN or using neutralizing antibodies against the immunosuppressive cytokines. Furthermore, we report that PTEN, as an alternative mechanism to promote the host immune response against cancer cells, represses the expression of programmed cell death 1 ligand, a known repressor of the host immune response. Finally, to establish the clinical significance of our results, we analyzed malignant melanoma patient samples with or without brisk host responses. These analyses confirmed that PTEN loss is associated with a higher percentage of malignant melanoma samples with non-brisk host responses compared with samples with brisk host responses. Collectively, these results establish that PTEN functions as a melanoma tumor suppressor in part by regulating the host immune response against melanoma cells and highlight the importance of assessing PTEN status before recruiting melanoma patients for immunotherapies.	[Dong, Y.; Gupta, R.; Kluger, Y.; Wajapeyee, N.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Dong, Y.] Hebei Med Univ, Coll Stomatol, Dept Oral & Maxillofacial Surg, Shijiazhuang, Peoples R China; [Richards, J-A E.; Aung, P. P.; Emley, A.; Mahalingam, M.] Boston Univ, Sch Med, Dept Dermatol, Dermatopathol Sect, Boston, MA 02118 USA; [Dogra, S. K.] ASTAR, Brenner Ctr Mol Med, Singapore Inst Clin Sci, Singapore, Singapore	Yale University; Hebei Medical University; Boston University; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Institute for Clinical Sciences (SICS)	Wajapeyee, N (corresponding author), Yale Univ, Sch Med, Dept Pathol, LH-214A,310 Cedar St, New Haven, CT 06510 USA.	mmahalin@bu.edu; Narendra.Wajapeyee@yale.edu	Dogra, Shaillay Kumar/K-7073-2015	Aung, Phyu/0000-0002-3398-0573	Melanoma Research Alliance; Melanoma Research Foundation; NATIONAL CANCER INSTITUTE [R33CA106709] Funding Source: NIH RePORTER	Melanoma Research Alliance; Melanoma Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	NW is a Sidney Kimmel Scholar for translational Cancer research and is supported by a team science award from Melanoma Research Alliance and a Career Development Award from Melanoma Research Foundation. NW and YK are members of the Yale Cancer Center.	Alcocer-Gonzalez JM, 2006, VIRAL IMMUNOL, V19, P481, DOI 10.1089/vim.2006.19.481; Blank C, 2007, CANCER IMMUNOL IMMUN, V56, P739, DOI 10.1007/s00262-006-0272-1; Brandl C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010800; Burikhanov R, 2009, CELL, V138, P377, DOI 10.1016/j.cell.2009.05.022; Caamano J, 2002, CLIN MICROBIOL REV, V15, P414, DOI 10.1128/CMR.15.3.414-429.2002; Cimica V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020188; Cozar Jose Manuel, 2008, J Med Case Rep, V2, P111, DOI 10.1186/1752-1947-2-111; Dadzie OE, 2009, BRIT J DERMATOL, V160, P368, DOI 10.1111/j.1365-2133.2008.08887.x; Dan HC, 2008, GENE DEV, V22, P1490, DOI 10.1101/gad.1662308; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Donia M, 2012, ONCOIMMUNOLOGY, V1, P1476, DOI 10.4161/onci.21940; Greene VR, 2009, J INVEST DERMATOL, V129, P1483, DOI 10.1038/jid.2008.374; Hart JR, 2011, P NATL ACAD SCI USA, V108, P13247, DOI 10.1073/pnas.1110486108; Khalaf H, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-26; Knight DA, 2013, J CLIN INVEST, V123, P1371, DOI 10.1172/JCI66236; Lengagne R, 2008, J IMMUNOL, V180, P130, DOI 10.4049/jimmunol.180.1.130; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li N, 2011, CANCER CELL, V19, P429, DOI 10.1016/j.ccr.2011.03.018; Liu L, 2005, P NATL ACAD SCI USA, V102, P8150, DOI 10.1073/pnas.0501643102; Loots GG, 2004, NUCLEIC ACIDS RES, V32, pW217, DOI 10.1093/nar/gkh383; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lund TC, 1999, CELL SIGNAL, V11, P789, DOI 10.1016/S0898-6568(99)00045-5; Mihm MC, 1996, LAB INVEST, V74, P43; Nguyen LT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013940; Nogueira C, 2010, ONCOGENE, V29, P6222, DOI 10.1038/onc.2010.349; O'Shea JJ, 2002, NAT REV IMMUNOL, V2, P37, DOI 10.1038/nri702; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Rosso Ritchie, 2009, J Invest Dermatol, V129, P1318, DOI 10.1038/jid.2009.107; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Santra MK, 2009, NATURE, V459, P722, DOI 10.1038/nature08011; Sumimoto H, 2006, J EXP MED, V203, P1651, DOI 10.1084/jem.20051848; Tsao H, 2003, J AM ACAD DERMATOL, V49, P865, DOI 10.1016/S0190-9622(03)02473-3; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Witten IH, 2011, MOR KAUF D, P1; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936	40	64	66	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2014	33	38					4632	4642		10.1038/onc.2013.409	http://dx.doi.org/10.1038/onc.2013.409			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3VX	24141770				2022-12-28	WOS:000342007200002
J	Cagnet, S; Faraldo, MM; Kreft, M; Sonnenberg, A; Raymond, K; Glukhova, MA				Cagnet, S.; Faraldo, M. M.; Kreft, M.; Sonnenberg, A.; Raymond, K.; Glukhova, M. A.			Signaling events mediated by alpha 3 beta 1 integrin are essential for mammary tumorigenesis	ONCOGENE			English	Article						integrin signaling; basal-like breast cancer; mouse models of breast cancer; Wnt/beta-catenin pathway; survival; proliferation	FOCAL ADHESION KINASE; BREAST-CANCER CELLS; GENE-EXPRESSION; EPITHELIAL-CELLS; PATHWAY ACTIVATION; BASAL; SURVIVAL; DIFFERENTIATION; LOCALIZATION; PROGENITORS	The constitutive activation of beta-catenin signaling in the mammary basal epithelial cell layer in transgenic K5 Delta N beta cat mice leads to basal-type tumor development. Integrins of the beta 1 family and integrin-mediated signaling events have an important role in breast tumor growth and progression. We show here that the deletion of alpha 3 beta 1 integrin, a major laminin receptor, from the basal layer of the mammary epithelium of K5 Delta N beta cat mice completely prevented the tumorigenesis induced by beta-catenin signaling. Moreover, the depletion of alpha 3 beta 1 integrin from a spontaneously transformed mouse mammary basal epithelial cell line (MEC) prevented the cells from forming colonies in soft agar and greatly reduced tumor development in orthotopic grafts. Inhibition of the integrin signaling intermediates Rac1 or PAK1 (P21-activated Kinase 1) in MEC affected tumor cell growth in soft agar, whereas the expression of activated forms of these effectors in alpha 3-depleted cells rescued the capacity of these cells to grow in non-adherent conditions. Similarly, the tumorigenic potential of alpha 3-depleted cells was restored by the expression of activated PAK1, as assessed by orthotopic transplantation assay. In three-dimensional Matrigel culture, MEC survival and proliferation were affected by the depletion of alpha 3 beta 1 integrin, which also significantly decreased the activation of focal adhesion kinase (FAK), mitogen-activated protein kinase (MAPK) and c-Jun NH2-terminal kinase (JNK). Our data suggest that the activation of signaling cascades downstream from alpha 3 beta 1 and involving the Rac1/PAK1 pathway, MAPK and JNK, promotes prosurvival and proproliferative signals required for the malignant growth of basal mammary epithelial cells, providing further insight into the molecular mechanisms underlying breast cancer initiation and progression.	[Cagnet, S.; Faraldo, M. M.; Raymond, K.; Glukhova, M. A.] Inst Curie, Ctr Rech, Paris, France; [Cagnet, S.; Faraldo, M. M.; Raymond, K.; Glukhova, M. A.] Inst Curie, CNRS, UMR144, Sect Rech, Paris, France; [Kreft, M.; Sonnenberg, A.] Netherlands Canc Inst, Div Cell Biol, Amsterdam, Netherlands	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Netherlands Cancer Institute	Raymond, K (corresponding author), Univ Paris 06, St Antoine Res Ctr, INSERM U938, F-75005 Paris, France.	karine.raymond@inserm.fr; marina.glukhova@curie.fr	Martin-Faraldo, Maria-Luisa/M-5811-2018; Raymond, Karine/E-2693-2017	Raymond, Karine/0000-0001-5892-8117; Faraldo, Marisa/0000-0001-9497-1171	La Ligue Nationale Contre le Cancer; Agence Nationale de la Recherche [ANR-08-BLAN-0078-01]; Association pour la Recherche sur le Cancer	La Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Agence Nationale de la Recherche(French National Research Agency (ANR)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council)	We are particularly grateful to Dr JL Jorcano for providing K5Cre transgenic mice. We thank Dr I Grandjean and S Jannet for excellent assistance with animal care, Z Maciorowski, A Viguier and S Grondin for excellent assistance with FACS analyses and M Denoyelle and A Di Cicco for technical help. We also thank the Nikon Imaging Centre at Institut Curie-CNRS for providing confocal microscopy facilities. This work was supported by La Ligue Nationale Contre le Cancer (Equipe Labelisee e 2009, 2013) and a grant from the Agence Nationale de la Recherche ANR-08-BLAN-0078-01 to MAG. SC received funding from Association pour la Recherche sur le Cancer; MAG is Directeur de Recherche and MMF and KR are Charge de Recherche at the Institut National de la Sante et de la Recherche Medicale (INSERM).	Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Bertucci F, 2012, CURR MOL MED, V12, P96, DOI 10.2174/156652412798376134; Bianchi-Smiraglia A, 2013, ONCOGENE, V32, P3049, DOI 10.1038/onc.2012.320; Cabodi S, 2010, NAT REV CANCER, V10, P858, DOI 10.1038/nrc2967; Cance WG, 2000, CLIN CANCER RES, V6, P2417; Choma DP, 2007, J INVEST DERMATOL, V127, P31, DOI 10.1038/sj.jid.5700505; Choma DP, 2004, J CELL SCI, V117, P3947, DOI 10.1242/jcs.01251; Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Huveneers S, 2009, J CELL SCI, V122, P1059, DOI 10.1242/jcs.039446; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; JONJIC N, 1993, PATHOL RES PRACT, V189, P979; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; Lahlou H, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2905; Lambert Arthur W, 2012, ISRN Oncol, V2012, P493283, DOI 10.5402/2012/493283; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005; Manohar A, 2004, J CELL SCI, V117, P4043, DOI 10.1242/jcs.01277; Margadant C, 2009, J CELL SCI, V122, P278, DOI 10.1242/jcs.029108; Mitchell K, 2010, CANCER RES, V70, P6359, DOI 10.1158/0008-5472.CAN-09-4283; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Morini M, 2000, INT J CANCER, V87, P336, DOI 10.1002/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3; Moumen M, MOL CANC; Moumen M, 2012, STEM CELLS, V30, P1246, DOI 10.1002/stem.1090; Novitskaya V, 2010, CANCER RES, V70, P4698, DOI 10.1158/0008-5472.CAN-09-4330; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; Prat A, 2012, NAT REV CLIN ONCOL, V9, P48, DOI 10.1038/nrclinonc.2011.178; Pylayeva Y, 2009, J CLIN INVEST, V119, P252, DOI 10.1172/JCI37160; Ramirez A, 2004, GENESIS, V39, P52, DOI 10.1002/gene.20025; Raymond K, 2005, J CELL SCI, V118, P1045, DOI 10.1242/jcs.01689; Raymond K, 2012, SEMIN CELL DEV BIOL, V23, P599, DOI 10.1016/j.semcdb.2012.03.008; Raymond K, 2011, EMBO J, V30, P1896, DOI 10.1038/emboj.2011.113; Reis JS, 2011, LANCET, V378, P1812, DOI 10.1016/S0140-6736(11)61539-0; Roskoski R, 2012, PHARMACOL RES, V66, P105, DOI 10.1016/j.phrs.2012.04.005; Sachs N, 2006, J CELL BIOL, V175, P33, DOI 10.1083/jcb.200603073; Sachs N, 2012, P NATL ACAD SCI USA, V109, P21468, DOI 10.1073/pnas.1204614110; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Streuli CH, 2009, BIOCHEM J, V418, P491, DOI 10.1042/BJ20081948; Subbaram S, 2011, EXPERT OPIN THER TAR, V15, P1197, DOI 10.1517/14728222.2011.609557; Taddei I, 2003, J MAMMARY GLAND BIOL, V8, P383, DOI 10.1023/B:JOMG.0000017426.74915.b9; Taddei I, 2008, NAT CELL BIOL, V10, P716, DOI 10.1038/ncb1734; Teuliere J, 2005, DEVELOPMENT, V132, P267, DOI 10.1242/dev.01583; Yao ES, 2007, CANCER RES, V67, P659, DOI 10.1158/0008-5472.CAN-06-2768; Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020	49	39	40	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2014	33	34					4286	4295		10.1038/onc.2013.391	http://dx.doi.org/10.1038/onc.2013.391			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MK	24077284				2022-12-28	WOS:000341156900002
J	Roh-Johnson, M; Bravo-Cordero, JJ; Patsialou, A; Sharma, VP; Guo, P; Liu, H; Hodgson, L; Condeelis, J				Roh-Johnson, M.; Bravo-Cordero, J. J.; Patsialou, A.; Sharma, V. P.; Guo, P.; Liu, H.; Hodgson, L.; Condeelis, J.			Macrophage contact induces RhoA GTPase signaling to trigger tumor cell intravasation	ONCOGENE			English	Article						cancer; tumor cell intravasation; macrophages; RhoA biosensor; invadopodia; heterotypic cell contact	EXTRACELLULAR-MATRIX DEGRADATION; TRANSENDOTHELIAL MIGRATION; E-SELECTIN; ENDOTHELIAL-CELLS; CANCER-CELLS; MAMMARY-TUMORS; BREAST-CANCER; IN-VIVO; TYROSINE PHOSPHORYLATION; MELANOMA-CELLS	Most cancer patients die as a result of metastasis, thus it is important to understand the molecular mechanisms of dissemination, including intra- and extravasation. Although the mechanisms of extravasation have been vastly studied in vitro and in vivo, the process of intravasation is still unclear. Furthermore, how cells in the tumor microenvironment facilitate tumor cell intravasation is still unknown. Using high-resolution imaging, we found that macrophages enhance tumor cell intravasation upon physical contact. Macrophage and tumor cell contact induce RhoA activity in tumor cells, triggering the formation of actin-rich degradative protrusions called invadopodia, enabling tumor cells to degrade and break through matrix barriers during tumor cell transendothelial migration. Interestingly, we show that macrophage-induced invadopodium formation and tumor cell intravasation also occur in patient-derived tumor cells and in vivo models, revealing a conserved mechanism of tumor cell intravasation. Our results illustrate a novel heterotypic cell contact-mediated signaling role for RhoA, as well as yield mechanistic insight into the ability of cells within the tumor microenvironment to facilitate steps of the metastatic cascade.	[Roh-Johnson, M.; Bravo-Cordero, J. J.; Patsialou, A.; Sharma, V. P.; Guo, P.; Hodgson, L.; Condeelis, J.] Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; [Roh-Johnson, M.; Bravo-Cordero, J. J.; Patsialou, A.; Sharma, V. P.; Guo, P.; Hodgson, L.; Condeelis, J.] Gruss Lipper Biophoton Ctr, Bronx, NY USA; [Liu, H.] Univ Chicago, Ben May Dept Canc Res, Chicago, IL USA	Yeshiva University; Albert Einstein College of Medicine; University of Chicago	Roh-Johnson, M (corresponding author), Yeshiva Univ Albert Einstein Coll Med, 1300 Morris Pk Ave,Price Ctr 208, Bronx, NY 10461 USA.	minna.roh@einstein.yu.edu	Guo, Peng/E-9858-2015	Bravo-Cordero, Jose Javier/0000-0001-9481-1231; Liu, Huiping/0000-0003-4822-7995; Sharma, Ved P/0000-0001-9998-5070; Hodgson, Louis/0000-0001-9188-7580	NIH [CA150344, CA100324, GM093121, CA159663]; Susan G. Komen for the Cure(C) [KG111405]; FOGARTY INTERNATIONAL CENTER [D43TW001429] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA150344, P01CA100324, U54CA163131, P30CA013330, F32CA159663] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM093121] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G. Komen for the Cure(C); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Brian Beaty for advice regarding invadopodium experiments; David Entenberg, Vera Desmarais, Jeffrey Wyckoff and the Analytical Imaging Facility for help with microscopy; Richard Stanley, Fernando Macian, Esther Arwert, Allison Harney and Veronika Micolski for guidance and reagents; Yarong Wang for help with animal injections; and the Albert Einstein shRNA Core, the Flow Cytometry Core facility and the Histology and Comparative Pathology Core for help with experiments. We also thank Jeffrey Segall, Dianne Cox, Anne Bresnick and Aviv Bergmann for helpful discussions, and the Condeelis, Segall, Cox and Hodgson labs for advice and reagents. This work was funded by NIH CA150344 (JC), NIH CA100324 (AP), NIH GM093121 (LH and JJB-C), Post-doctoral fellowship from Susan G. Komen for the Cure (c) KG111405 (VPS) and NIH CA159663 (MRJ).	Arthur WT, 2002, BIOL RES, V35, P239, DOI 10.4067/S0716-97602002000200016; Beaty BT, 2013, MOL BIOL CELL, V24, P1661, DOI 10.1091/mbc.E12-12-0908; Blouw B, 2008, EUR J CELL BIOL, V87, P555, DOI 10.1016/j.ejcb.2008.02.008; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Bravo-Cordero JJ, 2007, EMBO J, V26, P1499, DOI 10.1038/sj.emboj.7601606; Bravo-Cordero JJ, 2011, CURR BIOL, V21, P635, DOI 10.1016/j.cub.2011.03.039; Carmona-Fontaine C, 2008, NATURE, V456, P957, DOI 10.1038/nature07441; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; DAS SK, 1981, BLOOD, V58, P630; Gil-Henn H, 2013, ONCOGENE, V32, P2622, DOI 10.1038/onc.2012.284; Gligorijevic B, 2012, J CELL SCI, V125, P724, DOI 10.1242/jcs.092726; Haidari M, 2012, J BIOL CHEM, V287, P32981, DOI 10.1074/jbc.M112.395905; Haidari M, 2011, CARDIOVASC RES, V92, P456, DOI 10.1093/cvr/cvr240; Hu YY, 2001, J BIOL CHEM, V276, P48549, DOI 10.1074/jbc.M105513200; Hu YY, 2000, J IMMUNOL, V165, P2142, DOI 10.4049/jimmunol.165.4.2142; Jin FY, 2012, MOL CANCER RES, V10, P1021, DOI 10.1158/1541-7786.MCR-11-0498; KOOP S, 1995, CANCER RES, V55, P2520; KRAMER RH, 1979, P NATL ACAD SCI USA, V76, P5704, DOI 10.1073/pnas.76.11.5704; Laferriere J, 2001, J BIOL CHEM, V276, P33762, DOI 10.1074/jbc.M008564200; Lessey EC, 2012, BIOCHEMISTRY-US, V51, P7420, DOI 10.1021/bi300758e; Li B, 2006, FEBS LETT, V580, P4252, DOI 10.1016/j.febslet.2006.06.056; Linder S, 2011, ANNU REV CELL DEV BI, V27, P185, DOI 10.1146/annurev-cellbio-092910-154216; Lipschutz JH, 2001, CURR PROTOC CELL BIO; Liu HP, 2010, P NATL ACAD SCI USA, V107, P18115, DOI 10.1073/pnas.1006732107; Lovett DH, 2010, BIOCHEM BIOPH RES CO, V398, P482, DOI 10.1016/j.bbrc.2010.06.104; Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432; Magalhaes MAO, 2011, J CELL BIOL, V195, P903, DOI 10.1083/jcb.201103045; McGhee Ewan J, 2011, Small GTPases, V2, P239; Nethe M, 2012, J CELL SCI, V125, P3430, DOI 10.1242/jcs.100925; NICOLSON GL, 1982, J HISTOCHEM CYTOCHEM, V30, P214, DOI 10.1177/30.3.7061823; OHIGASHI H, 1989, JPN J CANCER RES, V80, P818, DOI 10.1111/j.1349-7006.1989.tb01720.x; Omelchenko T, 2012, CURR BIOL, V22, P278, DOI 10.1016/j.cub.2012.01.014; Oser M, 2010, J CELL SCI, V123, P3662, DOI 10.1242/jcs.068163; Patsialou A, 2013, INTRAVITAL IN PRESS; Patsialou A, 2009, CANCER RES, V69, P9498, DOI 10.1158/0008-5472.CAN-09-1868; Pertz O, 2006, NATURE, V440, P1069, DOI 10.1038/nature04665; Ponik SM, 2013, MOL BIOL CELL, V24, P1688, DOI 10.1091/mbc.E12-05-0386; Proebstl D, 2012, J EXP MED, V209, P1219, DOI 10.1084/jem.20111622; Reymond N, 2012, J CELL BIOL, V199, P653, DOI 10.1083/jcb.201205169; Reymond N, 2012, METHODS MOL BIOL, V827, P123, DOI 10.1007/978-1-61779-442-1_9; Robinson BD, 2009, CLIN CANCER RES, V15, P2433, DOI 10.1158/1078-0432.CCR-08-2179; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Roussos ET, 2011, J CELL SCI, V124, P2120, DOI 10.1242/jcs.086231; Sakurai-Yageta M, 2008, J CELL BIOL, V181, P985, DOI 10.1083/jcb.200709076; Saltel F, 2011, EUR J CELL BIOL, V90, P100, DOI 10.1016/j.ejcb.2010.05.011; Seals DF, 2005, CANCER CELL, V7, P155, DOI 10.1016/j.ccr.2005.01.006; Sharma VP, 2008, J LEUKOCYTE BIOL, V84, P440, DOI 10.1189/jlb.0907636; Sharma VP, 2013, METHODS MOL BIOL, V1046, P343, DOI 10.1007/978-1-62703-538-5_21; Spiering D, 2012, METHODS MOL BIOL, V827, P215, DOI 10.1007/978-1-61779-442-1_15; Stoletov K, 2007, P NATL ACAD SCI USA, V104, P17406, DOI 10.1073/pnas.0703446104; Timpson P, 2011, CANCER RES, V71, P747, DOI 10.1158/0008-5472.CAN-10-2267; Tremblay PL, 2006, ONCOGENE, V25, P6563, DOI 10.1038/sj.onc.1209664; Voura EB, 1998, MICROSC RES TECHNIQ, V43, P265, DOI 10.1002/(SICI)1097-0029(19981101)43:3<265::AID-JEMT9>3.0.CO;2-Z; Voura EB, 1998, CELL TISSUE RES, V293, P375, DOI 10.1007/s004410051129; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; Weiss TW, 2004, J MOL CELL CARDIOL, V36, P539, DOI 10.1016/j.yjmcc.2004.02.001; Witzel S, 2006, J CELL BIOL, V175, P791, DOI 10.1083/jcb.200606017; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823; Yamaguchi H, 2012, EUR J CELL BIOL, V91, P902, DOI 10.1016/j.ejcb.2012.04.005; Yoshida M, 2003, ARTERIOSCL THROM VAS, V23, P783, DOI 10.1161/01.ATV.0000067427.40133.59; Yu WF, 2008, J LEUKOCYTE BIOL, V84, P852, DOI 10.1189/jlb.0308171; Zervantonakis IK, 2012, P NATL ACAD SCI USA, V109, P13515, DOI 10.1073/pnas.1210182109	63	109	112	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2014	33	33					4203	4212		10.1038/onc.2013.377	http://dx.doi.org/10.1038/onc.2013.377			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MB	24056963	Green Accepted			2022-12-28	WOS:000341155800002
J	Bessede, E; Staedel, C; Amador, LAA; Nguyen, PH; Chambonnier, L; Hatakeyama, M; Belleannee, G; Megraud, F; Varon, C				Bessede, E.; Staedel, C.; Amador, L. A. Acuna; Nguyen, P. H.; Chambonnier, L.; Hatakeyama, M.; Belleannee, G.; Megraud, F.; Varon, C.			Helicobacter pylori generates cells with cancer stem cell properties via epithelial-mesenchymal transition-like changes	ONCOGENE			English	Article						gastric cancer; infection; CD44	GASTRIC-CANCER; INCREASED RISK; CAGA PROTEIN; IDENTIFICATION; EXPRESSION; INFECTION; CD44	Helicobacter pylori infection is the major risk factor for gastric adenocarcinoma. The link with gastric adenocarcinoma is partly due to the H. pylori CagA oncoprotein. CagA is responsible for a particular cell phenotype in vitro, the 'hummingbird' phenotype, that corresponds to an elongation of the cells, mimicking an epithelial-mesenchymal transition (EMT). EMT participates in the carcinogenesis process, and is involved in the generation of cancer stem cells (CSCs). However, its involvement in gastric carcinogenesis has yet not been studied. Therefore, the aim of this study was to determine the role of H. pylori in EMT and in the emergence of gastric CSCs. For this purpose, gastric epithelial cells were cocultured with a cagA-positive H. pylori strain or its isogenic-deleted mutants or were transfected with CagA expression vectors. Study of the expression of epithelial and mesenchymal markers showed that H. pylori, via CagA, is responsible for an EMT phenotype associated with an increase in mesenchymal markers as well as CD44 expression, a known gastric CSC marker. Moreover, infection led to an increased ability to migrate, to invade and to form tumorspheres. Cell sorting experiments showed that only the CD44(high) cells induced by H. pylori infection displayed the mesenchymal phenotype and CSC properties in vitro, and had higher tumorigenic properties than CD44(low) cells in xenografted mice. Immunohistochemistry analyses on human and mouse gastric mucosa tissue samples confirmed a high expression of CD44 and mesenchymal markers in H. pylori-infected cases, and in gastric dysplasia and carcinoma. All of these data suggest that H. pylori, via CagA, unveils CSC-like properties by induction of EMT-like changes in gastric epithelial cells.	[Bessede, E.; Amador, L. A. Acuna; Nguyen, P. H.; Chambonnier, L.; Megraud, F.; Varon, C.] Univ Bordeaux, Bacteriol Lab, F-33000 Bordeaux, France; [Bessede, E.; Amador, L. A. Acuna; Nguyen, P. H.; Chambonnier, L.; Megraud, F.; Varon, C.] INSERM, U853, Bordeaux, France; [Staedel, C.] Univ Bordeaux, RNA Nat & Artificial Regulat ARNA Lab, F-33000 Bordeaux, France; [Staedel, C.] INSERM, U869, Bordeaux, France; [Hatakeyama, M.] Univ Tokyo, Grad Sch Med, Div Microbiol, Tokyo, Japan; [Belleannee, G.] Univ Hosp Ctr, Haut Leveque Hosp, Dept Pathol, Bordeaux, France	UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Tokyo; CHU Bordeaux	Bessede, E (corresponding author), Univ Bordeaux, INSERM, Bacteriol Lab, U853, F-33000 Bordeaux, France.	emilie.bessede@chu-bordeaux.fr	STAEDEL, Cathy/M-7284-2014	Varon, Christine/0000-0003-4026-2016; Acuna-Amador, Luis/0000-0003-1009-3020; Staedel, Cathy/0000-0003-0488-0239	French 'Association pour la Recherche contre le Cancer' [8412]; Institut du Cancer [07/3D1616/IABC-23-12/NC-NG]; Conseil Regional d'Aquitaine [20071301017, 20081302203]	French 'Association pour la Recherche contre le Cancer'(Fondation ARC pour la Recherche sur le Cancer); Institut du Cancer(Institut National du Cancer (INCA) France); Conseil Regional d'Aquitaine(Region Nouvelle-Aquitaine)	This project was supported by the French 'Association pour la Recherche contre le Cancer' (grant number 8412), 'Institut du Cancer' (grant number 07/3D1616/IABC-23-12/NC-NG), 'Conseil Regional d'Aquitaine' (grant number 20071301017 and 20081302203). We thank D Collet (Digestive Surgery of Hospital Haut-Leveque, University Hospital Center of Bordeaux, France) and Professor JP Merlio (Tumor Bank of University Hospital Center of Bordeaux, France) for providing human gastric tissue samples from consenting patients. We thank A Giese (EA2406, Bordeaux, France), B Rousseau (level 2 animal facilities, Universite de Bordeaux), V Pitard and S Gonzalez (cytometry platform, Universite de Bordeaux), A Menard, M Alibert, E Siffre and L Biguet for technical support.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; Backert S, 2001, MOL MICROBIOL, V42, P631, DOI 10.1046/j.1365-2958.2001.02649.x; Backert S, 2008, CELL MICROBIOL, V10, P1573, DOI 10.1111/j.1462-5822.2008.01156.x; Baud J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060315; Bellizzi A, 2013, J CELL PHYSIOL, V228, P408, DOI 10.1002/jcp.24145; BLASER MJ, 1995, CANCER RES, V55, P2111; Ferrand J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029007; Franco AT, 2008, CANCER RES, V68, P379, DOI 10.1158/0008-5472.CAN-07-0824; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Gwack J, 2006, BRIT J CANCER, V95, P639, DOI 10.1038/sj.bjc.6603309; Hao JL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040716; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; IARC, 1994, IARC MON EV CARC RIS, V61, P177; Klarmann GJ, 2009, CLIN EXP METASTAS, V26, P433, DOI 10.1007/s10585-009-9242-2; Kure S, 2012, INT J ONCOL, V41, P1314, DOI 10.3892/ijo.2012.1565; Li CW, 2009, METHODS MOL BIOL, V568, P161, DOI 10.1007/978-1-59745-280-9_10; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Meng EH, 2012, CLIN EXP METASTAS, V29, P939, DOI 10.1007/s10585-012-9482-4; Mitsuno Y, 2001, GUT, V49, P18, DOI 10.1136/gut.49.1.18; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Murata-Kamiya N, 2007, ONCOGENE, V26, P4617, DOI 10.1038/sj.onc.1210251; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Ohnishi N, 2008, P NATL ACAD SCI USA, V105, P1003, DOI 10.1073/pnas.0711183105; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Saito Y, 2010, J EXP MED, V207, P2157, DOI 10.1084/jem.20100602; Su YJ, 2011, EMBO J, V30, P3186, DOI 10.1038/emboj.2011.211; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Varon C, 2009, GUT, V58, P629, DOI 10.1136/gut.2007.144501; Varon C, 2012, GASTROENTEROLOGY, V142, P281, DOI 10.1053/j.gastro.2011.10.036; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yin YF, 2010, GUT, V59, P1037, DOI 10.1136/gut.2009.199794	33	116	125	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2014	33	32					4123	4131		10.1038/onc.2013.380	http://dx.doi.org/10.1038/onc.2013.380			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YK	24096479				2022-12-28	WOS:000340595700003
J	Shain, KH; Tao, J				Shain, K. H.; Tao, J.			The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies	ONCOGENE			English	Review						BCR; microenviroment; lymphoma; drug resistance	CHRONIC LYMPHOCYTIC-LEUKEMIA; SPLEEN TYROSINE KINASE; NF-KAPPA-B; BONE-MARROW MICROENVIRONMENT; MULTIPLE-MYELOMA; STROMAL CELLS; MANTLE-CELL; THERAPEUTIC TARGET; ACTIVATING FACTOR; TUMOR-CELLS	Specific niches within the lymphoma tumor microenvironment (TME) provide sanctuary for subpopulations of tumor cells through stromal cell-tumor cell interactions. These interactions notably dictate growth, response to therapy and resistance of residual malignant B cells to therapeutic agents. This minimal residual disease (MRD) remains a major challenge in the treatment of B-cell malignancies and contributes to subsequent disease relapse. B-cell receptor (BCR) signaling has emerged as essential mediator of B-cell homing, survival and environment-mediated drug resistance (EMDR). Central to EMDR are chemokine- and integrin-mediated interactions between lymphoma and the TME. Further, stromal cell-B cell adhesion confers a sustained BCR signaling leading to chemokine and integrin activation. Recently, the inhibitors of BCR signaling have garnered a substantial clinical interest because of their effectiveness in B-cell disorders. The efficacy of these agents is, at least in part, attributed to attenuation of BCR-dependent lymphoma-TME interactions. In this review, we discuss the pivotal role of BCR signaling in the integration of intrinsic and extrinsic determinants of TME-mediated lymphoma survival and drug resistance.	[Shain, K. H.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Med Program, Tampa, FL 33612 USA; [Shain, K. H.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol & Chem Biol, Tampa, FL 33612 USA; [Tao, J.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Hematopathol, Tampa, FL 33612 USA; [Tao, J.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Lab Med & Chem Biol, Tampa, FL 33612 USA; [Tao, J.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Med Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Tao, J (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Med Program, Tampa, FL 33612 USA.	Jianguo.Tao@moffitt.org			NCI NIH HHS [P30 CA076292] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA076292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Advani RH, 2013, J CLIN ONCOL, V31, P88, DOI 10.1200/JCO.2012.42.7906; Arana E, 2008, J CELL SCI, V121, P2279, DOI 10.1242/jcs.017905; Attal M, 2012, NEW ENGL J MED, V366, P1782, DOI 10.1056/NEJMoa1114138; Azab AK, 2012, BLOOD, V119, P5782, DOI 10.1182/blood-2011-09-380410; Azab AK, 2009, BLOOD, V114, P619, DOI 10.1182/blood-2009-01-199281; Azab AK, 2009, BLOOD, V113, P4341, DOI 10.1182/blood-2008-10-186668; Baran-Marszak F, 2010, HAEMATOL-HEMATOL J, V95, P1865, DOI 10.3324/haematol.2009.019745; Bossen C, 2008, BLOOD, V111, P1004, DOI 10.1182/blood-2007-09-110874; Buchner M, 2009, CANCER RES, V69, P5424, DOI 10.1158/0008-5472.CAN-08-4252; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Burger JA, 2012, CURR OPIN ONCOL, V24, P643, DOI 10.1097/CCO.0b013e3283589950; Burger JA, 2009, BLOOD, V114, P3367, DOI 10.1182/blood-2009-06-225326; Byrd JC, 2012, BLOOD, V120, P21; Carrasco YR, 2006, EMBO J, V25, P889, DOI 10.1038/sj.emboj.7600944; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; de Gorter DJJ, 2007, IMMUNITY, V26, P93, DOI 10.1016/j.immuni.2006.11.012; de Gorter DJJ, 2007, J IMMUNOL, V178, P1405, DOI 10.4049/jimmunol.178.3.1405; de la Fuente MT, 1999, LEUKEMIA, V13, P266, DOI 10.1038/sj.leu.2401275; de Rooij MFM, 2012, BLOOD, V119, P2590, DOI 10.1182/blood-2011-11-390989; Do RKG, 2000, J EXP MED, V192, P953, DOI 10.1084/jem.192.7.953; Friedberg JW, 2010, BLOOD, V115, P2578, DOI 10.1182/blood-2009-08-236471; Gilbert LA, 2012, GENE DEV, V26, P1758, DOI 10.1101/gad.197590.112; Gilbert LA, 2010, CELL, V143, P355, DOI 10.1016/j.cell.2010.09.043; Gross JA, 2000, NATURE, V404, P995, DOI 10.1038/35010115; Grzesiak JJ, 2007, SURGERY, V141, P804, DOI 10.1016/j.surg.2006.12.016; Hall BM, 2004, CANCER LETT, V207, P229, DOI 10.1016/j.canlet.2003.10.033; Hall BM, 2004, LEUKEMIA LYMPHOMA, V45, P35, DOI 10.1080/1042819031000139620; Hallek M, 1997, EXP HEMATOL, V25, P1367; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Herman SEM, 2012, ASH ANN M, V120, P185; Herreros B, 2008, LEUKEMIA, V22, P49, DOI 10.1038/sj.leu.2404970; Hoellenriegel J, 2012, LEUKEMIA, V26, P1576, DOI 10.1038/leu.2012.24; Hoellenriegel J., 2012, ASH ANN M, V120, P186; Hoellenriegel J, 2011, BLOOD, V118, P3603, DOI 10.1182/blood-2011-05-352492; Ikeda H, 2010, BLOOD, V116, P1460, DOI 10.1182/blood-2009-06-222943; Kern C, 2004, BLOOD, V103, P679, DOI 10.1182/blood-2003-02-0540; Khare SD, 2000, P NATL ACAD SCI USA, V97, P3370, DOI 10.1073/pnas.050580697; Kurtova AV, 2009, BLOOD, V114, P4441, DOI 10.1182/blood-2009-07-233718; Lam KP, 1998, P NATL ACAD SCI USA, V95, P13171, DOI 10.1073/pnas.95.22.13171; Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315; Lannutti BJ, 2011, BLOOD, V117, P591, DOI 10.1182/blood-2010-03-275305; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Lu Y, 2004, CLIN EXP METASTAS, V21, P399, DOI 10.1007/s10585-005-0056-6; Lwin T, 2007, LEUKEMIA, V21, P1521, DOI 10.1038/sj.leu.2404723; Lwin T, 2009, LEUKEMIA, V23, P170, DOI 10.1038/leu.2008.266; Lwin T, 2007, BLOOD, V110, P1631, DOI 10.1182/blood-2006-11-060350; Mackay F, 1999, J EXP MED, V190, P1697, DOI 10.1084/jem.190.11.1697; McCaig AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048929; McCarthy PL, 2012, NEW ENGL J MED, V366, P1770, DOI 10.1056/NEJMoa1114083; McMillin DW, 2010, NAT MED, V16, P483, DOI 10.1038/nm.2112; Medina DJ, 2012, HAEMATOL-HEMATOL J, V97, P1255, DOI 10.3324/haematol.2011.040659; Moreaux J, 2004, BLOOD, V103, P3148, DOI 10.1182/blood-2003-06-1984; Ngo HT, 2008, BLOOD, V112, P150, DOI 10.1182/blood-2007-12-129395; Niedermeier M, 2009, BLOOD, V113, P5549, DOI 10.1182/blood-2008-06-165068; Pedersen IM, 2002, BLOOD, V100, P1795, DOI 10.1182/blood.V100.5.1795.h81702001795_1795_1801; Perez LE, 2008, J IMMUNOL, V180, P1545, DOI 10.4049/jimmunol.180.3.1545; Quiroga MP, 2009, BLOOD, V114, P1029, DOI 10.1182/blood-2009-03-212837; Rushworth SA, 2013, CELL SIGNAL, V25, P106, DOI 10.1016/j.cellsig.2012.09.008; Saito K, 2003, IMMUNITY, V19, P669, DOI 10.1016/S1074-7613(03)00297-8; Sanz-Rodriguez F, 2001, BLOOD, V97, P346, DOI 10.1182/blood.V97.2.346; Schweighoffer E, 2013, IMMUNITY, V38, P475, DOI 10.1016/j.immuni.2012.11.015; Shain KH, 2009, EXPERT REV HEMATOL, V2, P649, DOI [10.1586/ehm.09.55, 10.1586/EHM.09.55]; Shain KH, 2009, CANCER RES, V69, P1009, DOI 10.1158/0008-5472.CAN-08-2419; Shain KH, 2001, MOL CANCER THER, V1, P69; Shapiro-Shelef M, 2005, NAT REV IMMUNOL, V5, P230, DOI 10.1038/nri1572; Spaargaren M, 2003, J EXP MED, V198, P1539, DOI 10.1084/jem.20011866; Staudt LM, 2012, ASH ANN M, V120, pSCI; Stein R, 2010, BLOOD, V115, P5180, DOI 10.1182/blood-2009-06-228288; Tai YT, 2012, BLOOD, V120, P1877, DOI 10.1182/blood-2011-12-396853; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Thiel S, 2000, FEBS LETT, V470, P15, DOI 10.1016/S0014-5793(00)01276-X; Vij R, 2012, BLOOD, V120, P21; Vora KA, 2003, J IMMUNOL, V171, P547, DOI 10.4049/jimmunol.171.2.547; Woyach JA, 2012, BLOOD, V120, P1175, DOI 10.1182/blood-2012-02-362624; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Young RM, 2013, NAT REV DRUG DISCOV, V12, P229, DOI 10.1038/nrd3937; Zhang L, 2012, BLOOD, V120, P3783, DOI 10.1182/blood-2012-04-424630	81	22	23	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2014	33	32					4107	4113		10.1038/onc.2013.379	http://dx.doi.org/10.1038/onc.2013.379			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YK	24037527	Green Accepted			2022-12-28	WOS:000340595700001
J	Weizman, N; Krelin, Y; Shabtay-Orbach, A; Amit, M; Binenbaum, Y; Wong, RJ; Gil, Z				Weizman, N.; Krelin, Y.; Shabtay-Orbach, A.; Amit, M.; Binenbaum, Y.; Wong, R. J.; Gil, Z.			Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase	ONCOGENE			English	Article						pancreatic ductal adenocarcinoma; chemotherapy; gemcitabine; resistance; macrophages; cytidine deaminase	PHASE-III TRIAL; TUMOR MICROENVIRONMENT; CELL-MIGRATION; DUCTAL ADENOCARCINOMA; DRUG-RESISTANCE; BREAST-CANCER; MOUSE MODEL; EXPRESSION; INVASION; CHEMOTHERAPY	Resistance to pharmacologic agents used in chemotherapy is common in most human carcinomas, including pancreatic ductal adenocarcinoma (PDA), which is resistant to almost all drugs, including gemcitabine, a nucleoside analog used as a first-line treatment. Poor survival rates of PDA patients have, therefore, not changed much over 4 decades. Recent data indicated that tumor-associated macrophages (TAMs), which are abundant in the microenvironment of several tumors, including PDA, secrete pro-tumorigenic factors that contribute to cancer progression and dissemination. In this study, we show for the first time that TAMs can also induce chemoresistance of PDA by reducing gemcitabine-induced apoptosis. Macrophages co-cultured with cancer cells or TAM-conditioned medium significantly reduced apoptosis and activation of the caspase-3 pathway during gemcitabine treatment. In vivo PDA models of mice, which have reduced macrophage recruitment and activation, demonstrated improved response to gemcitabine compared with controls. Similarly, inhibition of monocytes/macrophages trafficking by a CSF1-receptor antagonist GW2580 augmented the effect of gemcitabine in a transgenic mouse PDA model that was resistant to gemcitabine alone. Analysis of multiple proteins involved in gemcitabine delivery and metabolism revealed that TAMs induced upregulation of cytidine deaminase (CDA), the enzyme that metabolizes the drug following its transport into the cell. Decreasing CDA expression by PDA cells blocked the protective effect of TAMs against gemcitabine. These results provide the first evidence of a paracrine effect of TAMs, which mediates acquired resistance of cancer cells to chemotherapy. Modulation of macrophage trafficking or inhibition of CDA may offer a new strategy for augmenting the response of PDA to chemotherapy.	[Weizman, N.; Krelin, Y.; Shabtay-Orbach, A.; Amit, M.; Binenbaum, Y.; Gil, Z.] Rambam Med Ctr, Dept Otolaryngol Head & Neck Surg, Lab Appl Canc Res, IL-31096 Haifa, Israel; [Amit, M.; Gil, Z.] Rambam Med Ctr, Technion Israel Inst Technol, Dept Otolaryngol Head & Neck Surg, IL-31096 Haifa, Israel; [Wong, R. J.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA	Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Memorial Sloan Kettering Cancer Center	Gil, Z (corresponding author), Rambam Med Ctr, Technion Israel Inst Technol, Dept Otolaryngol Head & Neck Surg, 6 Haaliya St,POB 9602, IL-31096 Haifa, Israel.	ziv@baseofskull.org			Israel Science Foundation; Israel Cancer Association; Israeli Ministry of Health [3-7355]; Rambam Medical Center; ICRF Barbara S Goodman endowed research career development award in Pancreatic Cancer [2011-601-BGPC]; US-Israel Binational Science Foundation	Israel Science Foundation(Israel Science Foundation); Israel Cancer Association; Israeli Ministry of Health; Rambam Medical Center; ICRF Barbara S Goodman endowed research career development award in Pancreatic Cancer; US-Israel Binational Science Foundation(US-Israel Binational Science Foundation)	Esther Eshkol is thanked for editorial assistance. This research was supported by the Legacy Heritage Biomedical Science Partnership Program of the Israel Science Foundation, the Israel Cancer Association (grant donated by Ellen and Emanuel Kronitz in memory of Dr Leon Kronitz), the Israeli Ministry of Health (No. 3-7355), the Rambam Medical Center Intramural Grant, the ICRF Barbara S Goodman endowed research career development award in Pancreatic Cancer (2011-601-BGPC) all to ZG, and the US-Israel Binational Science Foundation to ZG and RJW.	Ahn GO, 2010, P NATL ACAD SCI USA, V107, P8363, DOI 10.1073/pnas.0911378107; Akita H, 2009, ONCOGENE, V28, P2903, DOI 10.1038/onc.2009.158; Andre F, 2010, CURR OPIN ONCOL, V22, P547, DOI 10.1097/CCO.0b013e32833fb384; Bhutia YD, 2011, CANCER RES, V71, P1825, DOI 10.1158/0008-5472.CAN-10-2736; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Cavel O, 2012, CANCER RES, V72, P5733, DOI 10.1158/0008-5472.CAN-12-0764; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; Colucci G, 2010, J CLIN ONCOL, V28, P1645, DOI 10.1200/JCO.2009.25.4433; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cunningham D, 2009, J CLIN ONCOL, V27, P5513, DOI 10.1200/JCO.2009.24.2446; De Palma M, 2011, NATURE, V472, P303, DOI 10.1038/472303a; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Dijkgraaf EM, 2013, CANCER RES, V73, P2480, DOI 10.1158/0008-5472.CAN-12-3542; Esposito I, 2004, J CLIN PATHOL, V57, P630, DOI 10.1136/jcp.2003.014498; Ferrandina G, 2008, J CLIN ONCOL, V26, P890, DOI 10.1200/JCO.2007.13.6606; Gil Z, 2010, J NATL CANCER I, V102, P107, DOI 10.1093/jnci/djp456; Gilbert LA, 2011, CANCER RES, V71, P5062, DOI 10.1158/0008-5472.CAN-11-0277; Giovannetti E, 2006, MOL CANCER THER, V5, P1387, DOI 10.1158/1535-7163.MCT-06-0004; Green CE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006713; Greten FR, 2002, GASTROENTEROLOGY, V123, P2052, DOI 10.1053/gast.2002.37075; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Jinushi M, 2011, P NATL ACAD SCI USA, V108, P12425, DOI 10.1073/pnas.1106645108; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Korc M, 2007, AM J SURG, V194, pS84, DOI 10.1016/j.amjsurg.2007.05.004; Kozin SV, 2010, CANCER RES, V70, P5679, DOI 10.1158/0008-5472.CAN-09-4446; Loehrer PJ, 2011, J CLIN ONCOL, V29, P4105, DOI 10.1200/JCO.2011.34.8904; Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009; Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078-0432.CCR-07-2223; Mitchem JB, 2013, CANCER RES, V73, P1128, DOI 10.1158/0008-5472.CAN-12-2731; Morgan MA, 2005, CANCER RES, V65, P6835, DOI 10.1158/0008-5472.CAN-04-2246; Nefedova Y, 2003, LEUKEMIA, V17, P1175, DOI 10.1038/sj.leu.2402924; Niedergethmann M, 2007, BRIT J CANCER, V97, P1432, DOI 10.1038/sj.bjc.6604031; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Pahler J, 2008, NEOPLASIA, V10, P329, DOI 10.1593/neo.07871; Riccil F, 2005, CANCER BIOL THER, V4, P302, DOI 10.4161/cbt.4.3.1501; Schafer H, 2013, ONCOGENE, V32, P180, DOI 10.1038/onc.2012.44; Shree T, 2011, GENE DEV, V25, P2465, DOI 10.1101/gad.180331.111; Singh S, 2010, BRIT J CANCER, V103, P1671, DOI 10.1038/sj.bjc.6605968; STAROSELSKY AN, 1990, CANCER RES, V50, P7775; Steube KG, 1998, INT J CANCER, V78, P120, DOI 10.1002/(SICI)1097-0215(19980925)78:1<120::AID-IJC19>3.3.CO;2-J; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Summy JM, 2005, PANCREAS, V31, P263, DOI 10.1097/01.mpa.0000178280.50534.0c; Tempero M, 2003, J CLIN ONCOL, V21, P3402, DOI 10.1200/JCO.2003.09.140; Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI 10.1038/nri1415; van Rooijen N, 2003, METHOD ENZYMOL, V373, P3; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; YAMASHINA K, 1986, CANCER RES, V46, P2396; Zhang J, 2010, JNCI-J NATL CANCER I, V102, P522, DOI 10.1093/jnci/djq044; Zheng YH, 2009, BLOOD, V114, P3625, DOI 10.1182/blood-2009-05-220285	49	180	188	2	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3812	3819		10.1038/onc.2013.357	http://dx.doi.org/10.1038/onc.2013.357			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23995783				2022-12-28	WOS:000339394100007
J	Choi, C; Helfman, DM				Choi, C.; Helfman, D. M.			The Ras-ERK pathway modulates cytoskeleton organization, cell motility and lung metastasis signature genes in MDA-MB-231 LM2	ONCOGENE			English	Article						K-Ras; ERK; stress fiber; motility; lung metastasis signature; PI3K	BREAST-CANCER METASTASIS; SIGNALING PATHWAYS; DOWN-REGULATION; CROSS-TALK; IN-VITRO; INHIBITION; ACTIVATION; EXPRESSION; FIBROBLASTS; RHOA	MDA-MB-231 LM2 (herein referred to as LM2) is a derivative of MDA-MB-231 cells that was selected for its ability to metastasize to lung tissue in vivo. We investigated cellular properties of LM2 including actin cytoskeleton organization, motility and signaling pathways that drive the expression of genes associated with the lung metastasis signature. Parental cells exhibit well-developed stress fibers, whereas LM2 had poorly organized stress fibers. LM2 exhibited higher levels of K-Ras protein and corresponding higher levels of phosphorylated ERK compared with parental cells. The Ras-ERK pathway was responsible for the disruption of stress fibers because inhibition of MEK with UO126 or small interfering RNA (siRNA) against K-Ras or ERK1/2 resulted in restoration of stress fibers and focal adhesions. We observed that the K-Ras-ERK pathway is important for the expression of genes associated with the lung metastasis signature. Paradoxically, inhibition of the Ras-ERK pathway did not result in inhibition of cell motility but was accompanied by activation of the phosphatidylinositol 3-kinase (PI3K) pathway. Inhibition of both ERK and PI3K pathways was required to inhibit motility of LM2 cells. These results suggest that both ERK and PI3K pathways drive motile functions of metastatic LM2 cells and genes associated with the lung metastasis signature.	[Choi, C.; Helfman, D. M.] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; [Helfman, D. M.] Korea Adv Inst Sci & Technol, Grad Sch Nanosci & Technol WCU, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Helfman, DM (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 335 Gwahangno, Taejon 305701, South Korea.	dhelfman@kaist.ac.kr	Helfman, David M./C-2058-2011		WCU Program through the National Research Foundation of Korea - Ministry of Education Science and Technology [R31-2008-000-10071-0]; National Research Foundation of Korea [R1A-1A-2007-709]	WCU Program through the National Research Foundation of Korea - Ministry of Education Science and Technology; National Research Foundation of Korea(National Research Foundation of Korea)	We thank Jooyoung Yi and Sunyoung Lim for technical assistance. MDA-MB-231 parental, LM2 and BrM2 cells were kindly provided by Dr Joan Massague. DMH is supported by the WCU Program through the National Research Foundation of Korea funded by the Ministry of Education Science and Technology (R31-2008-000-10071-0) and grant from the National Research Foundation of Korea (R1A-1A-2007-709).	Bakin AV, 2004, MOL BIOL CELL, V15, P4682, DOI 10.1091/mbc.E04-04-0353; Barkan D, 2008, CANCER RES, V68, P6241, DOI 10.1158/0008-5472.CAN-07-6849; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; Ebi H, 2011, J CLIN INVEST, V121, P4311, DOI 10.1172/JCI57909; Eckert LB, 2004, CANCER RES, V64, P4585, DOI 10.1158/0008-5472.CAN-04-0396; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Hayashida T, 2003, FASEB J, V17, P1576, DOI 10.1096/fj.03-0037fje; Huntington JT, 2004, J BIOL CHEM, V279, P33168, DOI 10.1074/jbc.M405102200; Janssen RAJ, 1998, J BIOL CHEM, V273, P32182, DOI 10.1074/jbc.273.48.32182; Larreaa MD, 2009, P NATL ACAD SCI USA, V106, P9268, DOI 10.1073/pnas.0805057106; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Ljungdahl S, 1998, CELL GROWTH DIFFER, V9, P565; Makrodouli E, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-118; Merlot S, 2003, J CELL SCI, V116, P3471, DOI 10.1242/jcs.00703; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-02-0302; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Pollock CB, 2005, CANCER RES, V65, P1244, DOI 10.1158/0008-5472.CAN-04-1911; Prasad GL, 1999, ONCOGENE, V18, P2027, DOI 10.1038/sj.onc.1202264; Pritchard CA, 2004, MOL CELL BIOL, V24, P5937, DOI 10.1128/MCB.24.13.5937-5952.2004; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Stephens L, 2002, CURR OPIN CELL BIOL, V14, P203, DOI 10.1016/S0955-0674(02)00311-3; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Tourkina E, 2008, AM J PHYSIOL-LUNG C, V294, pL843, DOI 10.1152/ajplung.00295.2007; Turke AB, 2012, CANCER RES, V72, P3228, DOI 10.1158/0008-5472.CAN-11-3747; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Wang XQ, 2009, MOL BIOL CELL, V20, P791, DOI 10.1091/mbc.E08-07-0732; Won JK, 2012, J MOL CELL BIOL, V4, P153, DOI 10.1093/jmcb/mjs021; Yamashita Y, 2009, J OVARIAN RES, V2, DOI 10.1186/1757-2215-2-20	33	51	51	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3668	3676		10.1038/onc.2013.341	http://dx.doi.org/10.1038/onc.2013.341			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23995792				2022-12-28	WOS:000338942900006
J	Wolff, F; Loipetzberger, A; Gruber, W; Esterbauer, H; Aberger, F; Frischauf, AM				Wolff, F.; Loipetzberger, A.; Gruber, W.; Esterbauer, H.; Aberger, F.; Frischauf, A. M.			Imiquimod directly inhibits Hedgehog signalling by stimulating adenosine receptor/protein kinase A-mediated GLI phosphorylation	ONCOGENE			English	Article						Gli; imiquimod; basal cell carcinoma; Hedgehog signalling; adenosine receptor	BASAL-CELL CARCINOMAS; IMMUNE-RESPONSE; PROTEIN; PATHWAY; ACTIVATION; RECEPTORS; EXPRESSION; GENE; TRANSDUCTION; MANIPULATION	Imiquimod (IMQ), a nucleoside analogue of the imidazoquinoline family, is used in the topical treatment of basal cell carcinoma (BCC) and other skin diseases. It is reported to be a TLR7 and TLR8 agonist and, as such, initiates a Th1 immune response by activating sentinel cells in the vicinity of the tumour. BCC is a hedgehog (HH)-driven malignancy with oncogenic glioma-associated oncogene (GLI) signalling activated in a ligand-independent manner. Here we show that IMQ can also directly repress HH signalling by negatively modulating GLI activity in BCC and medulloblastoma cells. Further, we provide evidence that the repressive effect of IMQ on HH signalling is not dependent on TLR/MYD88 signalling. Our results suggest a mechanism for IMQ engaging adenosine receptors (ADORAs) to control GLI signalling. Pharmacological activation of ADORA with either an ADORA agonist or IMQ resulted in a protein kinase A (PKA)-mediated GLI phosphorylation and reduction in GLI activator levels. The activation of PKA and HH pathway target gene downregulation in response to IMQ were abrogated by ADORA inhibition. Furthermore, activated Smoothened signalling, which positively signals to GLI transcription factors, could be effectively counteracted by IMQ. These results reveal a previously unknown mode of action of IMQ in the treatment of BCC and also suggest a role for ADORAs in the regulation of oncogenic HH signalling.	[Wolff, F.; Loipetzberger, A.; Gruber, W.; Aberger, F.; Frischauf, A. M.] Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria; [Esterbauer, H.] Med Univ Vienna, Dept Lab Med, Vienna, Austria	Salzburg University; Medical University of Vienna	Frischauf, AM (corresponding author), Salzburg Univ, Dept Mol Biol, Hellbrunner Str 34, A-5020 Salzburg, Austria.	fritz.aberger@sbg.ac.at; annemarie.frischauf@sbg.ac.at	Aberger, Fritz/B-6357-2012; Wolff, Florian/L-4090-2015	Aberger, Fritz/0000-0003-2009-6305; Wolff, Florian/0000-0001-7271-0317; Esterbauer, Harald/0000-0001-7343-7455	international PhD programme Immunity in Cancer and Allergy (ICA) from the Austrian Science fund (FWF); FWF project [P20652]; Austrian Genome Programme GEN-AU; priority program Biosciences and Health of the University of Salzburg; Austrian Academy of Sciences (OAW)	international PhD programme Immunity in Cancer and Allergy (ICA) from the Austrian Science fund (FWF); FWF project(Austrian Science Fund (FWF)); Austrian Genome Programme GEN-AU; priority program Biosciences and Health of the University of Salzburg; Austrian Academy of Sciences (OAW)	We are especially thankful to Dr Matt Scott for providing the SMOM2 construct and to Dr Peter Hammerl for help with murine splenocytes. We are also grateful to Dr Maria Sibilia for the help with the use of IMQ treatment. Furthermore, we are grateful to Sabine Siller for excellent technical support. This work was supported by the international PhD programme Immunity in Cancer and Allergy (ICA) from the Austrian Science fund (FWF), the FWF project P20652, the Austrian Genome Programme GEN-AU and the priority program Biosciences and Health of the University of Salzburg. AL received a PhD Doc-fForte fellowship from the Austrian Academy of Sciences (OAW). We are grateful to Dr Sandra Laner-Plamberger for help with analysis of BCC and skin samples.	Altaba ARI, 2008, CANCER CELL, V14, P281, DOI 10.1016/j.ccr.2008.09.007; Ambach A, 2004, MOL IMMUNOL, V40, P1307, DOI 10.1016/j.molimm.2004.01.002; Aszterbaum M, 1998, J INVEST DERMATOL, V110, P885, DOI 10.1046/j.1523-1747.1998.00222.x; Atwood SX, 2012, J CELL BIOL, V199, P193, DOI 10.1083/jcb.201207140; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Buttitta L, 2003, DEVELOPMENT, V130, P6233, DOI 10.1242/dev.00851; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Di Virgilio F, 2012, CANCER RES, V72, P5441, DOI 10.1158/0008-5472.CAN-12-1600; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Dlugosz A, 2012, NAT REV DRUG DISCOV, V11, P437, DOI 10.1038/nrd3753; Drobits B, 2012, J CLIN INVEST, V122, P575, DOI 10.1172/JCI61034; Eichberger T, 2006, GENOMICS, V87, P616, DOI 10.1016/j.ygeno.2005.12.003; Fredholm BB, 2007, CELL DEATH DIFFER, V14, P1315, DOI 10.1038/sj.cdd.4402132; Gessi S, 2011, BBA-BIOMEMBRANES, V1808, P1400, DOI 10.1016/j.bbamem.2010.09.020; Gotschel F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065403; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Ikram MS, 2004, J INVEST DERMATOL, V122, P1503, DOI 10.1111/j.0022-202X.2004.22612.x; Ingham PW, 2011, NAT REV GENET, V12, P393, DOI 10.1038/nrg2984; JACOBSEN PF, 1985, J NEUROPATH EXP NEUR, V44, P472, DOI 10.1097/00005072-198509000-00003; Jacobson KA, 2006, NAT REV DRUG DISCOV, V5, P247, DOI 10.1038/nrd1983; Jahnisch H, 2013, CANCER LETT, V335, P119, DOI 10.1016/j.canlet.2013.02.003; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; Kasper M, 2012, J CLIN INVEST, V122, P455, DOI 10.1172/JCI58779; Kasper Maria, 2007, V397, P67; Kollisch G, 2005, IMMUNOLOGY, V114, P531, DOI 10.1111/j.1365-2567.2005.02122.x; Lacarrubba F, 2011, J DERMATOL TREAT, V22, P353, DOI 10.3109/09546634.2010.548503; Lear JT, 2012, NEW ENGL J MED, V366, P2225, DOI 10.1056/NEJMe1202170; Lebre MC, 2007, J INVEST DERMATOL, V127, P331, DOI 10.1038/sj.jid.5700530; Liem KF, 2009, P NATL ACAD SCI USA, V106, P13377, DOI 10.1073/pnas.0906944106; LoRusso PM, 2011, CLIN CANCER RES, V17, P2502, DOI 10.1158/1078-0432.CCR-10-2745; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Martin KJ, 2001, P NATL ACAD SCI USA, V98, P2646, DOI 10.1073/pnas.041622398; Matise MP, 1999, ONCOGENE, V18, P7852, DOI 10.1038/sj.onc.1203243; McDermott A, 2005, DEVELOPMENT, V132, P345, DOI 10.1242/dev.01537; Mill P, 2003, GENE DEV, V17, P282, DOI 10.1101/gad.1038103; Mondal BC, 2011, CELL, V147, P1589, DOI 10.1016/j.cell.2011.11.041; Pan Y, 2006, MOL CELL BIOL, V26, P3365, DOI 10.1128/MCB.26.9.3365-3377.2006; Pan Y, 2009, DEV BIOL, V326, P177, DOI 10.1016/j.ydbio.2008.11.009; Persson M, 2002, GENE DEV, V16, P2865, DOI 10.1101/gad.243402; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Regl G, 2004, CANCER RES, V64, P7724, DOI 10.1158/0008-5472.CAN-04-1085; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Rohatgi R, 2007, SCIENCE, V317, P372, DOI 10.1126/science.1139740; Rohatgi R, 2009, P NATL ACAD SCI USA, V106, P3196, DOI 10.1073/pnas.0813373106; Ruiz i Altaba A, 2007, TRENDS CELL BIOL, V17, P438, DOI 10.1016/j.tcb.2007.06.007; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Schon MP, 2007, BRIT J DERMATOL, V157, P8, DOI 10.1111/j.1365-2133.2007.08265.x; Schon MP, 2006, J INVEST DERMATOL, V126, P1338, DOI 10.1038/sj.jid.5700286; Schon M, 2003, J NATL CANCER I, V95, P1138, DOI 10.1093/jnci/djg016; Sekulic A, 2012, NEW ENGL J MED, V366, P2171, DOI 10.1056/NEJMoa1113713; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Smith V, 2011, J SKIN CANCER, V2011, DOI 10.1155/2011/380371; So PL, 2006, EXP DERMATOL, V15, P742, DOI 10.1111/j.1600-0625.2006.00465.x; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Taipale J, 2002, NATURE, V418, P892, DOI 10.1038/nature00989; Tang JY, 2012, NEW ENGL J MED, V366, P2180, DOI 10.1056/NEJMoa1113538; Tempe D, 2006, MOL CELL BIOL, V26, P4316, DOI 10.1128/MCB.02183-05; Teperino R, 2012, CELL, V151, P414, DOI 10.1016/j.cell.2012.09.021; Toriyama M, 2012, J BIOL CHEM, V287, P12691, DOI 10.1074/jbc.M111.316307; Trincavelli ML, 2010, CURR TOP MED CHEM, V10, P860, DOI 10.2174/156802610791268756; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Wang BW, 2006, P NATL ACAD SCI USA, V103, P33, DOI 10.1073/pnas.0509927103; Wang Y, 2009, P NATL ACAD SCI USA, V106, P2623, DOI 10.1073/pnas.0812110106; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Zeng HQ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015900	68	56	56	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2013	32	50					5574	5581		10.1038/onc.2013.343	http://dx.doi.org/10.1038/onc.2013.343			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272LF	23995793	Green Published, hybrid			2022-12-28	WOS:000328461400002
J	Bandey, I; Chiou, SH; Huang, AP; Tsai, JC; Tu, PH				Bandey, I.; Chiou, S-H; Huang, A-P; Tsai, J-C; Tu, P-h			Progranulin promotes Temozolomide resistance of glioblastoma by orchestrating DNA repair and tumor stemness	ONCOGENE			English	Article							GROWTH-FACTOR; ADJUVANT TEMOZOLOMIDE; GLIOMA PATIENTS; IN-VIVO; CELLS; EXPRESSION; BRAIN; CHEMORESISTANCE; IDENTIFICATION; RADIOTHERAPY	Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults with a dismal prognosis. Current therapy of surgical removal combined with Temozolomide (TMZ) and radiation therapy only slightly prolongs the survival of GBM patients. Thus, it is essential to elucidate mechanism underlying its highly malignant properties in order to develop efficacious therapeutic regimens. In this study, we showed that progranulin (PGRN) was overexpressed in most GBM cell lines and the majority of human tumor samples. PGRN overexpression conferred GBM cells with tumorigenic properties and TMZ resistance by upregulating DNA repair (PARP, ATM, BRCA1, Rad51, XRCC1 and so on) and cancer stemness (CD133, CD44, ABCG2) genes, in part via an AP-1 transcription factor, specifically cFos/JunB. Curcumin, an AP-1 inhibitor, was also found to regulate PGRN promoter activity and expression including its downstream effectors aforementioned. These data suggested a feedforward loop between PGRN signaling and AP-1. PGRN depletion significantly decreased unlimited self-renewal and multilineage differentiation and the malignant properties of GBMs cells S1R1, and enhanced their vulnerability to TMZ. In addition, S1R1 depleted of PGRN also lost the ability to form tumor in an orthotopic xenograft mouse model. In conclusion, PGRN had a critical role in the pathogenesis and chemoresistance of GBM and functioned at the top of the hierarchy of cellular machinery that modulates both DNA repair pathways and cancer stemness. Our data suggest that a new strategy combining current regimens with compounds targeting PGRN/AP-1 loop like curcumin may significantly improve the therapeutic outcome of GBM.	[Bandey, I.; Tu, P-h] Natl Yang Ming Univ, Taiwan Int Grad Program Mol Med, Taipei 112, Taiwan; [Bandey, I.; Tu, P-h] Acad Sinica, Taipei 11529, Taiwan; [Bandey, I.; Tu, P-h] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; [Chiou, S-H] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan; [Chiou, S-H] Natl Yang Ming Univ, Taipei 112, Taiwan; [Huang, A-P; Tsai, J-C] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Sect Neurosurg,Dept Surg, Taipei 10764, Taiwan; [Tsai, J-C] Natl Taiwan Univ, Coll Med, Ctr Optoelect Med, Taipei 10764, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Academia Sinica - Taiwan; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Tu, PH (corresponding author), Acad Sinica, Inst Biomed Sci, IBMS, N701,128,Sec 2,Acad Rd Nankang, Taipei 11529, Taiwan.	btu@ibms.sinica.edu.tw		HUANG, ABEL PO-HAO/0000-0002-5689-6761; TSAI, JUI-CHANG/0000-0003-2723-6841; bandey, irfan N/0000-0002-9330-2432	National Science Council; Academia Sinica of Taiwan	National Science Council(Ministry of Science and Technology, Taiwan); Academia Sinica of Taiwan(Academia Sinica - Taiwan)	We thank the Core Facility of the Institute of Biomedical Sciences (IBMS), National RNAi Core of Taiwan, and Taiwan Mouse Clinic for their excellent services; Dr Chen Chang and the staff Y.Y. Tung and C.M. Shih for MRI analysis, and Dr Anupam Agarwal, University of Birmingham, USA for the JunB construct. The study was funded by grants from the National Science Council and Academia Sinica of Taiwan.	Assimakopoulou M, 2001, J CANCER RES CLIN, V127, P727; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barazzuol L, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-65; Bateman A, 1998, J ENDOCRINOL, V158, P145, DOI 10.1677/joe.0.1580145; Beier D, 2008, BRAIN PATHOL, V18, P370, DOI 10.1111/j.1750-3639.2008.00130.x; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Cheung ST, 2011, GASTROENTEROLOGY, V140, P344, DOI 10.1053/j.gastro.2010.07.049; Debinski W, 2011, CANCER BIOL THER, V11, P254, DOI 10.4161/cbt.11.2.13953; Dhandapani KM, 2007, J NEUROCHEM, V102, P522, DOI 10.1111/j.1471-4159.2007.04633.x; Donald CD, 2001, ANTICANCER RES, V21, P3739; Filiano AJ, 2013, J NEUROSCI, V33, P5352, DOI 10.1523/JNEUROSCI.6103-11.2013; Frampton G, 2012, GUT, V61, P268, DOI 10.1136/gutjnl-2011-300643; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Garcia-Alloza M, 2007, J NEUROCHEM, V102, P1095, DOI 10.1111/j.1471-4159.2007.04613.x; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Jin LJ, 2013, CANCER RES, V73, P2884, DOI 10.1158/0008-5472.CAN-12-2162; Kang MK, 2007, STEM CELLS DEV, V16, P837, DOI 10.1089/scd.2007.0006; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Khoshyomn S, 2000, PEDIATR NEUROSURG, V33, P123, DOI 10.1159/000028993; Krishnamurthy P, 2004, J BIOL CHEM, V279, P24218, DOI 10.1074/jbc.M313599200; Lee PC, 2010, NEOPLASIA, V12, P376, DOI 10.1593/neo.10110; Lee PY, 2013, ONCOLOGY-BASEL, V84, P326, DOI 10.1159/000347021; Liau LM, 2000, CANCER RES, V60, P1353; Lin LT, 2013, MOL IMAGING BIOL, V15, P262, DOI 10.1007/s11307-012-0591-x; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Matsuwaki T, 2011, J REPROD DEVELOP, V57, P113, DOI 10.1262/jrd.10-116S; Nandhakumar S, 2011, J PHARMACOL PHARMACO, V2, P107, DOI 10.4103/0976-500X.81903; Pallini R, 2008, CLIN CANCER RES, V14, P8205, DOI 10.1158/1078-0432.CCR-08-0644; Pan CX, 2004, CLIN CANCER RES, V10, P1333, DOI 10.1158/1078-0432.CCR-1123-03; Piscopo P, 2010, NEUROCHEM INT, V57, P893, DOI 10.1016/j.neuint.2010.09.008; Rademakers R, 2007, CURR NEUROL NEUROSCI, V7, P434, DOI 10.1007/s11910-007-0067-6; Rebetz J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001936; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Seidel S, 2010, BRAIN, V133, P983, DOI 10.1093/brain/awq042; Serrero G, 2003, HUM PATHOL, V34, P1148, DOI 10.1016/S0046-8177(03)00425-8; Shervington A, 2008, CANCER INVEST, V26, P535, DOI 10.1080/07357900801904140; SHOYAB M, 1990, P NATL ACAD SCI USA, V87, P7912, DOI 10.1073/pnas.87.20.7912; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Swamydas M, 2011, CELL COMMUN ADHES, V18, P119, DOI 10.3109/15419061.2011.641042; Tao T, 2013, EUR J CANCER, V49, P3055, DOI 10.1016/j.ejca.2013.05.010; Wang MQ, 2012, MED ONCOL, V29, P2423, DOI 10.1007/s12032-011-0131-6; Xu Y, 2010, CANCER RES, V70, P2455, DOI 10.1158/0008-5472.CAN-09-2505; Zeppernick F, 2008, CLIN CANCER RES, V14, P123, DOI 10.1158/1078-0432.CCR-07-0932; Zhang Jihong, 2012, Curr Mol Pharmacol, V5, P102; Zhang MY, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-85; Zhang WD, 2003, FASEB J, V17, P2085, DOI 10.1096/fj.02-1131fje	49	38	41	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1853	1864		10.1038/onc.2014.92	http://dx.doi.org/10.1038/onc.2014.92			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24793792				2022-12-28	WOS:000352158000012
J	Tuominen, I; Heliovaara, E; Raitila, A; Rautiainen, MR; Mehine, M; Katainen, R; Donner, I; Aittomaki, V; Lehtonen, HJ; Ahlsten, M; Kivipelto, L; Schalin-Jantti, C; Arola, J; Hautaniemi, S; Karhu, A				Tuominen, I.; Heliovaara, E.; Raitila, A.; Rautiainen, M-R; Mehine, M.; Katainen, R.; Donner, I.; Aittomaki, V.; Lehtonen, H. J.; Ahlsten, M.; Kivipelto, L.; Schalin-Jantti, C.; Arola, J.; Hautaniemi, S.; Karhu, A.			AIP inactivation leads to pituitary tumorigenesis through defective G alpha(i)-cAMP signaling	ONCOGENE			English	Article							INTERACTING PROTEIN GENE; STIMULATORY G-PROTEIN; ADENOMA PREDISPOSITION; ADENYLYL-CYCLASE; CELL-PROLIFERATION; MUTATIONS; CAMP; EXPRESSION; SUBUNIT; XAP2	The aryl hydrocarbon receptor interacting protein (AIP) is a tumor-suppressor gene underlying the pituitary adenoma predisposition. Thus far, the exact molecular mechanisms by which inactivated AIP exerts its tumor-promoting action have been unclear. To better understand the role of AIP in pituitary tumorigenesis, we performed gene expression microarray analysis to examine changes between Aip wild-type and knockout mouse embryonic fibroblast (MEF) cell lines. Transcriptional analyses implied that Aip deficiency causes a dysfunction in cyclic adenosine monophosphate (cAMP) signaling, as well as impairments in signaling cascades associated with developmental and immune-inflammatory responses. In vitro experiments showed that AIP deficiency increases intracellular cAMP concentrations in both MEF and murine pituitary adenoma cell lines. Based on knockdown of various G protein a subunits, we concluded that AIP deficiency leads to elevated cAMP concentrations through defective G alpha(i)-2 and G alpha(i)-3 proteins that normally inhibit cAMP synthesis. Furthermore, immunostaining of G alpha(i)-2 revealed that AIP deficiency is associated with a clear reduction in G alpha(i)-2 protein expression levels in human and mouse growth hormone (GH)-secreting pituitary adenomas, thus indicating defective Gai signaling in these tumors. By contrast, all prolactin-secreting tumors showed prominent G alpha(i)-2 protein levels, irrespective of Aip mutation status. We additionally observed reduced expression of phosphorylated extracellular signal-regulated kinases 1/2 and cAMP response element-binding protein levels in mouse and human AIP-deficient somatotropinomas. This study implies for the first time that a failure to inhibit cAMP synthesis through dysfunctional G alpha(i) signaling underlies the development of GH-secreting pituitary adenomas in AIP mutation carriers.	[Tuominen, I.; Heliovaara, E.; Raitila, A.; Rautiainen, M-R; Mehine, M.; Katainen, R.; Donner, I.; Lehtonen, H. J.; Ahlsten, M.; Karhu, A.] Univ Helsinki, Inst Biomed Biomed Helsinki, Genome Scale Biol Res Program, Dept Med Genet, Helsinki 00014, Finland; [Aittomaki, V.; Hautaniemi, S.] Univ Helsinki, Inst Biomed Biomed Helsinki, Genome Scale Biol Res Program, Syst Biol Lab, Helsinki 00014, Finland; [Kivipelto, L.] Univ Helsinki, Dept Neurosurg, Helsinki 00014, Finland; [Kivipelto, L.; Schalin-Jantti, C.] Helsinki Univ Hosp, Helsinki, Finland; [Schalin-Jantti, C.] Univ Helsinki, Dept Med, Div Endocrinol, Helsinki 00014, Finland; [Tuominen, I.; Heliovaara, E.; Arola, J.] Univ Helsinki, Cent Hosp, HUSLAB, Dept Pathol, Helsinki 00014, Finland; [Arola, J.] Univ Helsinki, Haartman Inst, Helsinki 00014, Finland	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki	Karhu, A (corresponding author), Univ Helsinki, Inst Biomed Biomed Helsinki, Genome Scale Biol Res Program, Dept Med Genet, Helsinki 00014, Finland.	auli.karhu@helsinki.fi	Hautaniemi, Sampsa/A-3122-2009; Katainen, Riku/GYR-0921-2022; Hautaniemi, Sampsa/CAG-0362-2022	Hautaniemi, Sampsa/0000-0002-7749-2694; Hautaniemi, Sampsa/0000-0002-7749-2694; Karhu, Auli/0000-0002-7927-0796; Katainen, Riku/0000-0003-4575-4239	Academy of Finland [250345]; Cancer Society of Finland [4700325]; Novo Nordisk Foundation [A14582]; Association for International Cancer Research [13-1075]	Academy of Finland(Academy of Finland); Cancer Society of Finland; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Association for International Cancer Research	We thank Inga-Lill Svedberg, Mairi Kuris, Alison Ollikainen and Iina Vuoristo for technical assistance. The Biomedicum Imaging Unit is acknowledged for the microscopy service and the Biomedicum Functional Genomics Unit (FuGU) for expression array and virus core services. This study was supported by the Academy of Finland (250345), the Cancer Society of Finland (4700325), the Novo Nordisk Foundation (A14582) and the Association for International Cancer Research (13-1075). This work was supported in part by the Novo Nordisk Foundation (AK).	Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; Beckers A, 2013, ENDOCR REV, V34, P239, DOI 10.1210/er.2012-1013; Ben-Shlomo A, 2007, MOL ENDOCRINOL, V21, P2565, DOI 10.1210/me.2007-0081; Ben-Shlomo A, 2010, TRENDS ENDOCRIN MET, V21, P123, DOI 10.1016/j.tem.2009.12.003; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BERTHERAT J, 1995, MOL ENDOCRINOL, V9, P777, DOI 10.1210/me.9.7.777; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; Boikos SA, 2007, HUM MOL GENET, V16, pR80, DOI 10.1093/hmg/ddm019; Bolger GB, 2003, J BIOL CHEM, V278, P33351, DOI 10.1074/jbc.M303269200; Caunt CJ, 2006, TRENDS ENDOCRIN MET, V17, P276, DOI 10.1016/j.tem.2006.07.008; Chahal HS, 2012, J CLIN ENDOCR METAB, V97, pE1411, DOI 10.1210/jc.2012-1111; Daly AF, 2007, J CLIN ENDOCR METAB, V92, P1891, DOI 10.1210/jc.2006-2513; Daly AF, 2010, J CLIN ENDOCR METAB, V95, pE373, DOI 10.1210/jc.2009-2556; de Oliveira SK, 2007, J BIOL CHEM, V282, P13656, DOI 10.1074/jbc.M610942200; Formosa R, 2013, ENDOCR-RELAT CANCER, V20, P495, DOI 10.1530/ERC-13-0043; Georgitsi M, 2007, P NATL ACAD SCI USA, V104, P4101, DOI 10.1073/pnas.0700004104; Gohla A, 2007, P NATL ACAD SCI USA, V104, P3003, DOI 10.1073/pnas.0611434104; Grant M, 2008, MOL ENDOCRINOL, V22, P2278, DOI 10.1210/me.2007-0334; Gueorguiev M, 2011, NAT REV ENDOCRINOL, V7, P71, DOI 10.1038/nrendo.2010.233; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; Hayward BE, 2001, J CLIN INVEST, V107, pR31, DOI 10.1172/JCI11887; Heliovaara E, 2009, AM J PATHOL, V175, P2501, DOI 10.2353/ajpath.2009.081131; Jiang LI, 2008, J BIOL CHEM, V283, P23429, DOI 10.1074/jbc.M803281200; Jiang LI, 2007, J BIOL CHEM, V282, P10576, DOI 10.1074/jbc.M609695200; Kazlauskas A, 2000, J BIOL CHEM, V275, P41317, DOI 10.1074/jbc.M007765200; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; Lahlou H, 2003, J BIOL CHEM, V278, P39356, DOI 10.1074/jbc.M304524200; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Lania A, 2003, J CLIN ENDOCR METAB, V88, P1692, DOI 10.1210/jc.2002-021207; Lappano R, 2011, NAT REV DRUG DISCOV, V10, P47, DOI 10.1038/nrd3320; Leontiou CA, 2008, J CLIN ENDOCR METAB, V93, P2390, DOI 10.1210/jc.2007-2611; Liu YF, 1999, J BIOL CHEM, V274, P16444, DOI 10.1074/jbc.274.23.16444; LIU YF, 1994, J BIOL CHEM, V269, P13880; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Malbon CC, 2005, NAT REV MOL CELL BIO, V6, P689, DOI 10.1038/nrm1716; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; Moran TB, 2012, TOXICOL APPL PHARM, V265, P139, DOI 10.1016/j.taap.2012.08.026; Nakata A, 2009, EMBO REP, V10, P622, DOI 10.1038/embor.2009.35; Nesbit MA, 2013, NEW ENGL J MED, V368, P2476, DOI 10.1056/NEJMoa1300253; Nurnberg B, 2004, NAT REV DRUG DISCOV, V575, P577; Omori K, 2007, CIRC RES, V100, P309, DOI 10.1161/01.RES.0000256354.95791.f1; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Peri A, 2001, J CLIN ENDOCR METAB, V86, P2111, DOI 10.1210/jc.86.5.2111; Raitila A, 2010, AM J PATHOL, V177, P1969, DOI 10.2353/ajpath.2010.100138; Sandrini Fabiano, 2004, Arq Bras Endocrinol Metab, V48, P637, DOI 10.1590/S0004-27302004000500007; SCHWINDINGER WF, 1992, P NATL ACAD SCI USA, V89, P5152, DOI 10.1073/pnas.89.11.5152; Stefan E, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1605; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Trivellin G, 2011, J ENDOCRINOL, V210, P137, DOI 10.1530/JOE-11-0054; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vierimaa O, 2006, SCIENCE, V312, P1228, DOI 10.1126/science.1126100; Vlotides G, 2008, CANCER RES, V68, P6377, DOI 10.1158/0008-5472.CAN-08-0508; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; Wettschureck N, 2004, PHARMACOL THERAPEUT, V101, P75, DOI 10.1016/j.pharmthera.2003.10.005; Zatelli MC, 2003, J CLIN ENDOCR METAB, V88, P2797, DOI 10.1210/jc.2002-021825	61	65	68	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1174	1184		10.1038/onc.2014.50	http://dx.doi.org/10.1038/onc.2014.50			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662816				2022-12-28	WOS:000350122100010
J	Bajpe, PK; Prahallad, A; Horlings, H; Nagtegaal, I; Beijersbergen, R; Bernards, R				Bajpe, P. K.; Prahallad, A.; Horlings, H.; Nagtegaal, I.; Beijersbergen, R.; Bernards, R.			A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity	ONCOGENE			English	Article						SIRT2; drug resistance; chromatin modifiers; genetic screen	METASTATIC COLORECTAL-CANCER; FREQUENT MUTATIONS; CELL CARCINOMA; RAS MUTATIONS; BREAST-CANCER; CETUXIMAB; RESISTANCE; RECEPTOR; PATHWAY; MARKER	Resistance to targeted therapies is a major problem in cancer treatment. The epidermal growth factor receptor (EGFR) antibody drugs are effective in a subset of colorectal cancers, but the molecular mechanisms of resistance are understood poorly. Genes involved in epigenetic regulation are frequently deregulated in cancer, raising the possibility that such genes also contribute to drug resistance. Using a focused RNA interference library for genes involved in epigenetic regulation, we identify sirtuin2 (SIRT2), an NAD(+)-dependent deacetylase, as a modulator of the response to EGFR inhibitors in colon and lung cancer. SIRT2 loss also conferred resistance to BRAF and MEK inhibitors in BRAF mutant melanoma and KRAS mutant colon cancers, respectively. These results warrant further investigation into the potential role of SIRT2 in resistance to drugs that act in the receptor tyrosine kinase-RAS-RAF-MEK-ERK signaling pathway.	[Bajpe, P. K.; Prahallad, A.; Horlings, H.; Beijersbergen, R.; Bernards, R.] Netherlands Canc Inst, Div Mol Carcinogenesis, Canc Genom Ctr, NL-1066 CX Amsterdam, Netherlands; [Horlings, H.] Acad Medisch Cent, Dept Pathol, Amsterdam, Netherlands; [Nagtegaal, I.] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6525 ED Nijmegen, Netherlands	Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Radboud University Nijmegen	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Canc Genom Ctr, 121 Plesmanlaan, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl	Nagtegaal, Iris D/A-2448-2014	Nagtegaal, Iris D/0000-0003-0887-4127; Beijersbergen, Roderick/0000-0003-0116-4130; Bernards, Rene/0000-0001-8677-3423	Dutch Cancer Society (KWF); European Union [259015]	Dutch Cancer Society (KWF)(KWF Kankerbestrijding); European Union(European Commission)	We are grateful to Kees Punt, Sabine Tejpar, Josep Tabernero, Jose Jimenez, Adriana Lopez-Doriga Guerra, Ramon Salzar and Loredana Vecchione for providing clinical specimen of cetuximab-treated colon cancers. We thank Gerrit Hooiger and Marc van de Vijver (AMC, Amsterdam) for assistance in staining tissue microarrays and Alberto Bardelli for the kind gift of the Difi cells. We thank the NKI Genomics Core Facility, especially Iris de Rink, for support. We also thank Chong Sun and Sidong Huang for helpful discussions. This work was supported by grants from the Dutch Cancer Society (KWF) and the European Union Seventh Framework Program COLTHERES project, grant agreement 259015.	Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964; Barber MF, 2012, NATURE, V487, P114, DOI 10.1038/nature11043; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Brummelkamp TR, 2006, NAT CHEM BIOL, V2, P202, DOI 10.1038/nchembio774; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Geutjes EJ, 2012, ONCOGENE, V31, P3827, DOI 10.1038/onc.2011.552; Glasspool RM, 2006, BRIT J CANCER, V94, P1087, DOI 10.1038/sj.bjc.6603024; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Huang SD, 2012, CELL, V151, P937, DOI 10.1016/j.cell.2012.10.035; Huang SD, 2009, CANCER CELL, V15, P328, DOI 10.1016/j.ccr.2009.02.023; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Liu H, 2009, CANCER BIOL THER, V8, P1204, DOI 10.4161/cbt.8.13.8924; Marschalek R, 2011, BRIT J HAEMATOL, V152, P141, DOI 10.1111/j.1365-2141.2010.08459.x; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Reisman DN, 2003, CANCER RES, V63, P560; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Samowitz WS, 2000, CANCER EPIDEM BIOMAR, V9, P1193; Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Yeung F, ONCOGENE	27	30	33	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					531	536		10.1038/onc.2013.588	http://dx.doi.org/10.1038/onc.2013.588			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24469059				2022-12-28	WOS:000348451300014
J	Daniel, AR; Gaviglio, AL; Knutson, TP; Ostrander, JH; D'Assoro, AB; Ravindranathan, P; Peng, Y; Raj, GV; Yee, D; Lange, CA				Daniel, A. R.; Gaviglio, A. L.; Knutson, T. P.; Ostrander, J. H.; D'Assoro, A. B.; Ravindranathan, P.; Peng, Y.; Raj, G. V.; Yee, D.; Lange, C. A.			Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1-and estrogen receptor-containing transcription complexes	ONCOGENE			English	Article						estrogen receptor; progesterone receptor; PELP1; IGF1R; cathepsin-D; breast cancer	C-SRC; ENDOCRINE RESISTANCE; TAMOXIFEN RESISTANCE; HORMONE-RECEPTORS; GROWTH; ACTIVATION; PATHWAY; EXPRESSION; KINASE; PHOSPHORYLATION	Progesterone and estrogen are important drivers of breast cancer proliferation. Herein, we probed estrogen receptor-a (ER) and progesterone receptor (PR) cross-talk in breast cancer models. Stable expression of PR-B in PR-low/ER+ MCF7 cells increased cellular sensitivity to estradiol and insulin-like growth factor 1 (IGF1), as measured in growth assays performed in the absence of exogenous progestin; similar results were obtained in PR-null/ER+ T47D cells stably expressing PR-B. Genome-wide microarray analyses revealed that unliganded PR-B induced robust expression of a subset of estradiol-responsive ER target genes, including cathepsin-D (CTSD). Estradiol-treated MCF7 cells stably expressing PR-B exhibited enhanced ER Ser167 phosphorylation and recruitment of ER, PR and the proline-, glutamate-and leucine-rich protein 1 (PELP1) to an estrogen response element in the CTSD distal promoter; this complex co-immunoprecipitated with IGF1 receptor (IGFR1) in whole-cell lysates. Importantly, ER/PR/PELP1 complexes were also detected in human breast cancer samples. Inhibition of IGF1R or phosphoinositide 3-kinase blocked PR-B-dependent CTSD mRNA upregulation in response to estradiol. Similarly, inhibition of IGF1R or PR significantly reduced ER recruitment to the CTSD promoter. Stable knockdown of endogenous PR or onapristone treatment of multiple unmodified breast cancer cell lines blocked estradiol-mediated CTSD induction, inhibited growth in soft agar and partially restored tamoxifen sensitivity of resistant cells. Further, combination treatment of breast cancer cells with both onapristone and IGF1R tyrosine kinase inhibitor AEW541 was more effective than either agent alone. In summary, unliganded PR-B enhanced proliferative responses to estradiol and IGF1 via scaffolding of ER-alpha/PELP1/IGF1R-containing complexes. Our data provide a strong rationale for targeting PR in combination with ER and IGF1R in patients with luminal breast cancer.	[Daniel, A. R.; Gaviglio, A. L.; Knutson, T. P.; Ostrander, J. H.; Yee, D.; Lange, C. A.] Univ Minnesota, Mason Canc Ctr, Dept Med, Minneapolis, MN 55455 USA; [Daniel, A. R.; Gaviglio, A. L.; Knutson, T. P.; Yee, D.; Lange, C. A.] Univ Minnesota, Mason Canc Ctr, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ Minnesota, Mason Canc Ctr, Minneapolis, MN 55455 USA; [D'Assoro, A. B.] Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN USA; [Ravindranathan, P.; Raj, G. V.] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Peng, Y.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Mayo Clinic; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Lange, CA (corresponding author), Univ Minnesota, Mason Canc Ctr, Dept Med, Canc Cardiology Res Bldg,2231 6th St SE, Minneapolis, MN 55455 USA.	Lange047@umn.edu	Knutson, Todd P/H-8304-2012	Lange, Carol/0000-0003-2751-3976; Yee, Douglas/0000-0002-3387-4009	NIH [R01 CA159712, P30 CA077598, K07 CA131501]; NATIONAL CANCER INSTITUTE [P30CA077598, R01CA074285, K07CA131501, R01CA159712] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Deepali Sachdev (University of Minnesota) for the kind gift of the MCF7L cells. Onapristone was kindly provided by Arno Therapeutics Inc. (Flemington, NJ, USA). The Masonic Cancer Center Biostatistics and Bioinformatics core performed the normalization of the raw microarray data. AEW541 was a gift from Novartis Pharmaceuticals (Basel, Switzerland). This work was supported by NIH R01 CA159712 (CAL), P30 CA077598 (DY) and K07 CA131501 (JHO).	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Aupperlee MD, 2007, ENDOCRINOLOGY, V148, P2290, DOI 10.1210/en.2006-1721; Ballare C, 2003, MOL CELL BIOL, V23, P1994, DOI 10.1128/MCB.23.6.1994-2008.2003; Baselga J, 2011, ONCOLOGIST, V16, P12, DOI 10.1634/theoncologist.2011-S1-12; Becker MA, 2011, MOL ENDOCRINOL, V25, P516, DOI 10.1210/me.2010-0373; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Bretschneider N, 2008, MOL ONCOL, V2, P182, DOI 10.1016/j.molonc.2008.05.004; Brisken C, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003178; Byron SA, 2006, BRIT J CANCER, V95, P1220, DOI 10.1038/sj.bjc.6603354; Casa AJ, 2008, FRONT BIOSCI-LANDMRK, V13, P3273, DOI 10.2741/2925; Chakravarty D, 2010, IUBMB LIFE, V62, P163, DOI 10.1002/iub.287; Cheskis BJ, 2008, STEROIDS, V73, P901, DOI 10.1016/j.steroids.2007.12.028; Chia SK, 2012, CLIN CANCER RES, V18, P4465, DOI 10.1158/1078-0432.CCR-12-0286; Daniel AR, 2011, EXPERT REV ENDOCRINO, V6, P359, DOI 10.1586/EEM.11.25; Daniel AR, 2009, P NATL ACAD SCI USA, V106, P14287, DOI 10.1073/pnas.0905118106; Daniel AR, 2009, MOL CELL ENDOCRINOL, V308, P47, DOI 10.1016/j.mce.2009.01.004; Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8; de Leeuw R, 2011, INT J BREAST CANCER, V2011, DOI 10.4061/2011/232435; Doane AS, 2006, ONCOGENE, V25, P3994, DOI 10.1038/sj.onc.1209415; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; Fagan DH, 2012, CANCER RES, V72, P3372, DOI 10.1158/0008-5472.CAN-12-0684; Fagan D, 2008, J MAMMARY GLAND BIOL, V13, P423, DOI 10.1007/s10911-008-9098-0; Faivre EJ, 2007, MOL CELL BIOL, V27, P466, DOI 10.1128/MCB.01539-06; Fox EM, 2008, MOL ENDOCRINOL, V22, P1781, DOI 10.1210/me.2007-0419; Fox EM, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00145; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giulianelli S, 2012, CANCER RES, V72, P2416, DOI 10.1158/0008-5472.CAN-11-3290; Gupta A, 2013, J STEROID BIOCHEM, V133, P30, DOI 10.1016/j.jsbmb.2012.08.004; Hagan CR, 2011, MOL CELL BIOL, V31, P2439, DOI 10.1128/MCB.01246-10; Hilton HN, 2012, MOL CELL ENDOCRINOL, V361, P191, DOI 10.1016/j.mce.2012.04.010; JOHNSTON SRD, 1995, CANCER RES, V55, P3331; Knutson TP, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3211; Lanari C, 2012, ENDOCR-RELAT CANCER, V19, pR35, DOI 10.1530/ERC-11-0378; Leontovich AA, 2012, INT J ONCOL, V40, P1858, DOI 10.3892/ijo.2012.1407; Likhite VS, 2006, MOL ENDOCRINOL, V20, P3120, DOI 10.1210/me.2006-0068; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Mote PA, 2002, BREAST CANCER RES TR, V72, P163, DOI 10.1023/A:1014820500738; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Proietti CJ, 2009, MOL CELL BIOL, V29, P1249, DOI 10.1128/MCB.00853-08; Riggins RB, 2008, CANCER RES, V68, P8908, DOI 10.1158/0008-5472.CAN-08-2669; Riggins RB, 2007, CANCER LETT, V256, P1, DOI 10.1016/j.canlet.2007.03.016; Sachdev D, 2003, CANCER RES, V63, P627; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shimizu T, 2010, PHYSIOL GENOMICS, V42A, P290, DOI 10.1152/physiolgenomics.00107.2010; Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644; Tang QZ, 2011, CANCER RES, V71, P6940, DOI 10.1158/0008-5472.CAN-11-2091; Vadlamudi RK, 2005, CANCER RES, V65, P7724, DOI 10.1158/0008-5472.CAN-05-0614; Zhang Y, 2008, MOL CELLULAR BIOL; Zukiwski AA, 2013, ASCO AM SOC CLIN ONC	50	92	98	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					506	515		10.1038/onc.2013.579	http://dx.doi.org/10.1038/onc.2013.579			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24469035	Green Accepted			2022-12-28	WOS:000348451300011
J	Ren, T; Takahashi, Y; Liu, X; Loughran, TP; Sun, SC; Wang, HG; Cheng, H				Ren, T.; Takahashi, Y.; Liu, X.; Loughran, T. P.; Sun, S-C; Wang, H-G; Cheng, H.			HTLV-1 Tax deregulates autophagy by recruiting autophagic molecules into lipid raft microdomains	ONCOGENE			English	Article						HTLV-1 Tax; IKK; autophagy; lipid rafts; Beclin1; Bif-1	NF-KAPPA-B; STARVATION-INDUCED AUTOPHAGY; CELL LEUKEMIA-CELLS; IKK-BETA; PERSISTENT ACTIVATION; TRANSFORMING PROTEIN; METABOLIC STRESS; KINASE SUBUNITS; BECLIN 1; T-CELLS	The retroviral oncoprotein Tax from human T-cell leukemia virus type 1 (HTLV-1), an etiological factor that causes adult T-cell leukemia and lymphoma, has a crucial role in initiating T-lymphocyte transformation by inducing oncogenic signaling activation. We here report that Tax is a determining factor for dysregulation of autophagy in HTLV-1-transformed T cells and Tax-immortalized CD4 memory T cells. Tax facilitated autophagic process by activating inhibitor of kappa B (I kappa B) kinase (IKK) complex, which subsequently recruited an autophagy molecular complex containing Beclin1 and Bif-1 to the lipid raft microdomains. Tax engaged a crosstalk between IKK complex and autophagic molecule complex by directly interacting with both complexes, promoting assembly of LC3 + autophagosomes. Moreover, expression of lipid raft-targeted Bif-1 or Beclin1 was sufficient to induce formation of LC3+ autophagosomes, suggesting that Tax recruitment of autophagic molecules to lipid rafts is a dominant strategy to deregulate autophagy in the context of HTLV-1 transformation of T cells. Furthermore, depletion of autophagy molecules such as Beclin1 and PI3 kinase class III resulted in impaired growth of HTLV-1-transformed T cells, indicating a critical role of Tax-deregulated autophagy in promoting survival and transformation of virally infected T cells.	[Ren, T.; Liu, X.; Loughran, T. P.] Penn State Univ, Penn State Hershey Canc Inst, Coll Med, Hershey, PA USA; [Ren, T.] Penn State Univ, Dept Microbiol & Immunol, Coll Med, Hershey, PA USA; [Takahashi, Y.; Wang, H-G] Penn State Univ, Dept Pharmacol, Coll Med, Hershey, PA USA; [Sun, S-C] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Cheng, H.] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Texas System; UTMD Anderson Cancer Center; University System of Maryland; University of Maryland Baltimore	Cheng, H (corresponding author), Univ Maryland, Sch Med, Inst Human Virol, 725 W Lombard St,S219, Baltimore, MD 21201 USA.	hcheng@ihv.umaryland.edu	Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571; Takahashi, Yoshinori/0000-0002-8004-4817	National Institute of Allergy And Infectious Diseases of the National Institutes of Health [R01AI090113];  [CA129682]; NATIONAL CANCER INSTITUTE [R01CA129682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI090113] Funding Source: NIH RePORTER	National Institute of Allergy And Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Atsushi Koito and Takeo Ohsugi for MT-1 cell line, and Wen Dong, Li Chen, Dan Liu, Di Xiang and Huan Zhang for technical assistance. Research reported in this publication was supported by the National Institute of Allergy And Infectious Diseases of the National Institutes of Health under award number R01AI090113 to H Cheng and was partly supported by the award CA129682 to HG Wang.	ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; Ai HW, 2008, BMC BIOL, V6, DOI 10.1186/1741-7007-6-13; Balgi AD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007124; Baudhuin P, 1966, Brux Med, V46, P1059; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; Carew JS, 2007, AUTOPHAGY, V3, P464, DOI 10.4161/auto.4311; Carter RS, 2001, J BIOL CHEM, V276, P24445, DOI 10.1074/jbc.C000777200; Chen ZH, 2010, P NATL ACAD SCI USA, V107, P18880, DOI 10.1073/pnas.1005574107; Cheng H, 2005, MOL CELL BIOL, V25, P44, DOI 10.1128/MCB.25.1.44-59.2005; Chu WM, 2000, CELL, V103, P909, DOI 10.1016/S0092-8674(00)00194-X; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Dreux M, 2009, AUTOPHAGY, V5, P1224, DOI 10.4161/auto.5.8.10219; Dreux M, 2009, P NATL ACAD SCI USA, V106, P14046, DOI 10.1073/pnas.0907344106; Furuta S, 2004, ONCOGENE, V23, P3898, DOI 10.1038/sj.onc.1207539; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Harhaj NS, 2007, J BIOL CHEM, V282, P4185, DOI 10.1074/jbc.M611031200; Hatanaka M, 1992, Uirusu, V42, P13; Horiuchi S, 2006, INT J CANCER, V119, P823, DOI 10.1002/ijc.21918; Huang JN, 2009, J BIOL CHEM, V284, P6208, DOI 10.1074/jbc.M806390200; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Katayama M, 2007, CELL DEATH DIFFER, V14, P548, DOI 10.1038/sj.cdd.4402030; Lee DY, 2008, ONCOGENE, V27, P2833, DOI 10.1038/sj.onc.1210946; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liu Y, 2001, ONCOGENE, V20, P2514, DOI 10.1038/sj.onc.1204364; Maddodi N, 2010, J INVEST DERMATOL, V130, P1657, DOI 10.1038/jid.2010.26; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mathew R, 2009, METHOD ENZYMOL, V453, P53, DOI 10.1016/S0076-6879(08)04004-4; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mizui T, 2010, J GASTROENTEROL, V45, P195, DOI 10.1007/s00535-009-0132-9; MORI N, 1995, CANCER RES, V55, P3592; Nakamura N, 1999, ONCOGENE, V18, P2667, DOI 10.1038/sj.onc.1202608; Niso-Santano M, 2012, AUTOPHAGY, V8, P268, DOI 10.4161/auto.8.2.18845; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Omodei Zorini A, 1965, Lotta Tuberc, V35, P946; Paul S, 2012, IMMUNITY, V36, P947, DOI 10.1016/j.immuni.2012.04.008; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Ren T, 2012, J BIOL CHEM, V287, P34683, DOI 10.1074/jbc.M112.377143; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Senftleben U, 2001, IMMUNITY, V14, P217, DOI 10.1016/S1074-7613(01)00104-2; Shcherbo D, 2009, BIOCHEM J, V418, P567, DOI 10.1042/BJ20081949; Sir D, 2010, P NATL ACAD SCI USA, V107, P4383, DOI 10.1073/pnas.0911373107; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Song JR, 2009, AUTOPHAGY, V5, P1131, DOI 10.4161/auto.5.8.9996; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Tang H, 2009, HEPATOLOGY, V49, P60, DOI 10.1002/hep.22581; Tang SW, 2013, J VIROL, V87, P1699, DOI 10.1128/JVI.02147-12; Tomita M, 2007, BIOCHEM J, V406, P317, DOI 10.1042/BJ20070286; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; TSUDO M, 1983, BLOOD, V61, P1014; Valentin-Acevedo A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025467; Verkade P, 1997, HISTOCHEM CELL BIOL, V108, P211, DOI 10.1007/s004180050161; VONWILLEBRAND M, 1994, EUR J IMMUNOL, V24, P234, DOI 10.1002/eji.1830240137; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; WEISS RA, 1990, CANCER CELL-MON REV, V2, P281; Wen HJ, 2010, J VIROL, V84, P7448, DOI 10.1128/JVI.00024-10; Yan PR, 2007, AUTOPHAGY, V3, P600, DOI 10.4161/auto.4761; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	66	35	37	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					373	384		10.1038/onc.2013.552	http://dx.doi.org/10.1038/onc.2013.552			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24362528	Green Accepted			2022-12-28	WOS:000348145500011
J	Yang, Y; Liu, R; Qiu, R; Zheng, Y; Huang, W; Hu, H; Ji, Q; He, H; Shang, Y; Gong, Y; Wang, Y				Yang, Y.; Liu, R.; Qiu, R.; Zheng, Y.; Huang, W.; Hu, H.; Ji, Q.; He, H.; Shang, Y.; Gong, Y.; Wang, Y.			CRL4B promotes tumorigenesis by coordinating with SUV39H1/HP1/DNMT3 A in DNA methylation-based epigenetic silencing	ONCOGENE			English	Article						CRL4B; SUV39H1; DNMT3A; HP1; transcriptional repression	FACTOR-BINDING PROTEIN-3; HISTONE H2A UBIQUITINATION; METHYLTRANSFERASES DNMT3A; CHROMATIN MODIFICATIONS; HUMAN HOMOLOG; LYSINE 9; GENE; LIGASE; GROWTH; H3	Cullin 4B (CUL4B) is a component of the Cullin4B-Ring E3 ligase complex (CRL4B) that functions in proteolysis and is implicated in tumorigenesis. Here, we report that CRL4B is associated with histone methyltransferase SUV39H1, heterochromatin protein 1 (HP1) and DNA methyltransferases 3A (DNMT3A). We showed that CRL4B, through catalyzing H2AK119 nnonoubiquitination, facilitates H3K9 tri-methylation and DNA methylation, two key epigenetic modifications involved in DNA methylation-based gene silencing. Depletion of CUL4B resulted in loss of not only H2AK119 monoubiquitination but also H3K9 trimethylation and DNA methylation, leading to derepression of a collection of genes, including the tumor suppressor IGFBP3. We demonstrated that CUL4B promotes cell proliferation and invasion, which are consistent with a tumorigenic phenotype, at least partially by repressing IGFBP3. We found that the expression of CUL4B is markedly upregulated in samples of human cervical carcinoma and is negatively correlated with the expression of IGFBP3. Our experiments unveiled a coordinated action between histone ubiquitination/methylation and DNA methylation in transcription repression, providing a mechanism for CUL4B in tunnorigenesis.	[Yang, Y.; Liu, R.; Hu, H.; Ji, Q.; Gong, Y.; Wang, Y.] Shandong Univ, Sch Med, Inst Mol Med & Genet, Key Lab Expt Teratol,Minist Educ, Jinan 250100, Shandong, Peoples R China; [Qiu, R.; Zheng, Y.; Huang, W.; Shang, Y.; Wang, Y.] Tianjin Med Univ, Collaborat Innovat Ctr Tianjin Med Epigenet 2011, Dept Biochem & Mol Biol, Tianjin Key Lab Med Epigenet, Tianjin 300070, Peoples R China; [He, H.] Univ Hlth Network, Princess Margaret Canc Ctr, Ontario Canc Inst, Toronto, ON, Canada	Shandong University; Tianjin Medical University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Wang, Y (corresponding author), Tianjin Med Univ, Collaborat Innovat Ctr Tianjin Med Epigenet 2011, Dept Biochem & Mol Biol, Tianjin Key Lab Med Epigenet, 22 Qi Xiang Tai Rd, Tianjin 300070, Peoples R China.	yanwang@tmu.edu.cn			National Natural Science Foundation of China [81322032, 31171240, 90919053]; Ministry of Education of China [NECT-12-1067]; National Basic Research Program of China [2013CB910900]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of China(Ministry of Education, China); National Basic Research Program of China(National Basic Research Program of China)	This work was supported by grants (81322032,31171240 and 90919053 to YW) from the National Natural Science Foundation of China, grant (NECT-12-1067 to YW) from the Ministry of Education of China, and grant (2013CB910900 to YG) from the National Basic Research Program of China.	Aucott R, 2008, J CELL BIOL, V183, P597, DOI 10.1083/jcb.200804041; Baarends WM, 2005, MOL CELL BIOL, V25, P1041, DOI 10.1128/MCB.25.3.1041-1053.2005; Banks D, 2006, CELL CYCLE, V5, P1719, DOI 10.4161/cc.5.15.3150; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bhattacharyya N, 2006, J BIOL CHEM, V281, P24588, DOI 10.1074/jbc.M509463200; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Brown MA, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-26; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Cang Y, 2006, CELL, V127, P929, DOI 10.1016/j.cell.2006.09.045; Chang YS, 2002, CLIN CANCER RES, V8, P3669; Chen CY, 2012, HUM MOL GENET, V21, P4270, DOI 10.1093/hmg/dds261; CREUSOT F, 1982, J BIOL CHEM, V257, P2041; de Napoles M, 2004, DEV CELL, V7, P663, DOI 10.1016/j.devcel.2004.10.005; Dumbliauskas E, 2011, EMBO J, V30, P731, DOI 10.1038/emboj.2010.359; Feng J, 2005, J NEUROSCI RES, V79, P734, DOI 10.1002/jnr.20404; Feng J, 2010, NAT NEUROSCI, V13, P423, DOI 10.1038/nn.2514; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; GOLDKNOPF IL, 1975, J BIOL CHEM, V250, P7182; Grimberg A, 2000, MOL GENET METAB, V70, P85, DOI 10.1006/mgme.2000.3008; Guerrero-Santoro J, 2008, CANCER RES, V68, P5014, DOI 10.1158/0008-5472.CAN-07-6162; Hanafusa T, 2002, CANCER LETT, V176, P149, DOI 10.1016/S0304-3835(01)00736-4; Hanafusa T, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-9; He YZJ, 2006, GENE DEV, V20, P2949, DOI 10.1101/gad.1483206; Higa LA, 2006, CELL CYCLE, V5, P71, DOI 10.4161/cc.5.1.2266; Higa LA, 2006, NAT CELL BIOL, V8, P1277, DOI 10.1038/ncb1490; Hong Eun-Jin Erica, 2005, RNA Biol, V2, P106, DOI 10.4161/rna.2.3.2131; Horn PJ, 2005, GENE DEV, V19, P1705, DOI 10.1101/gad.1328005; Hu HL, 2012, CANCER CELL, V22, P781, DOI 10.1016/j.ccr.2012.10.024; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jackson S, 2009, TRENDS BIOCHEM SCI, V34, P562, DOI 10.1016/j.tibs.2009.07.002; Jason LJM, 2002, BIOESSAYS, V24, P166, DOI 10.1002/bies.10038; Jia ST, 2005, NAT CELL BIOL, V7, P1007, DOI 10.1038/ncb1300; Kapetanaki MG, 2006, P NATL ACAD SCI USA, V103, P2588, DOI 10.1073/pnas.0511160103; Kim J, 2005, MOL CELL, V20, P759, DOI 10.1016/j.molcel.2005.11.012; Kopanja D, 2011, DEV BIOL, V352, P278, DOI 10.1016/j.ydbio.2011.01.028; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lee JS, 2007, CELL, V131, P1084, DOI 10.1016/j.cell.2007.09.046; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li F, 2008, CELL, V135, P272, DOI 10.1016/j.cell.2008.08.036; Liu HC, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-112; Liu LR, 2009, MOL CELL, V34, P451, DOI 10.1016/j.molcel.2009.04.020; McGinty RK, 2008, NATURE, V453, P812, DOI 10.1038/nature06906; Migliori V, 2012, NAT STRUCT MOL BIOL, V19, P136, DOI 10.1038/nsmb.2209; Nag A, 2004, CANCER RES, V64, P8152, DOI 10.1158/0008-5472.CAN-04-2598; Nakagawa T, 2011, MOL CELL, V43, P381, DOI 10.1016/j.molcel.2011.05.033; Nakagawa T, 2008, GENE DEV, V22, P37, DOI 10.1101/gad.1609708; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nakayama J, 2000, CELL, V101, P307, DOI 10.1016/S0092-8674(00)80840-5; Nguyen' S, 2007, DEV DYNAM, V236, P1663, DOI 10.1002/dvdy.21176; Nishitani H, 2008, J BIOL CHEM, V283, P29045, DOI 10.1074/jbc.M806045200; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Qiao Q, 2011, J BIOL CHEM, V286, P8361, DOI 10.1074/jbc.M110.204115; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; Schindl M, 2007, ANTICANCER RES, V27, P949; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Siegmund KD, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000895; Singhal S, 2003, CANCER BIOL THER, V2, P291, DOI 10.4161/cbt.2.3.399; Stock JK, 2007, NAT CELL BIOL, V9, P1428, DOI 10.1038/ncb1663; SWERDLOW PS, 1990, MOL CELL BIOL, V10, P4905, DOI 10.1128/MCB.10.9.4905; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Tarpey PS, 2007, AM J HUM GENET, V80, P345, DOI 10.1086/511134; Thon G, 2000, GENETICS, V155, P551; Tomii K, 2007, INT J CANCER, V120, P566, DOI 10.1002/ijc.22341; Wang GG, 2007, NAT CELL BIOL, V9, P804, DOI 10.1038/ncb1608; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang HB, 2006, MOL CELL, V22, P383, DOI 10.1016/j.molcel.2006.03.035; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Watanabe D, 2006, NEUROSCIENCE, V142, P727, DOI 10.1016/j.neuroscience.2006.07.053; Wiley A, 2006, INT J GYNECOL CANCER, V16, P210, DOI 10.1111/j.1525-1438.2006.00299.x; Williams AC, 2000, CANCER RES, V60, P22; Wu H, 2010, SCIENCE, V329, P444, DOI 10.1126/science.1190485; Yin Y, 2011, DEV BIOL, V356, P51, DOI 10.1016/j.ydbio.2011.05.661; Zhang H, 2004, GENE DEV, V18, P1753, DOI 10.1101/gad.1194704; Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403; Zhao Q, 2009, NAT STRUCT MOL BIOL, V16, P304, DOI 10.1038/nsmb.1568; Zhao YB, 2010, J BIOL CHEM, V285, P4355, DOI 10.1074/jbc.M109.034710; Zhu B, 2005, MOL CELL, V20, P601, DOI 10.1016/j.molcel.2005.09.025; Zhu P, 2007, MOL CELL, V27, P609, DOI 10.1016/j.molcel.2007.07.024; Zou YX, 2007, AM J HUM GENET, V80, P561, DOI 10.1086/512489; Zou YX, 2009, J BIOL CHEM, V284, P33320, DOI 10.1074/jbc.M109.050427	86	62	64	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					104	118		10.1038/onc.2013.522	http://dx.doi.org/10.1038/onc.2013.522			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24292684				2022-12-28	WOS:000349740100010
J	Hall, WA; Petrova, AV; Colbert, LE; Hardy, CW; Fisher, SB; Saka, B; Shelton, JW; Warren, MD; Pantazides, BG; Gandhi, K; Kowalski, J; Kooby, DA; El-Rayes, BF; Staley, CA; Adsay, NV; Curran, WJ; Landry, JC; Maithel, SK; Yu, DS				Hall, W. A.; Petrova, A. V.; Colbert, L. E.; Hardy, C. W.; Fisher, S. B.; Saka, B.; Shelton, J. W.; Warren, M. D.; Pantazides, B. G.; Gandhi, K.; Kowalski, J.; Kooby, D. A.; El-Rayes, B. F.; Staley, C. A., III; Adsay, N. Volkan; Curran, W. J.; Landry, J. C.; Maithel, S. K.; Yu, D. S.			Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer	ONCOGENE			English	Article						CHD5; DNA damage response; biomarker; pancreatic cancer; tumor suppressor	REMODELING FACTOR CHD5; TUMOR-SUPPRESSOR; ANALYSIS REVEALS; DOWN-REGULATION; CHEMOTHERAPY; GENE; HYPERMETHYLATION; GEMCITABINE; FLUOROURACIL; PROGNOSIS	The DNA damage response (DDR) promotes genome integrity and serves as a cancer barrier in precancerous lesions but paradoxically may promote cancer survival. Genes that activate the DDR when dysregulated could function as useful biomarkers for outcome in cancer patients. Using a siRNA screen in human pancreatic cancer cells, we identified the CHD5 tumor suppressor as a gene, which, when silenced, activates the DDR. We evaluated the relationship of CHD5 expression with DDR activation in human pancreatic cancer cells and the association of CHD5 expression in 80 patients with resected pancreatic adenocarcinoma (PAC) by immunohistochemical analysis with clinical outcome. CHD5 depletion and low CHD5 expression in human pancreatic cancer cells lead to increased H2AX-Ser139 and CHK2-Thr68 phosphorylation and accumulation into nuclear foci. On Kaplan-Meier log-rank survival analysis, patients with low CHD5 expression had a median recurrence-free survival (RFS) of 5.3 vs 15.4 months for patients with high CHD5 expression (P = 0.03). In 59 patients receiving adjuvant chemotherapy, low CHD5 expression was associated with decreased RFS (4.5 vs 16.3 months; P = 0.001) and overall survival (OS) (7.2 vs 21.6 months; P = 0.003). On multivariate Cox regression analysis, low CHD5 expression remained associated with worse OS (HR: 3.187 (95% CI: 1.49-6.81); P = 0.003) in patients undergoing adjuvant chemotherapy. Thus, low CHD5 expression activates the DDR and predicts for worse OS in patients with resected PAC receiving adjuvant chemotherapy. Our findings support a model in which dysregulated expression of tumor suppressor genes that induce DDR activation can be utilized as biomarkers for poor outcome.	[Hall, W. A.; Petrova, A. V.; Colbert, L. E.; Hardy, C. W.; Shelton, J. W.; Warren, M. D.; Pantazides, B. G.; Curran, W. J.; Landry, J. C.; Yu, D. S.] Emory Univ, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA 30322 USA; [Fisher, S. B.; Kooby, D. A.; Staley, C. A., III; Maithel, S. K.] Emory Univ, Winship Canc Inst, Dept Surg, Div Surg Oncol, Atlanta, GA 30322 USA; [Saka, B.; Adsay, N. Volkan] Emory Univ, Winship Canc Inst, Dept Pathol, Atlanta, GA 30322 USA; [Gandhi, K.; Kowalski, J.] Winship Canc Inst, Atlanta, GA USA; [Kooby, D. A.] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA; [El-Rayes, B. F.] Emory Univ, Winship Canc Inst, Dept Med Oncol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Emory University	Yu, DS (corresponding author), Emory Univ, Sch Med, Dept Radiat Oncol, 1365 Clifton Rd NE,C3008, Atlanta, GA 30322 USA.	dsyu@emory.edu	Shelton, Joseph/AAH-1851-2020; Saka, Burcu/R-3487-2016; Adsay, Volkan/N-7130-2017; el-rayes, bassel/ABD-2901-2021; Colbert, Lauren/G-5860-2016	Adsay, Volkan/0000-0002-1308-3701; el-rayes, bassel/0000-0002-2661-5746; Colbert, Lauren/0000-0001-5806-4339; Kowalski, Jeanne/0000-0003-3458-3024; Fisher, Sarah/0000-0002-6881-2633	National Center for Advancing Translational Sciences of the National Institutes of Health [ULl TR000454, TLlTR000456]; PanCAN/AACR [16982]; DOD/PRCRP [CA110535]; Georgia Cancer Coalition [11072]; NATIONAL CANCER INSTITUTE [R44CA110535, R43CA110535] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER	National Center for Advancing Translational Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); PanCAN/AACR; DOD/PRCRP; Georgia Cancer Coalition; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank members of the Yu lab for helpful discussion. This work is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Numbers ULl TR000454 to LEC and SBF and TLlTR000456 to LEC, PanCAN/AACR 16982 to DSY, DOD/PRCRP CA110535 to DSY and Georgia Cancer Coalition 11072 to DSY.	Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Colbert LE, 2013, CANCER-AM CANCER SOC, V119, P3148, DOI 10.1002/cncr.28144; Du XL, 2013, CLIN TRANSL ONCOL, V15, P198, DOI 10.1007/s12094-012-0903-2; Fisher SL, 2012, TRANSFORMING PLACES: LESSONS FROM APPALACHIA, P1; Forbes S, 2006, BRIT J CANCER, V94, P318, DOI 10.1038/sj.bjc.6602928; Fujita T, 2008, JNCI-J NATL CANCER I, V100, P940, DOI 10.1093/jnci/djn176; Garcia I, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-277; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gorringe KL, 2008, NEOPLASIA, V10, P1253, DOI 10.1593/neo.08718; Iacobuzio-Donahue CA, 2009, J CLIN ONCOL, V27, P1806, DOI 10.1200/JCO.2008.17.7188; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Koyama H, 2012, CLIN CANCER RES, V18, P1588, DOI 10.1158/1078-0432.CCR-11-2644; Law ME, 2005, CANCER GENET CYTOGEN, V160, P1, DOI 10.1016/j.cancergencyto.2004.11.012; Maithel SK, 2011, ANN SURG ONCOL, V18, P2699, DOI 10.1245/s10434-011-1610-x; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Maupin KA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013002; Mokarram P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007012; Mulero-Navarro S, 2008, EPIGENETICS-US, V3, P210, DOI 10.4161/epi.3.4.6610; Neoptolemos JP, 2010, JAMA-J AM MED ASSOC, V304, P1073, DOI 10.1001/jama.2010.1275; Ng David, 2008, BMC Res Notes, V1, P86, DOI 10.1186/1756-0500-1-86; Oettle H, 2007, JAMA-J AM MED ASSOC, V297, P267, DOI 10.1001/jama.297.3.267; Okawa ER, 2008, ONCOGENE, V27, P803, DOI 10.1038/sj.onc.1210675; Paul S, 2013, CELL REP, V3, P92, DOI 10.1016/j.celrep.2012.12.009; Pei HD, 2009, CANCER CELL, V16, P259, DOI 10.1016/j.ccr.2009.07.016; Regine WF, 2008, JAMA-J AM MED ASSOC, V299, P1019, DOI 10.1001/jama.299.9.1019; Robbins CM, 2011, GENOME RES, V21, P47, DOI 10.1101/gr.107961.110; Wang J, 2011, ORAL ONCOL, V47, P601, DOI 10.1016/j.oraloncology.2011.05.003; Wang L, 2013, J CLIN NEUROSCI, V20, P958, DOI 10.1016/j.jocn.2012.07.021; Wang X, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-95; Wong RRY, 2011, GYNECOL OBSTET INVES, V72, P203, DOI 10.1159/000323883; Wu X, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3182; Zhao R, 2012, LUNG CANCER, V76, P324, DOI 10.1016/j.lungcan.2011.11.019	33	14	15	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2014	33	47					5450	5456		10.1038/onc.2013.488	http://dx.doi.org/10.1038/onc.2013.488			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MG	24276239				2022-12-28	WOS:000345120700007
J	Chitnis, MM; Lodhia, KA; Aleksic, T; Gao, S; Protheroe, AS; Macaulay, VM				Chitnis, M. M.; Lodhia, K. A.; Aleksic, T.; Gao, S.; Protheroe, A. S.; Macaulay, V. M.			IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination	ONCOGENE			English	Article						IGF-1R; radiosensitization; DNA repair; double-strand break; non-homologous end joining; homologous recombination	GROWTH-FACTOR RECEPTOR; PROSTATE-CANCER CELLS; DNA-DAMAGE RESPONSE; DEPENDENT PROTEIN-KINASE; PTEN WILD-TYPE; MITOTIC CATASTROPHE; IONIZING-RADIATION; DOWN-REGULATION; TUMOR-CELLS; CYCLIN D1	Inhibition of type 1 insulin-like growth factor receptor (IGF-1R) enhances tumor cell sensitivity to ionizing radiation. It is not clear how this effect is mediated, nor whether this approach can be applied effectively in the clinic. We previously showed that IGF-1R depletion delays repair of radiation-induced DNA double-strand breaks (DSBs), unlikely to be explained entirely by reduction in homologous recombination (HR) repair. The current study tested the hypothesis that IGF-1R inhibition induces a repair defect that involves non-homologous end joining (NHEJ). IGF-1R inhibitor AZ12253801 blocked cell survival and radiosensitized IGF-1R-overexpressing murine fibroblasts but not isogenic IGF-1R-null cells, supporting specificity for IGF-1R. IGF-1R inhibition enhanced radiosensitivity in DU145, PC3 and 22Rv1 prostate cancer cells, comparable to effects of Ataxia Telangiectasia Mutated inhibition. AZ12253801-treated DU145 cells showed delayed resolution of gamma H2AX foci, apparent within 1 h of irradiation and persisting for 24 h. In contrast, IGF-1R inhibition did not influence radiosensitivity or gamma H2AX focus resolution in LNCaP-LN3 cells, suggesting that radiosensitization tracks with the ability of IGF-1R to influence DSB repair. To differentiate effects on repair from growth and cell-survival responses, we tested AZ12253801 in DU145 cells at sub-SF50 concentrations that had no early (<= 48 h) effects on cell cycle distribution or apoptosis induction. Irradiated cultures contained abnormal mitoses, and after 5 days IGF-1R-inhibited cells showed enhanced radiation-induced polyploidy and nuclear fragmentation, consistent with the consequences of entry into mitosis with incompletely repaired DNA. AZ12253801 radiosensitized DNA-dependent protein kinase (DNA-PK)-proficient but not DNA-PK-deficient glioblastoma cells, and did not radiosensitize DNA-PK-inhibited DU145 cells, suggesting that in the context of DSB repair, IGF-1R functions in the same pathway as DNA-PK. Finally, IGF-1R inhibition attenuated repair by both NHEJ and HR in HEK293 reporter assays. These data indicate that IGF-1R influences DSB repair by both major DSB repair pathways, findings that may inform clinical application of this approach.	[Chitnis, M. M.; Lodhia, K. A.; Aleksic, T.; Gao, S.; Macaulay, V. M.] Univ Oxford, Weatherall Inst Mol Med, John Radcliffe Hosp, Dept Oncol Labs, Oxford OX3 9DS, England; [Chitnis, M. M.; Protheroe, A. S.; Macaulay, V. M.] Churchill Hosp, Canc & Haematol Ctr, Dept Oncol, Oxford OX3 7LJ, England	University of Oxford; University of Oxford	Macaulay, VM (corresponding author), Univ Oxford, Weatherall Inst Mol Med, John Radcliffe Hosp, Dept Oncol Labs, Oxford OX3 9DS, England.	valentine.macaulay@oncology.ox.ac.uk			NIHR Oxford Biomedical Research Centre; Molecular and Cellular Medicine Board of the MRC; Cancer Research UK Clinical Research Fellowship; Prostate Cancer UK; NIHR Research Capability Funding; Breast Cancer Campaign; MRC [G0601061] Funding Source: UKRI; Medical Research Council [G0601061] Funding Source: researchfish; Prostate Cancer UK [G2012-25] Funding Source: researchfish; Breast Cancer Campaign [2012NovPR046] Funding Source: researchfish	NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); Molecular and Cellular Medicine Board of the MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK Clinical Research Fellowship; Prostate Cancer UK; NIHR Research Capability Funding; Breast Cancer Campaign; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Prostate Cancer UK; Breast Cancer Campaign	This work was supported by the NIHR Oxford Biomedical Research Centre, Molecular and Cellular Medicine Board of the MRC, Cancer Research UK Clinical Research Fellowship to MMC, Prostate Cancer UK support to KL and TA, NIHR Research Capability Funding to KL, Breast Cancer Campaign for support to SG and HEFCE Clinical Senior Lectureship to VMM. We are grateful to Elaine Kilgour and Elizabeth Anderson at AstraZeneca for providing AZ12253801; Walter Bodmer for LNCaP-LN3 cells; Renato Baserga for R+ and R- cells; Dr Anne Kiltie for M059J and M059K cells; Jeremy Stark and Wojciech Niedzwiedz for HEK293 EJ5-GFP/TST and HEK293 DR-GFP/TST cells; Olga Perestenko for primary renal cancer cells; and Peter McHugh and Tim Humphrey for comments on the manuscript.	Aleksic T, 2010, CANCER RES, V70, P6412, DOI 10.1158/0008-5472.CAN-10-0052; ALLALUNISTURNER MJ, 1995, RADIAT RES, V144, P288, DOI 10.2307/3578948; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Bielen A, 2012, P NATL ACAD SCI USA, V109, pE1267, DOI 10.1073/pnas.1105034109; Bolderson E, 2009, CLIN CANCER RES, V15, P6314, DOI 10.1158/1078-0432.CCR-09-0096; Bowen C, 2002, J BIOL CHEM, V277, P44969, DOI 10.1074/jbc.M202000200; Carboni JM, 2009, MOL CANCER THER, V8, P3341, DOI 10.1158/1535-7163.MCT-09-0499; Cosaceanu D, 2007, ONCOGENE, V26, P2423, DOI 10.1038/sj.onc.1210037; Dittmann K, 2005, J BIOL CHEM, V280, P31182, DOI 10.1074/jbc.M506591200; Dupont J, 2003, CELL CYCLE, V2, P270, DOI 10.4161/cc.2.4.408; Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364; Fabbri F, 2008, J CELL PHYSIOL, V217, P494, DOI 10.1002/jcp.21522; Ferte C, 2013, MOL CANCER THER, V12, P1213, DOI 10.1158/1535-7163.MCT-12-1067; Flanigan SA, 2010, CLIN CANCER RES, V16, P5436, DOI 10.1158/1078-0432.CCR-10-2054; Fraser M, 2012, CLIN CANCER RES, V18, P1015, DOI 10.1158/1078-0432.CCR-11-2189; Gonzalez-Vasconcellos I, 2013, CANCER RES, V73, P4247, DOI 10.1158/0008-5472.CAN-12-3117; Goodarzi AA, 2008, MOL CELL, V31, P167, DOI 10.1016/j.molcel.2008.05.017; Grzmil M, 2004, J PATHOL, V202, P50, DOI 10.1002/path.1492; Harrington KJ, 2011, BRIT J CANCER, V105, P628, DOI 10.1038/bjc.2011.240; Hellawell GO, 2002, CANCER RES, V62, P2942; Hinz JM, 2005, DNA REPAIR, V4, P782, DOI 10.1016/j.dnarep.2005.03.005; Isebaert SF, 2011, INT J RADIAT ONCOL, V81, P239, DOI 10.1016/j.ijrobp.2011.03.030; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Javle M.M., 2011, J CLIN ONCOL S, V29; Jeon JH, 2008, CANCER LETT, V272, P232, DOI 10.1016/j.canlet.2008.07.011; Jirawatnotai S, 2011, NATURE, V474, P230, DOI 10.1038/nature10155; Johnson N, 2011, NAT MED, V17, P875, DOI 10.1038/nm.2377; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; Krueckl SL, 2004, CANCER RES, V64, P8620, DOI 10.1158/0008-5472.CAN-04-2446; Kuemmerle JF, 2004, AM J PHYSIOL-GASTR L, V286, pG412, DOI 10.1152/ajpgi.00403.2003; Kurmasheva RT, 2006, BBA-REV CANCER, V1766, P1, DOI 10.1016/j.bbcan.2006.05.003; Lehmann BD, 2007, CELL CYCLE, V6, P595, DOI 10.4161/cc.6.5.3901; Liao YD, 2005, HUM PATHOL, V36, P1186, DOI 10.1016/j.humpath.2005.07.023; Litzenburger BC, 2011, CLIN CANCER RES, V17, P2314, DOI 10.1158/1078-0432.CCR-10-1903; Lloret M, 2009, INT J RADIAT ONCOL, V73, P976, DOI 10.1016/j.ijrobp.2008.11.013; Lobrich M, 2010, CELL CYCLE, V9, P662, DOI 10.4161/cc.9.4.10764; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; McConkey DJ, 1996, CANCER RES, V56, P5594; Molife LR, 2010, BRIT J CANCER, V103, P332, DOI 10.1038/sj.bjc.6605767; Mujoo K, 2005, PROSTATE, V62, P91, DOI 10.1002/pros.20114; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Riesterer O, 2011, INT J RADIAT ONCOL, V79, P1179, DOI 10.1016/j.ijrobp.2010.10.003; Roberts DJ, 2012, ENVIRON MOL MUTAGEN, V53, P297, DOI 10.1002/em.21684; Rochester MA, 2005, CANCER GENE THER, V12, P90, DOI 10.1038/sj.cgt.7700775; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Sarfstein R, 2012, J BIOL CHEM, V287, P2766, DOI 10.1074/jbc.M111.281782; Scott SL, 2003, CANCER RES, V63, P7190; Scurr LL, 2010, CELL, V141, P717, DOI 10.1016/j.cell.2010.04.021; Sehat B, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000628; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; Shaw PHS, 2011, BRIT J CANCER, V105, P649, DOI 10.1038/bjc.2011.291; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; Solier S, 2011, CANCER RES, V71, P906, DOI 10.1158/0008-5472.CAN-10-3297; Solier S, 2009, CELL CYCLE, V8, P1853, DOI 10.4161/cc.8.12.8865; Sprenger CC, 2002, ONCOGENE, V21, P140, DOI 10.1038/sj.onc.1205021; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; Sroka IC, 2008, PROSTATE, V68, P463, DOI 10.1002/pros.20718; Steiner MS, 2000, CANCER GENE THER, V7, P360, DOI 10.1038/sj.cgt.7700151; Tezuka M, 2001, CLIN CANCER RES, V7, P3206; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; Turney BW, 2012, RADIOTHER ONCOL, V103, P402, DOI 10.1016/j.radonc.2012.03.009; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; Valenciano A, 2012, TRANSL ONCOL, V5, P1, DOI 10.1593/tlo.11265; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Wouters B., 2009, CELL DEATH IRRADIATI; Wu JD, 2005, CLIN CANCER RES, V11, P3065, DOI 10.1158/1078-0432.CCR-04-1586; Xu NH, 2012, J ONCOL, V2012, DOI 10.1155/2012/951724; Yata K, 2009, DNA REPAIR, V8, P6, DOI 10.1016/j.dnarep.2008.09.002; Yee D, 2012, JNCI-J NATL CANCER I, V104, P975, DOI 10.1093/jnci/djs258; Zhang RG, 2007, CELL CYCLE, V6, P784, DOI 10.4161/cc.6.7.4079; Zhao Y, 2006, CANCER RES, V66, P5354, DOI 10.1158/0008-5472.CAN-05-4275	73	62	62	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2014	33	45					5262	5273		10.1038/onc.2013.460	http://dx.doi.org/10.1038/onc.2013.460			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MD	24186206	Green Accepted			2022-12-28	WOS:000345120400004
J	Amelio, I; Markert, EK; Rufini, A; Antonov, AV; Sayan, BS; Tucci, P; Agostini, M; Mineo, TC; Levine, AJ; Melino, G				Amelio, I.; Markert, E. K.; Rufini, A.; Antonov, A. V.; Sayan, B. S.; Tucci, P.; Agostini, M.; Mineo, T. C.; Levine, A. J.; Melino, G.			p73 regulates serine biosynthesis in cancer	ONCOGENE			English	Article						serine; glucose; cancer metabolism; p73; GLS-2; lung adenocarcinoma	PYRUVATE-KINASE M2; CELL-SURVIVAL; P53; METABOLISM; APOPTOSIS; MICE; INSTABILITY; DELTA-NP73; SENESCENCE; DELTANP73	Activation of serine biosynthesis supports growth and proliferation of cancer cells. Human cancers often exhibit overexpression of phosphoglycerate dehydrogenase (PHGDH), the metabolic enzyme that catalyses the reaction that diverts serine biosynthesis from the glycolytic pathway. By refueling serine biosynthetic pathways, cancer cells sustain their metabolic requirements, promoting macromolecule synthesis, anaplerotic flux and ATP. Serine biosynthesis intersects glutaminolysis and together with this pathway provides substrates for production of antioxidant GSH. In human lung adenocarcinomas we identified a correlation between serine biosynthetic pathway and p73 expression. Metabolic profiling of human cancer cell line revealed that TAp73 activates serine biosynthesis, resulting in increased intracellular levels of serine and glycine, associated to accumulation of glutamate, tricarboxylic acid (TCA) anaplerotic intermediates and GSH. However, at molecular level p73 does not directly regulate serine metabolic enzymes, but transcriptionally controls a key enzyme of glutaminolysis, glutaminase-2 (GLS-2). p73, through GLS-2, favors conversion of glutamine in glutamate, which in turn drives the serine biosynthetic pathway. Serine and glutamate can be then employed for GSH synthesis, thus the p73-dependent metabolic switch enables potential response against oxidative stress. In knockdown experiment, indeed, TAp73 depletion completely abrogates cancer cell proliferation capacity in serine/glycine-deprivation, supporting the role of p73 to help cancer cells under metabolic stress. These findings implicate p73 in regulation of cancer metabolism and suggest that TAp73 influences glutamine and serine metabolism, affecting GSH synthesis and determining cancer pathogenesis.	[Amelio, I.; Rufini, A.; Antonov, A. V.; Sayan, B. S.; Tucci, P.; Agostini, M.; Melino, G.] Univ Leicester, Toxicol Unit, Med Res Council, Leicester LE1 9HN, Leics, England; [Markert, E. K.; Levine, A. J.] Inst Adv Study, Simons Ctr Syst Biol, Princeton, NJ 08540 USA; [Rufini, A.] Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE1 9HN, Leics, England; [Antonov, A. V.] Technol Univ, Mol Pharmacol Lab, St Petersburg, Russia; [Mineo, T. C.] Univ Roma Tor Vergata, Div Thorac Surg, Rome, Italy; [Melino, G.] Univ Roma Tor Vergata, Dept Expt Med & Surg, Rome, Italy	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Leicester; Institute for Advanced Study - USA; University of Leicester; University of Rome Tor Vergata; University of Rome Tor Vergata	Melino, G (corresponding author), Univ Leicester, Toxicol Unit, Med Res Council, Leicester LE1 9HN, Leics, England.	gm89@le.ac.uk	Amelio, Ivano/AAI-4686-2020; Agostini, Massimiliano/AAE-7971-2019; Agostini, Massimiliano/G-9579-2014	Agostini, Massimiliano/0000-0003-3124-2072; Agostini, Massimiliano/0000-0003-3124-2072; Sayan, Berna/0000-0003-2305-1970; TUCCI, PAOLA/0000-0002-9349-5203; Amelio, Ivano/0000-0002-9126-5391	Medical Research Council, United Kingdom; Ministry of Education and Science of the Russian Federation [11.G34.31.0069, 14.B37.21.1967]; MIUR, MinSan/IDI-IRCCS [RF73, RF57, ACC12]; AIRC [2011-IG11955]; AIRC 5xmille (MCO) [9979]; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	Medical Research Council, United Kingdom(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Ministry of Education and Science of the Russian Federation(Ministry of Education and Science, Russian Federation); MIUR, MinSan/IDI-IRCCS(Ministry of Education, Universities and Research (MIUR)); AIRC(Fondazione AIRC per la ricerca sul cancro); AIRC 5xmille (MCO)(Fondazione AIRC per la ricerca sul cancro); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work has been supported by the Medical Research Council, United Kingdom; MIUR, MinSan/IDI-IRCCS (RF73, RF57), ACC12, AIRC (2011-IG11955), AIRC 5xmille (MCO #9979) to GM Work was supported by Ministry of Education and Science of the Russian Federation (11.G34.31.0069) to GM & (14.B37.21.1967) to AAV.	Adams CM, 2007, J BIOL CHEM, V282, P16744, DOI 10.1074/jbc.M610510200; Al-Bahlani S, 2011, ONCOGENE, V30, P4219, DOI 10.1038/onc.2011.134; ASHIZAWA K, 1991, J BIOL CHEM, V266, P16842; Astle MV, 2012, ONCOGENE, V31, P1949, DOI 10.1038/onc.2011.394; Bantel H, 2010, CELL CYCLE, V9, P2710, DOI 10.4161/cc.9.14.12592; Boren J, 2012, CELL DEATH DIFFER, V19, P1561, DOI 10.1038/cdd.2012.34; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chaneton B, 2012, NATURE, V491, P458, DOI 10.1038/nature11540; Chang JY, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.36; Cho JH, 2012, CELL DEATH DIFFER, V19, P703, DOI 10.1038/cdd.2011.142; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Conforti F, 2013, ONCOGENE, V32, P4758, DOI 10.1038/onc.2012.497; Conforti F, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.27; Donzelli S, 2012, CELL DEATH DIFFER, V19, P1038, DOI 10.1038/cdd.2011.190; Dulloo I, 2010, P NATL ACAD SCI USA, V107, P4902, DOI 10.1073/pnas.0906782107; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Haruki N, 2001, AM J PATHOL, V159, P1345, DOI 10.1016/S0002-9440(10)62521-7; Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107; Huang BH, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.180; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Kibe R, 2012, CELL DEATH DIFFER, V19, P1139, DOI 10.1038/cdd.2011.203; Leonova KI, 2013, P NATL ACAD SCI USA, V110, pE89, DOI 10.1073/pnas.1216922110; Levine AJ, 2011, NAT REV MOL CELL BIO, V12, P259, DOI 10.1038/nrm3086; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Maddocks ODK, 2013, NATURE, V493, P542, DOI 10.1038/nature11743; Malatesta M, 2013, ONCOGENE, V32, P4721, DOI 10.1038/onc.2012.463; Masse I, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.62; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Nomura DK, 2010, CELL, V140, P49, DOI 10.1016/j.cell.2009.11.027; Okayama H, 2012, CANCER RES, V72, P100, DOI 10.1158/0008-5472.CAN-11-1403; Pollari S, 2011, BREAST CANCER RES TR, V125, P421, DOI 10.1007/s10549-010-0848-5; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Ravni A, 2010, CELL CYCLE, V9, P1523, DOI 10.4161/cc.9.8.11291; Rufini Alessandro, 2011, Genes Cancer, V2, P491, DOI 10.1177/1947601911408890; Sayan BS, 2010, P NATL ACAD SCI USA, V107, P12877, DOI 10.1073/pnas.0911828107; Seo J, 2009, DIABETES, V58, P2565, DOI 10.2337/db09-0335; Soria C, 2010, NATURE, V466, P1076, DOI 10.1038/nature09307; Suzuki S, 2010, P NATL ACAD SCI USA, V107, P7461, DOI 10.1073/pnas.1002459107; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Tomasini R, 2008, TRENDS CELL BIOL, V18, P244, DOI 10.1016/j.tcb.2008.03.003; Wilhelm MT, 2010, GENE DEV, V24, P549, DOI 10.1101/gad.1873910; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Ye JB, 2012, P NATL ACAD SCI USA, V109, P6904, DOI 10.1073/pnas.1204176109	47	77	82	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2014	33	42					5039	5046		10.1038/onc.2013.456	http://dx.doi.org/10.1038/onc.2013.456			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OB	24186203	Green Submitted			2022-12-28	WOS:000343768000008
J	Trautmann, M; Sievers, E; Aretz, S; Kindler, D; Michels, S; Friedrichs, N; Renner, M; Kirfel, J; Steiner, S; Huss, S; Koch, A; Penzel, R; Larsson, O; Kawai, A; Tanaka, S; Sonobe, H; Waha, A; Schirmacher, P; Mechtersheimer, G; Wardelmann, E; Buttner, R; Hartmann, W				Trautmann, M.; Sievers, E.; Aretz, S.; Kindler, D.; Michels, S.; Friedrichs, N.; Renner, M.; Kirfel, J.; Steiner, S.; Huss, S.; Koch, A.; Penzel, R.; Larsson, O.; Kawai, A.; Tanaka, S.; Sonobe, H.; Waha, A.; Schirmacher, P.; Mechtersheimer, G.; Wardelmann, E.; Buettner, R.; Hartmann, W.			SS18-SSX fusion protein-induced Wnt/beta-catenin signaling is a therapeutic target in synovial sarcoma	ONCOGENE			English	Article						Synovial sarcoma; SYT-SSX; beta-catenin; Wnt signaling pathway; PKF115-584; CGP049090; PKF118-310	SMALL-MOLECULE ANTAGONISTS; SOFT-TISSUE SARCOMA; CELLS IN-VITRO; BETA-CATENIN; GENE-EXPRESSION; BREAST-CANCER; COMPLEX; TRANSLOCATION; INHIBITORS; MUTATIONS	Synovial sarcoma is a high-grade soft tissue malignancy characterized by a specific reciprocal translocation t(X; 18), which leads to the fusion of the SS18 (SYT) gene to one of three SSX genes (SSX1, SSX2 or SSX4). The resulting chimeric SS18-SSX protein is suggested to act as an oncogenic transcriptional regulator. Despite multimodal therapeutic approaches, metastatic disease is often lethal and the development of novel targeted therapeutic strategies is required. Several expression-profiling studies identified distinct gene expression signatures, implying a consistent role of Wnt/beta-catenin signaling in synovial sarcoma tumorigenesis. Here we investigate the functional and therapeutic relevance of Wnt/beta-catenin pathway activation in vitro and in vivo. Immunohistochemical analyses of nuclear beta-catenin and Wnt downstream targets revealed activation of canonical Wnt signaling in a significant subset of 30 primary synovial sarcoma specimens. Functional aspects of Wnt signaling including dependence of Tcf/beta-catenin complex activity on the SS18-SSX fusion proteins were analyzed. Efficient SS18-SSX-dependent activation of the Tcf/beta-catenin transcriptional complex was confirmed by TOPflash reporter luciferase assays and immunoblotting. In five human synovial sarcoma cell lines, inhibition of the Tcf/beta-catenin protein-protein interaction significantly blocked the canonical Wnt/beta-catenin signaling cascade, accompanied by the effective downregulation of Wnt targets (AXIN2, CDC25A, c-MYC, DKK1, CyclinD1 and Survivin) and the specific suppression of cell viability associated with the induction of apoptosis. In SYO-1 synovial sarcoma xenografts, administration of small molecule Tcf/beta-catenin complex inhibitors significantly reduced tumor growth, associated with diminished AXIN2 protein levels. In summary, SS18-SSX-induced Wnt/beta-catenin signaling appears to be of crucial biological importance in synovial sarcoma tumorigenesis and progression, representing a potential molecular target for the development of novel therapeutic strategies.	[Trautmann, M.; Sievers, E.; Kindler, D.; Michels, S.; Friedrichs, N.; Huss, S.; Wardelmann, E.; Buettner, R.; Hartmann, W.] Univ Hosp Cologne, Dept Pathol, D-50937 Cologne, Germany; [Trautmann, M.; Kirfel, J.; Steiner, S.] Univ Hosp Bonn, Dept Pathol, Bonn, Germany; [Aretz, S.] Univ Bonn, Inst Human Genet, Bonn, Germany; [Renner, M.; Penzel, R.; Schirmacher, P.; Mechtersheimer, G.] Univ Heidelberg Hosp, Dept Pathol, Heidelberg, Germany; [Koch, A.] Charite, Dept Neuropathol, D-13353 Berlin, Germany; [Larsson, O.] Karolinska Inst, Dept Oncol & Pathol, Stockholm, Sweden; [Kawai, A.] Natl Canc Ctr, Div Orthopaed Surg, Tokyo, Japan; [Tanaka, S.] Hokkaido Univ, Grad Sch Med, Lab Mol & Cellular Pathol, Sapporo, Hokkaido, Japan; [Sonobe, H.] Chungoku Cent Hosp, Dept Lab Med, Fukuyama, Hiroshima, Japan; [Waha, A.] Univ Hosp Bonn, Dept Neuropathol, Bonn, Germany	University of Cologne; University of Bonn; University of Bonn; Ruprecht Karls University Heidelberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Karolinska Institutet; National Cancer Center - Japan; Hokkaido University; University of Bonn	Hartmann, W (corresponding author), Univ Hosp Cologne, Dept Pathol, Kerpener Str 62, D-50937 Cologne, Germany.	wolfgang.hartmann@uk-koeln.de	Trautmann, Marcel/B-4627-2015; Aretz, Stefan/C-1241-2008; Hartmann, Wolfgang/G-1893-2017; Tanaka, Shinya/D-3586-2011	Trautmann, Marcel/0000-0002-5842-1196; Aretz, Stefan/0000-0002-5228-1890; Hartmann, Wolfgang/0000-0002-7609-5021; 	Wilhelm Sander-Stiftung; Dr Eberhard und Hilde Rudiger Stiftung; Deutsche Krebshilfe (KoSar sarcoma competence network); BONFOR (Medical Faculty, University Hospital Bonn, Bonn); Fortune program (Medical Faculty, University of Cologne, Cologne)	Wilhelm Sander-Stiftung; Dr Eberhard und Hilde Rudiger Stiftung; Deutsche Krebshilfe (KoSar sarcoma competence network); BONFOR (Medical Faculty, University Hospital Bonn, Bonn); Fortune program (Medical Faculty, University of Cologne, Cologne)	PKF115-584, CGP049090 and PKF118-310 were generously provided by A Wood (Novartis Pharma AG, Basel, Switzerland). This study was supported by Wilhelm Sander-Stiftung, Dr Eberhard und Hilde Rudiger Stiftung, Deutsche Krebshilfe (KoSar sarcoma competence network), BONFOR (Medical Faculty, University Hospital Bonn, Bonn) and Fortune program (Medical Faculty, University of Cologne, Cologne).	Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Baird K, 2005, CANCER RES, V65, P9226, DOI 10.1158/0008-5472.CAN-05-1699; Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154; Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; de Bruijn DRH, 2006, CANCER RES, V66, P9474, DOI 10.1158/0008-5472.CAN-05-3726; Francis P, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-73; Friedrichs N, 2006, DIAGN MOL PATHOL, V15, P83, DOI 10.1097/00019606-200606000-00004; Friedrichs N, 2008, J PATHOL, V216, P428, DOI 10.1002/path.2438; Gandhirajan RK, 2010, NEOPLASIA, V12, P326, DOI 10.1593/neo.91972; Garcia CB, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-189; Haldar M, 2008, CLIN ORTHOP RELAT R, V466, P2156, DOI 10.1007/s11999-008-0340-2; Haldar M, 2007, CANCER CELL, V11, P375, DOI 10.1016/j.ccr.2007.01.016; Haldar M, 2009, CANCER RES, V69, P3657, DOI 10.1158/0008-5472.CAN-08-4127; Hasegawa T, 2001, HUM PATHOL, V32, P257, DOI 10.1053/hupa.2001.22764; Kadoch C, 2013, CELL, V153, P71, DOI 10.1016/j.cell.2013.02.036; Kawai A, 2004, CANCER LETT, V204, P105, DOI 10.1016/j.canlet.2003.09.031; Kim SY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008979; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Lubieniecka JM, 2008, CANCER RES, V68, P4303, DOI 10.1158/0008-5472.CAN-08-0092; Michels S, 2013, CANCER RES, V73, P2518, DOI 10.1158/0008-5472.CAN-12-3023; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nagayama S, 2002, CANCER RES, V62, P5859; Naka N, 2010, STEM CELLS, V28, P1119, DOI 10.1002/stem.452; Ng TL, 2005, MODERN PATHOL, V18, P68, DOI 10.1038/modpathol.3800272; Nguyen Anne, 2009, Sarcoma, V2009, P794901, DOI 10.1155/2009/794901; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; NOJIMA T, 1990, ACTA PATHOL JAPON, V40, P486; Pretto D, 2006, ONCOGENE, V25, P3661, DOI 10.1038/sj.onc.1209413; Provost E, 2005, ONCOGENE, V24, P2667, DOI 10.1038/sj.onc.1208346; Romagnolo B, 1999, CANCER RES, V59, P3875; Saito T, 2000, J PATHOL, V192, P342, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH705>3.0.CO;2-R; Saito T, 2002, J PATHOL, V196, P445, DOI 10.1002/path.1066; Sato H, 2001, VIRCHOWS ARCH, V438, P23; Segal NH, 2003, AM J PATHOL, V163, P691, DOI 10.1016/S0002-9440(10)63696-6; SONOBE H, 1992, LAB INVEST, V67, P498; Soulez M, 1999, ONCOGENE, V18, P2739, DOI 10.1038/sj.onc.1202613; Su L, 2012, CANCER CELL, V21, P333, DOI 10.1016/j.ccr.2012.01.010; Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200; Trosset JY, 2006, PROTEINS, V64, P60, DOI 10.1002/prot.20955; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V23, P93, DOI 10.1016/0165-4608(86)90153-6; Vijayakumar S, 2011, CANCER CELL, V19, P601, DOI 10.1016/j.ccr.2011.03.010; Webb J.L., 1966, ENZYME METABOLIC INH; Wei W, 2010, INT J CANCER, V126, P2426, DOI 10.1002/ijc.24810; Weiss SW, 2007, ENZINGER, DOI DOI 10.3109/02844319209035195; Zhang M, 2013, ACS MED CHEM LETT, V4, P306, DOI 10.1021/ml300367f	52	64	69	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2014	33	42					5006	5016		10.1038/onc.2013.443	http://dx.doi.org/10.1038/onc.2013.443			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OB	24166495				2022-12-28	WOS:000343768000005
J	Nam, S; Chang, HR; Kim, KT; Kook, MC; Hong, D; Kwon, CH; Jung, HR; Park, HS; Powis, G; Liang, H; Park, T; Kim, YH				Nam, S.; Chang, H. R.; Kim, K-T; Kook, M-C; Hong, D.; Kwon, C. H.; Jung, H. R.; Park, H. S.; Powis, G.; Liang, H.; Park, T.; Kim, Y. H.			PATHOME: an algorithm for accurately detecting differentially expressed subpathways	ONCOGENE			English	Article							SET ENRICHMENT ANALYSIS; GASTRIC-CANCER; INTEGRATIVE ANALYSIS; SIGNALING PATHWAY; DATABASE; GENOME; NETWORK; TRANSCRIPTION; MEDICINE; ONTOLOGY	The translation of high-throughput gene expression data into biologically meaningful information remains a bottleneck. We developed a novel computational algorithm, PATHOME, for detecting differentially expressed biological pathways. This algorithm employs straightforward statistical tests to evaluate the significance of differential expression patterns along subpathways. Applying it to gene expression data sets of gastric cancer (GC), we compared its performance with those of other leading programs. Based on a literature-driven reference set, PATHOME showed greater consistency in identifying known cancer-related pathways. For the WNT pathway uniquely identified by PATHOME, we validated its involvement in gastric carcinogenesis through experimental perturbation of both cell lines and animal models. We identified HNF4 alpha-WNT5A regulation in the cross-talk between the AMPK metabolic pathway and the WNT signaling pathway, and further identified WNT5A as a potential therapeutic target for GC. We have demonstrated PATHOME to be a powerful tool, with improved sensitivity for identifying disease-related dysregulated pathways.	[Nam, S.; Hong, D.; Kwon, C. H.] Natl Canc Ctr Korea, Canc Genom Branch, Goyang Si 410769, Gyeonggi Do, South Korea; [Chang, H. R.; Jung, H. R.; Park, H. S.; Kim, Y. H.] Natl Canc Ctr Korea, New Expt Therapeut Branch, Goyang Si 410769, Gyeonggi Do, South Korea; [Kim, K-T] Natl Canc Ctr Korea, Mol Epidemiol Branch, Goyang Si 410769, Gyeonggi Do, South Korea; [Kook, M-C] Natl Canc Ctr Korea, Dept Pathol, Goyang Si 410769, Gyeonggi Do, South Korea; [Powis, G.] Sanford Burnham Med Res Inst, Ctr Canc, La Jolla, CA USA; [Liang, H.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Park, T.] Seoul Natl Univ, Dept Stat, Seoul, South Korea	National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC); Sanford Burnham Prebys Medical Discovery Institute; University of Texas System; UTMD Anderson Cancer Center; Seoul National University (SNU)	Liang, H (corresponding author), Natl Canc Ctr Korea, New Expt Therapeut Branch, Goyang Si 410769, Gyeonggi Do, South Korea.	hliang1@mdanderson.org; tspark@stats.snu.ac.kr; yhkim@ncc.re.kr	Nam, Seungyoon/ACO-0914-2022	Nam, Seungyoon/0000-0002-0966-7915	National Cancer Center of the Republic of Korea [NCC-1210350-2, NCC-1210460]; National Research Foundation of Korea (NRF) - Republic of Korea (MSIP) [2012R1A3A2026438, 2008-0062618, 2013M3A9C4078158]; US National Institutes of Health [CA95060, CA129616, CA17094, CA98920, CA143883]; University of Texas MD Anderson Cancer Center-GS Hogan Gastrointestinal Research Fund; Lorraine Dell Program in Bioinformatics for Personalization of Cancer Medicine; NATIONAL CANCER INSTITUTE [P50CA098258, R01CA129616, P50CA095060, P30CA016672, R01CA098920, R01CA163541, P01CA017094, U24CA143883] Funding Source: NIH RePORTER	National Cancer Center of the Republic of Korea; National Research Foundation of Korea (NRF) - Republic of Korea (MSIP); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Texas MD Anderson Cancer Center-GS Hogan Gastrointestinal Research Fund; Lorraine Dell Program in Bioinformatics for Personalization of Cancer Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by grants from the National Cancer Center of the Republic of Korea, NCC-1210350-2 (to YHK), NCC-1210460 (to SN); the National Research Foundation of Korea (NRF) grant funded by the Republic of Korea (MSIP) 2012R1A3A2026438, 2008-0062618, 2013M3A9C4078158 (to TP); grants from the US National Institutes of Health, CA95060, CA129616, CA17094 and CA98920 (to GP), CA143883 (to HL); the University of Texas MD Anderson Cancer Center-GS Hogan Gastrointestinal Research Fund and the Lorraine Dell Program in Bioinformatics for Personalization of Cancer Medicine (to HL). The Korea Institute of Science and Technology Information provided SN with a high-performance computing resource. We thank LeeAnn Chastain for editorial assistance.	Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Backes C, 2007, NUCLEIC ACIDS RES, V35, pW186, DOI 10.1093/nar/gkm323; Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Chen XJ, 2011, BIOINFORMATICS, V27, P649, DOI 10.1093/bioinformatics/btq714; Cho JY, 2011, CLIN CANCER RES, V17, P1850, DOI 10.1158/1078-0432.CCR-10-2180; Colletti M, 2009, GASTROENTEROLOGY, V137, P660, DOI 10.1053/j.gastro.2009.05.038; Cui JA, 2011, NUCLEIC ACIDS RES, V39, P1197, DOI 10.1093/nar/gkq960; Euskirchen GM, 2007, GENOME RES, V17, P898, DOI 10.1101/gr.5583007; Fujita PA, 2011, NUCLEIC ACIDS RES, V39, pD876, DOI 10.1093/nar/gkq963; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huerta AM, 1998, NUCLEIC ACIDS RES, V26, P55, DOI 10.1093/nar/26.1.55; Kanehisa M, 1997, TRENDS GENET, V13, P375, DOI 10.1016/S0168-9525(97)01223-7; Karp PD, 2002, NUCLEIC ACIDS RES, V30, P59, DOI 10.1093/nar/30.1.59; Kato K, 2012, MOL CANCER THER, V11, P549, DOI 10.1158/1535-7163.MCT-11-0594; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Khatri P, 2004, NUCLEIC ACIDS RES, V32, pW449, DOI 10.1093/nar/gkh409; Khatri P, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002375; Kim YH, 2012, CANCER RES, V72, P2512, DOI 10.1158/0008-5472.CAN-11-3870; Kim YH, 2011, CANCER CHEMOTH PHARM, V68, P405, DOI 10.1007/s00280-010-1500-0; Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008-5472.CAN-06-2359; Nam D, 2008, BRIEF BIOINFORM, V9, P189, DOI 10.1093/bib/bbn001; Nam S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031685; Parkinson H, 2011, NUCLEIC ACIDS RES, V39, pD1002, DOI 10.1093/nar/gkq1040; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shendure J, 2005, SCIENCE, V309, P1728, DOI 10.1126/science.1117389; Soon WW, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2012.61; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takeno A, 2010, ANN SURG ONCOL, V17, P1033, DOI 10.1245/s10434-009-0854-1; Tarca AL, 2009, BIOINFORMATICS, V25, P75, DOI 10.1093/bioinformatics/btn577; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28	34	55	55	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2014	33	41					4941	4951		10.1038/onc.2014.80	http://dx.doi.org/10.1038/onc.2014.80			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OA	24681952	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000343767900007
J	Rosenfeldt, MT; Bell, LA; Long, JS; O'Prey, J; Nixon, C; Roberts, F; Dufes, C; Ryan, KM				Rosenfeldt, M. T.; Bell, L. A.; Long, J. S.; O'Prey, J.; Nixon, C.; Roberts, F.; Dufes, C.; Ryan, K. M.			E2F1 drives chemotherapeutic drug resistance via ABCG2	ONCOGENE			English	Article						E2F1; ABCG2; cancer; drug sensitivity; multidrug transporters	MULTIDRUG-RESISTANCE; PROTEIN; CANCER; EXPRESSION; DEATH; TRANSCRIPTION; PHEOPHORBIDE; INHIBITION; APOPTOSIS; AUTOPHAGY	Multidrug resistance is a major barrier against successful chemotherapy, and this has been shown in vitro to be often caused by ATP-binding cassette (ABC) transporters. These transporters are frequently overexpressed in human cancers and confer an adverse prognosis in many common malignancies. The genetic factors, however, that initiate their expression in cancer are largely unknown. Here we report that the major multidrug transporter ABCG2 (BCRP/MXR) is directly and specifically activated by the transcription factor E2F1-a factor perturbed in the majority of human cancers. E2F1 regulates ABCG2 expression in multiple cell systems, and, importantly, we have identified a significant correlation between elevated E2F1 and ABCG2 expression in human lung cancers. We show that E2F1 causes chemotherapeutic drug efflux both in vitro and in vivo via ABCG2. Furthermore, the E2F1-ABCG2 axis suppresses chemotherapy-induced cell death that can be restored by the inhibition of ABCG2. These findings therefore identify a new axis in multidrug resistance and highlight a radical new function of E2F1 that is relevant to tumor therapy.	[Rosenfeldt, M. T.; Bell, L. A.; Long, J. S.; O'Prey, J.; Nixon, C.; Ryan, K. M.] Canc Res UK Beatson Inst, Tumour Cell Death Lab, Glasgow, Lanark, Scotland; [Roberts, F.] Univ Glasgow, Western Infirm, Dept Pathol, Glasgow G11 6NT, Lanark, Scotland; [Dufes, C.] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland	Beatson Institute; University of Glasgow; University of Strathclyde	Ryan, KM (corresponding author), Canc Res UK Beatson Inst Canc Res, Tumour Cell Death Lab, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	k.ryan@beatson.gla.ac.uk	Rosenfeldt, Mathias/ABE-4736-2022; Dufès, Christine/AAQ-1604-2021	Rosenfeldt, Mathias/0000-0001-7650-8458; Dufès, Christine/0000-0002-7963-6364; Ryan, Kevin M./0000-0002-1059-9681	Association for International Cancer Research and Cancer Research UK; Wellcome trust [ME0442]; Cancer Research UK [15816] Funding Source: researchfish; Worldwide Cancer Research [12-1262] Funding Source: researchfish	Association for International Cancer Research and Cancer Research UK; Wellcome trust(Wellcome TrustEuropean Commission); Cancer Research UK(Cancer Research UK); Worldwide Cancer Research	This work was supported by Association for International Cancer Research and Cancer Research UK, and by a Wellcome trust equipment grant (ME0442) to CD. We thank Doron Ginsberg, Kristian Helin, Douglas Ross and Karen Vousden for reagents.	Alla V, 2012, CELL CYCLE, V11, P3067, DOI 10.4161/cc.21476; Allen JD, 2002, MOL CANCER THER, V1, P417; Bailey-Dell KJ, 2001, BBA-GENE STRUCT EXPR, V1520, P234, DOI 10.1016/S0167-4781(01)00270-6; Bell HS, 2007, J CLIN INVEST, V117, P1008, DOI 10.1172/JCI28920; Bell LA, 2006, ONCOGENE, V25, P5656, DOI 10.1038/sj.onc.1209580; Bui-Xuan NH, 2010, J ETHNOPHARMACOL, V131, P95, DOI 10.1016/j.jep.2010.06.007; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Diestra JE, 2002, J PATHOL, V198, P213, DOI 10.1002/path.1203; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Engelmann D, 2012, CANCER RES, V72, P571, DOI 10.1158/0008-5472.CAN-11-2575; Eymin B, 2001, ONCOGENE, V20, P1678, DOI 10.1038/sj.onc.1204242; Gorgoulis VG, 2002, J PATHOL, V198, P142, DOI 10.1002/path.1121; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Helgason GV, 2010, CANCER RES, V70, P4074, DOI 10.1158/0008-5472.CAN-09-2876; Iaquinta PJ, 2007, CURR OPIN CELL BIOL, V19, P649, DOI 10.1016/j.ceb.2007.10.006; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Natarajan K, 2012, BIOCHEM PHARMACOL, V83, P1084, DOI 10.1016/j.bcp.2012.01.002; Polager S, 2008, ONCOGENE, V27, P4860, DOI 10.1038/onc.2008.117; Polager S, 2008, TRENDS CELL BIOL, V18, P528, DOI 10.1016/j.tcb.2008.08.003; Robey RW, 2009, ADV DRUG DELIVER REV, V61, P3, DOI 10.1016/j.addr.2008.11.003; Robey RW, 2004, CANCER RES, V64, P1242, DOI 10.1158/0008-5472.CAN-03-3298; Robey RW, 2001, BBA-BIOMEMBRANES, V1512, P171, DOI 10.1016/S0005-2736(01)00308-X; Stewart DJ, 2010, CRIT REV ONCOL HEMAT, V75, P173, DOI 10.1016/j.critrevonc.2009.11.006; Wu ZL, 2009, INT J BIOCHEM CELL B, V41, P2389, DOI 10.1016/j.biocel.2009.06.004; Zhang W, 2009, DRUG METAB DISPOS, V37, P737, DOI 10.1124/dmd.108.023309; Zhang YM, 2007, CANCER RES, V67, P9389, DOI 10.1158/0008-5472.CAN-07-0944; Zhang YM, 2009, CANCER RES, V69, P5867, DOI 10.1158/0008-5472.CAN-08-4866	27	28	30	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2014	33	32					4164	4172		10.1038/onc.2013.470	http://dx.doi.org/10.1038/onc.2013.470			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YK	24276245	hybrid, Green Accepted			2022-12-28	WOS:000340595700007
J	Kosari, F; Ida, C; Aubry, MC; Yang, L; Kovtun, IV; Klein, JLS; Li, Y; Erdogan, S; Tomaszek, S; Murphy, SJ; Bolette, LC; Kolbert, CP; Yang, P; Wigle, DA; Vasmatzis, G				Kosari, F.; Ida, C. M.; Aubry, M-C; Yang, L.; Kovtun, I. V.; Klein, J. L. S.; Li, Y.; Erdogan, S.; Tomaszek, S. C.; Murphy, S. J.; Bolette, L. C.; Kolbert, C. P.; Yang, P.; Wigle, D. A.; Vasmatzis, G.			ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation	ONCOGENE			English	Article						prognostic biomarker; MASH1; lung cancer; neuroendocrine; microarray	MEDULLARY-THYROID CANCER; ACHAETE-SCUTE HOMOLOG-1; GENE-EXPRESSION; CIGARETTE-SMOKING; CELLS; MICE; PROTOONCOGENE; FEATURES; SUBTYPE; FUSIONS	ASCL1 is an important regulatory transcription factor in pulmonary neuroendocrine (NE) cell development, but its value as a biomarker of NE differentiation in lung adenocarcinoma (AD) and as a potential prognostic biomarker remains unclear. We examined ASCL1 expression in lung cancer samples of varied histologic subtype, clinical outcome and smoking status and compared with expression of traditional NE markers. ASCL1 mRNA expression was found almost exclusively in smokers with AD, in contrast to nonsmokers and other lung cancer subtypes. ASCL1 protein expression by immunohistochemical (IHC) analysis correlated best with synaptophysin compared with chromogranin and CD56/NCAM. Analysis of a compendium of 367 microarray-based gene expression profiles in stage I lung adenocarcinomas identified significantly higher expression levels of the RET oncogene in ASCL1-positive tumors (ASCL1(+)) compared with ASCL1(-) tumors (q-value < 10(-9)). High levels of RET expression in ASCL1(+) but not in ASCL1(-) tumors was associated with significantly shorter overall survival (OS) in stage 1 (P = 0.007) and in all AD (P = 0.037). RET protein expression by IHC had an association with OS in the context of ASCL1 expression. In silico gene set analysis and in vitro experiments by ASCL1 shRNA in AD cells with high endogenous expression of ASCL1 and RET implicated ASCL1 as a potential upstream regulator of the RET oncogene. Also, silencing ASCL1 in AD cells markedly reduced cell growth and motility. These results suggest that ASCL1 and RET expression defines a clinically relevant subgroup of similar to 10% of AD characterized by NE differentiation.	[Kosari, F.; Klein, J. L. S.; Murphy, S. J.; Vasmatzis, G.] Mayo Clin, Dept Mol Med, Rochester, MN 55905 USA; [Ida, C. M.; Aubry, M-C; Yang, L.; Erdogan, S.; Bolette, L. C.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA; [Kovtun, I. V.] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; [Li, Y.; Yang, P.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA; [Tomaszek, S. C.; Wigle, D. A.] Mayo Clin, Dept Surg & Adv Genom Technol Ctr, Rochester, MN 55905 USA; [Kolbert, C. P.] Mayo Clin, Adv Genom Technol Ctr, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Vasmatzis, G (corresponding author), Mayo Clin, Lab Med & Pathol, 200 First Str SW, Rochester, MN 55905 USA.	vasmatzis.george@mayo.edu	Kovtun, Irina/ABA-8484-2020		Waterman Biomarker Discovery grant; Mayo Clinic Center for Individualized Medicine; NATIONAL CANCER INSTITUTE [P30CA015083] Funding Source: NIH RePORTER	Waterman Biomarker Discovery grant; Mayo Clinic Center for Individualized Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a Waterman Biomarker Discovery grant and by the Mayo Clinic Center for Individualized Medicine.	Arighi E, 2005, CYTOKINE GROWTH F R, V16, P441, DOI 10.1016/j.cytogfr.2005.05.010; Boldrini L, 2009, ONCOL REP, V22, P683, DOI 10.3892/or_00000488; Borges M, 1997, NATURE, V386, P852, DOI 10.1038/386852a0; Bryant CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011712; Burton MD, 1997, J AUTONOM NERV SYST, V63, P137, DOI 10.1016/S0165-1838(97)00002-7; Chen H, 1996, SURGERY, V120, P168, DOI 10.1016/S0039-6060(96)80284-4; Dauger S, 2001, PHYSIOL GENOMICS, V7, P149, DOI 10.1152/physiolgenomics.00056.2001; Dauger S, 1999, PEDIATR RES, V46, P535, DOI 10.1203/00006450-199911000-00008; Freedman ND, 2008, LANCET ONCOL, V9, P649, DOI 10.1016/S1470-2045(08)70154-2; Fujiwara T, 2012, LUNG CANCER, V75, P119, DOI 10.1016/j.lungcan.2011.05.028; Huber K, 2005, DEV BIOL, V279, P501, DOI 10.1016/j.ydbio.2005.01.007; Huber K, 2002, DEVELOPMENT, V129, P4729; Ionescu DN, 2007, AM J SURG PATHOL, V31, P26, DOI 10.1097/01.pas.0000213319.04919.97; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Kang HC, 2004, CLIN CANCER RES, V10, P272, DOI 10.1158/1078-0432.CCR-1025-3; Khuder SA, 2001, LUNG CANCER, V31, P139, DOI 10.1016/S0169-5002(00)00181-1; Kohno T, 2012, NAT MED, V18, P375, DOI 10.1038/nm.2644; Kouvaraki MA, 2005, THYROID, V15, P531, DOI 10.1089/thy.2005.15.531; Landi MT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001651; Linnoila RI, 2000, CANCER RES, V60, P4005; Lo LC, 1998, DEVELOPMENT, V125, P609; Lodish MB, 2008, EXPERT REV ANTICANC, V8, P625, DOI 10.1586/14737140.8.4.625; Marsh DJ, 2011, ADV OTO-RHINO-LARYNG, V70, P84, DOI 10.1159/000322479; Massion PP, 2008, AM J RESP CRIT CARE, V178, P1164, DOI 10.1164/rccm.200801-142OC; Osada H, 2005, CANCER RES, V65, P10680, DOI 10.1158/0008-5472.CAN-05-1404; Osada H, 2008, CANCER RES, V68, P1647, DOI 10.1158/0008-5472.CAN-07-5039; Poulsen TT, 2008, CANCER GENE THER, V15, P563, DOI 10.1038/cgt.2008.24; Powell CA, 2003, AM J RESP CELL MOL, V29, P157, DOI 10.1165/rcmb.2002-0183RC; Rheinbay E, 2013, CELL REP, V3, P1567, DOI 10.1016/j.celrep.2013.04.021; Shaw AT, 2009, J CLIN ONCOL, V27, P4247, DOI 10.1200/JCO.2009.22.6993; Shoba T, 2002, NEUROSCI LETT, V318, P129, DOI 10.1016/S0304-3940(01)02491-0; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Takahashi T, 2010, ANN SURG ONCOL, V17, P889, DOI 10.1245/s10434-009-0808-7; Travis WD., 2004, TRAVIS WB WHO CLASSI; Wang R, 2012, J CLIN ONCOL, V30, P4352, DOI 10.1200/JCO.2012.44.1477	35	37	38	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3776	3783		10.1038/onc.2013.359	http://dx.doi.org/10.1038/onc.2013.359			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	24037524	Green Accepted			2022-12-28	WOS:000339394100003
J	Wang, W; Zhong, Q; Teng, L; Bhatnagar, N; Sharma, B; Zhang, X; Luther, W; Haynes, LP; Burgoyne, RD; Vidal, M; Volchenboum, S; Hill, DE; George, RE				Wang, W.; Zhong, Q.; Teng, L.; Bhatnagar, N.; Sharma, B.; Zhang, X.; Luther, W., II; Haynes, L. P.; Burgoyne, R. D.; Vidal, M.; Volchenboum, S.; Hill, D. E.; George, R. E.			Mutations that disrupt PHOXB interaction with the neuronal calcium sensor HPCAL1 impede cellular differentiation in neuroblastoma	ONCOGENE			English	Article						PHOX2B; HPCAL1; neuroblastoma; neuronal calcium sensor; differentiation; network perturbation	CENTRAL-HYPOVENTILATION-SYNDROME; BETA-HYDROXYLASE GENE; NEUROTRANSMITTER BIOSYNTHETIC GENES; ONSET CENTRAL-HYPOVENTILATION; VISININ-LIKE PROTEINS; HOMEOBOX GENE; POLYALANINE EXPANSIONS; FRAMESHIFT MUTATIONS; EDGETIC PERTURBATION; HOMEODOMAIN PROTEINS	Heterozygous germline mutations in PHOX2B, a transcriptional regulator of sympathetic neuronal differentiation, predispose to diseases of the sympathetic nervous system, including neuroblastoma and congenital central hypoventilation syndrome (CCHS). Although the PHOX2B variants in CCHS largely involve expansions of the second polyalanine repeat within the C-terminus of the protein, those associated with neuroblastic tumors are nearly always frameshift and truncation mutations. To test the hypothesis that the neuroblastoma-associated variants exert their effects through loss or gain of protein-protein interactions, we performed a large-scale yeast two-hybrid screen using both wild-type (WT) and six different mutant PHOX2B proteins against over 10 000 human genes. The neuronal calcium sensor protein HPCAL1 (VILIP-3) exhibited strong binding to WT PHOX2B and a CCHS-associated polyalanine expansion mutant but only weakly or not at all to neuroblastoma-associated frameshift and truncation variants. We demonstrate that both WT PHOX2B and the neuroblastoma-associated R100L missense and the CCHS-associated alanine expansion variants induce nuclear translocation of HPCAL1 in a Ca2+-independent manner, while the neuroblastoma-associated 676delG frameshift and K155X truncation mutants impair subcellular localization of HPCAL1, causing it to remain in the cytoplasm. HPCAL1 did not appreciably influence the ability of WT PHOX2B to transactivate the DBH promoter, nor did it alter the decreased transactivation potential of PHOX2B variants in 293T cells. Abrogation of the PHOX2B-HPCAL1 interaction by shRNA knockdown of HPCAL1 in neuroblastoma cells expressing PHOX2B led to impaired neurite outgrowth with transcriptional profiles indicative of inhibited sympathetic neuronal differentiation. Our results suggest that certain PHOX2B variants associated with neuroblastoma pathogenesis, because of their inability to bind to key interacting proteins such as HPCAL1, may predispose to this malignancy by impeding the differentiation of immature sympathetic neurons.	[Wang, W.; Bhatnagar, N.; Sharma, B.; Luther, W., II; George, R. E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Zhong, Q.; Vidal, M.; Hill, D. E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, CCSB, Boston, MA 02115 USA; [Zhong, Q.; Vidal, M.; Hill, D. E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Teng, L.; Volchenboum, S.] Univ Chicago, Chicago Ctr Childhood Canc & Blood Dis, Chicago, IL 60637 USA; [Zhang, X.] Chinese Acad Sci, High Field Magnet Lab, Hefei, Peoples R China; [Haynes, L. P.; Burgoyne, R. D.] Univ Liverpool, Inst Translat Med, Dept Cellular & Mol Physiol, Liverpool L69 3BX, Merseyside, England	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Chicago; Chinese Academy of Sciences; Hefei Institutes of Physical Science, CAS; University of Liverpool	George, RE (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, Dana 640E,450 Brookline Ave, Boston, MA 02115 USA.	rani_george@dfci.harvard.edu	Zhang, Xin/AAB-9359-2020; zhong, quan/AAE-8893-2021; George, Rani/AAG-7635-2019; Burgoyne, Robert D/P-6641-2019	Zhang, Xin/0000-0002-3499-2189; Burgoyne, Robert D/0000-0002-9219-0387; Zhong, Quan/0000-0003-2910-5597	Alex's Lemonade Stand Foundation; Abraham Research Fund; National Cancer Institute [R33CA132073]; National Human Genome Research [R01HG001715, P50HG004233]; Ellison Foundation; NATIONAL CANCER INSTITUTE [R33CA132073] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001715, P50HG004233] Funding Source: NIH RePORTER	Alex's Lemonade Stand Foundation; Abraham Research Fund; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Human Genome Research; Ellison Foundation(Lawrence Ellison Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank Dr Christo Goridis for the generous gift of the PHOX2B antibody. We thank Stacey Frumm and Dr Kimberly Stegmaier for data regarding the neuroblastoma cell differentiation signature before publication. This study was supported by Alex's Lemonade Stand Foundation (to REG), Abraham Research Fund (to WW), National Cancer Institute Grant R33CA132073 (to MV), National Human Genome Research Grants R01HG001715 and P50HG004233 (to MV and DEH) and The Ellison Foundation (to MV).	Adachi M, 2000, DNA CELL BIOL, V19, P539, DOI 10.1089/104454900439773; Amiel J, 2003, NAT GENET, V33, P459, DOI 10.1038/ng1130; Bachetti T, 2005, HUM MOL GENET, V14, P1815, DOI 10.1093/hmg/ddi188; Braunewell KH, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.20; Braunewell KH, 2009, CELL TISSUE RES, V335, P301, DOI 10.1007/s00441-008-0716-3; Burgoyne RD, 2007, NAT REV NEUROSCI, V8, P182, DOI 10.1038/nrn2093; Dreze M, 2010, METHOD ENZYMOL, V470, P281, DOI 10.1016/S0076-6879(10)70012-4; Dreze M, 2009, NAT METHODS, V6, P843, DOI [10.1038/NMETH.1394, 10.1038/nmeth.1394]; Dubreuil V, 2000, DEVELOPMENT, V127, P5191; Frumm SM, 2013, CHEM BIOL, V20, P713, DOI 10.1016/j.chembiol.2013.03.020; Hansford LM, 2003, CYTOGENET GENOME RES, V101, P17, DOI 10.1159/000073412; Haynes LP, 2008, NAT CHEM BIOL, V4, P90, DOI 10.1038/nchembio0208-90; Hong SJ, 2008, BIOCHEM BIOPH RES CO, V368, P650, DOI 10.1016/j.bbrc.2008.01.165; Ikura M, 2000, NAT STRUCT BIOL, V7, P525, DOI 10.1038/76721; Ikura M, 2002, BIOESSAYS, V24, P625, DOI 10.1002/bies.10105; Jheng FF, 2006, PROTEIN J, V25, P250, DOI 10.1007/s10930-006-9008-5; Lamesch P, 2007, GENOMICS, V89, P307, DOI 10.1016/j.ygeno.2006.11.012; LENZ SE, 1992, MOL BRAIN RES, V15, P133, DOI 10.1016/0169-328X(92)90160-D; Lim J, 2008, NATURE, V452, P713, DOI 10.1038/nature06731; Lo LC, 1999, NEURON, V22, P693, DOI 10.1016/S0896-6273(00)80729-1; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Matera I, 2004, J MED GENET, V41, P373, DOI 10.1136/jmg.2003.015412; Mosse YP, 2004, AM J HUM GENET, V75, P727, DOI 10.1086/424530; Nagashimada M, 2012, J CLIN INVEST, V122, P3145, DOI 10.1172/JCI63401; O'Callaghan DW, 2003, J CELL BIOL, V163, P715, DOI 10.1083/jcb.200306042; Park JR, 2008, PEDIATR CLIN N AM, V55, P97, DOI 10.1016/j.pcl.2007.10.014; Paterlini M, 2000, NEUROSCIENCE, V99, P205, DOI 10.1016/S0306-4522(00)00201-3; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Pei DS, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003533; Raabe EH, 2008, ONCOGENE, V27, P469, DOI 10.1038/sj.onc.1210659; Reiff T, 2010, J NEUROSCI, V30, P905, DOI 10.1523/JNEUROSCI.5368-09.2010; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Spilker C, 2002, BBA-PROTEINS PROTEOM, V1600, P118, DOI 10.1016/S1570-9639(02)00452-1; Swanson DJ, 1997, J BIOL CHEM, V272, P27382, DOI 10.1074/jbc.272.43.27382; Taraviras S, 2002, EUR J CELL BIOL, V81, P363, DOI 10.1078/0171-9335-00250; Trang H, 2004, PEDIATR PULM, V38, P349, DOI 10.1002/ppul.20074; Trochet D, 2004, AM J HUM GENET, V74, P761, DOI 10.1086/383253; van Limpt V, 2005, CANCER LETT, V228, P59, DOI 10.1016/j.canlet.2005.02.050; van Limpt V, 2004, ONCOGENE, V23, P9280, DOI 10.1038/sj.onc.1208157; Vidal M, 2011, CELL, V144, P986, DOI 10.1016/j.cell.2011.02.016; Weese-Mayer DE, 2003, AM J MED GENET A, V123A, P267, DOI 10.1002/ajmg.a.20527; Wu HT, 2009, HUM MUTAT, V30, P655, DOI 10.1002/humu.20929; Yang CY, 1998, J NEUROCHEM, V71, P1813; Zellmer E, 1995, J NEUROSCI, V15, P8109; Zhong Q, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.80	45	18	18	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3316	3324		10.1038/onc.2013.290	http://dx.doi.org/10.1038/onc.2013.290			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23873030	Green Accepted			2022-12-28	WOS:000338443400011
J	Shan, L; Li, X; Liu, L; Ding, X; Wang, Q; Zheng, Y; Duan, Y; Xuan, C; Wang, Y; Yang, F; Shang, Y; Shi, L				Shan, L.; Li, X.; Liu, L.; Ding, X.; Wang, Q.; Zheng, Y.; Duan, Y.; Xuan, C.; Wang, Y.; Yang, F.; Shang, Y.; Shi, L.			GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation	ONCOGENE			English	Article						breast cancer; cell proliferation; gene transcription	DNA-DAMAGE RESPONSE; LUMINAL CELL FATE; BREAST-CANCER; ESTROGEN-RECEPTOR; GENE-EXPRESSION; CYCLIN D1; MAMMARY-GLAND; DIFFERENTIATION; BINDING; METASTASIS	The transcription factor GATA3 is a key regulator of mammary gland development and a definitive marker of luminal breast cancer. However, the molecular mechanisms underlying the role of GATA3 in breast carcinogenesis is still not fully understood. We report here that GATA3 promotes cell proliferation and tumorigenesis by facilitating the G(1)/S transition through its transcription regulation of the CCND1 gene in breast cancer cells. We found that GATA3 is physically associated with poly-ADP ribose polymerase-1 (PARP1), an enzyme modifying nuclear proteins by poly(ADP-ribosyl)ation. We showed that PARP1 acts as a transcription coactivator for GATA3 in breast cancer cells and demonstrated that GATA3 cooperates with PARP1 in transactivation of the CCND1 gene. We demonstrated that PARP1 competes with linker histone H1 to maintain a transcriptional competent chromatin environment for CCND1 gene. Our results unveiled a molecular basis for the coordinated regulation between GATA3 and PARP1 in transcription activation, providing a mechanism for GATA3 in breast carcinogenesis.	[Shan, L.; Li, X.; Liu, L.; Wang, Q.; Zheng, Y.; Duan, Y.; Xuan, C.; Wang, Y.; Shang, Y.; Shi, L.] Tianjin Med Univ, Dept Biochem & Mol Biol, Tianjin Key Lab Med Epigenet, Tianjin 300070, Peoples R China; [Ding, X.; Yang, F.] Chinese Acad Sci, Inst Biophys, Lab Prote, Beijing 100080, Peoples R China	Tianjin Medical University; Chinese Academy of Sciences; Institute of Biophysics, CAS	Shi, L (corresponding author), Tianjin Med Univ, Dept Biochem & Mol Biol, Tianjin Key Lab Med Epigenet, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China.	shilei@tmu.edu.cn	duan, yang/GZA-6440-2022		National Natural Science Foundation of China [81130048, 81272284, 91219102]; Ministry of Science and Technology of China [2011CB504204]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China)	This work was supported by grants (81130048 to YS, 81272284 and 91219102 to Lei Shi) from the National Natural Science Foundation of China and grants (973 Program: 2011CB504204 to YS) from the Ministry of Science and Technology of China.	Aguilar-Quesada R, 2007, CURR MED CHEM, V14, P1179, DOI 10.2174/092986707780597998; Arnold A, 2005, J CLIN ONCOL, V23, P4215, DOI 10.1200/JCO.2005.05.064; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Blokzijl A, 2002, CURR BIOL, V12, P35, DOI 10.1016/S0960-9822(01)00623-6; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Ciocca V, 2009, HUM PATHOL, V40, P489, DOI 10.1016/j.humpath.2008.09.010; Cipak L, 2010, NEOPLASMA, V57, P401, DOI 10.4149/neo_2010_05_401; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Ewen ME, 2004, TRENDS MOL MED, V10, P158, DOI 10.1016/j.molmed.2004.02.005; FANTL V, 1993, CANCER SURV, V18, P77; GILLETT C, 1994, CANCER RES, V54, P1812; Haffner MC, 2011, CLIN CANCER RES, V17, P3858, DOI 10.1158/1078-0432.CCR-10-2044; Ho IC, 2009, NAT REV IMMUNOL, V9, P125, DOI 10.1038/nri2476; Hoch RV, 1999, INT J CANCER, V84, P122; Hoene V, 2009, BRIT J CANCER, V101, P1481, DOI 10.1038/sj.bjc.6605276; Huber A, 2004, DNA REPAIR, V3, P1103, DOI 10.1016/j.dnarep.2004.06.002; Hwang SS, 2010, IMMUNOLOGY, V131, P50, DOI 10.1111/j.1365-2567.2010.03271.x; Imagawa S, 1997, BLOOD, V89, P1430, DOI 10.1182/blood.V89.4.1430; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Kouros-Mehr H, 2008, CURR OPIN CELL BIOL, V20, P164, DOI 10.1016/j.ceb.2008.02.003; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006; Krishnakumar R, 2008, SCIENCE, V319, P819, DOI 10.1126/science.1149250; Krishnakumar R, 2010, MOL CELL, V39, P736, DOI 10.1016/j.molcel.2010.08.014; Krishnakumar R, 2010, MOL CELL, V39, P8, DOI 10.1016/j.molcel.2010.06.017; Kurokawa R, 2009, RNA BIOL, V6, P233, DOI 10.4161/rna.6.3.8329; Li RF, 2009, EMBO J, V28, P2763, DOI 10.1038/emboj.2009.211; Lonn P, 2010, MOL CELL, V40, P521, DOI 10.1016/j.molcel.2010.10.029; Mao ZY, 2011, SCIENCE, V332, P1443, DOI 10.1126/science.1202723; Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495; Ossovskaya V, 2010, GENES CANC, V1, P812, DOI 10.1177/1947601910383418; Parikh P, 2005, J AM COLL SURGEONS, V200, P705, DOI 10.1016/j.jamcollsurg.2004.12.025; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; Rojo F, 2012, ANN ONCOL, V23, P1156, DOI 10.1093/annonc/mdr361; Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Simsek D, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002080; Taghon T, 2007, NAT IMMUNOL, V8, P845, DOI 10.1038/ni1486; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; Tkocz D, 2012, ONCOGENE, V31, P3667, DOI 10.1038/onc.2011.531; Tsarovina K, 2004, DEVELOPMENT, V131, P4775, DOI 10.1242/dev.01370; Tulin A, 2011, NAT BIOTECHNOL, V29, P1078, DOI 10.1038/nbt.2058; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Wei G, 2011, IMMUNITY, V35, P299, DOI 10.1016/j.immuni.2011.08.007; Wilson BJ, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-49; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262; Yoon NK, 2010, HUM PATHOL, V41, P1794, DOI 10.1016/j.humpath.2010.06.010; Zhang C, 2007, STEM CELLS DEV, V16, P605, DOI 10.1089/scd.2006.0077; Zhang H, 2004, GENE DEV, V18, P1753, DOI 10.1101/gad.1194704; Zheng Rena, 2010, Genes Cancer, V1, P1178, DOI 10.1177/1947601911404223; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	58	30	30	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3205	3216		10.1038/onc.2013.270	http://dx.doi.org/10.1038/onc.2013.270			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23851505				2022-12-28	WOS:000338410000013
J	Ory, V; Tassi, E; Cavalli, LR; Sharif, GM; Saenz, F; Baker, T; Schmidt, MO; Mueller, SC; Furth, PA; Wellstein, A; Riegel, AT				Ory, V.; Tassi, E.; Cavalli, L. R.; Sharif, G. M.; Saenz, F.; Baker, T.; Schmidt, M. O.; Mueller, S. C.; Furth, P. A.; Wellstein, A.; Riegel, A. T.			The nuclear coactivator amplified in breast cancer 1 maintains tumor-initiating cells during development of ductal carcinoma in situ	ONCOGENE			English	Article						AIB1; DCIS; tumor-initiating cells; coactivator; xenografts	MAMMARY TUMORIGENESIS; MOLECULAR MARKERS; EPITHELIAL ACINI; SRC FAMILY; STEM-CELLS; RECEPTOR; AIB1; GENE; MICE; PROGRESSION	The key molecular events required for the formation of ductal carcinoma in situ (DCIS) and its progression to invasive breast carcinoma have not been defined. Here, we show that the nuclear receptor coactivator amplified in breast cancer 1 (AIB1) is expressed at low levels in normal breast but is highly expressed in DCIS lesions. This is of significance since reduction of AIB1 in human MCFDCIS cells restored a more normal three-dimensional mammary acinar structure. Reduction of AIB1 in MCFDCIS cells, both before DCIS development or in existing MCFDCIS lesions in vivo, inhibited tumor growth and led to smaller, necrotic lesions. AIB1 reduction in MCFDCIS cells was correlated with significant reduction in the CD24-/CD44+ breast cancer-initiating cell (BCIC) population, and a decrease in myoepithelial progenitor cells in the DCIS lesions in vitro and in vivo. The loss of AIB1 in MCFDCIS cells was also accompanied by a loss of expression of NOTCH 2, 3 and 4, JAG2, HES1, GATA3, human epidermal growth factor receptor 2 (HER2) and HER3 in vivo. These signaling molecules have been associated with differentiation of breast epithelial progenitor cells. These data indicate that AIB1 has a central role in the initiation and maintenance of DCIS and that reduction of AIB1 causes loss of BCIC, loss of components of the NOTCH, HER2 and HER3 signaling pathways and fewer DCIS myoepithelial progenitor cells in vivo. We propose that increased expression of AIB1, through the maintenance of BCIC, facilitates formation of DCIS, a necessary step before development of invasive disease.	[Ory, V.; Tassi, E.; Cavalli, L. R.; Sharif, G. M.; Saenz, F.; Baker, T.; Schmidt, M. O.; Mueller, S. C.; Furth, P. A.; Wellstein, A.; Riegel, A. T.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA	Georgetown University	Riegel, AT (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, E307 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.	ariege01@georgetown.edu	Schmidt, Marcel/AAV-8054-2021; Cavalli, Luciane R/J-6100-2012; Saenz, Francisco/ABE-7477-2020	Schmidt, Marcel/0000-0002-3991-2766; Saenz, Francisco/0000-0003-4738-4710; Wellstein, Anton/0000-0002-0570-4950; Cavalli, Luciane Regina/0000-0001-5619-9037	Department of Defense Breast Cancer Research Program [BC098103]; NIH/NCI [CA113477]; National Cancer Institute [P30CA051008]; NATIONAL CANCER INSTITUTE [R01CA113477, R01CA112176, T32CA009686, P30CA051008] Funding Source: NIH RePORTER	Department of Defense Breast Cancer Research Program(United States Department of Defense); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by the Department of Defense Breast Cancer Research Program BC098103 (VO) and by NIH/NCI Grants CA113477 (ATR). This project was also supported by Award Number P30CA051008 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Defense.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Al-Otaiby M, 2012, AM J PATHOL, V180, P1474, DOI 10.1016/j.ajpath.2011.12.032; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Balko JM, 2012, P NATL ACAD SCI USA, V109, P221, DOI 10.1073/pnas.1115802109; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Cavalli LR, 2008, CANCER GENET CYTOGEN, V186, P120, DOI 10.1016/j.cancergencyto.2008.06.011; Cavalli LR, 2008, CANCER GENET CYTOGEN, V187, P19, DOI 10.1016/j.cancergencyto.2008.07.004; Chien CD, 2011, J BIOL CHEM, V286, P26813, DOI 10.1074/jbc.M110.216200; Chin K, 2004, NAT GENET, V36, P984, DOI 10.1038/ng1409; Cody HS, 2007, ANN SURG ONCOL, V14, P2179, DOI 10.1245/s10434-006-9300-9; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Espina V, 2011, NAT REV CANCER, V11, P618, DOI 10.1038/nrc2950-c2; Fereshteh MP, 2008, CANCER RES, V68, P3697, DOI 10.1158/0008-5472.CAN-07-6702; Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Korkaya H, 2007, BIODRUGS, V21, P299, DOI 10.2165/00063030-200721050-00002; Korkaya H, 2009, CLIN CANCER RES, V15, P1845, DOI 10.1158/1078-0432.CCR-08-3087; Kuang SQ, 2005, CANCER RES, V65, P7993, DOI 10.1158/0008-5472.CAN-05-1179; Lahusen T, 2009, BREAST CANCER RES TR, V116, P225, DOI 10.1007/s10549-009-0405-2; Lauritsen KJ, 2002, ONCOGENE, V21, P7147, DOI 10.1038/sj.onc.1205943; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Long WW, 2010, MOL CELL, V37, P321, DOI 10.1016/j.molcel.2010.01.004; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Miller FR, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185A; Miller FR, 2000, J MAMMARY GLAND BIOL, V5, P379, DOI 10.1023/A:1009577811584; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nakles RE, 2011, MOL ENDOCRINOL, V25, P549, DOI 10.1210/me.2010-0114; Nofech-Mozes S, 2005, ADV ANAT PATHOL, V12, P256, DOI 10.1097/01.pap.0000184177.65919.5e; Oh A, 2004, CANCER RES, V64, P8299, DOI 10.1158/0008-5472.CAN-04-0354; Porter D, 2003, MOL CANCER RES, V1, P362; Pradeep CR, 2012, ONCOGENE, V31, P907, DOI 10.1038/onc.2011.279; Qutob MS, 2002, MOL CELL BIOL, V22, P6611, DOI 10.1128/MCB.22.18.6611-6626.2002; RADFORD DM, 1995, CANCER RES, V55, P5180; Rosenfield SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047876; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Stingl J, 2005, J MAMMARY GLAND BIOL, V10, P49, DOI 10.1007/s10911-005-2540-7; STRATTON MR, 1995, J PATHOL, V175, P195, DOI 10.1002/path.1711750207; Sung YM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007445; Torres-Arzayus MI, 2010, CANCER RES, V70, P4102, DOI 10.1158/0008-5472.CAN-09-4080; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; York B, 2010, J BIOL CHEM, V285, P38743, DOI 10.1074/jbc.R110.193367	44	11	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					3033	3042		10.1038/onc.2013.263	http://dx.doi.org/10.1038/onc.2013.263			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23851504	Green Accepted			2022-12-28	WOS:000337232200010
J	Adams, AK; Hallenbeck, GE; Casper, KA; Patil, YJ; Wilson, KM; Kimple, RJ; Lambert, PF; Witte, DP; Xiao, W; Gillison, ML; Wikenheiser-Brokamp, KA; Wise-Draper, TM; Wells, SI				Adams, A. K.; Hallenbeck, G. E.; Casper, K. A.; Patil, Y. J.; Wilson, K. M.; Kimple, R. J.; Lambert, P. F.; Witte, D. P.; Xiao, W.; Gillison, M. L.; Wikenheiser-Brokamp, K. A.; Wise-Draper, T. M.; Wells, S. I.			DEK promotes HPV-positive and -negative head and neck cancer cell proliferation	ONCOGENE			English	Article							HUMAN-PAPILLOMAVIRUS; EPIDERMAL MORPHOGENESIS; EPITHELIAL DEVELOPMENT; OROPHARYNGEAL CANCER; BREAST-CANCER; UNITED-STATES; E7 ONCOGENE; P63; EXPRESSION; CARCINOMA	Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide, and patient outcomes using current treatments remain poor. Tumor development is etiologically associated with tobacco or alcohol use and/or human papillomavirus (HPV) infection. HPV-positive HNSCCs, which frequently harbor wild-type p53, carry a more favorable prognosis and are a biologically distinct subgroup when compared with their HPV-negative counterparts. HPV E7 induces expression of the human DEK gene, both in vitro and in vivo. In keratinocytes, DEK overexpression is sufficient for causing oncogenic phenotypes in the absence of E7. Conversely, DEK loss results in cell death in HPV-positive cervical cancer cells at least in part through p53 activation, and Dek knockout mice are relatively resistant to the development of chemically induced skin papillomas. Despite the established oncogenic role of DEK in HPV-associated cervical cancer cell lines and keratinocytes, a functional role of DEK has not yet been explored in HNSCC. Using an established transgenic mouse model of HPV16 E7-induced HNSCC, we demonstrate that Dek is required for optimal proliferation of E7-transgenic epidermal cells and for the growth of HNSCC tumors. Importantly, these studies also demonstrate that DEK protein is universally upregulated in both HPV-positive and -negative human HNSCC tumors relative to adjacent normal tissue. Furthermore, DEK knockdown inhibited the proliferation of HPV-positive and -negative HNSCC cells, establishing a functional role for DEK in human disease. Mechanistic studies reveal that attenuated HNSCC cell growth in response to DEK loss was associated with reduced expression of the oncogenic p53 family member, Delta Np63. Exogenous Delta Np63 expression rescued the proliferative defect in the absence of DEK, thereby establishing a functional DEK-Delta Np63 oncogenic pathway that promotes HNSCC. Taken together, our data demonstrate that DEK stimulates HNSCC cellular growth and identify Delta Np63 as a novel DEK effector.	[Adams, A. K.; Hallenbeck, G. E.; Wise-Draper, T. M.; Wells, S. I.] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA; [Casper, K. A.; Patil, Y. J.; Wilson, K. M.] Univ Cincinnati, Dept Otolaryngol Head & Neck Surg, Cincinnati, OH 45267 USA; [Kimple, R. J.; Lambert, P. F.] Univ Wisconsin, Sch Med & Publ Hlth, McArdle Lab Canc Res, Madison, WI USA; [Witte, D. P.] Cincinnati Childrens Hosp Med Ctr, Div Pathol & Lab Med, Cincinnati, OH 45229 USA; [Xiao, W.; Gillison, M. L.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Wikenheiser-Brokamp, K. A.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Pathol & Lab Med & Pulm Biol, Cincinnati, OH 45267 USA; [Wise-Draper, T. M.] Univ Cincinnati, Univ Hosp, Div Hematol Oncol, Cincinnati, OH 45267 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Wisconsin System; University of Wisconsin Madison; Cincinnati Children's Hospital Medical Center; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Wise-Draper, TM (corresponding author), Univ Cincinnati, Dept Hematol Oncol, 231 Albert Sabin Way,ML 0562, Cincinnati, OH 45267 USA.	wiseth@uc.edu; Susanne.Wells@cchmc.org	Kimple, Randall/L-6460-2019	Kimple, Randall/0000-0001-8336-8000; Wise-Draper, Trisha/0000-0002-7279-4028	NIH [T32ES007250, R00 CA160639, AR-47363, DK78392, DK90971]; Clinical Scientist Training Program at the University of Cincinnati, Public Health Service from the NIH [R01 CA116316]; NATIONAL CANCER INSTITUTE [R01CA116316, R00CA160639, T32CA117846] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR047363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK090971, P30DK078392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007250] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Clinical Scientist Training Program at the University of Cincinnati, Public Health Service from the NIH; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by the Clinical Scientist Training Program at the University of Cincinnati (TWD), Public Health Service Grant R01 CA116316 from the NIH (SIW), NIH Training Grant T32ES007250 (AKA) and R00 CA160639 from the NIH (RJK). All flow cytometric data were acquired using equipment in the Research Flow Cytometry Core in the Division of Rheumatology at Cincinnati Children's Hospital Medical Center, supported in part by NIH AR-47363, NIH DK78392 and NIH DK90971. We would like to acknowledge the CCHMC pathology core with excellent technical support by Meredith Taylor for Ventana HPV in situ hybridization, Dr Madhavi Kadakia for providing the HA-Delta Np63 construct, Marie Matrka for providing protein lysates, and expert technical support by Dr Ronald Waclaw for use of his Leica microscope.	Alexandrova EM, 2013, CELL DEATH DIFFER, V20, P1698, DOI 10.1038/cdd.2013.122; Alexiadis V, 2000, GENE DEV, V14, P1308; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Bradford CR, 2003, HEAD NECK-J SCI SPEC, V25, P654, DOI 10.1002/hed.10274; Carro MS, 2006, CELL CYCLE, V5, P1202, DOI 10.4161/cc.5.11.2801; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; DeYoung MP, 2007, ONCOGENE, V26, P5169, DOI 10.1038/sj.onc.1210337; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Gupta S, 2009, INT J CANCER, V125, P2159, DOI 10.1002/ijc.24533; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Hoskins EE, 2009, ONCOGENE, V28, P674, DOI 10.1038/onc.2008.416; Jabbar S, 2010, VIROLOGY, V407, P60, DOI 10.1016/j.virol.2010.08.003; Kappes F, 2008, MOL CELL BIOL, V28, P3245, DOI 10.1128/MCB.01921-07; Khodadoust MS, 2009, CANCER RES, V69, P6405, DOI 10.1158/0008-5472.CAN-09-1063; Kimple RJ, 2013, CANCER RES, V73, P4791, DOI 10.1158/0008-5472.CAN-13-0587; Koster MI, 2007, P NATL ACAD SCI USA, V104, P3255, DOI 10.1073/pnas.0611376104; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Liu SP, 2012, PATHOL INT, V62, P176, DOI 10.1111/j.1440-1827.2011.02775.x; Lu ZL, 2005, WORLD J GASTROENTERO, V11, P3850; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moll UM, 2004, MOL CANCER RES, V2, P371; National Comprehensive Cancer Network, 2008, J Natl Compr Canc Netw, V6, P646; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pignon JC, 2013, P NATL ACAD SCI USA, V110, P8105, DOI 10.1073/pnas.1221216110; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Romano RA, 2012, DEVELOPMENT, V139, P772, DOI 10.1242/dev.071191; Sitwala KV, 2002, ONCOGENE, V21, P8862, DOI 10.1038/sj.onc.1206041; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Strati K, 2007, CANCER RES, V67, P11585, DOI 10.1158/0008-5472.CAN-07-3007; Strati K, 2006, P NATL ACAD SCI USA, V103, P14152, DOI 10.1073/pnas.0606698103; Su XH, 2013, NAT REV CANCER, V13, P136, DOI 10.1038/nrc3446; Truong AB, 2006, GENE DEV, V20, P3185, DOI 10.1101/gad.1463206; Vinnedge LMP, 2011, ONCOGENE, V30, P2741, DOI 10.1038/onc.2011.2; Vinnedge LMP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046985; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; Wise-Draper TM, 2005, J VIROL, V79, P14309, DOI 10.1128/JVI.79.22.14309-14317.2005; Wise-Draper TM, 2006, MOL CELL BIOL, V26, P7506, DOI 10.1128/MCB.00430-06; Wise-Draper TM, 2012, TRANSL RES, V160, P167, DOI 10.1016/j.trsl.2012.02.002; Wise-Draper TM, 2009, CANCER RES, V69, P1792, DOI 10.1158/0008-5472.CAN-08-2304; Wise-Draper TM, 2009, AM J PATHOL, V174, P71, DOI 10.2353/ajpath.2009.080330; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539	42	34	40	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					868	877		10.1038/onc.2014.15	http://dx.doi.org/10.1038/onc.2014.15			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24608431	Green Accepted			2022-12-28	WOS:000349472000007
J	Hsu, TI; Lin, SC; Lu, PS; Chang, WC; Hung, CY; Yeh, YM; Su, WC; Liao, PC; Hung, JJ				Hsu, T-I; Lin, S-C; Lu, P-S; Chang, W-C; Hung, C-Y; Yeh, Y-M; Su, W-C; Liao, P-C; Hung, J-J			MMP7-mediated cleavage of nucleolin at Asp255 induces MMP9 expression to promote tumor malignancy	ONCOGENE			English	Article							PROSTATE-CANCER CELLS; LUNG-CANCER; GASTRIC-CARCINOMA; MATRILYSIN MMP-7; IN-VITRO; APOPTOSIS; PROTEINS; BINDING; PROGRESSION; TARGET	Nucleolin (NCL) participates in DNA transcription, ribosomal biogenesis and the regulation of RNA stability. However, the contribution of NCL to tumor development is still not clear. Herein,we found that NCL expression correlated with poor prognosis in lung cancer patients. Overexpressed NCL was predominantly cleaved to C-terminal truncated NCL (TNCL). In lung cancer formation, activation of the epidermal growth factor receptor pathway induced NCL expression, and also the expression of matrix metalloproteinase (MMP) 7, which then cleaved NCL at Asp255 to generate TNCL of 55 kDa. TNCL increased the expression of several oncogenes, including MMP9, anaplastic lymphoma kinase (ALK), HIF1a and CBLB, and decreased the expression of tumor suppressors including BRD4, PCM1, TFG and KLF6 by modulating mRNA stability through binding to the 3'-untranslated regions of their transcripts, thus ultimately enhancing metastasis activity. In conclusion, this study identified a novel role of the cleavage form of NCL generated by MMP7 in stabilizing MMP9 mRNA. We also provide a new insight that MMP7 not only cleaves the extracellular matrix to promote tumor invasion but also cleaves NCL, which augment oncogenesis. Blocking NCL cleavage may provide a useful new strategy for lung cancer therapy.	[Hsu, T-I; Lin, S-C; Lu, P-S; Chang, W-C; Hung, J-J] Natl Cheng Kung Univ, Coll Biosci & Biotechnol, Inst Bioinformat & Biosignal Transduct, Tainan 701, Taiwan; [Hsu, T-I; Chang, W-C; Hung, J-J] Natl Cheng Kung Univ, Ctr Infect Dis & Signal Transduct, Tainan 701, Taiwan; [Chang, W-C; Hung, C-Y; Hung, J-J] Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan 701, Taiwan; [Chang, W-C; Hung, J-J] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan; [Chang, W-C; Hung, J-J] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan; [Yeh, Y-M; Su, W-C] Natl Cheng Kung Univ, Coll Med & Hosp, Dept Internal Med, Tainan 701, Taiwan; [Liao, P-C] Natl Cheng Kung Univ, Dept Environm & Occupat Hlth, Tainan 701, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Taipei Medical University; National Cheng Kung University; National Cheng Kung University	Hung, JJ (corresponding author), Natl Cheng Kung Univ, Inst Bioinformat & Biosignal Transduct, Tainan 701, Taiwan.	petehung@mail.ncku.edu.tw	Hsu, Tsung-I/AAK-9942-2020; Ogunwobi, Olorunseun/F-3172-2010	Hsu, Tsung-I/0000-0002-7524-7740; Su, Wu-Chou/0000-0003-2953-4105	National Cheng-Kung University project of the Program for Promoting Acedemic Excellence and Developing World Class Research Centers [100-2320-B-038-032-MY3, NSC101-2321-B-006-004-MY3]; Food and Drug Administration, Ministry of Health and Welfare, Executive Yuan, Taiwan [DOH102-TD-TB-111-NSC101]; Tissue Bank, Research Center of Clinical Medicine, National Cheng-Kung University Hospital; Headquarters of University Advancement at the National Cheng-Kung University - Ministry of Education, Taiwan	National Cheng-Kung University project of the Program for Promoting Acedemic Excellence and Developing World Class Research Centers; Food and Drug Administration, Ministry of Health and Welfare, Executive Yuan, Taiwan; Tissue Bank, Research Center of Clinical Medicine, National Cheng-Kung University Hospital; Headquarters of University Advancement at the National Cheng-Kung University - Ministry of Education, Taiwan	This work was supported by the National Cheng-Kung University project of the Program for Promoting Academic Excellence and Developing World Class Research Centers, together with grants 100-2320-B-038-032-MY3 and NSC101-2321-B-006-004-MY3 obtained from the National Science Council, Taiwan. This work was also supported by the Food and Drug Administration, Ministry of Health and Welfare, Executive Yuan, Taiwan (Grants DOH102-TD-TB-111-NSC101). This research received funding from the Headquarters of University Advancement at the National Cheng-Kung University, which is sponsored by the Ministry of Education, Taiwan. We are grateful for the support from the Tissue Bank, Research Center of Clinical Medicine, National Cheng-Kung University Hospital.	Abdelmohsen K, 2011, NUCLEIC ACIDS RES, V39, P8513, DOI 10.1093/nar/gkr488; Adachi Y, 1999, GUT, V45, P252, DOI 10.1136/gut.45.2.252; Aihara R, 2005, BRIT J SURG, V92, P454, DOI 10.1002/bjs.4868; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Bouvet P, 1998, J BIOL CHEM, V273, P19025, DOI 10.1074/jbc.273.30.19025; Britschgi A, 2013, P NATL ACAD SCI USA, V110, pE1026, DOI 10.1073/pnas.1217072110; Camidge DR, 2012, NAT REV CLIN ONCOL, V9, P268, DOI 10.1038/nrclinonc.2012.43; Chang WC, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-94; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Curtin JF, 2004, J BIOL CHEM, V279, P17090, DOI 10.1074/jbc.M307629200; Davies G, 2001, CLIN CANCER RES, V7, P3289; Dozier S, 2006, Med Chem, V2, P523, DOI 10.2174/157340606778250261; FANG SH, 1993, EXP CELL RES, V208, P48, DOI 10.1006/excr.1993.1221; Feng Y, 2012, CANCER RES, V72, P6502, DOI 10.1158/0008-5472.CAN-12-1909; Herrero R, 2011, J CLIN INVEST, V121, P1174, DOI 10.1172/JCI43004; Hsu TI, 2012, ONCOGENE, V31, P3973, DOI 10.1038/onc.2011.568; Hsu TI, 2012, MOL PHARMACOL, V82, P1115, DOI 10.1124/mol.112.078485; Joo EJ, 2010, J CELL BIOCHEM, V110, P1272, DOI 10.1002/jcb.22643; Kito S, 2005, J ORAL PATHOL MED, V34, P478, DOI 10.1111/j.1600-0714.2005.00346.x; Kito S, 2003, BIOCHEM BIOPH RES CO, V300, P950, DOI 10.1016/S0006-291X(02)02942-X; Komiya T, 2010, ONCOGENE, V29, P1672, DOI 10.1038/onc.2009.453; Kryczka J, 2012, J BIOL CHEM, V287, P36556, DOI 10.1074/jbc.M112.384909; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; McClelland M, 2009, AM J PATHOL, V174, P638, DOI 10.2353/ajpath.2009.080463; Mitsiades N, 2001, CANCER RES, V61, P577; Mongelard F, 2007, TRENDS CELL BIOL, V17, P80, DOI 10.1016/j.tcb.2006.11.010; Nishimura Y, 2013, BRIT J CANCER, V108, P1324, DOI 10.1038/bjc.2013.65; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; Remy L, 2006, CANCER RES, V66, P11228, DOI 10.1158/0008-5472.CAN-06-1187; Roger B, 2003, CHROMOSOMA, V111, P399, DOI 10.1007/s00412-002-0221-5; Rosebeck S, 2011, SCIENCE, V331, P468, DOI 10.1126/science.1198946; Sengupta TK, 2004, J BIOL CHEM, V279, P10855, DOI 10.1074/jbc.M309111200; Serin G, 1996, BIOCHIMIE, V78, P530, DOI 10.1016/0300-9084(96)84759-6; Tripathi M, 2011, PROSTATE, V71, P184, DOI 10.1002/pros.21233; Tsunezumi J, 2009, J CELL BIOCHEM, V106, P693, DOI 10.1002/jcb.22062; vonBredow DC, 1997, EXP CELL RES, V236, P341, DOI 10.1006/excr.1997.3711; Wang S, 2010, NEOPLASIA, V12, P284, DOI 10.1593/neo.91610; WARRENER P, 1991, BIOCHEM BIOPH RES CO, V180, P716, DOI 10.1016/S0006-291X(05)81124-6; Williams H, 2010, CARDIOVASC RES, V87, P137, DOI 10.1093/cvr/cvq042; Yamamoto H, 2001, J CLIN ONCOL, V19, P1118, DOI 10.1200/JCO.2001.19.4.1118; Yamamoto K, 2010, J BIOL CHEM, V285, P28862, DOI 10.1074/jbc.M110.136994; Zhang X, 2013, ONCOGENE, V32, P2782, DOI 10.1038/onc.2012.289; Zou HY, 2007, CANCER RES, V67, P4408, DOI 10.1158/0008-5472.CAN-06-4443	44	26	26	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					826	837		10.1038/onc.2014.22	http://dx.doi.org/10.1038/onc.2014.22			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24632608				2022-12-28	WOS:000349472000003
J	Nguyen, HN; Afkari, Y; Senoo, H; Sesaki, H; Devreotes, PN; Iijima, M				Nguyen, H. N.; Afkari, Y.; Senoo, H.; Sesaki, H.; Devreotes, P. N.; Iijima, M.			Mechanism of human PTEN localization revealed by heterologous expression in Dictyostelium	ONCOGENE			English	Article						PTEN; membrane localization; mutational analysis; Dictyostelium	TUMOR-SUPPRESSOR; PHOSPHATASE-ACTIVITY; BINDING; PHOSPHORYLATION	Phosphatase and tensin homolog (PTEN) is one of the most frequently mutated tumor suppressor genes in cancers. PTEN has a central role in phosphatidylinositol (3,4,5)-trisphosphate (PIP3) signaling and converts PIP3 to phosphatidylinositol (4,5)bisphosphate at the plasma membrane. Despite its importance, the mechanism that mediates membrane localization of PTEN is poorly understood. Here, we generated a library that contains green fluorescent protein fused to randomly mutated human PTEN and expressed the library in Dictyostelium cells. Using live cell imaging, we identified mutations that enhance the association of PTEN with the plasma membrane. These mutations were located in four separate regions, including the phosphatase catalytic site, the calcium-binding region 3 (CBR3) loop, the C alpha 2 loop and the C-terminal tail phosphorylation site. The phosphatase catalytic site, the CBR3 loop and the C alpha 2 loop formed the membrane-binding regulatory interface and interacted with the inhibitory phosphorylated C-terminal tail. Furthermore, we showed that membrane recruitment of PTEN is required for PTEN function in cells. Thus, heterologous expression system in Dictyostelium cells provides mechanistic and functional insight into membrane localization of PTEN.	[Nguyen, H. N.; Afkari, Y.; Senoo, H.; Sesaki, H.; Devreotes, P. N.; Iijima, M.] Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA	Johns Hopkins University	Devreotes, PN (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, 725 N Wolfe St, Baltimore, MD 21205 USA.	pnd@jhmi.edu; miijima@jhmi.edu			NIH [GM084015, GM28007, GM34933, GM089853, NS084154]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028007, R01GM034933, R01GM084015, R01GM028007, R01GM089853] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS084154] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by NIH grants to MI (GM084015), PND (GM28007 and GM34933) and HS (GM089853 and NS084154). We thank M Rahdar and KF Swaney for providing plasmids.	Baker SJ, 2007, CELL, V128, P25, DOI 10.1016/j.cell.2006.12.023; Cai HQ, 2011, METHODS MOL BIOL, V757, P451, DOI 10.1007/978-1-61779-166-6_26; Carracedo A, 2011, CANCER RES, V71, P629, DOI 10.1158/0008-5472.CAN-10-2488; Chen CL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002446; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Denning G, 2007, ONCOGENE, V26, P3930, DOI 10.1038/sj.onc.1210175; Fey P, 2007, NAT PROTOC, V2, P1307, DOI 10.1038/nprot.2007.178; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Iijima M, 2004, J BIOL CHEM, V279, P16606, DOI 10.1074/jbc.M312098200; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Iijima M, 2002, DEV CELL, V3, P469, DOI 10.1016/S1534-5807(02)00292-7; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie Nick R, 2012, Adv Biol Regul, V52, P205; Lumb CN, 2013, BIOPHYS J, V104, P613, DOI 10.1016/j.bpj.2012.12.002; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Rahdar M, 2009, P NATL ACAD SCI USA, V106, P480, DOI 10.1073/pnas.0811212106; Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10; Shenoy S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032591; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Tamguney T, 2007, J CELL SCI, V120, P4071, DOI 10.1242/jcs.015230; Vanhaesebroeck B, 2012, NAT REV MOL CELL BIO, V13, P195, DOI 10.1038/nrm3290; Vazquez F, 2006, P NATL ACAD SCI USA, V103, P3633, DOI 10.1073/pnas.0510570103; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839; Wang Y, 2011, MOL BIOL CELL, V22, P2270, DOI 10.1091/mbc.E10-11-0926; Zhang PB, 2010, P NATL ACAD SCI USA, V107, P11829, DOI 10.1073/pnas.1006153107	26	38	38	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2014	33	50					5688	5696		10.1038/onc.2013.507	http://dx.doi.org/10.1038/onc.2013.507			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW2AB	24292679	Green Accepted			2022-12-28	WOS:000346089300004
J	Zhang, C; Zhang, S; Zhang, Z; He, J; Xu, Y; Liu, S				Zhang, C.; Zhang, S.; Zhang, Z.; He, J.; Xu, Y.; Liu, S.			ROCK has a crucial role in regulating prostate tumor growth through interaction with c-Myc	ONCOGENE			English	Article						ROCK; c-Myc; prostate cancer cells; proliferation; protein stability	B-CELL LYMPHOMAS; PROTEIN STABILITY; GENE-EXPRESSION; BREAST-CANCER; KINASE; PHOSPHORYLATION; TRANSFORMATION; DEGRADATION; CYCLE; FBW7	Rho-associated kinase (ROCK) has an essential role in governing cell morphology and motility, and increased ROCK activity contributes to cancer cell invasion and metastasis. Burgeoning data suggest that ROCK is also involved in the growth regulation of tumor cells. However, thus far, the molecular mechanisms responsible for ROCK-governed tumor cell growth have not been clearly elucidated. Here we showed that inhibition of ROCK kinase activity, either by a selective ROCK inhibitor Y27632 or by specific ROCK small interfering RNA (siRNA) molecules, attenuated not only motility but also the proliferation of PC3 prostate cancer cells in vitro and in vivo. Importantly, mechanistic investigation revealed that ROCK endowed cancer cells with tumorigenic capability, mainly by targeting c-Myc. ROCK could increase the transcriptional activity of c-Myc by promoting c-Myc protein stability, and ROCK inhibition reduced c-Myc-mediated expression of mRNA targets (such as HSPC111) and microRNA targets (such as miR-17-92 cluster). We provided evidence demonstrating that ROCK1 directly interacted with and phosphorylated c-Myc, resulting in stabilization of the protein and activation of its transcriptional activity. Suppression of ROCK-c-Myc downstream molecules, such as c-Myc-regulated miR-17, also impaired tumor cell growth in vitro and in vivo. In addition, c-Myc was shown to exert a positive feedback regulation on ROCK by increasing RhoA mRNA expression. Therefore, inhibition of ROCK and its stimulated signaling might prove to be a promising strategy for restraining tumor progression in prostate cancer.	[Zhang, C.; Zhang, S.; Liu, S.] Chinese Acad Sci, State Key Lab Environm Chem & Ecotoxicol, Res Ctr Ecoenvironm Sci, Beijing 100085, Peoples R China; [Zhang, C.; Zhang, Z.; Xu, Y.] Tianjin Med Univ, Tianjin Inst Urol, Hosp 2, Dept Urol, Tianjin, Peoples R China; [He, J.] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA	Chinese Academy of Sciences; Research Center for Eco-Environmental Sciences (RCEES); Tianjin Medical University; Tufts University	Liu, S (corresponding author), Chinese Acad Sci, State Key Lab Environm Chem & Ecotoxicol, Res Ctr Ecoenvironm Sci, Beijing 100085, Peoples R China.	xuyong8816@sina.com; sjliu@rcees.ac.cn			National Natural Science Foundation of China [21377159, 81172451]; national '973' program [2014CB932000]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); national '973' program(National Basic Research Program of China)	This work was supported by the National Natural Science Foundation of China (grant numbers: 21377159, 81172451) and from the national '973' program (grant number: 2014CB932000). We thank lab members for their invaluable assistance with experiments and reagents, and Michael Rosenblatt, MD, of Merck & Co. Inc. for his review of the manuscript and helpful suggestions.	Alarcon-Vargas D, 2004, J BIOL CHEM, V279, P5008, DOI 10.1074/jbc.M312054200; Alarcon-Vargas D, 2002, ONCOGENE, V21, P4384, DOI 10.1038/sj.onc.1205543; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; Boku S, 2013, BRAIN RES, V1492, P7, DOI 10.1016/j.brainres.2012.11.034; Bu Qiang, 2011, Zhonghua Zhong Liu Za Zhi, V33, P202; Butt AJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1985; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; Gualco G, 2009, AM J SURG PATHOL, V33, P1815, DOI 10.1097/PAS.0b013e3181bb9a18; Hahmann C, 2010, CELL MOL LIFE SCI, V67, P171, DOI 10.1007/s00018-009-0189-x; Hann SR, 2006, SEMIN CANCER BIOL, V16, P288, DOI 10.1016/j.semcancer.2006.08.004; Hesan Luo JZ, 2012, BIOCHEM J, V442, P311; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; James K, 2007, J CARDIOVASC PHARM, V50, P17; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lane J, 2008, INT J ONCOL, V33, P585, DOI 10.3892/ijo_00000044; Lin SL, 2007, CARCINOGENESIS, V28, P310, DOI 10.1093/carcin/bgl134; Liu SJ, 2007, J CLIN INVEST, V117, P3296, DOI 10.1172/JCI32084; Liu SJ, 2011, MOL BIOL REP, V38, P1363, DOI 10.1007/s11033-010-0238-4; Liu SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011272; Liu SJ, 2009, CANCER RES, V69, P8742, DOI 10.1158/0008-5472.CAN-09-1541; Lochhead PA, 2010, ONCOGENE, V29, P2591, DOI 10.1038/onc.2010.3; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Narumiya S, 2009, CANCER METAST REV, V28, P65, DOI 10.1007/s10555-008-9170-7; Noguchi K, 2001, BIOCHEM BIOPH RES CO, V281, P1313, DOI 10.1006/bbrc.2001.4498; Popov N, 2007, CELL CYCLE, V6, P2327, DOI 10.4161/cc.6.19.4804; Riento K, 2005, EMBO J, V24, P1170, DOI 10.1038/sj.emboj.7600612; Routhier A, 2010, ONCOL REP, V23, P861, DOI 10.3892/or_00000708; Ruzinova MB, 2010, AM J SURG PATHOL, V34, P882, DOI 10.1097/PAS.0b013e3181db83af; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; SETH A, 1991, J BIOL CHEM, V266, P23521; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wang CG, 2011, CELL CYCLE, V10, P57, DOI 10.4161/cc.10.1.14449; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Zhang Y, 2009, J CELL SCI, V122, P2197, DOI 10.1242/jcs.040659	43	58	60	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2014	33	49					5582	5591		10.1038/onc.2013.505	http://dx.doi.org/10.1038/onc.2013.505			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZW	24317511				2022-12-28	WOS:000346088700002
J	Elsum, IA; Yates, LL; Pearson, HB; Phesse, TJ; Long, F; O'Donoghue, R; Ernst, M; Cullinane, C; Humbert, PO				Elsum, I. A.; Yates, L. L.; Pearson, H. B.; Phesse, T. J.; Long, F.; O'Donoghue, R.; Ernst, M.; Cullinane, C.; Humbert, P. O.			Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo	ONCOGENE			English	Article						polarity; scrib; ras; lung; cancer	CELL POLARITY; K-RAS; ACTIVATION; EXPRESSION; PATHWAY; GROWTH; TUMORIGENESIS; DEREGULATION; INFLAMMATION; MACROPHAGES	Lung cancer is the leading cause of cancer deaths worldwide with non small-cell lung cancer (NSCLC) accounting for 80% of all lung cancers. Although activating mutations in genes of the RAS-MAPK pathway occur in up to 30% of all NSCLC, the cooperating genetic lesions that are required for lung cancer initiation and progression remain poorly understood. Here we identify a role for the cell polarity regulator Scribble (Scrib) in NSCLC. A survey of genomic databases reveals deregulation of SCRIB in human lung cancer and we show that Scrib(-/-) mutant mice develop lung cancer by 540 days with a penetrance of 43%. To model NSCLC development in vivo, we used the extensively characterized LSL-KRas(G12D) murine model of NSCLC. We show that loss of Scrib and activated oncogenic KRas cooperate in vivo, resulting in more aggressive lung tumors, likely due to a synergistic elevation in RAS-MAPK signaling. Finally, we provide data consistent with immune infiltration having an important role in the acceleration of tumorigenesis in KRas(G12D) lung tumors following Scrib loss.	[Elsum, I. A.; Yates, L. L.; Pearson, H. B.; Long, F.; Humbert, P. O.] Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic 3002, Australia; [Pearson, H. B.; Cullinane, C.; Humbert, P. O.] Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Phesse, T. J.; O'Donoghue, R.; Ernst, M.] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Cell Signaling & Cell Death Div, Parkville, Vic 3050, Australia; [Cullinane, C.] Peter MacCallum Canc Ctr, Translat Res Lab, Canc Therapeut Program, Melbourne, Vic 3002, Australia; [Humbert, P. O.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; [Humbert, P. O.] Univ Melbourne, Dept Mol Biol & Biochem, Parkville, Vic 3052, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne	Humbert, PO (corresponding author), Peter MacCallum Canc Ctr, St Andrews Pl, Melbourne, Vic 3002, Australia.	Patrick.Humbert@petermac.org	Humbert, Patrick O/L-4264-2016; Ernst, Matthias/D-5111-2012	Humbert, Patrick O/0000-0002-1366-6691; Ernst, Matthias/0000-0002-6399-1177; Yates, Laura/0000-0002-1620-1603; Pearson, Helen/0000-0002-3284-0843; Elsum, Imogen/0000-0003-4525-0727; Phesse, Toby/0000-0001-9568-4916; Cullinane, Carleen/0000-0001-5833-6605	NHMRC of Australia [1025239, 1004434]; Movember/PCFA; Richard Pratt Foundation; Cancer Council Victoria Postgraduate Research Scholarship; Biomedical Career Development Award from the NHMRC of Australia	NHMRC of Australia(National Health and Medical Research Council (NHMRC) of Australia); Movember/PCFA; Richard Pratt Foundation; Cancer Council Victoria Postgraduate Research Scholarship(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Biomedical Career Development Award from the NHMRC of Australia(National Health and Medical Research Council (NHMRC) of Australia)	We thank Dr Jason Li, Dr David Bimms, Sam Williams, Olivia Cakebread, Tanja Kinwel and the microscopy and histology core at the Peter MacCallum Cancer Centre. We also thank Dr Alison Dooley and Prof Roderick Bronson from the Massachusetts Institute of Technology for their technical advice and to Drs Helena Richardson and Sarah Russell for critical reading of the manuscript. This study was supported by grants from the NHMRC of Australia (no. 1025239 for TJP and RJO; no. 1004434 for IAE and LLY), Movember/PCFA and Richard Pratt Foundation (for HBP). IAE was supported by a Cancer Council Victoria Postgraduate Research Scholarship and POH was supported by a Biomedical Career Development Award from the NHMRC of Australia.	Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Borrello MG, 2008, CANCER LETT, V267, P262, DOI 10.1016/j.canlet.2008.03.060; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Bryant PJ, 2000, NAT CELL BIOL, V2, pE141, DOI 10.1038/35019616; Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Chatterjee S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034343; Cullinane C, 2011, J NUCL MED, V52, P1261, DOI 10.2967/jnumed.110.086967; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Dow LE, 2008, ONCOGENE, V27, P5988, DOI 10.1038/onc.2008.219; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Elsum I, 2012, ESSAYS BIOCHEM, V53, P141, DOI [10.1042/bse0530141, 10.1042/BSE0530141]; Elsum IA, 2013, J CELL SCI, V126, P3990, DOI 10.1242/jcs.129387; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064; Funaba M, 2002, J BIOL CHEM, V277, P41361, DOI 10.1074/jbc.M204597200; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao NB, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/948098; Huang L, 2010, CURR OPIN GENET DEV, V20, P41, DOI 10.1016/j.gde.2009.12.001; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Ji H, 2006, ONCOGENE, V25, P2105, DOI 10.1038/sj.onc.1209237; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kamei Y, 2007, HUM PATHOL, V38, P1273, DOI 10.1016/j.humpath.2007.01.026; Karreth FA, 2009, CURR OPIN GENET DEV, V19, P4, DOI 10.1016/j.gde.2008.12.006; Kass DJ, 2012, AM J PATHOL, V180, P1963, DOI 10.1016/j.ajpath.2012.01.010; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kissil JL, 2007, CANCER RES, V67, P8089, DOI 10.1158/0008-5472.CAN-07-2300; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Muthuswamy SK, 2012, ANNU REV CELL DEV BI, V28, P599, DOI 10.1146/annurev-cellbio-092910-154244; Nagasaka K, 2010, ONCOGENE, V29, P5311, DOI 10.1038/onc.2010.265; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Pages F, 2010, ONCOGENE, V29, P1093, DOI 10.1038/onc.2009.416; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pearson HB, 2011, J CLIN INVEST, V121, P4257, DOI 10.1172/JCI58509; Ramakrishna GT, 2000, MOL CARCINOGEN, V28, P156, DOI 10.1002/1098-2744(200007)28:3<156::AID-MC4>3.0.CO;2-M; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Shaw AT, 2007, GENE DEV, V21, P694, DOI 10.1101/gad.1526207; Sica A, 2008, CANCER LETT, V267, P204, DOI 10.1016/j.canlet.2008.03.028; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Travis WD, 2002, CLIN CHEST MED, V23, P65, DOI 10.1016/S0272-5231(03)00061-3; Vaira V, 2011, AM J PATHOL, V178, P2478, DOI 10.1016/j.ajpath.2011.02.028; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045; Zhou YH, 2010, NAT BIOTECHNOL, V28, P71, DOI 10.1038/nbt.1595; Zhuo OY, 2010, ONCOL RES, V18, P593, DOI 10.3727/096504010X12767359114045	52	38	39	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2014	33	48					5523	5533		10.1038/onc.2013.498	http://dx.doi.org/10.1038/onc.2013.498			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZO	24276238				2022-12-28	WOS:000346087900005
J	Marivin, A; Berthelet, J; Cartier, J; Paul, C; Gemble, S; Morizot, A; Boireau, W; Saleh, M; Bertoglio, J; Solary, E; Dubrez, L				Marivin, A.; Berthelet, J.; Cartier, J.; Paul, C.; Gemble, S.; Morizot, A.; Boireau, W.; Saleh, M.; Bertoglio, J.; Solary, E.; Dubrez, L.			cIAP1 regulates TNF-mediated cdc42 activation and filopodia formation	ONCOGENE			English	Article						IAPs; TNF; RhoGTPases; cdc42; metastasis; Ras	NF-KAPPA-B; INDUCED ACTIN REORGANIZATION; ALPHA-DEPENDENT APOPTOSIS; SIGNALING PATHWAY; CELL-SURVIVAL; CANCER-CELLS; RHO GTPASES; E3 LIGASE; MIGRATION; IAPS	Tumour necrosis factor-alpha (TNF) is a cytokine endowed with multiple functions, depending on the cellular and environmental context. TNF receptor engagement induces the formation of a multimolecular complex including the TNFR-associated factor TRAF2, the receptor-interaction protein kinase RIP1 and the cellular inhibitor of apoptosis cIAP1, the latter being essential for NF-kappa B activation. Here, we show that cIAP1 also regulates TNF-induced actin cytoskeleton reorganization through a cdc42-dependent, NF-kappa B-independent pathway. Deletion of cIAP1 prevents TNF-induced filopodia and cdc42 activation. The expression of cIAP1 or its E3-ubiquitin ligase-defective mutant restores the ability of cIAP1(-/-) MEFs to produce filopodia, whereas a cIAP1 mutant unable to bind TRAF2 does not. Accordingly, the silencing of TRAF2 inhibits TNF-mediated filopodia formation, whereas silencing of RIP1 does not. cIAP1 directly binds cdc42 and promotes its RhoGDI alpha-mediated stabilization. TNF decreases cIAP1-cdc42 interaction, suggesting that TNF-induced recruitment of cIAP1/TRAF2 to the receptor releases cdc42, which in turn triggers actin remodeling. cIAP1 also regulates cdc42 activation in response to EGF and HRas-V12 expression. A downregulation of cIAP1 altered the cell polarization, the cell adhesion to endothelial cells and cell intercalation, which are cdc42-dependent processes. Finally, we demonstrated that the deletion of cIAP1 regulated the HRas-V12-mediated transformation process, including anchorage-dependent cell growth, tumour growth in a xenograft model and the development of experimental metastasis in the lung.	[Marivin, A.; Berthelet, J.; Cartier, J.; Gemble, S.; Dubrez, L.] Fac Med, INSERM, UMR866, 7 Blvd Jeanne Arc, F-21079 Dijon, France; [Marivin, A.; Berthelet, J.; Cartier, J.; Paul, C.; Gemble, S.; Dubrez, L.] Univ Bourgogne, IFR 100, Dijon, France; [Paul, C.] EPHE, Dijon, France; [Morizot, A.; Saleh, M.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Boireau, W.] Univ Franche Comte, Inst FEMTO ST, CLIPP, F-25030 Besancon, France; [Bertoglio, J.] IFR 54, Inserm UMR749, Villejuif, France; [Bertoglio, J.; Solary, E.] IFR 54, Inst Gustave Roussy, Villejuif, France; [Solary, E.] IFR 54, UMR1009, Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); McGill University; Universite de Franche-Comte; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Dubrez, L (corresponding author), Fac Med, INSERM, UMR866, 7 Blvd Jeanne Arc, F-21079 Dijon, France.	ldubrez@u-bourgogne.fr	Laurence, Dubrez/P-9472-2019; Dubrez, Laurence/I-4971-2016	Laurence, Dubrez/0000-0002-7030-2181; Dubrez, Laurence/0000-0002-7030-2181; Paul, Catherine/0000-0002-7657-5535; Solary, Eric/0000-0002-8629-1341; CARTIER, Jessy/0000-0002-0366-8546; Berthelet, Jean/0000-0003-2562-0575	Comite de Cote d'Or of the Ligue Contre le Cancer; 'Association pour la Recherche sur le Cancer' (ARC); Association 'Cent pour sang la Vie'; European Union; Conseil Regional de Bourgogne'; French National Research Agency under the program [ANR-11-LABX-0021]; 'Ministere de l'Enseignement Superieur et de la Recherche' of France; Societe Francaise d'Hematologie	Comite de Cote d'Or of the Ligue Contre le Cancer; 'Association pour la Recherche sur le Cancer' (ARC)(Fondation ARC pour la Recherche sur le Cancer); Association 'Cent pour sang la Vie'; European Union(European Commission); Conseil Regional de Bourgogne'(Region Bourgogne-Franche-Comte); French National Research Agency under the program(French National Research Agency (ANR)); 'Ministere de l'Enseignement Superieur et de la Recherche' of France; Societe Francaise d'Hematologie	We thank Dr J Silke, Dr E Lemichez, Dr S Gasman, Dr CL Day, Dr S Ansieu, Dr R Weil and S Monier for kindly providing plasmids and cell lines. We are grateful to Lydie Desoche, Aziza Aznague, Cedric Seignez and Benoit Simon (FEMTO-ST, CLIPP platform) for their technical assistance. We thank A Bouchot and B Gasquet (CellImaP Imagery Facility), A Hammann (Cytometry platform), V Saint-Giorgio (Animal Facility), A Oudot and B Collin (Precilinal imagery platform, Georges-Francois Leclerc Center) for the use of the imagery, cytometry and animal facilities. We thank P Meier, K Rajalingam, J Breard, M David and S Ansieu for helpful discussions. This work was supported by grants from the 'Comite de Cote d'Or of the Ligue Contre le Cancer' (LD), the 'Association pour la Recherche sur le Cancer' (ARC to LD), the Association 'Cent pour sang la Vie' (LD), the European Union and the 'Conseil Regional de Bourgogne', a French Government grant managed by the French National Research Agency under the program 'Investissements d'Avenir with reference ANR-11-LABX-0021', and fellowships from the 'Ministere de l'Enseignement Superieur et de la Recherche' of France (to AM, JB, JC), ARC (JC) and the 'Societe Francaise d'Hematologie' (AM).	Allen WE, 1997, J CELL SCI, V110, P707; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Boulter E, 2012, FASEB J, V26, P469, DOI 10.1096/fj.11-192252; Boulter E, 2010, NAT CELL BIOL, V12, P477, DOI 10.1038/ncb2049; Cartier J, 2011, J BIOL CHEM, V286, P26406, DOI 10.1074/jbc.M110.191239; Cheng CM, 2011, MOL CELL BIOL, V31, P983, DOI 10.1128/MCB.00137-10; Dogan T, 2008, NAT CELL BIOL, V10, P1447, DOI 10.1038/ncb1804; Dynek JN, 2010, EMBO J, V29, P4198, DOI 10.1038/emboj.2010.300; Etienne-Manneville S, 2004, J CELL SCI, V117, P1291, DOI 10.1242/jcs.01115; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; Fortin SP, 2012, MOL CANCER RES, V10, P958, DOI 10.1158/1541-7786.MCR-11-0616; Gadea G, 2004, J CELL SCI, V117, P6355, DOI 10.1242/jcs.01566; Garcia-Mata R, 2011, NAT REV MOL CELL BIO, V12, P493, DOI 10.1038/nrm3153; Geisbrecht ER, 2004, CELL, V118, P111, DOI 10.1016/j.cell.2004.06.020; Grandclement C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020444; Gyrd-Hansen M, 2008, NAT CELL BIOL, V10, P1309, DOI 10.1038/ncb1789; Gyrd-Hansen M, 2010, NAT REV CANCER, V10, P561, DOI 10.1038/nrc2889; Haas TL, 2009, MOL CELL, V36, P831, DOI 10.1016/j.molcel.2009.10.013; Haubert D, 2007, EMBO J, V26, P3308, DOI 10.1038/sj.emboj.7601778; Hehnly H, 2010, TRAFFIC, V11, P1067, DOI 10.1111/j.1600-0854.2010.01082.x; Iden S, 2008, NAT REV MOL CELL BIO, V9, P846, DOI 10.1038/nrm2521; Kant S, 2011, GENE DEV, V25, P2069, DOI 10.1101/gad.17224711; Liu JY, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.176982; Lopez J, 2011, MOL CELL, V42, P569, DOI 10.1016/j.molcel.2011.04.008; Mace PD, 2010, J MOL BIOL, V400, P8, DOI 10.1016/j.jmb.2010.04.055; Makrodouli E, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-118; Mathew SJ, 2009, J CELL SCI, V122, P1939, DOI 10.1242/jcs.044487; Mckenzie JAG, 2007, J CELL PHYSIOL, V213, P221, DOI 10.1002/jcp.21114; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Oberoi TK, 2012, EMBO J, V31, P14, DOI 10.1038/emboj.2011.423; Parameswaran N, 2010, CRIT REV EUKAR GENE, V20, P87, DOI 10.1615/CritRevEukarGeneExpr.v20.i2.10; Peppelenbosch M, 1999, J IMMUNOL, V162, P837; Puls A, 1999, J CELL SCI, V112, P2983; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; Reymond N, 2012, J CELL BIOL, V199, P653, DOI 10.1083/jcb.201205169; Silke J, 2011, CURR OPIN IMMUNOL, V23, P620, DOI 10.1016/j.coi.2011.08.002; Stengel K, 2011, CELL SIGNAL, V23, P1415, DOI 10.1016/j.cellsig.2011.04.001; Stengel KR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037317; Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678; Van Troys M, 2008, EUR J CELL BIOL, V87, P649, DOI 10.1016/j.ejcb.2008.04.001; Vanlangenakker N, 2011, CELL DEATH DIFFER, V18, P656, DOI 10.1038/cdd.2010.138; Varfolomeev E, 2008, J BIOL CHEM, V283, P24295, DOI 10.1074/jbc.C800128200; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Xu L, 2007, MOL CELL, V28, P914, DOI 10.1016/j.molcel.2007.10.027; Yang L, 2006, MOL BIOL CELL, V17, P4675, DOI 10.1091/mbc.E06-05-0466; Zarnegar BJ, 2008, NAT IMMUNOL, V9, P1371, DOI 10.1038/ni.1676; Zhuang M, 2013, MOL CELL, V49, P273, DOI 10.1016/j.molcel.2012.10.022	49	16	16	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2014	33	48					5534	5545		10.1038/onc.2013.499	http://dx.doi.org/10.1038/onc.2013.499			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZO	24276241				2022-12-28	WOS:000346087900006
J	Bersani, C; Xu, LD; Vilborg, A; Lui, WO; Wiman, KG				Bersani, C.; Xu, L-D; Vilborg, A.; Lui, W-O; Wiman, K. G.			Wig-1 regulates cell cycle arrest and cell death through the p53 targets FAS and 14-3-3 sigma	ONCOGENE			English	Article						Wig-1; p53; FAS; 14-3-3 sigma; AU-rich element; AU-rich element-binding proteins	MESSENGER-RNA DECAY; AU-RICH ELEMENTS; ZINC-FINGER PROTEIN; DNA-DAMAGE; P53-ACTIVATED GENE; CCR4-NOT COMPLEX; EXPRESSION; HUR; STABILITY; STRESS	Wig-1, also known as ZMAT3, is a p53 target gene that encodes an RNA-binding zinc-finger protein involved in the regulation of mRNA stability through binding to AU-rich elements (AREs). We have used microarray analysis to identify novel Wig-1 target mRNAs. We identified 2447 transcripts with >fourfold differential expression between Wig-1 and control small interfering (si) RNA-treated HCT116 cells. Several p53 target genes were among the deregulated transcripts. We found that Wig-1 regulates FAS and 14-3-3 sigma mRNA independently of p53. We show that Wig-1 binds to FAS mRNA 3'-UTR and decreases its stability through an ARE in the 3'-UTR. Depletion of Wig-1 was associated with increased cell death and reduced cell cycle arrest upon DNA damage. Our results suggest a role of Wig-1 as a survival factor that directs the p53 stress response toward cell cycle arrest rather than apoptosis through the regulation of FAS and 14-3-3 sigma mRNA levels.	[Bersani, C.; Xu, L-D; Vilborg, A.; Lui, W-O; Wiman, K. G.] Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, SE-17176 Stockholm, Sweden	Karolinska Institutet	Wiman, KG (corresponding author), Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, SE-17176 Stockholm, Sweden.	Klas.Wiman@ki.se	Lui, Weng-Onn/X-5957-2019; Bersani, Cinzia/M-7871-2014; Lui, Weng-Onn/G-6703-2013; Wiman, Klas/AAB-8399-2021	Lui, Weng-Onn/0000-0003-4717-4473; Bersani, Cinzia/0000-0001-7604-5211; Lui, Weng-Onn/0000-0003-4717-4473; Wiman, Klas/0000-0002-7113-524X; Vilborg, Anna/0000-0003-0917-9062	Swedish Cancer Society; Swedish Research Council (VR); Gustaf V Jubilee Fund; Karolinska Institutet Distinguished Professor award	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council (VR)(Swedish Research Council); Gustaf V Jubilee Fund; Karolinska Institutet Distinguished Professor award	We thank Stefano Caramuta for assistance with the microarray analysis and Dr Bert Vogelstein for HCT116 cells. This work was supported by grants from the Swedish Cancer Society, the Swedish Research Council (VR), the Gustaf V Jubilee Fund and a Karolinska Institutet Distinguished Professor award to KGW.	Al-Haj L, 2012, NUCLEIC ACIDS RES, V40, P7739, DOI 10.1093/nar/gks545; Anderson P, 2008, TRENDS BIOCHEM SCI, V33, P141, DOI 10.1016/j.tibs.2007.12.003; Atasoy U, 1998, J CELL SCI, V111, P3145; Ball CA, 2005, NUCLEIC ACIDS RES, V33, pD580; Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012; Beisang D, 2012, WIRES RNA, V3, P719, DOI 10.1002/wrna.1125; Chang N, 2010, MOL CELL BIOL, V30, P3875, DOI 10.1128/MCB.00169-10; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Cho SJ, 2010, NUCLEIC ACIDS RES, V38, P2256, DOI 10.1093/nar/gkp1229; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dolken L, 2008, RNA, V14, P1959, DOI 10.1261/rna.1136108; Doidge R, 2012, BIOCHEM SOC T, V40, P896, DOI 10.1042/BST20120074; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gareau C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020254; Gillardon F, 1999, MOL BRAIN RES, V73, P138, DOI 10.1016/S0169-328X(99)00251-X; Gouble A, 2002, CANCER RES, V62, P1489; Hellborg F, 2004, INT J ONCOL, V24, P1559; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Higashi Y, 2002, J BIOL CHEM, V277, P42224, DOI 10.1074/jbc.M203594200; Ishimaru D, 2010, J BIOL CHEM, V285, P27182, DOI 10.1074/jbc.M109.098830; Khabar KSA, 2010, CELL MOL LIFE SCI, V67, P2937, DOI 10.1007/s00018-010-0383-x; Kim BC, 2012, EMBO J, V31, P4289, DOI 10.1038/emboj.2012.286; Kim HH, 2009, GENE DEV, V23, P1743, DOI 10.1101/gad.1812509; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lu JY, 2006, RNA, V12, P883, DOI 10.1261/rna.2308106; Mcgray AJR, 2011, CELL MOL BIOL LETT, V16, P55, DOI 10.2478/s11658-010-0037-x; Mendez-Vidal C, 2002, NUCLEIC ACIDS RES, V30, P1991, DOI 10.1093/nar/30.9.1991; Miller JE, 2012, CRIT REV BIOCHEM MOL, V47, P315, DOI 10.3109/10409238.2012.667214; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Sanduja S, 2011, WIRES RNA, V2, P42, DOI 10.1002/wrna.28; Schoenberg DR, 2012, NAT REV GENET, V13, P246, DOI 10.1038/nrg3160; Sedaghat Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029429; Thomas PD, 2006, NUCLEIC ACIDS RES, V34, pW645, DOI 10.1093/nar/gkl229; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; VarmehZiaie S, 1997, ONCOGENE, V15, P2699, DOI 10.1038/sj.onc.1201454; Vidal CM, 2006, FEBS LETT, V580, P4401, DOI 10.1016/j.febslet.2006.07.005; Vilborg A, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.33; Vilborg A, 2011, CELL DEATH DIFFER, V18, P1434, DOI 10.1038/cdd.2011.20; Vilborg A, 2009, P NATL ACAD SCI USA, V106, P15756, DOI 10.1073/pnas.0900862106; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; von Roretz C, 2011, WIRES RNA, V2, P336, DOI 10.1002/wrna.55; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340	45	46	48	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2014	33	35					4407	4417		10.1038/onc.2013.594	http://dx.doi.org/10.1038/onc.2013.594			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MR	24469038	Green Published, hybrid			2022-12-28	WOS:000341157800005
J	Myatt, SS; Kongsema, M; Man, CWY; Kelly, DJ; Gomes, AR; Khongkow, P; Karunarathna, U; Zona, S; Langer, JK; Dunsby, CW; Coombes, RC; French, PM; Brosens, JJ; Lam, EWF				Myatt, S. S.; Kongsema, M.; Man, C. W-Y; Kelly, D. J.; Gomes, A. R.; Khongkow, P.; Karunarathna, U.; Zona, S.; Langer, J. K.; Dunsby, C. W.; Coombes, R. C.; French, P. M.; Brosens, J. J.; Lam, E. W-F			SUMOylation inhibits FOXM1 activity and delays mitotic transition	ONCOGENE			English	Article						FOXM1; SUMO; chemotherapy; drug resistance; breast cancer; cell cycle	BREAST-CANCER; TRANSCRIPTION FACTOR; POSTTRANSLATIONAL MODIFICATION; UBIQUITIN LIGASE; SUMO; CELLS; RNF4; EXPRESSION; RESISTANCE; PATHWAY	The forkhead box transcription factor FOXM1 is an essential effector of G2/M-phase transition, mitosis and the DNA damage response. As such, it is frequently deregulated during tumorigenesis. Here we report that FOXM1 is dynamically modified by SUMO1 but not by SUMO2/3 at multiple sites. We show that FOXM1 SUMOylation is enhanced in MCF-7 breast cancer cells in response to treatment with epirubicin and mitotic inhibitors. Mutation of five consensus conjugation motifs yielded a SUMOylation-deficient mutant FOXM1. Conversely, fusion of the E2 ligase Ubc9 to FOXM1 generated an auto-SUMOylating mutant (FOXM1-Ubc9). Analysis of wild-type FOXM1 and mutants revealed that SUMOylation inhibits FOXM1 activity, promotes translocation to the cytoplasm and enhances APC/Cdh1-mediated ubiquitination and degradation. Further, expression of the SUMOylation-deficient mutant enhanced cell proliferation compared with wild-type FOXM1, whereas the FOXM1-Ubc9 fusion protein resulted in persistent cyclin B1 expression and slowed the time from mitotic entry to exit. In summary, our findings suggest that SUMOylation attenuates FOXM1 activity and causes mitotic delay in cytotoxic drug response.	[Myatt, S. S.; Kongsema, M.; Kelly, D. J.; Gomes, A. R.; Khongkow, P.; Karunarathna, U.; Zona, S.; Langer, J. K.; Coombes, R. C.; Lam, E. W-F] Univ London Imperial Coll Sci Technol & Med, Imperial Ctr Translat & Expt Med, Dept Surg & Canc, London W12 0NN, England; [Man, C. W-Y] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Hong Kong, Peoples R China; [Kelly, D. J.; Dunsby, C. W.; French, P. M.] Univ London Imperial Coll Sci Technol & Med, Dept Phys, Photon Grp, London W12 0NN, England; [Brosens, J. J.] Univ Hosp, Warwick Med Sch, Div Reprod Hlth, Clin Sci Res Labs, Coventry, W Midlands, England	Imperial College London; Hong Kong Polytechnic University; Imperial College London; University of Warwick	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Imperial Ctr Translat & Expt Med, Dept Surg & Canc, Room 134,1st Floor,Du Cane Rd, London W12 0NN, England.	eric.lam@imperial.ac.uk	French, Paul/E-8649-2011; Kongsema, Mesayamas/H-3063-2017; Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576; Khongkow, Pasarat/0000-0003-3068-2412; Brosens, Jan/0000-0003-0116-9329; Coombes, Raoul Charles/0000-0002-4811-1100; French, Paul/0000-0002-0478-6755; Kongsema, Mesayamas/0000-0001-7146-9349	Breast Cancer Campaign; Cancer Research UK; Royal Thai Government; BBSRC; EPSRC; Biomedical Research Unit in Reproductive Health, University Hospital Coventry and Warwickshire, UK; Biotechnology and Biological Sciences Research Council [1243234] Funding Source: researchfish; Cancer Research UK [12011] Funding Source: researchfish; Breast Cancer Campaign [2012MayPR070, 2012NovPhD016] Funding Source: researchfish	Breast Cancer Campaign; Cancer Research UK(Cancer Research UK); Royal Thai Government; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Biomedical Research Unit in Reproductive Health, University Hospital Coventry and Warwickshire, UK; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Breast Cancer Campaign	This work was funded by grants from Breast Cancer Campaign and from Cancer Research UK. MK and PK are recipients of studentships from the Royal Thai Government, and UK is supported by BBSRC. ARG is a post-doctoral fellow supported by Cancer Research UK, and SZ is a post-doc funded by Breast Cancer Campaign. DJK is supported by a studentship from EPSRC. JJ.B was supported by the Biomedical Research Unit in Reproductive Health, University Hospital Coventry and Warwickshire, UK.	Alibhai D, 2013, J BIOPHOTONICS, V6, P398, DOI 10.1002/jbio.201200185; Alvarez-Fernandez M, 2010, EMBO REP, V11, P452, DOI 10.1038/embor.2010.46; Azuma Y, 2003, J CELL BIOL, V163, P477, DOI 10.1083/jcb.200304088; Bailey D, 2004, J BIOL CHEM, V279, P692, DOI 10.1074/jbc.M306195200; Behren A, 2010, ONCOGENE, V29, P1519, DOI 10.1038/onc.2009.436; Burrage PS, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2564; Carr JR, 2010, CANCER RES, V70, P5054, DOI 10.1158/0008-5472.CAN-10-0545; Chang DC, 2003, J BIOL CHEM, V278, P37865, DOI 10.1074/jbc.M306376200; Chien AJ, 2008, SEMIN ONCOL, V35, pS1, DOI 10.1053/j.seminoncol.2008.02.010; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Darieva Z, 2006, NATURE, V444, P494, DOI 10.1038/nature05339; de Olano N, 2012, MOL CANCER RES, V10, P1189, DOI 10.1158/1541-7786.MCR-11-0559; Down CF, 2012, BBA-GENE REGUL MECH, V1819, P855, DOI 10.1016/j.bbagrm.2012.03.008; Galanty Y, 2009, NATURE, V462, P935, DOI 10.1038/nature08657; Gill G, 2003, CURR OPIN GENET DEV, V13, P108, DOI 10.1016/S0959-437X(03)00021-2; Hakli M, 2005, EXP CELL RES, V304, P224, DOI 10.1016/j.yexcr.2004.10.029; Hannoun Z, 2010, TOXICOLOGY, V278, P288, DOI 10.1016/j.tox.2010.07.013; Heideker J, 2009, DNA REPAIR, V8, P517, DOI 10.1016/j.dnarep.2009.01.010; Hui RCY, 2008, MOL CELL BIOL, V28, P5886, DOI 10.1128/MCB.01265-07; Jakobs A, 2007, NAT METHODS, V4, P245, DOI 10.1038/NMETH1006; Jones MC, 2006, P NATL ACAD SCI USA, V103, P16272, DOI 10.1073/pnas.0603002103; Kho C, 2011, NATURE, V477, P601, DOI 10.1038/nature10407; Kim IM, 2005, J BIOL CHEM, V280, P22278, DOI 10.1074/jbc.M500936200; Knipscheer P, 2007, EMBO J, V26, P2797, DOI 10.1038/sj.emboj.7601711; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Kwok JMM, 2008, MOL CANCER THER, V7, P2022, DOI 10.1158/1535-7163.MCT-08-0188; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Laoukili J, 2008, CELL CYCLE, V7, P2720, DOI 10.4161/cc.7.17.6580; Leisner C, 2008, CURR BIOL, V18, P1249, DOI 10.1016/j.cub.2008.07.091; Leung TWC, 2001, FEBS LETT, V507, P59, DOI 10.1016/S0014-5793(01)02915-5; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Millour J, 2011, MOL CANCER THER, V10, P1046, DOI 10.1158/1535-7163.MCT-11-0024; Monteiro LJ, 2013, ONCOGENE, V32, P4634, DOI 10.1038/onc.2012.491; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Morris JR, 2009, NATURE, V462, P886, DOI 10.1038/nature08593; Park YY, 2012, CARCINOGENESIS, V33, P1843, DOI 10.1093/carcin/bgs167; Prudden J, 2007, EMBO J, V26, P4089, DOI 10.1038/sj.emboj.7601838; Ran Y, 2011, J MOL CELL BIOL, V3, P283, DOI 10.1093/jmcb/mjr020; Rytinki MM, 2009, J BIOL CHEM, V284, P26184, DOI 10.1074/jbc.M109.038943; Spengler ML, 2006, J BIOL CHEM, V281, P5567, DOI 10.1074/jbc.M600035200; Sun H, 2007, EMBO J, V26, P4102, DOI 10.1038/sj.emboj.7601839; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; Wadosky KM, 2012, AM J PHYSIOL-HEART C, V302, pH515, DOI 10.1152/ajpheart.00703.2011; Warren SC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070687; Werner A, 2012, MOL CELL, V46, P287, DOI 10.1016/j.molcel.2012.02.017; Xue Y, 2006, NUCLEIC ACIDS RES, V34, pW254, DOI 10.1093/nar/gkl207; Yin YL, 2012, GENE DEV, V26, P1196, DOI 10.1101/gad.189274.112; Zhang N, 2012, CLIN CANCER RES, V18, P5961, DOI 10.1158/1078-0432.CCR-12-0039; Zhang XD, 2008, MOL CELL, V29, P729, DOI 10.1016/j.molcel.2008.01.013; Zhou Y, 2003, J BIOL CHEM, V278, P12530, DOI 10.1074/jbc.M212853200	54	71	72	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2014	33	34					4316	4329		10.1038/onc.2013.546	http://dx.doi.org/10.1038/onc.2013.546			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MK	24362530	Green Accepted, Green Published			2022-12-28	WOS:000341156900005
J	Iliou, MS; da Silva-Diz, V; Carmona, FJ; Ramalho-Carvalho, J; Heyn, H; Villanueva, A; Munoz, P; Esteller, M				Iliou, M. S.; da Silva-Diz, V.; Carmona, F. J.; Ramalho-Carvalho, J.; Heyn, H.; Villanueva, A.; Munoz, P.; Esteller, M.			Impaired DICER1 function promotes stemness and metastasis in colon cancer	ONCOGENE			English	Article						DICER1; miRNA; colon cancer; stemness; metastasis	EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN COLORECTAL-CANCER; TUMOR-SUPPRESSOR MICRORNAS; MIR-200 FAMILY; BREAST-CANCER; CELL-LINES; PANCREATIC-CANCER; PROSTATE-CANCER; INVASIVE STATES; REPRESSORS ZEB1	Disruption of microRNA (miRNA) expression patterns is now being recognized as a hallmark of human cancer. The causes of these altered profiles are diverse, and, among them, we found the existence of defects in the miRNA processing machinery. However, little is known about how these alterations affect the biology of the underlying tumors. Herein, we show that colorectal cancer cells with an impairment in DICER1, a major miRNA biogenesis gene, undergo enrichment of tumor stemness features and an epithelialto- mesenchymal transition. These phenotypes are associated with the downregulation of miRNAs, such as miR-34a, miR-126 and those of the miR-200 family, that target critical coding genes in these pathways. Most importantly, DICER1 impairment also induces the acquisition of a greater capacity for tumor initiation and metastasis, two properties associated with cancer stem cells.	[Iliou, M. S.; da Silva-Diz, V.; Carmona, F. J.; Ramalho-Carvalho, J.; Heyn, H.; Munoz, P.; Esteller, M.] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Spain; [Villanueva, A.] Bellvitge Biomed Res Inst IDIBELL, Catalan Inst Oncol ICO, Lab Translat Res, Barcelona, Spain; [Esteller, M.] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Spain; [Esteller, M.] IDIBELL, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)	Munoz, P (corresponding author), Hosp Duran I Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, 3rd Floor,Avda Gran Via Km 2-7, Barcelona 08908, Catalonia, Spain.	p.munoz@idibell.cat; mesteller@idibell.cat	Ramalho-Carvalho, João/U-2356-2017; Esteller, Manel/L-5956-2014	Ramalho-Carvalho, João/0000-0001-6140-7363; Esteller, Manel/0000-0003-4490-6093; Carmona Sanz, F Javier/0000-0001-7904-8493; Heyn, Holger/0000-0002-3276-1889	Spanish Ministry of Science and Innovation [SAF200801173, SAF2011-22803]; European Research Council Advanced Grant EPINORC [268626]; European Community's Seventh Framework Programme (FP7) [HEALTH-F2-2011-259015-COLTHERES, HEALTH-F5-2010-258236-SYSCOL]; Cellex Foundation; Botin Foundation; Health and Science Departments of the Catalan Government (Generalitat de Catalunya); Spanish Ministry of Science and Innovation fellowship	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); European Research Council Advanced Grant EPINORC; European Community's Seventh Framework Programme (FP7)(European Commission); Cellex Foundation(Foundation CELLEX); Botin Foundation; Health and Science Departments of the Catalan Government (Generalitat de Catalunya); Spanish Ministry of Science and Innovation fellowship(Ministry of Science and Innovation, Spain (MICINN))	We thank Dr Bert Vogelstein (Johns Hopkins Kimmel Comprehensive Cancer Center) for the generous gift of the parental and Dicerex5 isogenic cell lines; R Alvarez, J Comas and E Castanco (Universitat de Barcelona-SCT) for technical support with flow cytometry; and the staff of the IDIBELL animal facility for mouse care. This work was supported by grants from the Spanish Ministry of Science and Innovation (SAF200801173 and SAF2011-22803), the European Research Council Advanced Grant EPINORC no. 268626, the European Community's Seventh Framework Programme (FP7/ 2007-2013) under grant agreements no. HEALTH-F2-2011-259015-COLTHERES project and HEALTH-F5-2010-258236-SYSCOL project, Cellex Foundation, Botin Foundation, and the Health and Science Departments of the Catalan Government (Generalitat de Catalunya). MSI was an ESTOOLS Postdoctoral Research Fellow. VdS-D was funded by a Spanish Ministry of Science and Innovation fellowship. ME is an ICREA Research Professor.	Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Anton R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026257; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Cho SH, 2012, INT J ONCOL, V41, P211, DOI 10.3892/ijo.2012.1453; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dallas NA, 2009, CANCER RES, V69, P1951, DOI 10.1158/0008-5472.CAN-08-2023; Dylla SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002428; Eramo A, 2006, CELL DEATH DIFFER, V13, P1238, DOI 10.1038/sj.cdd.4401872; Faber C, 2011, EUR J CANCER, V47, P1414, DOI 10.1016/j.ejca.2011.01.006; Faggad A, 2012, HISTOPATHOLOGY, V61, P552, DOI 10.1111/j.1365-2559.2011.04110.x; Feng RH, 2010, CANCER LETT, V298, P50, DOI 10.1016/j.canlet.2010.06.004; Fukagawa T, 2004, NAT CELL BIOL, V6, P784, DOI 10.1038/ncb1155; Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698; Ghislin S, 2012, CELL CYCLE, V11, P1634, DOI 10.4161/cc.20095; Gorges TM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-178; Gosens MJEM, 2007, MODERN PATHOL, V20, P221, DOI 10.1038/modpathol.3800733; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grelier G, 2009, BRIT J CANCER, V101, P673, DOI 10.1038/sj.bjc.6605193; Guo XF, 2012, J CANCER RES CLIN, V138, P49, DOI 10.1007/s00432-011-1058-1; Hamada S, 2012, MOL CANCER RES, V10, P3, DOI 10.1158/1541-7786.MCR-11-0272; Henry JC, 2010, BIOCHEM BIOPH RES CO, V403, P120, DOI 10.1016/j.bbrc.2010.10.130; Heravi-Moussavi A, 2012, NEW ENGL J MED, V366, P234, DOI 10.1056/NEJMoa1102903; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Iliou MS, 2011, EPIGENETICS-US, V6, P1344, DOI 10.4161/epi.6.11.18021; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Jeyapalan Z, 2011, NUCLEIC ACIDS RES, V39, P3026, DOI 10.1093/nar/gkq1003; Karube Y, 2005, CANCER SCI, V96, P111, DOI 10.1111/j.1349-7006.2005.00015.x; Kemper K, 2012, STEM CELLS, V30, P2378, DOI 10.1002/stem.1233; Khoshnaw SM, 2012, BREAST CANCER RES TR, V135, P403, DOI 10.1007/s10549-012-2169-3; Kim NH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001744; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu HP, 2010, P NATL ACAD SCI USA, V107, P18115, DOI 10.1073/pnas.1006732107; Lopez-Serra P, 2012, ONCOGENE, V31, P1609, DOI 10.1038/onc.2011.354; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Luo ZH, 2013, CARCINOGENESIS, V34, P415, DOI 10.1093/carcin/bgs329; Ma S, 2008, ONCOGENE, V27, P1749, DOI 10.1038/sj.onc.1210811; Maetzel D, 2009, NAT CELL BIOL, V11, P162, DOI 10.1038/ncb1824; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Melo SA, 2010, CANCER CELL, V18, P303, DOI 10.1016/j.ccr.2010.09.007; Melo SA, 2009, NAT GENET, V41, P365, DOI 10.1038/ng.317; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Mongroo Perry S, 2010, Cancer Biol Ther, V10, P219; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munoz P, 2012, MOL ONCOL, V6, P620, DOI 10.1016/j.molonc.2012.10.006; Munz M, 2004, ONCOGENE, V23, P5748, DOI 10.1038/sj.onc.1207610; Negrini M, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1867; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Png KJ, 2011, GENE DEV, V25, P226, DOI 10.1101/gad.1974211; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Saito Y, 2006, CELL CYCLE, V5, P2220, DOI 10.4161/cc.5.19.3340; Sasahira T, 2012, BRIT J CANCER, V107, P700, DOI 10.1038/bjc.2012.330; Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676; Shu GS, 2012, PATHOL RES PRACT, V208, P392, DOI 10.1016/j.prp.2012.05.001; Sparks AB, 1998, CANCER RES, V58, P1130; Stratmann J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-345; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Su YJ, 2011, EMBO J, V30, P3186, DOI 10.1038/emboj.2011.211; Tang F, 2007, GENE DEV, V21, P644, DOI 10.1101/gad.418707; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Tome M, 2011, CELL DEATH DIFFER, V18, P985, DOI 10.1038/cdd.2010.167; Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Wang CH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002420; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Wu DY, 2012, MOL MED REP, V5, P695, DOI 10.3892/mmr.2011.711; Yu Zuoren, 2012, Frontiers in Genetics, V3, P191, DOI 10.3389/fgene.2012.00191; Zhu DX, 2012, CANCER SCI, V103, P875, DOI 10.1111/j.1349-7006.2012.02234.x	88	55	56	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					4003	4015		10.1038/onc.2013.398	http://dx.doi.org/10.1038/onc.2013.398			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	24096488	Green Published, hybrid			2022-12-28	WOS:000339394700012
J	Iguchi, M; Osanai, M; Hayashi, Y; Koentgen, F; Lee, GH				Iguchi, M.; Osanai, M.; Hayashi, Y.; Koentgen, F.; Lee, G-H			The error-prone DNA polymerase iota provides quantitative resistance to lung tumorigenesis and mutagenesis in mice	ONCOGENE			English	Article						lung tumor susceptibility; quantitative trait locus; causative gene; DNA polymerase iota; mutagenesis	INDUCED PULMONARY ADENOMAS; TUMOR SUSCEPTIBILITY; POL-IOTA; URETHANE-INDUCTION; MAJOR MODIFIER; BALB/CBYJ MICE; LOCUS; CANCER; GENES; ETA	Opposite undamaged nucleotide T, DNA polymerase iota (Poli) preferentially incorporates G rather than A, violating the Watson-Crick rule. Although the actual biological role of Poli remains enigmatic, we have identified its coding gene as a candidate for pulmonary adenoma resistance 2 (Par2), a mouse quantitative trait locus modulating chemically induced lung tumor susceptibility. Notably, the most tumor-sensitive Par2 allele possessed by the 129X1/SvJ mouse is associated with a loss-of-function mutation in Poli. To determine whether the nonfunctional Poli is responsible for the 129X1/SvJ-specific Par2 phenotype, we knocked out Poli in a C57BL/6J mouse carrying a less tumor-sensitive Par2 allele. Disruption of the C57BL/6J Poli conferred 129X1/SvJ-like sensitivity on the C57BL/6J Par2 locus and increased the in vivo mutation frequency in the lung, providing definitive proof that Poli causes the Par2 effect and inhibits tumorigenesis and mutagenesis, despite its extreme replication infidelity.	[Iguchi, M.; Osanai, M.; Hayashi, Y.; Lee, G-H] Kochi Univ, Sch Med, Dept Pathol, Kochi 7838505, Japan; [Koentgen, F.] Ozgene Pty Ltd, Bentley Dc, WA, Australia	Kochi University	Lee, GH (corresponding author), Kochi Univ, Sch Med, Dept Pathol, Nanko Ku, Oko Cho, Kochi 7838505, Japan.	ghlee@kochi-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology; Smoking Research Foundation of Japan	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Smoking Research Foundation of Japan	We are grateful to Dr Yukari Totsuka and Dr Hitoshi Nakagama for their helpful advice on the gpt delta mouse assay. This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology, and the Smoking Research Foundation of Japan.	Albertella MR, 2005, DNA REPAIR, V4, P583, DOI 10.1016/j.dnarep.2005.01.005; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; Dragani TA, 1995, ADV CANCER RES, V67, P83, DOI 10.1016/S0065-230X(08)60711-3; Dumstorf CA, 2006, P NATL ACAD SCI USA, V103, P18083, DOI 10.1073/pnas.0605247103; Dwyer-Nield LD, 2010, INT J CANCER, V126, P125, DOI 10.1002/ijc.24743; Faili A, 2002, NATURE, V419, P944, DOI 10.1038/nature01117; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; Frank EG, 2001, EMBO J, V20, P2914, DOI 10.1093/emboj/20.11.2914; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; Gueranger Q, 2008, DNA REPAIR, V7, P1551, DOI 10.1016/j.dnarep.2008.05.012; Hayashi Y, 2011, CANCER SCI, V102, P1228, DOI 10.1111/j.1349-7006.2011.01910.x; Kannouche P, 2003, EMBO J, V22, P1223, DOI 10.1093/emboj/7595006; Karasaki H, 1997, ONCOGENE, V15, P1833, DOI 10.1038/sj.onc.1201357; Kirouac KN, 2011, P NATL ACAD SCI USA, V108, P3210, DOI 10.1073/pnas.1013909108; Lee GH, 2005, CANCER SCI, V96, P256, DOI 10.1111/j.1349-7006.2005.00042.x; Lee GH, 2003, ONCOGENE, V22, P2374, DOI 10.1038/sj.onc.1206387; Lee GH, 2001, ONCOGENE, V20, P3979, DOI 10.1038/sj.onc.1204562; Liu PY, 2009, CANCER RES, V69, P6290, DOI 10.1158/0008-5472.CAN-09-0782; Liu PY, 2006, NAT GENET, V38, P888, DOI 10.1038/ng1849; MALKINSON AM, 1985, J NATL CANCER I, V75, P971, DOI 10.1093/jnci/75.5.971; Malkinson AM, 2001, LUNG CANCER, V32, P265, DOI 10.1016/S0169-5002(00)00232-4; Manenti G, 2004, ONCOGENE, V23, P4495, DOI 10.1038/sj.onc.1207584; Manenti G, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000331; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McDonald JP, 2003, J EXP MED, V198, P635, DOI 10.1084/jem.20030767; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; Nohmi T, 1996, ENVIRON MOL MUTAGEN, V28, P465, DOI 10.1002/(SICI)1098-2280(1996)28:4<465::AID-EM24>3.0.CO;2-C; Obata M, 1996, ONCOGENE, V13, P1599; Ohkumo T, 2006, MOL CELL BIOL, V26, P7696, DOI 10.1128/MCB.01076-06; Petta TB, 2008, EMBO J, V27, P2883, DOI 10.1038/emboj.2008.210; Reif AE, 1999, ADV CANCER RES, V76, P161; Sakiyama T, 2005, INT J CANCER, V114, P730, DOI 10.1002/ijc.20790; Skovlund E, 2001, J CLIN EPIDEMIOL, V54, P86, DOI 10.1016/S0895-4356(00)00264-X; Vaisman A, 2002, MUTAT RES-FUND MOL M, V510, P9, DOI 10.1016/S0027-5107(02)00248-8; Vidal AE, 2009, DNA REPAIR, V8, P420, DOI 10.1016/j.dnarep.2008.12.007; Wang HB, 2010, NEURO-ONCOLOGY, V12, P679, DOI 10.1093/neuonc/nop074; Wang M, 2004, CANCER RES, V64, P1924, DOI 10.1158/0008-5472.CAN-03-3080; Wang WYS, 2005, NAT REV GENET, V6, P109, DOI 10.1038/nrg1522; Wong ML, 2005, BIOTECHNIQUES, V39, P75, DOI 10.2144/05391RV01; Yang J, 2004, CANCER RES, V64, P5597, DOI 10.1158/0008-5472.CAN-04-0603; Yokota J, 2010, ADV CANCER RES, V109, P51, DOI 10.1016/B978-0-12-380890-5.00002-8; Yuan BF, 2011, J BIOL CHEM, V286, P17503, DOI 10.1074/jbc.M111.232835; Zhou JD, 2012, CANCER SCI, V103, P1574, DOI 10.1111/j.1349-7006.2012.02309.x	43	16	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3612	3617		10.1038/onc.2013.331	http://dx.doi.org/10.1038/onc.2013.331			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23955086				2022-12-28	WOS:000338941100013
J	Chang, C; Lee, SO; Yeh, S; Chang, TM				Chang, C.; Lee, S. O.; Yeh, S.; Chang, T. M.			Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver	ONCOGENE			English	Review						androgen receptor; ARKO mice; cancers	UPPER URINARY-TRACT; TRANSITIONAL-CELL CARCINOMA; ACTIVATED-PROTEIN-KINASE; VIRUS X-PROTEIN; CANCER-CELLS; HEPATOCELLULAR-CARCINOMA; UROTHELIAL CARCINOMA; MALIGNANT-TRANSFORMATION; ONCOGENIC TRANSFORMATION; INTERMEDIATE CELLS	The androgen receptor (AR) is expressed in many cell types and the androgen/AR signaling has been found to have important roles in modulating tumorigenesis and metastasis in several cancers including prostate, bladder, kidney, lung, breast and liver. However, whether AR has differential roles in the individual cells within these tumors that contain a variety of cell types remains unclear. Generation of AR knockout (ARKO) mouse models with deletion of AR in selective cells within tumors indeed have uncovered many unique AR roles in the individual cell types during cancer development and progression. This review will discuss the results obtained from various ARKO mice and different human cell lines with special attention to the cell type- and tissue-specific ARKO models. The understanding of various results showing the AR indeed has distinct and contrasting roles in each cell type within many hormone-related tumors (as stimulator in bladder, kidney and lung metastases vs as suppressor in prostate and liver metastases) may eventually help us to develop better therapeutic approaches by targeting the AR or its downstream signaling in individual cell types to better battle these hormone-related tumors in different stages.	[Chang, C.; Lee, S. O.; Yeh, S.; Chang, T. M.] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA; [Chang, C.; Lee, S. O.; Yeh, S.; Chang, T. M.] Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY 14642 USA; [Chang, C.] China Med Univ Hosp, Sex Hormone Res Ctr, Taichung, Taiwan	University of Rochester; University of Rochester; China Medical University Taiwan; China Medical University Hospital - Taiwan	Chang, C (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, 601 Elmwood Ave, Rochester, NY 14642 USA.	chang@urmc.rochester.edu			NIH [CA127300, CA156700]; Taiwan Department of Health Clinical Trial and Research Center of Excellence (China Medical University, Taichung, Taiwan) [DOH99-TD-B-111-004]; NATIONAL CANCER INSTITUTE [R01CA127300, R01CA156700] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Taiwan Department of Health Clinical Trial and Research Center of Excellence (China Medical University, Taichung, Taiwan)(China Medical University); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	NIH Grants (CA127300 and CA156700), and Taiwan Department of Health Clinical Trial and Research Center of Excellence Grant DOH99-TD-B-111-004 (China Medical University, Taichung, Taiwan).	BERTRAM JS, 1972, EUR J CANCER, V8, P587, DOI 10.1016/0014-2964(72)90137-5; Boorjian S, 2004, UROLOGY, V64, P383, DOI 10.1016/j.urology.2004.03.025; Chao Y, 1996, CANCER, V77, P635, DOI 10.1002/(SICI)1097-0142(19960215)77:4<635::AID-CNCR8>3.3.CO;2-I; Chen CC, 2013, ONCOL REP, V30, P979, DOI 10.3892/or.2013.2506; Chiaverotti T, 2008, AM J PATHOL, V172, P236, DOI 10.2353/ajpath.2008.070602; Chow WH, 2010, NAT REV UROL, V7, P245, DOI 10.1038/nrurol.2010.46; Colleoni M, 1995, TUMORI, V81, P351, DOI 10.1177/030089169508100509; Couto SS, 2009, DIFFERENTIATION, V77, P103, DOI 10.1016/j.diff.2008.09.010; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Gago-Dominguez M, 1999, CANCER EPIDEM BIOMAR, V8, P999; Gingrich JR, 1996, CANCER RES, V56, P4096; Gingrich JR, 1997, CANCER RES, V57, P4687; GLEAVE M, 1991, CANCER RES, V51, P3753; Gonzalez-Montelongo MC, 2010, STEROIDS, V75, P533, DOI 10.1016/j.steroids.2009.09.012; Guo K, 2008, CANCER SCI, V99, P486, DOI 10.1111/j.1349-7006.2007.00702.x; Halin S, 2007, PROSTATE, V67, P370, DOI 10.1002/pros.20473; Hall MC, 1998, J UROLOGY, V160, P703, DOI 10.1016/S0022-5347(01)62763-0; Han GZ, 2005, P NATL ACAD SCI USA, V102, P1151, DOI 10.1073/pnas.0408925102; HARTGE P, 1990, J NATL CANCER I, V82, P1636, DOI 10.1093/jnci/82.20.1636; HECHT SS, 1994, CARCINOGENESIS, V15, P2721, DOI 10.1093/carcin/15.12.2721; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Heer R, 2007, J CELL PHYSIOL, V212, P572, DOI 10.1002/jcp.21154; Heinlein CA, 2002, MOL ENDOCRINOL, V16, P2181, DOI 10.1210/me.2002-0070; HEINLEIN CA, 2002, ENDOCR REV, V23, P175, DOI DOI 10.1210/ER.23.2.175; Hickey TE, 2012, MOL ENDOCRINOL, V26, P1252, DOI 10.1210/me.2012-1107; Hsieh TF, 2013, ONCOL LETT, V5, P1325, DOI 10.3892/ol.2013.1140; Hsu JW, 2013, AM J PATHOL, V182, P1811, DOI 10.1016/j.ajpath.2013.01.018; Izumi K, 2013, MOL CARCINOGEN, V52, P94, DOI 10.1002/mc.21833; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437; Jie X, 2007, ONCOGENE, V26, P5741, DOI 10.1038/sj.onc.1210362; Kalra M, 2008, WORLD J GASTROENTERO, V14, P5945, DOI 10.3748/wjg.14.5945; KEMP CJ, 1989, P NATL ACAD SCI USA, V86, P7505, DOI 10.1073/pnas.86.19.7505; Kinoshita H, 2000, CANCER RES, V60, P3623; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lai KP, 2013, AM J PATHOL, V182, P460, DOI 10.1016/j.ajpath.2012.10.029; Lai KP, 2012, EMBO MOL MED, V4, P791, DOI 10.1002/emmm.201101140; Lee SO, 2013, J MOL CELL BIOL, V5, P14, DOI 10.1093/jmcb/mjs042; Li CC, 2008, EUR UROL, V54, P1127, DOI 10.1016/j.eururo.2008.01.054; Li L, 2013, NEW THERAPY VI UNPUB; Li YR, 2008, J CELL MOL MED, V12, P2790, DOI 10.1111/j.1582-4934.2008.00279.x; Litvinov IV, 2003, J CLIN ENDOCR METAB, V88, P2972, DOI 10.1210/jc.2002-022038; Llovet JM, 2005, J GASTROENTEROL, V40, P225, DOI 10.1007/s00535-005-1566-3; Lu HH, 2011 AACR ANN M 2011; Ma WL, 2012, HEPATOLOGY, V56, P176, DOI 10.1002/hep.25644; Ma WL, GASTROENTEROLOGY, V3, p55e1; Marques RB, 2005, INT J CANCER, V117, P221, DOI 10.1002/ijc.21201; Matsumoto T, 2000, LIVER, V20, P228, DOI 10.1034/j.1600-0676.2000.020003228.x; McNamara KM, 2013, J STEROID BIOCHEM, V133, P66, DOI 10.1016/j.jsbmb.2012.08.007; Mikkonen L, 2010, MOL CELL ENDOCRINOL, V317, P14, DOI 10.1016/j.mce.2009.12.022; Mirosevich J, 1999, J ENDOCRINOL, V162, P341, DOI 10.1677/joe.0.1620341; Miyamoto H, 2007, J NATL CANCER I, V99, P558, DOI 10.1093/jnci/djk113; Mo L, 2005, AM J PHYSIOL-RENAL, V289, pF562, DOI 10.1152/ajprenal.00368.2004; Motzer RJ, 2000, J UROLOGY, V163, P408, DOI 10.1016/S0022-5347(05)67889-5; Munoz JJ, 2000, J UROLOGY, V164, P1523, DOI 10.1016/S0022-5347(05)67019-X; Nahleh Z, 2008, FUTURE ONCOL, V4, P15, DOI 10.2217/14796694.4.1.15; Ni M, 2013, GENE DEV, V27, P734, DOI 10.1101/gad.209569.112; Nijhara R, 2001, J VIROL, V75, P10348, DOI 10.1128/JVI.75.21.10348-10358.2001; Niu Y, 2010, ONCOGENE, V29, P3593, DOI 10.1038/onc.2010.121; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12188, DOI 10.1073/pnas.0804701105; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Olapade-Alaopa EO, 1999, CLIN CANCER RES, V5, P569; Ozsahin M, 1999, EUR J CANCER, V35, P738, DOI 10.1016/S0959-8049(99)00012-X; Panet-Raymond V, 2000, MOL CELL ENDOCRINOL, V167, P139, DOI 10.1016/S0303-7207(00)00279-3; Papatsoris AG, 2008, TUMORI, V94, P75; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Peters KM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-132; Prickett TD, 2007, MOL CELL BIOL, V27, P4217, DOI 10.1128/MCB.00067-07; Remzi M, 2011, THER ADV UROL, V3, P69, DOI 10.1177/1756287211403349; Ricke EA, 2012, CARCINOGENESIS, V33, P1391, DOI 10.1093/carcin/bgs153; Ricke WA, 2006, INT J CANCER, V118, P2123, DOI 10.1002/ijc.21614; Robey RW, 2007, CANCER METAST REV, V26, P39, DOI 10.1007/s10555-007-9042-6; Rogers AB, 2007, CANCER RES, V67, P11536, DOI 10.1158/0008-5472.CAN-07-1479; Roupret M, 2011, EUR UROL, V59, P584, DOI 10.1016/j.eururo.2010.12.042; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Salmi S, 2001, J UROLOGY, V166, P674, DOI 10.1016/S0022-5347(05)66041-7; Shyr CR, 2013, ENDOCRINE, V43, P191, DOI 10.1007/s12020-012-9762-4; Simanainen U, 2012, HORM CANCER-US, V3, P113, DOI 10.1007/s12672-012-0107-9; Singh M, 2003, REV MED VIROL, V13, P243, DOI 10.1002/rmv.392; Sutton LM, 2012, AM J CLIN PATHOL, V138, P511, DOI 10.1309/AJCP8AVF8FDPTZLH; Tavian D, 2002, HISTOL HISTOPATHOL, V17, P1113, DOI 10.14670/HH-17.1113; Tian J, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.395574; Tokar EJ, 2005, DIFFERENTIATION, V73, P463, DOI 10.1111/j.1432-0436.2005.00047.x; Trinchet JC, 2004, HEPATOLOGY, V40, P1361, DOI 10.1002/hep.20474; van Leenders G, 2000, LAB INVEST, V80, P1251, DOI 10.1038/labinvest.3780133; van Leenders G, 2002, PROSTATE, V51, P98, DOI 10.1002/pros.10073; van Leenders GJLH, 2001, J PATHOL, V195, P563, DOI 10.1002/path.993; VESSELINOVITCH SD, 1980, CANCER RES, V40, P1538; Walters KA, 2009, ENDOCRINOLOGY, V150, P3274, DOI 10.1210/en.2008-1750; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang XD, 2006, DEV BIOL, V290, P66, DOI 10.1016/j.ydbio.2005.11.009; Wilson CM, 1996, MOL CELL ENDOCRINOL, V120, P51, DOI 10.1016/0303-7207(96)03819-1; Wu CT, 2007, P NATL ACAD SCI USA, V104, P12679, DOI 10.1073/pnas.0704940104; Wu MH, 2010, SCI TRANSL MED; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Yang WJ, 2009, HEPATOLOGY, V49, P1515, DOI 10.1002/hep.22833; Yang ZM, 2007, NAT MED, V13, P348, DOI 10.1038/nm1547; Yeh SD, 2012 SIN S CLIN TRAN; Yeh SY, 2003, J EXP MED, V198, P1899, DOI 10.1084/jem.20031233; Yeh SY, 2002, P NATL ACAD SCI USA, V99, P13498, DOI 10.1073/pnas.212474399; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zhang ZT, 1999, CANCER RES, V59, P3512; Zheng YY, 2007, VIROLOGY, V363, P454, DOI 10.1016/j.virol.2007.01.040; Zhu CF, 2011, J BIOL CHEM, V286, P33478, DOI 10.1074/jbc.M111.269894	104	139	144	1	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3225	3234		10.1038/onc.2013.274	http://dx.doi.org/10.1038/onc.2013.274			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23873027				2022-12-28	WOS:000338443400002
J	Li, H; Li, J; Su, Y; Fan, Y; Guo, X; Li, L; Su, X; Rong, R; Ying, J; Mo, X; Liu, K; Zhang, Z; Yang, F; Jiang, G; Wang, J; Zhang, Y; Ma, D; Tao, Q; Han, W				Li, H.; Li, J.; Su, Y.; Fan, Y.; Guo, X.; Li, L.; Su, X.; Rong, R.; Ying, J.; Mo, X.; Liu, K.; Zhang, Z.; Yang, F.; Jiang, G.; Wang, J.; Zhang, Y.; Ma, D.; Tao, Q.; Han, W.			A novel 3p22.3 gene CMTM7 represses oncogenic EGFR signaling and inhibits cancer cell growth	ONCOGENE			English	Article						CMTM7; 3p22; tumor-suppressor gene; methylation; LOH	CHEMOKINE-LIKE FACTOR-1; TUMOR-SUPPRESSOR GENE; EPSTEIN-BARR-VIRUS; NASOPHARYNGEAL CARCINOMA; CPG METHYLATION; GASTRIC-CANCER; APOPTOSIS; RECEPTOR; PROTEIN; IDENTIFICATION	Deletion of 3p12-22 is frequent in multiple cancer types, indicating the presence of critical tumor-suppressor genes (TSGs) at this region. We studied a novel candidate TSG, CMTM7, located at the 3p22.3 CMTM-gene cluster, for its tumor-suppressive functions and related mechanisms. The three CMTM genes, CMTM6, 7 and 8, are broadly expressed in human normal adult tissues and normal epithelial cell lines. Only CMTM7 is frequently silenced Or downregulated in esophageal and nasopharyngeal cell lines, but uncommon in other carcinoma cell lines. Immunostaining of tissue microarrays for CMTM7 protein showed its downregulation or absence in esophageal, gastric, pancreatic, liver, lung and cervix tumor tissues. Promoter CpG methylation and loss of heterozygosity were both found contributing to CMTM7 downregulation. Ectopic expression of CMTM7 in carcinoma cells inhibits cell proliferation, motility and tumor formation in nude mice, but not in immortalized normal cells, suggesting a tumor inhibitory role of CMTM7. The tumor-suppressive function of CMTM7 is associated with its role in G1/S cell cycle arrest, through upregulating p27 and downregulating cyclin-dependent kinase 2 (CDK2) and 6 (CDK6). Moreover, CMTM7 could promote epidermal growth factor receptor (EGFR) internalization, and further suppress AKT signaling pathway. Thus, our findings suggest that CMTM7 is a novel 3p22 tumor suppressor regulating G1/S transition and EGFR/AKT signaling during tumor pathogenesis.	[Li, H.; Su, Y.; Guo, X.; Mo, X.; Liu, K.; Zhang, Y.; Ma, D.; Han, W.] Peking Univ, Dept Immunol, Ctr Human Dis Genom, Key Lab Med Immunol,Minist Hlth,Sch Basic Med Sci, Beijing 100191, Peoples R China; [Li, H.] Peking Univ, Peoples Hosp, Dept Clin Lab, Beijing 100191, Peoples R China; [Li, J.; Fan, Y.; Li, L.; Su, X.; Rong, R.; Tao, Q.] Chinese Univ Hong Kong, Canc Epigenet Lab, State Key Lab Oncol South China, Dept Clin Oncol,Sir YK Pao Ctr Canc, Shatin, Hong Kong, Peoples R China; [Li, J.; Fan, Y.; Li, L.; Su, X.; Rong, R.; Tao, Q.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China; [Li, J.; Fan, Y.; Li, L.; Su, X.; Rong, R.; Tao, Q.] Chinese Univ Hong Kong, Shenzhen Res Inst, Shatin, Hong Kong, Peoples R China; [Ying, J.] Peking Union Med Coll, Dept Pathol, Beijing 100021, Peoples R China; [Ying, J.] Chinese Acad Med Sci, Beijing 100730, Peoples R China; [Zhang, Z.] Guangxi Med Univ, Affiliated Hosp 1, Dept Otolaryngol Head & Neck Surg, Nanning, Peoples R China; [Yang, F.; Jiang, G.; Wang, J.] Peking Univ, Peoples Hosp, Dept Thorac Surg, Beijing 100191, Peoples R China	Peking University; Peking University; Chinese University of Hong Kong; State Key Lab Oncology South China; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Guangxi Medical University; Peking University	Tao, Q (corresponding author), Chinese Univ Hong Kong, Dept Clin Oncol, Ctr Canc, PWH, Shatin, Hong Kong, Peoples R China.	qtao@clo.cuhk.edu.hk; hanwl@bjmu.edu.cn	Guo, Xiaohuan/I-3710-2017; Tao, Qian/T-4743-2018; Li, Lili/Q-5750-2018	Guo, Xiaohuan/0000-0001-5152-3010; Tao, Qian/0000-0001-5383-4808; Li, Lili/0000-0002-0292-5889	National Natural Science Foundation of China [30972780, 30928012]; Program for Innovation of new drug [2009ZX09503-004]; Specialized Research Fund for the Doctoral Program of Higher Education [20100001110050]; Hong Kong RGC [474710]; Chinese University of Hong Kong	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Innovation of new drug; Specialized Research Fund for the Doctoral Program of Higher Education(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); Hong Kong RGC(Hong Kong Research Grants Council); Chinese University of Hong Kong(Chinese University of Hong Kong)	We thank Bert Vogelstein, George Tsao and Sun Young Rha for some tumor cell lines and samples, and DSMZ (German Collection of Microorganisms and Cell Cultures) for the KYSE cell lines (Shimada et at, Cancer 69: 277-284, 1992). This work was supported by grants from the National Natural Science Foundation of China (no. 30972780 and no. 30928012), Program for Innovation of new drug (no. 2009ZX09503-004); the Specialized Research Fund for the Doctoral Program of Higher Education (no. 20100001110050), Hong Kong RGC (no. 474710) and the Group Research Scheme of The Chinese University of Hong Kong.	Aviel-Ronen S, 2008, P NATL ACAD SCI USA, V105, P10155, DOI 10.1073/pnas.0709618105; Bill HM, 2004, MOL CELL BIOL, V24, P8586, DOI 10.1128/MCB.24.19.8586-8599.2004; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Buffart TE, 2008, BRIT J CANCER, V99, P1802, DOI 10.1038/sj.bjc.6604777; Cheng YD, 2010, CANCER RES, V70, P6516, DOI 10.1158/0008-5472.CAN-09-4566; Cheung ST, 1999, INT J CANCER, V83, P121, DOI 10.1002/(SICI)1097-0215(19990924)83:1<121::AID-IJC21>3.0.CO;2-F; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Guo XH, 2009, BIOCHEM BIOPH RES CO, V387, P139, DOI 10.1016/j.bbrc.2009.06.148; Han WL, 2003, GENOMICS, V81, P609, DOI 10.1016/S0888-7543(03)00095-8; Han WL, 2001, BIOCHEM J, V357, P127, DOI 10.1042/0264-6021:3570127; Harari PM, 2004, ENDOCR-RELAT CANCER, V11, P689, DOI 10.1677/erc.1.00600; Hu XT, 2009, ONCOGENE, V28, P2466, DOI 10.1038/onc.2009.92; Jin CN, 2007, J CELL PHYSIOL, V211, P112, DOI 10.1002/jcp.20914; Jin CN, 2005, FEBS LETT, V579, P6375, DOI 10.1016/j.febslet.2005.10.021; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Li D, 2007, INT J BIOCHEM CELL B, V39, P2107, DOI 10.1016/j.biocel.2007.06.002; Li HN, 2010, BMB REP, V43, P182, DOI 10.5483/BMBRep.2010.43.3.182; Li L, 2012, ONCOGENE, V31, P3901, DOI 10.1038/onc.2011.541; Li T, 2006, LIFE SCI, V79, P519, DOI 10.1016/j.lfs.2006.01.042; Lind GE, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-13; Lo PHY, 2006, CANCER LETT, V234, P184, DOI 10.1016/j.canlet.2005.03.036; Ma S, 2012, GASTROENTEROLOGY, V143, P675, DOI 10.1053/j.gastro.2012.06.007; Maddika S, 2007, DRUG RESIST UPDATE, V10, P13, DOI 10.1016/j.drup.2007.01.003; Mao L, 1996, CANCER RES, V56, P5128; Martin TA, 2010, INT J MOL MED, V26, P721, DOI 10.3892/ijmm_00000519; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; Miyazaki A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031829; Nakayama J, 2009, BLOOD, V113, P1483, DOI 10.1182/blood-2008-07-166355; Niu J, 2010, LEUKEMIA RES, V35, P771; Odintsova E, 2003, J CELL SCI, V116, P4557, DOI 10.1242/jcs.00793; Plate M, 2010, MOL CELLS, V29, P355, DOI 10.1007/s10059-010-0038-7; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; REMMELE W, 1987, PATHOLOGE, V8, P138; Sanchez-Pulido L, 2002, TRENDS BIOCHEM SCI, V27, P599, DOI 10.1016/S0968-0004(02)02229-6; Shao L, 2007, CLIN CANCER RES, V13, P5756, DOI 10.1158/1078-0432.CCR-06-3082; Shao LN, 2010, CELL IMMUNOL, V263, P188, DOI 10.1016/j.cellimm.2010.03.015; Shao LN, 2009, BIOCHEM BIOPH RES CO, V379, P866, DOI 10.1016/j.bbrc.2008.12.126; Sharp TV, 2008, P NATL ACAD SCI USA, V105, P19932, DOI 10.1073/pnas.0805003105; Shi S, 2005, INT J BIOCHEM CELL B, V37, P1633, DOI 10.1016/j.biocel.2004.04.028; Sinha S, 2008, CANCER SCI, V99, P1984, DOI 10.1111/j.1349-7006.2008.00952.x; Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Wang Y, 2006, LIFE SCI, V78, P614, DOI 10.1016/j.lfs.2005.05.070; Wang Y, 2008, BIOCHEM BIOPH RES CO, V371, P54, DOI 10.1016/j.bbrc.2008.03.143; Wang Y, 2009, CANCER RES, V69, P5194, DOI 10.1158/0008-5472.CAN-08-3694; WEINBERG RA, 1994, CA-CANCER J CLIN, V44, P160, DOI 10.3322/canjclin.44.3.160; Ying J, 2009, BRIT J CANCER, V100, P663, DOI 10.1038/sj.bjc.6604888; Zhong J, 2006, J BIOCHEM MOL BIOL, V39, P537	48	53	58	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3109	3118		10.1038/onc.2013.282	http://dx.doi.org/10.1038/onc.2013.282			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23893243				2022-12-28	WOS:000338410000004
J	Leithner, K; Hrzenjak, A; Trotzmuller, M; Moustafa, T; Kofeler, HC; Wohlkoenig, C; Stacher, E; Lindenmann, J; Harris, AL; Olschewski, A; Olschewski, H				Leithner, K.; Hrzenjak, A.; Troetzmueller, M.; Moustafa, T.; Koefeler, H. C.; Wohlkoenig, C.; Stacher, E.; Lindenmann, J.; Harris, A. L.; Olschewski, A.; Olschewski, H.			PCK2 activation mediates an adaptive response to glucose depletion in lung cancer	ONCOGENE			English	Article							HEPATIC ENERGY-METABOLISM; FLIGHT MASS-SPECTROMETRY; PHOSPHOENOLPYRUVATE CARBOXYKINASE; CELL METABOLISM; TUMOR-CELLS; NUTRIENT DEPRIVATION; EXPRESSION; LACTATE; GROWTH; COLON	Cancer cells are reprogrammed to utilize glycolysis at high rates, which provides metabolic precursors for cell growth. Consequently, glucose levels may decrease substantially in underperfused tumor areas. Gluconeogenesis results in the generation of glucose from smaller carbon substrates such as lactate and amino acids. The key gluconeogenic enzyme, phosphoenolpyruvate carboxykinase ( PEPCK), has been shown to provide metabolites for cell growth. Still, the role of gluconeogenesis in cancer is unknown. Here we show that the mitochondrial isoform of PEPCK (PCK2) is expressed and active in three lung cancer cell lines and in non-small cell lung cancer samples. PCK2 expression and activity were enhanced under low-glucose conditions. PEPCK activity was elevated threefold in lung cancer samples over normal lungs. To track the conversion of metabolites along the gluconeogenesis pathway, lung cancer cell lines were incubated with C-13(3)-lactate and label enrichment in the phosphoenolpyruvate (PEP) pool was measured. Under low glucose, all three carbons from C-13(3)-lactate appeared in the PEP pool, further supporting a conversion of lactate to pyruvate, via pyruvate carboxylase to oxaloacetate, and via PCK2 to phosphoenolpyruvate. PCK2 small interfering RNA and the pharmacological PEPCK inhibitor 3-mercaptopicolinate significantly enhanced glucose depletion-induced apoptosis in A549 and H23 cells, but not in H1299 cells. The growth of H23 multicellular spheroids was significantly reduced by 3-mercaptopicolinate. The results of this study suggest that lung cancer cells may utilize at least some steps of gluconeogenesis to overcome the detrimental metabolic situation during glucose deprivation and that in human lung cancers this pathway is activated in vivo.	[Leithner, K.; Hrzenjak, A.; Wohlkoenig, C.; Olschewski, H.] Med Univ Graz, Dept Internal Med, Div Pulmonol, A-8036 Graz, Austria; [Hrzenjak, A.; Olschewski, A.] Ludwig Boltzmann Inst Lung Vasc Res, Graz, Austria; [Troetzmueller, M.; Koefeler, H. C.] Med Univ Graz, Core Facil Mass Spectrometry & Lipid, A-8036 Graz, Austria; [Moustafa, T.] Karl Franzens Univ Graz, Inst Mol Biosci, Graz, Austria; [Stacher, E.] Med Univ Graz, Inst Pathol, A-8036 Graz, Austria; [Lindenmann, J.] Med Univ Graz, Dept Surg, Div Thorac & Hyperbar Surg, A-8036 Graz, Austria; [Harris, A. L.] Univ Oxford, Weatherall Inst Mol Med, Oxford, England; [Olschewski, A.] Med Univ Graz, Univ Clin Anesthesiol & Intens Care Med, A-8036 Graz, Austria	Medical University of Graz; Ludwig Boltzmann Institute; Medical University of Graz; University of Graz; Medical University of Graz; Medical University of Graz; University of Oxford; Medical University of Graz	Leithner, K (corresponding author), Med Univ Graz, Dept Internal Med, Div Pulmonol, Auenbruggerpl 15, A-8036 Graz, Austria.	katharina.leithner@medunigraz.at	Leithner, Katharina, MD, PhD/E-7662-2011; Harris, Adrian L/ABA-3343-2020; Olschewski, Horst/L-3547-2019; Moustafa, Tarek/P-9509-2016	Leithner, Katharina, MD, PhD/0000-0002-8252-9279; Harris, Adrian L/0000-0003-1376-8409; Olschewski, Horst/0000-0002-2834-7466; Moustafa, Tarek/0000-0002-6755-4687; Trotzmuller, Martin/0000-0003-0545-9892; Olschewski, Andrea/0000-0002-8189-3634; Kofeler, Harald/0000-0002-2725-9616	Oesterreichische Nationalbank (Anniversary Fund) [12713]; state government; Cancer Research UK; Inspire to Live; Cancer Research UK [11359] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10163] Funding Source: researchfish	Oesterreichische Nationalbank (Anniversary Fund); state government; Cancer Research UK(Cancer Research UK); Inspire to Live; Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))	We are grateful to Prof. Rudolf Zechner, Karl Franzens University, Graz, Austria, for his advice and valuable discussions. The excellent technical help by Astrid Knopf, Elisabeth Pollitzer and Alexandra Bertsch, and the contribution by Anna Katschnig are highly appreciated. We are grateful to Dr Guther Fauler and Christina Haas, Medical University of Graz, for their support. The study was supported by the Oesterreichische Nationalbank (Anniversary Fund, project number 12713 to HO) and by a research grant from the state government (KL). ALH is funded by Cancer Research UK and Inspire to Live.	Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Boidot R, 2012, CANCER RES, V72, P939, DOI 10.1158/0008-5472.CAN-11-2474; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345; Cheng TL, 2011, P NATL ACAD SCI USA, V108, P8674, DOI 10.1073/pnas.1016627108; Cheung EC, 2013, DEV CELL, V25, P463, DOI 10.1016/j.devcel.2013.05.001; Chun SY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-293; Dang CV, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-3; DeBerardinis RJ, 2012, CELL, V148, P1132, DOI 10.1016/j.cell.2012.02.032; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Fan TWM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-41; Fell DA, 2005, J EXP BOT, V56, P267, DOI 10.1093/jxb/eri011; GAUTHIER T, 1989, INT J BIOCHEM, V21, P191, DOI 10.1016/0020-711X(89)90108-0; Guenther GG, 2014, ONCOGENE, V33, P1776, DOI 10.1038/onc.2013.139; Halestrap AP, 2012, IUBMB LIFE, V64, P1, DOI 10.1002/iub.573; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Heist RS, 2012, J THORAC ONCOL, V7, P924, DOI 10.1097/JTO.0b013e31824cc334; Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806; Hirschhaeuser F, 2010, J BIOTECHNOL, V148, P3, DOI 10.1016/j.jbiotec.2010.01.012; Izuishi K, 2000, CANCER RES, V60, P6201; Kalhan SC, 2012, J BIOL CHEM, V287, P19786, DOI 10.1074/jbc.R112.357194; Kami K, 2013, METABOLOMICS, V9, P444, DOI 10.1007/s11306-012-0452-2; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Koukourakis MI, 2007, CANCER BIOL THER, V6, P1476, DOI 10.4161/cbt.6.9.4635; Kung C, 2012, CHEM BIOL, V19, P1187, DOI 10.1016/j.chembiol.2012.07.021; Landi MT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001651; Lee GH, 2011, ONCOL LETT, V2, P831, DOI 10.3892/ol.2011.353; MAKINEN AL, 1983, J BIOL CHEM, V258, P1654; Okar DO, 2001, TRENDS BIOCHEM SCI, V26, P30, DOI 10.1016/S0968-0004(00)01699-6; Pinheiro C, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/427694; Polet F, 2013, J INTERN MED, V273, P156, DOI 10.1111/joim.12016; Ramalingam SS, 2011, CA-CANCER J CLIN, V61, P91, DOI 10.3322/caac.20102; Roberts PJ, 2010, J CLIN ONCOL, V28, P4769, DOI 10.1200/JCO.2009.27.4365; Rocha CM, 2010, J PROTEOME RES, V9, P319, DOI 10.1021/pr9006574; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Schroeder T, 2005, CANCER RES, V65, P5163, DOI 10.1158/0008-5472.CAN-04-3900; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; SCOTT WJ, 1994, ANN THORAC SURG, V58, P698, DOI 10.1016/0003-4975(94)90730-7; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; She P, 2000, MOL CELL BIOL, V20, P6508, DOI 10.1128/MCB.20.17.6508-6517.2000; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Stark R, 2009, J BIOL CHEM, V284, P26578, DOI 10.1074/jbc.M109.011775; Stryer L., 1995, BIOCHEMISTRY-US, P559; THOMLINSON RH, 1955, BRIT J CANCER, V9, P539, DOI 10.1038/bjc.1955.55; Viollet B, 2009, ACTA PHYSIOL, V196, P81, DOI 10.1111/j.1748-1716.2009.01970.x; Walenta S, 2001, INT J RADIAT ONCOL, V51, P840, DOI 10.1016/S0360-3016(01)01700-X; WATFORD M, 1981, J BIOL CHEM, V256, P23; Xiong Y, 2011, COLD SH Q B, V76, P285, DOI 10.1101/sqb.2011.76.010942; Yang JQ, 2009, J BIOL CHEM, V284, P27031, DOI 10.1074/jbc.R109.040535; Yang JQ, 2009, J BIOL CHEM, V284, P27025, DOI 10.1074/jbc.R109.040543	51	119	123	0	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					1044	1050		10.1038/onc.2014.47	http://dx.doi.org/10.1038/onc.2014.47			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632615				2022-12-28	WOS:000350121300010
J	Miao, H; Gale, NW; Guo, H; Qian, J; Petty, A; Kaspar, J; Murphy, AJ; Valenzuela, DM; Yancopoulos, G; Hambardzumyan, D; Lathia, JD; Rich, JN; Lee, J; Wang, B				Miao, H.; Gale, N. W.; Guo, H.; Qian, J.; Petty, A.; Kaspar, J.; Murphy, A. J.; Valenzuela, D. M.; Yancopoulos, G.; Hambardzumyan, D.; Lathia, J. D.; Rich, J. N.; Lee, J.; Wang, B.			EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties	ONCOGENE			English	Article						EphA2; Akt; stem cells; glioma; invasion; ephrin-A	INTEGRATED GENOMIC ANALYSIS; HUMAN BRAIN; GLIOBLASTOMA; RECEPTOR; ACTIVATION; EXPRESSION; EPHRINA1; TUMORS; LIGAND; ROLES	Diffuse infiltrative invasion is a major cause for the dismal prognosis of glioblastoma multiforme (GBM), but the underlying mechanisms remain incompletely understood. Using human glioma stem cells (GSCs) that recapitulate the invasive propensity of primary GBM, we find that EphA2 critically regulates GBM invasion in vivo. EphA2 was expressed in all seven GSC lines examined, and overexpression of EphA2 enhanced intracranial invasion. The effects required Akt-mediated phosphorylation of EphA2 on serine 897. In vitro the Akt-EphA2 signaling axis is maintained in the absence of ephrin-A ligands and is disrupted upon ligand stimulation. To test whether ephrin-As in tumor microenvironment can regulate GSC invasion, the newly established Efna1;Efna3;Efna4 triple knockout mice (TKO) were used in an ex vivo brain slice invasion assay. We observed significantly increased GSC invasion through the brain slices of TKO mice relative to wild-type (WT) littermates. Mechanistically EphA2 knockdown suppressed stem cell properties of GSCs, causing diminished self-renewal, reduced stem marker expression and decreased tumorigenicity. In a subset of GSCs, the reduced stem cell properties were associated with lower Sox2 expression. Overexpression of EphA2 promoted stem cell properties in a kinase-independent manner and increased Sox2 expression. Disruption of Akt-EphA2 cross-talk attenuated stem cell marker expression and neurosphere formation while having minimal effects on tumorigenesis. Taken together, the results show that EphA2 endows invasiveness of GSCs in vivo in cooperation with Akt and regulates glioma stem cell properties.	[Miao, H.; Guo, H.; Qian, J.; Petty, A.; Kaspar, J.; Wang, B.] Case Western Reserve Univ, Sch Med, MetroHlth Med Ctr, Rammelkamp Ctr Res, Cleveland, OH 44109 USA; [Miao, H.; Guo, H.; Qian, J.; Petty, A.; Kaspar, J.; Wang, B.] Case Western Reserve Univ, Sch Med, Dept Pharmacol & Oncol, Cleveland, OH 44109 USA; [Gale, N. W.; Murphy, A. J.; Valenzuela, D. M.; Yancopoulos, G.] Regeneron Pharmaceut Inc, VelociGene Div, Tarrytown, NY 10591 USA; [Hambardzumyan, D.; Lathia, J. D.; Rich, J. N.; Lee, J.] Cleveland Clin, Dept Stem Cell Biol & Regenerat Med, Lerner Res Inst, Cleveland, OH 44106 USA; [Hambardzumyan, D.; Lathia, J. D.; Rich, J. N.; Lee, J.; Wang, B.] Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH 44109 USA	Case Western Reserve University; MetroHealth System; Case Western Reserve University; Regeneron; Cleveland Clinic Foundation; Case Western Reserve University	Wang, B (corresponding author), Case Western Reserve Univ, Sch Med, MetroHlth Med Ctr, Rammelkamp Ctr Res, R421,2500 MetroHlth Dr, Cleveland, OH 44109 USA.	bxw14@case.edu	Rich, Jeremy/AAM-1445-2021; Lathia, Justin/AHB-8296-2022	Murphy, Andrew/0000-0003-4152-4081	National Institute of Health [CA152371, CA155676]; FAMRI Foundation [072216_CIA]; Maria Foundation; Case Comprehensive Cancer Center [P30 CA43703]; NATIONAL CANCER INSTITUTE [T32CA059366, R01CA152371, R01CA155676, P30CA043703] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FAMRI Foundation; Maria Foundation; Case Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from National Institute of Health CA152371 (HM and BW), CA155676 (BW) and by awards to BW from FAMRI Foundation (072216_CIA) and Prayers From Maria Foundation. This research was also supported by the Case Comprehensive Cancer Center (P30 CA43703).	Annovazzi L, 2011, CANCER GENOM PROTEOM, V8, P139; [Anonymous], 1997, Cell, V90, P403; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Beauchamp A, 2012, MOL CELL BIOL, V32, P3253, DOI 10.1128/MCB.06791-11; Binda E, 2012, CANCER CELL, V22, P765, DOI 10.1016/j.ccr.2012.11.005; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chakravarti Arnab, 2008, P173; Cheng L, 2011, BIOCHEM BIOPH RES CO, V406, P643, DOI 10.1016/j.bbrc.2011.02.123; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Day BW, 2013, CANCER CELL, V23, P238, DOI 10.1016/j.ccr.2013.01.007; Dunn GP, 2012, GENE DEV, V26, P756, DOI 10.1101/gad.187922.112; Frattini V, 2013, NAT GENET, V45, P1141, DOI 10.1038/ng.2734; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Garcia JL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-454; Gu CY, 2013, STEM CELLS, V31, P870, DOI 10.1002/stem.1322; Guo H, 2006, CANCER RES, V66, P7050, DOI 10.1158/0008-5472.CAN-06-0004; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Holmberg J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018454; Ignatova TN, 2002, GLIA, V39, P193, DOI 10.1002/glia.10094; Johnson RA, 2010, NATURE, V466, P632, DOI 10.1038/nature09173; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lee J, 2008, CANCER CELL, V13, P69, DOI 10.1016/j.ccr.2007.12.005; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Miao H, 2012, SEMIN CELL DEV BIOL, V23, P16, DOI 10.1016/j.semcdb.2011.10.013; Miao H, 2009, CANCER CELL, V16, P9, DOI 10.1016/j.ccr.2009.04.009; Miao H, 2009, INT J BIOCHEM CELL B, V41, P762, DOI 10.1016/j.biocel.2008.07.019; Molina JR, 2010, NEOPLASIA, V12, P453, DOI 10.1593/neo.10126; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Petty A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042120; Pevny LH, 2010, INT J BIOCHEM CELL B, V42, P421, DOI 10.1016/j.biocel.2009.08.018; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Pollard SM, 2009, CELL STEM CELL, V4, P568, DOI 10.1016/j.stem.2009.03.014; Singh D, 2012, SCIENCE, V337, P1231, DOI 10.1126/science.1220834; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Valenzuela DM, 2003, NAT BIOTECHNOL, V21, P652, DOI 10.1038/nbt822; Venere M, 2011, GLIA, V59, P1148, DOI 10.1002/glia.21185; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wegner M, 2011, GENE DEV, V25, P2423, DOI 10.1101/gad.181487.111; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; Wykosky J, 2005, MOL CANCER RES, V3, P541, DOI 10.1158/1541-7786.MCR-05-0056; Wykosky J, 2008, ONCOGENE, V27, P7260, DOI 10.1038/onc.2008.328; Wykosky J, 2007, MOL CANCER THER, V6, P3208, DOI 10.1158/1535-7163.MCT-07-0200; Wykosky J, 2008, MOL CANCER RES, V6, P1795, DOI 10.1158/1541-7786.MCR-08-0244	55	101	106	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					558	567		10.1038/onc.2013.590	http://dx.doi.org/10.1038/onc.2013.590			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24488013	Green Accepted			2022-12-28	WOS:000348853500003
J	Gong, C; Qu, S; Liu, B; Pan, S; Jiao, Y; Nie, Y; Su, F; Liu, Q; Song, E				Gong, C.; Qu, S.; Liu, B.; Pan, S.; Jiao, Y.; Nie, Y.; Su, F.; Liu, Q.; Song, E.			MiR-106b expression determines the proliferation paradox of TGF-beta in breast cancer cells	ONCOGENE			English	Article						TGF-beta; microRNA; breast cancer; cell proliferation	GROWTH-FACTOR-BETA; MICRORNA CLUSTER; GENE-PRODUCT; PHOSPHORYLATION; INHIBITION; AP-1; PRB	TGF-beta has paradoxical effects on cancer cell proliferation, as it suppresses proliferation of normal epithelial and low-invasive cancer cells, but enhances that of high-invasive cancer cells. However, how cancer cells acquire the ability to evade the tumor-suppressing effects of TGF-beta, yet still take advantage of its tumor-promoting effects, remains elusive. Here, we identified miR-106b as a molecular switch to determine TGF-beta effects on cell proliferation. TGF-beta 1 enhances the transcription of miR-106b via a promoter independent of its host gene MCM7 by activating c-jun. In high-invasive breast cancer cells, miR-106b is upregulated by TGF-beta 1 at a much higher level than that in normal or low-invasive cancer cells. Accumulation of miR-106b counterbalances TGF-beta growth-inhibiting effects by eliminating activated retinoblastoma (RB) and results in enhanced proliferation. Furthermore, miR-106b mediates TGF-beta effects on tumor growth and metastasis in breast cancer xenografts. In addition, miR-106b expression is elevated in higher stage tumors and correlated with tumor progression in breast cancer patients. These findings suggest that high level of miR-106b induced by TGF-beta determines the tumor-promoting effects of TGF-beta in breast cancer.	[Gong, C.; Qu, S.; Pan, S.; Jiao, Y.; Nie, Y.; Su, F.; Liu, Q.; Song, E.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Guangdong, Peoples R China; [Gong, C.; Qu, S.; Liu, B.; Pan, S.; Jiao, Y.; Nie, Y.; Su, F.; Liu, Q.; Song, E.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou 510120, Guangdong, Peoples R China; [Liu, B.; Song, E.] Sun Yat Sen Univ, Sch Life Sci, State Key Lab Biocontrol, Key Lab Gene Engn Minist, Guangzhou 510120, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Liu, Q (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, 107 Yanjiang West Rd, Guangzhou 510120, Guangdong, Peoples R China.	victorlq@hotmail.com; songew@mail.sysu.edu.cn	Liu, Bodu/AAR-9402-2021; Liu, Bodu/G-5222-2016	Liu, Bodu/0000-0003-2097-725X; Liu, Bodu/0000-0003-2097-725X; Liu, Qiang/0000-0002-5451-4862	973 Projects from Ministry of Science and Technology of China [2010CB912800, 2011CB504203]; Natural Science Foundation of China [81230060, 81261140373, 81272893, 81172524, 81372817, 81272894, 81072178]; National S&T Major Special Project on New Drug Innovation of China [2011ZX09102-010-02]; Program for New Century Excellent Talents in University [NCET-12-0565]; Science Foundation of Guangdong Province [S2012030006287, 2012J2200092]; Sun Yat-sen University Training Project [11ykpy28, 11ykzd12]; Translational medicine public platform of Guangdong Province [4202037]; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun-Yat-Sen University [KLB09001]; Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology [[2013]163]	973 Projects from Ministry of Science and Technology of China; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National S&T Major Special Project on New Drug Innovation of China; Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Sun Yat-sen University Training Project; Translational medicine public platform of Guangdong Province; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun-Yat-Sen University; Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology	This work was supported by grants from 973 (2010CB912800, 2011CB504203) Projects from Ministry of Science and Technology of China, the Natural Science Foundation of China (81230060, 81261140373, 81272893, 81172524, 81372817, 81272894, 81072178), National S&T Major Special Project on New Drug Innovation of China (No. 2011ZX09102-010-02), Program for New Century Excellent Talents in University(NCET-12-0565), Science Foundation of Guangdong Province (S2012030006287, 2012J2200092), Sun Yat-sen University Training Project (11ykpy28, 11ykzd12) and Translational medicine public platform of Guangdong Province(4202037), Grant KLB09001 from the Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun-Yat-Sen University,Grant [2013]163 from Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology.	Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Cai KM, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-73; Davies M, 2005, J CELL BIOCHEM, V95, P918, DOI 10.1002/jcb.20458; Fang YJ, 2012, AM J PATHOL, V180, P650, DOI 10.1016/j.ajpath.2011.10.009; Francis SM, 2009, MOL CELL BIOL, V29, P4455, DOI 10.1128/MCB.00473-09; FURUKAWA Y, 1992, J BIOL CHEM, V267, P17121; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; Herrera RE, 1996, MOL BIOL CELL, V7, P1335, DOI 10.1091/mbc.7.9.1335; Kan T, 2009, GASTROENTEROLOGY, V136, P1689, DOI 10.1053/j.gastro.2009.02.002; Kappelmann M, 2013, ONCOGENE, V32, P2984, DOI 10.1038/onc.2012.307; KIM TA, 1994, J CELL PHYSIOL, V160, P1, DOI 10.1002/jcp.1041600102; Lee MK, 2007, EMBO J, V26, P3957, DOI 10.1038/sj.emboj.7601818; Li Y, 2009, CANCER SCI, V100, P1234, DOI 10.1111/j.1349-7006.2009.01164.x; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Poliseno L, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000594; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Singha PK, 2010, CANCER RES, V70, P6377, DOI 10.1158/0008-5472.CAN-10-1180; Smith AL, 2012, ONCOGENE, V31, P5162, DOI 10.1038/onc.2012.11; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; van den Heuvel S, 2008, NAT REV MOL CELL BIO, V9, P713, DOI 10.1038/nrm2469; Wang HL, 2010, BRAIN RES, V1357, P166, DOI 10.1016/j.brainres.2010.08.023; Zhang BX, 2010, GASTROENTEROLOGY, V138, P969, DOI 10.1053/j.gastro.2009.11.004; Zhu F, 2006, CANCER RES, V66, P5729, DOI 10.1158/0008-5472.CAN-05-4466	26	46	49	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					84	93		10.1038/onc.2013.525	http://dx.doi.org/10.1038/onc.2013.525			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24292682				2022-12-28	WOS:000349740100008
J	Drake, CG; Sharma, P; Gerritsen, W				Drake, C. G.; Sharma, P.; Gerritsen, W.			Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy	ONCOGENE			English	Review						androgen ablation; chemotherapy; immunotherapy; post-docetaxel; prostate cancer; radiotherapy	T-CELL RESPONSES; IMMUNE-RESPONSE; CTLA-4 BLOCKADE; INCREASED SURVIVAL; RECENT SUCCESSES; CLINICAL-TRIALS; LOCAL RADIATION; TUMOR-CELLS; OPEN-LABEL; PHASE-II	For the past decade, docetaxel has remained the global standard of care for frontline treatment of metastatic castration-resistant prostate cancer (mCRPC). Until recently, there were limited options for patients with mCRPC following docetaxel failure or resistance, but now the approved treatment choices for these patients have expanded to include abiraterone acetate, cabazitaxel and enzalutamide. Additionally, the radioactive therapeutic agent radium-223 dichloride has been recently approved in patients with CRPC with bone metastases. Although each of these agents has been shown to convey significant survival benefit as a monotherapy, preclinical findings suggest that combining such innovative strategies with traditional treatments may achieve additive or synergistic effects, further augmenting patient benefit. This review will discuss the transformation of the post-docetaxel space in mCRPC, highlighting the spectrum of newly approved agents in this setting in the USA and the European Union, as well as summarizing treatments with non-chemotherapeutic mechanisms of action that have demonstrated promising results in recent phase 3 trials. Lastly, this review will address the potential of combinatorial regimens in mCRPC, including the pairing of novel immunotherapeutic approaches with chemotherapy, radiotherapy or androgen ablation.	[Drake, C. G.] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, 1650 Orleans St CRB 410, Baltimore, MD 21231 USA; [Sharma, P.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Gerritsen, W.] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6525 ED Nijmegen, Netherlands	Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; UTMD Anderson Cancer Center; Radboud University Nijmegen	Drake, CG (corresponding author), Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, 1650 Orleans St CRB 410, Baltimore, MD 21231 USA.	cdrake@jhmi.edu	gerritsen, Winald/H-8031-2014		Bristol-Myers Squibb (BMS); NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER	Bristol-Myers Squibb (BMS)(Bristol-Myers Squibb); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Professional medical writing and editorial assistance was provided by Ami P. Modi, PhD, at StemScientific, and funded by Bristol-Myers Squibb (BMS).	Abdollah F, 2012, INT J UROL, V19, P836, DOI 10.1111/j.1442-2042.2012.03052.x; Angelergues A, 2013, J CLIN ONCOL, V31, p323s; [Anonymous], 2012, ZYT AB AC SUMM PROD; [Anonymous], 2013, US YERV IP PACK INS; [Anonymous], 2012, XTAND ENZ PACK INS; [Anonymous], PHAS 2 STUD AD PSA V; [Anonymous], 2012, ZYT AB AC PACK INS; [Anonymous], 2012, EU YERV IP PACK INS; [Anonymous], 2013, XOF RAD RA 223 DICHL; [Anonymous], 2013, XGEV DEN PACK INS; [Anonymous], 2011, PROV SIP T PACK INS; Antonarakis ES, 2012, CURR OPIN ONCOL, V24, P258, DOI 10.1097/CCO.0b013e32835205a0; Antonarakis ES, 2013, J CLIN ONCOL, V31, p312s; Aparicio A, 2012, CANC RES S8, V72; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Arlen PM, 2006, CLIN CANCER RES, V12, P1260, DOI 10.1158/1078-0432.CCR-05-2059; Berthold DR, 2008, J CLIN ONCOL, V26, P242, DOI 10.1200/JCO.2007.12.4008; Brown IE, 2006, J IMMUNOL, V177, P4521, DOI 10.4049/jimmunol.177.7.4521; Chakraborty M, 2004, CANCER RES, V64, P4328, DOI 10.1158/0008-5472.CAN-04-0073; Chakraborty M, 2003, J IMMUNOL, V170, P6338, DOI 10.4049/jimmunol.170.12.6338; *CLIN TRIALS, CONC VERS SEQ TREATM; *CLIN TRIALS, STUD DET SAF TOL ENZ; *CLIN TRIALS, SEQ SIP T ADT MEN NO; Clinical Trials.gov, PHAS 3 STUD IMM TREA; Clinical Trials.gov, STUD IMM TREAT ADV P; Clinical Trials.gov, IP ANDR DEPR THER; Clinical Trials.gov, IP COMB ANDR SUPPR T; Clinical Trials.gov, COMB IP AB ON AC PLU; Clinical Trials.gov NCT00450463, VACC THER PROSTVAC T; Clinical Trials.gov NCT01145508, DOC PREDN VACC THER; Clinical Trials.gov NCT01194271, NEOADJ IP PROST CANC; Clinical Trials.gov NCT01420965, SIP T CT 011 CYCL AD; Clinical Trials.gov NCT01436968, PHAS 3 STUD PROSTATA; Clinical Trials.gov NCT01696877, NEOADJ STUD ANDR ABL; Corn Paul G, 2012, Cancer Manag Res, V4, P183, DOI 10.2147/CMAR.S32839; Danila DC, 2011, CANCER J, V17, P438, DOI 10.1097/PPO.0b013e31823e69ac; Dayyani F, 2011, JNCI-J NATL CANCER I, V103, P1665, DOI 10.1093/jnci/djr362; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; Demaria S, 2005, CLIN CANCER RES, V11, P728; Dewan MZ, 2009, CLIN CANCER RES, V15, P5379, DOI 10.1158/1078-0432.CCR-09-0265; Dickinson M, 2010, INVEST NEW DRUG, V28, pS3, DOI 10.1007/s10637-010-9596-y; Drake CG, 2012, J CLIN ONCOL S, V30; Drake CG, 2010, NAT REV IMMUNOL, V10, P580, DOI 10.1038/nri2817; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; Gao J, 2012, CANC RES S8, V72; Garnett CT, 2008, CLIN CANCER RES, V14, P3536, DOI 10.1158/1078-0432.CCR-07-4025; Gulley JL, 2005, CLIN CANCER RES, V11, P3353, DOI 10.1158/1078-0432.CCR-04-2062; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris TJ, 2008, PROSTATE, V68, P1319, DOI 10.1002/pros.20794; Higano D, 2009, 2009 GEN CANC S ORL; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoos A, 2010, SEMIN ONCOL, V37, P533, DOI 10.1053/j.seminoncol.2010.09.015; Horwich A, 2010, ANN ONCOL, V21, pv129, DOI 10.1093/annonc/mdq174; Huang X, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-35; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jure-Kunkel MN, 2008, J CLIN ONCOL S, V26, p144s; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kodumudi KN, 2010, CLIN CANCER RES, V16, P4583, DOI 10.1158/1078-0432.CCR-10-0733; Kuroda K, 2009, PROSTATE, V69, P1579, DOI 10.1002/pros.21004; Lebbe C, 2012, ANN ONCOL, V23, P363; Lee Francis, 2011, Ther Adv Med Oncol, V3, P11, DOI 10.1177/1758834010386402; Levy MY, 2009, J PHARMACOL EXP THER, V330, P596, DOI 10.1124/jpet.109.152603; Lugade AA, 2005, J IMMUNOL, V174, P7516, DOI 10.4049/jimmunol.174.12.7516; Ma YT, 2011, CANCER METAST REV, V30, P71, DOI 10.1007/s10555-011-9283-2; Madan RA, 2008, CLIN CANCER RES, V14, P4526, DOI 10.1158/1078-0432.CCR-07-5048; Madan RA, 2012, LANCET ONCOL, V13, P501, DOI 10.1016/S1470-2045(12)70006-2; Maio M, 2012, ANN ONCOL, V23, P367; Maluf FC, 2012, CLINICS, V67, P389, DOI 10.6061/clinics/2012(04)13; Marin-Aguilera M, 2012, MOL CANCER THER, V11, P329, DOI 10.1158/1535-7163.MCT-11-0289; McCourt CM, 2013, J CLIN PATHOL, V66, P58, DOI 10.1136/jclinpath-2012-201140; McDonnell AM, 2011, SEMIN IMMUNOPATHOL, V33, P353, DOI 10.1007/s00281-011-0246-z; Mercader M, 2001, P NATL ACAD SCI USA, V98, P14565, DOI 10.1073/pnas.251140998; Mokyr MB, 1998, CANCER RES, V58, P5301; NCCN Clinical Practice Guidelines in Oncology, 2012, NCCN CLIN PRACT GUID; Nilsson S, 2013, J CLIN ONCOL, V31, p317s; Nowak AK, 2003, CANCER RES, V63, P4490; Parker C, 2012, 2012 AM SOC CLIN ONC; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Pilones KA, 2009, CLIN CANCER RES, V15, P597, DOI 10.1158/1078-0432.CCR-08-1277; Prieto PA, 2012, CLIN CANCER RES, V18, P2039, DOI 10.1158/1078-0432.CCR-11-1823; Rathkopf DE, 2013, J CLIN ONCOL, V31, p310s; Risk Michael, 2009, Rev Urol, V11, P16; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Ross RW, 2008, CANCER-AM CANCER SOC, V112, P1247, DOI 10.1002/cncr.23304; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Sanda MG, 1999, UROLOGY, V53, P260, DOI 10.1016/S0090-4295(98)00539-1; Scher HI, 2013, J CLIN ONCOL, V31; Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Sharma P, 2011, NAT REV CANCER, V11, P805, DOI 10.1038/nrc3153; Sheikh NA, 2013, CANCER IMMUNOL IMMUN, V62, P137, DOI 10.1007/s00262-012-1317-2; Shen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030815; Slovin SF, 2013, ANN ONCOL, V24, P1813, DOI 10.1093/annonc/mdt107; Slovin SR, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00043; Small E, 2006, J CLIN ONCOL S18, V24, P4609; Small EJ, 2013, J CLIN ONCOL, V31, p319s; Stevenson R, 2013, J CLIN ONCOL, V31; Sutherland JS, 2005, J IMMUNOL, V175, P2741, DOI 10.4049/jimmunol.175.4.2741; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Terry S, 2009, BRIT J CANCER, V101, P951, DOI 10.1038/sj.bjc.6605245; Tollefson MK, 2010, AM SOC CLIN ONC 2010; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; van den Eertwegh AJM, 2012, LANCET ONCOL, V13, P509, DOI 10.1016/S1470-2045(12)70007-4; Vanneman M, 2012, NAT REV CANCER, V12, P237, DOI 10.1038/nrc3237; Vicari AP, 2009, CANCER IMMUNOL IMMUN, V58, P615, DOI 10.1007/s00262-008-0586-2; Vogelzang NJ, 2013, J CLIN ONCOL, V31, p324s; Yuan JD, 2011, P NATL ACAD SCI USA, V108, P16723, DOI 10.1073/pnas.1110814108; Zitvogel L, 2008, J CLIN INVEST, V118, P1991, DOI 10.1172/JCI35180; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936	110	34	37	1	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2014	33	43					5053	5064		10.1038/onc.2013.497	http://dx.doi.org/10.1038/onc.2013.497			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OF	24276248	Green Accepted			2022-12-28	WOS:000343768400001
J	Liu, F; Gong, J; Huang, W; Wang, Z; Wang, M; Yang, J; Wu, C; Wu, Z; Han, B				Liu, F.; Gong, J.; Huang, W.; Wang, Z.; Wang, M.; Yang, J.; Wu, C.; Wu, Z.; Han, B.			MicroRNA-106b-5p boosts glioma tumorigensis by targeting multiple tumor suppressor genes	ONCOGENE			English	Article						glioma; miR-106b-5p; cell proliferation; apoptosis; retinoblastoma-like (RBL1/2); caspase-8	EXPRESSION; MICRORNAS; MIR-106B; APOPTOSIS; CASPASE-8; MIR-20A; CLUSTER; RNAS	Aberrant expression of microRNAs (miRNAs) has been implicated in cancer initiation and progression. However, little is known about the potential role of miRNAs in glioma tumorigenesis. In this study, we found that miRNA-106b-5p was significantly upregulated in glioma tumor samples and cell lines compared with normal brain tissues, and its expression level correlated with the pathological grading. Overexpression of miR-106b-5p in glioma tumor cells significantly promoted cell proliferation, although inhibited cell apoptosis in vitro and in vivo. In contrast, knockdown of miR-106b-5p significantly inhibited cell proliferation, although enhanced cell apoptosis. Mechanistic study revealed that two target genes, retinoblastoma-like 1 (RBL1) and RBL2, were involved in miR-106b-5p's regulation of cell proliferation and one target gene, caspase-8 (CASP8), mediated miR-106b-5p's regulation of apoptosis. We also investigated the function of the three targets in glioma tumorigenesis by RNA interference manipulation and demonstrated that knockdown of these target genes led to cell proliferation enhancement or cell apoptosis inhibition in vitro. More interestingly, the expression levels of these targets were significantly downregulated in glioma samples and knockdown of these targets in glioma cells inhibited the xenograft tumor formation in vivo. Moreover, we verified the regulation function of miR-106b-5p and its targets on cell proliferation and apoptosis of the primary cultured astrocytes isolated from glioma tumor samples and healthy controls. Collectively, our findings show the critical roles of miR-106b-5p and its targets, RBL1, RBL2 and CASP8, in glioma tumorigenesis and provide potential candidates for malignant glioma therapy.	[Liu, F.; Gong, J.; Huang, W.; Wang, M.; Yang, J.; Wu, C.; Wu, Z.; Han, B.] Changzhou 2 Peoples Hosp, Dept Neurosurg, Changzhou 213003, Jiangsu, Peoples R China; [Wang, Z.] Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, Suzhou, Jiangsu, Peoples R China	Soochow University - China	Huang, W (corresponding author), Changzhou 2 Peoples Hosp, Dept Neurosurg, Changzhou 213003, Jiangsu, Peoples R China.	doctorliu411@163.com; w13306208761@hotmail.com			Open Project Program of Jiangsu Province's Key Discipline/Laboratory of Medicine [KF200971]; Changzhou Health Bureau [ZD201112]	Open Project Program of Jiangsu Province's Key Discipline/Laboratory of Medicine; Changzhou Health Bureau	This work was supported by the Open Project Program of Jiangsu Province's Key Discipline/Laboratory of Medicine (KF200971), Key Project of Changzhou Health Bureau (ZD201112).	Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Ashley DM, 2005, CANCER-AM CANCER SOC, V104, P1487, DOI 10.1002/cncr.21323; Bogler O, 2005, J CELL BIOCHEM, V96, P16, DOI 10.1002/jcb.20475; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Cai KM, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-73; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Garcia DM, 2011, NAT STRUCT MOL BIOL, V18, P1139, DOI 10.1038/nsmb.2115; Guo CP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017734; Hu S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016221; Hudson RS, 2013, ONCOGENE, V32, P4139, DOI 10.1038/onc.2012.424; Ivanovska I, 2008, MOL CELL BIOL, V28, P2167, DOI 10.1128/MCB.01977-07; Kan T, 2009, GASTROENTEROLOGY, V136, P1689, DOI 10.1053/j.gastro.2009.02.002; Li BQ, 2011, PROSTATE, V71, P567, DOI 10.1002/pros.21272; Li Y, 2009, CANCER SCI, V100, P1234, DOI 10.1111/j.1349-7006.2009.01164.x; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Louis DN, 2006, ANNU REV PATHOL-MECH, V1, P97, DOI 10.1146/annurev.pathol.1.110304.100043; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Malzkorn B, 2010, BRAIN PATHOL, V20, P539, DOI 10.1111/j.1750-3639.2009.00328.x; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Reczko M, 2012, BIOINFORMATICS, V28, P771, DOI 10.1093/bioinformatics/bts043; Sharif A, 2012, METHODS MOL BIOL, V814, P137, DOI 10.1007/978-1-61779-452-0_11; Smith AL, 2012, ONCOGENE, V31, P5162, DOI 10.1038/onc.2012.11; Takahashi K, 2006, J IMMUNOL, V176, P4520, DOI 10.4049/jimmunol.176.8.4520; Trompeter HI, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016138; Wang HL, 2010, BRAIN RES, V1357, P166, DOI 10.1016/j.brainres.2010.08.023; Wang XW, 2008, RNA, V14, P1012, DOI 10.1261/rna.965408; Wang X, 2012, ONCOL REP, V28, P1293, DOI 10.3892/or.2012.1927; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wu H, 2012, CELL SIGNAL, V24, P2179, DOI 10.1016/j.cellsig.2012.07.001; Zhang Y, 2012, FRONT BIOSCI-LANDMRK, V17, P700, DOI 10.2741/3952	31	71	76	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2014	33	40					4813	4822		10.1038/onc.2013.428	http://dx.doi.org/10.1038/onc.2013.428			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0EH	24166509	Bronze			2022-12-28	WOS:000343240100003
J	Aga, M; Bentz, GL; Raffa, S; Torrisi, MR; Kondo, S; Wakisaka, N; Yoshizaki, T; Pagano, JS; Shackelford, J				Aga, M.; Bentz, G. L.; Raffa, S.; Torrisi, M. R.; Kondo, S.; Wakisaka, N.; Yoshizaki, T.; Pagano, J. S.; Shackelford, J.			Exosomal HIF1 alpha supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes	ONCOGENE			English	Article							INDUCIBLE FACTOR 1-ALPHA; MULTIVESICULAR BODIES; MESSENGER-RNAS; HYPOXIA; MICROVESICLES; MECHANISM; RELEASE; CELLS; PALMITOYLATION; INHIBITION	It has emerged recently that exosomes are potential carriers of pro-tumorigenic factors that participate in oncogenesis. However, whether oncogenic transcription factors are transduced by exosomes is unknown. Hypoxia-inducible factor-1 alpha (HIF1 alpha) transcriptionally regulates numerous key aspects of tumor development and progression by promoting a more aggressive tumor phenotype, characterized by increased proliferation and invasiveness coupled with neoangiogenesis. It has been shown that the principal oncoprotein of Epstein-Barr virus (EBV), latent membrane protein 1 (LMP1), drives oncogenic processes and tumor progression of the highly invasive EBV malignancy, nasopharyngeal carcinoma (NPC). We now demonstrate that endogenous HIF1 alpha is detectable in exosomes and that LMP1 significantly increases levels of HIF1 alpha in exosomes. HIF1 recovered from exosomes retains DNA-binding activity and is transcriptionally active in recipient cells after exosome uptake. We also show that treatment of EBV-negative cells with LMP1-exosomes increases migration and invasiveness of NP cell lines in functional assays, which correlates with the phenotype associated with epithelial-mesenchymal transition (EMT). In addition, we provide evidence that HIF1 alpha itself participates in exosome-mediated pro-metastatic effects in recipient cells, as exosome-mediated delivery of active and inactive forms of HIF1 alpha results in reciprocal changes in the expression of E- and N-cadherins associated with EMT. Further, immunohistochemical analysis of NPC tumor tissues revealed direct correlation between protein levels of LMP1 and of the endosome/exosome marker tetraspanin, CD63, which suggests an increase in exosome formation in this EBV-positive malignancy. We hypothesize that exosome-mediated transfer of functional pro-metastatic factors by LMP1-positive NPC cells to surrounding tumor cells promotes cancer progression.	[Aga, M.; Bentz, G. L.; Pagano, J. S.; Shackelford, J.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Aga, M.; Kondo, S.; Wakisaka, N.; Yoshizaki, T.] Kanazawa Univ, Grad Sch Med, Div Otolaryngol, Kanazawa, Ishikawa, Japan; [Raffa, S.; Torrisi, M. R.] Univ Roma La Sapienza, Dipartimento Med Clin & Mol, I-00185 Rome, Italy; [Shackelford, J.] Univ N Carolina, Dept Cell Biol & Physiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; Kanazawa University; Sapienza University Rome; University of North Carolina; University of North Carolina Chapel Hill	Pagano, JS (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	joseph_pagano@med.unc.edu	Raffa, Salvatore/GPX-5723-2022; RAFFA, SALVATORE/AAL-5514-2020; Raffa, Salvatore/AAW-7060-2020	Raffa, Salvatore/0000-0001-9501-7638; 	National Cancer Institute [2P01-CA19014-26]; International Training Program of Cancer Research Institute of Kanazawa University; NATIONAL CANCER INSTITUTE [P01CA019014] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [25670713] Funding Source: KAKEN	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); International Training Program of Cancer Research Institute of Kanazawa University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Meckes DG Jr. and Raab-Traub N (University of North Carolina, Chapel Hill, NC, USA) for providing helpful advice on the further experimental strategies and Richard DE (Centre de Recherche en Cancerologie de l'Universite Laval, Quebec, QC, Canada) for the HA-DN HIF1a plasmid. This work was supported by a grant from the National Cancer Institute 2P01-CA19014-26 and International Training Program of Cancer Research Institute of Kanazawa University.	Ceccarelli S, 2007, INT J CANCER, V121, P1494, DOI 10.1002/ijc.22844; Chairoungdua A, 2010, J CELL BIOL, V190, P1079, DOI 10.1083/jcb.201002049; Corrado C, 2013, INT J MOL SCI, V14, P5338, DOI 10.3390/ijms14035338; Daker M, 2012, CANCER CELL INT, V12, DOI 10.1186/1475-2867-12-34; Denzer K, 2000, J CELL SCI, V113, P3365; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; Gourzones C, 2012, SEMIN CANCER BIOL, V22, P127, DOI 10.1016/j.semcancer.2012.01.002; Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799; Hendrix A, 2011, INT J DEV BIOL, V55, P879, DOI 10.1387/ijdb.113391ah; Hong BS, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-556; Houali K, 2007, CLIN CANCER RES, V13, P4993, DOI 10.1158/1078-0432.CCR-06-2945; Johnstone RM, 2006, BLOOD CELL MOL DIS, V36, P315, DOI 10.1016/j.bcmd.2005.12.001; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kobayashi T, 2000, MOL BIOL CELL, V11, P1829, DOI 10.1091/mbc.11.5.1829; Kondo S, 2006, CANCER RES, V66, P9870, DOI 10.1158/0008-5472.CAN-06-1679; Kovalenko OV, 2004, BIOCHEM J, V377, P407, DOI 10.1042/BJ20031037; Kucharzewska P, 2013, P NATL ACAD SCI USA, V110, P7312, DOI 10.1073/pnas.1220998110; Lamparski HG, 2002, J IMMUNOL METHODS, V270, P211, DOI 10.1016/S0022-1759(02)00330-7; Le Bras GF, 2012, CELL ADHES MIGR, V6, P365, DOI 10.4161/cam.21326; Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006; Meckes DG, 2011, J VIROL, V85, P12844, DOI 10.1128/JVI.05853-11; Meckes DG, 2010, P NATL ACAD SCI USA, V107, P20370, DOI 10.1073/pnas.1014194107; Meckes Jr DG, P NATL ACAD IN PRESS, V110, pE2925; Pant S, 2012, BIOCHEM PHARMACOL, V83, P1484, DOI 10.1016/j.bcp.2011.12.037; Pegtel DM, 2010, P NATL ACAD SCI USA, V107, P6328, DOI 10.1073/pnas.0914843107; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Putz U, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003084; Raab-Traub N, 2012, CURR OPIN VIROL, V2, P453, DOI 10.1016/j.coviro.2012.07.001; Rana S, 2011, BIOCHEM SOC T, V39, P559, DOI 10.1042/BST0390559; Richard DE, 2000, J BIOL CHEM, V275, P26765; Salomon C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079636; Simpson RJ, 2009, EXPERT REV PROTEOMIC, V6, P267, DOI [10.1586/epr.09.17, 10.1586/EPR.09.17]; Staubach S, 2009, PROTEOMICS, V9, P2820, DOI 10.1002/pmic.200800793; Sund M, 2009, CANCER METAST REV, V28, P177, DOI 10.1007/s10555-008-9175-2; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017; Wakisaka N, 2004, MOL CELL BIOL, V24, P5223, DOI 10.1128/MCB.24.12.5223-5234.2004; Yang MH, 2008, CELL CYCLE, V7, P2090, DOI 10.4161/cc.7.14.6324; Yang XW, 2002, MOL BIOL CELL, V13, P767, DOI 10.1091/mbc.01-05-0275; Yoshizaki T, 2005, EPSTEIN-BARR VIRUS, P171; Yoshizaki T, 2013, CANCER LETT, V337, P1, DOI 10.1016/j.canlet.2013.05.018; Yu X, 2012, J MOL CELL CARDIOL, V53, P848, DOI 10.1016/j.yjmcc.2012.10.002	43	218	239	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2014	33	37					4613	4622		10.1038/onc.2014.66	http://dx.doi.org/10.1038/onc.2014.66			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3UZ	24662828	Green Published, Green Submitted, Green Accepted, hybrid			2022-12-28	WOS:000342004800008
J	Nair, R; Roden, DL; Teo, WS; McFarland, A; Junankar, S; Ye, S; Nguyen, A; Yang, J; Nikolic, I; Hui, M; Morey, A; Shah, J; Pfefferle, AD; Usary, J; Selinger, C; Baker, LA; Armstrong, N; Cowley, MJ; Naylor, MJ; Ormandy, CJ; Lakhani, SR; Herschkowitz, JI; Perou, CM; Kaplan, W; O'Toole, SA; Swarbrick, A				Nair, R.; Roden, D. L.; Teo, W. S.; McFarland, A.; Junankar, S.; Ye, S.; Nguyen, A.; Yang, J.; Nikolic, I.; Hui, M.; Morey, A.; Shah, J.; Pfefferle, A. D.; Usary, J.; Selinger, C.; Baker, L. A.; Armstrong, N.; Cowley, M. J.; Naylor, M. J.; Ormandy, C. J.; Lakhani, S. R.; Herschkowitz, J. I.; Perou, C. M.; Kaplan, W.; O'Toole, S. A.; Swarbrick, A.			c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer	ONCOGENE			English	Article						Her2; ERBB2; Myc; cancer stem cell; transcriptomics; oncogene cooperation	EPITHELIAL-MESENCHYMAL TRANSITION; BASAL-LIKE PHENOTYPE; LIPOPROTEIN-LIPASE; TRANSGENIC MICE; CELL-PROLIFERATION; MAMMARY-CARCINOMA; EXPRESSION; IDENTIFICATION; AMPLIFICATION; ONCOGENE	The HER2 (ERBB2) and MYC genes are commonly amplified in breast cancer, yet little is known about their molecular and clinical interaction. Using a novel chimeric mammary transgenic approach and in vitro models, we demonstrate markedly increased self-renewal and tumour-propagating capability of cells transformed with Her2 and c-Myc. Coexpression of both oncoproteins in cultured cells led to the activation of a c-Myc transcriptional signature and acquisition of a self-renewing phenotype independent of an epithelial-mesenchymal transition programme or regulation of conventional cancer stem cell markers. Instead, Her2 and c-Myc cooperated to induce the expression of lipoprotein lipase, which was required for proliferation and self-renewal in vitro. HER2 and MYC were frequently coamplified in breast cancer, associated with aggressive clinical behaviour and poor outcome. Lastly, we show that in HER2(+) breast cancer patients receiving adjuvant chemotherapy (but not targeted anti-Her2 therapy), MYC amplification is associated with a poor outcome. These findings demonstrate the importance of molecular and cellular context in oncogenic transformation and acquisition of a malignant stem-like phenotype and have diagnostic and therapeutic consequences for the clinical management of HER2(+) breast cancer.	[Nair, R.; Roden, D. L.; Teo, W. S.; McFarland, A.; Junankar, S.; Ye, S.; Nguyen, A.; Yang, J.; Nikolic, I.; Hui, M.; Cowley, M. J.; Naylor, M. J.; Ormandy, C. J.; O'Toole, S. A.; Swarbrick, A.] Garvan Inst Med Res, Kinghorn Canc Ctr, Canc Res Div, Darlinghurst, NSW 2010, Australia; [Nair, R.; Roden, D. L.; Teo, W. S.; McFarland, A.; Junankar, S.; Ye, S.; Nguyen, A.; Yang, J.; Nikolic, I.; Hui, M.; Cowley, M. J.; Naylor, M. J.; Ormandy, C. J.; O'Toole, S. A.; Swarbrick, A.] Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; [Teo, W. S.; Junankar, S.; Ye, S.; Morey, A.; Naylor, M. J.; Ormandy, C. J.; Kaplan, W.; O'Toole, S. A.; Swarbrick, A.] Univ New S Wales, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia; [Morey, A.] St Vincents Hosp, Dept Anat Pathol, Darlinghurst, NSW 2010, Australia; [Shah, J.] Univ New S Wales, Sch Med Sci, Camperdown, NSW, Australia; [Pfefferle, A. D.; Perou, C. M.] Dept Pathol & Lab Med, Chapel Hill, NC USA; [Pfefferle, A. D.; Usary, J.; Perou, C. M.] Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA; [Shah, J.; Perou, C. M.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA; [Selinger, C.; O'Toole, S. A.] Royal Prince Alfred Hosp, Deptt Tissue Pathol & Diagnost Oncol, Camperdown, NSW 2050, Australia; [Baker, L. A.] Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia; [Armstrong, N.] Univ Sydney, Sch Math & Stat, Sydney, NSW 2006, Australia; [Cowley, M. J.; Kaplan, W.] Garvan Inst Med Res, Peter Wills Bioinformat Ctr, Darlinghurst, NSW 2010, Australia; [Naylor, M. J.] Univ Sydney, Sch Med Sci, Discipline Physiol, Sydney, NSW 2006, Australia; [Naylor, M. J.] Univ Sydney, Sch Med Sci, Bosch Inst, Sydney, NSW 2006, Australia; [Lakhani, S. R.] Univ Queensland, UQ Ctr Clin Res, Sch Med & Pathol Queensland, Royal Brisbane & Womens Hosp, Herston, Qld, Australia; [Herschkowitz, J. I.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [O'Toole, S. A.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia	Garvan Institute of Medical Research; Garvan Institute of Medical Research; University of New South Wales Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney; University of North Carolina; University of North Carolina Chapel Hill; University of Sydney; University of New South Wales Sydney; University of Sydney; Garvan Institute of Medical Research; University of Sydney; University of Sydney; Royal Brisbane & Women's Hospital; University of Queensland; Baylor College of Medicine; University of Sydney	Swarbrick, A (corresponding author), Garvan Inst Med Res, Kinghorn Canc Ctr, Canc Res Div, 370 Victoria St, Darlinghurst, NSW 2010, Australia.	a.swarbrick@garvan.org.au	Junankar, Simon/O-2009-2019; Cowley, Mark/K-8731-2019; Lakhani, Sunil R/I-1970-2018; Perou, Charles M/H-9934-2014; Armstrong, Nicola J./AAF-3045-2021; Swarbrick, Alexander/E-6107-2010; Junankar, Simon/B-7677-2019; Yang, Jean/D-2920-2015	Junankar, Simon/0000-0002-3965-8278; Cowley, Mark/0000-0002-9519-5714; Lakhani, Sunil R/0000-0003-4067-2760; Perou, Charles M/0000-0001-9827-2247; Armstrong, Nicola J./0000-0002-4477-293X; Swarbrick, Alexander/0000-0002-3051-5676; Nikolic, Iva/0000-0002-0141-5975; Yang, Jean/0000-0002-5271-2603; Nair, Radhika/0000-0002-6585-3384; Shah, Jaynish/0000-0002-1089-7355; Ormandy, Christopher/0000-0002-2504-7919; Morey, Adrienne/0000-0002-7823-8276	International Postgraduate Research Scholarship (IPRS); Beth Yarrow Memorial Award in Medical Science; Victoria Taylor, Sydney Breast Cancer Foundation; CCNSW; Colin Biggers & Paisley, Sydney; Early Career Fellowship from the National Breast Cancer Foundation Australia; Cancer Institute NSW Clinical Research Fellowship [10-CRF 1-07]	International Postgraduate Research Scholarship (IPRS)(Australian Government); Beth Yarrow Memorial Award in Medical Science; Victoria Taylor, Sydney Breast Cancer Foundation; CCNSW; Colin Biggers & Paisley, Sydney; Early Career Fellowship from the National Breast Cancer Foundation Australia; Cancer Institute NSW Clinical Research Fellowship	We thank Professor JM Bishop and The GW Hooper Foundation (UCSF); Nikki Ailing and Alice Boulghourjian for technical assistance with Flow cytometry and Immunohistochemistry, respectively; and Aurelie Cazet for proof reading the manuscript. WST is a recipient of an International Postgraduate Research Scholarship (IPRS) and the Beth Yarrow Memorial Award in Medical Science. We would like to acknowledge funding from Victoria Taylor, Sydney Breast Cancer Foundation, CCNSW and Colin Biggers & Paisley, Sydney. This research was supported by an Early Career Fellowship from the National Breast Cancer Foundation Australia. AS is a Career Development Fellow of the National Health and Medical Research Council of Australia. SOT is funded by the Cancer Institute NSW Clinical Research Fellowship 10-CRF 1-07.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alonso SR, 2007, CANCER RES, V67, P3450, DOI 10.1158/0008-5472.CAN-06-3481; Axelrod R, 2006, P NATL ACAD SCI USA, V103, P13474, DOI 10.1073/pnas.0606053103; Bagaria SP, 2012, ANN SURG ONCOL, V19, P935, DOI 10.1245/s10434-011-2032-5; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; Bilban M, 2006, LEUKEMIA, V20, P1080, DOI 10.1038/sj.leu.2404220; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Carter SA, 2012, BRIT J CANCER, V107, P739, DOI 10.1038/bjc.2012.301; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Danilo C, 2012, CURR OPIN PHARMACOL, V12, P677, DOI 10.1016/j.coph.2012.07.009; Deming SL, 2000, BRIT J CANCER, V83, P1688, DOI 10.1054/bjoc.2000.1522; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hardy KM, 2010, J MAMMARY GLAND BIOL, V15, P191, DOI 10.1007/s10911-010-9172-2; Heintel D, 2005, LEUKEMIA, V19, P1216, DOI 10.1038/sj.leu.2403748; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hynes NE, 2001, J MAMMARY GLAND BIOL, V6, P141, DOI 10.1023/A:1009528918064; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Kim YH, 2006, ONCOGENE, V25, P130, DOI 10.1038/sj.onc.1208997; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Laudadio J, 2007, EXPERT REV MOL DIAGN, V7, P53, DOI 10.1586/14737159.7.1.53; Lee T, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000013; Liu H, 2008, HUM PATHOL, V39, P167, DOI 10.1016/j.humpath.2007.06.012; Liu JC, 2007, CANCER RES, V67, P8671, DOI 10.1158/0008-5472.CAN-07-1486; Llaverias G, 2011, AM J PATHOL, V178, P402, DOI 10.1016/j.ajpath.2010.11.005; Lo PK, 2012, ONCOGENE, V31, P2614, DOI [10.1038/onc.2011.439, 10.1038/onc.2012.147]; Lopez-Knowles E, 2010, INT J CANCER, V126, P1121, DOI 10.1002/ijc.24831; Lopez-Knowles E, 2010, CANCER EPIDEM BIOMAR, V19, P301, DOI 10.1158/1055-9965.EPI-09-0741; Magnifico A, TUMOR INITIATING CEL; Matthews L, 2009, NUCLEIC ACIDS RES, V37, pD619, DOI 10.1093/nar/gkn863; Mead JR, 2002, J MOL MED, V80, P753, DOI 10.1007/s00109-002-0384-9; Millar EKA, 2009, BRIT J CANCER, V100, P123, DOI 10.1038/sj.bjc.6604809; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; O'Toole SA, 2011, CANCER RES, V71, P4002, DOI 10.1158/0008-5472.CAN-10-3738; Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008; Park K, 2005, HUM PATHOL, V36, P634, DOI 10.1016/j.humpath.2005.04.016; Perez E, 2009, CANC RES S, V69, P56; Perez EA, 2011, J CLIN ONCOL, V29, P651, DOI 10.1200/JCO.2010.30.2125; Persons DL, 1997, MODERN PATHOL, V10, P720; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Roberts PJ, 2012, CLIN CANCER RES, V18, P5290, DOI 10.1158/1078-0432.CCR-12-0563; Rosenbloom KR, 2013, NUCLEIC ACIDS RES, V41, pD56, DOI 10.1093/nar/gks1172; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shachaf CM, 2008, CANCER RES, V68, P5132, DOI 10.1158/0008-5472.CAN-07-6192; Singh SK, 2003, CANCER RES, V63, P5821; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Stoelzle Tina, 2009, BMC Biol, V7, P63, DOI 10.1186/1741-7007-7-63; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swarbrick A, 2008, P NATL ACAD SCI USA, V105, P5402, DOI 10.1073/pnas.0801505105; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Welm AL, 2005, P NATL ACAD SCI USA, V102, P4324, DOI 10.1073/pnas.0500470102; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Wolfer A, 2010, P NATL ACAD SCI USA, V107, P3698, DOI 10.1073/pnas.0914203107; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Zhang WZ, 2010, P NATL ACAD SCI USA, V107, P18956, DOI 10.1073/pnas.1013420107	82	64	68	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3992	4002		10.1038/onc.2013.368	http://dx.doi.org/10.1038/onc.2013.368			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	24056965				2022-12-28	WOS:000339394700011
J	Witkiewicz, AK; Cox, DW; Rivadeneira, D; Ertel, AE; Fortina, P; Schwartz, GF; Knudsen, ES				Witkiewicz, A. K.; Cox, D. W.; Rivadeneira, D.; Ertel, A. E.; Fortina, P.; Schwartz, G. F.; Knudsen, E. S.			The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer	ONCOGENE			English	Article						tumor suppressor; epithelial-to-mesenchymal transition; cyclin-dependent kinase; cell cycle; E2F; CDK4/6; PD-0332991	CARCINOMA IN-SITU; GENE AMPLIFICATION; BASAL-LIKE; LUMINAL-B; HER-2 NEU; EXPRESSION; RB; MORPHOGENESIS; PROGRESSION; INHIBITION	The processes that control the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer remain poorly understood. Epidermal growth factor receptor 2 (ErbB2) overexpression is common in DCIS, as is disruption of the retinoblastoma tumor suppressor (RB) pathway. Here, we examined the cooperative impact of ErbB2 and RB deregulation on facets of disease progression. Our studies demonstrate that RB deficiency altered the expression of key molecules needed for proper cellular organization and epithelial cell-cell adhesion as part of a program related to the epithelial-to-mesenchymal transition (EMT). An increase in the invasive potential of ErbB2-overexpressing cells was observed upon RB depletion. Further, stable knockdown of RB resulted in invasive lesions in orthotopic xenograft assays, compared with DCIS-like lesions developing from RB-proficient cells. Conversely, the invasive phenotype observed in ErbB2-positive cancer models was inhibited through CDK4/6 inhibition in an RB-dependent manner. Finally, in a cohort of DCIS cases, we show that, although elevated levels of ErbB2 are associated with increased risk of a subsequent DCIS recurrence, it is not associated with progression to invasive disease. In contrast, RB loss in ErbB2-positive DCIS cases was associated with increased risk for invasive breast cancer. Taken together, these data demonstrate a key role for the RB pathway in invasion associated with breast tumor progression, and shed light on the key molecular events that promote the progression of DCIS to invasive disease.	[Witkiewicz, A. K.; Cox, D. W.; Knudsen, E. S.] UT Southwest Med Ctr, Dept Pathol, Dallas, TX 75390 USA; [Witkiewicz, A. K.; Knudsen, E. S.] UT Southwest Med Ctr, Simmons Canc Ctr, Dallas, TX USA; [Rivadeneira, D.; Ertel, A. E.; Fortina, P.] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA USA; [Schwartz, G. F.] Thomas Jefferson Univ, Dept Surg, Philadelphia, PA USA	Jefferson University; Jefferson University	Witkiewicz, AK (corresponding author), UT Southwest Med Ctr, Dept Pathol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	agnes.witkiewicz@utsouthwestern.edu	Fortina, Paolo/ABE-8350-2020	Fortina, Paolo/0000-0002-5898-2081	NIH [RO1-CA129134, RO1-CA137494, RO1-CA163863]; NATIONAL CANCER INSTITUTE [R01CA129134, R01CA137494, R01CA163863, P30CA142543] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank all of our colleagues who contributed to this study. This work was supported by NIH grants to ESK (RO1-CA129134 and RO1-CA137494) and AKW (RO1-CA163863).	Allegra CJ, 2010, J NATL CANCER I, V102, P161, DOI 10.1093/jnci/djp485; ALLRED DC, 1992, HUM PATHOL, V23, P974, DOI 10.1016/0046-8177(92)90257-4; BETSILL WL, 1978, JAMA-J AM MED ASSOC, V239, P1863, DOI 10.1001/jama.239.18.1863; Carlson RW, 2009, J NATL COMPR CANC NE, V7, P122, DOI 10.6004/jnccn.2009.0012; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Correa C, 2010, J NATL CANC I MONOGR, V2010, P162, DOI [DOI 10.1093/JNCIMONOGRAPHS/LGQ039, DOI 10.1093/JNCIM0N0GRAPHS/LGQ039]; Dean JL, 2010, ONCOGENE, V29, P4018, DOI 10.1038/onc.2010.154; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Erbas B, 2006, BREAST CANCER RES TR, V97, P135, DOI 10.1007/s10549-005-9101-z; Ernster VL, 2002, J NATL CANCER I, V94, P1546; Franke WW, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003061; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gauthier ML, 2007, CANCER CELL, V12, P479, DOI 10.1016/j.ccr.2007.10.017; Hackstadt AJ, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-11; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hebner C, 2008, ANNU REV PATHOL-MECH, V3, P313, DOI 10.1146/annurev.pathmechdis.3.121806.151526; Herschkowitz JI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2142; Hoque A, 2002, CANCER EPIDEM BIOMAR, V11, P587; Jiang Z, 2010, J CLIN INVEST, V120, P3296, DOI 10.1172/JCI41490; Jones JL, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1397; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Kerlikowske K, 2003, JNCI-J NATL CANCER I, V95, P1692, DOI 10.1093/jnci/djg097; Kerlikowske K, 2010, JNCI-J NATL CANCER I, V102, P627, DOI 10.1093/jnci/djq101; Kim YS, 2008, J KOREAN MED SCI, V23, P414, DOI 10.3346/jkms.2008.23.3.414; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Knudsen ES, 2012, JNCI-J NATL CANCER I, V104, P1825, DOI 10.1093/jnci/djs446; Knudsen ES, 2012, BREAST CANCER RES TR, V133, P1009, DOI 10.1007/s10549-011-1894-3; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Lee S, 2012, CANCER RES, V72, P4574, DOI 10.1158/0008-5472.CAN-12-0636; Leonard GD, 2004, JNCI-J NATL CANCER I, V96, P906, DOI 10.1093/jnci/djh164; McClendon AK, 2011, GASTROENTEROLOGY, V141, P1439, DOI 10.1053/j.gastro.2011.06.046; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; O'Brien LE, 2002, NAT REV MOL CELL BIO, V3, P531, DOI 10.1038/nrm859; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Rakovitch E, 2012, BRIT J CANCER, V106, P1160, DOI 10.1038/bjc.2012.41; Rivadeneira DB, 2010, GASTROENTEROLOGY, V138, P1920, DOI 10.1053/j.gastro.2010.01.007; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Romero L, 2004, AM J SURG, V188, P371, DOI 10.1016/j.amjsurg.2004.06.034; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; Schnitt Stuart J., 2010, Journal of the National Cancer Institute Monographs, P158, DOI 10.1093/jncimonographs/lgq031; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sotgia F, 2006, AM J PATHOL, V168, P292, DOI 10.2353/ajpath.2006.050429; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sutherland RL, 2004, J MAMMARY GLAND BIOL, V9, P95, DOI 10.1023/B:JOMG.0000023591.45568.77; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thangavel C, 2011, ENDOCR-RELAT CANCER, V18, P333, DOI 10.1530/ERC-10-0262; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Virnig BA, 2010, J NATL CANCER I, V102, P170, DOI 10.1093/jnci/djp482; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Witkiewicz AK, 2011, AM J PATHOL, V179, P1171, DOI 10.1016/j.ajpath.2011.05.043; Wu M, 2009, P NATL ACAD SCI USA, V106, P7022, DOI 10.1073/pnas.0811785106; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zhurinsky J, 2000, J CELL SCI, V113, P3127	55	18	21	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3980	3991		10.1038/onc.2013.367	http://dx.doi.org/10.1038/onc.2013.367			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	24121271	Green Accepted			2022-12-28	WOS:000339394700010
J	Bjerke, GA; Yang, CS; Frierson, HF; Paschal, BM; Wotton, D				Bjerke, G. A.; Yang, C-S; Frierson, H. F.; Paschal, B. M.; Wotton, D.			Activation of Akt signaling in prostate induces a TGF beta-mediated restraint on cancer progression and metastasis	ONCOGENE			English	Article						TGF beta; Akt; Pten; prostate cancer; signaling	TUMOR-SUPPRESSOR GENE; INTRAEPITHELIAL NEOPLASIA; CELL-PROLIFERATION; II RECEPTORS; PTEN; GROWTH; MOUSE; INACTIVATION; PTEN/MMAC1; EXPRESSION	Mutations in the PTEN tumor suppressor gene are found in a high proportion of human prostate cancers, and in mice, Pten deletion induces high-grade prostate intraepithelial neoplasia (HGPIN). However, progression from HGPIN to invasive cancer occurs slowly, suggesting that tumorigenesis is subject to restraint. We show that Pten deletion, or constitutive activation of the downstream kinase AKT, activates the transforming growth factor (TGF)beta pathway in prostate epithelial cells. TGF beta signaling is known to have a tumor suppressive role in many cancer types, and reduced expression of TGF beta receptors correlates with advanced human prostate cancer. We demonstrate that in combination either with loss of Pten or expression of constitutively active AKT1, inactivation of TGF beta signaling by deletion of the TGF beta type II receptor gene relieves a restraint on tumorigenesis. This results in rapid progession to lethal prostate cancer, including metastasis to lymph node and lung. In prostate epithelium, inactivation of TGF beta signaling alone is insufficient to initiate tumorigenesis, but greatly accelerates cancer progression. The activation of TGF beta signaling by Pten loss or AKT activation suggests that the same signaling events that have key roles in tumor initiation also induce the activity of a pathway that restrains disease progression.	[Bjerke, G. A.; Yang, C-S; Paschal, B. M.; Wotton, D.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; [Bjerke, G. A.; Yang, C-S; Paschal, B. M.; Wotton, D.] Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA; [Frierson, H. F.] Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Wotton, D (corresponding author), Univ Virginia, Dept Biochem & Mol Genet, Ctr Cell Signaling, Box 800577, Charlottesville, VA 22908 USA.	dw2p@virginia.edu		Wotton, David/0000-0002-4652-5350	National Cancer Institute [2P01CA104106]; UVA Cancer Center; James and Rebecca Craig Foundation [CCSG P30 CA44579]; UVA Women's Oncology fund; NATIONAL CANCER INSTITUTE [P30CA044579, P01CA104106] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UVA Cancer Center; James and Rebecca Craig Foundation; UVA Women's Oncology fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Sharon Birdsall and Marya Brown for technical assistance, Doug DeSimone for use of the Zeiss microscope, Anindya Dutta and Dan Gioeli for helpful discussions and Tiffany Melhuish for expert advice and assistance. This work was supported by a Program Project Grant from the National Cancer Institute (2P01CA104106 to B Paschal and D Wotton), and by a pilot grant from the UVA Cancer Center (funded from the CCSG P30 CA44579, the James and Rebecca Craig Foundation, and UVA Women's Oncology fund) to D Wotton.	Aitchison AA, 2008, PROSTATE, V68, P661, DOI 10.1002/pros.20730; Bartholin L, 2008, DEV BIOL, V319, P285, DOI 10.1016/j.ydbio.2008.04.027; Bayascas JR, 2005, CURR BIOL, V15, P1839, DOI 10.1016/j.cub.2005.08.066; Cairns P, 1997, CANCER RES, V57, P4997; Chen ML, 2006, GENE DEV, V20, P1569, DOI 10.1101/gad.1395006; Chytil A, 2002, GENESIS, V32, P73, DOI 10.1002/gene.10046; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Ding ZH, 2012, CELL, V148, P896, DOI 10.1016/j.cell.2012.01.039; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Galgano MT, 2009, HUM PATHOL, V40, P1434, DOI 10.1016/j.humpath.2009.02.008; Guo YP, 1997, INT J CANCER, V71, P573, DOI 10.1002/(SICI)1097-0215(19970516)71:4<573::AID-IJC11>3.3.CO;2-1; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Kim IY, 1996, CLIN CANCER RES, V2, P1255; Kim J, 2012, ONCOGENE, V31, P322, DOI 10.1038/onc.2011.236; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Ma XQ, 2005, CANCER RES, V65, P5730, DOI 10.1158/0008-5472.CAN-04-4519; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Powers SE, 2010, DEVELOPMENT, V137, P249, DOI 10.1242/dev.040782; Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Suzuki H, 1998, CANCER RES, V58, P204; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Truett GE, 2000, BIOTECHNIQUES, V29, P52, DOI 10.2144/00291bm09; Wang SI, 1998, CLIN CANCER RES, V4, P811; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Williams RH, 1996, CLIN CANCER RES, V2, P635; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Yamada KM, 2001, J CELL SCI, V114, P2375; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhao H, 2005, CANCER-AM CANCER SOC, V104, P44, DOI 10.1002/cncr.21135	42	23	23	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3660	3667		10.1038/onc.2013.342	http://dx.doi.org/10.1038/onc.2013.342			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23995785	Green Accepted			2022-12-28	WOS:000338942900005
J	AbuAli, G; Chaisaklert, W; Stelloo, E; Pazarentzos, E; Hwang, MS; Qize, D; Harding, SV; Al-Rubaish, A; Alzahrani, A; Al-Ali, A; Sanders, TAB; Aboagye, EO; Grimm, S				AbuAli, G.; Chaisaklert, W.; Stelloo, E.; Pazarentzos, E.; Hwang, M-S; Qize, D.; Harding, S. V.; Al-Rubaish, A.; Alzahrani, Aj; Al-Ali, A.; Sanders, T. A. B.; Aboagye, E. O.; Grimm, S.			The anticancer gene ORCTL3 targets stearoyl-CoA desaturase-1 for tumour-specific apoptosis	ONCOGENE			English	Article							CANCER-CELL METABOLISM; PROTEIN; DEATH; MEMBRANE; OBESITY; IDENTIFICATION; TRANSFORMATION; PROLIFERATION; METASTASIS; ADHESION	ORCTL3 is a member of a group of genes, the so-called anticancer genes, that cause tumour-specific cell death. We show that this activity is triggered in isogenic renal cells upon their transformation independently of the cells' proliferation status. For its cell death effect ORCTL3 targets the enzyme stearoyl-CoA desaturase-1 (SCD1) in fatty acid metabolism. This is caused by transmembrane domains 3 and 4, which are more efficacious in vitro than a low molecular weight drug against SCD1, and critically depend on their expression level. SCD1 is found upregulated upon renal cell transformation indicating that its activity, while not impacting proliferation, represents a critical bottleneck for tumourigenesis. An adenovirus expressing ORCTL3 leads to growth inhibition of renal tumours in vivo and to substantial destruction of patients' kidney tumour cells ex vivo. Our results indicate fatty acid metabolism as a target for tumour-specific apoptosis in renal tumours and suggest ORCTL3 as a means to accomplish this.	[AbuAli, G.; Chaisaklert, W.; Stelloo, E.; Pazarentzos, E.; Hwang, M-S; Qize, D.; Grimm, S.] Univ London Imperial Coll Sci Technol & Med, Div Expt Med, London W12 0NN, England; [Harding, S. V.; Sanders, T. A. B.] Kings Coll London, Diabet & Nutr Sci Div, London, England; [Al-Rubaish, A.; Alzahrani, Aj; Al-Ali, A.] Univ Dammam, Coll Med, Prince Mohammed Ctr Res & Consultat Studies, Dammam, Saudi Arabia; [Aboagye, E. O.] Univ London Imperial Coll Sci Technol & Med, Div Canc, London W12 0NN, England	Imperial College London; University of London; King's College London; Imam Abdulrahman Bin Faisal University; Imperial College London	Grimm, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ctr Pharmacol & Therapeut, Du Cane Rd, London W12 0NN, England.	s.grimm@imperial.ac.uk	Harding, Scott/K-9005-2012	Harding, Scott/0000-0002-7728-2339; Sanders, Thomas/0000-0001-9529-095X; Pazarentzos, Evangelos/0000-0002-5453-1646; Al-Rubaish, Abdullah Mohammed/0000-0002-9136-2853; ABOAGYE, Eric/0000-0003-2276-6771	Ministry of Higher Education in Saudi Arabia; Cancer Research UK; Development and Promotion of Science and Technology Talents Project (DPST), Royal Thai Government, Thailand; AstraZeneca Ltd.; National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London; MRC [MR/J007986/1] Funding Source: UKRI; Cancer Research UK [12011, 10337, 16584] Funding Source: researchfish; Medical Research Council [MR/J007986/1] Funding Source: researchfish; National Institute for Health Research [NIHR/CS/009/009] Funding Source: researchfish	Ministry of Higher Education in Saudi Arabia; Cancer Research UK(Cancer Research UK); Development and Promotion of Science and Technology Talents Project (DPST), Royal Thai Government, Thailand; AstraZeneca Ltd.(AstraZeneca); National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	GA was supported by the Ministry of Higher Education in Saudi Arabia. EP was supported by the Cancer Research UK, WC by the Development and Promotion of Science and Technology Talents Project (DPST), Royal Thai Government, Thailand and MSH by a stipend from AstraZeneca Ltd. We thank Joel Abraham for in vivo work and the Imperial's tissue bank, Dr David Hrouda, Ms Taneisha McFarlane, and Prof Gerry Thomas, for help. Tissue samples were provided by the Imperial College Healthcare NHS Trust Tissue Bank. Other investigators may have received samples from these same tissues. The research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author (s) and not necessarily those of the NHS, the NIHR or the Department of Health. We thank Mr Robert Gray for lipid extraction and primary GC analysis.	Brown JM, 2010, CURR OPIN LIPIDOL, V21, P192, DOI 10.1097/MOL.0b013e32833854ac; Burikhanov R, 2009, CELL, V138, P377, DOI 10.1016/j.cell.2009.05.022; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Ceschi M, 2007, SWISS MED WKLY, V137, P50; Cheong H, 2012, NAT BIOTECHNOL, V30, P671, DOI 10.1038/nbt.2285; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; DanenVanOorschot AAAM, 1997, P NATL ACAD SCI USA, V94, P5843; FUJITA J, 1988, CANCER RES, V48, P5251; Funaki NO, 2001, ONCOL REP, V8, P527; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gong ZH, 2007, CANCER-AM CANCER SOC, V109, P1192, DOI 10.1002/cncr.22534; Gordan JD, 2008, CANCER CELL, V14, P435, DOI 10.1016/j.ccr.2008.10.016; Grimm S, 2010, TRENDS MOL MED, V16, P88, DOI 10.1016/j.molmed.2009.12.002; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Igal RA, 2010, CARCINOGENESIS, V31, P1509, DOI 10.1093/carcin/bgq131; Irshad S, 2009, CELL DEATH DIFFER, V16, P890, DOI 10.1038/cdd.2009.21; Iwasawa R, 2011, EMBO J, V30, P556, DOI 10.1038/emboj.2010.346; JENSEN FC, 1964, P NATL ACAD SCI USA, V52, P53, DOI 10.1073/pnas.52.1.53; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; LEPAGE G, 1986, J LIPID RES, V27, P114; Linehan WM, 2011, CANC PRINCIPLES PRAC, P1161; Mahul-Mellier AL, 2012, CELL DEATH DIFFER, V19, P891, DOI 10.1038/cdd.2011.185; Meter Van, 2011, CELL CYCLE, V10, P3153; Minville-Walz M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014363; Morgan-Lappe SE, 2007, CANCER RES, V67, P4390, DOI 10.1158/0008-5472.CAN-06-4132; Muthana M, 2013, CANCER RES, V73, P490, DOI 10.1158/0008-5472.CAN-12-3056; Nalca A, 1999, J BIOL CHEM, V274, P29976, DOI 10.1074/jbc.274.42.29976; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Nevels Michael, 2007, Methods Mol Med, V131, P187; Noon AP, 2010, CANCER-AM CANCER SOC, V116, P780, DOI 10.1002/cncr.24841; Rohn JL, 2002, J BIOL CHEM, V277, P50820, DOI 10.1074/jbc.M208557200; Singer EA, 2011, CURR OPIN ONCOL, V23, P283, DOI 10.1097/CCO.0b013e32834479c0; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Valente MJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019337; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zeisig R, 2007, ARCH BIOCHEM BIOPHYS, V459, P98, DOI 10.1016/j.abb.2006.09.030	38	10	10	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1718	1728		10.1038/onc.2014.93	http://dx.doi.org/10.1038/onc.2014.93			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24769897	Green Accepted			2022-12-28	WOS:000351848400012
J	Jude, JG; Spencer, GJ; Huang, X; Somerville, TDD; Jones, DR; Divecha, N; Somervaille, TCP				Jude, J. G.; Spencer, G. J.; Huang, X.; Somerville, T. D. D.; Jones, D. R.; Divecha, N.; Somervaille, T. C. P.			A targeted knockdown screen of genes coding for phosphoinositide modulators identifies PIP4K2A as required for acute myeloid leukemia cell proliferation and survival	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; BREAST-CANCER; PTDINS5P; EXPRESSION; KINASE; INHIBITION; APOPTOSIS; PATHWAY; RATHER	Given the importance of deregulated phosphoinositide (PI) signaling in leukemic hematopoiesis, genes coding for proteins that regulate PI metabolism may have significant and as yet unappreciated roles in leukemia. We performed a targeted knockdown (KD) screen of PI modulator genes in human acute myeloid leukemia (AML) cells and identified candidates required to sustain proliferation or prevent apoptosis. One of these, the lipid kinase phosphatidylinositol-5-phosphate 4-kinase, type II, alpha (PIP4K2A) regulates cellular levels of phosphatidylinositol-5-phosphate (Ptslns5P) and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5) P-2). We found PIP4K2A to be essential for the clonogenic and leukemia-initiating potential of human AML cells, and for the clonogenic potential of murine MLL-AF9 AML cells. Importantly, PIP4K2A is also required for the clonogenic potential of primary human AML cells. Its KD results in accumulation of the cyclin-dependent kinase inhibitors CDKN1A and CDKN1B, G1 cell cycle arrest and apoptosis. Both CDKN1A accumulation and apoptosis were partially dependent on activation of the mTOR pathway. Critically, however, PIP4K2A KD in normal hematopoietic stem and progenitor cells, both murine and human, did not adversely impact either clonogenic or multilineage differentiation potential, indicating a selective dependency that we suggest may be the consequence of the regulation of different transcriptional programs in normal versus malignant cells. Thus, PIP4K2A is a novel candidate therapeutic target in myeloid malignancy.	[Jude, J. G.; Divecha, N.] Univ Manchester, Canc Res UK Manchester Inst, Inositide Lab, Manchester, Lancs, England; [Jude, J. G.; Spencer, G. J.; Huang, X.; Somerville, T. D. D.; Somervaille, T. C. P.] Univ Manchester, Canc Res UK Manchester Inst, Leukaemia Biol Lab, Manchester, Lancs, England	Cancer Research UK; University of Manchester; Cancer Research UK; University of Manchester	Divecha, N (corresponding author), Canc Res UK Manchester Inst, Manchester M20 4BX, Lancs, England.	nullin.divecha@cruk.manchester.ac.uk; tim.somervaille@cruk.manchester.ac.uk	Huang, Xu/N-5609-2019	Huang, Xu/0000-0001-6706-199X; Jude, Julian/0000-0002-9091-9867; divecha, nullin/0000-0001-9695-6039; Somervaille, Tim/0000-0002-9188-4379	Cancer Research UK [C5759/A12328]; Cancer Research UK [19280] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	We thank Morgan Blaylock, Jeff Barry, Michael Hughes, Gail Bruder, Angela Cooke and Yaoyong Li for technical support. This work was supported by Cancer Research UK grant number C5759/A12328.	Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bertagnolo V, 2006, INT J ONCOL, V28, P863; Bertagnolo V, 2007, CARCINOGENESIS, V28, P1638, DOI 10.1093/carcin/bgm078; Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040; Bunney TD, 2010, NAT REV CANCER, V10, P342, DOI 10.1038/nrc2842; Davis MI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054127; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; Emerling BM, 2013, CELL, V155, P844, DOI 10.1016/j.cell.2013.09.057; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Goardon N, 2011, CANCER CELL, V19, P138, DOI 10.1016/j.ccr.2010.12.012; Grimwade D, 2010, BLOOD, V116, P354, DOI 10.1182/blood-2009-11-254441; Halstead JR, 2001, CURR BIOL, V11, P386, DOI 10.1016/S0960-9822(01)00121-X; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Huang X, 2014, LEUKEMIA, V28, P1081, DOI 10.1038/leu.2013.316; Jones DR, 2006, MOL CELL, V23, P685, DOI 10.1016/j.molcel.2006.07.014; Jones DR, 2013, NAT PROTOC, V8, P1058, DOI 10.1038/nprot.2013.040; Jones DR, 2013, FASEB J, V27, P1644, DOI 10.1096/fj.12-218842; Keune WJ, 2013, CANCER RES, V73, P6913, DOI 10.1158/0008-5472.CAN-13-0424; Keune WJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003223; Kubota Y, 2004, LEUKEMIA, V18, P1438, DOI 10.1038/sj.leu.2403402; Lemmon MA, 2008, NAT REV MOL CELL BIO, V9, P99, DOI 10.1038/nrm2328; LING LE, 1989, J BIOL CHEM, V264, P5080; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; Migliorini G, 2013, BLOOD, V122, P3298, DOI 10.1182/blood-2013-03-491316; Min YH, 2003, LEUKEMIA, V17, P995, DOI 10.1038/sj.leu.2402874; Myhre S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014002; Ndamukong I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013396; Polak R, 2012, BLOOD, V119, P911, DOI 10.1182/blood-2011-07-366203; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Saito Y, 2010, NAT BIOTECHNOL, V28, P275, DOI 10.1038/nbt.1607; Sarkes D, 2010, BIOCHEM J, V428, P375, DOI 10.1042/BJ20100129; Schulze H, 2006, BLOOD, V107, P3868, DOI 10.1182/blood-2005-07-2755; Somervaille TCP, 2003, BRIT J HAEMATOL, V120, P876, DOI 10.1046/j.1365-2141.2003.04204.x; Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020; Somervaille TCP, 2009, CELL STEM CELL, V4, P129, DOI 10.1016/j.stem.2008.11.015; Sykes SM, 2011, CELL, V146, P697, DOI 10.1016/j.cell.2011.07.032; Szczepanek J, 2012, J APPL GENET, V53, P83, DOI 10.1007/s13353-011-0073-x; van den Bout I, 2009, J CELL SCI, V122, P3837, DOI 10.1242/jcs.056127; Vergez F, 2012, CURR TOP MICROBIOL, V362, P163, DOI 10.1007/978-94-007-5025-8_8; Viale A, 2009, NATURE, V457, P51, DOI 10.1038/nature07618; Wilcox A, 2008, FEBS LETT, V582, P1391, DOI 10.1016/j.febslet.2008.03.022; Wiseman DH, 2014, ONCOGENE, V33, P3091, DOI 10.1038/onc.2013.269; Wouters BJ, 2007, BLOOD, V109, P389, DOI 10.1182/blood-2006-08-042325; Xu H, 2013, JNCI-J NATL CANCER I, V105, P733, DOI 10.1093/jnci/djt042; Xu Q, 2003, BLOOD, V102, P972, DOI 10.1182/blood-2002-11-3429; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zhang L, 2007, CLIN CANCER RES, V13, P5314, DOI 10.1158/1078-0432.CCR-06-2660; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220	51	39	42	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1253	1262		10.1038/onc.2014.77	http://dx.doi.org/10.1038/onc.2014.77			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24681948	Green Accepted			2022-12-28	WOS:000350687100005
J	Shin, YJ; Kumarasamy, V; Camacho, D; Sun, D				Shin, Y-J; Kumarasamy, V.; Camacho, D.; Sun, D.			Involvement of G-quadruplex structures in regulation of human RET gene expression by small molecules in human medullary thyroid carcinoma TT cells	ONCOGENE			English	Article							PROXIMAL PROMOTER REGION; POLYPYRIMIDINE/POLYPURINE TRACT; DNA; PROTOONCOGENE; TRANSCRIPTION; TRANSITION; ONCOGENE; PATHWAY; PROTEIN; SYSTEM	The RET (rearranged during transfection) proto-oncogene encodes a receptor tyrosine kinase for members of the glial cell line-derived neurotrophic factor family of extracellular signaling molecules. The activating germline point mutations in the RET, which are known to induce oncogenic activation of RET tyrosine kinase, are associated with the development of medullary thyroid carcinoma (MTC) and pathogenesis of multiple endocrine neoplasia type 2 (MEN2). The polypurine/ polypyrimidine tract in the proximal promoter region of the human RET gene (similar to 51 to similar to 33 relative to transcription start site) is essential for basal transcriptional activity of this gene. This tract consists of a guanine-rich sequence containing five runs of at least three contiguous guanines separated by one or more bases, conforming to a general motif capable of forming an intramolecular G-quadruplex. Here, we show that specific G-quadruplex structures formed in the RET promoter region act to repress the transcription of this gene, and transcription of this gene can be controlled by ligand-mediated G-quadruplex stabilization. In this study, NSC194598, a derivative of indeno[1,2,3-de] quinazoline, was found to be a novel G-quadruplex interactive agent that interfered with transcriptional activation of mutated RET gene in human medullary thyroid carcinoma TT cells. This compound significantly reduced endogenous RET protein levels and increased apoptosis in these cells. Our results provide further support for the idea that G-quadruplex structures may have a critical role in transcriptional regulation of the RET gene in vivo, providing insight into a novel strategy for transcriptional repression of this gene by small molecules.	[Shin, Y-J; Kumarasamy, V.; Camacho, D.; Sun, D.] Univ Arizona, Dept Pharmacol & Toxicol, Coll Pharm, Tucson, AZ 85721 USA; [Sun, D.] BIO5 Inst, Tucson, AZ USA; [Sun, D.] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA	University of Arizona; Arizona Center Cancer Care; University of Arizona	Sun, D (corresponding author), Univ Arizona, Dept Pharmacol & Toxicol, Coll Pharm, 1657 E Helen St, Tucson, AZ 85721 USA.	sun@pharmacy.arizona.edu			American Cancer Society [RSGM-12-046-01-CDD]	American Cancer Society(American Cancer Society)	We thank the American Cancer Society for support of this work (RSGM-12-046-01-CDD).	Andrew SD, 2000, GENE, V256, P283, DOI 10.1016/S0378-1119(00)00302-4; Andrew SD, 2002, GENE, V298, P9, DOI 10.1016/S0378-1119(02)00919-8; Bachetti T, 2005, GENE EXPRESSION, V12, P137, DOI 10.3727/000000005783992106; BELLOC F, 1994, CYTOMETRY, V17, P59, DOI 10.1002/cyto.990170108; Biffi G, 2013, NAT CHEM, V5, P182, DOI [10.1038/NCHEM.1548, 10.1038/nchem.1548]; Carter MT, 2001, CYTOGENET CELL GENET, V95, P169, DOI 10.1159/000059341; Dai JX, 2006, J AM CHEM SOC, V128, P1096, DOI 10.1021/ja055636a; de Groot JWB, 2006, ENDOCR REV, V27, P535, DOI 10.1210/er.2006-0017; EVANS T, 1986, J BIOL CHEM, V261, P4771; Gray DM, 2002, ENANTIOMER, V7, P49, DOI 10.1080/10242430212192; Guo K, 2007, J AM CHEM SOC, V129, P10220, DOI 10.1021/ja072185g; Han HY, 1999, NUCLEIC ACIDS RES, V27, P537, DOI 10.1093/nar/27.2.537; Lam EYN, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2792; Lodish MB, 2008, EXPERT REV ANTICANC, V8, P625, DOI 10.1586/14737140.8.4.625; Massoll N, 2004, CLIN LAB MED, V24, P49, DOI 10.1016/j.cll.2004.01.006; MCCARTHY JG, 1987, NUCLEIC ACIDS RES, V15, P8069, DOI 10.1093/nar/15.19.8069; Nair RR, 2008, MOL PHARMACOL, V73, P919, DOI 10.1124/mol.107.042606; Niccoli-Sire P, 2007, ANN ENDOCRINOL-PARIS, V68, P317, DOI 10.1016/j.ando.2007.04.005; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755; Phan AT, 2004, J AM CHEM SOC, V126, P8710, DOI 10.1021/ja048805k; Plaza-Menacho I, 2006, TRENDS GENET, V22, P627, DOI 10.1016/j.tig.2006.09.005; Rahman KM, 2012, BIOORG MED CHEM LETT, V22, P3006, DOI 10.1016/j.bmcl.2012.02.020; Runeberg-Roos P, 2007, ANN MED, V39, P572, DOI 10.1080/07853890701646256; Rustighi A, 2002, BIOCHEMISTRY-US, V41, P1229, DOI 10.1021/bi011666o; Sassano Maria Florencia, 2012, Open Med Chem J, V6, P20, DOI 10.2174/1874104501206010020; Siddiqui-Jain A, 2002, P NATL ACAD SCI USA, V99, P11593, DOI 10.1073/pnas.182256799; Simonsson T, 2001, BIOL CHEM, V382, P621, DOI 10.1515/BC.2001.073; Sun DK, 2011, NUCLEIC ACIDS RES, V39, P1256, DOI 10.1093/nar/gkq926; Sun DY, 2005, NUCLEIC ACIDS RES, V33, P6070, DOI 10.1093/nar/gki917; Todd AK, 2008, NUCLEIC ACIDS RES, V36, P2700, DOI 10.1093/nar/gkn078; Wells SA, 2009, CLIN CANCER RES, V15, P7119, DOI 10.1158/1078-0432.CCR-08-2742; Yan CH, 2004, FASEB J, V18, P540, DOI 10.1096/fj.03-0960fje	33	30	31	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1292	1299		10.1038/onc.2014.65	http://dx.doi.org/10.1038/onc.2014.65			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24662821				2022-12-28	WOS:000350687100009
J	Wang, Q; Shen, B; Chen, L; Zheng, P; Feng, H; Hao, Q; Liu, X; Liu, L; Xu, S; Chen, J; Teng, J				Wang, Q.; Shen, B.; Chen, L.; Zheng, P.; Feng, H.; Hao, Q.; Liu, X.; Liu, L.; Xu, S.; Chen, J.; Teng, J.			Extracellular calumenin suppresses ERK1/2 signaling and cell migration by protecting fibulin-1 from MMP-13-mediated proteolysis	ONCOGENE			English	Article							MATRIX METALLOPROTEINASES; MOLECULAR-CLONING; PROTEIN; EXPRESSION; CANCER; PROGRESSION; FIBRONECTIN; MECHANISM; CLEAVAGE; ADHESION	Extracellular proteins are vital for cell activities, such as cell migration. Calumenin is highly conserved among eukaryotes, but its functions are largely unclear. Here, we identify extracellular calumenin as a suppressor of cell migration and tumor metastasis. Calumenin binds to and stabilizes fibulin-1, leading to inactivation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) signaling. We further identify the minimal functional domain of calumenin (amino acids 74-138 and 214-280). Depletion of calumenin induces fibulin-1-and phospho-ERK1/2 (pERK1/2)-dependent promotion of cell migration. Consistently, in hepatocellular and pancreatic carcinoma, both calumenin and fibulin-1 are downregulated. Furthermore, we show that matrix metalloproteinase13 (MMP-13) proteolyzes fibulin-1 and that calumenin protects fibulin-1 from cleavage by MMP-13. Calumenin, together with fibulin-1, also interacts with fibronectin and depends on both syndecan-4 and a5a1-integrin to suppress ERK1/2 signaling and inhibit cell migration. Thus, extracellular calumenin regulates fibulin-1 to have crucial roles in ERK1/2 signaling and cell migration.	[Wang, Q.; Shen, B.; Chen, L.; Zheng, P.; Feng, H.; Hao, Q.; Liu, X.; Liu, L.; Xu, S.; Chen, J.; Teng, J.] Peking Univ, State Key Lab Biomembrane & Membrane Bioengn, Key Lab Cell Proliferat & Differentiat, Minist Educ,Coll Life Sci,Dept Cell Biol & Genet, Beijing 100871, Peoples R China; [Chen, J.] Peking Univ, Ctr Quantitat Biol, Beijing 100871, Peoples R China	Peking University; Peking University	Chen, J (corresponding author), Peking Univ, State Key Lab Biomembrane & Membrane Bioengn, Key Lab Cell Proliferat & Differentiat, Minist Educ,Coll Life Sci, 5 Yiheyuan Rd, Beijing 100871, Peoples R China.	chenjg@pku.edu.cn; junlinteng@pku.edu.cn		Wang, Qiao/0000-0001-6416-1733; Shen, Birong/0000-0002-1208-506X; Zheng, Pengli/0000-0002-3797-4023	National Natural Science Foundation of China [31271424]; Major State Basic Research Development Program of China (973 program) [2010CB833705]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major State Basic Research Development Program of China (973 program)(National Basic Research Program of China)	We thank Dr W Scott Argraves at the Medical University of South Carolina for kindly providing anti-fibulin-1 antibody (3A11). The lentivirus system is a kind gift from Dr Jincai Luo at Peking University. We also thank Dr Li Yu and Dr Xiaofeng Wang at Tsinghua University, and Dr Zhengfan Jiang at Peking University for helpful discussion. We also thank Dr IC Bruce at Zhejiang University and Dr Xiaolei Su at the University of California, San Francisco, for reading the manuscript. This work was supported by the National Natural Science Foundation of China (31271424) and the Major State Basic Research Development Program of China (973 program) (2010CB833705).	Cooley MA, 2012, DEV DYNAM, V241, P303, DOI 10.1002/dvdy.23716; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Ding SJ, 2004, PROTEOMICS, V4, P982, DOI 10.1002/pmic.200300653; Duncia JV, 1998, BIOORG MED CHEM LETT, V8, P2839, DOI 10.1016/S0960-894X(98)00522-8; Feng H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.403; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Honore B, 2009, BIOESSAYS, V31, P262, DOI 10.1002/bies.200800186; Hseu MJ, 1999, FEBS LETT, V445, P440, DOI 10.1016/S0014-5793(99)00177-5; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009; Jones CB, 2003, CARDIOVASC RES, V59, P812, DOI 10.1016/S0008-6363(03)00516-9; Julovi SM, 2011, J ORTHOP RES, V29, P258, DOI 10.1002/jor.21216; Kanda M, 2011, MOL CARCINOGEN, V50, P571, DOI 10.1002/mc.20735; Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Klein T, 2011, AMINO ACIDS, V41, P271, DOI 10.1007/s00726-010-0689-x; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Labat-Robert J, 2012, PATHOL BIOL, V60, P15, DOI 10.1016/j.patbio.2011.10.003; Leeman MF, 2002, CRIT REV BIOCHEM MOL, V37, P149, DOI 10.1080/10409230290771483; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010; Lu Y, 2011, P NATL ACAD SCI USA, V108, P2957, DOI 10.1073/pnas.1009395108; Martinez-Quiles N, 2004, MOL CELL BIOL, V24, P5269, DOI 10.1128/MCB.24.12.5269-5280.2004; Mendoza MC, 2011, MOL CELL, V41, P661, DOI 10.1016/j.molcel.2011.02.031; Mikula M, 2010, FUNCT INTEGR GENOMIC; Moll F, 2002, ONCOGENE, V21, P1097, DOI 10.1038/sj.onc.1205171; Morgan MR, 2007, NAT REV MOL CELL BIO, V8, P957, DOI 10.1038/nrm2289; Morgan MR, 2013, DEV CELL, V24, P472, DOI 10.1016/j.devcel.2013.01.027; Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; Pupa SM, 2004, ONCOGENE, V23, P2153, DOI 10.1038/sj.onc.1207323; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; Roger P, 1998, AM J PATHOL, V153, P1579, DOI 10.1016/S0002-9440(10)65746-X; Shen CY, 2002, LUNG CANCER, V38, P235, DOI 10.1016/S0169-5002(02)00300-8; Teng JL, 2005, NAT CELL BIOL, V7, P474, DOI 10.1038/ncb1249; Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273; Twal WO, 2001, J CELL SCI, V114, P4587; Vandenbroucke RE, 2013, EMBO MOL MED, V5, P1000, DOI 10.1002/emmm.201202100; Vizoso FJ, 2006, SCAND J GASTROENTERO, V41, P1050, DOI 10.1080/00365520600554667; Voisin SN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016352; Vorum H, 1999, EXP CELL RES, V248, P473, DOI 10.1006/excr.1999.4431; Vorum H, 1998, BBA-PROTEIN STRUCT M, V1386, P121, DOI 10.1016/S0167-4838(98)00089-2; Wang Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035344; Wang Qiao, 2012, Front Biosci (Elite Ed), V4, P998, DOI 10.2741/E435; Wang QA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013252; Wang QA, 2010, CELL RES, V20, P713, DOI 10.1038/cr.2010.47; Wang XF, 2009, P NATL ACAD SCI USA, V106, P21288, DOI 10.1073/pnas.0908151106; Williams SA, 2009, MOL BIOL CELL, V20, P1141, DOI 10.1091/mbc.E08-06-0621; Wu WG, 2002, CLIN EXP METASTAS, V19, P319, DOI 10.1023/A:1015515119300; Xie L, 2008, EXP BIOL MED, V233, P155, DOI 10.3181/0706-RM-167; Yabe D, 1998, GENOMICS, V49, P331, DOI 10.1006/geno.1998.5245; Yang M, 2000, P NATL ACAD SCI USA, V97, P1206, DOI 10.1073/pnas.97.3.1206; Zhang H, 2008, ACTA BIOCH BIOPH SIN, V40, P375, DOI 10.1111/j.1745-7270.2008.00420.x; Zhang XR, 2012, CARTILAGE, V3, P267, DOI 10.1177/1947603511435273; Zigrino P, 2009, J INVEST DERMATOL, V129, P2686, DOI 10.1038/jid.2009.130	55	27	30	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					1006	1018		10.1038/onc.2014.52	http://dx.doi.org/10.1038/onc.2014.52			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632605				2022-12-28	WOS:000350121300007
J	Kim, G; Ouzounova, M; Quraishi, AA; Davis, A; Tawakkol, N; Clouthier, SG; Malik, F; Paulson, AK; D'Angelo, RC; Korkaya, S; Baker, TL; Esen, ES; Prat, A; Liu, S; Kleer, CG; Thomas, DG; Wicha, MS; Korkaya, H				Kim, G.; Ouzounova, M.; Quraishi, A. A.; Davis, A.; Tawakkol, N.; Clouthier, S. G.; Malik, F.; Paulson, A. K.; D'Angelo, R. C.; Korkaya, S.; Baker, T. L.; Esen, E. S.; Prat, A.; Liu, S.; Kleer, C. G.; Thomas, D. G.; Wicha, M. S.; Korkaya, H.			SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model	ONCOGENE			English	Article						breast cancer; triple negative subtype; p53; PTEN; inflammatory cytokine; IL6	SOCS3; CELLS; GENE; MECHANISMS; IDENTIFICATION; ACTIVATION; EXPRESSION; RESISTANCE; THERAPY; DISEASE	Somatic mutations or deletions of TP53 and PTEN in ductal carcinoma in situ lesions have been implicated in progression to invasive ductal carcinomas. A recent molecular and mutational analysis of breast cancers revealed that inactivation of tumor suppressors, p53 and PTEN, are strongly associated with triple negative breast cancer. In addition, these tumor suppressors have important roles in regulating self-renewal in normal and malignant stem cells. To investigate their role in breast carcinogenesis, we knocked down these genes in human mammary cells and in non-transformed MCF10A cells. p53 and PTEN knockdown synergized to activate pro-inflammatory interleukin-6 (IL6)/Stat3/nuclear factor kappa B signaling. This resulted in generation of highly metastatic epithelial-to-mesenchymal transition-like cancer stem cells resulting in tumors whose gene expression profile mimicked that found in basal/claudin-low molecular subtype within the triple negative breast tumors. Constitutive activation of this loop in transformed cells was dependent on proteolytic degradation of suppressor of cytokine signaling 3 (SOCS3) resulting in low levels of this protein in basal/claudin-low cell lines and primary tumors. In non-transformed cells, transient activation of the IL6 inflammatory loop induced SOCS3 expression leading to pathway inactivation. In transformed cells, enforced expression of SOCS3 or interfering with IL6 pathway via IL6R blockade inhibited tumor growth and metastasis in mouse xenograft models. Furthermore, circulating tumor cells were significantly reduced in tumor-bearing animals when treated with anti-IL6R antibodies. These studies uncover important connections between inflammation and carcinogenesis and suggest that blocking pro-inflammatory cytokines may be utilized as an attractive strategy to target triple negative breast tumors, which currently lacks molecularly targeted therapies.	[Kim, G.; Ouzounova, M.; Quraishi, A. A.; Davis, A.; Tawakkol, N.; Clouthier, S. G.; Malik, F.; Paulson, A. K.; D'Angelo, R. C.; Korkaya, S.; Baker, T. L.; Esen, E. S.; Liu, S.; Wicha, M. S.; Korkaya, H.] Univ Michigan, Dept Internal Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Kim, G.] CHA Univ, CHA Bundang Med Ctr, Dept Pathol, Songnam 463712, Gyeonggi, South Korea; [Malik, F.] Indian Inst Integrat Med, Dept Canc Pharmacol, Jammu, India; [Prat, A.] Vall dHebron Inst Oncol, Translat Genom Grp, Barcelona, Spain; [Kleer, C. G.; Thomas, D. G.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA	University of Michigan System; University of Michigan; Pochon Cha University; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Integrative Medicine (IIIM); Vall d'Hebron Institut d'Oncologia (VHIO); University of Michigan System; University of Michigan	Korkaya, H (corresponding author), Georgia Regents Univ, Ctr Canc, Dept Biochem & Mol Biol, 1410 Laney Walker Blvd CN2136, Augusta, GA 30912 USA.	hkorkaya@gru.edu	Ouzounova, Maria/B-7189-2014; Korkaya, Hasan/GRY-1016-2022; Wicha, Max/AAE-7268-2019; Liu, Suling/N-2796-2013; esen, elif serap/GPP-6880-2022; Paulson, Amanda/AAX-2334-2021; liu, suling/AAF-5249-2019; Korkaya, Hasan/ABD-6282-2020	Ouzounova, Maria/0000-0001-8934-3461; Liu, Suling/0000-0002-0475-0242; liu, suling/0000-0002-0475-0242; Korkaya, Hasan/0000-0002-0719-5862; Malik, Fayaz/0000-0001-5475-6610	NIH [CA101860, CA129765]; Breast Cancer Research Foundation; GRU Cancer Center; Komen grant [KG11230]; NATIONAL CANCER INSTITUTE [U01CA154224, R01CA125577, R01CA129765, R01CA101860] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; GRU Cancer Center; Komen grant(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the NIH grants; CA101860 and CA129765 and Breast Cancer Research Foundation grant to MSW and by the GRU Cancer Center and the Komen grant; KG11230 to HK.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Babon JJ, 2012, IMMUNITY, V36, P239, DOI 10.1016/j.immuni.2011.12.015; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Dandrea M, 2009, NUCLEIC ACIDS RES, V37, P6681, DOI 10.1093/nar/gkp723; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Keller PJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2755; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Li Y, 2012, CARCINOGENESIS, V33, P1889, DOI 10.1093/carcin/bgs214; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Niwa Y, 2005, ONCOGENE, V24, P6406, DOI 10.1038/sj.onc.1208788; Ogata H, 2006, GASTROENTEROLOGY, V131, P179, DOI 10.1053/j.gastro.2006.04.025; Ohsugi Y, 2008, EXPERT OPIN BIOL TH, V8, P669, DOI 10.1517/14712598.8.5.669 ; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Sasi W, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-178; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Sommer U, 2005, J BIOL CHEM, V280, P31478, DOI 10.1074/jbc.M506008200; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Yao Z, 2010, P NATL ACAD SCI USA, V107, P15535, DOI 10.1073/pnas.1009472107; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; Ying MZ, 2010, J CANCER RES CLIN, V136, P1617, DOI 10.1007/s00432-010-0819-6; Yoshimura A, 2007, NAT REV IMMUNOL, V7, P454, DOI 10.1038/nri2093	33	50	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					671	680		10.1038/onc.2014.4	http://dx.doi.org/10.1038/onc.2014.4			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24531711	Bronze, Green Accepted			2022-12-28	WOS:000348853800001
J	Kuhnemuth, B; Muhlberg, L; Schipper, M; Griesmann, H; Neesse, A; Milosevic, N; Wissniowski, T; Buchholz, M; Gress, TM; Michl, P				Kuehnemuth, B.; Muehlberg, L.; Schipper, M.; Griesmann, H.; Neesse, A.; Milosevic, N.; Wissniowski, T.; Buchholz, M.; Gress, T. M.; Michl, P.			CUX1 modulates polarization of tumor-associated macrophages by antagonizing NF-kappa B signaling	ONCOGENE			English	Article						CUX1; macrophage polarization; NF-kappa B; pancreatic cancer	GROWTH-FACTOR-BETA; TRANSCRIPTION FACTOR; PANCREATIC-CANCER; PROTEIN FUNCTION; MOUSE MODELS; GENE; ACTIVATION; DISTINCT; INFLAMMATION; EXPRESSION	Many solid cancers including pancreatic ductal adenocarcinoma (PDAC) are characterized by an extensive stromal reaction that is accompanied by infiltrating tumor-associated macrophages (TAMs). The role of TAMs in malignant tumors is only partially understood. Previously, we identified the transcription factor CUX1 as an important mediator of tumor progression in PDAC. Interestingly, we found that CUX1 is highly expressed not only in tumor cells but also in TAMs. On the basis of these data, we aimed to elucidate the effects of CUX1 in TAMs in vitro and in vivo. We analyzed the effects of CUX1 on cytokine expression using overexpression and knockdown strategies. The cytokine regulation by CUX1 was further assessed by reporter assays, DNA pulldown experiments and chromatin-immunoprecipitation. CUX1 expression in TAMs was analyzed in human pancreatic cancer tissues and in a genetic mouse model. Immunohistochemical analysis revealed strong expression levels of CUX1 in a distinct subset of TAMs in human PDAC tissues. Furthermore, its expression increased during tumor progression in a genetic mouse model of PDAC. Profiling experiments showed that CUX1 downregulates several NF-kappa B-regulated chemokines such as CXCL10, which have been associated with M1 polarization and inhibition of angiogenesis and tumor progression. We could demonstrate that CUX1 interacts with NF-kappa B p65, leading to reduced binding of NF-kappa B p65 to the chemokine promoters. In addition, CUX1 reduces acetylation of NF-kappa B p65 at K310 by recruiting HDAC1. Functionally, CUX1 expression in TAMs antagonizes T-cell attraction and enhances angiogenesis in vitro. We identified CUX1 as an important modulator of the TAMs phenotype and function by modulating NF-kappa B-dependent cytokines.	[Kuehnemuth, B.; Muehlberg, L.; Griesmann, H.; Neesse, A.; Milosevic, N.; Wissniowski, T.; Buchholz, M.; Gress, T. M.; Michl, P.] Univ Marburg, Univ Hosp, Dept Gastroenterol & Endocrinol, D-35043 Marburg, Germany; [Schipper, M.] Univ Marburg, Sch Med, Dept Biol, D-35043 Marburg, Germany	Philipps University Marburg; Philipps University Marburg	Michl, P (corresponding author), Univ Marburg, Dept Gastroenterol, Baldinger Str, D-35043 Marburg, Germany.	michlp@med.uni-marburg.de	Michl, Patrick/HDN-4172-2022; Michl, Patrick/AAG-3987-2021	Gress, Thomas/0000-0002-9333-5461	European Commisson FP7 (Collaborative Project 'EPC-TM-Net); Deutsche Forschungsgemeinschaft (DFG); LOEWE initiative of the state of Hessen; Behring-Roentgen Foundation; Deutsche Krebshilfe	European Commisson FP7 (Collaborative Project 'EPC-TM-Net); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); LOEWE initiative of the state of Hessen; Behring-Roentgen Foundation; Deutsche Krebshilfe(Deutsche Krebshilfe)	This work was supported in part by grants of the European Commisson FP7 grant (Collaborative Project 'EPC-TM-Net, to PM, AN and TMG), Deutsche Forschungsgemeinschaft (DFG) (to PM), the LOEWE initiative of the state of Hessen, the Behring-Roentgen Foundation (to PM), and the Deutsche Krebshilfe (to PM). This publication reflects only the authors' views. The European Community is not liable for any use that may be made of the information herein.	Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baumgart S, 2012, GASTROENTEROLOGY, V142, P388, DOI 10.1053/j.gastro.2011.11.001; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Beatty GL, 2011, SCIENCE, V331, P1612, DOI 10.1126/science.1198443; Benson DD, 2012, AM J PHYSIOL-REG I, V302, pR1067, DOI 10.1152/ajpregu.00320.2011; Biswas SK, 2006, BLOOD, V107, P2112, DOI 10.1182/blood-2005-01-0428; Biswas SK, 2008, J IMMUNOL, V180, P2011, DOI 10.4049/jimmunol.180.4.2011; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; BOGDAN C, 1992, J BIOL CHEM, V267, P23301; Cadieux C, 2009, CANCER RES, V69, P7188, DOI 10.1158/0008-5472.CAN-08-4899; Catt D, 1999, BLOOD, V94, P3151, DOI 10.1182/blood.V94.9.3151.421k38_3151_3160; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; Clark CE, 2009, CANCER LETT, V279, P1, DOI 10.1016/j.canlet.2008.09.037; Darsigny M, 2010, INFLAMM BOWEL DIS, V16, P1739, DOI 10.1002/ibd.21274; De Vos J, 2002, ONCOGENE, V21, P6848, DOI 10.1038/sj.onc.1205868; Fragiadaki M, 2011, MOL BIOL CELL, V22, P1836, DOI 10.1091/mbc.E10-08-0669; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; HARADA R, 1994, J BIOL CHEM, V269, P2062; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Huang LY, 2009, J CLIN MICROBIOL, V47, P3427, DOI 10.1128/JCM.00373-09; Huth J, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-24; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kedinger V, 2009, J BIOL CHEM, V284, P27701, DOI 10.1074/jbc.M109.031849; Kleeff J, 2007, INT J CANCER, V121, P699, DOI 10.1002/ijc.22871; Kurahara H, 2011, J SURG RES, V167, pE211, DOI 10.1016/j.jss.2009.05.026; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; Li SD, 2000, P NATL ACAD SCI USA, V97, P7166, DOI 10.1073/pnas.130028697; Liu ML, 2011, ONCOL LETT, V2, P583, DOI 10.3892/ol.2011.300; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Mahadevan D, 2007, MOL CANCER THER, V6, P1186, DOI 10.1158/1535-7163.MCT-06-0686; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Menen RS, 2012, IN VIVO, V26, P565; Michl P, 2005, CANCER CELL, V7, P521, DOI 10.1016/j.ccr.2005.05.018; Mihaly Z, 2013, BREAST CANCER RES TR, V140, P219, DOI 10.1007/s10549-013-2622-y; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Neesse A, 2013, P NATL ACAD SCI USA, V110, P12325, DOI 10.1073/pnas.1300415110; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; Nirodi C, 2001, J BIOL CHEM, V276, P26122, DOI 10.1074/jbc.M102872200; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Ripka S, 2010, GUT, V59, P1101, DOI 10.1136/gut.2009.189720; Saccani A, 2006, CANCER RES, V66, P11432, DOI 10.1158/0008-5472.CAN-06-1867; Sansregret L, 2008, GENE, V412, P84, DOI 10.1016/j.gene.2008.01.017; Schmitz ML, 2004, CHEMBIOCHEM, V5, P1348, DOI 10.1002/cbic.200400144; Sharma M, 2009, GENE, V439, P87, DOI 10.1016/j.gene.2009.03.014; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Sica A, 2000, J IMMUNOL, V164, P762, DOI 10.4049/jimmunol.164.2.762; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; Ueda Y, 2007, MELANOMA RES, V17, P91, DOI 10.1097/CMR.0b013e3280a60888; Werner F, 2000, J BIOL CHEM, V275, P36653, DOI 10.1074/jbc.M004536200; Yoshikawa K, 2012, CANCER SCI, V103, P2012, DOI 10.1111/j.1349-7006.2012.02411.x; Zhang WZ, 2002, AM J PHYSIOL-RENAL, V283, pF904, DOI 10.1152/ajprenal.00156.2002	60	23	24	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					177	187		10.1038/onc.2013.530	http://dx.doi.org/10.1038/onc.2013.530			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24336331				2022-12-28	WOS:000347790500005
J	Mukherjee, M; Ge, G; Zhang, N; Edwards, DG; Sumazin, P; Sharan, S; Rao, PH; Medina, D; Pati, D				Mukherjee, M.; Ge, G.; Zhang, N.; Edwards, D. G.; Sumazin, P.; Sharan, S. K.; Rao, P. H.; Medina, D.; Pati, D.			MMTV-Espl1 transgenic mice develop aneuploid, estrogen receptor alpha (ER alpha)-positive mammary adenocarcinomas	ONCOGENE			English	Article						Separase; Espl1; aneuploidy; p53; cohesin; mammary tumor animal model	HUMAN BREAST-CANCER; CHROMOSOMAL INSTABILITY; MOLECULAR CHARACTERIZATION; CLONAL EVOLUTION; GENE-EXPRESSION; TUMORS; TUMORIGENESIS; SEPARASE; CELLS; PROTEIN	Separase, a protease encoded by the ESPL1 gene, cleaves the chromosomal cohesin during mitosis. Separase protein and transcripts are overexpressed in a wide range of human cancers. To investigate the physiological consequence of Separase overexpression in animals, we have generated a transgenic MMTV-Espl1 mouse model that overexpresses Separase protein in the mammary glands. MMTV-Espl1 mice in a C57BL/6 genetic background develop aggressive, highly aneuploid and estrogen receptor alpha-positive (ER alpha-) mammary adenocarcinomas with an 80% penetrance. The mammary tumors caused by overexpression of Separase, alone or combined with p53 heterozygosity, in mammary epithelium mimic several aspects of the most aggressive forms of human breast cancer, including high levels of genetic instability, cell cycle defects, poor differentiation, distant metastasis and metaplasia. Histopathologically, MMTV-Espl1 tumors are highly heterogeneous showing features of both luminal as well as basal subtypes of breast cancers, with aggressive disease phenotype. In addition to aneuploidy, Separase overexpression results in chromosomal instability (CIN) including premature chromatid separation (PCS), lagging chromosomes, anaphase bridges, micronuclei, centrosome amplification, multinucleated cells, gradual accumulation of DNA damage and progressive loss of tumor suppressors p53 and cadherin gene loci. These results suggest that Separase-overexpressing mammary cells are not only susceptible to chromosomal missegregation-induced aneuploidy but also other genetic instabilities including DNA damage and loss of key tumor suppressor gene loci, which in combination can initiate tumorigenesis and disease progression.	[Mukherjee, M.; Ge, G.; Zhang, N.; Sumazin, P.; Rao, P. H.; Pati, D.] Texas Childrens Canc Ctr, Dep Pediat Hematol Oncol, Houston, TX USA; [Edwards, D. G.; Medina, D.; Pati, D.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Sharan, S. K.] NCI, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21701 USA	Texas Children's Cancer Center; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pati, D (corresponding author), Baylor Coll Med, Dept Pediat, 6621 Fannin St,MC3-3320 1102 Bates St, Houston, TX 77030 USA.	pati@bcm.edu	Sumazin, Pavel/AAE-6607-2020	Sumazin, Pavel/0000-0002-1215-4977	National Cancer Institute [1RO1 CA109330, 1RO1 CA109478]; NATIONAL CANCER INSTITUTE [R01CA109478, R01CA109330, ZIABC010387] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the grants from the National Cancer Institute (1RO1 CA109330 and 1RO1 CA109478) to D. Pati.	Arnold A, 2005, J CLIN ONCOL, V23, P4215, DOI 10.1200/JCO.2005.05.064; Berman J, 2010, NATURE, V468, P183, DOI 10.1038/468183a; Blackburn AC, 2004, CANCER RES, V64, P5140, DOI 10.1158/0008-5472.CAN-03-3435; Cardiff RD, 2010, J MAMMARY GLAND BIOL, V15, P225, DOI 10.1007/s10911-010-9184-y; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Duesberg P, 1998, P NATL ACAD SCI USA, V95, P13692, DOI 10.1073/pnas.95.23.13692; Fantozzi A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1530; Ganmore I, 2009, HUM MOL GENET, V18, pR84, DOI 10.1093/hmg/ddp084; Gao CF, 2007, P NATL ACAD SCI USA, V104, P8995, DOI 10.1073/pnas.0700631104; Han S, 1999, BREAST CANCER RES TR, V55, P161; Heilig CE, 2010, J CELL MOL MED, V14, P895, DOI 10.1111/j.1582-4934.2009.00905.x; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Holland AJ, 2012, EMBO REP, V13, P501, DOI 10.1038/embor.2012.55; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; Janssen A, 2011, SCIENCE, V333, P1895, DOI 10.1126/science.1210214; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kuukasjarvi T, 1997, CANCER RES, V57, P1597; Lacroix M, 2004, MOL CELL ENDOCRINOL, V219, P1, DOI 10.1016/j.mce.2004.02.021; Lacroix M, 2004, ENDOCR-RELAT CANCER, V11, P497, DOI 10.1677/erc.1.00758; Lu XD, 2011, MOL CANCER RES, V9, P430, DOI 10.1158/1541-7786.MCR-10-0277; McClelland SE, 2009, CELL CYCLE, V8, P3262, DOI 10.4161/cc.8.20.9690; McGranahan N, 2012, EMBO REP, V13, P528, DOI 10.1038/embor.2012.61; MEDINA D, 2000, METHODS MAMMARY GLAN, P137; Meyer R, 2009, CLIN CANCER RES, V15, P2703, DOI 10.1158/1078-0432.CCR-08-2454; Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200; Mukherjee M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022167; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nasmyth K, 2009, ANNU REV GENET, V43, P525, DOI 10.1146/annurev-genet-102108-134233; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; Panigrahi AK, 2009, CRIT REV ONCOL HEMAT, V72, P181, DOI 10.1016/j.critrevonc.2008.12.002; Pariente N, 2012, EMBO REP, V13, P472, DOI 10.1038/embor.2012.66; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Pati D, 2004, CANCER RES, V64, P5608, DOI 10.1158/0008-5472.CAN-03-0629; Pavelka N, 2010, NATURE, V468, P321, DOI 10.1038/nature09529; Prat A, 2013, ONCOLOGIST, V18, P123, DOI 10.1634/theoncologist.2012-0397; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Radaelli E, 2009, FUTURE ONCOL, V5, P1113, DOI [10.2217/fon.09.93, 10.2217/FON.09.93]; Sheltzer JM, 2011, TRENDS GENET, V27, P446, DOI 10.1016/j.tig.2011.07.003; Shepard JL, 2007, GENE DEV, V21, P55, DOI 10.1101/gad.1470407; Solomon DA, 2011, SCIENCE, V333, P1039, DOI 10.1126/science.1203619; SONNENBERG A, 1987, EMBO J, V6, P121, DOI 10.1002/j.1460-2075.1987.tb04728.x; Stefansson OA, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2334; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Swanton C, 2009, P NATL ACAD SCI USA, V106, P8671, DOI 10.1073/pnas.0811835106; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Williams BR, 2008, SCIENCE, V322, P703, DOI 10.1126/science.1160058; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; Zhang NG, 2008, P NATL ACAD SCI USA, V105, P13033, DOI 10.1073/pnas.0801610105	50	40	40	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2014	33	48					5511	5522		10.1038/onc.2013.493	http://dx.doi.org/10.1038/onc.2013.493			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZO	24276237	Green Accepted			2022-12-28	WOS:000346087900004
J	Chang, YW; Mai, RT; Fang, WH; Lin, CC; Chiu, CC; Lee, YHW				Chang, Y-W; Mai, R-T; Fang, W-H; Lin, C-C; Chiu, C-C; Lee, Y-H Wu			YB-1 disrupts mismatch repair complex formation, interferes with MutS alpha recruitment on mismatch and inhibits mismatch repair through interacting with PCNA	ONCOGENE			English	Article						YB-1; PCNA; PIP-box; mismatch repair; MutS alpha; genome instability	CELL NUCLEAR ANTIGEN; VIRUS CORE PROTEIN; BOX BINDING-PROTEIN; MICROSATELLITE INSTABILITY; ALKYLATING-AGENTS; MISPAIRED BASES; DNA-DAMAGE; GLIOBLASTOMA-MULTIFORME; GENE-EXPRESSION; REPLICATION	Y-box binding protein-1 (YB-1) is highly expressed in tumors and it participates in various cellular processes. Previous studies indicated that YB-1 binds to mispaired DNA and interacts with several mismatch repair (MMR)-related factors. However, its role in the MMR system remains undefined. Here, we found that YB-1 represses mutS homolog 6 (MSH6)-containing MMR complex formation and reduces MutS alpha mismatch binding activity by disrupting interactions among MMR-related factors. In an effort to elucidate how YB-1 exerts this inhibitory effect, we have identified two functional proliferating cell nuclear antigen (PCNA)interacting protein (PIP)-boxes that mediate YB-1/PCNA interaction and locate within the C-terminal region of YB-1. This interaction is critical for the regulatory role of YB-1 in repressing MutSa mismatch binding activity, disrupting MutS alpha/PCNA/G/T heteroduplex ternary complex formation and inhibiting in vitro MMR activity. The differential regulation of 3' and 5' nick-directed MMR activity by YB-1 was also observed. Moreover, YB-1 overexpression is associated with the alteration of microsatellite pattern and the enhancement of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced and spontaneous mutations. Furthermore, upregulation of other PIP-box-containing proteins, such as myeloid cell leukemia-1 (Mcl-1) and inhibitor of growth protein 1b (ING1b), has no impact on MMR complex formation and mutation accumulation, thus revealing the significant effect of YB-1 on regulating the MMR system. In conclusion, our study suggests that YB-1 functions as a PCNA-interacting factor to exert its regulatory role on the MMR process and involves in the induction of genome instability, which may partially account for the oncogenic potential of YB-1.	[Chang, Y-W; Mai, R-T; Lin, C-C; Chiu, C-C; Lee, Y-H Wu] Natl Yang Ming Univ, Sch Life Sci, Inst Biochem & Mol Biol, Taipei 112, Taiwan; [Mai, R-T; Lee, Y-H Wu] Natl Chiao Tung Univ, Coll Biol Sci & Technol, Dept Biol Sci & Technol, Hsinchu 300, Taiwan; [Fang, W-H] Natl Taiwan Univ Hosp, Dept Clin Lab Sci & Med Biotechnol, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Taiwan University; National Taiwan University Hospital	Lee, YHW (corresponding author), Natl Chiao Tung Univ, Coll Biol Sci & Technol, Dept Biol Sci & Technol, 1001 Ta Hsueh Rd, Hsinchu 300, Taiwan.	yhwulee@nctu.edu.tw		FANG, WOEI-HORNG/0000-0003-4728-5931	National Health Research Institute [NHRI-EX100-10014BI, NHRI-EX101-10014BI, NHRI-EX102-10014BI]; National Science Council [NSC-94-2320-B-010-005, NSC-95-2320-B-010-049-MY3, NSC-97-2320-B-010-014-MY3, NSC-97-2320-B-009-003-MY3, NSC-100-2320-B-009-007-MY3, NSC-101-2811-B-009-006, NSC-102-2811-B-009-007]; National Yang-Ming University; National Chiao-Tung University; Ministry of Education, Taiwan, Republic of China	National Health Research Institute(National Health Research Institutes - Taiwan); National Science Council(Ministry of Science and Technology, Taiwan); National Yang-Ming University; National Chiao-Tung University; Ministry of Education, Taiwan, Republic of China(Ministry of Education, Taiwan)	This study was supported by the following grants to Dr Yan-Hwa Wu Lee: the National Health Research Institute (NHRI-EX100-10014BI, NHRI-EX101-10014BI and NHRI-EX102-10014BI), the National Science Council (NSC-94-2320-B-010-005, NSC-95-2320-B-010-049-MY3, NSC-97-2320-B-010-014-MY3, NSC-97-2320-B-009-003-MY3, NSC-100-2320-B-009-007-MY3, NSC-101-2811-B-009-006 and NSC-102-2811-B-009-007) and the 'Aim for the Top University Program' of the National Yang-Ming University, the National Chiao-Tung University and the Ministry of Education, Taiwan, Republic of China. We thank Dr Tsung-Sheng Su and Dr Tzu-Hao Cheng for helpful discussions and suggestions, Dr Josef Jiricny, Dr Hsin-Fang Yang-Yen and Dr Zee-Fen Chang for kindly providing plasmids used in this study, Dr Shr-Jeng Leu for sharing experiences on baculovirus expression system and Dr Li-Li Li for critical reading and comments on this manuscript. We acknowledge the High-throughput Genome Analysis Core Facility of National Core Facility Program for Biotechnology, Taiwan (NSC 101-2319-B-010-001), for capillary electrophoresis and DNA sequencing.	Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Bignami M, 2000, MUTAT RES-REV MUTAT, V462, P71, DOI 10.1016/S1383-5742(00)00016-8; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; Casorelli I, 2008, ANTI-CANCER AGENT ME, V8, P368, DOI 10.2174/187152008784220276; Chen C, 1999, MOL CELL BIOL, V19, P7801; Chou CH, 2006, MOL BIOL CELL, V17, P3952, DOI 10.1091/mbc.E06-04-0319; Christmann M, 2000, J BIOL CHEM, V275, P36256, DOI 10.1074/jbc.M005377200; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Constantin N, 2005, J BIOL CHEM, V280, P39752, DOI 10.1074/jbc.M509701200; de Souza-Pinto NC, 2009, DNA REPAIR, V8, P704, DOI 10.1016/j.dnarep.2009.01.021; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Dietmaier W, 1997, CANCER RES, V57, P4749; Drobinskaya I, 2005, ANTICANCER RES, V25, P3251; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Dzantiev L, 2004, MOL CELL, V15, P31, DOI 10.1016/j.molcel.2004.06.016; Eliseeva IA, 2011, BIOCHEMISTRY-MOSCOW+, V76, P1402, DOI 10.1134/S0006297911130049; Evdokimova V, 2006, CELL CYCLE, V5, P1143, DOI 10.4161/cc.5.11.2784; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Faury D, 2007, J CLIN ONCOL, V25, P1196, DOI 10.1200/JCO.2006.07.8626; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; Fu D, 2012, NAT REV CANCER, V12, P104, DOI 10.1038/nrc3185; Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200; Gao YY, 2009, MOL CANCER THER, V8, P3276, DOI 10.1158/1535-7163.MCT-09-0478; Gaudreault I, 2004, NUCLEIC ACIDS RES, V32, P316, DOI 10.1093/nar/gkh170; Genschel J, 2002, J BIOL CHEM, V277, P13302, DOI 10.1074/jbc.M111854200; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Guo SL, 2004, J BIOL CHEM, V279, P16912, DOI 10.1074/jbc.M313213200; Hidaka M, 2005, NUCLEIC ACIDS RES, V33, P5703, DOI 10.1093/nar/gki878; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Huang DY, 2001, BIOCHEM J, V356, P829, DOI 10.1042/0264-6021:3560829; Huang YM, 2004, J BIOL CHEM, V279, P30228, DOI 10.1074/jbc.M401675200; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Imai K, 2008, CARCINOGENESIS, V29, P673, DOI 10.1093/carcin/bgm228; Ise T, 1999, CANCER RES, V59, P342; Iyer RR, 2010, J BIOL CHEM, V285, P11730, DOI 10.1074/jbc.M110.104125; Iyer RR, 2006, CHEM REV, V106, P302, DOI 10.1021/cr0404794; Jascur T, 2011, J BIOL CHEM, V286, P29531, DOI 10.1074/jbc.M111.221341; Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; Jorgensen PL, 2001, BBA-BIOENERGETICS, V1505, P57, DOI 10.1016/S0005-2728(00)00277-2; Kadyrov FA, 2006, CELL, V126, P297, DOI 10.1016/j.cell.2006.05.039; Kaina B, 2007, DNA REPAIR, V6, P1079, DOI 10.1016/j.dnarep.2007.03.008; Karran P, 2001, CARCINOGENESIS, V22, P1931, DOI 10.1093/carcin/22.12.1931; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Koptyra M, 2006, BLOOD, V108, P319, DOI 10.1182/blood-2005-07-2815; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; Kunz C, 2009, CELL MOL LIFE SCI, V66, P1021, DOI 10.1007/s00018-009-8739-9; Lau PJ, 2003, J BIOL CHEM, V278, P14, DOI 10.1074/jbc.C200627200; Lee SD, 2006, J MOL BIOL, V355, P175, DOI 10.1016/j.jmb.2005.10.059; Li GM, 2008, CELL RES, V18, P85, DOI 10.1038/cr.2007.115; Liberti SE, 2011, DNA REPAIR, V10, P73, DOI 10.1016/j.dnarep.2010.09.023; Lingrel JB, 1998, ACTA PHYSIOL SCAND, V163, P69; Lu ZH, 2005, MOL CELL BIOL, V25, P4625, DOI 10.1128/MCB.25.11.4625-4637.2005; Mai RT, 2006, ONCOGENE, V25, P448, DOI 10.1038/sj.onc.1209052; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; Martinez R, 2004, ONCOLOGY-BASEL, V66, P395, DOI 10.1159/000079488; Masih PJ, 2008, NUCLEIC ACIDS RES, V36, P67, DOI 10.1093/nar/gkm943; Matsumoto Ken, 2005, J Mol Genet Med, V1, P11; Modrich P, 2006, J BIOL CHEM, V281, P30305, DOI 10.1074/jbc.R600022200; Moldovan GL, 2007, CELL, V129, P665, DOI 10.1016/j.cell.2007.05.003; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; O'Brien V, 2006, CARCINOGENESIS, V27, P682, DOI 10.1093/carcin/bgi298; Oda Y, 2003, J PATHOL, V199, P251, DOI 10.1002/path.1282; Perez-Garcia A, 2012, FRONT BIOSCI-LANDMRK, V17, P1469, DOI 10.2741/3998; Pizzi C, 2007, ONCOL REP, V17, P193; Pluciennik A, 2010, P NATL ACAD SCI USA, V107, P16066, DOI 10.1073/pnas.1010662107; Sarkaria JN, 2008, CLIN CANCER RES, V14, P2900, DOI 10.1158/1078-0432.CCR-07-1719; Scott M, 2001, J CELL SCI, V114, P3455; Shell SS, 2007, MOL CELL, V26, P565, DOI 10.1016/j.molcel.2007.04.024; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; Soreide K, 2007, TUMOR BIOL, V28, P290, DOI 10.1159/000110427; Stojic L, 2004, DNA REPAIR, V3, P1091, DOI 10.1016/j.dnarep.2004.06.006; Stoklosa T, 2008, CANCER RES, V68, P2576, DOI 10.1158/0008-5472.CAN-07-6858; Tomita-Mitchell A, 2000, MUTAT RES-FUND MOL M, V450, P125, DOI 10.1016/S0027-5107(00)00020-8; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Umar A, 1997, CANCER RES, V57, P3949; Valentini AM, 2006, CANCER TREAT REV, V32, P607, DOI 10.1016/j.ctrv.2006.08.001; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Woolley AG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020603; Xie WX, 2012, TUMOR BIOL, V33, P63, DOI 10.1007/s13277-011-0246-6; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Zhang YB, 2005, CELL, V122, P693, DOI 10.1016/j.cell.2005.06.027	85	15	16	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2014	33	43					5065	5077		10.1038/onc.2013.450	http://dx.doi.org/10.1038/onc.2013.450			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OF	24141788				2022-12-28	WOS:000343768400002
J	Toska, E; Shandilya, J; Goodfellow, SJ; Medler, KF; Roberts, SGE				Toska, E.; Shandilya, J.; Goodfellow, S. J.; Medler, K. F.; Roberts, S. G. E.			Prohibitin is required for transcriptional repression by the WT1-BASP1 complex	ONCOGENE			English	Article						WT1; BASP1; prohibitin; transcription	TUMOR-SUPPRESSOR; WILMS-TUMOR; CHROMATIN; BASP1; ACTIVATION; GENE; BRG1; WT1; RB; IDENTIFICATION	The Wilms' tumor-1 protein (WT1) is a transcriptional regulator that can either activate or repress genes controlling cell growth, apoptosis and differentiation. The transcriptional corepressor BASP1 interacts with WT1 and mediates WT1's transcriptional repression activity. BASP1 is contained within large complexes, suggesting that it works in concert with other factors. Here we report that the transcriptional repressor prohibitin is part of the WT1-BASP1 transcriptional repression complex. Prohibitin interacts with BASP1, colocalizes with BASP1 in the nucleus, and is recruited to the promoter region of WT1 target genes to elicit BASP1-dependent transcriptional repression. We demonstrate that prohibitin and BASP1 cooperate to recruit the chromatin remodeling factor BRG1 to WT1-responsive promoters and that this results in the dissociation of CBP from the promoter region of WT1 target genes. As seen with BASP1, prohibitin can associate with phospholipids. We demonstrate that the recruitment of PIP2 and HDAC1 to WT1 target genes is also dependent on the concerted activity of BASP1 and prohibitin. Our findings provide new insights into the function of prohibitin in transcriptional regulation and uncover a BASP1-prohibitin complex that plays an essential role in the PIP2-dependent recruitment of chromatin remodeling activities to the promoter.	[Toska, E.; Shandilya, J.; Medler, K. F.; Roberts, S. G. E.] SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA; [Goodfellow, S. J.] Univ Dundee, Wellcome Trust Ctr Gene Regulat, Dundee, Scotland; [Roberts, S. G. E.] Univ Bristol, Sch Cellular & Mol Med, Bristol, Avon, England	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Dundee; University of Bristol	Roberts, SGE (corresponding author), SUNY Buffalo, Dept Biol Sci, Cooke Hall,North Campus, Buffalo, NY 14260 USA.	sr237@buffalo.edu	Toska, Eneda/AAQ-4369-2020; Roberts, Stefan GE/R-5537-2016; Toska, Eneda/AAO-1711-2020	Toska, Eneda/0000-0002-8974-9792; Roberts, Stefan GE/0000-0002-7535-6365; Medler, Kathryn/0000-0001-9664-3606; Shandilya, Jayasha/0000-0001-9911-8065	National Institute of General Medical Sciences [1R01GM098609]; Cancer Research UK [C1356/A6630]; National Science Foundation [DBI 0923133]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM098609] Funding Source: NIH RePORTER	National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Cancer Research UK(Cancer Research UK); National Science Foundation(National Science Foundation (NSF)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was funded by the National Institute of General Medical Sciences (1R01GM098609) (to KFM and SGER) and Cancer Research UK (C1356/A6630) (to SGER). We thank Alan Siegel for help with the confocal microscopy and the facility funded by National Science Foundation (DBI 0923133).	Ande SR, 2009, BIOCHEM BIOPH RES CO, V390, P1023, DOI 10.1016/j.bbrc.2009.10.101; Carpenter B, 2004, MOL CELL BIOL, V24, P537, DOI 10.1128/MCB.24.2.537-549.2004; Choi D, 2008, ONCOGENE, V27, P1716, DOI 10.1038/sj.onc.1210806; Dai Y, 2008, CARCINOGENESIS, V29, P1725, DOI 10.1093/carcin/bgn117; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; Essafi A, 2011, DEV CELL, V21, P559, DOI 10.1016/j.devcel.2011.07.014; Gamble SC, 2007, ONCOGENE, V26, P1757, DOI 10.1038/sj.onc.1209967; Goodfellow SJ, 2011, BIOCHEM J, V435, P113, DOI 10.1042/BJ20101734; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Green LM, 2009, NUCLEIC ACIDS RES, V37, P431, DOI 10.1093/nar/gkn955; Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709; Han BK, 2011, GENE DEV, V25, P984, DOI 10.1101/gad.1998611; Hartkamp J, 2010, MOL CELL, V37, P159, DOI 10.1016/j.molcel.2009.12.023; Hartl M, 2009, P NATL ACAD SCI USA, V106, P5604, DOI 10.1073/pnas.0812101106; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; He B, 2008, MOL ENDOCRINOL, V22, P344, DOI 10.1210/me.2007-0400; He B, 2011, ENDOCRINOLOGY, V152, P1047, DOI 10.1210/en.2010-0732; Hohenstein P, 2006, HUM MOL GENET, V15, pR196, DOI 10.1093/hmg/ddl196; Huff V, 2011, NAT REV CANCER, V11, P111, DOI 10.1038/nrc3002; Joshi B, 2003, BIOCHEM BIOPH RES CO, V312, P459, DOI 10.1016/j.bbrc.2003.10.148; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Kim HS, 2007, J BIOL CHEM, V282, P16278, DOI 10.1074/jbc.M700215200; McKay LM, 1999, ONCOGENE, V18, P6546, DOI 10.1038/sj.onc.1203046; Millard CJ, 2013, MOL CELL, V51, P57, DOI 10.1016/j.molcel.2013.05.020; Mishra S, 2006, J CELL MOL MED, V10, P353, DOI 10.1111/j.1582-4934.2006.tb00404.x; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Moribe T, 2008, INT J ONCOL, V33, P949, DOI 10.3892/ijo_00000082; Morrow IC, 2005, TRAFFIC, V6, P725, DOI 10.1111/j.1600-0854.2005.00318.x; Mosevitsky MI, 2005, INT REV CYTOL, V245, P245, DOI 10.1016/S0074-7696(05)45007-X; Rivera MN, 2005, NAT REV CANCER, V5, P699, DOI 10.1038/nrc1696; Roberts SGE, 2005, CURR OPIN GENET DEV, V15, P542, DOI 10.1016/j.gde.2005.08.004; Schneider M, 2010, DEVELOPMENT, V137, P4073, DOI 10.1242/dev.053405; Shandilya J, 2012, P NATL ACAD SCI USA, V10, P1073; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; Toska E, 2012, CELL REP, V2, P462, DOI 10.1016/j.celrep.2012.08.005; Trotter Kevin W, 2008, Nucl Recept Signal, V6, pe004, DOI 10.1621/nrs.06004; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Wang S, 2004, EMBO J, V23, P2293, DOI 10.1038/sj.emboj.7600231; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Wang WH, 2001, J BIOL CHEM, V276, P16810, DOI 10.1074/jbc.M009687200; Watson PJ, 2012, NATURE, V481, P335, DOI 10.1038/nature10728; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yildirim S, 2013, J CELL SCI, V126, P2730, DOI 10.1242/jcs.123661; Zhang B, 2007, ONCOGENE, V26, P7153, DOI 10.1038/sj.onc.1210509; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	48	22	23	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2014	33	43					5100	5108		10.1038/onc.2013.447	http://dx.doi.org/10.1038/onc.2013.447			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OF	24166496	Green Accepted			2022-12-28	WOS:000343768400005
J	Ouyang, H; Gore, J; Deitz, S; Korc, M				Ouyang, H.; Gore, J.; Deitz, S.; Korc, M.			microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-beta actions	ONCOGENE			English	Article						pancreatic cancer; miR-10b; EGF receptor; cell invasion	EPIDERMAL-GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; DUCTAL ADENOCARCINOMA; FACTOR RECEPTOR; SIGNALING PATHWAYS; BREAST-CANCER; LUNG-CANCER; MOUSE MODEL; METASTASIS; TUMORIGENESIS	Increased microRNA-10b (miR-10b) expression in the cancer cells in pancreatic ductal adenocarcinoma (PDAC) is a marker of disease aggressiveness. In the present study, we determined that plasma miR-10b levels are significantly increased in PDAC patients by comparison with normal controls. By gene profiling, we identified potential targets downregulated by miR-10b, including Tat-interacting protein 30 (TIP30). Immunoblotting and luciferase reporter assays confirmed that TIP30 was a direct miR-10b target. Downregulation of TIP30 by miR-10b or siRNA-mediated silencing of TIP30 enhanced epidermal growth factor (EGF)-dependent invasion. The actions of miR-10b were abrogated by expressing a modified TIP30 cDNA resistant to miR-10b. EGF-induced EGF receptor (EGFR) tyrosine phosphorylation and extracellular signal-regulated kinase phosphorylation were enhanced by miR-10b, and these effects were mimicked by TIP30 silencing. The actions of EGF in the presence of miR-10b were blocked by EGFR kinase inhibition with erlotinib and by dual inhibition of PI3K (phosphatidylinositol 3'-kinase) and MEK. Moreover, miR-10b, EGF and transforming growth factor-beta (TGF-beta) combined to markedly increase cell invasion, and this effect was blocked by the combination of erlotinib and SB505124, a type I TGF-beta receptor inhibitor. miR-10b also enhanced the stimulatory effects of EGF and TGF-beta on cell migration and epithelial-mesenchymal transition (EMT) and decreased the expression of RAP2A, EPHB2, KLF4 and NF1. Moreover, miR-10b overexpression accelerated pancreatic cancer cell (PCC) proliferation and tumor growth in an orthotopic model. Thus, plasma miR-10b levels may serve as a diagnostic marker in PDAC, whereas intra-tumoral miR-10b promotes PCC proliferation and invasion by suppressing TIP30, which enhances EGFR signaling, facilitates EGF-TGF-beta cross-talk and enhances the expression of EMT-promoting genes, whereas decreasing the expression of several metastasis-suppressing genes. Therefore, therapeutic targeting of miR-10b in PDAC may interrupt growth-promoting deleterious EGF-TGF-beta interactions and antagonize the metastatic process at various levels.	Indiana Univ Sch Med, Dept Med, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46202 USA; Indiana Univ Sch Med, Dept Biochem, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46202 USA; Indiana Univ Sch Med, Dept Mol Biol, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46202 USA; Indiana Univ Sch Med, Pancreat Canc Signature Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Korc, M (corresponding author), Indiana Univ Sch Med, Dept Med, 980 W Walnut St, Indianapolis, IN 46202 USA.	mkorc@iupui.edu			NIH [R37-CA-075059]; NATIONAL CANCER INSTITUTE [R37CA075059, R01CA075059] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is dedicated to the fond memory of Victor Fung, Ph.D., a former Program Officer at NCI and former Scientific Review Officer of the Cancer Etiology study section of CSR, NIH, for his wisdom, compassion, integrity, his love of sciences and the arts, his incredible culinary skills, and above all, his contributions to the career development of so many investigators during his own distinguished career. The work was supported, in part, by an NIH grant R37-CA-075059 to M K. HO was a Ph.D. candidate in the Program in Experimental and Molecular Medicine at the Geisel School of Medicine at Dartmouth. We thank the IUSCC Cancer Center at Indiana University School of Medicine for the use of the Tissue Procurement and Distribution Core, which provided pancreatic tissues and patient plasma for microRNA assays. We also thank Dr Hua Xiao at the Michigan State University for generously providing the anti-TIP30 antibody.	Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Bloomston M, 2007, JAMA-J AM MED ASSOC, V297, P1901, DOI 10.1001/jama.297.17.1901; Carriere C, 2011, GASTROENTEROLOGY, V141, P1091, DOI 10.1053/j.gastro.2011.05.041; Chai GL, 2010, CANCER SCI, V101, P1997, DOI 10.1111/j.1349-7006.2010.01616.x; Chou YT, 2010, CANCER RES, V70, P8822, DOI 10.1158/0008-5472.CAN-10-0638; Danilov AV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026815; Davies M, 2005, J CELL BIOCHEM, V95, P918, DOI 10.1002/jcb.20458; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; du Rieu MC, 2010, CLIN CHEM, V56, P603, DOI 10.1373/clinchem.2009.137364; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fang Y, 2010, P NATL ACAD SCI USA, V107, P13450, DOI 10.1073/pnas.1002120107; Friess H, 1995, CLIN CANCER RES, V1, P1413; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Gloerich M, 2012, NAT CELL BIOL, V14, P793, DOI 10.1038/ncb2537; Greither T, 2010, INT J CANCER, V126, P73, DOI 10.1002/ijc.24687; Hata A, 2010, ADV EXP MED BIOL, V700, P15, DOI 10.1007/978-1-4419-7823-3_2; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hinoda Y, 2003, J GASTROENTEROL, V38, P1162, DOI 10.1007/s00535-003-1224-6; Ibrahim SA, 2012, INT J CANCER, V131, pE884, DOI 10.1002/ijc.27629; Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317; Iorio MV, 2009, CANCER RES, V69, P2195, DOI 10.1158/0008-5472.CAN-08-2920; Ito M, 2003, CANCER RES, V63, P8763; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kang JS, 2009, TRENDS CELL BIOL, V19, P385, DOI 10.1016/j.tcb.2009.05.008; Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371; Kolch W, 2010, NAT REV CANCER, V10, P618, DOI 10.1038/nrc2900; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; Korc M, 1998, Surg Oncol Clin N Am, V7, P25; KORC M, 1986, P NATL ACAD SCI USA, V83, P5141, DOI 10.1073/pnas.83.14.5141; Korc M, 2007, AM J SURG, V194, pS84, DOI 10.1016/j.amjsurg.2007.05.004; Lau SKM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036753; Lee EJ, 2007, INT J CANCER, V120, P1046, DOI 10.1002/ijc.22394; Leveille N, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1519; Li A, 2013, ONCOGENE, V32, P2273, DOI 10.1038/onc.2012.253; Li QJ, 2012, TUMOR BIOL, V33, P1455, DOI 10.1007/s13277-012-0396-1; Lim JE, 2003, ANN SURG, V237, P74, DOI 10.1097/00000658-200301000-00011; Lin J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.134; Liu F, 2012, MOL CANCER THER, V11, P2138, DOI 10.1158/1535-7163.MCT-12-0562; Liu LX, 2012, FEBS J, V279, P3800, DOI 10.1111/j.1742-4658.2012.08741.x; Luga V, 2009, BIOCHEM J, V421, P119, DOI 10.1042/BJ20081131; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618; Matsuda K, 2002, CANCER RES, V62, P5611; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Moriarty CH, 2010, J BIOL CHEM, V285, P20541, DOI 10.1074/jbc.M110.121012; Nakata K, 2011, SURGERY, V150, P916, DOI 10.1016/j.surg.2011.06.017; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Neupane D, 2008, CLIN CANCER RES, V14, P7614, DOI 10.1158/1078-0432.CCR-08-1366; Nishida N, 2013, CELL RES, V23, P1157, DOI 10.1038/cr.2013.87; Nishida N, 2012, ANN SURG ONCOL, V19, P3065, DOI 10.1245/s10434-012-2246-1; Nishida N, 2011, CLIN CANCER RES, V17, P2725, DOI 10.1158/1078-0432.CCR-10-2132; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Preis M, 2011, CRIT REV EUKAR GENE, V21, P115, DOI 10.1615/CritRevEukarGeneExpr.v21.i2.20; Preis M, 2011, CLIN CANCER RES, V17, P5812, DOI 10.1158/1078-0432.CCR-11-0695; Seike M, 2009, P NATL ACAD SCI USA, V106, P12085, DOI 10.1073/pnas.0905234106; Sempere LF, 2011, CANCER BIOL THER, V12, P198, DOI 10.4161/cbt.12.3.15979; Senior PV, 2010, INT J COLORECTAL DIS, V25, P687, DOI 10.1007/s00384-010-0916-7; Setoyama T, 2011, CLIN CANCER RES, V17, P5527, DOI 10.1158/1078-0432.CCR-11-1477; Shen J, 2013, NATURE, V497, P383, DOI 10.1038/nature12080; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Szafranska AE, 2008, CLIN CHEM, V54, P1716, DOI 10.1373/clinchem.2008.109603; Teixeira Ana L., 2012, Frontiers in Genetics, V3, P286, DOI 10.3389/fgene.2012.00286; Tian YY, 2010, J BIOL CHEM, V285, P7986, DOI 10.1074/jbc.M109.062877; Tong X, 2009, AM J PATHOL, V174, P1931, DOI 10.2353/ajpath.2009.080846; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Wagner JP, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003994; Wang J, 2009, CANCER PREV RES, V2, P807, DOI 10.1158/1940-6207.CAPR-09-0094; Webster RJ, 2009, J BIOL CHEM, V284, P5731, DOI 10.1074/jbc.M804280200; YAMANAKA Y, 1993, HUM PATHOL, V24, P1127, DOI 10.1016/0046-8177(93)90194-L; Yori JL, 2011, NEOPLASIA, V13, P601, DOI 10.1593/neo.11260; Yu GZ, 2011, J CANCER RES CLIN, V137, P73, DOI 10.1007/s00432-010-0861-4; Zhang CL, 2011, J BIOL CHEM, V286, P9373, DOI 10.1074/jbc.M110.207720; Zhang CL, 2010, CANCER RES, V70, P10224, DOI 10.1158/0008-5472.CAN-10-3057; Zhang H, 2008, INT J CANCER, V123, P810, DOI 10.1002/ijc.23638; Zhao J, 2007, HUM PATHOL, V38, P293, DOI 10.1016/j.humpath.2006.08.005	81	106	114	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2014	33	38					4664	4674		10.1038/onc.2013.405	http://dx.doi.org/10.1038/onc.2013.405			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3VX	24096486	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000342007200005
J	Wang, F; Chen, X; Li, C; Sun, Q; Chen, Y; Wang, Y; Peng, H; Liu, Z; Chen, R; Liu, K; Yan, H; Ye, BH; Kwiatkowski, DJ; Zhang, H				Wang, F.; Chen, X.; Li, C.; Sun, Q.; Chen, Y.; Wang, Y.; Peng, H.; Liu, Z.; Chen, R.; Liu, K.; Yan, H.; Ye, B. H.; Kwiatkowski, D. J.; Zhang, H.			Pivotal role of augmented alpha B-crystallin in tumor development induced by deficient TSC1/2 complex	ONCOGENE			English	Article						alpha B-crystallin; mTOR; NF kappa B; TSC; tumor	TUBEROUS SCLEROSIS COMPLEX; SUPPRESSOR GENE-PRODUCT; NF-KAPPA-B; MAMMALIAN TARGET; INDUCED APOPTOSIS; BINDING PARTNER; CELL-ADHESION; UP-REGULATION; CANCER-CELLS; MTOR	Tuberous sclerosis complex 1 (TSC1) and TSC2 are suppressors of mechanistic target of rapamycin (mTOR). mTOR is the major component of two protein complexes: mTOR complex 1 (mTORC1) and mTORC2. Inactive mutation of either TSC1 or TSC2 unleashes mTOR signaling and consequently causes TSC, a benign tumor syndrome affecting multiple organs. We report here that expression of alpha B-crystallin was upregulated in Tsc1-/- or Tsc2-/- mouse embryonic fibroblasts, Eker rat uterine leiomyoma-derived Tsc2-deficient ELT3 cells, mutant Tsc2-associated mouse kidney tumors, and human lung lymphangioleiomyomatosis nodules. alpha B-crystallin was transcriptionally activated by mTOR complex 2 (mTORC2): nuclear factor-kappa B (NF kappa B) signaling cascade. The augmented alpha B-crystallin was critical for the migration, invasion and apoptotic resistance of Tsc2-defective cells. Disruption of alpha B-crystallin suppressed Tsc2-null cell proliferation and tumorigenesis. Therefore, enhanced alpha B-crystallin has an essential role in TSC1/2 complex deficiency-mediated tumorigenesis, and inhibition of alpha B-crystallin may complement the current therapy for TSC.	[Wang, F.; Chen, X.; Li, C.; Wang, Y.; Liu, Z.; Chen, R.; Zhang, H.] Peking Union Med Coll, Grad Sch, Inst Basic Med Sci, State Key Lab Med Mol Biol,Dept Physiol & Pathoph, Beijing 100005, Peoples R China; [Wang, F.; Chen, X.; Li, C.; Wang, Y.; Liu, Z.; Chen, R.; Zhang, H.] Peking Union Med Coll, Grad Sch, Sch Basic Med, Beijing 100005, Peoples R China; [Wang, F.; Chen, X.; Li, C.; Chen, Y.; Wang, Y.; Liu, Z.; Chen, R.; Yan, H.; Zhang, H.] Chinese Acad Med Sci, Beijing 100730, Peoples R China; [Sun, Q.] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Dept Immunol, Tianjin, Peoples R China; [Chen, Y.; Yan, H.] Peking Union Med Coll, Cardiovasc Inst, Ctr Coronary Heart Dis, Beijing 100005, Peoples R China; [Chen, Y.; Yan, H.] Peking Union Med Coll, Fu Wai Hosp, Beijing 100005, Peoples R China; [Peng, H.] Scripps Res Inst, Dept Canc Biol, Jupiter, FL USA; [Liu, K.] Zhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou 450052, Henan, Peoples R China; [Ye, B. H.] Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA; [Kwiatkowski, D. J.] Brigham & Womens Hosp, Div Translat Med, Boston, MA 02115 USA; [Kwiatkowski, D. J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Tianjin Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Peking Union Medical College; Scripps Research Institute; Zhengzhou University; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Zhang, H (corresponding author), Peking Union Med Coll, Grad Sch, Inst Basic Med Sci, Dept Physiol & Pathophysiol, Beijing 100005, Peoples R China.	hbzhang@ibms.pumc.edu.cn	Peng, Haiyong/S-8045-2016		National Basic Research Program of China 973 Program [2009CB522203, 2011CB965002]; National Natural Science Foundation of China [81130085, 81101516]	National Basic Research Program of China 973 Program(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by National Basic Research Program of China 973 Program Grants 2009CB522203 and 2011CB965002 and National Natural Science Foundation of China Grants 81130085 and 81101516.	AOYAMA A, 1993, INT J CANCER, V55, P760, DOI 10.1002/ijc.2910550511; Astrinidis A, 2002, ONCOGENE, V21, P8470, DOI 10.1038/sj.onc.1205962; Bhaskar PT, 2009, MOL CELL BIOL, V29, P5136, DOI 10.1128/MCB.01946-08; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Bittmann I, 2003, HUM PATHOL, V34, P95, DOI 10.1053/hupa.2003.50; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Dan HC, 2008, GENE DEV, V22, P1490, DOI 10.1101/gad.1662308; El-Hashemite N, 2003, LANCET, V361, P1348, DOI 10.1016/S0140-6736(03)13044-9; European Chromosome 16 Tuberous Sclerosis C., 1993, CELL, V75, P1305; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Goncharova EA, 2011, MOL CELL BIOL, V31, P2484, DOI 10.1128/MCB.01061-10; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; HOWE SR, 1995, AM J PATHOL, V146, P1568; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; IWAKI T, 1991, AM J PATHOL, V139, P1303; Kamradt MC, 2005, J BIOL CHEM, V280, P11059, DOI 10.1074/jbc.M413382200; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Krueger DA, 2010, NEW ENGL J MED, V363, P1801, DOI 10.1056/NEJMoa1001671; KUPSKY WJ, 1993, PEDIATR PATHOL, V13, P869, DOI 10.3109/15513819309048274; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Lang SA, 2010, BBA-MOL CELL RES, V1803, P435, DOI 10.1016/j.bbamcr.2010.01.009; Lee L, 2005, GENE CHROMOSOME CANC, V42, P213, DOI 10.1002/gcc.20118; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Ma JH, 2011, J GENET GENOMICS, V38, P533, DOI 10.1016/j.jgg.2011.10.002; Ma JH, 2010, J CLIN INVEST, V120, P103, DOI 10.1172/JCI37964; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384; McCormack FX, 2011, NEW ENGL J MED, V364, P1595, DOI 10.1056/NEJMoa1100391; Ousman SS, 2007, NATURE, V448, P474, DOI 10.1038/nature05935; Ozes ON, 1999, NATURE, V401, P82; Parcellier A, 2005, ANTIOXID REDOX SIGN, V7, P404, DOI 10.1089/ars.2005.7.404; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Roach ES, 1998, J CHILD NEUROL, V13, P624, DOI 10.1177/088307389801301206; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Shi T, 2004, MOL CARCINOGEN, V40, P47, DOI 10.1002/mc.20015; Sitterding SM, 2008, ANN DIAGN PATHOL, V12, P33, DOI 10.1016/j.anndiagpath.2007.02.004; Sun QA, 2011, P NATL ACAD SCI USA, V108, P4129, DOI 10.1073/pnas.1014769108; Tanaka K, 2011, CANCER DISCOV, V1, P524, DOI 10.1158/2159-8290.CD-11-0124; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Young LR, 2008, NEW ENGL J MED, V358, P199, DOI 10.1056/NEJMc0707517; Yu K, 2009, CANCER RES, V69, P6232, DOI 10.1158/0008-5472.CAN-09-0299; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang HB, 2007, J CLIN INVEST, V117, P730, DOI 10.1172/JCI28984	49	7	8	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2014	33	34					4352	4358		10.1038/onc.2013.401	http://dx.doi.org/10.1038/onc.2013.401			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MK	24077282				2022-12-28	WOS:000341156900008
J	Wallace, MD; Southard, TL; Schimenti, KJ; Schimenti, JC				Wallace, M. D.; Southard, T. L.; Schimenti, K. J.; Schimenti, J. C.			Role of DNA damage response pathways in preventing carcinogenesis caused by intrinsic replication stress	ONCOGENE			English	Article						DNA replication; DNA damage checkpoints; minichromosome maintenance proteins; 9-1-1; MCM2-7 helicase; replication stress	ATAXIA-TELANGIECTASIA; BREAST-CANCER; TUMOR SUSCEPTIBILITY; GENOMIC INSTABILITY; IONIZING-RADIATION; MOUSE MODEL; ATM; MICE; CHK2; PHOSPHORYLATION	Defective DNA replication can result in genomic instability, cancer and developmental defects. To understand the roles of DNA damage response (DDR) genes on carcinogenesis in mutants defective for core DNA replication components, we utilized the Mcm4Chaos3/Chaos3 ('Chaos3') mouse model that, by virtue of an amino-acid alteration in MCM4 that destabilizes the MCM2-7 DNA replicative helicase, has fewer dormant replication origins and an increased number of stalled replication forks. This leads to genomic instability and cancer in most Chaos3 mice. We found that animals doubly mutant for Chaos3 and components of the ataxia telangiectasia-mutated (ATM) double-strand break response pathway (Atm, p21/Cdkn1a and Chk2/Chek2) had decreased tumor latency and/or increased tumor susceptibility. Tumor latency and susceptibility differed between genetic backgrounds and genders, with females demonstrating an overall greater cancer susceptibility to Atm and p21 deficiency than males. Atm deficiency was semilethal in the Chaos3 background and impaired embryonic fibroblast proliferation, suggesting that ATM drug inhibitors might be useful against tumors with DNA replication defects. Hypomorphism for the 9-1-1 component Hus1 did not affect tumor latency or susceptibility in Chaos3 animals, and tumors in these mice did not exhibit impaired ATR pathway signaling. These and other data indicate that under conditions of systemic replication stress, the ATM pathway is particularly important both for cancer suppression and viability during development.	[Wallace, M. D.; Southard, T. L.; Schimenti, K. J.; Schimenti, J. C.] Cornell Univ, Dept Biomed Sci, Coll Vet Med, Ithaca, NY 14853 USA; [Wallace, M. D.; Schimenti, J. C.] Dept Mol Biol & Genet, Ithaca, NY USA; [Southard, T. L.] Sect Anat Pathol, Ithaca, NY USA; [Schimenti, J. C.] Cornell Univ, Ctr Vertebrate Genom, Ithaca, NY 14853 USA	Cornell University; Cornell University	Schimenti, JC (corresponding author), Cornell Univ, Dept Biomed Sci, Coll Vet Med, VRT 9014A, Ithaca, NY 14853 USA.	jcs92@cornell.edu		Wallace, Marsha/0000-0001-8588-9512	NIH Training [IT32HDO57854, 5T32GM007617]; Empire State Stem Cell Fund [C026442, C024174]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD057854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007617] Funding Source: NIH RePORTER	NIH Training(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Empire State Stem Cell Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank RS Weiss and T Mak for providing mice. We also thank RS Weiss and G Balmus for critical feedback on the manuscript. This study was supported by NIH Training Grants IT32HDO57854 and 5T32GM007617, and Empire State Stem Cell Fund Contract Numbers C026442 and C024174 to JCS.	Albertson TM, 2009, P NATL ACAD SCI USA, V106, P17101, DOI 10.1073/pnas.0907147106; Arana ME, 2010, SEMIN CANCER BIOL, V20, P304, DOI 10.1016/j.semcancer.2010.10.003; Bagley BN, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003034; Balmus G, 2012, HUM MOL GENET, V21, P3408, DOI 10.1093/hmg/dds173; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1999, NAT GENET, V21, P359, DOI 10.1038/7684; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Berger AH, 2011, NATURE, V476, P163, DOI 10.1038/nature10275; Bhatti S, 2011, CELL MOL LIFE SCI, V68, P2977, DOI 10.1007/s00018-011-0683-9; Cazzalini O, 2010, MUTAT RES-REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chuang CH, 2012, NUCLEIC ACIDS RES, V40, P4914, DOI 10.1093/nar/gks176; Chuang CH, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001110; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Curtin NJ, 2012, NAT REV CANCER, V12, P801, DOI 10.1038/nrc3399; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dorak M. Tevfik, 2012, Frontiers in Genetics, V3, P268, DOI 10.3389/fgene.2012.00268; El GS, 2011, PLOS GENET, V7; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Errico A, 2012, CRIT REV BIOCHEM MOL, V47, P222, DOI 10.3109/10409238.2012.655374; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Goldsby RE, 2001, NAT MED, V7, P638, DOI 10.1038/88963; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Honeycutt KA, 2006, ONCOGENE, V25, P4027, DOI 10.1038/sj.onc.1209435; Ilves I, 2010, MOL CELL, V37, P247, DOI 10.1016/j.molcel.2009.12.030; Jones RM, 2012, BIOCHEM J, V443, P13, DOI 10.1042/BJ20112100; Karabinis ME, 2001, CARCINOGENESIS, V22, P343, DOI 10.1093/carcin/22.2.343; Kawabata T, 2011, MAMM GENOME, V22, P506, DOI 10.1007/s00335-011-9333-7; Kawabata T, 2011, MOL CELL, V41, P543, DOI 10.1016/j.molcel.2011.02.006; Kemp M, 2009, CURR BIOL, V19, pR733, DOI 10.1016/j.cub.2009.07.026; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kunnev D, 2010, ONCOGENE, V29, P3630, DOI 10.1038/onc.2010.125; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Levitt PS, 2007, MOL CELL BIOL, V27, P2189, DOI 10.1128/MCB.01763-06; Levitt PS, 2005, GENOMICS, V86, P212, DOI 10.1016/j.ygeno.2005.04.007; Li XCL, 2011, GENETICS, V187, P1031, DOI 10.1534/genetics.110.125450; Lieberman HB, 2011, J MOL CELL BIOL, V3, P39, DOI 10.1093/jmcb/mjq039; Lopez-Contreras AJ, 2010, DNA REPAIR, V9, P1249, DOI 10.1016/j.dnarep.2010.09.012; Lu S, 2006, CARCINOGENESIS, V27, P848, DOI 10.1093/carcin/bgi302; Mao JH, 2008, ONCOGENE, V27, P6596, DOI 10.1038/onc.2008.280; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Mokrani-Benhelli H, 2013, HUM MUTAT, V34, P374, DOI 10.1002/humu.22245; Moyer SE, 2006, P NATL ACAD SCI USA, V103, P10236, DOI 10.1073/pnas.0602400103; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Murga M, 2009, NAT GENET, V41, P891, DOI 10.1038/ng.420; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Niida H, 2010, EMBO J, V29, P3558, DOI 10.1038/emboj.2010.218; Pabla N, 2008, J BIOL CHEM, V283, P6572, DOI 10.1074/jbc.M707568200; Petermann E, 2010, NAT REV MOL CELL BIO, V11, P683, DOI 10.1038/nrm2974; Preston BD, 2010, SEMIN CANCER BIOL, V20, P281, DOI 10.1016/j.semcancer.2010.10.009; Pruitt SC, 2007, STEM CELLS, V25, P3121, DOI 10.1634/stemcells.2007-0483; Reiman A, 2011, BRIT J CANCER, V105, P586, DOI 10.1038/bjc.2011.266; Schoppy DW, 2012, J CLIN INVEST, V122, P241, DOI 10.1172/JCI58928; Sclafani RA, 2007, ANNU REV GENET, V41, P237, DOI 10.1146/annurev.genet.41.110306.130308; Shechter D, 2004, P NATL ACAD SCI USA, V101, P10845, DOI 10.1073/pnas.0404143101; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shima N, 2007, NAT GENET, V39, P93, DOI 10.1038/ng1936; Spring K, 2002, NAT GENET, V32, P185, DOI 10.1038/ng958; Stracker TH, 2008, MOL CELL, V31, P21, DOI 10.1016/j.molcel.2008.04.028; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Thompson D, 2005, JNCI-J NATL CANCER I, V97, P813, DOI 10.1093/jnci/dji141; Vijayraghavan Sriram, 2012, Subcell Biochem, V62, P113, DOI 10.1007/978-94-007-4572-8_7; Wallace MD, 2012, GENETICS, V192, P385, DOI 10.1534/genetics.112.142802; Warmerdam DO, 2009, MUTAT RES, V704, P2; Weiss RS, 2000, GENE DEV, V14, P1886; Weiss RS, 2002, CURR BIOL, V12, P73, DOI 10.1016/S0960-9822(01)00626-1; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zheng YL, 2010, INT J CANCER, V126, P2199, DOI 10.1002/ijc.24771	78	16	17	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3688	3695		10.1038/onc.2013.339	http://dx.doi.org/10.1038/onc.2013.339			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23975433	Green Accepted			2022-12-28	WOS:000338942900008
J	Leufke, C; Leykauf, J; Krunic, D; Jauch, A; Holtgreve-Grez, H; Bohm-Steuer, B; Brocker, EB; Mauch, C; Utikal, J; Hartschuh, W; Purdie, KJ; Boukamp, P				Leufke, C.; Leykauf, J.; Krunic, D.; Jauch, A.; Holtgreve-Grez, H.; Boehm-Steuer, B.; Broecker, E-B; Mauch, C.; Utikal, J.; Hartschuh, W.; Purdie, K. J.; Boukamp, P.			The telomere profile distinguishes two classes of genetically distinct cutaneous squamous cell carcinomas	ONCOGENE			English	Article						non-melanoma skin cancer; telomere organization; telomere length; actinic keratosis	NONMELANOMA SKIN-CANCER; IN-SITU HYBRIDIZATION; GENOMIC INSTABILITY; ACTINIC KERATOSIS; P53 MUTATIONS; GENE; BASAL; HTERT; TRANSPLANTATION; LOCALIZATION	The incidence of skin cancer is increasing worldwide and cutaneous squamous cell carcinomas (SCCs) are associated with considerable morbidity and mortality, particularly in immunosuppressed individuals ('carcinomatous catastrophy'). Yet, molecular mechanisms are still insufficiently understood. Besides ultraviolet (UV)-indicative mutations, chromosomal aberrations are prominent. As telomeres are essential in preserving chromosome integrity, and telomere erosion as well as aberrant spatial telomere distribution contribute to genomic instability, we first established telomere length profiles across the whole tissue and identified normal skin (10/30) harboring discrete epidermal sites (stem cell territories) of evenly short telomeres. Precancerous actinic keratoses (AKs) (17) and SCCs (27) expressed two telomere phenotypes: (i) tissue-wide evenly short to intermediate and (ii) longer and tissue-wide heterogeneous telomere lengths, suggesting two modes of initiation, with one likely to originate in the epidermal stem cells. Although tumor histotype, location, patient gender or age failed to distinguish the two SCC telomere phenotypes, as did telomerase activity, we found a trend for a higher degree of aberrant p53 and cyclin D1 expression with long/heterogeneous telomeres. In addition, we established an association for the short/homogeneous telomeres with a simpler and the heterogeneous telomeres with a more complex karyotype correlating also with distinct chromosomal changes. SCCs (13) from renal transplant recipients displayed the same telomere dichotomy, suggesting that both telomere subtypes contribute to 'carcinomatous catastrophy' under immunosuppression by selecting for a common set (3, 9p and 17q) and subtype-specific aberrations (e.g., 6p gain, 13q loss). As a second mechanism of telomere-dependent genomic instability, we investigated changes in telomere distribution with its most severe form of telomeric aggregates (TAs). We identified a telomere length-independent but progression-dependent increase in cells with small telomere associations in AKs (17/17) and additional TAs in SCCs (24/32), basal cell carcinomas (30/31) and malignant melanomas (15/15), and provide evidence for a reactive oxygen species-dependent mechanism in this UV-induced telomere organization-dependent genomic instability.	[Leufke, C.; Leykauf, J.; Krunic, D.; Holtgreve-Grez, H.; Boukamp, P.] German Canc Res Ctr, Div Genet Skin Carcinogenesis, Heidelberg, Germany; [Jauch, A.; Holtgreve-Grez, H.; Boehm-Steuer, B.] Heidelberg Univ, Inst Human Genet, Heidelberg, Germany; [Broecker, E-B] Univ Wurzburg, Dept Dermatol, Wurzburg, Germany; [Mauch, C.] Univ Cologne, Dept Dermatol, Wurzburg, Germany; [Utikal, J.] German Canc Res Ctr Heidelberg, Skin Canc Unit, Heidelberg, Germany; [Utikal, J.] Heidelberg Univ, Univ Med Ctr Mannheim, Dept Dermatol Venereol & Allergol, Mannheim, Germany; [Hartschuh, W.] Heidelberg Univ, Dept Dermatol, Heidelberg, Germany; [Purdie, K. J.] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, UK Canc Res UK Skin Tumour Lab, London, England	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Wurzburg; University of Cologne; University of Wurzburg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of London; Queen Mary University London	Boukamp, P (corresponding author), German Canc Res Ctr, Div Genet Skin Carcinogenesis, Neuenheimer Feld 280,Postfach 101949, Heidelberg, Germany.	p.boukamp@dkfz.de		Utikal, Jochen/0000-0001-5316-0241	Deutsche Krebshilfe eV (Tumorstammzellverbund); Bmbf (UVA Kompetenzverbund); Tumorzentrum Heidelberg/Mannheim; Deutsche Forschungsgemeinschaft [SFB873, SFB 829, Z2]; 'Adulte epidermale Stammzellen' of the Baden-Wurttemberg Stiftung' [P-BWS-ASII/35]; Cancer Research UK [13044] Funding Source: researchfish	Deutsche Krebshilfe eV (Tumorstammzellverbund); Bmbf (UVA Kompetenzverbund); Tumorzentrum Heidelberg/Mannheim; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); 'Adulte epidermale Stammzellen' of the Baden-Wurttemberg Stiftung'; Cancer Research UK(Cancer Research UK)	We thank Angelika Lampe for her help in preparing the manuscript, Manuel Berning for constructive discussions and Iris Martin and Katrin Schmidt for their excellent technical assistance. We also thank Catherine Harwood, Charlotte Proby and Irene Leigh from the Cancer Research UK Skin Tumour Laboratory for providing us with the tumor material from the RT recipients. We further thank Dako (Denmark) for generously providing us with telomeric PNA probe. This work was supported by grants from the Deutsche Krebshilfe eV (Tumorstammzellverbund) and Bmbf (UVA Kompetenzverbund) (to PB), Tumorzentrum Heidelberg/Mannheim (to AJ and PB), the Deutsche Forschungsgemeinschaft (SFB873 to PB and SFB 829, Z2 to CM) and supported by contract research 'Adulte epidermale Stammzellen' of the Baden-Wurttemberg Stiftung' (P-BWS-ASII/35).	Armanios M, 2012, NAT REV GENET, V13, P693, DOI 10.1038/nrg3246; Bachor C, 1999, J CANCER RES CLIN, V125, P453, DOI 10.1007/s004320050302; Balasubramanian S, 2011, NAT REV DRUG DISCOV, V10, P261, DOI 10.1038/nrd3428; Boukamp P, 1997, GENE CHROMOSOME CANC, V19, P201, DOI 10.1002/(SICI)1098-2264(199708)19:4<201::AID-GCC1>3.0.CO;2-0; Boukamp P, 2005, CARCINOGENESIS, V26, P1657, DOI 10.1093/carcin/bgi123; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Burnworth B, 2006, ONCOGENE, V25, P4399, DOI 10.1038/sj.onc.1209474; Burnworth B, 2007, EUR J CELL BIOL, V86, P763, DOI 10.1016/j.ejcb.2006.11.002; Cerezo A, 2002, J CELL SCI, V115, P1305; Chuang TCY, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-12; de Fijter JW, 2007, NEPHROL DIAL TRANSPL, V22, pI23, DOI 10.1093/ndt/gfm086; Desmaze C, 2003, CANCER LETT, V194, P173, DOI 10.1016/S0304-3835(02)00704-8; DUMANOIR S, 1993, HUM GENET, V90, P590, DOI 10.1007/BF00202476; Dworkin AM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001136; Ermler S, 2004, EUR J CELL BIOL, V83, P681, DOI 10.1078/0171-9335-00430; Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137; Fabricius EM, 2009, INT J ONCOL, V35, P1377, DOI 10.3892/ijo_00000456; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Geigl JB, 2006, NAT PROTOC, V1, P1172, DOI 10.1038/nprot.2006.160; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Jin YS, 1999, GENE CHROMOSOME CANC, V26, P295, DOI 10.1002/(SICI)1098-2264(199912)26:4<295::AID-GCC3>3.0.CO;2-W; Jones MJK, 2012, DEV CELL, V23, P908, DOI 10.1016/j.devcel.2012.10.010; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kanellou P, 2008, CANCER LETT, V264, P145, DOI 10.1016/j.canlet.2008.01.042; Krunic D, 2009, BBA-MOL BASIS DIS, V1792, P297, DOI 10.1016/j.bbadis.2009.02.005; Lansdorp PM, 2009, EMBO J, V28, P2532, DOI 10.1038/emboj.2009.172; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Louis SF, 2005, P NATL ACAD SCI USA, V102, P9613, DOI 10.1073/pnas.0407512102; Murnane JP, 2012, MUTAT RES-FUND MOL M, V730, P28, DOI 10.1016/j.mrfmmm.2011.04.008; Pacifico A, 2008, BRIT J DERMATOL, V158, P291, DOI 10.1111/j.1365-2133.2007.08360.x; Perrem K, 2007, HUM PATHOL, V38, P351, DOI 10.1016/j.humpath.2006.08.019; Perrem K, 2008, HUM PATHOL, V39, P1034, DOI 10.1016/j.humpath.2007.11.008; Popp S, 2002, INT J CANCER, V99, P352, DOI 10.1002/ijc.10321; Purdie KJ, 2007, GENE CHROMOSOME CANC, V46, P661, DOI 10.1002/gcc.20447; Purdie KJ, 2009, J INVEST DERMATOL, V129, P1562, DOI 10.1038/jid.2008.408; Raz V, 2008, J CELL SCI, V121, P4018, DOI 10.1242/jcs.034876; Ren ZP, 1997, AM J PATHOL, V150, P1791; Salgado R, 2008, ACTAS DERMO-SIFILOGR, V99, P199, DOI 10.1016/S0001-7310(08)74656-8; Shay J W, 2001, Novartis Found Symp, V235, P116; Toll A, 2009, BRIT J DERMATOL, V161, P1112, DOI 10.1111/j.1365-2133.2009.09351.x; Utikal J, 2005, CANCER LETT, V219, P197, DOI 10.1016/j.canlet.2004.07.011; Xu L, 2012, ANNU REV PATHOL-MECH, V8, P49; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; Zimmer C, 2011, J CELL BIOL, V192, P723, DOI 10.1083/jcb.201010058	44	12	12	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3506	3518		10.1038/onc.2013.323	http://dx.doi.org/10.1038/onc.2013.323			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23955078	Bronze			2022-12-28	WOS:000338941100003
J	Moon, H; Lee, CS; Inder, KL; Sharma, S; Choi, E; Black, DM; Le Cao, KA; Winterford, C; Coward, JI; Ling, MT; Craik, DJ; Parton, RG; Russell, PJ; Hill, MM				Moon, H.; Lee, C. S.; Inder, K. L.; Sharma, S.; Choi, E.; Black, D. M.; Le Cao, K-A; Winterford, C.; Coward, J. I.; Ling, M. T.; Craik, D. J.; Parton, R. G.; Russell, P. J.; Hill, M. M.		Australian Prostate Canc BioResour	PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer	ONCOGENE			English	Article						PTRF; cavin-1; caveolin-1; caveolae; prostate cancer	RELEASE FACTOR PTRF; ANDROGEN RECEPTOR; SECRETED CAVEOLIN-1; STROMAL CAVEOLIN-1; SERUM CAVEOLIN-1; EXPRESSION; BREAST; GROWTH; INTERLEUKIN-6; FIBROBLASTS	Caveolin-1 has a complex role in prostate cancer and has been suggested to be a potential biomarker and therapeutic target. As mature caveolin-1 resides in caveolae, invaginated lipid raft domains at the plasma membrane, caveolae have been suggested as a tumor-promoting signaling platform in prostate cancer. However, caveola formation requires both caveolin-1 and cavin-1 (also known as PTRF; polymerase I and transcript release factor). Here, we examined the expression of cavin-1 in prostate epithelia and stroma using tissue microarray including normal, non-malignant and malignant prostate tissues. We found that caveolin-1 was induced without the presence of cavin-1 in advanced prostate carcinoma, an expression pattern mirrored in the PC-3 cell line. In contrast, normal prostate epithelia expressed neither caveolin-1 nor cavin-1, while prostate stroma highly expressed both caveolin-1 and cavin-1. Utilizing PC-3 cells as a suitable model for caveolin-1-positive advanced prostate cancer, we found that cavin-1 expression in PC-3 cells inhibits anchorage-independent growth, and reduces in vivo tumor growth and metastasis in an orthotopic prostate cancer xenograft mouse model. The expression of alpha-smooth muscle actin in stroma along with interleukin-6 (IL-6) in cancer cells was also decreased in tumors of mice bearing PC-3-cavin-1 tumor cells. To determine whether cavin-1 acts by neutralizing caveolin-1, we expressed cavin-1 in caveolin-1-negative prostate cancer LNCaP and 22Rv1 cells. Caveolin-1 but not cavin-1 expression increased anchorage-independent growth in LNCaP and 22Rv1 cells. Cavin-1 co-expression reversed caveolin-1 effects in caveolin-1-positive LNCaP cells. Taken together, these results suggest that caveolin-1 in advanced prostate cancer is present outside of caveolae, because of the lack of cavin-1 expression. Cavin-1 expression attenuates the effects of non-caveolar caveolin-1 microdomains partly via reduced IL-6 microenvironmental function. With circulating caveolin-1 as a potential biomarker for advanced prostate cancer, identification of the molecular pathways affected by cavin-1 could provide novel therapeutic targets.	[Moon, H.; Inder, K. L.; Choi, E.; Black, D. M.; Hill, M. M.] Univ Queensland, Diamantina Inst, Brisbane, Qld 4102, Australia; [Lee, C. S.; Sharma, S.] Univ Western Sydney, Sch Med, Discipline Pathol, Sydney, NSW, Australia; [Lee, C. S.; Sharma, S.] Univ Western Sydney, Mol Med Res Grp, Sydney, NSW, Australia; [Lee, C. S.; Sharma, S.] Liverpool Hosp, Dept Anat Pathol, Sydney, NSW, Australia; [Choi, E.] Univ Queensland, Sch Vet Sci, Brisbane, Qld 4102, Australia; [Le Cao, K-A] Univ Queensland, Queensland Facil Adv Bioinformat, Brisbane, Qld 4102, Australia; [Winterford, C.] Univ Queensland, Sch Med, Brisbane, Qld 4102, Australia; [Coward, J. I.] Translat Res Inst, Brisbane, Qld, Australia; [Ling, M. T.; Russell, P. J.] Queensland Univ Technol, Translat Res Inst, Australian Prostate Canc Res Ctr Queensland, Brisbane, Qld 4001, Australia; [Ling, M. T.; Russell, P. J.] Queensland Univ Technol, Translat Res Inst, Inst Biomed Hlth & Innovat, Brisbane, Qld 4001, Australia; [Craik, D. J.; Parton, R. G.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4102, Australia	University of Queensland; Western Sydney University; Western Sydney University; Liverpool Hospital; University of Queensland; University of Queensland; University of Queensland; Queensland University of Technology (QUT); Queensland University of Technology (QUT); University of Queensland	Hill, MM (corresponding author), Univ Queensland, Diamantina Inst, Translat Res Inst, Level 5,37 Kent St, Brisbane, Qld 4102, Australia.	m.hill2@uq.edu.au	Russell, Pamela J/G-1685-2010; Coward, Jermaine/C-1779-2012; Craik, David/B-1695-2010; Le Cao, Kim-Anh/B-6637-2013; Russell, Pamela/O-8504-2019; Hill, Michelle Mei Chih/G-4417-2010; Coward, Jermaine/F-2903-2016; Parton, Robert/C-5673-2009	Russell, Pamela J/0000-0002-3995-1239; Craik, David/0000-0003-0007-6796; Le Cao, Kim-Anh/0000-0003-3923-1116; Hill, Michelle Mei Chih/0000-0003-1134-0951; Coward, Jermaine/0000-0002-2309-9379; Parton, Robert/0000-0002-7494-5248; Lee, C. Soon/0000-0003-1058-5826; Moon, Hyeongsun/0000-0002-7479-1429	Association for International Cancer Research and Prostate Cancer Foundation Australia; National Health and Medical Research Council of Australia [569512]; NHMRC Project [631371]; NHMRC Australia Fellowship [569452]; University of Queensland International Postgraduate Research Scholarship; NHMRC Enabling [614296]; Prostate Cancer Foundation of Australia; Australian Cancer Research Foundation; Worldwide Cancer Research [10-0517] Funding Source: researchfish	Association for International Cancer Research and Prostate Cancer Foundation Australia; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Project(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Australia Fellowship(National Health and Medical Research Council (NHMRC) of Australia); University of Queensland International Postgraduate Research Scholarship; NHMRC Enabling(National Health and Medical Research Council (NHMRC) of Australia); Prostate Cancer Foundation of Australia; Australian Cancer Research Foundation; Worldwide Cancer Research	S. We thank Duka Skalamera and Mareike Dahmer of the UQDI ARVEC facility for producing lentivirus, and the participants who kindly donated tissues to the Australian Prostate Cancer BioResource. This work was supported by project grants from the Association for International Cancer Research and Prostate Cancer Foundation Australia. MMH received a Career Development Award from the National Health and Medical Research Council of Australia (no. 569512). RGP was supported by NHMRC Project Grant 631371 and an NHMRC Australia Fellowship (569452). HM is supported by University of Queensland International Postgraduate Research Scholarship. The Australian Prostate Cancer BioResource is supported by an NHMRC Enabling Grant (no. 614296) and by an infrastructure grant from the Prostate Cancer Foundation of Australia. The ARVEC facility received support from the Australian Cancer Research Foundation.	Aboulaich N, 2004, BIOCHEM J, V383, P237, DOI 10.1042/BJ20040647; Aung CS, 2011, EUR J CELL BIOL, V90, P136, DOI 10.1016/j.ejcb.2010.06.004; Bai L, 2012, J CELL BIOCHEM, V113, P322, DOI 10.1002/jcb.23358; Bastiani M, 2009, J CELL BIOL, V185, P1259, DOI 10.1083/jcb.200903053; Bennett N, 2009, IUBMB LIFE, V61, P961, DOI [10.1002/IUB.244, 10.1002/iub.244]; Bryant KG, 2011, INT J BIOCHEM CELL B, V43, P1318, DOI 10.1016/j.biocel.2011.04.019; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chung TDK, 1999, PROSTATE, V38, P199; Culig Z, 2012, MOL CELL ENDOCRINOL, V360, P52, DOI 10.1016/j.mce.2011.05.033; Di Vizio D, 2009, CELL CYCLE, V8, P2420, DOI 10.4161/cc.8.15.9116; Dorff TB, 2010, CLIN CANCER RES, V16, P3028, DOI 10.1158/1078-0432.CCR-09-3122; Giannoni E, 2010, CANCER RES, V70, P6945, DOI 10.1158/0008-5472.CAN-10-0785; Goetz JG, 2008, CANCER METAST REV, V27, P715, DOI 10.1007/s10555-008-9160-9; Goetz JG, 2011, CELL, V146, P148, DOI 10.1016/j.cell.2011.05.040; Gould ML, 2010, PROSTATE, V70, P1609, DOI 10.1002/pros.21195; Gumulec J, 2012, ONCOL REP, V27, P831, DOI 10.3892/or.2011.1587; Hansen CG, 2009, NAT CELL BIOL, V11, P807, DOI 10.1038/ncb1887; Hill MM, 2008, CELL, V132, P113, DOI 10.1016/j.cell.2007.11.042; Hill MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043041; Hudes G, 2013, INVEST NEW DRUG, V31, P669, DOI 10.1007/s10637-012-9857-z; Hugo HJ, 2012, CANCER MICROENVIRON, V5, P83, DOI 10.1007/s12307-012-0098-7; Inder KL, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.012245; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Karam JA, 2007, PROSTATE, V67, P614, DOI 10.1002/pros.20557; Kuo SR, 2012, HYBRIDOMA, V31, P77, DOI 10.1089/hyb.2011.0100; Li LK, 2009, MOL CANCER RES, V7, P1781, DOI 10.1158/1541-7786.MCR-09-0255; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Li X, 2008, CANCER SCI, V99, P1326, DOI 10.1111/j.1349-7006.2008.00816.x; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Luk SU, 2011, INT J CANCER, V128, P2182, DOI 10.1002/ijc.25546; Martinez R, 2009, EPIGENETICS-US, V4, P255, DOI 10.4161/epi.9130; McMahon KA, 2009, EMBO J, V28, P1001, DOI 10.1038/emboj.2009.46; Mouraviev V, 2002, J UROLOGY, V168, P1589, DOI 10.1016/S0022-5347(05)64526-0; Nasu Y, 1998, NAT MED, V4, P1062, DOI 10.1038/2048; Okamoto M, 1997, CANCER RES, V57, P141; Parton RG, 2007, NAT REV MOL CELL BIO, V8, P185, DOI 10.1038/nrm2122; Skalamera D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051733; Skalamera D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020057; Smith PC, 2001, CYTOKINE GROWTH F R, V12, P33, DOI 10.1016/S1359-6101(00)00021-6; Studebaker AW, 2008, CANCER RES, V68, P9087, DOI 10.1158/0008-5472.CAN-08-0400; Tahir SA, 2003, CLIN CANCER RES, V9, P3653; Tahir SA, 2001, CANCER RES, V61, P3882; Tahir SA, 2008, CANCER RES, V68, P731, DOI 10.1158/0008-5472.CAN-07-2668; Tahir SA, 2006, CLIN CANCER RES, V12, P4872, DOI 10.1158/1078-0432.CCR-06-0417; Wallner L, 2006, CANCER RES, V66, P3087, DOI 10.1158/0008-5472.CAN-05-3447; Wu CT, 2012, J MOL MED, V90, P1343, DOI 10.1007/s00109-012-0916-x; Xu XL, 2001, CANCER RES, V61, P7943; Yang G, 1999, CANCER RES, V59, P5719; Yang G, 1998, CLIN CANCER RES, V4, P1873	49	49	50	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3561	3570		10.1038/onc.2013.315	http://dx.doi.org/10.1038/onc.2013.315			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23934189	Green Submitted			2022-12-28	WOS:000338941100008
J	Guo, H; Gao, M; Lu, Y; Liang, J; Lorenzi, PL; Bai, S; Hawke, DH; Li, J; Dogruluk, T; Scott, KL; Jonasch, E; Mills, GB; Ding, Z				Guo, H.; Gao, M.; Lu, Y.; Liang, J.; Lorenzi, P. L.; Bai, S.; Hawke, D. H.; Li, J.; Dogruluk, T.; Scott, K. L.; Jonasch, E.; Mills, G. B.; Ding, Z.			Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules	ONCOGENE			English	Article						AKT; phosphorylation; NIA	PROTEIN-KINASE-B; RICTOR-MTOR COMPLEX; MEMBRANE LOCALIZATION; CANCER CELLS; ACTIVATION; AKT/PKB; GROWTH; ROLES; DOWNSTREAM; STABILITY	Aberrant AKT activation is prevalent across multiple human cancer lineages providing an important new target for therapy. Twenty-two independent phosphorylation sites have been identified on specific AKT isoforms likely contributing to differential isoform regulation. However, the mechanisms regulating phosphorylation of individual AKT isoform molecules have not been elucidated because of the lack of robust approaches able to assess phosphorylation of multiple sites on a single AKT molecule. Using a nanofluidic proteomic immunoassay (NIA), consisting of isoelectric focusing followed by sensitive chemiluminescence detection, we demonstrate that under basal and ligand-induced conditions that the pattern of phosphorylation events is markedly different between AKT1 and AKT2. Indeed, there are at least 12 AKT1 peaks and at least 5 AKT2 peaks consistent with complex combinations of phosphorylation of different sites on individual AKT molecules. Following insulin stimulation, AKT1 was phosphorylated at Thr308 in the T-loop and Ser473 in the hydrophobic domain. In contrast, AKT2 was only phosphorylated at the equivalent sites (Thr309 and Ser474) at low levels. Further, Thr308 and Ser473 phosphorylation occurred predominantly on the same AKT1 molecules, whereas Thr309 and Ser474 were phosphorylated primarily on different AKT2 molecules. Although basal AKT2 phosphorylation was sensitive to inhibition of phosphatidylinositol 3-kinase (PI3K), basal AKT1 phosphorylation was essentially resistant. PI3K inhibition decreased pThr451 on AKT2 but not pThr450 on AKT1. Thus, NIA technology provides an ability to characterize coordinate phosphorylation of individual AKT molecules providing important information about AKT isoform-specific phosphorylation, which is required for optimal development and implementation of drugs targeting aberrant AKT activation.	[Guo, H.; Gao, M.; Lu, Y.; Liang, J.; Li, J.; Mills, G. B.; Ding, Z.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Lorenzi, P. L.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Bai, S.; Jonasch, E.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Hawke, D. H.] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; [Dogruluk, T.; Scott, K. L.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Mills, GB (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	gmills@mdanderson.org; zding@mdanderson.org		Dogruluk, Turgut/0000-0002-9212-9471	National Institutes of Health (NIH) [5R21CA126700]; University of Texas MD Anderson Cancer Center Kidney Cancer Multidisciplinary Research Program; AstraZeneca; Clinical Proteomic Tumor Analysis Consortium (CPTAC) [U24 CA126477, U24 CA126479, U54 CA112970]; NCI CCSG [P30 CA016672]; NATIONAL CANCER INSTITUTE [R21CA126700, U24CA126477, P30CA016672, U24CA126479, U54CA112970, U01CA168394] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Texas MD Anderson Cancer Center Kidney Cancer Multidisciplinary Research Program; AstraZeneca(AstraZeneca); Clinical Proteomic Tumor Analysis Consortium (CPTAC); NCI CCSG; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Bert Vogelstein for providing HCT116 wt and knockout cell lines. The work is supported by National Institutes of Health (NIH) grant 5R21CA126700, a grant from the University of Texas MD Anderson Cancer Center Kidney Cancer Multidisciplinary Research Program, and research support from AstraZeneca to ZD, and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) grants (U24 CA126477, U24 CA126479, and U54 CA112970) to GBM and NCI CCSG grant (P30 CA016672).	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1023, DOI 10.1002/elps.11501401163; Bouzakri K, 2006, CELL METAB, V4, P89, DOI 10.1016/j.cmet.2006.04.008; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Chin YR, 2010, MOL CELL, V38, P333, DOI 10.1016/j.molcel.2010.02.031; Dillon RL, 2009, CANCER RES, V69, P5057, DOI 10.1158/0008-5472.CAN-08-4287; Ding ZY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009910; Endersby R, 2011, CANCER RES, V71, P4106, DOI 10.1158/0008-5472.CAN-10-3597; Ericson K, 2010, P NATL ACAD SCI USA, V107, P2598, DOI 10.1073/pnas.0914018107; Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120; Fan AC, 2009, NAT MED, V15, P566, DOI 10.1038/nm.1903; Gao DM, 2009, NAT CELL BIOL, V11, P397, DOI 10.1038/ncb1847; Gonzalez E, 2009, P NATL ACAD SCI USA, V106, P7004, DOI 10.1073/pnas.0901933106; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hornbeck PV, 2012, NUCLEIC ACIDS RES, V40, pD261, DOI 10.1093/nar/gkr1122; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Mahajan K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009646; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Mao ML, 2000, BIOCHEM J, V352, P475, DOI 10.1042/0264-6021:3520475; Oh WJ, 2010, EMBO J, V29, P3939, DOI 10.1038/emboj.2010.271; Powell DJ, 2003, MOL CELL BIOL, V23, P7794, DOI 10.1128/MCB.23.21.7794-7808.2003; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sundaresan NR, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001465; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065	28	31	34	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3463	3472		10.1038/onc.2013.301	http://dx.doi.org/10.1038/onc.2013.301			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23912456	Green Accepted			2022-12-28	WOS:000338779300013
J	Liu, LL; Xie, N; Sun, S; Plymate, S; Mostaghel, E; Dong, X				Liu, L. L.; Xie, N.; Sun, S.; Plymate, S.; Mostaghel, E.; Dong, X.			Mechanisms of the androgen receptor splicing in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; androgen deprivation therapy; RNA splice variant; alternative splicing	GENE-EXPRESSION; TRANSCRIPTION; PROGRESSION; VARIANTS; RESISTANCE; RECRUITMENT; THERAPIES; RESOURCE; PSF	Prostate tumors develop resistance to androgen deprivation therapy (ADT) by multiple mechanisms, one of which is to express constitutively active androgen receptor (AR) splice variants lacking the ligand-binding domain. AR splice variant 7 (AR-V7, also termed AR3) is the most abundantly expressed variant that drives prostate tumor progression under ADT conditions. However, the molecular mechanism by which AR-V7 is generated remains unclear. In this manuscript, we demonstrated that RNA splicing of AR-V7 in response to ADT was closely associated with AR gene transcription initiation and elongation rates. Enhanced AR gene transcription by ADT provides a prerequisite condition that further increases the interactions between AR pre-mRNA and splicing factors. Under ADT conditions, recruitment of several RNA splicing factors to the 3' splicing site for AR-V7 was increased. We identified two RNA splicing enhancers and their binding proteins (U2AF65 and ASF/SF2) that had critical roles in splicing AR pre-mRNA into AR-V7. These data indicate that ADT-induced AR gene transcription rate and splicing factor recruitment to AR pre-mRNA contribute to the enhanced AR-V7 levels in prostate cancer cells.	[Liu, L. L.; Xie, N.; Dong, X.] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, Vancouver, BC V6H 3Z6, Canada; [Sun, S.; Plymate, S.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98104 USA; [Sun, S.; Plymate, S.] VAPSHCS GRECC, Seattle, WA 98104 USA; [Mostaghel, E.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; [Dong, X.] Univ Toronto, Dept Obstet & Gynaecol, Toronto, ON, Canada	University of British Columbia; University of Washington; University of Washington Seattle; Geriatric Research Education & Clinical Center; Fred Hutchinson Cancer Center; University of Toronto	Plymate, S (corresponding author), Univ Washington, Sch Med, Dept Med, Box 359625,325 9th Ave, Seattle, WA 98104 USA.	splymate@u.washington.edu; xdong@prostatecentre.com	Dong, Xuesen/AGF-9228-2022		Pacific Northwest Prostate Cancer SPORE, National Cancer Institute [P50CA097186]; Prostate Cancer Canada [RS2013-58]; Canadian Institute of Health Research [MOP-97934]; Department of Defence plus Veterans Administration Grants; Prostate Cancer Foundation; NIH [P01 CA163227]; NATIONAL CANCER INSTITUTE [P01CA163227, P50CA097186] Funding Source: NIH RePORTER	Pacific Northwest Prostate Cancer SPORE, National Cancer Institute; Prostate Cancer Canada; Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Department of Defence plus Veterans Administration Grants; Prostate Cancer Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by Pacific Northwest Prostate Cancer SPORE, National Cancer Institute (P50CA097186; XD and SRP); Prostate Cancer Canada (RS2013-58; to XD) and Canadian Institute of Health Research (MOP-97934; XD); Department of Defence plus Veterans Administration Grants (SRP), NIH P01 CA163227 (SRP) and Prostate Cancer Foundation (SRP).	Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Batsche E, 2006, NAT STRUCT MOL BIOL, V13, P22, DOI 10.1038/nsmb1030; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777; Chen Y, 2009, LANCET ONCOL, V10, P981, DOI 10.1016/S1470-2045(09)70229-3; Cheng H, 2006, CANCER RES, V66, P10613, DOI 10.1158/0008-5472.CAN-06-0028; Chew SL, 1999, P NATL ACAD SCI USA, V96, P10655, DOI 10.1073/pnas.96.19.10655; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Dong XS, 2007, MOL CELL BIOL, V27, P4863, DOI 10.1128/MCB.02144-06; Goldstrohm AC, 2001, GENE, V277, P31, DOI 10.1016/S0378-1119(01)00695-3; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Heemers HV, 2010, PROSTATE, V70, P959, DOI 10.1002/pros.21130; Hornberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019059; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2011, PROSTATE, V71, P1656, DOI 10.1002/pros.21382; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Kadener S, 2001, EMBO J, V20, P5759, DOI 10.1093/emboj/20.20.5759; Kornblihtt AR, 2007, ADV EXP MED BIOL, V623, P175, DOI 10.1007/978-0-387-77374-2_11; Kornblihtt AR, 2005, CURR OPIN CELL BIOL, V17, P262, DOI 10.1016/j.ceb.2005.04.014; Li Y, 2012, ONCOGENE, V31, P4759, DOI 10.1038/onc.2011.637; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Li YM, 2011, CANCER RES, V71, P2108, DOI 10.1158/0008-5472.CAN-10-1998; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; Luco RF, 2011, CELL, V144, P16, DOI 10.1016/j.cell.2010.11.056; Luco RF, 2010, SCIENCE, V327, P996, DOI 10.1126/science.1184208; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Moore MJ, 2009, CELL, V136, P688, DOI 10.1016/j.cell.2009.02.001; Mostaghel EA, 2007, CANCER RES, V67, P5033, DOI 10.1158/0008-5472.CAN-06-3332; Nogues G, 2002, J BIOL CHEM, V277, P43110, DOI 10.1074/jbc.M208418200; Olshavsky NA, 2010, CANCER RES, V70, P3975, DOI 10.1158/0008-5472.CAN-09-3468; Paronetto MP, 2007, J CELL BIOL, V176, P929, DOI 10.1083/jcb.200701005; Rokhlin OW, 2006, MOL CANCER RES, V4, P113, DOI 10.1158/1541-7786.MCR-05-0085; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Sims RJ, 2007, MOL CELL, V28, P665, DOI 10.1016/j.molcel.2007.11.010; Srebrow A, 2006, J CELL SCI, V119, P2635, DOI 10.1242/jcs.03053; Stamm S, 2006, NUCLEIC ACIDS RES, V34, pD46, DOI 10.1093/nar/gkj031; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Welsbie DS, 2009, CANCER RES, V69, P958, DOI 10.1158/0008-5472.CAN-08-2216; Xie N, 2012, MOL ENDOCRINOL, V26, P1370, DOI 10.1210/me.2012-1088; Yang X, 2011, J BIOL CHEM, V286, P36152, DOI 10.1074/jbc.M111.265124; Zhang XT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027970	48	214	223	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3140	3150		10.1038/onc.2013.284	http://dx.doi.org/10.1038/onc.2013.284			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23851510	Green Accepted			2022-12-28	WOS:000338410000007
J	Buss, MC; Remke, M; Lee, J; Gandhi, K; Schniederjan, MJ; Kool, M; Northcott, PA; Pfister, SM; Taylor, MD; Castellino, RC				Buss, M. C.; Remke, M.; Lee, J.; Gandhi, K.; Schniederjan, M. J.; Kool, M.; Northcott, P. A.; Pfister, S. M.; Taylor, M. D.; Castellino, R. C.			The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants	ONCOGENE			English	Article							CXCR4 ACTIVATION; P53 FUNCTION; CHK2 KINASE; PPM1D; PHOSPHATASE; PATHWAY; EXPRESSION; MUTATIONS; CHILDREN; SUBGROUP	Recent studies suggest that medulloblastoma, the most common malignant brain tumor of childhood, is comprised of four disease variants. The WIP1 oncogene is overexpressed in Group 3 and 4 tumors, which contain medulloblastomas with the most aggressive clinical behavior. Our data demonstrate increased WIP1 expression in metastatic medulloblastomas, and inferior progression-free and overall survival of patients with WIP1 high-expressing medulloblastoma. Microarray analysis identified upregulation of genes involved in tumor metastasis, including the G protein-coupled receptor CXCR4, in medulloblastoma cells with high WIP1 expression. Stimulation with the CXCR4 ligand SDF1a activated PI-3 kinase signaling, and promoted growth and invasion of WIP1 highexpressing medulloblastoma cells in a p53-dependent manner. When xenografted into the cerebellum of immunodeficient mice, medulloblastoma cells with stable or endogenous high WIP1 expression exhibited strong expression of CXCR4 and activated AKT in primary and invasive tumor cells. WIP1 or CXCR4 knockdown inhibited medulloblastoma growth and invasion. WIP1 knockdown also improved the survival of mice xenografted with WIP1 high-expressing medulloblastoma cells. WIP1 knockdown inhibited cell surface localization of CXCR4 by suppressing expression of the G protein receptor kinase 5, GRK5. Restoration of wild-type GRK5 promoted Ser339 phosphorylation of CXCR4 and inhibited the growth of WIP1-stable medulloblastoma cells. Conversely, GRK5 knockdown inhibited Ser339 phosphorylation of CXCR4, increased cell surface localization of CXCR4 and promoted the growth of medulloblastoma cells with low WIP1 expression. These results demonstrate crosstalk among WIP1, CXCR4 and GRK5, which may be important for the aggressive phenotype of a subclass of medulloblastomas in children.	[Buss, M. C.; Lee, J.; Castellino, R. C.] Emory Univ, Dept Pediat, Aflac Canc & Blood Disorders Ctr, Childrens Healthcare Atlanta, Atlanta, GA 30322 USA; [Remke, M.; Taylor, M. D.] Univ Toronto, Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Program Dev & Stem Cell Biol,Div Neurosurg, Toronto, ON M5G 1X8, Canada; [Gandhi, K.] Emory Univ, Dept Human Genet, Sch Med, Atlanta, GA 30322 USA; [Schniederjan, M. J.] Emory Univ, Childrens Healthcare Atlanta, Dept Pathol, Sch Med, Atlanta, GA 30322 USA; [Kool, M.; Northcott, P. A.; Pfister, S. M.] German Canc Res Ctr, Div Pediat Neurooncol, Heidelberg, Germany; [Pfister, S. M.] Univ Heidelberg Hosp, Dept Pediat Hematol Oncol & Immunol, Heidelberg, Germany	Children's Healthcare of Atlanta (CHOA); Emory University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Emory University; Children's Healthcare of Atlanta (CHOA); Emory University; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Castellino, RC (corresponding author), Emory Univ, Dept Pediat, Sch Med, 1760 Haygood Dr NE,Room E394, Atlanta, GA 30322 USA.	rccaste@emory.edu	Northcott, Paul A/N-4022-2018; Pfister, Stefan M/F-6860-2013; Castellino, Robert/GRF-7847-2022	Northcott, Paul A/0000-0002-1220-5252; Pfister, Stefan M/0000-0002-5447-5322; Remke, Marc/0000-0002-9404-9993; Taylor, Michael/0000-0001-7009-3466	NIH [1R01CA172392-01, CA159859]; St Baldrick's Foundation; CURE Childhood Cancer Foundation; Southeastern Brain Tumor Foundation; Emory Egleston Children's Research Center; Dr Mildred-Scheel Foundation; NIH/NCI [P30CA138292]; NATIONAL CANCER INSTITUTE [R01CA172392, P30CA138292, R01CA159859] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); St Baldrick's Foundation; CURE Childhood Cancer Foundation; Southeastern Brain Tumor Foundation; Emory Egleston Children's Research Center; Dr Mildred-Scheel Foundation(Deutsche Krebshilfe); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Jeffrey Benovic, Lawrence Donehower, H Trent Spencer, Laurent Brault, Jurg Schwaller and Rita Nahta for gene expression constructs, Gregory Doho for assistance with analysis of microarrays, and Dr Rita Nahta for editorial assistance. This work was supported by grants from the NIH (1R01CA172392-01, RCC; CA159859, MD Taylor), St Baldrick's Foundation (RCC), CURE Childhood Cancer Foundation (RCC), Southeastern Brain Tumor Foundation (RCC), the Emory Egleston Children's Research Center (RCC) and the Dr Mildred-Scheel Foundation (MR). Research reported in this publication was supported in part by the NIH/NCI under award number P30CA138292. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Barker BL, 2011, BIOCHEMISTRY-US, V50, P6933, DOI 10.1021/bi2005202; BELZA MG, 1991, J NEUROSURG, V75, P575, DOI 10.3171/jns.1991.75.4.0575; Bian XW, 2007, NEUROSURGERY, V61, P570, DOI 10.1227/01.NEU.0000290905.53685.A2; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Buss MC, 2012, NEURO-ONCOLOGY, V14, P440, DOI 10.1093/neuonc/nos001; Calatozzolo C, 2006, CANCER BIOL THER, V5, P827, DOI 10.4161/cbt.5.7.2838; Castellino RC, 2008, J NEURO-ONCOL, V86, P245, DOI 10.1007/s11060-007-9470-8; Castellino RC, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-127; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; Clifford SC, 2006, CELL CYCLE, V5, P2666, DOI 10.4161/cc.5.22.3446; Demidov ON, 2007, ONCOGENE, V26, P2502, DOI 10.1038/sj.onc.1210032; Demidov ON, 2007, CELL STEM CELL, V1, P180, DOI 10.1016/j.stem.2007.05.020; Dhall G, 2009, J CHILD NEUROL, V24, P1418, DOI 10.1177/0883073809341668; Domanska UM, 2013, EUR J CANCER, V49, P219, DOI 10.1016/j.ejca.2012.05.005; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Dudgeon C, 2013, CELL CYCLE, V12, P2656, DOI 10.4161/cc.25694; Ellison DW, 2011, ACTA NEUROPATHOL, V121, P381, DOI 10.1007/s00401-011-0800-8; Ellison DW, 2011, J CLIN ONCOL, V29, P1400, DOI 10.1200/JCO.2010.30.2810; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Gajjar AJ, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.18_suppl.cra9501; Gajjar A, 2006, LANCET ONCOL, V7, P813, DOI 10.1016/S1470-2045(06)70867-1; Gessi M, 2012, J NEURO-ONCOL, V106, P135, DOI 10.1007/s11060-011-0648-8; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Grinkevich VV, 2009, CANCER CELL, V15, P441, DOI 10.1016/j.ccr.2009.03.021; Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146; Kleiblova P, 2013, J CELL BIOL, V201, P511, DOI 10.1083/jcb.201210031; Klein RS, 2001, DEVELOPMENT, V128, P1971; Kool M, 2012, ACTA NEUROPATHOL, V123, P473, DOI 10.1007/s00401-012-0958-8; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lamont JM, 2004, CLIN CANCER RES, V10, P5482, DOI 10.1158/1078-0432.CCR-03-0721; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; Mabbott DJ, 2005, J CLIN ONCOL, V23, P2256, DOI 10.1200/JCO.2005.01.158; McNeil DE, 2002, MED PEDIATR ONCOL, V39, P190, DOI 10.1002/mpo.10121; Mendrzyk F, 2005, J CLIN ONCOL, V23, P8853, DOI 10.1200/JCO.2005.02.8589; Mumert M, 2012, CANCER RES, V72, P4944, DOI 10.1158/0008-5472.CAN-12-1629; Nannenga B, 2006, MOL CARCINOGEN, V45, P594, DOI 10.1002/mc.20195; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; Pan E, 2005, CLIN CANCER RES, V11, P4733; Pandolfi S, 2013, ONCOGENE, V32, P4737, DOI 10.1038/onc.2012.502; Pfister S, 2012, ACTA NEUROPATHOL, V123, P463, DOI 10.1007/s00401-012-0966-8; Pfister S, 2009, J CLIN ONCOL, V27, P1627, DOI 10.1200/JCO.2008.17.9432; Pugh TJ, 2012, NATURE, V488, P106, DOI 10.1038/nature11329; Rao G, 2003, NEOPLASIA, V5, P198, DOI 10.1016/S1476-5586(03)80052-0; Remke M, 2011, J CLIN ONCOL, V29, P3852, DOI 10.1200/JCO.2011.36.2798; Remke M, 2011, J CLIN ONCOL, V29, P2717, DOI 10.1200/JCO.2011.34.9373; Ruark E, 2013, NATURE, V493, P406, DOI 10.1038/nature11725; Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Sengupta R, 2012, CANCER RES, V72, P122, DOI 10.1158/0008-5472.CAN-11-1701; Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Siu IM, 2003, CANCER RES, V63, P4773; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; TORRES CF, 1994, NEW ENGL J MED, V330, P892, DOI 10.1056/NEJM199403313301303; Traenka C, 2010, CANCER RES, V70, P8003, DOI 10.1158/0008-5472.CAN-10-0592; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; von Hoff K, 2009, EUR J CANCER, V45, P1209, DOI 10.1016/j.ejca.2009.01.015; Wang Z, 2010, TRANSL ONCOL, V3, P1, DOI 10.1593/tlo.09250; Woerner BM, 2005, CANCER RES, V65, P11392, DOI 10.1158/0008-5472.CAN-05-0847; Wu X, 2012, NATURE, V482, P529, DOI 10.1038/nature10825; Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386; Yoda A, 2006, J BIOL CHEM, V281, P24847, DOI 10.1074/jbc.M600403200	69	34	35	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1126	1140		10.1038/onc.2014.37	http://dx.doi.org/10.1038/onc.2014.37			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24632620	Green Accepted			2022-12-28	WOS:000350122100006
J	Goldenson, B; Crispino, JD				Goldenson, B.; Crispino, J. D.			The aurora kinases in cell cycle and leukemia	ONCOGENE			English	Review							ACUTE MYELOID-LEUKEMIA; ACUTE MEGAKARYOBLASTIC LEUKEMIA; SMALL-MOLECULE INHIBITOR; TUMOR-AMPLIFIED KINASE; CHROMOSOMAL PASSENGER PROTEIN; ACUTE MYELOGENOUS LEUKEMIA; BIPOLAR SPINDLE FORMATION; A KINASE; MITOTIC ENTRY; B-KINASE	The Aurora kinases, which include Aurora A (AURKA), Aurora B (AURKB) and Aurora C (AURKC), are serine/threonine kinases required for the control of mitosis (AURKA and AURKB) and meiosis (AURKC). Since their discovery nearly 20 years ago, Aurora kinases have been studied extensively in cell and cancer biology. Several early studies found that Aurora kinases are amplified and overexpressed at the transcript and protein level in various malignancies, including several types of leukemia. These discoveries and others provided a rationale for the development of small-molecule inhibitors of Aurora kinases as leukemia therapies. The first generation of Aurora kinase inhibitors did not fare well in clinical trials, owing to poor efficacy and high toxicity. However, the creation of second-generation, highly selective Aurora kinase inhibitors has increased the enthusiasm for targeting these proteins in leukemia. This review will describe the functions of each Aurora kinase, summarize their involvement in leukemia and discuss inhibitor development and efficacy in leukemia clinical trials.	[Goldenson, B.; Crispino, J. D.] Northwestern Univ, Div Hematol Oncol, Chicago, IL 60611 USA	Northwestern University	Crispino, JD (corresponding author), Northwestern Univ, Div Hematol Oncol, 303 East Super St,Lurie 5-113, Chicago, IL 60611 USA.	j-crispino@northwestern.edu		Goldenson, Benjamin/0000-0001-6724-7858; Crispino, John/0000-0002-8182-8306	NIH [R01s CA101774, HL112792]; Samuel Waxman Cancer Research Foundation; Leukemia and Lymphoma Society; National Center for Research Resources (NCRR); National Center for Advancing Translational Sciences (NCATS) [TL1R000108]; NATIONAL CANCER INSTITUTE [R01CA101774] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL112792] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Samuel Waxman Cancer Research Foundation; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences (NCATS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We apologize to those whose work could not be discussed due to space limitations. This review was supported by grants from the NIH (R01s CA101774 and HL112792), the Samuel Waxman Cancer Research Foundation and the Leukemia and Lymphoma Society. BG is supported by the National Center for Research Resources (NCRR) and the National Center for Advancing Translational Sciences (NCATS) (TL1R000108).	Adams RR, 2000, CURR BIOL, V10, P1075, DOI 10.1016/S0960-9822(00)00673-4; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Andrews PD, 2004, DEV CELL, V6, P253, DOI 10.1016/S1534-5807(04)00025-5; Arlot-Bonnemains Y, 2001, FEBS LETT, V508, P149, DOI 10.1016/S0014-5793(01)03048-4; Barr AR, 2007, J CELL SCI, V120, P2987, DOI 10.1242/jcs.013136; Bayliss R, 2003, MOL CELL, V12, P851, DOI 10.1016/S1097-2765(03)00392-7; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; BREITMAN TR, 1981, BLOOD, V57, P1000; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; Cowley DO, 2009, MOL CELL BIOL, V29, P1059, DOI 10.1128/MCB.01062-08; Crane R, 2004, J CELL SCI, V117, P5975, DOI 10.1242/jcs.01418; de Rooij JDE, 2013, LEUKEMIA, V27, P2280, DOI 10.1038/leu.2013.87; Dennis M, 2012, CANCER CHEMOTH PHARM, V70, P461, DOI 10.1007/s00280-012-1939-2; Dieterich K, 2007, NAT GENET, V39, P661, DOI 10.1038/ng2027; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Fei F, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-42; Fernandez-Miranda G, 2011, DEVELOPMENT, V138, P2661, DOI 10.1242/dev.066381; Ferrari S, 2005, BIOCHEM J, V390, P293, DOI 10.1042/BJ20050343; Fu JY, 2009, P NATL ACAD SCI USA, V106, P6939, DOI 10.1073/pnas.0900833106; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Geddis AE, 2004, BLOOD, V104, P1017, DOI 10.1182/blood-2004-02-0419; Geddis AE, 2007, CELL CYCLE, V6, P455, DOI 10.4161/cc.6.4.3836; Geddis AE, 2006, CELL CYCLE, V5, P538, DOI 10.4161/cc.5.5.2537; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; Giles FJ, 2007, BLOOD, V109, P500, DOI 10.1182/blood-2006-05-025049; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Goldberg SL, 2010, BLOOD, V6, P3273; Goto H, 2003, J BIOL CHEM, V278, P8526, DOI 10.1074/jbc.M210892200; Graux C, 2013, LEUKEMIA RES, V37, P1100, DOI 10.1016/j.leukres.2013.04.025; Gruber TA, 2012, CANCER CELL, V22, P683, DOI 10.1016/j.ccr.2012.10.007; Gu J, 2007, CARCINOGENESIS, V28, P350, DOI 10.1093/carcin/bgl149; Hachet V, 2007, DEV CELL, V12, P531, DOI 10.1016/j.devcel.2007.02.015; Hans F, 2009, MOL BIOL CELL, V20, P3491, DOI 10.1091/mbc.E09-05-0370; Hartsink-Segers SA, 2013, LEUKEMIA, V27, P560, DOI 10.1038/leu.2012.256; Haydon CE, 2003, MOL CELL PROTEOMICS, V2, P1055, DOI 10.1074/mcp.M300054-MCP200; Hegarat N, 2011, J CELL BIOL, V195, P1103, DOI 10.1083/jcb.201105058; Hirose K, 2001, J BIOL CHEM, V276, P5821, DOI 10.1074/jbc.M007252200; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hoar K, 2007, MOL CELL BIOL, V27, P4513, DOI 10.1128/MCB.02364-06; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Howard S, 2009, J MED CHEM, V52, P379, DOI 10.1021/jm800984v; Ikezoe T, 2007, MOL CANCER THER, V6, P1851, DOI 10.1158/1535-7163.MCT-07-0067; Jayanthan A, 2013, LEUKEMIA LYMPHOMA, V54, P1505, DOI 10.3109/10428194.2012.752079; Jelinek J, 2005, BLOOD, V106, P3370, DOI 10.1182/blood-2005-05-1800; Kaestner P, 2009, MOL CANCER THER, V8, P2046, DOI 10.1158/1535-7163.MCT-09-0323; Kantarjian HM, 2013, CANCER-AM CANCER SOC, V119, P2611, DOI 10.1002/cncr.28113; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Kawasaki A, 2001, J CELL BIOL, V152, P275, DOI 10.1083/jcb.152.2.275; Ke YW, 2003, CELL RES, V13, P69, DOI 10.1038/sj.cr.7290152; Kelly KR, 2012, INT J CANCER, V131, P2693, DOI 10.1002/ijc.27579; Kelly KR, 2011, J CELL MOL MED, V15, P2057, DOI 10.1111/j.1582-4934.2010.01218.x; Khan J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026512; Kimmins S, 2007, MOL ENDOCRINOL, V21, P726, DOI 10.1210/me.2006-0332; Kimura M, 1999, J BIOL CHEM, V274, P7334, DOI 10.1074/jbc.274.11.7334; Kimura M, 1998, CYTOGENET CELL GENET, V82, P147, DOI 10.1159/000015089; Kimura M, 2004, BIOCHEM BIOPH RES CO, V316, P930, DOI 10.1016/j.bbrc.2004.01.178; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Kiyoi H, 2007, LEUKEMIA, V21, P574, DOI 10.1038/sj.leu.2404527; Kollareddy M, 2012, INVEST NEW DRUG, V30, P2411, DOI 10.1007/s10637-012-9798-6; Krystyniak A, 2006, ONCOGENE, V25, P338, DOI 10.1038/sj.onc.1209056; Lan WJ, 2004, CURR BIOL, V14, P273, DOI 10.1016/j.cub.2004.01.055; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964; Leow S, 2011, HEMATOL ONCOL, V29, P211, DOI 10.1002/hon.987; Li QY, 2004, J BIOL CHEM, V279, P52175, DOI 10.1074/jbc.M406802200; Li XY, 2004, J BIOL CHEM, V279, P47201, DOI 10.1074/jbc.M403029200; Lim SK, 2007, BIOCHEM J, V403, P119, DOI 10.1042/BJ20061272; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Littlepage LE, 2002, P NATL ACAD SCI USA, V99, P15440, DOI 10.1073/pnas.202606599; Liu Q, 2006, P NATL ACAD SCI USA, V103, P5811, DOI 10.1073/pnas.0601425103; Lordier L, 2008, BLOOD, V112, P3164, DOI 10.1182/blood-2008-03-144956; Lordier L, 2010, BLOOD, V116, P2345, DOI 10.1182/blood-2010-01-265785; Lowenberg B, 2011, BLOOD, V118, P6030, DOI 10.1182/blood-2011-07-366930; Lu LY, 2008, J BIOL CHEM, V283, P31785, DOI 10.1074/jbc.M805880200; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Macurek L, 2008, NATURE, V455, P119, DOI 10.1038/nature07185; Malinge S, 2008, BLOOD, V112, P4220, DOI 10.1182/blood-2008-01-136366; Manfredi MG, 2007, P NATL ACAD SCI USA, V104, P4106, DOI 10.1073/pnas.0608798104; Manfredi MG, 2011, CLIN CANCER RES, V17, P7614, DOI 10.1158/1078-0432.CCR-11-1536; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Mao JH, 2007, CANCER CELL, V11, P161, DOI 10.1016/j.ccr.2006.11.025; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Mercher T, 2009, J CLIN INVEST, V119, P852, DOI 10.1172/JCI35901; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Mita M, 2013, TARGET ONCOL; Mori D, 2007, MOL CELL BIOL, V27, P352, DOI 10.1128/MCB.00878-06; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nair JS, 2012, CELL CYCLE, V11, P807, DOI 10.4161/cc.11.4.19323; Nguyen HG, 2009, FASEB J, V23, P2741, DOI 10.1096/fj.09-130963; Nguyen HG, 2005, MOL CELL BIOL, V25, P4977, DOI 10.1128/MCB.25.12.4977-4992.2005; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nikolaev SI, 2013, BLOOD, V122, P554, DOI 10.1182/blood-2013-03-491936; Ohi R, 2004, MOL BIOL CELL, V15, P2895, DOI 10.1091/mbc.E04-02-0082; Okabe S, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-32; Oke A, 2009, CANCER RES, V69, P4150, DOI 10.1158/0008-5472.CAN-08-3203; Ota T, 2002, CANCER RES, V62, P5168; Peset I, 2005, J CELL BIOL, V170, P1057, DOI 10.1083/jcb.200504037; Petretti C, 2006, EMBO REP, V7, P418, DOI 10.1038/sj.embor.7400639; Portier N, 2007, DEV CELL, V12, P515, DOI 10.1016/j.devcel.2007.01.019; Qi WQ, 2012, INT J CANCER, V130, P2997, DOI 10.1002/ijc.26324; Radtke I, 2009, P NATL ACAD SCI USA, V106, P12944, DOI 10.1073/pnas.0903142106; Raymond E, 2014, INVEST NEW DRUG, V32, P94, DOI 10.1007/s10637-013-9950-y; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Sasai K, 2004, CELL MOTIL CYTOSKEL, V59, P249, DOI 10.1002/cm.20039; Satinover DL, 2006, CELL CYCLE, V5, P2268, DOI 10.4161/cc.5.19.3316; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; Seki A, 2008, SCIENCE, V320, P1655, DOI 10.1126/science.1157425; Shah M, 2012, BLOOD CELL MOL DIS, V48, P199, DOI 10.1016/j.bcmd.2012.01.005; Shu FJ, 2003, MOL CELL BIOCHEM, V254, P157, DOI 10.1023/A:1027317014159; Steensma DP, 2006, LEUKEMIA, V20, P971, DOI 10.1038/sj.leu.2404206; Stenoien DL, 2003, CELL MOTIL CYTOSKEL, V55, P134, DOI 10.1002/cm.10120; Stewart S, 2005, CANCER RES, V65, P8730, DOI 10.1158/0008-5472.CAN-05-1500; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; SUNKEL CE, 1988, J CELL SCI, V89, P25; Taguchi S, 2002, FEBS LETT, V519, P59, DOI 10.1016/S0014-5793(02)02711-4; Tallman MS, 2002, BLOOD, V99, P759, DOI 10.1182/blood.V99.3.759; Tanaka M, 2002, J BIOL CHEM, V277, P10719, DOI 10.1074/jbc.M108252200; Tatsuka M, 2005, ONCOGENE, V24, P1122, DOI 10.1038/sj.onc.1208293; Terada Y, 2003, J CELL BIOL, V162, P757, DOI 10.1083/jcb.200305048; Terada Y, 2001, CELL STRUCT FUNCT, V26, P653, DOI 10.1247/csf.26.653; Thiollier C, 2012, J EXP MED, V209, P2017, DOI 10.1084/jem.20121343; Toji S, 2004, GENES CELLS, V9, P383, DOI 10.1111/j.1356-9597.2004.00732.x; Tsou JH, 2011, J PATHOL, V225, P243, DOI 10.1002/path.2934; Tsuboi K, 2011, LEUKEMIA RES, V35, P1384, DOI 10.1016/j.leukres.2011.04.008; Vader G, 2008, BBA-REV CANCER, V1786, P60, DOI 10.1016/j.bbcan.2008.07.003; Vagnarelli P, 2004, CHROMOSOMA, V113, P211, DOI 10.1007/s00412-004-0307-3; VERNOS I, 1995, TRENDS CELL BIOL, V5, P297, DOI 10.1016/S0962-8924(00)89045-5; Vitrat N, 1998, BLOOD, V91, P3711; Walsby E, 2008, HAEMATOLOGICA, V93, P662, DOI 10.3324/haematol.12148; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Walters DK, 2006, CANCER CELL, V10, P65, DOI 10.1016/j.ccr.2006.06.002; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wen Q, 2012, CELL, V150, P575, DOI 10.1016/j.cell.2012.06.032; Wen Q, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411002043; Wysong DR, 2009, CELL CYCLE, V8, P876, DOI 10.4161/cc.8.6.7897; Yamauchi T, 2013, CANCER SCI, V104, P926, DOI 10.1111/cas.12164; Yan XM, 2005, GENES CELLS, V10, P617, DOI 10.1111/j.1365-2443.2005.00863.x; Yang J, 2007, BLOOD, V110, P2034, DOI 10.1182/blood-2007-02-073700; Yang J, 2013, INT J CANCER, V133, P2706, DOI 10.1002/ijc.28277; Ye Dongjiu, 2009, J Hematop, V2, P2, DOI 10.1007/s12308-008-0019-3; Yoon Y, 2012, DEV BIOL, V371, P77, DOI 10.1016/j.ydbio.2012.08.010; Yoshida K, 2013, NAT GENET; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538; Yuan HF, 2012, CARCINOGENESIS, V33, P285, DOI 10.1093/carcin/bgr278; Zekri A, 2012, ONCOL RES, V20, P241, DOI 10.3727/096504013X13589503482978; Zhang Y, 2004, BLOOD, V103, P3717, DOI 10.1182/blood-2003-09-3365; Zhang Y, 2001, BIOCHEM BIOPH RES CO, V282, P844, DOI 10.1006/bbrc.2001.4635; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	153	188	193	1	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					537	545		10.1038/onc.2014.14	http://dx.doi.org/10.1038/onc.2014.14			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24632603	Green Accepted			2022-12-28	WOS:000348853500001
J	Sales, KU; Friis, S; Konkel, JE; Godiksen, S; Hatakeyama, M; Hansen, KK; Rogatto, SR; Szabo, R; Vogel, LK; Chen, W; Gutkind, JS; Bugge, TH				Sales, K. U.; Friis, S.; Konkel, J. E.; Godiksen, S.; Hatakeyama, M.; Hansen, K. K.; Rogatto, S. R.; Szabo, R.; Vogel, L. K.; Chen, W.; Gutkind, J. S.; Bugge, T. H.			Non-hematopoietic PAR-2 is essential for matriptase-driven pre-malignant progression and potentiation of ras-mediated squamous cell carcinogenesis	ONCOGENE			English	Article						epithelial carcinogenesis; inflammation; keratinocyte stem cells; pericellular proteolysis	PROTEINASE-ACTIVATED RECEPTOR-2; SERINE-PROTEASE MATRIPTASE; TISSUE MICROARRAY ANALYSIS; HUMAN KERATINOCYTES; CLINICOPATHOLOGICAL PARAMETERS; GENE-EXPRESSION; OVARIAN-CANCER; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; IN-VITRO	The membrane-anchored serine protease, matriptase, is consistently dysregulated in a range of human carcinomas, and high matriptase activity correlates with poor prognosis. Furthermore, matriptase is unique among tumor-associated proteases in that epithelial stem cell expression of the protease suffices to induce malignant transformation. Here, we use genetic epistasis analysis to identify proteinase-activated receptor (PAR)-2-dependent inflammatory signaling as an essential component of matriptase-mediated oncogenesis. In cell-based assays, matriptase was a potent activator of PAR-2, and PAR-2 activation by matriptase caused robust induction of nuclear factor (NF)kappa B through G alpha i. Importantly, genetic elimination of PAR-2 from mice completely prevented matriptase-induced pre-malignant progression, including inflammatory cytokine production, inflammatory cell recruitment, epidermal hyperplasia and dermal fibrosis. Selective ablation of PAR-2 from bone marrow-derived cells did not prevent matriptase-driven pre-malignant progression, indicating that matriptase activates keratinocyte stem cell PAR-2 to elicit its pro-inflammatory and pro-tumorigenic effects. When combined with previous studies, our data suggest that dual induction of PAR-2-NF kappa B inflammatory signaling and PI3K-Akt-mTor survival/proliferative signaling underlies the transforming potential of matriptase and may contribute to pro-tumorigenic signaling in human epithelial carcinogenesis.	[Sales, K. U.; Friis, S.; Konkel, J. E.; Godiksen, S.; Hansen, K. K.; Szabo, R.; Chen, W.; Gutkind, J. S.; Bugge, T. H.] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; [Sales, K. U.] Natl Inst Dent & Craniofacial Res, Clin Res Core, NIH, Bethesda, MD 20892 USA; [Friis, S.; Godiksen, S.; Vogel, L. K.] Univ Copenhagen, Fac Hlth & Med Sci, Dept Cellular & Mol Med, Copenhagen, Denmark; [Godiksen, S.] Univ Copenhagen, Fac Sci, Dept Biol, Copenhagen, Denmark; [Hatakeyama, M.; Rogatto, S. R.] Sao Paulo State Univ UNESP, Fac Med, Dept Urol, Botucatu, SP, Brazil; [Hatakeyama, M.; Rogatto, S. R.] AC Camargo Canc Ctr, Sao Paulo, Brazil	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Copenhagen; University of Copenhagen; Universidade Estadual Paulista; A.C.Camargo Cancer Center	Bugge, TH (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Room 211, Bethesda, MD 20892 USA.	thomas.bugge@nih.gov	Gutkind, J. Silvio/J-1201-2016; Rogatto, Silvia R/E-6535-2012; sales, katiuchia u/J-4880-2012	Gutkind, J. Silvio/0000-0002-5150-4482; sales, katiuchia/0000-0002-3768-5790; Vogel, Lotte K./0000-0001-9920-0982; Rogatto, Silvia/0000-0003-4637-5687	NIDCR Intramural Research Program; Augustinus Foundation, Kobmand Kristian Kjaer og hustrus Foundation; Kjaer-Foundation; Dagmar Marshalls Foundation; Snedkermester Sophus Jacobsen og Hustru Astrid Jacobsens Foundation; Grosserer Valdemar Foersom og Hustru Thyra Foersoms Foundation; Fabrikant Einar Willumsens Mindelegat; Sao Paulo Research Foundation (FAPESP); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000558, ZIADE000551, ZIADE000699] Funding Source: NIH RePORTER	NIDCR Intramural Research Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Augustinus Foundation, Kobmand Kristian Kjaer og hustrus Foundation; Kjaer-Foundation; Dagmar Marshalls Foundation; Snedkermester Sophus Jacobsen og Hustru Astrid Jacobsens Foundation; Grosserer Valdemar Foersom og Hustru Thyra Foersoms Foundation; Fabrikant Einar Willumsens Mindelegat; Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr Mary Jo Danton for critically reviewing this manuscript. Histology was performed by Histoserv, Germantown, MD, USA. We thank Dr Allessia Gallo, Shyh-Ing Jang, Colleen Doci, Patricia Pilla, Zhiyong Wang, Canstantinos Mikelis, Ramiro Iglesias-Bartolome and Morgan O'Hare for technical assistance. The study was supported by the NIDCR Intramural Research Program (THB, JSG, WC), the Augustinus Foundation, Kobmand Kristian Kjaer og hustrus Foundation, the Kjaer-Foundation, the Dagmar Marshalls Foundation, the Snedkermester Sophus Jacobsen og Hustru Astrid Jacobsens Foundation, the Grosserer Valdemar Foersom og Hustru Thyra Foersoms Foundation and Fabrikant Einar Willumsens Mindelegat (SG and LKV), and the Sao Paulo Research Foundation (FAPESP) (MH, SRR).	Benaud C, 2002, J BIOL CHEM, V277, P10539, DOI 10.1074/jbc.M109064200; Bocheva G, 2009, J INVEST DERMATOL, V129, P1816, DOI 10.1038/jid.2008.449; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Buddenkotte J, 2005, J INVEST DERMATOL, V124, P38, DOI 10.1111/j.0022-202X.2004.23539.x; Bugge TH, 2009, J BIOL CHEM, V284, P23177, DOI 10.1074/jbc.R109.021006; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Camerer E, 1996, J BIOL CHEM, V271, P29034, DOI 10.1074/jbc.271.46.29034; Camerer E, 2002, J BIOL CHEM, V277, P16081, DOI 10.1074/jbc.M108555200; Camerer E, 2010, DEV CELL, V18, P25, DOI 10.1016/j.devcel.2009.11.014; Cataisson C, 2012, J EXP MED, V209, P1689, DOI 10.1084/jem.20101355; Chokki M, 2004, AM J RESP CELL MOL, V30, P470, DOI 10.1165/rcmb.2003-0199OC; Coughlin SR, 2003, J CLIN INVEST, V111, P25, DOI 10.1172/JCI200317564; Frateschi S, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1162; Friis S, 2013, J BIOL CHEM, V288, P19028, DOI 10.1074/jbc.M113.469932; Hoang CD, 2004, CHEST, V125, P1843, DOI 10.1378/chest.125.5.1843; Hou L, 1998, IMMUNOLOGY, V94, P356, DOI 10.1046/j.1365-2567.1998.00528.x; Jin JS, 2006, MODERN PATHOL, V19, P447, DOI 10.1038/modpathol.3800495; Jin JS, 2006, INT J SURG PATHOL, V14, P65, DOI 10.1177/106689690601400111; Johnson MD, 2003, EXPERT REV MOL DIAGN, V3, P331, DOI 10.1586/14737159.3.3.331; Kang JY, 2003, CANCER RES, V63, P1101; Kanke T, 2001, J BIOL CHEM, V276, P31657, DOI 10.1074/jbc.M100377200; Kaufmann R, 2009, CARCINOGENESIS, V30, P1487, DOI 10.1093/carcin/bgp153; LeBeau AM, 2013, P NATL ACAD SCI USA, V110, P93, DOI 10.1073/pnas.1218694110; Lee JW, 2005, HUM PATHOL, V36, P626, DOI 10.1016/j.humpath.2005.03.003; Lindner JR, 2000, J IMMUNOL, V165, P6504, DOI 10.4049/jimmunol.165.11.6504; List K, 2006, AM J PATHOL, V168, P1513, DOI 10.2353/ajpath.2006.051071; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; List K, 2009, FUTURE ONCOL, V5, P97, DOI 10.2217/14796694.5.1.97; Lopez-Otin C, 2010, NAT REV CANCER, V10, P278, DOI 10.1038/nrc2823; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; Oberst M, 2001, AM J PATHOL, V158, P1301, DOI 10.1016/S0002-9440(10)64081-3; Oberst MD, 2002, CLIN CANCER RES, V8, P1101; Oikonomopoulou K, 2006, J BIOL CHEM, V281, P32095, DOI 10.1074/jbc.M513138200; Perez-Moreno M, 2006, CELL, V124, P631, DOI 10.1016/j.cell.2005.11.043; Ramsay AJ, 2008, J BIOL CHEM, V283, P12293, DOI 10.1074/jbc.M709493200; Rothmeier AS, SEMIN IMMUNOPATHOL, V34, P133; SANTULLI RJ, 1995, P NATL ACAD SCI USA, V92, P9151, DOI 10.1073/pnas.92.20.9151; Schaffner F, 2008, SEMIN THROMB HEMOST, V34, P147, DOI 10.1055/s-2008-1079254; Schmidlin F, 2002, J IMMUNOL, V169, P5315, DOI 10.4049/jimmunol.169.9.5315; Scott G, 2004, J INVEST DERMATOL, V122, P1214, DOI 10.1111/j.0022-202X.2004.22516.x; Scott G, 2003, J INVEST DERMATOL, V121, P529, DOI 10.1046/j.1523-1747.2003.12427.x; Seitz I, 2007, ARTERIOSCL THROM VAS, V27, P769, DOI 10.1161/01.ATV.0000258862.61067.14; Szabo R, 2011, ONCOGENE, V30, P2003, DOI 10.1038/onc.2010.586; Szabo R, 2008, J BIOL CHEM, V283, P29495, DOI 10.1074/jbc.M801970200; Szabo R, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002937; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tanimoto H, 2005, BRIT J CANCER, V92, P278, DOI 10.1038/sj.bjc.6602320; Vogel LK, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-176; Wakita H, 1997, P ASSOC AM PHYSICIAN, V109, P190; Wilson S, 2005, BIOCHEM J, V388, P967, DOI 10.1042/BJ20041066	51	37	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					288	298		10.1038/onc.2013.563	http://dx.doi.org/10.1038/onc.2013.563			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24469043	Green Accepted			2022-12-28	WOS:000348145500003
J	Kim, HP; Cho, GA; Han, SW; Shin, JY; Jeong, EG; Song, SH; Lee, WC; Lee, KH; Bang, D; Seo, JS; Kim, JI; Kim, TY				Kim, H-P; Cho, G-A; Han, S-W; Shin, J-Y; Jeong, E-G; Song, S-H; Lee, W-C; Lee, K-H; Bang, D.; Seo, J-S; Kim, J-Il; Kim, T-Y			Novel fusion transcripts in human gastric cancer revealed by transcriptome analysis	ONCOGENE			English	Article						gene fusion; fusion transcript; gastric cancer; transcriptome sequencing; next-generation sequencing	PROSTATE-CANCER; GENE FUSIONS; KINASE; MET; IDENTIFICATION; REARRANGEMENTS; INHIBITORS; DISCOVERY; RNAS	Gene fusion is involved in the development of various types of malignancies. Recent advances in sequencing technology have facilitated identification of gene fusions and have stimulated the research of this field in cancer. In the present study, we performed next-generation transcriptome sequencing in order to discover novel gene fusions in gastric cancer. A total of 282 fusion transcript candidates were detected from 12 gastric cancer cell lines by bioinformatic filtering. Among the candidates, we have validated 19 fusion transcripts, which are 7 inter-chromosomal and 12 intra-chromosomal fusions. A novel DUS4L-BCAP29 fusion transcript was found in 2 out of 12 cell lines and 10 out of 13 gastric cancer tissues. Knockdown of DUS4L-BCAP29 transcript using siRNA inhibited cell proliferation. Soft agar assay further confirmed that this novel fusion transcript has tumorigenic potential. We also identified that microRNA-coding gene PVT1, which is amplified in double minute chromosomes in SNU-16 cells, is recurrently involved in gene fusion. PVT1 produced six different fusion transcripts involving four different genes as fusion partners. Our findings provide better insight into transcriptional and genetic alterations of gastric cancer: namely, the tumorigenic effects of transcriptional read-through and a candidate region for genetic instability.	[Kim, H-P; Cho, G-A; Han, S-W; Jeong, E-G; Song, S-H; Lee, K-H; Kim, T-Y] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110744, South Korea; [Han, S-W; Lee, K-H; Kim, T-Y] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul Natl Univ Hosp, Seoul 110744, South Korea; [Shin, J-Y; Lee, W-C; Seo, J-S; Kim, J-Il] Seoul Natl Univ, Genom Med Inst, Med Res Ctr, Seoul 110744, South Korea; [Shin, J-Y; Seo, J-S; Kim, J-Il] Psoma Therapeut Inc, Seoul, South Korea; [Lee, W-C; Seo, J-S; Kim, J-Il] Seoul Natl Univ, Grad Sch, Dept Biomed Sci, Seoul 110744, South Korea; [Bang, D.] Yonsei Univ, Coll Sci, Dept Chem, Seoul 120749, South Korea; [Seo, J-S; Kim, J-Il] Seoul Natl Univ, Coll Med, Dept Biochem, Seoul 110744, South Korea; [Seo, J-S] Macrogen Inc, Seoul, South Korea; [Kim, T-Y] Seoul Natl Univ, Coll Med, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul 110744, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University (SNU); Yonsei University; Seoul National University (SNU); Macrogen, Inc.; Seoul National University (SNU)	Kim, TY (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, 101 Daehak Ro, Seoul 110744, South Korea.	kimty@snu.ac.kr	KIM, JONG-IL/D-1019-2011; Lee, Won-Chul/D-5789-2012; Seo, Jeong-Sun/J-2763-2012	KIM, JONG-IL/0000-0002-7240-3744; Lee, Won-Chul/0000-0001-8052-2420; 	Korean Healthcare 21 and Technology R& D project, Ministry for Health, Welfare & Family Affairs, Republic of Korea [A091081]; National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology, Republic of Korea [2009-0093820]	Korean Healthcare 21 and Technology R& D project, Ministry for Health, Welfare & Family Affairs, Republic of Korea; National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology, Republic of Korea(Ministry of Education, Science & Technology (MEST), Republic of KoreaNational Research Foundation of Korea)	This study was partially funded by the Korean Healthcare 21 and Technology R& D project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (Grant No. A091081), and by the Priority Research Centers Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology, Republic of Korea (2009-0093820).	Berger MF, 2010, GENOME RES, V20, P413, DOI 10.1101/gr.103697.109; Edgren H, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r6; Forment JV, 2012, NAT REV CANCER, V12, P663, DOI 10.1038/nrc3352; FUSHIDA S, 1993, INT J ONCOL, V3, P1067; Gozgit JM, 2012, MOL CANCER THER, V11, P690, DOI 10.1158/1535-7163.MCT-11-0450; Huppi K, 2008, MOL CANCER RES, V6, P212, DOI 10.1158/1541-7786.MCR-07-0105; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Ju YS, 2012, GENOME RES, V22, P436, DOI 10.1101/gr.133645.111; Jung KW, 2013, CANCER RES TREAT, V45, P15, DOI 10.4143/crt.2013.45.1.15; Kannan K, 2011, P NATL ACAD SCI USA, V108, P9172, DOI 10.1073/pnas.1100489108; Katoh Y, 2009, INT J MOL MED, V23, P307, DOI 10.3892/ijmm_00000132; Kawamata N, 2009, LEUKEMIA RES, V33, P569, DOI 10.1016/j.leukres.2008.07.030; Ku Ja-Lok, 2005, Cancer Res Treat, V37, P1, DOI 10.4143/crt.2005.37.1.1; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Letunic I, 2011, NUCLEIC ACIDS RES, V39, pW475, DOI [10.1093/nar/gkr201, 10.1093/nar/gkr931]; Li H, 2008, SCIENCE, V321, P1357, DOI 10.1126/science.1156725; Li H, 2009, CELL CYCLE, V8, P218, DOI 10.4161/cc.8.2.7358; Malumbres M, 2008, TRENDS PHARMACOL SCI, V29, P16, DOI 10.1016/j.tips.2007.10.012; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Nagoshi H, 2012, CANCER RES, V72, P4954, DOI 10.1158/0008-5472.CAN-12-0213; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Peters S, 2012, NAT REV CLIN ONCOL, V9, P314, DOI 10.1038/nrclinonc.2012.71; Pflueger D, 2011, GENOME RES, V21, P56, DOI 10.1101/gr.110684.110; Robinson DR, 2011, NAT MED, V17, P1646, DOI 10.1038/nm.2580; Savage DG, 2002, NEW ENGL J MED, V346, P683, DOI 10.1056/NEJMra013339; Sboner A, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r104; Seo JS, 2012, GENOME RES, V22, P2109, DOI 10.1101/gr.145144.112; Sigrist CJA, 2013, NUCLEIC ACIDS RES, V41, pE344, DOI 10.1093/nar/gks1067; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Tao J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001423; Underiner TL, 2010, ANTI-CANCER AGENT ME, V10, P7, DOI 10.2174/1871520611009010007; Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057; Zang ZJ, 2011, CANCER RES, V71, P29, DOI 10.1158/0008-5472.CAN-10-1749; Zhang YM, 2012, CANCER DISCOV, V2, P598, DOI 10.1158/2159-8290.CD-12-0042	35	60	67	1	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2014	33	47					5434	5441		10.1038/onc.2013.490	http://dx.doi.org/10.1038/onc.2013.490			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MG	24240688				2022-12-28	WOS:000345120700005
J	Tan, M; Li, H; Sun, Y				Tan, M.; Li, H.; Sun, Y.			Endothelial deletion of Sag/Rbx2/Roc2 E3 ubiquitin ligase causes embryonic lethality and blocks tumor angiogenesis	ONCOGENE			English	Article						angiogenesis; anti-angiogenesis therapy; MLN4924; Sag cKO mouse model; SAG-CRL E3 ligase; vasculogenesis	CULLIN-RING LIGASES; FOCAL ADHESION KINASE; NEDD8-ACTIVATING ENZYME; CELL-GROWTH; NEOPLASTIC TRANSFORMATION; APOPTOSIS PROTECTION; ANTIOXIDANT PROTEIN; ANTICANCER TARGETS; CANCER CELLS; SCF	SAG (Sensitive to Apoptosis Gene), also known as RBX2 or ROC2, is a RING protein required for the activity of Cullin-RING ligase (CRL). Our recent study showed that Sag total knockout caused embryonic lethality at E11.5-12.5 days with associated defects in vasculogenesis. Whether Sag is required for de novo vasculogenesis in embryos and angiogenesis in tumors is totally unknown. Here, we report that Sag endothelial deletion also causes embryonic lethality at E15.5 with poor vasculogenesis. Sag deletion in primary endothelial cells (ECs) or knockdown in MS-1 ECs inhibits migration, proliferation and tube formation, with p27 accumulation being responsible for the suppression of migration and proliferation. Furthermore, Sag deletion significantly inhibits angiogenesis in an in vivo Matrigel plug assay, and tumor angiogenesis and tumorigenesis in a B16F10 melanoma model. Finally, MLN4924, an investigational small molecule inhibitor of NEDD8-activating enzyme (NAE) that inhibits CRL, suppresses in vitro migration, proliferation and tube formation, as well as in vivo angiogenesis and tumorigenesis. Taken together, our study, using both genetic and pharmaceutical approaches, demonstrates that Sag is essential for embryonic vasculogenesis and tumor angiogenesis, and provides the proof-of-concept evidence that targeting Sag E3 ubiquitin ligase may have clinical value for anti-angiogenesis therapy of human cancer.	[Tan, M.; Li, H.; Sun, Y.] Univ Michigan, Div Radiat & Canc Biol, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Sun, Y (corresponding author), Univ Michigan, Div Radiat & Canc Biol, Dept Radiat Oncol, 4424B MS-1,1301 Catherine St, Ann Arbor, MI 48109 USA.	sunyi@umich.edu	Sun, Yi/K-1025-2014	Sun, Yi/0000-0002-5841-4287	NCI [CA118762, CA156744, CA170995, CA171277]; NATIONAL CANCER INSTITUTE [R21CA170995, R01CA156744, R01CA171277, R01CA118762] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Millennium Pharmaceuticals, Inc. for providing MLN4924. This work is supported by the NCI grants (CA118762, CA156744, CA170995, and CA171277) to YS.	Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Bockbrader KM, 2005, ONCOGENE, V24, P7381, DOI 10.1038/sj.onc.1208888; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Deshaies RJ, 2010, SUBCELL BIOCHEM, V54, P41, DOI 10.1007/978-1-4419-6676-6_4; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Diez-Juan Antonio, 2003, Current Vascular Pharmacology, V1, P99; Duan HJ, 1999, MOL CELL BIOL, V19, P3145; Duan HJ, 2001, MOL CARCINOGEN, V30, P37, DOI 10.1002/1098-2744(200101)30:1<37::AID-MC1011>3.0.CO;2-7; Duda DM, 2008, CELL, V134, P995, DOI 10.1016/j.cell.2008.07.022; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Goldenberg SJ, 2004, CELL, V119, P517, DOI 10.1016/j.cell.2004.10.019; Grunstein J, 1999, CANCER RES, V59, P1592; Gu QY, 2007, J CELL BIOL, V178, P1009, DOI 10.1083/jcb.200612067; Gu QY, 2007, CANCER RES, V67, P3616, DOI 10.1158/0008-5472.CAN-06-4020; He HB, 2008, CARCINOGENESIS, V29, P858, DOI 10.1093/carcin/bgn021; Huang YH, 2001, MOL CARCINOGEN, V30, P62, DOI 10.1002/1098-2744(200101)30:1<62::AID-MC1014>3.3.CO;2-1; Jia L, 2011, CURR CANCER DRUG TAR, V11, P347, DOI 10.2174/156800911794519734; Jia LJ, 2010, CLIN CANCER RES, V16, P814, DOI 10.1158/1078-0432.CCR-09-1592; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nawrocki ST, 2012, EXPERT OPIN INV DRUG, V21, P1563, DOI 10.1517/13543784.2012.707192; Park AYJ, 2009, J BIOL CHEM, V284, P9418, DOI 10.1074/jbc.M809040200; Rabut G, 2008, EMBO REP, V9, P969, DOI 10.1038/embor.2008.183; Schiappacassi M, 2008, MOL CANCER THER, V7, P1164, DOI 10.1158/1535-7163.MCT-07-2154; Shen TL, 2005, J CELL BIOL, V169, P941, DOI 10.1083/jcb.200411155; Soucy Teresa A, 2010, Genes Cancer, V1, P708, DOI 10.1177/1947601910382898; Soucy TA, 2009, CLIN CANCER RES, V15, P3912, DOI 10.1158/1078-0432.CCR-09-0343; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Sun Y, 2001, ANTIOXID REDOX SIGN, V3, P635, DOI 10.1089/15230860152542989; Sun Y, 1999, CARCINOGENESIS, V20, P1899, DOI 10.1093/carcin/20.10.1899; Sun Y, 2013, PROTEIN CELL, V4, P103, DOI 10.1007/s13238-012-2105-7; Swaroop M, 2000, ONCOGENE, V19, P2855, DOI 10.1038/sj.onc.1203635; Tan M, 2008, ONCOGENE, V27, P1404, DOI 10.1038/sj.onc.1210780; Tan MJ, 2006, NEOPLASIA, V8, P1042, DOI 10.1593/neo.06568; Tan MJ, 2011, DEV CELL, V21, P1062, DOI 10.1016/j.devcel.2011.09.014; Tan MJ, 2010, FREE RADICAL BIO MED, V49, P976, DOI 10.1016/j.freeradbiomed.2010.05.030; Tan M, 2009, P NATL ACAD SCI USA, V106, P6203, DOI 10.1073/pnas.0812425106; Wander SA, 2011, CLIN CANCER RES, V17, P12, DOI 10.1158/1078-0432.CCR-10-0752; Wang XQ, 2008, TUMOR BIOL, V29, P217, DOI 10.1159/000152939; Wei DP, 2012, CANCER RES, V72, P282, DOI 10.1158/0008-5472.CAN-11-2866; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Xirodimas DP, 2008, BIOCHEM SOC T, V36, P802, DOI 10.1042/BST0360802; Yamoah K, 2008, P NATL ACAD SCI USA, V105, P12230, DOI 10.1073/pnas.0806155105; Yang GY, 2001, J CEREBR BLOOD F MET, V21, P722, DOI 10.1097/00004647-200106000-00010; Zhao XF, 2010, J CELL BIOL, V189, P955, DOI 10.1083/jcb.200912094; Zhao YC, 2013, CURR PHARM DESIGN, V19, P3215, DOI 10.2174/13816128113199990300; Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101	49	20	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2014	33	44					5211	5220		10.1038/onc.2013.473	http://dx.doi.org/10.1038/onc.2013.473			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR9RZ	24213570	Green Accepted			2022-12-28	WOS:000343914900008
J	Ballesteros-Arias, L; Saavedra, V; Morata, G				Ballesteros-Arias, L.; Saavedra, V.; Morata, G.			Cell competition may function either as tumour-suppressing or as tumour-stimulating factor in Drosophila	ONCOGENE			English	Article						cell competition; apoptosis; Rab5; tumour development; imaginal discs	CASPASE DRONC; ENDOCYTIC CONTROL; APOPTOTIC CELLS; GENETIC SCREEN; JNK; PROLIFERATION; SURVIVAL; MUTANTS; DEATH; RAS	Drosophila endocytosis-defective cells develop tumour overgrowths in the imaginal discs. We have analysed the tumorigenic potential of cells mutant for Rab5, a gene involved in endocytosis. We found that while a compartment entirely made by Rab5 mutant cells can grow indefinitely, clones of Rab5 cells surrounded by normal cells are eliminated by cell competition. However, when a group of about 400 cells are simultaneously made mutant for Rab5, they form an overgrowing tumour: mutant cells in the periphery are eliminated, but those inside survive and continue proliferating because they are beyond the range of cell competition. These results identify group protection as a mechanism to evade the tumour-suppressing function of cell competition in Drosophila. Furthermore, we find that the growth of the tumour depends to a large extent on the presence of apoptosis inside the tumour: cells doubly mutant for Rab5 and the proapoptotic gene dronc do not form overgrowing tumours. These results suggest that the apoptosis caused by cell competition acts as a tumour-stimulating factor, bringing about high levels of Jun N-terminal kinase and subsequently Wg/Dpp signalling and high proliferation levels in the growing tumour. We conclude that under these circumstances cell competition facilitates the progression of the tumour, thus reversing its normal antitumour role.	[Ballesteros-Arias, L.; Saavedra, V.; Morata, G.] Univ Autonoma Madrid, CSIC, Ctr Biol Mol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Morata, G (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol, Nicolas Cabrera 1, E-28049 Madrid, Spain.	gmorata@cbm.uam.es		Morata, Gines/0000-0003-3274-5173; Ballesteros-Arias, Luna/0000-0002-5701-699X	Ministerio de Economia y Competitividad [BFU2008-03196, CSD2007-00008]; Comunidad de Madrid [CELDEV S2006/SAL-0190]; Fundacion Ramon Areces	Ministerio de Economia y Competitividad(Spanish Government); Comunidad de Madrid(Comunidad de Madrid); Fundacion Ramon Areces	We thank Ernesto Sanchez-Herrero and the members of the Morata laboratory for help during the work and comments on the manuscript. We also thank Kenneth Irvine for comments on the manuscript. We also thank Angelica Cantarero for general help. The work has been supported by the grants BFU2008-03196, CSD2007-00008 from the Ministerio de Economia y Competitividad, and CELDEV S2006/SAL-0190 from the Comunidad de Madrid. We also acknowledge the institutional grant from the Fundacion Ramon Areces to the Centro de Biologia Molecular.	Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Chen CL, 2012, P NATL ACAD SCI USA, V109, P484, DOI 10.1073/pnas.1113882109; Chew SK, 2004, DEV CELL, V7, P897, DOI 10.1016/j.devcel.2004.09.016; Daish TJ, 2004, DEV CELL, V7, P909, DOI 10.1016/j.devcel.2004.09.018; de Celis JF, 2009, INT J DEV BIOL, V53, P1385, DOI 10.1387/ijdb.072408jd; Devergne O, 2007, J CELL SCI, V120, P3457, DOI 10.1242/jcs.005926; Fischer JA, 2006, ANNU REV CELL DEV BI, V22, P181, DOI 10.1146/annurev.cellbio.22.010605.093205; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; Galliot B, 2010, TRENDS CELL BIOL, V20, P514, DOI 10.1016/j.tcb.2010.05.006; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hariharan IK, 2006, ANNU REV GENET, V40, P335, DOI 10.1146/annurev.genet.39.073003.100738; Herz HM, 2006, DEVELOPMENT, V133, P1871, DOI 10.1242/dev.02356; Huang Q, 2011, NAT MED, V17, P860, DOI 10.1038/nm.2385; Huh JR, 2004, CURR BIOL, V14, P1262, DOI 10.1016/j.cub.2004.06.015; Igaki T, 2009, DEV CELL, V16, P458, DOI 10.1016/j.devcel.2009.01.002; Leong GR, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-62; Li W, 2007, FLY, V1, P274, DOI 10.4161/fly.5247; Lu H, 2005, NAT CELL BIOL, V7, P1232, DOI 10.1038/ncb1324; Martin FA, 2009, INT J DEV BIOL, V53, P1341, DOI 10.1387/ijdb.072447fm; Martin FA, 2009, DEVELOPMENT, V136, P3747, DOI 10.1242/dev.038406; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Menendez J, 2010, P NATL ACAD SCI USA, V107, P14651, DOI 10.1073/pnas.1009376107; Menut L, 2007, GENETICS, V177, P1667, DOI 10.1534/genetics.107.078360; Moberg KH, 2005, DEV CELL, V9, P699, DOI 10.1016/j.devcel.2005.09.018; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Morata G, 2011, DEV GROWTH DIFFER, V53, P168, DOI 10.1111/j.1440-169X.2010.01225.x; Moreno E, 2002, NATURE, V416, P755, DOI 10.1038/416755a; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Perez-Garijo A, 2004, DEVELOPMENT, V131, P5591, DOI 10.1242/dev.01432; Perez-Garijo A, 2009, DEVELOPMENT, V136, P1169, DOI 10.1242/dev.034017; Ryoo HD, 2004, DEV CELL, V7, P491, DOI 10.1016/j.devcel.2004.08.019; Shivas JM, 2010, TRENDS CELL BIOL, V20, P445, DOI 10.1016/j.tcb.2010.04.003; Shlevkov E, 2012, CELL DEATH DIFFER, V19, P451, DOI 10.1038/cdd.2011.113; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Thompson BJ, 2005, DEV CELL, V9, P711, DOI 10.1016/j.devcel.2005.09.020; Torroja C, 2004, DEVELOPMENT, V131, P2395, DOI 10.1242/dev.01102; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401	39	52	52	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2014	33	35					4377	4384		10.1038/onc.2013.407	http://dx.doi.org/10.1038/onc.2013.407			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MR	24096487				2022-12-28	WOS:000341157800002
J	Ciarapica, R; De Salvo, M; Carcarino, E; Bracaglia, G; Adesso, L; Leoncini, PP; Dall'Agnese, A; Walters, ZS; Verginelli, F; De Sio, L; Boldrini, R; Inserra, A; Bisogno, G; Rosolen, A; Alaggio, R; Ferrari, A; Collini, P; Locatelli, M; Stifani, S; Screpanti, I; Rutella, S; Yu, Q; Marquez, VE; Shipley, J; Valente, S; Mai, A; Miele, L; Puri, PL; Locatelli, F; Palacios, D; Rota, R				Ciarapica, R.; De Salvo, M.; Carcarino, E.; Bracaglia, G.; Adesso, L.; Leoncini, P. P.; Dall'Agnese, A.; Walters, Z. S.; Verginelli, F.; De Sio, L.; Boldrini, R.; Inserra, A.; Bisogno, G.; Rosolen, A.; Alaggio, R.; Ferrari, A.; Collini, P.; Locatelli, M.; Stifani, S.; Screpanti, I.; Rutella, S.; Yu, Q.; Marquez, V. E.; Shipley, J.; Valente, S.; Mai, A.; Miele, L.; Puri, P. L.; Locatelli, F.; Palacios, D.; Rota, R.			The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx)	ONCOGENE			English	Article						EZH2; FBXO32; histone methyltransferases; PAX3-FOXO1; rhabdomyosarcoma; Polycomb proteins	COMBINED EPIGENETIC THERAPY; SKELETAL-MUSCLE; GENE-EXPRESSION; INHIBITOR 3-DEAZANEPLANOCIN; TRANSCRIPTION FACTORS; HISTONE METHYLATION; SELF-RENEWAL; CELLS; ATROPHY; DIFFERENTIATION	The Polycomb group (PcG) proteins regulate stem cell differentiation via the repression of gene transcription, and their deregulation has been widely implicated in cancer development. The PcG protein Enhancer of Zeste Homolog 2 (EZH2) works as a catalytic subunit of the Polycomb Repressive Complex 2 (PRC2) by methylating lysine 27 on histone H3 (H3K27me3), a hallmark of PRC2-mediated gene repression. In skeletal muscle progenitors, EZH2 prevents an unscheduled differentiation by repressing muscle-specific gene expression and is downregulated during the course of differentiation. In rhabdomyosarcoma (RMS), a pediatric soft-tissue sarcoma thought to arise from myogenic precursors, EZH2 is abnormally expressed and its downregulation in vitro leads to muscle-like differentiation of RMS cells of the embryonal variant. However, the role of EZH2 in the clinically aggressive subgroup of alveolar RMS, characterized by the expression of PAX3-FOXO1 oncoprotein, remains unknown. We show here that EZH2 depletion in these cells leads to programmed cell death. Transcriptional derepression of F-box protein 32 (FBXO32) (Atrogin1/MAFbx), a gene associated with muscle homeostasis, was evidenced in PAX3-FOXO1 RMS cells silenced for EZH2. This phenomenon was associated with reduced EZH2 occupancy and H3K27me3 levels at the FBXO32 promoter. Simultaneous knockdown of FBXO32 and EZH2 in PAX3-FOXO1 RMS cells impaired the pro-apoptotic response, whereas the overexpression of FBXO32 facilitated programmed cell death in EZH2-depleted cells. Pharmacological inhibition of EZH2 by either 3-Deazaneplanocin A or a catalytic EZH2 inhibitor mirrored the phenotypic and molecular effects of EZH2 knockdown in vitro and prevented tumor growth in vivo. Collectively, these results indicate that EZH2 is a key factor in the proliferation and survival of PAX3-FOXO1 alveolar RMS cells working, at least in part, by repressing FBXO32. They also suggest that the reducing activity of EZH2 could represent a novel adjuvant strategy to eradicate high-risk PAX3-FOXO1 alveolar RMS.	[Ciarapica, R.; De Salvo, M.; Bracaglia, G.; Adesso, L.; Leoncini, P. P.; Verginelli, F.; De Sio, L.; Stifani, S.; Locatelli, F.; Rota, R.] IRCCS, Osped Pediat Bambino Gesu, Dept Oncohematol, Rome, Italy; [Carcarino, E.; Dall'Agnese, A.; Puri, P. L.; Palacios, D.] IRCCS Fdn Santa Lucia, Rome, Italy; [Walters, Z. S.; Shipley, J.] Inst Canc Res, Div Mol Pathol & Canc Therapeut, Sutton, Surrey, England; [Boldrini, R.] IRCCS, Osped Pediat Bambino Gesu, Dept Pathol, Rome, Italy; [Inserra, A.] IRCCS, Osped Pediat Bambino Gesu, Dept Surg, Rome, Italy; [Bisogno, G.; Rosolen, A.] Univ Padua, Dept Pediat, Oncohematol Unit, Padua, Italy; [Alaggio, R.] Univ Padua, Med DIMED, Pathol Unit, Padua, Italy; [Ferrari, A.] Fdn IRCCS Ist Nazl Tumori, Pediat Oncol Unit, Milan, Italy; [Collini, P.] Fdn IRCCS Ist Nazl Tumori, Anat Pathol Unit 2, Milan, Italy; [Locatelli, M.] IRCCS, Osped Pediat Bambino Gesu, Sci Directorate, Rome, Italy; [Stifani, S.] McGill Univ, Ctr Neuronal Survival, Montreal Neurol Inst, Montreal, PQ, Canada; [Screpanti, I.] Univ Roma La Sapienza, Dept Mol Med, Rome, Italy; [Yu, Q.] Genome Inst Singapore, Agcy Sci Technol & Res, Singapore, Singapore; [Marquez, V. E.] Natl Canc Inst, CCR, Frederick Natl Lab Canc Res, Chem Biol Lab, Frederick, MD USA; [Valente, S.; Mai, A.] Univ Roma La Sapienza, Fdn Cenci Bolognetti, Ist Pasteur, Dipartimento Chim & Tecnol Farmaco, Rome, Italy; [Miele, L.] Univ Mississippi, Med Ctr, Inst Canc, Jackson, MS 39216 USA; [Puri, P. L.] Sanford Burnham Med Res Inst, Muscle Dev & Regenerat Program, La Jolla, CA USA; [Locatelli, F.] Univ Pavia, Dipartimento Sci Pediat, I-27100 Pavia, Italy	IRCCS Bambino Gesu; IRCCS Santa Lucia; University of London; Institute of Cancer Research - UK; IRCCS Bambino Gesu; IRCCS Bambino Gesu; University of Padua; University of Padua; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Bambino Gesu; McGill University; Sapienza University Rome; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fondazione Cenci Bolognetti; Sapienza University Rome; University of Mississippi; University of Mississippi Medical Center; Sanford Burnham Prebys Medical Discovery Institute; University of Pavia	Rota, R (corresponding author), IRCCS, Osped Pediat Bambino Gesu, Dept Oncohematol, Rome, Italy.	d.palacios@hsantalucia.it; rossella.rota@opbg.net	Valente, Sergio/K-2198-2016; Adesso, Laura/AAA-7708-2020; Rutella, Sergio/AAF-9187-2020; Palacios, Daniela/AAA-7608-2019; Inserra, Alessandro/H-3120-2012; Rota, Rossella/AAB-2497-2019; Leoncini, Pier Paolo/AAH-9343-2019; verginelli, federica/HGU-3834-2022; Collini, Paola/K-7354-2016; alaggio, rita/AAC-2348-2019; Marquez, Victor/AAP-3549-2021; Palacios, Daniela/K-4698-2016; Locatelli, Mattia/AAA-6241-2020; Mai, Antonello/AAC-2144-2019; Ferrari, Andrea/R-1028-2016; Rutella, Sergio/AAF-9210-2020; Bisogno, Gianni/K-9282-2016	Valente, Sergio/0000-0002-2241-607X; Adesso, Laura/0000-0003-2121-4924; Palacios, Daniela/0000-0002-2207-2369; Rota, Rossella/0000-0002-9408-7711; verginelli, federica/0000-0002-8762-8815; Collini, Paola/0000-0002-6158-210X; alaggio, rita/0000-0003-3915-3816; Palacios, Daniela/0000-0002-2207-2369; Ferrari, Andrea/0000-0002-4724-0517; Rutella, Sergio/0000-0003-1970-7375; Mai, Antonello/0000-0001-9176-2382; Miele, Lucio/0000-0002-5853-7287; Walters, Zoe/0000-0002-1835-5868; Bisogno, Gianni/0000-0003-4462-5523; Shipley, Janet/0000-0001-6748-8678; Yu, Qiang/0000-0003-2132-8278	Associazione Italiana per la Ricerca sul Cancro (AIRC) [10338]; Italian Ministry of Health Ricerca Corrente; Association for International Cancer Research (AICR-UK) [12-0168]; AIRC 5 per mille; NIH Intramural Research Program, National Cancer Institute, CCR; Cancer Research UK [C5066/A10399]; Sarcoma UK; Progetto IIT-Sapienza [A2]; FIRB [RBFR10ZJQT]; FP7 Project [BLUEPRINT/282510]; Worldwide Cancer Research [12-0168] Funding Source: researchfish	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health Ricerca Corrente(Ministry of Health, Italy); Association for International Cancer Research (AICR-UK); AIRC 5 per mille(Fondazione AIRC per la ricerca sul cancro); NIH Intramural Research Program, National Cancer Institute, CCR; Cancer Research UK(Cancer Research UK); Sarcoma UK; Progetto IIT-Sapienza; FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); FP7 Project; Worldwide Cancer Research	We thank E Giorda for fluorescence-activated cell sorting analysis. Myogenin (Wright WE) and MHC (Fishman DA) antibodies were obtained from the Developmental Studies Hybridoma Bank, developed under the auspices of the NICHD and maintained by The University of Iowa, Department of Biology, Iowa City, IA 52242, USA. This work was supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC, 10338) and Italian Ministry of Health Ricerca Corrente (RR); Association for International Cancer Research (AICR-UK, 12-0168) (DP); AIRC 5 per mille (FL); NIH Intramural Research Program, National Cancer Institute, CCR (VEM); Cancer Research UK (C5066/A10399) (ZSW); Sarcoma UK (ZSW, JS); Progetto IIT-Sapienza A2, FIRB RBFR10ZJQT and FP7 Project BLUEPRINT/282510 (AM). SS is a Chercheur National of the Fonds de la Recherche en Sante du Quebec.	Benoit YD, 2013, J CELL PHYSIOL, V228, P764, DOI 10.1002/jcp.24224; Boumber Y, 2011, ONCOLOGY-NY, V25, P220; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Bray M, 2000, ANTIVIR RES, V45, P135, DOI 10.1016/S0166-3542(00)00066-8; Cao LA, 2010, CANCER RES, V70, P6497, DOI 10.1158/0008-5472.CAN-10-0582; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; Cheng LL, 2012, CLIN CANCER RES, V18, P4201, DOI 10.1158/1078-0432.CCR-12-0036; Chng KR, 2012, EMBO J, V31, P2810, DOI 10.1038/emboj.2012.112; Ciarapica R, 2009, CELL CYCLE, V8, P172, DOI 10.4161/cc.8.1.7292; Crose LES, 2012, CLIN CANCER RES, V18, P3780, DOI 10.1158/1078-0432.CCR-10-3063; Davicioni E, 2010, J CLIN ONCOL, V28, P1240, DOI 10.1200/JCO.2008.21.1268; Davicioni E, 2009, AM J PATHOL, V174, P550, DOI 10.2353/ajpath.2009.080631; Fan T, 2011, MOL CANCER RES, V9, P418, DOI 10.1158/1541-7786.MCR-10-0511; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Fiskus W, 2012, CLIN CANCER RES, V18, P6227, DOI 10.1158/1078-0432.CCR-12-0873; Fiskus W, 2009, BLOOD, V114, P2733, DOI 10.1182/blood-2009-03-213496; Gannon OM, 2013, CLIN CANCER RES, V19, P428, DOI 10.1158/1078-0432.CCR-12-2505; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Hunt LC, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-17; Jiang YL, 2013, J CELL PHYSIOL, V228, P1989, DOI 10.1002/jcp.24365; Juan AH, 2011, GENE DEV, V25, P789, DOI 10.1101/gad.2027911; Juan AH, 2009, MOL CELL, V36, P61, DOI 10.1016/j.molcel.2009.08.008; Kalushkova A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011483; Kemp CD, 2012, CLIN CANCER RES, V18, P77, DOI 10.1158/1078-0432.CCR-11-0962; Kikuchi K, 2008, BIOCHEM BIOPH RES CO, V365, P568, DOI 10.1016/j.bbrc.2007.11.017; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; Lagirand-Cantaloube J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004973; Lanzuolo C, 2012, ANNU REV GENET, V46, P561, DOI 10.1146/annurev-genet-110711-155603; Lawlor ER, 2012, CLIN CANCER RES, V18, P2768, DOI 10.1158/1078-0432.CCR-11-1921; Lee MH, 2011, CANCER RES, V71, P3921, DOI 10.1158/0008-5472.CAN-10-3358; Mai A, 2007, CHEMMEDCHEM, V2, P987, DOI 10.1002/cmdc.200700023; Marchesi I, 2012, CELL CYCLE, V11, P3828, DOI 10.4161/cc.22025; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013; Missiaglia E, 2012, J CLIN ONCOL, V30, P1670, DOI 10.1200/JCO.2011.38.5591; Momparler RL, 2012, LEUKEMIA RES, V36, P1049, DOI 10.1016/j.leukres.2012.03.001; Moresi V, 2010, CELL, V143, P35, DOI 10.1016/j.cell.2010.09.004; Mousavi K, 2012, MOL CELL, V45, P255, DOI 10.1016/j.molcel.2011.11.019; Ogata T, 2009, MECH AGEING DEV, V130, P328, DOI 10.1016/j.mad.2009.02.001; Okada A, 2008, MUSCLE NERVE, V38, P1246, DOI 10.1002/mus.21110; Palacios D, 2010, CELL STEM CELL, V7, P455, DOI 10.1016/j.stem.2010.08.013; Peng JC, 2009, CELL, V139, P1290, DOI 10.1016/j.cell.2009.12.002; Puri PL, 2000, GENE DEV, V14, P574; Qi W, 2012, P NATL ACAD SCI USA, V109, P21360, DOI 10.1073/pnas.1210371110; Raaphorst FM, 2003, NEOPLASIA, V5, P481, DOI 10.1016/S1476-5586(03)80032-5; Raimondi L, 2012, CELL DEATH DIFFER, V19, P871, DOI 10.1038/cdd.2011.171; Ramirez-Peinado S, 2011, CANCER RES, V71, P6796, DOI 10.1158/0008-5472.CAN-11-0759; Rao ZY, 2010, CARCINOGENESIS, V31, P1576, DOI 10.1093/carcin/bgq150; Ren YX, 2008, CANCER RES, V68, P6587, DOI 10.1158/0008-5472.CAN-08-0859; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Serra C, 2007, MOL CELL, V28, P200, DOI 10.1016/j.molcel.2007.08.021; Shen XH, 2009, CELL, V139, P1303, DOI 10.1016/j.cell.2009.12.003; Simone C, 2004, NAT GENET, V36, P738, DOI 10.1038/ng1378; Suva ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Taulli R, 2009, J CLIN INVEST, V119, P2366, DOI 10.1172/JCI38075; Tintignac LA, 2005, J BIOL CHEM, V280, P2847, DOI 10.1074/jbc.M411346200; Valente S, 2012, BIOCHIMIE, V94, P2308, DOI 10.1016/j.biochi.2012.06.003; Valentijn LJ, 2012, P NATL ACAD SCI USA, V109, P19190, DOI 10.1073/pnas.1208215109; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vekony H, 2008, J CLIN PATHOL, V61, P744, DOI 10.1136/jcp.2007.054262; Wachtel M, 2004, CANCER RES, V64, P5539, DOI 10.1158/0008-5472.CAN-04-0844; Walters ZS, 2014, ONCOGENE, V33, P1148, DOI 10.1038/onc.2013.46; Wang C, 2011, CANCER RES, V72, P315; Wang H, 2008, CANCER CELL, V14, P369, DOI 10.1016/j.ccr.2008.10.006; Williamson D, 2010, J CLIN ONCOL, V28, P2151, DOI 10.1200/JCO.2009.26.3814; Wong CF, 2008, J BIOL CHEM, V283, P9836, DOI 10.1074/jbc.M709614200; Woodhouse S, 2013, J CELL SCI, V126, P565, DOI 10.1242/jcs.114843; Wu Z, 2011, CELL DEATH DIFFER, V18, P1771, DOI 10.1038/cdd.2011.48; Wu ZL, 2010, CELL DEATH DIFFER, V17, P801, DOI 10.1038/cdd.2009.162; Xie P, 2009, J BIOL CHEM, V284, P5488, DOI 10.1074/jbc.M806487200; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498	73	51	52	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2014	33	32					4173	4184		10.1038/onc.2013.471	http://dx.doi.org/10.1038/onc.2013.471			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YK	24213577	hybrid, Green Accepted			2022-12-28	WOS:000340595700008
J	Butinar, M; Prebanda, MT; Rajkovic, J; Jeric, B; Stoka, V; Peters, C; Reinheckel, T; Kruger, A; Turk, V; Turk, B; Vasiljeva, O				Butinar, M.; Prebanda, M. T.; Rajkovic, J.; Jeric, B.; Stoka, V.; Peters, C.; Reinheckel, T.; Krueger, A.; Turk, V.; Turk, B.; Vasiljeva, O.			Stefin B deficiency reduces tumor growth via sensitization of tumor cells to oxidative stress in a breast cancer model	ONCOGENE			English	Article						cathepsin inhibitor; stefin; breast cancer; mouse model; oxidative stress	PROGRESSIVE MYOCLONUS EPILEPSY; PEROXIDE-INDUCED APOPTOSIS; CYSTEINE CATHEPSINS; HYDROGEN-PEROXIDE; CYSTATIN-B; MULTISTAGE TUMORIGENESIS; PROTEASE ACTIVITY; CUTTING EDGE; MOUSE MODEL; MICE	Lysosomal cysteine cathepsins contribute to proteolytic events promoting tumor growth and metastasis. Their enzymatic activity, however, is tightly regulated by endogenous inhibitors. To investigate the role of cathepsin inhibitor stefin B (Stfb) in mammary cancer, Stfb null mice were crossed with transgenic polyoma virus middle T oncogene (PyMT) breast cancer mice. We show that ablation of Stfb resulted in reduced size of mammary tumors but did not affect their rate of metastasis. Importantly, decrease in tumor growth was correlated with an increased incidence of dead cell islands detected in tumors of Stfb-deficient mice. Ex vivo analysis of primary PyMT tumor cells revealed no significant effects of ablation of Stfb expression on proliferation, angiogenesis, migration and spontaneous cell death as compared with control cells. However, upon treatment with the lysosomotropic agent Leu-Leu-OMe, cancer cells lacking Stfb exhibited a significantly higher sensitivity to apoptosis. Moreover, Stfb-ablated tumor cells were significantly more prone to cell death under increased oxidative stress. These results indicate an in vivo role for Stfb in protecting cancer cells by promoting their resistance to oxidative stress and to apoptosis induced through the lysosomal pathway.	[Butinar, M.; Prebanda, M. T.; Rajkovic, J.; Jeric, B.; Stoka, V.; Turk, V.; Turk, B.; Vasiljeva, O.] Jozef Stefan Inst, Dept Biochem & Mol & Struct Biol, Ljubljana 1000, Slovenia; [Butinar, M.; Rajkovic, J.; Jeric, B.; Stoka, V.; Turk, V.; Vasiljeva, O.] Jozef Stefan Int Postgrad Sch, Ljubljana, Slovenia; [Peters, C.; Reinheckel, T.] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Inst Mol Med & Cell Res, D-79106 Freiburg, Germany; [Krueger, A.] Tech Univ Munich, Klinikums Rechts Isar, Inst Expt Onkol & Therapieforsch, D-80290 Munich, Germany; [Turk, V.; Turk, B.] Ctr Excellence Integrated Approaches Chem & Biol, Ljubljana, Slovenia; [Turk, B.] Univ Ljubljana, Fac Chem & Chem Technol, Ljubljana, Slovenia	Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute; Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute; University of Freiburg; Technical University of Munich; University of Ljubljana	Vasiljeva, O (corresponding author), Jozef Stefan Inst, Dept Biochem & Mol & Struct Biol, Jamova 39, Ljubljana 1000, Slovenia.	olga.vasiljeva@ijs.si	Stoka, Veronika/AAM-2283-2021; Reinheckel, Thomas/AAL-9761-2021	Reinheckel, Thomas/0000-0001-9866-9105; Turk, Boris/0000-0002-9007-5764	European Commission [201279]; Slovenian Research Agency [J3-4267, P1-0140]; Deutsche Forschungsgemeinschaft [SFB 850]	European Commission(European CommissionEuropean Commission Joint Research Centre); Slovenian Research Agency(Slovenian Research Agency - Slovenia); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Richard Myers and Len Pennacchio, formerly of Stanford University, for providing with Stfb knockout mouse strain, Georgy Mikhaylov and Matej Vizovisek for their technical and methodological assistance, Eva Zerovnik for valuable discussions and Roger H. Pain for critical reading of the manuscript. This work was supported by the European Commission FP7 grant 201279 (Microenvimet: CP, TR, AK, BT and OV), the Slovenian Research Agency (research grants no. J3-4267 to OV and P1-0140 to BT) and Deutsche Forschungsgemeinschaft SFB 850 project B7 (CP and TR).	Alakurtti K, 2005, EUR J HUM GENET, V13, P208, DOI 10.1038/sj.ejhg.5201300; Antunes F, 2001, BIOCHEM J, V356, P549, DOI 10.1042/0264-6021:3560549; Bell-McGuinn KM, 2007, CANCER RES, V67, P7378, DOI 10.1158/0008-5472.CAN-07-0602; Bojic L, 2007, FEBS LETT, V581, P5185, DOI 10.1016/j.febslet.2007.10.005; Brown NS, 2001, BREAST CANCER RES, V3, P323, DOI 10.1186/bcr315; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Datta K, 2002, INT J BIOCHEM CELL B, V34, P148, DOI 10.1016/S1357-2725(01)00106-6; Droga-Mazovec G, 2008, J BIOL CHEM, V283, P19140, DOI 10.1074/jbc.M802513200; Feldman AS, 2009, CLIN CANCER RES, V15, P1024, DOI 10.1158/1078-0432.CCR-08-1143; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Gocheva V, 2007, CELL CYCLE, V6, P60, DOI 10.4161/cc.6.1.3669; GOLDMAN R, 1973, BIOCHIM BIOPHYS ACTA, V318, P205, DOI 10.1016/0005-2736(73)90114-4; Gopinathan A, 2012, GUT, V61, P877, DOI 10.1136/gutjnl-2011-300850; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hileman EO, 2004, CANCER CHEMOTH PHARM, V53, P209, DOI 10.1007/s00280-003-0726-5; Ishisaka R, 2002, BIOSCI BIOTECH BIOCH, V66, P1865, DOI 10.1271/bbb.66.1865; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Kariya S, 2009, INT J RADIAT ONCOL, V75, P449, DOI 10.1016/j.ijrobp.2009.04.092; Kopitar-Jerala NA, 2005, FEBS LETT, V579, P2149, DOI 10.1016/j.febslet.2005.03.002; Kos J, 2000, CLIN CANCER RES, V6, P505; Kuopio T, 1998, CANCER RES, V58, P432; Lehtinen MK, 2009, J NEUROSCI, V29, P5910, DOI 10.1523/JNEUROSCI.0682-09.2009; Mao YB, 2006, CELL BIOL INT, V30, P332, DOI 10.1016/j.cellbi.2005.12.008; Mikhaylov G, 2011, NAT NANOTECHNOL, V6, P594, DOI [10.1038/nnano.2011.112, 10.1038/NNANO.2011.112]; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Pennacchio LA, 1998, NAT GENET, V20, P251, DOI 10.1038/3059; Pennacchio LA, 1996, SCIENCE, V271, P1731, DOI 10.1126/science.271.5256.1731; Repnik U, 2010, MITOCHONDRION, V10, P662, DOI 10.1016/j.mito.2010.07.008; Rygiel TP, 2008, J CELL SCI, V121, P1183, DOI 10.1242/jcs.017194; Sevenich L, 2010, P NATL ACAD SCI USA, V107, P2497, DOI 10.1073/pnas.0907240107; Shree T, 2011, GENE DEV, V25, P2465, DOI 10.1101/gad.180331.111; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Stoka V, 2007, BIOL CHEM, V388, P555, DOI 10.1515/BC.2007.064; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Takahashi T, 2004, INT J MOL MED, V14, P197; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; Turk B, 2002, CURR PHARM DESIGN, V8, P1623, DOI 10.2174/1381612023394124; Turk B, 1997, BIOL CHEM, V378, P141; Turk B, 2012, EMBO J, V31, P1630, DOI 10.1038/emboj.2012.42; Turk B, 2009, J BIOL CHEM, V284, P21783, DOI 10.1074/jbc.R109.023820; Turk V, 2004, CANCER CELL, V5, P409, DOI 10.1016/S1535-6108(04)00117-5; Turk V, 2008, FRONT BIOSCI-LANDMRK, V13, P5406, DOI 10.2741/3089; Turk V, 2012, BBA-PROTEINS PROTEOM, V1824, P68, DOI 10.1016/j.bbapap.2011.10.002; Uchimoto T, 1999, APOPTOSIS, V4, P357, DOI 10.1023/A:1009695221038; Vasiljeva O, 2008, ONCOGENE, V27, P4191, DOI 10.1038/onc.2008.59; Vasiljeva O, 2008, BIOCHIMIE, V90, P380, DOI 10.1016/j.biochi.2007.10.004; Vasiljeva O, 2007, CURR PHARM DESIGN, V13, P387, DOI 10.2174/138161207780162962; Vasiljeva O, 2006, CANCER RES, V66, P5242, DOI 10.1158/0008-5472.CAN-05-4463; Yang F, 2010, CELL DEATH DIFFER, V17, P1354, DOI 10.1038/cdd.2010.29; Yin L, 2005, J CELL BIOCHEM, V94, P433, DOI 10.1002/jcb.20277; Yu WF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013973; Zullani T, 2005, FREE RADICAL BIO MED, V38, P307, DOI 10.1016/j.freeradbiomed.2004.09.021	53	34	35	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3392	3400		10.1038/onc.2013.314	http://dx.doi.org/10.1038/onc.2013.314			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23955077				2022-12-28	WOS:000338779300006
J	Borsig, L; Wolf, MJ; Roblek, M; Lorentzen, A; Heikenwalder, M				Borsig, L.; Wolf, M. J.; Roblek, M.; Lorentzen, A.; Heikenwalder, M.			Inflammatory chemokines and metastasis-tracing the accessory	ONCOGENE			English	Review						tumor cell extravasation; inflammatory chemokines; CCL2; CCL5; metastasis	MONOCYTE CHEMOATTRACTANT PROTEIN-1; PROSTATE-CANCER GROWTH; BREAST-CANCER; TUMOR-GROWTH; ENDOTHELIAL-CELLS; LUNG METASTASIS; EXPRESSION; CCL2; MACROPHAGE; MCP-1	The tumor microenvironment consists of stromal cells and leukocytes that contribute to cancer progression. Cross-talk between tumor cells and their microenvironment is facilitated by a variety of soluble factors, including growth factors and cytokines such as chemokines. Due to a wide expression of chemokine receptors on cells in the tumor microenvironment, including tumor cells, chemokines affect various processes such as leukocyte recruitment, angiogenesis, tumor cell survival, tumor cell adhesion, proliferation, vascular permeability, immune suppression, invasion and metastasis. Inflammatory chemokines are instrumental players in cancer-related inflammation and significantly contribute to numerous steps during metastasis. Recruitment of myeloid-derived cells to metastatic sites is mainly mediated by the inflammatory chemokines CCL2 and CCL5. Tumor cell homing and extravasation from the circulation to distant organs are also regulated by inflammatory chemokines. Recent experimental evidence demonstrated that besides leukocyte recruitment, tumor cell-derived CCL2 directly activated endothelial cells and together with monocytes facilitated tumor cell extravasation, in a CCL2- and CCL5-dependent manner. Furthermore, CX3CL1 expression in the bone facilitated metastasis of CX3CR1 expressing tumor cells to this site. Current findings in preclinical models strongly suggest that inflammatory chemokines have an important role during metastasis and targeting of the chemokine axis might have a therapeutic potential.	[Borsig, L.; Roblek, M.] Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; [Borsig, L.; Roblek, M.] Zurich Ctr Integrat Human Physiol, CH-8057 Zurich, Switzerland; [Wolf, M. J.] Univ Zurich Hosp, Inst Surg Pathol, CH-8091 Zurich, Switzerland; [Lorentzen, A.; Heikenwalder, M.] Tech Univ Munich, Helmholtz Zentrum Munich, Inst Virol, D-80290 Munich, Germany	University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); University of Zurich; University Zurich Hospital; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich	Borsig, L (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	lborsig@access.uzh.ch	Heikenwalder, Mathias/AAA-2269-2020	Lorentzen, Anna/0000-0002-4405-935X; Borsig, Lubor/0000-0003-2263-9545	Swiss National Foundation [31003A-133025]; EuroNanoMed2; project NANODIATER; Helmholtz foundation; Starting ERC grant; Helmholtz alliance PCCC; Hofschneider foundation;  [SFB transregio 36]	Swiss National Foundation(Swiss National Science Foundation (SNSF)); EuroNanoMed2; project NANODIATER; Helmholtz foundation(Helmholtz Association); Starting ERC grant; Helmholtz alliance PCCC; Hofschneider foundation; 	LB was supported by Swiss National Foundation (31003A-133025) and by EuroNanoMed2 2nd call; project NANODIATER. MH was supported by the Helmholtz foundation, a Starting ERC grant, the SFB transregio 36, the Helmholtz alliance PCCC and the Hofschneider foundation.	Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269; Allavena P, 2011, EXP CELL RES, V317, P664, DOI 10.1016/j.yexcr.2010.11.013; Andre F, 2006, ANN ONCOL, V17, P945, DOI 10.1093/annonc/mdl053; Azenshtein E, 2002, CANCER RES, V62, P1093; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Ben-Baruch A, 2006, CANCER METAST REV, V25, P357, DOI 10.1007/s10555-006-9003-5; Buonamici S, 2009, NATURE, V459, P1000, DOI 10.1038/nature08020; Chiu HY, 2012, CYTOKINE, V59, P423, DOI 10.1016/j.cyto.2012.04.017; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; de Vasconcellos JF, 2011, PEDIATR BLOOD CANCER, V56, P568, DOI 10.1002/pbc.22941; Eisenkraft A, 2006, LEUKEMIA RES, V30, P1259, DOI 10.1016/j.leukres.2006.01.017; Fang WB, 2012, J BIOL CHEM, V287, P36593, DOI 10.1074/jbc.M112.365999; Feil C, 1998, BIOCHEM BIOPH RES CO, V247, P38, DOI 10.1006/bbrc.1998.8499; Forst B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010374; Fridlender ZG, 2011, AM J RESP CELL MOL, V44, P230, DOI 10.1165/rcmb.2010-0080OC; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Garin A, 2011, EXP CELL RES, V317, P602, DOI 10.1016/j.yexcr.2010.12.021; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Gu L, 2010, ENDOCR-RELAT CANCER, V17, P481, DOI 10.1677/ERC-09-0328; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hembruff SL, 2010, NEOPLASIA, V12, P425, DOI 10.1593/neo.10200; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Jamieson-Gladney WL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3016; Janowska-Wieczorek A, 2005, INT J CANCER, V113, P752, DOI 10.1002/ijc.20657; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Keeley EC, 2011, EXP CELL RES, V317, P685, DOI 10.1016/j.yexcr.2010.10.020; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; Krumbholz M, 2007, J NEUROIMMUNOL, V190, P72, DOI 10.1016/j.jneuroim.2007.07.024; Laubli H, 2009, BLOOD, V114, P4583, DOI 10.1182/blood-2008-10-186585; Lesokhin AM, 2012, CANCER RES, V72, P876, DOI 10.1158/0008-5472.CAN-11-1792; Li X, 2009, CANCER RES, V69, P1685, DOI 10.1158/0008-5472.CAN-08-2164; Liu YL, 2010, AM J PATHOL, V176, P2490, DOI 10.2353/ajpath.2010.090777; Loberg RD, 2006, NEOPLASIA, V8, P578, DOI 10.1593/neo.06280; Low-Marchelli JM, 2013, CANCER RES, V73, P662, DOI 10.1158/0008-5472.CAN-12-0653; Lu X, 2009, J BIOL CHEM, V284, P29087, DOI 10.1074/jbc.M109.035899; Lu Y, 2006, PROSTATE, V66, P1311, DOI 10.1002/pros.20464; Lu Y, 2009, CLIN EXP METASTAS, V26, P161, DOI 10.1007/s10585-008-9226-7; Lukanidin E, 2012, SEMIN CANCER BIOL, V22, P216, DOI 10.1016/j.semcancer.2012.02.006; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009; Mao YL, 2011, INT J COLORECTAL DIS, V26, P29, DOI 10.1007/s00384-010-1090-7; Marchesi F, 2008, CANCER RES, V68, P9060, DOI 10.1158/0008-5472.CAN-08-1810; Marchesi F, 2010, CYTOKINE GROWTH F R, V21, P77, DOI 10.1016/j.cytogfr.2009.11.001; Merritt WM, 2008, J NATL CANCER I, V100, P359, DOI 10.1093/jnci/djn024; Mishra P, 2011, J LEUKOCYTE BIOL, V89, P31, DOI 10.1189/jlb.0310182; Mizutani K, 2009, NEOPLASIA, V11, P1235, DOI 10.1593/neo.09988; Molloy AP, 2009, INT J CANCER, V124, P326, DOI 10.1002/ijc.23939; Moser B, 2004, TRENDS IMMUNOL, V25, P75, DOI 10.1016/j.it.2003.12.005; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami T, 2002, CANCER RES, V62, P7328; Nakasone Y, 2012, AM J PATHOL, V180, P365, DOI 10.1016/j.ajpath.2011.09.005; Nurnberg W, 1999, J PATHOL, V189, P546, DOI 10.1002/(SICI)1096-9896(199912)189:4<546::AID-PATH487>3.0.CO;2-L; Pan JD, 2006, J IMMUNOL, V176, P1456, DOI 10.4049/jimmunol.176.3.1456; Park SI, 2012, CANCER RES, V72, P2522, DOI 10.1158/0008-5472.CAN-11-2928; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Peinado H, 2011, SEMIN CANCER BIOL, V21, P139, DOI 10.1016/j.semcancer.2011.01.002; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Reed JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045877; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Robinson SC, 2003, CANCER RES, V63, P8360; Roca H, 2008, J BIOL CHEM, V283, P25057, DOI 10.1074/jbc.M801073200; Rollins BJ, 2006, EUR J CANCER, V42, P760, DOI 10.1016/j.ejca.2006.01.002; Said N, 2012, J CLIN INVEST, V122, P1503, DOI 10.1172/JCI61392; Saji H, 2001, CANCER, V92, P1085, DOI 10.1002/1097-0142(20010901)92:5<1085::AID-CNCR1424>3.0.CO;2-K; Salcedo R, 2000, BLOOD, V96, P34, DOI 10.1182/blood.V96.1.34.013a49_34_40; SCHEIBENBOGEN C, 1995, MELANOMA RES, V5, P179, DOI 10.1097/00008390-199506000-00006; Shulby SA, 2004, CANCER RES, V64, P4693, DOI 10.1158/0008-5472.CAN-03-3437; Soria G, 2008, CYTOKINE, V44, P191, DOI 10.1016/j.cyto.2008.08.002; Stormes KA, 2005, BREAST CANCER RES TR, V89, P209, DOI 10.1007/s10549-004-5328-3; Takahashi M, 2009, CLIN EXP METASTAS, V26, P817, DOI 10.1007/s10585-009-9281-8; Tremblay PL, 2006, ONCOGENE, V25, P6563, DOI 10.1038/sj.onc.1209664; Tsuyada A, 2012, CANCER RES, V72, P2768, DOI 10.1158/0008-5472.CAN-11-3567; Ueno T, 2000, CLIN CANCER RES, V6, P3282; Varney ML, 2006, AM J CLIN PATHOL, V125, P209, DOI 10.1309/VPL5R.JR7F1D6V03; Velasco-Velazquez M, 2012, CANCER RES, V72, P3839, DOI 10.1158/0008-5472.CAN-11-3917; Weber KSC, 1999, ARTERIOSCL THROM VAS, V19, P2085, DOI 10.1161/01.ATV.19.9.2085; Wendel C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030046; Wiley HE, 2001, J NATL CANCER I, V93, P1638, DOI 10.1093/jnci/93.21.1638; Wolf MJ, 2010, ONCOGENE, V29, P5006, DOI 10.1038/onc.2010.260; Wolf MJ, 2012, CANCER CELL, V22, P91, DOI 10.1016/j.ccr.2012.05.023; Wu S, 2012, CANCER MED-US, V1, P306, DOI 10.1002/cam4.28; Yaal-Hahoshen N, 2006, CLIN CANCER RES, V12, P4474, DOI 10.1158/1078-0432.CCR-06-0074; Yang C., 2011, CLIN DEV IMMUNOL, V2011, P842; Yoshidome H, 2009, INT J ONCOL, V34, P923, DOI 10.3892/ijo_00000218; Zhang J, 2010, CYTOKINE GROWTH F R, V21, P41, DOI 10.1016/j.cytogfr.2009.11.009; Zhao L, 2013, HEPATOLOGY, V57, P829, DOI 10.1002/hep.26094; Zijlmans HJMAA, 2006, J PATHOL, V208, P507, DOI 10.1002/path.1918; Zlotnik A, 2011, NAT REV IMMUNOL, V11, P597, DOI 10.1038/nri3049	91	150	152	1	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3217	3224		10.1038/onc.2013.272	http://dx.doi.org/10.1038/onc.2013.272			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23851506	Green Accepted			2022-12-28	WOS:000338443400001
J	Kim, HP; Han, SW; Song, SH; Jeong, EG; Lee, MY; Hwang, D; Im, SA; Bang, YJ; Kim, TY				Kim, H-P; Han, S-W; Song, S-H; Jeong, E-G; Lee, M-Y; Hwang, D.; Im, S-A; Bang, Y-J; Kim, T-Y			Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer	ONCOGENE			English	Article						Testican-1; epithelial-mesenchymal transition; lapatinib resistance; beta-catenin; XAV939; HER2-positive gastric cancer	TYROSINE KINASE INHIBITOR; CELL-LINES; BREAST-CANCER; LUNG-CANCER; TRASTUZUMAB RESISTANCE; GEFITINIB RESISTANCE; HER2; RECEPTOR; GROWTH; EXPRESSION	Human epidermal growth factor receptor 2 (HER2)-directed treatment using trastuzumab has shown clinical benefit in HER2-positive gastric cancer. Clinical trials using lapatinib in HER2-positive gastric cancer are also currently underway. As with other molecularly targeted agents, the emergence of acquired resistance to HER2-directed treatment is an imminent therapeutic problem for HER2-positive gastric cancer. In order to investigate the mechanisms of acquired resistance to HER2-directed treatment in gastric cancer, we generated lapatinib-resistant gastric cancer cell lines (SNU216 LR) in vitro by chronic exposure of a HER2-positive gastric cancer cell line (SNU216) to lapatinib. The resultant SNU216 LR cells were also resistant to gefitinib, cetuximab, trastuzumab, afatinib and dacomitinib. Interestingly, SNU216 LR cells displayed an epithelial-mesenchymal transition (EMT) phenotype and maintained the activation of MET, HER3, Stat3, Akt and mitogen-activated protein kinase signaling in the presence of lapatinib. Using gene expression arrays, we identified the upregulation of a variety of EMT-related genes and extracellular matrix molecules, such as Testican-1, in SNU216 LR cells. We showed that the inhibition of Testican-1 by small interfering RNA decreased Testican-1-induced, MET-dependent, downstream signaling, and restored sensitivity to lapatinib in these cells. Furthermore, treatment with XAV939 selectively inhibited beta-catenin-mediated transcription and Testican-1-induced EMT signaling, leading to G1 arrest. Taken together, these data support the potential role of EMT in acquired resistance to HER2-directed treatment in HER2-positive gastric cancer, and provide insights into strategies for preventing and/or overcoming this resistance in patients.	[Kim, H-P; Han, S-W; Song, S-H; Jeong, E-G; Im, S-A; Bang, Y-J; Kim, T-Y] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110744, South Korea; [Han, S-W; Im, S-A; Bang, Y-J; Kim, T-Y] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; [Lee, M-Y; Hwang, D.] Pohang Univ Sci & Technol POSTECH, Sch Interdisciplinary Biosci & Bioengn, Pohang, South Korea; [Kim, T-Y] Seoul Natl Univ, Coll Med, WCU Dept Mol Med & Biopharmaceut Sci, Seoul 110744, South Korea	Seoul National University (SNU); Seoul National University (SNU); Pohang University of Science & Technology (POSTECH); Seoul National University (SNU)	Kim, TY (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, 28 Yeongeon Dong, Seoul 110744, South Korea.	kimty@snu.ac.kr	Bang, Yung Jue/J-2759-2012	Bang, Yung Jue/0000-0001-6000-4597	Korean Healthcare 21 and Technology RD Project; National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [20090093820]; Ministry for Health, Welfare and Family Affairs [A091081]	Korean Healthcare 21 and Technology RD Project; National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of KoreaNational Research Foundation of Korea); Ministry for Health, Welfare and Family Affairs	This work was supported by grants from the Korean Healthcare 21 and Technology R&D Project; Ministry for Health, Welfare and Family Affairs (A091081) and in part by the Priority Research Centers Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (20090093820).	Anido J, 2006, EMBO J, V25, P3234, DOI 10.1038/sj.emboj.7601191; Bang YJ, 2010, LANCET, V376, P687, DOI 10.1016/S0140-6736(10)61121-X; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Chang TH, 2011, AM J RESP CRIT CARE, V183, P1071, DOI 10.1164/rccm.201009-1440OC; Chen FL, 2008, CLIN CANCER RES, V14, P6730, DOI 10.1158/1078-0432.CCR-08-0581; Colleoni M, 2008, ANN ONCOL, V19, P465, DOI 10.1093/annonc/mdm509; Edgell CJS, 2004, INT REV CYTOL, V236, P101, DOI 10.1016/S0074-7696(04)36003-1; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; GlaxoSmithKline, 2011, LAP OPT STUD ERBB2 H; Gravalos C, 2008, ANN ONCOL, V19, P1523, DOI 10.1093/annonc/mdn169; Guo SQ, 2004, MOL CELL BIOL, V24, P8681, DOI 10.1128/MCB.24.19.8681-8690.2004; Hofmann M, 2008, HISTOPATHOLOGY, V52, P797, DOI 10.1111/j.1365-2559.2008.03028.x; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Kim HP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005933; Kim JW, 2008, CANCER LETT, V272, P296, DOI 10.1016/j.canlet.2008.07.018; Kim SY, 2008, INT J ONCOL, V32, P89; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Lee MS, 2012, BBA-MOL CELL RES, V1823, P514, DOI 10.1016/j.bbamcr.2011.11.017; Leja J, 2009, MODERN PATHOL, V22, P261, DOI 10.1038/modpathol.2008.174; Li Y, 2013, GASTROENTEROLOGY, V144, P179, DOI 10.1053/j.gastro.2012.09.042; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2007, MOL CANCER THER, V6, P667, DOI 10.1158/1535-7163.MCT-06-0423; Nam HJ, 2011, CANCER LETT, V302, P155, DOI 10.1016/j.canlet.2011.01.010; Prenzel KL, 2006, ONCOL REP, V15, P1397; Rusnak DW, 2007, CELL PROLIFERAT, V40, P580, DOI 10.1111/j.1365-2184.2007.00455.x; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Tanner M, 2005, ANN ONCOL, V16, P273, DOI 10.1093/annonc/mdi064; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thomson S, 2005, CANCER RES, V65, P9455, DOI 10.1158/0008-5472.CAN-05-1058; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; White BD, 2012, GASTROENTEROLOGY, V142, P219, DOI 10.1053/j.gastro.2011.12.001; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; Wlazlinski A, 2007, PROSTATE, V67, P1770, DOI 10.1002/pros.20667; Xia WL, 2007, CANCER RES, V67, P1170, DOI 10.1158/0008-5472.CAN-06-2101; Xia W, 2006, P NATL ACAD SCI USA, V103, P7795, DOI 10.1073/pnas.0602468103; Xia WL, 2004, ONCOGENE, V23, P646, DOI 10.1038/sj.onc.1207166; Yauch RL, 2005, CLIN CANCER RES, V11, P8686, DOI 10.1158/1078-0432.CCR-05-1492	40	87	89	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3334	3341		10.1038/onc.2013.285	http://dx.doi.org/10.1038/onc.2013.285			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23873022				2022-12-28	WOS:000338443400013
J	Tan, EH; Morton, JP; Timpson, P; Tucci, P; Melino, G; Flores, ER; Sansom, OJ; Vousden, KH; Muller, PAJ				Tan, E. H.; Morton, J. P.; Timpson, P.; Tucci, P.; Melino, G.; Flores, E. R.; Sansom, O. J.; Vousden, K. H.; Muller, P. A. J.			Functions of TAp63 and p53 in restraining the development of metastatic cancer	ONCOGENE			English	Article						p63; mutant p53; pancreatic tumours; PDAC; metastasis	MUTANT P53; MOUSE MODEL; P63; GAIN; EXPRESSION; TARGET; TUMORIGENESIS; SUPPRESSOR; REGULATOR; MECHANISM	Many tumours harbour mutations in the p53 tumour-suppressor gene that result in the expression of a mutant p53 protein. This mutant p53 protein has, in most cases, lost wild-type transcriptional activity and can also acquire novel functions in promoting invasion and metastasis. One of the mechanisms underlying these novel functions involves the ability of the mutant p53 to interfere with other transcription factors, including the p53 family protein TAp63. To investigate whether simultaneous depletion of both p53 and TAp63 can recapitulate the effect of mutant p53 expression in vivo, we used a mouse model of pancreatic cancer in which the expression of mutant p53 resulted in the rapid appearance of primary tumours and metastases. As shown previously, loss of one allele of wild-type (WT) p53 accelerated tumour development. A change of one WT p53 allele into mutant p53 did not further accelerate tumour development, but did promote the formation of metastasis. By contrast, loss of TAp63 did not significantly accelerate tumour development or metastasis. However, simultaneous depletion of p53 and TAp63 led to both rapid tumour development and metastatic potential, although the incidence of metastases remained lower than that seen in mutant p53-expressing tumours. TAp63/p53-null cells derived from these mice also showed an enhanced ability to scatter and invade in tissue culture as was observed in mutant p53 cells. These data suggest that depletion of TAp63 in a p53-null tumour can promote metastasis and recapitulate-to some extent-the consequences of mutant p53 expression.	[Tan, E. H.; Morton, J. P.; Timpson, P.; Sansom, O. J.; Vousden, K. H.; Muller, P. A. J.] CR UK Beatson Inst, Glasgow G61 1BD, Lanark, Scotland; [Timpson, P.] Kinghorn Canc Ctr, Garvan Inst Med Res, Canc Program, Sydney, NSW, Australia; [Tucci, P.; Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England; [Tucci, P.] Univ Calabria, Dept Pharm Hlth & Nutr Sci, I-87036 Arcavacata Di Rende, CS, Italy; [Melino, G.] IRCCS, Ist Dermopat Immacolata, Biochem Lab, Rome, Italy; [Melino, G.] Univ Roma Tor Vergata, Rome, Italy; [Flores, E. R.] Univ Texas MD Anderson Canc Ctr, Grad Sch Biomed Sci, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Beatson Institute; Garvan Institute of Medical Research; University of Leicester; University of Calabria; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; University of Texas System; UTMD Anderson Cancer Center	Vousden, KH (corresponding author), CR UK Beatson Inst, Beatson Inst, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	k.vousden@beatson.gla.ac.uk; PM292@le.ac.uk	Muller, Patricia AJ/AAH-1888-2019; Morton, Jennifer P/E-1633-2011; Morton, Jennifer/AAJ-5113-2021; Timpson, Paul/A-9429-2016	Muller, Patricia AJ/0000-0002-0926-1499; Morton, Jennifer P/0000-0001-5766-9141; Morton, Jennifer/0000-0001-5766-9141; Tan, Ee Hong/0000-0002-5971-6455; TUCCI, PAOLA/0000-0002-9349-5203; Timpson, Paul/0000-0002-5514-7080; Sansom, Owen J./0000-0001-9540-3010	CRUK; AICR; AIRC [5471, 2011-IG11955]; AIRC 5xmille [9979]; Telethon [GGPO9133]; MRC [MC_U132670600] Funding Source: UKRI; Cancer Research UK [12481, 11650] Funding Source: researchfish; Medical Research Council [MC_U132670600] Funding Source: researchfish; Worldwide Cancer Research [11-0626] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [R01CA160394, P30CA016672] Funding Source: NIH RePORTER	CRUK(Cancer Research UK); AICR; AIRC(Fondazione AIRC per la ricerca sul cancro); AIRC 5xmille(Fondazione AIRC per la ricerca sul cancro); Telethon(Fondazione Telethon); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Worldwide Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Work in the labs of KHV and OJS was funded by CRUK. Work by PAJM and KHV was sponsored by the AICR. Part of the work was funded by AIRC (# 5471) (2011-IG11955), AIRC 5xmille (# 9979), Telethon Grant GGPO9133, Min. Salute (RF) to GM. We thank Dr N Rath and Dr M Olsen for providing the cDNA of mouse keratinocytes and Dr M Dobbelstein for providing the p63 promoter luciferase construct.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Bergholz J, 2012, CANCER MICROENVIRON, V5, P311, DOI 10.1007/s12307-012-0116-9; Buganim Y, 2010, CANCER RES, V70, P2274, DOI 10.1158/0008-5472.CAN-09-2661; Collisson EA, 2012, CANCER DISCOV, V2, P685, DOI 10.1158/2159-8290.CD-11-0347; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Dong P, 2012, ONCOGENE, V32, P1203; Edward M, 2005, CARCINOGENESIS, V26, P1215, DOI 10.1093/carcin/bgi064; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Girardini JE, 2011, CANCER CELL, V20, P79, DOI 10.1016/j.ccr.2011.06.004; Guo XC, 2009, NAT CELL BIOL, V11, P1451, DOI 10.1038/ncb1988; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Koster MI, 2007, P NATL ACAD SCI USA, V104, P3255, DOI 10.1073/pnas.0611376104; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Laurikkala J, 2006, DEVELOPMENT, V133, P1553, DOI 10.1242/dev.02325; Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69; Levine AJ, 2011, NAT REV MOL CELL BIO, V12, P259, DOI 10.1038/nrm3086; Liu K, 2011, MOL CELL BIOL, V31, P4464, DOI 10.1128/MCB.05574-11; Lozano G, 2007, CURR OPIN GENET DEV, V17, P66, DOI 10.1016/j.gde.2006.12.003; Mangiulli M, 2009, NUCLEIC ACIDS RES, V37, P6092, DOI 10.1093/nar/gkp674; Melar-New M, 2010, J VIROL, V84, P5212, DOI 10.1128/JVI.00078-10; Melino G, 2011, CELL DEATH DIFFER, V18, P1487, DOI 10.1038/cdd.2011.81; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Muller PAJ, 2013, ONCOGENE, V32, P1252, DOI 10.1038/onc.2012.148; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Neilsen PM, 2013, ONCOGENE, V32, P2992, DOI 10.1038/onc.2012.305; Neilsen PM, 2011, ONCOTARGET, V2, P1203; Neuzillet C, 2013, CANCER METAST REV, V32, P147, DOI 10.1007/s10555-012-9396-2; Noll JE, 2012, ONCOGENE, V31, P2836, DOI 10.1038/onc.2011.456; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Quintavalle C, 2013, ONCOGENE, V32, P4001, DOI 10.1038/onc.2012.410; Romano RA, 2007, J INVEST DERMATOL, V127, P1175, DOI 10.1038/sj.jid.5700652; Romano RA, 2012, DEVELOPMENT, V139, P772, DOI 10.1242/dev.071191; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; SCARPA A, 1993, AM J PATHOL, V142, P1534; Scheel AHJ, 2009, CELL CYCLE, V8, P1426, DOI 10.4161/cc.8.9.8324; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Su XH, 2013, NAT REV CANCER, V13, P136, DOI 10.1038/nrc3446; Su XH, 2012, CELL METAB, V16, P511, DOI 10.1016/j.cmet.2012.09.006; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Su XH, 2009, CELL STEM CELL, V5, P64, DOI 10.1016/j.stem.2009.04.003; Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Wang W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.97; Xu J, 2011, NAT CHEM BIOL, V7, P285, DOI 10.1038/nchembio.546	51	28	29	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3325	3333		10.1038/onc.2013.287	http://dx.doi.org/10.1038/onc.2013.287			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23873029	Green Accepted			2022-12-28	WOS:000338443400012
J	Zhang, N; Wang, X; Huo, Q; Sun, M; Cai, C; Liu, Z; Hu, G; Yang, Q				Zhang, N.; Wang, X.; Huo, Q.; Sun, M.; Cai, C.; Liu, Z.; Hu, G.; Yang, Q.			MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin	ONCOGENE			English	Article						miR-30a; metadherin; breast cancer; metastasis	ASTROCYTE-ELEVATED GENE-1; CANCER PROGRESSION; EXPRESSION; CELLS; HETEROZYGOSITY; IDENTIFICATION; APOPTOSIS; INVASION; REGIONS; HEAD	Accumulating data have shown the involvement of microRNAs in cancerous processes as either oncogenes or tumor suppressor genes. Here, we established miR-30a as a tumor suppressor gene in breast cancer development and metastasis. Ectopic expression of miR-30a in breast cancer cell lines resulted in the suppression of cell growth and metastasis in vitro. Consistently, the xenograft mouse model also unveiled the suppressive effects of miR-30a on tumor growth and distal pulmonary metastasis. With dual luciferase reporter assay, we revealed that miR-30a could bind to the 3'-untranslated region of metadherin (MTDH) gene, thus exerting inhibitory effect on MTDH. Furthermore, we demonstrated that silence of MTDH could recapitulate the effects of miR-30a overexpression, while overexpression of MTDH could partially abrogate miR-30a-mediated suppression. Of significance, expression level of miR-30a was found to be significantly lower in primary breast cancer tissues than in the paired normal tissues. Further evaluation verified that miR-30a was negatively correlated with the extent of lymph node and lung metastasis in patients with breast cancer. Taken together, our findings indicated miR-30a inhibits breast cancer proliferation and metastasis by directly targeting MTDH, and miR-30a can serve as a prognostic marker for breast cancer. Manipulation of miR-30a may provide a promising therapeutic strategy for breast cancer treatment.	[Zhang, N.; Wang, X.; Huo, Q.; Sun, M.; Cai, C.; Yang, Q.] Shandong Univ, Dept Breast Surg, Qilu Hosp, Jinan 250012, Peoples R China; [Liu, Z.] Shandong Univ, Sch Med, Inst Cell Biol, Jinan 250012, Peoples R China; [Hu, G.] Chinese Acad Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai, Peoples R China; [Hu, G.] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200030, Peoples R China; [Yang, Q.] Shandong Univ, Key Lab Expt Teratol, Minist Educ, Sch Med, Jinan 250012, Peoples R China; [Yang, Q.] Shandong Univ, Sch Med, Inst Mol Med & Genet, Jinan 250012, Peoples R China	Shandong University; Shandong University; Chinese Academy of Sciences; Shanghai Jiao Tong University; Shandong University; Shandong University	Yang, Q (corresponding author), Shandong Univ, Dept Breast Surg, Qilu Hosp, Wenhua Xi Rd 107, Jinan 250012, Peoples R China.	qifengy@gmail.com	yang, qiang/GYJ-0971-2022; Zhang, Ning/GNP-1966-2022; Zhang, Ning/GOJ-8058-2022	Zhang, Ning/0000-0002-6430-4236; Yang, Qifeng/0000-0003-0576-8513; Hu, Guohong/0000-0002-2980-5166	National Natural Science Foundation of China [30772133, 81072150, 81172529, 81272903]; Shandong Science and Technology Development Plan [2012GZC22115]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Science and Technology Development Plan	We thank Shi Yan, Cunzhong Yuan and Ning Yang for collecting the clinical samples. This work was supported by National Natural Science Foundation of China (no. 30772133; no. 81072150; no. 81172529; no. 81272903) and Shandong Science and Technology Development Plan (no. 2012GZC22115):	Agrawal R, 2009, DEVELOPMENT, V136, P3927, DOI 10.1242/dev.037432; Almeida MI, 2011, MUTAT RES-FUND MOL M, V717, P1, DOI 10.1016/j.mrfmmm.2011.03.009; Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bandres E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chappell SA, 1997, BRIT J CANCER, V75, P1324, DOI 10.1038/bjc.1997.224; Cheng CW, 2012, BREAST CANCER RES TR, V134, P1081, DOI 10.1007/s10549-012-2034-4; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Gaziel-Sovran A, 2011, CANCER CELL, V20, P104, DOI 10.1016/j.ccr.2011.05.027; Heckman KL, 2007, NAT PROTOC, V2, P924, DOI 10.1038/nprot.2007.132; Hu GH, 2009, CLIN CANCER RES, V15, P5615, DOI 10.1158/1078-0432.CCR-09-0049; Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013; Hui ABY, 2011, CLIN CANCER RES, V17, P7539, DOI 10.1158/1078-0432.CCR-11-2102; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; John B, 2005, PLOS BIOL, V3, P1328, DOI 10.1371/journal.pbio.0030264; Kikuno N, 2007, ONCOGENE, V26, P7647, DOI 10.1038/sj.onc.1210572; Kong XL, 2012, CANCER BIOL THER, V13, P43, DOI 10.4161/cbt.13.1.18868; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kumarswamy R, 2012, INT J CANCER, V130, P2044, DOI 10.1002/ijc.26218; Lagana A, 2009, DATABASE, V2009; Lee SG, 2009, ONCOGENE, V28, P2476, DOI 10.1038/onc.2009.93; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li C, 2011, J SURG ONCOL, V103, P184, DOI 10.1002/jso.21788; Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054; Martineza I, 2011, P NATL ACAD SCI USA, V108, P522, DOI 10.1073/pnas.1017346108; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Nohata N, 2011, J HUM GENET, V56, P595, DOI 10.1038/jhg.2011.66; Noviello C, 1996, CLIN CANCER RES, V2, P1601; Ouzounova M, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-139; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Rodriguez-Gonzalez FG, 2011, BREAST CANCER RES TR, V127, P43, DOI 10.1007/s10549-010-0940-x; Schickel R, 2008, ONCOGENE, V27, P5959, DOI 10.1038/onc.2008.274; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wang L, 2012, ONCOGENE, V31, P2499, DOI 10.1038/onc.2011.444; Ward A, 2013, ONCOGENE, V32, P1173, DOI 10.1038/onc.2012.128; Xia ZB, 2010, CLIN NEUROL NEUROSUR, V112, P413, DOI 10.1016/j.clineuro.2010.02.007; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yang S, 2013, ONCOGENE, V32, P4294, DOI 10.1038/onc.2012.432; Yoo BK, 2009, J CLIN INVEST, V119, P465, DOI 10.1172/JCI36460; Yu F, 2010, ONCOGENE, V29, P4194, DOI 10.1038/onc.2010.167; Zhang N, 2013, J BIOL CHEM, V288, P9396, DOI 10.1074/jbc.M112.395913; Zhang N, 2010, CANCER SCI, V101, P2375, DOI 10.1111/j.1349-7006.2010.01680.x; Zhu H, 2009, AUTOPHAGY, V5, P816, DOI 10.4161/auto.9064; Zou ZY, 2012, J BIOL CHEM, V287, P4148, DOI 10.1074/jbc.M111.307405	52	133	140	0	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3119	3128		10.1038/onc.2013.286	http://dx.doi.org/10.1038/onc.2013.286			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23851509				2022-12-28	WOS:000338410000005
J	Dieterle, AM; Bohler, P; Keppeler, H; Alers, S; Berleth, N; Driessen, S; Hieke, N; Pietkiewicz, S; Loffler, AS; Peter, C; Gray, A; Leslie, NR; Shinohara, H; Kurosaki, T; Engelke, M; Wienands, J; Bonin, M; Wesselborg, S; Stork, B				Dieterle, A. M.; Boehler, P.; Keppeler, H.; Alers, S.; Berleth, N.; Driessen, S.; Hieke, N.; Pietkiewicz, S.; Loeffler, A. S.; Peter, C.; Gray, A.; Leslie, N. R.; Shinohara, H.; Kurosaki, T.; Engelke, M.; Wienands, J.; Bonin, M.; Wesselborg, S.; Stork, B.			PDK1 controls upstream PI3K expression and PIP3 generation	ONCOGENE			English	Article						Akt; PDK1; PI3K; survival; B lymphocytes	3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1; SMALL-MOLECULE INHIBITORS; P70 S6 KINASE; SIGNALING PATHWAY; PHOSPHOINOSITIDE PHOSPHATASES; ONCOGENIC TRANSFORMATION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; MTOR COMPLEX; IN-VITRO	The PI3K/PDK1/Akt signaling axis is centrally involved in cellular homeostasis and controls cell growth and proliferation. Due to its key function as regulator of cell survival and metabolism, the dysregulation of this pathway is manifested in several human pathologies including cancers and immunological diseases. Thus, current therapeutic strategies target the components of this signaling cascade. In recent years, numerous feedback loops have been identified that attenuate PI3K/PDK1/Akt-dependent signaling. Here, we report the identification of an additional level of feedback regulation that depends on the negative transcriptional control of phosphatidylinositol 3-kinase (PI3K) class IA subunits. Genetic deletion of 3-phosphoinositide-dependent protein kinase 1 (PDK1) or the pharmacological inhibition of its downstream effectors, that is, Akt and mammalian target of rapamycin (mTOR), relieves this suppression and leads to the upregulation of PI3K subunits, resulting in enhanced generation of phosphatidylinositol-3,4,5-trisphosphate (PIP3). Apparently, this transcriptional induction is mediated by the concerted action of different transcription factor families, including the transcription factors cAMP-responsive element-binding protein and forkhead box O. Collectively, we propose that PDK1 functions as a cellular sensor that balances basal PIP3 generation at levels sufficient for survival but below a threshold being harmful to the cell. Our study suggests that the efficiency of therapies targeting the aberrantly activated PI3K/PDK1/Akt pathway might be increased by the parallel blockade of feedback circuits.	[Dieterle, A. M.; Keppeler, H.; Alers, S.] Univ Tubingen Hosp, Dept Internal Med 1, Tubingen, Germany; [Boehler, P.; Berleth, N.; Driessen, S.; Hieke, N.; Pietkiewicz, S.; Loeffler, A. S.; Peter, C.; Wesselborg, S.; Stork, B.] Univ Hosp Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; [Gray, A.; Leslie, N. R.] Univ Dundee, Coll Life Sci, Div Cell Signaling & Immunol, Dundee, Scotland; [Shinohara, H.; Kurosaki, T.] RIKEN Res Ctr Allergy & Immunol, Lab Lymphocyte Differentiat, Yokohama, Kanagawa, Japan; [Engelke, M.; Wienands, J.] Univ Tubingen Hosp, Inst Cellular & Mol Immunol, Tubingen, Germany; [Bonin, M.] Univ Tubingen Hosp, MFT Serv, Dept Med Genet, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; University of Dundee; RIKEN; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Stork, B (corresponding author), Univ Hosp Dusseldorf, Inst Mol Med, Bldg 23-12,Univ Str 1, D-40225 Dusseldorf, Germany.	bjoern.stork@uni-duesseldorf.de	Stork, Björn/C-2160-2011; Shinohara, Hisaaki/E-3969-2010; Peter, Christoph/ABB-4684-2020; Kurosaki, Tomohiro/D-1306-2009	Stork, Björn/0000-0002-4167-7806; Shinohara, Hisaaki/0000-0002-6331-2138; Peter, Christoph/0000-0002-0048-2279; Kurosaki, Tomohiro/0000-0002-6352-304X; Alers, Sebastian/0000-0002-9813-9451; Gray, Alexander/0000-0001-9227-0363; Bohler, Philip/0000-0002-7792-8304; LESLIE, Nicholas/0000-0001-5131-0541; Alers, Alexandra Maria/0000-0002-7863-3559; Wesselborg, Sebastian/0000-0002-5236-942X	Deutsche Forschungsgemeinschaft [SFB 773, GRK 1302]; Interdisciplinary Center of Clinical Research, Faculty of Medicine, Tubingen (Nachwuchsgruppe) [1866-0-0]; Medical Research Council [G0801865] Funding Source: researchfish; MRC [G0801865] Funding Source: UKRI	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Interdisciplinary Center of Clinical Research, Faculty of Medicine, Tubingen (Nachwuchsgruppe); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Dario Alessi for providing Akti-1/2/3 (MK-2206) and for helpful discussions. This study was supported by grants from the Deutsche Forschungsgemeinschaft SFB 773 and GRK 1302 (to SW and BS) and from the Interdisciplinary Center of Clinical Research, Faculty of Medicine, Tubingen (Nachwuchsgruppe 1866-0-0, to BS).	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Bayascas JR, 2008, MOL CELL BIOL, V28, P3258, DOI 10.1128/MCB.02032-07; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bujor AM, 2010, EXP DERMATOL, V19, P347, DOI 10.1111/j.1600-0625.2010.01065.x; Bunney TD, 2010, NAT REV CANCER, V10, P342, DOI 10.1038/nrc2842; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Carnero A, 2010, CURR PHARM DESIGN, V16, P34, DOI 10.2174/138161210789941865; Caron E, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.108; Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Denley A, 2009, MOL CANCER RES, V7, P1132, DOI 10.1158/1541-7786.MCR-09-0068; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fayard E, 2010, CURR TOP MICROBIOL, V346, P31, DOI 10.1007/82_2010_58; Feldman RI, 2005, J BIOL CHEM, V280, P19867, DOI 10.1074/jbc.M501367200; Figueroa C, 2003, ONCOGENE, V22, P5554, DOI 10.1038/sj.onc.1206496; Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668; Gray A, 2003, ANAL BIOCHEM, V313, P234, DOI 10.1016/S0003-2697(02)00607-3; Guertin DA, 2006, CURR BIOL, V16, P958, DOI 10.1016/j.cub.2006.03.084; Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Jiang XN, 2010, J BIOL CHEM, V285, P14980, DOI 10.1074/jbc.M109.085696; Kang S, 2006, P NATL ACAD SCI USA, V103, P1289, DOI 10.1073/pnas.0510772103; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Kok K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005145; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Kurosaki T, 2011, MOL IMMUNOL, V48, P1287, DOI 10.1016/j.molimm.2010.12.007; Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lindsley CW, 2010, CURR TOP MED CHEM, V10, P458, DOI 10.2174/156802610790980602; Liu Y, 2010, PROG LIPID RES, V49, P201, DOI 10.1016/j.plipres.2009.12.001; Los M, 2009, BIOESSAYS, V31, P492, DOI 10.1002/bies.200900005; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Nagashima T, 2010, MOL PHARMACOL, V78, P961, DOI 10.1124/mol.110.065714; Najafov A, 2012, BIOCHEM J, V448, P285, DOI 10.1042/BJ20121287; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Parcellier A, 2008, CELL SIGNAL, V20, P21, DOI 10.1016/j.cellsig.2007.07.010; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82_2010_43; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shin HW, 2005, J CELL BIOL, V170, P607, DOI 10.1083/jcb.200505128; Shinohara H, 2007, J EXP MED, V204, P3285, DOI 10.1084/jem.20070379; So L, 2012, BIOCHEM J, V442, P465, DOI 10.1042/BJ20112092; Song KS, 2008, J BIOL CHEM, V283, P26869, DOI 10.1074/jbc.M802507200; Stocker H, 2002, SCIENCE, V295, P2088, DOI 10.1126/science. 1068094; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; van den Bout I, 2009, J CELL SCI, V122, P3837, DOI 10.1242/jcs.056127; van Gorp AGM, 2006, CANCER RES, V66, P10760, DOI 10.1158/0008-5472.CAN-06-1111; Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Yamazoe M, 2004, DNA REPAIR, V3, P1175, DOI 10.1016/j.dnarep.2004.03.039	66	19	22	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					3043	3053		10.1038/onc.2013.266	http://dx.doi.org/10.1038/onc.2013.266			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23893244				2022-12-28	WOS:000337232200011
J	Lu, C; Li, JY; Ge, Z; Zhang, L; Zhou, GP				Lu, C.; Li, J-Y; Ge, Z.; Zhang, L.; Zhou, G-P			Par-4/THAP1 complex and Notch3 competitively regulated pre-mRNA splicing of CCAR1 and affected inversely the survival of T-cell acute lymphoblastic leukemia cells	ONCOGENE			English	Article						Par-4; THAP1; CCAR1; Notch3; apoptosis; leukemia	TARGET GENE; EXPRESSION; APOPTOSIS; IDENTIFICATION; TRANSCRIPTION; GROWTH; PAR-4; THAP1; CYCLE	Although the intensification of therapy for children with T-cell acute lymphoblastic leukemia (T-ALL) has substantially improved clinical outcomes, T-ALL remains an important challenge in pediatric oncology. Here, we report that the cooperative synergy between prostate apoptosis response factor-4 (Par-4) and THAP1 induces cell cycle and apoptosis regulator 1 (CCAR1) gene expression and cellular apoptosis in human T-ALL cell line Jurkat cells, CEM cells and primary cultured neoplastic T lymphocytes from children with T-ALL. Par-4 and THAP1 collaborated to activate the promoter of CCAR1 gene. Mechanistic investigations revealed that Par-4 and THAP1 formed a protein complex by the interaction of their carboxyl termini, and THAP1 bound to CCAR1 promoter though its zinc-dependent DNA-binding domain at amino terminus. Par-4/THAP1 complex and Notch3 competitively bound to CCAR1 promoter and competitively modulated alternative pre-mRNA splicing of CCAR1, which resulted in two different transcripts and played an opposite role in T-ALL cell survival. Despite Notch3 induced a shift splicing from the full-length isoform toward a shorter form of CCAR1 mRNA by splicing factor SRp40 and SRp55, Par-4/THAP1 complex strongly antagonized this inductive effect. Our finding revealed a mechanistic rationale for Par-4/THAP1-induced apoptosis in T-ALL cells that would be of benefit to develop a new therapy strategy for T-ALL.	[Lu, C.; Zhang, L.; Zhou, G-P] Nanjing Med Univ, Affiliated Hosp 1, Dept Pediat, Nanjing 210029, Jiangsu, Peoples R China; [Li, J-Y; Ge, Z.] Nanjing Med Univ, Affiliated Hosp 1, Dept Hematol, Nanjing 210029, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University	Lu, C (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Pediat, Guangzhou Rd 300, Nanjing 210029, Jiangsu, Peoples R China.	luchaodoctor@163.com; gpzhou2013@163.com			National Natural Science Foundation of China [81170487]; National Major Scientific and Technological Special Project for 'Significant New Drugs Development' [2011ZX09302-003-02]; Jiangsu Province Major Scientific and Technological Special Project [BM2011017]; Priority Academic Program Development of Jiangsu Higher Education Institutions	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Major Scientific and Technological Special Project for 'Significant New Drugs Development'; Jiangsu Province Major Scientific and Technological Special Project; Priority Academic Program Development of Jiangsu Higher Education Institutions	This work was supported by the National Natural Science Foundation of China (81170487), the National Major Scientific and Technological Special Project for 'Significant New Drugs Development' (2011ZX09302-003-02), the Jiangsu Province Major Scientific and Technological Special Project (BM2011017) and the Priority Academic Program Development of Jiangsu Higher Education Institutions.	Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Bellavia D, 2007, EMBO J, V26, P1670, DOI 10.1038/sj.emboj.7601626; Boehrer S, 2006, LEUKEMIA RES, V30, P597, DOI 10.1016/j.leukres.2005.09.003; Campagne S, 2010, NUCLEIC ACIDS RES, V38, P3466, DOI 10.1093/nar/gkq053; Cheema SK, 2003, J BIOL CHEM, V278, P19995, DOI 10.1074/jbc.M205865200; Chow KU, 2005, LEUKEMIA, V19, P1103, DOI 10.1038/sj.leu.2403739; Clouaire T, 2005, P NATL ACAD SCI USA, V102, P6907, DOI 10.1073/pnas.0406882102; Glienke W, 2006, LEUKEMIA LYMPHOMA, V47, P1629, DOI 10.1080/10428190600625398; Hebbar N, 2012, J CELL PHYSIOL, V227, P3715, DOI 10.1002/jcp.24098; Kent S, 2011, CELL CYCLE, V10; Kim JH, 2008, MOL CELL, V31, P510, DOI 10.1016/j.molcel.2008.08.001; Ling X, 2005, LUNG CANCER, V49, P353, DOI 10.1016/j.lungcan.2005.03.037; Lu CT, 2008, INT J ARTIF INTELL T, V17, P1; McFie PJ, 2006, J BIOL CHEM, V281, P18069, DOI 10.1074/jbc.M512734200; Ou CY, 2009, J BIOL CHEM, V284, P20629, DOI 10.1074/jbc.M109.014332; Park JT, 2008, CANCER RES, V68, P8852, DOI 10.1158/0008-5472.CAN-08-0517; Roussigne M, 2003, ONCOGENE, V22, P2432, DOI 10.1038/sj.onc.1206271; Schrappe M, 2012, NEW ENGL J MED, V366, P1371, DOI 10.1056/NEJMoa1110169; Tzoneva G, 2012, CURR TOP MICROBIOL, V360, P163, DOI 10.1007/82_2012_232; Van Vlierberghe P, 2012, J CLIN INVEST, V122, P3398, DOI 10.1172/JCI61269; Wei BB, 2010, J BIOMED RES, V24, P58, DOI 10.1016/S1674-8301(10)60009-7; Zhang DX, 2011, J BIOL CHEM, V286, P17746, DOI 10.1074/jbc.M110.206029; Zhang LY, 2007, MOL CANCER THER, V6, P1661, DOI 10.1158/1535-7163.MCT-06-0653	23	25	26	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2013	32	50					5602	5613		10.1038/onc.2013.349	http://dx.doi.org/10.1038/onc.2013.349			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272LF	23975424	Green Published, hybrid			2022-12-28	WOS:000328461400005
J	Sun, X; Jiao, X; Pestell, TG; Fan, C; Qin, S; Mirabelli, E; Ren, H; Pestell, RG				Sun, X.; Jiao, X.; Pestell, T. G.; Fan, C.; Qin, S.; Mirabelli, E.; Ren, H.; Pestell, R. G.			MicroRNAs and cancer stem cells: the sword and the shield	ONCOGENE			English	Review						miRNAs; anticancer treatment; cancer stem cells; targeted therapy; clinical therapeutics	EPITHELIAL-MESENCHYMAL TRANSITION; WNT SIGNALING PATHWAY; TUMOR-SUPPRESSOR; MULTIDRUG-RESISTANCE; OVARIAN-CANCER; SELF-RENEWAL; DOWN-REGULATION; FEEDBACK LOOP; EXPRESSION; TARGETS	Emerging chemotherapy drugs and targeted therapies have been widely applied in anticancer treatment and have given oncologists a promising future. Nevertheless, regeneration and recurrence are still huge obstacles on the way to cure cancer. Cancer stem cells (CSCs) are capable of self-renewal, tumor initiation, recurrence, metastasis, therapy resistance, and reside as a subset in many, if not all, cancers. Therefore, therapeutics specifically targeting and killing CSCs are being identified, and may be promising and effective strategies to eliminate cancer. MicroRNAs (miRNAs, miRs), small noncoding RNAs regulating gene expression in a post-transcriptional manner, are dysregulated in most malignancies and are identified as important regulators of CSCs. However, limited knowledge exists for biological and molecular mechanism by which miRNAs regulate CSCs. In this article, we review CSCs, miRNAs and the interactions between miRNA regulation and CSCs, with a specific focus on the molecular mechanisms and clinical applications. This review will help us to know in detail how CSCs are regulated by miRNAs networks and also help to develop more effective and secure miRNA-based clinical therapies.	[Sun, X.; Qin, S.; Ren, H.] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Oncol, Xian 710061, Shaanxi Provinc, Peoples R China; [Sun, X.; Jiao, X.; Mirabelli, E.; Pestell, R. G.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA; [Pestell, T. G.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Stem Cell Biol & Regenerat Med, Philadelphia, PA 19107 USA; [Fan, C.] Tianjin Med Univ, Affiliated Hosp 2, Cardiovasc Dept, Tianjin, Peoples R China; [Qin, S.] NYU Med Ctr, New York, NY 10016 USA	Xi'an Jiaotong University; Jefferson University; Jefferson University; Tianjin Medical University; New York University	Ren, H (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Sch Med, Dept Oncol, 277 Yanta West Rd, Xian 710061, Shaanxi Provinc, Peoples R China.	renhongs2000@aliyun.com; director@kimmelcancercenter.org	Sun, Xin/AAI-4648-2020		NIH [R01CA70896, R01CA75503, R01CA86072, R01CA137494, R01CA132115]; National Natural Science Foundation of China [81272418]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study is supported in part by NIH grants R01CA70896, R01CA75503, R01CA86072, R01CA137494 and R01CA132115 and National Natural Science Foundation of China 81272418. We are grateful to Elsa R Flores, Ph.D. (Department of Biochemistry and Molecular Biology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center) for her helpful advice and suggestions.	Bao B, 2011, CANCER LETT, V307, P26, DOI 10.1016/j.canlet.2011.03.012; Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116; Baumann M, 2008, NAT REV CANCER, V8, P545, DOI 10.1038/nrc2419; Beildeck ME, 2010, EXP CELL RES, V316, P1763, DOI 10.1016/j.yexcr.2010.02.001; Borel F, 2012, HEPATOLOGY, V55, P821, DOI 10.1002/hep.24682; Bourguignon LW, 2013, STEM CELLS CANC STEM, V9, P291; Boyerinas B, 2012, INT J CANCER, V130, P1787, DOI 10.1002/ijc.26190; Boyerinas B, 2010, ENDOCR-RELAT CANCER, V17, pF19, DOI 10.1677/ERC-09-0184; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Ceppi P, 2014, ONCOGENE, V33, P269, DOI 10.1038/onc.2013.55; Cheng WW, 2012, FEBS J, V279, P2047, DOI 10.1111/j.1742-4658.2012.08589.x; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861; Debeb BG, 2009, J MAMMARY GLAND BIOL, V14, P11, DOI 10.1007/s10911-009-9114-z; DeSano JT, 2009, AAPS J, V11, P682, DOI 10.1208/s12248-009-9147-7; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Dylla SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002428; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Giovannetti E, 2012, CRIT REV ONCOL HEMAT, V81, P103, DOI 10.1016/j.critrevonc.2011.03.010; Guzman ML, 2005, BLOOD, V105, P4163, DOI 10.1182/blood-2004-10-4135; Ha HT, 2013, AM J CLIN ONCOL-CANC, V36, P77, DOI 10.1097/COC.0b013e31823a4970; Ho MM, 2007, CANCER RES, V67, P4827, DOI 10.1158/0008-5472.CAN-06-3557; Hoey T, 2009, CELL STEM CELL, V5, P168, DOI 10.1016/j.stem.2009.05.019; Hu XW, 2013, MOL CANCER RES, V11, P240, DOI 10.1158/1541-7786.MCR-12-0432; Hu ZB, 2010, J CLIN ONCOL, V28, P1721, DOI 10.1200/JCO.2009.24.9342; Inomata M, 2009, BLOOD, V113, P396, DOI 10.1182/blood-2008-07-163907; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Katoh M, 2006, INT J MOL MED, V17, P681; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Khoshnaw SM, 2009, J CLIN PATHOL, V62, P422, DOI 10.1136/jcp.2008.060681; Kumar MS, 2008, P NATL ACAD SCI USA, V105, P3903, DOI 10.1073/pnas.0712321105; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Lathia JD, 2010, CELL STEM CELL, V6, P421, DOI 10.1016/j.stem.2010.02.018; Li M, 2009, WORLD J SURG, V33, P667, DOI 10.1007/s00268-008-9836-x; Li WQ, 2010, MED SCI MONITOR, V16, pHY27; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Li YQ, 2012, CANCER RES, V72, P576, DOI 10.1158/0008-5472.CAN-11-3070; Li YQ, 2009, CANCER RES, V69, P7569, DOI 10.1158/0008-5472.CAN-09-0529; Liep J, 2012, EPIGENETICS-US, V7, P315, DOI 10.4161/epi.19464; Liu B, 2010, CELL BIOL INT, V34, P21, DOI 10.1042/CBI20090129; Liu C, 2012, CANCER RES, V72, P3393, DOI 10.1158/0008-5472.CAN-11-3864; Liu C, 2011, CANCER RES, V71, P5950, DOI 10.1158/0008-5472.CAN-11-1035; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Lopez-Chavez A, 2009, CURR OPIN INVEST DR, V10, P1305; Mallick R, 2010, BIOL APPL DIAGNOSIS, V81, P410; Marcucci G, 2009, BEST PRACT RES CL HA, V22, P239, DOI 10.1016/j.beha.2009.05.003; McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084; Mendell JT, 2012, CELL, V148, P1172, DOI 10.1016/j.cell.2012.02.005; Mihatsch J, 2011, RADIOTHER ONCOL, V99, P300, DOI 10.1016/j.radonc.2011.06.003; Mishra PJ, 2009, PHARMACOGENOMICS, V10, P399, DOI 10.2217/14622416.10.3.399; Mohan M, 2010, GENE DEV, V24, P574, DOI 10.1101/gad.1898410; Murray MY, 2012, CELL SIGNAL, V24, P363, DOI 10.1016/j.cellsig.2011.09.021; Nguyen Giang Huong, 2011, Cancers (Basel), V3, P1232, DOI 10.3390/cancers3011232; Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184; O'Day E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2484; O'Hara AJ, 2009, BLOOD, V113, P5938, DOI 10.1182/blood-2008-09-179168; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Peitzsch C, 2013, RADIOTHER ONCOL, V108, P378, DOI 10.1016/j.radonc.2013.06.003; Pestell RG, 2013, AM J PATHOL, V183, P3, DOI 10.1016/j.ajpath.2013.03.001; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Pirollo KF, 2007, CANCER RES, V67, P2938, DOI 10.1158/0008-5472.CAN-06-4535; Plath K, 2012, CELL STEM CELL, V11, P607, DOI 10.1016/j.stem.2012.10.003; Plummer PN, 2013, CANCER RES, V73, P341, DOI 10.1158/0008-5472.CAN-12-0271; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Rich JN, 2007, CANCER RES, V67, P8980, DOI 10.1158/0008-5472.CAN-07-0895; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Samantarrai D, 2013, MOL CANCER RES, V11, P315, DOI 10.1158/1541-7786.MCR-12-0649; Sandhu S, 2011, SEMIN ONCOL, V38, P781, DOI 10.1053/j.seminoncol.2011.08.007; Sayed D, 2011, PHYSIOL REV, V91, P827, DOI 10.1152/physrev.00006.2010; Schatton T, 2009, BIOESSAYS, V31, P1038, DOI 10.1002/bies.200900058; Schramedei K, 2011, ONCOGENE, V30, P2975, DOI 10.1038/onc.2011.15; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shafee N, 2008, CANCER RES, V68, P3243, DOI 10.1158/0008-5472.CAN-07-5480; Shiiba M, 2013, BRIT J CANCER, V108, P1817, DOI 10.1038/bjc.2013.175; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Siemens H, 2011, CELL CYCLE, V10, P4256, DOI 10.4161/cc.10.24.18552; Sindhu C, 2012, J BIOL CHEM, V287, P30922, DOI 10.1074/jbc.R111.319046; Sun X, 2013, MED HYPOTHESES, V81, P410, DOI 10.1016/j.mehy.2013.05.033; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tamada M, 2012, CANCER RES, V72, P1438, DOI 10.1158/0008-5472.CAN-11-3024; Tamara Marie-Egyptienne D, 2012, CANC LETT; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; To K, 2010, CANCER RES, V70, P2840, DOI 10.1158/0008-5472.CAN-09-3155; Trang P, 2011, MOL THER, V19, P1116, DOI 10.1038/mt.2011.48; Turrini E, 2012, PHARMACOGENET GENOM, V22, P198, DOI 10.1097/FPC.0b013e328350012b; Vira D, 2012, CANCER METAST REV, V31, P733, DOI 10.1007/s10555-012-9382-8; Wang D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013067; Weng DS, 2013, J IMMUNOL, V191, P755, DOI 10.4049/jimmunol.1203286; Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655; Wu CY, 2012, TRENDS GENET, V28, P454, DOI 10.1016/j.tig.2012.05.005; Wu KM, 2011, J BIOL CHEM, V286, P2132, DOI 10.1074/jbc.M110.148395; Xu K, 2012, BIOCHEM J, V446, P291, DOI 10.1042/BJ20120386; Yang YP, 2012, BIOMATERIALS, V33, P1462, DOI 10.1016/j.biomaterials.2011.10.071; Yao JC, 2013, CANCER RES, V73, P1449, DOI 10.1158/0008-5472.CAN-12-3923; Yu F, 2010, ONCOGENE, V29, P4194, DOI 10.1038/onc.2010.167; Yu ZR, 2008, J CELL BIOL, V182, P509, DOI 10.1083/jcb.200801079; Yu ZR, 2012, INT J BIOCHEM CELL B, V44, P2144, DOI 10.1016/j.biocel.2012.08.022; Yu Zuoren, 2012, Frontiers in Genetics, V3, P191, DOI 10.3389/fgene.2012.00191; Zhang R, 2012, CANCER LETT, V314, P155, DOI 10.1016/j.canlet.2011.09.027; Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008-5472.CAN-10-2435; Zheng TS, 2010, INT J CANCER, V126, P2, DOI 10.1002/ijc.24782; Zhu YH, 2011, CLIN CANCER RES, V17, P7105, DOI 10.1158/1078-0432.CCR-11-0071; Zimmerman AL, 2011, CANCER LETT, V300, P10, DOI 10.1016/j.canlet.2010.09.019	107	140	147	0	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2014	33	42					4967	4977		10.1038/onc.2013.492	http://dx.doi.org/10.1038/onc.2013.492			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OB	24240682	Bronze			2022-12-28	WOS:000343768000001
J	Bonora, M; Wieckowsk, MR; Chinopoulos, C; Kepp, O; Kroemer, G; Galluzzi, L; Pinton, P				Bonora, M.; Wieckowsk, M. R.; Chinopoulos, C.; Kepp, O.; Kroemer, G.; Galluzzi, L.; Pinton, P.			Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition (vol 34, pg 1475, 2015)	ONCOGENE			English	Correction													Kepp, Oliver/GPX-8627-2022; Pinton, Paolo/J-8025-2012; Galluzzi, Lorenzo/AAH-3286-2021; Galluzzi, Lorenzo/AAG-6432-2019; KROEMER, Guido/B-4263-2013; Galluzzi, Lorenzo/AAG-6294-2019; Kroemer, Guido/AAY-9859-2020; Kepp, Oliver/N-2763-2017	Pinton, Paolo/0000-0001-7108-6508; KROEMER, Guido/0000-0002-9334-4405; Kepp, Oliver/0000-0002-6081-9558; Chinopoulos, Christos/0000-0003-0183-4149; Wieckowski, Mariusz/0000-0003-0789-4521	Telethon [GGP11139] Funding Source: Medline	Telethon(Fondazione Telethon)		Bonora M, 2015, ONCOGENE, V34, P1475, DOI 10.1038/onc.2014.96	1	142	151	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1608	1608		10.1038/onc.2014.462	http://dx.doi.org/10.1038/onc.2014.462			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	25790189	Bronze			2022-12-28	WOS:000351416800013
J	Hasegawa, Y; Takahashi, M; Ariki, S; Asakawa, D; Tajiri, M; Wada, Y; Yamaguchi, Y; Nishitani, C; Takamiya, R; Saito, A; Uehara, Y; Hashimoto, J; Kurimura, Y; Takahashi, H; Kuroki, Y				Hasegawa, Y.; Takahashi, M.; Ariki, S.; Asakawa, D.; Tajiri, M.; Wada, Y.; Yamaguchi, Y.; Nishitani, C.; Takamiya, R.; Saito, A.; Uehara, Y.; Hashimoto, J.; Kurimura, Y.; Takahashi, H.; Kuroki, Y.			Surfactant protein D suppresses lung cancer progression by downregulation of epidermal growth factor signalling (vol 34, pg 838, 2014)	ONCOGENE			English	Correction													Asakawa, Daiki/M-9393-2019; Yamaguchi, Yoshiki/N-5246-2015; Ariki, Shigeru/E-3861-2014; Asakawa, Daiki/L-7798-2016; Saito, Atsushi/M-7382-2018; Takahashi, Motoko/I-3154-2013	Asakawa, Daiki/0000-0002-9357-8420; Yamaguchi, Yoshiki/0000-0003-0100-5439; Ariki, Shigeru/0000-0001-5838-499X; Asakawa, Daiki/0000-0002-9357-8420; Saito, Atsushi/0000-0003-3430-884X; Takahashi, Motoko/0000-0002-2112-6142; Uehara, Yasuaki/0000-0002-6439-2715; Takamiya, Rina/0000-0002-5947-488X				Hasegawa Y, 2015, ONCOGENE, V34, P838, DOI [10.1038/onc.2014.20, 10.1038/onc.2015.266]	1	37	39	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4285	4286		10.1038/onc.2015.266	http://dx.doi.org/10.1038/onc.2015.266			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	26250851	Bronze			2022-12-28	WOS:000359199800015
J	Hasegawa, Y; Takahashi, M; Ariki, S; Asakawa, D; Tajiri, M; Wada, Y; Yamaguchi, Y; Nishitani, C; Takamiya, R; Saito, A; Uehara, Y; Hashimoto, J; Kurimura, Y; Takahashi, H; Kuroki, Y				Hasegawa, Y.; Takahashi, M.; Ariki, S.; Asakawa, D.; Tajiri, M.; Wada, Y.; Yamaguchi, Y.; Nishitani, C.; Takamiya, R.; Saito, A.; Uehara, Y.; Hashimoto, J.; Kurimura, Y.; Takahashi, H.; Kuroki, Y.			Surfactant protein D suppresses lung cancer progression by downregulation of epidermal growth factor signaling	ONCOGENE			English	Article							CARBOHYDRATE-RECOGNITION DOMAIN; IDIOPATHIC PULMONARY FIBROSIS; FACTOR RECEPTOR; TYROSINE KINASE; D BINDS; NEGATIVE COOPERATIVITY; EXTRACELLULAR DOMAINS; ALVEOLAR MACROPHAGES; MYCOBACTERIUM-AVIUM; GM3 BINDING	Surfactant protein D (SP-D) is a member of the collectin family that has an important role in maintaining pulmonary homeostasis. In this study, we demonstrated that SP-D inhibited the proliferation, migration and invasion of A549 human lung adenocarcinoma cells. We found that SP-D suppressed epidermal growth factor (EGF) signaling in A549 cells, H441 human lung adenocarcinoma cells and human EGF receptor (EGFR) stable expression CHO-K1 cells. A binding study using I-125-EGF demonstrated that SP-D downregulated the binding of EGF to EGFR. A ligand blot indicated that SP-D bound to EGFR, and a lectin blot suggested that EGFR in A549 cells had both high-mannose type and complex type N-glycans. We purified the recombinant extracellular domain of EGFR (soluble EGFR=soluble EGFR (sEGFR)), and demonstrated that SP-D directly bound to sEGFR in a Ca2+-dependent manner. The binding of SP-D to sEGFR was suppressed by EDTA, mannose or N-glycopeptidase F treatment. Mass spectrometric analysis indicated that N-glycans in domain III of EGFR were of a high-type. These data suggest that SP-D reduces EGF binding to EGFR through the interaction between the carbohydrate recognition domain of SP-D and N-glycans of EGFR, and downregulates EGF signaling. Our finding suggests the novel type of regulation system of EGF signaling involving lectin-to-carbohydrate interaction and downregulation of ligand binding.	[Hasegawa, Y.; Takahashi, M.; Ariki, S.; Nishitani, C.; Takamiya, R.; Saito, A.; Uehara, Y.; Hashimoto, J.; Kurimura, Y.; Kuroki, Y.] Sapporo Med Univ, Sch Med, Dept Biochem, Sapporo, Hokkaido 0608556, Japan; [Hasegawa, Y.; Saito, A.; Uehara, Y.; Takahashi, H.] Sapporo Med Univ, Sch Med, Dept Resp Med & Allergol, Sapporo, Hokkaido 0608556, Japan; [Asakawa, D.; Tajiri, M.; Wada, Y.] Osaka Med Ctr, Dept Mol Med, Osaka, Japan; [Asakawa, D.; Tajiri, M.; Wada, Y.] Res Inst Maternal & Child Hlth, Osaka, Japan; [Yamaguchi, Y.] RIKEN, Max Planck Joint Res Ctr, Syst Glycobiol Res Grp, Wako, Saitama, Japan; [Hashimoto, J.; Kurimura, Y.] Sapporo Med Univ, Sch Med, Dept Urol, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University; Sapporo Medical University; Osaka Medical Center for Cancer & Cardiovascular Diseases; RIKEN; Sapporo Medical University	Takahashi, M (corresponding author), Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, South 1 West 17, Sapporo, Hokkaido 0608556, Japan.	takam@sapmed.ac.jp	Asakawa, Daiki/M-9393-2019; Yamaguchi, Yoshiki/N-5246-2015; Ariki, Shigeru/E-3861-2014; Asakawa, Daiki/L-7798-2016; Saito, Atsushi/M-7382-2018; Takahashi, Motoko/I-3154-2013	Asakawa, Daiki/0000-0002-9357-8420; Yamaguchi, Yoshiki/0000-0003-0100-5439; Ariki, Shigeru/0000-0001-5838-499X; Asakawa, Daiki/0000-0002-9357-8420; Saito, Atsushi/0000-0003-3430-884X; Takahashi, Motoko/0000-0002-2112-6142; Uehara, Yasuaki/0000-0002-6439-2715; Takamiya, Rina/0000-0002-5947-488X	Japan Society for the Promotion of Science; Takeda Science Foundation; Suhara Foundation	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Takeda Science Foundation(Takeda Science Foundation (TSF)); Suhara Foundation	This work was supported in part by a Grant-in-Aid for Science Research from the Japan Society for the Promotion of Science, grants from the Takeda Science Foundation and from the Suhara Foundation.	Alvarado D, 2010, CELL, V142, P568, DOI 10.1016/j.cell.2010.07.015; Ariki S, 2011, J IMMUNOL, V187, P2586, DOI 10.4049/jimmunol.1100024; Aubry MC, 2002, MAYO CLIN PROC, V77, P763, DOI 10.4065/77.8.763; BASTACKY J, 1995, J APPL PHYSIOL, V79, P1615, DOI 10.1152/jappl.1995.79.5.1615; BETZ C, 1995, CANCER RES, V55, P4283; BREMER EG, 1986, J BIOL CHEM, V261, P2434; Dawson JP, 2007, STRUCTURE, V15, P942, DOI 10.1016/j.str.2007.06.013; HONDA Y, 1995, AM J RESP CRIT CARE, V152, P1860, DOI 10.1164/ajrccm.152.6.8520747; Hrustanovic G, 2013, CANCER BIOL THER, V14, P304, DOI 10.4161/cbt.23627; Hubbard R, 2000, AM J RESP CRIT CARE, V161, P5, DOI 10.1164/ajrccm.161.1.9906062; Ishii T, 2012, COPD, V9, P409, DOI 10.3109/15412555.2012.676110; Kawashima N, 2009, J BIOL CHEM, V284, P6147, DOI 10.1074/jbc.M808171200; Kingma PS, 2006, CURR OPIN PHARMACOL, V6, P277, DOI 10.1016/j.coph.2006.02.003; Kudo K, 2004, J IMMUNOL, V172, P7592, DOI 10.4049/jimmunol.172.12.7592; Kuroki Y, 2007, CELL MICROBIOL, V9, P1871, DOI 10.1111/j.1462-5822.2007.00953.x; Lin ZW, 2007, INT J ONCOL, V31, P181; Macdonald JL, 2008, P NATL ACAD SCI USA, V105, P112, DOI 10.1073/pnas.0707080105; Mason RJ, 2000, AM J PATHOL, V156, P175, DOI 10.1016/S0002-9440(10)64717-7; Nagae H, 1997, CLIN CHIM ACTA, V266, P157, DOI 10.1016/S0009-8981(97)00124-1; Nie XM, 2008, BIOCHEMISTRY-US, V47, P12878, DOI 10.1021/bi8010175; Ohya M, 2006, BIOCHEMISTRY-US, V45, P8657, DOI 10.1021/bi060176z; Oxnard GR, 2011, CLIN CANCER RES, V17, P5530, DOI 10.1158/1078-0432.CCR-10-2571; Park J, 2001, EUR RESPIR J, V17, P1216, DOI 10.1183/09031936.01.99055301; Partridge EA, 2004, SCIENCE, V306, P120, DOI 10.1126/science.1102109; Qi Zhi-li, 2002, Ai Zheng, V21, P772; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532; Restrepo CI, 1999, AM J RESP CELL MOL, V21, P576, DOI 10.1165/ajrcmb.21.5.3334; Sahly H, 2002, J IMMUNOL, V169, P3267, DOI 10.4049/jimmunol.169.6.3267; Sato Y, 2001, J BIOL CHEM, V276, P11956, DOI 10.1074/jbc.M008551200; Sawada K, 2010, J BIOL CHEM, V285, P8434, DOI 10.1074/jbc.M109.074765; Sin DD, 2008, CHEST, V134, P582, DOI 10.1378/chest.08-0600; Smith KD, 1996, GROWTH FACTORS, V13, P121, DOI 10.3109/08977199609034572; SODERQUIST AM, 1984, J BIOL CHEM, V259, P2586; Tajiri M, 2005, GLYCOBIOLOGY, V15, P1332, DOI 10.1093/glycob/cwj019; Tajiri M, 2009, J PROTEOME RES, V8, P688, DOI 10.1021/pr800727w; Takahashi H, 1996, RESPIRATION, V63, P390; Takahashi M, 2013, J BIOL CHEM, V288, P32910, DOI 10.1074/jbc.M113.491902; Tino MJ, 1999, AM J PHYSIOL-LUNG C, V276, pL164, DOI 10.1152/ajplung.1999.276.1.L164; Tsuda T, 2000, J BIOL CHEM, V275, P21988, DOI 10.1074/jbc.M003400200; Wada Y, 2004, ANAL CHEM, V76, P6560, DOI 10.1021/ac049062o; Wang XQ, 2001, GLYCOBIOLOGY, V11, P515, DOI 10.1093/glycob/11.7.515; Whitsett JA, 2002, NEW ENGL J MED, V347, P2141, DOI 10.1056/NEJMra022387; Wright JR, 2005, NAT REV IMMUNOL, V5, P58, DOI 10.1038/nri1528; Wright JR, 1997, PHYSIOL REV, V77, P931, DOI 10.1152/physrev.1997.77.4.931; Wu HX, 2003, J CLIN INVEST, V111, P1589, DOI 10.1172/JCI200316889; Yamazoe M, 2008, J BIOL CHEM, V283, P35878, DOI 10.1074/jbc.M807268200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yoon SJ, 2006, P NATL ACAD SCI USA, V103, P18987, DOI 10.1073/pnas.0609281103; Zhang F, 2004, CHEST, V125, p109S, DOI 10.1378/chest.125.5_suppl.109S	49	37	39	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					838	845		10.1038/onc.2014.20	http://dx.doi.org/10.1038/onc.2014.20			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	26250851				2022-12-28	WOS:000349472000004
